

The FEDERAL REGISTER is published daily, Monday through Friday, except official holidays, by the Office of the Federal Register, National Archives and Records Administration, Washington, DC 20408, under the Federal Register Act (44 U.S.C. Ch. 15) and the regulations of the Administrative Committee of the Federal Register ( 1 CFR Ch. I). The Superintendent of Documents, U.S. Government Printing Office, Washington, DC 20402 is the exclusive distributor of the official edition.
The Federal Register provides a uniform system for making available to the public regulations and legal notices issued by Federal agencies. These include Presidential proclamations and Executive Orders, Federal agency documents having general applicability and legal effect, documents required to be published by act of Congress, and other Federal agency documents of public interest.
Documents are on file for public inspection in the Office of the Federal Register the day before they are published, unless the issuing agency requests earlier filing. For a list of documents currently on file for public inspection, see http://www.nara.gov/ fedreg.
The seal of the National Archives and Records Administration authenticates the Federal Register as the official serial publication established under the Federal Register Act. Under 44 U.S.C. 1507, the contents of the Federal Register shall be judicially noticed.
The Federal Register is published in paper and on 24 x microfiche. It is also available online at no charge as one of the databases on GPO Access, a service of the U.S. Government Printing Office.
The online edition of the Federal Register is issued under the authority of the Administrative Committee of the Federal Register as the official legal equivalent of the paper and microfiche editions (44 U.S.C. 4101 and 1 CFR 5.10). It is updated by 6 a.m. each day the Federal Register is published and it includes both text and graphics from Volume 59, Number 1 (January 2, 1994) forward.
GPO Access users can choose to retrieve online Federal Register documents as TEXT (ASCII text, graphics omitted), PDF (Adobe Portable Document Format, including full text and all graphics), or SUMMARY (abbreviated text) files. Users should carefully check retrieved material to ensure that documents were properly downloaded.
On the World Wide Web, connect to the Federal Register at http:/ /www.access.gpo.gov/nara. Those without World Wide Web access can also connect with a local WAIS client, by Telnet to swais.access.gpo.gov, or by dialing (202) 512-1661 with a computer and modem. When using Telnet or modem, type swais, then log in as guest with no password.
For more information about GPO Access, contact the GPO Access User Support Team by E-mail at gpoaccess@gpo.gov; by fax at (202) 512-1262; or call (202) 512-1530 or 1-888-293-6498 (toll free) between 7 a.m. and 5 p.m. Eastern time, Monday-Friday, except Federal holidays.
The annual subscription price for the Federal Register paper edition is $\$ 555$, or $\$ 607$ for a combined Federal Register, Federal Register Index and List of CFR Sections Affected (LSA) subscription; the microfiche edition of the Federal Register including the Federal Register Index and LSA is $\$ 220$. Six month subscriptions are available for one-half the annual rate. The charge for individual copies in paper form is $\$ 8.00$ for each issue, or $\$ 8.00$ for each group of pages as actually bound; or $\$ 1.50$ for each issue in microfiche form. All prices include regular domestic postage and handling. International customers please add $25 \%$ for foreign handling. Remit check or money order, made payable to the Superintendent of Documents, or charge to your GPO Deposit Account, VISA, MasterCard or Discover. Mail to: New Orders, Superintendent of Documents, P.O. Box 371954, Pittsburgh, PA 15250-7954.
There are no restrictions on the republication of material appearing in the Federal Register.
How To Cite This Publication: Use the volume number and the page number. Example: 65 FR 12345.

## SUBSCRIPTIONS AND COPIES

| PUBLIC |  |
| :--- | ---: |
| $\quad$ Subscriptions: |  |
| $\quad$ Paper or fiche | 202-512-1800 |
| $\quad$ Assistance with public subscriptions | $\mathbf{5 1 2 - 1 8 0 6}$ |
| General online information | 202-512-1530; 1-888-293-6498 |
| Single copies/back copies: | $\mathbf{5 1 2 - 1 8 0 0}$ |
| $\quad$ Paper or fiche | $\mathbf{5 1 2 - 1 8 0 3}$ |
| Assistance with public single copies |  |
| FEDERAL AGENCIES |  |
| $\quad$ Subscriptions: |  |
| $\quad$ Paper or fiche | $\mathbf{5 2 3 - 5 2 4 3}$ |
| Assistance with Federal agency subscriptions | $\mathbf{5 2 3 - 5 2 4 3}$ |

## FEDERAL REGISTER WORKSHOP

## THE FEDERAL REGISTER: WHAT IT IS AND

 HOW TO USE ITFOR: Any person who uses the Federal Register and Code of Federal Regulations.
WHO: Sponsored by the Office of the Federal Register.
WHAT: Free public briefings (approximately 3 hours) to present:

1. The regulatory process, with a focus on the Federal Register system and the public's role in the development regulations.
2. The relationship between the Federal Register and Code of Federal Regulations.
3. The important elements of typical Federal Register documents.
4. An introduction to the finding aids of the FR/CFR system.

WHY: To provide the public with access to information necessary to research Federal agency regulations which directly affect them. There will be no discussion of specific agency regulations.

## WASHINGTON, DC

WHEN:
WHERE:
April 18, 2000
Conference Room, Suite 700
Office of the Federal Register
800 North Capitol Street, NW.
Washington, DC
(3 blocks north of Union Station Metro)
RESERVATIONS: 202-523-4538

Printed on recycled paper.

## Contents

## Federal Register

Vol. 65, No. 68
Friday, April 7, 2000

## Administration on Aging

See Aging Administration

## Aging Administration

## Notices

Agency information collection activities:
Submission for OMB review; comment request, 18336

## Agriculture Department

See Animal and Plant Health Inspection Service
See Cooperative State Research, Education, and Extension Service
See Farm Service Agency
See Forest Service
See National Agricultural Statistics Service
NOTICES
Agency information collection activities:
Submission for OMB review; comment request, 1827218273

## Animal and Plant Health Inspection Service NOTICES

Agency information collection activities:
Proposed collection; comment request, 18273-18274

## Architectural and Transportation Barriers Compliance Board

NOTICES
Meetings:
Public Rights-of-Way Access Advisory Committee, 18280

## Army Department

See Engineers Corps
NOTICES
Meetings:
Armed Forces Epidemiological Board, 18315-18316
Patent licenses; non-exclusive, exclusive, or partially exclusive:
Bulova Technologies, L.L.C., 18316
Liquid explosive composition of nitromethane, etc., 18316
Psuedo-monolithic laser with intracavity optical parametric oscillator, 18316

## Blind or Severely Disabled, Committee for Purchase From

 People Who AreSee Committee for Purchase From People Who Are Blind or Severely Disabled

## Centers for Disease Control and Prevention

NOTICES
Breath responsive powered air-purifying respirators; approval applications; evaluation criteria and standard test procedures, 18336

## Children and Families Administration <br> NOTICES

Grants and cooperative agreements; availability, etc.: Head Start-

Early Head Start programs; correction, 18336-18337
Organization, functions, and authority delegations:
Developmental Disabilities Administration, 18337-18338

## Coast Guard

RULES
Drawbridge operations:
Florida, 18242
Ports and waterways safety:
Tongass Narrows and Ketchikan Bay, AK; speed limit; safety zone redesignated as anchorage ground, 18242-18245

## PROPOSED RULES

Anchorage regulations and ports and waterways safety:
Tall Ships Delaware activities, DE, 18261-18264
Drawbridge operations:
Arkansas, 18264-18266

## Commerce Department

See Foreign-Trade Zones Board
See International Trade Administration
See National Oceanic and Atmospheric Administration

## Committee for Purchase From People Who Are Blind or Severely Disabled <br> notices

Procurement list; additions and deletions, 18280-18282

## Commodity Futures Trading Commission

 NOTICESContract market proposals:
Chicago Mercantile Exchange-
Block trading procedures, 18312-18314

## Cooperative State Research, Education, and Extension

 ServiceNOTICES
Grants and cooperative agreements; availability, etc.:
Integrated Research, Education, and Extension Competitive Grants Program-
National Food Safety Initiative, 18838-18849
Pest Management, 18822-18835
Water Quality, 18852-18863
Corporation for National and Community Service NOTICES
Agency information collection activities:
Proposed collection; comment request, 18314-18315

## Defense Department

See Army Department
See Engineers Corps

## Education Department

## Notices

Grants and cooperative agreements; availability, etc.:
Bilingual education and minority languages affairs-
Field-Initiated Research Program; correction, 1831718319

## Employment Standards Administration

## NOTICES

Minimum wages for Federal and federally-assisted construction; general wage determination decisions, 18352-18354

## Energy Department

See Federal Energy Regulatory Commission

## NOTICES

Meetings:
Biological and Environmental Research Advisory Committee, 18320
Environmental Management Site-Specific Advisory Board-
Los Alamos National Laboratory, NM, 18320
Pantex Plant, TX, 18320-18321

## Engineers Corps

## NOTICES

Environmental statements; notice of intent:
John Redmond Lake, KS; water storage reallocation study, 18316-18317

## Environmental Protection Agency <br> RULES

Air programs; approval and promulgation; State plans for designated facilities and pollutants:
Mississippi, 18252-18255
Pennsylvania, 18249-18252
Air quality implementation plans; approval and promulgation; various States:
Georgia, 18245-18249
PROPOSED RULES
Air programs; approval and promulgation; State plans for designated facilities and pollutants:
Mississippi, 18266-18267
Pennsylvania, 18266
Air quality implementation plans; approval and promulgation; various States:
Georgia, 18266
notices
Environmental statements; availability, etc.:
Agency statements-
Comment availability, 18321
Weekly receipts, 18321-18322
Pesticide, food, and feed additive petitions:
Ecolab Inc., 18322-18328
Novartis Crop Protection, Inc., 18328-18332
Superfund; response and remedial actions, proposed settlements, etc.:
Solvent Recovery Corp. Site, KS, 18332

## Executive Office of the President

See Trade Representative, Office of United States

## Farm Service Agency

## notices

Agency information collection activities:
Proposed collection; comment request, 18274

## Federal Aviation Administration <br> proposed rules

Airworthiness directives:
Airbus, 18258-18259
British Aerospace, 18260-18261

## Federal Communications Commission <br> RULES

Common carrier services:
Communications Assistance for Law Enforcement Act; implementation; correction, 18255-18256

Wireless telecommunications services-
Cellular Telecommunications Industry Association's petition for forbearance from commercial mobile radio services number portability obligations, etc., 18256-18257

## notices

Agency information collection activities:
Proposed collection; comment request, 18332-18333
Common carrier services:
Wireless telecommunications services-
Personal communications services; C block broadband spectrum auctions; reconsideration petitions, 18333-18334
Rulemaking proceedings; petitions filed, granted, denied, etc., 18334-18335

## Federal Energy Regulatory Commission RULES

Electric utilities (Federal Power Act):
Rate schedules filing-
Electric rate schedule sheets; designation procedures, 18221-18229
Section 205 filings; intervention and protest time frame; correction, 18229
Natural gas companies (Natural Gas Act):
Facilities construction and operation, etc.; filing of applications; correction, 18221
Practice and procedure:
Off-the-record communications Correction, 18229-18230

## Federal Highway Administration <br> notices

Agency information collection activities:
Proposed collection; comment request, 18421

## Federal Railroad Administration

notices
Agency information collection activities:
Submission for OMB review; comment request, 1842118422

## Federal Reserve System

notices
Banks and bank holding companies:
Formations, acquisitions, and mergers, 18335
Permissible nonbanking activities, 18335
Meetings; Sunshine Act, 18335-18336

## Federal Transit Administration

## NOTICES

Agency information collection activities:
Proposed collection; comment request, 18421

## Financial Management Service

See Fiscal Service

## Fiscal Service <br> RULES

Federal management services:
Automated Clearing House; Federal agencies
participation, 18866-18869

## Fish and Wildlife Service

notices
Environmental statements; availability, etc.:
Incidental take permitsBastrop County, TX; Houston toad, 18347-18348

Environmental statements; notice of intent:
Bair Island, Don Edwards San Francisco Bay National Wildlife Refuge, CA; restoration and management plan; correction, 18349

## Food and Drug Administration

RULES
Medical devices:
Dental devices-
Laser fluorescence caries detection device, 1823418236
Gastroenterology-urology devices-
Nonimplanted, peripheral electrical continence device, 18236-18237
Hematology and pathology devices-
Over-the-counter test sample collection systems for drugs of abuse testing; reclassification and designation as restricted devices, 18230-18234

## notices

Agency information collection activities:
Submission for OMB review; comment request, 1833818340
Meetings:
Medical Devices Advisory Committee, 18340-18341

## Foreign-Trade Zones Board

NOTICES
Applications, hearings, determinations, etc.:
Florida, 18282
Nebraska
Zeneca, Inc.; agricultural chemical products facility, 18282-18283
South Carolina
Fuji Photo Film, Inc.; imaging and information products manufacturing and distribution facilities, 18283

## Forest Service

## NOTICES

Committees; establishment, renewal, termination, etc.:
Lake Tahoe Basin Federal Advisory Committee, 1827418275
Environmental statements; notice of intent:
Rogue River National Forest, OR, 18275-18276
Wallowa-Whitman National Forest, OR, 18276-18278

## Health and Human Services Department

See Aging Administration
See Centers for Disease Control and Prevention
See Children and Families Administration
See Food and Drug Administration
See Health Care Financing Administration
See Substance Abuse and Mental Health Services Administration

## Health Care Financing Administration <br> RULES <br> Medicare:

Hospital outpatient services; prospective payment system, 18434-18820
NOTICES
Medicare:
Hospital Outpatient Prospective Payment System; special payment for new technologies and certain drugs, biologicals, and medical devices, 18341
Lifestyle Modification Program Demonstration Project; implementation
Cancellation, 18342

## Housing and Urban Development Department NOTICES

Agency information collection activities:
Proposed collection; comment request, 18344-18345
Submission for OMB review; comment request, 1834518347
Grants and cooperative agreements; availability, etc.:
Facilities to assist homeless-
Excess and surplus Federal property, 18347
Immigration and Naturalization Service
RULES
Irish Peace Process Cultural and Training Program; establishment
Correction, 18432

## Interior Department

See Fish and Wildlife Service
See Land Management Bureau
See Minerals Management Service
See National Park Service
See Surface Mining Reclamation and Enforcement Office

## Internal Revenue Service <br> NOTICES

Agency information collection activities:
Proposed collection; comment request, 18428-18429
Inflation adjustment factor, nonconventional source fuel credit, and reference price for 1999 CY, 18429-18430
Meetings:
Citizen Advocacy PanelsBrooklyn District, 18430 Midwest District, 18430 Pacific-Northwest District, 18430-18431 South Florida District, 18430

## International Trade Administration

notices
Antidumping:
Carbon steel wire rope fromMexico, 18283-18285
Corrosion-resistant carbon steel flat products fromCanada, 18286-18290
Cut-to-length carbon steel plate fromBelgium, 18292-18293 Canada, 18290-18292 Germany, 18294
Large newspaper printing presses and components, assembled or unassembled, fromGermany, 18294-18295
Stainless steel bar fromIndia, 18295-18296
Steel wire rope fromKorea, 18296-18300
Sulfanilic acid fromChina, 18300-18301
Welded carbon steel pipes and tubes fromThailand, 18301-18304
Countervailing duties:
Carbon steel products fromSweden, 18304-18305
Cut-to-length carbon steel plate fromSpain, 18307-18309 Sweden, 18305-18307 United Kingdom, 18309-18310

International Trade Commission
NOTICES
Meetings; Sunshine Act, 18350-18351

## Justice Department

See Immigration and Naturalization Service
NOTICES
Pollution control; consent judgments:
Arnet Realty Co. et al., 18351
Gulf States Steel, Inc., 18351
Young, Jane A., et al., 18351-18352

## Labor Department

See Employment Standards Administration
See Pension and Welfare Benefits Administration

## Land Management Bureau

Notices
Meetings:
Resource Advisory Councils-
Northwest Colorado, 18349

## Legal Services Corporation

## notices

Meetings; Sunshine Act, 18377-18378

## Minerals Management Service

RULES
Outer Continental Shelf; oil, gas, and sulphur operations:
Documents incorporated by reference; update; technical amendment
Correction, 18432

## NOTICES

Outer Continental Shelf operations:
Western Gulf of Mexico-
Oil and gas lease sales, 18349

## Mississippi River Commission

NOTICES
Meetings; Sunshine Act; correction, 18432

## National Agricultural Statistics Service

NOTICES
Agency information collection activities:
Proposed collection; comment request, 18278-18280
Meetings:
Agriculture Statistics Advisory Committee, 18280

## National Highway Traffic Safety Administration PROPOSED RULES

Insurer reporting requirements:
Insurers required to file report; lists, 18267-18270
National Oceanic and Atmospheric Administration
RULES
Fishery conservation and management:
Alaska; fisheries of Exclusive Economic ZoneAtka mackerel, 18257

## PROPOSED RULES

Fishery conservation and management:
Magnuson-Stevens Act provisions-
Domestic fisheries; exempted fishing permits for experimental fishing, 18270-18271

## NOTICES

Permits:
Endangered and threatened species, 18310-18312

## National Park Service <br> NOTICES

National Register of Historic Places:
Pending nominations, 18349-18350
Reports and guidance documents; availability, etc.:
Director's Order 47; soundscape preservation and noise management, 18350

Director's Order 87; non-NPS Federal-Aid roads and highways in NPS units, 18350

## National Science Foundation

NOTICES
Meetings:
Public Affairs Advisory Group, 18378
Nuclear Regulatory Commission
Notices
Meetings:
Reactor Safeguards Advisory Committee, 18383
Safety analysis and evaluation reports; availability, etc.:
Westinghouse Electric Co., 18383
Applications, hearings, determinations, etc.:
Consolidated Edison Co. of New York, Inc., 18378-18379
Consumers Energy Co., 18379-18380
North Atlantic Energy Service Corp. et al., 18380-18381
Northeast Nuclear Energy Co. et al., 18381-18382
U.S. Army Jefferson Proving Ground Site, IN, 1838218383

## Office of United States Trade Representative

See Trade Representative, Office of United States
Pension and Welfare Benefits Administration notices
Employee benefit plans; prohibited transaction exemptions:
McPhail, H. Ray, et al., 18354-18377
Pension Benefit Guaranty Corporation
notices
Agency information collection activities:
Proposed collection; comment request, 18383-18384

## Public Debt Bureau

See Fiscal Service

## Public Health Service

See Centers for Disease Control and Prevention
See Food and Drug Administration
See Substance Abuse and Mental Health Services Administration

## Research and Special Programs Administration notices

Hazardous materials transportation:
Preemption determinations-
Institute of Makers of Explosives, 18422-18426
Securities and Exchange Commission
Notices
Agency information collection activities:
Submission for OMB review; comment request, 1838418385
Investment Company Act of 1940:
Deregistration applications-
MIMLIC Cash Fund, Inc., et al., 18391-18393
Exemption applications-
Touchstone Advisors, Inc., et al., 18393-18395
Self-regulatory organizations; proposed rule changes:
American Stock Exchange LLC, 18395-18397
Chicago Board Options Exchange, Inc., 18397-18399
Depository Trust Co., 18399-18401
Emerging Markets Clearing Corp., 18401
Municipal Securities Rulemaking Board, 18401-18405
National Association of Securities Dealers, Inc., 1840518412

New York Stock Exchange, Inc., 18412-18416
Philadelphia Stock Exchange, Inc., 18416-18417
Applications, hearings, determinations, etc.:
Alexander Hamilton Life Insurance Co. of America et al., 18385-18390
Public utility holding company filings, 18390-18391

## Social Security Administration

## notices

Agency information collection activities:
Proposed collection and submission for OMB review; comment request, 18418

## Statistical Reporting Service

See National Agricultural Statistics Service

## Substance Abuse and Mental Health Services Administration

notices
Agency information collection activities:
Submission for OMB review; comment request, 18342
Federal agency urine drug testing; certified laboratories meeting minimum standards, list, 18342-18344

## Surface Mining Reclamation and Enforcement Office RULES

Permanent program and abandoned mine land reclamation plan submissions:
Illinois, 18237-18242

## Surface Transportation Board

 NOTICESMotor carriers:
Control applications-
Laidlaw Inc., 18426-18427
Railroad operation, acquisition, construction, etc.:
Colorado Transportation Department, 18427
Hammond, Court, et al., 18428

## Trade Representative, Office of United States notices

Generalized System of Preferences:
Annual product and country eligibility practices review (1999)-

Petitions submission deadline and hearings schedule, 18418-18421

## Transportation Department

See Coast Guard
See Federal Aviation Administration
See Federal Highway Administration
See Federal Railroad Administration
See Federal Transit Administration
See National Highway Traffic Safety Administration
See Research and Special Programs Administration
See Surface Transportation Board
Treasury Department
See Fiscal Service
See Internal Revenue Service

## Separate Parts In This Issue

## Part II

Health and Human Services Department, Health Care Finance Administration, 18433-18820

## Part III

Agriculture Department, Cooperative State Research, Education, and Extension Service, 18821-18835

## Part IV

Agriculture Department, Cooperative State Research, Education, and Extension Service, 18837-18849

## Part V

Agriculture Department, Cooperative State Research, Education, and Extension Service, 18851-18863

## Part VI

Treasury Department, Fiscal Service, 18865-18869

## Reader Aids

Consult the Reader Aids section at the end of this issue for phone numbers, online resources, finding aids, reminders, and notice of recently enacted public laws.

## CFR PARTS AFFECTED IN THIS ISSUE

A cumulative list of the parts affected this month can be found in the
Reader Aids section at the end of this issue.


# Rules and Regulations 

Federal Register
Vol. 65, No. 68
Friday, April 7, 2000

This section of the FEDERAL REGISTER contains regulatory documents having general applicability and legal effect, most of which are keyed to and codified in the Code of Federal Regulations, which is published under 50 titles pursuant to 44 U.S.C. 1510.

The Code of Federal Regulations is sold by the Superintendent of Documents. Prices of new books are listed in the first FEDERAL REGISTER issue of each week.

## DEPARTMENT OF ENERGY

## Federal Energy Regulatory Commission

## 18 CFR Part 2

[Docket No. RM98-9-000; Order No. 603]
Revision of Existing Regulation Under Part 157 and Related Sections of the Commission's Regulations Under the Natural Gas Act; Correction

March 31, 2000.
agency: Federal Energy Regulatory Commission, DOE.
ACTION: Final rule; correction.
SUMMARY: The Federal Energy Regulatory Commission
("Commission'") published in the
Federal Register of May 14, 1999, a
document updating its regulations governing the filing of applications for the construction and operation of facilities to provide service or to abandon facilities or service under section 7 of the Natural Gas Act. Two amendatory instructions for Part 2 were incorrectly stated. This document corrects those amendatory instructions.
DATES: Effective on April 7, 2000.
FOR FURTHER INFORMATION CONTACT: Julia
A. Lake, Attorney, Federal Energy Regulatory Commission, 888 First Street, NW, Washington, DC 20426; phone: 202-208-2019; e-mail: julia.lake@ferc.fed.us.
sUPPLEMENTARY INFORMATION: The Federal Energy Regulatory Commission ("Commission") published in the Federal Register of May 14, 1999, a document updating its regulations governing the filing of applications for the construction and operation of facilities to provide service or to abandon facilities or service under section 7 of the Natural Gas Act. Two amendatory instructions for Part 2 were
incorrectly stated. This document corrects those amendatory instructions.

In rule FR Doc. 99-11247, published on May 14, 1999 ( 64 FR 26571), make the following corrections.

1. On page 26603, in the first column, correct amendatory instruction 2 to read as follows:
'" 2 . In § 2.1, paragraph (a)(1)(viii) is removed."
2. On page 26603, in the first column, correct amendatory instruction 3 to read as follows:
" 3 . In § 2.55 , paragraph (a) is revised; (b)(1)(ii) is revised; (b)(4) heading is removed; (b)(4)(i) is removed and (b)(4)(ii) is redesignated as (b)(4); and paragraph (d) is removed and reserved, to read as follows:"

Dated: March 31, 2000.
Linwood A. Watson, Jr.,
Acting Secretary.
[FR Doc. 00-8457 Filed 4-6-00; 8:45 am]
BILLING CODE 6717-01-M

## DEPARTMENT OF ENERGY

## Federal Energy Regulatory Commission

## 18 CFR Part 35

[Docket No. RM99-12-000; Order No. 614]

## Designation of Electric Rate Schedule Sheets

Issued March 31, 2000.
AGENCY: Federal Energy Regulatory Commission, DOE.
ACTION: Final rule.
summary: The Federal Energy
Regulatory Commission (Commission) is amending its regulations to require prospectively the inclusion of a proposed designation for all rate schedule sheets filed with the Commission by public utilities. This rule will streamline rate schedule sheet designation procedures for the Commission and the electric industry. This rule will also conform public utility tariff filing procedures with those for interstate natural gas and oil pipelines. This revision to the regulations is necessary to accommodate the movement toward an integrated energy industry and to facilitate the development of common standards for the electronic filing of all electric, gas, and oil rate schedule sheets.
effective date: This final rule will become effective on June 1, 2000.

## FOR FURTHER INFORMATION CONTACT:

H. Keith Pierce (Technical Information), Office of Markets, Tariffs, and Rates, Federal Energy Regulatory Commission, 888 First Street, NE, Washington, DC 20426, (202) 2080525
Kathleen E. Nieman (Technical Information), Office of Markets, Tariffs, and Rates, Federal Energy Regulatory Commission, 888 First Street, NE, Washington, DC 20426, (202) 208-1070

Roger M. Gibian (Legal Information), Office of the General Counsel, Federal Energy Regulatory Commission, 888 First Street, NE, Washington, DC
20426, (202) 219-3108

## SUPPLEMENTARY INFORMATION:

## I. Introduction

The Federal Energy Regulatory Commission (Commission) is amending its regulations to require prospectively the inclusion of a proposed designation ${ }^{1}$ on all rate schedule sheets filed with the Commission by public utilities. ${ }^{2}$ This rule will streamline rate schedule sheet designation procedures for the Commission and the electric industry.
This rule will conform the procedures for identifying public utility tariff filings with those for interstate natural gas and oil pipelines. ${ }^{3}$ This revision to the

[^0]Continued
regulations is necessary to accommodate the movement toward an integrated energy industry and to facilitate the development of common standards for the electronic filing of all electric, gas, and oil rate schedule sheets. However, it has not been determined what the common standards for electronic filing will be or the format that will be followed. For example, it has not been decided whether a page-based or non-page-based system would be most effective. These determinations will be developed by the Commission as it moves forward with electronic filing.

## II. Background

## A. Notice of Proposed Rulemaking

This proceeding began with the issuance of a Notice of Proposed Rulemaking (NOPR) on October 28, 1999. ${ }^{4}$ The NOPR addressed the following issues dealing with streamlining rate schedule sheet designation procedures for the Commission and the electric industry: (1) Requirements for identification and numbering of tariffs to be submitted by the filing utilities; and (2) rejection of materials that fail to comply with the applicable requirements.

Comments were filed by four commenters. Three of the comments were generally favorable to the proposed changes. The other comment expressed concerns with the proposed changes. The comments will be discussed below on an issue-by-issue basis.

## B. Notice of Proposed Rulemaking's Origin

Section 205(c) of the Federal Power Act (FPA) ${ }^{5}$ and section 4(c) of the Natural Gas Act (NGA) ${ }^{6}$ provide that the Commission is charged with the responsibility to keep schedules showing all rates and charges, in such form as the Commission may designate, for any jurisdictional transmission or
compliance filing (Substitute Third Revised Sheet
No.'")). The gas guidelines also require additional information on each rate schedule sheet to further clarify what currently effective sheets will be changed if the filing is accepted and the date the applicant proposes for the rate schedule sheet to become effective. This information is necessary to determine both the utilities' compliance with their statutory notice obligation and when the
Commission must act under the FPA. Because the Commission's experience with the gas guidelines has been satisfactory, both in terms of the pipelines ability to conform with the guidelines and the Commission's ability to administer the gas program, the Commission proposed to use, and now has decided to use, the gas guidelines as the model for the electric program.
${ }^{4}$ Designation of Electric Rate Schedule Sheets, Notice of Proposed Rulemaking, 64 FR 60390 (November 5, 1999), FERC Stats. \& Regs. II 32,547 (October 28,1999).
${ }^{5} 16$ U.S.C. $824 \mathrm{~d}(\mathrm{c})$.
${ }^{6} 15$ U.S.C. 717(c).
sale of electricity and for any jurisdictional transportation or sale of natural gas, respectively. Similarly, section 6 of the Interstate Commerce Act (ICA) ${ }^{7}$ requires that the rate schedules for oil pipelines be published, filed, and posted in the form and manner
prescribed by the Commission. Parts 35, 154, and 341 of the Commission's Rules and Regulations ${ }^{8}$ implement these sections of the FPA, NGA, and ICA, respectively.

Pursuant to current Commission regulations under Parts 154 and 341, gas and oil pipelines are required to include proposed pagination on all tariff sheets filed with the Commission; the proposed pagination must be unique to the pertinent tariff sheets, i.e., the proposed pagination is newly created and has never been used previously. Additionally, both Parts 154 and 341 require that the proposed pagination convey information as to whether the tariff sheet being filed contains changes proposed by the pipeline or is filed in compliance with a Commission order. Gas or oil tariff sheets filed without pagination or incorrect pagination are deemed incomplete, and may be rejected as such. ${ }^{9}$

With regard to public utility rate schedules, Part 35 of the Commission's regulations provides that every rate schedule filing under the FPA "will be numbered by the Commission and the filing public utility advised of the Rate Schedule FERC number." ${ }^{10}$ Therefore, pursuant to that regulation, the Commission routinely designates each rate schedule filed by a public utility and informs the utility of the designation.

## III. Discussion

In this rule, we are revising 18 CFR Part 35. These revisions include: (1) Amending § 35.5 to allow the Director of the Office of Markets, Tariffs, and Rates (Director) to reject rate filings that fail to comply with Part 35; ${ }^{11}$ (2) revising $\S 35.9$ to provide instructions on how to identify and number proposed rate schedule sheets; and (3) removing and reserving § 35.18 .

This rule will streamline tariff sheet ${ }^{12}$ designation procedures for the

[^1]Commission and the electric industry. Under current procedures, a significant amount of staff time is required to assign designations for public utility tariff sheets. Staff is required to research underlying tariff sheets and proceedings to identify the status of the superseded tariff sheet (effective without suspension, suspended, or effective under suspension) and the nature of the proposed tariff sheet (a proposed rate change or a compliance filing) in order to establish the proper designation. This information must then be conveyed to the utility and the public through issuance of Commission orders.

Under the designation procedures established by this rule, staff will only need to confirm the appropriateness of the proposed designation. Commission orders, including delegated orders, will not have to list tariff sheets
individually, because the filings and the tariff sheets will be cross-referenced electronically. This will simplify the identification of any specific tariff sheet for any purpose from the time of filing. Also, the proposed designation procedure will allow tariff sheets to be more easily kept up to date, with superseded sheets archived for future reference.

Filing requirements for tariff sheets for the electric, gas, and oil industries have evolved independently over time. However, with the movement toward an integrated energy industry it now makes sense to have a common standard for all tariff sheets filed with the Commission. Further, as the Commission increases its use of electronic media for filing, storage, retrieval, and tracking of information and documents, greater uniformity in filing procedures, wherever practical, will greatly expedite and simplify this conversion to electronic media. Conforming the requirements for public utilities, interstate natural gas pipelines, and oil pipelines will position the Commission and the affected industries for a smooth transition to having the tariff sheets filed, tracked, and archived electronically. In addition, designing the electronic format for these filings will be simplified if all tariff sheets are filed uniformly.

The Commission believes that the transition from the existing designation procedure to that embodied by this rule will occur in an efficient manner if currently effective and paginated/ designated tariff sheets remain as filed. However, if a change is proposed in an existing tariff or rate schedule, the entire

[^2]tariff or rate schedule must be re-filed according to the new system. ${ }^{13}$ In this way, as tariff sheets are replaced over time, the old designations will disappear and the new system will be implemented in an orderly and efficient manner. Further, changes would be prospective only, alleviating any need to retroactively alter, modify, or re-file the tariff sheets currently on file.
"Tariff, Rate Schedule, and Service Agreement Pagination Guidelines" (Designation Guidelines) have been developed and are attached hereto as an appendix. The guidelines offer definitions and examples designed to assist interested parties during the period of transition. The guidelines also provide the name and telephone number of a staff person who can answer questions and provide additional guidance.

Comments are discussed in the following sections.

## A. Prospective Designation by Public Utilities of Tariff Sheets

## Introduction

Currently, staff is responsible for assigning designations for public utility tariff sheets. In the NOPR, we noted that a significant amount of staff time is required to establish the proper designation. Accordingly, we proposed to revise our regulations to require that the public utilities prospectively include proposed designation for all tariff sheets filed with the Commission.

## Comments

Southern Company Services, Inc. (Southern), Wisconsin Public Service Corporation (WPSC), and New England Power Company and Montaup Electric Company (NEP Companies) all filed comments generally supporting the Commission's efforts to standardize the designation of electric tariff sheets. Consumers Energy Company (Consumers) commented on the proposed requirement that public utilities, prospectively, include in their filings a proposed designation for all tariff sheets filed with the Commission. Consumers states that it does not support utility designation for nonstandard contracts and service agreements. Consumers suggests that it would be best for staff to continue to designate non-standard contracts and service agreements. Consumers argues that it is sometimes unclear as to whether the contracts will be deemed a new agreement for a new service or a supplement to an existing service. Also, Consumers states that, when the

[^3]contracts are drafted, it is not sure which agreements will be executed and when and in which order they will be filed. Consumers also questions the usefulness of retaining the sheet identifying canceled tariff sheets. Consumers argues that, once terminated, canceled tariff sheets will never have a future use. Consumers further indicates that, for electric utilities, volume identifications are not used.

## Commission Conclusion

The Commission is not persuaded by Consumers' argument that staff should continue to assign tariff sheet designations in certain circumstances. It is the responsibility of the utilities to clearly identify in their filings the nature of the services they are proposing and how those services relate to other services, if at all. It is not uncommon for there to be ambiguity as to the nature of a contract or when a tariff sheet will become effective. These issues, though, are separate from the issue of who should designate a tariff sheet. And, as an ultimate check, the Commission will review proposed designations to confirm their accuracy, and retains the right to require corrections to proposed designations that it believes are inaccurate.

The Designation Guidelines provide, in general, for proposed tariff sheets to identify the effective sheets to be superseded, except when the successive filings reflect underlying (and still pending) filings, in which case the utility should list the underlying but still pending sheets as the superseding sheets. (See Appendix, Example No. 1.) On joint services, each utility offering a service must file its own tariff sheets. This means that jointly offered services most likely will have different tariff sheet designations.

Consumers has a legitimate point concerning volume identification. Therefore, the Commission will permit the use of the rate schedule number as the identifier in the header of each tariff sheet.

The Commission is not directing utilities to use reserved tariff sheets in the future. Rather, the utilities may, at their option or as the needs of other tariff sheets require, use the reserved sheets, provided unique designations are applied.

Finally, Designation Guideline paragraph 11 and Example No. 7 originally provided that the canceling tariff sheet should be designated with the last sheet number of the canceled sheets. Consumers notes that this instruction differs from the Gas Guidelines’ instruction for the first of the canceled sheets, and recommends
that the Commission adopt the Gas Guidelines for the sake of continuity between the gas pipeline and utility programs. The Commission agrees, and will do so.

## B. Consistency Among Filings

## Introduction

Currently, public utility filing requirements differ from those for natural gas and oil pipelines. In the NOPR, we proposed conforming public utility filing procedures with those for natural gas and oil pipelines. We explained that this revision would be necessary to accommodate the movement toward an integrated energy industry and to facilitate the development of common standards for the electronic filing of all electric, gas, and oil rate schedule sheets.

## Comments

Consumers states that this rule will not make electric, gas pipeline, and oil pipeline rate filings more consistent. Consumers states that the proposed designation system goes beyond the designation system used for gas pipelines. ${ }^{14}$ Consumers recommends that the Commission adopt the procedures used for gas pipeline filings and not require the filing of electric service agreements.

## Commission Conclusion

Consumers misconstrues the limits of this rule change. This rule is limited to public utility tariff sheet designations. The continued convergence of the gas and electric industries and markets, and the Commission's ongoing involvement in this convergence, are likely to require additional, future modifications to the Commission's procedures and regulations. This rule is but one step. As such, public utilities will continue to be required to file all service agreements. This is no different from what was required of gas pipelines prior to the implementation of Order No. 516. ${ }^{15}$

## C. Non-Standard Contracts and Service Agreements <br> Comments

Consumers questions the need to apply tariff sheet designations to nonstandard electric service agreements. Consumers argues that because gas pipeline companies are not required to paginate non-standard contracts, public

[^4]utilities should not be required to do so either. Consumers, in further support of this request, claims that, because nonstandard service agreements are rarely, if ever, changed, the tariff sheet designation requirement is unnecessary. If designation is to be required, Consumers requests that the issue be deferred and taken up as part of the Commission's future efforts to create a standardized electronic tariff for public utilities, gas pipelines, and oil pipelines.

## Commission Conclusion

The Commission's intent in this rule is, in part, to improve the level of regulatory convergence. While Consumers may be correct in stating that most non-conforming contracts and service agreements will not change once filed, the Commission will not speculate as to which terms of service or rates may be revised. However, the Commission recognizes that service agreements constitute a large portion of the tariff filings made in the electric program. Therefore, to ease the administrative burden on filing utilities, this rule will not require the individual pages of service agreements to be paginated. However, the Commission will retain the requirement for utilities to designate service agreements. If a service agreement is revised or modified, the utility must file a complete revised service agreement with a new designation comporting with the Guidelines.

## D. Delegated Authority to Reject Tariff Filings and Related Issues

## Introduction

Currently, our regulations permit the Secretary to reject any material submitted for filing with the Commission that patently fails to substantially comply with the applicable requirements. ${ }^{16}$ The NOPR proposed a new $\S 35.5$ (b), which would permit the Director, pursuant to delegated authority, to reject rate filings that fail to comply with Part 35 of the Commission's regulations.

## Comments

Consumers, NEP Companies, WPSC, and Southern express concern that the Director may exercise the delegated authority to reject filings because of minor errors in the application. Consumers proposes a modification to the regulation that would permit the Director to reject only "patently deficient" filings. WPSC and Southern request that the Commission clarify that the Director could reject a tariff sheet,

[^5]but not the rate filing in total. The NEP Companies also suggest a six-to twelvemonth transition period. All parties filing comments expressed concern that rejection due to a minor error would result in delayed effective dates for rate changes or new services, thus causing economic harm to utilities and customers.

Consumers also claims that the authority in $\S 35.5$ (b) goes beyond the Director of the Office of Electric Regulation's existing delegated authority in 18 CFR § $375.308(\mathrm{a})(3) .^{17}$ Consumers claims that § 375.308(a)(3) does not delegate authority to reject any non-compliant filing, but only those that patently fail to comply. Consumers claims that a simple failure to designate, or a mis-designation, does not warrant rejection. ${ }^{18}$

## Commission Conclusion

New §35.5(b) references § $375.307(\mathrm{k})(3)$, and the Director may, pursuant to $\S 375.307(\mathrm{k})(3)$, reject any rate filing not containing a request for waiver if it "fails patently to comply with applicable statutory requirement or Commission rules, regulations and orders." Accurate designation of tariff sheets is essential; it allows the Commission and the public to identify the tariff sheets (and rates) the utilities propose to supersede and when they will be superseded, as well as the proposed replacement tariff sheets (and rates) and when they will go into effect. ${ }^{19}$ It is thus incumbent upon utilities to unambiguously identify their proposed changes in a manner conforming to the Commission's regulations including properly formatting and designating their proposed tariff sheets. The proposed effective dates of utilities' proposals, in particular, are usually a function of the

[^6]dates the utilities file and thus within the utilities' control. It is not the function of this Commission to speculate on the nature of an applicant's filing (for example, what a utility intends as the effective date,) nor is it our function to, on our own, perfect a utility's application.

The Commission anticipates the need, in the beginning, to provide assistance to utilities so they may become accustomed to the procedures established under the Designation Guidelines. The Commission has identified staff that affected utilities may contact to assist in initiating this new tariff designation process. Staff will work with applicants to facilitate correct filings. However, it remains the responsibility of the applicants in the first instance to file complete and accurate applications with properly formatted and designated tariff sheets.

Moreover, determinations as to whether tariff sheets are properly formatted and designated are matters properly delegated to the Director. Utilities may, of course, request rehearing of Director actions with which they disagree. ${ }^{20}$

Finally, the Commission will not establish a definitive transition period. Instead, as when the Commission introduced new pagination guidelines for the gas program, the Commission will rely on the Director to manage the transition.

## E. Issuance Date and Issuing Office

## Introduction

Section 35.9(b)(3) requires tariff sheets to include the issuing officer and the issuance date.

## Comments

Consumers requests clarification as to whom the officer should be and what the issuance date should be. Consumers claims that it is not possible to know what the issuance date will be when contracts are negotiated. Consumers also states that negotiating and executing a non-standard contract often takes a significant amount of time and that contracts often provide for an effective date at a date certain after Commission approval. As such, Consumers continues, it is often impossible to include a specific effective date when a non-standard contract is prepared.

## Commission Conclusion

The Commission clarifies that: (1) The issuing officer is the person responsible for filing the tariff sheet with the Commission; and (2) the issuance date is the date the tariff sheet is filed with

[^7]the Commission. Consumers appears to equate tariff sheets with actual contract pages. While a utility may choose to equate a tariff sheet with a contract page, the Commission's regulations do not prescribe such an interrelationship.
It is the utilities' responsibility to propose an effective date when they file tariff sheets with the Commission. ${ }^{21}$ This rulemaking does nothing to change this pre-existing requirement.
F. Mechanics of the Transition to the New Designation System

## Comments

Consumers requests clarification of certain issues related to the mechanics of the transition to the new designation system. It asks whether designation should start over at "Original Sheet No." when the superseded sheet already has a number. Consumers also requests clarification as to the effective date of tariff sheets that are filed with no changes except those necessary to comply with the designation rule. Consumers further notes that the requirement for additional data on each tariff sheet may result in tariff language rolling over to subsequent tariff sheets that differ from the pre-existing tariffs sheets.

## Commission Conclusion

The Commission has traditionally allowed gas pipelines that are not replacing an entire volume to simply pick a designation number higher than the most recently filed effective tariff sheet. Thus, for example, a utility may decide to redesignate all tariff sheets in its first rate change as " 7 th Revised Sheet No. $\qquad$ ," provided all existing tariff sheets are designated at some figure less than seven.

The effective date for the newly designated sheets will be the effective date for the changes contained on those sheets. Superseded sheets will be effective from the effective date allowed
by the Commission up to the date they are superseded.

Rolling of text from one sheet to another is acceptable. Staff can provide additional suggestions based on the gas program's experience in order to facilitate ease in re-designation. ${ }^{22}$

## G. Effective Date

## Comments

Consumers requests that the Commission delay the effective date of the designation rule for at least 90 days, or until it is clearer how electronic filing will be accomplished. Consumers states that considerable effort is required to assemble a rate filing and it will take significant time and effort to convert existing and lengthy tariffs over to the new designation system. Further, this conversion effort cannot start until the final rule is known.

## Commission Conclusion

The Commission will make the effective date of this rule June 1, 2000. Consumers seems to believe that this rule will require the refiling of its entire tariff. That will not be required. While it is the Commission's intent to eventually update utilities' tariffs, this rule will require only incremental adjustments. As changes are made to a portion of a tariff or rate schedule (including service agreements), the Commission will require the redesignation of only that individual tariff or rate schedule (including service agreements). ${ }^{23}$ Because the Commission is not requiring utilities to refile their entire tariffs, and because the
Commission has attempted to reduce the problems associated with this transition, we do not believe it is necessary to afford additional time, beyond June 1, 2000, to adapt to the new designation procedures.

The Commission has not established a standardized electronic tariff format for the electric, gas, and oil programs.

Therefore, delaying the effective date of this final rule to coincide with the outcome of a future proceeding addressing this subject would be the equivalent of terminating this proceeding. The NOPR identified several reasons for implementing the designation requirements: streamlining the designation process; convergence of the gas and electric industries; facilitating case tracking and research as to the status of tariff sheets; preparing utilities for the eventual transition to electronic tariff filing; and reducing the amount of staff time necessary to process utility rate filings. These reasons provide adequate justification to implement this new rule, effective May 1, 2000.

Self-designation of tariff sheets also permits quicker and more certain Commission action on certain types of filings. The Commission is permitting certain gas and oil tariff sheets to go into effect by operation of law. If, upon staff review, a filing is complete, complies with all applicable statutory, regulatory, and policy requirements, is not protested by any party, requires no additional Commission action, and raises no other issues, these tariff sheets can go into effect without suspension or refund obligation and without an order from the Commission. Designation of utility tariff sheets will permit the same process to apply to the electric program.

## IV. Information Collection Statement

The following collection of information contained in this rule is being submitted to the Office of Management and Budget (OMB) for review under section 3507(d) of the Paperwork Reduction Act of 1995. ${ }^{24}$ FERC identifies the information provided under Part 35 as FERC-516. The additional reporting burden to implement this proposed rule is as follows:


Total Additional Annual Hours for Collection (Reporting + Recordkeeping, if appropriate) $=8,320$.

The total annual reporting burden for FERC-516 under the current regulations is 536,800 hours. Currently, the

[^8]Commission devotes approximately 8,320 hours per year to assign tariff designations to an estimated 2,934 filings per year. The proposed change will require the utilities to perform the designation duties currently performed

[^9]by Commission staff. There will, therefore, be an increase in reporting burden from 536,800 hours to 545,120 hours as utilities adopt the proposed designation system for changes proposed in existing tariffs or rate

[^10]schedules and/or if an entire tariff or rate schedule must be re-filed. ${ }^{25}$

Information Collection Costs: The Commission has projected the average annualized cost for all respondents to be:
Annualized Capital/Startup Costs \$205,424 (tariff designations)
Annualized Costs (Operations \&
Maintenance): \$28,359,815 (tariff + rate schedule filings)
Total Annualized Costs: $\$ 28,565,239$
(tariff designations + rate schedule filings)
The OMB regulations require OMB to approve certain information collection requirements imposed by agency rule. ${ }^{26}$ Accordingly, pursuant to OMB regulations the Commission has provided notice of this information collection to OMB.
Title: FERC-516, Electric Rate Schedule Filings.
Action: Data Collection.
OMB Control No.: 1902-0096. The respondent shall not be penalized for failure to respond to this collection of information unless the collection of information displays a valid OMB control number.
Respondents: Business or other for profit, including small businesses.
Frequency of Responses: On Occasion.
Necessity of Information: The proposed rule revises the requirements contained in 18 CFR Part 35.
Internal Review: The Commission has assured itself, by means of its internal review, that there is specific, objective support for the burden estimates associated with the information requirements. Section 205 of the Federal Power Act (FPA) (16 USC 824d) requires that rates, terms, and conditions for jurisdictional service be filed with the Commission. In addition, the Commission uses the information provided to make determinations under sections 205 and 206 of the FPA (16 USC 824d-e) as to whether rates, terms and conditions of jurisdictional service are unjust, unreasonable, or unduly discriminatory or preferential and to prescribe just and reasonable rates, terms and conditions. Failure to issue these requirements would mean the Commission is not meeting its statutory obligations under Sections 205 and 206

[^11]of the FPA. These requirements also conform to the Commission's plan for the efficient collection, communication, and management of information for the electric industry.

Interested persons may obtain information on the reporting requirements by contacting the following: Federal Energy Regulatory Commission, 888 First Street, NE, Washington, DC 20426, [Attention: Michael Miller, Office of the Chief Information Officer, Phone: (202) 2081415, fax: (202) 208-2425, email: mike.miller@ferc.fed.us].

For submitting comments concerning the collection of information and the associated burden estimate, please send your comments to the contact listed above and to the Office of Management and Budget, Office of Information and Regulatory Affairs, Washington, DC 20503. [Attention: Desk Officer for the Federal Energy Regulatory Commission, phone: (202) 395-3087, fax: (202) 3957285.

## V. Environmental Statement

Issuance of this Final Rule does not represent a major federal action having a significant adverse effect on the human environment under the Commission's regulations implementing the National Environmental Policy Act. ${ }^{27}$ The Commission is required to prepare an Environmental Assessment or an Environmental Impact Statement for any action that may have a significant adverse effect on the human environment. The Commission has categorically excluded certain actions from these requirements as not having a significant effect on the human environment. The actions proposed to be taken here fall within categorical exclusions found in 18 CFR §380.4(a)(1) and (15).

## VI. Regulatory Flexibility Act Certification

The Regulatory Flexibility Act (RFA) (5 U.S.C. 601-612) requires rulemakings to contain either a description and analysis of the effect that a rule will have on small entities or a certification that a rule will not have a significant economic effect on a substantial number of small entities. Most filing entities do not fall within the RFA's definition of a small entity. ${ }^{28}$ Therefore, the Commission certifies that this rule will not have a significant economic impact on a substantial number of small

[^12]entities. Therefore, no regulatory flexibility analysis is required.

## VII. Document Availability

In addition to publishing the full text of this document in the Federal Register, the Commission provides all interested persons an opportunity to view and/or print the contents of this document via the Internet through FERC's Home Page (http:// www.ferc.fed.us) and in FERC's Public Reference Room during normal business hours (8:30 a.m. to 5:00 p.m. Eastern time) at 888 First Street, N.E., Room 2A, Washington, DC 20426.

From FERC's Home Page on the Internet, this information is available in both the Commission Issuance Posting System (CIPS) and the Records and Information Management System (RIMS).
-CIPS provides access to the texts of formal documents issued by the Commission since November 14, 1994.
-CIPS can be accessed using the CIPS link or the Energy Information Online icon. The full text of this document is available on CIPS in ASCII and WordPerfect 8.0 format for viewing, printing, and/or downloading.
-RIMS contains images of documents submitted to and issued by the Commission after November 16, 1981. Documents from November 1995 to the present can be viewed and printed from FERC's Home Page using the RIMS link or the Energy Information Online icon. Descriptions of documents back to November 16, 1981, are also available from RIMS-on-the-Web; requests for copies of these and other older documents should be submitted to the Public Reference Room.
User assistance is available for RIMS, CIPS, and the Website during normal business hours from our Help line at (202) 208-2222 (E-Mail to WebMaster@ferc.fed.us) or the Public Reference at (202) 208-1371 (E-Mail to public.referenceroom@ ferc.fed.us).

During normal business hours, documents can also be viewed and/or printed in FERC's Public Reference Room, where RIMS, CIPS, and the FERC Website are available. User assistance is also available.

## VIII. Effective Date and Congressional Notification

This Final Rule will take effect on June 1, 2000. The Commission has determined, with the concurrence of the Administrator of the Office of Information and Regulatory Affairs of the Office of Management and Budget, that this rule is not a "major rule"
within the meaning of section 251 of the Small Business Regulatory Enforcement Fairness Act of 1996. ${ }^{29}$ The Commission will submit the Final Rule to both houses of Congress and the General Accounting Office. ${ }^{30}$

## List of Subjects in 18 CFR Part 35

Electric power rates, Electric utilities, Electricity, Reporting and recordkeeping requirements.
By the Commission.
Linwood A. Watson, Jr.,
Acting Secretary.
In consideration of the foregoing, the Commission amends Part 35, Chapter I, Title 18, Code of Federal Regulations, as follows:

## PART 35-FILING OF RATE SCHEDULES

1. The authority citation for Part 35 continues to read as follows:
Authority: 16 U.S.C. 791a-825r, 26012645; 31 U.S.C. 9701; 42 U.S.C. 7101-7352.
2. Section 35.5 is amended by designating the existing text as paragraph (a) and by adding a paragraph (b) to read as follows:

## §35.5 Rejection of material submitted for filing.

(b) A rate filing that fails to comply with this Part may be rejected by the Director of the Office of Markets, Tariffs, and Rates pursuant to the authority delegated to the Director in § $375.307(\mathrm{k})(3)$ of this chapter.
3. Section 35.9 is revised to read as follows:

## §35.9 Identification and numbering of tariffs and rate schedules (including service agreements).

(a) All tariffs and rate schedules (including service agreements) must be numbered sequentially from the beginning of that tariff or rate schedule (or service agreement). Revised service agreements must be replaced in their entirety.
(b) All tariffs and rate schedules (not including service agreements, except as noted in paragraphs (b)(4) and (5) of this section) must have the following information placed in the margins of each sheet:
(1) Identification. At the top left of each page, the exact name of the company must be shown, under which must be set forth the words "FERC Electric Tariff" or "Rate Schedule FERC No. ___" together with volume identification, as appropriate.

```
29 5 U.S.C. 804(2).
30}5\mathrm{ U.S.C. 801(a)(1)(A).
```

(2) Numbering of sheets. Except for the title page, at the top right, the sheet number must appear as "(Original or Revised) Sheet No. (number)." All sheets must be numbered in the manner set forth in the Tariff, Rate Schedule and Service Agreement Pagination Guidelines, as modified from time to time.
(3) Issuing officer and issue date. On the lower left must be placed "Issued by:" followed by the name and title of the person authorized to issue the sheet. Immediately below must be placed "Issued on" followed by the date of issue.
(4) Effective date. On the lower right must be placed "Effective:" followed by the specific effective date proposed by the company. Service agreements must include this data on the same sheet containing the service agreement designation.
(5) Filings made to comply with Commission orders. Tariffs and rate schedules (including service agreements) filed to comply with Commission orders must carry the following notation in the bottom margin: "Filed to comply with order of the Federal Energy Regulatory Commission, Docket No. (number), issued (date), (FERC Reports citation)." Service agreements must include this data on the same sheet containing the service agreement designation.

## §35.18 [Removed and reserved]

4. Section 35.18 is removed and reserved.
[Note: This Appendix will not appear in the Code of Federal Regulations.]

## Appendix

## Tariff, Rate Schedule, and Service

 Agreement Pagination GuidelinesDue to the complexity of tariff filing situations, the Commission Staff provides the following guidelines. If you have questions or need assistance, please call Kathleen E. Nieman at (202) 208-1070, or such other persons as may be identified from time to time.
(1) Original Sheets. Paginate as "Original Sheet No. $\qquad$ " (a) all pages in initial filings,
(b) added sheets, and (c) all sheets in a revised tariff volume. Guideline (11) gives an exception for reserved sheets.
(2) Substitute Sheets. Paginate a sheet as "Substitute" if it is filed to replace a sheet filed in the same proceeding (e.g., as a result of a hearing order, or of a correction to a tariff sheet filed prior to the issuance of an order, or of a compliance filing) with the same effective date. If a substitute sheet needs to be replaced, paginate the new sheet as "Second Substitute", and so on. (See Example No. 1.)
(3) Revised Sheets. Paginate a sheet as "Revised" if it is (a) replacing a sheet filed in a different proceeding or (b) replacing a
sheet filed in the same proceeding but given a new proposed effective date. Each subsequent "Revised" pagination should be numbered sequentially, i.e., First Revised, Second Revised, Third Revised, etc. (See Examples Nos. 1 and 2.)
(4) Superseded Sheets. Each designation must refer to the designation of the sheet being superseded, if any. The superseded sheet is the sheet being replaced by a revised sheet. (There is an exception to this guideline for retroactive filings-see Guideline (9).) Never designate a rejected or suspended sheet as the superseded sheet. However, if a sheet designated as superseded is subsequently rejected, it is not necessary to re-file solely to correct the superseded sheet designation. (See Example No. 1.)
(5) Rejected Sheets. Do not reuse the pagination of a rejected sheet. Paginate a sheet "Substitute" if it is filed to replace a rejected sheet in the same proceeding, but do not refer to a rejected sheet as the superseded sheet in the designation. (See Guidelines (3) and (4).)
(6) Alternate Sheets. When filing two versions of a proposed tariff sheet, paginate the sheet " ___ Revised Sheet No. __," and "Alternate Revised Sheet No. Paginate a replacement alternate sheet "'Sub Alternate $\qquad$
(7) Inserted Sheets. Paginate sheets inserted between two consecutively numbered sheets using an uppercase letter following the first sheet number (e.g., sheets inserted between sheets 8 and 9 would be 8A, 8B, etc.). For sheets inserted between two consecutively lettered sheets, add a ".," followed by a two digit number (e.g., sheets inserted between sheets 8 A and 8 B would be 8A. 01 through 8A.99). For further insertions, add a lowercase letter (e.g., between sheets 8A. 01 and 8A. 02 would be 8A.01a, 8A.01b, etc.).
(8) '‘Squeezed" Sheets. When a sheet needs to be made effective between two sequentially paginated sheets already on file (all in different proceedings), paginate the new sheet by adding a " 1 st Rev"' designation to the older sheet's pagination. Commonly, this situation occurs when a sheet is suspended for five months and subsequent sheets need to be made effective prior to when the suspended sheet becomes effective. (See Example No. 3.)
(9) 'Retroactive"' Sheets. When filing a "retroactive" sheet change back to a certain date, all sheets in effect from that date forward need to be changed. The first sheet should be paginated either as "Substitute" (see Guideline (3) above) or "1st Rev" (see Guideline (8) above) depending on whether the retroactive filing is in the same or different docket as the sheet being replaced. For simplicity, the rest of the sheets should be paginated as a "Substitute" of each effective sheet already on file. Follow Guideline (4) in designating the superseded sheet for the first new sheet. However, the rest of the sheets should supersede each other in order, even though they are all filed in the same docket. In this way the superseded designation will reflect the latest sheet in effect on each given date. (See Examples Nos. 4 and 5.)
(10) Canceled Sheets. When canceling individual sheets, but retaining the tariff or
rate schedule, designate a blank sheet as a revised sheet superseding the prior sheets.
(11) Canceled Tariff or Rate Schedule. When canceling an entire tariff or rate schedule, file one sheet paginated as the first sheet of the tariff volume or Rate Schedule and refer to the tariff volume or Rate Schedule as canceled. (See Example No. 7.)
(12) Sheets Reserved For Future Use. When reserving a number of sheets for future use, file one sheet paginated "Sheet Nos. A-Z", where " $A$ " and " $Z$ " refer to the first and last reserved sheet numbers. In the body of the sheet state "Reserved for Future Use." (See Example No. 8.)
(13) Rate Schedule and Service Agreement Designations. Rate schedule and service agreement designation should follow the above principles and terminology. For example, if a change is made to Service Agreement No. 50, the designation should be 1st Revised Service Agreement No. 50.
(14) Abbreviations. Abbreviate from left to right using the Abbreviation Conventions List at the end of this document. Abbreviate only as needed. (See Example No. 6.) The following examples reflect the types of changes and corresponding designations that may be made over the life of a given tariff or rate schedule (all docket numbers and
dates are hypothetical, and are not intended to refer to actual proceedings):
Example No. 1: Revised and Substitute Sheets. "Original Sheet No. 4" is filed in Docket No. ER99-44-000 to be effective January 1, 1999. Subsequently, a sheet filed in Docket No. ER99-123-000 is to be effective February 1, 1999. Paginate the latter sheet as "First Revised Sheet No. 4 superseding Original Sheet No. 4". If a mistake is discovered and a corrected sheet needs to be filed in Docket No. ER99-123001, ${ }^{1}$ paginate that sheet "Substitute First Revised Sheet No. 4 superseding Original Sheet No. 4" . Note the superseded sheet is from the prior proceeding.

| Docket | Filed | Effective | Pagination | Superseded sheet |
| :---: | :---: | :---: | :---: | :---: |
| ER99-44-000 | 11/30/98 | 1/1/99 | Original. |  |
| ER99-123-000 | 12/31/98 | 2/1/99 | First Revised | Original. |
| ER99-123-001 | 2/15/99 | 2/1/99 | Sub First Revised | Original. |

If the utility proposes two separate changes to be effective the same date, and the second filing reflects the first filing's proposed changes, then it is appropriate to show the first filing's pagination as superseded.

| Docket | Filed | Effective | Pagination | Superseded sheet |
| :---: | :---: | :---: | :---: | :---: |
| ER99-44-000 | 11/30/98 | 1/1/99 | Original. |  |
| ER99-123-000 | 12/31/98 | 2/1/99 | First Revised | Original |
| ER99-124-000 ......................................... | 2/15/99 | 2/1/99 | Second Revised ........................................ | First Revised |

Example No. 2: Sheets Effective on the Same Date. "Second Revised Sheet No. 4" is filed in Docket No. ER99-200-000 to be
effective April 1, 1999. Subsequently, a sheet is filed in Docket No. ER99-504-000 to be effective on the same date. Paginate that
sheet with the next revision number, "Third Revised Sheet No. 4" even though it is to be effective on the same date.

| Docket | Filed | Effective | Pagination | Superseded sheet |  |
| :--- | ---: | ---: | ---: | :--- | :--- |
| ER99-200-000 ..................................................................................................... | $2 / 28 / 99$ | $3 / 31 / 99$ | $4 / 1 / 99$ | Sub First Rev. | Second Revised ................................................... |
| ER99-504-000 | Second Rev. |  |  |  |  |

Example No. 3: Squeezed Sheets. 'Fourth Revised Sheet No. 4"' is filed July 31, 1999, in Docket No. ER99-601-000 to be effective September 1, 1999. An order suspends this sheet until February 1, 2000. Subsequently, two filings are made to be effective prior to February 1, 2000. Paginate these sheets as
"1st Rev Third Revised Sheet No. 4" and "2nd Rev Third Revised Sheet No. 4". The utility will be required, if necessary, to file revised tariff sheets to update the suspended tariff sheets to include any changes to the tariff sheets that have been accepted by the Commission between the date of the
suspension and the effective date of the suspended rates. When filing to update the revised tariff sheets, paginate the revised tariff sheet as "Sub Fourth Revised Sheet No. 4 ". Note: using the alpha-numeric " 1 st, 2nd, etc." for the additional revision number assists in keeping the pagination clear.


Example No. 4: Retroactive Sheets. The sheet paginated in Example No. 1, "Sub First Revised Sheet No. 4" filed in Docket No. ER99-123-001 is in effect February 1, 1999, subject to the resolution of issues. A year later, settlement is reached resulting in a restatement of base rates back to that date. The revised sheets filed under Docket No. ER99-123-002 (using prior examples):

| Docket | Filed | Effective | Pagination | Superseded sheet |
| :---: | :---: | :---: | :---: | :---: |
| ER99-123-002 ..................................... | 2/15/00 | $\begin{array}{r} 2 / 1 / 99 \\ 4 / 1 / 99 \\ 4 / 1 / 99 \\ 10 / 1 / 99 \\ 11 / 1 / 99 \end{array}$ | 2nd Sub First Revised $\qquad$ <br> Sub Second Revised $\qquad$ <br> Sub Third Revised $\qquad$ <br> Sub 1st Rev Third Rev $\qquad$ <br> Sub 2nd Rev Third Rev $\qquad$ | Original. <br> 2nd Sub First Rev. <br> Sub Second Rev. <br> Sub Third Rev. <br> Sub 1st Rev Third Rev. |

[^13]the public of its intent to change its assignment of docket numbers to electric filings to a method
similar to that used for the gas and oil programs, effective June 1, 2000.

| Docket | Filed | Effective | Pagination | Superseded sheet |
| :---: | ---: | ---: | ---: | :---: |
|  |  | $2 / 1 / 00$ | 2nd Sub Fourth Rev .............................. | Sub 2nd Rev Third Rev. |

Example No. 5: Retroactive Sheets. Continuing from Example 4, a subsequent tracker filing retroactive to November 1, 1999:

| Docket | Filed | Effective | Pagination | Superseded sheet |
| :---: | :---: | :---: | :---: | :---: |
| ER00-77-000 | $\begin{array}{r} \text { 4/30/00 } \\ 2 / 1 / 00 \end{array}$ | 11/1/99 | 3rd Rev Third Rev $\qquad$ <br> 3rd Sub Fourth Rev $\qquad$ | Sub 2nd Rev Third Rev. 3rd Rev Third Rev. |

Example No. 6: Abbreviations. Abbreviate
"Fourth Revised Twenty-Third Revised Sheet No. 4" as " 4 th Rev Twenty-Third Revised Sheet No. 4".
Example No. 7: Canceled Rate Schedules and Tariffs. To cancel Rate Schedule FERC No. 26, which consists of Original Sheet Nos. 1-39, file First Revised Sheet No. 1.
Company Name; Rate Schedule FERC No. 26.

First Revised Sheet No. 1.
Cancels FERC Electric Rate Schedule No. 26.

Notice of Cancellation
Example No. 8: Reserved Sheets. Your general terms and conditions end on page 75 and you want to reserve sheets 76 through 99 for future use:

Company Name; FERC Electric Tariff,
Original Volume No. 2.
Sheet Nos. 76 through 99.
Sheet Nos. 76 through 99 are reserved for future use.

## Abbreviation Conventions List

Substitute: Sub
Alternate: Alt
Revised: Rev
First, Second, etc.: 1st, 2nd, etc.
Sheet No.: (omit these words)

## SAMPLE PAGE

Day and Light Power Company, FERC
Electric Tariff, Original Volume No. 1.
Original Sheet No. 4
Issued by: Harriet Officer, Rates Manager. Effective: July 1, 2000.
Issued on: June 10, 2000.
Filed to comply with order of the Federal Energy Regulatory Commission, Docket No. ER99-5374-000, issued October 27, 1999, 90 FERC II 61,010 (1999).
[FR Doc. 00-8459 Filed 4-6-00; 8:45 am] BILLING CODE 6717-01-P

## DEPARTMENT OF ENERGY

## Federal Energy Regulatory Commission

## 18 CFR Part 35

[Docket No. RM00-2-000, Order No. 612]
Time Frame for Intervening in and Protesting Federal Power Act Section 205 Filings; Correction

April 3, 2000.
AGENCY: Federal Energy Regulatory
Commission.

ACTION: Final rule; correction.
SUMMARY: The Federal Energy Regulation Commission (Commission) published in the Federal Register of December 28, 1999, a final rule amending its regulations to provide that, absent a notice providing some other time period, a twenty-one (21) calendar day time period from the date a Federal Power Act (FPA) Section 205 rate filing is filed, amended, or supplemented will be provided for interested parties to file any protest or intervention in the proceeding. Inadvertently, § 35.8(b) contained a typographical error. This document corrects that typographical error.

DATES: Effective on April 7, 2000.
FOR FURTHER INFORMATION CONTACT: Julia
A. Lake, Attorney, Federal Energy Regulatory Commission, 888 First Street, NW, Washington, DC 20426; phone: 202-208-2019; email:julia.lake@ferc.fed.us.

SUPPLEMENTARY INFORMATION: The Federal Energy Regulatory Commission (Commission) published in the Federal Register of December 28, 1999, a final rule amending its regulations to provide that, absent a notice providing some other time period, a twenty-one (21) calendar day time period time from the date a Federal Power Act (FPA) Section 205 rate filing is filed, amended, or supplemented will be provided for interested parties to file any protest or intervention in the proceeding. Inadvertently, § 35.8(d) contained a typographical error. This document corrects that typographical error.

In rule FR Doc. 99-33593, published on December 28, 1999 (64 FR 72535), make the following correction. On page 72537, in the second column, last paragraph, correct the word "§35.9" to read "§ 35.8 ".

## Dated: March 31, 2000.

Linwood A. Watson, Jr.,
Acting Secretary.
FR Doc. 00-8621 Filed 4-6-00; 8:45 am]
BILLING CODE 6717-01-M

## DEPARTMENT OF ENERGY

## Federal Energy Regulatory Commission

18 CFR Part 385

## [Docket No. RM98-1-000; Order No. 607]

## Regulations Governing Off-the-Record Communications; Correction

March 31, 2000.
AGENCY: Federal Energy Regulatory Commission, DOE.

ACTION: Final rule; correction.
SUMMARY: The Federal Energy Regulatory Commission
("Commission") published in the Federal Register of September 22, 1999, a document revising its rules concerning communications between persons outside the Commission and the Commission and its employees. One amendatory instruction for Part 385 was incorrectly stated. This document corrects that amendatory instruction.
DATES: Effective on April 7, 2000.
FOR FURTHER INFORMATION CONTACT: Julia
A. Lake, Attorney, Federal Energy Regulatory Commission, 888 First Street, NW, Washington, DC 20426; phone: 202-208-2019; e-mail: julia.lake@ferc.fed.us.
SUPPLEMENTARY INFORMATION: The Federal Energy Regulatory Commission ('Commission") published in the Federal Register of September 22, 1999, a document revising its rules concerning communications between persons outside the Commission and the Commission and its employees. One amendatory instruction for Part 385 was incorrectly stated. This document corrects that amendatory instruction.

In rule FR Doc. 99-24616 published on September 22, 1999 (64 FR 51222), make the following correction. On page 51234, in the first column, correct amendatory instruction 2 to read as follows:

$$
\begin{aligned}
& \text { "'2. In } \S 385.101 \text {, remove paragraph } \\
& \text { (b)(4)." }
\end{aligned}
$$

Dated: March 31, 2000.
Linwood A. Watson, Jr.,
Acting Secretary.
[FR Doc. 00-8458 Filed 4-6-00; 8:45 am] BILLING CODE 6717-01-M

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

## Food and Drug Administration

## 21 CFR Parts 809 and 864

## [Docket No. 97N-0135]

## Hematology and Pathology Devices; Reclassification; Restricted Devices; OTC Test Sample Collection Systems for Drugs of Abuse Testing

agency: Food and Drug Administration, HHS.
ACTION: Final rule.
SUMMARY: The Food and Drug Administration (FDA) is reclassifying over-the-counter (OTC) test sample collection systems for drugs of abuse testing from class III (premarket approval) into class I (general controls) and exempting them from premarket notification (510(k)) and current good manufacturing practice (CGMP) requirements. FDA is also designating OTC test sample collection systems for drugs of abuse testing as restricted devices under the Federal Food, Drug, and Cosmetic Act (the act) and establishing restrictions intended to assure consumers that: The underlying laboratory test(s) are accurate and reliable; the laboratory performing the test(s) has adequate expertise and competency; and the product has adequate labeling and methods of communicating test results to consumers. Finally, FDA is adding a conforming amendment to the existing classification regulation for specimen transport and storage containers to clarify that it does not apply to specimen transport and storage containers that are part of an OTC test sample collection system for the purpose of testing for the presence of drugs of abuse or their metabolites in a laboratory.
DATES: This rule is effective April 9, 2001.

ADDRESSES: Comments on the burden estimates or on any other aspect of the information collection provisions should be sent to the Office of Device Evaluation (HFZ-440), Center for Devices and Radiological Health, Food and Drug Administration, 2094 Gaither Rd., Rockville, MD 20850.

## FOR FURTHER INFORMATION CONTACT:

Steven Gutman, Center for Devices and Radiological Health (HFZ-440), Food and Drug Administration, 2098 Gaither Rd., Rockville, MD 20850, 301-5943084.

## SUPPLEMENTARY INFORMATION:

## I. Background

In the Federal Register of March 5, 1998 (63 FR 10792), FDA published a proposed rule to: (1) Reclassify OTC test sample collection systems for drugs of abuse testing from class III (premarket approval) into class I (general controls) and to exempt them from premarket notification (510(k)) and CGMP requirements; (2) to designate OTC test sample collection systems for drugs of abuse testing as restricted devices under the act; and (3) to establish restrictions intended to assure consumers that: The underlying laboratory test(s) are accurate and reliable, the laboratory performing the test(s) has adequate expertise and competency, and the product has adequate labeling and methods of communicating test results to consumers.

The proposed rule does not affect OTC tests for drugs of abuse that are performed in the home setting-i.e., the testing is performed in the home setting and the test results are read and interpreted directly by the consumer, without involvement or input from a health professional. These are referred to as "point of care" tests. When manufacturers or distributors market "point of care" tests, they are selling the consumers the actual test rather than a collection system that uses a laboratory to perform a test. Under these circumstances, FDA cannot determine whether the test is accurate and reliable without premarket review of the product. Accordingly, no changes are being proposed in FDA's current policy of reviewing "point of care" tests prior to marketing.

Interested persons were given until July 6, 1998, to submit written comments on the proposed rule. FDA received nine comments.

In the Federal Register of May 28, 1998 (63 FR 29174), FDA announced that on June 19, 1998, it would hold a public hearing on the proposed rule. FDA held that hearing as announced.

## II. Response to Comments

FDA received nine comments on the proposed rule from individuals, manufacturers, and professional societies. The majority of comments supported FDA's proposed rule. A summary of the written comments as well as comments made at the public
hearing and FDA's response is set forth in this section II.

## A. General Comments

1. Six comments generally supported regulating OTC test sample collection systems for drugs of abuse as class I devices exempt from the premarket notification requirements. These comments asserted that deregulation of home drug test collection systems outlined in the proposed rule made drug testing more affordable and more accessible. These comments indicated support for the testing laboratory to provide a health care professional to communicate the proper interpretation of test results from the laboratory to the lay user.

## B. Consumer Versus Workplace Test Kits

2. One comment stated that the rule fails to distinguish between test systems marketed directly to consumers and those intended for use in the workplace because the rule fails to take into account the additional safeguards that are present when drug testing is performed in the workplace. This comment went on to suggest that even if FDA concludes that it has jurisdiction to regulate all test systems, it should nevertheless exercise enforcement discretion with respect to drugs of abuse tests for the workplace because the workplace setting offers sufficient protections to "ensure sample integrity and test accuracy."
FDA disagrees with this comment. As explained in the proposed rule, FDA concluded that there should be consistency in its regulation of drugs of abuse test sample collection systems used in the home, workplace, insurance, and sports settings. Issues related to consumer use and quality are similar in all these settings, including concerns about sample integrity and test accuracy. FDA believes the need to provide assurance of test accuracy and reliability applies equally in all these areas.

However, FDA will continue to exercise its enforcement discretion with respect to the use of these products in the law enforcement setting because there are protections to ensure sample integrity and test accuracy that are not generally available in the home, workplace, insurance and sports settings. The additional protections include the use of rules of evidence in judicial proceedings and the representation of the accused (i.e., the person being tested) through the judicial process.

## C. FDA Oversight

3. One comment expressed concern over the proposal to exempt manufacturers from the $510(\mathrm{k})$ process and suggested the need for data to be presented to demonstrate that each analyte is unaffected by storage and transport, i.e., stored and not altered or interfered with. This comment stated that there is a potential for materials in collection cups to interfere with an accurate test result.
Mail-in drug testing is practiced routinely in many settings. The materials and methods for shipping urine are in widespread use for drugs of abuse testing in Substance Abuse and Mental Health Service Administration (SAMHSA) or equivalent certified laboratories. Data submitted to the FDA have shown drugs of abuse test specimens to be stable when shipped in accordance with the requirements of SAMHSA or equivalent certified laboratories. Although FDA has exempted the OTC test sample collection systems for drugs of abuse testing from premarket review, all of these systems will be required to use screening tests that have been approved, cleared, or otherwise recognized by FDA as accurate and reliable for testing. The final rule further requires manufacturers and suppliers to comply with medical device reporting requirements (21 CFR part 803) and report adverse events that may have been due to the OTC collection containers. FDA believes these general controls, without premarket notification, provide reasonable assurance that these products will be used safely and effectively.

## D. In-House Tests

4. One comment stated that FDA's proposed rule would impose on clinical laboratories using in-house (home brew) assays additional and burdensome requirements that are unnecessary under the Clinical Laboratory Improvement Amendments of 1988 (CLIA 88).

FDA disagrees with this comment. In order for products to be used OTC, they must be cleared by FDA. The agency believes that the FDA requirements will be complementary to those of CLIA and will address issues related to device safety and effectiveness outside the usual CLIA review program. CLIA requirements focus on the proficiency of the laboratories performing tests and the new regulation recognizes the need for such laboratories to have adequate expertise.
5. One comment stated that the rule unfairly discriminates against
companies using screening assays for which there are no FDA-cleared screening tests, thereby imposing premarket approval requirements for the test system.

FDA does not agree that the rule discriminates unfairly. This rule is designed to ensure that there is a level playing field and that all manufacturers marketing home test collection systems use testing methods that have been approved, cleared, or otherwise recognized by FDA as accurate and reliable.
6. One comment voiced opposition to the FDA proposal to require companies marketing drugs-of-abuse test systems that employ in-house screening tests to establish validity of these tests with FDA before marketing the test system. This comment stated that FDA lacks jurisdiction to regulate the provision of laboratory testing services by clinical laboratories.

The agency believes that in-house (home brew) laboratory tests are medical devices subject to regulation by FDA. FDA considers clinical laboratories that develop such tests to be acting as manufacturers. In a recent regulation to classify/reclassify analyte specific reagents FDA stated its desire to regulate in-house developed tests in a way that would not inhibit the development of such tests or diminish the contribution they make to public health ( 62 FR 62243 at 62249, November 21, 1997). However, in instances where these tests are part of systems intended for lay users, the agency believes that the additional oversight provided by agency premarket review of the test is necessary to ensure the safety and effectiveness of the device.
7. One comment asked if the drugs of abuse testing required under the proposed rule would be covered under CLIA requirements for high complexity testing.

The answer is yes. Because the confirmation testing of presumptive positives is designated as a high complexity test under CLIA, CLIA standards for high complexity testing would apply.

## E. Laboratory Standards

8. Three comments emphasized the importance of confirmation of presumptive results and suggested that this be a mandatory part of OTC test sample collection systems.

FDA agrees with these comments. The rule specifically requires that the laboratory performing the test shall have adequate capability to reliably perform the necessary screening and confirmatory testing.
9. One comment suggested that laboratories testing any drugs of abuse or their metabolites not covered by SAMHSA should meet standards of organizations with deemed accreditation status such as College of American Pathologists (CAP).

FDA agrees with this comment. The agency's rule clearly stated that the laboratory performing the test shall have, and shall be recognized as having, adequate capability to reliably perform the necessary screening and confirmatory tests. Such recognition would include CAP accreditation.
10. One comment expressed concern that a high complexity CLIA certified laboratory (e.g., toxicology laboratory) would not meet the SAMHSA standards that are required for laboratories performing Federal workplace drugtesting. The comment stated that OTC products relying on non-SAMHSA certified laboratories would lower the standards of competency for drugs of abuse testing.

FDA recognizes that there are differences in toxicology laboratory certification programs. However, the agency believes that the standards established by the rule, as proposed, are appropriate, because they ensure an acceptable level of testing performance. As discussed previously, the rule requires the laboratory to be recognized as being able to reliably perform screening and confirmatory testing, including the capability to check biological specimens for possible adulteration. FDA believes that such recognition of capability and good laboratory practice may be demonstrated in a number of ways including SAMHSA certification, CAP accreditation, and CLIA high complexity designation.
11. One comment suggested FDA consider allowing laboratories to report the lowest concentration of drug they are able to detect in order to encourage improvement in the sensitivity of the system.

FDA has not specified concentration levels for drugs being tested in these systems. The agency expects sponsors to label their products to reflect the chosen performance levels using appropriate cut-off points.
12. One comment suggested it would be helpful to clarify whether the screening and confirmation testing must be performed at the same physical site in the same laboratory.

The regulation requires the laboratory performing the test to have adequate capability to reliably perform the necessary screening and confirmatory testing. While the expectation is that this testing usually will be performed at
a single site, the rule does not preclude a laboratory operating as a single entity from housing different analytical functions at different sites. The rule also does not prevent laboratories from making contractual agreements to acquire or share analytical resources so long as the other laboratory meets the necessary standards.
13. One comment noted that laboratory customers are often not aware of the limits of the SAMHSA coverage and suggested that the regulation should make clear the actual jurisdiction of the SAMHSA standards.
FDA agrees that this is useful information. The dissemination of this information, however, falls outside of the scope of this rule.

## F. FDA Labeling

14. One comment suggested that the guidance document that FDA intends to develop should encourage manufacturers to list all drugs that will not be covered under the test.
The agency does not agree that an exhaustive listing of drugs not being tested is reasonable or user-friendly. FDA believes the labeling for the test should clearly indicate: (1) What drugs are being tested, (2) what limitations exist, and (3) examples of these limitations. For example, a label may include the information that strong oxidizing agents such as bleach can oxidize drug analytes and explain that, if a sample is suspected of being adulterated, a new sample must be obtained. The agency intends to include examples of appropriate labeling in its guidance.
15. One comment suggested that test labeling should explicitly offer guidance on how to contact a resource for test interpretation as well as identifying resources for counseling and treatment.
FDA agrees with this comment. The regulation does require labeling of these products to include adequate instructions on how to obtain test results from a person who can explain their meaning, including the probability of false positive and false negative results, as well as how to contact a trained health professional if additional information on interpretation of test results from the laboratory or followup counseling is desired. In the Federal Register of December 21, 1999 (64 FR 71461), FDA announced the availability of a draft guidance document entitled
"Draft Guidance on Labeling for Over-the-Counter Sample Collection Systems for Drugs of Abuse Testing.'’ The draft guidance provides to manufacturers FDA's thinking on ways to comply with the labeling requirements in this rule. For example, it states the labeling
should include advice on contacting a physician for options for identifying and/or treating substance use and abuse problems, and should include a statement on how to obtain information for talking to children about drug use and abuse. FDA intends to finalize the guidance before the effective date of this final rule.
16. One comment stated that training of users is essential in collection of these specimens.

FDA agrees that this is an important issue. Guidance on labeling of home use devices is available both from NCCLS (GP-14-A "Labeling for Home Use InVitro Products") and from FDA ("Write It Right" and "Points to Consider Regarding Labeling and Premarket Submissions for Home Use In-Vitro Diagnostic Devices"'). These guidances can help manufacturers to develop high quality instruction manuals for users of medical devices in the home that are easy to read, understand, and follow. The manufacturers also can enlist the aid of health care professionals and home medical equipment suppliers to stress the importance of the manual to the lay users.

## G. Hair Testing

17. One comment objected that OTC drugs of abuse test kits are not medical devices under section 201(h) of the act (21 U.S.C. 321(h)). The comment argued that FDA lacks jurisdiction to regulate test kits that detect drugs of abuse in hair because they are not considered devices for medical diagnosis and treatment. This comment stated that hair analysis provides no information concerning intoxication or addiction.

FDA disagrees with the comment. The definition of device as set forth in section 201(h) of the act includes the following:

The term "device" * * * means an instrument, apparatus, implement, machine, contrivance, implant, in vitro reagent, or other similar or related article, including any component, part, or accessory, which is- * * * (2) intended for use in the diagnosis of disease or other conditions * * * [emphasis added]

The test for evidence of drug abuse is intended to provide information about a condition, namely, whether drugs of abuse are being used or have been used by the subject. In addition, such information can be used to diagnose other conditions or diseases, including addiction or intoxication, and may also be used to eliminate such conditions as part of a diagnosis of an underlying disease.
18. One comment endorsed the use of hair testing and indicated that it provided a valuable extension of the
window for testing for hard drugs of abuse in children.
FDA agrees that hair testing may be a valuable test. To date the agency has not received a premarket submission for such a test. The agency does believe that these tests should be subject to appropriate premarket scientific review. The review standards applied to these tests will depend on the claims the manufacturer makes. FDA is committed to working with companies to develop appropriate study design and generate data sets to help characterize performance and establish labeling for these products that would be of benefit to lay users.
19. One comment said that, if FDA requires agency premarket review of tests for hair or other nonurine specimens, the agency cannot impose a higher regulatory burden on hair-based testing than on urine-based testing.

FDA is not imposing a higher regulatory burden on hair-based testing than on urine-based testing. This rule applies to the OTC test sample collection system, not the test itself, and applies equally, whether the sample collected is hair or urine. The regulatory burden imposed on a device is contingent upon the intended use, indications for use, and technological characteristics of the individual device.
20. One comment suggested FDA's proposal is irrational in requiring premarket notification for a specimen collection container for hair while exempting from premarket notification urine specimen collection containers and other specimen collection containers that are used in conjunction with screening tests previously approved, cleared, or otherwise recognized by FDA.

The comment appears to misunderstand the rule. FDA will treat all collection containers used in these products in an equivalent manner. Whenever such containers are part of a system that uses a cleared, approved, or recognized test performed in an appropriately regulated laboratory, the collection container will be exempt from any premarket review.

## III. Environmental Impact

The agency has determined under 21 CFR 25.34(b) that this proposed classification action is of a type that does not individually or cumulatively have a significant effect on the human environment. Therefore, neither an environmental assessment nor an environmental impact statement is required.

## IV. Analysis of Impacts

FDA has examined the impacts of the rule under Executive Order 12866, and the Regulatory Flexibility Act (5 U.S.C. 601-612) (as amended by subtitle D of the Small Business Regulatory Fairness Act of 1996 (Public Law 104-121), and the Unfunded Mandates Reform Act of 1995 (Public Law 104-4). Executive Order 12866 directs agencies to assess all costs and benefits of available regulatory alternatives and, when regulation is necessary, to select regulatory approaches that maximize net benefits (including potential economic, environmental, public health and safety, and other advantages; distributive impacts; and equity). The agency believes that this rule is consistent with the regulatory philosophy and principles identified in the Executive Order. The Office of Management and Budget (OMB) has determined that this final rule is a significant regulatory action subject to review under the Executive Order.
The reclassification of OTC test sample collection systems for drugs of abuse testing (class III into class I exempt) is reasonably expected to provide economic benefit to the health care system, individual consumers, and regulated industry. At this time, only a very limited number of OTC products for drugs of abuse testing (without professional assistance) are available to parents. By greatly increasing access, this reclassification may provide benefits to families. First, testing may serve as a deterrent to drug use and prevent the initial experimentation with drugs of abuse by children. Next, when drugs are being used, increased access to testing may allow for earlier detection of this condition and provide opportunities for earlier intervention and treatment. Early intervention and treatment has the potential to be more successful. Finally, products for drugs of abuse testing marketed to parents may be used to monitor children already undergoing treatment for drug use, deterring or at least detecting
recidivism, which is currently estimated at 30 to 50 percent. In addition, the regulation, which regulates such testing systems consistently in home, workplace, athletic, and insurance settings, will help ensure all consumers that the product produces accurate and reliable results.

FDA cannot quantify the beneficial effect on the public health that will result from easier access to these tests. Nevertheless, the agency finds that the product has significant potential to reduce drug use. As the nation's economic costs of drug abuse are staggering, estimated at up to \$110 billion in 1995, the potential benefit from even a modest reduction would be substantial.

Moreover, the cost to industry will fall. Under the current classification, OTC test sample collection systems for drugs of abuse testing are class III medical devices requiring a premarket approval application (PMA). FDA has found that the median development cost for a PMA ranges from $\$ 0.5$ to $\$ 1$ million. Reclassifying these devices as class I devices exempt from premarket notification, which do not undergo premarket review, means that neither new sponsors nor product purchasers will incur these costs. Consequently, FDA expects the rule to reduce regulatory costs at the same time that it decreases the economic burdens of drug abuse.

The Regulatory Flexibility Act requires agencies to analyze regulatory options that would minimize any significant impact of a rule on small entities. Reclassification of this device from class III to class I will relieve all manufacturers of the device of the cost of complying with the premarket approval requirements in section 515 of the act ( 21 U.S.C. 360 e ). Because this rule will not require premarket review of the vast majority of OTC test sample collection systems for drugs of abuse testing, the agency certifies that this rule will not have a significant economic impact on a substantial number of small
entities. In addition, this proposed rule will not impose costs of $\$ 100$ million or more in any one year on either the private sector or State, local, and tribal governments in the aggregate, and therefore a summary statement of analysis under section 202(a) of the Unfunded Mandates Reform Act of 1995 is not required.

## V. Paperwork Reduction Act of 1995

This final rule contains information collection provisions that are subject to review by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995 (44 U.S.C. 35013520). The title, description, and respondent description of these information collection provisions is given in this section $V$ with an estimate of the annual reporting and recordkeeping burden. Included in the estimate is the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing each collection of information.

Title: OTC Test Sample Collection Systems for Drugs of Abuse Testing.

Description: The final rule amends the labeling requirements for certain in vitro diagnostic products to require that manufacturers of OTC test sample collection systems for drugs of abuse testing provide certain information to consumers for the proper use of the test sample collection system and for interpreting the results. The purpose of the regulation is to ensure that lay persons collecting samples for testing have adequate instructions for sample collection and handling and for receiving and understanding the test results reported by laboratories performing the analyses.
Description of Respondents: Businesses and other for-profit organizations.
There were no comments on the paperwork provisions in the proposed rule.

Table1.-Estimated Annual Reporting Burden ${ }^{1}$

| 21 CFR Section | No. of Re- <br> spondents | Annual Fre- <br> quency per Re- <br> sponse | Total Annual <br> Responses | Hours per Re- <br> sponse | Total Hours |
| :--- | :---: | :---: | :---: | :---: | :---: |
| $809.10(f)$ | 20 | 1 | 20 | 100 | 2,000 |

${ }^{1}$ There are no capital costs or operating and maintenance costs associated with this collection of information.

Individuals and organizations may submit comments on these burden estimates or on any other aspect of these information collection provisions, including suggestions for reducing the
burden, and should direct them to the Office of Device Evaluation (HFZ-440), Center for Devices and Radiological Health, Food and Drug Administration, 2094 Gaither Rd., Rockville, MD 20850.

The information collection provisions in this final rule have been approved under OMB control number 0910-0368. This approval expires April 30, 2001. An agency may not conduct or sponsor,
and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number.

## List of Subjects

## 21 CFR Part 809

Labeling, Medical devices.

## 21 CFR Part 864

Biologics, Blood, Laboratories, Medical devices, Packaging and containers.
Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs, 21 CFR parts 809 and 864 are amended as follows:

## PART 809—IN VITRO DIAGNOSTIC PRODUCTS FOR HUMAN USE

1. The authority citation for 21 CFR part 809 continues to read as follows:
Authority: 21 U.S.C. 331, 351, 352, 355, 360b, 360c, 360d, 360h, 360i, 360j, 371, 372, 374, 381.
2. Section 809.10 is amended by adding paragraph (f) to read as follows:

## §809.10 Labeling for in vitro diagnostic products.

(f) The labeling for over-the-counter (OTC) test sample collection systems for drugs of abuse testing shall bear the following information in language appropriate for the intended users:
(1) Adequate instructions for specimen collection and handling, and for preparation and mailing of the specimen to the laboratory for testing.
(2) An identification system to ensure that specimens are not mixed up or otherwise misidentified at the laboratory, and that user anonymity is maintained.
(3) The intended use or uses of the product, including what drugs are to be identified in the specimen, a quantitative description of the performance characteristics for those drugs (e.g., sensitivity and specificity) in terms understandable to lay users, and the detection period.
(4) A statement that confirmatory testing will be conducted on all samples that initially test positive.
(5) A statement of warnings or precautions for users as established in the regulations contained in 16 CFR part 1500 and any other warnings appropriate to the hazard presented by the product.
(6) Adequate instructions on how to obtain test results from a person who can explain their meaning, including the probability of false positive and false negative results, as well as how to
contact a trained health professional if additional information on interpretation of test results from the laboratory or followup counseling is desired.
(7) Name and place of business of the manufacturer, packer, or distributor.
3. Section 809.40 is added to subpart C to read as follows:
§809.40 Restrictions on the sale, distribution, and use of OTC test sample collection systems for drugs of abuse testing.
(a) Over-the-counter (OTC) test sample collection systems for drugs of abuse testing ( 884.3260 of this chapter) are restricted devices under section 520(e) of the Act subject to the restrictions set forth in this section.
(b) Sample testing shall be performed in a laboratory using screening tests that have been approved, cleared, or otherwise recognized by the Food and Drug Administration as accurate and reliable for the testing of such specimens for identifying drugs of abuse or their metabolites.
(c) The laboratory performing the test(s) shall have, and shall be recognized as having, adequate capability to reliably perform the necessary screening and confirmatory tests, including adequate capability to perform integrity checks of the biological specimens for possible adulteration.
(d) All OTC test sample collection systems for drugs of abuse testing shall be labeled in accordance with § 809.10(f) and shall provide an adequate system to communicate the proper interpretation of test results from the laboratory to the lay purchaser.

## PART 864—HEMATOLOGY AND PATHOLOGY DEVICES

4. The authority citation for 21 CFR part 864 continues to read as follows:

Authority: 21 U.S.C. 351, 360, 360c, 360e, 360j, 371.
5. Section 864.3250 is amended in paragraph (a) by adding a sentence to the end of the paragraph to read as follows:

## §864.3250 Specimen transport and storage containers.

(a) * * * This section does not apply to specimen transport and storage containers that are intended for use as part of an over-the-counter test sample collection system for drugs of abuse testing.
6. Section 864.3260 is added to subpart D to read as follows:
§864.3260 OTC test sample collection systems for drugs of abuse testing.
(a) Identification. An over-the-counter (OTC) test sample collection system for drugs of abuse testing is a device intended to: Collect biological specimens (such as hair, urine, sweat, or saliva), outside of a medical setting and not on order of a health care professional (e.g., in the home, insurance, sports, or workplace setting); maintain the integrity of such specimens during storage and transport in order that the matter contained therein can be tested in a laboratory for the presence of drugs of abuse or their metabolites; and provide access to test results and counseling. This section does not apply to collection, transport, or laboratory testing of biological specimens for the presence of drugs of abuse or their metabolites that is performed to develop evidence for law enforcement purposes.
(b) Classification. Class I (general controls). The device is exempt from the premarket notification requirements in part 807, subpart E of this chapter subject to the limitations in $\S 864.9$ if it is sold, distributed, and used in accordance with the restrictions set forth in § 809.40 of this chapter. If the device is not labeled or otherwise represented as sterile, it is exempt from the current good manufacturing practice regulations in part 820 of this chapter, with the exception of $\S 820.198$ of this chapter with respect to complaint files.

## Dated: December 22, 1999.

## Jane E. Henney,

Commissioner of Food and Drugs.
Donna E. Shalala,
Secretary of Health and Human Services.
[FR Doc. 00-8598 Filed 4-6-00; 8:45 am] biLling Code 4160-01-F

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

## Food and Drug Administration

## 21 CFR Part 872

[Docket No. 00P-1209]

## Medical Devices; Laser Fluorescence Caries Detection Device

AGENCY: Food and Drug Administration, HHS.
ACTION: Final rule.
summary: The Food and Drug Administration (FDA) is classifying the laser fluorescence caries detection device into class II (special controls). The special controls that will apply to this device are set forth below. The
agency is taking this action in response to a petition submitted under the Federal Food, Drug, and Cosmetic Act (the act) as amended by the Medical Device Amendments of 1976 (the amendments), the Safe Medical Devices Act of 1990, and the Food and Drug Administration Modernization Act of 1997. The agency is classifying this device into class II (special controls) in order to provide a reasonable assurance of safety and effectiveness of the device. DATES: This rule is effective May 8, 2000.

## FOR FURTHER INFORMATION CONTACT:

Robert S. Betz, Center for Devices and Radiological Health (HFZ-480), Food and Drug Administration, 9200 Corporate Blvd., Rockville, MD 20850, 301-827-5283.

## SUPPLEMENTARY INFORMATION:

## I. Background

In accordance with section $513(\mathrm{f})(1)$ of the act (21 U.S.C. $360 \mathrm{c}(\mathrm{f})(1)$ ), devices that were not in commercial distribution before May 28, 1976, the date of enactment of the amendments, generally referred to as postamendments devices, are classified automatically by statute into class III without any FDA rulemaking process. These devices remain in class III and require premarket approval, unless and until the device is classified or reclassified into class I or II or FDA issues an order finding the device to be substantially equivalent, in accordance with section 513(i) of the act, to a predicate device that does not require premarket approval. The agency determines whether new devices are substantially equivalent to previously marketed devices by means of premarket notification procedures in section $510(\mathrm{k})$ of the act ( 21 U.S.C. $360(\mathrm{k})$ ) and part 807 (21 CFR part 807) of the FDA regulations.

Section 513(f)(2) of the act provides that any person who submits a premarket notification under section $510(k)$ of the act for a device that has not previously been classified may, within 30 days after receiving an order classifying the device in class III under section $513(f)(1)$ of the act, request FDA to classify the device under the criteria set forth in section 513(a)(1) of the act. FDA shall classify the device by written order within 60 days of receiving such a request. This classification shall be the initial classification of the device. Within 30 days after the issuance of an order classifying the device, FDA must publish a notice in the Federal Register announcing such classification.

On December 23, 1999, after review of KaVo America Corp.'s appeal, FDA
reopened their petition under section 513(f)(2) of the act requesting classification of its DIAGNOdent Laser Fluorescence Caries Detection Device intended for aiding in the diagnosis of dental caries. After review of the information submitted in the petition, its amendments, and the original $510(\mathrm{k})$ notification (K983658), FDA issued an order on February 22, 2000, classifying the DIAGNOdent Laser Fluorescence Caries Detection Device and substantially equivalent devices of this generic type into class II under the generic name "laser fluorescence caries detection device." FDA has determined that the laser fluorescence caries detection device can be classified in class II with the establishment of the following special controls:

1. That sale, distribution, and use of this device are restricted to prescription use in accordance with 21 CFR 801.109;
2. That premarket notifications
include clinical studies, or other relevant information, that demonstrates that the device aids in the detection of tooth decay by measuring increased laser induced fluorescence; and
3. That the labeling must include detailed use instructions with precautions that urge users to: (a) Read and understand all directions before using the device, (b) store probe tips under proper conditions, (c) properly sterilize the emitter-detector handpiece before each use, and (d) properly maintain and handle the instrument in the specified manner and condition.

FDA believes that these class II special controls, in addition to the general controls, provide reasonable assurance of the safety and effectiveness of the device.

## II. Environmental Impact

The agency has determined under 21 CFR 25.34(b) that this action is of a type that does not individually or
cumulatively have a significant effect on the human environment. Therefore, neither an environmental assessment nor an environmental impact statement is required.

## III. Analysis of Impacts

FDA has examined the impacts of the final rule under Executive Order 12866 and the Regulatory Flexibility Act (5 U.S.C. 601-612) (as amended by subtitle D of the Small Business Regulatory Fairness Act of 1996 (Public Law 104121)), and the Unfunded Mandates Reform Act of 1995 (Public Law 104-4). Executive Order 12866 directs agencies to assess all costs and benefits of available regulatory alternatives and, when regulation is necessary, to select regulatory approaches that maximize
net benefits (including potential economic, environmental, public health and safety, and other advantages; distributive impacts; and equity). The agency believes that this final rule is consistent with the regulatory philosophy and principles identified in the Executive Order. In addition, the final rule is not a significant regulatory action as defined by the Executive Order and so it is not subject to review under the Executive Order.

The Regulatory Flexibility Act requires agencies to analyze regulatory options that would minimize any significant impact of a rule on small entities. Classification of these devices into class II will relieve manufacturers of the device of the cost of complying with the premarket approval requirements of section 515 of the act (21 U.S.C. 360e), and may permit small potential competitors to enter the marketplace by lowering their costs. FDA knows of only one manufacturer of this type of device. Therefore, the agency certifies that this final rule will not have a significant impact on a substantial number of small entities. In addition, this final rule will not impose costs of $\$ 100$ million or more on either the private sector or State, local, and tribal governments in the aggregate, and, therefore, a summary statement of analysis under section 202(a) of the Unfunded Mandates Reform Act is not required.

## IV. Paperwork Reduction Act of 1995

This final rule contains no collections of information. Therefore, clearance by the Office of Management and Budget under the Paperwork Reduction Act of 1995 is not required.

## List of Subjects in 21 CFR Part 872

Medical devices.
Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs, 21 CFR part 872 is amended as follows:

## PART 872—DENTAL DEVICES

1. The authority citation for 21 CFR part 872 continues to read as follows:

Authority: 21 U.S.C. 351, 360, 360c, 360e, 360j, 371.
2. Section 872.1745 is added to subpart B to read as follows:

## §872.1745 Laser fluorescence caries detection device.

(a) Identification. A laser fluorescence caries detection device is a laser, a fluorescence detector housed in a dental handpiece, and a control console that performs device calibration, as well as
variable tone emitting and fluorescence measurement functions. The intended use of the device is to aid in the detection of tooth decay by measuring increased laser induced fluorescence.
(b) Classification. Class II, subject to the following special controls:
(1) Sale, distribution, and use of this device are restricted to prescription use in accordance with $\S 801.109$ of this chapter;
(2) Premarket notifications must include clinical studies, or other relevant information, that demonstrates that the device aids in the detection of tooth decay by measuring increased laser induced fluorescence; and
(3) The labeling must include detailed use instructions with precautions that urge users to:
(i) Read and understand all directions before using the device,
(ii) Store probe tips under proper conditions,
(iii) Properly sterilize the emitterdetector handpick before each use, and
(iv) Properly maintain and handle the instrument in the specified manner and condition.
Dated: March 29, 2000.

## Linda S. Kahan,

Deputy Director for Regulations Policy, Center for Devices and Radiological Health.
[FR Doc. 00-8597 Filed 4-6-00; 8:45 am] BILLING CODE 4160-01-F

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

## Food and Drug Administration

## 21 CFR Part 876

## [Docket No. 00P-1120]

## Medical Devices; GastroenterologyUrology Devices; Nonimplanted, Peripheral Electrical Continence Device

agency: Food and Drug Administration, HHS.
ACTION: Final rule.
summary: The Food and Drug Administration (FDA) is classifying the nonimplanted, peripheral electrical continence device into class II (special controls). The special controls that will apply to this device are set forth below. The agency is taking this action in response to a petition submitted under the Federal Food, Drug, and Cosmetic Act (the act) as amended by the Medical Device Amendments of 1976, the Safe Medical Devices Act of 1990, and the Food and Drug Administration Modernization Act of 1997. The agency is classifying this device into class II
(special controls) in order to provide a reasonable assurance of safety and effectiveness of the device.
DATES: This rule is effective May 8, 2000.

FOR FURTHER INFORMATION CONTACT:
Laura J. Byrd, Center for Devices and Radiological Health (HFZ-470), Food and Drug Administration, 9200 Corporate Blvd., Rockville, MD 20850, 301-594-2194.

## SUPPLEMENTARY INFORMATION:

## I. Background

In accordance with section $513(f)(1)$ of the act ( 21 U.S.C. $360 \mathrm{c}(\mathrm{f})(1)$ ), devices that were not in commercial distribution before May 28, 1976, the date of enactment of the Medical Device Amendments of 1976 (the amendments), generally referred to as postamendments devices, are classified automatically by statute into class III without any FDA rulemaking process. These devices remain in class III and require premarket approval, unless and until the device is classified or reclassified into class I or II or FDA issues an order finding the device to be substantially equivalent, in accordance with section 513(i) of the act, to a predicate device that does not require premarket approval. The agency determines whether new devices are substantially equivalent to previously marketed devices by means of premarket notification procedures in section $510(\mathrm{k})$ of the act ( 21 U.S.C. $360(\mathrm{k})$ ) and 21 CFR part 807 of the FDA regulations. Section 513(f)(2) of the act provides that any person who submits a premarket notification under section $510(\mathrm{k})$ of the act for a device that has not previously been classified may, within 30 days after receiving an order classifying the device in class III under section 513(f)(1), request FDA to classify the device under the criteria set forth in section 513(a)(1). FDA shall, within 60 days of receiving such a request, classify the device by written order. This classification shall be the initial classification of the device. Within 30 days after the issuance of an order classifying the device, FDA must publish a notice in the Federal Register announcing such classification.

On January 24, 2000, UroSurge, Inc., submitted a petition under section 513(f)(2) of the act requesting classification of its Percutaneous SANS Device intended for use in patients suffering from urinary urgency, frequency, or urge incontinence. After review of the information submitted in the petition and the premarket notification (K992069), FDA issued an order on February 9, 2000, classifying
the UroSurge Percutaneous SANS (Stoller Afferent Nerve Stimulator) Device and substantially equivalent devices of this generic type into class II under the generic name,
"nonimplanted, peripheral nerve stimulator for pelvic floor dysfunction." FDA has determined that the nonimplanted, peripheral nerve stimulator for pelvic floor dysfunction can be classified in class II with the establishment of the following special controls:

1. That sale, distribution, and use of this device are restricted to prescription use in accordance with § 801.109 (21 CFR 801.109).
2. That the labeling must bear all information required for the safe and effective use of the device as outlined in §801.109(c), including a detailed summary of the clinical information upon which the instructions are based.
FDA believes that these class II special controls, in addition to the general controls, provide reasonable assurance of the safety and effectiveness of the device.

## II. Environmental Impact

The agency has determined under 21 CFR 25.34(b) that this action is of a type that does not individually or cumulatively have a significant effect on the human environment. Therefore, neither an environmental assessment nor an environmental impact statement is required.

## III. Analysis of Impacts

FDA has examined the impacts of the final rule under Executive Order 12866 and the Regulatory Flexibility Act (5 U.S.C. 601-612) and the Unfunded Mandates Reform Act of 1995 (Public Law 104-4). Executive Order 12866 directs agencies to assess all costs and benefits of available regulatory alternatives and, when regulation is necessary, to select regulatory approaches that maximize net benefits (including potential economic, environmental, public health and safety, and other advantages; distributive impacts; and equity). The agency believes that this final rule is consistent with the regulatory philosophy and principles identified in the Executive Order. In addition, the final rule is not a significant regulatory action as defined by the Executive Order and so it is not subject to review under the Executive Order. The Regulatory Flexibility Act requires agencies to analyze regulatory options that would minimize any significant impact of a rule on small entities. Classification of these devices into class II will relieve manufacturers of the device of the cost of complying
with the premarket approval requirements of section 515 of the act (21 U.S.C. 360e), and may permit small potential competitors to enter the marketplace by lowering their costs.
FDA knows of only one manufacturer of this type of device. The agency therefore certifies that the final rule will not have a significant impact on a substantial number of small entities. In addition, this final rule will not impose costs of $\$ 100$ million or more on either the private sector or State, local, and tribal governments in the aggregate, and, therefore, a summary statement of analysis under section 202(a) of the Unfunded Mandates Reform Act is not required.

## IV. Paperwork Reduction Act of $\mathbf{1 9 9 5}$

This final rule contains no collections of information. Therefore, clearance by the Office of Management and Budget under the Paperwork Reduction Act of 1995 is not required.

## List of Subjects in 21 CFR Part 876

Medical devices.
Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs, 21 CFR part 876 is amended as follows:

## PART 876-GASTROENTEROLOGYUROLOGY DEVICES

1. The authority citation for 21 CFR part 876 continues to read as follows:
Authority: 21 U.S.C. 351, 360, 360c, 360e, 360j, 360l, 371.
2. Section 876.5310 is added to subpart F to read as follows:
§876.5310 Nonimplanted, peripheral electrical continence device.
(a) Identification. A nonimplanted, peripheral electrical continence device is a device that consists of an electrode that is connected by an electrical cable to a battery-powered pulse source. The electrode is placed onto or inserted into the body at a peripheral location and used to stimulate the nerves associated with pelvic floor function to maintain urinary continence. When necessary, the electrode may be removed by the user.
(b) Classification. Class II, subject to the following special controls:
(1) That sale, distribution, and use of this device are restricted to prescription use in accordance with $\S 801.109$ of this chapter.
(2) That the labeling must bear all information required for the safe and effective use of the device as outlined in §801.109(c) of this chapter, including a detailed summary of the clinical
information upon which the instructions are based.

Dated: March 29, 2000.

## Linda S. Kahan,

Deputy Director for Regulations Policy, Center for Devices and Radiological Health.
[FR Doc. 00-8596 Filed 4-6-00; 8:45 am]
BILLING CODE 4160-01-F

## DEPARTMENT OF THE INTERIOR

## Office of Surface Mining Reclamation and Enforcement

## 30 CFR Part 913

[SPATS No. IL-097-FOR, Part III]

## Illinois Regulatory Program

AGENCY: Office of Surface Mining Reclamation and Enforcement (OSM), Interior.
ACTION: Final rule.
SUMMARY: OSM is approving part of an amendment to the Illinois regulatory program (Illinois program) under the Surface Mining Control and Reclamation Act of 1977 (SMCRA). Illinois proposed revisions to its program concerning subsidence control, water replacement, adjustment of performance bond amounts, administrative review, release of performance bonds, siltation structures, impoundments, hydrologic balance, disposal of noncoal mine wastes, revegetation, backfilling and grading, prime farmland, and State inspections. This final rule document addresses Illinois' revisions concerning release of performance bonds, siltation structures, impoundments, hydrologic balance, disposal of noncoal mine wastes, revegetation, backfilling and grading, and prime farmland. We addressed the remaining program topics in two previous final rule documents. Illinois intends to revise its program to be consistent with the corresponding Federal regulations, to provide additional safeguards, and to improve operational efficiency.
EFFECTIVE DATE: April 7, 2000.
FOR FURTHER INFORMATION CONTACT:
Andrew R. Gilmore, Director, Indianapolis Field Office, Office of Surface Mining, Minton-Capehart Federal Building, 575 North Pennsylvania Street, Room 301, Indianapolis, Indiana 46204-1521. Telephone: (317) 226-6700. Internet: INFOMAIL@indgw.osmre.gov.

## SUPPLEMENTARY INFORMATION:

I. Background on the Illinois Program II. Submission of the Amendment
III. Director's Findings
IV. Summary and Disposition of Comments V. Director's Decision
VI. Procedural Determinations

## I. Background on the Illinois Program

On June 1, 1982, the Secretary of the Interior conditionally approved the Illinois program. You can find background information on the Illinois program, including the Secretary's findings, the disposition of comments, and the conditions of approval in the June 1, 1982, Federal Register (47 FR 23883). You can find later actions concerning the Illinois program and previous amendments at 30 CFR 913.15, 913.16, and 913.17.

## II. Submission of the Proposed Amendment

By letter dated August 2, 1999 (Administrative Record No. IL-5044), the Illinois Department of Natural Resources (Department) submitted an amendment to the Illinois program under the Federal regulations at 30 CFR 732.17(b). The Department proposed to amend Title 62 of the Illinois Administrative Code (IAC) in response to our letters dated May 20, 1996, June 17, 1997, October 30, 1997, and January 15, 1999 (Administrative Record Nos. IL-1900, IL-2000, IL-2002, and IL5036, respectively), that we sent to Illinois under 30 CFR 732.17(c). The amendment also includes changes made at the Department's own initiative.
We announced receipt of the amendment in the August 17, 1999, Federal Register (64 FR 44674). In the same document, we opened the public comment period and provided an opportunity for a public hearing or meeting on the adequacy of the amendment. The public comment period closed on September 16, 1999. No one requested an opportunity to speak at a public hearing, so no hearing was held.

During our review of the amendment, we identified concerns relating to siltation structures, impoundments, performance bonds, and State inspections. We also identified some nonsubstantive editorial errors. We notified Illinois of these concerns and editorial errors by letter dated September 21, 1999 (Administrative Record No. IL-5048). We also separated the amendment into three parts in order to expedite the State program amendment process. Part I concerned revisions to Illinois' regulations relating to subsidence control and water replacement. Because we did not identify any concerns relating to Illinois' revisions for subsidence control and water replacement, we made our final decision on them in a final rule on

December 6, 1999 (64 FR 68024). Part II concerned revisions to Illinois’ regulations relating to adjustment of performance bond amounts and administrative review. On December 2, 1999, the Department requested that we proceed with our decision on these revisions (Administrative Record No. IL-5049). Because we did not identify any concerns relating to Illinois' revisions for adjustment of performance bond amounts and administrative review, we made our decision on them in a final rule on December 27, 1999 (64 FR 72275). Part III concerns revisions to Illinois' regulations relating to release of performance bonds, siltation structures, impoundments, hydrologic balance, disposal of noncoal mine wastes, revegetation, backfilling and grading,
and prime farmland. This final rule Federal Register document addresses IL-097-FOR, Part III revisions.

By letter dated January 27, 2000 (Administrative Record No. IL-5052), Illinois sent us revisions to its proposed program amendment. On February 1, 2000, by telephone, Illinois notified us of additional revisions (Administrative Record No. IL-5053). Based upon
Illinois' revisions to its amendment, we reopened the public comment period in the February 14, 2000, Federal Register ( 65 FR 7331). The public comment period closed on February 29, 2000.

## III. Director's Findings

Following, under SMCRA and the Federal regulations at 30 CFR 732.15 and 732.17, are our findings concerning
the revisions to the Illinois program pertaining to definitions, release of performance bonds, siltation structures, impoundments, hydrologic balance, disposal of noncoal mine wastes, revegetation, backfilling and grading, and prime farmland.

## A. Revisions to Illinois' Regulations That Are Minor.

Throughout the amended regulation sections discussed in this final rule, Illinois corrected typographical errors, punctuation, citation references, and other editorial-type errors; made minor wording changes; and simplified its use of numbers. Illinois also made some of the same types of corrections and changes in the sections listed in the table below:

| Topic | State regulation | Federal regulation |
| :---: | :---: | :---: |
| Definitions | 62 IAC 1701.Appendix A | 30 CFR 701.5. |
| Hydrologic Information | 62 IAC 1784.14(a) | 30 CFR 784.14(a). |
| Subsidence Control Plan | 62 IAC 1784.20(b), (b)(2) | 30 CFR 784.20(b), (b)(2). |
| Period of Liability .................................................. | 62 IAC 1800.13. | 30 CFR 800.13. |
| Hydrologic Balance Protection ............................... | 62 IAC 1817.41(c), (d), and (e). ........................... | 30 CFR 817.41(c), (d), and (e). |
| Availability of Records .......................................... | 62 IAC 1840.14(b), (c)(2) .................................... | 30 CFR 840.14(b) and (c). |

These minor changes did not alter the requirements of the previously approved provisions in the Illinois regulations. Therefore, we find that they will not make the Illinois regulations less effective than the Federal regulations.
B. 62 IAC 1701.Appendix A, Definitions

Illinois removed the following definition of "Institute" because it is no longer applicable to the Illinois program:
"Institute" means the Department of Energy and Natural Resources or such other agency as designated by the Director in accordance with Section 7.03 of the State Act.
The Department of Energy and Natural Resources no longer exists. On March 1, 1995, the Governor of Illinois signed Executive Order Number 2 (1995) that merged the Department of Energy and Natural Resources into the Department of Natural Resources. On February 9, 1999 (64 FR 6191), we approved the changes to section 7.03 of the State Act and to Illinois' regulations at 62 IAC Part 1764 that removed references to the Department of Energy
and Natural Resources. Therefore, we find that the removal of this definition will not make the Illinois regulations less effective than the Federal Regulations.
C. Siltation Structures, Impoundments, Banks, Dams, and Embankments.

By letters dated June 17, 1997, and January 15, 1999, under 30 CFR 732.17(c), we notified Illinois that it needed to change the Illinois regulations relating to siltation structures, impoundments, banks, dams, and embankments to be no less effective than the changes that were made to the Federal regulations on October 20, 1994 (59 FR 53022). In the October 20, 1994, rulemaking, OSM included standards from the U. S. Department of Agriculture, Soil Conservation Service Technical Release No. 60 (210-VITR60, Oct. 1985) as part of the Federal requirements for siltation structures and impoundments. These changes were made as a result of decisions by the U.S. District Court of the District of Columbia in In Re: Permanent Surface Mining Regulation Litigation (II), No. 79-1144 (D.D.C. July 15, 1985) and In Re: NWF
v. Lujan, No. 88-3345 (D.D.C. August 30, 1990). In response to these notifications, Illinois proposed several changes to its regulations at 62 IAC $1780.25,1816.46$, and 1816.49 for surface mining operations and 62 IAC 1784.16, 1817.46, and 1817.49 for underground mining operations.

1. Illinois made minor wording changes, including changing the term "operator" to the term "permittee"; revised all outdated citation references; and revised cross-references and paragraph notations to reflect organizational changes resulting from this amendment. We find that these changes are nonsubstantive and will not make Illinois' regulations less effective than the Federal regulations.
2. Revisions to Illinois' Regulations That Are Substantively Identical to the Corresponding Provisions of the Federal Regulations. The changes made to the State regulations listed in the table below contain language that is the same as or similar to the corresponding changes made to the Federal regulations on October 20, 1994. Differences between the State regulations and the Federal regulations are minor.

| Topic | State regulation | Federal regulation |
| :---: | :---: | :---: |
| Reclamation Plan: Siltation Structures, Impoundments, Banks, Dams, and Embank- | $\begin{aligned} & 62 \text { IAC 1780.25(a), (a)(1)(A), (a)(2), (a)(2)(A) } \\ & \text { and (B), (a)(3), (a)(3)(A), (b), (f). } \end{aligned}$ | $\begin{aligned} & 30 \text { CFR } 780.25(\mathrm{a}) \text {, (a)(1)(i), (a)(2), (a)(2)(i) } \\ & \text { and (ii), (a)(3), (a)(3)(i), (b), (f). } \end{aligned}$ |


| Topic | State regulation | Federal regulation |
| :---: | :---: | :---: |
| Reclamation Plan: Siltation Structures, Impoundments, Banks, Dams, and Embankments. | 62 IAC 1784.16(a), (a)(1)(A), (a)(2), (a)(2)(A) and (B), (a)(3), (a)(3)(A) and (B), (b)(1), (f). | 30 CFR 784.16(a), (a)(1)(i), (a)(2), (a)(2)(i) and (ii), (a)(3), (a)(3)(i) and (ii), (b), (f). |
| Hydrologic Balance: Siltation Structures ... | 62 IAC 1816.46(c)(2). | 30 CFR 816.46(c)(2) |
| Impoundments ...................................... | 62 IAC 1816.49(a)(1), (a)(4)(A) and (B), (a)(5), (a)(6)(A), (a)(10)(A), (a)(11), (b)(9)(A) and (C), (c)(1), (c)(2)(B)(i) and (ii). | 30 CFR 816.49(a)(1), (a)(4)(i) and (ii), (a)(5), (a)(6)(i), (a)(9)(ii)(A) and (C), (a)(12), (c)(2)(i) and (ii). |
| Hydrologic Balance: Siltation Structures | 62 IAC 1817.46(c)(2) | 30 CFR 817.46(c)(2). |
| Impoundments .................... | 62 IAC 1817.49(a)(1), (a)(4)(A) and (B), (a)(5), (a)(6)(A), (a)(10)(A), (a)(11), (b)(9)(A) and (C), (c)(1), (c)(2)(B)(i) and (ii). | 30 CFR 817.49(a)(1), (a)(4)(i) and (ii), (a)(5), (a)(6)(i), (a)(9)(ii)(A) and (C), (a)(12), (c)(2)(i) and (ii). |

Because the changes made to the above State regulations have the same meaning as the changes made to the corresponding Federal regulations, we find that the Illinois regulations are no less effective than the Federal regulations.

## D. 62 IAC 1800.40, Requirement To Release Performance Bonds

## 1. Illinois revised 62 IAC

1800.40(a)(1) to allow permittees to authorize a person to act on their behalf in filing an application for bond release and to allow the Department to initiate an application for bond release. Illinois also added a provision that requires the Department to undertake the notification and certification requirements of the applicant for bond releases initiated by the Department.
While the counterpart Federal regulation at 30 CFR 800.40(a)(1) allows a permittee to file an application for bond release, the Federal regulations are silent as to whether a regulatory authority may initiate bond release proceedings. However, a similar provision was approved for the Kentucky program on December 31, 1990 (55 FR 53490). Under Illinois' proposal, bond release proceedings initiated by the Department must conform with the same procedural steps as a bond release initiated by the permittee. Thus, the public participation and notification requirements of section 519 of SMCRA and the Federal regulations at 30 CFR 800.40 would still apply when the regulatory authority initiated a bond release in Illinois. There are also circumstances, such as the release of jurisdiction from an abandoned but fully reclaimed site, where it may be necessary for a party other than the permittee to initiate bond release. For the above reasons, we find that allowing the regulatory authority to initiate bond release does not make the Illinois regulations at 62 IAC 1800.40 less effective than the Federal regulations at 30 CFR 800.40.
2. Illinois removed its reference to the "operator" in the first sentence of 62 IAC 1800.40(a)(2) and added a reference to the "applicant." Illinois removed its reference to the "operator's" in the second sentence of 62 IAC 1800.40(a)(2) and added a reference to the
"permittee's." Illinois removed its reference to the "permittee" in 62 IAC 1800.40(a)(3) and added a reference to the "applicant." These changes were appropriate and further clarified that the notification and certification requirements for bond release must be completed, regardless of whether the application was initiated by the permittee, a person authorized to act for the permittee, or the Department. We find that the changes made to 62 IAC 1800.40(a)(2) and (a)(3) will not make Illinois' regulations less effective than the counterpart Federal regulations at 30 CFR 800.40(a)(2) and (a)(3).
3. At 62 IAC 1800.40(b)(2), Illinois added a requirement that the Department notify, by certified mail, the municipality and county in which the surface coal mining operation is located of the Department's final administrative decision to release or not to release all or part of the performance bond. The counterpart Federal regulation requirement at 30 CFR 800.40(e) also requires the regulatory authority to notify the municipality by certified mail before the release of all or a portion of the bond. We find that Illinois' new requirement is consistent with and no less effective than the counterpart requirement in the Federal regulation at 30 CFR 800.40(e).

## E. 62 IAC 1816.89 (Surface Mining

 Operations) and 1817.89 (Underground Mining Operations) Disposal of Noncoal Mine WastesAt 62 IAC 1816.89(b) and 1817.89(b), Illinois is requiring that noncoal mine waste disposal areas reclaimed to cropland capability have a minimum of four feet of suitable soil cover. There is no counterpart Federal requirement for a minimum of four feet of soil cover at 30 CFR 816.89(b) and 817.89(b).

However, the Federal and State regulations for soil replacement on prime farmland at 30 CFR 823.14(b) and 62 IAC 1823.14(a), respectively, require a minimum depth of four feet of soil and substitute soil material in most cases. Also, at 62 IAC 1825.14(a)(3), the Illinois regulation for soil replacement on high capability lands requires a minimum depth of four feet of darkened surface soil and agricultural root medium with specified exceptions. Based on the above discussion, we find that Illinois' requirement for soil cover depth at 62 IAC 1816.89(b) and 1817.89(b) is consistent with the Federal regulation requirement and other Illinois regulation requirements for cropland capable land. Therefore, we are approving this requirement.

## F. 62 IAC 1817.101 (Underground Mining Operations)—Backfilling and Grading: General Requirements

Illinois revised 62 IAC 1817.101(a) to require that coal operators backfill and grade surface areas disturbed incident to underground mining activities in accordance with the time schedule approved by the Department in the permit, but not later than 12 months after cessation of active use as determined by the Department.
There is no specific Federal regulation counterpart. However, the Federal regulation at 30 CFR 817.100 requires that reclamation efforts, including backfilling and grading, occur as contemporaneously as practicable with underground coal mining operations. It also allows the regulatory authority to establish schedules that define contemporaneous reclamation. We find that Illinois' regulation requirements at 62 IAC 1817.101(a) are consistent with and no less effective than the Federal regulation requirements for contemporaneous reclamation at 30 CFR 817.100 .

## G. Revegetation

1. 62 IAC 1816.111 (Surface Mining Operations) and 1817.111

## (Underground Mining Operations)-

Revegetation: General Requirements. a. Illinois revised citation references in 62 IAC 1816.111(b)(5) for the Illinois Noxious Weed Law, the Illinois Seed Law, and the Illinois Pesticide Act. These changes did not alter the requirements of the previously approved provisions in the Illinois regulations. Therefore, we find that they will not make the Illinois regulations less effective than the Federal regulations.
b. Previously at 62 IAC 1816.111(d) and 1817.111 (d), Illinois required that prime farmlands granted an exemption in accordance with 62 IAC 1785.17(a)(5) must meet the requirements of 62 IAC 1823.15. (Illinois' regulation at 62 IAC 1823.15 contains the revegetation requirements for prime farmland soils.) Illinois removed this requirement. We approved Illinois' removal of its exemption at 62 IAC 1785.17(a)(5) on May 29, 1996 ( 61 FR 26801). Therefore, the requirement at 62 IAC 1816.111(d) and $1817.111(\mathrm{~d})$ is moot, and its removal is appropriate. We find that Illinois' revised regulations at 62 IAC 1816.111(d) and 1817.111(d) are consistent with and no less effective than the counterpart Federal regulations at 30 CFR 816.111(d) and 817.111(d).
2. 62 IAC 1816.116 (Surface Mining Operations) and 1817.116 (Underground Mining Operations)Success of Revegetation. For areas which have incurred five unsuccessful attempts to meet the production required by 62 IAC 1816.116/ 1817.116(a)(3)(C), 1816.116/ 1817.116(a)(3)(E), or 62 IAC 1823.15, Illinois added a provision at 62 IAC 1816.116(b)(2) and 1817.116(b)(2) that requires the person who conducts mining activities to initiate a soil compaction and fertility testing plan, subject to the approval of the Department. If the plan is not initiated, the person who conducts mining activities must initiate deep tillage on the areas. Sections 1816.116(a)(3)(C) and 1817.116(a)(3)(C) provide the production standards for cropland areas. Sections 1816.116(a)(3)(E) and
1817.116(a)(3)(E) contain the production standards for pasture, hayland, and grazing land. Section 1823.15 provides the revegetation requirements for prime farmland.
The Federal regulations at 30 CFR 816.116(b)(1) and 817.116(b)(1) provide the revegetation success standards for grazing land and pasture land. The Federal regulations at 30 CFR 816.116(b)(2) and 817.116(b)(2) contain the revegetation success standards for cropland. The Federal regulations at 30 CFR 823.15 provide the revegetation
success standards for prime farmland. None of these regulations contain a counterpart to Illinois' proposed provision. However, we have always maintained that the primary responsibility for regulating surface coal mining and reclamation operations should rest with the States. The Federal regulations for revegetation were specifically written to allow States to account for regional diversity in terrain, climate, soils, and other conditions where mining occurs. In the May 12, 1983, final rule for 30 CFR Part 823, we recognized the possibility of alternative reclamation approaches by the operator if soil productivity was not restored within five or six years after initial planting (48 FR 21446). On November 25, 1998, we approved a provision for the Arkansas program that required the permittee to submit a mitigation plan if he or she could not demonstrate revegetation success in the fifth year after completion of initial seeding on cropland areas ( 63 FR 65062). The permittee had to include a statement of the problem and a discussion of methods to correct the problem. We have historically recognized that compaction of soil horizons decreases vegetative growth and crop yields and that deep tillage alleviates compaction (30 CFR 823.14(d); 48 FR 21452, 21457, May 12, 1983). For the reasons discussed above, we find that the proposed revegetation requirements at 30 CFR 816.116(b)(2) and 817.116(b)(2) will not make the Illinois regulations less effective than the Federal regulations at 30 CFR 816.116, 817.116, and 823.15.
H. 62 IAC 1823.14 Prime Farmland: Soil Replacement

Illinois revised subsection (d) by adding the following new requirement:

In those areas where the B or C horizons were not removed but may have been compacted or otherwise damaged during the mining operation, the permittee shall engage in deep tillage or other appropriate means to restore premining capabilities.

We find that Illinois' proposed requirement is substantively identical to the counterpart Federal regulation requirement at 30 CFR 823.14(d), and we are approving it.

## IV. Summary and Disposition of Comments

Federal Agency Comments
On August 10, 1999, and February 3, 2000, we asked for comments from various Federal agencies who may have an interest in the Illinois program amendment (Administrative Record Nos. IL-5045 and IL-5054,
respectively). We requested comments under section 503(b) of SMCRA and 30 CFR 732.17(h)(11)(i) of the Federal regulations.

By letter dated September 2, 1999, the Natural Resources Conservation Services (NRCS) provided two comments (Administrative Record No. IL-5047). The NRCS commented that:
(1) For clarity, references to the "U.S. Department of Agriculture, Soil Conservation Service Technical Release No. 60 (210-VITR60, Oct. 1985), Technical Release No. 60 (TR-60)" should be recorded to read "U.S. Department of Agriculture, Soil Conservation Service Technical Release No. 60 (210-VITR60, Oct. 1985), herein after referred to as TR-60."
(2) In more than one instance, NRCS IL Technical Standard IL-378, "Ponds," June 1992 is cited. The NRCS may revise that standard at any time and does not archive Technical Guide Standards. The State will need to archive a copy of the IL-378, June 1992 for future reference.

The references cited in comment (1) are substantively identical to the Federal counterpart references. However, both comments were provided to Illinois for its consideration.

By letter dated February 14, 2000 (Administrative Record No. IL-5056), the NRCS commented on Illinois' duplication of the design requirements under sections 1780.25(a)(2) and 1780.25(a)(3). The NRCS recommend that Illinois eliminate subsection (a)(3) and state at subsection (a)(2) that all impoundments shall meet the design requirements under subsection (a)(2).

Illinois' regulations at sections 1780.25(a)(2) and 1780.25(a)(3) are not inconsistent with the counterpart Federal requirements. However this comment was provided to Illinois for its consideration.

## Environmental Protection Agency (EPA)

Under 30 CFR 732.17(h)(11)(i) and (ii), OSM is required to request comments and get the written concurrence of the EPA with respect to those provisions of the program amendment that relate to air or water quality standards promulgated under the authority of the Clean Water Act (33 U.S.C. 1251 et seq.) or the Clean Air Act (42 U.S.C. 7401 et seq.). None of the revisions that Illinois proposed to make in this amendment pertain to air or water quality standards. However, by letters dated August 10, 1999, and February 3, 2000, we requested comments from the EPA on the State's amendment (Administrative Record Nos. IL-5045 and IL-5054, respectively). The EPA did not respond to our request.

## State Historical Preservation Officer (SHPO) and the Advisory Council on Historic Preservation (ACHP)

Under 30 CFR 732.17(h)(4), we are required to request comments from the SHPO and ACHP on amendments that may have an effect on historic properties. On August 10, 1999, and February 3, 2000, we requested comments on Illinois' amendment (Administrative Record Nos. IL-5045 and IL-5054, respectively), but neither responded to our request.

## Public Comments

We requested public comments on the proposed amendment, but did not receive any.

## V. Director's Decision

Based on the above findings, we are approving the amendments to the Illinois program as submitted by the Department on August 2, 1999, and as revised on January 27 and February 1, 2000.

We approve the regulations that Illinois proposed with the provision that they be published in identical form to the regulations submitted to and reviewed by OSM and the public. To implement this decision, we are amending the Federal regulations at 30 CFR Part 913, which codify decisions concerning the Illinois program. We are making this final rule effective immediately to expedite the State program amendment process and to encourage Illinois to bring its program into conformity with the Federal standards. SMCRA requires consistency of State and Federal standards.

## VI. Procedural Determinations

Executive Order 12866—Regulatory Planning and Review
This rule is exempted from review by the Office of Management and Budget under Executive Order 12866.

## Executive Order 12630—Takings

This rule does not have takings implications. This determination is based on the analysis performed for the counterpart Federal regulation.

## Executive Order 13132—Federalism

This rule does not have federalism implications. SMCRA delineates the roles of the Federal and State governments with regard to the regulation of surface coal mining and reclamation operations. One of the purposes of SMCRA is to "establish a nationwide program to protect society and the environment from the adverse effects of surface coal mining operations." Section 503(a)(1) of

SMCRA requires that State laws regulating surface coal mining and reclamation operations be "in accordance with" the requirements of SMCRA, and section 503(a)(7) requires that State programs contain rules and regulations "consistent with" regulations issued by the Secretary under SMCRA.
Executive Order 12988—Civil Justice Reform

The Department of the Interior has conducted the reviews required by section 3 of Executive Order 12988 and has determined that, to the extent allowed by law, this rule meets the applicable standards of subsections (a) and (b) of that section. However, these standards are not applicable to the actual language of State regulatory programs and program amendments since each such program is drafted and promulgated by a specific State, not by OSM. Under sections 503 and 505 of SMCRA (30 U.S.C. 1253 and 1255) and 30 CFR 730.11, 732.15, and 732.17(h)(10), decisions on proposed State regulatory programs and program amendments submitted by the States must be based solely on a determination of whether the submittal is consistent with SMCRA and its implementing Federal regulations and whether the other requirements of 30 CFR Parts 730, 731, and 732 have been met.

## National Environmental Policy Act

Section 702(d) of SMCRA (30 U.S.C. 1292(d)) provides that a decision on a proposed State regulatory program provision does not constitute a major Federal action within the meaning of section 102(2)(C) of the National Environmental Policy Act (NEPA) (42 U.S.C. 4332(2)(C)). A determination has been made that such decisions are categorically excluded from the NEPA process (516 DM 8.4.A).

## Paperwork Reduction Act

This rule does not contain information collection requirements that require approval by the Office of Management and Budget under the Paperwork Reduction Act ( 44 U.S.C. 3507 et seq.).

## Regulatory Flexibility Act

The Department of the Interior has determined that this rule will not have a significant economic impact on a substantial number of small entities under the Regulatory Flexibility Act (5 U.S.C. 601 et seq.). The State submittal which is the subject of this rule is based upon counterpart Federal regulations for which an economic analysis was prepared and certification made that
such regulations would not have a significant economic effect upon a substantial number of small entities. Accordingly, this rule will ensure that existing requirements previously promulgated by OSM will be implemented by the State. In making the determination as to whether this rule would have a significant economic impact, the Department relied upon the data and assumptions for the counterpart Federal regulation.

## Small Business Regulatory Enforcement Fairness Act

This rule is not a major rule under 5 U.S.C. 804(2), the Small Business Regulatory Enforcement Fairness Act. This rule:
a. Does not have an annual effect on the economy of $\$ 100$ million.
b. Will not cause a major increase in costs or prices for consumers, individual industries, federal, state, or local government agencies, or geographic regions.
c. Does not have significant adverse effects on competition, employment, investment, productivity, innovation, or the ability of U.S. based enterprises to compete with foreign-based enterprises.
This determination is based upon the fact that the State submittal which is the subject of this rule is based upon counterpart Federal regulations for which an analysis was prepared and a determination made that the Federal regulation was not considered a major rule.

## Unfunded Mandates

This rule will not impose a cost of $\$ 100$ million or more in any given year on any governmental entity or the private sector.

## List of Subjects in 30 CFR Part 913

Intergovernmental relations, Surface mining, Underground mining.

## Dated: March 17, 2000.

## Charles E. Sandberg,

Acting Regional Director, Mid-Continent Regional Coordinating Center.

For the reasons set out in the preamble, 30 CFR part 913 is amended as set forth below:

## PART 913-ILLINOIS

1. The authority citation for part 913 continues to read as follows:
Authority: 30 U.S.C. 1201 et seq.
2. Section 913.15 is amended in the table by adding a new entry in chronological order by "Date of final publication" to read as follows:

## §913.15 Approval of Illinois regulatory

 program amendments.```
* * * * *
```

| Original amendment <br> submission date | Date of final <br> publication | Citation/description |
| :---: | :---: | :---: |

August 2, 1999
April 7, 200062 IAC 1701.Appendix A; 1780.25(a), (a)(1)(A), (a)(2), (a)(2)(A) and (B), (a)(3), (a)(3)(A), (b), (f); 1784.14(a); 1784.16(a), (a)(1)(A), (a)(2), (a)(2)(A) and (B), (a)(3), (a)(3)(A) and (B), (b)(1), (f); 1784.20(b), (b)(2); 1800.13(c), (d)(2); 1800.40(a)(1), (2), and (3), (b)(2); 1816.46(c)(2); 1816.49(a)(1) and (2), (a)(4)(A) and (B), (a)(5), (a)(6)(A), (a)(10)(A) and (C), (a)(11), (b)(9)(A) and (C), (c)(1) and (2), (c)(2)(B), (c)(2)(B)(i) and (ii); 1816.89(b); 1816.111(b)(5), (d); 1816.116(a), (b)(2); 1817.41 (c), (d), (e); 1817.46(c)(2); 1817.49(a)(1) and (3), (a)(4)(A) and (B), (a)(5), (a)(6)(A), (a)(10)(A), (B), and (C), (a)(11), (b)(7) and (8); (b)(9)(A) and (C), (c)(1), (c)(2), (c)(2)(B)(i) and (ii); 1817.89(b); 1817.101(a); 1817.111(d); 1817.116(a)(2)(C), (b)(2); 1823.14(d); 1840.14(b), (c)(2).
[FR Doc. 00-8665 Filed 4-6-00; 8:45 am] BILLING CODE 4310-05-P

## DEPARTMENT OF TRANSPORTATION

## Coast Guard

## 33 CFR Part 117

[CGD 07-00-023]
RIN 2115-AE47
Drawbridge Operation Regulations; Ortega River, Jacksonville, FL

Agencr: Coast Guard, DOT.
ACTION: Notice of temporary deviation from regulations.

SUMMARY: Notice is hereby given that the Commander, Seventh Coast Guard District has approved a temporary deviation from the regulations governing the operation of the CSX Railroad Drawbridge across Ortega River, mile 1.1, which parallels U.S. 17, at Jacksonville, Duval County, Florida. This deviation allows the drawbridge owner or operator to close the bridge from 7 a.m. to 7 p.m. each day on April 11 and 12, 2000, with alternative dates of April 18, 2000 and April 19, 2000. The draw shall open as soon as possible for public vessels of the United States, State and local vessels used in public safety, vessels in distress where a delay would endanger life or property, commercial vessels engaged in rescue or emergency salvage operations, and vessels seeking shelter from severe weather. This temporary deviation is issued to allow the bridge owner to safely conduct necessary repairs to the drawbridge.
DATES: This deviation is effective from 7 a.m on April 11, 2000, to 7 p.m. on April 19, 2000.
FOR FURTHER INFORMATION CONTACT: Mr. Brodie Rich, Project Manager, Seventh

Coast Guard District, Bridge Section at (305) 536-5117.

SUPPLEMENTARY INFORMATION: The CSX railroad drawbridge across Ortega River at Jacksonville, has a vertical clearance of 2 feet above mean high water (MHW) and 3 feet above mean low water (MLW) measured at the fenders in the closed position. On March 6, 2000, TIC The Industrial Company, the contractor representing the drawbridge owner, requested a deviation from the current operating schedule in 33 CFR 117.5. This temporary deviation was requested to allow necessary repairs to the drawbridge in a critical time sensitive manner. The contractor has advised us that the drawbridge is likely to suffer failure of operation and increase the intensity and length of time in order to complete the necessary repairs.

The District Commander has granted a temporary deviation from the operating requirements listed in 33 CFR 117.5 for the purpose of conducting repairs to the drawbridge. During this deviation period, the CSX Railroad Drawbridge need not open for the passage of vessels from $7 \mathrm{a} . \mathrm{m}$. to $7 \mathrm{p} . \mathrm{m}$. each day on April 11 and 12, 2000, with an alternate date of April 18 and 19, 2000, if inclement weather prevents repairs on April 11 and 12. The deviation period begins on April 11, 2000 and ends on April 19, 2000.

Dated: March 22, 2000.
T.W. Allen,

Admiral, U.S. Coast Guard, Commander, Seventh Coast Guard District.
[FR Doc. 00-8658 Filed 4-6-00; 8:45 am]
BILLING CODE 4910-15-P

## DEPARTMENT OF TRANSPORTATION

## Coast Guard

## 33 CFR Part 162

[CGD17-99-002]
RIN 2115-AF81

## Anchorage Ground; Safety Zone; Speed Limit; Tongass Narrows and Ketchikan, AK

AGENCY: Coast Guard, DOT.
ACTION: Interim rule; request for comments.
summary: The Coast Guard is revising its 1999 interim rule on the Tongass Narrows seven-knot speed limit and is requesting additional public comment before finalizing the rule. Numerous public comments received during 1999 criticized the speed limit exemption applicable to "non-commercial, open skiffs of less than 20 feet in length" as too restrictive. The Coast Guard is revising the exemption to include all small vessels of 23 feet or less, registered length. This change allows an increased number of small vessels that create little wake to transit crowded areas of Tongass Narrows more quickly, thereby relieving congestion.
DATES: The interim rule becomes effective May 8, 2000. Comments regarding this interim rule must be received by October 31, 2000.

A public hearing will be held on August 19, 2000 at 7 p.m. AST.
ADDRESSES: You may mail comments to Commander (m), Seventeenth Coast Guard District, Federal Building, 709 West 9th Street, seventh floor, room 753, Juneau, Alaska, between 8 a.m. and 4 p.m., Monday through Friday, except Federal holidays. The telephone number is 907-463-2187. The Seventeenth Coast Guard District, Marine Safety Division, maintains the public docket
for this rulemaking. Comments and material received from the public, as well as documents indicated in this preamble as being available in the docket, are part of the docket and are available for inspection or copying at room 753 between 8 a.m. and 4 p.m., Monday through Friday, except Federal holidays. The public hearing will be held at the Ted Ferry Civic Center, 888 Venetia Avenue, Ketchikan, Alaska.
FOR FURTHER INFORMATION CONTACT: For information concerning this document, call the Supervisor, U.S. Coast Guard Marine Safety Detachment, Ketchikan, Alaska, telephone 907-225-4496.

## SUPPLEMENTARY INFORMATION:

## Request for Comments

The Coast Guard encourages you to participate in this rulemaking by submitting written data, views, or arguments. Persons submitting comments should include their names and addresses, identify this rulemaking (CGD17-99-002) and the specific section of this document to which each comment applies, and give the reason for each comment. Please submit all comments and attachments in an unbound format, no larger than $8^{1 / 2}$ by 11 inches, suitable for copying and electronic filing. If you want acknowledgment of receipt of your comments, you should enclose a stamped, self-addressed postcard or envelope.
The Coast Guard will consider all comments received during the comment period. It may change this interim rule in view of the comments.

The Coast Guard has scheduled a public hearing for 7 p.m. (AST), August 19, 2000, at the Ted Ferry Civic Center, 888 Venetia Avenue, Ketchikan, Alaska.

Persons may request an additional public hearing by writing to Commander (m), Seventeenth Coast Guard District at the address under ADDRESSES. The request should include the reasons why an additional hearing would be beneficial. If it determines that the opportunity for additional oral presentations will aid this rulemaking, the Coast Guard will hold an additional public hearing at a time and place announced by later notice in the

## Federal Register.

## Regulatory History

On March 25, 1999, the Coast Guard published a Notice of Proposed
Rulemaking (NPRM) entitled
"Anchorage Ground, Safety Zone, Speed Limit, Tongass Narrows and Ketchikan, AK" in the Federal Register ( 64 FR 14414).

On June 1, 1999 an interim rule was published entitled "Anchorage Ground,

Safety Zone, Speed Limit, Tongass Narrows and Ketchikan, AK" in the Federal Register (64 FR 29554). A correction was issued on June 15, 1999 in the Federal Register (64 FR 32103).

## Background and Purpose

The interim rule published in 1999 revised the safety zone in Ketchikan Harbor as well as the 7-knot speed limit in Tongass Narrows. It redesignated the safety zone in Ketchikan Harbor as an anchorage ground and required transiting vessels, other than those engaged in anchoring evolutions, to proceed through the anchorage by the most direct route without delay or sudden course changes.

## Discussion of Comments and Changes

The Coast Guard received comments from 21 persons regarding the 1999 interim rule. The comments included oral comments made at the August 27th, 1999, public meeting and four letters. No comments were received concerning the anchorage area and this portion of the interim rule remains unchanged. Numerous comments criticized the speed limit exemption for being unnecessarily restrictive. Responses to these comments on the 1999 interim rule are discussed in the following paragraphs.

The most frequent comments addressed the exemption for "noncommercial open skiffs". Of the 21 persons that commented on the 1999 interim rule (several persons commented on multiple aspects), 10 commented on this exemption, stating that the term "non-commercial, open skiff" created confusion as to when a vessel was considered "open" vice enclosed. The Coast Guard agrees and the term "non-commercial, open skiff", has been removed.

Nine comments were received concerning the vessel length exemption from the 7 -knot speed limit based on vessel length of less than 20 feet. Seven of the comments favored increasing the size of vessels exempted to 26 feet and one favored increasing the size to 25 feet. Two comments favored keeping the size of vessel exempted from the 7 -knot speed limit at 20 feet or less.
Additionally, five comments favored an exemption for non-displacement hull vessels.

The Coast Guard agrees that the 20foot vessel length exemption can be increased without adversely affecting the safety of the waterway and without causing a significant increase in vessel wakes. However, numerous comments that were received as a result of the notice of proposed rulemaking concerned the impact of any rule that
split the charter fishing vessel fleet. Commenters were concerned that such a split would provide an unfair economic advantage to certain portions of the charter fishing vessel fleet.

According to data obtained by the Coast Guard from the State of Alaska Commercial Fisheries Entry Commission, there are 167 charter vessels that routinely operate in and around Tongass Narrows. This data, which is depicted in the following table, indicates:

Table 1.—Numbers of Charter Vessels That Routinely Operate on Tongass Narrows

| Size of charter vessels | Number of vessels | Percent of total number |
| :---: | :---: | :---: |
| $\leq 20$ feet | 15 | 9 |
| 21-23 feet .............. | 12 | 7.2 |
| 24-25 feet | 18 | 10.8 |
| $\geq 26$ feet | 122 | 73 |

Note:This table reflects the adjusted number of charter vessels that are registered as operating on Tongass Narrows. The numbers have been adjusted to remove those vessels that are homeported in areas other than Ketchikan or Metlakatla or that are located at outlying lodges and could not reasonably be expected to participate in the daily charters out of Tongass Narrows (i.e. vessels homeported in Craig, AK or operating out of Yes Bay Lodge, etc.)
that the length limit for vessels exempted from the seven knot speed limit can be set at 23 feet with the expectation that any economic impacts to the charter fleet would be minimal due to the small number of additional (12) charter vessels exempted from this regulation.

The Coast Guard disagrees with the five comments favoring exemption for planing hull vessels from the seven-knot speed limit. An exemption based on hull type would be very difficult to enforce due to the variety of hull types and nomenclature and possible confusion within the maritime community. For this reason, an exemption based on hull type will not be used.
Three persons commented on the southern boundaries of the seven-knot speed limit. One comment stated that the eastern channel boundary should be extended to the south to the Saxman City breakwater. Two persons commented that the western channel boundary should be moved to the south, away from the cable crossing area.

The Coast Guard disagrees that the eastern channel boundary should be extended. The eastern channel boundary was moved north in the 1999 interim rule in an effort to minimize the size of the seven-knot zone without
increasing the impacts caused by vessel wakes to private property. Vessel transit time for vessels using the east channel has been reduced and there have been no reports of wake damage to private property located along the waterway in the east channel. Therefore the eastern channel boundary remains unchanged.
One comment noted that the regulatory marker in the western channel should be located outside the cable crossing area. The published position of the western channel regulatory marker is outside of the charted cable crossing area. The buoy tender that services this buoy has been asked to check the actual location of this regulatory marker.
Two comments were received that favored extending the northern boundary of the seven-knot speed zone northward to Channel Island as a way to control wake damage to private and commercial property caused by large vessels transiting this area. The Coast Guard disagrees that the boundary should be extended any further than Tongass Narrows Buoy 9. The overwhelming majority of 129 comments received in 1998 favored a slight extension of the $7-\mathrm{knot}$ speed limit zone but these comments did not support extending the zone as far north as Channel Island. In light of all comments received, the Coast Guard believes that the present northerly boundary of the 7 -knot speed limit zone, located at Tongass Narrows Buoy 9, is appropriate and no change is made.
Two comments were received on making the speed limit seasonal to align with the summer tourist season. One facility operator stated that if the rule were made seasonal, it would increase the risk of a large wake parting a line on an oil barge during transfer operations, thereby potentially increasing the chances of an oil spill. During the entire rule making process, the majority of the comments favored the existence of the year round 7 -knot rule. The consensus expressed was that if the 7 -knot speed limit were seasonal, the risk on the waterway would not be reduced in the off months and the amount of wake damage to private and commercial property on Tongass Narrows would most likely increase. The Coast Guard agrees that the rule should apply year around and no change is made.

One comment favored the creation of a high-speed traffic corridor through the middle of the waterway. Other commenters felt that creating a highspeed corridor would unreasonably increase the risk to vessels operating on Tongass Narrows. This proposal is not adopted.

## Discussion of the Change to the Interim Rule

Based on all the comments, we are not finalizing the 1999 interim rule at this time. Instead, we are changing one provision of that rule ( 33 CFR 162.240(b)) and are providing an additional opportunity for comment. Section 110.231 of Title 33 CFR is not being changed and continues as an interim rule provision. By exempting "vessels of 23 feet registered length or less", the traffic congestion in the affected areas of Tongass Narrows should be eased and the safety of the small vessel operators enhanced. With the exemption for these small vessels, they will be able to depart from, or transit through the congested areas more quickly. This in turn should ease congestion and reduce navigational conflicts that have arisen between slow moving small boats and cruise ships and other large waterway users and will allow them to spend less time on the water during periods of inclement weather. Large wakes should not become a problem as the exemption is still limited to smaller vessels and because Tongass Narrows regularly experiences substantial wave action that is equivalent to the wake from these smaller vessels. The impacts to the charter fleet are considered minimal because the revised interim rule exempts only 12 of 152 charter vessels that are over 20 feet in length. The revised interim rule retains the 7 -knot speed limit for all other vessels except floatplanes and public law enforcement and emergency response vessels.

## Regulatory Evaluation

This interim rule is not a "significant regulatory action" under section $3(f)$ of Executive Order 12866 and does not require an assessment of potential costs and benefits under section 6(a)(3) of that Order. The Office of Management and Budget has not reviewed it under that Order. It is not "significant" under the regulatory policies and procedures of the Department of Transportation (DOT) (44 FR 11040, February 26, 1979).

The Coast Guard expects the economic impact of this interim rule to be so minimal that a full Regulatory Evaluation under paragraph 10(e) of the regulatory policies and procedures of DOT is unnecessary. This is because the regulation is designed to reduce the impacts of the existing speed limit upon waterway users. With regards to the size of vessel exempted from this 7-knot speed limit, the majority of the comments received recognized the need to control congestion, but objected to an exemption that was limited to "non-
commercial open skiffs". After
reviewing the written comments submitted and listening to the oral comments, the Coast Guard concurs and has revised the exemption to read "vessels of 23 feet registered length or less".

## Small Entities

Under the Regulatory Flexibility Act
[5 U.S.C. 601-612 et seq.], the Coast Guard considers whether this interim rule will have significant economic impact on a substantial number of small entities. The term "small entities" comprises small businesses, not-forprofit organizations that are independently owned and operated and are not dominant in their fields, and governmental jurisdictions with populations of less than 50,000 .

The Coast Guard believes there may be some impact to small entities, but that it will be minimal or non-existence, based on the extensive comments received from the charter sport fishing industry and the relevant data (only 12 of 152 charter vessels fall under the more generous exemption). Therefore, the Coast Guard certifies under 5 U.S.C. 605(b) that this rule will not have a significant economic impact on a substantial number of small entities. If however, you think that your business or organization qualifies as a small entity and that this proposed rule will have a significant economic impact on your business or organization, please submit a comment (see ADDRESSES) explaining why you think it qualifies and in what way and to what degree this proposed rule will economically affect it.

## Assistance for Small Entities

Under Section 213(a) of the Small Business Regulatory Enforcement Fairness Act of 1996 (Pub. L. 104-121), we offered to assist small entities in understanding the rule so that they could better evaluate its effect on them and participate in the rulemaking process.

## Collection of Information

This interim rule calls for no new collection of information under the Paperwork Reduction Act of 1995 [44 U.S.C. 3501 et seq.].

## Federalism

The Coast Guard has analyzed this interim rule under the principles and criteria contained in E.O. 12612 and has determined that this interim rule does not have sufficient implications for federalism to warrant the preparation of a Federalism Assessment.

## Unfunded Mandates Reform Act

The Unfunded Mandates Reform Act of 1995 (2 U.S.C. 1531et seq.) governs the issuance of Federal regulations that require unfunded government mandates. An unfunded mandate is a regulation that requires a State, local, or tribal government or the private sector to incur direct costs without the Federal Government's having first provided the funds to pay those unfunded mandate costs. This rule will not impose an unfunded mandate.

## Taking of Private Property

This rule will not effect a taking of private property or otherwise have taking implications under E.O. 12630, Governmental Actions and Interference with Constitutionally Protected Property Rights.

## Civil Justice Reform

This rule meets applicable standards in sections 3(a) and 3(b)(2) of E.O. 12988, Civil Justice Reform, to minimize litigation, eliminate ambiguity, and reduce burden.

## Protection of Children

We have analyzed this rule under E.O. 13045, Protection of Children from Environmental Health Risks and Safety Risks. This rule is not an economically significant rule and does not concern an environmental risk to health or risk to safety that may disproportionately affect children.

## Environment

The Coast Guard considered the environmental impact of this interim rule and concluded that under figure $2-$ 1, paragraph (34)(g) of COMDTINST M18475.1C, this interim rule is categorically excluded from further environmental documentation because it establishes a regulated navigation area. A "Categorical Exclusion Determination" is available in the docket for inspection or copying where indicated under ADDRESSES.

## List of Subjects in 33 CFR Part 162

Navigation (water), Waterways.

## Regulation

For the reasons discussed in the preamble, the Coast Guard amends 33 CFR Part 162 as follows:

## PART 162-[AMENDED]

1. The authority citation for Part 162 continues to read as follows:
Authority: 33 U.S.C. 1231; 49 CFR 1.46.
2. Revise § 162.240 (b) to read as follows:
§162.240 Tongass Narrows, Alaska; navigation.
(b) No vessel, except for public law enforcement and emergency response vessels, floatplanes during landings and take-offs, and vessels of 23 feet registered length or less, shall exceed a speed of 7 knots in the region of Tongass Narrows bounded to the north by Tongass Narrows Buoy 9 and to the south by Tongass Narrows East Channel Regulatory marker at position $55^{\circ} 19^{\prime}$ $22.0^{\prime \prime} \mathrm{N}, 131^{\circ} 36^{\prime} 40.5^{\prime \prime} \mathrm{W}$ and Tongass Narrows West Channel Regulatory marker at position $55^{\circ} 19^{\prime} 28.5^{\prime \prime} \mathrm{N}$, $131^{\circ}$ $39^{\prime} 09.7^{\prime \prime} \mathrm{W}$, respectively.

Dated: March 31, 2000.

## T.J. Barrett,

Admiral, U.S. Coast Guard, Commander, Seventeenth Coast Guard District. [FR Doc. 00-8659 Filed 4-6-00; 8:45 am] BILLING CODE 4910-15-U

## ENVIRONMENTAL PROTECTION AGENCY

## 40 CFR Part 52

[GA-48-200010(a); FRL-6573-5]
Approval and Promulgation of Implementation Plans; Georgia: Approval of Revisions to the Georgia State Implementation Plan: Transportation Conformity Interagency Memorandum of Agreement
agencr: Environmental Protection Agency (EPA).
ACTION: Direct final rule.
SUMMARY: EPA is approving a revision to the Georgia State Implementation Plan (SIP) that contains the transportation conformity rule pursuant to sections 110(k) and 176 of the Clean Act as amended in 1990 (Act). The transportation conformity rule assures that projected emissions from transportation plans and projects in air quality nonattainment or maintenance areas stay within the motor vehicle emissions ceiling contained in the SIP. The transportation conformity SIP revision enables the State to implement and enforce the Federal transportation conformity requirements at the State level per EPA regulation-Conformity to State or Federal Implementation Plans of Transportation Plans, Programs, and Projects Developed, Funded or Approved Under Title 23 U.S.C. of the Federal Transit Laws. This EPA approval action streamlines the conformity process and allows direct consultation among agencies at the local
level. This final approval action is limited to Transportation Conformity. Rationale for approving this SIP revision is provided in the "Supplementary Information" Section of this action.
DATES: This direct final rule is effective on June 6, 2000, without further notice, unless EPA receives adverse comment by May 8,2000 . If adverse comment is received, EPA will publish a timely withdrawal of the direct final rule in the Federal Register informing the public that this rule will not take effect.
ADDRESSES: All comments should be addressed to Kelly Sheckler at the EPA, Region 4 Air Planning Branch, 61 Forsyth Street, SW, Atlanta, Georgia 30303.

Copies of the state submittal are available at the following addresses for inspection during normal business hours:
Air and Radiation Docket and Information Center (Air Docket 6102),
U.S. Environmental Protection

Agency, 401 M Street, SW,
Washington, DC 20460.
Environmental Protection Agency, Atlanta Federal Center, Region 4 Air Planning Branch, 61 Forsyth Street
S.W., Atlanta, Georgia 30303-3104.

Attn: Kelly Sheckler, (404) 562-9042.
Georgia Department of Natural
Resources, Environmental Protection
Division, Air Protection Division,
4244 International Parkway, Suite
136, Atlanta, Georgia 30354.

## FOR FURTHER INFORMATION CONTACT:

Kelly Sheckler, at 404/562-9042, E-
mail: Sheckler.Kelly@epa.gov.
SUPPLEMENTARY INFORMATION: Outlined below are the contents of this document:

## I. Background

A. What is a SIP?
B. What is the Federal Approval Process for a SIP?
C. What is Transportation Conformity?
D. Why Must the State Submit a Transportation Conformity SIP?
E. How Does Transportation Conformity Work?
II. Approval of the State Transportation Conformity Rule
A. What Did the State Submit?
B. What is EPA Approving Today and Why?
C. How Did the State Satisfy the Interagency Consultation Process (40 CFR 93.105)?
D. How the State's Submittal Address the United States Court of Appeals for the District of Columbia Circuit Ruling Overturning the Grace Period for New Nonattainment Areas (40 CFR 93.102(d)) in the Sierra Club v. Environmental Protection Agency Lawsuit
E. What Other Parts of the Rule Are Excluded?
III. Opportunity for Public Comments
IV. Administrative Requirements

## I. Background

## A. What is a SIP?

The states, under section 110 of the Act, must develop air pollution regulations and control strategies to ensure that state air quality meets the National Ambient Air Quality Standards (NAAQS) established by EPA. The Act, under section 109, established these NAAQS which currently address six criteria pollutants. These pollutants are: carbon monoxide, nitrogen dioxide, ozone, lead, particulate matter, and sulfur dioxide.
Each state must send these regulations and control strategies to EPA for approval and incorporation into the Federally enforceable SIP, which protects air quality and contains emission control plans for NAAQS nonattainment areas. These SIPs can be extensive, containing state regulations or other enforceable documents and supporting information such as emission inventories, monitoring networks, and modeling demonstrations.
B. What is the Federal Approval Process for a SIP?
The states must formally adopt the regulations and control strategies consistent with state and Federal laws for incorporating the state regulations into the Federally enforceable SIP. This process generally includes a public notice, public comment period, public hearing, and a formal adoption by a state-authorized rulemaking body.

Once a state rule, regulation, or control strategy is adopted, the state will send these provisions to EPA for inclusion in the Federally enforceable SIP. EPA must then determine the appropriate Federal action, provide public notice, and request additional public comment on the action. The possible Federal actions include: approval, disapproval, conditional approval and limited approval/ disapproval. If adverse comments are received, EPA must consider and address the comments before taking final action.
EPA incorporates state regulations and supporting information (sent under section 110 of the Act) into the Federally approved SIP through the approval action. EPA maintains records of all such SIP actions in the CFR at Title 40, part 52, entitled "Approval and Promulgation of Implementation Plans." The EPA does not reproduce the text of the Federally approved state regulations in the CFR. They are "incorporated by reference," which means that the specific state regulation is cited in the CFR and is considered a part of the CFR
the same as if the text were fully printed in the CFR.

## C. What is Transportation Conformity?

Conformity first appeared as a requirement in the Act's 1977 amendments (Public Law 95-95). Although the Act did not define conformity, it stated that no Federal department could engage in, support in any way or provide financial assistance for, license or permit, or approve any activity which did not conform to a SIP which has been approved or promulgated.

The 1990 Amendments to the Act expanded the scope and content of the conformity concept by defining conformity to a SIP. Section 176(c) of the Act defines conformity as conformity to the SIP's purpose of eliminating or reducing the severity and number of violations of the NAAQS and achieving expeditious attainment of such standards. Also, the Act states that no Federal activity will: (1) Cause or contribute to any new violation of any standard in any area, (2) increase the frequency or severity of any existing violation of any standard in any area, or (3) delay timely attainment of any standard or any required interim emission reductions or other milestones in any area. The requirements of section 176(c) of the Clean Air Act apply to all departments, agencies and instrumentalities of the Federal government. Transportation conformity refers only to the conformity of transportation plans, programs and projects that are funded or approved under title 23 U.S.C. of the Federal Transit Act.

## D. Why Must the State Submit a Transportation Conformity SIP?

A transportation conformity SIP is a plan which contains criteria and procedures for the Department of Transportation (DOT), Metropolitan Planning Organizations (MPOs), and other state or local agencies to assess the conformity of transportation plans, programs and projects to ensure that they do not cause or contribute to new violations of a NAAQS in the area substantially affected by the project, increase the frequency or severity of existing violations of a standard in such area or delay timely attainment. 40 CFR 51.390, subpart T requires states to submit a SIP that establishes criteria for conformity to EPA. 40 CFR part 93, subpart A, provides the criteria the SIP must meet to satisfy 40 CFR 51.390 .

EPA was required to issue criteria and procedures for determining conformity of transportation plans, programs, and projects to a SIP by section 176(c) of the

Act. The Act also required the procedure to include a requirement that each state submit a revision to its SIP including conformity criteria and procedures. EPA published the first transportation conformity rule in the November 24, 1993, Federal Register (FR), and it was codified at 40 CFR part 51, subpart T and 40 CFR part 93, subpart A. EPA required the states to adopt and submit a transportation conformity SIP revision to the appropriate EPA Regional Office by November 25, 1994. The State of Georgia submitted a transportation conformity SIP to the EPA Region 4 on November 15, 1994. EPA did not take action on this SIP because the Agency was in the process of revising the transportation conformity requirements. EPA revised the transportation conformity rule on August 7, 1995 (60 FR 40098), November 14, 1995 (60 FR 57179), and August 15, 1997 (62 FR 43780), and codified the revisions under 40 CFR part 51, subpart T and 40 CFR part 93, subpart A-Conformity to State or Federal Implementation Plans of Transportation Plans, Programs, and Projects Developed, Funded or Approved Under Title 23 U.S.C. of the Federal Transit Laws (62 FR 43780). EPA's action of August 15, 1997, required the states to change their rules and submit a SIP revision to EPA by August 15, 1998. States may choose to develop in place of regulations, a memorandum of agreement (MOA) which establishes the roles and procedures for transportation conformity. The MOA includes the detailed consultation procedures developed for that particular area. The MOA's are enforceable through the signature of all the transportation and air quality agencies, including the Federal Highway Administration, Federal Transit Administration and the Environmental Protection Agency.

## E. How Does Transportation Conformity Work?

The Federal or state transportation conformity rule applies to all NAAQS nonattainment and maintenance areas in the state. The Metropolitan Planning Organizations (MPO), the State Department of Transportation (DOT) (in absence of a MPO), and U.S. Department of Transportation (USDOT) make conformity determinations. These agencies make conformity determinations on programs and plans such as transportation improvement programs (TIP), transportation plans, and projects. The MPOs calculate the projected emissions that will result from implementation of the transportation plans and programs and compare those
calculated emissions to the motor vehicle emissions ceiling established in the SIP. The calculated emissions must be smaller than the Federally approved motor vehicle emissions ceiling in order for USDOT to make a positive conformity determination with respect to the SIP.

## II. Approval of the State Transportation Conformity Rule

## A. What Did the State Submit?

The State of Georgia chose to address the transportation conformity SIP requirement through the development of an MOA. On February 16, 1999, the State of Georgia, through the Department of Natural Resources (DNR), submitted the State's transportation conformity and consultation interagency MOA to EPA as a revision to the SIP. The Georgia Air Quality Act, Article 1: Air Quality (O.C.G.A. 12-9-1, et seq.), approved by the Georgia General Assembly in 1992, contains the necessary authority for the revision to the SIP. DNR held a public hearing on August 13, 1998 and no comments from the general public were received. The MOA was developed with appropriate interagency consultation.

## B. What is EPA Approving Today and

 Why?
## EPA is approving the Georgia

 transportation conformity MOA that the Director of the Georgia DNR submitted to the Region 4 office of the EPA on February 16, 1999, except for the following sections: section 110 (c)(1)(ii); section 110 (c)(2)(ii); section 110 (d)(2)(i); section 110 (d)(3)(i); section 110 (e)(2)(i); section 110 (e)(3)(i); section 119 (e)(1); section 119b(a)(2); section 133; section 103(4)(d); section 106 (c) and, section 130 (1). The rationale for exclusion of these sections is discussed in section II.E of this action. The Georgia DNR Transportation Conformity MOA is the same as the Federal rule, with the exception of the specific interagency consultation procedures and the definition of "regionally significant".EPA has evaluated this SIP revision and has determined that the State has met the requirements of Federal transportation conformity rule as described in 40 CFR part 51, subpart T and 40 CFR part 93 , subpart A. The Georgia DNR has satisfied the public participation and comprehensive interagency consultation requirement during development and adoption of the MOA at the local level. Therefore, EPA is approving the MOA as a revision to the Georgia SIP.
C. How did the State Satisfy the Interagency Consultation Process (40 CFR 93.105)?

EPA's rule requires the states to develop their own processes and procedures for interagency consultation among the Federal, state, and local agencies and resolution of conflicts meeting the criteria in 40 CFR 93.105. The SIP revision must include processes and procedures to be followed by the MPO, state DOT, and USDOT in consulting with the state and local air quality agencies and EPA before making conformity determinations. The transportation conformity SIP revision must also include processes and procedures for the state and local air quality agencies and EPA to coordinate the development of applicable SIPs with MPOs, state DOTs, and USDOT.

The State of Georgia developed its consultation rule based on the elements contained in 40 CFR 93.105, and included it in the MOA, Exhibit 1, section 106. As a first step, the State worked with the existing transportation planning organization's interagency committee that included representatives from the State air quality agency, State Department of Transportation, the Atlanta Regional Commission (the MPO), Federal Highway
Administration-Georgia Division, Federal Transit Administration, Metropolitan Area Rapid Transit Authority, Cobb County Transit Authority, Douglas County Transit Authority, Gwinnett County Transit Authority and EPA. The interagency committee met regularly and drafted the consultation rules considering elements in 40 CFR 93.105 and 23 CFR part 450, and integrated the local procedures and processes into the consultation MOA. The consultation process developed in this MOA is unique to the State of Georgia. The MOA is enforceable against the parties by their consent in the MOA to allow the Attorney General for the State of Georgia to sue any or all of the agencies for specific performance or other relief on behalf of the citizens of Georgia in paren. patrial. We have determined that the State adequately included all elements of 40 CFR 93.105 and that the MOA meets the EPA SIP requirements.
D. How the State's Submittal Addresses
the United States Court of Appeals for the District of Columbia Circuit Ruling Overturning the Grace Period for New Nonattainment Areas (40 CFR 93.102(d)) in Sierra Club v. Environmental Protection Agency Lawsuit

The Sierra Club challenged this section of the second set of amendments to the transportation conformity rule arguing that allowing a 120 day grace period was unlawful under the Act. On November 4, 1997, the United States Court of Appeals for the District of Columbia Circuit held in Sierra Club v. Environmental Protection Agency, No. 96-1007, determined that EPA's grace period violates the plain terms of the Act and, therefore, is unlawful. Based on this court action, the State has excluded this section from its rule. EPA agrees with the State's action as it is consistent with the United States Court of Appeals for the District of Columbia Circuit ruling. Further, the exclusion of 40 CFR 93.102(d) will not prevent EPA from approving the State transportation conformity SIP.

## E. What Other Parts of the Rule Are Excluded?

EPA promulgated the third set amendments to the transportation conformity rule on August 15, 1997. On March 2, 1999, the United States Court of Appeals for the District of Columbia Circuit issued its opinion in Environmental Defense Fund v. Environmental Protection Agency, No. 97-1637. The Court granted the environmental group's petition for review and ruled that sections 40 CFR 93.102(c)(1), 93.121(a)(1), and 93.124(b) are unlawful and remanded 40 CFR 93.118(e) and 93.120(a)(2) to EPA for revision to harmonize these provisions with the requirements of the Act for an affirmative determination that Federal actions will not cause or increase violations or delay attainment. The sections of the rule that were impacted by this decision were:
(a) 40 CFR 93.102(c)(1) which allowed certain projects for which the National Environmental Policy Act (NEPA) process has been completed by the DOT to proceed toward implementation without further conformity determinations during a conformity "lapse". A lapse is a situation in which the conformity determination for the transportation plan or TIP has expired, and there is no currently conforming transportation plan and TIP. As such, there are restrictions on proceeding with federally funded and regionally significant projects;
(b) 40 CFR 93.118(e) which allowed use of motor vehicle emissions budgets (budgets) in the submitted SIPs after 45 days if EPA had not declared them inadequate;
(c) 40 CFR 93.120(a)(2) which allowed use of the budgets in a disapproved SIP for 120 days after disapproval;
(d) 40 CFR 93.121(a)(1) which allowed the nonfederally funded, regionally significant projects to proceed if included in the first three years of the most recent conforming transportation plan and transportation improvement program, even if conformity status is currently lapsed; and
(e) 40 CFR 93.124(b) which allowed areas to use a submitted SIP that allocated portions of a safety margin to transportation activities for conformity purposes before EPA approval.
States were required to submit transportation conformity SIPs to satisfy the requirements for the third set of amendments to the transportation conformity rule by August 15, 1998. Many of these SIP submittals, developed prior to the March 2, 1999 Court ruling, included provisions from the transportation conformity rule verbatim. As such, the State of Georgia's SIP revision included sections which the Court ruled unlawful or remanded for consistency with the Act. Therefore, in accordance with the Court's ruling, EPA can not approve the following sections of the Georgia MOA which relate to the above reference sections of the Federal conformity rule: Section 110 (c)(1)(ii); section 110 (c)(2)(ii); section 110 (d)(2)(i); section 110 (d)(3)(i); section 110 (e)(2)(i); section 110 (e)(3)(i); section 119 (e)(1); section 119b(a)(2); section 133; section 103 (4)(d); section 106 (c) and section 130 (1).
The State of Georgia submitted additional information which has complied with the EPA requirements for a transportation conformity SIP and has adopted the Federal rules in an MOA which were in effect at the time that the transportation conformity SIP was due to the EPA. If the Court had issued its ruling before adoption and SIP submittal by the Georgia DNR, EPA believes the Georgia DNR would have removed these sections from its MOA The Georgia DNR has expended its resources and time to prepare this SIP and meet the statutory deadline, and EPA acknowledges the agency's good faith effort in submitting the transportation conformity SIP in a timely manner.
The Georgia DNR will be required to submit a SIP revision in the future when EPA revises its rule to comply with the Court decision. Because the Court
decision has invalidated the aforementioned affected provisions, EPA believes that it is reasonable to exclude the corresponding sections of the State rules from this SIP approval action. As a result, EPA is not taking any SIP action on the following Sections of the Georgia MOA : 110 (c)(1)(ii); 110 (c)(2)(ii);110 (d)(2)(i);110 (d)(3)(i);110 (e)(2)(i); 110 (e)(3)(i); 119 (e)(1); 119b(a)(2); 133; 103 (4)(d); 106 (c) and, 130 (1) which relate to the Federal rule sections 93.102(c), 93.104(d), 93.109(c)(f), 93.118(e), 93.120(a)(2), 93.121(a)(1), and $93.124(\mathrm{~b})$. The conformity determinations affected by these sections should comply with the relevant requirements of the statutory provisions of the Act underlying the Court's decision on these issues. EPA will be issuing guidance on how to implement these provisions in the interim prior to EPA's amendment of the Federal transportation conformity rule. Once this Federal rule has been revised, conformity determinations in Georgia should comply with the requirements of the revised Federal rule until corresponding provisions of the Georgia conformity SIP have been approved by EPA.

## III. Opportunity for Public Comments

The EPA is publishing this rule without prior proposal because the Agency views this as a noncontroversial submittal and anticipates no adverse comment. However, in the "Proposed Rules" section of today's Federal
Register publication, EPA is publishing a separate document that will serve as the proposal to approve this SIP revision if adverse comments are filed. This rule will be effective on June 6, 2000, without further notice unless EPA receive adverse comment by May 8, 2000. If EPA receives adverse comment, EPA will publish a timely withdrawal in the Federal Register informing the public that the rule will not take effect. EPA will address all public comments in a subsequent final rule based on the proposed rule. EPA will not institute a second comment period on this action. Any parties interested in commenting must do so at this time.

## IV. Administrative Requirements

Under Executive Order 12866 (58 FR 51735, October 4, 1993), this action is not a "significant regulatory action" and therefore is not subject to review by the Office of Management and Budget. This action merely approves state law as meeting federal requirements and imposes no additional requirements beyond those imposed by state law. Accordingly, the Administrator certifies that this rule will not have a significant
economic impact on a substantial number of small entities under the Regulatory Flexibility Act (5 U.S.C. 601 et seq.). Because this rule approves preexisting requirements under state law and does not impose any additional enforceable duty beyond that required by state law, it does not contain any unfunded mandate or significantly or uniquely affect small governments, as described in the Unfunded Mandates Reform Act of 1995 (Public Law 104-4). For the same reason, this rule also does not significantly or uniquely affect the communities of tribal governments, as specified by Executive Order 13084 (63 FR 27655, May 10, 1998). This rule will not have substantial direct effects on the States, on the relationship between the national government and the States, or on the distribution of power and responsibilities among the various levels of government, as specified in Executive Order 13132 ( 64 FR 43255, August 10, 1999), because it merely approves a state rule implementing a federal standard, and does not alter the relationship or the distribution of power and responsibilities established in the Clean Air Act. This rule also is not subject to Executive Order 13045 ( 62 FR 19885, April 23, 1997), because it is not economically significant.

In reviewing SIP submissions, EPA's role is to approve state choices, provided that they meet the criteria of the Clean Air Act. In this context, in the absence of a prior existing requirement for the State to use voluntary consensus standards (VCS), EPA has no authority to disapprove a SIP submission for failure to use VCS. It would thus be inconsistent with applicable law for EPA, when it reviews a SIP submission, to use VCS in place of a SIP submission that otherwise satisfies the provisions of the Clean Air Act. Thus, the requirements of section 12(d) of the National Technology Transfer and Advancement Act of 1995 (15 U.S.C. 272 note) do not apply. As required by section 3 of Executive Order 12988 (61 FR 4729, February 7, 1996), in issuing this rule, EPA has taken the necessary steps to eliminate drafting errors and ambiguity, minimize potential litigation, and provide a clear legal standard for affected conduct. EPA has complied with Executive Order 12630 (53 FR 8859, March 15,1988 ) by examining the takings implications of the rule in accordance with the "Attorney General's Supplemental Guidelines for the Evaluation of Risk and Avoidance of Unanticipated Takings' issued under the executive order. This rule does not impose an information collection burden under the provisions of the

Paperwork Reduction Act of 1995 (44 U.S.C. 3501 et seq.).

The Congressional Review Act, 5 U.S.C. 801 et seq., as added by the Small Business Regulatory Enforcement Fairness Act of 1996, generally provides that before a rule may take effect, the agency promulgating the rule must submit a rule report, which includes a copy of the rule, to each House of the Congress and to the Comptroller General of the United States. EPA will submit a report containing this rule and other required information to the U.S. Senate, the U.S. House of Representatives, and the Comptroller General of the United States prior to publication of the rule in the Federal Register. A major rule cannot take effect until 60 days after it is published in the Federal Register. This action is not a "major rule" as defined by 5 U.S.C. 804(2).
Under section 307 (b)(1) of the Clean Air Act, petitions for judicial review of
this action must be filed in the United States Court of Appeals for the appropriate circuit by June 6, 2000. Filing a petition for reconsideration by the Administrator of this final rule does not affect the finality of this rule for the purposes of judicial review nor does it extend the time within which a petition for judicial review may be filed, and shall not postpone the effectiveness of such rule or action. This action may not be challenged later in proceedings to enforce its requirements. (See section 307(b)(2).)

## List of Subjects in 40 CFR Part 52

Environmental protection, Air pollution control, Carbon monoxide, Hydrocarbons, Intergovernmental relations, Lead, Nitrogen dioxide, Ozone, Particulate matter, Reporting and recordkeeping requirements, Sulfur oxides.

Dated: March 23, 2000.

## A. Stanley Meiburg,

Acting Regional Administrator, Region 4.
Part 52 of chapter I, title 40, Code of Federal Regulations is amended as follows:

## PART 52-[AMENDED]

1. The authority for citation for part 52 continues to read as follows:
Authority: 42 U.S.C. 7401 et seq.

## Subpart L—Georgia

2. Section 52.570 paragragh (e) is amended by adding a new entry at the end of the table to read as follows:

## §52.570 Identification of plan.

(e) EPA approved non-regulatory provisions.
epa Approved Georgia Non-Regulatory Provisions

| Name of nonregulatory SIP revision | Applicable geographic or non- <br> attainment area | State submittal date/effec- <br> tive date | EPA approval <br> date |
| :---: | :---: | :---: | :---: |
| 12. Georgia Interagency Transportation Conformity Memo- <br> randum of Agreement. | Atlanta Metropolitan Area ....... | Februrary 16, 1999 $\ldots \ldots . . . . .$. | April 7, 2000 |

[FR Doc. 00-8530 Filed 4-6-00; 8:45 am] BILLING CODE 6560-50-P

## ENVIRONMENTAL PROTECTION AGENCY

## 40 CFR Part 62

[PA152-4099a; FRL-6571-5]
Approval and Promulgation of State Air Quality Plans for Designated Facilities and Pollutants; Allegheny County, Pennsylvania; Control of Emissions From Existing Hospital/ Medical/Infectious Waste Incinerators
agency: Environmental Protection Agency (EPA).
ACTION: Direct final rule.
SUMMARY: EPA is aproving the Allegheny County, Pennsylvania hospital/medical/infectious waste incinerator (HMIWI) 111(d)/129 plan (the "plan'") submitted on June 24, 1999 by the Pennsylvania Department of Environmental Protection (PADEP) on behalf of the Allegheny County Health Department (ACHD). The plan establishes emission limitations and other requirements for existing HMIWIs, and provides for the implementation and enforcement of those limitations and requirements.
DATES: This final rule is effective June 6, 2000 unless within May 8, 2000
adverse or critical comments are received. If adverse comment is received, EPA will publish a timely withdrawal of the direct final rule in the Federal Register and inform the public that the rule will not take effect.

ADDRESSES: Comments may be mailed to Makeba A. Morris, Chief, Technical Assessment Branch, Mailcode 3AP22, Environmental Protection Agency, Region III, 1650 Arch Street, Philadelphia, Pennsylvania 19103. Copies of the documents relevant to this action are available for public inspection during normal business hours at the following locations: Air Protection Division, Environmental Protection Agency, Region III, 1650 Arch Street, Philadelphia, Pennsylvania 19103-2029; and the Allegheny County Health Department, Air Quality Program, 301 39th Street, Pittsburgh, Pennsylvania 15201-1891.

## FOR FURTHER INFORMATION CONTACT:

James B. Topsale at (215) 814-2190, or by e-mail at topsale.jim@epamail.gov.
SUPPLEMENTARY INFORMATION: This document is divided into Sections I through V and answers the questions posed below.

## I. General Provisions

What is EPA approving?
What is a State/local 111(d)/129 plan?
What pollutant(s) will this action control?

What are the expected environmental and public health benefits from controlling HMIWI emissions?
II. Federal Requirements the Allegheny County HMIWI 111(d)/129 Plan Must Meet for Approval
What general EPA requirements must the Allegheny County Health Department (ACHD) meet in order to receive approval of its County HMIWI 111(d)/129 plan?
What does the Allegheny County plan contain?
Does the Allegheny County plan meet all
EPA requirements for approval?

## III. Requirements for Affected HMIWI <br> Owners/Operators

How do I determine if my HMIWI is subject to the Allegheny County 111(d)/129 plan?
What general requirements must I meet under the approved EPA 111(d)/129 plan?
What emissions limits must I meet, and in what time frame?
Are there any operational requirements for my HMIWI and air pollution control system?
What are the testing, monitoring,
recordkeeping, and reporting requirements for my HMIWI?
Is there a requirement for obtaining a Title V permit?

## IV. Final EPA Action

## V. Administrative Requirements

## I. General Provisions

Q. What is EPA approving?
A. EPA is approving the Allegheny

County 111(d)/129 plan (the "plan") for
the control of air pollutant emissions
from hospital/medical/infectious waste incinerators (HMIWIs). The plan was developed by the Allegheny County Health Department (ACHD), Air Quality Program. In its capacity as the Commonwealth's air pollution control agency, on June 24, 1999 the Pennsylvania Department of Environmental Protection (PADEP) formally submitted the plan to EPA on behalf of the ACHD. EPA is publishing this approval action without prior proposal because we view this as a noncontroversial action and anticipate no adverse comments.
Q. What is a State/local 111(d)/129 plan?
A. Section 111(d) of the Clean Air Act (CAA) requires that "designated" pollutants, controlled under standards of performance for new stationary sources by Section 111(b) of the CAA, must also be controlled at existing sources in the same source category to a level stipulated in an emission guidelines (EG) document. Section 129 of the CAA specifically addresses solid waste combustion and emissions controls based on what is commonly referred to as maximum achievable control technology (MACT). Section 129 requires EPA to promulgate a MACT based emission guideline (EG) document, and then requires states to develop 111(d)/129 plans that implement and enforce the EG requirements. The HMIWI EG at 40 CFR part 60, subpart Ce, establish the MACT requirements under the authority of both Sections 111(d) and 129 of the CAA. These requirements must be incorporated into a State/local 111(d)/ 129 plan that is "at least as protective" as the EG, and is Federally enforceable upon approval by EPA.

The procedures for adoption and submittal of State 111(d)/129 plans are codified in 40 CFR part 60, subpart B. Additional information on the submittal of State plans is provided in the EPA document, "Hospital/Medical/Infectious Waste Incinerator Emission Guidelines: Summary of the Requirements for Section 111(d)/129 State Plan, EPA-456/R-97-007, November, 1997."
Q. What pollutant(s) will this action control?
A. The September 15, 1997 promulgated EG, Subpart Ce, are applicable to all existing HMIWIs (i.e., the designated facilities) that emit organics (dioxins/furans), carbon monoxide, metals (cadmium, lead, mercury, particulate matter), opacity, and acid gases (hydrogen chloride, sulphur dioxide, and nitrogen oxides). This action establishes emission limitations for each of these pollutants.
$Q$. What are the expected environmental and public health benefits from controlling HMIWI emissions?
A. HMIWI emissions can have adverse effects on both public health and the environment. Dioxin, lead, and mercury can bioaccumulate in the environment. Exposure to dioxins/furans has been linked to reproductive and developmental effects, changes in hormone level, and chloracne. Respiratory and other effects are associated with exposure to particulate matter, sulfur dioxide, cadmium, hydrogen chloride, and mercury. Health effects associated with exposure to cadmium, and lead included probable carcinogenic effects. Acid gases contribute to the acid rain that lowers the pH of surface waters and watersheds, harms forests, and damages buildings.

## II. Federal Requirements the Allegheny County, Pennsylvania HMIWI 111(d)/ 129 Plan Must Meet for Approval

$Q$. What general requirements must the ACHD meet to receive approval of its County 111(d)/129 plan?
A. The plan must meet the requirements of both 40 CFR part 60, subparts B, and Ce. Subpart B specifies detailed procedures for the adoption and submittal of State plans for designated pollutants and facilities. The EG, Subpart Ce, and the related new source performance (NSPS), Subpart Ec, contain the requirements for the control of designated pollutants, as listed above, in accordance with Sections 111(d) and 129 of the CAA. In general, the applicable provisions of Subpart Ec relate to compliance and performance testing, monitoring, reporting, and recordkeeping. More specifically, the Allegheny County plan must meet the requirements of: (1) 40 CFR part 60, subpart Ce, Sections 60.30e through 60.39c, and the related Subpart Ec provisions; and (2) 40 CFR part 60, subpart B, Sections 60.23 through 26.
Q. What does the Allegheny County plan contain?
A. Consistent with the requirements of Subparts B, Ce and Ec, the Allegheny County plan contains the following elements:

1. A demonstration of the County's legal authority to implement the plan under County and Pennsylvania law;
2. Identification of the County's enforceable mechanism, ACHD Rules and Regulations, Article XXI, Sections 2101.20 and 2105.32;
3. Source and emission inventories, as required;
4. Emission limitation requirements that are no less stringent than those in Subpart Ce;
5. A source compliance schedule, including increments of progress, as required;
6. Source testing, monitoring, recordkeeping, and reporting requirements;
7. HMIWI operator training and qualification requirements;
8. Requirements for development of a Waste Management Plan;
9. Records of the public hearing on the County plan;
10. Provision for County submittal to EPA of annual reports on progress in plan enforcement; and
11. A Title V permit application due date.
The ACHD HMIWI regulations were approved by the Allegheny County Board of Health on March 11, 1998 and by the Board of County Commissioners on November 19, 1998. The regulations became effective on September 1, 1999, and incorporate by reference (IBR) applicable Subpart Ec requirements.
Q. Does the Allegheny County 111(d)/ 129 plan meet all EPA requirements for approval?
A. Yes. The ACHD has submitted a plan that conforms to all EPA Subpart $B$ and Ce requirements. Each of the above listed plan elements is approvable. Details regarding the approvability of the plan elements are included in the technical support document (TSD) associated with this action. A copy of the TSD is available, upon request, from the EPA Regional Office listed in the ADDRESSES section of this document.

## III. Requirements Affected HMIWI Owners/Operators Must Meet

Q. How do I determine if my HMIWI is a designated facility subject to the Allegheny County 111(d)/129 plan?
A. If construction commenced on your HMIWI on or before June 20, 1996, your HMIWI is classified as an existing or designated facility that may be subject the plan. The plan contains no lower applicability threshold based on incinerator capacity. However, there are designated facility exemptions. Those exemptions include incinerators that burn only pathological, low level radioactive, and/or chemotherapeutic waste; co-fired combustors; incinerators permitted under Section 3005 of the Solid Waste Disposal Act; municipal waste combustors (MWC) subject to EPA's municipal waste combustor rule; pyrolysis units; and cement kilns.
Details regarding applicability and exemptions provisions are stipulated in Article XXI, Section 2105.32.e.
Q. As an affected HMIWI owner/ operator, what general requirements must I meet under the approved EPA 111(d)/129 plan?
A. In general, the Allegheny County HMIWI regulation establishes the following requirements:

- Emission limitations for particulate matter (PM), opacity, carbon monoxide (CO), dioxins/furans (CDD/CDF), hydrogen chloride ( HCl ), sulfur dioxide $\left(\mathrm{SO}_{2}\right)$, nitrogen oxides $\left(\mathrm{NO}_{\mathrm{x}}\right)$, lead ( Pb ), cadmium (Cd), and mercury ( Hg ).
- Compliance and performance testing.
- Operating parameter monitoring.
- Operator training and qualification.
- Development of a waste
management plan.
- Source testing, recordkeeping and reporting.
- A Title V permit.

A full and comprehensive statement of the above requirements is incorporated in the ACHD Rules and Regulations, Article XXI, Sections 2101.20 and 2105.32.
Q. What emissions limits must I meet, and in what time frame?
A. You must install an emissions controls system capable of meeting the maximum available control technology (MACT) emission limitations for the pollutants identified above. The pollutant emission limitations are stipulated in Article XXI, Sections 2105.32.f.1, Table 1, and f.2. Compliance is required on or before September 1, 2000 for all designated facilities. With adequate justification, you may petition the ACHD for a compliance schedule extension that does not extend beyond September 15, 2002. Petitions must be submitted no later than September 1, 2000, and must include documentation of your analysis undertaken to support the need for an extension, and your evaluation of the option to transport the waste offsite to a commercial medical waste treatment and disposal facility on a temporary or permanent basis. Also, your extension request must include increments of progress that are no less stringent than those specified in the plan and regulation, Section 2105.32.g.2.
$Q$. Are there any operational requirements for my HMIWI and emissions control system?
A. Yes, there are operational requirements. In summary, the operational requirements relate to: (1) The HMIWI and air pollution control devices (APCD) operating within certain established parameter limits, determined during the initial performance test; (2) the use of a trained and qualified HMIWI operator; and (3) the completion of an annual update of
operation and maintenance information, and its review by the HMIWI operators.

Failure to operate the HMIWI or APCD within the established operating parameter limits constitutes an emissions violation for the controlled air pollutants. However, as a HMIWI owner/operator, you are provided an opportunity to establish revised operating limits, and demonstrate that your facility is meeting the required emission limitations, providing a repeat performance test is conducted in a timely manner.

A fully trained and qualified operator must be available at your facility during the operation of the HMIWI, or the operator must be readily available to the facility within one hour. In order to be classified as a qualified operator, you must complete an appropriate HMIWI operator training course that meets the Subpart Ec criteria referenced in the regulation at Section 2105.32g.5. Compliance with this training requirement must be achieved within one year of the effective date of the County regulation (i.e., September 1, 2000).

Also, as a HMIWI owner/operator, you are required to develop and update annually site-specific information regarding your facilities' operations. Each of your HMIWI operators is required on an annual basis to review the updated operational information.

The ACHD regulation IBR the applicable operational requirements of the EG and the related NSPS. See Subpart Ec, §§ 60.56c, 60.53c, and 60.58 c , respectively for details regarding these operational requirements.
Q. What are the testing, monitoring, recordkeeping, and reporting requirements for my HMIWI?
A. Testing, monitoring, recordkeeping, and reporting requirements are summarized below: You are required to conduct an initial stack test to determine compliance with the emission limitations for PM,
opacity, CO, CDD/CDF, $\mathrm{HCl}, \mathrm{Pb}, \mathrm{Cd}$, and Hg. As noted above, operating parameter limits are monitored and established during the initial performance test. Monitored HMIWI operating parameters include, for example, waste charge rate, secondary chamber and bypass stack temperatures. APCD operating parameters include, for example, CDD/ CDF and Hg sorbent (e.g., carbon) flow rate, hydrogen chloride sorbent (e.g., lime) flow rate, PM control device inlet temperature, pressure drop across the control system, and liquid flow rate, including pH . After the initial stack test, compliance testing is then required annually to determine compliance with
the emission limitations for PM, CO, and HCl .

Recordkeeping and reporting are required in order to document (1) The results of the initial and annual performance tests, (2) monitoring of sitespecific operating parameters, (3) compliance with the operator training and qualification requirements, and (4) development of the waste management plan. Records must be maintained for at least five years.

The ACHD regulation IBR the applicable testing, monitoring, recordkeeping, and reporting requirements of the EG and related NSPS. See Subpart Ec, §§ 60.56c, 60.57 c , and 60.58 c , respectively for details regarding these requirements.
$Q$. Is there a requirement for obtaining a Title V permit?
A. Yes, affected facilities are required to operate under a Title V permit no later than September 15, 2000. This is required under Article XXI, section 2105.32d.

## IV. Final EPA Action

The Allegheny County 111 (d)/129 plan for controlling HMIWI emissions is approvable. This approval does not include provisions, such as siting and fugitive emission requirements, that relate solely to facilities subject to the NSPS, and are not referenced in the EG.

Based upon the rationale discussed above and in further detail in the TSD associated with this action, EPA is approving the Allegheny County 111(d)/ 129 plan for the control of HMIWI emissions from designated facilities. As provided by 40 CFR 60.28(c), any revisions to the Allegheny County plan or associated regulations will not be considered part of the applicable plan until submitted by the PADEP on behalf of ACHD in accordance with 40 CFR 60.28(a) or (b), as applicable, and until approved by EPA in accordance with 40 CFR Part 60, Subpart B.

As requested, no EPA action is taken on the State Implementation Plan (SIP) revision relating to Article XXI. EPA action on the SIP revision request will be taken under a separate action from this 111(d)/129 plan approval.
EPA is publishing this action without prior proposal because the Agency views this as a noncontroversial amendment and anticipates no adverse comments. However, in the proposed rules section of this Federal Register publication, EPA is publishing a separate document that will serve as the proposal to approve the 111(d) plan should relevant adverse or critical comments be filed. This rule will be effective June 6, 2000 without further notice unless the Agency receives
relevant adverse comments by May 8, 2000. If EPA receives such comments, then EPA will publish a document withdrawing the final rule and informing the public that the rule did not take effect. All public comments received will then be addressed in a subsequent final rule based on the proposed rule. The EPA will not institute a second comment period on this rule. Only parties interested in commenting on this rule should do so at this time. If no such comments are received, the public is advised that this rule will be effective on June 6, 2000 and no further action will be taken on the proposed rule.

## V. Administrative Requirements

## A. General Requirements

Under Executive Order 12866 (58 FR 51735, October 4, 1993), this action is not a "significant regulatory action" and therefore is not subject to review by the Office of Management and Budget. This action merely approves state law as meeting federal requirements and imposes no additional requirements beyond those imposed by state law. Accordingly, the Administrator certifies that this rule will not have a significant economic impact on a substantial number of small entities under the Regulatory Flexibility Act (5 U.S.C. 601 et seq.). Because this rule approves preexisting requirements under state law and does not impose any additional enforceable duty beyond that required by state law, it does not contain any unfunded mandate or significantly or uniquely affect small governments, as described in the Unfunded Mandates Reform Act of 1995 (Public Law 104-4). For the same reason, this rule also does not significantly or uniquely affect the communities of tribal governments, as specified by Executive Order 13084 (63 FR 27655, May 10, 1998). This rule will not have substantial direct effects on the States, on the relationship between the national government and the States, or on the distribution of power and responsibilities among the various levels of government, as specified in Executive Order 13132 (64 FR 43255, August 10, 1999), because it merely approves a state rule implementing a federal standard, and does not alter the relationship or the distribution of power and responsibilities established in the Clean Air Act. This rule also is not subject to Executive Order 13045 (62 FR 19885, April 23, 1997), because it is not economically significant.
In reviewing 111(d)/129 plan submissions, EPA's role is to approve state choices, provided that they meet the criteria of the Clean Air Act. In this
context, in the absence of a prior existing requirement for the State to use voluntary consensus standards (VCS), EPA has no authority to disapprove a 111(d)/129 plan submission for failure to use VCS. It would thus be inconsistent with applicable law for EPA, when it reviews a 111(d)/129 plan submission, to use VCS in place of a 111(d)/129 plan submission that otherwise satisfies the provisions of the Clean Air Act. Thus, the requirements of section 12(d) of the National
Technology Transfer and Advancement Act of 1995 (15 U.S.C. 272 note) do not apply. As required by section 3 of Executive Order 12988 (61 FR 4729, February 7, 1996), in issuing this rule, EPA has taken the necessary steps to eliminate drafting errors and ambiguity, minimize potential litigation, and provide a clear legal standard for affected conduct. EPA has complied with Executive Order 12630 (53 FR 8859 , March 15,1988 ) by examining the takings implications of the rule in accordance with the "Attorney General's Supplemental Guidelines for the Evaluation of Risk and Avoidance of Unanticipated Takings" issued under the executive order. This rule does not impose an information collection burden under the provisions of the Paperwork Reduction Act of 1995 (44 U.S.C. 3501 et seq.).

## B. Submission to Congress and the Comptroller General

The Congressional Review Act, 5 U.S.C. 801 et seq., as added by the Small Business Regulatory Enforcement Fairness Act of 1996, generally provides that before a rule may take effect, the agency promulgating the rule must submit a rule report, which includes a copy of the rule, to each House of the Congress and to the Comptroller General of the United States. EPA will submit a report containing this rule and other required information to the U.S. Senate, the U.S. House of Representatives, and the Comptroller General of the United States prior to publication of the rule in the Federal Register. This rule is not a "major rule" as defined by 5 U.S.C. 804(2).

## C. Petitions for Judicial Review

Under section 307(b)(1) of the Clean Air Act, petitions for judicial review of this action must be filed in the United States Court of Appeals for the appropriate circuit by June 6, 2000. Filing a petition for reconsideration by the Administrator of this final rule does not affect the finality of this rule for the purposes of judicial review nor does it extend the time within which a petition for judicial review may be filed, and
shall not postpone the effectiveness of such rule or action. This action may not be challenged later in proceedings to enforce its requirements. (See section 307(b)(2).)

## List of Subjects in $\mathbf{4 0}$ CFR Part 62

Environmental protection, Administrative practice and procedure, Air pollution control, Intergovernmental relations, Hospital/medical/infectious waste incinerators, Reporting and recordkeeping requirements.
Dated: March 23, 2000.

## Bradley M. Campbell,

Regional Administrator, EPA Region III.
40 CFR Part 62, Subpart NN, is amended as follows:

## PART 62-[AMENDED]

1. The authority citation for Part 62 continues to read as follows:
Authority: 42 U.S.C. 7401-7671q

## Subpart NN-Pennsylvania

2. A new undesignated center heading and $\S 62.9660,62.9661$, and 62.9662 are added to Subpart NN to read as follows:

## Emissions From Existing Hospital/ Medical/Infectious Waste Incinerators (HMIWIs)—Section 111(d)/129 Plan

## §62.9660 Identification of plan.

Section 111(d)/129 plan for HMIWIs and the associated Allegheny County Health Department (ACHD) regulations, as submitted on June 24, 1999.

## §62.9661 Identification of sources.

The plan applies to all Allegheny County, Pennsylvania existing HMIWI for which construction was commenced on or before June 20, 1996.

## § 62.9662 Effective date.

The effective date of the plan for municipal solid waste landfills is June 6, 2000.
[FR Doc. 00-8404 Filed 4-6-00; 8:45 am] BILLING CODE 6560-50-P

## ENVIRONMENTAL PROTECTION AGENCY

40 CFR Part 62
[MS23-200015a; FRL—6574-3]

## Approval and Promulgation of State Plans for Designated Facilities and Pollutants: Mississippi

Agency: Environmental Protection Agency.
ACTION: Direct final rule.
SUMMARY: The United States
Environmental Protection Agency (EPA)
is approving the section 111(d) Plan submitted by the Mississippi Department of Environmental Quality (DEQ) for the State of Mississippi on May 5, 1999, to implement and enforce the Emissions Guidelines (EG) for existing Hospital/Medical/Infectious Waste Incinerator (HMIWI) units.
DATES: This direct final rule is effective on June 6, 2000, without further notice, unless EPA receives adverse comment by May 8,2000 . If EPA receives adverse comment, we will publish a timely withdrawal of the direct final rule in the Federal Register and inform the public that the rule will not take effect.
ADDRESSES: You should address comments on this action to Michele Notarianni, EPA Region 4, Air Planning Branch, 61 Forsyth Street, SW, Atlanta, Georgia 30303-3104. [E-mail address: notarianni.michele@epa.gov.]
Copies of all materials considered in this rulemaking may be examined during normal business hours at the following locations: EPA Region 4, Sam Nunn Atlanta Federal Center, 61 Forsyth Street, SW, Atlanta, Georgia 30303-3104; and at the Mississippi Department of Environmental Quality, Air Division, P.O. Box 10385, Jackson, Mississippi 39289-0385.

## FOR FURTHER INFORMATION CONTACT:

Michele Notarianni at 404/562-9031 or Scott Davis at 404/562-9127. [E-mail addresses: notarianni.michele@epa.gov, davis.scottr@epa.gov.]

## SUPPLEMENTARY INFORMATION:

## Table of Contents

I. What action is being taken by EPA today?
II.

The HMIWI State Plan Requirement
What is a HMIWI State Plan?
Why are we requiring Mississippi to submit a HMIWI State Plan?
Why do we need to regulate air emissions from HMIWIs?
What criteria must a HMIWI State Plan meet to be approved?
III. What does the Mississippi HMIWI State Plan contain?
IV. Is my HMIWI subject to these regulations?
V. What steps do I need to take?
VI. Why is the Mississippi HMIWI State Plan approvable?
VII. Administrative Requirements

## I. What action is being taken by EPA today?

We are approving the Mississippi State Plan, as submitted on May 5, 1999, for the control of air emissions from HMIWIs, except for those HMIWIs located in Indian Country. When EPA developed our New Source Performance

Standard (NSPS) for HMIWIs, we also developed EG to control air emissions from older HMIWIs. (See 62 FR 4834848391, September 15, 1997, 40 CFR part 60, subpart Ce [Emission Guidelines and Compliance Times for HMIWIs] and subpart Ec [Standards of Performance for HMIWIs for Which Construction is Commenced After June 20, 1996]). The Mississippi DEQ developed a State Plan, as required by sections 111(d) and 129 of the Clean Air Act (the Act), to adopt the EG into their body of regulations, and we are acting today to approve it.

We are publishing this action without prior proposal because we view this as a noncontroversial amendment and anticipate no adverse comments. However, in a separate document in this Federal Register publication, we are proposing to approve the revision should significant, material, and adverse comments be filed. This action is effective June 6, 2000, unless by May 8, 2000, adverse or critical comments are received. If we receive such comments, this action will be withdrawn before the effective date by publishing a subsequent document that will withdraw the final action. All public comments received will be addressed in a subsequent final rule based on this action serving as a proposed rule. We will not institute a second comment period on this action. Any parties interested in commenting on this action should do so at this time. If no such comments are received, this action is effective June 6, 2000.

## II. The HMIWI State Plan Requirement

## What is a HMIWI State Plan?

A HMIWI State Plan is a plan to control air pollutant emissions from existing incinerators which burn hospital waste or medical/infectious waste. The plan also includes source and emission inventories of these incinerators in the State.
Why are we requiring Mississippi to submit a HMIWI State Plan?

States are required under sections 111(d) and 129 of the Act to submit State Plans to control emissions from existing HMIWIs in the State. The State Plan requirement was triggered when EPA published the EG for HMIWIs under 40 CFR part 60, subpart Ce (see 62 FR 48348, September 15, 1997).

Under section 129, EPA is required to promulgate EG for several types of existing solid waste incinerators. These EG establish the Maximum Achievable Control Technology (MACT) standards that States must adopt to comply with the Act. The HMIWI EG also establishes requirements for monitoring, operator
training, permits, and a waste management plan that must be included in State Plans.

The intent of the State Plan requirement is to reduce several types of air pollutants associated with waste incineration.
Why do we need to regulate air emissions from HMIWIs?

The State Plan establishes control requirements which reduce the following emissions from HMIWIs: particulate matter; sulfur dioxide; hydrogen chloride; nitrogen oxides; carbon monoxide; lead; cadmium; mercury; and dioxin/furans. These pollutants can cause adverse effects to the public health and the environment. Dioxin, lead, and mercury bioaccumulate through the food web. Serious developmental and adult effects in humans, primarily damage to the nervous system, have been associated with exposures to mercury. Exposure to dioxin and furans can cause skin disorders, cancer, and reproductive effects such as endometriosis. Dioxin and furans can also affect the immune system. Acid gases affect the respiratory tract, as well as contribute to the acid rain that damages lakes and harms forests and buildings. Exposure to particulate matter has been linked with adverse health effects, including aggravation of existing respiratory and cardiovascular disease and increased risk of premature death. Nitrogen oxide emissions contribute to the formation of ground level ozone, which is associated with a number of adverse health and environmental effects.

## What Criteria Must a HMIWI State Plan Meet to be Approved?

The criteria for approving a HMIWI State Plan include requirements from sections 111(d) and 129 of the Act and 40 CFR part 60, subpart B. Under the requirements of sections 111 (d) and 129 of the Act, a State Plan must be at least as protective as the EG regarding applicability, emission limits, compliance schedules, performance testing, monitoring and inspections, operator training and certification, waste management plans, and recordkeeping and reporting. Under section 129(e), State Plans must ensure that affected HMIWI facilities submit Title V permit applications to the State by September 15, 2000. Under the requirements of 40 CFR part 60, subpart B, the criteria for an approvable section 111(d) plan include demonstration of legal authority, enforceable mechanisms, public participation documentation, source and emission
inventories, and a State progress report commitment.

## III. What does the Mississippi HMIWI State Plan contain?

The Mississippi DEQ adopted the Federal EG into the Mississippi Code Annotated, "Air Emissions Regulations for the Prevention, Abatement, and Control of Air Contaminants," APC-S1, Section 12, and the Federal NSPS into APC-S-1, Section 6. The State rules were effective on April 22, 1999. The Mississippi State Plan contains:

1. A demonstration of the State's legal authority to implement the section 111(d) State Plan;
2. State rule, APC-S-1, Section 12, as the enforceable mechanism;
3. An inventory of approximately 30 known designated facilities, along with estimates of their potential air emissions;
4. Emission limits that are as protective as the EG;
5. A compliance date of September 15, 2000;
6. Testing, monitoring, reporting and recordkeeping requirements for the designated facilities;
7. Records from the public hearing on the State Plan; and,
8. Provisions for progress reports to EPA.

## IV. Is my HMIWI subject to these regulations?

The EG for existing HMIWIs affect any HMIWI built on or before June 20, 1996. If your facility meets this criterion, you are subject to these regulations.

## V. What steps do I need to take?

You must meet the requirements listed in the Mississippi Code Annotated, APC-S-1, Section 12, summarized as follows:

1. Determine the size of your incinerator by establishing its maximum design capacity.
2. Each size category of HMIWI has certain emission limits established which your incinerator must meet. See Table 1 of APC-S-1, Section 12, to determine the specific emission limits which apply to you. The emission limits apply at all times, except during startup, shutdown, or malfunctions, provided that no waste has been charged during these events.
3. There are provisions to address small rural incinerators (if your unit is applicable).
4. You must meet a $10 \%$ opacity limit on your discharge, averaged over a sixminute block.
5. You must have a qualified HMIWI operator available to supervise the operation of your incinerator. This
operator must be trained and qualified through a State-approved program, or a training program that meets the requirements listed under 40 CFR part 60.53c(c).
6. Your operator must be certified, as discussed in 5 above, no later than September 15, 2000.
7. You must develop and submit to Mississippi DEQ a waste management plan. This plan must be developed under guidance provided by the American Hospital Association publication, An Ounce of Prevention: Waste Reduction Strategies for Health Care Facilities, 1993, and must be submitted to Mississippi DEQ no later than 60 days following the initial performance test for the affected unit.
8. You must conduct an initial performance test to determine your incinerator's compliance with these emission limits. This performance test must be completed as required under 40 CFR 60.8.
9. You must install and maintain devices to monitor the parameters listed under Table 4 of APC-S-1, Section 12.
10. You must document and maintain information concerning pollutant concentrations, opacity measurements, charge rates, and other operational data. This information must be maintained for a period of five years.
11. You must submit an annual report to Mississippi DEQ containing records of annual equipment inspections, any required maintenance, and unscheduled repairs. This annual report must be signed by the facilities manager.

## VI. Why is the Mississippi HMIWI State Plan approvable?

EPA compared the Mississippi rules (Mississippi Code Annotated, APC-S-1, Section 12) against our HMIWI EG. EPA finds the Mississippi rules to be at least as protective as the EG. The Mississippi State Plan was reviewed for approval against the following criteria: 40 CFR 60.23 through 60.26, Subpart BAdoption and Submittal of State Plans for Designated Facilities; and, 40 CFR 60, 60.30e through 60.39e, Subpart Ce-Emission Guidelines and Compliance Times for Hospital/ Medical/Infectious Waste Incinerators. The Mississippi State Plan satisfies the requirements for an approvable section 111(d) plan under subparts B and Ce of 40 CFR part 60. For these reasons, we are approving the Mississippi HMIWI State Plan.

## VII. Administrative Requirements

Under Executive Order 12866 (58 FR 51735, October 4, 1993), this action is not a "significant regulatory action" and therefore is not subject to review by the

Office of Management and Budget. This action merely approves state law as meeting federal requirements and imposes no additional requirements beyond those imposed by state law. Accordingly, the Administrator certifies that this rule will not have a significant economic impact on a substantial number of small entities under the Regulatory Flexibility Act (5 U.S.C. 601 et seq.). Because this rule approves preexisting requirements under state law and does not impose any additional enforceable duty beyond that required by state law, it does not contain any unfunded mandate or significantly or uniquely affect small governments, as described in the Unfunded Mandates Reform Act of 1995 (Public Law 104-4). For the same reason, this rule also does not significantly or uniquely affect the communities of tribal governments, as specified by Executive Order 13084 (63 FR 27655, May 10, 1998). This rule will not have substantial direct effects on the states, on the relationship between the national government and the states, or on the distribution of power and responsibilities among the various levels of government, as specified in Executive Order 13132 (64 FR 43255, August 10, 1999), because it merely approves a state rule implementing a federal standard, and does not alter the relationship or the distribution of power and responsibilities established in the Clean Air Act. This rule also is not subject to Executive Order 13045 (62 FR 19885, April 23, 1997), because it is not economically significant.
In reviewing SIP submissions, EPA's role is to approve state choices, provided that they meet the criteria of the Clean Air Act. In this context, in the absence of a prior existing requirement for the State to use voluntary consensus standards (VCS), EPA has no authority to disapprove a SIP submission for failure to use VCS. It would thus be inconsistent with applicable law for EPA, when it reviews a SIP submission, to use VCS in place of a SIP submission that otherwise satisfies the provisions of the Clean Air Act. Thus, the requirements of section $12(\mathrm{~d})$ of the National Technology Transfer and Advancement Act of 1995 (15 U.S.C. 272 note) do not apply. As required by section 3 of Executive Order 12988 (61 FR 4729, February 7, 1996), in issuing this rule, EPA has taken the necessary steps to eliminate drafting errors and ambiguity, minimize potential litigation, and provide a clear legal standard for affected conduct. EPA has complied with Executive Order 12630 (53 FR 8859 , March 15,1988 ) by examining the takings implications of the rule in
accordance with the "Attorney General's Supplemental Guidelines for the Evaluation of Risk and Avoidance of Unanticipated Takings' issued under the Executive Order. This rule does not impose an information collection burden under the provisions of the Paperwork Reduction Act of 1995 (44 U.S.C. 3501 et seq.).

The Congressional Review Act, 5 U.S.C. section 801 et seq., as added by the Small Business Regulatory Enforcement Fairness Act of 1996, generally provides that before a rule may take effect, the agency promulgating the rule must submit a rule report, which includes a copy of the rule, to each House of the Congress and to the Comptroller General of the United States. EPA will submit a report containing this rule and other required information to the U.S. Senate, the U.S. House of Representatives, and the Comptroller General of the United States prior to publication of the rule in the Federal Register. A major rule cannot take effect until 60 days after it is published in the Federal Register. This action is not a "major rule" as defined by 5 U.S.C. section 804(2).

Under section 307(b)(1) of the Clean Air Act, petitions for judicial review of this action must be filed in the United States Court of Appeals for the appropriate circuit by June 6, 2000. Filing a petition for reconsideration by the Administrator of this final rule does not affect the finality of this rule for the purposes of judicial review nor does it extend the time within which a petition for judicial review may be filed, and shall not postpone the effectiveness of such rule or action. This action may not be challenged later in proceedings to enforce its requirements. (See section 307(b)(2).)

## List of Subjects in 40 CFR Part 62

Environmental protection, Administrative practice and procedure, Air pollution control, Hospital/medical/ infectious waste incineration,
Intergovernmental relations, Reporting and recordkeeping requirements.
Dated: March 16, 2000.
A. Stanley Meiburg,

Acting Regional Administrator, Region 4.
40 CFR part 62 of the Code of Federal Regulations is amended as follows:

## PART 62-[AMENDED]

1. The authority citation for part 62 continues to read as follows:
Authority: 42 U.S.C. 7401-7642.

## Subpart Z—Mississippi

2. Section 62.6100 is amended by adding paragraphs (b)(3) and (c)(4) to read as follows:

## §62.6100 Identification of plan.

(b) * * *
(3) Adopted State Plan for Control of Air Emissions from Existing Hospital/ Medical/Infectious Waste Incinerators, submitted on May 5, 1999, by the Mississippi Department of
Environmental Quality.
(c) * * *
(4) Existing hospital/medical/ infectious waste incinerators.
3. Subpart Z is amended by adding a new $\S 62.6124$ and a new undesignated center heading to read as follows:
Air Emissions from Hospital/Medical/ Infectious Waste Incinerators

## §62.6124 Identification of sources.

The plan applies to existing hospital/ medical/infectious waste incinerators for which construction, reconstruction, or modification was commenced before June 20, 1996, as described in 40 CFR part 60, subpart Ce.
[FR Doc. 00-8528 Filed 4-6-00; 8:45 am] BILLING CODE 6560-50-P

## FEDERAL COMMUNICATIONS COMMISSION

## 47 CFR Parts 24 and 64

[CC Docket No. 97-213, FCC 99-230]

## Communications Assistance for Law Enforcement Act

AGENCY: Federal Communications Commission.
ACTION: Correcting amendments.
summary: On August 31, 1999, the Commission released a Third Report and Order in the matter of Communications Assistance for Law Enforcement Act. This document contains corrections to the final regulations that appeared in the Federal Register of September 24, 1999 (64 FR 51710).

DATES: Effective April 7, 2000.
FOR FURTHER INFORMATION CONTACT:
Rodney Small, Office of Engineering and Technology, (202) 418-2452 .

## SUPPLEMENTARY INFORMATION:

## Background

The final regulations that are the subject of this correction relate to Communications Assistance for Law Enforcement Act under Sections
24.903(a), 24.903(b), 64.2203(a) and 64.2203(b) of the rules.

## Need for Correction

As published, the final regulations contain errors, which require correction.

## List of Subjects in 47 CFR Parts 24 and 64

Communications common carriers.
Accordingly, 47 CFR parts 24 and 64 are corrected by making the following amendments:

## PART 24-PERSONAL COMMUNICATIONS SERVICES

1. The authority citation for part 24 continues to read as follows:
Authority: 47 U.S.C. 154, 301, 302, 303, 309 and 332.
2. Section 24.903 is amended by revising paragraphs (a) and (b) introductory text to read as follows:
(a) Except as provided under paragraph (b) of this section, as of June 30, 2000, a broadband PCS telecommunications carrier shall provide to a LEA the assistance capability requirements of CALEA, see 47 U.S.C. 1002. A carrier may satisfy these requirements by complying with publicly available technical requirements or standards adopted by an industry association or standardsetting organization, such as J-STD-025.
(b) As of September 30, 2001, a broadband PCS telecommunications carrier shall provide to a LEA communications and call-identifying information transported by packet-mode communications and the following capabilities:

## PART 64-MISCELLANEOUS RULES RELATING TO COMMON CARRIERS

3. The authority citation for part 64 continues to read as follows:

Authority: 47 U.S.C. 151, 154, 201, 202, 205, 218-220, and 332 unless otherwise noted. Interpret or apply sections 201, 218, 225, 226, 227, 229, 332, 48 Stat. 1070, as amended, 47 U.S.C. 201-204, 208-, 225, 226, 227, 229, 332, 501 and 503 unless otherwise noted.
4. Section 64.2203 is amended by revising paragraphs (a) and (b) introductory text to read as follows:
(a) Except as provided under paragraph (b) of this section, as of June 30, 2000, a wireline telecommunications carrier shall provide to a LEA the assistance capability requirements of CALEA, see 47 U.S.C. 1002. A carrier may satisfy these requirements by complying with publicly available technical requirements or standards
adopted by an industry association or standard-setting organization, such as J-STD-025.
(b) As of September 30, 2001, a wireline telecommunications carrier shall provide to a LEA communications and call-identifying information transported by packet-mode communications and the following capabilities:

Federal Communications Commission.

```
Magalie Roman Salas,
Secretary.
[FR Doc. 00-8590 Filed 4-6-00; 8:45 am] BILLING CODE 6712-01-P
```


## FEDERAL COMMUNICATIONS COMMISSION

## 47 CFR Part 52

[WT Docket No. 98-229, CC Docket No. 95116; FCC 00-47]

Cellular Telecommunications Industry Association's Petition for Forbearance From Commercial Mobile Radio Services Number Portability Obligations; Telephone Number Portability

AGENCY: Federal Communications Commission.
ACTION: Final rule: Petition for Reconsideration.

SUMMARY: In this document, the Federal Communications Commission (Commission) denies four petitions for reconsideration or clarification of the Commission's Order forbearing from imposing service provider local number portability (LNP) requirements on commercial mobile radio service providers (CMRS providers) until November 24, 2002. The Commission finds that, in its forbearance decision, it adequately considered issues related to number conservation, competition in the wireless industry, and the Telecommunications Resellers Association's alternate LNP proposal. The Commission also finds that its forbearance analysis was consistent with the statutory standard. By this document, the Commission declines to extend or shorten the November 24, 2002 deadline for CMRS providers to support service provider LNP in the top 100 Metropolitan Statistical Areas (MSAs).
DATES: Effective April 7, 2000.
FOR FURTHER INFORMATION CONTACT: Joel Taubenblatt, Wireless
Telecommunications Bureau, at (202) 418-1513.

SUPPLEMENTARY INFORMATION: This is a summary of the Commission's Order on Reconsideration in WT Docket No. 98229 and CT Docket No. 95-116, adopted February 9, 2000, and released February 23,2000 . The complete text of this Order on Reconsideration is available for inspection and copying during normal business hours in the Commission's Reference Center, room CY-A257, 445 12th Street SW, Washington, DC. The complete text is also available through the Internet at http://www.fcc.gov/Bureaus/Wireless/ Orders/2000/fcc00047.doc. In addition, the complete text may be purchased from the Commission's duplicating contractor, International Transcription Service, Inc. (ITS, Inc.) at 1231 20th Street NW, Washington, DC 10036, (202) 857-3800.

## Synopsis of the Order on Reconsideration

1. On May 27, 1999, four parties filed petitions for reconsideration or clarification of the Commission's Order forbearing from imposing service provider LNP requirements on CMRS providers until November 24, 2002. See Cellular Telecommunications Industry Association's Petition for Forbearance From Commercial Mobile Radio Services Number Portability Obligations, 64 FR 22562, April 27, 1999 ("CMRS LNP Forbearance Order"). These parties are GTE Service Corporation (GTE), MCI WorldCom Inc. (MCI WorldCom), the
Telecommunications Resellers Association (TRA), and the
Pennsylvania Public Utility Commission (Pennsylvania Commission). The Commission denies these petitions for the reasons discussed.
2. Under the Commission's prior LNP decisions, CMRS providers were required to implement LNP in the top 100 MSAs and to support nationwide roaming by March 31, 2000.
Implementation of LNP by CMRS providers would enable wireless customers to "port" their telephone numbers in the event that they switch from one wireless carrier to another, or from a wireless to a wireline carrier.
3. In the CMRS LNP Forbearance Order, the Commission granted a petition filed by the Cellular Telecommunications Industry Association (CTIA) requesting forbearance from the Commission's service provider LNP requirements for CMRS providers until the expiration of the five-year buildout period for broadband PCS carriers. The Commission found that the limited forbearance granted in the CMRS LNP Forbearance Order satisfied the three-
prong test for granting forbearance set forth in section 10 of the
Communications Act. 47 U.S.C. 160.
Accordingly, the Commission extended the deadline for CMRS providers to support service provider LNP in the top 100 MSAs until November 24, 2002. The Commission also stated its intention to promptly initiate a rulemaking proposing certain non-LNP based numbering optimization techniques applicable to all telecommunications carriers and to develop standards for other number conservation methods, possibly including one or more pooling methods. On June 2, 1999, the Commission released a Notice of Proposed Rulemaking on numbering resource optimization. See Numbering Resource Optimization, 64 FR 32471, June 17, 1999 ("Numbering Resource Optimization Notice"').
4. In their petitions for reconsideration of the CMRS LNP Forbearance Order, MCI WorldCom, the Pennsylvania Commission, and TRA argue that the Commission should not have forborne from imposing service provider LNP requirements on CMRS providers for any length of time. GTE's petition for reconsideration of the CMRS LNP Forbearance Order, on the other hand, contends that the Commission should have forborne indefinitely from imposing service provider LNP requirements on CMRS providers. Generally, petitioners challenge the Commission's analysis of issues related to number conservation, competition in the wireless industry, and TRA's alternate LNP proposal. In addition, GTE and TRA challenge the Commission's application of the forbearance standard set forth in section 10 of the Communications Act. 47 U.S.C. 160.
5. This Order on Reconsideration finds that none of the petitions raises arguments that warrant reconsideration of the Commission's decision in the CMRS LNP Forbearance Order to forbear from imposing service provider LNP requirements on CMRS providers until November 24, 2002.
6. With respect to number conservation issues, the Order rejects assertions that: (1) the Commission's decision to extend the CMRS LNP deadline until November 24, 2002 will hamper the implementation of number optimization solutions that require LNP technology, such as thousands-block number pooling; and (2) the
Commission's consideration of number conservation issues as a basis for limiting forbearance was impermissible and inaccurate speculation. In addition, in response to a request for clarification,
the Order notes that whether, and the extent to which, the Commission should delegate additional authority to states to implement various numbering optimization measures is the subject of the Numbering Resource Optimization Notice. The Order also states the Commission's belief that the existing North American Numbering Council reporting mechanism, as well as the authority of the Wireless
Telecommunications Bureau to address any wireless LNP implementation problems that may arise, are sufficient to address the LNP implementation concerns raised by petitioners.
7. With respect to competition issues, the Order states that the Commission carefully considered the effect of forbearance from the CMRS LNP requirements on wireless-to-wireless and wireless-to-wireline competition and found that extending the wireless LNP deadline until November 24, 2002, but not beyond that date, would promote competition in the short term and in the long term. Regarding TRA's proposed alternative approach for implementing LNP, the Commission finds that the Commission adequately considered TRA's proposal in the CMRS LNP Forbearance Order.
8. Finally, with respect to section 10 issues, the Order affirms the Commission's findings that the forbearance granted in the CMRS LNP Forbearance Order is consistent with the statutory standard of section 10. In addition, the Order states that, as an alternative to section 10 forbearance, the Commission could have extended the CMRS LNP implementation deadline to November 24, 2002 by granting a waiver under § 1.3 of the Commission's rules. See 47 CFR 1.3.

## Ordering Clause

9. Accordingly, pursuant to § 1.106 of the Commission's rules, 47 CFR 1.106, the petitions for reconsideration of the CMRS LNP Forbearance Order filed by GTE Service Corporation, MCI
WorldCom Inc., the Pennsylvania Public Utility Commission, and the
Telecommunications Resellers
Association are denied.

## List of Subjects in 47 CFR Part 52

Telecommunications.
Federal Communications Commission.
Shirley S. Suggs,
Chief, Publications Group.
[FR Doc. 00-8651 Filed 4-6-00; 8:45 am]
BILLING CODE 6712-01-P

## DEPARTMENT OF COMMERCE

## National Oceanic and Atmospheric Administration

## 50 CFR Part 679

[Docket No.000211040-0040-01; I.D. 040300A]

Fisheries of the Exclusive Economic Zone Off Alaska; Atka Mackerel in the Central Aleutian District of the Bering Sea and Aleutian Islands
Agencr: National Marine Fisheries Service (NMFS), National Oceanic and Atmospheric Administration (NOAA), Commerce.
ACTION: Modification of a closure.
SUMMARY: NMFS is opening directed fishing for Atka mackerel in the Central Aleutian District of the Bering Sea and Aleutian Islands management area (BSAI) and is prohibiting trawling within Steller sea lion critical habitat in the Central Aleutian District of the BSAI. These actions are necessary to fully utilize the 2000 A season harvest specification of Atka mackerel total allowable catch (TAC) in the Central Aleutian District, and because the 2000 A season critical habitat percentage of Atka mackerel allocated to the Central Aleutian District has been reached.
DATES: Effective 1200 hrs, Alaska local time (A.l.t.), April 3, 2000, until 1200 hrs, A.l.t., April 15, 2000.
FOR FURTHER INFORMATION CONTACT: Andrew Smoker, 907-586-7228.
SUPPLEMENTARY INFORMATION: NMFS manages the groundfish fishery in the BSAI exclusive economic zone according to the Fishery Management Plan for the Groundfish Fishery of the Bering Sea and Aleutian Islands Area (FMP) prepared by the North Pacific Fishery Management Council under authority of the Magnuson-Stevens Fishery Conservation and Management Act. Regulations governing fishing by U.S. vessels in accordance with the FMP appear at subpart H of 50 CFR part 600 and 50 CFR part 679.

The A season apportionment of the 2000 TAC for Atka mackerel in the Central Aleutian District is 11,424, metric tons (mt), of which no more than $7,654 \mathrm{mt}$ may be harvested from critical habitat ( 65 FR 8282, February 18, 2000). See §679.20(c)(3)(iii) and 679.22(a)(8)(iii)(B).

The directed fishery for Atka mackerel in the Central Aleutian District
was closed to reserve amounts anticipated to be needed for incidental catch in other fisheries ( 65 FR 11249, March 2, 2000). NMFS has determined that as of March 18, 2000, approximately $2,000 \mathrm{mt}$ remains in the A season Central Aleutian District directed fishing allowance.

The Administrator, Alaska Region, NMFS (Regional Administrator) has determined that the 2000 A season directed fishing allowance for Atka mackerel in the Central Aleutian District has not been reached. Therefore, NMFS is terminating the previous closure and is opening directed fishing for Atka mackerel in the Central Aleutian District of the BSAI.

In accordance with § 679.22(a)(8)(iii)(A), the Regional Administrator, has determined that the A season allowable harvest of Atka mackerel in Steller Sea lion critical habitat within the Central Aleutian District as specified under the 2000 harvest specifications has been reached. Consequently, NMFS is prohibiting trawling in critical habitat, as defined at 50 CFR part 226, Table 1 and Table 2 in the Central Aleutian District of the BSAI.

## Classification

This action responds to the best available information recently obtained from the fishery. It must be implemented immediately to fully utilize the 2000 harvest specification of Atka mackerel TAC in the Central Aleutian District and to avoid jeopardy to the continued existence of Steller sea lions. Providing prior notice and opportunity for public comment for this action is impracticable and contrary to the public interest. NMFS finds for good cause that the implementation of this action cannot be delayed for 30 days. Accordingly, under 5 U.S.C. 553(d), a delay in the effective date is hereby waived.
This action is required by $\S 679.20$ and $\S 679.22$ and is exempt from review under E.O. 12866.

## Authority: 16 U.S.C. 1801 et seq.

Dated: April 3, 2000

## Bruce C. Morehead,

Acting Director, Office of Sustainable Fisheries, National Marine Fisheries Service.
[FR Doc. 00-8547 Filed 4-3-00; 4:55 pm]
BILLING CODE 3510-22-F

# Proposed Rules 

Federal Register
Vol. 65, No. 68
Friday, April 7, 2000

This section of the FEDERAL REGISTER contains notices to the public of the proposed issuance of rules and regulations. The purpose of these notices is to give interested persons an opportunity to participate in the rule making prior to the adoption of the final rules.

## DEPARTMENT OF TRANSPORTATION

## Federal Aviation Administration

## 14 CFR Part 39

[Docket No. 2000-NM-53-AD]
RIN 2120-AA64

## Airworthiness Directives; Airbus Model A330 and A340 Series Airplanes

AGENCY: Federal Aviation
Administration, DOT.
ACTION: Notice of proposed rulemaking (NPRM).

SUMMARY: This document proposes the adoption of a new airworthiness directive (AD) that is applicable to all Airbus Model A330 and A340 series airplanes. This proposal would require repetitive ultrasonic inspections to detect corrosion of the retraction links of the main landing gear (MLG), and replacement of the retraction link with a new retraction link, if necessary. This proposal is prompted by issuance of mandatory continuing airworthiness information by a foreign civil airworthiness authority. The actions specified by the proposed AD are intended to detect and correct corrosion of the retraction link of the MLG, which could result in reduced structural integrity and possible collapse of the MLG.
DATES: Comments must be received by May 8, 2000.
ADDRESSES: Submit comments in triplicate to the Federal Aviation Administration (FAA), Transport Airplane Directorate, ANM-114, Attention: Rules Docket No. 2000-NM-53-AD, 1601 Lind Avenue, SW., Renton, Washington 98055-4056. Comments may be inspected at this location between 9 a.m. and 3 p.m., Monday through Friday, except Federal holidays.
The service information referenced in the proposed rule may be obtained from Airbus Industrie, 1 Rond Point Maurice Bellonte, 31707 Blagnac Cedex, France.

This information may be examined at the FAA, Transport Airplane
Directorate, 1601 Lind Avenue, SW., Renton, Washington.

## FOR FURTHER INFORMATION CONTACT:

Norman B. Martenson, Manager, International Branch, ANM-116, Transport Airplane Directorate, 1601 Lind Avenue, SW., Renton, Washington 98055-4056; telephone (425) 227-2110; fax (425) 227-1149.

## SUPPLEMENTARY INFORMATION:

## Comments Invited

Interested persons are invited to participate in the making of the proposed rule by submitting such written data, views, or arguments as they may desire. Communications shall identify the Rules Docket number and be submitted in triplicate to the address specified above. All communications received on or before the closing date for comments, specified above, will be considered before taking action on the proposed rule. The proposals contained in this notice may be changed in light of the comments received.

Comments are specifically invited on the overall regulatory, economic, environmental, and energy aspects of the proposed rule. All comments submitted will be available, both before and after the closing date for comments, in the Rules Docket for examination by interested persons. A report summarizing each FAA-public contact concerned with the substance of this proposal will be filed in the Rules Docket.

Commenters wishing the FAA to acknowledge receipt of their comments submitted in response to this notice must submit a self-addressed, stamped postcard on which the following statement is made: "Comments to Docket Number 2000-NM-53-AD." The postcard will be date stamped and returned to the commenter.

## Availability of NPRMs

Any person may obtain a copy of this NPRM by submitting a request to the FAA, Transport Airplane Directorate, ANM-114, Attention: Rules Docket No. 2000-NM-53-AD, 1601 Lind Avenue, SW., Renton, Washington 98055-4056.

## Discussion

The Direction Generale de l'Aviation Civile (DGAC), which is the airworthiness authority for France,
recently notified the FAA that an unsafe condition may exist on all Airbus Model A330 and A340 series airplanes. The DGAC advises that, during a gear-down selection on an Airbus Model A330 series airplane, a retraction link (lefthand) of the main landing gear (MLG) ruptured. The MLG configuration of Airbus Model A330 series airplanes is similar in design to that of Airbus Model A340 series airplanes. Therefore, Airbus Model A340 series airplanes may be subject to the same unsafe condition revealed on the Airbus Model 330 series airplane. Investigation revealed that the internal face of the bore of the retraction link was heavily corroded. Such corrosion, if not detected and corrected, could result in reduced structural integrity and possible collapse of the MLG.

## Explanation of Relevant Service Information

The manufacturer has issued Airbus Service Bulletins A330-32-3105, Revision 01, dated December 14, 1999 (for Model A330 series airplanes), and A340-32-4148, Revision 01, dated December 14, 1999 (for Model A340 series airplanes). These service bulletins describe procedures for repetitive ultrasonic inspections to detect corrosion of the left- and right-hand retraction links of the MLG, and replacement of the retraction link with a new retraction link, if necessary. The DGAC classified the Airbus service bulletins as mandatory and issued French airworthiness directives 2000-013-107(B) R1, dated February 9, 2000 (for Model A330 series airplanes), and 2000-015-132(B), dated January 12, 2000 (for Model A340 series airplanes), in order to assure the continued airworthiness of these airplanes in France.

The Airbus service bulletins reference Messier-Dowty Service Bulletins A33/ 34-32-151, Revision 3, including Appendix A, and A33/34-32-152, Revision 3, including Appendix A, each dated January 11, 2000, as additional sources of service information for accomplishing the repetitive ultrasonic inspections.

## FAA's Conclusions

These airplane models are manufactured in France and are type certificated for operation in the United States under the provisions of section 21.29 of the Federal Aviation

Regulations (14 CFR 21.29) and the applicable bilateral airworthiness agreement. Pursuant to this bilateral airworthiness agreement, the DGAC has kept the FAA informed of the situation described above. The FAA has examined the findings of the DGAC, reviewed all available information, and determined that AD action is necessary for products of this type design that are certificated for operation in the United States.

## Explanation of Requirements of Proposed Rule

Since an unsafe condition has been identified that is likely to exist or develop on other airplanes of the same type design registered in the United States, the proposed AD would require repetitive ultrasonic inspections to detect corrosion of the retraction links of the MLG, and replacement of the retraction link with a new retraction link, if necessary. The actions would be required to be accomplished in accordance with the Airbus service bulletins described previously.

## Cost Impact

None of the airplanes affected by this action are on the U.S. Register. All airplanes included in the applicablity of this rule currently are operated by nonU.S. operators under foreign registry; therefore, they are not directly affected by this AD action. However, the FAA considers that this rule is necessary to ensure that the unsafe condition is addressed in the event that any of these subject airplanes are imported and placed on the U.S. Register in the future.
Should an affected airplane be imported and placed on the U.S. Register in the future, it would require approximately 1 work hour to accomplish the required inspection, at an average labor rate of $\$ 60$ per work hour. Based on these figures, the cost impact of this AD would be $\$ 60$ per airplane, per inspection cycle.

## Regulatory Impact

The regulations proposed herein would not have a substantial direct effect on the States, on the relationship between the national Government and the States, or on the distribution of power and responsibilities among the various levels of government. Therefore, it is determined that this proposal would not have federalism implications under Executive Order 13132.
For the reasons discussed above, I certify that this proposed regulation (1) is not a "significant regulatory action" under Executive Order 12866; (2) is not a "significant rule" under the DOT Regulatory Policies and Procedures (44

FR 11034, February 26, 1979); and (3) if promulgated, will not have a significant economic impact, positive or negative, on a substantial number of small entities under the criteria of the Regulatory Flexibility Act. A copy of the draft regulatory evaluation prepared for this action is contained in the Rules Docket. A copy of it may be obtained by contacting the Rules Docket at the location provided under the caption ADDRESSES.

## List of Subjects in 14 CFR Part 39

Air transportation, Aircraft, Aviation safety, Safety.

## The Proposed Amendment

Accordingly, pursuant to the authority delegated to me by the Administrator, the Federal Aviation Administration proposes to amend part 39 of the Federal Aviation Regulations (14 CFR part 39) as follows:

## PART 39—AIRWORTHINESS DIRECTIVES

1. The authority citation for part 39 continues to read as follows:

Authority: 49 U.S.C. 106(g), 40113, 44701.

## § 39.13 [Amended]

2. Section 39.13 is amended by adding the following new airworthiness directive:

Airbus Industrie: Docket 2000-NM-53-AD.
Applicability: All Model A330 and A340 series airplanes, certificated in any category;

Note 1: This AD applies to each airplane identified in the preceding applicability provision, regardless of whether it has been modified, altered, or repaired in the area subject to the requirements of this AD . For airplanes that have been modified, altered, or repaired so that the performance of the requirements of this AD is affected, the owner/operator must request approval for an alternative method of compliance in accordance with paragraph (b) of this AD. The request should include an assessment of the effect of the modification, alteration, or repair on the unsafe condition addressed by this AD ; and, if the unsafe condition has not been eliminated, the request should include specific proposed actions to address it.

Compliance: Required as indicated, unless accomplished previously.

To detect and correct corrosion of the retraction links of the main landing gear (MLG), which could result in reduced structural integrity and possible collapse of the MLG, accomplish the following:

## Repetitive Ultrasonic Inspections

(a) Within 36 months time-in-service on any new retraction link, or within 2 months after the effective date of this AD, whichever occurs later, perform an ultrasonic inspection to detect corrosion of the retraction links leftand right-hand of the MLG, in accordance with Airbus Service Bulletin A330-32-3105,

Revision 01, dated December 14, 1999 (for Model A330 series airplanes), or Airbus Service Bulletin A340-32-4148, Revision 01, dated December 14, 1999 (for Model A340 series airplanes), as applicable.
(1) If no corrosion is detected, or if corrosion is detected that is within the limits specified in the applicable service bulletin, repeat the inspection thereafter at intervals not to exceed 6 months.
(2) If any corrosion is detected that is outside the limits specified in the applicable service bulletin, replace the affected retraction link with a new retraction link at the time specified and in accordance with the procedures specified in the applicable service bulletin. Thereafter, repeat the inspection specified in paragraph (a) on any new retraction links, at the time specified in paragraph (a) of this AD.

Note 2: The Airbus service bulletins reference Messier-Dowty Service Bulletins A33/34-32-151, Revision 3, including Appendix A, and A33/34-32-152, Revision 3, including Appendix A, each dated January 11,2000 , as additional sources of service information for accomplishing the repetitive inspections.
Note 3: Although the inspection schedule of this AD applies to both left- and right-hand retraction links of the MLG, replacement of a retraction link, prior to scheduled replacement, would result in subsequent staggered inspections for the remainder of the retraction links.

## Alternative Methods of Compliance

(b) An alternative method of compliance or adjustment of the compliance time that provides an acceptable level of safety may be used if approved by the Manager,
International Branch, ANM-116, FAA, Transport Airplane Directorate. Operators shall submit their requests through an appropriate FAA Principal Maintenance Inspector, who may add comments and then send it to the Manager, International Branch, ANM-116.
Note 4: Information concerning the existence of approved alternative methods of compliance with this AD , if any, may be obtained from the International Branch, ANM-116.

## Special Flight Permits

(c) Special flight permits may be issued in accordance with sections 21.197 and 21.199 of the Federal Aviation Regulations (14 CFR 21.197 and 21.199) to operate the airplane to a location where the requirements of this AD can be accomplished.

Note 5: The subject of this AD is addressed in French airworthiness directives 2000-013-107(B) R1, dated February 9, 2000, and 2000-015-132(B), dated January 12, 2000.

Issued in Renton, Washington, on April 3, 2000.

## Donald L. Riggin,

Acting Manager, Transport Airplane Directorate, Aircraft Certification Service. [FR Doc. 00-8687 Filed 4-6-00; 8:45 am] BILLING CODE 4910-13-P

DEPARTMENT OF TRANSPORTATION

## Federal Aviation Administration

## 14 CFR Part 39

[Docket No. 99-NM-230-AD]

## RIN 2120-AA64

## Airworthiness Directives; British Aerospace BAe Model ATP Airplanes

agencr: Federal Aviation
Administration, DOT.
ACTION: Notice of proposed rulemaking (NPRM).

SUMMARY: This document proposes the adoption of a new airworthiness directive (AD) that is applicable to certain British Aerospace BAe Model ATP airplanes. This proposal would require repetitive inspections to detect discrepancies of the downlock support assembly and attachment of the nose landing gear (NLG), and of the bulkhead and adjacent structure in the NLG bay; and corrective action, if necessary. This proposal is prompted by issuance of mandatory continuing airworthiness information by a foreign civil airworthiness authority. The actions specified by the proposed AD are intended to detect and correct damage of the NLG downlock support, which could result in collapse of the NLG and consequent injury to passengers or flightcrew.
DATES: Comments must be received by May 8, 2000.
ADDRESSES: Submit comments in triplicate to the Federal Aviation Administration (FAA), Transport Airplane Directorate, ANM-114, Attention: Rules Docket No. 99-NM-230-AD, 1601 Lind Avenue, SW., Renton, Washington 98055-4056. Comments may be inspected at this location between 9 a.m. and 3 p.m., Monday through Friday, except Federal holidays.
The service information referenced in the proposed rule may be obtained from British Aerospace Regional Aircraft, 13850 Mclearen Road, Herndon, Virginia 20171. This information may be examined at the FAA, Transport Airplane Directorate, 1601 Lind Avenue, SW., Renton, Washington.

## FOR FURTHER INFORMATION CONTACT:

Norman B. Martenson, Manager, International Branch, ANM-116, FAA, Transport Airplane Directorate, 1601 Lind Avenue, SW., Renton, Washington 98055-4056; telephone (425) 227-2110; fax (425) 227-1149.
SUPPLEMENTARY INFORMATION:

## Comments Invited

Interested persons are invited to participate in the making of the proposed rule by submitting such written data, views, or arguments as they may desire. Communications shall identify the Rules Docket number and be submitted in triplicate to the address specified above. All communications received on or before the closing date for comments, specified above, will be considered before taking action on the proposed rule. The proposals contained in this notice may be changed in light of the comments received.

Comments are specifically invited on the overall regulatory, economic, environmental, and energy aspects of the proposed rule. All comments submitted will be available, both before and after the closing date for comments, in the Rules Docket for examination by interested persons. A report summarizing each FAA-public contact concerned with the substance of this proposal will be filed in the Rules Docket.

Commenters wishing the FAA to acknowledge receipt of their comments submitted in response to this notice must submit a self-addressed, stamped postcard on which the following statement is made: "Comments to Docket Number 99-NM-230-AD." The postcard will be date stamped and returned to the commenter.

## Availability of NPRMs

Any person may obtain a copy of this NPRM by submitting a request to the FAA, Transport Airplane Directorate, ANM-114, Attention: Rules Docket No. 99-NM-230-AD, 1601 Lind Avenue, SW., Renton, Washington 98055-4056.

## Discussion

The Civil Aviation Authority, which is the airworthiness authority for the United Kingdom, notified the FAA that an unsafe condition may exist on certain British Aerospace BAe Model ATP airplanes. The CAA advises that the downlock structure of the nose landing gear (NLG) has been found damaged. The exact cause of the damage has not yet been determined. This condition, if not corrected, could result in collapse of the NLG and consequent injury to passengers or flightcrew.

## Explanation of Relevant Service Information

British Aerospace has issued Service Bulletin ATP-53-36, Revision 1, dated February 21, 2000, which describes procedures for repetitive general visual inspections to detect discrepancies of the downlock support assembly and attachment of the NLG, and of the
bulkhead and adjacent structure in the NLG bay; and corrective action, if necessary. Discrepancies for which to inspect include damage of the NLG downlock support, downlock backup structure, and attachment locations; damage or loose nuts and bolts of the NLG downlock attachment; and damage of the bulkhead 378FS web, boundary angles, and attachment locations, and the airplane skin attached to bulkhead 378 FS . Corrective actions include repair of any damage and torquing of any loose nut or bolt to the limits specified in the service bulletin. Accomplishment of the actions specified in the service bulletin is intended to adequately address the identified unsafe condition. The CAA classified this service bulletin as mandatory, and issued British airworthiness directive 006-06-99, in order to ensure the continued airworthiness of these airplanes in the United Kingdom.

## FAA's Conclusions

This airplane model is manufactured in the United Kingdom and is type certificated for operation in the United States under the provisions of section 21.29 of the Federal Aviation Regulations (14 CFR 21.29) and the applicable bilateral airworthiness agreement. Pursuant to this bilateral airworthiness agreement, the CAA has kept the FAA informed of the situation described above. The FAA has examined the findings of the CAA, reviewed all available information, and determined that AD action is necessary for products of this type design that are certificated for operation in the United States.

## Explanation of Requirements of Proposed Rule

Since an unsafe condition has been identified that is likely to exist or develop on other airplanes of the same type design registered in the United States, the proposed AD would require accomplishment of the actions specified in the service bulletin described previously.

## Cost Impact

The FAA estimates that 10 airplanes of U.S. registry would be affected by this proposed AD, that it would take approximately 4 work hours per airplane to accomplish the proposed inspection, and that the average labor rate is $\$ 60$ per work hour. Based on these figures, the cost impact of the proposed AD on U.S. operators is estimated to be $\$ 2,400$, or $\$ 240$ per airplane, per inspection cycle.

The cost impact figure discussed above is based on assumptions that no
operator has yet accomplished any of the proposed requirements of this AD action, and that no operator would accomplish those actions in the future if this AD were not adopted.

## Regulatory Impact

The regulations proposed herein would not have a substantial direct effect on the States, on the relationship between the national Government and the States, or on the distribution of power and responsibilities among the various levels of government. Therefore, it is determined that this proposal would not have federalism implications under Executive Order 13132.

For the reasons discussed above, I certify that this proposed regulation (1) is not a "significant regulatory action" under Executive Order 12866; (2) is not a "significant rule" under the DOT Regulatory Policies and Procedures (44 FR 11034, February 26, 1979); and (3) if promulgated, will not have a significant economic impact, positive or negative, on a substantial number of small entities under the criteria of the Regulatory Flexibility Act. A copy of the draft regulatory evaluation prepared for this action is contained in the Rules Docket. A copy of it may be obtained by contacting the Rules Docket at the location provided under the caption ADDRESSES.

## List of Subjects in 14 CFR Part 39

Air transportation, Aircraft, Aviation safety, Safety.

## The Proposed Amendment

Accordingly, pursuant to the authority delegated to me by the Administrator, the Federal Aviation Administration proposes to amend part 39 of the Federal Aviation Regulations (14 CFR part 39) as follows:

## PART 39—AIRWORTHINESS DIRECTIVES

1. The authority citation for part 39 continues to read as follows:
Authority: 49 U.S.C. 106(g), 40113, 44701.

## §39.13 [Amended]

2. Section 39.13 is amended by adding the following new airworthiness directive:

## British Aerospace Regional Aircraft

[Formerly Jetstream Aircraft Limited; British Aerospace (Commercial Aircraft) Limited]: Docket 99-NM-230-AD.
Applicability: BAe Model ATP airplanes, constructor's numbers 2002 through 2063 inclusive, certificated in any category.
Note 1: This AD applies to each airplane identified in the preceding applicability provision, regardless of whether it has been
modified, altered, or repaired in the area subject to the requirements of this $A D$. For airplanes that have been modified, altered, or repaired so that the performance of the requirements of this AD is affected, the owner/operator must request approval for an alternative method of compliance in accordance with paragraph (b) of this AD. The request should include an assessment of the effect of the modification, alteration, or repair on the unsafe condition addressed by this AD ; and, if the unsafe condition has not been eliminated, the request should include specific proposed actions to address it.

Compliance: Required as indicated, unless accomplished previously.

To detect and correct damage of the nose landing gear (NLG) downlock support, which could result in collapse of the NLG, and consequent injury to passengers or flightcrew, accomplish the following:

## Repetitive Inspections and Corrective Action

(a) Within 6 months or 750 flight cycles after the effective date of this AD, whichever occurs first, perform a general visual inspection to detect discrepancies (e.g., damage, or loose nuts or bolts) of the NLG downlock support assembly, bulkhead, attachment locations, and adjacent structure in the NLG bay; in accordance with British Aerospace Service Bulletin ATP-53-36, Revision 1, dated February 21, 2000. Thereafter, repeat the inspection at intervals not to exceed 2 years or 3,000 flight cycles, whichever occurs first.
(1) If any damage is found during any inspection in accordance with paragraph (a) of this AD , prior to further flight, repair in accordance with the service bulletin.
(2) If any loose nut or bolt is found during any inspection in accordance with paragraph (a) of this AD , prior to further flight, torque the affected nut or bolt to the limits specified in the service bulletin, in accordance with the service bulletin.

Note 2: For the purposes of this AD, a general visual inspection is defined as: "A visual examination of an interior or exterior area, installation, or assembly to detect obvious damage, failure, or irregularity. This level of inspection is made under normally available lighting conditions such as daylight, hangar lighting, flashlight, or droplight, and may require removal or opening of access panels or doors. Stands, ladders, or platforms may be required to gain proximity to the area being checked."

Note 3: Inspections and corrective actions accomplished prior to the effective date of this AD in accordance with British Aerospace Service Bulletin ATP-53-36, dated June 9, 1999, are considered acceptable for compliance with the applicable actions specified in this amendment.

## Alternative Methods of Compliance

(b) An alternative method of compliance or adjustment of the compliance time that provides an acceptable level of safety may be used if approved by the Manager, International Branch, ANM-116, FAA, Transport Airplane Directorate. Operators shall submit their requests through an appropriate FAA Principal Maintenance

Inspector, who may add comments and then send it to the Manager, International Branch, ANM-116.

Note 4: Information concerning the existence of approved alternative methods of compliance with this AD, if any, may be obtained from the International Branch, ANM-116.

## Special Flight Permits

(c) Special flight permits may be issued in accordance with sections 21.197 and 21.199 of the Federal Aviation Regulations (14 CFR 21.197 and 21.199 ) to operate the airplane to a location where the requirements of this $A D$ can be accomplished.

Note 5: The subject of this AD is addressed in British airworthiness directive 006-06-99.

Issued in Renton, Washington, on April 3, 2000.

Donald L. Riggin,
Acting Manager, Transport Airplane
Directorate, Aircraft Certification Service.
[FR Doc. 00-8686 Filed 4-6-00; 8:45 am]
BILLING CODE 4910-13-P

## DEPARTMENT OF TRANSPORTATION

## Coast Guard

## 33 CFR Parts 110 and 165

[CGD 05-00-008]

## RIN 2115-AA97, AA98

Tall Ships Delaware, Delaware River, Wilmington, DE

AGENCY: Coast Guard, DOT.
ACTION: Notice of proposed rulemaking.
SUMMARY: The Coast Guard proposes to establish temporary regulations in the Delaware River, Wilmington, Delaware, for Tall Ships Delaware activities. This action is necessary to provide for the safety of life on navigable waters before, during, and after Tall Ships Delaware events. This action will restrict vessel traffic in the Delaware River between the mouth of the Christina River and New Castle, Delaware.
DATES: Comments and related material must reach the Coast Guard on or before May 8, 2000.
ADDRESSES: You may mail comments and related material to the Waterways and Waterfront Facilities Branch, Coast Guard Marine Safety Office/Group Philadelphia, One Washington Ave., Philadelphia, Pennsylvania 19147 or deliver them to the same address between 8 a.m. and 4 p.m., Monday through Friday, except Federal holidays. The Waterways and Waterfront Facilities Branch, Coast Guard Marine Safety Office/Group Philadelphia maintains the public docket for this
rulemaking. Comments and materials received from the public as well as documents indicated in this preamble as being available in the docket, will become part of this docket and will be available for inspection or copying at the above address between 8:30 a.m. and 2:30 p.m., Monday through Friday, except Federal holidays.
FOR FURTHER INFORMATION CONTACT:
Lieutenant (junior grade) Kirsten Codel, Waterways and Waterfront Facilities Branch, Coast Guard Marine Safety Office/Group Philadelphia, at (215) 271-4991.

## SUPPLEMENTARY INFORMATION:

## Request for Comments

We encourage you to participate in this rulemaking by submitting comments and related material. If you do so, please include your name and address, identify the docket number for this rulemaking (CGD05-00-008), indicate the specific section of this document to which each comment applies, and give the reason for each comment. Please submit all comments and related material in an unbound format, no larger than $8 \frac{1}{2}$ by 11 inches, suitable for copying. The comment period for this regulation is 30 days. This time period is adequate to allow local input because the event is highly publicized and the shortened comment period will allow the full 30-day publication requirement prior to the final rule becoming effective. If you would like to know they reached us, please enclose a stamped, self-addressed postcard or envelope. We will consider all comments and material received during the comment period. We may change this proposed rule in view of them.

## Public Meeting

We do not plan to hold a public meeting. But you may submit a request for a meeting by writing to Commanding Officer, Coast Guard Marine Safety Office/Group Philadelphia, One Washington Ave., Philadelphia, Pennsylvania 19147, explaining why one would be beneficial. If we determine that one would aid this rulemaking, we will hold one at a time and place announced by a later notice in the Federal Register.

## Background and Purpose

The Diamond State Port Corporation (Port of Wilmington) is sponsoring Tall Ships Delaware activities in the Delaware River, Wilmington, Delaware. The planned event includes a Parade of Sail from the confluence of the Christina River and the Delaware River, down river to New Castle, Delaware, and back
to the mouth of the Christina River on June 23, 2000.

The Coast Guard anticipates a large spectator fleet for this event. Operators should expect significant vessel congestion along the parade route.

The purpose of these regulations is to promote maritime safety and protect participants and the boating public immediately prior to, during, and after the scheduled event. The regulations provide a safety buffer around the participating vessels during the parade of sail and modify existing anchorage regulations for the benefit of participants and spectators. The regulations will affect the movement of all vessels operating in the specified areas of the Delaware River.

It may be necessary for the Coast Guard to establish safety or security zones in addition to these regulations to safeguard dignitaries and certain vessels participating in the event. If the Coast Guard deems it necessary to establish such zones at a later date, the details of those zones will be announced separately via the Federal Register, Local Notice to Mariners, Safety Voice Broadcasts, and any other means available.

All vessel operators and passengers are reminded that vessels carrying passengers for hire or that have been chartered and are carrying passengers may have to comply with certain additional rules and regulations beyond the safety equipment requirements for all pleasure craft. When a vessel is not being used exclusively for pleasure, but rather is engaged in carrying passengers for hire or has been chartered and is carrying the requisite number of passengers, the vessel operator must possess an appropriate license and the vessel may be subject to inspection. The definition of the term "passenger for hire" is found in 46 U.S.C. 2101(21a). In general, it means any passenger who has contributed any consideration (monetary or otherwise) either directly or indirectly for carriage onboard the vessel. The definition of the term "passenger" is found in 46 U.S.C. 2101(21). It varies depending on the type of vessel, but generally means individuals carried aboard vessels except for certain specified individuals engaged in the operation of the vessel or the business of the owner/charterer. The law provides for substantial penalties for any violation of applicable license and inspection requirements. If you have any questions concerning the application of the above law to your particular case, you should contact the Coast Guard at the address listed in ADDRESSES for additional information.

Vessel operators are reminded they must have sufficient facilities on board their vessels to retain all garbage and untreated sewage. Discharge of either into any waters of the United States is strictly forbidden. Violators may be assessed civil penalties up to $\$ 25,000$ or face criminal prosecution.
We recommend that vessel operators visiting the Wilmington area for this event obtain an up to date edition of National Ocean Service Chart 12311 to avoid anchoring within a charted cable or pipeline area.
With the arrival of Tall Ships Delaware and spectator vessels in the Wilmington area for this event, it will be necessary to curtail normal port operations to some extent. Interference will be kept to the minimum considered necessary to ensure the safety of life on the navigable waters immediately before, during, and after the scheduled events.

## Discussion of Proposed Rule

The Tall Ships Delaware vessels are scheduled to arrive and moor at various locations along the Christina River by June 23, 2000. The lead vessel is scheduled to begin the Parade of Sail at 12:00 p.m. on June 23, 2000, and will follow a parade route of approximately 4 nautical miles on the Delaware River from the mouth of the Christina River, outbound to New Castle, Delaware, sailing outside the western side of the channel. The parade vessels will then cross the federal navigation channel of the Delaware River and return to the eastern side of the channel adjacent to the mouth of the Christina River sailing outside the eastern side of the channel. The parade vessels will then cross the navigable channel and enter the Christina River. After the parade, the larger Tall Ships Delaware vessels will moor at the Port of Wilmington on the Christina River. The remainder of the vessels will proceed up the Christina River to various mooring locations.

The safety of parade participants and spectators will require that spectator craft be kept at a safe distance from the parade route during these vessel movements. The Coast Guard proposes using a moving safety zone around the Parade of Sail to keep all vessels not involved in the Parade of Sail a safe distance from the Tall Ships Delaware vessels. The Parade of Sail route is outside the federal navigation channel of the Delaware River, allowing the channel to remain open, except when the Parade of Sail is crossing the navigable channel. However, the Coast Guard expects that there will be increased vessel congestion in the
vicinity of the federal navigation channel.
The Coast Guard also proposes to temporarily modify the existing anchorage regulations found in 33 CFR 110.157 to accommodate Tall Ships Delaware vessels. A leg of the parade route runs through General Anchorage 6 (Deepwater Point Anchorage).
Therefore, General Anchorage 6 will be closed to all vessels except Tall Ships Delaware vessels from 12 p.m. to 4 p.m. on June 23, 2000. (A notice of proposed rulemaking affecting 33 CFR 110.157 has been published in the Federal
Register at 65 FR 16361. Those proposed temporary regulations affect Anchorages 9-13 and would be temporarily added at §110.157(d). Accordingly, the rules proposed here would be temporarily added at § 110.157(e).)

## Regulatory Evaluation

This proposed rule is not a "significant regulatory action" under section 3(f) of Executive Order 12866 and does not require an assessment of potential costs and benefits under section 6(a)(3) of that Order. The Office of Management and Budget has not reviewed it under that Order. It is not significant under the regulatory policies and procedures of the Department of Transportation (DOT) (44 FR 11040; February 26, 1979).
We expect the economic impact of this proposed rule to be so minimal that a full Regulatory Evaluation under paragraph 10e of the regulatory policies and procedures of DOT is unnecessary.
The primary impact of these regulations will be on vessels wishing to transit the affected waterways during the Parade of Sail on June 23, 2000. Although these regulations prevent traffic from transiting portions of the Delaware River during the event, that restriction is limited in duration, affects only a limited area, and will be well publicized to allow mariners to make alternative plans for transiting the affected area. Moreover, the parade route will be outside the federal navigational channel allowing the channel to remain open with the exception of when the Parade of Sail actually crosses the channel. This should minimize the effect on nonparticipant and spectator vessels intending to transit the federal navigation channel.

## Small Entities

Under the Regulatory Flexibility Act (5 U.S.C. 601-612), we considered whether this proposed rule would have a significant economic impact on a substantial number of small entities.

The term "small entities" comprises small businesses, not-for-profit organizations that are independently owned and operated and are not dominant in their fields, and governmental jurisdictions with populations of less than 50,000.

The Coast Guard certifies under 5 U.S.C. 605(b) that this proposed rule would not have a significant economic impact on a substantial number of small entities.

This proposed rule would affect the following entities, some of which may be small entities: the owners or operators of vessels intending to operate or anchor in portions of the Delaware River in the vicinity of Wilmington, Delaware. The regulations will not have a significant impact on a substantial number of small entities for the following reasons: the restrictions are limited in duration, affect only limited areas, and will be well publicized to allow mariners to make alternative plans for transiting the affected areas. Moreover, the parade route will be outside the federal navigational channel allowing the channel to remain open with the exception of when the Parade of Sail actually crosses the channel.

If you think that your business, organization or governmental jurisdiction qualifies as a small entity and that this proposed rule would have a significant economic impact on it, please submit a comment (see
ADDRESSES) explaining why you think it qualifies and how and to what degree this proposed rule would economically affect it.

## Assistance for Small Entities

Under section 213(a) of the Small Business Regulatory Enforcement Fairness Act of 1996 (Pub. L. 104-121), we want to assist small entities in understanding this proposed rule so that they can better evaluate its effects on them and participate in the rulemaking. If the rule would affect your small business, organization, or governmental jurisdiction and you have questions concerning its provisions or options for compliance, please contact Lieutenant (junior grade) Kirsten Codel, Waterways and Waterfront Facilities Branch, Coast Guard Marine Safety Office/Group Philadelphia, at (215) 271-4991.

## Collection of Information

This proposed rule would call for no new collection of information under the Paperwork Reduction Act of 1995 (44 U.S.C. 3501-3520).

## Federalism

We have analyzed this proposed rule under E.O. 13132 and have determined
that this rule does not have implications for federalism under that Order.

## Unfunded Mandates Reform Act

The Unfunded Mandates Reform Act of 1995 (2 U.S.C. 1531-1538) governs the issuance of Federal regulations that require unfunded mandates. An unfunded mandate is a regulation that requires a State, local, or tribal government or the private sector to incur direct costs without the Federal Government's having first provided the funds to pay those costs. This proposed rule would not impose an unfunded mandate.

## Taking of Private Property

This proposed rule would not effect a taking of private property or otherwise have taking implications under E.O. 12630, Governmental Actions and Interference with Constitutionally Protected Property Rights.

## Civil Justice Reform

This proposed rule meets applicable standards in sections 3(a) and 3(b)(2) of E.O. 12988, Civil Justice Reform, to minimize litigation, eliminate ambiguity, and reduce burden.

## Protection of Children

We have analyzed this proposed rule under E.O. 13045, Protection of Children from Environmental Health Risks and Safety Risks. This rule is not an economically significant rule and does not concern an environmental risk to health or risk to safety that may disproportionately affect children.

## Environment

We considered the environmental impact of this proposed rule and concluded that, under figure 2-1, paragraph (34)(g), of Commandant Instruction M16475.1C; this proposed rule is categorically excluded from further environmental documentation. A "Categorical Exclusion
Determination" will be available in the docket where indicated under
ADDRESSES. By controlling vessel traffic during these events, this proposed rule is intended to minimize environmental impacts of increased vessel traffic during the transits of event vessels.

## List of Subjects

## 33 CFR Part 110

Anchorage Grounds.

## 33 CFR Part 165

Harbors, Marine safety, Navigation (water), Reporting and recordkeeping requirements, Security measures, Waterways.

## Regulation

For the reasons discussed in the preamble, the Coast Guard proposes to amend 33 CFR Parts 110 and 165 as follows:

## PART 110-[AMENDED]

1. The authority citation for Part 110 continues to read as follows:

Authority: 33 U.S.C. 471, 1221 through 1236, 2030, 2035, 2071; 49 CFR 1.46 and 33 CFR $1.05-1(\mathrm{~g})$.
2. From 12:00 p.m. until 4:00 p.m. on June 23, 2000 temporarily add §110.157(e) to read as follows:

## §110.157 Delaware Bay and River

(e) Not withstanding the above, the following temporary regulations will be in effect from 12 p.m. through 4 p.m. on June 23, 2000 for Tall Ships Delaware: Anchorage 6 will be closed to all vessels except Tall Ships Delaware vessels.
"Tall Ships Delaware vessels" includes all vessels participating in Tall Ships Delaware under the auspices of the Marine Event Permit submitted for the Port of Wilmington, Delaware, and approved by the Commander, Fifth Coast Guard District.

## PART 165-[AMENDED]

3. The authority citation for Part 165 continues to read as follows:
Authority: 33 U.S.C. 1225 and 1231; 50 U.S.C. 191; 33 CFR 1.05-1(g), 6.04-1, 6.046, and 160.5; 49 CFR 1.46. Section 165.100 is also issued under authority of Sec. 311, Pub. L. 105-383.
4. Add temporary § 165.T05-008 to read as follows:

## §165.T05-008 Safety Zone; Tall Ships

 Delaware, Delaware River, Wilmington, DE.(a) Definitions: (1) Captain of the Port means the Commanding Officer of the Coast Guard Marine Safety Office/Group Philadelphia or any Coast Guard commissioned, warrant, or petty officer who has been authorized by the Captain of the Port to act on his behalf.
(2) Coast Guard Patrol Commander is a commissioned, warrant, or petty officer of the Coast Guard who has been designated by the Commanding Officer, Coast Guard Marine Safety Office/Group Philadelphia.
(3) Tall Ships Delaware Vessels includes all vessels participating in the Tall Ships Delaware under the auspices of the Marine Event Permit submitted for the Port of Wilmington, Delaware, and approved by Commander, Fifth Coast Guard District.
(b) Location. The following area is a moving safety zone: All waters from 500
yards forward of the lead Tall Ships Delaware vessel to 100 yards aft of the last Tall Ships Delaware vessel, and extending 50 yards outboard of each Tall Ships Delaware vessel participating in the Parade of Sail. This safety zone will move with the Parade of Sail as it transits the Delaware River from the mouth of the Christina River outbound to New Castle, Delaware, returns to the mouth of the Christina River, and as each Tall Ships Delaware vessel moors in Wilmington, Delaware.
(c) Regulations. (1) All persons are required to comply with the general regulations governing safety zones in § 165.23 of this part.
(2) No person or vessel may enter or navigate within this safety zone unless authorized to do so by the Coast Guard Patrol Commander. Any person or vessel authorized to enter the safety zone must operate in strict conformance with any directions given by the Coast Guard Patrol Commander and leave the safety zone immediately if the Coast Guard Patrol Commander so orders.
(3) The Coast Guard vessels enforcing this section can be contacted on VHF Marine Band Radio, channels 13 and 16. The Captain of the Port can be contacted at telephone number (215) 271-4940.
(4) The Coast Guard Patrol Commander will notify the public of changes in the status of this safety zone by Marine Safety Radio Broadcast on VHF-FM marine band radio, channel 22 (157.1 MHZ).
(d) Effective dates: These regulations are effective from 12 p.m. to 4 p.m. on June 23, 2000.

Dated: March 28, 2000.
J.W. Underwood,

Captain, U.S. Coast Guard, Acting Commander, Fifth Coast Guard District. [FR Doc. 00-8661 Filed 4-6-00; 8:45 am] BILLING CODE 4910-15-U

## DEPARTMENT OF TRANSPORTATION

## Coast Guard

## 33 CFR Part 117

[CCGD08-00-004]
RIN 2115-AE47
Drawbridge Operation Regulations for the Arkansas and White Rivers

AGENCY: Coast Guard, DOT.
ACTION: Notice of proposed rulemaking.
SUMMARY: The Coast Guard proposes to revise the regulation governing the operation of the Cotton Belt Railroad (Rob Roy) Bridge across the Arkansas River at mile 67.4, in the State of

Arkansas. For more than 20 years the Rob Roy Bridge has been operated using radiotelephones as the primary communications device between mariners and the bridge operator even though current regulations require horns and flashing lights. The change in this rule will merely make the regulation require the use of radiotelephone for primary communications in the operation of the bridge.
DATES: Comments must be received on or before June 6, 2000.
ADDRESSES: Comments may be mailed to Commander (obr), Eighth Coast Guard District, 1222 Spruce Street, St. Louis, MO 63103, or may be delivered to room 2.107 F at the same address between 8:00 a.m. and 4:00 p.m. Monday through Friday, except on Federal Holidays.
FOR FURTHER INFORMATION CONTACT:
Roger K. Wiebusch, Bridge
Administrator, Commander (obr), Eighth Coast Guard District, 314-539-3900, Ext. 378.

## SUPPLEMENTARY INFORMATION:

## Request for Comments

The Coast Guard encourages interested persons to participate in this rulemaking by submitting written data, views, or arguments. Persons submitting comments should include their names and addresses, identify this rulemaking (CGD08-00-004) and the specific section of this proposal to which the comment applies, and give the reason for each comment. Please submit all comments and attachments in an unbound format, no larger than $8^{1 / 2}$ by 11 inches, suitable for copying and electronic filing. Persons wanting acknowledgment of receipt of comments should enclose stamped, self-addressed postcards or envelopes.
The Coast Guard plans no public hearing. Individuals may request a public hearing by writing to the Commander (obr), at the address under ADDRESSES. The request should include the reasons why a hearing would be beneficial. If it determines that the opportunity for oral presentations will aid this rulemaking, the Coast Guard will hold a public hearing at a time and place announced by a later notice in the Federal Register.

## Background and Purpose

The Arkansas River is a part of the McClellan-Kerr Arkansas River Navigation System. The System rises in the vicinity of Catoosa, Oklahoma, and embraces improved natural waterways and a canal to empty into the Mississippi River in southeast Arkansas. The Arkansas River drawbridge operation regulations contained in 33

CFR 117.123(a), states that the Cotton Belt Railroad (Rob Roy) Bridge, Mile 67.4, requires the use of ship's horns and flashing lights on the bridge to communicate between mariners requesting openings and railroad dispatchers remotely operating the bridge. Although not stated in 33 CFR 117.123(a), records indicate that the method of communication outlined in 33 CFR 117.123(b)(1) was to be used by mariners and the remote bridge operator as a back-up means of communications. The Coast Guard, however, has determined that the primary method of communications outlined in 33 CFR 117.123(a) has not been used during the past 20 years. It is doubtful that the system of horns and flashing lights was ever used. Instead, mariners and remote bridge operators have used the method outlined in 33 CFR 117.123(b)(1) as the prime method of communications for opening the Rob Roy Bridge.

## Discussion of Proposed Rules

Drawbridge operation regulations should be realistic in meeting the needs of both navigation and land traffic, and be tempered with common sense and good judgment. The current regulations do not reflect the actual method of operation for the Rob Roy Bridge. A survey of towboat pilots and railroad personnel revealed that the use of radiotelephones as the primary means of communications is preferred. The people involved never favored the use of ship's horns and flashing bridge lights. This proposal will provide regulations for operation of the Rob Roy Bridge that are consistent with the way the bridge is actually operated.

## Regulatory Evaluation

This proposal is not a significant regulatory action under section 3 (f) of Executive Order 12866 and does not require an assessment of potential costs and benefits under section 6(a)(3) of that order. It has not been reviewed by the Office of Management and Budget under that order. It is not significant under the regulatory policies and procedures of the Department of Transportation (DOT) (44 FR 11040; February 26, 1979). The Coast Guard expects the economic impact of this proposal to be so minimal that a full Regulatory Evaluation under paragraph 10e of the regulatory policies and procedures of DOT is unnecessary. For more than 20 years the Rob Roy Bridge has been operated using radiotelephones as the primary communications device between mariners and the bridge operator even though current regulations require horns and flashing lights. The change in this rule will merely make the published
operation regulation conform to the actual method of operation.

## Small Entities

Under the Regulatory Flexibility Act (5 U.S.C. 601 et seq.), the Coast Guard must consider whether this proposal, if adopted, will have a significant economic impact on a substantial number of small entities. "Small entities" may include (1) small businesses and not-for-profit organizations that are independently owned and operated and are not dominant in their fields and (2) governmental jurisdictions with populations of less than 50,000 . Since the proposed regulation only changes the method used to communicate between mariners requesting bridge openings and railroad dispatchers remotely operating the bridge and does not affect the existing operating schedule of the bridge, there will be little, if any, impact on small entities. Because it expects the impact of this proposal to be minimal, the Coast Guard certified under 5 U.S.C. 605 (b) that this proposal will not have a significant economic impact on a substantial number of small entities.

## Collection of Information

This proposal contains no collection-of-information requirements under the Paperwork Reduction Act (44 U.S.C. 3501 et seq.).

## Federalism

The Coast Guard has analyzed this proposal under the principles and criteria contained in Executive Order 12612 and has determined that this proposal does not have sufficient federalism implications to warrant the preparation of a Federalism Assessment.

## Unfunded Mandates Reform Act

The Unfunded Mandates Reform Act of 1995 (2 U.S.C. 1531-1538) governs the issuance of Federal regulations that require unfunded mandates. An unfunded mandate is a regulation that requires a State, local, or tribal government or the private sector to incur direct costs without the Federal Government's having first provided the funds to pay those costs. This rule would not impose an unfunded mandate.

## Taking of Private Property

This rule would not effect a taking of private property or otherwise have taking implications under E.O. 12630, Governmental Actions and Interference with Constitutionally Protected Property Rights.

## Civil Justice Reform

This rule meets applicable standards in sections 3(a) and 3(b)(2) of E.O. 12988, Civil Justice Reform, to minimize litigation, eliminate ambiguity, and reduce burden.

## Protection of Children

We have analyzed this rule under E.O. 13045, Protection of Children from Environmental Health Risks and Safety Risks. This rule is not an economically significant rule and does not concern an environmental risk to health or risk to safety that may disproportionately affect children.

## Environment

The Coast Guard considered the environmental impact of this proposal and concluded that under paragraph 2.B.2.a. of Commandant Instructions M16475.1C, this proposal is categorically excluded from further environmental documentation. A "Categorical Exclusion Determination" is available in the docket for inspection or copying where indicated under ADDRESSES.

List of Subjects in 33 CFR Part 117
Bridges.

## Regulations

For the reasons set out in the preamble, the Coast Guard proposes to amend Part 117 of Title 33, Code of Federal Regulations, as follows:

## PART 117—DRAWBRIDGE OPERATION REGULATIONS

1. The authority citation for part 117 continues to read as follows:

Authority: 33 U.S.C. 499; 49 CFR 1.46; 33 CFR 1.05-1(g); section 117.255 also issued under the authority of Pub. L. 102-587, 106 Stat. 5039.
2. Section 117.123(a) is revised to read as follows:

## §117.123 Arkansas Waterway-Automated Railroad Bridges.

(a) Across the Arkansas River, the draw of the Cotton Belt Railroad (Rob Roy) Bridge, Mile 67.4, is maintained in the closed position and is remotely operated. Any vessel requiring an opening of the draw shall establish contact by radiotelephone with the remote drawbridge operator on VHFFM Channel 16 in Pine Bluff, Arkansas. The remote drawbridge operator will advise the vessel whether the bridge can be immediately opened and maintain constant contact with the vessel until the span has opened and the vessel passage has been completed. If the drawbridge cannot be opened
immediately, the remote drawbridge operator shall notify the calling vessel and provide an estimated time for opening.

Dated: March 29, 2000.
Paul J. Pluta,
Rear Admiral, U. S. Coast Guard Commander, Eighth Coast Guard District.
[FR Doc. 00-8660 Filed 4-6-00; 8:45 am] BILLING CODE 4910-15-P

## ENVIRONMENTAL PROTECTION AGENCY

## 40 CFR Part 52

[GA-48-200010(b); FRL-6573-4]

## Approval and Promulgation of Implementation Plans, Georgia: Approval of Revisions to the Georgia State Implementation Plan: Transportation Conformity Interagency Memorandum of Agreement

AGENCY: Environmental Protection Agency (EPA).
ACTION: Proposed rule.
SUMMARY: EPA is proposing to approve a revision to the Georgia State Implementation Plan (SIP) that contains transportation conformity rules. If EPA approves this transportation conformity SIP revision, the State will be able to implement and enforce the Federal transportation conformity requirements at the State level per EPA regulationsConformity to State or Federal Implementation Plans of Transportation Plans, Programs, and Projects Developed, Funded or Approved Under Title 23 U.S.C. of the Federal Transit Laws. EPA's proposed action would streamline the conformity process and allow direct consultation among agencies at the local levels. EPA's proposed approval is limited to Transportation Conformity.
In the Final Rules section of this Federal Register, the EPA is approving Georgia SIP revision, under sections 110(k) and 176 of the Clean Air Act, as a direct final rule without prior proposal because the Agency views this as a noncontroversial submittal and anticipates no adverse comments. A detailed rationale for the approval is set forth in the direct final rule. If no adverse comments are received in response to this action, no further activity is contemplated. If EPA receives adverse comments, the direct final rule will be withdrawn and all public comments received will be addressed in a subsequent final rule based on this proposed rule. The EPA will not
institute a second comment period on this document. Any parties interested in commenting on this document should do so at this time.
DATES: Written comments must be received on or before May 8, 2000. ADDRESSES: All comments should be addressed to Kelly Sheckler at the EPA, Region 4 Air Planning Branch, 61 Forsyth Street, SW, Atlanta, Georgia 30303.

Copies of the state submittal are available at the following addresses for inspection during normal business hours:
Environmental Protection Agency, Region 4, Air Planning Branch, 61 Forsyth Street, SW, Atlanta, Georgia 30303-8960. Attn: Kelly Sheckler, (404) 562-9042. Georgia Department of Natural Resources, Environmental Protection Division, Air Protection Division, 4244 International Parkway, Suite 136, Atlanta, Georgia 30354.

## FOR FURTHER INFORMATION CONTACT:

Kelly Sheckler at 404/562-9042, E-mail: Sheckler.Kelly@epa.gov.

Dated: March 23, 2000.

## A. Stanley Meiburg,

Acting Regional Administrator, Region 4.
[FR Doc. 00-8531 Filed 4-6-00; 8:45 am]
BILLING CODE 6560-50-P

## ENVIRONMENTAL PROTECTION AGENCY

40 CFR Part 62
[PA152-4099b; FRL-6571-4]
Approval and Promulgation of State Air Quality Plans for Designated Facilities and Pollutants; Allegheny County, Pennsylvania; Control of Emissions from Existing Hospital/ Medical/Infectious Waste Incinerators
agency: Environmental Protection Agency (EPA).
ACTION: Proposed rule.
SUMMARY: EPA is proposing to approve the Allegheny County, Pennsylvania hospital/medical/ infectious waste incinerator (HMIWI) 111(d)/129 plan submitted on June 24, 1999 by the Pennsylvania Department of Environmental Protection (PADEP) on behalf of the Allegheny County Health Department (ACHD). The plan establishes emission limitations for existing HMIWIs, and provides for the implementation and enforcement of those limitations. In the final rules section of the Federal Register, EPA is approving the plan. A detailed rationale for the approval is set forth in the direct final rule. If no adverse comments are
received in response to the direct final rule, no further activity is contemplated in relation to this rule. If EPA receives relevant adverse comments, the direct final rule will be withdrawn and all public comments received will be addressed in a subsequent final rule based on this rule. EPA will not institute a second comment period on this document. Any parties interested in commenting on this document should do so at this time.
DATES: Comments must be received in writing by May 8, 2000.
ADDRESSES: Comments may be mailed to Makeba A. Morris, Chief, Technical Assessment Branch, Mailcode 3AP22, Environmental Protection Agency, Region III, 1650 Arch Street, Philadelphia, Pennsylvania 191032029.

## FOR FURTHER INFORMATION CONTACT:

James B. Topsale at (215) 814-2190, or by e-mail at topsale.jim@epamail.gov.
SUPPLEMENTARY INFORMATION: See the information provided in the direct final rule, of the same title, which is located in the rules section of the Federal

## Register.

Authority: 42 U.S.C. 7401-7671q.
Dated: March 23, 2000.
Bradley M. Campbell,
Regional Administrator, EPA Region III.
[FR Doc. 00-8402 Filed 4-6-00; 8:45 am] BILLING CODE 6560-50-P

## ENVIRONMENTAL PROTECTION AGENCY

## 40 CFR Part 62

[MS23-200015b; FRL -6574-4]

## Approval and Promulgation of State Plans For Designated Facilities and Pollutants: Mississippi

Agency: Environmental Protection Agency (EPA).
ACTION: Proposed rule.
SUMMARY: EPA is proposing to apporve the Section 111(d) Plan for the State of Mississippi submitted by the Mississippi Department of Environmental Quality (DEQ) on May 5, 1999, for implementing and enforcing the Emissions Guidelines applicable to existing Hospital/Medical/Infectious Waste Incinerators. The Plan was submitted by the Mississippi DEQ to satisfy certain Federal Clean Air Act requirements. In the Final Rules Section of this Federal Register, EPA is approving the Mississippi State Plan submittal as a direct final rule without prior proposal because the Agency
views this as a noncontroversial submittal and anticipates that it will not receive any significant, material, and adverse comments. A detailed rationale for the approval is set forth in the direct final rule. If no significant, material, and adverse comments are received in response to that rule, no further activity is contemplated in relation to this rule. If EPA receives adverse comments, the direct final rule will be withdrawn and all public comments received will be addressed in a subsequent final rule based on this rule. EPA will not institute a second comment period on this action.

DATES: Comments must be received in writing by May 8, 2000.

ADDRESSES: Written comments should be addressed to Michele Notarianni at the EPA Regional Office listed below. Copies of the documents relevant to this rule are available for public inspection during normal business hours at the following locations. The interested persons wanting to examine these documents should make an appointment with the appropriate office at least 24 hours before the day of the visit.

Environmental Protection Agency,
Region 4, Air Planning Branch, 61 Forsyth Street, SW, Atlanta, Georgia 30303-3014. [Staff contact: Michele Notarianni at telephone number 404/ 562-9031 or e-mail address: notarianni.michele@epa.gov.]
Mississippi Department of
Environmental Quality, Air Division, P.O. Box 10385, Jackson, Mississippi 39289-0385.

## FOR FURTHER INFORMATION CONTACT:

Michele Notarianni at 404/562-9031 or Scott Davis at 404/562-9127.

SUPPLEMENTARY INFORMATION: See the information provided in the Direct Final action which is located in the Rules Section of this Federal Register.
Dated: March 16, 2000.
A. Stanley Meiburg,

Acting Regional Administrator, Region 4. [FR Doc. 00-8529 Filed 4-6-00; 8:45 am] BILLING CODE: 6560-50-P

DEPARTMENT OF TRANSPORTATION

## National Highway Traffic Safety Administration

## 49 CFR Part 544

[Docket No.: 2000-001; Notice 01]
RIN 2127-AH77

## Insurer Reporting Requirements; List of Insurers Required To File Reports

agency: National Highway Traffic Safety Administration (NHTSA), Department of Transportation (DOT). ACTION: Notice of proposed rulemaking.
SUMMARY: This document proposes to republish, without change, 2 lists of those passenger motor vehicle insurers that are required to file reports on their motor vehicle theft loss experiences and to amend a third list. An insurer included in any of these lists would be required to file a report for the 1997 calendar year before October 25, 2000. If the passenger motor vehicle insurers remain listed, they must submit reports by each subsequent October 25.
DATES: Comments must be submitted not later than June 6, 2000.
addresses: Comments on this proposed rule must refer to the docket number referenced in the heading of this notice and submit them to: Docket Section, NHTSA, Room 5109, 400 Seventh Street, SW, Washington, DC 20590. Docket hours are 9:30 a.m. to 4:00 p.m., Monday through Friday.
FOR FURTHER INFORMATION CONTACT: Dr. Henrietta L. Spinner, Office of Planning and Consumer Programs, NHTSA, 400 Seventh Street, SW, Washington, DC 20590. Dr. Spinner's telephone number is (202) 366-4802. Her fax number is (202) 493-2290.

## SUPPLEMENTARY INFORMATION:

## Background

Pursuant to 49 U.S.C. 33112, Insurer reports and information, NHTSA requires certain passenger motor vehicle insurers to file an annual report with the agency. Each insurer's report includes information about thefts and recoveries of motor vehicles, the rating rules used by the insurer to establish premiums for comprehensive coverage, the actions taken by the insurer to reduce such premiums, and the actions taken by the insurer to reduce or deter theft. Under the agency's regulation, 49 CFR Part 544, the following insurers are subject to the reporting requirements:
(1) Those issuers of motor vehicle insurance policies whose total premiums account for 1 percent or more of the total premiums of motor vehicle
insurance issued within the United States;
(2) Those issuers of motor vehicle insurance policies whose premiums account for 10 percent or more of total premiums written within any one state; and (3) rental and leasing companies with a fleet of 20 or more vehicles not covered by theft insurance policies issued by insurers of motor vehicles, other than any governmental entity.

Pursuant to its statutory exemption authority, the agency exempted certain passenger motor vehicle insurers from the reporting requirements.

## A. Small Insurers of Passenger Motor Vehicles

Section 33112(f)(2) provides that the agency shall exempt small insurers of passenger motor vehicles if NHTSA finds that such exemptions will not significantly affect the validity or usefulness of the information in the reports, either nationally or on a state-by-state basis. The term "small insurer" is defined, in Section 33112(f)(1)(A) and (B), as an insurer whose premiums for motor vehicle insurance issued directly or through an affiliate, including pooling arrangements established under state law or regulation for the issuance of motor vehicle insurance, account for less than 1 percent of the total premiums for all forms of motor vehicle insurance issued by insurers within the United States. However, that section also stipulates that if an insurance company satisfies this definition of a "small insurer," but accounts for 10 percent or more of the total premiums for all motor vehicle insurance issued in a particular state, the insurer must report about its operations in that state.
In the final rule establishing the insurer reports requirement ( 52 FR 59; January 2, 1987), 49 CFR part 544, NHTSA exercised its exemption authority by listing in Appendix A each insurer that must report because it had at least 1 percent of the motor vehicle insurance premiums nationally. Listing the insurers subject to reporting, instead of each insurer exempted from reporting because it had less than 1 percent of the premiums nationally, is
administratively simpler since the former group is much smaller than the latter. In Appendix B, NHTSA lists those insurers required to report for particular states because each insurer had a 10 percent or a greater market share of motor vehicle premiums in those states. In the January 1987 final rule, the agency stated that it would update Appendices A and B annually. NHTSA updates the appendices based on data voluntarily provided by insurance companies to A.M. Best,
which A.M. Best publishes in its State/ Line Report each spring. The agency uses the data to determine the insurers' market shares nationally and in each state.

## B. Self-insured Rental and Leasing Companies

In addition, upon making certain determinations, NHTSA grants exemptions to self-insurers, i.e., any person who has a fleet of 20 or more motor vehicles (other than any governmental entity) used for rental or lease whose vehicles are not covered by theft insurance policies issued by insurers of passenger motor vehicles, 49 U.S.C. 33112(b)(1) and (f). NHTSA may exempt a self-insurer from reporting, if the agency determines:
(1) The cost of preparing and furnishing such reports is excessive in relation to the size of the business of the insurer; and
(2) The insurer's report will not significantly contribute to carrying out the purposes of Chapter 331.
In a final rule published June 22, 1990 ( 55 FR 25606), the agency granted a class exemption to all companies that rent or lease fewer than 50,000 vehicles, because it believed that the largest companies' reports sufficiently represent the theft experience of rental and leasing companies. NHTSA concluded that smaller rental and leasing companies' reports do not significantly contribute to carrying out NHTSA's statutory obligations and that exempting such companies will relieve an unnecessary burden on them. As a result of the June 1990 final rule, the agency added Appendix C, consisting of an annually updated list of the selfinsurers subject to Part 544. Following the same approach as in Appendix A, NHTSA included, in Appendix C, each of the self-insurers subject to reporting instead of the self-insurers which are exempted. NHTSA updates Appendix C based primarily on information from Automotive Fleet Magazine and Business Travel News.

## C. When a Listed Insurer Must File a Report

Under Part 544, as long as an insurer is listed, it must file reports on or before October 25 of each year. Thus, any insurer listed in the appendices must file a report by October 25, and by each succeeding October 25, absent an amendment removing the insurer's name from the appendices.

## Proposal

## 1. Insurers of Passenger Motor Vehicles

Appendix A lists insurers that must report because each had 1 percent of the
motor vehicle insurance premiums on a national basis. The list was last amended in a final rule published on October 25, 1999 (See 64 FR 57393). Based on the 1997 calendar year data from A.M. Best, we are proposing to reissue appendix A without change.

Each of the 18 insurers listed in Appendix A is required to file a report before October 25, 2000, setting forth the information required by part 544 for each State in which it did business in the 1997 calendar year. As long as these 18 insurers remain listed, they will be required to submit reports by each subsequent October 25 for the calendar year ending slightly less than 3 years before.

Appendix B lists insurers required to report for particular States for calendar year 1997, because each insurer had a 10 percent or a greater market share of motor vehicle premiums in those States. Based on the 1997 calendar year data for market shares from A.M. Best, we are proposing to reissue Appendix B without change.

The 11 insurers listed in appendix B are required to report on their calendar year 1997 activities in every State where they had a 10 percent or a greater market share. These reports must be filed by October 25, 2000, and set forth the information required by Part 544. As long as these 11 insurers remain listed, they would be required to submit reports on or before each subsequent October 25 for the calendar year ending slightly less than 3 years before.

## 2. Rental and Leasing Companies

Appendix C lists rental and leasing companies required to file reports. Based on information in Automotive Fleet Magazine and Business Travel News for 1997, NHTSA proposes to remove Penske Truck Leasing Company from Appendix C and to add Ford-Rent-A-Car System to Appendix C. Each of the 19 companies (including franchisees and licensees) listed in Appendix C would be required to file reports for calendar year 1997 no later than October 25,2000 , and set forth the information required by Part 544. As long as those 19 companies remain listed, they would be required to submit reports before each subsequent October 25 for the calendar year ending slightly less than 3 years before.

## Regulatory Impacts

## 1. Costs and Other Impacts

This notice has not been reviewed under Executive Order 12866. NHTSA has considered the impact of this proposed rule and determined that the action is not "significant" within the
meaning of the Department of Transportation's regulatory policies and procedures. This proposed rule implements the agency's policy of ensuring that all insurance companies that are statutorily eligible for exemption from the insurer reporting requirements are in fact exempted from those requirements. Only those companies that are not statutorily eligible for an exemption are required to file reports.
NHTSA does not believe that this proposed rule, reflecting current data, affects the impacts described in the final regulatory evaluation prepared for the final rule establishing part 544 (52 FR 59; January 2, 1987). Accordingly, a separate regulatory evaluation has not been prepared for this rulemaking action. Using the Bureau of Labor Statistics Consumer Price Index for 1999, the cost estimates in the 1987 final regulatory evaluation were adjusted for inflation. The agency estimates that the cost of compliance is $\$ 83,300$ for any insurer added to Appendix A, $\$ 33,320$ for any insurer added to Appendix B, and $\$ 9,613$ for any insurer added to Appendix C. If this proposed rule is made final, for Appendices A and B, the agency would make no changes; for Appendix C, the agency would remove one company and add one company. The agency therefore estimates that the net effect of this proposal, if made final, would be no cost to insurers as a group.
Interested persons may wish to examine the 1987 final regulatory evaluation. Copies of that evaluation were placed in Docket No. T86-01; Notice 2. Any interested person may obtain a copy of this evaluation by writing to NHTSA, Docket Section, Room 5109, 400 Seventh Street, SW, Washington, DC 20590, or by calling (202) 366-4949.

## 2. Paperwork Reduction Act

The information collection requirements in this proposed rule were submitted and approved by the Office of Management and Budget (OMB) pursuant to the requirements of the Paperwork Reduction Act (44 U.S.C. 3501 et seq.). This collection of information is assigned OMB Control Number 2127-0547 ("Insurer Reporting Requirements'") and approved for use through July 31, 2000, and the agency will seek to extend the approval afterwards.

## 3. Regulatory Flexibility Act

The agency also considered the effects of this rulemaking under the Regulatory Flexibility Act (RFA) (5 U.S.C. 601 et seq.). I certify that this proposed rule
will not have a significant economic impact on a substantial number of small entities. The rationale for the certification is that none of the companies proposed for Appendices A, $B$, or $C$ are construed to be a small entity within the definition of the RFA. "Small insurer" is defined, in part under 49 U.S.C. 33112, as any insurer whose premiums for all forms of motor vehicle insurance account for less than 1 percent of the total premiums for all forms of motor vehicle insurance issued by insurers within the United States, or any insurer whose premiums within any State, account for less than 10 percent of the total premiums for all forms of motor vehicle insurance issued by insurers within the State. This notice would exempt all insurers meeting those criteria. Any insurer too large to meet those criteria is not a small entity. In addition, in this rulemaking, the agency proposes to exempt all "self insured rental and leasing companies" that have fleets of fewer than 50,000 vehicles. Any self insured rental and leasing company too large to meet that criterion is not a small entity.

## 4. Federalism

This action has been analyzed according to the principles and criteria contained in Executive Order 12612, and it has been determined that the proposed rule does not have sufficient federalism implications to warrant the preparation of a Federalism Assessment.

## 5. Environmental Impacts

In accordance with the National Environmental Policy Act, NHTSA has considered the environmental impacts of this proposed rule and determined that it would not have a significant impact on the quality of the human environment.
Interested persons are invited to submit comments on the proposal. It is requested but not required that two copies of the comments be submitted. All comments must not exceed 15 pages in length. (49 CFR 553.21). Necessary attachments may be appended to these submissions without regard to the $15-$ page limit. This limitation is intended to encourage commenters to detail their primary arguments in a concise fashion.
If a commenter wishes to submit certain information under a claim of confidentiality, two copies of the complete submission, including purportedly confidential business information, should be submitted to the Chief Counsel, NHTSA, at the street address given above, and one copy from which the purportedly confidential information has been deleted should be accompanied by cover letter setting
forth the information specified in the agency's confidential business information regulation. (49 CFR part 512).

All comments received before the close of business on the comment closing date indicated will be considered, and will be available for examination in the docket at the above address both before and after the date. To the extent possible, comments filed after the closing date will also be considered. Comments received too late for consideration regarding the final rule will be considered as suggestions for further rulemaking action. Comments on the proposal are available for inspection in the docket. NHTSA will continue to file relevant information, as it becomes available in the docket after the closing date. It is recommended that interested persons continue to examine the docket for new material.

Those persons wanting receipt of their comments in the rule docket should enclose a self-addressed, stamped postcard in the envelope with their comments. Upon receiving the comments, the docket supervisor will return the postcard by mail.

## List of Subjects in 49 CFR Part 544

Crime insurance, insurance, insurance companies, motor vehicles, reporting and recordkeeping requirements.

In consideration of the foregoing, 49 CFR Part 544 is proposed to be amended as follows:

## PART 544-[AMENDED]

1. The authority citation for part 544 is proposed to be revised to read as follows:

Authority: 49 U.S.C. 33112; delegation of authority at 49 CFR 1.50
2. Paragraph (a) of $\S 544.5$ is proposed to be revised to read as follows:

## §544.5 General requirements for reports.

(a) Each insurer to which this part applies shall submit a report annually before October 25, beginning on October 25,1986 . This report shall contain the information required by $\S 544.6$ of this part for the calendar year three years previous to the year in which the report is filed (e.g., the report due by October 25,2000 will contain the required information for the 1997 calendar year).
3. Appendix A to Part 544 is proposed to be republished to read as follows:
Appendix A-Insurers of Motor Vehicle Insurance Policies Subject to the Reporting Requirements in Each State in Which They Do Business
Allstate Insurance Group

American Family Insurance Group
American Financial Group
American International Group
California State Auto Association
CNA Insurance Group
Erie Insurance Group
Farmers Insurance Group
Berkshire Hathaway/GEICO Corporation Group
Hartford Insurance Group
Liberty Mutual Group
Nationwide Group
Progressive Group
Prudential of America Group
State Farm Group
Travelers PC Group
USAA Group
Zurich Insurance Group-U.S.
4. Appendix B to Part 544 is proposed to be revised to read as follows:

## Appendix B-Issuers of Motor Vehicle Insurance Policies Subject to the Reporting Requirements Only in Designated States

Alfa Insurance Group (Alabama) Allmerica P \& C Companies (Michigan)
Arbella Mutual Insurance (Massachusetts)
Auto Club of Michigan Group (Michigan)
Commerce Group, Inc. (Massachusetts)
Commercial Union Insurance Companies (Maine)
Concord Group Insurance Companies (Vermont)
Kentucky Farm Bureau Group (Kentucky)
Nodak Mutual Insurance Company (North Dakota)
Southern Farm Bureau Group (Arkansas, Mississippi)
Tennessee Farmers Companies (Tennessee)
5. Appendix C to Part 544 is proposed to be revised to read as follows:

Appendix C—Motor Vehicle Rental and
Leasing Companies (Including
Licensees and Franchisees) Subject to the Reporting Requirements of Part 544
Alamo Rent-A-Car, Inc.
ARI (Automotive Rentals, Inc.)
Associates Leasing Inc.
AT\&T Automotive Services, Inc.
Avis, Inc.
Budget Rent-A-Car Corporation
Dollar Rent-A-Car Systems, Inc.
Donlen Corporation
Enterprise Rent-A-Car
Ford Rent-A-Car-System ${ }^{1}$
GE Capital Fleet Services
Hertz Rent-A-Car Division (subsidiary of Hertz Corporation)
Lease Plan USA, Inc.

[^14]National Car Rental System, Inc. PHH Vehicle Management Services Ryder System, Inc. (Both rental and leasing operations)
U-Haul International, Inc. (Subsidiary of AMERCO)
USL Capital Fleet Services
Wheels Inc.
Issued on: April 4, 2000.
Stephen R. Kratzke,
Acting Associate Administrator for Safety Performance Standards.
[FR Doc. 00-8663 Filed 4-6-00; 8:45 am] BILLING CODE 4910-59-P

DEPARTMENT OF COMMERCE
National Oceanic and Atmospheric Administration

## 50 CFR Parts 600 and 648

[I.D. 032400C]

## Magnuson-Stevens Act Provisions; General Provisions for Domestic Fisheries; Applications for Exempted Fishing Permits (EFPs) to Conduct Experimental Fishing

Agency: National Marine Fisheries Service (NMFS), National Oceanic and Atmospheric Administration (NOAA), Commerce.
ACTION: Notification of EFP proposals to conduct experimental fishing; request for comments.

SUMMARY: NMFS announces that the Administrator, Northeast Region, NMFS (Regional Administrator), has made a preliminary determination to issue EFPs to conduct experimental fishing to two vessels participating in separate fisheries that would permit these vessels to conduct operations otherwise restricted by regulations governing the fisheries of the Northeastern United States. The EFPs would exempt vessels from regulations regarding: Days-at-sea (DAS) while fishing for, retaining, and landing Atlantic sea scallops; fishing in the scallop closed areas; and limiting the vessel's scallop and bycatch harvest. Regulations under the MagnusonStevens Fishery Conservation and Management Act require publication of this notification to provide interested parties the opportunity to comment on the proposed EFP to conduct experimental fishing. A decision to approve or disapprove the EFPs will be made following the comment period. DATES: Comments on this notification must be received on or before 5:00 p.m., local time, on April 24, 2000.
ADDRESSES: Comments should be sent to Patricia A. Kurkul, Regional

Administrator, NMFS, Northeast Regional Office, 1 Blackburn Drive, Gloucester, MA 01930. Mark on the outside of the envelope "Comments on Proposed Scallop EFP Proposals.'

Comments also may be sent via facsimile (fax) to (978) 281-9135. Comments will not be accepted if submitted via e-mail or Internet.

## FOR FURTHER INFORMATION CONTACT:

David Gouveia, Fishery Policy Analyst, 978-281-9280.
SUPPLEMENTARY INFORMATION: The
Virginia Institute of Marine Science (VIMS) proposes a scallop resource depletion study in selected locations within the Hudson Canyon and Virginia Beach Closure Areas chosen in consultation with the Northeast Fisheries Science Center's scallop survey stations. In addition, this study proposes to collect information on bycatch, habitat effects, and bio-fouling of sea scallops. Depending on the funding available, this study may also attempt to use an autonomous underwater vehicle to verify tow tracks and habitat modifications.

On a tow-by-tow basis, scientific staff and designated crew members will enumerate bycatch and estimate quantities of non-bycatch debris (mollusk shells) and will report on their general physical condition. The overall objective of the study is to assess the increased availability of commercial sea scallop biomass resulting from the area closures that commenced 2 years ago. A similar study in Georges Bank Closed Area II was not performed until 4 years after the closure. It is thought that more knowledge could be gained from a postdredge survey conducted closer to the cessation of mobile gear activity.

The survey would be conducted during the period June through July 2000 and would employ the use of two $15-\mathrm{ft}(4.57-\mathrm{m})$ commercial sea scallop dredges at 400 pre-designated stations. Sampling densities of approximately one station per $7.5 \mathrm{~nm}^{2}$ in the Hudson Canyon South Closure Area, and one station per $5.0 \mathrm{~nm}^{2}$ in the Virginia Beach Closure Area are proposed. Sampling density will be increased to one station per $5.0 \mathrm{~nm}^{2}$ on or near the edges of closed area boundaries. Set tow times of 10 minutes at a speed of 4.5 knots will be used to calibrate area gear coverage (width of gear $x$ length of dredge path). The dredge gear will comply with all mesh size and gear configuration provisions of Amendment 4 to the Atlantic Sea Scallop Fishery Management Plan (FMP). Therefore, no special twine-top configurations or rock chains will be used.

No other species besides Atlantic sea scallops will be retained or landed, except for unusual specimens of interest to scientists and only at the discretion of the chief scientist in charge of at-sea cruise operations. All fishing activities conducted by the participating vessel must only be research activities. All commercial operations would be prohibited. The participating vessel would be exempt from regulations on scallop harvest and bycatch ( 50 CFR 648.52 and 648.53 ) but would be allowed to retain and land no more than $9,100 \mathrm{lb}(4,127.76 \mathrm{~kg})(650 \mathrm{lb} /$ day ( $294.84 \mathrm{~kg} /$ day)) of Atlantic sea scallops. It would also be exempt from the Atlantic Sea Scallop DAS program when fishing under the EFP ( 50 CFR 648.10). Based on this landing limit, participants would be required to commit a maximum of 14 days to the study.
The vessel's crew will be instructed that low value sea scallops may not be discarded in favor of retaining high value sea scallops (high grading). VIMS' chief scientist is charged with monitoring all stages of the proposed cruise operations in support of the study objectives, and will ensure maximum integrity of data collection and organization of deck operations. The second proposal, submitted by Coonamessett Farm, proposes to test new gear designs to reduce yellowtail flounder and skate bycatch rates. The experimental dredge will have two modifications. The first modification adds a 10 -inch ( $25.40-\mathrm{cm}$ ) mesh panel between the depressor plate and the dredge bale that will follow the angle of the depressor plate. The second modification adds the equivalent of an old-style locomotive cow catcher under the bale frame that would direct skates and flatfish above the bale, along the mesh panel, and over the dredge frame. The applicant requests one 7 -day trip to the Georges Bank and South Channel sea scallop stock areas. The participating vessel would be allowed to retain up to $850 \mathrm{lb}(385.56 \mathrm{~kg})$ of scallop meats per day, not to exceed $5,950 \mathrm{lb}$ $(2,698.9 \mathrm{~kg})$ of scallop meats for the entire trip. An EFP issued to the vessel participating in the Coonamessett Farm proposal would exempt the vessel from the DAS restrictions (50 CFR 648.53) and limit the vessel's scallop and bycatch harvest (50 CFR 648.52 and 648.53). Although the dredge gear used by Coonamessett Farm is modified, the changes to the dredge are within the current dredge specifications found in the Atlantic Sea Scallop FMP. Therefore, no exemption of the dredge gear is necessary.
Coonamessett Farm and VIMS would each conduct experimental fishing
activities with a single commercial vessel with a Federal limited access Atlantic sea scallop permit. The vessels will be allowed to land and sell sea scallops caught during the conduct of the experiment, up to a maximum, which is determined based on the average scallop catch per DAS for the most recent 12 -month period available for the Atlantic sea scallop stock areas.

Authority: 16 U.S.C. 1801 et seq.
Dated: April 3, 2000.

## Bruce C. Morehead,

Acting Director, Office of Sustainable Fisheries, National Marine Fisheries Service. [FR Doc. 00-8667 Filed 4-6-00; 8:45 am] BILLING CODE 3510-22-F

## DEPARTMENT OF COMMERCE

## National Oceanic and Atmospheric Administration

## 50 CFR Parts 600 and 648

## [I.D. 032300D]

## Magnuson-Stevens Act Provisions; General Provisions for Domestic Fisheries; Application for Exempted Fishing Permit (EFP) to Conduct Experimental Fishing

agencr: National Marine Fisheries Service (NMFS), National Oceanic and Atmospheric Administration (NOAA), Commerce.
ACTION: Notification of EFP proposal to conduct experimental fishing; request for comments.
SUMMARY: NMFS announces that the
Administrator, Northeast Region, NMFS
(Regional Administrator), has made a
preliminary determination to issue an EFP to that would allow a single vessel to conduct operations otherwise restricted by regulations governing the fisheries of the Northeastern United States. Mount Desert Oceanarium of Southwest Harbor, Maine, submitted a complete application for an EFP, which warrants further consideration. The experimental fishery would involve fishing for, retention of, and landing of small numbers of regulated multispecies and various unmanaged species for the purpose of public education. Regulations issued under the Magnuson-Stevens Fishery Conservation and Management Act require publication of this notification to provide interested parties the opportunity to comment on the proposed EFP to conduct experimental fishing.
DATES: Comments on this notification must be received at the appropriate address or fax number (See ADDRESSES) on or before 5:00 p.m., local time, on April 24, 2000.
ADDRESSES: Written comments should be sent to Patricia Kurkul, Regional Administrator, NMFS, Northeast Regional Office, 1 Blackburn Drive, Gloucester, MA 01930. Mark on the outside of the envelope "Comments on Proposed EFP Proposal." Comments also may be sent via facsimile (fax) to (978) 281-9135. Comments will not be accepted if submitted via e-mail or Internet.

FOR FURTHER INFORMATION CONTACT: Tom Warren, Fishery Management Specialist, 978-281-9347.
SUPPLEMENTARY INFORMATION: The
Mount Desert Oceanarium, of Southwest

Harbor, Maine, submitted an application for an EFP on February 15, 2000, to collect various species of animals for public education. A single chartered vessel will use a modified $50-\mathrm{ft}$ ( $15.2-\mathrm{m}$ ) shrimp trawl to collect marine animals on 3 days during the time period from May 1, 2000, to May 20, 2000. The animals will be brought to shore, maintained in tanks for public display, and most will be returned to the sea in October 2000. Collection will be from the Small Mesh Northern Shrimp Fishery Exemption Area, off Maine. If the target species cannot be located in this area, collection will be farther east or southeast from the Gulf of Maine/ Georges Bank Regulated Mesh Area. The target species will include dabs, blackback and yellowtail flounder, plaice, halibut, monkfish, eel pouts, sculpins, sea ravens, cod, wolfish, spiny dogfish, little skate, barndoor skate, and unidentified species of the Phyla Arthropoda and Echinodermata. The vessel will collect a maximum of six individuals per species, juvenile and adult, with the exception of halibut, which will be limited to a total of one individual, with a minimum total length of 36 inches ( 91.4 cm ).

EFPs are required to exempt the vessel from the possession prohibition, mesh size, minimum fish size, and days-at-sea restrictions of the Northeast Multispecies Fishery Management Plan.

16 U.S.C. 1801 et seq.
Dated: March 31, 2000.

## Bruce C. Morehead,

Acting Director, Office of Sustainable Fisheries, National Marine Fisheries Service.
[FR Doc. 00-8668 Filed 4-6-00; 8:45 am]
BILLING CODE 3510-22-F

## Notices

## Federal Register

Vol. 65, No. 68
Friday, April 7, 2000

This section of the FEDERAL REGISTER contains documents other than rules or proposed rules that are applicable to the public. Notices of hearings and investigations, committee meetings, agency decisions and rulings, delegations of authority, filing of petitions and applications and agency statements of organization and functions are examples of documents appearing in this section.

## DEPARTMENT OF AGRICULTURE

## Submission for OMB Review; Comment Request

April 4, 2000.
The Department of Agriculture has submitted the following information collection requirement(s) to OMB for review and clearance under the Paperwork Reduction Act of 1995, Public Law 104-13. Comments regarding (a) whether the collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility; (b) the accuracy of the agency's estimate of burden including the validity of the methodology and assumptions used; (c) ways to enhance the quality, utility and clarity of the information to be collected; (d) ways to minimize the burden of the collection of information on those who are to respond, including through the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology should be addressed to: Desk Officer for Agriculture, Office of Information and Regulatory Affairs, Office of Management and Budget (OMB), Washington, DC 20503 and to Departmental Clearance Office, USDA, OCIO, Mail Stop 7602, Washington, DC 20250-7602. Comments regarding these information collections are best assured of having their full effect if received within 30 days of this notification. Copies of the submission(s) may be obtained by calling (202) 720-6746.

An agency may not conduct or sponsor a collection of information unless the collection of information displays a currently valid OMB control number and the agency informs potential persons who are to respond to the collection of information that such persons are not required to respond to the collection of information unless it
displays a currently valid OMB control number.

## Farm Service Agency

Title: Conservation Reserve Program (CRP)—7 CFR Part 1410.

OMB Control Number: 0560-0125.
Summary of Collection: Section 1231 of the Conservation Title of the Food Security Act of 1985 (Pub. L. 990198 Stat. 1354, as amended, 16 U.S.C. 38313844), as amended by the Food, Agriculture, Conservation and Trade Act (Pub. L. 101-624, 104 Stat. 3577) and the Federal Agriculture Improvement and Reform Act of 1996, (Pub. L. 104-127, Stat. 994) directs the Secretary of Agriculture to formulate and carry out a Conservation Reserve Program (CRP) during the 1986-2002 calendar years. Under the program, the Secretary is authorized to enter into 1015 year contracts to assist owners and operators of eligible land in conserving and improving the Nation's natural resources, including soil, water quality, air quality, and wildlife. The Farm Service Agency (FSA) will collect information using various CRP forms.

Need and Use of the Information: FSA will use the information collected on CRP forms to determine eligibility, quota and allotment reductions, incentive payments, maximum payment rates, and also record cropping history that is used by NRCS in determining land eligibility etc. The information is needed to implement and provide program benefits under the current legislation.

Description of Respondents: Farms; Individuals or households.

Number of Respondents: 160,497.
Frequency of Responses: Reporting:
Other (When applying for benefits).
Total Burden Hours: 70,088.

## Food Safety and Inspection Service

Title: Application for Inspection, Sanitation, and Exemption.

OMB Control Number: 0583-0082. Summary of Collection: The Food Safety and Inspection Service (FSIS) has been delegated the authority to exercise the functions of the Secretary as provided in the Federal Meat Inspection Act (FMIA) (21 U.S.C. 601 et seq.), the Poultry Products Inspection Act (PPIA) (21 U.S.C. 451, et seq.), and the Egg Products Inspection Act (EPIA) (21 U.S.C. 1031). FSIS requires meat, poultry, and egg product establishments and FSIS accredited non-Federal
analytical laboratories to maintain certain paperwork and records. FSIS will collect information using several FSIS forms.
Need and Use of the Information: FSIS will collect information to ensure that all meat and poultry establishments produce safe, wholesome, and unadulterated product, and that nonfederal laboratories accord with FSIS regulations. In addition, FSIS also collects information to ensure that meat and poultry establishments exempted from FSIS's inspection do not commingle inspected and non-inspected meat and poultry products.
Description of Respondents: Business or other for-profit
Number of Respondents: 9,885.
Frequency of Responses:
Recordkeeping; Reporting: On occasion.
Total Burden Hours: 1,091.

## Animal and Plant Health Inspection Service

Title: Pseudorabies in Swine; Payment of Indemnity.
OMB Control Number: 0579-NEW.
Summary of Collection: Title 21,
U.S.C. authorizes sections 111, 114, 114a, 114-1, 115, 120, 125, 126, 134a, 134c, 134f, and 134 g of 21 U.S.C. These authorities permit the Secretary to prevent, control and eliminate domestic diseases such as pseudorabies, as well as to take actions to prevent and to manage exotic diseases such as hog cholera, African swine fever, and other foreign animal diseases. More specifically, 21 U.S.C. 111, 115, 118, authorizes the Secretary of Agriculture to take such measures as he or she may deem proper to prevent the introduction or dissemination of any contagious or communicable disease of animals or live poultry from a foreign country into the United States or from one state to another. Disease prevention is the most effective method for maintaining a healthy animal population and enhancing our ability to compete in exporting animals and animal products. The Animal and Plant Health Inspection Service (APHIS) is conducting an Accelerated Pseudorabies Eradication program in an effort to eliminate pseudorabies from the United States. APHIS will collect information using a movement permit, an official seal to secure trucks that are carrying swine to slaughter, and a Report of Salvage Proceeds.

Need and Use of the Information: APHIS will collect information from herd owners on the number of animals being moved, their origin and destination sites, their disease status and identification, and the cleaning and disinfection requirements associated with the movement. If the information was not collected it would be impossible for APHIS to effectively ensure that pseudorabies-infected, exposed, or suspect swine are prevented from coming into contact with healthy animals.
Description of Respondents: Business or other for-profit; Farms; State, Local or Tribal Government.
Number of Respondents: 300.
Frequency of Responses: Reporting:

## On occasion.

Total Burden Hours: 998.
Agency has requested emergency approval by April 3, 2000.

## Agricultural Marketing Service

Title: Cranberries Grown in the States of MA, RI, CT, NJ, WI, MN, OR, WA, and Long Island in the State of NYMarketing Order No. 929.

OMB Control Number: 0581-0103.
Summary of Collection: Marketing Order No. 929 (7 CFR Part 929), regulates the handling of cranberries grown in the 10 mention states and emanates from enabling legislation (the Agricultural Marketing Agreement Act of 1937, Secs. 1-19, 48 Stat. 31, as amended; 7 U.S.C. 601-674). The act was designed to permit regulation of certain agricultural commodities for the purpose of providing orderly marketing conditions in interstate commerce and improving returns to growers. The objective of the marketing agreement and order is to correlate the supply of cranberries available for sale in the various trade channels with the demand in those outlets. The Agricultural Marketing Service will collect information using forms FV-53, -259, -260 , and -263 .
Need and Use of the Information: AMS will collect information from the form on cranberry production,
shipments, inspection, and export. The Cranberry Marketing Committee, which represents growers and locally administers the order. The committee and its staff are responsible for keeping information in individual handlers inventories and receipt confidential. Information gathered by the committee would only be reported in the aggregate, along with other pertinent cranberry data. If information was not collected it would eliminate data needed to keep the cranberry industry and the Secretary abreast of changes at the State and local level.

Description of Respondents: Business or other for-profit; Farms.

Number of Respondents: 1,285.
Frequency of Responses:
Recordkeeping; Reporting: Quarterly; Annually.

Total Burden Hours: 1,750.
William McAndrew,
Departmental Clearance Officer.
[FR Doc. 00-8678 Filed 4-6-00; 8:45 am] BILLING CODE 3410-01-M

## DEPARTMENT OF AGRICULTURE

## Animal and Plant Health Inspection Service

[Docket No. 00-020-1]

## Notice of Request for Extension of Approval of an Information Collection

agency: Animal and Plant Health Inspection Service, USDA.
ACTION: Extension of approval of an information collection; comment request.

SUMMARY: In accordance with the Paperwork Reduction Act of 1995, this notice announces the Animal and Plant Health Inspection Service's intention to request an extension of approval of an information collection in support of the regulations requiring permits for movement of restricted animals.
DATES: We invite you to comment on this docket. We will consider all comments that we receive by June 6, 2000.

ADDRESSES: Please send your comment and three copies to: Docket No. 00-0201, Regulatory Analysis and
Development, PPD, APHIS, Suite 3C03, 4700 River Road, Unit 118, Riverdale, MD 20737-1238.

Please state that your comment refers to Docket No. 00-020-1.

You may read any comments that we receive on this docket in our reading room. The reading room is located in room 1141 of the USDA South Building, 14th Street and Independence Avenue, SW., Washington, DC. Normal reading room hours are 8 a.m. to 4:30 p.m., Monday through Friday, except holidays. To be sure someone is there to help you, please call (202) 690-2817 before coming.

APHIS documents published in the Federal Register, and related information, including the names of organizations and individuals who have commented on APHIS dockets, are available on the Internet at http:// www.aphis.usda.gov/ppd/rad/ webrepor.html.

FOR FURTHER INFORMATION CONTACT: For information regarding the regulations requiring permits for movement of restricted animals, contact Dr. Diane Sutton, Senior Staff Veterinarian, National Animal Health Programs Staff, VS, APHIS, 4700 River Road Unit 43, Riverdale, MD 20737; (301) 734-7709. For copies of more detailed information on the information collection, contact Ms. Celeste Sickles, APHIS' Information Collection Coordinator, at (301) 7347477.

## SUPPLEMENTARY INFORMATION:

Title: Permit for Movement of Restricted Animals.

OMB Number: 0579-0051.
Expiration Date of Approval: April 30, 2000.

Type of Request: Extension of approval of an information collection.

Abstract: The United States Department of Agriculture is responsible for preventing the spread of contagious, infectious, or communicable animal diseases from one State to another and for eradicating such diseases from the United States. In connection with this mission, the Animal and Plant Health Inspection Service, Veterinary Services, carefully monitors animals which either have, or have been exposed to, diseases of quarantine significance as these animals are transported to appropriate slaughtering facilities.

When farm animals (such as cattle, swine, sheep, or horses) become sick or have been exposed to a disease of quarantine significance, it is important that they be removed promptly from the farm to prevent exposing and infecting other animals. In such situations, the owner of sick or exposed animals may have the animals transported from the farm to a slaughtering establishment. When this movement requires animals to be transported across State lines, the owner is required to complete a "Permit for Movement of Restricted Animals," also known as VS Form 1-27.
It is imperative that these animals not be removed from the vehicle during transport or be otherwise diverted from their destination, since such an event could result in the spread of a disease of quarantine significance among healthy animals. VS Form 1-27, which is completed by specified personnel at the farm of origin and again at the point of destination, is our primary means of ensuring that these animals move directly from the farm to the slaughtering establishment.

We are asking the Office of Management and Budget (OMB) to approve our use of this information collection activity for an additional 3 years.

The purpose of this notice is to solicit comments from the public (as well as affected agencies) concerning this information collection. We need this outside input to help us:
(1) Evaluate whether the collection of information is necessary for the proper performance of the functions of the Agency, including whether the information will have practical utility;
(2) Evaluate the accuracy of our estimate of the burden of the information collection, including the validity of the methodology and assumptions used;
(3) Enhance the quality, utility, and clarity of the information to be collected; and
(4) Minimize the burden of the information collection on those who are to respond, through use, as appropriate, of automated, electronic, mechanical, and other collection technologies, e.g., permitting electronic submission of responses.
Estimate of burden: The public reporting burden for this collection of information is estimated to average . 05 hours per response.
Respondents: State field personnel, accredited veterinarians, meat inspectors, animal health technicians, and other regulated entities, including owners of cattle, swine, horses, sheep, and goats.
Estimated annual number of respondents: 3,847.
Estimated annual number of responses per respondent: 2.5258 .
Estimated annual number of responses: 9,717.

Estimated total annual burden on respondents: 740 hours. (Due to rounding, the total annual burden hours may not equal the product of the annual number of responses multiplied by the average reporting burden per response.)
All responses to this notice will be summarized and included in the request for OMB approval. All comments will also become a matter of public record.
Done in Washington, DC, this 3rd day of April 2000.

## Bobby R. Acord,

Acting Administrator, Animal and Plant Health Inspection Service.
[FR Doc. 00-8680 Filed 4-6-00; 8:45 am]
BILLING CODE 3410-34-U

## DEPARTMENT OF AGRICULTURE

## Farm Service Agency

## Notice of Request for Extension of a Currently Approved Information Collection

agency: Farm Service Agency, USDA.

ACTION: Notice and request for comments.

SUMMARY: In accordance with the Paperwork Reduction Act of 1995, this notice announces the Farm Service Agency's (FSA) intention to request an extension for a currently approved information collection in support of the program for Guaranteed Farm Loans.
DATES: Comments on this notice must be received by June 6, 2000 to be assured of consideration.

## FOR FURTHER INFORMATION CONTACT:

Phillip Elder, Senior Loan Officer,
USDA, FSA, Farm Loan Programs, Loan
Servicing Division, STOP 0523, 1400
Independence Ave. SW, Washington,
D.C. 20250-0523, telephone (202) 690-

4012 or Electronic mail:
phillip__elder@wdc.usda.gov.
SUPPLEMENTARY INFORMATION:
Title: (7 CFR part 762) Guaranteed Farm Loans

OMB Control Number: 0560-0155.
Expiration Date of Approval: June 30, 2000.

Type of Request: Extension of a currently approved information collection.

Abstract: Section 309(h) of the Consolidated Farm and Rural Development Act (CONACT) (7 U.S.C. 1929(h)) authorizes the Secretary of Agriculture to guarantee loans for CONACT purposes made by legally authorized lending agencies to eligible farmers and ranchers. FSA must assure that farmers and ranchers, joint operators, farm cooperatives, private domestic corporations and partnerships that are controlled by farmers and ranchers engaged primarily and directly in farming or ranching in the United States comply with CONACT requirements and implementing regulations at 7 CFR part 762 in order to obtain the requested assistance. A guaranteed farm ownership loan applicant, for example, must be a citizen of the United States; own and operate or become the owner and operator of not larger than a family size farm; and be unable to obtain sufficient credit elsewhere at reasonable rates and terms. The reporting and record keeping requirements imposed on the public by regulations set out in 7 CFR part 762 are necessary to administer the Farm Loan Programs (FLP) guaranteed loan program in accordance with the statutory requirements listed above and are consistent with commonly performed lending practices. Periodic collection of information after loans are made is necessary to protect the Government's financial interest. The information is stored in the FSA county
office loan files or state office lender files.

Estimate of Burden: Public reporting for this collection of information is estimated to average 46 minutes per response.
Respondents: Individuals or households, businesses or other for profits, and farms.

Estimated Number of Respondents: 14,500.

Estimated Number of Responses per Respondent: 20.24.

Estimated Number of Responses: 293,538.
Estimated Total Annual Burden on Respondents: 226,935 hours.

Comments are invited on: (a) Whether the proposed collection of information is necessary for the proper performance of the functions of the subject Agency, including whether the information will have practical utility; (b) the accuracy of the Agency's estimate of the burden of the proposed collection of information including the validity of the methodology and assumptions used; (c) ways to enhance the quality, utility and clarity of the information to be collected; and (d) ways to minimize the burden of the collection of information on those who are to respond, including through the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology.

Comments should be sent to the Desk Office for Agriculture, Office of Information and Regulatory Affairs, Office of Management and Budget, Washington, D.C. 20503 and to Phillip Elder, Senior Loan Officer, USDA, FSA, Farm Loan Programs, Loan Servicing Division, 1400 Independence Avenue, SW, STOP 0523, Washington, D.C. 20250-0523.

Comments regarding paperwork burden will be summarized and included in the request for OMB approval. All comments will also become a matter of public record.
Signed at Washington, D.C., on March 31, 2000.

Keith Kelly,
Administrator, Farm Service Agency.
[FR Doc. 00-8679 Filed 3-6-00; 8:45 am] billing Code 3410-05-P

## DEPARTMENT OF AGRICULTURE

## Forest Service

## Lake Tahoe Basin Advisory Committee

AGENCY: Office of the Secretary, USDA.
ACTION: Notice, renewal of charter, and request for nominations.

SUMMARY: The Secretary of Agriculture intends to renew the charter of the Lake Tahoe Federal Advisory Committee, chartered under the Federal Advisory Committee Act, to provide advice to the Secretary of Agriculture on implementing the terms of the Federal Interagency Partnership on the Lake Tahoe Region. Nominations of persons to serve on the Committee are invited.
DATES: Nominations for membership on the Committee must be received in writing by May 1, 2000.
ADDRESSES: Send nominations and applications with telephone numbers for membership on the Committee to: FACA Nomination, Lake Tahoe Basin Management Unit, 870 Emerald Bay Road, South Lake Tahoe, California 96150.

## FOR FURTHER INFORMATION CONTACT:

Maribeth Gustafson, Forest Supervisor, Lake Tahoe Basin Management Unit, telephone (530) 573-2773.
SUPPLEMENTARY INFORMATION: Pursuant to the Federal Advisory Committee Act ( 5 U.S.C. App.), notice is hereby given that the Secretary of Agriculture intends to renew the charter of the Lake Tahoe Basin Federal Advisory Committee. The purpose of the Committee is to provide advice to the Secretary of Agriculture on implementing the terms of the Federal Interagency Partnership on the Lake Tahoe Basin and other matters raised by the Secretary.

The Secretary has determined that the work of the Committee is in the public interest and relevant to the duties of the Department of Agriculture.
The Committee will meet on a quarterly basis, conducting public meetings to discuss management strategies, gather information and review federal agency accomplishments, and prepare a progress report every six months for submission to regional federal executives. Representatives will be selected from the following sectors:
(1) Gaming, (2) Environmental, (3)

National environmental, (4) Ski resorts,
(5) North Shore economic/recreation, (6) South Shore economic/recreation, (7) Resort associations, (8) Education, (9) Property rights advocates, (10) Member-at-large, (11) Member-at-large, (12) Science and Research, (13) Local Government, (14) Washoe Tribe, (15) State of California, (16) State of Nevada, (17) Tahoe Regional Planning Agency, (18) Labor, (19) Transportation and (20) Member-at-large. Nominations to the Committee should describe and document the proposed member's qualifications for membership on the Lake Tahoe Basin Advisory Committee. The Committee Chair will be recommended by the Committee and
approved by the Secretary. Vacancies on the Committee will be filled in the manner in which the original appointment was made.

Appointments to the Committee will be made by the Secretary of Agriculture. Equal opportunity practices, in line with USDA policies, will be followed in all appointments to the Committee. To ensure that the recommendations of the Committee have taken into account the needs of the diverse groups served by the Department, membership should include to the extent practicable individuals with demonstrated ability to represent minorities, women, persons with disabilities, and senior citizens.

Dated: April 3, 2000.

## Edmund Gee,

Acting Forest Supervisor.
[FR Doc. 00-8683 Filed 4-6-00; 8:45 am]
BILLING CODE 3410-11-M

## DEPARTMENT OF AGRICULTURE

## Forest Service

## Big Butte Timber Sales and Related Activities, Rogue River National Forest Jackson County, OR

agency: Forest Service, USDA. ACTION: Notice of intent to prepare an Environmental Impact Statement.

SUMMARY: The USDA, Forest Service will prepare an environmental impact statement (EIS). The purpose of the EIS is to analyze and disclose the environmental impacts of a site specific proposal to commercially harvest and regenerate trees, construct, reconstruct, and decommission roads, implement vegetation density management activities, implement wildlife projects, and conduct prescribed burns. The activities are proposed in the Big Butte Springs watershed located on lands administered by the Rogue River National Forest, Butte Falls Ranger District, Jackson County, Oregon. The Proposed Action will tier to and be designed under the Rogue River National Forest Land and Resource Management Plan (1990), as amended by the Record of Decision for the Northwest Forest Plan (1994), which provides guidance for land management activities. This proposal is scheduled for implementation during fiscal years 2000-2003. The Cascade Zone invites written comments concerning the scope of the analysis in addition to those comments that will be solicited as a result of local public participation activities. The Forest Service will also give notice of the full environmental analysis and decision making process so
that interested and affected people are made aware as to how they may participate and contribute to the final decision.
DATES: Issues and comments concerning the scope, implementation, and analysis of the Proposed Action must be received by May 15, 2000.
ADDRESSES: Submit written comments regarding the Proposed Action to Joel King, District Ranger, Prospect Ranger District, 47201 Highway 62, Prospect, Oregon, 97536.

## FOR FURTHER INFORMATION CONTACT:

Direct questions about the Proposed Action and EIS to Don Boucher, Interdisciplinary Team Leader, Prospect Ranger District, 47201 Highway 62, Prospect, Oregon, 97536, phone: 541-560-3400, FAX: 541-560-3444, e-mail: dboucher@fs.fed.us.
SUPPLEMENTARY INFORMATION: The Big Butte Timber Sales and Related Activities Project will take place within the upper portion of the Big Butte Springs Watershed. This sub-watershed is also referred to as the Medford Watershed because it supplies domestic water to the city of Medford, Oregon and surrounding communities. The Big Butte Springs watershed is located approximately 18 miles east of Medford, Oregon, and is just north of State Highway 140. Only Forest Service managed lands would be treated. The legal description of the area being considered is: T 35 S, R 3 E, sections 13, 22-36; T 35 S, R 4 E, sections 7-34; T 36 S, R 3 E, sections 1-17, 21-28, 35, \& 36; T 36 S, R 4 E, sections 3-8, 1621, \& 27-33; Willamette Meridian.

The Forest Service Proposed Action implement activities which include, in part, one or more timber sales involving approximately 6,200 acres of harvest units. Silvicultural prescriptions include: density management of overstocked stands of trees (approximately 1,700 acres); treating mature stands with small group selections or even-aged management (approximately 2,000 acres); and, density management of small, younger stands for forest health and stand development (approximately 2,500 acres). Other projects include road decommissioning (approximately 13 miles), prescribed fire for wildlife habitat improvement and fuels reduction (approximately 500 acres), density management of stands of young trees less than six inches in diameter (approximately 1,500 acres), and other wildlife improvement projects. Minor amounts of new road construction or reconstruction may be necessary to access harvest units. These activities are proposed on Matrix lands in the

Northwest Forest Plan. The Big Butte Springs watershed is not a Tier 1 Key Watershed. No activities are planned within any inventoried roadless areas.

The Purpose and Need for the Proposed Action is to implement management direction from the Rogue River National Forest Land and Resource Management Plan as amended by the Northwest Forest Plan and to manage for ecosystem needs. Specifically for the Big Butte area, needs include; improvement of overall forest health by stimulating natural processes that encourage more stable and resilient forest vegetation conditions; management and improvement of stand densities and species composition in overstocked natural and created sapling and pole stands; management, maintenance or improvement of current soil and water quality conditions; management, maintenance or improvement of current big game winter range conditions and Forest Service road systems; and providing a sustainable yield of commercial timber and other commodities, in concert with land management allocation and direction.
The following preliminary issues are identified: direct, indirect, and cumulative impacts to soils; water quality, including domestic watershed values; vegetation condition (diversity of seral stages and control insects and disease); wildlife big game winter range and travel and migration corridors; and human and social values such as economic feasibility and preservation of currently unroaded areas. The Forest Service will consider these and other issues with the Proposed Action, and develop additional alternatives to the Proposed Action that respond to the significant issues. The no-action alternative will also be considered.
Public participation will be important during the analysis. Reviewers may refer to the Council on Environmental Quality Regulations for Implementing the procedural provisions of the National Environmental Policy Act at 40 CFR 1501.7. The Agency will be seeking written issues with the Proposed Action from Federal, State, and local agencies, any affected Indiana tribes, and other individuals who may be interested in or affected by the Proposed Action. This input will be used to develop additional alternatives
The Draft EIS is expected to be filed with the Environmental Protection Agency (EPA) and be available for review for June 2000. The comment period for the Draft EIS will be 45 days from the date that the EPA publishes the Notice of Availability in the Federal Register.

Comments received in response to this notice, including names and addresses of those who comment, will be considered part of the public record on this Proposed Action and will be available for public inspection. Comments submitted anonymously will be accepted and considered, however, those who submit anonymous comments will not have standing to appeal the subsequent decision under 36 CFR Part 215. Additionally, pursuant to 7 CFR 1.27(d), any person may request the agency to withhold a submission from the public record by showing how the Freedom of Information Act (FOIA) permits such confidentiality. Person requesting such confidentiality should be aware that, under the FOIA, confidentially may be granted in only very limited circumstances, such as to protect trade secrets. The Forest Service will inform the requester of the agency's decision regarding the request for confidentiality, and where the request is denied, the agency will return the submission and notify the requester that the comments may be resubmitted with or without name and address within a specified number of days.

The Forest Service believes it is important to give reviewers notice at this early stage of several court rulings related to public participation in the environmental review process. First, a reviewer of a Draft EIS must structure their participation in the environmental review process of the proposal so that it is specific, meaningful, and alerts an agency to the review's position and contentions. Vermont Yankee Power Corp. v. NRDC, 435 U.S. 519, 533 (1978). Also, environmental objections that could be raised at the Draft EIS stage, but that are not raised until after the completion of the final EIS, may be waived or dismissed by the courts. City of Angoon v. Hodel, 803 F.2d. 1016, 1022 (9th Cir. 1986) and Wisconsin Heritages Inc. v. Harris, 409 F. Supp. 1334, 1338 (E.D. Wis. 1980). Because of these court rulings, it is very important that those interested in this Proposed Action participate by the close of the 45 day comment period so that substantive comments and objections are made available to the Forest Service at a time when it can meaningfully consider and respond to them in the Final EIS.

To assist the Forest Service in
identifying and considering issues and concerns on the Proposed Action, comments on the Draft EIS should be as specific as possible. It is also helpful if comments refer to specific pages or chapters of the Draft EIS. Comments may also address the inadequacy of the Draft EIS or the merits of the
alternatives formulated and discussed in the EIS. Reviewers may wish to refer to the Council on Environmental Quality Regulations for implementing the procedural provisions of the National Environmental Policy Act at 40 CFR 1503.3 in addressing these points.

After the 45 day comment period ends on the Draft EIS, comment will be considered and analyzed by the Agency in preparing the Final EIS. The Final EIS is scheduled for completion by September 2000. In the Final EIS, the Forest Service is required to respond to the comments and responses received during the comment period that pertain to the environmental consequences discussed in the Draft EIS and applicable laws, regulations, and policies considered in making the decision regarding the proposal.
The Forest Service is the Lead Agency. The Forest Service Responsible Official is Joel King, Prospect District Ranger. The Responsible Official will consider the Final EIS, applicable laws, regulations, policies, and analysis files in making a decision. The Responsible Official will document the Big Butte Timber Sales and Related Activities decision and rationale in a Record of Decision. The decision will be subject to under Forest Service appeal regulation (36 CFR Part 215).
Dated: March 28, 2000.

## Joel T. King,

Prospect District Ranger.
[FR Doc. 00-8623 Filed 4-6-00; 8:45 am]
BILLING CODE 3410-11-M

## DEPARTMENT OF AGRICULTURE

## Forest Service

## Middle Imnaha River Range Planning Area, Hells Canyon National Recreation Area and Hells Canyon Wilderness, Wallowa-Whitman National Forest, Wallowa and Baker Counties, OR

AGENCY: Forest Service, USDA.
ACTION: Notice of intent to prepare an environmental impact statement.
summary: The USDA, Forest Service, will prepare an environmental impact statement (EIS) to update range management planning on seventeen (17) livestock (cattle and horse) grazing allotments and one administrative use pasture, which will result in the development of new Allotment Management Plans (AMPs). The allotments are Blackmore, Chalk, College Creek, Dunlap-Thorn, Dunn Creek, Grouseline, Himmelwright, Keeler, Middle Point, Saddle Creek,

Schleur, Snell, Mink, Needham, North Pine, Double Pine and Snake River. The administrative use pasture is called College Creek Administrative Horse Pasture. The southern end of the range planning area begins approximately 40 miles north and east of the town of Halfway, Oregon on Pine Ranger District, and continues north into Hells Canyon National Recreation Area (HCNRA), ending approximately 6 miles south of the town of Imnaha, Oregon. The allotments extend east into the Hells Canyon Wilderness and west into the Big Sheep Creek drainage. The allotments, combined, are called the Middle Imnaha River Range Planning Area. National Forest System (NFS) lands within the Wallowa-Whitman National Forests will be considered in the proposal. Management actions are planned to be implemented beginning in the year 2002. The agency gives notice of the full environmental analysis and decision-making process that will occur on the proposal so that interested and affected people may become aware of how they may participate in the process and contribute to the final decision.
DATES: Comments concerning the scope of the analysis should be received in writing by May 31, 2000.
ADDRESSES: Send written comments and suggestions concerning this proposal to Kendall Clark, District Ranger, Hells Canyon National Recreation Area, Wallowa-Whitman National Forest, 88401 Highway 82, Enterprise, Oregon 97828.

## FOR FURTHER INFORMATION CONTACT:

Direct questions about the proposed action and EIS to Howard Lyman, Project Co-Leader, Hells Canyon National Recreation Area, 88401 Highway 82, Enterprise, Oregon 97828, 541-426-5573 or to Lynne Smith, Project Co-Leader, Pine Ranger District, 38470 Pine Town Lane, Halfway, Oregon 97834, 541-742-6715.
SUPPLEMENTARY INFORMATION: The proposed action is to continue to permit livestock grazing on NFS lands. The proposed action will also incorporate pertinent management guidelines and direction found in the WallowaWhitman National Forest Land and Resource Management Plan, as amended, the Hells Canyon National Recreation Area Comprehensive Land Management Plan (CMP), Wild and Scenic River Plans for the Imnaha and Snake Rivers, and biological assessments and biological opinions for threatened Snake River Chinook salmon and steelhead. The proposed action is designed to continue the improving
trends in vegetation and watershed conditions relative to livestock grazing within the planning area. The action is needed to develop new AMPs which incorporate results of recent scientific research, analysis and documentation at the sub-basin level. Components of the proposed action include: (1) Protection of Endangered Species Act listed spawning and rearing habitat; (2) provide for sustained forage production through deferment and rest; (3) review utilization standards in riparian areas and analyze potential changes is required stubble heights; and (4) adjust allotment boundaries where the allotment has previously extended into the Wild and Scenic Snake River to outside the Wild and Scenic corridor.

The Wallowa-Whitman Forest Plan, as amended, recognized the continuing need for forage production for the Forest and recognized the seventeen allotments and the administrative pasture of the Middle Imnaha River Range Planning Area as containing lands which are capable and suitable for grazing by domestic livestock. The action is needed to continue this historic use.

The allotments are located within twenty-seven subwatersheds: Freezeout Creek; Imnaha River/mile 24; Squaw Creek; Big Sheep Creek/mile 4; Imnaha River/mile 37; Pumpkin Creek; Summit Creek; Rich Creek; Lower Grouse Creek; Imnaha River/mile 43; Crazyman Creek; Snake River/Rocky Bar; Snake River/ Hells Canyon; Lower Little Sheep Creek; Big Sheep Creek/mile 0; Marr Creek; Big Sheep Creek/mile 17; Snake River/Two Bars; Saddle Creek; Lower North Pine Creek; Upper North Pine Creek; Elk Creek; Lake Fork Creek; Imnaha River/ mile 55; Imnaha River/mile 58; Snake River/Big Bar; and McGraw Creek. These subwatersheds are contained within the Lower Imnaha River, Upper Imnaha River, Imnaha River, Snake River, Snake River/Hat Point, Big Sheep Creek and Pine Creek watersheds.

The Forest planning process allocated specific management direction across the Wallowa-Whitman National Forest. Within the area encompassed by the seventeen allotments, the management areas (MAs) are MA1—Timber
Production Emphasis, MA3—Big game winter range/timber; MA4-Wilderness; MA7-Wild and Scenic River; MA8HCNRA Snake River corridor; MA9HCNRA Dispersed Recreation/Native Vegetation, MA10-HCNRA Forage production; MA11-HCNRA Dispersed recreation/timber; MA12-Research Natural Areas, and MA15-Old Growth Preservation.

The seventeen allotments encompass approximately 86,268 acres of NFS Lands, with private land making up an
additional 7,603 acres. Approximately 30,695 acres in the Himmelwright, Saddle Creek and Snake River allotments are part of the Hells Canyon Wilderness. Points of interest in the allotments include portions of the Wallowa Loop Road (Forest Road 39); as well as many historic, prehistoric and scenic sites located along the area's extensive trail system. These include Barton Heights, Saulsbery Saddle, Lord Flat, Summit Ridge; Freezeout Saddle; Needham Butte,. and many others.

The Middle Imnaha River Range Planning Area provides habitat for many wildlife species including management indicator species (MIS) and their habitats. These MIS species include California wolverine, North American lynx, Rocky Mountain elk, marten, pileated woodpecker, goshawk, bald eagle and American peregrine falcon. Fish species within the planning area include native populations of inland redband/rainbow trout, bull trout, steelhead and Chinook salmon.
Preliminary issues include: (1) The effects of livestock grazing on riparian conditions (including water quality, water temperature and stream bank stability); (2) The effects of no grazing or reduced grazing on the local economy; (3) The reduction in soil productivity and in amounts of native bunchgrasses due to the encroachment of cheatgrass and sand dropseed species; (4) The effects of livestock grazing on Wild and Scenic River Outstandingly Remarkable Values and Wilderness values, (5) the effects of livestock grazing on TES species and (6) the effects of livestock grazing on big game winter range.

A detailed public involvement plan has been developed, and an interdisciplinary team has been selected to do the environmental analysis, prepare and accomplish scoping, and accomplish public involvement activities.
The proposed action is intended to provide the analysis needed to prepare new AMPs that meet all the Forest Plan amended requirements of Interim Strategies for Managing Pacific Anadromous Fish-producing Watersheds in Eastern Oregon and Washington, Idaho, and portions of California (PACFISH), Inland Native Strategies for Managing Fish-producing Watersheds in Eastern Oregon and Washington, Idaho, Western Montana, and Portions of Nevada (INFISH), Wild and Scenic River Plans, and are consistent with the scientific findings of the Interior Columbia Basin Ecosystem Management Program (ICBEMP). Consultation with the U.S. Fish and Wildlife Service, as required by the

Endangered Species Act (ESA), will be completed on all proposed activities.
Public involvement will be especially important at several points during the analysis, beginning with the scoping process. The Forest Service will be consulting with Tribes and seeking information, comments, and assistance from Federal, State, local agencies, current range permittees, and other individuals or organizations who may be interested in or affected by the proposals. The scoping process includes:

1. Identifying and clarifying issues.
2. Identifying key issues to be analyzed in depth.
3. Exploring alternatives based on themes which will be derived from issues recognized during scoping activities.
4. Identifying potential environmental effects of the proposals and alternatives (i.e., direct, indirect, and cumulative effects and connected actions).
5. Determining potential cooperating agencies and task assignments.
6. Developing a list of interested people to keep apprised of opportunities to participate through meetings, personal contacts, or written comments.
7. Developing a means of informing the public through the media and/or written material (e.g., newsletters, correspondence, etc.).
Public comments are appreciated throughout the analysis process. The draft EIS is expected to be filed with the Environmental Protection Agency (EPA) and be available for public review by March, 2001. The comment period on the draft EIS will be 45 days from the date the EPA publishes the notice of availability in the Federal Register. The final EIS is scheduled to be available October, 2001.
Comments received in response to this notice, including names and addresses of those who comment, will be considered part of the public record on this proposed action and will be available for public inspection. Comments submitted anonymously will be accepted and considered, however, those who submit anonymous comments will not have standing to appeal the subsequent decision under 36 CFR Parts 215. Additionally, pursuant to 7 CFR 1.27(d), any person may request the agency to withhold a submission from the public record by showing how the Freedom of Information Act (FOIA) permits such confidentiality. Persons requesting such confidentiality should be aware that, under the FOIA, confidentiality may be granted in only very limited circumstances, such as to protect trade secrets. The Forest Service will inform
the requester of the agency's decision regarding the request for confidentiality, and where the request is denied, the agency will return the submission and notify the requester that the comments may be resubmitted with or without name and address within a specified number of days.

The Forest Service believes it is important to give reviewers notice of this early stage of public participation and of several court rulings related to public participation in the environmental review process. First, reviewers of a draft EIS must structure their participation in the environmental review of the proposal so that it is meaningful and alerts an agency to the reviewer's position and contentions. Vermont Yankee Nuclear Power Corp. v. NRDC,, 435 U.S. 519, 553 (1978). Also, environmental objections that could have been raised at the draft stage may be waived or dismissed by the court if not raised until after completion of the final EIS. City of Angoon v. Hodel, 803 f.2d 1016, 1022 (9th Cir, 1986) and Wisconsin Heritages, Inc v. Harris, 490 F. Supp. 1334, 1338 (E.D. Wis. 1980). Because of these court rulings, it is very important that those interested in this proposed action participate by the close of the 45 -day comment period so substantive comments and objections are made available to the Forest Service at a time when it can meaningfully consider and respond to them in the final EIS.

To assist the Forest Service in identifying and considering issues and concerns on the proposed action, comments on the draft EIS should be as specific as possible. It is also helpful if comments refer to specific pages or chapters of the draft statement. Comments may also address the adequacy of the draft EIS or the merits of the alternatives formulated and discussed in the statement. (Reviewers may wish to refer to the Council on Environmental Quality Regulations for implementing the procedural provisions of the National Environmental Policy Act at 40 CFR 1503.3 in addressing these points.)

In the final EIS, the Forest Service is required to respond to substantive comments and responses received during the comment period that pertain to the environmental consequences discussed in the draft EIS and applicable laws, regulations, and policies considered in making a decision regarding the proposal. The Forest Service is the lead Agency. Karyn L. Wood, Forest Supervisor, is the Responsible Official. As the Responsible Official she will document the decision and rationale for the decision in the

Record of Decision. That decision will be subject to Forest Service Appeal Regulations (36 CFR part 215).
Dated: March 31, 2000.
Karyn L. Wood,
Forest Supervisor.
[FR Doc. 00-8622 Filed 4-6-00; 8:45 am]
BILLING CODE 3410-11-M

## DEPARTMENT OF AGRICULTURE

## National Agricultural Statistics Service

## Notice of Intent To Seek Approval To Conduct an Information Collection

agencr: National Agricultural Statistics Service, USDA.
ACTION: Notice and request for comments.

SUMMARY: In accordance with the Paperwork Reduction Act of 1995 (Pub. L. No. 104-13) and Office of Management and Budget regulations at 5 CFR part 1320 ( 60 FR 44978, August 29, 1995), this notice announces the intent of the National Agricultural Statistics Service (NASS) to request an extension of a currently approved information collection, the Honey Survey.
DATES: Comments on this notice must be received by June 12, 2000 to be assured of consideration.
AdDresses: Contact Rich Allen, Associate Administrator, National Agricultural Statistics Service, U.S. Department of Agriculture, 1400 Independence Avenue SW, Room 4117 South Building, Washington, DC 202502000, (202) 720-4333.

## SUPPLEMENTARY INFORMATION:

Title: Honey Survey.
OMB Control Number: 0535-0153.
Expiration Date of Approval: October 31, 2000.

Type of Request: To extend a currently approved information collection.

Abstract: The primary objective of the National Agricultural Statistics Service is to prepare and issue state and national estimates of crop and livestock production. The Honey Survey collects information on the number of colonies, honey production, stocks, and prices. The survey provides data needed by the U.S. Department of Agriculture and other government agencies to administer programs and to set trade quotas and tariffs. State universities and agriculture departments also use data from this survey. The Honey Survey has approval from OMB for a three year period. NASS intends to request that the survey be approved for another three years.

These data will be collected under the authority of 7 U.S.C. 2204(a). Individually identifiable data collected under this authority are governed by Section 1770 of the Food Security Act of 1985, 7 U.S.C. 2276, which requires USDA to afford strict confidentiality to non-aggregated data provided by respondents.
Estimate of Burden: Public reporting burden for this collection of information is estimated to average 20 minutes per response.

## Respondents: Farms.

Estimated Number of Respondents: 7,200.
Estimated Total Annual Burden on Respondents: 2,426 hours.

Copies of this information collection and related instructions can be obtained without charge from Ginny McBride, the Agency OMB Clearance Officer, at (202) 720-5778.

## Comments

Comments are invited on: (a) Whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility; (b) the accuracy of the agency's estimate of the burden of the proposed collection of information including the validity of the methodology and assumptions used; (c) ways to enhance the quality, utility, and clarity of the information to be collected; and (d) ways to minimize the burden of the collection of information on those who are to respond, including through the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology. Comments may be sent to: Ginny McBride, Agency OMB Clearance Officer, U.S. Department of Agriculture, 1400 Independence Avenue SW, Room 4162 South Building, Washington, DC 20250-2000.

All responses to this notice will become a matter of public record and be summarized in the request for OMB approval.

Signed at Washington, DC, March 24, 2000.

## Rich Allen,

Associate Administrator.
[FR Doc. 00-8609 Filed 4-6-00; 8:45 am]
BILLING CODE 3410-20-P

## DEPARTMENT OF AGRICULTURE

## National Agricultural Statistics Service

## Notice of Intent To Seek Approval To Conduct an Information Collection

Agencr: National Agricultural Statistics Service, USDA.
ACTION: Notice and request for comments.

SUMMARY: In accordance with the Paperwork Reduction Act of 1995 (Pub. L. 104-13) and Office of Management and Budget regulations at 5 CFR part 1320 (60 FR 44978, August 29, 1995), this notice announces the intent of the National Agricultural Statistics Service (NASS) to request approval for an information collection, the Monthly Hog Survey.
DATES: Comments on this notice must be received by June 12, 2000, to be assured of consideration.

## ADDITIONAL INFORMATION OR COMMENTS:

Contact Rich Allen, Associate Administrator, National Agricultural Statistics Service, U.S. Department of Agriculture, 1400 Independence Avenue SW, Room 4117 South Building, Washington, D.C. 20250-2000, (202) 720-4333.

## SUPPLEMENTARY INFORMATION:

Title: Monthly Hog Survey.
Type of Request: Intent to Seek Approval to Conduct an Information Collection.

Abstract: The National Agricultural Statistics Service is responsible for collecting and issuing state and national estimates of crop and livestock production, grain stocks, farm numbers, land values, on-farm pesticide usage, and pest crop management practices. Uses of this statistical information are extensive and varied. Producers, farm organizations, agribusinesses, state and national farm policy makers, and government agencies are important users of these statistics. Agricultural statistics are used to plan and administer other related Federal and state programs in such areas as consumer protection, conservation, foreign trade, education, and recreation.

The Monthly Hog Survey Program will supplement the Hog Survey Program currently conducted as part of the Quarterly Agricultural Surveys. The monthly surveys will use a shorter version of the quarterly questionnaire and will be conducted eight times a year, during the months between the Quarterly Hog Surveys. The sampling frame for the monthly program will be hog owners who reported breeding females on the December Quarterly Hog Survey.

NASS was directed to publish on a monthly basis the Hogs and Pigs Inventory Report with the passage by Congress and signature of the President of H.R. 1906, the FY2000 Department of Agriculture budget. The Monthly Hog Report will include estimates of (1) Inventory of breeding females, (2) breeding females mated, (3) litters farrowed, (4) pigs born alive, (5) average pigs/litter born, and (6) pigs weaned. Hog producers supported the provision that NASS publish the Hogs and Pigs Inventory Report on a monthly basis. Data users can utilize monthly data of breeding females and pig crop to get an indication of hog supplies coming to market over the next 6 months.
These data will be collected under the authority of 7 U.S.C. 2204(a).
Individually identifiable data collected under this authority are governed by Section 1770 of the Food Security Act of 1985, 7 U.S.C. 2276, which requires USDA to afford strict confidentiality to non-aggregated data provided by respondents.
Estimate of Burden: Experience with similar surveys indicates that the questionnaire will require approximately 10 minutes to complete. Respondents: Farms.
Estimated Number of Respondents: 2,805.

Estimated Total Annual Burden on Respondents: 3,740 hours.

Copies of this information collection and related instructions can be obtained without charge from Ginny McBride, Agency OMB Clearance Officer, at (202) 720-5778.

Comments: Comments are invited on: (a) Whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility; (b) the accuracy of the agency's estimate of the burden of the proposed collection of information including the validity of the methodology and assumptions used; (c) ways to enhance the quality, utility, and clarity of the information to be collected; and (d) ways to minimize the burden of the collection of information on those who are to respond, including through the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology. Comments may be sent to: Ginny McBride, Agency OMB Clearance Officer, U.S. Department of Agriculture, 1400 Independence Avenue SW, Room 4162 South Building, Washington, DC 20250-2000. All responses to this notice will become a matter of public record and be included in the request for OMB approval.

Signed at Washington, DC, March 24, 2000. Rich Allen,
Associate Administrator.
[FR Doc. 00-8611 Filed 4-6-00; 8:45 am] BILLING CODE 3410-20-P

## DEPARTMENT OF AGRICULTURE

## National Agricultural Statistics Service

## Notice of the Advisory Committee on Agriculture Statistics Meeting

AGENCY: National Agricultural Statistics Service, USDA.
ACTION: Notice of meeting.
SUMMARY: In accordance with the Federal Advisory Committee Act, 5 U.S.C. App. 2, the National Agricultural Statistics Service (NASS) announces a meeting of the Advisory Committee on Agriculture Statistics.
FOR FURTHER INFORMATION CONTACT: Rich
Allen, Executive Director, Advisory
Committee on Agriculture Statistics, U.S. Department of Agriculture, National Agricultural Statistics Service, 1400 Independence Avenue SW, Room 4117 South Building, Washington, D.C. 20250-2000. Telephone: 202-720-4333, Fax: 202-720-9013, or e-mail: rallen@nass.usda.gov.
SUPPLEMENTARY INFORMATION: The Advisory Committee on Agriculture Statistics, which consists of 25 members appointed from 7 categories covering a broad range of agricultural disciplines and interests, has scheduled a meeting on April 25-26, 2000. The Committee meeting will be held 8 a.m. $-4: 30 \mathrm{p} . \mathrm{m}$. on Tuesday, April 25, and 8:00 a.m.11:30 a.m. on Wednesday, April 26. During this time the Advisory Committee will discuss: (1) 2002 Census of Agriculture content, (2) NASS data use policy, (3) mandatory business reporting, and (4) census of agriculture procedures for American Indian reservations.

Dates and Locations: April 25-8 a.m. to $4: 30$ p.m., Advisory Committee Meeting, with an opportunity for public questions and comments at 3:30 p.m., Crowne Plaza Hotel, 1001 14th \& K Streets, NW, Washington, DC.

April 26-8 a.m. to 11:30 a.m., Advisory Committee Meeting, with an opportunity for public questions and comments at 9:45 a.m., Crowne Plaza Hotel, 1001 14th \& K Streets, NW, Washington, DC.
Type of Meeting: Open to the public.
Comments: The public may file written comments to the USDA Advisory Committee contact person before or within a reasonable time after the meeting. All statements will become
a part of the official records of the USDA Advisory Committee on Agriculture Statistics and will be kept on file for public review in the office of the Executive Director, Advisory Committee on Agriculture Statistics, U.S. Department of Agriculture, Washington, DC. 20250.
Dated: April 3, 2000, at Washington, DC.
R. Ronald Bosecker,

Administrator, National Agricultural Statistics Service.
[FR Doc. 00-8610 Filed 4-6-00; 8:45 am] BILLING CODE 3410-20-P

## ARCHITECTURAL AND TRANSPORTATION BARRIERS COMPLIANCE BOARD

Public Rights-of-Way Access Advisory Committee; Meeting

AGENCY: Architectural and
Transportation Barriers Compliance Board.
ACTION: Notice of meeting.
summary: The Architectural and Transportation Barriers Compliance Board (Access Board) established a Public Rights-of-Way Access Advisory Committee (committee) to assist the Board in developing a proposed rule on accessibility guidelines for newly constructed and altered public rights-ofway covered by the Americans with Disabilities Act of 1990 and the Architectural Barriers Act of 1968. This document announces the next meeting of the committee, which will be open to the public.
DATES: The third meeting of the committee is scheduled for May 18 and 19, 2000, beginning at $9 \mathrm{a} . \mathrm{m}$. and ending at 5:30 p.m. each day; and May 20, 2000 beginning at $9 \mathrm{a} . \mathrm{m}$ and ending at $3 \mathrm{p} . \mathrm{m}$. ADDRESSES: The meeting will be held in the 3rd floor training room at 1331 F Street, NW., Washington, DC.

## FOR FURTHER INFORMATION CONTACT:

Scott Windley, Office of Technical and Information Services, Architectural and Transportation Barriers Compliance Board, 1331 F Street, NW., suite 1000, Washington, DC 20004-1111. Telephone number (202) 272-5434 extension 125 (Voice); (202) 272-5449 (TTY). E-mail windley@accessboard.gov. This document is available in alternate formats (cassette tape, Braille, large print, or ASCII disk) upon request. This document is also available on the Board's Internet Site (http:// www.access-board.gov/notices/ prowmtg.htm).
SUPPLEMENTARY INFORMATION: On
October 20, 1999, the Architectural and

Transportation Barriers Compliance Board (Access Board) published a notice appointing members to a Public Rights-of-Way Access Advisory Committee (committee) to provide recommendations for developing a proposed rule addressing accessibility guidelines for newly constructed and altered public rights-of-way covered by the Americans with Disabilities Act of 1990 and the Architectural Barriers Act of 1968. 64 FR 56482 (October 20, 1999).
Committee meetings will be open to the public and interested persons can attend the meetings and communicate their views. Members of the public will have an opportunity to address the committee on issues of interest to them and the committee during the public comment period at the end of each meeting day. Members of groups or individuals who are not members of the committee may also have the opportunity to participate with subcommittees of the committee. Additionally, all interested persons will have the opportunity to comment when the proposed accessibility guidelines for public rights-of-way are issued in the Federal Register by the Access Board.

Individuals who require sign language interpreters or real-time captioning systems should contact Scott Windley by May 3, 2000. Notices of future meetings will be published in the Federal Register.

## Lawrence W. Roffee,

Executive Director.
[FR Doc. 00-8657 Filed 4-6-00; 8:45 am] billing Code 8150-01-P

## COMMITTEE FOR PURCHASE FROM PEOPLE WHO ARE BLIND OR SEVERELY DISABLED

## Procurement List Additions

agency: Committee for Purchase From People Who Are Blind or Severely Disabled.
ACTION: Additions to the procurement list.

SUMMARY: This action adds to the Procurement List services to be furnished by nonprofit agencies employing persons who are blind or have other severe disabilities.
EFFECTIVE DATE: May 8, 2000.
ADDRESSES: Committee for Purchase From People Who Are Blind or Severely Disabled, Crystal Gateway 3, Suite 310, 1215 Jefferson Davis Highway, Arlington, Virginia 22202-4302.
FOR FURTHER INFORMATION CONTACT:
Louis R. Bartalot (703) 603-7740.

## SUPPLEMENTARY INFORMATION: On

February 11, and 25, 2000, the Committee for Purchase From People Who Are Blind or Severely Disabled published notices (65 FR 6981 and 10047) of proposed additions to the Procurement List.
After consideration of the material presented to it concerning capability of qualified nonprofit agencies to provide the services and impact of the additions on the current or most recent contractors, the Committee has determined that the services listed below are suitable for procurement by the Federal Government under 41 U.S.C. 46-48c and 41 CFR 51-2.4.

I certify that the following action will not have a significant impact on a substantial number of small entities. The major factors considered for this certification were:

1. The action will not result in any additional reporting, recordkeeping or other compliance requirements for small entities other than the small organizations that will furnish the services to the Government.
2. The action will not have a severe economic impact on current contractors for the services.
3. The action will result in authorizing small entities to furnish the services to the Government.
4. There are no known regulatory alternatives which would accomplish the objectives of the Javits-WagnerO’Day Act (41 U.S.C. 46-48c) in connection with the services proposed for addition to the Procurement List.
Accordingly, the following services are hereby added to the Procurement List:

## Administrative Services

Internal Revenue Service Collections Department, 1100 Commerce Street, Dallas, Texas

Administrative Services
Internal Revenue Service Mailroom, 1100 Commerce Street, Dallas, Texas

Administrative Services
Internal Revenue Service Mailroom, 1919 Smith Street, Houston, Texas

Grounds Maintenance
Air National Guard Readiness Center, Andrews AFB, Maryland

Telephone Switchboard Operations
Department of Veterans Affairs Medical Center, 100 Emancipation Drive, Hampton, Virginia

This action does not affect current contracts awarded prior to the effective
date of this addition or options that may be exercised under those contracts.
Leon A. Wilson, Jr.,
Executive Director.
[FR Doc. 00-8681 Filed 4-6-00; 8:45 am] BILLING CODE 6353-01-P

## COMMITTEE FOR PURCHASE FROM PEOPLE WHO ARE BLIND OR SEVERELY DISABLED

## Procurement List; Proposed Addition and Deletions

agency: Committee for Purchase From People Who Are Blind or Severely Disabled.
ACTION: Proposed addition to and deletions from procurement list.

SUMMARY: The Committee has received proposals to add to the Procurement List a service to be furnished by nonprofit agencies employing persons who are blind or have other severe disabilities, and to delete commodities previously furnished by such agencies.
COMMENTS MUST BE RECEIVED ON OR BEFORE: May 8, 2000.
ADDRESSES: Committee for Purchase From People Who Are Blind or Severely Disabled, Crystal Gateway 3, Suite 310, 1215 Jefferson Davis Highway, Arlington, Virginia 22202-4302.
FOR FURTHER INFORMATION CONTACT: Louis R. Bartalot (703) 603-7740.
SUPPLEMENTARY INFORMATION: This notice is published pursuant to 41 U.S.C. 47(a) (2) and 41 CFR 51-2.3. Its purpose is to provide interested persons an opportunity to submit comments on the possible impact of the proposed actions.

## Addition

If the Committee approves the proposed addition, all entities of the Federal Government (except as otherwise indicated) will be required to procure the service listed below from nonprofit agencies employing persons who are blind or have other severe disabilities.

I certify that the following action will not have a significant impact on a substantial number of small entities. The major factors considered for this certification were:

1. The action will not result in any additional reporting, recordkeeping or other compliance requirements for small entities other than the small organizations that will furnish the service to the Government.
2. The action will result in authorizing small entities to furnish the service to the Government.
3. There are no known regulatory alternatives which would accomplish the objectives of the Javits-WagnerO'Day Act (41 U.S.C. 46-48c) in connection with the service proposed for addition to the Procurement List. Comments on this certification are invited. Commenters should identify the statement(s) underlying the certification on which they are providing additional information.
The following service has been proposed for addition to Procurement List for production by the nonprofit agency listed:

## Janitorial/Custodial

Fort Huachuca, Arizona
NPA: Cochise County Association for the Handicapped, Bisbee, Arizona

## Deletions

I certify that the following action will not have a significant impact on a substantial number of small entities. The major factors considered for this certification were:

1. The action will not result in any additional reporting, recordkeeping or other compliance requirements for small entities.
2. The action will result in authorizing small entities to furnish the commodities to the Government.
3. There are no known regulatory alternatives which would accomplish the objectives of the Javits-WagnerO’Day Act (41 U.S.C. 46-48c) in connection with the commodities proposed for deletion from the Procurement List.

The following commodities have been proposed for deletion from the Procurement List:
Cover, Shipping, Blade
1615-01-160-3748
Ladder, Straight (Wood)
5440-00-816-2585
Aerosol Paint, Lacquer
8010-00-584-3148
8010-00-721-9743
8010-00-141-2950
8010-00-965-2392
Enamel, Lacquer
8010-00-852-9033
8010-00-846-5117
8010-00-181-7371
8010-00-988-1458
8010-00-935-7085
Enamel, Aerosol, Waterbase
8010-01-350-5254
8010-01-350-5255
8010-01-350-4746
8010-01-350-4747
8010-01-350-4755
8010-01-350-5248
8010-01-350-5249
8010-01-350-5258
8010-01-397-3985
Enamel
8010-01-332-3743
8010-01-336-5061

8010-01-336-5063
8010-01-332-3742
8010-01-363-3376
Rinse Additive, Dishwashing
7930-00-619-9575
Leon A. Wilson, Jr.
Executive Director.
[FR Doc. 00-8682 Filed 4-6-00; 8:45 am] BILLING CODE 6353-01-P

## DEPARTMENT OF COMMERCE

## Foreign-Trade Zones Board

[Docket 12-2000]
Foreign-Trade Zone 79; Tampa, Florida: Application for Expansion

An application has been submitted to the Foreign-Trade Zones (FTZ) Board (the Board) by the City of Tampa, Florida, grantee of Foreign-Trade Zone 79, requesting authority to expand its zone to include the Tampa International Airport fuel system which consists of the airport hydrant and storage facilities, a pipeline, and two offsite terminals, within the Tampa Customs port of entry. The application was submitted pursuant to the provisions of the Foreign-Trade Zones Act, as amended (19 U.S.C. 81a-81u), and the regulations of the Board (15 CFR Part 400). It was formally filed on March 28, 2000.

FTZ 79 was approved on May 29, 1982 (Board Order 192, 47 FR 24760, 6/ 8/82) and expanded on December 29, 1993 (Board Order 676, 59 F.R. 1371, 1/ 10/94). The zone project currently consists of six sites in the Tampa area: Site 1 (600,000 sq. ft.) Tampa International Center at Adamo Drive and 22nd Street; Site 2 ( 35 acres) cargo complex adjacent to Tampa International Airport at Tampa Boulevard and Lauber Way, including a parcel at the airport's air cargo facility and the East Tampa Container Station (2 acres), located at 1831 Massaro Boulevard; Site 3 ( 50 acres) within the 127-acre Tampa Industrial Park, Malcolm McKinley Drive and Fowler Avenue; Site 4 (14 acres) Tampa Convention Center, 333 South Franklin Street; Site 5 (295 acres) at the Tampa Port Authority's Hooker's Point terminal complex at Maritime Boulevard; and Site 6 (33 acres) at Tampa Port Authority's George B. Howell terminal facility, located at 20th and Thrace Streets.
The applicant is now requesting authority to expand the general-purpose zone to include the jet fuel storage and distribution system (100 acres) at the Tampa International Airport. The
airport fuel system includes the jet fuel storage farm (3 acres) and hydrant systems (23 acres) at the Tampa International Airport; the petroleum products storage terminal of GATX (31 acres), Hookers Point, Port of Tampa section of the City of Tampa; the petroleum products storage terminal of Motiva ( 16 acres), 6500 W. Commerce Street, Port Tampa section of the City of Tampa; and, the Tampa Pipeline ( 26 acres), a dedicated jet fuel carrier line. The GATX terminal is owned and operated by GATX Terminals Corporation; the Motiva terminal is owned and operated by Motiva Enterprises LLC; and, the Tampa dedicated pipeline is owned by the Tampa Pipeline Limited Partnership. Hillsborough County Aviation Authority owns the property that contains the jet fuel storage and distribution facilities at the Tampa International Airport. The City of Tampa owns the land at the GATX terminal and the land at the Tampa Pipeline location. The airport property is leased to the member airlines of the Tampa Fuel Committee The Aircraft Services International Group (ASIG) will operate the jet fuel storage and distribution facilities at the airport. In addition to the storage of jet fuel, the Motiva and GATX terminals may also use zone status for the receipt and storage of other petroleum products.

No specific manufacturing requests are being made at this time. Such requests would be made to the Board on a case-by-case basis.

In accordance with the Board's regulations, a member of the FTZ Staff has been designated examiner to investigate the application and report to the Board.

Public comment on the application is invited from interested parties. Submissions (original and 3 copies) shall be addressed to the Board's Executive Secretary at the address below. The closing period for their receipt is June 6, 2000. Rebuttal comments in response to material submitted during the foregoing period may be submitted during the subsequent 15-day period (to June 21, 2000).

A copy of the application and accompanying exhibits will be available for public inspection at each of the following locations:
Office of the Airport Services
International Group, Tampa Airport Marriott Hotel, Suite A-23, Tampa, FL 33607
Office of the Executive Secretary,
Foreign-Trade Zones Board, Room 4008, U.S. Department of Commerce, 14th \& Pennsylvania Avenue, NW, Washington, DC 20230

Dated: March 30, 2000.
Dennis Puccinelli,
Acting Executive Secretary.
[FR Doc. 00-8703 Filed 4-6-00; 8:45 am]
BILLING CODE 3510-DS-P

## DEPARTMENT OF COMMERCE

## Foreign-Trade Zones Board

[Order No. 1082]

## Grant of Authority for Subzone Status; Zeneca, Inc. (Agricultural Chemical Products), Omaha, NE

Pursuant to its authority under the Foreign-Trade Zones Act of June 18, 1934, as amended (19 U.S.C. 81a-81u), the Foreign-Trade Zones Board (the Board) adopts the following Order:
Whereas, the Foreign-Trade Zones Act provides for "* * * the establishment * * * of foreign-trade zones in ports of entry of the United States, to expedite and encourage foreign commerce, and for other purposes," and authorizes the Foreign-Trade Zones Board to grant to qualified corporations the privilege of establishing foreign-trade zones in or adjacent to U.S. Customs ports of entry;

Whereas, the Board's regulations (15 CFR part 400) provide for the establishment of special-purpose subzones when existing zone facilities cannot serve the specific use involved, and when the activity results in a significant public benefit and is in the public interest;
Whereas, the Dock Board of the City of Omaha, grantee of Foreign-Trade Zone 19, has made application to the Board for authority to establish specialpurpose subzone status at the agricultural chemical products facility of Zeneca, Inc., located in Omaha, Nebraska (FTZ Docket 34-99, filed 6/25/ 99);

Whereas, notice inviting public comment has been given in the Federal Register (64 FR 37497, 7/12/99); and,

Whereas, the Board adopts the findings and recommendations of the examiner's report, and finds that the requirements of the FTZ Act and the Board's regulations are satisfied, and that approval of the application would be in the public interest;

Now, therefore, the Board hereby grants authority for subzone status at the agricultural chemical products facility of Zeneca, Inc., located in Omaha, Nebraska, (Subzone 19A), at the location described in the application, subject to the FTZ Act and the Board's regulations, including §400.28.

Signed at Washington, DC, this 24th day of March 2000.
Richard W. Moreland,
Acting Assistant Secretary of Commerce for Import Administration, Alternate Chairman, Foreign-Trade Zones Board.
Attest:
Dennis Puccinelli,
Acting Executive Secretary.
[FR Doc. 00-8704 Filed 4-6-00; 8:45 am]
BILLING CODE 3510-DS-P

## DEPARTMENT OF COMMERCE

## Foreign-Trade Zones Board

[Order No. 1084]
Grant of Authority for Subzone Status; Fuji Photo Film, Inc. (Imaging and Information Products), Greenwood, SC
Pursuant to its authority under the Foreign-Trade Zones Act of June 18, 1934, as amended (19 U.S.C. 81a-81u), the Foreign-Trade Zones Board (the Board) adopts the following Order:

Whereas, the Foreign-Trade Zones Act provides for " * * * the establishment * * * of foreign-trade zones in ports of entry of the United States, to expedite and encourage foreign commerce, and for other purposes," and authorizes the Foreign-Trade Zones Board to grant to qualified corporations the privilege of establishing foreign-trade zones in or adjacent to U.S. Customs ports of entry;

Whereas, the Board's regulations (15 CFR part 400) provide for the establishment of special-purpose subzones when existing zone facilities cannot serve the specific use involved, and when the activity results in a significant public benefit and is in the public interest;

Whereas, the South Carolina State Ports Authority, grantee of ForeignTrade zone 38, has made application to the Board for authority to establish special-purpose subzone status at the manufacturing and distribution facilities (imaging and information products) of Fuji Photo Film, Inc., located Greenwood, South Carolina (FTZ Docket 35-99, filed 6/28/99);

Whereas, notice inviting public comment has been given in the Federal Register (64 FR 37498, 7/12/99); and,

Whereas, the Board adopts the findings and recommendations of the examiner's report, and finds that the requirements of the FTZ Act and the Board's regulations are satisfied, and that approval of the application would be in the public interest;

Now, therefore, the Board hereby grants authority for subzone status at the imaging and information products
manufacturing and distribution facilities of Fuji Photo Film, Inc., located in Greenwood, South Carolina (Subzone 38C), at the location described in the application, subject to the FTZ Act and the Board's regulations, including § 400.28.

Signed at Washington, DC, this 27th day of March 2000.

## Robert S. LaRussa,

Assistant Secretary of Commerce for Import Administration, Alternate Chairman, ForeignTrade Zones Board.
Attest:
Dennis Puccinelli,
Acting Executive Secretary.
[FR Doc. 00-8705 Filed 4-6-00; 8:45 am]
BILLING CODE 3510-DS-P

## DEPARTMENT OF COMMERCE

## International Trade Administration

## [A-201-806]

Carbon Steel Wire Rope from Mexico:
Preliminary Results of Antidumping Duty Administrative Review and New Shipper Review, and Determination Not To Revoke the Antidumping Duty Order in Part

AGENCY: Import Administration, International Trade Administration, Department of Commerce.
ACTION: Notice of preliminary results of antidumping duty administrative review and new shipper review, and determination not to revoke the antidumping duty order in part.

SUMMARY: The Department of Commerce (the Department) is conducting an administrative review of the antidumping duty order on carbon steel wire rope from Mexico in response to requests by respondent Aceros Camesa S.A. de C.V. (Camesa) and petitioner, the Committee of Domestic Steel Wire Rope and Specialty Cable Manufacturers (the Committee). Camesa also requested that the order be revoked as it pertains to sales of its products to the United States. This review covers exports of subject merchandise to the United States during the period March 1, 1998 through February 28, 1999.

We have preliminarily determined that Camesa's sales have been made below normal value (NV). If these preliminary results are adopted in our final results of this administrative review, we will instruct the U.S. Customs Service to assess antidumping duties based on the difference between the export price (EP) or constructed export price (CEP) and the NV.

The Department is also conducting a new shipper review of the antidumping duty order on carbon steel wire rope from Mexico in response to a request by respondent Cablesa S.A. de C.V. (Cablesa). ${ }^{1}$ This new shipper review also covers exports of subject merchandise to the United States during the period March 1, 1998 through February 28, 1999.

We have preliminarily determined that Cablesa's sales have not been made below NV. If these preliminary results are adopted in our final results, we will instruct the U.S. Customs Service to liquidate appropriate entries without regard to antidumping duties.

Interested parties are invited to comment on these preliminary results. Parties who submit comments are requested to submit with each comment a statement of the issue and a brief summary of the comment.
EFFECTIVE DATE: April 7, 2000.
FOR FURTHER INFORMATION CONTACT:
Mark Hoadley, (202) 482-0666, or
Maureen Flannery, (202) 482-3020, AD/
CVD Enforcement, Import
Administration, International Trade Administration, U.S. Department of Commerce, 14th Street and Constitution Avenue, NW., Washington DC 20230.

## APPLICABLE STATUTE AND REGULATIONS:

Unless otherwise stated, all citations to the statute are references to the provisions effective January 1, 1995, the effective date of the amendments made to the Tariff Act of 1930 (the Act) by the Uruguay Round Agreements Act. In addition, unless otherwise stated, all citations to the Department's regulations are references to the regulations as codified at 19 CFR part 351 (April 1999).

## SUPPLEMENTARY INFORMATION:

## Background

The Department published in the Federal Register the antidumping duty order on steel wire rope from Mexico on March 25, 1993 (58 FR 16173). On March 9, 1999 we published in the Federal Register (64 FR 11439) a notice of opportunity to request an administrative review of the antidumping duty order on steel wire rope from Mexico covering the period March 1, 1998 through February 28, 1999.

In accordance with 19 CFR 351.213(b)(2), Camesa requested that we

[^15]conduct an administrative review of its sales. The Committee also requested a review of Camesa's sales, in accordance with 19 CFR 351.213(b)(1). We published a notice of initiation of this antidumping duty administrative review on April 30, 1999 (64 FR 23269).

In accordance with 19 CFR 351.214, Cablesa requested that we conduct a new shipper review of its sales. We published a notice of initiation of this new shipper review on May 7, 1999 (64 FR 24573).
In accordance with section 773(b)(2)(A)(ii), the Department initiated a sales-below-cost investigation of Camesa. The Department determined to initiate this inquiry because, during the immediately preceding review of this antidumping duty order, the second administrative review, the Department disregarded some of Camesa's belowcost sales. The final results of the second administrative review were published on July 27, 1999 (64 FR 40549). We received cost data from Camesa on August 2, 1999.
During this review, the Department conducted verifications of the information provided by Cablesa and information provided by Camesa concerning its further manufacturing of subject merchandise in the United States. We used standard verification procedures, including on-site inspection of the manufacturer's facilities and the examination of relevant sales and financial records. Our verification results for Cablesa are outlined in business-proprietary and public versions of the verification reports. Our verification results for Camesa are not available (refer to following paragraph).
On September 28, 1999, the Department received a letter from Camesa announcing its intention not to continue participating in this review, including the final days of verification scheduled for the following week. It stated that all material it had submitted during this review should be returned by the Department and the Committee and removed from the record. The Department destroyed all such material with the exception of Camesa's September 28 letter. See Memorandum to the File (November 5, 1999).

## Scope of the Review

The product covered by this review is carbon steel wire rope. Steel wire rope encompasses ropes, cables, and cordage of iron or carbon steel, other than stranded wire, not fitted with fittings or made up into articles, and not made up of brass plated wire. Imports of these products are currently classifiable under the following Harmonized Tariff Schedule (HTS) subheadings:
7312.10.9030, 7312.10.9060 and 7312.10.9090.

Excluded from this review is stainless steel wire rope, which is classifiable under the HTS subheading 7312.10.6000, and all forms of stranded wire, with the following exception.

Based on the affirmative final determination of circumvention of the antidumping duty order, 60 FR 10831 (Feb. 28, 1995), the Department has determined that steel wire strand, when manufactured in Mexico by Camesa and imported into the United States for use in the production of steel wire rope, falls within the scope of the antidumping duty order on steel wire rope from Mexico. Such merchandise is currently classifiable under subheading 7312.10.3020 of the HTS.

Although HTS subheadings are provided for convenience and Customs purposes, the written description of the scope of this order remains dispositive.

These reviews cover the period March 1, 1998 through February 28, 1999.

## Camesa

## Application of Facts Available

Section 776(a)(2) of the Act provides that if any interested party: (A) Withholds information that has been requested by the Department; (B) fails to provide such information in a timely manner or in the form or manner requested; (C) significantly impedes an antidumping proceeding; or (D) provides such information but the information cannot be verified, the Department shall use the facts otherwise available (FA) in reaching the applicable determination under this title.

As noted above, Camesa notified the Department of its intent not to continue participating in the administrative review and requested the return or destruction of all of its submissions. Additionally, Camesa informed the Department that it would not be participating further in verification. Thus, the Department does not have any information with which to calculate a margin. We determine that Camesa's actions amount to withholding information requested by the
Department, thus significantly impeding our review. As such, consistent with sections 776(a)(2)(A) and (C) of the Act, we are relying upon the facts otherwise available. Furthermore, we determine that Camesa did not cooperate to the best of its ability with our requests for information, and that, pursuant to section 776(b) of the Act, the use of adverse FA is appropriate.

Under section 776(b) of the Act, adverse FA may include reliance on information derived from: (1) The
petition, (2) a final determination in the investigation, (3) any previous review under section 751 of the Act or determination under section 753 of the Act, or (4) any other information placed on the record. For Camesa, we have used the highest rate from the investigation, 111.68 percent, which is the "all others rate" established in the investigation and which was Camesa's rate until the first review.
Section 776(c) of the Act provides that the Department shall, to the extent practicable, corroborate secondary information using independent sources reasonably at its disposal. The Statement of Administrative Action, H.R. Doc. No. 103-316, 870 (1994) (SAA) provides that "corroborate" means simply that the Department will satisfy itself that the secondary information to be used has probative value. See SAA, at 870 . In this case, the margin we are using is Camesa's margin from the investigation of sales at less than fair value (LTFV). Therefore, we consider the rate to have probative value.

## Determination Not To Revoke in Part

Section 351.222(b)(2)(i) requires that in order for the Department to revoke an order in part we must, among other requirements, determine that the exporter or producer has sold the merchandise at not less than NV for a period of at least three consecutive years. Because we have determined that Camesa has sold subject merchandise at less than NV during the current review period, we have determined not to revoke the order in part.

## Cablesa

## Product Comparisons

In accordance with section 771(16) of the Act, we considered all products produced by Cablesa covered by the description in the "Scope of Review" section, above, and sold in the home market during the period of review (POR) to be foreign like products for the purposes of determining appropriate product comparisons with U.S. sales. In the Product Concordance section (Appendix V) of our questionnaire, we provided the following hierarchy of product characteristics to be used for reporting identical and most similar comparisons of merchandise: (1) Type of steel wire (finishing type); (2) diameter of wire rope; (3) type of core; (4) class of wire rope; (5) grade of steel;
(6) number of wires per strand; (7) design of strands; and (8) lay of rope.

Cablesa requested that we allow it to limit its reporting of home market sales of steel wire rope to products having the
same finish and belonging to the same class as those products sold in the United States. Product finish can be either galvanized or non-galvanized. Product class is determined by the number of wires and strands twined together to produce a rope. Cablesa argued that sales with the same finish and within the same class would provide all necessary matches for the U.S. sale, because such products were most similar. Cablesa stressed that, because the Department was not conducting a sales-below-cost test, it could conduct its analysis with sales of these similar products alone, and that any other reported sales would be superfluous. We agreed that Cablesa could limit its reporting as requested, but stated that we might at a later date require the reporting of additional home market sales on short notice. See Letter from Barbara Tillman to Cablesa (July 31, 1999).
On January 11, 2000, the Department requested that Cablesa submit additional home market sales. On January 28, 2000, Cablesa submitted a response containing some additional sales information and requesting that the Department calculate NV using this additional information or information previously placed on the record. Upon reviewing Cablesa's submission, we determined that this additional information, combined with information already on the record, is sufficient for margin calculation purposes.
Specifically, Cablesa's submission demonstrates that, although the Department does not have sales data for all of Cablesa's home market sales during the POR, any additional home market sales data would not be of similar merchandise, and thus would not provide valid matches. For a more detailed discussion, see Memorandum to Edward Yang, Basis for Normal Value (March 30, 2000).

## United States Price

We based United States price on EP, as defined in section 772(a) of the Act, because the merchandise was sold directly by the manufacturer to an unaffiliated U.S. purchaser prior to the date of importation, and because CEP was not indicated by other facts of record.

The Department calculated EP for Cablesa based on packed, delivered prices to customers in the United States. We made deductions for domestic and foreign inland freight expenses, inland insurance, U.S. customs duties, and brokerage and handling, in accordance with section 772(c)(2)(A).

## Normal Value

We have preliminarily determined that none of the home market sales reported by Cablesa provides a suitable basis for calculating NV. Each reported home market sale is either not contemporaneous with the U.S. sale, would require a difference in merchandise adjustment of greater than 20 percent to be matched with the U.S. sale, or could not be shown to have been made on an arm's-length basis with home market customers. Therefore, we based NV on constructed value (CV). CV consists of the cost of manufacturing the product sold in the United States, plus amounts for selling, general, and administrative expenses, interest expenses, U.S. packing expenses, U.S. credit expenses, and profit made on sales of foreign like merchandise in the home market. We deducted an amount for home market credit expense in order to compare CV to the U.S. sale.

## Preliminary Results of the Review

For Camesa, based on adverse facts available, and for Cablesa, based on our comparison of CV and EP, we preliminarily determine that the following weighted-average dumping margins exist:

| Exporter/manufacturer | Weighted- <br> average <br> margin per- <br> centage |
| :--- | ---: |
| Aceros Camesa, S.A. de C.V. .. | 111.68 |
| Cablesa, S.A. de C.V. ............ | 0.00 |

The Department will disclose its calculations within 5 business days of the date of publication of this notice. Any interested party may request a hearing within 30 days of publication. Pursuant to 19 CFR § $351.310(\mathrm{~d})$, any hearing, if requested, will be held 37 days after the publication of this notice, or the first workday thereafter.
Interested parties may submit case briefs within 30 days of the date of publication of this notice. Rebuttal briefs, which must be limited to issues raised in the case briefs, may be filed not later than 35 days after the date of publication. The Department will publish a notice of final results of this administrative review, which will include the results of its analysis of issues raised in any such comments, not later than 120 days after the date of publication of this notice.

Upon issuance of the final results of review, the Department shall determine, and the Customs Service shall assess, antidumping duties on all appropriate entries. Upon completion of this review, the Department will issue appraisement
instructions directly to the Customs Service.

Furthermore, the following deposit rates will be effective upon publication of the final results of these reviews for all shipments of steel wire rope products from Mexico entered, or withdrawn from warehouse, for consumption on or after the publication date, as provided for by section 751(a)(2)(c) of the Act: (1) The cash deposit rate for the reviewed companies will be the rates established in the final results of these reviews; (2) For merchandise exported by manufacturers or exporters not covered in these reviews but covered in the original investigation of sales at LTFV or a previous review, the cash deposit will continue to be the company-specific rate published for the most recent period; (3) If the exporter is not a firm covered in this or a previous review, or the original LTFV investigation, but the manufacturer is, the cash deposit rate will be the rate established for the most recent period for the manufacturer of the merchandise; and (4) for all other producers and/or exporters of this merchandise, the cash deposit rate shall be 111.68 percent, the "all others" rate established in the LTFV investigation (58 FR 7531, February 8, 1993).
These deposit rates, when imposed, shall remain in effect until publication of the final results of the next administrative review. This notice also serves as a preliminary reminder to importers of their responsibility under $19 \mathrm{CFR} \S 351.402$ (f) to file a certificate regarding the reimbursement of antidumping duties prior to liquidation of the relevant entries during this review period. Failure to comply with this requirement could result in the Secretary's presumption that reimbursement of antidumping duties occurred and the subsequent assessment of double antidumping duties.

This administrative review and notice are issued and published in accordance with sections 751(a)(1) and (a)(2)(B) of the Act (19 USC 1675(a)) and 19 CFR §§ 351.213-14.

Dated: March 30, 2000.
Robert S. LaRussa,
Assistant Secretary for Import Administration.
[FR Doc. 00-8700 Filed 4-6-00; 8:45 am]
BILLING CODE 3510-DS-P

## DEPARTMENT OF COMMERCE

## International Trade Administration

## [A-122-822]

## Corrosion-Resistant Carbon Steel Flat Products From Canada; Preliminary Results of Full Sunset Review of Antidumping Duty Order

AGENCY: Import Administration, International Trade Administration, Department of Commerce.
ACTION: Notice of preliminary results of full sunset review: Corrosion-resistant carbon steel flat products from Canada.
summary: On September 1, 1999, the Department of Commerce ("the Department'") initiated a sunset review of the antidumping duty order on corrosion-resistant carbon steel flat products from Canada (64 FR 47767) pursuant to section 751(c) of the Tariff Act of 1930, as amended ("the Act"). On the basis of a notice of intent to participate and an adequate substantive response filed on behalf of domestic interested parties and inadequate response (in this case, because exports of the respondent account for less than the threshold amount of exports (i.e., 50 percent)), the Department determined to conduct an expedited review. However, upon reconsideration of our initial adequacy determination, the Department determines that it is appropriate in this case to conduct a full review. As a result of this review, the Department preliminarily finds that revocation of the antidumping duty order would likely lead to continuation or recurrence of dumping at the levels indicated in the Preliminary Results of Review section of this notice.

## effective date: April 7, 2000.

## FOR FURTHER INFORMATION CONTACT:

Kathryn B. McCormick or Melissa G. Skinner, Office of Policy for Import Administration, International Trade Administration, U.S. Department of Commerce, 14th Street and Constitution Avenue, NW, Washington, DC 20230; telephone: (202) 482-1930 or (202) 4821560, respectively.

## SUPPLEMENTARY INFORMATION:

## Statute and Regulations

Unless otherwise indicated, all citations to the Act are references to the provisions effective January 1, 1995, the effective date of the amendments made to the Act by the Uruguay Round Agreements Act ("URAA"). In addition, unless otherwise indicated, all citations to the Department regulations are to 19 CFR Part 351 (1999). Guidance on methodological or analytical issues
relevant to the Department's conduct of sunset reviews is set forth in the Department's Policy Bulletin 98.3Policies Regarding the Conduct of Fiveyear ('Sunset") Reviews of Antidumping and Countervailing Duty Orders; Policy Bulletin, 63 FR 18871 (April 16, 1998) ("Sunset Policy Bulletin').

## Background

On September 1, 1999, the Department initiated a sunset review of the antidumping duty order on cut-tolength carbon steel plate from Canada (64 FR 47767), pursuant to section 751(c) of the Act. The Department received a notice of intent to participate on behalf of the Bethlehem Steel Corporation and U.S. Steel Corporation a unit of USX Corporation, Ispat Inlad, Inc., and LTV Steel Company (collectively, "domestic interested parties'), within the applicable deadline (September 15, 1999) specified in section 351.218(d)(1)(i) of the Sunset Regulations.

On September 24, 1999, we received a request for an extension to file rebuttal comments from domestic interested parties. ${ }^{1}$ Pursuant to 19 CFR $351.302(\mathrm{~b})$, the Department extended the deadline for all participants eligible to file rebuttal comments until October 15, 1999. ${ }^{2}$ On October 1, 1999, we received a complete substantive response from domestic interested parties, within the 30-day deadline specified in the Sunset Regulations under section
351.218(d)(3)(i). On October 1, 1999, Dofasco Inc. ("Dofasco") and Sorveco, Inc. ("Soreveco") in separate submissions, notified the Department of their intend to participate in this review as respondent interested parties.
Domestic interested parties claimed interested-party status under section 771(9)(C) of the Act, as U.S. producers of a domestic like product; Dofasco and Sorevco are interested parties pursuant to section 771(9)(A) of the Act, as foreign producers and exporters of subject merchandise.

All interested parties claim that they have been involved in this proceeding since its inception. Domestic interested parties state that they have participated

[^16]in the investigation, all five administrative reviews, and all related appeals (see October 1, 1999, Substantive Response of domestic interested parties at 4). Likewise, Dofasco and Sorevco state that they participated as respondent parties in the original investigation, and have participated in each subsequent administrative review (see October 1, 1999, Substantive Responses of Dofasco at 3 and Sorevco at 2). Sorevco notes that, in the original investigation, the Department "collapsed" Sorevco with Dofasco Inc., another Canadian producer with a fifty percent ownership interest in Sorevco (see October 1, 1999, Substantive Response of Sorevco at 2). Further the Department has continued to "collapse" the two companies in each administrative review, and in the Department's notices, "Dofasco" incorporates both Dofasco and Sorevco. Id. However, the companies are represented by separate legal counsel. Id.

On October 15, 1999, we received rebuttal comments from domestic interested parties and Dofasco. On October 20, 1999, pursuant to 19 CFR 351.218 (e)(1)(ii)(A), the Department determined to conduct an expedited (120-day) sunset review of this order. ${ }^{3}$ On December 9, 1999, we received comments from Dofasco on the adequacy and appropriateness of an expedited sunset review concerning the subject order. Based on the comments received from Dofasco, we have now determined that it is appropriate to conduct a full review in this case.
In accordance with section 751(c)(5)(C)(v) of the Act, the Department may treat a review as extraordinarily complicated if it is a review of a transition order (i.e., an order in effect on January 1, 1995). This review concerns a transition order within the meaning of section 751(c)(6)(ii) of the Act. Accordingly, on December 22, 1999, the Department determined that the sunset review of cut-to-length carbon steel flat plate is extraordinarily complicated, and extended the time limit for completion of the final results of this review until not later than March 29, 2000, in accordance with section 751(c)(5)(B) of the Act. ${ }^{4}$
${ }^{3}$ See October 20, 1999, Memorandum for Jeffrey A. May, Re: Certain Cut-to-Length Carbon Steel Flat Plate from Canada: Adequacy of Respondent Interested Party Response to the Notice of Initiation.
${ }^{4}$ See Extension of Time Limit for Final Results of Expedited Five-Year Reviews, 64 FR 71726 (December 22, 1999).

## Scope of Review

These products include flat-rolled carbon steel products, of rectangular shape, either clad, plated, or coated with corrosion-resistant metals such as zinc, aluminum, or zinc-, aluminum-, nickel, or iron-based alloys, whether or not corrugated or painted, varnished or coated with plastics or other nonmetallic substances in addition to the metallic coating, in coils (whether or not in successively superimposed layers) and of a width of 0.5 inch or greater, or in straight lengths which, if of a thickness less than 4.75 millimeters, are of a width of 0.5 inch or greater and which measures at least 10 times the thickness or if of a thickness of 4.75 millimeters or more are of a width which exceeds 150 millimeters and measures at least twice the thickness, as currently classifiable in the Harmonized Tariff Schedule ("HTS') under item numbers: 7210.30.0030, 7210.30.0060, 7210.41.0000, 7210.49.0030, 7210.49.0090, 7210.61.0000, 7210.69.0000, 7210.70.6030, 7210.70.6060, 7210.70.6090, 7210.90.1000, 7210.90.6000, 7210.90.9000, 7212.20.0000, 7212.30.1030, 7212.30.1090, 7212.30.3000, 7212.30.5000, 7212.40.1000, 7212.40.5000, 7212.50.0000, 7212.60.0000, 7215.90.1000, 7215.90.5000, 7217.20.1500, 7217.30.1530, 7217.30.1560, 7217.90.1000, 7217.90.5030, 7217.90.5060, and 7217.90.5090.

Included in the scope are flat-rolled products of nonrectangular cross-section where such cross-section is achieved subsequent to the rolling process (i.e., products which have been "worked after rolling'"- for example, products which have been bevelled or rounded at the edges.

Excluded from the scope are flatrolled steel products either plated or coated with tin, lead, chromium, chromium oxides, both tin and lead ("terne plate"), or both chromium and chromium oxides ("tin-free steel"), whether or not painted, varnished or coated with plastics or other nonmetallic substances in addition to the metallic coating. Also excluded from the scope are certain clad stainless flatrolled products, which are three-layered corrosion-resistant carbon steel flatrolled products less than 4.75 millimeters in composite thickness that consist of a carbon steel flat-rolled product clad on both sides with stainless steel in a $20-60-20$ percent ratio.

## Analysis of Comments Received

All issues raised in the case and rebuttal briefs by parties to this sunset review are addressed in the "Issues and Decision Memorandum" ("Decision Memo'") from Jeffrey A. May, Director, Office of Policy, Import Administration, to Robert S. La Russa, Assistant Secretary for Import Administration, dated March 29, 2000, which is hereby adopted and incorporated by reference into this notice. The issues discussed in the attached Decision Memo include adequacy, the likelihood of continuation or recurrence of dumping, and the magnitude of the margin likely to prevail were the order revoked. Parties can find a complete discussion of all issues raised in this review and the corresponding recommendations in this public memorandum which is on file in the Central Records Unit, room B-099, of the main Commerce building.

In addition, a complete version of the Decision Memo can be accessed directly on the Web at www.ita.doc.gov/ import__admin/records/frn. The paper copy and electronic version of the Decision Memo are identical in content.

## Preliminary Results of Review:

We preliminarily determine that revocation of the antidumping duty order on corrosion-resistant carbon steel flat products from Canada would be likely to lead to continuation or recurrence of dumping at the following percentage weighted-average margins:

| Manufacturer/exporters | Margin (percent) |
| :---: | :---: |
| Dofasco, Inc | 11.71 |
| Stelco, Inc. | 22.70 |
| All Others ....... | 18.71 |

Any interested party may request a hearing within 30 days of publication of this notice in accordance with 19 CFR 351.310(c). Any hearing, if requested, will be held on May 17, 2000, in accordance with 19 CFR 351.310(d). Interested parties may submit case briefs no later than May 8, 2000, in accordance with 19 CFR 351.309(c)(1)(i). Rebuttal briefs, which must be limited to issues raised in the case briefs, may be filed not later than May 15, 2000. The Department will issue a notice of final results of this sunset review, which will include the results of its analysis of issues raised in any such comments, no later than July 27, 2000, in accordance with section 751(c)(5)(B) of the Act.

This five-year ("sunset") review and notice are in accordance with sections 751(c), 752, and 777(i)(1) of the Act.

Dated: March 29, 2000.
Joseph A. Spetrini,
Acting Assistant Secretary for Import Administration.
[FR Doc. 00-8688 Filed 4-6-00; 8:45 am] BILLING CODE 3510-DS-P

## DEPARTMENT OF COMMERCE

## International Trade Administration

[A-122-822, A-122-823]

## Certain Corrosion-Resistant Carbon Steel Flat Products and Certain Cut-toLength Carbon Steel Plate From Canada: Amended Final Results of Antidumping Duty Administrative Reviews and Determination Not To Revoke in Part

AGENCY: Import Administration, International Trade Administration, U.S. Department of Commerce.

ACTION: Notice of amended final results of the antidumping duty administrative review of certain corrosion-resistant carbon steel flat products and certain cut-to-length carbon steel plate from Canada and determination not to revoke in part.
SUMMARY: We are amending our final results of the 1997-98 administrative reviews of the antidumping duty orders on Certain Corrosion Resistant Carbon Steel Products and Certain Cut-toLength Carbon Steel Plate From Canada and Determination Not to Revoke in Part, published on February 24, 2000 (65 FR 9243), to reflect the correction of ministerial errors made in the model match and margin calculation in the final results for corrosion resistant carbon steel flat products. We are publishing this amendment to the final results in accordance with 19 CFR part 351 (1998).
effective date: March 30, 2000.
FOR FURTHER INFORMATION CONTACT: Elfi Blum (Stelco, Inc. (Stelco)) and Michael Strollo (Dofasco,Inc. and Sorevco, Inc., collectively Dofasco), Import Administration, International Trade Administration, U.S. Department of Commerce, 14th Street and Constitution Avenue, NW, Washington DC 20230; telephone (202) 482-0197 and (202) 482-5255, respectively.

## Applicable Statute

Unless otherwise stated, all citations to the statute are references to the provisions effective January 1, 1995, the effective date of the amendments made to the Tariff Act of 1930 (the Act) by the Uruguay Round Agreements Act (URAA). In addition, unless otherwise indicated, all citations to the

Department's regulations are to 19 CFR part 351 (1998).

## SUPPLEMENTARY INFORMATION:

## Background

On August 19, 1999, the Department of Commerce (the Department) published in the Federal Register (64 FR 45228) the preliminary results of its 1997-98 administrative reviews of the antidumping duty orders on certain corrosion-resistant carbon steel flat products and certain cut-to-length carbon steel plate from Canada. We published the final results of review on February 24, 2000 ( 65 FR 9243).

On February 28, 2000 and on March 6,2000 , we received timely allegations from petitioners (Bethlehem Steel Corporation, U.S. Steel Group (a unit of USX Corporation), Inland Steel Industries, Inc., AK Steel Corporation, LTV Steel Co., Inc. and National) that the Department made ministerial errors in the final results of reviews regarding Stelco and Dofasco, respectively. On March 6, 2000 we also received a timely allegation from Dofasco that the Department made clerical errors in the final results. On March 8, 2000 we received rebuttal comments from Dofasco.

## Scope of Review

The products covered by these administrative reviews constitute two separate "classes or kinds" of merchandise: (1) Certain corrosionresistant carbon steel flat products, and (2) certain cut-to-length carbon steel plate.
The first class or kind, certain corrosion-resistant steel, includes flatrolled carbon steel products, of rectangular shape, either clad, plated, or coated with corrosion-resistant metals such as zinc, aluminum, or zinc-, aluminum-, nickel- or iron-based alloys, whether or not corrugated or painted, varnished or coated with plastics or other nonmetallic substances in addition to the metallic coating, in coils (whether or not in successively superimposed layers) and of a width of 0.5 inch or greater, or in straight lengths which, if of a thickness less than 4.75 millimeters, are of a width of 0.5 inch or greater and which measures at least 10 times the thickness or if of a thickness of 4.75 millimeters or more are of a width which exceeds 150 millimeters and measures at least twice the thickness, as currently classifiable in the Harmonized Tariff Schedule (HTS) under item numbers 7210.30.0030, 7210.30.0060, 7210.41.0000,
7210.49.0030, 7210.49.0090, 7210.61.0000, 7210.69.0000, 7210.70.6030, 7210.70.6060,
7210.70.6090, 7210.90.1000, 7210.90.6000, 7210.90.9000, 7212.20.0000, 7212.30.1030, 7212.30.1090, 7212.30.3000, 7212.30.5000, 7212.40.1000, 7212.40.5000, 7212.50.0000, 7212.60.0000, 7215.90.1000, 7215.90.3000, 7215.90.5000, 7217.20.1500, 7217.30.1530, 7217.30.1560, 7217.90.1000, 7217.90.5030, 7217.90.5060, and 7217.90.5090. Included in this review are corrosion-resistant flat-rolled products of non-rectangular crosssection where such cross-section is achieved subsequent to the rolling process (i.e., products which have been "worked after rolling")-for example, products which have been beveled or rounded at the edges. Excluded from this review are flat-rolled steel products either plated or coated with tin, lead, chromium, chromium oxides, both tin and lead ("terne plate"), or both chromium and chromium oxides ("tinfree steel'"), whether or not painted, varnished or coated with plastics or other nonmetallic substances in addition to the metallic coating. Also excluded from this review are clad products in straight lengths of 0.1875 inch or more in composite thickness and of a width which exceeds 150 millimeters and measures at least twice the thickness. Also excluded from this review are certain clad stainless flatrolled products, which are three-layered corrosion-resistant carbon steel flatrolled products less than 4.75 millimeters in composite thickness that consist of a carbon steel flat-rolled product clad on both sides with stainless steel in a $20 \%-60 \%-20 \%$ ratio.

The second class or kind, certain cut-to-length plate, includes hot-rolled carbon steel universal mill plates (i.e., flat-rolled products rolled on four faces or in a closed box pass, of a width exceeding 150 millimeters but not exceeding 1,250 millimeters and of a thickness of not less than 4 millimeters, not in coils and without patterns in relief), of rectangular shape, neither clad, plated nor coated with metal, whether or not painted, varnished, or coated with plastics or other nonmetallic substances; and certain hotrolled carbon steel flat-rolled products in straight lengths, of rectangular shape, hot rolled, neither clad, plated, nor coated with metal, whether or not painted, varnished, or coated with plastics or other nonmetallic substances, 4.75 millimeters or more in thickness and of a width which exceeds 150 millimeters and measures at least twice the thickness, as currently classifiable in
the HTS under item numbers
7208.40.3030, 7208.40.3060, and
7208.51.0030, 7208.51.0045,
7208.51.0060, 7208.52.0000,
7208.53.0000, 7208.90.0000,
7210.70.3000, 7210.90.9000,
7211.13.0000, 7211.14.0030,
7211.14.0045, 7211.90.0000, 7212.40.1000, 7212.40.5000, 7212.50.0000. Included in this review are flat-rolled products of nonrectangular cross-section where such cross-section is achieved subsequent to the rolling process (i.e., products which have been "worked after rolling")-for example, products which have been beveled or rounded at the edges. Excluded from this review is grade X70 plate. Also excluded is cut-to-length carbon steel plate meeting the following criteria: (1) $100 \%$ dry steel plates, virgin steel, no scrap content (free of Cobalt-60 and other radioactive nuclides); (2) . 290 inches maximum thickness, plus 0.0, minus .030 inches; (3) 48.00 inch wide, plus .05, minus 0.0 inches; (4) 10 foot lengths, plus 0.5 , minus 0.0 inches; (5) flatness, plus/minus 0.5 inch over 10 feet; (6) AISI 1006; (7) tension leveled; (8) pickled and oiled; and (9) carbon content, 0.3 to 0.8 (maximum).
With respect to both classes or kinds, the HTS item numbers are provided for convenience and Customs purposes. The written description remains dispositive of the scope of these reviews.

## Amended Final Results

## Dofasco

On March 6, 2000, petitioners and Dofasco alleged that the Department made ministerial errors in calculating the final antidumping margin with respect to Dofasco, one of the respondents in the review of corrosionresistant carbon steel flat products from Canada.
Comment 1: Exclusion of sales under the arm's length test.
Petitioners argue that the Department did not exclude sales that failed the arm's length test from our model match program. Dofasco agrees with petitioners.
Department's Position: We agree with both petitioners and Dofasco that sales that failed the arm's length test were incorrectly included in our model match program and should have been excluded. Therefore, we have made the appropriate changes to the model match program to exclude these sales.

Comment 2: Credit expenses.
Petitioners allege that the Department erroneously calculated Dofasco's credit expenses. Dofasco agrees with
petitioners in this regard. For a further
discussion of this issue, please refer to the Memorandum to the File from Mike Strollo through Maureen Flannery: Analysis of Dofasco, Inc. and Sorevco, Inc. (Dofasco) for the amended final results of the fifth administrative review of corrosion-resistant carbon steel flat products from Canada, dated March 30, 2000.

Department's Position: We agree with both petitioners and Dofasco that we erroneously calculated credit expense and have made the relevant corrections to the programming language in the margin calculation program.

Comment 3: The Department miscalculated actual freight expenses when conducting the arm's length test.
Dofasco alleges that the Department tested for actual freight (ACTFRTH) to identify Dofasco's prepaid and charge transactions where ACTFRTH was not reported. However, Dofasco argued that ACTFRTH is never missing, but rather is reported as zero for such transactions. Thus, as a result, Dofasco alleges that movement expense (MOVEH) was not calculated correctly for these transactions. Petitioners did not comment on this issue.
Department's Position: We agree with Dofasco and have made the appropriate corrections to the programming language in the arm's length program.
Comment 4: The Department's arm's length test.
Dofasco argues that the Department improperly conducted the arm's length test by comparing the prices of the affiliated transactions to the prices of the unaffiliated transactions to the same customer instead of to the weightedaverage net price for each product sold to all unaffiliated customers. Dofasco contends that this was only possible since all of Dofasco's customers have since become unaffiliated during the extended review period. Petitioners did not comment on this issue.
Department's Position: We agree with Dofasco and have made the appropriate corrections to the programming language in the arm's length program.

Comment 5: The Department is not using the same home market sales dataset as submitted by Dofasco on February 3, 1999.
Dofasco argues that, although the Department is now using a file with the correct file name, and with the correct number of records, the original data submitted by Dofasco and Sorevco was processed prior to its use in these programs without any explanation by the Department. Dofasco concludes that as a result, the model match program was not run properly. As evidence of Dofasco's claim, it points to the following: (1) The log of the model
match program was sorted by SALEDTH instead of first by CONNUMH then by SALEDTH as Dofasco claims its data was sorted; (2) the number of home market models used to create the product concordance is 12,024 when Dofasco runs the data it submitted (i.e., the number of CONNUMH-MONTHH combinations in the home market sales data after the cost test has been performed as well as removing other unwanted sales) instead of 12,135 home market models that appeared in the log of the model match program; (3) there were differences in the number of pointers created by the model match program using Dofasco’s February 3, 1999 data; and (4) the product concordance from the output of the model match program demonstrates that the data used by the Department for the final results was different than that submitted by Dofasco in its February 3, 1999 supplemental response. Dofasco contends that, as further evidence that the Department has sorted the data it submitted on February 3, 1999 prior to its use in these programs, the margin calculation program generates 14,205 home market normal values whereas Dofasco claims its submission only generates 14,105 home market normal values. Petitioners did not comment on this issue.

Department's Position: We disagree with Dofasco. For the Final Results, the Department used the datasets Dofasco submitted in its February 3, 1999 submission. The fact that the data was sorted differently by the Department prior to its use in the program does not have an impact on the manner in which the model match program runs. In addition, Dofasco has admitted that the data it submitted on February 3, 1999 is in fact, the same home market data file which was used by the Department for the Final Results of review. Finally, we can not and do not know the exact contents of the model match program that Dofasco is running. This may account for the differences between the number of home market models, pointers, product concordance, and home market normal values in their program and ours. Therefore, as a result, we have not made any changes to the program or the data used by the Department to run the model match program.

Comment 6: The Department incorrectly calculated weighted-average production costs and performed the cost test by PRODUCTH.

Dofasco argues that the Department correctly recombined Dofasco's and Sorevco's production costs by PRODUCTH; however, the Department omitted certain steps in its recalculation
of the weighted-average production costs. Dofasco contends that the Department failed to eliminate duplicate records from Dofasco's and Sorevco's production costs, and that the Department should calculate a weighted average by production quantity. In addition, the Department erroneously conducted the cost test by PRODUCTH rather than CONNUMH. In each instance, Dofasco provided programming language to solve the identified problems. Petitioners did not comment on the issue.
Department's Position: We agree with Dofasco, in part. We agree that production costs were not weightaveraged, and we agree that we performed the cost test by PRODUCTH rather than CONNUMH; however, we disagree that the programming language that Dofasco submitted to rectify the alleged problems is appropriate. The language that Dofasco proposes fails to solve the problems identified. Dofasco states that we correctly recombined Dofasco's and Sorevco's costs by PRODUCT. Then, Dofasco claims that we should delete CONNUM from the model matching program at lines 191, 308 and 322. Following these and other changes, Dofasco claims that we should perform the cost test by CONNUMH rather than PRODUCTH. However, Dofasco has already claimed that we should eliminate references to CONNUM in earlier lines of code. These changes make it impossible to run the cost test by CONNUMH, as is the Department's standard practice. Therefore, in order to comply with the Department's standard practice of running the cost test by CONNUMH, we have determined that additional lines of code are needed in the model match program. See Memorandum to The File from Mike Strollo through Maureen Flannery: Analysis of Dofasco, Inc. and Sorevco, Inc. (Dofasco) for the amended final results of the fifth administrative review of corrosion-resistant carbon steel flat products from Canada, dated March 24, 2000. Therefore, for these final results of review, we have recalculated the weighted-average production costs for Dofasco and Sorevco and subsequently performed the cost test by CONNUM.

Comment 7: The Department failed to convert the recalculated CREDITU to U.S. dollars when the transaction was reported in Canadian dollars.
Dofasco argues that the Department failed to convert the recalculated CREDITU to U.S. dollars when the transaction was reported in Canadian dollars. Dofasco proposed programming language to rectify this problem.

Petitioners did not comment on this issue.

Department's Position: We agree with Dofasco and have made the appropriate corrections to the programming language in the margin calculation program.

Comment 8: A more fundamental error exists in the Department's recalculation of credit expenses.
Dofasco alleges that the Department made a more fundamental error in the calculation of its U.S. credit expenses. Dofasco contends that the Department must correct the methodology it used to recalculate these expenses.
Petitioners, however, argue that the comment submitted by Dofasco is unrelated to any ministerial error comments contained in petitioners' March 6, 2000 submission, and as such, does not constitute a reply pursuant to section 351.224(c)(3) of the Department's regulations. Instead, petitioners contend that this is simply an untimely submission of a new ministerial error comment pursuant to section 351.224(c)(1) of the Department's regulations and should not be considered by the Department.
Department's Position: We agree with petitioners that Dofasco's claim is not a rebuttal comment, but instead, an untimely submission of a new ministerial error comment. Therefore, in accordance with section $351.224(\mathrm{~d})$ of the Department's regulations, we have not considered this allegation for these amended final results.
As a result of the corrections made to the arm's length, model match, and margin calculation programs, the margin for corrosion-resistant carbon steel flat products from Canada for Dofasco has changed from 0.16 percent to 0.20 percent.

## Stelco

On February 28, 2000, petitioners alleged that the Department made ministerial errors in calculating the final antidumping duty margin with respect to Stelco, one of the respondents in the review of corrosion-resistant carbon steel flat products from Canada. Petitioners alleged that the Department made certain errors in its computer programming language for the model match and margin calculation programs, when implementing its adjustment to G\&A for Baycoat G\&A expenses in the cost of production (COP) and constructed value (CV) calculations. Petitioners argue that the Department should have renamed the G\&A variable when making the Baycoat adjustment, to avoid distortion of the value of Stelco's G\&A.

We agree with petitioners that we incorrectly calculated the revised G\&A expenses for Stelco by not renaming the G\&A variable in our COP and CV calculations after adjusting for Baycoat's G\&A expenses. We have made the pertinent corrections in the programming language of our model match and margin calculation programs, and renamed the respective variables to RGNA and RGNACV.

As a result of these corrections, the margin for corrosion-resistant carbon steel flat products from Canada for Stelco has changed from 0.68 percent to 4.24 percent.

## Amended Final Results of Review

Upon review of the submitted allegations, the Department has determined that the following margins exist for the period August 1, 1997, through July 31, 1998 :

| Manufacturer/exporter | Margin (percent) |
| :---: | :---: |
| Corrosion Resistant Steel: |  |
| CCC ... | 1.01 |
| Dofasco | 0.20 |
| National | 5.65 |
| Stelco ...... | 4.24 |
| Cut-to-Length Plate: |  |
| MRM ............... | 0.00 |
| Stelco ......................... | 0.00 |

The Department will determine, and the U.S. Customs Service shall assess, antidumping duties on all appropriate entries. For assessment purposes, we have calculated importer-specific ad valorem duty assessment rates for the merchandise based on the ratio of the total amount of antidumping duties calculated for the examined sales to the total quantity of sales examined. The Department will issue appraisement instructions directly to the Customs Service.

Furthermore, the following deposit requirements will be effective upon publication of these amended final results for all shipments of the subject merchandise entered, or withdrawn from warehouse, for consumption on or after the publication date as provided by section 751(a)(1) of the Act: (1) The cash deposit rate for each reviewed company will be the rates stated above (except that no deposit will be required for firms with zero or de minimis margins, i.e., margins less than 0.5 percent); (2) for exporters not covered in this review, but covered in the less-than-fair-value (LTFV) investigation or a previous review, the cash deposit rate will continue to be the company-specific rate published for the most recent period; (3) if the exporter is not a firm covered in this review, a previous review, or the
original LTFV investigation, but the manufacturer is, the cash deposit rate will be the rate established for the most recent period for the manufacturer of the merchandise; and (4) the cash deposit rate for all other manufacturers or exporters will continue to be the "all others" rates established in the LTFV investigations, which were 18.71 percent for corrosion-resistant steel products and 61.88 percent for plate (see Amended Final Determination of Sales at Less than Fair Value and AntiDumping Orders: Certain Corrosion Resistant Carbon Steel Flat Products and Certain Cut-to-Length Carbon Steel Plate from Canada, 60 FR 49582 (September 26, 1995)). These deposit requirements, when imposed, shall remain in effect until publication of the final results of the next administrative reviews.
These administrative reviews and this notice are in accordance with section 751(a)(1) of the Act (19 U.S.C. 1675(a)(1) and 19 CFR 351.213 and 19 CFR 351.221(b)(5).

Dated: March 30, 2000.
Robert S. LaRussa,
Assistant Secretary for Import Administration.
[FR Doc. 00-8699 Filed 4-6-00; 8:45 am]
BILLING CODE 3510-DS-P

## DEPARTMENT OF COMMERCE

## International Trade Administration

[A-122-823]

## Cut-to-Length Carbon Steel Plate From Canada; Preliminary Results of Full Sunset Review of Antidumping Duty Order

AGENCY: Import Administration, International Trade Administration, Department of Commerce.
ACTION: Notice of preliminary results of full sunset review: Cut-to-length carbon steel plate from Canada.
summary: On September 1, 1999, the Department of Commerce ("the Department") initiated a sunset review of the antidumping duty order on cut-to-length carbon steel plate from Canada (64 FR 47767) pursuant to section 751(c) of the Tariff Act of 1930, as amended ("the Act"). On the basis of a notice of intent to participate and an adequate substantive response filed on behalf of domestic interested parties and inadequate response from respondent interested parties (in this case, because exports of the respondent account for less than the threshold amount of exports (i.e. 50 percent)), the Department determined to conduct an
expedited review. However, upon reconsideration of initial adequacy determination, the Department determines that it is appropriate in this case to conduct a full review. As a result of this review, the Department preliminarily finds that revocation of the antidumping duty order would likely lead to continuation or recurrence of dumping at the levels indicated in the Preliminary Results of Review section of this notice.
EFFECTIVE DATE: April 7, 2000.

## FOR FURTHER INFORMATION CONTACT:

Kathryn B. McCormick or Melissa G. Skinner, Office of Policy for Import Administration, International Trade Administration, U.S. Department of Commerce, 14th Street and Constitution Avenue, NW, Washington, D.C. 20230;
telephone: (202) 482-1930 or (202) 4821560, respectively.

## SUPPLEMENTARY INFORMATION:

## Statute and Regulations

Unless otherwise indicated, all citations to the Act are references to the provisions effective January 1, 1995, the effective date of the amendments made to the Act by the Uruguay Round Agreements Act ("URAA"). In addition, unless otherwise indicated, all citations to the Department regulations are to 19 CFR Part 351 (1999). Guidance on methodological or analytical issues relevant to the Department's conduct of sunset reviews is set forth in the Department's Policy Bulletin 98.3Policies Regarding the Conduct of Fiveyear ('Sunset") Reviews of Antidumping and Countervailing Duty Orders; Policy Bulletin, 63 FR 18871 (April 16, 1998) ("Sunset Policy Bulletin").

## Background

On September 1, 1999, the Department initiated a sunset review of the antidumping duty order on cut-tolength carbon steel plate from Canada (64 FR 47767), pursuant to section 751(c) of the Act. The Department received a notice of intent to participate on behalf of the Bethlehem Steel Corporation and U.S. Steel Corporation, a unit of USX Corporation ("domestic interested parties"), within the applicable deadline (September 15, 1999) specified in section
351.218(d)(1)(i) of the Sunset Regulations. On October 1, 1999, Stelco Inc. ("Stelco") notified the Department of its intent to participate in this review as a respondent interested party. Domestic interested parties claimed interested-party status under section 771(9)(C) of the Act, as U.S. producers of a domestic like product; Stelco is an
interested party pursuant to section 771(9)(A) of the Act, as a foreign producer and exporter of subject merchandise.

On September 24, 1999, we received a request for an extension to file rebuttal comments from domestic interested parties. ${ }^{1}$ Pursuant to 19 CFR $351.302(b)$, the Department extended the deadline for all participants eligible to file rebuttal comments until October 15, 1999. ${ }^{2}$ On October 1, 1999, we received a complete substantive response from domestic interested parties, within the 30-day deadline specified in the Sunset Regulations under section 351.218(d)(3)(i), and a complete substantive response from Stelco. On October 15, 1999, we received rebuttal comments from domestic and respondent interested parties. On October 20, 1999, pursuant to 19 CFR 351.218(e)(1)(ii)(A), the Department determined to an conduct an expedited (120-day) sunset review of this order. ${ }^{3}$

Domestic interested parties and Stelco claim that they have been involved in this proceeding since its inception. Domestic interested parties state that they have participated in the investigation, all five administrative reviews, and all related appeals (see October 1, 1999, Substantive Response of domestic interested parties at 4). Likewise, Stelco states that it was a respondent party in the original investigation, and has participated in each subsequent administrative review (see October 1, 1999, Substantive Response of Stelco at 3).

On November 10, 1999, we received comments from the Government of Canada and Stelco on the adequacy and appropriateness of an expedited sunset review concerning the subject order.
Based on the comments we've received from Stelco, we have now determined that it is appropriate to conduct a full review in this case.

In accordance with section 751(c)(5)(C)(v) of the Act, the Department may treat a review as extraordinarily complicated if it is a review of a transition order (i.e., an

[^17]order in effect on January 1, 1995). This review concerns a transition order within the meaning of section 751(c)(6)(ii) of the Act. Accordingly, on December 22, 1999, the Department determined that the sunset review of cut-to-length carbon steel flat plate is extraordinarily complicated, and extended the time limit for completion of the final results of this review until not later than March 29, 2000, in accordance with section 751(c)(5)(B) of the Act. ${ }^{4}$

## Scope of Review

These products include hot-rolled carbon steel universal mill plates (i.e., flat-rolled products rolled on four faces or in a closed box pass, of a width exceeding 150 millimeters but not exceeding 1,250 millimeters and of a thickness of not less than 4 millimeters, not in coils and without patterns in relief), of rectangular shape, neither clad, plated, nor coated with metal, whether or not painted, varnished, or coated with plastics or other nonmetallic substances; and certain hotrolled carbon steel flat-rolled products in straight lengths, of rectangular shape, hot rolled, neither clad, plated, nor coated with metal, whether or not painted, varnished, or coated with plastics or other nonmetallic substances, 4.75 millimeters or more in thickness and of a width which exceeds 150 millimeters and measures at least twice the thickness, as currently classifiable in the Harmonized Tariff Schedule ("HTS") under item numbers: 7208.40.3030, 7208.40.3060,
7208.51.5030, 7208.51.0045,
7208.51.0060, 7208.52.0000,
7208.53.0000, 7208.90.0000,
7210.70.3000, 7210.90.9000,
7211.13.0000, 7211.14.0030,
7211.14.0045, 7211.90.0000,
7212.40.1000, 7212.40.5000, and 7212.50.0000.

Included in this order are flat-rolled products of non-rectangular crosssection where such cross-section is achieved subsequent to the rolling process (i.e., products which have been "worked after rolling")-for example, products which have been beveled or rounded at the edges.
Excluded from this order is grade $\mathrm{X}-$ 70 plate. Also excluded is cut-to-length carbon steel plate meeting the following criteria: (1) 100 percent dry steel plates, virgin steel, no scrap content (free of Cobalt-60 and other radioactive nuclides); (2) 0.290 inches maximum thickness, plus 0.0 , minus 0.030 inches;

[^18](3) 48.00 inch wide, plus 0.05 , minus 0.0 inches; (4) 10 foot lengths, plus 0.5 , minus 0.0 inches; (5) flatness, plus/ minus 0.5 inch over 10 feet; (6) AISI 1006; (7) tension leveled; (8) pickled and oiled; and (9) carbon content, 0.3 to 0.8 (maximum). On February 28, 1996, the Department revoked the order with respect to certain cut-to-length carbon steel plate free of cobalt-60 and other radioactive nuclides; and with certain dimensions and other characteristics. ${ }^{5}$ On February 12, 1999, the Department revoked the order with respect certain cut-to-length carbon steel plate free of cobalt-60 and other radioactive nuclides; and with certain dimensions and other characteristics. ${ }^{6}$ In addition, there has been one circumvention inquiry initiated with respect to imports of boron-added grader blade and draft key steel. ${ }^{7}$ These HTS item numbers are provided for convenience and customs purposes. The written description remains dispositive.

## Analysis of Comments Received

All issues raised in the case and rebuttal briefs by parties to this sunset review are addressed in the "Issues and Decision Memorandum" ("Decision Memo'") from Jeffrey A. May, Director, Office of Policy, Import Administration, to Robert S. La Russa, Assistant Secretary for Import Administration, dated March 29, 2000, which is hereby adopted by this notice. The issues discussed in the attached Decision Memo include adequacy, the likelihood of continuation or recurrence of dumping, and the magnitude of the margin likely to prevail were the order revoked. Parties can find a complete discussion of all issues raised in this review and the corresponding recommendations in this public memorandum which is on file in the Central Records Unit, room B-099, of the main Commerce building.
In addition, a complete version of the Decision Memo can be accessed directly on the Web at www.ita.doc.gov/ import__admin/records/frn. The paper copy and electronic version of the Decision Memo are identical in content.

[^19]
## Preliminary Results of Review

We preliminarily determine that revocation of the antidumping duty order on cut-to-length carbon steel plate from Canada would be likely to lead to continuation or recurrence of dumping at the following percentage weightedaverage margins:

| Manufacturer/exporters | Margin <br> (percent) |
| :--- | ---: |
| Stelco, Inc ................................................................ | 68.70 |
| All Others ........ |  |

Any interested party may request a hearing within 30 days of publication of this notice in accordance with 19 CFR 351.310(c). Any hearing, if requested, will be held on May 17, 2000, in accordance with 19 CFR 351.310(d). Interested parties may submit case briefs no later than May 8, 2000, in accordance with 19 CFR 351.309(c)(1)(i). Rebuttal briefs, which must be limited to issues raised in the case briefs, may be filed not later than May 15, 2000. The Department will issue a notice of final results of this sunset review, which will include the results of its analysis of issues raised in any such comments, no later than July 27, 2000, in accordance with section 751(c)(5)(B) of the Act.

This five-year ("sunset") review and notice are in accordance with sections 751(c), 752, and 777(i)(1) of the Act.

Dated: March 29, 2000.
Joseph A. Spetrini,
Acting Assistant Secretary for Import Administration.
[FR Doc. 00-8689 Filed 4-6-00; 8:45 am] BILLING CODE 3510-DS-P

## DEPARTMENT OF COMMERCE

## International Trade Administration

 [A-423-805]Cut-to-Length Carbon Steel Plate From Belgium; Final Results of Expedited Sunset Review of Antidumping Duty Order

AGENCY: Import Administration, International Trade Administration, Department of Commerce.
ACTION: Notice of final results of expedited sunset review: Cut-to-length carbon steel plate from Belgium.

SUMMARY: On September 1, 1999, the Department of Commerce ("the Department'") initiated a sunset review of the antidumping duty order on cut-to-length carbon steel plate from Belgium (64 FR 47767) pursuant to section 751(c) of the Tariff Act of 1930, as amended ("the Act"). On the basis of
a notice of intent to participate and an adequate substantive response filed on behalf of domestic interested parties and inadequate response from respondent interested parties, the Department determined to conduct an expedited review. As a result of this review, the Department finds that revocation of the antidumping duty order would likely lead to continuation or recurrence of dumping at the levels indicated in the Final Results of Review section of this notice.
effective date: April 7, 2000.

## FOR FURTHER INFORMATION CONTACT:

Kathryn B. McCormick or Melissa G. Skinner, Office of Policy for Import Administration, International Trade Administration, U.S. Department of Commerce, 14th Street and Constitution Avenue, NW, Washington, DC 20230; telephone: (202) 482-1930 or (202) 4821560, respectively.

## SUPPLEMENTARY INFORMATION:

## Statute and Regulations

Unless otherwise indicated, all citations to the Act are references to the provisions effective January 1, 1995, the effective date of the amendments made to the Act by the Uruguay Round Agreements Act ("URAA"). In addition, unless otherwise indicated, all citations to the Department regulations are to 19 CFR Part 351 (1999). Guidance on methodological or analytical issues relevant to the Department's conduct of sunset reviews is set forth in the Department's Policy Bulletin 98.3Policies Regarding the Conduct of Fiveyear ('Sunset") Reviews of Antidumping and Countervailing Duty Orders; Policy Bulletin, 63 FR 18871 (April 16, 1998) ("Sunset Policy Bulletin").

## Background

On September 1, 1999, the Department initiated a sunset review of the antidumping duty order on cut-tolength carbon steel plate from Belgium ( 64 FR 47767), pursuant to section 751(c) of the Act. The Department received a notice of intent to participate on behalf of the Bethlehem Steel Corporation and U.S. Steel Corporation, a unit of USX Corporation ("domestic interested parties"), within the applicable deadline (September 15, 1999) specified in section 351.218(d)(1)(i) of the Sunset Regulations. Domestic interested parties claimed interested-party status under section 771(9)(C) of the Act, as U.S. producers of a domestic like product.

On September 20, 1999, we received a request for an extension to file rebuttal comments from domestic interested
parties. ${ }^{1}$ Pursuant to 19 CFR 351.302(b)(1999), the Department extended the deadline for all participants eligible to file rebuttal comments until October 15, 1999. ${ }^{2}$

On October 1, 1999, we received a complete substantive response from domestic interested parties, within the 30-day deadline specified in the Sunset Regulations under section 351.218(d)(3)(i). Respondent interested parties Duferco La Loviere ("Duferco") and Fabrique de Fer de Charleroi ("FAFER"), each submitted incomplete responses on October 1, 1999.
Domestic interested parties assert that at least one of them has been involved in this proceeding since the petition was filed, and has participated in each subsequent segment of the case (see October 1, 1999, Substantive Response of domestic interested parties at 3). On October 15, 1999, the domestic interested parties submitted a letter to the Department requesting that the Department undertake an expedited review in this case. They assert that FAFER's October 1, 1999, letter to the Department is wholly inadequate as it fails to meet necessary procedural and substantive requirements of a response to a notice of initiation (see October 15, 1999, Letter from domestic interested parties at 2). Further, domestic interested parties urge the Department to deem FAFER's failure to file a complete response as a waiver of participation in this review. Id.
On October 21, 1999, pursuant to 19 CFR 351.218(e)(1)(ii)(A), the Department determined to conduct an expedited (120-day) sunset review of this order. ${ }^{3}$

In accordance with section 751(c)(5)(C)(v) of the Act, the Department may treat a review as extraordinarily complicated if it is a review of a transition order (i.e., an order in effect on January 1, 1995). This review concerns a transition order within the meaning of section 751(c)(6)(ii) of the Act. Accordingly, on

[^20]December 22, 1999, the Department determined that the sunset review of cut-to-length carbon steel plate from Belgium is extraordinarily complicated, and extended the time limit for completion of the final results of this review until not later than March 29, 2000, in accordance with section 751(c)(5)(B) of the Act. ${ }^{4}$

## Scope of Review

The scope of this order includes hotrolled carbon steel universal mill plates (i.e., flat-rolled products rolled on four faces or in a closed box pass, of a width exceeding 150 millimeters but not exceeding 1,250 millimeters and of a thickness of not less than 4 millimeters, not in coils and without patterns in relief), of rectangular shape, neither clad, plated, nor coated with metal, whether or not painted, varnished, or coated with plastics or other nonmetallic substances; and certain hotrolled carbon steel flat-rolled products in straight lengths, of rectangular shape, hot rolled, neither clad, plated, nor coated with metal, whether or not painted, varnished, or coated with plastics or other nonmetallic substances, 4.75 millimeters or more in thickness and of a width which exceeds 150 millimeters and measures at least twice the thickness, as currently classifiable in the Harmonized Tariff Schedule ("HTS") under item numbers: 7208.40.3030, 7208.40.3060, 7208.51.0030, 7208.51.0045, 7208.51.0060, 7208.52.0000, 7208.53.0000, 7208.90.0000, 7210.70.3000, 7210.90.9000, 7211.13.0000, 7211.14.0030, 7211.14.0045, 7211.90.0000, 7212.40.1000, 7212.40.5000, and 7212.50.0000. Included in this order are flat-rolled products of non-rectangular cross-section where such cross-section is achieved subsequent to the rolling process (i.e., products which have been "worked after rolling")-for example, products which have been beveled or rounded at the edges. Excluded from this order is grade $\mathrm{X}-70$ plate. These HTS item numbers are provided for convenience and customs purposes. The written description remains dispositive.

## Analysis of Comments Received

All issues raised in the case and rebuttal briefs by parties to this sunset review are addressed in the "Issues and Decision Memorandum" ("Decision Memo'") from Jeffrey A. May, Director, Office of Policy, Import Administration, to Robert S. La Russa, Assistant

[^21]Secretary for Import Administration, dated March 29, 2000, which is hereby adopted by this notice. The issues discussed in the attached Decision Memo include the likelihood of continuation or recurrence of dumping and the magnitude of the margin likely to prevail were the order revoked. Parties can find a complete discussion of all issues raised in this review and the corresponding recommendations in this public memorandum which is on file in the Central Records Unit, room B-099, of the main Commerce building.

In addition, a complete version of the Decision Memo can be accessed directly on the Web at www.ita.doc.gov/ import__admin/records/frn. The paper copy and electronic version of the Decision Memo are identical in content.

## Final Results of Review

We determine that revocation of the antidumping duty order on cut-to-length carbon steel plate from Belgium would be likely to lead to continuation or recurrence of dumping at the following percentage weighted-average margins:

| Manufacturer/exporters | Margin (percent) |
| :---: | :---: |
| Forges de Clabeca, S.A | 6.78 |
| Fabrique de Fer de Cherleroi, <br> S.A $\qquad$ | 27.5 |
| All Others ............................ | 6.75 |

This notice also serves as the only reminder to parties subject to administrative protective orders ("APO") of their responsibility concerning the return or destruction of proprietary information disclosed under APO in accordance with 19 CFR 351.305 of the Department's regulations. Timely notification of the return or destruction of APO materials or conversion to judicial protective order is hereby requested. Failure to comply with the regulations and terms of an APO is a violation which is subject to sanction.

This five-year ("sunset") review and notice are in accordance with sections 751(c), 752, and 777(i)(1) of the Act.

Dated: March 29, 2000.

## Joseph A. Spetrini,

Acting Assistant Secretary for Import Administration.
[FR Doc. 00-8693 Filed 4-6-00; 8:45 am]
BILLING CODE 3510-DS-P

## DEPARTMENT OF COMMERCE

## International Trade Administration

[A-428-816]
Notice of Postponement of Preliminary Results of Antidumping Duty Administrative Reviews: Certain Cut-to-Length Carbon Steel Plate From Germany

AGENCY: Import Administration, International Trade Administration, Department of Commerce.
ACTION: Notice of postponement of preliminary results of antidumping duty administrative reviews.
effective date: April 7, 2000. FOR FURTHER INFORMATION CONTACT: Doreen Chen or Robert Bolling, Office IX, DAS Group III, Import Administration, International Trade Administration, U.S. Department of Commerce, 14th Street and Constitution Avenue NW, Washington, DC 20230; telephone (202) 482-0408 and (202) 482-3434, respectively.

Postponement of Preliminary Results: The Department of Commerce (the Department) is postponing the preliminary results in the antidumping administrative reviews of Certain Cut-to-Length Carbon Steel Plate from Germany. The deadline for issuing the preliminary results in these administrative reviews is now August 30, 2000.
On October 29, 1999, the Department initiated these administrative reviews, setting May 2, 2000 as the date for issuing the preliminary results of the review. See Initiation of Antidumping and Countervailing Duty Administrative Reviews and Requests for Revocation in Part Thursday, July 29, 1999 (63 FR 58009 and 64 FR 53318). On February 15, 2000, the Department issued Sections A-C of the Department's questionnaires to the respondent, Reiner Brach GmbH \& Co. KG. Because of the reasons stated in the memorandum from Edward Yang to Joseph A. Spetrini: Extension of Time Limit for the Administrative Reviews of Certain Cut-to-Length Carbon Steel Plate from Germany, April 3, 2000, we determine that it is not practicable to complete these reviews within the normal time frame and are therefore extending the time limit for these preliminary results of the administrative reviews of Certain Cut-to-Length Carbon Steel Plate from Germany by 120 days, in accordance with section 751(a)(3)(A) of the Tariff Act of 1930, as amended.
The date for issuing the preliminary results is moved from May 2, 2000 to August 30, 2000.

Dated: April 3, 2000.
Joseph A. Spetrini,
Deputy Assistant Secretary, AD/CVD Enforcement Group III.
[FR Doc. 00-8702 Filed 4-6-00; 8:45 am] BILLING CODE 3510-DS-P

DEPARTMENT OF COMMERCE
International Trade Administration
[A-428-821]
Notice of Court Decision and Suspension of Liquidation: Large Newspaper Printing Presses and Components Thereof, Whether Assembled or Unassembled, From Germany

AGENCY: Import Administration, International Trade Administration, Department of Commerce.
ACTION: Notice.
SUMMARY: On March 8, 2000, in Koenig \& Bauer-Albert AG, et al., v. United States, Consol. Court No. 96-10-02298, Slip Op. 00-25, a lawsuit challenging the Department of Commerce's final affirmative antidumping duty determination of large newspaper printing presses and components thereof, whether assembled or unassembled, from Germany, the Court of International Trade affirmed the Department of Commerce's remand determination and entered a judgement order. In its remand determination, the Department addressed issues of collapsing and cost-averaging relevant to producer/exporter MAN Roland Druckmaschinen AG and its whollyowned subsidiary MAN Plamag Druckmaschinen AG. As a result, the final antidumping duty rate for MAN Roland Druckmaschinen AG and MAN Plamag Druckmaschinen AG has increased from 30.72 percent to 39.53 percent ad valorem. This decision was not in harmony with the Department's original final determination.

Consistent with the decision of the Court of Appeals for the Federal Circuit in Timken Co. v. United States, 893 F.2d 337 (Fed. Cir. 1990), the Department of Commerce will direct the Customs Service to change the cash deposit rate being used in connection with the suspension of liquidation of the subject merchandise and liquidate entries of the subject merchandise during the period March 1, 1996 through August 31, 1997, at the amended rate, as appropriate, once there is a "final and conclusive" decision in this case.
EFFECTIVE DATE: April 7, 2000.

## FOR FURTHER INFORMATION CONTACT:

David Goldberger at (202) 482-4136 or

Irene Darzenta Tzafolias at (202) 4820922, Office of Antidumping/ Countervailing Duty Enforcement, Import Administration, International Trade Administration, U.S. Department of Commerce, 14th Street and Constitution Avenue, NW, Washington, DC 20230.

## SUPPLEMENTARY INFORMATION:

## Background

On July 23, 1996, the Department of Commerce (the Department) published notice of its final determination of less-than-fair-value (LTFV) investigation of large newspaper printing presses and components thereof, whether assembled or unassembled (LNPP), from Germany. See Notice of Final Determination of Sales at Less Than Fair Value: Large Newspaper Printing Presses and Components Thereof, Whether Assembled or Unassembled, from Germany, 61 FR 38166 (July 23, 1996) (LNPP Germany Final Determination). In the final determination of the LTFV investigation, the Department established a final dumping margin of 30.80 percent ad valorem for MAN Roland Druckmaschinen AG (MAN Roland) and All Others (except Koenig Bauer-Albert AG (KBA) for which a 46.40 percent margin was established based on adverse facts available). On September 4, 1996, the Department published an antidumping duty order correcting ministerial errors made in the final determination and instructing the Customs Service to collect cash deposits at the rate of 30.72 percent ad valorem for MAN Roland and All Others (except KBA as indicated above), on entries of the subject merchandise entered or withdrawn from warehouse on or after that date. See Notice of Antidumping Duty Order and Amended Final Determination of Sales at Less Than Fair Value: Large Newspaper Printing Presses and Components Thereof, Whether Assembled or Unassembled, from Germany, 61 FR 46623 (September 4, 1996).
Following publication of the Department's antidumping duty order, the respondent MAN Roland and the petitioner Goss Graphic System, Inc., filed a lawsuit with the Court of International Trade (CIT) challenging various aspects of the Department's final determination of the LTFV
investigation. In its first decision in this case on June 23, 1998, Koenig \& BauerAlbert AG, et al., v. United States, 15 F. Supp. 2d 834, 849-850, 854-855 (CIT 1998), Slip Op. 98-83 at 28-30, 40-43, the CIT issued an order remanding two issues to the Department. In its remand instructions, the Court ordered the

Department to reconsider its decision not to combine certain production costs for MAN Roland and its affiliate MAN Plamag Druckmaschinen AG (MAN Plamag), and granted the Department's request to recalculate MAN Roland's selling, general and administrative (SG\&A) expenses using an appropriate cost allocation ratio. In its final remand determination on September 17, 1998, the Department declined to compute a single, weighted-average cost for MAN Roland and Man Plamag because the companies failed to satisfy the fundamental condition for averaging costs-that the products manufactured at their facilities be sufficiently similar in physical characteristics, such that they could be considered identical for product comparison purposes. However, the Department recalculated MAN Roland's SG\&A expenses using an appropriate allocation ratio. See September 17, 1998, Final Results of Redetermination Pursuant to Court Remand (Redetermination 1) at 9-10, 13-14. As a result of our recalculations pursuant to Court remand, the antidumping margin for MAN Roland changed from 30.72 to 39.60 percent.
In a later decision on March 16, 1999, Koenig $\&$ Bauer-Albert AG, et al., v. United States, 44 F. Supp. 2d 280, 287288 (CIT 1999), Slip Op. 99-25 at 1618, the CIT affirmed the Department's recalculation of MAN Roland's SG\&A expenses, but did not affirm the Department's final remand results pertaining to the issue of combining certain production costs of MAN Roland and its affiliate. The CIT held that the Department did not address the threshold question of whether MAN Roland and MAN Plamag should be collapsed in order to properly determine whether their production costs should be averaged, and remanded the issue to the Department again for reconsideration and explanation consistent with its opinion. Upon remand, on August 10, 1999, the Department found that MAN Roland and MAN Plamag should have been collapsed as a single entity in performing its antidumping analysis in accordance with 19 CFR 351.401(f). Moreover, the Department determined that treating these affiliated producers as a single entity necessitated that the inputs transferred between them be valued at the cost of producing the input, and adjusted its CV calculations accordingly. Furthermore, in light of the identical merchandise requirement for production cost averaging purposes, the Department maintained its previous remand determination not to weightaverage the production costs of the two
affiliated companies. In addition, because MAN Plamag made no sales of subject merchandise to the United States during the period of investigation, the Department's decision to collapse MAN Roland and MAN Plamag did not require any changes to the sales side of the Department's original final margin analysis. However, in contrast to its original final determination, the Department applied the same margin, as amended based on the above-described cost adjustments, to both MAN Roland and MAN Plamag. See August 10, 1998, Final Results of Redetermination Pursuant to Court Remand (Redetermination 2) at 5-8. As a result of the adjustments made in Redetermination 2, the revised antidumping margin for both MAN Roland and MAN Plamag changed from 39.60 percent (margin calculated based on Redetermination 1) to 39.53 percent.

In sum, as a result of the two remands in this case, the final dumping rate for MAN Roland and its affiliate MAN Plamag has increased from 30.72 percent (the original final LTFV margin for MAN Roland) to 39.53 percent ad valorem. The rate for All Others changes accordingly.

## Suspension of Liquidation

In its decision in Timken Co. v. United States, 893 F.2d 337 (Fed. Cir. 1990) (Timken), the Court of Appeals for the Federal Circuit (CAFC) held that the Department must publish notice of a decision of the CIT or the CAFC which is not in harmony with the Department's determination. Publication of this notice fulfills this obligation. The CAFC also held that the Department must suspend liquidation of the subject merchandise until there is a "final and conclusive" decision on the case. Therefore, pursuant to Timken, the Department must suspend liquidation of the subject merchandise pending the expiration of the period to appeal the CIT's March 8, 2000 ruling, or if that ruling is appealed, pending a final decision by the CAFC. However, because entries of the subject merchandise already are being suspended pursuant to the antidumping duty order in effect, the Department need not order the Customs Service to suspend liquidation. Further, consistent with Timken, the Department will order the Customs Service to change the relevant cash deposit rates in the event that the CIT's ruling is not appealed or
the CAFC issues a final decision affirming the CIT's ruling.
Robert S. LaRussa,
Assistant Secretary for Import Administration.
[FR Doc. 00-8695 Filed 4-6-00; 8:45 am] BILLING CODE 3510-DS-P

## DEPARTMENT OF COMMERCE

## International Trade Administration

## [A-533-810]

## Stainless Steel Bar From India; Initiation of antidumping new shipper review

AGENCY: Import Administration, International Trade Administration, Department of Commerce.
ACTION: Notice of Initiation of Antidumping New Shipper Review.

SUMMARY: The Department of Commerce has received a request to conduct a new shipper review of the antidumping duty order on stainless steel bar from India.
In accordance with section 751(a)(2)(B) of the Tariff Act and 19 CFR 351.214(d), we are initiating this review.
effective date: April 7, 2000.
FOR FURTHER INFORMATION CONTACT:
Blanche Ziv or Rosa Jeong, Import
Administration, International Trade Administration, U.S. Department of Commerce, 14th Street and Constitution Avenue, N.W., Washington, D.C. 20230; telephone (202) 482-4207 or (202) 4823853, respectively.

## Applicable Statute and Regulations

Unless otherwise indicated, all citations to the Tariff Act of 1930, as amended ("the Act"), are references to the provisions effective January 1, 1995, the effective date of the amendments made to the Act by the Uruguay Round Agreements Act. In addition, all references to the Department of Commerce's ("the Department's") regulations are to 19 CFR Part 351 (April 1999).

## SUPPLEMENTARY INFORMATION:

## Background

On February 18, 2000, the Department received a request from Atlas Stainless Corporation ("Atlas"), pursuant to section 751(a)(2)(B) of the Act, and in accordance with 19 CFR 351.214(b), for a new shipper review of the antidumping duty order on stainless steel bar from India. This order has a February anniversary month. On March 27, 2000, pursuant to the Department's request, Atlas submitted supplemental information regarding the required
documentation pursuant to section 351.214(a)(2) of the Department's regulations. Accordingly, we are initiating a new shipper review for Atlas as requested. The period of review is February 1, 1998 through January 31, 1999.

## Initiation of Review

In accordance with 19 CFR 351.214(b)(2), Atlas provided certification that it did not export subject merchandise to the United States during the period of investigation; certification that, since the investigation was initiated, it has never been affiliated with any exporter or producer who exported the subject merchandise to the United States during the period of investigation, including those not individually examined during the investigation; documentation establishing: (i) The date on which its stainless steel bar was first entered, or withdrawn from warehouse, for consumption, or if the exporter or producer could not establish the date of first entry, the date on which it first shipped the subject merchandise for export to the United States; (ii) the volume of that and subsequent shipments; and (iii) the date of the first sale to an unaffiliated customer in the United States. Therefore, in accordance with section 751(a)(2)(B)(ii) of the Act and 19 CFR 351.214(d)(1), we are initiating a new shipper review of the antidumping duty order on stainless steel bar from India. We intend to issue the final results of this review not later than 180 days after the date of publication of this notice in the Federal Register. All provisions of 19 CFR 351.214 will apply to Atlas throughout the duration of this new shipper review.

We will instruct the Customs Service to allow, at the option of the importer, the posting of a bond or security in lieu of a cash deposit, until the completion of the review, for each entry of the merchandise exported by the above listed company, in accordance with 19 CFR 351.214(e). Interested parties must submit applications for disclosure under administrative protective orders in accordance with 19 CFR 351.305 and 351.306.

This initiation and this notice are in accordance with section 751(a) of the Act.
Dated: March 31, 2000.
Richard W. Moreland,
Deputy Assistant Secretary for Import Administration.
[FR Doc. 00-8701 Filed 4-6-00; 8:45 am] BILLING CODE 3510-DS-P

## DEPARTMENT OF COMMERCE

## International Trade Administration [A-580-811]

Notice of Preliminary Results of Antidumping Duty Administrative Review, Partial Rescission of Antidumping Duty Administrative Review and Intent To Revoke Antidumping Duty Order in Part: Steel Wire Rope From the Republic of Korea

AGENCY: Import Administration, International Trade Administration, Department of Commerce.
SUMMARY: In response to a request by the petitioner, the Committee of Domestic Steel Wire Rope \& Specialty Cable Manufacturers, the Department of Commerce (the Department) is conducting an administrative review of the antidumping duty order on steel wire rope from Korea. The review covers 14 manufacturers/exporters of the subject merchandise. The period of review is March 1, 1998, through February 28, 1999.

We have preliminarily found that, for certain producers/exporters, sales of subject merchandise have been made below normal value (NV). If these preliminary results are adopted in our final results of this administrative review, we will instruct the Customs Service to assess antidumping duties based on the difference between the export price (EP) and the NV. Also, if these preliminary results are adopted in our final results of this administrative review, we intend to revoke the antidumping duty order with respect to Kumho Wire Rope Manufacturing Company (Kumho), based on three years of sales at not less than NV. See Intent to Revoke section of this notice.
EFFECTIVE DATE: April 7, 2000.
FOR FURTHER INFORMATION CONTACT:
James Kemp, at (202) 482-1276, or Abdelali Elouaradia, at (202) 482-0498, Import Administration, International
Trade Administration, U.S. Department of Commerce, 14th Street and
Constitution Avenue, NW, Washington, DC 20230.

## SUPPLEMENTARY INFORMATION:

## The Applicable Statute and Regulations

Unless otherwise indicated, all citations to the statute are references to the provisions effective January 1, 1995, the effective date of the amendments made to the Tariff Act of 1930 (the Act) by the Uruguay Round Agreements Act. In addition, unless otherwise indicated, all citations to the Department's regulations are to the regulations codified at 19 CFR part 351 (1999).

## Case History

On March 9, 1999, the Department published a notice providing an opportunity to request an administrative review of this antidumping duty order for the period March 1, 1998, through February 28, 1999 (POR). See 64 FR 11439. On March 31, 1999, the petitioner requested an administrative review of Boo Kook Corporation (Boo Kook), Dae Heung Industrial Company (Dae Heung), Dae Kyung Metal (Dae Kyung), Dong Il Steel Manufacturing Company (Dong Il), Dong Young, Hanboo Wire Rope Inc. (Hanboo), Jinyang Wire Rope Inc. (Jinyang), Korea Sangsa Company (Korea Sangsa), Kumho, Kwangshin Rope, Myung Jin Company, Seo Hae Industrial (Seo Hae), Sungsan Special Steel Processing (Sungsan) and Yeonsin Metal (Yeonsin). On March 31, 1999, Kumho requested a review and revocation of the order with respect to its sales of subject merchandise. On April 22, 1999, we initiated an administrative review of all 14 companies. See 64 FR 23269.
In early May 1999, in response to our inquiry, the Department was advised by the U.S. Embassy in Seoul that Boo Kook, Hanboo, Kwangshin Rope, and Seo Hae were out of business. We determined, based on data obtained from the Customs Service, that these companies had not exported subject merchandise during the POR. Accordingly, we did not issue antidumping questionnaires to these companies. We issued antidumping questionnaires to the remaining ten respondents. See Partial Rescission section of this notice.
On June 11, 1999, we received a letter from Dae Kyung stating that it had not exported subject merchandise to the United States during the POR. However, Customs Service data indicated that the company had shipments of subject merchandise during the POR. See Facts Available section of this notice.
On June 21, 1999, we received a letter from Dae Heung stating that it did not export subject merchandise to the United States during the POR. See Partial Rescission section of this notice.

On June 23, 1999, the Department received a response to the antidumping questionnaire from Kumho. This was the only response filed within the original deadline for the questionnaire. However, on September 8, 1999, Jinyang requested permission to submit a response to the questionnaire. While acknowledging that the deadline for submission of a response had elapsed, Jinyang cited extenuating factors, namely that it had moved its offices and did not receive the questionnaire until

August 1999. The petitioners objected to Jinyang's request. However, in view of the extenuating factors cited by Jinyang, the fact that there was still sufficient time in the proceeding to conduct a proper review and the availability of personnel to examine Jinyang's data, the Department agreed to accept Jinyang's response. See Memorandum from Steven Presing and Jim Kemp to Bernard Carreau, dated October 7, 1999, and on file with the Department's Central Records Unit (CRU), room B099 of the main Department building. Jinyang filed its response on November 12, 1999
We issued supplemental questionnaires to both respondents, and received timely responses.

On November 2, 1999, we extended the deadline for issuance of the preliminary results until March 30, 2000. See Decision Memorandum from Bernard T. Carreau to Robert S. LaRussa, dated November 2, 1999, on file in the Department's CRU. See also 64 FR 61276.

We verified the information submitted by Kumho and Jinyang during the weeks of January 31, and February 7, 2000, in Pusan, Korea.

## Scope of Review

The product covered by this review is steel wire rope. Steel wire rope encompasses ropes, cables, and cordage of iron or carbon steel, other than stranded wire, not fitted with fittings or made up into articles, and not made up of brass-plated wire. Imports of these products are currently classifiable under the following Harmonized Tariff Schedule (HTSUS) subheadings: 7312.10.9030, 7312.10.9060, and 7312.10.9090. Excluded from this review is stainless steel wire rope, i.e., ropes, cables and cordage other than stranded wire, of stainless steel, not fitted with fittings or made up into articles, which is classifiable under HTSUS subheading 7312.10.6000. Although HTSUS subheadings are provided for convenience and the Customs Service purposes, the written description of the scope of this review is dispositive.

## Partial Rescission

As noted above, the Department has determined that Boo Kook, Hanboo, Kwangshin Rope and Seo Hae closed their operations prior to the POR, and we have confirmed that none of these companies had shipments of subject merchandise to the United States during the POR. Therefore, in accordance with section 351.213(d)(3) of the Department's regulations, we are rescinding our review with respect to

Boo Kook, Hanboo, Kwangshin Rope and Seo Hae. This decision is consistent with the Department's practice. See, e.g., Certain Welded Carbon Steel Pipe and Tube from Turkey: Final Results and Partial Rescission of Antidumping Administrative Review, 63 FR 35190, 35191 (June 29, 1998) and Certain Fresh Cut Flowers From Colombia; Final Results and Partial Rescission of Antidumping Duty Administrative Review, 62 FR 53287, 53288 (October 14, 1997).

We are also rescinding our review with respect to Dae Heung. Pursuant to the antidumping duty order on steel wire rope issued after the completion of the investigation, merchandise produced by Dae Heung and sold through Young Heung Iron \& Steel Co., Ltd. (YHC) is excluded from the order. See 58 FR 16397, 16397 (March 26, 1993). Dae Heung has stated on the record that it did not ship subject merchandise directly to the United States during the POR; rather, its production for export was sold through YHC. We have confirmed, based on Customs Service information, that Dae Heung had no shipments of subject merchandise during the POR.

## Facts Available

We preliminarily find, in accordance with section 776(a) of the Act, that the use of facts available is appropriate for Dong Il, Dong Young, Korea Sangsa, Myung Jin Company, Sungsan and Yeonsin, since they did not respond to our antidumping questionnaire. We confirmed that theses companies received, but failed to respond to, the Department's questionnaire. Since these companies have not cooperated in providing necessary information for our review, the use of facts available is appropriate.

We also find that the use of facts available is appropriate for Dae Kyung. Although the company responded to our response with a statement that it had no shipments during the POR, we requested additional information on September 28, 1999, because Customs Service data indicated that Dae Kyung did have shipments of subject merchandise. Dae Kyung responded on October 4, 1999, claiming that it only produced stainless steel aircraft cables (i.e. non-subject merchandise). To support this claim, Dae Kyung included sales documents with its letter and argued that the prices on the invoice for the entry in question indicate that the merchandise is stainless steel. However, the documentation does not conclusively establish that the sales were only for stainless products, and we can not infer from price alone that the
products were stainless. Because we found that this documentation was inconclusive, on November 3, 1999, and February 18, 2000, we sent two more letters to Dae Kyung requesting additional clarification. We received no response to either of these letters. Dae Kyung has failed, despite repeated requests, to provide additional support for its claim that it only sold non-subject merchandise during the POR. Thus, since we were unable to confirm that Dae Kyung shipped only stainless steel aircraft cables to the United States, and, as such, did not have entries of subject merchandise during the POR, we preliminarily find that the use of facts available is appropriate for Dae Kyung.
Section 776(a)(2)(B) of the Act requires the Department to resort to facts available if necessary information is not available on the record or when an interested party or any other person "fails to provide [requested] information by the deadlines for submission of the information or in the form and manner requested, subject to subsections (c)(1) and (e) of section 782." As provided in section 782(c)(1) of the Act, if an interested party "promptly after receiving a request from [the Department] for information, notifies [the Department] that such party is unable to submit the information requested in the requested form and manner," the Department may modify the requirements to avoid imposing an unreasonable burden on that party. Because Dong Il, Dong Young, Korea Sangsa, Myung Jin Company, Sungsan and Yeonsin did not provide any notification or information to the Department, and Dae Kyung did not address adequately the issue of its U.S. shipments, nor did it respond to our requests for additional clarification, they have failed to comply with section 782(c)(1) and (e) of the Act.
Accordingly, we find preliminarily, in accordance with section 776(a)(2)(B) of the Act, that the use of facts available is appropriate for Dong Il, Dong Young, Korea Sangsa, Myung Jin Company, Sungsan, Yeonsin and Dae Kyung.

Where the Department must resort to facts available because a respondent failed to cooperate to the best of its ability, section 776(b) of the Act authorizes the use of an inference adverse to the interests of that respondent in selecting from among the facts available. The failure of Dong Il, Dong Young, Korea Sangsa, Myung Jin Company, Sungsan and Yeonsin to respond to our antidumping questionnaire, and the failure of Dae Kyung to respond to subsequent requests for information, demonstrate that these companies have not acted to
the best of their abilities to comply with the Department's review. Accordingly, we have preliminarily determined that an adverse inference with respect to these companies is warranted.

Section 776(b) of the Act also authorizes the Department to use as adverse facts available information derived from the petition, the final determination in the antidumping investigation, a previous administrative review, or any other information placed on the record. We have preliminarily assigned these seven companies the rate of 136.72 percent, which is the highest rate determined for any respondent in any segment of the proceeding and the rate currently applicable to several of these companies, as adverse facts available. We applied this rate to uncooperative companies in the previous administrative review. See Steel Wire Rope From the Republic of Korea; Final Results of Antidumping Duty Administrative Review and Partial Rescission of Antidumping Duty Administrative Review, 64 FR 17995, 17996 (April 13, 1999).
Section 776(c) of the Act provides that the Department shall, to the extent practicable, corroborate secondary information from independent sources reasonably at its disposal. The Statement of Administrative Action (SAA) provides that "corroborate" means simply that the Department will satisfy itself that the secondary information has probative value. See H.R. Doc. 103-316, 870 (1994).

To corroborate secondary information, the Department will, to the extent practicable, examine the reliability and relevance of the information to be used.
The adverse facts available rate being applied in this review is a simple average of all rates from the petition, which was applied to several companies in the prior review. As this rate is currently applicable to several companies and was corroborated to the extent possible in the previous review, we continue to find that it is reliable. To corroborate the EPs in the petition, we examined the Customs Service import statistics from 1991 for the HTSUS subheadings 7312.10.9030,
7312.10.9060, and 7312.10.9090. We concluded that the Customs Service data were not comparable to the prices in the petition, because the Customs Service data encompass a wide range of steel wire rope products, while the sales in the petition consist of a small number of specific product types. With regard to the NVs used in the petition's margin calculation, we were provided with no useful information by interested parties, and are aware of no other independent sources of information, which would
assist us in this aspect of the corroboration process. Notwithstanding the difficulties encountered in our attempts to corroborate the information from the petition, the Department has no evidence that suggests the petition does not continue to have probative value. Moreover, the fact that this margin is the rate currently applicable to several of these exporters/producers, and the fact that these exporters/ producers neither requested a review or cooperated in demonstrating that their actual margins were lower, indicates that the margin is reliable. If these companies could have demonstrated that their actual margins were lower, we presume that they would have done so.

With respect to the relevance aspect of corroboration, the Department will consider information reasonably at its disposal as to whether there are circumstances that would render a margin not relevant. Where circumstances indicate that the selected margin is not appropriate as adverse facts available, the Department will disregard the margin and determine an appropriate margin. See, e.g., Fresh Cut Flowers from Mexico: Final Results of Antidumping Duty Administrative Review, 61 FR 6812, 6814 (February 22, 1996). We are not aware of any circumstances that indicate that the selected margin is not appropriate as adverse facts available. Moreover, the rate used is the rate currently applicable to certain of these uncooperative companies. Assigning a lower rate to these firms would reward them for their failure to cooperate. Thus, these exporters' own current rate is relevant. Accordingly, we determine that the rate used is an appropriate basis for adverse facts available.

## Verification

As provided in section 782(i) of the Act, we verified information provided by Kumho and Jinyang. We used standard verification procedures, including examination of relevant sales and financial records. Our verification results are outlined in verification reports, dated March 3, 2000, which have been placed on the case file in the Department's CRU.

## Export Price

For sales to the United States, the Department used EP as defined in section 772(a) of the Act for Kumho and Jinyang, because the subject merchandise was sold to unaffiliated U.S. purchasers prior to the date of importation and the use of constructed export price was not otherwise indicated by the facts of record.

We calculated EP based on packed, cost insurance and freight (c.i.f.) and cost and freight (c\&f) prices to unaffiliated purchasers in the United States. Where appropriate, we made deductions from the starting price for domestic inland freight, brokerage and handling, ocean freight, marine insurance, terminal handling charges, wharfage expenses, bill of lading issuing fees and container taxes in accordance with section 772(c)(2)(A) of the Act. Based on our findings at verification, for Jinyang, we made adjustments to brokerage, wharfage and international freight expenses. See Memorandum to the File: Preliminary Results Calculation Memorandum for Jinyang Wire Rope Manufacturing Co., Ltd., March 30, 2000 (Jinyang Calculation Memo), which has been placed in the Department's CRU.
The merchandise involved in certain U.S. and home market sales reported by Kumho was produced by an unaffiliated Korean supplier. We included these sales by Kumho in our analysis because we determined that for Kumho's U.S. sales the supplier did not know at the time of the sale that the subject merchandise was to be exported to the United States. Pursuant to section 771(16) of the Act, we compared these U.S. sales to the appropriate home market sales of merchandise produced by the same supplier and sold by Kumho.

Kumho and Jinyang claimed a duty drawback adjustment based on a fixed rate amount per U.S. dollar exported. Consistent with our findings in previous reviews of steel wire rope from Korea, we did not allow the duty drawback adjustments claimed by Kumho and Jinyang because the companies did not demonstrate a connection between payment of import duties and receipt of duty drawback on exports of steel wire rope, and because they did not demonstrate that they had sufficient imports of raw materials to account for the duty drawback received on exports of the manufactured product. See Steel Wire Rope from the Republic of Korea; Preliminary Results of Antidumping Duty Administrative Review and Intent to Revoke Antidumping Duty Order in Part, 62 FR 64354, 64357 (December 5, 1997).

## Normal Value

We determined that, for both respondents, the aggregate volume of home market sales of the foreign like product was five percent or more of the aggregate volume of U.S. sales. In accordance with section 773(a)(1)(C) of the Act, we therefore based NV on home market sales.

Pursuant to section 777A(d)(2) of the Act, we compared the EPs of individual transactions to the monthly weightedaverage price of sales of the foreign like product. We compared EP sales to sales in the home market of identical merchandise.
We based NV on the price at which the foreign like product was first sold for consumption in the exporting country, in the usual commercial quantities, in the ordinary course of trade, and at the same level of trade as the EP, in accordance with section 773(a)(1)(B)(i) of the Act. We increased home market price by the amount of U.S. packing costs in accordance with section 773(a)(6)(A) of the Act, and reduced it by the amount of home market packing costs in accordance with section 773(a)(6)(B) of the Act. We note that for Jinyang we recalculated the reported home and U.S. market packing expense, as a result of the company's failure to fully support the reported packing expenses at verification. During verification, Jinyang was able to provide documentary support for the total packing expenses incurred during the POR. However, the company provided no documentary support for its allocation of packing costs to home market and U.S. sales. Company officials instead relied solely on allocation ratios. See the March 3, 2000, verification report on file in Department's CRU. Company officials claimed that the ratios utilized to calculate estimated costs were developed through business expertise and experience. However the officials could provide no documentation in support of the ratios. Therefore, we have not accepted Jinyang's packing cost allocations. As facts available, we have reallocated Jinyang's packing costs among U.S. and home market products to comport with the allocation ratios reflected in the data submitted by Kumho. For a more detailed discussion of the basis for this adjustment, which requires references to business proprietary information, See Memorandum to the File: Recalculation of Packing Expense for the Preliminary Results for Jinyang Wire Rope Manufacturing Co., Ltd., March 30, 2000.

We calculated NV based on delivered and ex-factory prices to unaffiliated customers. Where appropriate, we made adjustments for movement expenses consistent with section 773(a)(6)(B) of the Act. In addition, pursuant to section 773(a)(6)(C)(iii) of the Act and section 351.410 of the Department's regulations, we made circumstance-of-sale adjustments to NV. Specifically, we deducted home market credit expenses
and, where appropriate, added U.S. credit expenses, U.S. postage fees, U.S. letter of credit fees, delayed payment charges and document handling charges. Based on our findings at verification, for Jinyang, we made adjustments to U.S. letter of credit fees, U.S. postage fees, delayed payment charges and home market credit expenses, and, for Kumho, we adjusted delayed payment and document handling charges. See Jinyang Calculation Memo and Memorandum to the File: Preliminary Results Calculation Memorandum for Kumho Wire Rope Manufacturing Company, dated March 30, 2000, on file with the Department's CRU.

For Jinyang, we also made adjustments, in accordance with 19 CFR 351.410(e), for indirect selling expenses incurred on comparison market or U.S. sales where commissions were granted on sales in one market but not in the other (the "commission offset"). See Jinyang Calculation Memo.

## Intent To Revoke

On March 31, 1999, Kumho submitted a letter to the Department requesting, pursuant to 19 CFR 351.222(b), revocation of the order with respect to its sales of the subject merchandise. In accordance with 19 CFR
351.222(b)(2)(iii), Kumho provided with its letter a certification stating that the company: (1) Sold subject merchandise at not less than NV during the POR (and the preceding five reviews), and that in the future it would not sell such merchandise at less than NV; (2) sold the subject merchandise to the United States in commercial quantities during the POR and the last five reviews; and (3) agrees to its immediate reinstatement in the order, if the Department concludes that Kumho, subsequent to revocation, sold merchandise at less than NV.

Based on the preliminary results in this review and the final results of the two preceding reviews, Kumho has preliminarily demonstrated three consecutive years of sales at not less than NV. See Steel Wire Rope From the Republic of Korea; Final Results of Antidumping Duty Administrative Review and Partial Rescission of Antidumping Duty Administrative Review, 64 FR 17995 (April 13, 1999) and Steel Wire Rope From the Republic of Korea; Final Results of Antidumping Duty Administrative Review and Revocation in Part of Antidumping Duty Order, 63 FR 17986 (April 13, 1998). Additionally, we have determined that Kumho made sales of steel wire rope in commercial quantities during this review period and the previous two
review periods. See Memorandum from Jim Kemp and Abdelali Elouaradia to Gary Taverman, dated March 30, 2000, on file in the Department's CRU.

Given the results of the two preceding reviews, and the fact that Kumho continues to sell in commercial quantities, if the final results of this review demonstrate that Kumho sold the merchandise at prices not less than NV , and if we determine that the continued application of the antidumping duty order is no longer necessary to offset dumping, we intend to revoke the order with respect to merchandise produced and exported by Kumho. See 19 CFR 351.222(b) and Amended Regulation Concerning the Revocation of Antidumping and Countervailing Duty Orders, 64 FR 51236 (September 22, 1999).

## Currency Conversion

For purposes of the preliminary results, we made currency conversions in accordance with section 773A of the Act based on the exchange rates published by the Federal Reserve in effect on the dates of the U.S. sales. Section 773A of the Act directs the Department to use a daily exchange rate in effect on the date of sale of subject merchandise in order to convert foreign currencies into U.S. dollars, unless the daily rate involves a "fluctuation." In accordance with the Department's practice, we have determined as a general matter that a fluctuation exists when the daily exchange rate differs from a benchmark by 2.25 percent. The benchmark is defined as the rolling average of rates for the past 40 business days. When we determine that a fluctuation exists, we substitute the benchmark for the daily rate.

## Preliminary Results of Review

As a result of this review, we preliminarily determine that the following margin exists for the period March 1, 1998, through February 28, 1999:

| Manufacturer/exporter | Margin (percent) |
| :---: | :---: |
| Dae Kyung Metal Co., Ltd ... | *136.72 |
| Dong-II Steel Manufacturing |  |
| Co., Ltd .... | *136.72 |
| Dong Young | *136.72 |
| Jinyang Wire Rope, Inc ........... | 2.96 |
| Korea Sangsa Company ......... | *136.72 |
| Kumho Wire Rope Mfg. Co., <br> Ltd | 0.06 |
| Myung Jin Company ............... | *136.72 |
| Sungsan Special Steel Processing | *136.72 |
| Yeonsin Metal ........................ | *136.72 |

[^22]The Department will disclose the calculations performed to parties to the proceeding within five days of the date of publication of this notice. Any interested party may request a hearing within 30 days of publication of this notice. Any hearing, if requested, will be held 44 days after the publication of this notice, or the first workday thereafter. Interested parties may submit case briefs within 30 days of the date of publication of this notice. Parties who submit arguments in this proceeding are requested to submit with each argument: (1) A statement of the issues; and (2) a brief summary of the argument. Rebuttal briefs, which must be limited to issues raised in the case briefs, may be filed not later than 37 days after the date of publication. The Department will issue a notice of the final results of this administrative review, which will include the results of its analysis of issues raised in any such written comments or at the hearing, within 120 days from the publication of these preliminary results.
The Department shall determine, and the Customs Service shall assess, antidumping duties on all appropriate entries. The Department will issue appraisement instructions directly to the Customs Service. The final results of this review shall be the basis for the assessment of antidumping duties on entries of merchandise covered by the determination. For Kumho and Jinyang, for duty assessment purposes, we calculated importer-specific assessment rates by aggregating the dumping margins calculated for all U.S. sales to each importer and dividing this amount by the total entered value of total sales. In order to estimate the entered value, we subtracted international movement expenses from the gross sales value. The rate calculated for each importer will be used for the assessment of antidumping duties on the relevant entries of subject merchandise during the POR. Pursuant to 19 CFR 351.106(c)(2), we will instruct the Customs Service to liquidate without regard to antidumping duties all entries for any importer for whom the assessment rate is de minimis (i.e. less than 0.50 percent).

As a result of a Sunset Review of steel wire rope from Korea, the Department has revoked the antidumping duty order for this case, effective January 1, 2000. See 65 FR 3205 (January 20, 2000). Therefore, we have instructed the Customs Service to terminate suspension of liquidation for all entries of subject merchandise made after January 1, 2000. We will issue additional instructions directing the Customs Service to liquidate all entries of steel wire rope made after January 1,

2000, without regard to antidumping duties.

Entries of subject merchandise made prior to January 1, 2000, will continue to be subject to suspension of liquidation and antidumping duty deposit requirements. The Department will complete any pending reviews of this order and will conduct administrative reviews of subject merchandise entered prior to the effective date of revocation in response to appropriately filed requests for review.

This notice serves as a preliminary reminder to importers of their responsibility to file a certificate regarding the reimbursement of antidumping duties prior to liquidation of the relevant entries during this review period. Failure to comply with this requirement could result in the Secretary's presumption that reimbursement of antidumping duties occurred and the subsequent assessment of double antidumping duties.

This administrative review and notice are in accordance with sections 751(a)(1) and 777(i)(1) of the Act.

## Dated: March 30, 2000.

Robert S. LaRussa,
Assistant Secretary for Import Administration.
[FR Doc. 00-8698 Filed 4-6-00; 8:45 am] BILLING CODE 3510-DS-P

## DEPARTMENT OF COMMERCE

International Trade Administration
[A-570-815]
Sulfanilic Acid From the People's Republic of China: Amendment of Final Results of Antidumping Duty Administrative Review

AGENCY: Import Administration, International Trade Administration, Department of Commerce.
ACTION: Notice of amendment of final results of antidumping duty administrative review.

SUMMARY: On March 13, 2000, the Department of Commerce (the Department) published the final results of its administrative review of the antidumping duty order on sulfanilic acid from the People's Republic of China covering the period August 1, 1997 through July 31, 1998 (65 FR 13366). Based on the correction of a ministerial error made in the final results, we are publishing this amendment.

EFFECTIVE DATE: April 7, 2000.

FOR FURTHER INFORMATION CONTACT:
Sean Carey or Robert James, Office of AD/CVD Enforcement, Group III, Import Administration, International Trade Administration, U.S. Department of Commerce, 14th Street and Constitution Avenue, NW, Washington, DC 20230; telephone (202) 482-3964, or (202) 4820649, respectively.
SUPPLEMENTARY INFORMATION:

## Applicable Statute and Regulations

Unless otherwise indicated, all citations to the statute are references to the provisions effective January 1, 1995, the effective date of the amendments made to the Tariff Act of 1930 by the Uruguay Round Agreements Act (URAA). In addition, unless otherwise indicated, all references to the Department's regulations are to 19 CFR part 351 (1998).

## Background

On March 13, 2000, the Department published the final results of its administrative review of the antidumping duty order on sulfanilic acid from the People's Republic of China ( 65 FR 13366). This review covers two manufacturers/exporters of the subject merchandise, Zhenxing/ Mancheng (Zhenxing) and Yude/Xinyu (Yude), for the period August 1, 1997 through July 31, 1998. After publication of our final results, we received timely allegations from respondents that we had made a ministerial error in calculating the final results. No other party commented on the final results. We agree that we made a ministerial error and have corrected our calculations in accordance with section 751 (h) of the Tariff Act.

## Analysis of Ministerial Error Allegations Received From Interested Parties

We received one ministerial error allegation from respondents stating that the Department neglected to revise the surrogate value for electricity in its final calculations of normal value.
As defined by section 751(h) of the Tariff Act, the term "ministerial error" includes errors "in addition, subtraction, or other arithmetic function, clerical errors resulting from inaccurate copying, duplication, or the like, and any other type of unintentional error which the [Department] considers ministerial."

We agree with respondents that the correct surrogate value for electricity in our calculation of normal value should be the non-inflated value of 2.922 rupees per kilowatt-hour as per attachment six of the Department's Analysis Memorandum for the Final

Results of the 1997/98 Administrative Review of Sulfanilic Acid from the People's Republic of China, dated March 6, 2000. In the final results, we inadvertently used a higher figure of
3.039 rupees. This type of unintentional error meets the definition of ministerial error contained in the Tariff Act. We have made the suggested correction for the amended final results.

## Amended Final Results of Review

We determine that the following percentage weighted-average margins exist for the period August 1, 1997 through July 31, 1998:

| Manufacturer/producer/exporter | Time period | Margin (percent) |
| :---: | :---: | :---: |
| Yude (Yude/Xinyu) Chemical Industry, Co. and Zhenxing (Zhenxing/ Mancheng) Chemical Industry, Co ${ }^{1}$. <br> PRC Rate ${ }^{2}$. | $\begin{aligned} & 8 / 1 / 97-7 / 31 / 98 \\ & 8 / 1 / 97-7 / 31 / 98 \\ & \hline \end{aligned}$ | 18.65 85.20 |

[^23]The Department shall determine, and Customs shall assess, antidumping duties on all appropriate entries. In accordance with 19 CFR 351.212(b), we have calculated exporter/importerspecific assessment rates. With respect to both export price and constructed export price sales, we divided the total dumping margins for the reviewed sales by the total entered value of those reviewed sales for each importer. We will direct Customs to assess the resulting percentage margins against the entered Customs values for the subject merchandise on each of that importer's entries under the relevant order during the review period.

## Amended Cash Deposit Requirements

The following amended deposit requirements will be effective upon publication of this notice of amended final results of administrative review for all shipments of sulfanilic acid from the PRC entered, or withdrawn from warehouse, for consumption on or after the publication date, as provided for by section 751(a)(2)(c) of the Act: (1) the cash deposit rate for Yude/Xinyu and Zhenxing/Mancheng will be the rate shown above; (2) the cash deposit rate for all other PRC exporters (i.e., the PRC rate) will be 85.20 percent; and (3) the cash deposit rate for non-PRC exporters of subject merchandise from the PRC will be the rate applicable to the PRC supplier of that exporter. These deposit requirements shall remain in effect until publication of the final results of the next administrative review.

This notice also serves as a final reminder to importers of their responsibility under 19 CFR 351.402 (f) to file a certificate regarding the reimbursement of antidumping duties prior to liquidation of the relevant entries during this review period. Failure to comply with this requirement could result in the Secretary's presumption that reimbursement of
antidumping duties occurred and the subsequent assessment of double antidumping duties.

This notice also serves as a reminder to parties subject to administrative protective order (APO) of their responsibility concerning the return or destruction of proprietary information disclosed under APO in accordance with 19 CFR 351.305. Timely notification of the return or destruction of APO materials, or conversion to judicial protective order, is hereby requested. Failure to comply with the regulations and terms of an APO is a violation which is subject to sanction.

We are issuing and publishing this determination in accordance with sections 751(a)(1) and 777(i) of the Act.

Dated: March 31, 2000.

## Robert S. LaRussa,

Assistant Secretary for Import Administration.
[FR Doc. 00-8696 Filed 4-6-00; 8:45 am] BILLING CODE 3510-DS-P

## DEPARTMENT OF COMMERCE

## International Trade Administration

[A-549-502]

## Certain Welded Carbon Steel Pipes and Tubes From Thailand: Preliminary Results of Antidumping Duty Administrative Review

AGENCY: Import Administration, International Trade Administration, Department of Commerce.
ACTION: Notice of preliminary results of antidumping duty administrative review: Certain welded carbon steel pipes and tubes from Thailand.

SUMMARY: In response to requests by a Thai manufacturer, Saha Thai Steel Company, Ltd. ("Saha Thai"), and two importers, Ferro Union Inc. ("Ferro Union'"), and ASOMA Corp.
("ASOMA"), the Department of Commerce ("the Department") is conducting an administrative review of the antidumping duty order on certain welded carbon steel pipes and tubes from Thailand. This review covers Saha Thai Steel Pipe Co., Ltd. ("Saha Thai"), a Thai manufacturer of the subject merchandise to the United States. The period of review (POR) is March 1, 1998, through February 28, 1999.

We have preliminarily determined that the respondent sold subject merchandise at less than normal value ('NV'") during the POR. If these preliminary results are adopted in our final results, we will instruct U.S. Customs to assess antidumping duties based on the differences between the export price and NV.

Interested parties are invited to comment on these preliminary results. Parties who submit argument in this proceeding should also submit with the argument: (1) A statement of the issue; and (2) a brief summary of the argument.
EFFECTIVE DATE: April 7, 2000.
FOR FURTHER INFORMATION CONTACT:
Linda Ludwig or Javier Barrientos, AD/ CVD Enforcement Group III, Room 7866, Import Administration, International Trade Administration, U.S. Department of Commerce, 14th Street and Constitution Avenue, NW, Washington, DC 20230; telephone: (202) 482-3833 and (202) 482-2243, respectively.

## Applicable Statute

Unless otherwise indicated, all citations to the statute are references to the provisions effective January 1, 1995, the effective date of the amendments made to the Tariff Act of 1930 ("the Act") by the Uruguay Round Agreements Act ("URAA"). In addition, unless otherwise indicated, all citations to the Department's regulations are to those codified at 19 CFR part 351 (1999).

## SUPPLEMENTARY INFORMATION:

## Background

On March 11, 1986, the Department published in the Federal Register an antidumping duty order on certain welded carbon steel pipes and tubes from Thailand ( 51 FR 8341). On March 9, 1999, the Department published a notice of opportunity to request an administrative review of this order covering the period March 1, 1998, through February 28, 1999 (64 FR 11439). Timely requests for an administrative review of the antidumping order with respect to sales by Saha Thai during the POR were filed by Saha Thai, Ferro Union and ASOMA. The Department published a notice of initiation of this antidumping duty administrative review on May 28, 1999 (64 FR 28973).
Because the Department determined that it was not practicable to complete this review within statutory time limits, on December 3, 1999, we published in the Federal Register our notice of extension of the time limit for this review ( 64 FR 67876). As a result, we extended the deadline for these preliminary results. The deadline for the final results will continue to be 120 days after publication of these preliminary results.

## Scope of the Review

The products covered by this administrative review are certain welded carbon steel pipes and tubes from Thailand. The subject merchandise has an outside diameter of 0.375 inches or more, but not exceeding 16 inches. These products, which are commonly referred to in the industry as "standard pipe" or "structural tubing," are hereinafter designated as "pipe and tube." The merchandise is classifiable under the Harmonized Tariff Schedule (HTS) item numbers 7306.30.1000, 7306.30.5025, 7306.30.5032, 7306.30.5040, 7306.30.5055, 7306.30.5085, and 7306.30.5090. Although the HTS subheadings are provided for convenience and Customs purposes, our written description of the scope of the order is dispositive.

## Date of Sale

As in previous segments of this proceeding, Saha Thai reported invoice date as the date of sale. In order to determine whether invoice date was the appropriate date of sale, i.e., whether the material terms of sale were established on that or an earlier date, we examined the contracts provided by Saha Thai for its U.S. sales and found that the terms of sale changed in a significant number of sales. Therefore,
we have preliminarily determined that the invoice date is the appropriate date of sale. With respect to home market sales, the invoice is the first written document that establishes the terms of sale.

## Normal Value Comparisons

To determine whether sales of steel pipes and tubes from Thailand to the United States were made at less than NV, we compared the export price (EP) to the NV for Saha Thai as specified in the "Export Price" and "Normal Value" sections of this notice. In accordance with section $777 \mathrm{~A}(\mathrm{~d})(2)$ of the Act, we calculated monthly weighted-average prices for NV and compared these to individual U.S. transactions.

Saha Thai's reported U.S. sales include both its own sales and sales made by another company of subject merchandise processed by Saha Thai under a tolling agreement. We have included all of these sales in our analysis for these preliminary results. After reviewing the submissions we requested additional information regarding Saha Thai and its relationship with the other company to which it provided tolling services and the degree to which certain costs and expenses incurred by Saha Thai and this other company (e.g., the cost of tolling services, coil cost, interest expenses, exchange rate losses and selling expenses) were fully allocated and reported. We have also requested additional information regarding the various weight conversion methodologies used in reporting sales, costs and expenses. Due to the timing of these requests, we were not able to use this information for these preliminary results. Parties are invited to comment on this information as part of their case briefs and/or rebuttal briefs. This information plus any relevant comments will be fully considered in our final results of this review.

## Export Price

Based upon our review of the record evidence, we classified all Saha Thai sales to United States customers as EP sales because, as in previous segments of this proceeding, we found that Saha Thai is not affiliated with its U.S. distributors, which are the first purchasers in the United States. Certain Welded Carbon Steel Pipes and Tubes From Thailand: Final Results of Antidumping Duty Administrative Review, 61 FR 56515, 56517 (November 1, 1996). Therefore, we calculated the EP based on the price from Saha Thai to the first unaffiliated purchaser in the U.S. in accordance with section 772(a) of the Act.

Where appropriate, in accordance with section 772(c)(2) of the Act, we made deductions from the starting price for ocean freight to the U.S. port, foreign inland freight, foreign brokerage and handling, foreign inland insurance, bill of lading charge, U.S. duty and U.S. brokerage and handling charges. In addition, pursuant to section 772(c)(1)(B) of the Act, we have made an adjustment for duty drawback.

## Normal Value

In order to determine whether there is a sufficient volume of sales in the home market to serve as a viable basis for calculating NV, we compared the volume of Saha Thai's home market sales of the foreign like product to the volume of U.S. sales of subject merchandise, in accordance with section 773(a)(1) of the Act. Based on this comparison, we determined that the aggregate volume of Saha Thai's home market sales of the foreign like product is greater than five percent of the aggregate volume of Saha Thai's U.S. sales. Thus, we determined that Saha Thai had a viable home market during the POR. Consequently, we based NV on home market sales.
We applied the standard arm's length test to Saha Thai's sales to affiliated parties. Therefore, where Saha Thai's sales to affiliated parties were not made at arm's length prices, we excluded these sales from our home market normal value calculation.

Pursuant to section 773(b)(2)(A)(ii) of the Act, there were reasonable grounds to believe or suspect that Saha Thai had made home market sales at prices below its cost of production ("COP") in this review because the Department had disregarded sales that failed the cost test in the 1996-1997 administrative review (i.e., the most recently completed review at the time we issued our antidumping questionnaire). As a result, the Department initiated an investigation to determine whether Saha Thai made home market sales during the POR at prices below its COP. We calculated the COP based on the sum of respondent's cost of materials and fabrication for the foreign like product, plus amounts for SG\&A and packing costs, in accordance with section 773(b)(3) of the Act.

For these preliminary results we are using respondent's reported COP. We have requested additional information about Saha Thai's costs and those of another company for which Saha Thai provided tolling services. We invite parties to comment on this information and will consider this information for the final results.

We compared the COP figures to home market sales of the foreign like product as required under section 773(b) of the Act, in order to determine whether these sales had been made at prices below the COP. On a productspecific basis, we compared the COP to home market prices, less any applicable movement charges and discounts.
In determining whether to disregard home market sales made at prices below the COP, we examined: (1) Whether, within an extended period of time, such sales were made in substantial quantities, and (2) whether such sales were made at prices which permitted the recovery of all costs within a reasonable period of time in the normal course of trade.
Pursuant to section 773(b)(2)(C) of the Act, where less than 20 percent of the respondent's sales of a given product were at prices less than the COP, we did not disregard any below-cost sales of that product because we determined that the below-cost sales were not made in "substantial quantities." Where 20 percent or more of the respondent's sales of a given product during the POR were at prices less than the COP, we determined such sales to have been made in substantial quantities within an extended period of time in accordance with section 773(b)(1)(A) of the Act. In such cases, we also determined that such sales were not made at prices which would permit recovery of all costs within a reasonable period of time, in accordance with section 773(b)(1)(B) of the Act. Therefore, we disregarded the below-cost sales.

Where appropriate, we adjusted Saha Thai's home market sales for discounts, direct selling expenses and inland freight. In addition, in accordance with section 773(a)(6), we deducted home market packing costs and added U.S. packing costs, U.S imputed credit, bank charges, and penalty fees.
In accordance with section 773(e) of the Act, we calculated CV based on the sum of Saha Thai's cost of materials, fabrication, SG\&A, profit, and U.S.
packing costs. In accordance with section 773(e)(2)(A) of the Act, we based SG\&A expenses and profit on the amounts incurred and realized by Saha Thai in connection with the production and sale of the foreign like product in the ordinary course of trade, for consumption in the foreign country. For selling expenses, we used the average of the selling expenses reported for home market sales that passed the cost test, weighted by the total quantity of those sales. For actual profit, we first calculated the difference between the home market sales value and home market COP, and divided the difference by the home market COP. We then multiplied this percentage by the COP for each U.S. model to derive an actual profit.

## Level of Trade

As set forth in section 773(a)(1)(B)(i) of the Act and in the SAA, to the extent practicable, we determine NV based on sales in the comparison market at the same level of trade as the EP or the CEP. The NV level of trade is that of the starting-price sales in the comparison market or, when NV is based on CV, that of the sales from which we derive selling, general and administrative expenses and profit. For EP, the U.S. level of trade is the level of the startingprice sale, which is usually from exporter to importer.

To determine whether NV sales are at a different level of trade than EP or CEP, we examine stages in the marketing process and selling functions along the chain of distribution between the producer and the unaffiliated customer. If the comparison-market sales are at a different level of trade, and the difference affects price comparability, as manifested in a pattern of consistent price differences between the sales on which NV is based and comparisonmarket sales at the level of trade of the export transaction, we make a level of trade adjustment under section 773(a)(7)(A) of the Act. See Notice of

Final Determination of Sales at Less Than Fair Value: Certain Cut-to-Length Carbon Steel Plate from South Africa, 62 FR 61731 (November 19, 1997).
For the U.S. market, Saha Thai reported only one level of trade for its EP sales. This single level of trade represents large volume sales to unaffiliated trading companies/ distributors in the United States. In the home market, Saha Thai claimed that it made sales at one level of trade. These sales were made to unaffiliated trading companies and distributors (made at the same level of trade as U.S. sales). There are no significant differences in the selling functions Saha Thai performs for these customers in the home market or in the United States. Therefore, we conclude that EP and NV sales are made at the same LOT and no adjustment is warranted.

## Currency Conversion

We made currency conversions into U.S. dollars in accordance with section 773A of the Act, based on exchange rates in effect on the dates of the U.S. sales as certified by the Federal Reserve Bank. Section 773A(a) of the Act directs the Department to use a daily exchange rate in order to convert foreign currencies into U.S. dollars unless the daily rate involves a fluctuation. It is the Department's practice to find that a fluctuation exists when the daily exchange rate differs from the benchmark rate by 2.25 percent. The benchmark is defined as the moving average of rates for the past 40 business days. When we determine a fluctuation to have existed, we substitute the benchmark rate for the daily rate, in accordance with established practice. See Change in Policy Regarding Currency Conversions, 61 FR 9434 (March 8, 1996).

## Preliminary Results of the Review

We preliminarily determine that the following weighted-average dumping margins exist:


The Department will disclose to parties to this proceeding within 5 days after publication of these preliminary results. Any interested party may request a hearing within 30 days of publication. Any hearing, if requested, will be held 37 days after the date of publication or the first business day thereafter. Case briefs and/or other
written comments from interested parties may be submitted not later than 30 days after the date of publication. Rebuttal briefs and rebuttals to written comments, limited to issues raised in those comments, may be filed not later than 35 days after the date of publication of this notice. The Department will publish the final
results of this administrative review, which will include the results of its analysis of issues raised in any such comments, within 120 days from the date of publication of these preliminary results.
The Department shall determine, and the U.S. Customs Service shall assess, antidumping duties on all appropriate
entries. In accordance with 19 CFR 351.212(b), we calculated importerspecific ad valorem duty assessment rates for the class or kind of merchandise based on entered value. Upon completion of this review, the Department will issue appraisement instructions directly to the Customs Service.

Furthermore, the following deposit rates will be effective upon the publication of the final results of this administrative review for all shipments of certain welded carbon steel pipes and tubes from Thailand entered, or withdrawn from warehouse, for consumption on or after the publication date, as provided for by section 751(a)(2)(c) of the Act: (1) The cash deposit rate for the reviewed company will be that established in the final results of this review; (2) for previously reviewed or investigated companies not listed above, the cash deposit rate will continue to be the company-specific rate published for the most recent period; (3) if the exporter is not a firm covered in this review, or the original LTFV investigation, but the manufacturer is, the cash deposit rate will be the rate established for the most recent period for the manufacturer of the merchandise; (4) the cash deposit rate for all other manufacturers or exporters will continue to be 15.67 percent, the "All Others" rate made effective by the LTFV investigation. These requirements, when imposed, shall remain in effect until publication of the final results of the next administrative review.
This notice serves as a preliminary reminder to importers of their responsibility under 19 CFR 351.402(f) to file a certificate regarding the reimbursement of antidumping duties prior to liquidation of the relevant entries during this review period. Failure to comply with this requirement could result in the Secretary's presumption that reimbursement of antidumping duties occurred and the subsequent assessment of double antidumping duties.
These preliminary results of review are issued and published in accordance with sections 751(a)(1) and 777(i)(1) of the Act.

Dated: March 30, 2000.

## Robert S. LaRussa,

Assistant Secretary for Import
Administration.
[FR Doc. 00-8697 Filed 4-6-00; 8:45 am]
BILLING CODE 3510-DS-P

## DEPARTMENT OF COMMERCE

## International Trade Administration <br> [C-401-401]

Certain Carbon Steel Products From Sweden; Final Results of Expedited Sunset Review of Countervailing Duty Order

AGENCY: Import Administration, International Trade Administration, Department of Commerce.
ACTION: Notice of final results of expedited sunset review: Certain carbon steel products from Sweden.

SUMMARY: On September 1, 1999, the Department of Commerce ("the Department") initiated a sunset review of the countervailing duty order on certain carbon steel products from Sweden (64 FR 47767) pursuant to section 751(c) of the Tariff Act of 1930, as amended ("the Act"). On the basis of a notice of intent to participate and adequate substantive comments filed on behalf of the domestic interested parties, as well as inadequate response from respondent interested parties, the Department determined to conduct an expedited (120-day) sunset review. Based on our analysis of the comments received, we find that revocation of the countervailing duty order would be likely to lead to continuation or recurrence of a countervailable subsidy at the levels listed below in the section entitled Final Results of the Review.
EFFECTIVE DATE: April 7, 2000.
FOR FURTHER INFORMATION CONTACT: Kathryn B. McCormick or Melissa G. Skinner, Office of Policy for Import Administration, International Trade Administration, U.S. Department of Commerce, 14th Street and Constitution Avenue, NW, Washington, DC 20230; telephone: (202) 482-1930 or (202) 4821560, respectively.

## SUPPLEMENTARY INFORMATION:

## The Applicable Statute

Unless otherwise indicated, all citations to the Act are references to the provisions effective January 1, 1995, the effective date of the amendments made to the Act by the Uruguay Round Agreements Act ("URAA"). In addition, unless otherwise indicated, all citations to the Department regulations are to 19 CFR Part 351 (1999). Guidance on methodological or analytical issues relevant to the Department's conduct of sunset reviews is set forth in the Department Policy Bulletin 98:3Policies Regarding the Conduct of Fiveyear ('Sunset") Reviews of Antidumping and Countervailing Duty

Orders; Policy Bulletin, 63 FR 18871 (April 16, 1998) (Sunset Policy Bulletin).

## Background

On September 1, 1999, the Department initiated a sunset review of the countervailing duty order on carbon steel products from Sweden ( 64 FR 47767), pursuant to section 751(c) of the Act. The Department received a notice of intent to participate on behalf of Bethlehem Steel Corporation, Inland Ispat Inc., LTV Steel Company, Inc., National Steel Corporation, and U.S. Steel Group, a unit of USX Corporation ("domestic interested parties"), within the applicable deadline (September 15, 1999) specified in section 351.218(d)(1)(i) of the Sunset Regulations. Domestic interested parties claimed interested-party status under section 771(9)(C) of the Act, as U.S. producers of a domestic like product.

On September 24, 1999, we received a request for an extension to file rebuttal comments from domestic interested parties. ${ }^{1}$ Pursuant to 19 CFR 351.302(b), the Department extended the deadline for all participants eligible to file rebuttal comments until October 15, $1999 .{ }^{2}$
On October 1, 1999, we received a complete substantive response from domestic interested parties, within the 30-day deadline specified in the Sunset Regulations under section 351.218(d)(3)(i). Domestic interested parties claim that United States Steel Corporation ("USSC") now USX, was the petitioner in the original investigation, and one or more of the domestic interested parties participated in all subsequent administrative reviews (see October 1, 1999, Substantive Response of domestic interested parties at 5).

On September 29, 1999, and we received a response from the European Union Delegation of the European Commission ("EC'") expressing its intent to participate in this review as the authority responsible for defending the interest of the Member States of the European Union (see September 29, 1999, Substantive Response of the EU at 3). On September 30, 1999, we received a response from the Government of

[^24]Sweden ("GOS") expressing its intent to participate in this review, as the government of a country in which subject merchandise is produced and exported. The GOS notes that it has in the past participated in this proceeding (see September 30, 1999, Substantive Response of GOS at 2).
The Department did not receive a substantive response from any foreign producer/exporter of the subject merchandise as defined under section 771(9)(A) of the Act. Thus, pursuant to section 351.218(e)(1)(ii)(A) of the Sunset Regulations, the Department determined the EC's and GOS's substantive responses to be inadequate for purposes of conducting a full review. Consequently, on October 21, 1999, pursuant to 19 CFR 351.218 (e)(1)(ii)(A), the Department determined to conduct an expedited (120-day) sunset review of this order. ${ }^{3}$
The Department did not receive rebuttal comments from any interested parties.
In accordance with section 751(c)(5)(C)(v) of the Act, the Department may treat a review as extraordinarily complicated if it is a review of a transition order (i.e., an order in effect on January 1, 1995). This review concerns a transition order within the meaning of section 751(c)(6)(i) of the Act. Accordingly, on December 22, 1999, the Department determined that the sunset review of cold-rolled carbon steel products from Sweden is extraordinarily complicated, and extended the time limit for completion of the final results of this review until not later than March 29, 2000, in accordance with section 751(c)(5)(B) of the Act. ${ }^{4}$

## Scope of Review

The scope of this order covers carbon steel products from Sweden. These products include cold-rolled carbon steel, flat-rolled products, whether or not corrugated, or crimped; whether or not pickled, not cut, not pressed and not stamped to non-rectangular shape; not coated or plated with metal and not clad; over 12 inches in width and of any thickness; whether or not in coils. Such merchandise is classifiable under the Harmonized Tariff Schedule ("HTS") item numbers: 7209.11.0000,
7209.12.0000, 7209.13.0000,
7209.21.0000, 7209.22.0000,
7209.23.0000, 7209.24.5000,
${ }^{3}$ See October 20, 1999, Memorandum for Jeffrey A. May, Re: Certain Carbon Steel Products from Sweden: Adequacy of Respondent Interested Party Response to the Notice of Initiation.
${ }^{4}$ See Extension of Time Limit for Final Results of Expedited Five-Year Reviews, 64 FR 71726
(December 22, 1999).
7209.31.0000, 7209.32.0000, 7209.33.0000, 7209.34.0000, 7209.41.0000, 7209.43.0000, 7209.44.0000, 7209.90.0000, 7211.30.5000, 7211.41.7000, and 7211.49.5000. The written description remains dispostive.

## Analysis of Comments Received

All issues raised in substantive responses by parties to this sunset review are addressed in the Issues and Decision Memorandum ("Decision Memo'") from Jeffrey A. May, Director, Office of Policy, Import Administration, to Robert S. LaRussa, Assistant Secretary for Import Administration, dated March 29, 2000, which is hereby adopted by this notice. The issues discussed in the attached Decision Memo include the likelihood of continuation or recurrence of subsidy, the net countervailable subsidy likely to prevail were the order revoked, and the nature of the subsidy. Parties can find a complete discussion of all issues raised in this review and the corresponding recommendations in this public memorandum which is on file in B-099, the Central Records Unit, of the main Commerce building.

In addition, a complete version of the Decision Memo can be accessed directly on the Web at www.ita.doc.gov/ import__admin/records/frn. The paper copy and electronic version of the Decision Memo are identical in content.

## Final Results of Review

As a result of this review, the Department finds that revocation of the countervailing duty order would likely lead to continuation or recurrence of a countervailable subsidy at the rate listed below for all Swedish producers/ exporters, except for Surahammars Bruk $A B$, which was excluded from the order:

| Producer/exporter | Net <br> countervailable <br> subsidy <br> (percent) |
| :---: | :---: |
| All Producers/Exporters from <br> Sweden ............................. | 8.77 |

## Nature of the Subsidy

In the Sunset Policy Bulletin, the Department states that, consistent with section 752(a)(6) of the Act, the Department will provide to the Commission information concerning the nature of the subsidy, and whether the subsidy is a subsidy described in Article 3 or Article 6.1 of the Subsidies
Agreement. Because some programs not falling within the definition of an export subsidy under Article 3.1(a) of the Subsidies Agreement, could be found to
be inconsistent with Article 6 if the net countervailable subsidy exceeds five percent (as measured in accordance with Annex IV of the Subsidies Agreement), we are providing the Commission with program descriptions in our Decision Memo. ${ }^{5}$

This notice also serves as the only reminder to parties subject to administrative protective orders ("APO") of their responsibility concerning the return or destruction of proprietary information disclosed under APO in accordance with 19 CFR 351.305. Timely notification of the return or destruction of APO materials or conversion to judicial protective order is hereby requested. Failure to comply with the regulations and terms of an APO is a violation which is subject to sanction.
We are issuing and publishing this determination and notice in accordance with sections section 751(c), 752, and 777(i) of the Act.

Dated: March 29, 2000.

## Joseph A. Spetrini,

Acting Assistant Secretary for Import Administration.
[FR Doc. 00-8692 Filed 4-6-00; 8:45 am] BILLING CODE 3510-DS-P

## DEPARTMENT OF COMMERCE

## International Trade Administration

[C-401-804]
Cut-to-Length Carbon Steel Plate From Sweden; Final Results of Expedited Sunset Review of Countervailing Duty Order
AGENCY: Import Administration, International Trade Administration, Department of Commerce.
ACTION: Notice of final results of expedited sunset review: Cut-to-length carbon steel plate from Sweden.

SUMMARY: On September 1, 1999, the Department of Commerce ("the Department") initiated a sunset review of the countervailing duty order on cut-to-length carbon steel plate from Sweden (64 FR 47767) pursuant to section 751(c) of the Tariff Act of 1930, as amended ("the Act"). On the basis of a notice of intent to participate and adequate substantive comments filed on behalf of the domestic interested parties, as well as inadequate responses from respondent interested parties, the Department determined to conduct an expedited (120-day) sunset review.

[^25]Based on our analysis of the comments received, we find that revocation of the countervailing duty order would be likely to lead to continuation or recurrence of a countervailable subsidy at the levels listed below in the section entitled Final Results of the Review.
EFFECTIVE DATE: April 7, 2000.
FOR FURTHER INFORMATION CONTACT: Kathryn B. McCormick or Melissa G. Skinner, Office of Policy for Import Administration, International Trade Administration, U.S. Department of Commerce, 14th Street and Constitution Avenue, NW, Washington, DC 20230; telephone: (202) 482-1930 or (202) 4821560, respectively.

## SUPPLEMENTARY INFORMATION:

## The Applicable Statute

Unless otherwise indicated, all citations to the Act are references to the provisions effective January 1, 1995, the effective date of the amendments made to the Act by the Uruguay Round Agreements Act ("URAA"). In addition, unless otherwise indicated, all citations to the Department regulations are to 19 CFR Part 351 (1999). Guidance on methodological or analytical issues relevant to the Department's conduct of sunset reviews is set forth in the Department Policy Bulletin 98:3Policies Regarding the Conduct of Fiveyear ('Sunset") Reviews of Antidumping and Countervailing Duty Orders; Policy Bulletin, 63 FR 18871 (April 16, 1998) (Sunset Policy Bulletin).

## Background

On September 1, 1999, the
Department initiated a sunset review of the countervailing duty order on cut-tolength carbon steel plate from Sweden ( 64 FR 47767), pursuant to section 751(c) of the Act. The Department received a notice of intent to participate on behalf of the Bethlehem Steel Corporation and U.S. Steel Corporation, a unit of USX Corporation ("domestic interested parties"), within the applicable deadline (September 15, 1999) specified in section 351.218(d)(1)(i) of the Sunset Regulations. Domestic interested parties claimed interested-party status under section 771(9)(C) of the Act, as U.S. producers of a domestic like product.

On September 24, 1999, we received a request for an extension to file rebuttal comments from domestic interested parties. ${ }^{1}$ Pursuant to 19 CFR 351.302(b),

[^26]the Department extended the deadline for all participants eligible to file rebuttal comments until October 15, $1999 .{ }^{2}$

On October 1, 1999, we received a complete substantive response from domestic interested parties, within the 30-day deadline specified in the Sunset Regulations under section
351.218(d)(3)(i). Domestic interested parties assert that they have been involved in this proceeding since its inception throughout the investigation and in the only administrative review (see October 1, 1999, Substantive Response of domestic interested parties at 4).

On September 29, 1999, we received a response from the European Union Delegation of the European Commission ("EC") expressing its intent to participate in this review as the authority responsible for defending the interest of the Member States of the European Union ("EU") (see September 29, 1999, Substantive Response of the EU at 3). On September 30, 1999, we received a response from the Government of Sweden ("GOS") expressing its intent to participate in this review as the government of a country in which the subject merchandise is produced and exported. The GOS notes that it has in the past participated in this proceeding (see September 30, 1999, Substantive Response of the GOS at 2).

The Department did not receive a substantive response from any foreign producer/exporter, of the subject merchandise as defined under 771(9)(A) of the Act. Thus, pursuant to section 351.218(e)(1)(ii)(A) of the Sunset Regulations, the Department determined the EC's and GOS's substantive responses to be inadequate for the purposes of conducting a full review. Consequently, on October 21, 1999, pursuant to 19 CFR 351.218 (e)(1)(ii)(C)(2), the Department determined to conduct an expedited (120-day) sunset review of this order. ${ }^{3}$

In accordance with section
751(c)(5)(C)(v) of the Act, the
Department may treat a review as extraordinarily complicated if it is a review of a transition order (i.e., an order in effect on January 1, 1995). This review concerns a transition order

401-804, C-401-805, from Valerie S. Schindler, Skadden, Arps, Slate, Meagher \& Flom LLP, to Jeffrey A. May, Office of Policy.
${ }^{2}$ See September 30, 1999, Letter from Jeffrey A. May, Director, Office of Policy to Valerie S. Schindler, Skadden, Arps, Slate, Meagher \& Flom LLP.
${ }^{3}$ See October 20, 1999, Memorandum for Jeffrey A. May, Re: Certain Cut-to-Length Carbon Steel Flat Plate from Sweden: Adequacy of Respondent Interested Party Response to the Notice of Initiation.
within the meaning of section 751(c)(C)(6)(i) of the Act. Accordingly, on December 22, 1999, the Department determined that the sunset review of cut-to-length carbon steel flat plate from Sweden is extraordinarily complicated, and extended the time limit for completion of the final results of this review until not later than March 29, 2000, in accordance with section 751(c)(5)(B) of the Act. ${ }^{4}$

## Scope of Review

The scope of this order includes hotrolled carbon steel universal mill plates (i.e., flat-rolled products rolled on four faces or in a closed box pass, of a width exceeding 150 millimeters but not exceeding 1,250 millimeters and of a thickness of not less than 4 millimeters, not in coils and without patterns in relief), of rectangular shape, neither clad, plated, nor coated with metal, whether or not painted, varnished, or coated with plastics or other nonmetallic substances; and certain hotrolled carbon steel flat-rolled products in straight lengths, of rectangular shape, hot rolled, neither clad, plated, nor coated with metal, whether or not painted, varnished, or coated with plastics or other nonmetallic substances, 4.75 millimeters or more in thickness and of a width which exceeds 150 millimeters and measures at least twice the thickness, as currently classifiable in the Harmonized Tariff Schedule
("HTS") under item numbers: 7208.31.0000, 7208.38.0000, 7208.33.1000, 7208.33.5000, 7208.41.0000, 7208.22.0000, 7208.43.0000, 7208.90.0000, 7210.70.3000, 7210.90.9000, 7211.11.0000, 7211.12.0000, 7211.21.0000, 7211.22.0045, 7211.90.0000, 7212.40.1000, 7212.40.5000, and 7212.50.5000 (62 FR 16551, April 7, 1997).
Included in this order are flat-rolled products of non-rectangular crosssection where such cross-section is achieved subsequent to the rolling process (i.e., products which have been "worked after rolling")—for example, products which have been beveled or rounded at the edges. Excluded from this order is grade X-70 plate. These HTS item numbers are provided for convenience and customs purposes. The written description remains dispositive.

## Analysis of Comments Received

All issues raised in substantive responses by parties to this sunset review are addressed in the Issues and

[^27]Decision Memorandum ("Decision Memo"') from Jeffrey A. May, Director, Office of Policy, Import Administration, to Robert S. LaRussa, Assistant Secretary for Import Administration, dated March 29, 2000, which is hereby adopted by this notice. The issues discussed in the attached Decision Memo include the likelihood of continuation or recurrence of subsidy and the net countervailable subsidy likely to prevail were the order revoked. Parties can find a complete discussion of all issues raised in this review and the corresponding recommendations in this public memorandum which is on file in room B-099, the Central Records Unit, of the main Commerce building.
In addition, a complete version of the Decision Memo can be accessed directly on the Web at www.ita.doc.gov/ import__admin/records/frn. The paper copy and electronic version of the Decision Memo are identical in content.

## Final Results of Review

We determine that revocation of the countervailing duty order would be likely to lead to continuation or recurrence of the subsidy at the following net countervailable subsidy.

| Producer/exporter | Net countervailable subsidy (\%) |
| :---: | :---: |
| All Producers/Exporters from Sweden $\qquad$ | 4.27 |

## Nature of the Subsidy

In the Sunset Policy Bulletin, the Department states that, consistent with section 752(a)(6) of the Act, the Department will provide to the Commission information concerning the nature of the subsidy, and whether the subsidy is a subsidy described in Article 3 or Article 6.1 of the Subsidies Agreement. Although the programs at issue do not fall within Article 3 of the Subsidies Agreement, some or all of them could be found to be inconsistent with Article 6.1. For example, the net countervailable subsidy may exceed five percent, as measured in accordance with Annex IV of the Subsidies Agreement. The Department, however, has no information with which to make such a calculation; nor do we believe it appropriate to attempt such a calculation in the course of a sunset review. Moreover, we note that, as of January 1, 2000, Article 6.1 has ceased to apply (see Article 31 of the Subsidies Agreement). As such, we are providing the Commission with program descriptions in our Decision Memo.
This notice also serves as the only reminder to parties subject to
administrative protective orders ("APO") of their responsibility concerning the return or destruction of proprietary information disclosed under APO in accordance with 19 CFR 351.305 of the Department's regulations. Timely notification of the return or destruction of APO materials or conversion to judicial protective order is hereby requested. Failure to comply with the regulations and terms of an APO is a violation which is subject to sanction.

We are issuing and publishing this determination and notice in accordance with sections 751(c), 752, and 777(i) of the Act.

Dated: March 29, 2000.
Joseph A. Spetrini,
Acting Assistant Secretary for Import Administration.
[FR Doc. 00-8691 Filed 4-6-00; 8:45 am] BILLING CODE 3510-DS-P

## DEPARTMENT OF COMMERCE

International Trade Administration [C-469-804]

Cut-to-Length Carbon Steel Plate From Spain; Final Results of Expedited Sunset Review of Countervailing Duty Order

AGENCY: Import Administration, International Trade Administration, Department of Commerce.
ACTION: Notice of Final Results of Expedited Sunset Review: Cut-to-Length Carbon Steel Plate from Spain.
SUMMARY: On September 1, 1999, the Department of Commerce ("the Department") initiated a sunset review of the countervailing duty order on cut-to-length carbon steel plate from Spain (64 FR 47767) pursuant to section 751(c) of the Tariff Act of 1930, as amended ("the Act"). On the basis of a notice of intent to participate and adequate substantive comments filed on behalf of the domestic interested parties, as well as inadequate response from respondent interested parties, the Department determined to conduct an expedited (120-day) sunset review. Based on our analysis of the comments received, we find that revocation of the countervailing duty order would be likely to lead to continuation or recurrence of a countervailable subsidy at the levels listed below in the section entitled Final Results of the Review.
EfFECTIVE DATE: April 7, 2000.
FOR FURTHER INFORMATION CONTACT:
Kathryn B. McCormick or Melissa G. Skinner, Office of Policy for Import

Administration, International Trade Administration, U.S. Department of Commerce, 14th Street and Constitution Avenue, NW, Washington, DC 20230; telephone: (202) 482-1930 or (202) 4821560, respectively.

## SUPPLEMENTARY INFORMATION:

## The Applicable Statute

Unless otherwise indicated, all citations to the Act are references to the provisions effective January 1, 1995, the effective date of the amendments made to the Act by the Uruguay Round Agreements Act ("URAA"). In addition, unless otherwise indicated, all citations to the Department regulations are to 19 CFR Part 351 (1999). Guidance on methodological or analytical issues relevant to the Department's conduct of sunset reviews is set forth in the Department Policy Bulletin 98:3Policies Regarding the Conduct of Fiveyear ('Sunset") Reviews of Antidumping and Countervailing Duty Orders; Policy Bulletin, 63 FR 18871 (April 16, 1998) (Sunset Policy Bulletin).

## Background

On September 1, 1999, the
Department initiated a sunset review of the countervailing duty order on cut-tolength carbon steel plate from Spain (64 FR 47767), pursuant to section 751(c) of the Tariff Act of 1930, as amended, ("the Act"). The Department received a notice of intent to participate on behalf of the Bethlehem Steel Corporation and U.S. Steel Group, a unit of USX Corporation ("domestic interested parties'), within the applicable deadline (September 15, 1999) specified in section 351.218(d)(1)(i) of the Sunset Regulations. Domestic interested parties claimed interested-party status under section 771(9)(C) of the Act, as U.S. producers of a domestic like product.

On September 20, 1999, we received a request for an extension to file rebuttal comments from domestic interested parties. ${ }^{1}$ Pursuant to 19 CFR 351.302(b), the Department extended the deadline for all participants eligible to file

[^28]rebuttal comments until October 15, 1999. ${ }^{2}$

On October 1, 1999, we received a complete substantive response from domestic interested parties, within the 30-day deadline specified in the Sunset Regulations under section 351.218(d)(3)(i). On September 29, 1999, we received a response from the European Union Delegation of the European Commission ("EC') expressing its intent to participate in this review as the authority responsible for defending the interest of the Member States of the European Union (see September 29, 1999, Substantive Response of the EU at 3). On September 30, 1999, we received a response from the Government of Spain ('GOS") expressing its intent to participate in this review, as the government of a country in which subject merchandise is produced and exported. The GOS notes that it has in the past participated in this proceeding (see September 30, 1999, Response of GOS at 2).
The Department did not receive a substantive response from any foreign producer/exporter of the subject merchandise as defined under 771(9)(A) of the Act. Thus, pursuant to section 351.218(e)(1)(ii)(A) of the Sunset Regulations, the Department determined the EC's and GOS's responses to be inadequate for purposes of conducting a full review. Consequently, on October 21, 1999, pursuant to 19 CFR 351.218(e)(1)(ii)(A), the Department determined to conduct an expedited (120-day) sunset review of this order. ${ }^{3}$
In accordance with section 751(c)(5)(C)(v) of the Act, the Department may treat a review as extraordinarily complicated if it is a review of a transition order (i.e., an order in effect on January 1, 1995). This review concerns a transition order within the meaning of section 751(c)(6)(i) of the Act. Accordingly, on December 22, 1999, the Department determined that the sunset review of cut-to-length carbon steel flat plate from Spain is extraordinarily complicated, and extended the time limit for completion of the final results of this review until not later than March 29, 2000, in accordance with section 751(c)(5)(B) of the Act. ${ }^{4}$
${ }^{2}$ See September 30, 1999, Letter from Jeffrey A. May, Director, Office of Policy to Michael H. Stein, Dewey Ballantine LLP.
${ }^{3}$ See October 20, 1999, Memorandum for Jeffrey A. May, Re: Certain Cut-to-Length Carbon Steel Flat Plate from Sweden: Adequacy of Respondent Interested Party Response to the Notice of Initiation.
${ }^{4}$ See Extension of Time Limit for Final Results of Expedited Five-Year Reviews, 64 FR 71726 (December 22, 1999).

## Scope of Review

The scope of the order covers cut-tolength carbon steel plate including hotrolled carbon steel universal mill plates (i.e., flat-rolled products rolled on four faces or in a closed box pass, of a width exceeding 150 millimeters but not exceeding 1,250 millimeters and of a thickness of not less than 4 millimeters, not in coils and without patterns in relief), of rectangular shape, neither clad, plated nor coated with metal, whether or not painted, varnished, or coated with plastics or other nonmetallic substances; and certain hotrolled carbon steel flat-rolled products in straight lengths, of rectangular shape, hot rolled, neither clad, plated, nor coated with metal, whether or not painted, varnished, or coated with plastics or other nonmetallic substances, 4.75 millimeters or more in thickness and of a width which exceeds 150 millimeters and measures at least twice the thickness, as currently classifiable in the Harmonized Tariff Schedule of the United States ("HTS") under item numbers 7208.31.0000, 7208.32.0000,
7208.33.1000, 7208.33.5000, 7208.41.0000, 7208.42.0000,
7208.43.0000, 7208.90.0000, 7210.70.3000, 7210.90.9000, 7211.11.0000, 7211.12.0000, 7211.21.0000, 7211.22.0045, 7211.90.0000, 7212.40.1000, 7212.40.5000, and 7212.50.0000. Included in this investigation are flatrolled products of nonrectangular crosssection where such cross-section is achieved subsequent to the rolling process (i.e., products which have been "worked after rolling")—for example, products which have been bevelled or rounded at the edges. Excluded from this investigation is grade $\mathrm{X}-70$ plate. Although the HTS subheadings are provided for convenience and customs purposes, our written description of the scope of this proceeding is dispositive.

## Analysis of Comments Received

All issues raised in substantive responses by parties to this sunset review are addressed in the Issues and Decision Memorandum ("Decision Memo'") from Jeffrey A. May, Director, Office of Policy, Import Administration, to Robert S. LaRussa, Assistant Secretary for Import Administration, dated March 29, 2000, which is hereby adopted by this notice. The issues discussed in the attached Decision Memo include the likelihood of continuation or recurrence of subsidy and the net countervailable subsidy likely to prevail were the order revoked. Parties can find a complete discussion of all issues raised in this review and
the corresponding recommendations in this public memorandum which is on file in B-099, the Central Records Unit, of the main Commerce building.
In addition, a complete version of the Decision Memo can be accessed directly on the Web at www.ita.doc.gov/ import__admin/records/frn. The paper copy and electronic version of the Decision Memorandum are identical in content.

## Final Results of Review

We determine that revocation of the countervailing duty order would be likely to lead to continuation or recurrence of the subsidy at the following net countervailable subsidy.

| Producer/exporter | Net <br> countervailable <br> subsidy (per- <br> cent) |
| :---: | :---: |
| All Producers/Exporters from | 36.86 |

## Nature of the Subsidy

In the Sunset Policy Bulletin, the Department states that, consistent with section 752(a)(6) of the Act, the Department will provide to the Commission information concerning the nature of the subsidy, and whether the subsidy is a subsidy described in Article 3 or Article 6.1 of the Subsidies Agreement. Although the programs at issue do not fall within Article 3 of the Subsidies Agreement, some or all of them could be found to be inconsistent with Article 6.1. For example, the net countervailable subsidy may exceed five percent. The Department, however, has no information with which to make such a calculation; nor do we believe it appropriate to attempt such a calculation in the course of a sunset review. Moreover, we note that, as of January 1, 2000, Article 6.1 has ceased to apply (see Article 31 of the Subsidies Agreement). As such, we are providing the Commission with program descriptions in our Decision Memo.
This notice also serves as the only reminder to parties subject to administrative protective orders ("APO") of their responsibility concerning the return or destruction of proprietary information disclosed under APO in accordance with 19 CFR 351.305 of the Department's regulations. Timely notification of the return or destruction of APO materials or conversion to judicial protective order is hereby requested. Failure to comply with the regulations and terms of an APO is a violation which is subject to sanction.

We are issuing and publishing this determination and notice in accordance with sections 751(c), 752, and 777(i) of the Act.

Dated: March 29, 2000.
Joseph A. Spetrini,
Acting Assistant Secretary for Import Administration.
[FR Doc. 00-8694 Filed 4-6-00; 8:45 am] BILLING CODE 3510-DS-P

## DEPARTMENT OF COMMERCE

## International Trade Administration

[C-412-815]

## Cut-to-Length Carbon Steel Plate From the United Kingdom; Final Results of Expedited Sunset Review of Countervailing Duty Order

AGENCY: Import Administration, International Trade Administration, Department of Commerce.
ACTION: Notice of final results of expedited sunset review: Cut-to-length carbon steel plate from the United Kingdom.
summary: On September 1, 1999, the Department of Commerce ("the Department") initiated a sunset review of the countervailing duty order on cut-to-length carbon steel plate from the United Kingdom ('UK’’) (64 FR 47767) pursuant to section 751(c) of the Tariff Act of 1930, as amended ("the Act"). On the basis of a notice of intent to participate and adequate substantive comments filed on behalf of the domestic interested parties, as well as inadequate response from respondent interested parties, the Department determined to conduct an expedited (120-day) sunset review. Based on our analysis of the comments received, we find that revocation of the countervailing duty order would be likely to lead to continuation or recurrence of a countervailable subsidy at the levels listed below in the section entitled Final Results of Review.
effective date: April 7, 2000.

## FOR FURTHER INFORMATION CONTACT:

Kathryn B. McCormick or Melissa G.
Skinner, Office of Policy for Import
Administration, International Trade Administration, U.S. Department of Commerce, 14th Street and Constitution Avenue, NW, Washington, DC 20230; telephone: (202) 482-1930 or (202) 4821560, respectively.

## SUPPLEMENTARY INFORMATION:

## The Applicable Statute

Unless otherwise indicated, all citations to the Act are references to the
provisions effective January 1, 1995, the effective date of the amendments made to the Act by the Uruguay Round Agreements Act ("URAA"). In addition, unless otherwise indicated, all citations to the Department regulations are to 19 CFR Part 351 (1999). Guidance on methodological or analytical issues relevant to the Department's conduct of sunset reviews is set forth in the Department Policy Bulletin 98:3Policies Regarding the Conduct of Fiveyear ("Sunset") Reviews of Antidumping and Countervailing Duty Orders; Policy Bulletin, 63 FR 18871
(April 16, 1998) (Sunset Policy Bulletin).

## Background

On September 1, 1999, the Department initiated a sunset review of the countervailing duty order on cut-tolength carbon steel plate from the UK (64 FR 47767), pursuant to section 751(c) of the Tariff Act of 1930, as amended, ("the Act"). The Department received a notice of intent to participate on behalf of the Bethlehem Steel
Corporation and U.S. Steel Group, a unit of USX Corporation ("domestic interested parties"), within the applicable deadline (September 15, 1999) specified in section
351.218(d)(1)(i) of the Sunset

Regulations. Domestic interested parties claimed interested-party status under section 771(9)(C) of the Act, as U.S. producers of a domestic like product.

On September 20, 1999, we received a request for an extension to file rebuttal comments from domestic interested parties. ${ }^{1}$ Pursuant to 19 CFR $351.302(\mathrm{~b})$, the Department extended the deadline for all participants eligible to file rebuttal comments until October 15, $1999 .{ }^{2}$

On September 29, 1999, we received a response from the European Union Delegation of the European Commission ("EC’’) expressing its intent to participate in this review as the authority responsible for defending the interest of the Member States of the European Union ("EU") (see September 29, 1999, Response of the EU at 2). On

[^29]September 30, 1999, we received a response from the Government of the United Kingdom ('GOUK') expressing its intent to participate in this review, as the government of a country in which subject merchandise is produced and exported, and a request for an extension of the deadline to submit its substantive response to the Department's notice of initiation. ${ }^{3}$

On October 1, 1999, we received a complete substantive response from domestic interested parties, within the 30-day deadline specified in the Sunset Regulations under section 351.218(d)(3)(i). They claim that one or more of these domestic interested parties have been involved in these proceedings since the original petition was filed and have participated in each subsequent segment of the case and any court litigation arising from any segment (see October 1, 1999, Substantive Response of domestic interested parties at 3 ). On October 5, 1999, we received a response from the GOUK.
The Department did not receive a substantive response from any foreign producer/exporter, or the U.S. importer of the subject merchandise as defined under 771(9)(A) of the Act. Thus, pursuant to section 351.218(e)(1)(ii)(A) of the Sunset Regulations, the Department determined the EC's and GOUK's responses to be inadequate for purposes of conducting a full sunset review. Consequently, on October 21, 1999, pursuant to 19 CFR 351.218 (e)(1)(ii)(C), the Department determined to conduct an expedited (120-day) sunset review of this order. ${ }^{4}$

In accordance with section 751(c)(5)(C)(v) of the Act, the Department may treat a review as extraordinarily complicated if it is a review of a transition order (i.e., an order in effect on January 1, 1995). This review concerns a transition order within the meaning of section 751(c)(6)(C)(i) of the Act. Accordingly, on December 22, 1999, the Department determined that the sunset review of cut-to-length carbon steel plate from the UK is extraordinarily complicated and extended the time limit for completion of the final results of this review until not later than March 29, 2000, in accordance with section 751(c)(5)(B) of the Act. ${ }^{5}$

[^30]
## Scope of Review

The scope of this order includes hotrolled carbon steel universal mill plates (i.e., flat-rolled products rolled on four faces or in a closed box pass, of a width exceeding 150 millimeters but not exceeding 1,250 millimeters and of a thickness of not less than 4 millimeters, not in coils and without patterns in relief), of rectangular shape, neither clad, plated, nor coated with metal, whether or not painted, varnished, or coated with plastics or other nonmetallic substances; and certain hotrolled carbon steel flat-rolled products in straight lengths, of rectangular shape, hot rolled, neither clad, plated, nor coated with metal, whether or not painted, varnished, or coated with plastics or other nonmetallic substances, 4.75 millimeters or more in thickness and of a width which exceeds 150 millimeters and measures at least twice the thickness, as currently classifiable in the Harmonized Tariff Schedule ("HTS") under item numbers: 7208.31.0000, 7208.32.0000, 7208.33.1000, 7208.33.5000, 7208.41.0000, 7208.42.0000, 7208.43.0000, 7208.90.0000, 7210.70.3000, 7210.90.9000, 7211.11.0000, 7211.12.0000, 7211.21.0000, 7211.22.0045, 7211.90.0000, 7212.40.1000, 7212.40 .5000 , and 7212.50.5000. Included in this order are flat-rolled products of non-rectangular crosssection where such cross-section is achieved subsequent to the rolling process (i.e., products which have been "worked after rolling")-for example, products which have been beveled or rounded at the edges. Excluded from this order is grade X-70 plate. In addition, the Department issued a changed circumstances review with respect to this order ( 64 FR 46343, August 25, 1999). Changes made to the scope of the subject merchandise in this review covered cut-to-length carbon steel products consisting of plate products with a maximum thickness of 80 mm in steel grades BS 7191, 355 EM and 355 EMZ, as amended by Sable Offshore Energy Project specification XB MOO Y 15 0001, types 1 and 2. Id. These HTS item numbers are provided for convenience and customs purposes. The written description remains dispositive.

## Analysis of Comments Received

All issues raised in substantive responses by parties to this sunset review are addressed in the Issues and Decision Memorandum ("Decision Memo'") from Jeffrey A. May, Director, Office of Policy, Import Administration,
to Robert S. LaRussa, Assistant
Secretary for Import Administration, dated March 29, 2000, which is hereby adopted by this notice. The issues discussed in the attached Decision Memo include the likelihood of continuation or recurrence of subsidy and the net countervailable subsidy likely to prevail were the order revoked. Parties can find a complete discussion of all issues raised in this review and the corresponding recommendations in this public memorandum which is on file in B-099, the Central Records Unit, of the main Commerce building.

In addition, a complete version of the Decision Memo can be accessed directly on the Web at www.ita.doc.gov/ import__admin/records/frn. The paper copy and electronic version of the Decision Memo are identical in content.

## Final Results of Review

We determine that revocation of the countervailing duty order would be likely to lead to continuation or recurrence of a subsidy at the following net countervailable subsidy.

| Producer/exporter | Net <br> countervailable <br> subsidy (\%) |
| :---: | ---: |
| Glynwed Steels Limited ........ | 0.73 |
| "All Other" British Producers/ | 12.00 |

## Nature of the Subsidy

In the Sunset Policy Bulletin, the Department states that, consistent with section 752(a)(6) of the Act, the Department will provide to the Commission information concerning the nature of the subsidy, and whether the subsidy is a subsidy described in Article 3 or Article 6.1 of the Subsidies Agreement. Although the programs at issue do not fall within Article 3 of the Subsidies Agreement, some or all of them could be found to be inconsistent with Article 6.1. For example, the net countervailable subsidy may exceed five percent, as measured in accordance with Annex IV of the Subsidies Agreement. The Department, however, has no information with which to make such a calculation; nor do we believe it appropriate to attempt such a calculation in the course of a sunset review. Moreover, we note that, as of January 1, 2000, Article 6.1 has cease to apply (see Article 31 of the Subsidies Agreement). As such, we are providing the Commission with program descriptions in our Decision Memo.

This notice also serves as the only reminder to parties subject to administrative protective orders ("APO") of their responsibility
concerning the return or destruction of proprietary information disclosed under APO in accordance with 19 CFR 351.305 of the Department's regulations. Timely notification of the return or destruction of APO materials or conversion to judicial protective order is hereby requested. Failure to comply with the regulations and terms of an APO is a violation which is subject to sanction.

We are issuing and publishing this determination and notice in accordance with sections 751(c), 752, and 777(i) of the Act.

Dated: March 29, 2000.

## Joseph A. Spetrini,

Acting Assistant Secretary for Import Administration.
[FR Doc. 00-8690 Filed 4-6-00; 8:45 am] BILLING CODE 3510-DS-P

## DEPARTMENT OF COMMERCE

## National Oceanic and Atmospheric Administration

[I.D. 033100C]

## Endangered Species; Permits

agency: National Marine Fisheries Service (NMFS), National Oceanic and Atmospheric Administration (NOAA), Commerce.
ACTION: Receipt of applications to modify scientific research permits (900, 1116, 1141, 1152, 1156, 1212).

SUMMARY: Notice is hereby given that NMFS has received applications for permit modifications from: the Northwest Fisheries Science Center, NMFS at Seattle, WA (NWFSC)(900, 1212), Douglas County Public Utility District No. 1 at East Wenatchee, WA (DCPUD)(1116), Grant County Public Utility District No. 2 at Ephrata, WA (GCPUD)(1141), Oregon Department of Fish and Wildlife at LaGrande, OR (ODFW)(1152), and the U.S. Environmental Protection Agency at Corvallis, OR (USEPA)(1156).
DATES: Comments or requests for a public hearing on any of these modification requests must be received at the appropriate address or fax number no later than 5:00pm Pacific standard time on May 8, 2000.
ADDRESSES: Written comments on any of the modification requests should be sent to Protected Resources Division, F/ NWO3, 525 NE Oregon Street, Suite 500, Portland, OR 97232-2737.
Comments may also be sent via fax to 503-230-5435. Comments will not be accepted if submitted via e-mail or the internet. The applications and related
documents are available for review in the Protected Resources Division, F/ NWO3, 525 NE Oregon Street, Suite 500, Portland, OR $97232-2737$ (ph: 503-230-5400).

Documents may also be reviewed by appointment in the Office of Protected Resources, F/PR3, NMFS, 1315 EastWest Highway, Silver Spring, MD 20910-3226 (301-713-1401).

## FOR FURTHER INFORMATION CONTACT: For

 permits 900, 1152, and 1156:Leslie Schaeffer, Portland, OR (ph: 503-230-5433, fax: 503-230-5435, e-mail: Leslie.Schaeffer@noaa.gov).

For permits 1116, 1141, and 1212: Robert Koch, Portland, OR (ph: 503-230-5424, fax: 503-230-5435, e-mail: Robert.Koch@noaa.gov).

## SUPPLEMENTARY INFORMATION:

## Authority

Issuance of permits and permit modifications, as required by the Endangered Species Act of 1973 (16 U.S.C. 1531-1543) (ESA), is based on a finding that such permits/modifications: (1) Are applied for in good faith; (2) would not operate to the disadvantage of the listed species which are the subject of the permits; and (3) are consistent with the purposes and policies set forth in section 2 of the ESA. Authority to take listed species is subject to conditions set forth in the permits. Permits and modifications are issued in accordance with and are subject to the ESA and NMFS regulations governing listed fish and wildlife permits ( 50 CFR parts 222-226).
Those individuals requesting a
hearing on a modification request listed in this notice should set out the specific reasons why a hearing on that request would be appropriate (see ADDRESSES). The holding of such hearing(s) is at the discretion of the Assistant
Administrator for Fisheries, NOAA. All statements and opinions contained in the permit action summaries are those of the applicant and do not necessarily reflect the views of NMFS.

## Species Covered in this Notice

The following species, evolutionarily significant units (ESU's), and runs are covered in this notice:
Chinook salmon (Oncorhynchus tshawytscha): threatened Snake River (SnR) spring/summer, threatened $\operatorname{SnR}$ fall, endangered upper Columbia River (UCR) spring, threatened Puget Sound (PS), threatened upper Willamette River (UWR).
Coho salmon (O. kisutch): threatened Southern Oregon/Northern California Coast (SONCC).
Sockeye salmon (O. nerka): endangered SnR.

Steelhead (O. mykiss): threatened SnR, endangered UCR, threatened middle Columbia River (MCR), threatened lower Columbia River (LCR).

To date, final protective regulations for threatened PS and UWR chinook salmon and SnR, MCR, and LCR steelhead under section 4(d) of the ESA have not been promulgated by NMFS. Protective regulations are currently proposed for PS and UWR chinook salmon ( 65 FR 169, January 3, 2000) and SnR, MCR, and LCR steelhead (64 FR 73479, December 30, 1999). This notice of receipt of applications requesting takes of these species is issued as a precaution in the event that NMFS issues final protective regulations. The initiation of a 30-day public comment period on the applications, including their proposed takes of PS and UWR chinook salmon and SnR, MCR, and LCR steelhead does not presuppose the contents of the eventual final protective regulations.

## Modification Requests Received

On March 22, 2000, NMFS published a notice in the Federal Register ( 65 FR 15312) that an application had been received from NWFSC for a modification to permit 900. For the modification, NWFSC requested an annual take of juvenile MCR steelhead and an increase in the annual take of juvenile naturally produced UCR steelhead associated with the research. NMFS has received an amendment of NWFSC's application for a modification to permit 900 . In the application amendment, NWFSC requests an increase in the annual take of juvenile SnR fall chinook salmon associated with the research. The increased take is requested because fall chinook salmon stock abundance estimates in the Snake River have recently been revised. The ESA-listed juvenile fish are proposed to be captured at John Day Dam on the Columbia River and/or obtained from the Fish Passage Center's Smolt Monitoring Program, authorized to be collected under a separate permit. The fish are proposed to be handled and released or tagged with passive integrated transponders, transported to the Dalles Dam, held for up to 24 hours, and released in front of The Dalles Dam spillway, sluiceway, turbines, or downstream from the dam. PIT-tag interrogations made at Bonneville Dam and Rice Island will be used to estimate relative survival of the release groups. An associated increase in ESA-listed juvenile chinook salmon indirect mortalities is also requested. The modification as amended is requested to
be valid for the duration of the permit, which expires on December 31, 2000.

DCPUD requests a modification to permit 1116, which authorizes annual takes of juvenile naturally produced and artificially propagated UCR steelhead associated with five research studies. The purpose of Study 1 is to determine the survival and migration differences of juvenile fish as they pass downstream through Lake Pateros and Wells Dam on the Columbia River. The purpose of Study 2 is to understand the status of juvenile salmonid migration at Wells Dam by verifying hydroacoustic accuracy. For Study 2, ESA-listed juvenile fish are collected in fyke nets and sacrificed as a means to estimate the number of unguided fish at the dam. The purpose of Study 3 is to inventory the fish species in Wells Reservoir on the Columbia River. The purpose of Study 4 is to assess the survival of juvenile, artificially propagated, UCR steelhead as they pass Wells Dam. The purpose of Study 5 is to evaluate the relative benefits of passive integrated transponder (PIT) and radio tag technologies. The results from the research will be used to enhance the survival of emigrating smolts and improve the operation of the fish passage facilities at Wells Dam. For the modification, DCPUD requests a lethal take of juvenile naturally produced and artificially propagated UCR spring chinook salmon associated with the conduct of Study 2. The modification is requested to be valid for the duration of permit 1116, which expires on December 31, 2002.
GCPUD requests a modification to permit 1141, which authorizes annual takes of adult and juvenile, naturally produced and artificially propagated, UCR steelhead associated with four scientific research studies at or in the vicinity of Wanapum and Priest Rapids Dams located on the upper Columbia River in Washington. The purpose of Study 1 is to monitor outmigrating adult and juvenile steelhead condition, survival, and travel time relative to spill effectiveness at the dams. The purpose of Study 2 is to substantiate and document hydroacoustic accuracy at Wanapum Dam. The purpose of Study 3 is to evaluate the relative abundance of the fish fauna inhabiting the Priest Rapids project area. The purpose of Study 4 is to assess the survival of juvenile, artificially propagated, UCR steelhead as they migrate past Wanapum and Priest Rapids Dams. For Study 4, ESA-listed juvenile steelhead are collected with dip nets at the dam gatewells, anesthetized, tagged with radiotransmitters, allowed to recover, released downstream, and tracked
electronically. The results from the research will be used to enhance the survival of emigrating smolts and improve the operation of the fish passage facilities at Wanapum and Priest Rapids Dams. For the modification, GCPUD requests an increase in the annual take of juvenile artificially propagated UCR steelhead associated with Study 4. An associated increase in ESA-listed juvenile steelhead indirect mortalities is also requested. The modification is requested to be valid for the duration of permit 1141, which expires on December 31, 2002.
ODFW requests a modification to permit 1152, which authorizes annual takes of adult and juvenile naturally produced and artificially propagated SnR spring/summer chinook salmon associated with 5 scientific research studies conducted in the Grande Ronde and Imnaha River Basins in the state of OR: (1) Spring chinook salmon spawning ground surveys, (2) a spring chinook salmon early life history study, (3) habitat and fish inventory surveys, (4) passage and irrigation screening evaluations, and (5) residual hatchery steelhead monitoring. For the modification, ODFW requests an increase in the annual take of juvenile artificially propagated SnR spring/ summer chinook salmon associated with Study 2. Production levels for juvenile artificially propagated SnR spring/summer chinook salmon have increased for 2000, 2001 and 2002. ODFW also proposes to apply temporary marks to juvenile artificially propagated SnR spring/summer chinook salmon to determine trap efficiencies. An associated increase in ESA-listed juvenile fish indirect mortalities is also requested. The modification is requested to be valid for the duration of permit 1152, which expires on December 31, 2002.
USEPA requests a modification to permit 1156, which authorizes annual takes of juvenile SONCC coho salmon, juvenile SnR fall chinook salmon, and juvenile naturally produced and artificially propagated SnR spring/ summer chinook salmon associated with research designed to collect data used to enforce the Clean Water Act which will increase the recovery potential of ESA-listed species in various rivers in the Pacific Northwest. For the modification, USEPA requests an annual take of juvenile naturally produced and artificially propagated UCR spring chinook salmon, juvenile naturally produced and artificially propagated PS chinook salmon, juvenile UWR chinook salmon, juvenile SnR steelhead, juvenile naturally produced
and artificially propagated UCR steelhead, juvenile MCR steelhead, and juvenile LCR steelhead. ESA-listed juvenile fish are proposed to be captured using electrofishing, examined, and released. USEPA also requests an increase in the annual take of juvenile SnR fall chinook salmon and juvenile naturally produced and artificially propagated SnR spring/ summer chinook salmon. The modification is requested to be valid for the duration of permit 1156, which expires on December 31, 2002.

On March 21, 2000, NMFS published a notice in the Federal Register (65 FR 15131) that NWFSC had applied for a modification to permit 1212, which authorizes annual takes of juvenile $\operatorname{SnR}$ sockeye salmon, juvenile naturally produced and artificially propagated SnR spring/summer chinook salmon, juvenile SnR fall chinook salmon, juvenile naturally produced and artificially propagated UCR steelhead, and juvenile naturally produced and artificially propagated UCR spring chinook salmon associated with four studies at the hydropower dams on the Snake and Columbia Rivers in the Pacific Northwest. The goal of Study 1 is to provide up-to-date survival estimates of juvenile salmonids as they migrate past McNary Dam on the Columbia River. The goal of Study 2 is to evaluate the specific trouble areas in the juvenile fish bypass system at Lower Monumental Dam on the Snake River. The goal of Study 3 is to compare the performance of juvenile salmonids tagged with Sham radiotransmitters with juvenile salmonids tagged with PITs at Lower Granite Dam on the Snake River. The goal of Study 4 is to determine tailrace residence times of radio-tagged hatchery chinook salmon under varying operational conditions at Lower Monumental Dam and to identify spill conditions that utilize the smallest volumes of water to maximize fish passage efficiency at Ice Harbor Dam on the Snake River. The research will provide information that will be used to develop corrective measures to improve juvenile fish passage at the dams. For the modification, NWFSC requested an annual take of juvenile MCR steelhead associated with the research. NWFSC has amended their application for a modification to request an increase in the annual take of juvenile $\operatorname{SnR}$ fall chinook salmon associated with the research. The increased take is requested because fall chinook salmon stock abundance estimates in the Snake River have recently been revised. The ESA-listed juvenile fish are proposed to be captured at McNary Dam, sampled
for biological information, and released. An associated increase in ESA-listed juvenile chinook salmon indirect mortalities is also requested. The modification as amended is requested to be valid for the duration of permit 1212, which expires on December 31, 2003.

Dated: April 4, 2000.

## Barbara A. Schroeder,

Acting Chief, Endangered Species Division, Office of Protected Resources, National Marine Fisheries Service.
[FR Doc. 00-8672 Filed 4-6-00; 8:45 am] BILLING CODE 3510-22-F

## COMMODITY FUTURES TRADING COMMISSION

## Chicago Mercantile Exchange's Proposal To Adopt Block Trading Procedures

AGENCY: Commodity Futures Trading Commission.
ACTION: Notice of proposed new Chicago Mercantile Exchange Rule 526 to establish block trading procedures and request for comment.
summary: The Chicago Mercantile Exchange ("CME"' or "Exchange") has submitted proposed new Rule 526 to the Commodity Futures Trading Commission ("Commission") that would establish block trading procedures at the Exchange. Under these procedures, qualified market participants would be allowed to negotiate and arrange futures transactions of a minimum size bilaterally away from the centralized, competitive market. Once the specific terms of the block transaction have been agreed to, the counterparties would report the relevant details of the transaction to a designated Exchange official for clearing and settlement. The CME is seeking to allow block trading in its Five-Year and Ten-Year Agency Note futures contracts on a one-year pilot program basis. This proposal is the second contract market proposal that the Commission has received that would allow block trading.
Acting pursuant to the authority delegated by Commission Regulation 140.96(b), the Division of Trading and Markets ("Division") has determined to publish the CME's proposal for public comment. The Division believes that publication of the proposal is in the public interest and will assist the Commission in considering the views of interested persons.
DATES: Comments must be received on or before April 24, 2000.
ADDRESSES: Comments should be submitted to Jean A. Webb, Secretary,

Commodity Futures Trading
Commission, Three Lafayette Centre,
1155 21st Street, NW., Washington, DC
20581. Comments also may be sent by facsimile (202) 418-5221 or by electronic mail to secretary@cftc.gov. Reference should be made to the "Chicago Mercantile Exchange's Proposal to Adopt Block Trading Procedures."

## FOR FURTHER INFORMATION CONTACT:

David P. Van Wagner, Associate Director, Division of Trading and Markets, Commodity Futures Trading Commission, Three Lafayette Centre, 1155 21st Street, NW, Washington, DC 20581. Telephone (202) 418-5430.

## SUPPLEMENTARY INFORMATION:

## I. Background

On June 4, 1999, the Commission issued an Advisory on Alternative Execution, or Block Trading, Procedures for the Futures Industry. ${ }^{1}$ Through this Advisory, the Commission announced its intention to consider contract market proposals to adopt alternative execution, or block trading, procedures for large size or other types of orders on case-by-case basis under a flexible approach to the requirements of the Commodity Exchange Act ("Act") and the Commission's regulations. Under this approach, each contract market retains the discretion to permit alternative executive procedures and has the ability to develop procedures that reflect the particular characteristics and needs of its individual markets and market participants.

After the issuance of the Advisory, in September of 1999, the New York Board of Trade, on behalf of the Cantor Financial Futures Exchange, Inc. ("CX'"), submitted proposed new rules and rule amendments to the Commission that would establish block trading procedures at the CX ${ }^{2}$ The CX proposal was the first contract market proposal to allow block trading that the Commission has received. On February 11, 2000, the Commission approved the CX's block trading proposal for its U.S.

[^31]Treasury Bond, U.S. Treasury Ten-Year Note, Flexible Coupon U.S. Treasury Bond, and Flexible Coupon U.S.
Treasury Ten-Year Note futures contracts on a one-year pilot program basis pursuant to Section $5 \mathrm{a}(\mathrm{a})(12)(\mathrm{A})$ of the Act and Commission Regulations 1.38 and 1.41(c).

By letters dated February 25, 2000, through March 23, 2000, the CME submitted proposed new Rule 526 to the Commission pursuant to Section 5a(a)(12(A) of the Act and Commission Regulation 1.41(c). Proposed CME Rule 526 would establish block trading procedures at the Exchange whereby qualified market participants would be allowed to negotiate and arrange futures transactions of a minimum size bilaterally away from the centralized, competitive market. Once the specific terms of the block transaction have been agreed to, the counterparties would report the relevant details of the transaction to a designated Exchange official for clearing and settlement. Thus, under the proposed procedures, certain futures transactions could be executed noncompetitively rather than through the Exchange's open outcry trading platform or through its GLOBEX2 electronic trading system.

## II. Description of the Proposed Block Trading Procedures

## A. Eligible Contracts and Market Participants

At the present time, the only contracts that would be eligible for the CME's proposed block trading procedures are its Five-year and Ten-Year and Ten-Year Agency Note futures contracts. ${ }^{3}$ The CME is seeking to allow block trading in these contracts on a one-year pilot program basis. The CME could make additional contracts eligible for the block trading procedures subject to the approval of its Board of Directors (or a Committee appointed by the Board) and of the Commission.

Proposed CME Rule 526 would restrict block trading to those market participants that qualify as an "eligible participant" as that term is defined by Commission regulation 36.1. In addition, each block order must include specific instructions that such order is to be executed pursuant to the proposed block trading procedures.

[^32]In connection with block trades entered into by a commodity trading advisor ("CTA") on behalf of its customers, and provided that certain registration and financial conditions are satisfied, ${ }^{4}$ The CTA (and not its underlying customers) would be responsible for meeting the eligibility requirements described above. Accordingly, the CTA would be able to enter into such transactions on behalf of customers without these customers having to qualify as "eligible participants" under Commission regulation 36.1 or to specifically authorize the use of the block trading procedures.

## B. Size and Price Requirements

Under proposed CME Rule 526, each buy or sell order underlying a block trade must satisfy the applicable minimum size requirement as determined by the CME's Board of Directors or by a Committee appointed by the Board. In the case of the CME's Five-year and Ten-Year Agency Note futures contracts, the minimum threshold will be 200 contracts. ${ }^{5}$

The price at which a block trade is executed must be "fair and reasonable", in light of the following factors: (1) The size of such block trade; (2) the prices and sizes of other transactions in the same contract at the relevant time; (3) the prices and sizes of transactions in other relevant markets; including the underlying cash and futures markets, at the relevant time; and (4) the circumstances of the parties to the block trade.

## C. Transparency

Each block trade must be reported to a designated Exchange within five minutes of the time of execution. ${ }^{6}$ Such

[^33] Continued
report must include information identifying the relevant contract, contract month, price, and quantity of the transaction. In addition, clearing firms must report each block trade to the Exchange Clearing House-including the time of execution-in accordance with the Clearing House Manual of Operations. The CME will immediately publicize block trade information separately from the reports of transactions in the regular, competitive market.

## III. Request for Comment

The Commission request comment from interested persons concerning any aspects of the CME's proposed block trading procedures.

Copies of the CME's proposed new Rule 526 and related materials are available for inspection at the Office of the Secretariat, Commodity Futures Trading Commission, Three Lafayette Centre, 1155 21st Street, NW.,
Washington, DC 20581. Copies also may be obtained through the Office of the Secretariat at the above address or by telephoning (202) 418-5100.

Issued in Washington, DC, on April 3, 2000.

John C. Lawton,
Acting Director.
[FR Doc. 00-8604 Filed 4-6-00; 8:45 am] BILLING CODE 6351-01-M

## CORPORATION FOR NATIONAL AND COMMUNITY SERVICE

Renewal of Two Currently Approved Information Collections

## ACTION: Notice.

SUMMARY: The Corporation for National and Community Service (hereinafter "Corporation"), as part of its continuing effort to reduce paperwork and respondent burden, conducts a preclearance consultation program to provide the general public and Federal agencies with an opportunity to comment on proposed and/or continuing collections of information in accordance with the Paperwork Reduction Act of 1995 (PRA95) (44 U.S.C. 3506(c)(2)(A)). This program helps to ensure that requested data can be provided in the desired format, reporting burden (time and financial resources) is minimized, collection instruments are clearly understood, and the impact of collection requirement on respondents can be properly assessed.

[^34]Currently, the Corporation is soliciting comments concerning the proposed revision of two forms:

- Corporation for National Service Enrollment Form (OMB \#3045-0006), and
- Corporation for National Service End of Term/Exit Form (OMB \#30450015).

Copies of the forms can be obtained by contacting the office listed below in the ADDRESSES section of this notice.
DATES: Written comments must be submitted to the office listed in the
ADDRESSES section by June 6, 2000.
ADDRESSES: Send comments to the Corporation for National and Community Service, National Service Trust, Attn: Ms. Natalie Burch, 8th Floor, 1201 New York Avenue, N.W., Washington, D.C., 20525.

## FOR FURTHER INFORMATION CONTACT:

Natalie Burch, (202) 606-5000, ext. 159.
SUPPLEMENTARY INFORMATION: The
Corporation is particularly interested in comments which:

- Evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the Corporation, including whether the information will have practical utility;
- Evaluate the accuracy of the agency's estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used;
- Enhance the quality, utility and clarity of the information to be collected; and
- Minimize the burden of the collection of information on those who are to respond, including through the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology, e.g., permitting electronic submissions of responses.


## I. Background

The Corporation for National and Community Service supports programs that provide opportunities for individuals who want to become involved in national service. The service opportunities cover a wide range of activities over varying periods of time. Upon successfully completing an agreed-upon term of service in an AmeriCorps program, an AmeriCorps participant receives an "education award". This education award can be used to make a payment towards a qualified student loan or pay for educational expenses at qualified postsecondary institutions and approved school-to-work opportunities programs.

This award is an amount of money set aside in the AmeriCorps member's name in the National Service Trust Fund. Members have seven years in which to draw against any unused balance.

The National Service Trust is the office within the Corporation that administers the education award program. This involves:

- Tracking the service for all AmeriCorps members;
- Ensuring that the requirements of the Corporation's enabling legislation are met, vis-a-vis the education award;
- Processing school and loan payments that the members authorize; and
- Processing payments for the interest that accrues on certain qualified student loans during the member's service period.


## II. Current Action

The Corporation has been using several versions of the two forms contained in this Notice since the AmeriCorps program began in 1994. The Corporation proposes to ask the Office of Management and Budget (OMB) for permission to renew each form in basically the same format as the forms currently in use. The current forms are due to expire on June 30, 2000.

The Corporation's Enrollment Form serves two purposes essential to the functioning of the AmeriCorps program. It is the means by which programs certify that an individual is eligible to serve in an AmeriCorps program and the date service has begun. Second, it provides the Corporation, Grantees, program managers, and Congress with demographic data on AmeriCorps members.

The Enrollment Form is the beginning-of-service counterpart to the Corporation's End of Term/Exit Form, which concludes the tracking of members at the end of their term of service.

Submission of the End of Term/Exit form provides legal certification for the disbursement of an education award to an AmeriCorps member. It is the document by which an authorized program official at an AmeriCorps program site indicates whether an AmeriCorps member is eligible for an education award.

Several versions of both forms have been used since the AmeriCorps program began in 1994.

In 1999, the Corporation began using an electronic system to both enroll and exit AmeriCorps members. Many local projects can enter into a database information about their members’ enrollment and completion of service. This data is transferred to the Trust
periodically where it becomes the official record.
Currently, more than half of the nation's AmeriCorps programs use this system. The Corporation would like to have all programs use it, since it ultimately speeds up both collecting information and issuing education awards to members who have successfully completed their terms of service. However, many AmeriCorps programs, especially smaller ones, do not have the technological resources to afford the computer hardware and software.
The Corporation does not want to exclude any competent, otherwise qualified organizations from participating as a sponsor, so it is possible that there may always be a small number of organizations that will use forms. A separate discussion of each form follows.

## A. Enrollment Form-(OMB \#30450006)

Currently, AmeriCorps members use a form entitled Corporation for National Service Enrollment Form to enroll national service participants in the AmeriCorps program. The form requests program-related as well as demographic information. The program information includes the participant's start date, the code number of the program, the expected completion date, and whether the term of service is full or part time. This is the Corporation's sole source of data for individual members. The demographic information includes background information on the
AmeriCorps member (including gender, marital status, education level, and reasons for joining).
The program information is used to:

- Make liability projections for the Trust Fund;
- Verify national service participation when requested by a lender who holds an AmeriCorps member's student loan (members are eligible to have the repayment of certain student loans postponed if they are participating in national service),
- Plan and monitor programs (review recruiting efforts, identify programs with excessive early termination rates, establish and reconcile program's budgets)
The demographic information is used for recruiting purposes and to provide the Corporation, program managers, and the Congress with demographic data on AmeriCorps members.
In requesting permission for renewal of this form, the Corporation does not propose making any changes to the version currently in use.
Type of Review: Renewal.

Agency: Corporation for National and Community Service.

Title: Corporation for National Service Enrollment Form.

OMB Number: 3045-0006.
Agency Number: None.
Affected Public: Individuals about to participate in an AmeriCorps program.

Total Respondents: 5,000 annually.
Frequency: Once per service period
(average of once per year).
Average Time Per Response: Total of 7 minutes ( 4 minutes for the
AmeriCorps members; and 3 minutes for the program staff).

Estimated Total Burden Hours: 584
hours.
Total Burden Cost (capital/startup):
None.
Total Burden Cost (operating) maintenance): None.
B. End of Term/Exit Form-(3045-0015)

The Corporation's End of Term/Exit form is the means by which AmeriCorps programs certify that a member has, or has not, successfully satisfied conditions which must be met in order to receive an education award. When an AmeriCorps member successfully completes a term of national service, a designated program official certifies that the service was completed and the individual is eligible for an education award. The End of Term/Exit form is the document upon which this certification is recorded. Additional information requested on the form includes the member's service completion date, the current address where the education award documentation should be mailed, and two questions regarding the member's desire for post service information.

The Corporation proposes to eliminate the ten evaluation questions that are on the form currently being used. The Corporation's Evaluation Division has decided that relevant evaluation data will be collected through surveys.

Type of Review: Renewal.
Agency: Corporation for National and Community Service.

Title: Corporation for National Service End of Term/Exit Form.

OMB Number: None.
Agency Number: None.
Affected Public: AmeriCorps members who have ended their term of national service.

Total Respondents: 5,000 annually.
Frequency: Once per term of service (average of once per year).

Average Time Per Response: 7 minutes, total (4 minutes for the AmeriCorps members to complete the form and, 3 minutes for the program staff)

Estimated Total Burden Hours: 584 hours.

Total Burden Cost (capital/startup): None.

Total Burden Cost (operating/ maintenance): None.

Comments submitted in response to this notice will be summarized and/or included in the request for Office of Management and Budget approval of the information collection request; they will also become a matter of public record.
Dated: April 3, 2000.
Thomas L. Bryant,
Acting General Counsel.
[FR Doc. 00-8595 Filed 4-6-00; 8:45 am] BILLING CODE 6050-28-U

## DEPARTMENT OF DEFENSE

## Department of the Army

## Armed Forces Epidemiological Board (AFEB)

AGENCY: Office of the Surgeon General, DoD.
ACTION: Notice of partially-closed meeting.

SUMMARY: In accordance with section 10(a)(2) of Public Law 92-463, The Federal Advisory Committee Act, this announces the forthcoming AFEB meeting. This Board will meet from 0730-1600 on Tuesday, 30 May, and 0730-1300 on Wednesday, 31 May 2000. The purpose of the meeting is to address pending and new Board issues, provide briefings for Board members on topics related to ongoing and new Board issues conduct subcommittee meetings, conduct an executive working session, and to have a classified AFEB update on the DoD Immunization Program for Biological Warfare Defense in accordance with DoD Directive 6205.3. The meeting location will be at USAMRIID, Fort Detrick, Frederick, Maryland. This meeting will be open to the public on 30 May, but limited by space accommodations. The meeting will be closed to the public on 31 May in accordance with Section 552b(c) of Title 5, U.S.C., specifically subparagraph (1) thereof and Title 5, U.S.C., appendix 1, subsection 10 (d). Any interested person may attend, appear before or file statements with the committee at the time and in the manner permitted by the committee.
FOR FURTHER INFORMATION CONTACT: COL
Benedict Diniega, AFEB Executive
Secretary, Armed Forces
Epidemiological Board, Skyline Six, 5109 Leesburg Pike, Room 682, Falls Church, Virginia 22041-3258, (703) 681-8012/4.

SUPPLEMENTARY INFORMATION: None.
John A. Hall,
Alternate Federal Register Liaison Officer. [FR Doc. 00-8676 Filed 4-6-00; 8:45 am] BILLING CODE 3710-08-M

## DEPARTMENT OF DEFENSE

## Department of the Army

Announcement of Intent To Grant an Exclusive License for a U.S. ArmyOwned Patent Application and All Patents Resulting Therefrom Worldwide, Including All Foreign Counterpart Applications

Agencr: Picatinny Arsenal, New Jersey, DoD.

ACTION: Notice.
SUMMARY: The Department of the Army announces that unless there is objection, in sixty days it will grant an Exclusive license to Bulova Technologies, L.L.C,, 101 North Queen Street, Lancaster, Pennsylvania 17604-4787, on U.S. Army Patent Application serial number 09/511,641 filed on February 22, 2000, Army docket number DAR-63-99, entitled "Improved Self Destruct Fuze For Munitions" by Louis J. Adimari, Joseph A. Donini, Keith R. Fulton, Marc E. Ball, Edward F. Cooper, John R.

Hertzier, and John C. Yoo, together with all foreign counterpart patent applications, and all U.S. and worldwide patents resulting therefrom.
FOR FURTHER INFORMATION CONTACT: Mr. John Moran, Chief, Intellectual Property Law Division, AMSTA-AR-GCL, U.S. Army TACOM-ARDEC, Picatinny Arsenal, NJ 07806-5000, telephone (973) 724-6590.

SUPPLEMENTARY INFORMATION: Written objections must be filed within 60 days from publication date of this notice in the Federal Register.

John A. Hall,
Alternate Army Federal Register Liaison Officer.
[FR Doc. 00-8677 Filed 4-6-00; 8:45 am] BILLING CODE 3710-08-M

## DEPARTMENT OF DEFENSE

## Department of the Army

Availability of U.S. Patents for NonExclusive, Exclusive, or PartiallyExclusive Licensing

Agency: U.S. Army Research Laboratory, Adelphi, Maryland, DoD. ACTION: Notice.

SUMMARY: In accordance with 37 CFR 404.6, announcement is made of the availability of the following U.S. patent for non-exclusive, partially exclusive or exclusive licensing. The listed patent has been assigned to the United States of America as represented by the Secretary of the Army, Washington, DC.

This patent covers a wide variety of technical arts including: An improved liquid explosive composition of nitromethane, a nitromethane sensitizer and an energetic compound.

Under the authority of Section 11(a)(2) of the Federal Technology Transfer Act of 1986 (Public Law 99502) and Section 207 of Title 35, United States Code, the Department of the Army as represented by the U.S. Army Research Laboratory wish to license the U.S. patent listed below in a nonexclusive, exclusive or partially exclusive manner to any party interested in manufacturing, using, and/ or selling devices or processes covered by this patent.

Title: Liquid Explosive Composition.
Inventor: John D. Sullivan, Jr.
Patent Number: 6,007,648.
Issued Date: December 28, 1999.
FOR FURTHER INFORMATION CONTACT: Michael Rausa, Technology Transfer Office, AMSRL-CS-TT, U.S. Army Research Laboratory, Aberdeen Proving Ground, MD 21005-5055 tel: (410) 2785028; fax: (410) 278-5820.
SUPPLEMENTARY INFORMATION: None.
Gregory D. Showalter,
Army Federal Register Liaison Officer.
[FR Doc. 00-8673 Filed 4-6-00; 8:45 am]
BILLING CODE $3710-08-\mathrm{M}$

## DEPARTMENT OF THE DEFENSE

## Department of the Army

Notice To Seek Licensing Partners for Psuedo-Monolithic Laser With an Intracavity Optical Parametric Oscillator

AGENCY: U.S. Army, DoD.
ACTION: Notice of intent.
summary: The U.S. Army CERDEC's Night Vision \& Electronic Sensors Directorate (NVESD) has filed for a patent on a Pseudo-Monolithic Laser with an Intracavity Optical Parametric Oscillator. This is to announce that we are now seeking licensing partners for this technology, which has direct applications to military rangefinders as well as other commercial purposes. The laser was designed for simplicity and has no moving parts and few optical components. It can be tuned/ manufactured to laze at three discrete
frequencies. The design makes innovative use of existing flash bulb circuitry found in disposable cameras as the power source for the devices. The design is exceptionally small and compact. There is a plan for initial procurement of rangefinders utilizing this laser which will be announced separately. Other uses of this device include: ophthalmology applications; due to the precision of the beam it may also lend itself to applications in computer chip processing; and applications in surveying instruments. Due to the numerous applications of this technology the NVESD invites companies to consider Cooperative Research and Development Agreements for developing applications of this technology to their product lines. A preliminary design review package and license application for the required patent is available from NVESD. If interested please request information and respond with the required documents within 30 days.
FOR FURTHER INFORMATION CONTACT:
Karen Gordon, U.S. Army (CERDEC)
Night Vision \& Electronic Senors Directorate, ATTN: AMSEL-RD-NVOPS, 10221 Burbeck Road, Fort Belvoir, Virginia 22060-5806, Telephone: (703) 704-2279.
SUPPLEMENTARY INFORMATION: None.
Gregory D. Showalter,
Army Federal Register Liaison Officer. [FR Doc. 00-8675 Filed 4-6-00; 8:45 am] BILLING CODE 3710-08-M

## DEPARTMENT OF DEFENSE

Department of the Army, Corps of Engineers

## Notice of Intent To Prepare an Environmental Impact Statement (EIS) for the John Redmond Lake Reallocation Study, Kansas

agency: U.S. Army Corps of Engineers, Department of Defense.
ACTION: Notice of intent.
SUMMARY: The purpose of the EIS is to address alternatives and impacts pertaining to reallocation of water storage at John Redmond Lake, Kansas.
FOR FURTHER INFORMATION CONTACT:
Questions or comments concerning the proposed action should be addressed to Mr. David L. Combs, Chief, Environmental Analysis and Compliance Branch, 1645 South 101st East Avenue, Tulsa, Oklahoma 741284629, telephone 918-669-7660, e-mail: David L. Combs@usace.army.mil.

## SUPPLEMENTARY INFORMATION: John

Redmond Lake was authorized by the Flood Control Act approved May 17, 1950, Public Law 81-516a; Project Document HD 442, 80th Congress, 2d Session. Public Law 85-327, dated February 15, 1958, changed the project name from Strawn Dam to John Redmond Dam and Reservoir. It is located on the Grand (Neosho) River at river mile 343.7 , about 3 miles northwest of Burlington in Coffey County, Kansas. Project purposes include flood control, water supply, water quality, and recreation. Closure of the embankment was completed in September 1963 and the project was completed for full flood control operation in September 1964.
In 1975, the state of Kansas and the Federal government entered into a water supply agreement for an estimated 34,900 acre-feet of storage remaining after 50 years of sedimentation. After the agreement was signed, it was determined that sediment was entering the lake unevenly from what had been predicted. Over time, sedimentation in the lake has changed the amount of storage the lake has for flood control, water supply and other purposes. Storage available for water supply purposes in the lake has been depleted by sediment distribution such that the water supply agreement obligations are being infringed upon.
Most of the sediment deposited in the lake pool has been below elevation 1039.0 (top of conservation pool), National Geodetic Vertical Datum (NGVD). Based on the Corps sediment surveys for 1964-1993, it was predicted that adequate storage would be available below elevation 1068.0 feet NGVD (top of flood control pool) at the end of the economic life of the project (Year 2014) to meet all authorized project purposes. However, the top of the conservation pool should ultimately be established at a higher elevation to reapportion equitably the storage between the conservation and flood control pools.
When a lake is designed, each pool (flood control, conservation, sediment) is designed to capture a proportionate amount of sediment. In the case of John Redmond, the sediment load has been as predicted; however, the sediment is accumulating in the conservation pool while the flood control pool has experienced less than expected sedimentation losses.
The reallocation study and EIS will focus on ways to accommodate for the uneven distribution of sediment within the lake and evaluate a number of alternatives. Alternatives presently identified include the no action plan, which follows the current operational
practices and another alternative to raise the lake's conservation pool to accommodate for sediment buildup. This alternative includes a 2 -foot pool rise with the intentions of raising the conservation pool to elevation 1040.0 feet NGVD and using a phased pool raise of the remaining one-foot, in onehalf foot pool increments.

The EIS will evaluate the effects of alternatives on the authorized project purposes and other identified concerns. Significant issues to be addressed in the EIS include: (1) potential impacts to the Flint Hills National Wildlife Refuge; (2) impacts on recreation and recreation facilities; (3) impacts on structure of the dam; (4) impacts on fish and wildlife resources within and also above and below the lake; (5) impacts on downstream flows on the Neosho River; and (6) other impacts identified by the public, agencies, or Corps studies.

Scoping meetings for the project are planned to be conducted in March and April 2000. News releases informing the public and local, state, and Federal agencies of the proposed action will be published in local newspapers. Comments received as a result of this notice and the news releases will be used to assist the Tulsa District in identifying potential impacts to the quality of the human or natural environment. Affected local, state, or Federal agencies, affected Indian tribes, and other interested private organizations and parties may participate in the Scoping process by forwarding written comments to the above noted address or attending Scoping meetings.

The draft EIS (DEIS) is expected to be available for public review and comment by September 2001. Any comments and suggestions should be forwarded to the above noted address no later than June 1, 2000, to be considered in the DEIS.

Dated: March 27, 2000.
Leonardo V. Flor,
Colonel, U.S. Army District Engineer.
[FR Doc. 00-8674 Filed 4-6-00; 8:45 am] BILLING CODE 3710-39-M

## DEPARTMENT OF EDUCATION

[CFDA No.: 84.292B]

## Office of Bilingual Education: FieldInitiated Research Program

AGENCY: Department of Education.
ACTION: Correction and Extension notice.

SUMMARY: On March 17, 2000, a notice inviting applications for new awards for

FY 2000 was published in the Federal Register ( 65 FR 14730 through 14749). This notice was a complete application package and contained all of the information, application forms and instructions needed to apply for a grant under this program. There was one form inadvertently omitted from the application package. The form was "Bilingual Education: Field Initiated Research Program—Eligibility Certification"'. The form is included with this correction notice.
Note: This notice also extends the deadline for transmittal of application as follows:

## DEADLINE FOR TRANSMITTAL OF

APPLICATIONS: April 24, 2000.
DEADLINE FOR INTERGOVERNMENTAL REVIEW: May 24, 2000.
FOR FURTHER INFORMATION CONTACT:
Socorro Lara, U.S. Department of Education, 400 Maryland Ave., SW Room 5086, Switzer Building, Washington, DC 20202-6510. Telephone: (202) 205-9730. E-mail address: socorro__lara@ed.gov.
Individuals who use a telecommunications device for the deaf (TDD) may call the Federal Information Relay Services (FIRS) at 1-800-8778330.

Individuals with disabilities may obtain this document in an alternate format (e.g., Braille, large print, audiotape, or computer diskette) on request to the contact person listed in the preceding paragraph. Please, note, however, that the Department is not able to reproduce in an alternate format the standard forms included in the notice.

## Electronic Access to This Document

You may review this document, as well as all other Department of Education documents published in the Federal Register, in text or Adobe Portable Document Format (PDF) on the internet at either of the following sites:
http://ocfo.ed.gov/fedreg.htm
http://www.ed.gov/news.html
To use the PDF you must have the Adobe Acrobat Reader Program with Search, which is available free at either of the preceding sites. If you have questions about using the PDF, call the U.S. Government Printing Office toll free at 1-888-293-6498 or in the Washington, DC area at (202) 512-1530.
Note: The official version of this document is the document published in the Federal Register. Free Internet access to the official edition of the Federal Register and the Code of Federal Regulations is available on GPO Access at http://www.access.gpo.gov/nara/ index.html.

Program Authority

Dated: March 31, 2000.

## Art Love,

Acting Director, Office of Bilingual Education and Minority Languages Affairs.

BILLING CODE 4000-01-M

# BILINGUAL EDUCATION: FIELD-INITIATED RESEARCH PROGRAM 

## ELIGIBILITY CERTIFICATION

## Application Information

Name of Institution
$\qquad$
$\qquad$

Address (give city, county, state, zip code)

Type of Institution (IHE, NPO, SEA, LEA)

Grant(s) received under subpart 1 or 2 of Title VII of the Elementary and Secondary Education Act (or Parts A and B of Title VII of ESEA, as in effect prior to its amendment on October 20, 1994):

Grants must have been received within the previous five years.
$\qquad$
$\qquad$
$\qquad$
$\qquad$

Type of grant

## DEPARTMENT OF ENERGY

## Office of Science; Biological and Environmental Research Advisory Committee

AGENCY: Department of Energy.
ACTION: Notice of open meeting.
SUMMARY: This notice announces a meeting of the Biological and
Environmental Research Advisory Committee. Federal Advisory
Committee Act (Pub. L. 92-463, 86 Stat. 770 ) requires that public notice of these meetings be announced in the Federal
Register.
DATES: Thursday, April 27, 2000, 8:30 a.m. to 5 p.m.; and Friday, April 28, 2000, 8:30 a.m. to 12 p.m.
ADDRESSES: American Geophysical Union, 2000 Florida Avenue, N.W., Washington, D.C. 20009.
FOR FURTHER INFORMATION CONTACT: Dr.
David Thomassen (301-903-9817; david.thomassen@science.doe.gov), or Ms. Shirley Derflinger (301-903-0044; shirley.derflinger@science.doe.gov), Designated Federal Officers, Biological and Environmental Research Advisory Committee, U.S. Department of Energy, Office of Science, Office of Biological and Environmental Research, SC-70, 19901 Germantown Road, Germantown, Maryland 20874-1290. The most current information concerning this meeting can be found on the website http://www.sc.doe.gov/production/ ober/berac.html.

## SUPPLEMENTARY INFORMATION:

Purpose of the Meeting: To provide advice on a continuing basis to the Director, Office of Science of the Department of Energy, on the many complex scientific and technical issues that rise in the development and implementation of the biological and environmental research program.

## Tentative Agenda:

Thursday, April 27 and Friday, April 28, 2000:
Welcoming Remarks
Opening of Meeting
Remarks from Acting Director, Office of Science
Update on Office of Biological and Environmental Research Activities Review of Subcommittee Activities New Business
Public Comment (10-minute rule)
Public Participation: The day and a half meeting is open to the public. If you would like to file a written statement with the Committee, you may do so either before or after the meeting. If you would like to make oral statements regarding any of the items on the agenda, you should contact David Thomassen or Shirley Derflinger at the address or telephone numbers listed above. You must make your request for an oral statement at least five business days before
the meeting. Reasonable provision will be made to include the scheduled oral statements on the agenda. The Chairperson of the Committee will conduct the meeting to facilitate the orderly conduct of business. Public comment will follow the 10 -minute rule.

Minutes: The minutes of this meeting will be available for public review and copying within 30 days at the Freedom of Information Public Reading Room, 1E-190, Forrestal Building, 1000 Independence Avenue, S.W., Washington, D.C., between 9 a.m. and 4 p.m., Monday through Friday, except Federal holidays.

Issued in Washington, D.C. on April 4, 2000.

Rachel M. Samuel,
Deputy Advisory Committee Management Officer.
[FR Doc. 00-8655 Filed 4-6-00; 8:45 am] BILLING CODE 6450-01-P

## DEPARTMENT OF ENERGY

## Environmental Management SiteSpecific Advisory Board, Los Alamos

AGENCY: Department of Energy.
ACTION: Notice of Open Meeting.
SUMMARY: This notice announces a meeting of the Environmental Management Site-Specific Advisory Board (EM SSAB), Los Alamos. The Federal Advisory Committee Act (Pub. L. No. 92-463, 86 Stat. 770) requires that public notice of these meetings be announced in the Federal Register.
DATES: Wednesday, April 26, 2000, 6 p.m.-9 p.m.

ADDRESSES: Hotel Loretto, 211 Old Santa Fe Trail, Santa Fe, NM.

## FOR FURTHER INFORMATION CONTACT: Ann

 DuBois, Northern New Mexico Citizens' Advisory Board, 1640 Old Pecos Trail,Suite H, Santa Fe, NM 87505.
Phone:505-989-1662; Fax: 505-989-
1752; E-mail: adubois@doeal.gov; or Internet http:www.nmcab.org
SUPPLEMENTARY INFORMATION: Purpose of the Board: The purpose of the Board is to make recommendations to DOE and its regulators in the areas of environmental restoration, waste management, and related activities.

## Tentative Agenda

Opening Activities, 6 p.m.-6:30 p.m.
Public Comment, 6:30 p.m.-7 p.m.

## Committee Reports

Environmental Restoration
Monitoring and Surveillance
Waste Management
Community Outreach
Budget.
Other Board business will be conducted as necessary.

Public Participation: The meeting is open to the public. Written statements may be filed with the Committee either before or after the meeting. Individuals who wish to make oral statements pertaining to agenda items should contact Ann DuBois at the address or telephone number listed above.
Requests must be received 5 days prior to the meeting and reasonable provision will be made to include the presentation in the agenda. The Deputy Designated Federal Officer is empowered to conduct the meeting in a fashion that will facilitate the orderly conduct of business. Each individual wishing to make public comment will be provided a maximum of 5 minutes to present their comments at the beginning of the meeting.

Minutes: The minutes of this meeting will be available for public review and copying at the Freedom of Information Public Reading Room, 1E-190, Forrestal Building, 1000 Independence Avenue, SW, Washington, DC 20585 between 9 a.m. and 4 p.m., Monday-Friday, except Federal holidays. Minutes will also be available at the Public Reading Room located at the Board's office at 528 35th Street, Los Alamos, NM 87544. Hours of operation for the Public Reading Room are $9 \mathrm{a} . \mathrm{m}$. and 4 p.m. on Monday through Friday. Minutes will also be made available by writing or calling Ann DuBois at the Board's office address or telephone number listed above.
Issued at Washington, DC on April 4, 2000. Rachel M. Samuel,
Deputy Advisory Committee Management Officer.
[FR Doc. 00-8654 Filed 4-6-00; 8:45 am] BILLING CODE 6405-01-P

## DEPARTMENT OF ENERGY

## Environmental Management SiteSpecific Advisory Board, Pantex Plant

AGENCY: Department of Energy.
ACTION: Notice of open meeting.
SUMMARY: This notice announces a meeting of the Environmental Management Site-Specific Advisory Board (EM SSAB), Pantex Plant, Amarillo, Texas. The Federal Advisory Committee Act (Pub. L. 92-463, 86 Stat. 770 ) requires that public notice of these meetings be announced in the Federal Register.
date and time: Tuesday, April 25, 2000; 1 p.m.-5 p.m.
addresses: The Wellington Room, I-40 \& Georgia, Amarillo, Texas.

FOR FURTHER INFORMATION CONTACT: Jerry
S. Johnson, Assistant Area Manager,

Department of Energy, Amarillo Area Office, P.O. Box 30030, Amarillo, TX 79120 (806) 477-3125.

## SUPPLEMENTARY INFORMATION:

Purpose of the Board: The purpose of the Board is to advise the Department of Energy and its regulators in the areas of environmental restoration, waste management, and related activities.

## Tentative Agenda

1:00 Agenda Review/Approval of Minutes
1:15 Co-Chair Comments
1:30 Task Force/Subcommittee Reports
2:00 Ex-Officio Reports
2:30 Updates-Concurrence Reports-DOE
3:00 Break
3:15 Presentation (To Be Decided)
4:15 Public Comments
4:30 Closing Comments
4:45 Adjourn
Public Participation: The meeting is open to the public. Written statements may be filed with the Committee either before or after the meeting. Individuals who wish to make oral statements pertaining to agenda items should contact Jerry Johnson's office at the address or telephone number listed above. Requests must be received 5 days prior to the meeting and every reasonable provision will be made to accommodate the request in the agenda. The Deputy Designated Federal Officer is empowered to conduct the meeting in a fashion that will facilitate the orderly conduct of business. Each individual wishing to make public comment will be provided a maximum of 5 minutes to present their comments.
Minutes: The minutes of this meeting will be available for public review and copying at the Pantex Public Reading Rooms located at the Amarillo College Lynn Library and Learning Center, 2201 South Washington, Amarillo, TX, phone (806) 371-5400. Hours of operation are from 7:45 a.m. to 10 p.m. Monday through Thursday; 7:45 a.m. to 5 p.m. on Friday; 8:30 a.m. to 12 noon on Saturday; and 2 p.m. to 6 p.m. on Sunday, except for Federal holidays. Additionally, there is a Public Reading Room located at the Carson County Public Library, 401 Main Street, Panhandle, TX phone (806) 537-3742. Hours of operation are from 9 a.m. to 7 p.m. on Monday; 9 a.m. to 5 p.m. Tuesday through Friday; and closed Saturday and Sunday as well as Federal Holidays. Minutes will also be available by writing or calling Jerry S. Johnson at the address or telephone number listed above.

Issued at Washington, DC on April 4, 2000 Rachel M. Samuel,
Deputy Advisory Committee Management Officer.
[FR Doc. 00-8656 Filed 4-6-00; 8:45 am] BILLING CODE 6450-01-P

## ENVIRONMENTAL PROTECTION AGENCY

[ER-FRL-6253-1]
Environmental Impact Statements and Regulations; Availability of EPA Comments

Availability of EPA comments prepared March 20, 2000 Through March 24, 2000 pursuant to the Environmental Review Process (ERP), under Section 309 of the Clean Air Act and Section 102(2)(c) of the National Environmental Policy Act as amended. Requests for copies of EPA comments can be directed to the Office of Federal Activities at (202) 564-7167. An explanation of the ratings assigned to draft environmental impact statements (EISs) was published in FR dated April 09, 1999 ( 63 FR 17856).

## Draft EISs

ERP No. D-AFS-E65053-NC Rating EC2, Croatan National Forest Revised Land and Resource Management Plan (1986), Implementation, Carteret, Craven, and Jones Counties, NC.

Summary: EPA expressed concern regarding potential water quality impacts and that the preferred alternative could potentially clearcut too much timber too rapidly for conversion to longleaf pines and consequently be counterproductive to RCW recovery. EPA recommended that the alternatives discussion be modified to take this concern into account.

ERP No. D-AFS-J65320-MT Rating EC2, Knox-Brooks Timber Sales and Road Rehabilitation, Implementation, Lolo National Forest, Super Ranger District, Mineral County, MT.

Summary: EPA expressed environmental concerns regarding potential erosion impacts, wetland impacts, aquatic effects of herbicides, and the level of monitoring to detect effects of management activities. EPA requested additional information on these issues and mitigation measures to reduce the impacts of management actions.

ERP No. D-AFS-J65321-MT Rating EC2, Mill-Key-Wey Project, Proposed Timber Harvesting, Ecosystem Burning, Road Construction and Reconstruction, Implementation, Lolo National Forest, Superior Ranger District, Mineral County, MT.

Summary: EPA expressed concerns regarding harvests on erosive soils, wetland impacts, use of weed control chemical and the level of monitoring proposed to identify project impacts. The EPA requested additional information on these issues and
mitigation measures to reduce potential impacts of the management actions.

ERP No. D-SFW-K90030-CA Rating EC2, San Diequito Wetland Restoration Project, Implementation,
Comprehensive Restoration Plan, COE Section 404 Permit, Cities of Del Mar and San Diego, San Diego County, CA.

Summary: EPA expressed concern due to the potential for undiscovered contaminated soil and hazardous waste. EPA requested that soil contamination be monitored and that a monitoring, emergency response, and reporting plan be included as part of the restoration program.

## Final EISs

ERP No. F-BLM-J67028-CO North Fork Coal Program, Approval of Two Lease-By-Applications (LBA) and Exploration License for Iron Point and Elk Creek Coal Leases, Delta and Gunnison Counties, CO.

Summary: No formal comment letter sent to preparing agency.

ERP No. F-NPS-G02009-TX Padre Island National Seashore Oil and Gas Management Plan, Implementation, Kleberg, Kenedy and Willacy Counties, TX.

Summary: EPA previous concerns have been adequately responded to, therefore EPA has no objection to the action as proposed.
Dated: April 4, 2000.
Joseph C. Montgomery,
Director, Office of Federal Activities.
[FR Doc. 00-8669 Filed 4-6-00; 8:45 am] BILLING CODE 6560-50-P

## ENVIRONMENTAL PROTECTION AGENCY

[ER-FRL-6252-9]

## Environmental Impact Statements; Notice of Availability

Responsible Agency: Office of Federal Activities, General Information (202) 564-7167 or www.epa.gov/oeca/ofa.
Weekly Receipt of Environmental Impact Statements
Filed March 27, 2000 Through March 31, 2000
Pursuant to 40 CFR 1506.9
EIS No. 000087, Draft EIS, AFS, ID, Idaho Panhandle National Forests, Small Sales, Harvesting Dead and Damaged Timber, Coeur d'Alene River Range District, Kootenai and Shoshone Counties, ID, Due: May 15, 2000, Contact: Bob Rehnborg (208) 664-2318.
EIS No. 000088, Draft EIS, AFS, PA, Duck and Sheriff Project Area (DSPA), Timber Management, Road

Construction and Reconstruction, Trail Maintenance, Wildlife Habitat Improvement, and Recreation Management, Allegheny National Forest, Bradford Ranger District, Cherry Grove Township of Warren County, and Howe Township of Forest County, PA, Due: May 15, 2000, Contact: John Schultz (814) 362-4613.
EIS No. 000089, Draft EIS, AFS, ID, Warm Springs Ridge Vegetation Management Project, Improve Forest Conditions, Boise National Forest, Cascade Resource Area, Boise County, ID, Due: May 15, 2000, Contact: Kathy Ramirez (208) 392-6681.
EIS No. 000090, Final EIS, FAA, MA, Provincetown Municipal Airport Safety and Operational Enhancement Project, Improvements (1) Firefighter Equipment Garage; (2) General Aviation Parking Apron Expansion;
(3) Runaway Safety Areas, and (4) a

Runaway Extension, COE Section 404
Permit, Cape Cod National Seashore,
Barnstable County, MA, Due: May 01,
2000, Contact: Frank Smigelski (781)
238-7613.
EIS No. 000091, Draft Supplement, AFS, WA, ID, OR, MT, Interior Columbia
Basin Ecosystem Management Projects, Updated and New Information on three Management Alternatives, Implementation, WA, OR, ID and MT, Due: June 30, 2000, Contact: Cathy Humphrey (208) 3341770.

EIS No. 000092, Final EIS, FTA, CA, Vasona Corridor Light Rail Transit Project, Extension of existing Light Rail Transit (LRT), in portion of the Cities of San Jose, Campbell and Los Gatos, Santa Clara County, CA, Due: May 01, 2000, Contact: Jerome Wiggins (415) 744-3115.
EIS No. 000093, Draft EIS, AFS, ID, JJ (Jerry Johnson) Ecosystem Restoration Project, Implementation, Clearwater National Forest, Lochsa Ranger
District (Powell), Idaho County, ID,
Due: May 15, 2000, Contact: Ken Hotchkiss (208) 942-3113.
EIS No. 000094, Draft Supplement, COE, CA, Port of Los Angeles Channel Deepening Project, To Improve Navigation and Disposal of Dredge Material for the Inner Harbor Channels, Los Angeles County, CA, Due: May 22, 2000, Contact: Larry Smith (213) 452-3846.
Dated: April 4, 2000.
Joseph C. Montgomery,
Director, Office of Federal Activities.
[FR Doc. 00-8670 Filed 4-6-00; 8:45 am]
BILLING CODE 6560-50-P

## ENVIRONMENTAL PROTECTION AGENCY

[PF-933; FRL-6552-9]

## Notice of Filing a Pesticide Petition to Establish a Tolerance for Certain Pesticide Chemicals in or on Food

AGENCY: Environmental Protection Agency (EPA).
ACTION: Notice.
SUMMARY: This notice announces the initial filing of a pesticide petition proposing the establishment of regulations for residues of certain pesticide chemicals in or on various food commodities.
DATES: Comments, identified by docket control number PF-933, must be received on or before May 8, 2000.
ADDRESSES: Comments may be submitted by mail, electronically, or in person. Please follow the detailed instructions for each method as provided in Unit I.C. of the
"SUPPLEMENTARY INFORMATION." To ensure proper receipt by EPA, it is imperative that you identify docket control number PF-933 in the subject line on the first page of your response. FOR FURTHER INFORMATION CONTACT: By mail: Treva C. Alston, Registration Division (7505C), Office of Pesticide Programs, Environmental Protection Agency, Ariel Rios Bldg., 1200 Pennsylvania Ave., NW., Washington, DC 20460; telephone number: (703) 308-8373; and e-mail address: alston.treva@epa.gov.

## SUPPLEMENTARY INFORMATION:

## I. General Information

## A. Does this Action Apply to Me?

You may be affected by this action if you are an agricultural producer, food manufacturer or pesticide manufacturer. Potentially affected categories and entities may include, but are not limited to:

| Cat- <br> egories | NAICS <br> codes | Examples of poten- <br> tially affected entities |
| :---: | :--- | :--- |
| Industry | 111 | Crop production <br> Animal production <br>  <br>  <br>  <br>  <br>  <br> 3112 <br> 32532 | | Food manufacturing |
| :--- |
| Pesticide manufac- |
| turing |$\quad$

This listing is not intended to be exhaustive, but rather provides a guide for readers regarding entities likely to be affected by this action. Other types of entities not listed in the table could also be affected. The North American

Industrial Classification System (NAICS) codes have been provided to assist you and others in determining whether or not this action might apply to certain entities. If you have questions regarding the applicability of this action to a particular entity, consult the person listed in the "FOR FURTHER INFORMATION CONTACT" section.
B. How Can I Get Additional Information, Including Copies of this Document and Other Related Documents?

1. Electronically. You may obtain electronic copies of this document, and certain other related documents that might be available electronically, from the EPA Internet Home Page at http:// www.epa.gov/. To access this document, on the Home Page select "Laws and Regulations" and then look up the entry for this document under the "Federal Register--Environmental Documents." You can also go directly to the Federal Register listings at http:// www.epa.gov/fedrgstr/.
2. In person. The Agency has established an official record for this action under docket control number PF933. The official record consists of the documents specifically referenced in this action, any public comments received during an applicable comment period, and other information related to this action, including any information claimed as confidential business information (CBI). This official record includes the documents that are physically located in the docket, as well as the documents that are referenced in those documents. The public version of the official record does not include any information claimed as CBI. The public version of the official record, which includes printed, paper versions of any electronic comments submitted during an applicable comment period, is available for inspection in the Public Information and Records Integrity Branch (PIRIB), Rm. 119, Crystal Mall \#2, 1921 Jefferson Davis Highway, Arlington, VA, from 8:30 a.m. to 4 p.m., Monday through Friday, excluding legal holidays. The PIRIB telephone number is (703) 305-5805.

## C. How and to Whom Do I Submit Comments?

You may submit comments through the mail, in person, or electronically. To ensure proper receipt by EPA, it is imperative that you identify docket control number PF-933 in the subject line on the first page of your response.

1. By mail. Submit your comments to: Public Information and Records Integrity Branch (PIRIB), Information Resources and Services Division
(7502C), Office of Pesticide Programs (OPP), Environmental Protection Agency, Ariel Rios Bldg., 1200 Pennsylvania Ave., NW., Washington, DC 20460.
2. In person or by courier. Deliver your comments to: Public Information and Records Integrity Branch (PIRIB), Information Resources and Services Division (7502C), Office of Pesticide Programs (OPP), Environmental Protection Agency, Rm. 119, Crystal Mall \#2, 1921 Jefferson Davis Highway, Arlington, VA. The PIRIB is open from 8:30 a.m. to 4 p.m., Monday through Friday, excluding legal holidays. The PIRIB telephone number is (703) 3055805.
3. Electronically. You may submit your comments electronically by e-mail to: "opp-docket@epa.gov," or you can submit a computer disk as described above. Do not submit any information electronically that you consider to be CBI. Avoid the use of special characters and any form of encryption. Electronic submissions will be accepted in Wordperfect 6.1/8.0 or ASCII file format. All comments in electronic form must be identified by docket control number PF-933. Electronic comments may also be filed online at many Federal Depository Libraries.

## D. How Should I Handle CBI That I Want to Submit to the Agency?

Do not submit any information electronically that you consider to be CBI. You may claim information that you submit to EPA in response to this document as CBI by marking any part or all of that information as CBI. Information so marked will not be disclosed except in accordance with procedures set forth in 40 CFR part 2. In addition to one complete version of the comment that includes any information claimed as CBI, a copy of the comment that does not contain the information claimed as CBI must be submitted for inclusion in the public version of the official record. Information not marked confidential will be included in the public version of the official record without prior notice. If you have any questions about CBI or the procedures for claiming CBI, please consult the person identified under "FOR FURTHER INFORMATION CONTACT."

## E. What Should I Consider as I Prepare My Comments for EPA?

You may find the following suggestions helpful for preparing your comments:

1. Explain your views as clearly as possible.
2. Describe any assumptions that you used.
3. Provide copies of any technical information and/or data you used that support your views.
4. If you estimate potential burden or costs, explain how you arrived at the estimate that you provide.
5. Provide specific examples to illustrate your concerns.
6. Make sure to submit your comments by the deadline in this notice.
7. To ensure proper receipt by EPA, be sure to identify the docket control number assigned to this action in the subject line on the first page of your response. You may also provide the name, date, and Federal Register citation.

## II. What Action is the Agency Taking?

EPA has received a pesticide petition as follows proposing the establishment and/or amendment of regulations for residues of certain pesticide chemicals in or on various food commodities under section 408 of the Federal Food, Drug, and Comestic Act (FFDCA), 21 U.S.C. 346a. EPA has determined that this petition contains data or information regarding the elements set forth in section 408(d)(2); however, EPA has not fully evaluated the sufficiency of the submitted data at this time or whether the data support granting of the petition. Additional data may be needed before EPA rules on the petition.

## List of Subjects

Environmental protection, Agricultural commodities, Feed additives, Food additives, Pesticides and pests, Reporting and recordkeeping requirements.

Dated: March 30, 2000.
James Jones,
Director, Registration Division, Office of Pesticide Programs.

## Summary of Petition

The petitioner summary of the pesticide petition is printed below as required by section 408(d)(3) of the FFDCA. The summary of the petition was prepared by the petitioner and represents the views of the petitioner. EPA is publishing the petition summary verbatim without editing it in any way. The petition summary announces the availability of a description of the analytical methods available to EPA for the detection and measurement of the pesticide chemical residues or an explanation of why no such method is needed.

## Ecolab Inc.

OE6100
EPA has received a pesticide petition (OE6100) from Ecolab Inc., 370 N. Wabasha Street, St. Paul, MN 55102 proposing, pursuant to section 408(d) of the Federal Food, Drug, and Cosmetic Act (FFDCA), 21 U.S.C. 346a(d), to amend 40 CFR part 180 to establish an exemption from the requirement of a tolerance for 1,2 -ethanediamine, polymer with oxirane and methyloxirane (EDPOM) in or on raw agricultural commodities, in processed commodities, and in or on meat and meat by products of cattle, sheep, hogs, goats, horses, and poultry, milk, and dairy products, eggs, seafood and shellfish, and fruits and vegetables when such residues result from the use of EDPOM as a component of a food contact surface sanitizing solution for use in food handling establishments. The request is for an unlimited clearance. EPA has determined that the petition contains data or information regarding the elements set forth in section 408(d)(2) of the FFDCA; however, EPA has not fully evaluated the sufficiency of the submitted data at this time or whether the data supports granting of the petition. Additional data may be needed before EPA rules on the petition.

## A. Residue Chemistry

This is a high molecular weight alkoxylated amine polymer. No residue chemistry data or environmental fate data are presented in the petition as the Agency does not generally require some or all of the listed studies to rule on the exemption from the requirement of a tolerance for an inert ingredient.

## B. Toxicological Profile

The Agency has established a set of criteria, which identifies categories of polymers that present low risk. These criteria (described in 40 CFR 723.250) identify polymers that are relatively unreactive and stable compounds compared to other chemical substances as well as polymers that typically are not readily absorbed. These properties generally limit a polymer's ability to cause adverse effects. The Agency believes that polymers meeting the criteria noted above will present minimal or no risk. Ecolab Inc. believes that EDPOM conforms to the definition of a polymer given in 40 CFR 723.250 and meets the following criteria used to identify a low risk polymer.

1. EDPOM is not a cationic polymer, nor is it reasonably anticipated to become a cationic polymer in a natural aquatic environment.
2. EDPOM contains as an integral part of its composition the atomic elements carbon, nitrogen, hydrogen and oxygen.
3. EDPOM does not contain as an integral part of its composition, except as impurities, any element other than those listed in 40 CFR 723.250(d)(2)(ii).
4. EDPOM is not designed, nor is it reasonably anticipated to substantially degrade, decompose or depolymerize prior to, during, or after use.
5. EDPOM is not manufactured or imported from monomers and/or reactants that are not included on the Toxic Substances Control Act (TSCA) substance inventory or manufactured under an applicable TSCA section 5 exemption.
6. EDPOM is not a water absorbing polymer.
7. EDPOM has an minimum-average molecular weight of 25,000 . Substances with molecular weights greater than 400 generally are not absorbed through the intact skin, and substances with molecular weights greater than 1,000 generally are not absorbed through the gastrointestinal (GI) tract. Chemicals not absorbed through the skin or GI tract generally are incapable of eliciting a toxic response.
8. EDPOM has a minimum-average molecular weight of 25,000 . EDPOM meets the requirements for molecular weight distribution of oligomer contents of less than $25 \%$ with molecular weights below 1,000 and less than $10 \%$ with molecular weights below 500 .

Ecolab Inc. believes that sufficient information has been submitted to assess the hazards of EDPOM. No toxicology data are being submitted as the Agency does not generally require these data to rule on exemptions from the requirement of a tolerance for an inert ingredient. Because EDPOM conforms with the definition of a polymer and meets the criteria of a polymer under 40 CFR 723.250, Ecolab Inc. believes there are no concerns for risks associated with toxicity.

## C. Aggregate Exposure

1. Dietary exposure. Acute: Due to the low toxicity, there are no toxicological concerns for EDPOM. An acute dietary risk assessment is not appropriate. Chronic: Chronic exposure would not produce any effect since it is not absorbed. Therefore, no concerns are warranted.
i. Food. When EDPOM is used as a component of a food contact surface sanitizer, the residue that would be introduced into food will be insignificant. EDPOM is not absorbed from the GI tract. Based on this, there are no toxicological concerns resulting from exposures to residues of EDPOM
resulting from the use of sanitizing solutions.
ii. Drinking water. Acute: EDPOM is not expected to be introduced into drinking water, therefore an acute drinking water risk assessment is not required. Chronic: EDPOM is not expected to be introduced into drinking water; therefore, a chronic drinking water risk assessment is not required.
2. Non-dietary exposure. EDPOM is not absorbed from the GI tract or through the skin. The potential for significant additional non-occupational exposure to the general population (including children) is unlikely.

## D. Cumulative Effects

The amount of EDPOM exposure resulting from indirect exposure to sanitizing solutions will be miniscule. EDPOM is a high molecular weight alkoxylated amine polymer that is not absorbed by the body. EDPOM in the diet poses no cumulative toxicological risk. Ecolab Inc. believes that sufficient information has been submitted to assess the hazards of EDPOM. Because EDPOM conforms with the definition of a polymer and meets the criteria of a polymer under 40 CFR 723.250, Ecolab Inc. believes there are no concerns for risks associated with cumulative effects.

## E. Safety Determination

1. U.S. population. There are no adverse toxicological effects resulting from ingestion of trace amounts of EDPOM, so there is no need to determine aggregate risks, or to conduct a safety determination. EDPOM exposure due to its use as an inert ingredient in a food contact surface sanitizer is negligible. Ecolab Inc. believes that sufficient information has been submitted to assess the hazards of EDPOM. Because it conforms with the definition of a polymer and meets the criteria of a polymer under 40 CFR 723.250, there are no concerns for risks associated with any potential exposure to adults.
2. Infants and children. Children are at no greater risk from exposure to EDPOM. Therefore, as with adults, a safety determination is not appropriate. Ecolab Inc. believes that sufficient information has been submitted to assess the hazards of EDPOM. Because it conforms with the definition of a polymer and meets the criteria of a polymer under 40 CFR 723.250, there are no concerns for risks associated with any potential exposure to children.

## E. International Tolerances

No Codex Maximum Residue Levels have been established for EDPOM. [FR Doc. 00-8405 Filed 4-6-00; 8:45 am] BILLING CODE 6560-50-F

## ENVIRONMENTAL PROTECTION AGENCY

## [PF-932; FRL-6499-7]

## Notice of Filing a Pesticide Petition to Establish a Tolerance for Certain Pesticide Chemicals in or on Food

Agency: Environmental Protection Agency (EPA).
ACTION: Notice.
SUMMARY: This notice announces the initial filing of pesticide petitions proposing the establishment of regulations for residues of certain pesticide chemicals in or on various food commodities.
DATES: Comments, identified by docket control number PF-932, must be received on or before May 8, 2000.
ADDRESSES: Comments may be submitted by mail, electronically, or in person. Please follow the detailed instructions for each method as provided in Unit I.C. of the "SUPPLEMENTARY INFORMATION." To ensure proper receipt by EPA, it is imperative that you identify docket control number PF-932 in the subject line on the first page of your response. FOR FURTHER INFORMATION CONTACT: By mail: Treva C. Alston, Registration Division (7505C), Office of Pesticide Programs, Environmental Protection Agency, Ariel Rios Bldg., 1200
Pennsylvania Ave., NW., Washington, DC 20460; telephone number: (703) 308-8373; e-mail address: alston.treva@epa.gov.

## SUPPLEMENTARY INFORMATION:

## I. General Information

## A. Does this Action Apply to Me?

You may be affected by this action if you are an agricultural producer, food manufacturer or pesticide manufacturer. Potentially affected categories and entities may include, but are not limited to:

| Cat- <br> egories | NAICS | Examples of poten- <br> tially affected entities |
| :---: | :--- | :--- |
| Industry | 111 | Crop production <br> Animal production <br> Food manufacturing <br> Pesticide manufac- <br> turing |
|  | 311 |  |

This listing is not intended to be exhaustive, but rather provides a guide for readers regarding entities likely to be affected by this action. Other types of entities not listed in the table could also be affected. The North American Industrial Classification System (NAICS) codes have been provided to assist you and others in determining whether or not this action might apply to certain entities. If you have questions regarding the applicability of this action to a particular entity, consult the person listed under "FOR FURTHER INFORMATION CONTACT.,

## B. How Can I Get Additional Information, Including Copies of this Document and Other Related Documents?

1. Electronically. You may obtain electronic copies of this document, and certain other related documents that might be available electronically, from the EPA Internet Home Page at http:// www.epa.gov/. To access this document, on the Home Page select "Laws and Regulations" and then look up the entry for this document under the "Federal Register--Environmental Documents." You can also go directly to the Federal Register listings at http:// www.epa.gov/fedrgstr/.
2. In person. The Agency has established an official record for this action under docket control number PF932. The official record consists of the documents specifically referenced in this action, any public comments received during an applicable comment period, and other information related to this action, including any information claimed as confidential business information (CBI). This official record includes the documents that are physically located in the docket, as well as the documents that are referenced in those documents. The public version of the official record does not include any information claimed as CBI. The public version of the official record, which includes printed, paper versions of any electronic comments submitted during an applicable comment period, is available for inspection in the Public Information and Records Integrity Branch (PIRIB), Rm. 119, Crystal Mall \#2, 1921 Jefferson Davis Highway, Arlington, VA, from 8:30 a.m. to 4 p.m., Monday through Friday, excluding legal holidays. The PIRIB telephone number is (703) 305-5805.

## C. How and to Whom Do I Submit Comments?

You may submit comments through the mail, in person, or electronically. To ensure proper receipt by EPA, it is imperative that you identify docket
control number PF-932 in the subject line on the first page of your response.

1. By mail. Submit your comments to: Public Information and Records Integrity Branch (PIRIB), Information Resources and Services Division (7502C), Office of Pesticide Programs (OPP), Environmental Protection Agency, Ariel Rios Bldg., 1200 Pennsylvania Ave., NW., Washington, DC 20460.
2. In person or by courier. Deliver your comments to: Public Information and Records Integrity Branch (PIRIB), Information Resources and Services Division (7502C), Office of Pesticide Programs (OPP), Environmental Protection Agency, Rm. 119, Crystal Mall \#2, 1921 Jefferson Davis Highway, Arlington, VA. The PIRIB is open from 8:30 a.m. to 4 p.m., Monday through Friday, excluding legal holidays. The PIRIB telephone number is (703) 3055805.
3. Electronically. You may submit your comments electronically by e-mail to: "opp-docket@epa.gov,"' or you can submit a computer disk as described above. Do not submit any information electronically that you consider to be CBI. Avoid the use of special characters and any form of encryption. Electronic submissions will be accepted in Wordperfect 6.1/8.0 or ASCII file format. All comments in electronic form must be identified by docket control number PF-932. Electronic comments may also be filed online at many Federal Depository Libraries.

## D. How Should I Handle CBI That I Want to Submit to the Agency?

Do not submit any information electronically that you consider to be CBI. You may claim information that you submit to EPA in response to this document as CBI by marking any part or all of that information as CBI.
Information so marked will not be disclosed except in accordance with procedures set forth in 40 CFR part 2. In addition to one complete version of the comment that includes any information claimed as CBI, a copy of the comment that does not contain the information claimed as CBI must be submitted for inclusion in the public version of the official record. Information not marked confidential will be included in the public version of the official record without prior notice. If you have any questions about CBI or the procedures for claiming CBI, please consult the person identified under "FOR FURTHER INFORMATION CONTACT."
E. What Should I Consider as I Prepare My Comments for EPA?

You may find the following suggestions helpful for preparing your comments:

1. Explain your views as clearly as possible.
2. Describe any assumptions that you used.
3. Provide copies of any technical information and/or data you used that support your views.
4. If you estimate potential burden or costs, explain how you arrived at the estimate that you provide.
5. Provide specific examples to illustrate your concerns.
6. Make sure to submit your comments by the deadline in this notice.
7. To ensure proper receipt by EPA, be sure to identify the docket control number assigned to this action in the subject line on the first page of your response. You may also provide the name, date, and Federal Register citation.

## II. What Action is the Agency Taking?

EPA has received pesticide petitions as follows proposing the establishment and/or amendment of regulations for residues of certain pesticide chemicals in or on various food commodities under section 408 of the Federal Food, Drug, and Comestic Act (FFDCA), 21 U.S.C. 346a. EPA has determined that this petition contains data or information regarding the elements set forth in section 408(d)(2); however, EPA has not fully evaluated the sufficiency of the submitted data at this time or whether the data support granting of the petition. Additional data may be needed before EPA rules on the petition.

## List of Subjects

Environmental protection, Agricultural commodities, Feed additives, Food additives, Pesticides and pests, Reporting and recordkeeping requirements.
Dated: March 30, 2000.

## James Jones,

Director, Registration Division, Office of Pesticide Programs.

## Summary of Petition

The petitioner summary of the pesticide petition is printed below as required by section 408(d)(3) of the FFDCA. The summary of the petition was prepared by the petitioner and represents the view of the petitioners. EPA is publishing the petition summary verbatim without editing it in any way. The petition summary announces the availability of a description of the
analytical methods available to EPA for the detection and measurement of the pesticide chemical residues or an explanation of why no such method is needed.

## 1. Ecolab Inc.

## PP 9E6028

EPA has received a pesticide petition (PP 9E6028) from Ecolab Inc., 370 N. Wabasha Street, St. Paul, MN 55102 proposing, pursuant to section 408(d) of the Federal Food, Drug, and Cosmetic Act (FFDCA), 21 U.S.C. $346 \mathrm{a}(\mathrm{d})$, to amend 40 CFR part 180 to establish an exemption from the requirement of a tolerance for urea in or on raw agricultural commodities, in processed commodities, and in or on meat and meat by products of cattle, sheep, hogs, goats, horses, and poultry, milk, and dairy products, eggs, seafood and shellfish, and fruits and vegetables when such residues result from the use of urea as a component of a food contact surface sanitizing solution for use in food handling establishments. The request is for an unlimited clearance. EPA has determined that the petition contains data or information regarding the elements set forth in section 408(d)(2) of the FFDCA; however, EPA has not fully evaluated the sufficiency of the submitted data at this time or whether the data supports granting of the petition. Additional data may be needed before EPA rules on the petition.

## A. Residue Chemistry

1. Analytical method. Because Ecolab Inc. is petitioning for an exemption from the requirement of a tolerance, an enforcement method for urea is not needed.
2. Magnitude of residues. The residues which transfer from the sanitized dish or utensil to food are not of toxicological significance.

## B. Toxicological Profile

1. Acute toxicity. Urea is a direct food additive. Urea in concentrated form is severely irritating to the eyes and slightly irritating to the skin. It is essentially non-toxic for acute oral and dermal effects. From published
literature values the acute oral $\mathrm{LD}_{50}$ in rats was determined to be 14,300 milligrams/kilograms ( $\mathrm{mg} / \mathrm{kg}$ ). No value is assigned for dermal $\mathrm{LD}_{50}$ since it is essentially non-toxic via the dermal route.
2. Genotoxicity. Nothing in the available literature indicates that urea is a genotoxic material. There is no data that would indicate it has carcinogenic properties.
3. Reproductive and developmental toxicity. Nothing in the available
literature indicates that urea is a developmental or reproductive toxin. It is generally recognized as safe and is a normal constituent in the human diet.
4. Subchronic toxicity. Nothing in the available literature indicates chronic exposure of urea products any adverse toxicological effects unless it is ingested at extremely high doses. Urea has been used as a feed supplement in cattle. Levels of 5\% in their diet did not result in adverse effects. At dietary levels approaching $25 \%$, symptoms of ammonia toxicity such as central nervous system (CNS) effects develop. At normal dietary intake levels in the human diet, no adverse effects result. Due to the rapid excretion of urea, prolonged low level exposure does not produce cumulative toxicity. Most of the urea in the body is generated endogenously since urea is the major pathway of nitrogen excretion in man. The typical concentration of urea excreted in the urine is approximately is $1,000 \mathrm{mg} /$ deciliter (dl).
5. Chronic toxicity. Chronic exposure would not produce any additional effect over what is noted in subchronic exposure; therefore, no additional concerns are warranted. Nothing in the literature indicates that urea may be carcinogenic.
6. Animal metabolism.. Urea is a normal constituent of cellular metabolism in man.
7. Endocrine disruption. A review of information from the Agency for Toxic Substances and Disease Registry indicates that potential endocrine effects from exposure to urea have not been studied. To the best of our knowledge, nothing in the available literature suggests that urea acts as an endocrine disrupter or that it possesses intrinsic hormonal activity.

## C. Aggregate Exposure

1. Dietary exposure- i. Acute. Due to the low toxicity, there are no toxicological concerns for urea. An acute dietary risk assessment is not appropriated.
ii.Chronic. Chronic exposure would not produce any additional effect beyond what is noted in acute exposure, therefore, no additional concerns are warranted.
iii. Food- Chronic direct. A typical adult ingests significant quantities of urea via the diet. An even larger amount is generated endogenously by the liver as a part of nitrogen excretion. Following ingestion, urea is absorbed by the gastrointestinal tract. The approximate concentration of urea in the plasma is $15 \mathrm{mg} / \mathrm{dl}$. When urea is used as a component of a food contact surface sanitizer, the residue that would
be introduced into food will be insignificant compared to the normal dietary intake and endogenous production. Based on this, there are no toxicological concerns resulting from exposures to residues of urea resulting from the use of sanitizing solutions.
2. Drinking water- i. Acute. Since there are no acute toxicological concerns for urea, an acute drinking water risk assessment is not required.
ii. Chronic. There are no toxicological concerns about the exposure of low concentrations of urea in the drinking water. Although it is possible that trace amounts of urea resulting from its use as a sanitizer may ultimately get into drinking water, no adverse health effects would result.
3. Non-dietary exposure. The potential for significant additional nonoccupational exposure to the general population (including children) is unlikely.

## D. Cumulative Effects

Well over $99 \%$ of the exposure to urea is expected to be via natural sources in the diet and through endogenous generation. Potentially small amounts of urea exposure will be the result of nonfood uses. The amount of urea exposure resulting from indirect exposure to sanitizing solutions will be miniscule. Since urea in the diet poses no toxicological risk, the cumulative toxicity resulting from this additional exposure is negligible.

## E. Safety Determination

1. U.S. population. Since there are no adverse toxicological effects resulting from normal dietary concentrations of urea, there is no need to determine aggregate risks, or to conduct a safety determination. Urea is generally recognized as safe and the incremental exposure due to its use as an inert in a food contact surface sanitizer is negligible.
2. Infants and children. As in adults, infants and children produce urea as a basic process of cellular metabolism. Children are at no greater "risk" from exposure to urea. Therefore, as with adults, a safety determination is not appropriate.

## F. International Tolerances

No codex maximum residue levels have been established for urea.

## 2. Ecolab Inc.

## PP 9E6029

EPA has received a pesticide petition (9E6029) from Ecolab Inc., proposing, pursuant to section 408(d) of FFDCA, 21 U.S.C. 346a(d), to amend 40 CFR part 180 to establish an exemption from the
requirement of a tolerance for nitric acid in or on raw agricultural commodities, in processed commodities, and in or on meat and meat byproducts of cattle, sheep, hogs, goats, horses, and poultry, milk, and dairy products, eggs, seafood and shellfish, and fruits and vegetables when such residues result from the use of nitric acid as a component of a food contact surface sanitizing solution for use in food handling establishments at 1,000 parts per million (ppm). EPA has determined that the petition contains data or information regarding the elements set forth in section 408(d)(2) of the FFDCA; however, EPA has not fully evaluated the sufficiency of the submitted data at this time or whether the data supports granting of the petition. Additional data may be needed before EPA rules on the petition.

## A. Residue Chemistry

1 Analytical method. Because Ecolab Inc. is petitioning for an exemption from the requirement of a tolerance, an enforcement method for nitric acid is not needed.
2. Magnitude of residues. The residues which transfer from the sanitized dish or utensil to food are not of toxicological significance.

## B. Toxicological Profile

1. Acute toxicity. Nitric acid $\left(\mathrm{HNO}_{3}\right)$ in concentrated form is corrosive to the eyes and corrosive to the skin. In neutral solutions, nitric acid dissociates into nitrate ions $\left(\mathrm{NO}_{3}-\right.$ ). Nitrate is a normal constituent of the diet. Nitrate (as sodium nitrate) is allowed under 40 CFR 180.1001(d) as an inert ingredient in pesticide formulations applied to growing crops without limit in the formula. No data are available on the acute oral $\mathrm{LD}_{50}$ of nitric acid. The rat oral $\mathrm{LD}_{50}$ of sodium nitrate is approximately $2,000 \mathrm{mg} / \mathrm{kg}$. Acute or short-term exposure at relatively high doses of nitrate may result in the formation of methemoglobin. This is caused by the reduction of nitrate to nitrite by microorganisms in the oral cavity or gastrointestinal tract. Nitrite ion is capable of rapidly oxidizing the ferrous ion to ferric ion in hemoglobin, producing methemoglobin. The body possesses enzymes capable of reduction of the methemoglobin back to hemoglobin.
2. Genotoxicity. Nothing in the available literature indicates that nitric acid or nitrate are considered to be genotoxic or mutagenic.
3. Reproductive and developmental toxicity. Nothing in the available literature indicates that nitric acid or nitrate are developmental or reproductive toxins. Sodium nitrate has
been repeatedly tested for adverse reproductive effects. A series of teratology studies were conducted under the direction of the Food and Drug Administration (FDA) using mice, rats, hamsters and rabbits. Mice (doses up to $400 \mathrm{mg} / \mathrm{kg}$ ), rats (doses up to 250 $\mathrm{mg} / \mathrm{kg}$ ), hamsters (doses up to $400 \mathrm{mg} /$ kg ), and rabbits (doses up to $250 \mathrm{mg} / \mathrm{kg}$ ) were treated through the organogenesis phase of gestation and sacrificed just prior to parturition. There were no effects on fetal survival, reproductive parameters or incidence of malformations. Many other studies have corroborated these results. Some studies have demonstrated fetal death and other adverse effects, but only at doses that caused significant methemoglobinemia and maternal toxicity.
4. Subchronic toxicity. No studies are available on the long-term effects of nitric acid. In neutral solutions, nitric acid dissociates into nitrate ions. Data are available on long-term exposure to nitrate. Nitrate is a normal constituent of the diet. Studies on nitrate have focused on the effects on the blood, namely the induction of methemoglobin formation. Bacteria in the oral cavity and gastrointestinal tract reduce nitrate to nitrite $\left(\mathrm{NO}_{2}-\right)$. Approximately 5-10\% of a typical dose of nitrate is converted into nitrite. Nitrite is capable of oxidizing the hemoglobin iron from $\mathrm{a}+2$ valence to +3 valence resulting in the formation of methemoglobin.
Methemoglobin is not capable of oxygen transport. Normal levels of methemoglobin in human blood range from $1-2 \%$ of the total hemoglobin content. Methemoglobin levels below $10 \%$ are asymptomatic. Animal studies have demonstrated that chronic, low level exposure to nitrate does not result in adverse health effects. Rats drinking water containing $2,000 \mathrm{mg} / \mathrm{L}$ sodium nitrate $\left(\mathrm{NaNO}_{3}\right)$ (corresponding to doses of up to $150-300 \mathrm{mg}$ nitrate $/ \mathrm{kg} /$ day) did not demonstrate increased levels of methemoglobin. Other studies reported similar findings. Long-term exposure at very high levels can result in an increased red blood cell turnover and subsequent hemosiderosis and hepatic atrophy. Animals exposed to relatively low levels of nitrate do not demonstrate any hematological or histopathological effects. Nitrate does not accumulate in the body. It is excreted primarily in the urine or is converted to nitrite via bacteria in oral cavity and gastrointestinal tract. Nitrite in the blood quickly reacts with hemoglobin. The toxicological profile of nitrate clearly demonstrates that, except for the cases of large bolus doses, nitrate is not a chronic toxicant. Residue levels and
exposure limits should be based on the acute toxic effects rather than on longterm exposures.
5. Chronic toxicity. Chronic exposure would not produce any additional effect beyond what is noted in subchronic exposure, therefore, no additional concerns are warranted. Several studies have been conducted on nitrate. None have concluded nitrate is a carcinogen.
6. Animal metabolism. Nitrate is a normal constituent of the diet.
7. Endocrine disruption. A review of information from the Agency for Toxic Substances and Disease Registry indicates that potential endocrine effects from exposure to nitric acid or nitrate ion have not been studied. To the best of our knowledge, nothing in the available literature suggests that nitric acid acts as an endocrine disrupter or that it possesses intrinsic hormonal activity.

## C. Aggregate Exposure

1. Dietary exposure- i. Acute. Nitric acid is converted into nitrate in aqueous solutions. Nitrate is a common constituent of the human diet. Nitrate is found mostly in green leafy vegetables such as beets ( $2,400 \mathrm{ppm}$ ), celery ( 2,300 ppm ) and turnip greens ( $6,600 \mathrm{ppm}$ ). It is the acute toxicity, not chronic exposure that is a concern, especially in infants (0-3 months). Based on the acute toxicological effects of nitrate, an EPA IRIS oral reference dose (RfD) of 7.0 mg nitrate $/ \mathrm{kg} /$ day was established. This number assumes that the infant is the most susceptible sub-population and an uncertainty factor of 1 , since the results are based on actual human data.
ii. Chronic. Chronic exposure would not produce any additional effect beyond what is noted in acute exposure, therefore, no additional concerns are warranted.
iii. Food. A typical adult ingests significant quantities of nitrate in the diet. A typical adult's daily intake of nitrate is about 1.3 mg nitrate $/ \mathrm{kg} /$ day. The dietary intake of nitrate accounts for the vast majority of all nitrate exposure. Using a worst case scenario, exposure to nitrate resulting from the use of nitric acid as a component of a hard surface sanitizer at $1,000 \mathrm{ppm}$ would be $0.057 \mathrm{mg} / \mathrm{kg} /$ day for adults. This value is calculated by using standard FDA calculations for exposures to hard surface sanitizers.
2. Drinking water- i. Acute. Nitrate is commonly found in drinking water, most typically in well water. Although there have been several instances of chronic methemoglobinemia reported from people consuming water containing high nitrate levels, typically the concentration of nitrate is quite low.

The EPA has set the drinking water equivalent level (DWEL) for nitrate at 10 mg nitrate-nitrogen/L (44 mg nitrate/L).
ii. Chronic. There are no chronic toxicological concerns about the exposure of low concentrations (below $44 \mathrm{mg} / \mathrm{L}$ ) of nitrate in the drinking water. Although it is possible that trace amounts of nitrate from a sanitizer may ultimately get into drinking water, no adverse health effects would result. The amount of "naturally occurring nitrate" in drinking water (especially well water) will greatly exceed the amount derived from sanitizing solutions. Since only a small fraction of the population drinks well water with elevated concentrations of nitrate, this is not a concern for the general population.
3. Non-dietary exposure. The potential for significant additional nonoccupational exposure under the use proposed to the general population (including children) is unlikely.

## D. Cumulative Effects

Well over $99 \%$ of the exposure to nitric acid/nitrate is expected to be via natural sources in the diet and drinking water. Trace amounts of nitric acid/ nitrate exposure may result from nonfood uses. The amount of nitric acid/ nitrate exposure resulting from indirect exposure to sanitizing solutions will be virtually zero. Since nitric acid/nitrate in the diet poses little toxicological risk, the cumulative toxicity resulting from this additional exposure to hard surface sanitizers is negligible.

## E. Safety Determination

1. U.S. population. Since there are no adverse toxicological effects resulting from normal dietary concentrations of nitric acid/nitrate ion, and the additional exposure from sanitizers is miniscule, there is no need to determine aggregate risks, or to conduct a safety determination.
2. Infants and children. Infants under 3 months of age are the most susceptible population; however, their diet is unlikely to be in contact with food contact surface sanitizers.

## F. International Tolerances

No Codex maximum levels have been established for nitric acid.
[FR Doc. 00-8406 Filed 4-6-00; 8:45 am]
BILLING CODE 6560-50-F

## ENVIRONMENTAL PROTECTION AGENCY

[PF-930; FRL-6499-4]

## Notice of Filing a Pesticide Petition to Establish a Tolerance for Certain Pesticide Chemicals in or on Food

agencr: Environmental Protection Agency (EPA).
ACTION: Notice.
SUMMARY: This notice announces the initial filing of a pesticide petition proposing the establishment of regulations for residues of certain pesticide chemicals in or on various food commodities.
DATES: Comments, identified by docket control number PF-930, must be received on or before May 8, 2000.
ADDRESSES: Comments may be submitted by mail, electronically, or in person. Please follow the detailed instructions for each method as provided in Unit I.C. of the
"SUPPLEMENTARY INFORMATION." To ensure proper receipt by EPA, it is imperative that you identify docket control number PF-930 in the subject line on the first page of your response.
FOR FURTHER INFORMATION CONTACT: By mail: Thomas C. Harris, Registration Division (7505C), Office of Pesticide Programs, Environmental Protection Agency, Ariel Rios Bldg., 1200
Pennsylvania Ave., NW., Washington, DC 20460; telephone number: (703) 308-9423; e-mail address: harris.thomas@epa.gov.

## SUPPLEMENTARY INFORMATION:

## I. General Information

## A. Does this Action Apply to Me?

You may be affected by this action if you are an agricultural producer, food manufacturer or pesticide manufacturer. Potentially affected categories and entities may include, but are not limited to:

| Cat- <br> egories | NAICS <br> Codes | Examples of poten- <br> tially affected entities |
| :---: | :--- | :--- |
| Industry | 111 | Crop production <br>  <br>  <br>  <br>  <br>  <br>  <br> 311 <br> 32532 |
| Animal production <br> Food manufacturing <br> Pesticide manufac- <br> turing |  |  |

This listing is not intended to be exhaustive, but rather provides a guide for readers regarding entities likely to be affected by this action. Other types of entities not listed in the table could also be affected. The North American

Industrial Classification System (NAICS) codes have been provided to assist you and others in determining whether or not this action might apply to certain entities. If you have questions regarding the applicability of this action to a particular entity, consult the person listed under "FOR FURTHER INFORMATION CONTACT."

## B. How Can I Get Additional

 Information, Including Copies of this Document and Other Related Documents?1. Electronically. You may obtain electronic copies of this document, and certain other related documents that might be available electronically, from the EPA Internet Home Page at http:// www.epa.gov/. To access this document, on the Home Page select "Laws and Regulations" and then look up the entry for this document under the "Federal Register--Environmental Documents." You can also go directly to the Federal Register listings at http:// www.epa.gov/fedrgstr/.
2. In person. The Agency has established an official record for this action under docket control number PF930. The official record consists of the documents specifically referenced in this action, any public comments received during an applicable comment period, and other information related to this action, including any information claimed as confidential business information (CBI). This official record includes the documents that are physically located in the docket, as well as the documents that are referenced in those documents. The public version of the official record does not include any information claimed as CBI. The public version of the official record, which includes printed, paper versions of any electronic comments submitted during an applicable comment period, is available for inspection in the Public Information and Records Integrity Branch (PIRIB), Rm. 119, Crystal Mall \#2, 1921 Jefferson Davis Highway, Arlington, VA, from 8:30 a.m. to 4 p.m., Monday through Friday, excluding legal holidays. The PIRIB telephone number is (703) 305-5805.

## C. How and to Whom Do I Submit Comments?

You may submit comments through the mail, in person, or electronically. To ensure proper receipt by EPA, it is imperative that you identify docket control number PF-930 in the subject line on the first page of your response.

1. By mail. Submit your comments to: Public Information and Records Integrity Branch (PIRIB), Information Resources and Services Division
(7502C), Office of Pesticide Programs (OPP), Environmental Protection Agency, Ariel Rios Bldg., 1200 Pennsylvania Ave., NW., Washington, DC 20460.
2. In person or by courier. Deliver your comments to: Public Information and Records Integrity Branch (PIRIB), Information Resources and Services Division (7502C), Office of Pesticide Programs (OPP), Environmental Protection Agency, Rm. 119, Crystal Mall \#2, 1921 Jefferson Davis Highway, Arlington, VA. The PIRIB is open from 8:30 a.m. to 4 p.m., Monday through Friday, excluding legal holidays. The PIRIB telephone number is (703) 3055805.
3.Electronically. You may submit your comments electronically by e-mail to: "opp-docket@epa.gov," or you can submit a computer disk as described above. Do not submit any information electronically that you consider to be CBI. Avoid the use of special characters and any form of encryption. Electronic submissions will be accepted in Wordperfect 6.1/8.0 or ASCII file format. All comments in electronic form must be identified by docket control number PF-930. Electronic comments may also be filed online at many Federal Depository Libraries.

## D. How Should I Handle CBI That I Want to Submit to the Agency?

Do not submit any information electronically that you consider to be CBI. You may claim information that you submit to EPA in response to this document as CBI by marking any part or all of that information as CBI. Information so marked will not be disclosed except in accordance with procedures set forth in 40 CFR part 2. In addition to one complete version of the comment that includes any information claimed as CBI, a copy of the comment that does not contain the information claimed as CBI must be submitted for inclusion in the public version of the official record. Information not marked confidential will be included in the public version of the official record without prior notice. If you have any questions about CBI or the procedures for claiming CBI, please consult the person identified under "FOR FURTHER INFORMATION CONTACT."

## E. What Should I Consider as I Prepare My Comments for EPA?

You may find the following suggestions helpful for preparing your comments:

1. Explain your views as clearly as possible.
2. Describe any assumptions that you used.
3. Provide copies of any technical information and/or data you used that support your views.
4. If you estimate potential burden or costs, explain how you arrived at the estimate that you provide.
5. Provide specific examples to illustrate your concerns.
6. Make sure to submit your comments by the deadline in this notice.
7. To ensure proper receipt by EPA, be sure to identify the docket control number assigned to this action in the subject line on the first page of your response. You may also provide the name, date, and Federal Register citation.

## II. What Action is the Agency Taking?

EPA has received a pesticide petition as follows proposing the establishment and/or amendment of regulations for residues of certain pesticide chemical in or on various food commodities under section 408 of the Federal Food, Drug, and Comestic Act (FFDCA), 21 U.S.C. 346a. EPA has determined that this petition contains data or information regarding the elements set forth in section 408(d)(2); however, EPA has not fully evaluated the sufficiency of the submitted data at this time or whether the data supports granting of the petition. Additional data may be needed before EPA rules on the petition.

## List of Subjects

Environmental protection, Agricultural commodities, Feed additives, Food additives, Pesticides and pests, Reporting and recordkeeping requirements.

Dated: March 28, 2000.
James Jones,
Director, Registration Division, Office of Pesticide Programs.

## Summary of Petition

The petitioner summary of the pesticide petition is printed below as required by section 408(d)(3) of the FFDCA. The summary of the petition was prepared by the petitioner and represents the view of the petitioner. EPA is publishing the petition summary verbatim without editing it in any way. The petition summary announces the availability of a description of the analytical methods available to EPA for the detection and measurement of the pesticide chemical residues or an explanation of why no such method is needed.

## Novartis Crop Protection, Inc.

PP 9F5047
EPA has received a pesticide petition (PP 9F5047) from Novartis Crop Protection, Inc., P.O. Box 18300, Greensboro, NC 27419 proposing, pursuant to section 408(d) of the Federal Food, Drug, and Cosmetic Act (FFDCA), 21 U.S.C. $346 a(d)$, to amend 40 CFR part 180 by establishing a tolerance for residues of abamectin (avermectin $B_{1}$ ) and or its delta 8,9-isomer in or on the raw agricultural commodities plums at 0.01 parts per million ( ppm ), fruiting vegetables (except Cucurbits) group at 0.02 ppm , and leafy vegetables (except Brassica) group at 0.10 ppm . EPA has determined that the petition contains data or information regarding the elements set forth in section 408(d)(2) of the FFDCA; however, EPA has not fully evaluated the sufficiency of the submitted data at this time or whether the data support granting of the petition. Additional data may be needed before EPA rules on the petition.

## A. Residue Chemistry

1. Plant metabolism. The metabolism of abamectin in plants is adequately understood and the residues of concern include the parent insecticide, abamectin or avermectin $B_{1}$, which is a mixture of a minimum of $80 \%$ avermectin $B_{1 a}$ and a maximum of $20 \%$ avermectin $\mathrm{B}_{1 \mathrm{~b}}$ and the delta 8,9-isomer of the $\mathrm{B}_{1 \mathrm{a}}$ and of the $\mathrm{B}_{1 \mathrm{~b}}$ components of the parent insecticide. Animal metabolism also has been studied but is not relevant to this petition, since the crops involved are not significant animal feed items. Under photolytic conditions in the laboratory and in the field, abamectin under goes isomerization around the 8,9-double bond to produce small amounts of the delta-8,9 isomer. The photo-oxidative half-life of the delta-8,9 isomer is 4.5 hours and that of avermectin $\mathrm{B}_{1 \mathrm{a}}$ is 6.5 hours.
2. Analytical method. The analytical method involves homogenization, filtration, partition and cleanup with analysis by HPLC-fluorescence detection. The methods are sufficiently sensitive to detect residues at or above the tolerances proposed. All methods have undergone independent laboratory validation as required by PR Notice 885.
3. Magnitude of residues. Abamectin was applied to leaf lettuce and spinach in eleven trials in the following states: Colorado, California (4) sites; Florida, Texas, Arizona leaf lettuce; South Carolina spinach; New Jersey spinach; and New York leaf lettuce. Nine field trials were conducted in the principal
plum growing areas of the United States including California (6), Michigan (1), Oregon (1) and Washington (1). This data support the proposed tolerances of 0.01 ppm for residues of abamectin on plums and 0.10 ppm on leafy vegetables (except Brassica) group. Tolerances and residue data on tomatoes and peppers support the fruiting vegetable (except Cucurbits) group tolerance.

## B. Toxicological Profile

1. Acute toxicity. The data base includes the following studies: A rat acute oral study with a $\mathrm{LD}_{50}$ of 4.4 to 11.8 milligrams/kilograms ( $\mathrm{mg} / \mathrm{kg}$ ) (males) and 10.9 to $14.9 \mathrm{mg} / \mathrm{kg}$ (females); an acute oral toxicity in the CF-1 mouse with the delta 8,9-isomer has $\mathrm{LD}_{50}$ greater than $80 \mathrm{mg} / \mathrm{kg}$; a rabbit acute dermal study with a $\mathrm{LD}_{50}$ greater than $2,000 \mathrm{mg} / \mathrm{kg}$; a rat acute inhalation study with a LC Le $_{50}$ greater than 5.73 mg / L ; a primary eye irritation study in rabbits which showed irritation; a primary dermal irritation study in rabbits which showed no irritation; a primary dermal sensitization study in guinea pigs which showed no skin sensitization potential; an acute oral toxicity study in monkeys with no observed adverse effects level (NOAEL) of $1.0 \mathrm{mg} / \mathrm{kg}$ based upon emesis at 2.0 $\mathrm{mg} / \mathrm{kg}$.
2. Genotoxicity. The ames assays conducted with and without metabolic activation were both negative. The V-79 mammalian cell mutagenesis assays conducted with and without metabolic activation did not produce mutations. In an alkaline elution/rat hepatocyte assay, abamectin was found to induce single strand DNA breaks without significant toxicity in rat hepatocytes treated in vitro at doses greater than 0.2 mM . This in vitro dose of 0.2 mM is biologically unobtainable in vivo, due to the toxicity of the compound. However, at these potentially lethal doses, in vivo treatment did not induce DNA single strand breaks in hepatocytes. In the mouse bone marrow assay, abamectin was not found to induce chromosomal damage. There are also many studies and a great deal of clinical and followup experience with regard to ivermectin, a closely similar human and animal drug.
3. Reproductive and developmental toxicity. A 2-generation study in rats with a NOAEL of $0.12 \mathrm{mg} / \mathrm{kg} /$ day in pups based upon retinal folds, decreased body weight, and mortality. The NOAELs for systemic and reproductive toxicity were $0.4 \mathrm{mg} / \mathrm{kg} /$ day. In the $2-$ generation reproduction study in rats with the delta 8,9 -isomer, the NOAEL was $0.4 \mathrm{mg} / \mathrm{kg} /$ day and the NOAEL was greater than $0.4 \mathrm{mg} / \mathrm{kg} /$ day
(HDT). An oral teratology study in the CF-1 mouse with a maternal NOAEL of $0.05 \mathrm{mg} / \mathrm{kg} /$ day based upon decreased body weights and tremors. The fetal NOAEL was $0.20 \mathrm{mg} / \mathrm{kg} /$ day based upon cleft palates. An oral teratology study with the delta 8,9-isomer in CF-1 mice with a maternal NOAEL of $0.10 \mathrm{mg} / \mathrm{kg} /$ day based upon decreased body weights. The fetal NOAEL was $0.06 \mathrm{mg} /$ kg /day based upon cleft palate. An oral teratology study in rabbits with a maternal NOAEL of $1.0 \mathrm{mg} / \mathrm{kg} /$ day based upon decreased body weights and tremors. The fetal NOAEL was $1.0 \mathrm{mg} /$ $\mathrm{kg} /$ day based upon clubbed feet. An oral teratology study in rats with a maternal and fetal NOAEL at $1.6 \mathrm{mg} / \mathrm{kg} /$ day, the highest dose tested (HDT). An oral teratology study with the delta 8,9isomer with a maternal NOAEL in CF1 mice that expressed P-glycoprotein greater than $1.5 \mathrm{mg} / \mathrm{kg} /$ day, the highest and only dose tested. No cleft palates were observed in fetuses that expressed normal levels of P-glycoprotein, but fetuses with low or no levels of $P$ glycoprotein had increased incidence of cleft palates.
4. Subchronic toxicity. A rat 8-week feeding study with a NOAEL of $1.4 \mathrm{mg} /$ $\mathrm{kg} /$ day based upon tremors. A rat 14week oral toxicity study with a NOAEL of $0.4 \mathrm{mg} / \mathrm{kg} /$ day, the highest dose tested. A dog 12-week feeding study with a NOAEL of $0.5 \mathrm{mg} / \mathrm{kg} /$ day based upon mydriasis. A dog 18-week oral study with a NOAEL of $0.25 \mathrm{mg} / \mathrm{kg} /$ day based upon mortality. A CD-1 mouse 84-day feeding study with a NOAEL of $4 \mathrm{mg} / \mathrm{kg} /$ day based upon decreased body weights.
5. Chronic toxicity. A rat 53-week oncogenicity feeding study, negative for oncogenicity, with a NOAEL of $1.5 \mathrm{mg} /$ kg /day based upon tremors. A CD-1 mouse $94-$ week oncogenicity feeding study, negative for oncogenicity, with a NOAEL of $4 \mathrm{mg} / \mathrm{kg} /$ day based upon decreased body weights. A dog $53-$ week chronic feeding study, negative for oncogenicity, with a NOAEL of $0.25 \mathrm{mg} /$ $\mathrm{kg} /$ day based upon mydriasis.
6. Animal metabolism. Rats were given oral doses of 0.14 or $1.4 \mathrm{mg} / \mathrm{kg} /$ day of abamectin or $1.4 \mathrm{mg} / \mathrm{kg} /$ day of the delta-8,9 isomer. Over 7 days, the percent excreted in urine were $0.3-1 \%$ of the administered dose of abamectin and $0.4 \%$ of the dose of the isomer. The animals eliminated $69-82 \%$ of the dose of abamectin and $94 \%$ of the dose of isomer in feces. In rats, goats and cattle, unchanged parent compound accounted for up to $50 \%$ of the total radioactive residues in tissues. The 24-
hydroxymethyl derivative of abamectin was found in rats, goats and cattle treated with the compound and in rats
treated with the delta-8,9 isomer, and the $3^{\prime \prime}-\mathrm{O}$-demethyl derivative was found in rats and cattle administered abamectin and in rats administered the isomer.
7. Metabolite toxicology. There are no metabolites of concern based on a differential metabolism between plants and animals. The potential hazard of the 24-hydroxymethyl or the $3^{\prime \prime}-\mathrm{O}$ demethyl animal metabolites was evaluated in through toxicology studies with abamectin, photolytic break down product, the delta 8,9-isomer.
8. Endocrine disruption. There is no evidence that abamectin is an endocrine disrupter. Evaluation of the rat multigenerational study demonstrated no effect on the time to mating or on the mating and fertility indices, suggesting no effects on the estrous cycle, on mating behavior, or on male or female fertility at doses up to $0.4 \mathrm{mg} / \mathrm{kg} /$ day, the highest dose tested. Furthermore, the range finding study demonstrated no adverse effect on female fertility at doses up to $1.5 \mathrm{mg} / \mathrm{kg} /$ day, the highest dose tested. Similarly, chronic and subchronic toxicity studies in mice, rats, and dogs did not demonstrate any evidence of toxicity to the male or female reproductive tract, or to the thyroid or pituitary based upon organ weights and gross and histopathologic examination. In the developmental studies, the pattern of toxicity observed does not seem suggestive of any endocrine effect. Finally, experience with ivermectin in breeding animals, including sperm evaluations in multiple species, shows no adverse effects suggestive of endocrine disruption.

## C. Aggregate Exposure

Dietary exposure-i. Food. The acute dietary reference dose ( RfD ) is 0.0025 $\mathrm{mg} / \mathrm{kg} /$ day from a 1 -year dog study. The NOAEL is $0.25 \mathrm{mg} / \mathrm{kg} /$ day, and the lowest observed adverse effect level (LOAEL) is $0.50 \mathrm{mg} / \mathrm{kg} /$ day based on mydriasis (pupil dilation) which was observed after 1-week of dosing. An uncertainty factor of 100 to account for interspecies extrapolation (10x) and intraspecies variability (10x) was recommended. EPA has also retained the 10x safety factor for infants and children resulting in an aRfD of 0.00025 $\mathrm{mg} / \mathrm{kg}$ for appropriate populations. EPA has determined that the studies conducted with the CF-1 mouse are not relevant to human safety assessment. A Monte Carlo acute dietary exposure analysis predicted the percent RfD used for the general population is $39.9 \%$ at the $99.9 \%$. Children 1-6 years constitute the sub-population with the highest predicted exposure. The predicted percent RfD utilization for
this subgroup is $69.5 \%$ for $99.9 \%$ of the individuals.

EPA has established the RfD for abamectin at $0.0012 \mathrm{mg} / \mathrm{kg} /$ day from a 2 -generation reproduction study in rats. The developmental NOAEL is 0.12 mg / $\mathrm{kg} /$ day, and the developmental LOAEL is $0.40 \mathrm{mg} / \mathrm{kg} /$ day based on decreased pup body weight and viability during lactation, and increased incidence of retinal rosettes in F2b weanlings. An uncertainty factor of 100 to account for interspecies extrapolation (10x) and intraspecies variability (10x) was recommended. EPA has also retained the 10x safety factor for infants and children resulting in an RfD of 0.00012 $\mathrm{mg} / \mathrm{kg} /$ day for appropriate population dietary exposure analysis for abamectin in the most exposed population (nonnursing infants $<1$-year old) shows the percent RfD utilization to be only $20.0 \%$. For the average U.S. population (48 contiguous states), dietary exposure for abamectin shows a minimal utilization of 9.4\% of the RfD.
ii. Drinking water. EPA modeling data (Generic Expected Environmental Concentration/Screening Concentration In Ground Water (GENEEC/SCIGROW)) indicated the worst case estimated environmental concentrations (EEC) of $0.485 \mathrm{ug} / \mathrm{L}$ avermectin for acute and $0.239 \mathrm{ug} / \mathrm{L}$ for chronic exposure, both in surface water from the same use of abamectin on strawberries (the maximum use rate on the label). Refined modeling data pesticide root zone model exposure analysis modeling system (PRZM EXAM) indicate a worst case EEC of $0.88 \mathrm{ug} / \mathrm{L}$ for acute and 0.57 $\mathrm{ug} / \mathrm{L}$ for chronic, both calculated for an abamectin use on strawberries grown on black plastic mulch. EPA noted and Novartis agrees that the certainty of the concentrations estimated for strawberries is low, due to uncertainty on the amount of run off from plant beds covered in plastic mulch and uncertainty on the amount of degradation of abamectin on black plastic compared to soil.
Novartis believes the estimates of abamectin exposure in water derived from the PRZM-EXAMS model are overstated for several reasons. The PRZM-EXAMS model was designed to estimate exposure from ecological risk assessments and thus use a scenario of a body of water approximating the size of a 1 hectare ( 2.5 acres) pond. This tends to overstate drinking water exposure levels for the following reasons.
a. Surface water source drinking water generally comes from bodies of water that is substantially larger than a 1 hectare ( 2.5 acres) pond.
b. The modeled scenario also assumes that essentially the whole basin receives an application of the pesticide. Yet in virtually all cases, basins large enough to support a drinking water facility will contain a substantial fraction of the area which does not receive pesticide.
c. There is often at least some flow in a river or turnover in a reservoir or lake of water persistence to the pesticide near the drinking water facility is usually over estimated.
d. Even assuming a reservoir is directly adjacent to an agricultural field, the agricultural field may not be used to grow a crop on which the pesticide in question is registered for use.
e. The PRZM-EXAMS modeled scenario does not take into account reductions in residue loading due to applications of less than the maximum application rate or no treatment of the crop at all (percent crop treated data).

Although there is a high degree of uncertainty to this analysis, this is the best available estimate of concentrations of abamectin in drinking water.
Although the peak EEC of $0.88 \mathrm{ug} / \mathrm{L}$ slightly exceeds the acute DWLOC, 0.76 ug/L, considering the uncertain nature of the modeling estimate, Novartis does not expect aggregate acute exposure to avermectin will pose an unacceptable risk to human health.
2. Non-dietary exposure.

Avermectin's registered residential use include indoor crack/crevice and outdoor application to lawns. For lawn use, EPA conducted a risk assessment for adult applicators and post application exposure to avermectin using EPA's Draft SOP's for residential exposure assessments. The highest predicted exposure oral hand to mouth for children, resulted in a calculated margin of exposure 14,000 . For children's post application exposure to avermectin from indoor crack/crevice products, valid exposure studies demonstrate there is no exposure and therefore no risk for indoor residential scenarios. Short-and intermediate-term risk for registered uses do not exceed EPA's level of concern. Chronic exposure and risk for the residential use is not expected. Short-and intermediateterm exposure and risk for the registered uses do not exceed EPA's level of concern.

## D. Cumulative Effects

Section 408(b)(2)(D)(v) requires that, when considering whether to establish, modify, or revoke a tolerance, the Agency considers "available information" concerning the cumulative effects of a particular pesticide residue and "other substances that have a common mechanism of toxicity." EPA
stated in the FR notice published on April 7, 1999, that it does not have at this time available data to determine whether avermectin has a common mechanism of toxicity with other substances or how to include this pesticide in a cumulative risk assessment.

## E. Safety Determination

1. U.S. population. Using the exposure assumptions described above and based on the completeness and reliability of the toxicity data base, Novartis has calculated aggregate exposure levels for this chemical. The calculations show that chronic exposure is below $100 \%$ of the RfD and the predicted acute exposure is below 100\% of the acute RfD for all subpopulations. Novartis concludes that there is a reasonable certainty that no harm will result from aggregate exposure to abamectin residues.
2. Infants and children. The FQPA authorizes the employment of an additional safety factor of up to $10 x$ to guard against the possibility of prenatal or postnatal toxicity, or to account for an incomplete data base on toxicity or exposure. EPA has chosen to retain the FQPA 10x safety factor for abamectin based on several reasons including evidence of neurotoxicity, susceptibility of neonatal rat pups, similarity to ivermectin, lack of a developmental neurotoxicity study, and concern for exposure to infants and children. It is the opinion of Novartis that a 3x safety factor is more appropriate for abamectin at this time. EPA has evaluated abamectin repeatedly since its introduction in 1985 and has found repeatedly that the level of dietary exposure is sufficiently low to provide ample margins of safety to guard against any potential adverse effects of abamectin. In addition, valid exposure studies demonstrate there is no exposure via indoor applications of abamectin products. Novartis states that the data base for abamectin is complete and that the developmental neurotoxicity study is a new and not yet initially required study. Additionally, there is more information regarding human risk potential than is the case with most pesticides, because of the widespread animal drug and human drug uses of ivermectin, the closely related analog of abamectin.
It is the opinion of Novartis that the use of a full 10 x safety factor to address risks to infants and children is not necessary. The established chronic endpoint for abamectin in the neonatal rat is overly conservative. Similar endpoints for ivermectin are not used by the Food and Drug Administration to
support the allowable daily intake for ivermectin residues in food from treated animals. No evidence of toxicity was observed in neonatal rhesus monkeys after 14 days of repeated administration of $0.1 \mathrm{mg} / \mathrm{kg} /$ day highest dose tested in juvenile rhesus monkeys after repeated administration of $1.0 \mathrm{mg} / \mathrm{kg} /$ day, highest dose tested. The comparative data on abamectin and ivermectin in primates also clearly demonstrate the dose response for exposure to either compound is much less steep than that seen in the neonatal rat. Single doses as high as $24 \mathrm{mg} / \mathrm{kg}$ of either abamectin or ivermectin in rhesus monkeys did not result in mortality; however, this dose was more than two times the $\mathrm{LD}_{50}$ in the adult rat and more than 20 times the $\mathrm{LD}_{50}$ in the neonatal rat. The absence of steep dose response curve in primates provides a further margin of safety regarding the probability of toxicity occurring in infants or children exposed to avermectin compounds. The significant human clinical experience and widespread animal drug uses of ivermectin without systemically toxic, developmental, or postnatal effects supports the safety of abamectin to infants and children.

## F. International Tolerances

Codex has established an abamectin Maximum Residue Level of 0.02 ppm for peppers. The fruiting vegetable tolerance of 0.02 ppm for abamectin is harmonized with Codex.
[FR Doc. 00-8263 Filed 4-6-00; 8:45 am] BILLING CODE 6560-50-F

## ENVIRONMENTAL PROTECTION AGENCY

[FRL-6571-8]
Proposed Administrative Agreement Pursuant to the Comprehensive Environmental Response Compensation, and Liability Act and the Resource Conservation and Recovery Act; Solvent Recovery Corporation, Kansas City, Kansas, Docket Nos. CERCLA-7-2000-0014 and RCRA-7-2000-0027

AGENCY: Environmental Protection Agency.
ACTION: Notice; request for public comment.

SUMMARY: In accordance with Section 122(i) of the Comprehensive Environmental Response, Compensation, and Liability Act, as amended ("CERCLA"), 42 U.S.C. 9622(i), and Section 7003(d) of the Resource Conservation and Recovery Act ("RCRA"), notification is hereby
given of a proposed administrative agreement concerning the Solvent Recovery Corporation ("Respondent") at 100 South 1st Street, Kansas City, Kansas ("Site"). Under the agreement, the Respondent agrees to perform response actions in connection with the release and threatened release of hazardous substances at the Site. Respondent will remove and properly dispose of several thousand containers of waste, contaminated soil, and a 20,000 gallon tank of material. The Respondent agrees to pay oversight costs incurred by the U.S. EPA pursuant to an Administrative Order on Consent ("Order") dated March 16, 2000. The settlement includes a covenant not to sue the settling party pursuant to Section 106 and 107(a) of CERCLA, 42 U.S.C. 9606 and 9607(a) for past response costs incurred by EPA in connection with the Site, which total approximately $\$ 60,000$. This covenant not to sue shall take effect when all actions required by the Order have been completed and EPA has notified the Respondent, in writing, that the actions required by the Order have been completed.

For thirty (30) days following the date of publication of this notice, the Agency will receive written comments relating to the settlement. The Agency will consider all comments received and may modify or withdraw its consent to the settlement if comments received disclose facts or considerations which indicate that the settlement is inappropriate, improper, or inadequate. The Agency's response to any comments received will be available for public inspection at the Kansas City, Kansas, Public Library, 625 Minnesota, Kansas City, Kansas 66101, and Office of Regional Hearing Clerk, EPA, 901 North 5th Street, Kansas City, KS 66101. Commenters may request an opportunity for a public meeting in the affected area in accordance with Section 7003(d) of RCRA, 42 U.S.C. 6973(d).
DATES: Comments must be submitted on or before May 8, 2000.
ADDRESSES: The proposed settlement is available for public inspection at Office of Regional Hearing Clerk,
Environmental Protection Agency, 901 N. 5th Street, Kansas City, KS 66101. A copy of the proposed settlement may be obtained from Kathy Robinson, Regional Hearing Clerk, EPA, 901 N. 5th Street, Kansas City, KS 66101, telephone 913-551-7567. Comments should reference the Solvent Recovery Corporation, Kansas City, Kansas, Docket No. CERCLA 7-2000-0014 and Docket No. RCRA7-2000-0027 and should be addressed to Regional Hearing Clerk,

EPA, 901 N. 5th Street, Kansas City, KS 66101.

FOR FURTHER INFORMATION CONTACT: Kristina Gonzales, Assistant Regional Counsel, EPA, 901 N. 5th Street, Kansas City, KS 66101, telephone: 913-5517245.

Dated: March 21, 2000.

## Gale Hutton,

Acting Regional Administrator, Region VII. [FR Doc. 00-8535 Filed 4-6-00; 8:45 am] BILLING CODE 6560-50-P

## FEDERAL COMMUNICATIONS COMMISSION

## Notice of Public Information Collection(s) Being Reviewed by the Federal Communications Commission

March 30, 2000.
summary: The Federal Communications Commission, as part of its continuing effort to reduce paperwork burden invites the general public and other Federal agencies to take this opportunity to comment on the following information collection(s), as required by the Paperwork Reduction Act of 1995, Public Law 104-13. An agency may not conduct or sponsor a collection of information unless it displays a currently valid control number. No person shall be subject to any penalty for failing to comply with a collection of information subject to the Paperwork Reduction Act (PRA) that does not display a valid control number. Comments are requested concerning (a) whether the proposed collection of information is necessary for the proper performance of the functions of the Commission, including whether the information shall have practical utility; (b) the accuracy of the Commission's burden estimate; (c) ways to enhance the quality, utility, and clarity of the information collected; and (d) ways to minimize the burden of the collection of information on the respondents, including the use of automated collection techniques or other forms of information technology.
DATES: Written comments should be submitted on or before June 6, 2000. If you anticipate that you will be submitting comments, but find it difficult to do so within the period of time allowed by this notice, you should advise the contact listed below as soon as possible.
ADDRESSES: Direct all comments to Judy Boley, Federal Communications
Commission, Room 1-C804, 445 12th Street, SW, DC 20554 or via the Internet to jboley@fcc.gov.

FOR FURTHER INFORMATION CONTACT: For additional information or copies of the information collection(s), contact Judy Boley at 202-418-0214 or via the Internet at jboley@fcc.gov.

## SUPPLEMENTARY INFORMATION:

OMB Control No.: 3060-XXXX. Title: Interstate Telephone Service Provider Worksheet.
Form No.: FCC Form 159-W.
Type of Review: New collection.
Respondents: Business or other forprofit
Number of Respondents: 4,500.
Estimated Time Per Response: . 25 hours or 15 minutes.
Frequency of Response: Annual reporting requirement.

Total Annual Burden: 1,125 hours. Total Annual Cost: N/A.
Needs and Uses: The information supplied by will assist applicants in determining the correct amount of regulatory fees owed, and it will facilitate FCC verification that the correct fee amount has been paid.
Federal Communications Commission.
Magalie Roman Salas,
Secretary.
[FR Doc. 00-8593 Filed 4-6-00; 8:45 am] BILLING CODE 6712-01-P

## FEDERAL COMMUNICATIONS COMMISSION

## Notice of Public Information Collection(s) Being Reviewed by the Federal Communications Commission for Extension Under Delegated Authority, Comments Requested

March 30, 2000.
summary: The Federal Communications Commission, as part of its continuing effort to reduce paperwork burden invites the general public and other Federal agencies to take this opportunity to comment on the following information collection(s), as required by the Paperwork Reduction Act of 1995, Public Law 104-13. An agency may not conduct or sponsor a collection of information unless it displays a currently valid control number. No person shall be subject to any penalty for failing to comply with a collection of information subject to the Paperwork Reduction Act (PRA) that does not display a valid control number. Comments are requested concerning (a) Whether the proposed collection of information is necessary for the proper performance of the functions of the Commission, including whether the information shall have practical utility; (b) the accuracy of the Commission's burden estimate; (c) ways to enhance
the quality, utility, and clarity of the information collected; and (d) ways to minimize the burden of the collection of information on the respondents, including the use of automated collection techniques or other forms of information technology.
DATES: Written comments should be submitted on or before June 6, 2000. If you anticipate that you will be submitting comments, but find it difficult to do so within the period of time allowed by this notice, you should advise the contact listed below as soon as possible.
ADDRESSES: Direct all comments to Les Smith, Federal Communications
Commission, Room 1 A-804, 445
Twelfth Street, S.W., Washington, DC 20554 or via the Internet to lesmith@fcc.gov.
FOR FURTHER INFORMATION CONTACT: For additional information or copies of the information collections contact Les Smith at (202) 418-0217 or via the Internet at lesmith@fcc.gov.

## SUPPLEMENTARY INFORMATION:

OMB Control Number: 3060-0483.
Title: Section 73.687 Transmission system requirements.

Form Number: None.
Type of Review: Extension of currently approved collection.

Respondents: Business or other forprofit.

Number of Respondents: 6.
Estimated Time per Response: 1.0 hours.

Total Annual Burden: 6 hours.
Total Annual Costs: $\$ 0$.
Needs and Uses: Section 73.687(e)(3) requires TV broadcast stations operating on Channels 14 and 69 to take special precautions to avoid interference to adjacent spectrum land mobile operations. This requirement applies to all new Channel 14 and 69 TV broadcast stations and those authorized to change channel, increase effective radiated power (ERP), change directional antenna characteristics such that ERP increases in any azimuth direction or change location, involving an existing or proposed channel 14 or 69 assignment. Section 73.687(e)(4) requires these stations to submit evidence to the FCC that no interference is being caused before they will be permitted to transmit programming on the new facilities. The data is used by the FCC to ensure proper precautions have been taken to protect land mobile stations from interference. It will also both increase and improve service to the public by broadcasters and land mobile services operating in certain parts of the spectrum.

Federal Communications Commission.
Magalie Roman Salas,
Secretary.
[FR Doc. 00-8594 Filed 4-6-00; 8:45 am] BILLING CODE 6712-01-P

## FEDERAL COMMUNICATIONS COMMISSION

[DA 00-760]

## Wireless Telecommunications Bureau

 Sets Comment Schedule for Petitions for Reconsideration of the Order on Reconsideration of the Fourth Report and Order in WT Docket No. 97-82AGENCY: Federal Communications Commission.
ACTION: Notice.
SUMMARY: This document gives notice of a jointly filed petition for reconsideration of the Order on Reconsideration of the Fourth Report and Order in WT Docket No. 97-82 and sets an expedited schedule for filing oppositions.
DATES: Oppositions are due April 17, 2000.

ADDRESSES: Interested parties who choose to file by paper must file an original and four copies of their filing with the Office of the Secretary, Federal Communications Commission, TW B204, 445 12th Street, SW, Washington, DC 20554. In addition, parties should send two copies to Audrey Bashkin, Legal Branch, Auctions and Industry Analysis Division, Wireless Telecommunications Bureau, Federal Communications Commission, 445 12th St. SW Washington, DC 20554, and one copy to ITS, at 1231 20th Street, NW, Washington, D.C. 20036.
FOR FURTHER INFORMATION CONTACT: Audrey Bashkin at (202) 418-0660. The fax number is (202) 418-0890.
SUPPLEMENTARY INFORMATION: This is a summary of a Public Notice released April 5, 2000. The complete text of the public notice is available for inspection and copying during normal business hours in the FCC Reference Center (Room CY-A257), 445 12th Street, SW, Washington, D.C. 20554. It may also be purchased from the Commission's copy contractor, International Transcription Services, Inc. (ITS, Inc.) 1231 20th Street, NW, Washington, D.C. 20036, (202) 857-3800. It is also available on the Commission's web site at http:// www.fcc.gov.

1. Notice is hereby given that the parties listed have jointly petitioned the Commission for reconsideration of the Order on Reconsideration of the Fourth

Report and Order (Order on Reconsideration) in WT Docket No. 9782, FCC 00-54, 65 FR 14213 (March 16, 2000). The Order on Reconsideration addresses petitions for reconsideration of the C Block Fourth Report and Order, 63 FR 50791 (September 23, 1998), in which the Commission modified the rules governing auctions of C block broadband Personal Communications Services ("PCS") spectrum.
2. In light of the auction schedule for the upcoming PCS C and F block auction ("Auction No. 35"), and the requests of certain commenters that the Commission resolve all issues related to Auction No. 35 in an expedited manner, the Wireless Telecommunications Bureau ("Bureau") has determined that good cause exists in this instance to alter the periods specified in § 1.429 of the Commission's rules for oppositions to petitions for reconsideration. Preliminary review of the petition indicates that it raises issues regarding the eligibility of certain parties to participate in Auction No. 35. To provide timely guidance to prospective bidders, we must close the record on reconsideration issues on an expedited schedule. We note also that there are pending petitions for reconsideration on spectrum cap issues. Accordingly, oppositions to petitions for
reconsideration of the Order on Reconsideration shall be filed no later then April 17, 2000.
3. The petition listed reflects

Commission records as of April 4, 2000. Any timely filed petitions subsequently posted on the Electronic Comment Filing System (ECFS), or received in paper form, will be subject to a filing schedule for oppositions similar to that adopted herein. In addition, the record of comments and other documents filed in response to the petitions of Nextel Communications, Inc. and SBC Communications Inc. regarding PCS C and $F$ block rules will be incorporated into this docket. See PCS C and F Block Spectrum Public Notice, 65 FR 8363 (February 18, 2000). See also DA 00318, released February 18, 2000. Commenters therefore need not restate their positions on C and F block issues in response to this petition for reconsideration.

## Procedural Matters

4. Parties submitting oppositions should address the petitions for reconsideration in light of the requirements of 47 U.S.C. 309, 47 CFR 1.429 and any other public interest considerations. All oppositions should reference the docket number of this proceeding, i.e., WT Docket No. 97-82.
5. This proceeding has been designated as a "permit-but-disclose" proceeding in accordance with the Commission's ex parte rules. 47 CFR 1.1200(a), 1.1206. Persons making oral ex parte presentations are reminded that memoranda summarizing the presentations must contain summaries of the substance of the presentations and not merely a listing of the subjects discussed. More than a one or two sentence description of the views and arguments presented is generally required. See 47 CFR 1.1206(b). Other rules pertaining to oral and written $e x$ parte presentations in permit-butdisclose proceedings are set forth in §1.1206(b) of the Commission's rules, 47 CFR 1.1206(b).
6. Parties may obtain the Order on Reconsideration and petitions for reconsideration at the FCC website, http://www.fcc.gov/e-file/ecfs.html. The petitions are also available for public inspection and copying in the Reference Center, Room CY A257, 445 12th Street, SW, Washington, DC 20554. Copies of the petitions are also available from ITS at 1231 20th Street, N.W., Washington, DC 20036, or by calling (202) 857-3800.

> 7. Oppositions to petitions for reconsideration may be filed using the Commission's Electronic Comment Filing System (ECFS) or by filing paper copies. Oppositions filed through the ECFS can be sent as an electronic file via the Internet to http://www.fcc.gov/efile/ecfs.html. Generally, only one copy of an electronic submission must be filed. In completing the transmittal screen, parties should include their full name, Postal Service mailing address, and the applicable docket or rulemaking number. Parties may also submit an electronic opposition by Internet e-mail. To get filing instructions for e-mail filings, parties should send an e-mail message to ecfs@fcc.gov, including "get form to <your e-mail address>" in the body of the message. A sample form and directions will be sent in response.

## Parties Filing Petitions for Reconsideration in WT Docket 97-82

8. This list reflects the Commission's records as of April 4, 2000 of parties that have petitioned the Commission for reconsideration of the Order on Reconsideration. Sprint Spectrum L.P and US WEST Wireless, LLC (April 4, 2000) (filing jointly).

Federal Communications Commission.

## Louis J. Sigalos,

Deputy Chief, Auctions \& Industry Analysis Division.
[FR Doc. 00-8784 Filed 4-6-00; 8:45 am]
BILLING CODE 6712-01-P

FEDERAL COMMUNICATIONS COMMISSION

## [Report No. 2399]

## Petitions for Reconsideration and Clarification of Action in Rulemaking Proceeding

March 31, 2000.
Petitions for Reconsideration and Clarification have been filed in the Commission's rulemaking proceeding listed in this Public Notice and published pursuant to 47 CFR Section 1.429(e). The full text of these documents are available for viewing and copying in Room CY-A257, 445 12th Street, SW, Washington, DC or may be purchased from the Commission's copy contractor, ITS, Inc. (202) 857-3800 Oppositions to this petition must be filed by April 24, 2000. See Section 1.4(b)(1) of the Commission's rules (47 CFR 1.4(b)(1)). Replies to an opposition must be filed within 10 days after the time for filing oppositions has expired.
Subject: Federal-State Joint Board on Universal Service (CC Docket No. 9645). Access Charge Reform (CC Docket No. 96-262).
Number of Petitions Filed: 2.
Federal Communications Commission.
Magalie Roman Salas,
Secretary.
[FR Doc. 00-8591 Filed 4-6-00; 8:45 am] BILLING CODE 6712-01-M

## FEDERAL COMMUNICATIONS COMMISSION

## [Report No. 2400]

## Petitions for Reconsideration of Action in Rulemaking Proceedings

April 3, 2000
Petitions for Reconsideration have been filed in the Commission's rulemaking proceedings listed in this Public Notice and published pursuant to 47 CFR Section 1.429(e). The full text of these documents are available for viewing and copying in Room CYA257, 445 12th Street, S.W., Washington, DC or may be purchased from the Commission's copy contractor, ITS, Inc. (202) 857-3800. Oppositions to this petition must be filed by April 24, 2000. See Section 1.4(b)(1) of the Commission's rules (47 CFR 1.4(b)(1)). Replies to an opposition must be filed within 10 days after the time for filing oppositions has expired.
Subject: In the Matter of Creation of a Low Power Radio Service (MM Docket No. 99-25).
Number of Petitions Filed: 18.

Subject: Amendment of Part 90 of the Commission's Rules to Facilitate Future Development of SMR Systems in the 800 MHz Frequency Band (PR Docket No. 93-144).

Number of Petitions Filed: 1.
Federal Communications Commission.
Magalie Roman Salas,
Secretary.
[FR Doc. 00-8592 Filed 4-6-00; 8:45 am] BILLING CODE 6712-01-M

## FEDERAL RESERVE SYSTEM

## Formations of, Acquisitions by, and Mergers of Bank Holding Companies

The companies listed in this notice have applied to the Board for approval, pursuant to the Bank Holding Company Act of 1956 (12 U.S.C. 1841 et seq.) (BHC Act), Regulation Y (12 CFR Part 225), and all other applicable statutes and regulations to become a bank holding company and/or to acquire the assets or the ownership of, control of, or the power to vote shares of a bank or bank holding company and all of the banks and nonbanking companies owned by the bank holding company, including the companies listed below.
The applications listed below, as well as other related filings required by the Board, are available for immediate inspection at the Federal Reserve Bank indicated. The application also will be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing on the standards enumerated in the BHC Act (12 U.S.C. 1842(c)). If the proposal also involves the acquisition of a nonbanking company, the review also includes whether the acquisition of the nonbanking company complies with the standards in section 4 of the BHC Act (12 U.S.C. 1843). Unless otherwise noted, nonbanking activities will be conducted throughout the United States. Additional information on all bank holding companies may be obtained from the National Information Center website at www.ffiec.gov/nic/.

Unless otherwise noted, comments regarding each of these applications must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than May 1, 2000.
A. Federal Reserve Bank of Boston (Richard Walker, Community Affairs Officer) 600 Atlantic Avenue, Boston, Massachusetts 02106-2204:

1. SI Bancorp, Willimantic, Connecticut; to become a bank holding company by acquiring 100 percent of the voting shares of Savings Institute, Willimantic, Connecticut.
B. Federal Reserve Bank of New York (Betsy Buttrill White, Senior Vice President) 33 Liberty Street, New York, New York 10045-0001:
2. Niagara Bancorp, MHC, Lockport, New York, and Niagara Bancorp, Inc, Lockport, New York; to acquire 100 percent of the voting shares, and thereby merge with CNY Financial Corporation, Cortland, New York, and thereby indirectly acquire Cortland Savings Bank, Cortland, New York.
C. Federal Reserve Bank of

Minneapolis (JoAnne F. Lewellen, Assistant Vice President) 90 Hennepin Avenue, Minneapolis, Minnesota 55480-0291:

1. Business Bancorporation, Inc., Minnetonka, Minnesota; to become a bank holding company by acquiring 100 percent of the voting shares of The Business Bank, Minnetonka, Minnesota.
D. Federal Reserve Bank of San

Francisco (Maria Villanueva, Consumer Regulation Group) 101 Market Street,
San Francisco, California 94105-1579:

1. Dai-Ichi Kangyo Bank, Limited, Tokyo, Japan; indirectly through DaiIchi Kangyo Fuji Trust \& Banking Co., Ltd., Tokyo, Japan; to acquire 100 percent of the voting shares of DKF Trust Company (USA), New York, New York.

Board of Governors of the Federal Reserve System, April 3, 2000.

## Robert deV. Frierson,

Associate Secretary of the Board.
[FR Doc. 00-8619 Filed 4-6-00; 8:45 am] BILLING CODE 6210-01-P

## FEDERAL RESERVE SYSTEM

Notice of Proposals To Engage in Permissible Nonbanking Activities or To Acquire Companies That Are Engaged in Permissible Nonbanking Activities

The companies listed in this notice have given notice under section 4 of the Bank Holding Company Act (12 U.S.C. 1843) (BHC Act) and Regulation Y, (12 CFR Part 225) to engage de novo, or to acquire or control voting securities or assets of a company, including the companies listed below, that engages either directly or through a subsidiary or other company, in a nonbanking activity that is listed in § 225.28 of Regulation Y (12 CFR 225.28) or that the Board has determined by Order to be closely related to banking and permissible for bank holding companies. Unless otherwise noted, these activities will be conducted throughout the United States. Each notice is available for inspection at the Federal Reserve Bank indicated. The notice also will be available for
inspection at the offices of the Board of Governors. Interested persons may express their views in writing on the question whether the proposal complies with the standards of section 4 of the BHC Act. Additional information on all bank holding companies may be obtained from the National Information Center website at www.ffiec.gov/nic/.
Unless otherwise noted, comments regarding the applications must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than April 21, 2000.
A. Federal Reserve Bank of New York (Betsy Buttrill White, Senior Vice President) 33 Liberty Street, New York, New York 10045-0001:

1. TrustCo Bank Corp NY, Schenectady, New York; to acquire Landmark Financial Corp., Canajoharie, New York, and thereby indirectly acquire Landmark Community Bank, and thereby engage in operating a savings association, pursuant to § 225.28 (b)(4)(ii) of Regulation Y. Comments regarding this application must be received not later than May 1, 2000.
2. Banco Bilbao Vizcaya Argentaria, S.A., Bilbao, Spain; to acquire Argentaria International Securities Inc., New York, New York, and thereby engage in securities brokerage services; riskless principal transactions; and private placement services, pursuant to § 225.28(b)(7) of Regulation Y.
Board of Governors of the Federal Reserve System, April 3, 2000.

## Robert deV. Frierson,

Associate Secretary of the Board.
[FR Doc. 00-8620 Filed 4-6-00; 8:45 am] biLLING CODE 6210-01-P

## FEDERAL RESERVE SYSTEM

## Sunshine Act Meeting

time and date: 10 a.m., Wednesday, April 12, 2000.
PLACE: Marriner S. Eccles Federal Reserve Board Building, 20th and C Streets, N.W., Washington, DC 20551 status: Closed.
matters to be considered:

1. Personnel actions (appointments, promotions, assignments, reassignments, and salary actions) involving individual Federal Reserve System employees.
2. Any matters carried forward from a previously announced meeting.
CONTACT PERSON FOR MORE INFORMATION:
Lynn S. Fox, Assistant to the Board; 202-452-3204.
SUPPLEMENTARY INFORMATION: You may call 202-452-3206 beginning at approximately 5 p.m. two business days
before the meeting for a recorded announcement of bank and bank holding company applications scheduled for the meeting; or you may contact the Board's Web site at http:// www.federalreserve.gov for an electronic announcement that not only lists applications, but also indicates procedural and other information about the meeting.
Dated: April 5, 2000.

## Robert deV. Frierson,

Associate Secretary of the Board.
[FR Doc. 00-8741 Filed 4-5-00; 11:46 am]
BILLING CODE 6210-01-P

## DEPARTMENT OF HEALTH AND

## HUMAN SERVICES

## Administration on Aging

## Public Information Collection

Requirement Proposed To Be Submitted to the Office of Management and Budget (OMB) for Clearance

AGENCY: Administration on Aging (AoA), DHHS.
The Administration on Aging (AoA), Department of Health and Human Services, is submitting the following proposal for the collection of information in compliance with the Paperwork Reduction Act (Public Law 96-511): Title VI Program Performance Reports.

Title of Information Collection: Administration on Aging Title VI Program Performance Report.

Type of Request: Extension.
Use: To continue an existing information collection, Title VI Program Performance Report, from Title VI grantees to use in reporting information on programs funded by Title VI as required under Section 202(a)(19), Section 614(a)(3) of the Older Americans Act, as amended.

Frequency: Semi-Annually.
Respondent: Tribal Organizations and Non-profit Organizations representing Native Hawaiians.
Estimated Number of Responses: 227.
Estimated Burden Hours: 681.
Additional Information or Comments: The AoA announced the continuation of use of the Title VI Program Performance Reports in the Federal Register on November 9, 1999.
There were no responses to the 60-day notice.
Requests for a copy of the above mentioned Program Performance Report call M. Yvonne Jackson, Director, Office for American Indian, Alaskan Native and Native Hawaiian Programs,

Administration on Aging, 330 Independence Avenue, SW, Washington, DC 20201; telephone (202) 619-2713. Written comments and recommendations regarding the Program Performance Report should be sent within 30 days of the publication of this notice to the following address: Office of Information and Regulatory Affairs, Attention: Allison Eydt, OMD Desk Officer, Office of Management and Budget, Washington, DC 20503.

Dated: March 15, 2000.
Jeanette C. Takamura,
Assistant Secretary for Aging.
[FR Doc. 00-8607 Filed 4-6-00; 8:45 am] BILLING CODE 4154-01-M

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

## Centers for Disease Control and Prevention

## Breath Responsive Powered AirPurifying Respirators (PAPRs); Notice of Acceptance and Evaluation

AGENCY: Centers for Disease Control and Prevention (CDC), National Institute for Occupational Safety and Health (NIOSH), Department of Health and Human Services (DHHS).
ACTION: Notice.
SUMMARY: This notice announces the criteria and standard test procedure that are being used by NIOSH for the evaluation of applications for approval of breath responsive powered airpurifying respirators (PAPRs). FOR FURTHER INFORMATION CONTACT: Mr. Sam Terry, Team Leader, Respirator Certification Team, Respirator Branch, Division of Respiratory Disease Studies, NIOSH, 1095 Willowdale Road, Morgantown, West Virginia 26505, Telephone (304) 285-5907.
SUPPLEMENTARY INFORMATION: A breath responsive powered air-purifying respirator (PAPR) is designed to deliver filtered air to the user upon demand in order to match the respiratory requirements of the user. The requirements for the evaluation of PAPRs under Title 42, Code of Federal Regulations, part 84, do not address these design features. In accordance with 42 CFR 84.60 and 84.63 , and the past practice of NIOSH, the Institute will evaluate a breath responsive PAPR submitted for approval under the requirements for PAPRs in 42 CFR part 84 that are applicable to its design. Design features of breath responsive PAPRs that cannot be addressed under the present PAPR standards will be
evaluated under additional test procedures established to determine the quality, effectiveness and safety of the respirator. Since there is no applicable test for breath responsive PAPRs in the PAPR requirements, the Institute has determined that the airflow resistance for breath responsive PAPRs will be evaluated under the requirements of 42 CFR 84, subpart J, § 84.157, for pressuredemand supplied air respirators. For the convenience of the reader, $\S 84.157$ is republished as follows:
§84.157 Airflow resistance test; Type C supplied-air respirator, pressure-demand class; minimum requirements.
(a) The static pressure in the facepiece shall not exceed 38 mm . ( 1.5 inches) of water-column height.
(b) The pressure in the facepiece shall not fall below atmospheric at inhalation airflows less than 115 liters ( 4 cubic feet) per minute.
(c) The exhalation resistance to a flow of air at a rate of 85 liters ( 3 cubic feet) per minute shall not exceed the static pressure in the facepiece by more than 51 mm . ( 2 inches) of water-column height.

NIOSH has developed Standard Test Procedure APRS-STP-0065-00 which can adequately test the quality, effectiveness and safety of this type of design feature. Copies of this procedure are available upon request.

Linda Rosenstock,
Director, National Institute for Occupational Safety and Health, Centers for Disease Control and Prevention.
[FR Doc. 00-8371 Filed 4-6-00; 8:45 am] BILLING CODE 4160-18-U

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

## Administration for Children and Families

## [Program Announcement No. ACYF-PA-HS-2000-03A]

Fiscal Year 2000 Discretionary Announcement of the Availability of Funds and Request for Applications for Nationwide Expansion Competition of Early Head Start; Correction

AGENCY: Administration for Children, Youth and Families, ACF, DHHS.

ACTION: Correction.
SUMMARY: This document contains a correction to the Notice that was published in the Federal Register on Tuesday, February 29, 2000.

On page 10799, the County column mistakenly lists the following counties in Iowa: Des Moines County, Ida County, Lee County, Louisa County, Lyon County, Monroe County, Sioux

County, and Wayne County. These counties are unserved and open for competition for Early Head Start Programs.

On page 10803 the State column mistakenly lists Nuckolls. Nuckolls is a county in Nebraska and should appear in the county column. The county is currently being served and is not open for competition to new Early Head Start programs.
On page 10804, in New York State, Westchester County, in the community column it should read "excluding White Plains, New York." The County is being served, except for White Plains. Only White Plains is open to competition for new Early Head Start programs.
On page 10806, for Rhode Island, Bristol County, the community of Barrington should be added to the communities of Bristol and Warren. In Rhode Island, Providence County, the City of Cranston and the towns of E. Providence and Central Falls should be added to the towns of: Burrillville, Johnston, N. Providence, Smithfield, N. Smithfield, Glocester, Scituate and Foster. All these communities are currently being served and are not open for competition to new Early Head Start programs.
On page 10808, in Texas, in the County column, Tarran is mispelled and should be corrected to read Tarrant County. This county is currently being served and is not open to competition to new Early Head Start programs.
FOR FURTHER INFORMATION CONTACT: The ACYF Operations Center at 1-800-3512293 or send an email to ehs@lcgnet.com. You can also contact Judith Jerald, Early Head Start, Head Start Bureau at (202) 205-8074.
Dated: April 3, 2000.

## Patricia Montoya,

Commissioner, Administration on Children, Youth and Families.
[FR Doc. 00-8605 Filed 4-6-00; 8:45 am] BILLING CODE 4184-01-M

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

## Administration for Children and Families

## Administration on Developmental Disabilities Statement of Organization, Functions, and Delegations of Authority

This Notice amends Part K of the Statement of Organization, Functions and Delegations of Authority of the Department of Health and Human Services (DHHS), Administration for Children and Families (ACF) as follows:

Chapter KC, Administration on Developmental Disabilities (ADD), 56 FR 42338, dated August 27, 1991. This Notice reflects a revised ADD mission statement to reflect current legislative references and a realignment of functions within the Office of ADD.
I. Delete KC. 00 Mission in its entirety and replace with the following:

KC. 00 Mission. The Administration on Developmental Disabilities (ADD) advised the Secretary, through the Assistant Secretary for Children and Families, on matters relating to individuals with developmental disabilities and their families. ADD serves as the focal point in the Department to support and encourage the provision of quality services to individuals with developmental disabilities and their families. ADD assists states, through the design and implementation of a comprehensive and continuing state plan, in increasing the independence, productivity and community inclusion of individuals with developmental disabilities. These state plans make optimal use of existing federal and state resources for the provision of services and supports to these individuals and their families to achieve these outcomes. ADD works with states to ensure that the rights of all individuals with developmental disabilities are protected.

ADD administers two formula grant programs, State Developmental Disabilities Councils and Protection and Advocacy Systems, and two discretionary grant programs, University Affiliated Programs and Projects of National Significance, including Family Support. These programs support the provision of services to individuals with developmental disabilities and their families. In concert with other components of ACF as well as other public, private, and voluntary sector partners, ADD develops and implements research, demonstration and evaluation strategies for discretionary funding of activities designed to improve and enrich the lives of individuals with developmental disabilities. In addition, ADD serves as a resource in the development of policies and programs to reduce or eliminate barriers experienced by individuals with developmental disabilities through the identification of promising practices and dissemination of information. ADD supports and encourages programs or services, which prevent developmental disabilities and manages initiatives involving the private and voluntary sectors that benefit individuals with developmental and other disabilities and their families.
II. Delete KC. 10 Organization in its entirety and replace with the following:

KC. 10 Organization. The Administration on Development Disabilities is headed by a Commissioner who reports directly to the Assistant Secretary for Children and Families. The Administration on Developmental Disabilities consists of: Office of the Commissioner (КСА) Program Operations Division (KCB) Program Development Division (KCC)
III. Delete KC. 20 Functions in its entirety and replace with the following:

KC. 20 Functions. A. The Office of the Commissioner (OC) serves as the principal advisor to the Assistant Secretary for Children and Families, the Secretary, and other elements of the Department for individuals with developmental disabilities. OC provides executive direction and management strategy to ADD's components and establishes goals and objectives for ADD programs. The Deputy Commissioner assists the Commissioner in carrying out the responsibilities of the Office and acts as Commissioner in the absence of the Commissioner. The Staff within the office of the Commissioner plans, coordinates and controls ADD policy, planning, and management activities which include the development of legislative proposals, regulations and policy issuances for ADD. The Staff manages the formulation and execution of the program and operating budgets; provides administrative, personnel and information systems support services; serves as the ADD Executive Secretariat controlling the flow of correspondence; and coordinates with appropriate ACF components in implementing administrative requirements and procedures. The staff also coordinates interagency collaboration, program outreach, and convenor functions.
In coordination with the ACF Office of Public Affairs, OC develops a strategy for increasing public awareness of the needs of individuals with developmental disabilities and programs designed to address them.
B. Division of Program Operations (POD) is responsible for the coordination, management, and evaluation of the State Developmental Disabilities Councils Program and the Protection and Advocacy Grants Program, including the development of procedures and performance standards that ensure compliance with the Developmental Disabilities Assistance and Bill of Rights (DD) Act and improve the outcomes of Developmental Disabilities Councils and Protection and Advocacy Systems in increasing the independence, productivity and
community inclusion of persons with developmental disabilities.
The Division conducts routine and special analyses of state plans under the Basic State Grants Program, including an examination of priority area activities, to assure consistent application of ADD program goals and objectives. The Division conducts reviews of programs to ensure compliance with the DD Act and to improve program outcomes; and identifies and disseminates information regarding excellence in advancing the independence, productivity and community inclusion of people with developmental disabilities.
The Division initiates, executes, and supports the development of interagency, intergovernmental, and public-private sector agreements, committees, task forces, commissions, or joint funding efforts as appropriate.
The Division provides program and administrative guidance to regional offices on matters related to the implementation of the DD Act; and ensures timely and effective communication with the regional offices regarding program compliance, policy clarification, and the approval of required state plans and reports.
C. Division of Program Development (PDD) manages the discretionary grants and contracts mandated by the DD Act, and provides program development services. PDD originates cross-cutting research, demonstration and evaluation initiatives with other components of ADD, ACF, HHS, and other government agencies; and manages discretionary grants and contracts and assists in monitoring and evaluating discretionary grants at the national level.
The Division plans for and implements experimental program services based on advice from state and local organizations on program needs. The Division formulates and prepares annual demonstration and evaluation plans, coordinates and administers the University Affilatied Programs (UAP's) activities, and develops quality assurance criteria for the UAP Program.
The Division develops and initiates guidelines, policy issuances and actions with team participation by other components of ADD, ACF, HHS, and other government agencies to fulfill the mission and goals of the DD Act, as amended. The Division ensures the dissemination of project results and information produced by ADD grantees.
The Division coordinates national program trends with other ACF programs and HHS agencies; and studies, reviews and analyzes other federal programs providing services applicable to persons with
developmental disabilities for the purpose of integrating and coordinating program efforts.

Dated: March 30, 2000.

## Sue Swenson,

Commissioner, Administration on Developmental Disabilities.
[FR Doc. 00-8606 Filed 4-6-00; 8:45 am] BILLING CODE 4184-01-M

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

## Food and Drug Administration

[Docket No. 99D-0529]
Agency Information Collection
Activities; Submission for OMB Review; Comment Request; Guidance for Industry: Changes to an Approved NDA or ANDA

Agencr: Food and Drug Administration, HHS.
ACTION: Notice.
summary: The Food and Drug Administration (FDA) is announcing that the proposed collection of information listed below has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995 (PRA).
DATES: Submit written comments on the collection of information by May 8, 2000.

ADDRESSES: Submit written comments on the collection of information to the Office of Information and Regulatory Affairs, OMB, New Executive Office Bldg., 725 17th St. NW., rm. 10235, Washington, DC 20503, Attn: Wendy Taylor, Desk Officer for FDA.

## FOR FURTHER INFORMATION CONTACT:

Karen L. Nelson, Office of Information Resources Management (HFA-250), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-827-1482.

## SUPPLEMENTARY INFORMATION: In

compliance with 44 U.S.C. 3507, FDA has submitted the following proposed collection of information to OMB for review and clearance.

## Guidance for Industry: Changes to an Approved NDA or ANDA

On November 21, 1997, the President signed into law the FDA Modernization Act (the Modernization Act) (Public Law 105-115). Section 116 of the Modernization Act amended the Federal Food, Drug, and Cosmetic Act (the act) by adding section 506A ( 21 U.S.C. 356a), which describes requirements and procedures for making and
reporting manufacturing changes to approved new drug applications (NDA's) and abbreviated new drug applications (ANDA's), to new and abbreviated animal drug applications, and to license applications for biological products.
The guidance provides recommendations to holders of approved NDA's and ANDA's who intend to make postapproval changes in accordance with section 506A of the act. The guidance covers recommended reporting categories for postapproval changes for drugs, other than specified biotechnology and specified synthetic biological products. Recommendations are provided for postapproval changes in: (1) Components and composition, (2) sites, (3) manufacturing process, (4) specification(s), (5) package, (6) labeling, and (7) miscellaneous changes.
Section 116 of the Modernization Act amended the act by adding section 506A, which includes the following provisions:

1. A drug made with a manufacturing change, whether a major manufacturing change or otherwise, may be distributed only after the applicant validates the effects of the change on the identity strength, quality, purity, and potency of the drug as these factors may relate to the safety or effectiveness of the drug (section 506A(a)(1) and (b) of the act). This section recognizes that additional testing, beyond testing to ensure that an approved specification is met, is required to ensure unchanged identity, strength, quality, purity, or potency as these factors may relate to the safety or effectiveness of the drug.
2. A drug made with a major manufacturing change may be distributed only after the applicant submits a supplement application to FDA and the supplemental application is approved by the agency. The application is required to contain information determined to be appropriate by FDA and include the information developed by the applicant when "validating the effects of the change" (section 506A(c)(1) of the act).
3. A major manufacturing change is a manufacturing change determined by FDA to have substantial potential to adversely affect the identity, strength, quality, purity, or potency of the drug as these factors may relate to the safety or effectiveness of the drug. Such changes include: (1) A change made in the qualitative or quantitative formulation of the drug involved or in the specifications in the approved application or license unless exempted by FDA by regulation or guidance; (2) a change determined by FDA by regulation or guidance to require
completion of an appropriate clinical study demonstrating equivalence of the drug to the drug manufactured without the change; and (3) other changes determined by FDA by regulation or guidance to have a substantial potential to adversely affect the safety or effectiveness of the drug (section 506A(2) of the act).
4. FDA may require submission of a supplemental application for drugs made with manufacturing changes that are not major (section 506A(d)(1)(B) of the act) and establish categories of manufacturing changes for which a supplemental application is required (section 506A(d)(1)(C) of the act). In such a case the applicant may begin distribution of the drug 30 days after FDA receives a supplemental application unless the agency notifies the applicant within the 30-day period that prior approval of the application is required (section $506 \mathrm{~A}(\mathrm{~d})(3)(\mathrm{B})(\mathrm{i})$ of the act). FDA may also designate a category of manufacturing changes that permit the applicant to begin distributing a drug made with such changes upon receipt by the agency of a supplemental application for the change (section 506A(d)(3)(B)(ii)of the act). If FDA disapproves a supplemental application, the agency may order the manufacturer to cease the distribution of drugs that have been made with the disapproved change (section 506A(d)(3)(B)(iii) of the act).
5. FDA may authorize applicants to distribute drugs without submitting a
supplemental application (section 506A(d)(1)(A) of the act) and may establish categories of manufacturing changes that may be made without submitting a supplemental application (section $506 \mathrm{~A}(\mathrm{~d})(1)(\mathrm{C})$ of the act). The applicant is required to submit a report to FDA on such a change and the report is required to contain information the agency deems to be appropriate and information developed by the applicant when validating the effects of the change. FDA also may specify the date on which the report is to be submitted (section 506A(d)(2)(A) of the act). If during a single year an applicant makes more than one manufacturing change subject to an annual reporting requirement, FDA may authorize the applicant to submit a single report containing the required information for all the changes made during the year (annual report) (section 506A(d)(2)(B) of the act).

Section 506A of the act provides FDA with considerable flexibility to determine the information and filing mechanism required for the agency to assess the effect of manufacturing changes in the safety and effectiveness of the product. There is a corresponding need to retain such flexibility in the guidance on section 506A of the act to ensure that the least burdensome means for reporting changes are available. FDA believes that such flexibility will allow it to be responsive to increasing knowledge of and experience with certain types of changes and help ensure
the efficacy and safety of the products involved. For example, a change that may currently be considered to have a substantial potential to have an adverse effect on the safety or effectiveness of the product may, at a later date, based on new information or advances in technology, be determined to have a lesser potential to have such an adverse effect. Conversely, a change originally considered to have a minimal or moderate potential to have an adverse effect on the safety or effectiveness of the product may later, as a result of new information, be found to have an increased, substantial potential to adversely affect the product. The guidance enables the agency to respond more readily to knowledge gained from manufacturing experience, further research and data collection, and advances in technology. The guidance describes the agency's current interpretation of specific changes falling into the four filling categories. Section 506A of the act explicitly provides FDA the authority to use guidance documents to determine the type of changes that do or do not have a substantial potential to adversely affect the safety or effectiveness of the drug product. The use of guidance documents allows FDA to more easily and quickly modify and update important information.
FDA estimates the burden of this collection of information as follows:

Table 1.-Estimated Annual Reporting Burden ${ }^{1}$

| Federal Food, Drug, and Cosmetic Act Section | Number of <Respondents | Number of Responses per Respondent | Total Annual Responses | Hours per <Response | Total Hours |
| :---: | :---: | :---: | :---: | :---: | :---: |
| 506A(c)(1) and (c)(2) Prior approval supplement 506 A (d)(1)(C), and (d)(3)(B)(i) $\mathrm{CBE}^{2}$ in 30 -day supplement <br> $506 \mathrm{~A}(\mathrm{~d})(1)(\mathrm{B}),(\mathrm{d})(1)(\mathrm{C})$, and (d)(3)(B)(ii) $\mathrm{CBE}^{2}$ supplement 506A(d)(1)(A), (d)(1)(C), (d)(2)(A), and (d)(2)(B) Annual report Total | $\begin{aligned} & 594 \\ & 594 \\ & 486 \\ & 704 \end{aligned}$ | 3 5 1 10 | $\begin{array}{r} 1,744 \\ 2,754 \\ 486 \\ 6,929 \end{array}$ | $\begin{array}{r} 120 \\ 80 \\ 80 \\ 25 \end{array}$ | $\begin{gathered} 209,280 \\ 220,320 \\ 38,880 \\ 173,225 \\ 641,705 \end{gathered}$ |

${ }^{1}$ There are no capital costs or operating and maintenance costs associated with this collection of information.
${ }^{2}$ CBE means changes being effected.

Section 506A(a)(1) and (b) of the act requires the holder of an approved application to validate the effects of a manufacturing change on the identity, strength, quality, purity, or potency of the drug as these factors may relate to the safety or effectiveness of the drug before distributing a drug made with the change. Under section 506A(d)(3)(A) of the act, information developed by the applicant to validate the effects of the change regarding identity, strength,
quality, purity, and potency is required to be submitted to FDA as part of the supplement or annual report. Thus, no separate estimates are provided for these sections in table 1 of this document; estimates for validation requirements are included in the estimates for supplements and annual reports. The guidance does not provide recommendations on the specific information that should be developed by the applicant to validate the effect of
the change on the identity, strength (e.g., assay, content uniformity), quality (e.g., physical, chemical, and biological properties), purity (e.g., impurities and degradation products), or potency (e.g., biological activity, bioavailability, bioequivalence) of a product as they may relate to the safety or effectiveness of the product.

Section 506A(c)(1) and (c)(2) of the act sets forth requirements for changes requiring supplement submission and
approval prior to distribution of the product made using the change (major changes). Under this section, a supplement must be submitted for any change in the product, production process, quality controls, equipment, or facilities that have a substantial potential to have an adverse effect on the identity, strength, quality, purity, or potency of the product as the factors may relate to the safety or effectiveness of the product. The applicant must obtain approval of a supplement from FDA prior to distribution of a product made using the change.
Based on data concerning the number of supplements received by the agency, FDA estimates that approximately 1,744 supplements will be submitted annually under section 506A(c)(1) and (c)(2) of the act. FDA estimates that approximately 594 applicants will submit such supplements, and that it will take approximately 120 hours to prepare and submit to FDA each supplement.
Section 506A(d)(1)(B), (d)(1)(C), and (d)(3)(B)(i) of the act sets forth requirements for changes requiring supplement submission at least 30 days prior to distribution of the product made using the change (moderate changes). Under this section, a supplement must be submitted for any change in the product, production process, quality controls, equipment, or facilities that has a moderate potential to have an adverse effect on the identity, strength, quality, purity or potency of the product as these factors may relate to the safety or effectiveness of the product. Distribution of the product made using the change may begin not less than 30 days after receipt of the supplement by FDA.
Based on the data concerning the number of supplements received by the agency, FDA estimates that approximately 2,754 supplements will be submitted annually under section $506 \mathrm{~A}(\mathrm{~d})(1)(\mathrm{B}),(\mathrm{d})(1)(\mathrm{C})$, and $(\mathrm{d})(3)(\mathrm{B})(\mathrm{i})$ of the act. FDA estimates that approximately 594 applicants will submit such supplements, and that it will take approximately 80 hours to prepare and submit to FDA each supplement.

Under section 506A(d)(3)(B)(ii) of the act, FDA may designate a category of changes for the purpose of providing that, in the case of a change in such category, the holder of an approved application may commence distribution of the drug upon receipt by the agency of a supplement for the change. Based on the data concerning the number of supplements received by the agency, FDA estimates that approximately 486 supplements will be submitted annually
under section 506A(d)(3)(B)(ii) of the act. FDA estimates that approximately 486 applicants will submit such supplements, and that it will take approximately 80 hours to prepare and submit to FDA each supplement.

Section 506A(d)(1)(A), (d)(1)(C), and $(d)(2)(A)$, and $(d)(2)(B)$ of the act sets forth requirements for changes to be described in an annual report (minor changes). Under this section, changes in the product, production process, quality controls, equipment, or facilities that have a minimal potential to have an adverse effect on the identity, strength, quality, purity, or potency of the product as these factors may relate to the safety or effectiveness of the product must be documented by the applicant in the next annual report.

Based on the data concerning the number of supplements and annual reports received by the agency, FDA estimates that approximately 6,929 annual reports will include documentation of certain manufacturing changes as required under section 506A(d)(1)(A), (d)(1)(C), (d)(2)(A), and (d)(2)(B) of the act. FDA estimates that approximately 704 applicants will submit such information, and that it will take approximately 25 hours to prepare and submit to FDA the information for each annual report.

In the Federal Register of June 28, 1999 (64 FR 34608), FDA published a proposed rule to implement section 116 of the Modernization Act by revising current regulations at 21 CFR 314.70 on supplements and other changes to an approved application. In that same issue of the Federal Register ( 64 FR 34660), FDA published a notice of availability of a draft guidance for industry entitled "Changes to an Approved NDA or ANDA." On August 19, 1999, FDA held a public meeting to discuss and receive comments on the proposed regulations and the draft guidance ( 64 FR 42625, August 5, 1999).

The period for public comment on the proposed regulations closed on September 13, 1999 and FDA is currently reviewing the comments and preparing a final rule. The comment period for the draft guidance closed on August 27, 1999, and FDA has considered these comments when preparing the guidance that is the subject of this request.

FDA published in the Federal
Register of January 6, 2000 (65 FR 779), a 60 -day notice requesting comments on the extension of the proposed collection of information in this guidance. In response to this notice, no comments were received by the agency.

An agency may not conduct or sponsor, and a person is not required to
respond to, a collection of information unless it displays a currently valid OMB control number.

Dated: March 30, 2000.
William K. Hubbard,
Senior Associate Commissioner for Policy, Planning, and Legislation.
[FR Doc. 00-8599 Filed 4-6-00; 8:45 am] BILLING CODE 4160-01-F

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

## Food and Drug Administration

## Opthalmic Devices Panel of the Medical Devices Advisory Committee; Notice of Meeting

AgENCY: Food and Drug Administration, HHS.
ACTION: Notice.
This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). The meeting will be open to the public.
Name of Committee: Ophthalmic Devices Panel of the Medical Devices Advisory Committee.

General Function of the Committee: To provide advice and recommendations to the agency on FDA's regulatory issues.
Date and Time: The meeting will be held on May 11, 2000, 9:30 a.m. to 5 p.m., and May 12, 2000, 8:30 a.m. to 5 p.m.

Location: Hilton Hotel, Salons A and B, 620 Perry Pkwy., Gaithersburg, MD.

Contact Person: Sara M. Thornton, Center for Devices and Radiological Health (HFZ-460), Food and Drug Administration, 9200 Corporate Blvd., Rockville, MD 20850,

## SMT@CDRH.FDA.GOV, or FDA

Advisory Committee Information Line,
1-800-741-8138 (301-443-0572 in the Washington, DC area), code 12396. Please call the Information Line for up-to-date information on this meeting.
Agenda: On May 11, 2000, the committee will discuss, make recommendations, and vote on a premarket approval application (PMA) for reduction or elimination of hyperopia ( +0.5 to +5.00 diopters of sphere) with astigmatism ( +0.5 to +4.0 diopters of cylinder) using photorefractive keratectomy (PRK).

On May 12, 2000, the committee will discuss issues related to the design and development of clinical protocols to support claims of reduced posterior capsular opacification (PCO) for intraocular lenses (IOL's). The topics for discussion will include study,
methodology, controls, clinical endpoints, and data analysis. The committee will also discuss issues related to the development of guidance for refractive implants (phakic IOL's and corneal implants). The topics for discussion will include the scope of the proposed guidance, the maintenance of endothelial cell counts, and cataractogenesis due to the presence of an implant. As the materials become available, background information, questions for the panel, a bibliography for the PCO discussion, and an overview of the proposed clinical study section and questions for the panel for the refractive implants discussion will be made available to the public on FDA's website at http://www.fda.gov/ohrms/ dockets/ac/
cdrh00.htm\#ophthalmicdevices.
Procedure: Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person by May 1, 2000. Oral presentations from the public will be scheduled between approximately 9:15 a.m. and 9:45 a.m. on May 11, 2000, and between approximately 8:45 a.m. and 9:15 a.m. on May 12, 2000. On May 11, 2000, near the end of the committee deliberations on the PMA, a 30-minute open public session will be conducted for interested persons to address issues specific to the submission before the committee. Time allotted for each presentation may be limited. Those desiring to make formal oral presentations should notify the contact person before May 1, 2000, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation.
Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).

Dated: March 30, 2000.

## Linda A. Suydam,

Senior Associate Commissioner.
[FR Doc. 00-8600 Filed 4-6-00; 8:45 am]
BILLING CODE 4160-01-F

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

## Health Care Financing Administration [HCFA-1128-N] <br> RIN 0938-AK01

Medicare Program; Process for Requesting Recognition of New Technologies and Certain Drugs, Biologicals, and Medical Devices for Special Payment Under the Hospital Outpatient Prospective Payment System
agency: Health Care Financing Administration (HCFA), HHS.
ACTION: Notice.
SUMMARY: We expect to implement a prospective payment system for hospital outpatient services for the Medicare program on July 1, 2000. This system will recognize new technology as discrete payment groups within the ambulatory payment classification (APC) system. This payment system will also provide for additional payments to hospitals at amounts higher than the amounts that would otherwise be paid for certain specified items, such as: orphan drugs; drugs, biologic agents, and brachytherapy devices used for the treatment of cancer;
radiopharmaceutical drugs and biologic products; and certain new or innovative medical devices. We have identified items or services for inclusion in the new technology APC groups, as well as items potentially eligible for special additional payments. This notice addresses the process that interested parties must use to submit additional items for consideration.

## FOR FURTHER INFORMATION CONTACT:

 Diane Milstead, (410) 786-3355.SUPPLEMENTARY INFORMATION: We expect to implement a prospective payment system (PPS) for hospital outpatient services for Medicare on July 1, 2000. One aspect of this system will be to develop a process to recognize new technologies on an ongoing basis in a timely manner, and to establish special payments for a number of specified items, in accordance with section 201 of the Balanced Budget Refinement Act of 1999 (BBRA) (Pub. L. 106-113), enacted on November 29, 1999. New
technologies refer to services and items that have emerged since 1996, and therefore are not reflected in the cost data that are being used to develop our PPS. Additionally, section 201(b) of the BBRA requires us to make additional payments to hospitals for a period of 2 to 3 years for specific items at amounts higher than the amounts that would otherwise be paid under the hospital
outpatient PPS for items in the following categories: (a) current orphan drugs, as designated under section 526 of the Federal Food, Drug, and Cosmetic Act; (b) current drugs, biologic agents, and brachytherapy devices used for the treatment of cancer; (c) current radiopharmaceutical drugs and biologicals; and (d) new or innovative medical devices, new drugs, and biologic agents, in instances when we were not paying for the item as a hospital outpatient service as of December 31, 1996, and when the cost is "not insignificant" in relation to the hospital outpatient PPS payment amount. In this context, "current" refers to those items for which we are making hospital outpatient payment on the first date the new PPS is implemented.
We will include these items and services within payment groups called ambulatory payment classifications (APCs), which will be used in the payment system for hospital outpatient services. In addition to the APC-related payments, however, hospitals may receive additional payment for specified items. In order to appropriately assign items to the new technology APCs and make special payments for the relevant drugs, biologicals, and medical devices, we must be able to identify the specific items and services, and ensure that HCFA Common Procedure Coding System (HCPCS) codes are established for them. To facilitate this activity, we have placed on our Internet site at http://www.hcfa.gov/medicare/ hopsmain.htm the following information:
(a) A list of those items and services that we have already identified as potentially eligible for special payments or treatment as a new technology service; and
(b) The procedures interested parties must follow to bring to our attention additional items that may be eligible.

If you cannot access this information on our Internet site, you may request a paper copy by contacting Joan Briscoe in the Division of Practitioner and Ambulatory Care at (410) 786-4495.
Authority: Section 1833(t) of the Social Security Act (42 U.S.C. 1395l(t)).
(Catalog of Federal Domestic Assistance
Program No. 93.774, Medicare-
Supplementary Medical Insurance Program)
Dated: February 21, 2000.

## Nancy-Ann Min DeParle,

Administrator, Health Care Financing Administration.
Approved: March 31, 2000.

## Donna E. Shalala,

Secretary.
[FR Doc. 00-8744 Filed 4-6-00; 8:45 am]
BILLING CODE 4120-01-P

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

## Health Care Financing Administration <br> [HCFA-3028-N2]

## Medicare Program; Notice of the Solicitation for Proposals to Expand the Medicare Lifestyle Modification Program Demonstration; Cancellation Notice

AGENCY: Health Care Financing Administration (HCFA), HHS.
ACTION: Cancellation of notice.
SUMMARY: In the January 5, 2000 issue of the Federal Register (65 FR 495), we published a notice soliciting proposals to expand the Medicare Lifestyle Modification Program Demonstration to one additional, national multi-site cardiovascular lifestyle modification program. The original solicitation contained an inaccurate description of the intended population to be served by the proposed demonstration. We are withdrawing the request for solicitations of interest in order to correct this mistake, which may affect the types of organizations interested in participating and the composition of their applications, and expect to publish a new request at a later time with the correct description.
EFFECTIVE DATE: April 7, 2000.
FOR FURTHER INFORMATION CONTACT:
Armen Thoumaian, Ph.D., (410) 7866672.

Authority: Sections 402(a)(1)(G) and (a)(2) of the Social Security Amendments of 1967 (Public Law 90-248), as amended (42 U.S.C. 1395b-1(a)(1)(G) and (a)(2)).
(Catalog of Federal Domestic Assistance Program No. 93.779; Health Financing, Demonstrations, and Experiments) Dated: March 31, 2000.
Nancy-Ann Min DeParle,
Administrator, Health Care Financing Administration.
[FR Doc. 00-8589 Filed 4-3-00; 4:55 pm] BILLING CODE 4120-01-P

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

Substance Abuse and Mental Health Services Administration

## Agency Information Collection Activities: Submission for OMB Review; Comment Request

Periodically, the Substance Abuse and Mental Health Services Administration (SAMHSA) will publish a list of information collection requests under OMB review, in compliance with the Paperwork Reduction Act (44 U.S.C. Chapter 35). To request a copy of these documents, call the SAMHSA Reports Clearance Officer on (301) 443-7978.
Mandatory Guidelines for Federal Workplace Drug Testing Programs (0930-0158, revision)

SAMHSA is requesting OMB approval for the Federal Drug Testing Custody and Control Form for Federal agency
and federally regulated drug testing programs which must comply with the HHS Mandatory Guidelines for Federal Workplace Drug Testing Programs (59 FR 29908) dated June 9, 1994, and for the information provided by laboratories for the National Laboratory Certification Program (NLCP). The Federal Drug Testing Custody and Control Form is used by all Federal agencies and employers regulated by the Department of Transportation to document the collection and chain of custody of urine specimens at the collection site, for laboratories to report results, and for Medical Review Offices to make a determination.

The Federal Drug Testing Custody and Control Form is being revised. Major changes include eliminating the split specimen copy, simplifying the chain of custody requirements, revising the outcomes for the laboratory test results, revising the collection instructions, and ensuring that the form follows the sequence of events. Prior to an inspection, a laboratory is required to submit specific information regarding its laboratory procedures to allow inspectors to become familiar with a laboratory's procedures before arriving at the laboratory.

The annual total burden estimates for the Federal Drug Testing Custody and Control Form, the NLCP application, the NLCP inspection checklist, and NLCP recordkeeping requirements is $1,790,664$ hours.

| Form/respondent | Burden/response (hrs.) | Number of responses | Total annual burden (hrs.) |
| :---: | :---: | :---: | :---: |
| Custody and Control Form: |  |  |  |
| Donor | . 08 | 7,093,000 | 567,440 |
| Collector | . 07 | 7,093,000 | 496,510 |
| Laboratory | . 05 | 7,093,000 | 354,650 |
| Medical Review Officer | . 05 | 7,093,000 | 354,650 |
| Laboratory Application | 3.00 | 2 | 6 |
| Laboratory Inspection Checklist | 3.00 | 136 | 408 |
| Laboratory Recordkeeping | 250.00 | 68 | 17,000 |
| Total | ............................ | ......................... | 1,790,664 |

Written comments and recommendations concerning the proposed information collection should be sent within 30 days of this notice to: Allison Eydt, Human Resources and Housing Branch, Office of Management and Budget, New Executive Office Building, Room 10235, Washington, D.C. 20503.

## Dated: March 31, 2000.

Richard Kopanda,
Executive Officer, SAMHSA.
[FR Doc. 00-8624 Filed 4-6-00; 8:45 am]
BILLING CODE 4162-20-P

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

## Substance Abuse and Mental Health Services Administration

## Current List of Laboratories Which Meet Minimum Standards To Engage in Urine Drug Testing for Federal <br> Agencies, and Laboratories That Have Withdrawn From the Program

AGENCY: Substance Abuse and Mental Health Services Administration, HHS.

ACTION: Notice.
summary: The Department of Health and Human Services notifies Federal agencies of the laboratories currently certified to meet standards of Subpart C of Mandatory Guidelines for Federal Workplace Drug Testing Programs (59 FR 29916, 29925). A similar notice listing all currently certified laboratories will be published during the first week of each month, and updated to include laboratories which subsequently apply for and complete the certification process. If any listed laboratory's certification is totally suspended or revoked, the laboratory will be omitted from updated lists until such time as it is restored to full certification under the Guidelines.
If any laboratory has withdrawn from the National Laboratory Certification Program during the past month, it will be listed at the end, and will be omitted from the monthly listing thereafter.
This Notice is available on the internet at the following website: http://wmcare.samhsa.gov.
FOR FURTHER INFORMATION CONTACT: Mrs.
Giselle Hersh or Dr. Walter Vogl,
Division of Workplace Programs, 5600 Fishers Lane, Rockwall 2 Building,
Room 815, Rockville, Maryland 20857;
Tel.: (301) 443-6014, Fax: (301) 4433031.

Special Note: Please use the above address for all surface mail and correspondence. For all overnight mail service use the following address: Division of Workplace Programs, 5515 Security Lane, Room 815, Rockville, Maryland 20852.

## SUPPLEMENTARY INFORMATION:

Mandatory Guidelines for Federal Workplace Drug Testing were developed in accordance with Executive Order 12564 and section 503 of Pub. L. 10071. Subpart C of the Guidelines, "Certification of Laboratories Engaged in Urine Drug Testing for Federal Agencies," sets strict standards which laboratories must meet in order to conduct urine drug testing for Federal agencies. To become certified an applicant laboratory must undergo three rounds of performance testing plus an on-site inspection. To maintain that certification a laboratory must participate in a quarterly performance testing program plus periodic, on-site inspections.
Laboratories which claim to be in the applicant stage of certification are not to be considered as meeting the minimum requirements expressed in the HHS Guidelines. A laboratory must have its letter of certification from SAMHSA, HHS (formerly: HHS/NIDA) which attests that it has met minimum standards.

In accordance with Subpart C of the Guidelines, the following laboratories meet the minimum standards set forth in the Guidelines:
ACL Laboratories, 8901 W. Lincoln Ave., West Allis, WI 53227, 414-328-7840/800-877-7016, (Formerly: Bayshore Clinical Laboratory).
Advanced Toxicology Network, 3560 Air Center Cove, Suite 101, Memphis, TN 38118, 901-794-5770/888-290-1150. Aegis Analytical Laboratories, Inc., 345 Hill Ave., Nashville, TN 37210, 615-255-2400.
Alabama Reference Laboratories, Inc., 543 South Hull St., Montgomery, AL 36103, 800-541-4931/334-263-5745.
Alliance Laboratory Services, 3200 Burnet Ave., Cincinnati, OH 45229, 513-5859000, (Formerly: Jewish Hospital of Cincinnati, Inc.).
American Medical Laboratories, Inc., 14225 Newbrook Dr., Chantilly, VA 20151, 703-802-6900.
Associated Pathologists Laboratories, Inc., 4230 South Burnham Ave., Suite 250, Las Vegas, NV 89119-5412, 702-733-7866/ 800-433-2750.
Baptist Medical Center-Toxicology Laboratory, 9601 I-630, Exit 7, Little Rock, AR 72205-7299, 501-202-2783, (Formerly: Forensic Toxicology Laboratory Baptist Medical Center).
Clinical Reference Lab, 8433 Quivira Rd., Lenexa, KS 66215-2802, 800-445-6917.
Cox Health Systems, Department of Toxicology, 1423 North Jefferson Ave., Springfield, MO 65802, 800-876-3652/ 417-269-3093, (Formerly: Cox Medical Centers).
Dept. of the Navy, Navy Drug Screening Laboratory, Great Lakes, IL, P. O. Box 886819, Great Lakes, IL 60088-6819, 847-688-2045/847-688-4171.
Diagnostic Services Inc., dba DSI, 12700 Westlinks Drive, Fort Myers, FL 33913, 941-561-8200/800-735-5416.
Doctors Laboratory, Inc., P.O. Box 2658, 2906 Julia Dr., Valdosta, GA 31604, 912-2444468.

DrugProof, Division of Dynacare/Laboratory of Pathology, LLC, 1229 Madison St., Suite 500, Nordstrom Medical Tower, Seattle, WA 98104, 206-386-2672/800-898-0180, (Formerly: Laboratory of Pathology of Seattle, Inc., DrugProof, Division of Laboratory of Pathology of Seattle, Inc.).
DrugScan, Inc., P.O. Box 2969, 1119 Mearns Rd., Warminster, PA 18974, 215-674-9310.
Dynacare Kasper Medical Laboratories,* 14940-123 Ave., Edmonton, Alberta, Canada T5V 1B4, 780-451-3702/800-6619876.

ElSohly Laboratories, Inc., 5 Industrial Park Dr., Oxford, MS 38655, 601-236-2609.
Gamma-Dynacare Medical Laboratories*, A Division of the Gamma-Dynacare Laboratory Partnership, 245 Pall Mall St., London, ON, Canada N6A 1P4, 519-6791630.

General Medical Laboratories, 36 South Brooks St., Madison, WI 53715, 608-2676267.

Hartford Hospital Toxicology Laboratory, 80 Seymour St., Hartford, CT 06102-5037, 860-545-6023.

Integrated Regional Laboratories, 5361 NW 33rd Avenue, Fort Lauderdale, FL 33309, 954-777-0018, 800-522-0232, (Formerly: Cedars Medical Center, Department of Pathology).
Kroll Laboratory Specialists, Inc., 1111
Newton St., Gretna, LA 70053, 504-361-8989/800-433-3823, (Formerly: Laboratory Specialists, Inc.).
Laboratory Corporation of America Holdings, 1904 Alexander Drive, Research Triangle Park, NC 27709, 919-572-6900/800-8333984, (Formerly: LabCorp Occupational Testing Services, Inc., CompuChem Laboratories, Inc.; CompuChem Laboratories, Inc., A Subsidiary of Roche Biomedical Laboratory; Roche
CompuChem Laboratories, Inc., A Member of the Roche Group).
Laboratory Corporation of America Holdings, 4022 Willow Lake Blvd., Memphis, TN 38118, 901-795-1515/800-233-6339, (Formerly: LabCorp Occupational Testing Services, Inc., MedExpress/National Laboratory Center), LabOne, Inc., 10101 Renner Blvd., Lenexa, KS 66219, 913-888-3927/800-728-4064, (Formerly: Center for Laboratory Services, a Division of LabOne, Inc.).
Laboratory Corporation of America Holdings, 69 First Ave., Raritan, NJ 08869, 908-526-2400/800-437-4986, (Formerly: Roche Biomedical Laboratories, Inc.)
Marshfield Laboratories, Forensic Toxicology Laboratory, 1000 North Oak Ave.,
Marshfield, WI 54449, 715-389-3734/800-331-3734.
MAXXAM Analytics Inc.*, 5540 McAdam Rd., Mississauga, ON,, Canada L4Z 1P1, 905-890-2555, (Formerly: NOVAMANN (Ontario) Inc.)
Medical College Hospitals Toxicology Laboratory, Department of Pathology, 3000 Arlington Ave., Toledo, OH 43614, 419-383-5213.
MedTox Laboratories, Inc., 402 W. County Rd. D, St. Paul, MN 55112, 651-636-7466/ 800-832-3244.
MetroLab-Legacy Laboratory Services, 1225
NE 2nd Ave., Portland, OR 97232, 503-413-5295/800-950-5295.
Minneapolis Veterans Affairs Medical Center, Forensic Toxicology Laboratory, 1 Veterans Drive, Minneapolis, Minnesota 55417, 612-725-2088.
National Toxicology Laboratories, Inc., 1100 California Ave., Bakersfield, CA 93304, 661-322-4250.
NWT Drug Testing, 1141 E. 3900 South, Salt Lake City, UT 84124, 801-268-2431/800-322-3361, (Formerly: NorthWest Toxicology, Inc.).
One Source Toxicology Laboratory, Inc., 1705 Center Street, Deer Park, TX 77536, 713-920-2559, (Formerly: University of Texas Medical Branch, Clinical Chemistry Division; UTMB Pathology-Toxicology Laboratory).
Oregon Medical Laboratories, P.O. Box 972, 722 East 11th Ave., Eugene, OR 974400972, 541-687-2134.
Pacific Toxicology Laboratories, 6160 Variel Ave., Woodland Hills, CA 91367, 818-5983110, (Formerly: Centinela Hospital Airport Toxicology Laboratory).

Pathology Associates Medical Laboratories, 11604 E. Indiana, Spokane, WA 99206, 509-926-2400/800-541-7891.
PharmChem Laboratories, Inc., 1505-A O’Brien Dr., Menlo Park, CA 94025, 650-328-6200/800-446-5177.
PharmChem Laboratories, Inc., Texas Division, 7606 Pebble Dr., Fort Worth, TX 76118, 817-215-8800, (Formerly: Harris Medical Laboratory).
Physicians Reference Laboratory, 7800 West 110th St., Overland Park, KS 66210, 913-339-0372/800-821-3627.
Poisonlab, Inc., 7272 Clairemont Mesa Blvd., San Diego, CA 92111, 619-279-2600/800-882-7272.
Quest Diagnostics Incorporated, 3175 Presidential Dr., Atlanta, GA 30340, 770-452-1590, (Formerly: SmithKline Beecham Clinical Laboratories, SmithKline BioScience Laboratories).
Quest Diagnostics Incorporated, 4444 Giddings Road, Auburn Hills, MI 48326, 810-373-9120/800-444-0106, (Formerly: HealthCare/Preferred Laboratories, HealthCare/MetPath, CORNING Clinical Laboratories).
Quest Diagnostics Incorporated, National Center for Forensic Science, 1901 Sulphur Spring Rd., Baltimore, MD 21227, 410-536-1485, (Formerly: Maryland Medical Laboratory, Inc., National Center for Forensic Science, CORNING National Center for Forensic Science).
Quest Diagnostics Incorporated, 8000 Sovereign Row, Dallas, TX 75247, 214-638-1301, (Formerly: SmithKline Beecham Clinical Laboratories, SmithKline BioScience Laboratories).
Quest Diagnostics Incorporated, 4770 Regent Blvd., Irving, TX 75063, 972-916-3376/ 800-526-0947, (Formerly: Damon Clinical Laboratories, Damon/MetPath, CORNING Clinical Laboratories).
Quest Diagnostics Incorporated, 801 East Dixie Ave., Leesburg, FL 34748, 352-7879006, (Formerly: SmithKline Beecham Clinical Laboratories, Doctors \& Physicians Laboratory).
Quest Diagnostics Incorporated, 400 Egypt
Rd., Norristown, PA 19403, 610-631-4600/ 800-877-7484, (Formerly: SmithKline Beecham Clinical Laboratories, SmithKline Bio-Science Laboratories).
Quest Diagnostics Incorporated, 875 Greentree Rd., 4 Parkway Ctr., Pittsburgh, PA 15220-3610, 412-920-7733/800-5742474, (Formerly: Med-Chek Laboratories, Inc., Med-Chek/Damon, MetPath Laboratories, CORNING Clinical Laboratories).
Quest Diagnostics Incorporated, 506 E. State Pkwy., Schaumburg, IL 60173, 800-669-6995/847-885-2010, (Formerly: SmithKline Beecham Clinical Laboratories, International Toxicology Laboratories).
Quest Diagnostics Incorporated, 7470,
Mission Valley Rd., San Diego, CA 921084406, 619-686-3200/800-446-4728, (Formerly: Nichols Institute, Nichols Institute Substance Abuse Testing (NISAT), CORNING Nichols Institute, CORNING Clinical Laboratories).
Quest Diagnostics Incorporated, One Malcolm Ave., Teterboro, NJ 07608, 201-393-5590, (Formerly: MetPath, Inc.,

CORNING MetPath Clinical Laboratories, CORNING Clinical Laboratory).
Quest Diagnostics Incorporated, 7600 Tyrone Ave., Van Nuys, CA 91405, 818-989-2520/ 800-877-2520, (Formerly: SmithKline Beecham Clinical Laboratories).
San Diego Reference Laboratory, 6122 Nancy Ridge Dr., San Diego, CA 92121, 800-6777995.

Scientific Testing Laboratories, Inc., 463 Southlake Blvd., Richmond, VA 23236, 804-378-9130.
Scott \& White Drug Testing Laboratory, 600 S. 25th St., Temple, TX 76504, 254-771-8379/800-749-3788.
S.E.D. Medical Laboratories, 5601 Office Blvd., Albuquerque, NM 87109, 505-727-6300/800-999-5227.
South Bend Medical Foundation, Inc., 530 N. Lafayette Blvd., South Bend, IN 46601, 219-234-4176.
Southwest Laboratories, 2727 W. Baseline Rd., Tempe, AZ 85283, 602-438-8507.
Sparrow Health System, Toxicology Testing Center, St. Lawrence Campus, 1210 W. Saginaw, Lansing, MI 48915, 517-3770520, (Formerly: St. Lawrence Hospital \& Healthcare System).
St. Anthony Hospital Toxicology Laboratory, 1000 N. Lee St., Oklahoma City, OK 73101, 405-272-7052.
Toxicology \& Drug Monitoring Laboratory, University of Missouri Hospital \& Clinics, 2703 Clark Lane, Suite B, Lower Level, Columbia, MO 65202, 573-882-1273.
Toxicology Testing Service, Inc., 5426 N.W. 79th Ave., Miami, FL 33166, 305-5932260.

UNILAB, 18408 Oxnard St., Tarzana, CA 91356, 818-996-7300 / 800-492-0800, (Formerly: MetWest-BPL Toxicology Laboratory).
Universal Toxicology Laboratories, LLC, 10210 W. Highway 80, Midland, Texas 79706, 915-561-8851 / 888-953-8851. The following laboratory voluntarily withdrew from the NLCP program, effective March 31, 2000:
Quest Diagnostics of Missouri LLC, 2320 Schuetz Rd., St. Louis, MO 63146, 314-991-1311 / 800-288-7293, (Formerly: Quest Diagnostics Incorporated, Metropolitan Reference Laboratories, Inc., CORNING Clinical Laboratories, South Central Division).

* The Standards Council of Canada (SCC) voted to end its Laboratory Accreditation Program for Substance Abuse (LAPSA) effective May 12, 1998. Laboratories certified through that program were accredited to conduct forensic urine drug testing as required by U.S. Department of Transportation (DOT) regulations. As of that date, the certification of those accredited Canadian laboratories will continue under DOT authority. The responsibility for conducting quarterly performance testing plus periodic on-site inspections of those LAPSA-accredited laboratories was transferred to the U.S. DHHS, with the DHHS' National Laboratory Certification Program (NLCP) contractor continuing to have an active role in the performance testing and laboratory inspection processes. Other Canadian laboratories wishing to be considered for the NLCP may apply directly
to the NLCP contractor just as U.S. laboratories do.

Upon finding a Canadian laboratory to be qualified, the DHHS will recommend that DOT certify the laboratory (Federal Register, 16 July 1996) as meeting the minimum standards of the "Mandatory Guidelines for Workplace Drug Testing" (59 Federal Register, 9 June 1994, Pages 29908-29931). After receiving the DOT certification, the laboratory will be included in the monthly list of DHHS certified laboratories and participate in the NLCP certification maintenance program.

## Richard Kopanda,

Executive Officer, Substance Abuse and Mental Health Services Administration.
[FR Doc. 00-8309 Filed 4-6-00; 8:45 am] BILLING CODE 4160-20-U

## DEPARTMENT OF HOUSING AND URBAN DEVELOPMENT

[Docket No. FR-4566-N-04]

## Notice of Proposed Information Collection: Comment Request, Youthbuild Program

agency: Office of the Assistant Secretary for Community Planning and Development, HUD.
ACTION: Notice.
SUMMARY: The proposed information collection requirement described below will be submitted to the Office of Management and Budget (OMB) for review, as required by the Paperwork Reduction Act. The Department is soliciting public comments on the subject proposal.
DATES: Comments due date: June 6, 2000.

ADDRESSES: Interested persons are invited to submit comments regarding this proposal. Comments should refer to the proposal by name and/or OMB Control Number and should be sent to: Reports Liaison Officer, Sheila E. Jones, Department of Housing and Urban Development, 451 7th Street, SW, Room 7230, Washington, DC 20410.

## FOR FURTHER INFORMATION CONTACT:

Phyllis Williams, 202/708-2035 (this is not a toll-free number) for copies of the proposed forms and other available documents.
SUPPLEMENTARY INFORMATION: The Department is submitting the proposed information collection to OMB for review, as required by the Paperwork Reduction Act of 1995 (44 U.S.C. Chapter 35, as amended).
This Notice is soliciting comments from members of the public and affecting agencies concerning the proposed collection of information to:
(1) Evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility; (2) Evaluate the accuracy of the agency's estimate of the burden of the proposed collection of information; (3) Enhance the quality, utility, and clarity of the information to be collected; and (4) Minimize the burden of the collection of information on those who are to respond; including through the use of appropriate automated collection techniques or other forms of information technology, e.g., permitting electronic submission of responses.
This Notice also lists the following information:
Title of Proposal: Youthbuild Program.

OMB Control Number, if applicable: 2506-0142.
Description of the need for the information and proposed use: Information collected from NOFA will be used by HUD to select grant awardees as required by the HUD Reform Act. Information collected from reports will be used to monitor and evaluate progress of grantees and programs.

Agency form numbers, if applicable: Youthbuild Application, HUD-40202, SF 1199A, HUD-27054.
Members of affected public: Not-for profit institutions, and state or local governments.
Estimation of the total numbers of hours needed to prepare the information collection including number of
respondents, frequency of response, and hours of response:
Number of Respondents: 250.
Frequency of Reports: Semi-annually.
Hours of Response: hours per
response-45.
Status of the proposed information collection: reinstatement, with change, of a previously approved collection for which approval has expired.
Authority: The Paperwork Reduction Act of 1995, 44 U.S.C. Chapter 35, as amended.

Dated: February 18, 2000.
Joseph A. D'Agosta,
General Deputy Assistant Secretary for Community Planning and Development.
[FR Doc. 00-8634 Filed 4-6-00; 8:45 am] biLLING CODE 4210-29-M

## DEPARTMENT OF HOUSING AND URBAN DEVELOPMENT

[Docket No. FR-4561-N-20]
Notice of Submission of Proposed Information Collection to OMB; Evaluation of Environmental Interventions Conducted Under HUD Lead-Based Paint Abatement Program

AGENCY: Office of the Chief Information Officer, HUD.
ACTION: Notice.
SUMMARY: The proposed information collection requirement described below has been submitted to the Office of Management and Budget (OMB) for review, as required by the Paperwork Reduction Act. The Department is soliciting public comments on the subject proposal.
DATES: May 8, 2000.
ADDRESSES: Interested persons are invited to submit comments regarding this proposal. Comments should refer to the proposal by name and/or OMB approval number and should be sent to: Joseph F. Lackey, Jr., OMB Desk Officer, Office of Management and Budget, Room 10235, New Executive Office Building, Washington, DC 20503. FOR FURTHER INFORMATION CONTACT: Wayne Eddins, Reports Management Officer, Q, Department of Housing and Urban Development, 451 Seventh Street, Southwest, Washington, DC 20410; email Wayne__Eddins@HUD.gov; telephone (202) 708-2374. This is not a toll-free number. Copies of the proposed forms and other available documents submitted to OMB may be obtained from Mr. Eddins.
SUPPLEMENTARY INFORMATION: The Department has submitted the proposal
for the collection of information, as described below, to OMB for review, as required by the Paperwork Reduction Act (44 U.S.C. Chapter 35). The Notice lists the following information: (1) The title of the information collection proposal; (2) the office of the agency to collect the information; (3) the OMB approval number, if applicable; (4) the description of the need for the information and its proposed use; (5) the agency form number, if applicable; (6) what members of the public will be affected by the proposal; (7) how frequently information submissions will be required; (8) an estimate of the total number of hours needed to prepare the information submission including number of respondents, frequency of response, and hours of response; (9) whether the proposal is new, an extension, reinstatement, or revision of an information collection requirement; and (10) the name and telephone number of an agency official familiar with the proposal and of the OMB Desk Officer for the Department.
This Notice also lists the following information:
Title of Proposal: Evaluation of Environment Interventions Conducted Under HUD Lead-Based Paint Abatement Program.
OMB Approval Number: 2502— pending.

Form Numbers: None.
Description of the Need for the Information and Its Proposed Use: To evaluate the use of community service employees trained as lead abatement workers rather than certified lead abatement contractors. This evaluation is required under HUD's FY 1999 and FY 2000 appropriations. Information will be gathered from 15 locally based organizations which refer housing units for abatement work and from 350 housing occupants. This will be a onetime information collection.

Respondents: Individuals or households, not-for-profit institutions. Frequency of Submission: One-time. Reporting Burden:

|  | Number of respondents | $\times$ | Frequency of response | $\times$ | Hours per response | $=$ | Burden hours |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 365 |  |  | 1 |  | 0.1 |  | 43 |

Total Estimated Burden Hours: 43.
Status: New collection pending approval.

Authority: Section 3507 of the Paperwork Reduction Act of 1995, 44 U.S.C. 35, as amended.
Dated: March 31, 2000.
Wayne Eddins,
Departmental Reports Management Officer, Office of the Chief Information Officer.
[FR Doc. 00-8615 Filed 4-6-00; 8:45 am] BILLING CODE 4210-01-M

## DEPARTMENT OF HOUSING AND URBAN DEVELOPMENT

[Docket No. FR-4561-N-19]
Notice of Submission of Proposed Information Collection to OMB; Application for Approval as FHA Lender and/or Ginnie Mae MortgageBacked Securities Issuer

AGENCY: Office of the Chief Information Officer, HUD.
ACTION: Notice.
SUMMARY: The proposed information collection requirement described below has been submitted to the Office of Management and Budget (OMB) for review, as required by the Paperwork Reduction Act. The Department is soliciting public comments on the subject proposal.

DATES: Comments Due Date: May 8, 2000.

ADDRESSES: Interested persons are invited to submit comments regarding this proposal. Comments should refer to the proposal by name and/or OMB approval number (2502-0005) and should be sent to: Joseph F. Lackey, Jr., OMB Desk Officer, Office of Management and Budget, Room 10235, New Executive Office Building, Washington, DC 20503.
FOR FURTHER INFORMATION CONTACT: Wayne Eddins, Reports Management Officer, Q, Department of Housing and Urban Development, 451 Seventh Street, Southwest, Washington, DC 20410; email Wayne__Eddins@HUD.gov; telephone (202) 708-2374. This is not a toll-free number. Copies of the proposed forms and other available documents submitted to OMB may be obtained from Mr. Eddins.
SUPPLEMENTARY INFORMATION: The Department has submitted the proposal for the collection of information, as described below, to OMB for review, as required by the Paperwork Reduction Act (44 U.S.C. Chapter 35). The Notice lists the following information: (1) The title of the information collection proposal; (2) the office of the agency to collect the information; (3) the OMB approval number, if applicable; (4) the description of the need for the information and its proposed use; (5) the agency form number, if applicable;
(6) what members of the public will be affected by the proposal; (7) how frequently information submissions will be required; (8) an estimate of the total number of hours needed to prepare the information submission including number of respondents, frequency of response, and hours of response; (9) whether the proposal is new, an extension, reinstatement, or revision of an information collection requirement; and (10) the name and telephone number of an agency official familiar with the proposal and of the OMB Desk Officer for the Department.

This Notice also lists the following information:
Title of Proposal: Application for Approval as FHA Lender and/or Ginnie Mae Mortgage-Backed Securities Issuer
OMB Approval Number: 2502-0005
Form Numbers: HUD 11701/92001, HUD-92001-B
Description of the Need for the
Information and its Proposed Use: This information is collected from mortgagees upon their application for Approval as an FHA Lender and/or Ginnie Mae Mortgage-Backed Securities Issuer. The information is used to determine if the applicants’ qualifications justify approval.
Respondents: Business or Other-forProfit entities.

Frequency of Submission: On occasion of application.

Reporting Burden:

|  | Number of Respondents | $\times$ | Frequency of response | $\times$ | Hours per response | = | Burden hours |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| HUD-5378 | 4,130 |  | 1 |  | 0.8 |  | 3,438 |

## Total Estimated Burden Hours: 3,438.

Status: Reinstatement, with change.
Autority: Section 3507 of the Paperwork Reduction Act of 1995, 44 U.S.C. 35, as amended.

Dated: April 3, 2000.
Wayne Eddins,
Departmental Reports Management Officer, Office of the Chief Information Officer. [FR Doc. 00-8616 Filed 4-6-00; 8:45 am] BILLING CODE 4210-01-M

## DEPARTMENT OF HOUSING AND URBAN DEVELOPMENT

[Docket No. FR-4561-N-21]
Notice of Submission of Proposed Information Collection to OMB; Emergency Comment Request Lenders Qualification for Multifamily Accelerated Processing
agency: Officer of the Chief Information Officer, HUD.
ACTION: Notice.
SUMMARY: The proposed information collection requirement described below has been submitted to the Office of Management and Budget (OMB) for emergency review and approval, as required by the Paperwork Reduction Act. The Department is soliciting public comments on the subject proposal.
DATES: Comments Due Date: April 14, 2000.

ADDRESSES: Interested persons are invited to submit comments regarding this proposal. Comments should refer to the proposal by name or OMB approval number and should be sent to: Joseph F. Lackey, Jr., HUD Desk Officer, Office of Management and Budget, New Executive Office Building, Washington, DC 20410 (202) 395-7316.

## FOR FURTHER INFORMATION CONTACT:

Wayne Eddins, Reports Management
Officer, Department of Housing and Urban Development, 451 7th Street, SW, Washington, DC 20410; e-mail Wayne_Eddins@HUD.gov; telephone (202) 708-2374. This is not a toll-free number. Copies of the proposed forms and other available documents submitted to OMB may be obtained from Mr. Eddins.
SUPPLEMENTARY INFORMATION: The Department has submitted the proposal for the collection of information, as described below, to OMB for review as
required by the Paperwork Reduction Act (44 U.S.C. Chapter 35). HUD has requested OMB approval by April 21, 2000. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless collection displays a valid control number. This notice contains the following information:
(1) The title for the collection of information;
(2) A summary of the collection of information;
(3) A brief description of the need for the information and proposed use of the information;
(4) A description of the likely respondents, including the estimated number of likely respondents, and proposed frequency of response to the collection of information;
(5) An estimate of the total annual reporting and recordkeeping burden that will result from the collection of information;
This Notice also lists the following information:

Title of Proposed: Lender
Qualifications for multifamily
Accelerated Processing

OMB Control number, if Applicable: 2502-XXXX.

Agency Form Number, if Applicable: None.

Description of the Need for the Information and its Proposed Use: FHAapproved mortgagees (lenders) will be required to submit to HUD information to show that they have an experienced multifamily underwriter on staff, and that they have satisfactory record on lending on multifamily housing properties. These additional requirements will enable a qualified lender to take advantage of a mortgage application processing plan that should take substantially less processing time than traditional multifamily mortgage processing where HUD staff prepares many of the processing documents. The information includes (a) identification of the applicant lender; (b) names of those authorized to commit the lender to a mortgage insurance application; (c) copy of approval as an FHA multifamily mortgagee; (d) method of operation in multifamily lending; e.g. whether loans are serviced, and experience in construction loan administration; (e) Experience in multifamily lending,
including both conventional lending and FHA insured mortgage lending; ( $f$ ) experience of key personnel, including underwriter or underwriters; (g) and agreement that the lender will open its files and records to monitoring by HUD staff or one or more loans or originated by the lender under the MAP process.

Need and Use of the Information: The information is needed for HUD to qualify lenders to process applications for mortgage insurance under the Multifamily Accelerated processing guide. Once a lender is approved, its name will be posted on the web. Once approval is given, there are no requirements for further qualifications. Form Number (s): No form required. Qualified lenders will submit exhibits, such as resumes, and use a narrative description. Lender Qualifications are posted on the worldwide web. Chapter 2 of the MAP Guide is posted on worldwide web: The Netsite address is: http://@www.hud.gov/fha/mfh/map/ mapguide.html

Respondents: Lenders which are approved FHA multifamily mortgagees.

Reporting burden:.

|  | Number of respondents | $\times$ | Frequency of response | $\times$ | Hours per response | = | Burden hours |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 130 |  |  | 1 |  | 10 |  | 1,300 |

Status of The Proposed Information Collection: Emergency.
Authority: The Paperwork Reduction Act of 1995, 44 U.S.C. 35 , as amended.
Dated: April 3, 2000.

## Wayne Eddins,

Department Reports Management Officer, Office of the Chief Information Officer.
[FR Doc. 00-8633 Filed 4-6-00; 8:45 am] BILLING CODE 4210-01-M

## DEPARTMENT OF HOUSING AND URBAN DEVELOPMENT

## [Docket No. FR-4557-N-14]

## Federal Property Suitable as Facilities To Assist the Homeless

agency: Office of the Assistant Secretary for Community Planning and Development, HUD.
ACTION: Notice.
SUMMARY: This Notice identifies unutilized, underutilized, excess, and surplus Federal property reviewed by HUD for suitability for possible use to assist the homeless.
effective date: April 7, 2000.

## FOR FURTHER INFORMATION CONTACT:

Clifford Taffet, Department of Housing and Urban Development, Room 7262, 451 Seventh Street SW, Washington, DC 20410; telephone (202) 708-1234; TTY number for the hearing- and speechimpaired (202) 708-2565 (these telephone numbers are not toll-free), or call the toll-free Title V information line at 1-800-927-7588.
SUPPLEMENTARY INFORMATION: In accordance with the December 12, 1988 court order in National Coalition for the Homeless v. Veterans Administration, No. 88-2503-OG (D.D.C.), HUD publishes a Notice, on a weekly basis, identifying unutilized, underutilized, excess and surplus Federal buildings and real property that HUD has reviewed for suitability for use to assist the homeless.

Today's Notice is for the purpose of announcing that no additional properties have been determined suitable or unsuitable this week.

## Dated: March 30, 2000.

Fred Karnas, Jr.,
Deputy Assistant Secretary for Special Needs Assistance Programs.
[FR Doc. 00-8304 Filed 4-6-00; 8:45 am]
BILLING CODE 4210-29-M

## DEPARTMENT OF THE INTERIOR

## Fish and Wildlife Service

## Permit for the Incidental Take of the Houston Toad (Bufo Houstonensis); Bastrop County, TX

SUMMARY: Lorie Lopez (Applicant) has applied to the U.S. Fish and Wildlife Service (Service) for an incidental take permit pursuant to Section 10(a) of the Endangered Species Act (Act). The Applicant has been assigned permit numbers TE-024873. The requested permit, which is for a period of 5 years, would authorize the incidental take of the endangered Houston Toad (Bufo houstonensis). The proposed take would occur as a result of the construction and occupation of one single family residence on Lot 41 of the Circle D Estates Subdivision, Bastrop County, Texas.

The Service has prepared the Environmental Assessment/Habitat Conservation Plan (EA/HCP) for the incidental take application. A determination of jeopardy to the species or a Finding of No Significant Impact (FONSI) will not be made before 30 days from the date of publication of this
notice. This notice is provided pursuant to Section 10(c) of the Act and National Environmental Policy Act regulations (40 CFR 1506.6).

DATES: Written comments on the application should be received on or before May 8, 2000.
ADDRESSES: Persons wishing to review the application may obtain a copy by writing to the Regional Director, U.S. Fish and Wildlife Service, P.O. Box 1306, Albuquerque, New Mexico 87103. Persons wishing to review the EA/HCP may obtain a copy by contacting Scott Rowin, U.S. Fish and Wildlife Service, 10711 Burnet Road, Suite 200, Austin, Texas 78758 (512/490-0057). Documents will be available for public inspection by written request or by appointment only during normal business hours (8:00 to 4:30) at U.S. Fish and Wildlife Service, Austin, Texas. Written data or comments concerning the application and EA/HCP should be submitted to the Field Supervisor, U.S. Fish and Wildlife Service, Austin, Texas at the above address. Please refer to permit number TE-024873 when submitting comments.

FOR FURTHER INFORMATION CONTACT:
Scott Rowin at the above U.S. Fish and Wildlife Service Office.

SUPPLEMENTARY INFORMATION: Section 9 of the Act prohibits the "taking" of endangered species such as the Houston toad. However, the Service, under limited circumstances, may issue permits to take endangered wildlife species incidental to, and not the purpose of, otherwise lawful activities. Regulations governing permits for endangered species are at 50 CFR 17.22.

## Applicant

Lorie Lopez plans to construct one single family residence on 0.757 acres platted as Lot 41, in the Circle D Estates Subdivision, Bastrop County, Texas. This action will eliminate less than one acre of habitat and result in an unquantifiable amount of indirect impact. The applicant proposes to compensate for this incidental take of the Houston Toad by donating \$1,500.00 to the National Fish and Wildlife Foundation for the specific purpose of land acquisition and management within Houston toad habitat, as identified by the Service.
Alternatives to this action were rejected because not developing the subject property with federally listed species present was not economically feasible and alteration of the project
design would not alter the level of impacts.
Geoffrey L. Haskett,
Acting Regional Director, Region 2, Albuquerque, New Mexico.
[FR Doc. 00-8625 Filed 4-6-00; 8:45 am] BILLING CODE 4510-55-P

## DEPARTMENT OF THE INTERIOR

## Fish and Wildlife Service

## Notice of Availability of an

 Environmental Assessment/Habitat Conservation Plan for Issuance of an Endangered Species Act Section 10(a)(1)(B) Permit for the Incidental Take of the Houston Toad (Bufo houstonensis) During Construction of One Single Family Residence on 0.5 Acres of Each of 22 Lots in the Pine Oak Estates Subdivision, Bastrop County, Texassummary: John Schuelke (Applicant) has applied to the U.S. Fish and Wildlife Service (Service) for an incidental take permit pursuant to Section 10(a) of the Endangered Species Act (ESA). The Applicant has been assigned permit number TE-023822-0. The requested permit, which is for a period of 5 years, would authorize the incidental take of the endangered Houston toad (Bufo houstonensis). The proposed take would occur as a result of the construction and occupation of one single family residence each on Lots $5-8,10-15,22-24,25 \mathrm{~A}, 26 \mathrm{~A}, 27 \mathrm{~A} \& \mathrm{~B}$, 28A\&B, 29A\&B, 30A in the Pine Oak Estates Subdivision, Bastrop County, Texas.

The Service has prepared the Environmental Assessment/Habitat Conservation Plan (EA/HCP) for the incidental take application. A determination of jeopardy to the species or a Finding of No Significant Impact (FONSI) will not be made before 30 days from the date of publication of this notice. This notice is provided pursuant to Section 10(c) of the Act and National Environmental Policy Act regulations (40 CFR 1506.6).
DATES: Written comments on the application should be received on or before May 8, 2000.
ADDRESSES: Persons wishing to review the application may obtain a copy by writing to the Regional Director, U.S. Fish and Wildlife Service, P.O. Box 1306, Albuquerque, New Mexico 87103. Persons wishing to review the EA/HCP may obtain a copy by contacting Tannika Engelhard, U.S. Fish and Wildlife Service, 10711 Burnet Road, Suite 200, Austin, Texas 78758 (512/ 490-0057, extension 242). Documents
will be available for public inspection by written request or by appointment only during normal business hours (8:00 to $4: 30$ ) at the U.S. Fish and Wildlife Service office, Austin, Texas. Written data or comments concerning the application and EA/HCP should be submitted to the Supervisor, U.S. Fish and Wildlife Service, Austin, Texas at the above address. Please refer to permit number TE-023822-0 when submitting comments.

## FOR FURTHER INFORMATION CONTACT:

Tannika Engelhard at the above U.S. Fish and Wildlife Service office, Austin, Texas.

SUPPLEMENTARY INFORMATION: Section 9 of the Act prohibits the "taking" of endangered species such as the Houston toad. However, the Service, under limited circumstances, may issue permits to take endangered wildlife species incidental to, and not the purpose of, otherwise lawful activities. Regulations governing permits for endangered species are at 50 CFR 17.22.

## Applicant

John Schuelke proposes to construct one single family residence on 0.5 acres of each of twenty-two (22) lots (Lots 58, 10-15, 22-24, 25A, 26A, 27A\&B, 28A\&B, 29A\&B, 30A) in the Pine Oak Estates Subdivision, Bastrop County, Texas. This action will eliminate less than eleven acres of habitat ( 0.5 acres or less per homesite) and result in indirect impacts within the lot. The applicant proposes to compensate for this incidental take of the Houston toad by providing \$33,000.00 (\$1,500.00 per homesite) to the National Fish and Wildlife Foundation for the specific purpose of land acquisition and management within Houston toad habitat, as identified by the Service.

Alternatives to this action were rejected because not developing the subject properties with federally listed species present was not economically feasible and alteration of the project design would not alter the level of impacts.

## Geoffrey L. Haskett,

Acting Regional Director, Region 2, Albuquerque, New Mexico.
[FR Doc. 00-8626 Filed 4-6-00; 8:45 am]
BILLING CODE 4510-55-P

## DEPARTMENT OF THE INTERIOR

## Fish and Wildlife Service

Notice of Intent To Prepare an Environmental Impact Statement/ Environmental Impact Report on the Restoration and Management Plan for Bair Island, Don Edwards San Francisco Bay National Wildlife Refuge, San Mateo County, CA, and Announcement of Public Scoping Meeting
agency: Fish and Wildlife Service, Interior.
ACTION: Notice; correction.
SUMMARY: The Fish and Wildlife Service published a document in the Federal
Register of March 27, 2000, concerning a request for comments on the scope and content of the Restoration and Management Plan for Bair Island and EIS/EIR. This document contained an incorrect date for the comment period.
FOR FURTHER INFORMATION CONTACT: Clyde Morris, Refuge Manager, Don Edwards San Francisco Bay National Wildlife Refuge, Newark, California, telephone (510) 792-0222.

## Correction

In the Federal Register of March 27, 2000, in FR Doc. 00-7168, on page 16217, in the second column, correct the "Dates" caption to read:
DATES: A public scoping meeting will be held on April 27, 2000, from 7 p.m. to 9 p.m., see addresses for location. Written comments related to the scope and content of the Restoration and Management Plan and EIS/EIR should be received by the Service at the Newark address below by May 12, 2000.

Dated: March 29, 2000.
Toni Deery,
Manager, California/Nevada Operations Sacramento, California.
[FR Doc. 00-8367 Filed 4-6-00; 8:45 am] BILLING CODE 4310-55-P

## DEPARTMENT OF THE INTERIOR

## Bureau of Land Management

[CO-600-00-2810-PG]

## Northwest Colorado Resource Advisory Council Meeting

AGENCY: Bureau of Land Management, Interior.
ACTION: Notice of meeting.
SUMMARY: The next meeting of the Northwest Colorado Resource Advisory Council will be held on Friday, May 19, 2000, at the Bureau of Land

Management in Grand Junction, Colorado.
DATES: Friday, May 19, 2000.
ADDRESSES: Bureau of Land
Management, 2815 H Road, Grand Junction, Colorado 81506.
FOR FURTHER INFORMATION, CONTACT:
Lynn Barclay, Bureau of Land Management (BLM), 455 Emerson Street, Craig, Colorado 81625; Telephone (970) 826-5096. SUPPLEMENTARY INFORMATION: The Northwest Resource Advisory Council will meet on Friday, May 19, 2000, at the Bureau of Land Management, 2815 H Road, Grand Junction, Colorado. The meeting will start at $9 \mathrm{a} . \mathrm{m}$. and includes discussion of mission of Wildlife and Land Exchange subcommittees, subcommittee assignments, working with United States Forest Service, and defining meeting procedures and processes.

The meeting is open to the public. Interested persons may make oral statements at the meetings or submit written statements at the meeting. Perperson time limits for oral statements may be set to allow all interested persons an opportunity to speak. Summary minutes of council meetings are maintained at the Bureau of Land Management Offices in Grand Junction and Craig, Colorado. They are available for public inspection and reproduction during regular business hours within thirty (30) days following the meeting.

Dated: April 3, 2000.
Mary E. Trautner,
Acting Little Snake Field Office Manager. [FR Doc. 00-8684 Filed 4-6-00; 8:45 am] BILLING CODE 4310-JB-P

## DEPARTMENT OF THE INTERIOR

## Minerals Management Service

Outer Continental Shelf, Western Gulf of Mexico, Oil and Gas Lease Sale 177
agency: Minerals Management Service, Interior.
ACTION: Availability of the proposed notice of sale.

Gulf of Mexico Outer Continental Shelf (OCS) Notice of Availability of the Proposed Notice of Sale for proposed Oil and Gas Lease Sale 177 in the Western Gulf of Mexico. This Notice of Availability is published pursuant to 30 CFR 256.29(c), as a matter of information to the public.

With regard to oil and gas leasing on the OCS, the Secretary of the Interior, pursuant to section 19 of the OCS Lands Act, provides the affected States the
opportunity to review the proposed Notice. The proposed Notice sets forth the proposed terms and conditions, of the sale, including minimum bids, royalty rates, and rentals.

The proposed Notice of Sale for Sale 177 and a "Proposed Sale Notice Package" containing information essential to potential bidders may be obtained from the Public Information Unit, Gulf of Mexico Region, Minerals Management Service, 1201 Elmwood Park Boulevard, New Orleans, Louisiana 70123-2394. Telephone: (504) 7362519.

The final Notice of Sale will be published in the Federal Register at least 30 days prior to the date of bid opening. Bid opening is currently scheduled for August 23, 2000.
Dated: March 24, 2000.
Thomas R. Kitsos,
Acting Director, Minerals Management Service.
[FR Doc. 00-8608 Filed 4-06-00; 8:45 am] BILLING CODE 4310-MR-M

## DEPARTMENT OF THE INTERIOR

## National Park Service

## National Register of Historic Places; Notification of Pending Nominations

Nominations for the following properties being considered for listing in the National Register were received by the National Park Service before April 1, 2000. Pursuant to section 60.13 of 36 CFR part 60 , written comments concerning the significance of these properties under the National Register criteria for evaluation may be forwarded to the National Register, National Park Service, 1849 C St. NW, NC400, Washington, DC 20240. Written comments should be submitted by April 24, 2000.

## Beth M. Boland,

Acting Keeper of the National Register.
ILLINOIS
Adams County
Quincy Northwest Historic District, Roughly bounded by Broadway, N. Secod, Locust, and N. Twelfth Sts., Quincy, 00000414

## Champaign County

Library—University of Illinois at UrbanaChampaign, (University of Illinois Buildings designed by Charles A. Platt MPS) 1408 W. Gregory Dr., Urbana, 00000413

## Kane County

Spring—Douglas Historic District, Roughly Spring St. and Douglas Ave., bet. River Bluff Rd. and Kimball Ave. Elgin, 00000410

## Kankakee County

Illinois Central Railroad Depot, 199 S. East Ave., Kankakee, 00000409

Windrose Site, Address Restricted, Bourbonnais, 00000412
Sangamon County
Fisher Building-Latham Block, 111, 113, and 115 N. Sixth St., Springfield, 00000411

## MASSACHUSETTS

Hampshire County
Goodwin Memorial African Methodist Episcopal Zion Church, Woodside Ave., Amherst, 00000416

## Suffolk County

Harvard Avenue Historic District, Roughly bounded by Linden St., Commonwealth Ave., Harvard Ave., and Park Vale Ave., Boston, 00000415

## NEW YORK

Saratoga County
Arrowhead Casino Prehistoric Site, (Saratoga Lake-Fish Creek Area Archeological Sites MPS) Address Restricted, Saratoga Springs, 00000418

## NORTH CAROLINA

Davidson County
First Reformed Church, 22 E. Center S., Lexington, 00000417

## OHIO

Cuyahoga County
Falls River Rd., Falls Rd., Chagrin Falls, 00000421
Henn, Albert W., Mansion, 23131 Lake Shore Blvd., Euclid, 00000422
Morrow County
Benedict, Reuben, House, 1463 Cty. Rd. 24, Marengo, 00000419
Tuscarawas County
Lanning, T., \& Co. Department Store, 226-228 Grant St., Dennison, 00000420
PUERTO RICO
Hormigueros Municipality
Torrens Bridge, (Spanish-American War in Puerto Rico MPS) PR 319., Hormigueros, 00000423
[FR Doc. 00-8652 Filed 4-6-00; 8:45 am] BILLING CODE 4310-70-P

## DEPARTMENT OF THE INTERIOR

## National Park Service

Notice of Availability of Draft Director's Order \#47 Concerning Soundscape Preservation and Noise Management

AGENCY: National Park Service, Interior.
ACTION: Notice of availability.
summary: The National Park Service (NPS) is updating its current system of internal instructions. When these documents contain new policy or
procedural requirements that may affect parties outside the NPS, this information is being made available for public review and comment. Draft Director's Order \#47 establishes comprehensive operational policies and requirements to guide NPS soundscape preservation and noise management. DATES: Written comments will be accepted until May 8, 2000.
ADDRESSES: Draft Director's Order \#47 is available on the Internet at http:// www.nps.gov/refdesk/DOrders/ index.htm. Requests for copies and written comments should be sent to Wes Henry, National Park Service, Ranger Activities Division, 1849 C Street, NW., Room 7418, Washington, D.C. 20240.
FOR FURTHER INFORMATION CONTACT: Bill Schmidt at 202/501-9269.
SUPPLEMENTARY INFORMATION: The NPS is revising its operational policies and procedures to facilitate, to the fullest extent practicable, the protection, maintenance, or restoration of the natural soundscapes associated with units of the national park system. Natural sounds are vital to the natural function of many parks, and may provide valuable indicators of the health of various ecosystems. The natural sound environment is recognized as one of the resources found in parks, and is highly valued by most park visitors. Increasingly, even those parks that appear as they did in historical context no longer sound the way they once did. Natural sounds are slowly and inexorably being masked or obscured by a wide variety of human activities. Soundscape preservation and noise management is one dimension of the complex problem the NPS faces in preserving park resources unimpaired while providing appropriate enjoyment for current and future generations.

Dated: March 30, 2000.
Maureen Finnerty,
Associate Director, Park Operations and Education.
[FR Doc. 00-8613 Filed 4-6-00; 8:45 am] BILLING CODE 4310-70-U

DEPARTMENT OF THE INTERIOR

## National Park Service

Notice of Availability of Director's Orders 87, the Guidance for All NonNational Park Service Federal-Aid Roads and Highways in Units of the National Park Service

Agency: National Park Service, Interior. ACTION: Public notice.
summary: The National Park Service (NPS) has available for public review,
the proposed guidance document for all non-NPS Federal-Aid roads and highways in units of the NPS. This information was developed to provide guidance to managers in all units of the National Park System who deal with requests from State and other Department of Transportation (DOT) agencies for NPS land to be used for non-NPS Federal-Aid roads and highways. At the end of the review period, this material will appear as a Director's Order for Non-NPS FederalAid Roads in Parks distributed to all NPS units. The Director's Order will provide policy guidance to park managers concerning all aspects of requests for land for these purposes, from the initial contact and decisions, through $4(\mathrm{f})$ determinations, statutory requirements and NPS policy, ultimately resulting in official notification of denial or consent for the request for a deed of easement for highway purposes. The guidance document is a concise treatment of the entire subject of non-NPS Federal-Aid roads in parks including but not limited to requests for new roads and widening of existing roads.

Copies of the proposed guidance document will be made available upon request by writing: National Park Service, Ranger Activity Division, 1849 C St. NW, Suite 7408, Washington, DC 20240, or by calling 202-208-4874. The draft document is also available on the NPS website the following URL: www.nps.gov/refdesk/DOrders/ index.htm.

DATES: Public comments will be accepted on or before June 6, 2000.
ADDRESSES: Comments should be addressed to: Dick Young, Special Park Uses Program Manager, C/O Colonial NHP, P. O. Box 210, Yorktown, VA 23690.

FOR FURTHER INFORMATION CONTACT: Dick
Young at 757-898-7846, or 757-8983400, ext. 51.
Dated: March 31, 2000.

## Chris Andress,

Chief, Ranger Activities Division.
[FR Doc. 00-8612 Filed 4-6-00; 8:45 am]
BILLING CODE 4310-70-U

## INTERNATIONAL TRADE COMMISSION <br> [USITC SE-00-016]

## Sunshine Act Meeting

agency holding the meeting: United States International Trade Commission. TIME AND DATE: April 20, 2000 at 11:00 a.m.

PLACE: Room 101, 500 E Street SW,
Washington, DC 20436, Telephone: (202) 205-2000.
status: Open to the public.
matters to be considered: 1. Agenda
for future meeting: none.
2. Minutes
3. Ratification List.
4. Inv. Nos. 731-TA-406 and 408
(Review)(Electrolytic Manganese Dioxide from Greece and Japan)briefing and vote. (The Commission will transmit its determination to the
Secretary of Commerce on May 9, 2000.)
5. Outstanding action jackets: none.

In accordance with Commission policy, subject matter listed above, not disposed of at the scheduled meeting, may be carried over to the agenda of the following meeting.
Issued: April 3, 2000.
By order of the Commission.
Donna R. Koehnke,
Secretary.
[FR Doc. 00-8777 Filed 4-5-00; 2:06 pm] BILLING CODE 7020-02-P

## DEPARTMENT OF JUSTICE

## Notice of Lodging of Consent Decree Under the Comprehensive Environmental Response, Compensation, and Liability Act

Notice is hereby given that a Consent Decree in U.S. v. Arnet Realty Co., et al., Civil Action No. 00-1294 (AJL) (D.N.J.) was lodged with the United States District Court for the District of New Jersey on March 17, 2000.

The proposed consent decree resolves claims asserted by the United States, on behalf of the U.S. Environmental Protection Agency ("EPA"), against: Madison Industries, Inc.; Old Bridge Chemicals, Co.; Arnet Realty Company and its two partners, Arnold Asman and Nettie Bzura; and Ciba Specialty Chemicals Water Treatments, Inc. (formerly CPS Chemical Company, Inc., a subsidiary of Ciba Specialty Chemicals Corporation. ("Settling Defendants") under Section 107 of the
Comprehensive Environmental Response, Compensation, and Liability Act ("CERCLA"'), 42 U.S.C. 9607. The claims sought to recover past response costs incurred at the CPS/Madison site ("Site") in Middlesex County, New Jersey. The proposed Consent Decree requires the Settling Defendants to reimburse the United States $\$ 500,000$ in past response costs.
The Department of Justice will accept written comments relating to the proposed consent decree for thirty (30) days from the date of publication of this
notice. Please address comments to the Assistant Attorney General, Environment and Natural Resources Division, Department of Justice, P.O. Box 7611, Ben Franklin Station, Washington, D.C. 20044 and refer to U.S. v. Arnet Realty Co., et al., Civil Action No. 00-1294 (AJL) (D.N.J.), DJ \#90-11-3-1525.

Copies of the proposed consent decree may be examined at the Office of the United States Attorney for the District of New Jersey, 970 Broad Street, Newark, NJ 07102, or at the U.S. Environmental Protection Agency, Region II, 290 Broadway, New York, NY 10007-1866. A copy of the proposed Settlement Agreement may also be obtained by mail from the Consent Decree Library, P.O. Box 7611, Washington, D.C. 20044. When requesting a copy of the consent decree by mail, please enclose a check in the amount of $\$ 7.00$ (twenty-five cents per page reproduction costs) payable to the "Consent Decree Library."

## Joel M. Gross,

Chief, Environmental Enforcement Section, Environment and Natural Resources Division, U.S. Department of Justice.
[FR Doc. 00-8603 Filed 4-6-00; 8:45 am]
BILLING CODE 4410-15-M

## DEPARTMENT OF JUSTICE

## Notice of Lodging of Consent Decree

Pursuant to the Clean Water Act ("CWA") and the Comprehensive Environmental Response, Compensation and Liability Act ("CERCLA")

Consistent with Departmental policy, 28 CFR 50.7, notice is hereby given that a proposed Consent Decree in United States v. Gulf States Steel, Inc. was lodged with the United States District Court for the Northern District of Alabama on march 28, 2000 (CV-97-BU-2755-M). The United States filed a complaint pursuant to Section 309(b) of the Clean Water Act alleging that the defendant violated the CWA on numerous occasions. The proposed Consent Decree resolves the CWA liability of Gulf States Steel as alleged in the complaint. The United States also believes that the defendant is liable pursuant to Section 107 of the Comprehensive Environmental Response, Compensation, and Liability Act of 1980 ("CERCLA"), as amended, for costs incurred and to be incurred by the United States Environmental Protection Agency at the Gulf States Steel Superfund Site in Gadsden, Alabama. The proposed Consent Decree resolves certain such liabilities.

Under the Consent Decree, Gulf States Steel agrees to pay a civil penalty to the United States in the amount of $\$ 100,000$. In addition, Gulf States Steel agrees to operate its plant in compliance with its National Pollutant Discharge Elimination System (NPDES) Permit, and with the CWA. In addition, Gulf States Steel agrees to undertake certain Supplemental Environmental Projects (SEPs) in the amount of at least \$206 million. These SEPs will result in significant pollution prevention or reduction in excess of Gulf States Steel's legal obligations. In addition, one SEP will result in Gulf States Steel purchasing ecologically-valuable land for perpetual preservation. Gulf States Steel also agrees to pay $\$ 6.54$ million for cleanup of Lake Gadsden and Black Creek in Gadsden, Alabama. Gulf States Steel also agrees to purchase or donate appropriate real property for placement of sediments, if needed by EPA, Region 4.

The Department of Justice will receive, for a period of thirty (30) days from the date of this publication, comments relating to the proposed Consent Decree. Comments should be addressed to the Assistant Attorney General for the Environment and Natural Resources Division, U.S. Department of Justice, P.O. Box 7611, Washington, D.C. 20044; and refer to United States v. Gulf States Steel, Inc. DOJ Ref. \# 90-5-1-1-4211.
The proposed settlement agreement may be examined at the Office of the United States Attorney, 1800 Fifth Avenue, North, Birmingham, Alabama 35203, and at the office of the Environmental Protection Agency, Region 4, 61 Forsyth Street, S.W., Atlanta, GA 30303. In requesting a copy, please refer to the referenced case and enclose a check in the amount of $\$ 4.25$ ( 25 cents per page reproduction costs).

## Joel Gross,

Chief, Environmental Enforcement Section, Environment and Natural Resources Division. [FR Doc. 00-8602 Filed 4-6-00; 8:45 am] BILLING CODE 4410-15-M

## DEPARTMENT OF JUSTICE

## Notice of Lodging of Consent Decree Pursuant to the Clean Water Act

In accordance with Departmental Policy, 28 C.F.R. 50.7, notice is hereby given that a Consent Decree that would resolve the liability of Artemissa Farms, Inc., the last of four defendants in United States of America v. Jane A. Young, et al. Civil Action No. 95-4202JPG (S.D. Ill.), was lodged with the United States District Court for the

Southern District of Illinois on March 15, 2000.

The proposed Consent Decree concerns alleged violations of the Clean Water Act, 33 U.S.C. 1311, as a result of the discharge of dredged and fill materials onto approximately 100 acres of wetlands, in Hamilton County, Illinois (the "Site"), which is alleged to constitute "waters of the United States."

The Consent Decree permanently enjoins Artemissa Farms, Inc. from taking any actions, or causing others to take any actions, which result in the discharge of dredged or fill material into waters of the United States. The Consent Decree further requires Artemissa Farms, Inc. to pay $\$ 5,000$ into an interest-bearing Registry Account of the United States District Court for the Southern District of Illinois, to be used to conduct a wetland restoration on the Site.

The Consent Decree also requires Artemissa Farms, Inc., subject to the right of prior approval by the United States Army Corps of Engineers, to convey the Site to an appropriate entity for conservation after the wetland restoration is completed. The purpose of the conveyance is to provide a conservation area in which no development, excavation, or other disturbance will occur. To achieve that end, the conveyance shall contain several restrictions that are set forth in the Consent Decree.

The Department of Justice will receive written comments relating to the Consent Decree for a period of thirty (30) days from the date of this notice. Comments should be addressed to the Assistant Attorney General, Environment and Natural Resources Division, United States Department of Justice, Attention: Steven E. Rusak, Senior Attorney, Environmental Defense Section, P.O. Box 23986, Washington, D.C. 20026-3986, and should refer to United States of America v. Jane A. Young, et. al., DJ Reference No. 90-5-1-6-580.

The proposed Consent Decree may be examined at the Clerk's Office, United States District Court, United States Courthouse, 301 West Main Street, Benton, Illinois 62812.

Letitia J. Grishaw,
Chief, Environmental Defense Section, Environment \& Natural Resources Division, United States Department of Justice.
[FR Doc. 00-8601 Filed 4-6-00; 8:45 am]
BILLING CODE 4410-15-M

# DEPARTMENT OF LABOR 

## Employment Standards Administration, Wage and Hour Division

## Minimum Wages for Federal and Federally Assisted construction; General Wage Determination Decisions

General wage determination decisions of the Secretary of Labor are issued in accordance with applicable law and are based on the information obtained by the Department of Labor from its study of local wage conditions and data made available from other sources. They specify the basic hourly wage rates and fringe benefits which are determined to be prevailing for the described classes of laborers and mechanics employed on construction projects of a similar character and in the localities specified therein.

The determinations in these decisions of prevailing rates and fringe benefits have been made in accordance with 29 CFR Part 1, by authority of the Secretary of Labor pursuant to the provisions of the Davis-Bacon Act of March 3, 1931, as amended (46 Stat. 1494, as amended, 40 U.S.C. 276a) and of other Federal statues referred to in 29 CFR part 1, appendix, as well as such additional statutes as may from time to time be enacted containing provisions for the payment of wages determined to be prevailing by the Secretary of Labor in accordance with the Davis-Bacon Act. The prevailing rates and fringe benefits determined in these decisions shall, in accordance with the provisions of the foregoing statutes, constitute the minimum wages payable on Federal and federally assisted construction projects to laborers and mechanics of the specified classes engaged on contract work of the character and in the localities described therein.

Good cause is hereby found for not utilizing notice and public comment procedure thereon prior to the issuance of these determinations as prescribed in 5 U.S.C. 553 and not providing for delay in the effective date as prescribed in that section, because the necessity to issue current construction industry wage determinations frequently and in large volume causes procedures to be impractical and contrary to the public interest.

General wage determination decisions, and modifications and supersedes decisions thereto, contain no expiration dates and are effective from their date of notice in the Federal
Register, or on the date written notice is received by the agency, whichever is earlier. These decisions are to be used
in accordance with the provisions of 29 CFR parts 1 and 5. Accordingly, the applicable decision, together with any modifications issued, must be made a part of every contract for performance of the described work within the geographic area indicated as required by an applicable Federal prevailing wage law and 29 CFR part 5 . The wage rates and fringe benefits, notice of which is published herein, and which are contained in the Government Printing Office (GPO) document entitled
"General Wage Determinations Issued Under The Davis-Bacon And Related Acts," shall be the minimum paid by contractors and subcontractors to laborers and mechanics.

Any person, organization, or governmental agency having an interest in the rates determined as prevailing is encouraged to submit wage rate and fringe benefit information for consideration by the Department. Further information and selfexplanatory forms for the purpose of submitting this data may be obtained by writing to the U.S. Department of Labor, Employment Standards Administration, Wage and Hour Division, Division of Wage Determinations, 200 Constitution Avenue, NW, Room S-3014, Washington, DC 20210.

## Withdrawn General Wage Determination Decision

This is to advise all interest parties that the Department of Labor is withdrawing, from the date of this notice, the following General Wage Determinations:

NH000011-See NH000003
NH000012-See NH000003
NH000013-See NH000003
NH000014-See NH000003
NH000015-See NH000003
NH000016-See NH000003
IA000076-See IA000018
Contracts for which bids have been opened shall not be affected by this notice. Also, consistent with 29 CFR $1.6(\mathrm{c})(2)(\mathrm{i})(\mathrm{A})$, when the opening of bids is less than ten (10) days from the date of this notice, this action shall be effected unless the agency finds that there is insufficient time to notify bidders of the change and the finding is documented in the contract file.

## New General Wage Determination Decision

The number of the decisions added to the Government Printing Office document entitled "General Wage Determinations Issued Under the DavisBacon and Related Acts" are listed by Volume and States:

Volume I
New York
NY000079 (Apr. 7, 2000)
Volume II
Maryland
MD000060 (Apr. 7, 2000)

## Modifications to General Wage Determination Decisions

The number of decisions listed in the Government Printing Office document entitled "General Wage Determinations Issued Under the Davis-Bacon and Related Acts" being modified are listed by Volume and State. Dates of publication in the Federal Register are in parentheses following the decisions being modified.

## Volume I

New Hampshire
NH000002 (Feb. 11, 2000)
NH000003 (Feb. 11, 2000)
New Jersey
NJ000006 (Feb. 11, 2000)
New York
NY000002 (Feb. 11, 2000)
NY000006 (Feb. 11, 2000)
NY000010 (Feb. 11, 2000)
NY000017 (Feb. 11, 2000)
NY000018 (Feb. 11, 2000)
NY000022 (Feb. 11, 2000)
NY000026 (Feb. 11, 2000)
NY000033 (Feb. 11, 2000)
NY000042 (Feb. 11, 2000)
NY000049 (Feb. 11, 2000)
NY000074 (Feb. 11, 2000)
NY000076 (Feb. 11, 2000)
NY000079 (Feb. 11, 2000)
Volume II
Maryland
MD000018 (Feb. 11, 2000)
MD000020 (Feb. 11, 2000)
Pennsylvania
PA000001 (Feb. 11, 2000)
PA000002 (Feb. 11, 2000)
PA000006 (Feb. 11, 2000)
PA000017 (Feb. 11, 2000)
PA000018 (Feb. 11, 2000)
PA000020 (Feb. 11, 2000)
PA000027 (Feb. 11, 2000)
PA000031 (Feb. 11, 2000)
Volume III
Alabama
AL000034 (Feb. 11, 2000)
AL000052 (Feb. 11, 2000)
Florida
FL000001 (Feb. 11, 2000)
FL000004 (Feb. 11, 2000)
FL000009 (Feb. 11, 2000)
FL000010 (Feb. 11, 2000)
FL000015 (Feb. 11, 2000)
FL000017 (Feb. 11, 2000)
FL000032 (Feb. 11, 2000)
Kentucky
KY000004 (Feb. 11, 2000)
KY000029 (Feb. 11, 2000)
Volume IV
Illinois
IL000001 (Feb. 11, 2000)
IL000002 (Feb. 11, 2000)

IL000004 (Feb. 11, 2000)
IL000005 (Feb. 11, 2000)
IL000016 (Feb. 11, 2000)
IL000021 (Feb. 11, 2000)
IL000022 (Feb. 11, 2000)
IL000024 (Feb. 11, 2000)
IL000027 (Feb. 11, 2000)
IL000028 (Feb. 11, 2000)
IL000029 (Feb. 11, 2000)
IL000031 (Feb. 11, 2000)
IL000032 (Feb. 11, 2000)
IL000033 (Feb. 11, 2000)
IL000034 (Feb. 11, 2000)
IL000036 (Feb. 11, 2000)
IL000037 (Feb. 11, 2000)
IL000039 (Feb. 11, 2000)
IL000042 (Feb. 11, 2000)
IL000043 (Feb. 11, 2000)
IL000044 (Feb. 11, 2000)
IL000045 (Feb. 11, 2000)
IL000046 (Feb. 11, 2000)
IL000047 (Feb. 11, 2000)
IL000049 (Feb. 11, 2000)
IL000050 (Feb. 11, 2000)
IL000051 (Feb. 11, 2000)
IL000059 (Feb. 11, 2000)
IL000063 (Feb. 11, 2000)
IL000066 (Feb. 11, 2000)
IL000067 (Feb. 11, 2000)
IL000068 (Feb. 11, 2000)
IL000069 (Feb. 11, 2000)
IL000070 (Feb. 11, 2000)
Indiana
IN000001 (Feb. 11, 2000)
IN000002 (Feb. 11, 2000)
IN000003 (Feb. 11, 2000)
IN000004 (Feb. 11, 2000)
IN000006 (Feb. 11, 2000)
IN000007 (Feb. 11, 2000)
IN000017 (Feb. 11, 2000)
IN000018 (Feb. 11, 2000)
IN000020 (Feb. 11, 2000)
IN000021 (Feb. 11, 2000)
IN000047 (Feb. 11, 2000)
IN000048 (Feb. 11, 2000)
IN000049 (Feb. 11, 2000)

## Minnesota

MN000008 (Feb. 11, 2000)
MN000012 (Feb. 11, 2000)
MN000015 (Feb. 11, 2000)
MN000031 (Feb. 11, 2000)
MN000058 (Feb. 11, 2000)
MN000061 (Feb. 11, 2000)
Ohio
OH000029 (Feb. 11, 2000)
Volume V
Iowa
IA000018 (Feb. 11, 2000)
Kansas
KS000006 (Feb. 11, 2000)
KS000007 (Feb. 11, 2000)
KS000009 (Feb. 11, 2000)
KS000010 (Feb. 11, 2000)
KS000011 (Feb. 11, 2000)
KS000012 (Feb. 11, 2000)
KS000013 (Feb. 11, 2000)
KS000015 (Feb. 11, 2000)
KS000016 (Feb. 11, 2000)
KS000018 (Feb. 11, 2000)
KS000019 (Feb. 11, 2000)
KS000020 (Feb. 11, 2000)
KS000021 (Feb. 11, 2000)
KS000022 (Feb. 11, 2000)
KS000023 (Feb. 11, 2000)
KS000025 (Feb. 11, 2000)

KS000026 (Feb. 11, 2000)
KS000029 (Feb. 11, 2000)
KS000063 (Feb. 11, 2000)
KS000069 (Feb. 11, 2000)
KS000070 (Feb. 11, 2000)
Louisiana
LA000005 (Feb. 11, 2000)
LA000009 (Feb. 11, 2000)
LA000012 (Feb. 11, 2000)
LA000018 (Feb. 11, 2000)
New Mexico
NM000001 (Feb. 11, 2000)
NM000005 (Feb. 11, 2000)

## Texas

TX000002 (Feb. 11, 2000)
TX000005 (Feb. 11, 2000)
TX000010 (Feb. 11, 2000)
TX000014 (Feb. 11, 2000)
TX000018 (Feb. 11, 2000)
TX000054 (Feb. 11, 2000)
TX000055 (Feb. 11, 2000)
TX000093 (Feb. 11, 2000)
TX000117 (Feb. 11, 2000)
Volume VI
Colorado
CO000001 (Feb. 11, 2000)
CO000003 (Feb. 11, 2000)
CO000006 (Feb. 11, 2000)
CO000008 (Feb. 11, 2000)
CO000009 (Feb. 11, 2000)
Oregon
OR000001 (Feb. 11, 2000)
OR000004 (Feb. 11, 2000)
OR000017 (Feb. 11, 2000)

## Washington

WA000001 (Feb. 11, 2000)
WA000005 (Feb. 11, 2000)

## Volume VII

None

## General Wage Determination <br> Publication

General wage determinations issued under the Davis-Bacon and related Acts, including those noted above, may be found in the Government Printing Office (GPO) document entitled "General Wage Determinations Issued Under the DavisBacon and Related Acts." This publication is available at each of the 50 Regional Government Depository Libraries and many of the 1,400 Government Depository Libraries across the country.

The general wage determinations issued under the Davis-Bacon and Related Acts are available electronically by subscription to the FedWorld Bulletin Board System of the National Technical Information Service (NTIS) of the U.S. Department of Commerce at 1-800-363-2068

Hard-copy subscriptions may be purchased from: Superintendent of Documents, U.S. Government Printing Office, Washington, DC 20402, (202) 512-1800.

When ordering hard-copy
subscription(s), be sure to specify the State(s) of interest, since subscriptions may be ordered for any or all of the
seven separate volumes, arranged by State. Subscriptions include an annual edition (issued in January or February) which includes all current general wage determinations for the States covered by each volume. Throughout the remainder of the year, regular weekly updates are distributed to subscribers.
Signed at Washington, DC this 30th day of March, 2000.
Carl J. Poleskey,
Chief, Branch of Construction Wage Determinations.
[FR Doc. 00-8446 Filed 4-6-00; 8:45 am] BILLING CODE 4510-27-M

## DEPARTMENT OF LABOR

## Pension and Welfare Benefits Administration

## [Application No. D-10678, et al.]

## Proposed Exemptions; H. Ray McPhail (Mr. McPhail) and the H. Ray McPhail Profit Sharing Plan (the Plan)

Agency: Pension and Welfare Benefits Administration, Labor.
ACTION: Notice of proposed exemptions.
SUMMARY: This document contains notices of pendency before the Department of Labor (the Department) of proposed exemptions from certain of the prohibited transaction restrictions of the Employee Retirement Income Security Act of 1974 (the Act) and/or the Internal Revenue Code of 1986 (the Code).

## Written Comments and Hearing Requests

All interested persons are invited to submit written comments or request for a hearing on the pending exemptions, unless otherwise stated in the Notice of Proposed Exemption, within 45 days from the date of publication of this Federal Register Notice. Comments and requests for a hearing should state: (1) the name, address, and telephone number of the person making the comment or request, and (2) the nature of the person's interest in the exemption and the manner in which the person would be adversely affected by the exemption. A request for a hearing must also state the issues to be addressed and include a general description of the evidence to be presented at the hearing. ADDRESSES: All written comments and request for a hearing (at least three copies) should be sent to the Pension and Welfare Benefits Administration, Office of Exemption Determinations, Room N-5649, U.S. Department of Labor, 200 Constitution Avenue, NW, Washington, DC 20210. Attention: Application No. $\qquad$ , stated in each

Notice of Proposed Exemption. The applications for exemption and the comments received will be available for public inspection in the Public Documents Room of the Pension and Welfare Benefits Administration, U.S. Department of Labor, Room N-5638, 200 Constitution Avenue, NW, Washington, DC 20210.

## Notice to Interested Persons

Notice of the proposed exemptions will be provided to all interested persons in the manner agreed upon by the applicant and the Department within 15 days of the date of publication in the Federal Register. Such notice shall include a copy of the notice of proposed exemption as published in the Federal Register and shall inform interested persons of their right to comment and to request a hearing (where appropriate).
SUPPLEMENTARY INFORMATION: The proposed exemptions were requested in applications filed pursuant to section 408(a) of the Act and/or section 4975(c)(2) of the Code, and in accordance with procedures set forth in 29 CFR Part 2570, Subpart B (55 FR 32836, 32847, August 10, 1990). Effective December 31, 1978, section 102 of Reorganization Plan No. 4 of 1978, 5 U.S.C. App. 1 (1996), transferred the authority of the Secretary of the Treasury to issue exemptions of the type requested to the Secretary of Labor. Therefore, these notices of proposed exemption are issued solely by the Department.

The applications contain representations with regard to the proposed exemptions which are summarized below. Interested persons are referred to the applications on file with the Department for a complete statement of the facts and representations.
H. Ray McPhail (Mr. McPhail) and the H. Ray McPhail Profit Sharing Plan (the Plan) Located in Atlanta, Georgia
[Exemption Application No. D-10678]

## Proposed Exemption

The Department is considering granting an exemption under the authority of section 408(a) of the Act and section 4975(c)(2) of the Code and in accordance with the procedures set forth in 29 CFR Part 2570, Subpart B ( 55 FR 32826, 32847, August 10, 1990). If the exemption is granted, the sanctions resulting from the application of section 4975 of the Code, by reason of section 4975(c)(1)(A) through (E) of the Code, shall not apply to the proposed sale (the Sale) of four parcels of unimproved real property (the Property) and loan (the

Loan) from the Plan to Mr. McPhail, ${ }^{1}$ a disqualified person with respect to the Plan, provided that the following conditions are met:
(1) With respect to the Sale:
(A) The terms and conditions of the Sale will be at least as favorable to the Plan as those obtainable in an arm's length transaction with an unrelated party;
(B) The Sale will occur at a price which includes the greater of \$270,000 or the Property's fair market value as established by a qualified, independent appraiser;
(C) The Sale Price will also include a premium of \$30,000 (the Assemblage Value) due to Mr. McPhail's ownership of unimproved real property located adjacent to the Property;
(D) The Plan will pay no fees or commissions with respect to the Sale; and
(E) Mr. McPhail will pay $\$ 60,000$ or $20 \%$ of the Sale Price in cash with the balance paid for by the Loan; and
(2) With Respect to the Loan:
(A) The interest rate on the Loan (the Interest Rate) will be $7 \%$, a rate set by the Macon Bank for a real estate loan having terms similar to the Loan;
(B) The Loan terms are at least favorable to the Plan as those obtainable in an arm's length transaction with an unrelated party;
(C) The Loan is secured by a first security interest on the certain real property, which has been appraised by a qualified independent appraiser to have a fair market value not less than $150 \%$ of the principal amount of the Loan; and
(D) The outstanding balance of the Loan will never exceed $20 \%$ of the assets of the Plan throughout the duration of the Loan;
(E) The fair market value of the collateral remains at least equal to $150 \%$ of the outstanding principal balance plus accrued but not unpaid interest, throughout the duration of the Loan; and
(3) Should any employee of the Plan Sponsor become eligible for Plan participation, the new participant will be enrolled in another qualified retirement plan or the Loan will be immediately repaid.

## Summary of Facts and Representations

1. The H. Ray McPhail Company (the McPhail Co.) is a Georgia company engaged in the purchase and sale of real estate. The McPhail Co. is solely owned

[^35]by Mr. McPhail and is the sponsor of the Plan. The Plan is a defined contribution plan located in Atlanta, Georgia and having Mr. McPhail as its sole participant. The Plan had total assets of approximately $\$ 3,420,136$ as of October 31, 1998.
2. The assets of the Plan include the Property. The Property comprises approximately 3.66 acres of unimproved real property located in Highlands, North Carolina. The Property is divided into four lots. Two of the lots are interior lots and the other two lots have frontage on Lake Sequoyah. The Property was acquired for $\$ 293,000$ on November 23, 1994 from Elizabeth Nielson, an unrelated party.
3. Since its acquisition, the Property has not generated any income for the Plan. The Plan has, however, incurred certain expenses as a result of the Plan's ownership of the Property. In this regard, the applicant represents that the Plan has incurred a total of $\$ 3,169.33$ in property taxes. In addition, the applicant represents that the Plan has incurred expenses in the amount of $\$ 1,685$ for consulting fees resulting from the Plan's attempt to develop the Property.
4. The Property was appraised by Thomas Ringle (Mr. Ringle), an appraiser independent of the Plan and certified in the State of North Carolina. Mr. Ringle calculated the Property's fair market value (the Fair Market Value) using the sales comparison approach and compared the Property to similar unimproved properties located near the Property. Based on these comparisons, Mr. Ringle determined the Fair Market Value to be \$270,000 as of June 9, 1998.
Mr. Ringle also calculated an additional value for the Property for purposes of the Sale (i.e., the Assemblage Value). Mr. Ringle represents that the Assemblage Value is due to Mr. McPhail's ownership of unimproved real property located adjacent to the Property and reflects the higher value property owners are willing to pay for adjoining parcels of property. Based on his analysis of the Property, Mr. Ringle calculated that the Assemblage Value to be $\$ 30,000$.

Mr. Ringle determined that the sales price of the Property for purposes of the Sale (the Sale Price) should be a sum equal to the Fair Market Value and the Assemblage Value. As a result, Mr. Ringle determined the Sale Price to be \$300,000.
5. The applicant is proposing the sale of the Property from the Plan to Mr. McPhail for $\$ 300,000$ (i.e., the Sale). The applicant represents that Mr. McPhail proposes to pay $20 \%$ of the Sales Price in cash to the Plan as a down
payment on the Property with the Plan loaning Mr. McPhail the remaining $80 \%$ balance (i.e., the Loan). In this regard, the applicant represents that the Loan will be for 15 years at seven percent (7\%) interest (i.e., the Interest Rate). The Interest Rate represents an interest rate set by the Macon Savings Bank (Macon) located in Highlands, North Carolina, for a real estate loan having similar terms as the Loan. The applicant represents that Macon is an independent party with respect to the Plan.

As a result, Mr. McPhail proposes the following terms for the Sale: $\$ 60,000$ in cash paid by Mr. McPhail to the Plan as a down payment on the Property; and $\$ 2,157.19$ paid by Mr. McPhail to the Plan each month for 179 months. As security on the Loan, Mr. McPhail will pledge the Property and additional unimproved real property having a fair market value of $\$ 435,000$ as of September 3, 1999, as determined by John Meadows of John Cleveland Realty, an independent real estate broker. The security interest securing the Loan will be a first security interest and will be perfected in accordance with North Carolina law. In addition, the property securing the Loan, will be insured against casualty loss for an amount which is not less than the Loan balance throughout the duration of the Loan. The Plan will be listed as a loss payee on the insurance policy.
6. The applicant represents that the proposed Sale is in the best interest of the Plan due to the high expense the Plan anticipates will be necessary for a sale of the Property to unrelated third parties. The applicant further represents that the Property was originally purchased by the Plan with the intent that the Plan would resell the Property to unrelated parties. The applicant notes that, subsequent to the purchase of the Property by the Plan, the Plan determined that the Property could not be sold to third parties without the expenditure of Plan assets on certain costly improvements, including the construction, grading and paving of a road.

The applicant additionally represents that the proposed Loan is protective of the Plan since the Loan will be secured with real property having a fair market value in excess of the Property and the Interest Rate is set according to current market rates for similar transactions.

Finally, the applicant represents that the Sale is administratively feasible since the proposed Sale will allow the Plan to liquidate its investment in the Property at a price which will maximize value to the Plan and is a one-time
transaction in which the Plan will pay no fees or transaction costs.
7. In summary, the applicant represents that the proposed transaction satisfies the criteria of section 4975(c)(2) of the Code because,
(1) With respect to the Sale:
(A) The terms and conditions of the Sale will be at least as favorable to the Plan as those obtainable in an arm's length transaction with an unrelated party;
(B) The Sale will occur at a price which includes the greater of \$270,000 or the Property's fair market value as established by a qualified, independent appraiser;
(C) The Sale Price will also include a premium of $\$ 30,000$ (the Assemblage Value) due to Mr. McPhail's ownership of unimproved real property located adjacent to the Property;
(D) The Plan will pay no fees or commissions with respect to the Sale; and
(E) Mr. McPhail will pay $\$ 60,000$ or $20 \%$ of the Sale Price in cash with the balance paid for by the Loan; and
(2) With Respect to the Loan:
(A) The interest rate on the Loan (the Interest Rate) will be $7 \%$, a rate set by the Macon Bank for a real estate loan having terms similar to the Loan;
(B) The Loan terms are at least favorable to the Plan as those obtainable in an arm's length transaction with an unrelated party;
(C) The Loan is secured by a first security interest on the certain real property, which has been appraised by a qualified independent appraiser to have a fair market value not less than $150 \%$ of the principal amount of the Loan; and
(D) The outstanding balance of the Loan will never exceed $20 \%$ of the assets of the Plan throughout the duration of the Loan;
(E) The fair market value of the collateral remains at least equal to $150 \%$ of the outstanding principal balance plus accrued but not unpaid interest, throughout the duration of the Loan; and
(3) Should any employee of the Plan Sponsor become eligible for Plan participation, the new participant will be enrolled in another qualified retirement plan or the Loan will be immediately repaid.

For Further Information Contact: J. Martin Jara of the Department, telephone (202) 219-8883 (this is not a toll free number).

## Triumph Capital Group, Inc., Located in Boston, MA

[Application No. D-10708]

## Proposed Exemption

The Department is considering granting an exemption under the authority of section 408(a) of the Act and section 4975(c)(2) of the Code and in accordance with the procedures set forth in 29 CFR part 2570, subpart B (55 FR 32836, 32847, August 10, 1990). If the exemption is granted, the restrictions of sections 406(a) of the Act and the sanctions resulting from the application of section 4975 of the Code, by reason of section 4975 (c)(1)(A) through (D) of the Code, shall not apply, effective July 22, 1997, to the making, by an employee benefit plan subject to the Act (the Plan), of capital contributions to any private equity fund (the Triumph Fund) that is organized, sponsored and/ or managed by Triumph Capital Group, Inc. and/or any of its affiliates (collectively, Triumph) pursuant to a contractual obligation by a Plan having an interest in the Triumph Fund. ${ }^{2}$
This proposed exemption is subject to the following conditions:
a. At the time the Plan undertakes the obligation to make such capital contributions (the Determination Date), the Triumph Fund is not a party in interest with respect to the Plan.
b. The decision to make a capital contribution to a Triumph Fund is made on behalf of the Plan by a Plan fiduciary which is independent of and unrelated to Triumph and the portfolio company whose interest is acquired by the Triumph Fund.
c. Triumph does not otherwise provide investment advice as a fiduciary to the Plan, within the meaning of the Department's regulations at 29 CFR 2510.3-21(c), with respect to such Plan's assets that are invested in the Triumph Fund.
d. At the Determination Date, the Plan has aggregate assets that are in excess of $\$ 50$ million; provided, however, that in the case of:
(1) Two or more Plans which are not maintained by the same employer, controlled group of corporations or employee organization (the Unrelated Plans), whose assets are invested in a Triumph Fund through a group trust, an insurance company pooled separate account or any other form of entity the assets of which are "plan assets" under the Department's regulations at 29 CFR 2510.3-101 (the Plan Asset Regulation),

[^36]the foregoing $\$ 50$ million requirement shall be satisfied if such trust, separate account, or other entity has aggregate assets which are in excess of $\$ 50$ million, provided further that the fiduciary responsible for making the investment decision on behalf of such group trust, insurance company pooled separate account, or other entity has-
i. Full investment responsibility ${ }^{3}$ with respect to the plan assets invested therein; and
ii. Total assets under its management and control, exclusive of the assets invested in the Triumph Fund, which are in excess of $\$ 100$ million, for Triumph Funds established after the date this notice of proposed exemption is published in the Federal Register.
(2) Two or more Plans which are maintained by the same employer, controlled group of corporations or employee organization (the Related Plans), whose assets are invested in a Triumph Fund through a master trust or any other entity the assets of which are "plan assets" under the Plan Asset Regulation, the $\$ 50$ million requirement shall in any event be satisfied if such trust or other entity has aggregate assets which are in excess of $\$ 50$ million, provided, further, that, in the case of a Triumph Fund established after the date the notice granting the exemption is published in the Federal Register, in addition to the $\$ 50$ million requirement, if the fiduciary responsible for making the investment decision on behalf of such master trust or other entity is not the employer or an affiliate of the employer, then such fiduciary has total assets under its management and control, exclusive of the assets invested in the Triumph Fund, which are in excess of $\$ 100$ million.
e. The Triumph Fund is a party in interest with respect to the Plan solely by reason of a relationship to a portfolio company which is a service provider to a Plan, as described in Section 3(14)(H) or (I) of the Act, including a fiduciary with respect to such Plan.
f. The capital commitment of the Plan (together with the capital commitments of any other Plans maintained by the same employer, controlled group of corporations or employee organization) with respect to the Triumph Fund, does not exceed 15 percent of the total capital commitments made by all investors with respect to such Triumph Fund, determined at the later of (i) the Determination Date, or (ii) the date on

[^37]which the Triumph Fund first becomes a party in interest with respect to such Plan.
g. At the Determination Date the percentage of the Plan's assets committed to be invested in the Triumph Fund does not exceed 5 percent of the Plan's total assets.
h. At the Determination Date, a Plan's aggregate capital commitment to all Triumph Funds does not exceed 25 percent of the Plan's total assets.
i. The Plan receives the following initial and ongoing disclosures with respect to the Triumph Fund;
(1) A copy of the private placement memorandum applicable to the Triumph Fund or another comparable document containing substantially the same information;
(2) A copy of the limited partnership or other agreement establishing the Triumph Fund;
(3) A copy of the subscription agreement applicable to the Triumph Fund, if any;
(4) Copies of this proposed exemption and the final exemption, if granted, once such documents are published in the Federal Register; and
(5) Periodic, but no less frequently than annually, reports relating to the overall financial position and operational results of the Triumph Fund, including copies of the Triumph Fund's annual financial statements.
j. With respect to capital contributions made to a Triumph Fund by a Plan after the date this proposed exemption is granted, Triumph maintains or causes to be maintained, for a period of six (6) years from the date of the transaction, the records necessary to enable the persons described in paragraph ( k ) to determine whether the conditions of the exemption have been met, except that-
(1) A prohibited transaction will not be considered to have occurred, if due to circumstances beyond the control of Triumph, the records are lost or destroyed prior to the end of the six year period; and
(2) No party in interest, other than Triumph, shall be subject to the civil penalty that may be assessed under section 502(i) of the Act, or to the taxes imposed by section 4975(a) and (b) of the Code, if the records are not maintained, or are not available for examination as required by paragraph (k).
k. (1) Except as provided in paragraph $(\mathrm{k})(2)$ and notwithstanding any provisions of subsection (a)(2) and (b) of section 504 of the Act, the records referred to in paragraph (j) are unconditionally available at their customary location for examination during normal business hours by-
(A) Any duly authorized employee or representative of the Department or the Internal Revenue Service;
(B) Any fiduciary of a Plan which has an interest in the Triumph Fund and has the authority to acquire or dispose of the interest of the Plan in the Triumph Fund, or any duly authorized employee or representative of such fiduciary; and
(C) Any participant or beneficiary of any Plan which has an interest in the Triumph Fund, or duly authorized representative of such participant or beneficiary.
(2) None of the persons described in paragraph $(\mathrm{k})(1)(\mathrm{B})$ and $(\mathrm{k})(1)(\mathrm{C})$ shall be authorized to examine trade secrets of Triumph or commercial or financial information which is privileged or confidential.
Effective Date: If granted, this proposed exemption will be effective as of July 22, 1997.

## Summary of Facts and Representations

1. Triumph Capital Group, Inc., is a Delaware corporation which, together with its affiliates (collectively referred to herein as "Triumph") has organized, sponsored and/or managed six (6) private equity (or high-yield debt) funds, involving total capital commitments of approximately one (1) billion dollars. The investors in the Triumph Funds are primarily sophisticated institutional investors, including employee benefit plans that are subject to the Act, private foundations, government plans, endowments and other tax exempt organizations, and a few wealthy individuals. The applicant represents that private equity funds, such as the Triumph Funds, allow Plans, particularly those having significant asset bases, to achieve greater diversification by asset class. As such, many of the investors in the existing Triumph Funds, and many potential investors in future Triumph Funds, will be Plan investors that are covered by the Act.
2. Each Triumph Fund in which any Plan invests is organized and operated so that the assets of such Triumph Fund will not be deemed to be "plan assets" under the Plan Asset Regulation. In most cases, this results from the fact that the Triumph Fund is operated in a manner which causes such Fund to qualify as a venture capital operating company. ${ }^{4}$ In some cases, it may be the

[^38]result of the fact that the equity participation in the Triumph Fund by benefit plan investors is not significant (i.e., 75 percent or more of the equity interest in the entity is held by nonbenefit plan investors). ${ }^{5}$
3. The Triumph Funds have typically been structured as limited partnerships with Triumph serving as general partner and, in some cases, having an interest as limited partner. (Triumph Funds organized in the future may be organized using different structures, such as limited liability companies.) The Triumph Funds are managed by Triumph which receives a pre-specified management fee as well as a prespecified incentive allocation after investors have received distributions in excess of their capital contributions plus a pre-specified minimum rate of return. Because the Triumph Funds are generally expected to be organized as venture capital operating companies, the applicant represents that none of the Triumph Funds will hold "plan assets" and that the compensation paid to Triumph by the Triumph Funds will not be subject to the prohibitions under the Act. ${ }^{6}$

One of Triumph's more recent funds, Triumph Partners III, L.P., has aggregate capital commitments of approximately $\$ 595,550,000$ from 49 individual and institutional investors. Of the institutional investors, 6 investors are Plans that are covered under the provisions of the Act. These Plans have

## company" includes a "venture capital operating company."

29 CFR 2510.3-101(d) provides, in part, that an entity is a "venture capital operating company" if at least 50 percent of its assets are invested in venture capital investments, and the entity, in the ordinary course of its business, actually exercises management rights with respect to one or more operating companies in which it invests. 29 CFR 2510.3-101(d)(3) explains that a venture capital investment is an investment in an operating company (other than a venture capital operating company) as to which the investor has or obtains management rights. The term "management rights" is defined under 29 CFR 2510.3-101(d)(3)(ii) to mean contractual rights directly between the investor and an operating company to substantially participate in, or substantially influence the conduct of, the management of the operating company.
${ }^{5}$ The Department's regulation at 2510.3-101(f)(1) states, in pertinent part, that equity participation in an entity by benefit plan investors is "significant" on any date, if immediately after the most recent acquisition of any equity interest in the entity, 25 percent or more of the value of any class of equity interests in the entity is held by benefit plan investors.
${ }^{6}$ The Department is providing no opinion with regard to whether a Triumph Fund is a venture capital operating company or whether the equity participation by Plans investing in a Triumph Fund is not significant. In addition, the Department is not expressing any views with respect to the compensation that is paid to Triumph by a Triumph Fund.
made a total capital commitment to Triumph Partners III, L.P. of \$170,300,000.
4. Triumph Funds typically involve multiple closings with investors making their investment commitments (and therefore having a Determination Date) over a six to nine month period. Because of this staging, Triumph proposes, for purposes of the $15 \%$ limit contained in condition (f) above, to test each Plan investor's capital commitment with respect to the Triumph Fund in relation to the total capital commitments made by all the investors with respect to such Triumph Fund, at the later of (a) the Determination Date, or (b) the date on which the Triumph Fund first becomes a party in interest with respect to such Plan investor.
Each investor in a Triumph Fund, including each Plan investor, enters into a binding commitment to make capital contributions to the Triumph Fund in an amount specified by the investor. However, the investors' capital commitments typically are not funded at the outset. Rather, the capital is drawn down over time as the Triumph Fund identifies and makes its venture capital and other investments. Generally, capital is called down in installments ranging from 2.5 percent to 10 percent of the total commitment. In most cases, all of the capital commitments will have been drawn down within 3 to 5 years of the establishment of the Triumph Fund.
5. The Triumph Funds' investments include a wide variety of portfolio companies. ${ }^{7}$ Specifically, the Triumph Funds may acquire interests in portfolio companies which are involved, either directly or through subsidiaries, in various aspects of the financial services industry. Triumph believes that the flexibility to acquire such investments is necessary to enable the Triumph Funds to maximize investment opportunities and investment returns. In Triumph's view, business opportunities can arise in connection with start-up or laterstage companies (including spinoffs and management buy-outs of existing

[^39]business operations) in virtually any type of business.
6. Triumph Funds may acquire interests in portfolio companies that are involved in providing money management services, brokerage services or other types of services which may be utilized by Plans and institutional investors. The portfolio company may be, or may become, a party in interest with respect to one or more Plans which hold an interest in the Triumph Fund when such portfolio company, or any subsidiary thereof, performs services for a Plan. The services may include fiduciary services (e.g., management of assets of the Plan other than those invested in a Triumph Fund). In no event will the portfolio company or its subsidiary act in a fiduciary capacity with respect to the assets of the Plan that are invested in the Triumph Fund.
If the Triumph Fund owns, directly or indirectly, a 10 percent or more interest in a service provider to a Plan, Triumph notes that the Fund will become a party in interest with respect to such Plan under section 3(14)(H) or (I) of the Act. ${ }^{8}$ Since a Triumph Fund frequently purchases a 10 percent or more interest in a portfolio company, Triumph represents that it is possible that a Triumph Fund could become a 10 percent or more owner of a service provider and a party in interest with respect to each Plan as to which the portfolio company (or one of its subsidiaries) is a service provider. Once a Triumph Fund becomes a party in interest with respect to a Plan, Triumph states that the Plan would be prohibited from engaging in any transaction with that Triumph Fund.
If a Triumph Fund were to become a party in interest with respect to a Plan, Triumph is concerned that a capital contribution made by the Plan subsequent to the Triumph Fund's becoming a party in interest would violate section 406(a)(1)(D) of the Act notwithstanding the fact that the capital contribution is being made pursuant to a pre-existing binding contractual commitment made by the Plan at a time when the Triumph Fund was not a party in interest. Therefore, to resolve these potential technical violations of the Act,

[^40]Triumph has requested an administrative exemption from the Department. ${ }^{9}$
7. The requested exemption is subject to a number of conditions that will apply both retroactively and prospectively. First, the Triumph Fund's party in interest status will, in all cases, arise after the Determination Date, i.e., after the Plan investor has made a binding commitment to invest in the Triumph Fund, including its commitment to make future capital contributions to the Triumph Fund. Second, the decision to undertake the obligation to make a binding commitment must be made on behalf of the Plan by a Plan fiduciary which is independent of and unrelated to Triumph and the portfolio company. Third, Triumph must not otherwise provide investment advice to the Plan, within the meaning of the Department's regulation at 29 CFR 2510.3-21(c) (defining when an investment adviser to a plan becomes a fiduciary by reason of the advice), with respect to such Plan's assets that are invested in the Triumph Fund. Fourth, at the Determination Date, the Plan must have aggregate assets that are in excess of $\$ 50$ million, subject to special rules addressing investments in a Triumph Fund by entities holding the assets of multiple plans, such as group trusts and master trusts. Fifth, at the later of the Determination Date or the date on which the Triumph Fund first becomes a party in interest with respect to such Plan investor, the capital commitment of the Plan (together with the capital commitments of any other Plans maintained by the same employer, controlled group of corporations, or employee organization) with respect to the Triumph Fund, must not exceed 15 percent of the total capital commitments with respect to such Triumph Fund. Sixth, at the Determination Date, the percentage of the Plan's assets committed to be invested in the Triumph Fund must not exceed 5 percent of the Plan's total assets. Seventh, at the Determination Date, a Plan's aggregate capital commitment with respect to all Triumph Funds must not exceed 25 percent of such Plan's total assets.
8. The conditions of the proposed exemption also require that each Plan receive the following initial and ongoing written disclosures from Triumph: (a) A

[^41]copy of the private placement memorandum applicable to the Triumph Fund or another comparable document containing substantially the same information; (b) a copy of the limited partnership or other agreement establishing the Triumph Fund; (c) a copy of the subscription agreement applicable to the Triumph Fund, if any; (d) copies of the proposed exemption and the final exemption, if granted, once such documents are published in the Federal Register; and (e) periodic, but no less frequently than annually, reports relating to the overall financial position and operational results of the Triumph Fund including copies of the Triumph Fund's annual financial statements. In addition, with respect to capital contributions made to a Triumph Fund by a Plan after the date this proposed exemption is granted, Triumph will maintain or cause to be maintained for a period of six (6) years from the date of each transaction, records of each Plan investing in a Triumph Fund and each portfolio company comprising a Triumph Fund. Such records will enable the Department and other persons to determine whether the terms and conditions of the exemption are being met.
9. If the exemption is not granted, Triumph represents that it and the Triumph Funds would be required to make one of several adjustments designed to avoid the prohibited transaction concern that is the subject of this request. However, Triumph states that it does not believe these adjustments would be in the best interest of existing or prospective Plan investors. In this regard, Triumph represents that it might attempt to avoid the problem by not acquiring any portfolio companies which are, directly or indirectly, service providers to any of a Triumph Fund's Plan investors. However, Triumph does not consider this alternative satisfactory because it would limit the Triumph Fund's potential range of investments and diminish the expected investment return of such Fund. Moreover, Triumph points out that a portfolio company which is not a service provider at the time of the Triumph Fund's investment might become a service provider at some time in the future. Under these circumstances, Triumph represents that it would be impractical to restrict the activities of all portfolio companies in which the Triumph Fund invests to assure that no such portfolio company would ever become a service provider to any Triumph Fund's Plan investors. According to Triumph, such restriction
would be contrary to the best interest of the Triumph Funds and their investors, particularly, their Plan investors.

As another alternative, Triumph represents that it could limit the offering of interests in the Triumph Funds to those Plans which could take advantage of Prohibited Transaction Exemption (PTE) 84-14 (49 FR 9494 March 13, 1984), the Class Exemption for Plan Asset Transactions Determined by Independent Qualified Professional Asset Managers (QPAMs) or PTE 96-23 (61 FR 15975, April 10, 1996), the Class Exemption for Plan Asset Transactions Determined by In-House Asset Managers (INHAMs). ${ }^{10}$ However, Triumph believes that such an approach would be unduly restrictive and not in the best interest of the Plans since relatively few Plans could take advantage of PTE 9623. In addition, in the absence of this proposed exemption, each Plan would be forced to hire a QPAM in order to meet the conditions of PTE 84-14, and incur an additional expense in order to invest in a Triumph Fund, if the Plan's named fiduciary would otherwise make that decision itself.
10. In summary, it is represented that the proposed transactions satisfy the statutory criteria of section 408(a) of the Act because: (a) The Triumph Fund's party in interest status with respect to the Plan will arise after the Plan has made its binding commitment to invest in the Triumph Fund, including its commitment to make future capital contributions to the Triumph Fund; (b) the decision by a Plan to make capital contributions to the Triumph Fund has been and will be made on behalf of the Plan by a Plan fiduciary which is independent of and unrelated to Triumph and the portfolio company that is acquired by the Triumph Fund; (c) Triumph will not otherwise provide investment advice to the Plan, within the meaning of 29 CFR 2510.3-21(c) of the Act, with respect to such Plan's assets that are invested in the Triumph Fund; (d) at the later of the Determination Date, or the date on which the Triumph Fund first becomes a party in interest with respect to such Plan investor, the capital commitment

[^42]of the Plan (together with the capital commitment of any other related Plans maintained by the same employer, controlled group of corporations, or employee organization) will not exceed more than 15 percent of the total outstanding capital commitments made by all investors with respect to the Triumph Fund; (e) at the Determination Date, the percentage of the Plan's assets committed to be invested in the Triumph Fund has not and will not exceed 5 percent of the Plan's total assets, and the Plan's aggregate commitment to all Triumph Funds has not and will not exceed 25 percent of the Plan's total assets; (f) a Plan investing in a Triumph Fund has or will have, either alone or in combination with other plans, assets that are in excess of $\$ 50$ million (as described under the conditions contained herein); and (g) Triumph has made or will make written disclosures to the Plan regarding the Triumph Fund, both at the time of the initial commitment to invest in such Fund as well as on an ongoing basis.

## Notice to Interested Persons

Those persons who may be interested in the pendency of the requested exemption include fiduciaries of Plans whose assets are currently invested in a Triumph Fund. Accordingly, the Department has determined that the only practical form of providing notice to such Plan fiduciaries is the distribution, by Triumph, of a copy of the proposed exemption by first class mail within 15 days of the date of publication of the pendency notice in the Federal Register. The notice will include a copy of the notice of proposed exemption, as published in the Federal Register, as well as a supplemental statement, as required pursuant to 29 CFR 2570.43(b)(2), which shall inform interested persons of their right to comment on the pending exemption. Comments with respect to the proposed exemption are due 45 days after the date of publication of the proposed exemption in the Federal Register.

For Further Information Contact: Ms. Janet Schmidt of the Department, telephone (202) 219-8881. (This is not a toll-free number.)

## The Fidelity Mutual Life Insurance Company (In Rehabilitation) (FML) Located in Radnor, PA

[Application No. D-10712]

## Proposed Exemption

Based on the facts and representations set forth in the application, the Department is considering granting an exemption under the authority of section 408(a) of the Act and in
accordance with the procedures set forth in 29 CFR Part 2570, Subpart B (55 FR 32836, 32847, August 10, 1990). ${ }^{11}$

## Section I. Covered Transactions

If the exemption is granted, the restrictions of section 406(a) of the Act and the sanctions resulting from the application of section 4975 of the Code, by reason of section 4975 (c)(1)(A) through (D) of the Code, shall not apply to (1) the receipt of certain stock (the Plan Stock) issued by Fidelity Insurance Group, Inc. (Group), a wholly owned subsidiary of FML, or (2) the receipt of plan credits (the Plan Credits), by or on behalf of a mutual member (the Mutual Member) of FML, which is an employee benefit plan (the Plan), other than the Employee Pension Plan of Fidelity Mutual Life Insurance Company (the FML Plan), in exchange for such Mutual Member's membership interest (the Membership Interest) in FML, in accordance with the terms of a plan of rehabilitation (the Third Amended Plan of Rehabilitation), approved by the Pennsylvania Commonwealth Court (the Court) and supervised by both the Court and a rehabilitator (the Rehabilitator) appointed by the Pennsylvania Insurance Commissioner (the Commissioner).

This proposed exemption is subject to the following conditions set forth below in Section II.

## Section II. General Conditions

(a) The Third Amended Plan of Rehabilitation is approved by the Court, implemented in accordance with procedural and substantive safeguards that are imposed under Pennsylvania law and is subject to review and/or supervision by the Commissioner and the Rehabilitator. The Court determines whether the Third Amended Plan of Rehabilitation is fair and equitable to Mutual Members.
(b) Each Mutual Member has an opportunity to vote and comment on the Third Amended Plan of Rehabilitation at hearings held by the Court after full written disclosure is given to such Mutual Member by FML of the terms of the Plan.
(c) Participation by all Mutual Members in the Third Amended Plan of Rehabilitation, if approved by the Court, is mandatory, although Mutual Members may disclaim Plan Stock.
(d) Any determination by a Mutual Member which is a Plan to receive Plan Stock or Plan Credits is made by one or more independent fiduciaries of such

[^43]Plan and not by FML, Group or Fidelity Life Insurance Company (FLIC). Consequently, neither FML nor any of its affiliates will exercise investment discretion nor render "investment advice" within the meaning of 29 CFR 2510.3-21(c) with respect to an independent Plan fiduciary's decision to elect Plan Stock or Plan Credits.
(e) Twenty percent of the Plan Stock is allocated to a Mutual Member based upon voting rights and eighty percent is allocated to a Mutual Member on the basis of the contribution of the Mutual Member's insurance or annuity contract (the Contract) to the surplus of FML. The contribution to FML's surplus is the actuarial calculation of both the historical and expected future profit contribution of the Contracts that have contributed to the surplus (i.e., the net earnings) of FML. The actuarial formulas are approved by the Court and the Commissioner.
(f) The value of Plan Stock or Plan Credits that will be received by a Mutual Member will reflect the aggregate price paid by an independent investor (the Investor) to Group for common Stock (the Common Stock) and for plan credit shares (the Plan Credit Shares) in convertible preferred stock (the Preferred Stock) issued by Group.
(g) All Mutual Members that are Plans participate in the transactions on the same basis as all other Mutual Members that are not Plans.
(h) No Mutual Member pays any brokerage commissions or fees in connection with the receipt of Plan Stock or Plan Credits.
(i) All of FML's obligations to contractholders (the Contractholders) of the company which are Mutual Members remain in force upon endorsement and transfer to FLIC and are not affected by the Third Amended Plan of Rehabilitation.

## Section III. Definitions

For purposes of this proposed exemption:
(a) The term "FML" means the Fidelity Mutual Life Insurance Company (In Rehabilitation) and any affiliate of FML as defined in paragraph (c) of this Section III.
(b) The term "FLIC"' means the Fidelity Life Insurance Company and any affiliate of FLIC as defined in paragraph (c) of this Section III.
(c) An "affiliate" of FML or FLIC includes-
(1) Any person directly or indirectly through one or more intermediaries, controlling, controlled by, or under common control with FML or FLIC; (For purposes of this paragraph, the term "control" means the power to exercise
a controlling influence over the management or policies of a person other than an individual.) or
(2) Any officer, director or partner in such person.
(c) The term "Mutual Member" means a Contractholder whose name appears on FML's records as an owner of an FML Contract on the Record Date of the Third Amended Plan of Rehabilitation.
(d) The term "Investor"' means the person (e.g., individual, corporation, partnership, joint venture, etc.) selected by the Rehabilitator and approved by the Court to be the purchaser under the Investment Agreement.
(e) The term "Group Stock" refers to shares of Group Common Stock and to Group Preferred Stock, which will have a cumulative, annual dividend equal to 7 percent of its liquidation value. The Preferred Stock will be Series A stock having a par value of $\$ 0.01$ per share and a liquidation preference and a redemption value of $\$ 25$ per share.
(f) The term "Plan Stock" means the 3 million shares of Group Common Stock and the 2.8 million of Group Preferred Stock that will be allocated to Mutual Members.
(g) The term "Plan Credit" means either (1) additional paid up insurance for a traditional life policy or (2) credits to the account values for Contracts that are not traditional (such as a flexible premium policy). Under FML's Third Amended Plan of Plan of Rehabilitation, Plan Credits are to be allocated to certain Mutual Members in lieu of Plan Stock.
(h) The term "Plan Credit Shares" includes those shares of Plan Stock (i.e., the 15,000 to 180,000 shares of Group Common Stock) and any shares of Group Preferred Stock to be issued and sold by Group to the Investor to fund Plan Credits.
(i) The term "Policyholder Stock" means those shares of Group Common or Group Preferred Stock that will be issued and distributed to Mutual Members, consisting of Plan Stock plus any shares of Group Stock (in excess of Plan Stock) issued for purposes of correcting errors in the allocation of Plan Stock, less Plan Credit Shares and any disclaimed shares.
(j) The term "Investor Stock" means the 3.1 million shares of Group Common Stock (other than Plan Stock) and the Plan Credit Shares which, under the Third Amended Plan of Rehabilitation, are sold to the Investor pursuant to bid procedures and the Investment Agreement.

## Summary of Facts and Representations

1. FML is a mutual life insurance company that was founded in 1878 and
organized to conduct a life insurance business in Pennsylvania. FML maintains its principal place of business at 250 King of Prussia Road, Radnor, Pennsylvania. Prior to the rehabilitation proceedings that are described herein, FML was licensed to issue life insurance policies in 47 states and the District of Columbia.

Because FML has been organized as a mutual form of life insurance company, it has no stockholders. Instead, the owners of its Contracts (i.e., the Contractholders) have a dual legal relationship with FML. In this regard, the Contractholders are vested with rights in the company, such as such as the right to vote and the right to an allocable portion of the divisible surplus. In addition, the Contractholders have contractual rights under their Contracts with FML.
FML has approximately 3,997 Contracts that are related to qualified Plans. FML also sponsors the FML Plan, a defined benefit plan, which had 254 participants and total assets of \$17,282,009 as of December 31, 1998.
2. FML owns all of the stock of Group, a Pennsylvania-domiciled stock corporation. Group, in turn, owns all of the stock of FLIC, also a Pennsylvania corporation. Group purchased the FLIC stock from an unrelated party on June 30, 1995. FLIC is a stock life insurance company duly licensed, chartered and domesticated in Pennsylvania and is qualified to conduct a life insurance business in substantially all jurisdictions where FML has business, except in New York and New Hampshire. FLIC has filed applications for licenses to conduct business in these states.
3. During late 1990, the Pennsylvania Insurance Department began monitoring FML's operations because of concern over FML's extensive real estate holdings, decline in surplus and unrealized capital losses. In response to an increase in Contract surrenders and loan requests for the period October 26 to November 5, 1992, the Pennsylvania Insurance Department and FML's Board of Directors petitioned the Court for an Order of Rehabilitation. As a result, FML was placed in rehabilitation by an order of the Court on November 6, 1992, pursuant to the Pennsylvania Insurance Department Act, as amended. Under the Order of Rehabilitation, a moratorium was imposed on cash distributions, Contract surrenders, withdrawals and policy loans, except in certain hardship situations. At the time of the rehabilitation, FML had assets with a book value of approximately $\$ 1.2$ billion. Of this amount, a significant portion of FML's assets was comprised
of real estate and mortgages which were non-performing, illiquid and overvalued.
4. On June 30, 1994, the Rehabilitator filed the original Plan of Rehabilitation for The Fidelity Mutual Life Insurance Company (the Original Plan of Rehabilitation) with the Court. The Original Plan of Rehabilitation called for the transfer of FML insurance policies to "Newco," the name designated for the stock life insurance company that was to be purchased by FML and Group. Under the Original Plan of Rehabilitation, all Contractholders of FML would be allocated one share of Group Stock, all Mutual Members would be made whole for any "Impairment" 12 through the allocation of Group Stock, and any remaining Group Stock would be allocated to creditors on a pro rata basis. Contractholders could opt out of the Original Plan of Rehabilitation, surrender their policies and receive the liquidation value of their cash surrender values plus one share of Group Stock. Contractholders remaining with Newco would also be subject to a continued moratorium charge (i.e., a charge based upon the suspension, by the Court, of cash distributions, Contract surrenders, withdrawals and policy loans) of 16 percent during the first year and 8 percent during the second year if they surrendered their policies. Further, a trust was to be created under the Original Plan of Rehabilitation to hold the stock during the moratorium period and then dispose of such stock by distributing it to Contractholders and creditors. Finally, the Original Plan of Rehabilitation provided that an Investor could provide a capital infusion to Newco through Group that would be sufficient to meet risk-based capital requirements and that such Investor would receive unspecified securities of Group in return. Notice was sent to Contractholders and other interested persons of the filing of the Original Plan and objections were due by November 1, 1994.
5. After the filing of the Original Plan of Rehabilitation with the Court in June 1994, the Rehabilitator proceeded to work with an investment banker to solicit and select an Investor. ${ }^{13}$ On

[^44]January 12, 1995, the Rehabilitator filed an Amended Plan for the Rehabilitation of The Fidelity Mutual Life Insurance Company (the First Amended Plan of Rehabilitation) with the Court which included an Investment Agreement executed by the Presidential Life Insurance Company (Presidential). The framework for the First Amended Plan of Rehabilitation was similar to the Original Plan, with additional definition. The First Amended Plan of Rehabilitation provided that 10 million shares of Group Stock would be placed in a stock trust to be distributed to Contractholders for Impairment ${ }^{14}$ and thereafter, if any shares remained, to creditors with allowed claims. The First Amended Plan of Rehabilitation also provided that Group could sell up to 49.9 percent of Group Common Stock to Presidential in exchange for an investment of up to $\$ 45$ million and could sell $\$ 25$ million in debt instruments to the Presidential Life Corporation. The moratorium charge applicable to Contractholder cash values upon surrender after closing was reduced to 14 percent during the first year and 8 percent during the second year. Further, the liquidation value that Contractholders would receive if electing to opt out of the First Amended Plan of Rehabilitation was approximately 89 percent of their cash surrender value. Notice of the filing of the First Amended Plan of Rehabilitation was provided to all Contractholders and other interested persons and objections had to be filed by March 31, 1995.
6. In January 1995, a new Commissioner was appointed who became the new Rehabilitator for FML. In March 1995, the Court approved the appointment of a Policyholder Committee at the request of a group of former FML agents. Subsequently, the Policyholder Committee engaged counsel, an accounting firm and an investment banking firm. Also, in March 1995, a bidder who was not selected as the Investor objected to the First Amended Plan of Rehabilitation and ultimately sought permission to intervene and propose an alternative rehabilitation plan. In May 1995, the Policyholder Committee filed objections to the First Amended Plan of
an Investor and that there was no certainty that an Investor could be found.
${ }^{14}$ Impairment under the First Amended Plan of Rehabilitation was defined as "* * * the loss of liquidity due to the lack of access of Participating Contractholders to their Surrender Values measured from the Rehabilitation Date to the Closing Date * * *", Aggregate Impairment was estimated to have a value of $\$ 40$ million as of September 30, 1994.

Rehabilitation and specifically objected to the selected investor, Presidential. Also in May 1995, Presidential petitioned the Court for permission to intervene in the rehabilitation proceedings. In early September 1995, the Deputy Rehabilitator for FML resigned and a Deputy Commissioner from the Pennsylvania Insurance Department was assigned to oversee the daily affairs of FML. Negotiations with the Policyholder Committee,
Presidential, and the objecting bidder continued during the remainder of 1995 through 1996. In May 1996, Presidential filed a petition for payment of expenses and liquidated damages under the 1995 Stock Purchase Agreement and the Policyholder Committee and former FML agents objected to that petition.
7. On June 25, 1996, the Rehabilitator filed the Second Amended Plan for the Rehabilitation of The Fidelity Mutual Life Insurance Company (the Second Amended Plan of Rehabilitation) with the Court. The framework for the Second Amended Plan was substantially the same as the predecessor Plans but there were significant differences. For example, the concept of Plan Credits was introduced for the first time. In addition, Group could sell 35 percent of its issued and outstanding common stock to the Investor under bid procedures to be approved by the Court. However, Group could not issue any debt instruments. The other 65 percent of the Group Stock was to be allocated to Contractholders and creditors, except that the stock would no longer be held and distributed by a stock trust, but would be distributed directly to the Contractholders and creditors around the Closing Date. Based on an assumed Closing Date of June 30, 1997, Impairment had increased to an estimated total of $\$ 57.1$ million. Also, the Liquidation Value as of September 30, 1995 was estimated to be 95 percent of the cash surrender value of any Contractholder who elected to opt out of the Plan. The moratorium period of two years in the previous Plans was reduced to one year and the moratorium charge would be equal to the Liquidation Discount (5 percent of September 30, 1995).

Notice of the filing of the Second Amended Plan of Rehabilitation was not sent to Contractholders and other interested persons because the Policyholder Committee filed significant objections to both the Notice Package and the Second Amended Plan of Rehabilitation, including an objection asserting that the Contractholders should receive cash rather than Group Stock for Impairment. In July 1996,

Presidential filed a motion asking the Court to enjoin any new Investor selection process until their claim for relief was addressed. The Presidential claim was finally settled and approved by the Court in March 1997.
8. Negotiations with the Policyholder Committee continued and the Third Amended Plan for the Rehabilitation of The Fidelity Mutual Life Insurance Company (i.e., the Third Amended Plan of Rehabilitation) was filed with the Court on June 30, 1998. The Plan included several significant improvements for Contractholders due to the improved financial condition of FML. ${ }^{15}$ For example, under the Third Amended Plan of Rehabilitation, there are no moratorium charges after the Closing Date and Contractholders may immediately surrender their Contracts for the full cash surrender value. Consequently, no opt out period is necessary to allow the option of immediate surrender. Further, all creditor claims will be paid in full with 6 percent interest.
Subject to the approval of the Court, the Rehabilitator is proposing that FML transfer, on the Closing Date, ${ }^{16}$ pursuant to assumption reinsurance and transfer agreements, its insurance operations to FLIC, which will continue as a wholly owned subsidiary of Group and a successor to FML. In addition, FML will modify the terms of the FML Contracts by endorsement prior to their transfer to and assumption by FLIC. Group Common Stock and Preferred Stock ${ }^{17}$ that has been denominated as Plan Stock will be allocated and then distributed to Mutual Members in

[^45]exchange for their Membership Interests in FML rather than for the Impairment of their Contracts, except that Contractholders of certain tax-qualified retirement funding accounts (who have impediments to holding stock generally), will be entitled to have Plan Credits made to their Contracts in lieu of receiving Plan Stock.

Therefore, FML requests an administrative exemption from the Department with respect to the receipt of Plan Stock or the receipt of Plan Credits by Mutual Members that are Plans. FML is not requesting, nor is the Department providing, exemptive relief with respect to the receipt of Plan Stock by the FML Plan because it believes such stock will constitute "qualifying employer securities" within the meaning of section 407(d)(5) of the Act. Therefore, FML represents that the acquisition of Plan Stock by the FML Plan will satisfy the requirements of section 408(e) of the Act. ${ }^{18}$
9. As with the other Plans of Rehabilitation, under the Third Amended Plan of Rehabilitation, an independent party (i.e., the Investor), approved by the Court, will be selected pursuant to bid procedures ${ }^{19}$ to purchase Common Stock from Group so that immediately after the Closing Date, the Investor will own more than 50 percent of such Common Stock. The Investor will acquire Preferred Stock only through the required purchase of Plan Credit Shares but not through the bid process.

Under the Third Amended Plan of Rehabilitation, the Investor may be a foreign or domestic entity such as a life/ health insurer, a property/casualty insurer, an investment company or other investment fund, a joint venture, general partnership or a limited partnership. In addition, the Investor may be required to satisfy certain ratings or capitalization criteria. For example, if the Investor is a property/casualty insurer, it must have an A.M. Best rating of at least $\mathrm{A}-$, a minimum Total Adjusted Capital of $\$ 500$ million, and a ratio of Total Adjusted Capital to Authorized Control Level Risk Based Capital of 5:1 or better. If the Investor is not a publicly-rated entity but is an

[^46]investment company or other investment fund, it must have a net worth of at least $\$ 500$ million and minimum available equity of $\$ 150$ million. Further, the Investor must be either a Qualified Institutional Buyer within the meaning of Rule 144A under the Securities Exchange Act of 1933 (the 1933 Act), an Institutional Accredited Investor within the meaning of Rule 501(a)(1), (2), (3) or (7) under the 1933 Act, or a sophisticated institutional investor not requiring the protections of the registration requirements of the 1933 Act.
10. The rehabilitation strategy, which is aimed at maximizing the interests of FML's Contractholders and creditors, is to transfer FML's insurance operations into a stock life insurance company. The Contractholders and creditors will be provided benefits in accordance with the priorities for distribution to be determined under the Pennsylvania law applicable to insurance company rehabilitations. ${ }^{20}$
Thus, the treatment of FML's Contracts and the Contractholder's interests thereunder is a significant aspect of the Third Amended Plan of Rehabilitation. These Contracts include, but are not limited to, traditional ordinary life insurance Contracts and universal life insurance Contracts.
11. Section 2.01 of the Third Amended Plan of Rehabilitation specifies a classification of claims (the Claims) and interests and priorities governing the receipt of distributions. The rights provided the Contractholders under section 2.04 of the Third Amended Plan of Rehabilitation (for the Contracts to be modified by endorsement in FML and reinsured by FLIC) will have a Class 3 priority (along with certain other Claims under the Contracts), following certain secured and administrative claims which are classified as Class 1 and Class 2 Claims. Classes 4 through 9 Claims provide for claims for governments, general creditors, employees, debt holders, etc. Class 10, the last and residual category,

[^47]provides for the Claims of the
Membership Interests of FML's Mutual Members.
Allowed Claims 1 through 9 will be paid in full in cash. Each Contractholder having a Contract in force on the Closing Date will have his or her Contract assumed and reinsured by FLIC as of the Closing Date. In addition, at Closing, Class 10 Claims will be satisfied by an allocation of Plan Stock in exchange for the Mutual Member's relinquishment of his or her membership interest in FML. ${ }^{21}$ No other class of Claims will be paid or satisfied either partially or totally by a distribution or allocation of Plan Stock or Plan Credits. ${ }^{22}$
12. Under Section 4.05 of the Third Amended Plan of Rehabilitation, any Contract held in connection with a qualified retirement plan or an arrangement described in section 401(a), 403(a) or 408 of the Code, other than a Contract held by a trustee under a plan described in section 401(a) of the Code, (i.e., a Non-Trusteed Tax-Qualified Retirement Funding Contract) will be allocated Plan Credits in lieu of Plan Stock in exchange for the relinquishment of the Mutual Member's

[^48]Membership Interest under such Contract. The Plan Credits allocated to such Mutual Member's Contract will be equal in value to the Plan Stock otherwise allocable to the Non-Trusteed Tax-Qualified Retirement Funding Contract.
13. As noted above, the Plan Stock allocated to Mutual Members for Class 10 Claims will consist of Group Common Stock and Preferred Stock. Twenty percent of the Plan Stock will be allocated based on voting rights ${ }^{23}$ and 80 percent will be allocated based on a Contract's contribution to FML's surplus. If a Mutual Member has two or more Contracts, the Plan Stock allocated to such Mutual Member, based on voting rights, will be allocated in equal portions to each such Contract.
14. Each Mutual Member which is a Class 10 Claimant will be allocated Group Common Stock and Preferred Stock, in the ratio of 3 shares of Common Stock to 2.8 shares of Preferred Stock. At closing, the total value of the Plan Stock, immediately prior to the sale of Common Stock to the Investor, is projected at approximately $\$ 100$ million. Of this amount, 70 percent of the value of the Plan Stock will be represented by the Preferred Stock, which will have an estimated value of $\$ 70$ million. The 30 percent remaining Plan Stock will consist of Common Stock and it will have a value of approximately $\$ 30$ million. If desired, a Mutual Member may disclaim any interest in the Plan Stock. Although the Mutual Member will receive no consideration for any disclaimed Stock, such Mutual Member will continue to retain all benefits.

The distribution of the Group Stock will occur at Closing when Group will issue and distribute Plan Stock on behalf of FML to Mutual Members. FML, simultaneously, will return all Group Stock to Group for cancellation. Disclaimed shares will not be issued or, if issued, will be canceled and returned to Group.
15. There will be 40 million shares, par value $\$ .01$ per share, of Common Stock authorized and 6.1 million shares of such stock outstanding at the Closing Date. The Common Stock will have voting rights of one vote per share.

Group will sell approximately 3.1 million shares of its Common Stock to the Investor in a private placement pursuant to bid procedures approved by the Court and utilize the majority of the sale proceeds to supplement the capital

[^49]of FLIC. FML will designate a maximum of 3 million shares of the remaining Common Stock as the "Common Stock component" of Plan Stock. Included in this amount will be between 15,000 and 180,000 shares of Common Stock allocable to Mutual Members who will receive Plan Credits in lieu of Plan Stock. ${ }^{24}$

In addition, Group will sell to the Investor the shares of Common Stock and Preferred Stock equal to the Plan Credits ${ }^{25}$ and contribute to the capital of FLIC the sales proceeds of such sale. Consequently, the Investor will own, at the Closing Date, more than 50 percent of the total outstanding Group Common Stock, and such percentage will increase to the extent there are disclaimed shares and Plan Credits which require the Investor to purchase more Plan Stock.

At the Closing Date, Group will have authorized 10 million shares and will have outstanding 2.8 million shares of Preferred Stock, all of which will be allocated as Plan Stock. There will be no other class of Preferred Stock.

The Preferred Stock will have a liquidation preference and redemption value of $\$ 25$ per share. The holders of Preferred Stock will be entitled to cumulative annual dividends, payable quarterly, at the rate of 7 percent per annum of the liquidation preference, resulting in an annual dividend of $\$ 1.75$ per share. Shares of Preferred Stock will be non-voting except (a) when four quarterly dividends on such class of stock are in arrears, (b) for certain matters pertaining to that class of stock, or (c) as otherwise required by law. Upon liquidation of Group, a share of Preferred Stock will be entitled to a distribution preference of $\$ 25$ per share plus the amount of any accrued but unpaid dividends. Group, at its option, may redeem shares of Preferred Stock at any time after 20 years from the later of the issue date and the Closing Date, at a redemption price of $\$ 25$ per share plus the amount of any accrued but unpaid dividends.

[^50]A share of Preferred Stock is convertible into shares of Common Stock at any time at the option of the holder. The number of shares of Common Stock that will be received by a Mutual Member upon such a conversion will be determined by dividing $\$ 25$ by the result of multiplying 1.20 times the price per share paid by the Investor for the Common Stock (which price will be determined by the competitive bidding process approved by the Court). The conversion rate for the Preferred Stock is also subject to various anti-dilution provisions.
16. Under Section 4.10 of the Third Amended Plan of Rehabilitation, Policyholder Stock ${ }^{26}$ will be issued pursuant to the exemption from the registration requirements provided in section 3(a)(10) of the 1933 Act. In addition, Policyholder Stock will be publicly-traded and listed on the NASDAQ National Market or the New York or American Stock Exchange, as determined by the Rehabilitator prior to Closing.
Investor Stock will be issued in a private placement pursuant to the exemption from the registration requirements of the 1933 Act provided by section $4(2)$ thereof and the rules and regulations thereunder. Neither Policyholder Stock nor Investor Stock will be registered under the 1933 Act.
Group Stock will be registered under section $12(\mathrm{~g})$ of the Securities Exchange Act of 1934.
17. Since the participation by all Mutual Members in the Third Amended Plan of Rehabilitation will be mandatory (although Mutual Members may disclaim Plan Stock), any determination by a Mutual Member which is a Plan to receive Plan Stock or Plan Credits will be made by one or more Plan fiduciaries which are independent of FML and its affiliates. As a result, neither FML nor any of its affiliates will exercise investment discretion nor render "investment advice" within the meaning of 29 CFR 2510.3-21(c) with respect to an independent Plan fiduciary's decision to elect to receive Plan Stock or Plan Credits.
In addition, all Mutual Members that are Plans will participate in the transactions on the same basis as all other Mutual Members that are not

[^51]Plans. Moreover, no Mutual Member will pay any brokerage commissions or fees in connection with the receipt of Plan Stock or Plan Credits. Finally, all of FML's Contractholder obligations will remain in force upon endorsement and transfer to FLIC and will essentially be unaffected by the Third Amended Plan of Rehabilitation.
18. Mutual Members will not be restricted from selling or otherwise transferring the Plan Stock received, including converting the Preferred Stock to Common Stock, although Group, its affiliates and the Investor are subject to restrictions on purchasing or redeeming such Stock. ${ }^{27}$ In addition, Group will not be precluded from establishing a commission-free purchase or sales program after the Rehabilitation which would allow Mutual Members who receive a small number of shares of Plan Stock the opportunity to round-up those shares or sell such shares for a temporary period without the payment of any sales commissions. ${ }^{28}$ It is not contemplated that FLIC or any of its affiliates will be engaged in such transactions.
19. The Plan will be approved by and be under the continued jurisdiction of the Court. The Court's review will include, among other matters, (a) a determination, after hearings available to Contractholders, creditors and other interested parties, the procedural and substantive fairness of the terms and conditions of the allocation and distribution of the Plan Stock in exchange for Membership Interests, including a review of the methodology for allocating Plan Stock based on the basis of contribution to surplus and voting rights and (b) approval of the modification, by endorsement, of the terms and conditions of the Contract.

FLIC and Group will be subject to the jurisdiction of the Court and the supervision of the Rehabilitator prior to and through the Closing Date. In addition, the Court will retain, after the

[^52]Closing Date, exclusive jurisdiction over Group and FLIC to enforce the provisions of the Third Amended Plan of Rehabilitation to ensure that its intent and purposes are carried out and given effect.

FML will discontinue its business operations, liquidate and dissolve shortly after completing all transfers. FLIC will continue the business of FML in a substantially unchanged manner after the transfer from FML by receiving premiums, paying claims and generally administering the assumed Endorsed Contracts.
Further, for a period of 2 years following the Closing Date, the Investor will not be allowed to cause a change to the business plan for FLIC without the prior written approval of the Department if the change might reasonably result in the dissolution of FLIC or the operation of FLIC in a "run off' mode.
20. In summary, it is represented that the proposed transactions will satisfy the statutory criteria for an exemption under section 408(a) of the Act because:
(a) The Third Amended Plan of Rehabilitation will be implemented in accordance with procedural and substantive safeguards that are imposed under Pennsylvania law and by the Court and will be subject to review and supervision of the Court and/or the Rehabilitator.
(b) The Court will review the terms of the Third Amended Plan of Rehabilitation and will approve such Plan following a determination and public hearing or hearings that the Plan is fair and equitable to all Mutual Members.
(c) Each Mutual Member will have an opportunity to participate in any hearing or hearings before the Court regarding the approval of the Third Amended Plan of Rehabilitation.
(d) Although participation by all Mutual Members in FML's Third Amended Plan of Rehabilitation will be mandatory (although Mutual Members may disclaim Plan Stock), the determination of whether a Mutual Member receives Plan Stock or Plan Credits will be made by one or more independent fiduciaries of such Plan and not by FML, Group or FLIC. As a result, FML nor any of its affiliates will exercise investment discretion nor render "investment advice" within the meaning of 29 CFR 2510.3-21(c) with respect to the decision by the independent Plan fiduciary to elect Plan Stock or Plan Credits.
(e) After each Mutual Member is allocated its share of Plan Stock based on voting rights, the remaining consideration will be allocated based
upon actuarial formulas that take into account each Mutual Member's contribution to the surplus of FML, which formulas have been approved by the Rehabilitator and the Court.
(f) The value of Plan Stock or Plan Credits that will be received by a Mutual Member will reflect the prices paid by the Investor for Group Common Stock and for Plan Credit Shares.
(g) All Plans will participate in the exemption transaction on the same basis as other Mutual Members that are not Plans.
(h) No Plan will pay any brokerage commissions or fees in connection with receipt of Plan Stock or Plan Credits.
(i) FML's Contractholder obligations will remain in force upon endorsement and transfer to FLIC.

## Notice to Interested Persons

FML will provide notice of the proposed exemption to Mutual Members which are Plans within 5 days of the publication of the notice of proposed exemption in the Federal Register. Such notice will be provided to interested persons by first class mail and will include a copy of the notice of proposed exemption as published in the Federal Register as well as a supplemental statement, as required pursuant to 20 CFR 2570.43(b)(2) which shall inform interested persons of their right to comment on the proposed exemption. Comments with respect to the notice of proposed exemption are due within 35 days after the date of publication of this pendency notice in the Federal Register.
FOR FURTHER INFORMATION CONTACT: Ms.
Jan D. Broady of the Department, telephone (202) 219-8881. (This is not a toll-free number.)

## McDonald Investments Inc. (McDonald) Located in Cleveland, Ohio

[Application No. D-10857]

## Proposed Exemption

## I. Transactions

A. Effective January 4, 2000, the restrictions of sections 406(a) and 407(a) of the Act, and the taxes imposed by section 4975(a) and (b) of the Code by reason of section 4975(c)(1)(A) through (D) of the Code, shall not apply to the following transactions involving trusts and certificates evidencing interests therein:
(1) The direct or indirect sale, exchange or transfer of certificates in the initial issuance of certificates between the sponsor or underwriter and an employee benefit plan when the sponsor, servicer, trustee or insurer of a trust, the underwriter of the certificates
representing an interest in the trust, or an obligor is a party in interest with respect to such plan;
(2) The direct or indirect acquisition or disposition of certificates by a plan in the secondary market for such certificates; and
(3) The continued holding of certificates acquired by a plan pursuant to subsection I.A.(1) or (2).

Notwithstanding the foregoing, section I.A. does not provide an exemption from the restrictions of sections 406(a)(1)(E), 406(a)(2) and 407 for the acquisition or holding of a certificate on behalf of an Excluded Plan by any person who has discretionary authority or renders investment advice with respect to the assets of that Excluded Plan. ${ }^{29}$
B. Effective January 4, 2000, the restrictions of sections 406 (b)(1) and 406(b)(2) of the Act, and the taxes imposed by section 4975(a) and (b) of the Code by reason of section 4975(c)(1)(E) of the Code, shall not apply to:
(1) The direct or indirect sale, exchange or transfer of certificates in the initial issuance of certificates between the sponsor or underwriter and a plan when the person who has discretionary authority or renders investment advice with respect to the investment of plan assets in the certificates is (a) an obligor with respect to 5 percent or less of the fair market value of obligations or receivables contained in the trust, or (b) an affiliate of a person described in (a); if:
(i) The plan is not an Excluded Plan;
(ii) Solely in the case of an acquisition of certificates in connection with the initial issuance of the certificates, at least 50 percent of each class of certificates in which plans have invested is acquired by persons independent of the members of the Restricted Group and at least 50 percent of the aggregate interest in the trust is acquired by persons independent of the Restricted Group;
(iii) a plan's investment in each class of certificates does not exceed 25 percent of all of the certificates of that class outstanding at the time of the acquisition; and
(iv) immediately after the acquisition of the certificates, no more than 25 percent of the assets of a plan with respect to which the person has discretionary authority or renders investment advice are invested in certificates representing an interest in a

[^53]trust containing assets sold or serviced by the same entity. ${ }^{30}$ For purposes of this paragraph B.(1)(iv) only, an entity will not be considered to service assets contained in a trust if it is merely a subservicer of that trust;
(2) The direct or indirect acquisition or disposition of certificates by a plan in the secondary market for such certificates, provided that the conditions set forth in paragraphs B.(1)(i), (iii) and (iv) are met; and
(3) The continued holding of certificates acquired by a plan pursuant to subsection I.B.(1) or (2).
C. Effective January 4, 2000, the restrictions of sections 406(a), 406(b) and 407(a) of the Act, and the taxes imposed by section 4975(a) and (b) of the Code by reason of section 4975(c) of the Code, shall not apply to transactions in connection with the servicing, management and operation of a trust, provided:
(1) Such transactions are carried out in accordance with the terms of a binding pooling and servicing agreement; and
(2) The pooling and servicing agreement is provided to, or described in all material respects in, the prospectus or private placement memorandum provided to investing plans before they purchase certificates issued by the trust. ${ }^{31}$

Notwithstanding the foregoing, section I.C. does not provide an exemption from the restrictions of section 406(b) of the Act, or from the taxes imposed by reason of section 4975(c) of the Code, for the receipt of a fee by a servicer of the trust from a person other than the trustee or sponsor, unless such fee constitutes a "qualified administrative fee" as defined in section III.S.
D. Effective January 4, 2000, the restrictions of sections 406(a) and 407(a) of the Act, and the taxes imposed by sections 4975(a) and (b) of the Code by

[^54]reason of sections 4975 (c)(1)(A) through (D) of the Code, shall not apply to any transactions to which those restrictions or taxes would otherwise apply merely because a person is deemed to be a party in interest or disqualified person (including a fiduciary) with respect to a plan by virtue of providing services to the plan (or by virtue of having a relationship to such service provider described in section $3(14)(F)$, (G), (H) or (I) of the Act or section 4975(e)(2)(F), (G), (H) or (I) of the Code), solely because of the plan's ownership of certificates.

## II. General Conditions

A. The relief provided under Part I is available only if the following conditions are met:
(1) The acquisition of certificates by a plan is on terms (including the certificate price) that are at least as favorable to the plan as they would be in an arm's-length transaction with an unrelated party;
(2) The rights and interests evidenced by the certificates are not subordinated to the rights and interests evidenced by other certificates of the same trust;
(3) The certificates acquired by the plan have received a rating from a Rating Agency (as defined in section III.W.) at the time of such acquisition that is in one of the three highest generic rating categories;
(4) The trustee is not an affiliate of any other member of the Restricted Group. However, the trustee shall not be considered to be an affiliate of a servicer solely because the trustee has succeeded to the rights and responsibilities of the servicer pursuant to the terms of a pooling and servicing agreement providing for such succession upon the occurrence of one or more events of default by the servicer;
(5) The sum of all payments made to and retained by the underwriters in connection with the distribution or placement of certificates represents not more than reasonable compensation for underwriting or placing the certificates; the sum of all payments made to and retained by the sponsor pursuant to the assignment of obligations (or interests therein) to the trust represents not more than the fair market value of such obligations (or interests); and the sum of all payments made to and retained by the servicer represents not more than reasonable compensation for the servicer's services under the pooling and servicing agreement and reimbursement of the servicer's reasonable expenses in connection therewith;
(6) The plan investing in such certificates is an "accredited investor"
as defined in Rule 501(a)(1) of Regulation D of the Securities and Exchange Commission under the Securities Act of 1933; and
(7) In the event that the obligations used to fund a trust have not all been transferred to the trust on the closing date, additional obligations as specified in subsection III.B.(1) may be transferred to the trust during the pre-funding period (as defined in section III.BB.) in exchange for amounts credited to the pre-funding account (as defined in section III.Z.), provided that:
(a) The pre-funding limit (as defined in section III.AA.) is not exceeded;
(b) All such additional obligations meet the same terms and conditions for eligibility as those of the original obligations used to create the trust corpus (as described in the prospectus or private placement memorandum and/ or pooling and servicing agreement for such certificates), which terms and conditions have been approved by a Rating Agency. Notwithstanding the foregoing, the terms and conditions for determining the eligibility of an obligation may be changed if such changes receive prior approval either by a majority of the outstanding certificateholders or by a Rating Agency;
(c) The transfer of such additional obligations to the trust during the prefunding period does not result in the certificates receiving a lower credit rating from a rating agency upon termination of the pre-funding period than the rating that was obtained at the time of the initial issuance of the certificates by the trust;
(d) The weighted average annual percentage interest rate (the average interest rate) for all of the obligations in the trust at the end of the pre-funding period will not be more than 100 basis points lower than the average interest rate for the obligations which were transferred to the trust on the closing date;
(e) In order to ensure that the characteristics of the receivables actually acquired during the prefunding period are substantially similar to those which were acquired as of the closing date, the characteristics of the additional obligations will be either monitored by a credit support provider or other insurance provider which is independent of the sponsor, or an independent accountant retained by the sponsor will provide the sponsor with a letter (with copies provided to the Rating Agency, the underwriter and the trustees) stating whether or not the characteristics of the additional obligations conform to the characteristics of such obligations described in the prospectus, private
placement memorandum and/or pooling and servicing agreement. In preparing such letter, the independent accountant will use the same type of procedures as were applicable to the obligations which were transferred as of the closing date;
(f) The pre-funding period shall be described in the prospectus or private placement memorandum provided to investing plans; and
(g) The trustee of the trust (or any agent with which the trustee contracts to provide trust services) will be a substantial financial institution or trust company experienced in trust activities and familiar with its duties, responsibilities and liabilities as a fiduciary under the Act. The trustee, as the legal owner of the obligations in the trust, will enforce all the rights created in favor of certificateholders of such trust, including employee benefit plans subject to the Act.
B. Neither any underwriter, sponsor, trustee, servicer, insurer, nor any obligor, unless it or any of its affiliates has discretionary authority or renders investment advice with respect to the plan assets used by a plan to acquire certificates, shall be denied the relief provided under Part I, if the provision of subsection II.A.(6) above is not satisfied with respect to acquisition or holding by a plan of such certificates, provided that (1) such condition is disclosed in the prospectus or private placement memorandum; and (2) in the case of a private placement of certificates, the trustee obtains a representation from each initial purchaser which is a plan that it is in compliance with such condition, and obtains a covenant from each initial purchaser to the effect that, so long as such initial purchaser (or any transferee of such initial purchaser's certificates) is required to obtain from its transferee a representation regarding compliance with the Securities Act of 1933, any such transferees will be required to make a written representation regarding compliance with the condition set forth in subsection II.A.(6) above.

## III. Definitions

For purposes of this proposed exemption:
A. "Certificate" means:
(1) A certificate-
(a) That represents a beneficial ownership interest in the assets of a trust; and
(b) That entitles the holder to passthrough payments of principal, interest, and/or other payments made with respect to the assets of such trust; or
(2) A certificate denominated as a debt instrument-
(a) That represents an interest in a Real Estate Mortgage Investment Conduit (REMIC) or a Financial Asset Securitization Investment Trust (FASIT) within the meaning of section 860D(a) or section 860 L , respectively, of the Code; and
(b) That is issued by, and is an obligation of, a trust; with respect to certificates defined in (1) and (2) above for which McDonald or any of its affiliates is either (i) the sole underwriter or the manager or comanager of the underwriting syndicate, or (ii) a selling or placement agent.
For purposes of this proposed exemption, references to "certificates representing an interest in a trust" include certificates denominated as debt which are issued by a trust.
B. "Trust" means an investment pool, the corpus of which is held in trust and consists solely of:
(1) (a) Secured consumer receivables that bear interest or are purchased at a discount (including, but not limited to, home equity loans and obligations secured by shares issued by a cooperative housing association); and/or
(b) Secured credit instruments that bear interest or are purchased at a discount in transactions by or between business entities (including, but not limited to, qualified equipment notes secured by leases, as defined in section III.T); and/or
(c) Obligations that bear interest or are purchased at a discount and which are secured by single-family residential, multi-family residential and commercial real property (including obligations secured by leasehold interests on commercial real property); and/or
(d) Obligations that bear interest or are purchased at a discount and which are secured by motor vehicles or equipment, or qualified motor vehicle leases (as defined in section III.U); and/ or
(e) "Guaranteed governmental mortgage pool certificates," as defined in 29 CFR 2510.3-101(i)(2); and/or
(f) Fractional undivided interests in any of the obligations described in clauses (a)-(e) of this section B.(1);
(2) property which had secured any of the obligations described in subsection B. (1);
(3) (a) Undistributed cash or temporary investments made therewith maturing no later than the next date on which distributions are to be made to certificateholders; and/or
(b) Cash or investments made therewith which are credited to an account to provide payments to certificateholders pursuant to any yield supplement agreement or similar yield maintenance arrangement to
supplement the interest rates otherwise payable on obligations described in subsection III.B.(1) held in the trust, provided that such arrangements do not involve swap agreements or other notional principal contracts; and/or
(c) Cash transferred to the trust on the closing date and permitted investments made therewith which:
(i) Are credited to a pre-funding account established to purchase additional obligations with respect to which the conditions set forth in clauses (a)-(g) of subsection II.A.(7) are met and/or;
(ii) Are credited to a capitalized interest account (as defined in section III.X.); and
(iii) Are held in the trust for a period ending no later than the first distribution date to certificateholders occurring after the end of the prefunding period.

For purposes of this clause (c) of subsection III.B.(3), the term "permitted investments" means investments which are either: (i) Direct obligations of, or obligations fully guaranteed as to timely payment of principal and interest by the United States, or any agency or instrumentality thereof, provided that such obligations are backed by the full faith and credit of the United States or (ii) have been rated (or the obligor has been rated) in one of the three highest generic rating categories by a rating agency; are described in the pooling and servicing agreement; and are permitted by the rating agency; and
(4) Rights of the trustee under the pooling and servicing agreement, and rights under any insurance policies, third-party guarantees, contracts of suretyship, yield supplement agreements described in clause (b) of subsection III.B.(3) and other credit support arrangements with respect to any obligations described in subsection III.B.(1).

Notwithstanding the foregoing, the term "trust" does not include any investment pool unless: (i) the investment pool consists only of assets of the type described in clauses (a) through (f) of subsection III.B.(1) which have been included in other investment pools, (ii) certificates evidencing interests in such other investment pools have been rated in one of the three highest generic rating categories by a Rating Agency for at least one year prior to the plan's acquisition of certificates pursuant to this proposed exemption, and (iii) certificates evidencing interests in such other investment pools have been purchased by investors other than plans for at least one year prior to the plan's acquisition of certificates pursuant to this proposed exemption.
C. "Underwriter" means:
(1) McDonald;
(2) Any person directly or indirectly, through one or more intermediaries, controlling, controlled by or under common control with McDonald; or
(3) Any member of an underwriting syndicate or selling group of which McDonald or a person described in (2) is a manager or co-manager with respect to the certificates.
D. "Sponsor" means the entity that organizes a trust by depositing obligations therein in exchange for certificates.
E. "Master Servicer" means the entity that is a party to the pooling and servicing agreement relating to trust assets and is fully responsible for servicing, directly or through subservicers, the assets of the trust.
F. "Subservicer" means an entity which, under the supervision of and on behalf of the master servicer, services obligations contained in the trust, but is not a party to the pooling and servicing agreement.
G. "Servicer" means any entity which services obligations contained in the trust, including the master servicer and any subservicer.
H. "Trustee" means the trustee of the trust, and in the case of certificates which are denominated as debt instruments, also means the trustee of the indenture trust.
I. "Insurer" means the insurer or guarantor of, or provider of other credit support for, a trust. Notwithstanding the foregoing, a person is not an insurer solely because it holds securities representing an interest in a trust which are of a class subordinated to certificates representing an interest in the same trust.
J. "Obligor" means any person, other than the insurer, that is obligated to make payments with respect to any obligation or receivable included in the trust. Where a trust contains qualified motor vehicle leases or qualified equipment notes secured by leases, "obligor" shall also include any owner of property subject to any lease included in the trust, or subject to any lease securing an obligation included in the trust.
K. "Excluded Plan" means any plan with respect to which any member of the Restricted Group is a "plan sponsor" within the meaning of section 3 (16)(B) of the Act.
L. "Restricted Group" with respect to a class of certificates means:
(1) Each underwriter;
(2) Each insurer;
(3) The sponsor;
(4) The trustee;
(5) Each servicer;
(6) Any obligor with respect to obligations or receivables included in the trust constituting more than 5 percent of the aggregate unamortized principal balance of the assets in the trust, determined on the date of the initial issuance of certificates by the trust; or
(7) Any affiliate of a person described in (1)-(6) above.
M. "Affiliate" of another person includes:
(1) Any person directly or indirectly, through one or more intermediaries, controlling, controlled by, or under common control with such other person;
(2) Any officer, director, partner, employee, relative (as defined in section 3(15) of the Act), a brother, a sister, or a spouse of a brother or sister of such other person; and
(3) Any corporation or partnership of which such other person is an officer, director or partner.
N. "Control" means the power to exercise a controlling influence over the management or policies of a person other than an individual.
O. A person will be "independent" of another person only if:
(1) Such person is not an affiliate of that other person; and
(2) The other person, or an affiliate thereof, is not a fiduciary who has investment management authority or renders investment advice with respect to any assets of such person.
P. "Sale" includes the entrance into a forward delivery commitment (as defined in section Q below), provided:
(1) The terms of the forward delivery commitment (including any fee paid to the investing plan) are no less favorable to the plan than they would be in an arm's-length transaction with an unrelated party;
(2) The prospectus or private placement memorandum is provided to an investing plan prior to the time the plan enters into the forward delivery commitment; and
(3) At the time of the delivery, all conditions of this proposed exemption (if granted) applicable to sales are met. Q. "Forward delivery commitment" means a contract for the purchase or sale of one or more certificates to be delivered at an agreed future settlement date. The term includes both mandatory contracts (which contemplate obligatory delivery and acceptance of the certificates) and optional contracts (which give one party the right but not the obligation to deliver certificates to, or demand delivery of certificates from, the other party).
R. "Reasonable compensation" has the same meaning as that term is defined in 29 CFR 2550.408c-2.
S. "Qualified Administrative Fee" means a fee which meets the following criteria:
(1) The fee is triggered by an act or failure to act by the obligor other than the normal timely payment of amounts owing in respect of the obligations;
(2) The servicer may not charge the fee absent the act or failure to act referred to in (1);
(3) The ability to charge the fee, the circumstances in which the fee may be charged, and an explanation of how the fee is calculated are set forth in the pooling and servicing agreement; and
(4) The amount paid to investors in the trust will not be reduced by the amount of any such fee waived by the servicer
T. "Qualified Equipment Note Secured By A Lease" means an equipment note:
(1) Which is secured by equipment which is leased;
(2) Which is secured by the obligation of the lessee to pay rent under the equipment lease; and
(3) With respect to which the trust's security interest in the equipment is at least as protective of the rights of the trust as would be the case if the equipment note were secured only by the equipment and not the lease.
U. "Qualified Motor Vehicle Lease" means a lease of a motor vehicle where:
(1) The trust owns or holds a security interest in the lease;
(2) The trust owns or holds a security interest in the leased motor vehicle; and
(3) The trust's security interest in the leased motor vehicle is at least as protective of the trust's rights as would be the case if the trust consisted of motor vehicle installment loan contracts.
V. "Pooling and Servicing

Agreement" means the agreement or agreements among a sponsor, a servicer and the trustee establishing a trust. In the case of certificates which are denominated as debt instruments, "Pooling and Servicing Agreement" also includes the indenture entered into by the trustee of the trust issuing such certificates and the indenture trustee.
W. "Rating Agency" means Standard \& Poor’s Structured Rating Group (S\&P's), Moody's Investors Service, Inc. (Moody's), Duff \& Phelps Credit Rating Co. (D \& P) or Fitch IBCA, Inc. (Fitch) or their successors;
X. "Capitalized Interest Account" means a trust account: (i) which is established to compensate certificateholders for shortfalls, if any, between investment earnings on the pre-
funding account and the pass-through rate payable under the certificates; and (ii) which meets the requirements of clause (c) of subsection III.B.(3).
Y. "Closing Date" means the date the trust is formed, the certificates are first issued and the trust's assets (other than those additional obligations which are to be funded from the pre-funding account pursuant to subsection II.A.(7)) are transferred to the trust.
Z. "Pre-Funding Account" means a trust account: (i) Which is established to purchase additional obligations, which obligations meet the conditions set forth in clauses (a)-(g) of subsection II.A.(7); and (ii) which meets the requirements of clause (c) of subsection III.B.(3).
AA. "Pre-Funding Limit" means a percentage or ratio of the amount allocated to the pre-funding account, as compared to the total principal amount of the certificates being offered which is less than or equal to 25 percent.

BB. "Pre-Funding Period" means the period commencing on the closing date and ending no later than the earliest to occur of: (i) The date the amount on deposit in the pre-funding account is less than the minimum dollar amount specified in the pooling and servicing agreement; (ii) the date on which an event of default occurs under the pooling and servicing agreement; or (iii) the date which is the later of three months or 90 days after the closing date.
CC. "McDonald" means McDonald Investments Inc. and its affiliates.

The Department notes that this proposed exemption is included within the meaning of the term "Underwriter Exemption" as it is defined in section V(h) of Prohibited Transaction Exemption 95-60 (60 FR 35925, July 12, 1995), the Class Exemption for Certain Transactions Involving Insurance Company General Accounts at (see 60 FR 35932).

## Summary of Facts and Representations

1. McDonald is an indirect, whollyowned, separately capitalized investment banking and registered broker-dealer subsidiary of KeyCorp (the Corporation). As of September 30, 1999, McDonald's capitalization was approximately $\$ 310$ million. The Corporation is a diversified financial services company incorporated under the laws of Ohio and a multi-bank holding company registered under the Bank Holding Company Act of 1956, as amended. As of September 30, 1999, the Corporation's consolidated assets were approximately $\$ 81$ billion. The principal executive offices of the Corporation are located in Cleveland, Ohio. As of September 30, 1999, the Corporation directly owned a subsidiary
bank with offices located in twelve states. In addition, indirectly-held nonbank subsidiaries of the Corporation offer a wide range of insurance, securities brokerage, investment banking, venture capital investment, and consumer finance products and services.
KeyBank, National Association (the Bank), a direct, wholly-owned subsidiary of the Corporation, is a national banking association engaged in banking and related activities and is the largest bank in the Corporation's banking group. As of September 30, 1997, the Bank had total assets of approximately $\$ 80$ billion. The principal executive offices of the Bank are located in Cleveland, Ohio.

McDonald was incorporated in 1983 as an Ohio corporation. McDonald maintains its principal place of business in Cleveland, Ohio and has branch offices in 24 states.

McDonald is a member of the National Association of Securities Dealers and the Securities Investor Protection Corporation and underwrites and deals in corporate debt securities, commercial paper, municipal securities, high-yield securities and asset-backed securities, provides private placement and corporate finance advisory services, including merger and acquisition advisory services, publishes research on a wide range of securities and issuers, and engages in the syndication and arranging and trading of bank loans.

## Trust Assets

2. McDonald seeks exemptive relief to permit plans to invest in pass-through certificates representing undivided interests in the following categories of trusts: (1) Single and multi-family residential or commercial mortgage investment trusts; ${ }^{32}$ (2) motor vehicle receivable investment trusts; (3) consumer or commercial receivables investment trusts; and (4) guaranteed governmental mortgage pool certificate investment trusts. ${ }^{33}$

[^55]3. Commercial mortgage investment trusts may include mortgages on ground leases of real property. Commercial mortgages are frequently secured by ground leases on the underlying property, rather than by fee simple interests. The separation of the fee simple interest and the ground lease interest is generally done for tax reasons. Properly structured, the pledge of the ground lease to secure a mortgage provides a lender with the same level of security as would be provided by a pledge of the related fee simple interest. The terms of the ground leases pledged to secure leasehold mortgages will in all cases be at least ten years longer than the term of such mortgages. ${ }^{34}$

## Trust Structure

4. Each trust is established under a pooling and servicing agreement between a sponsor, a servicer and a trustee. ${ }^{35}$ The sponsor or servicer of a trust selects assets to be included in the trust. ${ }^{36}$ These assets are receivables which may have been originated, in the ordinary course of business, by a sponsor or servicer of the trust, an affiliate of the sponsor or servicer, or by an unrelated lender and subsequently acquired by the trust sponsor or servicer. ${ }^{37}$
"plan assets" (29 CFR 2510.3-101(i)) provides that where a plan acquires a guaranteed governmental mortgage pool certificate, the plan's assets include the certificate and all of its rights with respect to such certificate under applicable law, but do not, solely by reason of the plan's holding of such certificate, include any of the mortgages underlying such certificate. The applicant is requesting exemptive relief for trusts containing guaranteed governmental mortgage pool certificates because the certificates in the trusts may be plan assets.
${ }^{34}$ Trust assets may also include obligations that are secured by leasehold interests on residential real property. See PTE 90-32 involving PrudentialBache Securities, Inc. (55 FR 23147, June 6, 1990 at 23150).
${ }^{35}$ The Department is of the view that the term "trust" includes a trust: (a) the assets of which, although all specifically identified by the sponsor or the originator as of the closing date, are not all transferred to the trust on the closing date for administrative or other reasons but will be transferred to the trust shortly after the closing date, or (b) with respect to which certificates are not purchased by plans until after the end of the prefunding period at which time all receivables are contained in the trust.
${ }^{36}$ It is the Department's view that the definition of "trust" contained in section III.B. includes a twotier structure under which certificates issued by the first trust, which contains a pool of receivables described above, are transferred to a second trust which issues securities that are sold to plans. However, the Department is of the further view that, since the exemption provides relief for the direct or indirect acquisition or disposition of certificates that are not subordinated, no relief would be available if the certificates held by the second trust were subordinated to the rights and interests evidenced by other certificates issued by the first trust.
${ }^{37}$ It is the view of the Department that section III.B.(4) includes within the definition of the term

Typically, on or prior to the closing date, the sponsor acquires legal title to all assets selected for the trust, establishes the trust and designates an independent entity as trustee. On the closing date, the sponsor conveys to the trust legal title to the assets, and the trustee issues certificates representing fractional undivided interests in the trust assets. Typically, all receivables to be held in the trust are transferred as of the closing date, but in some transactions, as described more fully below, a limited percentage of the receivables to be held in the trust may be transferred during a limited period of time following the closing date, through the use of a pre-funding account.
McDonald, alone or together with other broker-dealers, acts as underwriter or placement agent with respect to the sale of the certificates. All of the public offerings of certificates presently contemplated have been or are to be underwritten by McDonald on a firm commitment basis. In addition, McDonald anticipates that it may privately place certificates on both a firm commitment and an agency basis. McDonald may also act as the lead underwriter for a syndicate of securities underwriters.

Certificateholders will be entitled to receive monthly, quarterly or semiannual installments of principal and/or interest, or lease payments due on the receivables, adjusted, in the case of payments of interest, to a specified rate-the pass-through rate-which may be fixed or variable.
When installments or payments are made on a semi-annual basis, funds are not permitted to be commingled with the servicer's assets for longer than would be permitted for a monthly-pay security. A segregated account is established in the name of the trustee (on behalf of certificateholders) to hold funds received between distribution dates. The account is under the sole control of the trustee, who invests the account's assets in short-term securities which have received a rating comparable to the rating assigned to the certificates. In some cases, the servicer may be permitted to make a single deposit into the account once a month. When the servicer makes such monthly deposits, payments received from

[^56]obligors by the servicer may be commingled with the servicer's assets during the month prior to deposit. Usually, the period of time between receipt of funds by the servicer and deposit of these funds in a segregated account does not exceed one month. Furthermore, in those cases where distributions are made semi-annually, the servicer will furnish a report on the operation of the trust to the trustee on a monthly basis. At or about the time this report is delivered to the trustee, it will be made available to certificateholders and delivered to or made available to each Rating Agency that has rated the certificates.
5. Some of the certificates will be multi-class certificates. McDonald requests exemptive relief for two types of multi-class certificates: "strip" certificates and "fast-pay/slow-pay" certificates. Strip certificates are a type of security in which the stream of interest payments on receivables is split from the flow of principal payments and separate classes of certificates are established, each representing rights to disproportionate payments of principal and interest. ${ }^{38}$
"Fast-pay/slow-pay" certificates involve the issuance of classes of certificates having different stated maturities or the same maturities with different payment schedules. Interest and/or principal payments received on the underlying receivables are distributed first to the class of certificates having the earliest stated maturity of principal, and/or earlier payment schedule, and only when that class of certificates has been paid in full (or has received a specified amount) will distributions be made with respect to the second class of certificates. Distributions on certificates having later stated maturities will proceed in like manner until all the certificateholders have been paid in full. The only difference between this multi-class passthrough arrangement and a single-class pass-through arrangement is the order in which distributions are made to certificateholders. In each case, certificateholders will have a beneficial ownership interest in the underlying assets. In neither case will the rights of

[^57]a plan purchasing a certificate be subordinated to the rights of another certificateholder in the event of default on any of the underlying obligations. In particular, if the amount available for distribution to certificateholders is less than the amount required to be so distributed, all senior certificateholders then entitled to receive distributions will share in the amount distributed on a pro rata basis. ${ }^{39}$
6. The trust will be maintained as an essentially passive entity. Therefore, both the sponsor's discretion and the servicer's discretion with respect to assets included in a trust are severely limited. Pooling and servicing agreements provide for the substitution of receivables by the sponsor only in the event of defects in documentation discovered within a short time after the issuance of trust certificates (within 120 days, except in the case of obligations having an original term of 30 years, in which case the period will not exceed two years). Any receivable so substituted is required to have characteristics substantially similar to the replaced receivable and will be at least as creditworthy as the replaced receivable.

In some cases, the affected receivable would be repurchased, with the purchase price applied as a payment on the affected receivable and passedthrough to certificateholders.

In some cases the trust will be maintained as a Financial Asset Securitization Investment Trust ("FASIT"), a statutory entity created by the Small Business Job Protection Act of 1996 , adding sections $860 \mathrm{H}, 860 \mathrm{~J}, 860 \mathrm{~K}$ and 860 L to the Code. In general, a FASIT is designed to facilitate the securitization of debt obligations, such as credit card receivables, home equity loans, and auto loans, and thus, allows certain features such as revolving pools of assets, trusts containing unsecured receivables and certain hedging types of investments. A FASIT is not a taxable entity and debt instruments issued by such trusts, which might otherwise be recharacterized as equity, will be treated as debt in the hands of the holder for tax purposes. However, a trust which is the subject of the proposed exemption will be maintained as a FASIT only where the assets held by the FASIT will be comprised of secured debt; revolving pools of assets or hedging investments will not be allowed unless specifically

[^58]authorized by the exemption, if granted, so that a trust maintained as a FASIT will be maintained as an essentially passive entity.

## Trust Structure With Pre-Funding Account

## Pre-Funding Accounts

7. As described briefly above, some transactions may be structured using a pre-funding account or a capitalized interest account. If pre-funding is used, cash sufficient to purchase the receivables to be transferred after the closing date will be transferred to the trust by the sponsor or originator on the closing date. During the pre-funding period, such cash and temporary investments, if any, made therewith will be held in a pre-funding account and used to purchase the additional receivables, the characteristics of which will be substantially similar to the characteristics of the receivables transferred to the trust on the closing date. The pre-funding period for any trust will be defined as the period beginning on the closing date and ending on the earliest to occur of: (i) The date on which the amount on deposit in the pre-funding account is less than a specified dollar amount, (ii) the date on which an event of default occurs under the related pooling and servicing agreement, or (iii) the date which is the later of three months or ninety (90) days after the closing date. Certain specificity and monitoring requirements described below will be met and will be disclosed in the pooling and servicing agreement and/or the prospectus or private placement memorandum.

For transactions involving a trust using pre-funding, on the closing date, a portion of the offering proceeds will be allocated to the pre-funding account generally in an amount equal to the excess of (i) the principal amount of certificates being issued over (ii) the principal balance of the receivables being transferred to the trust on such closing date. In certain transactions, the aggregate principal balance of the receivables intended to be transferred to the trust may be larger than the total principal balance of the certificates being issued. In these cases, the cash deposited in the pre-funding account will equal the excess of the principal balance of the total receivables intended to be transferred to the trust over the principal balance of the receivables being transferred on the closing date.
On the closing date, the sponsor transfers the assets to the trust in exchange for the certificates. The certificates are then sold to McDonald
for cash or to the certificateholders directly if the certificates are sold through McDonald as a placement agent. The cash received by the sponsor from the certificateholders (or McDonald) for the sale of the certificates issued by the trust in excess of the purchase price for the receivables and certain other trust expenses, such as underwriting or placement agent fees and legal and accounting fees, constitutes the cash to be deposited in the pre-funding account. Such funds are either held in the trust and accounted for separately, or are held in a sub-trust. In either event, these funds are not part of the assets of the sponsor.
Generally, the receivables are transferred at par value, unless the interest rate payable on the receivables is not sufficient to service both the interest rates to be paid on the certificates and the transaction fees (i.e., servicing fees, trustee fees and fees to credit support providers). In such cases, the receivables are sold to the trust at a discount, based on an objective, written, mechanical formula which is set forth in the pooling and servicing agreement and agreed upon in advance between the sponsor, the Rating Agency and any credit support provider or other insurer. The proceeds payable to the sponsor from the sale of the receivables transferred to the trust may also be reduced to the extent they are used to pay transaction costs (which typically include underwriting or placement agent fees and legal and accounting fees). In addition, in certain cases, the sponsor may be required by the Rating Agencies or credit support providers to set up trust reserve accounts to protect the certificateholders against credit losses.
The pre-funding account of any trust will be limited so that the percentage or ratio of the amount allocated to the prefunding account, as compared to the total principal amount of the certificates being offered (the pre-funding limit) will not exceed $25 \%$. The pre-funding limit (which may be expressed as a ratio or as a stated percentage or a combination thereof) will be specified in the prospectus or the private placement memorandum.

Any amounts paid out of the prefunding account are used solely to purchase receivables and to support the certificate pass-through rate (as explained below). Amounts used to support the pass-through rate are payable only from investment earnings and are not payable from principal. However, in the event that, after all of the requisite receivables have been transferred into the trust, any funds remain in the pre-funding account, such
funds will be paid to the certificateholders as principal prepayments. Upon termination of the trust, if no receivables remain in the trust and all amounts payable to certificateholders have been distributed, any amounts remaining in the trust would be returned to the sponsor.

A dramatic change in interest rates on the receivables held in a trust using a pre-funding account would be handled as follows. If the receivables (other than those with adjustable or variable rates) had already been originated prior to the closing date, no action would be required as the fluctuations in the market interest rates would not affect the receivables transferred to the trust after the closing date. In contrast, if interest rates fall after the closing date, loans originated after the closing date will tend to be originated at lower rates, with the possible result that the receivables will not support the certificate pass-through rate. In a situation where interest rates drop dramatically and the sponsor is unable to provide sufficient receivables at the requisite interest rates, the pool of receivables would be closed. In this latter event, under the terms of the pooling and servicing agreement, the certificateholders would receive a repayment of principal from the unused cash held in the pre-funding account. In transactions where the certificate passthrough rates are variable or adjustable, the effects of market interest rate fluctuations are mitigated. In no event will fluctuations in interest rates payable on the receivable affect the pass-through rate for fixed rate certificates.

The cash deposited into the trust and allocated to the pre-funding account is invested in certain permitted investments (see below), which may be commingled with other accounts of the trust. The allocation of investment earnings to each trust account is made periodically as earned in proportion to each account's allocable share of the investment returns. As pre-funding account investment earnings are required to be used to support (to the extent authorized in the particular transaction) the pass-through amounts payable to the certificateholders with respect to a periodic distribution date, the trustee is necessarily required to make periodic, separate allocations of the trust's earning to each trust account, thus ensuring that all allocable commingled investment earnings are properly credited to the pre-funding account on a timely basis.

## The Capitalized Interest Account

8. In certain transactions where a prefunding account is used, the sponsor and/or originator may also transfer to the trust additional cash on the closing date, which is deposited in a capitalized interest account and used during the pre-funding period to compensate the certificateholders for any shortfall between the investment earnings on the pre-funding account and the passthrough interest rate payable under the certificates.
The capitalized interest account is needed in certain transactions since the certificates are supported by the receivables and the earnings on the prefunding account, and it is unlikely that the investment earnings on the prefunding account will equal the interest rates on the certificates (although such investment earnings will be available to pay interest on the certificates). The capitalized interest account funds are paid out periodically to the certificateholders as needed on distribution dates to support the passthrough rate. In addition, a portion of such funds may be returned to the sponsor from time to time as the receivables are transferred into the trust and the need for the capitalized interest account diminishes. Any amounts held in the capitalized interest account generally will be returned to the sponsor and/or originator either at the end of the pre-funding period or periodically as receivables are transferred and the proportionate amount of funds in the capitalized interest account can be reduced. Generally, the capitalized interest account terminates no later than the end of the pre-funding period. However, there may be some cases where the capitalized interest account remains open until the first date distributions are made to certificateholders following the end of the pre-funding period.

In other transactions, a capitalized interest account is not necessary because the interest paid on the receivables exceeds the interest payable on the certificates at the applicable passthrough rate and the fees of the trust. Such excess is sufficient to make up any shortfall resulting from the pre-funding account earning less than the certificate pass-through rate. In certain of these transactions, this occurs because the aggregate principal amount of receivables exceeds the aggregate principal amount of certificates.

Pre-Funding Account and Capitalized Interest Account Payments and Investments
9. Pending the acquisition of additional receivables during the prefunding period, it is expected that amounts in the pre-funding account and the capitalized interest account will be invested in certain permitted investments or will be held uninvested. Pursuant to the pooling and servicing agreement, all permitted investments must mature prior to the date the actual funds are needed. The permitted types of investments in the pre-funding account and capitalized interest account are investments which are either: (i) Direct obligations of, or obligations fully guaranteed as to timely payment of principal and interest by, the United States or any agency or instrumentality thereof, provided that such obligations are backed by the full faith and credit of the United States, or (ii) have been rated (or the obligor has been rated) in one of the three highest generic rating categories by a rating agency, as set forth in the pooling and servicing agreement and as required by the Rating Agencies. The credit grade quality of the permitted investments is generally no lower than that of the certificates. The types of permitted investments will be described in the pooling and servicing agreement.

The ordering of interest payments to be made from the pre-funding and capitalized interest accounts is preestablished and set forth in the pooling and servicing agreement. The only principal payments which will be made from the pre-funding account are those made to acquire the receivables during the pre-funding period and those distributed to the certificateholders in the event that the entire amount in the pre-funding account is not used to acquire receivables. The only principal payments which will be made from the capitalized interest account are those made to certificateholders if necessary to support the certificate pass-through rate or those made to the sponsor either periodically as they are no longer needed or at the end of the pre-funding period when the capitalized interest account is no longer necessary.
The Characteristics of the Receivables Transferred During the Pre-Funding Period
10. In order to ensure that there is sufficient specificity as to the representations and warranties of the sponsor regarding the characteristics of the receivables to be transferred after the closing date:
(i) All such receivables will meet the same terms and conditions for eligibility
as those of the original receivables used to create the trust corpus (as described in the prospectus or private placement memorandum and/or pooling and servicing agreement for such certificates), which terms and conditions have been approved by a Rating Agency. However, the terms and conditions for determining the eligibility of a receivable may be changed if such changes receive prior approval either by a majority vote of the outstanding certificateholders or by a Rating Agency;
(ii) The transfer to the trust of the receivables acquired during the prefunding period will not result in the certificates receiving a lower credit rating from the Rating Agency upon termination of the pre-funding period than the rating that was obtained at the time of the initial issuance of the certificates by the trust;
(iii) The weighted average annual percentage interest rate (the average interest rate) for all of the obligations in the trust at the end of the pre-funding period will not be more than 100 basis points lower than the average interest rate for the obligations which were transferred to the trust on the closing date;
(iv) The trustee of the trust (or any agency with which the trustee contracts to provide trust services) will be a substantial financial institution or trust company experienced in trust activities and familiar with its duties, responsibilities, and liabilities as a fiduciary under the Act. The trustee, as the legal owner of the obligations in the trust, will enforce all the rights created in favor of certificateholders of such trust, including employee benefit plans subject to the Act.

In order to ensure that the characteristics of the receivables actually acquired during the prefunding period are substantially similar to receivables that were acquired as of the closing date, the characteristics of the additional obligations subsequently acquired will be either (i) monitored by a credit support provider or other insurance provider which is independent of the sponsor, or (ii) an independent accountant retained by the sponsor will provide the sponsor with a letter (with copies provided to the Rating Agency, McDonald and the trustee) stating whether or not the characteristics of the additional obligations acquired after the closing date conform to the characteristics of such obligations described in the prospectus, private placement memorandum and/or pooling and servicing agreement. In preparing such letter, the independent accountant will
use the same type of procedures as were applicable to the obligations which were transferred as of the closing date.
Each prospectus, private placement memorandum and/or pooling and servicing agreement will set forth the terms and conditions for eligibility of the receivables to be included in the trust as of the related closing date, as well as those to be acquired during the pre-funding period, which terms and conditions will have been agreed to by the Rating Agencies which are rating the applicable certificates as of the closing date. Also included among these conditions is the requirement that the trustee be given prior notice of the receivables to be transferred, along with such information concerning those receivables as may be requested. Each prospectus or private placement memorandum will describe the amount to be deposited in, and the mechanics of, the pre-funding account and will describe the pre-funding period for the trust.

## Parties to Transactions

11. The originator of a receivable is the entity that initially lends money to a borrower (obligor), such as a homeowner or automobile purchaser, or leases property to a lessee. The originator may either retain a receivable in its portfolio or sell it to a purchaser, such as a trust sponsor.
Originators of receivables included in the trusts will be entities that originate receivables in the ordinary course of their businesses, including finance companies for whom such origination constitutes the bulk of their operations, financial institutions for whom such origination constitutes a substantial part of their operations, and any kind of manufacturer, merchant, or service enterprise for whom such origination is an incidental part of its operations. Each trust may contain assets of one or more originators. The originator of the receivables may also function as the trust sponsor or servicer.
12. The sponsor will be one of three entities: (i) a special-purpose or other corporation unaffiliated with the servicer, (ii) a special-purpose or other corporation affiliated with the servicer, or (iii) the servicer itself. Where the sponsor is not also the servicer, the sponsor's role will generally be limited to acquiring the receivables to be included in the trust, establishing the trust, designating the trustee, and assigning the receivables to the trust.
13. The trustee of a trust is the legal owner of the obligations in the trust. The trustee is also a party to or beneficiary of all the documents and instruments deposited in the trust, and
as such is responsible for enforcing all the rights created thereby in favor of certificateholders.
The trustee will be an independent entity, and therefore will be unrelated to McDonald, the trust sponsor, the servicer or any other member of the Restricted Group (as defined in section III.L.). McDonald represents that the trustee will be a substantial financial institution or trust company experienced in trust activities. The trustee receives a fee for its services, which will be paid by the servicer or sponsor or out of the trust assets. The method of compensating the trustee will be specified in the pooling and servicing agreement and disclosed in the prospectus or private placement memorandum relating to the offering of the certificates.
14. The servicer of a trust administers the receivables on behalf of the certificateholders. The servicer's functions typically involve, among other things, notifying borrowers of amounts due on receivables, maintaining records of payments received on receivables and instituting foreclosure or similar proceedings in the event of default. In cases where a pool of receivables has been purchased from a number of different originators and deposited in a trust, the receivables may be "subserviced" by their respective originators and a single entity may "master service" the pool of receivables on behalf of the owners of the related series of certificates. Where this arrangement is adopted, a receivable continues to be serviced from the perspective of the borrower by the local subservicer, while the investor's perspective is that the entire pool of receivables is serviced by a single, central master servicer who collects payments from the local subservicers and passes them through to certificateholders.
Receivables of the type suitable for inclusion in a trust invariably are serviced with the assistance of a computer. After the sale, the servicer keeps the sold receivables on the computer system in order to continue monitoring the accounts. Although the records relating to sold receivables are kept in the same master file as receivables retained by the originator, the sold receivables are flagged as having been sold. To protect the investor's interest, the servicer ordinarily covenants that this "sold flag" will be included in all records relating to the sold receivables, including the master file, archives, tape extracts and printouts.
The sold flags are invisible to the obligor and do not affect the manner in
which the servicer performs the billing, posting and collection procedures related to the sold receivables. However, the servicer uses the sold flag to identify the receivables for the purpose of reporting all activity on those receivables after their sale to investors.

Depending on the type of receivable and the details of the servicer's computer system, in some cases the servicer's internal reports can be adapted for investor reporting with little or no modification. In other cases, the servicer may have to perform special calculations to fulfill the investor reporting responsibilities. These calculations can be performed on the servicer's main computer, or on a small computer with data supplied by the main system. In all cases, the numbers produced for the investors are reconciled to the servicer's books and reviewed by public accountants.

The underwriter (i.e., McDonald, its affiliate, or a member of an underwriting syndicate or selling group of which McDonald or its affiliate is a manager or co-manager) will be a registered brokerdealer that acts as underwriter or placement agent with respect to the sale of the certificates. Public offerings of certificates are generally made on a firm commitment basis. Private placement of certificates may be made on a firm commitment or agency basis. It is anticipated that the lead and comanaging underwriters will make a market in certificates offered to the public.

In some cases, the originator and servicer of receivables to be included in a trust and the sponsor of the trust (although they may themselves be related) will be unrelated to McDonald. In other cases, however, affiliates of McDonald may originate or service receivables included in a trust or may sponsor a trust.
Certificate Price, Pass-Through Rate and Fees
15. In some cases, the sponsor will obtain the receivables from various originators pursuant to existing contracts with such originators under which the sponsor continually buys receivables. In other cases, the sponsor will purchase the receivables at fair market value from the originator or a third party pursuant to a purchase and sale agreement related to the specific offering of certificates. In other cases, the sponsor will originate the receivables itself.

As compensation for the receivables transferred to the trust, the sponsor receives certificates representing the entire beneficial interest in the trust, or the cash proceeds of the sale of such
certificates. If the sponsor receives certificates from the trust, the sponsor sells all or a portion of these certificates for cash to investors or securities underwriters.
16. The price of the certificates, both in the initial offering and in the secondary market, is affected by market forces, including investor demand, the pass-through interest rate on the certificates in relation to the rate payable on investments of similar types and quality, expectations as to the effect on yield resulting from prepayment of underlying receivables, and expectations as to the likelihood of timely payment.

The pass-through rate for certificates is equal to the interest rate on receivables included in the trust minus a specified servicing fee. ${ }^{40}$ This rate is generally determined by the same market forces that determine the price of a certificate. The price of a certificate and its pass-through, or coupon, rate together determine the yield to investors. If an investor purchases a certificate at less than par, that discount augments the stated pass-through rate; conversely, a certificate purchased at a premium yields less than the stated coupon.
17. As compensation for performing its servicing duties, the servicer (who may also be the sponsor or an affiliate thereof, and receive fees for acting in that capacity) will retain the difference between payments received on the receivables in the trust and payments payable (at the pass-through rate) to certificateholders, except that in some cases a portion of the payments on receivables may be paid to a third party, such as a fee paid to a provider of credit support. The servicer may receive additional compensation by having the use of the amounts paid on the receivables between the time they are received by the servicer and the time they are due to the trust (which time is set forth in the pooling and servicing agreement). The servicer typically will be required to pay the administrative expenses of servicing the trust, including in some cases the trustee's fee, out of its servicing compensation.

The servicer is also compensated to the extent it may provide credit enhancement to the trust or otherwise arrange to obtain credit support from another party. This "credit support fee" may be aggregated with other servicing fees, and is either paid out of the interest income received on the

[^59]receivables in excess of the pass-through rate or paid in a lump sum at the time the trust is established.
18. The servicer may be entitled to retain certain administrative fees paid by a third party, usually the obligor. These administrative fees fall into three categories: (a) prepayment fees; (b) late payment and payment extension fees; and (c) expenses, fees and charges associated with foreclosure or repossession, or other conversion of a secured position into cash proceeds, upon default of an obligation.

Compensation payable to the servicer will be set forth or referred to in the pooling and servicing agreement and described in reasonable detail in the prospectus or private placement memorandum relating to the certificates.
19. Payments on receivables may be made by obligors to the servicer at various times during the period preceding any date on which passthrough payments to the trust are due. In some cases, the pooling and servicing agreement may permit the servicer to place these payments in non-interest bearing accounts maintained with itself or to commingle such payments with its own funds prior to the distribution dates. In these cases, the servicer would be entitled to the benefit derived from the use of the funds between the date of payment on a receivable and the passthrough date. Commingled payments may not be protected from the creditors of the servicer in the event of the servicer's bankruptcy or receivership. In those instances when payments on receivables are held in non-interest bearing accounts or are commingled with the servicer's own funds, the servicer is required to deposit these payments by a date specified in the pooling and servicing agreement into an account from which the trustee makes payments to certificateholders.
20. The underwriter will receive a fee in connection with the securities underwriting or private placement of certificates. In a firm commitment underwriting, this fee would consist of the difference between what the underwriter receives for the certificates that it distributes and what it pays the sponsor for those certificates. In a private placement, the fee normally takes the form of an agency commission paid by the sponsor. In a best efforts underwriting in which the underwriter would sell certificates in a public offering on an agency basis, the underwriter would receive an agency commission rather than a fee based on the difference between the price at which the certificates are sold to the public and what it pays the sponsor. In some private placements, the
underwriter may buy certificates as principal, in which case its compensation would be the difference between what it receives for the certificates that it sells and what it pays the sponsor for these certificates.

## Purchase of Receivables by the Servicer

21. The applicant represents that as the principal amount of the receivables in a trust is reduced by payments, the cost of administering the trust generally increases, making the servicing of the trust prohibitively expensive at some point. Consequently, the pooling and servicing agreement generally provides that the servicer may purchase the receivables remaining in the trust when the aggregate unpaid balance payable on the receivables is reduced to a specified percentage (usually 5 to 10 percent) of the initial aggregate unpaid balance.

The purchase price of a receivable is specified in the pooling and servicing agreement and will be at least equal to: (1) The unpaid principal balance on the receivable plus accrued interest, less any unreimbursed advances of principal made by the servicer; or (2) the greater of (a) the amount in (1) or (b) the fair market value of such obligations in the case of a REMIC, or the fair market value of the receivables in the case of a trust that is not a REMIC.

## Certificate Ratings

22. The certificates will have received one of the three highest ratings available from a Rating Agency. Insurance or other credit support (such as surety bonds, letters of credit, guarantees, or overcollateralization) will be obtained by the trust sponsor to the extent necessary for the certificates to attain the desired rating. The amount of this credit support is set by the Rating Agencies at a level that is a multiple of the worst historical net credit loss experience for the type of obligations included in the issuing trust.

## Provision of Credit Support

23. In some cases, the master servicer, or an affiliate of the master servicer, may provide credit support to the trust (i.e. act as an insurer). In these cases, the master servicer, in its capacity as servicer, will first advance funds to the full extent that it determines that such advances will be recoverable (a) out of late payments by the obligors, (b) from the credit support provider (which may be the master servicer or an affiliate thereof) or, (c) in the case of a trust that issues subordinated certificates, from amounts otherwise distributable to holders of subordinated certificates, and the master servicer will advance such funds in a timely manner. When the
servicer is the provider of the credit support and provides its own funds to cover defaulted payments, it will do so either on the initiative of the trustee, or on its own initiative on behalf of the trustee, but in either event it will provide such funds to cover payments to the full extent of its obligations under the credit support mechanism. In some cases, however, the master servicer may not be obligated to advance funds but instead would be called upon to provide funds to cover defaulted payments to the full extent of its obligations as insurer. Moreover, a master servicer typically can recover advances either from the provider of credit support or from future payments on the affected assets.
If the master servicer fails to advance funds, fails to call upon the credit support mechanism to provide funds to cover delinquent payments, or otherwise fails in its duties, the trustee would be required and would be able to enforce the certificateholders' rights, as both a party to the pooling and servicing agreement and the owner of the trust estate, including rights under the credit support mechanism. Therefore, the trustee, who is independent of the servicer, will have the ultimate right to enforce the credit support arrangement.
When a master servicer advances funds, the amount so advanced is recoverable by the master servicer out of future payments on receivables held by the trust to the extent not covered by credit support. However, where the master servicer provides credit support to the trust, there are protections in place to guard against a delay in calling upon the credit support to take advantage of the fact that the credit support declines proportionally with the decrease in the principal amount of the obligations in the trust as payments on receivables are passed through to investors. These safeguards include:
(a) There is often a disincentive to postponing credit losses because the sooner repossession or foreclosure activities are commenced, the more value that can be realized on the security for the obligation;
(b) The master servicer has servicing guidelines which include a general policy as to the allowable delinquency period after which an obligation ordinarily will be deemed uncollectible. The pooling and servicing agreement will require the master servicer to follow its normal servicing guidelines and will set forth the master servicer's general policy as to the period of time after which delinquent obligations ordinarily will be considered uncollectible;
(c) As frequently as payments are due on the receivables included in the trust (monthly, quarterly or semi-annually, as set forth in the pooling and servicing agreement), the master servicer is required to report to the independent trustee the amount of all past-due payments and the amount of all servicer advances, along with other current information as to collections on the receivables and draws upon the credit support. Further, the master servicer is required to deliver to the trustee annually a certificate of an executive officer of the master servicer stating that a review of the servicing activities has been made under such officer's supervision, and either stating that the master servicer has fulfilled all of its obligations under the pooling and servicing agreement or, if the master servicer has defaulted under any of its obligations, specifying any such default. The master servicer's reports are reviewed at least annually by independent accountants to ensure that the master servicer is following its normal servicing standards and that the master servicer's reports conform to the master servicer's internal accounting records. The results of the independent accountants' review are delivered to the trustee; and
(d) The credit support has a "floor" dollar amount that protects investors against the possibility that a large number of credit losses might occur towards the end of the life of the trust, whether due to servicer advances or any other cause. Once the floor amount has been reached, the servicer lacks an incentive to postpone the recognition of credit losses because the credit support amount thereafter is subject to reduction only for actual draws. From the time that the floor amount is effective until the end of the life of the trust, there are no proportionate reductions in the credit support amount caused by reductions in the pool principal balance. Indeed, since the floor is a fixed dollar amount, the amount of credit support ordinarily increases as a percentage of the pool principal balance during the period that the floor is in effect.

## Disclosure

24. In connection with the original issuance of certificates, the prospectus or private placement memorandum will be furnished to investing plans. The prospectus or private placement memorandum will contain information material to a fiduciary's decision to invest in the certificates, including:
(a) Information concerning the payment terms of the certificates, the rating of the certificates, any material
risk factors with respect to the certificates, and the fact that principal amounts left in the pre-funding account at the end of the pre-funding period will be paid to certificateholders as a repayment of principal;
(b) A description of the trust as a legal entity and a description of how the trust was formed by the seller/servicer or other sponsor of the transaction;
(c) Identification of the independent trustee for the trust;
(d) A description of the receivables contained in the trust, including the types of receivables, the diversification of the receivables, their principal terms, and their material legal aspects, and a description of any pre-funding account used or capitalized interest account used in connection with a pre-funding account;
(e) A description of the sponsor and servicer;
(f) A description of the pooling and servicing agreement, including a description of the seller's principal representations and warranties as to the trust assets, including the terms and conditions for eligibility of any receivables transferred during the prefunding period and the trustee's remedy for any breach thereof; a description of the procedures for collection of payments on receivables and for making distributions to investors, and a description of the accounts into which such payments are deposited and from which such distributions are made; a description of permitted investments for any pre-funding account or capitalized interest account; identification of the servicing compensation and any fees for credit enhancement that are deducted from payments on receivables before distributions are made to investors; a description of periodic statements provided to the trustee, and provided to or made available to investors by the trustee; and a description of the events that constitute events of default under the pooling and servicing contract and a description of the trustee's and the investors' remedies incident thereto;
(g) A description of the credit support;
(h) A general discussion of the principal federal income tax consequences of the purchase, ownership and disposition of the passthrough securities by a typical investor;
(i) A description of the underwriters' plan for distributing the pass-through securities to investors;
(j) Information about the scope and nature of the secondary market, if any, for the certificates; and
(k) A statement as to the duration of any pre-funding period and the prefunding limit for the trust.
25. Reports indicating the amount of payments of principal and interest are provided to certificateholders at least as frequently as distributions are made to certificateholders. Certificateholders will also be provided with periodic information statements setting forth material information concerning the underlying assets, including, where applicable, information as to the amount and number of delinquent and defaulted loans or receivables.
26. In the case of a trust that offers and sells certificates in a registered public offering, the trustee, the servicer or the sponsor will file such periodic reports as may be required to be filed under the Securities Exchange Act of 1934. Although some trusts that offer certificates in a public offering will file quarterly reports on Form 10-Q and Annual Reports on Form 10-K, many trusts obtain, by application to the Securities and Exchange Commission (SEC), a complete exemption from the requirement to file quarterly reports on Form 10-Q and a modification of the disclosure requirements for annual reports on Form 10-K. If such an exemption is obtained, these trusts normally would continue to have the obligation to file current reports on Form 8-K to report material developments concerning the trust and the certificates and copies of the statements sent to certificateholders. While the SEC's interpretation of the periodic reporting requirements is subject to change, periodic reports concerning a trust will be filed to the extent required under the Securities Exchange Act of 1934.
27. At or about the time distributions are made to certificateholders, a report will be delivered to the trustee as to the status of the trust and its assets, including underlying obligations. Such report will typically contain information regarding the trust's assets (including those purchased by the trust from any pre-funding account), payments received or collected by the servicer, the amount of prepayments, delinquencies, servicer advances, defaults and foreclosures, the amount of any payments made pursuant to any credit support, and the amount of compensation payable to the servicer. Such report also will be delivered to or made available to the rating agency or agencies that have rated the trust's certificates.

In addition, promptly after each distribution date, certificateholders will receive a statement prepared by the servicer, paying agent or trustee summarizing information regarding the trust and its assets, including underlying receivables. Such statement
will typically contain information regarding payments and prepayments, delinquencies, the remaining amount of the guaranty or other credit support and a breakdown of payments between principal and interest.

## Forward Delivery Commitments

28. To date, no forward delivery commitments have been entered into by McDonald in connection with the offering of any certificates, but McDonald may contemplate entering into such commitments. The utility of forward delivery commitments has been recognized with respect to offering similar certificates backed by pools of residential mortgages, and McDonald may find it desirable in the future to enter into such commitments for the purchase of certificates.

## Secondary Market Transactions

29. It is McDonald's normal policy to attempt to make a market for securities for which it is lead or co-managing underwriter, and it is McDonald's intention to make a market for any certificates for which it is lead or comanaging underwriter, although it is under no obligation to do so. At times McDonald will facilitate sales by investors who purchase certificates if McDonald has acted as agent or principal in the original private placement of the certificates and if such investors request McDonald's assistance.

## Retroactive Relief

30. McDonald represents that it has not engaged in transactions related to mortgage-backed and asset-backed securities based on the assumption that retroactive relief would be granted prior to the date of their application.
However, McDonald requests the exemptive relief granted to be retroactive to January 4, 1999, the date of their application, and would like to rely on such retroactive relief for transactions entered into prior to the date exemptive relief may be granted.

## Summary

31. In summary, the applicant represents that the transactions for which exemptive relief is requested satisfy the statutory criteria of section 408(a) of the Act due to the following:
(a) The trusts contain "fixed pools'" of assets. There is little discretion on the part of the trust sponsor to substitute receivables contained in the trust once the trust has been formed;
(b) In the case where a pre-funding account is used, the characteristics of the receivables to be transferred to the trust during the pre-funding period will
be substantially similar to the characteristics of those transferred to the trust on the closing date, thereby giving the sponsor and/or originator little discretion over the selection process, and compliance with this requirement will be assured by the specificity of the characteristics and the monitoring mechanisms contemplated under the proposed exemption. In addition, certain cash accounts will be established to support the certificate pass-through rate and such cash accounts will be invested in short-term, conservative investments; the prefunding period will be of a reasonably short duration; a pre-funding limit will be imposed; and any Internal Revenue Service requirements with respect to pre-funding intended to preserve the passive income character of the trust will be met. The fiduciary of the plans making the decision to invest in certificates is thus fully apprised of the nature of the receivables which will be held in the trust and has sufficient information to make a prudent investment decision.
(c) Certificates in which plans invest will have been rated in one of the three highest rating categories by a rating agency. Credit support will be obtained to the extent necessary to attain the desired rating;
(d) All transactions for which McDonald seeks exemptive relief will be governed by the pooling and servicing agreement, which is made available to plan fiduciaries for their review prior to the plan's investment in certificates;
(e) Exemptive relief from sections 406(b) and 407 for sales to plans is substantially limited; and
(f) McDonald anticipates that it will make a secondary market in certificates (although it is under no obligation to do so).

Notice to Interested Persons: The applicant represents that any securities offered in reliance upon the proposed exemption prior to the date the final exemption is published in the Federal Register shall disclose in the offering memorandum or prospectus: (a) The availability of the proposed exemption; (b) the right of potentially interested plan fiduciaries to comment on the proposed exemption; and (c) information on how an interested plan fiduciary can obtain a copy of the proposed exemption (once it is available) from McDonald.

Once this proposed exemption is granted, a copy of the exemption published in the Federal Register shall be distributed to any current or prospective plan investor in a security offered in reliance upon the exemption upon request of such investor, and each
offering memorandum or prospectus offering securities in reliance upon the exemption shall describe and disclose the availability of the exemption.

Comments and requests for a hearing must be received by the Department not later than 45 days from the date of publication of this notice of proposed exemption in the Federal Register.
For Further Information Contact: Gary Lefkowitz of the Department, telephone (202) 219-8881. (This is not a toll-free number.)

## General Information

The attention of interested persons is directed to the following:
(1) The fact that a transaction is the subject of an exemption under section 408(a) of the Act and/or section 4975(c)(2) of the Code does not relieve a fiduciary or other party in interest or disqualified person from certain other provisions of the Act and/or the Code, including any prohibited transaction provisions to which the exemption does not apply and the general fiduciary responsibility provisions of section 404 of the Act, which, among other things, require a fiduciary to discharge his duties respecting the plan solely in the interest of the participants and beneficiaries of the plan and in a prudent fashion in accordance with section 404(a)(1)(b) of the Act; nor does it affect the requirement of section 401(a) of the Code that the plan must operate for the exclusive benefit of the employees of the employer maintaining the plan and their beneficiaries;
(2) Before an exemption may be granted under section 408(a) of the Act and/or section 4975(c)(2) of the Code, the Department must find that the exemption is administratively feasible, in the interests of the plan and of its participants and beneficiaries, and protective of the rights of participants and beneficiaries of the plan;
(3) The proposed exemptions, if granted, will be supplemental to, and not in derogation of, any other provisions of the Act and/or the Code, including statutory or administrative exemptions and transitional rules. Furthermore, the fact that a transaction is subject to an administrative or statutory exemption is not dispositive of whether the transaction is in fact a prohibited transaction; and
(4) The proposed exemptions, if granted, will be subject to the express condition that the material facts and representations contained in each application are true and complete, and that each application accurately describes all material terms of the transaction which is the subject of the exemption.

Signed at Washington, DC, this 30th day of March, 2000.
Ivan Strasfeld,
Director of Exemption Determinations, Pension and Welfare Benefits Administration, U.S. Department of Labor.
[FR Doc. 00-8448 Filed 4-6-00; 8:45 am] BILLING CODE 4510-29-P

## LEGAL SERVICES CORPORATION

## Sunshine Act Meeting of the Board of Directors

time and date: The Board of Directors of the Legal Services Corporation will meet on April 15, 2000. The meeting will begin at $10 \mathrm{a} . \mathrm{m}$. and continue until conclusion of the Board's agenda.
location: Marriott Wardman Park Hotel, 2660 Woodley Road, NW, Washington, DC 20008.
status of meeting: Open, except that a portion of the meeting may be closed pursuant to a vote of the Board of Directors to hold an executive session. At the closed session, the Corporation's General Counsel will report to the Board on litigation to which the Corporation is or may become a party, and the Board may act on the matters reported. The closing is authorized by the relevant provisions of the Government in the Sunshine Act [5 U.S.C. 552b(c) (10)] and the corresponding provisions of the Legal Services Corporation's implementing regulation [45 CFR 1622.5(h)]. A copy of the General Counsel's Certification that the closing is authorized by law will be available upon request.

## MATTERS TO BE CONSIDERED:

## Open Session

1. Approval of agenda.
2. Approval of minutes of the Board's meeting of January 28-29, 2000.
3. Approval of minutes of the
executive session of the Board's meeting of January 28-29, 2000.
4. Approval of minutes of the Board's teleconference meeting of January 2829, 2000.
5. Approval of minutes of the Annual Performance Reviews Committee's teleconference meeting of November 19, 1999.
6. Approval of minutes of the Annual Performance Reviews Committee's teleconference meeting of January 24, 2000.
7. Approval of minutes of the

November 19, 1999 meeting of the
Committee on Provision for the Delivery of Legal Services.
8. Approval of minutes of the Operations \& Regulations Committee's meeting of November 19, 1999.
9. Chairman's Report.
10. Members' Report.
11. Inspector General's Report.
12. President's Report.
13. Report on the status of Strategic

Planning by the Corporation.
14. Review of the Corporation's Consolidated Operating Budget, Expenses and Other Funds Available through February 29, 2000.
15. Consider and act on the Board's meeting schedule, including designation of locations, for calendar year 2001.
16. Consider and act on the extension of John McKay's contract of employment as President of the Corporation.

## Closed Session

17. Briefing ${ }^{1}$ by the Inspector General on the activities of the Office of Inspector General.
18. Consider and act on the Office of Legal Affairs' report on potential and pending litigation involving the Corporation.

## Open Session

19. Consider and act on other business.
20. Public Comment.

## CONTACT PERSON FOR INFORMATION:

Victor M. Fortuno, Vice President for Legal Affairs, General Counsel and Secretary of the Corporation, at (202) 336-8800.
SPECIAL NEEDS: Upon request, meeting notices will be made available in alternate formats to accommodate visual and hearing impairments. Individuals who have a disability and need an accommodation to attend the meeting may notify Shannon Nicko Adaway, at (202) 336-8800.

Dated: April 4, 2000.
Victor M. Fortuno,
Vice President for Legal Affairs, General Counsel and Corporate Secretary.
[FR Doc. 00-8745 Filed 4-5-00; 12:45 pm]
BILLING CODE 7050-01-M

## LEGAL SERVICES CORPORATION

## Sunshine Act Meeting; Meeting of the Board of Directors Operations and Regulations Committee

time and date: The Operations and Regulations Committee of the Legal Services Corporation's Board of Directors will meet on April 14, 2000.

[^60]The meeting will begin at $2: 30 \mathrm{p} . \mathrm{m}$. and continue until the Committee concludes its agenda.
location: Marriott Wardman Park
Hotel, 2660 Woodley Road, NW,
Washington, DC 20008.
status of meeting: Open.
mATtERS TO BE CONSIDERED:

1. Approval of agenda.
2. Consider and act on proposed Operations and Regulations Committee procedures.
3. Consider and act on other business.
4. Public Comment.

## CONTACT PERSON FOR INFORMATION:

Victor M. Fortuno, Vice President for Legal Affairs, General Counsel and Secretary of the Corporation, at (202) 336-8800.
SPECIAL NEEDS: Upon request, meeting notices will be made available in alternate formats to accommodate visual and hearing impairments. Individuals who have a disability and need an accommodation to attend the meeting may notify Shannon Nicko Adaway, at (202) 336-8800.

Dated: April 4, 2000.
Victor M. Fortuno,
Vice President for Legal Affairs, General Counsel and Corporate Secretary.
[FR Doc. 00-8746 Filed 4-5-00; 12:45 pm] BILLING CODE 7050-01-P

## LEGAL SERVICES CORPORATION

## Sunshine Act Meeting of the Board of Directors Committee on Provision for the Delivery of Legal Services

time and date: The Committee on Provision for the Delivery of Legal Services of the Legal Services Corporation Board of Directors will meet on April 14, 2000. The meeting will begin at 10:00 a.m. and continue until the Committee concludes its agenda.
location: Marriott Wardman Park Hotel, 2660 Woodley Road, N.W., Washington, DC 20008.
status of meeting: Open.
mATtERS TO BE CONSIDERED:

1. Approval of agenda.
2. Report by Robert Gross, of the

Corporation's Office of Program
Performance, on State Planning.
3. Update by Michael Genz and Glenn Rawdon, of the Corporation's Office of Program Performance, on the Technology Initiatives Grants Process. 4. Report by Michael Genz and Cynthia Schneider, of the Corporation's Office of Program Performance, on the Migrant Workers Legal Services Conference held on March 19-22, 2000, in Boerne, Texas.
5. Consider and act on other business.
6. Public comment.

## CONTACT PERSON FOR INFORMATION:

Victor M. Fortuno, Vice President for Legal Affairs, General Counsel and Secretary of the Corporation, at (202) 336-8800.

SPECIAL NEEDS: Upon request, meeting notices will be made available in alternate formats to accommodate visual and hearing impairments. Individuals who have a disability and need an accommodation to attend the meeting may notify Shannon Nicko Adaway, at (202) 336-8800.

Dated: April 4, 2000.
Victor M. Fortuno,
Vice President for Legal Affairs, General Counsel and Corporate Secretary.
[FR Doc. 00-8747 Filed 4-5-00; 12:45 pm] BILLING CODE 7050-01-P

## NATIONAL SCIENCE FOUNDATION

## Public Affairs Advisory Group; Notice of Meeting

In accordance with the Federal Advisory Committee Act (Pub. L. 92463, as amended), the National Science Foundation announces the following meeting:
Name: Public Affairs Advisory Group (5292).

Date and Time: April 10, 2000, 6 p.m.-9 p.m. (This notice replaces previous submission erroneously listing meeting as April 2, 2000).
Place: 2132 Florida Avenue, NW,
Washington, DC 20008.
Type of Meeting: Open.
Contact Person: Mr. Michael Sieverts, Acting Director, Office of Legislative and Public Affairs, Room 1245, National Science Foundation, 4201 Wilson Boulevard,
Arlington, VA 22230. (703) 306-1070.
Purpose of Meeting: To provide advice and recommendations concerning NSF science and engineering outreach activities.
Agenda: Review of Outreach Programs and Initiatives; Strategic Planning for 2000 and Beyond.
Meeting Minutes: May be obtained from the contact person listed above.
Dated: April 4, 2000.

## Karen J. York,

Committee Management Officer.
[FR Doc. 00-8635 Filed 4-6-00; 8:45 am]
BILLING CODE 7555-01-M

## NUCLEAR REGULATORY COMMISSION

[Docket Nos. 50-003 and 50-247]
Consolidated Edison Company of New York, Inc.; Indian Point Nuclear Generating Units 1 and 2; Notice of Consideration of Approval of Application Regarding Proposed Merger and Opportunity for a Hearing

The U.S. Nuclear Regulatory Commission (the Commission) is considering the issuance of an order under 10 CFR 50.80 approving the indirect transfer of Facility Operating Licenses Nos. DPR-5 and DPR-26 for the Indian Point Nuclear Generating Units 1 and 2 (Indian Point Units 1 and 2), held by Consolidated Edison Company of New York, Inc. (Con Ed). The indirect transfer would be to a new Consolidated Edison, Inc., incorporated in Delaware (New CEI), resulting from the planned merger of Consolidated Edison, Inc. (CEI), the current parent of Con Ed, and Northeast Utilities (NU).

According to a January 13, 2000, application by Con Ed, North Atlantic Energy Service Corporation (NAESCO), and Northeast Nuclear Energy Company (NNECO), for approval of certain indirect license transfers, on October 13, 1999, NU entered into an Agreement and Plan of Merger with CEI. Upon consummation of the merger, NU will become a wholly owned subsidiary of New CEI. In addition, Con Ed, presently a subsidiary of CEI, will become a subsidiary of New CEI. Accordingly, consummation of the merger will effect an indirect transfer of the Indian Point Units 1 and 2 licenses to New CEI. Con Ed owns Indian Point Units 1 and 2 and is authorized to operate the units. Following the merger, Con Ed would continue to have responsibility for the management, operation, and maintenance of the Indian Point Units 1 and 2 and own the facility. No physical changes to Indian Point Units 1 and 2 or operational changes are being proposed. No direct transfer of the licenses will result from the proposed merger.

The application also seeks approval of certain proposed indirect license transfers in connection with the Millstone Nuclear Power Station, Units 1, 2, and 3, and the Seabrook Station, Unit 1, facilities, which will be the subject of separate notices.

Pursuant to 10 CFR 50.80, no license, or any right thereunder, shall be transferred, directly or indirectly, through transfer of control of the license, unless the Commission shall give its consent in writing. The Commission will approve an
application for the indirect transfer of a license, if the Commission determines that the underlying transaction that will effectuate the indirect transfer will not affect the qualifications of the holder of the license, and that the transfer is otherwise consistent with applicable provisions of law, regulations, and orders issued by the Commission pursuant thereto.

The filing of requests for hearing and petitions for leave to intervene, and written comments regarding the license transfer application, are discussed below.

By April 27, 2000, any person whose interest may be affected by the Commission's action on the application may request a hearing, and, if not the applicants, may petition for leave to intervene in a hearing proceeding on the Commission's action. Requests for a hearing and petitions for leave to intervene should be filed in accordance with the Commission's rules of practice set forth in Subpart M, "Public Notification, Availability of Documents and Records, Hearing Requests and Procedures for Hearings on License Transfer Applications," of 10 CFR Part 2. In particular, such requests and petitions must comply with the requirements set forth in 10 CFR 2.1306, and should address the considerations contained in 10 CFR 2.1308(a). Untimely requests and petitions may be denied, as provided in10 CFR 2.1308(b), unless good cause for failure to file on time is established. In addition, an untimely request or petition should address the factors that the Commission will also consider, in reviewing untimely requests or petitions, set forth in 10 CFR 2.1308(b)(1)-(2).

Requests for a hearing and petitions for leave to intervene should be served upon Brent L. Brandenburg, Esq., Consolidated Edison Co. of New York, Inc., 4 Irving Place-1830, New York, NY 10003 (telephone number (212) 4604333 and e-mail address brandenburgb@coned.com), attorney for Consolidated Edison, Inc., William J. Quinlan, Esq., Northeast Utilities, 107 Selden Street, Berlin, CT 06037 (telephone number (860) 665-3761 and e-mail address quinlwj@nu.com), attorney for Northeast Utilities; the General Counsel, U.S. Nuclear Regulatory Commission, Washington, DC 20555 (e-mail address for filings regarding license transfer cases only: OGCLT@NRC.gov); and the Secretary of the Commission, U.S. Nuclear Regulatory Commission, Washington, DC 20555-0001, Attention: Rulemakings and Adjudications Staff, in accordance with 10 CFR 2.1313.

The Commission will issue a notice or II order granting or denying a hearing request or intervention petition, designating the issues for any hearing that will be held and designating the Presiding Officer. A notice granting a hearing will be published in the Federal Register and served on the parties to the hearing.
As an alternative to requests for hearing and petitions to intervene, by May 8, 2000, persons may submit written comments regarding the license transfer application, as provided for in 10 CFR 2.1305. The Commission will consider and, if appropriate, respond to these comments, but such comments will not otherwise constitute part of the decisional record. Comments should be submitted to the Secretary, U.S. Nuclear Regulatory Commission, Washington, DC 20555-0001, Attention: Rulemakings and Adjudications Staff, and should cite the publication date and page number of this Federal Register notice.

For further details with respect to this action, see the application dated January 13,2000 , which is available for public inspection at the Commission's Public Document Room, the Gelman Building, 2120 L Street, NW., Washington, DC, and accessible electronically through the ADAMS Public Electronic Reading Room link at the NRC Website (http:// www.NRC.gov).
Dated at Rockville, Maryland this 3rd day of April 2000.
For the Nuclear Regulatory Commission.
Jefferey F. Harold,
Project Manager, Section 1, Project
Directorate I, Division of Licensing Project
Management, Office of Nuclear Reactor Regulation.
[FR Doc. 00-8629 Filed 4-6-00; 8:45 am] BILLING CODE 7590-01-P

## NUCLEAR REGULATORY COMMISSION

## [Docket No. 50-255]

## Consumers Energy Company (Palisades Plant); Exemption

I
Consumers Energy Company (the licensee) is the holder of Facility Operating License No. DPR-20, which authorizes operation of the Palisades Plant. The facility consists of a pressurized-water reactor at the licensee's site located in Van Buren County, Michigan. The license provides that the licensee is subject to all rules, regulations, and orders of the U.S. Nuclear Regulatory Commission (the Commission) now or hereafter in effect.

The Code of Federal Regulations, 10 CFR part 50, appendix R, "Fire Protection Program For Nuclear Power Facilities Operating Prior To January 1, 1979," Section III.O, "Oil Collection System for Reactor Coolant Pump," requires that primary coolant pumps be equipped with oil collection systems (if the containment is not inerted during normal operation) capable of collecting lube oil from potential leakage sites in the primary coolant pump lube oil systems. Section III.O includes a specific requirement regarding the capacity of the lube oil collection container: "Leakage shall be collected and drained to a vented closed container that can hold the entire lube oil system inventory." The underlying purpose of Section III.O requirements is to provide reasonable assurance that leakage from primary coolant pump lube oil systems will not lead to a fire that could damage safety-related equipment during normal or designbasis accident conditions.

Pursuant to 10 CFR 50.12(a), the Commission may grant exemptions from requirements of 10 CFR Part 50 that are authorized by law, will not present an undue risk to the public health and safety, and are consistent with the common defense and security, provided that special circumstances are present. Pursuant to 10 CFR 50.12(a)(2)(ii), special circumstances are present whenever "application of the regulation in the particular circumstances * * * is not necessary to achieve the underlying purpose of the rule."

## III

The Palisades Plant consists of a twoloop, pressurized water reactor with two primary coolant pumps returning flow from each of the two steam generators to the reactor core. Each of the four primary coolant pumps is powered by a vertical shaft motor with upper and lower bearing assemblies. Each bearing assembly has its own separate lubrication system consisting of an oil reservoir and associated piping. The upper reservoir for each pump motor could contain up to 87 gallons of lube oil, of which 76 gallons would be in the oil reservoir and 11 gallons in the associated piping systems (including lift and backstop pumps and their respective oil coolers). The nominal volume of the lower reservoir is 18 gallons, with no significant volume in the associated piping. Thus, the total inventory of lube oil that each primary coolant pump motor could contain is 105 gallons.

Each of the four primary coolant pump motors has a separate closed and vented oil collection tank to collect oil leakage. Each of the oil collection tanks for the motors of primary coolant pumps $\mathrm{P}-50 \mathrm{~A}, \mathrm{P}-50 \mathrm{~B}$, and $\mathrm{P}-50 \mathrm{C}$ has a usable capacity of 79 gallons, which is insufficient (by 26 gallons) to contain the entire lube oil inventory of the pump motor. There is reasonable assurance that the oil collection systems would withstand a safe shutdown earthquake.
Operating procedures and practices at the Palisades Plant are such that oil spillage due to overflowing an existing collection tank is unlikely. The operating levels in the upper and lower lubricating oil reservoirs must be maintained above a minimum level to keep the bearings properly lubricated during motor operation. The operating level for the upper reservoir is about 20 gallons and the operating level for the lower reservoir is about 5 gallons. Any significant leakage or change in leakage trends would be identified through regular monitoring by control room operators and by oil level alarms. The operators would shut down a primary coolant pump if oil leakage caused either reservoir to reach an operating level low enough to threaten motor bearing damage, or if the lubricating oil level dropped at a rate that would cause concern about safe pump operation. Stopping the pump (and its oil lift pump) would depressurize the leaking lubricating oil system. The cause of the oil leakage would be investigated and repaired, and the collection tank would be pumped out before returning the pump to operation. Stopping a primary coolant pump during reactor operation would result in an immediate reactor shutdown.
In the unlikely event that operators allowed leakage in a primary coolant pump motor's upper oil system to drain the entire system without taking action to stop the pump, approximately 8 gallons of oil could overflow the oil collection tank onto the floor in containment. Approximately 26 gallons could overflow onto the floor in the less likely event that both the upper and lower oil systems were to develop gross leakage simultaneously with no operator action.
Lubricating oil that might overflow an oil collection tank would flow down to lower floor elevations and eventually into the containment sump. The motor oil has a flash point of over $400^{\circ} \mathrm{F}$ and the containment atmosphere is nominally $80^{\circ} \mathrm{F}$ to $100^{\circ} \mathrm{F}$ when the primary coolant pumps are in operation. The oil would not come into contact with any hot pipes, hot equipment
surfaces, or electrical ignition sources in the tank areas or in the flow paths to the sump. Thus, the oil would not become a fire hazard and would drain to a safe location.

By its response to Question 6.2 of Generic Letter 86-10, "Implementation of Fire Protection Requirements," the NRC staff has previously addressed the use of splash shields and the containment sump for the collection tank volume. The NRC staff concluded that, although an exemption would be required, it would be acceptable if the collected overflow of lube oil drained to the sump, and there were no sources of ignition in the area. The NRC staff finds that the exemption requested for the Palisades Plant meets the guidelines for an acceptable exemption as addressed by the NRC staff in Generic Letter 8610.

Accordingly, the usable capacity of the existing lube oil collection tanks for the motors of primary coolant pumps $\mathrm{P}-$ $50 \mathrm{~A}, \mathrm{P}-50 \mathrm{~B}$, and $\mathrm{P}-50 \mathrm{C}$, in conjunction with the low risk associated with minor amounts of potential oil overflow to the containment sump, which would not lead to a fire, satisfies the underlying purpose of Section III.O of Appendix R to 10 CFR 50.
IV
Pursuant to 10 CFR 50.12(a), the Commission has determined that special circumstances exist at the Palisades Plant in that application of the regulation regarding the capacity of lube oil collection containers is not necessary to achieve the underlying purpose of that requirement in Appendix R to 10 CFR part 50. The Commission has also determined that this exemption is authorized by law, will not present an undue risk to public health and safety, and is consistent with the common defense and security. Therefore, the Commission hereby grants the licensee an exemption from the requirements of Section III.O of Appendix R to 10 CFR Part 50 regarding the specified capacity of lube oil collection containers. This exemption applies to the lube oil collection containers for the motors of primary coolant pumps $\mathrm{P}-50 \mathrm{~A}, \mathrm{P}-50 \mathrm{~B}$, and $\mathrm{P}-50 \mathrm{C}$, based on the facts set forth herein.

Pursuant to 10 CFR 51.32, the Commission has determined that the granting of this exemption will have no significant impact upon the quality of the human environment (65 FR 16971).
This exemption is effective upon issuance.
Dated at Rockville, Maryland, this 31st day of March 2000.

For the Nuclear Regulatory Commission. John A. Zwolinski,
Director, Division of Licensing Project Management, Office of Nuclear Reactor Regulation.
[FR Doc. 00-8631 Filed 4-6-00; 8:45 am] BILLING CODE 7590-01-P

## NUCLEAR REGULATORY COMMISSION

[Docket No. 50-443]
North Atlantic Energy Service Corporation, Et Al., Seabrook Station, Unit 1; Notice of Consideration of Approval of Application Regarding Proposed Merger and Opportunity for a Hearing

The U.S. Nuclear Regulatory Commission (the Commission) is considering the issuance of an order under 10 CFR 50.80 approving the indirect transfer of Facility Operating License No. NPF-86 for the Seabrook Station, Unit 1 (Seabrook Station), to the extent held by North Atlantic Energy Corporation (NAEC), Connecticut Light and Power Company (CL\&P), and North Atlantic Energy Service Corporation (NAESCO). The indirect transfer would be to a new Consolidated Edison, Inc., incorporated in Delaware (New CEI), resulting from the planned merger of Consolidated Edison, Inc. (CEI), the current parent of Consolidated Edison Company of New York, Inc. (Con Ed), and Northeast Utilities (NU), the parent company of NAEC, CL\&P, and NAESCO.

According to a January 13, 2000, application by Con Ed, NAESCO, and Northeast Nuclear Energy Company (NNECO) for approval of certain indirect license transfers, on October 13, 1999, NU entered into an Agreement and Plan of Merger with CEI. Upon consummation of the merger, NU will become a wholly owned subsidiary of New CEI. CL\&P, NAEC, and NAESCO are all subsidiaries of NU , and will remain as such following the merger, but will have a new indirect parent, New CEI. Accordingly, consummation of the merger will effect an indirect transfer of the Seabrook Station license to the extent held by the above NU subsidiaries, to New CEI. CL\&P and NAEC hold ownership interests in Seabrook Station and NAESCO is exclusively authorized to operate the unit. NAESCO would remain as the managing agent for the 11 joint owners of the facility and would continue to have exclusive responsibility for the management, operation, and maintenance of the Seabrook Station. The application does not propose a change in the rights, obligations, or
interests of the other nine joint owners of the Seabrook Station. In addition, no physical changes to the Seabrook Station or operational changes are being proposed. No direct transfer of the license will result from the proposed merger.

The application also seeks approval of certain proposed indirect license transfers in connection with the Millstone Nuclear Power Station, Units 1, 2, and 3 and the Indian Point Generating Station, Units 1 and 2 facilities, which will be the subject of separate published notices.

Pursuant to 10 CFR 50.80, no license, or any right thereunder, shall be transferred, directly or indirectly, through transfer of control of the license, unless the Commission shall give its consent in writing. The Commission will approve an application for the indirect transfer of a license, if the Commission determines that the underlying transaction that will effectuate the indirect transfer will not affect the qualifications of the holder of the license, and that the transfer is otherwise consistent with applicable provisions of law, regulations, and orders issued by the Commission pursuant thereto.
The filing of requests for hearing and petitions for leave to intervene, and written comments regarding the license transfer application, are discussed below.

By April 27, 2000, any person whose interest may be affected by the Commission's action on the application may request a hearing, and, if not the applicants, may petition for leave to intervene in a hearing proceeding on the Commission's action. Requests for a hearing and petitions for leave to intervene should be filed in accordance with the Commission's rules of practice set forth in Subpart M, "Public
Notification, Availability of Documents and Records, Hearing Requests and Procedures for Hearings on License Transfer Applications," of 10 CFR part 2. In particular, such requests and petitions must comply with the requirements set forth in 10 CFR 2.1306, and should address the considerations contained in 10 CFR 2.1308(a).
Untimely requests and petitions may be denied, as provided in 10 CFR 2.1308(b), unless good cause for failure to file on time is established. In addition, an untimely request or petition should address the factors that the Commission will also consider, in reviewing untimely requests or petitions, set forth in 10 CFR $2.1308(\mathrm{~b})(1)-(2)$.
Requests for a hearing and petitions for leave to intervene should be served
upon Brent L. Brandenburg, Esq., Consolidated Edison Co. of New York, Inc., 4 Irving Place-1830, New York, NY 10003 (telephone number (212) 4604333 and e-mail address
brandenburgb@coned.com), attorney for Consolidated Edison, Inc., William J. Quinlan, Esq., Northeast Utilities, 107 Selden Street, Berlin, CT 06037 (telephone number (860) 665-3761 and e-mail address quinlwj@nu.com), attorney for Northeast Utilities; the General Counsel, U.S. Nuclear Regulatory Commission, Washington, DC 20555 (e-mail address for filings regarding license transfer cases only: OGCLT@NRC.gov); and the Secretary of the Commission, U.S. Nuclear Regulatory Commission, Washington, DC 20555-0001, Attention: Rulemakings and Adjudications Staff, in accordance with 10 CFR 2.1313.
The Commission will issue a notice or order granting or denying a hearing request or intervention petition, designating the issues for any hearing that will be held and designating the Presiding Officer. A notice granting a hearing will be published in the Federal Register and served on the parties to the hearing.

As an alternative to requests for hearing and petitions to intervene, by May 8 , 2000, persons may submit written comments regarding the license transfer application, as provided for in 10 CFR 2.1305. The Commission will consider and, if appropriate, respond to these comments, but such comments will not otherwise constitute part of the decisional record. Comments should be submitted to the Secretary, U.S. Nuclear Regulatory Commission, Washington, DC 20555-0001, Attention: Rulemakings and Adjudications Staff, and should cite the publication date and page number of the Federal Register notice.
For further details with respect to this action, see the application dated January 13,2000 , which is available for public inspection at the Commission's Public Document Room, the Gelman Building, 2120 L Street, NW., Washington, DC, and Accessible electronically through the ADAMS Public Electronic Reading Room link at the NRC Web site (http:/ /www.NRC.gov).
For the Nuclear Regulatory Commission.
Dated at Rockville, Maryland this 3rd day of April 2000.

## Robert M. Pulsifer,

Project Manager, Section 2, Project Directorate I, Division of Licensing Project Management, Office of Nuclear Reactor Regulation.
[FR Doc. 00-8627 Filed 4-6-00; 8:45 am]
BILLING CODE 7590-01-P

## NUCLEAR REGULATORY COMMISSION

[Docket Nos. 50-245, 50-336, and 50-423]
Northeast Nuclear Energy Company, et al.; Millstone Nuclear Power Station, Units 1, 2, and 3; Notice of Consideration of Approval of Application Regarding Proposed Merger and Opportunity for a Hearing

The U.S. Nuclear Regulatory Commission (the Commission) is considering the issuance of an order under 10 CFR 50.80 approving the indirect transfer of Facility Operating Licenses Nos. DPR-21, DPR-65 and NPF-49 for the Millstone Nuclear Power Station, Units 1, 2, and 3, (Unit 1, Unit 2 , and Unit 3), respectively, to the extent held by Connecticut Light and Power Company (CL\&P), Western Massachusetts Electric Company (WMECO), Northeast Nuclear Energy Company (NNECO), and Public Service Company of New Hampshire (PSNH). The indirect transfer would be to a new Consolidated Edison, Inc., incorporated in Delaware (New CEI), resulting from the planned merger of Consolidated Edison, Inc. (CEI), the current parent of Consolidated Edison Company of New York, Inc. (Con Ed), and Northeast Utilities (NU), the parent company of WMECO, CL\&P, PSNH and NNECO.

According to a January 13, 2000, application by ConEd, NNECO, and North Atlantic Energy Service Corporation (NAESCO) for approval of certain indirect license transfers, on October 13, 1999, NU entered into an Agreement and Plan of Merger with CEI. Upon consummation of the merger, NU will become a wholly owned subsidiary of New CEI. CL\&P, WMECO, NNECO, and PSNH are all subsidiaries of NU, and will remain as such following the merger, but will have a new indirect parent, New CEI. Accordingly, consummation of the merger will effect an indirect transfer of the Millstone Units 1, 2, and 3 licenses to the extent held by the above NU subsidiaries, to New CEI. CL\&P and WMECO hold ownership interests in Units 1 and 2, and NNECO is exclusively authorized to operate both Units as well as Unit 3. CL\&P, WMECO, and PSNH hold ownership interests in Unit 3 along with 11 other co-owners not affiliated with NU. NNECO would remain as the managing agent for the joint owners of the facilities and would continue to have exclusive responsibility for the management, operation, and maintenance of Units 1, 2, and 3. The application does not propose a change in the rights, obligations, or interests of the other 11 joint owners of Unit 3
which are not affiliates of NU. In addition, no physical changes to Units 1,2 , and 3 or operational changes are being proposed. No direct transfer of the licenses will result from the proposed merger.
The application also seeks approval of certain proposed indirect license transfers in connection with Seabrook Station and Indian Point, Units 1 and 2 facilities, which will be the subject of separate published notices.

Pursuant to 10 CFR 50.80, no license, or any right thereunder, shall be transferred, directly or indirectly, through transfer of control of the license, unless the Commission shall give its consent in writing. The Commission will approve an application for the indirect transfer of a license, if the Commission determines that the underlying transaction that will effectuate the indirect transfer will not affect the qualifications of the holder of the license, and that the transfer is otherwise consistent with applicable provisions of law, regulations, and orders issued by the Commission pursuant thereto.

The filing of requests for hearing and petitions for leave to intervene, and written comments regarding the license transfer application, are discussed below.

By April 27, 2000, any person whose interest may be affected by the Commission's action on the application may request a hearing, and, if not the applicants, may petition for leave to intervene in a hearing proceeding on the Commission's action. Requests for a hearing and petitions for leave to intervene should be filed in accordance with the Commission's rules of practice set forth in Subpart M, "Public Notification, Availability of Documents and Records, Hearing Requests and Procedures for Hearings on License Transfer Applications," of 10 CFR Part 2. In particular, such requests and petitions must comply with the requirements set forth in 10 CFR 2.1306, and should address the considerations contained in 10 CFR 2.1308(a).
Untimely requests and petitions may be denied, as provided in 10 CFR 2.1308(b), unless good cause for failure to file on time is established. In addition, an untimely request or petition should address the factors that the Commission will also consider, in reviewing untimely requests or petitions, set forth in 10 CFR 2.1308(b)(1)-(2).

Requests for a hearing and petitions for leave to intervene should be served upon Brent L. Brandenburg, Esq., Consolidated Edison Co. of New York, Inc., 4 Irving Place-1830, New York,

NY 10003 (telephone number (212) 4604333 and e-mail address
brandenburgb@coned.com), attorney for Consolidated Edison, Inc., William J.
Quinlan, Esq., Northeast Utilities, 107 Selden Street, Berlin, CT 06037
(telephone number (860) 665-3761 and e-mail address quinlwj@nu.com), attorney for Northeast Utilities; the General Counsel, U.S. Nuclear Regulatory Commission, Washington, DC 20555-0001 (e-mail address for filings regarding license transfer cases only: OGCLT@NRC.gov); and the Secretary of the Commission, U.S. Nuclear Regulatory Commission, Washington, DC 20555-0001, Attention: Rulemakings and Adjudications Staff, in accordance with 10 CFR 2.1313.
The Commission will issue a notice or order granting or denying a hearing request or intervention petition, designating the issues for any hearing that will be held and designating the Presiding Officer. A notice granting a hearing will be published in the Federal Register and served on the parties to the hearing.
As an alternative to requests for hearing and petitions to intervene, by May 8 , 2000, persons may submit written comments regarding the license transfer application, as provided for in 10 CFR 2.1305. The Commission will consider and, if appropriate, respond to these comments, but such comments will not otherwise constitute part of the decisional record. Comments should be submitted to the Secretary, U.S. Nuclear Regulatory Commission, Washington, DC 20555-0001, Attention: Rulemakings and Adjudications Staff, and should cite the publication date and page number of the Federal Register notice.

For further details with respect to this action, see the application dated January 13,2000 , which is available for public inspection at the Commission's Public Document Room, the Gelman Building, 2120 L Street, NW., Washington, DC, and accessible electronically through the ADAMS Public Electronic Reading Room link at the NRC Web site (http:/ /www.NRC.gov).
Dated at Rockville, Maryland this 3rd day of April 2000.
For The Nuclear Regulatory Commission.

## Victor Nerses,

Senior Project Manager, Section 2, Project Directorate I, Division of Licensing Project Management, Office of Nuclear Reactor Regulation.
[FR Doc. 00-8628 Filed 4-6-00; 8:45 am]
BILLING CODE 7590-01-P

## NUCLEAR REGULATORY COMMISSION

[Docket No. 040-08838]

## Notice of Consideration of Amendment Request for U.S. Army Jefferson Proving Ground Site in Madison, IN and Opportunity for a Hearing

The U.S. Nuclear Regulatory Commission (NRC) is considering issuance of a license amendment to Materials License No. SUB-1435 issued to the U.S. Army (licensee) at the Jefferson Proving Ground (JPG) site in Madison, Indiana. The licensee requested, in a letter dated February 15, 2000, to: (1) Authorize transfer of licensing responsibilities for the Jefferson Proving Ground (JPG) site from the U.S. Army Test and Evaluation Command (TECOM) to the U.S. Army Soldier and Biological Chemical Command (SBCCOM), (2) designate Ms. Joyce E. Kuykendall as the Radiation Safety Officer (RSO) for the site, and (3) include the revised JPG Security Plan in the license.

From 1941 to 1994, the licensee conducted ordnance testing on the JPG site, and fired more than 24 million rounds of conventional explosive. From 1984 to 1994, the licensee conducted accuracy testing of depleted uranium (DU) tank penetrator rounds at the site. An NRC license was issued to authorize the U.S. Army to use, store, and perform testing of DU munitions at JPG. The DU penetrator rounds vary in size but can be generally described as rods comprised of a DU titanium alloy with a diameter of approximately 2.5 centimeters (cm) (1 inch) and a length as much as 61 cm ( 2 feet). The DU munitions testing contaminated approximately $5.1 \times 10^{6}$ square meters $\left(\mathrm{m}^{2}\right)(1260$ acres $)$ of the site with an estimated $7 \times 10^{4}$ kilograms $\left(1.5 \times 10^{5}\right.$ pounds) of DU. In accordance with the Defense Authorization Amendments and Base Realignment and Closure Act of 1988 (Public Law 100-526), the licensee was required to close the JPG base on September 30, 1995. Currently, the licensed material is kept onsite in the restricted area known as the "Depleted Uranium Impact Area." This area is located north of the firing line, and consists of approximately $12 \times 10^{6}$ $\mathrm{m}^{2}$ (3,000 acres).

An NRC administrative review, documented in a letter to the licensee dated March 15, 2000, found the license amendment application acceptable to begin a technical review. The application requested to: (1) Authorize transfer of licensing responsibilities for the JPG site from TECOM to SBCCOM, (2) designate Ms. Joyce E. Kuykendall as
the RSO for the site, and (3) include the revised JPG Security Plan in the license. The NRC Decommissioning Branch is currently changing its policy regarding listing the RSO by name in the license. Instead, the license will include the qualifications that an RSO must meet for the respective site. NRC staff plans to revise the JPG license condition on the RSO accordingly.

If the NRC approves the February 15, 2000, request, the approval will be documented in an amendment to NRC License No. SUB-1435. However, before approving the proposed amendment, the NRC will need to make the findings required by the Atomic Energy Act of 1954, as amended, and NRC's regulations. These findings will be documented in a Safety Evaluation Report and an Environmental Assessment or a Categorical Exclusion.

NRC hereby provides notice that this is a proceeding on an application for an amendment of a license falling within the scope of Subpart L, 'Informal Hearing Procedures for Adjudication in Materials Licensing Proceedings," of NRC's rules of practice for domestic licensing proceedings in 10 CFR Part 2. Pursuant to §2.1205(a), any person whose interest may be affected by this proceeding may file a request for a hearing in accordance with § 2.1205 (d). A request for a hearing must be filed within thirty (30) days of the date of publication of this Federal Register notice.
The request for a hearing must be filed with the Office of the Secretary either:

1. By delivery to Secretary, U.S. Nuclear Regulatory Commission, One White Flint North, 11555 Rockville Pike, Rockville, MD 20852-2738, between 7:45 am and 4:15 pm Federal workdays; or
2. By mail, telegram, or facsimile addressed to the Secretary, U.S. Nuclear Regulatory Commission, Washington,
DC 20555-0001. Attention: Rulemakings and Adjudications Staff.

In accordance with 10 CFR 2.1205(f), each request for a hearing must also be served, by delivering it personally or by mail, to:

1. The applicant, U.S. Army Soldier and Biological Chemical Command, 5183 Black Hawk Road, Aberdeen Proving Ground, MD 21010-5424, Attention: Mr. John M. Ferriter, and;
2. The NRC staff, by delivery to the Executive Director for Operations, U.S. Nuclear Regulatory Commission, One White Flint North, 11555 Rockville Pike, Rockville, MD 20852-2738, between 7:45 am and 4:15 pm Federal workdays, or by mail, addressed to the Executive Director for Operations, U.S.

Nuclear Regulatory Commission, Washington, DC 20555-0001.

In addition to meeting other applicable requirements of 10 CFR Part 2 of NRC's regulations, a request for a hearing filed by a person other than an applicant must describe in detail:

1. The interest of the requester in the proceeding;
2. How that interest may be affected by the results of the proceeding, including the reasons why the requester should be permitted a hearing, with particular reference to the factors set out in §2.1205(h):
3. The requester's areas of concern about the licensing activity that is the subject matter of the proceeding; and
4. The circumstance establishing that the request for a hearing is timely in accordance with § $2.1205(\mathrm{~d})$.
FOR FURTHER INFORMATION CONTACT: The application for license amendment and supporting documentation are available for inspection at NRC's Public
Electronic Reading Room on the NRC web site at http://www.nrc.gov/NRC/ ADAMS/index.html. Questions with respect to this action should be referred to Ms. Sherry W. Lewis,
Decommissioning Branch, Division of Waste Management, Office of Nuclear Material Safety and Safeguards, U.S. Nuclear Regulatory Commission, Washington, DC 20555-0001.
Telephone: (301) 415-6619. Fax: (301) 415-5398.
Dated at Rockville, Maryland, this 3rd day of April 2000.
For the Nuclear Regulatory Commission.

## Robert A. Nelson,

Acting Chief, Decommissioning Branch, Division of Waste Management, Office of Nuclear Material Safety and Safeguards. [FR Doc. 00-8630 Filed 4-6-00; 8:45 am] BILLING CODE 7590-01-P

NUCLEAR REGULATORY COMMISSION

## Advisory Committee on Reactor Safeguards Subcommittee Meeting on Thermal-Hydraulic Phenomena; Notice of Meeting

The ACRS Subcommittee on ThermalHydraulic Phenomena will hold a meeting on April 27, 2000, Room T2B3, 11545 Rockville Pike, Rockville, Maryland.
The agenda for the subject meeting shall be as follows:
Thursday, April 27, 2000-8:30 a.m. until 12 Noon
The Subcommittee will continue discussion of the NRC Code Guideline Documents (Proposed Regulatory Guide
and Standard Review Plan Section). The purpose of this meeting is to gather information, analyze relevant issues and facts, and to formulate proposed positions and actions, as appropriate, for deliberation by the full Committee.

Oral statements may be presented by members of the public with the concurrence of the Subcommittee Chairman. Written statements will be accepted and made available to the Committee. Electronic recordings will be permitted only during those portions of the meeting that are open to the public, and questions may be asked only by members of the Subcommittee, its consultants, and staff. Persons desiring to make oral statements should notify the cognizant ACRS staff engineer named below five days prior to the meeting, if possible, so that appropriate arrangements can be made.

During the initial portion of the meeting, the Subcommittee, along with any of its consultants who may be present, may exchange preliminary views regarding matters to be considered during the balance of the meeting.

The Subcommittee will then hear presentations by and hold discussions with representatives of the NRC staff, and other interested persons regarding this review.

Further information regarding topics to be discussed, whether the meeting has been canceled or rescheduled, and the Chairman's ruling on requests for the opportunity to present oral statements and the time allotted therefor, can be obtained by contacting the cognizant ACRS staff engineer, Mr. Paul A. Boehnert (telephone 301/4158065) between 7:30 a.m. and 4:15 p.m. (EST). Persons planning to attend this meeting are urged to contact the above named individual one or two working days prior to the meeting to be advised of any potential changes to the agenda, etc., that may have occurred.

Dated: March 31, 2000.

## Howard J. Larson,

Acting Associate Director for Technical Support, ACRS/ACNW.
[FR Doc. 00-8430 Filed 4-6-00; 8:45 am] BILLING CODE 7590-01-P

## NUCLEAR REGULATORY COMMISSION

Notice of Issuance of Final Design Approval and Final Safety Evaluation Report, Supplement 1, for AP600 Standard Plant Design Westinghouse Electric Company

The U.S. Nuclear Regulatory
Commission (NRC) has issued

Supplement 1 to the Final Safety Evaluation Report (FSER) related to certification of the AP600 Standard Plant Design. On the basis of the evaluation described in the FSER (NUREG-1512) and Supplement 1 thereto, the NRC staff concludes that the confirmatory issues in NUREG-1512 are resolved, the AP600 design documentation is acceptable, and Westinghouse's application for design certification meets the requirements of Subpart B to 10 CFR Part 52 that are applicable and technically relevant to the AP600 Standard Plant Design.

The NRC has also issued a revised final design approval (FDA) to Westinghouse for the AP600 design under 10 CFR part 52, appendix O. This FDA allows the AP600 design to be referenced in an application for a construction permit or an operating license under 10 CFR Part 50, or an application for a combined license under 10 CFR part 52. The FDA was revised to make it coterminous with the design certification rule that was issued on December 23, 1999 (Appendix C to 10 CFR part 52). This FDA supersedes the FDA dated September 3, 1998.

A copy of the AP600 FDA and Supplement 1 to the FSER have been placed in the NRC's Public Document Room, the Gelman Building, 2120 L Street, NW, Washington DC 20037, for review and copying by interested persons.
Dated at Rockville, Maryland, this 31st day of March 2000.

For the Nuclear Regulatory Commission. Christopher I. Grimes,
Chief, License Renewal and Standardization Branch, Division of Regulatory Improvement Programs, Office of Nuclear Reactor Regulation.
[FR Doc. 00-8632 Filed 4-6-00; 8:45 am] BILLING CODE 7590-01-P

## PENSION BENEFIT GUARANTY CORPORATION

Request for Extension of Approval of a Collection of Information Under the Paperwork Reduction Act; Customer Service Focus Groups and Surveys

AgEncy: Pension Benefit Guaranty Corporation.
ACTION: Notice of request for extension and expansion of OMB approval.
sUMMARY: The Pension Benefit Guaranty Corporation is requesting that the Office of Management and Budget extend and expand its approval of a collection of information under the Paperwork Reduction Act. The purpose of the information collection, which will be
conducted through focus groups and surveys over a three-year period, is to help the PBGC assess the efficiency and effectiveness with which it serves its customers and to design actions to address identified problems.
DATES: Comments should be submitted on or before June 6, 2000.
ADDRESSES: All written comments should be addressed to: Office of Information and Regulatory Affairs, OMB, Attention: Desk Officer for the Pension Benefit Guaranty Corporation, 725 17th Street, NW., Room 10235, Washington, DC 20503-0009. The request for approval of the proposed collection of information will be available for public inspection at the PBGC Communications and Public Affairs Department, suite 240, 1200 K Street, NW., Washington, DC 200054026, between the hours of $9 \mathrm{a} . \mathrm{m}$. and 5 p.m.
FOR FURTHER INFORMATION CONTACT:
Thomas H. Gabriel, Attorney, Office of the General Counsel, Suite 340, 1200 K Street, NW., Washington, DC 20005, 202-326-4024. (For TTY/TDD users, call the Federal relay service toll-free at 1-800-877-8339 and ask to be connected to 202-326-4024.)
SUPPLEMENTARY INFORMATION: An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number.
The PBGC is requesting that OMB extend its approval, for a three-year period, of a generic collection of information consisting of customer satisfaction focus groups and surveys (OMB No. 1212-0053; expires July 31, 2002). The PBGC also is requesting that OMB expand its approval to encompass a broader range of surveys than those approved under 1212-0053, which provided for surveys only as an adjunct to focus groups. The expanded information collection will further the goals of Executive Order 12862, Setting Customer Service Standards, which states the Federal Government must seek to provide "the highest quality of service delivered to customers by private organizations providing a comparable or analogous service."
The PBGC uses customer satisfaction focus groups and surveys to find out about the needs and expectations of its customers and assess how well it is meeting those needs and expectations. By keeping these avenues of communication open, the PBGC can continually improve service to its customers, including plan participants and beneficiaries, plan sponsors and their affiliates, plan administrators,
pension practitioners, and others involved in the establishment, operation and termination of plans covered by the PBGC's insurance program. Because the areas of concern to the PBGC and its customers vary and may quickly change, it is important that the PBGC have the ability to evaluate customer concerns quickly by developing new vehicles for gathering information under this generic approval. The focus groups and surveys will provide important information on customer attitudes about the delivery and quality of agency services and will be used as part of an ongoing process to improve PBGC programs. The PBGC is including in this information collection two surveys previously approved by OMB (OMB Approval Nos. 1212-0056 and 1212-0058).

Participation in the focus groups and surveys will be voluntary. The PBGC estimates that the average annual burden will total 2,500 burden hours for 9,500 respondents (an average of about one-quarter hour per respondent). The PBGC will consult with OMB regarding each specific information collection during the approval period.

On December 10, 1999, the PBGC published in the Federal Register a notice of intention to request extension of OMB approval of this collection. No comments were received in response to the notice.

Issued at Washington, D.C., this 31st day of March, 2000.
Stuart A. Sirkin,
Director, Corporate Policy and Research Department, Pension Benefit Guaranty Corporation.
[FR Doc. 00-8584 Filed 4-6-00; 8:45 am]
BILLING CODE 7708-01-P

## SECURITIES AND EXCHANGE COMMISSION

## Submission for OMB Review; Comment Request

Upon Written Request Copies Available From: Securities and Exchange Commission, Office of Filings and Information Services, Washington, DC 20549.

Extension: Form N-23C-1; SEC File No. 270-230; OMB Control No. 32350230.

Notice is hereby given that, pursuant to the Paperwork Reduction Act of 1995 (44 U.S.C. 3501-3520), the Securities and Exchange Commission (the "Commission") has submitted to the Office of Management and Budget ("OMB") a request for extension and approval on the collection of information discussed below.

Section 23(c) of the Investment Company Act of 1940 [15 U.S.C. 80a23(c)] ("Investment Company Act" or "Act") prohibits a registered closed-end investment company ("closed-end fund" or "fund") from purchasing any security it issues except on a securities exchange, pursuant to tender offers, or under such other circumstances as the Commission may permit by rules or orders designed to ensure that purchases are made in a manner that does not unfairly discriminate against any holders of the securities to be purchased. Rule 23c-1 [17 CFR 270.23c-1] under the Act permits a closed-end fund that meets certain requirements to repurchase its securities other than on an exchange or pursuant to a tender.
A registered closed-end fund that relies on rule 23c-1 may purchase its securities for cash if, among other conditions set forth in the rule, certain conditions are met:

- Payment of the purchase price is accompanied or preceded by a written confirmation of the purchase;
- The purchase is made at a price not above the market value, if any, or the asset value of the security, whichever is lower, at the time of the purchase; and
- If the security is stock, the issuer has, within the preceding six months, informed stockholders of its intention to purchase stock of the class by letter or report addressed to all the stockholders of the class.
In addition, the issuer must file with the Commission, on or before the tenth day of the month following the date in which the purchase occurs, two copies of Form $\mathrm{N}-23 \mathrm{C}-1$. The form requires the issuer to report all purchases in has made during the month, together with a copy of any written solicitation to purchase securities under rule 23c-1 sent or given during the month by or on behalf of the issuer to ten or more persons.

The purpose of rule $23 \mathrm{c}-1$ is to protect shareholders of closed-end funds from fraud in connection with the repurchase by funds of their own securities. The purpose of the rule's requirement that the fund file Form N $23 \mathrm{C}-1$ with the Commission is to allow the Commission to monitor funds' repurchase of securities as well as any written solicitation used by the fund to effect those repurchases, and to make that information available to the public. Investors may seek this information when determining whether to invest in certain funds.
The requirements to file Form $\mathrm{N}-$ $23 \mathrm{C}-1$ applies to a closed-end fund only when the fund has repurchased its securities. If the information provided
in the form were collected less frequently than a month after repurchases occur, the Commission and investing public would lack current information about closed-end funds that repurchase their own securities.

Commission staff estimates that each year approximately 19 closed-end funds use the repurchase procedures under rule $23 \mathrm{c}-1$, and that these funds file a total of 115 forms each year. ${ }^{1}$ The number of forms filed by each fund ranges from 1 to 12 depending on the number of months in which the fund repurchases its securities under rule $23 \mathrm{c}-1$. Commission staff estimates that each response requires 1 burden hour to prepare and file Form $\mathrm{N}-23 \mathrm{C}-1$ with a copy of any written solicitation to purchase securities under the rule (if necessary). Commission staff estimates each burden hour consists of 15 minutes of professional time and 45 minutes of support staff time. ${ }^{2}$ Commission staff further estimates that each of the 19 funds expends between 1 and 12 hours annually in filing Form N-23C-1. The total annual burden of the rule's paperwork requirements is estimated to be 115 hours.
These estimates represent an increase of 92 hours from the prior estimate of 23 hours. The increase results primarily from the increase in the number of funds relying on the rule to purchase their securities. At the time of the last submission the Commission estimated that 4 funds filed a total of 23 Form N$23 \mathrm{C}-1$ s annually with the Commission (with each fund filing between 1 and 12 forms during the year). In 1999, 19 funds filed 115 forms with the Commission.
The estimate of average burden hours is made solely for the purposes of the Paperwork Reduction Act. The estimate is not derived from a comprehensive or even a representative survey or study of the costs of Commission rules and forms.

Compliance with the collection of information requirements of the rule and form is necessary to obtain the benefit of relying on the rule and form. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid control number.
Please direct general comments regarding the above information to the following persons: (i) Desk Officer for the Securities and Exchange

[^61]Commission, Office of Information and Regulatory Affairs, Office of
Management and Budget, Room 3208, New Executive Office Building, Washington, DC 20503; and (ii) Michael E. Bartell, Associate Executive Director, Office of Information Technology, Securities and Exchange Commission, 450 5th Street, NW, Washington, DC 20549. Comments must be submitted to OMB within 30 days of this notice.

Dated: March 30, 2000.
Margaret H. McFarland,
Deputy Secretary.
[FR Doc. 00-8617 Filed 4-6-00; 8:45 am]
BILLING CODE 8010-01-M

## SECURITIES AND EXCHANGE COMMISSION

[Rel. No. IC-24374; File No. 812-11888]

## Alexander Hamilton Life Insurance Company of America, et al.

April 3, 2000.
AGENCY: Securities and Exchange
Commission (the "Commission" or "SEC").
ACTION: Notice of application for an order pursuant to Section 26(b) of the Investment Company Act of 1940 (the "1940 Act") approving a substitution of underlying fund shares (the
"Substitution") and pursuant to Section 17(b) of the 1940 Act exempting certain in-kind transactions from Section 17(a) of the 1940 Act in connection with the Substitution.

SUMMARY OF APPLICATION: Applicants request an order to permit certain registered unit investment trusts to substitute shares of the S\&P 500 Index Portfolio (the "JPVF 500 Portfolio") of the Jefferson Pilot Variable Fund, Inc. ("JPVF") for shares of the Fidelity Index 500 Portfolio (the "Fidelity 500 Portfolio'") of the Fidelity Variable Insurance Products Fund II ("FVIPF II'") currently held by those unit investment trusts, and to permit certain in-kind redemptions of portfolio securities in connection with the Substitution.
applicants: Alexander Hamilton Life Insurance Company of America ("AH Life"'), Alexander Hamilton Variable Annuity Separate Account ("AH Separate Account"), Jefferson Pilot Financial Insurance Company ("Jefferson Pilot Financial"), JPF Separate Account A ("JPF Account A"), JPF Separate Account C ("JPF Account C'), Jefferson Pilot LifeAmerica Insurance Company ("JP LifeAmerica"), JPF Separate Account B ("JPF Account B"), Jefferson-Pilot Life Insurance Company ("JP Life"), Jefferson-Pilot

Separate Account A ("JP Life Account A") and Jefferson Pilot Investment Advisory Corporation ("Jefferson Pilot Advisory")(collectively, the "Applicants").
FILING DATE: The application was filed on December 15, 1999, and amended and restated on March 8, 2000.
hearing or notification of hearing: An order granting the application will be issued unless the Commission orders a hearing. Interested persons may request a hearing by writing to the Secretary of the Commission and serving Applicants with a copy of the request, personally or by mail. Hearing requests should be received by the Commission by 5:30 p.m. on April 27, 2000, and should be accompanied by proof of service on Applicants, in the form of an affidavit or, for lawyers, a certificate of service. Hearing requests should state the nature of the writer's interest, the reason for the request, and the issues contested.
Persons who wish to be notified of a hearing may request notification by writing to the Secretary of the Commission.
ADDRESSES: Secretary, Securities and Exchange Commission, 450 Fifth Street NW 20549-0609. Applicants: c/o Jefferson Pilot Financial Insurance Company, One Granite Place, Concord, New Hampshire 03301, Attn: Shari J. Lease, Esq.
FOR FURTHER INFORMATION CONTACT: Kevin P. McEnery, Senior Counsel, or Susan M. Olson, Branch Chief, Office of Insurance Products, Division of Investment Management, at (202) 9420670.

SUPPLEMENTARY INFORMATION: The
following is a summary of the application. The complete application is available for a fee from the SEC's Public Reference Branch, 450 Fifth Street, NW, Washington, DC 20549-0102 (tel. (202) 942-8090).

## Applicants' Representations

1. AH Life is a stock life insurance company organized under the insurance laws of the State of Michigan in 1963. AH Life commenced operations on October 31, 1964, and is engaged primarily in the sale of annuity contracts and life insurance policies. AH Life is authorized to write annuities and life insurance in Canada, the District of Columbia, and all states except New York. Jefferson Pilot is a stock life insurance company chartered in 1903 in Tennessee. Prior to May 1, 1998, Jefferson Pilot Financial was known as Chubb Life Insurance Company of America ("Chubb Life"). In 1991 Chubb Life redomesticated from

Tennessee to New Hampshire and is now a New Hampshire life insurance company. Jefferson Pilot Financial is engaged primarily in the sale of annuities and life insurance. Jefferson Pilot Financial is authorized to write annuities and life insurance in 49 states, Puerto Rico, the U.S. Virgin Islands, Guam and the District of Columbia. JP LifeAmerica is a stock life insurance company chartered in 1897 in New Jersey. Prior to May 1, 1998, JP LifeAmerica was known as Chubb Colonial Life Insurance Company. JP LifeAmerica is engaged primarily in the sale of annuities and life insurance and writes individual life contracts, as well as group life policies. JP LifeAmerica is licensed to sell life insurance in all States, Puerto Rico, the U.S. Virgin Islands, Guam and the District of Columbia. JP Life is a stock life insurance company organized under the insurance laws of North Carolina in 1890. JP Life is primarily engaged in the writing of whole life, term, endowment, and annuity policies on an individual ordinary basis, plus industrial and group insurance. JP Life is authorized to write annuities and other insurance in the Virgin Islands, Puerto Rico, the District of Columbia, and all States except New York. These four life insurance companies are referred to in the application and herein as the "Life Company Applicants," and they are affiliated companies wholly-owned by Jefferson-Pilot Corporation, a North Carolina corporation.
2. AH Separate Account is a segregated asset account of AH Life. It was established by AH Life pursuant to a resolution of its Board of Directors on January 24, 1994, in accordance with the laws of Michigan and is registered as a unit investment trust under the 1940 Act. AH Life issues certain variable annuity contracts through the AH Separate Account.
3. JPF Account A was established by Jefferson Pilot Financial pursuant to a resolution of its Board of Directors on August 20, 1984 in accordance with laws of New Hampshire and is registered as a unit investment trust under the 1940 Act. JPF Account A is used to fund certain variable life insurance policies issued by Jefferson Pilot Financial.
4. JPF Account C is a segregated asset account of Jefferson Pilot Financial. It was established by Jefferson Pilot Financial pursuant to a resolution of its Board of Directors on August 3, 1993, in accordance with the laws of New Hampshire and is registered as a unit investment trust under the 1940 Act. JPF Account C is used to fund certain
variable life insurance policies issued by Jefferson Pilot Financial.
5. JPF Account B is a segregated asset account of JP LifeAmerica. It was established by JP LifeAmerica pursuant to a resolution of its Board of Directors on March 2, 1994, in accordance with the laws of New Jersey and is registered as a unit investment trust under the 1940 Act. JPF Account B is used to fund certain variable life insurance policies issued by JP LifeAmerica.
6. JP Life Account A is a segregated asset account of JP Life. Its predecessor was established pursuant to a resolution of the Board of Directors of JP Life on May 13, 1969. JP Life Account A was established under the laws of North Carolina and is registered as a unit investment trust under the 1940 Act. JP Life Account A is used to fund certain variable annuity contracts issued by JP Life.
7. The above described segregated asset accounts are referred to in the application and herein as the "Separate Account Applicants." The variable annuity and variable life contracts issued by the Life Company Applicants (through the Separate Account Applicants) that would be affected by the Substitution are referred to in the application and herein as the "Contracts." ${ }^{1}$ Each of the Contracts permits Contractowners to make a number of transfers between and among the sub-accounts of the respective Separate Account Applicant per contract or policy year and does not impose a transfer fee or charge on a number of such transfers.
8. Jefferson Pilot Advisory (formerly, Chubb Investment Advisory
Corporation) is the investment adviser to the Jefferson Pilot Variable Fund, Inc. ("JPVF"), which is registered as an open-end management investment company under the 1940 Act and which was incorporated in Maryland on October 19, 1984, and each of its portfolios. One of these portfolios is the S\&P 500 Index Portfolio (the "JPVF 500 Portfolio'’). Jefferson Pilot Advisory is a corporation organized under the laws of

[^62]Tennessee in 1984 and is registered as an investment adviser under the Investment Advisers Act of 1940. Jefferson Pilot Advisory is a whollyowned subsidiary of Jefferson-Pilot Corporation. Jefferson Pilot Advisory has obtained an SEC order granting relief from Section 15(a) of the 1940 Act and certain other provisions (the "JPVF Order"') permitting it to manage JPVF's portfolios pursuant to a "manager-ofmanagers" arrangement. ${ }^{2}$ Pursuant to the JPVF Order, Jefferson Pilot Advisory may, subject to certain conditions, including approval of the Board of JPVF, and without the approval of shareholders, (a) employ a new subadviser or sub-advisers for any portfolio of JPVF pursuant to terms of a new investment advisory agreement, in each case either as a replacement for an existing sub-adviser or as an additional sub-adviser; (b) change the terms of any investment advisory agreement pertaining to a sub-adviser; and (c) continue the employment of an existing sub-adviser on the same contract terms where a contract has been assigned because of a change of control of the sub-adviser. In such circumstances, Contractowners would receive notice of any such action, including information concerning any new sub-adviser that normally is provided in proxy materials.
9. The Fidelity Index 500 Portfolio ("Fidelity 500 Portfolio" or the "Replaced Fund") is a series of the Fidelity Variable Insurance Products Fund II ("FVIPF II'), an open-end management investment company established as a Massachusetts business trust under a Declaration of Trust dated March 21, 1988. Shares of the Fidelity 500 Portfolio are currently available only through the purchase of variable annuity and variable life insurance contracts and through certain tax qualified retirement plans. Fidelity Management \& Research Company ("FMR") acts as the Fidelity 500 Portfolio's investment adviser and has retained Bankers Trust Company ("BTC") to serve as sub-adviser to the Fidelity 500 Portfolio. The Fidelity 500 Portfolio is an investment option under each of the Contracts.

[^63]10. Applicants state that the Fidelity 500 Portfolio seeks investment results that correspond to the total return of common stocks publicly traded in the United States as represented by the Standard \& Poor's 500 Composite Stock Price Index ('S\&P 500 Index'’). Under normal circumstances, the Fidelity 500 Portfolio intends to invest at least $80 \%$ of its assets in common stocks included in the S\&P 500 Index. The Fidelity 500 Portfolio seeks to achieve a $98 \%$ or better correlation between its total return, before fees and expenses, and the total return of the S\&P 500 Index.
11. Applicants state that the JPVF 500 Portfolio was established pursuant to a resolution of the JPVF's Board of Directors at a Board meeting held on February 7, 2000. Applicants represent that JPVF filed a post-effective amendment to its registration statement on February 16, 2000 to register shares of the JPVF 500 Portfolio. The Substitution proposed by the application cannot go forward unless and until the post-effective amendment relating to JPVF 500 Portfolio's shares becomes effective. Upon such effectiveness, shares of JPVF 500 Portfolio will be offered only to corresponding sub-accounts of separate accounts established by the Life Company Applicants and in the future may be offered to other insurance companies, including insurance companies that are not affiliated with the Life Company Applicants. Jefferson Pilot Advisory will serve as investment manager of the JPVF 500 Portfolio and will retain Barclays Global Investors ('Barclays') to act as sub-adviser to the JPVF 500 Portfolio.
12. As disclosed in the post-effective amendment, the JPVF 500 Portfolio's investment objective is to seek to approximate as closely as practicable, before fees and expenses, the total rate of return of common stock publicly traded in the United States, as represented by the S\&P 500 Index. The JPVF 500 Portfolio will pursue its objective by investing in all the securities that make up the S\&P 500 Index and by investing in these securities in proportions that match their index weights, although the Portfolio reserves the right not to invest in every security in the S\&P 500 Index if it is not practical to do so under the circumstances. The JPVF 500 Portfolio may also invest in stock index futures as a substitute for a comparable market position in the securities underlying the S\&P 500 Index.
13. Applicants represent that the fees of the Fidelity 500 Portfolio were as follows. There is an annual management fee of $.24 \%$, and operating expenses for
the fiscal year ending December 31, 1998 were $.11 \%$. Applicants state that since the Fidelity 500 Portfolio is subject to an expense cap of $.28 \%, 07 \%$ of such expenses were reimbursed and shareholders were assessed annual fees of $.28 \%$ for that fiscal year. The Fidelity 500 Portfolio's expense cap is a noncontractual voluntary cap which may be terminated at any time. Applicants represent that, as to the JPVF 500 Portfolio, like the Fidelity 500 Portfolio, there will be an annual management fee of $.24 \%$. Annual operating expenses are anticipated to be . $10 \%$. Like the Fidelity 500 Portfolio, the JPVF 500 Portfolio will also be subject to an expense cap of $.28 \%$. Therefore, Jefferson Pilot Advisory would reimburse the JPVF 500 Portfolio $.06 \%$ of its expenses to maintain annual expenses at no greater than $.28 \%$. Like the Fidelity 500 Portfolio's expense cap, the JPVF 500 Portfolio's expense cap will be a noncontractual voluntary cap which can be terminated at any time. However, Applicant Jefferson Pilot Advisory has represented that it will waive investment management fees and reimburse expenses to the extent necessary to keep annual fees of the JPVF 500 Portfolio from exceeding . $28 \%$ of the average daily net assets through April 30, 2001.
14. Applicants represent that, as of June 30, 1999, the Fidelity 500 Portfolio had assets of approximately $\$ 8.3$ billion. Since the JPVF 500 Portfolio will be a newly organized fund, it presently does not have any assets and will not have any assets prior to the Substitution. Applicants further represent that they anticipate, based on current figures, that $\$ 150$ million in assets attributable to the Contracts would be invested in the Replacement Fund upon the consummation of the Substitution. Jefferson Pilot Advisory and Barclays have determined that the assets that will initially comprise the JPVF 500 Portfolio (whether redemptions are effected for cash and/or portfolio securities) upon consummation of the Substitution are entirely sufficient for purposes of meeting the JPVF 500 Portfolio's objectives and that the JPVF 500 Portfolio will not be disadvantaged in any way by virtue of its smaller initial asset base as compared with the present asset base of the Fidelity 500 Portfolio.
15. Applicants represent that Barclays presently manages a publicly available S\&P 500 fund called the Barclays Global Investors S\&P 500 Fund ("Barclays S\&P 500 Fund'"), a series of Barclays Global Investors fund, Inc., that has assets of approximately $\$ 2.6$ billion as of August 31, 1999. The Barclays S\&P 500 Fund seeks to approximate as closely as
practicable, before fees and expenses, the capitalization-weighted total return of the S\&P 500 Index. The Barlcays S\&P 500 Fund pursues its objectives by investing in all the securities that make up the S\&P 500 Index and by investing in these securities in proportions that match their index weights. The Barclays S\&P 500 Fund seeks to come within $95 \%$ of the total return of the S\&P 500 Index, before fees and expenses, in falling as well as rising markets and does not seek to "beat" the market and does not seek temporary defensive positions when markets appear overvalued. It is anticipated that Barclays would "bunch" orders for the purchase and sale of securities for the JPVF 500 Portfolio with the publicly available Barclays S\&P 500 Fund under appropriate circumstances, and subject to any regulatory requirements. Accordingly, the asset base of the publicly available Barclays S\&P 500 Fund managed by Barclays will afford the JPVF 500 Portfolio certain economies of scale and other tangible benefits.
16. Applicants state that the prospectuses by which the Contracts were offered reserve to the respective Life Company Applicants the right to replace the shares of any underlying registered investment company held by the applicable Separate Account Applicant with shares of another registered investment company, provided any such substitution is approved by the SEC to the extent required by applicable law.
17. The Life Company Applicants propose to redeem all of the shares of the Fidelity 500 Portfolio they currently hold on behalf of the Separate Account Applicants at the close of business on the effective date of the Substitution. Applicants state that, in connection with such redemptions and the purchase of portfolio securities by the JPVF 500 Portfolio, the Fidelity 500 and JPVF 500 Portfolios would normally incur brokerage costs as the Fidelity 500 Portfolio would have to dispose of portfolio securities to satisfy redemption requests and the JPVF 500 Portfolio would have to purchase securities with the redemption proceeds. In order that such costs can be avoided, the redemption of shares of the Fidelity 500 Portfolio may be effected in whole or in part for portfolio securities (i.e., "inkind" redemptions). Applicants state that to this end, at the effective date of the Substitution, the Fidelity 500 Portfolio will transfer to the Separate Account Applicants portfolio securities held by the Fidelity 500 Portfolio, and the Separate Account Applicants will purchase shares of the JPVF 500

Portfolio with these portfolio securities. Applicants represent that in connection with the proposed in-kind redemption transactions, the JPVF 500 Portfolio and the Separate Account Applicants will comply with the requirements of Rule 17a-7 under the 1940 Act and pertinent SEC no action letters and the procedures JPVF and the Separate Account Applicants have established thereunder. ${ }^{3}$ Applicants state that, in view of the identity of investment objectives and policies of both Portfolios and the above noted cost savings anticipated to be derived from in-kind redemption transactions, they have determined such transactions would be appropriate. Applicants state that the valuation of any in-kind redemptions will be made on a basis consistent with the normal valuation procedures of the Fidelity 500 Portfolio and the normal valuation procedures of the JPVF 500 Portfolio, as provided in those Portfolios' established valuation procedures. Applicants state that it is presently anticipated that $100 \%$ of the redemption orders of the Separate Account Applicants will be effected on an in-kind basis, and, thus, there will be no brokerage costs. To the extent that the Substitution requires the purchase of portfolio securities, the Life Company Applicants and/or Jefferson Pilot Advisory will pay the related brokerage costs.
18. Applicants state that in all cases, the Life Company Applicants on behalf of their respective Separate Account Applicants will simultaneously place redemption requests with the Fidelity 500 Portfolio and purchase orders with the JPVF 500 Portfolio so that purchases will be for the exact amount of the redemption proceeds. As a result, at all times, monies attributable to Contractowners who have allocated value to the Fidelity 500 Portfolio will remain fully invested.
19. Applicants represent that the full net asset value of the redeemed shares held by the Separate Account Applicants will be reflected in Contractowners' accumulation unit or

[^64]annuity unit values following the Substitution. The Life Company Applicants represent that they will assume all transaction costs and expenses relating to the Substitution.
20. The Life Company Applicants have determined, for reasons based upon administrative, economic and marketing concerns, to use a proprietary mutual fund to serve as the S\&P 500 fund that will serve as an underlying investment option for the Contracts, as well as other variable life and variable annuity contracts which they may offer in the future. Applicants state that the proposed Substitution will allow the Life Company Applicants to maintain a greater proprietary identity between their variable products and the S\&P 500 investment option, which historically has been one of the most popular investment options among Contractowners. The proposed Substitution will afford the Life Company Applicants greater control with respect to administrative and compliance issues over this investment option and afford Jefferson Pilot Advisory the ability to make sub-adviser changes when necessary or appropriate as consistent with the above-noted manager-of-managers arrangement, subject to the conditions as set forth in the application.
21. Applicants also believe that Jefferson Pilot Advisory, as an affiliate of each Life Company Applicants, will have greater incentive to provide superior shareholder services to Contractowners. Correspondingly, the Life Company Applicants will have greater opportunity to contribute to and review the adequacy of the services being provided in connection with this investment option. Given the relative simplicity involved in managing an S\&P 500 fund, Applicants believe that when comparing two S\&P 500 funds which have the same fee structures and which are managed by experienced and suitable investment advisers, the difference between the respective funds lies mainly in the nature and quality of the non-advisory services provided by management of the respective funds. In this regard, Applicants believe Contractowners will be better served if the S\&P 500 fund becomes a proprietary fund.
22. Applicants state that their desire to effect the Substitution also relates, in part, to BTC's role as sub-adviser to the Fidelity 500 Portfolio. Applicants represent that BTC has recently experienced turnover of portfolio management personnel which included the departure of the team which managed the Fidelity 500 Portfolio. Applicants believe that these events are
the kind of events that can be better managed for the benefit of Contractowners by including the JPVF 500 Portfolio in the funds over which Jefferson Pilot Advisory has overall management authority. Applicants further represent BTC recently encountered certain compliance problems that will require a permanent order to exemption issued by the SEC under Section 9(c) of the 1940 Act to permit it to continue to serve as an investment adviser to registered mutual funds. Applicants state that the substance of these compliance problems presently must be disclosed in the Fidelity 500 Portfolio's prospectus and will continue to be disclosed therein in the future. The Life Company Applicants find this type of disclosure to be troubling in connection with underlying mutual funds that serve as investment vehicles for their products.
23. Applicants represent that each of the Life Company Applicants supplemented the prospectus for its applicable Separate Account Applicant at the time of filing of the original application to reflect the proposed Substitution and its essential terms and mailed such supplement to Contractowners at that time. The supplement informed Contractowners (among other things) that they have the right to transfer amounts allocated to the Fidelity 500 Portfolio to any other investment option available under the Contracts at any time prior to the Substitution, and for a period of 31 days after the Substitution, and that any such transfer would not count toward the number of free transfers permitted in a Contract year. Within five (5) days after the Substitution, the Life Company Applicants will send to their respective Contractowners a written notice ("Notice") of the Substitution, identifying the shares of the Replaced Fund that have been eliminated and the shares of the Replacement Fund that have been substituted and other relevant information. The Applicants will include in such mailing the prospectus for the Replacement Fund and the applicable revised prospectus or supplement for the Contracts describing the Substitution.
24. Contractowners will be advised in the Notice that for a period of thirty-one (31) days from the mailing of the Notice, Contractowners may transfer any substituted assets to any other subaccount available under their Contracts without limitation or charge and without any such transfer counting as one of the free transfers permitted per

Contract year (the "Free Transfer Period"). ${ }^{4}$
25. Prior to effecting the Substitution, Applicants state that they will have satisfied themselves, based on advice of counsel familiar with insurance laws, that the Contracts allow the Substitution as described in the application, and that the transactions can be consummated as described therein under applicable insurance laws and under the Contracts.
26. Applicants further state that, prior to effecting the Substitution, they will have complied with any regulatory requirements they believe are necessary to complete the transactions in each jurisdiction where the Contracts are qualified for sale.

## Applicants' Legal Analysis

## 1. Section 26(b) of the 1940 Act

 provides that " $[i] t$ shall be unlawful for any depositor or trustee of a registered unit investment trust holding the security of a single issuer to substitute another security for such security unless the [SEC] shall have approved such substitution." Section 26(b) of the 1940 Act was enacted as part of the Investment Company Act Amendments of 1970. Prior to the enactment of these amendments, a depositor of a unit investment trust could substitute new securities for those held by the trust by notifying the trust's security holders of the substitution within five (5) days after the substitution. In 1966, the SEC, concerned with the high sales charges then common to most unit investment trusts and the disadvantageous position in which such charges placed investors who did not want to remain invested in the substituted security, recommended that Section 26 be amended to require that a proposed substitution of the underlying investments of a trust receive prior SEC approval. Congress responded to the SEC's concerns by enacting Section 26(b) to require that the Commission approve all substitutions by the depositor of investments held by unit investment trusts. As the legislative history makes clear, Congress intended Section 26(b) to provide SEC scrutiny of proposed substitutions which could otherwise, in[^65]effect, force shareholders dissatisfied with the substituted security to redeem their shares, thereby possibly incurring either a loss of the sales load deducted from initial purchase payments, an additional sales load upon reinvestment of the proceeds of redemption, or both.
2. Applicants submit that the purposes, terms, and conditions of the Substitution are consistent with the principles and purposes of Section 26(b) and do not entail any of the abuses that Section 26(b) is designed to prevent. Applicants assert that, simply put, Contractowners will be assessed no charges whatsoever in connection with the Substitution and their annual fund level charges will not increase. In addition, to the extent a Contractowner does not wish to participate in the Substitution, he or she is free to transfer to any other option available under the relevant Contract prior to the Substitution and after the Substitution during the Free Transfer Period, without such transfer counting toward the number of free transfers permitted per year under a Contract. Applicants assert that Contractowners will be substituted into a fund whose investment objectives, policies and expenses are substantially identical in all material respects to those of the Replaced Fund. Finally, Applicants have concluded that it would be appropriate and in the best interests of Contractowners to have a proprietary S\&P 500 mutual fund underlying their variable products.
3. Applicants submit that the Substitution presents none of the harms that Section 26(b) was intended to guard against and is consistent with the protection of investors and the purposes fairly intended by the 1940 Act for the following reasons:
(1) the Replacement Fund has objectives, policies, and restrictions substantially identical in all material respects to the objectives, policies, and restrictions of the Replaced Fund so as to continue to fulfill the Contractowners' objectives and risk expectations;
(2) after receipt of the Notice informing a Contractowner of the Substitution, a Contractowner may request that his or her assets be reallocated to another subaccount at any time during the Free Transfer Period. The Free Transfer Period provides sufficient time for Contractowners to consider their reinvestment options;
(3) the Substitution will be at net asset value of the respective shares, without the imposition of any transfer or similar charge;
(4) the Life Company Applicants have undertaken to assume all expenses and transaction costs (or ensure that an
affiliate assumes such expenses and costs), in connection with the Substitution;
(5) the Substitution will in no way alter the contractual obligations of the Life Company Applicants or the rights and privileges of Contractowners under the Contracts;
(6) Applicants anticipate that the JPVF 500 Portfolio will seek to rely upon the JPVF Order. Applicants will take no action in reliance on the JPVF Order with respect to JPVF 500 Portfolio unless and until the operation of JPVF 500 Portfolio in the manner contemplated by the JPVF Order, is approved by the holders of a majority of the outstanding voting securities of JPVF 500 Portfolio within the meaning of the 1940 Act, by vote obtained following the Substitution in a manner consistent with all outstanding relief granted by the SEC;
(7) the Substitution will in no way alter the tax benefits to Contractowners;
(8) Contractowners will not incur any fees or charges as a result of the proposed Substitution, nor will the Contractowners' rights or the Life Company Applicants' obligations under the Contracts be altered in any way. The Life Company Applicants will bear all expenses incurred in connection with the proposed Substitution and related filings and notices, including legal, accounting, and other fees and expenses. The proposed Substitution will not cause Contract fees and charges currently being paid by existing Contractowners to be greater after the proposed Substitution than before the proposed Substitution; and
(9) Contractowners may withdraw amounts under the Contracts or terminate their interest in a Contract, under the conditions that currently exist, including payment of any applicable withdrawal or surrender charge.
4. Applicants maintain that the Replacement Fund and the Replaced Fund will have investment objectives and policies that are substantially the same in all material respects. Accordingly, Life Company Applicants have specifically made the determination that the Replacement fund is a suitable and appropriate investment vehicle for Contractowners who have allocated value to the Replaced Fund and that the Substitution will be consistent with Contractowners' investment expectations.
5. Applicants assert that the fees and expenses of the Replacement Fund will be equal to (or less than) those of the Replaced Fund and that the Replacement Fund will receive comparable (or better) overall services.

Accordingly, Applicants argue that the proposed Substitution poses no concerns in connection with the fees and expenses that will arise therefrom.
6. Applicants state that the prospectuses by which the Contracts were offered reserve to the respective Life Company Applicants the right to replace the shares of any underlying registered investment company held by the applicable Separate Account Applicant with shares of another registered investment company, provided any such substitution is approved by the SEC to the extent required by applicable law.
7. Applicants submit that, for all the reasons stated in the application, that their request for approval meets the standard set forth in Section 26(b) of the 1940 Act and is consistent with applicable precedent and should, therefore, be granted.
8. Section 17(a)(1) of the 1940 Act prohibits any affiliated person of a registered investment company, or an affiliated person of such an affiliated person, from selling any security or other property to such registered investment company. Section 17(a)(2) of the 1940 Act prohibits any of the persons described above from purchasing any security or other property from such registered investment company.
9. Applicants state that the proposed transactions first involve a transfer of portfolio securities by the Fidelity 500 Portfolio to the Separate Account Applicants; immediately thereafter, the Separate Account Applicants purchase shares of the JPVF 500 Portfolio with the portfolio securities received from the Fidelity 500 Portfolio. Since the Separate Account Applicants and the JPVF 500 Portfolio could be affiliated persons under Section 2(a)(3)(C) of the 1940 Act due to their common control, Applicants submit that this aspect of the Substitution could be prohibited by Section 17(a). Accordingly, Applicants believe that it is prudent to seek relief from Section 17(a).
10. Section 17(b) of the 1940 Act provides that the SEC may grant an order exempting transactions prohibited by Section 17(a) of the 1940 Act upon application if evidence establishes that:
(1) the terms of the proposed transaction, including the consideration to be paid or received, are reasonable and fair and do not involve overreaching on the part of any person concerned;
(2) the proposed transaction is consistent with the investment policy of each registered investment company concerned, as recited in its registration
statement and reports filed under the 1940 Act; and
(3) the proposed transaction is consistent with the general purposes of the 1940 Act.
11. Applicants represent that the terms of the proposed transactions: Are reasonable and fair, including the consideration to be paid and received; do not involved overreaching; are consistent with the policies of the affected registered investment companies; and are consistent with the general purposes of the 1940 Act.
12. Applicants maintain that the Substitution transactions, including the redemption of the Fidelity 500 Portfolio shares on an in-kind basis and the purchase of the JPVF 500 Portfolio shares, will be effected in conformity with Section 22(c) of the 1940 Act and Rule 22c-1 thereunder. Applicants also maintain that Contractowners will not incur any fees or charges as a result of the transfer of account values. Contractowners' rights and privileges under the Contracts and the Life Company Applicants' obligations thereunder will not be affected by the Substitution. Applicants assert that the Substitution will not increase Contract or separate account fees and charges after the Substitution. Expenses incurred in connection with the Substitution, including legal, accounting and other expenses, will not be borne by Contractowners. Contract values will remain unchanged and fully invested following the consummation of the Substitution. Accordingly, Applicants represent that Contractowner interests after the Substitution, in practical economic terms, will not differ in any measurable way from such interests immediately prior to the Substitution. Applicants asserts that in each case, the consideration to be received and paid is, therefore, reasonable and fair.
13. Applicants assert that the investment objectives and policies of the JPVF 500 Portfolio are substantially similar to the investment objectives and policies of the Fidelity 500 Portfolio. Applicants maintain that, in this regard, the Substitution is consistent with the findings required under Section 17 (b) of the 1940 Act.
14. Applicants assert that the proposed Substitution is consistent with the general purposes of the 1940 Act and that the proposed transactions do not present any of the issues or abuses that the 1940 Act is designed to prevent.
15. Applicants submit that the proposed in-kind redemption transactions meet all of the requirements of Section 17(b) of the 1940 Act and that their request for an
order pursuant to that section
exempting the transactions from the provisions of Section 17(a) of the 1940 Act, to the extent necessary, should be granted.

## Conclusion

Applicants assert that, for the reasons summarized above, the requested order approving the substitutions and related in-kind transactions should be granted.

For the Commission, by the Division of Investment Management, pursuant to delegated authority.
Jonathan G. Katz,
Secretary.
[FR Doc. 00-8645 Filed 4-6-00; 8:45 am]
BILLING CODE 8010-01-M

## SECURITIES AND EXCHANGE COMMISSION

## [Release No. 35-27161]

## Filings Under the Public Utility Holding Company Act of 1935, as Amended ("Act")

March 31, 2000.
Notice is hereby given that the following filing(s) has/have been made with the Commission pursuant to provisions of the Act and rules promulgated under the Act. All interested persons are referred to the application(s) and/or declaration(s) for complete statements of the proposed transaction(s) summarized below. The application(s) and/or declaration(s) and any amendment(s) is/are available for public inspection through the Commission's Branch of Public Reference.
Interested persons wishing to comment or request a hearing on the application(s) and/or declaration(s) should submit their views in writing by April 25, 2000, to the Secretary Securities and Exchange Commission, Washington, D.C. 20549-0609, and serve a copy on the relevant applicant(s) and/or declarant(s) at the address(es) specified below. Proof of service (by affidavit or, in the case of an attorney at law, by certificate) should be filed with the request. Any request for hearing should identify specifically the issues of facts or law that are disputed. A person who so requests will be notified or any hearing, if ordered, and will receive a copy of any notice or order issued in the matter. After April 25, 2000, the application(s) and/or declaration(s), as filed or as amended, may be granted and/or permitted to become effective.

## GPU, Inc. (70-9629)

GPU, Inc. ("GPU"), 300 Madison
Avenue, Morristown, New Jersey 07960,
a registered holding company, has filed with this Commission an application under sections 9(a) and 10 and rule 54 of the Act.
GPU seeks authorization to acquire a $36 \%$ interest in a nonutility subsidiary. GPU and several of its subsidiary companies ${ }^{1}$ currently purchase workers compensation insurance from Utilities Mutual Insurance Company ('UMI'), a captive mutual insurer providing insurance to a limited number of companies. ${ }^{2}$ UMI is in the process of obtaining approval from the New York States Department of Insurance to convert from a mutual company to stock company status. It is contemplated, that once UMI becomes a stock company, each policy holder will receive shares of common stock, $\$ .01$ par value, of a newly formed holding company parent, UMICO Holdings, Inc. ("UMICO"), in proportion to its current ownership interest in UMI. GPU and its subsidiaries currently have an aggregate ownership interest in UMI of approximately $36 \%$ and would, therefore, receive approximately $36 \%$ of UMICO's voting shares upon UMI's demutualization. GPU would not pay any other consideration for the UMICO shares.
In connection with the demutualization, GPU expects UMI to sell its entire insurance portfolio to Cologne Re, which will assume all UMI obligations and liabilities for outstanding claims and future claims under policies written by UMI. GPU states that UMI will not conduct any active business. The workers compensation insurance previously provided by UMI will instead be provide by an affiliate of Cologne Re to the UMICO shareholders, at least through 2003. UMI and UMICO will not be liquidated and dissolved and will remain in existence until all claims or potential claims covered by outstanding UMI policies have either been resolved or adequately reinsured. Upon dissolution, the UMICO shareholders

[^66]will be entitled to their pro rata shares of any remaining UMI surplus.

Prior to demutualization, the GPU subsidiaries (other than Prime and Onondaga) have assigned their present interests in UMI to GPU. In contemplation of the demutualization, GPU and other utility policy holders have entered into a subscription agreement providing for their purchase of shares of UMICO in proportion to their respective interests in UMI. Under the subscription agreement, GPU has agreed to acquire approximately $36.52 \%$ of UMICO in exchange for its present interest in UMI. Following the acquisition, UMICO will become a nonutility subsidary of GPU.

For the Commission by the Division of Investment Management, under delegated authority.
Jonathan G. Katz,
Secretary.
[FR Doc. 00-8618 Filed 4-6-00; 8:45 am] BILLING CODE 8010-01-M

## SECURITIES AND EXCHANGE COMMISSION

## [Release No. IC-24372]

## Notice of Applications for Deregistration Under Section 8(f) of the Investment Company Act of 1940

March 31, 2000.
The following is a notice of applications for deregistration under section 8(f) of the Investment Company Act of 1940 for the month of March 2000. A copy of each application may be obtained for a fee at the SEC's Public Reference Branch, 450 Fifth St., N.W., Washington, DC 20549-0102 (tel. 202-$942-8090$ ). An order granting each application will be issued unless the SEC orders a hearing. Interested persons may request a hearing on any application by writing to the SEC's Secretary at the address below and serving the relevant applicant with a copy of the request, personally or by mail. Hearing requests should be received by the SEC by 5:30 p.m. on April 25, 2000, and should be accompanied by proof of service on the applicant, in the form of an affidavit or, for lawyers, a certificate of service. Hearing requests should state the nature of the writer's interest, the reason for the request, and the issues contested. Persons who wish to be notified of a hearing may request notification by writing to the Secretary, SEC, 450 Fifth Street, N.W., Washington, DC 205490609. For Further Information Contact: Daine L. Titus, at (202) 942-0564, SEC, Division of Investment Management,

Office of Investment Company
Regulation, 450 Fifth Street, N.W., Washington, DC 20549-0506.

## MIMLIC Cash Fund, Inc. [File No. 8115027]

Summary: Applicant seeks an order declaring that it has ceased to be an investment company. On September 24, 1999, applicant made a liquidating distribution to its shareholders based on net asset value. Expenses of \$1,000 incurred in connection with the liquidation were paid by Advantus Capital Management, Inc., the fund's investment adviser.

Filing Dates: The application was filed on September 29, 1999, and amended on March 8, 2000.

Applicant's Address: 400 Robert Street North, St. Paul, Minnesota 55101-2098.

## Sage/TSO [File No. 811-7573]

Summary: Applicant seeks an order declaring that it has ceased to be an investment company. On September 30, 1998, applicant made a liquidating distribution to its shareholders based on net asset value. Expenses of $\$ 15,000$ incurred in connection with the liquidation were paid by SAGE/TSO Investment Management L.P., applicant's investment adviser.
Filing Dates: The application was filed on January 7, 2000, and amended on March 3, 2000.

Applicant's Address: 1462 Waterfront Road, Reston, Virginia 20194.

## Anchor Strategic Assets Trust [File No. 811-5963]

Summary: Applicant seeks an order declaring that it has ceased to be an investment company. On September 1, 1999, applicant transferred its assets to Anchor Resource and Commodity Trust based on net asset value. Expenses of $\$ 37,000$ incurred in connection with the reorganization were paid by the acquiring fund.
Filing Date: The application was filed on March 8, 2000.

Applicant's Address: 579 Pleasant Street, Suite 4, Paxton, Massachusetts 01612.

Income Opportunities Fund 2006, Inc. [File No. 811-9621]

Summary: Applicant seeks an order declaring that it has ceased to be an investment company. Applicant has never made a public offering of its securities and does not propose to make any public offering or engage in business of any kind.

Filing Dates: The application was filed February 22, 2000, and amended on March 10, 2000.

Applicant's Address: c/o Fund Asset Management L.P., P.O. Box 9011,
Princeton, New Jersey 08543-9011.

## Alterman Investment Fund, Inc. [File No. 811-2998]

Summary: Applicant seeks an order declaring that it has ceased to be an investment company. On December 10, 1999, applicant transferred its assets to Smith Barney Muni Funds Georgia Portfolio, based on net asset value. Total expenses of $\$ 80,446$ were incurred in connection with the reorganization. Salomon Smith Barney, Inc., paid the first \$40,000 of the legal and accounting expenses, and the remaining expenses were paid equally by Salomon Smith Barney, Inc. and applicant. The acquiring fund bore all of the expenses it incurred in connection with the reorganization.
Filing Date: The application was filed on March 7, 2000.
Applicant's Address: 182 Hilderbrand Drive, Suite 102, Atlanta, Georgia 30328.

## Life \& Annuity Trust [File No. 8118118]

Summary: Applicant seeks an order declaring that it has ceased to be an investment company. On September 20, 1999, applicant transferred all of its assets to Wells Fargo Variable Trust, based on net asset value. Expenses of \$144,638 incurred in connection with the reorganization were paid by Wells Fargo Bank, N.A., investment adviser to the acquiring fund.
Filing Date: The application was filed on March 2, 2000.
Applicant's Address: 111 Center Street, Little Rock, Arkansas 72201.

Stagecoach Funds, Inc. [File No. 8116419]; Stagecoach Trust [File No. 8117780]

Summary: Each applicant seeks an order declaring that it has ceased to be an investment company. On November 8, 1999, each applicant transferred all of its assets to Wells Fargo Funds Trust, based on net asset value. Expenses of $\$ 1,933,236$ and $\$ 361,710$, respectively, incurred in connection with the reorganizations were paid by Wells Fargo Bank, N.A., investment adviser to the acquiring fund.
Filing Date: The applications were filed on March 2, 2000.
Applicant's Address: 111 Center Street, Little Rock, Arkansas 72201.

## Golf Associated Fund [File No. 8118819]

Summary: Applicant seeks an order declaring that it has ceased to be an investment company. On December 29,

1999, applicant made a liquidating distribution to its shareholders based on net asset value. Expenses of approximately $\$ 700$ incurred in connection with the liquidation were paid by applicant.
Filing Date: The application was filed on March 2, 2000.

Applicant's Address: 2801 Ocean Drive, Suite 204, Vero Beach, Florida 32963.

## Evergreen Quality Bond Fund (Formerly Keystone Quality Bond Fund (B-1)) [File No. 811-92]

Summary: Applicant seeks an order declaring that it has ceased to be an investment company. On January 24, 1998, applicant transferred its assets to Evergreen Diversified Bond Fund, a newly-created series of Evergreen Fixed Income Trust, based on net asset value. All expenses incurred in connection with the reorganization were paid by First Union National Bank, the parent of applicant's investment adviser.
Filing Date: The application was filed on February 18, 2000.

Applicant's Address: 200 Berkeley Street, Boston, Massachusetts 02116.
Nations Fund Portfolios, Inc. [File No. 811-8982]

Summary: Applicant seeks an order declaring that it has ceased to be an investment company. On August 20, 1999, applicant transferred its assets to Nations Reserves, based on net asset value. Expenses of \$15,400 incurred in connection with the reorganization were paid by NationsBanc Advisors, Inc. or its affiliates.

Filing Date: The application was filed on February 22, 2000.

Applicant's Address: 111 Center Street, Suite 300, Little Rock, Arkansas 72201.

## Master Investment Trust [File No. 811-

 6415]Summary: Applicant seeks an order declaring that it has ceased to be an investment company. On December 12, 1997, applicant made a liquidating distribution to its shareholders based on net asset value. Expenses of $\$ 26,392$ incurred in connection with the liquidation were paid by Wells Fargo Bank, N.A., applicant's administrator.

Filing Dates: The application was filed on September 30, 1999, and amended on March 1, 2000, and March 10, 2000.

Applicant's Address: 111 Center Street, Little rock, Arkansas 72201.

## The Hudson River Trust [File No. 8114185]

Summary: Applicant seeks an order declaring that it has ceased to be an
investment company. On October 18, 1999, applicant made a final liquidating distribution to its shareholders based on net asset value. Expenses of $\$ 8,000$ incurred in connection with the liquidation were paid by the Equitable, the indirect parent of applicant's investment adviser.

Filing Dates: The application was filed on December 30, 1999, and amended on January 21, 2000, and February 25, 2000.
Applicant's Address: 1345 Avenue of the Americas, New York, New York 10105.

## Overland Express Funds, Inc. [File No. 811-8275]

Summary: Applicant seeks an order declaring that it has ceased to be an investment company. On December 12, 1997, applicant transferred its assets to Stagecoach Funds, Inc. (the "Acquiring Fund") in exchange for shares of the corresponding series of the Acquiring Fund based on the relative net asset value per share. Expenses of $\$ 426,690$ incurred in connection with the reorganization were paid by Wells Fargo Bank, N.A., the administrator of the Acquiring Fund.

Filing Dates: The application was filed on September 30, 1999, and amended on February 25, 2000.

Applicant's Address: 111 Center Street, Little Rock, Arkansas 72201.

## Investa Management Co. [File No. 8118198]

Summary: Applicant seeks an order declaring that it has ceased to be an investment company. Applicant has not made a public offering of its securities and does not propose to make any public offering or engage in business of any kind.

Filing Date: The application was filed on March 17, 2000.

Applicant's Address: c/o Investa Management Co., Inc., 551 Fifth Avenue, New York, New York 10176.

## Variable Account D of Monarch Life Insurance Company [File No. 811-5226]

Summary: Applicant seeks an order declaring that it has ceased to be an investment company. Applicant has not made any public offering of its securities, is not now engaged, or intending to engage, in any business activities other than those necessary for winding up its affairs.

Filing Dates: The application was filed on December 23, 1999, and amended on February 24, 2000.

Applicant's Address: One Monarch Place, Springfield, Massachusetts 01133.

## Variable Account H of Monarch Life

 Insurance Company [File No. 811-5637]Summary: Applicant seeks an order declaring that it has ceased to be an investment company. Applicant has not made any public offering of its securities, is not now engaged, or intending to engage, in any business activities other than those necessary for winding up its affairs.
Filing Dates: The application was filed on December 23, 1999, and amended on February 24, 2000. Applicant's Address: One Monarch Place, Springfield, Massachusetts 01133.

## Variable Account G of Monarch Life

 Insurance Company [File No. 811-5403]Summary: Applicant seeks an order declaring that it has ceased to be an investment company. Applicant has not made any public offering of its securities, is not now engaged, or intending to engage, in any business activities other than those necessary for winding up its affairs.
Filing Dates: The application was filed on December 23, 1999, and amended on February 24, 2000.
Applicant's Address: One Monarch
Place, Springfield, Massachusetts 01133.
For the Commission, by the Division of Investment Management, pursuant to delegated authority.
Margaret H. McFarland,
Deputy Secretary.
[FR Doc. 00-8485 Filed 4-6-00; 8:45 am] BILLING CODE 8010-01-M

## SECURITIES AND EXCHANGE COMMISSION

[Investment Company Act Release No. 24371, 812-11952]

## Touchstone Advisors, Inc., et al.; Notice of Application

March 31, 2000.
agency: Securities and Exchange Commission ("Commission").
ACTION: Notice of an application under section 17 (b) of the Investment Company Act of 1940 (the "Act") for an exemption from section 17(a) of the Act.

SUMMARY OF APPLICATION: Applicants request an order to permit certain series of two registered open-end management investment companies to acquire all of the assets, subject to certain liabilities, of certain series of a third registered open-end management investment company. Because of certain affiliations, applicants may not rely on rule 17a-8 under the Act.
APPLICANTS: Touchstone Advisors, Inc. ('‘Touchstone Advisors’’), Touchstone

Series Trust ("'Touchstone Trust’), Countrywide Investment Trust ("Investment Trust'"), and Countrywide Strategic Trust ("Strategic Trust").
FILING DATES: The application was filed on January 24, 2000. Applicants have agreed to file an amendment during the notice period, the substance of which is reflected in this notice.
hearing or notification of hearing: An order granting the requested relief will be issued unless the Commission orders a hearing. Interested persons may request a hearing by writing to the Commission's Secretary and serving applicants with a copy of the request, personally or by mail. Hearing requests should be received by the Commission by 5:30 p.m. on April 25, 2000 and should be accompanied by proof of service on applicants, in the form of an affidavit or, for lawyers, a certificate of service. Hearing requests should state the nature of the writer's interest, the reason for the request, and the issues contested. Persons may request notification of a hearing by writing to the Commission's Secretary.
ADDRESSES: Secretary, Commission, 450 5th Street, NW, Washington, D.C.
20549-0609. Touchstone Advisors and Touchstone Trust, 311 Pike Street, Cincinnati, Ohio 45202; Investment Trust and Strategic Trust, 312 Walnut Street, Cincinnati, Ohio 45202.
FOR FURTHER INFORMATION CONTACT: Anu Dubey, Senior Counsel, at (202) 9420687, or George Zornada, Branch Chief, at (202) 942-0564 (Division of Investment Management, Office of Investment Company Regulation).
SUPPLEMENTARY INFORMATION: The
following is a summary of the application. The complete application may be obtained for a fee at the Commission's Public Reference Branch, 450 5th Street, NW, Washington, D.C. 20549-0102 (tel. 202-942-8090).

## Applicants' Representations

1. Touchstone Trust, a Massachusetts business trust, is registered under the Act as an open-end management investment company and offers eight series, including the Touchstone Bond Fund ('"TS Bond"), the Touchstone Growth \& Income Fund ('TS G \& I'), the Touchstone Value Plus Fund ("TS Value Plus"), the Touchstone International Equity Fund ("TS International") and the Touchstone Emerging Growth Fund ("TS Emerging") (together, the "Acquired Funds"). Investment Trust, a Massachusetts business trust, is registered under the Act as an open-end management investment company and offers six series, including Countrywide

Intermediate Bond Fund ("CW Bond"). Strategic Trust, a Massachusetts business trust, is registered under the Act as an open-end management investment company and will comprise nine series, including three newlyorganized series. Countrywide Value Plus ("CW Value Plus’’), Countrywide International Equity Fund ("CW International") and Countrywide Emerging Growth Fund ("CW Emerging’’). CW Value Plus, CW International and CW Emerging, together with CW Bond, are the "Acquiring Funds". The Acquiring Funds and the Acquired Funds are referred to collectively as the "Funds".
2. Touchstone Advisors, the investment adviser to the Acquired Funds, is a wholly-owned subsidiary of The Western-Southern Life Assurance Company ("Western-Southern"). Western-Southern is a wholly-owned subsidiary of The Western and Southern Life Insurance Company ("Western Southern Life"). Countrywide Investments, Inc. ("Countrywide"), the investment adviser to each Acquiring Fund, is an indirect wholly-owned subsidiary of Western Southern Life. Touchstone Advisors is the investment adviser to the Acquiring Funds. Both Touchstone Advisors and Countrywide are registered as investment advisers under the Investment Advisers Act of 1940.
3. Currently, Western Southern Life and/or Western-Southern own more than $5 \%$ (and in come cases more than $25 \%$ ) of the outstanding voting securities of each of the Acquired Funds. The initial investment in each of CW Value Plus, CW International and CW Emerging will be contributed by one or more entities controlling, controlled by or under common control with Touchstone Advisors ("Touchstone Affiliates") resulting in Touchstone Affiliates owning $100 \%$ of CW Value Plus, CW International and CW Emerging. ${ }^{1}$
3. On January 7, 2000 and February 15,2000 , the board of trustees of each of the Touchstone Trust, Investment Trust and Strategic Trust (together, the "Boards"), including a majority of the trustees who are not "interested persons" as defined in section 2(a)(19) of the Act ("Disinterested Trustees"), approved a plan of reorganization between the Acquiring Funds and the Acquired Funds (the "Reorganization Plan", and the transaction the

[^67]"Reorganization"). ${ }^{2}$ The Reorganization is expected to occur on April 28, 2000 ("Closing Date"). Under the Reorganization Plan, each Acquiring Fund will acquire all of the assets, subject to the liabilities, of each corresponding Acquired Fund in exchange for Class A and Class C shares of the respective Acquiring Fund having an aggregate net asset value equal to the aggregate net asset value of the corresponding Acquired Fund's shares determined on the date immediately prior to the Closing Date. The value of the assets of the Funds will be determined in the manner set forth in the Funds' then current prospectuses and statements of additional information. The Acquiring Fund shares received by the Acquired Funds will be distributed pro rata by each Acquired Fund to its shareholders and each Acquired Fund will liquidate and dissolve.

## 4. Applicants state that the

 investment objectives and policies of each Acquired Fund are substantially similar to those of its corresponding Acquiring Fund. Each Acquired Fund offers (i) class A shares, which are subject to a sales load and rule $12 \mathrm{~b}-1$ distribution fee, and (ii) class $C$ shares, which are subject to a contingent deferred sales charge ("CDSC') and rule 12b-1 distribution fee. ${ }^{3}$ The holding period used to determine whether a CDSC will apply to a holder of Class C shares of an Acquiring Fund who becomes a shareholder as a result of the Reorganization will include any period of time that the shareholder held shares of the Acquired Fund. No sales charges will be imposed in connection with the Reorganization. Touchstone Advisors[^68]and/or one of the Touchstone Affiliates will pay the Reorganization expenses.
5. The Boards, including a majority of the Disinterested Trustees, determined that the Reorganization is in the best interests of each Fund, and that the interests of the existing shareholders of each Fund will not be diluted by the Reorganization. In assessing the Reorganization, the Boards considered various factors, including (a) the terms and conditions of the Reorganization Plan, (b) the investment advisory and other fees projected to be paid by an Acquiring Fund, and the projected expense ratio of an Acquiring Fund, as compared to those of the corresponding Acquired Fund, ${ }^{4}$ (c) the investment objectives, policies, practices and restrictions of the Acquiring Fund and their compatibility with those of the corresponding Acquired Fund, (d) that Touchstone Advisors and/or one of the Touchstone Affiliates would pay the expenses of the Reorganization, (e) the potential economies of scale to be gained from combining the assets of the Acquired Funds into the corresponding Acquiring Funds, and (f) the anticipated tax-free nature of the Reorganization.
6. The Reorganization is subject to a number of conditions precedent, including that (a) the shareholders of each Acquired Fund shall have approved the Reorganization Plan; (b) applicants shall have received exemptive relief from the Commission that is the subject of the application; (c) a registration statement on Form $\mathrm{N}-14$, relating to the Acquiring Funds shall have become effective; and (d) applicants shall have received an opinion of counsel with respect to certain federal tax consequences of the Reorganization. The Reorganization Plan may be terminated and the Reorganization abandoned upon the mutual agreement of the Funds, upon a material breach of the Reorganization Plan by a Fund, or due to the failure to meet a condition precedent to consummation of the Reorganization Plan. Applicants agree not to make any material changes to the Reorganization Plan without prior approval of the Commission.
7. The definitive prospectus/proxy statement will be filed with the Commission and will be mailed to shareholders of the Acquired Funds on or about March 30, 2000. A special meeting of the shareholders will be held on or about April 19, 2000.

[^69]
## Applicant's Legal Analysis

1. Section 17(a) of the Act generally prohibits an affiliated person of a registered investment company, or an affiliated person, acting as principal, from selling any security to, or purchasing any security from, the company. Section 2(a)(3) of the Act defines an "affiliated person" of another person to include (a) any person directly or indirectly owning, controlling, or holding with power to vote $5 \%$ or more of the outstanding voting securities of the other person; (b) any person 5\% or more of whose securities are directly or indirectly owned, controlled, or held with power to vote by the other person; (c) any person directly or indirectly controlling, controlled by, or under common control with the other person, and (d) if the other person is an investment company, any investment adviser of that company. Applicants state that the Funds may be deemed affiliated persons and thus the Reorganization may be prohibited by section 17(a).
2. Rule 17a-8 under the Act exempts from the prohibitions of section 17(a) mergers, consolidations, or purchases or sales of substantially all of the assets of registered investment companies that are affiliated persons, or affiliated persons of an affiliated person, solely by reason of having a common investment adviser, common directors, and/or common officers, provided that certain conditions set forth in the rule are satisfied.
3. Applicants state that they may not reply on rule 17a-8 because the Funds may be deemed to be affiliated for reasons other than those set forth in the rule. By virtue of the direct or indirect ownership by one or more Touchstone Affiliates of $5 \%$ or more (and in some cases $25 \%$ or more) of the outstanding voting securities of each of the Acquired Funds and of each of the Acquiring Funds (except CW Bond), each Acquired Fund may be deemed to be an affiliated person of an affiliated person of the Acquiring Fund. Thus, each Acquired Fund may be deemed to be an affiliated person of an affiliated person of the Acquiring Fund for reasons other than having a common investment adviser, common directors and/or common officers.
4. Section 17(b) of the Act provides that the Commission may exempt a transaction from the provisions of section 17(a) if the evidence establishes that the terms of the proposed transaction, including the consideration to be paid, a reasonable and fair and do not involve overreaching on the part of any person concerned, and that the
proposed transaction is consistent with the policy of each registered investment company concerned and with the general purposes of the Act.
5. Applicants request an order under section 17(b) of the Act exempting them from section 17(a) of the Act to the extent necessary to permit applicants to consummate the Reorganization. Applicants submit that the Reorganization satisfied the standards of section 17(b) of the Act. Applicants states that the Boards, including a majority of the Disinterested Trustees, have found that participation in the Reorganization is in the best interests of each Fund, and that the interests of the existing shareholders will not be diluted as a result of the Reorganization. In addition, applicants state that the Reorganization will be on the basis of net asset value.
For the Commission, by the Division of Investment Management, pursuant to delegated authority.
Margaret H. McFarland,
Deputy Secretary.
[FR Doc. 00-8486 Filed 4-6-00; 8:45 am] BILLING CODE 8010-01-M

## SECURITIES AND EXCHANGE COMMISSION

[Release No. 34-42605; File No. SR-Amex-98-33]

## Self-Regulatory Organizations; Order Approving Proposed Rule Change and Amendment Nos. 1 and 2 to the Proposed Rule Change and Notice of Filing and Order Granting Accelerated Approval of Amendment No. 3 to the Proposed Rule Change by the American Stock Exchange LLC Relating to Margin Requirements

March 31, 2000.

## I. Introduction

On September 18, 1998, the American Stock Exchange LLC ("Amex" or "Exchange") filed with the Securities and Exchange Commission ('SEC"' or "Commission") a proposed rule change pursuant to Section 19(b)(1) of the Securities Exchange Act of 1934 ("Act"), ${ }^{1}$ and Rule 19b-4 thereunder, ${ }^{2}$ to allow specified Portfolio Depositary Receipts ("PDRs") ${ }^{3}$ or Index Fund Shares ${ }^{4}$ to serve as cover for short

[^70]positions in options on specified indexes. On March 5, 1999, the Amex filed Amendment Nos. 1 and 2 to the proposal. ${ }^{5}$ The proposed rule change and Amendment Nos. 1 and 2 were published for comment in the Federal Register on October 20, 1999. ${ }^{6}$ On September 24, 1999, the Amex provided data regarding the correlation between several PDRs or Index Fund Shares and indexes. ${ }^{7}$ On December 15, 1999, the Amex filed Amendment No. 3 to the proposal. ${ }^{8}$ The Commission received no comments regarding the proposal. This order approves the proposed rule change, as amended.

## II. Background and Description of the Proposal

In a letter dated February 1, 1993, the staff of the Board of Governors of the
the Investment Company Act of 1940, as amended, whose assets are a securities portfolio.
${ }^{5}$ See letter from Geraldine Brindisi, Vice President and Corporate Secretary, Amex, to Michael Walinskas, Deputy Associate Director, Office of Market Supervision, Commission, dated March 4, 1999 ("Amendment No. 1"); and letter from Michael Cavalier, Associate General Counsel, Legal and Regulatory Policy, Amex, to Michael A. Walinskas, Deputy Associate Director, Division of Market Regulation ("Division"), Commission, dated March 4, 1999 ("Amendment No. 2"). In
Amendment No. 1, the Amex (1) provided requirements for calculating the margin for an existing position in PDRs or Index Fund Shares serving as cover for short index options; and (2) added Commentary .10 to Amex Rule 462(d)(2)(H) to specify the PDRs or Fund Shares that may serve as cover for short index options positions. Specifically, Commentary .10 provided that: (1) Positions in Standard \& Poor's ("S\&P") Depositary Receipts ("SPDRs") shall be cover for positions in S\&P 500 Index options; S\&P 100 Index options, or Institutional Index options; (2) positions in S\&P MidCap 400 Depository Receipts ("MidCap SPDRs") shall be cover for positions in S\&P MidCap 400 Index options; (3) positions in DIAMONDS Trust Units ("DIAMONDS") shall be cover for positions in Dow Jones Industrial Index ("DJX") options or Major Market Index options; and (4) positions in Nasdaq-100 Shares shall be cover for positions in Nasdaq 100-Index options. Amendment No. 2 revised the caption for the notice provided with Amendment No. 1.
${ }^{6}$ See Securities Exchange Act Release No. 41999 (October 13, 1999), 64 FR 56545.
${ }^{7}$ See letter from Michael Cavalier, Associate General Counsel, Legal and Regulatory Policy, Amex, to Mandy Cohen, Special Counsel, Division, Commission, dated September 24, 1999.
${ }^{8}$ See letter from Michael Cavalier, Associate General Counsel, Legal and Regulatory Policy, Amex, to Yvonne Fraticelli, Special Counsel, Division, Commission, dated December 8, 1999 ("Amendment No. 3"). In Amendment No. 3, the Amex revised proposed Commentary .10 to provide that specified PDRs or Index Fund Shares may serve as cover only for options on the index that the PDR or Index Fund Share is designed to replicate. Specifically, Amendment No. 3 revised Commentary 10 to provide that: (1) Positions in SPDRs shall be cover for S\&P 500 Index options; (2) positions in MidCap SPDRs shall be cover for S\&P 400 Index options; (3) positions in DIAMONDS shall be cover for DJX options; and (4) positions in Nasdaq-100 Shares shall be cover for positions in Nasdaq-100 Index options. In addition, Amendment No. 3 requested permanent approval of the proposed changes.

Federal Reserve System ("Federal Reserve Board") indicated that it was compatible with Regulation $\mathrm{T}^{9}$ for the Amex to treat positions in Standard \& Poor's Depositary Receipts ('SPDRs") ${ }^{10}$ as "cover" for an Options Clearing Corporation ("OCC")-issued option on a broad-based stock index with at least $99 \%$ correlation with the S\&P 500 Index. ${ }^{11}$ Specifically, the 1993 Letter stated that the Amex may require no additional margin where one leg of a position consisted of SPDRs and the other leg was an OCC-issued index option on a broad-based stock index with at least $99 \%$ correlation with the S\&P 500 Index. ${ }^{12}$ According to the Amex, the Federal Reserve Board staff also indicated that MidCap SPDRs ${ }^{13}$ could serve as cover for S\&P MidCap 400 Index options. ${ }^{14}$
Federal Reserve Board amendments to Regulation T that became effective on June 1, 1997, modified or deleted certain margin requirements regarding options transactions in favor of rules to be adopted by the options exchanges, subject to approval by the Commission. ${ }^{15}$ Because exchange rules, as approved by the Commission, rather than Regulation T, now govern matters such as permitted offsets and cover for short options positions, the Amex proposes to revise Amex Rule 462, "Minimum Margins," to incorporate into Amex Rule 462 the Federal Reserve Board staff positions regarding SPDRs and MidCap SPDRs. In addition, the Amex proposes to amend Amex Rule

[^71]462 to allow DIAMONDS ${ }^{16}$ to serve as cover for DJX options and to allow Nasdaq-100 Shares ${ }^{17}$ to serve as cover for Nasdaq-100 Index options.

Specifically, the proposal amends Amex Rule 462(d)(2)(H) to provide that no margin need be required in respect of a call index option or a put index option carried in a short position where the same account carries a long position in the PDRs or Index Fund Shares specified in Commentary . 10 to the rule, and the PDRs or Index Fund Shares serving as cover have a market value at least equal to the aggregate current index value ${ }^{18}$ of the stocks underlying the index option contracts to be covered. Commentary .10 provides that: (1) Position in SPDRs shall be cover for position in S\&P 500 Index options; (2) positions in MidCap SPDRs shall be cover for positions in S\&P MidCap 400 Index options; (3) positions in DIAMONDS shall be cover for positions in DJX options; and (4) positions in Nasdaq-100 Shares shall be cover for positions in Nasdaq-100 Index options. ${ }^{19}$

In addition, the proposal states that in computing the margin on an existing position in PDRs or Index Fund Shares that covers a short index put or call, the

[^72]market value of the PDRs or Index Funds Shares to be used shall not be greater than the exercise price, in the case of a call, or less than the market value of the PDRs or Index Fund Shares, in the case of a put, and the required margin shall be increased by any unrealized loss on the short put security position. ${ }^{20}$

## III. Discussion

For the reasons discussed below, the Commission finds that the proposed rule change is consistent with the Act and the rules and regulations under the Act applicable to a national securities exchange. In particular, the Commission finds that the proposal is consistent with the Section 6(b)(5) ${ }^{21}$ requirements that the rules of an exchange be designed to promote just and equitable principles of trade, to remove impediments to and perfect the mechanism of a free and open market and, in general, to protect investors and the public interest. ${ }^{22}$

As noted above, the proposal will amend Amex Rule 462 to provide that no margin need be required for short call or put positions in specified index options when the account carrying the short index option position also holds a long position in specified corresponding PDRs or Index Fund Shares that have a market value at least equal to the aggregate current index value of the stocks underlying the index option contracts to be covered. Specifically, the proposal will allow positions in SPDRs to serve as cover for positions in S\&P 500 Index options; positions in MidCap SPDRs to serve as cover for positions in MidCap 400 Index options; positions in DIAMONDS to serve as cover for positions in DJX options; and positions in Nasdaq-100 Shares to served as cover for positions in Nasdaq-100 Index options. ${ }^{23}$

Thus, the proposal will allow long positions in specified PDRs or Index Fund Shares to cover short positions in options on the indexes that the PDRs or Index Fund Shares are designed to replicate. The values of the PDR or Index Fund Share and the index that the PDR or Index Fund Share is designed to replicate should move in tandem. In addition, the PDR or Index Fund Share serving as cover for an index option position must have a market value at least equal to the aggregate current index value of the stocks underlying the index option contracts to be covered.

[^73]Accordingly, the long PDR or Index Fund Share position service as cover for the short index option position should ensure that the index option writer would be able to deliver upon exercise the difference between the current index value and the exercise price of the option. Specifically, in an account that meets the requirements of the proposal, the amount earned from closing out the long PDR or Index Fund Share position would adequately cover the option writer's obligation upon exercise. Accordingly, the Commission believes that it is reasonable for the Amex to allow SPDRs, MidCap SPDRs, DIAMONDS, and Nasdaq-100 Shares to serve as cover for short positions in options on the indexes they are designed to replicate.
In addition, the Commission notes that the proposal incorporates into the Amex's rules the Federal Reserve Board staff's positions regarding SPDRs and MidCap SPDRs. ${ }^{24}$ For the reasons discussed above, the Commission believes that it is reasonable for the Amex to incorporate the Federal Reserve Board staff's positions into its rules and to provide the same treatment for DIAMONDS serving as cover for DJX options and for Nasdaq-100 Shares serving as cover for Nasdaq-100 Index options.
The Commission also believes that it is reasonable for the proposal to provide that in computing the margin on an existing position in PDRs or Index Fund Shares to be used shall not be greater than the exercise price, in the case of a call, or less than the market value of the PDRs or Index Fund Shares, in the case of a put, and that the required margin shall be increased by any unrealized loss on the short put security position. The Commission believes that these requirements will help to ensure that the writer of an index put or call option that is covered by a long position in PDRs or Index Fund Shares would be able to meet its obligation upon exercise of the option. In addition, the Commission notes that the proposed margin requirement for PDRs or Index Fund Shares serving as cover for short index option positions is consistent with current Amex Rule
462(d)(2)(H)iv), ${ }^{25}$ which establishes the margin requirement for an existing security position carried against a short put or call. ${ }^{26}$

[^74]The Commission notes that the current proposal applies solely to the PDRs or Index Fund Shares and the corresponding index options specified in the proposal. If the Amex intends to allow additional PDRs or Index Fund Shares to serve as cover for short positions in options on other indexes, the Amex must file a proposed rule change pursuant to Section 19(b)(1) of the Act and Rule 19b-4 thereunder to adopt the additional offsets.
The commission finds good cause for approving Amendment No. 3 to the proposed rule change prior to the thirtieth day after the date of publication of notice of filing thereof in the Federal Register. Specifically, Amendment No. 3 strengthens the proposal by clarifying the language of the proposed rule change and by providing that specified PDRs or Index Fund Shares may serve as cover for short positions in options on the index that the PDR or Index Fund Share is designed to replicate. Accordingly, the Commission believes that granting accelerated approval of Amendment No. is appropriate and consistent with Sections 6(b)(5) and 10(b)(2) of the Act. ${ }^{27}$

## IV. Solicitation of Comments

Interested persons are invited to submit written data, views and arguments concerning Amendment No. 3 including whether Amendment No. 3 is consistent with the Act. Persons making written submissions should file six copies thereof with the Secretary, Securities and Exchange Commission, 450 Fifth Street, NW, Washington DC 20549-0609. Copies of the submission, all subsequent amendments, all written statements with respect to the proposed rule change that are filed with the Commission, and all written communications relating to the proposed rule change between the Commission and any person, other than those that may be withheld from the public in accordance with the provisions of 5 U.S.C. 552 , will be available for inspection and copying at the Commission's Public Reference Room. Copies of the filing will also be available for inspection and copying at the principal office of the Exchange. All submissions should refer to File No. SR-Amex-98-33 and should be submitted by April 28, 2000.
not be greater than the exercise price in the case of a call or less than the current market price in the case of a put and the required margin shall be increased by an unrealized loss on the short security position.

2715 U.S.C. $78 \mathrm{f}(\mathrm{b})(5)$ and $78 \mathrm{~s}(\mathrm{~b})(2)$

## V. Conclusion

It is therefore ordered, pursuant to Section 19(b)(2) of the Act, ${ }^{28}$ that the proposed rule change (SR-Amex-9833), as amended, is approved.

For the Commission, by the Division of Market Regulation, pursuant to delegated authority. ${ }^{29}$
Margaret H. McFarland,
Deputy Secretary.
[FR Doc. 00-8647 Filed 4-6-00; 8:45 am] BILLING CODE 8010-01-M

## SECURITIES AND EXCHANGE COMMISSION

[Release No. 34-42596; File No. SR-CBOE-00-09]

## Self-Regulatory Organizations; Notice of Filing and Immediate Effectiveness of Proposed Rule Change by the Chicago Board Options Exchange, Inc. Extending for Six Months the Rapid Opening System ('ROS'") Pilot Program

March 30, 2000.
Pursuant to Section 19(b)(1) of the Securities Exchange Act of 1934 ("Act"), ${ }^{1}$ and Rule 19b-4 thereunder, ${ }^{2}$ notice is hereby given that on March 22, 2000, the Chicago Board Options Exchange, Inc. ("CBOE" or "Exchange") filed with the Securities and Exchange Commission ("SEC" or "Commission") the proposed rule change as described in Items I, II, and III below, which Items have been prepared by the Exchange. The Commission is publishing this notice to solicit comments on the proposed rule change.

## I. Self-Regulatory Organization's

 Statement of the Terms of Substance of the Proposed Rule ChangeThe Exchange requests an extension through September 30, 2000, of a pilot program established in Exchange Rule 6.2 A , which governs the operation of, and the eligibility to participate in, the Exchange's Rapid Opening System. ${ }^{3}$ The text of the proposed rule change is available at the Office of the Secretary, the Exchange, and at the Commission.

[^75]
## II. Self-Regulatory Organization's Statement of the Purpose of, and Statutory Basis for, the Proposed Rule Change

In its filing with the Commission, the Exchange included statements concerning the purpose of and basis for the proposed rule change and discussed any comments it received on the proposed rule change. The text of these statements may be examined at the places specified in Item IV below. The Exchange has prepared summaries, set forth in Sections A, B, and C below, of the most significant aspects of such statements.

## A. Self-Regulatory Organization's Statement of the Purpose of, and Statutory Basis for, the Proposed Rule Change

## 1. Purpose

The Exchange proposes to extend for six months the Rapid Opening System ("ROS") pilot program. ${ }^{4}$ Before the implementation of ROS, a trading crowd on CBOE arrived at the opening price by manually progressing through series after series of an options class. Open trading for any of the class' series could not commence until all series in the class had undergone the process. ${ }^{5}$ ROS allows the Exchange to automate the opening of its various option classes, thereby avoiding the lengthier opening rotations that can occur under circumstances when there is a large influx of orders entered before or during the opening rotation. As the opening occurs, fill reports on all participating orders are generated automatically, opening market quotes and last sales will be disseminated, and marketmakers will receive notification of assigned trades. In addition, as part of the pilot, the Exchange has developed a manual procedure for incorporating orders currently not included on CBOE's Electronic Book, known as nonbookable orders, ${ }^{6}$ into the opening process. ${ }^{7}$

The CBOE represents that its experience with ROS over the past year has been positive. Member firms have

[^76]told CBOE that they appreciate how ROS enables the Exchange to enter into opening trading much sooner, allowing them to represent their customer orders in open outcry. The Exchange believes that ROS has prevented large numbers of orders from queuing on the Exchange's book and "live ammo" screens immediately after the opening, thus providing Designated Primary Market-Maker ('DPM") staff with the ability to handle orders in a more expeditious manner. The Exchange further represents that trading crowds have been able to open classes using ROS within seconds of the dissemination of the opening part in the underlying security.
The Exchange also believes that the current procedure for manually incorporating non-bookable orders has been adequate to provide these orders with the executions that they deserve on the opening. In fact, the Exchange has observed that many firms currently choose to wait until after the opening has been completed to represent their orders because of the short time needed to complete a ROS opening and because the firms have a better sense of where they may trade the order after the opening and after opening quotes have been disseminated. The Exchange represents, however, that it will continue to explore possibilities for including non-bookable orders ${ }^{8}$ into ROS in an automated fashion. The Exchange is actively studying the possibility of changing its book to allow for the inclusion of non-bookable orders, ${ }^{9}$ at least at the opening. These changes to the Exchange's book would allow ROS to electronically accommodate non-bookable orders. ${ }^{10}$
In the Commission's approval order of the ROS system, the Commission requested the Exchange to study issues related to the SEC's concerns during the pilot period and to report back to the Commission at least sixty days prior to seeking permanent approval of ROS. ${ }^{11}$ The Exchange is now preparing a report to the Commission and will seek permanent approval of ROS in the next couple of months. In the meantime, the extension of the pilot period will allow the Exchange to continue to utilize ROS

[^77]
## 2. Statutory Basis

The proposed rule change is consistent with Section 6(b) of the Act ${ }^{12}$ in general and furthers the objectives of Section 6(b)(5) ${ }^{13}$ in particular in that it is designed to promote just and equitable principles of trade and to protect investors and the public interest.

## B. Self-Regulatory Organization's

 Statement on Burden on CompetitionCBOE does not believe that the proposed rule change will impose any burden on competition.

## C. Self-Regulatory Organization's Statement on Comments on the Proposed Rule Change Received From Members, Participants or Others

CBOE has neither solicited nor received comments on the proposed rule change.

## III. Date of Effectiveness of the Proposed Rule Change and Timing for Commission Action

The foregoing rule change has become effective pursuant to Section 19(b)(3)(A) of the Act ${ }^{14}$ and Rule 19b-4(f)(6) ${ }^{15}$ thereunder because the proposal: (1) Does not significantly affect the protection of investors or the public interest; (2) does not impose any significant burden on competition; and (3) does not become operative prior to 30 days after the date of filing or such shorter time as the Commission may designate if consistent with the protection of investors and the public interest. In addition, the Exchange provided the Commission with written notice of its intent to file the proposed rule change, along with a brief description and text of the proposed rule change, at least five business days prior to the date of the filing the proposed rule change as required by Rule 19b-4(f)(6).

A proposed rule change filed under Rule 19b-4(f)(16) ${ }^{16}$ normally does not become operative prior to 30 days after the date of filing. However, Rule 19b$4(\mathrm{f})(6)(\mathrm{iii}){ }^{17}$ permits the Commission to designate such shorter time if such action is consistent with the protection of investors and the public interest. The Exchange has requested that the Commission designate such shorter time period so that the proposed rule change may become operative no later than March 31, 2000. The immediate effectiveness would allow the current

[^78]ROS pilot program to continue uninterrupted, while allowing the Exchange the opportunity to prepare a report for the Commission prior to seeking permanent approval.

The Commission, consistent with the protection of investors and the public interest, has determined to make the proposed rule change operative immediately upon filing for the following reasons. The proposed rule change extends the expiration date of the ROS pilot program from March 31, 2000, to September 30, 2000. An extension would allow the Exchange to continue to offer ROS without interruption and provide the Exchange more time to complete its review and evaluation of the ROS pilot program. ${ }^{18}$ The Commission notes that the CBOE's filing was also the subject of prior notice and comment when it was first proposed over a year ago.
Among the issues that the
Commission expects the CBOE to explore in its report are: how and when market-makers set ROS risk and size thresholds; how often such thresholds are exceeded and result in the adjustment of AutoQuote; the effect of AutoQuote adjustments on the quality of customer executions; any effects on existing order execution priority; and the handling of an adjustments made for non-bookable orders. ${ }^{19}$ The Commission also expects that the Exchange will provide a workable plan for the electronic incorporation of nonbookable orders on ROS. ${ }^{20}$

Based on the above reasons, the Commission believes it is consistent with the protection of investors and the public interest that the proposed rule change become operative immediately upon the date of filing, March 22, 2000. At any time within 60 days of the filing of such proposed rule change, the Commission may summarily abrogate such rule change if it appears to the Commission that such action is necessary or appropriate in the public interest, for the protection of investors or otherwise in furtherance of the purposes of the Act. ${ }^{21}$

## IV. Solicitation of Comments

Interested persons are invited to submit written data, views, and arguments concerning the foregoing,

[^79]including whether the proposed rule change is consistent with the Act. Persons making written submissions should file six copies thereof with the Secretary, Securities and Exchange Commission, 450 Fifth Street, NW., Washington, DC 20549-0609. Copies of the submission, all subsequent amendments, all written statements with respect to the proposed rule change that are filed with the Commission, and all written communications relating to the proposed rule change between the Commission and any person, other than those that may be withheld from the public in accordance with the provisions of 5 U.S.C. 552 , will be available for inspection and copying at the Commission's Public Reference Room.

Copies of such filing will also be available for inspection and copying at the principal office of the Exchange. All submissions should refer to File No. SR-CBOE-00-09 and should be submitted by April 28, 2000.
For the Commission, by the Division of Market Regulations, pursuant to delegated authority. ${ }^{22}$
Margaret H. McFarland, Deputy Secretary.
[FR Doc. 00-8489 Filed 4-6-00; 8:45 am] BILLING CODE 8010-01-M

## SECURITIES AND EXCHANGE COMMISSION

[Release No. 34-42597; File No. SR-DTC-99-26]

## Self-Regulatory Organizations; The Depository Trust Company; Notice of Filing and Immediate Effectiveness of Proposed Rule Change Relating to an Enhancement of Custody Reorganization and Redemption Services

March 30, 2000.
Pursuant to Section 19(b)(1) of the Securities Exchange Act of 1934 ("Act"), ${ }^{1}$ notice is hereby given that on December 27, 1999, The Depository Trust Company ('DTC') filed with the Securities and Exchange Commission ('Commission') the proposed rule change as described in Items I, II, and III below, which items have been prepared primarily by DTC. The Commission is publishing this notice to solicit comments on the proposed rule change from interested parties.

[^80]
## I. Self-Regulatory Organization's

 Statement of the Terms of Substance of the Proposed Rule ChangeThe proposed rule change would implement the short-term redemption service as an ancillary service of the custody reorganization and redemption service.

## II. Self-Regulatory Organization's Statement of the Purpose of, and Statutory Basis for, the Proposed Rule Change

In its filing with the Commission, DTC included statements concerning the purpose of and basis for the proposed rule change and discussed any comments it received on the proposed rule change. The text of these statements may be examined at the places specified in Item IV below. DTC has prepared summaries, set forth in sections (A), (B), and (C) below, of the most significant aspects of these statements. ${ }^{2}$

## (A) Self-Regulatory Organization's Statement of the Purpose of, and Statutory Basis for, the Proposed Rule Change

The purpose of the proposed rule change is to implement the short-term redemption service. The short-term redemption service will enhance the custody reorganization and redemption services, which are a part of DTC's custody service. DTC believes that the proposed rule change will provide its participants with additional flexibility in their use of the custody reorganization and redemption services. ${ }^{3}$

The short-term redemption service will be available for the following instruments as they are handled within the custody reorganization and redemption services: certificated bankers acceptances, municipal variable-rate demand obligations issued in commercial paper mode, institutional certificates of deposit, and other instruments held in custody which must be presented to the paying agent on, but not before, the scheduled payable date with the agent making payment of principal or income proceeds later that same afternoon, which is too late for processing through DTC's settlement system. Some instruments may also have certificates with different payable dates identified by the same CUSIP number.

Under the short-term redemption service, the payable date and other relevant payment details are captured at

[^81]the certificate level by DTC when the eligible instruments are deposited into custody. A short-term redemption payment projection report detailing instruments with payable dates within the next five business days is produced daily and forwarded to the participant. It is the participant's responsibility to verify the completeness and accuracy of this report and to immediately notify DTC of any discrepancies (e.g., a security payable within the next five days is not shown on the report or an incorrect paying agent name or address is shown on the report). Securities shown on the projection report are automatically routed by DTC to the short-term redemption prep box. DTC then arranges for the securities to be delivered to the paying agent on the payable date. The securities are accompanied by a letter of transmittal instructing the agent to wire the proceeds directly to the bank account designated by the participant for this purpose. It is the participant's responsibility to follow-up with the agent to ensure timely payment and reconcile any payment discrepancies.
The fee per item for this enhanced service is $\$ 32.25$, which fee is an aggregate of several custody service fees previously filed with DTC’s 1999 fee schedule. ${ }^{4}$
DTC believes that the proposed rule change is consistent with the requirements of Section 17A of the Act ${ }^{5}$ and the rules and regulations thereunder because the proposal will give participants greater flexibility in use of the custody reorganization and redemption services. The proposed rule change will be implemented consistently with the safeguarding of securities and funds in DTC's custody or control or for which it is responsible since the operation of the custody reorganization and redemption services, as modified by the proposed rule charge, will be similar to the current operation of the function.

## (B) Self-Regulatory Organization's Statement on Burden on Competition

DTC perceives no adverse impact on competition by reason of the proposed rule change.

## (C) Self-Regulatory Organization's Statement on Comments on the Proposed Rule Change Received From Members, Participants or Others

The proposed rule change has been developed through discussions with several participants. Written comments

[^82]relating to the proposed rule change have not yet been solicited or received on the proposed rule change.

## III. Date of Effectiveness of the Proposed Rule Change and Timing for Commission Action

The foregoing rule change has become effective pursuant to Section 19(b)(3)(A)(iii) ${ }^{6}$ of the Act and Rule 19b-4(f)(4) ${ }^{7}$ promulgated thereunder because the proposal effects a change in an existing service of DTC that does not adversely affect the safeguarding of securities or funds in the custody or control of DTC and that does not significantly affect the respective rights or obligations of DTC or persons using the service. At any time within sixty days of the filing of such proposed rule change, the Commission may summarily abrogate such rule change if it appears to the Commission that such action is necessary or appropriate in the public interest, for the protection of investors, or otherwise in furtherance of the purposes of the Act.

## IV. Solicitation of Comments

Interested persons are invited to submit written data, views, and arguments concerning the foregoing, including whether the proposed rule change is consistent with the Act. Persons making written submissions should file six copies thereof with the Secretary, Securities and Exchange Commission, 450 Fifth Street, NW., Washington, DC 20549-0609. Copies of the submission, all subsequent amendments, all written statements with respect to the proposed rule change that are filed with the Commission, and all written communications relating to the proposed rule change between the Commission and any person, other than those that may be withheld from the public in accordance with the provisions of 5 U.S.C. 552, will be available for inspection and copying in the Commission's Public Reference Section, 450 Fifth Street, NW., Washington, DC 20549. Copies of such filing also will be available for inspection and copying at the principal office of DTC. All submissions should refer to File No. SR-DTC-99-26 and should be submitted by April 28, 2000.

[^83]For the Commission by the Division of Market Regulation, pursuant to delegated authority. ${ }^{8}$

## Margaret H. McFarland,

Deputy Secretary.
[FR Doc. 00-8492 Filed 4-6-00; 8:45 am]
BILLING CODE 8010-01-M

## SECURITIES AND EXCHANGE COMMISSION

[Release No. 34-42584; File No. SR-DTC-99-22]

## Self-Regulations Organizations; The Depository Trust Company; Order Approving a Proposed Rule Change Relating to Revisions to the Procedures for Running Call Lotteries for Book Entry Only Securities

March 28, 2000.
On September 23, 1999, the Depository Trust Company ("DTC") filed with the Securities and Exchange Commission ("Commission") a proposed rule change (File No. SR-DTC-99-22) pursuant to Section 19(b)(1) of the Securities Exchange Act of 1934 ("Act"). ${ }^{1}$ Notice of the proposal was published in the Federal Register on December 28, 1999. ${ }^{2}$ No comment letters were received. For the reasons discussed below, the Commission is approving the proposed rule change.

## I. Description

Currently, DTC's call lottery process allocates called book-entry only ("BEO") securities among participants having positions in the called securities as of the close of business on the day DTC announces the call lottery ("DTC call announcement date"). DTC adopted these procedures in March 1998 with the approval of the Commission and the endorsement of the Corporate Actions Division of the Securities Industry Association ("Corporate Actions
Division'"). ${ }^{3}$ Prior to March 1998, DTC ran its lotteries based on participants' positions as of the close of business on the day prior to the publication date ("call publication date"). ${ }^{4}$

[^84]At times, DTC receives notice of a call of BEO securities after the redemption date. Under DTC's current BEO call lottery procedures, the DTC call announcement date in such a situation will necessarily be after the date as of which the called securities are deemed to have been redeemed by the issuer. Use of the DTC call announcement date in these instances can have an adverse impact on participants and their customers who have acquired a security position during the period between the redemption date and the DTC call announcement date because they have acquired the called security without notice that the security has been redeemed. Therefore, for call notices received after the redemption date, DTC is amending its BEO securities call lottery procedures so that the allocation lotteries will be run using participants' positions as of the close of business on the day prior to the call publication date. Use of the call publication date to determine lottery allocations for calls of BEO securities where DTC receives notice of the call after the redemption date is consistent with DTC's procedures for lotteries in certificated issues. Allocation lotteries for other calls of BEO securities, where notice is received on or before the redemption date, will continue to be run using participant's positions as of the DTC call announcement date.

## II. Discussion

Section 17A(b)(3)(F) ${ }^{5}$ of the Act requires that the rules of a clearing agency be designed to promote the prompt and accurate clearance and settlement of securities transactions. The Commission believes that DTC's rule change is consistent with DTC's obligations under the Act because the new procedures will mitigate the negative impact of calls of BEO securities that are processed through DTC's lottery process where DTC receives the notification of the call after the redemption date.

[^85]
## III. Conclusion

On the basis of the foregoing, the Commission finds that the proposal is consistent with the requirements of the Act and in particular with the requirements of Section 17A of the Act and the rules and regulations thereunder.

It Is Therefore Ordered, pursuant to Section 19(b)(2) of the Act, that the proposed rule change (File No. SR-DTC-99-22) be, and hereby is, approved.
For the Commission by the Division of Market Regulation, pursuant to delegated authority. ${ }^{6}$
Margaret H. McFarland,
Deputy Secretary.
[FR Doc. 00-8648 Filed 4-6-00; 8:45 am]
BILLING CODE 8010-01-M

## SECURITIES AND EXCHANGE COMMISSION

[Release No. 34-42598; File No. SR-EMCC-99-11]

## Self-Regulatory Organizations; Emerging Markets Clearing Corporation; Notice of Filing and Immediate Effectiveness of Proposed Rule Change Relating to Revisions in Fee Schedule

March 30, 2000.
Pursuant to Section 19(b)(1) of the Securities Exchange Act of 1934 ("Act"), ${ }^{1}$ notice is hereby given that on November 22, 1999, the Emerging Markets Clearing Corporation ("EMCC") filed with the Securities and Exchange Commission ("Commission") the proposed rule change as described in Items I, II, and III below, which items have been prepared primarily by EMCC. The Commission is publishing this notice to solicit comments on the proposed rule change from interested parties.

## I. Self-Regulatory Organization's

Statement of the Terms of Substance of the Proposed Rule Change
The proposed rule change consists of changes to EMCC's fee schedule.

## II. Self-Regulatory Organization's Statement of the Purpose of, and Statutory Basis for, the Proposed Rule Change

In its filing with the Commission, EMCC included statements concerning the purpose of and basis for the proposed rule change and discussed any comments it received on the proposed

[^86]rule change. The text of these statements may be examined at the places specified in Item IV below. EMCC has prepared summaries, set forth in sections (A), (B), and (C) below, of the most significant aspects of these statements. ${ }^{2}$

## (A) Self-Regulatory Organization's

Statement of the Purpose of, and
Statutory Basis for, the Proposed Rule Change

EMCC has determined to charge its trade input fee so that inter-dealer broker members pay $\$ 1.50$ per compared bond side and dealer members pay $\$ 2.00$ per compared bond side.

The proposed rule change is consistent with the requirements of Section $17 \mathrm{~A}(\mathrm{~b})(3)(\mathrm{D})$ of the Act ${ }^{3}$ and the rules and regulations thereunder applicable to EMCC because it provides for the equitable allocation of dues, fees, and other charges among EMCC's participants.

## (B) Self-Regulatory Organization's Statement on Burden on Competition

EMCC does not believe that the proposed rule change will have any impact, or impose any burden, on competition.
(C) Self-Regulatory Organization's Statement on Comments on the Proposed Rule Change Received From Members, Participants or Others

One comment was received by EMCC. ${ }^{4}$ The commenter stated its belief that EMCC's additional fee makes it cost prohibitive to be a member of EMCC. ${ }^{5}$

## III. Date of Effectiveness of the Proposed Rule Change and Timing for Commission Action

The foregoing rule change has become effective pursuant to Section 19(b)(3)(A)(ii) ${ }^{6}$ of the Act and Rule 19b$4(f)(2)^{7}$ promulgated thereunder because the proposal establishes or changes a due, fee, or charge imposed by EMCC. At any time within sixty days of the filing of such proposed rule change, the Commission may summarily

[^87]abrogate such rule change if it appears to the Commission that such action is necessary or appropriate in the public interest, for the protection of investors, or otherwise in furtherance of the purposes of the Act.

## IV. Solicitation of Comments

Interested persons are invited to submit written data, views, and arguments concerning the foregoing, including whether the proposed rule change is consistent with the Act. Persons making written submissions should file six copies thereof with the Secretary, Securities and Exchange Commission, 450 Fifth Street, NW., Washington, DC 20549-0609. Copies of the submission, all subsequent amendments, all written statements with respect to the proposed rule change that are filed with the Commission, and all written communications relating to the proposed rule change between the Commission and any person, other than those that may be withheld from the public in accordance with the provisions of 5 U.S.C. 552, will be available for inspection and copying in the Commission's Public Reference Section, 450 Fifth Street, NW., Washington, DC 20549. Copies of such filing also will be available for inspection and copying at the principal office of EMCC. All submissions should refer to File No. SR-EMCC-99-11 and should be submitted by April 28, 2000.
For the Commission by the Division of Market Regulation, pursuant to delegated authority. ${ }^{8}$
Margaret H. McFarland,
Deputy Secretary.
[FR Doc. 00-8491 Filed 4-6-00; 8:45 am] BILLING CODE 8010-01-M

## SECURITIES AND EXCHANGE COMMISSION

[Release No. 34-42608; File No. SR-MSRB-00-05]

## Self-Regulatory Organizations;

 Municipal Securities Rulemaking Board; Notice of Filing and Immediate Effectiveness of Proposed Rule Change by the Municipal Securities Rulemaking Board Relating to Interpretation of Rule G-38, on ConsultantsApril 3, 2000.
Pursuant to Section 19(b)(1) of the Securities Exchange Act of 1934

[^88]("Act"') ${ }^{1}$ and Rule 19b-4 thereunder, ${ }^{2}$ notice is hereby given that on March 2, 2000, the Municipal Securities Rulemaking Board ("Board" or "MSRB") filed with the Securities and Exchange Commission ("Commission", or "SEC"') a proposed rule change as described in Items I, II, and III below, which Items have been prepared by the Board. The Commission is publishing this notice to solicit comments on the proposed rule change from interested persons.

## I. Self-Regulatory Organization's Statement of the Terms of Substance of the Proposed Rule Change

The MSRB is proposing a notice of interpretation, in question and answer format, concerning MSRB Rule G-38, on consultants. The purpose of the proposed rule change is to provide interpretative guidance concerning MSRB Rule G-38. The proposed rule change is as follows:
Rule G-38 Questions and Answers Concerning Information about Consultants' Political Contributions and Payments to State and Local Political Parties
General Requirements of New Amendments

1. $Q:$ What are the new amendments to rule $G-38$ about?
$A$ : The amendments will require dealers to collect from their consultants, and to disclose to the Board on revised Form $G-37 / G-38$, information regarding certain contributions to issuer officials and certain payments to state and local political parties made by such consultants.
2. Q: What political contributions and political party payments are subject to the new reporting requirement?
A: This depends upon whether the consultant is an individual or a company. If the consultant is an individual, then the contributions and payments that are covered (to the extent reportable under the rule) are those of (1) that individual and (2) any political action committee controlled by such individual. If the consultant is a company, then the contributions and payments that are covered (to the extent reportable under the rule) are those of (1) that company, (2) any partner, director, officer or employee of such company who communicates with an issuer to obtain municipal securities

[^89]business on behalf of the dealer, and (3) any political action committee controlled by such company or any of the individuals identified in the immediately preceding clause (2).
3. Q: May the dealer enter into a Consultant Agreement with either an individual or a company? ${ }^{3}$

A: Yes, provided that the dealer must enter into a Consultant Agreement with the actual party that is serving as the consultant. For example, if the consultant is in effect a company with several employees making actual contact with issuers on the dealer's behalf, a Consultant Agreement entered into only with one of these employees may not, depending upon all the relevant facts and circumstances, satisfy the requirement that the dealer enter into a Consultant Agreement with the consultant.
4. Q: Must a Consultant Agreement include any provisions regarding a consultant's reportable political contributions and reportable political party payments?

A: Yes. A dealer is required to include within its Consultant Agreement a provision to the effect that the consultant agrees to provide the dealer each calendar quarter with either (1) a listing of reportable political contributions to official(s) of an issuer and reportable payments to political parties of states and political subdivisions during such quarter, or (2) a report that no reportable political contributions or reportable political party payments were made during such quarter, as appropriate.
5. Q: Which contributions to issuer officials made by consultants are reportable under the rule?

A: Rule G-38(a)(vi) defines the term "reportable political contribution" to mean, if the consultant has had direct or indirect communication with an issuer on behalf of the dealer or obtain or retain municipal securities business for such dealer, a political contribution to an official(s) of such issuer made by any contributor referred to in rule $G$ 38(b)(i) (see Question and Answer number 2) during the period beginning six months prior to such communication and ending six months after such communication.
6. Q: Which payments to state and local political parties made by consultants are reportable under the rule?

A: Rule G-38(a)(vii) defines the term "reportable political party payment" to

[^90]mean, if a political party of a state or political subdivision operates within the geographic area (e.g., city, county and state parties) of an issuer with which the consultant has had direct or indirect communication to obtain or retain municipal securities business on behalf of the dealer, a payment to such party made by any contributor referred to in rule $G-38(b)$ (i) (see Question and Answer number 2) during the period beginning six months prior to such communication and ending six months after such communication.
7. $Q$ : Is there a de minimis exception for the reporting of political contributions and political party payments?
A: Yes. The de minimis exception for contributions to official(s) of an issuer provides that a consultant need not provide to a dealer information about contributions of the consultant (but only if the consultant is an individual) or by any partner, director, officer or employee of the consultant (if the consultant is a company) who communicates with issuers to obtain municipal securities business on behalf of the dealer made to any official of an issuer for whom such individual is entitled to vote if such individual's contributions, in total, are not in excess of $\$ 250$ to each official of such issuer, per election.

Similarly, the de minimis exception for political party payments provides that a consultant need not provide to a dealer information about payments of the consultant to political parties of a state or political subdivision (but only if the consultant is an individual) or by any partner, director, officer or employee of the consultant (if the consultant is a company) who communicates with issuers to obtain municipal securities business on behalf of the dealer and who is entitled to vote in such state or political subdivision if the payments made by the individual, in total, are not in excess of $\$ 250$ per political party, per year.

Again, the de minimis exception applies only to contributions or payments by individuals. There is no de minimis exception for contributions by the consultant if it is a company or for any PAC controlled by the company or individuals covered by the rule.
8. Q: If a consultant makes political contributions during a particular quarter but these contributions do not meet the definition of "reportable political contribution" as defined in rule $G-38$, is the consultant required to report any information about its political contributions to the dealer?

A: The consultant is required to report to the dealer that it made no reportable political contributions during the quarter.
9. Q: With respect to a particular issuer, if a consultant is communicating with one individual but has made a contribution to a different individual, would the consultant report this contribution to the dealer? For example, if the dealer is seeking municipal securities business from City $A$ and its consultant communicates with the Mayor of the City, would a non-de minimis political contribution to the City's Comptroller (an official of the issuer) have to be reported?
A: Yes. A consultant must report and a dealer must disclose contributions with respect to those "issuers" from which a consultant is seeking municipal securities business on behalf of the dealer, regardless of whether contributions are going to and communications are occurring with the same or different personnel within that particular issuer.
10. Q: What is the date that establishes the obligation for the collection of reportable political contributions and reportable political party payments?
A: The date of the consultant's communication with the issuer to obtain or retain municipal securities business on behalf of the dealer is the key date with respect to determining whether a contribution or payment is reportable. For the quarter in which a consultant first communicates with the issuer, the dealer is required to collect from the consultant its reportable political contributions and reportable political party payments for such quarter and, pursuant to the six-month look-back, for the six-month period preceding such first communication.
11. Q: How do the "look-back" and "look-forward" provisions operate?
A: Pursuant to the look-back provision, a consultant must disclose to the dealer the reportable political contributions and reportable political party payments made by the consultant during the six months prior to the date of the consultant's communication with the issuer. These contributions and payments become reportable in the calendar quarter in which the consultant first communicates with the issuer. Of coursed, any reportable political contributions and reportable political party payments made during the period that the consultant continues to communicate with the issuer are required to be disclosed. Once communication with an issuer ceases, the consultant still must disclose information with respect to reportable
political contributions and reportable political party payments made during the ensuing six months pursuant to the look-forward provision. Contributions and payments made simultaneously with or after the consultant's first communication with the issuer are reportable in the calendar quarter in which they are made.
12. $Q:$ When does the requirement cease for a dealer to collect contribution and payment information from its consultants?
$A$ : The requirement ceases when a consultant agreement has been terminated. Of course, dealers should not attempt to avoid the requirements of rule $G-38$ by terminating a consultant relationship after directing or soliciting the consultant to make a political contribution to an issuer official after such termination. Rule $G-37(d)$ prohibits a dealer from doing any act indirectly which would result in a violation of rule $G-37$ if done directly by the dealer. Thus, a dealer may violate rule $G-37$ by engaging in municipal securities business with an issuer after directing or soliciting any person to make a contribution to an official of such issuer.

## "Reasonable Efforts" Provision

13. $Q$ : What is the reasonable efforts provision contained in rule $G-38$ ?

A: This provision provides that a dealer will not be found to have violated rule $G$-38 if the dealer fails to receive from its consultants all required information about reportable political contributions and reportable political party payments and thus fails to report such information to the Board if the dealer can demonstrate that it used reasonable efforts in attempting to obtain the necessary information.
14. Q: What must a dealer do to avail itself of the reasonable efforts provision?

A: A dealer must: (1) state in the Consultant Agreement that Board rules require disclosure of consultant contributions to issuer officials and payments to state and local political parties; (2) send quarterly reminders to its consultants of the deadline for their submissions to the dealer of contribution and payment information; (3) include language in the Consultant Agreement to the effect that: (a) the Consultant Agreement will be terminated if, for any calendar quarter, the consultant fails to provide the dealer with information about its reportable contributions or payments, or a report noting that the consultant made no reportable contributions or payments, and such failure continues up to the date to be determined by the dealer but no later than the date by which the
dealer is required to send Form $G-37 / G-$ 38 to the Board with respect to the next succeeding calendar quarter, such termination to be effective upon the date the dealer must send its Form $G-37 / G-$ 38 to the Board, and (b) the dealer may not make any further payments to the consultant, including payments owed for services performed prior to the date of termination, as of the date of such termination; and (4) enforce the Consultant Agreement provisions described above in a full and timely manner and indicate the reason for and date of the termination on its Form $G$ -37/G-38 for the applicable quarter.
15. Q: If a dealer does not include the termination and non-payment provisions in a Consultant Agreement or enforce any such provision that may be contained in the Consultant Agreement, would this constitute a violation of rule $G-38$ ?
A: No. Failure to follow the requirements of the reasonable efforts provision would not result in a violation of rule G-38; however, the dealer would be precluded from invoking the reasonable efforts provision as a defense against a possible violation for failing to disclose consultant contribution information which the consultant may have withheld from the dealer. Of course, whether or not a dealer would be charged with a violation of rule $G$ 38 for failure to disclose consultant contribution information would depend upon a review of the facts and circumstances of the individual case by the appropriate regulatory agency.

## Disclosure on Form G-37/G-38

16. Q: What information concerning consultants' political contributions and payments to political parties is ${ }^{4}$ required to be reported to the Board on Form $G-37 / G-38$ ?

A: Forms $G-37 / G-38$ shall include the following information to the extent required to be obtained for a calendar quarter: (1) the name and title (including any city/county/state or political subdivision) of each official of an issuer and political party receiving reportable political contributions or reportable political party payments, listed by state, and contribution or payment amounts made and the contributor category; or (2) if applicable, a statement that the consultant reported that no reportable political contributions or reportable political payments were made; or (3) if applicable, a statement that the

[^91]consultant failed to provide any report of information to the dealer concerning reportable political contributions or reportable political party payments.
17. Q: Does a dealer have a reporting obligation if a consultant fails to provide a report for a particular quarter?

A: Yes. The dealer must disclose on Form $G-37 / G-38$ if the consultant has failed to provide it with a report of its reportable political contributions and reportable political party payments.
18. Q: In listing consultants' reportable political contributions and reportable political party payments on Form $G-37 / G-38$, how are the contributors to be identified?
A: By contributor category (i.e., company, individual, company controlled PAC or individual controlled PAC).
19. Q: How should look-back contributions and payments be disclosed on Form G-37/G-38?
A: Dealers must disclose, in addition to the other required information, the calendar quarter and year of any reportable political contributions and reportable political party payments that were made prior to the calendar quarter for which the form is being completed. Look-back contributions and payments should be disclosed on the Form G-37/ $G-38$ for the quarter in which the consultant has first communicated with an issuer to obtain municipal securities business on behalf of the dealer.

## Recordkeeping

20. Q: What records concerning consultants' political contributions and payments to political parties are required to be maintained?

A: Rule $G-8($ a)(xviii) requires a dealer to maintain: (1) Records of each reportable political contribution, (2) records of each reportable political party payment, (3) records indicating, if applicable, that a consultant made no reportable political contributions or no reportable political party payments, and (4) a statement, if applicable, that a consultant failed to provide any report of information to the dealer concerning reportable political contributions or reportable political party payments.
Effective Date of Requirements Concerning Consultants' Political Contributions and Payments to State and Local Political Parties
21. Q: What is the effective date of the amendments to rule $G-38$ concerning the disclosure of consultants' reportable political contributions and reportable political party payments?
A: The amendments will become effective on April 1, 2000. On the Forms $G-37 / G-38$ for the second quarter of

2000 (required to be sent to the Board by July 31, 2000) dealers are required to disclose their consultants' reportable political contributions and reportable political party payments for the second quarter of 2000 and include, if applicable, reportable political contributions and reportable political party payments made since October 1, 1999 pursuant to the six-month lookback provision.

## II. Self-Regulatory Organization's Statement of the Purpose of, and Statutory Basis for, the Proposed Rule Change

In its filing with the Commission, the MSRB included statements concerning the purpose of and basis for the proposed rule change and discussed any comments it received on the proposed rule change. The text of these statements may be examined at the places specified in Item IV below. The MSRB has prepared summaries, set forth in Sections A, B, and C below, of the most significant aspects of such statements.
A. Self-Regulatory Organization's Statement of the Purpose of, and Statutory Basis for, the Proposed Rule Change

## 1. Purpose

On January 17, 1996, the Commission approved Board rule G-38, on consultants. ${ }^{5}$ The Board adopted the rule because it was concerned about dealers' increasing use of consultants to obtain or retain municipal securities business, notwithstanding the requirements of rule G-37, on political contributions and prohibitions on municipal securities business, rule G20 , on gifts and gratuities, and rule G17, on fair dealing. Rule $\mathrm{G}-38$ requires dealers to disclose information about their consultant arrangements to issuers and the public. On December 7, 1999, the Commission approved amendments to rules G-38, G-37 and G-8, on books and records, as well as revisions to the attachment page to Form G-37/G-38. ${ }^{6}$ The amendments require dealers to obtain from their consultants information on the consultants' political contributions and payments to state and local political parties and to report such information to the Board on Form G-37/ $\mathrm{G}-38$. The amendments will become effective on April 1, 2000. In order to assist the municipal securities industry and, in particular, brokers, dealers and municipal securities dealers in

[^92]understanding and complying with rule $\mathrm{G}-38$, the Board has determined to publish this fifth notice of interpretation which sets forth, in question-andanswer format, general guidance on the amendments that will become effective on April 1, 2000. ${ }^{7}$ The Board will continue to monitor the application of rule G-38, and, from to time, will publish additional notices of interpretations, as necessary.

## IV. Statutory Basis

The MSRB represents that the proposed rule change is consistent with Section 15B(b)(2)(C) of the Act ${ }^{8}$ because it is designed to prevent fraudulent and manipulative acts and practices, to promote just and equitable principles of trade, to foster cooperation and coordination with persons engaged in regulating, clearing, settling, processing information with respect to, and facilitating transactions in municipal securities, to remove impediments to and perfect the mechanism of a free and open market in municipal securities, and, in general, to protect investors and the public interest. ${ }^{9}$

## B. Self-Regulatory Organization's Statement on Burden on Competition

The MSRB does not believe that the proposed rule change will impose any burden on competition not necessary or appropriate in furtherance of the purposes of the Act, since it would apply equally to all brokers, dealers and municipal securities dealers.

## C. Self-Regulatory Organization's

 Statement on Comments on the Proposed Rule Change Received from Members, Participants, or OthersThe MSRB has neither solicited nor received written comments on the proposed rule change.

## III. Date of Effectiveness of the Proposed Rule Change and Timing for Commission Action

The foregoing rule change, which constitutes a stated policy, practice, or interpretation with respect to the meaning, administration, or enforcement of an existing rule imposed by the Exchange, has become effective pursuant to Section 19(b)(3)(A) of the Act ${ }^{10}$ and subparagraph (f)(1) of Rule

[^93]19b-4 thereunder. ${ }^{11}$ At any time within 60 days of the filing of the proposed rule change, the Commission may summarily abrogate such rule change if it appears to the Commission that such action is necessary or appropriate in the public interest, for the protection of investors, or otherwise in furtherance of the purposes of the Act.

## IV. Solicitation of Comments

Interested persons are invited to submit written data, views, and arguments concerning the foregoing, including whether the proposed rule change is consistent with the Act. Persons making written submissions should file six copies thereof with the Secretary, Securities and Exchange Commission, 450 Fifth Street, NW, Washington, DC 20549-0609. Copies of the submission, all subsequent amendments, all written statements with respect to the proposed rule change that are filed with the Commission, and all written communications relating to the proposed rule change between the Commission and any person, other than those that may be withheld from the public in accordance with the provisions of 5 U.S.C. § 552, will be available for inspection and copying at the Commission's Public Reference Room. Copies of such filing also will be available for inspection and copying at the principal office of the MSRB. All submissions should refer to File No. SR-MSRB-00-05 and should be submitted by April 28, 2000.
For the Commission, by the Division of Market Regulation, pursuant to delegated authority. ${ }^{12}$

## Margaret H. McFarland,

Deputy Secretary.
[FR Doc. 00-8650 Filed 4-6-00; 8:45 am]
BILLING CODE 8010-01-M

[^94]
## SECURITIES AND EXCHANGE COMMISSION

[Release No. 34-42601; File No. SR-NASD-99-74]

Self-Regulatory Organizations; Notice of Filing of Proposed Rule Change and Amendment Nos. 1 and 2 by the National Association of Securities Dealers, Inc. Relating to an Exemption From NASD Conduct Rule 2710 for Closed-End Management Companies That Make Periodic Repurchases of Their Securities Under Rule 23c-3(b) of the Investment Company Act of 1940

March 30, 2000.
Pursuant to Section 19(b)(1) of the Securities Exchange Act of 1934 ("Act"), ${ }^{1}$ and Rule 19b-4 thereunder, ${ }^{2}$ notice is hereby given that on December 20, 1999, the National Association of Securities Dealers, Inc. ("NASD" or "Association"), through its wholly owned subsidiary, NASD Regulation, Inc. ("NASD Regulation"), filed with the Securities and Exchange Commission ("Commission" or "SEC') the proposed rule change as described in Items I, II, and III below, which Items have been prepared by NASD Regulation. The Association filed an amendment to the proposed rule change on February 29, 2000, which Amendment entirely replaces and supersedes the initial proposal. ${ }^{3}$ On March 20, 2000, the Association filed Amendment No. 2. ${ }^{4}$ The Commission is publishing this notice to solicit comments on the proposed rule change, as amended, from interested persons.

## I. Self-Regulatory Organization's Statement of the Terms of Substance of the Proposed Rule Change

NASD Regulation proposes to amend NASD Conduct Rules 2710 ("Corporate Financing Rule") and 2830 to exempt public offerings by closed-end investment management companies that make periodic tender offers for their securities in compliance with Rule 23c3(b) ${ }^{5}$ of the Investment Company Act of

[^95]$1940{ }^{6}$ (the " 1940 Act") from the filing requirements and limitations on underwriting compensation of the corporate Financing Rule and, instead, subject such offerings to the sales charge limitations of NASD Conduct Rule 2830. Below is the text of the proposed rule change. Proposed new language is in italics; proposed deletions are in brackets.

## 2710. Corporate Financing Rule-

 Underwriting Terms and Arrangements(a) No change.
(b) Filing Requirements.
(1)-(7) No change.
(8) Exempt Offerings.

Notwithstanding the provisions of subparagraph (1) above, the following offerings are exempt from this Rule, Rule 2720, and rule 2810. Documents and information relating to the following offerings need not be filed for review:
(A)-(B) No Change.
(C) securities of [investment companies registered under the Investment Company Act of 1940, as amended, except securities of a management company defined as a "closed-end company" in Section $5(\mathrm{a})(2)$ of that Act] "open-end" investment companies as defined in Section 5(a)(1) of the Investment Company Act of 1940 and securities of any "closed-end" investment company as defined in Section 5(a)(2) of that Act that:
(i) makes periodic repurchase offers pursuant to Rule 23c-3(b) under the Investment Company Act of 1940; and
(ii) offers its shares on a continuous basis pursuant to Rule 415(a)(1)(xi) under the Securities Act of 1933.
(D)-(J) No change.
(9)-(12) No change.
(c)-(d) No change.

## 2830. Investment Company Securities

(a)-(c) No change.
(d) Sales Charge.

No members shall offer or sell the shares of any open-end investment company, any Closed-end investment company that makes periodic repurchase offers pursuant to Rule 23c3(b) under the 1940 Act and offers its shares on a continuous basis pursuant to Rule 415(a)(1)(xi) under the Securities Act of 1933, or any "single payment" investment plan issued by a unit investment trust (collectively "investment companies") registered under the 1940 Act if the sales charges described in the prospectus are excessive. Aggregate sales charges shall

[^96]be deemed excessive if they do not conform to the following provisions:
(1)-(5) No change.
(e)-(i) No change.
(j) Repurchase from Dealer.

No member who is a principal underwriter of a security issued by an open-end [management] investment company or a closed-end investment company that makes periodic repurchase offers pursuant to Rule 23c3(b) under the 1940 Act and offers its shares on a continuous basis pursuant to Rule 415(a)(1)(xi) under the Securities Act of 1933 shall repurchase such security, either as principal or as agent for the issuer, from a dealer acting as principal who is not a party to a sales agreement with a principal underwriter, nor from any investor, unless such dealer or investor is the record owner of the security so tendered for repurchase. No member who is a principal underwriter shall participate in the offering or in the sale of any such security if the issuer voluntarily redeems or repurchases its securities from a dealer acting as principal who is not a party to such a sales agreement nor from any investor, unless such dealer or investor is the record owner of the security so tendered for repurchase. Nothing in this paragraph shall relate to the compulsory redemption of any security upon presentation to the issuer pursuant to the terms of the security.
Nothing in this Rule shall prevent any member, whether or not a party to a sales agreement, from selling any such security for the account of a record owner to the underwriter or issuer at the bid price next quoted by or for the issuer and charging the investor a reasonable charge for handling the transaction, provided that such member discloses to such record owner that direct redemption of the security can be accomplished by the record owner without incurring such charges.
(k)-(n) No change.

## II. Self-Regulatory Organization's Statement of the Purpose of, and Statutory Basis for, the Proposed Rule Change

In its filing with the Commission, NASD Regulation included statements concerning the purpose of and basis for the proposed rule change and discussed any comments it received on the proposed rule change. The text of these statements may be examined at the places specified in Item IV below. NASD Regulation has prepared summaries, set forth in sections A, B, and C below, of the most significant aspects of such statements.
A. Self-Regulatory Organization's Statement of the Purpose of, and Statutory Basis for, the Proposed Rule Change

## 1. Purpose

The Corporate Financing Rule regulates the underwriting terms and other arrangements of public offerings of securities. Subparagraph (b)(8)(C) of the Corporate Financing Rule provides that securities of investment companies registered under the 1940 Act $^{7}$ are exempt from filing and compliance with the Corporate Financing Rule, unless the offering is of securities of a management company defined as a "closed-end" company in Section $5(\mathrm{a})(2)^{8}$ of the $1940 \mathrm{Act}^{9}$ ("closed-end funds"). ${ }^{10}$ Thus, closed-end funds are subject to the filing requirements, filing fees, and regulations of the Corporate Financing Rule. Open-end investment management companies ("open-end funds'") that continuously offer redeemable securities are exempt from filing with NASD Regulation under the Corporate Financing Rule and a member's receipt of their sales charges is regulated under NASD Conduct Rule 2830.

Closed-end funds are subject to the core provisions of the 1940 Act ${ }^{11}$ that also apply to open-end funds, including prohibitions on affiliated transactions, obligations requiring shareholder approval of advisory contracts, antipyramiding restrictions, and board composition requirements. However, such funds are not subject to other 1940 Act ${ }^{12}$ restrictions applicable to openend funds, including limitations on leverage and obligations pertaining to the liquidity of investments. The Corporate Financing Rule and its predecessor rule have long been applied to members' sales of the securities of closed-end funds on the basis that closed-end fund offerings are structured and marketed in a manner that is more similar to and competitive with corporate securities offerings than to open-end funds. At the time the Corporate Financing Rule was adopted, closed-end funds conducted offerings of a fixed number of common shares at specified times; priced their shares

[^97]periodically; limited sales compensation of broker/dealers to a discount from a fixed offering price; did not redeem their securities; and generally listed their securities on a securities market.
Certain closed-end funds, commonly known as "interval funds," have developed a hybrid structure in which they engage in continuous offerings of their securities under Rule $415{ }^{13}$ under the Securities Act of 1933; ${ }^{14}$ price their shares daily; pay broker/dealers initial and continuing compensation that meets the sales charge limitations of NASD Conduct Rule 2830; do not list their securities on a securities market; and redeem shares by making periodic self-tenders in compliance with Rule $23 \mathrm{c}-3(\mathrm{~b})^{15}$ of the 1940 Act. ${ }^{16}$ Rule 23c$3(b)^{17}$ requires that the interval fund establish as a fundamental policy, changeable only by a majority vote of the outstanding voting securities of the company, that it will make periodic repurchase offers. Because the shares of interval funds are not redeemable on a daily basis, they are nonetheless classified as "closed-end" under the 1940 Act. ${ }^{18}$

In Notice to Members 98-81 (October, 1998), NASD Regulation requested public comment on whether any of the NASD's rules are obsolete. One commenter, the Investment Company Institute, proposed exempting interval funds from regulation by the Corporate Financing Rule. In addition, the Corporate Financing Department has received a rulemaking petition requesting an exemption from the Corporate Financing Rule for interval funds. NASD Regulation believes that the distribution of interval fund shares is conducted and financed in a manner more similar to that used by open-end management investment companies than the method used by traditional closed-end funds. Therefore, the calculation of members' compensation for the distribution of interval fund shares is more properly regulated by provision (d) of NASD Conduct Rule 2830 (provision (d) hereinafter, the "Sales Charge Rule"), rather than by the limitations on underwriting compensation in the Corporate Financing Rule.

Consequently, NASD Regulation proposes to amend the Corporate Financing Rule and NASD Conduct Rule 2830 to exempt interval funds from the filing requirements, filing fees, and

[^98]regulations of the Corporate Financing Rule and to, instead, subject them to NASD Conduct Rule 2830, which regulates the distribution and sales charges of open-end funds. ${ }^{19}$ The proposed amendment to the Corporate Financing Rule would amend subparagraph (b)(8)(C) to provide that closed-end fund offerings are exempt if the fund makes periodic repurchase offers pursuant to Rule $23 \mathrm{c}-3$ (b) ${ }^{20}$ and it offers its shares on a continuous basis pursuant to Rule $415^{21}$ under the Securities Act of 1933.22 Closed-end funds that do not meet these requirements will continue to be subject to the Corporate Financing Rule. The proposed amendment to NASD Conduct Rule 2830 would amend paragraphs (d) and (j) to provide that interval funds are subject to the provisions regulating sales charges and the repurchases of fund securities. ${ }^{23}$

## 2. Statutory Basis

NASD Regulation believes that the proposed rule change is consistent with the provisions of Section 15A(b)(6) of the Act, ${ }^{24}$ which requires, among other things, that the Association's rules must be designed to prevent fraudulent and manipulative acts and practices, to promote just and equitable principles of trade, and, in general, to protect investors and the public interest. NASD Regulation believes that the calculation of members' compensation for the distribution of interval fund shares is more properly regulated by the Sales

[^99]Charge Rule, rather than by the limitations on underwriting compensation in the Corporate Financing Rule.

## B. Self-Regulatory Organization's Statement on Burden on Competition

NASD Regulation does not believe that the proposed rule change will result in any burden on competition that is not necessary or appropriate in furtherance of the purposes of the Act, as amended.

## C. Self-Regulatory Organization's Statement on Comments on the Proposed Rule Change Received From Members, Participants or Others

NASD Notice to Members 98-81 (October, 1998) requested comment on whether any NASD rules are obsolete. A copy of the comment letter received from the Investment Company Institute in response to the Notice that requested the amendments proposed herein was filed with the proposed rule change. A copy of a petition for rulemaking requesting the amendments proposed herein submitted by the law firm of Stradley Ronon Stevens \& Young on behalf of Franklin/Templeton Distributors, Inc. was also attached to the proposed rule change.

## III. Date of Effectiveness of the Proposed rule Change and Timing for Commission Action

Within 35 days of the date of publication of this notice in the Federal Register or within such longer period (i) as the Commission may designate up to 90 days of such date if it finds such longer period to be appropriate and publishes its reasons for so finding or (ii) as to which the NASD consents, the Commission will:
a. By order approve such proposed rule change, or
b. Institute proceedings to determine whether the proposed rule change should be disapproved.

## IV. Solicitation of Comments

Interested persons are invited to submit written data, views and arguments concerning the foregoing, including whether the proposed rule change is consistent with the Act. Persons making written submissions should file six copies thereof with the Secretary, Securities and Exchange Commission, 450 Fifth Street, NW, Washington, DC 20549-0609. Copies of the submission, all subsequent amendments, all written statements with respect to the proposed rule change that are filed with the Commission, and all written communications relating to the proposed rule change between the

Commission and any person, other than those that may be withheld from the public in accordance with the provisions of 5 U.S.C. 552 , will be available for inspection and copying in the Commission's Public Reference Room. Copies of such filing will also be available for inspection and copying at the principal office of the NASD. All submissions should refer to file number SR-NASD-99-74 and should be submitted by April 28, 2000.

For the Commission by the Division of Market Regulation, pursuant to delegated authority. ${ }^{25}$
Margaret H. McFarland,
Deputy Secretary.
[FR Doc. 00-8490 Filed 4-6-00; 8:45 am] BILLING CODE 8010-01-M

## SECURITIES AND EXCHANGE COMMISSION

[Release No. 34-42606; File No. SR-NASD-00-02]

## Self-Regulatory Organizations; Notice of Filing of Proposed Rule Change by the National Association of Securities Dealers, Inc. Amending NASD Code of Arbitration Rules 10335 and 10205(h) Regarding Injunctive Relief

April 3, 2000.
Pursuant to Section 19(b)(1) of the Securities Exchange Act of 1934 ("Act") ${ }^{1}$ and Rule $19 \mathrm{~b}-4$ thereunder, ${ }^{2}$ notice is hereby given that on January 13, 2000, ${ }^{3}$ the National Association of Securities Dealers, Inc. ("NASD"' or "Association"), through its whollyowned subsidiary NASD Regulation, Inc. ("NASD Regulation'") filed with the Securities and Exchange Commission ('SEC'" or "Commission'') a proposed rule change as described in Items I, II, and III below, which Items have been prepared by NASD Regulation. The Commission is publishing this notice to solicit comments on the proposed rule change from interested persons.

## I. Self-Regulatory Organization's Statement of the Terms of Substance of the Proposed Rule Change

NASD Regulation is proposing to amend Rules 10335 and 10205(h) of the

[^100]Code of Arbitration Procedure of the NASD, to simplify and clarify the procedures for obtaining injunctive relief in certain disputes subject to arbitration. Below is the text of the proposed rule change. Proposed new language is in italics; proposed deletions are in brackets.

RULES OF THE ASSOCIATION
10000. CODE OF ARBITRATION PROCEDURE
10300. UNIFORM CODE OF ARBITRATION
Rule 10335. [Injunctions] Temporary Injunctive Orders; Requests for Permanent Injunctive Relief
[The current text of Rule 10335 is deleted in its entirety.]
(a) Temporary Injunctive Orders
(1) In industry or clearing disputes required to be submitted to arbitration pursuant to Rule 10201, parties may seek a temporary injunctive order, as defined in subparagraph (a)(2) of this Rule, from a court of competent jurisdiction. Parties to a pending arbitration may seek a temporary injunctive order from a court of competent jurisdiction even if another party has already filed a claim arising from the same dispute in arbitration pursuant to this paragraph, provided that an arbitration hearing on a request for permanent injunctive relief has not yet commenced.
(2) For purposes of this Rule, temporary injunctive order means a temporary restraining order, preliminary injunction or other form of initial, temporary injunctive relief.
(3) A party seeking a temporary injunctive order from a court with respect to an industry or clearing dispute required to be submitted to arbitration pursuant to Rule 10201 shall simultaneously file with the Director a Statement of Claim requesting permanent relief with respect to the same dispute in the manner specified under this Code, and shall simultaneously serve the Statement of Claim requesting permanent relief on all parties. Filings and service under this Rule may be made by facsimile, overnight delivery service or messenger. A party obtaining a court-issued temporary injunctive order shall notify the Director and the other parties of the issuance of the order within one business day.
(4) Unless otherwise stated, for purposes of computation of time under any paragraph of this Rule, any
reference to days means calendar days, including Saturdays, Sundays or any NASD holiday. However, if a party must provide notice or a response to the Director and the day on which that notice or response to the Director must be given falls on a Saturday, Sunday or any NASD holiday, then the time period is extended until the next business day.
(b) Hearing on Request for Permanent Injunctive Relief
(1) Scheduling of Hearing

If a court issues a temporary
injunctive order, an arbitration hearing on the request for permanent injunctive relief shall commence within 15 days of the date the court issues the temporary injunctive order. If the 15th day falls on a Saturday, Sunday, or NASD holiday, the 15-day period shall expire on the next business day. The Director shall provide to all parties notice of the date, time and place of the hearing at least three days prior to the commencement of the hearing.
(2) Composition of Arbitration Panel

The hearing on the request for permanent injunctive relief shall be heard by a panel of three arbitrators, who shall either be all non-public arbitrators as defined in Rule 10308(a)(4), or, if the underlying dispute would be heard by a public arbitrator or panel consisting of a majority of public arbitrators under rule 10202, a majority of public arbitrators as defined in Rule 10308(a)(5).
(3) Selection of Arbitrators and Chairperson
(A) In cases in which all of the members of the arbitration panel are non-public under paragraph (b)(2) of this Rule, the Director shall generate and provide to the parties a list of seven arbitrators from a national roster of arbitrators. At least a majority of the arbitrators listed shall be lawyers specializing in injunctive relief. Each party may exercise one strike to the arbitrators on the list. Within three days of receiving the list, each party shall inform the Director which arbitrator, if any, it wishes to strike, and shall rank the remaining arbitrators in order of preference.
(B) In cases in which the panel of arbitrators consists of a majority of public arbitrators under paragraph (b)(2) of this Rule, the Director shall generate and provide to the parties a list of nine arbitrators from a national roster of arbitrators. At least a majority of the arbitrators listed shall be (1) public arbitrators and (2) lawyers specializing in injunctive relief. Each party may exercise two strikes to the arbitrators on the list. Within three days of receiving the list, each party shall inform the Director which arbitrators, if any, it
wishes to strike, and shall rank the remaining arbitrators in order of preference.
(C) Each party shall inform the Director of its preference of chairperson of the arbitration panel by the close of business on the next business day after receiving notice of the panel members. If the parties do not agree on a chairperson within that time, the Director, shall select the chairperson. In cases in which the panel consists of a majority of public arbitrators, the chairperson shall be one of the public arbitrators who is a lawyer specializing in injunctive relief. In cases in which the panel consists of non-public arbitrators, the chairperson shall be a lawyer specializing in injunctive relief. Whenever possible, the Director shall select as chairperson the lawyer specializing in injunctive relief whom the parties have ranked the highest.
(D) The Director may exercise discretionary authority and make any decision that is consistent with the purposes of this Rule and Rule 10308 to facilitate the appointment of arbitration panels and the selection of chairperson.
(4) Applicable Legal Standard

The legal standard for granting or denying a request for permanent injunctive relief is that of the state where the events upon which the request is based occurred, or as specified in an enforceable choice of law agreement between the parties.
(5) Effect of Pending Temporary Injunctive Order

Upon a full and air presentation of the evidence from all relevant parties on the request for permanent injunctive relief, the panel may prohibit the parties from seeking an extension of any courtissued temporary injunctive order remaining in effect, or, if appropriate, order the parties jointly to move to modify or dissolve any such order. In the event that a panel's order conflicts with a pending court order, the panel's order will become effective upon expiration of the pending court order.
(6) Fees, Costs and Expenses, and Arbitrator Honorarium
(A) The parties shall jointly bear the travel-related costs and expenses of the arbitrators appointed to hear the request for permanent injunctive relief. The arbitrators shall not reallocate such costs and expenses among the parties.
(B) The party seeking injunctive relief shall pay the expedited hearing fees pursuant to Rule 10205(h), or, where both sides seek such relief, both parties shall pay such fees. In either event, however, the arbitrator(s) shall have the authority to allocate such fees among the parties.
(C) Notwithstanding any other provision in the Code, the chairperson of the panel hearing a request for permanent injunctive relief pursuant to this Rule shall receive an honorarium of $\$ 375$ for each single session, and \$700 for each double session, of the hearing. Each other member of the panel shall receive an honorarium $\$ 300$ for each single session, and $\$ 600$ for each double session, of the hearing. The parties shall equally pay the difference between these amounts and the amounts panel members and the chairperson receive under the Code pursuant to IM-10104. the arbitrators shall not reallocate such amount among the parties.
(c) Hearing on Damages or other Relief
(1) Upon completion of the hearing on the request for permanent relief, the panel, may, if necessary, set a date for any subsequent hearing on damages or other relief, which shall be held before the same panel of arbitrators and which shall include, but not be limited to, the same record.
(2) The parties shall jointly bear the travel-related costs and expenses of the arbitrators resulting from any subsequent hearings on damages or other relief. The arbitrators shall not reallocate such costs and expenses among the parties.
(d) Effective Date

This Rule shall apply to arbitration claims filed on or after [60 days from effective date.] Except as otherwise provided in this Rule, the remaining provisions of the Code shall apply to proceeding instituted under this Rule.

## 10200. INDUSTRY AND CLEARING CONTROVERSIES

10205. Schedule of Fees for Industry and Clearing Controversies
(h) [In each industry dispute of clearing controversy which is required to be submitted to arbitration before the Association as set forth in Rule 10201, above, where interim injunctive relief is requested or where a court has issued a temporary injunction and a party requests expedited proceedings, a total non-refundable surcharge of $\$ 2,500$ shall be paid by the party or parties requesting the expedited proceedings as provided by Rule 10335. For purposes of this Rule, where expedited
proceedings are mandated by Rule 10335(g), the party that sought and was granted injunctive relief by a court shall be deemed a party requesting expedited proceedings. These surcharges shall be in addition to all other non-refundable filing fees, hearing deposits, or costs which may be required. The arbitrator
may determine that a party shall reimburse another party for any nonrefundable surcharge it has paid.] $A$ party seeking a temporary injunctive order in court pursuant to Rule 10335 shall pay a total non-refundable surcharge of \$2,500 at the time the party files its Statement of Claim and Request for Permanent Relief as required by Rule 10335. Where more than one party seeks such relief, all such parties shall pay the surcharge. The arbitrator may determine that a party shall reimburse another party for part or all of any nonrefundable surcharge it has paid. These surcharge fees shall be in addition to all other non-refundable filing fees, hearing deposits, or costs which may be required.

## II. Self-Regulatory Organization's Statement of the Purpose of, and Statutory Basis for, the Proposed Rule Change

In its filing with the Commission, NASD Regulation included statements concerning the purpose of and basis for the proposed rule change and discussed any comments it received on the proposed rule change. The text of these statements may be examined at the places specified in Item IV below. NASD Regulation has prepared summaries, set forth in Sections A, B, and $C$ below, of the most significant aspects of such statements.
A. Self-Regulatory Organization's Statement of the Purpose of, and Statutory Basis for, the Proposed Rule Change

## 1. Purpose

Rule 10335, the NASD's pilot injunctive relief rule, allows interim injunctive relief to be obtained in controversies involving member firms and associated persons in arbitration. The rule has primarily been used in "raiding cases," or cases involving the transfer of an employee to another firm. Rule 10335 took effect on January 3, 1996 for a one-year pilot period. The Commission has periodically extended the initial pilot period in order to permit NASD Regulation's Office of Dispute Resolution to assess the effectiveness of the rule. The pilot rule is currently due to expire on January 5, 2001. ${ }^{4}$

In November 1997, the NASD published Notice to Members 97-59, which sought comment on how the injunctive relief and expedited proceedings work and how they could be improved, and identified more than

[^101]twenty specific questions based on previous comments received from users of the rule. Based on comments received in response to Notice to Members 9759, the NASD filed a rule to amend Rule 10335 and to make it a permanent part of the Code (SR-NASD-98-49) in July 1998. The NASD filed amendments and responses to comments received by the Commission regarding the rule filing in December 1998.
In response to additional formal and informal comments received after the amendments and responses to comments were filed, the Injunctive Relief Rule Subcommittee of NASD Regulation's Inc's National Arbitration and Mediation Committee ("NAMC") undertook to reconsider every aspect of the proposed rule change. In addition to its NAMC members, the Subcommittee included representatives from member firms that has expressed an interest in the rule, including all of the retail firms that commented negatively on the prior rule filing.

After lengthy deliberation and careful compromise, the Subcommittee recommended withdrawing the previous rule filing and replacing it with the proposed amendments summarized below. The NAMC approved the proposed amendments at its September 1999 meeting. The proposed amendments were then approved by the Small Firm Advisory Board and the Board of Directors of NASD Regulations in December 1999.

## Summary of the Current Rule

Rule 10335 currently provides, among other things, that:

- Parties may seek temporary injunctive relief either in court or in arbitration.
- Parties who seek temporary injunctive relief in court must simultaneously submit the claim to arbitration for permanent relief.
- Parties may obtain interim injunctive relief in arbitration rather than in court in the form of either an Immediate Injunctive Order or a Regular Injunctive Order.
- Permanent injunctive relief may be obtained in arbitration as part of the final relief sought by a party in connection with a claim.
- Applications for interim injunctive relief are expedited.
- Where a court grants interim injunctive relief to one of the parties, arbitration proceedings on the dispute must be expedited.


## Summary of Proposed Rule Change

The NASD continues to believe that it is important that parties be able to obtain immediate temporary injunctive
relief in cases that warrant such relief. However, users of the rule have complained that the bifurcated procedures and multiple layers of review provided by the current pilot rule are unnecessarily complex and confusing. The principal objectives of the proposed amendments are to simplify and expedite the procedures for seeking immediate injunctive relief in intra-industry disputes and to fairly and effectively integrate court-ordered initial injunctive relief with the arbitration of the underlying claims in the same disputes.

## Availability of Injunctive Relief in Arbitration

The most significant aspect of the proposed rule change is that it would eliminate the option of seeking temporary injunctive relief in arbitration. Under the current rule, parties may seek either an Immediate Injunctive Order or a Regular Injunctive Order in arbitration, which are roughly parallel to temporary restraining orders and preliminary injunctions available in court. The rule does not currently impose any time limits on the orders issued, and does not specify what standard should be applied in deciding applications for injunctive relief. Users of the pilot rule have complained that the terminology is confusing, that the lack of standards has created uncertainty, and that the lack of time limits permits parties who obtain relief to pressure the enjoined party to settle by delaying the hearing on the merits. In addition, experience with the rule has shown that, although temporary injunctive relief is available in arbitration on an expedited basis, it is still not possible to obtain such injunctive relief in arbitration as quickly as in court, due largely to the need to appoint and convene arbitrators specifically for each case.

Under the proposed amendments, parties would still be able to seek temporary injunctive relief in a court of competitive jurisdiction. The rule would continue to require parties seeking such relief to simultaneously file a Statement of Claim in arbitration requesting permanent relief regarding the same dispute. This requirement reflects the intent of the rule to provide parties with an ability to seek immediate relief, but to ensure that the underlying disputes remain subject to arbitration.
One question that has arisen in the application of the pilot rule is whether parties can seek temporary injunctive relief in court even if a Statement of Claim has already been filed in arbitration regarding the underlying
dispute. Under the proposed amendments, parties to a pending arbitration would be able to seek a temporary injunctive order in court even if another party has already filed a claim arising from the same dispute in arbitration, provided that an arbitration hearing on a request for permanent injunctive relief had not yet commenced.

## Hearing on Request for Permanent Relief; Selection of Arbitrators; Appointment of Chairperson

Under the proposed amendments, if a court issues a temporary injunctive order, the hearing on the request for permanent relief must commence within 15 days of the date the court issued its order. The hearing on the request for permanent injunctive relief would be heard by a panel of three arbitrators. In cases in which the underlying dispute would be heard by a panel of non-public arbitrators as defined in Rule 10308(a)(4), the three arbitrators would be non-public. In cases in which the underlying dispute would be heard by a public arbitrator or panel consisting of a majority of public arbitrators under Rule 10202, the panel hearing the request for permanent relief would consist of a majority of public arbitrators as defined in Rule 10308(a)(5).

In cases in which all of the members of the arbitration panel are non-public, the Director of Arbitration would generate and provide to the parties a list of seven arbitrators from a national roster of arbitrators, at least a majority of whom would be lawyers specializing in injunctive relief. Each party would be able to exercise one strike to the arbitrators on the list.

In cases in which the panel of arbitrators consists of a majority of public arbitrators, the Director of Arbitration would generate and provide to the parties a list of nine arbitrators from a national roster of arbitrators. At least a majority of the arbitrators in those cases would be (1) public arbitrators and (2) lawyers specializing in injunctive relief. In those cases, the parties would be able to exercise two strikes to the arbitrators on the list. Regardless of the number of strikes given to the parties, the rule would incorporate by reference other Code of Arbitration rules providing unlimited strikes for cause, so that parties would always be able to strike arbitrators who were unqualified due to conflicts of interest or for other reasons.

Under the proposed amendments, the parties would be required to inform the Director of their preference of chairperson of the arbitration panel by
the close of business on the next business day after receiving notice of the panel members. If the parties did not agree on a chairperson within that time, the Director would select the chairperson. In cases in which the panel consists of a majority of public arbitrators, the chairperson would be one of the public arbitrators who is a lawyer specializing in injunctive relief. In cases in which the panel consists of non-public arbitrators, the chairperson would be a lawyer specializing in injunctive relief. Whenever possible, the Director would select as chairperson the lawyer specializing in injunctive relief whom the parties have ranked the highest. The rule would also provide that the Director of Arbitration may exercise discretionary authority and make any decision that is consistent with the purposes of the rule and the arbitrator selection rule (Rule 10308) to facilitate the appointment of arbitration panels and the selection of the chairperson.
The timing of the hearing, the composition of the panel and the selection of the chairperson are the result of a carefully crafted compromise that is intended to balance the need to ensure fairness for all parties with the need to commence the arbitration process as quickly as possible.

## Applicable Legal Standard

The proposed rule would provide that the decision to grant or deny a request for permanent injunctive relief would be governed by an enforceable choice of law agreement between the parties, or, if there were no such agreement, then by the law of the state where the events upon which the request is based occurred.

## Temporary Injunctive Order in Effect During Hearing

One of the most difficult aspects of integrating court-ordered injunctive relief with arbitration of the underlying claims in the same dispute is the treatment of a pending court order in effect at the commencement of the hearing on the request for permanent relief. This becomes a potentially important issue in the event that the pending court order conflicts with the decision of the panel, because conflicting orders from a court and the arbitration panel could place parties in the position of either having to be in contempt of a pending court order or violation of an arbitration order.
NASD Regulation does not believe that arbitration panels have the authority to dissolve, modify or supersede a court order. However, arbitrators do have the authority to
order parties not to seek extensions of pending orders, or to jointly ask the court to modify or dissolve a pending order, if necessary. To address this issue, the proposed rule change would provide that, in the event that a courtissued temporary injunctive order is still in effect, after a full and fair presentation of evidence from all relevant parties, an arbitration panel may prohibit the parties from seeking an extension of the pending court order, and, if appropriate, may order the parties to jointly move the court to modify or dissolve the pending court order. In the event that a panel's order conflicts with a pending court order, the panel's order will become effective upon expiration of the pending court order.

## Fees

Expediting the hearing on the request for permanent relief and providing arbitrators who meet the special requirements of Rule 10335 may involve additional costs and expenses. For example, in order to appoint the required number of qualified arbitrators in the short time frame provided by the rule, it may be necessary to use arbitrators from cities other than the site of the hearing. Because expedition of the hearing on the request for permanent relief is in the interest of all parties, particularly the party against whom a court-ordered temporary restraining order has been entered, the proposed amendments provide that the parties would jointly bear the travelrelated costs and expenses of the arbitrators appointed to hear the request for permanent injunctive relief. To ensure that these additional expenses are borne equally by the parties, the rule would prohibit the arbitrators from reallocating arbitrator travel costs and expenses among the parties.
Similarly, the rule provides that, notwithstanding any other provision in the Code, the chairperson of the panel hearing a request for permanent injunctive relief pursuant to this rule shall receive an honorarium of $\$ 375$ for each single session, and $\$ 700$ for each double session, of the hearing. Each other member of the panel shall receive an honorarium of $\$ 300$ for each single session, and $\$ 600$ for each double session, of the hearing. The NASD believes that these additional amounts are necessary to ensure that a sufficient number of qualified arbitrators are available to participate in such hearings in the short time frame provided by the rule. Again, because both parties benefit from the expedition of the hearing on the request for permanent relief, the NASD believes that it is equitable that
the parties share the difference between these amounts and the amounts panel members and the chairperson would otherwise receive under the Code. As in the case of additional travel costs and expenses, the rule ensure this balance by prohibiting arbitrators from reallocating these amounts among the parties. ${ }^{5}$

Finally, the rule also provides that the party seeking injunctive relief shall pay the expedited hearing fees pursuant to Rule 10205(h), or, where both sides seek such relief, both parties shall pay such fees. In either event, the rule specifically provides that the arbitrators shall have the authority to allocate such fees among the parties. The rule has no effect on the obligations of parties to pay, or on the authority of arbitrators to allocate, any other hearing fees required under the Code.

## Subsequent Hearings on Damages or Other Relief

The hearing on the request for permanent relief is intended to address only the question of injunctive relief. It is not intended to address other forms of relief, such as damages, which do not need to be heard on an expedited basis. The rule provides that if, upon completion of the hearing on the request for permanent relief, a subsequent hearing on other forms of relief is necessary, the panel shall set the date for the subsequent hearing. This would provide parties the opportunity to develop a more complete record than might be possible within the constraints of the expedited injunctive relief hearing. Any subsequent hearing would be before the same panel that heard the request for permanent injunctive relief, and would include, but would not be limited to, the record developed at the earlier hearing. The rule would also provides that the parties would jointly bear the travel-related costs and expenses of the arbitrators resulting from any subsequent hearings on damages or other relief, and prohibits the arbitrators from reallocating those costs and expenses among the parties.

## Rule 10205(n)

Rule 10205(h), Schedule of Fees in Industry and Clearing Controversies, currently provides that when temporary injunctive relief is sought in arbitrators or in court, a non-refundable surcharge of $\$ 2,500$ shall be paid by the party or parties requesting the expedited proceedings as provided in Rule 10335. To harmonize Rule 10205(h) with the

[^102]proposed amendments to Rule 10335, the proposed rule change would also amend Rule 10205(h) to eliminate reference to the availability of temporary injunctive relief in arbitration, and to clarify the application of the provision of temporary injunctive orders sought in court.

## 2. Statutory Basis

NASD Regulation believes that the proposed rule change is consistent with the provisions of Section 15A(b)(6) of the Act, which requires, among other things, that the Association's rules must be designed to prevent fraudulent and manipulative acts and practices, to promote just and equitable principles of trade, and, in general, to protect investors and the public interest. The NASD believes that it is in the best interest of investors and the parties involved in intra-industry disputes to provide for fast and efficient resolution of requests for temporary injunctive relief, and to provide clear and simple rules governing the integration of courtordered relief with the arbitrator of the underlying disputes.

## B. Self-Regulation Organization's Statement on Burden on Competition

NASD Regulation does not believe that the proposed rule change will result in any burden on competition that is not necessary or appropriate in furtherance of the purposes of the Act, as amended.

## C. Self-Regulatory Organization's Statement on Comments on the

 Proposed Rule Change Received from Members, Participants, or OthersNo written comments were solicited or received with respect to the proposed rule change.

## III. Date of Effectiveness of the Proposed Rule Change and Timing for Commission Action

Within 35 days of the date of publication of this notice in the Federal Register or within such longer period (i) as the Commission may designated up to 90 days of such date if it finds such longer period to be appropriate and publishes its reasons for so finding or (ii) as to which the self-regulatory organization consents, the Commission will:
(A) by order approve such proposed rule change, or
(B) institute proceedings to determine whether the proposed rule change should be disapproved.

## IV. Solicitation of Comments

Interested persons are invited to submit written data, views, and
arguments concerning the foregoing. The Commission notes in particular that, under the proposal, the parties shall jointly bear the travel-related costs and expenses of the arbitrators appointed to hear the request for permanent injunctive relief. Further, the parties shall jointly bear the travelrelated costs and expenses resulting from any subsequent hearings on damages or other relief. In addition, the parties shall equally pay the difference between the honorarium under proposed paragraph (b)(6)(C) of Rule 10335 and the amounts the arbitrators are otherwise entitled to receive under the Code. The arbitrators may not reallocate these costs and expenses among the parties. The Commission seeks comments on this fee structure, including whether the proposal is consistent with the Act which, among other things, prohibits the imposition of inappropriate and unnecessary burdens on competition ${ }^{6}$ and requires that fees and charges be reasoanble and equitably allocated. ${ }^{7}$ In previous orders, the Commission has relied substantially on arbitrators' discretion in finding that fees and charges met this standard. ${ }^{8}$
Persons making written submissions should file six copies thereof with the Secretary, Securities and Exchange Commission, 450 Fifth Street, N.W., Washington, D.C. 20549-0609. Copies of the submission, all subsequent amendments, all written statements with respect to the proposed rule change that are filed with the Commission, and all written communications relating to the proposed rule change between the Commission and any person, other than those that may be withheld from the public in accordance with the provisions of 5 U.S.C. 552, will be available for inspection and copying in the Commission's Public Reference Room. Copies of such filing will also be available for inspection and copying at the principal office of the NASD. All submissions should refer to File No. SR-NASD-00-02 and should be submitted April 28, 2000.
For the Commission, by the Division of Market Regulation, pursuant to delegated authority. ${ }^{9}$
Margaret H. McFarland,
Deputy Secretary.
[FR Doc. 00-8649 Filed 4-6-00; 8:45 am]
BILLING CODE 8010-01-M

[^103]
## SECURITIES AND EXCHANGE COMMISSION

[Release No. 34-42579; File No. SR-NYSE-99-50]

## Self-Regulatory Organizations; Notice of Filing of Proposed Rule Change and Amendment Nos. 1 and 2 thereto by the New York Stock Exchange, Inc. Relating to Continued Listing Standards

Pursuant to Section 19(b)(1) of the Securities Exchange Act of 1934 ("Act"), ${ }^{1}$ and Rule 19b-4 thereunder, ${ }^{2}$ notice is hereby given that on December 21, 1999, the New York Stock Exchange, Inc. ("NYSE" or "Exchange") filed with the Securities and Exchange Commission ("SEC" or "Commission") the proposed rule change as described in Items I, II and III below, which Items have been prepared by the Exchange. On March 27, 2000, the Exchange submitted Amendment No. 1 to the proposed rule change. ${ }^{3}$ On March 27, 2000, the Exchange submitted Amendment No. 2 to the proposed rule change. ${ }^{4}$ The Commission is publishing this notice to solicit comments on the proposed rule change, as amended, from interested persons.

## I. Self-Regulatory Organization's

 Statement of the Terms of Substance of the Proposed Rule ChangeThe Exchange proposes to amend Section 802 of its Listed Company Manual (the "Manual") regarding its criteria governing the continued listing of securities (and corresponding changes to NYSE Rule 499).
Specifically, the Exchange proposes: (1) to define "market capitalization" for the purpose of its continued listing standards; (2) to clarify the appropriate measures for partnerships; and, (3) to

[^104]codify the Exchange's discretion to accept a financial plan for certain companies that have filed or that have announced an intent to file for bankruptcy, and that are below financial continued listing standards, but that are otherwise financially sound. The text of the proposed rule change is as follows: Proposed additions are italicized and proposed deletions are in brackets.

## NYSE Listed Company Manual

Section 8
Suspension and Delisting
801.00 Policy
802.00 Continued Listing
802.01 Continued Listing Criteria

The Exchange would normally give consideration to delisting a security of either a domestic or non-U.S. issuer when:
802.01B Numerical Criteria for Capital or Common Stock-
If a company falls below any of the following criteria, it is subject to the procedures outlined in Paras. 802.02 and 802.03:

- Total global market capitalization is less than \$50,000,000 and total stockholders' equity or, for partnerships, both the general and limited partners' capital as applicable, is less than $\$ 50,000,000(\mathrm{C})$; or
- Average global market capitalization over a consecutive 30 trading-day period is less than $\$ 15,000,000$; or
- For companies that qualify under the "global market capitalization" standard:
- Total global market capitalization is less than $\$ 500,000,000$ and total revenues are less than $\$ 50,000,000$ over the last 12 months (unless the resultant entity qualifies as an original listing under one of the other standards) (C) OR
- Average global market capitalization over a consecutive 30 trading-day period is less than \$100,000,000.
When applying the market capitalization test in any of the above three standards, the Exchange will generally look to the total common stock outstanding (excluding treasury shares) as well as any common stock that would be issued upon conversion of another outstanding equity security. The Exchange deems these securities to be reflected in market value to such an extent that the security is a "substantial equivalent" of common stock. In this regard, the Exchange will only consider
securities (1) Publicly traded (or quoted), or (2) Convertible into a publicly traded (or quoted) security. For partnerships, the Exchange will analyze the creation of the current capital structure to determine whether it is appropriate to include other publiclytraded securities in the calculation.


### 802.01D. Other Criteria-

If any of the following factors apply to a listed company, the Exchange may in its sole discretion subject the company to the procedures outlined in Paras. 802.02 and 802.03:

Bankruptcy and/or Liquidation-
An intent to file under any of the sections of the bankruptcy law has been announced or a filing has been made or liquidation has been authorized and the company is committed to proceed. If a company files or announces an intent to file for reorganization relief under the bankruptcy laws (or an equivalent foreign law), the Exchange may exercise its discretion to continue the listing and trading of the securities of the company. However, if a company that is below any continued listing standard enumerated in Para. 802.10B above (which may be determined on the basis of price indications) files or announces an intent to file for relief under any provisions of any bankruptcy laws, it is subject to immediate suspension and delisting. Similarly, if a company that files or announces an intent to file for relief under any provisions of any bankruptcy laws subsequently falls below any continued listing standard enumerated in Para. 802.10B above (which may be determined on the basis of price indications), it is subject to immediate suspension and delisting. Notwithstanding the foregoing, in the event that such a company is profitable (or has positive cash flow), or is demonstrably in sound financial health despite the bankruptcy proceedings, the Exchange may evaluate and accept a Plan submitted under the procedures of 802.02 and 802.03.

## NYSE Rules

## Delisting of Securities

## Suspension from Dealings or Removal from List by Action of the Exchange

The aim of the New York Stock Exchange is to provide the foremost auction market for securities of wellestablished companies in which there is a broad public interest and ownership.

## Rule 499.

. 20 NUMERICAL AND OTHER CRITERIA.-WHEN A COMPANY FALLS BELOW ANY OF THESE CRITERIA, THE EXCHANGE MAY GIVE CONSIDERATION TO ANY DEFINITIVE ACTION THAT A COMPANY WOULD PROPOSE TO TAKE THAT WOULD BRING IT ABOVE CONTINUED LISTING STANDARDS.
4. * Total global market capitalization is less than $\$ 50,000,000$ and total stockholders' equity or, for partnerships, both the general and limited partners' capital as applicable, is less than $\$ 50,000,000$. A company that is determined to be below this continued listing criteria must reestablish both its market capitalization and its stockholders' equity (or net assets for Funds) to be considered in conformity with continued listing standards pursuant to [Paras. 802.02 and 802.03] Sections . 50 and .60.
5. * Average global market capitalization over a consecutive threemonth period is less than $\$ 15,000,000$.
6. * For companies that qualify under the "global market capitalization" standard:

- Total global market capitalization is less than $\$ 500,000,000$ and total revenues are less than $\$ 50,000,000$ over the past 12 months. A company that is determined to be below this continued listing criteria must re-establish both its market capitalization and its revenues to be considered in conformity with continued listing standards pursuant to [Paras. 802.02 and 802.03] Sections . 50 and . 60 .

OR

- Average global market
capitalization over a consecutive 30 trading-day period is less than $\$ 100,000,000$.
* When applying the market capitalization test, the Exchange will generally look to the total common stock outstanding (excluding treasury shares) as well as any common stock that would be issued upon conversion of another outstanding equity security. The Exchange deems these securities to be reflected in market value to such an extent that the security is a "substantial equivalent" of common stock. In this regard, the Exchange will only consider securities (1) publicly traded (or quoted), or (2) convertible into a publicly traded (or quoted) security. For partnerships, the Exchange will analyze the creation of the current capital structure to determine whether it is appropriate to include other publiclytraded securities in the calculation.

Bankruptcy and/or Liquidation.-An intent to file under any of the sections
of the bankruptcy law has been announced or a filing has been made or that liquidation has been authorized and the company is committed to proceed. If a company files or announces an intent to file for reorganization relief under the bankruptcy laws (or an equivalent foreign law), the Exchange may exercise its discretion to continue the listing and trading of the securities of the company. However, if a company that is below any continued listing standard enumerated in sections 4-6, above (which may be determined on the basis of price indications) files or announces an intent to file for relief under any provisions of any bankruptcy laws, it is subject to immediate suspension and delisting. Similarly, if a company that files or announces an intent to file for relief under any provisions of any bankruptcy laws subsequently falls below any continued listing standard enumerated in sections $4-6$ above (which may be determined on the basis of price indications), it is subject to immediate suspension and delisting. Notwithstanding the foregoing, in the event that such a company is profitable (or has positive cash flow), or is demonstrably in sound financial health despite the bankruptcy proceedings, the Exchange may evaluate and accept a Plan submitted under the procedures of Sections . 50 and . 60 .

## II. Self-Regulatory Organization's Statement of the Purpose of, and Statutory Basis for, the Proposed Rule Change

In its filing with the Commission, the Exchange included statements concerning the purpose of and basis for the proposed rule change and discussed any comments it received on the proposed rule change. The text of these statements may be examined at the places specified in Item IV below. The Exchange has prepared summaries, set forth in Sections A, B, and C below, of the most significant aspects of such statements.

## A. Self-Regulatory Organization's

 Statement of the Purpose of, and Statutory Basis for, the Proposed Rule Change
## 1. Purpose

The purpose of this proposed rule change is to modify several of the Exchange's existing continued listing criteria. The Exchange recently revised its continued listing standards, ${ }^{5}$ and to this point several issues have come to light that necessitate clarification. First,

[^105]the Exchange proposes to define the term "market capitalization" in so far as it applies to the continued listing standards. Second, the Exchange proposes to clarify what is meant by "shareholders equity" in the context of partnerships. Third, the Exchange proposes to specify a set of circumstances in which it will exercise some discretion in determining the listing status of a company that has filed or has announced an intent to file for bankruptcy, and that is below the financial continued listing standards specified in Para. 802.01B of the Manual. These amendments are each discussed in detail below.

## (A) Market Capitalization Definition

Two of the new standards focus on the issuer's market capitalization. During the implementation of these new standards, several issues have arisen as to whether securities other than traditional equity instruments are intended to be included in the definition of the term "market capitalization."
The Exchange evaluated the comments and suggestions put forth by many issuers and discussed the issue with several outside consultants. As a result of this process, the Exchange proposes to specify that for purposes of its continued listing standards, the term "market capitalization" will encompass all common stock outstanding, whether publicly traded or not, so long as the Exchange is able to accurately attribute a value to it ${ }^{6}$ on the day the market capitalization is calculated. Thus, if such a security is publicly traded common stock, the closing price from the previous trading day will be the price used for purposes of the calculation.
In addition, the Exchange believes that it is appropriate to provide its staff with the discretion to evaluate the capital structure of the issuer and include common stock that would be issued upon conversion of an instrument that constitutes the issuer's capital. Traditional debt, related to financing activities, will be excluded. Similar to the procedure discussed above, but for convertible publiclytraded securities other than common stock, the applicable price will be the closing price of the common stock into which it is convertible from the previous trading day. For example, if a convertible preferred security trades at $\$ 15$ and the common stock into which
${ }^{6}$ For example, a privately-held Class B common stock convertible into the listed Class A common stock would be included and valued on an asconverted basis.
it is convertible trades at $\$ 10$, the price utilized would be the closing price of the common stock on the previous day (not the higher price of the preferred security) and the market capitalization would be computed on an as-converted basis.

Finally, if the issuer has outstanding privately-held securities, the calculation would be made as described above for convertible securities based upon the previous day's closing price of the publicly-traded security. Thus, a privately held Class B common stock convertible into the publicly-traded Class A would be valued at the price of the Class A. Likewise, a privately-held preferred Series A convertible into the publicly-traded Class A would be valued at the price of the Class A on an as-converted basis.

The Exchange notes that it will also review any applicable conversion restrictions when conducting its market capitalization analysis and factor any such restrictions into the computations as appropriate.
(B) "'Shareholders’ Equity" and Market Capitalization" of Partnerships.

Partnerships raise a unique set of issues that need to be incorporated into Exchange rules. Again, after consulting with various individuals, the Exchange proposes to create an additional provision in the market capitalization definition. The provision would enable the Exchange to evaluate the formation of the current capital structure of the partnership and, where appropriate, to include other publicly-traded securities in the calculation as a substantial equivalent to common stock.

Furthermore, the Exchange proposes to amend the stockholders' equity test to clarify that both general and limited partners' capital is the measure for the applicable calculation. The Exchange believes that this clarification is necessary because the concept of "shareholders' equity" is not applicable to partnerships. Instead, the notion of capital captures the appropriate analogous concept with respect to partnerships.

The Exchange's intent in codifying the concept of analyzing the creation of the current capital structure stems primarily from the recent expiration of an IRS grandfather provision that resulted in numerous recapitalizations of partnerships. The Exchange believes it is not equitable to penalize these partnerships for restructuring in order to prevent, among other things, double taxation. Thus, for instance, if a holder of $\$ 50$ of partnership units prior to the conversion were to receive $\$ 25$ in partnership units and $\$ 25$ in debt, the
"market value" of the holdings has not changed and should be calculated at $\$ 50$ for purposes of determining the continued listing status of the company. Consistent with the principles articulated above, the Exchange would require that the non-equity instrument be publicly traded so as to assure the ability to value the instrument.
(C) Companies That Have Field for Bankruptcy and That Are Below the Financial Continued Listing Criteria

The recently approved language that addresses companies that have filed or that have announced an intent to file for bankruptcy, and that are also below the Exchange's financial continued listing criteria, requires the Exchange to subject such a company to "immediate suspension and delisting." There are instances, however, where the Exchange has found that such a company should be afforded the opportunity to submit a financial plan for evaluation. For instance, a company that is profitable (or that has a positive cash flow), or is demonstrably in sound financial health despite the bankruptcy proceedings, should not be delisted if it can demonstrate that, within 18 months, it will be in compliance with the Exchange's financial criteria. In response to these circumstances, the Exchange proposes to amend this provision to create the authority to analyze the financial status of these companies on a case-by-case basis. However, if a company has previously filed an Exchange-approved plan to meet the Exchange's continued listing standards within 18 months, application of this provision to the company does not restart the 18-month clock. Thus, for instance, a company that declares bankruptcy midstream through an Exchange-approved plan would still only have the remainder of the plan period to come into compliance. It would not be afforded an additional 18 months, but would incorporate the projected effect of the bankruptcy into its Plan and resubmit it for consideration.

## 2. Statutory Basis

The Exchange believes the basis under the Act for the proposed rule change is the requirement under Section $6(\mathrm{~b})(5)^{7}$ that an exchange have rules that are designed to prevent fraudulent and manipulative acts and practices, to promote just and equitable principles of trade, to remove impediments to, and perfect the mechanism of a free and

[^106]open market and, in general, to protect investors and the public interest.

## B. Self-Regulatory Organization's Statement on Burden on Competition

The Exchange does not believe that the proposed rule change will impose any burden on competition that is not necessary or appropriate in furtherance of the purposes of the Act.

## C. Self-Regulatory Organization's

Statement on Comments on the Proposed Rule Change Received From Members, Participants or Others

The Exchange has neither solicited nor received any written comments with respect to the proposed rule change.

## III. Date of Effectiveness of the Proposed Rule Change and Timing for Commission Action

Within 35 days of the date of publication of this notice in the Federal Register or within such longer period (i) as the Commission may designate up to 90 days of such date if it finds such longer period to be appropriate and publishes its reasons for so finding or (ii) as to which the self-regulatory organization consents, the Commission will:
A. By order approve the proposed rule change, or
B. Institute proceedings to determine whether the proposed rule change should be disapproved.

## IV. Solicitation of Comments

Interested persons are invited to submit written data, views, and arguments concerning the foregoing, including whether the proposed rule change, as amended, is consistent with the Act. Persons making written submissions should file six copies thereof with the Secretary, Securities and Exchange Commission, 450 Fifth Street, N.W., Washington, D.C. 205490609. Copies of the submission, all subsequent amendments, all written statements with respect to the proposed rule change that are filed with the Commission, and all written communications relating to the proposed rule change between the Commission and any person, other than those that may be withheld from the public in accordance with the provisions of 5 U.S.C. § 552, will be available for inspection and copying at the Commission's Public Reference Room. Copies of such filing will also be available for inspection and copying at the principal office of the Exchange. All submissions should refer to File No. SR-NYSE-99-50 and should be submitted by April 28, 2000.

For the Commission, by the Division of Market Regulation, pursuant to delegated authority. ${ }^{6}$
Margaret H. McFarland,
Deputy Secretary.
[FR Doc. 00-8487 Filed 4-6-00; 8:45 am]
billing Code 8010-01-M

## SECURITIES AND EXCHANGE COMMISSION

[Release No. 34-42604; File No. SR-NYSE-00-10]

> Self-Regulatory Organizations; Notice of Filing and Order Granting Accelerated Approval of Proposed Rule Change and Amendment No. 1 by the New York Stock Exchange, Inc. Relating to Listed Company Fees

March 31, 2000.
Pursuant to Section 19(b)(1) of the Securities Exchange Act of 1934
("Act"), ${ }^{1}$ and Rule 19b-4 thereunder, ${ }^{2}$ notice is hereby given that on March 2, 2000, the New York Stock Exchange, Inc. ("NYSE" or "Exchange") filed with the Securities and Exchange Commission ("SEC'" or "Commission") the proposed rule change as described in Items I and II below, which Items have been prepared by the Exchange. On March 22, 2000, the Exchange submitted Amendment No. 1 to the proposed rule change. ${ }^{3}$ The Commission is publishing this notice to solicit comments on the proposed rule change, as amended, from interested persons and to grant accelerated approval to the proposed rule change and Amendment No. 1.

## I. Self-Regulatory Organization's

 Statement of the Terms of Substance of the Proposed Rule ChangeThe Exchange proposes to amend Paragraph 902.02 of the Exchange's Listed Company Manual (the
"Manual"). Paragraph 902.02 of the Manual contains the schedule of current listing fees for companies listing securities on the Exchange. The text of the proposed rule change is as follows. New text is italicized.
902.02 Schedule of Current Listing Fees

[^107]
## A. Original Listing Fee

A special charge of $\$ 36.800$ in addition to initial fees (described below) is payable in connection with the original listing of a company's stock. In any event, each issuer (excluding closed-end funds) is subject to a minimum original listing fee of \$150,000 inclusive of the special charge referenced in the preceding sentence. The special charge is also applicable to an application which in the opinion of the Exchange is a "back-door listing". See Para. 703.08 (F) for definition.

## II. Self-Regulatory Organization's Statement of the Purpose of, and

 Statutory Basis for, the Proposed Rule ChangeIn its filing with the Commission, the Exchange included statements concerning the purpose of and basis for the proposed rule change and discussed any comments it received on the proposed rule change. The text of these statements may be examined at the places specified in Item III below. The Exchange has prepared summaries, set forth Sections A, B, and C below, of the most significant aspects of such statements.
A. Self-Regulatory Organization's Statement of the Purpose of, and Statutory Basis for, the Proposed Rule Change

## 1. Purpose

The proposed rule change amends the listed company fee schedule, set forth in Paragraph 902.02 of the Manual, as it applies to original listing fees. The Exchange seeks to adopt a $\$ 150,000$ minimum original listing fee for each domestic new issuer (excluding closedend funds). This minimum would include the existing special charge of $\$ 36,800 .{ }^{4}$
By establishing this minimum fee, the Exchange is proposing to set a base fee that issuers (other than funds) will pay to the Exchange regardless of the number of shares listed by a particular company at the time of the original listing. ${ }^{5}$ The Exchange represents that the intent of the proposed rule change is to modestly enhance the revenue received by the Exchange at the time of certain original listings, while providing for potential applicants and their advisers a clear statement of the minimum that must be paid at the time

[^108]of an original listing. ${ }^{6}$ The Exchange proposes to implement the new minimum initial listing fee as of April 1, 2000.

## 2. Statutory Basis

The Exchange believes that the proposed rule change is consistent with the requirement under Section 6(b)(4) of the Act ${ }^{7}$ that an Exchange have rules that provide for the equitable allocation of reasonable dues, fees, and other charges among its members and issuer and other persons using its facilities.

## B. Self-Regulatory Organization's Statement on Burden on Competition

The Exchange does not believe that the proposed rule change will impose any burden on competition that is not necessary or appropriate in furtherance of the purposes of the Act.

## C. Self-Regulatory Organization's Statement on Comments on the Proposed Rule Change Received From Members, Participants or Others

The Exchange has neither solicited nor received written comments on the proposed rule change, as amended.

## III. Solicitation of Comments

Interested persons are invited to submit written data, views and arguments concerning the foregoing, including whether the proposed rule change, as amended, is consistent with the Act. Persons making written submissions should file six copies thereof with the Secretary, Securities and Exchange Commission, 450 Fifth Street NW, Washington, DC 205490609. Copies of the submission, all subsequent amendments, all written statements with respect to the proposed rule change that are filed with the Commission, and all written communications relating to the proposed rule change between the Commission and any person, other than those that may be withheld from the public in accordance with the provisions of 5 U.S.C. 552, will be available for inspection and copying in the Commission's Public Reference Room. Copies of such filing will also be available for inspection and copying at the principal office of the NYSE. All submissions should refer to File No. SR-NYSE-00-10 and should be submitted by April 28, 2000.
${ }^{6}$ Id.
${ }^{7} 15$ U.S.C. $78 f(b)(4)$.

## IV. Commission's Findings and Order Granting Accelerated Approval of Proposed Rule Change

The Commission finds that the proposed rule change, as amended, is consistent with the requirements of the Act and the rules and regulations thereunder applicable to a national securities exchange, ${ }^{8}$ and in particular, with the requirements of Section 6(b)(4), ${ }^{9}$ that the Exchange's rule provide for the equitable allocation of reasonable dues, fees, and other charges. Specifically, the Commission believes that the Exchange's proposal to establish a minimum original listing fee of $\$ 150,000$ is not unreasonable and should not inequitably allocate fees to the Exchange's issuers.

The NYSE has requested that the Commission find good cause for approving the proposed rule change, as amended, prior to the thirtieth day after the date of publication of notice in the Federal Register. Specifically, the Exchange requests that the Commission accelerate the effective date of the proposed rule change so the Exchange can implement the fee change by April 1, 2000, to coincide with the Exchange's quarterly billing cycle. ${ }^{10}$ The Commission believes that it is reasonable to permit the Exchange to implement the fee change on April 1, 2000, in conjunction with the beginning of the Exchange's next fiscal quarter. Accordingly, the Commission finds good cause, consistent with Sections 6(b)(5) and 19(b)(2) of the Act, ${ }^{11}$ to approve the proposed rule on an accelerated basis.

It is therefore ordered, pursuant to Section 19(b)(2) of the Act, ${ }^{12}$ that the proposed rule change (SR-NYSE-0010), as amended, is hereby approved on an accelerated basis.

For the Commission, by the Division of Market Regulation, pursuant to delegated authority. ${ }^{13}$
Margaret H. McFarland,
Deputy Secretary.
[FR Doc. 00-8646 Filed 4-6-00; 8:45 am]
BILLING CODE 8010-01-M

[^109]
## SECURITIES AND EXCHANGE COMMISSION

[Release No. 42600; File No. SR-Phlx-0022]

## Self-Regulatory Organizations; Notice of Filing and Immediate Effectiveness of Proposed Rule Change by the Philadelphia Stock Exchange, Inc. Amending PHLX Rule 237 To Add a Credit Limit Feature to the Volume Weighted Average Price Trading System (VTS)

March 30, 2000.
Pursuant to Section 19(b)(1) of the Securities Exchange Act of 1934 ("Act") ${ }^{1}$ and Rule 19b-4 thereunder, ${ }^{2}$ notice is hereby given that on March 3, 2000, the Philadelphia Stock Exchange, Inc. ("Phlx" or "Exchange") filed a proposed rule change with the Securities and Exchange Commission ("SEC"' or "Commission"). The proposed rule change is described in Items I, II, and III below, which Items have been prepared by the Exchange. The Commission is publishing this notice to solicit comments on the proposed rule change from interested persons.

## I. Self-Regulatory Organization's Statement of the Terms of Substance of the Proposed Rule Change

The Exchange proposes to amend Rule 237, "The Universal Trading System Morning Session," ${ }^{3}$ to implement a Credit Limit Feature ("Feature") to the Volume Weighted Average Price Trading System "VTS" TM). ${ }^{4}$ Specifically, proposed Rule 237(l) states that the Credit Limit Feature provides automated validation of credit limits imposed by SCCP/Phlx members on users and committers. The Credit Limit Feature is engaged when the SCCP/Phlx member provides credit limit instructions on a form prescribed by the Exchange. Rule 237(a) states that the VTS may remove orders and commitments that exceed the established credit limits. The text of the proposed rule change is available at the Exchange and at the Commission.

[^110]
## II. Self-Regulatory Organization's <br> Statements Regarding the Purpose of, and the Statutory Basis for, the Proposed Rule Change

In its filing with the Commission, the Exchange included statements concerning the purpose of and basis for the proposed rule change and discussed any comments it received on the proposed rule change. The text of these statements may be examined at the places specified in Item IV below. The Exchange has prepared summaries, set forth in sections A, B, and C below, of the most significant aspects of such statements.
A. Self-Regulatory Organization's Statement of the Purpose of, and Statutory Basis for, the Proposed Rule Change

## 1. Purpose

The VTS provides a morning matching session for the execution of large-sized orders at the volume weighted average price ("VWAP'). The receipt and matching of these orders is handled electronically through the VTS Non-member users may enter into the system so long as they have the appropriate give-up arrangements with a Stock Clearing Corporation of Philadelphia ("SCCP'") member, who must also be a Phlx member who has assumed responsibility for that order. ${ }^{5}$ In addition, Phlx member committers and member users who are not members of SCCP may have a clearing arrangement with SCCP member clearing firms who may want to impose credit limits on their customers. Currently, VTS users and committer credit limits must be monitored and enforced by the clearing firm by means external to the system. ${ }^{6}$ In this regard, a number of members have requested an automated credit limit validation feature to validate their customer's credit limit before allowing the VTS committer or user to match and execute orders.
Thus, the Exchange proposes to implement the Feature, which provides an automated means for SCCP/Phlx members to impose credit limits on their customers' use of the system. SCCP/Phlx members, through the Feature, may impose credit limits: (i) On an identified clearing customer, (ii) On an identified account, or (iii) On an identified clearing customer's use of an identified account. The Feature permits clearing firms to set credit limits to limit different order types such as buys, sells,

[^111]short sales, internal crosses and twosided commitments. The member will specify the appropriate credit limits or changes to credit limits to the authorized enrollment personnel on a form prescribed by the Exchange, prior to implementation of the Feature for that customer. Once engaged, the Feature precludes any daily commitments and incoming orders of clearing customers that would exceed established credit limits from entering into VTS. Consistent with current practice, in determining whether the credit limit has been reached, valuation of commitments and orders would be based on the previous day's closing prices. Similarly, the Feature also permits members to apply their customers' unsettled trades from previous day[s] match session[s] against such customers' credit limits.

The Exchange believes that this proposed system change should assist members in ensuring that agreed upon credit limits are enforced, and thereby reduce the burden on clearing firms to verify and enforce customer credit limits. In addition, the proposed feature should ensure that such customers are complying with agreed upon credit limits.

## 2. Statutory Basis

The Exchange believes the proposed rule change is consistent with Section $6(\mathrm{~b})$ of the Act in that it is designed to promote just and equitable principles of trade, prevent fraudulent and manipulative acts and practices and protect investors and the public interest by installing a Credit Limit Feature to ensure that VTS users and committers abide by the credit limit agreed upon with their clearing firms.

## B. Self-Regulatory Organization's Statement on Burden on Competition

The Exchange does not believe that the proposed rule change will result in any burden on competition that is not necessary or appropriate in furtherance of the purposes of the Act.

## C. Self-Regulatory Organization's Statement on Comments on the Proposed Rule Change Received From Members, Participants, or Others

The Exchange has neither solicited nor received written comments on the proposed rule change.

## III. Date of Effectiveness of the Proposed Rule Change and Timing for Commission Action

The foregoing rule change has become effective immediately under Section

19(b)(3)(A) of the Act ${ }^{7}$ and subparagraph (f)(5) of Rule 19b-4 thereunder, ${ }^{8}$ in that it constitutes a change in an existing order-entry or trading system that: does not significantly affect the protection of investors or the public interest; does not impose any significant burden on competition; and does not have the effect of limiting the access to or availability of the system. Specifically, the proposed rule change ensures that VTS users and committers abide by the credit limit agreed upon with their clearing firms by providing automated credit limit validation.

At any time within 60 days of the filing of such proposed rule change, the Commission may summarily abrogate such rule change if it appears to the Commission that such action is necessary or appropriate in the public interest or for the protection of investors, or otherwise in furtherance of the purposes of the Act.

## IV. Solicitation of Comments

Interested persons are invited to submit written data, views, and arguments concerning the foregoing, including whether the proposed rule change is consistent with the Act. Persons making written submissions should file six copies thereof with the Secretary, Securities and Exchange Commission, 450 Fifth Street, NW, Washington, DC 20549-0609. Copies of the submission, all subsequent amendments, all written statements with respect to the proposed rule change that are filed with the Commission, and all written communications relating to the proposed rule change between the Commission and any person, other than those they may be withheld from the public in accordance with the provisions of 5 U.S.C. 552 , will be available for inspection and copying at the Commission's Public Reference Room. Copies of such filing also will be available for inspection and copying at the principal office of the Exchange.

All submissions should refer to File No. SR-PHLX-00-22 and should be submitted by April 28, 2000.
For the Commission, by the Division of Market Regulation, pursuant to delegated authority. ${ }^{9}$
Margaret H. McFarland,
Deputy Secretary.
[FR Doc. 00-8488 Filed 4-6-00; 8:45 am] BILLING CODE 8010-01-M

[^112]
# SOCIAL SECURITY ADMINISTRATION 

## Agency Information Collection Activities: Proposed Request and Comment Request

In compliance with Public Law 10413, the Paperwork Reduction Act of 1995, SSA is providing notice of its information collections that require submission to the Office of Management and Budget (OMB). SSA is soliciting comments on the accuracy of the agency's burden estimate; the need for the information; its practical utility; ways to enhance its quality, utility and clarity; and on ways to minimize burden on respondents, including the use of automated collection techniques or other forms of information technology.
I. The information collections listed below will be submitted to OMB within 60 days from the date of this notice. Therefore, comments and recommendations regarding the information collections would be most useful if received by the Agency within 60 days from the date of this publication. Comments should be directed to the SSA Reports Clearance Officer at the address listed at the end of this publication. You can obtain a copy of the collection instruments by calling the SSA Reports Clearance Officer on (410) 965-4145, or by writing to him at the address listed at the end of this publication.

1. Request for Reconsideration-0960NEW. The information collected on Form SSA-561 is used by the Social Security Administration (SSA) to document and initiate the reconsideration process for determining entitlement to Social Security benefits under (title II), Supplemental Security Income payments (title XVI), Special Veterans Benefits (title VIII) and Medicare benefits (title XVIII). The respondents are individuals filing for such reconsideration.
Number of respondents: 1,455,000.
Number of Response: 1.
Average burden per response: 8 minutes.
Estimated Annual Burden: 194,000.
2. Disability Hearing Officer's Decision-Title XVI Disabled Child Continuing Disability Review-0960NEW. The information collected on form SSA-1209 will be used by State Disability Hearing Officers (DHO) to formalize disability decisions. The form will aid the DHO in addressing the crucial elements of the case in a sequential and logical fashion. The form is used as the official determination of the DHO's decision and the personalized portion of the notice to the claimant.

Number of Respondents: 40,000. Frequency of Response: 1.
Average Burden Per Response: 3.6 hours.

Estimated Annual Burden: 144,000 hours.
II. The information collections listed below have been submitted to OMB for clearance. Written comments and recommendations on the information collections would be most useful if received within 30 days from the date of this publication. Comments should be directed to the SSA Reports Clearance Officer and the OMB Desk Officer at the addresses listed at the end of this publication. You can obtain a copy of the OMB clearance packages by calling the SSA Reports Clearance Officer on (410) 965-4145, or by writing to him.

1. Claimant's Medications-09600289. SSA uses Form HA-4632 to request that applicants for disability benefits provide information to facilitate processing their title II, Old-Age, Survivors and Disability Insurance (OASDI) and Title XVI, Supplemental Security Income (SSI) claims. The form elicits from the claimants an updated list of medications used by the claimants. It enables the Administrative Law Judge hearing the case to fully inquire into medical treatment the claimant is receiving and the effect of medications on the claimant's medical impairments. The respondents are applicants for OASDI and SSI benefits.

Number of Respondents: 171,939.
Frequency of Response: 1.
Average Burden Per Response: 15 minutes.

Estimated Annual Burden: 42,985 hours.
2. Statement of Employer-0960-0030. The information collected on Form SSA-7011 is needed by SSA to substantiate allegations of wages paid to workers when those wages do not appear in SSA's records of earnings and the worker does not have proof that payment was made. This information is used to process claims for social security benefits and to resolve discrepancies in earnings records. The respondents are certain employers who can verify allegations of wages made by the wage earner.

Number of Respondents: 925,000.
Frequency of Response: 1.
Average Burden Per Response: 20 minutes.

Estimated Annual Burden: 308,333 hours.
3. Request for SSI Benefit Estimate-0960-0492. SSA uses Form SSA-3716 for an SSI beneficiary who wishes to request a 5-month estimate of what their benefits would be if they should return
to work in the future. The respondents are SSI recipients.

Number of Respondents: 50,000.
Frequency of Response: 1.
Average Burden Per Response: 5 minutes.

Estimated Annual Burden: 4,167
hours.
(SSA Address)
Social Security Administration,
DCFAM, Attn: Frederick W.
Brickenkamp, 6401 Security Blvd., 1-
A-21 Operations Bldg., Baltimore,
MD 21235.

## (OMB Address)

Office of Management and Budget, OIRA, Attn: Desk Officer for SSA, New Executive Office Building, Room 10230, 725 17th St., NW, Washington, D.C. 20503.

Dated: April 3, 2000.
Frederick W. Brickenkamp,
Reports Clearance Officer, Social Security Administration.
[FR Doc. 00-8637 Filed 4-6-00; 8:45 am] BILLING CODE 4191-02-U

## OFFICE OF THE UNITED STATES TRADE REPRESENTATIVE

Generalized System of Preferences (GSP); Public Hearings for the Petitions for the GSP 1999 IPR Country Practices Review, Additional Change in Schedule of Hearings and Deadline for Submitting Comments on Petitions for the GSP 1999 Country Practices Review
agency: Office of the United States Trade Representative (USTR).
action: Notice of Change in Schedule of Hearings and Deadline for Submitting Comments on Petitions for the GSP 1999 Country Practices Review.

SUPPLEMENTARY INFORMATION: Notice is hereby given of a change in the date, and a change in the date for submission of comments, for the GSP Public
Hearings to be held for country practice petitions accepted for review in the GSP 1999 Country Practices Review. These hearings were scheduled for April 3 and April 4, 2000, and then rescheduled for April 13 and April 14, beginning at 10:00 a.m. A Federal Register notice regarding these hearings was published on February 14, 2000 ( 65 FR 74107412), and then another published on March 1, 2000 ( 65 FR 11104-11105).
The scheduled dates for the GSP Public Hearings are changed from April 3 and April 4, 2000, and again from April 13 and April 14, to May 12. There is only one day of hearings. The location
of the GSP Hearings remains the same at the White House Conference Center, the Truman Room, 726 Jackson Place, NW, Washington, DC 20500. The deadline for submission of Post-hearing Briefs and Rebuttal Briefs is changed to

June 9. The Hearings will begin at 10:00 States Trade Representative, 600 17th a.m. See attached revised calendar.

All other information in the notice at 65 FR 7410 (February 14, 2000) remains the same.
FOR FURTHER INFORMATION CONTACT: GSP
Subcommittee, Office of the United

Street, NW, Room 518, Washington, DC 20508 (Tel. 202/395-6971).

## Jon Rosenbaum,

Assistant USTR for Trade and Development.

EXECUTIVE OFFICE OF THE PRESIDENT
OFFICE OF THE UNITED STATES TRADE REPRESENTATIVE WASHINGTON, D.C. 20508

* Rev. 4-4-2000 New Date For Hearings/Submission

| GENERALIZED SYSTE <br> 1999 GSP <br> IPR COUNTRY PRACTICE <br> Armenia <br> Dominican Re <br> Kazakhstan <br> Moldova <br> Ukraine <br> Uzbekistan <br> PUBLIC HEARINGS A | EM OF PREFERENCES (GSP) <br> ANNUAL REVIEW <br> CASES ACCEPTED FOR REVIEW <br> AND COMMENT SCHEDULE |
| :---: | :---: |
| March 16, 2000 | Deadline for REQUESTS TO APPEAR AT PUBLIC HEARINGS and submission of PREHEARING BRIEFS. <br> Deadline for providing the name, address, and organization of witnesses. |
| * May 12, 2000 - One Day Only | PUBLIC HEARINGS, LOCATION REMAINS SAME: White House Conference Center, 726 Jackson Place, N.W., Washington, D.C. 20500 |
| * June 9, 2000 | Deadline for submission of POST-HEARING BRIEFS and REBUTTAL BRIEFS. |
| Future Federal Register Notice | Date Modifications to GSP List of Beneficiary Developing Countries will take effect. |
| For further information contact: | GSP Information Center Office of the U.S. Trade Representative 600 17th Street <br> Washington, D.C. 20508 202-395-6971 |
| Notification of any changes will be given in the Federal Register. |  |

[FR Doc. 00-8707 Filed 4-6-00; 8:45 am] BILLING CODE 3190-01-M

## DEPARTMENT OF TRANSPORTATION

## Federal Highway Administration

## Federal Transit Administration

[FTA/FHWA Docket No. FTA-2000-7171]
Notice of Request for the Extension of Currently Approved Information Collections

AGENCIES: Federal Transit
Administration (FTA), Federal Highway Administration (FHWA), DOT.
ACTION: Notice of request for comments.
SUMMARY: In accordance with the Paperwork Reduction Act of 1995, this notice announces the intention of the FTA and FHWA to request the Office of Management and Budget (OMB) to extend the following currently approved information collection: Metropolitan and Statewide Transportation Planning.
DATES: Comments must be submitted before June 6, 2000.
ADDRESSES: All written comments must refer to the docket number that appears at the top of this document and be submitted to the United States Department of Transportation, Central Dockets Office, PL-401, 400 Seventh Street, SW, Washington, DC 20590. All comments received will be available for examination at the above address from 10:00 a.m. to 5:00 p.m., e.t., Monday through Friday, except federal holidays. Those desiring notification of receipt of comments must include a self-
addressed, stamped postcard/envelope.
FOR FURTHER INFORMATION CONTACT: Mr.
Robert Stout, FTA, (202) 366-1628 or Mr. Sheldon Edner, FHWA, (202) 3664066.

SUPPLEMENTARY INFORMATION: Interested parties are invited to send comments regarding any aspect of this information collection, including: (1) The necessity and utility of the information collection for the proper performance of the functions of the FTA and the FHWA; (2) the accuracy of the estimated burden; (3) ways to enhance the quality, utility, and clarity of the collected information; and (4) ways to minimize the collection burden without reducing the quality of the collected information. Comments submitted in response to this notice will be summarized and/or included in the request for OMB reinstatement of this information collection.

Title: Metropolitan and Statewide Transportation Planning (OMB Number: 2132-0529).

Background: The FTA and FHWA jointly carry out the Federal mandate to improve urban and rural transportation. 49 U.S.C. 5303-5306 and 23 U.S.C. 134 and 135 require metropolitan planning organizations (MPOs) and States to develop transportation plans and programs. The information collection activities involved in developing the Unified Planning Work Program (UPWP), the Metropolitan Transportation Plan, the Statewide Transportation Plan, the Metropolitan Transportation Improvement Program (TIP), and the Statewide Transportation Improvement Program (STIP) are necessary to identify and evaluate the transportation issues and needs in each urbanized area and throughout every State. These products of the transportation planning process are essential elements in the reasonable planning and programming of federallyfunded transportation investments.

In addition to serving as a management tool for MPOs and State DOTs, the UPWP is used by both FTA and FHWA to oversee the expenditure of federal transportation planning funds and to monitor the transportation planning activities of those agencies. It is also needed to develop policy on using funds, monitor State and local compliance with national technical emphasis areas, respond to congressional inquiries, prepare congressional testimony, and ensure efficiency in the use and expenditure of federal funds by determining that planning proposals are both reasonable and cost-effective. 49 U.S.C. Section 5304 and 23 U.S.C. 134(h) require the development of TIPs for urbanized areas; STIPS are mandated by 23 U.S.C. 135(f). After approval by the Governor and MPO, metropolitan TIPs in air quality attainment areas are to be incorporated directly into the STIP. For nonattainment areas, FTA/FHWA must make a conformity finding on the TIPs before including them into the STIP. The complete STIP is then jointly reviewed and approved or disapproved by FTA and FHWA. These conformity findings and approval actions constitute the determination that States are complying with the requirements of 23 U.S.C. 135 and 49 U.S.C. Section 5303 as a condition of eligibility for federal-aid funding. Without these documents, approvals and findings, capital and/or operating assistance, cannot be provided.

Respondents: State Departments of Transportation (DOTs) and Metropolitan Planning Organizations (MPOs).

Estimated Annual Burden on Respondents: 646 hours for each of the 392 respondents.

Estimated Total Annual Burden: 253,250 hours.
Frequency: Annually and biennially.
Issued: April 3, 2000.
Dorrie Y. Aldrich,
FTA Associate Administrator for Administration.

Dated: April 3, 2000.
Michael J. Vecchietti,
FHWA Acting Director of Administration.
[FR Doc. 00-8506 Filed 4-6-00; 8:45 am] biLLING CODE 4910-57-P

## DEPARTMENT OF TRANSPORTATION

## Federal Railroad Administration

Proposed Agency Information Collection Activities; Comment Request
AGENCY: Federal Railroad Administration, DOT.
ACTION: Notice and request for comments.

SUMMARY: In compliance with the Paperwork Reduction Act of 1995 (44 U.S.C. 3501 et seq.), this notice announces that the Information Collection Requirements (ICRs) abstracted below have been forwarded to the Office of Management and Budget (OMB) for review and comment. The ICRs describes the nature of the information collections and their expected burdens. The Federal Register notice with a 60 -day comment period soliciting comments on the following collections of information was published on January 26, 2000 (65 FR 4297).

DATES: Comments must be submitted on or before May 8, 2000.
FOR FURTHER INFORMATION CONTACT: Mr.
Robert Brogan, Office of Planning and
Evaluation Division, RRS-21, Federal Railroad Administration, 1120 Vermont Ave., NW, Mail Stop 17, Washington, DC 20590 (telephone: (202) 493-6292), or Dian Deal, Office of Information Technology and Productivity Improvement, RAD-20, Federal Railroad Administration, 1120 Vermont Ave., NW, Mail Stop 35, Washington, DC 20590 (telephone: (202) 493-6133). (These telephone numbers are not tollfree.)
SUPPLEMENTARY INFORMATION: The
Paperwork Reduction Act of 1995
(PRA), Pub. L. 104-13, § 2, 109 Stat. 163
(1995) (codified as revised at 44 U.S.C. 3501-3520), and its implementing regulations, 5 CFR part 1320, require Federal agencies to issue two notices seeking public comment on information collection activities before OMB may
approve paperwork packages. 44 U.S.C. 3506, 3507; 5 CFR 1320.5, 1320.8(d)(1), 1320.12. On January 26, 2000, FRA published a 60-day notice in the Federal Register soliciting comment on ICRs that the agency was seeking OMB approval. 65 FR 4297. FRA received no comments after issuing this notice. Accordingly, DOT announces that these information collection activities have been reevaluated and certified under 5 CFR 1320.5(a) and forwarded to OMB for review and approval pursuant to 5 CFR 1320.12(c).
Before OMB decides whether to approve these proposed collections of information, it must provide 30 days for public comment. 44 U.S.C. 3507 (b); 5 CFR 1320.12(d). Federal law requires OMB to approve or disapprove paperwork packages between 30 and 60 days after the 30 day notice is published. 44 U.S.C. 3507 (b)-(c); 5 CFR 1320.12(d); see also 60 FR 44978, 44983, Aug. 29, 1995. OMB believes that the 30 day notice informs the regulated community to file relevant comments and affords the agency adequate time to digest public comments before it renders a decision. 60 FR 44983, Aug. 29, 1995. Therefore respondents should submit their respective comments to OMB within 30 days of publication to best ensure having their full effect. 5 CFR 1320.12(c); see also 60 FR 44983, Aug. 29, 1995.
The summaries below describe the nature of the information collection requirements (ICRs) and the expected burden. The revised requirements are being submitted for clearance by OMB as required by the PRA.
Title: Identification of Cars Moved in Accordance with Order 13528.
OMB Control Number: 2130-0506.
Type of Request: Extension of a currently approved collection.
Affected Public: Railroads.
Form(s): None.
Abstract: This collection of information identifies a freight car being moved within the scope of Order 13528 (Order). See CFR part 232, appendix B. Otherwise, an exception will be taken, and the car will be set out of the train and not delivered. The information that must be recorded is specified at 49 CFR part 232, appendix $B$, requiring that a car be properly identified by a card attached to each side of the car and signed stating that such movement is being made under the authority of the order. The Order does not require retaining cards or tags. When a car bearing a tag for movement under the Order arrives at its destination, the tags are simply removed.
Annual Estimated Burden Hours: 67 hours.

Title: Railroad Police Officers.
OMB Control Number: 2130-0537.
Type of Request: Extension of a currently approved collection.

Affected Public: Railroads and States. Form(s): None.
Abstract: Under 49 CFR part 207, railroads are required to notify states of all designated police officers who are discharging their duties outside of their respective jurisdictions. This
requirement is necessary to verify proper police authority.

Annual Estimated Burden Hours: 155 hours.

Addressee: Send comments regarding these information collections to the Office of Information and Regulatory Affairs, Office of Management and Budget, 725 Seventeenth Street, NW, Washington, DC, 20503, Attention: FRA Desk Officer.

Comments are invited on the following: Whether the proposed collections of information are necessary for the proper performance of the functions of the Department, including whether the information will have practical utility; the accuracy of the Department's estimates of the burden of the proposed information collections; ways to enhance the quality, utility, and clarity of the information to be collected; and ways to minimize the burden of the collections of information on respondents, including the use of automated collection techniques or other forms of information technology.

A comment to OMB is best assured of having its full effect if OMB receives it within 30 days of publication of this notice in the Federal Register.

Authority: 44 U.S.C. 3501-3520.
Issued in Washington, DC on April 4, 2000. Margaret B. Reid,
Acting Director, Office of Information Technology and Support Systems, Federal Railroad Administration.
[FR Doc. 00-8706 Filed 4-6-00; 8:45 am] BILLING CODE 4910-06-P

## DEPARTMENT OF TRANSPORTATION

## Research and Special Programs

 Administration[Docket No. RSPA-00-7126 (PDA-24 (R))]
Application by the Institute of Makers
of Explosives for a Preemption
Determination as to New Jersey
Restrictions on Transportation of Blasting Caps With Other Commercial Explosives
agency: Research and Special Programs Administration (RSPA), DOT.

ACTION: Public notice and invitation to comment.

SUMMARY: Interested parties are invited to submit comments on an application by the Institute of Makers of Explosives (IME) for an administrative determination whether Federal hazardous materials transportation law preempts New Jersey law and regulations prohibiting the transportation of blasting caps on the same motor vehicle with more than 5,000 pounds of other commercial explosives.
DATES: Comments received on or before May 22, 2000, and rebuttal comments received on or before July 6, 2000 will be considered before issuance of an administrative ruling on IME's application. Rebuttal comments may discuss only those issues raised by comments received during the initial comment period and may not discuss new issues.
ADDRESSES: The application and all comments received may be reviewed in the Dockets Office, U.S. Department of Transportation, Room PL-401, 400 Seventh Street, SW, Washington, DC 20590-0001. The application and all comments are also available on-line through the home page of DOT's Docket Management System, at "http:// dms.dot.gov."
Comments must refer to Docket No. RSPA-00-7126 and may be submitted to the docket either in writing or electronically. Send three copies of each written comment to the Dockets Office at the above address. If you wish to receive confirmation of receipt of your written comments, include a selfaddressed, stamped postcard. To submit comments electronically, log onto the Docket Management System website at http://dms.dot.gov, and click on "Help \& Information" to obtain instructions.

A copy of each comment must also be sent to:
(1) Ms. Cynthia Hilton, Vice President, Institute of Makers of Explosives, 1120 Nineteenth Street, NW, Suite 310, Washington, DC 20036-3605, and
(2) Mr. Fred Cohen, Legal Liaison, New Jersey Department of Labor, P.O. Box 110, Trenton, NJ 08625-0110.
A certification that a copy has been sent to these persons must also be included with the comment. (The following format is suggested: "I certify that copies of this comment have been sent to Ms. Hilton and Mr. Cohen at the addresses specified in the Federal Register.")

A list and subject matter index of hazardous materials preemption cases,
including all inconsistency rulings and preemption determinations issued, are available through the home page of RSPA's Office of the Chief Counsel, at "http://rspa-atty.dot.gov." A paper copy of this list and index will be provided at no cost upon request to the individual named in FOR FURTHER INFORMATION CONTACT below.
FOR FURTHER INFORMATION CONTACT:
Frazer C. Hilder, Office of the Chief Counsel, Research and Special Programs Administration, U.S. Department of Transportation, Washington, DC 205900001 (Tel. No. 202-366-4400).

## SUPPLEMENTARY INFORMATION:

## I. Application for a Preemption Determination

IME has applied for a determination that Federal hazardous material transportation law, 49 U.S.C. 5125 et seq., preempts New Jersey statutory and regulatory restrictions against the transportation of blasting caps on the same motor vehicle with more than 5,000 pounds of other commercial explosives.
According to IME's application, New Jersey's Explosives Act, as codified in N.J.S.A. 21:1A-128 et seq., includes provisions governing the
"Transportation of explosives" at N.J.S.A. 21:1A-137. Paragraph F of that section provides:

Blasting caps or electric blasting caps, or both, may be transported in the same vehicle with other commercial explosives only when the net weight of the other commercial explosives does not exceed 5,000 pounds.
IME also states that, in 1998, the New Jersey Department of Labor adopted and began enforcing regulations governing off-highway transportation of explosives, including the provision in N.J.A.C. 12:190-6.5(d) that:

Blasting caps or electric blasting caps, or both, may be transported in the same vehicle with other commercial explosives only when the net weight of the other commercial explosives does not exceed 5,000 pounds.

IME asserts that these statutory and regulatory restrictions are preempted because they concern the "handling" of a hazardous material and are not substantively the same as the Hazardous Materials Regulations (HMR), 49 CFR Parts 171-180.1 In 49 CFR 177.835(g), the HMR provide that:

No detonator assembly or booster with detonator may be transported on the same motor vehicle with any Division 1.1, 1.2 or 1.3 (Class A or Class B explosive) material (except other detonator assemblies, boosters

[^113]with detonators or detonators), explosives for blasting or detonating cord Division 1.4 (Class C explosive) material. No detonator may be transported on the same motor vehicle with any Division 1.1, 1.2 or 1.3 (Class A or Class B explosive) material (except other detonators, detonator assemblies or boosters with detonators), explosives for blasting or detonating cord Division 1.4 (Class C explosive) material unless-
(1) It is packed in a specification MC 201 (§ 178.318 of this subchapter) container, or
(2) The package conforms with
requirements prescribed in $\S 173.63$ of this subchapter, and its use is restricted to instances when-
(i) There is no Division 1.1, 1.2, or 1.3 (Class A or Class B explosive) material or blasting agent loaded on the motor vehicle; and
(ii) A separation of 61 cm (24 inches) is maintained between each package of detonators and each package of detonating cord; or
3. It is packed and loaded in accordance with a method approved by the Department [of Transportation]. One method approved by the Department is as follows:
(i) The detonators are in packagings as prescribed in $\S 173.63$ of this subchapter which in turn are loaded into suitable containers or separate compartments. Both the detonators and the container or compartment must meet the requirements of the Institute of Makers of Explosives’
Standard (IME Safety Library Publication No. 22).

IME also contends that these New Jersey statutory and regulatory restrictions are preempted because they are an obstacle to the accomplishing and carrying out the Federal hazardous material transportation law and the HMR. IME states that a person using both blasting caps and more than 5,000 pounds of other commercial explosives at a site within New Jersey must either: (1) Use separate vehicles to transport the blasting caps and the other commercial explosives, from the origin of the transportation to the job site; or (2) at some point before leaving the public highway at the job site, transfer either the blasting caps or the other commercial explosives to a separate vehicle.

IME submitted three affidavits with its application. Each of the affiants stated that his company uses two separate vehicles to transport detonators and other explosives to meet New Jersey's requirements. The President of Maurer \& Scott, Inc., an explosives service and transportation company, testified that the use of separate vehicles to transport detonators and explosives
leads to more explosives vehicles on the road, trucks not loaded to capacity, inefficient transportation, excess handling of hazardous materials, and greater exposure to the public. Additionally, more vehicles end
up at the minesite which creates an increased safety hazard.

He also stated that the New Jersey Department of Labor has denied his company's requests for a waiver from the prohibition against transporting blasting caps on the same vehicle with more than 5,000 pounds of other commercial explosives.

IME argues that requiring separate vehicles for detonators and other commercial explosives exposes the public to greater overall risk, presumably both within and outside of New Jersey, because "the more trucks on the road, irrespective of the cargo, the higher likelihood of an accident." IME states that transferring either the detonators or the other explosives to a second vehicle, before leaving the public highway at the job site, also involves "unnecessary truck traffic" and creates "the added risk from the unnecessary handling during loading or reloading." IME notes that, in 49 CFR 177.835(j), the HMR specifically prohibit the transfer of any Division 1.1, 1.2 or 1.3 (Class A or B explosive) material
from one container to another, or from one motor vehicle to another vehicle, or from another vehicle to a motor vehicle, on any public highway, street, or road, except in the case of an emergency.

IME also states that it is unaware of any other State that imposes the same restrictions as New Jersey on the transportation of blasting caps with other commercial explosives. IME has not indicated whether New Jersey's restrictions cause shipments of blasting caps and other explosives to be routed around the State of New Jersey, rather than on highways through the State.

The text of IME's application and a list of the exhibits to the application are set forth in Appendix A to this notice. A paper copy of the exhibits to IME's application will be provided at no cost upon request to the individual named in FOR FURTHER INFORMATION CONTACT above.

## II. Federal Preemption

Section 5125 of Title 49 U.S.C. contains several preemption provisions that are relevant to IME's application. Subsection (a) provides that-in the absence of a waiver of preemption by DOT under §5125(e) or specific authority in another Federal law-a requirement of a State, political subdivision of a State, or Indian tribe is preempted if
(1) complying with a requirement of the State, political subdivision or tribe and a requirement of this chapter or a regulation issued under this chapter is not possible; or
(2) the requirement of the State, political subdivision, or Indian tribe, as applied or enforced, is an obstacle to the accomplishing and carrying out this chapter or a regulation prescribed under this chapter.

These two paragraphs set forth the "dual compliance" and "obstacle"" criteria which RSPA had applied in issuing inconsistency rulings prior to 1990, under the original preemption provision in the Hazardous Materials Transportation Act (HMTA). Public Law 93-633 section 112(a), 88 Stat. 2161 (1975). The dual compliance and obstacle criteria are based on U.S. Supreme Court decisions on preemption. Hines v. Davidowitz, 312 U.S. 52 (1941); Florida Lime \& Avocado Growers, Inc. v. Paul, 373 U.S. 132 (1963); Ray v. Atlantic Richfield, Inc., 435 U.S. 151 (1978).

Subsection (b)(1) of 49 U.S.C. 5125 provides that a non-Federal requirement concerning any of the following subjects, that is not "substantively the same as", a provision of Federal hazardous material transportation law or a regulation prescribed under that law, is preempted unless it is authorized by another Federal law or DOT grants a waiver of preemption:
(A) the designation, description, and classification of hazardous material.
(B) the packing, repacking, handling, labeling, marking, and placarding of hazardous material.
(C) the preparation, execution, and use of shipping documents related to hazardous material and requirements related to the number, contents, and placement of those documents.
(D) the written notification, recording, and reporting of the unintentional release in transportation of hazardous material.
(E) the design, manufacturing, fabricating, marking, maintenance, reconditioning, repairing, or testing of a packaging or a container represented, marked, certified, or sold as qualified for use in transporting hazardous material.

To be "substantively the same," the non-Federal requirement must "conform[] in every significant respect to the Federal requirement. Editorial and other similar de minimis changes are permitted." 49 CFR 107.202(d).

Subsection (c)(1) of 49 U.S.C. 5125 provides that, beginning two years after DOT prescribes regulations on standards to be applied by States and Indian tribes in establishing requirements on highway routing of hazardous materials,
a State or Indian tribe may establish,
maintain, or enforce a highway routing designation over which hazardous material may or may not be transported by motor vehicles, or a limitation or requirement related to highway routing, only if the
designation, limitation, or requirement complies with section 5112 (b). ${ }^{2}$

These preemption provisions in 49 U.S.C. 5125 carry out Congress' view that a single body of uniform Federal regulations promotes safety in the transportation of hazardous materials. In considering the HMTA, the Senate Commerce Committee "endorse[d] the principle of preemption in order to preclude a multiplicity of State and local regulations and the potential for varying as well as conflicting regulations in the area of hazardous materials transportation." S. Rep. No. 1102, 93rd Cong. 2nd Sess. 37 (1974). When it amended the HMTA in 1990, Congress specifically found that:
(3) many States and localities have enacted laws and regulations which vary from Federal laws and regulations pertaining to the transportation of hazardous materials, thereby creating the potential for unreasonable hazards in other jurisdictions and confounding shippers and carriers which attempt to comply with multiple and conflicting registration, permitting, routing, notification, and other regulatory requirements,
(4) because of the potential risks to life, property, and the environment posed by unintentional releases of hazardous materials, consistency in laws and regulations governing the transportation of hazardous materials is necessary and desirable,
(5) in order to achieve greater uniformity and to promote the public health, welfare, and safety at all levels, Federal standards for regulating the transportation of hazardous materials in intrastate, interstate, and foreign commerce are necessary and desirable.
Public Law 101-615 Section 2, 104 Stat. 3244. A Federal Court of Appeals has found that uniformity was the "linchpin" in the design of the HMTA, including the 1990 amendments that expanded the original preemption provisions. Colorado Pub. Util. Comm'n v. Harmon, 951 F.2d 1571, 1575 (10th Cir. 1991). (In 1994, Congress revised, codified and enacted the HMTA
"without substantive change," at 49
U.S.C. Chapter 51. Pub. L. 103-272, 108 Stat. 745.)

## III. Preemption Determinations

Under 49 U.S.C. 5125(d)(1), any directly affected person may apply to the Secretary of Transportation for a determination whether a State, political subdivision or Indian tribe requirement is preempted. The Secretary of Transportation has delegated authority to make determinations of preemption

[^114]that concern highway routing to the Federal Motor Carrier Safety Administration (FMCSA) and those concerning all other hazardous materials transportation issues to RSPA. 49 CFR $1.53(\mathrm{~b})$ and $1.73(\mathrm{~d})(2)$ (as added October 9, 1999, 64 FR 56720, 56721 [Oct. 19, 1999], and revised January 1, 2000, 65 FR 220, 221 [Jan. 4, 2000]).

Section 5125(d)(1) requires that notice of an application for a preemption determination must be published in the Federal Register. Following the receipt and consideration of written comments, RSPA will publish its determination in the Federal Register. See 49 CFR 107.209. If the comments show that New Jersey's statutory and regulatory restrictions cause diversions in highway routing of explosives, RSPA's determination may be issued jointly with FMCSA's Administrator. 49 CFR 397.211(a). A short period of time is allowed for filing of petitions for reconsideration. 49 CFR 107.211, 397.223. Any party to the proceeding may seek judicial review in a Federal district court. 49 U.S.C. 5125(f).

Preemption determinations do not address issues of preemption arising under the Commerce Clause, the Fifth Amendment or other provisions of the Constitution or under statutes other than the Federal hazardous material transportation law unless it is necessary to do so in order to determine whether a requirement is authorized by another Federal law. A State, local or Indian tribe requirement is not authorized by another Federal law merely because it is not preempted by another Federal statute. Colorado Pub. Util. Comm'n v. Harmon, above, 951 F.2d at 1581 n. 10.

In making preemption determinations under 49 U.S.C. 5125(d), RSPA (and FMCSA) are guided by the principles and policies set forth in Executive Order No. 13132, entitled 'Federalism" (64 FR 43255 (August 4, 1999). Section 4(a) of that Executive Order authorizes preemption of State laws only when a statute contains an express preemption provision, there is other clear evidence that Congress intended to preempt State law, or the exercise of State authority directly conflicts with the exercise of Federal authority. Section 5125 contains express preemption previsions, which RSPA (and FMCSA) have implemented through their regulations.

## IV. Public Comments

All comments should be limited to the issue whether 49 U.S.C. 5125 preempts N.J.S.A. 221:1A-137.F and N.J.A.C. 12:190-6.5(d). Comments should specifically address the preemption criteria detailed in Part II, above, and set forth in detail the manner
in which the New Jersey requirements are applied and enforced. Persons intending to comment should review the standards and procedures governing consideration of applications for preemption determinations, set forth at 49 CFR 107.201-107.211 and 397.201397.211 .

Issued in Washington, DC on April 3, 2000.
Robert A. McGuire,
Acting Associate Administrator for Hazardous Materials Safety, Research and Special Programs, Administration.

## Appendix A

## Before the United States Department of Transportation Office of Hazardous Materials Safety

Application of the Institute of Makers of Explosives to initiate a proceeding to determine whether various requirements imposed by the State of New Jersey on the transportation of certain Class 1 materials to, from or through the State are preempted by the Hazardous Materials Transportation Act February 28, 2000.

## Interest of the Petitioner

The Institute of Makers of Explosives (IME) represents companies that transport by truck Class 1 materials throughout the United States, including points to, from and through the State of New Jersey (State). Despite full compliance with the hazardous materials regulations (HMR), members of the IME are precluded from transporting Class 1 materials in amounts in excess of 5,000 pounds if blasting caps are transported in the same vehicle-a practice allowed by the HMR. The IME asserts that the State requirements contravene the Hazardous Materials Transportation Act (HMTA).

## Background

The State's Explosives Act (Statute) provides that " $[b]$ lasting caps or electric blasting caps, or both, may be transported in the same vehicle with other commercial explosives only when the net weight of the other commercial explosives does not exceed 5,000 pounds." ${ }^{1}$ The Statute allows for no exceptions. The Statute provides that "[v]iolations of the provisions of this act or rules and regulations made hereunder shall be punishable for the first offense by a penalty of not less than $\$ 100$ nor more than $\$ 5,000$ and for the third and each succeeding offense by a penalty of not less than $\$ 500$ nor more than $\$ 10,000 .{ }^{\prime \prime}$ If the State discovers a condition that exists in violation of the provisions of this Act, the State also has power to order such violation to cease. ${ }^{3}$
Up until 1998, this provision of law did not interfere with the transportation of Class 1 materials because implementing regulations did not address this statutory requirement. In 1998, this oversight was corrected. Rules issued by the NJ Department of Labor (NJDL), which oversees the

[^115]implementation of the Act, were amended to include the statutory restriction. ${ }^{4}$

The IME subsequently contracted the NJDL to advise the NJDL of the possible inconsistency with the HMTA. The NJDL acknowledged our concern, but felt that there was no recourse given the provision in the Statute. In fact, the regulatory version appears to temper the Statute by qualifying that the quantity restriction on Class 1 materials only applies when explosives are being transported "off-highway." ${ }^{5}$ The State Act, on the other hand, clearly pertains to any transportation of these materials by any mode. ${ }^{6}$

## State Requirements for Which a Determination Is Sought

This application seeks preemption of the following State requirements: ${ }^{7}$
N.J.S.A. 21:1A-37.F.
N.J.A.C. 12:190-6.5(d)

Federal Law Provides for the Preemption of Non-Federal Requirements When Those Non-Federal Requirements Fail Certain Federal Preemption Tests

The HMTA was enacted in 1975 to give the U.S. Department of Transportation (DOT) greater authority "to protect the Nation adequately against the risks to life and property which are inherent in the transportation of hazardous materials in commerce." ${ }^{8}$ By vesting primary authority over the transportation of hazardous materials in the DOT, Congress intended to
"make possible for the first time a comprehensive approach to minimization of the risks associated with the movement of valuable but dangerous materials." ${ }^{9}$ As originally enacted, the HMTA included a preemption provision "to preclude a multitude of State and local regulations and the potential for varying as well as conflicting regulations in the area of hazardous materials transportation." ${ }^{10}$ The HMTA preempted '"any requirement, of a State or political subdivision thereof, which is inconsistent with any requirement set forth in [the Act], or in a regulation issued under [the Act]." ${ }^{11}$ This preemption provision was implemented through an administrative process where DOT would issue
"inconsistency rulings" as to,
[w]hether compliance with both the State or political subdivision requirement and the Act or the regulations issued under the Act is possible, and [ t ]he extent to which the State or political subdivision requirement is an obstacle to the accomplishment and execution of the Act and the regulations issued under the Act. ${ }^{12}$

[^116]These criteria, commonly referred to as the "dual compliance" and "obstacle" tests, "comport with the test for conflicts between Federal and State statutes enunciated by the Supreme Court in Hines v. Davidowitz, 312 U.S. 52 (1941)." ${ }^{13}$

In 1990, Congress codified the dual compliance and obstacle tests as the general preemption provision of the HMTA. ${ }^{14}$ The 1990 amendments also expanded on DOT's preemption authorities. Among other new authorities, Congress expressly preempted non-federal requirements in five covered subject areas if they are not "substantively the same" as federal requirements. One of these covered subject areas includes " $[t] h e$ packing, repacking [and] handling . . . of hazardous materials." ${ }^{15}$
"Substantively the same" was defined to mean "conforms in every significant respect to the Federal requirement. Editorial and other similar de minimis, changes are permitted." ${ }^{16}$ These preemption authorities are limited only to the extent that non-federal requirements are "otherwise authorized" by federal law. A non-federal requirement is not "otherwise authorized by Federal law" merely because it is not preempted by another federal statute. ${ }^{17}$
The HMR has been promulgated in accordance with the HMTA's direction that the Secretary of Transportation "issue regulations for the safe transportation of hazardous material in intrastate, interstate, and foreign commerce." 18 '"Transportation', is defined as "the movement of property and loading, unloading, or storage incidental to the movement." ${ }^{19}$
Our review of federal law and the HMR leads us to believe that the above referenced State requirements, absent further modification and/or clarification, are subject to preemption pursuant to 49 U.S.C. 5125(a)(2) and/or (b)(1)(B). We ask for a determination of preemption based on the authority of 49 U.S.C. 5125(d).

## Discussion

The HMR provides that detonators, including blasting caps, may be transported by motor vehicle in commerce with Division $1.1,1.2,1.3,1.4$ or $1.5^{20}$ materials if the detonators are packaged and loaded on the vehicle under prescribed conditions. ${ }^{21}$ No restrictions are applied to the transportation of detonators and Division 1.6 materials. Because of the State's broad definition of "explosive," ${ }^{22}$ the State's requirement affects all Class 1 materials.
The IME knows of no other state that imposes limitations on explosives such as are

[^117]imposed in New Jersey. Consequently, shipments of explosives and detonators move in truckload quantities unimpeded in commerce as long as they are in compliance with the HMR until they enter or leave sites in New Jersey.
In order to comply with the State's quantity limitations, companies have few options. They can load detonators and explosives on separate vehicles or they can reconfigure detonator/explosive shipments to meet the State's restriction. These options present unacceptable safety risks.
In the first case, unnecessary truck traffic, and traffic carrying explosives, is added to the roadways. It has been shown that the more trucks on the road, irrespective of the cargo, the higher likelihood of an accident. The public along these routes of travel, which may include jurisdictions outside of New Jersey, is exposed to this relative increased risk.
In the second case, not only are two or more trucks needed to transport the same quantity of explosives that could efficiently be carried by one truck, but there is the added risk from the unnecessary handling during loading or re-loading to conform explosive/detonator shipments to New Jersey's restrictions. In the case of Division $1.1,1.2$, and 1.3 materials, the risk from this unnecessary handling is shifted to locations outside of the State because the HMR prohibit the transfer of these explosive materials "from one container to another, or from one motor vehicle to another vehicle, or from another vehicle to a motor vehicle, on any public highway, street, or road, except in case of emergency." ${ }^{23}$ New Jersey cannot, for whatever reason, be allowed to isolate itself from the risks associated with the commerce of these products.

We do not contest the authority of the State to regulate the movement of explosives that is outside of the scope of the HMTA. In short transportation that is entirely on private property is not transportation in commerce within the meaning of the HMTA and is not covered by the HMR. ${ }^{24}$ In our disussion with the NJDL over these requirements, we have endeavored to see if any accommodation could be made to restrict the applicability of the rule to vehicles transporting explosives between locations on one site where a public way is never entered or crossed. Regrettably, the NJDL said they could not interpret the rules that way, and that vehicles would be in violation if they carried both explosives and detonators the moment they left a public road. While admitting to the folly of a rule that would allow vehicles carrying explosives to off-load on a public road, rather than in the security of a consignee's site, the NJDL pointed to the plain words of the Statute which state that the quantity limitation for explosives transported with detonators applies to any transportation within the State. Heretofore, we have had to contend with the consequences of the State's requirement when it applies to commercial transportation at off-highway locations. However, we must ask RSPA to consider the

[^118]ramifications to safety and commerce if the State decided to implement its law verbatim

No transportation is risk-free. The packaging and handling provisions of the HMR related to explosives are intended to minimize the consequences of an incident if it should occur. The HMR have been incredibly effective in this regard as they apply to the transportation of Class 1 materials. The IME is aware of no fatalities occurring when detonators and explosives are transported and handled as required. Since 1990, there have been 200 incidents involving explosives of which 53 were serious. ${ }^{25}$ None of the 200 incidents resulted in a fatality. In all, there were 2 injuries that required hospitalization. Of the 200 incidents, only one, non-"serious" incident occurred in New Jersey and that incident did not involve a detonator/explosive shipment, which is the focus of this proceeding.

## Standard of Preemption

While "handling" is not a term defined in the HMTA, RSPA has defined this term to mean "the operation of loading and unloading." ${ }^{26}$ The State's requirements affect the handling of Class 1 materials being transported in commerce because the restriction demands loading and unloading activity beyond that contemplated in the HMR. Inasmuch as non-federal requirements "about any . . . handling . . . of hazardous materials" that are not substantively the same as the HMR are preempted, we ask that RSPA preempt these requirements on the basis of 49 U.S.C. 5125(b)(1)(B). Otherwise, we ask RSPA to preempt these requirements on the basis of its obstacle test authority at 49 U.S.C. 5125(a)(2). Without doubt, the State's requirements are "an obstacle to accomplishing and carrying out . . . a regulation prescribed under [the HMTA]," and are a detriment to safety.

## Conclusion

We believe the State's requirements imposed on the transportation of certain Class 1 materials are preempted by federal law. The State is enforcing the above suspect requirements. Despite efforts to resolve this matter directly with the State, affected parties believe a determination of preemption is the most effective way to address this matter. Consequently, we request timely consideration of the concerns we have raised.

## Certification

Pursuant to 49 CFR 107.205(a), we hereby certify that a copy of this application has been forwarded with an invitation to submit comments to: Fred Cohen, Legal Liaison, NJ Department of Labor, P.O. Box 110, Trenton, NJ 08625-0110.

[^119]Respectfully submitted,
Cynthia Hilton,
Vice President.

## Attachments

(A) N.J.S.A. 21:1A-129(f)—Definition of "Explosives"
(B) N.J.S.A. 21:1A-130—Enforcement
(C) N.J.S.A. 21:1A-137-Transportation of Explosives
(D) N.J.S.A. 21:1A-140—Violations; Penalties; Revocation of Permits; Nonconforming Uses
(E) N.J.A.C. 12:190-6.5-Off Highway Transportation of Explosives
(F) Affidavits of:

Jack E. Costello, Maurer \& Scott, Inc. Ronald J. Lutz, Jr., Explo Tech, Inc. Richard J. Coons, Energetic Solutions Quarry \& Construction Services
[FR Doc. 00-8662 Filed 4-6-00; 8:45 am]
BILLING CODE 4910-60-M

## DEPARTMENT OF TRANSPORTATION

## Surface Transportation Board

## STB Docket No. MC-F-20964

## Laidlaw Inc.-Continuance in Control-the Gray Line of Victoria Ltd.

AGENCY: Surface Transportation Board.
ACTION: Notice tentatively approving finance transaction.

SUMMARY: In an application filed under 49 U.S.C. 14303, Laidlaw Inc. (Laidlaw), a noncarrier, seeks approval of its continuance in control of The Gray Line of Victoria Ltd. (Gray Line) upon Gray Line's becoming a regulated motor carrier of passengers. Persons wishing to oppose the application must follow the rules under 49 CFR 1182.5 and 1182.8. The Board has tentatively approved the transaction, and, if no opposing comments are timely filed, this notice will be the final Board action.
DATES: Comments must be filed by May 22, 2000. Applicant may file a reply by June 6, 2000. If no comments are filed by May 22, 2000, this notice is effective on that date.
ADDRESSES: Send an original and 10 copies of any comments referring to STB Docket No. MC-F-20964 to: Surface Transportation Board, Office of the Secretary, Case Control Unit, 1925 K Street, NW, Washington, DC 204230001. In addition, send one copy of comments to applicant's representative: Fritz R. Kahn, Suite 750 West, 1100 New York Avenue, NW, Washington, DC 20005-3934.
FOR FURTHER INFORMATION CONTACT:
Joseph H. Dettmar, (202) 565-1600. [TDD for the hearing impaired: 1-800-877-8339].

SUPPLEMENTARY INFORMATION: Laidlaw controls Gray Line through Laidlaw Transit Ltd. (Laidlaw Ltd.), which is authorized to transport passengers, in charter and special operations, pursuant to authority in No. MC-102189. Gray Line conducts charter and special passenger carrier operations within Canada. Laidlaw seeks authority to continue in control of Gray Line through Laidlaw Ltd. upon Gray Line’s
becoming a regulated carrier pursuant to an application it has filed with the Federal Highway Administration.
Laidlaw currently controls 23 motor carriers of passengers, including Greyhound Lines, Inc. (Greyhound) (MC-1515), which Laidlaw considers its domestic flagship carrier. ${ }^{1}$ The controlled carrier's operations, with the exception of those of Greyhound, are largely limited to charter and special operations within the United States. Greyhound conducts mainly nationwide, scheduled regular-route operations.
Laidlaw asserts that, because Gray Line is an experienced and well regarded carrier that has established contacts with hotels, tourist attractions, and other institutions, the addition of Gray Line to the Laidlaw family of regulated carriers will contribute significantly to the breadth of services that Greyhound and the other Laidlaw affiliates will be able to provide the public. Laidlaw maintains also that the proposed transaction will inure to the benefit of Gray Line’s passengers. This benefit is expected to partly take the form of reasonable fares, in view of the access to the financial resources and expertise of the Laidlaw system that Gray Line will have following the transaction.

Under 49 U.S.C. 14303(b), we must approve and authorize a transaction we find consistent with the public interest, taking into consideration at least: (1) The effect of the transaction on the adequacy of transportation to the public; (2) The total fixed charges that result; and (3) The interest of affected carrier employees.
Applicant has submitted the information required by 49 CFR 1182.2, including information to demonstrate that the proposed transaction is consistent with the public interest under 49 U.S.C. 14303(b). Specifically, applicant has shown that the proposed transaction will have a positive effect on the adequacy of transportation to the public and will result in no increase in fixed charges and no changes in employment. See 49 CFR 1182.2(a)(7).

[^120]Additional information may be obtained from applicant's representative.

On the basis of the application, we find that the proposed transaction is consistent with the public interest and should be authorized. If any opposing comments are timely filed, this finding will be deemed vacated, and, unless a final decision can be made on the record as developed, a procedural schedule will be adopted to reconsider the application. See 49 CFR 1182.6(c). If no opposing comments are filed by the expiration of the comment period, this decision will take effect automatically and will be the final Board action.

Board decisions and notices are available on our website at
"WWW.STB.DOT.GOV."
This decision will not significantly affect either the quality of the human environment or the conservation of energy resources.

It is ordered:

1. The proposed continuance in control is approved and authorized, subject to the filing of opposing comments.
2. If timely opposing comments are filed, the findings made in this decision will be deemed as having been vacated.
3. This decision will be effective on May 22, 2000, unless timely opposing comments are filed.
4. A copy of this notice will be served on: (1) The U.S. Department of Transportation, Federal Motor Carrier Safety Administration-HMCE-20, 400 Virginia Avenue, SW, Suite 600, Washington, DC 20024; (2) The U.S. Department of Justice, Antitrust Division, 10th Street \& Pennsylvania Avenue, NW, Washington, DC 20530; and (3) The U.S. Department of Transportation, Office of the General Counsel, 400 7th Street, SW, Washington, DC 20590.
Decided: April 3, 2000.
By the Board, Chairman Morgan, Vice Chairman Burkes, and Commissioner Clyburn.
Vernon A. Williams,
Secretary.
[FR Doc. 00-8664 Filed 4-6-00; 8:45 am] BILLING CODE 4915-00-P

## DEPARTMENT OF TRANSPORTATION

## Surface Transportation Board

[STB Finance Docket No. 33857]
Colorado, Kansas \& Pacific Railway Company-Lease, Operation, and Future Purchase Exemption-Colorado Department of Transportation
a verified notice of exemption under 49 CFR 1150.31. CKPR has entered into an agreement with the Colorado Department of Transportation (CDOT) whereby CKPR will lease and initiate common carrier operations over an abandoned line of railroad between milepost 747.5, near Towner, and milepost 869.4, near NA Junction, in Kiowa, Crowley, and Pueblo Counties, CO, a distance of approximately 121.9 route miles (rail line). In addition, the agreement grants CKPR the right to purchase the rail line under specified conditions on or before December 31, 2001.

The parties report that they intended to consummate the transaction on or about March 29, 2000. The earliest the transaction could have been consummated was March 29, 2000, 7 days after the exemption was filed.
This transaction is related to STB Finance Docket No. 33856, Court Hammond, et al.-Continuance in Control Exemption-Colorado Central Railroad Company and Colorado, Kansas \& Pacific Railway Company, wherein Court Hammond, et al. have concurrently filed a verified notice to continue in control of Colorado Central Railroad Company and CKPR upon their becoming Class III rail carriers.

If the verified notice contains false or misleading information, the exemption is void ab initio. Petitions to reopen the proceeding to revoke the exemption under 49 U.S.C. 10502(d) may be filed at any time. The filing of a petition to revoke will not automatically stay the transaction.

An original and 10 copies of all pleadings, referring to STB Finance Docket No. 33857, must be filed with the Surface Transportation Board, Office of the Secretary, Case Control Unit, 1925 K Street, NW, Washington, DC 204230001. In addition, a copy of each pleading must be served on John D. Heffner, Esq., 1707 L Street, NW, Suite 570, Washington, DC 20036.

Board decisions and notices are available on our website at "WWW.STB.DOT.GOV."
Decided: March 31, 2000.
By the Board, David M. Konschnik, Director, Office of Proceedings.
Vernon A. Williams,
Secretary.
[FR Doc. 00-8575 Filed 4-6-00; 8:45 am]
BILLING CODE 4915-00-P

Colorado, Kansas \& Pacific Railway
Company (CKPR), a noncarrier, has filed

# DEPARTMENT OF TRANSPORTATION 

## Surface Transportation Board <br> [STB Finance Docket No. 33856]

Court Hammond, et al."Continuance in Control Exemption-Colorado Central Railroad Company and Colorado, Kansas \& Pacific Railway Company

Court Hammond and James Sanders ${ }^{1}$ (Hammond Group), who previously controlled Yreka Western Railroad Company (YWRR) and Rocky Mountain Railway and Mining Museum (RMRMM), ${ }^{2}$ have filed a verified notice of exemption to continue in control of Colorado Central Railroad Company (CCRR) and Colorado, Kansas \& Pacific Railway Company (CKPR), upon their becoming rail carriers.
CCRC is a new short line railroad that will become a Class III rail carrier when it consummates the authority granted to it in Colorado Central Railroad Company-Operation ExemptionYreka Western Railroad Company, STB Finance Docket No. 33849 (STB served Feb. 23, 2000). ${ }^{3}$ CKPR will become a Class III rail carrier upon consummation of the transaction covered by the simultaneously filed notice of exemption in STB Finance Docket No. 33857, Colorado, Kansas \& Pacific Railway Company—Lease, Operation, and Future Purchase ExemptionColorado Department of Transporation, wherein CKPR will lease and initiate common carrier operations over an abandoned line of railroad.
The transaction was expected to be consummated on March 29, 2000.
The Hammond Group states that: (i) The railroads will not connect with each other or any railroad in their corporate family; (ii) The continuance in control is not part of a series of anticipated transactions that would connect the railroads with each other or any railroad in their corporate family; and (iii) The transaction does not involve a Class I carrier. Therefore, the transaction is exempt from the prior approval requirements of 49 U.S.C. 11323. See 49 CFR 1180.2(d)(2).

[^121]Under 49 U.S.C. 10502(g), the Board may not use its exemption authority to relieve a rail carrier of its statutory obligation to protect the interests of its employees. Section 11326(c), however, does not provide for labor protection for transactions under sections 11324 and 11325 that involve only Class III rail carriers. Because this transaction involves Class III rail carriers only, the Board, under the statute, may not impose labor protective conditions for this transaction.

If the notice contains false or misleading information, the exemption is void $a b$ initio. Petitions to revoke the exemption under 49 U.S.C. 10502(d) may be filed at any time. The filing of a petition to revoke will not automatically stay the transaction.

An original and 10 copies of all pleadings, referring to STB Finance Docket No. 33856, must be filed with the Surface Transportation Board, Office of the Secretary, Case Control Unit, 1925 K Street, N.W., Washington, DC 204230001. In addition, a copy of each pleading must be served on John D. Heffner, Esq., Rea, Cross \& Auchincloss, 1707 L Street, N.W., Suite 570, Washington, DC 20036.

Decided: March 31, 2000.
By the Board, David M. Konschnik, Director, Office of Proceedings.
Vernon A. Williams,
Secretary.
[FR Doc. 00-8574 Filed 4-6-00; 8:45 am] BILLING CODE 4915-00-P

## DEPARTMENT OF THE TREASURY

## Internal Revenue Service

Proposed Collection; Comment
Request for Form 1040 TeleFile and Form 8855-V, TeleFile Payment Voucher

AGENCY: Internal Revenue Service (IRS), Treasury.
ACTION: Notice and request for
comments.
SUMMARY: The Department of the Treasury, as part of its continuing effort to reduce paperwork and respondent burden, invites the general public and other Federal agencies to take this opportunity to comment on proposed and/or continuing information collections, as required by the Paperwork Reduction Act of 1995, Pub. L. 104-13 (44 U.S.C. 3506(c)(2)(A)). Currently, the IRS is soliciting comments concerning Form 1040TeleFile and Form 8855-V, TeleFile Payment Voucher.

DATES: Written comments should be received on or before June 6, 2000, to be assured of consideration.
ADDRESSES: Direct all written comments to Garrick R. Shear, Internal Revenue Service, room 5244, 1111 Constitution Avenue NW., Washington, DC 20224.

## FOR FURTHER INFORMATION CONTACT:

Requests for additional information or copies of the form and instructions should be directed to Carol Savage, (202) 622-3945, Internal Revenue Service, room 5242, 1111 Constitution Avenue NW., Washington, DC 20224.

## SUPPLEMENTARY INFORMATION:

Title: Form 1040-TeleFile and TeleFile Payment Voucher (Form 8855V).

OMB Number: 1545-1277.
Form Number: 1040-TeleFile and Form 8855-V.
Abstract: Certain Form 1040EZ filers are given the option of using a simplified method of filing their tax return by telephone. The taxpayer enters certain minimal items of information on the TeleFile Tax Record and calls the IRS with a touch-tone telephone. The automated system figures the tax and any refund or balance due while the taxpayer is still on the phone.

Current Actions: There are no changes being made to the form at this time.
Type of Review: Extension of a currently approved collection.
Affected Public: Individuals or households.

Estimated Number of Responses: 5,900,000.
Estimated Time Per Respondent: 1 hour, 29 minutes.

Estimated Total Annual Burden Hours: 8,723,000.
The following paragraph applies to all of the collections of information covered by this notice:

An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless the collection of information displays a valid OMB control number. Books or records relating to a collection of information must be retained as long as their contents may become material in the administration of any internal revenue law. Generally, tax returns and tax return information are confidential, as required by 26 U.S.C. 6103.

## Request for Comments

Comments submitted in response to this notice will be summarized and/or included in the request for OMB approval. All comments will become a matter of public record. Comments are invited on: (a) Whether the collection of information is necessary for the proper performance of the functions of the
agency, including whether the information shall have practical utility; (b) the accuracy of the agency's estimate of the burden of the collection of information; (c) ways to enhance the quality, utility, and clarity of the information to be collected; (d) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques or other forms of information technology; and (e) estimates of capital or start-up costs and costs of operation, maintenance, and purchase of services to provide information.

Approved: March 31, 2000.

## Garrick R. Shear,

IRS Reports Clearance Officer.
[FR Doc. 00-8578 Filed 4-6-00; 8:45 am]
BILLING CODE 4830-01-U

## DEPARTMENT OF THE TREASURY

## Internal Revenue Service

## Proposed Collection; Comment Request for Voluntary Customer Surveys To Implement E.O. 12862 Coordinated by the Office of Program Evaluation and Risk Analysis on Behalf of All IRS Operations Functions

AGENCY: Internal Revenue Service (IRS), Treasury.
ACTION: Notice and request for comments.

SUMMARY: The Department of the Treasury, as part of its continuing effort to reduce paperwork and respondent burden, invites the general public and other Federal agencies to take this opportunity to comment on proposed and/or continuing information collections, as required by the Paperwork Reduction Act of 1995, Pub. L. 104-13 (44 U.S.C. 3506(c)(2)(A)). Currently, the IRS is soliciting comments concerning Voluntary Customer Surveys To Implement E.O. 12862 Coordinated by the Office of Program Evaluation and Risk Analysis on Behalf of All IRS Operations Functions.
DATES: Written comments should be received on or before June 6, 2000, to be assured of consideration.
ADDRESSES: Direct all written comments to Garrick R. Shear, Internal Revenue Service, room 5244, 1111 Constitution Avenue NW., Washington, DC 20224.

## FOR FURTHER INFORMATION CONTACT:

Requests for additional information or copies of the information collection should be directed to Carol Savage, (202) 622-3945, Internal Revenue

Service, room 5242, 1111 Constitution Avenue NW., Washington, DC 20224.

## SUPPLEMENTARY INFORMATION:

Title: Voluntary Customer Surveys To Implement E.O. 12862 Coordinated by the Office of Program Evaluation and Risk Analysis on Behalf of All IRS Operations Functions.

OMB Number: 1545-1432.
Abstract: This is a generic clearance for an undefined number of customer satisfaction and opinion surveys and focus group interviews to be conducted over the next three years. Surveys and focus groups conducted under the generic clearance are used by the Internal Revenue Service to determine levels of customer satisfaction, as well as determining issues that contribute to customer burden. This information will be used to make quality improvements to products and services.

Current Actions: We will be conducting different customer satisfaction and opinion surveys and focus group interviews during the next three years than in the past. At the present time, it is not determined what these surveys and focus groups will be.

Type of Review: Revision of a currently approved collection.

Affected Public: Individuals or households, business or other-for-profit organizations, not-for profit institutions, farms, and Federal, state, local or tribal governments.

## Estimated Number of Respondents:

 1,166,667.Estimated Time Per Respondent: 15 minutes.

## Estimated Total Annual Burden

 Hours: 91,667.The following paragraph applies to all of the collections of information covered by this notice:

An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless the collection of information displays a valid OMB control number. Books or records relating to a collection of information must be retained as long as their contents may become material in the administration of any internal revenue law. Generally, tax returns and tax return information are confidential, as required by 26 U.S.C. 6103.

## Request for Comments

Comments submitted in response to this notice will be summarized and/or included in the request for OMB approval. All comments will become a matter of public record. Comments are invited on: (a) Whether the collection of information is necessary for the proper performance of the functions of the agency, including whether the information shall have practical utility;
(b) the accuracy of the agency's estimate of the burden of the collection of information; (c) ways to enhance the quality, utility, and clarity of the information to be collected; (d) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques or other forms of information technology; and (e) estimates of capital or start-up costs and costs of operation, maintenance, and purchase of services to provide information.
Approved: March 27, 2000.
Garrick R. Shear,
IRS Reports Clearance Officer.
[FR Doc. 00-8579 Filed 4-6-00; 8:45 am]
BILLING CODE 4830-01-U

## DEPARTMENT OF THE TREASURY

## Internal Revenue Service

## Publication of Inflation Adjustment Factor, Nonconventional Source Fuel Credit, and Reference Price for Calendar Year 1999

AGENCY: Internal Revenue Service (IRS), Treasury.
ACTION: Publication of inflation adjustment factor, nonconventional source fuel credit, and reference price for calendar year 1999 as required by section 29 of the Internal Revenue Code (26 U.S.C. section 29).
summary: The inflation adjustment factor, nonconventional source fuel credit, and reference price are used in determining the tax credit allowable on the production of fuel from
nonconventional sources under section 29.

DATES: The 1999 inflation adjustment factor, nonconventional source fuel credit, and reference price apply to qualified fuels sold during calendar year 1999.
inflation factor: The inflation factor is calculated using GNP Implicit Price Deflators as computed and published by the Department of Commerce. The inflation factor for 1999, which is smaller than the factor published for 1998, reflects a comprehensive revision in 1999 of the national income and product accounts by the Department of Commerce. The inflation factor for calendar year 1999 is 2.0013 .
CREDIT: The nonconventional source fuel credit for calendar year 1999 is $\$ 6.00$ per barrel-of-oil equivalent of qualified fuels.
PRICE: The reference price for calendar year 1999 is $\$ 15.56$. Because this reference price does not exceed $\$ 23.50$
multiplied by the inflation adjustment factor, the phaseout of credit provided for in section 29(b)(1) does not occur for any qualified fuel sold in calendar year 1999.

FOR FURTHER INFORMATION CONTACT:
For the inflation factor and credit-
Thomas Thompson, OP:RS:R:E, Internal Revenue Service, 1111 Constitution Avenue, NW., Washington, DC 20224, Telephone Number (202) 874-0585 (not a tollfree number).
For the reference price-
Alan Cooper or David McMunn, CC:DOM:P\&SI:6, Internal Revenue Service, 1111 Constitution Avenue, NW., Washington, DC 20224, Telephone Number (202) 622-3110 (not a toll-free number).

Judith C. Dunn,
Associate Chief Counsel (Domestic).
[FR Doc. 00-8640 Filed 4-4-00; 2:10 pm] BILLING CODE 4830-01-U

## DEPARTMENT OF THE TREASURY

## Internal Revenue Service

Open Meeting of Citizen Advocacy Panel, Brooklyn District

AGENCY: Internal Revenue Service (IRS), Treasury.
ACTION: Notice.
SUMMARY: An open meeting of the Brooklyn District Citizen Advocacy Panel will be held in Brooklyn, New York.
DATES: The meeting will be held Friday April 28, 2000.
FOR FURTHER INFORMATION CONTACT:
Eileen Cain at 1-888-912-1227 or 718-488-3555.
SUPPLEMENTARY INFORMATION: Notice is hereby given pursuant to Section 10(a)(2) of the Federal Advisory Committee Act, 5 U.S.C. App. (1988) that an operational meeting of the Citizen Advocacy Panel will be held Friday, April 28, 2000, 6 p.m. to 9 p.m. at the Internal Revenue Service Brooklyn Building located at 625 Fulton Street, Brooklyn, NY 11201. For more information or to confirm attendance, notification of intent to attend the meeting must be made with Eileen Cain. Mrs. Cain can be reached at 1-888-9121227 or 718-488-3555. The public is invited to make oral comments from 8:30 p.m. to 9 p.m. on Friday, April 28, 2000. Individual comments will be limited to 5 minutes. If you would like to have the CAP consider a written statement, please call 1-888-912-1227
or 718-488-3555, or write Eileen Cain, CAP Office, P.O. Box R, Brooklyn, NY 11201. The Agenda will include the following: various IRS issues. Note: Last minute changes to the agenda are possible and could prevent effective advance notice.

Dated: March 21, 2000.
M. Cathy VanHorn,

CAP Program Manager.
[FR Doc. 00-8580 Filed 4-6-00; 8:45 am]
BILLING CODE 4830-01-M

DEPARTMENT OF THE TREASURY

## Internal Revenue Service

Open Meeting of Citizen Advocacy Panel, South Florida District

ACTION: Notice.
sUmmary: A Public meeting of the South Florida District Citizen Advocacy Panel will be held in Naples, Florida.

DATES: The meeting will be held Friday, April 28, 2000 and Saturday, April 29, 2000

## FOR FURTHER INFORMATION CONTACT:

Nancy Ferree at 1-888-912-1227 or 954-423-7974.

SUPPLEMENTARY INFORMATION: Notice is hereby given pursuant to Section 10(a)(2) of the Federal Advisory Committee Act, 5 U.S.C. App. (1988) that a Public meeting of the Citizen Advocacy Panel will be held Friday, April 28, 2000, 6 p.m. to 9 p.m. and Saturday, April 29, 2000, 9 a.m. to Noon at the YMCA, 5450 YMCA Road, Naples, FL 34109. For more information contact Nancy Ferree at 1-888-9121227 or 954-423-7974. The public is invited to make oral comments. Individual comments will be limited to 10 minutes. If you would like to have the CAP consider a written statement, please call 1-888-912-1227 or 954-4237974, or write Nancy Ferree, CAP Office, 7771 W. Oakland Park Blvd \#225, Sunrise, FL, 33351.

The Agenda will include the following: various IRS issues.

Note: Last minute changes to the agenda are possible and could prevent effective advance notice.

Dated: March 21, 2000.
M. Cathy VanHorn,

CAP Project Manager.
[FR Doc. 00-8581 Filed 4-6-00; 8:45 am]
BILLING CODE 4830-01-U

## DEPARTMENT OF THE TREASURY

## Internal Revenue Service

## Open Meeting of Citizen Advocacy Panel, Midwest District

agency: Internal Revenue Service (IRS), Treasury.
ACTION: Notice.
SUMMARY: An open meeting of the Midwest Citizen Advocacy Panel will be held in Milwaukee, Wisconsin.
DATES: The meeting will be held Thursday, April 27, 2000, and Friday, April 28, 2000.
FOR FURTHER INFORMATION CONTACT:
Sandra McQuin at 1-888-912-1227, or 414-297-1604.
SUPPLEMENTARY INFORMATION: Notice is hereby given pursuant to Section 10(a)(2) of the Federal Advisory Committee Act, 5 U.S.C. App. (1988) that a working meeting of the Citizen Advocacy Panel (CAP) will be held Thursday, April 27, 2000, from 9:00 a.m. to 5:00 p.m. and Friday, April 28, 2000, from 9:00 a.m. to Noon at Reuss Federal Building, Meeting Room 290B, 310 W. Wisconsin Avenue, Milwaukee, WI. The Citizen Advocacy Panel is soliciting public comment, ideas, and suggestions on improving customer service at the Internal Revenue Service. Written comments can be submitted to the panel by faxing to (414) 297-1623, or by mail to Citizen Advocacy Panel, Mail Stop 1006 MIL, 310 West Wisconsin Avenue, Milwaukee, WI 53203-2221.

The Agenda will include the following: Various IRS issue updates and reports by the CAP sub-groups, presentation of taxpayer issues by individual members, CAP office report, and discussion of issues.
Note: Last minute changes to the agenda are possible and could prevent effective advance notice.

Dated: March 24, 2000.
M. Cathy VanHorn,

CAP Project Manager.
[FR Doc. 00-8582 Filed 4-6-00; 8:45 am]
BILLING CODE 4830-01-U

## DEPARTMENT OF THE TREASURY

## Internal Revenue Service

## Open Meeting of Citizen Advocacy Panel, Pacific-Northwest District

Agencr: Internal Revenue Service (IRS), Treasury.
ACTION: Notice.
SUMMARY: An open meeting of the Pacific-Northwest Citizen Advocacy

Panel will be held in Pasco,
Washington.
DATES: The meeting will be held Saturday, April 8, 2000.
FOR FURTHER INFORMATION CONTACT: Lori M. Dupuis at 1-888-912-1227 or 206-220-6096.
SUPPLEMENTARY INFORMATION: Notice is hereby given pursuant to Section 10(a)(2) of the Federal Advisory Committee Act, 5 U.S.C. App. (1988) that an open meeting of the Citizen Advocacy Panel will be held Saturday,

April 8, 2000, 9 a.m. to Noon at the Doubletree Hotel, 2525 North 20th Avenue, Pasco, WA 99301. The public is invited to make oral comments.
Individual comments will be limited to 10 minutes. If you would like to have the CAP consider a written statement, please call 1-888-912-1227 or 206-220-6096, or write Lori M. Dupuis, CAP Office, 915 2nd Avenue, Room 442, Seattle, WA 98174. Due to limited conference space, notification of intent to attend the meeting must be made with Lori M. Dupuis. Ms. Dupuis can be
reached at 1-888-912-1227 or 206-220-6096.

The Agenda will include the following: various IRS issue updates and reports by the CAP sub-groups.
Note: Last minute changes to the agenda are possible and could prevent effective advance notice.

Dated: March 21, 2000.
M. Cathy VanHorn,

CAP Project Manager.
[FR Doc. 00-8583 Filed 4-6-00; 8:45 am]
BILLING CODE 4830-01-U

## Corrections

Federal Register
Vol. 65, No. 68
Friday, April 7, 2000

This section of the FEDERAL REGISTER contains editorial corrections of previously published Presidential, Rule, Proposed Rule, and Notice documents. These corrections are prepared by the Office of the Federal Register. Agency prepared corrections are issued as signed documents and appear in the appropriate document categories elsewhere in the issue.

## DEPARTMENT OF THE INTERIOR

## Minerals Management Service

## 30 CFR Part 250

## Oil and Gas and Sulphur Operations in the Outer Continental Shelf-Update on Revised/Reaffirmed Documents Incorporated by Reference

## Correction

In rule document 00-7267 beginning on page 15862 in the issue of Friday, March 24, 2000, make the following corrections:

## §250.198 [Corrected]

1. On page 15863, in §250.198(e), in the third line of the table, "Chapter," should read "Chapter 4,".
2. On the same page, in the same section, in the "Incorporated by reference at" column, in the sixth and seventh entries, " $\S 250.1202(\mathrm{a})(3)$ and (1)(4)" should read "§250.1202(a)(3) and (1)(4)".
[FR Doc. C0-7267 Filed 4-6-00; 8:45 am] BILLING CODE 1505-01-D

## DEPARTMENT OF JUSTICE

## Immigration and Naturalization Service

## 8 CFR Parts 214 and 248

[INS No. 2000-99]

## RIN 1115-AF51

## Irish Peace Process Cultural and Training Program

## Correction

In rule document 00-6818 beginning on page 14774 in the issue of Friday, March 17, 2000, make the following corrections:

1. On page 14774, in the first column, in the second line from the bottom, "Peach" should read, "Peace".
2. On the same page, in the third column, in the third paragraph, in the sixth line,"T\&A" should read, "T\&EA".

3 . On page 14775 , in the first column, 14 lines from the bottom, "Weihle" should read "Wiehle".
4. On the same page, in the second column, in the fourth line, after "promotion" add "agriculture/ horticulture diversification, food processing,"
5. On the same page, in the same column, in the second line from the bottom, "participation" should read "participate".
6. On page 14776, in the first column, second full paragraph, in the first line,
" 25.1 " should read, " 265.1 ".

## §214.2 [Corrected]

7. On page 14779 , in the second column, in §214.2(q)(15)(x), after the last line, add "******".
8. On the same page, in the same column, in amendatory instruction 8c.,
"Paragraph (q)(3)(iv);(D)" should read, "Paragraph (q)(3)(iv)(D);".
9. On the same page, in the third column, in amendatory instruction 10. , the last line should read "paragraphs (q)(5)(i), (q)(7)(ii), and (q)(8)(ii)".
10. On the same page, in the same column, in amendatory instruction 11. , in the fourth line, after "visitors", remove "to read international cultural exchange visitors".
11. On the same page, in the same column, in amendatory instruction 12., in the second and fourth lines,
"visitors" should read "visitor".
12. On the same page, in the same column, in amendatory instruction 14. , in the second line "revised" should read "revising".

## §248.3 [Corrected]

13. On page 14780, in §248.3(d), in the first column, in the seventh line, "free" should read "fee".
14. On the same page, $\S 248.3(\mathrm{e})(2)$ in the second column, in the third line, after "spouse", "of" should read "or". [FR Doc. C0-6818 Filed 4-6-00; 8:45 am] BILLING CODE 1505-01-D

## MISSISSIPPI RIVER COMMISSION

## Sunshine Act Meeting

## Correction

In notice document 00-6997 appearing on page 15019 in the issue of March 20, 2000, make the following correction:
In the second column, seven lines from the bottom,"April 10, 2000" should read "April 11, 2000". [FR Doc. C0-6997 Filed 4-6-00; 8:45 am] BILLING CODE 1505-01-D


## Friday,

April 7, 2000

## Part II

# Department of Health and Human Services 

## Health Care Financing Administration

42 CFR Parts 409, et al.
Office of the Inspector General; Medicare Program Prospective Payment System for Hospital Outpatient Services; Final Rule

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

## Health Care Financing Administration

42 CFR Parts 409, 410, 411, 412, 413, 419, 424, 489, 498, and 1003
[HCFA-1005-FC]

## RIN 0938-AI56

Office of Inspector General; Medicare Program; Prospective Payment System for Hospital Outpatient Services

AgENCY: Health Care Financing Administration (HCFA), HHS, and Office of Inspector General (OIG), HHS. ACTION: Final rule with comment period.

SUMMARY: This final rule with comment period implements a prospective payment system for hospital outpatient services furnished to Medicare beneficiaries, as set forth in section 1833(t) of the Social Security Act. It also establishes requirements for provider departments and provider-based entities, and it implements section 9343(c) of the Omnibus Budget Reconciliation Act of 1986, which prohibits Medicare payment for nonphysician services furnished to a hospital outpatient by a provider or supplier other than a hospital, unless the services are furnished under an arrangement with the hospital. In addition, this rule establishes in regulations the extension of reductions in payment for costs of hospital outpatient services required by section 4522 of the Balanced Budget Act of 1997, as amended by section 201(k) of the Balanced Budget Refinement Act of 1999.

DATES: Effective date: July 1, 2000, except that the changes to
§412.24(d)(6), new §413.65, and the changes to §489.24(h), §498.2, and $\S 498.3$ are effective October 10, 2000.
Applicability date: For Medicare services furnished by all hospitals, including hospitals excluded from the inpatient prospective payment system, and by community mental health centers, the applicability date for implementation of the hospital outpatient prospective payment system is July 1, 2000.
Comment date: Comments on the provisions of this rule resulting from the Balanced Budget Refinement Act of 1999 will be considered if we receive them at the appropriate address, as provided below, no later than $5 \mathrm{p} . \mathrm{m}$. on June 6, 2000. We will not consider comments concerning provisions that remain unchanged from the September

8, 1998 proposed rule or that were revised based on public comment.

See section VIII for a more detailed discussion of the provisions subject to comment.
ADDRESSES: Mail written comments (one original and three copies) to the following address ONLY: Health Care Financing Administration, Department of Health and Human Services, Attention: HCFA-1005-FC, P.O. Box 8013, Baltimore, MD 21244-8013.

If you prefer, you may deliver, by courier, your written comments (one original and three copies) to one of the following addresses:
Room 443-G, Hubert H. Humphrey
Building, 200 Independence Avenue,
SW., Washington, DC 20201, or
C5-14-03, Central Building, 7500
Security Boulevard, Baltimore, MD 21244-1850.
Comments mailed to those addresses may be delayed and could be considered late.

Because of staffing and resource
limitations, we cannot accept comments by facsimile (FAX) transmission. In commenting, please refer to file code HCFA-1005-FC.

Comments received timely will be available for public inspection as they are received, generally beginning approximately 3 weeks after publication of a document, in Room 443-G of the Department's offices at 200 Independence Avenue, SW., Washington, DC, on Monday through Friday of each week from 8:30 a.m. to 5 p.m. (Phone (202) 690-7890).

For comments that relate to information collection requirements, mail a copy of comments to:
Health Care Financing Administration, Office of Information Services, Security and Standards Group,
Division of HCFA Enterprise
Standards, Room N2-14-26, 7500
Security Boulevard, Baltimore, MD 21244-1850, Attn: John Burke,
HCFA-1005-FC; and
Lauren Oliven, HCFA Desk Officer, Office of Information and Regulatory Affairs, Room 3001, New Executive Office Building, Washington, DC 20503.

Copies: To order copies of the Federal Register containing this document, send your request to: New Orders, Superintendent of Documents, P.O. Box 371954, Pittsburgh, PA 15250-7954. Specify the date of the issue requested and enclose a check or money order payable to the Superintendent of Documents, or enclose your Visa or Master Card number and expiration date. Credit card orders can also be
placed by calling the order desk at (202)
$512-1800$ or by faxing to (202) 5122250 . The cost for each copy is $\$ 8$. As an alternative, you can view and photocopy the Federal Register document at most libraries designated as Federal Depository Libraries and at many other public and academic libraries throughout the country that receive the Federal Register.
FOR FURTHER INFORMATION CONTACT:
Janet Wellham, (410) 786-4510 or
Chuck Braver, (410) 786-6719 (for general information)
Joel Schaer (OIG), (202) 619-0089 (for information concerning civil money penalties)
Kitty Ahern, (410) 786-4515 (for information related to the classification of services into ambulatory payment classification (APC) groups)
George Morey (410) 786-4653 (for information related to the determination of provider-based status)
Janet Samen (410) 786-9161 (for information on the application of APCs to community mental health centers)
SUPPLEMENTARY INFORMATION: To assist readers in referencing sections contained in this document, we are providing the following table of contents. Within each section, we summarize pertinent material from our proposed rule of September 8, 1998 (63 FR 47552) followed by public comments and our responses.

## Table of Contents

## I. Background

A. General and Legislative History
B. Summary of Provisions of the Balanced Budget Act of 1997 (the BBA 1997)

1. Prospective Payment System (PPS)
2. Elimination of Formula-Driven Overpayment
3. Extension of Cost Reductions
C. The September 8, 1998 Proposed Rule
D. Overview of Public Comments
E. Summary of Relevant Provisions in the Balanced Budget Refinement Act of 1999 (the BBRA 1999)
4. Outlier Adjustment
5. Transitional Pass-Through for Additional Costs of Innovative Medical Devices, Drugs, and Biologicals
6. Budget Neutrality Applied to New Adjustments
7. Limitation on Judicial Review
8. Inclusion in the Hospital Outpatient PPS of Certain Implantable Items
9. Payment Weights Based on Mean Hospital Costs
10. Limitation on Variation of Costs of Services Classified Within a Group
11. Annual Review of the Hospital Outpatient PPS Components
12. Coinsurance Not Affected by PassThroughs
13. Extension of Cost Reductions
14. Clarification of Congressional Intent Regarding Base Amounts Used in Determining the Hospital Outpatient PPS
15. Transitional Corridors For Application of Outpatient PPS
16. Limitation on Coinsurance for a Procedure
17. Reclassification of Certain Hospitals
II. Prohibition Against Unbundling of Hospital Outpatient Services
A. Background
B. Office of Inspector General (OIG) Civil Money Penalty Authority and Civil
Money Penalties for Unbundling Hospital Outpatient Services
C. Summary of Final Regulations on Bundling of Hospital Outpatient Services
D. Comments and Responses
III. Hospital Outpatient Prospective Payment System (PPS)
A. Hospitals Included In or Excluded From the Outpatient PPS
B. Scope of Facility Services
18. Services Excluded from the Scope of Services Paid Under the Hospital Outpatient PPS
a. Background
b. Comments and Responses
c. Payment for Certain Implantable Items Under the BBRA 1999
d. Summary of Final Action
19. Services Included Within the Scope of the Hospital Outpatient PPS
a. Services for Patients Who Have Exhausted Their Part A Benefits
b. Partial Hospitalization Services
c. Services Designated by the Secretary
d. Summary of Final Action
20. Hospital Outpatient PPS Payment Indicators
C. Description of the Ambulatory Payment Classification (APC) Groups
21. Setting Payment Rates Based on Groups of Services Rather than on Individual Services
22. Packaging Under the APC System
a. Summary of Proposal
b. General Comments and Responses (Supporting or Objecting to Packaging)
c. Packaging of Casts and Splints
d. Packaging of Observation Services
e. Packaging Costs of Procuring Corneal Tissue
f. Packaging Costs of Blood and Blood Products
g. Packaging Costs for Drugs,

Pharmaceuticals, and Biologicals
h. Summary of Final Action
3. Treatment of Clinic and Emergency Department Visits
a. Provisions of the Proposed Rule
b. Comments and Responses
4. Treatment of Partial Hospitalization Services
5. Inpatient Only Procedures
6. Modification of APC Groups
a. How the Groups Were Constructed
b. Comments on Classification of Procedures and Services Within APC Groups
c. Effect of the BBRA 1999 on Final APC Groups
d. Summary of APC Modifications
e. Exceptions to the BBRA 1999 Limit on Variation of Costs Within APC Groups
7. Discounting of Surgical Procedures
8. Payment for New Technology Services
a. Background
b. Comments and Responses
D. Transitional Pass-Through for Innovative Medical Devices, Drugs, and Biologicals

1. Statutory Basis
2. Identifying Eligible Pass-Through Items
a. Drugs and Biologicals
b. Medical Devices
3. Criteria to Define New or Innovative Medical Devices Eligible for Pass-
through Payments
4. Determination of "Not Insignificant" Cost of New Items
5. Calculating the Additional Payment
6. Process to Identify Items and to Obtain Codes for Items Subject to Transitional Pass-Throughs
E. Calculation of Group Weights and Conversion Factor
7. Group Weights (Includes Table 1,

Packaged Services by Revenue Center)
2. Conversion Factor
a. Calculating Aggregate Calendar Year 1996 Medicare and Beneficiary Payments for Hospital Outpatient Services (PrePPS)
b. Sum of the Relative Weights
F. Calculation of Coinsurance Payments and Medicare Payments Under the PPS

1. Background
2. Determining the Unadjusted

Coinsurance Amount and Program
Payment Percentage
a. Calculating the Unadjusted Coinsurance

Amount for Each APC Group
b. Calculating the Program Payment

Percentage (Pre-deductible Payment
Percentage)
3. Calculating the Medicare Payment Amount and Beneficiary Coinsurance Amount
a. Calculating the Medicare Payment Amount
b. Calculating the Coinsurance Amount
4. Hospital Election to Offer Reduced Coinsurance
G. Adjustment for Area Wage Differences

1. Proposed Wage Index
2. Labor-Related Portion of Hospital Outpatient Department PPS Payment Rates
3. Adjustment of Hospital Outpatient

Department PPS Payment and
Coinsurance Amounts for Geographic
Wage Variations
4. Special Rules Under the BBRA 1999
H. Other Adjustments

1. Outlier Payments
2. Transitional Corridors/Interim Payments
3. Cancer Centers and Small Rural

Hospitals
I. Annual Updates

1. Revisions to APC Groups, Weights and
the Wage and Other Adjustments
2. Annual Update to the Conversion Factor
3. Advisory Panel for APC Updates
J. Volume Control Measures
K. Claims Submission and Processing and Medical Review
L. Prohibition Against Administrative or Judicial Review
IV. Provider-Based Status
A. Background
B. Provisions of the Proposed Rule
C. Comments and Responses
D. Requirements for Payment
V. Summary of and Response to MedPAC Recommendations
VI. Provisions of the Final Rule
VII. Collection of Information Requirements
VIII. Response to Comments
IX. Regulatory Impact Analysis
A. Introduction
B. Estimated Impact on the Medicare Program
C. Objectives
D. Limitations of Our Analysis
E. Hospitals Included In and Excluded From the Prospective Payment System
F. Quantitative Analysis of the Impact of Policy Changes on Payment Under the Hospital Outpatient PPS: Basis and Methodology of Estimates
G. Estimated Impact of the New APC System (Includes Table 2, Annual Impact of Hospital Outpatient Prospective Payment System in CY2000-CY2001)
X. Federalism
XI. Waiver of Proposed Rulemaking

Regulations Text

## Addenda

Addendum A—List of Hospital Outpatient Ambulatory Payment Classification Groups with Status Indicators, Relative Weights,
Payment Rates, and Coinsurance Amounts
Addendum B-Hospital Outpatient
Department (HOPD) Payment Rates and
Payment Status by HCPCS, and Related Information
Addendum C-Hospital Outpatient Payment
for Procedures by APC
Addendum D-1996 HCPCS Codes Used to Calculate Payment Rates That Are Not Active CY 2000 Codes
Addendum E-CPT Codes Which Will Be
Paid Only As Inpatient Procedures
Addendum F-Status Indicators
Addendum G-Service Mix Indices by Hospital
Addendum H-Wage Index for Urban Areas
Addendum I-Wage Index for Rural Areas
Addendum J—Wage Index for Hospitals That Are Reclassified
Addendum K-Drugs, Biologicals, and
Medical Devices Subject to Transitional
Pass-Through Payment

## Alphabetical List of Acronyms Appearing in the Final Rule

APC Ambulatory payment classification
APG Ambulatory patient group
ASC Ambulatory surgical center
AWP Average wholesale price
BBA 1997 Balanced Budget Act of 1997 BBRA 1999 Balanced Budget Refinement Act of 1999
CAH Critical access hospital
CAT Computerized axial tomography
CCI [HCFA's] Correct Coding Initiative
CCR Cost center specific cost-to-charge ratio
CCU Coronary care unit
CMHC Community mental health center
CMP Civil money penalty
CORF Comprehensive outpatient
rehabilitation facility
CPI Consumer Price Index
CPT [Physicians'] Current Procedural
Terminology, 4th Edition, 2000,
copyrighted by the American Medical Association
DME Durable medical equipment
DMEPOS DME, orthotics, prosthetics, prosthetic devices, prosthetic implants and supplies
DRG Diagnosis-related group
DSH Disproportionate share hospital
EACH Essential access community hospital
EBAA Eye Bank Association of America
ED Emergency department
EMS Emergency medical services
EMTALA Emergency Medical Treatment and Active Labor Act
ENT Ear/Nose/Throat
ESRD End-stage renal disease
FDA Food and Drug Administration
FDO Formula-driven overpayment
FQHC Federally qualified health center
HCPCS HCFA Common Procedure Coding System
HHA Home health agency
HRSA Health Resources and Services Administration
ICD-9-CM International Classification of Diseases, Ninth Edition, Clinical Modification
ICU Intensive care unit
IHS Indian Health Service
IME Indirect medical education
IOL Intraocular lens
JCAHO Joint Commission on Accreditation of Healthcare Organizations
LTH Long-term hospital
MDH Medicare-dependent hospital
MedPAC Medicare Payment Advisory
Commission
MRI Magnetic resonance imaging
MSA Metropolitan statistical area
NECMA New England County Metropolitan Area
OBRA Omnibus Budget Reconciliation Act
OT Occupational therapy
PPO Preferred provider organization
PPS Prospective payment system
RFA Regulatory Flexibility Act
RHC Rural health clinic
RPCH Rural primary care hospital
RRC Rural referral center
SCH Sole community hospital
SGR Sustainable growth rate
SNF Skilled nursing facility
TEFRA Tax Equity and Fiscal
Responsibility Act of 1982
TPA Tissue Plasminogen Activator
Y2K Year 2000

## I. Background

## A. General and Legislative History

When the Medicare program was first implemented, it paid for hospital services (inpatient and outpatient) based on hospital-specific reasonable costs attributable to serving Medicare beneficiaries. Later, the law was amended to limit payment to the lesser of a hospital's reasonable costs or its customary charges. In 1983, section 601 of the Social Security Amendments of 1983 (Pub. L. 98-21) completely revised the cost-based payment system for most hospital inpatient services by enacting section 1886(d) of the Social Security Act (the Act). This section provided for
a prospective payment system (PPS) for acute hospital inpatient stays, effective with hospital cost reporting periods beginning on or after October 1, 1983.

Although payment for most inpatient services became subject to the PPS, Medicare hospital outpatient services continued to be paid based on hospitalspecific costs, which provided little incentive for hospitals to furnish outpatient services efficiently. At the same time, advances in medical technology and changes in practice patterns were bringing about a shift in the site of medical care from the inpatient to the outpatient setting. During the 1980s, the Congress took steps to control the escalating costs of providing outpatient care. The Congress amended the statute to implement across-the-board reductions of 5.8 percent and 10 percent to the amounts otherwise payable by Medicare for hospital operating costs and capital costs, respectively, and enacted a number of different payment methods for specific types of hospital outpatient services. These methods included fee schedules for clinical diagnostic laboratory tests, orthotics, prosthetics, and durable medical equipment (DME); composite rate payment for dialysis for persons with end-stage renal disease (ESRD); and payments based on blends of hospital costs and the rates paid in other ambulatory settings such as separately certified ambulatory surgical centers (ASCs) or physician offices for certain surgery, radiology, and other diagnostic procedures. However, Medicare payment for services performed in the hospital outpatient setting remains largely cost-based

In the Omnibus Budget Reconciliation Act of 1986 (OBRA 1986) (Pub. L. 99509), the Congress paved the way for development of a PPS for hospital outpatient services. Section 9343(g) of OBRA 1986 mandated that fiscal intermediaries require hospitals to report claims for services under the HCFA Common Procedure Coding System (HCPCS). Section 9343(c) of OBRA 1986 extended the prohibition against unbundling of hospital services under section 1862(a)(14) of the Act to include outpatient services as well as inpatient services. The HCPCS coding enabled us to determine which specific procedures and services were being billed, while the extension of the prohibition against unbundling ensured that all nonphysician services provided to hospital outpatients would be billed only by the hospital, not by an outside supplier, and, therefore, would be reported on hospital bills and captured in the hospital outpatient data that
could be used to develop an outpatient PPS.

A proposed rule to implement section 9343(c) was published in the Federal Register on August 5, 1988. However, those regulations were never published as a final rule, so we included them in the hospital outpatient PPS proposed rule published in the Federal Register on September 8, 1998 (63 FR 47552) and will implement them as part of this final rule.

Section 1866(g) of the Act, as added by section 9343(c) of OBRA 1986, and amended by section 4085(i)(17) of the Omnibus Budget Reconciliation Act of 1987 (OBRA 1987) (Pub. L. 100-203), authorizes the Department of Health and Human Services’ Office of Inspector General to impose a civil money penalty (CMP), not to exceed \$2,000, against any individual or entity who knowingly and willfully presents a bill in violation of an arrangement (as defined in section 1861(w)(1) of the Act).

In section 9343(f) of the OBRA 1986 and section 4151(b)(2) of the Omnibus Budget Reconciliation Act of 1990 (Pub. L. 101-508), the Congress required that we develop a proposal to replace the current hospital outpatient payment system with a PPS and submit a report to the Congress on the proposed system.

The Secretary submitted a report to the Congress on March 17, 1995, summarizing the research we conducted searching for a way to classify outpatient services for purposes of developing an outpatient PPS. The report cited ambulatory patient groups (APGs), developed by 3M-Health Information Systems (3M-HIS) under a cooperative grant with HCFA, as the most promising classification system for grouping outpatient services and recommended that APG-like groups be used in designing a hospital outpatient PPS.

The report also presented a number of options that could be used, once a PPS was in place, for addressing the issue of rapidly growing beneficiary coinsurance. As a separate issue, we recommended that the Congress amend the provisions of the law pertaining to the blended payment methods for ASC surgery, radiology, and other diagnostic services to correct an anomaly that resulted in a less than full recognition of the amount paid by the beneficiary in calculating program payment (referred to as the formula-driven overpayment).

Three sections of the Balanced Budget Act of 1997 (the BBA 1997) (Pub. L. 105-33), enacted on August 5, 1997, affect Medicare payment for hospital outpatient services. Section 4521 of the BBA 1997 eliminates the formula-driven overpayment for ambulatory surgical
center procedures, radiology services, and diagnostic procedures furnished on or after October 1, 1997. In November 1998, we issued cost report instructions (Provider Reimbursement Manual, Part II, Chapter 36, Transmittal 4) that implemented this provision for services furnished on or after October 1, 1997. Section 4522 of the BBA 1997 amends section 1861(v)(1)(S)(ii) of the Act by extending cost reductions in payment for hospital outpatient operating costs and hospital capital costs, 5.8 percent and 10 percent respectively, before January 1, 2000. Section 4523 of the BBA 1997 amends section 1833 of the Act by adding subsection ( t ), which provides for implementation of a PPS for outpatient services. (Under Section 4523 of the BBA 1997 the outpatient PPS does not apply to cancer hospitals before January 1, 2000.) Set forth below in section I.B is a detailed description of the changes made by the BBA 1997.

On November 29, 1999, the Balanced Budget Refinement Act of 1999 (the BBRA 1999), Pub. L. 106-113, was enacted. This Act made major changes that affect the proposed hospital outpatient PPS. The legislative changes are summarized in section I.E, below. More specific details on individual provisions that we are implementing in this final rule with comment period are included under the various sections of this preamble.

## B. Summary of Provisions in the Balanced Budget Act of 1997 (the BBA 1997)

## 1. Prospective Payment System (PPS)

Section 4523 of the BBA 1997 amended section 1833 of the Act by adding subsection ( t ), which provides for a PPS for hospital outpatient department services. (The following citations reflect the statute as enacted by the BBA 1997.) Section 1833(t)(1)(B) of the Act authorizes the Secretary to designate the hospital outpatient services that would be paid under the PPS. That section also requires that the hospital outpatient PPS include hospital inpatient services designated by the Secretary that are covered under Part B for beneficiaries who are entitled to Part A benefits but who have exhausted them or otherwise are not entitled to them. Section 1833(t)(1)(B)(iii) of the Act specifically excludes ambulance, physical and occupational therapy, and speech-language pathology services, for which payment is made under a fee schedule.

Section 1833(t)(2) of the Act sets forth certain requirements for the hospital outpatient PPS. The Secretary is required to develop a classification
system for covered outpatient services that may consist of groups arranged so that the services within each group are comparable clinically and with respect to the use of resources.

Section 1833(t)(2)(C) of the Act specifies data requirements for establishing relative payment weights. The weights are to be based on the median hospital costs determined by 1996 claims data and data from the most recent available cost reports. Section 1833(t)(2)(D) of the Act requires that the portion of the Medicare payment and the beneficiary coinsurance that are attributable to labor and labor-related costs be adjusted for geographic wage differences in a budget neutral manner.

The Secretary is authorized under section $1833(\mathrm{t})(2)(\mathrm{E})$ of the Act to establish, in a budget neutral manner, other adjustments, such as outlier adjustments or adjustments for certain classes of hospitals, that are necessary to ensure equitable payments. Section 1833(t)(2)(F) of the Act requires the Secretary to develop a method for controlling unnecessary increases in the volume of covered outpatient services.

Section 1833(t)(3) of the Act specifies how beneficiary deductibles are to be treated in calculating the Medicare payment and beneficiary coinsurance amounts and requires that rules be established regarding determination of coinsurance amounts for covered services that were not furnished in 1996. The statute freezes beneficiary coinsurance at 20 percent of the national median charges for covered services (or group of covered services) furnished during 1996 and updated to 1999 using the Secretary's estimated charge growth from 1996 to 1999.

Section 1833(t)(3) of the Act also prescribes the formula for calculating the initial conversion factor used to determine Medicare payment amounts for 1999 and the method for updating the conversion factor in subsequent years.

Sections 1833(t)(4) and (t)(5) of the Act describe the method for determining the Medicare payment amount and the beneficiary coinsurance amount for services covered under the outpatient PPS. Section 1833(t)(5)(B) of the Act requires the Secretary to establish a procedure whereby hospitals may voluntarily elect to reduce beneficiary coinsurance for some or all covered services to an amount not less than 20 percent of the Medicare payment amount. Hospitals are further allowed to disseminate information on any such reductions of coinsurance amounts. Section 4451 of the BBA 1997 added section 1861(v)(1)(T) to the Act, which provides that any reduction in
coinsurance must not be treated as a bad debt.

Section 1833(t)(6) authorizes periodic review and revision of the payment groups, relative payment weights, wage index, and conversion factor.

Section 1833(t)(7) of the Act describes how payment is to be made for ambulance services, which are specifically excluded from the outpatient PPS under section 1833(t)(1)(B) of the Act.
Section 1833(t)(8) of the Act provides that the Secretary may establish a separate conversion factor for services furnished by cancer hospitals that are excluded from hospital inpatient PPS.

Section 1833(t)(9) of the Act prohibits administrative or judicial review of the hospital outpatient PPS classification system, the groups, relative payment weights, wage adjustment factors, other adjustments, calculation of base amounts, periodic adjustments, and the establishment of a separate conversion factor for those cancer hospitals excluded from hospital inpatient PPS.

Section 4523(d) of the BBA 1997 made a conforming
amendment to section 1833(a)(2)(B) of the Act to provide for payment under the hospital outpatient PPS for some services described in section 1832(a)(2) that are currently paid on a cost basis and furnished by providers of services, such as comprehensive outpatient rehabilitation facilities (CORFs), home health agencies (HHAs), hospices, and community mental health centers (CMHCs). This amendment provides that partial hospitalization services furnished by CMHCs be paid under the PPS.

## 2. Elimination of Formula-Driven Overpayment

Before enactment of section 4521(b) of the BBA 1997, using the blended payment formulas for ASC procedures, radiology, and other diagnostic services, the ASC or physician fee schedule portion was calculated as if the beneficiary paid 20 percent of the ASC rate or physician fee schedule amount instead of the actual amount paid, which was 20 percent of the hospital's billed charges. Section 4521(b), which amended sections 1833(i)(3)(B)(i)(II) and 1833(n)(1)(B)(i) of the Act, corrects this anomaly by changing the blended calculations so that all amounts paid by the beneficiary are subtracted from the total payment in the calculation to determine the amount due from the program. Effective for services furnished on or after October 1, 1997, payment for surgery, radiology, and other diagnostic services calculated by blended payment methods is now calculated by
subtracting the full amount of coinsurance due from the beneficiary (based on 20 percent of the hospital's billed charges).
3. Extension of Cost Reductions

Section 1861(v)(1)(S)(ii) of the Act was amended by section 4522 of the BBA 1997 to require that the amounts otherwise payable for hospital outpatient operating costs and capital costs be reduced by 5.8 percent and 10 percent, respectively, through December 31, 1999.
C. The September 8, 1998 Proposed Rule
We published a proposed rule in the Federal Register on September 8, 1998 ( 63 FR 47552) setting forth the proposed PPS for hospital outpatient services. In that proposed rule, we explained that, due to Year 2000 (Y2K) systems concerns, implementation of the new payment system would be delayed until after January 1, 1999. (The statement in the rule that the statute requires implementation "effective January 1, 1999," and other similar statements in other rules, were not intended to mean that the statute requires retroactive implementation of the hospital outpatient PPS. As noted elsewhere in this rule, the statute does not impose such a requirement.) As noted in that document, the scope of systems changes required to implement the hospital outpatient PPS is so enormous as to be impossible to accomplish concurrently with the critical work that we, our contractors, and our provider-partners had to perform to ensure that all of our respective systems were Y2K compliant. Section XI of the proposed rule (63 FR 47605) explains in greater detail the reasons for delaying implementation.
The proposed rule originally provided for a 60 -day comment period. However, the comment period was extended four times, ultimately ending on July 30 , 1999. (See 63 FR 63429, November 13, 1998; 64 FR 1784, January 12, 1999; 64 FR 12277, March 12, 1999; and 64 FR 36320; July 6, 1999.)

On June 30, 1999, we published a correction notice (64 FR 35258) to correct a number of technical and typographical errors contained in the September 8, 1998 proposed rule. The numerical values in the proposed rule reflected incorrect data and data programming. Among other corrections, the notice set forth revised numerical values for the current payment, total services (total units), relative weights, proposed payment rates, national unadjusted coinsurance, minimum unadjusted coinsurance, and servicemix index.

## D. Overview of Public Comments

We received approximately 10,500 comments in response to our September 8, 1998 proposed rule. That count includes the numerous requests from hospital and other interested groups and organizations that we extend the public comment period to allow additional time for analysis of the impact of our proposals. As we explain above, we extended the comment period four times, to end finally on July 30, 1999.

In addition to receiving comments from a number of organizations representing the full spectrum of the hospital industry, we received comments from beneficiaries and their families, physicians, health care workers, individual hospitals, professional associations and societies, legal and nonlegal representatives and spokespersons for beneficiaries and hospitals, members of the Congress, and other interested citizens. The majority of comments addressed our proposals regarding payment for: Corneal tissue; payment for high-cost technologies, both existing and future; payment for blood and blood products; and payment for high cost drugs, including chemotherapy agents. We also received numerous comments addressing: Our approach to ratesetting using the ambulatory payment classification (APC) system; our method of calculating the payment conversion factor; and the potentially negative impact of the proposed hospital outpatient PPS on hospital revenues. In addition, we received many comments concerning the proposed regulations for providerbased entities.

We carefully reviewed and considered all comments received timely. The many modifications that we made to our proposed regulations in response to commenters' suggestions and recommendations are reflected in the provisions of this final rule. Comments and our responses are addressed by topic in the sections that follow.

## E. Summary of Relevant Provisions in the Balanced Budget Refinement Act of 1999 (the BBRA 1999)

As noted above, subsequent to publication of the proposed rule, the BBRA 1999 was enacted on November 29, 1999. The BBRA 1999 made major changes that affect the proposed hospital outpatient PPS. Because these changes are effective with the implementation of the PPS, we have had to make some revisions from the September 8, 1998 proposed rule. The provisions of the BBRA 1999 that we are implementing in this final rule with comment period follow.

1. Outlier Adjustment

Section 201(a) of the BBRA 1999 amends section $1833(\mathrm{t})$ by redesignating paragraphs (5) through (9) as paragraphs (7) through (11) and adding a new paragraph (5). New section 1833(t)(5) of the Act provides that the Secretary will make payment adjustments for covered services whose costs exceed a given threshold (that is, an outlier payment). This section describes how the additional payments are to be calculated and caps the projected outlier payments at no more than 2.5 percent of the total projected payments (sum of both Medicare and beneficiary payments to the hospital) made under hospital outpatient PPS for years before 2004 and 3.0 percent of the total projected payments for 2004 and subsequent years.
2. Transitional Pass-Through for Additional Costs of Innovative Medical Devices, Drugs, and Biologicals

Section 201(b) of the BBRA 1999 adds new section 1833(t)(6) to the Act, establishing transitional pass-through payments for certain medical devices, drugs, and biologicals. This provision does the following: Specifies the types of items for which additional payments must be made; describes the amount of the additional payment; limits these payments to at least 2 years but not more than 3 years; and caps the projected payment adjustments annually at 2.5 percent of the total projected payments for hospital outpatient services each year before 2004 and no more than 2.0 percent in subsequent years. Under this provision, the Secretary has the authority to reduce pro rata the amount of the additional payments if, before the beginning of a year, she estimates that these payments would otherwise exceed the caps.

## 3. Budget Neutrality Applied to New Adjustments

Section 201(c) of the BBRA 1999 amends section 1833(t)(2)(E) of the Act to require that the establishment of outlier and transitional pass-through payment adjustments is to be made in a budget neutral manner.

## 4. Limitation on Judicial Review

Section 201(d) of the BBRA 1999 amends redesignated section 1833(t)(11) of the Act by extending the prohibition of administrative or judicial review to include the factors for determining outlier payments (that is, the fixed multiple, or a fixed dollar cutoff amount, the marginal cost of care, or applicable total payment percentage), and the determination of additional payments for certain medical devices,
drugs, and biologicals, the insignificant cost determination for these items, the duration of the additional payment or portion of the PPS payment amount associated with particular devices, drugs, or biologicals, and any pro rata reduction.
5. Inclusion in the Hospital Outpatient PPS of Certain Implantable Items

Section 201(e) of the BBRA 1999 amends section 1833(t)(1)(B) of the Act to include as covered outpatient services implantable prosthetics and DME and diagnostic x-ray, laboratory, and other tests associated with those implantable items.

## 6. Payment Weights Based on Mean Hospital Costs

Section 201(f) of the BBRA 1999 amends section 1833(t)(2)(C) of the Act, which specifies data requirements for establishing relative payment weights, to allow the Secretary the discretion to base the weights on either the median or mean hospital costs determined by data from the most recent available cost reports.
7. Limitation on Variation of Costs of Services Classified Within a Group

Section 201(g) of the BBRA 1999 amends section 1833(t)(2) of the Act to limit the variation of costs of services within each payment classification group by providing that the highest median (or mean cost, if elected by the Secretary) for an item or service within the group cannot be more than 2 times greater than the lowest median (or mean) cost for an item or service within the group. The provision allows the Secretary to make exceptions in unusual cases, such as for low volume items and services.

## 8. Annual Review of the Hospital Outpatient PPS Components

Section 201(h) of the BBRA 1999 amends redesignated section 1833(t)(8) of the Act to require at least annual review of the groups, relative payment weights, and the wage and other adjustments made by the Secretary to take into account changes in medical practice, the addition of new services, new cost data, and other relevant information and factors. That section of the Act is further amended to require the Secretary to consult with an expert outside advisory panel composed of an appropriate selection of provider representatives who will review the clinical integrity of the groups and weights and advise the Secretary accordingly. The panel may use data other than those collected or developed
by the Department of HHS for the review and advisory purposes.

## 9. Coinsurance Not Affected by PassThroughs

Section 201(i) of the BBRA 1999 amends redesignated section 1833(t)(7) of the Act to provide that the beneficiary coinsurance amount will be calculated as if the outlier and transitional passthroughs had not occurred; that is, there will be no coinsurance collected from beneficiaries for the additional payments made to hospitals by Medicare for these adjustments.

## 10. Extension of Cost Reductions

Section 201(k) of the BBRA 1999 amends section 1861(v)(1)(S)(ii) of the Act to extend until the first date that the hospital outpatient PPS is implemented, the 5.8 and 10 percent reductions for hospital operating and capital costs, respectively.
11. Clarification of Congressional Intent Regarding Base Amounts Used in Determining the Hospital Outpatient PPS

Section 201(l) of the BBRA 1999 provides that, "With respect to determining the amount of copayments described in paragraph (3)(A)(ii) of section 1833(t) of the Social Security Act, as added by section 4523(a) of the BBA, Congress finds that such amount should be determined without regard to such section, in a budget neutral manner with respect to aggregate payments to hospitals, and that the Secretary of Health and Human Services has the authority to determine such amount without regard to such section." Pursuant to this provision, we are calculating the aggregate PPS payment to hospitals in a budget neutral manner.

## 12. Transitional Corridors for Application of Outpatient PPS

Section 202 of the BBRA 1999 amends section 1833(t) of the Act by redesignating paragraphs (7) through (11) as paragraphs (8) through (12), and adding a new paragraph (7), which provides for a transitional adjustment to limit payment reductions under the hospital outpatient PPS. More specifically, for the years 2000 through 2003, a provider, including a CMHC, will receive an adjustment if its payment-to-cost ratio for outpatient services furnished during the year is less than a set percentage of its payment-to-cost ratio for those services in its cost reporting period ending in 1996 (the base year). Two categories of hospitals, rural hospitals with 100 or fewer beds and cancer hospitals, will be held harmless under this provision.

Small rural hospitals, for services furnished before January 1, 2004, will be maintained at the same payment-to-cost ratio as their base year cost report if their PPS payment-to-cost ratio is less. The hold-harmless provision applies permanently to cancer centers. Section 202 also requires the Secretary to make interim payments to affected hospitals subject to retrospective adjustments and requires that the provisions of this section do not affect beneficiary coinsurance. Finally, this provision is not subject to budget neutrality.
13. Limitation on Coinsurance for a Procedure

Section 204 of the BBRA 1999 amends redesignated section $1833(\mathrm{t})(8)$ of the Act to provide that the coinsurance amount for a procedure performed in a year cannot exceed the hospital inpatient deductible for that year.

## 14. Reclassification of Certain Hospitals

Section 401 of the BBRA 1999 adds section 1886(d)(8)(E) to the Act to permit reclassification of certain urban hospitals as rural hospitals. Section 401 adds section 1833(t)(13) to the Act to provide that a hospital being treated as a rural hospital under section 1886(d)(8)(E) also be treated as a rural hospital under the hospital outpatient PPS.

## II. Prohibition Against Unbundling of Hospital Outpatient Services

## A. Background

Sections 9343(c)(1) and (c)(2) of OBRA 1986 amended sections 1862(a)(14) and 1866(a)(1)(H) of the Act, respectively. As revised, section 1862(a)(14) of the Act prohibits payment for nonphysician services furnished to hospital patients (inpatients and outpatients), unless the services are furnished by the hospital, either directly or under an arrangement (as defined in section $1861(w)(1)$ of the Act). As revised, section 1866(a)(1)(H) of the Act requires each Medicare-participating hospital to agree to furnish directly all covered nonphysician services required by its patients (inpatients and outpatients) or to have the services furnished under an arrangement (as defined in section 1861(w)(1) of the Act). Section 9338(a)(3) of OBRA 1986 affected implementation of the bundling mandate by amending section 1861(s)(2)(K) of the Act to permit services of physician assistants to be covered and billed separately. Sections 4511(a)(2)(C) and (D) of the BBA 1997 further revised sections 1862(a)(14) and 1866(a)(1)(H) of the Act, respectively, to exclude services of nurse practitioners
and clinical nurse specialists, described in section 1861(s)(2)(K)(ii) of the Act, from the bundling requirement.

## B. Office of Inspector General (OIG) Civil Money Penalty Authority and Civil Money Penalties for Unbundling Hospital Outpatient Services

In order to deter the unbundling of nonphysician hospital services, section 9343(c)(3) of OBRA 1986 added section 1866(g) to the Act to provide for the imposition of civil money penalties (CMPs), not to exceed \$2,000, against any person who knowingly and willfully presents, or causes to be presented, a bill or request for payment for a hospital outpatient service under Part B of Medicare that violates the requirement for billing under arrangements specified in section $1866(\mathrm{a})(1)(\mathrm{H})$ of the Act. In addition, section 1866(g) includes authorization to impose a CMP, in the same manner as other CMPs are imposed under section 1128A of the Act when arrangements should have been made but were not. Section 4085(i)(17) of OBRA 1987 amended section $1866(\mathrm{~g})$ of the Act by deleting all references to hospital outpatient services under Part B of Medicare. The result of this amendment is that the CMP is now applicable for services furnished to hospital patients, whether paid for under Medicare Part A or B.
In order to implement section 1866(g) of the Act, we proposed in our August 5, 1988 proposed rule that the OIG would impose a CMP against any person who knowingly and willfully presents, or causes to be presented, a bill or request for payment for a hospital outpatient service under Part B of Medicare that violates the billing arrangement under section 1866(a)(1)(H) of the Act or the requirement for an arrangement. The amount of the CMP is to be limited to $\$ 2,000$ for each improper bill or request, even if the bill or request included more than one item or service.

## C. Summary of Final Regulations on Bundling of Hospital Outpatient Services

In our September 8, 1998 proposed rule, we proposed to make final most of the provisions of the August 5, 1988 proposed rule but with a number of revisions that we describe in detail in the proposed rule (63 FR 47558 through 47559). We are adopting as final regulations what we proposed in the September 8, 1998 rule with the following additional changes:

- We are adding a new paragraph (b)(7) to § 410.42 (Limitations on coverage of certain services furnished to
hospital outpatients) to provide an exception to the hospital bundling requirements for services hospitals furnish to SNF residents as defined in §411.15(p). (Section 410.42 has been redesignated from $\S 410.39$ in the proposed rule.)
- We are making a minor change to newly redesignated paragraph (m)(2) (this language was formerly included in paragraph $(\mathrm{m})(1)$ ) in $\S 411.15$ (Particular services excluded from coverage) to make it clearer that the exclusion discussed in this section is referring to excluding certain services from coverage.
- Except for minor wording changes in introductory paragraph (b) of § 1003.102 (Basis for civil money penalties and assessments), that section remains as it appeared in the August 5, 1988 proposed rule. Paragraph (b)(15) is redesignated from proposed paragraph (b)(4) in the August 5, 1988 proposed rule and (b)(14) in the September 8, 1998 proposed rule. Paragraphs (b)(12) through (b)(14) of § 1003.102 are reserved.
- We are adding a new paragraph (k) to § 1003.103 (Amount of penalty) to indicate that the OIG may impose a penalty of not more than $\$ 2,000$ for each bill or request for items and services furnished to hospital patients in violation of the bundling requirements.
- We are also amending § 1003.105 (Exclusion from participation in Medicare, Medicaid and other Federal health care programs) by revising paragraph (a)(1)(i) to reflect that the basis for imposition of a CMP is also a basis for exclusion from participation in Medicare, Medicaid and other Federal health care programs.


## D. Comments and Responses

Comment: One association requested that we clarify whether lab tests are subject to the bundling requirement or whether those services are included in the definition of diagnostic tests that are not required to be bundled. If lab tests are bundled, the association asked that we seek a legislative change to permit a provider, other than the lab that performs the test, to bill for the test.

Response: Laboratory tests, like all other services furnished to hospital patients, must be provided directly or under arrangements by the hospital and only the hospital may bill the program. Section 1833(h)(5)(A)(iii) of the Act provides an exception to the requirement that payment for a clinical diagnostic lab may be made only to the person or entity that performed or supervised the performance of the test. This section provides that in the case of a clinical diagnostic laboratory test
provided under arrangement made by a hospital or CAH, payment is made to the hospital.
All diagnostic tests that are furnished by a hospital, directly or under arrangements, to a registered hospital outpatient during an encounter at a hospital are subject to the bundling requirements. The hospital is not responsible for billing for the diagnostic test if a hospital patient leaves the hospital and goes elsewhere to obtain the diagnostic test.
Comment: The same association asked us to clarify that services billed to skilled nursing facilities (SNFs) under the consolidated billing requirement would be exempt from the bundling requirement for hospital outpatient services.
Response: We agree that in situations where a beneficiary receives outpatient services from a Medicare participating hospital or CAH while temporarily absent from the SNF, the beneficiary continues to be considered a SNF resident specifically with regard to the comprehensive care plan required under § 483.20(b). Such services are, therefore, subject to the SNF consolidated billing provision and should be exempt from the hospital outpatient bundling requirements. The final regulations at §410.42(b)(7) reflect this exception.

We note that the SNF consolidated billing requirements, under §411.15(p)(3)(iii), do not apply to a limited number of exceptionally intensive hospital outpatient services that lie well beyond the scope of care that SNFs would ordinarily furnish, and thus beyond the ordinary scope of SNF care plans. The hospital outpatient services that are currently included in this policy are: Cardiac catheterization; computerized axial tomography (CAT) scans; MRIs; ambulatory surgery involving the use of an operating room; emergency room services; radiation therapy; angiography; and lymphatic and venous procedures. When a hospital or CAH provides these services to a beneficiary, the beneficiary's status as a SNF resident ends, but only with respect to these services. The beneficiary is now considered to be a hospital outpatient and the services are subject to hospital outpatient bundling requirements. In November 1998, we issued Program Memorandum transmittal number A-98-37, which provides additional clarification on this exclusion as well as a list of specific HCPCS codes that identify the services that are excluded from SNF consolidated billing but subject to hospital outpatient bundling.

Comment: One commenter understood that the proposed rule
would permit payment for all diagnostic tests that are furnished by a hospital or other entity if the patient leaves the hospital and obtains the service elsewhere; however, the commenter requested clarification as to the treatment of "outsourced" hospital departments. The commenter stated that hospitals are increasingly outsourcing departments to providers that can furnish services efficiently. Often these providers do not operate as "under arrangements" providers to the hospital, but as free-standing providers offering outpatient services on hospital grounds. The commenter specifically asked whether a free-standing entity providing outpatient services on hospital grounds, but operated independently of the hospital is able to bill separately for services furnished or is the entity considered to be part of the hospital and required to furnish services "under arrangement."

Response: A free-standing entity, that is, one that is not provider-based, may bill for services furnished to beneficiaries who do not meet the definition of a hospital outpatient at the time the service is furnished. Our bundling requirements apply to services furnished to a "hospital outpatient," as defined in §410.2, during an
"encounter," also defined in §410.2.
Comment: One commenter indicated that while the proposed revision to § 1003.102(b) accurately reflected the statutory directive that the basis for imposing a CMP is a "bill or request for payment," the proposed amendment to § 1003.103(a) regarding the appropriate penalty amount to be imposed for bundling violations was in error. The commenter indicated that the OIG lacks the authority to impose a CMP in the amount of $\$ 10,000$ for these violations, and that such a penalty should be not more than $\$ 2,000$ for each violation.
Response: The commenter is correct. While section 231(c) of the Health Insurance Portability and
Accountability Act of 1996, Pub. L. 104191, increased the CMP maximum amount from $\$ 2,000$ to $\$ 10,000$, the statute sets forth "items or services" as the basis upon which a higher CMP amount may be assessed. However, with regard to bundling violations, the Secretary may impose a CMP only on the basis of a "bill or request for payment" rather than "for each item and service" as stated in the proposed revision to $\S 1003.103$. We are correcting this error by adding a new $\S 1003.103(\mathrm{k})$ to indicate that the OIG may impose a penalty of not more than $\$ 2,000$ for each bill or request for items and services furnished to hospital patients in violation of the bundling requirements.

## III. Hospital Outpatient Prospective Payment System (PPS)

In this section, we designate the services for which Medicare will make payment under the hospital outpatient PPS, the payment rates set for those services, and the method by which we determined the outpatient PPS payment and coinsurance amounts.

We explain the structure of the hospital outpatient PPS, respond to comments that we received about the proposed PPS, and describe modifications that we made to the proposed PPS in response to comments, such as provisions we are making to expedite appropriate payment for new technologies and provisions to pay for blood and blood products.

In this section, we also discuss how we will implement requirements enacted by the BBRA 1999, including transitional payment corridors and other payment adjustments such as outliers and transitional pass-throughs.

## A. Hospitals Included In or Excluded From the Outpatient PPS

This PPS applies to covered hospital outpatient services furnished by all hospitals participating in the Medicare program, except as noted below. Partial hospitalization services in community mental health centers (CMHCs) are also paid under this PPS. Exclusions from outpatient PPS are different and more limited than exclusions from inpatient PPS. Thus, hospitals or distinct parts of hospitals that are excluded from the inpatient PPS are included in the outpatient PPS, to the extent that the hospital or distinct part furnishes outpatient services. For example, we will make payment under the outpatient PPS for outpatient psychiatric services. The outpatient services provided by hospitals of the Indian Health Service (IHS) will continue to be paid under separately established rates which are published annually in the Federal
Register. We intend to develop a plan that will help these facilities transition to the PPS and will consult with the IHS to develop this plan.

The following hospitals are excluded from the outpatient PPS:

- Certain hospitals in Maryland qualify under section 1814(b)(3) of the Act for payment under the State's payment system. The excluded services are limited to those paid under the State's payment system as described in section 1814(b)(3) of the Act. Any other outpatient services furnished by the hospital are paid under the outpatient PPS.
- Critical access hospitals that are paid under a reasonable cost based
system, as required under section 1834(g) of the Act.

Comment: National and State associations representing children's hospitals and a number of individual children's hospitals located across the country strongly recommended that their hospitals be excluded from the hospital outpatient PPS just as they have been excluded from the hospital inpatient PPS. These commenters argued that the exclusion should apply to outpatient services furnished by children's hospitals because these hospitals treat a unique patient group whose health needs are different from those of adult beneficiaries entitled to Medicare benefits. The commenters further argued that services to Medicare patients are, on average, only 1 percent of the total inpatient and outpatient services that children's hospitals furnish and that these services are largely ESRD services that are already excluded from the hospital outpatient PPS. The commenters were concerned that the resources required to implement and comply with the new system would be disproportionately high relative to the small number of patients who would be affected by the new system. In addition, the impact analysis that accompanied the proposed rule estimated that children's hospitals would lose more than 20 percent of their Medicare revenues under the new system. Commenters expressed great concern about this loss of revenue.

Response: Our most recent analysis of the impact on hospitals of the PPS shows a negative effect for children's hospitals of 11.9 percent, which is significantly less than what we estimated in the proposed rule. However, the transitional corridor payments provided by the BBRA 1999 will protect these hospitals from even this level of loss through 2004. The estimated loss for CY 2000-2001 for children's hospitals is only 3.2 percent. (See Table 2 in section IX of this preamble.) As we discuss in section III.H. 2 below, we will conduct extensive analyses during the first years of implementation of the PPS to determine whether we should propose adjustments for certain types of hospitals, including children's hospitals, when the transitional corridor provision expires. In the meantime, we are not excluding any special class of hospital from the PPS.

## B. Scope of Facility Services

Section 1833(t)(1)(B)(i) of the Act gives us the authority to designate the services to be covered under the hospital outpatient PPS. In this section of the final rule, we designate the types
of services included or excluded under the hospital outpatient PPS.

1. Services Excluded From the Scope of Services Paid Under the Hospital Outpatient PPS

## a. Background

In developing a hospital outpatient PPS, we want to ensure that all services furnished in a hospital outpatient setting will be paid on a prospective basis. We have already been paying, in part, for some hospital outpatient services such as clinical diagnostic laboratory services, orthotics, and endstage renal disease (ESRD) dialysis services based on fee schedules or other prospectively determined rates that also apply across other sites of ambulatory care. Rather than duplicate existing payment systems that are effectively achieving consistency of payments across different service delivery sites, we proposed to exclude from the outpatient PPS those services furnished in a hospital outpatient setting that were already subject to an existing fee schedule or other prospectively determined payment rate. The similar payments across various settings create a more level playing field in which Medicare makes virtually the same payment for the same service, without regard to where the service is furnished.
We therefore proposed to exclude from the scope of services paid under the hospital outpatient PPS the following:

- Services already paid under fee schedules or other payment systems including, but not limited to: screening mammographies, services for patients with ESRD that are paid for under the ESRD composite rate; the professional services of physicians and nonphysician practitioners paid under the Medicare physician fee schedule; laboratory services paid under the clinical diagnostic laboratory fee schedule; and DME, orthotics, prosthetics, and prosthetics devices, prosthetic implants, and supplies (DMEPOS) paid under the DMEPOS fee schedule when the hospital is acting as a supplier of these items. An item such as crutches or a walker that is given to the patient to take home, but that may also be used while the patient is at the hospital, would be billed to the DME regional carrier rather than paid for under the hospital outpatient PPS.
- Hospital outpatient services furnished to SNF inpatients as part of his or her resident assessment or comprehensive care plan (and thus included under the SNF PPS) that are furnished by the hospital "under arrangements" but billable only by the

SNF, regardless of whether or not the patient is in a Part A SNF stay.

- Services and procedures that require inpatient care.

The statute excludes from the definition of "covered OPD services" ambulance services, physical and occupational therapy, and speechlanguage pathology services, specified in section 1833(t)(1)(B)(iii) of the Act (redesignated as section 1833(t)(1)(B)(iv) by section 201(e) of the BBRA 1999). These services are to be paid under fee schedules in all settings.

## b. Comments and Responses

Comment: One commenter urged that we exclude services furnished to ESRD patients from the scope of the hospital outpatient PPS.

Response: Services furnished to ESRD patients include dialysis, Epoietin (EPO), drugs, and supplies provided outside the composite rate, surgery specific to access grafts, and many other medical services related to renal disease or to other coexisting conditions. We will continue to base payment for dialysis services on the composite rate, and we will continue to pay for EPO based on the current rate established for that service. The drugs and supplies that are used within a dialysis session, but for which payment is not included in the composite rate, are paid outside that rate. We have to conduct further analyses in order to develop appropriate APC groups upon which to base payment. In the meantime, we will continue to pay on a reasonable cost basis for dialysis related drugs and supplies that are paid outside the composite rate.

Comment: A hospital industry association took exception to the requirement that hospitals obtain a separate supplier number, post a bond, and bill separately to the DME regional carrier for DME supplies such as crutches. They believe that this is an unnecessary requirement that results in additional costs for small rural hospitals. The commenter recommended that we include within the PPS rate supplies such as crutches that are directly related to the provison of the hospital outpatient services or that we permit hospitals to bill under the DME fee schedule without having to obtain a DME supplier number or post a bond.

Response: Section 1834(j)(1)(A) of the Act provides that no payment may be made for items furnished by a supplier of medical equipment and supplies unless the supplier obtains a supplier number. Section 1834(a)(1)(C) of the Act provides that payment for DME can be made only under the DME fee schedule.

Therefore, to receive payment for DME under Medicare, a hospital must obtain a supplier number and must meet the other requirements set by applicable Medicare rules and regulations.

Comment: Several major hospital associations and a number of other commenters opposed our proposal to exclude from payment certain procedures that we designate as "inpatient only." Other commenters, including a physician professional society, agree that many of the procedures that we designated in the proposed rule as "inpatient only" are currently performed appropriately and safely only in the inpatient setting. However, these commenters believe that our explicit exclusion of individual procedures, besides being unnecessary, could have an adverse effect on advances in surgical care. Some commenters alleged that we provided no concrete support for designating procedures as "inpatient only." A number of commenters argued that medicine is not practiced uniformly across the nation and that some services listed among the exclusions are currently being performed on an outpatient basis in various parts of the country with positive outcomes.
An industry association stated that we failed to consider surgical judgment and patient choice in determining the appropriate treatment setting for certain services that we proposed to exclude from coverage. Other commenters believe that the appropriate site for performing a medical service is best determined by physicians and their patients. One professional society stated that case law including medical malpractice case law is sufficient to ensure that medical services are delivered in the appropriate treatment setting and in conformance with prevailing medical standards.
Response: We recognize and acknowledge that our assigning "inpatient only" status to certain services and procedures raises numerous questions and concerns, and that some individual determinations can be reasonably debated. However, section 1833(t)(1)(B) of the Act explicitly authorizes the Secretary to designate which hospital outpatient services are to be "covered OPD services" subject to payment under the hospital outpatient PPS. Therefore, we have had to select from the universe of possible services those that we determine are reasonable, necessary, and appropriate for Medicare payment under the hospital outpatient PPS. We note that our designation of a service as "inpatient only" does not necessarily preclude the service from being furnished in a hospital outpatient
setting, but means only that Medicare will not make payment for the service were it to be furnished to a Medicare beneficiary in that setting. This unfortunately leaves the beneficiary liable for payment if the procedure is in fact performed in the outpatient setting. We hope that hospitals will advise beneficiaries of the consequences if procedures on the inpatient list are provided as outpatient services (that is, denial of Medicare payment with concomitant beneficiary liability). In section III.C. 5 of this preamble, we discuss in greater detail our rationale for designating specific procedures as "inpatient only." In response to comments, we have removed the "inpatient only" status from a number of services, which will allow them to be paid under the hospital outpatient PPS. We emphasize our intention to review annually, in consultation with hospital and professional societies and associations and the expert outside advisory panel mandated by the BBRA 1999, those procedures classified as "inpatient only" to ensure that the designation remains consistent with current standards of practice.
Comment: One industry association contends that the statutory and regulatory authorities that we cite in the proposed rule (section 1862(a)(1)(A) of the Act and 42 CFR 411.15(k)(1), respectively) do not support the proposed medical services exclusions. The commenter argues that those provisions are the basis for prohibiting coverage for services that are not reasonable and necessary for the diagnosis or treatment of an illness or injury or to improve the functioning of a malformed body member. The commenter states that these provisions are not the basis upon which we identified services for the "inpatient only" list. The commenter further states that use of these provisions as a basis for denying coverage of the services would be confusing to beneficiaries.

Response: The commenter is correct that the proper citations are not section 1862(a)(1) of the Act and 42 CFR 411.15(k)(1). In fact, the basis for our designating certain procedures as "inpatient only" is dependent on medical judgment regarding the proper site of service, and the proper citation for such designation is section 1833(t)(1)(B) of the Act. In some instances, the identification of services to be included or excluded from this PPS was perfectly clear. For example, emergency departments (EDs) are outpatient departments of hospitals. Thus emergency services rendered in EDs qualify as outpatient services. On the other hand, coronary artery bypass
graft surgery (CABG) requires many hours in surgery, part of the time with the patient's life being sustained by artificial means; a period of hours, if not days, in the surgical intensive care unit (ICU); and further care in an inpatient unit with frequent nursing attention. It clearly cannot be an outpatient procedure, and it would not be reasonable to consider it for inclusion in this PPS. There are many procedures which require similar intensity of care, including periods in specialty ICUs and several days of intense nursing attention.

Some procedures formerly performed only in the inpatient setting, however, have moved to the outpatient site of service. This movement has taken place due to new, less-invasive surgical techniques, such as laparoscopy, or new anesthesia agents that clear from the body more rapidly, allowing some patients to have general anesthesia in the morning and return home that afternoon. Thus we have had to decide which procedures may reasonably be performed in the outpatient setting, and which cannot. We have been guided in this decision by our medical advisors' clinical judgment regarding what is reasonable in various settings, comments we received in response to the proposed rule, and bill data which shows movement from one site to another. In section III.C.5, we discuss the criteria we considered in defining "inpatient only" procedures.

Comment: One hospital asked how we would pay a hospital that routinely performs on an outpatient basis a procedure that we proposed to designate as "inpatient only." The commenter recommended that a specific billing mechanism be used to guarantee payment in these situations.

Response: Services designated as "inpatient only" will be excluded from Medicare payment under the hospital outpatient PPS. If the service is performed on an outpatient basis and a claim is submitted, the claim will be denied, and the beneficiary may be billed for the service. We would consider this a very poor policy on the hospital's part, and would hope that hospitals decide to abide by the constraints of the inpatient list.

Comment: One commenter noted that hospital outpatient departments have never been limited to a list of approved procedures as are Medicare participating ASCs. The commenter stated that the "inpatient only" policy would exclude payment for a significant number of procedures that have traditionally been performed in the hospital outpatient setting. The commenter stated that some of the
excluded procedures incorporate an observation stay in a recovery care center. The commenter contended that many of the excluded procedures could be safely performed in the outpatient setting particularly if a 24 to 72 hour recovery care center is part of the outpatient surgical care provided.
Response: Routinely billing an observation stay for patients recovering from outpatient surgery is not allowed under current Medicare rules nor will it be allowed under the hospital outpatient PPS. As we state in section III.C. 5 of this preamble, one of the primary factors we considered as an indicator for the "inpatient only" designation is the need for at least 24 hours of postoperative care.

Comment: One commenter asked what option a hospital has if a beneficiary's secondary insurer requires that a procedure included on the Medicare inpatient only list be performed on an outpatient basis.
Response: Upon implementation, the provisions of this final rule will govern payment for Medicare covered outpatient services furnished by hospitals to Medicare beneficiaries. Medicare payment policy and rules are not binding on employer-provided retiree coverage that may supplement Medicare coverage. Medigap insurers, however, must follow Medicare's coverage determinations.

## c. Payment for Certain Implantable Items Under the BBRA 1999

In the course of identifying items and services whose costs we proposed to designate for payment under the hospital outpatient PPS, we gave considerable thought to including implantable items and services because these items and services are such an integral part of the procedure by which they are inserted or implanted. However, a number of the more common implants such as aqueous shunts, hallux valgus implants, infusion pumps, and neurostimulators, are classified as implantable prosthetics or DME. The statutory language governing payment for DMEPOS provides that, notwithstanding any other provision of the Medicare statute, DMEPOS must be paid for using the DMEPOS fee schedule. Therefore, under the proposed rule, the scope of services paid under the hospital outpatient PPS did not include implantable prosthetics and DME paid under the DMEPOS fee schedule. However, we did propose to package payment for implanted items such as stents, vascular catheters, and venous ports within the APC payment rate for the procedure related to the insertion of these items because we
define these items as supplies rather than as prosthetic implants or implantable DME.
Section 201(e) of the BBRA 1999 amends section 1833(t)(1)(B) of the Act to provide that "covered OPD services" include implantable items described in paragraph (3), (6), or (8) of section 1861(s) of the Act. The conference report accompanying the BBRA 1999, H. R. Rep. No. 436 (Part I), 106th Cong., 1st Sess. (1999), expresses the belief of the conferees that the current DMEPOS fee schedule is not appropriate for certain implantable medical items such as pacemakers, defibrillators, cardiac sensors, venous grafts, drug pumps, stents, neurostimulators, and orthopedic implants as well as items that come into contact with internal human tissue during invasive medical procedures, but are not permanently implanted. In the conference report agreement, the conferees state their intention that payment for these items be made through the outpatient PPS, regardless of how these products might be classified on current HCFA fee schedules. The implantable items affected by this BBRA 1999 requirement include prosthetic implants (other than dental) that replace all or part of an internal body organ (including colostomy bags and supplies directly related to colostomy care and including replacement of these devices);
implantable DME; and implantable items used in performing diagnostic x rays, diagnostic laboratory tests, and other diagnostic tests.

Comment: A number of commenters disagreed with our proposal to pay under the DMEPOS fee schedule for implantable items and devices that require surgical insertion. We received comments on specific implantable items, including Vitrasert (a drug delivery system that is implanted in the eye); cochlear devices, which allow the profoundly deaf to hear sound and in some cases recognize speech; nerve stimulators that treat intractable epilepsy and other diseases; new technology intraocular lenses implanted following cataract surgery; and access devices for dialysis treatment.
Commenters were also concerned that the costs of some implantable devices not paid under the DMEPOS fee schedule, which we packaged in our proposed rule, were not properly recognized in the APC payment.

Response: As we explain above, the amendments made to the statute by section 201(e) of the BBRA 1999 provide for payment to be made under the hospital outpatient PPS for implantable items that are part of diagnostic x-rays, diagnostic laboratory tests, and other
diagnostic tests; implantable durable medical equipment; and implantable prosthetic devices (other than dental). This BBRA 1999 provision requires that an implantable item be classified to the group that includes the service to which the item relates. Thus, under this final rule with comment period, we are including within the scope of the hospital outpatient PPS items such as aqueous shunts that would, absent the BBRA 1999 provision, have been paid under the DMEPOS fee schedule. Because implantable items are now packaged into the APC payment rate for the service or procedure with which they are associated, certain items may be candidates for the transitional passthrough payment, which is discussed in detail in section III.D of this preamble. The APC rates may not in every case perfectly recognize the cost of implantable items. We will continue to review the impact of packaging implantables in future updates.

## d. Summary of Final Action

We are modifying proposed § 419.22 to remove prosthetic implants from the list of services excluded from payment under the hospital outpatient PPS. We are adding subparagraphs (9), (10), and (11) to proposed $\S 419.2$ (b), to include the following in the list of items and services whose costs are included in hospital outpatient PPS payment rates: prosthetic implants (other than dental) that replace all or part of an internal body organ (including colostomy bags and supplies directly related to colostomy care), and including replacement of these devices; implantable DME; and implantable items used in performing diagnostic x rays, diagnostic laboratory tests, and other diagnostic tests.
2. Services Included Within the Scope of the Hospital Outpatient PPS

We proposed to include three categories of services within the scope of the outpatient PPS, as follows:

## a. Services for Patients Who Have Exhausted Their Part A Benefits

Section 1833(t)(1)(B)(ii) of the Act provides for Medicare payment under the hospital outpatient PPS for certain services designated by the Secretary that are furnished to inpatients who have exhausted their Part A benefits or who are otherwise not in a covered Part A stay. Examples of services covered under this provision include diagnostic x-rays and certain other diagnostic services and radiation therapy covered under section 1832 of the Act.

## b. Partial Hospitalization Services

Section 1833(a)(2)(B) of the Act provides that partial hospitalization services furnished in CMHCs be paid under the hospital outpatient PPS. Partial hospitalization is a distinct and organized intensive psychiatric outpatient day treatment program, designed to provide patients who have profound and disabling mental health conditions with an individualized, coordinated, comprehensive, and multidisciplinary treatment program.
c. Services Designated by the Secretary

We proposed to designate the following services to be paid under the hospital outpatient PPS:

- All hospital outpatient services, except those that are identified as excluded, above, in section III.B. 1 of this final rule. The types of services subject to payment under the hospital outpatient PPS include the following: surgical procedures; radiology, including radiation therapy; clinic visits; emergency department visits; diagnostic services and other diagnostic tests; partial hospitalization for the mentally ill; surgical pathology; and cancer chemotherapy.
- Specific hospital outpatient services furnished to a beneficiary who is admitted to a Medicare-participating SNF but who is not considered to be a SNF resident, for purposes of SNF consolidated billing, with respect to those services that are beyond the scope of SNF comprehensive care plans. The specific hospital outpatient services that are excluded from SNF consolidated billing are cardiac catheterization, computerized axial tomography (CAT) scans, MRIs, ambulatory surgery involving the use of an operating room, emergency room services, radiation therapy, angiography, and lymphatic and venous procedures.
- Supplies such as surgical dressings used during surgery or other treatments in the hospital outpatient setting that are also paid under the DMEPOS fee schedule. Payment for these supplies, when they are furnished in a hospital outpatient setting, is packaged into the APC payment rate for the procedure or service with which the items are associated.
- Certain preventive services furnished to healthy persons, such as colorectal cancer screening.

Section 4523(d)(3) of the BBA 1997 amended section 1833(a)(2)(B) of the Act to provide that we discontinue reasonable cost based payment and instead make Part B payment under the hospital outpatient PPS for certain medical and other health services when
they are furnished by other providers such as hospices, SNFs, and HHAs. Specifically, we proposed to pay under the hospital outpatient PPS for the following medical and other health services when they are furnished by a provider of services:

- Antigens (as defined in 1861(s)(2)(G) of the Act);
- Splints and casts (1861(s)(5) of the Act);
- Pneumococcal vaccine, influenza vaccine, hepatitis B vaccine (1861(s)(10) of the Act).

Upon implementation of the hospital outpatient PPS, we would make Part B payment for the above services under the outpatient PPS when they are furnished by an HHA or hospice program. We would also make payment for antigens and the vaccines under the PPS when they are furnished by CORFs. (Splints and casts furnished by CORFs are paid under the rehabilitation fee schedule.) However, this provision would not apply to services furnished by a CORF that fall within the definition of CORF services at section 1861(cc)(1) of the Act. It also would not apply to services furnished by a hospice within the scope of the hospice benefit. Nor would it apply to services furnished by HHAs to individuals under an HHA plan of treatment within the scope of the home health benefit.

## d. Summary of Final Action

We received no comments about the services we proposed to include within the scope of the hospital outpatient PPS. As noted in the preceding section III.B.1, we added certain implantable items to § 419.2 (b) to implement section 201(e) of the BBRA 1999.

## 3. Hospital Outpatient PPS Payment

 IndicatorsIn the September 8, 1998 proposed rule in the Federal Register, we proposed a payment status indicator for every code in the HCPCS to identify how the service or procedure described by the code would be paid under the hospital outpatient PPS. We received no comments on our proposal to assign a payment status indicator to every HCPCS code. (In section III.C.6, below, we respond to commenters who disagreed with the payment status indicator that we proposed for individual codes.) Therefore, we are implementing payment status indicators as part of the hospital outpatient PPS. Addendum B displays the final payment status indicator for each HCPCS code, including codes for incidental services that are packaged into APC payment rates. Addendum E identifies the HCPCS codes to which we have assigned payment status indicator " C " to identify inpatient services that are not payable under outpatient PPS as implemented by this final rule. We respond below, in section III.C.5, to public comments about the specific codes we classified as inpatient services in the proposed rule and our final determination regarding the payment status of those codes.

The following are the payment status indicators and description of the particular services each indicator identifies:

- We use "A" to indicate services that are paid under some other method such as the DMEPOS fee schedule or the physician fee schedule.
- We use "C" to indicate inpatient services that are not paid under the outpatient PPS.
- We use " $E$ " to indicate services for which payment is not allowed under the
hospital outpatient PPS. In some instances, the service is not covered by Medicare. In other instances, Medicare does not use the code in question, but does use another code to describe the service.
- We use " $F$ "' to indicate corneal tissue acquisition costs, which are paid separately.
- We use "G" to indicate a current drug or biological for which payment is made under the transitional passthrough.
- We use " H " to indicate a device for which payment is made under the transitional pass-through.
- We use " J " to indicate a new drug or biological for which payment is made under the transitional pass-through.
- We use " N " to indicate services that are incidental, with payment packaged into another service or APC group.
- We use "P" to indicate services that are paid only in partial hospitalization programs.
- We use " S " to indicate significant procedures for which payment is allowed under the hospital outpatient PPS but to which the multiple procedure reduction does not apply.
- We use " $T$ " to indicate surgical services for which payment is allowed under the hospital outpatient PPS. Services with this payment indicator are the only services to which the multiple procedure payment reduction applies.
- We use " $V$ " to indicate medical visits for which payment is allowed under the hospital outpatient PPS.
- We use " X " to indicate ancillary services for which payment is allowed under the hospital outpatient PPS.

The table below lists types of services, the hospital outpatient PPS payment status indicator assigned to each type of service, and the basis for Medicare payment for the service.

Medicare Hospital Outpatient PPS Payment Status Indicators: How Medicare Pays for Various Services When They Are Billed for Hospital Outpatients

| Indicator | Service | Status |
| :---: | :---: | :---: |
| A | Pulmonary Rehabilitation; Clinical Trial | Not paid. |
| C | Inpatient Procedures | Not paid. |
| A ................. | Orthotics, and Non-implantable Durable Medical Equipment and Prosthetics. | DMEPOS Fee Schedule. |
| E | Nonallowed Items and Services | Not paid. |
| A | Physical, Occupational and Speech Therapy .......................... | Rehab Fee Schedule. |
| A ................. | Ambulance | Reasonable cost or charge or, when implemented, Ambulance Fee Schedule. |
| A | EPO for ESRD Patients ....................................................... | National Rate. |
| A | Clinical Diagnostic Laboratory Services .................................. | Lab Fee Schedule. |
| A | Physician Services for ESRD Patients ................................... | Bill to Carrier. |
| A | Screening Mammography .................................................... | Lower of Charge or National Rate. |
| N | Incidental Services, Packaged into APC Rate ......................... | Packaged; No Additional Payment Allowed. |
| P | Partial Hospitalization Services ............................................. | Paid Per Diem. |
| S ................. | Significant Procedure, Not Reduced When Multiple Procedures Performed. | Paid Under Hospital Outpatient PPS (APC Rate). |
| T .................. | Significant Procedure, Multiple Procedure Reduction Applies ... | Hospital Paid Under Outpatient PPS (APC Rate). |

Medicare Hospital Outpatient PPS Payment Status Indicators: How Medicare Pays for Various Services When They are Billed for Hospital Outpatients-Continued

| Indicator | Service | Status |
| :---: | :---: | :---: |
| V | Visit to Clinic or Emergency Department | Paid Under Hospital Outpatient PPS (APC Rate). |
| X | Ancillary Service | Paid Under Hospital Outpatient PPS (APC Rate). |
| F | Acquisition of Corneal Tissue ............................................... | Paid at reasonable cost. |
| G | Current Drug/Biological Pass-Through ................................... | Additional payment. |
| H. | Device Pass-Through ......................................................... | Additional payment. |
| J ... | New Drug/Biological Pass-Through | Additional payment. |

## C. Description of the Ambulatory Payment Classification (APC) Groups

1. Setting Payment Rates Based on Groups of Services Rather Than on Individual Services
In our March 17, 1995 report to Congress, we recommended that groups similar to the ambulatory patient groups (APGs) developed by 3M Health Information Systems (3M) be used as the basis for the hospital outpatient PPS. We made this recommendation after examining a number of other payment systems that were already in place or under development, including DRGs that are the basis for Medicare payment for hospital inpatient services, the Medicare physician fee schedule that was implemented in 1992, and the payment groups that have been the basis for Medicare payments for ambulatory surgical center (ASC) facility services since 1982.

As provided by the BBA 1997, section 1833(t)(2)(A) of the Act requires the Secretary to develop a classification system for covered outpatient services. Section 1833(t)(2)(B) provides that this classification system may be composed of groups, so that services within each group are comparable clinically and with respect to the use of resources. The statute refers to "each such service (or group of services)," confirming that the Secretary may choose or not choose to group services.

We explain in our proposed rule that we revised the APGs, based on more recent Medicare data than that used by 3 M , to create the ambulatory payment classification (APC) system. We proposed to group services identified by HCPCS codes and descriptors within APC groups as the basis for setting payment rates under the hospital outpatient PPS. We indicated that we organized the APC groups so that the services within each group would be homogeneous both clinically and in terms of resource utilization. We invited comments on our proposal to set rates on the basis of groups of services rather than on individual codes.

Comments: Some commenters claimed that basing payment on APC
groups rather than on individual services would result in underpayment for services that are more resource intensive, causing hospitals with a more resource intensive case mix to lose money. An organization representing physicians strongly opposed the use of APCs, because it believes that it is not possible to achieve an incentive-neutral, "level playing field" payment system using groups of codes or services. This organization favored replacing the APC system with a fee schedule based on individual services, similar to the Medicare physician fee schedule, as MedPAC recommends in its 1999 report to Congress. (We address the MedPAC recommendation later in this section.) The same physician organization is concerned that the broad range of services included in each APC will create an incentive for hospitals to provide lower cost services, even though a patient might require higher cost services. This organization expressed concern about the negative impact on physicians if a payment methodology similar to the APC system were applied to payment for physician services. To facilitate pricing new codes using individual services rather than APC groups, the same organization suggested that we establish a "relative value relationship in direct costs" between the new code and a comparable code, or that we consult AMA's Specialty Society RVS Updating Committee (RUC) for advice on relative cost relationships.

One major hospital association expressed its preference for a servicespecific fee schedule because of the wide variation in costs represented by groups of codes. Another hospital association advocated using individual services rather than groups of services as the basis for ratesetting, but recommended, if we were to use some form of grouping, that we apply tight limits on the variations of costs for services within a group.

Response: We understand the concerns of commenters that setting payment weights using groups of services rather than individual services could result in payment for particular
services that might not fully offset the costs that hospitals incur when they furnish expensive, resource-intensive services. However, we believe these concerns are in large measure addressed by the provisions of this final rule. As we explain in section III.C.6, we significantly restructured the proposed APC groups, first in response to comments and, second, to comply with section 1833(t)(2) of the Act, as amended by the BBRA 1999, which limits the variation of costs of services classified within a group. The result is more APC groups with fewer codes and a narrower range of costs in each group. In addition, other provisions of the BBRA 1999, such as the transitional pass-throughs (see section III.D, below), and outlier payments and transitional corridors (see section III.H, below) protect hospital revenues while hospitals gain experience with the PPS.

## Medicare Payment Advisory <br> Commission (MedPAC)

Recommendation
In both its March 1998 and March 1999 reports to the Congress on Medicare payment policy, MedPAC recommends that payment rates under the hospital outpatient PPS be based upon costs of individual services rather than groups of similar services to help ensure consistent payments across ambulatory settings. In its March 1999 report, MedPAC asserts its belief that the burden imposed by our proposed APC system outweighs its benefits in ambulatory settings. MedPAC gives several reasons to support its position.

- The use of groups to calculate weights masks questionable cost data for low volume and new procedures.
- Different classes of hospitals face disproportionate impacts, suggesting APC groups may not be as homogeneous as we believe.
- Grouping services will likely create additional administrative burdens for hospitals, because hospitals may have to purchase or develop new software and will experience additional education and training costs.

Response: We carefully reviewed the concerns about using groups of services
expressed by MedPAC in its March 1998 report, and we responded to those concerns in our proposed rule (63 FR 47562). Even though MedPAC concedes in its March 1999 report that using groups to set rates has certain potential advantages, MedPAC continues to oppose using groups because, according to MedPAC, they entail considerable costs and drawbacks and necessitate "a much more complicated design logic" than would be required using a servicelevel fee schedule.
We do not share MedPAC's concerns. We have a high level of confidence in the ratesetting method using APC groups that we implement in this final rule with comment period. As we explain below, in section III.C.6, we have extensively restructured the APC groups to respond to comments on the proposed rule, to incorporate specific provisions of the BBRA 1999, and to correct some errors that had come to our attention. We believe that by using median costs in the calculation of group weights, we limit the extent to which infrequently performed services with suspect costs can affect the payment rate of an APC group.

As discussed below in the impact analysis (section IX of this preamble), the provisions of this final rule with comment period, which include setting rates using APC groups, alleviate to a large extent the disproportionate impacts on different classes of hospitals estimated in our proposed rule. In addition, as we explain in section III.C.6, when we restructured the APC groups, we were particularly attentive to the degree of provider concentration associated with the individual services within a group in order to avoid biasing the payment system against any subset of hospitals.
Finally, none of the commenters cited increased administrative burden as an argument against using groups. Even though we are using APC groups to set rates under the hospital outpatient PPS, hospitals will bill for services using HCPCS codes (not APCs) using the same claims forms that they use currently. Although to receive payment under the new system, hospitals will have to more fully code the services they furnish, they will not have to know to which APC the service is assigned in order to determine the payment amount. We are publishing the payment rate applicable to each HCPCS code in Addendum B of this final rule. Any burdens on hospitals necessitating additional technical assistance, training, or systems changes are more a function of implementing an entirely new payment system than of our setting rates on the basis of groups of services.

Final Action: The payment rates implemented by this final rule with comment period are determined based on APC groups that use HCPCS codes to describe individual services. The codes assigned to an APC group are comparable clinically and in terms of resource use.
2. Packaging Under the APC System

## a. Summary of Proposal

In our proposed rule, we described packaged services as those items or services that we recognized as contributing to the cost of the procedures or services in an APC group, and for which we would not make separate payment. We proposed to include as packaged services use of the operating room and recovery room, anesthesia, medical/surgical supplies, pharmaceuticals, observation, blood, intraocular lenses, casts and splints, the costs of acquiring tissue such as corneal tissue for surgical insertion and various incidental services such as
venipuncture. We packaged the services (and their costs) within the APC group of procedures with which they were delivered in the base year. For a list of proposed packaged services grouped by hospital revenue centers, refer to the June 30, 1999 correction notice ( 64 FR 35258).

## b. General Comments and Responses (Supporting or Objecting to Packaging)

Comment: Few commenters disagreed with our proposal to aggregate into one payment the costs for a "package" of services variously related to a procedure or to the principal service being furnished. However, many commenters did object to our packaging costs for certain specific items such as expensive drugs and pharmaceuticals, observation services in the emergency department, blood and blood products, corneal tissue acquisition costs, and chemotherapy and supportive drugs. Commenters, fearful that packaging items and services will result in lower payments that do not offset the high costs of particularly expensive items, raised the prospect of dire consequences such as forcing hospitals to use only the cheapest drugs, being unable to employ oncology nurses, eliminating otherwise clinically necessary ancillary services, or not being able to hold emergency room patients for observation.

Response: We are persuaded by commenters' arguments that packaging payment for certain expensive items and services into an APC group rate could have such a potentially negative impact as to jeopardize beneficiary access to these items and services in the hospital
outpatient setting. Therefore, in response to comments, we are not packaging within an APC payment rate the costs associated with certain specified items and services. Instead, we will make a separate APC payment for these particular items and services under the outpatient PPS. However, as we explain in section III.C.2.d, we do not concur with commenters who urge separate payment for observation services; rather, we are packaging the costs in the APC for each service with which observation services were billed in our 1996 database. We discuss in further detail below, in section III.C.2.d through section III.C.2.g, and in section III.C.6, the changes that we are making to the packaging we originally proposed. We address in section III.B.1, above, the BBRA 1999 provision that requires us to package into APC group rates payment for certain implantable items and devices. In section III.D, below, we describe additional payments for certain packaged medical devices, drugs, and biologicals that are provided as transitional pass-throughs under section 201(b) of the BBRA 1999.

As we gain experience with and collect additional cost data under the hospital outpatient PPS, we will review our policy to pay separately for certain items and services that would otherwise be packaged into the APC payment. Should we decide to modify this policy, we will do so through the rulemaking process as part of our annual hospital outpatient PPS update.
MedPAC Recommendation: In its March 1999 report to the Congress, MedPAC cites two models that Medicare uses to define a unit of payment: the DRG-based payment model for hospital inpatient services, and the Medicare physician fee schedule. MedPAC contends that services provided in the hospital outpatient setting more closely parallel those furnished in an office-based setting than those furnished as part of a hospital inpatient admission. Therefore, MedPAC recommends that, in establishing ambulatory care prospective payment systems in general, we define the unit of payment for ambulatory care facilities as an individually coded service, consisting of the primary service that is the reason for the encounter, and the necessary and essential ancillary services and supplies integral to it, including limited followup care if it is integral to the primary service, but not including physicians' services. MedPAC further recommends that the unit of payment be defined consistently across all ambulatory care settings.

Response: The packaging that we proposed as the basis for determining APC payment rates and that we will implement under the hospital outpatient PPS is generally consistent with MedPAC's recommendation. However, we did not propose to include "limited follow-up services" in our packaged groups under the hospital outpatient PPS because of the difficulty of matching in our database the costs of these services with their associated primary encounter. For now, hospitals are to bill follow-up care, such as suture removal, using an appropriate medical visit code. We did not propose, nor have we included in this final rule with comment period, provision for a global period for hospital outpatient services analogous to the global period affecting payments for professional services made under the Medicare physician fee schedule.

## c. Packaging of Casts and Splints

Comment: One commenter stated that we should not package costs for casts and splints with other procedures.

Response: We proposed to assign payment status indicator " N " to CPT codes for strapping and casting services (CPT codes 29000-29750) to designate that these are incidental services for which payment is packaged into the APC rate for another service or procedure, in this case, the repair or reduction of a fracture or dislocation. After further review, we determined that strapping and casting services can be performed independently, for example, when a cast placed as a part of a procedure must later be replaced with another cast. Therefore, we have decided that strapping and casting services will not be packaged and we are creating two APCs (0058 and 0059) to pay for these services. The BBA 1997 required that we pay under the outpatient PPS for casting and strapping services furnished in HHAs and hospices, to the extent that these services are provided and are not within the patient's plan of care.

## d. Packaging of Observation Services

We received many comments urging us to pay separately for observation services, particularly when patients are seen in the emergency department. Observation service is placing a patient in an inpatient area, adjacent to the emergency department, or, according to some comments, in the intensive care unit (ICU) or coronary care unit (CCU), in order to monitor the patient while determining whether he or she needs to be admitted, have further outpatient treatment, or be discharged. After 1983, many hospitals began to rely heavily on
the use of observation services when peer review organizations questioned admissions under the hospital inpatient prospective payment system. However, in some cases, patients were kept in "outpatient" observation for days or even weeks at a time. This resulted in excess payments both from the Medicare program and from beneficiaries who generally paid a higher coinsurance. In response to this practice, in November 1996, we issued instructions limiting covered observation services to no more than 48 hours except in the most extreme circumstances. However, the cost data upon which the APC system is based contain all costs for observation in 1996, including those that exceeded the 48hour limit imposed at the end of that year. We have packaged those costs into the service with which they were furnished in the base year. Thus, APC payments for emergency room visits include the costs of observation within the payment.

Comment: Some commenters acknowledged that being paid separately for observation following a surgical procedure was not necessary; the packaged recovery room and observation services were sufficient. However, a major concern of commenters was observation of patients with chest pain who had equivocal results on initial diagnostic testing. Commenters were concerned that the APC payment for these cases would not be adequate.

Response: We assume that chest pain patients, such as those described by the commenters, are sent to the CCU or ICU for observation. We believe that, in general, if a patient needs to be monitored in the ICU or CCU for any length of time, then that patient should be admitted as an inpatient.
Furthermore, we have never considered care furnished in an ICU or CCU to be outpatient services. Existing cost reporting instructions allow for the use of these specialty beds during a shortage of regular inpatient beds, but charges are to reflect routine care, not intensive care.

Although, as noted above, we received many comments urging that observation services be covered as a separate APC, we continue to believe that these services have been used so inappropriately in the past that we will have to gather data under the PPS before considering constructing a separate APC. We have packaged observation wherever it was billed. Roughly $\$ 139$ million was identified by revenue code 762 as representing observation services. An additional $\$ 253$ million was identified in revenue codes 760,

761 , and 769 , which could be used for either observation or treatment room use. That $\$ 253$ million is also packaged. (Both figures are in 1996 dollars.)

Further analyses will be necessary on the use of observation as an adjunct to emergency treatment, as in the case of chest pain. In order to ensure that we will have sufficient data for our future analyses, hospitals must continue to bill for observation using revenue center 762 and showing hours in the units field. Observation that is billed must represent some level of active monitoring by medical personnel. It must not be billed as a way to capture room and board for outpatients. During our first review of the APC groups, we will assess whether patients with certain conditions use observation services that should be separately recognized. Thus, correct diagnosis coding is required.

## e. Packaging Costs of Procuring Corneal Tissue

Comment: We received about 2,000 comments from physicians, eye banks, and health care associations opposing our proposal to package corneal tissue acquisition costs into the APC payment for corneal transplant procedures. Most commenters argued that the payment for the procedures in proposed APC group 670, Corneal transplant, is grossly inadequate and that we have failed to recognize the high costs associated with tissue screening and testing procedures required by the Food and Drug Administration that are reflected in the fees charged by eye banks. In addition, commenters contended that we failed to recognize the wide variation in tissue acquisition costs resulting from the level of philanthropic contributions in different areas of the country and in different years. Commenters asserted that by packaging corneal tissue acquisition costs with the payment for corneal transplant surgery, we would limit beneficiary access to quality care, force eye banks that are nonprofit, lowcost operations to close, provide disincentives for philanthropic contributions, and impede our goal to increase tissue availability.

As part of their comments, the Eye Bank Association of America (EBAA) submitted a report of a study the EBAA commissioned on corneal tissue acquisition costs. The study was conducted by the Lewin Group which collected and analyzed data on corneal tissue acquisition costs incurred by 74 of EBAA's 100 members that are charitable nonprofit organizations. The report states that these 74 eye banks supplied approximately 82 percent of the corneal tissue distributed
throughout the United States in 1997. Based on the data that they collected, the Lewin Group found that the median gross acquisition cost per transplant is \$1,689 in 1999 dollars. Of this amount, approximately $\$ 233$ represents the national median value of donated inkind services such as volunteer staff. The Lewin Group concluded that the proposed hospital outpatient PPS payment of $\$ 1,583$ did not adequately reflect the cost of procuring corneal tissue.
Additionally, the report states that "fund raising and in-kind service values are not as well centered on their median values as the underlying cost data.
Variability in fund raising and in-kind contributions not only exists between eye banks, but from year to year, within the same eye bank." According to the study, charitable contributions in the form of cash and in-kind services represented 28 percent of the eye banks' total gross cost for tissues furnished in 1997. The Lewin Group finds that "If HCFA were to move to fee schedule or other fixed-payment rate, and pays the adjusted median Gross cost Per
Transplant * * * payment of \$1689, HCFA would overpay some banks and underpay others, depending on philanthropy and in-kind services which varies from community to community and from year to year. The variation is too extreme to determine a fair rate-based system, without destroying the philanthropy the community is built upon."
Response: Based on the concerns raised by the commenters and the data presented in the Lewin Group study, we have decided not to package payment for corneal tissue acquisition costs with the APC payment for corneal transplant surgical procedures at this time. Instead we will make separate payment, based on the hospital's reasonable costs incurred to acquire corneal tissue. Final payment will be subject to cost report settlement. To receive payment for corneal acquisition costs, hospitals must submit a bill using HCPCS code V2785, Processing, preserving and transporting corneal tissue, and indicate the acquisition cost rather than the hospital's charge on the bill. We intend to review this policy after we have acquired updated data on corneal procedures.

## f. Packaging Costs of Blood and Blood Products

Comment: Many commenters, including the American Red Cross, a major medical association, teaching hospitals, and community oncology centers, believe that the payments we proposed for blood and blood-related
products and for APCs that required the use of blood and blood-related products, were too low. Commenters claimed that the proposed payments are so much lower than actual costs that hospitals might be forced to stop providing a range of blood services, especially those more complex than a simple transfusion. The commenters were concerned that our proposed payment would not allow hospitals to furnish the most clinically appropriate blood products and services. The commenters also stated that blood and blood product exchange were not assigned to appropriate APCs, thus skewing payment rates and not recognizing the true costs of services with which blood and blood product exchange are associated. Commenters attributed this deficiency to the fact that certain bloodrelated products were incorrectly billed in the 1996 data we used as the basis for pricing APCs. Commenters were also concerned that we excluded procedures whose costs fell outside 3 standard deviations of the mean cost. One major organization recommended that we separate payment for blood and blood products from the service with which it is associated. This commenter also recommended separate payment for infusible blood-derived drugs, and that we base payment for transfusable blood products on costs. Some commenters recommended a transition period prior to full implementation of the proposed PPS.

Response: Based on the recommendations of commenters, we have created separate APC groups to pay for blood and blood products. We agree with the commenters that blood use varies enough that packaging blood units with their administration could lead to inequities. Because we were not able to capture enough claims data in the base year to accurately price the blood and blood-product APCs, we have based payment rates for these APCs on data provided by commenters, including suppliers of blood and blood products. We have based payment on current costs rather than 1996 costs so that we recognize the costs of recently developed blood safety tests. The safety of the nation's blood supply is a major concern of the Department of Health and Human Services, and we want to encourage appropriate testing and follow-up care.

## g. Packaging Costs for Drugs,

Pharmaceuticals, and Biologicals
We proposed to package the cost of drugs, pharmaceuticals, and biologicals with APC groups because we believe drugs are usually provided in connection with some other treatment
or procedure. We collected aggregate cost data on all drugs that were billed with HCPCS codes and those billed with revenue center codes, whether or not a HCPCS was entered. By so doing, we captured historical patterns of drug use within the APC groups with which the drugs were billed during the base year. However, because we did not require HCPCS coding of drugs, we could not isolate costs associated with individual drugs, some of which are very expensive even though they are rarely used and may be used by only a few hospitals. As a result, we acknowledge that our proposed APC payment rates may not fully reflect costs of very expensive drugs or biologicals.
We also proposed to create separate drug groups for chemotherapeutic agents because those were separately identified in the APG system designed by 3 M . However, because we did not have bills that were coded to identify drugs individually, we were concerned that the APC groups for
chemotherapeutic groups may not have completely reflected the costs of these drugs.

## Comment: Many commenters

 criticized the proposed APC payment rates because they were developed using cost data from 1996 that do not reflect the cost of many new drugs, pharmaceuticals, and biologicals. Some commenters expressed particular concern about oncology drugs such as paclitaxil (Taxol) and topotecan. Some advised that Taxol and carboplatin chemotherapy have become the standard treatment for ovarian carcinoma. A number of commenters believe that our proposal did not provide sufficient financial incentives to dissuade hospitals from using the older less effective chemotherapy regimens even though there is significantly greater toxicity and reduced chances of favorable outcomes associated with their use. Many commenters strongly suggested that we carve out new drugs and biologicals and those introduced after 1996 from the PPS and pay for them on a reasonable cost basis. Several commenters asserted that packaging drugs and pharmaceuticals within the APC groups understates their cost to hospitals and their value to patients.Response: We believe the
commenters' concerns have, to a great extent, been addressed by implementation of the BBRA 1999 passthrough provisions for drugs and biologicals. Addendum K includes a complete list of all drugs, biologicals, and medical devices that are eligible for pass-through payments. We encourage interested parties to follow the process outlined below in section III.I. 4 of this
preamble to submit requests for consideration of drugs, biologicals, and medical devices that may be eligible for additional payment under the transitional pass-through provision but that are not listed in Addendum K.

## h. Summary of Final Action

After consideration of comments received about packaging of services and of the requirements set forth in the amendments made to section 1833(t) of the Act by section 201(b) and section 201(e) of the BBRA 1999, we have revised the package of services directly related and integral to performing a procedure or furnishing a service on an outpatient basis whose costs will determine the national payment rate for that procedure or service under the hospital outpatient PPS.

- We will package into the APC payment rate for a given procedure or service any costs incurred to furnish the following items and services: Use of an operating suite, procedure room or treatment room; use of the recovery room or area; use of an observation bed; anesthesia; medical and surgical supplies and equipment; surgical dressings; supplies and equipment for administering and monitoring anesthesia or sedation; intraocular lenses; capital-related costs; costs incurred to procure donor tissue other than corneal tissue; and, various incidental services such as venipuncture.
- In general, we will package the cost of drugs, pharmaceuticals and biologicals into the APC payment rate for the primary procedure or treatment with which they are used. Additional payment for some drugs,
pharmaceuticals, and biologics may be allowed under the transitional passthrough provisions, which we explain below, in section III.D.
- We will not package payment for corneal tissue acquisition costs into the payment rate for corneal transplant surgical procedures at this time. We will make separate payment for these acquisition costs based on the hospital's reasonable costs incurred to acquire corneal tissue.
- We will not package into the APC payment rate for another procedure or service costs incurred to furnish the following items and services: blood and blood products, including antihemophilic agents; casting, splinting, and strapping services; immunosuppressive drugs for patients following organ transplant; and certain other high cost drugs that are infrequently administered. We have created new APC groups for these items
and services, which allows separate payment to be made for them.

3. Treatment of Clinic and Emergency Department Visits

## a. Provisions of the Proposed Rule

As we discussed in our proposed rule, determining payment for hospital clinic and emergency department (ED) visits requires a variety of considerations such as the following:

- The impact of packaging on setting payment rates.
- How to code visits in a manner that recognizes variations in service intensity and levels of resource consumption.
- How to keep the system administratively manageable.
- How to define critical care in terms of facility as opposed to physician input.
- Data problems associated with identifying costs from claims that list multiple services.
- How to move toward greater uniformity of payments across ambulatory settings so as to remove payment as an incentive for determining site of service.

The major issue we faced in determining payment for hospital clinic and ED visits is whether to include diagnosis as well as Physicians' Current Procedural Terminology (CPT) codes in setting payment rates.

In our proposed rule, we considered several approaches to setting prospective payment rates for hospital clinic and ED visits. Potential options included: (1) Using diagnosis codes only; (2) using CPT codes only; and (3) using a CPT-diagnosis code hybrid. We solicited comments on these approaches to setting payment rates for clinic and ED visits as well as comments on alternative approaches that we did not set forth in the proposed rule. In the proposed rule, we discussed in detail our assessment of the advantages and disadvantages of each approach.

In addition, we proposed to create a HCPCS code that would be used to bill when a patient presents to an ED, requests a screening, and is screened in accordance with section 1867(a) of the Act. Payment for this new code would be minimal because we included no treatment costs in the screening service. Payment for the screening APC would be made only when no additional services were furnished by the emergency department. If nonemergency treatment was furnished, the appropriate emergency department visit would be billed, and not the screening. Similarly, if the screening reveals that an emergency does exist
and treatment is instituted immediately, the screening would not be billed because we would consider payment to be subsumed into the payment for further treatment.
We proposed paying for critical care as the highest level of "visit." In our proposed rule, we stated that hospitals would use CPT code 99291 to bill for outpatient encounters in which critical care services are furnished.
We used the CPT definition of "critical care" which is the evaluation and management of the critically ill or injured patient. Under the outpatient PPS, we would allow the hospital to use CPT code 99291 in place of, but not in addition to, a code for a medical visit or for an emergency department service. Although the CPT system allows the physician to bill in 30-minute increments following the first 74-minute period of providing critical care, we proposed to pay separately for only the initial period (CPT code 99291), packaging the few instances in which the 30-minute increments (CPT code 99292) were billed. If other services, such as surgery, x-rays, or cardiopulmonary resuscitation, were furnished on the same day as the critical care services, we would allow the hospital to bill for them separately.

## b. Comments and Responses

Comment: The major hospital associations argued that none of our three proposed approaches fully explains facility resource use in connection with clinic and emergency visits. Hospitals did not see a clear benefit in the payment ranges created by using the СРТ and diagnosis hybrid approach. A major medical association adamantly opposed the use of diagnosis codes. One major HMO that does not currently use CPT codes was opposed to the use of CPT codes to describe clinic and emergency visits.

Response: In this final rule, we are not using patient diagnosis codes to compute payment rates for medical visits to clinics and emergency departments under the outpatient PPS because a number of concerns were raised about basing payment for medical visits on both HCPCS codes and ICD-9 diagnosis codes. The final payment groups for medical visits are constructed using CPT procedure codes only, which is consistent with our overall PPS grouping strategy and with the approach we have followed to establish payment groups for surgical and diagnostic services. However, we will continue to require hospitals to provide accurate diagnosis coding on claims for payment. We will continue to assess the value of using patient diagnosis for application
to our payment system for possible use in the future.
In developing medical visit APCs based on CPT procedure codes only (a change from the proposed rule), we are collapsing 31 CPT codes that define clinic and emergency visits into six groups, three each for the clinics and the emergency department. The final APC groups for clinic and emergency visits are as follows: APC 0600, Low Level Clinic Visits; APC 0601, MidLevel Clinic Visits; APC 0602, High Level Clinic Visits; APC 0603, Interdisciplinary Team Conference; APC 0610, Low Level Emergency Visits; APC 0611, Mid-Level Emergency Visits; APC 0612, High Level Emergency Visits; and APC 0620, Critical Care.
When basing payment on CPT codes alone, the range of costs reflects hospitals' billing patterns in increasing level of intensity. However, those increasing increments are due largely to hospitals' use of "chargemaster" systems, which generate bills using predetermined charges for codes. Thus, billing patterns reflect standard bills, not the resources used in any particular case.

We had been concerned that certain hospitals' use of the lowest level code, CPT code 99201, to bill for all clinic visits would distort the data, causing inflation in both the volume and cost of low-level clinic visits, and a corresponding underreporting of midand high-level visits. (Costs for mid- and high-level visits would presumably have been correct, because individual hospitals would have reported appropriate charges with these codes; there simply would have been fewer reported visits at those levels.)
We have developed the weights for clinic visits by using claims data only from a subset of hospitals that billed a wider range of visits rather than relying solely on claims with CPT code 99201. We chose to use this subset of hospitals (for this purpose only) because we do not know what CPT code 99201 indicates when hospitals use it exclusively to bill all visits.

We emphasize the importance of hospitals assessing from the outset the intensity of their clinic visits and reporting codes properly based on internal assessment of the charges for those codes, rather than failing to distinguish between low-and mid-level visits "because the payment is the same." The billing information that hospitals report during the first years of implementation of the hospital outpatient PPS will be vitally important to our revision of weights and other adjustments that affect payment in future years. We realize that while these

HCPCS codes appropriately represent different levels of physician effort, they do not adequately describe nonphysician resources. However, in the same way that each HCPCS code represents a different degree of physician effort, the same concept can be applied to each code in terms of the differences in resource utilization. Therefore, each facility should develop a system for mapping the provided services or combination of services furnished to the different levels of effort represented by the codes. (The meaning of "new" and "established" pertain to whether or not the patient already has a hospital medical record number.)

We will hold each facility accountable for following its own system for assigning the different levels of HCPCS codes. As long as the services furnished are documented and medically necessary and the facility is following its own system, which reasonably relates the intensity of hospital resources to the different levels of HCPCS codes, we will assume that it is in compliance with these reporting requirements as they relate to the clinic/ emergency department visit code reported on the bill. Therefore, we would not expect to see a high degree of correlation between the code reported by the physician and that reported by the facility.

Hospitals are required to use HCPCS code 99291 to report outpatient encounters in which critical care services are furnished. (See the American Medical Association's CPT 2000 coding manual for the definition of this code.) The hospital is required to use HCPCS code 99291 in place of, but not in addition to, a code for a medical visit or for an emergency department service.

We will work with the American Hospital Association and the American Medical Association to propose the establishment of appropriate facilitybased patient visit codes in time for the next proposed rule.

Comment: Several commenters expressed concern that resources expended in the emergency department are not fully explained by the codes at their disposal. One commenter pointed out that some hospitals use internal coding systems to capture differing charges based on whether or not a case requires one-on-one nursing care.

Response: While we share
commenters' concerns on this point, we remind hospitals that they can receive additional payment under the outpatient PPS for services such as diagnostic testing and administration of infused drugs, and for therapeutic procedures including resuscitation that
are furnished during the course of an emergency visit. We will also pay separately for certain high cost drugs, such as the expensive "clotbuster" drugs that must be given within a short period of time following a heart attack or stroke, if these drugs are furnished during an emergency visit. Even though some ED patients will be transferred to another hospital for inpatient treatment, the hospital that administers the drugs will be paid for them. Cases that fall far outside the normal range of costs will be eligible for an outlier adjustment established by section 201(a) of the BBRA 1999. (See section III.H, below.) In addition, one of the first topics of review to be addressed by the expert outside advisory panel, required by section 201(h)(1)(B) of the BBRA 1999, will be to determine if emergency department visits can be categorized in a way that better recognizes the underlying resources, especially nursing resources, involved in the visit.

Comment: Several commenters expressed concern about the appropriate level of payment for patients who die in the ED. One commenter believes that services furnished to these patients are resource-intensive and recommends that we continue to pay for the services on a reasonable cost basis.

Response: We are directing fiscal intermediaries to use the following guidelines in determining how to make payment when a patient dies in the ED or is sent directly to surgery and dies there.

- If the patient dies in the ED, make payment under the outpatient PPS for services furnished.
- If the ED or other physician orders the patient to the operating room for a surgical procedure, and the patient dies in surgery, payment will be made based on the status of the patient. If the patient had been admitted as an inpatient, pay under the hospital inpatient PPS (a DRG-based payment). If the patient was not admitted as an inpatient, pay under the outpatient PPS (an APC-based payment). If the patient was not admitted as an inpatient and the procedure is designated as an inpatientonly procedure (payment status indicator " C "), no Medicare payment will be made for the procedure, but payment will be made for ED services.

Comment: Some commenters objected to our proposal to restrict payment for critical care services to CPT code 99291 and not allow payment for CPT code 99292. One commenter recommended that we create an APC group for the additional increments of time a physician spends in critical care for which the physician may bill.

Response: We do not believe that paying hospitals for incremental time as critical care would better reflect facility resources. The most resource-intensive period for the hospital is generally the first hour of critical care. In addition, we believe it would be burdensome for hospitals to keep track of minutes for billing purposes. Therefore, we will pay for critical care as the most resourceintensive visit possible as defined by CPT code 99291. Critical care services will be assigned to APC 0620.
Comment: Several commenters advised that a screening code was not necessary because an emergency visit code could be billed for ED screening services.
Response: We agree with the commenters, and we will instead use the appropriate emergency department codes for screening services (as defined in section 1867(a) of the Act). If no treatment is furnished, we would expect screening to be billed with a low-level emergency department code.

Comment: Some commenters expressed concern about our proposal to allow hospitals to create a separate claim for each visit when two or more medical visits occur on the same day for different diagnoses. Commenters feared that this would result in our paying under the outpatient PPS for clinic care furnished at sites other than hospital outpatient departments, and that we are promoting fragmented care. One commenter was concerned that, to the extent that patients see multiple specialists, tests will be repeated unnecessarily, hospitalizations will rise, and beneficiaries and the Medicare program will be burdened with additional, unnecessary costs.

Response: Our decision not to use diagnosis codes as a factor in determining payment for clinic visits largely negates these concerns because the need to prepare different claims for visits for different diagnoses has been eliminated. When patients are seen in different clinics on the same day, hospitals should bill using the proper codes for the level of the visits, using the units field if appropriate to reflect more than one visit at the same level.
However, we note that the comment did prompt us to develop a code for billing those visits during which numerous physicians see a patient concurrently, for example, a surgeon, medical oncologist, and radiation oncologist for a cancer patient, to discuss treatment options and to ensure that the patient is fully informed. In this instance, each physician is addressing the patient's care from a unique perspective. If several physicians see a patient concurrently in the same clinic
for the same reason, the hospital would bill for one clinic visit using an appropriate visit code even though each physician would bill individually for his or her professional services. We have established a code for hospitals to use in reporting a scheduled medical conference with the patient involving a combination of at least three health care professionals, at least one of whom is a physician. That code is G0175, Scheduled interdisciplinary team conference (minimum of three, exclusive of patient care nursing staff) with patient present.

## 4. Treatment of Partial Hospitalization

 ServicesAs we explained in the proposed rule, partial hospitalization is an intensive outpatient program of psychiatric services provided to patients in lieu of inpatient psychiatric care. Partial hospitalization may be provided by a hospital to its outpatients or by a Medicare-certified community mental health center (CMHC). It is important to note that the services of physicians, clinical psychologists, clinical nurse specialists (CNSs), nurse practitioners (NPs), and physician assistants (PAs) furnished to partial hospitalization patients would continue to be billed separately to the carrier as professional services and are not considered to be partial hospitalization services. Thus, payment for partial hospitalization services represents the provider's overhead costs, support staff, and the services of clinical social workers (CSWs) and occupational therapists (OTs), whose professional services are considered to be partial hospitalization services for which payment is made to the provider. Including CSW and OT services reflects historical patterns of treatment billed during the base year.

Because a day of care is the unit that defines the structure and scheduling of partial hospitalization services, we proposed a per diem payment methodology for the partial hospitalization APC. We analyzed the service components billed by hospitals over the course of a billing period and determined the median hospital cost of furnishing a day of partial
hospitalization. As noted in the June 30, 1999 correction notice, this analysis resulted in a proposed APC payment rate of $\$ 206.71$ per day, of which $\$ 46.78$ is the beneficiary's coinsurance.

We also solicited comments on a number of issues related to partial hospitalization. We asked for information on the mix of services that constitute a typical partial hospitalization day and average duration of a partial hospitalization
episode, whether we should impose a minimum number of services for each covered partial hospitalization day, and whether we should establish a limit on routine outpatient mental health services furnished on a given day to equal the partial hospitalization per diem amount. Finally, we indicated that we are considering specifying a timeframe for physician recertification of need for partial hospitalization services as a method of ensuring that a patient's condition continues to require the intensity of a partial hospitalization program.
We did not receive a significant number of public comments on this issue. A summary of the comments we received and our responses follow.

Comment: We received many similar comments from rural hospitals that operate partial hospitalization programs. The hospitals indicated that the proposed per diem amount does not cover their direct cost of providing services. Each commenter included an estimate of their partial hospitalization program cost (without depreciation or allocation of overhead costs). The estimates range from $\$ 270$ to $\$ 325$ per patient per day. The commenters indicated that approximately 65 to 70 percent of the costs are personnelrelated.
Response: The commenters did not indicate why their costs were higher than the per diem amount, but only that a significant proportion of their costs are related to personnel. In the future, we are committed to assessing the extent to which the per diem reflects special needs of rural hospitals. In the meantime, the BBRA 1999 includes provisions that offer relief to rural hospitals during the early years of the outpatient PPS. (See section III.H of this preamble.)

Comment: We received several other comments regarding the proposed per diem amount. One commenter stated that the proposed per diem rate is equivalent to 3.3 psychotherapy units. The commenter believed this is an inadequate level of therapy for partial hospitalization patients and suggested that a per diem rate equal to 4 psychotherapy units would provide payment for a more appropriate level of service intensity. Several other commenters suggested that we set a single rate using a therapeutic hour of treatment (for example, the group psychotherapy APC rate) as the unit of service coupled with an overall aggregate limit for a course of treatment. These commenters estimated that a typical partial hospitalization day costs $\$ 275$. Another commenter, a national association, conducted a survey of its
member hospitals which showed that the median cost per day of treatment was approximately $\$ 210$. Other commenters urged us to establish separate per diem amounts for partial hospitalization programs serving geriatric beneficiaries and those serving disabled beneficiaries under age 65 . They indicated that programs designed to serve geriatric beneficiaries consist of different treatment modalities that are costlier than programs that serve younger beneficiaries. One commenter stated that programs serving younger beneficiaries typically average high patient volume and therefore have much lower costs per patient day than do the programs that serve geriatric patients. Other commenters urged us to establish a half day rate, although some stated that a half-day benefit does not reduce administrative costs appreciably.
Response: In accordance with section $1833(\mathrm{t})(2)(\mathrm{C})$ of the Act, the proposed per diem amount represents the national median cost of providing partial hospitalization services. We used all the data from hospital bills that included the condition code 41, which identifies the claim as partial hospitalization. Because providers do not report on the claim the specific services provided each day, we do not currently have data that would permit us to establish an aggregate limit for a course of treatment or to analyze differences in the mix of services provided to various populations. As discussed in the preamble to the proposed rule and in Transmittal 7 of the CMHC Manual (issued November 1999) and Transmittal 747 of the Hospital Manual (issued December 1999), beginning April 1, 2000, hospitals and CMHCs will be required to indicate line item dates of service on claims. Once we have accumulated these data, we will be better able to determine if refinements to the per diem methodology are warranted, including the extent to which half-days are utilized.

Comment: Several commenters expressed concern that no CMHC data were used to establish the partial hospitalization per diem payment rate. The commenters stated that CMHC costs are significantly different from hospitalbased programs and urged us to collect CMHC cost data and base payments to CMHCs on CMHC-specific information. Another commenter stated that implementing PPS for partial hospitalization services provided by CMHCs is intended to contain costs and urged us to track the impact of the PPS on CMHCs. Still another commenter expressed concern that the per diem amount is insufficient for CMHCs to provide quality services. The
commenter admitted, however, that historically their service area has had limited resources to provide minimum support for the persistent and chronically mentally ill. Two commenters expressed concern about certification requirements for CMHCs. One urged us to require accreditation by a national accrediting body and another commenter noted that reliance on the statutory definition established for CMHCs under the Public Health Service Act in 1963 is no longer appropriate and urged us to redefine a CMHC for Medicare certification purposes.

Response: Partial hospitalization services are covered services under the hospital outpatient PPS. Section 1833(a)(2)(B) of the Act provides that partial hospitalization services furnished by CMHCs are to be paid under the hospital outpatient PPS. And, section 1833(t)(2)(C) of the Act requires that we establish relative payment weights based on median (or mean, at the election of the Secretary) hospital costs determined by 1996 claims data and data from the most recent available cost reports. As stated above, we are committed to analyzing future data from hospitals and CMHCs to determine if refinements to the per diem are warranted. As we noted in the proposed rule, the Medicare partial hospitalization benefit is designed to furnish services to patients who have been discharged from inpatient psychiatric care, and partial hospitalization services are provided in lieu of continued inpatient treatment, and for patients who exhibit disabling psychiatric/psychological symptoms or experience an acute exacerbation of a severe and persistent mental disorder. Because the statute requires a physician to certify that the patient would otherwise require inpatient psychiatric care in the absence of the partial hospitalization services, we do not believe the Medicare partial hospitalization benefit was intended to provide support for the persistent and chronically mentally ill except when they are in an acute phase of their mental illness. With regard to accreditation requirements for CMHCs and substantively revising the definition of a CMHC, this final rule is not the appropriate vehicle in which to address these issues. We are, however,
amending $\S 410.2$ to remove an obsolete provision from the definition of a CMHC.

Comment: Several commenters questioned whether the proposed per diem approach meets the definition of an APC, that is, a group of services that are comparable clinically and in resource use. They believed that partial
hospitalizations vary widely in their treatment approach and cost. Therefore, creating one payment amount for all partial hospitalization days is not consistent with our proposed classification system.
Response: We continue to believe that the structure of the average partial hospitalization day is more similar than the commenters believe. We followed the basic analytical methodology used to establish all the APC payment amounts, except that we determined that, for partial hospitalization services, the unit of service is a day. Nonetheless, requiring providers to submit claims by date of service and by service provided will allow for future analysis to determine if the APC grouping for partial hospitalization can be improved.

Comment: One commenter expressed concern about the use of 1996 data as the basis for the per diem amount. They referenced testimony by the Inspector General that indicated a significant improvement in the accuracy of provider billing in 1998 audits. They urged us to use 1997 or 1998 cost reports by region to develop the APC rate.

Response: Section 1833(t)(2)(C) of the Act requires that we use 1996 claims data and the most recent cost reports as the basis for ratesetting under the hospital outpatient PPS. For purposes of the final rule, we primarily used cost reports for periods beginning in FY 1997.

Comment: Several commenters, including national industry associations, expressed concern that partial hospitalization programs are required by their individual fiscal intermediaries to meet different medical necessity and programmatic requirements. For this reason, programs vary widely in program content and resultant cost. The commenters urged us to establish national coverage criteria before implementing a PPS for partial hospitalization services. Another commenter urged us to rely on more recent claims data that identify all services provided on each date of service in order to determine the relative resource cost of various outpatient mental health treatment programs.
Response: Section 1833(a)(2)(B) of the Act provides that partial hospitalization services are paid under section 1833(t). We will refine the system, as needed, based on our review of more specific bill data. Movement to a per diem payment methodology will necessitate changes in the medical review approach used by fiscal intermediaries. It will become necessary to ensure that all patients receive the level of service their
individual condition requires. Some patients will require days of service that cost the provider more than the per diem payment amount. Other patients may require less intensive days of service during an acute episode of partial hospitalization care or as they transition out of the partial
hospitalization program. We will be developing medical review guidance for fiscal intermediaries, which we believe will lead to more consistency in medical review.
Comment: One commenter noted that, in the past, a daily or partial-day payment approach was commonly used and was abandoned in favor of component billing for each partial hospitalization service. The commenter now believes that component billing provides a more accurate indication of the services provided to individual patients.

Response: We believe that a per diem payment approach is a more appropriate methodology than billing for each program component. This approach is supported by the major industry groups involved with partial hospitalization and is used by other governmental and private insurers to pay for partial hospitalization program services. A per diem approach also incorporates and recognizes the cost of services that are not separately billable as outpatient psychiatric services, such as nursing services, training and education services, activity therapy, and support staff costs.

Comment: Several commenters requested additional information on the HCPCS codes to which the partial hospitalization indicator applies and questioned how codes will group to APC 20 rather than grouping to psychotherapy APCs 91 through 94.

They also asked whether substance abuse day programs will group to APC 20.

Response: We issued revised billing instructions for partial hospitalization services provided by CMHCs in November 1999 and for hospital programs in December 1999. We instructed CMHCs to use HCPCS codes to bill for their partial hospitalization services; we required hospitals and CMHCs to report line item dates of service; and we established new HCPCS codes for occupational therapy and training and educational services furnished as a component of a partial hospitalization treatment program. We included in the instructions a complete listing of the revenue codes and HCPCS codes that may be billed as partial hospitalization services as follows:

| Revenue codes | Description | HCPCS code |
| :---: | :---: | :---: |
| 43X | Occupational Therapy (Partial Hospitalization) ....................... | G0129. |
| 904 .. | Activity Therapy (Partial Hospitalization) ................................. | Q0082. |
| 910 | Psychiatric General Services ................................................ | 90801, 90802, 90875, 90876, 90899, or 97770. |
| 914 | Individual Psychotherapy | 90816, 90818, 90821, 90823, 90826, or 90828. |
| 915 | Group Psychotherapy | 90849, 90853, or 90857. |
| 916 | Family Psychotherapy ......................................................... | 90846, 90847, or 90849. |
| 918 | Psychiatric Testing .............................................................. | 96100, 96115, or 96117. |
| 942 .......... | Education Training (Partial Hospitalization) ............................. | G0172. |

To bill for partial hospitalization services under the hospital outpatient PPS, hospitals are to use these HCPCS and revenue codes and are to specify condition code 41 on the HCFA-1450 claim form. Before assigning a claim for payment to APC 0033 (the final APC for partial hospitalization services), the outpatient code editor (OCE) will check for errors; for example, the OCE will verify that the claim includes a mental health diagnosis, and at least three partial hospitalization HCPCS codes for each day of service, one of which must be a psychotherapy HCPCS code (other than brief). Claims that do not pass the OCE edits will undergo further prepayment review.
With regard to the comments regarding substance abuse day programs, the Medicare benefit category is partial hospitalization services. Because there is no separate benefit category for substance abuse programs, any such program would have to meet requirements established for partial hospitalization programs in order for claims to group to APC 0033, including the requirements that a physician certify that the patient would otherwise require inpatient psychiatric care in the absence of the partial hospitalization services
and that the program provides active treatment.

Comment: In regard to physician recertification, we received several comments expressing support for establishing a specific timeframe and recommending a range from 7 to 31 days.

Response: We agree that physicians should initially certify a patient's need for partial hospitalization services and recertify continued need for this intensive level of treatment. Because partial hospitalization is the outpatient substitute for inpatient psychiatric care, we believe it is appropriate to adopt the standard currently used for inpatient psychiatric care. Therefore, in this final rule, we are amending $\S 424.24(\mathrm{e})$ to establish physician recertification requirements for partial hospitalization services. The initial physician certification establishing the need for partial hospitalization must be received by the partial hospitalization program upon admission. Thus, services provided to establish a patient's need for partial hospitalization services would continue to be billed to the carrier as professional services. The first recertification is required as of the 18th day of services and subsequent
recertifications are required no less frequently than every 30 days. Each recertification must address the patient's response to the intensive, therapeutic interventions provided by the active treatment program which make up partial hospitalization services, changes in functioning and status of the serious psychiatric symptoms that place the patient at risk of hospitalization, and treatment plan and goals for coordination of services such as community supports and less intensive treatment options to facilitate discharge from the partial hospitalization program.

Comment: We received several comments regarding our proposal to limit payment for less intensive outpatient mental health treatment at the partial hospitalization per diem rate. One commenter did not believe the law supports establishment of a payment ceiling and that any such action is arbitrary. Other commenters believe that treatment should be determined by the clinical needs of each patient. However, the commenters conceded that additional requirements may have to be added to the final rule to prevent duplication or overlap of partial
hospitalization and routine outpatient mental health services.
Response: Our rationale for this proposal was that the costs associated with administering a partial hospitalization program represent the most resource intensive of all outpatient mental health treatment and, therefore, we should not pay more for a day of individual services. We are also concerned that a provider may disregard a patient's need for the intensive active treatment offered by a partial
hospitalization program and opt to bill for individual services. In addition, the per diem amount represents the cost of an average day of partial hospitalization because the data used to calculate the per diem were derived from all the partial hospitalization data and include the most and the least intensive days. It would not be appropriate for a provider to obtain more payment through component billing.
Comment: Several commenters expressed concern about staffing services that are bundled in the per diem payment and other staffing issues. One commenter stated that due to increased medical review by the fiscal intermediary, no partial hospitalization services may be furnished by unlicensed personnel. The commenter urged that the necessity for upgrades in staffing be taken into consideration in establishing a per diem rate. One commenter believes that all services, except for physician services, should be bundled into the per diem rate.
Response: The list of covered partial hospitalization services is located in section 1861 (ff) of the Act. The list includes several services such as patient education and training and activity therapy that may be provided by unlicensed but qualified staff who are specifically trained to work with the mentally ill. We note that the billing instructions issued in November 1999 (for CMHCs) and in December 1999 (for hospitals) announced a new HCPCS code for patient training and education services as a component of a partial hospitalization program. (A HCPCS code for activity therapy as part of a partial hospitalization program has been in place for several years.) Although the list also specifically references the services of social workers, trained psychiatric nurses, and other staff trained to work with psychiatric patients, there are no specific HCPCS codes for these services. Certain other partial hospitalization services, for example, individual and group psychotherapy, family counseling, occupational therapy (OT), and diagnostic services, must be provided by
licensed staff, authorized by the State to provide these services.

With regard to the content and staffing of partial hospitalization programs, we believe that all the covered services listed in section 1861(ff) of the Act and the disciplines of the staff who provide the services, that is, the multidisciplinary team, are an important element in creating the therapeutic milieu that distinguishes partial hospitalization programs from other outpatient mental health treatment. We believe it would be inappropriate if providers no longer offered the full range of partial hospitalization services, especially services such as OT that continue to be bundled in the per diem amount. We plan to monitor the extent to which providers change their programming in response to implementation of the PPS. Because the data on which the per diem was based included the full range of services and the use of certain bundled professionals, we will monitor changes in services or increased use of unbundled practitioners to evaluate and update the per diem rate. In response to the comment recommending that we bundle more professional services into the per diem rate, we captured historical patterns of treatment and staffing during the base year. Thus, the partial hospitalization per diem amount is limited to the provider's overhead costs, support staff, and the services of clinical social workers and occupational therapists, whose professional services are defined as partial hospitalization services. We have amended § 410.43(b) to update the list of services that are not paid as partial hospitalization services.

Comment: One commenter took issue with our characterizing partial hospitalization to be the result of an acute exacerbation of a beneficiary's severe and persistent mental illness for which partial hospitalization services are provided in lieu of an inpatient psychiatric admission. They urged us to clarify that admission to a partial hospitalization is based on a physician certification that the patient would otherwise require inpatient psychiatric care, but continued stay in a partial hospitalization program would serve as a maintenance program for the chronically mentally ill. The commenter raised many other concerns about how we described partial hospitalization in the proposed rule, noting specific concern with regard to active treatment, community-based support, and frequency and duration of services.

Response: It was not our intention in the proposed rule to generate public comment on the nature and coverage of partial hospitalization under the

Medicare program. Rather, the information presented has appeared in various program memoranda and was included to describe the benefit and explain the per diem payment methodology. We continue to believe that partial hospitalization is a covered Medicare benefit category only when provided as an alternative to inpatient psychiatric care for acutely mentally ill beneficiaries.

## Result of Evaluation of Comments

We are adopting as final our proposal to-

- Establish a per diem payment of $\$ 202.19$ for the partial hospitalization APC (APC 0033); and
- Limit the payment for outpatient mental health treatment furnished on a day of services to the partial hospitalization APC payment amount.
In addition, we are amending $\S 424.24(\mathrm{e})$ to establish requirements for physician recertification for partial hospitalization services.


## 5. Inpatient Only Procedures

In our proposed rule, we assigned payment status indicator "C' to 1,803 codes that represent procedures that our medical advisors and staff determined require inpatient care because of the invasive nature of the procedure, the need for postoperative care, or the underlying physical condition of the patient who would require the surgery. We did not assign these procedures to an APC group, and we proposed to make no payment for these services under the hospital outpatient PPS. Above, in section III.B.1.b of this preamble, we respond to the numerous general comments we received challenging both our classification of various procedures as inpatient procedures and our exclusion of these procedures from the scope of services paid under the hospital outpatient PPS.

Comment: Commenters objected on the grounds that medical practice and new technology have allowed many procedures that formerly were performed only in the inpatient setting to be safely and effectively performed on an outpatient basis. In addition, they believe we are making decisions that should be left to the discretion of surgeons and their patients. Finally, the commenters believe that it is better for the patient if procedures are performed on an outpatient basis whenever possible. Commenters requested that we remove the payment status indicator of "inpatient only" from 195 codes and include them in an appropriate APC. Response: Under section
1833(t)(1)(B)(i) of the Act, the Secretary has broad authority to designate which
services fall within the definition of "covered OPD [outpatient department] services" that will be subject to payment under the prospective payment system. We believe that certain surgically invasive procedures on the brain, heart, and abdomen, such as craniotomies, coronary-artery bypass grafting, and laparotomies, indisputably require inpatient care, and therefore are outside the scope of outpatient services. Certain other procedures that we proposed as "inpatient only" may not be so clearly classified as such, but they are performed virtually always on an inpatient basis for the Medicare population. We acknowledge that emerging new technologies and innovative medical practice are blurring the difference between the need for inpatient care and the sufficiency of outpatient care for many procedures, although we are concerned that some of the procedures that commenters claim to be performing on an outpatient basis may actually have been performed with overnight postoperative care furnished in observation units. And, regardless of how a procedure is classified for purposes of payment, we expect, as we stated in our proposed rule, that in every case the surgeon and the hospital will assess the risk of a procedure or service to the individual patient, taking site of service into account, and will act in that patient's best interests.
After a careful review of comments by our medical advisors and staff, we have assigned to APC groups certain procedures that we had proposed as inpatient only. We made some changes because we were convinced by commenters' arguments that certain procedures are often performed safely in the outpatient setting; others because we believe that the simplest procedure described by the code may be performed safely in the outpatient setting; and yet others because they were related to codes we moved (for example, the radiologic part of an interventional cardiology procedure). The procedures we moved to the outpatient APCs include codes from within the following families: Explorations of penetrating wounds; repairs of some cranial and facial fractures; planned tracheostomies; diagnostic thoracoscopies; some insertion/removal/replacement of pacemakers, pulse generators, electrodes and cardioverter-defibrillators; embolectomies and thrombectomies; transluminal balloon angioplasty and peripheral atherectomy; transcatheter therapies; bone marrow transplantation; gastrostomies; percutaneous nephrostolithotomy; surgical laparoscopies, including
cholecystectomies; ovarian biopsies; and surgeries on the orbit. Although we are moving these procedures into APC groups and they can receive outpatient payment, we emphasize that we expect only the simplest and least resource intensive procedures of each type to be performed in the outpatient setting. For example, several codes could be used to describe initial insertion of a pacemaker or replacement of the pacemaker or its electrodes. We believe most initial pacemaker insertions are performed on an inpatient basis, so codes billed in this range are most likely to be for replacement of a pacemaker, which requires fewer facility resources.

Because of the risk involved with invasive cardiovascular procedures, including angioplasty and atherectomy, we are placing an additional requirement on their performance that we do not think is necessary with other procedures. That is, Medicare will pay for these procedures only in those settings in which the patient can immediately be placed on cardiopulmonary bypass in the event of a complication such as perforation of a coronary artery, which would require an immediate thoracotomy.

When our medical advisors and staff disagreed with the recommendation of commenters to reclassify a particular procedure, they based their decision to retain a procedure as "inpatient only" on several considerations. In general terms, as stated above, we define inpatient procedures as those that require inpatient care because of the invasive nature of the procedure, the need for at least 24 hours of postoperative recovery time or monitoring before the patient can be safely discharged, or the underlying physical condition of the patient who would require the surgery. In other words, inpatient procedures are those that, in the judgment of our medical advisors and staff, would not be safe, appropriate, or considered to fall within the boundaries of acceptable medical practice if they were performed on other than a hospital inpatient basis.

Among the procedures cited by commenters that we believe should remain as "inpatient only" are: Breast reconstruction using myocutaneous flaps; radical resections of tumors of the mandible; open treatment of certain craniofacial fractures; osteotomies of the femur and tibia; sinus endoscopy with repair of cerebrospinal fluid leaks; carinal reconstruction; surgical thoracoscopies; pacemaker procedures by thoracotomy; certain thromboendarterectomies; excision of mediastinal cysts and tumors; excisions of stomach tumors; enterostomies;
hepatotomies; ureterotomies and ureteral endoscopies through ureterotomies; transcranial approaches to the orbit; and laminectomies. Our medical advisors and staff, as well as consulting physicians, believe these procedures are too invasive (for example, thoracotomies), too extensive (for example, breast reconstruction with myocutaneous flaps), or too risky by virtue of proximity to major organs (for example, repairs of spinal fluid leaks and carinal reconstruction) to be performed on an outpatient basis. The procedures that we exclude from outpatient payment because we believe they should be performed on an inpatient basis are listed in Addendum E. This list represents national Medicare policy and is binding on fiscal intermediaries and peer review organizations as well as on hospitals and Medicare participating ASCs. Note, however, that services included in outpatient PPS and assigned to an APC may be performed on an inpatient basis when the patient's condition warrants inpatient admission.

In the future, as part of our annual update process, we will be working with professional societies and hospital associations, as well as with the expert outside advisory panel that we will be convening as required by new section 1833(t)(9)(A) of the Act, to reevaluate procedures on the "inpatient only" list and we will propose to move procedures to the outpatient setting whenever we determine it to be appropriate. For example, a decreasing length of inpatient stay for a procedure may signal that it is appropriate for consideration for payment under the outpatient PPS. If hospitals find that surgeons are discharging patients successfully on the day of surgery, they should bring this to our attention as well, because hospitals may become aware of this trend before our payment data disclose it. Thus, assignment of a "C" payment status indicator in this final rule should not be considered as a permanent or irrevocable designation.

Comment: One professional society recommended that we assign payment status indicator "C" to CPT codes 21343, open treatment of depressed frontal sinus fracture, 42842, radical resection of tonsil, tonsillar pillars, and/ or retromolar trigone-without closure, and 69150, radical excision external auditory canal lesion-without neck dissection, because these procedures require inpatient care.
Response: We accepted the commenters' recommendation that these CPT codes should not be performed in an outpatient setting. We also reclassified as an inpatient procedure

CPT code 94762, noninvasive ear or pulse oximetry for oxygen saturation; by continuous overnight monitoring (separate procedure), because it requires an overnight stay.

Comment: One commenter noted that, to the extent that we require that certain surgical procedures be performed in an inpatient setting in order to receive Medicare payment, the beneficiary will incur the higher deductible associated with a hospital inpatient service.

Response: The commenter is correct that the Part A hospital inpatient deductible amount that a beneficiary will have to pay may be higher than coinsurance and deductibles the beneficiary would have paid as an outpatient for a surgical procedure. However, our decisions concerning whether to pay for certain surgical procedures under the PPS are based on patient safety concerns and the medical appropriateness of performing the procedures in the hospital inpatient versus outpatient setting.

## Final Action

Under the hospital outpatient PPS, we will not make payment for procedures that are designated as "inpatient only." We have, however, revised the list of procedures that are designated as "inpatient only" based on comments. (See Addendum E.)

## 6. Modification of APC Groups

## a. How the Groups Were Constructed

Section 1833(t)(2)(A) of the Act requires the Secretary to develop a classification system for covered outpatient services. Within that classification system, the Secretary is given the authority under section 1833(t)(2)(B) of the Act to establish groups of covered services so that the services within each group are comparable clinically and with respect to the use of resources. In the proposed rule, we explain how we constructed the APC groups that are the basis for ratesetting under the hospital outpatient PPS.
Our medical advisors and staff used the ambulatory patient groups (APGs) developed by 3M-Health Information Systems as a starting point for the APC groups, but we modified the APGs to take into account 1996 outpatient claims data, data collected in a 1994 survey of ambulatory surgical center (ASC) costs and charges, data collected in 1995 and 1996 to establish resource-based practice expense relative values under the Medicare physician fee schedule, and comments offered by a broad range of professional and trade societies and associations. For a more detailed
discussion of this process, see section V.B of the proposed rule ( 63 FR 47561).

## b. Comments on Classification of Procedures and Services Within APC Groups

In the proposed rule, we invited comments on the composition of the APC groups, and we requested that commenters support their recommendations for changes with resource cost data and clinical arguments. We received a large number of comments on our proposed grouping of individual procedures and services. The most common comment was that the APC groups generally lacked consistency in terms of clinical characteristics and resource utilization. Below, in section III.C.6.d of this preamble, we address recommendations from commenters that specific HCPCS codes be assigned to a group other than the one we proposed. In addition to reviewing the APC groups that were the subject of comments, our medical advisors and staff reviewed every APC group to take into account the effect across all related groups of commenters' recommended changes.

## Criteria for Evaluating Changes Recommended by Commenters

In determining whether or not to accept a recommended change, we focused on five criteria that are fundamental to the definition of a group within the APC system. The decision to accept or decline a modification to an APC group was measured by whether the change enhanced, detracted from, or had no effect on the integrity of an APC group within the context of these five criteria. The five criteria are as follows:

- Resource Homogeneity

The amount and type of facility resources, for example, operating room time, medical surgical supplies, and equipment, that are used to furnish or perform the individual procedures or services within each APC should be homogeneous. That is, the resources used are relatively constant across all procedures or services even though resource use may vary somewhat among individual patients. If the procedures within an APC require widely varying resources, it would be difficult to develop equitable payment rates. Aggregated payments to a facility that performed a disproportionate share of either the expensive or inexpensive procedures within an APC would be distorted. Further, the facility might be encouraged to furnish only the less costly procedures within the APC, resulting in a potential access problem for the more costly services.

It is important to note that procedures within an individual HCPCS code can vary widely in resource use. The coefficient of variation of cost for the procedures within one HCPCS code can be as high as the overall coefficient of variation across all the HCPCS codes that comprise an APC group. Thus, a significant amount of the variability in resource use within some APC groups can be attributed to the variability of resources within individual HCPCS codes. Nevertheless, if resource use is reasonably homogeneous among the HCPCS codes within an APC group, the average pattern of resource use among a group of cases in an APC can be accurately predicted. In section III.C.6.c, below, we discuss the BBRA 1999 provision that sets limits on the variation in resource cost within an APC.

- Clinical Homogeneity

The definition of each APC group should be "clinically meaningful," that is, the procedures or services included within the APC group relate generally to a common organ system or etiology, have the same degree of extensiveness, and utilize the same method of treatment, for example, surgical, endoscopic, etc. The definition of clinical meaningfulness is, of course, dependent on the goal of the classification system. For APCs, the definition of clinical meaningfulness relates to the medical rationale for differences in resource use. If, on the other hand, classifying patient prognosis were the goal, the definition of patient characteristics that were clinically meaningful might be different.

- Provider Concentration

We considered the degree of provider concentration associated with the individual services that comprise the APC. If a particular service is offered only in a limited number of hospitals, then the impact of payment for the service is concentrated in a subset of hospitals. Therefore, it is particularly important to have an accurate payment level for services with a high degree of provider concentration. Conversely, the accuracy of payment levels for services that are routinely offered by most hospitals does not bias the payment system against any subset of hospitals. Thus, differences in the resource requirements for individual services within an APC are of less significance if all the services within the APC are routinely offered by most hospitals because the impact of the difference should average out at the hospital level.

- Frequency of Service

Unless we found a high degree of provider concentration, we avoided creating separate APC groups for
services that are infrequently performed. It is difficult to establish reliable payment rates for low volume APC groups. Therefore, we assigned the HCPCS codes to the APC that was the most similar in terms of resource use and clinical coherence.

Some procedures, such as craniotomies, are clearly inpatient procedures, and are rarely performed in an outpatient setting. However, there are some procedures that, while they are normally performed on an inpatient basis, can also be safely performed on an outpatient basis. The performance of those procedures on an outpatient basis is infrequent and is limited to the simplest cases. Therefore, when we included these procedures in APC groups, we assumed a level of resource use that would apply only to the simplest cases rather than that typical of more complex cases that would be performed on an inpatient basis.

- Minimal Opportunities for Upcoding and Code Fragmentation

The APC system is intended to discourage using a code in a higher paying group to define a case. That is, putting two related codes, such as the codes for excising a lesion of 1.1 cm and one of 1.0 cm , in different APC groups may create an incentive to exaggerate the size of the lesions in order to justify the incrementally higher payment. APC groups based on subtle distinctions would be susceptible to this kind of upcoding. Therefore, we kept the APC groups as broad and inclusive as possible without sacrificing resource or clinical homogeneity.
In general, HCPCS codes that are nonspecific (such as 20999, "unlisted procedure, musculoskeletal system, general") were assigned to the lowest paying APC that was consistent with the clinical characteristics of the service. In the case of 20999, the codes to which it is related are in the range 20000-20979. The APCs to which they group range from 0004, with a payment rate of $\$ 89.22$, to 0050 , with a payment rate of $\$ 1,024.53$. We placed 20999 in the lowest paying, related group, 0004.
c. Effect of the BBRA 1999 on Final APC Groups

Section 201(g) of the BBRA 1999 amends section 1833(t)(2) of the Act to limit the variation in resource use among the procedures or services within an APC group. Specifically, section $1833(\mathrm{t})(2)$ of the Act now provides that the items and services within a group cannot be considered comparable with respect to the use of resources if the highest cost item or service within a group is more than 2 times greater than the lowest cost item or service within
the same group. The Secretary is to use either the mean or median cost of the item or service. We are using the median cost because we have continued to set the relative payment weights for each APC based on median hospital costs in this final rule. (See the discussion in section III.E of this preamble.)

Section 1833(t)(2) of the Act as amended also allows the Secretary to make exceptions to this limit on the variation of costs within each group in unusual cases such as low volume items and services, although we may not make such an exception in the case of a drug or biological that has been designated as an orphan drug under section 526 of the Federal Food, Drug, and Cosmetic Act. See the discussion of the classification of orphan drugs in section II.D of this preamble and the discussion of APC groups that we excepted from the " 2 times" limit in section III.C.6.e.

We applied the limit on variation on median costs required by section 201(g) to the revised APC groups. (See section C.6.d, below.) As a result of our analysis of the array of median costs within the revised APC groups, we had to split some otherwise clinically homogeneous APC groups into smaller groups. We are concerned that this further subdivision of groups may create vulnerabilities for upcoding, which conflicts with one of the five criteria described above that we used to evaluate the construction of the APC groups. We will be examining the extent to which the APC reorganization due to the " 2 times" rule results in upcoding.

## d. Summary of APC Modifications

In this section, we summarize and explain our response to comments on individual or serial APCs. We use the APC number that appeared in the proposed rule to identify a group that was changed. In most instances, we moved a HCPCS code from its proposed APC group to a different APC group either in response to comments or to comply with section $1833(\mathrm{t})(2)(\mathrm{C})$ of the Act. In some cases, we moved codes when a change in response to a comment or the cost variation limit resulted in a grouping that seriously compromised one of the criteria we used to evaluate changes recommended by commenters. Because we made so many changes in the APC groups, we renumbered all the groups and, in many cases, renamed groups. In our response to comments in connection with an APC, the final designation for a HCPCS code corresponds to the renumbered APC group found in the addenda.

APC 121: Level I Needle Biopsy/ Aspiration

Comment: One specialty society commented that there was significant variation in resource consumption for the procedures performed in this APC and that the proposed payment rate of $\$ 33.95$ for APC 121 does not accurately reflect the preparation, examination, and consultation expenses for a pathologist to thoroughly perform these procedures. The commenter recommended including CPT codes 85095, 85102, 88170, and 88171 in proposed APC 122.
Response: The procedures we proposed to classify in APC 121 were considered sufficiently similar from a clinical perspective. We found no provider concentration associated with the procedures proposed for this APC. Therefore, any variation in cost across the procedures in this APC should average out at the hospital level. However, to be consistent with the BBRA 1999 "two times" provision concerning comparable resources, we have moved CPT codes 85095 and 85102 to final APC 0003, and CPT codes 88170 and 88171 remain in final APC 0002.

APC 122: Level II Needle Biopsy/ Aspiration

Comment: A number of commenters indicated that there was significant variation in resource consumption for the procedures proposed in this APC group. For example, one commenter stated that although all the codes within this group are needle biopsies, they range dramatically in complexity, they are quite dissimilar in terms of resource use, they are not clinically similar, and the proposed grouping results in inappropriate payment for the more complex procedures.
Response: We decided that CPT code 67415, Fine needle aspiration of orbital contents, was more appropriately grouped from a clinical perspective with ophthalmic procedures in final APC 0239. We further divided the codes in proposed APC groups 121 and 122 for needle biopsy/aspiration into final APC groups 0002, 0003, 0004, and 0005 to be consistent with the BBRA 1999 "two times" requirement.

## APC 131: Level I incision \& drainage

Although we received no comments on proposed APC group 131, based on internal review of this APC, we moved CPT code 11976, Removal, implantable contraceptive capsules, to final APC 019 because this procedure represents an excision rather than an incision. We divided proposed APC 131 into final

APC groups 0006, 0007, and 0008 to be consistent with the BBRA 1999 "two times" requirement.
APC 141: Level I Destruction of lesion APC 142: Level II Destruction of lesion

Comment: One commenter questioned our proposed assignment of CPT codes 17106 through 17108, which describe destruction of cutaneous vascular proliferative lesions, to APC groups 141 and 142.
Response: We moved CPT code 17106 to final APC 0011 because its median cost is significantly higher than the other codes in 0010. However, the median cost for that code is greater than we would have expected it to be. We will review the appropriateness of this placement in the course of future updates of the APC groups.

## APC 151: Level I debridement/

 destructionAPC 152: Level II debridement/ destruction

Comment: We received general comments questioning the resource homogeneity of the proposed skin APC groups. One commenter recommended including removal of skin lesion with laser on other body parts in proposed APC 152 rather than restricting the APC to vulva, anus, and penis procedures. The commenter believes that removal of these benign lesions, including papillomas, should include other areas of the body.
Response: We agree with commenters' general concerns about resource homogeneity. We reclassified the codes in proposed APCs 151 and 152 into final APC groups 00012 through 00017 to better differentiate resource use and clinical characteristics and to be consistent with the "two times" BBRA 1999 requirement. We also moved CPT code 42809, Removal of foreign body from pharynx, to final APC 251 because it is an otorhinolaryngology (Ear/Nose/ Throat (ENT)) procedure.

## APC 161: Level I excision/biopsy

APC 162: Level II excision/biopsy
APC 163: Level III excision/biopsy
Comment: Numerous commenters were concerned about the variation of resource use among the procedures in proposed APC groups 161, 162, and 163. Commenters requested that we consider classifying procedures in these groups based on anatomic location where functionality is of high importance in combination with the size of excision.
Response: We made a number of modifications to the excision APC groups to satisfy the BBRA 1999 "two
times" requirement, resulting in final APC groups 0018 through 0022. We reclassified CPT codes 11043 and 11044 to APC groups 0016 and 0017 because these codes describe debridement of skin, subcutaneous tissue, muscle, and bone.

In the final excision/biopsy APC groups, we endeavored to make distinctions based on the location and size of the excision. For example, excisions of malignant lesions from the face, ears, eyelids, nose, lips greater than 4 cm were placed in an APC requiring more resource use than excisions of malignant lesions from the trunk, arms or legs greater than 4 cm because "functionality" is of greater importance when the site is the face, ears, eyelids, nose, or lips. We moved excisions involving the eye to ophthalmic procedure APCs. We did not make grouping distinctions between benign and malignant lesions of the same size and location because resource use for both types is similar.

We moved benign and malignant excisions larger than 2 cm to final APC group 0020 because these excisions require more resources than, for example, excisions smaller than 1 cm .

We moved CPT code 20220, superficial biopsy of bone (e.g., ilium, sternum, spinous process, ribs) with trocar or needle, to final APC 0019, because the resources used in connection with this procedure are similar to those required for excisions of small benign or malignant lesions.

As noted above, we classified two debridement procedures (CPT codes 11043 and 11044) to final APC groups 0016 and 0017, respectively.

We also moved seven codes from proposed APC 162 to the ophthalmic APC groups.
APC 181: Level I skin repair
APC 182: Level II skin repair
APC 183: Level III skin repair APC 184: Level IV skin repair

Comment: We received numerous comments expressing concern about the consistency of resource use and clinical homogeneity of the procedures in the four proposed skin repair APC groups. Many commenters recommended moving more complex procedures, such as large layer closures, to an APC with a higher payment rate because the procedures require more operating room and recovery time. Some commenters recommended moving some of the skin repair codes to other body systems.

Response: Our review of proposed APC groups 181, 182, 183, and 184 resulted in our regrouping the skin repair codes based more on cost than on
clinical considerations. The volume of claims in most of the codes, however, is quite low. In addition, we moved CPT code 33222, Revision or relocation of skin pocket for pacemaker, from proposed APC 360 to final APC 0026, because this procedure is so similar to the other skin repair procedures in terms of clinical content and resource consumption. We will review these groups carefully as data become available.
APC 197: Incision/excision breast
APC 198: Breast reconstruction/ mastectomy

Comment: One commenter observed that the procedures in proposed APC group 198 are related both to the definitive treatment of breast cancer and to plastic and reconstructive operations of the breast. The commenter recommended moving CPT code 19162, Mastectomy, partial with axillary lymphadenectomy, and CPT code 19182, Mastectomy, subcutaneous, into an APC group with a higher payment rate because both procedures are more complex and involve more time and resources than the other procedures in proposed APC group 198. Another commenter stated that CPT code 19162, and CPT code 19318, Reduction mammoplasty, require significantly longer operating times than the other procedures in proposed APC group 198. The same commenter further observed that CPT code 19162 essentially involves performing two procedures.

Response: Our medical advisors and staff carefully reviewed the comments submitted in connection with the procedures in proposed APC group 198 within the context of the criteria that we discuss at the beginning of this section. They concluded that, although reduction mammoplasty (CPT code 19318) could require slightly more resources, a reduction mammoplasty is still fundamentally similar to other procedures in proposed APC 198 such as CPT code 19162, Partial mastectomy with axillary lymphadenectomy. Our medical advisors and staff concluded that the procedures in proposed APC groups 197 and 198 were sufficiently similar clinically and in terms of resource use to retain the proposed groupings. Therefore, we are retaining our proposed grouping in final APC groups 0029 and 0030.
APC 207: Closed treatment fracture finger/toe/trunk

Although we did not receive comments about this APC group, our medical advisors and staff determined that treatment of closed fractures
pertaining to the larynx should be moved to the ENT APC groups because they are more similar from a clinical and resource use perspective to ENT procedures. The larynx procedures do not involve casts and, more importantly, they require completely different resources and ancillary personnel than, for example, the setting of a finger fracture. Proposed APC 207 is renumbered final APC 0043.

APC 209: Closed treatment fracture/ dislocation except finger/toe/trunk

Comment: One commenter objected to including multiple procedures for dislocation and fractures in proposed APC group 209, when the cost of drugs and supplies alone for these procedures probably exceeds $\$ 100$. The commenter believed that the proposed payment rate for APC 209 was \$71.00.
Response: We note that the proposed payment for APC 209 was $\$ 98.75$, rather than $\$ 71.00$, as the commenter quoted. Although we included in proposed APC 209 some procedures that could involve considerable time and resources, only the simplest cases of these potentially more complex procedures would be performed on an outpatient basis, with proportionally lower costs than would be incurred when the procedures are performed in an inpatient setting. Therefore, we retained in final APC 0044 the codes in proposed APC 209, except we moved CPT code 31586, Treatment of closed laryngeal fracture, to final APC 0256, because this is primarily an ENT procedure.
APC 216: Open/percutaneous treatment fracture or dislocation
Comment: Numerous commenters took issue with the variation in resource use among the procedures that include the open treatment of almost all bone fractures, ranging from relatively simple finger and toe fractures to major long bone fractures.
Response: We expect that only the simplest of the procedures proposed in APC group 216 would be performed on an outpatient basis. Therefore, we kept open/percutaneous treatment of fractures in one APC rather than splitting these procedures into multiple APCs. We find it unlikely that one provider would specialize in, for example, only open fractures of fingers or only open fractures of long bones. Because the CPT code descriptors for so many procedures in this APC group indicate "with and/or without internal fixation," it is impossible to make distinctions based on whether or not internal fixation is applied. Proposed APC 216 is renumbered final APC 0046.

APC 226: Maxillofacial prostheses
APC 231: Level I skull and facial bone procedures
APC 232: Level II skull and facial bone procedures

Although we did not receive specific recommendations for these APCs, our medical advisors and staff determined that the procedures in these groups are more similar to ENT procedures from a clinical and resource use perspective. Therefore, we moved all of the procedures in these proposed APC groups to the final APCs 0251 through 0256, the ENT APCs.
APC 251: Level I Musculoskeletal Procedures

APC 252: Level II Musculoskeletal Procedures

Comment: One commenter expressed concerns about the clinical homogeneity of the codes in these two groups. The commenter stated that proposed APC 251 contains 77 widely disparate procedures, including CPT code 23100 and CPT code 24100, which describe arthrotomies with biopsies, CPT code 25248, Exploration with removal of deep foreign body, forearm or wrist, and CPT code 27704, Removal of ankle implant. The commenter further stated that proposed APC 252 contains equally diverse procedures ranging from: CPT code 20900, Bone graft, any donor area; minor or small, to CPT code 25251, Removal of wrist prosthesis; complicated, including "total wrist," to CPT codes 27396, 27580, and 27665, which are different types of tendon procedures. The commenter recommended that procedures that require specialized equipment and more operating room time be moved into a group with a higher payment rate.

Response: Our medical advisors and staff, after careful consideration of the commenter's concerns and after reviewing alternative groupings of the numerous codes in these two proposed musculoskeletal APC groups, concluded that splitting these groups to address the disparities cited by the commenter would result in too many small, lowvolume groups for which we would be unable to establish reliable payment rates. The broad inclusiveness of these two APC groups is in part a reflection of the magnitude of the musculoskeletal system. Given the homogeneity of resource use across the many procedures within each group, we concluded that the factors supporting retention of the two groups outweighed the concerns raised by the commenter. We did, however, move CPT code 27086, Removal of foreign body, pelvis
or hip; subcutaneous tissue, to final APC 0019.

## APC 280: Diagnostic Arthroscopy

APC 281: Level I Surgical Arthroscopy APC 282: Level II Surgical Arthroscopy

Comment: A number of commenters expressed concerns about the homogeneity of codes in the proposed surgical arthroscopy APC groups. In particular, commenters stated that while an arthroscope is needed for all the procedures assigned to proposed APC group 281, the nature of the repair may mandate different additional equipment and differing times to complete. Commenters did not find the procedures in proposed APC 281 to be homogeneous with respect to the time required to perform the procedures nor their associated costs. Commenters specifically recommended transferring complex elbow and wrist procedures represented by CPT codes 29826, 29838, 29839, 29846, 29847, 29848, 29861, 29862, and 29863 into an APC group with a higher payment rate.

Response: Upon revisiting the assignment of codes to proposed APC groups 280, 281, and 282, and considering the concerns expressed by commenters, our medical advisors and staff concluded that collapsing the three proposed APC groups into a single group would result in a more homogeneous grouping in terms of resource use. Hence, final APC 0041 contains the codes proposed as APC groups 280, 281, and 282. The relatively low volume of many of the procedures in the proposed APCs supports combining them into a single group. Further, we found that, from a facility perspective, the resource use for all the codes in final APC 0041 is similar. For example, we had proposed to place CPT code 29881, Arthroscopy, knee, surgical; with meniscectomy (medial or lateral, including any meniscal shaving), and CPT code 29882, Arthroscopy, knee, surgical; with meniscus repair (medial or lateral), in two different APC groups. However, the resources required for these two procedures is sufficiently comparable to warrant placing both into the same APC.

APC 286: Arthroscopically-Aided Procedures

We considered including the procedures in proposed APC group 286 with the other arthroscopic procedures in final APC 0041 because they are so infrequently performed in an outpatient setting for Medicare beneficiaries. However, the resources required to perform the procedures in proposed

APC 286 are so strikingly distinct from those used in connection with the procedures in final APC group 0041 as to warrant being retained in a separate group. Further, it is unlikely that an individual provider specializes in the particular type of arthroscopic procedure contained in this APC, so separating all of the codes in final APC 042 from those in APC 041 should not disadvantage any one hospital.

## APC 311: Level I ENT Procedures

## APC 312: Level II ENT Procedures

APC 313: Level III ENT Procedures
APC 314: Level IV ENT Procedures
We received numerous comments about the composition of the four proposed ENT APC groups. After careful review of the comments, our medical advisors and staff recognized the need for a major reorganization of the groups we proposed for ENT procedures. The outcome of our review was the creation of five final APC groups for ENT procedures: APC groups 0251, 0252, 0253, 0254, and 0256. We moved a large number of bone procedures involving the facial and ENT areas from musculoskeletal groups to ENT groups. We transferred some codes out of the ENT groups altogether, and we shifted codes among the five final ENT groups to comply with the BBRA 1999 "two times" requirement. We respond to recommendations regarding specific codes below.

Comment: One commenter observed that CPT codes 31603 and 31605, emergency tracheostomy procedures, are risky and life-threatening no matter how quickly they are performed, and, as such, they should not be grouped with procedures for removing a foreign body from the ear canal or removing cerumen (proposed APC 311).
Response: We agree. We created new APC group 0340 to which we assigned CPT code 69200, removal of foreign body from external auditory canal; without general anesthesia, and CPT code 69210, Removal impacted cerumen (separate procedure), one or both ears. We shifted these two procedures to the Minor Ancillary Procedures APC group because of their relative high frequency, their low cost in terms of resource use with low disposable equipment cost, and because these procedures generally do not require scheduling. Removing CPT code 69210 from the final ENT groups also corrects any pricing distortions that may have resulted from the disproportionately high volume of that procedure.

We also moved the tracheostomy emergency procedures to final APC 0254.

We moved several other procedures such as CPT code 41870, Periodontal mucosal grafting, to final APC 0253, a group with higher cost procedures.

We moved several abscess drainage procedures such as CPT code 41800, Drainage of abscess, cyst, hematoma from dentoalveolar structures, to final APC group 0251 because of their relatively low cost.

Comment: One commenter stated that all the procedures in proposed APC 312 appear to be reasonably priced with the exception of CPT code 69436, Tympanostomy (requiring insertion of ventilating tube), general anesthesia. In the view of the commenter, the extra supplies and time required for this procedure necessitate a higher payment.

Response: We moved CPT code 69433, Tympanostomy (requiring insertion of ventilating tube, local or topical anesthesia), to final APC 0252 because of its lower resource use relative to CPT code 69436. CPT code 69436 is assigned to final APC 0253.

We moved a large number of procedures such as CPT code 42335, Sialolithotomy; submandibular (submaxillary), complicated, intraoral from original APC 313 to final APC 0253 to reflect a similarity of resource use. In terms of resource use, CPT code 30115, Excision, nasal polyp(s), extensive, is more similar to CPT code 42300, Drainage of abscess, parotid, simple, than it is to CPT 42410, Excision of parotid tumor or parotid gland; lateral lobe without nerve dissection.

We shifted CPT code 21040, Excision of benign cyst or tumor of mandible, from the musculoskeletal group to final APC 0253 with other ENT procedures.

Comment: One commenter stated that procedures directed towards cancer treatment were inappropriately assigned to proposed APC 313. As examples, the commenter cited CPT codes 30150 and 30160, rhinectomy procedures; СРT code 41120, Glossectomy; less than onehalf tongue; and CPT code 69210, Excision external ear, complete amputation. The commenter also indicated concern that proposed APC group 313 includes a disproportionately large percentage of resource-consuming ENT procedures and commonly performed sinus procedures. Other commenters recommended that more complex otorhinolaryngology procedures in the group that have longer operating and recovery room times be moved to a group with a higher payment rate.

Response: We moved CPT code 69210 to final APC group 0340, and we assigned CPT codes 30150, 30160, and 41120 to final APC group 0256. We also moved CPT code 42215, Palatoplasty for
cleft palate; major revision to final APC group 0256.

Comment: One commenter suggested placing certain thyroid procedures in the ENT groups.

Response: While we agree that CPT code 60280, Thyroglossal cyst excisions, is somewhat similar to CPT code 42440, Excision of submandibular, submaxillary gland, we nonetheless believe that the former type of excision is more appropriately placed from a clinical perspective with other thyroid procedures.

## APC 318: Nasal Cauterization/Packing

Comment: A number of commenters addressed generally the range of resource use among the procedures within this proposed APC. One commenter observed that CPT code 30901 is almost always a simple office procedure within the context of an otolaryngology practice. The same commenter indicated that CPT codes 30903, 30905, and 30906 frequently require several hours of direct physician contact and monitoring and recommended that we consider reclassifying CPT codes 30903, 30905, and 30906 to proposed APC group 332, Level II Endoscopy Upper Airway. Another commenter was concerned that CPT codes 30905 and 30906 stand out as inappropriate for this APC level because they require much more time and expertise and are used in more lifethreatening situations than the other codes in the group.
Response: While there is a range of procedures in this APC pertaining to control of nasal hemorrhage, hospitals normally treat the entire range of these procedures, and there is no concentration of certain of these procedures in a subset of hospitals. Our medical advisors and staff also found that there can be a range of resource consumption within many of the procedures themselves as well as across procedures in this APC. We therefore are not reassigning the codes.
We did, however, move CPT codes 30999 and 42999 for unlisted procedures to final APC 0251 and 0252, respectively, to be consistent with our policy of placing unlisted codes in the lowest paid related group.

## APC 331: Level I Endoscopy Upper Airway

Comment: One commenter noted that the relative weight and payment rate proposed for APC group 331 approximated the relative weight and payment rate proposed for APC groups 997 or 987. The commenter stated that CPT codes 31575 and 31579 should have a higher relative weight and
payment rate than that proposed for APC 331 because both procedures require more time, higher skill levels, and more equipment than the procedures in APC 997 or 987. A professional association, echoing the first commenter, noted that CPT codes 31575 and 31579 are the most complex of all noninvasive laryngeal diagnostic procedures performed by otolaryngologists and speech language pathologists, further justifying a higher relative weight and payment rate for these procedures.
Response: Proposed APC groups 997 and 987, Manipulation therapy and Subcutaneous chemotherapy, respectively, are clinically very different from proposed APC group 331. The professional skill and expertise of the physician performing the laryngoscopy are recognized separately and are not costs that are packaged with the payment rate for services furnished by the hospital in connection with the procedure. Further, it is very unlikely that there will be systematic differences among facilities with some only doing the most difficult of the basic
laryngoscopies that are contained in this group and others only specializing in the simplest variety. However, we have reorganized the proposed endoscopy, upper airway groups into final APC groups 0071 through 0075 to be consistent with the BBRA 1999 "two times" requirement.

APC 341: Level I Needle and Catheter Placement
APC 342: Level II Needle and Catheter Placement
APC 343: Level III Needle and Catheter Placement
APC 347: Injection Procedures for Interventional Radiology

Based on our cost data, our medical advisors and staff determined that the codes in these proposed APC groups should be assigned status indicator " N ," which designates incidental services whose costs are packaged into the APC payment rate. Injection procedures themselves are low cost but, more importantly, they are an integral portion of another procedure. The needle and catheter placement are typically an integral portion of interventional radiology procedures. An exception was made for CPT code 36420, cutdown on a child under age one, which was placed in final APC 0032, to recognize its infrequent use but high median cost.

APC 360: Removal/Revision,
Pacemaker/Vascular Device
Comment: Most commenters recommended changing a number of
pacemaker codes from "inpatient only" payment status to allow payment under the hospital outpatient PPS. One commenter noted that whereas we proposed to exclude most pacemaker and implantable cardioverter defibrillator (ICD) replacement procedures from the outpatient PPS, we did include pacemaker revision/removal procedures in proposed APC 360 even though both types of procedures require very similar steps to perform. The commenter is concerned that by not paying for pacemaker replacement procedures under the outpatient PPS, we are forcing physicians to perform these replacement procedures on an inpatient basis. By so doing, the commenter suggested that we are adding costs to the entire system that could be saved, because the pacemaker replacement procedures can be safely performed in the outpatient setting, with less inconvenience to the patient.

Response: After careful consideration of commenters' recommendations, our medical advisors and staff agreed that paying for pacemaker insertion or replacement codes under the outpatient PPS is appropriate if the outpatient setting is determined to be reasonable and medically necessary for the individual beneficiary. We assigned procedures for revising or removing implanted infusion pumps and venous access ports in proposed APC 360 and pacemaker insertion or replacement codes payable under the outpatient PPS to final APCs 0089 and 0090. Also, we moved CPT code 33222, Revision or relocation of skin pocket for pacemaker, and CPT code 33223, Revision or relocation of skin pocket for implantable cardioverter-defibrillator, to final APC 0026 because the resource use for these two procedures is similar to that of the skin repair procedures in APC 0027.

## APC 367: Vascular Ligation

Comment: One commenter wrote that the procedures in proposed APC 367 include ligation of major arteries and veins, which are usually performed as emergencies in the inpatient setting, and elective ligation and stripping of lower extremity varicose veins of variable complexity. The commenter contended that costs for these procedures vary dramatically, with simple ligation and division of the saphenous vein at the low end of the cost scale, and the stripping of long and saphenous veins at the high end.

Response: We split proposed APC 367 into two groups, final APCs 0091 and 0092, to conform with the BBRA 1999 "two times" requirement. Although we are not sure to which codes the comment refers, codes 37780 and 37730
are now in different groups. These represent ligation and division of the short saphenous vein, and ligation, division and stripping of long and short saphenous veins, respectively.
APC 368: Vascular Repair/Fistula Construction

Comment: Commenters disagreed with the codes assigned to proposed APC 368, especially services related to insertion of implantable hemodialysis access ports. Commenters did not find the services in APC 368 to be comparable clinically. In particular, they recommended moving cannula insertion and declotting procedures to proposed APC groups 341, 342, and 343, which consist of needle and catheter placement procedures.

Response: We split the codes in proposed APC 368 into APC groups 0088, 0090, 0092, and 0093. The resulting classifications are more clinically homogeneous, and they meet the BBRA 1999 "two times" requirement. We also moved CPT code 35875, Thrombectomy of arterial or venous graft (other than hemodialysis graft or fistula), into final APC 0088.
APC 369: Blood and Blood Product Exchange

Comments: As we noted in section III.C.2.f, above, many commenters disagreed with both our proposed payment rates and our proposed classification for blood and bloodrelated products. Most commenters disagreed with our classifying in one APC group therapeutic apheresis, stem cell procedures, and blood transfusion services. The commenters stated that therapeutic apheresis and stem cell procedures are very costly and resource intensive procedures which cost more than 3 times the proposed payment rate for APC 369, yet we are proposing to pay a median amount for these services that is appropriate for blood transfusions only. Commenters questioned whether we had taken into account the costs associated with the specialized equipment, supplies and personnel that are required to perform therapeutic apheresis and stem cell procedures. Commenters stated that the payment rate proposed for APC 369 would not offset the costs hospitals incur to furnish therapeutic apheresis services because outpatient apheresis procedures often combine dissimilar kinds and combinations of plasma replacement products, causing widely differing costs per service.
A major association representing community cancer centers stated that our data for stem cell harvesting claims (CPT 38231) include a range of costs so
large as to suggest that there are errors in the data. The commenter believes that the very small sample of claims (reduced by HCFA's exclusion of multiple procedure claims and claims without codes) further renders the data unreliable. The same commenter cited bone marrow harvesting (CPT 38230) as an example to argue that our data, which indicates a median cost of $\$ 18.00$ for what is normally a lengthy procedure performed under general anesthesia, are problematic.

Some commenters stated that the proposed payment rate was not sufficient for transfusion services if the rate was supposed to pay for both the blood product and the transfusion procedure, because even though outpatient transfusion services are relatively simple and low-cost, they are associated with a costly blood product that is far more variable.

Commenters expressed concern that the proposed payment rate for APC 369 was insufficient to pay for extracorporeal photopheresis (CPT 36522), whose actual cost is approximately $\$ 1,000$, and would have an especially negative impact for patients with cutaneous T-cell lymphoma.

A major organization recommended that we separate payment for a service from payment for the blood product associated with that service. The same commenter also recommends separate payment for infusible blood-derived drugs, and that payment for transfusable blood products be based on costs. This organization recommends that APC 369 be split into several APCs because payment for services such as transfusion services, therapeutic apheresis, stem cell collection, Staph column pheresis, and others are distinct, and deserve separate APC payments. The same commenter also recommended that we accelerate the HCPCS coding process for blood-related products.

Response: In response to commenters' recommendations, we are creating different APC groups for blood-related procedures and transfusions, and we are paying for blood and blood products separately, instead of packaging them with the procedures or services with which they are associated. We were convinced by commenters' illustrations of the variability in the use of blood and blood products in various procedures, and by our desire to recognize the costs of tests now being performed on
donated blood that were not captured in our 1996 data. The procedures we proposed in APC 369 are split among final APC groups 0109, 0110, 0111, and 0112. We have also created individual APC groups for blood and blood related
products. The final APC 0109 that we created to capture bone marrow harvesting and bone marrow/stem cell transplant had a median cost of only $\$ 15.00$. This is due to the few, highly variable claims in our database. Based on the information available to us at this time, we have assigned a rate of $\$ 200.00$, and will adjust the rate to reflect actual claims as we collect data under PPS.
APC 407: Esophagoscopy
APC 417: Diagnostic Upper GI Endoscopy
APC 418: Therapeutic Upper GI Endoscopy

Comment: Commenters were concerned about low payment rates set for these three proposed APC groups.

Response: Our medical advisors reviewed the proposed groups and determined that combining the codes into a single APC group for upper gastrointestinal endoscopic procedures conformed with the criteria we used to define APC coherence and resulted in a reasonable payment rate supported by cost data. Resource use for all procedures in final APC 0141 is similar because each procedure involves an endoscopic examination. In addition, most of the procedures involve diagnostic and therapeutic tests such as brushings or fulgurations.
APC 426: Diagnostic Lower GI Endoscopy

## APC 427: Therapeutic Lower GI Endoscopy

Comment: Commenters were concerned that the payment rates proposed for APC groups 426 and 427 were too low to offset costs incurred to perform these procedures. One commenter indicated that a diagnostic colonoscopy (CPT code 45379), without any mark up or consideration of room time and equipment use, costs $\$ 350$, with additional costs if a polyp has to be removed ( $\$ 155$ just for a bicap). The commenter indicated that the current cost of a hot biopsy forceps is $\$ 45$. Given these costs, the provider would necessarily incur a loss when performing these procedures.

Response: Our medical advisors and staff, after reviewing the cost data for these two proposed groups, combined the diagnostic and therapeutic APCs into a single group, final APC 0143. Resource use for the procedures in this APC is similar because they all involve an endoscopic examination. More importantly, even though resource use may vary relative to the clinical requirements of individual cases, facilities are not likely to specialize in
just therapeutic or diagnostic endoscopic services. Therefore, costs should even out across all cases.

Comment: One commenter found the low rate proposed for CPT code 45378, Diagnostic colonoscopy, to be inconsistent with our major policy initiative to screen persons at high risk for colorectal cancer.

Response: We moved HCPCS code G0105, Colorectal Cancer Screening: Colonoscopy,to its own group, final APC 0158, because it is preventive rather than diagnostic or therapeutic in nature.
APC 446: Diagnostic Sigmoidoscopy
APC 447: Therapeutic
Proctosigmoidoscopy
APC 448: Therapeutic Flexible Sigmoidoscopy

We reassigned the different types of sigmoidoscopy procedures into two groups, final APC 0146 and final APC 0147. The procedures within each group are similar both clinically and in terms of resource use. We moved HCPCS code G0104, CA screening; flexible sigmoidoscopy, to its own group, final APC 0159, because it is preventive rather than diagnostic or therapeutic in nature.

APC 451: Level I Anal/Rectal Procedures
APC 452: Level II Anal/Rectal Procedures

To conform with the BBRA 1999 "two times" requirement, our medical advisors and staff reclassified procedures in the proposed APC groups resulting in final APC groups 0148 and 0149. We believe the final APC groups are more consistent both clinically and in terms of resource use.

## APC 470: Tube Procedures

Comments: We split the codes in proposed APC group 470 into final APC groups 0121, 0122, and 0123 to conform with the BBRA 1999 "two times" requirement. Also, we moved CPT code 50398, Change of nephrostomy or pyelostomy tube, from proposed APC 521 to final APC 0122.
APC 523: Level III Cystourethroscopy and Other Genitourinary Procedures

Comment: A number of commenters recommended moving CPT code 52240, Cystourethroscopy, with fulguration (including cryosurgery or laser surgery) and/or resection of; large bladder tumor(s), to the APC for Level IV Cystourethroscopy and other Genitourinary Procedures because the magnitude of the procedure most
closely resembles that of the codes in the higher payment group.
Response: We agree with commenters' recommendations; we moved CPT code 52240 to final APC group 0163 because of the extensive time and equipment required to perform the procedure.

Comment: One commenter
recommended placing CPT codes 52335 through 52338 in their own group, given the complexity and technical demands of these ureteroscopic procedures. The same commenter suggested as an acceptable alternative placing these codes in the APC group for Level IV Cystourethroscopy and other Genitourinary Procedures, to reflect more accurately their cost, complexity, and need for expensive single use items such as dilation balloons, baskets and stents. Other commenters recommended moving CPT codes 51020 through 51880 (cystotomy procedures) to the APC group for Level IV Cystourethroscopy and other Genitourinary Procedures.
Response: After a careful review of comments and our cost data, our medical advisors and staff concluded that the cystotomy codes are similar enough in terms of equipment and the time required to perform the procedures to justify keeping them together in final APC 162. Our medical advisors and staff also concluded that the facility equipment and time duration for CPT code 52335, Cystourethroscopy, with ureteroscopy and/or pyeloscopy (includes dilation of the ureter and/or pyeloureteral junction by any method), was sufficiently similar to be retained with the other procedures in final APC 0162.

APC 524: Level IV Cystourethroscopy and other Genitourinary Procedures
Comment: Numerous commenters were concerned that the payment rate proposed for APC 524 was insufficient to offset the costs associated with CPT code 53850, Transurethral destruction of prostate tissue, by microwave thermotherapy (TUMT). The commenters argue that TUMT is a very expensive procedure due to its high capital equipment costs and the need to construct a special microwave area, the high cost of disposable probes and other disposable supplies required for the procedure, and the need for specially trained nursing staff. The commenters urged us to establish a unique APC group for this procedure and to provide a payment rate that is consistent with its anticipated costs, which they predict would total approximately $\$ 2,200$.
Response: After careful consideration of comments and available cost data, our medical advisors and staff determined that CPT code 53850
satisfies the criteria discussed below, in section III.C.8, as a new technology service. Payment for this procedure will be made under new technology APC 0980.

APC 529: Simple Urinary Studies and
Procedures Procedures

Comment: A number of commenters proposed that we classify CPT code 51726, Complex cystometrogram, to its own unique APC and keep the other urinary study procedures together in proposed APC 529.

Response: After a careful review of comments and our data, our medical advisors and staff agreed with commenters' concerns and subdivided proposed APC group 529. The resulting final APC groups 0164 and 0165 are more homogeneous both in terms of clinical coherence and resource use. We also added simple anal procedures such as CPT code 91122, Anorectal manometry, to final APC 0165 because of the similarity of resource use.
APC 546: Testes/Epididymis Procedures
Comment: A number of commenters disagreed with our classification of scrotal procedures with inguinal procedures in proposed APC group 546. The commenters observed that the scrotal procedures vary considerably from the inguinal procedures in terms of resource usage. The commenters recommended that we move CPT codes 54530, 54550, 54640, 55520, 55530, 55535 and 55540 to proposed APC 466, Hernia/Hydrocele Procedures, because they all involve operating on vessels at the internal ring, and are therefore similar to a hernia repair.

Response: We agree with comments that these procedures are similar to hernia repairs. We moved CPT codes 54530, 54550, 54640, 55535, and 55540 to final APC group 0154.

## APC 551: Level I Laparoscopy

APC 552: Level II Laparoscopy
Comment: We received two categories of comments pertaining to laparoscopic procedures: Numerous commenters disagreed with our proposal to define certain laparoscopic procedures as inpatient only, and numerous commenters claimed that the resource costs among the procedures within proposed APC groups 551 and 552 varied too greatly for the groups to be considered homogeneous. Most commenters stated that the costs associated with the procedures in proposed APC groups 551 and 552 exceed their respective proposed payment rates because of the expensive equipment and disposable supplies and
the length of time required to perform laparoscopic procedures.

Response: Our medical advisors and staff, after a thorough review and consideration of comments, agreed with commenters who claimed that most laparoscopic procedures can and are being safely and appropriately performed in an outpatient setting. We therefore moved most of the laparoscopic codes to which we proposed to assign a payment status indicator " C ," indicating that the procedures would not be covered under the hospital outpatient PPS, into an APC group with a payment status indicator "T" (significant procedure, multiple procedure reduction applies, payable under the outpatient PPS). In order to absorb these additional procedures within the APC system, we created a third laparoscopic APC group in order to accommodate the wide range of resource use and time that is required to perform the expanded list of laparoscopic procedures.

Although the AMA revised the coding of laparoscopic procedures in CPT 2000, in order to set rates for the laparoscopy APC groups, we used the codes that were in our database of 1996 claims. That is, we moved CPT codes 56362 and 56363 to the Level I laparoscopic group, final APC group 0130, because the resources used in connection with these procedures are less compared to the Level II procedures generally. For example, CPT code 56362, Laparoscopy with guided transhepatic cholangiography, primarily involves the laparoscopy without any associated removal of tissue. Conversely, we shifted CPT codes 56303 and 56304 from Level I to Level II (final APC 0131). CPT code 56303, Laparoscopy, surgical, with fulguration or excision of lesions of the ovary, pelvic viscera, or peritoneal surface, requires more resources than, for example, CPT code 56300, Diagnostic laparoscopy, the most common laparoscopic procedure within Level I, final APC group 0130.

The new Level III laparoscopy group, final APC group 0132, consists largely of laparoscopic procedures that we had proposed to classify as inpatient. In addition, we moved CPT code 56312, Laparoscopy, surgical; with bilateral total pelvic lymphadenectomy, and CPT code 56313, Laparoscopy, surgical; with bilateral total pelvic lymphadenectomy and peri-aortic lymph node sampling (biopsy), single or multiple, to final APC group 0132 because of the extensive resources and time involved in performing these procedures. Refer to Current Procedural Terminology 2000, published by the American Medical Association, for a summary of coding
changes and crosswalks for laparoscopic procedures.
APC 561: Level I Female Reproductive Procedures
APC 562: Level II Female Reproductive Procedures

APC 563: Level III Female Reproductive Procedures

Comment: One commenter expressed concern that the payment rate for proposed APC group 563 would have a negative effect on certain treatment options for women suffering with incontinence. The commenter contrasted the proposed payment of $\$ 848$ with a current median cost calculated at $\$ 1,931$ for CPT code 57288, Sling operation for stress incontinence (e.g., fascia or synthetic).
Response: After reviewing the procedures in proposed APCs 561, 562, and 563 , and to be consistent with the BBRA 1999 "two times" requirement, we split the proposed groups into final APCs 0191 through 0195. The cost of CPT code 57288, to which the commenter refers, is still at the high end of the highest weighted group, but the volume of claims for that service is so low that splitting the group again would be problematic. If these more intense surgeries move to the outpatient setting in greater numbers, we will be able to price them more precisely.
APC 601: Level I Nervous System Injections
APC 602: Level II Nervous System Injections
Comment: Commenters contended that there are no similarities among the procedures in the proposed APC groups for nervous system injections.
Response: We disagree. We find the range of services included within each APC group to be generally consistent from a clinical perspective. And, even though an injection into the subarachnoid space may be a more complex injection than some of the others in the group, no institution is likely to specialize solely in one kind of injection. Because all the services within the APC group are offered by most hospitals, the impact of the variation in resource consumption among the different codes should average out at the hospital level. Therefore, we are keeping intact in final APC groups 0211 and 0212 the two levels of nervous system injections that we proposed, with the exception of CPT codes 62194 and 62225, which we moved to final APC group 0121 because they are catheter replacement procedures.

APC 616: Implantation of Neurostimulator Electrodes
APC 617: Revision/Removal Neurological Device
APC 618: Implantation of Neurological Device

Comment: One commenter was concerned that the payment rate proposed for APC group 616 falls far short of the costs incurred to implant a neurostimulator system that embodies a vagus nerve stimulator for the treatment of patients with refractory epilepsy. The commenter estimated that hospitals incur costs between $\$ 2,000$ and $\$ 5,000$ to surgically insert the Neurocybernetic Prosthesis system (NCP), which includes an implantable neurostimulator, pulse generator, and implantable electrodes. The commenter stated that the NCP costs $\$ 9,100$. The commenter recommended that we create a separate APC group for the procedure to ensure appropriate payment. The commenter also expressed concern that the broad range of procedures in proposed APC 618 results in inappropriate payment rates. The commenter noted that the median cost of the procedures in proposed APC group 618 varies from a low of $\$ 269.44$ to a high of $\$ 3,890.70$, with a proposed payment rate of $\$ 1,274$.

Another commenter stated that vagus nerve stimulation, approved by the FDA in 1997, which can sometimes be performed as an outpatient procedure, would be inappropriately paid under our PPS. The commenter stated that the reported cost for the device is $\$ 6,900$ for the implantable neurostimulator pulse generator and $\$ 2,030$ for the implantable vagus nerve stimulator leads. A manufacturer of this new system, which is used in treating intractable epilepsy, also expressed concern that the proposed PPS will underpay hospitals for new technologies such as its system and deny beneficiaries access to them.

Response: In response to these and other comments, we made several changes in proposed APC groups 616, 617, and 618. We moved CPT code 63650, Percutaneous implantation of neurostimulator electrodes, peripheral, to final APC 0224 because the procedure is less time intensive and uses fewer facility resources than the implant procedures in final APC 0225. We also shifted CPT codes 64585 and 64595 to final APC 0225. We will re-evaluate APCs 0223, 0224, and 0225 as we accumulate data and will incorporate our findings in a subsequent hospital outpatient PPS rule. Additionally, we will determine whether the implantable neurostimulator system is eligible for
treatment as a "pass-through" device under section 201(b) of the BBRA 1999. The criteria for assessing a medical device's eligibility for additional payment under this provision are discussed in section III.D.4, below.
Ophthalmic Procedures: We received numerous comments concerning the APC groups proposed for eye procedures. Based on their analysis of these comments and recommended changes, a review of our data, and consideration of the limit on variation within a group required by section 201(g) of the BBRA 1999, our medical advisors and staff have significantly restructured the ophthalmic APC groups. Eye procedures and services are assigned to final APC groups 0230 through 0248.

## APC 930: Minor Eye Examinations

## APC 931: Level I Eye Tests

APC 932: Level II Eye Tests
We assigned to final APC groups 0230 and 0231 the procedures in proposed APC groups 930, 931, and 932 in addition to codes from proposed APC groups 681, 682, and 683 that are either tests or minor ophthalmologic procedures requiring relatively low resource use.

APC 651: Level I Anterior Segment Eye Procedure

APC 652: Level II Anterior Segment Procedure
Comment: We received a number of comments about these proposed APC groups. Commenters were primarily concerned that the payment rates proposed for the two levels of anterior segment eye procedures are significantly less than the costs incurred to perform the procedures assigned to these groups, especially those for glaucoma surgery (CPT codes 66150 through 66170). One commenter indicated that the rate proposed for CPT 66180 is acceptable only if separate payment is made for the aqueous shunt and patch graft.

Response: Based on their review of comments and to be consistent with the BBRA 1999 "two times" requirement, our medical advisors and staff added a third APC group for anterior segment eye procedures. The anterior segment eye procedures are assigned to final APC groups 0232, 0233, and 0234. We made a number of code changes among the three groups. We moved CPT codes 66155, 66160, 66165, and 66170 for glaucoma surgery to final APC group 0234. We shifted CPT code 65800, Paracentesis of anterior chamber of eye (separate procedure) with diagnostic aspiration of aqueous, from proposed APC 683 to final APC 0232 because the
instruments used in connection with CPT code 65800 are similar to those used in all procedures that are primarily paracentesis and because operating room time is likewise similar.
APC 667: Cataract Procedures
APC 668: Cataract Procedures With IOL Insert
Based on our data, the median cost for final APC group 0245 (cataract extraction without lens insert) was slightly higher than that for final APC group 0246 (cataract extraction with lens insertion). We attribute the discrepancy to poor coding, and we have increased the payment rate for APC group 0246 to equal the payment rate for APC group 0245. Proper coding in the future should result in better differentiated costs between these two groups.
Comment: One commenter objected to assigning payment status indicator "T," Significant procedure, multiple procedure reduction applies, to the procedures in proposed APC group 668. The commenter contended that CPT code 66984, Cataract removal with lens insertion, is often performed in conjunction with other procedures such as CPT code 67010, partial removal of eye fluid, CPT code 65875, incise inner eye adhesions, and 66170, Glaucoma surgery, which also have a " T " payment status indicator. The commenter believes that the multiple procedure reduction would undercompensate for these services and that all these procedures should be given an "S" payment status indicator, which would not subject them to the multiple procedure discount.

Response: We disagree. When more than one surgical procedure is performed during a single operative session, full Medicare payment and the full beneficiary coinsurance payment are made for the procedure that has the highest payment rate. The costs associated with anesthesia, operating and recovery room use, and other services for any additional procedures are incremental and are accounted for within the discounted additional payment.

## APC 670: Corneal Transplant

Comment: The numerous comments that we received about this proposed APC focused on our proposal to package the cost of procuring corneal tissue as part of the costs associated with corneal transplant surgery. Commenters feared that this fixed payment method would underpay some hospitals while overpaying others because hospitals acquire corneal tissue from eye banks
whose charges are dependent upon the amount of philanthropic contributions the bank receives during the course of a year. A national association representing eye banks reported that fee data from different member facilities show that the corneal tissue acquisition fee alone nearly consumes or, in some cases, exceeds, the entire payment rate proposed for APC group 670.
Commenters expressed great concern that we would significantly reduce the supply of corneas available for transplant if we were to package corneal tissue acquisition costs within the APC rate.

Response: Given the current basis for pricing corneal tissue, we are accepting commenters' recommendations that corneal tissue acquisition costs be paid separately and in addition to the payment rate for corneal transplant procedures. At least until we gather data regarding costs associated with the acquisition of corneal tissue, this will ensure that individual hospital's reasonable corneal tissue procurement costs are covered under the PPS. Corneal transplant procedures are in final APC group 0244.
APC 676: Posterior Segment Eye Procedures

Comment: Commenters were concerned that the payment rate for proposed APC group 676 was too low given the costs incurred to perform a number of procedures in the group. For example, one commenter noted that CPT code 67005 requires the same draping as a cataract extraction.

Response: In response to commenters’ concerns and to be consistent with the BBRA 1999 "two times" requirement, we split the procedures in proposed APC group 676 into final APC groups 0235 through 0237. We also moved procedures such as CPT code 67025, Replace eye fluid, and CPT code 67027, Implant eye drug system, to final APC 0237 because of the similarity of resource use. CPT code 67025 involves injection of a vitreous substitute, usually gas, silicone, or a similar substance, and the procedure may also involve an aspiration.
APC 681: Level I Eye Procedure
APC 682: Level II Eye Procedure
APC 683: Level III Eye Procedure
APC 684: Level IV Eye Procedure
Comment: Commenters were concerned about the wide variation of resource use and clinical characteristics among the procedures within proposed APC groups 681, 682, 683, and 684. Commenters noted that the surgical complexity of individual procedures in
proposed APC group 684 ranges from simple suturing (CPT code 67914, Repair of ectropion; suture) to complex eyelid reconstructions with full thickness tarsoconjunctival flap transfer (CPT code 67971). Commenters recommended that these proposed APC groups be revised and that the more complex procedures that require longer operating room time be paid a higher rate.

Response: We agree. Guided by commenters' recommendations as well as the "two times" limit on cost variation required by the BBRA 1999, we created several new groups and we completely reorganized the procedures in proposed APC groups 681, 682, 683, and 684 into the final APC groups 0230 through 0234 and 0238 through 0242.

## APC 690: Vitrectomy

Comment: Several commenters were concerned that the cost of an intravitreal implant ( $\$ 4,000$, according to one commenter) would not be adequately recognized if payment for the device were to be packaged with payment for the insertion procedure (CPT code 67027, Implant eye drug system). Commenters were concerned that beneficiary access to this implant would be restricted if we did not make adequate payment. Commenters supported our proposal to make separate payment for the intravitreal implant.

Response: We assigned all of the procedures in proposed APC 690 to final APC group 0237. As we explain in section III.B.1.c, above, section 201(e) of the BBRA 1999 requires us to classify implantable items to the group that includes the service to which the item relates. However, the intravitreal implant that dispenses ganciclovir is an orphan drug that qualifies for a transitional pass-through payment under the BBRA 1999, which is explained in section III.D, below. Thus, we have assigned the entire drug delivery system to its own APC, 0913. We believe that the payment rate set for CPT code 67027 combined with the additional payment for ganciclovir results in an appropriate payment for this service.

## APC 700: Plain Film

Comment: We received numerous comments about the structure of proposed APC group 700. Commenters recommended breaking down the proposed APC group into a number of smaller, more congruous groups. For example, one commenter found no justification for the assumption that resource costs are the same for all plain films listed in APC 700, noting that
there is a significant difference in capital costs, room costs, and maintenance costs between an x-ray room that is designed to take chest x rays compared to an x-ray room with a table used to take abdominal x-rays. The commenter pointed out that there is a substantial increase in cost when cineradiography capabilities are added. The same commenter questioned our assumption that therapeutic radiology port films are clinically similar to diagnostic radiology films or that bone density studies are clinically similar to and have the same resource costs as plain film radiography.

Response: We agree with commenters' concerns about the composition of proposed APC group 700. In response to commenters' recommendations and applying the "two times" limit on cost variation required by the BBRA 1999, we split proposed APC group 700 into final APC groups 0260 through 0262. We assigned CPT code 70300, Radiologic examination, teeth; single view; CPT code 70310, Radiologic examination, teeth; partial examination, less than full mouth; and, CPT code 70320, Radiologic examination, teeth; complete, full mouth, to their own group, final APC group 0262, because these procedures require minimal time and relatively little radiographic film and technical equipment. We classified the remaining codes to final APC groups 0260 and 0261 . We believe that these two groups are sufficient to distinguish clinical consistency and similar resource use. Facilities perform, relatively, a similar proportion of the different plain film procedures, and hospitals do not systematically use one type of plain film over another type, with the exception of dental films, which we moved to a separate group. The absolute magnitude of the difference in resource use among different plain films is not as significant as the difference between dental and other types of plain film. Additionally, our data indicate minimal differences in the amount of resource use between bone density measurement tests and plain films.
APC 706: Miscellaneous Radiological Procedures

Comment: A number of commenters found the tests grouped in proposed APC group 706 to vary significantly in the amount of time, effort, and costs required to provide the service.
Response: As a result of applying the "two times" limit on cost variation required by the BBRA 1999, we divided proposed APC 706 into two levels: final APC 0263 and final APC 0264. We also moved CPT code 76075, Bone Density

Study, one or more sites, to final APC 0261. We explain below, in section III.C.6.e, why we are making an exception to the BBRA 1999 "two times" limit on cost variation in the case of final APC group 264.
APC 710: Computerized Axial Tomography
APC 720: Magnetic Resonance Angiography
APC 726: Magnetic Resonance Imaging

## Comment: A number of commenters

 believe that assigning all computerized axial tomography (CAT) to a single group and all magnetic resonance imaging (MRI) to a single group results in a lack of homogeneity among the procedures within each group. These commenters were concerned that we ignored the cost of contrast materials, labor, and equipment within proposed APC group 710 and proposed APC group 726 and that combining contrast and non-contrast studies represents an inconsistency in resource use because an examination that uses contrast will be more costly than one without contrast. One commenter observed that an MRI examination with the use of contrast material requires approximately 30 percent more time and effort than an examination performed without contrast material and that a bilateral examination requires 50 percent more staff time and effort to complete. The same commenter expressed concern that proposed APC 720 consists of only one procedure, CPT code 70541, Magnetic image, head (MRA). The commenter recommended that we place this code and the other MRA codes that we now cover into two APC groups, one with and the other without contrast. A number of commenters recommended that we pay separately for contrast material, as a cost pass-through. One commenter believes that including diagnostic studies with placement of radiation therapy fields in proposed APC 710 violates the "clinically similar" criterion.Response: Our medical advisors and staff carefully reviewed our data for the procedures in proposed APC group 710, proposed APC group 720, and proposed APC group 726 in light of commenters' concerns about the extent to which these groups take into account the costs associated with the use of contrast material. We concluded that costs associated with the use of contrast material are reflected in the payment rate in proportion to its frequency of use. We believe it is reasonable to have the CAT scans and MRIs with and without contrast together in their respective APC groups because facilities do not specialize based on whether or
not they use contrast material. Further, the cost of contrast material relative to the overall inherent cost of CAT scans and MRI procedures alone is small. Moreover, the use of contrast material with CAT scans and MRI procedures differs significantly when compared to the use of contrast with plain films. Contrast comprises a significant portion of the cost of plain film services, and not all facilities perform plain films with contrast. A plain film can be ordered without being scheduled, but any plain film with contrast has to be scheduled. This scheduling distinction does not apply to a CAT or MRI scan with or without contrast. We did find that applying the "two times" limit on cost variation required by the BBRA 1999 resulted in the creation of two CAT groups, final APC groups 0282, to which we assigned CPT codes 70486, 76370, 76375, and 76380, and final APC 0283, to which the remaining codes in proposed APC group 710 are assigned. We further eliminated proposed APC group 720 and combined CPT code 70541, Magnetic image, head (MRA), with the other MRI procedures in final APC group 0284 because the base procedure, magnetic resonance imaging, is the same.

## APC 716: Fluoroscopy

Comment: A number of commenters recommended that we pay separately for the fluoroscopy portion of procedures that include this radiologic service.

Response: We have assigned payment status indicator " X " to the procedures in final APC groups 0272 and 0273 to indicate that these are ancillary services that are paid separately under the hospital outpatient PPS.

Comment: A professional society commented that CPT code 74340, X-ray guide for GI tube, requires
approximately 10 times the amount of radiologic technologist and room time, approximately 15 times the amount of film and many more supplies than does CPT code 71023, Chest x-ray and fluoroscopy. The commenter recommended that we divide proposed APC 716 into three separate and distinct levels based on the extent of the procedures and that we recalculate the relative weight and associated payment rate for the resulting groups.

Response: We disagree with the commenter. Our medical advisors and staff, after reviewing the procedures in proposed APC group 716, concluded that the fluoroscopic portion of these procedures is sufficiently similar in terms of clinical characteristics and resource requirements to be grouped together. However, applying the "two times" limit on cost variation required
by the BBRA 1999 results in the formation of two groups, final APC groups 0272 and 0273.

## APC 728: Myelography

Comment: Commenters objected to assigning the same payment amount to procedures regardless of whether or not a contrast agent is used. One commenter was concerned that this payment policy will dissuade hospitals from utilizing contrast agents even in cases where the use of contrast is medically appropriate.
Response: We agree that median costs vary more among the procedures in proposed APC 728 than their clinical similarities would suggest. However, although we found that final APC group 0274 did not satisfy the "two times" limit on cost variation required by the BBRA 1999, we are making an exception in this case as we explain below, in section III.C.6.e., and we are retaining all myelographic procedures in final APC 0274.

## APC 730: Arthrography

Comment: Some commenters suggested reassigning various arthrographic procedures that were assigned to proposed APC 730.
Response: We find the procedures in this group to be sufficiently homogeneous in terms of clinical definition and resource use. The procedures are comparable with respect to the use of resources in that the highest median cost procedure is less than twice the lowest median cost procedure, consistent with the standard set by the BBRA 1999. Therefore, we are retaining the proposed grouping of arthrographic procedures in final APC 0275.

## APC 736: Digestive Radiology

To be consistent with the limit on cost variation required by section $201(\mathrm{~g})$ of the BBRA 1999, we divided the procedures in proposed APC 736 into final APC groups 0276 and 0277.

## APC 738: Therapeutic Radiologic

 ProceduresTo be consistent with the limit on cost variation required by section $201(\mathrm{~g})$ of the BBRA 1999, we split the procedures in proposed APC 738 into final APC groups 0296 and 0297.

APC 739: Diagnostic Angiography and Venography

Comment: Numerous commenters expressed concern about the lack of homogeneity among procedures in proposed APC 739. One commenter recommended that we divide proposed APC 739 into three groups: one for CPT code 75790, Angiography, arteriovenous
shunt; one for all other angiography procedures; and one for venography procedures.

Response: In response to these comments, we created final APC group 0281, Venography of Extremity, to reflect the significant clinical and resource consumption differences between venographic procedures performed on extremities and diagnostic angiography and venography performed on other parts of the body. Venographic procedures on the extremities consume less time and fewer resources than other angiography and venography procedures. To be consistent with the limit on cost variation required by the BBRA 1999, we split the other procedures in proposed APC 739 into final APC groups 0279 and 0280. With respect to final APC group 0279, we explain in section III.C.6.e why we are making an exception to the BBRA 1999 limit on cost variation.
APC 747: Diagnostic Ultrasound Except Vascular

Comment: A number of commenters suggested that we restructure proposed APC group 747 according to body site because the APC criterion of clinical homogeneity is violated by including within one group body sites that range from the eye to the pregnant uterus to the scrotum and contents.

Response: Our medical advisors and staff carefully weighed the suggestion of commenters that clinical homogeneity would be better served if the procedures in proposed APC group 747 were divided into groups according to body site. We concluded that resource costs based on the type of technology used are what primarily dictates the definition of groups for various diagnostic services. Thus, we did not assign plain film of the chest in the same APC group with MRI of the chest. Because ultrasound is the type of technology common to all procedures in proposed APC group 747 and because resource use for the various procedures is similar irrespective of body site, we did not break this group up according to body site. However, to be consistent with the limit on cost variation required by the BBRA 1999, we split the procedures in proposed APC 747 into final APC groups 0265 and 0266.

APC 749: Guidance Under Ultrasound
Although there is a range of sites for the procedures in proposed APC group 749, as we explain above in our response to the comments submitted in connection with proposed APC 747, we are keeping this group intact in final APC group 0268 because the base procedure, ultrasonography, is the same
for all procedures. Also, the procedures in final APC group 0268 are comparable with respect to the use of resources in accordance with the "two times" limit on cost variation.

## APC 750: Therapeutic Radiation Treatment Planning

Comment: Commenters were concerned that radiation physics services are not appropriately recognized in proposed APC group 750. One commenter observed that proposed APC 750 lacks clinical homogeneity by including HCPCS codes for calculations and computer-based treatment planning with codes for the construction of treatment devices. Another commenter objected to including CPT codes 77261, $77262,77263,77431$, and 77432 in proposed APC 750 because these codes are for professional services only and do not include a technical or facility component. As such, there are no facility costs associated with the codes. The commenter noted that if these codes were removed from proposed APC group 750, three medical physics consultation codes, CPT codes 77336, 77370 , and 77399 would remain in the group. The commenter suggested that the resource requirements for two of the three remaining codes are dramatically different.
Response: We agree with commenters’ concerns about proposed APC group 750, and we modified this group accordingly. First, we assigned payment status indicator "E," which designates certain items and services that are not paid under the hospital outpatient PPS, to five codes that describe professional services, which would not be billed by hospitals: CPT code 77261, Therapeutic radiology treatment planning; simple; CPT code 77262, Therapeutic radiology treatment planning; intermediate; CPT code 77263, Therapeutic radiology treatment planning; complex; CPT code 77431, Radiation therapy management with complete course of therapy consisting of one or two factions only; and CPT code 77432, Stereotactic radiation treatment management of cerebral lesion(s) (complete course of treatment consisting of one session).
We renamed the remaining group of codes as final APC 0311, Radiation Physics Services. The codes specific to radiation physics that we classified in this APC are CPT code 77336, Continuing medical physics consultation, including assessment of treatment parameters, quality assurance of dose delivery, and review of patient treatment documentation in support of the radiation oncologist, reported per week of therapy; CPT code 77370, Special medical radiation physics
consultation; and CPT code 77399,
Unlisted procedure, medical radiation physics, dosimetry and treatment devices, and special services.

APC 751: Level I Therapeutic Radiation Treatment Preparation
APC 752: Level II Therapeutic Radiation Treatment Preparation

Comment: One commenter objected to including CPT code 77295, Therapeutic radiology simulation-aided field setting; three-dimensional, in proposed APC 752 because this service has dramatically different resource requirements than the other CPT codes in group. Another commenter believes that the resources used in connection with simple intracavitatory applications, which are normally performed with re-usable Cs-137 sources, are totally dissimilar from the resources required for remote afterloading high intensity brachytherapy in proposed APC 751. This commenter noted that the equipment and room costs associated with remote afterloading high intensity brachytherapy may well exceed $\$ 500,000$.
Response: We agree. In response to commenters' concerns, we made a number of modifications to proposed APC group 751 and proposed APC group 752. First, we assigned payment status indicator "E," which designates certain items and services that are not paid under the hospital outpatient PPS, to CPT code 77299, Unlisted procedure, therapeutic radiology clinical treatment planning, thereby removing it from an APC group.
We created final APC group 0303, which consists of the following three codes: CPT code 77332, Unlisted procedure, therapeutic radiology clinical treatment planning; CPT code 77333, Treatment devices, design and construction; intermediate (multiple blocks, stents, bite blocks, special bolus); and, CPT code 77334, Treatment devices, design and construction; complex (irregular blocks, special shields, compensators, wedges, molds or casts). We created final APC 0303 because the resources needed for device construction are unique. We decided to put these three codes together in one group rather than assigning each to its own individual group because we could make no clear cost distinctions among the three codes and because we expect that facilities do not specialize in one type of device over another, but rather construct all of the types of devices encompassed within the three codes.

We created final APC group 0310, to which we assigned CPT code 77295,

Therapeutic radiology simulation-aided field setting, three-dimensional. We assigned CPT code 77295 to its own individual APC group because it requires significantly greater resource consumption than the procedures in either final APC group 0304 or final APC group 0305.

We assigned the codes remaining in proposed APC groups 751 and 752 to final APC groups 0304 and 0305. Both APC groups 0304 and 0305 are comparable with respect to the use of resources in accordance with the "two times" requirement set by the BBRA 1999.

## APC 757: Radiation Therapy

Comment: We received a number of comments about the assignment to proposed APC 757 of CPT code 61793, Stereotactic radiosurgery, particle beam, gamma ray or linear accelerator, one or more sessions. Commenters indicated that CPT code 61793 is clinically distinct from other forms of radiation treatment delivery and that this service generally involves significantly greater treatment time and costs. One commenter stated that if we were to keep CPT code 61793 in proposed APC 757 , we would be prejudicing use of this new, proven technology. Another commenter contended that radiation therapy is not the same as a surgical procedure. The commenter urged us to separate stereotactic radiation therapy (SRT) and intensity-modulated radiation therapy (IMRT) services from the conventional radiation therapy procedures in APC 757 and to assign them a higher payment rate due to their higher cost.

Response: We created final APC group 0302, to which we assigned stereotactic radiosurgery, which requires significantly more costly resources than the procedures assigned to final APC groups 0300 and 0301 . Note that we have created two codes, G0173 and G0174, to use in place of CPT code 61793. They represent stereotactic radiosurgery completed in one session, and that which requires multiple sessions, respectively. We also assigned CPT code 77470 to APC 0302, since we believe it requires resources similar to those required for radiosurgery. We will continue to track the data for these codes to ensure their proper placement. The procedures in final APC group 300 and in final APC group 301 are comparable with respect to the use of resources in accordance with the "two times" limit on cost variation.

APC 759: Brachytherapy and Complex Radioelement Applications

Comment: One commenter expressed concern because we did not identify a payment amount for the radioactive seeds used in brachytherapy. Another commenter referred to low dose rate interstitial brachytherapy that is used to treat complex gynecologic tumors, prostate cancers, and head and neck cancers, noting that this type of radiation therapy employs single-use radioactive sources (iodine, gold, iridium, and palladium seeds) and various disposable applicators. The commenter pointed out that only a limited number of vendors produce these radioactive sources and that the seeds cost as much as $\$ 200$ each with the number of implants varying depending on the size, stage, and location of the cancer. The commenter stated that some patients with prostate cancer may require as many as 100 to 150 seeds. The commenter asserted that we have not captured the costs of these radiopharmaceuticals in the APC payment.
Response: We have changed how we pay for brachytherapy and the other services we proposed to classify to APC 759 in response both to comments and to the provisions of section 201(b) of the BBRA 1999, which provide for an additional payment to be made for innovative medical devices, including "a (current) device of brachytherapy." (See section III.D., below.) Within this framework, we recognize the seeds provided during brachytherapy. For bill processing purposes, we have assigned brachytherapy seeds to APC 0918. We will make payment for brachytherapy seeds under the transitional passthrough rules explained in section III.D., below.

Based on commenters' suggestions, a review of our data, and the BBRA 1999 "two times" requirement, we have classified the procedures in proposed APC 759 in final APC 0312, Radioelement Applications, and final APC 0313, Brachytherapy. APC 0313 consists of CPT code 77781, Remote afterloading high intensity brachytherapy; 1-4 source positions or catheters; CPT code 77782, Remote afterloading high intensity brachytherapy; 5-8 source positions or catheters; CPT code 77783, Remote afterloading high intensity brachytherapy; 9-12 source positions or catheters; CPT code 77784, Remote afterloading high intensity brachytherapy; over 12 source positions or catheters; and, CPT code 77799, Unlisted procedure, clinical brachytherapy. Because these
procedures are all different types of brachytherapy, final APC 313 is more coherent clinically than was proposed APC 759.
We moved CPT code 77750, Infusion or instillation of radioelement solution, to final APC 301, Level II Radiation Therapy, and CPT code 77789, Surface application of radioelement, were moved to final APC 300, Level I Radiation Therapy. The remaining procedures from proposed APC 759 constitute final APC 312, Radioelement Applications. The procedures in final APC group 312 and in final APC group 313 are comparable with respect to the use of resources in accordance with the "two times" limit on cost variation.
APC 761: Standard Non-Imaging Nuclear Medicine
APC 762: Complex Non-Imaging Nuclear Medicine
APC 771: Standard Planar Nuclear Medicine
APC 772: Complex Planar Nuclear Medicine

APC 781: Standard SPECT Nuclear Medicine

APC 782: Complex SPECT Nuclear Medicine
APC 791: Standard Therapeutic Nuclear Medicine
APC 792: Complex Therapeutic Nuclear Medicine

Comment: We received numerous comments about the proposed nuclear medicine APC groups. Commenters addressed what they believe to be discrepancies in the payment weights among the proposed groups. Commenters also asserted that the proposed payment levels are inadequate to offset the cost of
radiopharmaceuticals. They believe, in part, that our use of single-procedure claims in constructing our database failed to capture the costs associated with the various radiopharmaceuticals that may be used in combination during multiple procedures performed during a single session on various patients. One commenter disagrees with our decision to consider therapeutic
radiopharmaceuticals and radionuclides as incidental services, bundling their costs into nuclear medicine and radiation therapy procedures. The commenter recommended that we develop unique APC groups for radiopharmaceuticals and radionuclides. One manufacturer expressed particular concern about our proposed payment for a
radiopharmaceutical used to relieve the pain of bone metastasis (CPT code
79400) that we proposed to package into APC 791 for which the proposed payment was $\$ 758$. The commenter stated that this new
radiopharmaceutical, which has generated a very high clinical response rate, costs more than $\$ 2,000$ per dose.

Response: In response to these and other comments, as well as the changes made by the BBRA 1999 to the outpatient PPS, our medical advisors and staff have reconstructed the nuclear medicine APC groups. First, we have placed radiopharmaceuticals into a separate set of APC groups that are listed in Addendum K. As we state above, new section 1833(t)(6) of the Act provides for additional payment for current and new radiopharmaceuticals. We list in Addendum K those radiopharmaceuticals that are eligible for additional payment effective with services furnished on or after July 1, 2000. In accordance with the process outlined below, in section III.D.4, we invite requests to consider other radiopharmaceuticals as potential candidates for additional pass-through payments.

Next, we reconfigured the nuclear medicine APC groups based on the resources required for the procedures themselves, exclusive of costly radiopharmaceuticals. We took into account the fact that SPECT equipment, which costs significantly more than the non-SPECT equipment that was initially used most frequently for planar medicine, is now commonly used to conduct planar studies. As a final step, we further reorganized the groups to satisfy the requirement set by the BBRA 1999 "two times" requirement, resulting in final APC groups 0286, 0290, 0291, 0292, 0294, and 0295.

Comment: We received a number of comments concerning the clinical efficacy of iodine 131 tositumomab in the treatment of cancer. One commenter stated that iodine 131 tositumomab, which was reported to be pending final FDA approval, has the potential to be the first radioimmunotherapeutic agent to be approved for the treatment of cancer. The commenter expected this pharmaceutical to be the first in its class, and characterized it as neither a chemotherapeutic agent nor a radiopharmaceutical. The commenter stated that the cost of this pharmaceutical will be significantly higher than the payment amount proposed for any of the APC groups containing drugs used for cancer therapies. The commenter believes that we should have proposed an outlier policy to ensure equitable payment for pharmaceuticals such as iodine 131 tositumomab.

Response: If iodine 131 tositumomab receives final FDA approval, we strongly encourage interested parties to submit the appropriate materials to us for determination of this product's eligibility for additional payment under the pass-through provision as described below in section II.D. 6 .
Comment: One commenter finds our method of paying for new products to be flawed. The commenter sees it as highly probable that a new product will be inserted into an APC procedure category where the payment rate is significantly lower than the actual cost of the newly developed product. The commenter cites our proposed payment for a new product, In-111 Octreo Scan, which is used for tumor imaging. The product costs four times the payment rate for proposed APC 772, Complex Planar Nuclear Medicine. The commenter believes that this enormous discrepancy will discourage hospital outpatient departments from utilizing procedures that require this product and that Medicare beneficiaries may be denied access to the most appropriate care available as a result.

Response: We are firmly committed to ensuring that the provisions of the hospital outpatient PPS do not in any way obstruct or limit Medicare beneficiaries' access to reasonable medically necessary and appropriate care. We further recognize that the development of new technology and products is a highly dynamic enterprise that is constantly evolving and changing the character and cost of current diagnostic and treatment modalities. New section 1833(t)(6) of the Act provides for an additional transitional pass-through payment for certain innovative medical devices, drugs, and biologicals. We are also creating a series of transitional APCs for the express purpose of providing appropriate payment for new technology services when they emerge into the marketplace while we collect data to enable us ultimately to incorporate the new technology service within an APC group, making payment adjustments as needed. We expect to continue working closely with hospitals and their representatives throughout this process to ensure that payment does not inhibit beneficiary access to appropriate care. We discuss the transitional pass-through payment groups in greater detail in section III.D and provisions for payment for new technology in section III.C.8.

APC 881: Level I Pathology
APC 882: Level II Pathology

## APC 883: Level III Pathology

Comment: We received numerous comments on the proposed pathology APC groups. One commenter expressed concern that our proposed assignment of tests among the three groups may create an incentive for physicians to order complex and unnecessary tests when simpler, less comprehensive tests may be adequate, because we have grouped together and are paying the same amount for tests that are clinically similar but that are comprehensively more difficult than one another.
Response: Our medical advisors and staff reviewed and completely reorganized the grouping of pathology tests in light of commenters' concerns and the BBRA 1999 "two times" requirement. Pathology tests are in final APC groups 0342, 0343, and 0344.
APC 906: Infusion Therapy Except Chemotherapy
APC 907: Intramuscular Injections
Comment: We received many comments about proposed APC groups 906 and 907 . The commenters were generally concerned that packaging payment for nonchemotherapeutic infused and injected drugs in the payment rates for the administration of nonchemotherapy drugs does not take into account the great variation among these products with regard to their indication/application and cost nor the cost of new drugs that have been introduced since 1996. Commenters fear that we will underpay hospitals and inhibit the introduction of new drugs into the system.
Response: In response to the concerns expressed by commenters, we have created additional groups for certain expensive pharmaceuticals. These highcost, nonchemotherapy, nonorphan drugs are captured in the following APCs: 0886-0891, 0907, 0908, 0911, 0914, 0915, 0917, 7007, 7036, and 7042. We have set the rates for these high-cost drug APCs based on data we obtained from a contracted study of drug costs. In section III.D, below, we discuss the process for pricing new high cost drugs as they are introduced into the marketplace to assure adequate payment until these new drugs can be assigned to an appropriate APC. Final APC 120, Infusion Therapy Except Chemotherapy, and final APC 359, Intramuscular injections, are priced based on the resources used to perform the procedures, including many less expensive drugs that are packaged into the two APCs.

## APC 957: Echocardiography

Comment: Numerous commenters remarked on the lack of homogeneity in resource consumption in this APC. One commenter objected to our not distinguishing between procedures performed with or without contrast agents. Another commenter contends that proposed APC 957 does not account for the diversity of services in costs based on type of equipment, use of conscious sedation medication, and use of contrast agents.

Response: Conscious sedation and contrast media were packaged where they were used in the base year. We believe that packaging of items into the payment amount is appropriate because hospitals do not specialize in providing only services with or only services without sedation or contrast. To the extent that different equipment is used for different procedures, and has different costs, those differing costs are captured and recognized in our payment algorithm.

Comment: Several commenters referred to the fact that some of the echocardiograms are part of more comprehensive codes pertaining to echocardiograms that are in the same APC. For example, one commenter noted that CPT code 93880, the basic vascular ultrasound service, is defined as a "duplex scan." The commenter stated that all duplex vascular ultrasound codes involve three components and that, to the extent all three components are incorporated into this single vascular code, a provider is paid for only one procedure. On the other hand, CPT code 93307, the basic echocardiography service, incorporates only one of the three types of services included in the basic vascular service, CPT code 93880. Other codes, CPT 93320 and 93325 are used to bill for the other services that are a standard part of all vascular ultrasound procedures like CPT code 93880. This approach results in a provider receiving three separate payments for an echocardiogram with Doppler and color flow mapping as compared to a single payment for an equivalent vascular study.

Response: We agree that duplex vascular ultrasound scanning procedures include two dimensional and doppler signal display. However, for the example cited by the commenter, there is no separate code that includes both the two dimensional and the doppler ultrasound spectral analysis. To report a duplex vascular ultrasound of the heart, the only codes available are CPT codes 93307, 93320 and 93325, unlike the duplex vascular ultrasound scan of the extracranial arteries, which
is coded with CPT code 93880 . We agree that this limitation of the coding system affects the payment system, since the APC system is based on charges associated with each of the codes. We will bring this issue to the attention of the American Medical Association's CPT Editorial Panel.

However, in those instances where there is a code for the comprehensive service and separate codes for services that are inherent components of the comprehensive service, the Correct Coding Initiative (CCI) edits, which we are incorporating into the hospital outpatient PPS claims processing system, will address this concern. The CCI edits have been in place in the Part B claims processing system since January 1996. These edits detect when codes representing component services are reported with the code for the more comprehensive service. For example, there is an edit that prohibits the payment of CPT code 93875, a doppler study of the extracranial arteries when reported with CPT code 93880, the duplex scan of the extracranial arteries.
APC 960: Cardiac Electrophysiologic Tests/Procedures APC

Comment: Many commenters cited extreme variations in resource use among the procedures in proposed APC 960 . One commenter noted that the procedures involve the use of one or more catheters, and argued that the proposed payment does not cover the cost of even one catheter. Another commenter claims that, at a minimum, the total cost of the four diagnostic catheters and one ablation catheter used in performing these procedures is \$1,955.

Response: In response to these concerns, we moved CPT code 93660, Evaluation of cardiovascular function with tilt table evaluation, with continuous ECG monitoring and intermittent blood pressure monitoring, with or without pharmacological intervention, to final APC 0101, and CPT code 93724, Electronic analysis of antitachycardia pacemaker system, to final APC 0100. We reclassified the remaining procedures in proposed CPT 960 into final APC groups 0084, 0085, 0086 , and 0087 to be consistent with the BBRA 1999 "two times" requirement.

## APC 966: Electronic Analysis of

 Pacemakers/Other DevicesComment: A number of commenters stated that the procedures in proposed APC 966 are not related clinically or in terms of resource cost. One commenter indicated that analyzing a spine infusion pump or neuroreceiver is a very different process from analyzing a
pacemaker or cardio/defibrillator and hence uses very different resources.

Response: Although the devices that are the subject of electronic analysis in proposed APC group 966 differ, we believe that the resource use among the services in the group is, on average, relatively similar. We determined that the procedures in proposed APC 966 meet the "two times" test for comparability with respect to the use of resources set by the BBRA 1999. In addition, we find it unlikely that facilities will specialize in one particular type of electronic analysis of pacemakers/other devices to the exclusion of others. Therefore, we did not change the procedures in final APC group 102 from what we had proposed.
APC 968: Vascular Ultrasound

## Comment: One commenter

 recommended removing CPT code 93875, Non-invasive physiologic studies of extracranial arteries, complete bilateral study (for example, periorbital flow direction with arterial compression, ocular pneumoplethysmography, Doppler ultrasound spectral analysis), from proposed APC 968 because this study is a physiologic procedure and should be in the same group with other noninvasive physiologic vascular studies.Response: We agree. We moved CPT code 93875 to final APC 0096.

Comment: One commenter recommended creating additional APC groups for CAT, MRI, and general ultrasound procedures to distinguish between diagnostic procedures that utilize contrast media and those that do not. The commenter believes that additional APC groups that properly recognize the resources required for contrast agents will encourage hospitals to use the procedures most suitable for the clinical needs of different patients.

Response: As we explained above, in our response to comments about proposed APC groups 710, 720, and 726, our medical advisors and staff carefully reviewed our data and concluded that costs associated with the use of contrast material are reflected in the payment rate for vascular ultrasound procedures in proportion to its frequency of use. We believe it is reasonable to have vascular ultrasound procedures with and without contrast together in one group because facilities do not specialize based on whether or not they use contrast material. Further, the cost of contrast material is small relative to the overall cost of the ultrasound. Moreover, facilities are not likely to schedule ultrasound according to whether or not contrast is used. Therefore, with the
exception of moving CPT code 93875, we did not further change the procedures in final APC group 0267. Final APC group 0267 is within the limit on cost variation required by the BBRA 1999.

## APC 969: Hyperbaric Oxygen

Comment: Many commenters were concerned that our cost data for hyperbaric oxygen therapy are flawed because of poor coding, and that the proposed payment rate is, as a consequence, inadequate. One commenter suggested that we did not use a common definition of hyperbaric oxygen therapy across all hospitals and that, due to ambiguity in codes, there is wide variation in how hyperbaric oxygen therapy services are defined for billing purposes.

Response: We cannot subdivide final APC 0031 because we have no mechanism for creating clinically distinct groups related to differences in resource consumption among facilities within a single CPT code. However, we explain below, in section III.H, that we intend to make adjustments in future years to APC group weights, once the hospital outpatient PPS is implemented. If commenters believe that current codes are inadequate to describe these services, they should seek new CPT codes from the American Medical Association.

Comment: One commenter was concerned about not only the low payment rate proposed for hyperbaric oxygen therapy, but also the fact that the proposed national unadjusted coinsurance amount exceeds the proposed total payment rate for the service.

Response: We calculated the payment rate and coinsurance amount for APC 0031 using the same method that we followed for the other APC groups. Charges for hyperbaric oxygen are much higher than their costs, which accounts for the unusually high national unadjusted coinsurance rate relative to the total payment rate for CPT code 99183. Note, however, that hospitals may elect to offer a reduced coinsurance rate for the service as described below in section III.F. 4.

APC 971: Level 1 Pulmonary Tests
APC 972: Level II Pulmonary Tests APC 973: Level III Pulmonary Tests

Comment: Commenters generally questioned the clinical consistency of procedures in the proposed pulmonary test APC groups and expressed concern about the variability of resources required to perform the procedures within each group. One commenter
disagreed with our combining procedures before and after medication with procedures before rest and after exercise.

Response: After carefully reviewing the assignment of codes among the three proposed pulmonary test groups, our medical advisors and staff made a number of changes. To better recognize their median costs, we moved CPT code 94060, Bronchospasm evaluation before and after bronchodilator, and CPT code 94260, Thoracic gas volume, to final APC group 0368, and classified CPT code 94720, Carbon monoxide diffusing capacity, to final APC group 0367. We made additional changes among the three groups to ensure comparability of resources within each pulmonary test APC group in accordance with the "two times" standard set by the BBRA 1999.

## APC 976: Pulmonary Therapy

Comment: Commenters generally questioned the clinical consistency of procedures in the proposed pulmonary therapy APC group and expressed concern about the variability of resources required to perform the procedures within the group. One professional association wrote that the respiratory therapy procedures in proposed APC group 976 are significantly different in complexity and require significantly different equipment and expertise to perform. The same commenter noted that CPT code 94657, Ventilation assist and management, initiation of pressure or volume preset ventilators for assisted or controlled breathing, subsequent days; CPT code 94660 , Continuous positive airway pressure ventilation (CPAP), initiation and management; and, CPT code 94662, Continuous negative pressure ventilation (CNP), initiation and management, all require close monitoring, more costly equipment, and, often, more expertise than do other therapies in proposed APC group 976.

Response: We agree with the commenter. We moved the CPT codes describing ventilation initiation and management (CPT codes 94657, 94660, 94662) into their own APC, final APC 0079, Ventilation Initiation and Management, to recognize that these procedures represent a completely different type of clinical service and because they utilize resources that are materially different from those used in connection with other pulmonary therapy procedures. We further divided the procedures in proposed APC 976 to meet the definition of comparable resources required by the BBRA 1999, resulting in final APC groups 0077 and 0078.

APC 979: Extended EEG Studies and Sleep Studies
APC 980: Electroencephalogram
APC 981: Level I Nerve and Muscle Tests
APC 982: Level II Nerve and Muscle Tests

Comment: One commenter expressed concern about our grouping sleep medicine services in proposed APC 979 with EEG and Epilepsy diagnostic services. Another commenter is concerned about the clinical homogeneity of our proposed groups for the numerous different neurologic and neuromuscular diagnostic codes that are encompassed within the range of services described by CPT code 95805 through CPT code 95958. The commenter believes that our proposed groups do not make appropriate distinctions among the many different tests relating to different parts of the body, taking different amounts of time, using different equipment, and measuring different outcomes. One commenter asked that we add two codes created in 1998 for sleep services to the list of procedures in the APC system. The commenter recommended assigning CPT 95811, Polysomnography with CPAPP, to proposed APC group 979. The commenter also recommended that CPT code 95806, Sleep study, unattended by a technologist, not be assigned to proposed APC group 979 to avoid creating an incentive for hospitals to use that procedure, which the commenter asserts is both less costly and less conclusive than other studies in proposed APC 979, in place of more comprehensive tests. One commenter claimed that the variety of neurological and neuromuscular diagnostic tests warrants an expansion of the number of APCs for these procedures to six, because the resources used vary widely. The commenter prefers that payments be made on a per service rather than on a per group basis. However, if we retain groups, the commenter recommended, on the basis of cost-based practice expenses, separate APCs for sleep and polysomnography services, for EEG studies, for EEG monitoring codes, for EMG codes, for nerve conduction and H reflex tests, and for sensory evoked potential and autonomic nerve function tests.
Response: Our medical advisors and staff decided that CPT codes 95806 and 95811 are both most appropriately assigned to final APC 0213. While sleep studies unattended by a technologist may consume less resources than those studies which involve the presence of a technologist, we believe that physicians
are likely to order a mix of sleep studies, and that institutions are unlikely to specialize in sleep studies with or without the presence of a technologist. We added CPT code 95951 to APC group 0213. We believe the codes we proposed in APC groups 979 and 980 are sufficiently comparable clinically and in terms of resource use not to require further subdivision into smaller groups. Therefore, we retained our proposed classification in final APC groups 213 and 214.

We created a third APC group for the nerve and muscle test codes, and we split the codes in proposed APCs 981 and 982 among final APC groups 0215, 0216 , and 0217 to ensure comparability of resources within each of the three nerve and muscle test APC groups in accordance with the "two times" requirement set by section $201(\mathrm{~g})$ of the BBRA 1999.
APC 987: Subcutaneous or Intramuscular Chemotherapy
APC 988: Chemotherapy except by Extended Infusion
APC 989: Chemotherapy by Extended Infusion

## APC 990: Photochemotherapy

Comments: We received numerous comments that criticized our proposed payments for chemotherapy services. The commenters argued that the proposed payment for chemotherapy and radiation therapy would severely reduce payments to hospitals and create perverse incentives for hospitals to substitute the older, less effective therapies for the newer ones. The commenters asserted that the proposed payment would not cover the costs of supportive care such as drugs to control nausea and vomiting. They expected that low payment rates to hospitals would force them to discontinue chemotherapy services, and that patients would be faced with trips to distant facilities to obtain services.
Response: We believe that the concerns raised by the commenters have been addressed through the transitional pass-through provision set forth in section 1833(t)(6) of the Act, as added by section 201(b) of the BBRA 1999. In accordance with that provision, we have separately identified current drugs and biologicals used in the treatment of cancer. These are listed in Addendum K of this final rule, and are eligible for additional payment under this provision. We have obtained codes for any anticancer, supportive, or adjunctive drugs we could identify. Thus, we will pay for chemotherapy by recognizing the mode(s) of administration and each of the covered
drugs given, whether they are to treat the cancer, to protect the patient against the toxic effects of the treatment, or to relieve the side effects of treatment. In section III.D.4, below, we discuss how to request codes for new drugs.

Note that we moved CPT-based chemotherapy infusion codes into the "E" (noncovered) category because HCPCS "Q" codes for these services will be used to identify chemotherapy infusions. Hospitals had been instructed in the past not to bill using the CPT codes.

## APC 999: Therapeutic Phlebotomy

Comment: One commenter is concerned that facilities will lose money because the proposed payment rate does not cover the cost incurred to provide the nursing care, phlebotomy bag and other supplies, overhead, scheduling time and disposal of hazardous waste that are all required to furnish this service.

Response: We have carefully reviewed the costs associated with APC 999 and believe that the CPT code 99195 was mistakenly used to report simple venipuncture in some cases, thus lowering the cost of proposed APC 999. However, we believe it is appropriate to base payment for this APC on the median amount billed, since CPT code 99195 was billed more than 20,000 times. Hospitals must use this code only when therapeutic phlebotomy is furnished, and charge an appropriate rate for the resources involved. Appropriate reporting will enable us to determine a more precise weight for this APC in future years.
Final APC 081: Non-Coronary Angioplasty or Atherectomy
Final APC 082: Coronary Atherectomy
Final APC 083: Coronary Angioplasty
We created these three new APC groups to accommodate atherectomy and angioplasty procedures that we originally proposed to classify as inpatient only. We discuss in section III.C. 5 our response to commenters' concerns about our proposing to designate certain procedures as "inpatient only" and our final decision to change the status of these atherectomy and angioplasty procedures.
Final APC 058: Strapping
Final APC 059: Casting
We proposed to assign the procedures in these new APC groups a payment status indicator " N " as incidental services for which payment is packaged into the APC rate for another service or procedure. However, we determined
that the procedures in the final APC groups 0058 and 0059 could be performed independently, that is, the procedures for which a strapping has been previously applied and/or a new cast has previously been placed. We explain in more detail in section III.C.2.c our rationale for not packaging the costs associated with these services. We therefore created APC groups 0058 and 0059 for these codes to which we assigned payment status indicator " S " to indicate that these are significant procedures paid under the hospital outpatient PPS to which the multiple procedure discount does not apply.
e. Exceptions to BBRA 1999 Limit on Variation of Costs Within APC Groups
As we note above, section $201(\mathrm{~g})$ of
BBRA 1999 amends section 1833(t)(2) of the Act to define what constitutes comparable use of resources among the procedures or services within an ambulatory payment classification group under the hospital outpatient PPS. The standard set by section $1833(\mathrm{t})(2)$ of the Act is that the items and services within a group cannot be considered comparable with respect to the use of resources if the highest median (elected by the Secretary, as opposed to the mean) cost item or service within a group is more than 2 times greater than the lowest median cost item or service within the same group (the "two-times" requirement).

Section 1833(t)(2) of the Act allows the Secretary to make exceptions to the "two-times", requirement in unusual cases, such as low volume items and services, although the Secretary may not make such an exception in the case of a drug or biological that has been designated as an orphan drug under section 526 of the Federal Food, Drug, and Cosmetic Act. As we explain in the preceding section of this preamble, after we had modified the composition of the APC groups based on the
recommendations of commenters, we made numerous additional changes to the APC groups to conform with the BBRA 1999 "two times" requirement. In the resulting groups, we found certain anomalies that were irreconcilable with the principles underlying formation of the APC groups. After carefully evaluating the various combinations resulting from further subdividing groups or reassigning codes to other groups to resolve the anomalies, and after reviewing our data, we decided to maintain the composition of certain APC groups, as exceptions to the "two times" requirement. We based exceptions on factors such as low procedure volume, suspect or incomplete cost data, concerns about
inaccurate or incorrect coding, or compelling clinical arguments. We believe that as hospitals gain experience under the hospital outpatient PPS, and as they refine their coding of services, a number of the apparent anomalies within the groups that we are treating as exceptions to the "two times" will be resolved.

Below we list the APC groups that are exceptions to the "two times" requirement, and our reasons for the exception. We use the final APC number to identify the group.
APC 0016: Level IV Debridement and Destruction

We are retaining CPT code 56501 in final APC group 0016, even though its median cost exceeds the "two times limit." We believe the higher costs that are reflected in the data are the result of incorrect coding. The descriptor for CPT code 56501 defines the procedure as the simple destruction of skin and superficial subcutaneous tissues. In the judgment of our medical advisors, costs associated with simple destruction of skin and superficial subcutaneous tissues are typically within the range of costs associated with the other procedures in final APC group 0016, and the median cost that our data attribute to CPT code 56501 is higher than the code description warrants.

## APC 0030: Breast Reconstruction/ Mastectomy

Although the range of costs for procedures in final APC group 0030 exceeds the "two times limit," we believe that only the simplest breast procedures will be done in the outpatient setting. Most of the procedures with median costs over $\$ 1000$ used observation services in order to provide an overnight stay. We expect these cases to revert to the more appropriate inpatient setting.
APC 0058: Level I Strapping/Casting
The codes in final APC group 0058 are the simpler casting, splinting, and strapping procedures. Costs associated with the more resource-intensive procedures in final APC group 0059 are fairly uniform, but the median costs of procedures in final APC group 0058 vary widely. We are excepting final APC group 0058 from the "two times limit" until we can review the data for the first year of the outpatient PPS.

## APC 0060: Manipulation Therapy

Taken collectively, the codes in final APC group 0060 are low in volume and erratically priced. For example, although the number of areas treated increases within the range of CPT codes

98925 through 98929, suggesting progressively increasing resource utilization, our data show median costs associated with the codes in the range
98925-98929 as $\$ 38, \$ 11, \$ 16, \$ 17$, and $\$ 19$, respectively. Although costs associated with treating 9 to 10 body regions might not be 5 to 10 times greater than treating one or two regions, we would still expect costs for the more extensive procedures to be higher than those for the less extensive procedures, and certainly not lower as suggested by our data. Nor do we expect a hospital to specialize in treating more or fewer body areas. Therefore, the median payment set for final APC 0060 should average out, providing adequate payment for any number of body areas treated.

## APC 0079: Ventilation Initiation and

 ManagementThese codes all represent respiratory treatment and support within the outpatient setting. Their costs should be roughly the same, even though our data suggest otherwise. We are excepting final APC group 0079 from the "two times limit" at this time, pending the collection of more conclusive cost data.

## APC 0080: Diagnostic Cardiac Catheterization

The data for CPT code 93524 reflect costs that are lower than we would expect. We can find no apparent explanation for the wide variation in costs among the cardiac catheterization codes, although we suspect that the accuracy of the chargemaster system, when assigning charges in other than the surgical suite, may be problematic. We expect costs to even out once hospitals decide which cases may be handled on an outpatient basis without requiring an overnight stay.

## APC 0081: Non-Coronary Angioplasty

We are excepting final APC group 0081 from the "two times limit" because of the low volume of cases for the codes in the group. For some of the codes in this group, the data reflect lower than expected median costs, which we attribute to low volume and to miscoding, which would account for the erratic sequences of costs found in our data.
APC 0093: Vascular Repair/Fistula Construction

We believe the median costs for CPT codes 36530 and 36810 are aberrant. These codes are very similar clinically to the other codes in APC 0093, and we would expect their costs to be similar. We believe low volume may account for the variability in cost.

APC 0094: Resuscitation and Cardioversion
We believe the median costs for CPT codes 92953 and 31500 are aberrant, perhaps due to misuse of the codes. Therefore, we are excepting this APC group from the "two times limit," until we collect and analyze more accurate data once the hospital outpatient PPS is implemented.

## APC 210: Spinal Tap

The two CPT codes that comprise this group are essentially the same procedure, one performed for diagnostic reasons and the other therapeutic. We suspect the disparity in median costs is attributable to the much higher volume of diagnostic spinal taps. Therefore, we are excepting this APC group from the "two times limit," until we collect and analyze more accurate data once the hospital outpatient PPS is implemented

## APC 0233: Level II Anterior Segment

 EyeWe are excepting final APC group 233 from the "two times limit" because many of the codes in this APC are low volume and the coding seems erratic. For example, CPT designates a number of codes that are in final APC group 0233 as "relatively small" surgical' procedures, which suggests that miscoding may have resulted in inflated cost data.

## APC 0251: Level I ENT Procedures

A combination of low volume and unlisted codes obscures the fact that this APC represents the least intense ENT procedures. Because there are so many ENT codes, consistent agreement on what the codes represent may be difficult to achieve. Therefore, we are excepting this APC group from the "two times limit," until we collect more accurate data under outpatient PPS.

## APC 0264: Level II Miscellaneous Radiology Procedures

In the judgment of our medical advisors, the median costs for CPT codes 74740 and 76102 are aberrant. These procedures would be underpaid if they were paid separately and on the basis of what our data show to be their median cost. Therefore, we are excepting this APC group from the "two times limit," until we collect more accurate cost data under outpatient PPS.

## APC 0274: Myelography

In the judgment of our medical advisors, the median costs for CPT codes 70010 and 70015 are aberrant. These codes would be underpaid if they were moved to their own APC and paid on the basis of their median cost. All
codes in this APC should cluster around the same cost. Therefore, we are excepting this APC group from the "two times limit," until we collect more accurate cost data under outpatient PPS.
APC 0279: Level I Diagnostic Angiography

We believe the median costs for the codes at the low end of this APC may be inaccurate, because, clinically, these codes are homogeneous. Therefore, we are excepting this APC group from the "two times limit," until we collect more accurate cost data under outpatient PPS.

## APC 0302: Level III Radiation Therapy

We are retaining CPT code 77470 in final APC group 302, because the median cost seems low for the code description, possibly because this code may have been billed improperly in the past. We are also uncertain of the appropriate median cost of CPT code 61793, because we have been told that CPT code 61793 was used for both single-session gamma knife procedures and for each of multiple sessions of treatment with linear accelerators. Therefore, we have created two codes to be used in place of CPT code 61793, in order to collect more reliable data: G0173 (Stereotactic radiosurgery, complete course of therapy in one session), and G0174 (Stereotactic radiosurgery, requiring more than one session).

We will initially pay both codes at the same rate; however, we expect differences in cost would become apparent during the first year or 18 months of the outpatient PPS.

## APC 0311: Radiation Physics Services

We are retaining CPT code 77370 in final APC group 0311, because we believe a special medical radiation physics consultation (outside the weekly management of a patient) is probably more costly than our data indicate.

## APC 0341: Immunology Tests

We think the variation in costs among the procedures within final APC group 0341 may be the result of erratic coding. Because these services are so similar clinically, we would expect their individual costs to cluster around the median. Therefore, we are excepting this APC group from the "two times limit," until we collect more accurate cost data under outpatient PPS.

## APC 0371: Allergy Injections

We attribute the variation in median costs among the procedures within final APC group 0371 to erratic coding. Because these services are so similar
clinically, we would expect their individual costs to cluster around the median. Therefore, we are excepting this APC group from the "two times limit," until we collect more accurate cost data under outpatient PPS.

APC 0373: Neuropsychological Testing
With one exception, the codes in final APC group 0373 are billed per hour, so facility costs should all cluster around the median. Therefore, we are excepting this APC group from the "two times limit," until we collect more accurate cost data under outpatient PPS.

## 7. Discounting of Surgical Procedures

To be consistent with Medicare policy and regulations governing payment for ambulatory surgical services furnished in a physician's office and in an ASC, we proposed under the hospital outpatient PPS to discount payment amounts when more than one procedure is performed during a single operative session or when a surgical procedure is terminated prior to completion. Specifically, we proposed that when more than one surgical procedure with payment status indicator " T " is performed during a single operative session, we would pay the full Medicare payment and the beneficiary would pay the coinsurance for the procedure having the highest payment rate. Fifty percent of the usual Medicare PPS payment amount and beneficiary coinsurance amount would be paid for all other procedures performed during the same operative session to reflect the savings associated with having to prepare the patient only once and the incremental costs associated with anesthesia, operating and recovery room use, and other services required for the second and subsequent procedures.
We also proposed to require hospitals to use modifiers on bills to indicate procedures that are terminated before completion. Modifier -73 (Discontinued Outpatient Procedure Prior to Anesthesia Administration) would identify a procedure that is terminated after the patient has been prepared for surgery, including sedation when provided, and taken to the room where the procedure is to be performed, but before anesthesia is induced (for example, local, regional block(s), or general anesthesia). Modifier-52 (Reduced Services) would be used to indicate a procedure that did not require anesthesia, but was terminated after the patient has been prepared for the procedure, including sedation when provided and taken to the room where the procedure is to be performed. We proposed to pay 50 percent of the usual Medicare PPS payment amount and
beneficiary coinsurance amount for a procedure terminated before anesthesia is induced. Modifier-74 (Discontinued Procedure) would be used to indicate that a surgical procedure was started but discontinued after the induction of anesthesia (for example, local, regional block, or general anesthesia), or after the procedure was started (incision made, intubation begun, scope inserted) due to extenuating circumstances or circumstances that threatened the wellbeing of the patient. To recognize the costs incurred by the hospital to prepare the patient for surgery and the resources expended in the operating room and recovery room, the hospital will receive full payment for a procedure that was started but discontinued after the induction of anesthesia or after the procedure was started, as indicated by a modifier-74. The elective cancellation of procedures would not be reported. If multiple procedures were planned, only the procedure actually initiated would be billed.

Comment: Some commenters asked us to clarify how the policy would be applied. For example, one commenter asked whether the surgical discounting methodology would apply in the following situation: Contrast x-ray of lower spine (CPT code 72265) is followed by contrast CAT of the spine (CPT code 72132). Both procedures have related surgical codes (CPT codes 62270 and 62284). Other commenters provided examples that were similar in nature but involved other codes.

Response: We proposed to apply the reduced payment for multiple procedures to surgical procedures only, that is, those CPT codes that have a payment status indicator "T." Therefore, services such as CPT codes 72265 and 72132 that have a payment status indicator of " S " would not be subject to the multiple procedure discount, whereas CPT codes 62270 and 62284 , which are surgical procedures and have a payment status indicator of "T," would be subject to the multiple procedure discount. Hypothetically, if all four codes were provided in a single operative session, as suggested by this commenter, then the reduced payment would apply only to the surgical procedure with the lower payment rate. (For the record, we have responded to the commenter's example in order to clarify how the multiple procedure discount would apply in a hypothetical situation. However, we question whether the suggested combination of codes would be covered if actually performed during the course of a single patient encounter.)

Comment: Commenters asked what factors guided our assignment of payment status indicator "T" to a code.

Response: We generally assigned the payment status indicator " T "' to surgical services. Our medical advisors and staff will continue to review the designation of status indicators and we may propose revisions in the future.

Comment: A variety of commenters stated that the reduced payments for multiple procedures would inappropriately reduce payments for a second procedure. Some were concerned that application of the multiple procedure discount could result in hospitals being less likely to offer procedures assigned the payment status indicator "T." These commenters recommended that we change all " T " payment indicators to a different indicator such as " $S$," which we define as a significant procedure not reduced when multiple, until we have had an opportunity to collect reliable cost data upon which to base payment decisions about discounting.

Response: We continue to believe that the proposed reduced payment for multiple surgical procedures is reasonable. We disagree that hospitals would be less likely to provide these services. We believe there clearly are savings achieved when more than one surgical procedure is performed during a single operative session. The patient has to be prepared for surgery only once, and the costs associated with anesthesia, operating and recovery room use, and other services required for the second procedure are incremental.

Comment: Some commenters questioned whether the reduced payment for multiple procedures applied to the beneficiary coinsurance as well as to the Medicare program payment. Others did not understand how this reduced payment was accounted for in determining the conversion factor.

Response: The reduced payment for multiple procedures would apply to both the beneficiary coinsurance and the Medicare payment. In order to do this in a "budget neutral" manner, we increased the conversion factor to account for the reduced payments for multiple procedures. In this way, total payments in the aggregate are not affected.

Comment: One commenter believes we should exclude from the multipleprocedure discount those procedures that were subject to a 50 percent reduction under the previous cost-based system because those procedures were recognized as being an adjunct to a primary procedure. The commenter believes that we had already factored
these discounts into our cost determinations and would therefore be inappropriately reducing payment even further for these procedures.
Response: We disagree with the commenter. In determining the weights for the APC groups, we included only single procedure claims. Multiple procedure reductions existing under the previous cost-based system would not have been reflected in these single procedure claims, and, therefore, do not affect the APC payment weights.

## Final Action

Under the hospital outpatient PPS, we will discount payment amounts for surgical procedures when more than one procedure is performed during a single operative session or when a surgical procedure is terminated prior to completion. Parallel discounts will apply to beneficiary coinsurance amounts.
8. Payment for New Technology Services

## a. Background

We proposed to price a new item or service that was assigned a new HCPCS code by classifying the new code to whichever existing APC group most closely resembled the item or service in terms of its clinical characteristics and estimated resource use. We proposed to use the group weight, payment rate, and coinsurance amount established for the existing APC to price the new code for at least 2 years to give us an opportunity to collect cost data for the new item or service.

After we published our proposed rule, the Congress expressed concern in the conference report accompanying the BBRA 1999, that our proposed PPS does not adequately address "issues pertaining to the treatment of * * * new technology." (See H. R. Rep. No. 436 (Part I), 106th Cong., 1st Sess. 868 (1999).) Therefore, the Congress enacted "transitional pass-throughs" in section 201(b) of the BBRA 1999 that provide an additional payment for "new medical devices, drugs, and biologicals" that do not otherwise meet the definition of current orphan drugs, or current cancer therapy drugs and biologicals and brachytherapy, or current radiopharmaceutical drugs and biological products. (See section III.D of this preamble for a discussion of how we are implementing the transitional pass-throughs.)

## b. Comments and Responses

Comment: The most frequent commenters regarding our treatment of new technology under the proposed
hospital outpatient PPS were device manufacturers and pharmaceutical companies and their trade associations. Commenters were concerned because the proposed APC payment rates were developed using 1996 cost data that do not reflect the cost of many new technologies introduced subsequent to 1996. Commenters believe that the proposed method of ratesetting under the APC system lacks the flexibility needed to recognize emergent
technologies in a timely manner. In the view of the commenters, assigning new technologies to existing APC groups pending the collection of cost data would result in underpayment, thereby discouraging the adoption of new technologies.

Commenters further stated that the proposed payment rates for current yet relatively new devices were too low and would favor continued use of older, less effective regimens on the basis of financial pressures rather than on the improved clinical outcomes of newer technology. Some commenters, concerned that we will not update codes or payment rates quickly enough to allow hospitals to pay for new technologies, recommended that we assign HCPCS codes as soon as products become available and alter APC group weights to account for a new technology. These commenters believe that the time lapse between coding updates is a barrier to innovation because it can take several years for a code to be issued for a new surgical technique, and until a new code is issued, facilities must bill for new surgical techniques as "unlisted procedures' resulting in the lowest payment rate for the category of surgery.

One commenter urged that we implement a payment carve-out for certain drug and biological therapies and pay for these items on a reasonable cost basis in order to provide timely patient access to many new pharmaceutical and biotechnology products. The same commenter recommended that if we reject a complete carve-out, then, at a minimum, we should pay for new products introduced after 1996 on a reasonable cost basis for 1 year to adequately compensate companies for developing new and more effective products. Another commenter recommended that we increase the number of APC groups to better reflect services with similar cost structures.
One professional association recommended abandoning the APC group system altogether and pricing services individually because assigning new technology and most costly procedures to APC groups with
established lower cost procedures creates a strong disincentive for hospitals to provide new or improved items or services and, in the case of newer, higher cost drugs, encourages hospitals to develop formularies and practice patterns based on financial considerations rather than on the medical value of drugs.

Technologies that commenters cited as being inadequately addressed by the proposed outpatient PPS include new technologies based on molecular genetics; gamma knife procedures used in radiation surgery; and prostatic microwave thermotherapy (transurethral microwave thermotherapy (TUMT)) which a commenter said has a direct cost of $\$ 1,918$ and, factoring in indirect costs, a total cost of $\$ 2,623$.

Response: The concerns expressed by commenters regarding new technology items and services highlight two issues. The first is specific to the data used to construct APC groups and calculate their prices at the start of the PPS. As required by section $1833(\mathrm{t})(2)(\mathrm{C})$ of the Act, we are using claims data from 1996 as the basis for determining APC group weights and payment rates under the new system. The 1996 data do not capture items and services that have emerged since that time and that are now in use. The second issue relates to new items and services that will be introduced in the future, after the outpatient PPS is implemented. Postponing the adjustment of APC groups and weights for several years to allow for the collection of cost data would potentially inhibit the dissemination of medically desirable innovations.

We recognize the concerns raised by commenters about our proposed treatment of new codes under the hospital outpatient PPS. We therefore have developed a process that we believe will allow us to recognize new technologies on an ongoing basis as expeditiously as our systems permit. We expect that this process, which we explain below, combined with the transitional pass-throughs established by section 201(b) of the BBRA 1999 (which we describe in section III.D of this preamble), will provide additional payment for a significant share of new technologies.

In this final rule, we have created special APC groups to accommodate payment for new technology services. In contrast to the other APC groups, the new technology APC groups do not take into account clinical aspects of the services they are to contain, but only their costs. We will assign new items and services that we determine cannot appropriately be placed in existing APC
groups for established procedures and services to the new technology APC groups.
The new technology APC groups, which are now largely unpopulated, are already defined in our claims processing system for the outpatient PPS, and we have established payment rates for the APC groups based on the midpoint of ranges of possible costs, for example, the payment amount for a new technology APC group reflecting a range of costs from $\$ 300$ to $\$ 500$ would be set at $\$ 400$. The cost range for the groups reflects current cost distributions, and we reserve the right to modify the ranges as we gain experience under the outpatient PPS. The final APC groups for new technology are groups 0970 through 0984 and cover a range of costs from less than $\$ 50$ to $\$ 6,000$. Upon implementation of the outpatient PPS, we will make payment for the following new technology services under the new technology APCs:
53850 Transurethral destruction of prostate tissue; by microwave thermotherapy
53852 Transurethral destruction of prostate tissue; by radiofrequency thermotherapy
96570 Photodynamic therapy, first 30 minutes
96751 Photodynamic therapy, each additional 15 minutes
G0125 PET lung imaging of solitary pulmonary nodules, using 2-(Fluorine-18)-Fluoro-2-Deoxy-D-Glucose (FDG), following CT ( $71250 / 71260$ or 71270)
G0126 PET lung imaging of solitary pulmonary nodules, using 2-(Fluorine-18)-Fluoro-2-Deoxy-D-Glucose (FDG), following CT (71250/71260 or 71270); initial staging of pathologically diagnosed non-small cell lung cancer
G0163 Positron emission tomography (PET), whole body, for recurrence of colorectal metastatic cancer
G0164 Positron emission tomography (PET), whole body, for staging and characterization of lymphoma
G0165 Positron emission tomography (PET), whole body, for recurrence of melanoma or melanoma metastatic cancer G0166 External counterpulsation, per treatment session
G0168 Wound closure by adhesive
The new technology APC groups give us a mechanism for initiating payment at an appropriate level within a relatively short timeframe, and certainly less than the 2 or 3 years that we contemplated in our proposed rule. As in the case of items qualifying for the transitional pass-through payment, placement in a new technology APC will be temporary. After we gain information about actual hospital costs incurred to furnish a new technology service, we will move it to a clinicallyrelated APC group with comparable resource costs. If we cannot move the new technology service to an existing

APC because it is dissimilar clinically and with respect to resource costs from all other APCs, we will create a separate APC for such service. We will retain a service within a new technology APC group for at least 2 years, but no more than 3 years, consistent with the time duration allowed for the transitional pass-through payments. Movement from a new technology APC to a clinicallyrelated APC would occur as part of the annual update of APC groups.
Beneficiary coinsurance amounts for items and services in the new technology APC groups are 20 percent of the payment rate set for the new technology APCs.
We ask that interested parties take the following steps to bring to our attention services that they believe merit consideration for pricing using the new technology APC groups. Mail requests for consideration of possible new technology services that have established HCPCS codes to the following address ONLY: PPS New Tech/Pass-Throughs, Division of Practitioner and Ambulatory Care, Mailstop C4-03-06, Health Care Financing Administration, 7500 Security Boulevard, Baltimore, MD 21244-1850.
To be considered, requests MUST include the following information:

- Trade/brand name of item.
- A detailed description of the clinical application of the item, including HCPCS code(s) to identify the procedure(s) with which the item is used.
- Current cost of the item to hospitals (i.e., actual cost paid by hospitals net of all discounts, rebates, and incentives in cash or in-kind). In other words, submit the best and latest information available that provides evidence of the hospital's actual cost for a specific item.
- If the item is a service, itemize the costs required to perform the procedure, e.g., labor, equipment, supplies, overhead, etc.
- If the item requires FDA approval/ clearance, submit information that confirms receipt of FDA approval/ clearance and the date obtained.
- If the item already has an assigned HCPCS code, include the code and its descriptor in your submission plus a dated copy of the HCPCS code "recommendation application" previously submitted for this item.
- If the item does not have an assigned HCPCS code, follow the procedure discussed, below, for obtaining HCPCS codes and submit a copy of the application with our payment request.
- Name, address, and telephone number of the party making the request.
- Other information as HCFA may require to evaluate specific requests.

We believe some items not yet known to us do not yet have assigned HCPCS codes. We expect to use national HCPCS codes in the hospital outpatient PPS to the greatest extent possible. These codes are established by a well-ordered process that operates on an annual cycle, starting with submission of information by interested parties due by April 1 and leading to announcement of new codes in October of each year. This process is described, and relevant application forms are available, on the following HCFA website: http:// www.hcfa.gov/medicare/hcpcs.htm.

Considering the exigencies of implementing a new system, we intend to establish temporary codes in 2000 to permit implementation of additional payments for other eligible items effective beginning October 1, 2000. The process for submitting information will be the same as for national codes.

For new technology services that DO NOT have established HCPCS codes, submit the regular application for a national HCPCS code in accordance with the instructions found on the internet at http://www.hcfa.gov/ medicare/hcpcs.htm. Send applications for national HCPCS codes to: C. Kaye Riley, HCPCS Coordinator, Health Care Financing Administration, Mailstop C5-08-27, 7500 Security Boulevard, Baltimore, Maryland 21244-1850. A fuller discussion of the HCPCS process and schedule is in section III.D. 6 of this preamble.

Because of staffing and resource limitations, we cannot accept requests by facsimile (FAX) transmission. Because of claims processing systems constraints, a new technology payment rate can only be initiated at the start of a calendar quarter. Since we will update our outpatient PPS quarterly to include new technology additional services, October 1, 2000 is the earliest date that we will implement payment for additional new technology services other than for those items beginning on July 1, 2000. In general, we expect to be able to complete action on requests to assign an item or service to a new technology APC group in about 6 months from the date we receive the request.

In order to be considered for assignment to a new technology APC group, an item or service must meet the following criteria:

- The item or service is one that could not have been billed to the Medicare program in 1996 or, if it was available in 1996, the costs of the item or service could not have been adequately represented in 1996 data.
- The item or service does not qualify for an additional payment under the transitional pass-through provided for by section $1833(t)(6)$ of the Act, as amended by section 201(b) of the BBRA 1999, and 42 CFR 419.43(e) as a current orphan drug, as a current cancer therapy drug or biological or brachytherapy, as a current radiopharmaceutical drug or biological product, or as a new medical device, drug, or biological.
- The item or service has a HCPCS code. (See section III.D for additional information about obtaining HCPCS codes.)
- The item or service falls within the scope of Medicare benefits under section 1832(a) of the Act.
- The item or service has been determined to be reasonable and necessary in accordance with section 1862(a)(1)(A) of the Act.


## Final Action

We are initiating a method to pay for new technology services that are not addressed by the transitional passthrough provisions of the BBRA 1999.
D. Transitional Pass-Through for Innovative Medical Devices, Drugs, and Biologicals

## 1. Statutory Basis

Section 201(b) of the BBRA 1999 amended section 1833(t) of the Act by adding a new section 1833(t)(6). This provision requires the Secretary to make additional payments to hospitals for a period of 2 to 3 years for specific items. The items designated by the law are the following: current orphan drugs, as designated under section 526 of the Federal Food, Drug, and Cosmetic Act; current drugs, biologic agents, and brachytherapy devices used for treatment of cancer; current radiopharmaceutical drugs and biological products; and new medical devices, drugs, and biologic agents, in instances where the item was not being paid for as a hospital outpatient service as of December 31, 1996, and where the cost of the item is "not insignificant" in relation to the hospital outpatient PPS payment amount. In this context, "current" refers to those items for which hospital outpatient payment is being made on the first date the new PPS is implemented.
Section 1833(t)(6)(C)(i) of the Act sets the additional payment amounts for the drugs and biologicals as the amount by which the amount determined under section 1842(o) of the Act ( 95 percent of the average wholesale price (AWP)) exceeds the portion of the otherwise applicable hospital outpatient department fee schedule amount that
the Secretary determines to be associated with the drug or biological. Section 1833(t)(6)(C)(ii) provides that the additional payment for medical devices be the amount by which the hospital's charges for the device, adjusted to cost, exceed the portion of the otherwise applicable hospital outpatient department fee schedule amount determined by the Secretary to be associated with the device. Under section 1833(t)(6)(D), the total amount of pass-through payments for a given year cannot be projected to exceed an "applicable percentage" of total payments. For a year (or a portion of a year) before 2004, the applicable percentage is 2.5 percent; for 2004 and subsequent years, the applicable percentage is 2.0 percent. If the Secretary estimates that total passthrough payments would exceed the caps, the statute requires the Secretary to reduce the additional payments uniformly to ensure the ceiling is not exceeded.

Section 201(c) of the BBRA amended section 1833(t)(2)(E) of the Act to require that these pass-through payments be made in a budget neutral manner. In accordance with section 1833(t)(7) of the Act, as amended by section 201(i) of the BBRA 1999, these additional payments do not affect the computation of the beneficiary coinsurance amount.
Implementation of this pass-through provision requires us to-

- Identify eligible pass-through items;
- Designate a Billing Code for each;
- Determine the term "not insignificant" in the context of determining whether an additional payment is appropriate;
- Determine an appropriate cost-tocharge ratio to use to adjust the hospital's charges for a new medical device to cost;
- Determine the portion of the applicable APC that would be associated with the drug, biological or device; and
- Determine the additional payment amount.
As with other provisions of this final rule that reflect implementation of the BBRA 1999, we are soliciting comments on our implementation of the transitional pass-through payments, as set forth below.

2. Identifying Eligible Pass-Through Items

## a. Drugs and Biologicals

Section 1833(t)(6)(A) of the Act establishes definitions and examples of the drugs and biologicals that are candidates for pass-through payments.

As indicated above, these drugs and biologicals are characterized as both current and new. Current refers to those drugs and biologicals for which payment is made on the first date the hospital outpatient PPS is implemented, that is, on July 1, 2000. They include the following:

1. Orphan drugs. These are drugs or biologicals that have been designated as an orphan drug under section 526 of the Federal Food, Drug and Cosmetic Act.
2. Cancer therapy drugs, biologicals, and brachytherapy. These items are those drugs or biologicals that are used in cancer therapy, including (but not limited to) chemotherapeutic agents, antiemetics, hematopoietic growth factors, colony stimulating factors, biological response modifiers, bisphosphonates, and a device of brachytherapy.
3. Radiopharmaceutical drugs and biological products. These are radiopharmaceutical drug or biological products used in nuclear medicine for diagnostic, monitoring, or therapeutic purposes.

A new drug or biological is defined as a product that was not paid as a hospital outpatient service prior to January 1, 1997 and for which the cost is not insignificant in relation to the payment for the APC to which it is assigned. These items are not reflected in the 1996 claims data we are required to use in developing the outpatient PPS. Before payment can be made for these new drugs and biologicals, a determination must be made that these items are reasonable and necessary for the diagnosis or treatment of an illness or injury or to improve the functioning of a malformed body member as required by section 1862(a)(1)(A) of the Act. Drugs that can be self-administered are not covered under Part B of Medicare (with specific exemptions for certain oral chemotherapeutic agents and antiemetics, blood-clotting factors, immunosuppressives, and erythropoietin for dialysis patients).

## b. Medical Devices

Under section 201(b) of the BBRA 1999, for purposes of making passthrough payments, a new or innovative medical device is one for which payment as a hospital outpatient service was not being made as of December 31, 1996 and for which the cost of the device "is not insignificant" in relation to the hospital outpatient department fee schedule amount payable for the service involved. For the purpose of identifying "new medical devices" that may be eligible for pass-through payments, we are excluding equipment, instruments, apparatuses, implements
or items that are generally used for diagnostic or therapeutic purposes, that are not implanted or incorporated into a body part, and that are used on more than one patient (that is, are reusable). This material is generally considered to be hospital overhead costs and the depreciation expenses associated with them are reflected in the APC payments. The unit of payment for the outpatient PPS is a service or procedure.
Equipment or instrumentation is a method or means of delivering that service. We are not establishing separate APC payments for equipment, instruments, apparatuses, implements, or items because payment for these types of devices is packaged in the APC payment for the service or item with which they are used. However, as we discuss above in section III.C.8, we have created new technology APCs to accommodate new technology services that may be performed using equipment or instrumentation that is capitalized and depreciated and used on more than one patient. An example of a new technology service is CPT code 53850, Transurethral destruction of prostate tissue; by microwave thermotherapy. We have assigned this procedure to new technology APC 0980. (See section III.C. 8 of this preamble for further discussion of payment for new technology under the hospital outpatient PPS.)

Section 201(e) of the BBRA 1999 amends section 1833(t)(1)(B) of the Act to include as "covered OPD services" implantable items described in paragraphs (3), (6), or (8) of section 1861(s) of the Act. Paragraph (3) refers to diagnostic tests including diagnostic x-rays, mammographies, laboratory tests, and other diagnostic tests. Paragraph (6) refers to implantable durable medical equipment (DME), and paragraph (8) refers to prosthetic devices that replace all or part of an internal body organ (including colostomy bags and supplies directly related to colostomy care). Implantables are not mentioned specifically in these paragraphs, but we consider a prosthetic device that replaces all or part of an internal body organ that is mentioned in section 1861(s)(8) to be an implantable. The BBRA 1999 Conference Report lists pacemakers, defibrillators, cardiac sensors, venous grafts, drug pumps, stents, neurostimulators, and orthopedic implants, as well as items that come in contact with human tissue during invasive procedures as examples of implantable items.

Implantable items covered under section 201(e) of the BBRA 1999 may be considered eligible for the transitional pass-through payments allowed under
section 201(b) of the BBRA 1999 to the extent that these implantables meet the statutory requirements set forth in section 201(b) and the criteria established in this final rule for payment of these devices.
Although we are recognizing the implantable items identified in section 201(e) of the BBRA 1999 for possible pass-through payments, we are not applying the pass-through provision to any DME, orthotics, and prosthetic devices that are not covered under section 201(e) of the BBRA 1999. Rather, we will pay for these items under the DMEPOS fee schedule when the hospital is acting as a supplier.
3. Criteria To Define New or Innovative Medical Devices Eligible for PassThrough Payments
In summary, we will make passthrough payment for new or innovative medical devices that meet the following criteria:
a. They were not recognized for payment as a hospital outpatient service prior to 1997.
b. They have been approved/cleared for use by the FDA.
c. They are determined to be reasonable and necessary for the diagnosis or treatment of an illness or injury or to improve the functioning of a malformed body part, as required by section 1862(a)(1)(A) of the Act. We recognize that some investigational devices are refinements of existing technologies or replications of existing technologies and may be considered reasonable and necessary. We will consider devices for coverage under the outpatient PPS if they have received an FDA investigational device exemption (IDE) and are classified by the FDA as Category B devices. (See $\S \S 405.203$ to 405.215.) However, in accordance with §405.209, payment for a nonexperimental investigational device "is based on, and may not exceed, the amount that would have been paid for a currently used device serving the same medical purpose that has been approved or cleared for marketing by the FDA."
d. They are an integral and subordinate part of the procedure performed, are used for one patient only, are surgically implanted or inserted, and remain with that patient after the patient is released from the hospital outpatient department.
e. The associated cost is not insignificant in relation to the APC payment for the service in which the innovative medical equipment is packaged. (See section III.D. 4 below for the definition of "not insignificant.")
f. They are not equipment,
instruments, apparatuses, implements,
or such items for which depreciation and financing expenses are recovered as depreciable assets as defined in Chapter 1 of the Medicare Provider
Reimbursement Manual (HCFA Pub.
15-1). (As indicated above, these costs are considered overhead expenses that have been factored into the APC payment.)
g. They are not materials and supplies such as sutures, clips, or customized surgical kits furnished incident to a service or procedure.
h. They are not materials such as biologicals or synthetics that may be used to replace human skin.

Comment: Some commenters asked how we would pay for new technology intraocular lenses (IOLs) under the hospital outpatient PPS.

Response: We will use the same criteria established in the June 16, 1999 final rule ( 64 FR 32198) titled "Medicare Program; Adjustment in Payment Amounts for New Technology Intraocular Lenses Furnished by Ambulatory Surgical Centers" to identify IOLs that may be considered new technology and eligible for passthrough payments. In accordance with that rule, IOLs must first be approved by the FDA before they can be considered as a new technology IOL. The rule establishes only one criterion for distinguishing new technology IOLs from other IOLs. Specifically, all claims of the IOL's clinical advantages and superiority over existing IOLs must have been approved by the FDA for labeling and advertising purposes. For further discussion on the reasons for relying on the FDA's determination, we refer the reader to the IOL proposed rule published on September 4, 1997 (62 FR 46700 through 46701). We recognize that this criterion has been developed to define the characteristics that distinguish a new technology IOL from other IOLs in order to comply with section 141(b) of the Social Security Act Amendments of 1994 (Pub. L. 103-432) that is specific to IOLs furnished in ASCs and not hospital outpatient departments. However, we believe that it is appropriate to rely on an established approach to assist us in distinguishing this new technology since more than 1 million IOLs are inserted annually during or subsequent to cataract surgery performed in the outpatient setting. Moreover, we believe that consistent application of the criterion in both the ASC and hospital outpatient prospective payment systems is less burdensome to those requesting recognition of new technology IOLs. Therefore, when IOLs that are recognized as "new technology IOLs" in accordance with the provisions of the

June 16, 1999 final rule are furnished in a hospital outpatient setting, we will pay for such new technology IOLs in accordance with the hospital outpatient PPS method for determining additional payments under the pass-through provision set forth in this final rule.

Comment: We received many comments urging that we establish appropriate payments for brachytherapy seeds used in the treatment of prostate cancer.
Response: In accordance with section 1833(t)(6)(A)(ii), as added by section 201(b) of the BBRA 1999, we will provide additional payments for brachytherapy seeds as an implanted device. The brachytherapy device is assigned to APC 0918.

## 4. Determination of "Not Insignificant"

 Cost of New ItemsSection 1833(t)(6)(A)(iv)(II) of the Act, as added by section 201(b) of the BBRA 1999 provides that the transitional passthroughs apply to new drugs, biologicals, and devices whose cost is not insignificant in relation to the hospital outpatient PPS payment amount. Section 1833(t)(6)(C) defines the additional payment as the difference between an amount specified by the law and the portion of the applicable fee schedule amount determined to be associated with the item. The objective of this section is to prevent the hospital outpatient PPS from creating disincentives for the diffusion of valuable new technology by initially paying a rate significantly below the costs of these items. We believe that the "not insignificant" criterion was included in recognition that: (1) The costs of some new technologies would not be large enough relative to the fee schedule amount to provide disincentives for their use in the short run; and (2) that an excessive number of pass-through items could place a substantial burden on the claims processing systems of both HCFA and individual hospitals in a way that could hamper the rapid processing of passthrough payments for those items that would be significantly more costly than the applicable fee schedule amount. Therefore, in order to be consistent with the objectives of this section, we are establishing the following criteria for determining whether the costs of drugs, biologicals, and devices are "not insignificant" relative to the hospital outpatient department fee schedule amount:
(1) Its expected reasonable cost exceeds 25 percent of the applicable fee schedule amount for the associated service.
(2) The expected reasonable cost of the new drug, biological, or device must exceed the portion of the fee schedule amount determined to be associated with the drug, biological, or device by 25 percent.
(3) The difference between the expected, reasonable cost of the item and the portion of the hospital outpatient department fee schedule amount determined to be associated with the item exceed 10 percent of the applicable hospital outpatient department fee schedule amount.
The following illustrates the application of these three criteria.
Example: Let us assume that the reasonable cost of the new device ZZ is $\$ 32.00$. ZZ is associated with HCPCS code 00000 assigned to APC 0001. The fee schedule amount for APC 0001 is $\$ 100.00$. The portion of the fee schedule amount included in APC 0001 that represents the cost associated with the former device is $\$ 25.00$.

1. (a) Multiply the fee schedule amount for APC 0001 by 25 percent $\$ 100.00 \times .25=\$ 25.00$
(b) Compare the reasonable cost for ZZ to the product derived in Step 1 \$32.00 > \$25.00

Finding: The first criterion is met.
2. (a) Multiply the portion of the fee schedule amount for APC 0001 that is associated with a device by 25 percent $\$ 25.00 \times .25=\$ 6.25$
(b) Subtract the portion of the fee schedule amount for APC 0001 attributable to a device from the reasonable cost for ZZ
$\$ 32.00-\$ 25.00=\$ 7.00$
(c) Compare the remainder in Step 4 to the product in Step 2(a)

## $\$ 7.00>\$ 6.25$

Finding: The second criterion is met.
3. (a) Multiply the fee schedule amount for APC 0001 by 10 percent $\$ 100.00 \times .10=\$ 10.00$
(b) Compare the remainder in Step 3 to the product derived in Step 3(a) $\$ 7.00<\$ 10.00$

Finding: The third criterion is not met. Therefore, new device ZZ is not eligible for transitional pass-through payment.

## 5. Calculating the Additional Payment

Section 1833(t)(6)(C)(i) of the Act requires that for drugs, biologicals, and radiopharmaceuticals, the additional payment be determined as the difference between the amount determined under section 1842(o) of the Act (95 percent of AWP) and the portion of the hospital outpatient department fee schedule amount determined by the

Secretary to be associated with those items. For devices, the additional payment is the difference between the hospital's charges adjusted to costs and the portion of the applicable hospital outpatient department fee schedule amount associated with the device. Under section 1833(t)(7) of the Act, as added by section 201(i) of the BBRA 1999, the coinsurance amounts for beneficiaries are not affected by passthrough payments.

We will determine, on an item-byitem basis, the amount of the applicable fee schedule amount associated with the relevant drug, biological, or device. To the extent possible, hospital outpatient department claims data will be used to make these estimates. When necessary, external data pertaining to the costs of the drugs, biologicals and devices already included in the fee schedule amounts will be used to make these determinations.
Before January 1, 2002, charges for devices eligible for pass-throughs will be adjusted to cost on each claim by applying the individual hospital's average cost-to-charge ratio across all outpatient departments. The 1996 data do not allow for determination of which revenue center-specific ratios might be used for this purpose. We will examine claims for the latter half of 2000 and for 2001 in order to determine if a revenue center-specific set of cost-to-charge ratios should be used for 2002 and beyond.

A one-time exception to the general methodology described above pertains to current drugs and biologicals that will be eligible for transitional passthroughs when the PPS is implemented. For this final rule, we revised many APC groups by removing, to the extent possible, many of these drugs and radiopharmaceuticals. Therefore, the payment rates for the APC groups with which these drugs are associated exclude the costs of these drugs and the total amount paid to hospitals for the drugs will be 95 percent of the applicable AWP. In order to be able to determine a coinsurance amount for these drugs, we needed to estimate what portion of this payment would have been included as part of the APC payment amount associated with these drugs and what portion would be the pass-through amount. Using an external survey of hospitals' drug acquisition costs, we determined the APC payment amount for many of these drugs as their average acquisition cost adjusted to year 2000 dollars. Where valid cost data were not available for individual drugs, we applied the following average ratios of acquisition cost to AWP calculated from the survey to determine the fee schedule
amount: . 68 for drugs with one manufacturer, . 61 for multi-source drugs, and .43 multi-source drugs with generic competitors. In either case, the coinsurance amounts were determined as 20 percent of these fee schedule amounts. It is important to note that these estimates do not affect the total payment to hospitals for these drugs (95 percent of AWP).

Because claims data are not available for most items that will be eligible for transitional pass-through payments for 2000 and 2001, it is extremely difficult to project expenditures under this provision. For this reason, and because many eligible items will be added after the system's implementation, we cannot estimate if, and to what extent, these payments would exceed 2.5 percent of total payments in 2000 and 2001. Therefore, there will be no uniform reduction factor applied to these payments during this period.
6. Process To Identify Items and To Obtain Codes for Items Subject to Transitional Pass-Throughs

We have identified a large number of items subject to the transitional passthrough payment through our own datagathering activities or through comments on the proposed rule. Many of them already have HCPCS codes, and we are taking steps to establish temporary codes for the remaining items. We will make additional payments for these items when the hospital outpatient PPS system is implemented on July 1. A list of the items already known to us is set forth in Addendum K.
Other items potentially eligible for additional pass-through payments may not be known to us at this time. Because of systems limitations, if we do not know about an item, we will not be able to make additional payments for those items beginning on July 1, 2000. However, we will update our outpatient PPS on a quarterly basis beginning October 1, 2000 to add other items that are eligible for pass-through payments. Therefore, implementation of additional payment for any such item must wait until a later release of systems
instructions, that is, in October 2000, January 2001 (annual update), or later.

A manufacturer or other interested party who wishes to bring items that may be eligible for additional transitional pass-through payments to our attention should mail requests for consideration of items to the following address ONLY: PPS New Tech/PassThroughs, Division of Practitioner and Ambulatory Care, Mailstop C4-03-06, Health Care Financing Administration,

7500 Security Boulevard, Baltimore, MD 21244-1850.

To be considered, requests MUST include the following information:

- Trade/brand name of item.
- A detailed description of the clinical application of the item, including HCPCS code(s) to identify the procedure(s) with which the item is used. If the item replaces or improves upon an existing item, identify the predecessor item by trade/brand name and HCPCS code.
- Current cost of the item to hospitals (i.e., actual cost paid by hospitals net of all discounts, rebates, and incentives in cash or in-kind). In other words, submit the best and latest information available that provides evidence of the hospital's actual cost for a specific item.
- Date of sale of first unit.
- For drugs, submit the most recent average wholesale price (AWP) of the drug and the date associated with the AWP quote.
- If the item requires FDA approval/ clearance, submit information that confirms receipt of FDA approval/ clearance and the date obtained.
- If the item already has an assigned HCPCS code, include the code and its descriptor in your submission plus a dated copy of the HCPCS code "recommendation application" previously submitted for this item.
- If the item does not have an assigned HCPCS code, follow the procedure discussed, below, for obtaining HCPCS codes and submit a copy of the application with your payment request.
- Name, address, and telephone number of the party making the request.
- Other information as HCFA may require to evaluate specific requests.
We believe some items not yet known to us do not yet have assigned HCPCS codes. We expect to use national HCPCS codes in the hospital outpatient PPS to the greatest extent possible. These codes are established by a well-ordered process that operates on an annual cycle, starting with submission of information by interested parties due by April 1 and leading to announcement of new codes in October of each year. This process is described, and relevant application forms are available, on the following HCFA website: http:// www.hcfa.gov/medicare/hcpes. htm.
Considering the exigencies of implementing a new system, we intend to establish temporary codes in 2000 to permit implementation of additional payments for other eligible items effective beginning October 1, 2000. The process for submitting information will be the same as for national codes.

For items that might be candidates for additional transitional pass-through payments but that DO NOT have established HCPCS codes, submit the regular application for a national HCPCS code in accordance with the instructions found on the internet at http://www.hcfa.gov/medicare/ hcpcs.htm. Send applications for national HCPCS codes to: C. Kaye Riley, HCPCS Coordinator, Health Care Financing Administration, Mailstop C5-08-27, 7500 Security Boulevard, Baltimore, Maryland 21244-1850.

Because of staffing and resource limitations, we cannot accept requests by facsimile (FAX) transmission.

As indicated in the instructions posted at our website address cited above, the deadline for submission of applications for a national HCPCS code for the CY 2001 cycle is April 1, 2000. The HCPCS process will proceed to assign national codes as warranted, and we expect these codes will be used in the hospital outpatient PPS starting January 1, 2001. Because the coding application will contain information vital to determining a specific item or product's eligibility for pass-through payments, we are requesting that a copy of the application be sent concurrently to ATTN: PPS New Tech/Pass-Throughs at the address shown above.

This year, we plan to implement additional payment for appropriate items on October 1, 2000. Requests submitted to us with appropriate information will be evaluated for payment effective October 1. We will use the same submissions made for national HCPCS codes as the basis for making temporary code assignments. However, a very large volume of requests or systems constraints could affect our ability to achieve this goal.

Any applications for HCPCS codes that are received after April 1 will be retained for the next cycle of the national HCPCS code assignment process starting the following April 1. We will also consider these items for assignment of temporary codes that might take effect in January or later in the next year.

How quickly additional payment for a new item can be implemented will depend on processing and systems constraints; it will in general require at least 6 months and may require as many as 9 or more months. Thus, a submission that we receive in May (which is too late for October implementation) might be assigned a temporary code to be used for implementing additional payments starting the following January.

As previously stated, pass-through payment for each item is temporary.

After we obtain information about actual hospital costs incurred to furnish a pass-through item, we will package it into the service with which it is clinically associated.

Comment: A number of commenters expressed concern about the extensive amount of time required to obtain HCPCS codes for new items or services. They argued that the lag-time in coding updates creates a barrier to innovation, claiming that it can be several years before a code is issued for a new surgical technique or product. Some commenters noted that when facilities are forced to code new surgical techniques as "unlisted procedures," pending issuance of a specific code for the procedure, it would result in the facility receiving payment for the lowest related APC group. Some commenters recommended that we assign HCPCS codes as soon as products become available.

Response: We recognize the urgency expressed by commenters. We believe the process we have outlined above will assist interested parties in obtaining HCPCS codes for new items and services in the most expeditious manner possible within the constraints imposed by our system requirements.

## E. Calculation of Group Weights and Conversion Factor

1. Group Weights (Includes Table 1, Packaged Services by Revenue Center)

Section 1833(t)(2)(C) of the Act requires the Secretary to establish relative payment weights for covered hospital outpatient services. That section requires that the weights be developed using data on claims from 1996 and data from the most recent available hospital cost reports. Before enactment of the BBRA 1999, we were required to base the relative payment weights on median hospital costs. Section 201(f) of the BBRA 1999 amended section $1833(\mathrm{t})(2)(\mathrm{ii})$ of the Act to authorize the Secretary to base the relative payment weights on either the median or mean hospital costs. In constructing the database for the outpatient PPS proposed rule group weights and conversion factor, we used a universe of approximately 98 million calendar year 1996 final action claims for hospital outpatient department services received through June 1997 to match to the most recent hospital cost reports available. We have decided to continue to base the relative payments weights in this final rule on median (as opposed to mean) costs because, among other things, reconstructing our database to evaluate the impact of using mean costs after the BBRA 1999 was
enacted would have delayed implementation of the hospital outpatient PPS.
To derive weights based on median hospital costs for services in the hospital outpatient APC groups, we converted billed charges to costs and aggregated them to the procedure or visit level. To accomplish this, we first identified the cost-to-charge ratio that was specific to each hospital's cost centers ("cost center specific cost-tocharge ratios" or CCRs). We then developed a crosswalk to match the hospital's CCRs to revenue centers used on the hospital's 1996 outpatient bills. The CCRs included operating and capital costs but excluded costs associated with direct graduate medical education and allied health education.

To determine the hospital CCRs, the most recent available cost report from each hospital was identified. For the proposed rule, we used cost reports from cost reporting periods beginning on or after October 1, 1994 and before October 1, 1995 (referred to as PPS-12) or earlier. For this final rule, more recent cost reports were available for hospitals. We used cost reports from cost reporting periods beginning on or after October 1, 1996 and before October 1, 1997 (PPS-14) for approximately 94 percent of the hospitals in our database.
If the most recent available cost report for a hospital was one that had been submitted but not settled, we calculated a factor to adjust for the differences that generally exist between settled and "as submitted" cost reports. The adjustment factor was determined by dividing the outpatient department cost-to-charge ratio from the hospital's most recent settled cost report by the outpatient department cost-to-charge ratio from the hospital's "as submitted" cost report for the same period. The resulting ratio was used to adjust each of the CCRs in the hospital's most recent "as submitted" cost report. We repeated this process for every hospital for which the most recent available cost report was a cost report that had not been settled.
The Office of Inspector General (OIG) for DHHS is concerned that the cost reports we are using may reflect some unallowable costs. Therefore, the OIG, in conjunction with HCFA, is proposing to examine the extent to which the cost reports used reflect costs that were inappropriately allowed. If this examination reveals excessive inappropriate costs, we will address this issue in a future proposed rule, or perhaps seek legislation to adjust future payment rates downward.
We next eliminated from the hospital CCR database 258 hospitals that we have identified as having reported
charges on their cost reports that were not actual charges (for example, they make uniform charges for all services). These excluded hospitals were Kaiser, New York Health and Hospital
Corporation, and all-inclusive rate hospitals. After removing these hospitals, we calculated the geometric mean of the total operating CCRs of hospitals remaining in our CCR database. We identified 58 hospitals whose total operating CCR exceeded the geometric mean by more than 3 standard deviations. These hospitals were also removed from our CCR database.

After assembling and editing our new CCR database, we matched revenue centers from approximately 80 million claims to CCRs of approximately 5,700 hospitals. We excluded from the crosswalk approximately 15 million claims in which the bill type denoted services that would not be covered under the PPS (for example, bill type 72X for dialysis services for patients with ESRD). We also excluded almost 3 million claims from the hospitals that we had removed or trimmed from the hospital CCR database. The table below shows the five cost reporting periods used and the percentage of the cost reports within each PPS period for which we were able to match 1996 claims.

| Reporting period | Percent- <br> age of <br> cost re- <br> ports <br> matched |
| ---: | ---: |
| PPS-15 (cost reporting period be- <br> ginning on or after 10/1/97 and <br> before 10/1/98) .................. | 0.1 |
| PPS-14 (cost reporting period be- |  |
| ginning on or after 10/1/96 and |  |
| before 10/1/97) ......................... |  |$\quad 94.2$

Next, we took the estimated 80 million claims that we had matched with a cost report and separated them into two distinct groups: Singleprocedure claims and multipleprocedure claims. Single-procedure claims were those that included only one HCPCS code (other than laboratory and incidentals such as packaged drugs and venipuncture) that could be grouped to an APC. Multiple-procedure
claims included more than one HCPCS code that could be mapped to an APC. There were approximately 45.4 million single-procedure claims and 34.6 million multiple-procedure claims.

To calculate median costs for services within an APC, we used only the singleprocedure bills. (Of the roughly 45.4 million single-procedure claims, about 24 million were excluded from the conversion process largely because the only HCPCS codes reported on the claims were for laboratory procedures or other outpatient services not paid under the outpatient PPS.) This approach was taken because the information on claims does not enable us to specifically allocate charges or costs for packaged items and services such as anesthesia, recovery room, drugs, or supplies to a particular procedure when more than one significant procedure or medical visit was billed on a claim. Use of the single-procedure bills minimizes the risk of improperly assigning costs to the wrong procedure or visit. Although we used only single-procedure/visit bills to determine APC relative payment weights, we used multiple-procedure bills in the conversion factor and service mix calculations, regressions, and impact analyses.
For each single-procedure claim, we calculated a cost for every billed line item charge by multiplying each revenue center charge by the appropriate hospital-specific CCR. If the appropriate cost center did not exist for a given hospital, we crosswalked the revenue center to a secondary cost center when possible, or to the hospital's overall cost-to-charge ratio for outpatient department services. We excluded from this calculation all charges associated with HCPCS codes previously defined as not paid under this PPS (for example, laboratory, ambulance, and therapy services).
To calculate the per-procedure or pervisit costs, we used the charges shown in the revenue centers that contained items integral to performing the procedure or visit. These included those items that we previously discussed as being subject to our proposed packaging provision. For instance, in calculating the surgical procedure cost, we included charges for the operating room, treatment rooms, recovery, observation, medical and surgical supplies, pharmacy, anesthesia, casts and splints, and donor tissue, bone, and organ. For medical visit cost estimates, we included charges for items such as medical and surgical supplies, drugs, and observation. A complete listing of the revenue centers that we used is shown below in Table 1, Packaged Services by Revenue Center.

## Table 1.-Packaged Services by Revenue Center

ASC AND OTHER SURGERY
250 PHARMACY
251 GENERIC
252 NONGENERIC
257 NONPRESCRIPTION DRUGS
258 IV SOLUTIONS
259 OTHER PHARMACY
260 IV THERAPY, GENERAL CLASS
262 IV THERAPY/PHARMACY SERVICES
263 IV THERAPY/DRUG/SUPPLY/DELIVERY
264 IV THERAPY/SUPPLIES
269 OTHER IV THERAPY
270 M\&S SUPPLIES
271 NONSTERILE SUPPLIES
272 STERILE SUPPLIES
276 INTRAOCULAR LENS
279 OTHER M\&S SUPPLIES
370 ANESTHESIA
379 OTHER ANESTHESIA
390 BLOOD STORAGE AND PROC-
ESSING
399 OTHER BLOOD STORAGE AND
PROCESSING
630 DRUGS REQUIRING SPECIFIC IDEN-
TIFICATION, GENERAL CLASS
631 SINGLE SOURCE DRUG
632 MULTIPLE SOURCE DRUG
633 RESTRICTIVE PRESCRIPTION
700 CAST ROOM
709 OTHER CAST ROOM
710 RECOVERY ROOM
719 OTHER RECOVERY ROOM
720 LABOR ROOM
721 LABOR
723 CIRCUMCISION
762 OBSERVATION ROOM
810 ORGAN ACQUISITION
819 OTHER ORGAN ACQUISITION
890 OTHER DONOR BANK
891 BONE
892 ORGAN
893 SKIN
899 OTHER DONOR BANK

## MEDICAL VISIT

250 PHARMACY
251 GENERIC
252 NONGENERIC
257 NONPRESCRIPTION DRUGS
258 IV SOLUTIONS
259 OTHER PHARMACY
270 M\&S SUPPLIES
271 NONSTERILE SUPPLIES
272 STERILE SUPPLIES
279 OTHER M\&S SUPPLIES
630 DRUGS REQUIRING SPECIFIC IDEN-
TIFICATION, GENERAL CLASS
631 SINGLE SOURCE DRUG
632 MULTIPLE SOURCE DRUG
633 RESTRICTIVE PRESCRIPTION
700 CAST ROOM
709 OTHER CAST ROOM
762 OBSERVATION ROOM
OTHER DIAGNOSTIC (BLENDED SERVICES)

254 PHARMACY INCIDENT TO OTHER DIAGNOSTIC
372 ANESTHESIA INCIDENT TO OTHER DIAGNOSTIC
622 SUPPLIES INCIDENT TO OTHER DIAGNOSTIC

## Table 1.-Packaged Services by Revenue Center-Continued

710 RECOVERY ROOM
719 OTHER RECOVERY ROOM
762 OBSERVATION ROOM
RADIOLOGY SUBJECT TO THE FEE SCHEDULE AND OTHER RADIOLOGY
255 PHARMACY INCIDENT TO RADIOLOGY
371 ANESTHESIA INCIDENT TO RADIOLOGY
621 SUPPLIES INCIDENT TO RADIOLOGY
710 RECOVERY ROOM
719 OTHER RECOVERY ROOM
762 OBSERVATION ROOM

## ALL OTHER APC GROUPS

250 PHARMACY
251 GENERIC
252 NONGENERIC
257 NONPRESCRIPTION DRUGS
258 IV SOLUTIONS
259 OTHER PHARMACY
260 IV THERAPY, GENERAL CLASS
262 IV THERAPY PHARMACY SERVICES
263 IV THERAPY DRUG/SUPPLY/DELIV-
ERY
264 IV THERAPY SUPPLIES
269 OTHER IV THERAPY
270 M\&S SUPPLIES
271 NONSTERILE SUPPLIES
272 STERILE SUPPLIES
279 OTHER M\&S SUPPLIES
630 DRUGS REQUIRING SPECIFIC IDEN-
TIFICATION, GENERAL CLASS
631 SINGLE SOURCE DRUG
632 MULTIPLE SOURCE DRUG
633 RESTRICTIVE PRESCRIPTION
762 OBSERVATION ROOM
We then applied to these cost estimates an adjustment to calibrate the costs to calendar year 1996 for those services in hospitals whose CCRs were calculated using FY 1997 or later cost reports. On average, hospital charges were rising faster than costs in FY 1997. We therefore made this adjustment for the calculation of the weights, as well as for the hospital costs used in the conversion factor and impact model, to ensure that we did not underestimate costs and payments. We based this hospital specific CCR adjustment on the observed change in each hospital's overall CCR (total operating + total capital) from the proposed rule cost report database to the new final rule database. If applicable, we then calculated a monthly rate of change and applied it based on the number of months past 1996 encompassed in a hospital's cost reporting period; if a hospital's period coincided completely within calendar year 1996, no adjustment was made.

After calibrating the costs to calendar year 1996, we standardized costs for geographic wage variation by dividing the labor-related portion of the
operating and capital costs for each billed item by the FY 2000 hospital inpatient prospective payment system wage index published in the Federal
Register on July 30, 1999 (64 FR 41585). As in the proposed rule and correction notice, we used 60 percent to represent our estimate of that portion of costs attributable, on average, to labor. A more detailed discussion of wage index adjustments is found below in section III.G of this document.

The standardized labor-related cost and the nonlabor-related cost component were summed for each billed item to derive the total standardized cost for each procedure or medical visit. Extremely unusual costs that appeared to be errors in the data were trimmed from standardized procedure and visit costs. This trimming methodology is analogous to that used in calculating the DRG weights for the inpatient PPS: eliminate any bills with costs outside of 3 standard deviations from the geometric mean. We used the geometric mean and the associated standard deviation because the distribution of costs more closely resembles a lognormal distribution than a normal distribution: There are no negative costs, and the average cost is greater than the median cost. Use of the geometric mean minimizes the impact of the most unusual bills in the determination of the mean. The geometric mean is calculated by taking the mean of the natural logarithm cost. Because the distribution of the natural logarithms of a set of numbers is more compact than the distribution of the numbers themselves, bills with extreme costs do not appear as extreme as they would if non-logged costs were examined. This ensures that only the most aberrant data will be removed from the calculation.

After trimming the procedure and visit level costs, we mapped each procedure or visit cost to its assigned APC and calculated the median cost for each APC weighted by procedure volume. Using the median APC costs, we calculated the relative payment weights for each APC. We scaled all the relative payment weights to APC 601, a mid-level clinic visit, because it is one of the most frequently performed services. This approach is consistent with that used in developing relative value units for the Medicare physician fee schedule. By assigning APC 601 a relative payment weight of 1.0, hospitals can easily compare the relative relationship of one APC to another. Next, we divided the median cost for each APC by the median cost for a midlevel clinic visit, APC 601, to derive the relative payment weight for each APC.

The median cost for APC 601 is $\$ 47.00$. In the proposed rule, we also used a mid-level clinic visit, APC 91336, which had a median cost of $\$ 54.00$, as the scaler of APC weights. On average, due to the reduced value of the scaler used for this notice, the final weights will be higher than those published in the proposed rule.

Comment: Some commenters believe that the ratesetting methodology does not reflect complex cases because we eliminate statistical "outlier" claims from the calculation of the median costs and the weights.
Response: As noted above, we trimmed claims with estimated costs that were outside of three standard deviations from the geometric mean. Because we removed claims above or below the mean, we corrected for data errors that would have skewed the estimates of median costs and group weights upward or downward. We believe this trim is a valid method of removing extremely unusual costs that are most likely associated with data submission errors and do not represent actual costs. In addition, it is consistent with the method we use to set inpatient hospital diagnosis-related group (DRG) weights.

Comment: Numerous commenters disagreed with our use of singleprocedure claims only in the calculation of the relative payment weights. One commenter was concerned that we could be masking differences in resource use attributable to patient characteristics by using only singleprocedure claims to calculate relative weights.
Response: We used single-procedure claims to calculate the relative weight for each APC because we could not accurately allocate costs to a particular procedure when the costs were part of a bill for multiple procedures. Bills with a single major procedure provided are, in most cases, the best estimate of relative procedure costs. It is important to note that for all other calculations, including calculation of the conversion factor, we used both single-procedure and multiple-procedure bills.
We do not believe that using singleprocedure bills biases the relative cost of any particular procedure. Although patients with more complex healthcare needs might have several procedures performed, hospital charges for an individual procedure would not be greater. Our most significant concern was that distribution of single bill procedures within an APC would not reflect the correct distribution of those procedure on all bills. However, careful statistical analyses demonstrated that the distribution of procedures within an

APC group did not differ when single bill procedure frequencies were compared with all bills. It is also important to note that when items or services were to be packaged with a major procedure, we added their costs to that procedure prior to making the single bill determination. Therefore, the costs of contrast media, for example, are included in the relative weights. In some cases, we agreed with the commenters that this approach needed to be modified. For example, for chemotherapy, we are not grouping drugs, but rather paying for each one separately. Moreover, as a result of the transitional pass-through provisions of the BBRA 1999, radiopharmaceuticals will be paid separately from the nuclear medicine APCs.

Comment: Several commenters expressed concern that the 1996 claims data are insufficient or inadequate to develop the PPS model. For example, some commenters asserted that the 1996 data are not recent enough to reflect the current mix of outpatient services. Some commenters also argued that undercoding in the data would lead to underestimates of median costs. Other commenters recommended that we address alleged inadequacies in the data by gathering cost data on new procedures and by basing payment on these data until we can determine whether to place a new procedure in an existing APC or create a new APC.

Response: While we acknowledge limitations of setting payment rates with historical claims data, section 1833(t)(2)(C) of the Act requires us to use 1996 claims in developing the PPS. We discuss how we will price new procedures that are not reflected in our database in section III.C. 8 of this preamble.

Comment: Commenters were concerned about the cost-to-charge ratios used to estimate median APC costs and pre-BBA payments. For example, one medical organization recommended that we account for the capital-intensive nature of radiology services by adjusting the cost-to-charge ratios applicable to these services for the step-down methodology that allocates capital expenses by square footage. The belief is that these allocation methods underestimate radiological equipment costs and certain cost-to-charge ratios, leading to underestimates of the median costs for relevant APC groups.

Response: Although capital-related costs may be allocated to routine and ancillary service cost centers using the step-down methodology based on square footage, as an alternative, the "dollar value" method may be used by hospitals. This method is made
available to hospitals in Worksheet B1 of the hospital cost report (HCFA 2552-96). The dollar value method more accurately distributes the capital costs associated with equipment to the revenue-producing cost center to which the equipment is assigned. We are not able to adjust the cost-to-charge ratios of those hospitals that allocate equipment based on square footage because we have no way of knowing which specific equipment costs should be allocated to revenue-producing cost centers in each hospital.

## 2. Conversion Factor

Section 1833(t)(3)(C)(i) of the Act requires that we establish a conversion factor for 1999 to determine the Medicare payment amounts for each covered group of services. For the proposed rule as corrected, we derived the conversion factor from a base amount of payments described in section 1833(t)(3)(A) of the Act, as enacted in the BBA 1997. Such base amount was calculated for the services included in the outpatient PPS as an estimate of the sum of (1) total payments that would be payable from the Trust Fund under the current (non-PPS) payment system in 1999, plus (2) the beneficiary coinsurance that would have been paid under the new (PPS) system in 1999. For the final rule, however, we derived the conversion factor from a base amount that includes beneficiary coinsurance that would have been made under the current (non-PPS) system rather than the proposed (PPS) system. Section 201(l) of the BBRA 1999 states: "With respect to determining the amount of copayments described in paragraph (3)(A)(ii) of section 1833(t) of the Social Security Act, as added by section 4523(a) of the BBA, Congress finds that such amount should be determined without regard to such section, in a budget neutral manner with respect to aggregate payments to hospitals, and that the Secretary of Health and Human Services has the authority to determine such amount without regard to such section."

Section 1833(t)(2)(C) of the Act requires us to project utilization for hospital outpatient services. We were unable to make precise projections of increases in the volume and intensity of services because we were not able to quantify some of the factors that affect utilization. For instance, we would anticipate that Medicare beneficiaries who choose to migrate to managed care plans may be healthier than those who choose to stay in fee-for-service plans. Thus, we could assume a decrease in the volume of services coupled with an increase in the intensity of services
furnished for Medicare beneficiaries in the fee-for-service program. Another factor that we believe will affect future utilization is the incentive to code billed services more accurately. Currently, hospitals are paid for the majority of the outpatient services they furnish on a cost basis, and inaccurate or improper coding does not necessarily affect the amount of payment. In contrast, under the PPS, hospitals are required to use HCPCS codes in order to receive payment. We expect that the frequency of some services may increase as a result of the coding requirements. We believe each of these assumptions will affect the reporting of volume and intensity of services, although we are not able to quantify them individually to project 1999 utilization. Therefore, we used what we believe to be a more reliable and valid approach to computing the conversion factor under the methodology described below.

Comment: A large national trade association commented that the exclusion of claims for unclassified services (for example, those claims for which we cannot identify the service to be paid) from the PPS model could bias the conversion factor downward if the excluded claims have a disproportionate number of services with high payment to cost ratios, such as clinic and emergency room visits.

Response: In order to set the conversion factor as accurately as possible, we used only claims for which the costs and volume of services could be identified on the bill. As noted by the commenter, this decision resulted in the exclusion of claims with unclassifiable services. Upon examination of these claims, we have determined that services with high payment to cost ratios (those that would gain under the PPS system) were not
disproportionately represented.
Therefore, we believe the exclusion of unclassifiable services does not bias the conversion factor.

## Setting the Rates

In order to convert the relative weights determined for each APC (see section III.E.1) into payment rates, we calculated a conversion factor that would result in total estimated payments to hospitals under the PPS in 1999 equal to the total estimated payments that would have been payable from the Trust Fund in 1999 if PPS had not been enacted plus estimated beneficiary coinsurance for the same services during the same period. The prospective payment rate for each APC is calculated by multiplying the APC's relative weight by the conversion factor. For the calculation of the conversion
factor, we have excluded all data from the 58 Maryland providers that qualify under section 1814(b)(3) of the Act for payment under the State's payment system. We computed the conversion factor by first adding together the aggregate Medicare hospital outpatient payments made under the cost-based payment system (referred to in this section as pre-PPS payments) for calendar year 1996, plus the estimated beneficiary coinsurance amounts made under pre-PPS law for the same services. We then divided that amount by a wage-adjusted sum of the relative weights for all APCs under the hospital outpatient PPS. The methodology we used to determine current law Medicare hospital outpatient payments and beneficiary coinsurance is discussed below in section III.E.2.a. A discussion of the sum of the relative weights follows in section III.E.2.b.
a. Calculating Aggregate Calendar Year 1996 Medicare and Beneficiary Payments for Hospital Outpatient Services (Pre-PPS)

To calculate Medicare hospital outpatient payment amounts before implementation of the PPS, we first identified calendar year 1996 single and multiple procedure bills for all the services that we will recognize under the outpatient PPS. As we identified services that will be paid under the outpatient PPS, we eliminated invalid or noncovered HCPCS codes.

Hospital payments include both operating and capital costs for the HCPCS coded services for which payment is to be made under the outpatient PPS. We summed these two types of costs by HCPCS code at the provider level. Consolidating the data in this manner allowed us to simulate provider payment on an aggregate basis. Then (as required by section
1861(v)(1)(S)(ii) of the Act as amended by section 201(k) of the BBRA 1999), we applied the capital cost reductions of 10 percent and operating cost reductions of 5.8 percent.

We determined for each HCPCS code the applicable payment methodology under the current system. Payment before implementation of PPS for procedures in the baseline was calculated using one of the following equations, as appropriate:

- For radiology procedures paid for under the radiology fee schedule, we determined payment in the aggregate for each provider as the lower of the cost, charge, or blended amount. We use the following equation to determine the radiology blended amount: ( $0.42 \times$ lower of cost or charge minus beneficiary coinsurance $)+(0.58 \times((0.62 \times$ global
physician fee schedule amount) beneficiary coinsurance)).
- For surgical procedures for which Medicare pays an ASC facility fee, we determined payment in the aggregate for each provider as the lower of the cost, charge, or blended amount. We used the following equation to determine the ASC blended amount: ( $0.42 \times$ lower of cost or charge minus beneficiary coinsurance $)+(0.58 \times($ ASC payment rate - beneficiary coinsurance)).
- For diagnostic procedures paid for under the diagnostic fee schedule, we determined payment in the aggregate for each provider as the lower of the cost, charge, or blended amount. We used the following equation to determine the blended amount for diagnostic procedures: $(0.50 \times$ lower of cost or charge minus beneficiary coinsurance) + $(0.50 \times((0.42 \times$ global physician fee schedule amount) - beneficiary coinsurance)).
For all other covered services not subject to one of the blended payment method categories, we determined payment as the lower of costs or charges less beneficiary coinsurance. Because the formula-driven overpayment (FDO) was corrected beginning October 1, 1997, the blended equations eliminate FDO.
We then determined the Medicare payment amount for each provider by summing the aggregate amounts computed for each of the four types of payment methodologies discussed above. In addition, we determined the amount of the beneficiary coinsurance for each provider using the beneficiary coinsurance amounts that would have been paid before implementation of PPS. The total amount (Medicare and beneficiary payments) reflects the amount hospitals would be paid under the PPS and is the numerator in the equation for calculating the unadjusted conversion factor.


## b. Sum of the Relative Weights

Next we summed the discounted relative weights for services that are within the scope of the outpatient PPS. (See discussion of discounting for surgical procedures in section III.C.7.) Specifically, we multiplied (using single and multiple procedure claims in a hospital) the discounted volume of procedures or visits in each APC group by the relative weights for each APC group; we wage-adjusted 60 percent of this total by each hospital's wage index, and we then summed the wage-adjusted and nonadjusted weights across all hospitals. (The wage indices used are included in Addenda H, I, and J.) The resulting sum equals the denominator in the calculation of the conversion factor.

We calculated the conversion factor by dividing the sum of the discounted relative weights into the total payment explained in section III.E.2.a, above, including both Medicare payment and beneficiary coinsurance. We then adjusted the conversion factor so that the outlier and pass-through payments are implemented in a budget neutral manner, as described in sections III.H. 1 and III.D. The adjusted calendar year 1996 conversion factor is $\$ 43.023$. To inflate the 1996 conversion factor to 1999, our Office of the Actuary estimated an update factor of 1.106. Therefore, the adjusted 1999 conversion factor is $\$ 47.583$.
For calendar year 2000, we updated the conversion factor as specified in section 1833(t)(3)(C)(iii) of the Act. The update is the market basket percentage increase applied to hospital discharges occurring during the fiscal year ending in calendar year 2000 minus 1 percentage point. For 2000, the updated conversion factor is $\$ 48.487$.

Comment: A number of commenters suggested that we remove the behavioral offset that we proposed to apply to the conversion factor. As proposed, the intent of the offset was to adjust for hospital coding changes that take place in response to reductions in beneficiary coinsurance.
Response: We have decided not to include a behavioral offset to the conversion factor in this final rule. Hospital coding changes are expected to occur under the outpatient PPS; however, we believe changes that occur during the first PPS years will result from hospitals billing more accurately under the new system. A behavioral offset implemented in the initial PPS years may distort the incentives to bill accurately. We may reconsider implementation of a behavioral offset in future years as we gather data and gain experience under the new system.
Comment: A large national trade association expressed concern that application of the 5.8 percent and 10.0 percent reduction to costs for all hospital outpatient services included in the PPS model underestimates the conversion factor. They recommended that we exclude the Part B services provided to inpatients who exhaust their Part A benefits from the reductions.
Response: Our analysis shows that fewer than 5,000 of the more than 80 million claims used to set the conversion factor were associated with these types of services. Total costs associated with these claims were less than $\$ 1.4$ million, which is too small to have a measurable effect on the conversion factor.

Comment: Many commenters strongly argued that we misinterpreted the provisions of section 1833(t)(3) of the Act in calculating beneficiary coinsurance for purposes of setting the base amount of the conversion factor. The commenters noted that this methodology contributed significantly to the estimated 5.7 percent reduction in Medicare outpatient payments to hospitals reflected in the proposed rule. Most commenters further argued that the Congress did not intend for this loss to occur and that we had the authority to interpret the methodology described in the statute so that no net change in payments would result from the conversion factor.

Response: Section 1833(t)(3)(A) of the Act, as added by the BBA 1997, states that, for purposes of calculating the base amount used to determine the conversion factor, the Secretary shall calculate "the total amount of copayments estimated to be paid under this subsection. * * *" (Emphasis added.) For the proposed rule, we estimated the coinsurance that would be paid under PPS. In section 201(1) of the BBRA 1999, the Congress addressed the calculation of the base amount, stating, "With respect to determining the amount of copayments described in paragraph (3)(A)(ii) of section 1833(t) of the Social Security Act, as added by section 4523(a) of the BBA, Congress finds that such amount should be determined without regard to such section, in a budget neutral manner with respect to aggregate payments to hospitals, and the Secretary of Health and Human Services has the authority to determine such amount without regard to such section." Therefore, for this final rule, we estimated the coinsurance that would have been paid if PPS had not been enacted.
F. Calculation of Coinsurance Payments and Medicare Program Payments Under the PPS

## 1. Background

In section III.E, above, we explained how we determined APC group weights, calculated an outpatient PPS conversion factor, and determined national prospective payment rates, standardized for area wage variations, for the APC groups. We will now explain how we calculated beneficiary coinsurance amounts for each APC group.

The outpatient PPS established by section $1833(\mathrm{t})$ of the Act includes a mechanism designed to eventually achieve a beneficiary coinsurance level equal to 20 percent of the prospectively determined payment rate established for the service. As discussed in the
proposed rule, for each APC we calculate an amount referred to in section 1833(t)(3)(B) of the Act as the "unadjusted copayment amount." The unadjusted coinsurance amount is calculated by taking 20 percent of the national median charges billed in 1996 for the services that are in the APC, trended forward to 1999; however, the coinsurance amount cannot be less than 20 percent of the APC payment rate. The unadjusted coinsurance amount for an APC remains frozen, while the payment rate for the APC is increased by adjustments based on the Medicare market basket. As the APC rate increases and the coinsurance amount remains frozen, the unadjusted coinsurance amount will eventually become 20 percent of the payment rate for all APC groups. Once the unadjusted coinsurance amount is 20 percent of the payment amount, both the APC payment rate and the unadjusted coinsurance amount will be updated by the annual market basket adjustment.

In the proposed rule, we proposed to not adopt new APCs for new procedures or services for at least 2 years, but instead assign them to existing groups while accumulating data on their costs. In the final rule we do provide for APCs for new procedures that do not fit well into another APC. When an APC is added that consists of HCPCS codes for which we do not have 1996 charge data upon which to calculate the unadjusted coinsurance amount, coinsurance will be calculated as 20 percent of the APC payment amount.
There is an exception to the coinsurance provisions for screening colonoscopies and screening sigmoidoscopies. Section 4104 of the BBA 1997 provided coverage for colorectal screening. This section, in part, added new sections 1834(d)(2) and (3) to the Act, which provide that for covered screening sigmoidoscopies and colonoscopies performed in hospital outpatient departments and ambulatory surgical centers (ASCs), payment is to be based on the lesser of the hospital or the ASC payment rates and coinsurance for both screening colonoscopies and screening sigmoidoscopies is to be 25 percent of the rate used for payment.

Section 4104 of the BBA 1997 also allows, at the Secretary's discretion, coverage of screening barium enemas as a colorectal cancer screening tool. We are including screening barium enemas as a covered service under the hospital outpatient PPS. The payment rate for screening barium enemas is the same as for diagnostic barium enemas.
Coinsurance for a screening barium enema is based on 20 percent of the APC payment rate.

Sections 201(a) and (b) of the BBRA 1999 amend section 1833( t ) of the Act to provide for additional payments to hospitals for outlier cases and for certain medical devices, drugs, and biologicals. These additional payments to hospitals will not affect coinsurance amounts. Redesignated section 1833(t)(8)(D) of the Act, as amended by section 201(i) of the BBRA 1999, provides that the coinsurance amount is to be computed as if outlier adjustments, adjustments for certain medical devices, drugs, and biologicals, as well as any other adjustments we may establish under section 1833(t)(2)(E) of the Act, had not occurred. Section 202 of the BBRA 1999 adds a new section 1833(t)(7) to the Act to provide transitional corridor payments to certain hospitals through calendar year 2003 and indefinitely for certain cancer centers.
Section 1833(t)(7)(H) of the Act provides that the transitional corridor payment provisions will have no effect on determining copayment amounts.

Section 204(a) of the BBRA 1999 amended redesignated section 1833(t)(8)(C) of the Act to provide that the coinsurance amount for a hospital outpatient procedure cannot exceed the amount of the inpatient hospital deductible for that year. The inpatient hospital deductible for calendar year 2000 is $\$ 776.00$. We will apply the limitation to the wage adjusted coinsurance amount (not the unadjusted coinsurance amount) after any Part B deductible amounts are taken into account. Therefore, although the published unadjusted coinsurance amount for any APC may be higher or lower than $\$ 776.00$ in 2000, the actual coinsurance amount for an APC, determined after any deductible amounts and adjustments for variations in geographic areas are taken into account, will be limited to the Medicare inpatient hospital deductible. Any reductions in copayments that occur in applying the limitation will be paid to hospitals as additional program payments. (See section III.F.3.a, below, for discussion of calculating the Medicare payment amount.)
MedPAC Comment: In its March 1999 report to the Congress, MedPAC expressed concern that the statute's approach to addressing the reduction in coinsurance could mean that it will be decades before coinsurance is 20 percent of all APC payment rates. MedPAC recommended that the Secretary seek and the Congress legislate a more rapid phase-in and that the cost be financed by increases in program spending, rather than through additional reductions in payments to
hospitals. MedPAC agrees that the approach to calculating the coinsurance delineated in section 1833(t) of the Act is methodologically sound, but they recommend a shorter period to complete the coinsurance reduction.

Response: The coinsurance reductions enacted by the BBA 1997 already provide significantly higher levels of financial protection for beneficiaries than have existed in the past. While an acceleration of this protection might be desirable, the costs of such a policy must be balanced against other needs for increased Medicare spending and protection of the trust funds. The President's budget for FY 2001 does not contain such a proposal.

Comment: Three commenters discussed the delay in implementing the outpatient PPS until after January 1, 2000. A hospital association stated that it strongly believes that the outpatient PPS should not be implemented until all systems are ready, and suggested that implementation occur at the start of a calendar year so that Medigap insurers did not receive an unearned windfall by reason of a midyear decrease in beneficiary coinsurance amounts. Stating that the delay in implementation was of serious concern to it, an insurance group strongly urged us to implement the outpatient PPS as soon as possible. Finally, a beneficiary advocacy group stated that it is deeply concerned about the delay in implementation. While stating that it understood the magnitude of the Y2K problem, this group urged us to find a way to proceed with the phase-down of beneficiary coinsurance or, failing that, to offer our assurance that the phasedown will not be delayed beyond January 1, 2000.

Response: As noted elsewhere in this final rule, we intend to implement the outpatient PPS effective for services furnished on or after July 1, 2000. As noted in the proposed rule, we concluded that attempting to make the massive computer changes required to implement PPS at the same time we were trying to ensure that Medicare's computers were Y2K compliant would have jeopardized the compliance effort, which was HCFA's highest priority. Now that HCFA's efforts to make its computer systems, and those of its contractors, Y2K compliant are complete, we believe that July 1, 2000 is the earliest date on which we can feasibly implement the PPS. Pursuant to HCFA's contracts with the contractors responsible for maintaining its computer systems, HCFA makes programming changes such as those required to implement the outpatient PPS at the beginning of fiscal quarters.

Thus, pursuant to this practice, after January 1, 2000, there are only three dates in 2000 on which the programming changes necessary to implement outpatient PPS can be put into effect-April 1, 2000, July 1, 2000 and October 1, 2000.

The first step in changing HCFA's computer systems to allow for implementation of the outpatient PPS is to expand the claim record of several HCFA and contractor systems to accept and retain specific information related to how a service is being paid or why it is denied. The claim record expansion is an indispensable prerequisite to implementation of outpatient PPS. Once expansion of the claim form is completed, we can then make the remaining programming changes necessary to implement the outpatient PPS. As we noted in the proposed rule, 63 FR 47605, these are massive changes that will require extensive testing. We anticipate that these software coding changes cannot be completed before the end of the second quarter of 2000.
Therefore, the earliest possible date on which they can be installed and made operational is July 1, 2000.

We do not believe that it is technically feasible to complete installation of both the claims-form line item expansion and the coding changes needed to implement PPS any sooner than July 1, 2000. Each of these two stages of preparing HCFA's computer system for PPS constitutes major systems changes in and of itself. To attempt to make both changes simultaneously would be to run the risk that the system would not function properly at all, potentially requiring implementation to be delayed beyond July 1, 2000. We believe that the twostage approach discussed above is the only feasible way to make the systems changes necessary to implement PPS and to be certain that they will work. The soonest date on which PPS can be implemented after the millennium is therefore July 1, 2000.

Despite one commenter's request that we implement the outpatient PPS at the start of a calendar year, we do not believe it would be appropriate to delay implementation beyond July 1, 2000. We see no reason to delay implementation beyond the time necessary for HCFA to have completed its Y2K efforts and make all the systems changes necessary for PPS. As with all of the other aspects of PPS, we believe that the beneficiary coinsurance reform contained in the outpatient PPS should be put into effect as soon as possible, so that beneficiaries can be subject to the lower coinsurance amounts under the new payment methodology at the
earliest date. We believe that this consideration outweighs any concern that Medigap insurers might receive a windfall because they set premiums for a given year assuming coinsurance amounts would be at one level only to see those amounts decrease in the middle of the year. In addition, we note that, if insurers received a large enough windfall for the reasons described by the commenter, the insurers might be required to refund premiums to beneficiaries or offer them a credit on premiums pursuant to section 1882(r) of the Act.
While none of the commenters specifically requested that we do so, we have considered the possibility of applying the outpatient PPS payment methodology retroactively to services furnished on or after January 1, 1999. We have decided not to make these retroactive payments for the reasons described below.
The first reason is the practical problem that the information needed to implement PPS retroactively does not exist in a usable form. Under current payment methodologies for many outpatient services, hospitals submit bills for furnished services based on their charges for the services. For these services, HCFA does not require hospitals to submit bills containing the HCPCS code for the furnished service and other data (such as the dates of service of multiple services submitted on the same bill) necessary to process bills under the new prospective payment methodology. Without the HCPCS code for a given service, we would be unable to determine retroactively into which APC group the service should be placed for payment under PPS. In turn, that would mean that we could not determine the appropriate payment amount for the service. Thus, given the information currently available to us, we could not now simply reprocess bills for outpatient services that had been furnished between January 1, 1999 and July 1, 2000 and recompute payment and coinsurance amounts for these services. As a result, the data needed to implement PPS retroactively do not exist in a form that would allow for such implementation.
Nor would it have been feasible to attempt to capture the information necessary for retroactive application during 1999. As noted above, we concluded that it would not have been prudent to make the computer programming changes necessary to implement PPS until our Y2K efforts were complete. Those same changes would have been necessary to allow us to capture the more detailed claims data
needed to perform a retroactive application of PPS back to January 1, 1999 once the system was implemented prospectively. Because we delayed those changes out of concern that they would interfere with our Y2K efforts, no automated process existed for the period January 1, 1999 through July 1, 2000 by which we could have captured the more detailed claims data necessary to effect an eventual retroactive implementation of PPS. Publication of a final rule before January 1, 1999 would not have altered this situation. Even if we had published such a rule, it could not have become effective until we could make the computer changes necessary to implement PPS-the functional equivalent of what we have done through publication of the proposed rule and this final rule-and until we could make those changes, we could not compile by computer the data needed to later reprocess claims under PPS.

In theory, we might have been able to implement PPS retroactively despite the lack of an automated method of compiling the data necessary to do so. But it simply would not have been practicable to maintain and later process by hand such data for the period between January 1, 1999 and July 1, 2000, given the millions of claims for outpatient services submitted during that period. (Based on the latest data available, we process approximately 160 million claims for outpatient services over an 18-month period.) Neither HCFA nor its contractors have the staff needed to accomplish such a task.

We might also have conceivably required hospitals to maintain the data required for a later retroactive implementation of PPS, but this approach has practical difficulties. First, during the interim period between January 1, 1999 and implementation of PPS, hospitals themselves were exerting significant efforts to ensure the Y2K compliance of their own automated Medicare billing systems, and it is doubtful that those systems could have accommodated the necessary programming changes any more than Medicare's systems could have. Even if hospitals could have maintained the information (or if HCFA could have maintained it by hand or could obtain it from any source now), the burden associated with attempting to implement the new prospective payment methodology both retroactively and prospectively at the same time would have been prohibitive. As noted in the proposed rule and in this final rule, effecting the transition between the old payment methodologies and the new prospective payment methodology constitutes a massive programmatic
undertaking. Any effort to reprocess the huge number of bills for outpatient services that would be involved in any attempt to retroactively implement PPS would compete for the same resources needed to implement PPS prospectively, and would compromise our ability to ensure the smoothest prospective implementation.

This is especially so if paper records of claims from the interim period would have to be manually input into Medicare's automated payment systems in order to make retroactive payments for services furnished on or after January 1, 1999. Undertaking an effort, once PPS is implemented, to review hospital records of every outpatient service furnished between January 1, 1999 and July 1, 2000; translate those records into the data needed to process a Medicare claim for the service under PPS; and issue a retroactive payment reflecting the PPS rate for the service would cause a huge backlog of current bills to be processed (and of other carrier tasks), and thus would not be practicable. Therefore, there was no feasible way to have captured the information necessary to make PPS apply retroactively.

In addition to the practical problems described above, the statute does not require retroactive application of PPS. The statutory requirement to implement the PPS for services furnished on or after January 1, 1999 is ambiguous. While section 1833(t)(1)(A)'s reference to outpatient services "furnished during a year beginning with 1999" might be read as imposing such a requirement, it is also true that section $1833(\mathrm{t})(1)(\mathrm{B})(\mathrm{i})$ does not expressly set a time limit for HCFA to designate which services are "covered" outpatient services for purposes of payment under PPS. Nor does it set a deadline for HCFA to issue regulations implementing the outpatient PPS. As a result, the statute can also be read to require implementation of PPS for services furnished in a year beginning in 1999 if HCFA has designated in its implementing regulations those services as covered services for purposes of PPS. The better reading is that the system applies prospectively only.

We recognize that, under section 1833(a)(2)(B), Congress arguably made the old payment methodologies for outpatient services inapplicable to services furnished on or after January 1, 1999. Again, though, Congress imposed no corresponding limit on the time within which HCFA must designate the services that would be "covered" services for purposes of PPS. While it is therefore possible to read the statute in such a way that an outpatient service
furnished after January 1, 1999 but not yet designated as a covered outpatient service by HCFA for purposes of PPS would have no payment methodology applicable to it, we do not believe that Congress intended such a result. We believe that where HCFA, because of significant Y2K concerns, has not yet designated a given outpatient service as a covered service for purposes of PPS, the most appropriate reading of section 1833(t)(1)(A) is that it authorizes the Secretary to continue to pay for the service under the existing methodology until PPS can be implemented. If the Congress had known about the Y2K problem at the time it enacted the PPS statute, this is the only rational approach it could have adopted.

We believe that a clear expression of Congressional intent not to require retroactive application of PPS can be found in the legislative history of amendments to section 1833(t) of the Act, enacted as sections 201, 202, and 204 of the BBRA 1999. In each instance, the legislation provides that the "amendments made by this section shall be effective as if included in the enactment of the BBA," that is, the original enactment of PPS in section 1833(t) (sections 201(m), 202(b), and 204(c) of the BBRA 1999). This language was taken from the House version of the bill (H.R. Rep. No. 436 (Part I), 106th Cong., 1st Sess. 14, 16 (1999)). The House Report stated that the outpatient payment reforms contained in the BBRA 1999 (and hence in the BBA 1997) were intended to take effect "upon implementation of the hospital prospective payment system" by HCFA, id. at 52, 55, 56, not on January 1, 1999. The House Conference Committee Report reiterated the understanding that the payment and coinsurance provisions of the BBA and BBRA do not take effect until after implementation by HCFA. H. Conf. Rep. No. 479, 106th Cong., 1st Sess. 866 (1999) ('’[c]urrently, beneficiaries pay $20 \%$ of charges for outpatient services," but "[u]nder the outpatient PPS, beneficiary coinsurance will be limited to frozen dollar amounts based on $20 \%$ of national median charges for services in 1996, updated to the year of implementation of the PPS"); id. at 867 (" $[t]$ he conferees fully expect that the beneficiary coinsurance phasedown will commence, as scheduled, on July 1, 2000"); 870 ("'[h]ospital outpatient PPS is to be implemented simultaneously and in full for all services and hospitals (estimated for July 2000)'").
Both the House Report and the Conference Report expressly acknowledge, without disapproval, HCFA's decision to delay
implementation of the outpatient PPS until after January 1, 2000. H.R. Rep. No. 436 (Part I) at 51 (stating that Secretary "delayed implementation of the new system until after the start of CY 2000 in order to ensure that 'year 2000' data processing problems are fully resolved before the new system is implemented" and that "HCFA currently estimates that the outpatient department prospective payment system will be implemented in July 2000"); 145 Cong. Rec. at H12529 (daily ed. Nov. 17, 1999) (H. Conf. Rep. No. 479) (acknowledging " $[t]$ here has already been a one-year delay in implementation of the BBA 97 provision" and stating that conferees "fully expect" that the outpatient prospective payment system "will commence, as scheduled, on July 1, 2000'). These statements indicate Congressional intent that payments and coinsurance for covered hospital outpatient services would be governed prospectively by PPS only after HCFA promulgated and made effective final implementing regulations.

Finally, there is a serious question as to whether retroactive implementation of PPS might constitute prohibited retroactive rulemaking. In Bowen v. Georgetown University Hospital, 488 U.S. 204, 208 (1988), the Supreme Court stated that a statutory grant of legislative rulemaking authority does not encompass the power to promulgate retroactive rules unless that power is conveyed by Congress in express terms, even where some substantial justification for retroactive rulemaking might exist. The Court then declined to find this express authorization for retroactive rulemaking in the Medicare statute's general grant of rulemaking authority.

We do not find this express authorization in section 1833(t) or any other statutory provision concerning the outpatient PPS. Section 1833(t)(1) requires that payment for outpatient services that are furnished during any calendar year beginning after January 1, 1999 and that are designated by HCFA as "covered" outpatient services shall be made under a prospective payment system. While Congress may have presumed, when it enacted section $1833(\mathrm{t})$ as part of the BBA, that HCFA would be able to designate covered outpatient services and implement the outpatient PPS by January 1, 1999, Congress did not foresee at that time that Y2K concerns would prevent the agency from doing so. As a result, the statute is silent as to what was to occur if HCFA was unable to designate covered outpatient services and implement PPS by January 1, 1999. We
do not believe that this silence constitutes the express authorization of retroactive rulemaking required by the Supreme Court's Georgetown decision.
Comment: Several commenters contended that the proposed rules for beneficiary coinsurance are overly complex and that the phase-in period is too long. One commenter asked HCFA to consider a less involved method and a more aggressive time period for implementation. Another commenter suggested using a 5 -year phase-in period. One commenter requested that we recommend a legislative change to the Congress to reduce beneficiary coinsurance to 20 percent by January 1, 2003. Still another commenter expressed concern that calculations of coinsurance amounts for each hospital will be particularly burdensome to Medicare fiscal intermediaries and, as a result of the increased workload, errors may occur. The commenter also recommended a more rapid reduction of coinsurance to 20 percent of the payment amount.
Response: We agree that the rules governing how coinsurance is to be calculated under the PPS are complex, and the phase-in to 20 percent coinsurance is a lengthy one. However, the methods for calculating coinsurance are dictated by the statute. The legislative changes were made in order to put some control on rapidly increasing beneficiary coinsurance payments, to begin to decrease the proportion of beneficiary liability for hospital outpatient services, and to continue to reduce beneficiary liability over time. As we have stated, the impetus to accelerate the reduction of beneficiary coinsurance has to be viewed within the context of other needs for increased Medicare expenditures and long-term protection of the trust funds. The delay in implementing the hospital outpatient PPS past the statutory effective date was unavoidable due to systems constraints imposed by Y2K compliance requirements.
Comment: One commenter noted that the proposed rule set beneficiary coinsurance at 20 percent of median charges, but the commenter believes that coinsurance amounts should be recalculated to equal 20 percent of the average charge for the applicable APC group. The commenter indicates that such a change would provide some financial relief to hospitals.
Response: Section 1833(t)(3)(B)(i) of the Act requires that unadjusted coinsurance amounts be calculated as 20 percent of the national median of the charges for services within the APC group.

Comment: One commenter stated that because coinsurance is based on the median charges of the APC, some beneficiaries would pay a higher coinsurance than they would under the current system. The commenter believes that beneficiaries who require less intensive services in an APC group will essentially subsidize other beneficiaries who receive more intensive services within the group. The commenter asserted that fairness would dictate beneficiaries be charged coinsurance amounts that more appropriately reflect the services received, not an amount based on a median of multiple services they did not receive.
Response: Section 1833(t)(3)(B)(ii) of the Act provides that the unadjusted coinsurance amounts are based on the national median of the charges for the "services within" an APC. Because an APC group consists of services that are both clinically similar and similar with respect to the resources required to perform the service, we would expect that charges for the services should also be fairly homogeneous. We believe that services within a group are homogeneous enough to warrant a single payment amount and a single coinsurance amount.
In the following sections, we describe how we determined the beneficiary coinsurance amount and the Medicare program payment amount for services paid for under the hospital outpatient PPS.
2. Determining the Unadjusted Coinsurance Amount and Program Payment Percentage
To calculate Medicare program payment amounts and beneficiary coinsurance amounts, we first determined for each APC group two base amounts, in accordance with statutory provisions:

- An unadjusted copayment amount, described in section $1833(\mathrm{t})(3)(\mathrm{B})$ of the Act; and
- The predeductible payment percentage, which we call the program payment percentage, described in section $1833(\mathrm{t})(3)(\mathrm{E})$ of the Act.


## a. Calculating the Unadjusted Coinsurance Amount for Each APC Group

In the proposed rule, we described the specific steps used to calculate the unadjusted coinsurance amounts for each APC group as follows:
(i) We determined the national median of the charges billed in 1996 for the services that constitute an APC group after standardizing charges for geographic variations attributable to labor costs. (To determine the labor
adjustment, we divided the portion of each charge that we estimated was attributable to labor costs ( 60 percent) by the hospital's inpatient wage index value and added the result to the nonlabor portion of the charge (40 percent)).
(ii) We updated charge values to projected 1999 levels by multiplying the 1996 median charge for the APC group by 13.0 percent (increased to 14.7 percent in this final rule), which the HCFA Office of the Actuary estimates to be the rate of growth of charges between 1996 and 1999.
(iii) To obtain the unadjusted coinsurance amount for the APC group, we multiplied the estimated 1999 national median charge for the APC group by 20 percent. The unadjusted coinsurance amount is frozen at the 1999 level until such time as the program payment percentage (as determined below) equals or exceeds 80 percent (section 1833(t)(3)(B)(ii) of the Act).

## b. Calculating the Program Payment Percentage (Predeductible Payment Percentage)

In the proposed rule and in this final rule, we use the term "program payment percentage" to replace the term "predeductible payment percentage," which is referred to in section 1833(t)(3)(E) of the Act. The program payment percentage is calculated annually for each APC group, until the value of the program payment percentage equals 80 percent. To determine the program payment percentage for each APC group, we-
(i) Subtract the APC group's unadjusted coinsurance amount from the payment rate set for the APC group; and
(ii) Divide the difference (APC payment rate minus unadjusted coinsurance amount) by the APC payment rate, and multiply by 100.

The program payment percentage will be recalculated each year because APC payment rates will change when APC rates are increased by annual market basket updates and whenever we revise an APC.

Comment: One commenter expressed concern about how the coinsurance amounts are determined. The commenter stated that the calculation is flawed and penalizes beneficiaries in those States where charges for services tend to be lower than in other States. The commenter alleged that if the hospitals in those States where charges for services tend to be lower accept a reduced coinsurance in order to hold beneficiaries harmless, the hospitals will be penalized. The commenter also
asserted that Medigap policies and Medicaid programs will also be affected. The commenter further stated that coinsurance should be based on regional, not national, charges. The commenter contended that the provision does not achieve the intended outcome of equalizing payment across the nation.
Response: Sections 1833(t)(3) and (t)(8) of the Act prescribe how coinsurance amounts are to be calculated under the PPS. Our method of calculating unadjusted coinsurance amounts for each APC group based on 20 percent of national median charges follows the requirements of section 1833(t)(3)(B) of the Act.
Comment: A number of commenters believe that the payment system as proposed would create gross anomalies in coinsurance for particular chemotherapy drugs. For example, the proposed $\$ 36.61$ coinsurance for fluorouracil is 10 times the hospital's cost to purchase that drug. The commenters asserted that this excessive coinsurance represents an abuse of patients and would undermine beneficiary confidence in the new system. They recommended that coinsurance be limited to 20 percent of the payment amount for each drug.

Several other commenters noted that classifying drugs with widely varying costs in the same APC will have a significant negative effect on beneficiary coinsurance, and in some cases beneficiaries could be required to pay a greater percentage of coinsurance for less effective therapies. For example, one commenter alleged that the coinsurance for the drug 5-FU, which the commenter believes has a current coinsurance of approximately $\$ 1$, would increase to $\$ 40$ under the proposed system.
Response: The coinsurance anomalies for chemotherapy drugs that appeared in the proposed rule are not an issue under this final rule. Unlike the proposed chemotherapy drug APCs, which grouped all chemotherapy drugs under four APCs, in this final rule, each chemotherapy drug is assigned to a separate APC. As discussed in section III.D. 5 of this preamble, the unadjusted coinsurance amounts for these APCs is calculated as 20 percent of the APC payment rate.
Comment: One commenter noted that the proposed national unadjusted coinsurance amounts for cardiovascular stress testing and perfusion imaging result in beneficiaries bearing 85 percent of the total payment for stress testing and 60 percent for perfusion imaging, which many beneficiaries will be unable to afford. Another commenter
requested that we either exclude cataract procedures and angioplasty from the hospital outpatient PPS or create an outlier policy that affords special treatment for these procedures in order to protect beneficiaries from excessive coinsurance amounts.
Response: Coinsurance amounts, by law, are based on 20 percent of the median of the charges actually billed in 1996 (updated to 1999) for the services within an APC. The fact that coinsurance is a larger proportion of the total payment for some APCs than for others reflects the differences in hospital charging practices for different services. For example, in examining departmental cost-to-charge ratios reflected on hospital cost reports, we have found that most hospitals have higher mark-ups in charges for radiology and diagnostic services than they do for clinic visits.
3. Calculating the Medicare Payment Amount and Beneficiary Coinsurance Amount

## a. Calculating the Medicare Payment Amount

The national APC payment rate that we calculate for each APC group is the basis for determining the total payment (subject to wage-index adjustment) the hospital will receive from the beneficiary and the Medicare program. (A hospital that elects to reduce coinsurance, as described below in section III.F.4, may receive a total payment that is less than the APC payment rate.) The Medicare payment amount takes into account the wage index adjustment and the beneficiary deductible and coinsurance amounts. In addition, the amount calculated for an APC group applies to all the services that are classified within that APC group. The Medicare payment amount for a specific service classified within an APC group under the outpatient PPS is calculated as follows:
(i) Apply the appropriate wage index adjustment to the national payment rate that is set annually for each APC group.
(ii) Subtract from the adjusted APC payment rate the amount of any applicable deductible as provided under § 410.160 .
(iii) Multiply the adjusted APC payment rate, from which the applicable deductible has been subtracted, by the program payment percentage determined for the APC group or 80 percent, whichever is lower. This amount is the preliminary Medicare payment amount.
(iv) If the wage-index adjusted coinsurance amount for the APC is reduced because it exceeds the inpatient
deductible amount for the calendar year, add the amount of this reduction to the amount determined in (iii) above. The resulting amount is the final Medicare payment amount.

## b. Calculating the Coinsurance Amount

A coinsurance amount is calculated annually for each APC group. The coinsurance amount calculated for an APC group applies to all the services that are classified within the APC group. The beneficiary coinsurance amount for an APC is calculated as follows:

Subtract the APC group's Medicare payment amount from the adjusted APC group payment rate less deductible; for example, coinsurance amount $=$ (adjusted APC group payment rate less deductible)-APC group preliminary Medicare payment amount. If the resulting amount does not exceed the annual hospital inpatient deductible amount for the calendar year, the resulting amount is the beneficiary coinsurance amount. If the resulting amount exceeds the annual inpatient hospital deductible amount, the beneficiary coinsurance amount is limited to the inpatient hospital deductible. For example, assume that the wage-adjusted payment rate for an APC is $\$ 300$; the program payment percentage for the APC group is 70 percent; the wage-adjusted coinsurance amount for the APC group is $\$ 90$; and the beneficiary has not yet satisfied any portion of his or her \$100 annual Part B deductible.
(A) Adjusted APC payment rate: $\$ 300$.
(B) Subtract the applicable deductible: $\$ 300-\$ 100=\$ 200$
(C) Multiply the remainder by the program payment percentage to determine the preliminary Medicare payment amount:

## $0.7 \times \$ 200=\$ 140$

(D) Subtract the Medicare payment amount from the adjusted APC payment rate less deductible to determine the coinsurance amount, which cannot exceed the inpatient hospital deductible for the calendar year:
$\$ 200-\$ 140=\$ 60$
(E) Calculate the final Medicare payment amount by adding the preliminary Medicare payment amount determined in step (C) to the amount that the coinsurance was reduced as a result of the inpatient hospital deductible limitation.
$\$ 140+\$ 0=\$ 140$
In this case, the beneficiary pays a deductible of \$100 and a \$60
coinsurance, and the program pays
$\$ 140$, for a total payment to the hospital of $\$ 300$. Applying the program payment
percentage ensures that the program and the beneficiary pay the same proportion of payment that they would have paid
if no deductible were taken.
If the annual Part B deductible has already been satisfied, the calculation is:
(A) Adjusted APC payment rate: $\$ 300$.
(B) Subtract the applicable deductible: $\$ 300-0=\$ 300$
(C) Multiply the remainder by the program payment percentage to determine the preliminary Medicare payment amount:

## $0.7 \times \$ 300=\$ 210$

(D) Subtract the Medicare payment amount from the adjusted APC payment rate less deductible to determine the coinsurance amount. The coinsurance amount cannot exceed the amount of the inpatient hospital deductible for the calendar year:
$\$ 300-\$ 210=\$ 90$
(E) Calculate the final Medicare payment amount by adding the preliminary Medicare payment amount determined in step (C) to the amount that the coinsurance was reduced as a result of the inpatient hospital deductible limitation.
$\$ 210+\$ 0=\$ 210$
In this case, the beneficiary makes a $\$ 90$ coinsurance payment, and the program pays $\$ 210$, for a total payment to the hospital of \$300.
The following example illustrates a case in which the inpatient hospital deductible limit on coinsurance amounts applies. Assume that the wageadjusted payment rate for an APC is \$2,000; the wage-adjusted coinsurance amount for the APC is $\$ 900$; the program payment percentage is 55 percent; the inpatient hospital deductible amount for the calendar year is $\$ 776$ and the beneficiary has not yet satisfied any portion of his or her \$100 Part B deductible.
(A) Adjusted APC payment rate: \$2,000.
(B) Subtract the applicable deductible: $\$ 2000-\$ 100=\$ 1,900$
(C) Multiply the remainder by the program payment percentage to determine the preliminary Medicare payment amount:
$0.55 \times \$ 1,900=\$ 1,045$
(D) Subtract the preliminary Medicare payment amount from the adjusted APC payment rate less deductible to determine the coinsurance amount. The coinsurance amount cannot exceed the inpatient hospital deductible amount of \$776:
$\$ 1,900-\$ 1,045=\$ 855$, but
coinsurance limited to $\$ 776$
(E) Calculate the final Medicare
payment amount by adding the
preliminary Medicare payment amount determined in step (C) to the amount that the coinsurance was reduced as a result of the inpatient hospital deductible limitation (\$855-\$776 = \$79).

## $\$ 1,045+\$ 79=\$ 1,124$

In this case, the beneficiary pays a deductible of $\$ 100$ and coinsurance that is limited to $\$ 776$. The program pays $\$ 1,124$ (which includes the amount of the reduction in beneficiary coinsurance due to the inpatient hospital deductible limitation) for a total payment to the hospital of \$2,000.
4. Hospital Election To Offer Reduced Coinsurance

For most APCs, the transition to the standard Medicare coinsurance rate (20 percent of the APC payment rate) will be gradual. For those APC groups for which coinsurance is currently a relatively high proportion of the total payment, the process will be correspondingly lengthy. The law offers hospitals, but not CMHCs, the option of electing to reduce coinsurance amounts and permits hospitals to disseminate information on their reduced rates. In this section, we discuss the procedure by which hospitals can elect to offer a reduced coinsurance amount, and the effect of the election on calculation of the program payment and beneficiary coinsurance.

Section 1833(t)(5)(B) of the Act, as added by section 4523 of the BBA 1997, requires the Secretary to establish a procedure under which a hospital, before the beginning of a year, may elect to reduce the coinsurance amount otherwise established for some or all hospital outpatient services to an amount that is not less than 20 percent of the hospital outpatient prospective payment amount. The statute further provides that the election of a reduced coinsurance amount will apply without change for the entire year, and that the hospital may disseminate information on its reduced copayments. Section 1833(t)(5)(C) of the Act, as added by the BBA 1997, provides that deductibles cannot be waived. Finally, section 1861(v)(1)(T) of the Act (as added by section 4451 of the BBA 1997) provides that no reduction in coinsurance elected by the hospital under section 1833(t)(5)(B) of the Act may be treated as a bad debt. We note that section 1833(t)(5) of the Act has been
redesignated as section 1833(t)(8) of the Act by sections 201(a) and 202(a) of the BBRA 1999.

Elections to reduce coinsurance will not be taken into account in calculating transitional corridor payments to
hospitals (discussed in section III.H. 2 of this preamble). That is, a hospital's transitional corridor payment will be determined as if the hospital received unreduced coinsurance amounts from beneficiaries.

In the proposed rule, we stated that we would require that hospitals make the election to reduce coinsurance on a calendar year basis. The proposed rule required that the hospital must notify its fiscal intermediary of its election to reduce coinsurance no later than 90 days prior to the date the PPS is implemented or 90 days prior to the start of any subsequent calendar year and that the hospital's notification must be in writing. It must specifically identify the APC groups to which the hospital's election will apply and the coinsurance amount (within the limits identified below) that the hospital has elected for each group. The election of reduced coinsurance must remain in effect and unchanged during the year for which the election is made. Because the law states that hospitals may disseminate information on any reduced coinsurance amounts, we provided in the proposed rule that hospitals would be allowed to publicly advertise this information.

The proposed regulations provided that a hospital may elect to reduce the coinsurance amount for any or all APC groups. A hospital may not elect to reduce the coinsurance amount for some, but not all, services within the same APC group.

As proposed, a hospital may not elect a coinsurance amount for an APC group that is less than 20 percent of the adjusted APC payment rate for that hospital. In determining whether to make such an election, hospitals should note that the national coinsurance amount under this system, based on 20 percent of national median charges for each APC, may yield coinsurance amounts that are significantly higher or lower than the coinsurance that the hospital previously has collected. This is because the median of the national charges for an APC group, from which the coinsurance amount is ultimately derived, may be higher or lower than the hospital's historic charges. Therefore, in determining whether to elect lower coinsurance and the level at which to make the election, we advise that hospitals carefully study the wageadjusted coinsurance amounts for each APC group in relation to the coinsurance amount that the hospital has previously collected.

As discussed in section III.F.1, under sections 1834(d)(2)(C)(ii) and 1834(d)(3)(C)(ii) of the Act the coinsurance for screening
sigmoidoscopies furnished by hospitals and screening colonoscopies furnished by hospital outpatient departments and ASCs is 25 percent of the applicable payment rate. The payment rate for these colorectal cancer screening tests is the lower of the hospital outpatient rate or the ASC payment rate. The payment rate for screening barium enemas is the same as that for diagnostic barium enemas. However, the coinsurance amount for screening barium enemas is 20 percent of the APC payment rate. Hospitals may not elect to reduce coinsurance for screening sigmoidoscopies, screening colonoscopies, or screening barium enemas.

Calculation of coinsurance amounts on the basis of a hospital's election of reduced coinsurance is similar to the formula described in section III.F.3. For example, assume that the adjusted APC payment rate is $\$ 300$; the program payment percentage for the APC group is 60 percent; the hospital has elected a $\$ 60$ reduced coinsurance amount for the APC group; and the beneficiary has not satisfied the annual Part B deductible.
(A) Adjusted APC payment rate: $\$ 300$.
(B) Subtract the applicable deductible: $\$ 300-\$ 100=\$ 200$
(C) Multiply the remainder by the program payment percentage to determine the Medicare payment amount:

## $0.6 \times \$ 200=\$ 120$

(D) Beneficiary's coinsurance is the difference between the APC payment rate reduced by any deductible amount and the Medicare payment amount, but not to exceed the lesser of the reduced coinsurance amount or the inpatient hospital deductible amount:
$\$ 200-\$ 120=\$ 80$ (limited to $\$ 60$ because of the hospital-elected reduced coinsurance amount)
(E) Calculate the final Medicare payment amount by adding the preliminary Medicare payment amount determined in step ( C ) to the amount that the coinsurance was reduced as a result of the inpatient hospital deductible limitation.

## $\$ 120+\$ 0=\$ 120$

In this case, Medicare makes its regular payment of $\$ 120$, and the beneficiary pays a $\$ 100$ deductible and a reduced coinsurance amount of $\$ 60$. The hospital receives a total payment of $\$ 280$ instead of the $\$ 300$ that it would have received if it had not made its election to reduce coinsurance.

Comment: One commenter stated that it is currently illegal to accept lower coinsurance amounts from beneficiaries and asked for an explanation as to how
we could propose to encourage hospitals to lower coinsurance.

Response: Although Medicare, in general, has prohibitions against reducing beneficiary coinsurance, redesignated section $1833(\mathrm{t})(8)(\mathrm{B})$ of the Act specifically provides the legal authority for hospitals to make elections to reduce coinsurance amounts for purposes of the outpatient PPS.
However, those coinsurance amounts cannot be reduced below 20 percent of the adjusted APC payment rate for the hospital.

Comment: One commenter asked whether, in view of our proposal to allow hospitals to elect lower coinsurance, Medigap insurance plans will be permitted to offer a waiver of a participating hospital's coinsurance. That is, can a Medigap plan act as a preferred provider organization (PPO) with a financial incentive to select those hospitals that elect to reduce coinsurance?

Response: There are two kinds of Medigap policies-regular Medigap and Medicare SELECT. While regular Medigap policies must pay full supplemental benefits on all claims that are submitted by all Medicare providers and are approved by Medicare carriers and intermediaries, Medicare SELECT plans, which are a managed care form of Medigap, may restrict payment of supplemental benefits to network providers. Thus, by design, Medicare SELECT plans are permitted to negotiate selectively with hospitals. Ordinarily, Medicare SELECT plans contract with certain hospitals to waive the hospital deductible for inpatient services.

Since the Congress has expressly permitted hospitals to reduce outpatient coinsurance to no less than 20 percent of the PPS payment amount, a Medicare SELECT plan is free to contract selectively with these hospitals. We note that a hospital's election to reduce coinsurance under redesignated section 1833(t)(8)(B) of the Act requires that the reduction be across-the-board for some or all APC groups. Thus, an agreement between a Medicare SELECT plan and a hospital to reduce coinsurance would result in coinsurance reductions for all beneficiaries who receive those APC group services at the hospital, whether or not they are enrolled in the Medicare SELECT plan.

Comment: One commenter requested that we seek a legislative change to offer hospitals more flexibility under the coinsurance reduction provision by permitting them to review and revise coinsurance amounts every 3 months.
Response: We believe that there would be a significant impact on contractors if hospitals were allowed to
revise their reduced coinsurance more often than annually. More frequent coinsurance changes may also be confusing to beneficiaries. Because we do not have a good estimate of how many hospitals will make the elections and we do not yet know whether those hospitals that do make elections will elect to reduce coinsurance for just a few or for a significant number of APCs we do not support allowing hospitals to make or change elections more often than annually. However, we may reconsider our position after we gain more experience under the PPS and can better assess what the impact of more frequent elections would be on hospitals, beneficiaries, and HCFA and its contractors.

Comment: One commenter noted that if we intend to publish a final rule no more than 90 days before implementation of the PPS, hospitals would not have sufficient time to make coinsurance election decisions. The commenter recommended that hospitals be permitted to make the election 60 days before implementation of the system.

Response: This final rule will not be published more than 90 days before the date of implementation of the PPS. Therefore, the final regulations require that hospitals inform their fiscal intermediaries (FIs) of their elections to reduce coinsurance not later than June 1, 2000. Beginning with elections for calendar year 2001, elections are required to be made by December 1 preceding the calendar year. At this time, we do not know how many hospitals will choose to reduce coinsurance or for how many APCs these hospitals will elect reductions. While we want to provide hospitals sufficient time to make their elections, we also must provide fiscal intermediaries with enough time to incorporate the elections into their systems.

Comment: Several commenters disagreed with our proposal to allow hospitals to advertise reduced coinsurance amounts. They noted that, although the BBA 1997 provision with respect to hospitals' election to reduce coinsurance amounts provides that hospitals may "disseminate information'" on their reductions, we have interpreted that to mean that hospitals may "advertise" their reductions. Two commenters stated that disseminating information is not synonymous with granting one category of hospitals the unique opportunity to advertise to attract customers. They believe that this interpretation is antithetical to the spirit underlying provisions of the Health Insurance

Portability and Accountability Act of 1996 (HIPAA) that prohibit beneficiary inducements and may conflict with State anti-kickback laws. Some commenters were also concerned that under our proposal to allow hospitals to advertise, hospitals may issue a general advertisement of reduced coinsurance when the reduction may apply only to certain services. Other commenters were concerned that hospital advertising may lead Medicare beneficiaries to believe that hospital outpatient care is more economical than other ambulatory settings, even when that is not the case, or beneficiaries may become confused and believe that all ambulatory providers have the ability to reduce coinsurance. These commenters asked us to reconsider our proposal to allow hospitals to advertise rather than to disseminate information. In addition, they asked us to establish additional requirements for hospitals' dissemination of information concerning coinsurance reductions so that beneficiaries are made aware that reduced coinsurance applies only to certain specified services, that it applies only to coinsurance billed by hospitals for those services, and that the law does not permit reduced coinsurance for other Part B services such as physician services.

Several other commenters stated that for the election to reduce coinsurance to be effective, hospitals must have the right to advertise and, therefore, the commenters supported our proposal to permit hospitals to advertise coinsurance reductions.

Response: We believe that hospitals must be able to advertise their coinsurance reductions in order to achieve what we believe to be the intent of the BBA provision, that is, to provide hospitals with some ability to compete with other ambulatory settings (where coinsurance is already 20 percent of the applicable Medicare payment rate) and to reduce beneficiary coinsurance liability.

Hospitals would have less incentive to reduce coinsurance if they could not advertise. In addition, beneficiaries need to be fully informed so that they can make informed decisions. We believe that advertising as a way of disseminating information has merit.

We were persuaded by some commenters' concerns that beneficiaries may not understand that reduced coinsurance applies to specific hospital outpatient services furnished by specific hospitals that choose to elect reductions and that similar reductions cannot be made by other providers of ambulatory services. We, therefore, are amending the regulations to require that all
advertisements or other information furnished to beneficiaries must specify that the coinsurance reductions advertised apply only to the specified services of that hospital and that these coinsurance reductions are available only where a hospital elects to reduce coinsurance for hospital outpatient services and reductions are not allowed in other ambulatory settings or physician offices.

Comment: One commenter, noting the complexity of the PPS coinsurance requirements, requested that we provide a phase-in period in the final rule to allow hospitals sufficient time to implement the changes necessary to meet the requirements.
Response: The method required to be used in calculating coinsurance under the PPS results in an overall decrease in the total coinsurance amounts beneficiaries pay for hospital outpatient services. Total coinsurance is somewhat reduced in the first year of implementation and will be reduced even more in future years, until coinsurance for all PPS services equal 20 percent of the applicable APC payment rate. It is only by fully implementing the coinsurance provisions under section $1833(\mathrm{t})(3)(\mathrm{B})$ of the Act that beneficiaries will realize these reductions. We, therefore, do not support a phase-in period.

Comment: One commenter recommended that we include, as part of the public record, year by year estimates of the total economic burden placed on beneficiaries by the prolonged coinsurance phase-in period, assuming hospitals charge the maximum and minimum coinsurance amounts. The commenter believes these estimates would be useful as a basis for future discussions of how to remedy the coinsurance problem.

Response: As a rule, we develop estimates of impacts for legislative proposals that are under consideration by the Congress and for final legislation as we are developing regulations to implement the law. Although we do not have the resources available to model any number of other data analyses that may have merit, our data are made available to the public, so the commenter and any other interested party may perform the coinsurance analysis.

Comment: One commenter stated that the proposed PPS creates new complexities for Medicare beneficiaries in that they will have to wait for hospitals to do the calculations necessary to determine coinsurance. The beneficiaries will also receive multiple bills and explanations of benefits for multiple hospital visits
occurring on the same day. The commenter stated that we will need to have an extensive process in place to explain why, in most cases, beneficiaries are paying 50 to 70 percent of their outpatient services and why they are receiving separate statements when they have multiple visits on the same day.

Response: In the proposed rule, we assigned medical visits, that is, clinic and emergency room visits, to APCs based on both the level of visit as defined by a HCPCS code and the diagnosis of the patient. In order to implement that type of APC assignment, we would have to require hospitals to submit a separate bill for each medical visit that occurred on the same day; however, under the final rule, medical visits are assigned to APCs based solely on the HCPCS code, and it will be possible for hospitals to bill for multiple medical visits on the same bill. We agree that the way coinsurance is determined under the PPS is a significant change. We are developing a brochure for beneficiaries that will explain the new system and the policies under the outpatient PPS that will affect them.

Comment: One commenter recommended that we make information available to beneficiaries that compares the average coinsurance for high volume procedures performed at hospitals in a particular geographic area so that beneficiaries can make informed health care decisions about their care.

Response: We believe that beneficiaries will be informed about the coinsurance reductions elected by hospitals in their area through advertisements and other information made available by hospitals.

Comment: One commenter asked whether the EOMB (Explanation of Medicare Benefits) notice to the beneficiary will clearly explain that a hospital's decision to reduce coinsurance applies to a specific service furnished at that specific hospital.

Response: We are reviewing the EOMB in light of the changes in Medicare payments and coinsurance amounts under the PPS, but we have not yet finalized our work. We will take the commenter's suggestion into consideration as we investigate changes we will make to the EOMB.

## G. Adjustment for Area Wage Differences

## 1. Proposed Wage Index

Under section 1833(t)(2)(D) of the Act, the Secretary is required to determine a wage adjustment factor to adjust, in a budget-neutral manner, the portion of
the payment rate and the coinsurance amount that is attributable to laborrelated costs for relative differences in labor and labor-related costs across geographic regions. As stated in the proposed rule, we considered several options and we proposed using the hospital inpatient PPS wage index as the source of an adjustment factor for geographic wage differences for the hospital outpatient department PPS. We believe that using the hospital inpatient PPS wage index is both reasonable and logical, given the inseparable, subordinate status of the outpatient department within the hospital overall. Use of a hospital outpatient-specific wage index was not required by the Congress and we did not have either the time or resources necessary to construct one. We explained in our proposed rule that there are several possible versions of the hospital inpatient wage index that can be developed by extracting the basic wage and salary data from hospital cost reports, depending on the methodology that is applied to the data. For the hospital outpatient PPS, we proposed to adopt the same version that is used to determine payments to hospitals under the hospital inpatient PPS to adjust for relative differences in labor and laborrelated costs across geographic areas. This version reflects the effect of hospital redesignation under 1886(d)(8)(B) of the Act and hospital reclassification under 1886(d)(10) of the Act.

By statute, we implement the annual updates of the hospital inpatient PPS on a fiscal year basis. However, we proposed to update the hospital outpatient department PPS on a calendar year basis. Therefore, the hospital inpatient PPS wage index values that are updated annually on October 1 would be implemented for the hospital outpatient department PPS on the January 1 immediately following. We proposed this schedule so that wage index changes will be implemented on a calendar year basis concurrently with other revisions and updates, such as the conversion factor update or changes in the APC groups resulting from new or deleted CPT codes. Subsequent to our proposal, section 201(h) of the BBRA 1999 amended section 1833(t)(8)(A) of the Act (as redesignated by section 201(a) of the BBRA 1999) to require the Secretary to review and revise the outpatient PPS wage index adjustment factor at least annually rather than on a periodic basis. (This section of the Act was further redesignated as section 1833(t)(9)(A) by section 202(a) of the BBRA 1999.)

## 2. Labor-Related Portion of Hospital Outpatient Department PPS Payment Rates

We proposed to recognize 60 percent of the hospital's outpatient department costs as labor-related costs that would be standardized for geographic wage differences. We initially estimated this percentage by comparing the percentage of costs attributed to labor by other systems (that is, hospital inpatient PPS and ASC) and by considering health care market factors such as the shift in more complex services from the inpatient to the outpatient setting, which could influence labor intensity and costs. We stated that 60 percent represented a reasonable estimate of outpatient costs attributable to labor, as it fell between the hospital inpatient PPS operating cost labor factor of 71.1 percent and the ASC labor factor of 34.45 percent, and is close to the laborrelated costs under the hospital inpatient operating cost PPS attributed directly to wages, salaries, and employee benefits ( 61.4 percent) under the rebased 1992 hospital market basket that was used to develop the fiscal year 1997 update factor for inpatient PPS rates (published August 30, 1996 at 61 FR 46187).
We confirmed our estimate through regression analysis. Using this approach, we analyzed the percentage change in hospital costs attributable to a 1 percent increase in the wage index as expressed by the hospital wage index coefficient. The coefficient from a fully specified payment regression of the hospital cost per unit, standardized for the service mix on the wage index, disproportionate share patient percentage, modified teaching, rural, and urban variables, is approximately 0.60 , suggesting a labor share of 60 percent. Even though we decided not to propose additional adjustments, we believed that the coefficient from this specification provided the best estimate of the labor share for the proposed PPS. This judgment was based on a policy to use a labor share that reflects the relationship between the wage index and costs, rather than the effects of correlated factors.
After calculating 60 percent of each hospital's total operating and capital costs, we divided that amount by the hospital's FY 1998 hospital inpatient PPS wage index value to standardize costs to remove the differences that are attributable to geographic wage differences. Therefore, as we explained in the proposed rule, the total cost of performing a procedure or visit would include standardized operating and capital costs, as well as related costs (for
example, operating room time, medical/ surgical supplies, anesthesia, recovery room, observation) and minor ancillary procedures such as venipuncture that we packaged.

Comment: Some commenters urged that we annually update the wage index applied to the outpatient PPS as we do under the hospital inpatient PPS.

Response: We proposed to update the wage index annually, on a calendar year basis. In addition, section 1833(t)(9)(A) of the Act, redesignated and amended by the BBRA 1999, requires us to review and revise the wage adjustment at least annually.

Comment: A professional society recommended eliminating the "regional variation for radiologic technologists working in small and rural practices" and applying the "same wage scale" used for their urban counterparts. The commenter asserted that our wage index methodology is biased against rural hospital radiology departments that must compete with the urban areas to attract and retain radiologic technologists. The commenter stated that hospitals are operating in a very competitive labor market in which rural facilities are forced to match or exceed wages paid in the urban areas for reduced workloads. The commenter further stated that the impact of higher hourly technologist wages does not result in a corresponding increase in a higher wage index for radiologic technologists in rural hospitals because these wages are averaged with those for all other hospital inpatient personnel working in the same area.

Response: The commenter is correct that the wage index is calculated based upon all of the wages paid and hours worked of hospital personnel within areas of the hospital that are paid under the inpatient PPS. The wages and hours are then totaled for a particular labor market area (defined as a Metropolitan Statistical Area [MSA] or all of the counties of a State that are not part of an MSA). We believe the inpatient wage index is an appropriate measure of the relative costs of labor across geographic areas for purposes of outpatient PPS.

Currently, we do not have data available that would allow us to calculate the wage index for the costs of employing staff in particular occupational categories. Collecting these data would require significant recordkeeping and reporting efforts for hospitals, and the impacts of adjusting the wage index using the data are uncertain. Although some analyses have indicated that the wage indices of rural areas could rise as a result of such an adjustment, these findings are limited by the lack of a national database
through which to fully assess the impacts.

Comment: Several commenters viewed our proposal to establish a 60 percent labor share as an arbitrary decision for which we provided no rational support. One commenter stated that "Congress did not expect HCFA to invent a number."
Response: As we explained in the proposed rule (63 FR 47581), we used a statistical tool, that is, regression analysis, to validate the percentage of costs that we had initially estimated could be attributed to labor and, therefore, subject to the wage adjustment. We adopted this approach because we did not have adequate and appropriate data readily available through a reputable source from which we could derive a hospital outpatient labor share within the time allotted to develop our new system. While hospital outpatient costs, including labor costs, are reported annually on the hospital cost report, they are not reported in a manner and format that allow us to capture the statistical and cost data necessary to calculate a precise hospital outpatient labor share. Therefore, we decided to use regression analysis to test our estimate of that labor share. Within the constraints imposed by a lack of accessible, reliable data and the compressed timeframe under which we were working to develop the outpatient PPS, we believe our approach was appropriate and the best available option.
Comment: Several commenters urged us to use more current hospital cost report data to determine the appropriate hospital outpatient labor share.

Response: As stated above, at this time the Medicare hospital cost report is not a feasible data source for determining a hospital outpatient labor share.

Comment: One commenter asserted that setting the labor-related share at 60 percent fails to recognize all labor costs associated with the delivery of hospital outpatient services. The commenter stated that the labor-related percentage for the outpatient PPS should be the same as that used for the hospital inpatient PPS, that is, 71.1 percent. Another commenter supported 60 percent as a "maximum" labor percentage on an interim basis and suggested that we reconsider our decision to use the inpatient PPS hospital wage index to adjust the outpatient PPS payments because of the commenter's concerns about flaws inherent in the system used to derive the inpatient PPS wage index values. A third commenter proposed that the
labor-related portion should be closer to the 34.45 percent currently applied to adjust ASC payment for wage variation. The latter commenter contended that apportioning 60 percent of the outpatient PPS payment rate for wage adjustment would adversely affect rural hospitals because the wage index values for these areas are generally below 1.0.

Response: We note that commenters' opinions regarding an appropriate labor percentage are mixed. However, beyond expressing a preference for a percentage other than 60 percent, none of the commenters provided data to assist us in re-evaluating our proposal. We realize that rural hospitals would benefit from using a labor share that is less than 60 percent and that some other hospitals would derive advantages from a labor share greater than 60 percent. However, we believe the approach that we used to determine the labor share that will be applied to all hospitals paid under our new system is reasonable and the best option available at this time. We will re-evaluate our decision as we gain more experience with the new system and as new data become available.
3. Adjustment of Hospital Outpatient Department PPS Payment and Coinsurance Amounts for Geographic Wage Variations

In the proposed rule, we noted our intent to use fiscal year 1999 hospital inpatient PPS wage index values to compute the initial outpatient PPS rates. However, we have decided to use fiscal year 2000 inpatient PPS wage index values in determining the payment rates set forth in this final rule. The rationale for using the fiscal year 2000 wage index includes availability of the more recent wage index, that it is more current than the 1999 wage index would have been, and that it is being used to calculate FY 2000 payments under the hospital inpatient PPS.
We proposed to use the annually updated hospital inpatient PPS wage index values to adjust both program payment and coinsurance amounts under the outpatient PPS for area wage variations. Under our proposal, when intermediaries calculate actual payment amounts, they would multiply the prospectively determined APC payment rate and coinsurance amount by that labor-related percentage to determine the labor-related portion of the base payment rate and coinsurance amount that is to be adjusted using the applicable wage index factor. We proposed that the labor-related portion would then be multiplied by the hospital's inpatient PPS wage index factor, and the resulting wage-adjusted
labor-related portion would be added to the nonlabor-related portion, resulting in wage-adjusted payment and coinsurance rates. The wage-adjusted coinsurance amount would then be subtracted from the wage-adjusted APC payment rate, and the remainder would be the Medicare payment amount for the service or procedure. Note that even if a hospital elects to reduce the coinsurance or if the coinsurance is capped at the inpatient deductible, the full coinsurance is assumed for purposes of determining the Medicare payment percentage. (See section III.F. 3 for a discussion on how Medicare program payments are calculated when the Part B deductible applies.)

The following is an example of how an intermediary would calculate the Medicare payment for a surgical procedure with a hypothetical APC payment rate of $\$ 300$ that is performed in the outpatient department of a hospital located in Heartland, USA. The coinsurance amount for the procedure is $\$ 120$. The hospital inpatient PPS wage index value for hospitals located in Heartland, USA is 1.0234. The laborrelated portion of the payment rate is $\$ 180(\$ 300 \times 60$ percent), and the nonlabor-related portion of the payment rate is $\$ 120$ ( $\$ 300 \times 40$ percent). The labor-related portion of the unadjusted coinsurance amount is $\$ 72$ ( $\$ 120 \times 60$ percent), and the nonlabor-related portion of the unadjusted coinsurance amount is $\$ 48$ ( $\$ 120 \times 40$ percent). It is assumed that the beneficiary deductible has been met.
Wage-Adjusted Payment Rate (rounded to nearest dollar):
$=(\$ 180 \times 1.0234)+\$ 120$
$=\$ 184+\$ 120$
= \$304
Wage-Adjusted Coinsurance Amount (rounded to nearest dollar):
$=(\$ 72 \times 1.0234)+\$ 48$
$=\$ 74+\$ 48$
= \$122
Calculate Medicare Program Payment Amount:
$\$ 304-\$ 122=\$ 182$
4. Special Rules Under the BBRA 1999

We issued the federal fiscal year (FY) 2000 hospital inpatient PPS wage index values in the Federal Register on July 30, 1999, in a final rule titled "Changes to the Hospital Inpatient Prospective Payment Systems and Fiscal Year 2000 Rates" (64 FR 41490). Subsequent to that publication, section 152 of the BBRA 1999 reclassified certain counties and labor market areas for purposes of payment under the Medicare hospital inpatient PPS; section 153 of the BBRA 1999 enacted a "wage index correction"; and section 154 of the BBRA 1999
provided for the calculation and application of a wage index floor for a specified area. These changes are effective for FY 2000 and will be explained in detail in an interim final rule with comment that we expect to issue in the Federal Register shortly. The wage index values in Addendum H , Addendum I, and Addendum J reflect the changes made by the BBRA 1999.

## H. Other Adjustments

## 1. Outlier Payments

Section 1833(t)(2)(E) of the Act, as enacted by the BBA 1997, authorized, but did not require, an outlier adjustment. In the proposed rule, we discussed our reasons for not implementing an outlier adjustment policy. We explained that we had reached that decision after carefully evaluating several factors. For the following reasons, we believed an outlier policy was not necessary: (a) in the proposed PPS, unlike the hospital inpatient PPS, we would use limited packaging of services and allow payment for multiple services delivered to a given patient on a given day; (b) payment for critical care services would reflect the intensity and higher costs associated with providing this type of medical care; and (c) we would make higher payment for serious medical cases even if critical care were not provided and additional payments would be made for any other laboratory work, x-rays, or surgical interventions resulting from medical visits to the emergency room.

Section 201(a) of the BBRA 1999 amended section 1833(t) of the Act by adding an outlier adjustment provision, section 1833(t)(5). Under this new provision, the statute now requires that we make an additional payment (that is, an outlier adjustment) for outpatient services for which a hospital's charges, adjusted to cost, exceed a fixed multiple of the outpatient PPS payment as adjusted by pass-through payments. The Secretary determines this fixed multiple and the percent of costs above the threshold that is to be paid under this outlier provision. The statute sets a limit on projected aggregate outlier payments. Under the statute, projected outlier payments may not exceed an "applicable percentage" of projected total payments. The applicable percentage means a percentage specified by the Secretary (projected percentage of outlier payments relative to total payments), subject to the following limits: for years before 2004, the projected percentage that we specify cannot exceed 2.5 percent; for 2004 and later, the projected percentage cannot
exceed 3.0 percent. Section 201(c) of the BBRA 1999 amended section 1833(t)(2)(E) of the Act to require that these payments be budget neutral.

Section 1833(t)(5)(D) of the Act grants the Secretary authority until 2002 to identify outliers on a bill basis rather than on a specific service basis and to use an overall hospital cost-to-charge ratio (CCR) to calculate costs on the bill rather than using department-specific CCRs for each hospital.
To set the threshold or fixed multiple and the payment percent of costs above that multiple for which an outlier payment would be made, we first had to determine what specified percentage of total program payment, up to 2.5 percent, we should select. We decided to set the outlier target at 2.0 percent. In order to set the fixed multiple outlier threshold and payment percentage, we simulated PPS payments, as described below in section $G$ of the preamble. As explained further below, we calibrated the threshold and the payment percentage applying an iterative process so that the simulated outlier payments were 2.5 percent of simulated total payments. For purposes of the simulation, we set a "target" of 2.5 percent (rather than 2.0 percent), because we believe that a given set of numerical criteria would result in a higher percentage of outlier payments under the simulation using 1996 data than under the PPS. This is because we believe that the 1996 data reflects undercoding of services, which means simulated total payments would likely be understated and it in turn means the percentage of outlier payments would be overstated. In addition, we are unable to fully estimate the amount and distribution of pass-through payments using the 1996 data. Our inability to make these estimates further understates the total payments under the simulation. We believe that a set of numerical criteria that results in simulated outlier payments of 2.5 percent using the 1996 data would result in outlier payments of 2.0 percent under PPS. The difference arises from the effect of undercoding in the historical data and the payment of passthroughs under PPS. Under the budget neutrality requirement in section 1833(t)(2)(E) of the Act, as amended by section 201(c) of the BBRA 1999, we make a corresponding 2.0 percent reduction to the otherwise applicable conversion factor. We will monitor outlier payment and make any necessary refinements to the outlier methodology when we set outlier policies for CY 2002.
After setting the outlier target percentage and reducing the unadjusted
conversion factor to reflect the 2 percent outlier reduction and the 2.5 percent pass-through adjustment (see discussion in section III.D), we identified those claims in our 1996 database with at least one payable service under the PPS system. For these bills, we first calculated the total PPS payment for the bill using the reduced conversion factor Next, we calculated for each claim the total charges attributed to services being paid under the PPS system. These charges were then adjusted to cost, using a hospital-specific CCR. We used the sum of the hospital's total operating CCR and total capital CCR as the hospital specific CCR. These CCRs were calculated from the most current cost report data available and were adjusted to calendar year 1996.

We also identified all bills for the 1,800-plus hospitals that we had previously identified as having coded only the lowest level clinic visit code (CPT code 99201) for all visits. For these hospitals, we isolated those claims with at least one service with the CPT code 99201 and one or more additional PPS covered service. Due to the undercoding on these bills and the inherent problem in determining a possible outlier condition, we excluded these bills from the calculation process but set aside a proportional amount of outlier payments based on the proportional cost of these bills to the total cost of all bills used in the outlier calculation.

After determining the PPS payment and the cost for all 42 million claims for which there was at least one billable service under the PPS system, we experimented with several combinations of thresholds or fixed multiples and payment percent of costs over these multiples. We found that the combination of using a multiple of 2.5 for the threshold and the use of a payment percent of 75 percent of cost over this threshold achieved our target of a 2.5 percent outlier payment. Approximately 1.6 million claims in our 1996 claims database had calculated bill costs that exceeded the PPS payments on the claim by more than 2.5 times and thus qualified for an outlier payment in our model.

Comment: We received several comments that supported our proposal not to create outlier payments. However, most commenters opposed it and supported including an outlier policy. Several commenters disagreed that multiple payment for multiple services furnished during a given visit would absolve the need for outliers. One commenter stated that outlier payments are necessary because of the limited number of APC groups. Several commenters believe that outlier
payments are necessary to recognize variability in APC groups stemming from treatment options and patient complexity. Some argued that our own data demonstrate that an outlier policy is necessary to ensure equitable payments. Several commenters stated that the data trimming algorithm that we used, excluding from our PPS database claims that were greater than three standard deviations from the geometric mean, probably eliminated claims that included high cost items and services that should have been reflected in our data and that may have been associated with the later technologies. A professional association noted that an examination of our PPS data indicated that " 20 percent of outpatient services subject to the PPS (excluding clinic and emergency room visits) include maximum costs that are at least 10 times higher than the corresponding rate; 100 services have maximum costs that are at least 40 times higher than the corresponding payment rate."
One commenter believes that an outlier policy is necessary for a payment system based on averaging to provide additional payments for potentially variable and expensive items such as pharmaceuticals and supplies. Several commenters suggested that outlier payments would be necessary if we did implement their option to carve out all pharmaceuticals and certain supplies from the hospital outpatient PPS and pay them separately based on reasonable costs or average wholesale price (AWP). Most commenters who urged establishing outlier payments advocated them for high cost drugs, supplies, and new technologies. Some commenters advised that a drug such as Activase administered to a cardiac patient in the emergency room prior to inpatient admission or transfer to another hospital for inpatient admission would be costly. One commenter estimated that the cost for two doses of the drug would exceed $\$ 4,000$. One commenter urged an outlier policy that would adequately pay for iodine I 131 tositomomab. Another commenter recommended that we make an outlier payment for Hemophilia Factor Concentrate that could be packaged in APC 906 (Infusion Therapy, except Chemotherapy) or APC 907 (Intramuscular Injections) and Tissue Plasminogen Activator (TPA) and IV therapy drugs as outliers.

A professional association expressed the need for an outlier policy for tests whose costs exceed a reasonable range of costs for similar procedures. They identified CPT codes 95951 and 95956 as examples of those tests. Another association recommended adoption of
an outlier policy to recognize higher costs associated with new technologies. The commenter suggested that the policy remain in effect a full year after the hospital outpatient PPS is
implemented to allow us adequate time to collect the appropriate data for use in updating the payment rates. Several other commenters believe that we may need to adopt an outlier policy on an interim basis while data are collected to determine the appropriate assignment of certain services and items to an APC. One commenter advocated outlier payments for hospitals whose aggregate costs exceed total payments under the hospital outpatient PPS in a given year. A number of other commenters stated that the hospital outpatient PPS outlier policy should be similar to that currently used for the inpatient PPS.

Response: As we discussed above, section 201(a) of the BBRA 1999 amended the Act by adding a new section 1833(t)(5). This provision now requires the Secretary to make an additional outlier payment for outpatient services for which a hospital's or a CMHC's charges, adjusted to cost, exceed a fixed multiple of the new PPS payment as adjusted by passthrough payments. The Secretary is required to determine the fixed multiple and the percent of costs above the threshold that is to be paid under the outlier provision. As we explain above, to implement the outlier adjustment, we have determined that an outlier payment will be made when calculated bill costs exceed the PPS payments on a claim by more than 2.5 times. In addition, the provision of transitional pass-throughs under section 201(b) of the BBRA 1999, which requires the Secretary to make an additional payment for certain high cost medical devices, drugs, and biologicals, constitutes a kind of outlier adjustment (see section III.D of this preamble), and our decision to create special transitional payments for new technology items and services (see section III.C.8) will also provide additional payments to hospitals that incur higher costs under the outpatient PPS.

## 2. Transitional Corridors/Interim Payments

As we developed the proposed rule, we conducted extensive regression analysis of the relationship between outpatient hospital costs and several factors that affect costs, such as teaching intensity and disproportionate share percentage, as part of the analysis to determine whether payment adjustments should be proposed for the outpatient PPS. Ultimately, we did not
propose any adjustments other than the wage index used to adjust for local variation in labor costs. One of the main reasons we did not propose any special adjustments was that the estimated effects of measured factors on costs were small and, in most cases, not statistically significant. In addition, we believe that the negative impacts estimated in the proposed rule for certain classes of hospitals were partially attributable to undercoding and coding variations in the data because coding did not affect the payment of many services under the current payment system, especially medical visits.

Since publication of our proposed policy, section 202(a)(3) of the BBRA 1999 added new paragraph (7) to section 1833(t) of the Act to require the Secretary to make payment adjustments during a transition period to limit the decline in payments under PPS for hospitals. These additional payments are to be implemented without regard to budget neutrality and are in effect through 2003.

Under paragraphs (A), (B), and (C) of section $1833(\mathrm{t})(7)$ of the Act, the amount of the payment adjustment for an individual hospital depends on the difference between the hospital's "PPS amount" and the hospital's "pre-BBA amount." Section 1833(t)(7)(E) of the Act defines the "PPS amount" as the amount payable under PPS for the hospital's covered outpatient department services, excluding the effects of the transitional corridor and including coinsurance and deductibles. For purposes of calculating the PPS amount, we include the full copayment amounts; if a hospital chooses to reduce the copayment for some or all of the services that it furnishes, we will count the full copayment amounts rather than the reduced copayment amounts. Section 1833(t)(7)(F) of the Act defines the "pre-BBA amount" for a period as the amount equal to the product of (1) the hospital's reasonable cost for covered outpatient department services, and (2) the base outpatient department payment-to-cost ratio for the hospital. The statute defines "base payment-tocost ratio" as the ratio of (1) the hospital's reimbursement for covered outpatient department services during the cost reporting period ending in 1996, to (2) the reasonable cost of the services for the period. The base payment-to-cost ratio will be calculated as if the amendments to sections 1833(i)(3)(B)(i)(II) and 1833(n)(1)(B)(i) of the Act made by section 4521 of the BBA 1997, to require that the full amount beneficiaries paid as coinsurance under section 1862(a)(2)(A)
of the Act are taken into account in determining Medicare Part B Trust Fund payment to the hospital, were in effect in 1996.
For calendar years 2000 and 2001, payment to hospitals whose PPS payment is less than 100 percent, but is at least 90 percent, of the pre-BBA payment, is increased by 80 percent of the difference. Hospitals whose PPS payment is less than 90 percent, but is at least 80 percent, of the pre-BBA payment, will receive additional payment equal to the amount by which 71 percent of the estimated pre-BBA payment exceeds 70 percent of the PPS payment. Hospitals whose PPS payment is less than 80 percent, but is at least 70 percent, of the pre-BBA payment will receive additional payment equal to the amount by which 63 percent of the preBBA payment exceeds 60 percent of the PPS payment. Payments to hospitals whose PPS payment is less than 70 percent of the pre-BBA payment will be increased by 21 percent of the pre-BBA payment. For calendar years 2001 through 2003, the number of corridors and the associated percentage increases decline over time. As required by statute, interim payments will be made subject to retrospective adjustments. Section 1833(t)(7) of the Act provides special transition payments for cancer centers and small rural hospitals, which are discussed below in section III.H.3.

Comment: Hundreds of commenters, including associations, hospitals, and entities providing goods and services to hospitals, expressed grave concerns about the estimated impact of our proposed system on certain classes of hospitals. Many commenters noted that the case mix and service mix for specific classes of hospitals such as rehabilitation, cancer, children's, rural, and teaching hospitals are different than for other hospitals. They argued that a number of these hospitals deal with patients who typically require more resources. The commenters noted that we have authority under the statute to make adjustments for specific classes of hospitals. Some reasoned that given our estimates of substantial losses for certain classes of hospitals under the proposed hospital outpatient PPS, we should use our authority to exclude these classes of hospitals from the outpatient PPS for 2 years, require proper coding of bills from those hospitals, and have an opportunity to analyze the results of the improved coding. These commenters urged that we examine reasons other than coding that may contribute to the disparity. Many commenters recommended that a separate conversion factor be developed
for the hospitals whose payments are adversely affected by the new system.

Response: As discussed above, section 1833(t)(7) of the Act, as added by section 202(a) of the BBRA 1999, provides that, for several years, additional payments be made to any facility for which the PPS payment is less than an estimate of the hospital's pre-PPS payment and that these payments are in addition to the total payments under the PPS. Our estimate of the impacts of this change in policy along with other payment-related provisions of the BBRA 1999 (discussed in further detail in section IX) show improved payments under PPS relative to pre-BBRA law for nearly all classes of hospitals. Our simulations show that hospitals overall receive an additional 4.6 percent in payments under PPS compared to pre-PPS law. Long-term care and children's hospitals show losses (1.7 percent and 3.2 percent, respectively). Moreover, urban hospitals with no indirect teaching or disproportionate share inpatient adjustments show a loss of 0.3 percent. In addition, we reexamined and reestimated the multivariate regression specifications described in the proposed rule to reflect the changes described in this rule. Based on the results of regression analysis, we believe further adjustments are not warranted at this time. We found, for example, the disproportionate share percentage did not have a statistically significant effect on unit costs standardized by service mix. In addition, positive and significant results did not occur for most teaching variables that we specified. For instance, positive and significant results did not occur for hospitals whose ratio of residents to inpatient and outpatient days was less than .28. Hospitals with a large number of residents to inpatient and outpatient days did demonstrate slightly higher standardized costs, but only when the regression model included independent variables for urban/rural location. Moreover, the parameter estimate was small and payment was not greatly improved when a corresponding adjustment was made to these teaching hospitals. Therefore, we are not making such adjustments for these hospital groups. We do not believe that this action will restrict beneficiary access to care because the projected losses are relatively small and could reflect undercoding on the part of these hospitals before PPS.
We will begin comprehensive analyses of cost and payment differentials between different classes of hospitals as soon as there is a sufficient amount of claims data submitted under
the PPS. We will use data from the initial years of the PPS to conduct regression and simulation analyses. In addition, we will carefully track and analyze the additional payment made to hospitals under section 1833(t)(7) of the Act. These analyses will be used to consider and possibly propose adjustments in the system, particularly beginning in 2004 when the BBRA 1999 transition provisions expire.

Comment: Commenters from organizations representing teaching hospitals recommended that we include a budget-neutral payment adjustment for certain classes of hospitals such as teaching hospitals. For example, the concern is that PPS payments are not adequate for academic medical centers because they provide more resourceintensive outpatient services than other hospital types.

Response: As noted above, we are not making adjustments for specific classes of hospitals in this final rule. The primary reason for this decision is that section $1833(t)(7)$ of the Act requires additional payments through 2003 to all hospitals whose PPS payment falls below estimates of pre-PPS payment. We will conduct analyses and studies of cost and payment differential among different classes of hospitals, including teaching facilities, when sufficient data under the PPS have been submitted. We will carefully consider whether permanent adjustments should be made in the system once the BBRA 1999 transition provisions expire.
3. Cancer Centers and Small Rural Hospitals

## Cancer Centers

In the BBA 1997, the Congress did not exclude from the hospital outpatient PPS the 10 cancer centers that are currently excluded from the inpatient PPS, but section 1833(t)(8) of the Act (as enacted in the BBA 1997) provides special consideration for these hospitals under the outpatient PPS. More specifically, that section provides that the outpatient PPS would not apply to the 10 cancer centers before January 1, 2000, and that the Secretary may establish a separate conversion factor for cancer centers to take into account the unique costs they incur due to their patient population and the intensity of their services.

In the proposed rule, we stated that, because we had no choice but to delay implementation of the PPS for all hospitals until sometime after January 1, 2000 due to Y2K concerns, we would begin paying cancer centers under hospital outpatient PPS at the same time. Also, we did not propose a
separate conversion factor for cancer centers. Although our proposed impact analysis indicated that, under the PPS, the cancer centers could lose 32 percent of their current outpatient Medicare payments, we proposed to do additional work to try to explain the impact before we provided for a separate conversion factor or other payment adjustment.
Section 1833(t)(7)(D)(ii) of the Act, as added by the BBRA 1999, provides that the 10 cancer centers excluded from the inpatient PPS are permanently held harmless with respect to their pre-BBA 1997 amount.
Comment: The cancer centers commented that they are unlike other hospitals in that they treat the most difficult cases (patients often referred by community hospitals) and they are usually the first hospitals to use the latest technology related to cancer treatments. They also pointed out that their clinic visits often involve consultations with a number of physicians and therefore are longer and require more hospital resources than clinic visits in other hospitals. They believe that our proposed payments for clinic visits would seriously underpay them for their more comprehensive visits. The cancer centers also stated that any delay in recognizing and paying appropriately for new technology would affect them more adversely than it would other hospitals.
During the comment period for the proposed rule, the cancer centers submitted for our consideration an alternative payment methodology. Under their methodology, we would calculate a separate conversion factor for each of the 10 centers based on their individual base year Medicare payments and service mix. Subsequently, the conversion factors would be updated using the Congressionally determined update factor applicable to all hospitals. Hospitals would be paid interim payment amounts during the year, but payment would ultimately be based on the lesser of-

- The PPS payments they would receive using their individual conversion factor; or
- The payments they would receive based on their cost reports by applying the current (that is, pre-PPS) outpatient services payment methodology.
Capital costs would be excluded from this comparison and be paid on a reasonable cost pass-through basis. The proposal also envisioned some payment penalties and incentives similar to the penalties and incentives provided under the reasonable payment cost limit methodology applicable to hospitals excluded from the inpatient PPS.

Response: As noted above, new section 1833(t)(7)(D)(ii) of the Act holds cancer centers harmless on a permanent basis by providing that, in instances where Medicare payment to a cancer center under the hospital outpatient PPS would be lower than a specified preBBA Medicare payment for the same services, we are to pay the full pre-BBA amount. Therefore, an alternative approach to paying cancer centers under the hospital outpatient PPS is no longer needed.

## Small Rural Hospitals

We noted in the proposed rule that rural hospitals generally receive a relatively high percentage of their Medicare income from outpatient services (greater than the national average), which compounds the impact of the reduction in Medicare payments to rural hospitals that we projected would result upon implementation of the hospital outpatient PPS. We attributed these reduced revenues to undercoding, lack of economies of scale, and reliance on the median instead of the geometric mean in the calculation of APC weights. Because our impact analysis revealed that low-volume rural hospitals that are sole community hospitals or Medicare-dependent hospitals could experience a considerable reduction in revenues under the outpatient PPS, we solicited comments in the proposed rule on two possible approaches to phasing in the outpatient PPS for these types of hospitals.
Section 1833(t)(7)(D)(i) of the Act provides that hospitals located in a rural area with 100 or fewer beds are held harmless with respect to their pre-BBA 1997 amount for outpatient services furnished before January 1, 2004. For purposes of implementing this provision, bed size will be determined in the same way it is for inpatient PPS for the indirect medical education adjustment as defined in $\S 412.105(\mathrm{~b})$, Determination of number of beds. A hospital's location in a rural area will also be determined as it is in the inpatient PPS; see §412.63(b), Geographic classifications.
Comment: Many commenters were concerned that the projected negative impact of the proposed outpatient PPS on rural hospitals would be magnified because outpatient revenues make up such a large part of rural hospitals' total revenues. Some commenters believe that our proposed PPS ratesetting method favors high volume, urban hospitals. Some commenters supported phasing in the outpatient PPS for rural disproportionate share hospitals because those facilities may not have
the resources to improve their coding in the near future. One association opposed phasing in the PPS because doing so would postpone but not resolve the financial jeopardy imposed on rural hospitals by the hospital outpatient PPS. Some commenters recommended that we provide an "addon" to the prospective rate for emergency services in low-volume sole community and rural disproportionate share hospitals. One commenter expressed concern about the numerous factors contributing to rural hospitals’ negative margins that limit their ability to absorb losses, including a disproportionately high share of Medicare, Medicaid, and indigent patients, significant problems recruiting practitioners, low population density, and limited patient volume. Numerous commenters recommended that we establish a payment floor for lowvolume rural hospitals. One association requested that we either revise the payment methodology or put in place a payment floor that guarantees health care services will continue to be available to Medicare beneficiaries served by rural hospitals.

Response: As we discuss above, in order to limit potential reductions in payment to hospitals under the outpatient PPS, section 1833(t)(7) of the Act, as added by section 202(a)(3) of the BBRA 1999, requires us to establish payment adjustments for hospitals whose PPS payments are less than our estimate of the hospital's pre-BBA payments. These additional payments are to be implemented in a non-budget neutral manner and are to be paid through 2003. Section 1833(t)(7)(D)(i) of the Act includes a special "hold harmless" provision, which is to be paid through 2003, for hospitals that are located in a rural area and that have no more than 100 beds. Under section 1833(t)(7)(D)(i) of the Act, as added by the BBRA 1999, small rural hospitals will be paid a predetermined pre-BBA amount for services covered under the outpatient PPS if payment under the PPS would be less than the pre-BBA amount. This hold harmless provision establishes a payment floor until January 1, 2004 for small rural hospitals. During this period, we will collect and analyze data under the PPS in order to assess whether any special adjustments will need to be made for rural hospitals once the hold harmless provision expires.

## I. Annual Updates

1. Revisions to APC Groups, Weights and the Wage and Other Adjustments

Prior to enactment of the BBRA 1999, section 1833(t)(6)(A) of the Act required the Secretary to periodically review and revise the APC groups, the relative payment weights, and the wage and other adjustments to take into account changes in medical practice, changes in technology, the addition of new services, new cost data, and other relevant information and factors.

In the proposed rule, we described our plan to update the various components of the outpatient PPS. We proposed to keep the composition of all the APC groups essentially intact from one year to the next, with the exception of the few changes that may be necessary as a consequence of annual revisions to HCPCS and ICD-9-CM (International Classification of Diseases, Ninth Edition, Clinical Modification) codes. We stated that we did not plan to routinely reclassify services and procedures from one APC to another. We proposed to make these changes based on evidence that a reassignment would improve the group(s) either clinically or with respect to resource consumption. However, we specifically solicited comments on how frequently to recalibrate the APC weights and on the method and data that should be used. We defined recalibration as the updating of all the APC group weights based on more recent information.

We proposed to update the wage index values used to calculate program payment and coinsurance amounts on a calendar year basis, adopting, effective for services furnished each January 1, the wage index value established for a hospital under the inpatient PPS the previous October 1. The first update to the wage index values will be effective for calendar year 2001 beginning January 1, 2001.

Section 201(h)(1)(A) of the BBRA 1999 amended section 1833(t)(8)(A) of the Act (as redesignated by section 201(a) of the BBRA 1999) to require the Secretary to review the components of the outpatient PPS not less often than annually and revise the groups, the relative payment weights, and the wage and other adjustments to take into account changes in medical practice, changes in technology, and the addition of new services, new cost data, and other relevant information and factors. (Section 202(a) of the BBRA 1999 further redesignated section 1833(t)(8) as section 1833(t)(9).)
Section 201(h)(1)(B) of the BBRA 1999 further amended this section of the Act to require that the Secretary consult
with an expert outside advisory panel composed of an appropriate selection of representatives of providers to review (and advise the Secretary concerning) the clinical integrity of the groups and weights. This provision allows these experts to use data other than those collected or developed by us during our review of the APC groups and weights. Section 201(h)(2) of the BBRA 1999 requires the Secretary to initiate the annual review process beginning in 2001 for the PPS payments that would take effect January 1, 2002.

Comment: A number of commenters urged that we adopt an annual update cycle for APC recalibration. Some commented that the APC update frequency should not be less often than the annual cycles that we have instituted for both the hospital inpatient PPS and physician fee schedule payment system. Many commenters maintained that annual updating is necessary to ensure that the APCs appropriately reflect changes in new technologies, standards of care, and other marketplace patterns. Several commenters stated that an annual update cycle is needed to take into account changes in drug prices and appropriately reflect advancements in nuclear medicine. Some commenters believe that updating the APCs less frequently than annually would adversely impact hospitals that would incur financial losses attributable to inappropriate payment for new technologies. Some commenters contended that infrequent updating would be a disincentive for manufacturers to develop new outpatient therapies.
Response: In accordance with the amendments enacted by the BBRA 1999, we will review and update annually, for implementation effective January 1 of each year, the APC groups, the relative payment weights, and the wage and other adjustments that are components of the outpatient PPS, beginning with the update to be effective January 1, 2002.

## 2. Annual Update to the Conversion Factor

We stated in the proposed rule that section 1833(t)(3)(C)(ii) of the Act requires us to update annually the conversion factor used to determine APC payment rates. Section 1833(t)(3)(C)(iii) of the Act provides that the update be equal to the hospital inpatient market basket percentage increase applicable to hospital discharges under section
1886(b)(3)(B)(iii) of the Act, reduced by one percentage point for the years 2000 , 2001, and 2002. The Secretary also has
the option (under section 1833(t)(3)(C)(iii) of the Act) of developing a market basket that is specific to hospital outpatient services. We advised in our proposed rule that we are considering this option, and specifically invited comments on possible sources of data that are suitable for constructing a market basket specific to hospital outpatient services. We did not receive any comments regarding potential data sources for constructing a hospital outpatient-specific market basket. Therefore, we will update the conversion factor annually by the hospital inpatient market basket increase (as specified in section 1886(b)(3)(B) of the Act), reduced by one percentage point for the years 2000 , 2001, and 2002.

## 3. Advisory Panel for APC Updates

As stated above, section 1833(t)(9)(A) of the Act (as redesignated by section 201(a) of the BBRA 1999 and further redesignated by section 202(a) of the BBRA 1999) requires the Secretary, beginning in 2001, to consult with an expert outside advisory panel of appropriately selected provider representatives when annually reviewing and updating the APC groups and the relative group weights. The statute specifies that the expert panel will act in an advisory capacity on matters pertaining to the clinical integrity of the groups and weights and that it may use data other than those developed or collected by us in executing this function. We will initiate this review process in 2001 for the hospital outpatient PPS payments that will take effect for services furnished on or after January 1, 2002. We will adopt a process for identifying and appropriately selecting provider representatives to serve as members of an expert advisory panel. We anticipate informing the hospital community of the formation of an expert advisory panel through timely notice in the Federal Register.

## J. Volume Control Measures

Section 1833(t)(2)(F) of the Act requires the Secretary to develop a method for controlling unnecessary increases in the volume of covered outpatient department services. Section $1833(\mathrm{t})(6)(\mathrm{C})$ of the Act, as added by the BBA 1997, authorizes the Secretary to adjust the update of the conversion factor if we determine that the volume of services paid for under the outpatient PPS increases beyond amounts we establish under section 1833(t)(2)(F) of the Act.

In the proposed rule, we proposed a volume control measure for services
furnished in CY 2000 only. We discussed several long-term alternatives to control volume for services furnished in subsequent years, and we solicited comments on those options. We stated that we would propose an appropriate volume control mechanism for services furnished in CY 2001 and beyond after we completed further analysis. Given the complexities of developing an appropriate volume control mechanism for hospital outpatient services, we believed additional study was necessary.

For CY 2000, we proposed to use a modified version of the physician sustainable growth rate system (SGR), which is required under section 1848(d)(3) of the Act, for purposes of the hospital outpatient PPS. As we stated in the proposed rule, this appeared to be the most feasible initial approach. Using this approach, we proposed to update the target amount specified under section $1833(\mathrm{t})(3)(\mathrm{A})$ for CY 1999 as an expenditure target for services furnished in CY 2000. We stated that we would update the CY 1999 target for inflation (based on the projected change in the hospital market basket minus one percentage point), estimate changes in the volume and intensity of hospital outpatient services, and estimate Part B fee-for-service changes in enrollment. If volume exceeded the target for CY 2000, we proposed to adjust the update to the conversion factor for CY 2002. We further stated that we would compare the CY 2000 target to an estimate of CY 2000 actual payments to hospitals as determined by our Office of the Actuary using the best available data. We proposed that if unnecessary volume increases, as reflected by expenditure levels, caused payment to exceed the target, we would determine the percentage by which the target is exceeded, and adjust the CY 2002 update to the conversion factor by the same percentage.

We indicated that we would respond in the final rule to comments on our proposed volume control measure for services furnished in CY 2000, but not to comments about volume control options for services furnished after CY 2000, which will be addressed in a later proposed rule.
Comment: We received many comments opposing our proposed use of an SGR-like system to control unnecessary volume increases under the hospital outpatient PPS. Most commenters strongly urged us to exercise the discretionary authority allowed under section 1833(t)(9)(C) of the Act (as redesignated) not to adjust the update to the conversion factor. A few commenters endorsed the provision
of the "President's Plan to Modernize and Strengthen Medicare for the 21st Century" (issued July 2, 1999) to delay adoption of a volume control measure in order to give hospitals additional time to adjust to the new system. Several commenters, including one national physicians' association, contended that we did not have the statutory authority to establish and use an expenditure target in the manner that we had proposed. The physicians' association stated that the law limits use of the SGR system to physician services. Some commenters believe that we lack the expertise needed to set an accurate target amount. Others argued that an expenditure target is not a reliable way to distinguish the growth of necessary versus unnecessary services and that our proposal would therefore have consequences not intended by the statute (that is, affecting all services rather than only those that would be considered unnecessary). Some commenters stated that expenditure caps only work when they directly affect those who control the volume. These commenters contended that a volume control measure is unfair to hospitals because it is physicians, not hospitals, who order services and therefore control volume. Some commenters were concerned that adopting a volume control measure would penalize hospitals for increases in outpatient volume attributable to technological changes that appropriately shift service delivery from the inpatient to outpatient setting. In addition, numerous organizations recommended that we not implement the volume expenditure targets and control measures because payments would be reduced to inadequate levels and affect beneficiary access to care.
Response: We are delaying implementation of a volume control mechanism as suggested by the "President's Plan to Modernize and Strengthen Medicare for the 21st Century" (the statute does not specify an implementation date). This delay gives hospitals time to adjust to the PPS, and it gives us additional time to study appropriate methods of controlling outpatient volume over the long term. We are currently working with a contractor to study options for volume control measures for outpatient services. In the future, before we make any final decision, we will publish a notice in which we will discuss our proposal and will provide a public comment period.

## K. Claims Submission and Processing and Medical Review

Comment: Numerous commenters expressed a variety of concerns related
to information exchange processes required by the new PPS. Several commenters stated that the remittance advice documents will need to reflect all of the components used in calculating payment for each claim, as well as possible coinsurance reductions. The commenters also were concerned that, with the complexity of the APC system, hospitals will need the ability to verify payment. One health system that had experience with 3M's APGs offered the experience of their member hospitals to assist us by providing input on the data needed by hospitals to manage APCs. This same commenter stated that hospitals must be given detailed instructions on claims submission, changes to the UB-92, and changes to the Correct Coding Initiative (CCI) in advance to ensure that systems and personnel can comply with Medicare requirements.

Response: We released specific hospital billing instructions that address line item reporting and reporting of service units on December 23, 1999 (Transmittals 1787 and 747). We will be issuing final instructions for implementation of this PPS in a program memorandum to fiscal intermediaries. The program memorandum addresses a range of issues such as appropriate use of revenue center/HCPCS codes for compliance with Medicare requirements and changes to Remittance Advice messages and Medicare Summary Notices/EOMBs.

All current correct coding initiative (CCI) edits with the exception of laboratory and anesthesiology edits have been incorporated in the outpatient code editor (OCE) that fiscal intermediaries use to process claims for hospital outpatient services for payment. We will address OCE changes in a program memorandum to fiscal intermediaries. The effective date of these edits is July 1, 2000.

We have decided not to pursue changes to the UB-92 claim form to allow line item diagnosis because, as we discuss in section III.C.3, we will not be using diagnosis to determine payments for clinic and emergency visits when the PPS is first implemented. Diagnosis codes, however, are still required to be reported on hospital outpatient bills.

## Medical Review Under the Hospital Outpatient PPS

We have received inquiries regarding the anticipated medical review process for hospital outpatient PPS claims. The methodology of review for outpatient claims does not change under the PPS. The goal of medical review is to identify inappropriate billing and to ensure that
payment is not made for noncovered services. Contractors may review any claim at any time, including requesting medical records, to ensure that payment is appropriate. In accordance with this final rule, Medicare will make payment under the PPS for hospital outpatient services including partial
hospitalization services; certain Part B services furnished to inpatients who have no Part A coverage; partial hospitalization services furnished by CMHCs; vaccines, splints, casts and antigens provided by HHAs and CORFs that provide medical and other health services; and splints, casts and antigens provided to hospice patients for the treatment of a nonterminal illness. In addition, we expect focused reviews will include the adjustments we have made to the hospital outpatient PPS as a result of the enactment of the BBRA 1999, especially the transitional passthrough payments for innovative drugs, biologicals, and medical devices that are discussed in section III.D. Fiscal intermediaries will continue focused and random review of services such as ambulance, clinical diagnostic laboratory, orthotics, prosthetics, take home surgical dressings, chronic dialysis, screening mammographies, and outpatient rehabilitation (physical therapy including speech language pathology and occupational therapy) even though these services are excluded from the scope of services paid under the hospital outpatient PPS.

## L. Prohibition Against Administrative or Judicial Review

Section 1833(t)(9) of the Act, as added by the BBA 1997, prohibits
administrative or judicial review of the development of the PPS classification system, the groups, relative payment weights, wage adjustment factors, other adjustments, volume control methods, calculation of base amounts, periodic control methods, periodic adjustments, and the establishment of a separate conversion factor for cancer hospitals. Section 201(a) of the BBRA 1999 redesignates this section as section 1833(t)(11) of the Act, and section 201(d) of the BBRA 1999 amends the section by adding the following to the list of adjustments subject to the limitation on judicial review: the factors used to determine outlier payments, that is, the fixed multiple, or a fixed dollar cutoff amount; the marginal cost of care, or applicable total payment percentage; and the factors used to determine additional payments for certain medical devices, drugs, and biologicals such as the determination of insignificant cost, the duration of the additional payments, the portion of the outpatient PPS
payment amount associated with particular devices, drugs, or biologicals, and any pro rata reduction. Section 202(a) of the BBRA 1999 further redesignates section 1833(t)(11) as section 1833(t)(12).

## IV. Provider-Based Status

## A. Background

The Medicare law (section 1861(u) of the Act) lists the types of facilities that are regarded as providers of services, but does not use or define the term "provider-based." However, from the beginning of the Medicare program, some providers, which we refer to in this section as "main providers," have owned and operated other facilities, such as SNFs or HHAs, that were administered financially and clinically by the main provider. The subordinate facilities may have been located on the main provider campus or may have been located away from the main provider. In order to accommodate the financial integration of the two facilities without creating an administrative burden, we have permitted the subordinate facility to be considered provider-based. The determination of provider-based status allowed the main provider to achieve certain economies of scale. To the extent that overhead costs of the main provider, such as administrative, general, housekeeping, etc., were shared by the subsidiary facility, these costs were allowed to flow to the subordinate facility through the cost allocation process in the cost report. This was considered appropriate because these facilities were also operationally integrated, and the provider-based facility was sharing the overhead costs and revenue producing services controlled by the main provider.

Before implementation of the hospital inpatient PPS in 1983, there was little incentive for providers to affiliate with one another merely to increase Medicare revenues or to misrepresent themselves as being provider-based, because at that time each provider was paid primarily on a retrospective, cost-based system. At that time, it was in the best interest of both the Medicare program and the providers to allow the subordinate facilities to claim provider-based status, because the main providers achieved certain economies, primarily on overhead costs, due to the low incremental nature of the additional costs incurred.
In the proposed rule, we pointed out the increase of provider-based facilities and the financial and organizational incentives for that increase since 1983. A variety of factors such as the
emergence of integrated delivery systems and the pressure to enhance revenues have combined to create incentives for providers to affiliate with one another and to acquire control of nonprovider treatment settings, such as physician offices.

We noted in the proposed rule that it is essential that we make decisions regarding provider-based status appropriately, and that we have clear rules for identifying provider-based entities. By failing to distinguish properly between provider-based and free-standing facilities or organizations, we risk increasing program payments and beneficiary coinsurance with no commensurate benefit to the Medicare program or its beneficiaries and we jeopardize the delivery of safe and appropriate health care services to our beneficiaries.

Although there is no direct statutory requirement to maintain explicit criteria for determination of provider-based status, there are statutory references acknowledging the existence of this payment outcome. For example, section 1881(b) of the Act provides for separate payment rates for hospital-based ESRD facilities. There is currently no general definition of "provider-based facility" in the CFR. However, in the proposed rule, we cited issuances that do contain provisions for recognition of specific types of entities as provider-based, including Program Memorandum A-967, published on August 27, 1996, which pulled together instructions for specific entity types from previously published documents and consolidated them into a general instruction for the designation of provider-based status for all facilities or organizations. That Program Memorandum was subsequently reissued, without substantive change, as Program Memoranda A-98-15 and A-99-24 and, in October 1999, was manualized by the Provider Reimbursement Manual, Part I, Transmittal 411 (adding new section 2446), and the State Operations Manual, Transmittal 11 (replacing previous section 2003 and adding new section 2004). Our policy will continue to follow the principles we articulated in Program Memorandum A-96-7 and the Provider Reimbursement Manual and State Operations Manual sections cited above until October 10, 2000. After that date, we shall apply the policies set forth in these final regulations.

## B. Provisions of the Proposed Rule

We announced our intention to implement §§413.24(d)(6)(i) and (ii), 413.65, 489.24(b), and 498.3, as revised based on our consideration of public comments, with respect to services
furnished on or after 30 days following publication of a final rule. We describe these sections below and explain that we have now provided a 6 -month delay in the effective date of the regulations on provider-based status.
We proposed to add a new §413.65 on the determination of provider-based status. In paragraph (a), we proposed to define the following terms: department of a provider, free-standing facility, main provider, provider-based entity, and provider-based status. In paragraph (b), we proposed that a facility or organization would not be entitled to be treated as provider-based simply because it or the provider believe it to be provider-based. The facility or organization, or the provider, would have to contact HCFA and obtain an affirmative provider-based determination before billing of the facility's or organization's costs through the main provider, or inclusion of those costs on the main provider's cost report, is initiated. Further, we proposed to presume a facility not located on the campus of a hospital and used as a site of physician services of the kind ordinarily furnished in physician offices to be a free-standing facility unless we determined it to have provider-based status.
We proposed to require, in paragraph (c), that a main provider that acquires a facility or organization for which it wishes to claim provider-based status must report its acquisition of the facility or organization to us if the facility or organization is off the campus of the main provider, or is located on the campus of the main provider and, if acquired, would increase the main provider's costs by 5 percent or more. The main provider must also furnish all information needed for a determination as to whether the facility or organization meets the criteria in this section for provider-based status. A main provider that has had one or more facilities or organizations determined to have provider-based status also must report to us any material change in the relationship between it and any department or provider-based entity, such as a change in ownership of the entity or entry into a new or different management contract, that could affect the provider-based status of the department or entity.

In paragraph (d), we proposed the requirements for a determination of provider-based status. In paragraph (d)(1), we proposed to set forth licensure requirements for facilities or organizations seeking provider-based status.

In paragraph (d)(2), we proposed to require that a facility or organization be
under the ownership and control of the main provider.

In paragraph (d)(3), with respect to administration and direct supervision of the main provider, we proposed to require that a facility or organization seeking provider-based status have a reporting relationship to the main provider that is characterized by the same frequency, intensity, and level of accountability that exists in the relationship between the main provider and one of its departments.
In paragraph (d)(4), we proposed that a facility or organization seeking provider-based status and the main provider share integrated clinical services, as evidenced by privileging of the professional staff of the department or entity at the main provider, and the main provider's maintenance of the same monitoring and oversight of the department or entity as of other departments. Also, the medical director of the department or entity would be required to maintain a day-to-day reporting relationship with the chief medical officer (or equivalent) of the main provider, and be under the same supervision as any other director of the main provider.
In paragraph (d)(5), we proposed to require that the department or entity and the main provider be fully financially integrated within the main provider's financial system, as evidenced by the sharing of income and expenses. The department's or entity's costs should be reported in a cost center of the provider, and the department's or entity's financial status should be incorporated into, and readily identifiable in, the main provider's trial balance.
In paragraph (d)(6), we proposed to require that the main provider and the facility seeking status as a department of the provider be held out to the public as a single entity, so that when patients enter the department they are aware that they are entering the provider and will be billed accordingly. (This requirement would not apply to a provider-based entity that is itself a provider, such as a SNF.)
In paragraph (d)(7), we proposed to require that the department of a provider or provider-based entity and the main provider be located on the same campus, except where requirements relating to service to the same patient population are met.

Paragraph (e) would specifically prohibit the approval of provider-based status for any proposed department or entity that is owned by two or more providers engaged in a joint venture.

In proposed paragraph (f), we proposed to state that facilities or
organizations operated under management contracts would be considered provider-based only if specific requirements are met related to: Staff employment, administrative functions, day-to-day control of operations, and holding of the management contract by the provider itself rather than by a parent organization.
In proposed paragraph (g), we proposed to specify nine obligations of hospital outpatient departments and hospital-based entities. We explained that these obligations ensure that facilities seeking recognition as hospital outpatient departments or hospitalbased entities are in fact what they represent themselves to be, and are not simply the private offices of individual physicians or of physicians in group practices.

We also proposed to preclude any facility or organization that furnishes all services under arrangements from qualifying as provider-based. We believe the provision of services under arrangement was intended to be allowed only to a limited extent, in situations where cost-effectiveness or clinical considerations, or both, necessitate the provision of services by someone other than the provider's own staff. The "under arrangement" provision in section 1861(w)(1) of the Act and $\S 409.3$ is not intended to allow a facility merely to act as a billing agent for another.

Proposed paragraph (h) states that, if we learn of a provider that has inappropriately treated a facility or organization as provider-based, before obtaining our determination of providerbased status, we would reconsider all payments to that main provider for those periods subject to reopening, and we would investigate to determine whether the designation was appropriate.
In proposed paragraph (i), we would apply the principles in paragraph (h) to situations involving inappropriate billing for services furnished in a physician's office or other facility or organization as if they had been furnished in a hospital outpatient or other department of a provider or in a provider-based entity.

We also proposed to add a new paragraph ( j ) that would allow us to review past determinations. If we find that a designation was in error, and the facility or organization in question does not meet the requirements of this section, we will notify the main provider that the provider-based status will cease as of the first day of the next cost report period following notification of the redetermination.

In addition, we proposed to add to §413.24(d) new paragraphs (6)(i) and (6)(ii) to clarify that main providers, in completing their Medicare cost reports, may not allocate overhead costs to the provider-based or other cost centers that incur similar costs directly through management contracts or other arrangements. These changes are needed to prevent misallocation of management costs, which would result in excessive payment to those types of providers paid on a reasonable cost basis.
To provide an administrative appeals process for entities that have been denied provider-based status, we proposed to revise the regulations on provider appeals at $\S 498.3$. As revised, these rules would specify that a provider seeking a determination that a facility or an organization is a department of the provider or a provider-based entity under proposed $\S 413.65$ would be included in the definition of "prospective provider" for purposes of part 498, and would be afforded the same appeal rights as a prospective provider, such as a hospital or SNF, that we have found not to qualify for participation as a provider.

## C. Comments and Responses

In response to our proposals, we received approximately 120 letters of comment, most of which raised a number of issues. Included among the commenters were hospitals and hospital and other provider associations, physicians, attorneys, and other individuals. Here we respond to comments submitted on the proposed rule.

## General Comments

Many comments were not directed to a specific provision or criterion, but concerned the implementation of the regulations or the application of provider-based criteria to specific types of facilities. These are summarized below.

## Effective Date

Comment: A commenter requested clarification as to when the parts of the final rule setting forth criteria for provider-based status would be effective, and a number of commenters requested an extended grace period or a delay in effective date of the final rules, with some commenters requesting delays as long as 12 to 18 months. Various reasons were cited, including the pressures on providers to prepare their systems and staff for the outpatient PPS, the need to bring operations into compliance with the provider-based criteria, and the anticipated workloads of HCFA regional offices that may
receive a large number of requests for provider-based determinations.
Commenters argued that it is unrealistic to expect that a hospital would engage in a full-blown analysis of its providerbased arrangements and modify each arrangement until it knows against which exact criteria it is measuring those arrangements. Any changes in status will require hospitals to implement billing and other operational changes. Thus, commenters argued that it is not reasonable to expect hospitals to complete such steps within a 30-day period.

Response: We agree, and are providing a delay in the effective date until October 10, 2000. Moreover, as stated in our response to comments on proposed $\S 413.65(j)$ below, any redetermination of provider-based status that finds the facility or organization not to be provider-based will not take effect for at least 6 months after the date the provider is notified of the redetermination.

## Application to Specific Facilities

Comment: One commenter stated that under the Balanced Budget Act of 1997 (the BBA 1997) long-term hospitals established on or before September 30, 1995 are entitled to retain their longterm hospital classification notwithstanding their location in the same building or campus of another hospital. In the commenter's view, these hospitals should not now have this classification revoked by this proposed regulation.

Response: The provision referred to by the commenter, section 4417(a) of the BBA 1997, is codified in section 1886(d)(1)(B) of the Act and is implemented under regulations at $\S 412.22(\mathrm{f})$. That provision authorizes certain hospitals to continue being excluded from the Medicare hospital inpatient prospective payment system (PPS) based on their exclusion status and configuration on or before September 30, 1995, even though they would not otherwise qualify for this exclusion. The criteria for providerbased status do not conflict with or even directly relate to the section 4417 (a) provision, and we have therefore not made any change in the regulations based on this comment.

Comment: The commenter believes that rural health clinics (RHCs) should be exempted from provider-based designation requirements if they meet the intent of the enabling regulation. The commenter requested that an RHC be granted provider-based status if it meets one of the following criteria: Is the sole source of primary care for the community; has traditionally served the
community with an open door policy; or treats a disproportionate share of the community's Medicare and Medicaid population

Response: We share the commenter's concern, but believe the criteria suggested are overly inclusive and could lead to a proliferation of RHCs in areas where there are no true shortages of care. While we do not believe a blanket exemption from the criteria is warranted, we have developed a special provision for RHCs affiliated with small rural hospitals, as described below in our responses to comments on $\S 415.65(d)(7)$, Location in immediate vicinity.

Comment: A commenter stated that there may be instances where the Medicare regulations related to provider-based definitions conflict with the Medicaid provider-based regulations, and asked whether Medicaid will be required to comply with the new Medicare provider-based regulations.

Response: Because hospitals under Medicaid are required to meet the same standards as Medicare facilities, these final rules would affect the Medicaid definition of these facilities as well as the Medicare definitions.

Comment: Commenters stated that the reasons cited for establishing providerbased requirements that are found in the preamble do not apply to clinical laboratories and thus these requirements should not apply. The commenters asked that we explicitly state in the final regulations that the provider-based requirements are not applicable to clinical laboratories. They believe the regulations have little bearing where, as with clinical laboratory services, reimbursement is under a fee schedule amount, and neither the Medicare program nor the beneficiary will pay anyone differently as a result of the treatment of the laboratory in the manner proposed.

Response: As explained more fully in the preamble to the proposed rule, our objective in issuing specific criteria for provider-based status is to ensure that higher levels of Medicare payment and increases in beneficiary liability for deductibles or coinsurance (which can all be associated with provider-based status) are limited to situations where the facility or organization is clearly and unequivocally an integral and subordinate part of a provider. Under this principle, we agree with the commenter's view that it would not be either necessary or appropriate to make provider-based determinations with respect to facilities or organizations if by law their status (that is, provider-based or free-standing) would not affect either

Medicare payment levels or beneficiary liability. However, we believe that it is not necessary to specify in the regulations that specific facility types are excluded, since these facilities or organizations are unlikely to seek a provider-based determination. We will be careful to clarify this policy in program operating instructions.

Comment: A commenter stated that the proposed provider-based requirements seem to preclude the possibility of a Comprehensive Outpatient Rehabilitation Facility (CORF) meeting these new requirements. The commenter believes that in the past, CORFs have been permitted to be either provider-based or free-standing and asked whether the final rules will give CORFs the option of being either free-standing or providerbased.

Response: As explained more fully in the preamble to the proposed rule, our objective in issuing specific criteria for provider-based status is to ensure that higher levels of Medicare payment and increases in beneficiary liability for deductibles or coinsurance (which can all be associated with provider-based status) are limited to situations where the facility or organization is clearly and unequivocally an integral and subordinate part of a provider. We are aware that, under the cost-based payment system that applied to CORFs prior to January 1, 1999, approximately 17 percent of participating CORFs claimed provider-based status. However, effective January 1, 1999, in accordance with the BBA 1997, payment for all CORF services is made no longer on the basis of cost reimbursement but on the basis of the physician fee schedule. Beneficiary liability is also determined under the fee schedule, regardless of the organizational structure or affiliations of the CORF. The switch to fee schedule payment from a cost-based system eliminates or removes any payment incentives to be a provider-based rather than a free-standing CORF. Thus, as in the case of the preceding comment, we agree with the commenter's view that it would not be either necessary or appropriate to make provider-based determinations with respect to facilities or organizations if by law their status (that is, provider-based or free-standing) would not affect either Medicare payment levels or beneficiary liability. We also note that existing regulations at $\S 413.174$ specify rules for determining whether ESRD facilities are independent or hospital-based, and we have revised $\S 413.65(\mathrm{a})$ to state that determinations with respect to ESRD facilities will continue to be made under $\S 413.174$,
not $\S 413.65$. However, we believe that it is not necessary to specify in the regulations that most specific facility types are excluded, since these facilities or organizations are unlikely to seek a provider-based determination. We will be careful to clarify this policy in program operating instructions.

## Application to Specific FacilitiesIndian Health Service (IHS)

Comment: Several commenters requested an exception or exemption from the rules for IHS and tribal facilities. One commenter was concerned that the implementation of these proposed regulations will have the effect of denying Medicare participation as provider-based entities to a number of IHS facilities that are currently operated by Indian tribes under the auspices of Public Law 93-638. They will also cause a disruption of the coordinated health care delivery system(s) that exist between IHS and numerous tribes, and jeopardize statutorily authorized contracting and compacting relationships between the IHS and these tribes due to the conflict between these proposed regulations and the statutory opportunities for selfdetermination by the Indian tribes. The IHS strongly recommended that these proposed regulations not apply to IHS and tribal health systems as written. Recommendations were also made to deem satellite facilities within a discrete Indian reservation as meeting the definition of a provider-based entity as well as satellite facilities within a historical service unit. Finally, the IHS recommended that the current system be "grandfathered" to meet the definition of provider-based entity.
Response: We share many of these concerns and have provided special treatment for IHS and tribal facilities as described below.

Comment: A commenter was concerned that the proposed regulations would severely restrict a number of IHS satellite clinics from receiving reimbursement for the provision of Medicare Part B services. The commenter believes that a number of the requirements that must be met before an entity can be designated as provider-based for Medicare payment purposes are unrealistic for IHS satellite clinics, which are often the only Medicare providers on remote tribal lands. The commenter recommended that HCFA provide for an exemption for IHS satellite facilities that are generally located on a main hospital campus or within a short distance of a hospital. Also, the commenter recommended that the final rule clarify that IHS and tribal outpatient departments or satellite
clinics are eligible to receive designation as a department of a provider or a provider-based entity and are eligible for Part B reimbursement.

Response: We share many of these concerns and have provided special treatment for IHS and tribal facilities as described below.

Comment: Many tribes have acquired operations of outpatient facilities and are in the process of acquiring the affiliated hospitals. The commenter stated that this trend, coupled with the complexities of the Indian SelfDetermination Act (Pub. L. 93-638), the Indian Health Care Improvement Act (Pub. L. 94-437), and a moratorium on tribal compacting and contracting, requires special consideration by HCFA. The commenter requested that facilities be recognized as provider-based if-
(1) The outpatient facility is owned and operated by the tribe that owns the majority of the tribal shares utilized in funding the main hospital;
(2) The tribe has previously compacted programs that were historically administered by the hospital and are now administered through a committee or board comprised of medical staff of both facilities;
(3) The outpatient facility is in the same State as the hospital;
(4) There is coordination and integration of services, to the extent practicable, between the outpatient facility seeking provider-based status and the main provider.

Response: We recognize that the provision of health services to members of Federally recognized Tribes is based on a special and legally recognized relationship between Indian tribes and the United States Government. To address this relationship, the IHS has developed an integrated system to provide care that has its foundation in IHS hospitals. Because of these special circumstances, not present in the case of private, non-Federal facilities and organizations that serve patients generally, we agree that it would not be appropriate to apply the provider-based criteria to IHS facilities or organizations or to most tribal facilities or organizations. Therefore, we have revised the final rule to state that facilities and organizations operated by the IHS or Tribes will be considered to be departments of hospitals operated by the Indian Health Service or Tribes if, on or before April 7, 2000, they furnished only services that were billed as if they had been furnished by a department of a hospital operated by the Indian Health Service or a Tribe and they are: (1) owned and operated by the IHS; (2) owned by the Tribe but leased from the Tribe by the IHS under the

Indian Self-Determination Act in accordance with applicable regulations and policies of the Indian Health Service in consultation with Tribes: or (3) owned by the IHS but leased and operated by the Tribe under the Indian Self-Determination Act in accordance with applicable regulations and policies of the Indian Health Service in consultation with Tribes. Facilities or organizations that are neither leased nor owned by the IHS would not be eligible for this special treatment, even if operated on Tribal land by members of the Tribe. These facilities would, of course, be eligible to participate in Medicare as FQHCs if applicable requirements in our regulations at 42 CFR part 405, subpart X are met. We did not adopt the conditions recommended by one commenter because we believe they may not apply to all Tribes.

## Application to Specific FacilitiesFederally Qualified Health Centers (FQHCs)

Comment: A commenter stated that despite specific acknowledgment of the eligibility of FQHCs to qualify as provider-based entities, certain proposed ownership, governance, and supervision criteria in connection with the determination of provider-based status would effectively prohibit entities from maintaining concurrent providerbased and FQHC designations. The commenter believe the criteria should be modified, or some other special provision created, to allow FQHCs to be departments of a provider.
Response: We understand the commenter's concerns and have provided special treatment for FQHCs as described below.

Comment: The commenter, a hospital that is affiliated with a number of offsite community health centers, believes the criteria in the proposed rule would deny provider-based status to community controlled, urban taxexempt health centers operated under the license of a "main provider." Several of the commenter's health centers are FQHCs that must fulfill certain criteria to maintain this status. In the commenter's view, it is not feasible to require the "main provider" to own and control these health centers or to require that the health centers and the "main provider" strictly meet all of the requirements set forth in the proposed rule. The commenter asked that the final rule be revised to take into account these historical relationships and "grandfather" the provider-based status of health centers that have been on the license of a disproportionate share hospital for at least 10 years. The recommended "grandfathering"
provisions also could, in the commenter's view, require common Joint Commission on Accreditation of Healthcare Organizations (JCAHO) accreditation, integration of clinical care committees, main provider approval of clinical guidelines and protocols, and financial oversight and review by the main provider.
Response: We share many of these concerns and have provided special treatment for FQHCs as described below.

Comment: A commenter requested that we provide a transition period of at least five years for health centers that have been treated as provider-based entities for a significant period of time (for example, 10 years or more), so that the centers will have adequate time to achieve compliance with the providerbased criteria. In the commenter's view, an extended time period for compliance would permit continuity of care to the populations served by the health centers while granting the affected health centers an opportunity to find alternative funding streams.
Response: We recognize that FQHC qualification criteria effectively require these facilities to be governed by community-based boards independent of hospitals and other providers, while our provider-based criteria require facilities seeking provider-based status to be operated under the ownership and control of the main provider, and to be under the direct supervision of that provider. This does not preclude an FQHC from participating in Medicare as a free-standing entity; on the contrary, this participation is entirely appropriate. However, it does preclude the facility from qualifying as a department of a hospital or other provider under our criteria.
Despite the difference between HRSA and HCFA requirements, we are aware that some FQHCs may have been treated by hospitals as departments for purposes of Medicare and Medicaid billing, and we are concerned that an abrupt change in status for them could force some or all to close, leading to shortages of care in some areas.
Therefore, we plan to establish special provisions for FQHCs and FQHC "lookalikes" (facilities that are structured like FQHCs and meet all requirements for grant funding, but have not actually received these grants). Specifically, we have revised the regulations to state that if a facility has since April 7, 1995 furnished only services that were billed as if they had been furnished by a department of a provider and either (1) received a grant before 1995 under section 330 of the Public Health Service Act or, before 1995, received funding
from such a grant under a contract with the recipient of such a grant and meets the requirements to receive a grant under section 330 of the Public Health Service Act; or (2) based on the recommendation of the PHS, was determined by HCFA before 1995 to meet the requirements for receiving such a grant, the facility will continue to be treated, for purposes of this section, as a department of the provider without regard to whether it complies with the criteria for provider-based status in §413.65. We note that both types of facilities would be obligated, for as long as they are treated as a department of a provider, to comply with the applicable requirements for departments of providers as stated in §413.65(g).

## Application of Standards

Comment: One commenter believes that the proposed rule did not make clear how it would apply to existing entities, because some language in the rule could be read to require that existing entities would not receive provider-based status until we have issued a determination letter. Another commenter requested that we clarify whether we expect to review all clinics prospectively or just new clinics. The commenter stated that requirements that only new clinics seek designation does not preclude us from auditing currently designated clinics. Another commenter asked if there will be a set time frame during which current providers with provider-based departments or entities under Program Memorandum A-96-7 must contact us and receive an official designation in order to continue billing as they currently do. More specifically, the commenter asked whether, if there is such a time frame, compliance with the criteria in the Program
Memorandum would constitute a good faith effort as referred to in §413.65(i)(2). Additional guidance was also requested as to what providers should do now to demonstrate that they have made a good faith effort.

Response: We plan to review all new requests for provider-based status. At present, we have no plans to systematically review all providers to determine whether they may be claiming provider-based status for some facilities or organizations inappropriately. However, we will review the status of specific facilities or organizations in response to complaints or any other credible information that indicates that provider-based status requirements are not being met. If the regional office determines that this is the case, it will take action in accordance with the rules in new
§413.65(h) and (i). In response to the comment about possible retroactive application of the new regulations, we note that they will apply only on or after their effective date of October 10, 2000. We will not apply the provider-based criteria in the new regulations to periods prior to that date; on the contrary, decisions for such periods will be reviewed only under the criteria in effect at the time, as stated in Program Memoranda and the Provider Reimbursement Manual and State Operations Manual.

Comment: Two commenters pointed out the proposed rules do not state whether the required approval status is retroactive to when the provider applied or to when we granted approval. These commenters believe it should be retroactive to the date of the provider's application for the determination.
Response: We plan to make providerbased status applicable as of the earliest date on which a request for providerbased status has been made and all requirements for provider-based status are shown to have been met, not on the date of our determination. Thus, if a provider requests provider-based status for a facility on May 1 and demonstrates that applicable criteria were met on that date, but the regional office did not make a formal determination until June 1, the determination would be effective on May 1.
Comment: The commenter stated that we should not have published important provider-based policies in a Federal Register document that some providers, such as skilled nursing facilities and home health agencies, may not have read. The commenter recommended that we re-issue these proposed rules separately from the proposed hospital outpatient prospective payment rules.
Response: We do not agree that the proposed rules were published in an obscure location. On the contrary, the number of written comments received, many of them from providers other than hospitals, indicates that our proposals were widely known among providers that could be affected. Therefore, we do not intend to republish the proposed rules.

Comment: A commenter expressed concern that these provider-based provisions are unnecessarily restrictive and will unreasonably limit practice arrangements. The commenter went on to state that in the current health care environment, physicians and hospitals need flexibility to adapt to local market conditions and participate in a variety of practice arrangements to provide cost effective, high quality care. An unnecessary strict definition of
"provider-based entity" could have a chilling effect on the evolution of new care delivery structures that would expand access to care, especially in rural areas.
Response: We share the commenter's concern with preserving Medicare beneficiaries' access to care, but do not agree that the provider-based rules will limit access. We note that the rules do not prohibit hospitals from purchasing physician practices or taking other actions to enhance access to care in remote rural areas; they only set minimum standards for the type of affiliations that will be recognized for provider-based designation.
For example, an institutional provider such as a hospital or SNF may elect to use part of its institutional complex to house physician offices or other facilities that provide services complementing those of the provider. Those facilities'costs will have to be included in the trial balance of the institutional complex, in order to allow costs to be allocated accurately to all parts of the complex, and permit the costs of the provider to be determined. However, inclusion of such facilities' costs on the institutional complex trial balance does not make the facilities provider-based. On the contrary such facilities would have to meet the criteria in §413.65 to qualify for provider-based status.
Comment: Different views were expressed on how much
discretion regional offices should have in applying the provider-based criteria. One commenter asked that we make the rules as clear and concise as possible. The commenter argued that rules allowing for great latitude in interpretation could be dangerous for the provider community. On the other hand, another commenter stated that we should allow Medicare regional offices greater latitude for determining when sufficient integration exists for a facility to qualify as provider-based, and should avoid adopting regulations that "micromanage" a hospital's operations.
Another commenter suggested that rather than requiring that all criteria must be met to achieve provider-based status, we change the test to substantially all. There may be circumstances where criteria are not fully met, but an overall assessment supports a provider-based determination. This same commenter recommended that a "pending" status be incorporated into the evaluation process, whereby hospitals not meeting the criteria for provider-based status would be afforded an opportunity to make the modifications necessary. Another commenter asked that instead
of meeting all criteria, we permit the regional offices to evaluate a facility's status with respect to the main provider with input from local government and the fiscal intermediary. Another commenter also suggested that the standards only be enforced to the extent that they are applicable and relevant, consistent with state laws, and relate to practices that are subject to the control of the particular provider.

Response: We have tried to balance the need to apply standards that can be adapted to fit particular circumstances, and agree that the standards should not be overly prescriptive, but rely on regional judgment to ensure appropriate decision making. Because providerbased status is a matter of extreme importance to many facilities, published standards provide a basis for advance assessment and planning of particular organizational and financial arrangements. Therefore, we have decided that a facility or organization will be found to be provider-based only when it is in compliance with all standards set forth in these final rules.

With respect to the comment regarding situations in which all but a few criteria for provider-based status are met, we note that nothing prohibits the main provider from re-applying for approval of provider-based status for a facility or organization after having made the changes necessary to come into compliance. Regional offices would in such cases only need to verify compliance with whatever criteria had not been previously met, unless the amount of time that elapses between requests, or other factors, make a full reevaluation necessary. Because facilities have this flexibility under the rules as proposed, we did not make any changes based on this comment.

Comment: One commenter believes that we had not fully addressed the impact of these rules on service delivery. The commenter suggested that changes would affect deemed status, survey and certification requirements, state licensure requirements, physician referral requirements, and a host of related issues. Another commenter stated that the new requirement regarding administration and supervision found in §413.65(d)(3) could impact more than our estimated 105 providers. The commenter believes that if providers are required to convert management firm employees to hospital employees and then revert back when outpatient PPS becomes effective, this could impact 5,000 inpatient PPS hospitals.

Response: We again reviewed our requirements, but do not believe they will have the far-reaching effects
envisioned by these commenters. In particular, to the extent a facility or organization that claims to be a department of a provider must be accredited, surveyed, or licensed as a part of that provider, or must adapt to the physician referral requirements of the main provider, that result does not flow from the existence of criteria for provider-based status, but instead is a direct result of the provider's decision to claim the facility or entity as a department. We also do not think it is reasonable to assume that any significant number of hospitals will restructure themselves repeatedly because of the final rules set forth below. As noted earlier, both the proposed and final rules closely parallel policies that have been stated explicitly on program instructions since 1996, and we are providing a 6 -month delay in effective date for the final rule. Thus, hospitals and other providers have had ample time to assess the impact of any changes and to make necessary adjustments in an orderly way.

Comment: A commenter requested clarification as to how the proposed rules would apply to two hospitals seeking consolidation into a single provider. The commenter also asked whether two small PPS hospitals located approximately 15 to 25 miles apart in separate towns within a metropolitan statistical area (MSA) who wish to consolidate would be prohibited from doing so because of patient population or licensure requirements. Furthermore, if these two hospitals are already certified as a single provider, would the proposed rules require them to separate and create separate providers? Another commenter requested that the final regulatory text state that the provider-based
requirements do not apply to any facility where there are inpatient beds since such a facility would be viewed as a "main provider." The provider-based requirements should apply only to facilities or organizations other than main providers.

Response: Although the Program Memorandum and proposed rules were issued in response to situations primarily involving outpatient facilities, we believe the policies set forth in these documents are equally applicable to inpatient facilities, and should be applied in the many cases in which a determination about inpatient facilities must be made. The rules would not prohibit two previously separate hospitals from merging to become a single provider. However, for either facility to be considered provider-based with respect to the main provider, the facility would have to meet the criteria
in this final rule. To clarify the scope of application of these regulations, we have added a definition of "remote location of a hospital" and a reference to hospital satellite facilities to § 413.65(a) Definitions, and have clarified the wording of several later sections by including references to remote locations and satellites. We have defined a "remote location of a hospital" as a facility or an organization that is either created by, or acquired by, a hospital that is a main provider for the purpose of furnishing inpatient hospital services under the name, ownership, and financial and administrative control of the main provider, in accordance with the provisions of this section. A remote location of a hospital may not be licensed to provide inpatient hospital services in its own right, and Medicare conditions of participation do not apply to a department as an independent entity. The term "remote location of a hospital" does not include a satellite facility as defined in $\S 412.22(\mathrm{~h})(1)$ and §412.25(e)(1). Hospitals may acquire remote locations by various means, but often do so by mergers or acquisitions, in which a single hospital purchases other, previously separate hospitals, and operates them as remote locations that are not separately organized as departments, but instead furnish the same types of services as the original hospital. For example, a long-term care or other specialty hospital might acquire one or more other hospitals, terminate their separate participation in Medicare, but continue to use them as sites of the same type of care as the original hospital. Satellite facilities are currently defined in our regulations at §412.22(h)(1) (for hospitals) and §412.25(e)(1) (for units). In general, a satellite facility is a part of a hospital (or of a hospital unit) that provides services in a building also used by another hospital, or in one or more buildings on the same campus as buildings also used by another hospital. Satellite status always involves co-location with another hospital, while remote locations are not co-located with other hospitals' facilities.

Comment: A commenter requested clarification that the provider-based requirements apply only to providers who are paid under the reasonable cost methodology. The preamble language in section VI implies that these requirements would also apply to providers under the outpatient PPS. The commenter believe that if this were the case, the requirements found in $\S \S 413.24(\mathrm{~d})(6)$ and 413.65 would be appropriately placed in Subchapter E
(for example, Part 482, Conditions of Participation for Hospitals).

Response: The rules set forth below are not limited in their scope to providers paid on a reasonable cost basis but, except where specifically stated in the text of the rules, apply to all providers and facilities seeking Medicare payment. While many of the problems associated with inappropriate accordance of provider-based status relate to cost reimbursement, the different payment systems used for various providers may produce some unintended incentives for one type of facility to gain an unfair payment advantage by misrepresenting itself. The specific requirements cited do not, like the Medicare conditions of participation, implement section 1861(e) of the Act, nor do they primarily concern patient health and safety. Therefore, we did not adopt the suggestion that the section be relocated to part 482.

Comment: A commenter would support a provision that prohibits hospitals from acquiring free-standing physician practices and converting them to hospital-based entities.

Response: We understand the commenter's concern, but do not have authority under the Medicare law to prohibit this practice. We do believe that the rules set forth below will keep hospitals from misrepresenting physicians' practices as hospital outpatient departments.
Section 413.24(d)(6) Adequate cost data and cost finding: Management contracts

Comment: The proposed cost reporting requirements state that if an overhead administrative cost center does not perform services for the off-site clinic or department, no costs should be allocated to that function. The commenter pointed out that this contradicts generally established Medicare cost reporting principles that have always required that the administrative costs be allocated to allowed and nonallowed cost centers.

Response: Our position, as expressed in the Provider Reimbursement Manual, Part II, Chapter 36 for hospitals, is to allow the provider to bypass the allocation of overhead through the cost report to avoid inappropriate allocations. An example of this would be lab services under arrangement, where there is obviously no administrative activity by the main provider. Our electronic cost report systems are set up to "skip" that particular cost center and to re-allocate the costs to the remaining cost centers. Likewise, where administrative costs
such as billing are performed by the subordinate provider, no billing cost from the main provider should be allocated to that cost center from the main provider.

Comment: Several commenters suggested clarification of "like" costs by adding a definition or providing examples. Also, a commenter stated that since the main concern is costs, this provision should be applied when management costs exceed the hospital's operating costs of the department by 10 percent on a comparable basis. Another commenter stated that: (1) Management services benefit only the specific department to which they are expensed, and provide no direct services to other hospital departments; (2) A department under the management contract receives necessary services from other hospital overhead departments; (3) such overhead departments do not represent duplicate services provided under the management contract. Since management agreements can be drastically diverse, the commenter believes this clarification would assist in avoiding any confusion, as well as allow for consistency with generally accepted cost finding principles. Another commenter stated that most entities that contract to manage an area of a hospital manage just that area.
Therefore, if they offer assistance with a particular function, it is only for that area and not for the whole hospital. The commenter believes the same principles of reimbursement should be applied whether the hospital provides the service directly or contracts for the service to be provided.
Response: Examples of similar costs when management contracts provide services also available through the main provider are the following: billing services, computer services, accounting services, and, possibly, general administrative staff. When the same services are included in the administrative and general costs of the main provider, and allocated down to subordinate cost centers or providers incurring and reporting these same costs in the trial balance, the result is a duplication of costs to the subordinate cost center or provider. As long as the main provider has the ability to identify these "like" service costs, these costs should be re-allocated to the remaining reimbursable and non-reimbursable cost centers in proportion to each cost center's total costs as prescribed in the Provider Reimbursement Manual, Part II, Chapter 36. However, if the main provider is not able to identify the costs of these same services to permit the exclusion of allocation to the subordinate providers or cost centers,
the cost of the management contract of the subordinate provider or cost center must be reclassified to the main provider's administrative and general cost center, and allocated down to all reimbursable and non-reimbursable cost centers in proportion to each cost center's total cost.

Comment: With regard to the language in paragraph (d)(6)(ii), Medicare principles of reimbursement require that, when two entities are related, and one contracts from the other, reimbursement for these services is at cost due to the "related party principle." The commenter stated that the cost of a service is both direct and indirect; Medicare reimbursement has a longstanding methodology concerning nonrevenue producing costs and their allocation on a provider's cost report. A separate work paper should not be required. The appropriate methodology for stepping down administrative costs should be based on the cost of the entity utilizing the service. The cost of the free-standing entity must be placed on the main provider's cost report to step down cost appropriately. Additional work papers would allow room for error and would delay any necessary adjustments.
Response: The intent of $\S 413.24(\mathrm{~d})(6)(\mathrm{ii})$ was to require the main provider to report costs of related party entities that would not be reported through their accounting system on the main provider's books and records, for example, trial balance. Consequently, when there is a sharing of administrative services, for example, managerial staff, the related entity escapes any administrative overhead allocation when that same related entity is not reported on the main provider's trial balance of the cost report. While the commenter is correct regarding the proper reporting of related transactions at cost of the related entity, this regulation section goes further to require the main provider to develop the total cost of the related entity, utilizing and maintaining workpapers to justify the amount to be reported, and to report those costs by the main provider on the cost report trial balance.

## Section 413.65(a) Definitions (retitled in this final rule as Section 413.65(a) Scope and definitions)

Comment: Two commenters requested that a definition be provided for "a provider's campus." A definition would be important since the proposed regulation specifies additional requirements for off-campus locations.
Response: We agree that location on or off a hospital's campus is important. To provide a clear standard, we have
revised the final rule to define "campus" as "the physical area immediately adjacent to the provider's main buildings, other areas and structures that are not strictly contiguous to the main buildings but are located within 250 yards of the main buildings, and any other areas determined on an individual case basis, by our regional office, to be part of the provider's campus." This definition would encompass not only institutions that are located in self-contained, welldefined settings, but other locations, such as in central city areas, where there may be a group of buildings that function as a campus but are not strictly contiguous and may even be crossed by public streets. This would also allow the regional offices to determine, on a case-by-case basis, what comprises a hospital's campus. We believe allowing regional office discretion to make these determinations will allow us to take a flexible and realistic approach to the many physical configurations that hospitals and other providers can adopt.

Comment: The commenter expressed concern regarding the definition of provider-based facilities as many hospital-owned outpatient services are often provided with leased employees with ambulatory care experience. It is not clear that such an arrangement would satisfy the intent of the regulation.

Response: The regulations do not explicitly prohibit the use of leased employees, and each situation will be evaluated relative to the criteria in the regulations set forth below.

Comment: One commenter stated that the difference between "department of a provider" and "provider-based entity" is not clear from the definitions given of those terms. The commenter requested that we clarify in the regulations text whether a provider-based entity must be certified in its own right, and what type of certification this encompasses. The commenter also requested clarification in the regulations text concerning whether the term "provider" in the definition is intended to mean only entities that satisfy the Medicare definition of "provider" contained in §400.202.

Response: We have clarified §413.65(a) to state that a "department of a provider" is a facility or organization that could not by itself be qualified to participate in Medicare as a provider under $\S 489.2$, while a "provider-based entity" could be so qualified. For example, a skilled nursing facility (SNF) could be a "provider-based entity," whereas an entity that furnishes ambulatory surgical services could not be a provider-based entity, and could
participate in Medicare (for example, receive Medicare payment for services furnished to beneficiaries), only as a department of a provider, as a physician office, or as an ambulatory surgical center approved by Medicare under part 416, if at all. We have further revised the final rule to clarify that a department of a provider furnishes services of the same type as the main provider (for example, a department of a hospital furnishes hospital services), while a provider-based entity furnishes services of a different type from those of the main provider (for example, a hospital-based RHC furnishes RHC services, not hospital services).

Comment: A commenter believes the proposed rule should be revised for medically underserved populations and health manpower shortage areas to allow the referral of beneficiaries back to their community for treatment of community-based therapy providers. Therapy services provided under such a referral would be included under the provider-based designation.

Response: We do not oppose use of such referrals where they are medically appropriate, but believe that referral arrangements should not be equated to provider-based status.

Comment: A commenter questioned the requirement that services be furnished "under the name" of the main provider entity. The commenter argued that the requirement is inconsistent with the commenter's view that health care in the late 1990s is, and in many markets must be, "marketed" in a highly competitive environment. The commenter's view is that having provider-based status turn on the names used will inevitably invite micromanagement of the way the main provider's name is used by the department or other hospital-based entity.

Response: We disagree with any suggestion that health care is merely a generic commodity that can be repackaged under another name for marketing purposes. On the contrary, we believe that operating under the name of the main provider, and holding oneself forward to patients under that name, is an important indicator of status as an integral and subordinate part of that provider. Therefore, we did not make any changes in the regulation based on this comment.

Section 413.65(b) Responsibility for obtaining provider-based determinations

Comment: A commenter stated that the proposed rule does not state clearly enough whether our approval is required in order to permit billing each
time a provider sets up a new service, regardless of whether the service is acquired, managed, new, located on the main campus, or off the main campus. Some commenters stated that if approval is required in all instances, it will cause a significant paperwork backlog and will be quite costly to administer.
Response: Section 413.65(b) states explicitly that a determination by us that a facility or organization is provider-based is required before the main provider may treat the facility or organization as provider-based for billing or cost reporting purposes. We recognize that this may generate some administrative cost, but believe the cost will be much less than the amounts that would be spent improperly if payment were made to a free-standing facility as if it were provider-based.

Comment: A commenter urged that the new determination process be applied to all current as well as new hospital-based services.

Response: We have no plans at present to review all hospitals and other providers with respect to provider-based criteria, but will look into any situations that come to our attention in which it appears that a facility does not meet the requirements of the new regulations but is being treated as provider-based. If the facility or organization does not qualify as provider-based, action will be taken as described later in this preamble and in §413.65(i).

Comment: A commenter stated that there should be some mechanism in place for a long-term hospital (LTH) to seek an advance determination or advisory ruling that a proposed LTH satellite will be granted provider-based status. Because establishing an LTH requires a huge expenditure of time and human resources, an LTH main provider needs to know in advance whether or not its proposed satellite will receive a favorable provider-based determination. It is suggested that we institute a system by which advance rulings or determinations are available before the satellite is established.
Response: We understand the commenter's concern, but do not have the staff or facilities to provide advance approvals of restructuring proposals. We suggest that providers review the new criteria carefully and avoid forms of organization that are not clearly in compliance with them.

Comment: Two commenters suggested that we provide guidance on the application process providers must complete in order to receive a providerbased determination. In addition, time limits for approval of these determinations should be established.

Furthermore, existing provider-based entities should not be required to change their billing and accounting procedures. A commenter also asked for clarification as to whether the intermediary and regional office is to be the contact, and who will make the actual determination of provider-based status.
Response: We are developing an application process and intend to have it in place and ready for use before the effective date of the regulation. We expect that determinations of providerbased status will be made by our regional offices. Involvement by other entities, such as fiscal intermediaries or State survey agencies, will be for information-gathering purposes and under the direction of the regional office.

Comment: A commenter suggested that if a determination goes against the provider, the provider should be given the option to come into compliance with the requirements or file an appeal.

Response: As noted earlier, the regulations do not prohibit a provider that meets most but not all criteria from taking action to fully meet the criteria, thus qualifying a facility or organization for provider-based status. In the case of a provider that believes that the determination of the regional office is incorrect, an appeals process is provided under part 498.

Comment: A commenter stated that the requirement in paragraph (b)(3) establishes an adverse presumption against provider status for "off-campus" physician practice sites, and that the focus on "campus" boundaries will prove elusive, and serve no real policy purpose.

Response: As explained later, we believe location in the immediate vicinity is an important indicator of provider-based status, and that location can be a good basis for identifying facilities for further scrutiny.

## Section 413.65(c) Reporting

Comment: Several commenters pointed out that the regulatory language does not reflect the preamble language regarding off-campus entities and the five percent increase in a provider's costs.

Response: We have revised the final rule to correct this oversight.

Comment: One commenter asked whether this language applies only to entities that are applying for providerbased status, or also applies to entities that have already achieved providerbased status.

Response: The requirement applies to both types of providers, but providers that have entities with provider-based
status are required to report only newly created or acquired facilities or organizations.

Comment: Two commenters stated that the five percent and off-campus criteria with regard to provider-based status do not take into account the characteristics of rural and frontier areas, and could lead to lower payments to some facilities, thus reducing the flow of Federal money into rural areas and possibly creating a shortage of care. In addition, considering the small budget of RHCs and other rural facilities, 5 percent is an inappropriately low and unreasonable growth limit.

Response: We understand the commenter's concern but do not agree that a 5 percent threshold for reporting is too low. Therefore, we made no change based on this comment.

Comment: A commenter asked whether this reporting requirement also applies to all newly developed services (that is, department on the campus of the hospital).

Response: The requirement applies to all newly developed on-campus services that could increase the costs of the provider by 5 percent or more.

Comment: A commenter requested clarification that a main provider that "creates" as well as "acquires" a facility or organization is responsible for reporting to us. The commenter also suggested specific items to be included in the reporting and approval process. These include specific data elements to be reported by the main provider, specifying our component with primary responsibility; specifying our approval process; adding a preliminary conditional approval process; adding a specific time period for our approval; and adding requirements for the effective date that the costs of the provider-based entity can be included on the main provider's cost report.

Response: We have revised the regulation to clarify that it applies to facilities or organizations created by the main provider, as well as those ongoing operations acquired by purchase or other means. We have not included the procedural detail requested by the commenter in regulations, but will consider including it in program instructions.

Comment: A commenter stated that the use of the phrase "any material change" in paragraph (c)(2) of this section is too vague and open to interpretation. It is suggested that the section be revised to clearly designate changes of ownership and new management agreements as the only two material changes that require reporting by provider-based entities.

Response: We do not agree that the range of reportable events should be limited in this way. On the contrary, we intend to require reporting of any change that could have a significant ("material") effect on compliance with the provider-based criteria.

Comment: A commenter asked if the reporting requirements are coordinated with the notification of change of ownership requirements at $\S 489.18$ (b), where notice is to be given in advance, and whether there should be a cross reference or clarification with respect to the change in ownership regulation and this proposed regulation.

Response: We believe this suggestion has merit, and will consider revising our program instructions to specify that a report under §489.18(b) should be reviewed for its applicability to provider-based determinations.

## Section 413.65(d) Requirements

Comment: A commenter suggested that we clarify whether all requirements, or only a majority of the requirements, must be met to obtain provider-based status.
Response: We have revised the first sentence of paragraph (d) to state that all of the stated requirements must be met by a facility or organization that wishes to be classified as provider-based.

## Section 413.65(d)(1) Licensure

Comment: Many commenters objected to the requirement that provider-based facilities share a common license with the main provider unless the State requires separate licensure for the subordinate facility. One commenter listed several reasons for this concern. First, in the commenter's opinion, licensure determinations may be made based on factors that are different from those that would be important for provider-based determinations. Another reason cited by the commenter is that State licensure laws may vary from State to State. Some State hospital licensure definitions are building specific, and do not include off-site outpatient facilities, thus giving what the commenter argues is undue weight to physical location in evaluating provider-based status. Finally, the commenter believes that requiring common licensure will create a situation where some States may have a large number of provider-based entities and others will have few or none, thus leading to inconsistent application of our rules. One commenter recommended that the same licensure requirement be waived for States with idiosyncratic licensure requirements. An alternative would be accreditation with the provider as a deemed status for meeting a common license requirement.

The commenter suggested that the proposed language could be reworded to clarify that offsite clinics would not have to be licensed or operated under the same license as the provider in those States that do not license them.

Response: We recognize that licensure may not be an appropriate indicator of provider-based status in all States, and have therefore revised the regulations to require common licensure only in States with laws that permit common licensure of the provider and the prospective provider-based department under a single license. This means that in States that do not allow licensure of certain types of facilities, such as those providing ambulatory care or those located off the provider's main campus, the licensure criterion would not be applied. We do not agree that JCAHO or other accreditation should be accepted in lieu of licensure, since such accreditation may not necessarily reflect an on-site evaluation of the prospective provider-based department. In recognition of the fact that some hospitals are not licensed by the State because they are Indian Health Service (Federal) hospitals or are located on Tribal lands, we also will not apply the licensure requirement to departments of those hospitals.

Comment: Under paragraph (d)(1) as proposed, clinics in another State from the main provider could not be under the hospital's license. Several commenters argued that this requirement would arbitrarily affect rural and urban health care delivery, where the main provider is close to a State line. A commenter recommended that close proximity be used instead, where a hospital-based clinic is in another State from the main provider. For urban hospitals in large metropolitan statistical areas that cross State boundaries, the commenter believes that the market area of the main provider should be the primary determinant of the potential for integration with the main provider.

Response: Under the regulations as revised based on the comments summarized above, common licensure would not be required of facilities located across State lines if the law of the State in which the main provider is located does not allow such licensing. However, see the discussion, later in this preamble, of § 413.65(d)(7)(ii).

Comment: A commenter pointed out that the proposed rule appears to limit the licensure requirement to "departments" of the main provider. The commenter asked whether this requirement only applied to "providerbased entities." The commenter also suggested that where a State has two
licensure schemes for the same type of facility, we should not prefer one licensure scheme over the other for purposes of determining the providerbased status of the facility.
Response: The commenter is correct in noting that the common licensure requirement in the proposed rule would have applied only to provider-based departments. We did not propose to apply a common licensure requirement to provider-based entities such as SNFs and HHAs, because they are providers of services in their own right, and typically would be separately licensed without regard to their affiliation with the provider. We disagree with the commenter's view that licensure should not be viewed as an indicator of integration. On the contrary, our view is that if a facility could be licensed as part of a main provider but chooses not to be, the facility cannot reasonably be seen as an integral and subordinate part of that provider.
Comment: With regard to the proposed requirement that states that our determination regarding providerbased status will be based on a State health facilities' review commission, one commenter argued that relying on the commission's criteria for purposes of making provider-based determinations is arbitrary and inappropriate. The commenter believes imposing this criterion could disadvantage providers and discourage expansion to off-site locations, thus indirectly leading to shortages of care. Another commenter requested that there be a delay in implementation during which time changes can be made to the commission's definition of what rates it can regulate.

Response: We continue to believe it would be inappropriate for a facility to claim to be separate from the provider for State rate-setting purposes while also claiming to be an integral and subordinate part of the provider for Medicare purposes. To allow this practice would authorize providers to misrepresent their structures and affiliations in whatever way will yield the highest payment. Thus, we did not make changes to reflect the comment.

Section 413.65(d)(2) Operation under the ownership and control of the main provider

Comment: Regarding §413.65(d)(2), the commenter suggested that the regulations provide a separate set of criteria that would allow a provider that is operated within one legal entity to be provider-based to a provider that is operated within another legal entity, as long as the two entities are under common control. Another commenter
stated that this ownership and control requirement is unnecessarily rigid, since a hospital-based clinic, which was strictly an administrative division of the hospital, might qualify while another similar clinic, wholly owned by the hospital with slightly different
governing bodies and documents, would not be eligible.

Response: We do not agree that common control of two separate entities by the same parent organization should be sufficient to meet a requirement for ownership and control by the main provider. While this arrangement may be an appropriate way to manage two separate entities, it does not establish provider-based status for either. With respect to the second comment, we agree that the form of administration of an entity can determine whether or not the entity is found to be provider-based. We believe this would be an appropriate result, since it would help ensure that only facilities that are organized as provider-based entities or departments of a provider are given this status.

Comment: One commenter believes it is unrealistic to require a potential provider-based facility or organization to be owned by the main provider and share bylaws and an identical governing body. The commenter stated that in the present business climate an entity can operate as a provider-based entity without meeting these criteria. It is recommended that we replace the proposed 100 percent ownership standard with a majority standard, require only overlapping governing bodies, and eliminate the requirement for organization under the same organizational documents. Another commenter believes that the key consideration should be whether the provider is in control of the day-to-day operations of that portion of the facility in which the provider seeks providerbased status, and not necessarily whether the building is 100 percent owned by the provider. The commenter believes we should rephrase this provision to require that the operations of that portion of the facility or organization in which the provider is seeking provider-based status be controlled by the provider.

Response: In response to the first comment, we recognize that many organizations enter into business relationships that involve overlapping of ownership, governance, and applicability of bylaws. However, this degree of collaboration does not mean that one facility is an integral and subordinate part of another. Therefore, we made no change based on this comment. Regarding the second comment, we wish to clarify that it is
ownership of the business enterprise, not of the buildings or other physical assets of the enterprise, that is required under paragraph (b)(1). We have therefore revised the regulation text to refer to ownership of the business enterprise.

Comment: A commenter stated that the requirements contained in paragraph (d)(2) would preclude entities that are jointly owned through legitimate joint ventures or those separately organized subordinate facilities from qualifying for providerbased status. Additionally, to require the level of integration suggested by our proposed rule would prevent providers from establishing efficient systems of delegation and management, solely to qualify for provider-based status.

Response: We agree that this criterion would have the stated effect. As explained further in our discussion of comments on proposed $\S 413.65(\mathrm{e})$, facilities operated jointly by two or more providers cannot appropriately be considered integral and subordinate parts of either provider. With respect to the second comment, we do not oppose systems of operation that stress separate, decentralized operation where this leads to greater efficiency. However, we believe such facilities or organizations should be recognized as the separate enterprises that they are, not considered integral and subordinate parts of another institution.

Comment: A commenter suggested that the requirement under paragraph (d)(2) be modified for medically underserved populations and health manpower shortage areas.

Response: We are also concerned that our criteria not limit access to care for any vulnerable populations and have, to avoid this potential problem, created special provisions for FQHCs and IHS and tribal facilities. As described later in this preamble, we have also created an exception to the location
requirements in paragraph (d)(7), which is designed to help avoid restricting access to primary care furnished by RHCs in remote, underserved areas. In view of these provisions, we do not believe it is necessary to also modify our requirement relating to ownership of the facility or organization.

Comment: A commenter stated that the proposed requirements in paragraph (d)(2) are inherently inconsistent with section 330 of the Public Health Service Act statutory and regulatory requirements and the Bureau of Primary Health Care expectations necessary to obtain and maintain section 330 funding (and FQHC status). The commenter believes HCFA should not require FQHCs to be 100 percent owned by the
main provider or share a common governing body and common bylaws with the main provider. The commenter also suggested that we accept appropriate reporting relationships and satisfaction of other criteria (for example, licensure, quality assurance, integration of certain administrative and clinical functions, such as billing, purchasing, retention of medical records, quality assurance and utilization review procedures; and public awareness of the relationship between the health center and the main provider) as a sufficient basis for provider-based status.

Response: As described earlier, we have provided a special transition period for FQHCs. We believe this period will be adequate to avoid the problems envisioned in this comment.
Section 413.65(d)(3) Administration and supervision

Comment: A commenter recommended that the daily reporting relationship stated in $\S 413.65(\mathrm{~d})(3)$ should be replaced with the standard of having the reporting relationships have the same intensity as on-site departments. The commenter stated that in practice at the hospital, there may be very little day-to-day contact between medical directors of various hospital services. Also, the commenter believes it is unlikely that departmental directors report directly to the chief executive officer, but rather to a chief operating officer or other designee. Finally, the commenter argued that under the common governance requirement, while all hospital employees are theoretically accountable to the governing body, the accountability may be directed through the CEO, and multiple executives may not have an independent reporting with the board. Another commenter also believes that the standards for the provider-based entity should mirror those of the main facility; personnel reporting structure needs to be respected within the regulations. Still another commenter found "intensity" to be a subjective standard and asked how it will be measured.

Response: We agree that reporting need not be daily in all cases, and have revised the final rule to state that the reporting relationship between the facility or organization seeking provider-based status and the main provider must have the same frequency, intensity, and level of accountability that exists in the relationship between the main provider and one of its departments. We agree with the commenter that the intensity of supervision will have to be assessed on a case-by-case basis, but do not believe
this will lead to imprecise or poorly reasoned decisions.

Comment: Several commenters believe that this requirement limits the flexibility of the entity to operate efficiently and effectively in the current environment, since hospitals frequently turn to many specialized management companies to operate more efficiently and effectively than with hospital resources. Another commenter stated that whether the administrative department utilizes employees at one location and contracts at another location should be irrelevant as long as the function is integrated with the main provider, follows the policies and procedures of the main provider, and is accountable to the governing body of the main provider as is any other department. Still another disagreed, and believes that it may be appropriate to require that the main provider manage such contracts.
Response: We do not agree that the provision unreasonably limits hospital flexibility. Paragraph (3)(iii)(B) explicitly allows different management contracts to be used for the facility or organization and the main provider, as long as the provider manages the contracts. Thus, we did not make any changes in the proposal based on these comments.

Comment: A commenter asked whether the administrative functions listed in paragraph (d)(3)(iii) are the only services that must be integrated between the main provider and the subordinate facility.

Response: The commenter was correct in understanding that the functions listed are the only administrative functions that must be integrated. There are also requirements for integration of certain financial functions, as described below.

Comment: One commenter posed several questions concerning this proposed requirement. First, in a certain situation, the facility fee is billed to the intermediary by the hospital billing department using the provider number, while the professional fee is billed to the Part B carrier by the faculty practice billing organization under its physician group number. The commenter asked if the different provider number and tax identification impact on the providerbased status, and if there is a more appropriate way to obtain billing numbers for hospital-based clinics. Also, the commenter asked if clinic space can be shared by two clinics, when one is provider-based and one is free-standing, without impacting the provider-based status of the first clinic.

Response: In the circumstances described, the use of separate billing
and tax identification numbers for provider and physician services would not adversely affect a facility's request for provider-based status, since such billings are required under Medicare to be separate in the case of services in hospitals. The question regarding sharing of space, however, can be answered only in the context of a specific case, and we expect that such decisions will be made by our regional offices.

Comment: With respect to the oversight of contracts under paragraph (3)(B)(iii)(B), several commenters stated that it is common for hospitals to subcontract out the billing for different departments, especially the hospital outpatient department, due to the complexity and number of claims. These commenters stated that while it may be appropriate to require the main provider to manage such contracts, departments other than the billing department should be permitted to perform this management function. One commenter suggested revising the criterion on billing under the integration of administrative functions to state, "common billing or the contract for billing services is held by the provider where it is based."

Response: We agree that departments other than the main provider's billing department may appropriately manage billing contracts, and have revised the criterion to state that the contract for a provider-based facility or organization must be managed by the main provider.

## Section 413.65(d)(4) Clinical services

Comment: A commenter asked for clarification of paragraph (4)(iv) of this section, specifically concerning whether this language would require a Medicare certified HHA's improvement activities to be overseen by hospital medical staff, rather than the advisory committee as is now being done. The commenter believes that having the hospital medical staff overseeing the quality assurance activities of a HHA may not be appropriate or cost effective and may even slow the process of performance changes.

Response: The commenter is correct in understanding that compliance with this criterion would require oversight of a hospital-based HHA's quality improvement activities by the hospital's medical staff. We do not agree with the commenter that the outcome would be to substitute the judgment of the hospital for the HHA's own committee or that it would be inappropriate. The hospital conditions of participation contain a number of separate requirements that must be read together to make complete sense of this
provision. Conditions spelled out at § 482.12 (Governing body), § 482.21 (Quality assurance), and §482.22 (Medical staff) establish a chain of accountability in a hospital for the quality of care it provides. The requirements are clearly applicable to any activity (for example, providerbased entity) that is an integral part of the hospital. Thus, a quality improvement activity of the HHA is likely to be firmly grounded in the hospital's operating and governance fabric even when the group is "established" by the HHA, and staffed by employees and physicians who work primarily in home health. We would expect the linkages to be formal (that is, known to the governing bodies and medical staffs of both providers), and the quality assurance mechanisms interrelated to the extent that shared patients are the subject of the effort.

Comment: Regarding paragraph (d)(4)(v) of this provision, some commenters requested clarification of what is meant by a "unified retrieval system," or for guidance as to what types of cross referencing are acceptable. Another commenter asked for an explanation of the practical expectations regarding the maintenance of medical records. Finally, a commenter expressed support for the requirement for a unified retrieval system (or cross references), saying the latter system would be used in States that mandate a unified system.

Response: We would like to clarify that what is intended is that a system be maintained under which both the potential provider-based entity or department of a provider and the main provider have access to the beneficiary's record, so that practitioners in either location can obtain relevant medical information about care in the other setting. We did not, however, make any changes in the requirement based on these comments.

Comment: A commenter believes that functions of operations should not be regulated to dissuade cost efficiency, and that laundry and housekeeping would be examples where shared services may not be the most effective manner of operation.

Response: We agree that in some cases it may be less expensive for a facility to obtain services independently, but continue to believe such separateness is an indicator that the facility is not an integral and subordinate part of a provider.
Comment: With regard to paragraph (d)(4)(vi) requiring integration of services of the main and provider-based entity, the commenter expressed concern about the potential impact of
this section on a patient's freedom of choice. The commenter believes that the entity's efforts to meet this standard would limit a patient's freedom of choice. The commenter suggested that we clarify our position so that providers acting in good faith will not be sanctioned for attempting to comply with this requirement.

Response: Paragraph (d)(4)(vi) requires only that patients have access to the services of the main provider and that they be referred to it where the referral is appropriate. We wish to clarify that these criteria are not intended to restrict patient freedom of choice or the practitioner's freedom to refer patients to other locations, where doing so will result in better care for the patient.

## Section 413.65(d)(5) Financial integration

Comment: A commenter believes that §413.65(d)(5), which requires full integration of financial operations, is too rigid. An alternative approach is suggested that would allow managers of provider-based entities to retain some control over both the resources and information required to administer these units.
Response: Section 413.65(d)(5) requires that there be financial integration of the potential providerbased facility or organization and the main provider, but does not preclude normal management control of resources. Thus, we made no change in the regulation based on this comment.

Comment: A commenter stated that the criteria for common resource usage of building, equipment, and service personnel is not even relevant for multicampus systems or even buildings that are across the street from each other, much less off-site hospital outpatient departments.
Response: Although the providerbased program memoranda required that there be significant common resource usage of buildings, equipment, and service personnel on a daily basis, this requirement does not appear in the proposed rule. Thus, we made no change in the regulation based on this comment.

Comment: One commenter stated that the requirement for financial integration seems unnecessary in light of the requirement for 100 percent ownership by the main provider. The commenter stated that some providers may wish to segregate the operations of certain departments in their financial systems, and expressed the view that as long as the costs of a department can be adequately identified on the cost report, the practice should be acceptable.

Response: We do not believe that these two requirements are duplicative. On the contrary, in some cases a provider may own 100 percent of another facility or organization, but not be financially integrated with it, either because the other facility or organization is engaged in a different, non-health care activity, or because it is organized and operated separately from the main provider. In these circumstances, we believe the criteria on financial integration apply appropriately to deny provider-based status to separate facilities or organizations.
Section 413.65(d)(6) Public awareness
Comment: Section 413.65(d)(6) requires that provider-based entities be identified as part of the main provider organization. The commenter did not understand the importance of this criterion, particularly when the provider-based organization is licensed and Medicare certified separately from the main provider.

Response: The proposed rule would not apply this criterion to providerbased entities (which may participate separately as providers), but only to provider-based departments. In the latter case, we think it is not unreasonable for such a department to be expected to identify itself with the provider of which it claims to be a part.

## Section 413.65(d)(7) Location in immediate vicinity

Comment: A commenter stated that if off-site RHCs cannot be considered provider-based, it will be much harder to deliver care in rural areas. The commenter asked that RHCs be allowed to continue as provider-based RHCs even though they are off campus.

Response: We continue to believe close physical proximity is an important indicator of provider-based status. We note, however, that paragraph (d)(7) does allow off-campus facilities to be treated as provider-based if they meet the criterion relating to service to the same patient population.

Comment: Many commenters believe that more specific tests of service to the same patient population are needed. One commenter suggested that an appropriate criterion would be that the proposed provider-based facility or organization be located within the same geographic area that accounts for a high percentage of patients in the main provider. The commenter believes this test is consistent with Program Memorandum No. 96-7 and with the qualification requirements for sole community hospitals. Other commenters suggested that the main
provider's geographical service area be considered the area from which the main provider drew 80 percent of its Medicare inpatients for the previous three years.

Response: We agree that more precise criteria are needed. Therefore, we have revised the regulations to provide that a prospective provider-based facility or organization will be considered to serve the same patient population as the main provider if, during the 12 -month period immediately preceding the first day of the month in which the application for provider-based status is filed with us, at least 75 percent of the patients served by the facility or organization seeking provider-based status reside in the same zip code areas as at least 75 percent of the patients served by the main provider. As an alternative, we would consider a facility or organization to serve the same patient population if, during the same 12 -month period described above, at least 75 percent of the patients served by the prospective provider-based facility or organization who required the type of care furnished by the main provider received that care from the main provider. We require this "same patient population" test to be met for the 12 -month period used to support an initial determination of providerbased status, and it must continue to be met for each subsequent 12 -month period to justify a continuation of provider-based status. Application of population/geographic standards to newly established facilities or organizations is discussed below.
Comment: Commenters suggested we show some flexibility with regard to the definition of patient population for teaching hospitals. The commenter stated that it will not always be the case that the patient populations for the teaching program will be the same as the overall mix or patient population for the main provider.

Response: We recognize that patient populations will not be identical in all cases, and thus have adopted a patient population criterion under which there may be a divergence of up to 25 percent between the main provider and the facility or organization seeking provider-based status. We believe this provides a reasonable allowance for differences in patient population. Moreover, we note that under section 1886 of the Act, Medicare provides much flexibility for teaching hospitals in other ways, for example, under section 1886(h)(4)(E), permitting the counting of residents for purposes of payment to teaching hospitals for the time the residents spend in nonhospital settings.

Comment: Two commenters suggested that the criterion on service to the same patient population be dropped. One commenter believes the criterion is overly vague, could limit access to care as facilities seek to control their service patterns, and, in general, represents a geographically based approach that is out of keeping with modern technology and communications. Another commenter stated that the criterion is unclear, and providers could find it burdensome to assemble the data to show compliance. Other commenters shared the second commenter's concern, but instead of recommending elimination of the criterion, they suggested that a more administrable solution would be to use regional or state standards to define "same geographic area," such as, health systems area, a specified mileage amount, or our wage area.
Response: As described above, we have developed a more precisely stated test of service to the same patient population. We believe that test will be clear and understandable, not impose unrealistic burdens on providers, and allow provider-based designations that parallel service patterns.

Comment: With respect to paragraph (d)(7)(i), a commenter asserted that many currently operating facilities that are treated as provider-based by us provide types of service that are the same as those of the main provider, but serve patient populations from different geographic areas. The commenter believes these entities provide care under the direction of, and utilize substantial services from, the main provider. An example would be the geographically separate campuses of a single parent hospital that are located at various sites throughout a region. The commenter suggested that such campuses be presumed to be providerbased if they provide substantially the same services as the main provider, do not exceed the size of the main provider, and comply with all other provider-based requirements. Another commenter stated that the "same patient population" requirement should not apply to multi-campus long term care hospital locations. These locations are fundamentally different from other provider-based entities that the regulation addresses, since a long-term care hospital main provider and its remote campus furnish the same services, and offer the same programs of care, but operate in slightly different geographic areas. The commenter suggested that so long as all of the strict financial and administrative integration requirements of the proposed providerbased regulation are satisfied, the "same
patient population" requirements should not apply to long-term care hospitals. The result of this criterion would be that satellites will not be established in many underserved areas where long term services are needed. Another commenter believes a specialty facility, such as a long-term care hospital, should be exempt from the geographic proximity requirement if it can demonstrate that it will improve the quality of patient care, and offer services that are not otherwise provided in that area.

Response: We recognize that there may be some cases in which a hospital and another facility seeking providerbased status as a remote location of that hospital may meet most or all other criteria in §413.65, yet not qualify because the two facilities serve different patient populations. However, we do not agree that this result should lead us to abandon the "same patient population" test. On the contrary, we continue to believe that criterion is a valid indicator of provider-based status. Thus, we did not revise the regulation based on this comment. In this context, we note that there is no Medicare rule that would prohibit a hospital from setting up another hospital in another area. We do not agree with the commenter's assumption that because the program memorandum and proposed rule were issued in response to situations primarily involving outpatient facilities, they can apply only to such facilities. On the contrary, we believe the policies set forth in these documents are equally applicable to inpatient facilities, and should be applied in the many cases in which a determination about inpatient facilities must be made. In particular, the rules apply to remote locations of long-term care and other hospitals that are main providers, as well as to satellite facilities of hospitals and hospital units that are excluded from the hospital inpatient prospective payment system. Remote locations and satellite facilities are discussed more fully earlier in this preamble, and "satellite facilities" are specifically described in our regulations in $\S \S 412.22(\mathrm{~h})$ and $412.25(\mathrm{e})$. (As explained in that document, we are concerned that establishment of satellites by hospitals and units excluded from the inpatient PPS could lead to payment abuses, such as circumvention of certain payment caps mandated by section 4414 of the Balanced Budget Act of 1997, and we have therefore established special payment rules for those facilities. Facilities seeking to qualify as "satellites" under the inpatient payment
criteria in $\S \S 412.22(\mathrm{~h})$ and $412.25(\mathrm{e})$ would first need to comply with the provider-based requirements before being eligible for satellite status.) We have revised the final rule to clarify its application to remote locations of hospitals and satellite facilities.

Comment: The commenter believes that flexibility in the definition of "located in the immediate vicinity" needs to be met with additional considerations when viewing rural and underserved areas; for example, it should not be our intention to eliminate the provider-based designation of a rural health clinic (RHC), when the purpose of the RHC is to be an outreach to geographically isolated areas.

Response: We share the commenter's concern and have developed a special provision for RHCs, as described below.

Comment: A commenter believes that the requirement that provider-based entities serve the same population as the main provider could cause significant problems for RHCs. The unique situations addressed by hospital-based RHCs attempting to satisfy the health care needs of medically underserved areas should be considered as exceptions to the proposed rule.
Response: We continue to believe close physical proximity is an important indicator of provider-based status; however, we recognize that small rural hospitals and their RHCs may not be able to demonstrate that a substantial number of clinic patients receive services from the main provider. Small rural hospitals typically provide limited inpatient care compared to their urban counterparts, which may cause the RHC patients to seek inpatient service from other providers. In light of this, we believe small rural hospitals (less than 50 beds) that own and operate RHCs should not be expected to demonstrate that they serve the same patient population as the main provider. Therefore, we are revising the regulation to allow off-campus RHCs affiliated with small rural hospitals (less than 50 beds) to retain their provider-based status without satisfying that requirement.
Comment: Several commenters opposed the inclusion of paragraph (d)(7)(ii), since they view a State border as an arbitrary boundary inhibiting a hospital's ability to serve patients, which seems counterproductive. They also argued that a regulation that fails to recognize the operation of health care systems that function across State lines is unrealistic. Another commenter suggested that we rely on the proposal concerning serving the same patient population. It was also stated that in one case a provider can be located in a city
split by the State border with its related facility located one mile away, but in another state, while in another case, the provider and its subordinate facility can be a mile apart and in the same State. Another commenter believes that, since Medicare beneficiaries often cross borders for health care services, disallowing hospitals in these areas from establishing provider-based entities eliminates choices and prohibits the development of new services. The commenter recommended that we revise or eliminate this criterion. Another commenter suggested that LTHs and their satellites not be subject to this requirement if the main provider and its satellite are located in two contiguous States. Alternatively, the commenter suggested that we consider using the wage index areas as guidelines for the areas to be served by provider-based entities even if that area crosses State lines.
Response: After reviewing these comments, we have decided to revise the regulations to allow providers in one State to have provider-based facilities in an adjacent State, if doing so is not inconsistent with the law of either State, and other criteria are met, including those related to service to the same patient population.

Comment: With regard to paragraph (d)(7)(i), while the proposed rule permits a provider to show that a "high percentage" of patients of the main provider and the facility come from the same geographic region, new facilities would not have any historical data upon which to base this assertion, and therefore would fail to be able to demonstrate the criteria prior to operation. Another commenter believes the requirement may pose an impediment to new facilities being located in underserved or outlying areas. Thus, the commenters believe the same patient population requirement should not apply to new facilities, including new long-term care hospital satellites.
Response: We agree that it would be appropriate to establish a criterion that could be met by new facilities or organizations, and therefore have revised the final rule to include a special provision for new facilities or organizations. Under this revision, a new facility or organization, (one that has not been in operation for all of the 12 -month period immediately preceding the first day of the month in which the application for provider-based status is filed with us), may be considered to meet the criterion on service to the same patient population, if it is located in a zip code area included among those that (during the 12-month period described
above) accounted for at least 75 percent of the patients served by the main provider. We note that this provision would not be limited to long-term care hospitals' satellites or their remote locations, but would be available to all new facilities or organizations.
Section 413.65(e) Provider-based status not applicable to joint ventures

Comment: Several commenters expressed concern that this criterion would prohibit the use of joint ventures for entities that want to participate as provider-based entities, and argued that such a prohibition would unnecessarily restrict hospital flexibility. One believes this provision should be eliminated. Another commenter suggested modification of paragraph (d)(2) of the rule to establish majority ownership as the standard rather than 100 percent ownership. Still other commenters suggested that provider-based status for facilities or organizations run as joint ventures should be permitted, as long as the hospital at which the facility is located has the equipment or service under its control.

Response: We reviewed these comments carefully, but did not make any changes in the regulations based on them. When a facility or organization is run as a joint venture of two or more providers, it is by definition under their joint control, and therefore cannot be an integral and subordinate part of any individual provider. We have no interest in discouraging such ventures, but continue to believe they do not qualify as provider-based.

## Section 413.65(f) Management contracts

Comment: Several commenters expressed the view that the criterion under which the staff of the facility or organization must be employed by the provider or another organization other than a management company is too restrictive, and should be deleted. One commenter argued that, if the written contract maintains the responsibility and control for services in the hands of the main provider, the employer of the staff working at the site is not relevant Another believes the criterion will discourage economic efficiencies. If a provider is able to demonstrate integration and subordination of the offsite facility based upon other providerbased criteria, the fact that a hospital chooses to provide certain services either directly through its own employees or indirectly through an independent contractor/management arrangements is irrelevant. Another commenter argued that the proposed criterion is inconsistent with: the
provision of the Medicare statute that expressly permits coverage of "services under arrangement"; with the hospital conditions of participation that recognize that contractors may be used to furnish patient care services; and with the Provider Reimbursement Manual, which recognizes that providers commonly contract for management services and the costs of the contract services may be allowed under Medicare principles of reimbursement. Still another commenter believes the proposed criterion would negatively impact the therapy profession, and could impact the health and safety of Medicare beneficiaries.
Response: We do not believe the criterion is overly restrictive, nor do we agree that employment of the staff of a facility or organization is irrelevant to the question of whether that facility or organization is an integral and subordinate part of a provider. On the contrary, employment of the staff of such a facility or organization will normally give the provider significant control over it, thus promoting integration. Conversely, if a facility or organization is staffed by personnel who are employed by another entity that has only a contractual relationship with the provider, the facility or organization may well be an integral and subordinate part of the management company, not of the provider.
We also do not agree that the criterion is inconsistent with section 1861(w)(1) of the Act, which permits providers to make arrangements for the provision of specific health services, nor do we believe adopting this criterion will undercut the ability of providers to have selective services provided under arrangements. In this regard, we point out that existing Medicare policy, stated in section 207 of the Medicare Hospital Manual (HCFA Publication 10), emphasizes the need for the hospital to exercise professional responsibility for the arranged-for services, not merely to serve as a billing mechanism for the other party. This is consistent with our view that section 1861(w)(1) was intended to allow specific health care services to be furnished under arrangements, but was never meant to be a vehicle by which a provider could nominally operate a facility or organization, but, in fact, contract out its operation to another entity. Finally, we note that while there are various sections of the hospital conditions of participation and the Provider Reimbursement Manual that recognize the possibility that specialized health care services or management services may be provided under contract, this does not indicate that providers may
contract out entire departments or services while claiming them as provider-based. To clarify the scope of the requirement on contracted services, we have revised it to state that management staff of the facility or organization (rather than health care or support staff) need not be employed directly by the provider. We have also revised the rule to clarify that if staff of the facility or organization (other than management staff) are employed by an organization other than the management company or the provider, it must be the same organization that also employs the staff of the main provider.
Section 413.65(g) Obligations of hospital outpatient departments and hospital-based entities

## Section 413.65(g)(1)

Because of the direct relationship between the proposed changes in this section and those in $\S 489.24$ (b), comments on both proposals are discussed later, under $\S 489.24$ (b), "Special responsibilities of Medicare hospitals in emergency cases."

Comment: A commenter requested clarification as to the application of the anti-dumping requirement in the home health setting.
Response: Section 413.65(g)(1) states that the EMTALA requirements apply to hospital outpatient departments. EMTALA requirements would not apply to off-campus provider-based entities that are not hospital departments, such as home health agencies.

## Section 413.65(g)(2)

Comment: While one commenter agreed with the requirement under $\S 413.65(\mathrm{~g})(2)$ for billing of physician services with the appropriate site-ofservice indicator, another commenter also believes there should be clarification that correct billing is the responsibility of the entity performing the billing function. Both commenters suggested that the hospital notify physicians who do their own billing that they must use the correct indicator; they agree that it should not be the responsibility of the hospital.
Response: We agree that physicians (or those to whom they assign their billing privileges) are responsible for appropriate billing, but note that physicians who practice in hospitals, including off-site hospital departments, do so under privileges granted by the hospital. Thus, we believe the hospital has a role in ensuring proper billing.

## Section 413.65(g)(5)

Comment: Presently, provider-based clinics bill Medicare for the facility
charge on a UB-92 form, and the physician fee is billed separately on a HCFA-1500 form, while other payers may accept a single bill for both charges. A commenter believes it is inappropriate to mandate that two bills be submitted for all patients, as long as charges for similar services are uniform regardless of payer.

Response: As explained further below, we have revised the final rule to eliminate the part of this criterion relating to billing of services to nonMedicare patients. We believe this responds to this commenter's concern.

Comment: Many commenters stated that Medicare should treat a facility that claims a facility fee as being providerbased even when other payers do not do so, reasoning that as long as the hospital claims that the patient is an outpatient for Medicare purposes, the practices of other payers, with respect to similar patients, are not significant, and should be ignored. Another commenter believes this requirement should be eliminated, because, in the commenter's view, it has no bearing on the outpatient services delivered to Medicare beneficiaries, and therefore does not affect Medicare reimbursement. To illustrate, a large commercial insurer does not have the capability to accept certain types of outpatient claims from hospitals; therefore, it requires claims for those services to be billed on a physician claim form, so hospitals will receive the proper reimbursement. If this criteria is retained as proposed, many hospitalbased departments would not meet our criteria due to the nuances of other payers' policies, that are often contractual issues with providers. Still another commenter believes that we should reexamine the proposal made in paragraph (g)(5), and at a minimum, clarify what it means by its proposal mandating uniform "treatment of all patients, for billing purposes, as hospital outpatients." If we are proposing to mandate that all outpatients be billed on the same basis, this would effectively extend Medicare direct billing or rebundling rules to all payers. In addition, this proposed requirement would not only be contrary to past policy and practice, but would affect departments that have
differentiated billing practices. Another commenter stated that payers typically determine payments based upon how they define a particular service or their individual market power; Medicare certification of outpatient departments should not be influenced by how unrelated third parties pay for services to the patients they cover at these sites. Moreover, this criterion would be very difficult to implement, because
hospitals can have hundreds of contracts with insurance companies and the providers that subcontract for part of the risk for plans.
Response: After review of the comments on this section, we have decided to revise it to restrict the requirement for uniform billing to Medicare patients only, thus allowing hospitals to bill other payers in whatever manner is appropriate under those payers' rules. As revised, $\S 413.65(\mathrm{~g})(6)$ states that hospital outpatient departments (other than RHCs) must treat all Medicare patients, for billing purposes, as hospital outpatients. The department must not treat some Medicare patients as hospital outpatients and others as physician office patients.

Comment: A commenter stated that there appears to be some confusion as to whether this requirement applies to "departments" or all facilities and organizations seeking provider-based status. Also, the commenter asked if there is a provision of the proposed rule that mandates that a facility fee be charged to patients of facilities and organizations receiving provider-based status.
Response: As noted earlier, the proposed rule would not apply this criterion to provider-based entities (which may participate separately as providers) but only to provider-based departments. Regarding the second issue, we have, as described in response to the preceding comment, revised the final rule to eliminate the criterion regarding billing of payers other than Medicare.

## Section 413.65(g)(7)

Comment: A commenter stated that requiring written notice for each patient (presumably signed by the patient), would be an overly burdensome requirement, and requested that the requirement allow for a clear, prominently displayed sign in lieu of individual notice. Another commenter believes that the proposed requirement would apply a standard to hospital outpatient departments that is not applied to any other site of service.

Response: First, we emphasize that notice is required only for Medicare beneficiaries, not for all patients. We recognize that providing notice will generate some burden for the provider, but believe that the protection it affords to patients warrants the requirement. We considered allowing the notice requirement to be satisfied through the posting of signs, as recommended by one commenter, but concluded that use of individual written notices would more effectively ensure that each
beneficiary receives the necessary information. In response to the comment concerning settings other than hospital outpatient departments, we note that in other settings, a patient is unlikely to be misled as to what type of facility is the site of treatment, so provision of notice is not required. To avoid confusion as to when the requirement applies, we have revised the final rule to state that notice is required only if the hospital outpatient department or provider-based entity is not located on the campus of the hospital that is the main provider. We have revised this final rule to specify that the notice must be in writing, must be one the beneficiary can read and understand, and must be given to the beneficiary's authorized representative if the beneficiary is unconscious, under great duress, or for any other reason unable to read a written notice and understand and act on his or her own rights.
Section 413.65(g)(9) (redesignated in this final rule as Section 413.65(h), Furnishing all services under arrangement)

Comment: A commenter observed that $\S 413.65(\mathrm{~g})(9)$ does not preclude an outpatient facility from obtaining a certain type of service from an off-site supplier. If this is correct, if the service is provided on-site in the hospital's outpatient facility, it is not clear how the proposed regulations are intended to be applied. It would appear that if the facility is looked at as a whole, all services are not provided "under arrangements"; therefore, paragraph (g)(9) of this section would not preclude the facility from being recognized as provider-based. However, in this case, the commenter stated that both licensure and ownership requirements would be difficult to satisfy. In most cases, that portion of the facility that is operated "under arrangements" with the hospital will not be on the hospital's license, nor will that portion necessarily be owned by the hospital. Thus, the commenter urged that the "under arrangements" portion of an outpatient facility be excluded from the licensure and ownership analyses.
Response: We agree that where a facility offers a variety of services, provision of a single type of service under arrangement would not prevent the facility from meeting this criterion. The criterion could not, of course, be met by a facility that furnished only a specific type of service (such as physical therapy), and provided that service only under arrangement. In the case envisioned by the second commenter, the facility would be out of compliance
with licensure and ownership requirements, as well as the requirement involving services under arrangement, and we would agree that it could not be provider-based.

Comment: A commenter asked for clarification of "under arrangements", in reference to our other regulations that contain these terms. Also, the commenter requested clarification on the types of services to which this standard applies, that is, direct patient care as opposed to facility related services.

Response: The term "arrangements" is defined in section 1861(w)(1) of the Act and the Medicare regulations $\S 409.3$, in that "arrangements" refers to arrangements that provide that Medicare payment made to the provider that arranged for the services discharges the liability of the beneficiary or any other person to pay for the services. We wish to emphasize that the provision will apply to patient care services, not housekeeping, security, billing, or other services that are not patient care services but are needed to support their provision.

## Section 413.65(h) Inappropriate

 treatment of a facility or organization as provider-based (redesignated in this final rule as paragraph (i))Comment: This section establishes sanctions that may be used to address a main provider that has treated an entity as provider-based without our review and approval. A commenter believes that the investigation phase should precede the review of payments to the main provider. A commenter was also concerned that the individuals involved in these reviews and investigations are properly trained to make the required determinations.

Response: We believe review of payments will encompass two activities-investigation to determine whether applicable provider-based requirements were met, and a calculation of the amount of overpayment if they were not. Thus, investigation necessarily precedes recovery, but is a part of the overall effort, which is to reconsider payment amounts. To respond more effectively to concerns about how the review and recovery activities will occur, and to clarify the specific actions we will take in cases of inappropriate billing, we have reorganized paragraph (i) to deal separately with the processes of determination and review, recovery of overpayments, and the good faith effort exception. With respect to determination and review, we state that if we learn that a provider has treated a facility or organization as provider-
based and the provider had not obtained a determination of provider-based status under this section, we will review current payments and, if necessary, take action in accordance with the rules on inappropriate billing in paragraph (j), investigate and determine whether the requirements for provider-based status in paragraph (d) of $\S 413.65$ (or, for periods prior to October 10, 2000, the requirements in applicable program instructions) were met, and review all previous payments to that provider for all cost reporting periods subject to reopening in accordance with § 405.1885 and $\S 405.1889$ of this chapter. With respect to recovery of overpayments and the good faith exception, we have clarified that we will recover only the difference between the amount of payments that actually were made and the amount of payments that we estimate should have been made in the absence of a determination of providerbased status, and that recovery will not be made for any period prior to the effective date of these final rules if during all of that period the management of the entity made a good faith effort to operate it as a providerbased facility or organization, as described in paragraph (h)(3) of $\S 413.65$. In response to the comment about the competence of individuals involved in these activities, we wish to emphasize that we will ensure that staff involved in these activities have the necessary expertise.

Comment: A commenter believes that it would be unfair to apply the proposed regulations retroactively, that is, to periods before the effective date of the final rule. Even though paragraphs (h) and (i) provide for a good faith exception, it is still unfair to provide that the conditions for this exception will apply prior to the effective date of the final regulation. The commenter requested that these sections be revised to provide that the period of recovery will not extend to any period prior to the effective date of the final regulations. Another commenter also believes that any payment changes be prospective (unless the hospital did not make a good faith effort to operate the site as provider-based).

Response: We agree that it would be inappropriate to apply the rules in paragraph (h) to any period prior to their effective date, and have revised the final rule to clarify that for such periods, we will make determinations based on the program memoranda or other instructions in effect at the time. However, the criteria in paragraph (i) that form the basis for a good faith exception were in effect prior to the issuance of these regulations. Regarding
the last comment, we cannot agree to ignore possible overpayments resulting from noncompliance with published criteria in effect at that time.

Comment: A commenter believes that the term "good faith effort" should be defined to provide more direction and opportunity to comply. Also, entities making "good faith efforts" should be given an opportunity to correct those factors or criteria that render it out of compliance with the provider-based requirements.
Response: The conditions under which a provider will be found to have made a good faith effort were clarified in $\S 413.65(\mathrm{i})(2)$, and have been restated in the final rule.

## Section 413.65(i) Inappropriate billing

 (redesignated in this final rule as paragraph (j))Comment: A commenter believes that suspending all payments for outpatient services to facilities that have billed inappropriately as provider-based entities until the provider can demonstrate that payments are proper is too onerous. Instead, the commenter suggested that we consider suspending the reimbursement differential between a provider-based entity and a nonprovider-based entity until a determination is made or the facility has had a reasonable opportunity to comply.
Response: We understand the commenter's concern and have revised the final rule to authorize partial suspension of payment (that is, a reduction in payment) to the extent needed to prevent creation of an overpayment to the provider. This rule will allow payment to continue at a reduced rate, thus avoiding creation of financial hardship for the provider. To describe more clearly how we will deal with instances of inappropriate billing, we have reorganized paragraph (j) of § 413.65 to spell out more clearly the actions we will take, and the extent to which payment will be adjusted. Specifically, we state that if we find that a facility or organization is being treated as provider-based without having obtained a determination of providerbased status under this section, we will notify the provider, adjust future payments, review previous payments, determine whether the facility or organization qualifies for provider-based status under this paragraph, and continue payments only under specific conditions. The notice to the provider will explain that payments for past cost reporting periods may be reviewed and recovered, that future payments for services in or of the facility or organization will be adjusted, and that
a determination of provider-based status will be made.

We further state that we will not stop all payment in such cases, but instead, will adjust future payments to approximate as closely as possible the amounts that would be paid in the absence of a provider-based determination, if all other requirements for billing were met. We also explain that we will review previous payments and, if necessary, take action in accordance with the rules on inappropriate treatment of a facility or organization described above. The regulation states that we will determine whether the facility or organization qualifies for provider-based status under the criteria in this section. If we determine that the facility or organization qualifies for provider-based status, future payment for services at or by the facility or organization will be adjusted to reflect that determination. Even if the facility or organization does not qualify for provider-based status, however, we will continue paying, at an appropriately adjusted level, for a limited time period in order to avoid disruption of services to program beneficiaries at that site and to allow an orderly transition to freestanding status.

The notice of denial of provider-based status sent to the provider will ask the provider to notify us in writing, within 30 days of the date the notice is issued, as to whether the facility or organization (or, where applicable, the practitioners who staff the facility or organization) will be seeking to enroll and meet other requirements to bill for services in a free-standing facility. If the provider indicates that the facility, organization, or practitioners will not be seeking to enroll, or if we do not receive a response within 30 days of the date the notice was issued, all payment will end as of the 30th day after the date of notice. If the provider indicates that the facility or organization, or its practitioners, will be seeking to enroll and meet other requirements for billing for services in a free-standing facility, payment for services of the facility or organization will continue, at the adjusted amounts described in paragraph (j)(2) of this section for as long as is required for all billing requirements to be met (but not longer than 6 months) if-

- The facility or organization, or its practitioners, submit a complete enrollment application and provide all other required information within 90 days after the date of notice, and
- The facility or organization, or its practitioners, furnish all other information we need to process the enrollment application and verify that other billing requirements are met.

If the necessary applications or information are not provided, we will terminate all payment to the provider, facility, or organization as of the date we issue notice that necessary applications or information have not been submitted. We have clarified the final rule to state that these reductions will occur where inappropriate billing is or has been taking place.

Comment: A commenter believes that there are already existing mechanisms for overpayment and recoupment that may be used in the situations described in this section. At the very least, administrative actions of this type should be subject to time frames in order to protect providers from the impact of extended investigations.
Response: We plan to conduct any recovery efforts in accordance with applicable law and regulations on overpayment recovery. However, investigations may be complex and require examination of many records, and we do not agree that they should be limited by additional, self-imposed restrictions.

Comment: A commenter stated that a facility or organization that requests a provider-based determination prior to the effective date of the final rule, and meets the good faith requirements, should not be subject to recovery of overpayment for periods either before or after the effective date of the final rule. This will prevent disruptions to existing arrangements that meet the good faith exception during the time that the request is being processed.
Response: If we were to adopt this proposal, we would be guaranteeing an overpayment to providers who, for a specific time period, knowingly billed for services as those of provider-based entities, even though they met only a few of the provider-based criteria. Thus, we did not adopt this comment.

Comment: A commenter requested that the requirement found at paragraph (i)(2)(iii) be clarified to state that management is only responsible for professional services billed by the hospital.
Response: As explained earlier, we believe hospitals' privileging mechanisms give them adequate leverage to prevent inappropriate billing by practitioners using their facilities. Therefore, we did not adopt this comment.
Comment: As to the good faith criteria found in paragraph (i)(2), a commenter questioned why requirements related to public awareness were chosen for inclusion. An organization can represent itself to the public in any number of inaccurate ways in order to mislead our officials and others. The
commenter believes that we should focus our attention on more tangible expressions of good faith efforts to operate a provider based entity.
Response: We believe inclusion of this requirement is needed to help ensure that beneficiaries are protected from unexpected deductible and coinsurance liability. While we agree with the commenter that some providers may misrepresent the status of off-site facilities, we believe such providers cannot reasonably be said to have acted in good faith, and should not receive favorable treatment with respect to past overpayments.
Section 413.65(j) Correction of errors (redesignated in this final rule as paragraph ( $k$ ))

Comment: A commenter disagreed with the language in this subsection that would allow us to review and rescind, if appropriate, any past determinations. The commenter believes that this subsection should be removed and any previous determinations should be grandfathered in under the new regulations. Other commenters recommended that we grandfather facilities or organizations that had previously been determined by the regional office to be provider-based, or that have not received such a determination but have been billing as provider-based without a determination for a period of at least ten years, so that those facilities or organizations could retain provider-based status even though they do not meet the criteria in the regulations.
Response: We do not agree that it would be appropriate to grandfather existing facilities or organizations, since this would in effect create an ongoing double standard, under which some facilities or organizations are held to higher standards than others. Moreover, the fact that improper billing may have continued undetected for a long period is not a reason to continue to permit such billing. As explained in the response to the following comment, however, any adverse determination regarding provider-based status of facilities or organizations which we previously determined were providerbased will not be effective until the start of the cost reporting period after the period in which the provider is notified of the redetermination, or for at least 6 months, whichever date is later.
Comment: A commenter believes that our proposal that we may review past provider-based determinations inserts needless uncertainty into the process for making provider-based designations. The commenter is concerned that providers may file before the final rule
is published in order to avoid a crush of applications and subsequent disruption in payment, if they do not have a determination within 30 days of the rule becoming final. The commenter stated that providers need to be able to receive prompt determinations on which they can rely.

Response: We understand the concern about avoiding the need to process a large number of applications in a short time, and agree that it would not be appropriate to make abrupt changes in provider-based status. To avoid a possible crush of applications within a 30-day period, as envisioned by the commenter, we are providing the delayed effective date described earlier in this document. In addition, under § $413.65(\mathrm{j})$ of these regulations, when a facility or organization that previously was determined to be provider-based is found to no longer qualify for providerbased status, treatment of the facility or organization as provider-based will not cease until the first day of the first cost reporting period following notification of the redetermination, but not less than 6 months after the date the provider is notified of the redetermination. If there has been no prior determination of provider-based status, and a facility or organization is later found not to meet the criteria, that determination may be effective up to 6 months after the date the provider is notified of the determination, if within 30 days of the determination, the provider indicates that the facility or organization, or its practitioners, will enroll separately and, within 90 days, the facility or organization, or its practitioners, take other necessary action to enroll.
Section 489.24(b) Special responsibilities of Medicare hospitals in emergency cases

Comment: One commenter disagreed strongly with the proposed revisions to the regulation defining "comes to the emergency department," and in particular expressed the view that patients arriving on the campus, sidewalk, driveway, or parking lot of hospital facilities should not be considered to have come to the emergency department. The commenter stated the view that an obligation under section 1867 of the Act (sometimes referred to as the Emergency Medical Treatment and Active Labor Act (EMTALA), after the original title of the legislation adding section 1867) and our regulations at $\S \S 489.20(\mathrm{l})$, (m), (q), and (r), and § 489.24 should be triggered only by a presentation to the emergency department, and that only in exceptional situations should EMTALA apply to someone not technically in the
emergency department. The commenter recommended that the regulations be revised to state that in these cases, the hospital may rely on a variety of transport options, consistent with the individual's condition and established policies that are applied in a nondiscriminatory manner. The commenter also recommended that the statute be interpreted as requiring only that hospitals with emergency departments have policies and procedures to assure that a person who presents to the hospital requesting emergency services is provided a medical screening examination and, if needed, stabilization or an appropriate transfer.

Another commenter raised several arguments against the proposed change. The commenter stated that there is a legal and ethical conflict in requiring hospital personnel to leave an area of patient care and furnish assistance to another patient in a remote area of the hospital. The commenter also believes that ED personnel are not well-trained or practiced in immobilization or scene safety, and patients and staff may be put at risk if staff are asked to go into the field and render aid to a victim who needs the expert care and experience for which field emergency medical services (EMS) personnel are trained. Finally, the commenter expressed concern about possible increases in the liability insurance cost to hospitals as a result of the proposed change.

Response: We do not agree that the proposed language inappropriately extends the scope of hospitals' EMTALA responsibilities. On the contrary, existing regulations at § 489.24 make it clear that EMTALA applies to hospitals that offer services for emergency medical conditions, and we believe it would defeat the purpose of EMTALA if we were to allow hospitals to rely on narrow, legalistic definitions of "comes to the emergency department" or of "emergency department" to escape their EMTALA obligations. We would also note, as discussed further below, that there is no requirement that all areas of the hospital be equipped to provide emergency care or that treatment always be provided outside the emergency area or department. Similarly, there is no prohibition of appropriate transfers to other facilities where such a transfer is conducted in accordance with $\S 489.24$. On the contrary, the intent of the revised regulation is to ensure that patients who come to the hospital and request examination or treatment for what may be an emergency medical condition are not denied EMTALA protection simply because they enter the
wrong part of the hospital or fail to make their way to the emergency room.

Comment: Two commenters recommended clarification of the applicability of section 1867 of the Act regarding transfer requirements to scheduled patients at an "off-campus" hospital site, to ensure that the movement of scheduled patients unexpectedly requiring a higher level of care to another site of the same hospital is not construed as a "transfer" under the emergency access law, and that only those patients taken from one hospital's off-campus facility to another hospital's emergency department or inpatient unit be considered "transfers" that must be in accordance with the requirements of section 1867.

Response: We agree that movement of a patient from one part of a hospital to another, including movement from a remote location to a main hospital campus, does not constitute a "transfer"' for EMTALA purposes, nor does it require compliance with the appropriate transfer requirements in $\S 489.24$ (d). The final regulations at $\S 489.24(\mathrm{i})(3)(\mathrm{i})$ clarify this policy.

Comment: A commenter expressed the view that the proposed revision to § 489.24 does not recognize the role that EMS personnel play in emergency situations and the true medical benefit provided by EMS personnel to patients in emergency situations. The commenter recommended that language be included in the regulation to authorize hospitals' use of EMS in responding to emergency situations on hospital grounds.

Response: We agree that EMS personnel can play a valuable role in transporting patients to appropriate sources of emergency care. A hospital may not, however, meet its EMTALA obligations merely by summoning EMS personnel. EMS may be used appropriately in conjunction with an appropriate hospital response to treat and move an individual who is already on hospital property. We therefore did not make any change to these
regulations to authorize exclusive use of EMS to respond to emergency situations on hospital property.

Comment: A number of commenters stated that the anti-dumping rules implemented under section 1867 of the Act (EMTALA requirements) and our regulations at $\S \S 489.20(\mathrm{l})$, (m), (q), and (r), and § 489.24 should apply to the hospital's main campus and to all emergency departments. However, they argued that it is not reasonable to apply these rules to outpatient departments located off-campus that would not be set up to provide emergency services. In the commenters' view, it should suffice that
patients in an emergency situation be directed to the hospital's emergency room. Another commenter stated that EMTALA obligations should be limited to those hospital entities that hold themselves out as providing emergency services, and should not be enforceable anywhere outside the emergency department or anywhere on hospital property, including an outpatient department or provider-based entity. Another commenter stated that the enforcement of this requirement would lead to the elimination of servicespecific outpatient departments located off a main campus, and asked that we reconsider our policy. One commenter expressed concern that patients identifying a facility as a hospital-based department could mistakenly assume it is equipped to handle emergency cases. Another commenter believes that hospitals should be required to have policies and procedures in place to assure that all parts of the hospital are prepared to deal with getting an individual the appropriate medical screening.

Response: Existing regulations at $\S 489.24(\mathrm{~b})$ define "hospital with an emergency department" to include all hospitals that offer services for emergency medical conditions, not just those that have organized emergency rooms or departments. To the extent a hospital acquires or creates an offcampus location, identifies it to us and to the public as a part of that hospital, and claims payment for services at that location as hospital services, we believe it is not unreasonable to expect that hospital also to assume the obligations, including compliance with EMTALA requirements, which flow from hospital status. This principle does not mean, of course, that a hospital must have a fully equipped and staffed emergency department at each location. It also does not mean that every appearance by an individual at an off-campus hospital department that does not offer services for emergency medical conditions will necessarily trigger an EMTALA obligation on the part of the hospital. Individuals come to these departments for many medical purposes which may not involve potential emergency medical conditions. Under these circumstances, the hospital would not have an EMTALA obligation with respect to that individual. This principle does mean, however, that if an individual comes to an off-campus department of a hospital and a request is made for examination or treatment for a potential emergency medical condition, the hospital incurs an obligation to provide, within its
capability, an appropriate medical screening examination and necessary stabilizing treatment. In some cases, the patient may need to be taken back to the main hospital campus for a full screening and/or stabilizing treatment. Under these circumstances, the hospital is responsible for moving the patient or arranging his or her safe transport, but this movement would not be considered a "transfer"' under §489.24(b), since the patient is merely going from one part of the hospital to another. If it is necessary to transfer the patient to another medical facility, the hospital must provide an appropriate transfer in accordance with $\S 489.24(\mathrm{~d})$.

After review of the comments on this issue, we have decided to revise the regulations to state more clearly the extent of a hospital's EMTALA obligations with respect to patients who come to a hospital department located off the hospital's main campus. Provider-based entities, such as SNFs or HHAs, located off the hospital campus would not, of course, be subject to EMTALA since a patient coming to such an entity would not have come to the hospital. We will require that each offcampus hospital department, during its regular hours of operation, have in effect procedures for: (1) assessing the possibility that an emergency medical condition exists, and providing such screening (as defined in §489.24(a) and (b)) and necessary stabilization (as defined in $\S 489.24(\mathrm{c})$ ) at the off-campus site); (2) transporting the patient to the hospital's emergency room or department for screening and necessary stabilization meeting the requirements of $\S 489.24$; or (3) providing an appropriate transfer to another facility in accordance with the requirements in $\S 489.24(\mathrm{c})$. To meet these requirements, the hospital will need to develop procedures that permit staff of the offcampus department to contact emergency physicians or other qualified emergency practitioners at the main hospital campus, to obtain advice and direction regarding the handling of any potential emergencies, and to obtain prompt medical transport, by hospitalowned or other ambulance or other appropriate vehicle, either to the main hospital campus or, where an appropriate transfer is being provided, to another medical facility.

Specifically, we are adding new paragraph (i) to § 489.24 to describe a hospital's obligations. The paragraph states that, if an individual comes to a facility or organization that is located off the main hospital campus as defined in $\S 413.65(\mathrm{~b})$, but has been determined under $\S 413.65$ of this chapter to be a department of the hospital, and a
request is made on the individual's behalf for examination or treatment of a potential emergency medical condition as otherwise described in paragraph (a) of §489.24, the hospital is obligated to provide the individual with an appropriate medical screening examination and any necessary stabilizing treatment.
The capability of the hospital includes that of the hospital as a whole, not just the capability of the off-campus facility or organization. Except for cases described in paragraph (i)(3)(iii) (those in which the main hospital campus does not have the specialized capability or facilities needed to treat the individual, or the individual's condition is deteriorating so rapidly that transport to the main campus would significantly jeopardize the life or health of the individual), the obligation of a hospital under this section must be discharged within the hospital as a whole. However, the hospital is not required to locate additional personnel or staff to off-site locations to be on standby for possible emergencies.
In §489.24(i)(2), Protocols for offcampus departments, we further state that the hospital must establish protocols for the handling of potential emergency cases at off-campus departments. These protocols must include provision for direct contact between personnel at the off-campus department and emergency personnel at the main hospital campus, and may provide for dispatch of practitioners, when appropriate, from the main hospital campus to the off-campus department to provide screening or stabilization services. The intent of these requirements is to ensure timely exchange of information between the two sites, and to allow the hospital the flexibility to bring emergency personnel to the patient, rather than the opposite, where doing so is the best medical approach to meeting the patient's needs.

Under the final rule, if the off-campus department is an urgent care center, primary care center, or other facility that is routinely staffed by physicians, RNs, or LPNs, these personnel must be trained, and given appropriate protocols, for the handling of emergency cases. At least one individual on duty at the off-campus department during its regular hours of operation must be designated as a qualified medical person as described in paragraph (d). The qualified medical person must initiate screening of individuals who come to the off-campus department with a potential emergency medical condition, and may be able to complete the screening and provide any necessary stabilizing treatment at the off-campus
department, or to arrange an appropriate transfer.

The final rule further states that if the off-campus department is a physical therapy, radiology, or other facility not routinely staffed with physicians, RNs, or LPNs, the department's personnel must be given protocols that direct them to contact emergency personnel at the main hospital campus for direction. Under this direction, and in accordance with protocols established in advance by the hospital, the personnel at the offcampus department must describe patient appearance and reported symptoms and, if appropriate, arrange transportation of the individual to the main hospital campus (if the main hospital campus has the capability required by the individual, and movement to the main campus would not significantly jeopardize the individual's life or health), or assist in an appropriate transfer. Movement of the individual to the main campus of the hospital is not considered a transfer under this section, since the individual is simply being moved from one department of a hospital to another department or facility of the same hospital.

Finally, specific rules apply if the individual's condition warrants movement to a facility other than the main hospital campus, either because the main hospital campus does not have the specialized capability or facilities required by the individual, or because the individual's condition is deteriorating so quickly that taking the time required to move the individual to the main hospital campus could place the life or health of the individual in significant jeopardy. Under these circumstances, personnel at the offcampus department must, in accordance with protocols established in advance by the hospital, assist in arranging an appropriate transfer of the individual to a medical facility other than the main hospital. The hospital must have protocols to ensure that the movement is an appropriate transfer in accordance with paragraph (d)(2) of this section. The protocol must include procedures and agreements established in advance with other hospitals or medical facilities in the area of the off-campus department to facilitate these anticipated transfers. We note that the interpretive guidelines for enforcement of EMTALA requirements will be revised to conform to these new rules.

## Section 498.3 Scope and applicability

Comment: A commenter asked for clarification as to whether appeal rights would be available in the event of
revocation by us of provider-based status.

Response: We have revised § 489.3(b)(2) to specify that a determination that a facility or organization no longer qualifies for provider-based status is an initial determination, thus providing an administrative appeals mechanism for these decisions.

## D. Requirements for Payment

We proposed to revise §410.27, Outpatient Hospital Services and Supplies Incident to a Physician Service: Conditions, to require that services furnished at a location other than an RHC or an FQHC that we designate as having provider-based status under $\S 413.65$ must be under the direct supervision of a physician as defined in §410.32(b)(3)(ii).
Comment: Several commenters requested clarification of what we mean by "direct supervision." One commenter asked that we further define the nature and extent of the supervision needed to comply with our proposal. One commenter asked whether the supervision requirement would be met if a physician is in the hospital or whether the physician must be in the department while the procedure is being performed. The same commenter asked whether the physician billing for the incident to services must be of the same specialty as the procedure being performed. A large trade association stated that we appear to be replacing our current policy in section 3112.4(A) of the Intermediary Manual, which states that we assume the physician supervision requirement to be met when incident to services are furnished on hospital premises, with a policy requiring direct physician supervision at all times, in all outpatient departments, regardless of whether or not they are located on the hospital campus. The commenter recommended that if we retain a direct supervision requirement, it should be limited to outpatient departments located off-site of the main provider. One commenter stated that facilities and organizations accorded provider-based status that are located on the main provider's campus should be subject to the same physician supervision requirements that apply to "incident to" services provided elsewhere on the campus.
Response: We regret that our proposal to define "direct supervision" by referring to the definition of "direct supervision of a physician" given at §410.32(b)(3)(ii) may have been confusing to some commenters. Section 410.32(b)(3)(ii) defines "direct supervision" within (a physician) office
setting as meaning that the physician must be present in the office suite and immediately available to furnish assistance and direction throughout the performance of the procedure. The definition at $\S 410.32$ (b)(3)(ii) goes on to state that "direct supervision" does not mean that the physician must be present in the room when the procedure is performed.
Our intention in the proposed rule was to define "direct supervision" of hospital outpatient services incident to physician services when they are furnished at a department of a hospital to mean that a physician must be present on the premises of the entity accorded status as a department of the hospital and, therefore, immediately available to furnish assistance and direction for as long as patients are being treated at the site. By "direct supervision"' we do not mean that the physician must physically be in the room where a procedure or service is furnished. Nor does the supervising physician necessarily have to be of the same specialty as the procedure or service that is being performed. We emphasize that our proposed amendment of $\S 410.27$ to require direct supervision of hospital services furnished incident to a physician service to outpatients applies to services furnished at an entity that is located off the campus of a hospital that we designate as having provider-based status as a department of a hospital in accordance with the provisions of $\S 413.65$. Our proposed amendment of $\S 410.27$ to require direct supervision of hospital services furnished incident to a physician service to outpatients does not apply to services furnished in a department of a hospital that is located on the campus of that hospital. For hospital services furnished incident to a physician service to outpatients in a department of a hospital that is located on the campus of the hospital, we assume the direct supervision requirement to be met as we explain in section 3112.4(A) of the Intermediary Manual. The requirement at § 410.27 does not affect the definition of physician supervision in section 3112.4(A) of the Intermediary Manual. In response to these comments, we have revised our definition of "direct supervision by a physician" in the final regulation.
Comment: A major trade association asserted that requiring a physician to be on-site at a provider-based entity throughout the performance of all "incident to" services would be burdensome and costly for hospitals where there are a limited number of physicians available to provide
coverage, particularly in rural settings. Another commenter believes that entities with provider-based status should not be subject to physician supervision requirements that are more stringent than those applicable to freestanding facilities. A third commenter believes that this requirement is unnecessary because the requirements for integration with the hospital and other requirements for provider-based status include adequate checks and balances to ensure quality care. The commenter recommended that this proposal be omitted from the final rule with the potential for a separate, better defined, proposal at a later date.

Response: We disagree with commenters who believe the proposed supervision requirement is not necessary or that it would be burdensome to the hospital. First, the supervision requirement is separate from and independent of the providerbased requirements, and hospitals and physicians already have to meet a direct supervision of "incident to" services requirement that is unrelated to provider-based issues. That is, we require that hospital services and supplies furnished to outpatients that are incident to physician services be furnished on a physician's order by hospital personnel and under a physician's supervision (Intermediary Manual, section 3112.4(A)). We assume the physician supervision requirement is met on hospital premises because staff physicians would always be nearby within the hospital. The effect of the regulations in this final rule is to extend this assumption to a department of a provider that is located on the campus of a hospital. However, the regulation does not extend the assumption of supervision to a department of a hospital that is located off the campus of the hospital. We would not extend this assumption to a provider-based entity, regardless of its location, because the "incident to" requirement in §410.27(a)(1)(iii) applies only to hospitals. Also, as we state above, satisfying the requirements to be designated provider-based is unrelated to our requirement that hospital services furnished incident to a physician service to outpatients at an entity that has provider-based status be under the direct supervision of a physician.
Finally, this supervision requirement is entirely consistent with the direct supervision requirements currently set forth in the Medicare Carriers Manual, Part 3, section 2050.1(B).

Comment: One commenter suggested that partial hospitalization services furnished by a hospital to its outpatients be exempt from the outpatient
department "incident to" requirements, or that other requirements be drafted that would, in the commenter's opinion, be more appropriate to the nature of this care.
Response: Section 1861(s)(2)(B) restricts coverage of partial hospitalization services furnished by a hospital to its outpatients to services that meet "incident to" requirements. We do not have the discretion to ignore this statutory restriction.
Comment: One commenter asked that we provide an exception to the direct supervision requirement in the case of physical therapy services. The commenter questioned why therapists who furnish the same services in a provider-based entity that they would furnish in an independent practice should be subject to direct physician supervision in one setting and not the other.

Response: The provision on coverage for outpatient physical therapy and occupational therapy services does not require that they be "incident to" physician services (see section 1861(s)(2)(D) of the Act). Therefore, there is no need to exempt them from the supervision requirement for outpatient hospital services incident to a physician service that is furnished at a provider-based entity. We therefore made no change in the final regulation based on this comment.
Comment: One commenter suggested that we modify our proposed regulation to waive the direct supervision requirement in entities with providerbased status for certain procedures for which we already waive the direct supervision requirement when the procedures are performed on homebound patients, as set forth in section 2051 of the Medicare Carriers Manual. The commenter believes that general supervision is sufficient for these waived services, for example, the physician need not be present, but the services must be performed under a physician's overall supervision and control, and ordered by a physician.
Response: Under section 2050.2 of the Medicare Carriers Manual, subject to certain requirements, we waive the direct supervision requirement when the following services are furnished to homebound patients: injections; venipuncture; EKGs; therapeutic exercises; insertion and sterile irrigation of a catheter; changing of catheters and collection of catheterized specimen for urinalysis and culture; dressing changes, for example, the most common chronic conditions that may need dressing changes are decubitus care and gangrene; replacement and/or insertion of nasogastric tubes; removal of fecal
impaction, including enemas; sputum collection for gram stain and culture, and possible acid-fast and/or fungal stain and culture; paraffin bath therapy for hands and/or feet in rheumatoid arthritis or osteoarthritis; and, teaching and training the patient for the care of colostomy and ileostomy, the care of permanent tracheostomy, testing urine and care of the feet (diabetic patients only), and blood pressure monitoring. While we believe the commenter's suggestion has merit, we do not believe it would be appropriate to adopt it before we have had time to analyze the issue further. Therefore, we did not revise the final rule based on this comment.
In our proposed rule, we proposed to require that the same supervision levels established for diagnostic x-ray and other diagnostic tests in accordance with $\S 410.32(\mathrm{~b})(3)$ be required when these tests are furnished at an entity that has been accorded provider-based status by us.

Comment: A large industry federation generally favored our requiring that diagnostic tests be furnished at provider-based entities under levels of physician supervision that we specify, consistent with the definitions of general, direct, and personal supervision established at $\S 410.32(\mathrm{~b})(3)$. The commenter suggested that we modify the definition of general supervision to make it clear that the training of nonphysician personnel and the maintenance of necessary equipment and supplies are the responsibility of the hospital, not the physicians.
Response: We agree and we will modify our regulation accordingly.

Comment: Numerous commenters, including radiology and imaging specialty groups, neurologists, vascular technologists, and sonographers, questioned the level of supervision required for various specific diagnostic tests and services.
Response: Our model for this proposed requirement was the requirement for physician supervision for diagnostic tests payable under the Medicare physician fee schedule that was issued in the October 31, 1997 physician fee schedule final rule (for CY 1998) ( 62 FR 59048). There have been issues raised about the appropriate level of supervision for some specific diagnostic services, similar to the comments we received about our proposed regulation. We have not yet resolved these issues, and this final rule is not the place to convey decisions about appropriate supervision levels for specific diagnostic tests and services by individual HCPCS code. In January

1998, we sent a memorandum to all Associate Regional Administrators advising them to instruct carriers to follow their existing policies on physician supervision of diagnostic tests until we provide further instruction. We intend to instruct hospitals and intermediaries to use the October 31, 1997 physician supervision requirements as a guide, pending issuance of updated requirements. In the meantime, fiscal intermediaries, in consultation with their medical directors, will define appropriate supervision levels for services not listed in the October 31, 1997 final rule when those services are furnished at an entity with provider-based status in order to determine whether claims for these services are reasonable and necessary.

## V. Summary of and Response to MedPAC Recommendations

The following are additional recommendations contained in the report on Medicare payment policy that the Medicare Payment Advisory Commission submitted to the Congress in March 1999. (MedPAC, Report to the Congress: Medicare Payment Policy, March 1999.) We respond to recommendations that are specifically related to a particular component of the hospital outpatient PPS in the appropriate section of this preamble.

MedPAC Recommendation: MedPAC recommends that the Secretary evaluate payment amounts under the hospital outpatient PPS and the ambulatory surgical center (ASC) PPS along with the practice expense payments under the Medicare physician fee schedule for services furnished in physicians' offices to ensure that the differing payments made under the three payment systems do not create unwarranted financial incentives regarding site of care.

Response: We agree that the three payment systems should avoid creating unnecessary financial incentives to deliver care in particular settings. We will consider this matter further and evaluate differences in payments.

MedPAC Recommendation: MedPAC recommends that the Secretary study means of adjusting base prospective payment rates across ambulatory settings for patient characteristics such as age, frailty, comorbidities and coexisting conditions, and other measurable traits. Under this approach, payment would be less dependent on the type of facility and more dependent on the relative costliness of furnishing specific services to individual patients. MedPAC notes that no viable patientlevel adjuster currently exists that could be used in this fashion.

As an interim measure, MedPAC recommends, with reservations, that HCFA evaluate facility-level adjustments in order to preserve access to care for particularly vulnerable segments of the Medicare population.
Response: The underlying premise in this recommendation, as MedPAC states, is that HCFA should move toward development of a more unified and rational payment system for ambulatory care. Many powerful arguments favor such a system, but the challenges of creating and implementing it are substantial. We will give further consideration to the recommendation to study possible adjustments that could be used in various settings.
We agree that we should evaluate the need for facility-level adjustments. We believe the best course is to evaluate the need for these adjustments during the next several years as we gain actual experience with the operation of the hospital outpatient PPS and are able to observe the effects on particular provider groups. In consideration of the transitional protections provided by the BBRA 1999, we have not adopted facility-level adjustments, other than an adjustment for local labor costs, at this time.
MedPAC Recommendation: MedPAC recommends that the Secretary seek legislation to develop and implement a single update mechanism that would link conversion factor updates to volume growth across all ambulatory care settings. These settings include hospital outpatient departments, physicians' offices, and ASCs, as well as other specific settings mentioned.
Response: We believe that this proposal requires further study to determine its feasibility and possible impact. Therefore, we are not prepared to seek legislation at this time.
MedPAC Recommendation: MedPAC recommends that we not use patient diagnosis to calculate relative weights or make payments for medical visits, "given the current state of the available data and the lack of definitive rules for reporting patients' diagnoses under the proposed system."

Response: As discussed in section III.C.3, we have dropped diagnosis from our characterization of medical visit APCs. We hope to develop procedure codes for medical visits that are more descriptive of hospital outpatient resource use, rather than physician services. Once we revise procedure coding to better reflect hospital services, we will assess whether accurate diagnosis coding further improves recognition of resources.
MedPAC Recommendation: MedPAC recommends that the Secretary closely
monitor the use of hospital outpatient services to ensure that beneficiary access to care is not compromised.
Response: We plan to evaluate the operation of the new PPS to address a variety of issues, including beneficiary access to care. We note that the provisions of the BBRA 1999 should mitigate substantially any payment reductions and hence the possibility of reduced access.
MedPAC Recommendation: MedPAC recommends that the Secretary consider making payment adjustments in addition to the proposed adjustment for local area wages under the new system. These adjustments should be tied to patient characteristics. The facility-level adjustments that are made until the time that a patient-level adjuster is available should reflect the population of Medicare patients treated by facilities identified to receive the adjustments.

MedPAC points out that HCFA, in setting Medicare payment rates for hospital inpatient services, adjusts payments based on the costs or provider characteristics of hospitals (for example, sole community hospitals). Rather than continuing this practice in the outpatient setting, MedPAC recommends that HCFA move toward making adjustments based on patient characteristics and the relative costliness of resources required in furnishing care to differing patients. Any differences in the payment of the same ambulatory care service should be based on patient characteristics, rather than on the setting. MedPAC recommends that HCFA evaluate any relationships between immutable patient characteristics and the cost of furnishing care.

## Response: Other than those

 adjustments specified in sections 201 and 202 of the BBRA 1999, we have made no additional adjustments in this final rule. We will consider the possibility of adjustments in the future once we have actual experience with operation of the hospital outpatient PPS and can examine its effects. The extent to which adjustments at the level of patient characteristics will be feasible is unclear and would require further study.
## VI. Provisions of the Final Rule

The provisions of this final rule reflect the provisions of the September 8, 1998 proposed rule, except as noted elsewhere in this preamble. Following is a synopsis of the major changes we have made, either in response to comments or in order to implement provisions of the BBRA 1999 that apply to the hospital outpatient prospective payment system.

For our proposal to adjust the CY 2002 update of the conversion factor by the percentage that actual CY 2000 payments exceed the estimated CY 2000 expenditure target, we are delaying implementation of the volume control mechanism for 2 years.

For our proposal to package costs that are directly related and integral to performing a procedure or furnishing a service on an outpatient basis, we are making the following changes:

- We are creating separate APC groups to pay for blood, blood products, and anti-hemophilic factors, for splints and casts, and for certain very costly drugs that are not included in the transitional pass-through payment provision.
- We are paying separately, at cost, for the acquisition of corneal tissue.
- As required by section 201(e) of the BBRA 1999, we are not paying for certain implantable items under the DMEPOS fee schedule, but are including them as covered outpatient services. We are packaging the costs of these items into the APC payment rate for the procedures or services with which they are associated. These include implantable items used in connection with diagnostic tests, implantable DME, and implantable prosthetic devices.

For our proposal to base payment for medical visits to clinics and emergency departments on diagnosis codes as well as HCPCS codes, we are not using diagnosis codes at this time.

For our proposal to classify a new technology procedure or service within the APC group that it most closely resembles in terms of clinical characteristics and resource utilization, pending collection of additional pricing data, we are creating separate APC groups to which we can temporarily classify new technology services while we gather additional data and gain pricing experience. We are also creating a process under which interested parties may submit requests for consideration of services that may be eligible for payment as new technology.

For our proposal to pay for drugs, pharmaceuticals, and biologicals (except for cancer therapy drugs and certain infrequently used but very expensive drugs) as part of the APC payment for the service or procedure with which they are used, we are establishing transitional pass-through payments, as directed by section 201(b) of the BBRA 1999. Under this provision, an additional payment will be made for current orphan drugs, current cancer therapy drugs, biologicals, and brachytherapy, and current
radiopharmaceutical drugs and biological products.
For our proposal to classify a new or innovative medical device, drug or biological (for which we were not making payment as of December 31, 1996) within the APC group that it most closely resembles in terms of clinical characteristics and resource utilization, pending collection of additional pricing data, we are establishing transitional pass-through payments. Under this provision, as directed by section 201(b) of the BBRA 1999, an additional payment will be made for new or innovative devices, drugs, and biologicals whose cost is not insignificant in relation to the APC payment for the group of services with which they are used.

For our proposal not to establish an outlier adjustment, as directed by section 201(a) of the BBRA 1999, we will make an outlier payment when calculated bill costs exceed 2.5 times the PPS payment for a service.

For our proposal to determine comparability of resources and clinical characteristics among the codes within an APC group based on our claims data and the analyses and judgment of our medical advisors, supported by comments from medical specialty societies and trade associations, as provided in section $201(\mathrm{~g})$ of the BBRA 1999, we are limiting the variation so that the highest median cost of an item or service in an APC group is no more than two times the lowest median cost of an item or service within that group. We will also consult with an expert outside advisory panel regarding the clinical integrity of the APC groups and weights as part of our update of the PPS.

For our proposal to periodically review and update payment weights, APC groups, and other elements of the hospital outpatient PPS, as required by section 201(h) of the BBRA 1999, we will annually review the groups, relative payment weights, and the wage and other adjustments that are a part of the PPS.
For our proposal to implement the hospital outpatient PPS fully and in its entirety for all hospitals beginning as early as possible in CY 2000, with no phase-in period, as required by section 202(a) of the BBRA 1999, we are establishing transitional corridors for services furnished before January 1, 2004 to limit losses facilities might otherwise face.
For our proposal not to make any adjustments for any specific classes of hospitals, we are holding small rural hospitals harmless through CY 2003 in accordance with the requirements set by section 202(a)(3) of the BBRA 1999,
which added section $1833(\mathrm{t})(7)(\mathrm{D})(\mathrm{i})$ to the Act. Also, we are holding cancer centers permanently harmless in accordance with the requirements set by section 202(a)(3) of the BBRA 1999.
For our proposal on beneficiary coinsurance payment amounts, we are limiting the coinsurance amount for a procedure to be no more than the hospital inpatient deductible, as specified in section 204(a)(3) of the BBRA 1999.
The following is a synopsis of the principal changes that we are making in the provider-based requirements:
For our proposal to require main providers and provider-based entities to share a common license, we will require common licensure only where State law permits it. Where State law prohibits it or is silent, we will not apply the licensure requirement. We will also exempt IHS facilities and facilities located on Tribal lands from this requirement.
For our proposal requiring a main provider and a provider-based entity to serve a common service area indicated largely by overlapping patient populations, we have redefined "common service area" to mean a 75 percent threshold of patients who reside in a zip code area that is common to the main provider and the provider-based entity.
For our proposal to require providerbased entities to be in the same State as the main provider, we will allow providers in one State to have providerbased facilities in an adjacent State, if doing so is consistent both with the law of the affected States and with other criteria, including those related to a common service area.
For our proposal to require that a provider-based outpatient department bill all payers as an outpatient department, we have rescinded this requirement.
For our proposal to require FQHCs that have been billing Medicare as hospital outpatient departments to comply with the provider-based requirements, we are grandfathering both FQHCs and FQHC "look-alikes" (facilities that are organized as FQHCs but do not receive grants) so that these facilities will be considered departments of providers without having to meet $\S 413.65$ requirements.
For our proposal to apply the provider-based requirements to Indian Health Service (including tribally operated) entities, we are creating a permanent exception for those entities that were billing as departments of IHS or Tribal hospitals on or before October 10, 2000.

For our proposal to consider providerbased entities to be part of the hospital for Emergency Medical Treatment and Active Labor Act (EMTALA) ("antidumping' purposes), we are maintaining the principle that off-site hospital facilities are subject to EMTALA. We have clarified the obligations of hospitals with respect to these locations to ensure they are consistent with staffing patterns and resources.

For our proposal to apply providerbased criteria to inpatient facilities such as multi-campus hospitals created by mergers and satellites of PPS-excluded hospitals that are created by hospitals leasing space in other hospitals, we have clarified the applicability of provider-based criteria to remote locations of hospitals and hospital satellite facilities.

## VII. Collection of Information Requirements

Under the Paperwork Reduction Act (PRA) of 1995, we are required to provide 30-day notice in the Federal Register and solicit public comment before a collection of information requirement is submitted to the Office of Management and Budget (OMB) for review and approval. In order to fairly evaluate whether an information collection should be approved by OMB, section 3506(c)(2)(A) of the PRA requires that we solicit comment on the following issues:

- The need for the information collection and its usefulness in carrying out the proper functions of our agency.
- The accuracy of our estimate of the information collection burden.
- The quality, utility, and clarity of the information to be collected.
- Recommendations to minimize the information collection burden on the affected public, including automated collection techniques.

We are soliciting public comment on each of these issues for the provisions summarized below that contain information collection requirements:

## Section 413.24 Adequate cost data and cost finding

Section 413.24(d)(6)(ii) states that a provider must develop detailed work papers showing the exact cost of the services (including overhead) provided to or by the free-standing entity and show those carved out costs as nonreimbursable cost centers in the provider's trial balance. While these information collection requirements are subject to the PRA, the burden associated with these requirements is captured under §§413.65(c)(1) and (c)(2) below.

Section 413.65 Requirements for a determination that a facility or an organization is a department of a provider or a provider-based entity

Section 413.65(b)(2) states that a provider or a facility or organization must contact HCFA and the facility or organization must be determined by HCFA to be provider-based before the main provider begins billing for services of the facility or organization as if they were furnished by a department of the provider-based entity, or before it includes costs of those services on its cost report. While these information collection requirements are subject to the PRA, the burden associated with these requirements is captured under §§ 413.65(c)(1) and (c)(2) below.
Sections 413.65(c)(1) and (c)(2) state that a main provider that acquires a facility or organization for which it wishes to claim provider-based status, including any physician offices that a hospital wishes to operate as a hospital outpatient department or clinic, must report its acquisition of the facility or organization to HCFA and must furnish all information needed for a determination as to whether the facility or organization meets the requirements in paragraph (d) of this section for provider-based status, if the facility or organization is located off the campus of the provider or would increase the provider's total costs by at least 5 percent. Furthermore, a main provider that has had one or more entities considered provider-based also must report to HCFA any material change in the relationship between it and any provider-based facility or organization, such as a change in ownership of the facility or organization or entry into a new or different management contract that could affect the provider-based status of the facility or organization.

The burden associated with this requirement is the time for the main provider to report its acquisition to HCFA, furnish all information needed for a determination, report to HCFA any material change in the relationship between it and any provider-based facility or organization, such as a change in ownership of the facility or organization or entry into a new or different management contract that could affect the provider-based status of the facility or organization. It is estimated that 105 main providers will take 10 hours for a total of 1,050 hours.

Section 413.65(d)(4)(v) states that medical records for patients treated in a facility or organization must be integrated and maintained into a unified retrieval system (or cross reference) of the main provider. The burden
associated with this requirement is the time required for the main provider to maintain medical records in a unified retrieval system. While this requirement is subject to the PRA, we believe this requirement is a usual and customary business activity and the burden associated with this requirement is exempt from the PRA, as stipulated under 5 CFR 1320.3(b)(2) and (b)(3).

Section $413.65(d)(7)(i)$ requires that for a facility or organization and the main provider that is not located on the same campus, the facility or organization must demonstrate a high level of integration with the main provider by showing that it meets all of the other provider-based criteria, and demonstrates that it serves the same patient population as the main provider, by submitting records showing that, during the 12 -month period immediately preceding the first day of the month in which the application for provider-based status is filed with HCFA, and for each subsequent 12month period meet the requirements of paragraphs (d)(7)(i)(A), (B), or (C) of this section. While the information collection requirements listed below are subject to the PRA, the burden associated with these requirements is captured under §§413.65(c)(1) and (c)(2).

Section 413.65(g)(7) states that when a Medicare beneficiary is treated in a hospital outpatient department or hospital-based entity, the hospital has a duty to notify the beneficiary, prior to the delivery of services, of the beneficiary's potential financial liability (that is, a coinsurance liability for a facility visit as well as for the physician service).
The burden associated with this requirement is the time for the provider to disseminate information to each beneficiary of the beneficiary's potential financial liability (that is, a coinsurance liability for a facility visit as well as for the physician service). It is estimated that 750 providers will make on average 667 disclosures on an annual basis, at 3 minutes per disclosure, for a total annual burden of 25,013 hours.
Section 413.65(j)(5) requires that upon notice of denial of provider-based status sent to the provider by HCFA, the notice will ask the provider to notify HCFA in writing, within 30 days of the date the notice is issued, of whether the facility or organization (or, where applicable, the practitioners who staff the facility or organization) will be seeking to enroll and meet other requirements to bill for services in a free-standing facility. This requirement is exempt from the PRA as stipulated under 5 CFR 1320.4(a)(2).

Further, if the provider indicates that the facility or organization, or its practitioners, will be seeking to meet enrollment and other requirements for billing for services in a free-standing facility, the facility or organization must submit a complete enrollment application and provide all other required information within 90 days after the date of notice; and the facility or organization, or its practitioners, furnish all other information needed by HCFA to process the enrollment application and verify that other billing requirements are met. The requirements and burden associated with the provider enrollment process are currently approved under OMB control number 0938-0685, with a current expiration date of September 30, 2001.

## Section 424.24 Requirements for Medical and Other Health Services Furnished by Providers Under Medicare Part B

Section 424.24(e)(3)(i) requires that when a partial hospitalization service occurs the physician recertification must be signed by a physician who is treating the patient and has knowledge of the patient's response to treatment. While this signature requirement is subject to the PRA, the overall requirements associated with physician recertification, as currently referenced in HCFA regulation number HCFA1006, published in the Federal Register on June 5, 1998, have not yet been approved by OMB under the PRA. Therefore, we continue to solicit comment on all of the requirements and associated burden referenced in §424.24.

## Section 419.42 Hospital Election To Reduce Copayment

Sections 419.42(b) and (c) state that a hospital must notify its fiscal intermediary of its election to reduce copayments no later than June 1, 2000 prior to the date the PPS is implemented or for subsequent calendar years, beginning with elections for calendar year 2001, no later than December 1 of the preceding calendar year. The hospital's election must be properly documented. It must specifically identify the ambulatory payment classification to which it applies and the coinsurance amounts (within the limits identified within this regulation) that the hospital has elected for each group.

The burden associated with these requirements is the time it takes a hospital to compile, review, and analyze data for both revenues and coinsurance; prepare and present the data to the hospital board; make a business decision as to whether the hospital
would elect to reduce coinsurance; and then notify its fiscal intermediary of its election. A hospital would notify its fiscal intermediary of its election to reduce coinsurance only if there were other providers, in close proximity, that would attract a majority of the hospital's business if they did not reduce their coinsurance. Since hospitals do not want to lose money by absorbing coinsurance, we anticipate that this requirement will affect 750 hospitals and take them 10 hours each for a total of 7,500 hours.

Section 419.42(e) states that the hospital may advertise and otherwise disseminate information concerning the reduced level(s) of coinsurance that it has elected. All advertisements and information furnished to Medicare beneficiaries must specify that the coinsurance reductions advertised apply only to the specified services of that hospital and that these coinsurance reductions are available only for hospitals that choose to reduce coinsurance for hospital outpatient services and are not applicable in any other ambulatory settings or physician offices.

The burden associated with this requirement is the time for the hospital to disseminate information concerning its coinsurance election. It is estimated that 750 hospitals will each take 10 hours annually to disseminate this information via newsletters and information sessions at senior citizen centers for a total of 7,500 hours.

We have submitted a copy of this final rule to OMB for its review of the information collection requirements. These requirements are not effective until they have been approved by OMB. A notice will be published in the Federal Register when approval is obtained.

If you comment on any of these information collection and record keeping requirements, please mail copies directly to the following:
Health Care Financing Administration, Office of Information Services, Information Technology Investment Management Group, Division of HCFA Enterprise Standards, Room C2-26-17, 7500 Security Boulevard, Baltimore, MD 21244-1850, Attn: John Burke HCFA-1005-FC/R-240, and
Office of Information and Regulatory
Affairs, Office of Management and Budget, Room 10235, New Executive Office Building, Washington, DC 20503, Attn.: Allison Herron Eydt, HCFA-1005-FC.

## VIII. Response to Comments

Because of the large number of items of correspondence we normally receive on Federal Register documents published for comment, we are not able to acknowledge or respond to them individually. Comments on the provision of this final rule that implement provisions of the BBRA 1999 will be considered if we receive them by the date and time specified in the DATES section of this preamble. We will not consider comments concerning provisions that remain unchanged from the September 8, 1998 proposed rule or that were changed based on public comments.

## IX. Regulatory Impact Analysis

## A. Introduction

Section 804(2) of title 5, United States Code (as added by section 251 of Pub. L. 104-121), specifies that a "major rule" is any rule that the Office of Management and Budget finds is likely to result in-

- An annual effect on the economy of \$100 million or more;
- A major increase in costs or prices for consumers, individual industries, Federal, State, or local government agencies, or geographic regions; or
- Significant adverse effects on competition, employment, investment productivity, innovation, or on the ability of United States based enterprises to compete with foreignbased enterprises in domestic and export markets.
We estimate, based on a simulation model, that the effect on hospitals participating in the Medicare program associated with this final rule would be to increase Medicare payments by $\$ 600$ million in calendar year 2000. This figure includes beneficiary copayments. We estimate that the additional expenditures to hospitals from the Part B Trust Fund associated with this final rule will be $\$ 490$ million in fiscal year 2000. Therefore, this rule is a major rule as defined in Title 5, United States Code, section 804(2).

We have examined the impacts of this final rule as required by Executive Order 12866, the Unfunded Mandates Reform Act of 1995, and the Regulatory Flexibility Act (RFA) (Public Law 96354). Executive Order 12866 directs agencies to assess all costs and benefits of available regulatory alternatives and, when regulation is necessary, to select regulatory approaches that maximize net benefits (including potential economic, environmental, public health and safety effects, distributive impacts, and equity). A regulatory impact analysis (RIA) must be prepared for
major rules with economically
significant effects ( $\$ 100$ million or more annually). Because the projected spending resulting from this final rule is expected to exceed $\$ 100$ million, it is considered a major rule for purposes of the RFA.

The Unfunded Mandates Reform Act of 1995 also requires (in section 202) that agencies prepare an assessment of anticipated costs and benefits for any rule that may result in an expenditure in any 1 year by State, local, or tribal governments, in the aggregate, or by the private sector, of $\$ 100$ million. This final rule does not mandate any requirements for State, local, or tribal governments.

We generally prepare a regulatory flexibility analysis that is consistent with the RFA (5 U.S.C. 601 through 612), unless we certify that a final rule will not have a significant economic impact on a substantial number of small entities. For purposes of the RFA, we consider all hospitals to be small entities.

Also, section 1102(b) of the Social Security Act requires us to prepare a regulatory impact analysis for any final rule that may have a significant impact on the operations of a substantial number of small rural hospitals. Such an analysis must conform to the provisions of section 604 of the RFA. With the exception of hospitals located in certain New England counties, for purposes of section $1102(\mathrm{~b})$ of the Act, we define a small rural hospital as a hospital with fewer than 100 beds that is located outside of a Metropolitan Statistical Area (MSA) or New England County Metropolitan Area (NECMA). Section 601(g) of the Social Security Amendments of 1983 (Pub. L. 98-21) designated hospitals in certain New England counties as belonging to the adjacent NECMA. Thus, for purposes of the proposed prospective payment system, we classify these hospitals as urban hospitals.

## B. Estimated Impact on the Medicare Program

Our Office of the Actuary projects that the additional benefit expenditures from the Part B Trust Fund resulting from implementation of the hospital outpatient PPS for hospital outpatient services furnished on or after July 1, 2000, and the hospital outpatient provisions enacted by the BBRA 1999, are as follows:

| Fiscal year | Impact <br> (In millions of dollars) |
| :---: | :--- |
| 2000 ......................... | 490 |
| 2001 ........................ | 3,030 |


| Fiscal year | Impact (In millions of dollars) |
| :---: | :---: |
| 2002 | 3,520 |
| 2003 .................... | 4,230 |
| 2004 | 4,670 |

The primary objective of the hospital outpatient prospective payment system is to simplify the payment system and encourage hospital efficiency in providing outpatient services, while at the same time ensuring that payments are sufficient to compensate hospitals adequately for their legitimate costs. Another important goal of the new system is to reduce beneficiaries' share of outpatient payment to hospitals by freezing coinsurance amounts at an absolute level until they equal 20 percent of the total payment amounts.

We believe that implementation of the final PPS will ultimately further each of these goals while maintaining the financial viability of the hospital industry and ensuring access to high quality health care for Medicare beneficiaries. We expect that the provisions of this final rule with comment period will ensure that the outcomes of the PPS are reasonable and equitable while avoiding or minimizing unintended adverse consequences.

## D. Limitations of Our Analysis

The following quantitative analysis presents the projected effects of our policy changes resulting from comments, as well as statutory changes enacted by the BBRA 1999, on various hospital groups. We use the best data available. In addition, we do not make adjustments for future changes in such variables as volume and intensity. For this final rule with comment period, we are soliciting comments and information about the anticipated effects of the changes on hospitals resulting from implementation of the hospital outpatient provisions of the BBRA 1999, and our methodology for estimating them.

## E. Hospitals Included In and Excluded From the Prospective Payment System

The outpatient prospective payment system encompasses nearly all hospitals that participate in the Medicare program. However, Maryland hospitals that are paid under a cost containment waiver in accordance with section 1814(b)(3) of the Act are excluded from the PPS. Critical access hospitals (CAHs) are also excluded and are paid at cost under section $1834(\mathrm{~g})$ of the Act.
F. Quantitative Analysis of the Impact of Policy Changes on Payment Under the Hospital Outpatient PPS: Basis and Methodology of Estimates
We have analyzed the impact on hospital payment under the outpatient PPS. Our analysis compares the payment impact of PPS compared to current law. The definition and calculation of current law used in the impact analysis is the same used in estimating the conversion factor. That is, current law reflects pre-PPS payment methodologies in effect on January 1, 2000, and prior to July 1, 2000, which include the elimination of the formuladriven overpayment and application of the capital and operating cost reductions. A detailed explanation of the current law calculation can be found in section III.E.2.a.
The data used in developing the quantitative analyses presented below are taken from the CY 1996 cost and charge data and the most current provider-specific file that is used for payment purposes. Our analysis has several qualifications. First, we draw upon various sources for the data used to categorize hospitals in Table 2, below. In some cases, there is a degree of variation in the data from the different sources. We have attempted to construct these variables with the best available source overall. For individual hospitals, however, some miscategorizations are possible.
Using CY 1996 cost and charge data, we simulated payments using the prePPS and PPS payment methodologies. Although we used only singleprocedure/visit bills to determine APC relative payment weights, we used both single and multiple-procedure bills in the conversion factor and service mix calculations, regressions, and impact analyses. Both pre-PPS and PPS payment estimates include operating and capital costs, adjusted to the calendar year 1996 cost reporting period. We excluded Kaiser, New York Health and Hospital Corporation, and all-inclusive providers because reported charges on their cost reports are not actual charges. Cost-to-charge ratios for these hospitals are not comparable to all other hospitals. The excluded Maryland hospitals were not included in the calculation of the conversion factor and the simulations; however, we did include the 10 cancer hospitals that will be paid under the PPS.
We also trimmed outlier hospitals from the impact analysis because inclusion of hospitals with extremely high and low unit costs would not allow us to assess the impacts among the various classes of hospitals accurately.

First, we identified all of the outlier hospitals by using an edit of 3 standard deviations from the mean of the logged unit costs. Trimming the data in this manner ensures that only the hospitals with aberrantly high and low costs are eliminated from the impact analysis. In doing this, we removed 97 hospitals of which 41 hospitals had extremely low unit costs and 56 hospitals had extremely high unit costs. We conducted a thorough analysis of these hospitals to ensure that we did not remove any particular type of hospital (for example, teaching hospitals) that would further harm the integrity of the data. We speculate that many of these hospitals are not coding accurately, and we will continue to perform further analysis in this area following implementation of the PPS.

After we removed the 58 excluded Maryland hospitals, the all-inclusive rate hospitals, the statistical outlier hospitals, and hospitals for which we could not identify payment variables, we used the remaining 5,362 hospitals as the basis for our analysis. Table 2, Annual Impact of Outpatient Prospective Payment System in CY2000-CY2001, below, demonstrates the results of our analysis. The table categorizes hospitals by various geographic and special payment consideration groups to illustrate the varying impacts on different types of hospitals. The first column represents the number of hospitals in each category. The second column shows the hospitals' Medicare outpatient payments under the current (non-PPS) payment system as a percentage of the hospitals' total Medicare payment. The third and fourth columns show the impact of the PPS excluding the transitional corridor payments enacted by the BBRA 1999. Column three shows the percentage change in total Medicare outpatient payments comparing pre-PPS payments with payments under the PPS. The fourth column shows the change in total (outpatient and inpatient) Medicare payments resulting from implementation of the PPS for outpatient services. The fifth and sixth columns show the impact of the PPS including the transitional corridor payments enacted by the BBRA 1999. Column five shows the percentage change in Medicare outpatient payments comparing pre-PPS payments with payments under the PPS. Column six shows the change in total (outpatient and inpatient) Medicare payments resulting from implementation of the PPS for outpatient services.

The first row of Table 2 shows the overall impact on the 5,362 hospitals included in the analysis. We included
as much data as possible to the extent that we were able to capture all the provider information necessary to determine payment. Our estimates include the same set of services for both pre-PPS and PPS payments so that we could determine the impact of the PPS as accurately as possible. Because payment under the hospital outpatient PPS can only be determined if bills are accurately coded, the data upon which the impacts were developed do not reflect all CY 1996 hospital outpatient services, but only those that were coded using valid HCPCS codes.
The second row of Table 2 shows the overall impact of the PPS on the 4,828 hospitals that remain when we exclude psychiatric, long-term care, children's, and rehabilitation hospitals.

The next four rows of the table contain hospitals categorized according to their geographic location (all urban, which is subdivided into large urban and other urban, and rural). We include 2,665 hospitals located in urban areas (MSAs or NECMAs) in our analysis. Among these, 1,505 hospitals are located in large urban areas (populations over 1 million), and 1,160 hospitals are located in other urban areas (populations of 1 million or less). In addition, we include 2,160 hospitals located in rural areas in our analysis. The next two groupings are by bed-size categories, shown separately for urban and rural hospitals. The next category groups urban and rural hospitals by volume of outpatient services. We then show the distribution of urban and rural hospitals by regional census divisions.
The next three categories group hospitals according to whether or not they have residency programs (teaching hospitals that receive an indirect medical education (IME) adjustment), receive disproportionate share hospital (DSH) payments, or some combination of these two adjustments. In our analysis we show the impact of the PPS on the 3,738 nonteaching hospitals, the 821 teaching hospitals with fewer than 100 residents, and the 269 teaching hospitals with 100 or more residents.
In the DSH categories, hospitals are grouped according to their DSH payment status. The next category groups hospitals considered urban after geographic reclassification, in terms of whether they receive the IME adjustment, the DSH adjustment, both, or neither. The next five rows examine the impacts of the changes on rural hospitals by special payment groups (rural referral centers (RRCs), sole community hospitals/essential access community hospitals (SCHs/EACHs), Medicare dependent hospitals (MDHs), and hospitals that are both SCHs and

RRCs), as well as rural hospitals not receiving a special payment designation. The RRCs (164), SCH/EACHs (634), MDHs (358), and SCH and RRCs (56) shown here were not reclassified for purposes of the standardized amount.

The next grouping is based on type of ownership. These data are taken primarily from the FY 1996 Medicare cost report files, if available; otherwise, earlier cost report data are used.
The final two groups are specialty hospitals. The first set includes eye and ear hospitals, trauma hospitals (hospitals having a level one trauma center), and cancer hospitals, which are TEFRA hospitals. The last group lists all other TEFRA hospitals, specifically, rehabilitation, psychiatric, long-term care, and children's hospitals.
G. Estimated Impact of the New APC System (Includes Table 2, Annual Impact of Hospital Outpatient Prospective Payment System in CY2000-CY2001)
Column 3 compares our estimate of PPS payments without application of the BBRA 1999 transitional corridors, but incorporating policy changes and all other BBRA 1999 provisions contained in this final rule, to our estimate of payments under the current system. The percent differences shown in columns 3 and 4 between current and PPS payment (without the BBRA 1999 transitional corridors) reflect the impact of the BBRA 1999 outlier and pass-through payment adjustments and nonbudgetneutral hold-harmless provisions for cancer hospitals, as well as distributional differences attributable to variation in cost and charge structures among hospitals.
The percent changes in columns 5 and 6 are the result of comparing our estimate of PPS payments with application of the BBRA 1999 transitional corridors, as well as the statutory and policy changes contained in this final rule, to our estimate of payments under the pre-PPS system. Percent differences between the pre-PPS and the PPS payment (with the BBRA 1999 transition) reflect the combined impact of the transitional corridor adjustments, outlier and pass-through payment adjustments and the holdharmless provision for cancer hospitals, in addition to distributional differences attributable to variation in cost and charge structures among hospitals.
Basing the conversion factor on prePPS program and pre-PPS beneficiary payments and on budget-neutral outlier and pass-through adjustments results in no net change in payments to hospitals overall relative to pre-PPS payments. (As noted above, in section III.E. 2 of this
preamble, pursuant to section 201(l) of the BBRA 1999, we set the conversion factor by estimating pre-PPS rather than PPS copayments.) However, the BBRA hold-harmless provision for cancer hospitals results in a 0.2 percent increase in payments to hospitals overall because this provision is not budget neutral. Including the BBRA 1999 transitional corridor adjustments further increases payment to hospitals overall. We estimate that in calendar year 2000, payment will increase by an annual rate of 4.6 percent under the PPS compared to the pre-PPS payments.

Without the BBRA 1999 transitional corridor payments, the impact on shortterm acute care hospitals is negative for a substantial number of hospital classifications. That is, for certain groups of hospitals, payments under the PPS without the transitional corridor payments would be several percentage points below pre-PPS payments. For nearly all of these hospital groups, the BBRA 1999 transitional corridor payments mitigate this negative impact. In addition, hospital groups that experience net gains without the BBRA 1999 transitional corridor payments experience even greater gains with them. The reason is that even though the average impact for hospitals in these groups is positive, some individual hospitals experience net losses in payments and, thus, benefit from the transitional corridor payments. The hospital groups that gain without the transitional corridor payments receive even greater increases in payments with the transitional corridor payments. The following discussion highlights some of the changes in payments among hospital classifications.

Comparing the pre-PPS and PPS payment estimates, payment to lowvolume hospitals would decrease substantially without the BBRA 1999 transitional corridor payments (12.2 percent annually for rural and 7.7 percent annually for urban hospitals with fewer than 5,000 units of service). These hospitals experience a net gain with the BBRA 1999 transitional corridor payments ( 2.5 percent annually and 0.2 percent annually for lowvolume rural and urban hospitals, respectively), although these payment increases are relatively small compared to the 4.6 percent annual increase for hospitals overall. We believe several factors contribute to this outcome, including undercoding, lack of economies of scale, and the reliance on the median instead of the geometric mean in the calculation of APC weights. The majority of these hospitals (about 75 percent) are rural. For these small hospitals, some of the higher
standardized unit costs could be attributed to economies of scale. These low-volume rural hospitals also receive a greater percentage of their Medicare income (18.5 percent) from outpatient services than the national average (9.9 percent).
Major teaching hospitals, whose payments would decrease annually by 3.7 percentage points without the BBRA 1999 transitional corridor payments, gain 2.6 percent annually with the BBRA 1999 transitional corridor payments relative to pre-PPS payments. Major teaching hospitals receive less of their total Medicare income (9.1 percent) from outpatient services than the national average. This results in a 0.2 percent annual gain in their total Medicare payments. Minor teaching and nonteaching hospitals would experience marginal gains in outpatient payment without the BBRA 1999 transitional corridor payments. Payment to both hospital groups increases by 5.0 percent annually relative to the pre-PPS payment system.
Without the BBRA 1999 transitional corridor payments, hospitals with a high percentage of low-income patients (disproportionate share patient percentage greater than or equal to 0.35 ) would have a 2.5 percent annual decrease in payment relative to pre-PPS payments. But payments to these hospitals increase annually by 3.5 percent relative to pre-PPS payments with the BBRA 1999 transitional corridor payments. These hospitals have lower than average volume, and, like major teaching hospitals, receive a smaller than average percentage of their Medicare income from outpatient services. Thus, their total Medicare payments increase marginally, by 0.3 percent, with the BBRA 1999 transitional corridor payments.

Without the BBRA 1999 adjustments, payment to rural hospitals would decrease 1.8 percent annually and payment to large urban hospitals would decrease 0.3 percent annually, while payment to other urban hospitals would increase 1.8 percent annually relative to pre-PPS payments. These hospitals all experience net gains in PPS payment with the BBRA 1999 transitional corridor payments, at an annual rate of 4.4 percent, 4.3 percent, and 5.1 percent, respectively. Even though rural hospitals receive a greater percentage of their Medicare income (14.7 percent) from outpatient services compared to the national average, their total Medicare payments increase by only a fraction, 0.6 percent.
Negative impacts for urban hospitals in the Mid-Atlantic and the West North Central regions are also reversed under
the BBRA 1999 transitional corridor payments, changing from -3.4 percent to 2.4 percent on an annual basis, and from -3.5 percent to 2.5 percent on an annual basis, respectively. Similarly, rural hospitals in nearly all census regions experience net increases in payment relative to pre-PPS payments with the BBRA 1999 transitional corridor payments.
The impact on TEFRA hospitals is shown separately at the end of the table. The TEFRA hospitals were not included in determining the impact on any of the other categories discussed above (for example, geographic location, bed size, volume, etc.). These hospitals demonstrated a very low service mix, but an average unit cost that approximates the national average. We believe that undercoding or billing an all-inclusive rate could account for their low-volume, low-service mix, and average cost per unit. We expect that
once these hospitals begin to code services accurately under the PPS, payments will more closely approximate pre-PPS payments.
If the effect of the BBRA 1999 transition payments were removed, differences between pre-PPS payments and PPS payments among hospitals would still exist. These distributional differences are the result of many factors. First, cost variations among hospitals result in differences between pre-PPS payments and PPS payments, and charge structure variations result in differences between pre-PPS payments and PPS beneficiary copayment amounts. Hospitals whose costs are low relative to payment would gain under the PPS even without the BBRA 1999 transitional corridor payments. Because the transitional corridor payments are not budget neutral, these hospitals continue to gain relative to pre-PPS payments.

Redistributions may also occur as a result of current payment methods. Total Medicare outpatient payments are less than reported total costs because (in addition to the 5.8 and 10 percent reductions for operating and capital costs) the blended payment methods applicable to many surgical and diagnostic services often result in payments that are less than reported costs. Other services such as medical visits, chemotherapy services, and nonASC approved surgeries are paid based on hospital costs. The new system redistributes the current total Medicare payments, based in part on cost-based payments and in part on blended payment amounts, across all services. Hospitals, in the aggregate, will receive proportionately less for services that are currently paid based on costs, and more for services that had been paid under blended payment methods.

Table 2. Annual Impact Of Hospital Outpatient Prospective Payment System In CY2000-CY2001

|  | Number of hospitals <br> (1) | Outpatient percent(2) | Excluding BBRA transitional corridors ${ }^{1}$ |  | Including BBRA transitional corridors |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  |  | Percent change in Medicare outpatient payments ${ }^{3}$ <br> (3) | Percent change in total Medicare payments <br> (4) | Percent change in Medicare outpatient payments ${ }^{3}$ <br> (5) | Percent change in total Medicare payments <br> (6) |
| ALL HOSPITALS | 5,362 | 9.9 | 0.2 | 0.0 | 4.6 | 0.5 |
| NON-TEFRA HOSPITALS | 4,828 | 10 | 0.1 | 0.0 | 4.6 | 0.5 |
| URBAN HOSPS ${ }^{2}$ | 2,665 | 9.3 | 0.6 | 0.1 | 4.6 | 0.4 |
| LARGE URBAN ${ }^{2}$ (GT 1 MILL.) ................................ | 1,505 | 9.1 | -0.3 | 0.0 | 4.3 | 0.4 |
| OTHER URBAN ${ }^{2}$ (LE 1 MILL.) ................................. | 1,160 | 9.7 | 1.8 | 0.2 | 5.1 | 0.5 |
| RURAL HOSPS ...................................................... | 2,160 | 14.7 | -1.8 | -0.3 | 4.4 | 0.6 |
| BEDS (URBAN): ${ }^{2}$ |  |  |  |  |  |  |
| 0-99 BEDS | 672 | 14.9 | 0.6 | 0.1 | 4.6 | 0.7 |
| 100-199 BEDS | 924 | 10.5 | 1.3 | 0.1 | 5.2 | 0.5 |
| 200-299 BEDS ................................................. | 533 | 9.2 | 0.8 | 0.1 | 4.4 | 0.4 |
| 300-499 BEDS | 399 | 8.5 | 1.8 | 0.2 | 5.2 | 0.4 |
| $500+$ BEDS | 137 | 8.4 | -2.9 | -0.2 | 2.8 | 0.2 |
| BEDS (RURAL): |  |  |  |  |  |  |
| 0-49 BEDS ................................................. | 1,170 | 19.5 | -8.5 | -1.7 | 3.3 | 0.6 |
| 50-99 BEDS .................................................. | 615 | 15.5 | -2.7 | -0.4 | 4.4 | 0.7 |
| 100-149 BEDS ................................................ | 223 | 13.3 | -0.2 | 0.0 | 3.8 | 0.5 |
| 150-199 BEDS ................................................ | 81 | 13 | 2.5 | 0.3 | 5.5 | 0.7 |
| 200 + BEDS .... | 71 | 11.6 | 2.7 | 0.3 | 6.1 | 0.7 |
| VOLUME (URBAN): |  |  |  |  |  |  |
| LT 5,000 | 349 | 12 | -7.7 | -0.9 | 0.2 | 0.0 |
| 5,000-10,999 | 504 | 9.8 | 0.0 | 0.0 | 4.2 | 0.4 |
| 11,000-20,999 ................................................. | 596 | 9.1 | 0.1 | 0.0 | 4.4 | 0.4 |
| 21,000-42,999 ................................................. | 773 | 8.8 | 1.3 | 0.1 | 4.9 | 0.4 |
| GT 42,999 | 443 | 9.7 | 0.4 | 0.0 | 4.6 | 0.4 |
| VOLUME (RURAL): |  |  |  |  |  |  |
| LT 5,000 .......................................................... | 1,049 | 18.5 | - 12.2 | -2.3 | 2.5 | 0.5 |
| 5,000-10,999 ................................................... | 595 | 15.2 | -5.2 | -0.8 | 2.9 | 0.4 |
| 11,000-20,999 .................................................... | 322 | 13.8 | 0.1 | 0.0 | 4.7 | 0.6 |
| 21,000-42,999 ................................................... | 173 | 13.6 | 2.4 | 0.3 | 5.7 | 0.8 |
| GT 42,999 ...................................................... | 21 | 13.2 | 3.0 | 0.4 | 6.8 | 0.9 |
| REGION (URBAN): ${ }^{3}$ |  |  |  |  |  |  |
| NEW ENGLAND ............................................... | 146 | 10.7 | 3.8 | 0.4 | 6.7 | 0.7 |
| MIDDLE ATLANTIC .......................................... | 393 | 8.4 | -3.4 | -0.3 | 2.4 | 0.2 |
| SOUTH ATLANTIC ........................................... | 401 | 8.6 | 0.3 | 0.0 | 4.2 | 0.4 |
| EAST NORTH CENT. ........................................ | 465 | 10.7 | 1.0 | 0.1 | 4.5 | 0.5 |

Table 2. Annual Impact Of Hospital Outpatient Prospective Payment System In Cy2000-Cy2001—Continued

|  | Number of hospitals <br> (1) | Outpatient percent <br> (2) | Excluding BBRA transitional corridors ${ }^{1}$ |  | Including BBRA transitional corridors |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  |  | Percent change in Medicare outpatient payments ${ }^{3}$ <br> (3) | Percent change in total Medicare payments <br> (4) | Percent change in Medicare outpatient payments ${ }^{3}$ <br> (5) | Percent change in total Medicare payments <br> (6) |
| EAST SOUTH CENT. | 161 | 7.9 | 1.8 | 0.1 | 4.6 | 0.4 |
| WEST NORTH CENT. | 183 | 9.5 | 0.9 | 0.1 | 4.9 | 0.5 |
| WEST SOUTH CENT. | 335 | 9.7 | -2.7 | -0.3 | 2.5 | 0.2 |
| MOUNTAIN | 123 | 10.2 | 3.1 | 0.3 | 6.1 | 0.6 |
| PACIFIC. | 423 | 9.4 | 5.6 | 0.5 | 8.6 | 0.8 |
| PUERTO RICO | 35 | 6.6 | 10.8 | 0.7 | 13.2 | 0.9 |
| REGION (RURAL): |  |  |  |  |  |  |
| NEW ENGLAND | 53 | 17.2 | -3.2 | -0.6 | 3.3 | 0.6 |
| MIDDLE ATLANTIC | 80 | 13.6 | 7.1 | 1.0 | 10.1 | 1.4 |
| SOUTH ATLANTIC | 285 | 11.8 | -1.8 | -0.2 | 3.6 | 0.4 |
| EAST NORTH CENT. | 282 | 15.7 | -1.2 | -0.2 | 4.3 | 0.7 |
| EAST SOUTH CENT. | 260 | 11.1 | 0.1 | 0.0 | 4.9 | 0.5 |
| WEST NORTH CENT. | 508 | 19.8 | -5.2 | -1.0 | 3.0 | 0.6 |
| WEST SOUTH CENT. | 337 | 14.2 | -5.7 | -0.8 | 3.0 | 0.4 |
| MOUNTAIN | 213 | 16.9 | -3.4 | -0.6 | 4.7 | 0.8 |
| PACIFIC | 140 | 15.9 | 0.7 | 0.1 | 6.3 | 1.0 |
| PUERTO RICO | 2 | 6.6 | 32.1 | 2.1 | 32.1 | 2.1 |
| TEACHING STATUS: |  |  |  |  |  |  |
| NON-TEACHING | 3,738 | 11.3 | 0.5 | 0.1 | 5.0 | 0.6 |
| MINOR | 821 | 9.1 | 1.6 | 0.1 | 5.0 | 0.5 |
| MAJOR | 269 | 9.1 | -3.7 | -0.3 | 2.6 | 0.2 |
| DSH PATIENT PERCENT: |  |  |  |  |  |  |
| 0 | 101 | 10.9 | -5.8 | -0.6 | 0.7 | 0.1 |
| GT 0-0.10 | 1,139 | 10.5 | 0.8 | 0.1 | 4.6 | 0.5 |
| 0.10-0.16 | 986 | 11 | 2.0 | 0.2 | 5.6 | 0.6 |
| 0.16-0.23 | 880 | 10.1 | 0.8 | 0.1 | 4.9 | 0.5 |
| 0.23-0.35 | 855 | 9.5 | -1.5 | -0.1 | 3.7 | 0.4 |
| GE 0.35 | 867 | 9.2 | -2.5 | -0.2 | 3.5 | 0.3 |
| URBAN IME/DSH: ${ }^{2}$ ( ${ }^{\text {a }}$ |  |  |  |  |  |  |
| IME \& DSH | 994 | 9 | -0.4 | 0.0 | 4.1 | 0.4 |
| IME/NO DSH | 17 | 9.2 | -3.6 | -0.3 | 1.1 | 0.1 |
| NO IME/DSH | 1,611 | 9.9 | 1.9 | 0.2 | 5.4 | 0.5 |
| NO IME/NO DSH | 43 | 14.7 | -8.2 | -1.2 | -0.3 | 0.0 |
| RURAL HOSP. TYPES: |  |  |  |  |  |  |
| NO SPECIAL STATUS | 864 | 15 | -2.2 | -0.3 | 4.4 | 0.7 |
| RRC ..... | 164 | 12.3 | 5.0 | 0.6 | 7.3 | 0.9 |
| SCH/EACH | 634 | 16.5 | -7.7 | -1.3 | 2.2 | 0.4 |
| MDH | 358 | 18.3 | -5.4 | -1.0 | 3.5 | 0.6 |
| SCH AND RRC | 56 | 13.9 | -1.4 | -0.2 | 3.1 | 0.4 |
| TYPE OF OWNERSHIP: |  |  |  |  |  |  |
| VOLUNTARY | 2,816 | 9.9 | 0.6 | 0.1 | 4.7 | 0.5 |
| PROPRIETARY ................................................ | 752 | 8.3 | -0.1 | 0.0 | 4.7 | 0.4 |
| GOVERNMENT | 1,260 | 12.2 | -2.3 | -0.3 | 3.6 | 0.4 |
| SPECIALTY HOSPITALS: |  |  |  |  |  |  |
| EYE AND EAR ................................................. | 10 | 31.1 | 20.1 | 6.3 | 20.2 | 6.3 |
| TRAUMA | 159 | 9.1 | -1.2 | -0.1 | 4.0 | 0.4 |
| CANCER | 10 | 22 | 0.8 | 0.2 | 0.8 | 0.2 |
| TEFRA HOSPITALS (NOT INCLUDED ON OTHER LINES): |  |  |  |  |  |  |
| REHAB ........................................................... | 147 | 3.7 | -9.4 | -0.3 | 1.7 | 0.1 |
| PSYCH ........................................................... | 281 | 9 | 21.3 | 1.9 | 27.9 | 2.5 |
| LTC ............................................................... | 65 | 3.7 | -15.3 | -0.6 | -1.7 | -0.1 |
| CHILDREN ........................................................ | 41 | 16.5 | -11.9 | -2.0 | -3.2 | -0.5 |

[^122]
## X. Federalism

We have examined this rule in accordance with Executive Order 13132, Federalism, and have determined that this final rule will not have any negative impact on the rights, roles, and responsibilities of State, local or Tribal governments.

## XI. Waiver of Proposed Rulemaking

We ordinarily publish a notice of proposed rulemaking in the Federal Register and invite public comment on the proposed rule. The notice of proposed rulemaking includes a reference to the legal authority under which the rule is proposed, and the terms and substance of the proposed rule or a description of the subjects and issues involved. This procedure can be waived, however, if an agency finds good cause that a notice-and-comment procedure is impracticable, unnecessary, or contrary to the public interest, and incorporates a statement of the finding and its reasons in the rule. We find that the circumstances surrounding this rule make it impracticable to pursue a process of notice-and-comment rulemaking before the provisions of this rule take effect.
The BBRA 1999 was enacted on November 29, 1999. This final rule incorporates the following hospital outpatient PPS provisions in the BBRA 1999: outlier adjustment for high cost cases; transitional pass-through payment adjustments for additional costs (over the payments for APCs otherwise made) for new medical devices, drugs, and biologicals; definition of APCs so that the variation of costs of items within an APC is subject to certain limits; establishment of "transitional corridors" for the first $3^{1 / 2}$ years of the new system that limit losses hospitals might otherwise face; payment for implantable devices under the hospital outpatient PPS, rather than under the Durable Medical Equipment Fee Schedule; limitation of the copayment on an outpatient procedure to the amount of the inpatient hospital deductible; requirement to review annually the APC groups, relative weights, and wage and other adjustments; and calculation of the conversion factor in a budget-neutral manner, eliminating the 5.7 percent reduction indicated in the proposed rule.
As discussed earlier in this rule, July 1,2000 is the earliest date on which we can feasibly implement the PPS. The provisions of the BBRA 1999, enacted on November 29, 1999, made numerous refinements to the PPS. With respect to the BBRA 1999 provisions, it would
have been impracticable to complete notice and comment procedures by July 1, 2000. Given the limited timeframe, given the nature and scope of the BBRA 1999 refinements, and given the time required to complete notice and comment rulemaking (to develop proposed policies, draft the proposed rule, provide a 60 -day public comment period, consider public comments, develop final policies, draft a final rule), it would not have been possible to issue this document as a proposed rule and issue a final rule by July 1.

In addition, it would not be feasible to implement the hospital outpatient PPS without the BBRA 1999 provisions, not only because of the nature of the BBRA 1999 provisions, but also because section 201(m) of the BBRA 1999 states: "Except as provided in this section, the amendments made by this section shall be effective as if included in the enactment of BBA." Therefore, if we undertook prior notice and comment procedures with respect to the BBRA 1999 provisions, then (because such procedures could not be completed by July 1, 2000) the PPS would not be implemented by July 1, 2000.

Accordingly, we find good cause to waive the procedures for prior notice and comment with respect to the provisions of this document that implement the BBRA 1999 refinements to hospital outpatient PPS. We are providing a 60-day period for public comment with respect to the provisions of this final rule with comment period that implement the BBRA refinements. We are not accepting comments with respect to the other aspects of this document (for which the public has already had an extensive opportunity to comment).

## List of Subjects

42 CFR Part 409
Health facilities, Medicare.

## 42 CFR Part 410

Health facilities, Health professions, Kidney diseases, Laboratories, Medicare, Rural areas, X-rays.

## 42 CFR Part 411

Kidney diseases, Medicare, Reporting and recordkeeping requirements.

## 42 CFR Part 412

Administrative practice and procedure, Health facilities, Medicare, Puerto Rico, Reporting and recordkeeping requirements.

## 42 CFR Part 413

Health facilities, Kidney diseases, Medicare, Puerto Rico, Reporting and recordkeeping requirements.

## 42 CFR Part 419

Health facilities, Hospitals, Medicare.

## 42 CFR Part 424

Emergency medical services, Health facilities, Health professions, Medicare.

## 42 CFR Part 489

Health facilities, Medicare, Reporting and recordkeeping requirements.

## 42 CFR Part 498

Administrative practice and procedure, Health facilities, Health professions, Medicare, Reporting and recordkeeping requirements.

## 42 CFR Part 1003

Administrative practice and procedure, Archives and records, Grant program-social programs, Maternal and Child Health, Medicaid, Medicare, Penalties.
For the reasons set forth in the preamble, 42 CFR chapter IV is amended as follows:

## PART 409—HOSPITAL INSURANCE BENEFITS

A. Part 409 is amended as set forth below:

1. The authority citation for part 409 continues to read as follows:
Authority: Secs. 1102 and 1871 of the Social Security Act (42 U.S.C. 1302 and 1395hh).

## Subpart B-Inpatient Hospital Services and Inpatient Critical Access Hospital Services

2. In § 409.10, paragraph (b) is revised to read as follows:

## §409.10 Included services.

(b) Inpatient hospital services does not include the following types of services:
(1) Posthospital SNF care, as described in $\S 409.20$, furnished by a hospital or a critical access hospital that has a swing-bed approval.
(2) Nursing facility services, described in §440.155 of this chapter, that may be furnished as a Medicaid service under title XIX of the Act in a swing-bed hospital that has an approval to furnish nursing facility services.
(3) Physician services that meet the requirements of $\S 415.102(\mathrm{a})$ of this chapter for payment on a fee schedule basis.
(4) Physician assistant services, as defined in section 1861(s)(2)(K)(i) of the Act.
(5) Nurse practitioner and clinical nurse specialist services, as defined in section 1861(s)(2)(K)(ii) of the Act.
(6) Certified nurse mid-wife services, as defined in section $1861(\mathrm{gg})$ of the Act.
(7) Qualified psychologist services, as defined in section 1861(ii) of the Act.
(8) Services of an anesthetist, as defined in § 410.69 of this chapter.

## PART 410-SUPPLEMENTARY MEDICAL INSURANCE (SMI) BENEFITS

B. Part 410 is amended as set forth below:

1. The authority citation for part 410 continues to read as follows:
Authority: Secs. 1102 and 1871 of the Social Security Act (42 U.S.C. 1302 and 1395hh).

## Subpart A-General Provisions

2. In §410.2, the introductory text is republished, the definition of
"Community mental health center (CMHC)" is revised, and the definitions of "Encounter" and "Outpatient" are added in alphabetical order to read as follows:

## §410.2 Definitions.

As used in this part-
Community mental health center (CMHC) means an entity that-
(1) Provides outpatient services, including specialized outpatient services for children, the elderly, individuals who are chronically mentally ill, and residents of its mental health service area who have been discharged from inpatient treatment at a mental health facility;
(2) Provides 24-hour-a-day emergency care services;
(3) Provides day treatment or other partial hospitalization services, or psychosocial rehabilitation services;
(4) Provides screening for patients being considered for admission to State mental health facilities to determine the appropriateness of this admission; and
(5) Meets applicable licensing or certification requirements for CMHCs in the State in which it is located.
Encounter means a direct personal contact between a patient and a physician, or other person who is authorized by State licensure law and, if applicable, by hospital or CAH staff bylaws, to order or furnish hospital services for diagnosis or treatment of the patient.

Outpatient means a person who has not been admitted as an inpatient but who is registered on the hospital or CAH records as an outpatient and receives services (rather than supplies
alone) directly from the hospital or CAH.

## Subpart B-Medical and Other Health Services

3. In §410.27:
A. The section heading is revised;
B. The introductory text to paragraph
(a) is revised;
C. The introductory text to paragraph (a)(1) is republished;
D. The word "and" at the end of paragraph (a)(1)(i) is removed; and
E. New paragraphs (a)(1)(iii), (e), and (f) are added to read as follows:
§410.27 Outpatient hospital services and supplies incident to a physician service: Conditions.
(a) Medicare Part B pays for hospital services and supplies furnished incident to a physician service to outpatients, including drugs and biologicals that cannot be self-administered, if-
(1) They are furnished-
(iii) In the hospital or at a location (other than an RHC or an FQHC) that HCFA designates as a department of a provider under § 413.65 of this chapter; and
(e) Services furnished by an entity other than the hospital are subject to the limitations specified in §410.42(a).
(f) Services furnished at a location (other than an RHC or an FQHC) that HCFA designates as a department of a provider under $\S 413.65$ of this chapter must be under the direct supervision of a physician. "Direct supervision" means the physician must be present and on the premises of the location and immediately available to furnish assistance and direction throughout the performance of the procedure. It does not mean that the physician must be present in the room when the procedure is performed.
4. In §410.28, paragraph (a)(4) is removed, paragraph (c) is redesignated as paragraph (d), and new paragraphs (c) and (e) are added to read as follows:
§410.28 Hospital or CAH diagnostic services furnished to outpatients: Conditions.
(c) Diagnostic services furnished by an entity other than the hospital or CAH are subject to the limitations specified in §410.42(a).
(e) Medicare Part B makes payment under section 1833(t) of the Act for diagnostic services furnished at a facility (other than an RHC or an FQHC)
that HCFA designates as having provider-based status only when the diagnostic services are furnished under the appropriate level of physician supervision specified by HCFA in accordance with the definitions in $\S 410.32(\mathrm{~b})(3)(\mathrm{i})$, (b)(3)(ii), and (b)(3)(iii). Under general supervision at a facility accorded provider-based status, the training of the nonphysician personnel who actually perform the diagnostic procedure and the maintenance of the necessary equipment and supplies are the continuing responsibility of the facility.
5. A new $\S 410.42$ is added to read as follows:

## §410.42 Limitations on coverage of

 certain services furnished to hospital outpatients.(a) General rule. Except as provided in paragraph (b) of this section, Medicare Part B does not pay for any item or service that is furnished to a hospital outpatient (as defined in § 410.2) during an encounter (as defined in $\S 410.2$ ) by an entity other than the hospital unless the hospital has an arrangement (as defined in $\S 409.3$ of this chapter) with that entity to furnish that particular service to its patients. As used in this paragraph, the term "hospital" includes a CAH.
(b) Exception. The limitations stated in paragraph (a) of this section do not apply to the following services:
(1) Physician services that meet the requirements of $\S 415.102$ (a) of this chapter for payment on a fee schedule basis.
(2) Physician assistant services, as defined in section 1861(s)(2)(K)(i) of the Act.
(3) Nurse practitioner and clinical nurse specialist services, as defined in section 1861(s)(2)(K)(ii) of the Act.
(4) Certified nurse mid-wife services, as defined in section $1861(\mathrm{gg})$ of the Act.
(5) Qualified psychologist services, as defined in section 1861(ii) of the Act.
(6) Services of an anesthetist, as defined in §410.69.
(7) Services furnished to SNF residents as defined in $\S 411.15(\mathrm{p})$ of this chapter.
6. In § 410.43, paragraph (b) is revised to read as follows:

## §410.43 Partial hospitalization services: Conditions and exclusions.

(b) The following services are separately covered and not paid as partial hospitalization services:
(1) Physician services that meet the requirements of §415.102(a) of this chapter for payment on a fee schedule basis.
(2) Physician assistant services, as defined in section 1861(s)(2)(K)(i) of the Act.
(3) Nurse practitioner and clinical nurse specialist services, as defined in section 1861(s)(2)(K)(ii) of the Act.
(4) Qualified psychologist services, as defined in section 1861(ii) of the Act.
(5) Services furnished to SNF residents as defined in §411.15(p) of this chapter.

## PART 411-EXCLUSIONS FROM MEDICARE AND LIMITATIONS ON MEDICARE PAYMENT

C. Part 411 is amended as set forth below:

1. The authority citation for part 411 continues to read as follows:

Authority: Secs. 1102 and 1871 of the Social Security Act (42 U.S.C. 1302 and 1395hh).

## Subpart A-General Exclusions and Exclusion of Particular Services

## 2. In § 411.15:

A. The introductory text is republished;
B. The section heading to paragraph $(\mathrm{m})$ is revised;
C. Paragraph (m)(1) is revised;
D. Paragraph (m)(2) is redesignated as paragraph (m)(3);
E. The introductory text to newly redesignated paragraph (m)(3) is republished;
F. Newly redesignated paragraphs $(\mathrm{m})(3)(\mathrm{iii}),(\mathrm{m})(3)(\mathrm{iv})$, and (m)(3)(v) are redesignated as paragraphs (m)(3)(iv), $(\mathrm{m})(3)(\mathrm{v})$, and (m)(3)(vi), respectively; and
G. New paragraphs (m)(2) and (m)(3)(iii) are added to read as follows:
§411.15 Particular services excluded from coverage.
The following services are excluded from coverage:
(m) Services to hospital patients-(1) Basic rule. Except as provided in paragraph (m)(3) of this section, any service furnished to an inpatient of a hospital or to a hospital outpatient (as defined in § 410.2 of this chapter) during an encounter (as defined in $\S 410.2$ of this chapter) by an entity other than the hospital unless the hospital has an arrangement (as defined in § 409.3 of this chapter) with that entity to furnish that particular service to the hospital's patients. As used in this paragraph (m)(1), the term
"hospital" includes a CAH.
(2) Scope of exclusion. Services subject to exclusion from coverage under the provisions of this paragraph
(m) include, but are not limited to, clinical laboratory services; pacemakers and other prostheses and prosthetic devices (other than dental) that replace all or part of an internal body organ (for example, intraocular lenses); artificial limbs, knees, and hips; equipment and supplies covered under the prosthetic device benefits; and services incident to a physician service.
(3) Exceptions. The following services are not excluded from coverage:
(iii) Nurse practitioner and clinical nurse specialist services, as defined in section 1861(s)(2)(K)(ii) of the Act.

## PART 412—PROSPECTIVE PAYMENT SYSTEMS FOR INPATIENT HOSPITAL SERVICES

D. Part 412 is amended as set forth below:

1. The authority citation for part 412 continues to read as follows:

Authority: Secs. 1102 and 1871 of the Social Security Act (42 U.S.C. 1302 and 1395hh).

## Subpart C-Conditions for Payment Under the Prospective Payment Systems for Inpatient Operating Costs and Inpatient Capital-Related Costs

2. In §412.50, paragraphs (a) and (b) are revised to read as follows:
§412.50 Furnishing of inpatient hospital services directly or under arrangements.
(a) The applicable payments made under the prospective payment systems, as described in subparts H and M of this part, are payment in full for all inpatient hospital services, as defined in $\S 409.10$ of this chapter. Inpatient hospital services do not include the following types of services:
(1) Physician services that meet the requirements of $\S 415.102$ (a) of this chapter for payment on a fee schedule basis.
(2) Physician assistant services, as defined in section 1861(s)(2)(K)(i) of the Act.
(3) Nurse practitioner and clinical nurse specialist services, as defined in section 1861(s)(2)(K)(ii) of the Act.
(4) Certified nurse mid-wife services, as defined in section $1861(\mathrm{gg})$ of the Act.
(5) Qualified psychologist services, as defined in section 1861 (ii) of the Act.
(6) Services of an anesthetist, as defined in $\S 410.69$ of this chapter.
(b) HCFA does not pay any provider or supplier other than the hospital for services furnished to a beneficiary who is an inpatient, except for the services
described in paragraphs (a)(1) through (a)(6) of this section.

## PART 413-PRINCIPLES OF REASONABLE COST REIMBURSEMENT; PAYMENT FOR END-STAGE RENAL DISEASE SERVICES; PROSPECTIVELY DETERMINED PAYMENT RATES FOR SKILLED NURSING FACILITIES

E. Part 413 is amended as set forth below:

1. The authority citation for part 413 continues to read as follows:
Authority: Secs. 1102, 1812(d), 1814(b), 1815, 1833(a), (i), and (n), 1871, 1881, 1883, and 1886 of the Social Security Act ( 42 U.S.C. 1302, 1395f(b), 1395g, 13951, 13951(a), (i), and (n), 1395x(v), 1395hh, 1395rr, 1395tt, and 1395 ww ).

## Subpart A—Introduction and General Rules

## §413.1 [Amended]

2. In §413.1, paragraph (a)(2)(viii) is removed.

## Subpart B—Accounting Records and Reports

3. In $\S 413.24$, the heading to paragraph (d) is republished, and a new paragraph (d)(6) is added to read as follows:

## §413.24 Adequate cost data and cost

 finding.(d) Cost finding methods. * * *
(6) Management contracts. (i) If the main provider purchases services for a department of the provider or a provider-based entity through a management contract or otherwise directly assigns costs to the department or entity, the like costs of the main provider must be carved out to ensure that they are not allocated to the department of the provider or providerbased entity. However, if the like costs of the main provider cannot be separately identified, the costs of the services purchased through a management contract must be included in the main provider's administrative and general costs and allocated among the provider's overall statistics.
(ii) Costs of free-standing entities may not be shown in the provider's trial balance for purposes of stepping down overhead costs to these entities. The provider must develop detailed work papers showing the exact cost of the services (including overhead) provided to or by the free-standing entity and show those carved out costs as
nonreimbursable cost centers in the provider's trial balance.

## Subpart E-Payments to Providers

4. A new $\S 413.65$ is added to read as follows:
§413.65 Requirements for a determination that a facility or an organization has provider-based status.
(a) Scope and definitions. (1) Scope. This section applies to all facilities or organizations for which provider-based status is sought, including remote locations of hospitals, as defined in paragraph (a)(2) of this section and satellite facilities as defined in $\S 412.22(\mathrm{~h})(1)$ and $\S 412.25(\mathrm{e})(1)$ of this chapter, other than ESRD facilities. Determinations for ESRD facilities are made under § 413.174 of this chapter.
(2) Definitions. In this subpart E, unless the context indicates otherwise-

Campus means the physical area immediately adjacent to the provider's main buildings, other areas and structures that are not strictly contiguous to the main buildings but are located within 250 yards of the main buildings, and any other areas determined on an individual case basis, by the HCFA regional office, to be part of the provider's campus.
Department of a provider means a facility or organization or a physician office that is either created by, or acquired by, a main provider for the purpose of furnishing health care services of the same type as those furnished by the main provider under the name, ownership, and financial and administrative control of the main provider, in accordance with the provisions of this section. A department of a provider may not be licensed to provide health care services in its own right, may not by itself be qualified to participate in Medicare as a provider under $\S 489.2$ of this chapter, and Medicare conditions of participation do not apply to a department as an independent entity. For purposes of this part, the term "department of a provider" does not include an RHC or, except as specified in paragraph (m)(1) of this section, an FQHC.
Free-standing facility means an entity that furnishes health care services to Medicare beneficiaries and that is not integrated with any other entity as a main provider, a department of a provider, remote location of a hospital, satellite facility, or a provider-based entity.
Main provider means a provider that either creates, or acquires ownership of, another entity to deliver additional
health care services under its name, ownership, and financial and administrative control.

Provider-based entity means a provider of health care services, or an RHC or an FQHC as defined in $\S 405.2401$ (b) of this chapter, that is either created by, or acquired by, a main provider for the purpose of furnishing health care services of a different type from those of the main provider under the name, ownership, and administrative and financial control of the main provider, in accordance with the provisions of this section.

Provider-based status means the relationship between a main provider and a provider-based entity or a department of a provider, remote location of a hospital, or satellite facility, that complies with the provisions of this section.

Remote location of a hospital means a facility or an organization that is either created by, or acquired by, a hospital that is a main provider for the purpose of furnishing inpatient hospital services under the name, ownership, and financial and administrative control of the main provider, in accordance with the provisions of this section. A remote location of a hospital may not be licensed to provide inpatient hospital services in its own right, and Medicare conditions of participation do not apply to a remote location of a hospital as an independent entity. For purposes of this part, the term "remote location of a hospital" does not include a satellite facility as defined in § 412.22(h)(1) and § $412.25(\mathrm{e})(1)$ of this chapter.
(b) Responsibility for obtaining provider-based determinations. (1) A facility or organization is not entitled to be treated as provider-based simply because it or the main provider believe it is provider-based.
(2) A main provider or a facility or organization must contact HCFA and the facility or organization must be determined by HCFA to be providerbased before the main provider bills for services of the facility or organization as if the facility or organization were provider-based, or before it includes costs of those services on its cost report.
(3) A facility that is not located on the campus of a hospital and is used as a site of physician services of the kind ordinarily furnished in physician offices will be presumed to be a free-standing facility, unless it is determined by HCFA to have provider-based status.
(c) Reporting. (1) A main provider that creates or acquires a facility or organization for which it wishes to claim provider-based status, including any physician offices that a hospital wishes to operate as a hospital
outpatient department or clinic, must report its acquisition of the facility or organization to HCFA if the facility or organization is located off the campus of the provider, or inclusion of the costs of the facility or organization in the provider's cost report would increase the total costs on the provider's cost report by at least 5 percent, and must furnish all information needed for a determination as to whether the facility or organization meets the requirements in paragraph (d) of this section for provider-based status.
(2) A main provider that has had one or more facilities or organizations considered provider-based also must report to HCFA any material change in the relationship between it and any provider-based facility or organization, such as a change in ownership of the facility or organization or entry into a new or different management contract that could affect the provider-based status of the facility or organization.
(d) Requirements. An entity must meet all of the following requirements to be determined by HCFA to have provider-based status.
(1) Licensure. The department of the provider, remote location of a hospital, or satellite facility and the main provider are operated under the same license, except in areas where the State requires a separate license for the department of the provider, remote location of a hospital, or satellite facility, or in States where State law does not permit licensure of the provider and the prospective department of the provider, remote location of a hospital, or satellite facility under a single license. If a State health facilities' cost review commission or other agency that has authority to regulate the rates charged by hospitals or other providers in a State finds that a particular facility or organization is not part of a provider, HCFA will determine that the facility or organization does not have providerbased status.
(2) Operation under the ownership and control of the main provider. The facility or organization seeking provider-based status is operated under the ownership and control of the main provider, as evidenced by the following:
(i) The business enterprise that constitutes the facility or organization is 100 percent owned by the provider.
(ii) The main provider and the facility or organization seeking status as a department of the provider, remote location of a hospital, or satellite facility have the same governing body.
(iii) The facility or organization is operated under the same organizational documents as the main provider. For
example, the facility or organization seeking provider-based status must be subject to common bylaws and operating decisions of the governing body of the provider where it is based.
(iv) The main provider has final responsibility for administrative decisions, final approval for contracts with outside parties, final approval for personnel actions, final responsibility for personnel policies (such as fringe benefits/code of conduct), and final approval for medical staff appointments in the facility or organization.
(3) Administration and supervision. The reporting relationship between the facility or organization seeking provider-based status and the main provider must have the same frequency, intensity, and level of accountability that exists in the relationship between the main provider and one of its departments, as evidenced by compliance with all of the following requirements:
(i) The facility or organization is under the direct supervision of the main provider.
(ii) The facility or organization is operated under the same monitoring and oversight by the provider as any other department of the provider, and is operated just as any other department of the provider with regard to supervision and accountability. The facility or organization director or individual responsible for daily operations at the entity-
(A) Maintains a reporting relationship with a manager at the main provider that has the same frequency, intensity, and level of accountability that exists in the relationship between the main provider and its departments; and
(B) Is accountable to the governing body of the main provider, in the same manner as any department head of the provider.
(iii) The following administrative functions of the facility or organization are integrated with those of the provider where the facility or organization is based: billing services, records, human resources, payroll, employee benefit package, salary structure, and purchasing services. Either the same employees or group of employees handle these administrative functions for the facility or organization and the main provider, or the administrative functions for both the facility or organization and the entity are-
(A) Contracted out under the same contract agreement; or
(B) Handled under different contract agreements, with the contract of the facility or organization being managed by the main provider.
(4) Clinical services. The clinical services of the facility or organization seeking provider-based status and the main provider are integrated as evidenced by the following:
(i) Professional staff of the facility or organization have clinical privileges at the main provider.
(ii) The main provider maintains the same monitoring and oversight of the facility or organization as it does for any other department of the provider.
(iii) The medical director of the facility or organization seeking provider-based status maintains a reporting relationship with the Chief Medical Officer or other similar official of the main provider that has the same frequency, intensity, and level of accountability that exists in the relationship between the medical director of a department of the main provider and the Chief Medical Officer or other similar official of the main provider, and is under the same type of supervision and accountability as any other director, medical or otherwise, of the main provider.
(iv) Medical staff committees or other professional committees at the main provider are responsible for medical activities in the facility or organization including quality assurance, utilization review, and the coordination and integration of services, to the extent practicable, between the facility or organization seeking provider-based status and the main provider.
(v) Medical records for patients treated in the facility or organization are integrated into a unified retrieval system (or cross reference) of the main provider.
(vi) Inpatient and outpatient services of the facility or organization and the main provider are integrated, and patients treated at the facility or organization who require further care have full access to all services of the main provider and are referred where appropriate to the corresponding inpatient or outpatient department or service of the main provider.
(5) Financial integration. The financial operations of the facility or organization are fully integrated within the financial system of the main provider, as evidenced by shared income and expenses between the main provider and the facility or organization. The costs of the facility or organization are reported in a cost center of the provider, and the financial status of the facility or organization is incorporated and readily identified in the main provider's trial balance.
(6) Public awareness. The facility or organization seeking status as a department of a provider, remote
location of a hospital, or satellite facility is held out to the public and other payers as part of the main provider. When patients enter the provider-based facility or organization, they are aware that they are entering the main provider and are billed accordingly.
(7) Location in immediate vicinity. The facility or organization and the main provider are located on the same campus, except where the following requirements are met:
(i) The facility or organization demonstrates a high level of integration with the main provider by showing that it meets all of the other provider-based criteria, and demonstrates that it serves the same patient population as the main provider, by submitting records showing that, during the 12 -month period immediately preceding the first day of the month in which the application for provider-based status is filed with HCFA, and for each subsequent 12month period-
(A) At least 75 percent of the patients served by the facility or organization reside in the same zip code areas as at least 75 percent of the patients served by the main provider;
(B) At least 75 percent of the patients served by the facility or organization who required the type of care furnished by the main provider received that care from that provider (for example, at least 75 percent of the patients of an RHC seeking provider-based status received inpatient hospital services from the hospital that is the main provider); or
(C) If the facility or organization is unable to meet the criteria in paragraph $(d)(7)(i)(A)$ or $(d)(7)(i)(B)$ of this section because it was not in operation during all of the 12-month period described in the previous sentence, the facility or organization is located in a zip code area included among those that, during all of the 12-month period described in the previous sentence, accounted for at least 75 percent of the patients served by the main provider.
(ii) A facility or organization is not considered to be in the "immediate vicinity" of the main provider unless the facility or organization and the main provider are located in the same State or, where consistent with the laws of both States, adjacent States.
(iii) A rural health clinic that is otherwise qualified as a provider-based entity of a hospital that is located in a rural area, as defined in $\S 412.62(\mathrm{f})(1)$ (iii) of this chapter, and has fewer than 50 beds, as determined under §412.105(b) of this chapter, is not subject to the criterion in this paragraph (d)(7).
(e) Provider-based status not applicable to joint ventures. A facility or
organization cannot be considered provider-based if the entity is owned by two or more providers engaged in a joint venture. For example, where a hospital has jointly purchased or jointly created free-standing facilities under joint venture arrangements, neither party to the joint venture arrangement can claim the free-standing facility as a providerbased entity.
(f) Management contracts. Facilities and organizations that otherwise meet the requirements of paragraph (d) of this section, but are operated under management contracts, must also meet all of the following criteria:
(1) The staff of the facility or organization, other than management staff, are employed by the provider or by another organization, other than the management company, which also employs the staff of the main provider.
(2) The administrative functions of the facility or organization are integrated with those of the main provider, as determined under criteria in paragraph (d)(3)(iii) of this section.
(3) The main provider has significant control over the operations of the facility or organization as determined under criteria in paragraph (b)(3)(ii) of this section.
(4) The management contract is held by the main provider itself, not by a parent organization that has control over both the main provider and the facility or organization.
(g) Obligations of hospital outpatient departments and hospital-based entities. (1) Hospital outpatient departments located either on or off the campus of the hospital that is the main provider must comply with the antidumping rules in §§ 489.20(l), (m), (q), and (r) and $\S 489.24$ of this chapter. If any individual comes to any hospitalbased entity (including an RHC) located on the main hospital campus, and a request is made on the individual's behalf for examination or treatment of a medical condition, as described in $\S 489.24$ of this chapter, the hospital must comply with the anti-dumping rules in $\S 489.24$ of this chapter.
(2) Physician services furnished in hospital outpatient departments or hospital-based entities (other than RHCs) must be billed with the correct site-of-service indicator, so that applicable site-of-service reductions to physician and practitioner payment amounts can be applied.
(3) Hospital outpatient departments must comply with all the terms of the hospital's provider agreement.
(4) Physicians who work in hospital outpatient departments or hospitalbased entities are obligated to comply
with the non-discrimination provisions in $\S 489.10(\mathrm{~b})$ of this chapter.
(5) Hospital outpatient departments (other than RHCs) must treat all Medicare patients, for billing purposes, as hospital outpatients. The department must not treat some Medicare patients as hospital outpatients and others as physician office patients.
(6) In the case of a patient admitted to the hospital as an inpatient after receiving treatment in the hospital outpatient department or hospital-based entity, payments for services in the hospital outpatient department or hospital-based entity are subject to the payment window provisions applicable to PPS hospitals and to hospitals and units excluded from PPS set forth at §412.2(c)(5) of this chapter and at $\S 413.40(\mathrm{c})(2)$, respectively.
(7) When a Medicare beneficiary is treated in a hospital outpatient department or hospital-based entity (other than an RHC) that is not located on the main provider's campus, the hospital has a duty to provide written notice to the beneficiary, prior to the delivery of services, of the amount of the beneficiary's potential financial liability (that is, of the fact that the beneficiary will incur a coinsurance liability for an outpatient visit to the hospital as well as for the physician service, and of the amount of that liability). The notice must be one that the beneficiary can read and understand. If the beneficiary is unconscious, under great duress, or for any other reason unable to read a written notice and understand and act on his or her own rights, the notice must be provided, prior to the delivery of services, to the beneficiary's authorized representative.
(8) Hospital outpatient departments must meet applicable hospital health and safety rules for Medicareparticipating hospitals in part 482 of this chapter.
(h) Furnishing all services under arrangement. A facility or organization may not qualify for provider-based status if all patient care services furnished at the facility are furnished under arrangement.
(i) Inappropriate treatment of a facility or organization as providerbased. (1) Determination and review. If HCFA learns that a provider has treated a facility or organization as providerbased and the provider had not obtained a determination of provider-based status under this section, HCFA will-
(i) Review current payments and, if necessary, take action in accordance with the rules on inappropriate billing in paragraph ( j ) of this section;
(ii) Investigate and determine whether the requirements in paragraph (d) of this section (or, for periods prior to October 10,2000 , the requirements in applicable program instructions) were met; and
(iii) Review all previous payments to that provider for all cost reporting periods subject to re-opening in accordance with § 405.1885 and $\S 405.1889$ of this chapter.
(2) Recovery of overpayments. If HCFA finds that payments for services at the facility or organization have been made as if the facility or organization were provider-based, even though HCFA had not previously determined that the facility or organization qualified for provider-based status, HCFA will recover the difference between the amount of payments that actually were made and the amount of payments that HCFA estimates should have been made in the absence of a determination of provider-based status, except that recovery will not be made for any period prior to October 10, 2000 if during all of that period the management of the entity made a good faith effort to operate it as a providerbased facility or organization, as described in paragraph (h)(3) of this section.
(3) Exception for good faith effort. HCFA determines that the management of a facility or organization has made a good faith effort to operate it as a provider-based entity if-
(i) The requirements regarding licensure and public awareness in paragraphs $(\mathrm{d})(1)$ and $(\mathrm{d})(6)$ of this section are met;
(ii) All facility services were billed as if they had been furnished by a department of a provider, remote location of a hospital, satellite facility, or a provider-based entity of the main provider; and
(iii) All professional services of physicians and other practitioners were billed with the correct site-of-service indicator, as described in paragraph $(\mathrm{g})(2)$ of this section.
(j) Inappropriate billing. If HCFA finds that a facility or organization is being treated as provider-based without having obtained a determination of provider-based status under this section, HCFA will notify the provider, adjust future payments, review previous payments, determine whether the facility or organization qualifies for provider-based status under this paragraph, and continue payments only under specific conditions, as described in paragraphs (j)(1), (j)(2), (j)(3), and (j)(4) of this section.
(1) Notice to provider. If HCFA finds that inappropriate billing has occurred or is occurring since no provider-based
determination has been made by HCFA, HCFA will issue written notice to the provider that payments for past cost reporting periods may be reviewed and recovered as described in paragraph (i) of this section, that future payments for services in or of the facility or organization will be adjusted as described in paragraph $(\mathrm{j})(2)$ of this section, and that a determination of provider-based status will be made.
(2) Adjustment of payments. If HCFA finds that inappropriate billing has occurred or is occurring since no provider-based determination has been made by HCFA, HCFA will adjust future payments to the provider, the facility or organization, or both, to approximate as closely as possible the amounts that would be paid, in the absence of a provider-based determination, if all other requirements for billing were met.
(3) Review of previous payments. If HCFA finds that inappropriate billing has occurred or is occurring since no provider-based determination has been made by HCFA, HCFA will review previous payments and, if necessary, take action in accordance with the rules on inappropriate treatment of a facility or organization as provider-based in paragraph (h) of this section.
(4) Determination regarding providerbased status. If HCFA finds that inappropriate billing has occurred or is occurring since no provider-based determination has been made by HCFA, HCFA will determine whether the facility or organization qualifies for provider-based status under the criteria in this section. If HCFA determines that the facility or organization qualifies for provider-based status, future payment for services at or by the facility or organization will be adjusted to reflect that determination. If HCFA determines that the facility or organization does not qualify for provider-based status, future payment for services at or by the facility or organization will be made only in accordance with the rules in paragraph (i)(5) of this section.
(5) Continuation of payment. The notice of denial of provider-based status sent to the provider will ask the provider to notify HCFA in writing, within 30 days of the date the notice is issued, of whether the facility or organization (or, where applicable, the practitioners who staff the facility or organization) will be seeking to enroll and meet other requirements to bill for services in a free-standing facility. If the provider indicates that the facility, organization, or practitioners will not be seeking to enroll, or if HCFA does not receive a response within 30 days of the date the notice was issued, all payment under this paragraph (i)(5) will end as
of the 30th day after the date of notice. If the provider indicates that the facility or organization, or its practitioners, will be seeking to meet enrollment and other requirements for billing for services in a free-standing facility, payment for services of the facility or organization will continue, at the adjusted amounts described in paragraph $(\mathrm{j})(2)$ of this section for as long as is required for all billing requirements to be met (but not longer than 6 months) if the facility or organization, or its practitioners, submit a complete enrollment application and provide all other required information within 90 days after the date of notice; and the facility or organization, or its practitioners, furnish all other information needed by HCFA to process the enrollment application and verify that other billing requirements are met. If the necessary applications or information are not provided, HCFA will terminate all payment to the provider, facility, or organization as of the date HCFA issues notice that necessary applications or information have not been submitted.
(k) Correction of errors. HCFA may review a past determination of providerbased status for a facility or organization or may review the status of a facility or organization (that is, whether the facility or organization is providerbased) if no determination regarding provider-based status has previously been made, if HCFA believes that status may be inappropriate, based on the provisions of this section. If HCFA determines that a previous determination was in error, and the entity should not be considered provider-based, HCFA notifies the main provider. Treatment of the facility or organization as provider-based ceases with the first day of the next cost report period following notification of the redetermination, but not less than 6 months after the date of notification.
(1) Status of Indian Health Service and Tribal facilities and organizations. Facilities and organizations operated by the Indian Health Service or Tribes will be considered to be departments of hospitals operated by the Indian Health Service or Tribes if, on or before April 7, 2000, they furnished only services that were billed as if they had been furnished by a department of a hospital operated by the Indian Health Service or a Tribe and they are:
(1) Owned and operated by the Indian Health Service;
(2) Owned by the Tribe but leased from the Tribe by the IHS under the Indian Self-Determination Act (Pub. L. 93-638) in accordance with applicable regulations and policies of the Indian

Health Service in consultation with Tribes: or
(3) Owned by the Indian Health Service but leased and operated by the Tribe under the Indian Self-
Determination Act (Pub. L. 93-638) in accordance with applicable regulations and policies of the Indian Health Service in consultation with Tribes.
(m) FQHCs and "look-alikes". A facility that has, since April 7, 1995, furnished only services that were billed as if they had been furnished by a department of a provider will continue to be treated, for purposes of this section, as a department of the provider without regard to whether it complies with the criteria for provider-based status in this section, if the facility-
(1) Received a grant before 1995 under section 330 of the Public Health Service Act, or is receiving funding from such a grant under a contract with the recipient of such a grant and meets the requirements to receive a grant under section 330 of the Public Health Service Act; or
(2) Based on the recommendation of the Public Health Service, was determined by HCFA before 1995 to meet the requirements for receiving such a grant.
(n) Effective date of provider-based status. Provider-based status for a facility or organization is effective on the earliest date on which a request for provider-based status has been made, and all requirements of this part have been met.

## Subpart F-Specific Categories of Costs

5. In §413.118, the heading to paragraph (d) is republished, and a new paragraph (d)(5) is added to read as follows:
§ 413.118 Payment for facility services related to covered ASC surgical procedures performed in hospitals on an outpatient basis.
(d) Blended payment amount. * * *
(5) For portions of cost reporting periods beginning on or after October 1, 1997, for purposes of calculating the blended payment amount under paragraph (d)(4) of this section, the ASC payment amount is the sum of the standard overhead amounts reduced by deductibles and coinsurance as defined in section 1866(a)(2)(ii) of the Act.

## 6. In § 413.122:

A. The heading to paragraph (b) is republished
B. A new paragraph (b)(5) is added
C. The heading to paragraph (c) is republished; and
D. A new paragraph (c)(4) is added to read as follows:
§413.122 Payment for hospital outpatient radiology services and other diagnostic procedures.
(b) Payment for hospital outpatient radiology services. * * *
(5) For hospital outpatient radiology services furnished on or after October 1, 1997, the blended payment amount is equal to the sum of-
(i) 42 percent of the hospital-specific amount; and
(ii) 58 percent of the fee schedule amount calculated as 62 percent of the sum of the fee schedule amounts payable for the same services when furnished by participating physicians in their offices in the same locality, less deductible and coinsurance as defined in section 1866(a)(2)(A)(ii) of the Act.
(c) Payment for other diagnostic procedures. * * *
(4) For other diagnostic services furnished on or after October 1, 1997, the blended payment amount is equal to the sum of-
(i) 50 percent of the hospital-specific amount; and
(ii) 50 percent of the fee schedule amount calculated as 42 percent of the sum of the fee schedule amounts payable for the same services when furnished by participating physicians in their offices in the same locality less deductible and coinsurance as defined in section 1866(a)(2)(A)(ii) of the Act.
7. In $\S 413.124$, paragraph (a) is revised to read as follows:
§413.124 Reduction to hospital outpatient operating costs.
(a) Except for sole community
hospitals, as defined in $\S 412.92$ of this chapter, and critical access hospitals, the reasonable costs of outpatient hospital services (other than capitalrelated costs of these services) are reduced by 5.8 percent for services furnished during portions of cost reporting periods occurring on or after October 1, 1990 and until the first date that the prospective payment system under part 419 of this chapter is implemented.

## Subpart G-Capital-Related Costs

8. In §413.130, the heading to paragraph ( j ) and the introductory text to paragraph (j)(1) are republished, and paragraph $(\mathrm{j})(1)(\mathrm{ii})$ is revised to read as follows:

## §413.130 Introduction to capital-related costs.

(j) Reduction to capital-related costs. (1) Except for sole community hospitals and critical access hospitals, the amount of capital-related costs of all hospital outpatient services is reduced by-
(ii) 10 percent for portions of cost reporting periods occurring on or after October 1, 1991 and until the first date that the prospective payment system under part 419 of this chapter is implemented.
F. A new part 419, consisting of §§ 419.1, 419.2, 419.20, 419.21, 419.22, 419.30, 419.31, 419.32, 419.40, 419.41, 419.42, 419.43, 419.44, 419.50, 419.60, and 419.70, is added to read as follows:

## PART 419—PROSPECTIVE PAYMENT SYSTEM FOR HOSPITAL OUTPATIENT DEPARTMENT SERVICES

## Subpart A-General Provisions

Sec.
419.1 Basis and scope.
419.2 Basis of payment.

## Subpart B—Categories of Hospitals and Services Subject to and Excluded From the Hospital Outpatient Prospective Payment System

419.20 Hospitals subject to the hospital outpatient prospective payment system.
419.21 Hospital outpatient services subject to the outpatient prospective payment system.
419.22 Hospital outpatient services excluded from payment under the hospital outpatient prospective payment system.

## Subpart C—Basic Methodology for Determining Prospective Payment Rates for Hospital Outpatient Services

419.30 Base expenditure target for calendar year 1999.
419.31 Ambulatory payment classification (APC) system and payment weights.
419.32 Calculation of prospective payment rates for hospital outpatient services.

## Subpart D—Payments to Hospitals

419.40 Payment concepts.
419.41 Calculation of national beneficiary copayment amounts and national Medicare program payment amounts.
419.42 Hospital election to reduce copayment.
419.43 Adjustments to national program payment and beneficiary copayment amounts.
419.44 Payment reductions for surgical procedures.

## Subpart E—Updates

419.50 Annual updates.

## Subpart F-Limitations on Review

419.60 Limitations on administrative and judicial review.

## Subpart G—Transitional Corridors

419.70 Transitional adjustment to limit decline in payment.
Authority: Secs. 1102, 1833(t), and 1871 of the Social Security Act (42 U.S.C. 1302, $13951(\mathrm{t})$, and 1395hh).

## PART 419—PROSPECTIVE PAYMENT SYSTEM FOR HOSPITAL OUTPATIENT DEPARTMENT SERVICES

## Subpart A—General Provisions

## §419.1 Basis and scope.

(a) Basis. This part implements section 1833(t) of the Act by establishing a prospective payment system for services furnished on or after July 1, 2000 by hospital outpatient departments to Medicare beneficiaries who are registered on hospital records as outpatients.
(b) Scope. This subpart describes the basis of payment for outpatient hospital services under the prospective payment system. Subpart B sets forth the categories of hospitals and services that are subject to the outpatient hospital prospective payment system and those categories of hospitals and services that are excluded from the outpatient hospital prospective payment system. Subpart C sets forth the basic methodology by which prospective payment rates for hospital outpatient services are determined. Subpart D describes Medicare payment amounts, beneficiary copayment amounts, and methods of payment to hospitals under the hospital outpatient prospective payment system. Subpart E describes how the hospital outpatient prospective payment system may be updated. Subpart F describes limitations on administrative and judicial review. Subpart G describes the transitional payment adjustments that are made before 2004 to limit declines in payment for outpatient services.

## §419.2 Basis of payment.

(a) Unit of payment. Under the hospital outpatient prospective payment system, predetermined amounts are paid for designated services furnished to Medicare beneficiaries. These services are identified by codes established under the Health Care Financing Administration Common Procedure Coding System (HCPCS). The prospective payment rate for each service or procedure for which payment is allowed under the hospital outpatient prospective payment system is
determined according to the methodology described in subpart C of this part. The manner in which the Medicare payment amount and the beneficiary copayment amount for each service or procedure are determined is described in subpart D of this part.
(b) Determination of hospital outpatient prospective payment rates: Included costs. The prospective payment system establishes a national payment rate, standardized for geographic wage differences, that includes operating and capital-related costs that are directly related and integral to performing a procedure or furnishing a service on an outpatient basis. In general, these costs include, but are not limited to-
(1) Use of an operating suite, procedure room, or treatment room;
(2) Use of recovery room;
(3) Use of an observation bed;
(4) Anesthesia, certain drugs, biologicals, and other pharmaceuticals; medical and surgical supplies and equipment; surgical dressings; and devices used for external reduction of fractures and dislocations;
(5) Supplies and equipment for administering and monitoring anesthesia or sedation;
(6) Intraocular lenses (IOLs);
(7) Incidental services such as venipuncture;
(8) Capital-related costs;
(9) Implantable items used in connection with diagnostic X-ray tests, diagnostic laboratory tests, and other diagnostic tests;
(10) Durable medical equipment that is implantable;
(11) Implantable prosthetic devices (other than dental) which replace all or part of an internal body organ (including colostomy bags and supplies directly related to colostomy care), including replacement of these devices; and
(12) Costs incurred to procure donor tissue other than corneal tissue.
(c) Determination of hospital outpatient prospective payment rates: Excluded costs. The following costs are excluded from the hospital outpatient prospective payment rates:
(1) Medical education costs for approved nursing and allied health education programs.
(2) Corneal tissue acquisition costs incurred by hospitals that are paid for on a reasonable cost basis.
(3) Costs for services listed in §419.22.

Subpart B-Categories of Hospitals and Services Subject to and Excluded From the Hospital Outpatient Prospective Payment System
§419.20 Hospitals subject to the hospital outpatient prospective payment system.
(a) Applicability. The hospital outpatient prospective payment system is applicable to any hospital participating in the Medicare program, except those specified in paragraph (b) of this section, for services furnished on or after July 1, 2000.
(b) Hospitals excluded from the outpatient prospective payment system. (1) Those services furnished by Maryland hospitals that are paid under a cost containment waiver in accordance with section 1814(b)(3) of the Act are excluded from the hospital outpatient prospective payment system.
(2) Critical access hospitals (CAHs) are excluded from the hospital outpatient prospective payment system.

## §419.21 Hospital outpatient services subject to the outpatient prospective payment system.

Except for services described in $\S 419.22$, effective for services furnished on or after July 1, 2000, payment is made under the hospital outpatient prospective payment system for the following:
(a) Medicare Part B services furnished to hospital outpatients designated by the Secretary under this part.
(b) Services designated by the Secretary that are covered under Medicare Part B when furnished to hospital inpatients who are either not entitled to benefits under Part A or who have exhausted their Part A benefits but are entitled to benefits under Part B of the program.
(c) Partial hospitalization services furnished by community mental health centers (CMHCs).
(d) The following medical and other health services furnished by a comprehensive outpatient rehabilitation facility (CORF) when they are provided outside the patient's plan (of care); or by a home health agency (HHA) to patients who are not under an HHA plan or treatment; or by a hospice program furnishing services to patients outside the hospice benefit:
(1) Antigens.
(2) Splints and casts.
(3) Pneumococcal vaccine, influenza vaccine, and hepatitis $B$ vaccine.
§419.22 Hospital outpatient services excluded from payment under the hospital outpatient prospective payment system.

The following services are not paid for under the hospital outpatient prospective payment system:
(a) Physician services that meet the requirements of $\S 415.102$ (a) of this chapter for payment on a fee schedule basis.
(b) Nurse practitioner and clinical nurse specialist services, as defined in section 1861(s)(2)(K)(ii) of the Act.
(c) Physician assistant services, as defined in section 1861(s)(2)(K)(i) of the Act.
(d) Certified nurse-midwife services, as defined in section $1861(\mathrm{gg})$ of the Act.
(e) Services of qualified psychologists, as defined in section 1861(ii) of the Act.
(f) Services of an anesthetist as defined in §410.69 of this chapter.
(g) Clinical social worker services as defined in section 1861(hh)(2) of the Act.
(h) Outpatient therapy services described in section 1833(a)(8) of the Act.
(i) Ambulance services, as described in section 1861(v)(1)(U) of the Act, or, if applicable, the fee schedule established under section 1834(l).
(j) Except as provided in
§419.22(b)(11), prosthetic devices, prosthetics, prosthetic supplies, and orthotic devices.
(k) Except as provided in § 419.2(b)(10), durable medical equipment supplied by the hospital for the patient to take home.
(l) Clinical diagnostic laboratory services.
(m) Services for patients with ESRD that are paid under the ESRD composite rate and drugs and supplies furnished during dialysis but not included in the composite rate.
(n) Services and procedures that the Secretary designates as requiring inpatient care.
(o) Hospital outpatient services furnished to SNF residents (as defined in $\S 411.15(\mathrm{p})$ of this chapter) as part of the patient's resident assessment or comprehensive care plan (and thus included under the SNF PPS) that are furnished by the hospital "under arrangements" but billable only by the SNF, regardless of whether or not the patient is in a Part A SNF stay.
(p) Services that are not covered by Medicare by statute.
(q) Services that are not reasonable or necessary for the diagnosis or treatment of an illness or disease.

## Subpart C-Basic Methodology for Determining Prospective Payment Rates for Hospital Outpatient Services

§419.30 Base expenditure target for calendar year 1999.
(a) HCFA estimates the aggregate amount that would be payable for
hospital outpatient services in calendar year 1999 by summing-
(1) The total amounts that would be payable from the Trust Fund for covered hospital outpatient services without regard to the outpatient prospective payment system described in this part; and
(2) The total amounts of coinsurance that would be payable by beneficiaries to hospitals for covered hospital outpatient services without regard to the outpatient prospective payment system described in this part.
(b) The estimated aggregate amount under paragraph (a) of this section is determined as though the deductible required under section 1833(b) of the Act did not apply.

## §419.31 Ambulatory payment classification (APC) system and payment weights.

(a) APC groups. (1) HCFA classifies outpatient services and procedures that are comparable clinically and in terms of resource use into APC groups. Except as specified in paragraph (a)(2) of this section, items and services within a group are not comparable with respect to the use of resources if the highest median cost for an item or service within the group is more than 2 times greater than the lowest median cost for an item or service within the group.
(2) HCFA may make exceptions to the requirements set forth in paragraph (a)(1) in unusual cases, such as low volume items and services, but may not make such an exception in the case of a drug or biological that has been designated as an orphan drug under section 526 of the Federal Food, Drug and Cosmetic Act.
(3) The payment rate determined for an APC group in accordance with §419.32, and the copayment amount and program payment amount determined for an APC group in accordance with subpart D of this part, apply to every HCPCS code classified within an APC group.
(b) APC weighting factors. (1) Using hospital outpatient claims data from calendar year 1996 and data from the most recent available hospital cost reports, HCFA determines the median costs for the services and procedures within each APC group.
(2) HCFA assigns to each APC group an appropriate weighting factor to reflect the relative median costs for the services within the APC group compared to the median costs for the services in all APC groups.
(c) Standardizing amounts. (1) HCFA determines the portion of costs determined in paragraph (b)(1) of this section that is labor-related. This is
known as the "labor-related portion" of hospital outpatient costs.
(2) HCFA standardizes the median costs determined in paragraph (b)(1) of this section by adjusting for variations in hospital labor costs across geographic areas.

## §419.32 Calculation of prospective payment rates for hospital outpatient services.

(a) Conversion factor for 1999. HCFA calculates a conversion factor in such a manner that payment for hospital outpatient services furnished in 1999 would have equaled the base expenditure target calculated in $\S 419.30$, taking into account APC group weights and estimated service frequencies and reduced by the amounts that would be payable in 1999 as outlier payments under §419.43(d) and transitional pass-through payments under §419.43(e).
(b) Conversion factor for calendar year 2000 and subsequent years. (1) Subject to paragraph (b)(2) of this section, the conversion factor for a calendar year is equal to the conversion factor calculated for the previous year adjusted as follows:
(i) For calendar years 2000, 2001, and 2002, by the hospital inpatient market basket percentage increase applicable under section 1886(b)(3)(B)(iii) of the Act reduced by one percentage point.
(ii) For calendar years 2003 and subsequent years, by the hospital inpatient market basket percentage increase applicable under section 1886(b)(3)(B)(iii) of the Act.
(2) Beginning in calendar year 2000, HCFA may substitute for the hospital inpatient market basket percentage in paragraph (b) of this section a market basket percentage increase that is determined and applied to hospital outpatient services in the same manner that the hospital inpatient market basket percentage increase is determined and applied to inpatient hospital services.
(c) Payment rates. The payment rate for services and procedures for which payment is made under the hospital outpatient prospective payment system is the product of the conversion factor calculated under paragraph (a) or paragraph (b) of this section and the relative weight determined under § 419.31(b).
(d) Budget neutrality. HCFA adjusts the conversion factor as needed to ensure that updates and adjustments under §419.50(a) are budget neutral.

## Subpart D—Payments to Hospitals

## §419.40 Payment concepts.

(a) In addition to the payment rate described in §419.32, for each APC
group there is a predetermined beneficiary coinsurance amount as described in §419.41(a). The Medicare program payment amount for each APC group is calculated by applying the program payment percentage as described in § 419.41(b).
(b) For purposes of this section-
(1) Coinsurance percentage is calculated as the difference between the program payment percentage and 100 percent. The coinsurance percentage in any year is thus defined for each APC group as the greater of the following: the ratio of the APC group unadjusted copayment amount to the annual APC group payment rate, or 20 percent.
(2) Program payment percentage is calculated as the lower of the following: the ratio of the APC group payment rate minus the APC group unadjusted coinsurance amount, to the APC group payment rate, or 80 percent.
(3) Unadjusted coinsurance amount is calculated as 20 percent of the wageadjusted national median of charges for services within an APC group furnished during 1996, updated to 1999 using an actuarial projection of charge increases for hospital outpatient department services during the period 1996 to 1999.
(c) Limitation of coinsurance amount to inpatient hospital deductible amount. The coinsurance amount for a procedure performed in a year cannot exceed the amount of the inpatient hospital deductible established under section 1813(b) of the Act for that year.

## §419.41 Calculation of national beneficiary coinsurance amounts and national Medicare program payment amounts.

(a) To calculate the unadjusted coinsurance amount for each APC group, HCFA-
(1) Standardizes 1996 hospital charges for the services within each APC group to offset variations in hospital labor costs across geographic areas;
(2) Identifies the median of the wageneutralized 1996 charges for each APC group; and
(3) Determines the value equal to 20 percent of the wage-neutralized 1996 median charge for each APC group and multiplies that value by an actuarial projection of increases in charges for hospital outpatient department services during the period 1996 to 1999. The result is the unadjusted beneficiary coinsurance amount for the APC group.
(b) HCFA calculates annually the program payment percentage for every APC group on the basis of each group's unadjusted coinsurance amount and its payment rate after the payment rate is adjusted in accordance with §419.32.
(c) To determine payment amounts due for a service paid under the hospital
outpatient prospective payment system, HCFA makes the following calculations:
(1) Makes the wage index adjustment in accordance with $\S 419.43$.
(2) Subtracts the amount of the applicable Part B deductible provided under $\S 410.160$ of this chapter.
(3) Multiplies the remainder by the program payment percentage for the group to determine the preliminary Medicare program payment amount.
(4) Subtracts the program payment amount from the amount determined in paragraph (c)(2) of this section to determine the coinsurance amount.
(i) The coinsurance amount for an APC cannot exceed the amount of the inpatient hospital deductible established under section 1813(b) of the Act for that year.
(ii) The coinsurance amount is computed as if the adjustments under $\S 419.43(\mathrm{~d})$ and (e) (and any adjustment made under $\S 419.43$ (f) in relation to these adjustments) had not been paid.
(5) Adds the amount by which the coinsurance amount would have exceeded the inpatient hospital deductible for that year to the preliminary Medicare program payment amount determined in paragraph (c)(3) of this section to determine the final Medicare program payment amount.

## §419.42 Hospital election to reduce coinsurance.

(a) A hospital may elect to reduce coinsurance for any or all APC groups on a calendar year basis. A hospital may not elect to reduce copayment for some, but not all, services within the same group.
(b) A hospital must notify its fiscal intermediary of its election to reduce coinsurance no later than-
(1) June 1, 2000, for coinsurance elections for the period July 1, 2000 through December 31, 2000; or
(2) December 1 preceding the beginning of each subsequent calendar year.
(c) The hospital's election must be properly documented. It must specifically identify the APCs to which it applies and the coinsurance amount (within the limits identified below) that the hospital has selected for each group.
(d) The election of reduced coinsurance remains in effect unchanged during the year for which the election was made.
(e) In electing reduced coinsurance, a hospital may elect a level that is less than that year's wage-adjusted coinsurance amount for the group but not less than 20 percent of the APC payment rate as determined in $\S 419.32$.
(f) The hospital may advertise and otherwise disseminate information
concerning the reduced level of coinsurance that it has elected. All advertisements and information furnished to Medicare beneficiaries must specify that the coinsurance reductions advertised apply only to the specified services of that hospital and that coinsurance reductions are available only for hospitals that choose to reduce coinsurance for hospital outpatient services and are not allowed in any other ambulatory settings or physician offices.
§419.43 Adjustments to national program payment and beneficiary coinsurance amounts.
(a) General rule. HCFA determines national prospective payment rates for hospital outpatient department services and determines a wage adjustment factor to adjust the portion of the APC payment and national beneficiary coinsurance amount attributable to labor-related costs for relative differences in labor and labor-related costs across geographic regions in a budget neutral manner.
(b) Labor-related portion of payment and copayment rates for hospital outpatient services. HCFA determines the portion of hospital outpatient costs attributable to labor and labor-related costs (known as the "labor-related portion", of hospital outpatient costs) in accordance with $\S 419.31$ (c)(1).
(c) Wage index factor. HCFA uses the hospital inpatient prospective payment system wage index established in accordance with part 412 of this chapter to make the adjustment referred to in paragraph (a) of this section.
(d) Outlier adjustment-(1) General rule. Subject to paragraph (d)(4) of this section, HCFA provides for an additional payment for each hospital outpatient service (or group of services) for which a hospital's charges, adjusted to cost, exceed the following:
(i) A fixed multiple of the sum of-
(A) The applicable Medicare hospital outpatient payment amount determined under § 419.32(c), as adjusted under $\S 419.43$ (other than for adjustments under this paragraph (d) or paragraph (e) of this section); and
(B) Any transitional pass-through payment under paragraph (e) of this section.
(ii) At the option of HCFA, a fixed dollar amount.
(2) Amount of adjustment. The amount of the additional payment under paragraph (d)(1) of this section is determined by HCFA and approximates the marginal cost of care beyond the applicable cutoff point under paragraph (d)(1) of this section.
(3) Limit on aggregate outlier adjustments_(i) In general. The total of the additional payments made under this paragraph (d) for covered hospital outpatient department services furnished in a year (as estimated by HCFA before the beginning of the year) may not exceed the applicable percentage specified in paragraph (d)(3)(ii) of this section of the total program payments (sum of both the Medicare and beneficiary payments to the hospital) estimated to be made under this part for all hospital outpatient services furnished in that year. If this paragraph is first applied to less than a full year, the limit applies only to the portion of the year.
(ii) Applicable percentage. For purposes of paragraph (d)(3)(i) of this section, the term "applicable percentage" means a percentage specified by HCFA up to (but not to exceed)-
(A) For a year (or portion of a year) before 2004, 2.5 percent; and
(B) For 2004 and thereafter, 3.0 percent.
(4) Transitional authority. In applying paragraph (d)(1) of this section for hospital outpatient services furnished before January 1, 2002, HCFA may-
(i) Apply paragraph (d)(1) of this section to a bill for these services related to an outpatient encounter (rather than for a specific service or group of services) using hospital outpatient payment amounts and transitional passthrough payments covered under the bill; and
(ii) Use an appropriate cost-to-charge ratio for the hospital or CMHC (as determined by HCFA), rather than for specific departments within the hospital.
(e) Transitional pass-through for additional costs of innovative medical devices, drugs, and biologicals-(1) General rule. HCFA provides for an additional payment under this paragraph for any of the following that are provided as part of a hospital outpatient service (or group of services):
(i) Current orphan drugs. A drug or biological that is used for a rare disease or condition with respect to which the drug or biological has been designated as an orphan drug under section 526 of the Federal Food, Drug and Cosmetic Act if payment for the drug or biological as an outpatient hospital service under this part was being made on the first date that the system under this part is implemented.
(ii) Current cancer therapy drugs and biologicals and brachytherapy. A drug or biological that is used in cancer therapy, including, but not limited to, a chemotherapeutic agent, an antiemetic,
a hematopoietic growth factor, a colony stimulating factor, a biological response modifier, a bisphosphonate, and a device of brachytherapy, if payment for the drug, biological, or device as an outpatient hospital service under this part was being made on the first date that the system under this part is implemented.
(iii) Current radiopharmaceutical drugs and biological products. A radiopharmaceutical drug or biological product used in diagnostic, monitoring, and therapeutic nuclear medicine procedures if payment for the drug or biological as an outpatient hospital service under this part was being made on the first date that the system under this part is implemented.
(iv) New medical devices, drugs, and biologicals. A medical device, drug, or biological not described in paragraph (e)(1)(i), (e)(1)(ii), or (e)(1)(iii) of this section if-
(A) Payment for the device, drug, or biological as an outpatient hospital service under this part was not being made as of December 31, 1996; and
(B) The cost of the device, drug, or biological is not insignificant (as defined in paragraph (e)(1)(iv)(C) of this section) in relation to the hospital outpatient fee schedule amount (as calculated under §419.32(c)) payable for the service (or group of services) involved.
(C) The cost of the device, drug, or biological is considered not insignificant if it meets all of the following thresholds:
(1) Its expected reasonable cost exceeds 25 percent of the applicable fee schedule amount for the associated service.
(2) The expected reasonable cost of the new drug, biological, or device must exceed the current portion of the fee schedule amount determined to be associated with the drug, biological, or device by 25 percent.
(3) The difference between the expected reasonable cost of the item and the portion of the hospital outpatient fee schedule amount determined to be associated with the item exceeds 10 percent of the applicable hospital outpatient fee schedule amount.
(2) Limited period of payment. The payment under this paragraph (e) with respect to a medical device, drug, or biological applies during a period of at least 2 years, but not more than 3 years, that begins-
(i) On the first date this section is implemented in the case of a drug, biological, or device described in paragraphs (e)(2)(i), (e)(2)(ii), or (e)(2)(iii) of this section and in the case of a device, drug, or biological described
in paragraph (e)(1)(iv) of this section and for which payment under this part is made as an outpatient hospital service before the first date; or
(ii) In the case of a device, drug, or biological described in paragraph (e)(1)(iv) of this section not described in paragraph (e)(2)(i) of this section, on the first date on which payment is made under this part for the device, drug, or biological as an outpatient hospital service.
(3) Amount of additional payment. Subject to paragraph (e)(4)(iii) of this section, the amount of the payment under this paragraph is-
(i) In the case of a drug or biological, the amount by which the amount determined under section 1842(o) of the Act for the drug or biological exceeds the portion of the otherwise applicable Medicare hospital outpatient fee schedule amount that HCFA determines is associated with the drug or biological; or
(ii) In the case of a medical device, the amount by which the hospital's charges for the device, adjusted to cost, exceeds the portion of the otherwise applicable Medicare hospital outpatient fee schedule amount that HCFA determines is associated with the device.
(4) Limit on aggregate annual adjustment-(i) General rule. The total of the additional payments made under this paragraph for hospital outpatient services furnished in a year, as estimated by HCFA before the beginning of the year, may not exceed the applicable percentage specified in paragraph (e)(4)(ii) of this section of the total program payments estimated to be made under this section for all hospital outpatient services furnished in that year. If this paragraph is first applied to less than a full year, the limit applies only to the portion of the year.
(ii) Applicable percentage. For purposes of paragraph (e)(4)(i) of this section, the term "applicable percentage" means-
(A) For a year (or portion of a year) before 2004, 2.5 percent; and
(B) For 2004 and thereafter, a percentage specified by HCFA up to (but not to exceed) 2.0 percent.
(iii) Uniform prospective reduction if aggregate limit projected to be exceeded. If HCFA estimates before the beginning of a year that the amount of the additional payments under this paragraph (e) for the year (or portion thereof) as determined under paragraph (e)(4)(i) of this section without regard to this paragraph (e)(4)(iii) would exceed the limit established under this paragraph (e)(4)(iii), HCFA reduces pro rata the amount of each of the additional payments under this paragraph for that
year (or portion thereof) in order to ensure that the aggregate additional payments under this paragraph (as so estimated) do not exceed the limit.
(f) Budget neutrality. Outlier adjustments under paragraph (d) of this section and transitional pass-through payments under paragraph (e) of this section are established in a budgetneutral manner.

## §419.44 Payment reductions for surgical procedures.

(a) Multiple surgical procedures. When more than one surgical procedure for which payment is made under the hospital outpatient prospective payment system is performed during a single surgical encounter, the Medicare program payment amount and the beneficiary copayment amount are based on-
(1) The full amounts for the procedure with the highest APC payment rate; and
(2) One-half of the full program and the beneficiary payment amounts for all other covered procedures.
(b) Terminated procedures. When a surgical procedure is terminated prior to completion due to extenuating circumstances or circumstances that threaten the well-being of the patient, the Medicare program payment amount and the beneficiary copayment amount are based on-
(1) The full amounts if the procedure is discontinued after the induction of anesthesia or after the procedure is started; or
(2) One-half of the full program and the beneficiary coinsurance amounts if the procedure is discontinued after the patient is prepared for surgery and taken to the room where the procedure is to be performed but before anesthesia is induced.

## Subpart E—Updates

## §419.50 Annual review.

(a) General rule. Not less often than annually, HCFA reviews and updates groups, relative payment weights, and the wage and other adjustments to take into account changes in medical practice, changes in technology, the addition of new services, new cost data, and other relevant information and factors.
(b) Consultation requirement. HCFA will consult with an expert outside advisory panel composed of an appropriate selection of representatives of providers to review (and advise HCFA concerning) the clinical integrity of the groups and weights. The panel may use data collected or developed by entities and organizations (other than the Department of Health and Human Services) in conducting the review.
(c) Effective dates. HCFA conducts the first annual review under paragraph (a) of this section in 2001 for payments made in 2002.

## Subpart F-Limitations on Review

§419.60 Limitations on administrative and judicial review.
There can be no administrative or judicial review under sections 1869 and 1878 of the Act or otherwise of the following:
(a) The development of the APC system, including-
(1) Establishment of the groups and relative payment weights;
(2) Wage adjustment factors;
(3) Other adjustments; and
(4) Methods for controlling
unnecessary increases in volume.
(b) The calculation of base amounts described in section 1833(t)(3) of the Act.
(c) Periodic adjustments described in section 1833(t)(9) of the Act.
(d) The establishment of a separate conversion factor for hospitals described in section 1886(d)(1)(B)(v) of the Act.
(e) The determination of the fixed multiple, or a fixed dollar cutoff amount, the marginal cost of care, or applicable percentage under $\S 419.43$ (d) or the determination of insignificance of cost, the duration of the additional payments (consistent with §419.43(e)), the portion of the Medicare hospital outpatient fee schedule amount associated with particular devices, drugs, or biologicals, and the application of any pro rata reduction under §419.43(e).

## Subpart G—Transitional Corridors

## \$419.70 Transitional adjustment to limit decline in payment.

(a) Before 2002. Except as provided in paragraph (d) of this section, for covered hospital outpatient services furnished before January 1, 2002, for which the prospective payment system amount (as defined in paragraph (e) of this section) is-
(1) At least 90 percent, but less than 100 percent, of the pre-BBA amount (as defined in paragraph (f) of this section), the amount of payment under this part is increased by 80 percent of the amount of this difference;
(2) At least 80 percent, but less than 90 percent, of the pre-BBA amount, the amount of payment under this part is increased by the amount by which the product of 0.71 and the pre-BBA amount exceeds the product of 0.70 and the prospective payment system amount;
(3) At least 70 percent, but less than 80 percent, of the pre-BBA amount, the
amount of payment under this part is increased by the amount by which the product of 0.63 and the pre-BBA amount, exceeds the product of 0.60 and the PPS amount; or
(4) Less than 70 percent of the preBBA amount, the amount of payment under this part shall be increased by 21 percent of the pre-BBA amount.
(b) For 2002. Except as provided in paragraph (d) of this section, for covered hospital outpatient services furnished during 2002, for which the prospective payment system amount is-
(1) At least 90 percent, but less than 100 percent, of the pre-BBA amount, the amount of payment under this part is increased by 70 percent of the amount of this difference;
(2) At least 80 percent, but less than 90 percent, of the pre-BBA amount, the amount of payment under this part is increased by the amount by which the product of 0.61 and the pre-BBA amount exceeds the product of 0.60 and the prospective payment system amount; or
(3) Less than 80 percent of the preBBA amount, the amount of payment under this part is increased by 13 percent of the pre-BBA amount.
(c) For 2003. Except as provided in paragraph (d) of this section, for covered hospital outpatient services furnished during 2003, for which the prospective payment system amount is-
(1) At least 90 percent, but less than 100 percent, of the pre-BBA amount, the amount of payment under this part is increased by 60 percent of the amount of this difference; or
(2) Less than 90 percent of the preBBA amount, the amount of payment under this part is increased by 6 percent of the pre-BBA amount.
(d) Hold harmless provisions-(1) Temporary treatment for small rural hospitals. For covered hospital outpatient services furnished in a calendar year before January 1, 2004 for which the prospective payment system amount is less than the pre-BBA amount, the amount of payment under this part is increased by the amount of that difference if the hospital-
(i) Is located in a rural area as defined in $\S 412.63(\mathrm{~b})$ of this chapter or is treated as being located in a rural area under section 1886(d)(8)(E) of the Act; and
(ii) Has 100 or fewer beds as defined in $\S 412.105(\mathrm{~b})$ of this chapter.
(2) Permanent treatment for cancer hospitals. In the case of a hospital described in §412.23(f) of this chapter for which the prospective payment system amount is less than the pre-BBA amount for covered hospital outpatient services, the amount of payment under
this part is increased by the amount of this difference.
(e) Prospective payment system amount defined. In this paragraph, the term "prospective payment system amount" means, with respect to covered hospital outpatient services, the amount payable under this part for these services (determined without regard to this paragraph or any reduction in coinsurance elected under $\S 419.42$ ), including amounts payable as copayment under $\S 419.41$, coinsurance under section 1866(a)(2)(A)(ii) of the Act, and the deductible under section 1833(b) of the Act.
(f) Pre-BBA amount defined-(1) General rule. In this paragraph, the "pre-BBA amount" means, with respect to covered hospital outpatient services furnished by a hospital or a community mental health center (CMHC) in a year, an amount equal to the product of the reasonable cost of the provider for these services for the portions of the provider's cost reporting period (or periods) occurring in the year and the base provider outpatient payment-tocost ratio for the provider (as defined in paragraph (f)(2) of this section).
(2) Base payment-to-cost-ratio defined. For purposes of this paragraph, HCFA shall determine these ratios as if the amendments to sections 1833(i)(3)(B)(i)(II) and 1833(n)(1)(B)(i) of the Act made by section 4521 of the BBA, to require that the full amount beneficiaries paid as coinsurance under section 1862(a)(2)(A) of the Act are taken into account in determining Medicare Part B Trust Fund payment to the hospital, were in effect in 1996. The "base payment-to-cost ratio" for a hospital or CMHC means the ratio of-
(i) The provider's payment under this part for covered outpatient services furnished during the cost reporting period ending in 1996, including any payment for these services through costsharing described in paragraph (e) of this section; and
(ii) The reasonable cost of these services for this period, without applying the cost reductions under section 1861(v)(1)(S) of the Act.
(g) Interim payments. HCFA makes payments under this paragraph to hospitals and CMHCs on an interim basis, subject to retrospective adjustments based on settled cost reports.
(h) No effect on coinsurance. No payment made under this section affects the unadjusted coinsurance amount or the coinsurance amount described in § 419.41.
(i) Application without regard to budget neutrality. The additional payments made under this paragraph-
(1) Are not considered an adjustment under § 419.43 (f); and
(2) Are not implemented in a budget neutral manner.

## PART 424-CONDITIONS FOR MEDICARE PAYMENT

G. Part 424 is amended as set forth below:

1. The authority citation for part 424 continues to read as follows:
Authority: Secs. 1102 and 1871 of the Social Security Act (42 U.S.C. 1302 and 1395hh).
2. In $\S 424.24$, the heading to paragraph (e) is republished, and a new paragraph (e)(3) is added to read as follows:
§424.24 Requirements for medical and other health services furnished by providers under Medicare Part B.
(e) Partial hospitalization services: Content of certification and plan of treatment requirements-
(3) Recertification requirements.
(i) Signature. The physician recertification must be signed by a physician who is treating the patient and has knowledge of the patient's response to treatment.
(ii) Timing. The first recertification is required as of the 18th day of partial hospitalization services. Subsequent recertifications are required at intervals established by the provider, but no less frequently than every 30 days.
(iii) Content. The recertification must specify that the patient would otherwise require inpatient psychiatric care in the absence of continued stay in the partial hospitalization program and describe the following:
(A) The patient's response to the therapeutic interventions provided by the partial hospitalization program.
(B) The patient's psychiatric symptoms that continue to place the patient at risk of hospitalization.
(C) Treatment goals for coordination of services to facilitate discharge from the partial hospitalization program.

## PART 489—PROVIDER AGREEMENTS AND SUPPLIER APPROVAL

H. Part 489 is amended as set forth below:

1. The authority citation to part 489 continues to read as follows:
Authority: Secs. 1102 and 1871 of the Social Security Act (42 U.S.C. 1302 and 1395hh).

## Subpart B—Essentials of Provider Agreements

2. In $\S 489.20$, the introductory text to the section is republished; the introductory text to paragraph (d) is revised; paragraphs (d)(3), (d)(4), and (d)(5) are redesignated as paragraphs (d)(4), (d)(5), and (d)(6), respectively; and a new paragraph (d)(3) is added to read as follows:

## §489.20 Basic commitments.

The provider agrees to the following:
(d) In the case of a hospital or a CAH that furnishes services to Medicare beneficiaries, either to furnish directly or to make arrangements (as defined in §409.3 of this chapter) for all Medicarecovered services to inpatients and outpatients of a hospital or a CAH except the following:
(3) Nurse practitioner and clinical nurse specialist services, as defined in section $1861(\mathrm{~s})(2)(\mathrm{K})(\mathrm{ii})$ of the Act.
3. In §489.24, the definition for "Comes to the emergency department" in paragraph (b) is revised, and a new paragraph (i) is added to read as follows:

## §489.24 Special responsibilities of

 Medicare hospitals in emergency cases.(b) * * *

Comes to the emergency department means, with respect to an individual requesting examination or treatment, that the individual is on the hospital property. For purposes of this section, "property" means the entire main hospital campus as defined in $\S 413.65(\mathrm{~b})$ of this chapter, including the parking lot, sidewalk, and driveway, as well as any facility or organization that is located off the main hospital campus but has been determined under $\S 413.65$ of this chapter to be a department of the hospital. The responsibilities of hospitals with respect to these offcampus facilities or organizations are described in paragraph (i) of this section. Property also includes ambulances owned and operated by the hospital even if the ambulance is not on hospital grounds. An individual in a nonhospital-owned ambulance on hospital property is considered to have come to the hospital's emergency department. An individual in a nonhospital-owned ambulance off hospital property is not considered to have come to the hospital's emergency department even if a member of the ambulance staff contacts the hospital by telephone or telemetry communications
and informs the hospital that they want to transport the individual to the hospital for examination and treatment. In these situations, the hospital may deny access if it is in "diversionary status," that is, it does not have the staff or facilities to accept any additional emergency patients. If, however, the ambulance staff disregards the hospital's instructions and transports the individual on to hospital property, the individual is considered to have come to the emergency department.
(i) Off-campus departments. If an individual comes to a facility or organization that is located off the main hospital campus but has been determined under $\S 416.35$ of this chapter to be a department of the hospital and a request is made on the individual's behalf for examination or treatment of a potential emergency medical condition as otherwise described in paragraph (a) of this section, the hospital is obligated in accordance with the rules in this paragraph to provide the individual with an appropriate medical screening examination and any necessary stabilizing treatment or an appropriate transfer.
(1) Capability of the hospital. The capability of the hospital includes that of the hospital as a whole, not just the capability of the off-campus department. Except for cases described in paragraph (i)(3)(ii) of this section, the obligation of a hospital under this section must be discharged within the hospital as a whole. However, the hospital is not required to locate additional personnel or staff to off-campus departments to be on standby for possible emergencies.
(2) Protocols for off-campus departments. The hospital must establish protocols for the handling of individuals with potential emergency conditions at off-campus departments. These protocols must provide for direct contact between personnel at the offcampus department and emergency personnel at the main hospital campus and may provide for dispatch of practitioners, when appropriate, from the main hospital campus to the offcampus department to provide screening or stabilization services.
(i) If the off-campus department is an urgent care center, primary care center, or other facility that is routinely staffed by physicians, RNs, or LPNs, these department personnel must be trained, and given appropriate protocols, for the handling of emergency cases. At least one individual on duty at the offcampus department during its regular hours of operation must be designated
as a qualified medical person as described in paragraph (d) of this section. The qualified medical person must initiate screening of individuals who come to the off-campus department with a potential emergency medical condition, and may be able to complete the screening and provide any necessary stabilizing treatment at the off-campus department, or to arrange an appropriate transfer.
(ii) If the off-campus department is a physical therapy, radiology, or other facility not routinely staffed with physicians, RNs, or LPNs, the department's personnel must be given protocols that direct them to contact emergency personnel at the main hospital campus for direction. Under this direction, and in accordance with protocols established in advance by the hospital, the personnel at the offcampus department must describe patient appearance and report symptoms and, if appropriate, either arrange transportation of the individual to the main hospital campus in accordance with paragraph (i)(3)(i) of this section or assist in an appropriate transfer as described in paragraphs (i)(3)(ii) and (d)(2) of this section.
(3) Movement or appropriate transfer from off-campus departments-(i) If the main hospital campus has the capability required by the individual and movement of the individual to the main campus would not significantly jeopardize the life or health of the individual, the personnel at the offcampus department must assist in arranging this movement. Movement of the individual to the main campus of the hospital is not considered a transfer under this section, since the individual is simply being moved from one department of a hospital to another department or facility of the same hospital.
(ii) If transfer of an individual with a potential emergency condition to a medical facility other than the main hospital campus is warranted, either because the main hospital campus does not have the specialized capability or facilities required by the individual, or because the individual's condition is deteriorating so rapidly that taking the time needed to move the individual to the main hospital campus would significantly jeopardize the life or health of the individual, personnel at the offcampus department must, in accordance with protocols established in advance by the hospital, assist in arranging an appropriate transfer of the individual to a medical facility other than the main hospital. The protocols must include procedures and agreements established in advance with other hospitals or
medical facilities in the area of the offcampus department to facilitate these appropriate transfers. Such a transfer would require-
(A) That there be either a request by or on behalf of the individual as described in paragraph (d)(1)(ii)(A) of this section or a certification by a physician or a qualified medical person as described in paragraph (d)(1)(ii)(B) or (d)(1)(ii)(C) of this section; and
(B) That the transfer comply with the requirements described in paragraph (d)(2) of this section.
(iii) If the individual is being appropriately transferred to another medical facility from the off-campus department, the requirement for the provision of medical treatment in paragraph (d)(2)(i) of this section would be met by provision of medical treatment within the capability of the transferring off-campus department.
PART 498-APPEALS PROCEDURES FOR DETERMINATIONS THAT AFFECT PARTICIPATION IN THE MEDICARE PROGRAM AND FOR
DETERMINATIONS THAT AFFECT THE PARTICIPATION OF ICFs/MR AND CERTAIN NFs IN THE MEDICAID PROGRAM
I. Part 498 is amended as set forth below:

1. The authority citation for part 498 continues to read as follows:

Authority: Secs. 1102 and 1871 of the Social Security Act (42 U.S.C. 1302 and 1395hh).
2. In $\S 498.2$, the introductory text is republished, and the definition of "Provider" is revised to read as follows:

## §498.2 Definitions.

As used in this part-
Provider means a hospital, critical access hospital (CAH), skilled nursing facility (SNF), comprehensive outpatient rehabilitation facility (CORF), home health agency (HHA), or hospice, that has in effect an agreement to participate in Medicare, that has in effect an agreement to participate in Medicaid, or a clinic, rehabilitation agency, or public health agency that has a similar agreement but only to furnish outpatient physical therapy or outpatient speech pathology services, and prospective provider means any of the listed entities that seeks to participate in Medicare as a provider or to have any facility or organization determined to be a department of the provider or provider-based entity under $\S 413.65$ of this chapter.
3. In §498.3, the introductory text to paragraph (b) is republished; paragraphs (b)(2) through (b)(15) are redesignated as paragraphs (b)(3) through (b)(16), respectively; and a new paragraph (b)(2) is added to read as follows:

## §498.3 Scope and applicability.

(b) Initial determinations by HCFA. HCFA makes initial determinations with respect to the following matters:
(2) Whether a prospective department of a provider, remote location of a hospital, satellite facility, or providerbased entity qualifies for provider-based status under $\S 413.65$ of this chapter, or whether such a facility or entity currently treated as a department of a provider, remote location of a hospital, satellite facility, or a provider-based entity no longer qualifies for that status under § 413.65 of this chapter.

## PART 1003—CIVIL MONEY PENALTIES, ASSESSMENTS AND EXCLUSIONS

J. Part 1003 is amended as set forth below:

1. The authority citation for part 1003 is revised to read as follows:

Authority: 42 U.S.C. 1302, 1320-7, 1320a7a, 1320a-7e, 1320b-10, 1395u(j), 1395u(k), $1395 \mathrm{cc}(\mathrm{g}), 1395 \mathrm{dd}(\mathrm{d})(1), 1395 \mathrm{~mm}, 1395 \mathrm{nn}(\mathrm{g})$, 1395ss(d), 1396(m), 11131(c), and 11137(b)(2).
2. Section 1003.100 is amended by revising paragraph (a), by republishing the introductory text to paragraphs (b) and (b)(1), by revising paragraphs (b)(1)(xi) and (b)(1)(xii), and by adding paragraph (b)(1)(xiii) to read as follows:

## § 1003.100 Basis and purpose.

(a) Basis. This part implements sections 1128(c), 1128A, 1128E, 1140, $1866(\mathrm{~g}), 1876(\mathrm{i}), 1877(\mathrm{~g}), 1882(\mathrm{~d})$ and 1903(m)(5) of the Social Security Act, and sections 421(c) and 427(b)(2) of Pub. L. 99-660 (42 U.S.C. 1320a-7, 1320a-7a, 1320a-7e, 1320a-7c, 1320b$10,1395 \mathrm{cc}(\mathrm{g}), 1395 \mathrm{~mm}, 1395 \mathrm{ss}(\mathrm{d})$, 1396(m), 11131(c), and 11137(b)(2)).
(b) Purpose. This part-
(1) Provides for the imposition of civil money penalties and, as applicable, assessments against persons who-
(xi) Are physicians or entities that enter into an arrangement or scheme that they know or should know has as a principal purpose the assuring of referrals by the physician to a particular entity that, if made directly, would violate the provisions of $\S 411.353$ of this title;
(xii) Violate the Federal health care programs' anti-kickback statute as set forth in section 1128B of the Act; or
(xiii) Knowingly and willfully present, or cause to be presented, a bill or request for payment for nonphysician services furnished to hospital patients (unless the services are furnished by the hospital, either directly or under an arrangement) in violation of sections 1862(a)(14) and 1866(a)(1)(H) of the Act.
3. Section 1003.102 is amended by republishing the introductory text to paragraph (b), by adding and reserving paragraphs (b)(12) through (b)(14), and by adding a new paragraph (b)(15) to read as follows:
§ 1003.102 Basis for civil money penalties and assessments.
(b) The OIG may impose a penalty, and where authorized, an assessment against any person (including an insurance company in the case of paragraphs (b)(5) and (b)(6) of this section) whom it determines in accordance with this part-
(15) Has knowingly and willfully presented, or caused to be presented, a bill or request for payment for items and services furnished to a hospital patient for which payment may be made under the Medicare or another Federal health care program, if that bill or request is inconsistent with an arrangement under section 1866(a)(1)(H) of the Act, or violates the requirements for such an arrangement.
4. Section 1003.103 is amended by revising paragraph (a), by adding and reserving paragraphs (i) and (j), and by adding a new paragraph (k) to read as follows:

## §1003.103 Amount of penalty.

(a) Except as provided in paragraphs (b) and (d) through (k) of this section,
the OIG may impose a penalty of not more than $\$ 10,000$ for each item or service that is subject to a determination under § 1003.102.
(k) For violations of section 1862(a)(14) of the Act and § 1003.102(b)(15), the OIG may impose a penalty of not more than $\$ 2,000$ for each bill or request for payment for items and services furnished to a hospital patient.
5. Section 1003.105 is amended by republishing the introductory text to paragraph (a)(1) and by revising paragraph (a)(1)(i) to read as follows:

## § 1003.105 Exclusion from participation in Medicare, Medicaid and other Federal health care programs.

(a)(1) Except as set forth in paragraph (b) of this section, in lieu of or in addition to any penalty or assessment, the OIG may exclude from participation in Medicare, Medicaid and other Federal health care programs the following persons for a period of time determined under § 1003.107-
(i) Any person who is subject to a penalty or assessment under
§ 1003.102(a), (b)(1) through (b)(4), or (b)(15).
(Catalog of Federal Domestic Assistance 93.774, Medicare-Supplementary Medical Insurance Program)

Dated: March 3, 2000.

## Nancy-Ann Min DeParle,

Administrator, Health Care Financing Administration.

Dated: March 28, 2000.

## June G. Brown,

Inspector General, Department of Health and Human Services.

Approved: March 29, 2000.

## Donna E. Shalala,

Secretary.
Note: The following addenda will not appear in the Code of Federal Regulations.

Note to Addenda A, B, C, E and F: Addenda A, B, and C have a number of errors in the following columns: APC, status indicator, payment rate, and national unadjusted coinsurance and minimum unadjusted coinsurance. We identified these errors too late in preparing this rule for publication to correct them. Some of the errors are related to the status codes assigned to the HCPCS codes and APCs.
Some errors affect addenda B, C, and E. Several of these errors involve procedures incorrectly identified as inpatient procedures, and one inpatient procedure incorrectly identified as an outpatient procedure. Certain PET scan codes and other codes are shown in incorrect APCs.
Screening sigmoidoscopy and colonoscopy
APCs have the wrong HCPCS codes and incorrect payment rates and coinsurance amounts. Certain dental codes were inadvertently identified as errors, so their correct APC assignments, payment rate and coinsurance amounts were not shown in the addenda. Two breath tests are subject to the clinical diagnostic lab fee schedule. We have listed below the corrections that have payment implications.
Addendum F does not include status indicators G and H which identify items that are eligible for pass-through payments. (See section III.B. 3 of the preamble for a complete description of all status indications used in conjunction with this final rule.)
We also note that the word "proposed" should not appear on any Addenda contained in this final rule such as on Addendum A or C .
The fiscal intermediaries will receive the necessary changes to process outpatient PPS claims correctly. We will post the corrected Addendum B on our Website and publish a correction document in the Federal Register.
Our Website address is http://
www.hcfa.gov/medicare/hopsmain.htm.

List Accompanying Note To Addenda A, B, C, E and F

| $\begin{aligned} & \text { CPT/ } \\ & \text { HCPCS } \end{aligned}$ | HOPD Status Indicator | Description | APC | Relative Weight | Proposed Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 20979 | E | US bone stimulation. |  |  |  |  |  |
| 31375 | C | Partial removal of larynx. |  |  |  |  |  |
| 35481 | T | Atherectomy, open | 0081 | 19.36 | \$938.71 | \$434.25 | \$187.74 |
| 61795 | S | Brain surgery using computer | 0302 | 8.21 | \$398.08 | \$216.55 | \$79.62 |
| 61886 | T | Implant neurostim arrays | 0222 | 25.48 | \$1,235.45 | \$780.07 | \$247.09 |
| 75945 | S | Intravascular us | 0267 | 2.72 | \$131.88 | \$80.06 | \$26.38 |
| 75946 | S | Intravascular us add-on | 0267 | 2.72 | \$131.88 | \$80.06 | \$26.38 |
| 78267 | A | Breath test attain/anal, c-14. |  |  |  |  |  |
| 78268 | A | Breath test analysis, c-14. |  |  |  |  |  |
| 92978 | S | Intravasc us, heart add-on | 0267 | 2.72 | \$131.88 | \$80.06 | \$26.38 |
| 92979 | S | Intravasc us, heart add-on .................................... | 0267 | 2.72 | \$131.88 | \$80.06 | \$26.38 |
| 96570 | T | Photodynamic Tx, 30 min | 0973 | 5.16 | \$250.19 |  | \$50.04 |
| 96571 | T | Photodynamic Tx, addl 15 min | 0973 | 5.16 | \$250.19 |  | \$50.04 |
| D0277 | S | Vert bitewings-sev to eight ..................................... | 0330 | 1.51 | \$73.22 | \$14.64 | \$14.64 |
| D0472 | S | Gross exam, prep \& report | 0330 | 1.51 | \$73.22 | \$14.64 | \$14.64 |

List Accompanying Note To Addenda A, B, C, E and F-Continued

| CPT/ <br> HCPCS | HOPD <br> Status <br> Indicator |  | Description | Relative <br> Weight | Proposed <br> Payment <br> Rate | National <br> Unadjusted <br> Coinsurance |
| :--- | :---: | :--- | ---: | ---: | ---: | ---: | ---: |
| D0473 | S | Micro exam, prep \& report .................................. | 0330 | 1.51 | $\$ 73.22$ | $\$ 14.64$ |
| Coinsurance |  |  |  |  |  |  |

addendum A.-List of Hospital Outpatient Ambulatory Payment Classes With Status indicators, Relative Weights, Payment Rates, and Coinsurance Amounts

| APC | Group Title | Status Indicator | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 0001 | Photochemotherapy | S | 0.47 | \$22.79 | \$8.49 | \$4.56 |
| 0002 | Fine needle Biopsy/Aspiration | T | 0.62 | \$30.06 | \$17.66 | \$6.01 |
| 0003 | Bone Marrow Biopsy/Aspiration | T | 0.98 | \$47.52 | \$27.99 | \$9.50 |
| 0004 | Level I Needle Biopsy/Aspiration Except Bone Marrow | T | 1.84 | \$89.22 | \$32.57 | \$17.84 |
| 0005 | Level II Needle Biopsy/Aspiration Except Bone Marrow ... | T | 5.41 | \$262.32 | \$119.75 | \$52.46 |
| 0006 | Level I Incision \& Drainage .......................................................... | T | 2.00 | \$96.97 | \$33.95 | \$19.39 |
| 0007 | Level II Incision \& Drainage | T | 3.68 | \$178.43 | \$72.03 | \$35.69 |
| 0008 | Level III Incision \& Drainage | T | 6.15 | \$298.20 | \$113.67 | \$59.64 |
| 0009 | Nail Procedures ................. | T | 0.74 | \$35.88 | \$9.63 | \$7.18 |
| 0010 | Level I Destruction of Lesion | T | 0.55 | \$26.67 | \$9.86 | \$5.33 |
| 0011 | Level II Destruction of Lesion | T | 2.72 | \$131.88 | \$50.01 | \$26.38 |
| 0012 | Level I Debridement \& Destruction | T | 0.53 | \$25.70 | \$9.18 | \$5.14 |
| 0013 | Level II Debridement \& Destruction | T | 0.91 | \$44.12 | \$17.66 | \$8.82 |
| 0014 | Level III Debridement \& Destruction | T | 1.50 | \$72.73 | \$24.55 | \$14.55 |
| 0015 | Level IV Debridement \& Destruction | T | 1.77 | \$85.82 | \$31.20 | \$17.16 |
| 0016 | Level V Debridement \& Destruction | T | 3.53 | \$171.16 | \$74.67 | \$34.23 |
| 0017 | Level VI Debridement \& Destruction | T | 12.45 | \$603.66 | \$289.16 | \$120.73 |
| 0018 | Biopsy Skin, Subcutaneous Tissue or Mucous Membrane | T | 0.94 | \$45.58 | \$17.66 | \$9.12 |
| 0019 | Level I Excision/Biopsy | T | 4.00 | \$193.95 | \$78.91 | \$38.79 |
| 0020 | Level II Excision/Biopsy | T | 6.51 | \$315.65 | \$130.53 | \$63.13 |
| 0021 | Level III Excision/Biopsy | T | 10.49 | \$508.63 | \$236.51 | \$101.73 |
| 0022 | Level IV Excision/Biopsy | T | 12.49 | \$605.60 | \$292.94 | \$121.12 |
| 0023 | Exploration Penetrating Wound | T | 1.98 | \$96.00 | \$40.37 | \$19.20 |
| 0024 | Level I Skin Repair | T | 2.43 | \$117.82 | \$44.50 | \$23.56 |
| 0025 | Level II Skin Repair | T | 3.74 | \$181.34 | \$70.66 | \$36.27 |
| 0026 | Level III Skin Repair | T | 12.11 | \$587.18 | \$277.92 | \$117.44 |
| 0027 | Level IV Skin Repair | T | 15.80 | \$766.10 | \$383.10 | \$153.22 |
| 0029 | Incision/Excision Breast | T | 12.85 | \$623.06 | \$303.50 | \$124.61 |
| 0030 | Breast Reconstruction/Mastectomy | T | 20.19 | \$978.95 | \$523.95 | \$195.79 |
| 0031 | Hyperbaric Oxygen | S | 3.00 | \$145.46 | \$140.85 | \$29.09 |
| 0032 | Placement Transvenous Catheters/Arterial Cutdown ........................ | T | 5.40 | \$261.83 | \$119.52 | \$52.37 |
| 0033 | Partial Hospitalization | P | 4.17 | \$202.19 | \$48.17 | \$40.44 |
| 0040 | Arthrocentesis \& Ligament/Tendon Injection .................................. | T | 2.11 | \$102.31 | \$40.60 | \$20.46 |
| 0041 | Arthroscopy | T | 24.57 | \$1,191.33 | \$592.08 | \$238.27 |
| 0042 | Arthroscopically-Aided Procedures | T | 29.22 | \$1,416.79 | \$804.74 | \$283.36 |
| 0043 | Closed Treatment Fracture Finger/Toe/Trunk ................................ | T | 1.64 | \$79.52 | \$25.46 | \$15.90 |
| 0044 | Closed Treatment Fracture/Dislocation Except Finger/Toe/Trunk ....... | T | 2.17 | \$105.22 | \$38.08 | \$21.04 |
| 0045 | Bone/Joint Manipulation Under Anesthesia .................................... | T | 11.02 | \$534.33 | \$277.12 | \$106.87 |
| 0046 | Open/Percutaneous Treatment Fracture or Dislocation .................... | T | 22.29 | \$1,080.78 | \$535.76 | \$216.16 |
| 0047 | Arthroplasty without Prosthesis | T | 22.09 | \$1,071.08 | \$537.03 | \$214.22 |
| 0048 | Arthroplasty with Prosthesis ....................................................... | T | 29.06 | \$1,409.03 | \$725.94 | \$281.81 |
| 0049 | Level I Musculoskeletal Procedures Except Hand and Foot .............. | T | 15.04 | \$729.25 | \$356.95 | \$145.85 |
| 0050 | Level II Musculoskeletal Procedures Except Hand and Foot ............. | T | 21.13 | \$1,024.53 | \$513.86 | \$204.91 |
| 0051 | Level III Musculoskeletal Procedures Except Hand and Foot ............ | T | 27.76 | \$1,346.00 | \$675.24 | \$269.20 |
| 0052 | Level IV Musculoskeletal Procedures Except Hand and Foot ............ | T | 36.16 | \$1,753.29 | \$930.91 | \$350.66 |
| 0053 | Level I Hand Musculoskeletal Procedures ...................................... | T | 11.32 | \$548.87 | \$253.49 | \$109.77 |
| 0054 | Level II Hand Musculoskeletal Procedures ..................................... | T | 19.66 | \$953.26 | \$472.33 | \$190.65 |
| 0055 | Level I Foot Musculoskeletal Procedures ....................................... | T | 15.47 | \$750.10 | \$355.34 | \$150.02 |
| 0056 | Level II Foot Musculoskeletal Procedures ...................................... | T | 17.30 | \$838.83 | \$405.81 | \$167.77 |

[^123]
## addendum A.-List of Hospital Outpatient Ambulatory Payment Classes With Status Indicators, Relative Weights, Payment Rates, and Coinsurance Amounts-Continued

| APC | Group Title | Status Indicator | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 0057 | Bunion Procedures | T | 21.00 | \$1,018.23 | \$496.65 | \$203.65 |
| 0058 | Level I Strapping and Cast Application | S | 1.09 | \$52.85 | \$19.27 | \$10.57 |
| 0059 | Level II Strapping and Cast Application | S | 1.74 | \$84.37 | \$29.59 | \$16.87 |
| 0060 | Manipulation Therapy | S | 0.77 | \$37.34 | \$7.80 | \$7.47 |
| 0070 | Thoracentesis/Lavage Procedures | T | 3.64 | \$176.49 | \$79.60 | \$35.30 |
| 0071 | Level I Endoscopy Upper Airway . | T | 0.55 | \$26.67 | \$14.22 | \$5.33 |
| 0072 | Level II Endoscopy Upper Airway | T | 1.26 | \$61.09 | \$41.52 | \$12.22 |
| 0073 | Level III Endoscopy Upper Airway | T | 4.11 | \$199.28 | \$91.07 | \$39.86 |
| 0074 | Level IV Endoscopy Upper Airway | T | 13.61 | \$659.91 | \$347.54 | \$131.98 |
| 0075 | Level V Endoscopy Upper Airway | T | 18.55 | \$899.44 | \$467.29 | \$179.89 |
| 0076 | Endoscopy Lower Airway | T | 8.06 | \$390.81 | \$197.05 | \$78.16 |
| 0077 | Level I Pulmonary Treatment | S | 0.43 | \$20.85 | \$12.62 | \$4.17 |
| 0078 | Level II Pulmonary Treatment | S | 1.34 | \$64.97 | \$29.13 | \$12.99 |
| 0079 | Ventilation Initiation and Management | S | 3.18 | \$154.19 | \$107.70 | \$30.84 |
| 0080 | Diagnostic Cardiac Catheterization | T | 25.77 | \$1,249.51 | \$713.89 | \$249.90 |
| 0081 | Non-Coronary Angioplasty or Atherectomy | T | 19.36 | \$938.71 | \$434.25 | \$187.74 |
| 0082 | Coronary Atherectomy ................... | T | 40.34 | \$1,955.97 | \$859.56 | \$391.19 |
| 0083 | Coronary Angiosplasty | T | 45.79 | \$2,220.22 | \$1,322.95 | \$444.04 |
| 0084 | Level I Electrophysiologic Evaluation | S | 10.70 | \$518.81 | \$177.79 | \$103.76 |
| 0085 | Level II Electrophysiologic Evaluation | S | 27.06 | \$1,312.06 | \$654.48 | \$262.41 |
| 0086 | Ablate Heart Dysrhythm Focus | S | 47.62 | \$2,308.95 | \$1,265.37 | \$461.79 |
| 0087 | Cardiac Electrophysiologic Recording/Mapping | S | 9.53 | \$462.08 | \$214.72 | \$92.42 |
| 0088 | Thrombectomy | T | 26.49 | \$1,284.42 | \$678.68 | \$256.88 |
| 0089 | Level I Implantation/Removal/Revision of Pacemaker, AICD or Vascular Device. | T | 6.49 | \$314.68 | \$130.07 | \$62.94 |
| 0090 | Level II Implantation/Removal/Revision of Pacemaker, AICD or Vascular Device. | T | 20.96 | \$1,016.29 | \$573.04 | \$203.26 |
| 0091 | Level I Vascular Ligation ............................................................. | T | 14.79 | \$717.12 | \$348.23 | \$143.42 |
| 0092 | Level II Vascular Ligation | T | 20.21 | \$979.92 | \$505.37 | \$195.98 |
| 0093 | Vascular Repair/Fistula Construction | T | 17.95 | \$870.34 | \$422.33 | \$174.07 |
| 0094 | Resuscitation and Cardioversion | S | 4.51 | \$218.68 | \$105.29 | \$43.74 |
| 0095 | Cardiac Rehabilitation | S | 0.64 | \$31.03 | \$16.98 | \$6.21 |
| 0096 | Non-Invasive Vascular Studies | S | 2.06 | \$99.88 | \$61.48 | \$19.98 |
| 0097 | Cardiovascular Stress Test | S | 1.62 | \$78.55 | \$62.40 | \$15.71 |
| 0098 | Injection of Sclerosing Solution | T | 1.19 | \$57.70 | \$20.88 | \$11.54 |
| 0099 | Continuous Cardiac Monitoring .................................................... | S | 0.38 | \$18.43 | \$14.68 | \$3.69 |
| 0100 | Continuous ECG ........................................................................ | S | 1.70 | \$82.43 | \$71.57 | \$16.49 |
| 0101 | Tilt Table Evaluation | S | 4.47 | \$216.74 | \$128.84 | \$43.35 |
| 0102 | Electronic Analysis of Pacemakers/other Devices ............................ | S | 0.45 | \$21.82 | \$12.62 | \$4.36 |
| 0109 | Bone Marrow Harvesting and Bone Marrow/Stem Cell Transplant ..... | S | 4.13 | \$200.25 | \$40.05 | \$40.05 |
| 0110 | Transfusion ............................................................................... | S | 5.83 | \$282.68 | \$122.73 | \$56.54 |
| 0111 | Blood Product Exchange | S | 14.17 | \$687.06 | \$300.74 | \$137.41 |
| 0112 | Extracorporeal Photopheresis | S | 39.60 | \$1,920.09 | \$663.65 | \$384.02 |
| 0113 | Excision Lymphatic System ......................................................... | T | 13.89 | \$673.49 | \$326.55 | \$134.70 |
| 0114 | Thyroid/Lymphadenectomy Procedures | T | 19.56 | \$948.41 | \$493.78 | \$189.68 |
| 0116 | Chemotherapy Administration by Other Technique Except Infusion ... | S | 2.34 | \$113.46 | \$22.69 | \$22.69 |
| 0117 | Chemotherapy Administration by Infusion Only ............................... | S | 1.84 | \$89.22 | \$71.80 | \$17.84 |
| 0118 | Chemotherapy Administration by Both Infusion and Other Technique | S | 2.90 | \$140.61 | \$72.03 | \$28.12 |
| 0120 | Infusion Therapy Except Chemotherapy ......................................... | S | 1.66 | \$80.49 | \$42.67 | \$16.10 |
| 0121 | Level I Tube changes and Repositioning ....................................... | T | 2.36 | \$114.43 | \$52.53 | \$22.89 |
| 0122 | Level II Tube changes and Repositioning ...................................... | T | 5.04 | \$244.37 | \$114.93 | \$48.88 |
| 0123 | Level III Tube changes and Repositioning | T | 13.89 | \$673.49 | \$350.75 | \$134.70 |
| 0130 | Level I Laparoscopy ................................................................... | T | 25.36 | \$1,229.63 | \$659.53 | \$245.93 |
| 0131 | Level II Laparoscopy | T | 41.81 | \$2,027.24 | \$1,089.88 | \$405.45 |
| 0132 | Level III Laparoscopy | T | 48.91 | \$2,371.50 | \$1,239.22 | \$474.30 |
| 0140 | Esophageal Dilation without Endoscopy | T | 4.74 | \$229.83 | \$107.24 | \$45.97 |
| 0141 | Upper Gl Procedures .................................................................. | T | 7.15 | \$346.68 | \$184.67 | \$69.34 |
| 0142 | Small Intestine Endoscopy | T | 7.45 | \$361.23 | \$162.42 | \$72.25 |
| 0143 | Lower GI Endoscopy . | T | 7.98 | \$386.93 | \$199.12 | \$77.39 |
| 0144 | Diagnostic Anoscopy .................................................................. | T | 2.23 | \$108.13 | \$49.32 | \$21.63 |
| 0145 | Therapeutic Anoscopy | T | 7.46 | \$361.71 | \$179.39 | \$72.34 |
| 0146 | Level I Sigmoidoscopy | T | 2.83 | \$137.22 | \$65.15 | \$27.44 |
| 0147 | Level II Sigmoidoscopy | T | 6.26 | \$303.53 | \$149.11 | \$60.71 |
| 0148 | Level I Anal/Rectal Procedure | T | 2.34 | \$113.46 | \$43.59 | \$22.69 |
| 0149 | Level II Anal/Rectal Procedure | T | 12.86 | \$623.54 | \$293.06 | \$124.71 |
| 0150 | Level III Anal/Rectal Procedure | T | 17.68 | \$857.25 | \$437.12 | \$171.45 |
| 0151 | Endoscopic Retrograde Cholangio-Pancreatography (ERCP) ........... | T | 10.53 | \$510.57 | \$245.46 | \$102.11 |
| 0152 | Percutaneous Biliary Endoscopic Procedures ... | T | 8.22 | \$398.56 | \$207.38 | \$79.71 |
| 0153 | Peritoneal and Abdominal Procedures | T | 19.62 | \$951.32 | \$496.31 | \$190.26 |
| 0154 | Hernia/Hydrocele Procedures | T | 22.43 | \$1,087.57 | \$556.98 | \$217.51 |
| ${ }^{2} 0157$ | Colorectal Cancer Screening: Barium Enema ................................. | S | 1.79 | \$86.79 |  | \$17.36 |
| ${ }^{1} 0158$ | Colorectal Cancer Screening: Colonoscopy ................................... | S | 7.98 | \$386.93 |  | \$96.73 |
| ${ }^{1} 0159$ | Colorectal Cancer Screening: Flexible Sigmoidoscopy | S | 7.98 | \$137.22 |  | \$34.31 |

[^124]addendum A.-List of Hospital Outpatient Ambulatory Payment Classes With Status indicators, Relative Weights, Payment Rates, and Coinsurance Amounts-Continued

| APC | Group Title | Status Indicator | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 0160 | Level I Cystourethroscopy and other Geni | T | 5.43 | \$263.28 | \$110.11 | 2.66 |
| 0161 | Level II Cystourethroscopy and other Genitourinary Procedures | T | 10.94 | \$530.45 | \$249.36 | \$106.09 |
| 0162 | Level III Cystourethroscopy and other Genitourinary Procedures ....... | T | 17.49 | \$848.04 | \$427.49 | \$169.61 |
| 0163 | Level IV Cystourethroscopy and other Genitourinary Procedures ...... | T | 28.98 | \$1,405.16 | \$792.58 | \$281.03 |
| 0164 | Level I Urinary and Anal Procedures | T | 2.17 | \$105.23 | \$33.03 | \$21.05 |
| 0165 | Level II Urinary and Anal Procedures | T | 3.89 | \$188.61 | \$91.76 | \$37.72 |
| 0166 | Level I Urethral Procedures .............. | T | 10.17 | \$493.11 | \$218.73 | \$98.62 |
| 0167 | Level II Urethral Procedures | T | 21.06 | \$1,021.14 | \$555.84 | \$204.23 |
| 0168 | Level III Urethral Procedures | T | 24.94 | \$1,209.27 | \$536.11 | \$241.85 |
| 0169 | Lithotripsy | T | 46.72 | \$2,265.32 | \$1,384.20 | \$453.06 |
| 0170 | Dialysis for Other Than ESRD Patients ......................................... | S | 6.68 | \$323.89 | \$72.26 | \$64.78 |
| 0180 | Circumcision | T | 13.62 | \$660.39 | \$304.87 | \$132.08 |
| 0181 | Penile Procedures | T | 32.37 | \$1,569.53 | \$906.36 | \$313.91 |
| 0182 | Insertion of Penile Prosthesis | T | 52.11 | \$2,526.66 | \$1,525.05 | \$505.33 |
| 0183 | Testes/Epididymis Procedures | T | 18.26 | \$885.37 | \$448.94 | \$177.07 |
| 0184 | Prostate Biopsy | T | 4.94 | \$239.53 | \$122.96 | \$47.91 |
| 0190 | Surgical Hysteroscopy | T | 17.85 | \$865.49 | \$443.89 | \$173.10 |
| 0191 | Level I Female Reproductive Procedures | T | 1.19 | \$57.70 | \$17.43 | \$11.54 |
| 0192 | Level II Female Reproductive Procedures | T | 2.38 | \$115.40 | \$35.33 | \$23.08 |
| 0193 | Level III Female Reproductive Procedures | T | 8.93 | \$432.99 | \$171.13 | \$86.60 |
| 0194 | Level IV Female Reproductive Procedures | T | 16.21 | \$785.98 | \$395.94 | \$157.20 |
| 0195 | Level V Female Reproductive Procedures .. | T | 18.68 | \$905.74 | \$483.80 | \$181.15 |
| 0196 | Dilatation \& Curettage | T | 14.47 | \$701.61 | \$357.98 | \$140.32 |
| 0197 | Infertility Procedures | T | 2.40 | \$116.37 | \$49.55 | \$23.27 |
| 0198 | Pregnancy and Neonatal Care Procedures | T | 1.34 | \$64.97 | \$33.03 | \$12.99 |
| 0199 | Vaginal Delivery | T | 11.20 | \$543.06 | \$157.83 | \$108.61 |
| 0200 | Therapeutic Abortion | T | 13.89 | \$673.49 | \$373.23 | \$134.70 |
| 0201 | Spontaneous Abortion | T | 13.00 | \$630.33 | \$329.65 | \$126.07 |
| 0210 | Spinal Tap | T | 3.00 | \$145.46 | \$62.40 | \$29.09 |
| 0211 | Level I Nervous System Injections | T | 3.32 | \$160.98 | \$74.78 | \$32.20 |
| 0212 | Level II Nervous System Injections | T | 3.64 | \$176.49 | \$88.78 | \$35.30 |
| 0213 | Extended EEG Studies and Sleep Studies | S | 11.15 | \$540.63 | \$290.42 | \$108.13 |
| 0214 | Electroencephalogram | S | 2.32 | \$112.49 | \$58.50 | \$22.50 |
| 0215 | Level I Nerve and Muscle Tests | S | 1.15 | \$55.76 | \$30.05 | \$11.15 |
| 0216 | Level II Nerve and Muscle Tests | S | 2.87 | \$139.16 | \$64.69 | \$27.83 |
| 0217 | Level III Nerve and Muscle Tests | S | 5.87 | \$287.62 | \$156.68 | \$56.92 |
| 0220 | Level I Nerve Procedures | T | 13.96 | \$676.88 | \$326.21 | \$135.38 |
| 0221 | Level II Nerve Procedures | T | 18.36 | \$890.22 | \$463.62 | \$178.04 |
| 0222 | Implantation of Neurological Device | T | 25.48 | \$1,235.45 | \$780.07 | \$247.09 |
| 0223 | Level I Revision/Removal Neurological Device . | T | 6.34 | \$307.41 | \$153.24 | \$61.48 |
| 0224 | Level II Revision/Removal Neurological Device ... | T | 15.94 | \$772.88 | \$374.61 | \$154.58 |
| 0225 | Implantation of Neurostimulator Electrodes | T | 3.43 | \$166.31 | \$64.46 | \$33.26 |
| 0230 | Level I Eye Tests | S | 0.98 | \$47.52 | \$22.48 | \$9.50 |
| 0231 | Level II Eye Tests | S | 2.64 | \$128.01 | \$59.87 | \$25.60 |
| 0232 | Level I Anterior Segment Eye | T | 6.04 | \$292.86 | \$134.66 | \$58.57 |
| 0233 | Level II Anterior Segment Eye | T | 13.79 | \$668.64 | \$331.60 | \$133.73 |
| 0234 | Level III Anterior Segment Eye Procedures | T | 20.64 | \$1,000.77 | \$502.16 | \$200.15 |
| 0235 | Level I Posterior Segment Eye Procedures | T | 2.94 | \$142.55 | \$78.91 | \$28.51 |
| 0236 | Level II Posterior Segment Eye Procedures ................................... | T | 6.70 | \$324.86 | \$147.96 | \$64.97 |
| 0237 | Level III Posterior Segment Eye Procedures .................................... | T | 33.96 | \$1,646.62 | \$852.68 | \$329.32 |
| 0238 | Level I Repair and Plastic Eye Procedures ............................. | T | 2.80 | \$135.76 | \$58.96 | \$27.15 |
| 0239 | Level II Repair and Plastic Eye Procedures ..................................... | T | 6.26 | \$303.53 | \$123.42 | \$60.71 |
| 0240 | Level III Repair and Plastic Eye Procedures | T | 13.47 | \$653.12 | \$315.31 | \$130.62 |
| 0241 | Level IV Repair and Plastic Eye Procedures | T | 16.60 | \$804.89 | \$384.47 | \$160.98 |
| 0242 | Level V Repair and Plastic Eye Procedures. | T | 23.70 | \$1,149.14 | \$597.36 | \$229.83 |
| 0243 | Strabismus/Muscle Procedures ..... | T | 17.99 | \$872.28 | \$431.39 | \$174.46 |
| 0244 | Corneal Transplant | T | 32.88 | \$1,594.26 | \$851.42 | \$318.85 |
| 0245 | Cataract Procedures without IOL Insert ......................................... | T | 26.55 | \$1,287.33 | \$623.85 | \$257.47 |
| 0246 | Cataract Procedures with IOL Insert | T | 26.55 | \$1,287.33 | \$623.85 | \$257.47 |
| 0247 | Laser Eye Procedures Except Retinal | T | 4.89 | \$237.10 | \$112.86 | \$47.42 |
| 0248 | Laser Retinal Procedures... | T | 4.19 | \$203.16 | \$94.05 | \$40.63 |
| 0250 | Nasal Cauterization/Packing | T | 2.21 | \$107.16 | \$38.54 | \$21.43 |
| 0251 | Level I ENT Procedures | T | 1.68 | \$81.46 | \$27.99 | \$16.29 |
| 0252 | Level II ENT Procedures | T | 5.18 | \$251.16 | \$114.24 | \$50.23 |
| 0253 | Level III ENT Procedures | T | 12.02 | \$582.81 | \$284.00 | \$116.56 |
| 0254 | Level IV ENT Procedures | T | 12.45 | \$603.66 | \$272.41 | \$120.73 |
| 0256 | Level V ENT Procedures | T | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 0257 | Implantation of Cochlear Device | T | 115.31 | \$5,591.04 | \$3,498.58 | \$1,118.21 |
| 0258 | Tonsil and Adenoid Procedures | x | 18.62 | \$902.83 | \$462.81 | \$180.57 |
| 0260 | Level I Plain Film Except Teeth | X | 0.79 | \$38.30 | \$22.02 | \$7.66 |
| 0261 | Level II Plain Film Except Teeth Including Bone Density Measurement. | X | 1.38 | \$66.91 | \$38.77 | \$13.38 |
| 0262 | Plain Film of Teeth | X | 0.40 | \$19.39 | \$10.90 | \$3.88 |

[^125]
## addendum A.-List of Hospital Outpatient Ambulatory Payment Classes With Status Indicators, Relative Weights, Payment Rates, and Coinsurance Amounts-Continued

| APC | Group Title | Status Indicator | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 0263 | Level I Miscellaneous Radiology Procedures | X | 1.68 | \$81.46 | \$45.88 | \$16.29 |
| 0264 | Level II Miscellaneous Radiology Procedures | X | 3.83 | \$185.71 | \$108.97 | \$37.14 |
| 0265 | Level I Diagnostic Ultrasound Except Vascular | S | 1.17 | \$56.73 | \$38.08 | \$11.35 |
| 0266 | Level II Diagnostic Ultrasound Except Vascular | S | 1.79 | \$86.79 | \$57.35 | \$17.36 |
| 0267 | Vascular Ultrasound ......................................... | S | 2.72 | \$131.88 | \$80.06 | \$26.38 |
| 0268 | Guidance Under Ultrasound | X | 2.23 | \$108.13 | \$69.51 | \$21.63 |
| 0269 | Echocardiogram Except Transesophageal | S | 4.40 | \$213.34 | \$114.01 | \$42.67 |
| 0270 | Transesophageal Echocardiogram ............................................... | S | 5.55 | \$269.10 | \$150.26 | \$53.82 |
| 0271 | Mammography | S | 0.70 | \$33.94 | \$19.50 | \$6.79 |
| 0272 | Level I Fluoroscopy | X | 1.40 | \$67.88 | \$39.00 | \$13.58 |
| 0273 | Level II Fluoroscopy | X | 2.49 | \$120.73 | \$61.02 | \$24.15 |
| 0274 | Myelography .............................................................................. | S | 4.83 | \$234.19 | \$128.12 | \$46.84 |
| 0275 | Arthrography | S | 2.74 | \$132.85 | \$72.26 | \$26.57 |
| 0276 | Level I Digestive Radiology | S | 1.79 | \$86.79 | \$49.78 | \$17.36 |
| 0277 | Level II Digestive Radiology | S | 2.47 | \$119.76 | \$69.28 | \$23.95 |
| 0278 | Diagnostic Urography | S | 2.85 | \$138.19 | \$81.67 | \$27.64 |
| 0279 | Level I Diagnostic Angiography and Venography Except Extremity ... | S | 6.30 | \$305.47 | \$174.57 | \$61.09 |
| 0280 | Level II Diagnostic Angiography and Venography Except Extremity .. | S | 14.98 | \$726.34 | \$380.12 | \$145.27 |
| 0281 | Venography of Extremity .............................................................. | S | 4.40 | \$213.34 | \$115.16 | \$42.67 |
| 0282 | Level I Computerized Axial Tomography | S | 2.38 | \$115.40 | \$94.51 | \$23.08 |
| 0283 | Level II Computerized Axial Tomography | S | 4.89 | \$237.10 | \$179.39 | \$47.42 |
| 0284 | Magnetic Resonance Imaging ...................................................... | S | 8.02 | \$388.87 | \$257.39 | \$77.77 |
| 0285 | Positron Emission Tomography (PET) | S | 15.06 | \$730.22 | \$415.21 | \$146.04 |
| 0286 | Myocardial Scans | S | 7.28 | \$352.99 | \$200.04 | \$70.60 |
| 0290 | Standard Non-Imaging Nuclear Medicine | S | 1.94 | \$94.06 | \$55.51 | \$18.81 |
| 0291 | Level I Diagnostic Nuclear Medicine Excluding Myocardial Scans ..... | S | 3.15 | \$152.73 | \$93.14 | \$30.55 |
| 0292 | Level II Diagnostic Nuclear Medicine Excluding Myocardial Scans .... | S | 4.36 | \$211.40 | \$126.63 | \$42.28 |
| 0294 | Level I Therapeutic Nuclear Medicine ........................................... | S | 5.13 | \$248.74 | \$144.06 | \$49.75 |
| 0295 | Level II Therapeutic Nuclear Medicine ........................................... | S | 19.85 | \$962.47 | \$609.17 | \$192.49 |
| 0296 | Level I Therapeutic Radiologic Procedures .................................... | S | 3.57 | \$173.10 | \$100.25 | \$34.62 |
| 0297 | Level II Therapeutic Radiologic Procedures ................................... | S | 6.13 | \$297.23 | \$172.51 | \$59.45 |
| 0300 | Level I Radiation Therapy ........................................................... | S | 1.98 | \$96.00 | \$47.72 | \$19.20 |
| 0301 | Level II Radiation Therapy | S | 2.21 | \$107.16 | \$52.53 | \$21.43 |
| 0302 | Level III Radiation Therapy | S | 8.21 | \$398.08 | \$216.55 | \$79.62 |
| 0303 | Treatment Device Construction | X | 2.83 | \$137.22 | \$69.28 | \$27.44 |
| 0304 | Level I Therapeutic Radiation Treatment Preparation ...................... | X | 1.49 | \$72.25 | \$41.52 | \$14.45 |
| 0305 | Level II Therapeutic Radiation Treatment Preparation ...................... | X | 4.06 | \$196.86 | \$97.50 | \$39.37 |
| 0310 | Level III Therapeutic Radiation Treatment Preparation ..................... | X | 13.98 | \$677.85 | \$339.05 | \$135.57 |
| 0311 | Radiation Physics Services .......................................................... | X | 1.32 | \$64.00 | \$31.66 | \$12.80 |
| 0312 | Radioelement Applications .......................................................... | S | 4.09 | \$198.31 | \$109.65 | \$39.66 |
| 0313 | Brachytherapy .......................................................................... | S | 7.89 | \$382.56 | \$164.02 | \$76.51 |
| 0314 | Hyperthermic Therapies .............................................................. | S | 5.88 | \$285.10 | \$150.95 | \$57.02 |
| 0320 | Electroconvulsive Therapy | S | 3.68 | \$178.43 | \$80.06 | \$35.69 |
| 0321 | Biofeedback and Other Training | S | 1.26 | \$61.09 | \$29.25 | \$12.22 |
| 0322 | Brief Individual Psychotherapy ..................................................... | S | 1.32 | \$64.00 | \$14.22 | \$12.80 |
| 0323 | Extended Individual Psychotherapy ............................................. | S | 1.85 | \$89.70 | \$22.48 | \$17.94 |
| 0324 | Family Psychotherapy ............................................................... | S | 1.87 | \$90.67 | \$20.19 | \$18.13 |
| 0325 | Group Psychotherapy ................................................................. | S | 1.55 | \$75.16 | \$19.96 | \$15.03 |
| 0330 | Dental Procedures ...................................................................... | S | 1.51 | \$73.22 | \$14.64 | \$14.64 |
| 0340 | Minor Ancillary Procedures | X | 1.04 | \$50.43 | \$12.85 | \$10.09 |
| 0341 | Immunology Tests ...................................................................... | X | 0.13 | \$6.30 | \$3.67 | \$1.26 |
| 0342 | Level I Pathology ....................................................................... | X | 0.26 | \$12.61 | \$8.03 | \$2.52 |
| 0343 | Level II Pathology | X | 0.45 | \$21.82 | \$12.16 | \$4.36 |
| 0344 | Level III Pathology .................................................................... | X | 0.79 | \$38.30 | \$23.63 | \$7.66 |
| ${ }^{2} 0354$ | Administration of Influenza Vaccine ............................................... | X | 0.13 | \$6.19 |  |  |
| 0355 | Level I Immunizations ................................................................ | X | 0.19 | \$9.21 | \$5.05 | \$1.84 |
| 0356 | Level II Immunizations | X | 0.36 | \$17.46 | \$4.82 | \$3.49 |
| 0357 | Level III Immunizations | X | 1.85 | \$89.70 | \$38.31 | \$17.94 |
| 0358 | Level IV Immunizations | X | 6.98 | \$338.44 | \$126.74 | \$67.69 |
| 0359 | Injections | X | 0.96 | \$46.55 | \$9.31 | \$9.31 |
| 0360 | Level I Alimentary Tests ............................................................. | X | 1.38 | \$66.91 | \$34.75 | \$13.38 |
| 0361 | Level II Alimentary Tests ............................................................. | X | 3.53 | \$171.16 | \$88.09 | \$34.23 |
| 0362 | Fitting of Vision Aids | X | 0.51 | \$24.73 | \$9.63 | \$4.95 |
| 0363 | Otorhinolaryngologic Function Tests ............................................. | X | 2.83 | \$137.22 | \$53.22 | \$27.44 |
| 0364 | Level I Audiometry ..................................................................... | X | 0.68 | \$32.97 | \$13.31 | \$6.59 |
| 0365 | Level II Audiometry | X | 1.47 | \$71.28 | \$22.48 | \$14.26 |
| 0366 | Electrocardiogram (ECG) | X | 0.38 | \$18.43 | \$15.60 | \$3.69 |
| 0367 | Level I Pulmonary Test ............................................................... | X | 0.83 | \$40.24 | \$20.65 | \$8.05 |
| 0368 | Level II Pulmonary Tests | X | 1.66 | \$80.49 | \$42.44 | \$16.10 |
| 0369 | Level III Pulmonary Tests ........................................................... | X | 2.34 | \$113.46 | \$58.50 | \$22.69 |
| 0370 | Allergy Tests ................ | X | 0.57 | \$27.64 | \$11.81 | \$5.53 |
| 0371 | Allergy Injections | X | 0.32 | \$15.52 | \$3.67 | \$3.10 |
| 0372 | Therapeutic Phlebotomy | X | 0.43 | \$20.85 | \$10.09 | \$4.17 |

[^126]Addendum A.-List of Hospital Outpatient Ambulatory Payment Classes With Status Indicators, Relative
Weights, Payment Rates, and Coinsurance Amounts-Continued

| APC | Group Title | Status Indicator | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 0373 | Neuropsychological Testing | x | 3.21 | \$155.64 | \$44.96 | \$31.13 |
| 0374 | Monitoring Psychiatric Drugs | X | 1.17 | \$56.73 | \$13.08 | \$11.35 |
| 0600 | Low Level Clinic Visits | V | 0.98 | \$47.52 | \$9.50 | \$9.50 |
| 0601 | Mid Level Clinic Visits | V | 1.00 | \$48.49 | \$9.70 | \$9.70 |
| 0602 | High Level Clinic Visits | V | 1.66 | \$80.49 | \$16.29 | \$16.10 |
| 0603 | Interdisciplinary Team Conference | v | 1.66 | \$80.49 | \$16.29 | \$16.10 |
| 0610 | Low Level Emergency Visits ......... | V | 1.34 | \$64.97 | \$20.65 | \$12.99 |
| 0611 | Mid Level Emergency Visits | V | 2.11 | \$102.31 | \$36.47 | \$20.46 |
| 0612 | High Level Emergency Visits | v | 3.19 | \$154.67 | \$54.14 | \$30.93 |
| 0620 | Critical Care ......................... | S | 8.60 | \$416.99 | \$152.78 | \$83.40 |
| ${ }^{3} 0701$ | Strontium | X |  |  |  | \$84.76 |
| ${ }^{3} 0702$ | Samariam | X |  |  |  | \$139.06 |
| ${ }^{3} 0704$ | Satumomab Pendetide | X |  |  |  | \$63.13 |
| ${ }^{3} 0705$ | Tc99 Tetrofosmin | X | ................... |  |  | \$71.08 |
| ${ }^{3} 0725$ | Leucovorin Calcium | X |  |  |  | \$1.07 |
| ${ }^{3} 0726$ | Dexrazoxane Hydrochloride | X |  |  |  | \$18.81 |
| ${ }^{3} 0727$ | Injection, Etidronate Disodium | X |  |  |  | \$9.31 |
| ${ }^{3} 0728$ | Filgrastim (G-CSF) | X |  |  |  | \$25.21 |
| ${ }^{3} 0730$ | Pamidronate Disodium | X |  |  |  | \$30.93 |
| ${ }^{3} 0731$ | Sargramostim (GM-CSF) | X |  |  |  | \$16.97 |
| ${ }^{3} 0732$ | Mesna | X |  |  |  | \$2.42 |
| ${ }^{3} 0733$ | Epoetin Alpha | X |  |  |  | \$1.75 |
| ${ }^{3} 0750$ | Dolasetron Mesylate 10 mg | X |  |  |  | \$1.94 |
| ${ }^{3} 0754$ | Metoclopramide HCL | X |  |  |  | \$. 19 |
| ${ }^{3} 0755$ | Thiethylperazine Maleate ........ | x |  |  | ................ | \$. 68 |
| ${ }^{3} 0761$ | Oral Substitute for IV Antiemtic | X |  |  |  | \$. 10 |
| ${ }^{3} 0762$ | Dronabinol | X |  |  |  | \$. 48 |
| 30763 30764 | Dolasetron Mesylate 100 mg Oral | x |  |  | ............... | \$8.53 |
| ${ }^{3} 0764$ | Granisetron HCL, 100 mcg | X |  |  |  | \$2.33 |
| 30765 | Granisetron HCL, 1mg Oral | x | ...................... |  |  | \$3.20 |
| ${ }^{3} 0768$ | Ondansetron Hydrochloride per 1 mg Injection.. | X | ..................... |  |  | \$. 87 |
| ${ }^{3} 0769$ | Ondansetron Hydrochloride 8 mg oral | X |  |  |  | \$2.62 |
| ${ }^{3} 0800$ | Leuprolide Acetate per 3.75 mg | x | ..................... | .................... | .................... | \$68.56 |
| ${ }^{3} 0801$ | Cyclophosphamide | X | .................... |  | .................... | \$. 19 |
| ${ }^{3} 0802$ | Etoposide | X | .............. |  |  | \$3.10 |
| ${ }^{3} 0803$ | Melphalan. | X | ................. | .................... | ...................... | \$. 19 |
| ${ }^{3} 0807$ | Aldesleukin single use vial ....................................................... | X | ...................... |  | .................... | \$65.07 |
| ${ }^{3} 0809$ | BCG (Intravesical) one vial | X | ..................... | ................ | ..................... | \$19.78 |
| ${ }^{3} 0810$ | Goserelin Acetate Implant, per 3.6 mg | x |  |  |  | \$59.74 |
| ${ }^{3} 0811$ | Carboplatin 50 mg | X |  | .................... | ..................... | \$13.96 |
| ${ }^{3} 0812$ | Carmustine 100 mg | X | .................... | ............... | ..................... | \$10.57 |
| 30813 | Cisplatin 10 mg | x | ................. | ..................... | ..................... | \$4.56 |
| ${ }^{3} 0814$ | Asparaginase, 10,000 units | x |  |  |  | \$8.34 |
| ${ }^{3} 0815$ | Cyclophosphamide 100 mg .............................................................. | x |  |  | .................... | \$. 48 |
| ${ }^{3} 0816$ | Cyclophosphamide, Lyophilized 100 mg ........................................ | X |  |  |  | \$1.16 |
| ${ }^{3} 0817$ | Cytrabine 100 mg ..................................................................... | X |  | ..................... | .................... | \$.68 |
| 30818 | Dactinomycin 0.5 mg ... | x | ................... | ................. | ..................... | \$1.75 |
| $\begin{aligned} & 30819 \\ & 30820 \end{aligned}$ | Dacarbazine 100 mg ..... | X $\times$ - |  |  |  | \$1.26 |
| ${ }^{3} 0821$ | Daunorubicin Citrate, Liposomal Formulation, 10 mg ........................ | X |  |  |  | \$7.76 |
| ${ }^{3} 0822$ | Diethylstibestrol Diphosphate 250 mg ............. | X |  |  |  | \$2.13 |
| ${ }^{3} 0823$ | Docetaxel 20 mg ............... | X | ..................... | ................ | ..................... | \$34.72 |
| ${ }^{3} 0824$ | Etoposide 10 mg | X | ..................... | ................ | ..................... | \$. 58 |
| ${ }^{3} 0826$ | Methotrexate Oral 2.5 mg | x |  |  |  | \$. 29 |
| 30827 | Floxuridine 500 mg . | X | ..................... | ...................... |  | \$18.81 |
| ${ }^{3} 0828$ | Gemcitabine HCL 200 mg | x | ................... |  |  | \$9.31 |
| ${ }^{3} 0830$ | lrinotecan 20 mg | x | $\ldots$ |  |  | \$14.16 |
| ${ }^{3} 0831$ | Ifosfamide per 1 gram ............................................................... | X | .................... |  | ..................... | \$13.58 |
| ${ }^{3} 0832$ | Idarubicin Hydrochloride 5 mg ............................... | x | $\ldots \ldots \ldots \ldots \ldots$ | ................ | ................. | \$46.45 |
| ${ }^{3} 0833$ | Interferon Alfacon-1, Recombinant, 1 mcg .......... | x | ................. |  |  | \$. 19 |
| ${ }^{3} 0834$ | Interferon, Alfa-2A, Recombinant 3 million units .............................. | x | ..................... |  | ................ | \$3.20 |
| ${ }^{3} 0836$ | Interferon, Alfa-2B, Recombinant, 1 million units ... | x | .................. | .................. | ................. | \$1.36 |
| ${ }^{3} 0838$ | Interferon, Gamma 1-B, 3 million units ................. | x | ................. |  |  | \$22.79 |
| 30839 30840 | Mechlorethamine HCl 10 mg ..................................................... | X | $\ldots$ | ..................... | .................... | $\$ 1.65$ $\$ 44.71$ |
| ${ }^{3} 0841$ | Methotrexate Sodium 5 mg ........................................................................................... | X |  |  |  | \$44.71 |
| ${ }^{3} 0842$ | Fludarabine Phosphate 50 mg | X |  |  | .... | \$30.84 |
| ${ }^{3} 0843$ | Pegaspargase per single dose vial | X |  |  |  | \$178.72 |
| ${ }^{3} 0844$ | Pentostatin 10 mg | X |  |  |  | \$133.73 |
| ${ }^{3} 0847$ | Doxorubicin HCL 10 mg | x |  |  |  | \$2.81 |
| ${ }^{3} 0849$ | Rituximab, 100 mg .......... | X | ..................... | .................... | ..................... | \$51.40 |
| ${ }^{3} 0850$ | Streptozocin $1 \mathrm{gm} .$. | X | ..................... | $\ldots . . . . . . . . . . . . . . . . . . . ~$ | ...................... | \$14.64 |
| ${ }^{3} 0851$ | Thiotepa 15 mg |  |  |  |  | \$9.50 |

[^127]
## addendum A.-List of Hospital Outpatient Ambulatory Payment Classes With Status Indicators, Relative Weights, Payment Rates, and Coinsurance Amounts-Continued

| APC | Group Title | Status Indicator | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| ${ }^{3} 0852$ | Topotecan 4 mg | X |  |  |  | \$73.22 |
| ${ }^{3} 0853$ | Vinblastine Sulfate 1 mg | X |  |  |  | \$. 39 |
| ${ }^{3} 0854$ | Vincristine Sulfate 1 mg | X |  |  |  | \$2.23 |
| ${ }^{3} 0855$ | Vinorelbine Tartrate per 10 mg | X |  |  |  | \$9.60 |
| ${ }^{3} 0856$ | Porfimer Sodium 75 mg | X |  |  |  | \$34.62 |
| ${ }^{3} 0857$ | Bleomycin Sulfate 15 units | X |  |  |  | \$48.29 |
| ${ }^{3} 0858$ | Cladribine, 1 mg | X |  |  |  | \$8.24 |
| ${ }^{3} 0859$ | Fluorouracil | X |  |  |  | \$. 19 |
| ${ }^{3} 0860$ | Plicamycin 2.5 mg | X |  |  |  | \$1.36 |
| ${ }^{3} 0861$ | Leuprolide Acetate 1 mg | X |  |  |  | \$19.39 |
| ${ }^{3} 0862$ | Mitomycin, 5mg | X |  |  |  | \$19.88 |
| ${ }^{3} 0863$ | Paclitaxel, 30 mg | X |  |  |  | \$30.16 |
| ${ }^{3} 0864$ | Mitoxantrone HCl, per 5mg | X |  |  |  | \$25.80 |
| ${ }^{3} 0865$ | Interferon alfa-N3, 250,000 IU | X |  |  |  | \$1.07 |
| ${ }^{3} 0884$ | Rho (D) Immune Globulin, Human one dose pack | X |  |  |  | \$3.78 |
| ${ }^{2} 0886$ | Azathioprine, 50 mg oral | X | 0.02 | \$.97 |  | \$. 19 |
| ${ }^{2} 0887$ | Azathioprine, Parenteral $100 \mathrm{mg}, 20 \mathrm{ml}$ each injection | X | 1.40 | \$67.88 |  | \$13.58 |
| ${ }^{2} 0888$ | Cyclosporine, Oral 100 mg | X | 0.08 | \$3.88 |  | \$.78 |
| ${ }^{2} 0889$ | Cyclosporine, Parenteral | X | 0.36 | \$17.46 |  | \$3.49 |
| ${ }^{2} 0890$ | Lymphocyte Immune Globulin $50 \mathrm{mg} / \mathrm{ml}, 5 \mathrm{ml}$ each | X | 3.79 | \$183.77 |  | \$36.75 |
| ${ }^{2} 0891$ | Tacrolimus per 1 mg oral | X | 3.15 | \$152.73 |  | \$30.55 |
| ${ }^{3} 0892$ | Daclizumab, Parenteral, 25 mg | X |  |  |  | \$54.11 |
| ${ }^{3} 0900$ | Injection, Alglucerase per 10 units | X |  |  |  | \$5.14 |
| ${ }^{3} 0901$ | Alpha I, Proteinase Inhibitor, Human per 10mg | X |  |  |  | \$15.22 |
| ${ }^{3} 0902$ | Botulinum Toxin, Type A per unit | X |  |  |  | \$56.05 |
| ${ }^{3} 0903$ | CMV Immune Globulin | X |  |  |  | \$54.11 |
| ${ }^{3} 0905$ | Immune Globulin per 500 mg | X |  |  |  | \$6.40 |
| ${ }^{3} 0906$ | RSV Immune Globulin | X |  |  |  | \$85.53 |
| ${ }^{2} 0907$ | Ganciclovir Sodium 500 mg injection | X | 0.51 | \$24.73 |  | \$4.95 |
| ${ }^{2} 0908$ | Tetanus Immune Globulin, Human, up to 250 units | X | 0.90 | \$43.64 |  | \$8.73 |
| ${ }^{3} 0909$ | Interferon Beta-1a 33 mcg | X |  |  |  | \$28.70 |
| ${ }^{3} 0910$ | Interferon Beta-1b 0.25 mg | X |  |  |  | \$8.44 |
| ${ }^{2} 0911$ | Streptokinase per 250,000 iu | X | 1.64 | \$79.69 |  | \$15.94 |
| ${ }^{3} 0913$ | Ganciclovir 4.5 mg , Implant | X |  |  |  | \$701.51 |
| ${ }^{2} 0914$ | Reteplase, 37.6 mg (Two Single Use Vials) | X | 38.20 | \$1,852.21 |  | \$370.44 |
| ${ }^{2} 0915$ | Alteplase recombinant, 10mg . | X | 5.85 | \$283.70 |  | \$56.74 |
| ${ }^{3} 0916$ | Imiglucerase per unit | X |  |  |  | \$.58 |
| ${ }^{2} 0917$ | Dipyridamole, 10mg Adenosine 6MG | X | 0.36 | \$17.46 |  | \$3.49 |
| ${ }^{3} 0918$ | Brachytherapy Seeds, Any type, Each | S |  |  |  | \$9.99 |
| ${ }^{3} 0925$ | Factor VIII (Antihemophilic Factor, Human) per iu | X |  |  |  | \$. 19 |
| ${ }^{3} 0926$ | Factor VIII (Antihemophilic Factor, Porcine) per iu | X | ..................... |  |  | \$. 19 |
| ${ }^{3} 0927$ | Factor VIII (Antihemophilic Factor, Recombinant) per iu | X |  |  |  | \$. 19 |
| ${ }^{3} 0928$ | Factor IX, Complex ........ | X | ..................... |  |  | \$. 08 |
| ${ }^{3} 0929$ | Other Hemophilia Clotting Factors per iu | X | ...... |  |  | \$. 27 |
| ${ }^{3} 0930$ | Antithrombin III (Human) per iu | X |  |  |  | \$. 19 |
| ${ }^{3} 0931$ | Factor IX (Antihemophilic Factor, Purified, Non-Recombinant) ........... | X | ..................... |  |  | \$. 04 |
| ${ }^{3} 0932$ | Factor IX (Antihemophilic Factor, Recombinant) ............................. | X |  |  |  | \$. 10 |
| ${ }^{2} 0949$ | Plasma, Pooled Multiple Donor, Solvent/Detergent Treated, Frozen .. | S | 3.49 | \$169.22 |  | \$33.84 |
| ${ }^{2} 0950$ | Blood (Whole) For Transfusion | S | 2.08 | \$101.02 |  | \$20.20 |
| ${ }^{2} 0952$ | Cryoprecipitate ....... | S | 0.70 | \$33.92 |  | \$6.78 |
| ${ }^{2} 0953$ | Fibrinogen Unit | S | 0.48 | \$23.27 |  | \$4.65 |
| ${ }^{2} 0954$ | Leukocyte Poor Blood | S | 2.83 | \$137.21 |  | \$27.44 |
| ${ }^{2} 0955$ | Plasma, Fresh Frozen | S | 2.26 | \$109.35 |  | \$21.87 |
| ${ }^{2} 0956$ | Plasma Protein Fraction | S | 1.26 | \$61.09 |  | \$12.22 |
| ${ }^{2} 0957$ | Platelet Concentrate | S | 0.98 | \$47.46 |  | \$9.49 |
| ${ }^{2} 0958$ | Platelet Rich Plasma | S | 1.16 | \$56.25 |  | \$11.25 |
| ${ }^{2} 0959$ | Red Blood Cells | S | 2.04 | \$99.04 |  | \$19.81 |
| ${ }^{2} 0960$ | Washed Red Blood Cells | S | 3.81 | \$184.53 |  | \$36.91 |
| ${ }^{2} 0961$ | Infusion, Albumin (Human) 5\%, 500 ml | X | 2.77 | \$134.31 |  | \$26.86 |
| ${ }^{2} 0962$ | Infusion, Albumin (Human) 25\%, 50 ml .......................................... | X | 1.38 | \$66.91 | . | \$13.38 |
| ${ }^{2} 0970$ | New Technology-Level I (\$0-\$50) | T | 0.52 | \$25.21 |  | \$5.04 |
| ${ }^{2} 0971$ | New Technology-Level II (\$50-\$100) | S | 1.55 | \$75.16 |  | \$15.03 |
| ${ }^{2} 0972$ | New Technology—Level III (\$100-\$200) ....................................... | T | 3.09 | \$149.83 |  | \$29.97 |
| ${ }^{2} 0973$ | New Technology-Level IV (\$200-\$300) | T | 5.16 | \$250.19 |  | \$50.04 |
| ${ }^{2} 0974$ | New Technology-Level V (\$300-\$500) | T | 8.25 | \$400.02 |  | \$80.00 |
| ${ }^{2} 0975$ | New Technology-Level VI (\$500-\$750) ...................................... | T | 12.90 | \$625.48 | ..................... | \$125.10 |
| ${ }^{2} 0976$ | New Technology-Level VII (\$750-\$1000) | T | 18.05 | \$875.19 |  | \$175.04 |
| ${ }^{2} 0977$ | New Technology-Level VIII (\$1000-\$1250) | T | 23.20 | \$1,124.90 |  | \$224.98 |
| ${ }^{2} 0978$ | New Technology-Level IX (\$1250-\$1500) | T | 28.36 | \$1,375.09 | ..................... | \$275.02 |
| ${ }^{2} 0979$ | New Technology-Level X (\$1500-\$1750) | T | 33.51 | \$1,624.80 |  | \$324.96 |
| ${ }^{2} 0980$ | New Technology-Level XI (\$1750-\$2000) | S | 38.67 | \$1,875.00 | .................... | \$375.00 |
| ${ }^{2} 0981$ | New Technology-Level XII (\$2000-\$2500) | T | 46.40 | \$2,249.80 |  | \$449.96 |
| ${ }^{2} 0982$ | New Technology—Level XIII (\$2500-\$3500) | T | 61.87 | \$2,999.90 |  | \$599.98 |

[^128]Addendum A.-List of Hospital Outpatient Ambulatory Payment Classes With Status Indicators, Relative
Weights, Payment Rates, and Coinsurance Amounts-Continued

| APC | Group Title | Status Indicator | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| ${ }^{2} 0983$ | New Technology-Level XIV (\$3500-\$5000) | T | 87.65 | \$4,249.89 |  | \$849.98 |
| ${ }^{2} 0984$ | New Technology-Level XV (\$5000-\$6000) | T | 113.43 | \$5,499.89 |  | \$1,099.98 |
| ${ }^{3} 7000$ | Amifostine, 500 mg | X |  |  |  | \$41.99 |
| ${ }^{3} 7001$ | Amphotericin B lipid complex, 50 mg , Inj | X |  |  |  | \$12.12 |
| ${ }^{3} 7002$ | Clonidine, $\mathrm{HCl}, 1 \mathrm{MG}$ | X | ................... |  |  | \$4.17 |
| ${ }^{3} 7003$ | Epoprostenol, 0.5 MG, inj | X |  |  |  | \$2.23 |
| ${ }^{3} 7004$ | Immune globulin intravenous human 5 g , inj | X |  |  |  | \$45.48 |
| ${ }^{3} 7005$ | Gonadorelin hcl, 100 mcg .............. | X |  |  |  | \$9.12 |
| ${ }^{2} 7007$ | Milrinone lacetate, per 5 ml , inj | X | 0.47 | \$22.79 |  | \$4.56 |
| ${ }^{3} 7010$ | Morphine sulfate concentrate (preservative free) per 10 mg | X |  |  |  | \$.68 |
| ${ }^{3} 7011$ | Oprelevekin, inj, 5 mg | X |  |  |  | \$30.35 |
| ${ }^{3} 7012$ | Pentamidine isethionate, 300 mg | X |  |  |  | \$8.73 |
| ${ }^{3} 7014$ | Fentanyl citrate, inj, up to 2 ml | X | ...................... | ...................... |  | \$. 19 |
| ${ }^{3} 7015$ | Busulfan, oral 2 mg | X |  |  |  | \$. 19 |
| ${ }^{3} 7019$ | Aprotinin, 10,000 kiu | X |  |  |  | \$2.42 |
| ${ }^{3} 7021$ | Baclofen, intrathecal, 50 mcg | X |  |  |  | \$. 10 |
| ${ }^{3} 7022$ | Elliotts B Solution, per ml | X |  |  |  | \$19.20 |
| ${ }^{3} 7023$ | Treatment for bladder calculi, I.e. Renacidin per 500 ml .................. | X |  |  |  | \$4.46 |
| ${ }^{3} 7024$ | Corticorelin ovine triflutate, 0.1 mg | X |  |  |  | \$45.77 |
| ${ }^{3} 7025$ | Digoxin immune FAB (Ovine), 10 mg | X | ...................... |  | .................... | \$14.06 |
| ${ }^{3} 7026$ | Ethanolamine oleate, 1000 ml | X |  |  | ...................... | \$2.13 |
| ${ }^{3} 7027$ | Fomepizole, 1.5 G | X |  |  |  | \$141.29 |
| ${ }^{3} 7028$ | Fosphenytoin, 50 mg | X | ...................... |  |  | \$.78 |
| ${ }^{3} 7029$ | Glatiramer acetate, 25 mg | X |  |  |  | \$3.59 |
| ${ }^{3} 7030$ | Hemin, 1 mg ....... | X |  |  |  | \$. 10 |
| ${ }^{3} 7031$ | Octreotide Acetate, 500 mcg | X |  |  |  | \$5.43 |
| ${ }^{3} 7032$ | Sermorelin acetate, 0.5 mg | X | ..................... | .................... | ..................... | \$53.34 |
| ${ }^{3} 7033$ | Somatrem, 5 mg | X | ...................... |  | ..................... | \$28.03 |
| ${ }^{3} 7034$ | Somatropin, 1 mg | X |  |  |  | \$5.04 |
| ${ }^{3} 7035$ | Teniposide, 50 mg | X |  |  | . | \$20.85 |
| 27036 | Urokinase, inj, IV, 250,000 I.U. | X | 0.73 | \$35.40 |  | \$7.08 |
| ${ }^{3} 7037$ | Urofollitropin, 75 I.U. | X | ...................... |  | .................... | \$8.24 |
| ${ }^{3} 7038$ | Muromonab-CD3, 5 mg | X |  |  |  | \$89.60 |
| ${ }^{3} 7039$ | Pegademase bovine inj 25 I.U. .................................................... | X | ............... |  | ..................... | \$1.16 |
| ${ }^{3} 7040$ | Pentastarch 10\% inj, 100 ml ........................................................ | X |  |  | ...................... | \$2.04 |
| 27041 | Tirofiban HCL, 0.5 mg | X | 0.02 | \$. 97 |  | \$. 19 |
| ${ }^{3} 7042$ | Capecitabine, oral 150 mg ........................................................... | X | ...................... | $\qquad$ | . | \$. 19 |
| ${ }^{3} 7043$ | Infliximab, 10 MG ....................................................................... | X | ...................... | ...................... | ...................... | \$6.89 |
| ${ }^{3} 7045$ | Trimetrexate Glucoronate ........................................................... | X | ........ | ...................... | ...... | \$8.15 |
| ${ }^{3} 7046$ | Doxorubicin Hcl Liposome .............................................................. | X |  |  |  | \$39.18 |

## Addendum B.-Hospital Outpatient Department (HOPD) Payment Status by HCPCS Code and Related INFORMATION

| $\begin{aligned} & \text { CPT/ } \\ & \text { HCPCS } \end{aligned}$ | HOPD Status Indicator | Description | APC | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 00100 | N | Anesth, salivary gland |  |  |  |  |  |
| 00102 | N | Anesth, repair of cleft lip ........................................ |  |  |  |  |  |
| 00103 | N | Anesth, blepharoplasty |  |  |  |  |  |
| 00104 | N | Anesth, electroshock |  |  |  |  |  |
| 00120 | N | Anesth, ear surgery |  |  |  |  |  |
| 00124 | N | Anesth, ear exam ... |  |  |  |  |  |
| 00126 | N | Anesth, tympanotomy |  |  |  |  |  |
| 00140 | N | Anesth, procedures on eye .................................... |  |  |  |  |  |
| 00142 | N | Anesth, lens surgery |  |  |  |  |  |
| 00144 | N | Anesth, corneal transplant ...................................... |  |  |  |  |  |
| 00145 | N | Anesth, vitrectomy .. |  |  | ...................... | ...................... |  |
| 00147 | N | Anesth, iridectomy ................................................ |  |  |  |  |  |
| 00148 | N | Anesth, eye exam |  |  |  |  |  |
| 00160 | N | Anesth, nose/sinus surgery |  |  |  |  |  |
| 00162 | N | Anesth, nose/sinus surgery .................................... |  |  | ......... | .................. |  |
| 00164 | N | Anesth, biopsy of nose |  |  |  |  |  |
| 00170 | N | Anesth, procedure on mouth ................................... |  |  |  | .................... |  |
| 00172 | N | Anesth, cleft palate repair.. |  |  |  | ...................... |  |
| 00174 | C | Anesth, pharyngeal surgery |  |  |  |  |  |
| 00176 | C | Anesth, pharyngeal surgery |  |  |  |  |  |
| 00190 | N | Anesth, facial bone surgery ..................................... | ...................... |  | ...................... | .................... | ................... |
| 00192 | C | Anesth, facial bone surgery |  |  |  |  |  |
| 00210 | N | Anesth, open head surgery |  |  |  |  |  |
| 00212 | N | Anesth, skull drainage ...... |  |  |  |  |  |

[^129]
# Addendum B.-Hospital Outpatient Department (HOPD) Payment Status by HCPCS Code and Related INFORMATION-Continued 

| CPT/ HCPCS | HOPD Status Indicator | Description | APC | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 00214 | C | Anesth, skull drainage |  |  |  |  |  |
| 00215 | C | Anesth, skull fracture |  |  |  |  |  |
| 00216 | N | Anesth, head vessel surgery | .................... | .................... | ................... | .................... |  |
| 00218 | N | Anesth, special head surgery |  |  |  |  |  |
| 00220 | N | Anesth, spinal fluid shunt |  |  |  |  |  |
| 00222 | N | Anesth, head nerve surgery ................................... |  |  |  |  |  |
| 00300 | N | Anesth, head/neck/ptrunk |  |  |  |  |  |
| 00320 | N | Anesth, neck organ surgery ................................... |  | ..................... | ...... |  |  |
| 00322 | N | Anesth, biopsy of thyroid ... |  |  |  |  |  |
| 00350 | N | Anesth, neck vessel surgery |  |  |  |  |  |
| 00352 | N | Anesth, neck vessel surgery .................................. |  |  |  |  |  |
| 00400 | N | Anesth, skin, ext/per/atrunk |  |  |  |  |  |
| 00402 | N | Anesth, surgery of breast.. |  |  |  |  |  |
| 00404 | C | Anesth, surgery of breast |  |  |  |  |  |
| 00406 | C | Anesth, surgery of breast | .................... |  | ............... |  |  |
| 00410 | N | Anesth, correct heart rhythm |  |  |  |  |  |
| 00450 | N | Anesth, surgery of shoulder ................................... |  |  |  |  |  |
| 00452 | C | Anesth, surgery of shoulder |  |  |  |  |  |
| 00454 | N | Anesth, collar bone biopsy |  |  |  |  |  |
| 00470 | N | Anesth, removal of rib ........................................... |  |  |  |  |  |
| 00472 | N | Anesth, chest wall repair |  |  |  |  |  |
| 00474 | C | Anesth, surgery of rib(s) ........................................ |  |  |  |  |  |
| 00500 | N | Anesth, esophageal surgery |  |  |  |  |  |
| 00520 | N | Anesth, chest procedure |  |  |  |  |  |
| 00522 | N | Anesth, chest lining biopsy |  |  |  |  |  |
| 00524 | C | Anesth, chest drainage |  |  |  |  |  |
| 00528 | N | Anesth, chest partition view .................................... |  |  |  |  |  |
| 00530 | C | Anesth, pacemaker insertion |  |  |  |  |  |
| 00532 | N | Anesth, vascular access ........................................ |  |  |  |  |  |
| 00534 | N | Anesth, cardioverter/defib |  |  |  |  |  |
| 00540 | C | Anesth, chest surgery |  |  |  | ................... |  |
| 00542 | C | Anesth, release of lung ......................................... |  |  |  |  |  |
| 00544 | C | Anesth, chest lining removal |  |  |  |  |  |
| 00546 | C | Anesth, lung, chest wall surg .................................. |  |  |  | .................... |  |
| 00548 | N | Anesth, trachea, bronchi surg |  |  |  |  |  |
| 00560 | C | Anesth, open heart surgery |  |  |  |  |  |
| 00562 | C | Anesth, open heart surgery .................................... |  |  |  | ...................... |  |
| 00580 | C | Anesth heart/lung transplant .................................. |  |  |  |  |  |
| 00600 | N | Anesth, spine, cord surgery .................................... |  |  |  |  |  |
| 00604 | C | Anesth, surgery of vertebra |  |  |  |  |  |
| 00620 | N | Anesth, spine, cord surgery .................................... |  |  |  |  |  |
| 00622 | C | Anesth, removal of nerves |  |  |  |  |  |
| 00630 | N | Anesth, spine, cord surgery .................................... |  |  |  |  |  |
| 00632 | C | Anesth, removal of nerves |  |  |  | ..................... |  |
| 00634 | C | Anesth for chemonucleolysis |  |  |  |  |  |
| 00670 | C | Anesth, spine, cord surgery .................................... |  |  |  |  |  |
| 00700 | N | Anesth, abdominal wall surg .................................. |  |  |  |  |  |
| 00702 | N | Anesth, for liver biopsy |  |  |  |  |  |
| 00730 | N | Anesth, abdominal wall surg |  |  |  |  |  |
| 00740 | N | Anesth, upper gi visualize ...................................... |  |  |  | ... |  |
| 00750 | N | Anesth, repair of hernia |  |  |  | ..................... |  |
| 00752 | N | Anesth, repair of hernia ......................................... |  |  |  |  |  |
| 00754 | N | Anesth, repair of hernia .......................................... |  |  |  |  |  |
| 00756 | N | Anesth, repair of hernia |  |  |  |  |  |
| 00770 | N | Anesth, blood vessel repair .................................... |  |  |  |  |  |
| 00790 | N | Anesth, surg upper abdomen ................................. |  |  |  |  |  |
| 00792 | C | Anesth, part liver removal |  |  |  | ..................... |  |
| 00794 | C | Anesth, pancreas removal |  |  |  | ...................... |  |
| 00796 | C | Anesth, for liver transplant |  |  |  |  |  |
| 00800 | N | Anesth, abdominal wall surg ................................... |  |  | ..................... | ..................... |  |
| 00802 | C | Anesth, fat layer removal. |  |  | ..................... | ..................... |  |
| 00810 | N | Anesth, low intestine scope .................................... |  |  |  |  |  |
| 00820 | N | Anesth, abdominal wall surg |  |  |  |  |  |
| 00830 | N | Anesth, repair of hernia ......................................... | . | ..................... | .................... | ..................... |  |
| 00832 | N | Anesth, repair of hernia |  |  |  |  |  |
| 00840 | N | Anesth, surg lower abdomen ................................... |  |  |  |  |  |
| 00842 | N | Anesth, amniocentesis . | ...................... | ..................... | ..................... | ...................... |  |
| 00844 | C | Anesth, pelvis surgery |  |  | .................... |  |  |
| 00846 | C | Anesth, hysterectomy ........................................... |  |  |  |  |  |
| 00848 | C | Anesth, pelvic organ surg .. | ...................... | ...................... | ..................... | ...................... |  |
| 00850 | C | Anesth, cesarean section | ...................... |  | ..................... | ...................... |  |
| 00855 | C | Anesth, hysterectomy ......... | ...................... | ...................... | .................... |  |  |
| 00857 | C | Analgesia, labor \& c-section |  |  |  |  |  |

[^130]
# Addendum B.—Hospital Outpatient Department (HOPD) Payment Status by hCPCS Code and Related INFORMATION-Continued 

| CPT/ HCPCS | HOPD Status Indicator | Description | APC | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 00860 | N | Anesth, surgery of abdomen |  |  |  | $\cdot$ |  |
| 00862 | N | Anesth, kidney/ureter surg . |  |  |  | . |  |
| 00864 | C | Anesth, removal of bladder |  |  |  |  |  |
| 00865 | C | Anesth, removal of prostate |  |  |  |  |  |
| 00866 | C | Anesth, removal of adrenal |  |  |  |  |  |
| 00868 | C | Anesth, kidney transplant |  |  |  |  |  |
| 00870 | N | Anesth, bladder stone surg |  |  |  |  |  |
| 00872 | N | Anesth kidney stone destruct |  |  |  | ...................... |  |
| 00873 | N | Anesth kidney stone destruct |  |  |  | . |  |
| 00880 | N | Anesth, abdomen vessel surg |  |  |  |  |  |
| 00882 | C | Anesth, major vein ligation ..... |  |  |  |  |  |
| 00884 | C | Anesth, major vein revision . |  |  |  |  |  |
| 00900 | N | Anesth, perineal procedure |  |  |  |  |  |
| 00902 | N | Anesth, anorectal surgery ... |  |  |  |  |  |
| 00904 | C | Anesth, perineal surgery |  |  |  |  |  |
| 00906 | N | Anesth, removal of vulva |  |  |  |  |  |
| 00908 | C | Anesth, removal of prostate |  |  |  |  |  |
| 00910 | N | Anesth, bladder surgery |  |  |  |  |  |
| 00912 | N | Anesth, bladder tumor surg |  |  |  | .................... |  |
| 00914 | N | Anesth, removal of prostate |  |  |  | ...................... |  |
| 00916 | N | Anesth, bleeding control |  |  |  |  |  |
| 00918 | N | Anesth, stone removal . |  |  |  | .................... |  |
| 00920 | N | Anesth, genitalia surgery |  |  |  |  |  |
| 00922 | N | Anesth, sperm duct surgery |  |  |  |  |  |
| 00924 | N | Anesth, testis exploration .... |  |  |  |  |  |
| 00926 | N | Anesth, removal of testis |  |  |  | ..................... |  |
| 00928 | C | Anesth, removal of testis |  |  |  |  |  |
| 00930 | N | Anesth, testis suspension |  |  |  | .................... |  |
| 00932 | C | Anesth, amputation of penis |  |  |  |  |  |
| 00934 | C | Anesth, penis, nodes removal |  |  |  |  |  |
| 00936 | C | Anesth, penis, nodes removal. |  |  |  |  |  |
| 00938 | N | Anesth, insert penis device |  |  |  | ...................... |  |
| 00940 | N | Anesth, vaginal procedures |  |  |  | .................... |  |
| 00942 | N | Anesth, surgery on vagina |  |  |  |  |  |
| 00944 | C | Anesth, vaginal hysterectomy |  |  |  |  |  |
| 00946 | N | Anesth, vaginal delivery .. |  |  |  | ..................... |  |
| 00948 | N | Anesth, repair of cervix |  |  |  |  |  |
| 00950 | N | Anesth, vaginal endoscopy |  |  |  |  |  |
| 00952 | N | Anesth, hysteroscope/graph |  |  |  | ...................... |  |
| 00955 | C | Analgesia, vaginal delivery |  |  |  |  |  |
| 01120 | N | Anesth, pelvis surgery |  |  |  |  |  |
| 01130 | N | Anesth, body cast procedure |  |  |  |  |  |
| 01140 | C | Anesth, amputation at pelvis |  |  |  | ..................... |  |
| 01150 | C | Anesth, pelvic tumor surgery |  |  |  |  |  |
| 01160 | N | Anesth, pelvis procedure |  |  |  | ..................... |  |
| 01170 | N | Anesth, pelvis surgery |  |  |  | ..................... |  |
| 01180 | N | Anesth, pelvis nerve removal |  |  |  |  |  |
| 01190 | C | Anesth, pelvis nerve removal . |  |  |  | ...................... |  |
| 01200 | N | Anesth, hip joint procedure |  |  |  | ..................... |  |
| 01202 | N | Anesth, arthroscopy of hip |  |  |  |  |  |
| 01210 | N | Anesth, hip joint surgery |  |  |  |  |  |
| 01212 | C | Anesth, hip disarticulation |  |  |  | . |  |
| 01214 | C | Anesth, replacement of hip |  |  |  |  |  |
| 01220 | N | Anesth, procedure on femur |  |  |  |  |  |
| 01230 | N | Anesth, surgery of femur |  |  |  | ..................... |  |
| 01232 | C | Anesth, amputation of femur |  |  |  | .................... |  |
| 01234 | C | Anesth, radical femur surg |  |  |  |  |  |
| 01250 | N | Anesth, upper leg surgery ...................................... |  |  |  | ..................... |  |
| 01260 | N | Anesth, upper leg veins surg .... |  |  |  | ...................... |  |
| 01270 | N | Anesth, thigh arteries surg |  |  |  |  |  |
| 01272 | C | Anesth, femoral artery surg ... |  |  |  | .................... |  |
| 01274 | C | Anesth, femoral embolectomy |  |  |  |  |  |
| 01320 | N | Anesth, knee area surgery ..................................... |  |  |  |  |  |
| 01340 | N | Anesth, knee area procedure |  |  |  |  |  |
| 01360 | $N$ | Anesth, knee area surgery ..................................... |  |  |  | ...................... |  |
| 01380 | N | Anesth, knee joint procedure .. |  |  |  | ...................... |  |
| 01382 | N | Anesth, knee arthroscopy .... |  |  |  |  |  |
| 01390 | N | Anesth, knee area procedure .................................. |  |  |  | ..................... |  |
| 01392 | N | Anesth, knee area surgery ..................................... |  |  |  | ... |  |
| 01400 | N | Anesth, knee joint surgery ...................................... |  |  |  |  |  |
| 01402 | C | Anesth, replacement of knee ................................... |  |  |  |  |  |
| 01404 | C | Anesth, amputation at knee ..................................... | ...................... | ...................... |  | ...................... |  |
| 01420 | N | Anesth, knee joint casting |  |  |  |  |  |

[^131]
# Addendum B.-Hospital Outpatient Department (HOPD) Payment Status by HCPCS Code and Related Information-Continued 

| CPT/ <br> HCPCS | HOPD Status Indicator | Description | APC | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 01430 | N | Anesth, knee veins surgery |  |  |  |  |  |
| 01432 | N | Anesth, knee vessel surg ... |  |  |  |  |  |
| 01440 | N | Anesth, knee arteries surg |  |  | .................... | .................... |  |
| 01442 | C | Anesth, knee artery surg |  |  |  |  |  |
| 01444 | C | Anesth, knee artery repair |  |  |  |  |  |
| 01462 | N | Anesth, lower leg procedure .... |  |  |  |  |  |
| 01464 | N | Anesth, ankle arthroscopy ....... |  |  |  |  |  |
| 01470 | N | Anesth, lower leg surgery |  |  | ..................... |  |  |
| 01472 | N | Anesth, achilles tendon surg |  |  |  |  |  |
| 01474 | N | Anesth, lower leg surgery . |  |  |  |  |  |
| 01480 | N | Anesth, lower leg bone surg |  |  |  |  |  |
| 01482 | N | Anesth, radical leg surgery |  |  |  |  |  |
| 01484 | N | Anesth, lower leg revision |  |  |  |  |  |
| 01486 | C | Anesth, ankle replacement |  |  |  |  |  |
| 01490 | N | Anesth, lower leg casting |  | .................... | ............ |  |  |
| 01500 | N | Anesth, leg arteries surg |  |  |  |  |  |
| 01502 | C | Anesth, Iwr leg embolectomy |  |  |  |  |  |
| 01520 | N | Anesth, lower leg vein surg |  |  |  |  |  |
| 01522 | N | Anesth, lower leg vein surg |  |  |  |  |  |
| 01610 | N | Anesth, surgery of shoulder |  |  |  |  |  |
| 01620 | N | Anesth, shoulder procedure |  |  |  |  |  |
| 01622 | N | Anesth, shoulder arthroscopy |  |  |  |  |  |
| 01630 | N | Anesth, surgery of shoulder |  |  |  |  |  |
| 01632 | C | Anesth, surgery of shoulder |  |  |  |  |  |
| 01634 | C | Anesth, shoulder joint amput |  |  |  |  |  |
| 01636 | C | Anesth, forequarter amput |  |  |  |  |  |
| 01638 | C | Anesth, shoulder replacement |  |  |  |  |  |
| 01650 | N | Anesth, shoulder artery surg |  |  |  |  |  |
| 01652 | C | Anesth, shoulder vessel surg .. |  |  |  |  |  |
| 01654 | C | Anesth, shoulder vessel surg |  |  |  |  |  |
| 01656 | C | Anesth, arm-leg vessel surg |  |  |  |  |  |
| 01670 | N | Anesth, shoulder vein surg |  |  |  |  |  |
| 01680 | N | Anesth, shoulder casting |  |  |  |  |  |
| 01682 | N | Anesth, airplane cast .. |  |  | .................... |  |  |
| 01710 | N | Anesth, elbow area surgery |  |  |  |  |  |
| 01712 | N | Anesth, uppr arm tendon surg |  |  |  |  |  |
| 01714 | N | Anesth, uppr arm tendon surg ................................. |  |  |  |  |  |
| 01716 | N | Anesth, biceps tendon repair |  |  |  |  |  |
| 01730 | N | Anesth, uppr arm procedure |  |  |  |  |  |
| 01732 | N | Anesth, elbow arthroscopy |  |  |  |  |  |
| 01740 | N | Anesth, upper arm surgery |  |  |  |  |  |
| 01742 | N | Anesth, humerus surgery |  |  |  |  |  |
| 01744 | N | Anesth, humerus repair |  |  |  |  |  |
| 01756 | C | Anesth, radical humerus surg .................................. |  |  |  |  |  |
| 01758 | N | Anesth, humeral lesion surg |  |  |  |  |  |
| 01760 | N | Anesth, elbow replacement |  |  |  |  |  |
| 01770 | N | Anesth, uppr arm artery surg .................................. |  |  |  |  |  |
| 01772 | C | Anesth, uppr arm embolectomy |  |  |  |  |  |
| 01780 | N | Anesth, upper arm vein surg |  |  |  |  |  |
| 01782 | C | Anesth, uppr arm vein repair .................................. |  |  |  |  |  |
| 01784 | N | Anesth, av fistula repair .... |  |  |  | ..................... |  |
| 01810 | N | Anesth, lower arm surgery ..................................... |  |  |  |  |  |
| 01820 | N | Anesth, lower arm procedure .................................. |  |  |  |  |  |
| 01830 | N | Anesth, lower arm surgery |  |  |  |  |  |
| 01832 | N | Anesth, wrist replacement ...................................... |  |  |  |  |  |
| 01840 | N | Anesth, Iwr arm artery surg .................................... |  |  |  |  |  |
| 01842 | C | Anesth, Iwr arm embolectomy ................................. |  |  |  |  |  |
| 01844 | N | Anesth, vascular shunt surg |  |  |  | ...................... |  |
| 01850 | N | Anesth, lower arm vein surg |  |  |  |  |  |
| 01852 | C | Anesth, Iwr arm vein repair .................................... |  |  |  |  |  |
| 01860 | N | Anesth, lower arm casting . |  |  |  | ..................... |  |
| 01904 | C | Anesth, skull x-ray inject |  |  |  |  |  |
| 01906 | N | Anesth, lumbar myelography |  |  |  |  |  |
| 01908 | N | Anesth, cervical myelography .................................. |  |  |  | ..................... |  |
| 01910 | N | Anesth, skull myelography .. |  |  |  |  |  |
| 01912 | N | Anesth, lumbar diskography |  |  |  |  |  |
| 01914 | N | Anesth, cervical diskography .................................. |  |  |  | ...................... |  |
| 01916 | N | Anesth, head arteriogram ... |  |  |  |  |  |
| 01918 | N | Anesth, limb arteriogram |  |  |  |  |  |
| 01920 | N | Anesth, catheterize heart .... |  | ..................... | ...................... | ...................... |  |
| 01921 | N | Anesth, vessel surgery ........ |  |  |  | ...................... |  |
| 01922 | N | Anesth, cat or MRI scan | ...................... | ...................... | ...................... |  |  |
| 01990 | C | Support for organ donor |  |  |  |  |  |

[^132]
## Addendum B.-Hospital Outpatient Department (HOPD) Payment Status by hCPCS Code and Related Information-Continued

| CPT/ HCPCS | HOPD Status Indicator | Description | APC | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 01995 | N | Regional anesthesia, limb |  |  |  | ..................... |  |
| 01996 | N | Manage daily drug therapy |  |  |  | ..................... |  |
| 01999 | N | Unlisted anesth procedure . |  |  |  |  |  |
| 10040 | T | Acne surgery of skin abscess | 0006 | 2.00 | \$96.97 | \$33.95 | \$19.39 |
| 10060 | T | Drainage of skin abscess ...... | 0006 | 2.00 | \$96.97 | \$33.95 | \$19.39 |
| 10061 | T | Drainage of skin abscess | 0006 | 2.00 | \$96.97 | \$33.95 | \$19.39 |
| 10080 | T | Drainage of pilonidal cyst | 0006 | 2.00 | \$96.97 | \$33.95 | \$19.39 |
| 10081 | T | Drainage of pilonidal cyst | 0007 | 3.68 | \$178.43 | \$72.03 | \$35.69 |
| 10120 | T | Remove foreign body ...... | 0006 | 2.00 | \$96.97 | \$33.95 | \$19.39 |
| 10121 | T | Remove foreign body | 0020 | 6.51 | \$315.65 | \$130.53 | \$63.13 |
| 10140 | T | Drainage of hematoma/fluid | 0007 | 3.68 | \$178.43 | \$72.03 | \$35.69 |
| 10160 | T | Puncture drainage of lesion | 0006 | 2.00 | \$96.97 | \$33.95 | \$19.39 |
| 10180 | T | Complex drainage, wound .. | 0007 | 3.68 | \$178.43 | \$72.03 | \$35.69 |
| 11000 | T | Debride infected skin | 0015 | 1.77 | \$85.82 | \$31.20 | \$17.16 |
| 11001 | T | Debride infected skin add-on | 0015 | 1.77 | \$85.82 | \$31.20 | \$17.16 |
| 11010 | T | Debride skin, fx | 0022 | 12.49 | \$605.60 | \$292.94 | \$121.12 |
| 11011 | T | Debride skin/muscle, fx | 0022 | 12.49 | \$605.60 | \$292.94 | \$121.12 |
| 11012 | T | Debride skin/muscle/bone, fx | 0022 | 12.49 | \$605.60 | \$292.94 | \$121.12 |
| 11040 | T | Debride skin, partial ............. | 0015 | 1.77 | \$85.82 | \$31.20 | \$17.16 |
| 11041 | T | Debride skin, full ... | 0015 | 1.77 | \$85.82 | \$31.20 | \$17.16 |
| 11042 | T | Debride skin/tissue | 0016 | 3.53 | \$171.16 | \$74.67 | \$34.23 |
| 11043 | T | Debride tissue/muscle | 0016 | 3.53 | \$171.16 | \$74.67 | \$34.23 |
| 11044 | T | Debride tissue/muscle/bone | 0017 | 12.45 | \$603.66 | \$289.16 | \$120.73 |
| 11055 | T | Trim skin lesion | 0015 | 1.77 | \$85.82 | \$31.20 | \$17.16 |
| 11056 | T | Trim skin lesions, 2 to 4 | 0015 | 1.77 | \$85.82 | \$31.20 | \$17.16 |
| 11057 | T | Trim skin lesions, over 4 | 0015 | 1.77 | \$85.82 | \$31.20 | \$17.16 |
| 11100 | T | Biopsy of skin lesion | 0018 | 0.94 | \$45.58 | \$17.66 | \$9.12 |
| 11101 | T | Biopsy, skin add-on | 0018 | 0.94 | \$45.58 | \$17.66 | \$9.12 |
| 11200 | T | Removal of skin tags | 0015 | 1.77 | \$85.82 | \$31.20 | \$17.16 |
| 11201 | T | Remove skin tags add-on | 0015 | 1.77 | \$85.82 | \$31.20 | \$17.16 |
| 11300 | T | Shave skin lesion | 0013 | 0.91 | \$44.12 | \$17.66 | \$8.82 |
| 11301 | T | Shave skin lesion | 0013 | 0.91 | \$44.12 | \$17.66 | \$8.82 |
| 11302 | T | Shave skin lesion | 0014 | 1.50 | \$72.73 | \$24.55 | \$14.55 |
| 11303 | T | Shave skin lesion | 0015 | 1.77 | \$85.82 | \$31.20 | \$17.16 |
| 11305 | T | Shave skin lesion | 0013 | 0.91 | \$44.12 | \$17.66 | \$8.82 |
| 11306 | T | Shave skin lesion | 0013 | 0.91 | \$44.12 | \$17.66 | \$8.82 |
| 11307 | T | Shave skin lesion | 0014 | 1.50 | \$72.73 | \$24.55 | \$14.55 |
| 11308 | T | Shave skin lesion | 0015 | 1.77 | \$85.82 | \$31.20 | \$17.16 |
| 11310 | T | Shave skin lesion | 0013 | 0.91 | \$44.12 | \$17.66 | \$8.82 |
| 11311 | T | Shave skin lesion | 0013 | 0.91 | \$44.12 | \$17.66 | \$8.82 |
| 11312 | T | Shave skin lesion | 0015 | 1.77 | \$85.82 | \$31.20 | \$17.16 |
| 11313 | T | Shave skin lesion | 0016 | 3.53 | \$171.16 | \$74.67 | \$34.23 |
| 11400 | T | Removal of skin lesion | 0019 | 4.00 | \$193.95 | \$78.91 | \$38.79 |
| 11401 | T | Removal of skin lesion | 0019 | 4.00 | \$193.95 | \$78.91 | \$38.79 |
| 11402 | T | Removal of skin lesion | 0019 | 4.00 | \$193.95 | \$78.91 | \$38.79 |
| 11403 | T | Removal of skin lesion | 0020 | 6.51 | \$315.65 | \$130.53 | \$63.13 |
| 11404 | T | Removal of skin lesion | 0020 | 6.51 | \$315.65 | \$130.53 | \$63.13 |
| 11406 | T | Removal of skin lesion | 0020 | 6.51 | \$315.65 | \$130.53 | \$63.13 |
| 11420 | T | Removal of skin lesion | 0019 | 4.00 | \$193.95 | \$78.91 | \$38.79 |
| 11421 | T | Removal of skin lesion | 0019 | 4.00 | \$193.95 | \$78.91 | \$38.79 |
| 11422 | T | Removal of skin lesion | 0019 | 4.00 | \$193.95 | \$78.91 | \$38.79 |
| 11423 | T | Removal of skin lesion | 0020 | 6.51 | \$315.65 | \$130.53 | \$63.13 |
| 11424 | T | Removal of skin lesion | 0020 | 6.51 | \$315.65 | \$130.53 | \$63.13 |
| 11426 | T | Removal of skin lesion | 0022 | 12.49 | \$605.60 | \$292.94 | \$121.12 |
| 11440 | T | Removal of skin lesion | 0019 | 4.00 | \$193.95 | \$78.91 | \$38.79 |
| 11441 | T | Removal of skin lesion | 0019 | 4.00 | \$193.95 | \$78.91 | \$38.79 |
| 11442 | T | Removal of skin lesion | 0019 | 4.00 | \$193.95 | \$78.91 | \$38.79 |
| 11443 | T | Removal of skin lesion ...................................... | 0020 | 6.51 | \$315.65 | \$130.53 | \$63.13 |
| 11444 | T | Removal of skin lesion | 0020 | 6.51 | \$315.65 | \$130.53 | \$63.13 |
| 11446 | T | Removal of skin lesion | 0022 | 12.49 | \$605.60 | \$292.94 | \$121.12 |
| 11450 | T | Removal, sweat gland lesion .................................. | 0022 | 12.49 | \$605.60 | \$292.94 | \$121.12 |
| 11451 | T | Removal, sweat gland lesion ................................. | 0022 | 12.49 | \$605.60 | \$292.94 | \$121.12 |
| 11462 | T | Removal, sweat gland lesion ................................... | 0022 | 12.49 | \$605.60 | \$292.94 | \$121.12 |
| 11463 | T | Removal, sweat gland lesion ................................... | 0022 | 12.49 | \$605.60 | \$292.94 | \$121.12 |
| 11470 | T | Removal, sweat gland lesion .................................. | 0022 | 12.49 | \$605.60 | \$292.94 | \$121.12 |
| 11471 | T | Removal, sweat gland lesion .................................. | 0022 | 12.49 | \$605.60 | \$292.94 | \$121.12 |
| 11600 | T | Removal of skin lesion | 0019 | 4.00 | \$193.95 | \$78.91 | \$38.79 |
| 11601 | T | Removal of skin lesion .......................................... | 0019 | 4.00 | \$193.95 | \$78.91 | \$38.79 |
| 11602 | T | Removal of skin lesion | 0019 | 4.00 | \$193.95 | \$78.91 | \$38.79 |
| 11603 | T | Removal of skin lesion | 0020 | 6.51 | \$315.65 | \$130.53 | \$63.13 |
| 11604 | T | Removal of skin lesion | 0020 | 6.51 | \$315.65 | \$130.53 | \$63.13 |
| 11606 | T | Removal of skin lesion .......................................... | 0021 | 10.49 | \$508.63 | \$236.51 | \$101.73 |
| 11620 | T | Removal of skin lesion | 0019 | 4.00 | \$193.95 | \$78.91 | \$38.79 |

[^133]
## Addendum B.-Hospital Outpatient Department (HOPD) Payment Status by HCPCS Code and Related Information-Continued

| $\begin{aligned} & \text { CPT/ } \\ & \text { HCPCS } \end{aligned}$ | HOPD <br> Status Indicator | Description | APC | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 11621 | T | Removal of skin lesion | 0019 | 4.00 | \$193.95 | \$78.91 | \$38.79 |
| 11622 | T | Removal of skin lesion | 0019 | 4.00 | \$193.95 | \$78.91 | \$38.79 |
| 11623 | T | Removal of skin lesion | 0020 | 6.51 | \$315.65 | \$130.53 | \$63.13 |
| 11624 | T | Removal of skin lesion | 0020 | 6.51 | \$315.65 | \$130.53 | \$63.13 |
| 11626 | T | Removal of skin lesion | 0022 | 12.49 | \$605.60 | \$292.94 | \$121.12 |
| 11640 | T | Removal of skin lesion | 0019 | 4.00 | \$193.95 | \$78.91 | \$38.79 |
| 11641 | T | Removal of skin lesion | 0019 | 4.00 | \$193.95 | \$78.91 | \$38.79 |
| 11642 | T | Removal of skin lesion | 0019 | 4.00 | \$193.95 | \$78.91 | \$38.79 |
| 11643 | T | Removal of skin lesion | 0020 | 6.51 | \$315.65 | \$130.53 | \$63.13 |
| 11644 | T | Removal of skin lesion | 0020 | 6.51 | \$315.65 | \$130.53 | \$63.13 |
| 11646 | T | Removal of skin lesion | 0022 | 12.49 | \$605.60 | \$292.94 | \$121.12 |
| 11719 | T | Trim nail(s) | 0009 | 0.74 | \$35.88 | \$9.63 | \$7.18 |
| 11720 | T | Debride nail, 1-5 | 0009 | 0.74 | \$35.88 | \$9.63 | \$7.18 |
| 11721 | T | Debride nail, 6 or more | 0009 | 0.74 | \$35.88 | \$9.63 | \$7.18 |
| 11730 | T | Removal of nail plate | 0013 | 0.91 | \$44.12 | \$17.66 | \$8.82 |
| 11732 | T | Remove nail plate, add-on | 0012 | 0.53 | \$25.70 | \$9.18 | \$5.14 |
| 11740 | T | Drain blood from under nail | 0009 | 0.74 | \$35.88 | \$9.63 | \$7.18 |
| 11750 | T | Removal of nail bed | 0019 | 4.00 | \$193.95 | \$78.91 | \$38.79 |
| 11752 | T | Remove nail bed/finger tip | 0022 | 12.49 | \$605.60 | \$292.94 | \$121.12 |
| 11755 | T | Biopsy, nail unit | 0019 | 4.00 | \$193.95 | \$78.91 | \$38.79 |
| 11760 | T | Repair of nail bed | 0024 | 2.43 | \$117.82 | \$44.50 | \$23.56 |
| 11762 | T | Reconstruction of nail bed | 0024 | 2.43 | \$117.82 | \$44.50 | \$23.56 |
| 11765 | T | Excision of nail fold, toe | 0015 | 1.77 | \$85.82 | \$31.20 | \$17.16 |
| 11770 | T | Removal of pilonidal lesion | 0021 | 10.49 | \$508.63 | \$236.51 | \$101.73 |
| 11771 | T | Removal of pilonidal lesion | 0022 | 12.49 | \$605.60 | \$292.94 | \$121.12 |
| 11772 | T | Removal of pilonidal lesion | 0022 | 12.49 | \$605.60 | \$292.94 | \$121.12 |
| 11900 | T | Injection into skin lesions .. | 0012 | 0.53 | \$25.70 | \$9.18 | \$5.14 |
| 11901 | T | Added skin lesions injection | 0013 | 0.91 | \$44.12 | \$17.66 | \$8.82 |
| 11920 | T | Correct skin color defects | 0024 | 2.43 | \$117.82 | \$44.50 | \$23.56 |
| 11921 | T | Correct skin color defects | 0024 | 2.43 | \$117.82 | \$44.50 | \$23.56 |
| 11922 | T | Correct skin color defects | 0024 | 2.43 | \$117.82 | \$44.50 | \$23.56 |
| 11950 | T | Therapy for contour defects | 0024 | 2.43 | \$117.82 | \$44.50 | \$23.56 |
| 11951 | T | Therapy for contour defects | 0024 | 2.43 | \$117.82 | \$44.50 | \$23.56 |
| 11952 | T | Therapy for contour defects | 0024 | 2.43 | \$117.82 | \$44.50 | \$23.56 |
| 11954 | T | Therapy for contour defects | 0024 | 2.43 | \$117.82 | \$44.50 | \$23.56 |
| 11960 | T | Insert tissue expander(s) ........................................ | 0026 | 12.11 | \$587.18 | \$277.92 | \$117.44 |
| 11970 | T | Replace tissue expander .... | 0026 | 12.11 | \$587.18 | \$277.92 | \$117.44 |
| 11971 | T | Remove tissue expander(s) | 0022 | 12.49 | \$605.60 | \$292.94 | \$121.12 |
| 11975 | E | Insert contraceptive cap |  |  |  |  |  |
| 11976 | T | Removal of contraceptive cap | 0019 | 4.00 | \$193.95 | \$78.91 | \$38.79 |
| 11977 | E | Removal/reinsert contra cap |  |  |  |  |  |
| 11980 | E | Implant hormone pellet(s) |  |  |  |  |  |
| 12001 | T | Repair superficial wound(s) | 0024 | 2.43 | \$117.82 | \$44.50 | \$23.56 |
| 12002 | T | Repair superficial wound(s) | 0024 | 2.43 | \$117.82 | \$44.50 | \$23.56 |
| 12004 | T | Repair superficial wound(s) | 0024 | 2.43 | \$117.82 | \$44.50 | \$23.56 |
| 12005 | T | Repair superficial wound(s) | 0024 | 2.43 | \$117.82 | \$44.50 | \$23.56 |
| 12006 | T | Repair superficial wound(s) | 0024 | 2.43 | \$117.82 | \$44.50 | \$23.56 |
| 12007 | T | Repair superficial wound(s) | 0024 | 2.43 | \$117.82 | \$44.50 | \$23.56 |
| 12011 | T | Repair superficial wound(s) | 0024 | 2.43 | \$117.82 | \$44.50 | \$23.56 |
| 12013 | T | Repair superficial wound(s) | 0024 | 2.43 | \$117.82 | \$44.50 | \$23.56 |
| 12014 | T | Repair superficial wound(s) | 0024 | 2.43 | \$117.82 | \$44.50 | \$23.56 |
| 12015 | T | Repair superficial wound(s) | 0024 | 2.43 | \$117.82 | \$44.50 | \$23.56 |
| 12016 | T | Repair superficial wound(s) .................................... | 0024 | 2.43 | \$117.82 | \$44.50 | \$23.56 |
| 12017 | T | Repair superficial wound(s) | 0024 | 2.43 | \$117.82 | \$44.50 | \$23.56 |
| 12018 | T | Repair superficial wound(s) | 0024 | 2.43 | \$117.82 | \$44.50 | \$23.56 |
| 12020 | T | Closure of split wound ....... | 0024 | 2.43 | \$117.82 | \$44.50 | \$23.56 |
| 12021 | T | Closure of split wound. | 0024 | 2.43 | \$117.82 | \$44.50 | \$23.56 |
| 12031 | T | Layer closure of wound(s) | 0024 | 2.43 | \$117.82 | \$44.50 | \$23.56 |
| 12032 | T | Layer closure of wound(s) .................................... | 0024 | 2.43 | \$117.82 | \$44.50 | \$23.56 |
| 12034 | T | Layer closure of wound(s) ...................................... | 0024 | 2.43 | \$117.82 | \$44.50 | \$23.56 |
| 12035 | T | Layer closure of wound(s) | 0024 | 2.43 | \$117.82 | \$44.50 | \$23.56 |
| 12036 | T | Layer closure of wound(s) | 0024 | 2.43 | \$117.82 | \$44.50 | \$23.56 |
| 12037 | T | Layer closure of wound(s) ...... | 0026 | 12.11 | \$587.18 | \$277.92 | \$117.44 |
| 12041 | T | Layer closure of wound(s) | 0024 | 2.43 | \$117.82 | \$44.50 | \$23.56 |
| 12042 | T | Layer closure of wound(s) | 0024 | 2.43 | \$117.82 | \$44.50 | \$23.56 |
| 12044 | T | Layer closure of wound(s) | 0024 | 2.43 | \$117.82 | \$44.50 | \$23.56 |
| 12045 | T | Layer closure of wound(s) | 0024 | 2.43 | \$117.82 | \$44.50 | \$23.56 |
| 12046 | T | Layer closure of wound(s) | 0024 | 2.43 | \$117.82 | \$44.50 | \$23.56 |
| 12047 | T | Layer closure of wound(s) ...................................... | 0026 | 12.11 | \$587.18 | \$277.92 | \$117.44 |
| 12051 | T | Layer closure of wound(s) ...................................... | 0024 | 2.43 | \$117.82 | \$44.50 | \$23.56 |
| 12052 | T | Layer closure of wound(s) | 0024 | 2.43 | \$117.82 | \$44.50 | \$23.56 |
| 12053 | T | Layer closure of wound(s) | 0024 | 2.43 | \$117.82 | \$44.50 | \$23.56 |
| 12054 | T | Layer closure of wound(s) .................................... | 0024 | 2.43 | \$117.82 | \$44.50 | \$23.56 |

[^134]
## Addendum B.-Hospital Outpatient Department (HOPD) Payment Status by hCPCS Code and Related Information-Continued

| CPT/ HCPCS | HOPD Status Indicator | Description | APC | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 12055 | T | Layer closure of wound(s) | 0024 | 2.43 | \$117.82 | \$44.50 | \$23.56 |
| 12056 | T | Layer closure of wound(s) | 0024 | 2.43 | \$117.82 | \$44.50 | \$23.56 |
| 12057 | T | Layer closure of wound(s) | 0026 | 12.11 | \$587.18 | \$277.92 | \$117.44 |
| 13100 | T | Repair of wound or lesion | 0025 | 3.74 | \$181.34 | \$70.66 | \$36.27 |
| 13101 | T | Repair of wound or lesion | 0025 | 3.74 | \$181.34 | \$70.66 | \$36.27 |
| 13102 | T | Repair wound/lesion add-on | 0025 | 3.74 | \$181.34 | \$70.66 | \$36.27 |
| 13120 | T | Repair of wound or lesion | 0025 | 3.74 | \$181.34 | \$70.66 | \$36.27 |
| 13121 | T | Repair of wound or lesion | 0025 | 3.74 | \$181.34 | \$70.66 | \$36.27 |
| 13122 | T | Repair wound/lesion add-on | 0025 | 3.74 | \$181.34 | \$70.66 | \$36.27 |
| 13131 | T | Repair of wound or lesion | 0025 | 3.74 | \$181.34 | \$70.66 | \$36.27 |
| 13132 | T | Repair of wound or lesion | 0025 | 3.74 | \$181.34 | \$70.66 | \$36.27 |
| 13133 | T | Repair wound/lesion add-on | 0025 | 3.74 | \$181.34 | \$70.66 | \$36.27 |
| 13150 | T | Repair of wound or lesion .. | 0026 | 12.11 | \$587.18 | \$277.92 | \$117.44 |
| 13151 | T | Repair of wound or lesion | 0025 | 3.74 | \$181.34 | \$70.66 | \$36.27 |
| 13152 | T | Repair of wound or lesion ................................. | 0025 | 3.74 | \$181.34 | \$70.66 | \$36.27 |
| 13153 | T | Repair wound/lesion add-on .............................. | 0025 | 3.74 | \$181.34 | \$70.66 | \$36.27 |
| 13160 | T | Late closure of wound | 0026 | 12.11 | \$587.18 | \$277.92 | \$117.44 |
| 14000 | T | Skin tissue rearrangement | 0026 | 12.11 | \$587.18 | \$277.92 | \$117.44 |
| 14001 | T | Skin tissue rearrangement | 0026 | 12.11 | \$587.18 | \$277.92 | \$117.44 |
| 14020 | T | Skin tissue rearrangement | 0026 | 12.11 | \$587.18 | \$277.92 | \$117.44 |
| 14021 | T | Skin tissue rearrangement | 0026 | 12.11 | \$587.18 | \$277.92 | \$117.44 |
| 14040 | T | Skin tissue rearrangement | 0026 | 12.11 | \$587.18 | \$277.92 | \$117.44 |
| 14041 | T | Skin tissue rearrangement | 0026 | 12.11 | \$587.18 | \$277.92 | \$117.44 |
| 14060 | T | Skin tissue rearrangement | 0026 | 12.11 | \$587.18 | \$277.92 | \$117.44 |
| 14061 | T | Skin tissue rearrangement | 0026 | 12.11 | \$587.18 | \$277.92 | \$117.44 |
| 14300 | T | Skin tissue rearrangement | 0026 | 12.11 | \$587.18 | \$277.92 | \$117.44 |
| 14350 | T | Skin tissue rearrangement | 0026 | 12.11 | \$587.18 | \$277.92 | \$117.44 |
| 15000 | T | Skin graft | 0026 | 12.11 | \$587.18 | \$277.92 | \$117.44 |
| 15001 | T | Skin graft add-on | 0026 | 12.11 | \$587.18 | \$277.92 | \$117.44 |
| 15050 | T | Skin pinch graft | 0026 | 12.11 | \$587.18 | \$277.92 | \$117.44 |
| 15100 | T | Skin split graft | 0026 | 12.11 | \$587.18 | \$277.92 | \$117.44 |
| 15101 | T | Skin split graft add-on | 0026 | 12.11 | \$587.18 | \$277.92 | \$117.44 |
| 15120 | T | Skin split graft | 0026 | 12.11 | \$587.18 | \$277.92 | \$117.44 |
| 15121 | T | Skin split graft add-on | 0026 | 12.11 | \$587.18 | \$277.92 | \$117.44 |
| 15200 | T | Skin full graft | 0026 | 12.11 | \$587.18 | \$277.92 | \$117.44 |
| 15201 | T | Skin full graft add-on | 0026 | 12.11 | \$587.18 | \$277.92 | \$117.44 |
| 15220 | T | Skin full graft | 0026 | 12.11 | \$587.18 | \$277.92 | \$117.44 |
| 15221 | T | Skin full graft add-on | 0026 | 12.11 | \$587.18 | \$277.92 | \$117.44 |
| 15240 | T | Skin full graft ............. | 0026 | 12.11 | \$587.18 | \$277.92 | \$117.44 |
| 15241 | T | Skin full graft add-on | 0026 | 12.11 | \$587.18 | \$277.92 | \$117.44 |
| 15260 | T | Skin full graft | 0026 | 12.11 | \$587.18 | \$277.92 | \$117.44 |
| 15261 | T | Skin full graft add-on | 0026 | 12.11 | \$587.18 | \$277.92 | \$117.44 |
| 15350 | T | Skin homograft ......... | 0026 | 12.11 | \$587.18 | \$277.92 | \$117.44 |
| 15351 | T | Skin homograft add-on | 0026 | 12.11 | \$587.18 | \$277.92 | \$117.44 |
| 15400 | T | Skin heterograft | 0026 | 12.11 | \$587.18 | \$277.92 | \$117.44 |
| 15401 | T | Skin heterograft add-on | 0026 | 12.11 | \$587.18 | \$277.92 | \$117.44 |
| 15570 | T | Form skin pedicle flap | 0026 | 12.11 | \$587.18 | \$277.92 | \$117.44 |
| 15572 | T | Form skin pedicle flap | 0026 | 12.11 | \$587.18 | \$277.92 | \$117.44 |
| 15574 | T | Form skin pedicle flap | 0026 | 12.11 | \$587.18 | \$277.92 | \$117.44 |
| 15576 | T | Form skin pedicle flap | 0026 | 12.11 | \$587.18 | \$277.92 | \$117.44 |
| 15600 | T | Skin graft ....... | 0026 | 12.11 | \$587.18 | \$277.92 | \$117.44 |
| 15610 | T | Skin graft | 0026 | 12.11 | \$587.18 | \$277.92 | \$117.44 |
| 15620 | T | Skin graft | 0026 | 12.11 | \$587.18 | \$277.92 | \$117.44 |
| 15630 | T | Skin graft | 0026 | 12.11 | \$587.18 | \$277.92 | \$117.44 |
| 15650 | T | Transfer skin pedicle flap ..... | 0026 | 12.11 | \$587.18 | \$277.92 | \$117.44 |
| 15732 | T | Muscle-skin graft, head/neck | 0027 | 15.80 | \$766.10 | \$383.10 | \$153.22 |
| 15734 | T | Muscle-skin graft, trunk | 0027 | 15.80 | \$766.10 | \$383.10 | \$153.22 |
| 15736 | T | Muscle-skin graft, arm .......... | 0027 | 15.80 | \$766.10 | \$383.10 | \$153.22 |
| 15738 | T | Muscle-skin graft, leg .......... | 0027 | 15.80 | \$766.10 | \$383.10 | \$153.22 |
| 15740 | T | Island pedicle flap graft | 0027 | 15.80 | \$766.10 | \$383.10 | \$153.22 |
| 15750 | T | Neurovascular pedicle graft .................................... | 0027 | 15.80 | \$766.10 | \$383.10 | \$153.22 |
| 15756 | C | Free muscle flap, microvasc ... |  |  |  |  |  |
| 15757 | C | Free skin flap, microvasc ....................................... |  |  |  |  |  |
| 15758 | C | Free fascial flap, microvasc .................................... |  |  |  |  |  |
| 15760 | T | Composite skin graft .............................................. | 0027 | 15.80 | \$766.10 | \$383.10 | \$153.22 |
| 15770 | T | Derma-fat-fascia graft .......... | 0027 | 15.80 | \$766.10 | \$383.10 | \$153.22 |
| 15775 | T | Hair transplant punch grafts | 0026 | 12.11 | \$587.18 | \$277.92 | \$117.44 |
| 15776 | T | Hair transplant punch grafts ..... | 0026 | 12.11 | \$587.18 | \$277.92 | \$117.44 |
| 15780 | T | Abrasion treatment of skin ......... | 0022 | 12.49 | \$605.60 | \$292.94 | \$121.12 |
| 15781 | T | Abrasion treatment of skin ...................................... | 0022 | 12.49 | \$605.60 | \$292.94 | \$121.12 |
| 15782 | T | Abrasion treatment of skin | 0022 | 12.49 | \$605.60 | \$292.94 | \$121.12 |
| 15783 | T | Abrasion treatment of skin ...................................... | 0015 | 1.77 | \$85.82 | \$31.20 | \$17.16 |
| 15786 | T | Abrasion, lesion, single ........ | 0013 | 0.91 | \$44.12 | \$17.66 | \$8.82 |

[^135]Addendum B.—Hospital Outpatient Department (hopd) Payment Status by hCPCS Code and Related
Information-Continued

| $\begin{aligned} & \text { CPT/ } \\ & \text { HCPCS } \end{aligned}$ | HOPD <br> Status Indicator | Description | APC | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 15787 | T | Abrasion, lesions, add-on | 0016 | 3.53 | \$171.16 | \$74.67 | \$34.23 |
| 15788 | T | Chemical peel, face, epiderm | 0013 | 0.91 | \$44.12 | \$17.66 | \$8.82 |
| 15789 | T | Chemical peel, face, dermal | 0015 | 1.77 | \$85.82 | \$31.20 | \$17.16 |
| 15792 | T | Chemical peel, nonfacial | 0016 | 3.53 | \$171.16 | \$74.67 | \$34.23 |
| 15793 | T | Chemical peel, nonfacial | 0016 | 3.53 | \$171.16 | \$74.67 | \$34.23 |
| 15810 | T | Salabrasion | 0016 | 3.53 | \$171.16 | \$74.67 | \$34.23 |
| 15811 | T | Salabrasion | 0022 | 12.49 | \$605.60 | \$292.94 | \$121.12 |
| 15819 | T | Plastic surgery, neck | 0026 | 12.11 | \$587.18 | \$277.92 | \$117.44 |
| 15820 | T | Revision of lower eyelid | 0026 | 12.11 | \$587.18 | \$277.92 | \$117.44 |
| 15821 | T | Revision of lower eyelid | 0026 | 12.11 | \$587.18 | \$277.92 | \$117.44 |
| 15822 | T | Revision of upper eyelid | 0026 | 12.11 | \$587.18 | \$277.92 | \$117.44 |
| 15823 | T | Revision of upper eyelid | 0026 | 12.11 | \$587.18 | \$277.92 | \$117.44 |
| 15824 | T | Removal of forehead wrinkles | 0027 | 15.80 | \$766.10 | \$383.10 | \$153.22 |
| 15825 | T | Removal of neck wrinkles | 0026 | 12.11 | \$587.18 | \$277.92 | \$117.44 |
| 15826 | T | Removal of brow wrinkles | 0027 | 15.80 | \$766.10 | \$383.10 | \$153.22 |
| 15828 | T | Removal of face wrinkles | 0027 | 15.80 | \$766.10 | \$383.10 | \$153.22 |
| 15829 | T | Removal of skin wrinkles | 0026 | 12.11 | \$587.18 | \$277.92 | \$117.44 |
| 15831 | T | Excise excessive skin tissue | 0027 | 15.80 | \$766.10 | \$383.10 | \$153.22 |
| 15832 | T | Excise excessive skin tissue | 0027 | 15.80 | \$766.10 | \$383.10 | \$153.22 |
| 15833 | T | Excise excessive skin tissue | 0027 | 15.80 | \$766.10 | \$383.10 | \$153.22 |
| 15834 | T | Excise excessive skin tissue | 0027 | 15.80 | \$766.10 | \$383.10 | \$153.22 |
| 15835 | T | Excise excessive skin tissue | 0026 | 12.11 | \$587.18 | \$277.92 | \$117.44 |
| 15836 | T | Excise excessive skin tissue | 0027 | 15.80 | \$766.10 | \$383.10 | \$153.22 |
| 15837 | T | Excise excessive skin tissue | 0027 | 15.80 | \$766.10 | \$383.10 | \$153.22 |
| 15838 | T | Excise excessive skin tissue | 0022 | 12.49 | \$605.60 | \$292.94 | \$121.12 |
| 15839 | T | Excise excessive skin tissue | 0027 | 15.80 | \$766.10 | \$383.10 | \$153.22 |
| 15840 | T | Graft for face nerve palsy | 0027 | 15.80 | \$766.10 | \$383.10 | \$153.22 |
| 15841 | T | Graft for face nerve palsy | 0027 | 15.80 | \$766.10 | \$383.10 | \$153.22 |
| 15842 | T | Graft for face nerve palsy | 0027 | 15.80 | \$766.10 | \$383.10 | \$153.22 |
| 15845 | T | Skin and muscle repair, face | 0027 | 15.80 | \$766.10 | \$383.10 | \$153.22 |
| 15850 | T | Removal of sutures | 0013 | 0.91 | \$44.12 | \$17.66 | \$8.82 |
| 15851 | T | Removal of sutures | 0013 | 0.91 | \$44.12 | \$17.66 | \$8.82 |
| 15852 | T | Dressing change, not for burn | 0012 | 0.53 | \$25.70 | \$9.18 | \$5.14 |
| 15860 | N | Test for blood flow in graft ..... |  |  |  |  |  |
| 15876 | T | Suction assisted lipectomy | 0027 | 15.80 | \$766.10 | \$383.10 | \$153.22 |
| 15877 | T | Suction assisted lipectomy | 0027 | 15.80 | \$766.10 | \$383.10 | \$153.22 |
| 15878 | T | Suction assisted lipectomy | 0027 | 15.80 | \$766.10 | \$383.10 | \$153.22 |
| 15879 | T | Suction assisted lipectomy | 0027 | 15.80 | \$766.10 | \$383.10 | \$153.22 |
| 15920 | T | Removal of tail bone ulcer | 0022 | 12.49 | \$605.60 | \$292.94 | \$121.12 |
| 15922 | T | Removal of tail bone ulcer | 0027 | 15.80 | \$766.10 | \$383.10 | \$153.22 |
| 15931 | T | Remove sacrum pressure sore | 0022 | 12.49 | \$605.60 | \$292.94 | \$121.12 |
| 15933 | T | Remove sacrum pressure sore | 0022 | 12.49 | \$605.60 | \$292.94 | \$121.12 |
| 15934 | T | Remove sacrum pressure sore | 0027 | 15.80 | \$766.10 | \$383.10 | \$153.22 |
| 15935 | T | Remove sacrum pressure sore | 0027 | 15.80 | \$766.10 | \$383.10 | \$153.22 |
| 15936 | T | Remove sacrum pressure sore | 0027 | 15.80 | \$766.10 | \$383.10 | \$153.22 |
| 15937 | T | Remove sacrum pressure sore | 0027 | 15.80 | \$766.10 | \$383.10 | \$153.22 |
| 15940 | T | Remove hip pressure sore ..................................... | 0022 | 12.49 | \$605.60 | \$292.94 | \$121.12 |
| 15941 | T | Remove hip pressure sore | 0022 | 12.49 | \$605.60 | \$292.94 | \$121.12 |
| 15944 | T | Remove hip pressure sore | 0027 | 15.80 | \$766.10 | \$383.10 | \$153.22 |
| 15945 | T | Remove hip pressure sore | 0027 | 15.80 | \$766.10 | \$383.10 | \$153.22 |
| 15946 | T | Remove hip pressure sore | 0027 | 15.80 | \$766.10 | \$383.10 | \$153.22 |
| 15950 | T | Remove thigh pressure sore | 0022 | 12.49 | \$605.60 | \$292.94 | \$121.12 |
| 15951 | T | Remove thigh pressure sore | 0022 | 12.49 | \$605.60 | \$292.94 | \$121.12 |
| 15952 | T | Remove thigh pressure sore | 0027 | 15.80 | \$766.10 | \$383.10 | \$153.22 |
| 15953 | T | Remove thigh pressure sore | 0027 | 15.80 | \$766.10 | \$383.10 | \$153.22 |
| 15956 | T | Remove thigh pressure sore .............................. | 0027 | 15.80 | \$766.10 | \$383.10 | \$153.22 |
| 15958 | T | Remove thigh pressure sore ................................... | 0027 | 15.80 | \$766.10 | \$383.10 | \$153.22 |
| 15999 | T | Removal of pressure sore | 0022 | 12.49 | \$605.60 | \$292.94 | \$121.12 |
| 16000 | T | Initial treatment of burn(s) ................................... | 0015 | 1.77 | \$85.82 | \$31.20 | \$17.16 |
| 16010 | T | Treatment of burn(s) .............................................. | 0015 | 1.77 | \$85.82 | \$31.20 | \$17.16 |
| 16015 | T | Treatment of burn(s) | 0017 | 12.45 | \$603.66 | \$289.16 | \$120.73 |
| 16020 | T | Treatment of burn(s) .............................................. | 0015 | 1.77 | \$85.82 | \$31.20 | \$17.16 |
| 16025 | T | Treatment of burn(s) | 0014 | 1.50 | \$72.73 | \$24.55 | \$14.55 |
| 16030 | T | Treatment of burn(s) | 0015 | 1.77 | \$85.82 | \$31.20 | \$17.16 |
| 16035 | T | Incision of burn scab | 0020 | 6.51 | \$315.65 | \$130.53 | \$63.13 |
| 17000 | T | Destroy benign/premal lesion ................................. | 0010 | 0.55 | \$26.67 | \$9.86 | \$5.33 |
| 17003 | T | Destroy lesions, 2-14 ........................................... | 0010 | 0.55 | \$26.67 | \$9.86 | \$5.33 |
| 17004 | T | Destroy lesions, 15 or more | 0011 | 2.72 | \$131.88 | \$50.01 | \$26.38 |
| 17106 | T | Destruction of skin lesions. | 0011 | 2.72 | \$131.88 | \$50.01 | \$26.38 |
| 17107 | T | Destruction of skin lesions ...................................... | 0011 | 2.72 | \$131.88 | \$50.01 | \$26.38 |
| 17108 | T | Destruction of skin lesions ...................................... | 0011 | 2.72 | \$131.88 | \$50.01 | \$26.38 |
| 17110 | T | Destruct lesion, 1-14..... | 0010 | 0.55 | \$26.67 | \$9.86 | \$5.33 |
| 17111 | T | Destruct lesion, 15 or more ................................. | 0011 | 2.72 | \$131.88 | \$50.01 | \$26.38 |

[^136]
## Addendum B.-Hospital Outpatient Department (HOPD) Payment Status by hCPCS Code and Related Information-Continued

| CPT/ HCPCS | HOPD <br> Status <br> Indicator | Description | APC | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 17250 | T | Chemical cautery, tissue | 0014 | 1.50 | \$72.73 | \$24.55 | \$14.55 |
| 17260 | T | Destruction of skin lesions | 0013 | 0.91 | \$44.12 | \$17.66 | \$8.82 |
| 17261 | T | Destruction of skin lesions | 0013 | 0.91 | \$44.12 | \$17.66 | \$8.82 |
| 17262 | T | Destruction of skin lesions | 0013 | 0.91 | \$44.12 | \$17.66 | \$8.82 |
| 17263 | T | Destruction of skin lesions | 0013 | 0.91 | \$44.12 | \$17.66 | \$8.82 |
| 17264 | T | Destruction of skin lesions | 0015 | 1.77 | \$85.82 | \$31.20 | \$17.16 |
| 17266 | T | Destruction of skin lesions | 0016 | 3.53 | \$171.16 | \$74.67 | \$34.23 |
| 17270 | T | Destruction of skin lesions | 0015 | 1.77 | \$85.82 | \$31.20 | \$17.16 |
| 17271 | T | Destruction of skin lesions | 0013 | 0.91 | \$44.12 | \$17.66 | \$8.82 |
| 17272 | T | Destruction of skin lesions | 0013 | 0.91 | \$44.12 | \$17.66 | \$8.82 |
| 17273 | T | Destruction of skin lesions .................................. | 0015 | 1.77 | \$85.82 | \$31.20 | \$17.16 |
| 17274 | T | Destruction of skin lesions .................................. | 0015 | 1.77 | \$85.82 | \$31.20 | \$17.16 |
| 17276 | T | Destruction of skin lesions | 0015 | 1.77 | \$85.82 | \$31.20 | \$17.16 |
| 17280 | T | Destruction of skin lesions | 0015 | 1.77 | \$85.82 | \$31.20 | \$17.16 |
| 17281 | T | Destruction of skin lesions | 0015 | 1.77 | \$85.82 | \$31.20 | \$17.16 |
| 17282 | T | Destruction of skin lesions | 0015 | 1.77 | \$85.82 | \$31.20 | \$17.16 |
| 17283 | T | Destruction of skin lesions | 0015 | 1.77 | \$85.82 | \$31.20 | \$17.16 |
| 17284 | T | Destruction of skin lesions | 0016 | 3.53 | \$171.16 | \$74.67 | \$34.23 |
| 17286 | T | Destruction of skin lesions | 0016 | 3.53 | \$171.16 | \$74.67 | \$34.23 |
| 17304 | T | Chemosurgery of skin lesion | 0020 | 6.51 | \$315.65 | \$130.53 | \$63.13 |
| 17305 | T | 2nd stage chemosurgery | 0020 | 6.51 | \$315.65 | \$130.53 | \$63.13 |
| 17306 | T | 3rd stage chemosurgery | 0020 | 6.51 | \$315.65 | \$130.53 | \$63.13 |
| 17307 | T | Followup skin lesion therapy | 0020 | 6.51 | \$315.65 | \$130.53 | \$63.13 |
| 17310 | T | Extensive skin chemosurgery | 0020 | 6.51 | \$315.65 | \$130.53 | \$63.13 |
| 17340 | T | Cryotherapy of skin ............... | 0012 | 0.53 | \$25.70 | \$9.18 | \$5.14 |
| 17360 | T | Skin peel therapy | 0016 | 3.53 | \$171.16 | \$74.67 | \$34.23 |
| 17380 | T | Hair removal by electrolysis | 0016 | 3.53 | \$171.16 | \$74.67 | \$34.23 |
| 17999 | T | Skin tissue procedure ......... | 0004 | 1.84 | \$89.22 | \$32.57 | \$17.84 |
| 19000 | T | Drainage of breast lesion | 0004 | 1.84 | \$89.22 | \$32.57 | \$17.84 |
| 19001 | T | Drain breast lesion add-on | 0004 | 1.84 | \$89.22 | \$32.57 | \$17.84 |
| 19020 | T | Incision of breast lesion | 0008 | 6.15 | \$298.20 | \$113.67 | \$59.64 |
| 19030 | N | Injection for breast x-ray |  |  |  |  |  |
| 19100 | T | Biopsy of breast | 0005 | 5.41 | \$262.32 | \$119.75 | \$52.46 |
| 19101 | T | Biopsy of breast | 0029 | 12.85 | \$623.06 | \$303.50 | \$124.61 |
| 19110 | T | Nipple exploration | 0029 | 12.85 | \$623.06 | \$303.50 | \$124.61 |
| 19112 | T | Excise breast duct fistula | 0029 | 12.85 | \$623.06 | \$303.50 | \$124.61 |
| 19120 | T | Removal of breast lesion | 0029 | 12.85 | \$623.06 | \$303.50 | \$124.61 |
| 19125 | T | Excision, breast lesion | 0029 | 12.85 | \$623.06 | \$303.50 | \$124.61 |
| 19126 | T | Excision, addl breast lesion | 0029 | 12.85 | \$623.06 | \$303.50 | \$124.61 |
| 19140 | T | Removal of breast tissue | 0029 | 12.85 | \$623.06 | \$303.50 | \$124.61 |
| 19160 | T | Removal of breast tissue | 0030 | 20.19 | \$978.95 | \$523.95 | \$195.79 |
| 19162 | T | Remove breast tissue, nodes | 0030 | 20.19 | \$978.95 | \$523.95 | \$195.79 |
| 19180 | T | Removal of breast | 0030 | 20.19 | \$978.95 | \$523.95 | \$195.79 |
| 19182 | T | Removal of breast | 0030 | 20.19 | \$978.95 | \$523.95 | \$195.79 |
| 19200 | C | Removal of breast | ........ | ......... | ...................... | ...................... | .................... |
| 19220 | C | Removal of breast |  | ....... |  |  |  |
| 19240 | C | Removal of breast .... |  |  |  |  |  |
| 19260 | C | Removal of chest wall lesion |  | ....... |  |  |  |
| 19271 | C | Revision of chest wall .. |  |  |  |  |  |
| 19272 | C | Extensive chest wall surgery ............................... |  |  |  |  |  |
| 19290 | T | Place needle wire, breast ...................................... | 0029 | 12.85 | \$623.06 | \$303.50 | \$124.61 |
| 19291 | T | Place needle wire, breast | 0029 | 12.85 | \$623.06 | \$303.50 | \$124.61 |
| 19316 | T | Suspension of breast | 0030 | 20.19 | \$978.95 | \$523.95 | \$195.79 |
| 19318 | T | Reduction of large breast ....................................... | 0030 | 20.19 | \$978.95 | \$523.95 | \$195.79 |
| 19324 | T | Enlarge breast .... | 0030 | 20.19 | \$978.95 | \$523.95 | \$195.79 |
| 19325 | T | Enlarge breast with implant .................................... | 0030 | 20.19 | \$978.95 | \$523.95 | \$195.79 |
| 19328 | T | Removal of breast implant ...................................... | 0030 | 20.19 | \$978.95 | \$523.95 | \$195.79 |
| 19330 | T | Removal of implant material ................................... | 0030 | 20.19 | \$978.95 | \$523.95 | \$195.79 |
| 19340 | T | Immediate breast prosthesis ................................... | 0030 | 20.19 | \$978.95 | \$523.95 | \$195.79 |
| 19342 | T | Delayed breast prosthesis ..................................... | 0030 | 20.19 | \$978.95 | \$523.95 | \$195.79 |
| 19350 | T | Breast reconstruction ...... | 0030 | 20.19 | \$978.95 | \$523.95 | \$195.79 |
| 19355 | T | Correct inverted nipple(s) | 0030 | 20.19 | \$978.95 | \$523.95 | \$195.79 |
| 19357 | T | Breast reconstruction ............................................ | 0030 | 20.19 | \$978.95 | \$523.95 | \$195.79 |
| 19361 | C | Breast reconstruction |  |  |  |  |  |
| 19364 | C | Breast reconstruction |  |  |  |  |  |
| 19366 | T | Breast reconstruction ............................................. | 0030 | 20.19 | \$978.95 | \$523.95 | \$195.79 |
| 19367 | C | Breast reconstruction |  |  |  |  | ............. |
| 19368 | C | Breast reconstruction ............................................. |  |  |  |  | ................... |
| 19369 | C | Breast reconstruction ............................................. |  |  |  |  |  |
| 19370 | T | Surgery of breast capsule ...................................... | 0030 | 20.19 | \$978.95 | \$523.95 | \$195.79 |
| 19371 | T | Removal of breast capsule ..................................... | 0030 | 20.19 | \$978.95 | \$523.95 | \$195.79 |
| 19380 | T | Revise breast reconstruction .................................. | 0030 | 20.19 | \$978.95 | \$523.95 | \$195.79 |
| 19396 | T | Design custom breast implant ................................. | 0029 | 12.85 | \$623.06 | \$303.50 | \$124.61 |

[^137]
# Addendum B.-Hospital Outpatient Department (HOPD) Payment Status by HCPCS Code and Related Information-Continued 

| CPT/ HCPCS | HOPD Status Indicator | Description | APC | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 19499 | T | Breast surgery procedure | 0029 | 12.85 | \$623.06 | \$303.50 | \$124.61 |
| 20000 | T | Incision of abscess | 0006 | 2.00 | \$96.97 | \$33.95 | \$19.39 |
| 20005 | T | Incision of deep abscess | 0049 | 15.04 | \$729.25 | \$356.95 | \$145.85 |
| 20100 | T | Explore wound, neck ..... | 0023 | 1.98 | \$96.00 | \$40.37 | \$19.20 |
| 20101 | T | Explore wound, chest | 0026 | 12.11 | \$587.18 | \$277.92 | \$117.44 |
| 20102 | T | Explore wound, abdomen | 0026 | 12.11 | \$587.18 | \$277.92 | \$117.44 |
| 20103 | T | Explore wound, extremity | 0023 | 1.98 | \$96.00 | \$40.37 | \$19.20 |
| 20150 | T | Excise epiphyseal bar ..... | 0051 | 27.76 | \$1,346.00 | \$675.24 | \$269.20 |
| 20200 | T | Muscle biopsy | 0020 | 6.51 | \$315.65 | \$130.53 | \$63.13 |
| 20205 | T | Deep muscle biopsy | 0021 | 10.49 | \$508.63 | \$236.51 | \$101.73 |
| 20206 | T | Needle biopsy, muscle | 0005 | 5.41 | \$262.32 | \$119.75 | \$52.46 |
| 20220 | T | Bone biopsy, trocar/needle | 0019 | 4.00 | \$193.95 | \$78.91 | \$38.79 |
| 20225 | T | Bone biopsy, trocar/needle | 0020 | 6.51 | \$315.65 | \$130.53 | \$63.13 |
| 20240 | T | Bone biopsy, excisional . | 0022 | 12.49 | \$605.60 | \$292.94 | \$121.12 |
| 20245 | T | Bone biopsy, excisional | 0022 | 12.49 | \$605.60 | \$292.94 | \$121.12 |
| 20250 | T | Open bone biopsy | 0049 | 15.04 | \$729.25 | \$356.95 | \$145.85 |
| 20251 | T | Open bone biopsy | 0049 | 15.04 | \$729.25 | \$356.95 | \$145.85 |
| 20500 | T | Injection of sinus tract | 0252 | 5.18 | \$251.16 | \$114.24 | \$50.23 |
| 20501 | N | Inject sinus tract for x-ray |  |  |  |  |  |
| 20520 | T | Removal of foreign body | 0019 | 4.00 | \$193.95 | \$78.91 | \$38.79 |
| 20525 | T | Removal of foreign body | 0022 | 12.49 | \$605.60 | \$292.94 | \$121.12 |
| 20550 | T | Inject tendon/ligament/cyst | 0040 | 2.11 | \$102.31 | \$40.60 | \$20.46 |
| 20600 | T | Drain/inject, joint/bursa | 0040 | 2.11 | \$102.31 | \$40.60 | \$20.46 |
| 20605 | T | Drain/inject, joint/bursa | 0040 | 2.11 | \$102.31 | \$40.60 | \$20.46 |
| 20610 | T | Drain/inject, joint/bursa | 0040 | 2.11 | \$102.31 | \$40.60 | \$20.46 |
| 20615 | T | Treatment of bone cyst | 0004 | 1.84 | \$89.22 | \$32.57 | \$17.84 |
| 20650 | T | Insert and remove bone pin | 0049 | 15.04 | \$729.25 | \$356.95 | \$145.85 |
| 20660 | C | Apply, remove fixation device .................................. | ...................... | ...................... | ..................... | ...................... | ...................... |
| 20661 | C | Application of head brace ... |  |  |  |  |  |
| 20662 | C | Application of pelvis brace | ........ | .................. |  |  |  |
| 20663 | C | Application of thigh brace ....................................... | ..................... |  |  | ..................... |  |
| 20664 | C | Halo brace application .... |  |  |  |  |  |
| 20665 | N | Removal of fixation device |  |  |  |  |  |
| 20670 | T | Removal of support implant .................................... | 0021 | 10.49 | \$508.63 | \$236.51 | \$101.73 |
| 20680 | T | Removal of support implant | 0022 | 12.49 | \$605.60 | \$292.94 | \$121.12 |
| 20690 | T | Apply bone fixation device | 0050 | 21.13 | \$1,024.53 | \$513.86 | \$204.91 |
| 20692 | T | Apply bone fixation device | 0050 | 21.13 | \$1,024.53 | \$513.86 | \$204.91 |
| 20693 | T | Adjust bone fixation device | 0049 | 15.04 | \$729.25 | \$356.95 | \$145.85 |
| 20694 | T | Remove bone fixation device | 0049 | 15.04 | \$729.25 | \$356.95 | \$145.85 |
| 20802 | C | Replantation, arm, complete |  |  |  |  |  |
| 20805 | C | Replant, forearm, complete .................................... | ...... | ..................... | .................... | ..................... | ..................... |
| 20808 | C | Replantation hand, complete |  | ....... |  |  |  |
| 20816 | C | Replantation digit, complete ................................... |  |  |  |  |  |
| 20822 | C | Replantation digit, complete ................................... |  |  |  |  |  |
| 20824 | C | Replantation thumb, complete ................................. |  | ........ |  | ................... | ..................... |
| 20827 | C | Replantation thumb, complete |  |  |  |  |  |
| 20838 | C | Replantation foot, complete .................................... |  |  |  |  |  |
| 20900 | T | Removal of bone for graft | 0050 | 21.13 | \$1,024.53 | \$513.86 | \$204.91 |
| 20902 | T | Removal of bone for graft ....................................... | 0050 | 21.13 | \$1,024.53 | \$513.86 | \$204.91 |
| 20910 | T | Remove cartilage for graft | 0026 | 12.11 | \$587.18 | \$277.92 | \$117.44 |
| 20912 | T | Remove cartilage for graft | 0026 | 12.11 | \$587.18 | \$277.92 | \$117.44 |
| 20920 | T | Removal of fascia for graft ..................................... | 0026 | 12.11 | \$587.18 | \$277.92 | \$117.44 |
| 20922 | T | Removal of fascia for graft | 0026 | 12.11 | \$587.18 | \$277.92 | \$117.44 |
| 20924 | T | Removal of tendon for graft ..................................... | 0050 | 21.13 | \$1,024.53 | \$513.86 | \$204.91 |
| 20926 | T | Removal of tissue for graft ..................................... | 0026 | 12.11 | \$587.18 | \$277.92 | \$117.44 |
| 20930 | C | Spinal bone allograft .............................................. |  |  |  |  |  |
| 20931 | C | Spinal bone allograft .............................................. |  |  |  |  |  |
| 20936 | C | Spinal bone autograft ............................................ | .................... | .................... | .................... | .................... | ..................... |
| 20937 | C | Spinal bone autograft ............................................ |  |  |  |  |  |
| 20938 | C | Spinal bone autograft ......... |  |  |  |  |  |
| 20950 | T | Fluid pressure, muscle .......................................... | 0008 | 6.15 | \$298.20 | \$113.67 | \$59.64 |
| 20955 | C | Fibula bone graft, microvasc .................................. |  |  |  |  |  |
| 20956 | C | Iliac bone graft, microvasc ...................................... |  |  |  |  |  |
| 20957 | C | Mt bone graft, microvasc ........................................ |  | .................... |  | ................... | ...................... |
| 20962 | C | Other bone graft, microvasc ................................... |  |  |  | ...................... |  |
| 20969 | C | Bone/skin graft, microvasc ..................................... |  |  |  |  |  |
| 20970 | C | Bone/skin graft, iliac crest ...................................... |  |  |  |  |  |
| 20972 | C | Bone/skin graft, metatarsal ..................................... |  |  |  | .................... |  |
| 20973 | C | Bone/skin graft, great toe ....................................... |  |  |  |  |  |
| 20974 | A | Electrical bone stimulation ...................................... |  |  |  |  |  |
| 20975 | T | Electrical bone stimulation | 0049 | 15.04 | \$729.25 | \$356.95 | \$145.85 |
| 20979 | T | Us bone stimulation | 0049 | 15.04 | \$729.25 | \$356.95 | \$145.85 |
| 20999 | N | Musculoskeletal surgery |  |  |  |  |  |

[^138]
# Addendum B.-Hospital Outpatient Department (HOPD) Payment Status by hCPCS Code and Related INFORMATION-Continued 

| CPT/ HCPCS | HOPD <br> Status Indicator | Description | APC | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 21010 | T | Incision of jaw joint | 0254 | 12.45 | \$603.66 | \$272.41 | \$120.73 |
| 21015 | T | Resection of facial tumor | 0254 | 12.45 | \$603.66 | \$272.41 | \$120.73 |
| 21025 | T | Excision of bone, lower jaw | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 21026 | T | Excision of facial bone(s) .. | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 21029 | T | Contour of face bone lesion | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 21030 | T | Removal of face bone lesion | 0254 | 12.45 | \$603.66 | \$272.41 | \$120.73 |
| 21031 | T | Remove exostosis, mandible | 0253 | 12.02 | \$582.81 | \$284.00 | \$116.56 |
| 21032 | T | Remove exostosis, maxilla . | 0253 | 12.02 | \$582.81 | \$284.00 | \$116.56 |
| 21034 | T | Removal of face bone lesion | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 21040 | T | Removal of jaw bone lesion | 0253 | 12.02 | \$582.81 | \$284.00 | \$116.56 |
| 21041 | T | Removal of jaw bone lesion | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 21044 | T | Removal of jaw bone lesion | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 21045 | C | Extensive jaw surgery ......... |  |  |  |  |  |
| 21050 | T | Removal of jaw joint . | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 21060 | T | Remove jaw joint cartilage | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 21070 | T | Remove coronoid process | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 21076 | T | Prepare face/oral prosthesis | 0254 | 12.45 | \$603.66 | \$272.41 | \$120.73 |
| 21077 | T | Prepare face/oral prosthesis | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 21079 | T | Prepare face/oral prosthesis | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 21080 | T | Prepare face/oral prosthesis | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 21081 | T | Prepare face/oral prosthesis | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 21082 | T | Prepare face/oral prosthesis | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 21083 | T | Prepare face/oral prosthesis | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 21084 | T | Prepare face/oral prosthesis | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 21085 | T | Prepare face/oral prosthesis | 0253 | 12.02 | \$582.81 | \$284.00 | \$116.56 |
| 21086 | T | Prepare face/oral prosthesis | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 21087 | T | Prepare face/oral prosthesis | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 21088 | T | Prepare face/oral prosthesis | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 21089 | T | Prepare face/oral prosthesis | 0253 | 12.02 | \$582.81 | \$284.00 | \$116.56 |
| 21100 | T | Maxillofacial fixation | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 21110 | T | Interdental fixation | 0254 | 12.45 | \$603.66 | \$272.41 | \$120.73 |
| 21116 | N | Injection, jaw joint x-ray |  |  |  |  |  |
| 21120 | T | Reconstruction of chin | 0254 | 12.45 | \$603.66 | \$272.41 | \$120.73 |
| 21121 | T | Reconstruction of chin | 0254 | 12.45 | \$603.66 | \$272.41 | \$120.73 |
| 21122 | T | Reconstruction of chin | 0254 | 12.45 | \$603.66 | \$272.41 | \$120.73 |
| 21123 | T | Reconstruction of chin | 0254 | 12.45 | \$603.66 | \$272.41 | \$120.73 |
| 21125 | T | Augmentation, lower jaw bone | 0254 | 12.45 | \$603.66 | \$272.41 | \$120.73 |
| 21127 | T | Augmentation, lower jaw bone | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 21137 | T | Reduction of forehead | 0254 | 12.45 | \$603.66 | \$272.41 | \$120.73 |
| 21138 | T | Reduction of forehead | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 21139 | T | Reduction of forehead | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 21141 | C | Reconstruct midface, lefort |  |  |  |  |  |
| 21142 | C | Reconstruct midface, lefort |  |  |  |  |  |
| 21143 | C | Reconstruct midface, lefort |  |  |  |  |  |
| 21145 | C | Reconstruct midface, lefort |  | ...... | ......... |  |  |
| 21146 | C | Reconstruct midface, lefort |  |  |  |  |  |
| 21147 | C | Reconstruct midface, lefort |  |  |  |  |  |
| 21150 | C | Reconstruct midface, lefort |  | ...................... | ...................... | ...................... |  |
| 21151 | C | Reconstruct midface, lefort |  |  |  |  |  |
| 21154 | C | Reconstruct midface, lefort |  |  |  |  |  |
| 21155 | C | Reconstruct midface, lefort ..................................... | . | . | . | . |  |
| 21159 | C | Reconstruct midface, lefort |  |  |  |  |  |
| 21160 | C | Reconstruct midface, lefort |  |  |  |  |  |
| 21172 | C | Reconstruct orbit/forehead | .................... | ......... | ..................... | ..................... | ..................... |
| 21175 | C | Reconstruct orbit/forehead |  |  | ..................... |  |  |
| 21179 | C | Reconstruct entire forehead |  |  |  |  |  |
| 21180 | C | Reconstruct entire forehead |  |  |  |  |  |
| 21181 | T | Contour cranial bone lesion | 0254 | 12.45 | \$603.66 | \$272.41 | \$120.73 |
| 21182 | C | Reconstruct cranial bone |  |  |  |  |  |
| 21183 | C | Reconstruct cranial bone |  | .................... | .................... | .................... | .......... |
| 21184 | C | Reconstruct cranial bone |  |  |  |  |  |
| 21188 | C | Reconstruction of midface ..................................... |  |  |  |  |  |
| 21193 | C | Reconstruct lower jaw bone .................................... |  |  |  |  |  |
| 21194 | C | Reconstruct lower jaw bone .................................... |  |  |  |  |  |
| 21195 | C | Reconstruct lower jaw bone .................................... |  |  |  |  |  |
| 21196 | C | Reconstruct lower jaw bone .................................... |  |  |  |  |  |
| 21198 | T | Reconstruct lower jaw bone .................................... | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 21206 | T | Reconstruct upper jaw bone .... | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 21208 | T | Augmentation of facial bones | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 21209 | T | Reduction of facial bones | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 21210 | T | Face bone graft .................................................... | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 21215 | T | Lower jaw bone graft ............................................ | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 21230 | T | Rib cartilage graft ............................................... | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |

[^139]
# Addendum B.-Hospital Outpatient Department (HOPD) Payment Status by HCPCS Code and Related Information-Continued 

| $\begin{aligned} & \text { CPT/ } \\ & \text { HCPCS } \end{aligned}$ | HOPD Status Indicator | Description | APC | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 21235 | T | Ear cartilage graft | 0254 | 12.45 | \$603.66 | \$272.41 | \$120.73 |
| 21240 | T | Reconstruction of jaw joint | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 21242 | T | Reconstruction of jaw joint | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 21243 | T | Reconstruction of jaw joint | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 21244 | T | Reconstruction of lower jaw | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 21245 | T | Reconstruction of jaw ......... | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 21246 | T | Reconstruction of jaw | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 21247 | C | Reconstruct lower jaw bone |  |  |  |  |  |
| 21248 | T | Reconstruction of jaw | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 21249 | T | Reconstruction of jaw | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 21255 | C | Reconstruct lower jaw bone |  |  |  |  |  |
| 21256 | C | Reconstruction of orbit |  |  |  |  |  |
| 21260 | T | Revise eye sockets | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 21261 | T | Revise eye sockets | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 21263 | T | Revise eye sockets | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 21267 | T | Revise eye sockets | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 21268 | C | Revise eye sockets ............................................... |  |  |  |  |  |
| 21270 | T | Augmentation, cheek bone ..................................... | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 21275 | T | Revision, orbitofacial bones | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 21280 | T | Revision of eyelid | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 21282 | T | Revision of eyelid | 0253 | 12.02 | \$582.81 | \$284.00 | \$116.56 |
| 21295 | T | Revision of jaw muscle/bone | 0253 | 12.02 | \$582.81 | \$284.00 | \$116.56 |
| 21296 | T | Revision of jaw muscle/bone | 0254 | 12.45 | \$603.66 | \$272.41 | \$120.73 |
| 21299 | T | Cranio/maxillofacial surgery | 0253 | 12.02 | \$582.81 | \$284.00 | \$116.56 |
| 21300 | T | Treatment of skull fracture | 0253 | 12.02 | \$582.81 | \$284.00 | \$116.56 |
| 21310 | T | Treatment of nose fracture | 0253 | 12.02 | \$582.81 | \$284.00 | \$116.56 |
| 21315 | T | Treatment of nose fracture | 0253 | 12.02 | \$582.81 | \$284.00 | \$116.56 |
| 21320 | T | Treatment of nose fracture | 0253 | 12.02 | \$582.81 | \$284.00 | \$116.56 |
| 21325 | T | Treatment of nose fracture | 0253 | 12.02 | \$582.81 | \$284.00 | \$116.56 |
| 21330 | T | Treatment of nose fracture | 0254 | 12.45 | \$603.66 | \$272.41 | \$120.73 |
| 21335 | T | Treatment of nose fracture | 0254 | 12.45 | \$603.66 | \$272.41 | \$120.73 |
| 21336 | T | Treat nasal septal fracture | 0046 | 22.29 | \$1,080.78 | \$535.76 | \$216.16 |
| 21337 | T | Treat nasal septal fracture | 0253 | 12.02 | \$582.81 | \$284.00 | \$116.56 |
| 21338 | T | Treat nasoethmoid fracture | 0254 | 12.45 | \$603.66 | \$272.41 | \$120.73 |
| 21339 | T | Treat nasoethmoid fracture | 0254 | 12.45 | \$603.66 | \$272.41 | \$120.73 |
| 21340 | T | Treatment of nose fracture | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 21343 | C | Treatment of sinus fracture |  |  |  |  |  |
| 21344 | C | Treatment of sinus fracture |  |  |  |  |  |
| 21345 | T | Treat nose/jaw fracture | 0254 | 12.45 | \$603.66 | \$272.41 | \$120.73 |
| 21346 | C | Treat nose/jaw fracture .......................................... |  |  |  |  |  |
| 21347 | C | Treat nose/jaw fracture |  |  |  | ..................... |  |
| 21348 | C | Treat nose/jaw fracture |  |  |  |  |  |
| 21355 | T | Treat cheek bone fracture | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 21356 | C | Treat cheek bone fracture |  |  |  |  |  |
| 21360 | C | Treat cheek bone fracture |  |  |  |  |  |
| 21365 | C | Treat cheek bone fracture |  |  |  |  |  |
| 21366 | C | Treat cheek bone fracture |  |  |  |  |  |
| 21385 | C | Treat eye socket fracture |  | ...... |  | .................. |  |
| 21386 | C | Treat eye socket fracture |  |  |  |  |  |
| 21387 | C | Treat eye socket fracture ........................................ |  | .................... |  | .................... |  |
| 21390 | C | Treat eye socket fracture |  |  |  |  |  |
| 21395 | C | Treat eye socket fracture ........................................ |  |  |  |  |  |
| 21400 | T | Treat eye socket fracture | 0252 | 5.18 | \$251.16 | \$114.24 | \$50.23 |
| 21401 | T | Treat eye socket fracture ........................................ | 0253 | 12.02 | \$582.81 | \$284.00 | \$116.56 |
| 21406 | T | Treat eye socket fracture | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 21407 | T | Treat eye socket fracture | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 21408 | C | Treat eye socket fracture |  |  |  |  |  |
| 21421 | T | Treat mouth roof fracture | 0254 | 12.45 | \$603.66 | \$272.41 | \$120.73 |
| 21422 | C | Treat mouth roof fracture |  |  |  |  |  |
| 21423 | C | Treat mouth roof fracture |  |  |  | .......... |  |
| 21431 | C | Treat craniofacial fracture |  |  |  | .................... |  |
| 21432 | C | Treat craniofacial fracture |  |  |  |  |  |
| 21433 | C | Treat craniofacial fracture |  |  |  |  |  |
| 21435 | C | Treat craniofacial fracture |  |  |  | .................. |  |
| 21436 | C | Treat craniofacial fracture |  |  |  |  |  |
| 21440 | T | Treat dental ridge fracture | 0253 | 12.02 | \$582.81 | \$284.00 | \$116.56 |
| 21445 | T | Treat dental ridge fracture | 0254 | 12.45 | \$603.66 | \$272.41 | \$120.73 |
| 21450 | T | Treat lower jaw fracture ......................................... | 0251 | 1.68 | \$81.46 | \$27.99 | \$16.29 |
| 21451 | T | Treat lower jaw fracture .......................................... | 0254 | 12.45 | \$603.66 | \$272.41 | \$120.73 |
| 21452 | T | Treat lower jaw fracture ......................................... | 0253 | 12.02 | \$582.81 | \$284.00 | \$116.56 |
| 21453 | T | Treat lower jaw fracture ......................................... | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 21454 | T | Treat lower jaw fracture | 0254 | 12.45 | \$603.66 | \$272.41 | \$120.73 |
| 21461 | T | Treat lower jaw fracture | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |

[^140]
## Addendum B.—Hospital Outpatient Department (HOPD) Payment Status by hCPCS Code and Related Information-Continued

| CPT/ HCPCS | HOPD Status Indicator | Description | APC | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 21462 | T | Treat lower jaw fracture ........................................... | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 21465 | T | Treat lower jaw fracture .......................................... | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 21470 | T | Treat lower jaw fracture | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 21480 | T | Reset dislocated jaw | 0251 | 1.68 | \$81.46 | \$27.99 | \$16.29 |
| 21485 | T | Reset dislocated jaw | 0253 | 12.02 | \$582.81 | \$284.00 | \$116.56 |
| 21490 | T | Repair dislocated jaw | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 21493 | T | Treat hyoid bone fracture | 0252 | 5.18 | \$251.16 | \$114.24 | \$50.23 |
| 21494 | T | Treat hyoid bone fracture | 0252 | 5.18 | \$251.16 | \$114.24 | \$50.23 |
| 21495 | C | Treat hyoid bone fracture |  |  |  |  |  |
| 21497 | T | Interdental wiring ....... | 0253 | 12.02 | \$582.81 | \$284.00 | \$116.56 |
| 21499 | T | Head surgery procedure | 0253 | 12.02 | \$582.81 | \$284.00 | \$116.56 |
| 21501 | T | Drain neck/chest lesion | 0008 | 6.15 | \$298.20 | \$113.67 | \$59.64 |
| 21502 | T | Drain chest lesion | 0050 | 21.13 | \$1,024.53 | \$513.86 | \$204.91 |
| 21510 | C | Drainage of bone lesion ........................................ |  |  |  |  |  |
| 21550 | T | Biopsy of neck/chest | 0019 | 4.00 | \$193.95 | \$78.91 | \$38.79 |
| 21555 | T | Remove lesion, neck/chest | 0022 | 12.49 | \$605.60 | \$292.94 | \$121.12 |
| 21556 | T | Remove lesion, neck/chest .................................... | 0022 | 12.49 | \$605.60 | \$292.94 | \$121.12 |
| 21557 | C | Remove tumor, neck/chest |  |  |  |  |  |
| 21600 | T | Partial removal of rib | 0050 | 21.13 | \$1,024.53 | \$513.86 | \$204.91 |
| 21610 | T | Partial removal of rib | 0050 | 21.13 | \$1,024.53 | \$513.86 | \$204.91 |
| 21615 | C | Removal of rib |  |  |  |  |  |
| 21616 | C | Removal of rib and nerves |  |  |  |  |  |
| 21620 | C | Partial removal of sternum |  |  |  |  |  |
| 21627 | C | Sternal debridement ............................................. |  | ...... |  |  |  |
| 21630 | C | Extensive sternum surgery ..................................... |  |  |  |  |  |
| 21632 | C | Extensive sternum surgery ..................................... |  |  |  |  |  |
| 21700 | T | Revision of neck muscle ......................................... | 0008 | 6.15 | \$298.20 | \$113.67 | \$59.64 |
| 21705 | C | Revision of neck muscle/rib |  |  |  |  |  |
| 21720 | T | Revision of neck muscle | 0008 | 6.15 | \$298.20 | \$113.67 | \$59.64 |
| 21725 | T | Revision of neck muscle | 0008 | 6.15 | \$298.20 | \$113.67 | \$59.64 |
| 21740 | C | Reconstruction of sternum ...................................... |  |  |  |  |  |
| 21750 | C | Repair of sternum separation |  |  |  |  |  |
| 21800 | T | Treatment of rib fracture ........ | 0043 | 1.64 | \$79.52 | \$25.46 | \$15.90 |
| 21805 | T | Treatment of rib fracture | 0046 | 22.29 | \$1,080.78 | \$535.76 | \$216.16 |
| 21810 | C | Treatment of rib fracture(s) |  |  |  |  |  |
| 21820 | T | Treat sternum fracture. | 0043 | 1.64 | \$79.52 | \$25.46 | \$15.90 |
| 21825 | C | Treat sternum fracture |  |  |  |  |  |
| 21899 | T | Neck/chest surgery procedure | 0252 | 5.18 | \$251.16 | \$114.24 | \$50.23 |
| 21920 | T | Biopsy soft tissue of back | 0020 | 6.51 | \$315.65 | \$130.53 | \$63.13 |
| 21925 | T | Biopsy soft tissue of back | 0022 | 12.49 | \$605.60 | \$292.94 | \$121.12 |
| 21930 | T | Remove lesion, back or flank .................................. | 0022 | 12.49 | \$605.60 | \$292.94 | \$121.12 |
| 1935 | T | Remove tumor, back | 0022 | 12.49 | \$605.60 | \$292.94 | \$121.12 |
| 22100 | C | Remove part of neck vertebra |  | ......... |  |  |  |
| 22101 | C | Remove part, thorax vertebra ................................. |  | ..................... |  |  |  |
| 22102 | C | Remove part, lumbar vertebra ................................. |  |  |  |  |  |
| 22103 | C | Remove extra spine segment |  |  |  | ...................... |  |
| 22110 | C | Remove part of neck vertebra | .................. | ..................... | ...................... | ...................... |  |
| 22112 | C | Remove part, thorax vertebra |  |  |  |  |  |
| 22114 | C | Remove part, lumbar vertebra ................................. |  |  |  | ..................... |  |
| 22116 | C | Remove extra spine segment .................................. |  | ..................... | ..................... | ...................... |  |
| 22210 | C | Revision of neck spine |  |  |  |  |  |
| 22212 | C | Revision of thorax spine .. |  |  |  |  |  |
| 22214 | C | Revision of lumbar spine ........................................ | ...... | ..................... | ..................... | .................... | ................... |
| 22216 | C | Revise, extra spine segment ................................... |  |  |  |  |  |
| 22220 | C | Revision of neck spine ........................................... |  |  |  |  |  |
| 22222 | C | Revision of thorax spine ......................................... | ................... | .................... | .................... | .................... | ..................... |
| 22224 | C | Revision of lumbar spine |  |  |  |  |  |
| 22226 | C | Revise, extra spine segment ................................... |  |  |  |  |  |
| 22305 | T | Treat spine process fracture .................................... | 0043 | 1.64 | \$79.52 | \$25.46 | \$15.90 |
| 22310 | T | Treat spine fracture | 0043 | 1.64 | \$79.52 | \$25.46 | \$15.90 |
| 22315 | T | Treat spine fracture .............................................. | 0043 | 1.64 | \$79.52 | \$25.46 | \$15.90 |
| 22318 | C | Treat odontoid fx w/o graft ..................................... |  |  |  |  |  |
| 22319 | C | Treat odontoid fx w/graft ........................................ |  |  | .................... | ..................... |  |
| 22325 | C | Treat spine fracture ............................................... |  |  |  |  |  |
| 22326 | C | Treat neck spine fracture ........................................ |  |  |  |  |  |
| 22327 | C | Treat thorax spine fracture ..................................... |  |  |  | ...................... |  |
| 22328 | C | Treat each add spine fx ... |  |  |  |  |  |
| 22505 | T | Manipulation of spine ............................................ | 0045 | 11.02 | \$534.33 | \$277.12 | \$106.87 |
| 22548 | C | Neck spine fusion ................................................. | ...................... | ...................... | ...................... | ...................... | ..................... |
| 22554 | C | Neck spine fusion ................................................. | ...................... | ...................... | ...................... | .......... | ..................... |
| 22556 | C | Thorax spine fusion .............................................. | ...................... | ..................... |  | ...................... |  |
| 22558 | C | Lumbar spine fusion ............................................. | ...................... |  | .................... | ..................... |  |
| 22585 | C | Additional spinal fusion |  |  |  |  |  |

[^141]
# Addendum B.-Hospital Outpatient Department (HOPD) Payment Status by HCPCS Code and Related Information-Continued 

| $\begin{aligned} & \text { CPT/ } \\ & \text { HCPCS } \end{aligned}$ | HOPD <br> Status <br> Indicator | Description | APC | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 22590 | C | Spine \& skull spinal fusion ... |  |  |  |  |  |
| 22595 | C | Neck spinal fusion |  |  |  |  |  |
| 22600 | C | Neck spine fusion | ... | ........... | ............ |  |  |
| 22610 | C | Thorax spine fusion |  |  |  |  |  |
| 22612 | C | Lumbar spine fusion |  |  |  |  |  |
| 22614 | C | Spine fusion, extra segment | ... | .................... | .................... |  |  |
| 22630 | C | Lumbar spine fusion |  | .................... |  | ............. |  |
| 22632 | C | Spine fusion, extra segment |  |  |  |  |  |
| 22800 | C | Fusion of spine ....... |  |  |  |  |  |
| 22802 | C | Fusion of spine |  | .................... | .................... | ... |  |
| 22804 | C | Fusion of spine |  |  | ...................... |  |  |
| 22808 | C | Fusion of spine |  |  |  |  |  |
| 22810 | C | Fusion of spine |  |  |  |  |  |
| 22812 | C | Fusion of spine |  |  |  |  |  |
| 22818 | C | Kyphectomy, 1-2 segments |  |  |  |  |  |
| 22819 | C | Kyphectomy, 3 or more |  |  |  |  |  |
| 22830 | C | Exploration of spinal fusion | ................... | ................... | .................... | ................... |  |
| 22840 | C | Insert spine fixation device |  |  |  |  |  |
| 22841 | C | Insert spine fixation device |  |  |  |  |  |
| 22842 | C | Insert spine fixation device | .................... | .................... | .................... | .................... |  |
| 22843 | C | Insert spine fixation device |  |  |  |  |  |
| 22844 | C | Insert spine fixation device |  |  |  |  |  |
| 22845 | C | Insert spine fixation device |  |  |  |  |  |
| 22846 | C | Insert spine fixation device |  |  |  |  |  |
| 22847 | C | Insert spine fixation device .. |  |  |  |  |  |
| 22848 | C | Insert pelv fixation device |  |  |  |  |  |
| 22849 | C | Reinsert spinal fixation |  | .................. | ................... | .................... |  |
| 22850 | C | Remove spine fixation device |  |  |  |  |  |
| 22851 | C | Apply spine prosth device |  |  |  |  |  |
| 22852 | C | Remove spine fixation device |  |  |  |  |  |
| 22855 | C | Remove spine fixation device |  |  |  |  |  |
| 22899 | T | Spine surgery procedure | 0043 | 1.64 | \$79.52 | \$25.46 | \$15.90 |
| 22900 | T | Remove abdominal wall lesion | 0022 | 12.49 | \$605.60 | \$292.94 | \$121.12 |
| 22999 | T | Abdomen surgery procedure | 0022 | 12.49 | \$605.60 | \$292.94 | \$121.12 |
| 23000 | T | Removal of calcium deposits | 0021 | 10.49 | \$508.63 | \$236.51 | \$101.73 |
| 23020 | T | Release shoulder joint | 0051 | 27.76 | \$1,346.00 | \$675.24 | \$269.20 |
| 23030 | T | Drain shoulder lesion | 0008 | 6.15 | \$298.20 | \$113.67 | \$59.64 |
| 23031 | T | Drain shoulder bursa | 0008 | 6.15 | \$298.20 | \$113.67 | \$59.64 |
| 23035 | C | Drain shoulder bone lesion |  |  |  |  |  |
| 23040 | T | Exploratory shoulder surgery | 0050 | 21.13 | \$1,024.53 | \$513.86 | \$204.91 |
| 23044 | T | Exploratory shoulder surgery | 0050 | 21.13 | \$1,024.53 | \$513.86 | \$204.91 |
| 23065 | T | Biopsy shoulder tissues | 0021 | 10.49 | \$508.63 | \$236.51 | \$101.73 |
| 23066 | T | Biopsy shoulder tissues | 0022 | 12.49 | \$605.60 | \$292.94 | \$121.12 |
| 23075 | T | Removal of shoulder lesion | 0021 | 10.49 | \$508.63 | \$236.51 | \$101.73 |
| 23076 | T | Removal of shoulder lesion | 0022 | 12.49 | \$605.60 | \$292.94 | \$121.12 |
| 23077 | T | Remove tumor of shoulder | 0022 | 12.49 | \$605.60 | \$292.94 | \$121.12 |
| 23100 | T | Biopsy of shoulder joint ..... | 0049 | 15.04 | \$729.25 | \$356.95 | \$145.85 |
| 23101 | T | Shoulder joint surgery | 0050 | 21.13 | \$1,024.53 | \$513.86 | \$204.91 |
| 23105 | T | Remove shoulder joint lining | 0050 | 21.13 | \$1,024.53 | \$513.86 | \$204.91 |
| 23106 | T | Incision of collarbone joint | 0050 | 21.13 | \$1,024.53 | \$513.86 | \$204.91 |
| 23107 | T | Explore treat shoulder joint | 0050 | 21.13 | \$1,024.53 | \$513.86 | \$204.91 |
| 23120 | T | Partial removal, collar bone | 0051 | 27.76 | \$1,346.00 | \$675.24 | \$269.20 |
| 23125 | C | Removal of collar bone |  |  |  |  |  |
| 23130 | T | Remove shoulder bone, part | 0051 | 27.76 | \$1,346.00 | \$675.24 | \$269.20 |
| 23140 | T | Removal of bone lesion | 0049 | 15.04 | \$729.25 | \$356.95 | \$145.85 |
| 23145 | T | Removal of bone lesion | 0050 | 21.13 | \$1,024.53 | \$513.86 | \$204.91 |
| 23146 | T | Removal of bone lesion | 0050 | 21.13 | \$1,024.53 | \$513.86 | \$204.91 |
| 23150 | T | Removal of humerus lesion | 0050 | 21.13 | \$1,024.53 | \$513.86 | \$204.91 |
| 23155 | T | Removal of humerus lesion | 0050 | 21.13 | \$1,024.53 | \$513.86 | \$204.91 |
| 23156 | T | Removal of humerus lesion | 0050 | 21.13 | \$1,024.53 | \$513.86 | \$204.91 |
| 23170 | T | Remove collar bone lesion | 0050 | 21.13 | \$1,024.53 | \$513.86 | \$204.91 |
| 23172 | T | Remove shoulder blade lesion | 0050 | 21.13 | \$1,024.53 | \$513.86 | \$204.91 |
| 23174 | T | Remove humerus lesion | 0050 | 21.13 | \$1,024.53 | \$513.86 | \$204.91 |
| 23180 | T | Remove collar bone lesion | 0050 | 21.13 | \$1,024.53 | \$513.86 | \$204.91 |
| 23182 | T | Remove shoulder blade lesion | 0050 | 21.13 | \$1,024.53 | \$513.86 | \$204.91 |
| 23184 | T | Remove humerus lesion | 0050 | 21.13 | \$1,024.53 | \$513.86 | \$204.91 |
| 23190 | T | Partial removal of scapula ...................................... | 0050 | 21.13 | \$1,024.53 | \$513.86 | \$204.91 |
| 23195 | C | Removal of head of humerus ... |  |  |  |  |  |
| 23200 | C | Removal of collar bone |  |  |  | .................... |  |
| 23210 | C | Removal of shoulder blade |  |  |  |  |  |
| 23220 | C | Partial removal of humerus | ................... | .................... | ................... | ................... |  |
| 23221 | C | Partial removal of humerus .................................... | ... |  | ...................... |  |  |
| 23222 | C | Partial removal of humerus |  |  |  |  |  |

[^142]
## Addendum B.-Hospital Outpatient Department (HOPD) Payment Status by HCPCS Code and Related Information-Continued

| CPT/ <br> HCPCS | HOPD Status Indicator | Description | APC | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 23330 | T | Remove shoulder foreign body | 0019 | 4.00 | \$193.95 | \$78.91 | \$38.79 |
| 23331 | T | Remove shoulder foreign body | 0022 | 12.49 | \$605.60 | \$292.94 | \$121.12 |
| 23332 | C | Remove shoulder foreign body .. |  |  |  |  |  |
| 23350 | N | Injection for shoulder x-ray ......... |  |  |  |  |  |
| 23395 | C | Muscle transfer, shoulder/arm |  |  |  |  |  |
| 23397 | C | Muscle transfers .......... | $\ldots$ |  |  |  |  |
| 23400 | C | Fixation of shoulder blade |  |  |  |  |  |
| 23405 | T | Incision of tendon \& muscle | 0050 | 21.13 | \$1,024.53 | \$513.86 | \$204.91 |
| 23406 | T | Incise tendon(s) \& muscle(s) | 0050 | 21.13 | \$1,024.53 | \$513.86 | \$204.91 |
| 23410 | T | Repair of tendon(s) | 0052 | 36.16 | \$1,753.29 | \$930.91 | \$350.66 |
| 23412 | T | Repair of tendon(s) | 0052 | 36.16 | \$1,753.29 | \$930.91 | \$350.66 |
| 23415 | T | Release of shoulder ligament | 0051 | 27.76 | \$1,346.00 | \$675.24 | \$269.20 |
| 23420 | T | Repair of shoulder | 0052 | 36.16 | \$1,753.29 | \$930.91 | \$350.66 |
| 23430 | T | Repair biceps tendon | 0052 | 36.16 | \$1,753.29 | \$930.91 | \$350.66 |
| 23440 | C | Remove/transplant tendon |  |  |  |  |  |
| 23450 | T | Repair shoulder capsule .. | 0052 | 36.16 | \$1,753.29 | \$930.91 | \$350.66 |
| 23455 | T | Repair shoulder capsule | 0052 | 36.16 | \$1,753.29 | \$930.91 | \$350.66 |
| 23460 | T | Repair shoulder capsule | 0052 | 36.16 | \$1,753.29 | \$930.91 | \$350.66 |
| 23462 | T | Repair shoulder capsule | 0052 | 36.16 | \$1,753.29 | \$930.91 | \$350.66 |
| 23465 | T | Repair shoulder capsule | 0052 | 36.16 | \$1,753.29 | \$930.91 | \$350.66 |
| 23466 | T | Repair shoulder capsule | 0052 | 36.16 | \$1,753.29 | \$930.91 | \$350.66 |
| 23470 | C | Reconstruct shoulder joint |  |  |  |  |  |
| 23472 | C | Reconstruct shoulder joint |  |  |  |  |  |
| 23480 | T | Revision of collar bone | 0051 | 27.76 | \$1,346.00 | \$675.24 | \$269.20 |
| 23485 | T | Revision of collar bone | 0051 | 27.76 | \$1,346.00 | \$675.24 | \$269.20 |
| 23490 | T | Reinforce clavicle | 0051 | 27.76 | \$1,346.00 | \$675.24 | \$269.20 |
| 23491 | T | Reinforce shoulder bones | 0051 | 27.76 | \$1,346.00 | \$675.24 | \$269.20 |
| 23500 | T | Treat clavicle fracture | 0043 | 1.64 | \$79.52 | \$25.46 | \$15.90 |
| 23505 | T | Treat clavicle fracture | 0043 | 1.64 | \$79.52 | \$25.46 | \$15.90 |
| 23515 | T | Treat clavicle fracture | 0046 | 22.29 | \$1,080.78 | \$535.76 | \$216.16 |
| 23520 | T | Treat clavicle dislocation | 0043 | 1.64 | \$79.52 | \$25.46 | \$15.90 |
| 23525 | T | Treat clavicle dislocation | 0043 | 1.64 | \$79.52 | \$25.46 | \$15.90 |
| 23530 | T | Treat clavicle dislocation | 0046 | 22.29 | \$1,080.78 | \$535.76 | \$216.16 |
| 23532 | T | Treat clavicle dislocation | 0046 | 22.29 | \$1,080.78 | \$535.76 | \$216.16 |
| 23540 | T | Treat clavicle dislocation | 0043 | 1.64 | \$79.52 | \$25.46 | \$15.90 |
| 23545 | T | Treat clavicle dislocation | 0043 | 1.64 | \$79.52 | \$25.46 | \$15.90 |
| 23550 | T | Treat clavicle dislocation | 0046 | 22.29 | \$1,080.78 | \$535.76 | \$216.16 |
| 23552 | T | Treat clavicle dislocation | 0046 | 22.29 | \$1,080.78 | \$535.76 | \$216.16 |
| 23570 | T | Treat shoulder blade fx | 0043 | 1.64 | \$79.52 | \$25.46 | \$15.90 |
| 23575 | T | Treat shoulder blade fx | 0043 | 1.64 | \$79.52 | \$25.46 | \$15.90 |
| 23585 | T | Treat scapula fracture | 0046 | 22.29 | \$1,080.78 | \$535.76 | \$216.16 |
| 23600 | T | Treat humerus fracture | 0044 | 2.17 | \$105.22 | \$38.08 | \$21.04 |
| 23605 | T | Treat humerus fracture | 0044 | 2.17 | \$105.22 | \$38.08 | \$21.04 |
| 23615 | T | Treat humerus fracture | 0046 | 22.29 | \$1,080.78 | \$535.76 | \$216.16 |
| 23616 | T | Treat humerus fracture | 0046 | 22.29 | \$1,080.78 | \$535.76 | \$216.16 |
| 23620 | T | Treat humerus fracture | 0044 | 2.17 | \$105.22 | \$38.08 | \$21.04 |
| 23625 | T | Treat humerus fracture | 0044 | 2.17 | \$105.22 | \$38.08 | \$21.04 |
| 23630 | T | Treat humerus fracture | 0046 | 22.29 | \$1,080.78 | \$535.76 | \$216.16 |
| 23650 | T | Treat shoulder dislocation | 0043 | 1.64 | \$79.52 | \$25.46 | \$15.90 |
| 23655 | T | Treat shoulder dislocation | 0045 | 11.02 | \$534.33 | \$277.12 | \$106.87 |
| 23660 | T | Treat shoulder dislocation | 0046 | 22.29 | \$1,080.78 | \$535.76 | \$216.16 |
| 23665 | T | Treat dislocation/fracture | 0044 | 2.17 | \$105.22 | \$38.08 | \$21.04 |
| 23670 | T | Treat dislocation/fracture | 0046 | 22.29 | \$1,080.78 | \$535.76 | \$216.16 |
| 23675 | T | Treat dislocation/fracture | 0044 | 2.17 | \$105.22 | \$38.08 | \$21.04 |
| 23680 | T | Treat dislocation/fracture | 0046 | 22.29 | \$1,080.78 | \$535.76 | \$216.16 |
| 23700 | T | Fixation of shoulder | 0045 | 11.02 | \$534.33 | \$277.12 | \$106.87 |
| 23800 | T | Fusion of shoulder joint | 0051 | 27.76 | \$1,346.00 | \$675.24 | \$269.20 |
| 23802 | T | Fusion of shoulder joint | 0051 | 27.76 | \$1,346.00 | \$675.24 | \$269.20 |
| 23900 | C | Amputation of arm \& girdle |  |  |  |  |  |
| 23920 | C | Amputation at shoulder joint |  |  |  |  |  |
| 23921 | T | Amputation follow-up surgery ................................. | 0026 | 12.11 | \$587.18 | \$277.92 | \$117.44 |
| 23929 | T | Shoulder surgery procedure .... | 0043 | 1.64 | \$79.52 | \$25.46 | \$15.90 |
| 23930 | T | Drainage of arm lesion | 0008 | 6.15 | \$298.20 | \$113.67 | \$59.64 |
| 23931 | T | Drainage of arm bursa | 0008 | 6.15 | \$298.20 | \$113.67 | \$59.64 |
| 23935 | T | Drain arm/elbow bone lesion | 0049 | 15.04 | \$729.25 | \$356.95 | \$145.85 |
| 24000 | T | Exploratory elbow surgery ....... | 0050 | 21.13 | \$1,024.53 | \$513.86 | \$204.91 |
| 24006 | T | Release elbow joint ... | 0050 | 21.13 | \$1,024.53 | \$513.86 | \$204.91 |
| 24065 | T | Biopsy arm/elbow soft tissue .................................. | 0020 | 6.51 | \$315.65 | \$130.53 | \$63.13 |
| 24066 | T | Biopsy arm/elbow soft tissue .................................. | 0020 | 6.51 | \$315.65 | \$130.53 | \$63.13 |
| 24075 | T | Remove arm/elbow lesion | 0021 | 10.49 | \$508.63 | \$236.51 | \$101.73 |
| 24076 | T | Remove arm/elbow lesion ...................................... | 0022 | 12.49 | \$605.60 | \$292.94 | \$121.12 |
| 24077 | T | Remove tumor of arm/elbow ................................... | 0022 | 12.49 | \$605.60 | \$292.94 | \$121.12 |
| 24100 | T | Biopsy elbow joint lining | 0049 | 15.04 | \$729.25 | \$356.95 | \$145.85 |

[^143]
# Addendum B.-Hospital Outpatient Department (HOPD) Payment Status by HCPCS Code and Related Information-Continued 

| $\begin{aligned} & \text { CPT/ } \\ & \text { HCPCS } \end{aligned}$ | HOPD Status Indicator | Description | APC | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 24101 | T | Explore/treat elbow joint | 0050 | 21.13 | \$1,024.53 | \$513.86 | \$204.91 |
| 24102 | T | Remove elbow joint lining | 0050 | 21.13 | \$1,024.53 | \$513.86 | \$204.91 |
| 24105 | T | Removal of elbow bursa | 0049 | 15.04 | \$729.25 | \$356.95 | \$145.85 |
| 24110 | T | Remove humerus lesion | 0049 | 15.04 | \$729.25 | \$356.95 | \$145.85 |
| 24115 | T | Remove/graft bone lesion | 0050 | 21.13 | \$1,024.53 | \$513.86 | \$204.91 |
| 24116 | T | Remove/graft bone lesion | 0050 | 21.13 | \$1,024.53 | \$513.86 | \$204.91 |
| 24120 | T | Remove elbow lesion ..... | 0049 | 15.04 | \$729.25 | \$356.95 | \$145.85 |
| 24125 | T | Remove/graft bone lesion | 0050 | 21.13 | \$1,024.53 | \$513.86 | \$204.91 |
| 24126 | T | Remove/graft bone lesion | 0050 | 21.13 | \$1,024.53 | \$513.86 | \$204.91 |
| 24130 | T | Removal of head of radius | 0050 | 21.13 | \$1,024.53 | \$513.86 | \$204.91 |
| 24134 | T | Removal of arm bone lesion | 0050 | 21.13 | \$1,024.53 | \$513.86 | \$204.91 |
| 24136 | T | Remove radius bone lesion | 0050 | 21.13 | \$1,024.53 | \$513.86 | \$204.91 |
| 24138 | T | Remove elbow bone lesion | 0050 | 21.13 | \$1,024.53 | \$513.86 | \$204.91 |
| 24140 | T | Partial removal of arm bone | 0050 | 21.13 | \$1,024.53 | \$513.86 | \$204.91 |
| 24145 | T | Partial removal of radius | 0050 | 21.13 | \$1,024.53 | \$513.86 | \$204.91 |
| 24147 | T | Partial removal of elbow | 0050 | 21.13 | \$1,024.53 | \$513.86 | \$204.91 |
| 24149 | C | Radical resection of elbow |  |  |  | ..................... |  |
| 24150 | C | Extensive humerus surgery |  |  |  |  |  |
| 24151 | C | Extensive humerus surgery |  |  |  |  |  |
| 24152 | C | Extensive radius surgery .. | ...... | ....... |  | ..................... |  |
| 24153 | C | Extensive radius surgery |  |  |  |  |  |
| 24155 | T | Removal of elbow joint | 0051 | 27.76 | \$1,346.00 | \$675.24 | \$269.20 |
| 24160 | T | Remove elbow joint implant | 0050 | 21.13 | \$1,024.53 | \$513.86 | \$204.91 |
| 24164 | T | Remove radius head implant | 0050 | 21.13 | \$1,024.53 | \$513.86 | \$204.91 |
| 24200 | T | Removal of arm foreign body | 0019 | 4.00 | \$193.95 | \$78.91 | \$38.79 |
| 24201 | T | Removal of arm foreign body | 0021 | 10.49 | \$508.63 | \$236.51 | \$101.73 |
| 24220 | N | Injection for elbow x-ray .. |  |  |  |  |  |
| 24301 | T | Muscle/tendon transfer | 0050 | 21.13 | \$1,024.53 | \$513.86 | \$204.91 |
| 24305 | T | Arm tendon lengthening | 0050 | 21.13 | \$1,024.53 | \$513.86 | \$204.91 |
| 24310 | T | Revision of arm tendon | 0049 | 15.04 | \$729.25 | \$356.95 | \$145.85 |
| 24320 | T | Repair of arm tendon | 0051 | 27.76 | \$1,346.00 | \$675.24 | \$269.20 |
| 24330 | T | Revision of arm muscles | 0051 | 27.76 | \$1,346.00 | \$675.24 | \$269.20 |
| 24331 | T | Revision of arm muscles | 0051 | 27.76 | \$1,346.00 | \$675.24 | \$269.20 |
| 24340 | T | Repair of biceps tendon | 0051 | 27.76 | \$1,346.00 | \$675.24 | \$269.20 |
| 24341 | T | Repair arm tendon/muscle | 0051 | 27.76 | \$1,346.00 | \$675.24 | \$269.20 |
| 24342 | T | Repair of ruptured tendon | 0051 | 27.76 | \$1,346.00 | \$675.24 | \$269.20 |
| 24350 | T | Repair of tennis elbow ..... | 0050 | 21.13 | \$1,024.53 | \$513.86 | \$204.91 |
| 24351 | T | Repair of tennis elbow | 0050 | 21.13 | \$1,024.53 | \$513.86 | \$204.91 |
| 24352 | T | Repair of tennis elbow | 0050 | 21.13 | \$1,024.53 | \$513.86 | \$204.91 |
| 24354 | T | Repair of tennis elbow | 0050 | 21.13 | \$1,024.53 | \$513.86 | \$204.91 |
| 24356 | T | Revision of tennis elbow | 0050 | 21.13 | \$1,024.53 | \$513.86 | \$204.91 |
| 24360 | T | Reconstruct elbow joint | 0047 | 22.09 | \$1,071.08 | \$537.03 | \$214.22 |
| 24361 | T | Reconstruct elbow joint | 0048 | 29.06 | \$1,409.03 | \$725.94 | \$281.81 |
| 24362 | T | Reconstruct elbow joint | 0048 | 29.06 | \$1,409.03 | \$725.94 | \$281.81 |
| 24363 | T | Replace elbow joint | 0048 | 29.06 | \$1,409.03 | \$725.94 | \$281.81 |
| 24365 | T | Reconstruct head of radius | 0047 | 22.09 | \$1,071.08 | \$537.03 | \$214.22 |
| 24366 | T | Reconstruct head of radius | 0048 | 29.06 | \$1,409.03 | \$725.94 | \$281.81 |
| 24400 | T | Revision of humerus | 0050 | 21.13 | \$1,024.53 | \$513.86 | \$204.91 |
| 24410 | T | Revision of humerus | 0050 | 21.13 | \$1,024.53 | \$513.86 | \$204.91 |
| 24420 | T | Revision of humerus | 0051 | 27.76 | \$1,346.00 | \$675.24 | \$269.20 |
| 24430 | T | Repair of humerus | 0051 | 27.76 | \$1,346.00 | \$675.24 | \$269.20 |
| 24435 | T | Repair humerus with graft | 0051 | 27.76 | \$1,346.00 | \$675.24 | \$269.20 |
| 24470 | T | Revision of elbow joint ........................................... | 0051 | 27.76 | \$1,346.00 | \$675.24 | \$269.20 |
| 24495 | T | Decompression of forearm | 0050 | 21.13 | \$1,024.53 | \$513.86 | \$204.91 |
| 24498 | T | Reinforce humerus | 0051 | 27.76 | \$1,346.00 | \$675.24 | \$269.20 |
| 24500 | T | Treat humerus fracture | 0044 | 2.17 | \$105.22 | \$38.08 | \$21.04 |
| 24505 | T | Treat humerus fracture | 0044 | 2.17 | \$105.22 | \$38.08 | \$21.04 |
| 24515 | T | Treat humerus fracture | 0046 | 22.29 | \$1,080.78 | \$535.76 | \$216.16 |
| 24516 | T | Treat humerus fracture | 0046 | 22.29 | \$1,080.78 | \$535.76 | \$216.16 |
| 24530 | T | Treat humerus fracture ........................................... | 0044 | 2.17 | \$105.22 | \$38.08 | \$21.04 |
| 24535 | T | Treat humerus fracture | 0044 | 2.17 | \$105.22 | \$38.08 | \$21.04 |
| 24538 | T | Treat humerus fracture | 0046 | 22.29 | \$1,080.78 | \$535.76 | \$216.16 |
| 24545 | T | Treat humerus fracture | 0046 | 22.29 | \$1,080.78 | \$535.76 | \$216.16 |
| 24546 | T | Treat humerus fracture | 0046 | 22.29 | \$1,080.78 | \$535.76 | \$216.16 |
| 24560 | T | Treat humerus fracture | 0044 | 2.17 | \$105.22 | \$38.08 | \$21.04 |
| 24565 | T | Treat humerus fracture | 0044 | 2.17 | \$105.22 | \$38.08 | \$21.04 |
| 24566 | T | Treat humerus fracture | 0046 | 22.29 | \$1,080.78 | \$535.76 | \$216.16 |
| 24575 | T | Treat humerus fracture | 0046 | 22.29 | \$1,080.78 | \$535.76 | \$216.16 |
| 24576 | T | Treat humerus fracture | 0044 | 2.17 | \$105.22 | \$38.08 | \$21.04 |
| 24577 | T | Treat humerus fracture | 0044 | 2.17 | \$105.22 | \$38.08 | \$21.04 |
| 24579 | T | Treat humerus fracture | 0046 | 22.29 | \$1,080.78 | \$535.76 | \$216.16 |
| 24582 | T | Treat humerus fracture | 0046 | 22.29 | \$1,080.78 | \$535.76 | \$216.16 |
| 24586 | T | Treat elbow fracture | 0046 | 22.29 | \$1,080.78 | \$535.76 | \$216.16 |

[^144]
## Addendum B.-Hospital Outpatient Department (HOPD) Payment Status by hCPCS Code and Related Information-Continued

| CPT/ HCPCS | HOPD <br> Status <br> Indicator | Description | APC | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 24587 | T | Treat elbow fracture | 0046 | 22.29 | \$1,080.78 | \$535.76 | \$216.16 |
| 24600 | T | Treat elbow dislocation | 0044 | 2.17 | \$105.22 | \$38.08 | \$21.04 |
| 24605 | T | Treat elbow dislocation | 0045 | 11.02 | \$534.33 | \$277.12 | \$106.87 |
| 24615 | T | Treat elbow dislocation | 0046 | 22.29 | \$1,080.78 | \$535.76 | \$216.16 |
| 24620 | T | Treat elbow fracture | 0044 | 2.17 | \$105.22 | \$38.08 | \$21.04 |
| 24635 | T | Treat elbow fracture | 0046 | 22.29 | \$1,080.78 | \$535.76 | \$216.16 |
| 24640 | T | Treat elbow dislocation | 0044 | 2.17 | \$105.22 | \$38.08 | \$21.04 |
| 24650 | T | Treat radius fracture | 0044 | 2.17 | \$105.22 | \$38.08 | \$21.04 |
| 24655 | T | Treat radius fracture | 0044 | 2.17 | \$105.22 | \$38.08 | \$21.04 |
| 24665 | T | Treat radius fracture | 0046 | 22.29 | \$1,080.78 | \$535.76 | \$216.16 |
| 24666 | T | Treat radius fracture | 0046 | 22.29 | \$1,080.78 | \$535.76 | \$216.16 |
| 24670 | T | Treat ulnar fracture .. | 0044 | 2.17 | \$105.22 | \$38.08 | \$21.04 |
| 24675 | T | Treat ulnar fracture | 0044 | 2.17 | \$105.22 | \$38.08 | \$21.04 |
| 24685 | T | Treat ulnar fracture | 0046 | 22.29 | \$1,080.78 | \$535.76 | \$216.16 |
| 24800 | T | Fusion of elbow joint | 0051 | 27.76 | \$1,346.00 | \$675.24 | \$269.20 |
| 24802 | T | Fusion/graft of elbow joint | 0051 | 27.76 | \$1,346.00 | \$675.24 | \$269.20 |
| 24900 | C | Amputation of upper arm ......... |  |  |  |  |  |
| 24920 | C | Amputation of upper arm ....................................... |  |  |  |  |  |
| 24925 | T | Amputation follow-up surgery .................................. | 0049 | 15.04 | \$729.25 | \$356.95 | \$145.85 |
| 24930 | C | Amputation follow-up surgery |  |  | $\qquad$ | $\qquad$ |  |
| 24931 | C | Amputate upper arm \& implant ............................ |  |  |  |  |  |
| 24935 | T | Revision of amputation ....................................... | 0052 | 36.16 | \$1,753.29 | \$930.91 | \$350.66 |
| 24940 | C | Revision of upper arm |  |  |  |  |  |
| 24999 | T | Upper arm/elbow surgery | 0044 | 2.17 | \$105.22 | \$38.08 | \$21.04 |
| 25000 | T | Incision of tendon sheath | 0049 | 15.04 | \$729.25 | \$356.95 | \$145.85 |
| 25020 | T | Decompression of forearm | 0049 | 15.04 | \$729.25 | \$356.95 | \$145.85 |
| 25023 | T | Decompression of forearm | 0050 | 21.13 | \$1,024.53 | \$513.86 | \$204.91 |
| 25028 | T | Drainage of forearm lesion | 0049 | 15.04 | \$729.25 | \$356.95 | \$145.85 |
| 25031 | T | Drainage of forearm bursa | 0049 | 15.04 | \$729.25 | \$356.95 | \$145.85 |
| 25035 | T | Treat forearm bone lesion | 0049 | 15.04 | \$729.25 | \$356.95 | \$145.85 |
| 25040 | T | Explore/treat wrist joint | 0050 | 21.13 | \$1,024.53 | \$513.86 | \$204.91 |
| 25065 | T | Biopsy forearm soft tissues | 0020 | 6.51 | \$315.65 | \$130.53 | \$63.13 |
| 25066 | T | Biopsy forearm soft tissues | 0022 | 12.49 | \$605.60 | \$292.94 | \$121.12 |
| 25075 | T | Removal of forearm lesion | 0020 | 6.51 | \$315.65 | \$130.53 | \$63.13 |
| 25076 | T | Removal of forearm lesion | 0022 | 12.49 | \$605.60 | \$292.94 | \$121.12 |
| 25077 | T | Remove tumor, forearm/wrist | 0022 | 12.49 | \$605.60 | \$292.94 | \$121.12 |
| 25085 | T | Incision of wrist capsule | 0049 | 15.04 | \$729.25 | \$356.95 | \$145.85 |
| 25100 | T | Biopsy of wrist joint | 0049 | 15.04 | \$729.25 | \$356.95 | \$145.85 |
| 25101 | T | Explore/treat wrist joint | 0050 | 21.13 | \$1,024.53 | \$513.86 | \$204.91 |
| 25105 | T | Remove wrist joint lining | 0050 | 21.13 | \$1,024.53 | \$513.86 | \$204.91 |
| 25107 | T | Remove wrist joint cartilage | 0050 | 21.13 | \$1,024.53 | \$513.86 | \$204.91 |
| 25110 | T | Remove wrist tendon lesion .................................... | 0049 | 15.04 | \$729.25 | \$356.95 | \$145.85 |
| 25111 | T | Remove wrist tendon lesion | 0053 | 11.32 | \$548.87 | \$253.49 | \$109.77 |
| 25112 | T | Reremove wrist tendon lesion | 0053 | 11.32 | \$548.87 | \$253.49 | \$109.77 |
| 25115 | T | Remove wrist/forearm lesion | 0049 | 15.04 | \$729.25 | \$356.95 | \$145.85 |
| 25116 | T | Remove wrist/forearm lesion | 0049 | 15.04 | \$729.25 | \$356.95 | \$145.85 |
| 25118 | T | Excise wrist tendon sheath | 0050 | 21.13 | \$1,024.53 | \$513.86 | \$204.91 |
| 25119 | T | Partial removal of ulna | 0050 | 21.13 | \$1,024.53 | \$513.86 | \$204.91 |
| 25120 | T | Removal of forearm lesion | 0050 | 21.13 | \$1,024.53 | \$513.86 | \$204.91 |
| 25125 | T | Remove/graft forearm lesion | 0050 | 21.13 | \$1,024.53 | \$513.86 | \$204.91 |
| 25126 | T | Remove/graft forearm lesion ................................... | 0050 | 21.13 | \$1,024.53 | \$513.86 | \$204.91 |
| 25130 | T | Removal of wrist lesion | 0050 | 21.13 | \$1,024.53 | \$513.86 | \$204.91 |
| 25135 | T | Remove \& graft wrist lesion | 0050 | 21.13 | \$1,024.53 | \$513.86 | \$204.91 |
| 25136 | T | Remove \& graft wrist lesion ................................... | 0050 | 21.13 | \$1,024.53 | \$513.86 | \$204.91 |
| 25145 | T | Remove forearm bone lesion .................................. | 0050 | 21.13 | \$1,024.53 | \$513.86 | \$204.91 |
| 25150 | T | Partial removal of ulna | 0050 | 21.13 | \$1,024.53 | \$513.86 | \$204.91 |
| 25151 | T | Partial removal of radius | 0050 | 21.13 | \$1,024.53 | \$513.86 | \$204.91 |
| 25170 | C | Extensive forearm surgery ..................................... |  |  |  |  |  |
| 25210 | T | Removal of wrist bone ........................................... | 0054 | 19.66 | \$953.26 | \$472.33 | \$190.65 |
| 25215 | T | Removal of wrist bones ......................................... | 0054 | 19.66 | \$953.26 | \$472.33 | \$190.65 |
| 25230 | T | Partial removal of radius | 0050 | 21.13 | \$1,024.53 | \$513.86 | \$204.91 |
| 25240 | T | Partial removal of ulna | 0050 | 21.13 | \$1,024.53 | \$513.86 | \$204.91 |
| 25246 | N | Injection for wrist x-ray .......................................... |  |  |  |  |  |
| 25248 | T | Remove forearm foreign body ................................ | 0049 | 15.04 | \$729.25 | \$356.95 | \$145.85 |
| 25250 | T | Removal of wrist prosthesis ................................... | 0050 | 21.13 | \$1,024.53 | \$513.86 | \$204.91 |
| 25251 | T | Removal of wrist prosthesis ................................... | 0050 | 21.13 | \$1,024.53 | \$513.86 | \$204.91 |
| 25260 | T | Repair forearm tendon/muscle ................................ | 0050 | 21.13 | \$1,024.53 | \$513.86 | \$204.91 |
| 25263 | T | Repair forearm tendon/muscle ................................ | 0050 | 21.13 | \$1,024.53 | \$513.86 | \$204.91 |
| 25265 | T | Repair forearm tendon/muscle ................................ | 0050 | 21.13 | \$1,024.53 | \$513.86 | \$204.91 |
| 25270 | T | Repair forearm tendon/muscle ................................ | 0050 | 21.13 | \$1,024.53 | \$513.86 | \$204.91 |
| 25272 | T | Repair forearm tendon/muscle ................................ | 0050 | 21.13 | \$1,024.53 | \$513.86 | \$204.91 |
| 25274 | T | Repair forearm tendon/muscle ................................ | 0050 | 21.13 | \$1,024.53 | \$513.86 | \$204.91 |
| 25280 | T | Revise wrist/forearm tendon ................................... | 0050 | 21.13 | \$1,024.53 | \$513.86 | \$204.91 |

[^145]
# Addendum B.-Hospital Outpatient Department (HOPD) Payment Status by HCPCS Code and Related Information-Continued 

| $\begin{gathered} \text { CPT/ } \\ \text { HCPCS } \end{gathered}$ | HOPD <br> Status <br> Indicator | Description | APC | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 25290 | T | Incise wrist/forearm tendon | 0050 | 21.13 | \$1,024.53 | \$513.86 | \$204.91 |
| 25295 | T | Release wrist/forearm tendon | 0049 | 15.04 | \$729.25 | \$356.95 | \$145.85 |
| 25300 | T | Fusion of tendons at wrist | 0050 | 21.13 | \$1,024.53 | \$513.86 | \$204.91 |
| 25301 | T | Fusion of tendons at wrist | 0050 | 21.13 | \$1,024.53 | \$513.86 | \$204.91 |
| 25310 | T | Transplant forearm tendon | 0051 | 27.76 | \$1,346.00 | \$675.24 | \$269.20 |
| 25312 | T | Transplant forearm tendon | 0051 | 27.76 | \$1,346.00 | \$675.24 | \$269.20 |
| 25315 | T | Revise palsy hand tendon(s) | 0051 | 27.76 | \$1,346.00 | \$675.24 | \$269.20 |
| 25316 | T | Revise palsy hand tendon(s) .................................. | 0051 | 27.76 | \$1,346.00 | \$675.24 | \$269.20 |
| 25320 | T | Repair/revise wrist joint .......................................... | 0051 | 27.76 | \$1,346.00 | \$675.24 | \$269.20 |
| 25332 | T | Revise wrist joint | 0047 | 22.09 | \$1,071.08 | \$537.03 | \$214.22 |
| 25335 | T | Realignment of hand | 0051 | 27.76 | \$1,346.00 | \$675.24 | \$269.20 |
| 25337 | T | Reconstruct ulna/radioulnar | 0051 | 27.76 | \$1,346.00 | \$675.24 | \$269.20 |
| 25350 | T | Revision of radius ............ | 0051 | 27.76 | \$1,346.00 | \$675.24 | \$269.20 |
| 25355 | T | Revision of radius | 0051 | 27.76 | \$1,346.00 | \$675.24 | \$269.20 |
| 25360 | T | Revision of ulna | 0050 | 21.13 | \$1,024.53 | \$513.86 | \$204.91 |
| 25365 | T | Revise radius \& ulna | 0050 | 21.13 | \$1,024.53 | \$513.86 | \$204.91 |
| 25370 | T | Revise radius or ulna | 0051 | 27.76 | \$1,346.00 | \$675.24 | \$269.20 |
| 25375 | T | Revise radius \& ulna | 0051 | 27.76 | \$1,346.00 | \$675.24 | \$269.20 |
| 25390 | C | Shorten radius or ulna |  |  |  | ...................... |  |
| 25391 | C | Lengthen radius or ulna |  |  |  |  |  |
| 25392 | C | Shorten radius \& ulna |  | ..... |  |  |  |
| 25393 | C | Lengthen radius \& ulna |  |  |  |  |  |
| 25400 | T | Repair radius or ulna | 0050 | 21.13 | \$1,024.53 | \$513.86 | \$204.91 |
| 25405 | C | Repair/graft radius or ulna |  |  |  |  |  |
| 25415 | T | Repair radius \& ulna ............................................. | 0050 | 21.13 | \$1,024.53 | \$513.86 | \$204.91 |
| 25420 | C | Repair/graft radius \& ulna ....................................... |  |  |  |  |  |
| 25425 | T | Repair/graft radius or ulna | 0051 | 27.76 | \$1,346.00 | \$675.24 | \$269.20 |
| 25426 | T | Repair/graft radius \& ulna | 0051 | 27.76 | \$1,346.00 | \$675.24 | \$269.20 |
| 25440 | T | Repair/graft wrist bone | 0051 | 27.76 | \$1,346.00 | \$675.24 | \$269.20 |
| 25441 | T | Reconstruct wrist joint | 0048 | 29.06 | \$1,409.03 | \$725.94 | \$281.81 |
| 25442 | T | Reconstruct wrist joint | 0048 | 29.06 | \$1,409.03 | \$725.94 | \$281.81 |
| 25443 | T | Reconstruct wrist joint | 0048 | 29.06 | \$1,409.03 | \$725.94 | \$281.81 |
| 25444 | T | Reconstruct wrist joint | 0048 | 29.06 | \$1,409.03 | \$725.94 | \$281.81 |
| 25445 | T | Reconstruct wrist joint | 0048 | 29.06 | \$1,409.03 | \$725.94 | \$281.81 |
| 25446 | T | Wrist replacement | 0048 | 29.06 | \$1,409.03 | \$725.94 | \$281.81 |
| 25447 | T | Repair wrist joint(s) | 0047 | 22.09 | \$1,071.08 | \$537.03 | \$214.22 |
| 25449 | T | Remove wrist joint implant | 0047 | 22.09 | \$1,071.08 | \$537.03 | \$214.22 |
| 25450 | T | Revision of wrist joint | 0051 | 27.76 | \$1,346.00 | \$675.24 | \$269.20 |
| 25455 | T | Revision of wrist joint | 0051 | 27.76 | \$1,346.00 | \$675.24 | \$269.20 |
| 25490 | T | Reinforce radius | 0051 | 27.76 | \$1,346.00 | \$675.24 | \$269.20 |
| 25491 | T | Reinforce ulna | 0051 | 27.76 | \$1,346.00 | \$675.24 | \$269.20 |
| 25492 | T | Reinforce radius and ulna | 0051 | 27.76 | \$1,346.00 | \$675.24 | \$269.20 |
| 25500 | T | Treat fracture of radius | 0044 | 2.17 | \$105.22 | \$38.08 | \$21.04 |
| 25505 | T | Treat fracture of radius | 0044 | 2.17 | \$105.22 | \$38.08 | \$21.04 |
| 25515 | T | Treat fracture of radius | 0046 | 22.29 | \$1,080.78 | \$535.76 | \$216.16 |
| 25520 | T | Treat fracture of radius | 0044 | 2.17 | \$105.22 | \$38.08 | \$21.04 |
| 25525 | T | Treat fracture of radius | 0046 | 22.29 | \$1,080.78 | \$535.76 | \$216.16 |
| 25526 | T | Treat fracture of radius | 0046 | 22.29 | \$1,080.78 | \$535.76 | \$216.16 |
| 25530 | T | Treat fracture of ulna ............................................. | 0044 | 2.17 | \$105.22 | \$38.08 | \$21.04 |
| 25535 | T | Treat fracture of ulna | 0044 | 2.17 | \$105.22 | \$38.08 | \$21.04 |
| 25545 | T | Treat fracture of ulna | 0046 | 22.29 | \$1,080.78 | \$535.76 | \$216.16 |
| 25560 | T | Treat fracture radius \& ulna | 0044 | 2.17 | \$105.22 | \$38.08 | \$21.04 |
| 25565 | T | Treat fracture radius \& ulna | 0044 | 2.17 | \$105.22 | \$38.08 | \$21.04 |
| 25574 | T | Treat fracture radius \& ulna | 0046 | 22.29 | \$1,080.78 | \$535.76 | \$216.16 |
| 25575 | T | Treat fracture radius/ulna ....................................... | 0046 | 22.29 | \$1,080.78 | \$535.76 | \$216.16 |
| 25600 | T | Treat fracture radius/ulna | 0044 | 2.17 | \$105.22 | \$38.08 | \$21.04 |
| 25605 | T | Treat fracture radius/ulna | 0044 | 2.17 | \$105.22 | \$38.08 | \$21.04 |
| 25611 | T | Treat fracture radius/ulna | 0046 | 22.29 | \$1,080.78 | \$535.76 | \$216.16 |
| 25620 | T | Treat fracture radius/ulna | 0046 | 22.29 | \$1,080.78 | \$535.76 | \$216.16 |
| 25622 | T | Treat wrist bone fracture | 0044 | 2.17 | \$105.22 | \$38.08 | \$21.04 |
| 25624 | T | Treat wrist bone fracture | 0044 | 2.17 | \$105.22 | \$38.08 | \$21.04 |
| 25628 | T | Treat wrist bone fracture | 0046 | 22.29 | \$1,080.78 | \$535.76 | \$216.16 |
| 25630 | T | Treat wrist bone fracture | 0044 | 2.17 | \$105.22 | \$38.08 | \$21.04 |
| 25635 | T | Treat wrist bone fracture | 0044 | 2.17 | \$105.22 | \$38.08 | \$21.04 |
| 25645 | T | Treat wrist bone fracture ........................................ | 0046 | 22.29 | \$1,080.78 | \$535.76 | \$216.16 |
| 25650 | T | Treat wrist bone fracture | 0044 | 2.17 | \$105.22 | \$38.08 | \$21.04 |
| 25660 | T | Treat wrist dislocation | 0044 | 2.17 | \$105.22 | \$38.08 | \$21.04 |
| 25670 | T | Treat wrist dislocation ............................................ | 0046 | 22.29 | \$1,080.78 | \$535.76 | \$216.16 |
| 25675 | T | Treat wrist dislocation ............................................ | 0044 | 2.17 | \$105.22 | \$38.08 | \$21.04 |
| 25676 | T | Treat wrist dislocation ............................................ | 0046 | 22.29 | \$1,080.78 | \$535.76 | \$216.16 |
| 25680 | T | Treat wrist fracture | 0044 | 2.17 | \$105.22 | \$38.08 | \$21.04 |
| 25685 | T | Treat wrist fracture ............................................... | 0046 | 22.29 | \$1,080.78 | \$535.76 | \$216.16 |
| 25690 | T | Treat wrist dislocation ............................................ | 0044 | 2.17 | \$105.22 | \$38.08 | \$21.04 |

[^146]
## Addendum B.-Hospital Outpatient Department (HOPD) Payment Status by hCPCS Code and Related Information-Continued

| CPT/ HCPCS | HOPD Status Indicator | Description | APC | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 25695 | T | Treat wrist dislocation | 0046 | 22.29 | \$1,080.78 | \$535.76 | \$216.16 |
| 25800 | T | Fusion of wrist joint | 0051 | 27.76 | \$1,346.00 | \$675.24 | \$269.20 |
| 25805 | T | Fusion/graft of wrist joint | 0051 | 27.76 | \$1,346.00 | \$675.24 | \$269.20 |
| 25810 | T | Fusion/graft of wrist joint | 0051 | 27.76 | \$1,346.00 | \$675.24 | \$269.20 |
| 25820 | T | Fusion of hand bones | 0053 | 11.32 | \$548.87 | \$253.49 | \$109.77 |
| 25825 | T | Fuse hand bones with graft | 0054 | 19.66 | \$953.26 | \$472.33 | \$190.65 |
| 25830 | T | Fusion, radioulnar jnt/ulna | 0051 | 27.76 | \$1,346.00 | \$675.24 | \$269.20 |
| 25900 | C | Amputation of forearm ..... |  |  |  |  |  |
| 25905 | C | Amputation of forearm |  |  |  |  |  |
| 25907 | T | Amputation follow-up surgery | 0049 | 15.04 | \$729.25 | \$356.95 | \$145.85 |
| 25909 | C | Amputation follow-up surgery |  |  |  |  |  |
| 25915 | C | Amputation of forearm |  |  |  |  |  |
| 25920 | C | Amputate hand at wrist |  |  |  |  |  |
| 25922 | T | Amputate hand at wrist | 0049 | 15.04 | \$729.25 | \$356.95 | \$145.85 |
| 25924 | C | Amputation follow-up surgery |  |  |  |  |  |
| 25927 | C | Amputation of hand |  |  |  |  |  |
| 25929 | T | Amputation follow-up surgery | 0026 | 12.11 | \$587.18 | \$277.92 | \$117.44 |
| 25931 | C | Amputation follow-up surgery |  |  |  |  |  |
| 25999 | T | Forearm or wrist surgery | 0044 | 2.17 | \$105.22 | \$38.08 | \$21.04 |
| 26010 | T | Drainage of finger abscess | 0006 | 2.00 | \$96.97 | \$33.95 | \$19.39 |
| 26011 | T | Drainage of finger abscess | 0007 | 3.68 | \$178.43 | \$72.03 | \$35.69 |
| 26020 | T | Drain hand tendon sheath | 0053 | 11.32 | \$548.87 | \$253.49 | \$109.77 |
| 26025 | T | Drainage of palm bursa | 0053 | 11.32 | \$548.87 | \$253.49 | \$109.77 |
| 26030 | T | Drainage of palm bursa(s) | 0053 | 11.32 | \$548.87 | \$253.49 | \$109.77 |
| 26034 | T | Treat hand bone lesion | 0053 | 11.32 | \$548.87 | \$253.49 | \$109.77 |
| 26035 | T | Decompress fingers/hand | 0053 | 11.32 | \$548.87 | \$253.49 | \$109.77 |
| 26037 | T | Decompress fingers/hand | 0053 | 11.32 | \$548.87 | \$253.49 | \$109.77 |
| 26040 | T | Release palm contracture | 0054 | 19.66 | \$953.26 | \$472.33 | \$190.65 |
| 26045 | T | Release palm contracture | 0054 | 19.66 | \$953.26 | \$472.33 | \$190.65 |
| 26055 | T | Incise finger tendon sheath | 0053 | 11.32 | \$548.87 | \$253.49 | \$109.77 |
| 26060 | T | Incision of finger tendon | 0053 | 11.32 | \$548.87 | \$253.49 | \$109.77 |
| 26070 | T | Explore/treat hand joint | 0053 | 11.32 | \$548.87 | \$253.49 | \$109.77 |
| 26075 | T | Explore/treat finger joint | 0053 | 11.32 | \$548.87 | \$253.49 | \$109.77 |
| 26080 | T | Explore/treat finger joint | 0053 | 11.32 | \$548.87 | \$253.49 | \$109.77 |
| 26100 | T | Biopsy hand joint lining | 0053 | 11.32 | \$548.87 | \$253.49 | \$109.77 |
| 26105 | T | Biopsy finger joint lining | 0053 | 11.32 | \$548.87 | \$253.49 | \$109.77 |
| 26110 | T | Biopsy finger joint lining | 0053 | 11.32 | \$548.87 | \$253.49 | \$109.77 |
| 26115 | T | Removal of hand lesion | 0022 | 12.49 | \$605.60 | \$292.94 | \$121.12 |
| 26116 | T | Removal of hand lesion | 0022 | 12.49 | \$605.60 | \$292.94 | \$121.12 |
| 26117 | T | Remove tumor, hand/finger | 0022 | 12.49 | \$605.60 | \$292.94 | \$121.12 |
| 26121 | T | Release palm contracture | 0054 | 19.66 | \$953.26 | \$472.33 | \$190.65 |
| 26123 | T | Release palm contracture | 0054 | 19.66 | \$953.26 | \$472.33 | \$190.65 |
| 26125 | T | Release palm contracture | 0054 | 19.66 | \$953.26 | \$472.33 | \$190.65 |
| 26130 | T | Remove wrist joint lining | 0053 | 11.32 | \$548.87 | \$253.49 | \$109.77 |
| 26135 | T | Revise finger joint, each | 0054 | 19.66 | \$953.26 | \$472.33 | \$190.65 |
| 26140 | T | Revise finger joint, each | 0053 | 11.32 | \$548.87 | \$253.49 | \$109.77 |
| 26145 | T | Tendon excision, palm/finger | 0053 | 11.32 | \$548.87 | \$253.49 | \$109.77 |
| 26160 | T | Remove tendon sheath lesion | 0053 | 11.32 | \$548.87 | \$253.49 | \$109.77 |
| 26170 | T | Removal of palm tendon, each | 0053 | 11.32 | \$548.87 | \$253.49 | \$109.77 |
| 26180 | T | Removal of finger tendon | 0053 | 11.32 | \$548.87 | \$253.49 | \$109.77 |
| 26185 | T | Remove finger bone ........ | 0053 | 11.32 | \$548.87 | \$253.49 | \$109.77 |
| 26200 | T | Remove hand bone lesion | 0053 | 11.32 | \$548.87 | \$253.49 | \$109.77 |
| 26205 | T | Remove/graft bone lesion | 0054 | 19.66 | \$953.26 | \$472.33 | \$190.65 |
| 26210 | T | Removal of finger lesion .. | 0053 | 11.32 | \$548.87 | \$253.49 | \$109.77 |
| 26215 | T | Remove/graft finger lesion | 0053 | 11.32 | \$548.87 | \$253.49 | \$109.77 |
| 26230 | T | Partial removal of hand bone | 0053 | 11.32 | \$548.87 | \$253.49 | \$109.77 |
| 26235 | T | Partial removal, finger bone ................................ | 0053 | 11.32 | \$548.87 | \$253.49 | \$109.77 |
| 26236 | T | Partial removal, finger bone ..... | 0053 | 11.32 | \$548.87 | \$253.49 | \$109.77 |
| 26250 | T | Extensive hand surgery | 0053 | 11.32 | \$548.87 | \$253.49 | \$109.77 |
| 26255 | T | Extensive hand surgery ......................................... | 0054 | 19.66 | \$953.26 | \$472.33 | \$190.65 |
| 26260 | T | Extensive finger surgery | 0053 | 11.32 | \$548.87 | \$253.49 | \$109.77 |
| 26261 | T | Extensive finger surgery ........................................ | 0053 | 11.32 | \$548.87 | \$253.49 | \$109.77 |
| 26262 | T | Partial removal of finger ........................................ | 0053 | 11.32 | \$548.87 | \$253.49 | \$109.77 |
| 26320 | T | Removal of implant from hand | 0020 | 6.51 | \$315.65 | \$130.53 | \$63.13 |
| 26350 | T | Repair finger/hand tendon .................................... | 0054 | 19.66 | \$953.26 | \$472.33 | \$190.65 |
| 26352 | T | Repair/graft hand tendon | 0054 | 19.66 | \$953.26 | \$472.33 | \$190.65 |
| 26356 | T | Repair finger/hand tendon ...................................... | 0054 | 19.66 | \$953.26 | \$472.33 | \$190.65 |
| 26357 | T | Repair finger/hand tendon ...................................... | 0054 | 19.66 | \$953.26 | \$472.33 | \$190.65 |
| 26358 | T | Repair/graft hand tendon | 0054 | 19.66 | \$953.26 | \$472.33 | \$190.65 |
| 26370 | T | Repair finger/hand tendon ...................................... | 0054 | 19.66 | \$953.26 | \$472.33 | \$190.65 |
| 26372 | T | Repair/graft hand tendon ........................................ | 0054 | 19.66 | \$953.26 | \$472.33 | \$190.65 |
| 26373 | T | Repair finger/hand tendon ...................................... | 0054 | 19.66 | \$953.26 | \$472.33 | \$190.65 |
| 26390 | T | Revise hand/finger tendon ................................. | 0054 | 19.66 | \$953.26 | \$472.33 | \$190.65 |

[^147]
# Addendum B.-Hospital Outpatient Department (HOPD) Payment Status by HCPCS Code and Related Information-Continued 

| $\begin{aligned} & \text { CPT/ } \\ & \text { HCPCS } \end{aligned}$ | HOPD <br> Status Indicator | Description | APC | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 26392 | T | Repair/graft hand tendon | 0054 | 19.66 | \$953.26 | \$472.33 | \$190.65 |
| 26410 | T | Repair hand tendon ... | 0053 | 11.32 | \$548.87 | \$253.49 | \$109.77 |
| 26412 | T | Repair/graft hand tendon | 0054 | 19.66 | \$953.26 | \$472.33 | \$190.65 |
| 26415 | T | Excision, hand/finger tendon | 0054 | 19.66 | \$953.26 | \$472.33 | \$190.65 |
| 26416 | T | Graft hand or finger tendon | 0054 | 19.66 | \$953.26 | \$472.33 | \$190.65 |
| 26418 | T | Repair finger tendon ........ | 0053 | 11.32 | \$548.87 | \$253.49 | \$109.77 |
| 26420 | T | Repair/graft finger tendon | 0054 | 19.66 | \$953.26 | \$472.33 | \$190.65 |
| 26426 | T | Repair finger/hand tendon | 0054 | 19.66 | \$953.26 | \$472.33 | \$190.65 |
| 26428 | T | Repair/graft finger tendon | 0054 | 19.66 | \$953.26 | \$472.33 | \$190.65 |
| 26432 | T | Repair finger tendon ....... | 0053 | 11.32 | \$548.87 | \$253.49 | \$109.77 |
| 26433 | T | Repair finger tendon | 0053 | 11.32 | \$548.87 | \$253.49 | \$109.77 |
| 26434 | T | Repair/graft finger tendon | 0054 | 19.66 | \$953.26 | \$472.33 | \$190.65 |
| 26437 | T | Realignment of tendons | 0053 | 11.32 | \$548.87 | \$253.49 | \$109.77 |
| 26440 | T | Release palm/finger tendon | 0053 | 11.32 | \$548.87 | \$253.49 | \$109.77 |
| 26442 | T | Release palm \& finger tendon | 0054 | 19.66 | \$953.26 | \$472.33 | \$190.65 |
| 26445 | T | Release hand/finger tendon | 0053 | 11.32 | \$548.87 | \$253.49 | \$109.77 |
| 26449 | T | Release forearm/hand tendon | 0054 | 19.66 | \$953.26 | \$472.33 | \$190.65 |
| 26450 | T | Incision of palm tendon | 0053 | 11.32 | \$548.87 | \$253.49 | \$109.77 |
| 26455 | T | Incision of finger tendon | 0053 | 11.32 | \$548.87 | \$253.49 | \$109.77 |
| 26460 | T | Incise hand/finger tendon | 0053 | 11.32 | \$548.87 | \$253.49 | \$109.77 |
| 26471 | T | Fusion of finger tendons | 0053 | 11.32 | \$548.87 | \$253.49 | \$109.77 |
| 26474 | T | Fusion of finger tendons | 0053 | 11.32 | \$548.87 | \$253.49 | \$109.77 |
| 26476 | T | Tendon lengthening | 0053 | 11.32 | \$548.87 | \$253.49 | \$109.77 |
| 26477 | T | Tendon shortening . | 0053 | 11.32 | \$548.87 | \$253.49 | \$109.77 |
| 26478 | T | Lengthening of hand tendon | 0053 | 11.32 | \$548.87 | \$253.49 | \$109.77 |
| 26479 | T | Shortening of hand tendon | 0053 | 11.32 | \$548.87 | \$253.49 | \$109.77 |
| 26480 | T | Transplant hand tendon .... | 0054 | 19.66 | \$953.26 | \$472.33 | \$190.65 |
| 26483 | T | Transplant/graft hand tendon | 0054 | 19.66 | \$953.26 | \$472.33 | \$190.65 |
| 26485 | T | Transplant palm tendon | 0054 | 19.66 | \$953.26 | \$472.33 | \$190.65 |
| 26489 | T | Transplant/graft palm tendon | 0054 | 19.66 | \$953.26 | \$472.33 | \$190.65 |
| 26490 | T | Revise thumb tendon | 0054 | 19.66 | \$953.26 | \$472.33 | \$190.65 |
| 26492 | T | Tendon transfer with graft | 0054 | 19.66 | \$953.26 | \$472.33 | \$190.65 |
| 26494 | T | Hand tendon/muscle transfer | 0054 | 19.66 | \$953.26 | \$472.33 | \$190.65 |
| 26496 | T | Revise thumb tendon | 0054 | 19.66 | \$953.26 | \$472.33 | \$190.65 |
| 26497 | T | Finger tendon transfer | 0054 | 19.66 | \$953.26 | \$472.33 | \$190.65 |
| 26498 | T | Finger tendon transfer | 0054 | 19.66 | \$953.26 | \$472.33 | \$190.65 |
| 26499 | T | Revision of finger ....... | 0054 | 19.66 | \$953.26 | \$472.33 | \$190.65 |
| 26500 | T | Hand tendon reconstruction | 0053 | 11.32 | \$548.87 | \$253.49 | \$109.77 |
| 26502 | T | Hand tendon reconstruction | 0054 | 19.66 | \$953.26 | \$472.33 | \$190.65 |
| 26504 | T | Hand tendon reconstruction | 0054 | 19.66 | \$953.26 | \$472.33 | \$190.65 |
| 26508 | T | Release thumb contracture | 0053 | 11.32 | \$548.87 | \$253.49 | \$109.77 |
| 26510 | T | Thumb tendon transfer | 0054 | 19.66 | \$953.26 | \$472.33 | \$190.65 |
| 26516 | T | Fusion of knuckle joint | 0054 | 19.66 | \$953.26 | \$472.33 | \$190.65 |
| 26517 | T | Fusion of knuckle joints | 0054 | 19.66 | \$953.26 | \$472.33 | \$190.65 |
| 26518 | T | Fusion of knuckle joints | 0054 | 19.66 | \$953.26 | \$472.33 | \$190.65 |
| 26520 | T | Release knuckle contracture | 0053 | 11.32 | \$548.87 | \$253.49 | \$109.77 |
| 26525 | T | Release finger contracture | 0053 | 11.32 | \$548.87 | \$253.49 | \$109.77 |
| 26530 | T | Revise knuckle joint | 0047 | 22.09 | \$1,071.08 | \$537.03 | \$214.22 |
| 26531 | T | Revise knuckle with implant | 0048 | 29.06 | \$1,409.03 | \$725.94 | \$281.81 |
| 26535 | T | Revise finger joint ........ | 0047 | 22.09 | \$1,071.08 | \$537.03 | \$214.22 |
| 26536 | T | Revise/implant finger joint | 0048 | 29.06 | \$1,409.03 | \$725.94 | \$281.81 |
| 26540 | T | Repair hand joint | 0053 | 11.32 | \$548.87 | \$253.49 | \$109.77 |
| 26541 | T | Repair hand joint with graft | 0054 | 19.66 | \$953.26 | \$472.33 | \$190.65 |
| 26542 | T | Repair hand joint with graft | 0053 | 11.32 | \$548.87 | \$253.49 | \$109.77 |
| 26545 | T | Reconstruct finger joint | 0054 | 19.66 | \$953.26 | \$472.33 | \$190.65 |
| 26546 | T | Repair nonunion hand | 0054 | 19.66 | \$953.26 | \$472.33 | \$190.65 |
| 26548 | T | Reconstruct finger joint ........................................... | 0054 | 19.66 | \$953.26 | \$472.33 | \$190.65 |
| 26550 | T | Construct thumb replacement ................................. | 0054 | 19.66 | \$953.26 | \$472.33 | \$190.65 |
| 26551 | C | Great toe-hand transfer |  |  |  |  |  |
| 26553 | C | Single transfer, toe-hand ........................................ |  | .................... |  | .................... |  |
| 26554 | C | Double transfer, toe-hand |  |  |  |  |  |
| 26555 | T | Positional change of finger | 0054 | 19.66 | \$953.26 | \$472.33 | \$190.65 |
| 26556 | C | Toe joint transfer .............. |  |  |  |  |  |
| 26560 | T | Repair of web finger | 0053 | 11.32 | \$548.87 | \$253.49 | \$109.77 |
| 26561 | T | Repair of web finger | 0054 | 19.66 | \$953.26 | \$472.33 | \$190.65 |
| 26562 | T | Repair of web finger ............................................. | 0054 | 19.66 | \$953.26 | \$472.33 | \$190.65 |
| 26565 | T | Correct metacarpal flaw ......................................... | 0054 | 19.66 | \$953.26 | \$472.33 | \$190.65 |
| 26567 | T | Correct finger deformity | 0054 | 19.66 | \$953.26 | \$472.33 | \$190.65 |
| 26568 | T | Lengthen metacarpal/finger .................................... | 0054 | 19.66 | \$953.26 | \$472.33 | \$190.65 |
| 26580 | T | Repair hand deformity ........................................... | 0054 | 19.66 | \$953.26 | \$472.33 | \$190.65 |
| 26585 | T | Repair finger deformity .......................................... | 0054 | 19.66 | \$953.26 | \$472.33 | \$190.65 |
| 26587 | T | Reconstruct extra finger ......................................... | 0053 | 11.32 | \$548.87 | \$253.49 | \$109.77 |
| 26590 | T | Repair finger deformity ........................................ | 0054 | 19.66 | \$953.26 | \$472.33 | \$190.65 |

[^148]
## Addendum B.-Hospital Outpatient Department (HOPD) Payment Status by hCPCS Code and Related Information-Continued

| CPT/ <br> HCPCS | HOPD Status Indicator | Description | APC | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 26591 | T | Repair muscles of hand | 0054 | 19.66 | \$953.26 | \$472.33 | \$190.65 |
| 26593 | T | Release muscles of hand | 0053 | 11.32 | \$548.87 | \$253.49 | \$109.77 |
| 26596 | T | Excision constricting tissue | 0054 | 19.66 | \$953.26 | \$472.33 | \$190.65 |
| 26597 | T | Release of scar contracture | 0054 | 19.66 | \$953.26 | \$472.33 | \$190.65 |
| 26600 | T | Treat metacarpal fracture | 0044 | 2.17 | \$105.22 | \$38.08 | \$21.04 |
| 26605 | T | Treat metacarpal fracture | 0044 | 2.17 | \$105.22 | \$38.08 | \$21.04 |
| 26607 | T | Treat metacarpal fracture | 0044 | 2.17 | \$105.22 | \$38.08 | \$21.04 |
| 26608 | T | Treat metacarpal fracture | 0046 | 22.29 | \$1,080.78 | \$535.76 | \$216.16 |
| 26615 | T | Treat metacarpal fracture | 0046 | 22.29 | \$1,080.78 | \$535.76 | \$216.16 |
| 26641 | T | Treat thumb dislocation | 0044 | 2.17 | \$105.22 | \$38.08 | \$21.04 |
| 26645 | T | Treat thumb fracture | 0044 | 2.17 | \$105.22 | \$38.08 | \$21.04 |
| 26650 | T | Treat thumb fracture | 0046 | 22.29 | \$1,080.78 | \$535.76 | \$216.16 |
| 26665 | T | Treat thumb fracture | 0046 | 22.29 | \$1,080.78 | \$535.76 | \$216.16 |
| 26670 | T | Treat hand dislocation | 0044 | 2.17 | \$105.22 | \$38.08 | \$21.04 |
| 26675 | T | Treat hand dislocation | 0045 | 11.02 | \$534.33 | \$277.12 | \$106.87 |
| 26676 | T | Pin hand dislocation | 0046 | 22.29 | \$1,080.78 | \$535.76 | \$216.16 |
| 26685 | T | Treat hand dislocation | 0046 | 22.29 | \$1,080.78 | \$535.76 | \$216.16 |
| 26686 | T | Treat hand dislocation | 0046 | 22.29 | \$1,080.78 | \$535.76 | \$216.16 |
| 26700 | T | Treat knuckle dislocation | 0043 | 1.64 | \$79.52 | \$25.46 | \$15.90 |
| 26705 | T | Treat knuckle dislocation | 0045 | 11.02 | \$534.33 | \$277.12 | \$106.87 |
| 26706 | T | Pin knuckle dislocation | 0044 | 2.17 | \$105.22 | \$38.08 | \$21.04 |
| 26715 | T | Treat knuckle dislocation | 0046 | 22.29 | \$1,080.78 | \$535.76 | \$216.16 |
| 26720 | T | Treat finger fracture, each | 0043 | 1.64 | \$79.52 | \$25.46 | \$15.90 |
| 26725 | T | Treat finger fracture, each | 0043 | 1.64 | \$79.52 | \$25.46 | \$15.90 |
| 26727 | T | Treat finger fracture, each | 0046 | 22.29 | \$1,080.78 | \$535.76 | \$216.16 |
| 26735 | T | Treat finger fracture, each | 0046 | 22.29 | \$1,080.78 | \$535.76 | \$216.16 |
| 26740 | T | Treat finger fracture, each | 0043 | 1.64 | \$79.52 | \$25.46 | \$15.90 |
| 26742 | T | Treat finger fracture, each | 0044 | 2.17 | \$105.22 | \$38.08 | \$21.04 |
| 26746 | T | Treat finger fracture, each | 0046 | 22.29 | \$1,080.78 | \$535.76 | \$216.16 |
| 26750 | T | Treat finger fracture, each | 0043 | 1.64 | \$79.52 | \$25.46 | \$15.90 |
| 26755 | T | Treat finger fracture, each | 0043 | 1.64 | \$79.52 | \$25.46 | \$15.90 |
| 26756 | T | Pin finger fracture, each .. | 0046 | 22.29 | \$1,080.78 | \$535.76 | \$216.16 |
| 26765 | T | Treat finger fracture, each | 0046 | 22.29 | \$1,080.78 | \$535.76 | \$216.16 |
| 26770 | T | Treat finger dislocation | 0043 | 1.64 | \$79.52 | \$25.46 | \$15.90 |
| 26775 | T | Treat finger dislocation | 0045 | 11.02 | \$534.33 | \$277.12 | \$106.87 |
| 26776 | T | Pin finger dislocation | 0046 | 22.29 | \$1,080.78 | \$535.76 | \$216.16 |
| 26785 | T | Treat finger dislocation | 0046 | 22.29 | \$1,080.78 | \$535.76 | \$216.16 |
| 26820 | T | Thumb fusion with graft | 0054 | 19.66 | \$953.26 | \$472.33 | \$190.65 |
| 26841 | T | Fusion of thumb ........... | 0054 | 19.66 | \$953.26 | \$472.33 | \$190.65 |
| 26842 | T | Thumb fusion with graft | 0054 | 19.66 | \$953.26 | \$472.33 | \$190.65 |
| 26843 | T | Fusion of hand joint ..... | 0054 | 19.66 | \$953.26 | \$472.33 | \$190.65 |
| 26844 | T | Fusion/graft of hand joint | 0054 | 19.66 | \$953.26 | \$472.33 | \$190.65 |
| 26850 | T | Fusion of knuckle | 0054 | 19.66 | \$953.26 | \$472.33 | \$190.65 |
| 26852 | T | Fusion of knuckle with graft | 0054 | 19.66 | \$953.26 | \$472.33 | \$190.65 |
| 26860 | T | Fusion of finger joint ........... | 0054 | 19.66 | \$953.26 | \$472.33 | \$190.65 |
| 26861 | T | Fusion of finger jnt, add-on | 0054 | 19.66 | \$953.26 | \$472.33 | \$190.65 |
| 26862 | T | Fusion/graft of finger joint .................................. | 0054 | 19.66 | \$953.26 | \$472.33 | \$190.65 |
| 26863 | T | Fuse/graft added joint ...... | 0054 | 19.66 | \$953.26 | \$472.33 | \$190.65 |
| 26910 | T | Amputate metacarpal bone | 0054 | 19.66 | \$953.26 | \$472.33 | \$190.65 |
| 26951 | T | Amputation of finger/thumb | 0053 | 11.32 | \$548.87 | \$253.49 | \$109.77 |
| 26952 | T | Amputation of finger/thumb | 0053 | 11.32 | \$548.87 | \$253.49 | \$109.77 |
| 26989 | T | Hand/finger surgery ............ | 0043 | 1.64 | \$79.52 | \$25.46 | \$15.90 |
| 26990 | T | Drainage of pelvis lesion | 0049 | 15.04 | \$729.25 | \$356.95 | \$145.85 |
| 26991 | T | Drainage of pelvis bursa | 0049 | 15.04 | \$729.25 | \$356.95 | \$145.85 |
| 26992 | C | Drainage of bone lesion .... |  |  |  |  |  |
| 27000 | T | Incision of hip tendon | 0049 | 15.04 | \$729.25 | \$356.95 | \$145.85 |
| 27001 | T | Incision of hip tendon | 0050 | 21.13 | \$1,024.53 | \$513.86 | \$204.91 |
| 27003 | T | Incision of hip tendon ...... | 0050 | 21.13 | \$1,024.53 | \$513.86 | \$204.91 |
| 27005 | C | Incision of hip tendon ............................................ |  |  |  |  |  |
| 27006 | C | Incision of hip tendons .... |  |  |  |  |  |
| 27025 | C | Incision of hip/thigh fascia ...................................... |  |  |  |  |  |
| 27030 | C | Drainage of hip joint ............... |  |  |  |  |  |
| 27033 | T | Exploration of hip joint .......... | 0051 | 27.76 | \$1,346.00 | \$675.24 | \$269.20 |
| 27035 | C | Denervation of hip joint .......................................... |  |  |  |  |  |
| 27036 | C | Excision of hip joint/muscle .................................... |  |  |  |  |  |
| 27040 | T | Biopsy of soft tissues ............................................. | 0021 | 10.49 | \$508.63 | \$236.51 | \$101.73 |
| 27041 | T | Biopsy of soft tissues ............................................ | 0022 | 12.49 | \$605.60 | \$292.94 | \$121.12 |
| 27047 | T | Remove hip/pelvis lesion ........................................ | 0022 | 12.49 | \$605.60 | \$292.94 | \$121.12 |
| 27048 | T | Remove hip/pelvis lesion | 0022 | 12.49 | \$605.60 | \$292.94 | \$121.12 |
| 27049 | T | Remove tumor, hip/pelvis ...................................... | 0022 | 12.49 | \$605.60 | \$292.94 | \$121.12 |
| 27050 | T | Biopsy of sacroiliac joint ........................................ | 0049 | 15.04 | \$729.25 | \$356.95 | \$145.85 |
| 27052 | T | Biopsy of hip joint .................... | 0049 | 15.04 | \$729.25 | \$356.95 | \$145.85 |
| 27054 | C | Removal of hip joint lining ....... |  |  |  |  |  |

[^149]
## Addendum B.-Hospital Outpatient Department (HOPD) Payment Status by HCPCS Code and Related INFORMATION-Continued

| CPT/ HCPCS | HOPD Status Indicator | Description | APC | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 27060 | T | Removal of ischial bursa | 0049 | 15.04 | \$729.25 | \$356.95 | \$145.85 |
| 27062 | T | Remove femur lesion/bursa | 0049 | 15.04 | \$729.25 | \$356.95 | \$145.85 |
| 27065 | T | Removal of hip bone lesion | 0049 | 15.04 | \$729.25 | \$356.95 | \$145.85 |
| 27066 | T | Removal of hip bone lesion | 0050 | 21.13 | \$1,024.53 | \$513.86 | \$204.91 |
| 27067 | T | Remove/graft hip bone lesion | 0050 | 21.13 | \$1,024.53 | \$513.86 | \$204.91 |
| 27070 | C | Partial removal of hip bone .................................... |  |  |  |  |  |
| 27071 | C | Partial removal of hip bone .................................... |  |  |  |  |  |
| 27075 | C | Extensive hip surgery ............................................ |  |  |  | ...................... |  |
| 27076 | C | Extensive hip surgery | ....... |  |  |  |  |
| 27077 | C | Extensive hip surgery |  |  |  |  |  |
| 27078 | C | Extensive hip surgery | .... |  |  |  |  |
| 27079 | C | Extensive hip surgery ............................................ |  |  |  |  |  |
| 27080 | T | Removal of tail bone | 0050 | 21.13 | \$1,024.53 | \$513.86 | \$204.91 |
| 27086 | T | Remove hip foreign body ...................................... | 0019 | 4.00 | \$193.95 | \$78.91 | \$38.79 |
| 27087 | T | Remove hip foreign body ....................................... | 0049 | 15.04 | \$729.25 | \$356.95 | \$145.85 |
| 27090 | C | Removal of hip prosthesis |  |  |  |  |  |
| 27091 | C | Removal of hip prosthesis |  |  |  |  |  |
| 27093 | N | Injection for hip x-ray .. |  |  |  |  |  |
| 27095 | N | Injection for hip x-ray ............................................. |  |  |  |  |  |
| 27096 | N | Inject sacroiliac joint . |  |  |  |  |  |
| 27097 | T | Revision of hip tendon | 0050 | 21.13 | \$1,024.53 | \$513.86 | \$204.91 |
| 27098 | T | Transfer tendon to pelvis | 0050 | 21.13 | \$1,024.53 | \$513.86 | \$204.91 |
| 27100 | T | Transfer of abdominal muscle | 0051 | 27.76 | \$1,346.00 | \$675.24 | \$269.20 |
| 27105 | T | Transfer of spinal muscle | 0051 | 27.76 | \$1,346.00 | \$675.24 | \$269.20 |
| 27110 | T | Transfer of iliopsoas muscle | 0051 | 27.76 | \$1,346.00 | \$675.24 | \$269.20 |
| 27111 | T | Transfer of iliopsoas muscle | 0051 | 27.76 | \$1,346.00 | \$675.24 | \$269.20 |
| 27120 | C | Reconstruction of hip socket |  |  |  |  |  |
| 27122 | C | Reconstruction of hip socket ................................... | ...... | ..................... | .................... | ..................... |  |
| 27125 | C | Partial hip replacement |  |  |  |  |  |
| 27130 | C | Total hip replacement |  |  |  |  |  |
| 27132 | C | Total hip replacement ........................................... |  |  |  | .................... |  |
| 27134 | C | Revise hip joint replacement |  |  |  |  |  |
| 27137 | C | Revise hip joint replacement |  |  |  |  |  |
| 27138 | C | Revise hip joint replacement |  |  |  |  |  |
| 27140 | C | Transplant femur ridge ........ |  |  |  | .................... |  |
| 27146 | C | Incision of hip bone |  |  |  |  |  |
| 27147 | C | Revision of hip bone |  |  |  |  |  |
| 27151 | C | Incision of hip bones |  | ...... |  | ..................... |  |
| 27156 | C | Revision of hip bones | ................... | .................... | .................... | .................... |  |
| 27158 | C | Revision of pelvis |  |  |  |  |  |
| 27161 | C | Incision of neck of femur |  | ...................... | ...................... | ...................... |  |
| 27165 | C | Incision/fixation of femur |  |  |  | .................... |  |
| 27170 | C | Repair/graft femur head/neck |  |  |  |  |  |
| 27175 | C | Treat slipped epiphysis .......................................... |  | ..................... |  | ..................... |  |
| 27176 | C | Treat slipped epiphysis .......................................... |  | ..................... |  | ...................... |  |
| 27177 | C | Treat slipped epiphysis .......................................... |  |  |  |  |  |
| 27178 | C | Treat slipped epiphysis .......................................... |  |  |  |  |  |
| 27179 | C | Revise head/neck of femur |  |  |  |  |  |
| 27181 | C | Treat slipped epiphysis .......................................... |  |  |  |  |  |
| 27185 | C | Revision of femur epiphysis ................................... |  |  |  |  |  |
| 27187 | C | Reinforce hip bones |  |  |  |  |  |
| 27193 | T | Treat pelvic ring fracture ......................................... | 0044 | 2.17 | \$105.22 | \$38.08 | \$21.04 |
| 27194 | T | Treat pelvic ring fracture | 0045 | 11.02 | \$534.33 | \$277.12 | \$106.87 |
| 27200 | T | Treat tail bone fracture | 0043 | 1.64 | \$79.52 | \$25.46 | \$15.90 |
| 27202 | T | Treat tail bone fracture | 0046 | 22.29 | \$1,080.78 | \$535.76 | \$216.16 |
| 27215 | C | Treat pelvic fracture(s) ........................................... |  |  |  |  |  |
| 27216 | C | Treat pelvic ring fracture ......................................... |  |  |  |  |  |
| 27217 | C | Treat pelvic ring fracture ......................................... | ................... | .................... |  | .................... |  |
| 27218 | C | Treat pelvic ring fracture ......................................... |  |  |  |  |  |
| 27220 | T | Treat hip socket fracture | 0044 | 2.17 | \$105.22 | \$38.08 | \$21.04 |
| 27222 | C | Treat hip socket fracture ......................................... |  |  |  |  |  |
| 27226 | C | Treat hip wall fracture |  |  |  |  |  |
| 27227 | C | Treat hip fracture(s) |  |  |  |  |  |
| 27228 | C | Treat hip fracture(s) ............................................... |  |  |  |  |  |
| 27230 | T | Treat thigh fracture ............................................... | 0044 | 2.17 | \$105.22 | \$38.08 | \$21.04 |
| 27232 | C | Treat thigh fracture ................................................ |  |  |  |  |  |
| 27235 | C | Treat thigh fracture |  |  |  |  |  |
| 27236 | C | Treat thigh fracture ................................................ |  |  |  |  |  |
| 27238 | T | Treat thigh fracture ................................................. | 0044 | 2.17 | \$105.22 | \$38.08 | \$21.04 |
| 27240 | C | Treat thigh fracture ................................................ |  |  |  |  |  |
| 27244 | C | Treat thigh fracture . |  | ..................... | .................. | ...................... | ...... |
| 27245 | C | Treat thigh fracture |  |  |  |  |  |
| 27246 | T | Treat thigh fracture | 0044 | 2.17 | \$105.22 | \$38.08 | \$21.04 |

[^150]
## Addendum B.—Hospital Outpatient Department (HOPD) Payment Status by hCPCS Code and Related Information-Continued

| $\begin{aligned} & \text { CPT/ } \\ & \text { HCPCS } \end{aligned}$ | HOPD Status Indicator | Description | APC | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 27248 | C | Treat thigh fracture |  |  |  |  |  |
| 27250 | T | Treat hip dislocation | 0044 | 2.17 | \$105.22 | \$38.08 | \$21.04 |
| 27252 | T | Treat hip dislocation | 0045 | 11.02 | \$534.33 | \$277.12 | \$106.87 |
| 27253 | C | Treat hip dislocation |  |  |  |  |  |
| 27254 | C | Treat hip dislocation |  |  |  |  |  |
| 27256 | T | Treat hip dislocation | 0044 | 2.17 | \$105.22 | \$38.08 | \$21.04 |
| 27257 | T | Treat hip dislocation ............................................. | 0045 | 11.02 | \$534.33 | \$277.12 | \$106.87 |
| 27258 | C | Treat hip dislocation ............................................ | ...................... | ...................... |  | .................... |  |
| 27259 | C | Treat hip dislocation |  |  |  |  |  |
| 27265 | T | Treat hip dislocation | 0044 | 2.17 | \$105.22 | \$38.08 | \$21.04 |
| 27266 | T | Treat hip dislocation | 0047 | 22.09 | \$1,071.08 | \$537.03 | \$214.22 |
| 27275 | T | Manipulation of hip joint | 0045 | 11.02 | \$534.33 | \$277.12 | \$106.87 |
| 27280 | C | Fusion of sacroiliac joint |  |  |  |  |  |
| 27282 | C | Fusion of pubic bones ...... |  |  |  |  |  |
| 27284 | C | Fusion of hip joint ............................................ |  |  |  |  |  |
| 27286 | C | Fusion of hip joint .. |  | .................... |  |  |  |
| 27290 | C | Amputation of leg at hip |  |  |  |  |  |
| 27295 | C | Amputation of leg at hip |  |  |  |  |  |
| 27299 | T | Pelvis/hip joint surgery | 0043 | 1.64 | \$79.52 | \$25.46 | \$15.90 |
| 27301 | T | Drain thigh/knee lesion | 0008 | 6.15 | \$298.20 | \$113.67 | \$59.64 |
| 27303 | C | Drainage of bone lesion |  |  |  |  |  |
| 27305 | T | Incise thigh tendon \& fascia .................................... | 0049 | 15.04 | \$729.25 | \$356.95 | \$145.85 |
| 27306 | T | Incision of thigh tendon | 0049 | 15.04 | \$729.25 | \$356.95 | \$145.85 |
| 27307 | T | Incision of thigh tendons | 0049 | 15.04 | \$729.25 | \$356.95 | \$145.85 |
| 27310 | T | Exploration of knee joint | 0050 | 21.13 | \$1,024.53 | \$513.86 | \$204.91 |
| 27315 | T | Partial removal, thigh nerve | 0220 | 13.96 | \$676.88 | \$326.21 | \$135.38 |
| 27320 | T | Partial removal, thigh nerve | 0220 | 13.96 | \$676.88 | \$326.21 | \$135.38 |
| 27323 | T | Biopsy, thigh soft tissues | 0021 | 10.49 | \$508.63 | \$236.51 | \$101.73 |
| 27324 | T | Biopsy, thigh soft tissues | 0022 | 12.49 | \$605.60 | \$292.94 | \$121.12 |
| 27327 | T | Removal of thigh lesion | 0022 | 12.49 | \$605.60 | \$292.94 | \$121.12 |
| 27328 | T | Removal of thigh lesion | 0022 | 12.49 | \$605.60 | \$292.94 | \$121.12 |
| 27329 | T | Remove tumor, thigh/knee | 0022 | 12.49 | \$605.60 | \$292.94 | \$121.12 |
| 27330 | T | Biopsy, knee joint lining | 0050 | 21.13 | \$1,024.53 | \$513.86 | \$204.91 |
| 27331 | T | Explore/treat knee joint | 0050 | 21.13 | \$1,024.53 | \$513.86 | \$204.91 |
| 27332 | T | Removal of knee cartilage | 0050 | 21.13 | \$1,024.53 | \$513.86 | \$204.91 |
| 27333 | T | Removal of knee cartilage | 0050 | 21.13 | \$1,024.53 | \$513.86 | \$204.91 |
| 27334 | T | Remove knee joint lining | 0050 | 21.13 | \$1,024.53 | \$513.86 | \$204.91 |
| 27335 | T | Remove knee joint lining ....................................... | 0050 | 21.13 | \$1,024.53 | \$513.86 | \$204.91 |
| 27340 | T | Removal of kneecap bursa ..................................... | 0049 | 15.04 | \$729.25 | \$356.95 | \$145.85 |
| 27345 | T | Removal of knee cyst | 0049 | 15.04 | \$729.25 | \$356.95 | \$145.85 |
| 27347 | T | Remove knee cyst ................................................ | 0049 | 15.04 | \$729.25 | \$356.95 | \$145.85 |
| 27350 | T | Removal of kneecap | 0050 | 21.13 | \$1,024.53 | \$513.86 | \$204.91 |
| 27355 | T | Remove femur lesion | 0050 | 21.13 | \$1,024.53 | \$513.86 | \$204.91 |
| 27356 | T | Remove femur lesion/graft | 0050 | 21.13 | \$1,024.53 | \$513.86 | \$204.91 |
| 27357 | T | Remove femur lesion/graft | 0050 | 21.13 | \$1,024.53 | \$513.86 | \$204.91 |
| 27358 | T | Remove femur lesion/fixation | 0050 | 21.13 | \$1,024.53 | \$513.86 | \$204.91 |
| 27360 | T | Partial removal, leg bone(s) .................................... | 0050 | 21.13 | \$1,024.53 | \$513.86 | \$204.91 |
| 27365 | C | Extensive leg surgery ............................................ |  |  |  |  |  |
| 27370 | N | Injection for knee x-ray |  |  |  |  |  |
| 27372 | T | Removal of foreign body | 0022 | 12.49 | \$605.60 | \$292.94 | \$121.12 |
| 27380 | T | Repair of kneecap tendon ...................................... | 0049 | 15.04 | \$729.25 | \$356.95 | \$145.85 |
| 27381 | T | Repair/graft kneecap tendon .................................. | 0049 | 15.04 | \$729.25 | \$356.95 | \$145.85 |
| 27385 | T | Repair of thigh muscle ........................................... | 0049 | 15.04 | \$729.25 | \$356.95 | \$145.85 |
| 27386 | T | Repair/graft of thigh muscle | 0049 | 15.04 | \$729.25 | \$356.95 | \$145.85 |
| 27390 | T | Incision of thigh tendon .......................................... | 0049 | 15.04 | \$729.25 | \$356.95 | \$145.85 |
| 27391 | T | Incision of thigh tendons | 0049 | 15.04 | \$729.25 | \$356.95 | \$145.85 |
| 27392 | T | Incision of thigh tendons | 0049 | 15.04 | \$729.25 | \$356.95 | \$145.85 |
| 27393 | T | Lengthening of thigh tendon .................................... | 0050 | 21.13 | \$1,024.53 | \$513.86 | \$204.91 |
| 27394 | T | Lengthening of thigh tendons | 0050 | 21.13 | \$1,024.53 | \$513.86 | \$204.91 |
| 27395 | T | Lengthening of thigh tendons .................................. | 0051 | 27.76 | \$1,346.00 | \$675.24 | \$269.20 |
| 27396 | T | Transplant of thigh tendon ..................................... | 0050 | 21.13 | \$1,024.53 | \$513.86 | \$204.91 |
| 27397 | T | Transplants of thigh tendons ................................... | 0051 | 27.76 | \$1,346.00 | \$675.24 | \$269.20 |
| 27400 | T | Revise thigh muscles/tendons ................................. | 0051 | 27.76 | \$1,346.00 | \$675.24 | \$269.20 |
| 27403 | T | Repair of knee cartilage ...................................... | 0050 | 21.13 | \$1,024.53 | \$513.86 | \$204.91 |
| 27405 | T | Repair of knee ligament ........................................ | 0051 | 27.76 | \$1,346.00 | \$675.24 | \$269.20 |
| 27407 | T | Repair of knee ligament ........................................ | 0051 | 27.76 | \$1,346.00 | \$675.24 | \$269.20 |
| 27409 | T | Repair of knee ligaments ....................................... | 0051 | 27.76 | \$1,346.00 | \$675.24 | \$269.20 |
| 27418 | T | Repair degenerated kneecap .................................. | 0051 | 27.76 | \$1,346.00 | \$675.24 | \$269.20 |
| 27420 | T | Revision of unstable kneecap ................................ | 0051 | 27.76 | \$1,346.00 | \$675.24 | \$269.20 |
| 27422 | T | Revision of unstable kneecap ................................. | 0051 | 27.76 | \$1,346.00 | \$675.24 | \$269.20 |
| 27424 | T | Revision/removal of kneecap .................................. | 0051 | 27.76 | \$1,346.00 | \$675.24 | \$269.20 |
| 27425 | T | Lateral retinacular release ...................................... | 0050 | 21.13 | \$1,024.53 | \$513.86 | \$204.91 |
| 27427 | T | Reconstruction, knee | 0052 | 36.16 | \$1,753.29 | \$930.91 | \$350.66 |

[^151]
# Addendum B.-Hospital Outpatient Department (HOPD) Payment Status by HCPCS Code and Related Information-Continued 

| $\begin{gathered} \text { CPT/ } \\ \text { HCPCS } \end{gathered}$ | HOPD Status Indicator | Description | APC | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 27428 | T | Reconstruction, knee | 0052 | 36.16 | \$1,753.29 | \$930.91 | \$350.66 |
| 27429 | T | Reconstruction, knee | 0052 | 36.16 | \$1,753.29 | \$930.91 | \$350.66 |
| 27430 | T | Revision of thigh muscles | 0051 | 27.76 | \$1,346.00 | \$675.24 | \$269.20 |
| 27435 | T | Incision of knee joint ....... | 0051 | 27.76 | \$1,346.00 | \$675.24 | \$269.20 |
| 27437 | T | Revise kneecap | 0047 | 22.09 | \$1,071.08 | \$537.03 | \$214.22 |
| 27438 | T | Revise kneecap with implant | 0048 | 29.06 | \$1,409.03 | \$725.94 | \$281.81 |
| 27440 | T | Revision of knee joint ...... | 0047 | 22.09 | \$1,071.08 | \$537.03 | \$214.22 |
| 27441 | T | Revision of knee joint ............................................ | 0047 | 22.09 | \$1,071.08 | \$537.03 | \$214.22 |
| 27442 | T | Revision of knee joint | 0047 | 22.09 | \$1,071.08 | \$537.03 | \$214.22 |
| 27443 | T | Revision of knee joint | 0047 | 22.09 | \$1,071.08 | \$537.03 | \$214.22 |
| 27445 | C | Revision of knee joint |  |  |  |  |  |
| 27446 | C | Revision of knee joint | ...... | .................... | ...................... | .................... |  |
| 27447 | C | Total knee replacement |  |  |  |  |  |
| 27448 | C | Incision of thigh ....... |  |  |  |  |  |
| 27450 | C | Incision of thigh |  |  |  | ..................... |  |
| 27454 | C | Realignment of thigh bone |  |  |  |  |  |
| 27455 | C | Realignment of knee ......... |  |  |  |  |  |
| 27457 | C | Realignment of knee |  |  |  |  |  |
| 27465 | C | Shortening of thigh bone ....................................... |  | .................... |  |  |  |
| 27466 | C | Lengthening of thigh bone |  |  |  |  |  |
| 27468 | C | Shorten/lengthen thighs |  |  |  |  |  |
| 27470 | C | Repair of thigh |  |  |  | .................... |  |
| 27472 | C | Repair/graft of thigh |  |  |  |  |  |
| 27475 | C | Surgery to stop leg growth |  |  |  |  |  |
| 27477 | C | Surgery to stop leg growth ..................................... |  |  |  | .................... |  |
| 27479 | C | Surgery to stop leg growth |  |  |  |  |  |
| 27485 | C | Surgery to stop leg growth |  |  |  |  |  |
| 27486 | C | Revise/replace knee joint ....................................... | ....... | .................... | .................... | ................ |  |
| 27487 | C | Revise/replace knee joint |  |  |  |  |  |
| 27488 | C | Removal of knee prosthesis | .... |  |  |  |  |
| 27495 | C | Reinforce thigh ..................................................... |  |  |  |  |  |
| 27496 | T | Decompression of thigh/knee | 0049 | 15.04 | \$729.25 | \$356.95 | \$145.85 |
| 27497 | T | Decompression of thigh/knee | 0049 | 15.04 | \$729.25 | \$356.95 | \$145.85 |
| 27498 | T | Decompression of thigh/knee | 0049 | 15.04 | \$729.25 | \$356.95 | \$145.85 |
| 27499 | T | Decompression of thigh/knee .................................. | 0049 | 15.04 | \$729.25 | \$356.95 | \$145.85 |
| 27500 | T | Treatment of thigh fracture | 0044 | 2.17 | \$105.22 | \$38.08 | \$21.04 |
| 27501 | T | Treatment of thigh fracture | 0044 | 2.17 | \$105.22 | \$38.08 | \$21.04 |
| 27502 | T | Treatment of thigh fracture | 0044 | 2.17 | \$105.22 | \$38.08 | \$21.04 |
| 27503 | T | Treatment of thigh fracture | 0044 | 2.17 | \$105.22 | \$38.08 | \$21.04 |
| 27506 | C | Treatment of thigh fracture |  |  |  |  |  |
| 27507 | C | Treatment of thigh fracture ..................................... |  |  |  |  |  |
| 27508 | T | Treatment of thigh fracture ...................................... | 0044 | 2.17 | \$105.22 | \$38.08 | \$21.04 |
| 27509 | T | Treatment of thigh fracture | 0046 | 22.29 | \$1,080.78 | \$535.76 | \$216.16 |
| 27510 | T | Treatment of thigh fracture ..................................... | 0044 | 2.17 | \$105.22 | \$38.08 | \$21.04 |
| 27511 | C | Treatment of thigh fracture | ........ | ..................... |  | ...................... |  |
| 27513 | C | Treatment of thigh fracture |  |  |  |  |  |
| 27514 | C | Treatment of thigh fracture ..................................... |  |  |  |  |  |
| 27516 | T | Treat thigh fx growth plate | 0044 | 2.17 | \$105.22 | \$38.08 | \$21.04 |
| 27517 | T | Treat thigh fx growth plate ...................................... | 0044 | 2.17 | \$105.22 | \$38.08 | \$21.04 |
| 27519 | C | Treat thigh fx growth plate ...................................... |  |  |  |  |  |
| 27520 | T | Treat kneecap fracture ..... | 0044 | 2.17 | \$105.22 | \$38.08 | \$21.04 |
| 27524 | C | Treat kneecap fracture .......................................... |  |  |  |  |  |
| 27530 | T | Treat knee fracture | 0044 | 2.17 | \$105.22 | \$38.08 | \$21.04 |
| 27532 | T | Treat knee fracture ................................................ | 0044 | 2.17 | \$105.22 | \$38.08 | \$21.04 |
| 27535 | C | Treat knee fracture |  |  |  |  |  |
| 27536 | C | Treat knee fracture ................................................ |  |  |  |  |  |
| 27538 | T | Treat knee fracture(s) ............................................ | 0044 | 2.17 | \$105.22 | \$38.08 | \$21.04 |
| 27540 | C | Treat knee fracture |  |  |  |  |  |
| 27550 | T | Treat knee dislocation | 0044 | 2.17 | \$105.22 | \$38.08 | \$21.04 |
| 27552 | T | Treat knee dislocation | 0045 | 11.02 | \$534.33 | \$277.12 | \$106.87 |
| 27556 | T | Treat knee dislocation ........................................... | 0046 | 22.29 | \$1,080.78 | \$535.76 | \$216.16 |
| 27557 | C | Treat knee dislocation |  |  |  |  |  |
| 27558 | C | Treat knee dislocation ........................................... |  |  |  |  |  |
| 27560 | T | Treat kneecap dislocation ....................................... | 0044 | 2.17 | \$105.22 | \$38.08 | \$21.04 |
| 27562 | T | Treat kneecap dislocation ....................................... | 0045 | 11.02 | \$534.33 | \$277.12 | \$106.87 |
| 27566 | T | Treat kneecap dislocation ....................................... | 0046 | 22.29 | \$1,080.78 | \$535.76 | \$216.16 |
| 27570 | T | Fixation of knee joint ............................................. | 0045 | 11.02 | \$534.33 | \$277.12 | \$106.87 |
| 27580 | C | Fusion of knee ...................................................... |  |  |  |  |  |
| 27590 | C | Amputate leg at thigh ............................................ |  |  |  |  |  |
| 27591 | C | Amputate leg at thigh ............................................ |  |  |  |  |  |
| 27592 | C | Amputate leg at thigh ............................................ |  |  |  |  |  |
| 27594 | T | Amputation follow-up surgery .................................. | 0049 | 15.04 | \$729.25 | \$356.95 | \$145.85 |
| 27596 | C | Amputation follow-up surgery |  |  |  |  |  |

[^152]
## Addendum B.-Hospital Outpatient Department (HOPD) Payment Status by hCPCS Code and Related Information-Continued

| CPT/ HCPCS | HOPD <br> Status <br> Indicator | Description | APC | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 27598 | C | Amputate lower leg at knee ... |  |  |  |  |  |
| 27599 | T | Leg surgery procedure | 0044 | 2.17 | \$105.22 | \$38.08 | \$21.04 |
| 27600 | T | Decompression of lower leg | 0049 | 15.04 | \$729.25 | \$356.95 | \$145.85 |
| 27601 | T | Decompression of lower leg | 0049 | 15.04 | \$729.25 | \$356.95 | \$145.85 |
| 27602 | T | Decompression of lower leg | 0049 | 15.04 | \$729.25 | \$356.95 | \$145.85 |
| 27603 | T | Drain lower leg lesion | 0008 | 6.15 | \$298.20 | \$113.67 | \$59.64 |
| 27604 | T | Drain lower leg bursa | 0049 | 15.04 | \$729.25 | \$356.95 | \$145.85 |
| 27605 | T | Incision of achilles tendon | 0055 | 15.47 | \$750.10 | \$355.34 | \$150.02 |
| 27606 | T | Incision of achilles tendon | 0049 | 15.04 | \$729.25 | \$356.95 | \$145.85 |
| 27607 | T | Treat lower leg bone lesion | 0049 | 15.04 | \$729.25 | \$356.95 | \$145.85 |
| 27610 | T | Explore/treat ankle joint | 0050 | 21.13 | \$1,024.53 | \$513.86 | \$204.91 |
| 27612 | T | Exploration of ankle joint | 0050 | 21.13 | \$1,024.53 | \$513.86 | \$204.91 |
| 27613 | T | Biopsy lower leg soft tissue | 0020 | 6.51 | \$315.65 | \$130.53 | \$63.13 |
| 27614 | T | Biopsy lower leg soft tissue | 0022 | 12.49 | \$605.60 | \$292.94 | \$121.12 |
| 27615 | T | Remove tumor, lower leg | 0046 | 22.29 | \$1,080.78 | \$535.76 | \$216.16 |
| 27618 | T | Remove lower leg lesion | 0021 | 10.49 | \$508.63 | \$236.51 | \$101.73 |
| 27619 | T | Remove lower leg lesion | 0022 | 12.49 | \$605.60 | \$292.94 | \$121.12 |
| 27620 | T | Explore/treat ankle joint | 0050 | 21.13 | \$1,024.53 | \$513.86 | \$204.91 |
| 27625 | T | Remove ankle joint lining | 0050 | 21.13 | \$1,024.53 | \$513.86 | \$204.91 |
| 27626 | T | Remove ankle joint lining | 0050 | 21.13 | \$1,024.53 | \$513.86 | \$204.91 |
| 27630 | T | Removal of tendon lesion | 0049 | 15.04 | \$729.25 | \$356.95 | \$145.85 |
| 27635 | T | Remove lower leg bone lesion | 0050 | 21.13 | \$1,024.53 | \$513.86 | \$204.91 |
| 27637 | T | Remove/graft leg bone lesion | 0050 | 21.13 | \$1,024.53 | \$513.86 | \$204.91 |
| 27638 | T | Remove/graft leg bone lesion | 0050 | 21.13 | \$1,024.53 | \$513.86 | \$204.91 |
| 27640 | T | Partial removal of tibia | 0051 | 27.76 | \$1,346.00 | \$675.24 | \$269.20 |
| 27641 | T | Partial removal of fibula | 0050 | 21.13 | \$1,024.53 | \$513.86 | \$204.91 |
| 27645 | C | Extensive lower leg surgery |  |  |  |  |  |
| 27646 | C | Extensive lower leg surgery |  |  |  |  |  |
| 27647 | T | Extensive ankle/heel surgery | 0051 | 27.76 | \$1,346.00 | \$675.24 | \$269.20 |
| 27648 | N | Injection for ankle x-ray ... |  |  |  |  |  |
| 27650 | T | Repair achilles tendon | 0051 | 27.76 | \$1,346.00 | \$675.24 | \$269.20 |
| 27652 | T | Repair/graft achilles tendon | 0051 | 27.76 | \$1,346.00 | \$675.24 | \$269.20 |
| 27654 | T | Repair of achilles tendon | 0051 | 27.76 | \$1,346.00 | \$675.24 | \$269.20 |
| 27656 | T | Repair leg fascia defect | 0049 | 15.04 | \$729.25 | \$356.95 | \$145.85 |
| 27658 | T | Repair of leg tendon, each | 0049 | 15.04 | \$729.25 | \$356.95 | \$145.85 |
| 27659 | T | Repair of leg tendon, each | 0049 | 15.04 | \$729.25 | \$356.95 | \$145.85 |
| 27664 | T | Repair of leg tendon, each | 0049 | 15.04 | \$729.25 | \$356.95 | \$145.85 |
| 27665 | T | Repair of leg tendon, each | 0050 | 21.13 | \$1,024.53 | \$513.86 | \$204.91 |
| 27675 | T | Repair lower leg tendons.. | 0049 | 15.04 | \$729.25 | \$356.95 | \$145.85 |
| 27676 | T | Repair lower leg tendons | 0050 | 21.13 | \$1,024.53 | \$513.86 | \$204.91 |
| 27680 | T | Release of lower leg tendon | 0050 | 21.13 | \$1,024.53 | \$513.86 | \$204.91 |
| 27681 | T | Release of lower leg tendons | 0050 | 21.13 | \$1,024.53 | \$513.86 | \$204.91 |
| 27685 | T | Revision of lower leg tendon | 0050 | 21.13 | \$1,024.53 | \$513.86 | \$204.91 |
| 27686 | T | Revise lower leg tendons | 0050 | 21.13 | \$1,024.53 | \$513.86 | \$204.91 |
| 27687 | T | Revision of calf tendon ... | 0050 | 21.13 | \$1,024.53 | \$513.86 | \$204.91 |
| 27690 | T | Revise lower leg tendon | 0051 | 27.76 | \$1,346.00 | \$675.24 | \$269.20 |
| 27691 | T | Revise lower leg tendon | 0051 | 27.76 | \$1,346.00 | \$675.24 | \$269.20 |
| 27692 | T | Revise additional leg tendon | 0051 | 27.76 | \$1,346.00 | \$675.24 | \$269.20 |
| 27695 | T | Repair of ankle ligament ...... | 0050 | 21.13 | \$1,024.53 | \$513.86 | \$204.91 |
| 27696 | T | Repair of ankle ligaments | 0050 | 21.13 | \$1,024.53 | \$513.86 | \$204.91 |
| 27698 | T | Repair of ankle ligament | 0050 | 21.13 | \$1,024.53 | \$513.86 | \$204.91 |
| 27700 | T | Revision of ankle joint ........................................... | 0047 | 22.09 | \$1,071.08 | \$537.03 | \$214.22 |
| 27702 | C | Reconstruct ankle joint |  |  |  |  |  |
| 27703 | C | Reconstruction, ankle joint ..................................... |  |  |  |  |  |
| 27704 | T | Removal of ankle implant ....................................... | 0049 | 15.04 | \$729.25 | \$356.95 | \$145.85 |
| 27705 | T | Incision of tibia | 0051 | 27.76 | \$1,346.00 | \$675.24 | \$269.20 |
| 27707 | T | Incision of fibula | 0049 | 15.04 | \$729.25 | \$356.95 | \$145.85 |
| 27709 | T | Incision of tibia \& fibula | 0050 | 21.13 | \$1,024.53 | \$513.86 | \$204.91 |
| 27712 | C | Realignment of lower leg ........................................ |  |  |  |  |  |
| 27715 | C | Revision of lower leg .... |  |  |  |  |  |
| 27720 | C | Repair of tibia ...................................................... |  |  | ...................... | ...................... |  |
| 27722 | C | Repair/graft of tibia ................................................ |  |  |  | ..................... |  |
| 27724 | C | Repair/graft of tibia ............................................... |  |  |  |  |  |
| 27725 | C | Repair of lower leg ............................................... |  |  | ............ | .................... |  |
| 27727 | C | Repair of lower leg ............................................... |  |  |  |  |  |
| 27730 | T | Repair of tibia epiphysis ......................................... | 0050 | 21.13 | \$1,024.53 | \$513.86 | \$204.91 |
| 27732 | T | Repair of fibula epiphysis ...................................... | 0050 | 21.13 | \$1,024.53 | \$513.86 | \$204.91 |
| 27734 | T | Repair lower leg epiphyses .................................... | 0050 | 21.13 | \$1,024.53 | \$513.86 | \$204.91 |
| 27740 | T | Repair of leg epiphyses ........................................ | 0050 | 21.13 | \$1,024.53 | \$513.86 | \$204.91 |
| 27742 | T | Repair of leg epiphyses ......................................... | 0051 | 27.76 | \$1,346.00 | \$675.24 | \$269.20 |
| 27745 | T | Reinforce tibia ...................................................... | 0051 | 27.76 | \$1,346.00 | \$675.24 | \$269.20 |
| 27750 | T | Treatment of tibia fracture ...................................... | 0044 | 2.17 | \$105.22 | \$38.08 | \$21.04 |
| 27752 | T | Treatment of tibia fracture | 0044 | 2.17 | \$105.22 | \$38.08 | \$21.04 |

[^153]
# Addendum B.-Hospital Outpatient Department (HOPD) Payment Status by HCPCS Code and Related Information-Continued 

| $\begin{gathered} \text { CPT/ } \\ \text { HCPCS } \end{gathered}$ | HOPD Status Indicator | Description | APC | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 27756 | T | Treatment of tibia fracture | 0046 | 22.29 | \$1,080.78 | \$535.76 | \$216.16 |
| 27758 | T | Treatment of tibia fracture | 0046 | 22.29 | \$1,080.78 | \$535.76 | \$216.16 |
| 27759 | T | Treatment of tibia fracture | 0046 | 22.29 | \$1,080.78 | \$535.76 | \$216.16 |
| 27760 | T | Treatment of ankle fracture | 0044 | 2.17 | \$105.22 | \$38.08 | \$21.04 |
| 27762 | T | Treatment of ankle fracture | 0044 | 2.17 | \$105.22 | \$38.08 | \$21.04 |
| 27766 | T | Treatment of ankle fracture | 0046 | 22.29 | \$1,080.78 | \$535.76 | \$216.16 |
| 27780 | T | Treatment of fibula fracture | 0044 | 2.17 | \$105.22 | \$38.08 | \$21.04 |
| 27781 | T | Treatment of fibula fracture | 0044 | 2.17 | \$105.22 | \$38.08 | \$21.04 |
| 27784 | T | Treatment of fibula fracture | 0046 | 22.29 | \$1,080.78 | \$535.76 | \$216.16 |
| 27786 | T | Treatment of ankle fracture | 0044 | 2.17 | \$105.22 | \$38.08 | \$21.04 |
| 27788 | T | Treatment of ankle fracture | 0044 | 2.17 | \$105.22 | \$38.08 | \$21.04 |
| 27792 | T | Treatment of ankle fracture | 0046 | 22.29 | \$1,080.78 | \$535.76 | \$216.16 |
| 27808 | T | Treatment of ankle fracture | 0044 | 2.17 | \$105.22 | \$38.08 | \$21.04 |
| 27810 | T | Treatment of ankle fracture | 0044 | 2.17 | \$105.22 | \$38.08 | \$21.04 |
| 27814 | T | Treatment of ankle fracture | 0046 | 22.29 | \$1,080.78 | \$535.76 | \$216.16 |
| 27816 | T | Treatment of ankle fracture | 0044 | 2.17 | \$105.22 | \$38.08 | \$21.04 |
| 27818 | T | Treatment of ankle fracture | 0044 | 2.17 | \$105.22 | \$38.08 | \$21.04 |
| 27822 | T | Treatment of ankle fracture | 0046 | 22.29 | \$1,080.78 | \$535.76 | \$216.16 |
| 27823 | T | Treatment of ankle fracture | 0046 | 22.29 | \$1,080.78 | \$535.76 | \$216.16 |
| 27824 | T | Treat lower leg fracture | 0044 | 2.17 | \$105.22 | \$38.08 | \$21.04 |
| 27825 | T | Treat lower leg fracture | 0044 | 2.17 | \$105.22 | \$38.08 | \$21.04 |
| 27826 | T | Treat lower leg fracture | 0046 | 22.29 | \$1,080.78 | \$535.76 | \$216.16 |
| 27827 | T | Treat lower leg fracture | 0046 | 22.29 | \$1,080.78 | \$535.76 | \$216.16 |
| 27828 | T | Treat lower leg fracture | 0046 | 22.29 | \$1,080.78 | \$535.76 | \$216.16 |
| 27829 | T | Treat lower leg joint | 0046 | 22.29 | \$1,080.78 | \$535.76 | \$216.16 |
| 27830 | T | Treat lower leg dislocation | 0044 | 2.17 | \$105.22 | \$38.08 | \$21.04 |
| 27831 | T | Treat lower leg dislocation | 0045 | 11.02 | \$534.33 | \$277.12 | \$106.87 |
| 27832 | T | Treat lower leg dislocation | 0046 | 22.29 | \$1,080.78 | \$535.76 | \$216.16 |
| 27840 | T | Treat ankle dislocation | 0044 | 2.17 | \$105.22 | \$38.08 | \$21.04 |
| 27842 | T | Treat ankle dislocation | 0045 | 11.02 | \$534.33 | \$277.12 | \$106.87 |
| 27846 | T | Treat ankle dislocation | 0046 | 22.29 | \$1,080.78 | \$535.76 | \$216.16 |
| 27848 | T | Treat ankle dislocation | 0046 | 22.29 | \$1,080.78 | \$535.76 | \$216.16 |
| 27860 | T | Fixation of ankle joint ............................................. | 0045 | 11.02 | \$534.33 | \$277.12 | \$106.87 |
| 27870 | T | Fusion of ankle joint | 0051 | 27.76 | \$1,346.00 | \$675.24 | \$269.20 |
| 27871 | T | Fusion of tibiofibular joint | 0051 | 27.76 | \$1,346.00 | \$675.24 | \$269.20 |
| 27880 | C | Amputation of lower leg .......................................... | ........ | ......... | ...................... | ..................... | ..................... |
| 27881 | C | Amputation of lower leg |  |  |  |  |  |
| 27882 | C | Amputation of lower leg |  |  |  |  |  |
| 27884 | T | Amputation follow-up surgery ................................. | 0049 | 15.04 | \$729.25 | \$356.95 | \$145.85 |
| 27886 | C | Amputation follow-up surgery .................................. |  |  |  |  |  |
| 27888 | C | Amputation of foot at ankle |  |  |  |  |  |
| 27889 | T | Amputation of foot at ankle | 0050 | 21.13 | \$1,024.53 | \$513.86 | \$204.91 |
| 27892 | T | Decompression of leg | 0049 | 15.04 | \$729.25 | \$356.95 | \$145.85 |
| 27893 | T | Decompression of leg | 0049 | 15.04 | \$729.25 | \$356.95 | \$145.85 |
| 27894 | T | Decompression of leg | 0049 | 15.04 | \$729.25 | \$356.95 | \$145.85 |
| 27899 | T | Leg/ankle surgery procedure ................................... | 0044 | 2.17 | \$105.22 | \$38.08 | \$21.04 |
| 28001 | T | Drainage of bursa of foot ........................................ | 0008 | 6.15 | \$298.20 | \$113.67 | \$59.64 |
| 28002 | T | Treatment of foot infection | 0049 | 15.04 | \$729.25 | \$356.95 | \$145.85 |
| 28003 | T | Treatment of foot infection | 0049 | 15.04 | \$729.25 | \$356.95 | \$145.85 |
| 28005 | T | Treat foot bone lesion | 0055 | 15.47 | \$750.10 | \$355.34 | \$150.02 |
| 28008 | T | Incision of foot fascia | 0055 | 15.47 | \$750.10 | \$355.34 | \$150.02 |
| 28010 | T | Incision of toe tendon | 0055 | 15.47 | \$750.10 | \$355.34 | \$150.02 |
| 28011 | T | Incision of toe tendons | 0055 | 15.47 | \$750.10 | \$355.34 | \$150.02 |
| 28020 | T | Exploration of foot joint | 0055 | 15.47 | \$750.10 | \$355.34 | \$150.02 |
| 28022 | T | Exploration of foot joint | 0055 | 15.47 | \$750.10 | \$355.34 | \$150.02 |
| 28024 | T | Exploration of toe joint ........................................... | 0055 | 15.47 | \$750.10 | \$355.34 | \$150.02 |
| 28030 | T | Removal of foot nerve | 0220 | 13.96 | \$676.88 | \$326.21 | \$135.38 |
| 28035 | T | Decompression of tibia nerve | 0220 | 13.96 | \$676.88 | \$326.21 | \$135.38 |
| 28043 | T | Excision of foot lesion. | 0021 | 10.49 | \$508.63 | \$236.51 | \$101.73 |
| 28045 | T | Excision of foot lesion | 0055 | 15.47 | \$750.10 | \$355.34 | \$150.02 |
| 28046 | T | Resection of tumor, foot | 0055 | 15.47 | \$750.10 | \$355.34 | \$150.02 |
| 28050 | T | Biopsy of foot joint lining ..................................... | 0055 | 15.47 | \$750.10 | \$355.34 | \$150.02 |
| 28052 | T | Biopsy of foot joint lining ........................................ | 0055 | 15.47 | \$750.10 | \$355.34 | \$150.02 |
| 28054 | T | Biopsy of toe joint lining | 0055 | 15.47 | \$750.10 | \$355.34 | \$150.02 |
| 28060 | T | Partial removal, foot fascia ..................................... | 0056 | 17.30 | \$838.83 | \$405.81 | \$167.77 |
| 28062 | T | Removal of foot fascia | 0056 | 17.30 | \$838.83 | \$405.81 | \$167.77 |
| 28070 | T | Removal of foot joint lining ...... | 0056 | 17.30 | \$838.83 | \$405.81 | \$167.77 |
| 28072 | T | Removal of foot joint lining ........ | 0056 | 17.30 | \$838.83 | \$405.81 | \$167.77 |
| 28080 | T | Removal of foot lesion ........................................... | 0055 | 15.47 | \$750.10 | \$355.34 | \$150.02 |
| 28086 | T | Excise foot tendon sheath ...................................... | 0055 | 15.47 | \$750.10 | \$355.34 | \$150.02 |
| 28088 | T | Excise foot tendon sheath ...................................... | 0055 | 15.47 | \$750.10 | \$355.34 | \$150.02 |
| 28090 | T | Removal of foot lesion | 0055 | 15.47 | \$750.10 | \$355.34 | \$150.02 |
| 28092 | T | Removal of toe lesions ........................................ | 0055 | 15.47 | \$750.10 | \$355.34 | \$150.02 |

[^154]
## Addendum B.-Hospital Outpatient Department (HOPD) Payment Status by hCPCS Code and Related Information-Continued

| CPT/ HCPCS | HOPD Status Indicator | Description | APC | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 28100 | T | Removal of ankle/heel lesion | 0055 | 15.47 | \$750.10 | \$355.34 | \$150.02 |
| 28102 | T | Remove/graft foot lesion | 0056 | 17.30 | \$838.83 | \$405.81 | \$167.77 |
| 28103 | T | Remove/graft foot lesion | 0056 | 17.30 | \$838.83 | \$405.81 | \$167.77 |
| 28104 | T | Removal of foot lesion | 0055 | 15.47 | \$750.10 | \$355.34 | \$150.02 |
| 28106 | T | Remove/graft foot lesion | 0056 | 17.30 | \$838.83 | \$405.81 | \$167.77 |
| 28107 | T | Remove/graft foot lesion | 0056 | 17.30 | \$838.83 | \$405.81 | \$167.77 |
| 28108 | T | Removal of toe lesions .. | 0055 | 15.47 | \$750.10 | \$355.34 | \$150.02 |
| 28110 | T | Part removal of metatarsal | 0057 | 21.00 | \$1,018.23 | \$496.65 | \$203.65 |
| 28111 | T | Part removal of metatarsal | 0055 | 15.47 | \$750.10 | \$355.34 | \$150.02 |
| 28112 | T | Part removal of metatarsal | 0055 | 15.47 | \$750.10 | \$355.34 | \$150.02 |
| 28113 | T | Part removal of metatarsal | 0055 | 15.47 | \$750.10 | \$355.34 | \$150.02 |
| 28114 | T | Removal of metatarsal heads | 0055 | 15.47 | \$750.10 | \$355.34 | \$150.02 |
| 28116 | T | Revision of foot | 0055 | 15.47 | \$750.10 | \$355.34 | \$150.02 |
| 28118 | T | Removal of heel bone | 0055 | 15.47 | \$750.10 | \$355.34 | \$150.02 |
| 28119 | T | Removal of heel spur | 0055 | 15.47 | \$750.10 | \$355.34 | \$150.02 |
| 28120 | T | Part removal of ankle/heel | 0055 | 15.47 | \$750.10 | \$355.34 | \$150.02 |
| 28122 | T | Partial removal of foot bone | 0055 | 15.47 | \$750.10 | \$355.34 | \$150.02 |
| 28124 | T | Partial removal of toe | 0055 | 15.47 | \$750.10 | \$355.34 | \$150.02 |
| 28126 | T | Partial removal of toe | 0055 | 15.47 | \$750.10 | \$355.34 | \$150.02 |
| 28130 | T | Removal of ankle bone | 0055 | 15.47 | \$750.10 | \$355.34 | \$150.02 |
| 28140 | T | Removal of metatarsal | 0055 | 15.47 | \$750.10 | \$355.34 | \$150.02 |
| 28150 | T | Removal of toe | 0055 | 15.47 | \$750.10 | \$355.34 | \$150.02 |
| 28153 | T | Partial removal of toe | 0055 | 15.47 | \$750.10 | \$355.34 | \$150.02 |
| 28160 | T | Partial removal of toe | 0055 | 15.47 | \$750.10 | \$355.34 | \$150.02 |
| 28171 | T | Extensive foot surgery | 0055 | 15.47 | \$750.10 | \$355.34 | \$150.02 |
| 28173 | T | Extensive foot surgery | 0055 | 15.47 | \$750.10 | \$355.34 | \$150.02 |
| 28175 | T | Extensive foot surgery | 0055 | 15.47 | \$750.10 | \$355.34 | \$150.02 |
| 28190 | T | Removal of foot foreign body | 0019 | 4.00 | \$193.95 | \$78.91 | \$38.79 |
| 28192 | T | Removal of foot foreign body | 0021 | 10.49 | \$508.63 | \$236.51 | \$101.73 |
| 28193 | T | Removal of foot foreign body | 0020 | 6.51 | \$315.65 | \$130.53 | \$63.13 |
| 28200 | T | Repair of foot tendon ............ | 0055 | 15.47 | \$750.10 | \$355.34 | \$150.02 |
| 28202 | T | Repair/graft of foot tendon | 0056 | 17.30 | \$838.83 | \$405.81 | \$167.77 |
| 28208 | T | Repair of foot tendon | 0055 | 15.47 | \$750.10 | \$355.34 | \$150.02 |
| 28210 | T | Repair/graft of foot tendon | 0055 | 15.47 | \$750.10 | \$355.34 | \$150.02 |
| 28220 | T | Release of foot tendon | 0055 | 15.47 | \$750.10 | \$355.34 | \$150.02 |
| 28222 | T | Release of foot tendons | 0055 | 15.47 | \$750.10 | \$355.34 | \$150.02 |
| 28225 | T | Release of foot tendon | 0055 | 15.47 | \$750.10 | \$355.34 | \$150.02 |
| 28226 | T | Release of foot tendons | 0055 | 15.47 | \$750.10 | \$355.34 | \$150.02 |
| 28230 | T | Incision of foot tendon(s) | 0055 | 15.47 | \$750.10 | \$355.34 | \$150.02 |
| 28232 | T | Incision of toe tendon ... | 0055 | 15.47 | \$750.10 | \$355.34 | \$150.02 |
| 28234 | T | Incision of foot tendon | 0055 | 15.47 | \$750.10 | \$355.34 | \$150.02 |
| 28238 | T | Revision of foot tendon | 0056 | 17.30 | \$838.83 | \$405.81 | \$167.77 |
| 28240 | T | Release of big toe ...... | 0055 | 15.47 | \$750.10 | \$355.34 | \$150.02 |
| 28250 | T | Revision of foot fascia | 0056 | 17.30 | \$838.83 | \$405.81 | \$167.77 |
| 28260 | T | Release of midfoot joint | 0056 | 17.30 | \$838.83 | \$405.81 | \$167.77 |
| 28261 | T | Revision of foot tendon | 0056 | 17.30 | \$838.83 | \$405.81 | \$167.77 |
| 28262 | T | Revision of foot and ankle | 0056 | 17.30 | \$838.83 | \$405.81 | \$167.77 |
| 28264 | T | Release of midfoot joint | 0056 | 17.30 | \$838.83 | \$405.81 | \$167.77 |
| 28270 | T | Release of foot contracture | 0055 | 15.47 | \$750.10 | \$355.34 | \$150.02 |
| 28272 | T | Release of toe joint, each ....... | 0055 | 15.47 | \$750.10 | \$355.34 | \$150.02 |
| 28280 | T | Fusion of toes ................. | 0055 | 15.47 | \$750.10 | \$355.34 | \$150.02 |
| 28285 | T | Repair of hammertoe | 0055 | 15.47 | \$750.10 | \$355.34 | \$150.02 |
| 28286 | T | Repair of hammertoe | 0055 | 15.47 | \$750.10 | \$355.34 | \$150.02 |
| 28288 | T | Partial removal of foot bone | 0056 | 17.30 | \$838.83 | \$405.81 | \$167.77 |
| 28289 | T | Repair hallux rigidus | 0056 | 17.30 | \$838.83 | \$405.81 | \$167.77 |
| 28290 | T | Correction of bunion | 0057 | 21.00 | \$1,018.23 | \$496.65 | \$203.65 |
| 28292 | T | Correction of bunion | 0057 | 21.00 | \$1,018.23 | \$496.65 | \$203.65 |
| 28293 | T | Correction of bunion | 0057 | 21.00 | \$1,018.23 | \$496.65 | \$203.65 |
| 28294 | T | Correction of bunion | 0057 | 21.00 | \$1,018.23 | \$496.65 | \$203.65 |
| 28296 | T | Correction of bunion | 0057 | 21.00 | \$1,018.23 | \$496.65 | \$203.65 |
| 28297 | T | Correction of bunion | 0057 | 21.00 | \$1,018.23 | \$496.65 | \$203.65 |
| 28298 | T | Correction of bunion | 0057 | 21.00 | \$1,018.23 | \$496.65 | \$203.65 |
| 28299 | T | Correction of bunion | 0057 | 21.00 | \$1,018.23 | \$496.65 | \$203.65 |
| 28300 | T | Incision of heel bone | 0056 | 17.30 | \$838.83 | \$405.81 | \$167.77 |
| 28302 | T | Incision of ankle bone | 0056 | 17.30 | \$838.83 | \$405.81 | \$167.77 |
| 28304 | T | Incision of midfoot bones | 0056 | 17.30 | \$838.83 | \$405.81 | \$167.77 |
| 28305 | T | Incise/graft midfoot bones ..................................... | 0056 | 17.30 | \$838.83 | \$405.81 | \$167.77 |
| 28306 | T | Incision of metatarsal ............................................ | 0056 | 17.30 | \$838.83 | \$405.81 | \$167.77 |
| 28307 | T | Incision of metatarsal | 0056 | 17.30 | \$838.83 | \$405.81 | \$167.77 |
| 28308 | T | Incision of metatarsal ............................................. | 0056 | 17.30 | \$838.83 | \$405.81 | \$167.77 |
| 28309 | T | Incision of metatarsals .......................................... | 0056 | 17.30 | \$838.83 | \$405.81 | \$167.77 |
| 28310 | T | Revision of big toe ................................................. | 0055 | 15.47 | \$750.10 | \$355.34 | \$150.02 |
| 28312 | T | Revision of toe ..................................................... | 0055 | 15.47 | \$750.10 | \$355.34 | \$150.02 |

[^155]
# Addendum B.-Hospital Outpatient Department (HOPD) Payment Status by HCPCS Code and Related INFORMATION-Continued 

| $\begin{aligned} & \text { CPT/ } \\ & \text { HCPCS } \end{aligned}$ | HOPD Status Indicator | Description | APC | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 28313 | T | Repair deformity of toe | 0055 | 15.47 | \$750.10 | \$355.34 | \$150.02 |
| 28315 | T | Removal of sesamoid bone | 0055 | 15.47 | \$750.10 | \$355.34 | \$150.02 |
| 28320 | T | Repair of foot bones | 0056 | 17.30 | \$838.83 | \$405.81 | \$167.77 |
| 28322 | T | Repair of metatarsals | 0056 | 17.30 | \$838.83 | \$405.81 | \$167.77 |
| 28340 | T | Resect enlarged toe tissue | 0055 | 15.47 | \$750.10 | \$355.34 | \$150.02 |
| 28341 | T | Resect enlarged toe | 0055 | 15.47 | \$750.10 | \$355.34 | \$150.02 |
| 28344 | T | Repair extra toe(s). | 0056 | 17.30 | \$838.83 | \$405.81 | \$167.77 |
| 28345 | T | Repair webbed toe(s) | 0056 | 17.30 | \$838.83 | \$405.81 | \$167.77 |
| 28360 | T | Reconstruct cleft foot | 0056 | 17.30 | \$838.83 | \$405.81 | \$167.77 |
| 28400 | T | Treatment of heel fracture | 0044 | 2.17 | \$105.22 | \$38.08 | \$21.04 |
| 28405 | T | Treatment of heel fracture | 0044 | 2.17 | \$105.22 | \$38.08 | \$21.04 |
| 28406 | T | Treatment of heel fracture | 0046 | 22.29 | \$1,080.78 | \$535.76 | \$216.16 |
| 28415 | T | Treat heel fracture | 0046 | 22.29 | \$1,080.78 | \$535.76 | \$216.16 |
| 28420 | T | Treat/graft heel fracture | 0046 | 22.29 | \$1,080.78 | \$535.76 | \$216.16 |
| 28430 | T | Treatment of ankle fracture | 0044 | 2.17 | \$105.22 | \$38.08 | \$21.04 |
| 28435 | T | Treatment of ankle fracture | 0044 | 2.17 | \$105.22 | \$38.08 | \$21.04 |
| 28436 | T | Treatment of ankle fracture | 0046 | 22.29 | \$1,080.78 | \$535.76 | \$216.16 |
| 28445 | T | Treat ankle fracture | 0046 | 22.29 | \$1,080.78 | \$535.76 | \$216.16 |
| 28450 | T | Treat midfoot fracture, each | 0044 | 2.17 | \$105.22 | \$38.08 | \$21.04 |
| 28455 | T | Treat midfoot fracture, each | 0044 | 2.17 | \$105.22 | \$38.08 | \$21.04 |
| 28456 | T | Treat midfoot fracture .. | 0046 | 22.29 | \$1,080.78 | \$535.76 | \$216.16 |
| 28465 | T | Treat midfoot fracture, each | 0046 | 22.29 | \$1,080.78 | \$535.76 | \$216.16 |
| 28470 | T | Treat metatarsal fracture | 0044 | 2.17 | \$105.22 | \$38.08 | \$21.04 |
| 28475 | T | Treat metatarsal fracture | 0044 | 2.17 | \$105.22 | \$38.08 | \$21.04 |
| 28476 | T | Treat metatarsal fracture | 0046 | 22.29 | \$1,080.78 | \$535.76 | \$216.16 |
| 28485 | T | Treat metatarsal fracture | 0046 | 22.29 | \$1,080.78 | \$535.76 | \$216.16 |
| 28490 | T | Treat big toe fracture | 0043 | 1.64 | \$79.52 | \$25.46 | \$15.90 |
| 28495 | T | Treat big toe fracture | 0043 | 1.64 | \$79.52 | \$25.46 | \$15.90 |
| 28496 | T | Treat big toe fracture | 0046 | 22.29 | \$1,080.78 | \$535.76 | \$216.16 |
| 28505 | T | Treat big toe fracture | 0046 | 22.29 | \$1,080.78 | \$535.76 | \$216.16 |
| 28510 | T | Treatment of toe fracture | 0043 | 1.64 | \$79.52 | \$25.46 | \$15.90 |
| 28515 | T | Treatment of toe fracture | 0043 | 1.64 | \$79.52 | \$25.46 | \$15.90 |
| 28525 | T | Treat toe fracture | 0046 | 22.29 | \$1,080.78 | \$535.76 | \$216.16 |
| 28530 | T | Treat sesamoid bone fracture | 0044 | 2.17 | \$105.22 | \$38.08 | \$21.04 |
| 28531 | T | Treat sesamoid bone fracture | 0046 | 22.29 | \$1,080.78 | \$535.76 | \$216.16 |
| 28540 | T | Treat foot dislocation | 0044 | 2.17 | \$105.22 | \$38.08 | \$21.04 |
| 28545 | T | Treat foot dislocation | 0045 | 11.02 | \$534.33 | \$277.12 | \$106.87 |
| 28546 | T | Treat foot dislocation | 0046 | 22.29 | \$1,080.78 | \$535.76 | \$216.16 |
| 28555 | T | Repair foot dislocation | 0046 | 22.29 | \$1,080.78 | \$535.76 | \$216.16 |
| 28570 | T | Treat foot dislocation | 0044 | 2.17 | \$105.22 | \$38.08 | \$21.04 |
| 28575 | T | Treat foot dislocation | 0045 | 11.02 | \$534.33 | \$277.12 | \$106.87 |
| 28576 | T | Treat foot dislocation | 0046 | 22.29 | \$1,080.78 | \$535.76 | \$216.16 |
| 28585 | T | Repair foot dislocation | 0046 | 22.29 | \$1,080.78 | \$535.76 | \$216.16 |
| 28600 | T | Treat foot dislocation | 0044 | 2.17 | \$105.22 | \$38.08 | \$21.04 |
| 28605 | T | Treat foot dislocation | 0045 | 11.02 | \$534.33 | \$277.12 | \$106.87 |
| 28606 | T | Treat foot dislocation | 0046 | 22.29 | \$1,080.78 | \$535.76 | \$216.16 |
| 28615 | T | Repair foot dislocation | 0046 | 22.29 | \$1,080.78 | \$535.76 | \$216.16 |
| 28630 | T | Treat toe dislocation .. | 0043 | 1.64 | \$79.52 | \$25.46 | \$15.90 |
| 28635 | T | Treat toe dislocation | 0045 | 11.02 | \$534.33 | \$277.12 | \$106.87 |
| 28636 | T | Treat toe dislocation | 0046 | 22.29 | \$1,080.78 | \$535.76 | \$216.16 |
| 28645 | T | Repair toe dislocation | 0046 | 22.29 | \$1,080.78 | \$535.76 | \$216.16 |
| 28660 | T | Treat toe dislocation | 0043 | 1.64 | \$79.52 | \$25.46 | \$15.90 |
| 28665 | T | Treat toe dislocation | 0045 | 11.02 | \$534.33 | \$277.12 | \$106.87 |
| 28666 | T | Treat toe dislocation ............................................. | 0046 | 22.29 | \$1,080.78 | \$535.76 | \$216.16 |
| 28675 | T | Repair of toe dislocation | 0046 | 22.29 | \$1,080.78 | \$535.76 | \$216.16 |
| 28705 | T | Fusion of foot bones | 0056 | 17.30 | \$838.83 | \$405.81 | \$167.77 |
| 28715 | T | Fusion of foot bones | 0056 | 17.30 | \$838.83 | \$405.81 | \$167.77 |
| 28725 | T | Fusion of foot bones | 0056 | 17.30 | \$838.83 | \$405.81 | \$167.77 |
| 28730 | T | Fusion of foot bones | 0056 | 17.30 | \$838.83 | \$405.81 | \$167.77 |
| 28735 | T | Fusion of foot bones | 0056 | 17.30 | \$838.83 | \$405.81 | \$167.77 |
| 28737 | T | Revision of foot bones | 0055 | 15.47 | \$750.10 | \$355.34 | \$150.02 |
| 28740 | T | Fusion of foot bones | 0056 | 17.30 | \$838.83 | \$405.81 | \$167.77 |
| 28750 | T | Fusion of big toe joint ............................................ | 0055 | 15.47 | \$750.10 | \$355.34 | \$150.02 |
| 28755 | T | Fusion of big toe joint ........ | 0055 | 15.47 | \$750.10 | \$355.34 | \$150.02 |
| 28760 | T | Fusion of big toe joint | 0056 | 17.30 | \$838.83 | \$405.81 | \$167.77 |
| 28800 | C | Amputation of midfoot |  |  |  |  |  |
| 28805 | C | Amputation thru metatarsal ........ |  |  |  |  |  |
| 28810 | T | Amputation toe \& metatarsal ................................... | 0055 | 15.47 | \$750.10 | \$355.34 | \$150.02 |
| 28820 | T | Amputation of toe ................................................. | 0055 | 15.47 | \$750.10 | \$355.34 | \$150.02 |
| 28825 | T | Partial amputation of toe ....................................... | 0055 | 15.47 | \$750.10 | \$355.34 | \$150.02 |
| 28899 | T | Foot/toes surgery procedure | 0043 | 1.64 | \$79.52 | \$25.46 | \$15.90 |
| 29000 | S | Application of body cast | 0059 | 1.74 | \$84.37 | \$29.59 | \$16.87 |
| 29010 | S | Application of body cast ...................................... | 0059 | 1.74 | \$84.37 | \$29.59 | \$16.87 |

[^156]
## Addendum B.-Hospital Outpatient Department (HOPD) Payment Status by hCPCS Code and Related Information-Continued

| CPT/ HCPCS | HOPD Status Indicator | Description | APC | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 29015 | S | Application of body cast | 0059 | 1.74 | \$84.37 | \$29.59 | \$16.87 |
| 29020 | S | Application of body cast | 0059 | 1.74 | \$84.37 | \$29.59 | \$16.87 |
| 29025 | S | Application of body cast | 0059 | 1.74 | \$84.37 | \$29.59 | \$16.87 |
| 29035 | S | Application of body cast | 0059 | 1.74 | \$84.37 | \$29.59 | \$16.87 |
| 29040 | S | Application of body cast | 0059 | 1.74 | \$84.37 | \$29.59 | \$16.87 |
| 29044 | S | Application of body cast | 0059 | 1.74 | \$84.37 | \$29.59 | \$16.87 |
| 29046 | S | Application of body cast ........................................ | 0059 | 1.74 | \$84.37 | \$29.59 | \$16.87 |
| 29049 | S | Application of figure eight ....................................... | 0059 | 1.74 | \$84.37 | \$29.59 | \$16.87 |
| 29055 | S | Application of shoulder cast | 0059 | 1.74 | \$84.37 | \$29.59 | \$16.87 |
| 29058 | S | Application of shoulder cast | 0059 | 1.74 | \$84.37 | \$29.59 | \$16.87 |
| 29065 | S | Application of long arm cast | 0059 | 1.74 | \$84.37 | \$29.59 | \$16.87 |
| 29075 | S | Application of forearm cast ..................................... | 0059 | 1.74 | \$84.37 | \$29.59 | \$16.87 |
| 29085 | S | Apply hand/wrist cast | 0059 | 1.74 | \$84.37 | \$29.59 | \$16.87 |
| 29105 | S | Apply long arm splint | 0059 | 1.74 | \$84.37 | \$29.59 | \$16.87 |
| 29125 | S | Apply forearm splint . | 0059 | 1.74 | \$84.37 | \$29.59 | \$16.87 |
| 29126 | S | Apply forearm splint | 0059 | 1.74 | \$84.37 | \$29.59 | \$16.87 |
| 29130 | S | Application of finger splint | 0059 | 1.74 | \$84.37 | \$29.59 | \$16.87 |
| 29131 | S | Application of finger splint | 0059 | 1.74 | \$84.37 | \$29.59 | \$16.87 |
| 29200 | S | Strapping of chest ........... | 0059 | 1.74 | \$84.37 | \$29.59 | \$16.87 |
| 29220 | S | Strapping of low back | 0059 | 1.74 | \$84.37 | \$29.59 | \$16.87 |
| 29240 | S | Strapping of shoulder | 0059 | 1.74 | \$84.37 | \$29.59 | \$16.87 |
| 29260 | S | Strapping of elbow or wrist | 0059 | 1.74 | \$84.37 | \$29.59 | \$16.87 |
| 29280 | S | Strapping of hand or finger | 0059 | 1.74 | \$84.37 | \$29.59 | \$16.87 |
| 29305 | S | Application of hip cast | 0059 | 1.74 | \$84.37 | \$29.59 | \$16.87 |
| 29325 | S | Application of hip casts | 0059 | 1.74 | \$84.37 | \$29.59 | \$16.87 |
| 29345 | S | Application of long leg cast | 0059 | 1.74 | \$84.37 | \$29.59 | \$16.87 |
| 29355 | S | Application of long leg cast | 0059 | 1.74 | \$84.37 | \$29.59 | \$16.87 |
| 29358 | S | Apply long leg cast brace | 0059 | 1.74 | \$84.37 | \$29.59 | \$16.87 |
| 29365 | S | Application of long leg cast | 0059 | 1.74 | \$84.37 | \$29.59 | \$16.87 |
| 29405 | S | Apply short leg cast | 0059 | 1.74 | \$84.37 | \$29.59 | \$16.87 |
| 29425 | S | Apply short leg cast | 0059 | 1.74 | \$84.37 | \$29.59 | \$16.87 |
| 29435 | S | Apply short leg cast | 0059 | 1.74 | \$84.37 | \$29.59 | \$16.87 |
| 29440 | S | Addition of walker to cast | 0059 | 1.74 | \$84.37 | \$29.59 | \$16.87 |
| 29445 | S | Apply rigid leg cast | 0059 | 1.74 | \$84.37 | \$29.59 | \$16.87 |
| 29450 | S | Application of leg cast | 0059 | 1.74 | \$84.37 | \$29.59 | \$16.87 |
| 29505 | S | Application, long leg splint | 0058 | 1.09 | \$52.85 | \$19.27 | \$10.57 |
| 29515 | S | Application lower leg splint | 0058 | 1.09 | \$52.85 | \$19.27 | \$10.57 |
| 29520 | S | Strapping of hip ... | 0058 | 1.09 | \$52.85 | \$19.27 | \$10.57 |
| 29530 | S | Strapping of knee | 0058 | 1.09 | \$52.85 | \$19.27 | \$10.57 |
| 29540 | S | Strapping of ankle | 0058 | 1.09 | \$52.85 | \$19.27 | \$10.57 |
| 29550 | S | Strapping of toes | 0058 | 1.09 | \$52.85 | \$19.27 | \$10.57 |
| 29580 | S | Application of paste boot | 0058 | 1.09 | \$52.85 | \$19.27 | \$10.57 |
| 29590 | S | Application of foot splint | 0058 | 1.09 | \$52.85 | \$19.27 | \$10.57 |
| 29700 | S | Removal/revision of cast | 0058 | 1.09 | \$52.85 | \$19.27 | \$10.57 |
| 29705 | S | Removal/revision of cast | 0058 | 1.09 | \$52.85 | \$19.27 | \$10.57 |
| 29710 | S | Removal/revision of cast | 0058 | 1.09 | \$52.85 | \$19.27 | \$10.57 |
| 29715 | S | Removal/revision of cast | 0058 | 1.09 | \$52.85 | \$19.27 | \$10.57 |
| 29720 | S | Repair of body cast | 0058 | 1.09 | \$52.85 | \$19.27 | \$10.57 |
| 29730 | S | Windowing of cast ....... | 0058 | 1.09 | \$52.85 | \$19.27 | \$10.57 |
| 29740 | S | Wedging of cast | 0058 | 1.09 | \$52.85 | \$19.27 | \$10.57 |
| 29750 | S | Wedging of clubfoot cast | 0058 | 1.09 | \$52.85 | \$19.27 | \$10.57 |
| 29799 | S | Casting/strapping procedure | 0058 | 1.09 | \$52.85 | \$19.27 | \$10.57 |
| 29800 | T | Jaw arthroscopy/surgery | 0041 | 24.57 | \$1,191.33 | \$592.08 | \$238.27 |
| 29804 | T | Jaw arthroscopy/surgery | 0041 | 24.57 | \$1,191.33 | \$592.08 | \$238.27 |
| 29815 | T | Shoulder arthroscopy ............................................ | 0041 | 24.57 | \$1,191.33 | \$592.08 | \$238.27 |
| 29819 | T | Shoulder arthroscopy/surgery | 0041 | 24.57 | \$1,191.33 | \$592.08 | \$238.27 |
| 29820 | T | Shoulder arthroscopy/surgery | 0041 | 24.57 | \$1,191.33 | \$592.08 | \$238.27 |
| 29821 | T | Shoulder arthroscopy/surgery ................................. | 0041 | 24.57 | \$1,191.33 | \$592.08 | \$238.27 |
| 29822 | T | Shoulder arthroscopy/surgery | 0041 | 24.57 | \$1,191.33 | \$592.08 | \$238.27 |
| 29823 | T | Shoulder arthroscopy/surgery | 0041 | 24.57 | \$1,191.33 | \$592.08 | \$238.27 |
| 29825 | T | Shoulder arthroscopy/surgery ................................ | 0041 | 24.57 | \$1,191.33 | \$592.08 | \$238.27 |
| 29826 | T | Shoulder arthroscopy/surgery ................................. | 0041 | 24.57 | \$1,191.33 | \$592.08 | \$238.27 |
| 29830 | T | Elbow arthroscopy | 0041 | 24.57 | \$1,191.33 | \$592.08 | \$238.27 |
| 29834 | T | Elbow arthroscopy/surgery ..................................... | 0041 | 24.57 | \$1,191.33 | \$592.08 | \$238.27 |
| 29835 | T | Elbow arthroscopy/surgery ..................................... | 0041 | 24.57 | \$1,191.33 | \$592.08 | \$238.27 |
| 29836 | T | Elbow arthroscopy/surgery ..................................... | 0041 | 24.57 | \$1,191.33 | \$592.08 | \$238.27 |
| 29837 | T | Elbow arthroscopy/surgery ..................................... | 0041 | 24.57 | \$1,191.33 | \$592.08 | \$238.27 |
| 29838 | T | Elbow arthroscopy/surgery ..................................... | 0041 | 24.57 | \$1,191.33 | \$592.08 | \$238.27 |
| 29840 | T | Wrist arthroscopy ................................................. | 0041 | 24.57 | \$1,191.33 | \$592.08 | \$238.27 |
| 29843 | T | Wrist arthroscopy/surgery | 0041 | 24.57 | \$1,191.33 | \$592.08 | \$238.27 |
| 29844 | T | Wrist arthroscopy/surgery ...................................... | 0041 | 24.57 | \$1,191.33 | \$592.08 | \$238.27 |
| 29845 | T | Wrist arthroscopy/surgery ....................................... | 0041 | 24.57 | \$1,191.33 | \$592.08 | \$238.27 |
| 29846 | T | Wrist arthroscopy/surgery | 0041 | 24.57 | \$1,191.33 | \$592.08 | \$238.27 |

[^157]
# Addendum B.-Hospital Outpatient Department (HOPD) Payment Status by HCPCS Code and Related Information-Continued 

| $\begin{gathered} \text { CPT/ } \\ \text { HCPCS } \end{gathered}$ | HOPD Status Indicator | Description | APC | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 29847 | T | Wrist arthroscopy/surgery | 0041 | 24.57 | \$1,191.33 | \$592.08 | \$238.27 |
| 29848 | T | Wrist endoscopy/surgery ....................................... | 0041 | 24.57 | \$1,191.33 | \$592.08 | \$238.27 |
| 29850 | T | Knee arthroscopy/surgery | 0042 | 29.22 | \$1,416.79 | \$804.74 | \$283.36 |
| 29851 | T | Knee arthroscopy/surgery | 0042 | 29.22 | \$1,416.79 | \$804.74 | \$283.36 |
| 29855 | T | Tibial arthroscopy/surgery | 0042 | 29.22 | \$1,416.79 | \$804.74 | \$283.36 |
| 29856 | T | Tibial arthroscopy/surgery | 0042 | 29.22 | \$1,416.79 | \$804.74 | \$283.36 |
| 29860 | T | Hip arthroscopy, dx ......... | 0041 | 24.57 | \$1,191.33 | \$592.08 | \$238.27 |
| 29861 | T | Hip arthroscopy/surgery | 0041 | 24.57 | \$1,191.33 | \$592.08 | \$238.27 |
| 29862 | T | Hip arthroscopy/surgery | 0041 | 24.57 | \$1,191.33 | \$592.08 | \$238.27 |
| 29863 | T | Hip arthroscopy/surgery | 0041 | 24.57 | \$1,191.33 | \$592.08 | \$238.27 |
| 29870 | T | Knee arthroscopy, dx | 0041 | 24.57 | \$1,191.33 | \$592.08 | \$238.27 |
| 29871 | T | Knee arthroscopy/drainage | 0041 | 24.57 | \$1,191.33 | \$592.08 | \$238.27 |
| 29874 | T | Knee arthroscopy/surgery . | 0041 | 24.57 | \$1,191.33 | \$592.08 | \$238.27 |
| 29875 | T | Knee arthroscopy/surgery | 0041 | 24.57 | \$1,191.33 | \$592.08 | \$238.27 |
| 29876 | T | Knee arthroscopy/surgery | 0041 | 24.57 | \$1,191.33 | \$592.08 | \$238.27 |
| 29877 | T | Knee arthroscopy/surgery | 0041 | 24.57 | \$1,191.33 | \$592.08 | \$238.27 |
| 29879 | T | Knee arthroscopy/surgery | 0041 | 24.57 | \$1,191.33 | \$592.08 | \$238.27 |
| 29880 | T | Knee arthroscopy/surgery | 0041 | 24.57 | \$1,191.33 | \$592.08 | \$238.27 |
| 29881 | T | Knee arthroscopy/surgery ...................................... | 0041 | 24.57 | \$1,191.33 | \$592.08 | \$238.27 |
| 29882 | T | Knee arthroscopy/surgery | 0041 | 24.57 | \$1,191.33 | \$592.08 | \$238.27 |
| 29883 | T | Knee arthroscopy/surgery | 0041 | 24.57 | \$1,191.33 | \$592.08 | \$238.27 |
| 29884 | T | Knee arthroscopy/surgery | 0041 | 24.57 | \$1,191.33 | \$592.08 | \$238.27 |
| 29885 | T | Knee arthroscopy/surgery | 0042 | 29.22 | \$1,416.79 | \$804.74 | \$283.36 |
| 29886 | T | Knee arthroscopy/surgery | 0041 | 24.57 | \$1,191.33 | \$592.08 | \$238.27 |
| 29887 | T | Knee arthroscopy/surgery | 0041 | 24.57 | \$1,191.33 | \$592.08 | \$238.27 |
| 29888 | T | Knee arthroscopy/surgery | 0042 | 29.22 | \$1,416.79 | \$804.74 | \$283.36 |
| 29889 | T | Knee arthroscopy/surgery | 0042 | 29.22 | \$1,416.79 | \$804.74 | \$283.36 |
| 29891 | T | Ankle arthroscopy/surgery | 0041 | 24.57 | \$1,191.33 | \$592.08 | \$238.27 |
| 29892 | T | Ankle arthroscopy/surgery | 0042 | 29.22 | \$1,416.79 | \$804.74 | \$283.36 |
| 29893 | T | Scope, plantar fasciotomy | 0055 | 15.47 | \$750.10 | \$355.34 | \$150.02 |
| 29894 | T | Ankle arthroscopy/surgery | 0041 | 24.57 | \$1,191.33 | \$592.08 | \$238.27 |
| 29895 | T | Ankle arthroscopy/surgery | 0041 | 24.57 | \$1,191.33 | \$592.08 | \$238.27 |
| 29897 | T | Ankle arthroscopy/surgery | 0041 | 24.57 | \$1,191.33 | \$592.08 | \$238.27 |
| 29898 | T | Ankle arthroscopy/surgery | 0041 | 24.57 | \$1,191.33 | \$592.08 | \$238.27 |
| 29909 | T | Arthroscopy of joint | 0041 | 24.57 | \$1,191.33 | \$592.08 | \$238.27 |
| 30000 | T | Drainage of nose lesion | 0251 | 1.68 | \$81.46 | \$27.99 | \$16.29 |
| 30020 | T | Drainage of nose lesion | 0251 | 1.68 | \$81.46 | \$27.99 | \$16.29 |
| 30100 | T | Intranasal biopsy | 0252 | 5.18 | \$251.16 | \$114.24 | \$50.23 |
| 30110 | T | Removal of nose polyp(s) | 0253 | 12.02 | \$582.81 | \$284.00 | \$116.56 |
| 30115 | T | Removal of nose polyp(s) | 0253 | 12.02 | \$582.81 | \$284.00 | \$116.56 |
| 30117 | T | Removal of intranasal lesion | 0253 | 12.02 | \$582.81 | \$284.00 | \$116.56 |
| 30118 | T | Removal of intranasal lesion | 0254 | 12.45 | \$603.66 | \$272.41 | \$120.73 |
| 30120 | T | Revision of nose | 0253 | 12.02 | \$582.81 | \$284.00 | \$116.56 |
| 30124 | T | Removal of nose lesion | 0252 | 5.18 | \$251.16 | \$114.24 | \$50.23 |
| 30125 | T | Removal of nose lesion | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 30130 | T | Removal of turbinate bones | 0253 | 12.02 | \$582.81 | \$284.00 | \$116.56 |
| 30140 | T | Removal of turbinate bones | 0253 | 12.02 | \$582.81 | \$284.00 | \$116.56 |
| 30150 | T | Partial removal of nose | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 30160 | T | Removal of nose | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 30200 | T | Injection treatment of nose | 0253 | 12.02 | \$582.81 | \$284.00 | \$116.56 |
| 30210 | T | Nasal sinus therapy | 0252 | 5.18 | \$251.16 | \$114.24 | \$50.23 |
| 30220 | T | Insert nasal septal button | 0252 | 5.18 | \$251.16 | \$114.24 | \$50.23 |
| 30300 | T | Remove nasal foreign body | 0251 | 1.68 | \$81.46 | \$27.99 | \$16.29 |
| 30310 | T | Remove nasal foreign body | 0253 | 12.02 | \$582.81 | \$284.00 | \$116.56 |
| 30320 | T | Remove nasal foreign body .................................... | 0253 | 12.02 | \$582.81 | \$284.00 | \$116.56 |
| 30400 | T | Reconstruction of nose | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 30410 | T | Reconstruction of nose | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 30420 | T | Reconstruction of nose | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 30430 | T | Revision of nose | 0254 | 12.45 | \$603.66 | \$272.41 | \$120.73 |
| 30435 | T | Revision of nose | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 30450 | T | Revision of nose | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 30460 | T | Revision of nose | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 30462 | T | Revision of nose | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 30520 | T | Repair of nasal septum ......................................... | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 30540 | T | Repair nasal defect .............................................. | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 30545 | T | Repair nasal defect .............................................. | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 30560 | T | Release of nasal adhesions | 0251 | 1.68 | \$81.46 | \$27.99 | \$16.29 |
| 30580 | T | Repair upper jaw fistula ......................................... | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 30600 | T | Repair mouth/nose fistula ....................................... | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 30620 | T | Intranasal reconstruction ....................................... | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 30630 | T | Repair nasal septum defect .................................... | 0254 | 12.45 | \$603.66 | \$272.41 | \$120.73 |
| 30801 | T | Cauterization, inner nose ....................................... | 0252 | 5.18 | \$251.16 | \$114.24 | \$50.23 |
| 30802 | T | Cauterization, inner nose ....................................... | 0253 | 12.02 | \$582.81 | \$284.00 | \$116.56 |

[^158]
## Addendum B.—Hospital Outpatient Department (HOPD) Payment Status by hCPCS Code and Related Information-Continued

| CPT/ HCPCS | HOPD Status Indicator | Description | APC | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 30901 | T | Control of nosebleed | 0250 | 2.21 | \$107.16 | \$38.54 | \$21.43 |
| 30903 | T | Control of nosebleed | 0250 | 2.21 | \$107.16 | \$38.54 | \$21.43 |
| 30905 | T | Control of nosebleed | 0250 | 2.21 | \$107.16 | \$38.54 | \$21.43 |
| 30906 | T | Repeat control of nosebleed | 0250 | 2.21 | \$107.16 | \$38.54 | \$21.43 |
| 30915 | T | Ligation, nasal sinus artery . | 0091 | 14.79 | \$717.12 | \$348.23 | \$143.42 |
| 30920 | T | Ligation, upper jaw artery | 0092 | 20.21 | $\$ 979.92$ | \$505.37 | \$195.98 |
| 30930 | T | Therapy, fracture of nose | 0253 | 12.02 | \$582.81 | \$284.00 | \$116.56 |
| 30999 | T | Nasal surgery procedure | 0251 | 1.68 | \$81.46 | \$27.99 | \$16.29 |
| 31000 | T | Irrigation, maxillary sinus | 0251 | 1.68 | \$81.46 | \$27.99 | \$16.29 |
| 31002 | T | Irrigation, sphenoid sinus | 0252 | 5.18 | \$251.16 | \$114.24 | \$50.23 |
| 31020 | T | Exploration, maxillary sinus | 0253 | 12.02 | \$582.81 | \$284.00 | \$116.56 |
| 31030 | T | Exploration, maxillary sinus | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 31032 | T | Explore sinus, remove polyps | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 31040 | T | Exploration behind upper jaw | 0254 | 12.45 | \$603.66 | \$272.41 | \$120.73 |
| 31050 | T | Exploration, sphenoid sinus | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 31051 | T | Sphenoid sinus surgery ..... | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 31070 | T | Exploration of frontal sinus | 0254 | 12.45 | \$603.66 | \$272.41 | \$120.73 |
| 31075 | T | Exploration of frontal sinus | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 31080 | T | Removal of frontal sinus ... | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 31081 | T | Removal of frontal sinus | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 31084 | T | Removal of frontal sinus | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 31085 | T | Removal of frontal sinus | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 31086 | T | Removal of frontal sinus | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 31087 | T | Removal of frontal sinus | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 31090 | T | Exploration of sinuses | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 31200 | T | Removal of ethmoid sinus | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 31201 | T | Removal of ethmoid sinus | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 31205 | T | Removal of ethmoid sinus | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 31225 | C | Removal of upper jaw |  |  |  |  |  |
| 31230 | C | Removal of upper jaw |  |  |  |  |  |
| 31231 | T | Nasal endoscopy, dx | 0071 | 0.55 | \$26.67 | \$14.22 | \$5.33 |
| 31233 | T | Nasal/sinus endoscopy, dx | 0072 | 1.26 | \$61.09 | \$41.52 | \$12.22 |
| 31235 | T | Nasal/sinus endoscopy, dx | 0074 | 13.61 | \$659.91 | \$347.54 | \$131.98 |
| 31237 | T | Nasal/sinus endoscopy, surg | 0074 | 13.61 | \$659.91 | \$347.54 | \$131.98 |
| 31238 | T | Nasal/sinus endoscopy, surg | 0074 | 13.61 | \$659.91 | \$347.54 | \$131.98 |
| 31239 | T | Nasal/sinus endoscopy, surg | 0075 | 18.55 | \$899.44 | \$467.29 | \$179.89 |
| 31240 | T | Nasal/sinus endoscopy, surg | 0074 | 13.61 | \$659.91 | \$347.54 | \$131.98 |
| 31254 | T | Revision of ethmoid sinus | 0075 | 18.55 | \$899.44 | \$467.29 | \$179.89 |
| 31255 | T | Removal of ethmoid sinus | 0075 | 18.55 | \$899.44 | \$467.29 | \$179.89 |
| 31256 | T | Exploration maxillary sinus | 0075 | 18.55 | \$899.44 | \$467.29 | \$179.89 |
| 31267 | T | Endoscopy, maxillary sinus | 0075 | 18.55 | \$899.44 | \$467.29 | \$179.89 |
| 31276 | T | Sinus endoscopy, surgical . | 0075 | 18.55 | \$899.44 | \$467.29 | \$179.89 |
| 31287 | T | Nasal/sinus endoscopy, surg | 0075 | 18.55 | \$899.44 | \$467.29 | \$179.89 |
| 31288 | T | Nasal/sinus endoscopy, surg | 0075 | 18.55 | \$899.44 | \$467.29 | \$179.89 |
| 31290 | C | Nasal/sinus endoscopy, surg | ........ | ...................... | ...................... | ...................... | ..................... |
| 31291 | C | Nasal/sinus endoscopy, surg |  | ....... | ......... | .......... |  |
| 31292 | C | Nasal/sinus endoscopy, surg |  |  | .................... | ............ |  |
| 31293 | C | Nasal/sinus endoscopy, surg |  |  |  |  |  |
| 31294 | C | Nasal/sinus endoscopy, surg |  |  |  |  |  |
| 31299 | T | Sinus surgery procedure | 0252 | 5.18 | \$251.16 | \$114.24 | \$50.23 |
| 31300 | T | Removal of larynx lesion | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 31320 | T | Diagnostic incision, larynx . | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 31360 | C | Removal of larynx ......... |  |  |  |  |  |
| 31365 | C | Removal of larynx |  |  |  |  |  |
| 31367 | C | Partial removal of larynx ......................................... | ...... |  | ........... | .................... |  |
| 31368 | C | Partial removal of larynx |  |  |  |  |  |
| 31370 | C | Partial removal of larynx |  |  |  |  |  |
| 31375 | T | Partial removal of larynx ........................................ | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 31380 | C | Partial removal of larynx |  |  |  |  |  |
| 31382 | C | Partial removal of larynx |  |  |  |  |  |
| 31390 | C | Removal of larynx \& pharynx .................................. |  |  |  |  |  |
| 31395 | C | Reconstruct larynx \& pharynx |  |  |  |  |  |
| 31400 | T | Revision of larynx | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 31420 | T | Removal of epiglottis | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 31500 | S | Insert emergency airway ... | 0094 | 4.51 | \$218.68 | \$105.29 | \$43.74 |
| 31502 | T | Change of windpipe airway ... | 0121 | 2.36 | \$114.43 | \$52.53 | \$22.89 |
| 31505 | T | Diagnostic laryngoscopy | 0072 | 1.26 | \$61.09 | \$41.52 | \$12.22 |
| 31510 | T | Laryngoscopy with biopsy ...................................... | 0074 | 13.61 | \$659.91 | \$347.54 | \$131.98 |
| 31511 | T | Remove foreign body, larynx ... | 0072 | 1.26 | \$61.09 | \$41.52 | \$12.22 |
| 31512 | T | Removal of larynx lesion ........................................ | 0074 | 13.61 | \$659.91 | \$347.54 | \$131.98 |
| 31513 | T | Injection into vocal cord ......................................... | 0073 | 4.11 | \$199.28 | \$91.07 | \$39.86 |
| 31515 | T | Laryngoscopy for aspiration ................................... | 0074 | 13.61 | \$659.91 | \$347.54 | \$131.98 |
| 31520 | T | Diagnostic laryngoscopy ........................................ | 0072 | 1.26 | \$61.09 | \$41.52 | \$12.22 |

[^159]
## Addendum B.-Hospital Outpatient Department (HOPD) Payment Status by HCPCS Code and Related INFORMATION-Continued

| $\begin{aligned} & \text { CPT/ } \\ & \text { HCPCS } \end{aligned}$ | HOPD Status Indicator | Description | APC | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 31525 | T | Diagnostic laryngoscopy | 0074 | 13.61 | \$659.91 | \$347.54 | \$131.98 |
| 31526 | T | Diagnostic laryngoscopy | 0074 | 13.61 | \$659.91 | \$347.54 | \$131.98 |
| 31527 | T | Laryngoscopy for treatment | 0075 | 18.55 | \$899.44 | \$467.29 | \$179.89 |
| 31528 | T | Laryngoscopy and dilatation | 0074 | 13.61 | \$659.91 | \$347.54 | \$131.98 |
| 31529 | T | Laryngoscopy and dilatation | 0074 | 13.61 | \$659.91 | \$347.54 | \$131.98 |
| 31530 | T | Operative laryngoscopy ... | 0075 | 18.55 | \$899.44 | \$467.29 | \$179.89 |
| 31531 | T | Operative laryngoscopy | 0075 | 18.55 | \$899.44 | \$467.29 | \$179.89 |
| 31535 | T | Operative laryngoscopy | 0075 | 18.55 | \$899.44 | \$467.29 | \$179.89 |
| 31536 | T | Operative laryngoscopy | 0075 | 18.55 | \$899.44 | \$467.29 | \$179.89 |
| 31540 | T | Operative laryngoscopy | 0075 | 18.55 | \$899.44 | \$467.29 | \$179.89 |
| 31541 | T | Operative laryngoscopy | 0075 | 18.55 | \$899.44 | \$467.29 | \$179.89 |
| 31560 | T | Operative laryngoscopy | 0075 | 18.55 | \$899.44 | \$467.29 | \$179.89 |
| 31561 | T | Operative laryngoscopy | 0075 | 18.55 | \$899.44 | \$467.29 | \$179.89 |
| 31570 | T | Laryngoscopy with injection | 0075 | 18.55 | \$899.44 | \$467.29 | \$179.89 |
| 31571 | T | Laryngoscopy with injection | 0075 | 18.55 | \$899.44 | \$467.29 | \$179.89 |
| 31575 | T | Diagnostic laryngoscopy | 0071 | 0.55 | \$26.67 | \$14.22 | \$5.33 |
| 31576 | T | Laryngoscopy with biopsy | 0074 | 13.61 | \$659.91 | \$347.54 | \$131.98 |
| 31577 | T | Remove foreign body, larynx | 0073 | 4.11 | \$199.28 | \$91.07 | \$39.86 |
| 31578 | T | Removal of larynx lesion | 0074 | 13.61 | \$659.91 | \$347.54 | \$131.98 |
| 31579 | T | Diagnostic laryngoscopy | 0073 | 4.11 | \$199.28 | \$91.07 | \$39.86 |
| 31580 | T | Revision of larynx .. | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 31582 | C | Revision of larynx |  |  |  |  |  |
| 31584 | C | Treat larynx fracture |  |  |  |  |  |
| 31585 | T | Treat larynx fracture | 0253 | 12.02 | \$582.81 | \$284.00 | \$116.56 |
| 31586 | T | Treat larynx fracture | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 31587 | C | Revision of larynx |  |  |  |  |  |
| 31588 | T | Revision of larynx | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 31590 | T | Reinnervate larynx | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 31595 | T | Larynx nerve surgery | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 31599 | T | Larynx surgery procedure | 0253 | 12.02 | \$582.81 | \$284.00 | \$116.56 |
| 31600 | T | Incision of windpipe ......... | 0254 | 12.45 | \$603.66 | \$272.41 | \$120.73 |
| 31601 | T | Incision of windpipe | 0254 | 12.45 | \$603.66 | \$272.41 | \$120.73 |
| 31603 | T | Incision of windpipe | 0254 | 12.45 | \$603.66 | \$272.41 | \$120.73 |
| 31605 | T | Incision of windpipe | 0254 | 12.45 | \$603.66 | \$272.41 | \$120.73 |
| 31610 | T | Incision of windpipe | 0254 | 12.45 | \$603.66 | \$272.41 | \$120.73 |
| 31611 | T | Surgery/speech prosthesis | 0254 | 12.45 | \$603.66 | \$272.41 | \$120.73 |
| 31612 | T | Puncture/clear windpipe | 0253 | 12.02 | \$582.81 | \$284.00 | \$116.56 |
| 31613 | T | Repair windpipe opening | 0254 | 12.45 | \$603.66 | \$272.41 | \$120.73 |
| 31614 | T | Repair windpipe opening | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 31615 | T | Visualization of windpipe | 0076 | 8.06 | \$390.81 | \$197.05 | \$78.16 |
| 31622 | T | Dx bronchoscope/wash | 0076 | 8.06 | \$390.81 | \$197.05 | \$78.16 |
| 31623 | T | Dx bronchoscope/brush | 0076 | 8.06 | \$390.81 | \$197.05 | \$78.16 |
| 31624 | T | Dx bronchoscope/lavage | 0076 | 8.06 | \$390.81 | \$197.05 | \$78.16 |
| 31625 | T | Bronchoscopy with biopsy | 0076 | 8.06 | \$390.81 | \$197.05 | \$78.16 |
| 31628 | T | Bronchoscopy with biopsy | 0076 | 8.06 | \$390.81 | \$197.05 | \$78.16 |
| 31629 | T | Bronchoscopy with biopsy | 0076 | 8.06 | \$390.81 | \$197.05 | \$78.16 |
| 31630 | T | Bronchoscopy with repair ....................................... | 0076 | 8.06 | \$390.81 | \$197.05 | \$78.16 |
| 31631 | T | Bronchoscopy with dilation | 0076 | 8.06 | \$390.81 | \$197.05 | \$78.16 |
| 31635 | T | Remove foreign body, airway .................................. | 0076 | 8.06 | \$390.81 | \$197.05 | \$78.16 |
| 31640 | T | Bronchoscopy \& remove lesion ............................... | 0076 | 8.06 | \$390.81 | \$197.05 | \$78.16 |
| 31641 | T | Bronchoscopy, treat blockage ................................. | 0076 | 8.06 | \$390.81 | \$197.05 | \$78.16 |
| 31643 | T | Diag bronchoscope/catheter | 0076 | 8.06 | \$390.81 | \$197.05 | \$78.16 |
| 31645 | T | Bronchoscopy, clear airways | 0076 | 8.06 | \$390.81 | \$197.05 | \$78.16 |
| 31646 | T | Bronchoscopy, reclear airway ................................. | 0076 | 8.06 | \$390.81 | \$197.05 | \$78.16 |
| 31656 | T | Bronchoscopy, inj for x-ray | 0076 | 8.06 | \$390.81 | \$197.05 | \$78.16 |
| 31700 | T | Insertion of airway catheter | 0072 | 1.26 | \$61.09 | \$41.52 | \$12.22 |
| 31708 | N | Instill airway contrast dye ....................................... | ........ | ..................... | ...................... | ..................... | ..................... |
| 31710 | N | Insertion of airway catheter |  |  |  | - |  |
| 31715 | N | Injection for bronchus x-ray |  |  |  |  |  |
| 31717 | T | Bronchial brush biopsy .......................................... | 0073 | 4.11 | \$199.28 | \$91.07 | \$39.86 |
| 31720 | T | Clearance of airways ........ | 0072 | 1.26 | \$61.09 | \$41.52 | \$12.22 |
| 31725 | C | Clearance of airways |  |  |  |  |  |
| 31730 | T | Intro, windpipe wire/tube ........................................ | 0073 | 4.11 | \$199.28 | \$91.07 | \$39.86 |
| 31750 | T | Repair of windpipe ................................................ | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 31755 | T | Repair of windpipe ................................................ | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 31760 | C | Repair of windpipe .... |  |  |  |  |  |
| 31766 | C | Reconstruction of windpipe .................................... |  |  |  | .................... |  |
| 31770 | C | Repair/graft of bronchus ........................................ |  | .................... |  | ...................... |  |
| 31775 | C | Reconstruct bronchus ............................................ |  |  |  |  |  |
| 31780 | C | Reconstruct windpipe ............................................ |  | ...................... |  | ..................... |  |
| 31781 | C | Reconstruct windpipe ............................................ | ....... | ...................... | ...................... | ..... | ..................... |
| 31785 | C | Remove windpipe lesion ......................................... | .................... | ...................... | ...................... |  |  |
| 31786 | C | Remove windpipe lesion |  |  |  |  |  |

[^160]
# Addendum B.—Hospital Outpatient Department (HOPD) Payment Status by hCPCS Code and Related Information-Continued 

| $\begin{aligned} & \text { CPT/ } \\ & \text { HCPCS } \end{aligned}$ | HOPD Status Indicator | Description | APC | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 31800 | C | Repair of windpipe injury |  |  |  |  |  |
| 31805 | C | Repair of windpipe injury |  |  |  |  |  |
| 31820 | T | Closure of windpipe lesion | 0253 | 12.02 | \$582.81 | \$284.00 | \$116.56 |
| 31825 | T | Repair of windpipe defect | 0254 | 12.45 | \$603.66 | \$272.41 | \$120.73 |
| 31830 | T | Revise windpipe scar | 0254 | 12.45 | \$603.66 | \$272.41 | \$120.73 |
| 31899 | T | Airways surgical procedure | 0076 | 8.06 | \$390.81 | \$197.05 | \$78.16 |
| 32000 | T | Drainage of chest | 0070 | 3.64 | \$176.49 | \$79.60 | \$35.30 |
| 32002 | T | Treatment of collapsed lung | 0070 | 3.64 | \$176.49 | \$79.60 | \$35.30 |
| 32005 | T | Treat lung lining chemically | 0070 | 3.64 | \$176.49 | \$79.60 | \$35.30 |
| 32020 | T | Insertion of chest tube | 0070 | 3.64 | \$176.49 | \$79.60 | \$35.30 |
| 32035 | C | Exploration of chest |  |  |  |  |  |
| 32036 | C | Exploration of chest |  |  |  |  |  |
| 32095 | C | Biopsy through chest wall | .................. | ................... | ................... | ................... |  |
| 32100 | C | Exploration/biopsy of chest .................................... | ................ | ................ | .................... | ................... |  |
| 32110 | C | Explore/repair chest |  |  |  |  |  |
| 32120 | C | Re-exploration of chest ... |  |  |  |  |  |
| 32124 | C | Explore chest free adhesions |  |  |  |  |  |
| 32140 | C | Removal of lung lesion(s) |  |  |  |  |  |
| 32141 | C | Remove/treat lung lesions ...................................... |  | ..................... | ................... | ................... |  |
| 32150 | C | Removal of lung lesion(s) .. |  |  |  |  |  |
| 32151 | C | Remove lung foreign body ..................................... |  |  |  |  |  |
| 32160 | C | Open chest heart massage .................................... |  |  |  |  |  |
| 32200 | C | Drain, open, lung lesion |  |  |  |  |  |
| 32201 | C | Drain, percut, lung lesion |  | ................. | .................... |  |  |
| 32215 | C | Treat chest lining |  |  |  |  |  |
| 32220 | C | Release of lung |  |  |  |  |  |
| 32225 | C | Partial release of lung |  |  |  |  |  |
| 32310 | C | Removal of chest lining |  |  |  |  |  |
| 32320 | C | Free/remove chest lining |  |  |  |  |  |
| 32400 | T | Needle biopsy chest lining | 0005 | 5.41 | \$262.32 | \$119.75 | \$52.46 |
| 32402 | C | Open biopsy chest lining |  |  |  |  |  |
| 32405 | T | Biopsy, lung or mediastinum | 0005 | 5.41 | \$262.32 | \$119.75 | \$52.46 |
| 32420 | T | Puncture/clear lung | 0070 | 3.64 | \$176.49 | \$79.60 | \$35.30 |
| 32440 | C | Removal of lung |  |  |  |  |  |
| 32442 | C | Sleeve preumonectomy |  |  |  |  |  |
| 32445 | C | Removal of lung |  |  |  |  |  |
| 32480 | C | Partial removal of lung |  |  |  |  |  |
| 32482 | C | Bilobectomy |  |  |  |  |  |
| 32484 | C | Segmentectomy |  |  |  |  |  |
| 32486 | C | Sleeve lobectomy |  | ................ | ..................... | ..................... |  |
| 32488 | C | Completion pneumonectomy |  |  |  |  |  |
| 32491 | C | Lung volume reduction |  |  |  |  |  |
| 32500 | C | Partial removal of lung |  |  |  |  |  |
| 32501 | C | Repair bronchus add-on ........................................ |  |  | ................... |  |  |
| 32520 | C | Remove lung \& revise chest |  |  |  |  |  |
| 32522 | C | Remove lung \& revise chest |  |  |  |  |  |
| 32525 | C | Remove lung \& revise chest |  |  | .................... |  |  |
| 32540 | C | Removal of lung lesion |  |  |  |  |  |
| 32601 | T | Thoracoscopy, diagnostic ...................................... | 0076 | 8.06 | \$390.81 | \$197.05 | \$78.16 |
| 32602 | T | Thoracoscopy, diagnostic ....................................... | 0076 | 8.06 | \$390.81 | \$197.05 | \$78.16 |
| 32603 | T | Thoracoscopy, diagnostic | 0076 | 8.06 | \$390.81 | \$197.05 | \$78.16 |
| 32604 | T | Thoracoscopy, diagnostic | 0076 | 8.06 | \$390.81 | \$197.05 | \$78.16 |
| 32605 | T | Thoracoscopy, diagnostic ....................................... | 0076 | 8.06 | \$390.81 | \$197.05 | \$78.16 |
| 32606 | T | Thoracoscopy, diagnostic ....................................... | 0076 | 8.06 | \$390.81 | \$197.05 | \$78.16 |
| 32650 | C | Thoracoscopy, surgical ........................................... |  |  |  |  |  |
| 32651 | C | Thoracoscopy, surgical .......................................... | .................... |  | .................... |  |  |
| 32652 | C | Thoracoscopy, surgical |  |  |  |  |  |
| 32653 | C | Thoracoscopy, surgical ........................................... |  |  |  |  |  |
| 32654 | C | Thoracoscopy, surgical ........................................... |  |  |  |  |  |
| 32655 | C | Thoracoscopy, surgical | ................... |  | ................... |  |  |
| 32656 | C | Thoracoscopy, surgical .......................................... |  |  |  |  |  |
| 32657 | C | Thoracoscopy, surgical |  |  |  |  |  |
| 32658 | C | Thoracoscopy, surgical .......................................... | .................... |  | ..................... | .................... |  |
| 32659 | C | Thoracoscopy, surgical ........................................... |  |  |  |  |  |
| 32660 | C | Thoracoscopy, surgical .......................................... |  |  |  |  |  |
| 32661 | C | Thoracoscopy, surgical ........................................... |  |  |  |  |  |
| 32662 | C | Thoracoscopy, surgical |  |  |  |  |  |
| 32663 | C | Thoracoscopy, surgical |  |  |  |  |  |
| 32664 | C | Thoracoscopy, surgical .... |  |  |  |  |  |
| 32665 | C | Thoracoscopy, surgical .......................................... | .................... | .................... | ...................... | ...................... | .................. |
| 32800 | C | Repair lung hernia |  | ..................... | ...................... |  |  |
| 32810 | C | Close chest after drainage |  |  |  |  |  |
| 32815 | C | Close bronchial fistula |  |  |  |  |  |

[^161]
# Addendum B.-Hospital Outpatient Department (HOPD) Payment Status by hCPCS Code and Related Information-Continued 

| CPT/ HCPCS | HOPD Status Indicator | Description | APC | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 32820 | C | Reconstruct injured chest . |  |  |  |  |  |
| 32850 | C | Donor pneumonectomy |  |  |  |  |  |
| 32851 | C | Lung transplant, single |  |  |  | ...................... |  |
| 32852 | C | Lung transplant with bypass | ........ | ..................... | ..................... | ..................... |  |
| 32853 | C | Lung transplant, double |  |  |  |  |  |
| 32854 | C | Lung transplant with bypass. |  |  |  |  |  |
| 32900 | C | Removal of rib(s) .. |  |  |  |  |  |
| 32905 | C | Revise \& repair chest wall |  |  |  |  |  |
| 32906 | C | Revise \& repair chest wall |  |  |  |  |  |
| 32940 | C | Revision of lung |  |  |  |  |  |
| 32960 | T | Therapeutic pneumothorax | 0070 | 3.64 | \$176.49 | \$79.60 | \$35.30 |
| 32997 | C | Total lung lavage |  |  |  |  |  |
| 32999 | T | Chest surgery procedure | 0070 | 3.64 | \$176.49 | \$79.60 | \$35.30 |
| 33010 | T | Drainage of heart sac | 0070 | 3.64 | \$176.49 | \$79.60 | \$35.30 |
| 33011 | T | Repeat drainage of heart sac | 0070 | 3.64 | \$176.49 | \$79.60 | \$35.30 |
| 33015 | C | Incision of heart sac |  |  |  |  |  |
| 33020 | C | Incision of heart sac |  |  |  |  |  |
| 33025 | C | Incision of heart sac |  |  |  |  |  |
| 33030 | C | Partial removal of heart sac |  | .................... |  | .................... |  |
| 33031 | C | Partial removal of heart sac |  |  |  |  |  |
| 33050 | C | Removal of heart sac lesion |  |  |  |  |  |
| 33120 | C | Removal of heart lesion |  |  |  | ................... |  |
| 33130 | C | Removal of heart lesion |  |  |  |  |  |
| 33140 | C | Heart revascularize (tmr) |  |  |  |  |  |
| 33200 | C | Insertion of heart pacemaker |  |  |  |  |  |
| 33201 | C | Insertion of heart pacemaker |  |  |  |  |  |
| 33206 | T | Insertion of heart pacemaker | 0090 | 20.96 | \$1,016.29 | \$573.04 | \$203.26 |
| 33207 | T | Insertion of heart pacemaker | 0090 | 20.96 | \$1,016.29 | \$573.04 | \$203.26 |
| 33208 | T | Insertion of heart pacemaker | 0090 | 20.96 | \$1,016.29 | \$573.04 | \$203.26 |
| 33210 | T | Insertion of heart electrode | 0089 | 6.49 | \$314.68 | \$130.07 | \$62.94 |
| 33211 | T | Insertion of heart electrode | 0089 | 6.49 | \$314.68 | \$130.07 | \$62.94 |
| 33212 | T | Insertion of pulse generator | 0090 | 20.96 | \$1,016.29 | \$573.04 | \$203.26 |
| 33213 | T | Insertion of pulse generator | 0090 | 20.96 | \$1,016.29 | \$573.04 | \$203.26 |
| 33214 | T | Upgrade of pacemaker system | 0090 | 20.96 | \$1,016.29 | \$573.04 | \$203.26 |
| 33216 | T | Revise eltrd pacing-defib .. | 0090 | 20.96 | \$1,016.29 | \$573.04 | \$203.26 |
| 33217 | T | Revise eltrd pacing-defib | 0090 | 20.96 | \$1,016.29 | \$573.04 | \$203.26 |
| 33218 | T | Revise eltrd pacing-defib | 0090 | 20.96 | \$1,016.29 | \$573.04 | \$203.26 |
| 33220 | T | Revise eltrd pacing-defib | 0089 | 6.49 | \$314.68 | \$130.07 | \$62.94 |
| 33222 | T | Revise pocket, pacemaker | 0026 | 12.11 | \$587.18 | \$277.92 | \$117.44 |
| 33223 | T | Revise pocket, pacing-defib | 0026 | 12.11 | \$587.18 | \$277.92 | \$117.44 |
| 33233 | T | Removal of pacemaker system | 0090 | 20.96 | \$1,016.29 | \$573.04 | \$203.26 |
| 33234 | T | Removal of pacemaker system | 0090 | 20.96 | \$1,016.29 | \$573.04 | \$203.26 |
| 33235 | T | Removal pacemaker electrode | 0090 | 20.96 | \$1,016.29 | \$573.04 | \$203.26 |
| 33236 | C | Remove electrode/thoracotomy ............................... |  |  |  |  |  |
| 33237 | C | Remove electrode/thoracotomy ............................... |  | ................... |  | ...................... |  |
| 33238 | C | Remove electrode/thoracotomy |  |  |  |  |  |
| 33240 | T | Insert pulse generator ........................................... | 0090 | 20.96 | \$1,016.29 | \$573.04 | \$203.26 |
| 33241 | T | Remove pulse generator | 0089 | 6.49 | \$314.68 | \$130.07 | \$62.94 |
| 33243 | C | Remove eltrd/thoracotomy ..................................... |  |  |  |  |  |
| 33244 | T | Remove eltrd, transven ......................................... | 0090 | 20.96 | \$1,016.29 | \$573.04 | \$203.26 |
| 33245 | C | Insert epic eltrd pace-defib |  |  |  |  |  |
| 33246 | C | Insert epic eltrd/generator ....................................... |  |  |  |  |  |
| 33249 | T | Eltrd/insert pace-defib | 0090 | 20.96 | \$1,016.29 | \$573.04 | \$203.26 |
| 33250 | C | Ablate heart dysrhythm focus .................................. |  |  |  |  |  |
| 33251 | C | Ablate heart dysrhythm focus .................................. |  |  |  | ...................... |  |
| 33253 | C | Reconstruct atria |  |  |  |  |  |
| 33261 | C | Ablate heart dysrhythm focus |  |  |  |  |  |
| 33282 | C | Implant pat-active ht record .................................... | .................... | .................... | .................... | ..................... | .................... |
| 33284 | C | Remove pat-active ht record |  |  |  |  |  |
| 33300 | C | Repair of heart wound. |  |  |  |  |  |
| 33305 | C | Repair of heart wound |  |  | .................... | .................... |  |
| 33310 | C | Exploratory heart surgery |  | - | ...................... | ..................... |  |
| 33315 | C | Exploratory heart surgery |  |  |  |  |  |
| 33320 | C | Repair major blood vessel(s) ................................... | ..................... | ...................... | ...................... | ..................... | .................... |
| 33321 | C | Repair major vessel .......... |  |  |  | ... |  |
| 33322 | C | Repair major blood vessel(s) |  |  |  |  |  |
| 33330 | C | Insert major vessel graft |  |  |  |  |  |
| 33332 | C | Insert major vessel graft ......................................... | ..................... | ..................... | ..................... | ..... |  |
| 33335 | C | Insert major vessel graft ......................................... |  |  |  |  |  |
| 33400 | C | Repair of aortic valve .... |  |  |  |  |  |
| 33401 | C | Valvuloplasty, open .............................................. | ...................... | ...................... | ...................... | ...................... | ................... |
| 33403 | C | Valvuloplasty, w/cp bypass . |  | ...................... | ...................... | ...................... |  |
| 33404 | C | Prepare heart-aorta conduit |  |  |  |  |  |

[^162]
# Addendum B.—Hospital Outpatient Department (HOPD) Payment Status by hCPCS Code and Related Information-Continued 

| $\begin{aligned} & \text { CPT/' } \\ & \text { HCPCS } \end{aligned}$ | HOPD Status Indicator | Description | APC | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 33405 | C | Replacement of aortic valve |  |  |  |  |  |
| 33406 | C | Replacement of aortic valve |  |  |  |  |  |
| 33410 | C | Replacement of aortic valve |  |  |  |  |  |
| 33411 | C | Replacement of aortic valve . |  |  |  |  |  |
| 33412 | C | Replacement of aortic valve . |  |  |  |  |  |
| 33413 | C | Replacement of aortic valve .... |  |  |  |  |  |
| 33414 | C | Repair of aortic valve ............. |  |  |  |  |  |
| 33415 <br> 33416 | C | Revision, subvalvular tissue ... Revise ventricle muscle |  |  |  |  |  |
| 33417 | C | Revair of aortic valve .......... |  |  |  |  |  |
| 33420 | C | Revision of mitral valve |  |  |  |  |  |
| 33422 | C | Revision of mitral valve .. |  |  |  |  |  |
| 33425 | C | Repair of mitral valve ...... |  |  |  |  |  |
| 33426 | C | Repair of mitral valve ... |  |  |  |  |  |
| 33427 | C | Repair of mitral valve |  |  |  |  |  |
| 33430 | C | Replacement of mitral valve |  |  |  |  |  |
| 33460 | C | Revision of tricuspid valve ... |  |  |  |  |  |
| 33463 | C | Valvuloplasty, tricuspid ..... |  |  |  |  |  |
| 33464 | C | Valvuloplasty, tricuspid ....................................... |  |  |  |  |  |
| $\begin{aligned} & 33465 \\ & 33468 \end{aligned}$ | C | Replace tricuspid valve Revision of tricuspid valve $\qquad$ $\qquad$ |  |  |  |  |  |
| 33470 | C | Revision of pulmonary valve |  |  |  |  |  |
| 33471 | C | Valvotomy, pulmonary valve ... |  |  |  |  |  |
| 33472 | C | Revision of pulmonary valve |  |  |  |  |  |
|  |  | Revision of pulmonary valve ... |  |  |  |  |  |
| 33476 | c | Revision of heart chamber ... |  |  |  |  |  |
| 33478 | C | Revision of heart chamber . |  |  |  |  |  |
| 33496 | C | Repair, prosth valve clot ...... |  |  |  |  |  |
| 33500 | C | Repair heart vessel fistula |  |  |  |  |  |
| 33501 | C | Repair heart vessel fistula ................................... |  |  |  |  |  |
| 33502 33503 | C | Coronary artery correction .................................................................................. |  |  |  |  |  |
| 33504 | C | Coronary artery graft ..... |  |  |  |  |  |
| 33505 | C | Repair artery w/tunnel |  |  |  | ................... |  |
| 33506 | C | Repair artery, translocation |  |  |  |  |  |
| 33510 | C | CABG, vein, single ........... |  |  |  |  |  |
| 33511 | C | CABG, vein, two .............. |  |  |  |  |  |
| 33512 | C | CABG, vein, three ...... |  |  |  |  |  |
| 33513 | C | CABG, vein, four |  | -.... |  |  |  |
| 33516 | C | Cabg, vein, six or more |  |  |  |  |  |
| 33517 | C | CABG, artery-vein, single |  |  |  |  |  |
| 33518 | C | CABG, artery-vein, two .......................................... |  |  |  | ...................... |  |
| 33519 | C | CABG, artery-vein, three .. |  |  |  |  |  |
| 33521 | C | CABG, artery-vein, four .... |  |  |  |  |  |
| 33522 | C | CABG, artery-vein, five ....................................... |  |  |  | .................... |  |
| 33523 | C | Cabg, art-vein, six or more |  |  |  |  |  |
| 33530 33533 | C | Coronary artery, bypass/reop .. |  |  |  |  |  |
| 33534 | c | CABG, arterial, single .................................................................................. |  |  |  |  |  |
| 33535 | C | CABG, arterial, three |  |  |  |  |  |
| 33536 | C | Cabg, arterial, four or more .................................... |  |  |  | ..................... |  |
| 33542 | C | Removal of heart lesion .... |  |  |  |  |  |
| 33545 | C | Repair of heart damage |  |  |  |  |  |
| 33572 | C | Open coronary endarterectomy ............................. |  |  |  |  |  |
| 33600 | C | Closure of valve .... |  |  |  |  |  |
| 33602 33606 | C | Closure of valve |  |  |  |  |  |
| 33608 | c | Anastomosis/artery-aorta .. |  |  |  |  |  |
| 33610 | C | Repair by enlargement ..... |  |  |  |  |  |
| 33611 | C | Repair double ventricle ......................................... |  |  |  |  |  |
| 33612 | C | Repair double ventricle .... |  |  |  |  |  |
| 33615 | C | Repair, simple fontan |  |  |  |  |  |
| 33617 | C | Repair, modified fontan .. |  |  |  |  |  |
| 33619 | C | Repair single ventricle .. |  |  |  |  |  |
| 33641 | C | Repair heart septum defect ......... |  |  |  |  |  |
| 33645 33647 | C | Revision of heart veins $\qquad$ <br> Repair heart septum defects |  |  |  |  |  |
| 33660 | c | Repair of heart defects ....... |  |  |  |  |  |
| 33665 | C | Repair of heart defects ... | - | ..................... | ..................... | ................... |  |
| 33670 | C | Repair of heart chambers | ................... |  |  |  |  |
| 33681 |  | Repair heart septum defect |  |  |  |  |  |

[^163]
# Addendum B.-Hospital Outpatient Department (HOPD) Payment Status by HCPCS Code and Related Information-Continued 

| $\begin{aligned} & \text { CPT/ } \\ & \text { HCPCS } \end{aligned}$ | HOPD Status Indicator | Description | APC | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 33684 | C | Repair heart septum defect ..................................... |  | ..................... | ..................... | ..................... |  |
| 33688 | C | Repair heart septum defect |  |  |  | ...................... |  |
| 33690 | C | Reinforce pulmonary artery |  |  |  |  |  |
| 33692 | C | Repair of heart defects ..... |  |  |  |  |  |
| 33694 | C | Repair of heart defects |  |  |  | ..................... |  |
| 33697 | C | Repair of heart defects |  |  |  |  |  |
| 33702 | C | Repair of heart defects |  |  |  |  |  |
| 33710 | C | Repair of heart defects |  |  |  |  |  |
| 33720 | C | Repair of heart defect. |  |  |  |  |  |
| 33722 | C | Repair of heart defect |  |  |  |  |  |
| 33730 | C | Repair heart-vein defect(s) |  |  |  |  |  |
| 33732 | C | Repair heart-vein defect .. |  |  |  |  |  |
| 33735 | C | Revision of heart chamber |  |  |  |  |  |
| 33736 | C | Revision of heart chamber |  |  |  |  |  |
| 33737 | C | Revision of heart chamber |  |  |  |  |  |
| 33750 | C | Major vessel shunt |  |  |  |  |  |
| 33755 | C | Major vessel shunt |  |  |  |  |  |
| 33762 | C | Major vessel shunt |  |  |  |  |  |
| 33764 | C | Major vessel shunt \& graft |  |  |  |  |  |
| 33766 | C | Major vessel shunt |  |  |  |  |  |
| 33767 | C | Major vessel shunt |  |  |  |  |  |
| 33770 | C | Repair great vessels defect |  |  |  |  |  |
| 33771 | C | Repair great vessels defect |  |  |  |  |  |
| 33774 | C | Repair great vessels defect |  |  |  |  |  |
| 33775 | C | Repair great vessels defect |  |  |  |  |  |
| 33776 | C | Repair great vessels defect |  |  |  | ..................... |  |
| 33777 | C | Repair great vessels defect |  |  |  |  |  |
| 33778 | C | Repair great vessels defect |  |  |  |  |  |
| 33779 | C | Repair great vessels defect |  |  |  |  |  |
| 33780 | C | Repair great vessels defect | ...................... | ...................... | .................... | ...................... |  |
| 33781 | C | Repair great vessels defect |  |  |  |  |  |
| 33786 | C | Repair arterial trunk |  |  |  | .................... |  |
| 33788 | C | Revision of pulmonary artery |  | ................... | .................... | ..................... |  |
| 33800 | C | Aortic suspension |  |  |  |  |  |
| 33802 | C | Repair vessel defect |  |  |  |  |  |
| 33803 | C | Repair vessel defect |  |  |  | .................... |  |
| 33813 | C | Repair septal defect |  |  |  |  |  |
| 33814 | C | Repair septal defect |  |  |  |  |  |
| 33820 | C | Revise major vessel |  |  |  |  |  |
| 33822 | C | Revise major vessel |  |  |  |  |  |
| 33824 | C | Revise major vessel |  |  |  |  |  |
| 33840 | C | Remove aorta constriction |  |  |  |  |  |
| 33845 | C | Remove aorta constriction |  |  |  |  |  |
| 33851 | C | Remove aorta constriction |  |  |  |  |  |
| 33852 | C | Repair septal defect ............................................. |  |  |  | ..................... |  |
| 33853 | C | Repair septal defect |  |  |  |  |  |
| 33860 | C | Ascending aortic graft ............................................ |  |  |  |  |  |
| 33861 | C | Ascending aortic graft |  |  |  |  |  |
| 33863 | C | Ascending aortic graft ............................................ |  |  |  | . |  |
| 33870 | C | Transverse aortic arch graft ................................... |  |  |  |  |  |
| 33875 | C | Thoracic aortic graft |  |  |  |  |  |
| 33877 | C | Thoracoabdominal graft |  |  |  | .................... |  |
| 33910 | C | Remove lung artery emboli .................................... |  |  |  |  |  |
| 33915 | C | Remove lung artery emboli .. |  |  |  |  |  |
| 33916 | C | Surgery of great vessel ......................................... |  |  |  | ................... |  |
| 33917 | C | Repair pulmonary artery |  |  |  | ...................... |  |
| 33918 | C | Repair pulmonary atresia |  |  |  |  |  |
| 33919 | C | Repair pulmonary atresia ....................................... |  |  |  | ..................... |  |
| 33920 | C | Repair pulmonary atresia ...................................... |  |  |  | ...................... |  |
| 33922 | C | Transect pulmonary artery ...................................... |  |  |  |  |  |
| 33924 | C | Remove pulmonary shunt |  |  |  |  |  |
| 33930 | C | Removal of donor heart/lung ................................... |  |  |  |  |  |
| 33935 | C | Transplantation, heart/lung ..................................... |  |  | ...... |  |  |
| 33940 | C | Removal of donor heart |  |  |  |  |  |
| 33945 | C | Transplantation of heart ........................................ |  |  |  | ..................... |  |
| 33960 | C | External circulation assist |  |  | ..................... | ...................... |  |
| 33961 | C | External circulation assist |  |  |  |  |  |
| 33968 | C | Remove aortic assist device . |  |  | ................... | ...................... |  |
| 33970 | C | Aortic circulation assist |  | ................ | .................... | .................... |  |
| 33971 | C | Aortic circulation assist .......................................... |  |  |  |  |  |
| 33973 | C | Insert balloon device |  |  |  |  |  |
| 33974 | C | Remove intra-aortic balloon .................................... | ..................... | ... | ... | ..... |  |
| 33975 | C | Implant ventricular device |  |  |  |  |  |

[^164]
# Addendum B.—Hospital Outpatient Department (HOPD) Payment Status by hCPCS Code and Related Information-Continued 

| $\begin{aligned} & \text { CPT/ } \\ & \text { HCPCS } \end{aligned}$ | HOPD Status Indicator | Description | APC | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 33976 | C | Implant ventricular device |  |  |  |  |  |
| 33977 | C | Remove ventricular device |  |  |  |  |  |
| 33978 | C | Remove ventricular device |  |  |  |  |  |
| 33999 | T | Cardiac surgery procedure | 0070 | 3.64 | \$176.49 | \$79.60 | \$35.30 |
| 34001 | C | Removal of artery clot .. |  |  |  |  |  |
| 34051 | C | Removal of artery clot ... |  |  |  |  |  |
| 34101 | T | Removal of artery clot | 0088 | 26.49 | \$1,284.42 | \$678.68 | \$256.88 |
| 34111 | T | Removal of arm artery clot | 0088 | 26.49 | \$1,284.42 | \$678.68 | \$256.88 |
| 34151 | C | Removal of artery clot ..... |  |  |  |  |  |
| 34201 | T | Removal of artery clot | 0088 | 26.49 | \$1,284.42 | \$678.68 | \$256.88 |
| 34203 | T | Removal of leg artery clot | 0088 | 26.49 | \$1,284.42 | \$678.68 | \$256.88 |
| 34401 | C | Removal of vein clot |  |  |  |  |  |
| 34421 | C | Removal of vein clot | .................. | ................... |  |  |  |
| 34451 | C | Removal of vein clot |  |  |  |  |  |
| 34471 | T | Removal of vein clot | 0088 | 26.49 | \$1,284.42 | \$678.68 | \$256.88 |
| 34490 | T | Removal of vein clot | 0088 | 26.49 | \$1,284.42 | \$678.68 | \$256.88 |
| 34501 | T | Repair valve, femoral vein | 0088 | 26.49 | \$1,284.42 | \$678.68 | \$256.88 |
| 34502 | C | Reconstruct vena cava |  |  |  |  |  |
| 34510 | T | Transposition of vein valve | 0088 | 26.49 | \$1,284.42 | \$678.68 | \$256.88 |
| 34520 | T | Cross-over vein graft | 0088 | 26.49 | \$1,284.42 | \$678.68 | \$256.88 |
| 34530 | T | Leg vein fusion | 0088 | 26.49 | \$1,284.42 | \$678.68 | \$256.88 |
| 35001 | C | Repair defect of artery |  |  |  | ..................... |  |
| 35002 | C | Repair artery rupture, neck |  |  |  |  |  |
| 35005 | C | Repair defect of artery |  | ..................... |  |  |  |
| 35011 | C | Repair defect of artery |  |  |  |  |  |
| 35013 | C | Repair artery rupture, arm ...................................... |  | ...................... |  | ..................... |  |
| 35021 | C | Repair defect of artery |  |  |  |  |  |
| 35022 | C | Repair artery rupture, chest |  |  |  |  |  |
| 35045 | C | Repair defect of arm artery |  |  |  |  |  |
| 35081 | C | Repair defect of artery |  | ..................... | ................... | ..................... |  |
| 35082 | C | Repair artery rupture, aorta |  |  |  |  |  |
| 35091 | C | Repair defect of artery |  |  |  |  |  |
| 35092 | C | Repair artery rupture, aorta |  | ...................... | .................... | .................... |  |
| 35102 | C | Repair defect of artery |  |  | ...................... | ...................... |  |
| 35103 | C | Repair artery rupture, groin |  |  |  |  |  |
| 35111 | C | Repair defect of artery | .-1..... | ...................... | ..................... | ...................... |  |
| 35112 | C | Repair artery rupture, spleen |  |  |  | ................... |  |
| 35121 | C | Repair defect of artery |  |  |  |  |  |
| 35122 | C | Repair artery rupture, belly ..................................... |  |  |  |  |  |
| 35131 | C | Repair defect of artery .... |  | ..................... | ...................... | ...................... |  |
| 35132 | C | Repair artery rupture, groin |  |  |  |  |  |
| 35141 | C | Repair defect of artery |  |  |  |  |  |
| 35142 | C | Repair artery rupture, thigh |  |  | ...................... | ..................... |  |
| 35151 | C | Repair defect of artery |  |  |  |  |  |
| 35152 | C | Repair artery rupture, knee |  |  |  |  |  |
| 35161 | C | Repair defect of artery .. |  |  |  |  |  |
| 35162 | C | Repair artery rupture |  |  |  |  |  |
| 35180 | T | Repair blood vessel lesion | 0081 | 19.36 | \$938.71 | \$434.25 | \$187.74 |
| 35182 | C | Repair blood vessel lesion |  |  |  |  |  |
| 35184 | T | Repair blood vessel lesion ..................................... | 0081 | 19.36 | \$938.71 | \$434.25 | \$187.74 |
| 35188 | T | Repair blood vessel lesion | 0088 | 26.49 | \$1,284.42 | \$678.68 | \$256.88 |
| 35189 | C | Repair blood vessel lesion ..................................... |  |  |  |  |  |
| 35190 | T | Repair blood vessel lesion ..................................... | 0081 | 19.36 | \$938.71 | \$434.25 | \$187.74 |
| 35201 | T | Repair blood vessel lesion ..................................... | 0081 | 19.36 | \$938.71 | \$434.25 | \$187.74 |
| 35206 | T | Repair blood vessel lesion | 0081 | 19.36 | \$938.71 | \$434.25 | \$187.74 |
| 35207 | T | Repair blood vessel lesion ..................................... | 0088 | 26.49 | \$1,284.42 | \$678.68 | \$256.88 |
| 35211 | C | Repair blood vessel lesion |  |  |  |  |  |
| 35216 | C | Repair blood vessel lesion |  |  |  |  |  |
| 35221 | C | Repair blood vessel lesion ..................................... |  |  |  |  |  |
| 35226 | T | Repair blood vessel lesion ..................................... | 0081 | 19.36 | \$938.71 | \$434.25 | \$187.74 |
| 35231 | T | Repair blood vessel lesion ..................................... | 0081 | 19.36 | \$938.71 | \$434.25 | \$187.74 |
| 35236 | T | Repair blood vessel lesion | 0081 | 19.36 | \$938.71 | \$434.25 | \$187.74 |
| 35241 | C | Repair blood vessel lesion |  |  |  |  |  |
| 35246 | C | Repair blood vessel lesion |  |  |  |  |  |
| 35251 | C | Repair blood vessel lesion |  |  |  |  |  |
| 35256 | T | Repair blood vessel lesion | 0081 | 19.36 | \$938.71 | \$434.25 | \$187.74 |
| 35261 | T | Repair blood vessel lesion | 0081 | 19.36 | \$938.71 | \$434.25 | \$187.74 |
| 35266 | T | Repair blood vessel lesion ..................................... | 0081 | 19.36 | \$938.71 | \$434.25 | \$187.74 |
| 35271 | C | Repair blood vessel lesion ..................................... | ...................... | ...................... |  | ...................... | ...................... |
| 35276 | C | Repair blood vessel lesion ..................................... |  |  |  |  |  |
| 35281 | C | Repair blood vessel lesion |  |  |  |  |  |
| 35286 | T | Repair blood vessel lesion | 0081 | 19.36 | \$938.71 | \$434.25 | \$187.74 |
| 35301 | C | Rechanneling of artery .... |  |  |  |  |  |

[^165]
# Addendum B.-Hospital Outpatient Department (HOPD) Payment Status by HCPCS Code and Related INFORMATION-Continued 

| $\begin{aligned} & \text { CPT/ } \\ & \text { HCPCS } \end{aligned}$ | HOPD Status Indicator | Description | APC | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 35311 | C | Rechanneling of artery |  |  |  |  |  |
| 35321 | T | Rechanneling of artery | 0081 | 19.36 | \$938.71 | \$434.25 | \$187.74 |
| 35331 | C | Rechanneling of artery |  |  |  |  |  |
| 35341 | C | Rechanneling of artery .......................................... | ...................... | ...................... |  | ..................... | ..................... |
| 35351 | C | Rechanneling of artery .......................................... | ..................... |  |  |  |  |
| 35355 | C | Rechanneling of artery . |  |  |  |  |  |
| 35361 | C | Rechanneling of artery .......................................... | ..................... |  |  | ...................... |  |
| 35363 | C | Rechanneling of artery .......................................... |  |  |  | ...................... |  |
| 35371 | C | Rechanneling of artery .......................................... |  |  |  | ...................... |  |
| 35372 | C | Rechanneling of artery ... |  |  |  |  |  |
| 35381 | C | Rechanneling of artery |  |  |  |  |  |
| 35390 | C | Reoperation, carotid add-on |  |  |  |  |  |
| 35400 | C | Angioscopy |  |  |  |  |  |
| 35450 | C | Repair arterial blockage |  |  |  |  |  |
| 35452 | C | Repair arterial blockage | ... | ... | $\ldots$ | $\ldots$ |  |
| 35454 | C | Repair arterial blockage |  |  |  |  |  |
| 35456 | C | Repair arterial blockage |  |  |  |  |  |
| 35458 | C | Repair arterial blockage |  |  |  |  |  |
| 35459 | T | Repair arterial blockage | 0081 | 19.36 | \$938.71 | \$434.25 | \$187.74 |
| 35460 | T | Repair venous blockage | 0081 | 19.36 | \$938.71 | \$434.25 | \$187.74 |
| 35470 | T | Repair arterial blockage | 0081 | 19.36 | \$938.71 | \$434.25 | \$187.74 |
| 35471 | T | Repair arterial blockage | 0081 | 19.36 | \$938.71 | \$434.25 | \$187.74 |
| 35472 | T | Repair arterial blockage | 0081 | 19.36 | \$938.71 | \$434.25 | \$187.74 |
| 35473 | T | Repair arterial blockage | 0081 | 19.36 | \$938.71 | \$434.25 | \$187.74 |
| 35474 | T | Repair arterial blockage | 0081 | 19.36 | \$938.71 | \$434.25 | \$187.74 |
| 35475 | T | Repair arterial blockage | 0081 | 19.36 | \$938.71 | \$434.25 | \$187.74 |
| 35476 | T | Repair venous blockage | 0081 | 19.36 | \$938.71 | \$434.25 | \$187.74 |
| 35480 | C | Atherectomy, open ... |  |  |  |  |  |
| 35481 | C | Atherectomy, open ... |  |  |  |  |  |
| 35482 | C | Atherectomy, open |  |  |  |  |  |
| 35483 | C | Atherectomy, open . |  |  |  |  |  |
| 35484 | T | Atherectomy, open | 0081 | 19.36 | \$938.71 | \$434.25 | \$187.74 |
| 35485 | T | Atherectomy, open | 0081 | 19.36 | \$938.71 | \$434.25 | \$187.74 |
| 35490 | T | Atherectomy, percutaneous | 0081 | 19.36 | \$938.71 | \$434.25 | \$187.74 |
| 35491 | T | Atherectomy, percutaneous | 0081 | 19.36 | \$938.71 | \$434.25 | \$187.74 |
| 35492 | T | Atherectomy, percutaneous | 0081 | 19.36 | \$938.71 | \$434.25 | \$187.74 |
| 35493 | T | Atherectomy, percutaneous | 0081 | 19.36 | \$938.71 | \$434.25 | \$187.74 |
| 35494 | T | Atherectomy, percutaneous | 0081 | 19.36 | \$938.71 | \$434.25 | \$187.74 |
| 35495 | T | Atherectomy, percutaneous | 0081 | 19.36 | \$938.71 | \$434.25 | \$187.74 |
| 35500 | T | Harvest vein for bypass | 0081 | 19.36 | \$938.71 | \$434.25 | \$187.74 |
| 35501 | C | Artery bypass graft ................................................ | ...................... | ...................... |  | ..................... | ..................... |
| 35506 | C | Artery bypass graft |  |  |  |  |  |
| 35507 | C | Artery bypass graft ............................................... |  |  |  |  |  |
| 35508 | C | Artery bypass graft ................................................ |  |  |  |  |  |
| 35509 | C | Artery bypass graft ............................................... | .................... | .................... |  | ...................... |  |
| 35511 | C | Artery bypass graft ............................................... |  |  |  |  |  |
| 35515 | C | Artery bypass graft |  |  |  |  |  |
| 35516 | C | Artery bypass graft ............................................... |  | ..................... |  | ..................... |  |
| 35518 | C | Artery bypass graft ............................................... |  |  |  |  |  |
| 35521 | C | Artery bypass graft |  |  |  |  |  |
| 35526 | C | Artery bypass graft ............................................... |  |  |  | .................... |  |
| 35531 | C | Artery bypass graft ............................................ |  | ..................... |  |  |  |
| 35533 | C | Artery bypass graft |  |  |  |  |  |
| 35536 | C | Artery bypass graft ............................................... |  |  |  |  |  |
| 35541 | C | Artery bypass graft ............................................... |  |  |  |  |  |
| 35546 | C | Artery bypass graft ............................................... |  |  |  |  |  |
| 35548 | C | Artery bypass graft |  |  |  |  |  |
| 35549 | C | Artery bypass graft ............................................... | .................... | ............ |  |  |  |
| 35551 | C | Artery bypass graft ............................................... |  |  |  |  |  |
| 35556 | C | Artery bypass graft |  |  |  |  |  |
| 35558 | C | Artery bypass graft ............................................... |  | ................... |  | .................... |  |
| 35560 | C | Artery bypass graft |  | .................. |  |  |  |
| 35563 | C | Artery bypass graft |  |  |  |  |  |
| 35565 | C | Artery bypass graft ............................................... |  | ..................... |  | ...................... | ............... |
| 35566 | C | Artery bypass graft ................................................ |  | ..................... |  | ..................... |  |
| 35571 | C | Artery bypass graft |  |  |  |  |  |
| 35582 | C | Vein bypass graft |  |  |  | .................... |  |
| 35583 | C | Vein bypass graft .................................................. | ..................... | ...................... |  | ..... |  |
| 35585 | C | Vein bypass graft |  |  |  |  |  |
| 35587 | C | Vein bypass graft |  |  |  |  |  |
| 35601 | C | Artery bypass graft | ..................... |  | ..................... | ..... | ............... |
| 35606 | C | Artery bypass graft | ..................... | ..................... | ..................... | ..................... |  |
| 35612 | C | Artery bypass graft |  |  |  |  |  |

[^166]
# Addendum B.—Hospital Outpatient Department (HOPD) Payment Status by hCPCS Code and Related INFORMATION-Continued 

| CPT/ HCPCS | HOPD Status Indicator | Description | APC | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 35616 | C | Artery bypass graft |  |  |  | ..................... |  |
| 35621 | C | Artery bypass graft |  |  |  |  |  |
| 35623 | C | Bypass graft, not vein |  |  |  |  |  |
| 35626 | C | Artery bypass graft .. |  |  |  |  |  |
| 35631 | C | Artery bypass graft |  |  |  |  |  |
| 35636 | C | Artery bypass graft | .................... |  | - |  |  |
| 35641 | C | Artery bypass graft |  |  |  |  |  |
| 35642 | C | Artery bypass graft |  |  |  |  |  |
| 35645 | C | Artery bypass graft |  |  |  |  |  |
| 35646 | C | Artery bypass graft |  |  |  |  |  |
| 35650 | C | Artery bypass graft |  |  |  |  |  |
| 35651 | C | Artery bypass graft |  |  |  |  |  |
| 35654 | C | Artery bypass graft | .................... |  | .................... |  |  |
| 35656 | C | Artery bypass graft |  |  | .................... |  |  |
| 35661 | C | Artery bypass graft |  |  |  |  |  |
| 35663 | C | Artery bypass graft |  |  |  |  |  |
| 35665 | C | Artery bypass graft |  |  |  |  |  |
| 35666 | C | Artery bypass graft |  |  |  |  |  |
| 35671 | C | Artery bypass graft | .................... |  |  | ..................... |  |
| 35681 | C | Composite bypass graft |  |  |  |  |  |
| 35682 | C | Composite bypass graft |  |  |  |  |  |
| 35683 | C | Composite bypass graft |  |  |  |  |  |
| 35691 | C | Arterial transposition |  |  |  |  |  |
| 35693 | C | Arterial transposition |  |  |  |  |  |
| 35694 | C | Arterial transposition |  |  |  |  |  |
| 35695 | C | Arterial transposition |  | ...................... | .................... | ...................... |  |
| 35700 | C | Reoperation, bypass graft |  |  |  |  |  |
| 35701 | C | Exploration, carotid artery | .................... |  | ...................... |  |  |
| 35721 | C | Exploration, femoral artery |  |  |  |  |  |
| 35741 | C | Exploration popliteal artery |  |  |  | ................... |  |
| 35761 | C | Exploration of artery/vein |  |  |  | ...................... |  |
| 35800 | C | Explore neck vessels |  |  |  |  |  |
| 35820 | C | Explore chest vessels | . | .................... | . | .................... | ................... |
| 35840 | C | Explore abdominal vessels |  |  |  |  |  |
| 35860 | C | Explore limb vessels |  |  |  |  |  |
| 35870 | C | Repair vessel graft defect |  |  |  |  |  |
| 35875 | T | Removal of clot in graft | 0088 | 26.49 | \$1,284.42 | \$678.68 | \$256.88 |
| 35876 | T | Removal of clot in graft | 0088 | 26.49 | \$1,284.42 | \$678.68 | \$256.88 |
| 35879 | T | Revise graft w/vein | 0088 | 26.49 | \$1,284.42 | \$678.68 | \$256.88 |
| 35881 | T | Revise graft w/vein | 0088 | 26.49 | \$1,284.42 | \$678.68 | \$256.88 |
| 35901 | C | Excision, graft, neck |  |  |  |  |  |
| 35903 | C | Excision, graft, extremity |  |  |  |  |  |
| 35905 | C | Excision, graft, thorax |  |  |  |  |  |
| 35907 | C | Excision, graft, abdomen |  |  |  |  |  |
| 36000 | N | Place needle in vein |  |  |  |  |  |
| 36005 | N | Injection, venography |  |  |  | ...................... |  |
| 36010 | N | Place catheter in vein |  | .................... | .................... | ..................... |  |
| 36011 | N | Place catheter in vein |  |  |  |  |  |
| 36012 | N | Place catheter in vein |  |  |  | .................... |  |
| 36013 | N | Place catheter in artery |  |  | .................... | ..................... |  |
| 36014 | N | Place catheter in artery |  |  |  |  |  |
| 36015 | N | Place catheter in artery |  |  |  |  |  |
| 36100 | N | Establish access to artery |  |  |  | ...................... |  |
| 36120 | N | Establish access to artery ...................................... |  |  |  |  |  |
| 36140 | N | Establish access to artery ...................................... |  |  |  |  |  |
| 36145 | N | Artery to vein shunt |  | .................... | .................... | .................... | ..................... |
| 36160 | N | Establish access to aorta |  |  |  |  |  |
| 36200 | N | Place catheter in aorta |  |  |  |  |  |
| 36215 | N | Place catheter in artery |  | ...................... | .................... | ...................... |  |
| 36216 | N | Place catheter in artery |  | ...................... |  | ...................... |  |
| 36217 | N | Place catheter in artery |  |  |  |  |  |
| 36218 | N | Place catheter in artery ......................................... |  |  |  | ..................... |  |
| 36245 | N | Place catheter in artery |  | ...................... | ...................... | ...................... |  |
| 36246 | N | Place catheter in artery |  |  |  |  |  |
| 36247 | N | Place catheter in artery |  |  |  |  |  |
| 36248 | N | Place catheter in artery |  |  |  |  |  |
| 36260 | T | Insertion of infusion pump | 0093 | 17.95 | \$870.34 | \$422.33 | \$174.07 |
| 36261 | T | Revision of infusion pump | 0089 | 6.49 | \$314.68 | \$130.07 | \$62.94 |
| 36262 | T | Removal of infusion pump | 0089 | 6.49 | \$314.68 | \$130.07 | \$62.94 |
| 36299 | T | Vessel injection procedure | 0089 | 6.49 | \$314.68 | \$130.07 | \$62.94 |
| 36400 | N | Drawing blood | ...................... | ...................... | ...................... | ...................... |  |
| 36405 | N | Drawing blood | ...................... | ..................... | ...................... | ..................... |  |
| 36406 | N | Drawing blood |  |  |  |  |  |

[^167]
# Addendum B.-Hospital Outpatient Department (HOPD) Payment Status by HCPCS Code and Related Information-Continued 

| CPT/ HCPCS | HOPD Status Indicator | Description | APC | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 36410 | N | Drawing blood |  |  |  |  |  |
| 36415 | E | Drawing blood |  |  |  |  |  |
| 36420 | T | Establish access to vein | 0032 | 5.40 | \$261.83 | \$119.52 | \$52.37 |
| 36425 | T | Establish access to vein | 0032 | 5.40 | \$261.83 | \$119.52 | \$52.37 |
| 36430 | S | Blood transfusion service | 0110 | 5.83 | \$282.68 | \$122.73 | \$56.54 |
| 36440 | S | Blood transfusion service | 0110 | 5.83 | \$282.68 | \$122.73 | \$56.54 |
| 36450 | S | Exchange transfusion service | 0110 | 5.83 | \$282.68 | \$122.73 | \$56.54 |
| 36455 | S | Exchange transfusion service | 0110 | 5.83 | \$282.68 | \$122.73 | \$56.54 |
| 36460 | S | Transfusion service, fetal | 0110 | 5.83 | \$282.68 | \$122.73 | \$56.54 |
| 36468 | T | Injection(s), spider veins | 0098 | 1.19 | \$57.70 | \$20.88 | \$11.54 |
| 36469 | T | Injection(s), spider veins | 0098 | 1.19 | \$57.70 | \$20.88 | \$11.54 |
| 36470 | T | Injection therapy of vein | 0098 | 1.19 | \$57.70 | \$20.88 | \$11.54 |
| 36471 | T | Injection therapy of veins | 0098 | 1.19 | \$57.70 | \$20.88 | \$11.54 |
| 36481 | N | Insertion of catheter, vein |  |  |  |  |  |
| 36488 | T | Insertion of catheter, vein | 0032 | 5.40 | \$261.83 | \$119.52 | \$52.37 |
| 36489 | T | Insertion of catheter, vein | 0032 | 5.40 | \$261.83 | \$119.52 | \$52.37 |
| 36490 | T | Insertion of catheter, vein | 0032 | 5.40 | \$261.83 | \$119.52 | \$52.37 |
| 36491 | T | Insertion of catheter, vein | 0032 | 5.40 | \$261.83 | \$119.52 | \$52.37 |
| 36493 | T | Repositioning of cvc | 0032 | 5.40 | \$261.83 | \$119.52 | \$52.37 |
| 36500 | N | Insertion of catheter, vein |  |  |  |  |  |
| 36510 | C | Insertion of catheter, vein |  |  |  |  |  |
| 36520 | S | Plasma and/or cell exchange | 0111 | 14.17 | \$687.06 | \$300.74 | \$137.41 |
| 36521 | S | Apheresis w/adsorp/reinfuse | 0111 | 14.17 | \$687.06 | \$300.74 | \$137.41 |
| 36522 | S | Photopheresis | 0112 | 39.60 | \$1,920.09 | \$663.65 | \$384.02 |
| 36530 | T | Insertion of infusion pump | 0093 | 17.95 | \$870.34 | \$422.33 | \$174.07 |
| 36531 | T | Revision of infusion pump | 0089 | 6.49 | \$314.68 | \$130.07 | \$62.94 |
| 36532 | T | Removal of infusion pump | 0089 | 6.49 | \$314.68 | \$130.07 | \$62.94 |
| 36533 | T | Insertion of access device | 0093 | 17.95 | \$870.34 | \$422.33 | \$174.07 |
| 36534 | T | Revision of access device | 0089 | 6.49 | \$314.68 | \$130.07 | \$62.94 |
| 36535 | T | Removal of access device | 0089 | 6.49 | \$314.68 | \$130.07 | \$62.94 |
| 36550 | C | Declot vascular device |  |  |  | ..................... |  |
| 36600 | N | Withdrawal of arterial blood | ..................... | ....... | ..................... | .................... |  |
| 36620 | N | Insertion catheter, artery |  |  |  |  |  |
| 36625 | N | Insertion catheter, artery |  |  |  |  |  |
| 36640 | T | Insertion catheter, artery | 0032 | 5.40 | \$261.83 | \$119.52 | \$52.37 |
| 36660 | C | Insertion catheter, artery |  |  |  |  |  |
| 36680 | S | Insert needle, bone cavity | 0120 | 1.66 | \$80.49 | \$42.67 | \$16.10 |
| 36800 | T | Insertion of cannula | 0093 | 17.95 | \$870.34 | \$422.33 | \$174.07 |
| 36810 | T | Insertion of cannula | 0093 | 17.95 | \$870.34 | \$422.33 | \$174.07 |
| 36815 | T | Insertion of cannula | 0093 | 17.95 | \$870.34 | \$422.33 | \$174.07 |
| 36819 | T | Av fusion by basilic vein | 0093 | 17.95 | \$870.34 | \$422.33 | \$174.07 |
| 36821 | T | Av fusion direct any site | 0088 | 26.49 | \$1,284.42 | \$678.68 | \$256.88 |
| 36822 | C | Insertion of cannula(s) ...... |  |  |  |  |  |
| 36823 | C | Insertion of cannula(s) |  |  |  |  |  |
| 36825 | T | Artery-vein graft | 0088 | 26.49 | \$1,284.42 | \$678.68 | \$256.88 |
| 36830 | T | Artery-vein graft | 0088 | 26.49 | \$1,284.42 | \$678.68 | \$256.88 |
| 36831 | T | Av fistula excision | 0088 | 26.49 | \$1,284.42 | \$678.68 | \$256.88 |
| 36832 | T | Av fistula revision | 0088 | 26.49 | \$1,284.42 | \$678.68 | \$256.88 |
| 36833 | T | Av fistula revision | 0088 | 26.49 | \$1,284.42 | \$678.68 | \$256.88 |
| 36834 | C | Repair A-V aneurysm |  |  |  |  |  |
| 36835 | T | Artery to vein shunt | 0093 | 17.95 | \$870.34 | \$422.33 | \$174.07 |
| 36860 | T | External cannula declotting | 0090 | 20.96 | \$1,016.29 | \$573.04 | \$203.26 |
| 36861 | T | Cannula declotting | 0090 | 20.96 | \$1,016.29 | \$573.04 | \$203.26 |
| 37140 | C | Revision of circulation |  |  |  | ...................... |  |
| 37145 | C | Revision of circulation |  |  |  |  |  |
| 37160 | C | Revision of circulation |  |  |  |  |  |
| 37180 | C | Revision of circulation |  |  |  |  |  |
| 37181 | C | Splice spleen/kidney veins |  |  |  | ................... |  |
| 37195 | C | Thrombolytic therapy, stroke |  |  |  |  |  |
| 37200 | C | Transcatheter biopsy |  | ................. |  | ..................... | .................... |
| 37201 | C | Transcatheter therapy infuse |  |  |  | ................... |  |
| 37202 | C | Transcatheter therapy infuse |  |  |  |  |  |
| 37203 | T | Transcatheter retrieval ......... | 0089 | 6.49 | \$314.68 | \$130.07 | \$62.94 |
| 37204 | T | Transcatheter occlusion | 0081 | 19.36 | \$938.71 | \$434.25 | \$187.74 |
| 37205 | T | Transcatheter stent | 0081 | 19.36 | \$938.71 | \$434.25 | \$187.74 |
| 37206 | T | Transcatheter stent add-on | 0081 | 19.36 | \$938.71 | \$434.25 | \$187.74 |
| 37207 | T | Transcatheter stent | 0081 | 19.36 | \$938.71 | \$434.25 | \$187.74 |
| 37208 | T | Transcatheter stent add-on | 0081 | 19.36 | \$938.71 | \$434.25 | \$187.74 |
| 37209 | T | Exchange arterial catheter | 0081 | 19.36 | \$938.71 | \$434.25 | \$187.74 |
| 37250 | T | Iv us first vessel add-on | 0081 | 19.36 | \$938.71 | \$434.25 | \$187.74 |
| 37251 | T | Iv us each add vessel add-on | 0081 | 19.36 | \$938.71 | \$434.25 | \$187.74 |
| 37565 | T | Ligation of neck vein | 0081 | 19.36 | \$938.71 | \$434.25 | \$187.74 |
| 37600 | T | Ligation of neck artery | 0081 | 19.36 | \$938.71 | \$434.25 | \$187.74 |

[^168]
## Addendum B.—Hospital Outpatient Department (HOPD) Payment Status by hCPCS Code and Related INFORMATION-Continued

| $\begin{aligned} & \text { CPT/ } \\ & \text { HCPCS } \end{aligned}$ | HOPD Status Indicator | Description | APC | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 37605 | T | Ligation of neck artery | 0091 | 14.79 | \$717.12 | \$348.23 | \$143.42 |
| 37606 | T | Ligation of neck artery | 0091 | 14.79 | \$717.12 | \$348.23 | \$143.42 |
| 37607 | T | Ligation of a-v fistula | 0092 | 20.21 | \$979.92 | \$505.37 | \$195.98 |
| 37609 | T | Temporal artery procedure | 0020 | 6.51 | \$315.65 | \$130.53 | \$63.13 |
| 37615 | T | Ligation of neck artery | 0091 | 14.79 | \$717.12 | \$348.23 | \$143.42 |
| 37616 | C | Ligation of chest artery .......................................... |  |  |  |  |  |
| 37617 | C | Ligation of abdomen artery | .................... | ...................... |  |  |  |
| 37618 | E | Ligation of extremity artery |  |  |  |  |  |
| 37620 | C | Revision of major vein ........................................... |  |  |  |  |  |
| 37650 | T | Revision of major vein | 0091 | 14.79 | \$717.12 | \$348.23 | \$143.42 |
| 37660 | C | Revision of major vein |  |  |  |  |  |
| 37700 | T | Revise leg vein | 0091 | 14.79 | \$717.12 | \$348.23 | \$143.42 |
| 37720 | T | Removal of leg vein | 0092 | 20.21 | \$979.92 | \$505.37 | \$195.98 |
| 37730 | T | Removal of leg veins | 0092 | 20.21 | \$979.92 | \$505.37 | \$195.98 |
| 37735 | T | Removal of leg veins/lesion | 0092 | 20.21 | \$979.92 | \$505.37 | \$195.98 |
| 37760 | T | Revision of leg veins | 0091 | 14.79 | \$717.12 | \$348.23 | \$143.42 |
| 37780 | T | Revision of leg vein | 0091 | 14.79 | \$717.12 | \$348.23 | \$143.42 |
| 37785 | T | Revise secondary varicosity | 0091 | 14.79 | \$717.12 | \$348.23 | \$143.42 |
| 37788 | C | Revascularization, penis ..... |  |  |  |  |  |
| 37790 | T | Penile venous occlusion | 0181 | 32.37 | \$1,569.53 | \$906.36 | \$313.91 |
| 37799 | T | Vascular surgery procedure | 0020 | 6.51 | \$315.65 | \$130.53 | \$63.13 |
| 38100 | C | Removal of spleen, total |  |  |  |  |  |
| 38101 | C | Removal of spleen, partial |  |  |  |  |  |
| 38102 | C | Removal of spleen, total |  | ...... | .................... |  |  |
| 38115 | C | Repair of ruptured spleen |  |  |  |  |  |
| 38120 | T | Laparoscopy, splenectomy | 0131 | 41.81 | \$2,027.24 | \$1,089.88 | \$405.45 |
| 38129 | T | Laparoscope proc, spleen | 0130 | 25.36 | \$1,229.63 | \$659.53 | \$245.93 |
| 38200 | N | Injection for spleen x-ray |  |  |  |  |  |
| 38230 | S | Bone marrow collection . | 0109 | 4.13 | \$200.25 | \$40.05 | \$40.05 |
| 38231 | S | Stem cell collection | 0111 | 14.17 | \$687.06 | \$300.74 | \$137.41 |
| 38240 | S | Bone marrow/stem transplant | 0109 | 4.13 | \$200.25 | \$40.05 | \$40.05 |
| 38241 | S | Bone marrow/stem transplant | 0109 | 4.13 | \$200.25 | \$40.05 | \$40.05 |
| 38300 | T | Drainage, lymph node lesion | 0008 | 6.15 | \$298.20 | \$113.67 | \$59.64 |
| 38305 | T | Drainage, lymph node lesion | 0008 | 6.15 | \$298.20 | \$113.67 | \$59.64 |
| 38308 | T | Incision of lymph channels | 0113 | 13.89 | \$673.49 | \$326.55 | \$134.70 |
| 38380 | C | Thoracic duct procedure ......................................... | ...................... | ...................... | ...................... | ...................... | ...................... |
| 38381 | C | Thoracic duct procedure |  | .... |  |  |  |
| 38382 | C | Thoracic duct procedure |  |  |  |  |  |
| 38500 | T | Biopsy/removal, lymph nodes | 0113 | 13.89 | \$673.49 | \$326.55 | \$134.70 |
| 38505 | T | Needle biopsy, lymph nodes . | 0005 | 5.41 | \$262.32 | \$119.75 | \$52.46 |
| 38510 | T | Biopsy/removal, lymph nodes | 0113 | 13.89 | \$673.49 | \$326.55 | \$134.70 |
| 38520 | T | Biopsy/removal, lymph nodes | 0113 | 13.89 | \$673.49 | \$326.55 | \$134.70 |
| 38525 | T | Biopsy/removal, lymph nodes | 0113 | 13.89 | \$673.49 | \$326.55 | \$134.70 |
| 38530 | T | Biopsy/removal, lymph nodes | 0113 | 13.89 | \$673.49 | \$326.55 | \$134.70 |
| 38542 | T | Explore deep node(s), neck | 0114 | 19.56 | \$948.41 | \$493.78 | \$189.68 |
| 38550 | T | Removal, neck/armpit lesion | 0113 | 13.89 | \$673.49 | \$326.55 | \$134.70 |
| 38555 | T | Removal, neck/armpit lesion | 0114 | 19.56 | \$948.41 | \$493.78 | \$189.68 |
| 38562 | C | Removal, pelvic lymph nodes |  |  |  |  |  |
| 38564 | C | Removal, abdomen lymph nodes ............................ |  |  |  |  |  |
| 38570 | T | Laparoscopy, lymph node biop ............................... | 0131 | 41.81 | \$2,027.24 | \$1,089.88 | \$405.45 |
| 38571 | T | Laparoscopy, lymphadenectomy | 0132 | 48.91 | \$2,371.50 | \$1,239.22 | \$474.30 |
| 38572 | T | Laparoscopy, lymphadenectomy ............................. | 0131 | 41.81 | \$2,027.24 | \$1,089.88 | \$405.45 |
| 38589 | T | Laparoscope proc, lymphatic ................................... | 0130 | 25.36 | \$1,229.63 | \$659.53 | \$245.93 |
| 38700 | C | Removal of lymph nodes, neck ............................... |  |  |  |  |  |
| 38720 | T | Removal of lymph nodes, neck ............................... | 0114 | 19.56 | \$948.41 | \$493.78 | \$189.68 |
| 38724 | C | Removal of lymph nodes, neck ............................... |  |  |  |  |  |
| 38740 | T | Remove armpit lymph nodes ................................... | 0114 | 19.56 | \$948.41 | \$493.78 | \$189.68 |
| 38745 | T | Remove armpit lymph nodes .................................. | 0114 | 19.56 | \$948.41 | \$493.78 | \$189.68 |
| 38746 | C | Remove thoracic lymph nodes ................................ |  |  |  |  |  |
| 38747 | C | Remove abdominal lymph nodes ............................. |  |  |  |  |  |
| 38760 | T | Remove groin lymph nodes. | 0114 | 19.56 | \$948.41 | \$493.78 | \$189.68 |
| 38765 | C | Remove groin lymph nodes .................................... |  |  |  | ................ | ............ |
| 38770 | C | Remove pelvis lymph nodes .................................. |  |  |  |  |  |
| 38780 | C | Remove abdomen lymph nodes ............................... |  |  |  |  |  |
| 38790 | N | Inject for lymphatic x-ray ........ |  |  |  |  |  |
| 38792 | N | Identify sentinel node ............................................ |  |  | .................... | .................... | .................... |
| 38794 | N | Access thoracic lymph duct |  |  |  |  |  |
| 38999 | T | Blood/lymph system procedure | 0008 | 6.15 | \$298.20 | \$113.67 | \$59.64 |
| 39000 | C | Exploration of chest ............................................... | ...................... | ...................... | ...................... | ...................... | ...................... |
| 39010 | C | Exploration of chest ............................................... | ...................... | ...................... | ...................... | ...................... |  |
| 39200 | C | Removal chest lesion ............................................ |  |  |  |  |  |
| 39220 | C | Removal chest lesion ............................................ |  |  |  |  |  |
| 39400 | T | Visualization of chest | 0076 | 8.06 | \$390.81 | \$197.05 | \$78.16 |

[^169]
# Addendum B.-Hospital Outpatient Department (HOPD) Payment Status by HCPCS Code and Related Information-Continued 

| $\begin{aligned} & \text { CPT/ } \\ & \text { HCPCS } \end{aligned}$ | HOPD Status Indicator | Description | APC | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 39499 | C | Chest procedure |  |  |  |  |  |
| 39501 | C | Repair diaphragm laceration |  |  |  |  |  |
| 39502 | C | Repair paraesophageal hernia ............................ | ................. | .................... | ... | ................... |  |
| 39503 | C | Repair of diaphragm hernia |  |  |  |  |  |
| 39520 | C | Repair of diaphragm hernia |  |  |  |  |  |
| 39530 | C | Repair of diaphragm hernia ................................ | ......... | .................. | ..................... | .................... |  |
| 39531 | C | Repair of diaphragm hernia |  |  |  |  |  |
| 39540 | C | Repair of diaphragm hernia |  |  | ................. |  |  |
| 39541 | C | Repair of diaphragm hernia |  |  |  |  |  |
| 39545 | C | Revision of diaphragm |  | .................. | .................. | ............... |  |
| 39560 | C | Resect diaphragm, simple |  | ................... | ................. | ..................... |  |
| 39561 | C | Resect diaphragm, complex |  |  |  |  |  |
| 39599 | C | Diaphragm surgery procedure |  |  |  |  |  |
| 40490 | T | Biopsy of lip ...................... | 0252 | 5.18 | \$251.16 | \$114.24 | \$50.23 |
| 40500 | T | Partial excision of lip | 0253 | 12.02 | \$582.81 | \$284.00 | \$116.56 |
| 40510 | T | Partial excision of lip | 0254 | 12.45 | \$603.66 | \$272.41 | \$120.73 |
| 40520 | T | Partial excision of lip | 0253 | 12.02 | \$582.81 | \$284.00 | \$116.56 |
| 40525 | T | Reconstruct lip with flap | 0254 | 12.45 | \$603.66 | \$272.41 | \$120.73 |
| 40527 | T | Reconstruct lip with flap | 0254 | 12.45 | \$603.66 | \$272.41 | \$120.73 |
| 40530 | T | Partial removal of lip | 0254 | 12.45 | \$603.66 | \$272.41 | \$120.73 |
| 40650 | T | Repair lip | 0253 | 12.02 | \$582.81 | \$284.00 | \$116.56 |
| 40652 | T | Repair lip | 0253 | 12.02 | \$582.81 | \$284.00 | \$116.56 |
| 40654 | T | Repair lip | 0254 | 12.45 | \$603.66 | \$272.41 | \$120.73 |
| 40700 | T | Repair cleft lip/nasal | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 40701 | T | Repair cleft lip/nasal | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 40702 | T | Repair cleft lip/nasal | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 40720 | T | Repair cleft lip/nasal | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 40761 | T | Repair cleft lip/nasal | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 40799 | T | Lip surgery procedure | 0253 | 12.02 | \$582.81 | \$284.00 | \$116.56 |
| 40800 | T | Drainage of mouth lesion | 0251 | 1.68 | \$81.46 | \$27.99 | \$16.29 |
| 40801 | T | Drainage of mouth lesion | 0252 | 5.18 | \$251.16 | \$114.24 | \$50.23 |
| 40804 | T | Removal, foreign body, mouth | 0251 | 1.68 | \$81.46 | \$27.99 | \$16.29 |
| 40805 | T | Removal, foreign body, mouth | 0252 | 5.18 | \$251.16 | \$114.24 | \$50.23 |
| 40806 | T | Incision of lip fold | 0251 | 1.68 | \$81.46 | \$27.99 | \$16.29 |
| 40808 | T | Biopsy of mouth lesion | 0251 | 1.68 | \$81.46 | \$27.99 | \$16.29 |
| 40810 | T | Excision of mouth lesion | 0253 | 12.02 | \$582.81 | \$284.00 | \$116.56 |
| 40812 | T | Excise/repair mouth lesion | 0252 | 5.18 | \$251.16 | \$114.24 | \$50.23 |
| 40814 | T | Excise/repair mouth lesion | 0253 | 12.02 | \$582.81 | \$284.00 | \$116.56 |
| 40816 | T | Excision of mouth lesion | 0253 | 12.02 | \$582.81 | \$284.00 | \$116.56 |
| 40818 | T | Excise oral mucosa for graft | 0251 | 1.68 | \$81.46 | \$27.99 | \$16.29 |
| 40819 | T | Excise lip or cheek fold | 0252 | 5.18 | \$251.16 | \$114.24 | \$50.23 |
| 40820 | T | Treatment of mouth lesion | 0253 | 12.02 | \$582.81 | \$284.00 | \$116.56 |
| 40830 | T | Repair mouth laceration | 0251 | 1.68 | \$81.46 | \$27.99 | \$16.29 |
| 40831 | T | Repair mouth laceration | 0253 | 12.02 | \$582.81 | \$284.00 | \$116.56 |
| 40840 | T | Reconstruction of mouth | 0254 | 12.45 | \$603.66 | \$272.41 | \$120.73 |
| 40842 | T | Reconstruction of mouth | 0254 | 12.45 | \$603.66 | \$272.41 | \$120.73 |
| 40843 | T | Reconstruction of mouth | 0254 | 12.45 | \$603.66 | \$272.41 | \$120.73 |
| 40844 | T | Reconstruction of mouth | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 40845 | T | Reconstruction of mouth | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 40899 | T | Mouth surgery procedure ....................................... | 0252 | 5.18 | \$251.16 | \$114.24 | \$50.23 |
| 41000 | T | Drainage of mouth lesion | 0253 | 12.02 | \$582.81 | \$284.00 | \$116.56 |
| 41005 | T | Drainage of mouth lesion | 0251 | 1.68 | \$81.46 | \$27.99 | \$16.29 |
| 41006 | T | Drainage of mouth lesion ....................................... | 0253 | 12.02 | \$582.81 | \$284.00 | \$116.56 |
| 41007 | T | Drainage of mouth lesion | 0253 | 12.02 | \$582.81 | \$284.00 | \$116.56 |
| 41008 | T | Drainage of mouth lesion | 0253 | 12.02 | \$582.81 | \$284.00 | \$116.56 |
| 41009 | T | Drainage of mouth lesion | 0251 | 1.68 | \$81.46 | \$27.99 | \$16.29 |
| 41010 | T | Incision of tongue fold ... | 0253 | 12.02 | \$582.81 | \$284.00 | \$116.56 |
| 41015 | T | Drainage of mouth lesion | 0252 | 5.18 | \$251.16 | \$114.24 | \$50.23 |
| 41016 | T | Drainage of mouth lesion | 0253 | 12.02 | \$582.81 | \$284.00 | \$116.56 |
| 41017 | T | Drainage of mouth lesion ....................................... | 0253 | 12.02 | \$582.81 | \$284.00 | \$116.56 |
| 41018 | T | Drainage of mouth lesion | 0253 | 12.02 | \$582.81 | \$284.00 | \$116.56 |
| 41100 | T | Biopsy of tongue | 0252 | 5.18 | \$251.16 | \$114.24 | \$50.23 |
| 41105 | T | Biopsy of tongue ..... | 0253 | 12.02 | \$582.81 | \$284.00 | \$116.56 |
| 41108 | T | Biopsy of floor of mouth | 0252 | 5.18 | \$251.16 | \$114.24 | \$50.23 |
| 41110 | T | Excision of tongue lesion | 0253 | 12.02 | \$582.81 | \$284.00 | \$116.56 |
| 41112 | T | Excision of tongue lesion ....................................... | 0253 | 12.02 | \$582.81 | \$284.00 | \$116.56 |
| 41113 | T | Excision of tongue lesion ....................................... | 0253 | 12.02 | \$582.81 | \$284.00 | \$116.56 |
| 41114 | T | Excision of tongue lesion | 0254 | 12.45 | \$603.66 | \$272.41 | \$120.73 |
| 41115 | T | Excision of tongue fold | 0253 | 12.02 | \$582.81 | \$284.00 | \$116.56 |
| 41116 | T | Excision of mouth lesion | 0253 | 12.02 | \$582.81 | \$284.00 | \$116.56 |
| 41120 | T | Partial removal of tongue ....................................... | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 41130 | C | Partial removal of tongue ....................................... | ..................... | ..................... |  |  |  |
| 41135 | C | Tongue and neck surgery |  |  |  |  |  |

[^170]
## Addendum B.-Hospital Outpatient Department (HOPD) Payment Status by hCPCS Code and Related Information-Continued

| CPT/ HCPCS | HOPD Status Indicator | Description | APC | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 41140 | C | Removal of tongue |  |  |  |  |  |
| 41145 | C | Tongue removal, neck surgery | .................... |  |  |  |  |
| 41150 | C | Tongue, mouth, jaw surgery ............................... |  |  |  |  |  |
| 41153 | C | Tongue, mouth, neck surgery .............................. |  |  |  |  |  |
| 41155 | C | Tongue, jaw, \& neck surgery |  |  |  |  |  |
| 41250 | T | Repair tongue laceration | 0251 | 1.68 | \$81.46 | \$27.99 | \$16.29 |
| 41251 | T | Repair tongue laceration | 0253 | 12.02 | \$582.81 | \$284.00 | \$116.56 |
| 41252 | T | Repair tongue laceration | 0253 | 12.02 | \$582.81 | \$284.00 | \$116.56 |
| 41500 | T | Fixation of tongue | 0253 | 12.02 | \$582.81 | \$284.00 | \$116.56 |
| 41510 | T | Tongue to lip surgery | 0253 | 12.02 | \$582.81 | \$284.00 | \$116.56 |
| 41520 | T | Reconstruction, tongue fold | 0253 | 12.02 | \$582.81 | \$284.00 | \$116.56 |
| 41599 | T | Tongue and mouth surgery | 0251 | 1.68 | \$81.46 | \$27.99 | \$16.29 |
| 41800 | T | Drainage of gum lesion | 0251 | 1.68 | \$81.46 | \$27.99 | \$16.29 |
| 41805 | T | Removal foreign body, gum | 0253 | 12.02 | \$582.81 | \$284.00 | \$116.56 |
| 41806 | T | Removal foreign body, jawbone | 0253 | 12.02 | \$582.81 | \$284.00 | \$116.56 |
| 41820 | T | Excision, gum, each quadrant . | 0252 | 5.18 | \$251.16 | \$114.24 | \$50.23 |
| 41821 | T | Excision of gum flap | 0252 | 5.18 | \$251.16 | \$114.24 | \$50.23 |
| 41822 | T | Excision of gum lesion | 0253 | 12.02 | \$582.81 | \$284.00 | \$116.56 |
| 41823 | T | Excision of gum lesion | 0253 | 12.02 | \$582.81 | \$284.00 | \$116.56 |
| 41825 | T | Excision of gum lesion | 0253 | 12.02 | \$582.81 | \$284.00 | \$116.56 |
| 41826 | T | Excision of gum lesion | 0253 | 12.02 | \$582.81 | \$284.00 | \$116.56 |
| 41827 | T | Excision of gum lesion | 0253 | 12.02 | \$582.81 | \$284.00 | \$116.56 |
| 41828 | T | Excision of gum lesion | 0253 | 12.02 | \$582.81 | \$284.00 | \$116.56 |
| 41830 | T | Removal of gum tissue | 0253 | 12.02 | \$582.81 | \$284.00 | \$116.56 |
| 41850 | T | Treatment of gum lesion | 0253 | 12.02 | \$582.81 | \$284.00 | \$116.56 |
| 41870 | T | Gum graft | 0253 | 12.02 | \$582.81 | \$284.00 | \$116.56 |
| 41872 | T | Repair gum | 0253 | 12.02 | \$582.81 | \$284.00 | \$116.56 |
| 41874 | T | Repair tooth socket | 0253 | 12.02 | \$582.81 | \$284.00 | \$116.56 |
| 41899 | T | Dental surgery procedure | 0253 | 12.02 | \$582.81 | \$284.00 | \$116.56 |
| 42000 | T | Drainage mouth roof lesion | 0251 | 1.68 | \$81.46 | \$27.99 | \$16.29 |
| 42100 | T | Biopsy roof of mouth | 0252 | 5.18 | \$251.16 | \$114.24 | \$50.23 |
| 42104 | T | Excision lesion, mouth roof | 0253 | 12.02 | \$582.81 | \$284.00 | \$116.56 |
| 42106 | T | Excision lesion, mouth roof | 0253 | 12.02 | \$582.81 | \$284.00 | \$116.56 |
| 42107 | T | Excision lesion, mouth roof | 0254 | 12.45 | \$603.66 | \$272.41 | \$120.73 |
| 42120 | T | Remove palate/lesion | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 42140 | T | Excision of uvula | 0252 | 5.18 | \$251.16 | \$114.24 | \$50.23 |
| 42145 | T | Repair palate, pharynx/uvula | 0254 | 12.45 | \$603.66 | \$272.41 | \$120.73 |
| 42160 | T | Treatment mouth roof lesion | 0253 | 12.02 | \$582.81 | \$284.00 | \$116.56 |
| 42180 | T | Repair palate | 0251 | 1.68 | \$81.46 | \$27.99 | \$16.29 |
| 42182 | T | Repair palate | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 42200 | T | Reconstruct cleft palate | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 42205 | T | Reconstruct cleft palate | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 42210 | T | Reconstruct cleft palate | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 42215 | T | Reconstruct cleft palate | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 42220 | T | Reconstruct cleft palate | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 42225 | T | Reconstruct cleft palate | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 42226 | T | Lengthening of palate | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 42227 | T | Lengthening of palate | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 42235 | T | Repair palate ... | 0254 | 12.45 | \$603.66 | \$272.41 | \$120.73 |
| 42260 | T | Repair nose to lip fistula | 0253 | 12.02 | \$582.81 | \$284.00 | \$116.56 |
| 42280 | T | Preparation, palate mold | 0251 | 1.68 | \$81.46 | \$27.99 | \$16.29 |
| 42281 | T | Insertion, palate prosthesis | 0253 | 12.02 | \$582.81 | \$284.00 | \$116.56 |
| 42299 | T | Palate/uvula surgery | 0251 | 1.68 | \$81.46 | \$27.99 | \$16.29 |
| 42300 | T | Drainage of salivary gland | 0253 | 12.02 | \$582.81 | \$284.00 | \$116.56 |
| 42305 | T | Drainage of salivary gland ...................................... | 0253 | 12.02 | \$582.81 | \$284.00 | \$116.56 |
| 42310 | T | Drainage of salivary gland | 0251 | 1.68 | \$81.46 | \$27.99 | \$16.29 |
| 42320 | T | Drainage of salivary gland | 0251 | 1.68 | \$81.46 | \$27.99 | \$16.29 |
| 42325 | T | Create salivary cyst drain ....................................... | 0252 | 5.18 | \$251.16 | \$114.24 | \$50.23 |
| 42326 | T | Create salivary cyst drain | 0252 | 5.18 | \$251.16 | \$114.24 | \$50.23 |
| 42330 | T | Removal of salivary stone | 0252 | 5.18 | \$251.16 | \$114.24 | \$50.23 |
| 42335 | T | Removal of salivary stone ...................................... | 0253 | 12.02 | \$582.81 | \$284.00 | \$116.56 |
| 42340 | T | Removal of salivary stone ....... | 0253 | 12.02 | \$582.81 | \$284.00 | \$116.56 |
| 42400 | T | Biopsy of salivary gland | 0004 | 1.84 | \$89.22 | \$32.57 | \$17.84 |
| 42405 | T | Biopsy of salivary gland .......................................... | 0253 | 12.02 | \$582.81 | \$284.00 | \$116.56 |
| 42408 | T | Excision of salivary cyst ....................................... | 0253 | 12.02 | \$582.81 | \$284.00 | \$116.56 |
| 42409 | T | Drainage of salivary cyst ....................................... | 0253 | 12.02 | \$582.81 | \$284.00 | \$116.56 |
| 42410 | T | Excise parotid gland/lesion ..................................... | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 42415 | T | Excise parotid gland/lesion ..................................... | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 42420 | T | Excise parotid gland/lesion .................................... | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 42425 | T | Excise parotid gland/lesion | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 42426 | C | Excise parotid gland/lesion .................................... |  |  |  |  |  |
| 42440 | T | Excise submaxillary gland ...................................... | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 42450 | T | Excise sublingual gland | 0253 | 12.02 | \$582.81 | \$284.00 | \$116.56 |

[^171]
## Addendum B.-Hospital Outpatient Department (HOPD) Payment Status by HCPCS Code and Related Information-Continued

| $\begin{aligned} & \text { CPT/ } \\ & \text { HCPCS } \end{aligned}$ | HOPD Status Indicator | Description | APC | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 42500 | T | Repair salivary duct | 0254 | 12.45 | \$603.66 | \$272.41 | \$120.73 |
| 42505 | T | Repair salivary duct | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 42507 | T | Parotid duct diversion | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 42508 | T | Parotid duct diversion | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 42509 | T | Parotid duct diversion | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 42510 | T | Parotid duct diversion | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 42550 | N | Injection for salivary x-ray |  |  |  |  |  |
| 42600 | T | Closure of salivary fistula | 0253 | 12.02 | \$582.81 | \$284.00 | \$116.56 |
| 42650 | T | Dilation of salivary duct | 0252 | 5.18 | \$251.16 | \$114.24 | \$50.23 |
| 42660 | T | Dilation of salivary duct | 0252 | 5.18 | \$251.16 | \$114.24 | \$50.23 |
| 42665 | T | Ligation of salivary duct | 0253 | 12.02 | \$582.81 | \$284.00 | \$116.56 |
| 42699 | T | Salivary surgery procedure | 0253 | 12.02 | \$582.81 | \$284.00 | \$116.56 |
| 42700 | T | Drainage of tonsil abscess | 0251 | 1.68 | \$81.46 | \$27.99 | \$16.29 |
| 42720 | T | Drainage of throat abscess | 0253 | 12.02 | \$582.81 | \$284.00 | \$116.56 |
| 42725 | T | Drainage of throat abscess | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 42800 | T | Biopsy of throat | 0252 | 5.18 | \$251.16 | \$114.24 | \$50.23 |
| 42802 | T | Biopsy of throat | 0253 | 12.02 | \$582.81 | \$284.00 | \$116.56 |
| 42804 | T | Biopsy of upper nose/throat | 0253 | 12.02 | \$582.81 | \$284.00 | \$116.56 |
| 42806 | T | Biopsy of upper nose/throat | 0253 | 12.02 | \$582.81 | \$284.00 | \$116.56 |
| 42808 | T | Excise pharynx lesion | 0253 | 12.02 | \$582.81 | \$284.00 | \$116.56 |
| 42809 | T | Remove pharynx foreign body | 0251 | 1.68 | \$81.46 | \$27.99 | \$16.29 |
| 42810 | T | Excision of neck cyst | 0253 | 12.02 | \$582.81 | \$284.00 | \$116.56 |
| 42815 | T | Excision of neck cyst | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 42820 | T | Remove tonsils and adenoids | 0258 | 18.62 | \$902.83 | \$462.81 | \$180.57 |
| 42821 | T | Remove tonsils and adenoids | 0258 | 18.62 | \$902.83 | \$462.81 | \$180.57 |
| 42825 | T | Removal of tonsils | 0258 | 18.62 | \$902.83 | \$462.81 | \$180.57 |
| 42826 | T | Removal of tonsils | 0258 | 18.62 | \$902.83 | \$462.81 | \$180.57 |
| 42830 | T | Removal of adenoids | 0258 | 18.62 | \$902.83 | \$462.81 | \$180.57 |
| 42831 | T | Removal of adenoids | 0258 | 18.62 | \$902.83 | \$462.81 | \$180.57 |
| 42835 | T | Removal of adenoids | 0258 | 18.62 | \$902.83 | \$462.81 | \$180.57 |
| 42836 | T | Removal of adenoids | 0258 | 18.62 | \$902.83 | \$462.81 | \$180.57 |
| 42842 | C | Extensive surgery of throat |  |  |  |  |  |
| 42844 | T | Extensive surgery of throat | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 42845 | C | Extensive surgery of throat |  |  |  |  |  |
| 42860 | T | Excision of tonsil tags | 0258 | 18.62 | \$902.83 | \$462.81 | \$180.57 |
| 42870 | T | Excision of lingual tonsil ......................................... | 0258 | 18.62 | \$902.83 | \$462.81 | \$180.57 |
| 42890 | T | Partial removal of pharynx ...................................... | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 42892 | T | Revision of pharyngeal walls | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 42894 | C | Revision of pharyngeal walls . |  |  |  |  |  |
| 42900 | T | Repair throat wound | 0253 | 12.02 | \$582.81 | \$284.00 | \$116.56 |
| 42950 | T | Reconstruction of throat | 0254 | 12.45 | \$603.66 | \$272.41 | \$120.73 |
| 42953 | C | Repair throat, esophagus |  |  |  |  |  |
| 42955 | T | Surgical opening of throat | 0254 | 12.45 | \$603.66 | \$272.41 | \$120.73 |
| 42960 | T | Control throat bleeding | 0250 | 2.21 | \$107.16 | \$38.54 | \$21.43 |
| 42961 | C | Control throat bleeding |  |  |  |  |  |
| 42962 | T | Control throat bleeding .......................................... | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 42970 | T | Control nose/throat bleeding .................................. | 0250 | 2.21 | \$107.16 | \$38.54 | \$21.43 |
| 42971 | C | Control nose/throat bleeding |  |  |  |  |  |
| 42972 | T | Control nose/throat bleeding | 0253 | 12.02 | \$582.81 | \$284.00 | \$116.56 |
| 42999 | T | Throat surgery procedure | 0252 | 5.18 | \$251.16 | \$114.24 | \$50.23 |
| 43020 | T | Incision of esophagus ............................................ | 0254 | 12.45 | \$603.66 | \$272.41 | \$120.73 |
| 43030 | C | Throat muscle surgery |  |  |  |  |  |
| 43045 | C | Incision of esophagus ............................................ | ...... | ..................... |  | .................... |  |
| 43100 | C | Excision of esophagus lesion ... |  |  |  | ...................... |  |
| 43101 | C | Excision of esophagus lesion ... |  |  |  |  |  |
| 43107 | C | Removal of esophagus ........... |  |  |  | ...................... |  |
| 43108 | C | Removal of esophagus |  | .................... | .................... | .................... |  |
| 43112 | C | Removal of esophagus .......................................... |  |  |  |  |  |
| 43113 | C | Removal of esophagus |  |  |  |  |  |
| 43116 | C | Partial removal of esophagus .................................. | .................... | . | ..................... | ............ |  |
| 43117 | C | Partial removal of esophagus ... |  |  |  | ...................... |  |
| 43118 | C | Partial removal of esophagus |  |  |  |  |  |
| 43121 | C | Partial removal of esophagus ................................. |  |  | ..................... | .................... | ................... |
| 43122 | C | Parital removal of esophagus | - | .................. | - | ................... |  |
| 43123 | C | Partial removal of esophagus |  |  |  |  |  |
| 43124 | C | Removal of esophagus .......................................... |  | .................... |  | .................... |  |
| 43130 | C | Removal of esophagus pouch ................................. |  |  |  | ..................... |  |
| 43135 | C | Removal of esophagus pouch ................................. |  |  |  |  |  |
| 43200 | T | Esophagus endoscopy | 0141 | 7.15 | \$346.68 | \$184.67 | \$69.34 |
| 43202 | T | Esophagus endoscopy, biopsy ................................ | 0141 | 7.15 | \$346.68 | \$184.67 | \$69.34 |
| 43204 | T | Esophagus endoscopy \& inject ............................... | 0141 | 7.15 | \$346.68 | \$184.67 | \$69.34 |
| 43205 | T | Esophagus endoscopy/ligation ................................ | 0141 | 7.15 | \$346.68 | \$184.67 | \$69.34 |
| 43215 | T | Esophagus endoscopy ....................................... | 0141 | 7.15 | \$346.68 | \$184.67 | \$69.34 |

[^172]
# Addendum B.-Hospital Outpatient Department (HOPD) Payment Status by HCPCS Code and Related Information-Continued 

| CPT/ HCPCS | HOPD Status Indicator | Description | APC | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 43216 | T | Esophagus endoscopy/lesion | 0141 | 7.15 | \$346.68 | \$184.67 | \$69.34 |
| 43217 | T | Esophagus endoscopy ........ | 0141 | 7.15 | \$346.68 | \$184.67 | \$69.34 |
| 43219 | T | Esophagus endoscopy | 0141 | 7.15 | \$346.68 | \$184.67 | \$69.34 |
| 43220 | T | Esoph endoscopy, dilation | 0141 | 7.15 | \$346.68 | \$184.67 | \$69.34 |
| 43226 | T | Esoph endoscopy, dilation | 0141 | 7.15 | \$346.68 | \$184.67 | \$69.34 |
| 43227 | T | Esoph endoscopy, repair | 0141 | 7.15 | \$346.68 | \$184.67 | \$69.34 |
| 43228 | T | Esoph endoscopy, ablation | 0141 | 7.15 | \$346.68 | \$184.67 | \$69.34 |
| 43234 | T | Upper GI endoscopy, exam | 0141 | 7.15 | \$346.68 | \$184.67 | \$69.34 |
| 43235 | T | Uppr gi endoscopy, diagnosis | 0141 | 7.15 | \$346.68 | \$184.67 | \$69.34 |
| 43239 | T | Upper Gl endoscopy, biopsy | 0141 | 7.15 | \$346.68 | \$184.67 | \$69.34 |
| 43241 | T | Upper Gl endoscopy with tube . | 0141 | 7.15 | \$346.68 | \$184.67 | \$69.34 |
| 43243 | T | Upper gi endoscopy \& inject .... | 0141 | 7.15 | \$346.68 | \$184.67 | \$69.34 |
| 43244 | T | Upper Gl endoscopy/ligation | 0141 | 7.15 | \$346.68 | \$184.67 | \$69.34 |
| 43245 | T | Operative upper Gl endoscopy | 0141 | 7.15 | \$346.68 | \$184.67 | \$69.34 |
| 43246 | T | Place gastrostomy tube | 0141 | 7.15 | \$346.68 | \$184.67 | \$69.34 |
| 43247 | T | Operative upper Gl endoscopy | 0141 | 7.15 | \$346.68 | \$184.67 | \$69.34 |
| 43248 | T | Uppr gi endoscopy/guide wire | 0141 | 7.15 | \$346.68 | \$184.67 | \$69.34 |
| 43249 | T | Esoph endoscopy, dilation | 0141 | 7.15 | \$346.68 | \$184.67 | \$69.34 |
| 43250 | T | Upper GI endoscopy/tumor .................................... | 0141 | 7.15 | \$346.68 | \$184.67 | \$69.34 |
| 43251 | T | Operative upper Gl endoscopy | 0141 | 7.15 | \$346.68 | \$184.67 | \$69.34 |
| 43255 | T | Operative upper Gl endoscopy | 0141 | 7.15 | \$346.68 | \$184.67 | \$69.34 |
| 43258 | T | Operative upper Gl endoscopy | 0141 | 7.15 | \$346.68 | \$184.67 | \$69.34 |
| 43259 | T | Endoscopic ultrasound exam | 0141 | 7.15 | \$346.68 | \$184.67 | \$69.34 |
| 43260 | T | Endo cholangiopancreatograph | 0151 | 10.53 | \$510.57 | \$245.46 | \$102.11 |
| 43261 | T | Endo cholangiopancreatograph ............................... | 0151 | 10.53 | \$510.57 | \$245.46 | \$102.11 |
| 43262 | T | Endo cholangiopancreatograph ............................... | 0151 | 10.53 | \$510.57 | \$245.46 | \$102.11 |
| 43263 | T | Endo cholangiopancreatograph | 0151 | 10.53 | \$510.57 | \$245.46 | \$102.11 |
| 43264 | T | Endo cholangiopancreatograph | 0151 | 10.53 | \$510.57 | \$245.46 | \$102.11 |
| 43265 | T | Endo cholangiopancreatograph | 0151 | 10.53 | \$510.57 | \$245.46 | \$102.11 |
| 43267 | T | Endo cholangiopancreatograph | 0151 | 10.53 | \$510.57 | \$245.46 | \$102.11 |
| 43268 | T | Endo cholangiopancreatograph | 0151 | 10.53 | \$510.57 | \$245.46 | \$102.11 |
| 43269 | T | Endo cholangiopancreatograph | 0151 | 10.53 | \$510.57 | \$245.46 | \$102.11 |
| 43271 | T | Endo cholangiopancreatograph | 0151 | 10.53 | \$510.57 | \$245.46 | \$102.11 |
| 43272 | T | Endo cholangiopancreatograph | 0151 | 10.53 | \$510.57 | \$245.46 | \$102.11 |
| 43280 | T | Laparoscopy, fundoplasty ....................................... | 0132 | 48.91 | \$2,371.50 | \$1,239.22 | \$474.30 |
| 43289 | T | Laparoscope proc, esoph ... | 0130 | 25.36 | \$1,229.63 | \$659.53 | \$245.93 |
| 43300 | C | Repair of esophagus |  |  |  |  |  |
| 43305 | C | Repair esophagus and fistula |  |  |  |  |  |
| 43310 | C | Repair of esophagus |  |  |  | .................... |  |
| 43312 | C | Repair esophagus and fistula |  |  |  |  |  |
| 43320 | C | Fuse esophagus \& stomach . |  |  |  |  |  |
| 43324 | C | Revise esophagus \& stomach |  |  |  |  |  |
| 43325 | C | Revise esophagus \& stomach |  | ..... |  | ..................... |  |
| 43326 | C | Revise esophagus \& stomach ................................. |  |  |  |  |  |
| 43330 | C | Repair of esophagus ............................................. | ...... | ....... |  | ..................... |  |
| 43331 | C | Repair of esophagus ............................................ |  |  |  |  |  |
| 43340 | C | Fuse esophagus \& intestine ................................... |  |  |  |  |  |
| 43341 | C | Fuse esophagus \& intestine ................................... |  |  |  | ...................... |  |
| 43350 | C | Surgical opening, esophagus ................................. |  |  |  | ..................... |  |
| 43351 | C | Surgical opening, esophagus .................................. |  |  |  |  |  |
| 43352 | C | Surgical opening, esophagus |  |  |  |  |  |
| 43360 | C | Gastrointestinal repair ........................................... | - | - | .................... | .................... |  |
| 43361 | C | Gastrointestinal repair .......................................... |  |  |  |  |  |
| 43400 | C | Ligate esophagus veins ......................................... |  |  |  |  |  |
| 43401 | C | Esophagus surgery for veins .................................. |  |  |  | ..................... | ...................... |
| 43405 | C | Ligate/staple esophagus |  |  |  | ..................... |  |
| 43410 | C | Repair esophagus wound |  |  |  |  |  |
| 43415 | C | Repair esophagus wound ....................................... |  |  |  | .................... |  |
| 43420 | C | Repair esophagus opening .................................... |  |  |  |  |  |
| 43425 | C | Repair esophagus opening .................................... |  |  |  |  |  |
| 43450 | T | Dilate esophagus | 0140 | 4.74 | \$229.83 | \$107.24 | \$45.97 |
| 43453 | T | Dilate esophagus ... | 0140 | 4.74 | \$229.83 | \$107.24 | \$45.97 |
| 43456 | T | Dilate esophagus ................................................. | 0140 | 4.74 | \$229.83 | \$107.24 | \$45.97 |
| 43458 | T | Dilate esophagus | 0140 | 4.74 | \$229.83 | \$107.24 | \$45.97 |
| 43460 | C | Pressure treatment esophagus ............................... |  |  |  |  |  |
| 43496 | C | Free jejunum flap, microvasc .................................. |  |  |  |  |  |
| 43499 | T | Esophagus surgery procedure | 0140 | 4.74 | \$229.83 | \$107.24 | \$45.97 |
| 43500 | C | Surgical opening of stomach .................................. |  |  |  | ..................... |  |
| 43501 | C | Surgical repair of stomach ...................................... |  |  |  | ...................... |  |
| 43502 | C | Surgical repair of stomach ...................................... |  |  |  |  |  |
| 43510 | C | Surgical opening of stomach ................................... |  |  |  |  |  |
| 43520 | C | Incision of pyloric muscle ....................................... | .................... | ..................... |  |  |  |
| 43600 | T | Biopsy of stomach | 0141 | 7.15 | \$346.68 | \$184.67 | \$69.34 |

[^173]
# Addendum B.-Hospital Outpatient Department (HOPD) Payment Status by HCPCS Code and Related INFORMATION-Continued 

| $\begin{gathered} \text { CPT/ } \\ \text { HCPCS } \end{gathered}$ | HOPD Status Indicator | Description | APC | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 43605 | C | Biopsy of stomach |  |  |  |  |  |
| 43610 | C | Excision of stomach lesion |  |  |  |  |  |
| 43611 | C | Excision of stomach lesion |  |  |  |  |  |
| 43620 | C | Removal of stomach | ..................... | .................... | ..................... | .................... |  |
| 43621 | C | Removal of stomach |  |  |  |  |  |
| 43622 | C | Removal of stomach |  |  |  |  |  |
| 43631 | C | Removal of stomach, partial |  |  |  |  |  |
| 43632 | C | Removal of stomach, partial |  |  |  |  |  |
| 43633 | C | Removal of stomach, partial |  |  |  |  |  |
| 43634 | C | Removal of stomach, partial |  |  |  |  |  |
| 43635 | C | Removal of stomach, partial | ..................... | .................... |  | ..................... |  |
| 43638 | C | Removal of stomach, partial | ..................... | ..................... | ..................... | .................... |  |
| 43639 | C | Removal of stomach, partial |  |  |  |  |  |
| 43640 | C | Vagotomy \& pylorus repair . |  |  |  |  |  |
| 43641 | C | Vagotomy \& pylorus repair . |  |  |  |  |  |
| 43651 | T | Laparoscopy, vagus nerve | 0132 | 48.91 | \$2,371.50 | \$1,239.22 | \$474.30 |
| 43652 | T | Laparoscopy, vagus nerve | 0132 | 48.91 | \$2,371.50 | \$1,239.22 | \$474.30 |
| 43653 | T | Laparoscopy, gastrostomy | 0131 | 41.81 | \$2,027.24 | \$1,089.88 | \$405.45 |
| 43659 | T | Laparoscope proc, stom ......................................... | 0130 | 25.36 | \$1,229.63 | \$659.53 | \$245.93 |
| 43750 | T | Place gastrostomy tube | 0141 | 7.15 | \$346.68 | \$184.67 | \$69.34 |
| 43760 | T | Change gastrostomy tube | 0121 | 2.36 | \$114.43 | \$52.53 | \$22.89 |
| 43761 | T | Reposition gastrostomy tube | 0121 | 2.36 | \$114.43 | \$52.53 | \$22.89 |
| 43800 | C | Reconstruction of pylorus |  |  |  |  |  |
| 43810 | C | Fusion of stomach and bowel |  |  |  |  |  |
| 43820 | C | Fusion of stomach and bowel |  |  |  |  |  |
| 43825 | C | Fusion of stomach and bowel |  |  |  |  |  |
| 43830 | T | Place gastrostomy tube | 0141 | 7.15 | \$346.68 | \$184.67 | \$69.34 |
| 43831 | T | Place gastrostomy tube .......................................... | 0141 | 7.15 | \$346.68 | \$184.67 | \$69.34 |
| 43832 | C | Place gastrostomy tube |  |  |  |  |  |
| 43840 | C | Repair of stomach lesion |  |  |  |  |  |
| 43842 | C | Gastroplasty for obesity ......................................... |  |  |  | ..................... |  |
| 43843 | C | Gastroplasty for obesity |  |  |  |  |  |
| 43846 | C | Gastric bypass for obesity ...................................... |  |  |  |  |  |
| 43847 | C | Gastric bypass for obesity .... |  |  |  |  |  |
| 43848 | C | Revision gastroplasty . |  |  |  | ..................... |  |
| 43850 | C | Revise stomach-bowel fusion |  |  |  |  |  |
| 43855 | C | Revise stomach-bowel fusion |  |  |  |  |  |
| 43860 | C | Revise stomach-bowel fusion |  |  |  |  |  |
| 43865 | C | Revise stomach-bowel fusion |  |  |  |  |  |
| 43870 | T | Repair stomach opening | 0025 | 3.74 | \$181.34 | \$70.66 | \$36.27 |
| 43880 | C | Repair stomach-bowel fistula |  |  |  |  |  |
| 43999 | T | Stomach surgery procedure | 0121 | 2.36 | \$114.43 | \$52.53 | \$22.89 |
| 44005 | C | Freeing of bowel adhesion |  |  |  |  |  |
| 44010 | C | Incision of small bowel |  |  |  |  |  |
| 44015 | C | Insert needle cath bowel |  |  |  |  |  |
| 44020 | C | Exploration of small bowel |  |  |  |  |  |
| 44021 | C | Decompress small bowel ... |  |  |  |  |  |
| 44025 | C | Incision of large bowel |  |  |  |  |  |
| 44050 | C | Reduce bowel obstruction |  |  |  |  |  |
| 44055 | C | Correct malrotation of bowel |  |  |  |  |  |
| 44100 | T | Biopsy of bowel | 0141 | 7.15 | \$346.68 | \$184.67 | \$69.34 |
| 44110 | C | Excision of bowel lesion(s) ..................................... |  |  |  |  |  |
| 44111 | C | Excision of bowel lesion(s) ..................................... |  |  |  |  |  |
| 44120 | C | Removal of small intestine |  |  |  |  |  |
| 44121 | C | Removal of small intestine |  |  |  |  |  |
| 44125 | C | Removal of small intestine |  |  |  |  |  |
| 44130 | C | Bowel to bowel fusion |  |  |  |  |  |
| 44139 | C | Mobilization of colon |  |  |  |  |  |
| 44140 | C | Partial removal of colon |  |  |  |  |  |
| 44141 | C | Partial removal of colon |  |  |  |  |  |
| 44143 | C | Partial removal of colon |  |  |  |  |  |
| 44144 | C | Partial removal of colon |  |  |  |  |  |
| 44145 | C | Partial removal of colon |  |  |  |  |  |
| 44146 | C | Partial removal of colon |  |  |  |  |  |
| 44147 | C | Partial removal of colon | .................... | .................... |  | .................... | - |
| 44150 | C | Removal of colon |  |  |  |  |  |
| 44151 | C | Removal of colon/ileostomy |  |  |  |  |  |
| 44152 | C | Removal of colon/ileostomy .................................... |  |  |  | ...................... |  |
| 44153 | C | Removal of colon/ileostomy |  |  |  |  |  |
| 44155 | C | Removal of colon/ileostomy .................................... |  |  |  |  |  |
| 44156 | C | Removal of colon/ileostomy .................................... |  |  |  |  |  |
| 44160 | C | Removal of colon ......... | ..................... | .................... |  |  |  |
| 44200 | T | Laparoscopy, enterolysis | 0131 | 41.81 | \$2,027.24 | \$1,089.88 | \$405.45 |

[^174]
# Addendum B.—Hospital Outpatient Department (hopd) Payment Status by hCPCS Code and Related Information-Continued 

| CPT/ HCPCS | HOPD Status Indicator | Description | APC | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 44201 | T | Laparoscopy, jejunostomy | 0131 | 41.81 | \$2,027.24 | \$1,089.88 | \$405.45 |
| 44202 | C | Laparo, resect intestine |  |  |  |  |  |
| 44209 | T | Laparoscope proc, intestine | 0130 | 25.36 | \$1,229.63 | \$659.53 | \$245.93 |
| 44300 | C | Open bowel to skin ............ |  |  |  |  |  |
| 44310 | C | lleostomy/jejunostomy |  |  |  |  |  |
| 44312 | T | Revision of ileostomy . | 0026 | 12.11 | \$587.18 | \$277.92 | \$117.44 |
| 44314 | C | Revision of ileostomy |  |  |  |  |  |
| 44316 | C | Devise bowel pouch |  |  |  |  |  |
| 44320 | C | Colostomy ... |  |  |  |  |  |
| 44322 | C | Colostomy with biopsies |  |  |  |  |  |
| 44340 | T | Revision of colostomy ... | 0026 | 12.11 | \$587.18 | \$277.92 | \$117.44 |
| 44345 | C | Revision of colostomy |  |  |  |  |  |
| 44346 | C | Revision of colostomy |  |  |  |  |  |
| 44360 | T | Small bowel endoscopy | 0142 | 7.45 | \$361.23 | \$162.42 | \$72.25 |
| 44361 | T | Small bowel endoscopy/biopsy | 0142 | 7.45 | \$361.23 | \$162.42 | \$72.25 |
| 44363 | T | Small bowel endoscopy | 0142 | 7.45 | \$361.23 | \$162.42 | \$72.25 |
| 44364 | T | Small bowel endoscopy | 0142 | 7.45 | \$361.23 | \$162.42 | \$72.25 |
| 44365 | T | Small bowel endoscopy | 0142 | 7.45 | \$361.23 | \$162.42 | \$72.25 |
| 44366 | T | Small bowel endoscopy | 0142 | 7.45 | \$361.23 | \$162.42 | \$72.25 |
| 44369 | T | Small bowel endoscopy | 0142 | 7.45 | \$361.23 | \$162.42 | \$72.25 |
| 44372 | T | Small bowel endoscopy | 0142 | 7.45 | \$361.23 | \$162.42 | \$72.25 |
| 44373 | T | Small bowel endoscopy | 0142 | 7.45 | \$361.23 | \$162.42 | \$72.25 |
| 44376 | T | Small bowel endoscopy | 0142 | 7.45 | \$361.23 | \$162.42 | \$72.25 |
| 44377 | T | Small bowel endoscopy/biopsy | 0142 | 7.45 | \$361.23 | \$162.42 | \$72.25 |
| 44378 | T | Small bowel endoscopy ........... | 0142 | 7.45 | \$361.23 | \$162.42 | \$72.25 |
| 44380 | T | Small bowel endoscopy | 0142 | 7.45 | \$361.23 | \$162.42 | \$72.25 |
| 44382 | T | Small bowel endoscopy | 0142 | 7.45 | \$361.23 | \$162.42 | \$72.25 |
| 44385 | T | Endoscopy of bowel pouch | 0143 | 7.98 | \$386.93 | \$199.12 | \$77.39 |
| 44386 | T | Endoscopy, bowel pouch/biop | 0143 | 7.98 | \$386.93 | \$199.12 | \$77.39 |
| 44388 | T | Colon endoscopy | 0143 | 7.98 | \$386.93 | \$199.12 | \$77.39 |
| 44389 | T | Colonoscopy with biopsy | 0143 | 7.98 | \$386.93 | \$199.12 | \$77.39 |
| 44390 | T | Colonoscopy for foreign body | 0143 | 7.98 | \$386.93 | \$199.12 | \$77.39 |
| 44391 | T | Colonoscopy for bleeding | 0143 | 7.98 | \$386.93 | \$199.12 | \$77.39 |
| 44392 | T | Colonoscopy \& polypectomy | 0143 | 7.98 | \$386.93 | \$199.12 | \$77.39 |
| 44393 | T | Colonoscopy, lesion removal | 0143 | 7.98 | \$386.93 | \$199.12 | \$77.39 |
| 44394 | T | Colonoscopy w/snare | 0143 | 7.98 | \$386.93 | \$199.12 | \$77.39 |
| 44500 | C | Intro, gastrointestinal tube | ...................... |  |  | ..................... | ..................... |
| 44602 | C | Suture, small intestine ..... |  |  |  |  |  |
| 44603 | C | Suture, small intestine |  |  |  |  |  |
| 44604 | C | Suture, large intestine |  |  |  |  |  |
| 44605 | C | Repair of bowel lesion |  |  |  |  |  |
| 44615 | C | Intestinal stricturoplasty |  |  |  |  |  |
| 44620 | C | Repair bowel opening |  |  |  |  |  |
| 44625 | C | Repair bowel opening |  |  |  |  | ..................... |
| 44626 | C | Repair bowel opening |  |  |  |  |  |
| 44640 | C | Repair bowel-skin fistula |  |  |  |  |  |
| 44650 | C | Repair bowel fistula ............................................... |  |  |  |  |  |
| 44660 | C | Repair bowel-bladder fistula ................................... |  | ...................... |  | ...................... |  |
| 44661 | C | Repair bowel-bladder fistula |  |  |  |  |  |
| 44680 | C | Surgical revision, intestine .... |  |  |  |  |  |
| 44700 | C | Suspend bowel w/prosthesis .................................. |  |  |  |  |  |
| 44799 | T | Intestine surgery procedure | 0142 | 7.45 | \$361.23 | \$162.42 | \$72.25 |
| 44800 | C | Excision of bowel pouch |  |  |  |  |  |
| 44820 | C | Excision of mesentery lesion .... | ................... | ....... | .................... | ..................... | ..................... |
| 44850 | C | Repair of mesentery |  |  | - | ..................... |  |
| 44899 | C | Bowel surgery procedure |  |  |  |  |  |
| 44900 | C | Drain app abscess, open ....................................... |  |  |  |  | ..................... |
| 44901 | C | Drain app abscess, percut .... |  |  |  | ...................... | ...................... |
| 44950 | C | Appendectomy |  |  |  |  |  |
| 44955 | C | Appendectomy add-on ......................................... |  | ..................... | ................... | ..................... | ..................... |
| 44960 | C | Appendectomy ....... |  |  |  |  |  |
| 44970 | T | Laparoscopy, appendectomy ................................. | 0130 | 25.36 | \$1,229.63 | \$659.53 | \$245.93 |
| 44979 | T | Laparoscope proc, app .......................................... | 0130 | 25.36 | \$1,229.63 | \$659.53 | \$245.93 |
| 45000 | T | Drainage of pelvic abscess .................................... | 0149 | 12.86 | \$623.54 | \$293.06 | \$124.71 |
| 45005 | T | Drainage of rectal abscess ..................................... | 0148 | 2.34 | \$113.46 | \$43.59 | \$22.69 |
| 45020 | T | Drainage of rectal abscess ..................................... | 0149 | 12.86 | \$623.54 | \$293.06 | \$124.71 |
| 45100 | T | Biopsy of rectum .................................................. | 0149 | 12.86 | \$623.54 | \$293.06 | \$124.71 |
| 45108 | T | Removal of anorectal lesion | 0150 | 17.68 | \$857.25 | \$437.12 | \$171.45 |
| 45110 | C | Removal of rectum .............................................. |  |  |  | ..................... |  |
| 45111 | C | Partial removal of rectum ....................................... |  |  |  |  |  |
| 45112 | C | Removal of rectum | .................... | ..................... | ..................... | ..... | ..................... |
| 45113 | C | Partial proctectomy ....... | ..................... | ..................... | ..................... |  |  |
| 45114 | C | Partial removal of rectum |  |  |  |  |  |

[^175]
# Addendum B.-Hospital Outpatient Department (HOPD) Payment Status by HCPCS Code and Related INFORMATION-Continued 

| $\begin{aligned} & \text { CPT/ } \\ & \text { HCPCS } \end{aligned}$ | HOPD Status Indicator | Description | APC | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 45116 | C | Partial removal of rectum |  |  |  |  |  |
| 45119 | C | Remove rectum w/reservoir |  |  |  |  |  |
| 45120 | C | Removal of rectum | .................. | ... | .... | ................... | ................. |
| 45121 | C | Removal of rectum and colon |  |  |  |  |  |
| 45123 | C | Partial proctectomy |  |  |  |  |  |
| 45126 | C | Pelvic exenteration | ........ | ............... | ............... | ............... | $\ldots$ |
| 45130 | C | Excision of rectal prolapse |  | ............. |  |  |  |
| 45135 | C | Excision of rectal prolapse |  |  |  |  |  |
| 45150 | T | Excision of rectal stricture | 0150 | 17.68 | \$857.25 | \$437.12 | \$171.45 |
| 45160 | T | Excision of rectal lesion | 0150 | 17.68 | \$857.25 | \$437.12 | \$171.45 |
| 45170 | T | Excision of rectal lesion | 0150 | 17.68 | \$857.25 | \$437.12 | \$171.45 |
| 45190 | T | Destruction, rectal tumor | 0150 | 17.68 | \$857.25 | \$437.12 | \$171.45 |
| 45300 | T | Proctosigmoidoscopy | 0146 | 2.83 | \$137.22 | \$65.15 | \$27.44 |
| 45303 | T | Proctosigmoidoscopy | 0146 | 2.83 | \$137.22 | \$65.15 | \$27.44 |
| 45305 | T | Proctosigmoidoscopy \& biopsy | 0146 | 2.83 | \$137.22 | \$65.15 | \$27.44 |
| 45307 | T | Proctosigmoidoscopy | 0146 | 2.83 | \$137.22 | \$65.15 | \$27.44 |
| 45308 | T | Proctosigmoidoscopy | 0147 | 6.26 | \$303.53 | \$149.11 | \$60.71 |
| 45309 | T | Proctosigmoidoscopy | 0147 | 6.26 | \$303.53 | \$149.11 | \$60.71 |
| 45315 | T | Proctosigmoidoscopy | 0147 | 6.26 | \$303.53 | \$149.11 | \$60.71 |
| 45317 | T | Proctosigmoidoscopy | 0146 | 2.83 | \$137.22 | \$65.15 | \$27.44 |
| 45320 | T | Proctosigmoidoscopy | 0147 | 6.26 | \$303.53 | \$149.11 | \$60.71 |
| 45321 | T | Proctosigmoidoscopy | 0147 | 6.26 | \$303.53 | \$149.11 | \$60.71 |
| 45330 | T | Diagnostic sigmoidoscopy | 0146 | 2.83 | \$137.22 | \$65.15 | \$27.44 |
| 45331 | T | Sigmoidoscopy and biopsy | 0146 | 2.83 | \$137.22 | \$65.15 | \$27.44 |
| 45332 | T | Sigmoidoscopy | 0146 | 2.83 | \$137.22 | \$65.15 | \$27.44 |
| 45333 | T | Sigmoidoscopy \& polypectomy | 0147 | 6.26 | \$303.53 | \$149.11 | \$60.71 |
| 45334 | T | Sigmoidoscopy for bleeding | 0147 | 6.26 | \$303.53 | \$149.11 | \$60.71 |
| 45337 | T | Sigmoidoscopy \& decompress | 0147 | 6.26 | \$303.53 | \$149.11 | \$60.71 |
| 45338 | T | Sigmoidoscopy ........ | 0147 | 6.26 | \$303.53 | \$149.11 | \$60.71 |
| 45339 | T | Sigmoidoscopy | 0147 | 6.26 | \$303.53 | \$149.11 | \$60.71 |
| 45355 | T | Surgical colonoscopy | 0143 | 7.98 | \$386.93 | \$199.12 | \$77.39 |
| 45378 | T | Diagnostic colonoscopy | 0143 | 7.98 | \$386.93 | \$199.12 | \$77.39 |
| 45379 | T | Colonoscopy | 0143 | 7.98 | \$386.93 | \$199.12 | \$77.39 |
| 45380 | T | Colonoscopy and biopsy | 0143 | 7.98 | \$386.93 | \$199.12 | \$77.39 |
| 45382 | T | Colonoscopy/control bleeding | 0143 | 7.98 | \$386.93 | \$199.12 | \$77.39 |
| 45383 | T | Lesion removal colonoscopy | 0143 | 7.98 | \$386.93 | \$199.12 | \$77.39 |
| 45384 | T | Colonoscopy ....... | 0143 | 7.98 | \$386.93 | \$199.12 | \$77.39 |
| 45385 | T | Lesion removal colonoscopy | 0143 | 7.98 | \$386.93 | \$199.12 | \$77.39 |
| 45500 | T | Repair of rectum | 0150 | 17.68 | \$857.25 | \$437.12 | \$171.45 |
| 45505 | T | Repair of rectum | 0150 | 17.68 | \$857.25 | \$437.12 | \$171.45 |
| 45520 | T | Treatment of rectal prolapse | 0098 | 1.19 | \$57.70 | \$20.88 | \$11.54 |
| 45540 | C | Correct rectal prolapse ...... |  |  |  |  |  |
| 45541 | C | Correct rectal prolapse .......................................... |  |  |  |  |  |
| 45550 | C | Repair rectum/remove sigmoid |  |  |  |  |  |
| 45560 | T | Repair of rectocele | 0150 | 17.68 | \$857.25 | \$437.12 | \$171.45 |
| 45562 | C | Exploration/repair of rectum ................................... |  |  |  | ...................... |  |
| 45563 | C | Exploration/repair of rectum | ....... | ........ | ...................... | .................... | .................... |
| 45800 | C | Repair rect/bladder fistula ....................................... |  |  |  |  |  |
| 45805 | C | Repair fistula w/colostomy |  |  |  |  |  |
| 45820 | C | Repair rectourethral fistula ..................................... | ................... | ...... |  | ..................... |  |
| 45825 | C | Repair fistula w/colostomy ..................................... |  |  |  |  |  |
| 45900 | T | Reduction of rectal prolapse | 0148 | 2.34 | \$113.46 | \$43.59 | \$22.69 |
| 45905 | T | Dilation of anal sphincter .. | 0149 | 12.86 | \$623.54 | \$293.06 | \$124.71 |
| 45910 | T | Dilation of rectal narrowing | 0149 | 12.86 | \$623.54 | \$293.06 | \$124.71 |
| 45915 | T | Remove rectal obstruction ...................................... | 0148 | 2.34 | \$113.46 | \$43.59 | \$22.69 |
| 45999 | T | Rectum surgery procedure | 0148 | 2.34 | \$113.46 | \$43.59 | \$22.69 |
| 46030 | T | Removal of rectal marker | 0149 | 12.86 | \$623.54 | \$293.06 | \$124.71 |
| 46040 | T | Incision of rectal abscess | 0148 | 2.34 | \$113.46 | \$43.59 | \$22.69 |
| 46045 | T | Incision of rectal abscess | 0150 | 17.68 | \$857.25 | \$437.12 | \$171.45 |
| 46050 | T | Incision of anal abscess ......................................... | 0148 | 2.34 | \$113.46 | \$43.59 | \$22.69 |
| 46060 | T | Incision of rectal abscess | 0150 | 17.68 | \$857.25 | \$437.12 | \$171.45 |
| 46070 | T | Incision of anal septum | 0148 | 2.34 | \$113.46 | \$43.59 | \$22.69 |
| 46080 | T | Incision of anal sphincter. | 0149 | 12.86 | \$623.54 | \$293.06 | \$124.71 |
| 46083 | T | Incise external hemorrhoid | 0148 | 2.34 | \$113.46 | \$43.59 | \$22.69 |
| 46200 | T | Removal of anal fissure | 0150 | 17.68 | \$857.25 | \$437.12 | \$171.45 |
| 46210 | T | Removal of anal crypt ............................................ | 0149 | 12.86 | \$623.54 | \$293.06 | \$124.71 |
| 46211 | T | Removal of anal crypts .......................................... | 0150 | 17.68 | \$857.25 | \$437.12 | \$171.45 |
| 46220 | T | Removal of anal tab | 0149 | 12.86 | \$623.54 | \$293.06 | \$124.71 |
| 46221 | T | Ligation of hemorrhoid(s) ...................................... | 0148 | 2.34 | \$113.46 | \$43.59 | \$22.69 |
| 46230 | T | Removal of anal tabs ...... | 0149 | 12.86 | \$623.54 | \$293.06 | \$124.71 |
| 46250 | T | Hemorrhoidectomy ............................................... | 0150 | 17.68 | \$857.25 | \$437.12 | \$171.45 |
| 46255 | T | Hemorrhoidectomy | 0150 | 17.68 | \$857.25 | \$437.12 | \$171.45 |
| 46257 | T | Remove hemorrhoids \& fissure | 0150 | 17.68 | \$857.25 | \$437.12 | \$171.45 |

[^176]
# Addendum B.—Hospital Outpatient Department (hopd) Payment Status by hCPCS Code and Related INFORMATION-Continued 

| $\begin{aligned} & \text { CPT/ } \\ & \text { HCPCS } \end{aligned}$ | HOPD Status Indicator | Description | APC | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 46258 | T | Remove hemorrhoids \& fistula | 0150 | 17.68 | \$857.25 | \$437.12 | \$171.45 |
| 46260 | T | Hemorrhoidectomy | 0150 | 17.68 | \$857.25 | \$437.12 | \$171.45 |
| 46261 | T | Remove hemorrhoids \& fissure | 0150 | 17.68 | \$857.25 | \$437.12 | \$171.45 |
| 46262 | T | Remove hemorrhoids \& fistula | 0150 | 17.68 | \$857.25 | \$437.12 | \$171.45 |
| 46270 | T | Removal of anal fistula | 0150 | 17.68 | \$857.25 | \$437.12 | \$171.45 |
| 46275 | T | Removal of anal fistula | 0150 | 17.68 | \$857.25 | \$437.12 | \$171.45 |
| 46280 | T | Removal of anal fistula | 0150 | 17.68 | \$857.25 | \$437.12 | \$171.45 |
| 46285 | T | Removal of anal fistula | 0150 | 17.68 | \$857.25 | \$437.12 | \$171.45 |
| 46288 | T | Repair anal fistula | 0150 | 17.68 | \$857.25 | \$437.12 | \$171.45 |
| 46320 | T | Removal of hemorrhoid clot | 0148 | 2.34 | \$113.46 | \$43.59 | \$22.69 |
| 46500 | T | Injection into hemorrhoids | 0148 | 2.34 | \$113.46 | \$43.59 | \$22.69 |
| 46600 | N | Diagnostic anoscopy ............................................. |  |  |  |  |  |
| 46604 | T | Anoscopy and dilation | 0144 | 2.23 | \$108.13 | \$49.32 | \$21.63 |
| 46606 | T | Anoscopy and biopsy ............................................ | 0145 | 7.46 | \$361.71 | \$179.39 | \$72.34 |
| 46608 | T | Anoscopy/remove for body ..................................... | 0144 | 2.23 | \$108.13 | \$49.32 | \$21.63 |
| 46610 | T | Anoscopy/remove lesion ........................................ | 0145 | 7.46 | \$361.71 | \$179.39 | \$72.34 |
| 46611 | T | Anoscopy | 0145 | 7.46 | \$361.71 | \$179.39 | \$72.34 |
| 46612 | T | Anoscopy/remove lesions | 0145 | 7.46 | \$361.71 | \$179.39 | \$72.34 |
| 46614 | T | Anoscopy/control bleeding | 0145 | 7.46 | \$361.71 | \$179.39 | \$72.34 |
| 46615 | T | Anoscopy | 0145 | 7.46 | \$361.71 | \$179.39 | \$72.34 |
| 46700 | T | Repair of anal stricture | 0150 | 17.68 | \$857.25 | \$437.12 | \$171.45 |
| 46705 | C | Repair of anal stricture |  |  |  |  |  |
| 46715 | C | Repair of anovaginal fistula |  |  |  |  |  |
| 46716 | C | Repair of anovaginal fistula |  |  |  |  |  |
| 46730 | C | Construction of absent anus |  |  |  | ....... |  |
| 46735 | C | Construction of absent anus |  |  |  |  |  |
| 46740 | C | Construction of absent anus |  | ...... |  | ........ |  |
| 46742 | C | Repair of imperforated anus | ...... | ........ | ........... | ..................... |  |
| 46744 | C | Repair of cloacal anomaly |  | ..................... | ..................... | ...................... |  |
| 46746 | C | Repair of cloacal anomaly |  |  |  |  |  |
| 46748 | C | Repair of cloacal anomaly ..................................... |  |  |  |  |  |
| 46750 | T | Repair of anal sphincter ........................................ | 0150 | 17.68 | \$857.25 | \$437.12 | \$171.45 |
| 46751 | C | Repair of anal sphincter |  |  |  |  |  |
| 46753 | T | Reconstruction of anus | 0150 | 17.68 | \$857.25 | \$437.12 | \$171.45 |
| 46754 | T | Removal of suture from anus | 0149 | 12.86 | \$623.54 | \$293.06 | \$124.71 |
| 46760 | T | Repair of anal sphincter | 0150 | 17.68 | \$857.25 | \$437.12 | \$171.45 |
| 46761 | T | Repair of anal sphincter | 0150 | 17.68 | \$857.25 | \$437.12 | \$171.45 |
| 46762 | T | Implant artificial sphincter | 0150 | 17.68 | \$857.25 | \$437.12 | \$171.45 |
| 46900 | T | Destruction, anal lesion(s) | 0016 | 3.53 | \$171.16 | \$74.67 | \$34.23 |
| 46910 | T | Destruction, anal lesion(s) | 0016 | 3.53 | \$171.16 | \$74.67 | \$34.23 |
| 46916 | T | Cryosurgery, anal lesion(s) | 0016 | 3.53 | \$171.16 | \$74.67 | \$34.23 |
| 46917 | T | Laser surgery, anal lesions .................................... | 0014 | 1.50 | \$72.73 | \$24.55 | \$14.55 |
| 46922 | T | Excision of anal lesion(s) | 0017 | 12.45 | \$603.66 | \$289.16 | \$120.73 |
| 46924 | T | Destruction, anal lesion(s) | 0017 | 12.45 | \$603.66 | \$289.16 | \$120.73 |
| 46934 | T | Destruction of hemorrhoids | 0148 | 2.34 | \$113.46 | \$43.59 | \$22.69 |
| 46935 | T | Destruction of hemorrhoids | 0148 | 2.34 | \$113.46 | \$43.59 | \$22.69 |
| 46936 | T | Destruction of hemorrhoids | 0149 | 12.86 | \$623.54 | \$293.06 | \$124.71 |
| 46937 | T | Cryotherapy of rectal lesion .................................... | 0150 | 17.68 | \$857.25 | \$437.12 | \$171.45 |
| 46938 | T | Cryotherapy of rectal lesion | 0150 | 17.68 | \$857.25 | \$437.12 | \$171.45 |
| 46940 | T | Treatment of anal fissure | 0149 | 12.86 | \$623.54 | \$293.06 | \$124.71 |
| 46942 | T | Treatment of anal fissure | 0149 | 12.86 | \$623.54 | \$293.06 | \$124.71 |
| 46945 | T | Ligation of hemorrhoids ..... | 0148 | 2.34 | \$113.46 | \$43.59 | \$22.69 |
| 46946 | T | Ligation of hemorrhoids ......................................... | 0148 | 2.34 | \$113.46 | \$43.59 | \$22.69 |
| 46999 | T | Anus surgery procedure ...................................... | 0149 | 12.86 | \$623.54 | \$293.06 | \$124.71 |
| 47000 | T | Needle biopsy of liver ............................................ | 0005 | 5.41 | \$262.32 | \$119.75 | \$52.46 |
| 47001 | C | Needle biopsy, liver add-on .................................... |  |  |  |  |  |
| 47010 | C | Open drainage, liver lesion |  |  |  |  |  |
| 47011 | C | Percut drain, liver lesion ......................................... | .................... | .................... | ..................... | .................... | ..................... |
| 47015 | C | Inject/aspirate liver cyst ......................................... |  |  |  |  |  |
| 47100 | C | Wedge biopsy of liver ........................................... |  | ..................... | ..................... | ..................... |  |
| 47120 | C | Partial removal of liver ........................................... |  | ...................... |  | ..................... |  |
| 47122 | C | Extensive removal of liver |  | ...................... | ...................... | ..................... | ..................... |
| 47125 | C | Partial removal of liver |  |  |  |  |  |
| 47130 | C | Partial removal of liver | ................... | ...................... | ..................... | ..................... | ..................... |
| 47133 | C | Removal of donor liver |  |  |  |  |  |
| 47134 | C | Partial removal, donor liver ..................................... |  | . |  |  |  |
| 47135 | C | Transplantation of liver .......................................... |  |  |  |  |  |
| 47136 | C | Transplantation of liver .......................................... | ................... | .................. | ...................... | ..................... | ..................... |
| 47300 | C | Surgery for liver lesion ........................................... | ..................... | ..................... | ..................... | ...................... |  |
| 47350 | C | Repair liver wound ........ |  |  |  |  |  |
| 47360 | C | Repair liver wound ................................................ | .................... | ..................... | ..................... | ..................... |  |
| 47361 | C | Repair liver wound ................................................ |  | ...................... | ..................... | ... |  |
| 47362 | C | Repair liver wound |  |  |  |  |  |

[^177]
# Addendum B.-Hospital Outpatient Department (HOPD) Payment Status by HCPCS Code and Related INFORMATION-Continued 

| CPT/ HCPCS | HOPD Status Indicator | Description | APC | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 47399 | T | Liver surgery procedure | 0005 | 5.41 | \$262.32 | \$119.75 | \$52.46 |
| 47400 | C | Incision of liver duct |  |  |  |  |  |
| 47420 | C | Incision of bile duct |  |  |  |  |  |
| 47425 | C | Incision of bile duct |  |  |  |  | ..................... |
| 47460 | C | Incise bile duct sphincter |  |  |  |  |  |
| 47480 | C | Incision of gallbladder. |  |  |  |  |  |
| 47490 | C | Incision of gallbladder ............................................ |  |  |  |  |  |
| 47500 | N | Injection for liver x-rays .......................................... |  |  |  |  |  |
| 47505 | N | Injection for liver x-rays ......................................... |  |  |  |  |  |
| 47510 | T | Insert catheter, bile duct | 0152 | 8.22 | \$398.56 | \$207.38 | \$79.71 |
| 47511 | T | Insert bile duct drain | 0152 | 8.22 | \$398.56 | \$207.38 | \$79.71 |
| 47525 | T | Change bile duct catheter | 0122 | 5.04 | \$244.37 | \$114.93 | \$48.88 |
| 47530 | T | Revise/reinsert bile tube | 0121 | 2.36 | \$114.43 | \$52.53 | \$22.89 |
| 47550 | C | Bile duct endoscopy add-on ... |  |  |  |  |  |
| 47552 | T | Biliary endoscopy thru skin ..................................... | 0152 | 8.22 | \$398.56 | \$207.38 | \$79.71 |
| 47553 | T | Biliary endoscopy thru skin | 0152 | 8.22 | \$398.56 | \$207.38 | \$79.71 |
| 47554 | T | Biliary endoscopy thru skin | 0152 | 8.22 | \$398.56 | \$207.38 | \$79.71 |
| 47555 | T | Biliary endoscopy thru skin | 0152 | 8.22 | \$398.56 | \$207.38 | \$79.71 |
| 47556 | T | Biliary endoscopy thru skin | 0152 | 8.22 | \$398.56 | \$207.38 | \$79.71 |
| 47560 | T | Laparoscopy w/cholangio | 0130 | 25.36 | \$1,229.63 | \$659.53 | \$245.93 |
| 47561 | T | Laparo w/cholangio/biopsy | 0130 | 25.36 | \$1,229.63 | \$659.53 | \$245.93 |
| 47562 | T | Laparoscopic cholecystectomy | 0131 | 41.81 | \$2,027.24 | \$1,089.88 | \$405.45 |
| 47563 | T | Laparo cholecystectomy/graph | 0131 | 41.81 | \$2,027.24 | \$1,089.88 | \$405.45 |
| 47564 | T | Laparo cholecystectomy/explr | 0131 | 41.81 | \$2,027.24 | \$1,089.88 | \$405.45 |
| 47570 | T | Laparo cholecystoenterostomy | 0131 | 41.81 | \$2,027.24 | \$1,089.88 | \$405.45 |
| 47579 | T | Laparoscope proc, biliary | 0130 | 25.36 | \$1,229.63 | \$659.53 | \$245.93 |
| 47600 | C | Removal of gallbladder . |  |  |  |  |  |
| 47605 | C | Removal of gallbladder |  |  |  |  |  |
| 47610 | C | Removal of gallbladder |  |  |  |  |  |
| 47612 | C | Removal of gallbladder .......................................... |  |  |  |  |  |
| 47620 | C | Removal of gallbladder |  |  |  |  |  |
| 47630 | T | Remove bile duct stone | 0152 | 8.22 | \$398.56 | \$207.38 | \$79.71 |
| 47700 | C | Exploration of bile ducts |  |  |  |  |  |
| 47701 | C | Bile duct revision |  |  |  |  |  |
| 47711 | C | Excision of bile duct tumor ..................................... | ..................... | ...................... |  | ................... |  |
| 47712 | C | Excision of bile duct tumor |  |  |  |  |  |
| 47715 | C | Excision of bile duct cyst |  |  |  |  |  |
| 47716 | C | Fusion of bile duct cyst ........................................... |  |  |  | ..................... |  |
| 47720 | C | Fuse gallbladder \& bowel |  |  |  |  |  |
| 47721 | C | Fuse upper gi structures |  |  |  |  |  |
| 47740 | C | Fuse gallbladder \& bowel ....................................... | ...................... | .................... | ..................... | ...................... | ..................... |
| 47741 | C | Fuse gallbladder \& bowel |  |  |  |  |  |
| 47760 | C | Fuse bile ducts and bowel |  |  |  |  |  |
| 47765 | C | Fuse liver ducts \& bowel |  |  |  | ..................... |  |
| 47780 | C | Fuse bile ducts and bowel |  | .................... |  | ...................... |  |
| 47785 | C | Fuse bile ducts and bowel |  |  |  |  |  |
| 47800 | C | Reconstruction of bile ducts |  |  |  |  |  |
| 47801 | C | Placement, bile duct support ................................... |  |  |  | ..................... |  |
| 47802 | C | Fuse liver duct \& intestine ..................................... |  |  |  |  |  |
| 47900 | C | Suture bile duct injury ........................................... |  |  |  |  |  |
| 47999 | T | Bile tract surgery procedure .................................... | 0121 | 2.36 | \$114.43 | \$52.53 | \$22.89 |
| 48000 | C | Drainage of abdomen ............................................ |  |  |  |  |  |
| 48001 | C | Placement of drain, pancreas |  |  |  |  |  |
| 48005 | C | Resect/debride pancreas ....................................... |  |  |  |  |  |
| 48020 | C | Removal of pancreatic stone ................................... |  |  |  |  |  |
| 48100 | C | Biopsy of pancreas .............................................. |  |  |  |  |  |
| 48102 | T | Needle biopsy, pancreas | 0005 | 5.41 | \$262.32 | \$119.75 | \$52.46 |
| 48120 | C | Removal of pancreas lesion ................................... |  |  |  |  |  |
| 48140 | C | Partial removal of pancreas .................................... |  |  |  |  |  |
| 48145 | C | Partial removal of pancreas .................................... |  |  |  |  |  |
| 48146 | C | Pancreatectomy ................................................... |  |  |  | .................... |  |
| 48148 | C | Removal of pancreatic duct .................................... |  |  |  |  |  |
| 48150 | C | Partial removal of pancreas .................................... |  |  |  |  |  |
| 48152 | C | Pancreatectomy .................................................... |  | ...................... |  | ..................... |  |
| 48153 | C | Pancreatectomy |  |  |  | ..................... |  |
| 48154 | C | Pancreatectomy |  |  |  |  |  |
| 48155 | C | Removal of pancreas |  |  |  |  |  |
| 48160 | E | Pancreas removal/transplant .................................. | ..................... | ................... |  | .................... |  |
| 48180 | C | Fuse pancreas and bowel ...................................... |  |  |  |  |  |
| 48400 | C | Injection, intraop add-on ......................................... |  |  |  |  |  |
| 48500 | C | Surgery of pancreas cyst ........................................ | ..................... | - | ...................... | ................... | .............. |
| 48510 | C | Drain pancreatic pseudocyst .................................. | .................... | ..................... | ..................... | ..................... |  |
| 48511 | C | Drain pancreatic pseudocyst |  |  |  |  |  |

[^178]
# Addendum B.-Hospital Outpatient Department (HOPD) Payment Status by hCPCS Code and Related INFORMATION-Continued 

| CPT/ HCPCS | HOPD Status Indicator | Description | APC | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 48520 | C | Fuse pancreas cyst and bowel. |  |  | . | ..................... |  |
| 48540 | C | Fuse pancreas cyst and bowel |  |  | ...................... | .................... |  |
| 48545 | C | Pancreatorrhaphy |  |  |  |  |  |
| 48547 | C | Duodenal exclusion |  |  |  |  |  |
| 48550 | E | Donor pancreatectomy |  |  |  |  |  |
| 48554 | E | Transpl allograft pancreas |  |  |  |  |  |
| 48556 | C | Removal, allograft pancreas |  |  |  |  |  |
| 48999 | T | Pancreas surgery procedure | 0005 | 5.41 | \$262.32 | \$119.75 | \$52.46 |
| 49000 | C | Exploration of abdomen ........................................ |  |  |  |  |  |
| 49002 | C | Reopening of abdomen ......................................... |  |  |  |  |  |
| 49010 | C | Exploration behind abdomen. |  |  |  |  |  |
| 49020 | C | Drain abdominal abscess |  |  |  |  |  |
| 49021 | C | Drain abdominal abscess ...................................... |  |  | .................... | ..................... |  |
| 49040 | C | Drain, open, abdom abscess |  |  |  |  |  |
| 49041 | C | Drain, percut, abdom abscess |  | .... |  |  |  |
| 49060 | C | Drain, open, retrop abscess |  |  |  |  |  |
| 49061 | C | Drain, percut, retroper absc |  |  |  |  |  |
| 49062 | C | Drain to peritoneal cavity |  |  |  |  |  |
| 49080 | T | Puncture, peritoneal cavity ..................................... | 0070 | 3.64 | \$176.49 | \$79.60 | \$35.30 |
| 49081 | T | Removal of abdominal fluid | 0070 | 3.64 | \$176.49 | \$79.60 | \$35.30 |
| 49085 | T | Remove abdomen foreign body | 0153 | 19.62 | \$951.32 | \$496.31 | \$190.26 |
| 49180 | T | Biopsy, abdominal mass | 0005 | 5.41 | \$262.32 | \$119.75 | \$52.46 |
| 49200 | C | Removal of abdominal lesion |  |  |  |  |  |
| 49201 | C | Removal of abdominal lesion | .... | ... |  |  |  |
| 49215 | C | Excise sacral spine tumor ...................................... |  |  |  |  |  |
| 49220 | C | Multiple surgery, abdomen ..................................... |  |  |  |  |  |
| 49250 | T | Excision of umbilicus | 0153 | 19.62 | \$951.32 | \$496.31 | \$190.26 |
| 49255 | C | Removal of omentum |  |  |  |  |  |
| 49320 | T | Diag laparo separate proc | 0130 | 25.36 | \$1,229.63 | \$659.53 | \$245.93 |
| 49321 | T | Laparoscopy, biopsy | 0130 | 25.36 | \$1,229.63 | \$659.53 | \$245.93 |
| 49322 | T | Laparoscopy, aspiration | 0130 | 25.36 | \$1,229.63 | \$659.53 | \$245.93 |
| 49323 | T | Laparo drain lymphocele | 0130 | 25.36 | \$1,229.63 | \$659.53 | \$245.93 |
| 49329 | T | Laparo proc, abdm/per/oment ................................. | 0130 | 25.36 | \$1,229.63 | \$659.53 | \$245.93 |
| 49400 | N | Air injection into abdomen ...................................... |  |  |  |  |  |
| 49420 | T | Insert abdominal drain | 0153 | 19.62 | \$951.32 | \$496.31 | \$190.26 |
| 49421 | T | Insert abdominal drain | 0153 | 19.62 | \$951.32 | \$496.31 | \$190.26 |
| 49422 | T | Remove perm cannula/catheter | 0123 | 13.89 | \$673.49 | \$350.75 | \$134.70 |
| 49423 | T | Exchange drainage catheter ................................... | 0153 | 19.62 | \$951.32 | \$496.31 | \$190.26 |
| 49424 | N | Assess cyst, contrast inject .................................... |  |  |  |  |  |
| 49425 | C | Insert abdomen-venous drain |  |  |  |  |  |
| 49426 | T | Revise abdomen-venous shunt | 0153 | 19.62 | \$951.32 | \$496.31 | \$190.26 |
| 49427 | N | Injection, abdominal shunt ...................................... |  |  |  |  |  |
| 49428 | C | Ligation of shunt |  |  |  |  |  |
| 49429 | T | Removal of shunt | 0123 | 13.89 | \$673.49 | \$350.75 | \$134.70 |
| 49495 | T | Repair inguinal hernia, init ...................................... | 0154 | 22.43 | \$1,087.57 | \$556.98 | \$217.51 |
| 49496 | T | Repair inguinal hernia, init | 0154 | 22.43 | \$1,087.57 | \$556.98 | \$217.51 |
| 49500 | T | Repair inguinal hernia | 0154 | 22.43 | \$1,087.57 | \$556.98 | \$217.51 |
| 49501 | T | Repair inguinal hernia, init | 0154 | 22.43 | \$1,087.57 | \$556.98 | \$217.51 |
| 49505 | T | Repair inguinal hernia ............................................ | 0154 | 22.43 | \$1,087.57 | \$556.98 | \$217.51 |
| 49507 | T | Repair inguinal hernia | 0154 | 22.43 | \$1,087.57 | \$556.98 | \$217.51 |
| 49520 | T | Rerepair inguinal hernia | 0154 | 22.43 | \$1,087.57 | \$556.98 | \$217.51 |
| 49521 | T | Repair inguinal hernia, rec ..................................... | 0154 | 22.43 | \$1,087.57 | \$556.98 | \$217.51 |
| 49525 | T | Repair inguinal hernia | 0154 | 22.43 | \$1,087.57 | \$556.98 | \$217.51 |
| 49540 | T | Repair lumbar hernia | 0154 | 22.43 | \$1,087.57 | \$556.98 | \$217.51 |
| 49550 | T | Repair femoral hernia ............................................ | 0154 | 22.43 | \$1,087.57 | \$556.98 | \$217.51 |
| 49553 | T | Repair femoral hernia, init | 0154 | 22.43 | \$1,087.57 | \$556.98 | \$217.51 |
| 49555 | T | Repair femoral hernia | 0154 | 22.43 | \$1,087.57 | \$556.98 | \$217.51 |
| 49557 | T | Repair femoral hernia, recur .................................... | 0154 | 22.43 | \$1,087.57 | \$556.98 | \$217.51 |
| 49560 | T | Repair abdominal hernia ........................................ | 0154 | 22.43 | \$1,087.57 | \$556.98 | \$217.51 |
| 49561 | T | Repair incisional hernia | 0154 | 22.43 | \$1,087.57 | \$556.98 | \$217.51 |
| 49565 | T | Rerepair abdominal hernia ..................................... | 0154 | 22.43 | \$1,087.57 | \$556.98 | \$217.51 |
| 49566 | T | Repair incisional hernia | 0154 | 22.43 | \$1,087.57 | \$556.98 | \$217.51 |
| 49568 | T | Hernia repair w/mesh | 0154 | 22.43 | \$1,087.57 | \$556.98 | \$217.51 |
| 49570 | T | Repair epigastric hernia .......................................... | 0154 | 22.43 | \$1,087.57 | \$556.98 | \$217.51 |
| 49572 | T | Repair epigastric hernia ......................................... | 0154 | 22.43 | \$1,087.57 | \$556.98 | \$217.51 |
| 49580 | T | Repair umbilical hernia .......................................... | 0154 | 22.43 | \$1,087.57 | \$556.98 | \$217.51 |
| 49582 | T | Repair umbilical hernia | 0154 | 22.43 | \$1,087.57 | \$556.98 | \$217.51 |
| 49585 | T | Repair umbilical hernia .......................................... | 0154 | 22.43 | \$1,087.57 | \$556.98 | \$217.51 |
| 49587 | T | Repair umbilical hernia .......................................... | 0154 | 22.43 | \$1,087.57 | \$556.98 | \$217.51 |
| 49590 | T | Repair abdominal hernia ........................................ | 0154 | 22.43 | \$1,087.57 | \$556.98 | \$217.51 |
| 49600 | T | Repair umbilical lesion ........................................... | 0154 | 22.43 | \$1,087.57 | \$556.98 | \$217.51 |
| 49605 | C | Repair umbilical lesion ........................................... | ...................... | ...................... | ...................... | ...................... | ...................... |
| 49606 | C | Repair umbilical lesion |  |  |  |  |  |

[^179]
# Addendum B.-Hospital Outpatient Department (HOPD) Payment Status by HCPCS Code and Related Information-Continued 

| $\begin{aligned} & \text { CPT/ } \\ & \text { HCPCS } \end{aligned}$ | HOPD Status Indicator | Description | APC | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 49610 | C | Repair umbilical lesion |  |  |  |  |  |
| 49611 | C | Repair umbilical lesion |  |  |  |  |  |
| 49650 | T | Laparo hernia repair initial | 0131 | 41.81 | \$2,027.24 | \$1,089.88 | \$405.45 |
| 49651 | T | Laparo hernia repair recur | 0131 | 41.81 | \$2,027.24 | \$1,089.88 | \$405.45 |
| 49659 | T | Laparo proc, hernia repair | 0131 | 41.81 | \$2,027.24 | \$1,089.88 | \$405.45 |
| 49900 | C | Repair of abdominal wall ..... |  |  |  |  |  |
| 49905 | C | Omental flap |  |  |  |  |  |
| 49906 | C | Free omental flap, microvasc |  |  |  |  |  |
| 49999 | T | Abdomen surgery procedure | 0121 | 2.36 | \$114.43 | \$52.53 | \$22.89 |
| 50010 | C | Exploration of kidney |  |  |  |  |  |
| 50020 | C | Renal abscess, open drain |  |  |  |  |  |
| 50021 | C | Renal abscess, percut drain |  |  |  |  |  |
| 50040 | C | Drainage of kidney ........... |  |  |  |  |  |
| 50045 | C | Exploration of kidney |  |  |  |  |  |
| 50060 | C | Removal of kidney stone | .................... | .................... | .................... | .................... |  |
| 50065 | C | Incision of kidney |  |  |  |  |  |
| 50070 | C | Incision of kidney . |  |  |  |  |  |
| 50075 | C | Removal of kidney stone |  |  |  |  |  |
| 50080 | T | Removal of kidney stone | 0163 | 28.98 | \$1,405.16 | \$792.58 | \$281.03 |
| 50081 | T | Removal of kidney stone | 0163 | 28.98 | \$1,405.16 | \$792.58 | \$281.03 |
| 50100 | C | Revise kidney blood vessels |  |  |  |  |  |
| 50120 | C | Exploration of kidney |  |  |  |  |  |
| 50125 | C | Explore and drain kidney |  |  |  |  |  |
| 50130 | C | Removal of kidney stone |  |  |  |  |  |
| 50135 | C | Exploration of kidney |  |  |  |  |  |
| 50200 | T | Biopsy of kidney | 0005 | 5.41 | \$262.32 | \$119.75 | \$52.46 |
| 50205 | C | Biopsy of kidney .................................................. |  |  |  |  |  |
| 50220 | C | Removal of kidney |  |  |  |  |  |
| 50225 | C | Removal of kidney |  |  |  |  |  |
| 50230 | C | Removal of kidney |  |  |  |  |  |
| 50234 | C | Removal of kidney \& ureter |  | ..................... |  | ................... |  |
| 50236 | C | Removal of kidney \& ureter |  |  |  |  |  |
| 50240 | C | Partial removal of kidney |  |  |  |  |  |
| 50280 | C | Removal of kidney lesion |  |  |  |  |  |
| 50290 | C | Removal of kidney lesion |  | ..................... | ..................... | .................... |  |
| 50300 | C | Removal of donor kidney |  |  |  |  |  |
| 50320 | C | Removal of donor kidney |  | ...................... |  | ..................... |  |
| 50340 | C | Removal of kidney |  | ..................... |  | ................... |  |
| 50360 | C | Transplantation of kidney |  |  |  |  |  |
| 50365 | C | Transplantation of kidney ... |  | ..................... |  | ..................... |  |
| 50370 | C | Remove transplanted kidney |  |  |  |  |  |
| 50380 | C | Reimplantation of kidney |  |  |  |  |  |
| 50390 | T | Drainage of kidney lesion | 0005 | 5.41 | \$262.32 | \$119.75 | \$52.46 |
| 50392 | T | Insert kidney drain | 0160 | 5.43 | \$263.28 | \$110.11 | \$52.66 |
| 50393 | T | Insert ureteral tube | 0160 | 5.43 | \$263.28 | \$110.11 | \$52.66 |
| 50394 | N | Injection for kidney x-ray |  |  |  |  |  |
| 50395 | T | Create passage to kidney ...................................... | 0160 | 5.43 | \$263.28 | \$110.11 | \$52.66 |
| 50396 | T | Measure kidney pressure | 0165 | 3.89 | \$188.61 | \$91.76 | \$37.72 |
| 50398 | T | Change kidney tube | 0122 | 5.04 | \$244.37 | \$114.93 | \$48.88 |
| 50400 | C | Revision of kidney/ureter ........................................ |  |  |  | ..................... |  |
| 50405 | C | Revision of kidney/ureter ........................................ |  |  |  |  |  |
| 50500 | C | Repair of kidney wound ......................................... |  |  |  |  |  |
| 50520 | C | Close kidney-skin fistula |  |  |  |  |  |
| 50525 | C | Repair renal-abdomen fistula .................................. |  |  |  |  |  |
| 50526 | C | Repair renal-abdomen fistula |  |  |  |  |  |
| 50540 | C | Revision of horseshoe kidney ................................. |  |  |  |  |  |
| 50541 | T | Laparo ablate renal cyst ......................................... | 0131 | 41.81 | \$2,027.24 | \$1,089.88 | \$405.45 |
| 50544 | T | Laparoscopy, pyeloplasty | 0131 | 41.81 | \$2,027.24 | \$1,089.88 | \$405.45 |
| 50546 | C | Laparoscopic nephrectomy |  |  |  |  |  |
| 50547 | C | Laparo removal donor kidney ................................. |  |  |  |  |  |
| 50548 | T | Laparo-asst remove k/ureter | 0132 | 48.91 | \$2,371.50 | \$1,239.22 | \$474.30 |
| 50549 | T | Laparoscope proc, renal | 0130 | 25.36 | \$1,229.63 | \$659.53 | \$245.93 |
| 50551 | T | Kidney endoscopy ................................................ | 0161 | 10.94 | \$530.45 | \$249.36 | \$106.09 |
| 50553 | T | Kidney endoscopy . | 0161 | 10.94 | \$530.45 | \$249.36 | \$106.09 |
| 50555 | T | Kidney endoscopy \& biopsy | 0161 | 10.94 | \$530.45 | \$249.36 | \$106.09 |
| 50557 | T | Kidney endoscopy \& treatment ................................ | 0161 | 10.94 | \$530.45 | \$249.36 | \$106.09 |
| 50559 | T | Renal endoscopy/radiotracer ................................... | 0161 | 10.94 | \$530.45 | \$249.36 | \$106.09 |
| 50561 | T | Kidney endoscopy \& treatment ............................... | 0161 | 10.94 | \$530.45 | \$249.36 | \$106.09 |
| 50570 | C | Kidney endoscopy |  |  |  |  |  |
| 50572 | C | Kidney endoscopy ................................................ |  | .................... |  | ...................... |  |
| 50574 | C | Kidney endoscopy \& biopsy ................................... | ...................... | ...................... | ...................... | ...................... | ..................... |
| 50575 | C | Kidney endoscopy ................................................ |  | ..... | ..... |  |  |
| 50576 | C | Kidney endoscopy \& treatment |  |  |  |  |  |

[^180]
# Addendum B.—Hospital Outpatient Department (HOPD) Payment Status by hCPCS Code and Related INFORMATION-Continued 

| CPT/ HCPCS | HOPD Status Indicator | Description | APC | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 50578 | C | Renal endoscopy/radiotracer |  |  |  |  |  |
| 50580 | C | Kidney endoscopy \& treatment |  |  |  |  |  |
| 50590 | T | Fragmenting of kidney stone | 0169 | 46.72 | \$2,265.32 | \$1,384.20 | \$453.06 |
| 50600 | C | Exploration of ureter ... |  |  |  |  |  |
| 50605 | C | Insert ureteral support |  |  |  |  |  |
| 50610 | C | Removal of ureter stone |  |  |  |  |  |
| 50620 | C | Removal of ureter stone |  |  |  |  |  |
| 50630 | C | Removal of ureter stone |  |  |  |  |  |
| 50650 | C | Removal of ureter |  |  |  |  |  |
| 50660 | C | Removal of ureter |  |  |  |  |  |
| 50684 | N | Injection for ureter x-ray |  |  |  |  |  |
| 50686 | T | Measure ureter pressure | 0165 | 3.89 | \$188.61 | \$91.76 | \$37.72 |
| 50688 | T | Change of ureter tube | 0121 | 2.36 | \$114.43 | \$52.53 | \$22.89 |
| 50690 | N | Injection for ureter x-ray |  |  |  |  |  |
| 50700 | C | Revision of ureter ......... |  |  |  |  |  |
| 50715 | C | Release of ureter |  |  |  |  |  |
| 50722 | C | Release of ureter |  |  |  |  |  |
| 50725 | C | Release/revise ureter |  |  |  |  |  |
| 50727 | C | Revise ureter ..... | ................... | .................... | .................... | ..................... |  |
| 50728 | C | Revise ureter |  | ...................... |  | ...................... |  |
| 50740 | C | Fusion of ureter \& kidney |  |  |  |  |  |
| 50750 | C | Fusion of ureter \& kidney |  |  |  |  |  |
| 50760 | C | Fusion of ureters |  |  |  |  |  |
| 50770 | C | Splicing of ureters |  |  |  |  |  |
| 50780 | C | Reimplant ureter in bladder |  |  |  |  |  |
| 50782 | C | Reimplant ureter in bladder |  | ..................... |  | ...................... |  |
| 50783 | C | Reimplant ureter in bladder |  |  |  |  |  |
| 50785 | C | Reimplant ureter in bladder | ....... | ................... | ................... | .................... |  |
| 50800 | C | Implant ureter in bowel ... |  |  |  |  |  |
| 50810 | C | Fusion of ureter \& bowel |  | ..................... | ..................... | ..................... |  |
| 50815 | C | Urine shunt to bowel |  |  |  |  |  |
| 50820 | C | Construct bowel bladder |  | ..................... |  | ...................... |  |
| 50825 | C | Construct bowel bladder |  | .................... | . | ..................... |  |
| 50830 | C | Revise urine flow |  |  |  |  |  |
| 50840 | C | Replace ureter by bowel. |  |  |  |  |  |
| 50845 | C | Appendico-vesicostomy |  |  |  |  |  |
| 50860 | C | Transplant ureter to skin |  |  |  |  |  |
| 50900 | C | Repair of ureter |  |  |  |  |  |
| 50920 | C | Closure ureter/skin fistula | ................... | ..................... | .................... | .................... | ..................... |
| 50930 | C | Closure ureter/bowel fistula |  |  |  |  |  |
| 50940 | C | Release of ureter |  |  |  |  |  |
| 50945 | T | Laparoscopy ureterolithotomy | 0131 | 41.81 | \$2,027.24 | \$1,089.88 | \$405.45 |
| 50951 | T | Endoscopy of ureter | 0162 | 17.49 | \$848.04 | \$427.49 | \$169.61 |
| 50953 | T | Endoscopy of ureter | 0162 | 17.49 | \$848.04 | \$427.49 | \$169.61 |
| 50955 | T | Ureter endoscopy \& biopsy .... | 0162 | 17.49 | \$848.04 | \$427.49 | \$169.61 |
| 50957 | T | Ureter endoscopy \& treatment | 0162 | 17.49 | \$848.04 | \$427.49 | \$169.61 |
| 50959 | T | Ureter endoscopy \& tracer | 0162 | 17.49 | \$848.04 | \$427.49 | \$169.61 |
| 50961 | T | Ureter endoscopy \& treatment | 0162 | 17.49 | \$848.04 | \$427.49 | \$169.61 |
| 50970 | C | Ureter endoscopy ...... |  |  |  |  |  |
| 50972 | C | Ureter endoscopy \& catheter |  |  |  |  |  |
| 50974 | C | Ureter endoscopy \& biopsy |  |  |  |  |  |
| 50976 | C | Ureter endoscopy \& treatment | ................... | .................... | ..................... | .................... |  |
| 50978 | C | Ureter endoscopy \& tracer |  |  |  |  |  |
| 50980 | C | Ureter endoscopy \& treatment |  |  |  |  |  |
| 51000 | T | Drainage of bladder | 0165 | 3.89 | \$188.61 | \$91.76 | \$37.72 |
| 51005 | T | Drainage of bladder | 0164 | 2.17 | \$105.23 | \$33.03 | \$21.05 |
| 51010 | T | Drainage of bladder | 0165 | 3.89 | \$188.61 | \$91.76 | \$37.72 |
| 51020 | T | Incise \& treat bladder | 0162 | 17.49 | \$848.04 | \$427.49 | \$169.61 |
| 51030 | T | Incise \& treat bladder | 0162 | 17.49 | \$848.04 | \$427.49 | \$169.61 |
| 51040 | T | Incise \& drain bladder | 0162 | 17.49 | \$848.04 | \$427.49 | \$169.61 |
| 51045 | T | Incise bladder/drain ureter | 0162 | 17.49 | \$848.04 | \$427.49 | \$169.61 |
| 51050 | T | Removal of bladder stone | 0162 | 17.49 | \$848.04 | \$427.49 | \$169.61 |
| 51060 | C | Removal of ureter stone |  |  |  |  |  |
| 51065 | T | Removal of ureter stone | 0162 | 17.49 | \$848.04 | \$427.49 | \$169.61 |
| 51080 | T | Drainage of bladder abscess .................................. | 0008 | 6.15 | \$298.20 | \$113.67 | \$59.64 |
| 51500 | T | Removal of bladder cyst .. | 0154 | 22.43 | \$1,087.57 | \$556.98 | \$217.51 |
| 51520 | T | Removal of bladder lesion | 0162 | 17.49 | \$848.04 | \$427.49 | \$169.61 |
| 51525 | C | Removal of bladder lesion |  |  |  |  | ............ |
| 51530 | C | Removal of bladder lesion | .................... | .................... | ...................... | .................... | ................... |
| 51535 | C | Repair of ureter lesion ........................................... |  |  |  |  |  |
| 51550 | C | Partial removal of bladder ...................................... |  |  |  |  |  |
| 51555 | C | Partial removal of bladder ...................................... | ..... | ................ | ............. | ............... | ..................... |
| 51565 | C | Revise bladder \& ureter(s) |  |  |  |  |  |

[^181]
# Addendum B.-Hospital Outpatient Department (HOPD) Payment Status by HCPCS Code and Related Information-Continued 

| $\begin{aligned} & \text { CPT/ } \\ & \text { HCPCS } \end{aligned}$ | HOPD Status Indicator | Description | APC | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 51570 | C | Removal of bladder |  |  |  |  |  |
| 51575 | C | Removal of bladder \& nodes |  |  |  |  |  |
| 51580 | C | Remove bladder/revise tract | ................ | .................... | ... | .................... | .......... |
| 51585 | C | Removal of bladder \& nodes |  |  |  |  |  |
| 51590 | C | Remove bladder/revise tract |  |  |  |  |  |
| 51595 | C | Remove bladder/revise tract |  | ................ | .............. | ........ | .......... |
| 51596 | C | Remove bladder/create pouch | ..... | ..... |  | ................ |  |
| 51597 | C | Removal of pelvic structures |  | ............... | ................ | ................... |  |
| 51600 | N | Injection for bladder x-ray |  |  |  |  |  |
| 51605 | N | Preparation for bladder x-ray |  | ................ | ................ | .................... |  |
| 51610 | N | Injection for bladder x-ray |  |  |  |  |  |
| 51700 | T | Irrigation of bladder | 0164 | 2.17 | \$105.23 | \$33.03 | \$21.05 |
| 51705 | T | Change of bladder tube | 0121 | 2.36 | \$114.43 | \$52.53 | \$22.89 |
| 51710 | T | Change of bladder tube | 0121 | 2.36 | \$114.43 | \$52.53 | \$22.89 |
| 51715 | T | Endoscopic injection/implant | 0167 | 21.06 | \$1,021.14 | \$555.84 | \$204.23 |
| 51720 | T | Treatment of bladder lesion. | 0165 | 3.89 | \$188.61 | \$91.76 | \$37.72 |
| 51725 | T | Simple cystometrogram | 0165 | 3.89 | \$188.61 | \$91.76 | \$37.72 |
| 51726 | T | Complex cystometrogram | 0165 | 3.89 | \$188.61 | \$91.76 | \$37.72 |
| 51736 | T | Urine flow measurement | 0164 | 2.17 | \$105.23 | \$33.03 | \$21.05 |
| 51741 | T | Electro-uroflowmetry, first | 0164 | 2.17 | \$105.23 | \$33.03 | \$21.05 |
| 51772 | T | Urethra pressure profile | 0165 | 3.89 | \$188.61 | \$91.76 | \$37.72 |
| 51784 | T | Anal/urinary muscle study | 0164 | 2.17 | \$105.23 | \$33.03 | \$21.05 |
| 51785 | T | Anal/urinary muscle study | 0164 | 2.17 | \$105.23 | \$33.03 | \$21.05 |
| 51792 | T | Urinary reflex study | 0165 | 3.89 | \$188.61 | \$91.76 | \$37.72 |
| 51795 | T | Urine voiding pressure study | 0164 | 2.17 | \$105.23 | \$33.03 | \$21.05 |
| 51797 | T | Intraabdominal pressure test | 0164 | 2.17 | \$105.23 | \$33.03 | \$21.05 |
| 51800 | C | Revision of bladder/urethra.. |  |  |  |  |  |
| 51820 | C | Revision of urinary tract |  |  |  |  |  |
| 51840 | C | Attach bladder/urethra | ....... | ............... |  | .......... |  |
| 51841 | C | Attach bladder/urethra |  |  |  |  |  |
| 51845 | C | Repair bladder neck | ....... | .................... | ..................... | .................... |  |
| 51860 | C | Repair of bladder wound |  |  |  |  |  |
| 51865 | C | Repair of bladder wound |  |  |  |  |  |
| 51880 | T | Repair of bladder opening | 0162 | 17.49 | \$848.04 | \$427.49 | \$169.61 |
| 51900 | C | Repair bladder/vagina lesion |  |  |  |  |  |
| 51920 | C | Close bladder-uterus fistula .. |  |  | . | ..................... |  |
| 51925 | C | Hysterectomy/bladder repair |  |  |  | .................... |  |
| 51940 | C | Correction of bladder defect |  |  |  |  |  |
| 51960 | C | Revision of bladder \& bowel |  |  |  |  |  |
| 51980 | C | Construct bladder opening |  |  |  |  |  |
| 51990 | T | Laparo urethral suspension | 0131 | 41.81 | \$2,027.24 | \$1,089.88 | \$405.45 |
| 51992 | T | Laparo sling operation | 0132 | 48.91 | \$2,371.50 | \$1,239.22 | \$474.30 |
| 52000 | T | Cystoscopy | 0160 | 5.43 | \$263.28 | \$110.11 | \$52.66 |
| 52005 | T | Cystoscopy \& ureter catheter | 0161 | 10.94 | \$530.45 | \$249.36 | \$106.09 |
| 52007 | T | Cystoscopy and biopsy | 0161 | 10.94 | \$530.45 | \$249.36 | \$106.09 |
| 52010 | T | Cystoscopy \& duct catheter | 0161 | 10.94 | \$530.45 | \$249.36 | \$106.09 |
| 52204 | T | Cystoscopy .............. | 0161 | 10.94 | \$530.45 | \$249.36 | \$106.09 |
| 52214 | T | Cystoscopy and treatment | 0161 | 10.94 | \$530.45 | \$249.36 | \$106.09 |
| 52224 | T | Cystoscopy and treatment | 0161 | 10.94 | \$530.45 | \$249.36 | \$106.09 |
| 52234 | T | Cystoscopy and treatment | 0162 | 17.49 | \$848.04 | \$427.49 | \$169.61 |
| 52235 | T | Cystoscopy and treatment | 0162 | 17.49 | \$848.04 | \$427.49 | \$169.61 |
| 52240 | T | Cystoscopy and treatment | 0163 | 28.98 | \$1,405.16 | \$792.58 | \$281.03 |
| 52250 | T | Cystoscopy and radiotracer .................................... | 0162 | 17.49 | \$848.04 | \$427.49 | \$169.61 |
| 52260 | T | Cystoscopy and treatment | 0161 | 10.94 | \$530.45 | \$249.36 | \$106.09 |
| 52265 | T | Cystoscopy and treatment | 0160 | 5.43 | \$263.28 | \$110.11 | \$52.66 |
| 52270 | T | Cystoscopy \& revise urethra | 0161 | 10.94 | \$530.45 | \$249.36 | \$106.09 |
| 52275 | T | Cystoscopy \& revise urethra | 0161 | 10.94 | \$530.45 | \$249.36 | \$106.09 |
| 52276 | T | Cystoscopy and treatment | 0161 | 10.94 | \$530.45 | \$249.36 | \$106.09 |
| 52277 | T | Cystoscopy and treatment | 0162 | 17.49 | \$848.04 | \$427.49 | \$169.61 |
| 52281 | T | Cystoscopy and treatment ...................................... | 0161 | 10.94 | \$530.45 | \$249.36 | \$106.09 |
| 52282 | T | Cystoscopy, implant stent | 0162 | 17.49 | \$848.04 | \$427.49 | \$169.61 |
| 52283 | T | Cystoscopy and treatment | 0161 | 10.94 | \$530.45 | \$249.36 | \$106.09 |
| 52285 | T | Cystoscopy and treatment | 0161 | 10.94 | \$530.45 | \$249.36 | \$106.09 |
| 52290 | T | Cystoscopy and treatment | 0161 | 10.94 | \$530.45 | \$249.36 | \$106.09 |
| 52300 | T | Cystoscopy and treatment | 0161 | 10.94 | \$530.45 | \$249.36 | \$106.09 |
| 52301 | T | Cystoscopy and treatment ...................................... | 0161 | 10.94 | \$530.45 | \$249.36 | \$106.09 |
| 52305 | T | Cystoscopy and treatment ...................................... | 0161 | 10.94 | \$530.45 | \$249.36 | \$106.09 |
| 52310 | T | Cystoscopy and treatment | 0161 | 10.94 | \$530.45 | \$249.36 | \$106.09 |
| 52315 | T | Cystoscopy and treatment | 0161 | 10.94 | \$530.45 | \$249.36 | \$106.09 |
| 52317 | T | Remove bladder stone | 0162 | 17.49 | \$848.04 | \$427.49 | \$169.61 |
| 52318 | T | Remove bladder stone | 0162 | 17.49 | \$848.04 | \$427.49 | \$169.61 |
| 52320 | T | Cystoscopy and treatment ...................................... | 0162 | 17.49 | \$848.04 | \$427.49 | \$169.61 |
| 52325 | T | Cystoscopy, stone removal .................................. | 0162 | 17.49 | \$848.04 | \$427.49 | \$169.61 |

[^182]
## Addendum B.-Hospital Outpatient Department (HOPD) Payment Status by hCPCS Code and Related Information-Continued

| CPT/ HCPCS | HOPD Status Indicator | Description | APC | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 52327 | T | Cystoscopy, inject material | 0161 | 10.94 | \$530.45 | \$249.36 | \$106.09 |
| 52330 | T | Cystoscopy and treatment | 0162 | 17.49 | \$848.04 | \$427.49 | \$169.61 |
| 52332 | T | Cystoscopy and treatment | 0162 | 17.49 | \$848.04 | \$427.49 | \$169.61 |
| 52334 | T | Create passage to kidney | 0162 | 17.49 | \$848.04 | \$427.49 | \$169.61 |
| 52335 | T | Endoscopy of urinary tract | 0162 | 17.49 | \$848.04 | \$427.49 | \$169.61 |
| 52336 | T | Cystoscopy, stone removal | 0162 | 17.49 | \$848.04 | \$427.49 | \$169.61 |
| 52337 | T | Cystoscopy, stone removal ............................... | 0162 | 17.49 | \$848.04 | \$427.49 | \$169.61 |
| 52338 | T | Cystoscopy and treatment ................................. | 0162 | 17.49 | \$848.04 | \$427.49 | \$169.61 |
| 52339 | T | Cystoscopy and treatment | 0162 | 17.49 | \$848.04 | \$427.49 | \$169.61 |
| 52340 | T | Cystoscopy and treatment | 0162 | 17.49 | \$848.04 | \$427.49 | \$169.61 |
| 52450 | T | Incision of prostate .......... | 0162 | 17.49 | \$848.04 | \$427.49 | \$169.61 |
| 52500 | T | Revision of bladder neck | 0162 | 17.49 | \$848.04 | \$427.49 | \$169.61 |
| 52510 | T | Dilation prostatic urethra | 0161 | 10.94 | \$530.45 | \$249.36 | \$106.09 |
| 52601 | T | Prostatectomy (TURP) . | 0163 | 28.98 | \$1,405.16 | \$792.58 | \$281.03 |
| 52606 | T | Control postop bleeding | 0162 | 17.49 | \$848.04 | \$427.49 | \$169.61 |
| 52612 | T | Prostatectomy, first stage | 0163 | 28.98 | \$1,405.16 | \$792.58 | \$281.03 |
| 52614 | T | Prostatectomy, second stage | 0163 | 28.98 | \$1,405.16 | \$792.58 | \$281.03 |
| 52620 | T | Remove residual prostate | 0163 | 28.98 | \$1,405.16 | \$792.58 | \$281.03 |
| 52630 | T | Remove prostate regrowth | 0163 | 28.98 | \$1,405.16 | \$792.58 | \$281.03 |
| 52640 | T | Relieve bladder contracture | 0162 | 17.49 | \$848.04 | \$427.49 | \$169.61 |
| 52647 | T | Laser surgery of prostate | 0163 | 28.98 | \$1,405.16 | \$792.58 | \$281.03 |
| 52648 | T | Laser surgery of prostate | 0163 | 28.98 | \$1,405.16 | \$792.58 | \$281.03 |
| 52700 | T | Drainage of prostate abscess | 0162 | 17.49 | \$848.04 | \$427.49 | \$169.61 |
| 53000 | T | Incision of urethra | 0166 | 10.17 | \$493.11 | \$218.73 | \$98.62 |
| 53010 | T | Incision of urethra | 0166 | 10.17 | \$493.11 | \$218.73 | \$98.62 |
| 53020 | T | Incision of urethra | 0166 | 10.17 | \$493.11 | \$218.73 | \$98.62 |
| 53025 | T | Incision of urethra | 0166 | 10.17 | \$493.11 | \$218.73 | \$98.62 |
| 53040 | T | Drainage of urethra abscess | 0166 | 10.17 | \$493.11 | \$218.73 | \$98.62 |
| 53060 | T | Drainage of urethra abscess | 0166 | 10.17 | \$493.11 | \$218.73 | \$98.62 |
| 53080 | T | Drainage of urinary leakage | 0166 | 10.17 | \$493.11 | \$218.73 | \$98.62 |
| 53085 | C | Drainage of urinary leakage |  |  |  |  |  |
| 53200 | T | Biopsy of urethra ................ | 0166 | 10.17 | \$493.11 | \$218.73 | \$98.62 |
| 53210 | T | Removal of urethra | 0168 | 24.94 | \$1,209.27 | \$536.11 | \$241.85 |
| 53215 | T | Removal of urethra | 0168 | 24.94 | \$1,209.27 | \$536.11 | \$241.85 |
| 53220 | T | Treatment of urethra lesion | 0168 | 24.94 | \$1,209.27 | \$536.11 | \$241.85 |
| 53230 | T | Removal of urethra lesion | 0168 | 24.94 | \$1,209.27 | \$536.11 | \$241.85 |
| 53235 | T | Removal of urethra lesion | 0168 | 24.94 | \$1,209.27 | \$536.11 | \$241.85 |
| 53240 | T | Surgery for urethra pouch | 0168 | 24.94 | \$1,209.27 | \$536.11 | \$241.85 |
| 53250 | T | Removal of urethra gland | 0166 | 10.17 | \$493.11 | \$218.73 | \$98.62 |
| 53260 | T | Treatment of urethra lesion | 0166 | 10.17 | \$493.11 | \$218.73 | \$98.62 |
| 53265 | T | Treatment of urethra lesion | 0166 | 10.17 | \$493.11 | \$218.73 | \$98.62 |
| 53270 | T | Removal of urethra gland | 0167 | 21.06 | \$1,021.14 | \$555.84 | \$204.23 |
| 53275 | T | Repair of urethra defect | 0166 | 10.17 | \$493.11 | \$218.73 | \$98.62 |
| 53400 | T | Revise urethra, stage 1 | 0168 | 24.94 | \$1,209.27 | \$536.11 | \$241.85 |
| 53405 | T | Revise urethra, stage 2 .. | 0168 | 24.94 | \$1,209.27 | \$536.11 | \$241.85 |
| 53410 | T | Reconstruction of urethra | 0168 | 24.94 | \$1,209.27 | \$536.11 | \$241.85 |
| 53415 | C | Reconstruction of urethra |  |  |  |  |  |
| 53420 | T | Reconstruct urethra, stage 1 | 0168 | 24.94 | \$1,209.27 | \$536.11 | \$241.85 |
| 53425 | T | Reconstruct urethra, stage 2 | 0168 | 24.94 | \$1,209.27 | \$536.11 | \$241.85 |
| 53430 | T | Reconstruction of urethra | 0168 | 24.94 | \$1,209.27 | \$536.11 | \$241.85 |
| 53440 | T | Correct bladder function | 0182 | 52.11 | \$2,526.66 | \$1,525.05 | \$505.33 |
| 53442 | T | Remove perineal prosthesis | 0166 | 10.17 | \$493.11 | \$218.73 | \$98.62 |
| 53443 | C | Reconstruction of urethra |  |  |  |  |  |
| 53445 | T | Correct urine flow control | 0182 | 52.11 | \$2,526.66 | \$1,525.05 | \$505.33 |
| 53447 | T | Remove artificial sphincter ..... | 0168 | 24.94 | \$1,209.27 | \$536.11 | \$241.85 |
| 53449 | T | Correct artificial sphincter | 0168 | 24.94 | \$1,209.27 | \$536.11 | \$241.85 |
| 53450 | T | Revision of urethra | 0168 | 24.94 | \$1,209.27 | \$536.11 | \$241.85 |
| 53460 | T | Revision of urethra | 0168 | 24.94 | \$1,209.27 | \$536.11 | \$241.85 |
| 53502 | T | Repair of urethra injury .......................................... | 0166 | 10.17 | \$493.11 | \$218.73 | \$98.62 |
| 53505 | T | Repair of urethra injury .......................................... | 0167 | 21.06 | \$1,021.14 | \$555.84 | \$204.23 |
| 53510 | T | Repair of urethra injury ......................................... | 0166 | 10.17 | \$493.11 | \$218.73 | \$98.62 |
| 53515 | T | Repair of urethra injury ........................................... | 0168 | 24.94 | \$1,209.27 | \$536.11 | \$241.85 |
| 53520 | T | Repair of urethra defect .......................................... | 0168 | 24.94 | \$1,209.27 | \$536.11 | \$241.85 |
| 53600 | T | Dilate urethra stricture .. | 0164 | 2.17 | \$105.23 | \$33.03 | \$21.05 |
| 53601 | T | Dilate urethra stricture | 0164 | 2.17 | \$105.23 | \$33.03 | \$21.05 |
| 53605 | T | Dilate urethra stricture | 0161 | 10.94 | \$530.45 | \$249.36 | \$106.09 |
| 53620 | T | Dilate urethra stricture | 0165 | 3.89 | \$188.61 | \$91.76 | \$37.72 |
| 53621 | T | Dilate urethra stricture | 0164 | 2.17 | \$105.23 | \$33.03 | \$21.05 |
| 53660 | T | Dilation of urethra | 0164 | 2.17 | \$105.23 | \$33.03 | \$21.05 |
| 53661 | T | Dilation of urethra | 0164 | 2.17 | \$105.23 | \$33.03 | \$21.05 |
| 53665 | T | Dilation of urethra ................................................ | 0166 | 10.17 | \$493.11 | \$218.73 | \$98.62 |
| 53670 | N | Insert urinary catheter ............................................ |  |  |  |  |  |
| 53675 | T | Insert urinary catheter ............................................ | 0164 | 2.17 | \$105.23 | \$33.03 | \$21.05 |

[^183]
## Addendum B.-Hospital Outpatient Department (HOPD) Payment Status by HCPCS Code and Related INFORMATION-Continued

| $\begin{aligned} & \text { CPT/ } \\ & \text { HCPCS } \end{aligned}$ | HOPD Status Indicator | Description | APC | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 253850 | T | Prostatic microwave thermotx | 0980 | 38.67 | \$1,875.00 |  | \$375.00 |
| ${ }^{2} 53852$ | T | Prostatic rf thermotx | 0980 | 38.67 | \$1,875.00 |  | \$375.00 |
| 53899 | T | Urology surgery procedure | 0165 | 3.89 | \$188.61 | \$91.76 | \$37.72 |
| 54000 | T | Slitting of prepuce | 0166 | 10.17 | \$493.11 | \$218.73 | \$98.62 |
| 54001 | T | Slitting of prepuce | 0166 | 10.17 | \$493.11 | \$218.73 | \$98.62 |
| 54015 | T | Drain penis lesion | 0008 | 6.15 | \$298.20 | \$113.67 | \$59.64 |
| 54050 | T | Destruction, penis lesion(s) | 0013 | 0.91 | \$44.12 | \$17.66 | \$8.82 |
| 54055 | T | Destruction, penis lesion(s) | 0016 | 3.53 | \$171.16 | \$74.67 | \$34.23 |
| 54056 | T | Cryosurgery, penis lesion(s) | 0013 | 0.91 | \$44.12 | \$17.66 | \$8.82 |
| 54057 | T | Laser surg, penis lesion(s) | 0017 | 12.45 | \$603.66 | \$289.16 | \$120.73 |
| 54060 | T | Excision of penis lesion(s) | 0017 | 12.45 | \$603.66 | \$289.16 | \$120.73 |
| 54065 | T | Destruction, penis lesion(s) | 0017 | 12.45 | \$603.66 | \$289.16 | \$120.73 |
| 54100 | T | Biopsy of penis ................. | 0020 | 6.51 | \$315.65 | \$130.53 | \$63.13 |
| 54105 | T | Biopsy of penis | 0021 | 10.49 | \$508.63 | \$236.51 | \$101.73 |
| 54110 | T | Treatment of penis lesion | 0181 | 32.37 | \$1,569.53 | \$906.36 | \$313.91 |
| 54111 | T | Treat penis lesion, graft | 0181 | 32.37 | \$1,569.53 | \$906.36 | \$313.91 |
| 54112 | T | Treat penis lesion, graft | 0181 | 32.37 | \$1,569.53 | \$906.36 | \$313.91 |
| 54115 | T | Treatment of penis lesion | 0008 | 6.15 | \$298.20 | \$113.67 | \$59.64 |
| 54120 | T | Partial removal of penis | 0181 | 32.37 | \$1,569.53 | \$906.36 | \$313.91 |
| 54125 | C | Removal of penis . |  |  |  |  |  |
| 54130 | C | Remove penis \& nodes | ...... | ...... | ..................... | ................... |  |
| 54135 | C | Remove penis \& nodes |  |  |  |  |  |
| 54150 | T | Circumcision | 0180 | 13.62 | \$660.39 | \$304.87 | \$132.08 |
| 54152 | T | Circumcision | 0180 | 13.62 | \$660.39 | \$304.87 | \$132.08 |
| 54160 | T | Circumcision | 0180 | 13.62 | \$660.39 | \$304.87 | \$132.08 |
| 54161 | T | Circumcision | 0180 | 13.62 | \$660.39 | \$304.87 | \$132.08 |
| 54200 | T | Treatment of penis lesion | 0165 | 3.89 | \$188.61 | \$91.76 | \$37.72 |
| 54205 | T | Treatment of penis lesion | 0181 | 32.37 | \$1,569.53 | \$906.36 | \$313.91 |
| 54220 | T | Treatment of penis lesion | 0165 | 3.89 | \$188.61 | \$91.76 | \$37.72 |
| 54230 | N | Prepare penis study |  |  |  |  |  |
| 54231 | T | Dynamic cavernosometry | 0165 | 3.89 | \$188.61 | \$91.76 | \$37.72 |
| 54235 | T | Penile injection | 0164 | 2.17 | \$105.23 | \$33.03 | \$21.05 |
| 54240 | T | Penis study | 0164 | 2.17 | \$105.23 | \$33.03 | \$21.05 |
| 54250 | T | Penis study | 0165 | 3.89 | \$188.61 | \$91.76 | \$37.72 |
| 54300 | T | Revision of penis | 0181 | 32.37 | \$1,569.53 | \$906.36 | \$313.91 |
| 54304 | T | Revision of penis | 0181 | 32.37 | \$1,569.53 | \$906.36 | \$313.91 |
| 54308 | T | Reconstruction of urethra | 0181 | 32.37 | \$1,569.53 | \$906.36 | \$313.91 |
| 54312 | T | Reconstruction of urethra | 0181 | 32.37 | \$1,569.53 | \$906.36 | \$313.91 |
| 54316 | T | Reconstruction of urethra | 0181 | 32.37 | \$1,569.53 | \$906.36 | \$313.91 |
| 54318 | T | Reconstruction of urethra | 0181 | 32.37 | \$1,569.53 | \$906.36 | \$313.91 |
| 54322 | T | Reconstruction of urethra | 0181 | 32.37 | \$1,569.53 | \$906.36 | \$313.91 |
| 54324 | T | Reconstruction of urethra | 0181 | 32.37 | \$1,569.53 | \$906.36 | \$313.91 |
| 54326 | T | Reconstruction of urethra | 0181 | 32.37 | \$1,569.53 | \$906.36 | \$313.91 |
| 54328 | T | Revise penis/urethra | 0181 | 32.37 | \$1,569.53 | \$906.36 | \$313.91 |
| 54332 | C | Revise penis/urethra |  |  |  |  |  |
| 54336 | C | Revise penis/urethra |  |  |  |  |  |
| 54340 | T | Secondary urethral surgery .................................... | 0181 | 32.37 | \$1,569.53 | \$906.36 | \$313.91 |
| 54344 | T | Secondary urethral surgery | 0181 | 32.37 | \$1,569.53 | \$906.36 | \$313.91 |
| 54348 | T | Secondary urethral surgery | 0181 | 32.37 | \$1,569.53 | \$906.36 | \$313.91 |
| 54352 | T | Reconstruct urethra/penis ...................................... | 0181 | 32.37 | \$1,569.53 | \$906.36 | \$313.91 |
| 54360 | T | Penis plastic surgery | 0181 | 32.37 | \$1,569.53 | \$906.36 | \$313.91 |
| 54380 | T | Repair penis | 0181 | 32.37 | \$1,569.53 | \$906.36 | \$313.91 |
| 54385 | T | Repair penis | 0181 | 32.37 | \$1,569.53 | \$906.36 | \$313.91 |
| 54390 | C | Repair penis and bladder |  |  |  |  |  |
| 54400 | T | Insert semi-rigid prosthesis | 0182 | 52.11 | \$2,526.66 | \$1,525.05 | \$505.33 |
| 54401 | T | Insert self-contd prosthesis | 0182 | 52.11 | \$2,526.66 | \$1,525.05 | \$505.33 |
| 54402 | T | Remove penis prosthesis ....................................... | 0181 | 32.37 | \$1,569.53 | \$906.36 | \$313.91 |
| 54405 | T | Insert multi-comp prosthesis | 0182 | 52.11 | \$2,526.66 | \$1,525.05 | \$505.33 |
| 54407 | T | Remove multi-comp prosthesis | 0181 | 32.37 | \$1,569.53 | \$906.36 | \$313.91 |
| 54409 | T | Revise penis prosthesis ...... | 0181 | 32.37 | \$1,569.53 | \$906.36 | \$313.91 |
| 54420 | T | Revision of penis ... | 0181 | 32.37 | \$1,569.53 | \$906.36 | \$313.91 |
| 54430 | C | Revision of penis |  |  |  |  |  |
| 54435 | T | Revision of penis | 0181 | 32.37 | \$1,569.53 | \$906.36 | \$313.91 |
| 54440 | T | Repair of penis ..................................................... | 0181 | 32.37 | \$1,569.53 | \$906.36 | \$313.91 |
| 54450 | T | Preputial stretching | 0165 | 3.89 | \$188.61 | \$91.76 | \$37.72 |
| 54500 | T | Biopsy of testis | 0005 | 5.41 | \$262.32 | \$119.75 | \$52.46 |
| 54505 | T | Biopsy of testis | 0183 | 18.26 | \$885.37 | \$448.94 | \$177.07 |
| 54510 | T | Removal of testis lesion | 0183 | 18.26 | \$885.37 | \$448.94 | \$177.07 |
| 54520 | T | Removal of testis | 0183 | 18.26 | \$885.37 | \$448.94 | \$177.07 |
| 54530 | T | Removal of testis | 0154 | 22.43 | \$1,087.57 | \$556.98 | \$217.51 |
| 54535 | C | Extensive testis surgery ........ |  |  |  |  |  |
| 54550 | T | Exploration for testis | 0154 | 22.43 | \$1,087.57 | \$556.98 | \$217.5 |
| 54560 | C | Exploration for testis |  |  |  |  |  |

[^184]
## Addendum B.-Hospital Outpatient Department (HOPD) Payment Status by hCPCS Code and Related Information-Continued

| CPT/ HCPCS | HOPD <br> Status <br> Indicator | Description | APC | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 54600 | T | Reduce testis torsion | 0183 | 18.26 | \$885.37 | \$448.94 | \$177.07 |
| 54620 | T | Suspension of testis | 0183 | 18.26 | \$885.37 | \$448.94 | \$177.07 |
| 54640 | T | Suspension of testis | 0154 | 22.43 | \$1,087.57 | \$556.98 | \$217.51 |
| 54650 | C | Orchiopexy (Fowler-Stephens) |  |  |  |  |  |
| 54660 | T | Revision of testis .................... | 0183 | 18.26 | \$885.37 | \$448.94 | \$177.07 |
| 54670 | T | Repair testis injury | 0183 | 18.26 | \$885.37 | \$448.94 | \$177.07 |
| 54680 | T | Relocation of testis(es) | 0183 | 18.26 | \$885.37 | \$448.94 | \$177.07 |
| 54690 | T | Laparoscopy, orchiectomy | 0131 | 41.81 | \$2,027.24 | \$1,089.88 | \$405.45 |
| 54692 | T | Laparoscopy, orchiopexy . | 0132 | 48.91 | \$2,371.50 | \$1,239.22 | \$474.30 |
| 54699 | T | Laparoscope proc, testis | 0130 | 25.36 | \$1,229.63 | \$659.53 | \$245.93 |
| 54700 | T | Drainage of scrotum | 0183 | 18.26 | \$885.37 | \$448.94 | \$177.07 |
| 54800 | T | Biopsy of epididymis | 0004 | 1.84 | \$89.22 | \$32.57 | \$17.84 |
| 54820 | T | Exploration of epididymis | 0183 | 18.26 | \$885.37 | \$448.94 | \$177.07 |
| 54830 | T | Remove epididymis lesion | 0183 | 18.26 | \$885.37 | \$448.94 | \$177.07 |
| 54840 | T | Remove epididymis lesion | 0183 | 18.26 | \$885.37 | \$448.94 | \$177.07 |
| 54860 | T | Removal of epididymis ..... | 0183 | 18.26 | \$885.37 | \$448.94 | \$177.07 |
| 54861 | T | Removal of epididymis | 0183 | 18.26 | \$885.37 | \$448.94 | \$177.07 |
| 54900 | T | Fusion of spermatic ducts | 0183 | 18.26 | \$885.37 | \$448.94 | \$177.07 |
| 54901 | T | Fusion of spermatic ducts | 0183 | 18.26 | \$885.37 | \$448.94 | \$177.07 |
| 55000 | T | Drainage of hydrocele | 0004 | 1.84 | \$89.22 | \$32.57 | \$17.84 |
| 55040 | T | Removal of hydrocele | 0154 | 22.43 | \$1,087.57 | \$556.98 | \$217.51 |
| 55041 | T | Removal of hydroceles | 0154 | 22.43 | \$1,087.57 | \$556.98 | \$217.51 |
| 55060 | T | Repair of hydrocele | 0183 | 18.26 | \$885.37 | \$448.94 | \$177.07 |
| 55100 | T | Drainage of scrotum abscess | 0008 | 6.15 | \$298.20 | \$113.67 | \$59.64 |
| 55110 | T | Explore scrotum | 0183 | 18.26 | \$885.37 | \$448.94 | \$177.07 |
| 55120 | T | Removal of scrotum lesion | 0183 | 18.26 | \$885.37 | \$448.94 | \$177.07 |
| 55150 | T | Removal of scrotum | 0183 | 18.26 | \$885.37 | \$448.94 | \$177.07 |
| 55175 | T | Revision of scrotum | 0183 | 18.26 | \$885.37 | \$448.94 | \$177.07 |
| 55180 | T | Revision of scrotum | 0183 | 18.26 | \$885.37 | \$448.94 | \$177.07 |
| 55200 | T | Incision of sperm duct | 0183 | 18.26 | \$885.37 | \$448.94 | \$177.07 |
| 55250 | T | Removal of sperm duct(s) | 0183 | 18.26 | \$885.37 | \$448.94 | \$177.07 |
| 55300 | N | Prepare, sperm duct x-ray ...................................... |  |  |  |  |  |
| 55400 | T | Repair of sperm duct | 0183 | 18.26 | \$885.37 | \$448.94 | \$177.07 |
| 55450 | T | Ligation of sperm duct | 0183 | 18.26 | \$885.37 | \$448.94 | \$177.07 |
| 55500 | T | Removal of hydrocele | 0183 | 18.26 | \$885.37 | \$448.94 | \$177.07 |
| 55520 | T | Removal of sperm cord lesion | 0183 | 18.26 | \$885.37 | \$448.94 | \$177.07 |
| 55530 | T | Revise spermatic cord veins | 0183 | 18.26 | \$885.37 | \$448.94 | \$177.07 |
| 55535 | T | Revise spermatic cord veins | 0154 | 22.43 | \$1,087.57 | \$556.98 | \$217.51 |
| 55540 | T | Revise hernia \& sperm veins | 0154 | 22.43 | \$1,087.57 | \$556.98 | \$217.51 |
| 55550 | T | Laparo ligate spermatic vein | 0131 | 41.81 | \$2,027.24 | \$1,089.88 | \$405.45 |
| 55559 | T | Laparo proc, spermatic cord | 0130 | 25.36 | \$1,229.63 | \$659.53 | \$245.93 |
| 55600 | C | Incise sperm duct pouch ...... |  | ......... | ...................... | ...................... | ..................... |
| 55605 | C | Incise sperm duct pouch ...... |  | ..................... | ................... | ..................... |  |
| 55650 | C | Remove sperm duct pouch |  |  |  |  |  |
| 55680 | T | Remove sperm pouch lesion | 0183 | 18.26 | \$885.37 | \$448.94 | \$177.07 |
| 55700 | T | Biopsy of prostate | 0184 | 4.94 | \$239.53 | \$122.96 | \$47.91 |
| 55705 | T | Biopsy of prostate | 0184 | 4.94 | \$239.53 | \$122.96 | \$47.91 |
| 55720 | T | Drainage of prostate abscess | 0162 | 17.49 | \$848.04 | \$427.49 | \$169.61 |
| 55725 | T | Drainage of prostate abscess | 0162 | 17.49 | \$848.04 | \$427.49 | \$169.61 |
| 55801 | C | Removal of prostate ..... |  |  |  |  |  |
| 55810 | C | Extensive prostate surgery |  |  |  |  |  |
| 55812 | C | Extensive prostate surgery ..................................... | .................... | . | .................... | .................... | ...................... |
| 55815 | C | Extensive prostate surgery | ...................... | ...................... | ...................... | ...................... |  |
| 55821 | C | Removal of prostate ..... |  |  | ............... | ..................... |  |
| 55831 | C | Removal of prostate .............................................. | ................... | ..................... | ...................... | ...................... | ...................... |
| 55840 | C | Extensive prostate surgery .................................... |  |  | ...................... | ..................... | ..................... |
| 55842 | C | Extensive prostate surgery |  |  |  |  |  |
| 55845 | C | Extensive prostate surgery ..................................... |  |  |  |  |  |
| 55859 | T | Percut/needle insert, pros ....................................... | 0162 | 17.49 | \$848.04 | \$427.49 | \$169.61 |
| 55860 | C | Surgical exposure, prostate .................................... |  |  |  |  |  |
| 55862 | C | Extensive prostate surgery .................................... |  |  |  | .................... |  |
| 55865 | C | Extensive prostate surgery .................................... |  |  |  |  |  |
| 55870 | T | Electroejaculation ................................................ | 0197 | 2.40 | \$116.37 | \$49.55 | \$23.27 |
| 55899 | T | Genital surgery procedure ...................................... | 0164 | 2.17 | \$105.23 | \$33.03 | \$21.05 |
| 55970 | E | Sex transformation, M to F ..................................... |  |  |  |  |  |
| 55980 | E | Sex transformation, F to M .... |  |  |  |  |  |
| 56405 | T | I \& D of vulva/perineum | 0192 | 2.38 | \$115.40 | \$35.33 | \$23.08 |
| 56420 | T | Drainage of gland abscess ..................................... | 0192 | 2.38 | \$115.40 | \$35.33 | \$23.08 |
| 56440 | T | Surgery for vulva lesion ......................................... | 0194 | 16.21 | \$785.98 | \$395.94 | \$157.20 |
| 56441 | T | Lysis of labial lesion(s) .......................................... | 0193 | 8.93 | \$432.99 | \$171.13 | \$86.60 |
| 56501 | T | Destruction, vulva lesion(s) .................................... | 0016 | 3.53 | \$171.16 | \$74.67 | \$34.23 |
| 56515 | T | Destruction, vulva lesion(s) .................................... | 0017 | 12.45 | \$603.66 | \$289.16 | \$120.73 |
| 56605 | T | Biopsy of vulva/perineum ...................................... | 0019 | 4.00 | \$193.95 | \$78.91 | \$38.79 |

[^185]
## Addendum B.-Hospital Outpatient Department (HOPD) Payment Status by HCPCS Code and Related INFORMATION-Continued

| $\begin{aligned} & \text { CPT/ } \\ & \text { HCPCS } \end{aligned}$ | HOPD Status Indicator | Description | APC | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 56606 | T | Biopsy of vulva/perineum | 0019 | 4.00 | \$193.95 | \$78.91 | \$38.79 |
| 56620 | T | Partial removal of vulva | 0195 | 18.68 | \$905.74 | \$483.80 | \$181.15 |
| 56625 | T | Complete removal of vulva | 0195 | 18.68 | \$905.74 | \$483.80 | \$181.15 |
| 56630 | C | Extensive vulva surgery . |  |  |  |  |  |
| 56631 | C | Extensive vulva surgery | ..... | ....... |  |  |  |
| 56632 | C | Extensive vulva surgery. | ....... |  | . | ..................... |  |
| 56633 | C | Extensive vulva surgery ... |  |  |  |  |  |
| 56634 | C | Extensive vulva surgery ......................................... | .... | ................ | ................. | ................... |  |
| 56637 | C | Extensive vulva surgery |  |  |  |  |  |
| 56640 | C | Extensive vulva surgery |  |  |  |  |  |
| 56700 | T | Partial removal of hymen | 0194 | 16.21 | \$785.98 | \$395.94 | \$157.20 |
| 56720 | T | Incision of hymen .... | 0193 | 8.93 | \$432.99 | \$171.13 | \$86.60 |
| 56740 | T | Remove vagina gland lesion | 0194 | 16.21 | \$785.98 | \$395.94 | \$157.20 |
| 56800 | T | Repair of vagina | 0194 | 16.21 | \$785.98 | \$395.94 | \$157.20 |
| 56805 | C | Repair clitoris |  |  |  |  |  |
| 56810 | T | Repair of perineum | 0194 | 16.21 | \$785.98 | \$395.94 | \$157.20 |
| 57000 | T | Exploration of vagina | 0194 | 16.21 | \$785.98 | \$395.94 | \$157.20 |
| 57010 | T | Drainage of pelvic abscess | 0194 | 16.21 | \$785.98 | \$395.94 | \$157.20 |
| 57020 | T | Drainage of pelvic fluid | 0193 | 8.93 | \$432.99 | \$171.13 | \$86.60 |
| 57061 | T | Destruction vagina lesion(s) | 0194 | 16.21 | \$785.98 | \$395.94 | \$157.20 |
| 57065 | T | Destruction vagina lesion(s) | 0194 | 16.21 | \$785.98 | \$395.94 | \$157.20 |
| 57100 | T | Biopsy of vagina | 0192 | 2.38 | \$115.40 | \$35.33 | \$23.08 |
| 57105 | T | Biopsy of vagina | 0194 | 16.21 | \$785.98 | \$395.94 | \$157.20 |
| 57106 | T | Remove vagina wall, partial | 0194 | 16.21 | \$785.98 | \$395.94 | \$157.20 |
| 57107 | T | Remove vagina tissue, part | 0194 | 16.21 | \$785.98 | \$395.94 | \$157.20 |
| 57109 | T | Vaginectomy partial w/nodes | 0194 | 16.21 | \$785.98 | \$395.94 | \$157.20 |
| 57110 | C | Remove vagina wall, complete |  |  |  |  |  |
| 57111 | C | Remove vagina tissue, compl |  | ......... |  | .................... |  |
| 57112 | C | Vaginectomy w/nodes, compl | ...... |  |  |  |  |
| 57120 | C | Closure of vagina |  |  |  |  |  |
| 57130 | T | Remove vagina lesion | 0194 | 16.21 | \$785.98 | \$395.94 | \$157.20 |
| 57135 | T | Remove vagina lesion | 0194 | 16.21 | \$785.98 | \$395.94 | \$157.20 |
| 57150 | T | Treat vagina infection | 0192 | 2.38 | \$115.40 | \$35.33 | \$23.08 |
| 57160 | T | Insert pessary/other device | 0191 | 1.19 | \$57.70 | \$17.43 | \$11.54 |
| 57170 | T | Fitting of diaphragm/cap | 0191 | 1.19 | \$57.70 | \$17.43 | \$11.54 |
| 57180 | T | Treat vaginal bleeding | 0192 | 2.38 | \$115.40 | \$35.33 | \$23.08 |
| 57200 | T | Repair of vagina | 0194 | 16.21 | \$785.98 | \$395.94 | \$157.20 |
| 57210 | T | Repair vagina/perineum | 0194 | 16.21 | \$785.98 | \$395.94 | \$157.20 |
| 57220 | T | Revision of urethra | 0195 | 18.68 | \$905.74 | \$483.80 | \$181.15 |
| 57230 | T | Repair of urethral lesion | 0194 | 16.21 | \$785.98 | \$395.94 | \$157.20 |
| 57240 | T | Repair bladder \& vagina | 0195 | 18.68 | \$905.74 | \$483.80 | \$181.15 |
| 57250 | T | Repair rectum \& vagina | 0195 | 18.68 | \$905.74 | \$483.80 | \$181.15 |
| 57260 | T | Repair of vagina | 0195 | 18.68 | \$905.74 | \$483.80 | \$181.15 |
| 57265 | T | Extensive repair of vagina | 0195 | 18.68 | \$905.74 | \$483.80 | \$181.15 |
| 57268 | T | Repair of bowel bulge | 0195 | 18.68 | \$905.74 | \$483.80 | \$181.15 |
| 57270 | C | Repair of bowel pouch |  |  |  |  |  |
| 57280 | C | Suspension of vagina ........................................... | ...... | ........ |  | ..................... |  |
| 57282 | C | Repair of vaginal prolapse |  |  |  |  |  |
| 57284 | T | Repair paravaginal defect | 0195 | 18.68 | \$905.74 | \$483.80 | \$181.15 |
| 57288 | T | Repair bladder defect ... | 0195 | 18.68 | \$905.74 | \$483.80 | \$181.15 |
| 57289 | T | Repair bladder \& vagina | 0195 | 18.68 | \$905.74 | \$483.80 | \$181.15 |
| 57291 | T | Construction of vagina | 0195 | 18.68 | \$905.74 | \$483.80 | \$181.15 |
| 57292 | C | Construct vagina with graft .. |  |  |  |  |  |
| 57300 | T | Repair rectum-vagina fistula ................................... | 0195 | 18.68 | \$905.74 | \$483.80 | \$181.15 |
| 57305 | C | Repair rectum-vagina fistula ................................... |  |  |  |  |  |
| 57307 | C | Fistula repair \& colostomy ... |  |  |  |  |  |
| 57308 | C | Fistula repair, transperine |  |  |  | .................... | .................... |
| 57310 | C | Repair urethrovaginal lesion |  |  |  | ................... |  |
| 57311 | C | Repair urethrovaginal lesion |  |  |  |  |  |
| 57320 | C | Repair bladder-vagina lesion | .... | ....... |  | ..................... | .................... |
| 57330 | C | Repair bladder-vagina lesion |  |  |  | ..................... |  |
| 57335 | C | Repair vagina |  |  |  |  |  |
| 57400 | T | Dilation of vagina | 0194 | 16.21 | \$785.98 | \$395.94 | \$157.20 |
| 57410 | T | Pelvic examination ... | 0194 | 16.21 | \$785.98 | \$395.94 | \$157.20 |
| 57415 | T | Remove vaginal foreign body | 0194 | 16.21 | \$785.98 | \$395.94 | \$157.20 |
| 57452 | T | Examination of vagina | 0191 | 1.19 | \$57.70 | \$17.43 | \$11.54 |
| 57454 | T | Vagina examination \& biopsy | 0192 | 2.38 | \$115.40 | \$35.33 | \$23.08 |
| 57460 | T | Cervix excision ..................................................... | 0193 | 8.93 | \$432.99 | \$171.13 | \$86.60 |
| 57500 | T | Biopsy of cervix | 0193 | 8.93 | \$432.99 | \$171.13 | \$86.60 |
| 57505 | T | Endocervical curettage .......................................... | 0192 | 2.38 | \$115.40 | \$35.33 | \$23.08 |
| 57510 | T | Cauterization of cervix | 0193 | 8.93 | \$432.99 | \$171.13 | \$86.60 |
| 57511 | T | Cryocautery of cervix . | 0192 | 2.38 | \$115.40 | \$35.33 | \$23.08 |
| 57513 | T | Laser surgery of cervix | 0193 | 8.93 | \$432.99 | \$171.13 | \$86.60 |

[^186]
# Addendum B.—Hospital Outpatient Department (HOPD) Payment Status by hCPCS Code and Related INFORMATION-Continued 

| CPT/ HCPCS | HOPD Status Indicator | Description | APC | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 57520 | T | Conization of cervix | 0194 | 16.21 | \$785.98 | \$395.94 | \$157.20 |
| 57522 | T | Conization of cervix | 0195 | 18.68 | \$905.74 | \$483.80 | \$181.15 |
| 57530 | T | Removal of cervix | 0195 | 18.68 | \$905.74 | \$483.80 | \$181.15 |
| 57531 | C | Removal of cervix, radical |  |  |  |  |  |
| 57540 | C | Removal of residual cervix | .................... | .................... | ................. | .................... |  |
| 57545 | C | Remove cervix/repair pelvis |  |  |  |  |  |
| 57550 | T | Removal of residual cervix | 0195 | 18.68 | \$905.74 | \$483.80 | \$181.15 |
| 57555 | T | Remove cervix/repair vagina | 0195 | 18.68 | \$905.74 | \$483.80 | \$181.15 |
| 57556 | T | Remove cervix, repair bowel | 0195 | 18.68 | \$905.74 | \$483.80 | \$181.15 |
| 57700 | T | Revision of cervix | 0194 | 16.21 | \$785.98 | \$395.94 | \$157.20 |
| 57720 | T | Revision of cervix | 0194 | 16.21 | \$785.98 | \$395.94 | \$157.20 |
| 57800 | T | Dilation of cervical canal | 0193 | 8.93 | \$432.99 | \$171.13 | \$86.60 |
| 57820 | T | D \& c of residual cervix | 0196 | 14.47 | \$701.61 | \$357.98 | \$140.32 |
| 58100 | T | Biopsy of uterus lining | 0191 | 1.19 | \$57.70 | \$17.43 | \$11.54 |
| 58120 | T | Dilation and curettage | 0196 | 14.47 | \$701.61 | \$357.98 | \$140.32 |
| 58140 | C | Removal of uterus lesion |  |  |  |  |  |
| 58145 | T | Removal of uterus lesion | 0195 | 18.68 | \$905.74 | \$483.80 | \$181.15 |
| 58150 | C | Total hysterectomy |  |  |  |  |  |
| 58152 | C | Total hysterectomy |  |  |  |  |  |
| 58180 | C | Partial hysterectomy |  |  |  |  |  |
| 58200 | C | Extensive hysterectomy |  |  |  |  |  |
| 58210 | C | Extensive hysterectomy |  |  |  | ................... |  |
| 58240 | C | Removal of pelvis contents |  |  |  |  |  |
| 58260 | C | Vaginal hysterectomy |  |  |  |  |  |
| 58262 | C | Vaginal hysterectomy | ... |  |  | .................... |  |
| 58263 | C | Vaginal hysterectomy |  |  |  |  |  |
| 58267 | C | Hysterectomy \& vagina repair |  |  |  |  |  |
| 58270 | C | Hysterectomy \& vagina repair | .... | ..................... | ........... | .................... | ..................... |
| 58275 | C | Hysterectomy/revise vagina | .................... | ..................... | ................... | ...................... |  |
| 58280 | C | Hysterectomy/revise vagina |  |  |  |  |  |
| 58285 | C | Extensive hysterectomy |  |  |  |  |  |
| 58300 | E | Insert intrauterine device |  |  |  |  |  |
| 58301 | T | Remove intrauterine device | 0191 | 1.19 | \$57.70 | \$17.43 | \$11.54 |
| 58321 | T | Artificial insemination | 0197 | 2.40 | \$116.37 | \$49.55 | \$23.27 |
| 58322 | T | Artificial insemination | 0197 | 2.40 | \$116.37 | \$49.55 | \$23.27 |
| 58323 | T | Sperm washing | 0197 | 2.40 | \$116.37 | \$49.55 | \$23.27 |
| 58340 | N | Catheter for hysterography |  |  |  |  |  |
| 58345 | T | Reopen fallopian tube | 0194 | 16.21 | \$785.98 | \$395.94 | \$157.20 |
| 58350 | T | Reopen fallopian tube | 0194 | 16.21 | \$785.98 | \$395.94 | \$157.20 |
| 58400 | C | Suspension of uterus |  |  |  |  |  |
| 58410 | C | Suspension of uterus |  |  |  |  |  |
| 58520 | C | Repair of ruptured uterus |  |  |  |  |  |
| 58540 | C | Revision of uterus |  |  |  |  |  |
| 58550 | T | Laparo-asst vag hysterectomy | 0132 | 48.91 | \$2,371.50 | \$1,239.22 | \$474.30 |
| 58551 | T | Laparoscopy, remove myoma | 0131 | 41.81 | \$2,027.24 | \$1,089.88 | \$405.45 |
| 58555 | T | Hysteroscopy, dx, sep proc | 0191 | 1.19 | \$57.70 | \$17.43 | \$11.54 |
| 58558 | T | Hysteroscopy, biopsy | 0190 | 17.85 | \$865.49 | \$443.89 | \$173.10 |
| 58559 | T | Hysteroscopy, lysis ....... | 0190 | 17.85 | \$865.49 | \$443.89 | \$173.10 |
| 58560 | T | Hysteroscopy, resect septum .................................. | 0190 | 17.85 | \$865.49 | \$443.89 | \$173.10 |
| 58561 | T | Hysteroscopy, remove myoma ............................... | 0190 | 17.85 | \$865.49 | \$443.89 | \$173.10 |
| 58562 | T | Hysteroscopy, remove fb | 0190 | 17.85 | \$865.49 | \$443.89 | \$173.10 |
| 58563 | T | Hysteroscopy, ablation ....... | 0190 | 17.85 | \$865.49 | \$443.89 | \$173.10 |
| 58578 | T | Laparo proc, uterus | 0190 | 17.85 | \$865.49 | \$443.89 | \$173.10 |
| 58579 | T | Hysteroscope procedure | 0190 | 17.85 | \$865.49 | \$443.89 | \$173.10 |
| 58600 | C | Division of fallopian tube ........................................ | ...................... | ...................... |  | ..................... |  |
| 58605 | C | Division of fallopian tube ....................................... | ...................... | ...................... |  | ...................... |  |
| 58611 | C | Ligate oviduct(s) add-on |  |  |  |  |  |
| 58615 | C | Occlude fallopian tube(s) ........................................ |  |  |  |  |  |
| 58660 | T | Laparoscopy, lysis | 0131 | 41.81 | \$2,027.24 | \$1,089.88 | \$405.45 |
| 58661 | T | Laparoscopy, remove adnexa ................................ | 0131 | 41.81 | \$2,027.24 | \$1,089.88 | \$405.45 |
| 58662 | T | Laparoscopy, excise lesions ................................... | 0131 | 41.81 | \$2,027.24 | \$1,089.88 | \$405.45 |
| 58670 | T | Laparoscopy, tubal cautery .................................... | 0131 | 41.81 | \$2,027.24 | \$1,089.88 | \$405.45 |
| 58671 | T | Laparoscopy, tubal block | 0131 | 41.81 | \$2,027.24 | \$1,089.88 | \$405.45 |
| 58672 | T | Laparoscopy, fimbrioplasty ..................................... | 0131 | 41.81 | \$2,027.24 | \$1,089.88 | \$405.45 |
| 58673 | T | Laparoscopy, salpingostomy .................................. | 0131 | 41.81 | \$2,027.24 | \$1,089.88 | \$405.45 |
| 58679 | T | Laparo proc, oviduct-ovary ..................................... | 0130 | 25.36 | \$1,229.63 | \$659.53 | \$245.93 |
| 58700 | C | Removal of fallopian tube ....................................... |  | ..................... |  |  |  |
| 58720 | C | Removal of ovary/tube(s) ....................................... |  | ...................... |  | ...................... |  |
| 58740 | C | Revise fallopian tube(s) ......................................... | .................... | ..................... | ..................... | ..................... |  |
| 58750 | C | Repair oviduct ...................................................... |  |  |  |  |  |
| 58752 | C | Revise ovarian tube(s) ........................................... | .................... | .................... | ..................... | ..................... | ..................... |
| 58760 | C | Remove tubal obstruction ....................................... | ..................... | ..................... | ..................... | ........ |  |
| 58770 | C | Create new tubal opening |  |  |  |  |  |

[^187]
# Addendum B.-Hospital Outpatient Department (HOPD) Payment Status by HCPCS Code and Related Information-Continued 

| CPT/ HCPCS | HOPD Status Indicator | Description | APC | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 58800 | T | Drainage of ovarian cyst(s) | 0195 | 18.68 | \$905.74 | \$483.80 | \$181.15 |
| 58805 | C | Drainage of ovarian cyst(s) .............................. |  |  |  |  |  |
| 58820 | T | Drain ovary abscess, open ................................ | 0195 | 18.68 | \$905.74 | \$483.80 | \$181.15 |
| 58822 | C | Drain ovary abscess, percut |  |  |  |  |  |
| 58823 | C | Drain pelvic abscess, percut | .... |  |  |  |  |
| 58825 | C | Transposition, ovary(s) ......... |  |  |  |  |  |
| 58900 | T | Biopsy of ovary(s) ....... | 0195 | 18.68 | \$905.74 | \$483.80 | \$181.15 |
| 58920 | T | Partial removal of ovary(s) | 0195 | 18.68 | \$905.74 | \$483.80 | \$181.15 |
| 58925 | T | Removal of ovarian cyst(s) | 0195 | 18.68 | \$905.74 | \$483.80 | \$181.15 |
| 58940 | C | Removal of ovary(s) ........ |  |  |  |  |  |
| 58943 | C | Removal of ovary(s) | $\ldots$ | ..................... |  |  |  |
| 58950 | C | Resect ovarian malignancy |  |  |  |  |  |
| 58951 | C | Resect ovarian malignancy |  |  |  |  |  |
| 58952 | C | Resect ovarian malignancy |  |  |  |  |  |
| 58960 | C | Exploration of abdomen ... |  |  |  |  |  |
| 58970 | T | Retrieval of oocyte | 0194 | 16.21 | \$785.98 | \$395.94 | \$157.20 |
| 58974 | T | Transfer of embryo | 0197 | 2.40 | \$116.37 | \$49.55 | \$23.27 |
| 58976 | T | Transfer of embryo | 0197 | 2.40 | \$116.37 | \$49.55 | \$23.27 |
| 58999 | T | Genital surgery procedure | 0019 | 4.00 | \$193.95 | \$78.91 | \$38.79 |
| 59000 | T | Amniocentesis ............... | 0198 | 1.34 | \$64.97 | \$33.03 | \$12.99 |
| 59012 | T | Fetal cord puncture, prenatal | 0198 | 1.34 | \$64.97 | \$33.03 | \$12.99 |
| 59015 | T | Chorion biopsy | 0198 | 1.34 | \$64.97 | \$33.03 | \$12.99 |
| 59020 | T | Fetal contract stress test | 0198 | 1.34 | \$64.97 | \$33.03 | \$12.99 |
| 59025 | T | Fetal non-stress test | 0198 | 1.34 | \$64.97 | \$33.03 | \$12.99 |
| 59030 | T | Fetal scalp blood sample | 0198 | 1.34 | \$64.97 | \$33.03 | \$12.99 |
| 59050 | T | Fetal monitor w/report | 0198 | 1.34 | \$64.97 | \$33.03 | \$12.99 |
| 59051 | E | Fetal monitor/interpret only |  |  |  |  |  |
| 59100 | C | Remove uterus lesion |  |  |  | .................... |  |
| 59120 | C | Treat ectopic pregnancy | .................... | ..................... |  |  |  |
| 59121 | C | Treat ectopic pregnancy |  |  |  |  |  |
| 59130 | C | Treat ectopic pregnancy ........................................ | ..................... | .................... | ..................... | .................. |  |
| 59135 | C | Treat ectopic pregnancy | ..................... | .................... |  | ..................... |  |
| 59136 | C | Treat ectopic pregnancy |  |  |  |  |  |
| 59140 | C | Treat ectopic pregnancy ......................................... |  |  |  |  |  |
| 59150 | T | Treat ectopic pregnancy ........................................ | 0131 | 41.81 | \$2,027.24 | \$1,089.88 | \$405.45 |
| 59151 | T | Treat ectopic pregnancy | 0131 | 41.81 | \$2,027.24 | \$1,089.88 | \$405.45 |
| 59160 | T | D \& c after delivery | 0196 | 14.47 | \$701.61 | \$357.98 | \$140.32 |
| 59200 | T | Insert cervical dilator | 0191 | 1.19 | \$57.70 | \$17.43 | \$11.54 |
| 59300 | T | Episiotomy or vaginal repair | 0194 | 16.21 | \$785.98 | \$395.94 | \$157.20 |
| 59320 | T | Revision of cervix | 0194 | 16.21 | \$785.98 | \$395.94 | \$157.20 |
| 59325 | C | Revision of cervix |  |  |  | ...................... | ..................... |
| 59350 | C | Repair of uterus |  |  |  |  |  |
| 59400 | E | Obstetrical care ... |  |  |  |  |  |
| 59409 | T | Obstetrical care | 0199 | 11.20 | \$543.06 | \$157.83 | \$108.61 |
| 59410 | E | Obstetrical care |  |  |  |  |  |
| 59412 | T | Antepartum manipulation | 0199 | 11.20 | \$543.06 | \$157.83 | \$108.61 |
| 59414 | T | Deliver placenta .................................................... | 0199 | 11.20 | \$543.06 | \$157.83 | \$108.61 |
| 59425 | E | Antepartum care only |  |  |  |  |  |
| 59426 | E | Antepartum care only ............................................ |  |  |  |  |  |
| 59430 | E | Care after delivery ................................................ |  | ..................... |  | ...................... |  |
| 59510 | E | Cesarean delivery ................................................. |  |  |  | ...................... |  |
| 59514 | C | Cesarean delivery only .......................................... |  |  |  |  |  |
| 59515 | E | Cesarean delivery |  |  |  |  |  |
| 59525 | C | Remove uterus after cesarean ................................ |  |  |  | ................... |  |
| 59610 | E | Vbac delivery ....................................................... |  |  |  |  |  |
| 59612 | T | Vbac delivery only ................................................ | 0199 | 11.20 | \$543.06 | \$157.83 | \$108.61 |
| 59614 | E | Vbac care after delivery ......................................... | ...................... |  |  | ...................... | ..................... |
| 59618 | E | Attempted vbac delivery |  |  |  |  |  |
| 59620 | C | Attempted vbac delivery only .................................. |  |  |  |  |  |
| 59622 | E | Attempted vbac after care ...................................... |  |  |  |  |  |
| 59812 | T | Treatment of miscarriage ....................................... | 0201 | 13.00 | \$630.33 | \$329.65 | \$126.07 |
| 59820 | T | Care of miscarriage ............................................... | 0201 | 13.00 | \$630.33 | \$329.65 | \$126.07 |
| 59821 | T | Treatment of miscarriage ....................................... | 0201 | 13.00 | \$630.33 | \$329.65 | \$126.07 |
| 59830 | C | Treat uterus infection ....... |  |  |  |  |  |
| 59840 | T | Abortion | 0200 | 13.89 | \$673.49 | \$373.23 | \$134.70 |
| 59841 | T | Abortion | 0200 | 13.89 | \$673.49 | \$373.23 | \$134.70 |
| 59850 | C | Abortion |  |  |  |  |  |
| 59851 | C | Abortion ............................................................. | ..................... | .................... |  | .................... |  |
| 59852 | C | Abortion .............................................................. |  |  |  |  |  |
| 59855 | C | Abortion |  |  |  |  |  |
| 59856 | C | Abortion | .................... | , | .................... | ..................... | ..................... |
| 59857 | C | Abortion .............................................................. | ...................... | ...................... | ..................... |  |  |
| 59866 | C | Abortion (mpr) |  |  |  |  |  |

[^188]
# Addendum B.—Hospital Outpatient Department (HOPD) Payment Status by hCPCS Code and Related INFORMATION-Continued 

| CPT/ HCPCS | HOPD Status Indicator | Description | APC | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 59870 | T | Evacuate mole of uterus | 0201 | 13.00 | \$630.33 | \$329.65 | \$126.07 |
| 59871 | T | Remove cerclage suture | 0194 | 16.21 | \$785.98 | \$395.94 | \$157.20 |
| 59898 | T | Laparo proc, ob care/deliver | 0130 | 25.36 | \$1,229.63 | \$659.53 | \$245.93 |
| 59899 | T | Maternity care procedure | 0198 | 1.34 | \$64.97 | \$33.03 | \$12.99 |
| 60000 | T | Drain thyroid/tongue cyst | 0253 | 12.02 | \$582.81 | \$284.00 | \$116.56 |
| 60001 | T | Aspirate/inject thyriod cyst | 0002 | 0.62 | \$30.06 | \$17.66 | \$6.01 |
| 60100 | T | Biopsy of thyroid | 0004 | 1.84 | \$89.22 | \$32.57 | \$17.84 |
| 60200 | T | Remove thyroid lesion | 0114 | 19.56 | \$948.41 | \$493.78 | \$189.68 |
| 60210 | T | Partial thyroid excision | 0114 | 19.56 | \$948.41 | \$493.78 | \$189.68 |
| 60212 | C | Parital thyroid excision |  |  |  |  |  |
| 60220 | T | Partial removal of thyroid | 0114 | 19.56 | \$948.41 | \$493.78 | \$189.68 |
| 60225 | T | Partial removal of thyroid | 0114 | 19.56 | \$948.41 | \$493.78 | \$189.68 |
| 60240 | T | Removal of thyroid ... | 0114 | 19.56 | \$948.41 | \$493.78 | \$189.68 |
| 60252 | C | Removal of thyroid |  |  |  |  |  |
| 60254 | C | Extensive thyroid surgery |  |  |  |  |  |
| 60260 | C | Repeat thyroid surgery .. |  |  |  |  |  |
| 60270 | C | Removal of thyroid |  |  |  |  |  |
| 60271 | C | Removal of thyroid |  |  |  |  |  |
| 60280 | T | Remove thyroid duct lesion | 0114 | 19.56 | \$948.41 | \$493.78 | \$189.68 |
| 60281 | T | Remove thyroid duct lesion | 0114 | 19.56 | \$948.41 | \$493.78 | \$189.68 |
| 60500 | T | Explore parathyroid glands | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 60502 | C | Re-explore parathyroids |  |  |  |  |  |
| 60505 | C | Explore parathyroid glands |  |  |  |  |  |
| 60512 | C | Autotransplant parathyroid | .... | .................... | .................... |  |  |
| 60520 | C | Removal of thymus gland. |  |  |  |  |  |
| 60521 | C | Removal of thymus gland.. |  | ..................... | .................... | .................... |  |
| 60522 | C | Removal of thymus gland |  |  |  | ..................... |  |
| 60540 | C | Explore adrenal gland .... | ................. | .................. | .................. | ..................... |  |
| 60545 | C | Explore adrenal gland |  |  |  |  |  |
| 60600 | C | Remove carotid body lesion |  | ................... | ..................... | .................... |  |
| 60605 | C | Remove carotid body lesion |  |  |  |  |  |
| 60650 | C | Laparoscopy adrenalectomy |  |  |  |  |  |
| 60659 | T | Laparo proc, endocrine | 0130 | 25.36 | \$1,229.63 | \$659.53 | \$245.93 |
| 60699 | T | Endocrine surgery procedure | 0004 | 1.84 | \$89.22 | \$32.57 | \$17.84 |
| 61000 | T | Remove cranial cavity fluid | 0212 | 3.64 | \$176.49 | \$88.78 | \$35.30 |
| 61001 | T | Remove cranial cavity fluid | 0212 | 3.64 | \$176.49 | \$88.78 | \$35.30 |
| 61020 | T | Remove brain cavity fluid | 0212 | 3.64 | \$176.49 | \$88.78 | \$35.30 |
| 61026 | T | Injection into brain canal | 0212 | 3.64 | \$176.49 | \$88.78 | \$35.30 |
| 61050 | T | Remove brain canal fluid | 0212 | 3.64 | \$176.49 | \$88.78 | \$35.30 |
| 61055 | T | Injection into brain canal ..... | 0212 | 3.64 | \$176.49 | \$88.78 | \$35.30 |
| 61070 | T | Brain canal shunt procedure | 0212 | 3.64 | \$176.49 | \$88.78 | \$35.30 |
| 61105 | C | Twist drill hole |  |  |  |  |  |
| 61107 | C | Drill skull for implantation |  |  |  | ...................... |  |
| 61108 | C | Drill skull for drainage |  |  |  |  |  |
| 61120 | C | Burr hole for puncture |  |  |  |  |  |
| 61140 | C | Pierce skull for biopsy |  |  |  |  |  |
| 61150 | C | Pierce skull for drainage |  | ..................... | ..................... | ..................... |  |
| 61151 | C | Pierce skull for drainage |  |  |  |  |  |
| 61154 | C | Pierce skull \& remove clot |  |  |  | ..................... |  |
| 61156 | C | Pierce skull for drainage |  |  |  |  |  |
| 61210 | C | Pierce skull, implant device |  |  |  |  |  |
| 61215 | T | Insert brain-fluid device | 0222 | 25.48 | \$1,235.45 | \$780.07 | \$247.09 |
| 61250 | C | Pierce skull \& explore ..... |  |  |  |  |  |
| 61253 | C | Pierce skull \& explore |  |  |  |  |  |
| 61304 | C | Open skull for exploration |  |  |  |  |  |
| 61305 | C | Open skull for exploration ....................................... |  |  |  | .................... |  |
| 61312 | C | Open skull for drainage |  |  |  |  |  |
| 61313 | C | Open skull for drainage .......................................... |  |  |  |  |  |
| 61314 | C | Open skull for drainage |  |  |  | .................... |  |
| 61315 | C | Open skull for drainage ......................................... |  |  |  | ...................... |  |
| 61320 | C | Open skull for drainage ......................................... |  |  |  |  |  |
| 61321 | C | Open skull for drainage |  |  |  |  |  |
| 61330 | T | Decompress eye socket | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 61332 | C | Explore/biopsy eye socket |  |  |  |  |  |
| 61333 | C | Explore orbit/remove lesion |  |  |  |  |  |
| 61334 | C | Explore orbit/remove object .................................... |  |  |  |  |  |
| 61340 | C | Relieve cranial pressure |  |  |  |  |  |
| 61343 | C | Incise skull (press relief) |  |  |  |  |  |
| 61345 | C | Relieve cranial pressure ......................................... | ...................... | ..................... | ..................... | ..................... | .................... |
| 61440 | C | Incise skull for surgery ........................................... | ...................... | ...................... | ...................... | .. |  |
| 61450 | C | Incise skull for surgery |  | ...................... |  |  |  |
| 61458 | C | Incise skull for brain wound .................................... |  | ................... |  |  |  |
| 61460 | C | Incise skull for surgery . |  |  |  |  |  |

[^189]
# Addendum B.—Hospital Outpatient Department (HOPD) Payment Status by hCPCS Code and Related Information-Continued 

| CPT/ HCPCS | HOPD Status Indicator | Description | APC | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 61470 | C | Incise skull for surgery |  |  |  |  |  |
| 61480 | C | Incise skull for surgery |  |  |  |  |  |
| 61490 | C | Incise skull for surgery | .................... | .................... | .................... | ..................... |  |
| 61500 | C | Removal of skull lesion |  |  |  |  |  |
| 61501 | C | Remove infected skull bone |  |  |  |  |  |
| 61510 | C | Removal of brain lesion |  | ..................... | ...................... | ...................... |  |
| 61512 | C | Remove brain lining lesion |  |  |  |  |  |
| 61514 | C | Removal of brain abscess ...................................... |  | ..................... | .................... | ..................... |  |
| 61516 | C | Removal of brain lesion |  |  |  |  |  |
| 61518 | C | Removal of brain lesion |  |  |  |  |  |
| 61519 | C | Remove brain lining lesion ..................................... |  |  |  |  |  |
| 61520 | C | Removal of brain lesion |  |  |  |  |  |
| 61521 | C | Removal of brain lesion |  |  |  |  |  |
| 61522 | C | Removal of brain abscess |  |  |  |  |  |
| 61524 | C | Removal of brain lesion | .................... |  | ................ |  |  |
| 61526 | C | Removal of brain lesion |  |  |  |  |  |
| 61530 | C | Removal of brain lesion |  |  |  |  |  |
| 61531 | C | Implant brain electrodes |  |  |  |  |  |
| 61533 | C | Implant brain electrodes |  |  |  |  |  |
| 61534 | C | Removal of brain lesion |  |  |  |  |  |
| 61535 | C | Remove brain electrodes |  |  |  |  |  |
| 61536 | C | Removal of brain lesion |  |  |  |  |  |
| 61538 | C | Removal of brain tissue |  |  |  |  |  |
| 61539 | C | Removal of brain tissue |  |  |  |  |  |
| 61541 | C | Incision of brain tissue |  |  | ................... |  |  |
| 61542 | C | Removal of brain tissue |  |  |  |  |  |
| 61543 | C | Removal of brain tissue |  |  |  |  |  |
| 61544 | C | Remove \& treat brain lesion |  |  |  |  |  |
| 61545 | C | Excision of brain tumor |  |  |  |  |  |
| 61546 | C | Removal of pituitary gland |  |  |  |  |  |
| 61548 | C | Removal of pituitary gland ...................................... |  |  |  |  |  |
| 61550 | C | Release of skull seams |  |  |  |  |  |
| 61552 | C | Release of skull seams |  |  |  |  |  |
| 61556 | C | Incise skull/sutures |  |  |  |  |  |
| 61557 | C | Incise skull/sutures |  |  |  |  |  |
| 61558 | C | Excision of skull/sutures |  |  |  |  |  |
| 61559 | C | Excision of skull/sutures ........................................ |  |  | ..................... | ..................... |  |
| 61563 | C | Excision of skull tumor |  |  |  |  |  |
| 61564 | C | Excision of skull tumor |  |  |  |  |  |
| 61570 | C | Remove foreign body, brain |  |  |  |  |  |
| 61571 | C | Incise skull for brain wound |  |  |  |  |  |
| 61575 | C | Skull base/brainstem surgery |  |  |  |  |  |
| 61576 | C | Skull base/brainstem surgery ................................. |  |  |  |  |  |
| 61580 | C | Craniofacial approach, skull |  |  |  | ..................... |  |
| 61581 | C | Craniofacial approach, skull |  |  |  |  |  |
| 61582 | C | Craniofacial approach, skull ................................... |  |  |  |  |  |
| 61583 | C | Craniofacial approach, skull ................................... |  |  |  |  |  |
| 61584 | C | Orbitocranial approach/skull |  |  |  |  |  |
| 61585 | C | Orbitocranial approach/skull |  |  |  |  |  |
| 61586 | C | Resect nasopharynx, skull ...................................... |  |  |  |  |  |
| 61590 | C | Infratemporal approach/skull |  |  |  | .................... |  |
| 61591 | C | Infratemporal approach/skull .................................. |  |  |  |  |  |
| 61592 | C | Orbitocranial approach/skull ................................... |  |  |  |  |  |
| 61595 | C | Transtemporal approach/skull |  |  |  |  |  |
| 61596 | C | Transcochlear approach/skull ................................. |  |  |  |  |  |
| 61597 | C | Transcondylar approach/skull .................................. |  |  |  |  |  |
| 61598 | C | Transpetrosal approach/skull .................................. |  |  |  | .................... |  |
| 61600 | C | Resect/excise cranial lesion | ..................... |  | ..................... | ...................... |  |
| 61601 | C | Resect/excise cranial lesion |  |  |  |  |  |
| 61605 | C | Resect/excise cranial lesion ................................... |  |  |  |  |  |
| 61606 | C | Resect/excise cranial lesion | ...................... |  | .................... | .................... |  |
| 61607 | C | Resect/excise cranial lesion ................................... |  |  |  |  |  |
| 61608 | C | Resect/excise cranial lesion |  |  |  |  |  |
| 61609 | C | Transect artery, sinus ............................................ | .. | ..................... | .................... | ..................... |  |
| 61610 | C | Transect artery, sinus |  |  |  |  |  |
| 61611 | C | Transect artery, sinus |  |  |  |  |  |
| 61612 | C | Transect artery, sinus ............................................ |  |  |  |  |  |
| 61613 | C | Remove aneurysm, sinus |  |  | ................... |  |  |
| 61615 | C | Resect/excise lesion, skull |  |  |  |  |  |
| 61616 | C | Resect/excise lesion, skull |  |  | ...................... |  |  |
| 61618 | C | Repair dura ... | .................... |  | .................... | .................... |  |
| 61619 | C | Repair dura .... | ...................... | ...................... | ..................... |  |  |
| 61624 | C | Occlusion/embolization cath |  |  |  |  |  |

CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
Copyright American Dental Association. All rights reserved.
${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment.
${ }^{2}$ Not subject to national coinsurance.
${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

# Addendum B.—Hospital Outpatient Department (HOPD) Payment Status by hCPCS Code and Related INFORMATION-Continued 

| CPT/ HCPCS | HOPD Status Indicator | Description | APC | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 61626 | C | Occlusion/embolization cath |  |  |  |  |  |
| 61680 | C | Intracranial vessel surgery |  |  |  |  |  |
| 61682 | C | Intracranial vessel surgery |  |  |  |  |  |
| 61684 | C | Intracranial vessel surgery |  |  |  |  |  |
| 61686 | C | Intracranial vessel surgery |  |  |  |  |  |
| 61690 | C | Intracranial vessel surgery | .................... | .................... | . | ...................... |  |
| 61692 | C | Intracranial vessel surgery |  |  |  |  |  |
| 61700 | C | Inner skull vessel surgery. |  |  |  |  |  |
| 61702 | C | Inner skull vessel surgery |  |  |  |  |  |
| 61703 | C | Clamp neck artery |  |  |  |  |  |
| 61705 | C | Revise circulation to head |  | ................ |  |  |  |
| 61708 | C | Revise circulation to head |  |  |  |  |  |
| 61710 | C | Revise circulation to head |  |  |  |  |  |
| 61711 | C | Fusion of skull arteries |  | ... | ... | .................... |  |
| 61720 | C | Incise skull/brain surgery |  |  |  |  |  |
| 61735 | C | Incise skull/brain surgery |  |  |  |  |  |
| 61750 | C | Incise skull/brain biopsy |  |  |  |  |  |
| 61751 | C | Brain biopsy w/ct/mr guide |  |  |  |  |  |
| 61760 | C | Implant brain electrodes ... |  |  |  |  |  |
| 61770 | C | Incise skull for treatment |  |  |  |  |  |
| 61790 | T | Treat trigeminal nerve | 0220 | 13.96 | \$676.88 | \$326.21 | \$135.38 |
| 61791 | C | Treat trigeminal tract |  |  |  |  |  |
| 61793 | E | Focus radiation beam |  |  |  |  |  |
| 61795 | C | Brain surgery using computer |  | ..................... |  |  |  |
| 61850 | C | Implant neuroelectrodes . |  |  |  |  |  |
| 61860 | C | Implant neuroelectrodes |  |  |  |  |  |
| 61862 | C | Implant neurostimul, subcort |  |  |  | .................... |  |
| 61870 | C | Implant neuroelectrodes |  |  |  |  |  |
| 61875 | C | Implant neuroelectrodes |  |  |  |  |  |
| 61880 | C | Revise/remove neuroelectrode |  |  |  |  |  |
| 61885 | T | Implant neurostim one array | 0222 | 25.48 | \$1,235.45 | \$780.07 | \$247.09 |
| 61886 | C | Implant neurostim arrays |  |  |  |  |  |
| 61888 | C | Revise/remove neuroreceiver |  | .................... | .................... | ... |  |
| 62000 | C | Treat skull fracture |  | .................. |  | ...................... |  |
| 62005 | C | Treat skull fracture |  |  |  |  |  |
| 62010 | C | Treatment of head injury |  |  |  |  |  |
| 62100 | C | Repair brain fluid leakage |  |  |  | ..................... |  |
| 62115 | C | Reduction of skull defect |  |  |  |  |  |
| 62116 | C | Reduction of skull defect |  |  |  |  |  |
| 62117 | C | Reduction of skull defect |  | ...................... | .................... | ...................... |  |
| 62120 | C | Repair skull cavity lesion |  |  |  |  |  |
| 62121 | C | Incise skull repair |  |  |  |  |  |
| 62140 | C | Repair of skull defect |  |  |  | ..................... |  |
| 62141 | C | Repair of skull defect |  |  |  | .................... |  |
| 62142 | C | Remove skull plate/flap |  |  |  |  |  |
| 62143 | C | Replace skull plate/flap |  |  |  |  |  |
| 62145 | C | Repair of skull \& brain |  | .................... |  | .................... |  |
| 62146 | C | Repair of skull with graft |  |  |  |  |  |
| 62147 | C | Repair of skull with graft |  |  |  | ..................... |  |
| 62180 | C | Establish brain cavity shunt |  |  |  | ...................... |  |
| 62190 | C | Establish brain cavity shunt |  |  |  |  |  |
| 62192 | C | Establish brain cavity shunt . |  |  |  |  |  |
| 62194 | T | Replace/irrigate catheter | 0121 | 2.36 | \$114.43 | \$52.53 | \$22.89 |
| 62200 | C | Establish brain cavity shunt .................................... |  |  |  |  |  |
| 62201 | C | Establish brain cavity shunt |  |  |  |  |  |
| 62220 | C | Establish brain cavity shunt .................................... |  |  |  |  |  |
| 62223 | C | Establish brain cavity shunt |  |  |  |  |  |
| 62225 | T | Replace/irrigate catheter | 0121 | 2.36 | \$114.43 | \$52.53 | \$22.89 |
| 62230 | T | Replace/revise brain shunt | 0224 | 15.94 | \$772.88 | \$374.61 | \$154.58 |
| 62256 | C | Remove brain cavity shunt . |  |  |  | ...................... |  |
| 62258 | C | Replace brain cavity shunt . |  |  |  |  |  |
| 62263 | T | Lysis epidural adhesions | 0212 | 3.64 | \$176.49 | \$88.78 | \$35.30 |
| 62268 | T | Drain spinal cord cyst ............................................ | 0212 | 3.64 | \$176.49 | \$88.78 | \$35.30 |
| 62269 | T | Needle biopsy, spinal cord | 0005 | 5.41 | \$262.32 | \$119.75 | \$52.46 |
| 62270 | T | Spinal fluid tap, diagnostic. | 0210 | 3.00 | \$145.46 | \$62.40 | \$29.09 |
| 62272 | T | Drain spinal fluid ..... | 0210 | 3.00 | \$145.46 | \$62.40 | \$29.09 |
| 62273 | T | Treat epidural spine lesion | 0212 | 3.64 | \$176.49 | \$88.78 | \$35.30 |
| 62280 | T | Treat spinal cord lesion. | 0212 | 3.64 | \$176.49 | \$88.78 | \$35.30 |
| 62281 | T | Treat spinal cord lesion | 0212 | 3.64 | \$176.49 | \$88.78 | \$35.30 |
| 62282 | T | Treat spinal canal lesion ........................................ | 0212 | 3.64 | \$176.49 | \$88.78 | \$35.30 |
| 62284 | N | Injection for myelogram . |  |  |  |  |  |
| 62287 | T | Percutaneous diskectomy ...................................... | 0220 | 13.96 | \$676.88 | \$326.21 | \$135.38 |
| 62290 | N | Inject for spine disk x-ray ...... |  |  |  |  |  |

CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
Copyright American Dental Association. All rights reserved.
${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment.
${ }^{2}$ Not subject to national coinsurance.
${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

# Addendum B.-Hospital Outpatient Department (HOPD) Payment Status by HCPCS Code and Related INFORMATION-Continued 

| CPT/ HCPCS | HOPD Status Indicator | Description | APC | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 62291 | N | Inject for spine disk x-ray |  |  |  |  |  |
| 62292 | T | Injection into disk lesion | 0212 | 3.64 | \$176.49 | \$88.78 | \$35.30 |
| 62294 | T | Injection into spinal artery | 0212 | 3.64 | \$176.49 | \$88.78 | \$35.30 |
| 62310 | T | Inject spine c/t | 0212 | 3.64 | \$176.49 | \$88.78 | \$35.30 |
| 62311 | T | Inject spine l/s (cd) | 0212 | 3.64 | \$176.49 | \$88.78 | \$35.30 |
| 62318 | T | Inject spine w/cath, c/t | 0212 | 3.64 | \$176.49 | \$88.78 | \$35.30 |
| 62319 | T | Inject spine w/cath l/s (cd) | 0212 | 3.64 | \$176.49 | \$88.78 | \$35.30 |
| 62350 | T | Implant spinal canal cath . | 0223 | 6.34 | \$307.41 | \$153.24 | \$61.48 |
| 62351 | C | Implant spinal canal cath |  |  |  |  |  |
| 62355 | T | Remove spinal canal catheter | 0223 | 6.34 | \$307.41 | \$153.24 | \$61.48 |
| 62360 | T | Insert spine infusion device | 0222 | 25.48 | \$1,235.45 | \$780.07 | \$247.09 |
| 62361 | T | Implant spine infusion pump | 0222 | 25.48 | \$1,235.45 | \$780.07 | \$247.09 |
| 62362 | T | Implant spine infusion pump | 0222 | 25.48 | \$1,235.45 | \$780.07 | \$247.09 |
| 62365 | T | Remove spine infusion device | 0224 | 15.94 | \$772.88 | \$374.61 | \$154.58 |
| 62367 | S | Analyze spine infusion pump | 0102 | 0.45 | \$21.82 | \$12.62 | \$4.36 |
| 62368 | S | Analyze spine infusion pump | 0102 | 0.45 | \$21.82 | \$12.62 | \$4.36 |
| 63001 | C | Removal of spinal lamina .... |  |  |  |  |  |
| 63003 | C | Removal of spinal lamina |  |  |  | .................... |  |
| 63005 | C | Removal of spinal lamina |  |  |  |  |  |
| 63011 | C | Removal of spinal lamina |  |  |  |  |  |
| 63012 | C | Removal of spinal lamina |  |  |  | ................... |  |
| 63015 | C | Removal of spinal lamina |  |  |  | ..................... |  |
| 63016 | C | Removal of spinal lamina |  |  |  |  |  |
| 63017 | C | Removal of spinal lamina | ..................... | ..................... |  | ..................... |  |
| 63020 | C | Neck spine disk surgery |  |  |  |  |  |
| 63030 | C | Low back disk surgery |  |  |  |  |  |
| 63035 | C | Spinal disk surgery add-on |  |  |  |  |  |
| 63040 | C | Neck spine disk surgery |  |  |  |  |  |
| 63042 | C | Low back disk surgery |  |  |  |  |  |
| 63045 | C | Removal of spinal lamina ....................................... |  |  |  |  |  |
| 63046 | C | Removal of spinal lamina |  |  |  |  |  |
| 63047 | C | Removal of spinal lamina |  |  |  |  |  |
| 63048 | C | Remove spinal lamina add-on |  |  |  |  |  |
| 63055 | C | Decompress spinal cord |  |  |  |  |  |
| 63056 | C | Decompress spinal cord |  |  |  |  |  |
| 63057 | C | Decompress spine cord add-on .............................. |  |  |  |  |  |
| 63064 | C | Decompress spinal cord |  |  |  |  |  |
| 63066 | C | Decompress spine cord add-on |  |  |  |  |  |
| 63075 | C | Neck spine disk surgery |  |  |  |  |  |
| 63076 | C | Neck spine disk surgery |  |  |  |  |  |
| 63077 | C | Spine disk surgery, thorax ...................................... |  | ..................... |  | ..................... |  |
| 63078 | C | Spine disk surgery, thorax |  |  |  |  |  |
| 63081 | C | Removal of vertebral body |  |  |  |  |  |
| 63082 | C | Remove vertebral body add-on |  |  |  |  |  |
| 63085 | C | Removal of vertebral body ..................................... |  |  |  |  |  |
| 63086 | C | Remove vertebral body add-on ............................... |  |  |  |  |  |
| 63087 | C | Removal of vertebral body |  |  |  |  |  |
| 63088 | C | Remove vertebral body add-on ............................... |  |  |  |  |  |
| 63090 | C | Removal of vertebral body .................................... |  |  |  |  |  |
| 63091 | C | Remove vertebral body add-on |  |  |  |  |  |
| 63170 | C | Incise spinal cord tract(s) ....................................... |  |  |  |  |  |
| 63172 | C | Drainage of spinal cyst ....................................... |  |  |  |  |  |
| 63173 | C | Drainage of spinal cyst |  |  |  |  |  |
| 63180 | C | Revise spinal cord ligaments .................................. |  |  |  |  |  |
| 63182 | C | Revise spinal cord ligaments .................................. |  |  |  |  |  |
| 63185 | C | Incise spinal column/nerves ................................... |  |  |  |  |  |
| 63190 | C | Incise spinal column/nerves |  |  |  |  |  |
| 63191 | C | Incise spinal column/nerves ................................... | .................... | ................... |  | ..................... |  |
| 63194 | C | Incise spinal column \& cord |  |  |  |  |  |
| 63195 | C | Incise spinal column \& cord |  |  |  |  |  |
| 63196 | C | Incise spinal column \& cord ................................... |  |  |  | .................... |  |
| 63197 | C | Incise spinal column \& cord |  |  |  |  |  |
| 63198 | C | Incise spinal column \& cord |  |  |  |  |  |
| 63199 | C | Incise spinal column \& cord .................................... |  | ..................... |  | ..................... |  |
| 63200 | C | Release of spinal cord ....... |  |  |  | ...................... |  |
| 63250 | C | Revise spinal cord vessels ..................................... |  |  |  |  |  |
| 63251 | C | Revise spinal cord vessels |  |  |  |  |  |
| 63252 | C | Revise spinal cord vessels ..................................... | ..................... |  |  | ..................... |  |
| 63265 | C | Excise intraspinal lesion |  |  |  |  |  |
| 63266 | C | Excise intraspinal lesion ........................................ |  |  |  |  |  |
| 63267 | C | Excise intraspinal lesion ........................................ | ...................... | ...................... | ..................... | - | ..................... |
| 63268 | C | Excise intraspinal lesion ........................................ | ... | ...................... | ... | ...................... |  |
| 63270 | C | Excise intraspinal lesion |  |  |  |  |  |

CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
Copyright American Dental Association. All rights reserved
${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment
${ }^{2}$ Not subject to national coinsurance.
${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

# Addendum B.-Hospital Outpatient Department (HOPD) Payment Status by HCPCS Code and Related INFORMATION-Continued 

| CPT/ HCPCS | HOPD Status Indicator | Description | APC | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 63271 | C | Excise intraspinal lesion |  |  |  |  |  |
| 63272 | C | Excise intraspinal lesion |  |  |  |  |  |
| 63273 | C | Excise intraspinal lesion |  |  |  |  |  |
| 63275 | C | Biopsy/excise spinal tumor |  |  |  |  |  |
| 63276 | C | Biopsy/excise spinal tumor | .................... | .................... | .................... | ..................... |  |
| 63277 | C | Biopsy/excise spinal tumor |  |  |  |  |  |
| 63278 | C | Biopsy/excise spinal tumor .................................... |  |  |  |  |  |
| 63280 | C | Biopsy/excise spinal tumor |  |  | ..................... | .................... |  |
| 63281 | C | Biopsy/excise spinal tumor |  |  |  |  |  |
| 63282 | C | Biopsy/excise spinal tumor |  |  |  |  |  |
| 63283 | C | Biopsy/excise spinal tumor |  |  |  |  |  |
| 63285 | C | Biopsy/excise spinal tumor ..................................... |  |  |  |  |  |
| 63286 | C | Biopsy/excise spinal tumor |  |  |  |  |  |
| 63287 | C | Biopsy/excise spinal tumor |  |  |  |  |  |
| 63290 | C | Biopsy/excise spinal tumor |  |  |  |  |  |
| 63300 | C | Removal of vertebral body ..................................... |  |  |  |  |  |
| 63301 | C | Removal of vertebral body |  |  |  |  |  |
| 63302 | C | Removal of vertebral body ..................................... |  |  |  |  |  |
| 63303 | C | Removal of vertebral body ... |  |  |  |  |  |
| 63304 | C | Removal of vertebral body |  |  |  |  |  |
| 63305 | C | Removal of vertebral body |  |  |  |  |  |
| 63306 | C | Removal of vertebral body |  |  |  |  |  |
| 63307 | C | Removal of vertebral body |  |  |  |  |  |
| 63308 | C | Remove vertebral body add-on |  |  |  |  |  |
| 63600 | T | Remove spinal cord lesion | 0220 | 13.96 | \$676.88 | \$326.21 | \$135.38 |
| 63610 | T | Stimulation of spinal cord | 0220 | 13.96 | \$676.88 | \$326.21 | \$135.38 |
| 63615 | T | Remove lesion of spinal cord | 0220 | 13.96 | \$676.88 | \$326.21 | \$135.38 |
| 63650 | T | Implant neuroelectrodes | 0224 | 15.94 | \$772.88 | \$374.61 | \$154.58 |
| 63655 | C | Implant neuroelectrodes |  |  |  |  |  |
| 63660 | T | Revise/remove neuroelectrode | 0224 | 15.94 | \$772.88 | \$374.61 | \$154.58 |
| 63685 | T | Implant neuroreceiver ............................................ | 0222 | 25.48 | \$1,235.45 | \$780.07 | \$247.09 |
| 63688 | T | Revise/remove neuroreceiver | 0224 | 15.94 | \$772.88 | \$374.61 | \$154.58 |
| 63700 | C | Repair of spinal herniation |  |  |  |  |  |
| 63702 | C | Repair of spinal herniation |  |  |  |  |  |
| 63704 | C | Repair of spinal herniation |  |  |  | ..................... |  |
| 63706 | C | Repair of spinal herniation |  | ..................... |  | ..................... |  |
| 63707 | C | Repair spinal fluid leakage |  |  |  |  |  |
| 63709 | C | Repair spinal fluid leakage ..................................... |  |  |  |  |  |
| 63710 | C | Graft repair of spine defect |  |  |  | ..................... |  |
| 63740 | C | Install spinal shunt |  |  |  |  |  |
| 63741 | C | Install spinal shunt ................................................ |  |  |  |  |  |
| 63744 | T | Revision of spinal shunt ......................................... | 0224 | 15.94 | \$772.88 | \$374.61 | \$154.58 |
| 63746 | T | Removal of spinal shunt ........................................ | 0223 | 6.34 | \$307.41 | \$153.24 | \$61.48 |
| 64400 | T | Injection for nerve block | 0211 | 3.32 | \$160.98 | \$74.78 | \$32.20 |
| 64402 | T | Injection for nerve block | 0211 | 3.32 | \$160.98 | \$74.78 | \$32.20 |
| 64405 | T | Injection for nerve block ........................................ | 0211 | 3.32 | \$160.98 | \$74.78 | \$32.20 |
| 64408 | T | Injection for nerve block ........................................ | 0211 | 3.32 | \$160.98 | \$74.78 | \$32.20 |
| 64410 | T | Injection for nerve block ......................................... | 0211 | 3.32 | \$160.98 | \$74.78 | \$32.20 |
| 64412 | T | Injection for nerve block | 0211 | 3.32 | \$160.98 | \$74.78 | \$32.20 |
| 64413 | T | Injection for nerve block ........................................ | 0211 | 3.32 | \$160.98 | \$74.78 | \$32.20 |
| 64415 | T | Injection for nerve block ......................................... | 0211 | 3.32 | \$160.98 | \$74.78 | \$32.20 |
| 64417 | T | Injection for nerve block ........................................ | 0211 | 3.32 | \$160.98 | \$74.78 | \$32.20 |
| 64418 | T | Injection for nerve block ......................................... | 0211 | 3.32 | \$160.98 | \$74.78 | \$32.20 |
| 64420 | T | Injection for nerve block ........................................ | 0211 | 3.32 | \$160.98 | \$74.78 | \$32.20 |
| 64421 | T | Injection for nerve block ......................................... | 0211 | 3.32 | \$160.98 | \$74.78 | \$32.20 |
| 64425 | T | Injection for nerve block | 0211 | 3.32 | \$160.98 | \$74.78 | \$32.20 |
| 64430 | T | Injection for nerve block | 0211 | 3.32 | \$160.98 | \$74.78 | \$32.20 |
| 64435 | T | Injection for nerve block | 0211 | 3.32 | \$160.98 | \$74.78 | \$32.20 |
| 64445 | T | Injection for nerve block | 0211 | 3.32 | \$160.98 | \$74.78 | \$32.20 |
| 64450 | T | Injection for nerve block ........................................ | 0211 | 3.32 | \$160.98 | \$74.78 | \$32.20 |
| 64470 | T | Inj paravertebral c/t ............................................... | 0211 | 3.32 | \$160.98 | \$74.78 | \$32.20 |
| 64472 | T | Inj paravertebral c/t add-on .................................... | 0211 | 3.32 | \$160.98 | \$74.78 | \$32.20 |
| 64475 | T | Inj paravertebral I/s ............................................... | 0211 | 3.32 | \$160.98 | \$74.78 | \$32.20 |
| 64476 | T | Inj paravertebral I/s add-on ..................................... | 0211 | 3.32 | \$160.98 | \$74.78 | \$32.20 |
| 64479 | T | Inj foramen epidural c/t .... | 0211 | 3.32 | \$160.98 | \$74.78 | \$32.20 |
| 64480 | T | Inj foramen epidural add-on ................................... | 0211 | 3.32 | \$160.98 | \$74.78 | \$32.20 |
| 64483 | T | Inj foramen epidural I/s ............ | 0211 | 3.32 | \$160.98 | \$74.78 | \$32.20 |
| 64484 | T | Inj foramen epidural add-on ................................... | 0211 | 3.32 | \$160.98 | \$74.78 | \$32.20 |
| 64505 | T | Injection for nerve block ........................................ | 0211 | 3.32 | \$160.98 | \$74.78 | \$32.20 |
| 64508 | T | Injection for nerve block | 0211 | 3.32 | \$160.98 | \$74.78 | \$32.20 |
| 64510 | T | Injection for nerve block ........................................ | 0211 | 3.32 | \$160.98 | \$74.78 | \$32.20 |
| 64520 | T | Injection for nerve block ......................................... | 0211 | 3.32 | \$160.98 | \$74.78 | \$32.20 |
| 64530 | T | Injection for nerve block | 0211 | 3.32 | \$160.98 | \$74.78 | \$32.20 |

[^190]
## Addendum B.-Hospital Outpatient Department (HOPD) Payment Status by HCPCS Code and Related INFORMATION-Continued

| $\begin{gathered} \text { CPT/ } \\ \text { HCPCS } \end{gathered}$ | HOPD Status Indicator | Description | APC | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 64550 | A | Apply neurostimulator |  |  |  |  |  |
| 64553 | T | Implant neuroelectrodes | 0225 | 3.43 | \$166.31 | \$64.46 | \$33.26 |
| 64555 | T | Implant neuroelectrodes | 0225 | 3.43 | \$166.31 | \$64.46 | \$33.26 |
| 64560 | T | Implant neuroelectrodes | 0225 | 3.43 | \$166.31 | \$64.46 | \$33.26 |
| 64565 | T | Implant neuroelectrodes | 0225 | 3.43 | \$166.31 | \$64.46 | \$33.26 |
| 64573 | T | Implant neuroelectrodes | 0225 | 3.43 | \$166.31 | \$64.46 | \$33.26 |
| 64575 | T | Implant neuroelectrodes | 0225 | 3.43 | \$166.31 | \$64.46 | \$33.26 |
| 64577 | T | Implant neuroelectrodes | 0225 | 3.43 | \$166.31 | \$64.46 | \$33.26 |
| 64580 | T | Implant neuroelectrodes | 0225 | 3.43 | \$166.31 | \$64.46 | \$33.26 |
| 64585 | T | Revise/remove neuroelectrode | 0225 | 3.43 | \$166.31 | \$64.46 | \$33.26 |
| 64590 | T | Implant neuroreceiver | 0222 | 25.48 | \$1,235.45 | \$780.07 | \$247.09 |
| 64595 | T | Revise/remove neuroreceiver | 0225 | 3.43 | \$166.31 | \$64.46 | \$33.26 |
| 64600 | T | Injection treatment of nerve | 0211 | 3.32 | \$160.98 | \$74.78 | \$32.20 |
| 64605 | T | Injection treatment of nerve | 0211 | 3.32 | \$160.98 | \$74.78 | \$32.20 |
| 64610 | T | Injection treatment of nerve | 0211 | 3.32 | \$160.98 | \$74.78 | \$32.20 |
| 64612 | T | Destroy nerve, face muscle | 0211 | 3.32 | \$160.98 | \$74.78 | \$32.20 |
| 64613 | T | Destroy nerve, spine muscle | 0211 | 3.32 | \$160.98 | \$74.78 | \$32.20 |
| 64620 | T | Injection treatment of nerve | 0211 | 3.32 | \$160.98 | \$74.78 | \$32.20 |
| 64622 | T | Destr paravertebrl nerve I/s | 0211 | 3.32 | \$160.98 | \$74.78 | \$32.20 |
| 64623 | T | Destr paravertebral n add-on | 0211 | 3.32 | \$160.98 | \$74.78 | \$32.20 |
| 64626 | T | Destr paravertebrl nerve c/t | 0211 | 3.32 | \$160.98 | \$74.78 | \$32.20 |
| 64627 | T | Destr paravertebral n add-on | 0211 | 3.32 | \$160.98 | \$74.78 | \$32.20 |
| 64630 | T | Injection treatment of nerve | 0211 | 3.32 | \$160.98 | \$74.78 | \$32.20 |
| 64640 | T | Injection treatment of nerve | 0211 | 3.32 | \$160.98 | \$74.78 | \$32.20 |
| 64680 | T | Injection treatment of nerve | 0211 | 3.32 | \$160.98 | \$74.78 | \$32.20 |
| 64702 | T | Revise finger/toe nerve | 0220 | 13.96 | \$676.88 | \$326.21 | \$135.38 |
| 64704 | T | Revise hand/foot nerve | 0220 | 13.96 | \$676.88 | \$326.21 | \$135.38 |
| 64708 | T | Revise arm/leg nerve | 0220 | 13.96 | \$676.88 | \$326.21 | \$135.38 |
| 64712 | T | Revision of sciatic nerve | 0220 | 13.96 | \$676.88 | \$326.21 | \$135.38 |
| 64713 | T | Revision of arm nerve(s) | 0220 | 13.96 | \$676.88 | \$326.21 | \$135.38 |
| 64714 | T | Revise low back nerve(s) | 0220 | 13.96 | \$676.88 | \$326.21 | \$135.38 |
| 64716 | T | Revision of cranial nerve | 0220 | 13.96 | \$676.88 | \$326.21 | \$135.38 |
| 64718 | T | Revise ulnar nerve at elbow | 0220 | 13.96 | \$676.88 | \$326.21 | \$135.38 |
| 64719 | T | Revise ulnar nerve at wrist | 0220 | 13.96 | \$676.88 | \$326.21 | \$135.38 |
| 64721 | T | Carpal tunnel surgery | 0220 | 13.96 | \$676.88 | \$326.21 | \$135.38 |
| 64722 | T | Relieve pressure on nerve(s) | 0220 | 13.96 | \$676.88 | \$326.21 | \$135.38 |
| 64726 | T | Release foot/toe nerve | 0220 | 13.96 | \$676.88 | \$326.21 | \$135.38 |
| 64727 | T | Internal nerve revision | 0220 | 13.96 | \$676.88 | \$326.21 | \$135.38 |
| 64732 | T | Incision of brow nerve | 0220 | 13.96 | \$676.88 | \$326.21 | \$135.38 |
| 64734 | T | Incision of cheek nerve | 0220 | 13.96 | \$676.88 | \$326.21 | \$135.38 |
| 64736 | T | Incision of chin nerve | 0220 | 13.96 | \$676.88 | \$326.21 | \$135.38 |
| 64738 | T | Incision of jaw nerve | 0220 | 13.96 | \$676.88 | \$326.21 | \$135.38 |
| 64740 | T | Incision of tongue nerve | 0220 | 13.96 | \$676.88 | \$326.21 | \$135.38 |
| 64742 | T | Incision of facial nerve | 0220 | 13.96 | \$676.88 | \$326.21 | \$135.38 |
| 64744 | T | Incise nerve, back of head | 0220 | 13.96 | \$676.88 | \$326.21 | \$135.38 |
| 64746 | T | Incise diaphragm nerve .... | 0220 | 13.96 | \$676.88 | \$326.21 | \$135.38 |
| 64752 | C | Incision of vagus nerve .... |  |  |  |  |  |
| 64755 | C | Incision of stomach nerves |  |  |  |  |  |
| 64760 | C | Incision of vagus nerve ......................................... |  |  |  |  |  |
| 64761 | T | Incision of pelvis nerve ........................................... | 0220 | 13.96 | \$676.88 | \$326.21 | \$135.38 |
| 64763 | C | Incise hip/thigh nerve |  |  |  |  |  |
| 64766 | C | Incise hip/thigh nerve ............................................ |  |  |  |  |  |
| 64771 | T | Sever cranial nerve | 0220 | 13.96 | \$676.88 | \$326.21 | \$135.38 |
| 64772 | T | Incision of spinal nerve | 0220 | 13.96 | \$676.88 | \$326.21 | \$135.38 |
| 64774 | T | Remove skin nerve lesion | 0220 | 13.96 | \$676.88 | \$326.21 | \$135.38 |
| 64776 | T | Remove digit nerve lesion ...................................... | 0220 | 13.96 | \$676.88 | \$326.21 | \$135.38 |
| 64778 | T | Digit nerve surgery add-on | 0220 | 13.96 | \$676.88 | \$326.21 | \$135.38 |
| 64782 | T | Remove limb nerve lesion ...................................... | 0220 | 13.96 | \$676.88 | \$326.21 | \$135.38 |
| 64783 | T | Limb nerve surgery add-on .................................... | 0220 | 13.96 | \$676.88 | \$326.21 | \$135.38 |
| 64784 | T | Remove nerve lesion | 0220 | 13.96 | \$676.88 | \$326.21 | \$135.38 |
| 64786 | T | Remove sciatic nerve lesion | 0221 | 18.36 | \$890.22 | \$463.62 | \$178.04 |
| 64787 | T | Implant nerve end | 0220 | 13.96 | \$676.88 | \$326.21 | \$135.38 |
| 64788 | T | Remove skin nerve lesion ...................................... | 0220 | 13.96 | \$676.88 | \$326.21 | \$135.38 |
| 64790 | T | Removal of nerve lesion | 0220 | 13.96 | \$676.88 | \$326.21 | \$135.38 |
| 64792 | T | Removal of nerve lesion | 0221 | 18.36 | \$890.22 | \$463.62 | \$178.04 |
| 64795 | T | Biopsy of nerve ..................................................... | 0220 | 13.96 | \$676.88 | \$326.21 | \$135.38 |
| 64802 | C | Remove sympathetic nerves |  |  |  |  |  |
| 64804 | C | Remove sympathetic nerves |  |  |  |  |  |
| 64809 | C | Remove sympathetic nerves ................................... |  |  |  | .................... | ..................... |
| 64818 | C | Remove sympathetic nerves ................................... |  |  |  | ..................... |  |
| 64820 | C | Remove sympathetic nerves |  |  |  |  |  |
| 64831 | T | Repair of digit nerve .............................................. | 0221 | 18.36 | \$890.22 | \$463.62 | \$178.04 |
| 64832 | T | Repair nerve add-on .............................................. | 0221 | 18.36 | \$890.22 | \$463.62 | \$178.04 |

[^191]
## Addendum B.-Hospital Outpatient Department (HOPD) Payment Status by hCPCS Code and Related Information-Continued

| CPT/ HCPCS | HOPD <br> Status Indicator | Description | APC | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 64834 | T | Repair of hand or foot nerve | 0221 | 18.36 | \$890.22 | \$463.62 | \$178.04 |
| 64835 | T | Repair of hand or foot nerve | 0221 | 18.36 | \$890.22 | \$463.62 | \$178.04 |
| 64836 | T | Repair of hand or foot nerve | 0221 | 18.36 | \$890.22 | \$463.62 | \$178.04 |
| 64837 | T | Repair nerve add-on ........... | 0221 | 18.36 | \$890.22 | \$463.62 | \$178.04 |
| 64840 | T | Repair of leg nerve | 0221 | 18.36 | \$890.22 | \$463.62 | \$178.04 |
| 64856 | T | Repair/transpose nerve | 0221 | 18.36 | \$890.22 | \$463.62 | \$178.04 |
| 64857 | T | Repair arm/leg nerve | 0221 | 18.36 | \$890.22 | \$463.62 | \$178.04 |
| 64858 | T | Repair sciatic nerve | 0221 | 18.36 | \$890.22 | \$463.62 | \$178.04 |
| 64859 | T | Nerve surgery | 0221 | 18.36 | \$890.22 | \$463.62 | \$178.04 |
| 64861 | T | Repair of arm nerves | 0221 | 18.36 | \$890.22 | \$463.62 | \$178.04 |
| 64862 | T | Repair of low back nerves | 0221 | 18.36 | \$890.22 | \$463.62 | \$178.04 |
| 64864 | T | Repair of facial nerve ...... | 0221 | 18.36 | \$890.22 | \$463.62 | \$178.04 |
| 64865 | T | Repair of facial nerve | 0221 | 18.36 | \$890.22 | \$463.62 | \$178.04 |
| 64866 | C | Fusion of facial/other nerve |  |  |  |  |  |
| 64868 | C | Fusion of facial/other nerve |  |  |  |  |  |
| 64870 | T | Fusion of facial/other nerve | 0221 | 18.36 | \$890.22 | \$463.62 | \$178.04 |
| 64872 | T | Subsequent repair of nerve | 0221 | 18.36 | \$890.22 | \$463.62 | \$178.04 |
| 64874 | T | Repair \& revise nerve add-on | 0221 | 18.36 | \$890.22 | \$463.62 | \$178.04 |
| 64876 | T | Repair nerve/shorten bone | 0221 | 18.36 | \$890.22 | \$463.62 | \$178.04 |
| 64885 | T | Nerve graft, head or neck | 0221 | 18.36 | \$890.22 | \$463.62 | \$178.04 |
| 64886 | T | Nerve graft, head or neck | 0221 | 18.36 | \$890.22 | \$463.62 | \$178.04 |
| 64890 | T | Nerve graft, hand or foot | 0221 | 18.36 | \$890.22 | \$463.62 | \$178.04 |
| 64891 | T | Nerve graft, hand or foot | 0221 | 18.36 | \$890.22 | \$463.62 | \$178.04 |
| 64892 | T | Nerve graft, arm or leg | 0221 | 18.36 | \$890.22 | \$463.62 | \$178.04 |
| 64893 | T | Nerve graft, arm or leg | 0221 | 18.36 | \$890.22 | \$463.62 | \$178.04 |
| 64895 | T | Nerve graft, hand or foot | 0221 | 18.36 | \$890.22 | \$463.62 | \$178.04 |
| 64896 | T | Nerve graft, hand or foot | 0221 | 18.36 | \$890.22 | \$463.62 | \$178.04 |
| 64897 | T | Nerve graft, arm or leg | 0221 | 18.36 | \$890.22 | \$463.62 | \$178.04 |
| 64898 | T | Nerve graft, arm or leg | 0221 | 18.36 | \$890.22 | \$463.62 | \$178.04 |
| 64901 | T | Nerve graft add-on | 0221 | 18.36 | \$890.22 | \$463.62 | \$178.04 |
| 64902 | T | Nerve graft add-on | 0221 | 18.36 | \$890.22 | \$463.62 | \$178.04 |
| 64905 | T | Nerve pedicle transfer | 0221 | 18.36 | \$890.22 | \$463.62 | \$178.04 |
| 64907 | T | Nerve pedicle transfer | 0221 | 18.36 | \$890.22 | \$463.62 | \$178.04 |
| 64999 | T | Nervous system surgery | 0211 | 3.32 | \$160.98 | \$74.78 | \$32.20 |
| 65091 | T | Revise eye ................... | 0242 | 23.70 | \$1,149.14 | \$597.36 | \$229.83 |
| 65093 | T | Revise eye with implant | 0241 | 16.60 | \$804.89 | \$384.47 | \$160.98 |
| 65101 | T | Removal of eye | 0242 | 23.70 | \$1,149.14 | \$597.36 | \$229.83 |
| 65103 | T | Remove eye/insert implant | 0242 | 23.70 | \$1,149.14 | \$597.36 | \$229.83 |
| 65105 | T | Remove eye/attach implant | 0242 | 23.70 | \$1,149.14 | \$597.36 | \$229.83 |
| 65110 | T | Removal of eye | 0242 | 23.70 | \$1,149.14 | \$597.36 | \$229.83 |
| 65112 | T | Remove eye/revise socket | 0242 | 23.70 | \$1,149.14 | \$597.36 | \$229.83 |
| 65114 | T | Remove eye/revise socket | 0242 | 23.70 | \$1,149.14 | \$597.36 | \$229.83 |
| 65125 | T | Revise ocular implant | 0240 | 13.47 | \$653.12 | \$315.31 | \$130.62 |
| 65130 | T | Insert ocular implant | 0241 | 16.60 | \$804.89 | \$384.47 | \$160.98 |
| 65135 | T | Insert ocular implant | 0241 | 16.60 | \$804.89 | \$384.47 | \$160.98 |
| 65140 | T | Attach ocular implant | 0242 | 23.70 | \$1,149.14 | \$597.36 | \$229.83 |
| 65150 | T | Revise ocular implant | 0241 | 16.60 | \$804.89 | \$384.47 | \$160.98 |
| 65155 | T | Reinsert ocular implant | 0242 | 23.70 | \$1,149.14 | \$597.36 | \$229.83 |
| 65175 | T | Removal of ocular implant ...................................... | 0240 | 13.47 | \$653.12 | \$315.31 | \$130.62 |
| 65205 | S | Remove foreign body from eye ........................... | 0231 | 2.64 | \$128.01 | \$59.87 | \$25.60 |
| 65210 | S | Remove foreign body from eye | 0231 | 2.64 | \$128.01 | \$59.87 | \$25.60 |
| 65220 | S | Remove foreign body from eye | 0231 | 2.64 | \$128.01 | \$59.87 | \$25.60 |
| 65222 | S | Remove foreign body from eye ............................... | 0231 | 2.64 | \$128.01 | \$59.87 | \$25.60 |
| 65235 | T | Remove foreign body from eye ............................... | 0232 | 6.04 | \$292.86 | \$134.66 | \$58.57 |
| 65260 | T | Remove foreign body from eye ............................... | 0237 | 33.96 | \$1,646.62 | \$852.68 | \$329.32 |
| 65265 | T | Remove foreign body from eye ............................... | 0237 | 33.96 | \$1,646.62 | \$852.68 | \$329.32 |
| 65270 | T | Repair of eye wound ............................................. | 0240 | 13.47 | \$653.12 | \$315.31 | \$130.62 |
| 65272 | T | Repair of eye wound ............................................. | 0232 | 6.04 | \$292.86 | \$134.66 | \$58.57 |
| 65273 | C | Repair of eye wound ............................................. |  |  |  |  |  |
| 65275 | T | Repair of eye wound ............................................. | 0233 | 13.79 | \$668.64 | \$331.60 | \$133.73 |
| 65280 | T | Repair of eye wound ............................................. | 0233 | 13.79 | \$668.64 | \$331.60 | \$133.73 |
| 65285 | T | Repair of eye wound | 0234 | 20.64 | \$1,000.77 | \$502.16 | \$200.15 |
| 65286 | T | Repair of eye wound ...... | 0232 | 6.04 | \$292.86 | \$134.66 | \$58.57 |
| 65290 | T | Repair of eye socket wound.. | 0243 | 17.99 | \$872.28 | \$431.39 | \$174.46 |
| 65400 | T | Removal of eye lesion ........................................... | 0232 | 6.04 | \$292.86 | \$134.66 | \$58.57 |
| 65410 | T | Biopsy of cornea | 0233 | 13.79 | \$668.64 | \$331.60 | \$133.73 |
| 65420 | T | Removal of eye lesion ........................................... | 0233 | 13.79 | \$668.64 | \$331.60 | \$133.73 |
| 65426 | T | Removal of eye lesion .......................................... | 0233 | 13.79 | \$668.64 | \$331.60 | \$133.73 |
| 65430 | S | Corneal smear | 0231 | 2.64 | \$128.01 | \$59.87 | \$25.60 |
| 65435 | T | Curette/treat cornea | 0239 | 6.26 | \$303.53 | \$123.42 | \$60.71 |
| 65436 | T | Curette/treat cornea ............................................... | 0232 | 6.04 | \$292.86 | \$134.66 | \$58.57 |
| 65450 | T | Treatment of corneal lesion .................................... | 0232 | 6.04 | \$292.86 | \$134.66 | \$58.57 |
| 65600 | T | Revision of cornea | 0240 | 13.47 | \$653.12 | \$315.31 | \$130.62 |

[^192]
## Addendum B.-Hospital Outpatient Department (HOPD) Payment Status by HCPCS Code and Related Information-Continued

| $\begin{aligned} & \text { CPT/ } \\ & \text { HCPCS } \end{aligned}$ | HOPD Status Indicator | Description | APC | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 65710 | T | Corneal transplant | 0244 | 32.88 | \$1,594.26 | \$851.42 | \$318.85 |
| 65730 | T | Corneal transplant | 0244 | 32.88 | \$1,594.26 | \$851.42 | \$318.85 |
| 65750 | T | Corneal transplant | 0244 | 32.88 | \$1,594.26 | \$851.42 | \$318.85 |
| 65755 | T | Corneal transplant | 0244 | 32.88 | \$1,594.26 | \$851.42 | \$318.85 |
| 65760 | E | Revision of cornea |  |  |  |  |  |
| 65765 | E | Revision of cornea | ...... | ..................... | .................... | ..................... | ................... |
| 65767 | E | Corneal tissue transplant |  |  |  |  |  |
| 65770 | T | Revise cornea with implant | 0244 | 32.88 | \$1,594.26 | \$851.42 | \$318.85 |
| 65771 | E | Radial keratotomy ............................................ |  |  |  |  |  |
| 65772 | T | Correction of astigmatism | 0232 | 6.04 | \$292.86 | \$134.66 | \$58.57 |
| 65775 | T | Correction of astigmatism | 0233 | 13.79 | \$668.64 | \$331.60 | \$133.73 |
| 65800 | T | Drainage of eye | 0232 | 6.04 | \$292.86 | \$134.66 | \$58.57 |
| 65805 | T | Drainage of eye | 0233 | 13.79 | \$668.64 | \$331.60 | \$133.73 |
| 65810 | T | Drainage of eye | 0233 | 13.79 | \$668.64 | \$331.60 | \$133.73 |
| 65815 | T | Drainage of eye | 0233 | 13.79 | \$668.64 | \$331.60 | \$133.73 |
| 65820 | T | Relieve inner eye pressure | 0232 | 6.04 | \$292.86 | \$134.66 | \$58.57 |
| 65850 | T | Incision of eye | 0234 | 20.64 | \$1,000.77 | \$502.16 | \$200.15 |
| 65855 | T | Laser surgery of eye | 0247 | 4.89 | \$237.10 | \$112.86 | \$47.42 |
| 65860 | T | Incise inner eye adhesions | 0247 | 4.89 | \$237.10 | \$112.86 | \$47.42 |
| 65865 | T | Incise inner eye adhesions | 0233 | 13.79 | \$668.64 | \$331.60 | \$133.73 |
| 65870 | T | Incise inner eye adhesions | 0233 | 13.79 | \$668.64 | \$331.60 | \$133.73 |
| 65875 | T | Incise inner eye adhesions | 0233 | 13.79 | \$668.64 | \$331.60 | \$133.73 |
| 65880 | T | Incise inner eye adhesions | 0232 | 6.04 | \$292.86 | \$134.66 | \$58.57 |
| 65900 | T | Remove eye lesion | 0232 | 6.04 | \$292.86 | \$134.66 | \$58.57 |
| 65920 | T | Remove implant from eye | 0233 | 13.79 | \$668.64 | \$331.60 | \$133.73 |
| 65930 | T | Remove blood clot from eye | 0233 | 13.79 | \$668.64 | \$331.60 | \$133.73 |
| 66020 | T | Injection treatment of eye | 0232 | 6.04 | \$292.86 | \$134.66 | \$58.57 |
| 66030 | T | Injection treatment of eye | 0232 | 6.04 | \$292.86 | \$134.66 | \$58.57 |
| 66130 | T | Remove eye lesion | 0233 | 13.79 | \$668.64 | \$331.60 | \$133.73 |
| 66150 | T | Glaucoma surgery | 0233 | 13.79 | \$668.64 | \$331.60 | \$133.73 |
| 66155 | T | Glaucoma surgery | 0234 | 20.64 | \$1,000.77 | \$502.16 | \$200.15 |
| 66160 | T | Glaucoma surgery | 0234 | 20.64 | \$1,000.77 | \$502.16 | \$200.15 |
| 66165 | T | Glaucoma surgery | 0234 | 20.64 | \$1,000.77 | \$502.16 | \$200.15 |
| 66170 | T | Glaucoma surgery | 0234 | 20.64 | \$1,000.77 | \$502.16 | \$200.15 |
| 66172 | T | Incision of eye | 0234 | 20.64 | \$1,000.77 | \$502.16 | \$200.15 |
| 66180 | T | Implant eye shunt | 0234 | 20.64 | \$1,000.77 | \$502.16 | \$200.15 |
| 66185 | T | Revise eye shunt | 0234 | 20.64 | \$1,000.77 | \$502.16 | \$200.15 |
| 66220 | T | Repair eye lesion | 0236 | 6.70 | \$324.86 | \$147.96 | \$64.97 |
| 66225 | T | Repair/graft eye lesion | 0234 | 20.64 | \$1,000.77 | \$502.16 | \$200.15 |
| 66250 | T | Follow-up surgery of eye | 0233 | 13.79 | \$668.64 | \$331.60 | \$133.73 |
| 66500 | T | Incision of iris | 0232 | 6.04 | \$292.86 | \$134.66 | \$58.57 |
| 66505 | T | Incision of iris | 0232 | 6.04 | \$292.86 | \$134.66 | \$58.57 |
| 66600 | T | Remove iris and lesion | 0233 | 13.79 | \$668.64 | \$331.60 | \$133.73 |
| 66605 | T | Removal of iris | 0233 | 13.79 | \$668.64 | \$331.60 | \$133.73 |
| 66625 | T | Removal of iris | 0232 | 6.04 | \$292.86 | \$134.66 | \$58.57 |
| 66630 | T | Removal of iris | 0233 | 13.79 | \$668.64 | \$331.60 | \$133.73 |
| 66635 | T | Removal of iris | 0233 | 13.79 | \$668.64 | \$331.60 | \$133.73 |
| 66680 | T | Repair iris \& ciliary body | 0233 | 13.79 | \$668.64 | \$331.60 | \$133.73 |
| 66682 | T | Repair iris \& ciliary body | 0233 | 13.79 | \$668.64 | \$331.60 | \$133.73 |
| 66700 | T | Destruction, ciliary body | 0232 | 6.04 | \$292.86 | \$134.66 | \$58.57 |
| 66710 | T | Destruction, ciliary body | 0232 | 6.04 | \$292.86 | \$134.66 | \$58.57 |
| 66720 | T | Destruction, ciliary body | 0232 | 6.04 | \$292.86 | \$134.66 | \$58.57 |
| 66740 | T | Destruction, ciliary body ........................................ | 0233 | 13.79 | \$668.64 | \$331.60 | \$133.73 |
| 66761 | T | Revision of iris | 0247 | 4.89 | \$237.10 | \$112.86 | \$47.42 |
| 66762 | T | Revision of iris | 0247 | 4.89 | \$237.10 | \$112.86 | \$47.42 |
| 66770 | T | Removal of inner eye lesion | 0247 | 4.89 | \$237.10 | \$112.86 | \$47.42 |
| 66820 | T | Incision, secondary cataract .................................... | 0232 | 6.04 | \$292.86 | \$134.66 | \$58.57 |
| 66821 | T | After cataract laser surgery | 0247 | 4.89 | \$237.10 | \$112.86 | \$47.42 |
| 66825 | T | Reposition intraocular lens ...... | 0233 | 13.79 | \$668.64 | \$331.60 | \$133.73 |
| 66830 | T | Removal of lens lesion | 0232 | 6.04 | \$292.86 | \$134.66 | \$58.57 |
| 66840 | T | Removal of lens material | 0245 | 26.55 | \$1,287.33 | \$623.85 | \$257.47 |
| 66850 | T | Removal of lens material | 0245 | 26.55 | \$1,287.33 | \$623.85 | \$257.47 |
| 66852 | T | Removal of lens material | 0245 | 26.55 | \$1,287.33 | \$623.85 | \$257.47 |
| 66920 | T | Extraction of lens | 0245 | 26.55 | \$1,287.33 | \$623.85 | \$257.47 |
| 66930 | T | Extraction of lens | 0245 | 26.55 | \$1,287.33 | \$623.85 | \$257.47 |
| 66940 | T | Extraction of lens | 0245 | 26.55 | \$1,287.33 | \$623.85 | \$257.47 |
| 66983 | T | Remove cataract/insert lens ......... | 0246 | 26.55 | \$1,287.33 | \$623.85 | \$257.47 |
| 66984 | T | Remove cataract/insert lens | 0246 | 26.55 | \$1,287.33 | \$623.85 | \$257.47 |
| 66985 | T | Insert lens prosthesis | 0246 | 26.55 | \$1,287.33 | \$623.85 | \$257.47 |
| 66986 | T | Exchange lens prosthesis ....................................... | 0246 | 26.55 | \$1,287.33 | \$623.85 | \$257.47 |
| 66999 | T | Eye surgery procedure .......................................... | 0247 | 4.89 | \$237.10 | \$112.86 | \$47.42 |
| 67005 | T | Partial removal of eye fluid | 0237 | 33.96 | \$1,646.62 | \$852.68 | \$329.32 |
| 67010 | T | Partial removal of eye fluid .................................. | 0237 | 33.96 | \$1,646.62 | \$852.68 | \$329.32 |

[^193]
## Addendum B.—Hospital Outpatient Department (HOPD) Payment Status by hCPCS Code and Related Information-Continued

| CPT/ HCPCS | HOPD Status Indicator | Description | APC | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 67015 | T | Release of eye fluid | 0237 | 33.96 | \$1,646.62 | \$852.68 | \$329.32 |
| 67025 | T | Replace eye fluid | 0237 | 33.96 | \$1,646.62 | \$852.68 | \$329.32 |
| 67027 | T | Implant eye drug system ..... | 0237 | 33.96 | \$1,646.62 | \$852.68 | \$329.32 |
| 67028 | T | Injection eye drug | 0236 | 6.70 | \$324.86 | \$147.96 | \$64.97 |
| 67030 | T | Incise inner eye strands | 0236 | 6.70 | \$324.86 | \$147.96 | \$64.97 |
| 67031 | T | Laser surgery, eye strands | 0247 | 4.89 | \$237.10 | \$112.86 | \$47.42 |
| 67036 | T | Removal of inner eye fluid | 0237 | 33.96 | \$1,646.62 | \$852.68 | \$329.32 |
| 67038 | T | Strip retinal membrane | 0237 | 33.96 | \$1,646.62 | \$852.68 | \$329.32 |
| 67039 | T | Laser treatment of retina | 0237 | 33.96 | \$1,646.62 | \$852.68 | \$329.32 |
| 67040 | T | Laser treatment of retina | 0237 | 33.96 | \$1,646.62 | \$852.68 | \$329.32 |
| 67101 | T | Repair detached retina | 0236 | 6.70 | \$324.86 | \$147.96 | \$64.97 |
| 67105 | T | Repair detached retina | 0248 | 4.19 | \$203.16 | \$94.05 | \$40.63 |
| 67107 | T | Repair detached retina | 0237 | 33.96 | \$1,646.62 | \$852.68 | \$329.32 |
| 67108 | T | Repair detached retina . | 0237 | 33.96 | \$1,646.62 | \$852.68 | \$329.32 |
| 67110 | T | Repair detached retina | 0236 | 6.70 | \$324.86 | \$147.96 | \$64.97 |
| 67112 | T | Rerepair detached retina | 0237 | 33.96 | \$1,646.62 | \$852.68 | \$329.32 |
| 67115 | T | Release encircling material | 0236 | 6.70 | \$324.86 | \$147.96 | \$64.97 |
| 67120 | T | Remove eye implant material | 0236 | 6.70 | \$324.86 | \$147.96 | \$64.97 |
| 67121 | T | Remove eye implant material | 0237 | 33.96 | \$1,646.62 | \$852.68 | \$329.32 |
| 67141 | T | Treatment of retina | 0235 | 2.94 | \$142.55 | \$78.91 | \$28.51 |
| 67145 | T | Treatment of retina | 0248 | 4.19 | \$203.16 | \$94.05 | \$40.63 |
| 67208 | T | Treatment of retinal lesion | 0235 | 2.94 | \$142.55 | \$78.91 | \$28.51 |
| 67210 | T | Treatment of retinal lesion | 0248 | 4.19 | \$203.16 | \$94.05 | \$40.63 |
| 67218 | T | Treatment of retinal lesion | 0237 | 33.96 | \$1,646.62 | \$852.68 | \$329.32 |
| 67220 | T | Treatment of choroid lesion | 0237 | 33.96 | \$1,646.62 | \$852.68 | \$329.32 |
| 67227 | T | Treatment of retinal lesion | 0235 | 2.94 | \$142.55 | \$78.91 | \$28.51 |
| 67228 | T | Treatment of retinal lesion | 0248 | 4.19 | \$203.16 | \$94.05 | \$40.63 |
| 67250 | T | Reinforce eye wall | 0240 | 13.47 | \$653.12 | \$315.31 | \$130.62 |
| 67255 | T | Reinforce/graft eye wall | 0237 | 33.96 | \$1,646.62 | \$852.68 | \$329.32 |
| 67299 | T | Eye surgery procedure | 0248 | 4.19 | \$203.16 | \$94.05 | \$40.63 |
| 67311 | T | Revise eye muscle ........ | 0243 | 17.99 | \$872.28 | \$431.39 | \$174.46 |
| 67312 | T | Revise two eye muscles | 0243 | 17.99 | \$872.28 | \$431.39 | \$174.46 |
| 67314 | T | Revise eye muscle | 0243 | 17.99 | \$872.28 | \$431.39 | \$174.46 |
| 67316 | T | Revise two eye muscles | 0243 | 17.99 | \$872.28 | \$431.39 | \$174.46 |
| 67318 | T | Revise eye muscle(s) | 0243 | 17.99 | \$872.28 | \$431.39 | \$174.46 |
| 67320 | T | Revise eye muscle(s) add-on | 0243 | 17.99 | \$872.28 | \$431.39 | \$174.46 |
| 67331 | T | Eye surgery follow-up add-on | 0243 | 17.99 | \$872.28 | \$431.39 | \$174.46 |
| 67332 | T | Rerevise eye muscles add-on | 0243 | 17.99 | \$872.28 | \$431.39 | \$174.46 |
| 67334 | T | Revise eye muscle w/suture | 0243 | 17.99 | \$872.28 | \$431.39 | \$174.46 |
| 67335 | T | Eye suture during surgery ... | 0243 | 17.99 | \$872.28 | \$431.39 | \$174.46 |
| 67340 | T | Revise eye muscle add-on ... | 0243 | 17.99 | \$872.28 | \$431.39 | \$174.46 |
| 67343 | T | Release eye tissue | 0243 | 17.99 | \$872.28 | \$431.39 | \$174.46 |
| 67345 | T | Destroy nerve of eye muscle | 0238 | 2.80 | \$135.76 | \$58.96 | \$27.15 |
| 67350 | S | Biopsy eye muscle ........... | 0231 | 2.64 | \$128.01 | \$59.87 | \$25.60 |
| 67399 | T | Eye muscle surgery procedure | 0243 | 17.99 | \$872.28 | \$431.39 | \$174.46 |
| 67400 | T | Explore/biopsy eye socket | 0241 | 16.60 | \$804.89 | \$384.47 | \$160.98 |
| 67405 | T | Explore/drain eye socket | 0241 | 16.60 | \$804.89 | \$384.47 | \$160.98 |
| 67412 | T | Explore/treat eye socket | 0241 | 16.60 | \$804.89 | \$384.47 | \$160.98 |
| 67413 | T | Explore/treat eye socket | 0241 | 16.60 | \$804.89 | \$384.47 | \$160.98 |
| 67414 | T | Explr/decompress eye socket | 0242 | 23.70 | \$1,149.14 | \$597.36 | \$229.83 |
| 67415 | T | Aspiration, orbital contents ....... | 0239 | 6.26 | \$303.53 | \$123.42 | \$60.71 |
| 67420 | T | Explore/treat eye socket | 0242 | 23.70 | \$1,149.14 | \$597.36 | \$229.83 |
| 67430 | T | Explore/treat eye socket | 0242 | 23.70 | \$1,149.14 | \$597.36 | \$229.83 |
| 67440 | T | Explore/drain eye socket ...... | 0242 | 23.70 | \$1,149.14 | \$597.36 | \$229.83 |
| 67445 | T | Explr/decompress eye socket | 0242 | 23.70 | \$1,149.14 | \$597.36 | \$229.83 |
| 67450 | T | Explore/biopsy eye socket | 0242 | 23.70 | \$1,149.14 | \$597.36 | \$229.83 |
| 67500 | S | Inject/treat eye socket ........ | 0231 | 2.64 | \$128.01 | \$59.87 | \$25.60 |
| 67505 | T | Inject/treat eye socket ..... | 0238 | 2.80 | \$135.76 | \$58.96 | \$27.15 |
| 67515 | T | Inject/treat eye socket | 0239 | 6.26 | \$303.53 | \$123.42 | \$60.71 |
| 67550 | T | Insert eye socket implant ....... | 0242 | 23.70 | \$1,149.14 | \$597.36 | \$229.83 |
| 67560 | T | Revise eye socket implant ...................................... | 0241 | 16.60 | \$804.89 | \$384.47 | \$160.98 |
| 67570 | T | Decompress optic nerve | 0242 | 23.70 | \$1,149.14 | \$597.36 | \$229.83 |
| 67599 | T | Orbit surgery procedure ......................................... | 0239 | 6.26 | \$303.53 | \$123.42 | \$60.71 |
| 67700 | T | Drainage of eyelid abscess .................................... | 0238 | 2.80 | \$135.76 | \$58.96 | \$27.15 |
| 67710 | T | Incision of eyelid ..... | 0239 | 6.26 | \$303.53 | \$123.42 | \$60.71 |
| 67715 | T | Incision of eyelid fold ............................................. | 0240 | 13.47 | \$653.12 | \$315.31 | \$130.62 |
| 67800 | T | Remove eyelid lesion .......................................... | 0238 | 2.80 | \$135.76 | \$58.96 | \$27.15 |
| 67801 | T | Remove eyelid lesions ........................................... | 0239 | 6.26 | \$303.53 | \$123.42 | \$60.71 |
| 67805 | T | Remove eyelid lesions ........................................... | 0238 | 2.80 | \$135.76 | \$58.96 | \$27.15 |
| 67808 | T | Remove eyelid lesion(s) ........................................ | 0240 | 13.47 | \$653.12 | \$315.31 | \$130.62 |
| 67810 | T | Biopsy of eyelid ................................................... | 0238 | 2.80 | \$135.76 | \$58.96 | \$27.15 |
| 67820 | T | Revise eyelashes ................................................. | 0238 | 2.80 | \$135.76 | \$58.96 | \$27.15 |
| 67825 | T | Revise eyelashes ................................................ | 0238 | 2.80 | \$135.76 | \$58.96 | \$27.15 |

[^194]
## Addendum B.-Hospital Outpatient Department (HOPD) Payment Status by HCPCS Code and Related Information-Continued

| CPT/ HCPCS | HOPD Status Indicator | Description | APC | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 67830 | T | Revise eyelashes | 0239 | 6.26 | \$303.53 | \$123.42 | \$60.71 |
| 67835 | T | Revise eyelashes | 0240 | 13.47 | \$653.12 | \$315.31 | \$130.62 |
| 67840 | T | Remove eyelid lesion | 0239 | 6.26 | \$303.53 | \$123.42 | \$60.71 |
| 67850 | T | Treat eyelid lesion ... | 0239 | 6.26 | \$303.53 | \$123.42 | \$60.71 |
| 67875 | T | Closure of eyelid by suture | 0239 | 6.26 | \$303.53 | \$123.42 | \$60.71 |
| 67880 | T | Revision of eyelid .............. | 0232 | 6.04 | \$292.86 | \$134.66 | \$58.57 |
| 67882 | T | Revision of eyelid | 0240 | 13.47 | \$653.12 | \$315.31 | \$130.62 |
| 67900 | T | Repair brow defect | 0240 | 13.47 | \$653.12 | \$315.31 | \$130.62 |
| 67901 | T | Repair eyelid defect | 0240 | 13.47 | \$653.12 | \$315.31 | \$130.62 |
| 67902 | T | Repair eyelid defect | 0240 | 13.47 | \$653.12 | \$315.31 | \$130.62 |
| 67903 | T | Repair eyelid defect | 0240 | 13.47 | \$653.12 | \$315.31 | \$130.62 |
| 67904 | T | Repair eyelid defect | 0240 | 13.47 | \$653.12 | \$315.31 | \$130.62 |
| 67906 | T | Repair eyelid defect | 0240 | 13.47 | \$653.12 | \$315.31 | \$130.62 |
| 67908 | T | Repair eyelid defect | 0240 | 13.47 | \$653.12 | \$315.31 | \$130.62 |
| 67909 | T | Revise eyelid defect | 0240 | 13.47 | \$653.12 | \$315.31 | \$130.62 |
| 67911 | T | Revise eyelid defect | 0240 | 13.47 | \$653.12 | \$315.31 | \$130.62 |
| 67914 | T | Repair eyelid defect | 0240 | 13.47 | \$653.12 | \$315.31 | \$130.62 |
| 67915 | T | Repair eyelid defect | 0239 | 6.26 | \$303.53 | \$123.42 | \$60.71 |
| 67916 | T | Repair eyelid defect | 0240 | 13.47 | \$653.12 | \$315.31 | \$130.62 |
| 67917 | T | Repair eyelid defect | 0240 | 13.47 | \$653.12 | \$315.31 | \$130.62 |
| 67921 | T | Repair eyelid defect | 0240 | 13.47 | \$653.12 | \$315.31 | \$130.62 |
| 67922 | T | Repair eyelid defect | 0239 | 6.26 | \$303.53 | \$123.42 | \$60.71 |
| 67923 | T | Repair eyelid defect | 0240 | 13.47 | \$653.12 | \$315.31 | \$130.62 |
| 67924 | T | Repair eyelid defect | 0240 | 13.47 | \$653.12 | \$315.31 | \$130.62 |
| 67930 | T | Repair eyelid wound | 0240 | 13.47 | \$653.12 | \$315.31 | \$130.62 |
| 67935 | T | Repair eyelid wound | 0240 | 13.47 | \$653.12 | \$315.31 | \$130.62 |
| 67938 | T | Remove eyelid foreign body | 0238 | 2.80 | \$135.76 | \$58.96 | \$27.15 |
| 67950 | T | Revision of eyelid | 0240 | 13.47 | \$653.12 | \$315.31 | \$130.62 |
| 67961 | T | Revision of eyelid | 0240 | 13.47 | \$653.12 | \$315.31 | \$130.62 |
| 67966 | T | Revision of eyelid | 0240 | 13.47 | \$653.12 | \$315.31 | \$130.62 |
| 67971 | T | Reconstruction of eyelid | 0241 | 16.60 | \$804.89 | \$384.47 | \$160.98 |
| 67973 | T | Reconstruction of eyelid | 0241 | 16.60 | \$804.89 | \$384.47 | \$160.98 |
| 67974 | T | Reconstruction of eyelid | 0241 | 16.60 | \$804.89 | \$384.47 | \$160.98 |
| 67975 | T | Reconstruction of eyelid | 0240 | 13.47 | \$653.12 | \$315.31 | \$130.62 |
| 67999 | T | Revision of eyelid | 0240 | 13.47 | \$653.12 | \$315.31 | \$130.62 |
| 68020 | T | Incise/drain eyelid lining | 0240 | 13.47 | \$653.12 | \$315.31 | \$130.62 |
| 68040 | T | Treatment of eyelid lesions | 0239 | 6.26 | \$303.53 | \$123.42 | \$60.71 |
| 68100 | T | Biopsy of eyelid lining | 0232 | 6.04 | \$292.86 | \$134.66 | \$58.57 |
| 68110 | S | Remove eyelid lining lesion | 0231 | 2.64 | \$128.01 | \$59.87 | \$25.60 |
| 68115 | T | Remove eyelid lining lesion | 0239 | 6.26 | \$303.53 | \$123.42 | \$60.71 |
| 68130 | T | Remove eyelid lining lesion | 0233 | 13.79 | \$668.64 | \$331.60 | \$133.73 |
| 68135 | T | Remove eyelid lining lesion | 0239 | 6.26 | \$303.53 | \$123.42 | \$60.71 |
| 68200 | S | Treat eyelid by injection ..... | 0230 | 0.98 | \$47.52 | \$22.48 | \$9.50 |
| 68320 | T | Revise/graft eyelid lining | 0240 | 13.47 | \$653.12 | \$315.31 | \$130.62 |
| 68325 | T | Revise/graft eyelid lining | 0242 | 23.70 | \$1,149.14 | \$597.36 | \$229.83 |
| 68326 | T | Revise/graft eyelid lining | 0241 | 16.60 | \$804.89 | \$384.47 | \$160.98 |
| 68328 | T | Revise/graft eyelid lining | 0241 | 16.60 | \$804.89 | \$384.47 | \$160.98 |
| 68330 | T | Revise eyelid lining | 0233 | 13.79 | \$668.64 | \$331.60 | \$133.73 |
| 68335 | T | Revise/graft eyelid lining ........................................ | 0241 | 16.60 | \$804.89 | \$384.47 | \$160.98 |
| 68340 | T | Separate eyelid adhesions | 0240 | 13.47 | \$653.12 | \$315.31 | \$130.62 |
| 68360 | T | Revise eyelid lining | 0234 | 20.64 | \$1,000.77 | \$502.16 | \$200.15 |
| 68362 | T | Revise eyelid lining | 0234 | 20.64 | \$1,000.77 | \$502.16 | \$200.15 |
| 68399 | T | Eyelid lining surgery | 0239 | 6.26 | \$303.53 | \$123.42 | \$60.71 |
| 68400 | T | Incise/drain tear gland | 0238 | 2.80 | \$135.76 | \$58.96 | \$27.15 |
| 68420 | T | Incise/drain tear sac | 0240 | 13.47 | \$653.12 | \$315.31 | \$130.62 |
| 68440 | T | Incise tear duct opening ......................................... | 0238 | 2.80 | \$135.76 | \$58.96 | \$27.15 |
| 68500 | T | Removal of tear gland | 0241 | 16.60 | \$804.89 | \$384.47 | \$160.98 |
| 68505 | T | Partial removal, tear gland | 0241 | 16.60 | \$804.89 | \$384.47 | \$160.98 |
| 68510 | T | Biopsy of tear gland .... | 0240 | 13.47 | \$653.12 | \$315.31 | \$130.62 |
| 68520 | T | Removal of tear sac | 0241 | 16.60 | \$804.89 | \$384.47 | \$160.98 |
| 68525 | T | Biopsy of tear sac | 0240 | 13.47 | \$653.12 | \$315.31 | \$130.62 |
| 68530 | T | Clearance of tear duct | 0240 | 13.47 | \$653.12 | \$315.31 | \$130.62 |
| 68540 | T | Remove tear gland lesion ....................................... | 0241 | 16.60 | \$804.89 | \$384.47 | \$160.98 |
| 68550 | T | Remove tear gland lesion | 0242 | 23.70 | \$1,149.14 | \$597.36 | \$229.83 |
| 68700 | T | Repair tear ducts | 0241 | 16.60 | \$804.89 | \$384.47 | \$160.98 |
| 68705 | T | Revise tear duct opening ....................................... | 0238 | 2.80 | \$135.76 | \$58.96 | \$27.15 |
| 68720 | T | Create tear sac drain | 0242 | 23.70 | \$1,149.14 | \$597.36 | \$229.83 |
| 68745 | T | Create tear duct drain | 0241 | 16.60 | \$804.89 | \$384.47 | \$160.98 |
| 68750 | T | Create tear duct drain . | 0242 | 23.70 | \$1,149.14 | \$597.36 | \$229.83 |
| 68760 | T | Close tear duct opening ........................................ | 0238 | 2.80 | \$135.76 | \$58.96 | \$27.15 |
| 68761 | S | Close tear duct opening ........................................ | 0231 | 2.64 | \$128.01 | \$59.87 | \$25.60 |
| 68770 | T | Close tear system fistula ........................................ | 0240 | 13.47 | \$653.12 | \$315.31 | \$130.62 |
| 68801 | S | Dilate tear duct opening ........................................ | 0231 | 2.64 | \$128.01 | \$59.87 | \$25.60 |

[^195]
## Addendum B.—Hospital Outpatient Department (HOPD) Payment Status by hCPCS Code and Related Information-Continued

| CPT/ HCPCS | HOPD Status Indicator | Description | APC | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 68810 | S | Probe nasolacrimal duct | 0231 | 2.64 | \$128.01 | \$59.87 | \$25.60 |
| 68811 | T | Probe nasolacrimal duct | 0240 | 13.47 | \$653.12 | \$315.31 | \$130.62 |
| 68815 | T | Probe nasolacrimal duct | 0240 | 13.47 | \$653.12 | \$315.31 | \$130.62 |
| 68840 | S | Explore/irrigate tear ducts | 0231 | 2.64 | \$128.01 | \$59.87 | \$25.60 |
| 68850 | N | Injection for tear sac x-ray |  |  |  |  |  |
| 68899 | S | Tear duct system surgery | 0231 | 2.64 | \$128.01 | \$59.87 | \$25.60 |
| 69000 | T | Drain external ear lesion | 0006 | 2.00 | \$96.97 | \$33.95 | \$19.39 |
| 69005 | T | Drain external ear lesion | 0007 | 3.68 | \$178.43 | \$72.03 | \$35.69 |
| 69020 | T | Drain outer ear canal lesion | 0006 | 2.00 | \$96.97 | \$33.95 | \$19.39 |
| 69090 | E | Pierce earlobes |  |  |  |  |  |
| 69100 | T | Biopsy of external ear ....................................... | 0019 | 4.00 | \$193.95 | \$78.91 | \$38.79 |
| 69105 | T | Biopsy of external ear canal ............................... | 0253 | 12.02 | \$582.81 | \$284.00 | \$116.56 |
| 69110 | T | Remove external ear, partial | 0020 | 6.51 | \$315.65 | \$130.53 | \$63.13 |
| 69120 | T | Removal of external ear | 0253 | 12.02 | \$582.81 | \$284.00 | \$116.56 |
| 69140 | T | Remove ear canal lesion(s) | 0254 | 12.45 | \$603.66 | \$272.41 | \$120.73 |
| 69145 | T | Remove ear canal lesion(s) | 0020 | 6.51 | \$315.65 | \$130.53 | \$63.13 |
| 69150 | C | Extensive ear canal surgery |  |  |  |  |  |
| 69155 | C | Extensive ear/neck surgery ................................ |  |  |  |  |  |
| 69200 | X | Clear outer ear canal ......... | 0340 | 1.04 | \$50.43 | \$12.85 | \$10.09 |
| 69205 | T | Clear outer ear canal | 0022 | 12.49 | \$605.60 | \$292.94 | \$121.12 |
| 69210 | X | Remove impacted ear wax | 0340 | 1.04 | \$50.43 | \$12.85 | \$10.09 |
| 69220 | T | Clean out mastoid cavity | 0012 | 0.53 | \$25.70 | \$9.18 | \$5.14 |
| 69222 | T | Clean out mastoid cavity | 0253 | 12.02 | \$582.81 | \$284.00 | \$116.56 |
| 69300 | T | Revise external ear | 0254 | 12.45 | \$603.66 | \$272.41 | \$120.73 |
| 69310 | T | Rebuild outer ear canal | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 69320 | T | Rebuild outer ear canal | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 69399 | T | Outer ear surgery procedure | 0252 | 5.18 | \$251.16 | \$114.24 | \$50.23 |
| 69400 | T | Inflate middle ear canal | 0251 | 1.68 | \$81.46 | \$27.99 | \$16.29 |
| 69401 | N | Inflate middle ear canal |  |  |  |  |  |
| 69405 | T | Catheterize middle ear canal | 0252 | 5.18 | \$251.16 | \$114.24 | \$50.23 |
| 69410 | T | Inset middle ear (baffle) | 0252 | 5.18 | \$251.16 | \$114.24 | \$50.23 |
| 69420 | T | Incision of eardrum | 0252 | 5.18 | \$251.16 | \$114.24 | \$50.23 |
| 69421 | T | Incision of eardrum | 0253 | 12.02 | \$582.81 | \$284.00 | \$116.56 |
| 69424 | T | Remove ventilating tube | 0252 | 5.18 | \$251.16 | \$114.24 | \$50.23 |
| 69433 | T | Create eardrum opening | 0252 | 5.18 | \$251.16 | \$114.24 | \$50.23 |
| 69436 | T | Create eardrum opening | 0253 | 12.02 | \$582.81 | \$284.00 | \$116.56 |
| 69440 | T | Exploration of middle ear | 0253 | 12.02 | \$582.81 | \$284.00 | \$116.56 |
| 69450 | T | Eardrum revision | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 69501 | T | Mastoidectomy | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 69502 | C | Mastoidectomy |  |  |  |  |  |
| 69505 | T | Remove mastoid structures | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 69511 | T | Extensive mastoid surgery | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 69530 | T | Extensive mastoid surgery | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 69535 | C | Remove part of temporal bone |  |  |  |  |  |
| 69540 | T | Remove ear lesion ... | 0253 | 12.02 | \$582.81 | \$284.00 | \$116.56 |
| 69550 | T | Remove ear lesion | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 69552 | T | Remove ear lesion | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 69554 | C | Remove ear lesion |  |  |  |  |  |
| 69601 | T | Mastoid surgery revision | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 69602 | T | Mastoid surgery revision | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 69603 | T | Mastoid surgery revision | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 69604 | T | Mastoid surgery revision | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 69605 | T | Mastoid surgery revision | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 69610 | T | Repair of eardrum | 0253 | 12.02 | \$582.81 | \$284.00 | \$116.56 |
| 69620 | T | Repair of eardrum | 0253 | 12.02 | \$582.81 | \$284.00 | \$116.56 |
| 69631 | T | Repair eardrum structures | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 69632 | T | Rebuild eardrum structures | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 69633 | T | Rebuild eardrum structures | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 69635 | T | Repair eardrum structures ....... | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 69636 | T | Rebuild eardrum structures | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 69637 | T | Rebuild eardrum structures | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 69641 | T | Revise middle ear \& mastoid | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 69642 | T | Revise middle ear \& mastoid | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 69643 | T | Revise middle ear \& mastoid | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 69644 | T | Revise middle ear \& mastoid | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 69645 | T | Revise middle ear \& mastoid | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 69646 | T | Revise middle ear \& mastoid | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 69650 | T | Release middle ear bone ....................................... | 0254 | 12.45 | \$603.66 | \$272.41 | \$120.73 |
| 69660 | T | Revise middle ear bone | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 69661 | T | Revise middle ear bone | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 69662 | T | Revise middle ear bone ......................................... | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 69666 | T | Repair middle ear structures ................................... | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 69667 | T | Repair middle ear structures | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |

[^196]
## Addendum B.-Hospital Outpatient Department (HOPD) Payment Status by HCPCS Code and Related INFORMATION-Continued

| $\begin{aligned} & \text { CPT/ } \\ & \text { HCPCS } \end{aligned}$ | HOPD <br> Status Indicator | Description | APC | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 69670 | T | Remove mastoid air cells | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 69676 | T | Remove middle ear nerve | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 69700 | T | Close mastoid fistula | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 69710 | E | Implant/replace hearing aid |  |  |  |  |  |
| 69711 | T | Remove/repair hearing aid | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 69720 | T | Release facial nerve | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 69725 | T | Release facial nerve | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 69740 | T | Repair facial nerve | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 69745 | T | Repair facial nerve | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 69799 | T | Middle ear surgery procedure | 0253 | 12.02 | \$582.81 | \$284.00 | \$116.56 |
| 69801 | T | Incise inner ear | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 69802 | T | Incise inner ear | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 69805 | T | Explore inner ear | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 69806 | T | Explore inner ear | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 69820 | T | Establish inner ear window | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 69840 | T | Revise inner ear window | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 69905 | T | Remove inner ear | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 69910 | T | Remove inner ear \& mastoid | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 69915 | T | Incise inner ear nerve | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 69930 | T | Implant cochlear device | 0257 | 115.31 | \$5,591.04 | \$3,498.58 | \$1,118.21 |
| 69949 | T | Inner ear surgery procedure | 0253 | 12.02 | \$582.81 | \$284.00 | \$116.56 |
| 69950 | C | Incise inner ear nerve |  |  |  |  |  |
| 69955 | T | Release facial nerve | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 69960 | T | Release inner ear canal | 0256 | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
| 69970 | C | Remove inner ear lesion |  |  |  |  |  |
| 69979 | T | Temporal bone surgery | 0252 | 5.18 | \$251.16 | \$114.24 | \$50.23 |
| 69990 | N | Microsurgery add-on .. |  |  |  |  |  |
| 70010 | S | Contrast x-ray of brain | 0274 | 4.83 | \$234.19 | \$128.12 | \$46.84 |
| 70015 | S | Contrast x-ray of brain | 0274 | 4.83 | \$234.19 | \$128.12 | \$46.84 |
| 70030 | X | X-ray eye for foreign body | 0260 | 0.79 | \$38.30 | \$22.02 | \$7.66 |
| 70100 | X | X-ray exam of jaw | 0260 | 0.79 | \$38.30 | \$22.02 | \$7.66 |
| 70110 | X | X-ray exam of jaw | 0260 | 0.79 | \$38.30 | \$22.02 | \$7.66 |
| 70120 | X | X-ray exam of mastoids | 0260 | 0.79 | \$38.30 | \$22.02 | \$7.66 |
| 70130 | X | X-ray exam of mastoids | 0260 | 0.79 | \$38.30 | \$22.02 | \$7.66 |
| 70134 | X | X-ray exam of middle ear | 0261 | 1.38 | \$66.91 | \$38.77 | \$13.38 |
| 70140 | X | X-ray exam of facial bones | 0260 | 0.79 | \$38.30 | \$22.02 | \$7.66 |
| 70150 | X | X-ray exam of facial bones | 0260 | 0.79 | \$38.30 | \$22.02 | \$7.66 |
| 70160 | X | X-ray exam of nasal bones | 0260 | 0.79 | \$38.30 | \$22.02 | \$7.66 |
| 70170 | X | X-ray exam of tear duct | 0263 | 1.68 | \$81.46 | \$45.88 | \$16.29 |
| 70190 | X | X-ray exam of eye sockets | 0260 | 0.79 | \$38.30 | \$22.02 | \$7.66 |
| 70200 | X | X-ray exam of eye sockets | 0260 | 0.79 | \$38.30 | \$22.02 | \$7.66 |
| 70210 | X | X-ray exam of sinuses | 0260 | 0.79 | \$38.30 | \$22.02 | \$7.66 |
| 70220 | X | X-ray exam of sinuses | 0260 | 0.79 | \$38.30 | \$22.02 | \$7.66 |
| 70240 | X | X-ray exam, pituitary saddle | 0260 | 0.79 | \$38.30 | \$22.02 | \$7.66 |
| 70250 | X | X-ray exam of skull | 0260 | 0.79 | \$38.30 | \$22.02 | \$7.66 |
| 70260 | X | X-ray exam of skull | 0261 | 1.38 | \$66.91 | \$38.77 | \$13.38 |
| 70300 | X | X-ray exam of teeth | 0262 | 0.40 | \$19.39 | \$10.90 | \$3.88 |
| 70310 | X | X-ray exam of teeth | 0262 | 0.40 | \$19.39 | \$10.90 | \$3.88 |
| 70320 | X | Full mouth x-ray of teeth | 0262 | 0.40 | \$19.39 | \$10.90 | \$3.88 |
| 70328 | X | X-ray exam of jaw joint. | 0260 | 0.79 | \$38.30 | \$22.02 | \$7.66 |
| 70330 | X | X-ray exam of jaw joints | 0260 | 0.79 | \$38.30 | \$22.02 | \$7.66 |
| 70332 | S | X-ray exam of jaw joint | 0275 | 2.74 | \$132.85 | \$72.26 | \$26.57 |
| 70336 | S | Magnetic image, jaw joint ....................................... | 0284 | 8.02 | \$388.87 | \$257.39 | \$77.77 |
| 70350 | X | X-ray head for orthodontia | 0260 | 0.79 | \$38.30 | \$22.02 | \$7.66 |
| 70355 | X | Panoramic x -ray of jaws ........................................ | 0260 | 0.79 | \$38.30 | \$22.02 | \$7.66 |
| 70360 | X | X-ray exam of neck ...... | 0260 | 0.79 | \$38.30 | \$22.02 | \$7.66 |
| 70370 | X | Throat x-ray \& fluoroscopy ..................................... | 0273 | 2.49 | \$120.73 | \$61.02 | \$24.15 |
| 70371 | X | Speech evaluation, complex | 0272 | 1.40 | \$67.88 | \$39.00 | \$13.58 |
| 70373 | X | Contrast x-ray of larynx | 0263 | 1.68 | \$81.46 | \$45.88 | \$16.29 |
| 70380 | X | X-ray exam of salivary gland ................................... | 0260 | 0.79 | \$38.30 | \$22.02 | \$7.66 |
| 70390 | X | X-ray exam of salivary duct ..... | 0263 | 1.68 | \$81.46 | \$45.88 | \$16.29 |
| 70450 | S | CAT scan of head or brain | 0283 | 4.89 | \$237.10 | \$179.39 | \$47.42 |
| 70460 | S | Contrast CAT scan of head | 0283 | 4.89 | \$237.10 | \$179.39 | \$47.42 |
| 70470 | S | Contrast CAT scans of head | 0283 | 4.89 | \$237.10 | \$179.39 | \$47.42 |
| 70480 | S | CAT scan of skull | 0283 | 4.89 | \$237.10 | \$179.39 | \$47.42 |
| 70481 | S | Contrast CAT scan of skull | 0283 | 4.89 | \$237.10 | \$179.39 | \$47.42 |
| 70482 | S | Contrast CAT scans of skull ....... | 0283 | 4.89 | \$237.10 | \$179.39 | \$47.42 |
| 70486 | S | Cat scan of face/jaw | 0282 | 2.38 | \$115.40 | \$94.51 | \$23.08 |
| 70487 | S | Contrast CAT scan, face/jaw ................................... | 0283 | 4.89 | \$237.10 | \$179.39 | \$47.42 |
| 70488 | S | Contrast cat scans, face/jaw .................................. | 0283 | 4.89 | \$237.10 | \$179.39 | \$47.42 |
| 70490 | S | CAT scan of neck tissue ........................................ | 0283 | 4.89 | \$237.10 | \$179.39 | \$47.42 |
| 70491 | S | Contrast CAT of neck tissue | 0283 | 4.89 | \$237.10 | \$179.39 | \$47.42 |
| 70492 | S | Contrast CAT of neck tissue | 0283 | 4.89 | \$237.10 | \$179.39 | \$47.42 |

[^197]
## Addendum B.-Hospital Outpatient Department (HOPD) Payment Status by hCPCS Code and Related Information-Continued

| CPT/ HCPCS | HOPD <br> Status <br> Indicator | Description | APC | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 70540 | S | Magnetic image, face/neck | 0284 | 8.02 | \$388.87 | \$257.39 | \$77.77 |
| 70541 | S | Magnetic image, head (MRA) | 0284 | 8.02 | \$388.87 | \$257.39 | \$77.77 |
| 70551 | S | Magnetic image, brain (MRI) | 0284 | 8.02 | \$388.87 | \$257.39 | \$77.77 |
| 70552 | S | Magnetic image, brain (MRI) | 0284 | 8.02 | \$388.87 | \$257.39 | \$77.77 |
| 70553 | S | Magnetic image, brain (mri) | 0284 | 8.02 | \$388.87 | \$257.39 | \$77.77 |
| 71010 | X | Chest x-ray | 0260 | 0.79 | \$38.30 | \$22.02 | \$7.66 |
| 71015 | X | Chest x -ray | 0260 | 0.79 | \$38.30 | \$22.02 | \$7.66 |
| 71020 | X | Chest x-ray | 0260 | 0.79 | \$38.30 | \$22.02 | \$7.66 |
| 71021 | X | Chest x-ray ......................................................... | 0260 | 0.79 | \$38.30 | \$22.02 | \$7.66 |
| 71022 | X | Chest x-ray | 0260 | 0.79 | \$38.30 | \$22.02 | \$7.66 |
| 71023 | X | Chest x-ray and fluoroscopy | 0272 | 1.40 | \$67.88 | \$39.00 | \$13.58 |
| 71030 | X | Chest x-ray .......................................................... | 0260 | 0.79 | \$38.30 | \$22.02 | \$7.66 |
| 71034 | X | Chest x-ray and fluoroscopy | 0272 | 1.40 | \$67.88 | \$39.00 | \$13.58 |
| 71035 | X | Chest x-ray | 0260 | 0.79 | \$38.30 | \$22.02 | \$7.66 |
| 71036 | X | X-ray guidance for biopsy ....................................... | 0273 | 2.49 | \$120.73 | \$61.02 | \$24.15 |
| 71040 | X | Contrast x-ray of bronchi ........................................ | 0263 | 1.68 | \$81.46 | \$45.88 | \$16.29 |
| 71060 | X | Contrast x-ray of bronchi | 0263 | 1.68 | \$81.46 | \$45.88 | \$16.29 |
| 71090 | X | X-ray \& pacemaker insertion | 0273 | 2.49 | \$120.73 | \$61.02 | \$24.15 |
| 71100 | X | X-ray exam of ribs ......... | 0260 | 0.79 | \$38.30 | \$22.02 | \$7.66 |
| 71101 | X | X-ray exam of ribs/chest | 0260 | 0.79 | \$38.30 | \$22.02 | \$7.66 |
| 71110 | X | X-ray exam of ribs | 0260 | 0.79 | \$38.30 | \$22.02 | \$7.66 |
| 71111 | X | X-ray exam of ribs/chest | 0261 | 1.38 | \$66.91 | \$38.77 | \$13.38 |
| 71120 | X | X-ray exam of breastbone | 0260 | 0.79 | \$38.30 | \$22.02 | \$7.66 |
| 71130 | X | X-ray exam of breastbone | 0260 | 0.79 | \$38.30 | \$22.02 | \$7.66 |
| 71250 | S | Cat scan of chest | 0283 | 4.89 | \$237.10 | \$179.39 | \$47.42 |
| 71260 | S | Contrast CAT scan of chest | 0283 | 4.89 | \$237.10 | \$179.39 | \$47.42 |
| 71270 | S | Contrast CAT scans of chest | 0283 | 4.89 | \$237.10 | \$179.39 | \$47.42 |
| 71550 | S | Magnetic image, chest (mri) | 0284 | 8.02 | \$388.87 | \$257.39 | \$77.77 |
| 71555 | E | Magnetic image, chest (mra) .............................. |  |  |  |  |  |
| 72010 | X | X-ray exam of spine | 0261 | 1.38 | \$66.91 | \$38.77 | \$13.38 |
| 72020 | X | X-ray exam of spine | 0260 | 0.79 | \$38.30 | \$22.02 | \$7.66 |
| 72040 | X | X-ray exam of neck spine | 0260 | 0.79 | \$38.30 | \$22.02 | \$7.66 |
| 72050 | X | X-ray exam of neck spine | 0261 | 1.38 | \$66.91 | \$38.77 | \$13.38 |
| 72052 | X | X-ray exam of neck spine | 0261 | 1.38 | \$66.91 | \$38.77 | \$13.38 |
| 72069 | X | X-ray exam of trunk spine | 0260 | 0.79 | \$38.30 | \$22.02 | \$7.66 |
| 72070 | X | X-ray exam of thoracic spine | 0260 | 0.79 | \$38.30 | \$22.02 | \$7.66 |
| 72072 | X | X-ray exam of thoracic spine | 0260 | 0.79 | \$38.30 | \$22.02 | \$7.66 |
| 72074 | X | X-ray exam of thoracic spine | 0260 | 0.79 | \$38.30 | \$22.02 | \$7.66 |
| 72080 | X | X-ray exam of trunk spine ...................................... | 0260 | 0.79 | \$38.30 | \$22.02 | \$7.66 |
| 72090 | X | X-ray exam of trunk spine | 0260 | 0.79 | \$38.30 | \$22.02 | \$7.66 |
| 72100 | X | X-ray exam of lower spine ...................................... | 0260 | 0.79 | \$38.30 | \$22.02 | \$7.66 |
| 72110 | X | X-ray exam of lower spine ...................................... | 0261 | 1.38 | \$66.91 | \$38.77 | \$13.38 |
| 72114 | X | X-ray exam of lower spine | 0261 | 1.38 | \$66.91 | \$38.77 | \$13.38 |
| 72120 | X | X-ray exam of lower spine | 0260 | 0.79 | \$38.30 | \$22.02 | \$7.66 |
| 72125 | S | CAT scan of neck spine .... | 0283 | 4.89 | \$237.10 | \$179.39 | \$47.42 |
| 72126 | S | Contrast CAT scan of neck | 0283 | 4.89 | \$237.10 | \$179.39 | \$47.42 |
| 72127 | S | Contrast CAT scans of neck | 0283 | 4.89 | \$237.10 | \$179.39 | \$47.42 |
| 72128 | S | CAT scan of thorax spine ....................................... | 0283 | 4.89 | \$237.10 | \$179.39 | \$47.42 |
| 72129 | S | Contrast CAT scan of thorax ................................... | 0283 | 4.89 | \$237.10 | \$179.39 | \$47.42 |
| 72130 | S | Contrast CAT scans of thorax | 0283 | 4.89 | \$237.10 | \$179.39 | \$47.42 |
| 72131 | S | CAT scan of lower spine ........................................ | 0283 | 4.89 | \$237.10 | \$179.39 | \$47.42 |
| 72132 | S | Contrast CAT of lower spine ................................... | 0283 | 4.89 | \$237.10 | \$179.39 | \$47.42 |
| 72133 | S | Contrast cat scans, low spine ................................. | 0283 | 4.89 | \$237.10 | \$179.39 | \$47.42 |
| 72141 | S | Magnetic image, neck spine ................................... | 0284 | 8.02 | \$388.87 | \$257.39 | \$77.77 |
| 72142 | S | Magnetic image, neck spine .................................... | 0284 | 8.02 | \$388.87 | \$257.39 | \$77.77 |
| 72146 | S | Magnetic image, chest spine .................................. | 0284 | 8.02 | \$388.87 | \$257.39 | \$77.77 |
| 72147 | S | Magnetic image, chest spine .................................. | 0284 | 8.02 | \$388.87 | \$257.39 | \$77.77 |
| 72148 | S | Magnetic image, lumbar spine ................................ | 0284 | 8.02 | \$388.87 | \$257.39 | \$77.77 |
| 72149 | S | Magnetic image, lumbar spine ................................ | 0284 | 8.02 | \$388.87 | \$257.39 | \$77.77 |
| 72156 | S | Magnetic image, neck spine ................................... | 0284 | 8.02 | \$388.87 | \$257.39 | \$77.77 |
| 72157 | S | Magnetic image, chest spine .................................. | 0284 | 8.02 | \$388.87 | \$257.39 | \$77.77 |
| 72158 | S | Magnetic image, lumbar spine ................................ | 0284 | 8.02 | \$388.87 | \$257.39 | \$77.77 |
| 72159 | E | Magnetic image, spine (mra) .................................. |  |  |  |  |  |
| 72170 | X | X-ray exam of pelvis ............................................. | 0260 | 0.79 | \$38.30 | \$22.02 | \$7.66 |
| 72190 | X | X-ray exam of pelvis .............................................. | 0260 | 0.79 | \$38.30 | \$22.02 | \$7.66 |
| 72192 | S | CAT scan of pelvis ............................................... | 0283 | 4.89 | \$237.10 | \$179.39 | \$47.42 |
| 72193 | S | Contrast CAT scan of pelvis ................................... | 0283 | 4.89 | \$237.10 | \$179.39 | \$47.42 |
| 72194 | S | Contrast CAT scans of pelvis ................................. | 0283 | 4.89 | \$237.10 | \$179.39 | \$47.42 |
| 72196 | S | Magnetic image, pelvis .......................................... | 0284 | 8.02 | \$388.87 | \$257.39 | \$77.77 |
| 72198 | E | Magnetic image, pelvis (mra) ................................. |  |  |  |  |  |
| 72200 | X | X-ray exam sacroiliac joints .................................... | 0260 | 0.79 | \$38.30 | \$22.02 | \$7.66 |
| 72202 | X | X-ray exam sacroiliac joints .................................... | 0260 | 0.79 | \$38.30 | \$22.02 | \$7.66 |
| 72220 | X | X-ray exam of tailbone .......................................... | 0260 | 0.79 | \$38.30 | \$22.02 | \$7.66 |

[^198]
## Addendum B.-Hospital Outpatient Department (HOPD) Payment Status by HCPCS Code and Related Information-Continued

| $\begin{gathered} \text { CPT/ } \\ \text { HCPCS } \end{gathered}$ | HOPD Status Indicator | Description | APC | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 72240 | S | Contrast x-ray of neck spine | 0274 | 4.83 | \$234.19 | \$128.12 | \$46.84 |
| 72255 | S | Contrast x-ray, thorax spine | 0274 | 4.83 | \$234.19 | \$128.12 | \$46.84 |
| 72265 | S | Contrast x-ray, lower spine . | 0274 | 4.83 | \$234.19 | \$128.12 | \$46.84 |
| 72270 | S | Contrast x -ray of spine ...... | 0274 | 4.83 | \$234.19 | \$128.12 | \$46.84 |
| 72275 | S | Epidurography | 0274 | 4.83 | \$234.19 | \$128.12 | \$46.84 |
| 72285 | S | X-ray c/t spine disk | 0274 | 4.83 | \$234.19 | \$128.12 | \$46.84 |
| 72295 | S | X-ray of lower spine disk | 0274 | 4.83 | \$234.19 | \$128.12 | \$46.84 |
| 73000 | X | X-ray exam of collar bone | 0260 | 0.79 | \$38.30 | \$22.02 | \$7.66 |
| 73010 | X | X-ray exam of shoulder blade | 0260 | 0.79 | \$38.30 | \$22.02 | \$7.66 |
| 73020 | X | X-ray exam of shoulder | 0260 | 0.79 | \$38.30 | \$22.02 | \$7.66 |
| 73030 | X | X-ray exam of shoulder | 0260 | 0.79 | \$38.30 | \$22.02 | \$7.66 |
| 73040 | S | Contrast x-ray of shoulder | 0275 | 2.74 | \$132.85 | \$72.26 | \$26.57 |
| 73050 | X | X-ray exam of shoulders | 0260 | 0.79 | \$38.30 | \$22.02 | \$7.66 |
| 73060 | X | X-ray exam of humerus | 0260 | 0.79 | \$38.30 | \$22.02 | \$7.66 |
| 73070 | X | X-ray exam of elbow ..... | 0260 | 0.79 | \$38.30 | \$22.02 | \$7.66 |
| 73080 | X | X-ray exam of elbow | 0260 | 0.79 | \$38.30 | \$22.02 | \$7.66 |
| 73085 | S | Contrast x-ray of elbow | 0275 | 2.74 | \$132.85 | \$72.26 | \$26.57 |
| 73090 | X | X-ray exam of forearm | 0260 | 0.79 | \$38.30 | \$22.02 | \$7.66 |
| 73092 | X | X-ray exam of arm, infant | 0260 | 0.79 | \$38.30 | \$22.02 | \$7.66 |
| 73100 | X | X-ray exam of wrist | 0260 | 0.79 | \$38.30 | \$22.02 | \$7.66 |
| 73110 | X | X-ray exam of wrist | 0260 | 0.79 | \$38.30 | \$22.02 | \$7.66 |
| 73115 | S | Contrast x-ray of wrist | 0275 | 2.74 | \$132.85 | \$72.26 | \$26.57 |
| 73120 | X | X-ray exam of hand | 0260 | 0.79 | \$38.30 | \$22.02 | \$7.66 |
| 73130 | X | X-ray exam of hand | 0260 | 0.79 | \$38.30 | \$22.02 | \$7.66 |
| 73140 | X | X-ray exam of finger(s) | 0260 | 0.79 | \$38.30 | \$22.02 | \$7.66 |
| 73200 | S | CAT scan of arm | 0283 | 4.89 | \$237.10 | \$179.39 | \$47.42 |
| 73201 | S | Contrast CAT scan of arm | 0283 | 4.89 | \$237.10 | \$179.39 | \$47.42 |
| 73202 | S | Contrast CAT scans of arm | 0283 | 4.89 | \$237.10 | \$179.39 | \$47.42 |
| 73220 | S | Magnetic image, arm/hand | 0284 | 8.02 | \$388.87 | \$257.39 | \$77.77 |
| 73221 | S | Magnetic image, joint of arm | 0284 | 8.02 | \$388.87 | \$257.39 | \$77.77 |
| 73225 | E | Magnetic image, upper (mra) .................................. |  |  |  |  |  |
| 73500 | X | X-ray exam of hip | 0260 | 0.79 | \$38.30 | \$22.02 | \$7.66 |
| 73510 | X | X-ray exam of hip | 0260 | 0.79 | \$38.30 | \$22.02 | \$7.66 |
| 73520 | X | X-ray exam of hips | 0260 | 0.79 | \$38.30 | \$22.02 | \$7.66 |
| 73525 | S | Contrast x-ray of hip | 0275 | 2.74 | \$132.85 | \$72.26 | \$26.57 |
| 73530 | X | X-ray exam of hip | 0261 | 1.38 | \$66.91 | \$38.77 | \$13.38 |
| 73540 | X | X-ray exam of pelvis \& hips | 0260 | 0.79 | \$38.30 | \$22.02 | \$7.66 |
| 73542 | S | X-ray exam, sacroiliac joint | 0275 | 2.74 | \$132.85 | \$72.26 | \$26.57 |
| 73550 | X | X-ray exam of thigh ..... | 0260 | 0.79 | \$38.30 | \$22.02 | \$7.66 |
| 73560 | X | X-ray exam of knee, 1 or 2 | 0260 | 0.79 | \$38.30 | \$22.02 | \$7.66 |
| 73562 | X | X-ray exam of knee, 3 | 0260 | 0.79 | \$38.30 | \$22.02 | \$7.66 |
| 73564 | X | X-ray exam, knee, 4 or more | 0260 | 0.79 | \$38.30 | \$22.02 | \$7.66 |
| 73565 | X | X-ray exam of knees | 0260 | 0.79 | \$38.30 | \$22.02 | \$7.66 |
| 73580 | S | Contrast x-ray of knee joint .................................... | 0275 | 2.74 | \$132.85 | \$72.26 | \$26.57 |
| 73590 | X | X-ray exam of lower leg .... | 0260 | 0.79 | \$38.30 | \$22.02 | \$7.66 |
| 73592 | X | X-ray exam of leg, infant | 0261 | 1.38 | \$66.91 | \$38.77 | \$13.38 |
| 73600 | X | X-ray exam of ankle | 0260 | 0.79 | \$38.30 | \$22.02 | \$7.66 |
| 73610 | X | X-ray exam of ankle | 0260 | 0.79 | \$38.30 | \$22.02 | \$7.66 |
| 73615 | S | Contrast x-ray of ankle .......................................... | 0275 | 2.74 | \$132.85 | \$72.26 | \$26.57 |
| 73620 | X | X-ray exam of foot ................................................ | 0260 | 0.79 | \$38.30 | \$22.02 | \$7.66 |
| 73630 | X | X-ray exam of foot | 0260 | 0.79 | \$38.30 | \$22.02 | \$7.66 |
| 73650 | X | X-ray exam of heel ............................................... | 0260 | 0.79 | \$38.30 | \$22.02 | \$7.66 |
| 73660 | X | X-ray exam of toe(s) | 0260 | 0.79 | \$38.30 | \$22.02 | \$7.66 |
| 73700 | S | CAT scan of leg .................................................... | 0283 | 4.89 | \$237.10 | \$179.39 | \$47.42 |
| 73701 | S | Contrast CAT scan of leg ........................................ | 0283 | 4.89 | \$237.10 | \$179.39 | \$47.42 |
| 73702 | S | Contrast CAT scans of leg ..................................... | 0283 | 4.89 | \$237.10 | \$179.39 | \$47.42 |
| 73720 | S | Magnetic image, leg/foot .................................... | 0284 | 8.02 | \$388.87 | \$257.39 | \$77.77 |
| 73721 | S | Magnetic image, joint of leg ................................... | 0284 | 8.02 | \$388.87 | \$257.39 | \$77.77 |
| 73725 | E | Magnetic image/lower (mra) .................................... |  |  |  |  |  |
| 74000 | X | X-ray exam of abdomen | 0260 | 0.79 | \$38.30 | \$22.02 | \$7.66 |
| 74010 | X | X-ray exam of abdomen ........................................ | 0260 | 0.79 | \$38.30 | \$22.02 | \$7.66 |
| 74020 | X | X-ray exam of abdomen ... | 0260 | 0.79 | \$38.30 | \$22.02 | \$7.66 |
| 74022 | X | X-ray exam series, abdomen .................................. | 0261 | 1.38 | \$66.91 | \$38.77 | \$13.38 |
| 74150 | S | CAT scan of abdomen ........................................... | 0283 | 4.89 | \$237.10 | \$179.39 | \$47.42 |
| 74160 | S | Contrast CAT scan of abdomen .............................. | 0283 | 4.89 | \$237.10 | \$179.39 | \$47.42 |
| 74170 | S | Contrast CAT scans, abdomen ............................... | 0283 | 4.89 | \$237.10 | \$179.39 | \$47.42 |
| 74181 | S | Magnetic image/abdomen (mri) ............................... | 0284 | 8.02 | \$388.87 | \$257.39 | \$77.77 |
| 74185 | E | Magnetic image/abdomen (MRA) ............................. |  |  |  |  |  |
| 74190 | X | X-ray exam of peritoneum ...................................... | 0263 | 1.68 | \$81.46 | \$45.88 | \$16.29 |
| 74210 | S | Contrast x-ray exam of throat .................................. | 0276 | 1.79 | \$86.79 | \$49.78 | \$17.36 |
| 74220 | S | Contrast x-ray, esophagus ..................................... | 0276 | 1.79 | \$86.79 | \$49.78 | \$17.36 |
| 74230 | S | Cinema x-ray, throat/esoph .................................... | 0276 | 1.79 | \$86.79 | \$49.78 | \$17.36 |
| 74235 | S | Remove esophagus obstruction .............................. | 0296 | 3.57 | \$173.10 | \$100.25 | \$34.62 |

[^199]
## addendum B.-Hospital Outpatient Department (hopd) Payment Status by hCPCS Code and Related Information-Continued

| CPT/ HCPCS | HOPD Status Indicator | Description | APC | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 74240 | S | X-ray exam, upper gi tract | 0276 | 1.79 | \$86.79 | \$49.78 | \$17.36 |
| 74241 | S | X-ray exam, upper gi tract | 0276 | 1.79 | \$86.79 | \$49.78 | \$17.36 |
| 74245 | S | X-ray exam, upper gi tract | 0277 | 2.47 | \$119.76 | \$69.28 | \$23.95 |
| 74246 | S | Contrast x-ray uppr gi tract | 0276 | 1.79 | \$86.79 | \$49.78 | \$17.36 |
| 74247 | S | Contrast x-ray uppr gi tract | 0276 | 1.79 | \$86.79 | \$49.78 | \$17.36 |
| 74249 | S | Contrast x-ray uppr gi tract | 0277 | 2.47 | \$119.76 | \$69.28 | \$23.95 |
| 74250 | S | X-ray exam of small bowel | 0276 | 1.79 | \$86.79 | \$49.78 | \$17.36 |
| 74251 | S | X-ray exam of small bowel | 0277 | 2.47 | \$119.76 | \$69.28 | \$23.95 |
| 74260 | S | X-ray exam of small bowel | 0277 | 2.47 | \$119.76 | \$69.28 | \$23.95 |
| 74270 | S | Contrast x-ray exam of colon | 0276 | 1.79 | \$86.79 | \$49.78 | \$17.36 |
| 74280 | S | Contrast x-ray exam of colon | 0277 | 2.47 | \$119.76 | \$69.28 | \$23.95 |
| 74283 | S | Contrast x-ray exam of colon .................................. | 0276 | 1.79 | \$86.79 | \$49.78 | \$17.36 |
| 74290 | S | Contrast x-ray, gallbladder | 0276 | 1.79 | \$86.79 | \$49.78 | \$17.36 |
| 74291 | S | Contrast x-rays, gallbladder | 0276 | 1.79 | \$86.79 | \$49.78 | \$17.36 |
| 74300 | C | X-ray bile ducts/pancreas .... |  |  |  |  |  |
| 74301 | C | X-rays at surgery add-on ....... |  |  |  |  |  |
| 74305 | X | X-ray bile ducts/pancreas | 0263 | 1.68 | \$81.46 | \$45.88 | \$16.29 |
| 74320 | X | Contrast $x$-ray of bile ducts | 0264 | 3.83 | \$185.71 | \$108.97 | \$37.14 |
| 74327 | S | X-ray bile stone removal .... | 0296 | 3.57 | \$173.10 | \$100.25 | \$34.62 |
| 74328 | X | X-ray bile duct endoscopy | 0264 | 3.83 | \$185.71 | \$108.97 | \$37.14 |
| 74329 | X | X-ray for pancreas endoscopy | 0264 | 3.83 | \$185.71 | \$108.97 | \$37.14 |
| 74330 | X | X-ray bile/panc endoscopy ..... | 0264 | 3.83 | \$185.71 | \$108.97 | \$37.14 |
| 74340 | X | X-ray guide for Gl tube | 0272 | 1.40 | \$67.88 | \$39.00 | \$13.58 |
| 74350 | X | X-ray guide, stomach tube | 0264 | 3.83 | \$185.71 | \$108.97 | \$37.14 |
| 74355 | X | X-ray guide, intestinal tube | 0264 | 3.83 | \$185.71 | \$108.97 | \$37.14 |
| 74360 | S | X-ray guide, Gl dilation ...... | 0296 | 3.57 | \$173.10 | \$100.25 | \$34.62 |
| 74363 | S | X-ray, bile duct dilation | 0297 | 6.13 | \$297.23 | \$172.51 | \$59.45 |
| 74400 | S | Contrast x-ray, urinary tract | 0278 | 2.85 | \$138.19 | \$81.67 | \$27.64 |
| 74410 | S | Contrast x-ray, urinary tract | 0278 | 2.85 | \$138.19 | \$81.67 | \$27.64 |
| 74415 | S | Contrast x-ray, urinary tract | 0278 | 2.85 | \$138.19 | \$81.67 | \$27.64 |
| 74420 | S | Contrast x-ray, urinary tract | 0278 | 2.85 | \$138.19 | \$81.67 | \$27.64 |
| 74425 | S | Contrast x-ray, urinary tract | 0278 | 2.85 | \$138.19 | \$81.67 | \$27.64 |
| 74430 | S | Contrast x-ray, bladder | 0278 | 2.85 | \$138.19 | \$81.67 | \$27.64 |
| 74440 | S | X-ray, male genital tract | 0278 | 2.85 | \$138.19 | \$81.67 | \$27.64 |
| 74445 | S | X-ray exam of penis | 0278 | 2.85 | \$138.19 | \$81.67 | \$27.64 |
| 74450 | S | X-ray, urethra/bladder | 0278 | 2.85 | \$138.19 | \$81.67 | \$27.64 |
| 74455 | S | X-ray, urethra/bladder | 0278 | 2.85 | \$138.19 | \$81.67 | \$27.64 |
| 74470 | X | X-ray exam of kidney lesion | 0264 | 3.83 | \$185.71 | \$108.97 | \$37.14 |
| 74475 | S | X-ray control, cath insert .... | 0297 | 6.13 | \$297.23 | \$172.51 | \$59.45 |
| 74480 | S | X-ray control, cath insert | 0297 | 6.13 | \$297.23 | \$172.51 | \$59.45 |
| 74485 | S | X-ray guide, GU dilation | 0296 | 3.57 | \$173.10 | \$100.25 | \$34.62 |
| 74710 | X | X-ray measurement of pelvis | 0260 | 0.79 | \$38.30 | \$22.02 | \$7.66 |
| 74740 | X | X-ray, female genital tract | 0264 | 3.83 | \$185.71 | \$108.97 | \$37.14 |
| 74742 | X | X-ray, fallopian tube | 0264 | 3.83 | \$185.71 | \$108.97 | \$37.14 |
| 74775 | S | X-ray exam of perineum | 0278 | 2.85 | \$138.19 | \$81.67 | \$27.64 |
| 75552 | S | Magnetic image, myocardium | 0284 | 8.02 | \$388.87 | \$257.39 | \$77.77 |
| 75553 | S | Magnetic image, myocardium | 0284 | 8.02 | \$388.87 | \$257.39 | \$77.77 |
| 75554 | S | Cardiac MRI/function | 0284 | 8.02 | \$388.87 | \$257.39 | \$77.77 |
| 75555 | S | Cardiac MRI/limited study .................................... | 0284 | 8.02 | \$388.87 | \$257.39 | \$77.77 |
| 75556 | E | Cardiac MRI/flow mapping ..................................... |  |  |  |  |  |
| 75600 | S | Contrast x-ray exam of aorta | 0280 | 14.98 | \$726.34 | \$380.12 | \$145.27 |
| 75605 | S | Contrast x-ray exam of aorta | 0280 | 14.98 | \$726.34 | \$380.12 | \$145.27 |
| 75625 | S | Contrast x-ray exam of aorta | 0280 | 14.98 | \$726.34 | \$380.12 | \$145.27 |
| 75630 | S | X-ray aorta, leg arteries ...................................... | 0280 | 14.98 | \$726.34 | \$380.12 | \$145.27 |
| 75650 | S | Artery x-rays, head \& neck ..................................... | 0280 | 14.98 | \$726.34 | \$380.12 | \$145.27 |
| 75658 | S | Artery x-rays, arm | 0280 | 14.98 | \$726.34 | \$380.12 | \$145.27 |
| 75660 | S | Artery x-rays, head \& neck ............................... | 0279 | 6.30 | \$305.47 | \$174.57 | \$61.09 |
| 75662 | S | Artery x-rays, head \& neck | 0279 | 6.30 | \$305.47 | \$174.57 | \$61.09 |
| 75665 | S | Artery x-rays, head \& neck ..................................... | 0280 | 14.98 | \$726.34 | \$380.12 | \$145.27 |
| 75671 | S | Artery x-rays, head \& neck | 0280 | 14.98 | \$726.34 | \$380.12 | \$145.27 |
| 75676 | S | Artery x-rays, neck .... | 0280 | 14.98 | \$726.34 | \$380.12 | \$145.27 |
| 75680 | S | Artery x-rays, neck ................................................ | 0280 | 14.98 | \$726.34 | \$380.12 | \$145.27 |
| 75685 | S | Artery x-rays, spine ................................................ | 0279 | 6.30 | \$305.47 | \$174.57 | \$61.09 |
| 75705 | S | Artery x-rays, spine ............................................... | 0279 | 6.30 | \$305.47 | \$174.57 | \$61.09 |
| 75710 | S | Artery x-rays, arm/leg ............................................ | 0280 | 14.98 | \$726.34 | \$380.12 | \$145.27 |
| 75716 | S | Artery x-rays, arms/legs ......................................... | 0280 | 14.98 | \$726.34 | \$380.12 | \$145.27 |
| 75722 | S | Artery x-rays, kidney ............................................. | 0280 | 14.98 | \$726.34 | \$380.12 | \$145.27 |
| 75724 | S | Artery x-rays, kidneys ............................................ | 0280 | 14.98 | \$726.34 | \$380.12 | \$145.27 |
| 75726 | S | Artery x-rays, abdomen ......................................... | 0280 | 14.98 | \$726.34 | \$380.12 | \$145.27 |
| 75731 | S | Artery x-rays, adrenal gland ................................... | 0280 | 14.98 | \$726.34 | \$380.12 | \$145.27 |
| 75733 | S | Artery x-rays, adrenals .......................................... | 0280 | 14.98 | \$726.34 | \$380.12 | \$145.27 |
| 75736 | S | Artery x-rays, pelvis .............................................. | 0280 | 14.98 | \$726.34 | \$380.12 | \$145.27 |
| 75741 | S | Artery x-rays, lung ................. | 0279 | 6.30 | \$305.47 | \$174.57 | \$61.09 |

[^200]
## Addendum B.-Hospital Outpatient Department (HOPD) Payment Status by HCPCS Code and Related INFORMATION-Continued

| CPT/ HCPCS | HOPD <br> Status <br> Indicator | Description | APC | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 75743 | S | Artery x-rays, lungs | 0280 | 14.98 | \$726.34 | \$380.12 | \$145.27 |
| 75746 | S | Artery x-rays, lung | 0279 | 6.30 | \$305.47 | \$174.57 | \$61.09 |
| 75756 | S | Artery x-rays, chest | 0279 | 6.30 | \$305.47 | \$174.57 | \$61.09 |
| 75774 | S | Artery x-ray, each vessel | 0280 | 14.98 | \$726.34 | \$380.12 | \$145.27 |
| 75790 | S | Visualize A-V shunt | 0281 | 4.40 | \$213.34 | \$115.16 | \$42.67 |
| 75801 | X | Lymph vessel x-ray, arm/leg | 0264 | 3.83 | \$185.71 | \$108.97 | \$37.14 |
| 75803 | X | Lymph vessel x-ray, arms/legs | 0264 | 3.83 | \$185.71 | \$108.97 | \$37.14 |
| 75805 | X | Lymph vessel x-ray, trunk | 0264 | 3.83 | \$185.71 | \$108.97 | \$37.14 |
| 75807 | X | Lymph vessel x-ray, trunk | 0264 | 3.83 | \$185.71 | \$108.97 | \$37.14 |
| 75809 | X | Nonvascular shunt, x-ray | 0264 | 3.83 | \$185.71 | \$108.97 | \$37.14 |
| 75810 | S | Vein x-ray, spleen/liver .. | 0279 | 6.30 | \$305.47 | \$174.57 | \$61.09 |
| 75820 | S | Vein x-ray, arm/leg | 0281 | 4.40 | \$213.34 | \$115.16 | \$42.67 |
| 75822 | S | Vein x-ray, arms/legs | 0281 | 4.40 | \$213.34 | \$115.16 | \$42.67 |
| 75825 | S | Vein x-ray, trunk ..... | 0279 | 6.30 | \$305.47 | \$174.57 | \$61.09 |
| 75827 | S | Vein x-ray, chest | 0279 | 6.30 | \$305.47 | \$174.57 | \$61.09 |
| 75831 | S | Vein x-ray, kidney | 0279 | 6.30 | \$305.47 | \$174.57 | \$61.09 |
| 75833 | S | Vein x-ray, kidneys | 0279 | 6.30 | \$305.47 | \$174.57 | \$61.09 |
| 75840 | S | Vein x-ray, adrenal gland | 0279 | 6.30 | \$305.47 | \$174.57 | \$61.09 |
| 75842 | S | Vein x-ray, adrenal glands | 0279 | 6.30 | \$305.47 | \$174.57 | \$61.09 |
| 75860 | S | Vein x-ray, neck | 0279 | 6.30 | \$305.47 | \$174.57 | \$61.09 |
| 75870 | S | Vein x-ray, skull | 0279 | 6.30 | \$305.47 | \$174.57 | \$61.09 |
| 75872 | S | Vein x-ray, skull | 0279 | 6.30 | \$305.47 | \$174.57 | \$61.09 |
| 75880 | S | Vein x-ray, eye socket | 0279 | 6.30 | \$305.47 | \$174.57 | \$61.09 |
| 75885 | S | Vein x-ray, liver | 0279 | 6.30 | \$305.47 | \$174.57 | \$61.09 |
| 75887 | S | Vein x-ray, liver | 0280 | 14.98 | \$726.34 | \$380.12 | \$145.27 |
| 75889 | S | Vein x-ray, liver | 0279 | 6.30 | \$305.47 | \$174.57 | \$61.09 |
| 75891 | S | Vein x-ray, liver | 0279 | 6.30 | \$305.47 | \$174.57 | \$61.09 |
| 75893 | N | Venous sampling by catheter |  |  |  |  |  |
| 75894 | S | X-rays, transcath therapy | 0297 | 6.13 | \$297.23 | \$172.51 | \$59.45 |
| 75896 | S | X-rays, transcath therapy | 0297 | 6.13 | \$297.23 | \$172.51 | \$59.45 |
| 75898 | X | Follow-up angiogram | 0264 | 3.83 | \$185.71 | \$108.97 | \$37.14 |
| 75900 | C | Arterial catheter exchange |  |  |  |  |  |
| 75940 | C | X-ray placement, vein filter |  |  |  |  |  |
| 75945 | C | Intravascular us ........ | ................. | .................. | .................. | ...................... | .................... |
| 75946 | C | Intravascular us add-on | ...................... | ..................... | ...................... | ...................... |  |
| 75960 | C | Transcatheter intro, stent |  |  |  |  |  |
| 75961 | C | Retrieval, broken catheter | ............... | .......... | ................... | ...................... | .................... |
| 75962 | C | Repair arterial blockage ...... |  | ...... | ................... | ..................... |  |
| 75964 | C | Repair artery blockage, each |  |  |  |  |  |
| 75966 | C | Repair arterial blockage ... | .................... | .................. | ..................... | ..................... |  |
| 75968 | C | Repair artery blockage, each |  | ...... | ................... | ..................... |  |
| 75970 | C | Vascular biopsy |  |  |  |  |  |
| 75978 | C | Repair venous blockage |  |  |  |  |  |
| 75980 | S | Contrast x-ray exam bile duct | 0297 | 6.13 | \$297.23 | \$172.51 | \$59.45 |
| 75982 | S | Contrast x-ray exam bile duct | 0297 | 6.13 | \$297.23 | \$172.51 | \$59.45 |
| 75984 | S | X-ray control catheter change | 0296 | 3.57 | \$173.10 | \$100.25 | \$34.62 |
| 75989 | X | Abscess drainage under $x$-ray | 0273 | 2.49 | \$120.73 | \$61.02 | \$24.15 |
| 75992 | C | Atherectomy, x-ray exam ... |  |  |  | ...................... |  |
| 75993 | C | Atherectomy, x-ray exam |  |  |  |  |  |
| 75994 | C | Atherectomy, x-ray exam ........................................ | -................... | .................. | .................... | ..................... | .................... |
| 75995 | C | Atherectomy, x-ray exam |  |  |  |  |  |
| 75996 | C | Atherectomy, x-ray exam |  |  |  |  |  |
| 76000 | X | Fluoroscope examination | 0272 | 1.40 | \$67.88 | \$39.00 | \$13.58 |
| 76001 | X | Fluoroscope exam, extensive | 0273 | 2.49 | \$120.73 | \$61.02 | \$24.15 |
| 76003 | X | Needle localization by x-ray | 0272 | 1.40 | \$67.88 | \$39.00 | \$13.58 |
| 76005 | X | Fluoroguide for spine inject | 0273 | 2.49 | \$120.73 | \$61.02 | \$24.15 |
| 76006 | X | X-ray stress view ............ | 0261 | 1.38 | \$66.91 | \$38.77 | \$13.38 |
| 76010 | X | X-ray, nose to rectum | 0260 | 0.79 | \$38.30 | \$22.02 | \$7.66 |
| 76020 | X | X-rays for bone age | 0261 | 1.38 | \$66.91 | \$38.77 | \$13.38 |
| 76040 | X | X-rays, bone evaluation ...... | 0260 | 0.79 | \$38.30 | \$22.02 | \$7.66 |
| 76061 | X | X-rays, bone survey ........ | 0261 | 1.38 | \$66.91 | \$38.77 | \$13.38 |
| 76062 | X | X-rays, bone survey | 0261 | 1.38 | \$66.91 | \$38.77 | \$13.38 |
| 76065 | X | X-rays, bone evaluation | 0261 | 1.38 | \$66.91 | \$38.77 | \$13.38 |
| 76066 | X | Joint(s) survey, single film ........ | 0260 | 0.79 | \$38.30 | \$22.02 | \$7.66 |
| 76070 | E | CT scan, bone density study .... |  |  |  |  |  |
| 76075 | X | Dual energy x-ray study | 0261 | 1.38 | \$66.91 | \$38.77 | \$13.38 |
| 76076 | X | Dual energy x-ray study | 0261 | 1.38 | \$66.91 | \$38.77 | \$13.38 |
| 76078 | X | Photodensitometry | 0261 | 1.38 | \$66.91 | \$38.77 | \$13.38 |
| 76080 | X | X-ray exam of fistula | 0263 | 1.68 | \$81.46 | \$45.88 | \$16.29 |
| 76086 | X | X-ray of mammary duct | 0263 | 1.68 | \$81.46 | \$45.88 | \$16.29 |
| 76088 | X | X-ray of mammary ducts | 0263 | 1.68 | \$81.46 | \$45.88 | \$16.29 |
| 76090 | S | Mammogram, one breast | 0271 | 0.70 | \$33.94 | \$19.50 | \$6.79 |
| 76091 | S | Mammogram, both breasts | 0271 | 0.70 | \$33.94 | \$19.50 | \$6.79 |

[^201]
## Addendum B.-Hospital Outpatient Department (HOPD) Payment Status by hCPCS Code and Related Information-Continued

| CPT/ HCPCS | HOPD <br> Status <br> Indicator | Description | APC | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 76092 | A | Mammogram, screening |  |  |  |  |  |
| 76093 | S | Magnetic image, breast | 0284 | 8.02 | \$388.87 | \$257.39 | \$77.77 |
| 76094 | S | Magnetic image, both breasts | 0284 | 8.02 | \$388.87 | \$257.39 | \$77.77 |
| 76095 | X | Stereotactic breast biopsy | 0264 | 3.83 | \$185.71 | \$108.97 | \$37.14 |
| 76096 | X | X-ray of needle wire, breast | 0263 | 1.68 | \$81.46 | \$45.88 | \$16.29 |
| 76098 | X | X-ray exam, breast specimen | 0260 | 0.79 | \$38.30 | \$22.02 | \$7.66 |
| 76100 | X | X-ray exam of body section | 0261 | 1.38 | \$66.91 | \$38.77 | \$13.38 |
| 76101 | X | Complex body section x-ray | 0263 | 1.68 | \$81.46 | \$45.88 | \$16.29 |
| 76102 | X | Complex body section x-rays .................................. | 0264 | 3.83 | \$185.71 | \$108.97 | \$37.14 |
| 76120 | X | Cinematic x-rays | 0261 | 1.38 | \$66.91 | \$38.77 | \$13.38 |
| 76125 | X | Cinematic x-rays add-on | 0261 | 1.38 | \$66.91 | \$38.77 | \$13.38 |
| 76140 | E | X-ray consultation ......... |  |  |  |  |  |
| 76150 | X | X-ray exam, dry process | 0260 | 0.79 | \$38.30 | \$22.02 | \$7.66 |
| 76350 | N | Special x-ray contrast study |  |  |  |  |  |
| 76355 | S | CAT scan for localization | 0283 | 4.89 | \$237.10 | \$179.39 | \$47.42 |
| 76360 | S | CAT scan for needle biopsy | 0283 | 4.89 | \$237.10 | \$179.39 | \$47.42 |
| 76365 | S | CAT scan for cyst aspiration | 0283 | 4.89 | \$237.10 | \$179.39 | \$47.42 |
| 76370 | S | CAT scan for therapy guide | 0282 | 2.38 | \$115.40 | \$94.51 | \$23.08 |
| 76375 | S | 3D/holograph reconstr add-on | 0282 | 2.38 | \$115.40 | \$94.51 | \$23.08 |
| 76380 | S | CAT scan follow-up study | 0282 | 2.38 | \$115.40 | \$94.51 | \$23.08 |
| 76390 | S | Mr spectroscopy | 0284 | 8.02 | \$388.87 | \$257.39 | \$77.77 |
| 76400 | S | Magnetic image, bone marrow | 0284 | 8.02 | \$388.87 | \$257.39 | \$77.77 |
| 76499 | X | Radiographic procedure | 0260 | 0.79 | \$38.30 | \$22.02 | \$7.66 |
| 76506 | S | Echo exam of head | 0266 | 1.79 | \$86.79 | \$57.35 | \$17.36 |
| 76511 | S | Echo exam of eye | 0266 | 1.79 | \$86.79 | \$57.35 | \$17.36 |
| 76512 | S | Echo exam of eye | 0266 | 1.79 | \$86.79 | \$57.35 | \$17.36 |
| 76513 | S | Echo exam of eye, water bath | 0265 | 1.17 | \$56.73 | \$38.08 | \$11.35 |
| 76516 | S | Echo exam of eye | 0266 | 1.79 | \$86.79 | \$57.35 | \$17.36 |
| 76519 | S | Echo exam of eye | 0266 | 1.79 | \$86.79 | \$57.35 | \$17.36 |
| 76529 | S | Echo exam of eye | 0265 | 1.17 | \$56.73 | \$38.08 | \$11.35 |
| 76536 | S | Echo exam of head and neck | 0265 | 1.17 | \$56.73 | \$38.08 | \$11.35 |
| 76604 | S | Echo exam of chest | 0266 | 1.79 | \$86.79 | \$57.35 | \$17.36 |
| 76645 | S | Echo exam of breast(s) | 0265 | 1.17 | \$56.73 | \$38.08 | \$11.35 |
| 76700 | S | Echo exam of abdomen | 0266 | 1.79 | \$86.79 | \$57.35 | \$17.36 |
| 76705 | S | Echo exam of abdomen | 0266 | 1.79 | \$86.79 | \$57.35 | \$17.36 |
| 76770 | S | Echo exam abdomen back wall | 0266 | 1.79 | \$86.79 | \$57.35 | \$17.36 |
| 76775 | S | Echo exam abdomen back wall | 0266 | 1.79 | \$86.79 | \$57.35 | \$17.36 |
| 76778 | S | Echo exam kidney transplant | 0266 | 1.79 | \$86.79 | \$57.35 | \$17.36 |
| 76800 | S | Echo exam spinal canal ........ | 0266 | 1.79 | \$86.79 | \$57.35 | \$17.36 |
| 76805 | S | Echo exam of pregnant uterus | 0266 | 1.79 | \$86.79 | \$57.35 | \$17.36 |
| 76810 | S | Echo exam of pregnant uterus | 0265 | 1.17 | \$56.73 | \$38.08 | \$11.35 |
| 76815 | S | Echo exam of pregnant uterus | 0265 | 1.17 | \$56.73 | \$38.08 | \$11.35 |
| 76816 | S | Echo exam follow-up/repeat | 0265 | 1.17 | \$56.73 | \$38.08 | \$11.35 |
| 76818 | S | Fetal biophysical profile | 0266 | 1.79 | \$86.79 | \$57.35 | \$17.36 |
| 76825 | S | Echo exam of fetal heart | 0269 | 4.40 | \$213.34 | \$114.01 | \$42.67 |
| 76826 | S | Echo exam of fetal heart | 0269 | 4.40 | \$213.34 | \$114.01 | \$42.67 |
| 76827 | S | Echo exam of fetal heart | 0269 | 4.40 | \$213.34 | \$114.01 | \$42.67 |
| 76828 | S | Echo exam of fetal heart | 0269 | 4.40 | \$213.34 | \$114.01 | \$42.67 |
| 76830 | S | Echo exam, transvaginal ........................................ | 0266 | 1.79 | \$86.79 | \$57.35 | \$17.36 |
| 76831 | S | Echo exam, uterus | 0266 | 1.79 | \$86.79 | \$57.35 | \$17.36 |
| 76856 | S | Echo exam of pelvis | 0266 | 1.79 | \$86.79 | \$57.35 | \$17.36 |
| 76857 | S | Echo exam of pelvis .............................................. | 0265 | 1.17 | \$56.73 | \$38.08 | \$11.35 |
| 76870 | S | Echo exam of scrotum | 0266 | 1.79 | \$86.79 | \$57.35 | \$17.36 |
| 76872 | S | Echo exam, transrectal | 0266 | 1.79 | \$86.79 | \$57.35 | \$17.36 |
| 76873 | S | Echograp trans r, pros study ................................... | 0266 | 1.79 | \$86.79 | \$57.35 | \$17.36 |
| 76880 | S | Echo exam of extremity ......................................... | 0266 | 1.79 | \$86.79 | \$57.35 | \$17.36 |
| 76885 | S | Echo exam, infant hips | 0266 | 1.79 | \$86.79 | \$57.35 | \$17.36 |
| 76886 | S | Echo exam, infant hips .......................................... | 0266 | 1.79 | \$86.79 | \$57.35 | \$17.36 |
| 76930 | X | Echo guide for heart sac tap ................................... | 0268 | 2.23 | \$108.13 | \$69.51 | \$21.63 |
| 76932 | X | Echo guide for heart biopsy | 0268 | 2.23 | \$108.13 | \$69.51 | \$21.63 |
| 76934 | X | Echo guide for chest tap ....................................... | 0268 | 2.23 | \$108.13 | \$69.51 | \$21.63 |
| 76936 | X | Echo guide for artery repair ..... | 0268 | 2.23 | \$108.13 | \$69.51 | \$21.63 |
| 76938 | X | Echo exam for drainage ........................................ | 0268 | 2.23 | \$108.13 | \$69.51 | \$21.63 |
| 76941 | X | Echo guide for transfusion ...................................... | 0268 | 2.23 | \$108.13 | \$69.51 | \$21.63 |
| 76942 | X | Echo guide for biopsy ........................................... | 0268 | 2.23 | \$108.13 | \$69.51 | \$21.63 |
| 76945 | X | Echo guide, villus sampling .................................... | 0268 | 2.23 | \$108.13 | \$69.51 | \$21.63 |
| 76946 | X | Echo guide for amniocentesis ................................. | 0268 | 2.23 | \$108.13 | \$69.51 | \$21.63 |
| 76948 | X | Echo guide, ova aspiration ..................................... | 0268 | 2.23 | \$108.13 | \$69.51 | \$21.63 |
| 76950 | X | Echo guidance radiotherapy ................................... | 0268 | 2.23 | \$108.13 | \$69.51 | \$21.63 |
| 76960 | X | Echo guidance radiotherapy ................................... | 0268 | 2.23 | \$108.13 | \$69.51 | \$21.63 |
| 76965 | X | Echo guidance radiotherapy ................................... | 0268 | 2.23 | \$108.13 | \$69.51 | \$21.63 |
| 76970 | S | Ultrasound exam follow-up ..................................... | 0265 | 1.17 | \$56.73 | \$38.08 | \$11.35 |
| 76975 | S | GI endoscopic ultrasound ....................................... | 0266 | 1.79 | \$86.79 | \$57.35 | \$17.36 |

[^202]Addendum B.-Hospital Outpatient Department (HOPD) Payment Status by hCPCS Code and Related
INFormation-Continued

| CPT/ HCPCS | HOPD Status Indicator | Description | APC | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 76977 | S | Us bone density measure | 0265 | 1.17 | \$56.73 | \$38.08 | \$11.35 |
| 76986 | S | Echo exam at surgery | 0266 | 1.79 | \$86.79 | \$57.35 | \$17.36 |
| 76999 | S | Echo examination procedure | 0266 | 1.79 | \$86.79 | \$57.35 | \$17.36 |
| 77261 | E | Radiation therapy planning ..................................... |  |  |  |  |  |
| 77262 | E | Radiation therapy planning .. | $\ldots$ | ...................... |  |  |  |
| 77263 | E | Radiation therapy planning ..................................... |  |  |  |  |  |
| 77280 | X | Set radiation therapy field. | 0304 | 1.49 | \$72.25 | \$41.52 | \$14.45 |
| 77285 | X | Set radiation therapy field | 0305 | 4.06 | \$196.86 | \$97.50 | \$39.37 |
| 77290 | X | Set radiation therapy field | 0305 | 4.06 | \$196.86 | \$97.50 | \$39.37 |
| 77295 | X | Set radiation therapy field | 0310 | 13.98 | \$677.85 | \$339.05 | \$135.57 |
| 77299 | E | Radiation therapy planning |  |  |  |  |  |
| 77300 | X | Radiation therapy dose plan | 0304 | 1.49 | \$72.25 | \$41.52 | \$14.45 |
| 77305 | X | Radiation therapy dose plan | 0304 | 1.49 | \$72.25 | \$41.52 | \$14.45 |
| 77310 | X | Radiation therapy dose plan | 0304 | 1.49 | \$72.25 | \$41.52 | \$14.45 |
| 77315 | X | Radiation therapy dose plan | 0305 | 4.06 | \$196.86 | \$97.50 | \$39.37 |
| 77321 | X | Radiation therapy port plan | 0305 | 4.06 | \$196.86 | \$97.50 | \$39.37 |
| 77326 | X | Radiation therapy dose plan | 0305 | 4.06 | \$196.86 | \$97.50 | \$39.37 |
| 77327 | X | Radiation therapy dose plan | 0305 | 4.06 | \$196.86 | \$97.50 | \$39.37 |
| 77328 | X | Radiation therapy dose plan | 0305 | 4.06 | \$196.86 | \$97.50 | \$39.37 |
| 77331 | X | Special radiation dosimetry | 0304 | 1.49 | \$72.25 | \$41.52 | \$14.45 |
| 77332 | X | Radiation treatment aid(s) | 0303 | 2.83 | \$137.22 | \$69.28 | \$27.44 |
| 77333 | X | Radiation treatment aid(s) | 0303 | 2.83 | \$137.22 | \$69.28 | \$27.44 |
| 77334 | X | Radiation treatment aid(s) | 0303 | 2.83 | \$137.22 | \$69.28 | \$27.44 |
| 77336 | X | Radiation physics consult | 0311 | 1.32 | \$64.00 | \$31.66 | \$12.80 |
| 77370 | X | Radiation physics consult | 0311 | 1.32 | \$64.00 | \$31.66 | \$12.80 |
| 77399 | X | External radiation dosimetry | 0311 | 1.32 | \$64.00 | \$31.66 | \$12.80 |
| 77401 | S | Radiation treatment delivery | 0300 | 1.98 | $\$ 96.00$ | \$47.72 | \$19.20 |
| 77402 | S | Radiation treatment delivery | 0300 | 1.98 | \$96.00 | \$47.72 | \$19.20 |
| 77403 | S | Radiation treatment delivery | 0300 | 1.98 | \$96.00 | \$47.72 | \$19.20 |
| 77404 | S | Radiation treatment delivery | 0300 | 1.98 | \$96.00 | \$47.72 | \$19.20 |
| 77406 | S | Radiation treatment delivery | 0300 | 1.98 | $\$ 96.00$ | \$47.72 | \$19.20 |
| 77407 | S | Radiation treatment delivery | 0300 | 1.98 | \$96.00 | \$47.72 | \$19.20 |
| 77408 | S | Radiation treatment delivery | 0300 | 1.98 | \$96.00 | \$47.72 | \$19.20 |
| 77409 | S | Radiation treatment delivery | 0300 | 1.98 | \$96.00 | \$47.72 | \$19.20 |
| 77411 | S | Radiation treatment delivery | 0301 | 2.21 | \$107.16 | \$52.53 | \$21.43 |
| 77412 | S | Radiation treatment delivery | 0301 | 2.21 | \$107.16 | \$52.53 | \$21.43 |
| 77413 | S | Radiation treatment delivery | 0301 | 2.21 | \$107.16 | \$52.53 | \$21.43 |
| 77414 | S | Radiation treatment delivery | 0300 | 1.98 | \$96.00 | \$47.72 | \$19.20 |
| 77416 | S | Radiation treatment delivery | 0301 | 2.21 | \$107.16 | \$52.53 | \$21.43 |
| 77417 | X | Radiology port film(s) ............................................. | 0260 | 0.79 | \$38.30 | \$22.02 | \$7.66 |
| 77427 | E | Radiation tx management, x5 |  | ...................... |  |  |  |
| 77431 | E | Radiation therapy management |  |  |  |  |  |
| 77432 | E | Stereotactic radiation trmt ......... |  |  |  |  |  |
| 77470 | S | Special radiation treatment | 0302 | 8.21 | \$398.08 | \$216.55 | \$79.62 |
| 77499 | E | Radiation therapy management |  |  |  |  |  |
| 77520 | S | Proton beam delivery | 0301 | 2.21 | \$107.16 | \$52.53 | \$21.43 |
| 77523 | S | Proton beam delivery ............................................ | 0301 | 2.21 | \$107.16 | \$52.53 | \$21.43 |
| 77600 | S | Hyperthermia treatment | 0314 | 5.88 | \$285.10 | \$150.95 | \$57.02 |
| 77605 | S | Hyperthermia treatment | 0314 | 5.88 | \$285.10 | \$150.95 | \$57.02 |
| 77610 | S | Hyperthermia treatment ......................................... | 0314 | 5.88 | \$285.10 | \$150.95 | \$57.02 |
| 77615 | S | Hyperthermia treatment | 0314 | 5.88 | \$285.10 | \$150.95 | \$57.02 |
| 77620 | S | Hyperthermia treatment | 0314 | 5.88 | \$285.10 | \$150.95 | \$57.02 |
| 77750 | S | Infuse radioactive materials | 0301 | 2.21 | \$107.16 | \$52.53 | \$21.43 |
| 77761 | S | Radioelement application ....................................... | 0312 | 4.09 | \$198.31 | \$109.65 | \$39.66 |
| 77762 | S | Radioelement application | 0312 | 4.09 | \$198.31 | \$109.65 | \$39.66 |
| 77763 | S | Radioelement application | 0312 | 4.09 | \$198.31 | \$109.65 | \$39.66 |
| 77776 | S | Radioelement application ....................................... | 0312 | 4.09 | \$198.31 | \$109.65 | \$39.66 |
| 77777 | S | Radioelement application | 0312 | 4.09 | \$198.31 | \$109.65 | \$39.66 |
| 77778 | S | Radioelement application | 0312 | 4.09 | \$198.31 | \$109.65 | \$39.66 |
| 77781 | S | High intensity brachytherapy .................................. | 0313 | 7.89 | \$382.56 | \$164.02 | \$76.51 |
| 77782 | S | High intensity brachytherapy .... | 0313 | 7.89 | \$382.56 | \$164.02 | \$76.51 |
| 77783 | S | High intensity brachytherapy | 0313 | 7.89 | \$382.56 | \$164.02 | \$76.51 |
| 77784 | S | High intensity brachytherapy .................................. | 0313 | 7.89 | \$382.56 | \$164.02 | \$76.51 |
| 77789 | S | Radioelement application ............. | 0300 | 1.98 | \$96.00 | \$47.72 | \$19.20 |
| 77790 | N | Radioelement handling ..... |  |  |  |  |  |
| 77799 | S | Radium/radioisotope therapy | 0313 | 7.89 | \$382.56 | \$164.02 | \$76.51 |
| 78000 | S | Thyroid, single uptake ........................................... | 0290 | 1.94 | \$94.06 | \$55.51 | \$18.81 |
| 78001 | S | Thyroid, multiple uptakes ....................................... | 0290 | 1.94 | \$94.06 | \$55.51 | \$18.81 |
| 78003 | S | Thyroid suppress/stimul .. | 0290 | 1.94 | \$94.06 | \$55.51 | \$18.81 |
| 78006 | S | Thyroid imaging with uptake ................................... | 0291 | 3.15 | \$152.73 | \$93.14 | \$30.55 |
| 78007 | S | Thyroid image, mult uptakes .................................. | 0291 | 3.15 | \$152.73 | \$93.14 | \$30.55 |
| 78010 | S | Thyroid imaging ...... | 0290 | 1.94 | \$94.06 | \$55.51 | \$18.81 |
| 78011 | S | Thyroid imaging with flow | 0290 | 1.94 | \$94.06 | \$55.51 | \$18.81 |

[^203]
## Addendum B.—Hospital Outpatient Department (HOPD) Payment Status by hCPCS Code and Related Information-Continued

| CPT/ HCPCS | HOPD <br> Status <br> Indicator | Description | APC | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 78015 | S | Thyroid met imaging | 0291 | 3.15 | \$152.73 | \$93.14 | \$30.55 |
| 78016 | S | Thyroid met imaging/studies | 0292 | 4.36 | \$211.40 | \$126.63 | \$42.28 |
| 78018 | S | Thyroid met imaging, body | 0292 | 4.36 | \$211.40 | \$126.63 | \$42.28 |
| 78020 | S | Thyroid met uptake ............ | 0292 | 4.36 | \$211.40 | \$126.63 | \$42.28 |
| 78070 | S | Parathyroid nuclear imaging | 0292 | 4.36 | \$211.40 | \$126.63 | \$42.28 |
| 78075 | S | Adrenal nuclear imaging | 0292 | 4.36 | \$211.40 | \$126.63 | \$42.28 |
| 78099 | S | Endocrine nuclear procedure | 0290 | 1.94 | \$94.06 | \$55.51 | \$18.81 |
| 78102 | S | Bone marrow imaging, Itd ... | 0291 | 3.15 | \$152.73 | \$93.14 | \$30.55 |
| 78103 | S | Bone marrow imaging, mult | 0292 | 4.36 | \$211.40 | \$126.63 | \$42.28 |
| 78104 | S | Bone marrow imaging, body | 0292 | 4.36 | \$211.40 | \$126.63 | \$42.28 |
| 78110 | S | Plasma volume, single | 0291 | 3.15 | \$152.73 | \$93.14 | \$30.55 |
| 78111 | S | Plasma volume, multiple | 0291 | 3.15 | \$152.73 | \$93.14 | \$30.55 |
| 78120 | S | Red cell mass, single .... | 0291 | 3.15 | \$152.73 | \$93.14 | \$30.55 |
| 78121 | S | Red cell mass, multiple | 0291 | 3.15 | \$152.73 | \$93.14 | \$30.55 |
| 78122 | S | Blood volume | 0292 | 4.36 | \$211.40 | \$126.63 | \$42.28 |
| 78130 | S | Red cell survival study | 0292 | 4.36 | \$211.40 | \$126.63 | \$42.28 |
| 78135 | S | Red cell survival kinetics | 0292 | 4.36 | \$211.40 | \$126.63 | \$42.28 |
| 78140 | S | Red cell sequestration | 0292 | 4.36 | \$211.40 | \$126.63 | \$42.28 |
| 78160 | S | Plasma iron turnover . | 0292 | 4.36 | \$211.40 | \$126.63 | \$42.28 |
| 78162 | S | Iron absorption exam | 0292 | 4.36 | \$211.40 | \$126.63 | \$42.28 |
| 78170 | S | Red cell iron utilization | 0292 | 4.36 | \$211.40 | \$126.63 | \$42.28 |
| 78172 | S | Total body iron estimation | 0292 | 4.36 | \$211.40 | \$126.63 | \$42.28 |
| 78185 | S | Spleen imaging | 0291 | 3.15 | \$152.73 | \$93.14 | \$30.55 |
| 78190 | S | Platelet survival, kinetics | 0291 | 3.15 | \$152.73 | \$93.14 | \$30.55 |
| 78191 | S | Platelet survival | 0291 | 3.15 | \$152.73 | \$93.14 | \$30.55 |
| 78195 | S | Lymph system imaging | 0292 | 4.36 | \$211.40 | \$126.63 | \$42.28 |
| 78199 | S | Blood/lymph nuclear exam | 0290 | 1.94 | \$94.06 | \$55.51 | \$18.81 |
| 78201 | S | Liver imaging | 0291 | 3.15 | \$152.73 | \$93.14 | \$30.55 |
| 78202 | S | Liver imaging with flow | 0291 | 3.15 | \$152.73 | \$93.14 | \$30.55 |
| 78205 | S | Liver imaging (3D) | 0292 | 4.36 | \$211.40 | \$126.63 | \$42.28 |
| 78206 | S | Liver image (3D) w/flow | 0292 | 4.36 | \$211.40 | \$126.63 | \$42.28 |
| 78215 | S | Liver and spleen imaging | 0291 | 3.15 | \$152.73 | \$93.14 | \$30.55 |
| 78216 | S | Liver \& spleen image/flow | 0291 | 3.15 | \$152.73 | \$93.14 | \$30.55 |
| 78220 | S | Liver function study | 0292 | 4.36 | \$211.40 | \$126.63 | \$42.28 |
| 78223 | S | Hepatobiliary imaging | 0292 | 4.36 | \$211.40 | \$126.63 | \$42.28 |
| 78230 | S | Salivary gland imaging | 0291 | 3.15 | \$152.73 | \$93.14 | \$30.55 |
| 78231 | S | Serial salivary imaging | 0291 | 3.15 | \$152.73 | \$93.14 | \$30.55 |
| 78232 | S | Salivary gland function exam | 0291 | 3.15 | \$152.73 | \$93.14 | \$30.55 |
| 78258 | S | Esophageal motility study ....................................... | 0291 | 3.15 | \$152.73 | \$93.14 | \$30.55 |
| 78261 | S | Gastric mucosa imaging | 0291 | 3.15 | \$152.73 | \$93.14 | \$30.55 |
| 78262 | S | Gastroesophageal reflux exam | 0291 | 3.15 | \$152.73 | \$93.14 | \$30.55 |
| 78264 | S | Gastric emptying study ...... | 0292 | 4.36 | \$211.40 | \$126.63 | \$42.28 |
| ${ }^{2} 78267$ | T | Breath tst attain/anal c-14 | 0971 | 1.55 | \$75.16 |  | \$15.03 |
| ${ }^{2} 78268$ | T | Breath test analysis, $\mathrm{c}-14$ | 0970 | 0.52 | \$25.21 |  | \$5.04 |
| 78270 | S | Vit B-12 absorption exam ...................................... | 0290 | 1.94 | \$94.06 | \$55.51 | \$18.81 |
| 78271 | S | Vit B-12 absorp exam, IF ....................................... | 0290 | 1.94 | \$94.06 | \$55.51 | \$18.81 |
| 78272 | S | Vit B-12 absorp, combined | 0291 | 3.15 | \$152.73 | \$93.14 | \$30.55 |
| 78278 | S | Acute Gl blood loss imaging | 0292 | 4.36 | \$211.40 | \$126.63 | \$42.28 |
| 78282 | S | Gl protein loss exam ............ | 0290 | 1.94 | \$94.06 | \$55.51 | \$18.81 |
| 78290 | S | Meckel's divert exam | 0291 | 3.15 | \$152.73 | \$93.14 | \$30.55 |
| 78291 | S | Leveen/shunt patency exam | 0292 | 4.36 | \$211.40 | \$126.63 | \$42.28 |
| 78299 | S | GI nuclear procedure ............................................. | 0290 | 1.94 | \$94.06 | \$55.51 | \$18.81 |
| 78300 | S | Bone imaging, limited area ..................................... | 0291 | 3.15 | \$152.73 | \$93.14 | \$30.55 |
| 78305 | S | Bone imaging, multiple areas ................................. | 0292 | 4.36 | \$211.40 | \$126.63 | \$42.28 |
| 78306 | S | Bone imaging, whole body ..................................... | 0292 | 4.36 | \$211.40 | \$126.63 | \$42.28 |
| 78315 | S | Bone imaging, 3 phase ........................................ | 0292 | 4.36 | \$211.40 | \$126.63 | \$42.28 |
| 78320 | S | Bone imaging (3D) | 0292 | 4.36 | \$211.40 | \$126.63 | \$42.28 |
| 78350 | X | Bone mineral, single photon ................................... | 0261 | 1.38 | \$66.91 | \$38.77 | \$13.38 |
| 78351 | E | Bone mineral, dual photon ..................................... |  |  |  |  |  |
| 78399 | S | Musculoskeletal nuclear exam ................................ | 0290 | 1.94 | \$94.06 | \$55.51 | \$18.81 |
| 78414 | S | Non-imaging heart function .................................... | 0292 | 4.36 | \$211.40 | \$126.63 | \$42.28 |
| 78428 | S | Cardiac shunt imaging ........................................... | 0292 | 4.36 | \$211.40 | \$126.63 | \$42.28 |
| 78445 | S | Vascular flow imaging ........................................... | 0291 | 3.15 | \$152.73 | \$93.14 | \$30.55 |
| 78455 | S | Venous thrombosis study ....................................... | 0291 | 3.15 | \$152.73 | \$93.14 | \$30.55 |
| 78456 | S | Acute venous thrombus image ................................ | 0291 | 3.15 | \$152.73 | \$93.14 | \$30.55 |
| 78457 | S | Venous thrombosis imaging ................................... | 0291 | 3.15 | \$152.73 | \$93.14 | \$30.55 |
| 78458 | S | Ven thrombosis images, bilat | 0291 | 3.15 | \$152.73 | \$93.14 | \$30.55 |
| 78459 | E | Heart muscle imaging (PET) .................................. |  |  |  |  |  |
| 78460 | S | Heart muscle blood, single ..................................... | 0286 | 7.28 | \$352.99 | \$200.04 | \$70.60 |
| 78461 | S | Heart muscle blood, multiple ................................... | 0286 | 7.28 | \$352.99 | \$200.04 | \$70.60 |
| 78464 | S | Heart image (3D), single ........................................ | 0286 | 7.28 | \$352.99 | \$200.04 | \$70.60 |
| 78465 | S | Heart image (3D), multiple ..................................... | 0286 | 7.28 | \$352.99 | \$200.04 | \$70.60 |
| 78466 | S | Heart infarct image ............................................... | 0292 | 4.36 | \$211.40 | \$126.63 | \$42.28 |

[^204]
## Addendum B.-Hospital Outpatient Department (HOPD) Payment Status by HCPCS Code and Related INFORMATION-Continued

| $\begin{aligned} & \text { CPT/ } \\ & \text { HCPCS } \end{aligned}$ | HOPD Status Indicator | Description | APC | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 78468 | S | Heart infarct image (ef) | 0292 | 4.36 | \$211.40 | \$126.63 | \$42.28 |
| 78469 | S | Heart infarct image (3D) | 0292 | 4.36 | \$211.40 | \$126.63 | \$42.28 |
| 78472 | S | Gated heart, planar, single | 0286 | 7.28 | \$352.99 | \$200.04 | \$70.60 |
| 78473 | S | Gated heart, multiple | 0286 | 7.28 | \$352.99 | \$200.04 | \$70.60 |
| 78478 | S | Heart wall motion add-on | 0286 | 7.28 | \$352.99 | \$200.04 | \$70.60 |
| 78480 | S | Heart function add-on | 0286 | 7.28 | \$352.99 | \$200.04 | \$70.60 |
| 78481 | S | Heart first pass, single | 0286 | 7.28 | \$352.99 | \$200.04 | \$70.60 |
| 78483 | S | Heart first pass, multiple | 0286 | 7.28 | \$352.99 | \$200.04 | \$70.60 |
| 78491 | E | Heart image (pet), single |  |  |  |  |  |
| 78492 | E | Heart image (pet), multiple |  |  |  |  |  |
| 78494 | S | Heart image, spect ........... | 0296 | 3.57 | \$173.10 | \$100.25 | \$34.62 |
| 78496 | S | Heart first pass add-on | 0296 | 3.57 | \$173.10 | \$100.25 | \$34.62 |
| 78499 | S | Cardiovascular nuclear exam | 0292 | 4.36 | \$211.40 | \$126.63 | \$42.28 |
| 78580 | S | Lung perfusion imaging | 0291 | 3.15 | \$152.73 | \$93.14 | \$30.55 |
| 78584 | S | Lung V/Q image single breath | 0292 | 4.36 | \$211.40 | \$126.63 | \$42.28 |
| 78585 | S | Lung V/Q imaging | 0292 | 4.36 | \$211.40 | \$126.63 | \$42.28 |
| 78586 | S | Aerosol lung image, single | 0292 | 4.36 | \$211.40 | \$126.63 | \$42.28 |
| 78587 | S | Aerosol lung image, multiple | 0292 | 4.36 | \$211.40 | \$126.63 | \$42.28 |
| 78588 | S | Perfusion lung image | 0292 | 4.36 | \$211.40 | \$126.63 | \$42.28 |
| 78591 | S | Vent image, 1 breath, 1 proj | 0291 | 3.15 | \$152.73 | \$93.14 | \$30.55 |
| 78593 | S | Vent image, 1 proj, gas | 0292 | 4.36 | \$211.40 | \$126.63 | \$42.28 |
| 78594 | S | Vent image, mult proj, gas | 0292 | 4.36 | \$211.40 | \$126.63 | \$42.28 |
| 78596 | S | Lung differential function | 0292 | 4.36 | \$211.40 | \$126.63 | \$42.28 |
| 78599 | S | Respiratory nuclear exam | 0291 | 3.15 | \$152.73 | \$93.14 | \$30.55 |
| 78600 | S | Brain imaging, Itd static | 0292 | 4.36 | \$211.40 | \$126.63 | \$42.28 |
| 78601 | S | Brain imaging, Itd w/flow | 0292 | 4.36 | \$211.40 | \$126.63 | \$42.28 |
| 78605 | S | Brain imaging, complete | 0291 | 3.15 | \$152.73 | \$93.14 | \$30.55 |
| 78606 | S | Brain imaging, compl w/flow | 0292 | 4.36 | \$211.40 | \$126.63 | \$42.28 |
| 78607 | S | Brain imaging (3D) | 0292 | 4.36 | \$211.40 | \$126.63 | \$42.28 |
| 78608 | E | Brain imaging (PET) |  |  |  |  |  |
| 78609 | E | Brain imaging (PET) |  |  |  |  |  |
| 78610 | S | Brain flow imaging only | 0291 | 3.15 | \$152.73 | \$93.14 | \$30.55 |
| 78615 | S | Cerebral blood flow imaging | 0292 | 4.36 | \$211.40 | \$126.63 | \$42.28 |
| 78630 | S | Cerebrospinal fluid scan | 0292 | 4.36 | \$211.40 | \$126.63 | \$42.28 |
| 78635 | S | CSF ventriculography | 0292 | 4.36 | \$211.40 | \$126.63 | \$42.28 |
| 78645 | S | CSF shunt evaluation | 0292 | 4.36 | \$211.40 | \$126.63 | \$42.28 |
| 78647 | S | Cerebrospinal fluid scan | 0292 | 4.36 | \$211.40 | \$126.63 | \$42.28 |
| 78650 | S | CSF leakage imaging | 0292 | 4.36 | \$211.40 | \$126.63 | \$42.28 |
| 78655 | S |  | 0292 | 4.36 | \$211.40 | \$126.63 | \$42.28 |
| 78660 | S | Nuclear exam of tear flow | 0291 | 3.15 | \$152.73 | \$93.14 | \$30.55 |
| 78699 | S | Nervous system nuclear exam | 0292 | 4.36 | \$211.40 | \$126.63 | \$42.28 |
| 78700 | S | Kidney imaging, static | 0291 | 3.15 | \$152.73 | \$93.14 | \$30.55 |
| 78701 | S | Kidney imaging with flow | 0291 | 3.15 | \$152.73 | \$93.14 | \$30.55 |
| 78704 | S | Imaging renogram | 0292 | 4.36 | \$211.40 | \$126.63 | \$42.28 |
| 78707 | S | Kidney flow/function image | 0292 | 4.36 | \$211.40 | \$126.63 | \$42.28 |
| 78708 | S | Kidney flow/function image | 0292 | 4.36 | \$211.40 | \$126.63 | \$42.28 |
| 78709 | S | Kidney flow/function image | 0292 | 4.36 | \$211.40 | \$126.63 | \$42.28 |
| 78710 | S | Kidney imaging (3D) | 0292 | 4.36 | \$211.40 | \$126.63 | \$42.28 |
| 78715 | S | Renal vascular flow exam | 0291 | 3.15 | \$152.73 | \$93.14 | \$30.55 |
| 78725 | S | Kidney function study | 0291 | 3.15 | \$152.73 | \$93.14 | \$30.55 |
| 78730 | S | Urinary bladder retention | 0291 | 3.15 | \$152.73 | \$93.14 | \$30.55 |
| 78740 | S | Ureteral reflux study | 0291 | 3.15 | \$152.73 | \$93.14 | \$30.55 |
| 78760 | S | Testicular imaging | 0291 | 3.15 | \$152.73 | \$93.14 | \$30.55 |
| 78761 | S | Testicular imaging/flow .......................................... | 0291 | 3.15 | \$152.73 | \$93.14 | \$30.55 |
| 78799 | S | Genitourinary nuclear exam | 0292 | 4.36 | \$211.40 | \$126.63 | \$42.28 |
| 78800 | S | Tumor imaging, limited area | 0292 | 4.36 | \$211.40 | \$126.63 | \$42.28 |
| 78801 | S | Tumor imaging, mult areas . | 0292 | 4.36 | \$211.40 | \$126.63 | \$42.28 |
| 78802 | S | Tumor imaging, whole body | 0292 | 4.36 | \$211.40 | \$126.63 | \$42.28 |
| 78803 | S | Tumor imaging (3D) | 0292 | 4.36 | \$211.40 | \$126.63 | \$42.28 |
| 78805 | S | Abscess imaging, Itd area .... | 0292 | 4.36 | \$211.40 | \$126.63 | \$42.28 |
| 78806 | S | Abscess imaging, whole body .. | 0292 | 4.36 | \$211.40 | \$126.63 | \$42.28 |
| 78807 | S | Nuclear localization/abscess | 0292 | 4.36 | \$211.40 | \$126.63 | \$42.28 |
| 78810 | E | Tumor imaging (PET) ......... | ........ | ....... |  | ..................... |  |
| 78890 | N | Nuclear medicine data proc ....... |  | ...... |  | .................... |  |
| 78891 | N | Nuclear med data proc |  |  |  |  |  |
| 78990 | N | Provide diag radionuclide(s) ...... |  |  |  |  |  |
| 78999 | S | Nuclear diagnostic exam ..... | 0291 | 3.15 | \$152.73 | \$93.14 | \$30.55 |
| 79000 | S | Init hyperthyroid therapy | 0294 | 5.13 | \$248.74 | \$144.06 | \$49.75 |
| 79001 | S | Repeat hyperthyroid therapy | 0294 | 5.13 | \$248.74 | \$144.06 | \$49.75 |
| 79020 | S | Thyroid ablation ................................................... | 0294 | 5.13 | \$248.74 | \$144.06 | \$49.75 |
| 79030 | S | Thyroid ablation, carcinoma | 0294 | 5.13 | \$248.74 | \$144.06 | \$49.75 |
| 79035 | S | Thyroid metastatic therapy | 0294 | 5.13 | \$248.74 | \$144.06 | \$49.75 |
| 79100 | S | Hematopoetic nuclear therapy | 0294 | 5.13 | \$248.74 | \$144.06 | \$49.75 |

[^205]
# Addendum B.-Hospital Outpatient Department (HOPD) Payment Status by hCPCS Code and Related Information-Continued 

| CPT/ HCPCS | HOPD Status Indicator | Description | APC | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 79200 | S | Intracavitary nuclear trmt | 0295 | 19.85 | \$962.47 | \$609.17 | \$192.49 |
| 79300 | S | Interstitial nuclear therapy | 0294 | 5.13 | \$248.74 | \$144.06 | \$49.75 |
| 79400 | S | Nonhemato nuclear therapy | 0295 | 19.85 | \$962.47 | \$609.17 | \$192.49 |
| 79420 | S | Intravascular nuclear ther | 0295 | 19.85 | \$962.47 | \$609.17 | \$192.49 |
| 79440 | S | Nuclear joint therapy | 0294 | 5.13 | \$248.74 | \$144.06 | \$49.75 |
| 79900 | N | Provide ther radiopharm(s) |  |  |  |  |  |
| 79999 | S | Nuclear medicine therapy | 0294 | 5.13 | \$248.74 | \$144.06 | \$49.75 |
| 80048 | A | Basic metabolic panel . |  |  |  |  |  |
| 80050 | A | General health panel |  |  |  |  |  |
| 80051 | A | Electrolyte panel |  |  |  |  |  |
| 80053 | A | Comprehen metabolic panel |  |  |  |  |  |
| 80055 | A | Obstetric panel .. |  |  |  |  |  |
| 80061 | A | Lipid panel |  |  |  |  |  |
| 80069 | A | Renal function panel |  |  |  |  |  |
| 80072 | A | Arthritis panel .. |  |  |  |  |  |
| 80074 | A | Acute hepatitis panel |  |  |  |  |  |
| 80076 | A | Hepatic function panel |  |  |  |  |  |
| 80090 | A | Torch antibody panel |  |  |  |  |  |
| 80100 | A | Drug screen ....... | .................... | ................... |  |  |  |
| 80101 | A | Drug screen |  |  |  |  |  |
| 80102 | A | Drug confirmation |  |  |  |  |  |
| 80103 | N | Drug analysis, tissue prep |  |  |  |  |  |
| 80150 | A | Assay of amikacin |  |  |  |  |  |
| 80152 | A | Assay of amitriptyline |  |  |  |  |  |
| 80154 | A | Assay of benzodiazepines |  |  |  |  |  |
| 80156 | A | Assay of carbamazepine |  |  |  |  |  |
| 80158 | A | Assay of cyclosporine |  |  |  |  |  |
| 80160 | A | Assay of desipramine |  |  |  |  |  |
| 80162 | A | Assay of digoxin |  |  |  |  |  |
| 80164 | A | Assay, dipropylacetic acid |  |  |  | ..................... |  |
| 80166 | A | Assay of doxepin |  |  |  |  |  |
| 80168 | A | Assay of ethosuximide |  |  |  |  |  |
| 80170 | A | Assay of gentamicin |  | .................... |  | .................... |  |
| 80172 | A | Assay of gold |  | .................. | ..................... | ...................... |  |
| 80174 | A | Assay of imipramine |  |  |  |  |  |
| 80176 | A | Assay of lidocaine |  |  |  |  |  |
| 80178 | A | Assay of lithium |  | .................... |  |  |  |
| 80182 | A | Assay of nortriptyline |  |  |  |  |  |
| 80184 | A | Assay of phenobarbital |  |  |  |  |  |
| 80185 | A | Assay of phenytoin, total |  |  |  |  |  |
| 80186 | A | Assay of phenytoin, free |  |  |  |  |  |
| 80188 | A | Assay of primidone |  |  |  | ... |  |
| 80190 | A | Assay of procainamide |  |  |  |  |  |
| 80192 | A | Assay of procainamide |  |  |  |  |  |
| 80194 | A | Assay of quinidine |  |  |  |  |  |
| 80196 | A | Assay of salicylate |  |  |  |  |  |
| 80197 | A | Assay of tacrolimus |  | .................... |  |  |  |
| 80198 | A | Assay of theophylline |  |  |  |  |  |
| 80200 | A | Assay of tobramycin |  |  |  |  |  |
| 80201 | A | Assay of topiramate |  |  |  |  |  |
| 80202 | A | Assay of vancomycin |  |  |  |  |  |
| 80299 | A | Quantitative assay, drug ........................................ |  |  |  |  |  |
| 80400 | A | Acth stimulation panel ........................................... |  | ..................... |  | .................... |  |
| 80402 | A | Acth stimulation panel |  |  |  |  |  |
| 80406 | A | Acth stimulation panel |  |  |  |  |  |
| 80408 | A | Aldosterone suppression eval ................................. |  |  |  |  |  |
| 80410 | A | Calcitonin stimul panel |  |  |  |  |  |
| 80412 | A | CRH stimulation panel |  |  |  |  |  |
| 80414 | A | Testosterone response |  |  |  | ...................... |  |
| 80415 | A | Estradiol response panel |  |  |  |  |  |
| 80416 | A | Renin stimulation panel |  |  |  |  |  |
| 80417 | A | Renin stimulation panel .. |  |  |  | .................... |  |
| 80418 | A | Pituitary evaluation panel .... |  |  |  | ..................... |  |
| 80420 | A | Dexamethasone panel |  |  |  |  |  |
| 80422 | A | Glucagon tolerance panel |  |  |  |  |  |
| 80424 | A | Glucagon tolerance panel ....................................... | ..................... | .................. |  | ...................... | ................... |
| 80426 | A | Gonadotropin hormone panel | ...................... | ..................... |  |  |  |
| 80428 | A | Growth hormone panel . |  |  |  |  |  |
| 80430 | A | Growth hormone panel | ..................... | .................. |  | . | .................... |
| 80432 | A | Insulin suppression panel ....................................... | ..................... | ...................... | ...................... | ... | ............... |
| 80434 | A | Insulin tolerance panel |  |  |  |  |  |
| 80435 | A | Insulin tolerance panel .......................................... |  |  |  |  |  |
| 80436 | A | Metyrapone panel ....... |  |  |  |  |  |

[^206]
# Addendum B.—Hospital Outpatient Department (HOPD) Payment Status by hCPCS Code and Related Information-Continued 

| CPT/ HCPCS | HOPD Status Indicator | Description | APC | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 80438 | A | TRH stimulation panel |  |  |  |  |  |
| 80439 | A | TRH stimulation panel ............................................ |  |  |  |  |  |
| 80440 | A | TRH stimulation panel |  |  |  |  |  |
| 80500 | X | Lab pathology consultation | 0343 | 0.45 | \$21.82 | \$12.16 | \$4.36 |
| 80502 | X | Lab pathology consultation | 0343 | 0.45 | \$21.82 | \$12.16 | \$4.36 |
| 81000 | A | Urinalysis, nonauto w/scope ................................... |  | ...................... |  | ...................... |  |
| 81001 | A | Urinalysis, auto w/scope ........................................ |  |  |  |  |  |
| 81002 | A | Urinalysis nonauto w/o scope ................................. | ..................... | ..................... | ..................... | ..................... |  |
| 81003 | A | Urinalysis, auto, w/o scope ..................................... |  |  |  |  |  |
| 81005 | A | Urinalysis |  |  |  |  |  |
| 81007 | A | Urine screen for bacteria |  |  |  |  |  |
| 81015 | A | Microscopic exam of urine |  |  |  |  |  |
| 81020 | A | Urinalysis, glass test ........ |  |  |  |  |  |
| 81025 | A | Urine pregnancy test |  |  |  |  |  |
| 81050 | A | Urinalysis, volume measure | ..................... |  | .................... |  |  |
| 81099 | A | Urinalysis test procedure |  |  |  |  |  |
| 82000 | A | Assay of blood acetaldehyde ................................. | .................... |  | .................... | ..................... |  |
| 82003 | A | Assay of acetaminophen ........................................ |  |  |  |  |  |
| 82009 | A | Test for acetone/ketones |  |  |  |  |  |
| 82010 | A | Acetone assay |  |  |  |  |  |
| 82013 | A | Acetylcholinesterase assay |  |  |  |  |  |
| 82016 | A | Acylcarnitines, qual ............................................... |  |  |  |  |  |
| 82017 | A | Acylcarnitines, quant ............................................. |  |  |  |  |  |
| 82024 | A | Assay of acth |  |  |  |  |  |
| 82030 | A | Assay of adp \& amp |  |  |  |  |  |
| 82040 | A | Assay of serum albumin |  |  |  |  |  |
| 82042 | A | Assay of urine albumin .......................................... |  |  |  | .................... |  |
| 82043 | A | Microalbumin, quantitative ...................................... |  |  |  |  |  |
| 82044 | A | Microalbumin, semiquant ........................................ |  |  |  |  |  |
| 82055 | A | Assay of ethanol |  |  |  |  |  |
| 82075 | A | Assay of breath ethanol ......................................... | .................... |  |  | ................... |  |
| 82085 | A | Assay of aldolase ................................................. |  |  |  |  |  |
| 82088 | A | Assay of aldosterone |  |  |  |  |  |
| 82101 | A | Assay of urine alkaloids ......................................... | ..................... | ...................... | .................... | ...................... |  |
| 82103 | A | Alpha-1-antitrypsin, total |  |  |  |  |  |
| 82104 | A | Alpha-1-antitrypsin, pheno ...................................... |  |  |  |  |  |
| 82105 | A | Alpha-fetoprotein, serum ........................................ |  |  | ...................... | ...................... |  |
| 82106 | A | Alpha-fetoprotein, amniotic |  |  |  |  |  |
| 82108 | A | Assay of aluminum ............................................... |  |  |  |  |  |
| 82120 | A | Amines, vaginal fluid qual |  |  |  |  |  |
| 82127 | A | Amino acid, single qual |  |  |  | ...................... |  |
| 82128 | A | Amino acids, mult qual .......................................... |  |  |  |  |  |
| 82131 | A | Amino acids, single quant ...................................... |  |  |  |  |  |
| 82135 | A | Assay, aminolevulinic acid |  |  |  |  |  |
| 82136 | A | Amino acids, quant, 2-5 |  |  | ................... |  |  |
| 82139 | A | Amino acids, quan, 6 or more ................................. |  |  |  |  |  |
| 82140 | A | Assay of ammonia ................................................ |  |  |  |  |  |
| 82143 | A | Amniotic fluid scan |  |  | .................... | .................... |  |
| 82145 | A | Assay of amphetamines ........................................ |  |  |  |  |  |
| 82150 | A | Assay of amylase ................................................ |  |  |  | .................... |  |
| 82154 | A | Androstanediol glucuronide |  |  |  | ..................... |  |
| 82157 | A | Assay of androstenedione ...................................... |  |  |  |  |  |
| 82160 | A | Assay of androsterone .......................................... |  |  |  |  |  |
| 82163 | A | Assay of angiotensin II |  |  |  |  |  |
| 82164 | A | Angiotensin I enzyme test ...................................... |  |  |  |  |  |
| 82172 | A | Assay of apolipoprotein ......................................... |  |  |  |  |  |
| 82175 | A | Assay of arsenic ................................................... |  |  |  | ..................... |  |
| 82180 | A | Assay of ascorbic acid |  |  | ...................... | ...................... |  |
| 82190 | A | Atomic absorption |  |  |  |  |  |
| 82205 | A | Assay of barbiturates ............................................. | ..................... |  | ..................... | $\ldots$ |  |
| 82232 | A | Assay of beta-2 protein | ...................... |  | ...................... | ..................... |  |
| 82239 | A | Bile acids, total ..................................................... |  |  |  |  |  |
| 82240 | A | Bile acids, cholylglycine |  |  |  |  |  |
| 82247 | A | Bilirubin, total ........................................................ | . | ..................... | . | ..................... | ................... |
| 82248 | A | Bilirubin, direct |  |  |  |  |  |
| 82251 | A | Assay of bilirubin .................................................. |  |  |  |  |  |
| 82252 | A | Fecal bilirubin test |  |  |  |  |  |
| 82261 | A | Assay of biotinidase |  |  | ...................... |  |  |
| 82270 | A | Test for blood, feces .............................................. |  |  |  |  |  |
| 82273 | A | Test for blood, other source |  | ...................... | ...................... |  |  |
| 82286 | A | Assay of bradykinin .............................................. | ... | .................... | . | .................... |  |
| 82300 | A | Assay of cadmium | ...................... | ...................... | ...................... | ..................... |  |
| 82306 | A | Assay of vitamin D |  |  |  |  |  |

CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
Copyright American Dental Association. All rights reserved.
${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment.
${ }^{2}$ Not subject to national coinsurance.
${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

# Addendum B.—Hospital Outpatient Department (HOPD) Payment Status by hCPCS Code and Related Information-Continued 

| CPT/ HCPCS | HOPD Status Indicator | Description | APC | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 82307 | A | Assay of vitamin D |  |  |  | ..................... |  |
| 82308 | A | Assay of calcitonin |  |  |  | ...................... |  |
| 82310 | A | Assay of calcium |  |  |  |  |  |
| 82330 | A | Assay of calcium |  |  |  |  |  |
| 82331 | A | Calcium infusion test |  |  |  |  |  |
| 82340 | A | Assay of calcium in urine |  |  |  |  |  |
| 82355 | A | Calculus (stone) analysis |  |  |  |  |  |
| 82360 | A | Calculus (stone) assay .. |  |  |  |  |  |
| 82365 | A | Calculus (stone) assay |  |  |  |  |  |
| 82370 | A | X-ray assay, calculus |  |  |  |  |  |
| 82374 | A | Assay, blood carbon dioxide |  |  |  |  |  |
| 82375 | A | Assay, blood carbon monoxide |  |  |  |  |  |
| 82376 | A | Test for carbon monoxide .. |  | ......... |  |  |  |
| 82378 | A | Carcinoembryonic antigen |  |  |  |  |  |
| 82379 | A | Assay of carnitine . |  |  |  |  |  |
| 82380 | A | Assay of carotene |  |  |  |  |  |
| 82382 | A | Assay, urine catecholamines |  |  |  |  |  |
| 82383 | A | Assay, blood catecholamines |  |  |  |  |  |
| 82384 | A | Assay, three catecholamines |  |  |  | .................... |  |
| 82387 | A | Assay of cathepsin-d |  |  |  |  |  |
| 82390 | A | Assay of ceruloplasmin |  |  |  |  |  |
| 82397 | A | Chemiluminescent assay |  |  |  |  |  |
| 82415 | A | Assay of chloramphenicol |  |  |  |  |  |
| 82435 | A | Assay of blood chloride |  |  |  |  |  |
| 82436 | A | Assay of urine chloride |  |  |  |  |  |
| 82438 | A | Assay, other fluid chlorides |  |  |  | ..................... |  |
| 82441 | A | Test for chlorohydrocarbons |  |  |  |  |  |
| 82465 | A | Assay of serum cholesterol. |  |  |  | .................... |  |
| 82480 | A | Assay, serum cholinesterase |  |  |  |  |  |
| 82482 | A | Assay, rbc cholinesterase |  |  |  |  |  |
| 82485 | A | Assay, chondroitin sulfate |  |  |  |  |  |
| 82486 | A | Gas/liquid chromatography |  |  |  | ..................... |  |
| 82487 | A | Paper chromatography |  |  |  | .................... |  |
| 82488 | A | Paper chromatography |  |  |  |  |  |
| 82489 | A | Thin layer chromatography |  |  |  |  |  |
| 82491 | A | Chromotography, quant, sing |  |  |  | ...................... |  |
| 82492 | A | Chromotography, quant, mult |  |  |  |  |  |
| 82495 | A | Assay of chromium . |  |  |  |  |  |
| 82507 | A | Assay of citrate |  |  |  | .................... |  |
| 82520 | A | Assay of cocaine |  |  |  |  |  |
| 82523 | A | Collagen crosslinks |  |  |  |  |  |
| 82525 | A | Assay of copper |  |  |  | ...................... |  |
| 82528 | A | Assay of corticosterone |  |  |  |  |  |
| 82530 | A | Cortisol, free |  |  |  |  |  |
| 82533 | A | Total cortisol |  |  |  | ...................... |  |
| 82540 | A | Assay of creatine |  |  |  |  |  |
| 82541 | A | Column chromotography, qual |  |  |  |  |  |
| 82542 | A | Column chromotography, quant |  |  |  |  |  |
| 82543 | A | Column chromotograph/isotope |  |  |  | ..................... |  |
| 82544 | A | Column chromotograph/isotope ............................... |  |  |  |  |  |
| 82550 | A | Assay of ck (cpk) |  |  |  |  |  |
| 82552 | A | Assay of cpk in blood |  |  |  | .................... |  |
| 82553 | A | Creatine, MB fraction |  |  |  | ...................... |  |
| 82554 | A | Creatine, isoforms |  |  |  |  |  |
| 82565 | A | Assay of creatinine |  |  |  | ...................... |  |
| 82570 | A | Assay of urine creatinine |  |  |  | ..................... |  |
| 82575 | A | Creatinine clearance test |  |  |  |  |  |
| 82585 | A | Assay of cryofibrinogen |  |  |  | .................... |  |
| 82595 | A | Assay of cryoglobulin. |  |  |  | ...................... |  |
| 82600 | A | Assay of cyanide |  |  |  |  |  |
| 82607 | A | Vitamin B-12 ...... |  |  |  |  |  |
| 82608 | A | $\mathrm{B}-12$ binding capacity |  |  |  |  |  |
| 82615 | A | Test for urine cystines |  |  |  |  |  |
| 82626 | A | Dehydroepiandrosterone |  |  |  |  |  |
| 82627 | A | Dehydroepiandrosterone |  |  |  |  |  |
| 82633 | A | Desoxycorticosterone . |  |  |  | ...................... |  |
| 82634 | A | Deoxycortisol ..... |  |  |  |  |  |
| 82638 | A | Assay of dibucaine number |  |  |  | ..................... |  |
| 82646 | A | Assay of dihydrocodeinone |  |  |  | ...................... |  |
| 82649 | A | Assay of dihydromorphinone .................................. |  |  |  |  |  |
| 82651 | A | Assay of dihydrotestosterone .................................. |  |  |  | ..................... |  |
| 82652 | A | Assay of dihydroxyvitamin d ................................... | ..................... | ..................... | ..................... | ..................... |  |
| 82654 | A | Assay of dimethadione |  |  |  |  |  |

CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
Copyright American Dental Association. All rights reserved.
${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment.
${ }^{2}$ Not subject to national coinsurance.
${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

# Addendum B.—Hospital Outpatient Department (HOPD) Payment Status by hCPCS Code and Related Information-Continued 

| CPT/ HCPCS | HOPD Status Indicator | Description | APC | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 82657 | A | Enzyme cell activity |  |  |  |  |  |
| 82658 | A | Enzyme cell activity, ra . |  |  |  |  |  |
| 82664 | A | Electrophoretic test | .................... | .................... | .................... | ..................... |  |
| 82666 | A | Assay of epiandrosterone |  |  |  |  |  |
| 82668 | A | Assay of erythropoietin |  |  |  |  |  |
| 82670 | A | Assay of estradiol |  |  |  |  |  |
| 82671 | A | Assay of estrogens |  |  |  |  |  |
| 82672 | A | Assay of estrogen ................................................. |  | ..................... | .................... |  |  |
| 82677 | A | Assay of estriol .................................................... |  |  |  |  |  |
| 82679 | A | Assay of estrone |  |  |  |  |  |
| 82690 | A | Assay of ethchlorvynol |  |  |  |  |  |
| 82693 | A | Assay of ethylene glycol |  |  |  |  |  |
| 82696 | A | Assay of etiocholanolone |  |  |  |  |  |
| 82705 | A | Fats/lipids, feces, qual |  |  |  |  |  |
| 82710 | A | Fats/lipids, feces, quant | .................... |  | .................... |  |  |
| 82715 | A | Assay of fecal fat |  |  |  |  |  |
| 82725 | A | Assay of blood fatty acids ...................................... |  |  |  |  |  |
| 82726 | A | Long chain fatty acids ............................................ |  |  |  |  |  |
| 82728 | A | Assay of ferritin |  |  |  |  |  |
| 82731 | A | Assay of fetal fibronectin ........................................ |  |  |  |  |  |
| 82735 | A | Assay of fluoride |  |  |  |  |  |
| 82742 | A | Assay of flurazepam ............................................. |  |  |  |  |  |
| 82746 | A | Blood folic acid serum |  |  |  |  |  |
| 82747 | A | Assay of folic acid, rbc |  |  |  |  |  |
| 82757 | A | Assay of semen fructose |  |  |  |  |  |
| 82759 | A | Assay of rbc galactokinase |  |  |  |  |  |
| 82760 | A | Assay of galactose |  |  |  |  |  |
| 82775 | A | Assay galactose transferase .................................. |  |  |  |  |  |
| 82776 | A | Galactose transferase test ...................................... |  |  |  |  |  |
| 82784 | A | Assay of gammaglobulin igm |  |  |  |  |  |
| 82785 | A | Assay of gammaglobulin ige .................................. |  |  |  | ................... |  |
| 82787 | A | Igg 1, 2, 3 and 4 ................................................... |  |  |  |  |  |
| 82800 | A | Blood pH |  |  |  |  |  |
| 82803 | A | Blood gases: pH, pO2 \& pCO2 ............................... |  |  | ..................... | ..................... |  |
| 82805 | A | Blood gases W/02 saturation |  |  |  |  |  |
| 82810 | A | Blood gases, O2 sat only ....................................... |  |  |  |  |  |
| 82820 | A | Hemoglobin-oxygen affinity .................................... |  |  |  | ...................... |  |
| 82926 | A | Assay of gastric acid |  |  |  | ..................... |  |
| 82928 | A | Assay of gastric acid ............................................ |  |  |  |  |  |
| 82938 | A | Gastrin test |  |  |  |  |  |
| 82941 | A | Assay of gastrin |  |  |  | ..................... |  |
| 82943 | A | Assay of glucagon ................................................ |  |  |  |  |  |
| 82946 | A | Glucagon tolerance test .......................................... |  |  |  |  |  |
| 82947 | A | Assay of glucose, quant |  |  |  | ...................... |  |
| 82948 | A | Reagent strip/blood glucose .................................. |  |  |  |  |  |
| 82950 | A | Glucose test |  |  |  |  |  |
| 82951 | A | Glucose tolerance test (GTT) ................................. |  |  |  |  |  |
| 82952 | A | GTT-added samples |  |  |  | ..................... |  |
| 82953 | A | Glucose-tolbutamide test |  |  |  |  |  |
| 82955 | A | Assay of g6pd enzyme .......................................... |  |  |  | .................... |  |
| 82960 | A | Test for G6PD enzyme |  |  |  | ..................... |  |
| 82962 | A | Glucose blood test ................................................ |  |  |  |  |  |
| 82963 | A | Assay of glucosidase ............................................. |  |  |  |  |  |
| 82965 | A | Assay of gdh enzyme |  |  |  |  |  |
| 82975 | A | Assay of glutamine ............................................... |  |  |  |  |  |
| 82977 | A | Assay of GGT ...................................................... |  |  |  |  |  |
| 82978 | A | Assay of glutathione ............................................. |  |  |  | ..................... |  |
| 82979 | A | Assay, rbc glutathione |  |  | ...................... | ...................... |  |
| 82980 | A | Assay of glutethimide |  |  |  |  |  |
| 82985 | A | Glycated protein ................................................... |  |  | ................... | $\ldots$ |  |
| 83001 | A | Gonadotropin (FSH) | ...................... |  | ...................... | ..................... |  |
| 83002 | A | Gonadotropin (LH) . |  |  |  |  |  |
| 83003 | A | Assay, growth hormone (hgh) ................................. |  |  |  | ...................... |  |
| 83008 | A | Assay of guanosine | . | ..................... | ..................... | ...................... | ................... |
| 83010 | A | Assay of haptoglobin, quant |  |  |  |  |  |
| 83012 | A | Assay of haptoglobins |  |  |  |  |  |
| 83013 | A | H pylori breath tst analysis ..................................... |  | ...................... | . | ...................... |  |
| 83014 | A | H pylori drug admin/collect |  |  | ...................... |  |  |
| 83015 | A | Heavy metal screen ..... |  |  |  |  |  |
| 83018 | A | Quantitative screen, metals | ...................... | ...................... | ...................... | ...................... |  |
| 83020 | A | Hemoglobin electrophoresis | ...................... | ...................... | ...................... | ...................... |  |
| 83021 | A | Hemoglobin chromotography | ...................... | ...................... | ...................... |  |  |
| 83026 | A | Hemoglobin, copper sulfate |  |  |  |  |  |

CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
Copyright American Dental Association. All rights reserved.
${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment.
${ }^{2}$ Not subject to national coinsurance.
${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

# Addendum B.—Hospital Outpatient Department (HOPD) Payment Status by hCPCS Code and Related Information-Continued 

| $\begin{gathered} \text { CPT/' } \\ \text { HCPCS } \end{gathered}$ | HOPD Status Indicator | Description | APC | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 83030 | A | Fetal hemoglobin assay |  |  |  |  |  |
| 83033 | A | Fetal fecal hemoglobin assay ....... |  |  |  |  |  |
| 83036 | A | Glycated hemoglobin test ...... |  |  |  |  |  |
| 83045 | A | Blood methemoglobin test |  |  |  |  |  |
| 83050 | A | Blood methemoglobin assay ..... |  |  |  |  |  |
| 83051 | A | Assay of plasma hemoglobin .... |  |  |  |  |  |
| 83055 | A | Blood sulthemoglobin test ......... |  |  |  |  |  |
| 83060 | A | Blood sulfhemoglobin assay ... |  |  |  |  |  |
| 83065 83068 | A | Assay of hemoglobin heat ... |  |  |  |  |  |
| 83069 | A | Assay of urine hemoglobin |  |  |  |  |  |
| 83070 | A | Assay of hemosiderin, qual |  |  |  |  |  |
| 83071 | A | Assay of hemosiderin, quant .. |  |  |  |  |  |
| 83080 | A | Assay of b hexosaminidase. |  |  |  |  |  |
| 83088 83150 | A | Assay of histamine $\qquad$ |  |  |  |  |  |
| 83491 | A | Assay of corticosteroids .... |  |  |  |  |  |
| 83497 | A | Assay of 5-hiaa |  |  |  |  |  |
| 83498 | A | Assay of progesterone ..... |  |  | ...... | ...................... |  |
|  |  | Assay of progesterone |  |  |  |  |  |
| 83500 83505 | A |  |  |  |  |  |  |
| 83505 83516 | A | Assay, total hydroxyproline .............................................................................. |  |  |  |  |  |
| 83518 | A | Immunoassay, dipstick ..... |  |  |  |  |  |
| 83519 | A | Immunoassay, nonantibody |  |  |  | ........ |  |
| 83520 | A | Immunoassay, RIA ....... |  |  |  |  |  |
| 83525 | A | Assay of insulin |  |  |  |  |  |
| 83527 | A | Assay of insulin .... |  |  |  | .................... |  |
| 83528 |  | Assay of intrinsic factor. |  |  |  |  |  |
| 83550 | A | Assay of iron ...................................................... |  |  |  |  |  |
| 83570 | A | Assay of idh enzyme |  |  |  | .............. |  |
| 83582 | A | Assay of ketogenic steroids |  |  |  |  |  |
| 83586 |  | Assay 17-ketosteroids ...... |  |  |  |  |  |
| 83593 | A | Fractionation, ketosteroids.. |  |  |  |  |  |
| 83605 | A | Assay of lactic acid ............. |  |  |  |  |  |
| 83615 83625 | A | Lactate (LD) (LDH) enzyme |  |  |  |  |  |
| 83632 | A | Placental lactogen $\qquad$ |  |  |  |  |  |
| 83633 | A | Test urine for lactose |  |  |  |  |  |
| 83634 | A | Assay of urine for lactose. |  |  |  |  |  |
| 83655 | A | Assay of lead. |  |  |  | .................... |  |
| 83661 |  | Assay of $1 /$ s ratio ....... |  |  |  |  |  |
| 83662 | A | L/S ratio, foam stability ... |  | ........ | .......... |  |  |
| 83670 83690 | A | Assay of lap enzyme ......................................... |  |  |  |  |  |
| 83690 83715 | A | Assay of lipase .......... |  |  |  | .............. |  |
| 83715 83716 | A | Assay of blood lipoproteins |  |  |  |  |  |
| 83716 83718 | A | Assay of blood lipoproteins ................................... |  |  |  |  |  |
| 83718 83719 | A | Assay of lipoprotein ........ |  |  |  | .................... |  |
| 883721 | A | Assay of blood lipoprotein .................................... |  |  |  |  |  |
| 83727 | A | Assay of Irh hormone |  |  |  |  |  |
| 83735 | A | Assay of magnesium ....... |  |  |  |  |  |
| 83775 | A | Assay of md enzyme ............................................. |  |  |  | ..................... |  |
| 83785 | A | Assay of manganese . |  |  |  | .................... |  |
| 83788 | A | Mass spectrometry qual |  |  |  |  |  |
| 83789 | A | Mass spectrometry quant ........................................ |  |  |  | ..................... |  |
| 83805 | A | Assay of meprobamate ... |  |  |  | ..................... |  |
| 83825 | A | Assay of mercury .............. |  |  |  |  |  |
| 83835 83840 | A | Assay of metanephrines ...................................... |  |  |  | ...... |  |
| 83840 8385 | A | Assay of methadone ....... |  |  |  | ..................... |  |
| 83858 | A | Assay of methsuximide ...... |  |  |  |  |  |
| 83864 | A | Mucopolysaccharides |  |  |  |  |  |
| 83866 | A | Mucopolysaccharides screen. |  |  |  |  |  |
| 83872 | A | Assay synovial fluid mucin .................................... |  | ........ | ..................... | .................... |  |
| 83873 | A | Assay of csf protein ............... |  |  |  |  |  |
| 83874 | A | Assay of myoglobin .... |  |  |  |  |  |
| 83883 | A | Assay, nephelometry not spec | .................. | -.................. | ......... | ..................... |  |
| 83885 | A | Assay of nickel .......... | ................ | ................ |  | ............. |  |
| 83887 83890 | A | Assay of nicotine ...... Molecule isolate |  |  |  |  |  |
| 83891 | A | Molecule isolate nuclei |  |  |  |  |  |

CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
Copyright American Dental Association. All rights reserved.
${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment.
${ }^{2}$ Not subject to national coinsurance.
${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

# Addendum B.—Hospital Outpatient Department (HOPD) Payment Status by hCPCS Code and Related Information-Continued 

| CPT/ HCPCS | HOPD Status Indicator | Description | APC | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 83892 | A | Molecular diagnostics |  |  |  |  |  |
| 83893 | A | Molecule dot/slot/blot |  |  |  |  |  |
| 83894 | A | Molecule gel electrophor | .................... | .................... | ................... | ..................... |  |
| 83896 | A | Molecular diagnostics |  |  |  |  |  |
| 83897 | A | Molecule nucleic transfer |  |  |  |  |  |
| 83898 | A | Molecule nucleic ampli .......................................... |  |  |  |  |  |
| 83901 | A | Molecule nucleic ampli ... |  |  |  |  |  |
| 83902 | A | Molecular diagnostics ........................................... |  | ..................... | .............. |  |  |
| 83903 | A | Molecule mutation scan .......................................... |  |  |  |  |  |
| 83904 | A | Molecule mutation identify |  |  |  |  |  |
| 83905 | A | Molecule mutation identify |  |  |  |  |  |
| 83906 | A | Molecule mutation identify |  |  |  |  |  |
| 83912 | A | Genetic examination |  |  |  |  |  |
| 83915 | A | Assay of nucleotidase |  |  |  |  |  |
| 83916 | A | Oligoclonal bands |  |  | ............... |  |  |
| 83918 | A | Assay, organic acids quant |  |  |  |  |  |
| 83919 | A | Assay, organic acids qual ...................................... |  |  |  |  |  |
| 83925 | A | Assay of opiates ................................................. |  |  |  |  |  |
| 83930 | A | Assay of blood osmolality |  |  |  |  |  |
| 83935 | A | Assay of urine osmolality ........................................ |  |  |  |  |  |
| 83937 | A | Assay of osteocalcin |  |  |  |  |  |
| 83945 | A | Assay of oxalate ................................................... |  |  |  |  |  |
| 83970 | A | Assay of parathormone |  |  |  |  |  |
| 83986 | A | Assay of body fluid acidity |  |  |  |  |  |
| 83992 | A | Assay for phencyclidine |  |  |  |  |  |
| 84022 | A | Assay of phenothiazine |  |  |  |  |  |
| 84030 | A | Assay of blood pku ............................................... |  |  |  |  |  |
| 84035 | A | Assay of phenylketones |  |  |  |  |  |
| 84060 | A | Assay acid phosphatase ....................................... |  |  |  |  |  |
| 84061 | A | Phosphatase, forensic exam |  |  |  |  |  |
| 84066 | A | Assay prostate phosphatase .................................. |  |  |  | .................... |  |
| 84075 | A | Assay alkaline phosphatase ................................... |  |  |  |  |  |
| 84078 | A | Assay alkaline phosphatase |  |  |  |  |  |
| 84080 | A | Assay alkaline phosphatases ................................. |  |  | .................... | ..................... |  |
| 84081 | A | Amniotic fluid enzyme test |  |  |  |  |  |
| 84085 | A | Assay of rbc pg6d enzyme ..................................... |  |  |  |  |  |
| 84087 | A | Assay phosphohexose enzymes ............................. |  |  |  | ...................... |  |
| 84100 | A | Assay of phosphorus ....... |  |  |  | ..................... |  |
| 84105 | A | Assay of urine phosphorus ..................................... |  |  |  |  |  |
| 84106 | A | Test for porphobilinogen |  |  |  |  |  |
| 84110 | A | Assay of porphobilinogen ....................................... |  |  |  | ..................... |  |
| 84119 | A | Test urine for porphyrins |  |  |  |  |  |
| 84120 | A | Assay of urine porphyrins ....................................... |  |  |  |  |  |
| 84126 | A | Assay of feces porphyrins ...................................... |  |  |  |  |  |
| 84127 | A | Assay of feces porphyrins |  |  |  |  |  |
| 84132 | A | Assay of serum potassium ..................................... |  |  |  |  |  |
| 84133 | A | Assay of urine potassium ...................................... |  |  |  |  |  |
| 84134 | A | Assay of prealbumin |  |  |  | ..................... |  |
| 84135 | A | Assay of pregnanediol |  |  |  |  |  |
| 84138 | A | Assay of pregnanetriol ........................................... |  |  |  | .................... |  |
| 84140 | A | Assay of pregnenolone ..... |  |  |  | ..................... |  |
| 84143 | A | Assay of 17-hydroxypregneno ................................ |  |  |  |  |  |
| 84144 | A | Assay of progesterone .......................................... |  |  |  |  |  |
| 84146 | A | Assay of prolactin |  |  |  |  |  |
| 84150 | A | Assay of prostaglandin .......................................... |  |  |  |  |  |
| 84153 | A | Assay of psa, total ................................................ |  |  |  |  |  |
| 84154 | A | Assay of psa, free |  |  |  | ..................... |  |
| 84155 | A | Assay of protein . |  |  | ..................... | ...................... |  |
| 84160 | A | Assay of serum protein |  |  |  |  |  |
| 84165 | A | Assay of serum proteins ......................................... |  |  | .................... | $\ldots$ |  |
| 84181 | A | Western blot test | ...................... |  | ..................... | ...................... |  |
| 84182 | A | Protein, western blot test |  |  |  |  |  |
| 84202 | A | Assay RBC protoporphyrin ..................................... |  |  |  |  |  |
| 84203 | A | Test RBC protoporphyrin ........................................ | . | ..................... | .................... | ..................... |  |
| 84206 | A | Assay of proinsulin |  |  |  |  |  |
| 84207 | A | Assay of vitamin b-6 ............................................ |  |  |  |  |  |
| 84210 | A | Assay of pyruvate ................................................. | ...................... | .................... | ..................... | ...................... |  |
| 84220 | A | Assay of pyruvate kinase |  |  | .................... |  |  |
| 84228 | A | Assay of quinine . |  |  |  |  |  |
| 84233 | A | Assay of estrogen | ...................... | ...................... | ..................... | ...................... |  |
| 84234 | A | Assay of progesterone ....... | ...................... | ...................... | ..................... | ...................... |  |
| 84235 | A | Assay of endocrine hormone . | ...................... | ...................... | ..................... |  |  |
| 84238 | A | Assay, nonendocrine receptor |  |  |  |  |  |

CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
Copyright American Dental Association. All rights reserved.
${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment.
${ }^{2}$ Not subject to national coinsurance.
${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

# Addendum B.—Hospital Outpatient Department (HOPD) Payment Status by hCPCS Code and Related Information-Continued 

| CPT/ HCPCS | HOPD Status Indicator | Description | APC | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 84244 | A | Assay of renin |  |  |  | . |  |
| 84252 | A | Assay of vitamin b-2 |  |  |  | ...................... |  |
| 84255 | A | Assay of selenium |  |  |  |  |  |
| 84260 | A | Assay of serotonin |  |  |  |  |  |
| 84270 | A | Assay of sex hormone globul |  |  |  |  |  |
| 84275 | A | Assay of sialic acid |  |  |  |  |  |
| 84285 | A | Assay of silica ....... |  |  |  |  |  |
| 84295 | A | Assay of serum sodium |  |  |  |  |  |
| 84300 | A | Assay of urine sodium |  |  |  | ..................... |  |
| 84305 | A | Assay of somatomedin |  |  |  |  |  |
| 84307 | A | Assay of somatostatin . |  |  |  |  |  |
| 84311 | A | Spectrophotometry |  |  |  |  |  |
| 84315 | A | Body fluid specific gravity |  |  |  |  |  |
| 84375 | A | Chromatogram assay, sugars |  |  |  |  |  |
| 84376 | A | Sugars, single, qual ... |  |  |  |  |  |
| 84377 | A | Sugars, multiple, qual |  |  |  |  |  |
| 84378 | A | Sugars single quant |  |  |  |  |  |
| 84379 | A | Sugars multiple quant |  |  |  |  |  |
| 84392 | A | Assay of urine sulfate |  |  |  | ..... |  |
| 84402 | A | Assay of testosterone |  |  |  |  |  |
| 84403 | A | Assay of total testosterone |  |  |  |  |  |
| 84425 | A | Assay of vitamin b-1 |  |  |  |  |  |
| 84430 | A | Assay of thiocyanate |  |  |  |  |  |
| 84432 | A | Assay of thyroglobulin |  |  |  |  |  |
| 84436 | A | Assay of total thyroxine |  |  |  |  |  |
| 84437 | A | Assay of neonatal thyroxine |  |  |  | .................... |  |
| 84439 | A | Assay of free thyroxine |  |  |  |  |  |
| 84442 | A | Assay of thyroid activity |  |  |  |  |  |
| 84443 | A | Assay thyroid stim hormone |  |  |  |  |  |
| 84445 | A | Assay of tsi |  |  |  |  |  |
| 84446 | A | Assay of vitamin e |  |  |  |  |  |
| 84449 | A | Assay of transcortin |  |  |  | ..................... |  |
| 84450 | A | Transferase (AST) (SGOT) |  |  |  | .................... |  |
| 84460 | A | Alanine amino (ALT) (SGPT) |  |  |  |  |  |
| 84466 | A | Assay of transferrin . |  |  |  |  |  |
| 84478 | A | Assay of triglycerides |  |  |  | ...................... |  |
| 84479 | A | Assay of thyroid (t3 or t4) |  |  |  |  |  |
| 84480 | A | Assay, triiodothyronine ( t ) |  |  |  |  |  |
| 84481 | A | Free assay (FT-3) .. |  |  |  | ................... |  |
| 84482 | A | T3 reverse |  |  |  |  |  |
| 84484 | A | Assay of troponin, quant |  |  |  |  |  |
| 84485 | A | Assay duodenal fluid trypsin |  |  |  |  |  |
| 84488 | A | Test feces for trypsin |  |  |  |  |  |
| 84490 | A | Assay of feces for trypsin |  |  |  |  |  |
| 84510 | A | Assay of tyrosine .................................................. |  |  |  | .................... |  |
| 84512 | A | Assay of troponin, qual |  |  |  |  |  |
| 84520 | A | Assay of urea nitrogen ... |  |  |  |  |  |
| 84525 | A | Urea nitrogen semi-quant |  |  |  |  |  |
| 84540 | A | Assay of urine/urea-n |  |  |  | .................... |  |
| 84545 | A | Urea-N clearance test |  |  |  |  |  |
| 84550 | A | Assay of blood/uric acid |  |  |  |  |  |
| 84560 | A | Assay of urine/uric acid |  |  |  | .................... |  |
| 84577 | A | Assay of feces/urobilinogen |  |  |  | ...................... |  |
| 84578 | A | Test urine urobilinogen |  |  |  |  |  |
| 84580 | A | Assay of urine urobilinogen |  |  |  | .................... |  |
| 84583 | A | Assay of urine urobilinogen |  |  |  | ...................... |  |
| 84585 | A | Assay of urine vma |  |  |  |  |  |
| 84586 | A | Assay of vip ..... |  |  |  | .................... |  |
| 84588 | A | Assay of vasopressin |  |  |  | ..................... |  |
| 84590 | A | Assay of vitamin a |  |  |  |  |  |
| 84597 | A | Assay of vitamin k ................................................ |  |  |  |  |  |
| 84600 | A | Assay of volatiles |  |  |  |  |  |
| 84620 | A | Xylose tolerance test ............................................. |  |  |  |  |  |
| 84630 | A | Assay of zinc .. |  |  |  |  |  |
| 84681 | A | Assay of c-peptide |  |  |  | ..................... |  |
| 84702 | A | Chorionic gonadotropin test ... |  |  |  | ...................... |  |
| 84703 | A | Chorionic gonadotropin assay |  |  |  |  |  |
| 84830 | A | Ovulation tests ..................................................... |  |  |  |  |  |
| 84999 | A | Clinical chemistry test |  |  |  | ..................... |  |
| 85002 | A | Bleeding time test .................................................. |  |  |  |  |  |
| 85007 | A | Differential WBC count ........................................... |  |  |  |  |  |
| 85008 | A | Nondifferential WBC count ..................................... | ..................... | ... | ..................... | .... |  |
| 85009 | A | Differential WBC count |  |  |  |  |  |

CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
Copyright American Dental Association. All rights reserved.
${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment.
${ }^{2}$ Not subject to national coinsurance.
${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

# Addendum B.—Hospital Outpatient Department (HOPD) Payment Status by hCPCS Code and Related Information-Continued 

| CPT/ HCPCS | HOPD Status Indicator | Description | APC | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 85013 | A | Hematocrit |  |  |  |  |  |
| 85014 | A | Hematocrit |  |  |  |  |  |
| 85018 | A | Hemoglobin | .................... | .................... | ..................... | ..................... | ..................... |
| 85021 | A | Automated hemogram | ...................... |  |  |  |  |
| 85022 | A | Automated hemogram |  |  |  |  |  |
| 85023 | A | Automated hemogram ........................................... |  |  |  |  |  |
| 85024 | A | Automated hemogram .. |  |  |  |  |  |
| 85025 | A | Automated hemogram ........................................... | ..................... | ................... | ...... | .................... |  |
| 85027 | A | Automated hemogram |  |  |  |  |  |
| 85031 | A | Manual hemogram, cbc |  |  |  |  |  |
| 85041 | A | Red blood cell (RBC) count |  |  |  |  |  |
| 85044 | A | Reticulocyte count |  |  |  |  |  |
| 85045 | A | Reticulocyte count |  |  |  |  |  |
| 85046 | A | Reticyte/hgb concentrate |  |  |  |  |  |
| 85048 | A | White blood cell (WBC) count |  |  |  |  |  |
| 85060 | X | Blood smear interpretation | 0342 | 0.26 | \$12.61 | \$8.03 | \$2.52 |
| 85095 | T | Bone marrow aspiration | 0003 | 0.98 | \$47.52 | \$27.99 | \$9.50 |
| 85097 | X | Bone marrow interpretation | 0344 | 0.79 | \$38.30 | \$23.63 | \$7.66 |
| 85102 | T | Bone marrow biopsy | 0003 | 0.98 | \$47.52 | \$27.99 | \$9.50 |
| 85130 | A | Chromogenic substrate assay ................................. |  |  |  |  |  |
| 85170 | A | Blood clot retraction |  |  |  |  |  |
| 85175 | A | Blood clot lysis time .............................................. |  | .................... |  |  |  |
| 85210 | A | Blood clot factor II test |  |  |  |  |  |
| 85220 | A | Blood clot factor V test |  |  |  |  |  |
| 85230 | A | Blood clot factor VII test |  |  | .................... |  |  |
| 85240 | A | Blood clot factor VIII test |  |  |  |  |  |
| 85244 | A | Blood clot factor VIII test ........................................ |  |  |  |  |  |
| 85245 | A | Blood clot factor VIII test |  | .................... | .................... | .................... |  |
| 85246 | A | Blood clot factor VIII test ........................................ |  |  |  |  |  |
| 85247 | A | Blood clot factor VIII test |  |  |  |  |  |
| 85250 | A | Blood clot factor IX test | ................... | ..................... | .................... | ................... |  |
| 85260 | A | Blood clot factor X test |  |  | .................... | .................... |  |
| 85270 | A | Blood clot factor XI test |  |  |  |  |  |
| 85280 | A | Blood clot factor XII test |  |  |  |  |  |
| 85290 | A | Blood clot factor XIII test |  |  |  |  |  |
| 85291 | A | Blood clot factor XIII test ........................................ |  |  |  |  |  |
| 85292 | A | Blood clot factor assay .......................................... |  |  |  |  |  |
| 85293 | A | Blood clot factor assay .......................................... |  |  |  | ..................... |  |
| 85300 | A | Antithrombin III test ................................................ |  |  |  |  |  |
| 85301 | A | Antithrombin III test |  |  |  |  |  |
| 85302 | A | Blood clot inhibitor antigen ..................................... |  |  | . | ...................... |  |
| 85303 | A | Blood clot inhibitor test |  |  |  |  |  |
| 85305 | A | Blood clot inhibitor assay ........................................ |  |  |  |  |  |
| 85306 | A | Blood clot inhibitor test |  |  |  |  |  |
| 85335 | A | Factor inhibitor test |  |  | ................... | .................... |  |
| 85337 | A | Thrombomodulin |  |  |  |  |  |
| 85345 | A | Coagulation time ................................................... |  |  |  |  |  |
| 85347 | A | Coagulation time . |  |  | . | ...................... |  |
| 85348 | A | Coagulation time |  |  |  |  |  |
| 85360 | A | Euglobulin lysis .................................................... |  |  |  | .................... |  |
| 85362 | A | Fibrin degradation products |  |  | .................... | ..................... |  |
| 85366 | A | Fibrinogen test ..................................................... |  |  |  |  |  |
| 85370 | A | Fibrinogen test ...................................................... |  |  |  |  |  |
| 85378 | A | Fibrin degradation |  |  |  |  |  |
| 85379 | A | Fibrin degradation ................................................. |  |  |  |  |  |
| 85384 | A | Fibrinogen |  |  |  |  |  |
| 85385 | A | Fibrinogen ........................................................... |  |  |  |  |  |
| 85390 | A | Fibrinolysins screen |  |  | .................... | ...................... |  |
| 85400 | A | Fibrinolytic plasmin |  |  |  |  |  |
| 85410 | A | Fibrinolytic antiplasmin .......................................... | .................... | ..................... | ................. | .................... |  |
| 85415 | A | Fibrinolytic plasminogen | .................... | ..................... | ...................... | ..................... |  |
| 85420 | A | Fibrinolytic plasminogen ........................................ |  |  |  |  |  |
| 85421 | A | Fibrinolytic plasminogen ......................................... |  |  |  |  |  |
| 85441 | A | Heinz bodies, direct ............................................... | . | ..................... | . | ..................... | .................... |
| 85445 | A | Heinz bodies, induced |  |  |  |  |  |
| 85460 | A | Hemoglobin, fetal ................................................... |  |  |  |  |  |
| 85461 | A | Hemoglobin, fetal ................................................... | ...................... | ...................... | . | .................... | .................... |
| 85475 | A | Hemolysin ... |  |  | ...................... |  |  |
| 85520 | A | Heparin assay |  |  |  |  |  |
| 85525 | A | Heparin ..... | ...................... | ...................... | ...................... | ...................... |  |
| 85530 | A | Heparin-protamine tolerance .................................. | ...................... | ...................... | ...................... | ...................... |  |
| 85535 | A | Iron stain, blood cells ........ | ...................... | ...................... | ...................... | ..................... |  |
| 85540 | A | Wbc alkaline phosphatase |  |  |  |  |  |

CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
Copyright American Dental Association. All rights reserved.
${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment.
${ }^{2}$ Not subject to national coinsurance.
${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

# Addendum B.—Hospital Outpatient Department (HOPD) Payment Status by hCPCS Code and Related INFORMATION-Continued 

| CPT/ HCPCS | HOPD Status Indicator | Description | APC | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 85547 | A | RBC mechanical fragility |  |  |  | ..................... |  |
| 85549 | A | Muramidase |  |  |  | ...................... |  |
| 85555 | A | RBC osmotic fragility |  |  |  |  |  |
| 85557 | A | RBC osmotic fragility |  |  |  |  |  |
| 85576 | A | Blood platelet aggregation |  |  |  |  |  |
| 85585 | A | Blood platelet estimation |  |  |  |  |  |
| 85590 | A | Platelet count, manual |  |  |  |  |  |
| 85595 | A | Platelet count, automated |  |  |  |  |  |
| 85597 | A | Platelet neutralization |  |  |  | .................... |  |
| 85610 | A | Prothrombin time |  |  |  |  |  |
| 85611 | A | Prothrombin test |  |  |  |  |  |
| 85612 | A | Viper venom prothrombin time |  |  |  |  |  |
| 85613 | A | Russell viper venom, diluted |  |  |  |  |  |
| 85635 | A | Reptilase test ...... |  |  |  |  |  |
| 85651 | A | Rbc sed rate, nonautomated |  |  |  |  |  |
| 85652 | A | Rbc sed rate, automated |  |  |  |  |  |
| 85660 | A | RBC sickle cell test |  |  |  |  |  |
| 85670 | A | Thrombin time, plasma |  |  |  |  |  |
| 85675 | A | Thrombin time, titer .. |  |  | . | .................... |  |
| 85705 | A | Thromboplastin inhibition |  |  |  | ...................... |  |
| 85730 | A | Thromboplastin time, partial |  |  |  |  |  |
| 85732 | A | Thromboplastin time, partial |  |  |  | .................... |  |
| 85810 | A | Blood viscosity examination |  |  |  |  |  |
| 85999 | A | Hematology procedure |  |  |  |  |  |
| 86000 | A | Agglutinins, febrile ..... |  |  |  |  |  |
| 86003 | A | Allergen specific lgE |  |  |  | ..................... |  |
| 86005 | A | Allergen specific lgE |  |  |  |  |  |
| 86021 | A | WBC antibody identification |  |  |  | .................... |  |
| 86022 | A | Platelet antibodies |  |  |  |  |  |
| 86023 | A | Immunoglobulin assay |  |  |  |  |  |
| 86038 | A | Antinuclear antibodies |  |  |  |  |  |
| 86039 | A | Antinuclear antibodies (ANA) |  |  |  | ..................... |  |
| 86060 | A | Antistreptolysin o, titer |  |  |  |  |  |
| 86063 | A | Antistreptolysin o, screen |  |  |  |  |  |
| 86077 | X | Physician blood bank service | 0343 | 0.45 | \$21.82 | \$12.16 | \$4.36 |
| 86078 | X | Physician blood bank service | 0344 | 0.79 | \$38.30 | \$23.63 | \$7.66 |
| 86079 | X | Physician blood bank service | 0344 | 0.79 | \$38.30 | \$23.63 | \$7.66 |
| 86140 | A | C-reactive protein |  |  |  |  |  |
| 86147 | A | Cardiolipin antibody |  | .................... |  | .................... |  |
| 86148 | A | Phospholipid antibody |  |  |  |  |  |
| 86155 | A | Chemotaxis assay .... |  |  |  |  |  |
| 86156 | A | Cold agglutinin, screen |  |  |  | ...................... |  |
| 86157 | A | Cold agglutinin, titer |  |  |  |  |  |
| 86160 | A | Complement, antigen |  |  |  |  |  |
| 86161 | A | Complement/function activity |  | ..................... |  | .................... |  |
| 86162 | A | Complement, total (CH50) |  |  |  |  |  |
| 86171 | A | Complement fixation, each |  |  |  |  |  |
| 86185 | A | Counterimmunoelectrophoresis |  |  |  |  |  |
| 86215 | A | Deoxyribonuclease, antibody |  |  |  | ..................... |  |
| 86225 | A | DNA antibody |  |  |  |  |  |
| 86226 | A | DNA antibody, single strand |  |  |  |  |  |
| 86235 | A | Nuclear antigen antibody |  |  |  | .................... |  |
| 86243 | A | Fc receptor |  | ......... |  | ..................... |  |
| 86255 | A | Fluorescent antibody, screen |  |  |  |  |  |
| 86256 | A | Fluorescent antibody, titer ...... |  |  |  | ...................... |  |
| 86277 | A | Growth hormone antibody |  |  |  | ...................... |  |
| 86280 | A | Hemagglutination inhibition |  |  |  |  |  |
| 86308 | A | Heterophile antibodies .. |  |  |  |  |  |
| 86309 | A | Heterophile antibodies |  |  |  | ...................... |  |
| 86310 | A | Heterophile antibodies |  |  |  |  |  |
| 86316 | A | Immunoassay, tumor antigen .. |  |  |  |  |  |
| 86317 | A | Immunoassay, infectious agent |  |  |  |  |  |
| 86318 | A | Immunoassay, infectious agent |  |  |  |  |  |
| 86320 | A | Serum immunoelectrophoresis ................................. |  |  |  |  |  |
| 86325 | A | Other immunoelectrophoresis |  |  |  |  |  |
| 86327 | A | Immunoelectrophoresis assay |  |  |  | ...................... |  |
| 86329 | A | Immunodiffusion .... |  |  |  |  |  |
| 86331 | A | Immunodiffusion ouchterlony .................................. |  |  |  | ..................... |  |
| 86332 | A | Immune complex assay ......................................... |  |  |  | ...................... |  |
| 86334 | A | Immunofixation procedure ...................................... |  |  |  |  |  |
| 86337 | A | Insulin antibodies ................................................... |  |  |  |  |  |
| 86340 | A | Intrinsic factor antibody .......................................... | ...................... | ...................... | ...................... | ..................... |  |
| 86341 | A | Islet cell antibody |  |  |  |  |  |

CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
Copyright American Dental Association. All rights reserved.
${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment
${ }^{2}$ Not subject to national coinsurance.
${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

# Addendum B.—Hospital Outpatient Department (HOPD) Payment Status by hCPCS Code and Related Information-Continued 

| CPT/ HCPCS | HOPD Status Indicator | Description | APC | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 86343 | A | Leukocyte histamine release .. |  |  |  |  |  |
| 86344 | A | Leukocyte phagocytosis ....... |  |  |  |  |  |
| 86353 | A | Lymphocyte transformation | ................... | ... | .......... |  |  |
| 86359 | A | T cells, total count |  |  |  |  |  |
| 86360 | A | T cell, absolute count/ratio |  |  |  |  |  |
| 86361 | A | T cell, absolute count | ....... | $\ldots$ | .... | .................... |  |
| 86376 | A | Microsomal antibody |  |  |  |  |  |
| 86378 | A | Migration inhibitory factor |  |  |  |  |  |
| 86382 | A | Neutralization test, viral .......................................... |  |  |  |  |  |
| 86384 | A | Nitroblue tetrazolium dye |  | .................... | ..................... | .................... |  |
| 86403 | A | Particle agglutination test |  | ...................... | ...................... |  |  |
| 86406 | A | Particle agglutination test .. |  |  |  |  |  |
| 86430 | A | Rheumatoid factor test |  |  |  |  |  |
| 86431 | A | Rheumatoid factor, quant |  |  |  |  |  |
| 86485 | X | Skin test, candida | 0341 | 0.13 | \$6.30 | \$3.67 | \$1.26 |
| 86490 | X | Coccidioidomycosis skin test | 0341 | 0.13 | \$6.30 | \$3.67 | \$1.26 |
| 86510 | X | Histoplasmosis skin test | 0341 | 0.13 | \$6.30 | \$3.67 | \$1.26 |
| 86580 | X | TB intradermal test | 0341 | 0.13 | \$6.30 | \$3.67 | \$1.26 |
| 86585 | X | TB tine test | 0341 | 0.13 | \$6.30 | \$3.67 | \$1.26 |
| 86586 | X | Skin test, unlisted | 0341 | 0.13 | \$6.30 | \$3.67 | \$1.26 |
| 86590 | A | Streptokinase, antibody |  |  |  |  |  |
| 86592 | A | Blood serology, qualitative |  |  |  |  |  |
| 86593 | A | Blood serology, quantitative |  |  |  |  |  |
| 86602 | A | Antinomyces antibody |  |  |  |  |  |
| 86603 | A | Adenovirus antibody |  |  |  |  |  |
| 86606 | A | Aspergillus antibody |  |  |  |  |  |
| 86609 | A | Bacterium antibody |  |  | .................... |  |  |
| 86612 | A | Blastomyces antibody |  |  |  |  |  |
| 86615 | A | Bordetella antibody |  |  |  |  |  |
| 86617 | A | Lyme disease antibody |  |  |  |  |  |
| 86618 | A | Lyme disease antibody |  | ..................... | ................... | ..................... |  |
| 86619 | A | Borrelia antibody . |  |  |  |  |  |
| 86622 | A | Brucella antibody |  | .................... | ..................... | ..................... |  |
| 86625 | A | Campylobacter antibody |  | .................... | ...................... | ...................... |  |
| 86628 | A | Candida antibody |  |  |  |  |  |
| 86631 | A | Chlamydia antibody |  | ..................... |  |  |  |
| 86632 | A | Chlamydia igm antibody ......................................... |  |  | .................... | .................... |  |
| 86635 | A | Coccidioides antibody ............................................ |  |  |  |  |  |
| 86638 | A | Q fever antibody |  |  |  |  |  |
| 86641 | A | Cryptococcus antibody |  |  |  |  |  |
| 86644 | A | CMV antibody ...................................................... |  |  |  |  |  |
| 86645 | A | CMV antibody, IgM |  |  |  |  |  |
| 86648 | A | Diphtheria antibody |  |  |  |  |  |
| 86651 | A | Encephalitis antibody |  |  |  |  |  |
| 86652 | A | Encephalitis antibody |  |  |  |  |  |
| 86653 | A | Encephalitis antibody ............................................. |  |  |  | ..................... |  |
| 86654 | A | Encephalitis antibody |  |  |  | ..................... |  |
| 86658 | A | Enterovirus antibody ............................................. |  |  |  |  |  |
| 86663 | A | Epstein-barr antibody |  |  |  |  |  |
| 86664 | A | Epstein-barr antibody ............................................. |  |  |  |  |  |
| 86665 | A | Epstein-barr antibody ............................................ |  |  |  |  |  |
| 86668 | A | Francisella tularensis |  |  |  |  |  |
| 86671 | A | Fungus antibody ................................................... |  |  |  |  |  |
| 86674 | A | Giardia lamblia antibody |  |  |  |  |  |
| 86677 | A | Helicobacter pylori ............................................... |  |  |  |  |  |
| 86682 | A | Helminth antibody ........... |  |  |  |  |  |
| 86684 | A | Hemophilus influenza |  |  |  | .................... |  |
| 86687 | A | Htlv-i antibody ....................................................... |  |  |  |  |  |
| 86688 | A | Htlv-ii antibody |  |  |  |  |  |
| 86689 | A | HTLV/HIV confirmatory test .................................... |  | .. | . | .................... |  |
| 86692 | A | Hepatitis, delta agent |  |  |  | ...................... |  |
| 86694 | A | Herpes simplex test |  |  |  |  |  |
| 86695 | A | Herpes simplex test ............................................... | ..................... | ...................... | ...................... | ..................... |  |
| 86698 | A | Histoplasma |  | ..................... | ...................... | ...................... |  |
| 86701 | A | HIV-1 |  |  |  |  |  |
| 86702 | A | HIV-2 |  |  |  |  |  |
| 86703 | A | HIV-1/HIV-2, single assay ..................................... |  |  |  | .................... |  |
| 86704 | A | Hep b core antibody, igg/igm |  |  |  |  |  |
| 86705 | A | Hep b core antibody, igm ....... | .................. | ................... | ................... | .................... | ................... |
| 86706 | A | Hep b surface antibody ...... |  | ................... |  | ..................... |  |
| 86707 | A | Hep be antibody |  | .................... | .................... | .................... |  |
| 86708 | A | Hep a antibody, igg/igm .......................................... |  | ..................... |  |  |  |
| 86709 | A | Hep a antibody, igm |  |  |  |  |  |

[^207]
# Addendum B.—Hospital Outpatient Department (HOPD) Payment Status by hCPCS Code and Related INFORMATION-Continued 

| $\begin{gathered} \text { CPT/' } \\ \text { HCPCS } \end{gathered}$ | HOPD Status Indicator | Description | APC | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 86710 | A | Influenza virus antibody |  |  |  |  |  |
| 86713 | A | Legionella antibody ............ |  |  |  |  |  |
| 86717 | A | Leishmania antibody .... |  |  |  |  |  |
| 86720 | A | Leptospira antibody |  |  |  |  |  |
| 86723 | A | Listeria monocytogenes ab .. |  |  |  |  |  |
| 86727 | A | Lymph choriomeningitis ab. |  |  |  |  |  |
| 86729 | A | Lympho venereum antibody |  |  |  |  |  |
| 86732 | A | Mucormycosis antibody ...... |  |  |  |  |  |
|  |  | Mumps antibody ............... |  |  |  |  |  |
| 886741 | A | Mycoplasma antibody .................................................................................... |  |  |  |  |  |
| 86744 | A | Nocardia antibody ........ |  |  |  |  |  |
| 86747 | A | Parvovirus antibody ....... |  |  |  |  |  |
| 86750 | A | Malaria antibody ......... |  |  |  |  |  |
| 86753 | A | Protozoa antibody nos |  |  |  |  |  |
| 86756 | A | Respiratory virus antibody .. |  |  |  | ..................... |  |
| 86759 |  | Rotavirus antibody ...... |  |  |  |  |  |
| 86765 | A | Rubella antibody . Rubeola antibody |  |  |  |  |  |
| 86768 | A | Salmonella antibody .. |  |  |  |  |  |
| 86771 | A | Shigella antibody |  |  |  |  |  |
| 86774 | A | Tetanus antibody ..... |  |  |  |  |  |
| 86777 |  | Toxoplasma antibody |  |  |  |  |  |
| 867781 86781 | A | Toxoplasma antibody, igm Treponema palidum, confirm |  |  |  |  |  |
| 86784 | A | Trichinella antibody ........... |  |  |  |  |  |
| 86787 | A | Varicella-zoster antibody |  |  |  |  |  |
| 86790 | A | Virus antibody nos ........... |  |  |  | .................... |  |
|  |  | Yersinia antibody |  |  |  |  |  |
| 86800 86803 | A | Thyroglobulin antibody .... Hepatitis c ab test ......... |  |  |  |  |  |
| 86804 | A | Hep c ab test, confirm ..... |  |  |  | .............. |  |
| 86805 | A | Lymphocytotoxicity assay |  |  |  |  |  |
| 86806 | A | Lymphocytotoxicity assay ... |  |  |  |  |  |
| 86807 | A | Cytotoxic antibody screening |  |  |  |  |  |
| 86808 86812 | A | Cytotoxic antibody screening ................................. |  |  |  |  |  |
| 86812 86813 | A | HLA typing, A, B, or C ................. | - |  |  |  |  |
| 86816 | A | HLA typing, A, B, or C |  |  |  |  |  |
| 86817 | A | HLA typing, DR/DQ ... |  |  |  |  |  |
| 86821 | A | Lymphocyte culture, mixed |  |  |  |  |  |
| 86822 | A | Lymphocyte culture, primed |  |  |  |  |  |
| 86849 | A | Immunology procedure ..... |  |  |  |  |  |
| 86850 | A | RBC antibody screen ......... |  | ........ | ......... |  |  |
| 86860 | A | RBC antibody elution .......... |  |  |  |  |  |
| 86870 | A | RBC antibody identification |  |  |  |  |  |
| 86880 86885 | A | Coombs test |  |  |  |  |  |
| 86885 86886 | A | Coombs test ...................................................... |  |  |  |  |  |
| 86886 8689 | A | oombs test |  |  |  | .................... |  |
| 86890 86891 | A | Autologous blood process |  |  |  |  |  |
| 86891 86900 | A | Autologous blood, op salvage ................................ | ....... |  |  |  |  |
| 86900 86901 | A | Blood typing, ABO | ....... |  |  | ................... |  |
| 86903 | A | Blood typing, Rh (D) ............................................................................ |  |  |  |  |  |
| 86904 | A | Blood typing, patient serum ... |  |  |  |  |  |
| 86905 | A | Blood typing, RBC antigens |  |  |  |  |  |
| 86906 | A | Blood typing, Rh phenotype .................................. | -..... |  | ........ | ..................... |  |
| 86910 | E | Blood typing, paternity test ... |  |  |  | ..................... |  |
| 86911 | E | Blood typing, antigen system .. |  |  |  |  |  |
| 86915 | A | Bone marrow/stem cell prep .... |  |  |  | ..................... |  |
| 86920 | A | Compatibility test ... |  | ...... |  | .................... |  |
| 86921 | A | Compatibility test... |  |  |  |  |  |
| 86922 | A | Compatibility test .... | .................. |  |  | ....... |  |
| 86927 8693 | A | Plasma, fresh frozen |  | ...... |  | ...... |  |
| 86931 | A | Frozen blood thaw .... |  |  |  |  |  |
| 86932 | A | Frozen blood freeze/thaw |  |  |  |  |  |
| 86940 | A | Hemolysins/agglutinins, auto |  |  |  |  |  |
| 86941 | A | Hemolysins/agglutinins ........ |  | .................... | ........ | .................... |  |
| 86945 | A | Blood productirradiation .... |  |  |  |  |  |
| 86950 | A | Leukacyte transfusion ................................... | -............... | .............. |  |  |  |
| 86965 86970 | A | Pooling blood platelets ...... RBC pretreatment | ..................... |  |  |  |  |

[^208]
# Addendum B.—Hospital Outpatient Department (HOPD) Payment Status by hCPCS Code and Related Information-Continued 

| CPT/ HCPCS | HOPD Status Indicator | Description | APC | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 86971 | A | RBC pretreatment |  |  |  |  |  |
| 86972 | A | RBC pretreatment. |  |  |  |  |  |
| 86975 | A | RBC pretreatment, serum | .................... | .................... | ................... | ..................... |  |
| 86976 | A | RBC pretreatment, serum |  |  |  |  |  |
| 86977 | A | RBC pretreatment, serum |  |  |  |  |  |
| 86978 | A | RBC pretreatment, serum . |  |  |  |  |  |
| 86985 | A | Split blood or products ...... |  |  |  |  |  |
| 86999 | A | Transfusion procedure ........................................... |  | ...... | ..... |  |  |
| 87001 | A | Small animal inoculation ......................................... |  |  |  |  |  |
| 87003 | A | Small animal inoculation |  |  |  |  |  |
| 87015 | A | Specimen concentration ........................................ |  |  |  |  |  |
| 87040 | A | Blood culture for bacteria |  |  |  |  |  |
| 87045 | A | Stool culture for bacteria |  |  |  |  |  |
| 87060 | A | Nose/throat culture, bact |  |  |  |  |  |
| 87070 | A | Culture specimen, bacteria | .................... |  | ............... |  |  |
| 87072 | A | Culture of specimen by kit |  |  |  |  |  |
| 87075 | A | Culture specimen, bacteria ..................................... |  |  |  |  |  |
| 87076 | A | Bacteria identification |  |  |  |  |  |
| 87081 | A | Bacteria culture screen |  |  |  |  |  |
| 87082 | A | Culture of specimen by kit |  |  |  |  |  |
| 87083 | A | Culture of specimen by kit |  |  |  |  |  |
| 87084 | A | Culture of specimen by kit ...................................... |  |  |  |  |  |
| 87085 | A | Culture of specimen by kit |  |  |  |  |  |
| 87086 | A | Urine culture/colony count |  |  |  |  |  |
| 87087 | A | Urine bacteria culture |  |  | ............... |  |  |
| 87088 | A | Urine bacteria culture |  |  |  |  |  |
| 87101 | A | Skin fungus culture ............................................... |  |  |  |  |  |
| 87102 | A | Fungus isolation culture |  |  |  |  |  |
| 87103 | A | Blood fungus culture .............................................. |  |  |  |  |  |
| 87106 | A | Fungus identification |  |  |  |  |  |
| 87109 | A | Mycoplasma culture |  |  |  | .................... |  |
| 87110 | A | Culture, chlamydia ................................................ |  |  |  |  |  |
| 87116 | A | Mycobacteria culture |  |  |  |  |  |
| 87117 | A | Mycobacteria culture ............................................. |  |  | .................... | ...................... |  |
| 87118 | A | Mycobacteria identification |  |  |  |  |  |
| 87140 | A | Culture typing, fluorescent ...................................... |  |  |  |  |  |
| 87143 | A | Culture typing, GLC method .................................... |  |  |  | ...................... |  |
| 87145 | A | Culture typing, phage method |  |  |  |  |  |
| 87147 | A | Culture typing, serologic ......................................... |  |  |  |  |  |
| 87151 | A | Culture typing, serologic |  |  |  |  |  |
| 87155 | A | Culture typing, precipitin ......................................... |  |  |  | ..................... |  |
| 87158 | A | Culture typing, added method ................................. |  |  |  |  |  |
| 87163 | A | Special microbiology culture . |  |  |  |  |  |
| 87164 | A | Dark field examination ........................................... |  |  |  |  |  |
| 87166 | A | Dark field examination |  |  | ................... | ... |  |
| 87174 | A | Endotoxin, bacterial .............................................. |  |  |  |  |  |
| 87175 | A | Assay, endotoxin, bacterial ..................................... |  |  |  |  |  |
| 87176 | A | Endotoxin, bacterial ... |  |  |  | ..................... |  |
| 87177 | A | Ova and parasites smears |  |  |  |  |  |
| 87181 | A | Antibiotic sensitivity, each ....................................... |  |  |  | .................... |  |
| 87184 | A | Antibiotic sensitivity, each |  |  |  | ..................... |  |
| 87186 | A | Antibiotic sensitivity, MIC ........................................ |  |  |  |  |  |
| 87187 | A | Antibiotic sensitivity, MBC ...................................... |  |  |  |  |  |
| 87188 | A | Antibiotic sensitivity, each |  |  |  |  |  |
| 87190 | A | TB antibiotic sensitivity .......................................... |  |  |  |  |  |
| 87192 | A | Antibiotic sensitivity, each ...................................... |  |  |  |  |  |
| 87197 | A | Bactericidal level, serum ......................................... |  |  |  |  |  |
| 87205 | A | Smear, stain \& interpret |  |  | .................. | .................... |  |
| 87206 | A | Smear, stain \& interpret |  |  |  |  |  |
| 87207 | A | Smear, stain \& interpret .......................................... |  |  | ........ | .................... |  |
| 87208 | A | Smear, stain \& interpret | .................... |  | ..................... | ..................... |  |
| 87210 | A | Smear, stain \& interpret ......................................... |  |  |  |  |  |
| 87211 | A | Smear, stain \& interpret .......................................... |  |  |  |  |  |
| 87220 | A | Tissue exam for fungi ............................................ | $\ldots$ | ..................... | .................... | ..................... |  |
| 87230 | A | Assay, toxin or antitoxin |  |  |  |  |  |
| 87250 | A | Virus inoculation for test ........................................ |  |  |  |  |  |
| 87252 | A | Virus inoculation for test | ...................... | ...................... | ..................... | ...................... | ..................... |
| 87253 | A | Virus inoculation for test | ...................... |  | ..................... | ...................... |  |
| 87260 | A | Adenovirus ag, dfa ............................................... |  |  |  |  |  |
| 87265 | A | Pertussis ag, dfa ..... | ...................... | ...................... | ..................... | ...................... |  |
| 87270 | A | Chylmd trach ag, dfa ............................................. | ..................... | ..................... | .................... | ...................... |  |
| 87272 | A | Cryptosporidum ag, dfa | ...................... | ...................... | ..................... |  |  |
| 87274 | A | Herpes simplex ag, dfa |  |  |  |  |  |

[^209]
# Addendum B.—Hospital Outpatient Department (HOPD) Payment Status by hCPCS Code and Related INFORMATION-Continued 

| $\begin{aligned} & \text { CPT/ } \\ & \text { HCPCS } \end{aligned}$ | HOPD Status Indicator | Description | APC | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 87276 | A | Influenza ag, dfa |  |  |  |  |  |
| 87278 | A | Legion pneumo ag, dfa ..... |  |  |  |  |  |
| 87280 | A | Resp syncytial ag, dfa .- |  |  |  |  |  |
| 87285 | A | Trepon pallidum ag, dfa ... |  |  |  |  |  |
| 87290 | A | Varicella ag, dfa ............... |  |  |  |  |  |
| 87299 87301 | A | Ag detection nos, dfa $\qquad$ |  |  |  |  |  |
| 87320 | A | Chylmd trach ag, eia . |  |  |  |  |  |
| 87324 | A | Clostridium ag, eia . |  |  |  |  |  |
| 87328 | A | Cryptospor ag, eia |  |  |  |  |  |
| 87332 | A | Cytomegalovirus ag, eia .... |  |  |  |  |  |
| 87335 | A | E coli 0157 ag , eia ............. |  |  |  |  |  |
| 87338 87340 | A | Hpylori, stool, eia |  |  |  |  |  |
| 887350 | A | Hepatitis be ag, eia |  |  |  |  |  |
| 87380 | A | Hepatitis delta ag, eia |  |  |  |  |  |
| 87385 | A | Histoplasma capsul ag, eia |  |  |  |  |  |
| 87390 | A | Hiv-1 ag, eia ................... |  |  |  |  |  |
| 87391 | A | Hiv-2 ag, eia |  |  |  |  |  |
| 877425 | A | Resp syncytial ag, eia .......................................... |  |  |  |  |  |
| 87430 | A | Strep a ag, eia |  |  |  |  |  |
| 87449 | A | Ag detect nos, eia, mult |  |  |  |  |  |
| 87450 | A | Ag detect nos, eia, single ....................................... |  |  |  |  |  |
| 87470 |  | Bartonella, dna, dir probe .. |  |  |  |  |  |
| 887472 | A |  |  |  |  |  |  |
| 87475 | A | Lyme dis, dna, dir probe |  |  |  |  |  |
| 87476 | A | Lyme dis, dna, amp probe |  |  |  |  |  |
| 87477 | A | Lyme dis, dna, quant ........ | ................... | ...................... | ................... | ..................... |  |
| 87480 | A | Candida, dna, dir probe |  |  |  |  |  |
| 87481 87482 | A | Candida, dna, amp probe |  |  |  |  |  |
| 87485 | A | Chylmd pneum, dna, dir probe |  |  |  |  |  |
| 87486 | A | Chylmd pneum, dna, amp probe |  |  |  |  |  |
| 87487 | A | Chylmd pneum, dna, quant ......... | .................... | ...................... | ...................... | ...................... |  |
| 87490 | A | Chylmd trach, dna, dir probe .. | ........ | .................. |  |  |  |
| 87491 87492 | A | Chylmd trach, dna, amp probe |  |  |  |  |  |
| 87495 | A | Cytomeg, dna, dir probe .... |  |  |  |  |  |
| 87496 | A | Cytomeg, dna, amp probe |  |  |  |  |  |
| 87497 | A | Cytomeg, dna, quant ....... |  |  | ........ |  |  |
| ${ }_{8}^{87510}$ | A | Gardner vag, dna, dir probe |  |  |  |  |  |
| 87511 87512 | A |  |  |  |  |  |  |
| 87515 | A |  |  |  |  |  |  |
| 87516 | A | Hepatitis b, dna, amp probe |  |  |  |  |  |
| 87517 | A | Hepatitis b, dna, quant ....... |  |  |  | ........... |  |
| 87520 | A | Hepatitis c, rna, dir probe |  | ....... |  |  |  |
| 87521 | A | Hepatitis c, rna, amp probe Hepatitis c , rna, quant |  |  |  |  |  |
| 87525 | A | Hepatitis g, dna, dir probe ... |  |  |  |  |  |
| 87526 | A | Hepatitis g, dna, amp probe |  |  |  |  |  |
| 87527 | A | Hepatitis g, dna, quant ......... |  |  |  |  |  |
| 87528 | A | Hsv, dna, dir probe |  |  |  |  |  |
| 87530 | A | Hsv, dna, amp probe. <br> Hsv, dna, quant |  |  |  |  |  |
| 87531 | A | Hhv-6, dna, dir probe |  |  |  |  |  |
| 87532 | A | Hhv-6, dna, amp probe ... |  |  |  |  |  |
| 87533 | A | Hhv-6, dna, quant ....... |  |  |  |  |  |
| 87534 | A | Hiv-1, dna, dir probe |  |  |  |  |  |
| 87535 | A | Hiv-1, dna, amp probe |  |  |  |  |  |
| 87536 87537 | A | Hiv-1, dna, quant |  |  |  |  |  |
| 875378 8 | A | Hiv-2, dna, dir probe ... |  |  |  |  |  |
| 87539 | A | Hiv-2, dna, amp probe . <br> Hiv-2, dna, quant |  |  |  |  |  |
| 87540 | A | Legion pneumo, dna, dir prob |  |  |  |  |  |
| 87541 | A | Legion preumo, dna, amp prob ............................. |  |  |  |  |  |
| 87542 | A | Legion pneumo, dna, quant |  |  |  |  |  |
| 87550 | A | Mycobacteria, dna, dir probe .... |  |  | ..................... |  |  |
| 87551 | A | Mycobacteria, dna, amp probe .... | .................... | .................. | ............... | .................... | .-................ |
| 87552 | A | Mycobacteria, dna, quant |  |  |  |  |  |
| 87555 |  | M.tuberculo, dna, dir prob |  |  |  |  |  |

[^210]
# Addendum B.-Hospital Outpatient Department (HOPD) Payment Status by HCPCS Code and Related INFORMATION-Continued 

| CPT/ <br> HCPCS | HOPD <br> Status <br> Indicator | Description | APC | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 87556 | A | M.tuberculo, dna, amp probe |  | ..................... | . | ..................... |  |
| 87557 | A | M.tuberculo, dna, quant ........ |  |  |  |  |  |
| 87560 | A | M.avium-intra, dna, dir prob |  |  |  |  |  |
| 87561 | A | M.avium-intra, dna, amp prob |  |  |  |  |  |
| 87562 | A | M.avium-intra, dna, quant |  |  |  |  |  |
| 87580 | A | M.pneumon, dna, dir probe |  |  |  |  |  |
| 87581 | A | M.pneumon, dna, amp probe ................................. |  |  |  |  |  |
| 87582 | A | M.pneumon, dna, quant ........................................ |  |  | ..................... |  |  |
| 87590 | A | N.gonorrhoeae, dna, dir prob |  |  |  |  |  |
| 87591 | A | N.gonorrhoeae, dna, amp prob |  |  |  |  |  |
| 87592 | A | N.gonorrhoeae, dna, quant .. |  |  |  |  |  |
| 87620 | A | Hpv, dna, dir probe |  |  |  |  |  |
| 87621 | A | Hpv, dna, amp probe |  |  |  |  |  |
| 87622 | A | Hpv , dna, quant ..... |  |  |  |  |  |
| 87650 | A | Strep a, dna, dir probe .......................................... |  |  |  | . |  |
| 87651 | A | Strep a, dna, amp probe |  |  |  |  |  |
| 87652 | A | Strep a, dna, quant ........ |  |  |  |  |  |
| 87797 | A | Detect agent nos, dna, dir |  |  |  |  |  |
| 87798 | A | Detect agent nos, dna, amp |  |  |  |  |  |
| 87799 | A | Detect agent nos, dna, quant |  |  |  |  |  |
| 87810 | A | Chylmd trach assay w/optic ... |  |  |  |  |  |
| 87850 | A | N. gonorrhoeae assay w/optic |  |  |  | ..................... |  |
| 87880 | A | Strep a assay w/optic |  |  |  |  |  |
| 87899 | A | Agent nos assay w/optic |  |  |  |  |  |
| 87999 | A | Microbiology procedure |  |  |  |  |  |
| 88000 | E | Autopsy (necropsy), gross ...................................... |  |  |  |  |  |
| 88005 | E | Autopsy (necropsy), gross .. |  |  |  |  |  |
| 88007 | E | Autopsy (necropsy), gross |  |  |  |  |  |
| 88012 | E | Autopsy (necropsy), gross |  |  |  | .................... |  |
| 88014 | E | Autopsy (necropsy), gross |  |  |  |  |  |
| 88016 | E | Autopsy (necropsy), gross |  |  |  |  |  |
| 88020 | E | Autopsy (necropsy), complete |  |  |  | ..................... |  |
| 88025 | E | Autopsy (necropsy), complete |  |  |  |  |  |
| 88027 | E | Autopsy (necropsy), complete |  |  |  | .................... |  |
| 88028 | E | Autopsy (necropsy), complete |  |  |  | ..................... |  |
| 88029 | E | Autopsy (necropsy), complete |  |  |  |  |  |
| 88036 | E | Limited autopsy |  |  |  |  |  |
| 88037 | E | Limited autopsy |  |  |  | ...................... |  |
| 88040 | E | Forensic autopsy (necropsy) |  |  |  |  |  |
| 88045 | E | Coroner's autopsy (necropsy) |  |  |  |  |  |
| 88099 | E | Necropsy (autopsy) procedure ................................ |  |  |  |  |  |
| 88104 | X | Cytopathology, fluids ............................................ | 0343 | 0.45 | \$21.82 | \$12.16 | \$4.36 |
| 88106 | X | Cytopathology, fluids | 0343 | 0.45 | \$21.82 | \$12.16 | \$4.36 |
| 88107 | X | Cytopathology, fluids | 0343 | 0.45 | \$21.82 | \$12.16 | \$4.36 |
| 88108 | X | Cytopath, concentrate tech .................................... | 0343 | 0.45 | \$21.82 | \$12.16 | \$4.36 |
| 88125 | X | Forensic cytopathology | 0343 | 0.45 | \$21.82 | \$12.16 | \$4.36 |
| 88130 | A | Sex chromatin identification |  |  |  |  |  |
| 88140 | A | Sex chromatin identification |  |  |  | ...................... |  |
| 88141 | N | Cytopath, c/v, interpret .......................................... |  |  |  |  |  |
| 88142 | A | Cytopath, c/v, thin layer ......................................... |  |  |  |  |  |
| 88143 | A | Cytopath c/v thin layer redo ................................... |  |  |  | .................... |  |
| 88144 | A | Cytopath, c/v thin lyr redo ...................................... |  |  |  | ..................... |  |
| 88145 | A | Cytopath, $\mathrm{c} / \mathrm{v}$ thin lyr sel ....... |  |  |  |  |  |
| 88147 | A | Cytopath, c/v, automated ...................................... |  |  |  | .................... |  |
| 88148 | A | Cytopath, c/v, auto rescreen .................................. |  |  |  | ...................... |  |
| 88150 | A | Cytopath, c/v, manual ............................................ |  |  |  |  |  |
| 88152 | A | Cytopath, c/v, auto redo ......................................... |  |  |  |  |  |
| 88153 | A | Cytopath, c/v, redo ........ |  |  |  |  |  |
| 88154 | A | Cytopath, c/v, select |  |  |  |  |  |
| 88155 | A | Cytopath, c/v, index add-on .................................... |  |  |  |  |  |
| 88160 | X | Cytopath smear, other source ................................. | 0342 | 0.26 | \$12.61 | \$8.03 | \$2.52 |
| 88161 | X | Cytopath smear, other source ................................. | 0343 | 0.45 | \$21.82 | \$12.16 | \$4.36 |
| 88162 | X | Cytopath smear, other source ................................. | 0343 | 0.45 | \$21.82 | \$12.16 | \$4.36 |
| 88164 | A | Cytopath tbs, c/v, manual ....................................... |  |  |  | ...................... |  |
| 88165 | A | Cytopath tbs, c/v, redo .......................................... |  |  |  |  |  |
| 88166 | A | Cytopath tbs, c/v, auto redo |  |  |  |  |  |
| 88167 | A | Cytopath tbs, c/v, select ......................................... |  |  |  |  |  |
| 88170 | T | Fine needle aspiration ........................................... | 0002 | 0.62 | \$30.06 | \$17.66 | \$6.01 |
| 88171 | T | Fine needle aspiration | 0002 | 0.62 | \$30.06 | \$17.66 | \$6.01 |
| 88172 | X | Evaluation of smear ... | 0343 | 0.45 | \$21.82 | \$12.16 | \$4.36 |
| 88173 | X | Interpretation of smear .......................................... | 0343 | 0.45 | \$21.82 | \$12.16 | \$4.36 |
| 88180 | X | Cell marker study . | 0344 | 0.79 | \$38.30 | \$23.63 | \$7.66 |
| 88182 | X | Cell marker study . | 0344 | 0.79 | \$38.30 | \$23.63 | \$7.66 |

[^211]
# Addendum B.-Hospital Outpatient Department (HOPD) Payment Status by hCPCS Code and Related Information-Continued 

| $\begin{aligned} & \text { CPT/ } \\ & \text { HCPCS } \end{aligned}$ | HOPD Status Indicator | Description | APC | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 88199 | X | Cytopathology procedure | 0342 | 0.26 | \$12.61 | \$8.03 | \$2.52 |
| 88230 | A | Tissue culture, lymphocyte |  |  |  |  |  |
| 88233 | A | Tissue culture, skin/biopsy |  |  |  |  |  |
| 88235 | A | Tissue culture, placenta .... |  |  |  |  |  |
| 88237 | A | Tissue culture, bone marrow |  |  |  |  |  |
| 88239 | A | Tissue culture, tumor ........ |  |  | ...................... | ..................... |  |
| 88240 | A | Cell cryopreserve/storage |  |  |  |  |  |
| 88241 | A | Frozen cell preparation ... |  |  |  |  |  |
| 88245 | A | Chromosome analysis, 20-25 |  |  |  | .................... |  |
| 88248 | A | Chromosome analysis, 50-100 |  |  |  |  |  |
| 88249 | A | Chromosome analysis, $100 .$. |  |  |  |  |  |
| 88261 | A | Chromosome analysis, 5 .... |  |  |  |  |  |
| 88262 | A | Chromosome analysis, 15-20 | .................. | ..................... | ................... | ................... |  |
| 88263 | A | Chromosome analysis, 45 |  |  | ..................... | .................... |  |
| 88264 | A | Chromosome analysis, 20-25 |  |  |  |  |  |
| 88267 | A | Chromosome analys, placenta |  |  |  |  |  |
| 88269 | A | Chromosome analys, amniotic |  |  |  |  |  |
| 88271 | A | Cytogenetics, dna probe |  |  |  |  |  |
| 88272 | A | Cytogenetics, 3-5 ......... |  | .................... | ..................... | ..................... |  |
| 88273 | A | Cytogenetics, 10-30 |  |  |  |  |  |
| 88274 | A | Cytogenetics, 25-99 |  |  |  |  |  |
| 88275 | A | Cytogenetics, 100-300 |  |  |  |  |  |
| 88280 | A | Chromosome karyotype study |  |  |  |  |  |
| 88283 | A | Chromosome banding study | .................... | .................... | ................... | .................... |  |
| 88285 | A | Chromosome count, additional |  |  |  |  |  |
| 88289 | A | Chromosome study, additional | ...... | ..................... | ..................... | ..................... | ..................... |
| 88291 | A | Cyto/molecular report |  |  |  |  |  |
| 88299 | A | Cytogenetic study |  |  |  |  |  |
| 88300 | X | Surgical path, gross | 0342 | 0.26 | \$12.61 | \$8.03 | \$2.52 |
| 88302 | X | Tissue exam by pathologist | 0342 | 0.26 | \$12.61 | \$8.03 | \$2.52 |
| 88304 | X | Tissue exam by pathologist | 0343 | 0.45 | \$21.82 | \$12.16 | \$4.36 |
| 88305 | X | Tissue exam by pathologist | 0343 | 0.45 | \$21.82 | \$12.16 | \$4.36 |
| 88307 | X | Tissue exam by pathologist | 0344 | 0.79 | \$38.30 | \$23.63 | \$7.66 |
| 88309 | X | Tissue exam by pathologist | 0344 | 0.79 | \$38.30 | \$23.63 | \$7.66 |
| 88311 | X | Decalcify tissue | 0342 | 0.26 | \$12.61 | \$8.03 | \$2.52 |
| 88312 | X | Special stains | 0343 | 0.45 | \$21.82 | \$12.16 | \$4.36 |
| 88313 | X | Special stains | 0342 | 0.26 | \$12.61 | \$8.03 | \$2.52 |
| 88314 | X | Histochemical stain | 0343 | 0.45 | \$21.82 | \$12.16 | \$4.36 |
| 88318 | X | Chemical histochemistry | 0343 | 0.45 | \$21.82 | \$12.16 | \$4.36 |
| 88319 | X | Enzyme histochemistry | 0342 | 0.26 | \$12.61 | \$8.03 | \$2.52 |
| 88321 | X | Microslide consultation | 0342 | 0.26 | \$12.61 | \$8.03 | \$2.52 |
| 88323 | X | Microslide consultation | 0343 | 0.45 | \$21.82 | \$12.16 | \$4.36 |
| 88325 | X | Comprehensive review of data | 0343 | 0.45 | \$21.82 | \$12.16 | \$4.36 |
| 88329 | X | Pathology consult in surgery | 0343 | 0.45 | \$21.82 | \$12.16 | \$4.36 |
| 88331 | X | Pathology consult in surgery | 0343 | 0.45 | \$21.82 | \$12.16 | \$4.36 |
| 88332 | X | Pathology consult in surgery | 0343 | 0.45 | \$21.82 | \$12.16 | \$4.36 |
| 88342 | X | Immunocytochemistry .......... | 0344 | 0.79 | \$38.30 | \$23.63 | \$7.66 |
| 88346 | X | Immunofluorescent study | 0343 | 0.45 | \$21.82 | \$12.16 | \$4.36 |
| 88347 | X | Immunofluorescent study | 0344 | 0.79 | \$38.30 | \$23.63 | \$7.66 |
| 88348 | X | Electron microscopy | 0344 | 0.79 | \$38.30 | \$23.63 | \$7.66 |
| 88349 | X | Scanning electron microscopy | 0344 | 0.79 | \$38.30 | \$23.63 | \$7.66 |
| 88355 | X | Analysis, skeletal muscle ...... | 0344 | 0.79 | \$38.30 | \$23.63 | \$7.66 |
| 88356 | X | Analysis, nerve ......... | 0344 | 0.79 | \$38.30 | \$23.63 | \$7.66 |
| 88358 | X | Analysis, tumor | 0344 | 0.79 | \$38.30 | \$23.63 | \$7.66 |
| 88362 | X | Nerve teasing preparations | 0343 | 0.45 | \$21.82 | \$12.16 | \$4.36 |
| 88365 | X | Tissue hybridization | 0344 | 0.79 | \$38.30 | \$23.63 | \$7.66 |
| 88371 | A | Protein, western blot tissue |  |  |  |  |  |
| 88372 | A | Protein analysis w/probe |  |  |  |  |  |
| 88399 | X | Surgical pathology procedure | 0342 | 0.26 | \$12.61 | \$8.03 | \$2.52 |
| 89050 | A | Body fluid cell count .... |  |  |  |  |  |
| 89051 | A | Body fluid cell count |  |  |  |  |  |
| 89060 | A | Exam, synovial fluid crystals . |  |  |  |  |  |
| 89100 | X | Sample intestinal contents ...................................... | 0361 | 3.53 | \$171.16 | \$88.09 | \$34.23 |
| 89105 | X | Sample intestinal contents | 0360 | 1.38 | \$66.91 | \$34.75 | \$13.38 |
| 89125 | A | Specimen fat stain .......... |  |  |  |  |  |
| 89130 | X | Sample stomach contents ...................................... | 0360 | 1.38 | \$66.91 | \$34.75 | \$13.38 |
| 89132 | X | Sample stomach contents | 0360 | 1.38 | \$66.91 | \$34.75 | \$13.38 |
| 89135 | X | Sample stomach contents ...................................... | 0360 | 1.38 | \$66.91 | \$34.75 | \$13.38 |
| 89136 | X | Sample stomach contents ...................................... | 0360 | 1.38 | \$66.91 | \$34.75 | \$13.38 |
| 89140 | X | Sample stomach contents ...................................... | 0360 | 1.38 | \$66.91 | \$34.75 | \$13.38 |
| 89141 | X | Sample stomach contents ...................................... | 0361 | 3.53 | \$171.16 | \$88.09 | \$34.23 |
| 89160 | A | Exam feces for meat fibers .................................... | ...................... | ...................... | ...................... | ...................... |  |
| 89190 | A | Nasal smear for eosinophils |  |  |  |  |  |

[^212]
# Addendum B.-Hospital Outpatient Department (HOPD) Payment Status by HCPCS Code and Related Information-Continued 

| CPT/ HCPCS | HOPD <br> Status <br> Indicator | Description | APC | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 89250 | A | Fertilization of oocyte |  |  |  |  |  |
| 89251 | A | Culture oocyte w/embryos | ..................... |  |  |  |  |
| 89252 | A | Assist oocyte fertilization ................................... | ..................... | ... | ....... |  |  |
| 89253 | A | Embryo hatching |  |  |  |  |  |
| 89254 | A | Oocyte identification |  |  |  |  |  |
| 89255 | A | Prepare embryo for transfer |  | ................. | ..... |  |  |
| 89256 | A | Prepare cryopreserved embryo ............................... |  | ......... | ................ | ................... |  |
| 89257 | A | Sperm identification |  | ................ | .................... |  |  |
| 89258 | A | Cryopreservation, embryo |  |  |  |  |  |
| 89259 | A | Cryopreservation, sperm ....................................... |  | ..................... | ..................... | ... |  |
| 89260 | A | Sperm isolation, simple ......................................... |  | .................. | .................... | ...................... |  |
| 89261 | A | Sperm isolation, complex .. |  |  |  |  |  |
| 89264 | A | Identify sperm tissue ...... |  |  |  |  |  |
| 89300 | A | Semen analysis |  | ................ | ..................... | .................... |  |
| 89310 | A | Semen analysis ...... |  |  |  |  |  |
| 89320 | A | Semen analysis ...... |  |  |  |  |  |
| 89325 | A | Sperm antibody test | ..... | ..................... | ................... | ................... |  |
| 89329 | A | Sperm evaluation test |  |  |  |  |  |
| 89330 | A | Evaluation, cervical mucus |  |  |  |  |  |
| 89350 | X | Sputum specimen collection | 0344 | 0.79 | \$38.30 | \$23.63 | \$7.66 |
| 89355 | A | Exam feces for starch |  |  |  |  |  |
| 89360 | X | Collect sweat for test | 0344 | 0.79 | \$38.30 | \$23.63 | \$7.66 |
| 89365 | A | Water load test |  |  |  |  |  |
| 89399 | X | Pathology lab procedure | 0343 | 0.45 | \$21.82 | \$12.16 | \$4.36 |
| 90281 | E | Human ig, im |  |  |  |  |  |
| 90283 | E | Human ig, iv |  |  |  |  |  |
| 90287 | X | Botulinum antitoxin | 0357 | 1.85 | \$89.70 | \$38.31 | \$17.94 |
| 90288 | E | Botulism ig, iv |  |  |  |  |  |
| 90291 | E | Cmv ig, iv |  |  |  |  |  |
| 90296 | X | Diphtheria antitoxin | 0357 | 1.85 | \$89.70 | \$38.31 | \$17.94 |
| 90371 | X | Hep b ig, im | 0356 | 0.36 | \$17.46 | \$4.82 | \$3.49 |
| 90375 | X | Rabies ig, im/sc | 0357 | 1.85 | \$89.70 | \$38.31 | \$17.94 |
| 90376 | X | Rabies ig, heat treated | 0357 | 1.85 | \$89.70 | \$38.31 | \$17.94 |
| 90378 | X | Rsv ig, im | 0357 | 1.85 | \$89.70 | \$38.31 | \$17.94 |
| 90379 | X | Rsv ig, iv | 0357 | 1.85 | \$89.70 | \$38.31 | \$17.94 |
| 90384 | X | Rh ig, full-dose, im | 0357 | 1.85 | \$89.70 | \$38.31 | \$17.94 |
| 90385 | X | Rh ig, minidose, im | 0357 | 1.85 | \$89.70 | \$38.31 | \$17.94 |
| 90386 | X | Rh ig, iv | 0357 | 1.85 | \$89.70 | \$38.31 | \$17.94 |
| 90389 | X | Tetanus ig, im | 0356 | 0.36 | \$17.46 | \$4.82 | \$3.49 |
| 90393 | X | Vaccina ig, im | 0357 | 1.85 | \$89.70 | \$38.31 | \$17.94 |
| 90396 | X | Varicella-zoster ig, im | 0356 | 0.36 | \$17.46 | \$4.82 | \$3.49 |
| 90399 | E | Immune globulin |  |  |  |  |  |
| 90471 | N | Immunization admin | .... | ..... |  |  | ..... |
| 90472 | N | Immunization admin, each add |  |  |  |  |  |
| 90476 | X | Adenovirus vaccine, type 4 | 0356 | 0.36 | \$17.46 | \$4.82 | \$3.49 |
| 90477 | X | Adenovirus vaccine, type 7 | 0356 | 0.36 | \$17.46 | \$4.82 | \$3.49 |
| 90581 | X | Anthrax vaccine, sc | 0357 | 1.85 | \$89.70 | \$38.31 | \$17.94 |
| 90585 | X | Bcg vaccine, percut | 0356 | 0.36 | \$17.46 | \$4.82 | \$3.49 |
| 90586 | X | Bcg vaccine, intravesical | 0356 | 0.36 | \$17.46 | \$4.82 | \$3.49 |
| 90632 | X | Hep a vaccine, adult im ...... | 0356 | 0.36 | \$17.46 | \$4.82 | \$3.49 |
| 90633 | X | Hep a vacc, ped/adol, 2 dose | 0356 | 0.36 | \$17.46 | \$4.82 | \$3.49 |
| 90634 | X | Hep a vacc, ped/adol, 3 dose | 0356 | 0.36 | \$17.46 | \$4.82 | \$3.49 |
| 90636 | X | Hep a/hep b vacc, adult im .................................... | 0357 | 1.85 | \$89.70 | \$38.31 | \$17.94 |
| 90645 | X | Hib vaccine, hboc, im .... | 0355 | 0.19 | \$9.21 | \$5.05 | \$1.84 |
| 90646 | X | Hib vaccine, prp-d, im ............................................ | 0355 | 0.19 | \$9.21 | \$5.05 | \$1.84 |
| 90647 | X | Hib vaccine, prp-omp, im | 0355 | 0.19 | \$9.21 | \$5.05 | \$1.84 |
| 90648 | X | Hib vaccine, prp-t, im ...... | 0355 | 0.19 | \$9.21 | \$5.05 | \$1.84 |
| 90657 | X | Flu vaccine, 6-35 mo, im ....................................... | 0355 | 0.19 | \$9.21 | \$5.05 | \$1.84 |
| 90658 | X | Flu vaccine, 3 yrs , im | 0355 | 0.19 | \$9.21 | \$5.05 | \$1.84 |
| 90659 | X | Flu vaccine, whole, im .......................................... | 0355 | 0.19 | \$9.21 | \$5.05 | \$1.84 |
| 90660 | X | Flu vaccine, nasal | 0355 | 0.19 | \$9.21 | \$5.05 | \$1.84 |
| 90665 | X | Lyme disease vaccine, im | 0357 | 1.85 | \$89.70 | \$38.31 | \$17.94 |
| 90669 | X | Pneumococcal vaccine, ped .................................... | 0357 | 1.85 | \$89.70 | \$38.31 | \$17.94 |
| 90675 | X | Rabies vaccine, im ......... | 0357 | 1.85 | \$89.70 | \$38.31 | \$17.94 |
| 90676 | X | Rabies vaccine, id | 0357 | 1.85 | \$89.70 | \$38.31 | \$17.94 |
| 90680 | X | Rotovirus vaccine, oral .......................................... | 0356 | 0.36 | \$17.46 | \$4.82 | \$3.49 |
| 90690 | X | Typhoid vaccine, oral ............................................. | 0356 | 0.36 | \$17.46 | \$4.82 | \$3.49 |
| 90691 | X | Typhoid vaccine, im ............................................... | 0356 | 0.36 | \$17.46 | \$4.82 | \$3.49 |
| 90692 | X | Typhoid vaccine, h-p, sc/id ..................................... | 0356 | 0.36 | \$17.46 | \$4.82 | \$3.49 |
| 90693 | X | Typhoid vaccine, akd, sc ........................................ | 0356 | 0.36 | \$17.46 | \$4.82 | \$3.49 |
| 90700 | X | Dtap vaccine, im ................................................... | 0355 | 0.19 | \$9.21 | \$5.05 | \$1.84 |
| 90701 | X | Dtp vaccine, im .................................................... | 0356 | 0.36 | \$17.46 | \$4.82 | \$3.49 |
| 90702 | X | Dt vaccine, im ...... | 0355 | 0.19 | \$9.21 | \$5.05 | \$1.84 |

[^213]
## Addendum B.-Hospital Outpatient Department (HOPD) Payment Status by hCPCS Code and Related Information-Continued

| CPT/ HCPCS | HOPD Status Indicator | Description | APC | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 90703 | X | Tetanus vaccine, im | 0356 | 0.36 | \$17.46 | \$4.82 | \$3.49 |
| 90704 | X | Mumps vaccine, sc . | 0355 | 0.19 | \$9.21 | \$5.05 | \$1.84 |
| 90705 | X | Measles vaccine, sc | 0357 | 1.85 | \$89.70 | \$38.31 | \$17.94 |
| 90706 | X | Rubella vaccine, sc . | 0358 | 6.98 | \$338.44 | \$126.74 | \$67.69 |
| 90707 | X | Mmr vaccine, sc | 0356 | 0.36 | \$17.46 | \$4.82 | \$3.49 |
| 90708 | X | Measles-rubella vaccine, sc | 0358 | 6.98 | \$338.44 | \$126.74 | \$67.69 |
| 90709 | X | Rubella \& mumps vaccine, sc | 0358 | 6.98 | \$338.44 | \$126.74 | \$67.69 |
| 90710 | X | Mmrv vaccine, sc .................. | 0356 | 0.36 | \$17.46 | \$4.82 | \$3.49 |
| 90712 | X | Oral poliovirus vaccine | 0356 | 0.36 | \$17.46 | \$4.82 | \$3.49 |
| 90713 | X | Poliovirus, ipv, sc | 0355 | 0.19 | \$9.21 | \$5.05 | \$1.84 |
| 90716 | X | Chicken pox vaccine, sc | 0355 | 0.19 | \$9.21 | \$5.05 | \$1.84 |
| 90717 | X | Yellow fever vaccine, sc | 0356 | 0.36 | \$17.46 | \$4.82 | \$3.49 |
| 90718 | X | Td vaccine, im | 0356 | 0.36 | \$17.46 | \$4.82 | \$3.49 |
| 90719 | X | Diphtheria vaccine, im | 0357 | 1.85 | \$89.70 | \$38.31 | \$17.94 |
| 90720 | X | Dtp/hib vaccine, im .... | 0355 | 0.19 | \$9.21 | \$5.05 | \$1.84 |
| 90721 | X | Dtap/hib vaccine, im | 0355 | 0.19 | \$9.21 | \$5.05 | \$1.84 |
| 90725 | X | Cholera vaccine, injectable | 0358 | 6.98 | \$338.44 | \$126.74 | \$67.69 |
| 90727 | X | Plague vaccine, im ............ | 0355 | 0.19 | \$9.21 | \$5.05 | \$1.84 |
| 90732 | X | Pneumococcal vaccine, adult | 0355 | 0.19 | \$9.21 | \$5.05 | \$1.84 |
| 90733 | X | Meningococcal vaccine, sc ..................................... | 0357 | 1.85 | \$89.70 | \$38.31 | \$17.94 |
| 90735 | X | Encephalitis vaccine, sc .................................... | 0357 | 1.85 | \$89.70 | \$38.31 | \$17.94 |
| 90744 | X | Hep b vaccine, ped/adol, im | 0356 | 0.36 | \$17.46 | \$4.82 | \$3.49 |
| 90746 | X | Hep b vaccine, adult, im ......................................... | 0356 | 0.36 | \$17.46 | \$4.82 | \$3.49 |
| 90747 | X | Hep b vaccine, ill pat, im | 0356 | 0.36 | \$17.46 | \$4.82 | \$3.49 |
| 90748 | X | Hep b/hib vaccine, im .... | 0358 | 6.98 | \$338.44 | \$126.74 | \$67.69 |
| 90749 | X | Vaccine toxoid | 0355 | 0.19 | \$9.21 | \$5.05 | \$1.84 |
| 90780 | E | IV infusion therapy, 1 hour ................................. |  |  |  |  |  |
| 90781 | E | IV infusion, additional hour ................................. |  |  |  |  |  |
| 90782 | X | Injection, sc/im | 0359 | 0.96 | \$46.55 | \$9.31 | \$9.31 |
| 90783 | X | Injection, ia | 0359 | 0.96 | \$46.55 | \$9.31 | \$9.31 |
| 90784 | X | Injection, iv | 0359 | 0.96 | \$46.55 | \$9.31 | \$9.31 |
| 90788 | X | Injection of antibiotic | 0359 | 0.96 | \$46.55 | \$9.31 | \$9.31 |
| 90799 | X | Ther/prophylactic/dx inject | 0359 | 0.96 | \$46.55 | \$9.31 | \$9.31 |
| 90801 | S | Psy dx interview ............... | 0323 | 1.85 | \$89.70 | \$22.48 | \$17.94 |
| 90802 | S | Intac psy dx interview | 0323 | 1.85 | \$89.70 | \$22.48 | \$17.94 |
| 90804 | S | Psytx, office, 20-30 min | 0322 | 1.32 | \$64.00 | \$14.22 | \$12.80 |
| 90805 | S | Psytx, off, 20-30 min w/e\&m | 0322 | 1.32 | \$64.00 | \$14.22 | \$12.80 |
| 90806 | S | Psytx, off, 45-50 min ............ | 0323 | 1.85 | \$89.70 | \$22.48 | \$17.94 |
| 90807 | S | Psytx, off, 45-50 min w/e\&m | 0323 | 1.85 | \$89.70 | \$22.48 | \$17.94 |
| 90808 | S | Psytx, office, 75-80 min ............ | 0323 | 1.85 | \$89.70 | \$22.48 | \$17.94 |
| 90809 | S | Psytx, off, 75-80, w/e\&m ........... | 0323 | 1.85 | \$89.70 | \$22.48 | \$17.94 |
| 90810 | S | Intac psytx, off, 20-30 min | 0322 | 1.32 | \$64.00 | \$14.22 | \$12.80 |
| 90811 | S | Intac psytx, 20-30, w/e\&m ................................ | 0322 | 1.32 | \$64.00 | \$14.22 | \$12.80 |
| 90812 | S | Intac psytx, off, 45-50 min | 0323 | 1.85 | \$89.70 | \$22.48 | \$17.94 |
| 90813 | S | Intac psytx, 45-50 min w/e\&m | 0323 | 1.85 | \$89.70 | \$22.48 | \$17.94 |
| 90814 | S | Intac psytx, off, 75-80 min ...... | 0323 | 1.85 | \$89.70 | \$22.48 | \$17.94 |
| 90815 | S | Intac psytx, 75-80 w/e\&m ..... | 0323 | 1.85 | \$89.70 | \$22.48 | \$17.94 |
| 90816 | S | Psytx, hosp, 20-30 min ....... | 0322 | 1.32 | \$64.00 | \$14.22 | \$12.80 |
| 90817 | S | Psytx, hosp, 20-30 min w/e\&m | 0322 | 1.32 | \$64.00 | \$14.22 | \$12.80 |
| 90818 | S | Psytx, hosp, 45-50 min ...................................... | 0323 | 1.85 | \$89.70 | \$22.48 | \$17.94 |
| 90819 | S | Psytx, hosp, 45-50 min w/e\&m ............................... | 0323 | 1.85 | \$89.70 | \$22.48 | \$17.94 |
| 90821 | S | Psytx, hosp, 75-80 min ......................................... | 0323 | 1.85 | \$89.70 | \$22.48 | \$17.94 |
| 90822 | S | Psytx, hosp, 75-80 min w/e\&m ............................... | 0323 | 1.85 | \$89.70 | \$22.48 | \$17.94 |
| 90823 | S | Intac psytx, hosp, 20-30 min ............................... | 0322 | 1.32 | \$64.00 | \$14.22 | \$12.80 |
| 90824 | S | Intac psytx, hsp 20-30 w/e\&m ............................... | 0322 | 1.32 | \$64.00 | \$14.22 | \$12.80 |
| 90826 | S | Intac psytx, hosp, 45-50 min ............................... | 0323 | 1.85 | \$89.70 | \$22.48 | \$17.94 |
| 90827 | S | Intac psytx, hsp 45-50 w/e\&m ................................ | 0323 | 1.85 | \$89.70 | \$22.48 | \$17.94 |
| 90828 | S | Intac psytx, hosp, 75-80 min .................................. | 0323 | 1.85 | \$89.70 | \$22.48 | \$17.94 |
| 90829 | S | Intac psytx, hsp 75-80 w/e\&m .............................. | 0323 | 1.85 | \$89.70 | \$22.48 | \$17.94 |
| 90845 | S | Psychoanalysis ................................................... | 0323 | 1.85 | \$89.70 | \$22.48 | \$17.94 |
| 90846 | S | Family psytx w/o patient ........................................ | 0324 | 1.87 | \$90.67 | \$20.19 | \$18.13 |
| 90847 | S | Family psytx w/patient | 0324 | 1.87 | \$90.67 | \$20.19 | \$18.13 |
| 90849 | S | Multiple family group psytx ..................................... | 0325 | 1.55 | \$75.16 | \$19.96 | \$15.03 |
| 90853 | S | Group psychotherapy ........................................... | 0325 | 1.55 | \$75.16 | \$19.96 | \$15.03 |
| 90857 | S | Intac group psytx ................................................. | 0325 | 1.55 | \$75.16 | \$19.96 | \$15.03 |
| 90862 | X | Medication management ....................................... | 0374 | 1.17 | \$56.73 | \$13.08 | \$11.35 |
| 90865 | S | Narcosynthesis .................................................... | 0323 | 1.85 | \$89.70 | \$22.48 | \$17.94 |
| 90870 | S | Electroconvulsive therapy ...................................... | 0320 | 3.68 | \$178.43 | \$80.06 | \$35.69 |
| 90871 | S | Electroconvulsive therapy ...................................... | 0320 | 3.68 | \$178.43 | \$80.06 | \$35.69 |
| 90875 | E | Psychophysiological therapy .................................. |  |  |  |  |  |
| 90876 | E | Psychophysiological therapy .................................. |  |  |  |  |  |
| 90880 | S | Hypnotherapy ...................................................... | 0323 | 1.85 | \$89.70 | \$22.48 | \$17.94 |
| 90882 | E | Environmental manipulation ................................... |  |  |  |  |  |

[^214]
# Addendum B.-Hospital Outpatient Department (HOPD) Payment Status by HCPCS Code and Related INFORMATION-Continued 

| CPT/ HCPCS | HOPD Status Indicator | Description | APC | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 90885 | N | Psy evaluation of records |  | ..................... | ..................... | ..................... |  |
| 90887 | N | Consultation with family ... |  |  |  | ...................... |  |
| 90889 | N | Preparation of report |  |  |  |  |  |
| 90899 | S | Psychiatric service/therapy | 0322 | 1.32 | \$64.00 | \$14.22 | \$12.80 |
| 90901 | S | Biofeedback train, any meth | 0321 | 1.26 | \$61.09 | \$29.25 | \$12.22 |
| 90911 | S | Biofeedback peri/uro/rectal . | 0321 | 1.26 | \$61.09 | \$29.25 | \$12.22 |
| 90918 | A | ESRD related services, month |  |  |  |  |  |
| 90919 | A | ESRD related services, month |  |  |  |  |  |
| 90920 | A | ESRD related services, month | .................... | .................... | .................... | .................... | ..................... |
| 90921 | A | ESRD related services, month |  |  |  |  |  |
| 90922 | A | ESRD related services, day |  |  |  |  |  |
| 90923 | A | Esrd related services, day | ...... |  | .................. |  |  |
| 90924 | A | Esrd related services, day |  |  |  |  |  |
| 90925 | A | Esrd related services, day |  |  |  |  |  |
| 90935 | S | Hemodialysis, one evaluation | 0170 | 6.68 | \$323.89 | \$72.26 | \$64.78 |
| 90937 | E | Hemodialysis, repeated eval |  |  |  |  |  |
| 90945 | S | Dialysis, one evaluation ... | 0170 | 6.68 | \$323.89 | \$72.26 | \$64.78 |
| 90947 | E | Dialysis, repeated eval |  |  |  |  |  |
| 90989 | E | Dialysis training, complete | .................... | .................... | ..................... | .................... |  |
| 90993 | E | Dialysis training, incompl |  |  |  |  |  |
| 90997 | E | Hemoperfusion |  |  |  |  |  |
| 90999 | E | Dialysis procedure |  |  |  |  |  |
| 91000 | X | Esophageal intubation | 0361 | 3.53 | \$171.16 | \$88.09 | \$34.23 |
| 91010 | X | Esophagus motility study | 0361 | 3.53 | \$171.16 | \$88.09 | \$34.23 |
| 91011 | X | Esophagus motility study | 0361 | 3.53 | \$171.16 | \$88.09 | \$34.23 |
| 91012 | X | Esophagus motility study | 0361 | 3.53 | \$171.16 | \$88.09 | \$34.23 |
| 91020 | X | Gastric motility | 0361 | 3.53 | \$171.16 | \$88.09 | \$34.23 |
| 91030 | X | Acid perfusion of esophagus | 0360 | 1.38 | \$66.91 | \$34.75 | \$13.38 |
| 91032 | X | Esophagus, acid reflux test | 0361 | 3.53 | \$171.16 | \$88.09 | \$34.23 |
| 91033 | X | Prolonged acid reflux test ... | 0361 | 3.53 | \$171.16 | \$88.09 | \$34.23 |
| 91052 | X | Gastric analysis test | 0361 | 3.53 | \$171.16 | \$88.09 | \$34.23 |
| 91055 | X | Gastric intubation for smear | 0360 | 1.38 | \$66.91 | \$34.75 | \$13.38 |
| 91060 | X | Gastric saline load test | 0361 | 3.53 | \$171.16 | \$88.09 | \$34.23 |
| 91065 | X | Breath hydrogen test | 0360 | 1.38 | \$66.91 | \$34.75 | \$13.38 |
| 91100 | X | Pass intestine bleeding tube | 0360 | 1.38 | \$66.91 | \$34.75 | \$13.38 |
| 91105 | X | Gastric intubation treatment | 0360 | 1.38 | \$66.91 | \$34.75 | \$13.38 |
| 91122 | T | Anal pressure record | 0165 | 3.89 | \$188.61 | \$91.76 | \$37.72 |
| 91299 | X | Gastroenterology procedure | 0360 | 1.38 | \$66.91 | \$34.75 | \$13.38 |
| 92002 | V | Eye exam, new patient | 0601 | 1.00 | \$48.49 | \$9.70 | \$9.70 |
| 92004 | V | Eye exam, new patient ... | 0602 | 1.66 | \$80.49 | \$16.29 | \$16.10 |
| 92012 | V | Eye exam established pat | 0601 | 1.00 | \$48.49 | \$9.70 | \$9.70 |
| 92014 | V | Eye exam \& treatment | 0602 | 1.66 | \$80.49 | \$16.29 | \$16.10 |
| 92015 | E | Refraction |  |  |  |  |  |
| 92018 | S | New eye exam \& treatment | 0231 | 2.64 | \$128.01 | \$59.87 | \$25.60 |
| 92019 | S | Eye exam \& treatment | 0231 | 2.64 | \$128.01 | \$59.87 | \$25.60 |
| 92020 | S | Special eye evaluation | 0230 | 0.98 | \$47.52 | \$22.48 | \$9.50 |
| 92060 | S | Special eye evaluation | 0230 | 0.98 | \$47.52 | \$22.48 | \$9.50 |
| 92065 | S | Orthoptic/pleoptic training | 0230 | 0.98 | \$47.52 | \$22.48 | \$9.50 |
| 92070 | N | Fitting of contact lens ..... |  |  |  |  |  |
| 92081 | S | Visual field examination(s) | 0230 | 0.98 | \$47.52 | \$22.48 | \$9.50 |
| 92082 | S | Visual field examination(s) | 0230 | 0.98 | \$47.52 | \$22.48 | \$9.50 |
| 92083 | S | Visual field examination(s) | 0230 | 0.98 | \$47.52 | \$22.48 | \$9.50 |
| 92100 | N | Serial tonometry exam(s) ..... |  |  |  |  |  |
| 92120 | S | Tonography \& eye evaluation | 0230 | 0.98 | \$47.52 | \$22.48 | \$9.50 |
| 92130 | S | Water provocation tonography | 0230 | 0.98 | \$47.52 | \$22.48 | \$9.50 |
| 92135 | S | Opthalmic dx imaging ........... | 0231 | 2.64 | \$128.01 | \$59.87 | \$25.60 |
| 92140 | S | Glaucoma provocative tests | 0231 | 2.64 | \$128.01 | \$59.87 | \$25.60 |
| 92225 | S | Special eye exam, initial | 0230 | 0.98 | \$47.52 | \$22.48 | \$9.50 |
| 92226 | S | Special eye exam, subsequent | 0231 | 2.64 | \$128.01 | \$59.87 | \$25.60 |
| 92230 | S | Eye exam with photos ...... | 0231 | 2.64 | \$128.01 | \$59.87 | \$25.60 |
| 92235 | S | Eye exam with photos | 0231 | 2.64 | \$128.01 | \$59.87 | \$25.60 |
| 92240 | S | Icg angiography ................................................... | 0231 | 2.64 | \$128.01 | \$59.87 | \$25.60 |
| 92250 | S | Eye exam with photos .... | 0230 | 0.98 | \$47.52 | \$22.48 | \$9.50 |
| 92260 | S | Ophthalmoscopy/dynamometry | 0230 | 0.98 | \$47.52 | \$22.48 | \$9.50 |
| 92265 | S | Eye muscle evaluation ...... | 0230 | 0.98 | \$47.52 | \$22.48 | \$9.50 |
| 92270 | S | Electro-oculography .......... | 0230 | 0.98 | \$47.52 | \$22.48 | \$9.50 |
| 92275 | S | Electroretinography | 0216 | 2.87 | \$139.16 | \$64.69 | \$27.83 |
| 92283 | S | Color vision examination | 0230 | 0.98 | \$47.52 | \$22.48 | \$9.50 |
| 92284 | S | Dark adaptation eye exam | 0231 | 2.64 | \$128.01 | \$59.87 | \$25.60 |
| 92285 | S | Eye photography ....... | 0230 | 0.98 | \$47.52 | \$22.48 | \$9.50 |
| 92286 | S | Internal eye photography | 0231 | 2.64 | \$128.01 | \$59.87 | \$25.60 |
| 92287 | T | Internal eye photography ........................................ | 0231 | 2.64 | \$128.01 | \$59.87 | \$25.60 |
| 92310 | E | Contact lens fitting ..... |  |  |  |  |  |

[^215]
## Addendum B.—Hospital Outpatient Department (HOPD) Payment Status by hCPCS Code and Related Information-Continued

| CPT/ HCPCS | HOPD Status Indicator | Description | APC | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 92311 | X | Contact lens fitting | 0362 | 0.51 | \$24.73 | \$9.63 | \$4.95 |
| 92312 | X | Contact lens fitting | 0362 | 0.51 | \$24.73 | \$9.63 | \$4.95 |
| 92313 | X | Contact lens fitting | 0362 | 0.51 | \$24.73 | \$9.63 | \$4.95 |
| 92314 | E | Prescription of contact lens |  |  |  |  |  |
| 92315 | X | Prescription of contact lens | 0362 | 0.51 | \$24.73 | \$9.63 | \$4.95 |
| 92316 | X | Prescription of contact lens | 0362 | 0.51 | \$24.73 | \$9.63 | \$4.95 |
| 92317 | X | Prescription of contact lens | 0362 | 0.51 | \$24.73 | \$9.63 | \$4.95 |
| 92325 | X | Modification of contact lens | 0362 | 0.51 | \$24.73 | \$9.63 | \$4.95 |
| 92326 | X | Replacement of contact lens | 0362 | 0.51 | \$24.73 | \$9.63 | \$4.95 |
| 92330 | S | Fitting of artificial eye | 0230 | 0.98 | \$47.52 | \$22.48 | \$9.50 |
| 92335 | N | Fitting of artificial eye | ........ | ..................... |  | ..................... |  |
| 92340 | E | Fitting of spectacles .. | ....... | .................... | ..................... |  |  |
| 92341 | E | Fitting of spectacles |  |  |  |  |  |
| 92342 | E | Fitting of spectacles |  |  |  |  |  |
| 92352 | X | Special spectacles fitting | 0362 | 0.51 | \$24.73 | \$9.63 | \$4.95 |
| 92353 | X | Special spectacles fitting | 0362 | 0.51 | \$24.73 | \$9.63 | \$4.95 |
| 92354 | X | Special spectacles fitting | 0362 | 0.51 | \$24.73 | \$9.63 | \$4.95 |
| 92355 | X | Special spectacles fitting | 0362 | 0.51 | \$24.73 | \$9.63 | \$4.95 |
| 92358 | X | Eye prosthesis service | 0362 | 0.51 | \$24.73 | \$9.63 | \$4.95 |
| 92370 | E | Repair \& adjust spectacles |  |  |  |  |  |
| 92371 | X | Repair \& adjust spectacles | 0362 | 0.51 | \$24.73 | \$9.63 | \$4.95 |
| 92390 | E | Supply of spectacles |  |  |  |  |  |
| 92391 | E | Supply of contact lenses | .................... |  |  |  |  |
| 92392 | E | Supply of low vision aids | ...... | ...... |  | ..................... | ..................... |
| 92393 | E | Supply of artificial eye |  |  |  |  |  |
| 92395 | E | Supply of spectacles | ...................... |  |  |  |  |
| 92396 | E | Supply of contact lenses |  |  |  |  |  |
| 92499 | S | Eye service or procedure | 0230 | 0.98 | \$47.52 | \$22.48 | \$9.50 |
| 92502 | T | Ear and throat examination | 0251 | 1.68 | \$81.46 | \$27.99 | \$16.29 |
| 92504 | N | Ear microscopy examination ... |  |  |  | ..................... |  |
| 92506 | A | Speech/hearing evaluation ..... | ................... | ..................... | ...................... | ...................... | ...................... |
| 92507 | A | Speech/hearing therapy | ..................... | ..................... | .................... |  |  |
| 92508 | A | Speech/hearing therapy | .... | ...... |  |  |  |
| 92510 | A | Rehab for ear implant ... |  |  |  |  |  |
| 92511 | T | Nasopharyngoscopy | 0071 | 0.55 | \$26.67 | \$14.22 | \$5.33 |
| 92512 | X | Nasal function studies | 0363 | 2.83 | \$137.22 | \$53.22 | \$27.44 |
| 92516 | X | Facial nerve function test | 0363 | 2.83 | \$137.22 | \$53.22 | \$27.44 |
| 92520 | X | Laryngeal function studies | 0363 | 2.83 | \$137.22 | \$53.22 | \$27.44 |
| 92525 | A | Oral function evaluation |  |  | ............ | ......... |  |
| 92526 | A | Oral function therapy |  |  |  |  |  |
| 92531 | N | Spontaneous nystagmus study |  |  |  |  |  |
| 92532 | N | Positional nystagmus study | ..................... | .................... | .......... | ......... |  |
| 92533 | N | Caloric vestibular test | ....... |  |  |  |  |
| 92534 | N | Optokinetic nystagmus ....... |  |  |  |  |  |
| 92541 | X | Spontaneous nystagmus test | 0363 | 2.83 | \$137.22 | \$53.22 | \$27.44 |
| 92542 | X | Positional nystagmus test | 0363 | 2.83 | \$137.22 | \$53.22 | \$27.44 |
| 92543 | X | Caloric vestibular test | 0363 | 2.83 | \$137.22 | \$53.22 | \$27.44 |
| 92544 | X | Optokinetic nystagmus test | 0363 | 2.83 | \$137.22 | \$53.22 | \$27.44 |
| 92545 | X | Oscillating tracking test | 0363 | 2.83 | \$137.22 | \$53.22 | \$27.44 |
| 92546 | X | Sinusoidal rotational test | 0363 | 2.83 | \$137.22 | \$53.22 | \$27.44 |
| 92547 | X | Supplemental electrical test .................................... | 0363 | 2.83 | \$137.22 | \$53.22 | \$27.44 |
| 92548 | X | Posturography | 0363 | 2.83 | \$137.22 | \$53.22 | \$27.44 |
| 92551 | E | Pure tone hearing test, air |  |  |  |  |  |
| 92552 | X | Pure tone audiometry, air | 0364 | 0.68 | \$32.97 | \$13.31 | \$6.59 |
| 92553 | X | Audiometry, air \& bone | 0364 | 0.68 | \$32.97 | \$13.31 | \$6.59 |
| 92555 | X | Speech threshold audiometry | 0364 | 0.68 | \$32.97 | \$13.31 | \$6.59 |
| 92556 | X | Speech audiometry, complete | 0364 | 0.68 | \$32.97 | \$13.31 | \$6.59 |
| 92557 | X | Comprehensive hearing test ..... | 0365 | 1.47 | \$71.28 | \$22.48 | \$14.26 |
| 92559 | E | Group audiometric testing |  |  |  |  |  |
| 92560 | E | Bekesy audiometry, screen .................................... |  |  |  |  |  |
| 92561 | X | Bekesy audiometry, diagnosis | 0365 | 1.47 | \$71.28 | \$22.48 | \$14.26 |
| 92562 | X | Loudness balance test | 0365 | 1.47 | \$71.28 | \$22.48 | \$14.26 |
| 92563 | X | Tone decay hearing test | 0365 | 1.47 | \$71.28 | \$22.48 | \$14.26 |
| 92564 | X | Sisi hearing test | 0365 | 1.47 | \$71.28 | \$22.48 | \$14.26 |
| 92565 | X | Stenger test, pure tone .......................................... | 0365 | 1.47 | \$71.28 | \$22.48 | \$14.26 |
| 92567 | X | Tympanometry | 0364 | 0.68 | \$32.97 | \$13.31 | \$6.59 |
| 92568 | X | Acoustic reflex testing ........................................... | 0365 | 1.47 | \$71.28 | \$22.48 | \$14.26 |
| 92569 | X | Acoustic reflex decay test .... | 0365 | 1.47 | \$71.28 | \$22.48 | \$14.26 |
| 92571 | X | Filtered speech hearing test | 0365 | 1.47 | \$71.28 | \$22.48 | \$14.26 |
| 92572 | X | Staggered spondaic word test ................................. | 0365 | 1.47 | \$71.28 | \$22.48 | \$14.26 |
| 92573 | X | Lombard test ........................................................ | 0365 | 1.47 | \$71.28 | \$22.48 | \$14.26 |
| 92575 | X | Sensorineural acuity test ....................................... | 0365 | 1.47 | \$71.28 | \$22.48 | \$14.26 |
| 92576 | X | Synthetic sentence test .......................................... | 0365 | 1.47 | \$71.28 | \$22.48 | \$14.26 |

[^216]
## Addendum B.-Hospital Outpatient Department (HOPD) Payment Status by HCPCS Code and Related INFORMATION-Continued

| $\begin{gathered} \text { CPT/ } \\ \text { HCPCS } \end{gathered}$ | HOPD Status Indicator | Description | APC | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 92577 | X | Stenger test, speech | 0365 | 1.47 | \$71.28 | \$22.48 | \$14.26 |
| 92579 | X | Visual audiometry (vra) | 0365 | 1.47 | \$71.28 | \$22.48 | \$14.26 |
| 92582 | X | Conditioning play audiometry | 0365 | 1.47 | \$71.28 | \$22.48 | \$14.26 |
| 92583 | X | Select picture audiometry ..... | 0365 | 1.47 | \$71.28 | \$22.48 | \$14.26 |
| 92584 | X | Electrocochleography | 0363 | 2.83 | \$137.22 | \$53.22 | \$27.44 |
| 92585 | S | Auditory evoked potential | 0216 | 2.87 | \$139.16 | \$64.69 | \$27.83 |
| 92587 | X | Evoked auditory test | 0363 | 2.83 | \$137.22 | \$53.22 | \$27.44 |
| 92588 | X | Evoked auditory test .............................................. | 0363 | 2.83 | \$137.22 | \$53.22 | \$27.44 |
| 92589 | X | Auditory function test(s) | 0365 | 1.47 | \$71.28 | \$22.48 | \$14.26 |
| 92590 | E | Hearing aid exam, one ear |  |  |  |  |  |
| 92591 | E | Hearing aid exam, both ears ................................... | ...... | ..... | ..................... | .................... |  |
| 92592 | E | Hearing aid check, one ear .................................... | ........ | ..................... | .................. | ...................... |  |
| 92593 | E | Hearing aid check, both ears |  |  |  |  |  |
| 92594 | E | Electro hearng aid test, one .................................... |  |  |  |  |  |
| 92595 | E | Electro hearng aid tst, both ..................................... |  |  |  |  |  |
| 92596 | X | Ear protector evaluation ........................................ | 0365 | 1.47 | \$71.28 | \$22.48 | \$14.26 |
| 92597 | A | Oral speech device eval |  |  |  |  |  |
| 92598 | A | Modify oral speech device |  |  |  |  |  |
| 92599 | X | ENT procedure/service .......................................... | 0364 | 0.68 | \$32.97 | \$13.31 | \$6.59 |
| 92950 | S | Heart/lung resuscitation cpr | 0094 | 4.51 | \$218.68 | \$105.29 | \$43.74 |
| 92953 | S | Temporary external pacing | 0094 | 4.51 | \$218.68 | \$105.29 | \$43.74 |
| 92960 | S | Cardioversion electric, ext | 0094 | 4.51 | \$218.68 | \$105.29 | \$43.74 |
| 92961 | S | Cardioversion, electric, int | 0094 | 4.51 | \$218.68 | \$105.29 | \$43.74 |
| 92970 | C | Cardioassist, internal |  |  |  |  |  |
| 92971 | C | Cardioassist, external |  | ...... | .... | ...................... |  |
| 92975 | C | Dissolve clot, heart vessel ...................................... |  | . |  |  |  |
| 92977 | C | Dissolve clot, heart vessel |  |  |  |  |  |
| 92978 | C | Intravasc us, heart add-on ...................................... | ...... | ................... | ........ | .................... |  |
| 92979 | C | Intravasc us, heart add-on |  |  |  |  |  |
| 92980 | T | Insert intracoronary stent | 0083 | 45.79 | \$2,220.22 | \$1,322.95 | \$444.04 |
| 92981 | T | Insert intracoronary stent ........................................ | 0083 | 45.79 | \$2,220.22 | \$1,322.95 | \$444.04 |
| 92982 | T | Coronary artery dilation | 0083 | 45.79 | \$2,220.22 | \$1,322.95 | \$444.04 |
| 92984 | T | Coronary artery dilation | 0083 | 45.79 | \$2,220.22 | \$1,322.95 | \$444.04 |
| 92986 | C | Revision of aortic valve .... |  |  |  |  |  |
| 92987 | C | Revision of mitral valve |  | .................... | ....... | .................... |  |
| 92990 | C | Revision of pulmonary valve |  |  |  |  |  |
| 92992 | C | Revision of heart chamber |  |  |  |  |  |
| 92993 | C | Revision of heart chamber |  |  |  |  |  |
| 92995 | T | Coronary atherectomy | 0082 | 40.34 | \$1,955.97 | \$859.56 | \$391.19 |
| 92996 | T | Coronary atherectomy add-on | 0082 | 40.34 | \$1,955.97 | \$859.56 | \$391.19 |
| 92997 | C | Pul art balloon repr, percut ..................................... | ..................... | ...................... | ...................... | ..................... | ...................... |
| 92998 | C | Pul art balloon repr, percut |  |  |  |  |  |
| 93000 | E | Electrocardiogram, complete |  |  |  |  |  |
| 93005 | X | Electrocardiogram, tracing ...................................... | 0366 | 0.38 | \$18.43 | \$15.60 | \$3.69 |
| 93010 | E | Electrocardiogram report ........................................ |  |  |  |  |  |
| 93012 | S | Transmission of ECG | 0099 | 0.38 | \$18.43 | \$14.68 | \$3.69 |
| 93014 | E | Report on transmitted ECG |  |  |  |  |  |
| 93015 | E | Cardiovascular stress test |  |  |  |  |  |
| 93016 | E | Cardiovascular stress test |  |  |  |  |  |
| 93017 | S | Cardiovascular stress test | 0097 | 1.62 | \$78.55 | \$62.40 | \$15.71 |
| 93018 | E | Cardiovascular stress test |  |  |  |  |  |
| 93024 | S | Cardiac drug stress test ......................................... | 0097 | 1.62 | \$78.55 | \$62.40 | \$15.71 |
| 93040 | E | Rhythm ECG with report |  |  |  |  |  |
| 93041 | X | Rhythm ECG, tracing ............................................. | 0366 | 0.38 | \$18.43 | \$15.60 | \$3.69 |
| 93042 | E | Rhythm ECG, report .............................................. |  |  |  |  |  |
| 93224 | E | ECG monitor/report, 24 hrs ..................................... |  |  |  |  |  |
| 93225 | S | ECG monitor/record, 24 hrs .................................... | 0100 | 1.70 | \$82.43 | \$71.57 | \$16.49 |
| 93226 | S | ECG monitor/report, 24 hrs .................................... | 0100 | 1.70 | \$82.43 | \$71.57 | \$16.49 |
| 93227 | E | ECG monitor/review, 24 hrs .................................... |  |  |  |  |  |
| 93230 | E | ECG monitor/report, 24 hrs .................................... |  |  |  |  |  |
| 93231 | S | ECG monitor/record, 24 hrs ................................... | 0100 | 1.70 | \$82.43 | \$71.57 | \$16.49 |
| 93232 | S | ECG monitor/report, 24 hrs ..... | 0100 | 1.70 | \$82.43 | \$71.57 | \$16.49 |
| 93233 | E | ECG monitor/review, 24 hrs |  |  |  |  |  |
| 93235 | E | ECG monitor/report, 24 hrs ..................................... |  |  |  |  |  |
| 93236 | S | ECG monitor/report, 24 hrs .................................... | 0100 | 1.70 | \$82.43 | \$71.57 | \$16.49 |
| 93237 | E | ECG monitor/review, 24 hrs .................................... |  |  |  |  |  |
| 93268 | S | ECG record/review | 0100 | 1.70 | \$82.43 | \$71.57 | \$16.49 |
| 93270 | S | ECG recording ..................................................... | 0099 | 0.38 | \$18.43 | \$14.68 | \$3.69 |
| 93271 | S | ECG/monitoring and analysis .................................. | 0100 | 1.70 | \$82.43 | \$71.57 | \$16.49 |
| 93272 | E | ECG/review, interpret only ...................................... |  |  |  |  |  |
| 93278 | S | ECG/signal-averaged ............................................ | 0099 | 0.38 | \$18.43 | \$14.68 | \$3.69 |
| 93303 | S | Echo transthoracic .... | 0269 | 4.40 | \$213.34 | \$114.01 | \$42.67 |
| 93304 | S | Echo transthoracic ....... | 0269 | 4.40 | \$213.34 | \$114.01 | \$42.67 |

[^217]
## Addendum B.—Hospital Outpatient Department (HOPD) Payment Status by hCPCS Code and Related Information-Continued

| CPT/ HCPCS | HOPD <br> Status <br> Indicator | Description | APC | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 93307 | S | Echo exam of heart | 0269 | 4.40 | \$213.34 | \$114.01 | \$42.67 |
| 93308 | S | Echo exam of heart | 0269 | 4.40 | \$213.34 | \$114.01 | \$42.67 |
| 93312 | S | Echo transesophageal | 0270 | 5.55 | \$269.10 | \$150.26 | \$53.82 |
| 93313 | S | Echo transesophageal ........................................... | 0270 | 5.55 | \$269.10 | \$150.26 | \$53.82 |
| 93314 | N | Echo transesophageal ........................................... |  |  |  |  |  |
| 93315 | S | Echo transesophageal | 0270 | 5.55 | \$269.10 | \$150.26 | \$53.82 |
| 93316 | S | Echo transesophageal | 0270 | 5.55 | \$269.10 | \$150.26 | \$53.82 |
| 93317 | N | Echo transesophageal |  |  |  |  |  |
| 93320 | S | Doppler echo exam, heart | 0269 | 4.40 | \$213.34 | \$114.01 | \$42.67 |
| 93321 | S | Doppler echo exam, heart | 0269 | 4.40 | \$213.34 | \$114.01 | \$42.67 |
| 93325 | S | Doppler color flow add-on | 0269 | 4.40 | \$213.34 | \$114.01 | \$42.67 |
| 93350 | S | Echo transthoracic | 0269 | 4.40 | \$213.34 | \$114.01 | \$42.67 |
| 93501 | T | Right heart catheterization | 0080 | 25.77 | \$1,249.51 | \$713.89 | \$249.90 |
| 93503 | T | Insert/place heart catheter | 0080 | 25.77 | \$1,249.51 | \$713.89 | \$249.90 |
| 93505 | T | Biopsy of heart lining | 0080 | 25.77 | \$1,249.51 | \$713.89 | \$249.90 |
| 93508 | N | Cath placement, angiography |  |  |  |  |  |
| 93510 | T | Left heart catheterization | 0080 | 25.77 | \$1,249.51 | \$713.89 | \$249.90 |
| 93511 | T | Left heart catheterization | 0080 | 25.77 | \$1,249.51 | \$713.89 | \$249.90 |
| 93514 | T | Left heart catheterization | 0080 | 25.77 | \$1,249.51 | \$713.89 | \$249.90 |
| 93524 | T | Left heart catheterization | 0080 | 25.77 | \$1,249.51 | \$713.89 | \$249.90 |
| 93526 | T | Rt \& Lt heart catheters | 0080 | 25.77 | \$1,249.51 | \$713.89 | \$249.90 |
| 93527 | T | Rt \& Lt heart catheters | 0080 | 25.77 | \$1,249.51 | \$713.89 | \$249.90 |
| 93528 | T | Rt \& Lt heart catheters | 0080 | 25.77 | \$1,249.51 | \$713.89 | \$249.90 |
| 93529 | T | Rt, Lt heart catheterization | 0080 | 25.77 | \$1,249.51 | \$713.89 | \$249.90 |
| 93530 | T | Rt heart cath, congenital | 0080 | 25.77 | \$1,249.51 | \$713.89 | \$249.90 |
| 93531 | T | R \& I heart cath, congenital | 0080 | 25.77 | \$1,249.51 | \$713.89 | \$249.90 |
| 93532 | T | R \& I heart cath, congenital | 0080 | 25.77 | \$1,249.51 | \$713.89 | \$249.90 |
| 93533 | T | R \& I heart cath, congenital | 0080 | 25.77 | \$1,249.51 | \$713.89 | \$249.90 |
| 93536 | T | Insert circulation assi ......... | 0080 | 25.77 | \$1,249.51 | \$713.89 | \$249.90 |
| 93539 | N | Injection, cardiac cath |  |  |  |  |  |
| 93540 | N | Injection, cardiac cath |  |  |  |  |  |
| 93541 | N | Injection for lung angiogram ................................... |  |  |  | ........... |  |
| 93542 | N | Injection for heart x-rays ........................................ |  | ..................... | .................... | ..................... |  |
| 93543 | N | Injection for heart x-rays |  |  |  |  |  |
| 93544 | N | Injection for aortography ........................................ |  | .... |  | .................... |  |
| 93545 | N | Inject for coronary x-rays |  |  |  | ..................... |  |
| 93555 | N | Imaging, cardiac cath |  |  |  |  |  |
| 93556 | N | Imaging, cardiac cath ... |  | ...... | ..................... | ..................... |  |
| 93561 | N | Cardiac output measurement .................................. | -................... | ....... | ..................... | ..................... | ..................... |
| 93562 | N | Cardiac output measurement |  | ..... |  |  |  |
| 93571 | N | Heart flow reserve measure |  |  |  |  |  |
| 93572 | N | Heart flow reserve measure |  |  |  |  |  |
| 93600 | S | Bundle of His recording | 0087 | 9.53 | \$462.08 | \$214.72 | \$92.42 |
| 93602 | S | Intra-atrial recording | 0087 | 9.53 | \$462.08 | \$214.72 | \$92.42 |
| 93603 | S | Right ventricular recording ...................................... | 0087 | 9.53 | \$462.08 | \$214.72 | \$92.42 |
| 93607 | S | Left ventricular recording ....................................... | 0087 | 9.53 | \$462.08 | \$214.72 | \$92.42 |
| 93609 | S | Mapping of tachycardia ......................................... | 0087 | 9.53 | \$462.08 | \$214.72 | \$92.42 |
| 93610 | S | Intra-atrial pacing | 0087 | 9.53 | \$462.08 | \$214.72 | \$92.42 |
| 93612 | S | Intraventricular pacing ........................................... | 0087 | 9.53 | \$462.08 | \$214.72 | \$92.42 |
| 93615 | S | Esophageal recording ............................................ | 0087 | 9.53 | \$462.08 | \$214.72 | \$92.42 |
| 93616 | S | Esophageal recording | 0087 | 9.53 | \$462.08 | \$214.72 | \$92.42 |
| 93618 | S | Heart rhythm pacing .............................................. | 0087 | 9.53 | \$462.08 | \$214.72 | \$92.42 |
| 93619 | S | Electrophysiology evaluation | 0085 | 27.06 | \$1,312.06 | \$654.48 | \$262.41 |
| 93620 | S | Electrophysiology evaluation | 0085 | 27.06 | \$1,312.06 | \$654.48 | \$262.41 |
| 93621 | S | Electrophysiology evaluation .................................. | 0085 | 27.06 | \$1,312.06 | \$654.48 | \$262.41 |
| 93622 | S | Electrophysiology evaluation .................................. | 0085 | 27.06 | \$1,312.06 | \$654.48 | \$262.41 |
| 93623 | S | Stimulation, pacing heart | 0087 | 9.53 | \$462.08 | \$214.72 | \$92.42 |
| 93624 | S | Electrophysiologic study ........................................ | 0087 | 9.53 | \$462.08 | \$214.72 | \$92.42 |
| 93631 | S | Heart pacing, mapping ........ | 0087 | 9.53 | \$462.08 | \$214.72 | \$92.42 |
| 93640 | S | Evaluation heart device | 0084 | 10.70 | \$518.81 | \$177.79 | \$103.76 |
| 93641 | S | Electrophysiology evaluation .................................. | 0084 | 10.70 | \$518.81 | \$177.79 | \$103.76 |
| 93642 | S | Electrophysiology evaluation .................................. | 0084 | 10.70 | \$518.81 | \$177.79 | \$103.76 |
| 93650 | S | Ablate heart dysrhythm focus ................................. | 0086 | 47.62 | \$2,308.95 | \$1,265.37 | \$461.79 |
| 93651 | S | Ablate heart dysrhythm focus | 0086 | 47.62 | \$2,308.95 | \$1,265.37 | \$461.79 |
| 93652 | S | Ablate heart dysrhythm focus .................................. | 0086 | 47.62 | \$2,308.95 | \$1,265.37 | \$461.79 |
| 93660 | S | Tilt table evaluation ...... | 0101 | 4.47 | \$216.74 | \$128.84 | \$43.35 |
| 93720 | E | Total body plethysmography |  |  |  |  |  |
| 93721 | S | Plethysmography tracing ....................................... | 0096 | 2.06 | \$99.88 | \$61.48 | \$19.98 |
| 93722 | E | Plethysmography report ......................................... |  |  |  |  |  |
| 93724 | S | Analyze pacemaker system .................................... | 0100 | 1.70 | \$82.43 | \$71.57 | \$16.49 |
| 93727 | S | Analyze ilr system ................................................. | 0102 | 0.45 | \$21.82 | \$12.62 | \$4.36 |
| 93731 | S | Analyze pacemaker system .................................... | 0102 | 0.45 | \$21.82 | \$12.62 | \$4.36 |
| 93732 | S | Analyze pacemaker system .................................... | 0102 | 0.45 | \$21.82 | \$12.62 | \$4.36 |

[^218]
# Addendum B.-Hospital Outpatient Department (HOPD) Payment Status by HCPCS Code and Related INFORMATION-Continued 

| $\begin{aligned} & \text { CPT/ } \\ & \text { HCPCS } \end{aligned}$ | HOPD Status Indicator | Description | APC | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 93733 | S | Telephone analy, pacemaker | 0102 | 0.45 | \$21.82 | \$12.62 | \$4.36 |
| 93734 | S | Analyze pacemaker system .. | 0102 | 0.45 | \$21.82 | \$12.62 | \$4.36 |
| 93735 | S | Analyze pacemaker system | 0102 | 0.45 | \$21.82 | \$12.62 | \$4.36 |
| 93736 | S | Telephone analy, pacemaker | 0102 | 0.45 | \$21.82 | \$12.62 | \$4.36 |
| 93737 | S | Analyze cardio/defibrillator. | 0102 | 0.45 | \$21.82 | \$12.62 | \$4.36 |
| 93738 | S | Analyze cardio/defibrillator | 0102 | 0.45 | \$21.82 | \$12.62 | \$4.36 |
| 93740 | S | Temperature gradient studies | 0096 | 2.06 | \$99.88 | \$61.48 | \$19.98 |
| 93741 | S | Analyze ht pace device sngl | 0102 | 0.45 | \$21.82 | \$12.62 | \$4.36 |
| 93742 | S | Analyze ht pace device sngl ................................... | 0102 | 0.45 | \$21.82 | \$12.62 | \$4.36 |
| 93743 | S | Analyze ht pace device dual | 0102 | 0.45 | \$21.82 | \$12.62 | \$4.36 |
| 93744 | S | Analyze ht pace device dual | 0102 | 0.45 | \$21.82 | \$12.62 | \$4.36 |
| 93760 | E | Cephalic thermogram .......... |  |  |  |  |  |
| 93762 | E | Peripheral thermogram |  |  |  |  |  |
| 93770 | N | Measure venous pressure |  | ..... |  | ... |  |
| 93784 | E | Ambulatory BP monitoring |  |  |  |  |  |
| 93786 | E | Ambulatory BP recording .. |  |  |  |  |  |
| 93788 | E | Ambulatory BP analysis | ...... | ...... | ................ | ................... | .................. |
| 93790 | E | Review/report BP recording |  |  |  |  |  |
| 93797 | S | Cardiac rehab | 0095 | 0.64 | \$31.03 | \$16.98 | \$6.21 |
| 93798 | S | Cardiac rehab/monitor | 0095 | 0.64 | \$31.03 | \$16.98 | \$6.21 |
| 93799 | S | Cardiovascular procedure | 0096 | 2.06 | \$99.88 | \$61.48 | \$19.98 |
| 93875 | S | Extracranial study | 0096 | 2.06 | \$99.88 | \$61.48 | \$19.98 |
| 93880 | S | Extracranial study | 0267 | 2.72 | \$131.88 | \$80.06 | \$26.38 |
| 93882 | S | Extracranial study | 0267 | 2.72 | \$131.88 | \$80.06 | \$26.38 |
| 93886 | S | Intracranial study | 0267 | 2.72 | \$131.88 | \$80.06 | \$26.38 |
| 93888 | S | Intracranial study | 0267 | 2.72 | \$131.88 | \$80.06 | \$26.38 |
| 93922 | S | Extremity study | 0096 | 2.06 | \$99.88 | \$61.48 | \$19.98 |
| 93923 | S | Extremity study | 0096 | 2.06 | \$99.88 | \$61.48 | \$19.98 |
| 93924 | S | Extremity study | 0096 | 2.06 | \$99.88 | \$61.48 | \$19.98 |
| 93925 | S | Lower extremity study | 0267 | 2.72 | \$131.88 | \$80.06 | \$26.38 |
| 93926 | S | Lower extremity study | 0267 | 2.72 | \$131.88 | \$80.06 | \$26.38 |
| 93930 | S | Upper extremity study | 0267 | 2.72 | \$131.88 | \$80.06 | \$26.38 |
| 93931 | S | Upper extremity study | 0267 | 2.72 | \$131.88 | \$80.06 | \$26.38 |
| 93965 | S | Extremity study | 0096 | 2.06 | \$99.88 | \$61.48 | \$19.98 |
| 93970 | S | Extremity study | 0267 | 2.72 | \$131.88 | \$80.06 | \$26.38 |
| 93971 | S | Extremity study | 0267 | 2.72 | \$131.88 | \$80.06 | \$26.38 |
| 93975 | S | Vascular study | 0267 | 2.72 | \$131.88 | \$80.06 | \$26.38 |
| 93976 | S | Vascular study | 0267 | 2.72 | \$131.88 | \$80.06 | \$26.38 |
| 93978 | S | Vascular study | 0267 | 2.72 | \$131.88 | \$80.06 | \$26.38 |
| 93979 | S | Vascular study | 0267 | 2.72 | \$131.88 | \$80.06 | \$26.38 |
| 93980 | S | Penile vascular study | 0267 | 2.72 | \$131.88 | \$80.06 | \$26.38 |
| 93981 | S | Penile vascular study | 0267 | 2.72 | \$131.88 | \$80.06 | \$26.38 |
| 93990 | S | Doppler flow testing | 0267 | 2.72 | \$131.88 | \$80.06 | \$26.38 |
| 94010 | X | Breathing capacity test | 0367 | 0.83 | \$40.24 | \$20.65 | \$8.05 |
| 94014 | X | Patient recorded spirometry | 0369 | 2.34 | \$113.46 | \$58.50 | \$22.69 |
| 94015 | X | Patient recorded spirometry | 0369 | 2.34 | \$113.46 | \$58.50 | \$22.69 |
| 94016 | X | Review patient spirometry | 0369 | 2.34 | \$113.46 | \$58.50 | \$22.69 |
| 94060 | X | Evaluation of wheezing | 0368 | 1.66 | \$80.49 | \$42.44 | \$16.10 |
| 94070 | X | Evaluation of wheezing | 0369 | 2.34 | \$113.46 | \$58.50 | \$22.69 |
| 94150 | N | Vital capacity test ....... |  |  |  |  |  |
| 94200 | X | Lung function test (MBC/MVV) | 0367 | 0.83 | \$40.24 | \$20.65 | \$8.05 |
| 94240 | X | Residual lung capacity ............. | 0368 | 1.66 | \$80.49 | \$42.44 | \$16.10 |
| 94250 | X | Expired gas collection ............................................ | 0367 | 0.83 | \$40.24 | \$20.65 | \$8.05 |
| 94260 | X | Thoracic gas volume | 0368 | 1.66 | \$80.49 | \$42.44 | \$16.10 |
| 94350 | X | Lung nitrogen washout curve | 0368 | 1.66 | \$80.49 | \$42.44 | \$16.10 |
| 94360 | X | Measure airflow resistance | 0368 | 1.66 | \$80.49 | \$42.44 | \$16.10 |
| 94370 | X | Breath airway closing volume . | 0368 | 1.66 | \$80.49 | \$42.44 | \$16.10 |
| 94375 | X | Respiratory flow volume loop | 0367 | 0.83 | \$40.24 | \$20.65 | \$8.05 |
| 94400 | X | CO 2 breathing response curve | 0367 | 0.83 | \$40.24 | \$20.65 | \$8.05 |
| 94450 | X | Hypoxia response curve ........................................ | 0367 | 0.83 | \$40.24 | \$20.65 | \$8.05 |
| 94620 | X | Pulmonary stress test/simple | 0368 | 1.66 | \$80.49 | \$42.44 | \$16.10 |
| 94621 | X | Pulm stress test/complex ..... | 0369 | 2.34 | \$113.46 | \$58.50 | \$22.69 |
| 94640 | S | Airway inhalation treatment .................................... | 0077 | 0.43 | \$20.85 | \$12.62 | \$4.17 |
| 94642 | S | Aerosol inhalation treatment | 0078 | 1.34 | \$64.97 | \$29.13 | \$12.99 |
| 94650 | S | Pressure breathing (IPPB) | 0077 | 0.43 | \$20.85 | \$12.62 | \$4.17 |
| 94651 | S | Pressure breathing (IPPB) ...................................... | 0077 | 0.43 | \$20.85 | \$12.62 | \$4.17 |
| 94652 | C | Pressure breathing (IPPB) ...................................... |  |  |  |  |  |
| 94656 | S | Initial ventilator mgmt . | 0079 | 3.18 | \$154.19 | \$107.70 | \$30.84 |
| 94657 | S | Continued ventilator mgmt ...................................... | 0079 | 3.18 | \$154.19 | \$107.70 | \$30.84 |
| 94660 | S | Pos airway pressure, CPAP ................................... | 0079 | 3.18 | \$154.19 | \$107.70 | \$30.84 |
| 94662 | S | Neg press ventilation, cnp ...................................... | 0079 | 3.18 | \$154.19 | \$107.70 | \$30.84 |
| 94664 | S | Aerosol or vapor inhalations ................................... | 0077 | 0.43 | \$20.85 | \$12.62 | \$4.17 |
| 94665 | S | Aerosol or vapor inhalations ................................. | 0077 | 0.43 | \$20.85 | \$12.62 | \$4.17 |

[^219]
## Addendum B.-Hospital Outpatient Department (HOPD) Payment Status by hCPCS Code and Related Information-Continued

| CPT/ HCPCS | HOPD <br> Status <br> Indicator | Description | APC | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 94667 | S | Chest wall manipulation | 0077 | 0.43 | \$20.85 | \$12.62 | \$4.17 |
| 94668 | S | Chest wall manipulation | 0077 | 0.43 | \$20.85 | \$12.62 | \$4.17 |
| 94680 | X | Exhaled air analysis, 02 | 0367 | 0.83 | \$40.24 | \$20.65 | \$8.05 |
| 94681 | X | Exhaled air analysis, o2/co2 | 0368 | 1.66 | \$80.49 | \$42.44 | \$16.10 |
| 94690 | X | Exhaled air analysis | 0367 | 0.83 | \$40.24 | \$20.65 | \$8.05 |
| 94720 | X | Monoxide diffusing capacity | 0367 | 0.83 | \$40.24 | \$20.65 | \$8.05 |
| 94725 | X | Membrane diffusion capacity | 0368 | 1.66 | \$80.49 | \$42.44 | \$16.10 |
| 94750 | X | Pulmonary compliance study | 0368 | 1.66 | \$80.49 | \$42.44 | \$16.10 |
| 94760 | N | Measure blood oxygen level. |  |  |  |  |  |
| 94761 | N | Measure blood oxygen level |  |  |  |  |  |
| 94762 | C | Measure blood oxygen level |  |  |  |  |  |
| 94770 | X | Exhaled carbon dioxide test | 0367 | 0.83 | \$40.24 | \$20.65 | \$8.05 |
| 94772 | X | Breath recording, infant | 0369 | 2.34 | \$113.46 | \$58.50 | \$22.69 |
| 94799 | X | Pulmonary service/procedure | 0367 | 0.83 | \$40.24 | \$20.65 | \$8.05 |
| 95004 | X | Allergy skin tests ................. | 0370 | 0.57 | \$27.64 | \$11.81 | \$5.53 |
| 95010 | X | Sensitivity skin tests | 0370 | 0.57 | \$27.64 | \$11.81 | \$5.53 |
| 95015 | X | Sensitivity skin tests | 0370 | 0.57 | \$27.64 | \$11.81 | \$5.53 |
| 95024 | X | Allergy skin tests | 0370 | 0.57 | \$27.64 | \$11.81 | \$5.53 |
| 95027 | X | Skin end point titration | 0370 | 0.57 | \$27.64 | \$11.81 | \$5.53 |
| 95028 | X | Allergy skin tests | 0370 | 0.57 | \$27.64 | \$11.81 | \$5.53 |
| 95044 | X | Allergy patch tests | 0370 | 0.57 | \$27.64 | \$11.81 | \$5.53 |
| 95052 | X | Photo patch test .. | 0370 | 0.57 | \$27.64 | \$11.81 | \$5.53 |
| 95056 | X | Photosensitivity tests | 0370 | 0.57 | \$27.64 | \$11.81 | \$5.53 |
| 95060 | X | Eye allergy tests | 0370 | 0.57 | \$27.64 | \$11.81 | \$5.53 |
| 95065 | X | Nose allergy test | 0370 | 0.57 | \$27.64 | \$11.81 | \$5.53 |
| 95070 | X | Bronchial allergy tests | 0369 | 2.34 | \$113.46 | \$58.50 | \$22.69 |
| 95071 | X | Bronchial allergy tests | 0369 | 2.34 | \$113.46 | \$58.50 | \$22.69 |
| 95075 | X | Ingestion challenge test | 0361 | 3.53 | \$171.16 | \$88.09 | \$34.23 |
| 95078 | X | Provocative testing | 0370 | 0.57 | \$27.64 | \$11.81 | \$5.53 |
| 95115 | X | Immunotherapy, one injection | 0371 | 0.32 | \$15.52 | \$3.67 | \$3.10 |
| 95117 | X | Immunotherapy injections | 0371 | 0.32 | \$15.52 | \$3.67 | \$3.10 |
| 95120 | E | Immunotherapy, one injection |  |  |  |  |  |
| 95125 | E | Immunotherapy, many antigens ..... | .... |  |  |  |  |
| 95130 | E | Immunotherapy, insect venom | ... | ...... | ..................... | ..................... |  |
| 95131 | E | Immunotherapy, insect venoms |  | ..... | .................. | ................... |  |
| 95132 | E | Immunotherapy, insect venoms |  |  |  |  |  |
| 95133 | E | Immunotherapy, insect venoms | $\ldots$ | ................... | .................... | ..................... | .................... |
| 95134 | E | Immunotherapy, insect venoms |  |  |  |  |  |
| 95144 | X | Antigen therapy services | 0371 | 0.32 | \$15.52 | \$3.67 | \$3.10 |
| 95145 | X | Antigen therapy services | 0371 | 0.32 | \$15.52 | \$3.67 | \$3.10 |
| 95146 | X | Antigen therapy services | 0371 | 0.32 | \$15.52 | \$3.67 | \$3.10 |
| 95147 | X | Antigen therapy services | 0371 | 0.32 | \$15.52 | \$3.67 | \$3.10 |
| 95148 | X | Antigen therapy services | 0371 | 0.32 | \$15.52 | \$3.67 | \$3.10 |
| 95149 | X | Antigen therapy services | 0371 | 0.32 | \$15.52 | \$3.67 | \$3.10 |
| 95165 | X | Antigen therapy services | 0371 | 0.32 | \$15.52 | \$3.67 | \$3.10 |
| 95170 | X | Antigen therapy services | 0371 | 0.32 | \$15.52 | \$3.67 | \$3.10 |
| 95180 | X | Rapid desensitization | 0370 | 0.57 | \$27.64 | \$11.81 | \$5.53 |
| 95199 | X | Allergy immunology services | 0370 | 0.57 | \$27.64 | \$11.81 | \$5.53 |
| 95805 | S | Multiple sleep latency test | 0213 | 11.15 | \$540.63 | \$290.42 | \$108.13 |
| 95806 | S | Sleep study, unattended | 0213 | 11.15 | \$540.63 | \$290.42 | \$108.13 |
| 95807 | S | Sleep study, attended ........... | 0213 | 11.15 | \$540.63 | \$290.42 | \$108.13 |
| 95808 | S | Polysomnography, 1-3 | 0213 | 11.15 | \$540.63 | \$290.42 | \$108.13 |
| 95810 | S | Polysomnography, 4 or more | 0213 | 11.15 | \$540.63 | \$290.42 | \$108.13 |
| 95811 | S | Polysomnography w/cpap ...... | 0213 | 11.15 | \$540.63 | \$290.42 | \$108.13 |
| 95812 | S | Electroencephalogram (EEG) | 0213 | 11.15 | \$540.63 | \$290.42 | \$108.13 |
| 95813 | S | Electroencephalogram (EEG) | 0213 | 11.15 | \$540.63 | \$290.42 | \$108.13 |
| 95816 | S | Electroencephalogram (EEG) ................................. | 0214 | 2.32 | \$112.49 | \$58.50 | \$22.50 |
| 95819 | S | Electroencephalogram (EEG) .... | 0214 | 2.32 | \$112.49 | \$58.50 | \$22.50 |
| 95822 | S | Sleep electroencephalogram | 0214 | 2.32 | \$112.49 | \$58.50 | \$22.50 |
| 95824 | S | Electroencephalography ........................................ | 0214 | 2.32 | \$112.49 | \$58.50 | \$22.50 |
| 95827 | S | Night electroencephalogram | 0213 | 11.15 | \$540.63 | \$290.42 | \$108.13 |
| 95829 | S | Surgery electrocorticogram ..................................... | 0214 | 2.32 | \$112.49 | \$58.50 | \$22.50 |
| 95830 | E | Insert electrodes for EEG ....................................... |  |  |  |  |  |
| 95831 | N | Limb muscle testing, manual .................................. |  |  | ......... |  |  |
| 95832 | N | Hand muscle testing, manual .................................. | ...... | .................... | .................... |  | ................. |
| 95833 | N | Body muscle testing, manual .................................. |  |  |  |  |  |
| 95834 | N | Body muscle testing, manual ................................. |  |  | .................... | .................... | ..................... |
| 95851 | N | Range of motion measurements .............................. |  |  |  |  |  |
| 95852 | N | Range of motion measurements ............................. |  |  |  |  |  |
| 95857 | S | Tensilon test | 0215 | 1.15 | \$55.76 | \$30.05 | \$11.15 |
| 95858 | S | Tensilon test \& myogram ....................................... | 0215 | 1.15 | \$55.76 | \$30.05 | \$11.15 |
| 95860 | S | Muscle test, one limb ............................................ | 0215 | 1.15 | \$55.76 | \$30.05 | \$11.15 |
| 95861 | S | Muscle test, two limbs ................... | 0215 | 1.15 | \$55.76 | \$30.05 | \$11.15 |

[^220]
## Addendum B.-Hospital Outpatient Department (HOPD) Payment Status by HCPCS Code and Related Information-Continued

| $\begin{aligned} & \text { CPT/ } \\ & \text { HCPCS } \end{aligned}$ | HOPD Status Indicator | Description | APC | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 95863 | S | Muscle test, 3 limbs | 0216 | 2.87 | \$139.16 | \$64.69 | \$27.83 |
| 95864 | S | Muscle test, 4 limbs | 0215 | 1.15 | \$55.76 | \$30.05 | \$11.15 |
| 95867 | S | Muscle test, head or neck | 0216 | 2.87 | \$139.16 | \$64.69 | \$27.83 |
| 95868 | S | Muscle test, head or neck | 0216 | 2.87 | \$139.16 | \$64.69 | \$27.83 |
| 95869 | S | Muscle test, thor paraspinal | 0215 | 1.15 | \$55.76 | \$30.05 | \$11.15 |
| 95870 | S | Muscle test, nonparaspinal . | 0215 | 1.15 | \$55.76 | \$30.05 | \$11.15 |
| 95872 | S | Muscle test, one fiber ... | 0215 | 1.15 | \$55.76 | \$30.05 | \$11.15 |
| 95875 | S | Limb exercise test | 0217 | 5.87 | \$284.62 | \$156.68 | \$56.92 |
| 95900 | S | Motor nerve conduction test | 0215 | 1.15 | \$55.76 | \$30.05 | \$11.15 |
| 95903 | S | Motor nerve conduction test | 0215 | 1.15 | \$55.76 | \$30.05 | \$11.15 |
| 95904 | S | Sense/mixed n conduction tst | 0215 | 1.15 | \$55.76 | \$30.05 | \$11.15 |
| 95920 | C | Intraop nerve test add-on |  |  |  |  |  |
| 95921 | S | Autonomic nerv function test | 0216 | 2.87 | \$139.16 | \$64.69 | \$27.83 |
| 95922 | S | Autonomic nerv function test | 0216 | 2.87 | \$139.16 | \$64.69 | \$27.83 |
| 95923 | S | Autonomic nerv function test | 0216 | 2.87 | \$139.16 | \$64.69 | \$27.83 |
| 95925 | S | Somatosensory testing | 0216 | 2.87 | \$139.16 | \$64.69 | \$27.83 |
| 95926 | S | Somatosensory testing | 0216 | 2.87 | \$139.16 | \$64.69 | \$27.83 |
| 95927 | S | Somatosensory testing | 0216 | 2.87 | \$139.16 | \$64.69 | \$27.83 |
| 95930 | S | Visual evoked potential test | 0216 | 2.87 | \$139.16 | \$64.69 | \$27.83 |
| 95933 | S | Blink reflex test | 0215 | 1.15 | \$55.76 | \$30.05 | \$11.15 |
| 95934 | S | H-reflex test | 0215 | 1.15 | \$55.76 | \$30.05 | \$11.15 |
| 95936 | S | H-reflex test | 0216 | 2.87 | \$139.16 | \$64.69 | \$27.83 |
| 95937 | S | Neuromuscular junction test | 0215 | 1.15 | \$55.76 | \$30.05 | \$11.15 |
| 95950 | S | Ambulatory eeg monitoring | 0217 | 5.87 | \$284.62 | \$156.68 | \$56.92 |
| 95951 | S | EEG monitoring/videorecord | 0213 | 11.15 | \$540.63 | \$290.42 | \$108.13 |
| 95953 | S | EEG monitoring/computer | 0213 | 11.15 | \$540.63 | \$290.42 | \$108.13 |
| 95954 | S | EEG monitoring/giving drugs | 0213 | 11.15 | \$540.63 | \$290.42 | \$108.13 |
| 95955 | S | EEG during surgery | 0214 | 2.32 | \$112.49 | \$58.50 | \$22.50 |
| 95956 | N | Eeg monitoring, cable/radio . |  |  |  |  |  |
| 95957 | N | EEG digital analysis |  |  |  |  |  |
| 95958 | S | EEG monitoring/function test | 0213 | 11.15 | \$540.63 | \$290.42 | \$108.13 |
| 95961 | C | Electrode stimulation, brain |  |  |  |  |  |
| 95962 | C | Electrode stim, brain add-on |  |  |  |  |  |
| 95970 | S | Analyze neurostim, no prog .................................... | 0102 | 0.45 | \$21.82 | \$12.62 | \$4.36 |
| 95971 | S | Analyze neurostim, simple ...................................... | 0102 | 0.45 | \$21.82 | \$12.62 | \$4.36 |
| 95972 | S | Analyze neurostim, complex | 0102 | 0.45 | \$21.82 | \$12.62 | \$4.36 |
| 95973 | S | Analyze neurostim, complex | 0102 | 0.45 | \$21.82 | \$12.62 | \$4.36 |
| 95974 | S | Cranial neurostim, complex | 0102 | 0.45 | \$21.82 | \$12.62 | \$4.36 |
| 95975 | S | Cranial neurostim, complex | 0102 | 0.45 | \$21.82 | \$12.62 | \$4.36 |
| 95999 | N | Neurological procedure ......................................... |  |  |  |  |  |
| 96100 | X | Psychological testing ............................................. | 0373 | 3.21 | \$155.64 | \$44.96 | \$31.13 |
| 96105 | X | Assessment of aphasia | 0373 | 3.21 | \$155.64 | \$44.96 | \$31.13 |
| 96110 | X | Developmental test, lim | 0373 | 3.21 | \$155.64 | \$44.96 | \$31.13 |
| 96111 | X | Developmental test, extend | 0373 | 3.21 | \$155.64 | \$44.96 | \$31.13 |
| 96115 | X | Neurobehavior status exam | 0373 | 3.21 | \$155.64 | \$44.96 | \$31.13 |
| 96117 | X | Neuropsych test battery | 0373 | 3.21 | \$155.64 | \$44.96 | \$31.13 |
| 96400 | E | Chemotherapy, sc/im ............................................ | ...................... | ...................... | ............ |  |  |
| 96405 | E | Intralesional chemo admin |  | ....... | ...... | ..................... |  |
| 96406 | E | Intralesional chemo admin |  |  |  |  |  |
| 96408 | E | Chemotherapy, push technique .............................. |  | ..................... |  | ..................... |  |
| 96410 | E | Chemotherapy, infusion method |  | ........ |  | ..................... |  |
| 96412 | E | Chemo, infuse method add-on ................................ |  |  |  |  |  |
| 96414 | E | Chemo, infuse method add-on ................................ |  |  |  |  |  |
| 96420 | E | Chemotherapy, push technique .............................. |  | ..................... |  | .................. |  |
| 96422 | E | Chemotherapy, infusion method .............................. |  |  |  |  |  |
| 96423 | E | Chemo, infuse method add-on ................................ |  |  |  |  |  |
| 96425 | E | Chemotherapy, infusion method .............................. |  |  |  | .................... | .................... |
| 96440 | E | Chemotherapy, intracavitary ...... |  |  |  |  |  |
| 96445 | E | Chemotherapy, intracavitary ................................... |  |  |  |  |  |
| 96450 | E | Chemotherapy, into CNS ........................................ |  |  |  | ..................... | ................... |
| 96520 | E | Pump refilling, maintenance ................................... |  |  |  | ..................... |  |
| 96530 | E | Pump refilling, maintenance ................................... |  |  |  |  |  |
| 96542 | E | Chemotherapy injection ......................................... |  |  |  | ..................... | .................... |
| 96545 | E | Provide chemotherapy agent .................................. |  |  |  | ..................... |  |
| 96549 | E | Chemotherapy, unspecified .................................... |  |  |  |  |  |
| 96570 | T | Photodynamic tx, 30 min ........................................ | 0075 | 18.55 | \$899.44 | \$467.29 | \$179.89 |
| 96571 | T | Photodynamic tx, addl 15 min ................................. | 0075 | 18.55 | \$899.44 | \$467.29 | \$179.89 |
| 96900 | S | Ultraviolet light therapy .......................................... | 0001 | 0.47 | \$22.79 | \$8.49 | \$4.56 |
| 96902 | N | Trichogram .......................................................... |  |  |  |  |  |
| 96910 | S | Photochemotherapy with UV-B ............................... | 0001 | 0.47 | \$22.79 | \$8.49 | \$4.56 |
| 96912 | S | Photochemotherapy with UV-A ............................... | 0001 | 0.47 | \$22.79 | \$8.49 | \$4.56 |
| 96913 | S | Photochemotherapy, UV-A or B .............................. | 0001 | 0.47 | \$22.79 | \$8.49 | \$4.56 |
| 96999 | S | Dermatological procedure | 0001 | 0.47 | \$22.79 | \$8.49 | \$4.56 |

[^221]
# Addendum B.—Hospital Outpatient Department (HOPD) Payment Status by hCPCS Code and Related Information-Continued 

| CPT/ HCPCS | HOPD Status Indicator | Description | APC | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 97001 | A | Pt evaluation |  | ....... |  |  |  |
| 97002 | A | Pt re-evaluation |  |  |  | ...................... |  |
| 97003 | A | Ot evaluation |  |  |  |  |  |
| 97004 | A | Ot re-evaluation |  |  |  |  |  |
| 97010 | A | Hot or cold packs therapy |  |  |  |  |  |
| 97012 | A | Mechanical traction therapy |  | .................... | .................... | ...................... |  |
| 97014 | A | Electric stimulation therapy |  |  |  |  |  |
| 97016 | A | Vasopneumatic device therapy |  |  |  |  |  |
| 97018 | A | Paraffin bath therapy |  |  |  |  |  |
| 97020 | A | Microwave therapy |  |  |  |  |  |
| 97022 | A | Whirlpool therapy |  |  |  |  |  |
| 97024 | A | Diathermy treatment |  |  |  |  |  |
| 97026 | A | Infrared therapy |  |  |  |  |  |
| 97028 | A | Ultraviolet therapy |  |  | ..................... |  |  |
| 97032 | A | Electrical stimulation |  |  |  |  |  |
| 97033 | A | Electric current therapy |  |  |  |  |  |
| 97034 | A | Contrast bath therapy |  |  |  |  |  |
| 97035 | A | Ultrasound therapy |  |  |  |  |  |
| 97036 | A | Hydrotherapy |  |  |  |  |  |
| 97039 | A | Physical therapy treatment |  |  |  |  |  |
| 97110 | A | Therapeutic exercises |  |  |  |  |  |
| 97112 | A | Neuromuscular reeducation |  |  |  |  |  |
| 97113 | A | Aquatic therapy/exercises |  |  |  |  |  |
| 97116 | A | Gait training therapy |  |  |  |  |  |
| 97124 | A | Massage therapy |  |  |  |  |  |
| 97139 | A | Physical medicine procedure |  |  |  |  |  |
| 97140 | A | Manual therapy |  |  |  |  |  |
| 97150 | A | Group therapeutic procedures |  |  |  |  |  |
| 97504 | A | Orthotic training |  |  |  |  |  |
| 97520 | A | Prosthetic training | .................... |  | ..................... | ..................... |  |
| 97530 | A | Therapeutic activities |  |  |  |  |  |
| 97535 | A | Self care mngment training |  |  |  |  |  |
| 97537 | A | Community/work reintegration | ................... | ..................... | ..................... | .................... |  |
| 97542 | A | Wheelchair mngment training |  |  | ........... | ...................... |  |
| 97545 | A | Work hardening .... |  |  |  |  |  |
| 97546 | A | Work hardening add-on |  |  |  |  |  |
| 97703 | A | Prosthetic checkout |  |  |  |  |  |
| 97750 | A | Physical performance test |  |  |  |  |  |
| 97770 | A | Cognitive skills development |  |  |  |  |  |
| 97780 | E | Acupuncture w/o stimul |  |  |  | ..................... |  |
| 97781 | E | Acupuncture w/stimul |  |  |  |  |  |
| 97799 | A | Physical medicine procedure |  |  |  |  |  |
| 98925 | S | Osteopathic manipulation | 0060 | 0.77 | \$37.34 | \$7.80 | \$7.47 |
| 98926 | S | Osteopathic manipulation | 0060 | 0.77 | \$37.34 | \$7.80 | \$7.47 |
| 98927 | S | Osteopathic manipulation | 0060 | 0.77 | \$37.34 | \$7.80 | \$7.47 |
| 98928 | S | Osteopathic manipulation | 0060 | 0.77 | \$37.34 | \$7.80 | \$7.47 |
| 98929 | S | Osteopathic manipulation | 0060 | 0.77 | \$37.34 | \$7.80 | \$7.47 |
| 98940 | S | Chiropractic manipulation | 0060 | 0.77 | \$37.34 | \$7.80 | \$7.47 |
| 98941 | S | Chiropractic manipulation | 0060 | 0.77 | \$37.34 | \$7.80 | \$7.47 |
| 98942 | S | Chiropractic manipulation | 0060 | 0.77 | \$37.34 | \$7.80 | \$7.47 |
| 98943 | E | Chiropractic manipulation |  |  |  |  |  |
| 99000 | E | Specimen handling ... |  |  |  |  |  |
| 99001 | E | Specimen handling | ................... | .................... |  | ...................... |  |
| 99002 | E | Device handling |  |  |  |  |  |
| 99024 | E | Postop follow-up visit |  |  |  |  |  |
| 99025 | E | Initial surgical evaluation ........................................ |  | .................... |  | .................... |  |
| 99050 | E | Medical services after hrs |  |  |  | ...................... |  |
| 99052 | E | Medical services at night ........................................ |  |  |  |  |  |
| 99054 | E | Medical servcs, unusual hrs |  |  |  | ...................... |  |
| 99056 | E | Non-office medical services |  | ...................... |  | ...................... |  |
| 99058 | E | Office emergency care .. |  |  |  |  |  |
| 99070 | E | Special supplies |  |  |  |  |  |
| 99071 | E | Patient education materials | ..................... | .................... | .................... | ..................... |  |
| 99075 | E | Medical testimony |  |  |  |  |  |
| 99078 | E | Group health education |  |  |  |  |  |
| 99080 | E | Special reports or forms |  |  |  |  |  |
| 99082 | E | Unusual physician travel |  |  |  | ............ |  |
| 99090 | E | Computer data analysis |  |  |  |  |  |
| 99100 | E | Special anesthesia service |  |  |  |  |  |
| 99116 | E | Anesthesia with hypothermia |  |  |  |  |  |
| 99135 | E | Special anesthesia procedure ................................. |  | ...................... |  | ...................... |  |
| 99140 | E | Emergency anesthesia .... | .................. |  |  |  |  |
| 99141 | N | Sedation, iv/im or inhalant |  |  |  |  |  |

[^222]
# Addendum B.-Hospital Outpatient Department (HOPD) Payment Status by HCPCS Code and Related INFORMATION-Continued 

| $\begin{gathered} \text { CPT/ } \\ \text { HCPCS } \end{gathered}$ | HOPD Status Indicator | Description | APC | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 99142 | N | Sedation, oral/rectal/nasal |  |  |  |  |  |
| 99170 | T | Anogenital exam, child | 0192 | 2.38 | \$115.40 | \$35.33 | \$23.08 |
| 99173 | N | Visual screening test |  |  |  |  |  |
| 99175 | N | Induction of vomiting |  |  |  |  |  |
| 99183 | S | Hyperbaric oxygen therapy | 0031 | 3.00 | \$145.46 | \$140.85 | \$29.09 |
| 99185 | N | Regional hypothermia .. |  |  |  |  |  |
| 99186 | N | Total body hypothermia |  |  |  |  |  |
| 99190 | C | Special pump services. |  |  |  |  |  |
| 99191 | C | Special pump services |  |  |  |  |  |
| 99192 | C | Special pump services |  |  |  |  |  |
| 99195 | X | Phlebotomy | 0372 | 0.43 | \$20.85 | \$10.09 | \$4.17 |
| 99199 | E | Special service/proc/report |  |  |  |  |  |
| 99201 | V | Office/outpatient visit, new | 0600 | 0.98 | \$47.52 | \$9.50 | \$9.50 |
| 99202 | V | Office/outpatient visit, new | 0600 | 0.98 | \$47.52 | \$9.50 | \$9.50 |
| 99203 | V | Office/outpatient visit, new | 0601 | 1.00 | \$48.49 | \$9.70 | \$9.70 |
| 99204 | V | Office/outpatient visit, new | 0602 | 1.66 | \$80.49 | \$16.29 | \$16.10 |
| 99205 | V | Office/outpatient visit, new | 0602 | 1.66 | \$80.49 | \$16.29 | \$16.10 |
| 99211 | V | Office/outpatient visit, est | 0600 | 0.98 | \$47.52 | \$9.50 | \$9.50 |
| 99212 | V | Office/outpatient visit, est | 0600 | 0.98 | \$47.52 | \$9.50 | \$9.50 |
| 99213 | V | Office/outpatient visit, est | 0601 | 1.00 | \$48.49 | \$9.70 | \$9.70 |
| 99214 | V | Office/outpatient visit, est | 0602 | 1.66 | \$80.49 | \$16.29 | \$16.10 |
| 99215 | V | Office/outpatient visit, est | 0602 | 1.66 | \$80.49 | \$16.29 | \$16.10 |
| 99217 | N | Observation care discharge |  |  |  |  |  |
| 99218 | N | Observation care . | ................... | .................... | .................... | .................... |  |
| 99219 | N | Observation care . |  |  | ...................... |  |  |
| 99220 | N | Observation care | ..... | ..................... | ...................... | ..................... | ...................... |
| 99221 | E | Initial hospital care |  |  |  | ...................... |  |
| 99222 | E | Initial hospital care | ....... | ................. | ..................... | ...................... |  |
| 99223 | E | Initial hospital care |  |  |  |  |  |
| 99231 | E | Subsequent hospital care |  | ................... | ..................... | ... |  |
| 99232 | E | Subsequent hospital care |  |  |  | ...................... |  |
| 99233 | E | Subsequent hospital care |  |  |  |  |  |
| 99234 | C | Observ/hosp same date . | .................... | .................... | .................... | ................. | .................... |
| 99235 | C | Observ/hosp same date . |  | ...... |  | ..................... |  |
| 99236 | C | Observ/hosp same date |  |  |  |  |  |
| 99238 | E | Hospital discharge day |  | ..................... |  | ..................... |  |
| 99239 | E | Hospital discharge day |  |  |  |  |  |
| 99241 | V | Office consultation | 0600 | 0.98 | \$47.52 | \$9.50 | \$9.50 |
| 99242 | V | Office consultation | 0600 | 0.98 | \$47.52 | \$9.50 | \$9.50 |
| 99243 | V | Office consultation | 0601 | 1.00 | \$48.49 | \$9.70 | \$9.70 |
| 99244 | V | Office consultation | 0602 | 1.66 | \$80.49 | \$16.29 | \$16.10 |
| 99245 | V | Office consultation | 0602 | 1.66 | \$80.49 | \$16.29 | \$16.10 |
| 99251 | C | Initial inpatient consult |  |  |  | ...................... |  |
| 99252 | C | Initial inpatient consult |  |  |  |  |  |
| 99253 | C | Initial inpatient consult |  |  |  |  |  |
| 99254 | C | Initial inpatient consult |  |  |  | ..................... | ...................... |
| 99255 | C | Initial inpatient consult .... | ................... | .................... | ..................... | .................... | .................... |
| 99261 | C | Follow-up inpatient consult |  |  |  |  |  |
| 99262 | C | Follow-up inpatient consult |  |  |  |  |  |
| 99263 | C | Follow-up inpatient consult |  |  |  |  |  |
| 99271 | V | Confirmatory consultation | 0600 | 0.98 | \$47.52 | \$9.50 | \$9.50 |
| 99272 | V | Confirmatory consultation | 0600 | 0.98 | \$47.52 | \$9.50 | \$9.50 |
| 99273 | V | Confirmatory consultation ....................................... | 0601 | 1.00 | \$48.49 | \$9.70 | \$9.70 |
| 99274 | V | Confirmatory consultation | 0602 | 1.66 | \$80.49 | \$16.29 | \$16.10 |
| 99275 | V | Confirmatory consultation | 0602 | 1.66 | \$80.49 | \$16.29 | \$16.10 |
| 99281 | V | Emergency dept visit ............................................. | 0610 | 1.34 | \$64.97 | \$20.65 | \$12.99 |
| 99282 | V | Emergency dept visit | 0610 | 1.34 | \$64.97 | \$20.65 | \$12.99 |
| 99283 | V | Emergency dept visit | 0611 | 2.11 | \$102.31 | \$36.47 | \$20.46 |
| 99284 | V | Emergency dept visit .... | 0612 | 3.19 | \$154.67 | \$54.14 | \$30.93 |
| 99285 | V | Emergency dept visit | 0612 | 3.19 | \$154.67 | \$54.14 | \$30.93 |
| 99288 | E | Direct advanced life support |  |  |  |  |  |
| 99291 | S | Critical care, first hour | 0620 | 8.60 | \$416.99 | \$152.78 | \$83.40 |
| 99292 | N | Critical care, addl 30 min ........................................ |  |  | ...................... | .... |  |
| 99295 | C | Neonatal critical care |  |  |  |  |  |
| 99296 | C | Neonatal critical care |  |  |  |  |  |
| 99297 | C | Neonatal critical care | ........... |  | ...................... | ..................... | .................... |
| 99298 | C | Neonatal critical care | .......... |  |  | .................... |  |
| 99301 | E | Nursing facility care |  |  |  |  |  |
| 99302 | E | Nursing facility care ............................................... | ..................... | .................... | .................... | ..................... | .................... |
| 99303 | E | Nursing facility care ............................................... | ...................... | ...................... | ...................... | ................ | ...................... |
| 99311 | E | Nursing fac care, subseq |  |  | ...................... |  |  |
| 99312 | E | Nursing fac care, subseq ....................................... | ................... | ..................... | .................... | ..................... | ..................... |
| 99313 | E | Nursing fac care, subseq |  |  |  |  |  |

[^223]
# Addendum B.—Hospital Outpatient Department (HOPD) Payment Status by hCPCS Code and Related INFORMATION-Continued 

| CPT/ HCPCS | HOPD Status Indicator | Description | APC | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 99315 | E | Nursing fac discharge day . |  |  |  | $\cdot$ |  |
| 99316 | E | Nursing fac discharge day |  |  |  | $\cdot$ |  |
| 99321 | E | Rest home visit, new patient |  |  |  |  |  |
| 99322 | E | Rest home visit, new patient |  |  |  |  |  |
| 99323 | E | Rest home visit, new patient |  |  |  |  |  |
| 99331 | E | Rest home visit, est pat |  |  |  |  |  |
| 99332 | E | Rest home visit, est pat |  |  |  |  |  |
| 99333 | E | Rest home visit, est pat |  |  |  | .................... |  |
| 99341 | E | Home visit, new patient |  |  |  | ..................... |  |
| 99342 | E | Home visit, new patient |  |  |  |  |  |
| 99343 | E | Home visit, new patient . |  |  |  |  |  |
| 99344 | E | Home visit, new patient . |  |  |  |  |  |
| 99345 | E | Home visit, new patient |  |  |  |  |  |
| 99347 | E | Home visit, est patient |  |  |  |  |  |
| 99348 | E | Home visit, est patient |  |  |  |  |  |
| 99349 | E | Home visit, est patient |  |  |  |  |  |
| 99350 | E | Home visit, est patient |  |  |  |  |  |
| 99354 | N | Prolonged service, office |  |  |  |  |  |
| 99355 | N | Prolonged service, office |  |  |  | .................... |  |
| 99356 | C | Prolonged service, inpatient |  |  |  | ...................... |  |
| 99357 | C | Prolonged service, inpatient |  |  |  |  |  |
| 99358 | N | Prolonged serv, w/o contact |  |  |  | .................... |  |
| 99359 | N | Prolonged serv, w/o contact |  |  |  |  |  |
| 99360 | E | Physician standby services |  |  |  |  |  |
| 99361 | E | Physician/team conference .. |  |  |  |  |  |
| 99362 | E | Physician/team conference |  |  |  | ..................... |  |
| 99371 | E | Physician phone consultation |  |  |  |  |  |
| 99372 | E | Physician phone consultation |  |  |  | .................... |  |
| 99373 | E | Physician phone consultation |  |  |  |  |  |
| 99374 | E | Home health care supervision |  |  |  |  |  |
| 99375 | E | Home health care supervision |  |  |  |  |  |
| 99377 | E | Hospice care supervision .. |  |  |  | ...................... |  |
| 99378 | E | Hospice care supervision |  |  |  | .................... |  |
| 99379 | E | Nursing fac care supervision |  |  |  |  |  |
| 99380 | E | Nursing fac care supervision |  |  |  |  |  |
| 99381 | E | Prev visit, new, infant |  |  |  | ..................... |  |
| 99382 | E | Prev visit, new, age 1-4 |  |  |  |  |  |
| 99383 | E | Prev visit, new, age 5-11 |  |  |  |  |  |
| 99384 | E | Prev visit, new, age 12-17 |  |  |  | ...................... |  |
| 99385 | E | Prev visit, new, age 18-39 |  |  |  |  |  |
| 99386 | E | Prev visit, new, age 40-64 |  |  |  |  |  |
| 99387 | E | Prev visit, new, 65 \& over |  |  |  |  |  |
| 99391 | E | Prev visit, est, infant ... |  |  |  | ...................... |  |
| 99392 | E | Prev visit, est, age 1-4 |  |  |  |  |  |
| 99393 | E | Prev visit, est, age 5-11 |  |  |  | ...................... |  |
| 99394 | E | Prev visit, est, age 12-17 |  |  |  |  |  |
| 99395 | E | Prev visit, est, age 18-39 |  |  |  |  |  |
| 99396 | E | Prev visit, est, age 40-64 |  |  |  | ...................... |  |
| 99397 | E | Prev visit, est, 65 \& over |  |  |  | ..................... |  |
| 99401 | E | Preventive counseling, indiv |  |  |  |  |  |
| 99402 | E | Preventive counseling, indiv |  |  |  |  |  |
| 99403 | E | Preventive counseling, indiv |  |  |  | .................... |  |
| 99404 | E | Preventive counseling, indiv .... |  |  |  | ...................... |  |
| 99411 | E | Preventive counseling, group ................................. |  |  |  |  |  |
| 99412 | E | Preventive counseling, group .................................. |  |  |  | ... |  |
| 99420 | E | Health risk assessment test |  |  |  | .................... |  |
| 99429 | E | Unlisted preventive service |  |  |  |  |  |
| 99431 | N | Initial care, normal newborn |  |  |  | ..................... |  |
| 99432 | N | Newborn care, not in hosp ... |  |  |  | ...................... |  |
| 99433 | C | Normal newborn care/hospital |  |  |  |  |  |
| 99435 | E | Newborn discharge day hosp . |  |  |  |  |  |
| 99436 | N | Attendance, birth |  |  |  |  |  |
| 99440 | S | Newborn resuscitation | 0094 | 4.51 | \$218.68 | \$105.29 | \$43.74 |
| 99450 | E | Life/disability evaluation. |  |  |  |  |  |
| 99455 | E | Disability examination ............................................ |  |  |  | ...................... |  |
| 99456 | E | Disability examination ........................................... |  |  |  | ... |  |
| 99499 | E | Unlisted e\&m service |  |  |  |  |  |
| A0021 | E | Outside state ambulance serv |  |  |  | ..................... |  |
| A0030 | A | Air ambulance service |  | ..................... |  | $\ldots$ |  |
| A0040 | A | Helicopter ambulance service ................................. |  |  |  |  |  |
| A0050 | A | Water amb service emergency ................................ | ................. |  | ................... | ..................... |  |
| A0080 | E | Noninterest escort in non er .................................... | ..................... | ..................... | ...................... | $\ldots$ |  |
| A0090 | E | Interest escort in non er |  |  |  |  |  |

CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
Copyright American Dental Association. All rights reserved.
${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment.
${ }^{2}$ Not subject to national coinsurance.
${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

# Addendum B.-Hospital Outpatient Department (HOPD) Payment Status by HCPCS Code and Related INFORMATION-Continued 

| CPT/ HCPCS | HOPD Status Indicator | Description | APC | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| A0100 | E | Nonemergency transport taxi |  |  |  |  |  |
| A0110 | E | Nonemergency transport bus .. |  |  |  |  |  |
| A0120 | E | Noner transport mini-bus ..... |  |  | .................... | .................... |  |
| A0130 | E | Noner transport wheelch van |  |  |  |  |  |
| A0140 | E | Nonemergency transport air . |  |  |  |  |  |
| A0160 | E | Noner transport case worker ... |  |  | ..................... |  |  |
| A0170 | E | Noner transport parking fees ... |  |  |  |  |  |
| A0180 | E | Noner transport lodgng recip .................................. |  |  | .................... |  |  |
| A0190 | E | Noner transport meals recip . |  |  |  |  |  |
| A0200 | E | Noner transport lodgng escrt |  |  |  |  |  |
| A0210 | E | Noner transport meals escort |  |  |  |  |  |
| A0225 | A | Neonatal emergency transport |  |  |  |  |  |
| A0300 | A | Ambulance basic non-emer all |  |  |  |  |  |
| A0302 | A | Ambulance basic emergeny all |  |  |  |  |  |
| A0304 | A | Amb adv non-er no serv all |  | .................... | ................... |  |  |
| A0306 | A | Amb adv non-er spec serv all |  |  |  |  |  |
| A0308 | A | Amb adv er no spec serv all .. |  |  |  |  |  |
| A0310 | A | Amb adv er spec serv all |  |  |  |  |  |
| A0320 | A | Amb basic non-er + supplies |  |  |  |  |  |
| A0322 | A | Amb basic emerg + supplies. |  |  |  |  |  |
| A0324 | A | Adv non-er serv sep mileage |  |  |  |  |  |
| A0326 | A | Adv non-er no serv sep mile |  |  |  |  |  |
| A0328 | A | Adv er no serv sep mileage |  |  |  |  |  |
| A0330 | A | Adv er spec serv sep mile |  |  |  |  |  |
| A0340 | A | Amb basic non-er + mileage |  |  | .................... |  |  |
| A0342 | A | Ambul basic emer + mileage |  |  |  |  |  |
| A0344 | A | Amb adv non-er no serv +mile |  |  |  |  |  |
| A0346 | A | Amb adv non-er serv + mile |  |  | .................... |  |  |
| A0348 | A | Adv emer no spec serv + mile |  |  |  |  |  |
| A0350 | A | Adv emer spec serv + mileage |  |  |  |  |  |
| A0360 | A | Basic non-er sep mile \& supp |  |  |  |  |  |
| A0362 | A | Basic emer sep mile \& supply |  |  |  |  |  |
| A0364 | A | Adv non-er no serv sep mi\&su |  |  |  |  |  |
| A0366 | A | Adv non-er serv sep mil\&supp |  |  | ..................... |  |  |
| A0368 | A | Adv er no serv sep mile\&supp |  |  |  |  |  |
| A0370 | A | Adv er spec serv sep mi\&supp |  |  |  |  |  |
| A0380 | A | Basic life support mileage ...... |  |  |  |  |  |
| A0382 | A | Basic support routine suppls |  |  |  |  |  |
| A0384 | A | Bls defibrillation supplies |  |  |  |  |  |
| A0390 | A | Advanced life support mileag |  |  |  |  |  |
| A0392 | A | Als defibrillation supplies |  |  |  |  |  |
| A0394 | A | Als IV drug therapy supplies |  |  |  |  |  |
| A0396 | A | Als esophageal intub suppls |  |  |  |  |  |
| A0398 | A | Als routine disposble suppls |  |  |  |  |  |
| A0420 | A | Ambulance waiting $1 / 2 \mathrm{hr}$ |  |  |  |  |  |
| A0422 | A | Ambulance 02 life sustaining ... |  |  |  |  |  |
| A0424 | A | Extra ambulance attendant |  |  |  |  |  |
| A0888 | E | Noncovered ambulance mileage |  |  |  |  |  |
| A0999 | A | Unlisted ambulance service |  |  |  |  |  |
| A4206 | A | 1 CC sterile syringe \& needle ................................ |  |  |  |  |  |
| A4207 | A | 2 CC sterile syringe \& needle |  |  |  | .................... |  |
| A4208 | A | 3 CC sterile syringe \& needle ................................ |  |  |  |  |  |
| A4209 | A | 5+ CC sterile syringe \& needle ............................... |  |  |  |  |  |
| A4210 | E | Nonneedle injection device .. |  |  |  |  |  |
| A4211 | A | Supp for self-adm injections |  |  |  |  |  |
| A4212 | A | Non coring needle or stylet ... |  |  |  |  |  |
| A4213 | A | 20+ CC syringe only |  |  |  |  |  |
| A4214 | A | 30 CC sterile water/saline |  |  | ...................... | ...................... |  |
| A4215 | A | Sterile needle ... |  |  |  |  |  |
| A4220 | A | Infusion pump refill kit |  |  |  |  |  |
| A4221 | A | Maint drug infus cath per wk |  |  |  |  |  |
| A4222 | A | Drug infusion pump supplies .................................. |  |  |  |  |  |
| A4230 | E | Infus insulin pump non needl |  |  |  |  |  |
| A4231 | E | Infusion insulin pump needle ................................... |  |  |  | ..................... |  |
| A4232 | E | Syringe w/needle insulin 3cc |  |  |  |  |  |
| A4244 | A | Alcohol or peroxide per pint. |  |  |  |  |  |
| A4245 | A | Alcohol wipes per box ..... |  |  |  | ..................... |  |
| A4246 | A | Betadine/phisohex solution |  |  |  |  |  |
| A4247 | A | Betadine/iodine swabs/wipes |  |  |  |  |  |
| A4250 | E | Urine reagent strips/tablets ..... |  | ...................... |  | ...................... |  |
| A4253 | A | Blood glucose/reagent strips .... |  |  |  | ...................... |  |
| A4254 | A | Battery for glucose monitor |  | ...................... | ...................... |  |  |
| A4255 | A | Glucose monitor platforms. |  |  |  |  |  |

CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
Copyright American Dental Association. All rights reserved.
${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment.
${ }^{2}$ Not subject to national coinsurance.
${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

# Addendum B.-Hospital Outpatient Department (HOPD) Payment Status by hCPCS Code and Related INFORMATION-Continued 

| CPT/ HCPCS | HOPD Status Indicator | Description | APC | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| A4256 | A | Calibrator solution/chips |  |  |  |  |  |
| A4258 | A | Lancet device each ....... |  |  |  | ...................... |  |
| A4259 | A | Lancets per box |  |  |  |  |  |
| A4260 | E | Levonorgestrel implant |  |  |  |  |  |
| A4261 | E | Cervical cap contraceptive |  |  |  |  |  |
| A4262 | N | Temporary tear duct plug |  | .................... |  |  |  |
| A4263 | A | Permanent tear duct plug |  |  |  |  |  |
| A4265 | A | Paraffin ...................... |  |  |  |  |  |
| A4270 | A | Disposable endoscope sheath |  |  |  |  |  |
| A4280 | A | Brst prsths adhsv attchmnt |  |  |  |  |  |
| A4300 | A | Cath impl vasc access portal |  |  |  |  |  |
| A4301 | A | Implantable access syst perc |  |  |  |  |  |
| A4305 | A | Drug delivery system >=50 ML |  |  |  |  |  |
| A4306 | A | Drug delivery system <=5 ML |  |  |  |  |  |
| A4310 | A | Insert tray w/o bag/cath ...... |  |  |  |  |  |
| A4311 | A | Catheter w/o bag 2-way latex |  |  |  |  |  |
| A4312 | A | Cath w/o bag 2-way silicone |  |  |  |  |  |
| A4313 | A | Catheter w/bag 3-way .. |  |  |  |  |  |
| A4314 | A | Cath w/drainage 2-way latex |  |  |  |  |  |
| A4315 | A | Cath w/drainage 2-way silcne |  |  |  |  |  |
| A4316 | A | Cath w/drainage 3-way |  |  |  |  |  |
| A4320 | A | Irrigation tray |  |  |  |  |  |
| A4321 | A | Cath therapeutic irrig agent |  |  |  |  |  |
| A4322 | A | Irrigation syringe |  |  |  |  |  |
| A4323 | A | Saline irrigation solution |  |  |  |  |  |
| A4326 | A | Male external catheter |  |  |  |  |  |
| A4327 | A | Fem urinary collect dev cup |  |  |  |  |  |
| A4328 | A | Fem urinary collect pouch |  |  |  |  |  |
| A4329 | A | External catheter start set |  |  |  |  |  |
| A4330 | A | Stool collection pouch |  |  |  | .................... |  |
| A4335 | A | Incontinence supply |  |  |  |  |  |
| A4338 | A | Indwelling catheter latex |  |  |  |  |  |
| A4340 | A | Indwelling catheter special |  |  |  | ... |  |
| A4344 | A | Cath indw foley 2 way silicn |  | ...................... |  | ...................... |  |
| A4346 | A | Cath indw foley 3 way |  |  |  |  |  |
| A4347 | A | Male external catheter |  |  |  | ...................... |  |
| A4351 | A | Straight tip urine catheter |  |  |  |  |  |
| A4352 | A | Coude tip urinary catheter |  |  |  |  |  |
| A4353 | A | Intermittent urinary cath |  |  |  |  |  |
| A4354 | A | Cath insertion tray w/bag |  |  |  | ...................... |  |
| A4355 | A | Bladder irrigation tubing |  |  |  |  |  |
| A4356 | A | Ext ureth clmp or compr dvc |  |  |  | .................... |  |
| A4357 | A | Bedside drainage bag |  |  |  |  |  |
| A4358 | A | Urinary leg bag |  |  |  |  |  |
| A4359 | A | Urinary suspensory w/o leg b |  |  |  |  |  |
| A4361 | A | Ostomy face plate |  |  |  |  |  |
| A4362 | A | Solid skin barrier |  |  |  | .................... |  |
| A4364 | A | Ostomy/cath adhesive |  |  |  |  |  |
| A4365 | A | Ostomy adhesive remover wipe |  |  |  |  |  |
| A4367 | A | Ostomy belt |  |  |  | ...................... |  |
| A4368 | A | Ostomy filter |  |  |  |  |  |
| A4369 | A | Skin barrier liquid per oz |  |  |  |  |  |
| A4370 | A | Skin barrier paste per oz |  |  |  | $\ldots$ |  |
| A4371 | A | Skin barrier powder per oz |  |  |  |  |  |
| A4372 | A | Skin barrier solid $4 \times 4$ equiv |  |  |  |  |  |
| A4373 | A | Skin barrier with flange |  | .................... |  | .................... |  |
| A4374 | A | Skin barrier extended wear |  |  |  |  |  |
| A4375 | A | Drainable plastic pch w fcpl .................................... |  |  |  |  |  |
| A4376 | A | Drainable rubber pch w fcplt ................................... |  |  |  | .................... |  |
| A4377 | A | Drainable plstic pch w/ofp |  |  |  | ...................... |  |
| A4378 | A | Drainable rubber pch w/ofp |  |  |  |  |  |
| A4379 | A | Urinary plastic pouch w fcpl |  |  |  | .................... |  |
| A4380 | A | Urinary rubber pouch w fcplt |  |  |  | ...................... |  |
| A4381 | A | Urinary plastic pouch w/ofp |  |  |  |  |  |
| A4382 | A | Urinary hvy plstc pch w/ofp |  |  |  |  |  |
| A4383 | A | Urinary rubber pouch w/o fp. |  |  |  | ...................... |  |
| A4384 | A | Ostomy faceplt/silicone ring . |  | ..................... |  |  |  |
| A4385 | A | Ost skn barrier sld ext wear |  |  |  |  |  |
| A4386 | A | Ost skn barrier w flng ex wr |  |  |  | ...................... |  |
| A4387 | A | Ost clsd pouch w att st barr . | ..................... | .... | ...................... | ...... |  |
| A4388 | A | Drainable pch w ex wear barr |  |  |  |  |  |
| A4389 | A | Drainable pch w st wear barr .................................. |  |  |  |  |  |
| A4390 | A | Drainable pch ex wear convex |  |  |  |  |  |

[^224]
# Addendum B.-Hospital Outpatient Department (HOPD) Payment Status by HCPCS Code and Related INFORMATION-Continued 

| CPT/ HCPCS | HOPD Status Indicator | Description | APC | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| A4391 | A | Urinary pouch w ex wear barr |  |  |  |  |  |
| A4392 | A | Urinary pouch w st wear barr |  |  |  |  |  |
| A4393 | A | Urine pch w ex wear bar conv | .................... |  | ..................... | .................... |  |
| A4394 | A | Ostomy pouch liq deodorant |  |  |  |  |  |
| A4395 | A | Ostomy pouch solid deodorant |  |  |  |  |  |
| A4397 | A | Irrigation supply sleeve ............ |  |  |  |  |  |
| A4398 | A | Ostomy irrigation bag |  |  |  |  |  |
| A4399 | A | Ostomy irrig cone/cath w brs .................................. |  |  | .................... |  |  |
| A4400 | A | Ostomy irrigation set .. |  |  |  |  |  |
| A4402 | A | Lubricant per ounce |  |  |  |  |  |
| A4404 | A | Ostomy ring each ... |  |  |  |  |  |
| A4421 | A | Ostomy supply misc |  |  |  |  |  |
| A4454 | A | Tape all types all sizes |  |  |  |  |  |
| A4455 | A | Adhesive remover per ounce |  |  |  |  |  |
| A4460 | A | Elastic compression bandage |  | .................... | .................... |  |  |
| A4462 | A | Abdmnl drssng holder/binder |  |  |  |  |  |
| A4465 | A | Non-elastic extremity binder .. |  |  |  |  |  |
| A4470 | A | Gravlee jet washer |  |  |  |  |  |
| A4480 | A | Vabra aspirator |  |  |  |  |  |
| A4481 | A | Tracheostoma filter |  |  |  |  |  |
| A4483 | A | Moisture exchanger |  |  |  |  |  |
| A4490 | E | Above knee surgical stocking ................................. |  |  |  |  |  |
| A4495 | E | Thigh length surg stocking |  |  |  |  |  |
| A4500 | E | Below knee surgical stocking |  |  |  |  |  |
| A4510 | E | Full length surg stocking ... |  |  |  |  |  |
| A4550 | E | Surgical trays |  |  |  |  |  |
| A4554 | E | Disposable underpads |  |  |  |  |  |
| A4556 | A | Electrodes, pair |  |  | ...................... |  |  |
| A4557 | A | Lead wires, pair |  |  |  |  |  |
| A4558 | A | Conductive paste or gel |  |  |  |  |  |
| A4560 | A | Pessary |  |  |  |  |  |
| A4565 | A | Slings |  |  |  |  |  |
| A4570 | A | Splint |  |  |  |  |  |
| A4572 | A | Rib belt |  |  |  |  |  |
| A4575 | E | Hyperbaric o2 chamber disps |  |  |  |  |  |
| A4580 | A | Cast supplies (plaster) |  |  |  |  |  |
| A4590 | A | Special casting material .... |  |  | ..................... | ..................... |  |
| A4595 | A | TENS suppl 2 lead per month |  |  | ...................... | ................... |  |
| A4611 | A | Heavy duty battery |  |  |  |  |  |
| A4612 | A | Battery cables |  |  |  |  |  |
| A4613 | A | Battery charger |  |  |  |  |  |
| A4614 | A | Hand-held PEFR meter |  |  |  |  |  |
| A4615 | A | Cannula nasal |  |  |  |  |  |
| A4616 | A | Tubing (oxygen) per foot ........................................ |  |  |  |  |  |
| A4617 | A | Mouth piece |  |  |  |  |  |
| A4618 | A | Breathing circuits |  |  |  |  |  |
| A4619 | A | Face tent ..... |  |  |  |  |  |
| A4620 | A | Variable concentration mask |  |  | .................... | .................... |  |
| A4621 | A | Tracheotomy mask or collar |  |  |  |  |  |
| A4622 | A | Tracheostomy or larngectomy ................................. |  |  |  |  |  |
| A4623 | A | Tracheostomy inner cannula |  |  |  | ..................... |  |
| A4624 | A | Tracheal suction tube ............................................ |  |  |  |  |  |
| A4625 | A | Trach care kit for new trach |  |  |  |  |  |
| A4626 | A | Tracheostomy cleaning brush |  |  |  |  |  |
| A4627 | E | Spacer bag/reservoir |  |  |  |  |  |
| A4628 | A | Oropharyngeal suction cath .................................... |  |  |  |  |  |
| A4629 | A | Tracheostomy care kit ........................................... |  |  |  |  |  |
| A4630 | A | Repl bat t.e.n.s. own by pt |  |  | ...................... | ...................... |  |
| A4631 | A | Wheelchair battery |  |  |  |  |  |
| A4635 | A | Underarm crutch pad ............................................. |  |  |  |  |  |
| A4636 | A | Handgrip for cane etc . |  |  |  | ..................... |  |
| A4637 | A | Repl tip cane/crutch/walker .................................... |  |  |  |  |  |
| A4640 | A | Alternating pressure pad |  |  |  |  |  |
| A4641 | N | Diagnostic imaging agent ....................................... |  |  | - | ..................... |  |
| ${ }^{3}$ A4642 | X | Satumomab pendetide per dose | 0704 |  |  |  | \$63.13 |
| A4643 | N | High dose contrast MRI |  |  |  |  |  |
| A4644 | N | Contrast 100-199 MGs iodine . |  |  | ...................... | ................... |  |
| A4645 | N | Contrast 200-299 MGs iodine |  |  | ...................... | ...................... |  |
| A4646 | N | Contrast 300-399 MGs iodine |  |  |  |  |  |
| A4647 | N | Supp-paramagnetic contr mat ................................. | ..................... | ...................... | ...................... | ...................... |  |
| A4649 | A | Surgical supplies ................. |  |  |  | ...................... |  |
| A4650 | A | Supp esrd centrifuge | ...................... | ...................... | ...................... |  |  |
| A4655 | A | Esrd syringe/needle .. |  |  |  |  |  |

[^225]
# Addendum B.-Hospital Outpatient Department (HOPD) Payment Status by hCPCS Code and Related Information-Continued 

| CPT/ HCPCS | HOPD Status Indicator | Description | APC | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| A4660 | A | Esrd blood pressure device |  |  |  | . |  |
| A4663 | A | Esrd blood pressure cuff |  |  |  | . |  |
| A4670 | E | Auto blood pressure monitor |  |  |  |  |  |
| A4680 | A | Activated carbon filters ..... |  |  |  |  |  |
| A4690 | A | Dialyzers |  |  |  |  |  |
| A4700 | A | Standard dialysate solution |  |  |  |  |  |
| A4705 | A | Bicarb dialysate solution. |  |  |  |  |  |
| A4712 | A | Sterile water |  |  |  |  |  |
| A4714 | A | Treated water for dialysis |  |  |  | ...................... |  |
| A4730 | A | Fistula cannulation set dial |  |  |  |  |  |
| A4735 | A | Local/topical anesthetics |  |  |  |  |  |
| A4740 | A | Esrd shunt accessory |  |  |  |  |  |
| A4750 | A | Arterial or venous tubing |  |  |  |  |  |
| A4755 | A | Arterial and venous tubing |  |  |  |  |  |
| A4760 | A | Standard testing solution |  |  |  |  |  |
| A4765 | A | Dialysate concentrate . |  |  |  |  |  |
| A4770 | A | Blood testing supplies |  |  |  |  |  |
| A4771 | A | Blood clotting time tube |  |  |  |  |  |
| A4772 | A | Dextrostick/glucose strips |  |  |  | .... |  |
| A4773 | A | Hemostix |  |  |  | ..................... |  |
| A4774 | A | Ammonia test paper |  |  |  |  |  |
| A4780 | A | Esrd sterilizing agent |  |  |  |  |  |
| A4790 | A | Esrd cleansing agents |  |  |  |  |  |
| A4800 | A | Heparin/antidote dialysis |  |  |  |  |  |
| A4820 | A | Supplies hemodialysis kit |  |  |  |  |  |
| A4850 | A | Rubber tipped hemostats |  |  |  | .................... |  |
| A4860 | A | Disposable catheter caps |  |  |  |  |  |
| A4870 | A | Plumbing/electrical work |  |  |  | ................... |  |
| A4880 | A | Water storage tanks |  |  |  |  |  |
| A4890 | A | Contracts/repair/maintenance |  |  |  |  |  |
| A4900 | A | Capd supply kit |  |  |  |  |  |
| A4901 | A | Ccpd supply kit |  |  |  | ..................... |  |
| A4905 | A | Ipd supply kit |  |  |  | .................... |  |
| A4910 | A | Esrd nonmedical supplies |  |  |  |  |  |
| A4912 | A | Gomco drain bottle |  |  |  |  |  |
| A4913 | A | Esrd supply |  |  |  | ...................... |  |
| A4914 | A | Preparation kit |  |  |  |  |  |
| A4918 | A | Venous pressure clamp |  |  |  |  |  |
| A4919 | A | Supp dialysis dialyzer holde |  |  |  | ................... |  |
| A4920 | A | Harvard pressure clamp |  |  |  |  |  |
| A4921 | A | Measuring cylinder ....... |  |  |  |  |  |
| A4927 | A | Gloves |  |  |  | ...................... |  |
| A5051 | A | Pouch clsd w barr attached |  |  |  | ................. |  |
| A5052 | A | Clsd ostomy pouch w/o barr |  |  |  |  |  |
| A5053 | A | Clsd ostomy pouch faceplate |  |  |  | ..................... |  |
| A5054 | A | Clsd ostomy pouch w/flange |  |  |  |  |  |
| A5055 | A | Stoma cap |  |  |  |  |  |
| A5061 | A | Pouch drainable w barrier at |  |  |  |  |  |
| A5062 | A | Drnble ostomy pouch w/o barr |  |  |  | .................... |  |
| A5063 | A | Drain ostomy pouch w/flange |  |  |  |  |  |
| A5064 | E | Drain ostomy pouch w/fceplte |  |  |  |  |  |
| A5065 | E | Drain ostomy pouch on fcple |  |  |  | .................... |  |
| A5071 | A | Urinary pouch w/barrier |  |  |  |  |  |
| A5072 | A | Urinary pouch w/o barrier |  |  |  |  |  |
| A5073 | A | Urinary pouch on barr w/flng |  |  |  | .................... |  |
| A5074 | E | Urinary pouch w/faceplate |  |  |  | ...................... |  |
| A5075 | E | Urinary pouch on faceplate |  |  |  |  |  |
| A5081 | A | Continent stoma plug . |  |  |  |  |  |
| A5082 | A | Continent stoma catheter |  |  |  | ..................... |  |
| A5093 | A | Ostomy accessory convex inse |  |  |  |  |  |
| A5102 | A | Bedside drain btl w/wo tube |  |  |  |  |  |
| A5105 | A | Urinary suspensory . |  |  |  |  |  |
| A5112 | A | Urinary leg bag |  |  |  |  |  |
| A5113 | A | Latex leg strap |  |  |  |  |  |
| A5114 | A | Foam/fabric leg strap |  |  |  |  |  |
| A5119 | A | Skin barrier wipes box pr 50 |  |  |  | ...................... |  |
| A5121 | A | Solid skin barrier 6x6 |  |  |  |  |  |
| A5122 | A | Solid skin barrier 8x8 |  |  |  | ..................... |  |
| A5123 | A | Skin barrier with flange .... |  |  |  | ...................... |  |
| A5126 | A | Disk/foam pad +or- adhesive .................................. |  |  |  |  |  |
| A5131 | A | Appliance cleaner .................................................. |  |  |  |  |  |
| A5149 | A | Incontinence/ostomy supply ................................... | ...................... | ..................... | .................... | .... |  |
| A5200 | A | Percutaneous catheter anchor |  |  |  |  |  |

[^226]
# Addendum B.-Hospital Outpatient Department (HOPD) Payment Status by HCPCS Code and Related Information-Continued 

| CPT/ HCPCS | HOPD Status Indicator | Description | APC | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| A5500 | A | Diab shoe for density insert |  |  |  |  |  |
| A5501 | A | Diabetic custom molded shoe |  |  |  |  |  |
| A5502 | A | Diabetic shoe density insert |  |  | .................... | .................... |  |
| A5503 | A | Diabetic shoe w/roller/rockr |  |  | ..................... |  |  |
| A5504 | A | Diabetic shoe with wedge |  |  |  |  |  |
| A5505 | A | Diab shoe w/metatarsal bar |  |  |  |  |  |
| A5506 | A | Diabetic shoe w/off set heel |  |  |  |  |  |
| A5507 | A | Modification diabetic shoe |  | ..................... | ..................... |  |  |
| A5508 | A | Diabetic deluxe shoe |  |  |  |  |  |
| A6020 | A | Collagen wound dressing |  |  |  |  |  |
| A6025 | E | Silicone gel sheet, each . |  |  |  |  |  |
| A6154 | A | Wound pouch each |  |  |  |  |  |
| A6196 | A | Alginate dressing <=16 sq in |  |  |  |  |  |
| A6197 | A | Alginate drsg $>16<=48$ sq in |  |  |  |  |  |
| A6198 | A | alginate dressing > 48 sq in |  | .................... | .............. |  |  |
| A6199 | A | Alginate drsg wound filler |  |  |  |  |  |
| A6200 | A | Compos drsg <=16 no border |  |  |  |  |  |
| A6201 | A | Compos drsg >16<=48 no bdr |  |  |  |  |  |
| A6202 | A | Compos drsg $>48$ no border |  |  |  |  |  |
| A6203 | A | Composite drsg <= 16 sq in .... |  |  |  |  |  |
| A6204 | A | Composite drsg >16<=48 sq in |  |  |  |  |  |
| A6205 | A | Composite drsg > 48 sq in ..................................... |  |  |  |  |  |
| A6206 | A | Contact layer <= 16 sq in |  |  |  |  |  |
| A6207 | A | Contact layer $>16<=48 \mathrm{sq}$ in |  |  |  |  |  |
| A6208 | A | Contact layer > 48 sq in |  |  | .................... |  |  |
| A6209 | A | Foam drsg <=16 sq in w/o bdr |  |  |  |  |  |
| A6210 | A | Foam drg > $16<=48$ sq in w/o b |  |  |  |  |  |
| A6211 | A | Foam drg $>48 \mathrm{sq}$ in w/o brdr |  |  |  |  |  |
| A6212 | A | Foam drg $<=16 \mathrm{sq}$ in w/border |  |  |  |  |  |
| A6213 | A | Foam drg $>16<=48 \mathrm{sq}$ in w/bdr |  |  |  |  |  |
| A6214 | A | Foam drg > 48 sq in w/border |  |  |  |  |  |
| A6215 | A | Foam dressing wound filler |  |  |  |  |  |
| A6216 | A | Non-sterile gauze<=16 sq in |  |  |  |  |  |
| A6217 | A | Non-sterile gauze>16<=48 sq |  |  |  |  |  |
| A6218 | A | Non-sterile gauze > 48 sq in |  |  |  |  |  |
| A6219 | A | Gauze <= 16 sq in w/border |  |  |  |  |  |
| A6220 | A | Gauze >16 <=48 sq in w/bordr |  |  |  |  |  |
| A6221 | A | Gauze > 48 sq in w/border |  |  | ..................... |  |  |
| A6222 | A | Gauze <=16 in no w/sal w/o b |  |  |  |  |  |
| A6223 | A | Gauze >16<=48 no w/sal w/o b |  |  |  |  |  |
| A6224 | A | Gauze > 48 in no w/sal w/o b |  |  |  |  |  |
| A6228 | A | Gauze <= 16 sq in water/sal |  |  |  |  |  |
| A6229 | A | Gauze >16<=48 sq in watr/sal |  |  |  |  |  |
| A6230 | A | Gauze > 48 sq in water/salne |  |  |  |  |  |
| A6234 | A | Hydrocolld drg <=16 w/o bdr |  |  |  |  |  |
| A6235 | A | Hydrocolld drg >16<=48 w/o b |  |  |  |  |  |
| A6236 | A | Hydrocolld drg > 48 in w/o b .................................. |  |  |  |  |  |
| A6237 | A | Hydrocolld drg <=16 in w/bdr |  |  |  |  |  |
| A6238 | A | Hydrocolld drg >16<=48 w/bdr |  |  |  |  |  |
| A6239 | A | Hydrocolld drg > 48 in w/bdr .................................. |  |  |  |  |  |
| A6240 | A | Hydrocolld drg filler paste. |  |  |  | .................... |  |
| A6241 | A | Hydrocolloid drg filler dry ........................................ |  |  |  |  |  |
| A6242 | A | Hydrogel drg <=16 in w/o bdr |  |  |  |  |  |
| A6243 | A | Hydrogel drg $>16<=48 \mathrm{w} / \mathrm{o} \mathrm{bdr}$ |  |  |  |  |  |
| A6244 | A | Hydrogel drg >48 in w/o bdr ................................... |  |  |  |  |  |
| A6245 | A | Hydrogel drg <= 16 in w/bdr |  |  |  |  |  |
| A6246 | A | Hydrogel drg >16<=48 in w/b .................................. |  |  |  |  |  |
| A6247 | A | Hydrogel drg > 48 sq in w/b. |  |  |  | ...................... |  |
| A6248 | A | Hydrogel drsg gel filler ... |  |  |  |  |  |
| A6250 | A | Skin seal protect moisturizr |  |  |  |  |  |
| A6251 | A | Absorpt drg <=16 sq in w/o b |  |  |  | .................... |  |
| A6252 | A | Absorpt drg >16 <=48 w/o bdr ................................ |  |  |  |  |  |
| A6253 | A | Absorpt drg > 48 sq in w/o b |  |  |  |  |  |
| A6254 | A | Absorpt drg <=16 sq in w/bdr .................................. |  |  | ..................... | ..................... |  |
| A6255 | A | Absorpt drg >16<=48 in w/bdr |  |  |  |  |  |
| A6256 | A | Absorpt drg > 48 sq in w/bdr. |  |  |  |  |  |
| A6257 | A | Transparent film <= 16 sq in ... |  |  |  |  |  |
| A6258 | A | Transparent film >16<=48 in ... |  |  | .................... |  |  |
| A6259 | A | Transparent film > 48 sq in |  |  |  |  |  |
| A6260 | A | Wound cleanser any type/size .... |  |  |  |  |  |
| A6261 | A | Wound filler gel/paste/oz ....... |  |  |  | .................... |  |
| A6262 | A | Wound filler dry form/gram | ...................... | ...................... | ...................... |  |  |
| A6263 | A | Non-sterile elastic gauze/yd |  |  |  |  |  |

[^227]
# Addendum B.—Hospital Outpatient Department (HOPD) Payment Status by hCPCS Code and Related Information-Continued 

| CPT/ HCPCS | HOPD Status Indicator | Description | APC | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| A6264 | A | Non-sterile no elastic gauze |  |  |  |  |  |
| A6265 | A | Tape per 18 sq inches ....... |  |  |  |  |  |
| A6266 | A | Impreg gauze no h20/sal/yard |  |  |  |  |  |
| A6402 | A | Sterile gauze <= 16 sq in ...... |  |  |  |  |  |
| A6403 | A | Sterile gauze>16<= 48 sq in |  |  |  |  |  |
| A6404 | A | Sterile gauze > 48 sq in ....... |  |  |  |  |  |
| A6405 | A | Sterile elastic gauze/yd |  |  |  |  |  |
| A6406 | A | Sterile non-elastic gauze/yd |  |  |  |  |  |
| A7000 | A | Disposable canister for pump |  |  |  |  |  |
| A7001 | A | Nondisposable pump canister |  |  |  |  |  |
| A7002 | A | Tubing used w suction pump |  |  |  |  |  |
| A7003 | A | Nebulizer administration set |  |  |  |  |  |
| A7004 | A | Disposable nebulizer sml vol |  |  |  |  |  |
| A7005 | A | Nondisposable nebulizer set |  |  |  |  |  |
| A7006 | A | Filtered nebulizer admin set |  |  |  |  |  |
| A7007 | A | Lg vol nebulizer disposable |  |  |  |  |  |
| A7008 | A | Disposable nebulizer prefill |  |  |  |  |  |
| A7009 | A | Nebulizer reservoir bottle |  |  |  |  |  |
| A7010 | A | Disposable corrugated tubing |  |  |  |  |  |
| A7011 | A | Nondispos corrugated tubing |  |  |  |  |  |
| A7012 | A | Nebulizer water collec devic |  |  |  |  |  |
| A7013 | A | Disposable compressor filter |  |  |  |  |  |
| A7014 | A | Compressor nondispos filter |  |  |  |  |  |
| A7015 | A | Aerosol mask used w nebulize |  |  |  |  |  |
| A7016 | A | Nebulizer dome \& mouthpiece |  |  |  |  |  |
| A7017 | A | Nebulizer not used w oxygen |  |  |  |  |  |
| A9150 | E | Misc/exper non-prescript dru |  |  |  |  |  |
| A9160 | E | Podiatrist non-covered servi |  |  |  |  |  |
| A9170 | E | Chiropractor non-covered ser |  |  |  |  |  |
| A9190 | E | Misc/expe personal comfort i . |  |  |  |  |  |
| A9270 | E | Non-covered item or service |  |  |  |  |  |
| A9300 | E | Exercise equipment |  |  |  |  |  |
| A9500 | N | Technetium TC 99m sestamibi |  |  |  |  |  |
| ${ }^{3}$ A9502 | X | Technetium TC99M tetrofosmin | 0705 |  |  |  | \$71.08 |
| A9503 | N | Technetium TC 99m medronate |  |  |  |  |  |
| A9504 | N | Technetium tc 99m apcitide |  |  |  |  |  |
| A9505 | N | Thallous chloride TL 201/mci |  |  |  |  |  |
| A9507 | N | Indium/111 capromab pendetid |  |  |  |  |  |
| ${ }^{3}$ A9600 | X | Strontium-89 chloride | 0701 |  |  |  | \$84.76 |
| ${ }^{3}$ A9605 | X | Samarium sm153 lexidronamm | 0702 |  |  | ...................... | \$139.06 |
| A9900 | E | Supply/accessory/service |  |  |  |  |  |
| A9901 | E | Delivery/set up/dispensing |  |  |  |  |  |
| B4034 | A | Enter feed supkit syr by day |  |  |  |  |  |
| B4035 | A | Enteral feed supp pump per d |  |  |  |  |  |
| B4036 | A | Enteral feed sup kit grav by |  |  |  |  |  |
| B4081 | A | Enteral ng tubing w/stylet |  |  |  |  |  |
| B4082 | A | Enteral ng tubing w/o stylet |  |  |  |  |  |
| B4083 | A | Enteral stomach tube levine |  |  |  |  |  |
| B4084 | A | Gastrostomy/jejunostomy tubi |  |  |  |  |  |
| B4085 | A | Gastrostomy tube w/ring each |  |  |  | ..................... |  |
| B4150 | A | Enteral formulae category i |  |  |  |  |  |
| B4151 | A | Enteral formulae category i- |  |  |  |  |  |
| B4152 | A | Enteral formulae category ii |  |  |  |  |  |
| B4153 | A | Enteral formulae category ii |  |  |  |  |  |
| B4154 | A | Enteral formulae category IV |  |  |  |  |  |
| B4155 | A | Enteral formulae category v |  |  |  |  |  |
| B4156 | A | Enteral formulae category vi |  |  |  |  |  |
| B4164 | A | Parenteral 50\% dextrose solu ................................. |  |  |  |  |  |
| B4168 | A | Parenteral sol amino acid 3. |  |  |  |  |  |
| B4172 | A | Parenteral sol amino acid 5. |  |  |  | .................... |  |
| B4176 | A | Parenteral sol amino acid 7- |  |  |  |  |  |
| B4178 | A | Parenteral sol amino acid > |  |  |  |  |  |
| B4180 | A | Parenteral sol carb > 50\% |  |  |  | ..................... |  |
| B4184 | A | Parenteral sol lipids 10\% |  |  |  |  |  |
| B4186 | A | Parenteral sol lipids 20\% |  |  |  |  |  |
| B4189 | A | Parenteral sol amino acid \& |  |  |  | ...................... | .................... |
| B4193 | A | Parenteral sol 52-73 gm prot |  |  |  |  |  |
| B4197 | A | Parenteral sol $74-100 \mathrm{gm}$ pro |  |  |  |  |  |
| B4199 | A | Parenteral sol > 100gm prote .................................. |  |  |  | . | .................... |
| B4216 | A | Parenteral nutrition additiv ...... | ...................... | ...................... | ..................... | ...... | ..................... |
| B4220 | A | Parenteral supply kit premix |  | ...................... |  |  |  |
| B4222 | A | Parenteral supply kit homemi .................................. | ..................... |  |  |  |  |
| B4224 | A | Parenteral administration ki |  |  |  |  |  |

CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
Copyright American Dental Association. All rights reserved.
${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment
${ }^{2}$ Not subject to national coinsurance.
${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

# Addendum B.-Hospital Outpatient Department (HOPD) Payment Status by HCPCS Code and Related INFORMATION-Continued 

| CPT/ HCPCS | HOPD Status Indicator | Description | APC | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| B5000 | A | Parenteral sol renal-amirosy . |  | ..................... | . | ..................... |  |
| B5100 | A | Parenteral sol hepatic-fream .................................. |  |  |  |  |  |
| B5200 | A | Parenteral sol stres-brnch c |  |  |  |  |  |
| B9000 | A | Enter infusion pump w/o alrm |  |  | ..................... | ..................... |  |
| B9002 | A | Enteral infusion pump w/ala |  |  | ...................... |  |  |
| B9004 | A | Parenteral infus pump portab |  |  |  |  |  |
| B9006 | A | Parenteral infus pump statio ... |  |  |  |  |  |
| B9998 | A | Enteral supp not otherwise c ................................... |  |  | .................... |  |  |
| B9999 | A | Parenteral supp not othrws c ................................. |  |  | ..................... |  |  |
| D0120 | E | Periodic oral evaluation |  |  |  |  |  |
| D0140 | E | Limit oral eval problm focus |  |  |  |  |  |
| D0150 | S | Comprehensve oral evaluation ................................ | 0330 | 1.51 | \$73.22 | \$14.64 | \$14.64 |
| D0160 | E | Extensv oral eval prob focus |  |  |  |  |  |
| D0170 | E | Re-eval, est pt, problem focus |  |  |  |  |  |
| D0210 | E | Intraor complete film series ... | .................... | .................... | ..................... | ... |  |
| D0220 | E | Intraoral periapical first f |  |  |  |  |  |
| D0230 | E | Intraoral periapical ea add |  |  |  |  |  |
| D0240 | S | Intraoral occlusal film | 0330 | 1.51 | \$73.22 | \$14.64 | \$14.64 |
| D0250 | S | Extraoral first film | 0330 | 1.51 | \$73.22 | \$14.64 | \$14.64 |
| D0260 | S | Extraoral ea additional film | 0330 | 1.51 | \$73.22 | \$14.64 | \$14.64 |
| D0270 | S | Dental bitewing single film | 0330 | 1.51 | \$73.22 | \$14.64 | \$14.64 |
| D0272 | S | Dental bitewings two films | 0330 | 1.51 | \$73.22 | \$14.64 | \$14.64 |
| D0274 | S | Dental bitewings four films | 0330 | 1.51 | \$73.22 | \$14.64 | \$14.64 |
| D0277 | E | Vert bitewings-sev to eight ..................................... |  |  | ..................... | ...................... | ...................... |
| D0290 | E | Dental film skull/facial bon ... |  |  |  |  |  |
| D0310 | E | Dental saliography |  |  |  |  |  |
| D0320 | E | Dental tmj arthrogram incl i |  |  |  |  |  |
| D0321 | E | Dental other tmj films |  |  |  |  |  |
| D0322 | E | Dental tomographic survey |  |  | .................... |  |  |
| D0330 | E | Dental panoramic film |  |  |  |  |  |
| D0340 | E | Dental cephalometric film . |  |  |  |  |  |
| D0350 | E | Oral/facial images |  |  |  |  |  |
| D0415 | E | Bacteriologic study |  |  |  |  |  |
| D0425 | E | Caries susceptibility test |  |  |  |  |  |
| D0460 | S | Pulp vitality test | 0330 | 1.51 | \$73.22 | \$14.64 | \$14.64 |
| D0470 | E | Diagnostic casts |  |  |  |  |  |
| D0472 | E | Gross exam, prep \& report |  |  |  |  |  |
| D0473 | E | Micro exam, prep \& report ...................................... |  | ...................... | ...................... | ..................... |  |
| D0474 | E | Micro w exam of surg margins |  |  |  |  |  |
| D0480 | E | Cytopath smear prep \& report |  |  |  |  |  |
| D0501 | S | Histopathologic examinations .................................. | 0330 | 1.51 | \$73.22 | \$14.64 | \$14.64 |
| D0502 | S | Other oral pathology procedu .................................. | 0330 | 1.51 | \$73.22 | \$14.64 | \$14.64 |
| D0999 | S | Unspecified diagnostic proce | 0330 | 1.51 | \$73.22 | \$14.64 | \$14.64 |
| D1110 | E | Dental prophylaxis adult ........................................ |  |  |  |  |  |
| D1120 | E | Dental prophylaxis child . |  |  | . | .................... |  |
| D1201 | E | Topical fluor w prophy child |  |  |  |  |  |
| D1203 | E | Topical fluor w/o prophy chi |  |  |  |  |  |
| D1204 | E | Topical fluor w/o prophy adu |  |  |  |  |  |
| D1205 | E | Topical fluoride w/prophy a .................................... |  |  |  |  |  |
| D1310 | E | Nutri counsel-control caries |  |  |  |  |  |
| D1320 | E | Tobacco counseling |  |  |  |  |  |
| D1330 | E | Oral hygiene instruction |  |  |  |  |  |
| D1351 | E | Dental sealant per tooth |  |  |  |  |  |
| D1510 | S | Space maintainer fxd unilat .................................... | 0330 | 1.51 | \$73.22 | \$14.64 | \$14.64 |
| D1515 | S | Fixed bilat space maintainer .... | 0330 | 1.51 | \$73.22 | \$14.64 | \$14.64 |
| D1520 | S | Remove unilat space maintain | 0330 | 1.51 | \$73.22 | \$14.64 | \$14.64 |
| D1525 | S | Remove bilat space maintain .................................. | 0330 | 1.51 | \$73.22 | \$14.64 | \$14.64 |
| D1550 | S | Recement space maintainer ................................... | 0330 | 1.51 | \$73.22 | \$14.64 | \$14.64 |
| D2110 | E | Amalgam one surface primary ................................ |  |  |  |  |  |
| D2120 | E | Amalgam two surfaces primary . |  |  |  |  |  |
| D2130 | E | Amalgam three surfaces prima ............................... |  |  |  |  |  |
| D2131 | E | Amalgam four/more surf prima ................................ |  |  |  |  |  |
| D2140 | E | Amalgam one surface permanen ............................. |  |  |  |  |  |
| D2150 | E | Amalgam two surfaces permane .............................. |  |  |  |  |  |
| D2160 | E | Amalgam three surfaces perma .............................. |  |  |  | ..................... |  |
| D2161 | E | Amalgam 4 or > surfaces perm ............................... |  |  |  |  |  |
| D2330 | E | Resin one surface-anterior |  |  |  |  |  |
| D2331 | E | Resin two surfaces-anterior | ...................... | ...................... |  | ..................... |  |
| D2332 | E | Resin three surfaces-anterio |  |  |  |  |  |
| D2335 | E | Resin 4/> surf or wincis an |  |  |  |  |  |
| D2336 | E | Composite resin crown .......................................... | ...................... | ...................... | . | ...................... | ...................... |
| D2337 | E | Compo resin crown ant-perm .................................. | ... | ... | ...................... | ..... |  |
| D2380 | E | Resin one surf poster primar |  |  |  |  |  |

[^228]
# Addendum B.—Hospital Outpatient Department (HOPD) Payment Status by hCPCS Code and Related INFORMATION-Continued 

| CPT/ HCPCS | HOPD Status Indicator | Description | APC | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| D2381 | E | Resin two surf poster primar |  |  |  | $\cdot$ |  |
| D2382 | E | Resin three/more surf post p |  |  |  | ..................... |  |
| D2385 | E | Resin one surf poster perman |  |  |  |  |  |
| D2386 | E | Resin two surf poster perman |  |  |  |  |  |
| D2387 | E | Resin three/more surf post p . |  |  |  |  |  |
| D2388 | E | Resin four/more, post perm |  |  |  |  |  |
| D2410 | E | Dental gold foil one surface |  |  |  |  |  |
| D2420 | E | Dental gold foil two surface . |  |  |  |  |  |
| D2430 | E | Dental gold foil three surfa. |  | ..................... |  | . |  |
| D2510 | E | Dental inlay metalic 1 surf. |  |  |  |  |  |
| D2520 | E | Dental inlay metallic 2 surf .. |  |  |  |  |  |
| D2530 | E | Dental inlay metl $3 /$ more sur |  |  |  |  |  |
| D2542 | E | Dental onlay metallic 2 surf . |  |  |  |  |  |
| D2543 | E | Dental onlay metallic 3 surf |  |  |  |  |  |
| D2544 | E | Dental onlay metl 4 /more sur |  |  |  |  |  |
| D2610 | E | Inlay porcelain/ceramic 1 su |  |  |  |  |  |
| D2620 | E | Inlay porcelain/ceramic 2 su |  |  |  |  |  |
| D2630 | E | Dental onlay porc 3/more sur |  |  |  |  |  |
| D2642 | E | Dental onlay porcelin 2 surf |  |  |  | ..................... |  |
| D2643 | E | Dental onlay porcelin 3 surf |  |  |  | ...................... |  |
| D2644 | E | Dental onlay porc 4/more sur |  |  |  |  |  |
| D2650 | E | Inlay composite/resin one su |  |  |  | .................... |  |
| D2651 | E | Inlay composite/resin two su |  |  |  |  |  |
| D2652 | E | Dental inlay resin 3/mre sur |  |  |  |  |  |
| D2662 | E | Dental onlay resin 2 surface . |  |  |  |  |  |
| D2663 | E | Dental onlay resin 3 surface |  |  |  | ..................... |  |
| D2664 | E | Dental onlay resin 4/mre sur |  |  |  |  |  |
| D2710 | E | Crown resin laboratory |  |  |  | .................... |  |
| D2720 | E | Crown resin w/high noble me |  |  |  |  |  |
| D2721 | E | Crown resin w/base metal |  |  |  |  |  |
| D2722 | E | Crown resin w/noble metal |  |  |  |  |  |
| D2740 | E | Crown porcelain/ceramic subs |  |  |  |  |  |
| D2750 | E | Crown porcelain w/h noble m |  |  |  | ..................... |  |
| D2751 | E | Crown porcelain fused base m |  |  |  |  |  |
| D2752 | E | Crown porcelain w/noble met |  |  |  |  |  |
| D2780 | E | Crown 3/4 cast hi noble met |  |  |  | .................... |  |
| D2781 | E | Crown 3/4 cast base metal |  |  |  |  |  |
| D2782 | E | Crown 3/4 cast noble metal . |  |  |  |  |  |
| D2783 | E | Crown 3/4 porcelain/ceramic |  |  |  | ...................... |  |
| D2790 | E | Crown full cast high noble m |  |  |  |  |  |
| D2791 | E | Crown full cast base metal |  |  |  |  |  |
| D2792 | E | Crown full cast noble metal |  |  |  | ...................... |  |
| D2799 | E | Provisional crown |  |  |  | .................... |  |
| D2910 | E | Dental recement inlay |  |  |  |  |  |
| D2920 | E | Dental recement crown |  |  |  | ..................... |  |
| D2930 | E | Prefab stnlss steel crwn pri |  |  |  | ...................... |  |
| D2931 | E | Prefab stnlss steel crown pe |  |  |  |  |  |
| D2932 | E | Prefabricated resin crown |  |  |  |  |  |
| D2933 | E | Prefab stainless steel crown |  |  |  | .................... |  |
| D2940 | E | Dental sedative filling |  |  |  |  |  |
| D2950 | E | Core build-up incl any pins |  |  |  |  |  |
| D2951 | E | Tooth pin retention ...... |  |  |  | .................... |  |
| D2952 | E | Post and core cast + crown |  |  |  | ..................... |  |
| D2953 | E | Each addtnl cast post .... |  |  |  |  |  |
| D2954 | E | Prefab post/core + crown |  |  |  | ..................... |  |
| D2955 | E | Post removal |  |  |  | ...................... |  |
| D2957 | E | Each addtnl prefab post |  |  |  |  |  |
| D2960 | E | Laminate labial veneer. |  |  |  | ..................... |  |
| D2961 | E | Lab labial veneer resin |  |  |  | ...................... |  |
| D2962 | E | Lab labial veneer porcelain |  |  |  |  |  |
| D2970 | S | Temporary-fractured tooth | 0330 | 1.51 | \$73.22 | \$14.64 | \$14.64 |
| D2980 | E | Crown repair |  |  |  |  |  |
| D2999 | S | Dental unspec restorative pr .................................. | 0330 | 1.51 | \$73.22 | \$14.64 | \$14.64 |
| D3110 | E | Pulp cap direct |  |  |  |  |  |
| D3120 | E | Pulp cap indirect |  |  |  | ..................... |  |
| D3220 | E | Therapeutic pulpotomy .......................................... |  |  |  | ..................... |  |
| D3221 | E | Gross pulpal debridement |  |  |  |  |  |
| D3230 | E | Pulpal therapy anterior prim ................................... |  |  |  | ..................... |  |
| D3240 | E | Pulpal therapy posterior pri .................................... |  |  |  | .......... |  |
| D3310 | E | Anterior ............................................................... |  |  |  | ..................... |  |
| D3320 | E | Root canal therapy 2 canals ................................... |  |  |  |  |  |
| D3330 | E | Root canal therapy 3 canals ................................... | ...................... | ...................... | .................... | ...................... |  |
| D3331 | E | Non-surg tx root canal obs |  |  |  |  |  |

CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
Copyright American Dental Association. All rights reserved.
${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment.
${ }^{2}$ Not subject to national coinsurance.
${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

# Addendum B.-Hospital Outpatient Department (HOPD) Payment Status by HCPCS Code and Related INFORMATION-Continued 

| CPT/ HCPCS | HOPD Status Indicator | Description | APC | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| D3332 | E | Incomplete endodontic tx |  | ..................... | ..................... | ..................... |  |
| D3333 | E | Internal root repair ......... |  |  |  |  |  |
| D3346 | E | Retreat root canal anterior |  |  |  |  |  |
| D3347 | E | Retreat root canal bicuspid |  |  |  | ...................... |  |
| D3348 | E | Retreat root canal molar |  |  |  |  |  |
| D3351 | E | Apexification/recalc initial |  |  |  |  |  |
| D3352 | E | Apexification/recalc interim |  |  |  |  |  |
| D3353 | E | Apexification/recalc final ... |  |  |  |  |  |
| D3410 | E | Apicoect/perirad surg anter |  |  | ..................... |  |  |
| D3421 | E | Root surgery bicuspid ... |  |  |  |  |  |
| D3425 | E | Root surgery molar |  |  |  |  |  |
| D3426 | E | Root surgery ea add root |  |  |  |  |  |
| D3430 | E | Retrograde filling |  |  |  |  |  |
| D3450 | E | Root amputation |  |  |  |  |  |
| D3460 | S | Endodontic endosseous implan | 0330 | 1.51 | \$73.22 | \$14.64 | \$14.64 |
| D3470 | E | Intentional replantation |  |  |  |  |  |
| D3910 | E | Isolation-tooth w rubb dam |  |  |  |  |  |
| D3920 | E | Tooth splitting |  |  |  |  |  |
| D3950 | E | Canal prep/fitting of dowel |  |  |  |  |  |
| D3999 | S | Endodontic procedure | 0330 | 1.51 | \$73.22 | \$14.64 | \$14.64 |
| D4210 | E | Gingivectomy/plasty per quad |  |  |  |  |  |
| D4211 | E | Gingivectomy/plasty per toot |  |  |  |  |  |
| D4220 | E | Gingival curettage per quadr |  |  |  |  |  |
| D4240 | E | Gingival flap proc w/planin ... | ..................... | ..................... | ..................... | ..................... |  |
| D4245 | E | Apically positioned flap |  |  |  |  |  |
| D4249 | E | Crown lengthen hard tissue |  |  |  |  |  |
| D4260 | S | Osseous surgery per quadrant | 0330 | 1.51 | \$73.22 | \$14.64 | \$14.64 |
| D4263 | S | Bone replce graft first site | 0330 | 1.51 | \$73.22 | \$14.64 | \$14.64 |
| D4264 | S | Bone replce graft each add | 0330 | 1.51 | \$73.22 | \$14.64 | \$14.64 |
| D4266 | E | Guided tiss regen resorble |  |  |  |  |  |
| D4267 | E | Guided tiss regen nonresorb |  |  |  |  |  |
| D4268 | E | Surgical revision procedure |  |  |  |  |  |
| D4270 | S | Pedicle soft tissue graft pr | 0330 | 1.51 | \$73.22 | \$14.64 | \$14.64 |
| D4271 | S | Free soft tissue graft proc | 0330 | 1.51 | \$73.22 | \$14.64 | \$14.64 |
| D4273 | S | Subepithelial tissue graft | 0330 | 1.51 | \$73.22 | \$14.64 | \$14.64 |
| D4274 | E | Distal/proximal wedge proc |  |  |  |  |  |
| D4320 | E | Provision splnt intracoronal |  |  |  |  |  |
| D4321 | E | Provisional splint extracoro |  |  |  |  |  |
| D4341 | E | Periodontal scaling \& root |  |  |  |  |  |
| D4355 | S | Full mouth debridement | 0330 | 1.51 | \$73.22 | \$14.64 | \$14.64 |
| D4381 | S | Localized chemo delivery | 0330 | 1.51 | \$73.22 | \$14.64 | \$14.64 |
| D4910 | E | Periodontal maint procedures |  |  |  |  |  |
| D4920 | E | Unscheduled dressing change |  |  |  |  |  |
| D4999 | E | Unspecified periodontal proc |  |  |  | ..................... |  |
| D5110 | E | Dentures complete maxillary |  | ..................... |  | ..................... |  |
| D5120 | E | Dentures complete mandible |  |  |  |  |  |
| D5130 | E | Dentures immediat maxillary |  |  |  |  |  |
| D5140 | E | Dentures immediat mandible |  |  |  |  |  |
| D5211 | E | Dentures maxill part resin |  |  |  |  |  |
| D5212 | E | Dentures mand part resin |  |  |  |  |  |
| D5213 | E | Dentures maxill part metal |  |  |  | ..................... |  |
| D5214 | E | Dentures mandibl part metal |  |  | ..................... |  |  |
| D5281 | E | Removable partial denture |  |  |  |  |  |
| D5410 | E | Dentures adjust cmplt maxil |  |  |  | .................... |  |
| D5411 | E | Dentures adjust cmplt mand |  |  |  |  |  |
| D5421 | E | Dentures adjust part maxill |  |  |  |  |  |
| D5422 | E | Dentures adjust part mandbl |  |  |  |  |  |
| D5510 | E | Dentur repr broken compl bas | .................... |  | .................... | .................... |  |
| D5520 | E | Replace denture teeth complt ................................. |  |  |  |  |  |
| D5610 | E | Dentures repair resin base .. |  |  |  |  |  |
| D5620 | E | Rep part denture cast frame |  |  |  | ..................... |  |
| D5630 | E | Rep partial denture clasp |  |  |  |  |  |
| D5640 | E | Replace part denture teeth |  |  |  |  |  |
| D5650 | E | Add tooth to partial denture | ...................... | ..................... | ...................... | ..................... | .................... |
| D5660 | E | Add clasp to partial denture |  |  | ..................... | ..................... |  |
| D5710 | E | Dentures rebase cmplt maxil ................................... |  |  |  |  |  |
| D5711 | E | Dentures rebase cmplt mand |  |  |  |  |  |
| D5720 | E | Dentures rebase part maxill ................................... | ... |  | . | ..................... |  |
| D5721 | E | Dentures rebase part mandbl |  |  |  |  |  |
| D5730 | E | Denture reln cmplt maxil ch. |  |  |  |  |  |
| D5731 | E | Denture reln cmplt mand chr ................................... | ..................... | ..................... | . | ...................... | .............. |
| D5740 | E | Denture reln part maxil chr ..................................... | ................... | ..................... | ...................... | ..... | ..................... |
| D5741 | E | Denture reln part mand chr |  |  |  |  |  |

[^229]
# Addendum B.—Hospital Outpatient Department (HOPD) Payment Status by hCPCS Code and Related INFORMATION-Continued 

| CPT/ HCPCS | HOPD Status Indicator | Description | APC | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| D5750 | E | Denture reln cmplt max lab | .................... |  |  |  |  |
| D5751 | E | Denture reln cmplt mand lab |  |  |  | .................... |  |
| D5760 | E | Denture reln part maxil lab |  |  |  |  |  |
| D5761 | E | Denture reln part mand lab |  |  |  |  |  |
| D5810 | E | Denture interm cmplt maxill |  |  |  |  |  |
| D5811 | E | Denture interm cmplt mandbl |  |  |  |  |  |
| D5820 | E | Denture interm part maxill |  |  |  |  |  |
| D5821 | E | Denture interm part mandbl |  |  |  | ...................... |  |
| D5850 | E | Denture tiss conditn maxill |  |  |  | ...................... |  |
| D5851 | E | Denture tiss condtin mandbl |  |  |  |  |  |
| D5860 | E | Overdenture complete .... |  |  |  |  |  |
| D5861 | E | Overdenture partial .. |  |  |  |  |  |
| D5862 | E | Precision attachment |  |  |  |  |  |
| D5867 | E | Replacement of precision att |  |  |  |  |  |
| D5875 | E | Prosthesis modification |  |  |  |  |  |
| D5899 | E | Removable prosthodontic proc |  |  |  |  |  |
| D5911 | S | Facial moulage sectional | 0330 | 1.51 | \$73.22 | \$14.64 | \$14.64 |
| D5912 | S | Facial moulage complete | 0330 | 1.51 | \$73.22 | \$14.64 | \$14.64 |
| D5913 | E | Nasal prosthesis .................................................. |  |  |  | ...................... |  |
| D5914 | E | Auricular prosthesis ............................................. |  |  |  |  |  |
| D5915 | E | Orbital prosthesis |  |  |  |  |  |
| D5916 | E | Ocular prosthesis |  |  |  | ................... |  |
| D5919 | E | Facial prosthesis |  |  |  |  |  |
| D5922 | E | Nasal septal prosthesis |  |  |  |  |  |
| D5923 | E | Ocular prosthesis interim |  |  |  |  |  |
| D5924 | E | Cranial prosthesis |  |  |  | ..................... |  |
| D5925 | E | Facial augmentation implant |  |  |  |  |  |
| D5926 | E | Replacement nasal prosthesis ................................ | ..................... |  |  |  |  |
| D5927 | E | Auricular replacement |  |  |  |  |  |
| D5928 | E | Orbital replacement .............................................. |  |  |  |  |  |
| D5929 | E | Facial replacement |  |  |  |  |  |
| D5931 | E | Surgical obturator |  |  |  |  |  |
| D5932 | E | Postsurgical obturator ............................................ |  | .................... |  | ..................... |  |
| D5933 | E | Refitting of obturator |  |  |  |  |  |
| D5934 | E | Mandibular flange prosthesis .................................. |  |  |  |  |  |
| D5935 | E | Mandibular denture prosth |  |  |  |  |  |
| D5936 | E | Temp obturator prosthesis |  |  |  |  |  |
| D5937 | E | Trismus appliance |  |  |  |  |  |
| D5951 | E | Feeding aid |  |  |  | ................... | ..................... |
| D5952 | E | Pediatric speech aid |  |  |  |  |  |
| D5953 | E | Adult speech aid |  |  |  |  |  |
| D5954 | E | Superimposed prosthesis |  |  |  | ..................... |  |
| D5955 | E | Palatal lift prosthesis |  |  |  |  |  |
| D5958 | E | Intraoral con def inter plt ........................................ |  |  |  |  |  |
| D5959 | E | Intraoral con def mod palat .................................... |  | ...................... | ...................... | ...................... | ..................... |
| D5960 | E | Modify speech aid prosthesis ................................. |  |  |  |  |  |
| D5982 | E | Surgical stent |  |  |  |  |  |
| D5983 | S | Radiation applicator | 0330 | 1.51 | \$73.22 | \$14.64 | \$14.64 |
| D5984 | S | Radiation shield | 0330 | 1.51 | \$73.22 | \$14.64 | \$14.64 |
| D5985 | S | Radiation cone locator | 0330 | 1.51 | \$73.22 | \$14.64 | \$14.64 |
| D5986 | E | Fluoride applicator |  |  |  |  |  |
| D5987 | S | Commissure splint ................................................ | 0330 | 1.51 | \$73.22 | \$14.64 | \$14.64 |
| D5988 | E | Surgical splint ..................................................... |  |  |  |  |  |
| D5999 | E | Maxillofacial prosthesis .......................................... |  |  |  |  |  |
| D6010 | E | Odontics endosteal implant .................................... |  |  |  | ...................... |  |
| D6020 | E | Odontics abutment placement |  |  |  |  |  |
| D6040 | E | Odontics eposteal implant |  |  |  |  |  |
| D6050 | E | Odontics transosteal implnt .................................... |  |  |  |  | ..................... |
| D6055 | E | Implant connecting bar |  |  |  |  |  |
| D6056 | E | Prefabricated abutment |  |  |  |  |  |
| D6057 | E | Custom abutment |  |  |  |  |  |
| D6058 | E | Abutment supported crown |  |  |  |  |  |
| D6059 | E | Abutment supported mtl crown ................................ |  |  |  |  |  |
| D6060 | E | Abutment supported mtl crown |  |  |  |  |  |
| D6061 | E | Abutment supported mtl crown ................................ |  |  |  |  |  |
| D6062 | E | Abutment supported mtl crown ................................ |  |  |  | ..................... |  |
| D6063 | E | Abutment supported mtl crown |  |  |  |  |  |
| D6064 | E | Abutment supported mtl crown ................................ |  |  |  | ..................... | .................... |
| D6065 | E | Implant supported crown ........................................ |  | ..................... |  | ..................... |  |
| D6066 | E | Implant supported mtl crown ................................... |  |  |  |  |  |
| D6067 | E | Implant supported mtl crown ................................... |  |  |  |  |  |
| D6068 | E | Abutment supported retainer .................................. | ..................... | ..................... | ..................... | .................... | ..................... |
| D6069 | E | Abutment supported retainer |  |  |  |  |  |

[^230]
# Addendum B.-Hospital Outpatient Department (HOPD) Payment Status by HCPCS Code and Related INFORMATION-Continued 

| CPT/ <br> HCPCS | HOPD Status Indicator | Description | APC | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| D6070 | E | Abutment supported retainer |  |  |  |  |  |
| D6071 | E | Abutment supported retainer ................................... |  |  |  |  |  |
| D6072 | E | Abutment supported retainer |  | .................... | ..................... | ...................... |  |
| D6073 | E | Abutment supported retainer |  |  |  |  |  |
| D6074 | E | Abutment supported retainer . |  |  |  |  |  |
| D6075 | E | Implant supported retainer ...... |  |  |  |  |  |
| D6076 | E | Implant supported retainer ... |  |  |  |  |  |
| D6077 | E | Implant supported retainer ...................................... |  |  | ..................... |  |  |
| D6078 | E | Implnt/abut suprtd fixd dent |  |  |  |  |  |
| D6079 | E | Implnt/abut suprtd fixd dent |  |  |  |  |  |
| D6080 | E | Implant maintenance |  |  |  |  |  |
| D6090 | E | Repair implant |  |  |  |  |  |
| D6095 | E | Odontics repr abutment |  |  |  |  |  |
| D6100 | E | Removal of implant |  |  |  |  |  |
| D6199 | E | Implant procedure |  | ..................... | ..................... | ..................... |  |
| D6210 | E | Prosthodont high noble metal |  |  |  |  |  |
| D6211 | E | Bridge base metal cast .. |  |  |  |  |  |
| D6212 | E | Bridge noble metal cast |  |  |  |  |  |
| D6240 | E | Bridge porcelain high noble |  |  |  |  |  |
| D6241 | E | Bridge porcelain base metal |  |  |  |  |  |
| D6242 | E | Bridge porcelain nobel metal |  |  |  |  |  |
| D6245 | E | Bridge porcelain/ceramic |  |  |  |  |  |
| D6250 | E | Bridge resin w/high noble |  |  |  |  |  |
| D6251 | E | Bridge resin base metal |  |  |  |  |  |
| D6252 | E | Bridge resin w/noble metal |  |  |  |  |  |
| D6519 | E | Inlay/onlay porce/ceramic |  |  |  |  |  |
| D6520 | E | Dental retainer two surfaces |  |  |  |  |  |
| D6530 | E | Retainer metallic 3+ surface |  |  |  |  |  |
| D6543 | E | Dental retainr onlay 3 surf |  |  |  |  |  |
| D6544 | E | Dental retainr onlay 4/more |  |  |  |  |  |
| D6545 | E | Dental retainr cast metl |  |  | ..................... | .................... |  |
| D6548 | E | Porcelain/ceramic retainer |  |  |  |  |  |
| D6720 | E | Retain crown resin w hi nble |  |  |  |  |  |
| D6721 | E | Crown resin w/base metal |  |  |  |  |  |
| D6722 | E | Crown resin w/noble metal |  | ..................... | .................... | .................... |  |
| D6740 | E | Crown porcelain/ceramic |  |  |  |  |  |
| D6750 | E | Crown porcelain high noble |  |  |  | ...................... |  |
| D6751 | E | Crown porcelain base metal |  |  | ...................... | ...................... |  |
| D6752 | E | Crown porcelain noble metal |  |  |  |  |  |
| D6780 | E | Crown 3/4 high noble metal ................................... |  |  |  | .................... |  |
| D6781 | E | Crown 3/4 cast based metal |  |  | ..................... | . |  |
| D6782 | E | Crown 3/4 cast noble metal |  |  |  |  |  |
| D6783 | E | Crown 3/4 porcelain/ceramic |  |  |  |  |  |
| D6790 | E | Crown full high noble metal |  |  |  |  |  |
| D6791 | E | Crown full base metal cast |  |  |  |  |  |
| D6792 | E | Crown full noble metal cast |  |  |  |  |  |
| D6920 | S | Dental connector bar | 0330 | 1.51 | \$73.22 | \$14.64 | \$14.64 |
| D6930 | E | Dental recement bridge |  |  |  |  |  |
| D6940 | E | Stress breaker |  |  |  |  |  |
| D6950 | E | Precision attachment |  |  |  |  |  |
| D6970 | E | Post \& core plus retainer |  |  |  |  |  |
| D6971 | E | Cast post bridge retainer |  |  |  |  |  |
| D6972 | E | Prefab post \& core plus reta |  |  |  |  |  |
| D6973 | E | Core build up for retainer ....................................... |  |  |  | .................... |  |
| D6975 | E | Coping metal ....................................................... |  |  |  |  |  |
| D6976 | E | Each addtnl cast post ............................................ |  |  |  |  |  |
| D6977 | E | Each addtl prefab post .......................................... |  |  |  | .................... |  |
| D6980 | E | Bridge repair |  |  |  |  |  |
| D6999 | E | Fixed prosthodontic proc ........................................ |  |  |  |  |  |
| D7110 | S | Oral surgery single tooth | 0330 | 1.51 | \$73.22 | \$14.64 | \$14.64 |
| D7120 | S | Each add tooth extraction | 0330 | 1.51 | \$73.22 | \$14.64 | \$14.64 |
| D7130 | S | Tooth root removal | 0330 | 1.51 | \$73.22 | \$14.64 | \$14.64 |
| D7210 | S | Rem imp tooth w mucoper flp ................................. | 0330 | 1.51 | \$73.22 | \$14.64 | \$14.64 |
| D7220 | S | Impact tooth remov soft tiss ...... | 0330 | 1.51 | \$73.22 | \$14.64 | \$14.64 |
| D7230 | S | Impact tooth remov part bony | 0330 | 1.51 | \$73.22 | \$14.64 | \$14.64 |
| D7240 | S | Impact tooth remov comp bony ............................... | 0330 | 1.51 | \$73.22 | \$14.64 | \$14.64 |
| D7241 | S | Impact tooth rem bony w/comp ............................... | 0330 | 1.51 | \$73.22 | \$14.64 | \$14.64 |
| D7250 | S | Tooth root removal ............................................... | 0330 | 1.51 | \$73.22 | \$14.64 | \$14.64 |
| D7260 | S | Oral antral fistula closure | 0330 | 1.51 | \$73.22 | \$14.64 | \$14.64 |
| D7270 | E | Tooth reimplantation .............................................. |  |  |  | ..................... | ..................... |
| D7272 | E | Tooth transplantation ..... | ...................... | ...................... | ...................... | ............... |  |
| D7280 | E | Exposure impact tooth orthod ................................. |  | ...................... |  |  |  |
| D7281 | E | Exposure tooth aid eruption ..... |  |  |  |  |  |

[^231]
# Addendum B.—Hospital Outpatient Department (HOPD) Payment Status by hCPCS Code and Related Information-Continued 

| CPT/ HCPCS | HOPD Status Indicator | Description | APC | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| D7285 | E | Biopsy of oral tissue hard |  |  |  |  |  |
| D7286 | E | Biopsy of oral tissue soft |  |  |  |  |  |
| D7290 | E | Repositioning of teeth |  |  |  |  |  |
| D7291 | S | Transseptal fiberotomy | 0330 | 1.51 | \$73.22 | \$14.64 | \$14.64 |
| D7310 | E | Alveoplasty w/extraction |  |  |  |  |  |
| D7320 | E | Alveoplasty w/o extraction |  | ..................... | ...................... | ..................... |  |
| D7340 | E | Vestibuloplasty ridge extens |  |  |  |  |  |
| D7350 | E | Vestibuloplasty exten graft .. |  |  |  |  |  |
| D7410 | E | Rad exc lesion up to 1.25 cm |  |  |  | .................... |  |
| D7420 | E | Lesion > 1.25 cm |  |  |  |  |  |
| D7430 | E | Exc benign tumor to 1.25 cm |  |  |  |  |  |
| D7431 | E | Benign tumor exc $>1.25 \mathrm{~cm}$ |  |  |  |  |  |
| D7440 | E | Malig tumor exc to 1.25 cm |  |  |  |  |  |
| D7441 | E | Malig tumor > 1.25 cm |  |  |  |  |  |
| D7450 | E | Rem odontogen cyst to 1.25 cm |  |  |  |  |  |
| D7451 | E | Rem odontogen cyst $>1.25 \mathrm{~cm}$ |  |  |  |  |  |
| D7460 | E | Rem nonodonto cyst to 1.25 cm |  |  |  |  |  |
| D7461 | E | Rem nonodonto cyst $>1.25 \mathrm{~cm}$ |  |  |  |  |  |
| D7465 | E | Lesion destruction |  |  |  |  |  |
| D7471 | E | Rem exostosis any site |  |  |  |  |  |
| D7480 | E | Partial ostectomy |  |  |  |  |  |
| D7490 | E | Mandible resection |  |  |  |  |  |
| D7510 | E | I\&d absc intraoral soft tiss |  |  |  |  |  |
| D7520 | E | I\&d abscess extraoral |  |  |  |  |  |
| D7530 | E | Removal fb skin/areolar tiss |  |  |  |  |  |
| D7540 | E | Removal of fb reaction |  |  |  |  |  |
| D7550 | E | Removal of sloughed off bone |  |  |  |  |  |
| D7560 | E | Maxillary sinusotomy |  |  |  |  |  |
| D7610 | E | Maxilla open reduct simple |  |  |  |  |  |
| D7620 | E | Clsd reduct simpl maxilla fx |  |  |  | ................... |  |
| D7630 | E | Open red simpl mandible fx |  |  |  |  |  |
| D7640 | E | Clsd red simpl mandible fx |  |  |  |  |  |
| D7650 | E | Open red simp malar/zygom fx |  |  |  | .................... |  |
| D7660 | E | Clsd red simp malar/zygom fx |  |  |  | ...................... |  |
| D7670 | E | Closd rductn splint alveolus |  |  |  |  |  |
| D7680 | E | Reduct simple facial bone fx |  |  |  | ..................... |  |
| D7710 | E | Maxilla open reduct compound |  |  |  |  |  |
| D7720 | E | Clsd reduct compd maxilla fx |  |  |  |  |  |
| D7730 | E | Open reduct compd mandble fx |  |  |  | .................... |  |
| D7740 | E | Clsd reduct compd mandble fx |  |  |  |  |  |
| D7750 | E | Open red comp malar/zygma fx |  |  |  |  |  |
| D7760 | E | Clsd red comp malar/zygma fx |  |  |  | ..................... |  |
| D7770 | E | Open reduc compd alveolus fx |  |  |  |  |  |
| D7780 | E | Reduct compnd facial bone fx |  |  |  |  |  |
| D7810 | E | Tmj open reduct-dislocation |  |  |  |  |  |
| D7820 | E | Closed tmp manipulation |  |  |  |  |  |
| D7830 | E | Tmj manipulation under anest |  |  |  |  |  |
| D7840 | E | Removal of tmj condyle |  |  |  |  |  |
| D7850 | E | Tmj meniscectomy |  |  |  |  |  |
| D7852 | E | Tmj repair of joint disc |  |  |  |  |  |
| D7854 | E | Tmj excisn of joint membrane |  |  |  |  |  |
| D7856 | E | Tmj cutting of a muscle ......... |  |  |  |  |  |
| D7858 | E | Tmj reconstruction |  |  |  | .................... |  |
| D7860 | E | Tmj cutting into joint |  |  |  |  |  |
| D7865 | E | Tmj reshaping components |  |  |  |  |  |
| D7870 | E | Tmj aspiration joint fluid. |  |  |  | .................... |  |
| D7871 | E | Lysis + lavage w catheters |  |  |  |  |  |
| D7872 | E | Tmj diagnostic arthroscopy |  |  |  |  |  |
| D7873 | E | Tmj arthroscopy lysis adhesn |  |  |  | .................... |  |
| D7874 | E | Tmj arthroscopy disc reposit |  |  |  |  |  |
| D7875 | E | Tmj arthroscopy synovectomy |  |  |  |  |  |
| D7876 | E | Tmj arthroscopy discectomy .. |  |  |  | ..................... |  |
| D7877 | E | Tmj arthroscopy debridement . |  |  |  |  |  |
| D7880 | E | Occlusal orthotic appliance . |  |  |  |  |  |
| D7899 | E | Tmj unspecified therapy |  |  |  |  |  |
| D7910 | E | Dent sutur recent wnd to 5 cm |  |  |  | ................. | ........ |
| D7911 | E | Dental suture wound to 5 cm |  |  |  | ...................... |  |
| D7912 | E | Suture complicate wnd $>5 \mathrm{~cm}$ |  |  |  |  |  |
| D7920 | E | Dental skin graft .... |  |  |  |  |  |
| D7940 | S | Reshaping bone orthognathic | 0330 | 1.51 | \$73.22 | \$14.64 | \$14.64 |
| D7941 | E | Bone cutting ramus closed |  |  |  |  |  |
| D7943 | E | Cutting ramus open w/graft .................................... |  |  |  | ................... |  |
| D7944 | E | Bone cutting segmented ... |  |  |  |  |  |

[^232]
# Addendum B.-Hospital Outpatient Department (HOPD) Payment Status by HCPCS Code and Related Information-Continued 

| CPT/ HCPCS | HOPD Status Indicator | Description | APC | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| D7945 | E | Bone cutting body mandible ................................... |  | ... | . | ..................... |  |
| D7946 | E | Reconstruction maxilla total .................................... |  |  |  |  |  |
| D7947 | E | Reconstruct maxilla segment |  |  |  |  |  |
| D7948 | E | Reconstruct midface no graft .................................. |  |  |  |  |  |
| D7949 | E | Reconstruct midface w/graft |  |  |  |  |  |
| D7950 | E | Mandible graft |  |  |  |  |  |
| D7955 | E | Repair maxillofacial defects |  |  |  |  |  |
| D7960 | E | Frenulectomy/frenulotomy ..................................... |  |  | ..................... |  |  |
| D7970 | E | Excision hyperplastic tissue .................................... |  |  |  |  |  |
| D7971 | E | Excision pericoronal gingiva |  |  |  |  |  |
| D7980 | E | Sialolithotomy ....... |  |  |  |  |  |
| D7981 | E | Excision of salivary gland |  |  |  |  |  |
| D7982 | E | Sialodochoplasty .. |  |  |  |  |  |
| D7983 | E | Closure of salivary fistula |  |  |  |  |  |
| D7990 | E | Emergency tracheotomy ........................................ |  |  |  |  |  |
| D7991 | E | Dental coronoidectomy |  |  |  |  |  |
| D7995 | E | Synthetic graft facial bones |  |  |  |  |  |
| D7996 | E | Implant mandible for augment |  |  |  |  |  |
| D7997 | E | Appliance removal |  |  |  |  |  |
| D7999 | E | Oral surgery procedure |  |  |  |  |  |
| D8010 | E | Limited dental tx primary |  |  |  |  |  |
| D8020 | E | Limited dental tx transition |  |  | ...................... | ...................... |  |
| D8030 | E | Limited dental tx adolescent |  |  |  |  |  |
| D8040 | E | Limited dental tx adult |  |  |  |  |  |
| D8050 | E | Intercep dental tx primary |  |  |  |  |  |
| D8060 | E | Intercep dental tx transitn |  |  |  |  |  |
| D8070 | E | Compre dental tx transition |  |  |  |  |  |
| D8080 | E | Compre dental tx adolescent |  |  |  |  |  |
| D8090 | E | Compre dental tx adult |  |  |  |  |  |
| D8210 | E | Orthodontic rem appliance tx |  |  |  |  |  |
| D8220 | E | Fixed appliance therapy habt |  |  |  |  |  |
| D8660 | E | Preorthodontic tx visit ..... |  |  | ..................... |  |  |
| D8670 | E | Periodic orthodontc tx visit |  |  |  |  |  |
| D8680 | E | Orthodontic retention |  |  |  |  |  |
| D8690 | E | Orthodontic treatment |  |  |  |  |  |
| D8691 | E | Repair ortho appliance |  |  |  |  |  |
| D8692 | E | Replacement retainer |  |  |  |  |  |
| D8999 | E | Orthodontic procedure |  |  |  |  |  |
| D9110 | N | Tx dental pain minor proc |  |  |  |  |  |
| D9210 | E | Dent anesthesia w/o surgery |  |  |  |  |  |
| D9211 | E | Regional block anesthesia |  |  |  | ................... |  |
| D9212 | E | Trigeminal block anesthesia |  |  |  |  |  |
| D9215 | E | Local anesthesia . |  |  |  |  |  |
| D9220 | E | General anesthesia |  |  |  |  |  |
| D9221 | E | General anesthesia ea ad 15m |  |  | . | ...................... |  |
| D9230 | N | Analgesia |  |  |  |  |  |
| D9241 | E | Intravenous sedation |  |  |  |  |  |
| D9242 | E | IV sedation ea ad 30 m |  |  |  | ..................... |  |
| D9248 | E | Sedation (non-iv) .................................................. |  |  |  |  |  |
| D9310 | E | Dental consultation |  |  |  |  |  |
| D9410 | E | Dental house call |  |  |  | .................... |  |
| D9420 | E | Hospital call |  |  |  |  |  |
| D9430 | E | Office visit during hours |  |  |  |  |  |
| D9440 | E | Office visit after hours ........................................... |  |  |  |  |  |
| D9610 | E | Dent therapeutic drug inject ................................... |  |  |  |  |  |
| D9630 | S | Other drugs/medicaments ..................................... | 0330 | 1.51 | \$73.22 | \$14.64 | \$14.64 |
| D9910 | E | Dent appl desensitizing med .................................. |  |  |  |  |  |
| D9911 | E | Appl desensitizing resin ......................................... |  |  |  |  |  |
| D9920 | E | Behavior management .......................................... |  |  |  |  |  |
| D9930 | S | Treatment of complications .................................... | 0330 | 1.51 | \$73.22 | \$14.64 | \$14.64 |
| D9940 | S | Dental occlusal guard ........................................... | 0330 | 1.51 | \$73.22 | \$14.64 | \$14.64 |
| D9941 | E | Fabrication athletic guard ....................................... |  |  |  |  |  |
| D9950 | S | Occlusion analysis ................................................ | 0330 | 1.51 | \$73.22 | \$14.64 | \$14.64 |
| D9951 | S | Limited occlusal adjustment ................................... | 0330 | 1.51 | \$73.22 | \$14.64 | \$14.64 |
| D9952 | S | Complete occlusal adjustment ................................. | 0330 | 1.51 | \$73.22 | \$14.64 | \$14.64 |
| D9970 | E | Enamel microabrasion ........................................... |  |  |  |  |  |
| D9971 | E | Odontoplasty 1-2 teeth |  |  |  |  |  |
| D9972 | E | Extrnl bleaching per arch ........................................ |  |  |  |  |  |
| D9973 | E | Extrnl bleaching per tooth ....................................... |  |  |  |  |  |
| D9974 | E | Intrnl bleaching per tooth. |  |  |  |  |  |
| D9999 | E | Adjunctive procedure ............................................. | ...................... | ...................... | . | ...................... | ...................... |
| E0100 | A | Cane adjust/fixed with tip ...................................... | ... | .............. | ..................... | .............. |  |
| E0105 | A | Cane adjust/fixed quad/3 pro |  |  |  |  |  |

[^233]
# Addendum B.-Hospital Outpatient Department (HOPD) Payment Status by hCPCS Code and Related Information-Continued 

| CPT/ HCPCS | HOPD Status Indicator | Description | APC | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| E0110 | A | Crutch forearm pair |  |  |  |  |  |
| E0111 | A | Crutch forearm each |  |  |  |  |  |
| E0112 | A | Crutch underarm pair wood |  |  |  |  |  |
| E0113 | A | Crutch underarm each wood |  |  |  |  |  |
| E0114 | A | Crutch underarm pair no wood |  |  |  |  |  |
| E0116 | A | Crutch underarm each no wood |  |  |  | .................... |  |
| E0130 | A | Walker rigid adjust/fixed ht |  |  |  |  |  |
| E0135 | A | Walker folding adjust/fixed |  |  |  |  |  |
| E0141 | A | Rigid walker wheeled wo seat |  |  |  |  |  |
| E0142 | A | Walker rigid wheeled with se |  |  |  |  |  |
| E0143 | A | Walker folding wheeled w/o s |  |  |  |  |  |
| E0144 | A | Enclosed walker w rear seat |  |  |  |  |  |
| E0145 | A | Walker whled seat/crutch att |  |  |  |  |  |
| E0146 | A | Folding walker wheels w seat |  |  |  |  |  |
| E0147 | A | Walker variable wheel resist. |  |  |  |  |  |
| E0153 | A | Forearm crutch platform atta |  |  |  |  |  |
| E0154 | A | Walker platform attachment |  |  |  |  |  |
| E0155 | A | Walker wheel attachment, pair |  |  |  |  |  |
| E0156 | A | Walker seat attachment .......... |  |  |  |  |  |
| E0157 | A | Walker crutch attachment |  |  |  |  |  |
| E0158 | A | Walker leg extenders set of 4 |  |  |  |  |  |
| E0159 | A | Brake for wheeled walker |  |  |  |  |  |
| E0160 | A | Sitz type bath or equipment |  |  |  |  |  |
| E0161 | A | Sitz bath/equipment w/faucet |  |  |  |  |  |
| E0162 | A | Sitz bath chair |  |  |  |  |  |
| E0163 | A | Commode chair stationry fxd |  |  |  |  |  |
| E0164 | A | Commode chair mobile fixed a |  |  |  |  |  |
| E0165 | A | Commode chair stationry det |  |  |  |  |  |
| E0166 | A | Commode chair mobile detach |  |  |  |  |  |
| E0167 | A | Commode chair pail or pan |  |  |  |  |  |
| E0175 | A | Commode chair foot rest |  |  |  |  |  |
| E0176 | A | Air pressre pad/cushion nonp |  |  |  |  |  |
| E0177 | A | Water press pad/cushion nonp |  |  |  | ..................... |  |
| E0178 | A | Gel pressre pad/cushion nonp |  | ...................... |  | ...................... |  |
| E0179 | A | Dry pressre pad/cushion nonp |  |  |  |  |  |
| E0180 | A | Press pad alternating w pump |  |  |  | ...................... |  |
| E0181 | A | Press pad alternating w/pum |  | ................... |  | ..................... |  |
| E0182 | A | Pressure pad alternating pum |  |  |  |  |  |
| E0184 | A | Dry pressure mattress ....... |  |  |  |  |  |
| E0185 | A | Gel pressure mattress pad |  |  |  | ..................... |  |
| E0186 | A | Air pressure mattress |  |  |  |  |  |
| E0187 | A | Water pressure mattress |  |  |  | .................... |  |
| E0188 | E | Synthetic sheepskin pad ... |  |  |  |  |  |
| E0189 | E | Lambswool sheepskin pad |  |  |  |  |  |
| E0191 | A | Protector heel or elbow |  |  |  |  |  |
| E0192 | A | Pad wheelchr low press/posit |  |  |  |  |  |
| E0193 | A | Powered air flotation bed |  |  |  | .................... |  |
| E0194 | A | Air fluidized bed |  |  |  |  |  |
| E0196 | A | Gel pressure mattress |  |  |  |  |  |
| E0197 | A | Air pressure pad for mattres |  |  |  | ...................... |  |
| E0198 | A | Water pressure pad for mattr |  |  |  |  |  |
| E0199 | A | Dry pressure pad for mattres |  |  |  |  |  |
| E0200 | A | Heat lamp without stand ......................................... |  |  |  | $\ldots$ |  |
| E0202 | A | Phototherapy light w/photom |  |  |  |  |  |
| E0205 | A | Heat lamp with stand |  |  |  |  |  |
| E0210 | A | Electric heat pad standard |  | .................... |  | .................... |  |
| E0215 | A | Electric heat pad moist |  |  |  |  |  |
| E0217 | A | Water circ heat pad w pump .................................. |  |  |  |  |  |
| E0218 | A | Water circ cold pad w pump ................................... |  |  |  | ..................... |  |
| E0220 | A | Hot water bottle |  | ...................... |  | ...................... |  |
| E0225 | A | Hydrocollator unit |  |  |  |  |  |
| E0230 | A | Ice cap or collar |  |  |  | ..................... |  |
| E0235 | A | Paraffin bath unit portable ... |  |  |  | ..................... |  |
| E0236 | A | Pump for water circulating p |  |  |  |  |  |
| E0238 | A | Heat pad non-electric moist |  |  |  |  |  |
| E0239 | A | Hydrocollator unit portable .. |  | ... |  | ... |  |
| E0241 | E | Bath tub wall rail | ..................... | ..................... | ...................... | ..................... |  |
| E0242 | E | Bath tub rail floor |  |  |  |  |  |
| E0243 | E | Toilet rail |  | ..................... |  | ...................... |  |
| E0244 | E | Toilet seat raised | .................... | .... | ...................... | ...... |  |
| E0245 | E | Tub stool or bench |  |  |  |  |  |
| E0246 | A | Transfer tub rail attachment ................................... |  |  |  |  |  |
| E0249 | A | Pad water circulating heat u |  |  |  |  |  |

CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
Copyright American Dental Association. All rights reserved.
${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment.
${ }^{2}$ Not subject to national coinsurance.
${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

# Addendum B.-Hospital Outpatient Department (HOPD) Payment Status by HCPCS Code and Related INFORMATION-Continued 

| CPT/ HCPCS | HOPD Status Indicator | Description | APC | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| E0250 | A | Hosp bed fixed ht w/mattres |  |  |  |  |  |
| E0251 | A | Hosp bed fixd ht w/o mattres |  |  |  |  |  |
| E0255 | A | Hospital bed var ht w/mattr |  | ............. | ........ |  |  |
| E0256 | A | Hospital bed var ht w/o matt |  |  |  |  |  |
| E0260 | A | Hosp bed semi-electr w/matt |  |  |  |  |  |
| E0261 | A | Hosp bed semi-electr w/o mat |  |  | $\ldots$ | .................... |  |
| E0265 | A | Hosp bed total electr w/mat . |  |  |  |  |  |
| E0266 | A | Hosp bed total elec w/o matt |  |  |  |  |  |
| E0270 | A | Hospital bed institutional t ..... |  |  |  |  |  |
| E0271 | A | Mattress innerspring |  | .................... | .................... |  |  |
| E0272 | A | Mattress foam rubber |  | ...................... | ...................... |  |  |
| E0273 | A | Bed board |  |  |  |  |  |
| E0274 | A | Over-bed table |  |  |  |  |  |
| E0275 | A | Bed pan standard |  |  | ..................... |  |  |
| E0276 | A | Bed pan fracture |  |  |  |  |  |
| E0277 | A | Powered pres-redu air mattrs |  |  |  |  |  |
| E0280 | A | Bed cradle |  |  | ................... |  |  |
| E0290 | A | Hosp bed fx ht w/o rails w/m |  |  |  |  |  |
| E0291 | A | Hosp bed fx ht w/o rail w/o. |  |  |  |  |  |
| E0292 | A | Hosp bed var ht w/o rail w/o |  |  |  |  |  |
| E0293 | A | Hosp bed var ht w/o rail w/ |  |  |  |  |  |
| E0294 | A | Hosp bed semi-elect w/mattr |  |  |  |  |  |
| E0295 | A | Hosp bed semi-elect w/o matt |  |  |  |  |  |
| E0296 | A | Hosp bed total elect w/matt |  |  |  |  |  |
| E0297 | A | Hosp bed total elect w/o mat. |  |  |  |  |  |
| E0305 | A | Rails bed side half length |  |  |  |  |  |
| E0310 | A | Rails bed side full length |  |  |  |  |  |
| E0315 | A | Bed accessory brd/tbl/supprt |  |  |  |  |  |
| E0325 | A | Urinal male jug-type |  |  |  |  |  |
| E0326 | A | Urinal female jug-type |  |  |  |  |  |
| E0350 | A | Control unit bowel system |  |  | ................... |  |  |
| E0352 | A | Disposable pack w/bowel syst |  |  |  |  |  |
| E0370 | A | Air elevator for heel |  |  |  | ..................... |  |
| E0371 | A | Nonpower mattress overlay |  |  | ................... |  |  |
| E0372 | A | Powered air mattress overlay |  |  |  |  |  |
| E0373 | A | Nonpowered pressure mattress |  |  |  |  |  |
| E0424 | A | Stationary compressed gas 02 |  |  |  | .................... |  |
| E0425 | A | Gas system stationary compre ................................ |  |  |  |  |  |
| E0430 | A | Oxygen system gas portable ... |  |  |  |  |  |
| E0431 | A | Portable gaseous 02 |  |  |  |  |  |
| E0434 | A | Portable liquid 02 |  |  |  |  |  |
| E0435 | A | Oxygen system liquid portabl |  |  |  |  |  |
| E0439 | A | Stationary liquid 02 |  |  |  |  |  |
| E0440 | A | Oxygen system liquid station |  |  |  |  |  |
| E0441 | A | Oxygen contents gas per/unit |  |  |  |  |  |
| E0442 | A | Oxygen contents liq per/unit .. |  |  |  |  |  |
| E0443 | A | Port 02 contents gas/unit ...................................... |  |  |  | .................... |  |
| E0444 | A | Port 02 contents liq/unit |  |  |  |  |  |
| E0450 | A | Volume vent stationary/porta |  |  |  |  |  |
| E0455 | A | Oxygen tent excl croup/ped t |  |  |  |  |  |
| E0457 | A | Chest shell |  |  |  |  |  |
| E0459 | A | Chest wrap |  |  |  |  |  |
| E0460 | A | Neg press vent portabl/statn ................................... |  |  |  |  |  |
| E0462 | A | Rocking bed w/ or w/o side r . |  |  |  |  |  |
| E0480 | A | Percussor elect/pneum home m .............................. |  |  |  |  |  |
| E0500 | A | Ippb all types ...... |  |  |  |  |  |
| E0550 | A | Humidif extens supple w ippb ................................. |  |  |  |  |  |
| E0555 | A | Humidifier for use w/regula |  |  |  |  |  |
| E0560 | A | Humidifier supplemental w/i ... |  |  |  |  |  |
| E0565 | A | Compressor air power source ................................. |  |  |  | .................... |  |
| E0570 | A | Nebulizer with compression ..... |  |  |  | ...................... |  |
| E0575 | A | Nebulizer ultrasonic |  |  |  |  |  |
| E0580 | A | Nebulizer for use w/regulat ..................................... |  |  |  |  |  |
| E0585 | A | Nebulizer w/compressor \& he |  |  |  |  |  |
| E0590 | A | Dispensing fee dme neb drug |  |  |  |  |  |
| E0600 | A | Suction pump portab hom modl .............................. |  |  |  | .................... |  |
| E0601 | A | Cont airway pressure device ................................... |  |  |  | ...................... |  |
| E0602 | A | Breast pump ...... |  |  |  |  |  |
| E0605 | A | Vaporizer room type ..... | .................. | .................... | .................... | ..................... |  |
| E0606 | A | Drainage board postural ..... |  |  |  | ...................... |  |
| E0607 | A | Blood glucose monitor home ................................... |  | .................... |  | .................... |  |
| E0608 | A | Apnea monitor ...................................................... |  | ...................... |  |  |  |
| E0609 | A | Blood gluc mon w/special fea |  |  |  |  |  |

CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
Copyright American Dental Association. All rights reserved
${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment.
${ }^{2}$ Not subject to national coinsurance.
${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

# Addendum B.-Hospital Outpatient Department (hopd) Payment Status by hCPCS Code and Related Information-Continued 

| CPT/ HCPCS | HOPD Status Indicator | Description | APC | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| E0610 | A | Pacemaker monitr audible/vis |  |  |  |  |  |
| E0615 | A | Pacemaker monitr digital/vis |  |  |  |  |  |
| E0616 | A | Cardiac event recorder .... |  |  |  |  |  |
| E0621 | A | Patient lift sling or seat |  |  |  |  |  |
| E0625 | A | Patient lift bathroom or toi | ... | ................... | ................... | ..................... |  |
| E0627 | A | Seat lift incorp lift-chair |  |  |  |  |  |
| E0628 | A | Seat lift for pt furn-electr |  |  |  |  |  |
| E0629 | A | Seat lift for pt furn-non-el |  |  |  | - |  |
| E0630 | A | Patient lift hydraulic |  |  |  |  |  |
| E0635 | A | Patient lift electric .. |  |  |  |  |  |
| E0650 | A | Pneuma compresor non-segment ........................... |  |  |  |  |  |
| E0651 | A | Pneum compressor segmental ................................ |  |  |  |  |  |
| E0652 | A | Pneum compres w/cal pressure |  |  |  |  |  |
| E0655 | A | Pneumatic appliance half arm ... |  |  |  |  |  |
| E0660 | A | Pneumatic appliance full leg.. |  |  |  |  |  |
| E0665 | A | Pneumatic appliance full arm... |  |  |  |  |  |
| E0666 | A | Pneumatic appliance half leg .. |  |  |  |  |  |
| E0667 | A | Seg pneumatic appl full leg.. |  |  |  |  |  |
| E0668 | A | Seg pneumatic appl full arm |  |  |  |  |  |
| E0669 | A | Seg pneumatic appli half leg |  |  |  |  |  |
| E0671 | A | Pressure pneum appl full leg. |  |  |  |  |  |
| E0672 | A | Pressure pneum appl full arm |  |  |  |  |  |
| E0673 | A | Pressure pneum appl half leg |  |  |  |  |  |
| E0690 | A | Ultraviolet cabinet |  |  |  |  |  |
| E0700 | A | Safety equipment |  |  |  |  |  |
| E0710 | A | Restraints any type |  |  |  |  |  |
| E0720 | A | Tens two lead. |  |  |  |  |  |
| E0730 | A | Tens four lead |  |  |  | .................... |  |
| E0731 | A | Conductive garment for tens/ |  |  |  | ..................... |  |
| E0740 | A | Incontinence treatment systm |  |  |  |  |  |
| E0744 | A | Neuromuscular stim for scoli |  |  |  |  |  |
| E0745 | A | Neuromuscular stim for shock . |  |  |  | ...................... |  |
| E0746 | A | Electromyograph biofeedback |  |  |  |  |  |
| E0747 | A | Elec osteogen stim not spine .. |  |  |  |  |  |
| E0748 | A | Elec osteogen stim spinal ......... |  |  |  |  |  |
| E0749 | A | Elec osteogen stim implanted |  |  |  |  |  |
| E0751 | A | Pulse generator or receiver |  |  |  |  |  |
| E0753 | A | Neurostimulator electrodes |  |  |  |  |  |
| E0755 | A | Electronic salivary reflex s |  |  |  |  |  |
| E0760 | A | Osteogen ultrasound stimltor |  |  |  |  |  |
| E0776 | A | Iv pole . |  |  |  |  |  |
| E0779 | A | Amb infusion pump mechanical |  |  |  |  |  |
| E0780 | A | Mech amb infusion pump <8hrs |  |  |  |  |  |
| E0781 | A | External ambulatory infus pu |  |  |  |  |  |
| E0782 | A | Non-programble infusion pump |  |  |  |  |  |
| E0783 | A | Programmable infusion pump |  |  |  |  |  |
| E0784 | A | Ext amb infusn pump insulin |  |  |  |  |  |
| E0785 | A | Replacement impl pump cathet ............................... |  |  |  |  |  |
| E0791 | A | Parenteral infusion pump sta .................................. |  |  |  |  |  |
| E0840 | A | Tract frame attach headboard ................................. |  |  |  |  |  |
| E0850 | A | Traction stand free standing .................................... |  |  |  |  |  |
| E0855 | A | Cervical traction equipment .................................... |  |  |  |  |  |
| E0860 | A | Tract equip cervical tract |  |  |  |  |  |
| E0870 | A | Tract frame attach footboard |  |  |  |  |  |
| E0880 | A | Trac stand free stand extrem .................................. |  |  |  | $\ldots$ |  |
| E0890 | A | Traction frame attach pelvic ................................... |  |  |  |  |  |
| E0900 | A | Trac stand free stand pelvic ................................... |  |  |  |  |  |
| E0910 | A | Trapeze bar attached to bed ................................... |  |  |  | ...................... |  |
| E0920 | A | Fracture frame attached to b |  |  |  |  |  |
| E0930 | A | Fracture frame free standing .................................. |  |  |  |  |  |
| E0935 | A | Exercise device passive moti .................................. |  |  |  | ..................... |  |
| E0940 | A | Trapeze bar free standing ...................................... |  |  |  | ..................... |  |
| E0941 | A | Gravity assisted traction de .................................... |  |  |  |  |  |
| E0942 | A | Cervical head harness/halter |  |  |  | ..................... |  |
| E0943 | A | Cervical pillow ..................................................... |  |  |  |  |  |
| E0944 | A | Pelvic belt/harness/boot ......................................... |  |  |  | ..................... |  |
| E0945 | A | Belt/harness extremity ........................................... |  |  |  |  |  |
| E0946 | A | Fracture frame dual w cross .................................... |  |  |  |  |  |
| E0947 | A | Fracture frame attachmnts pe ................................. |  |  |  | .................... |  |
| E0948 | A | Fracture frame attachmnts ce ................................. |  |  |  |  |  |
| E0950 | A | Tray .... |  |  |  |  |  |
| E0951 | A | Loop heel ........................................................... |  | .................... | .................... |  |  |
| E0952 | A | Loop tie .... |  |  |  |  |  |

CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
Copyright American Dental Association. All rights reserved.
${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment.
${ }^{2}$ Not subject to national coinsurance.
${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

# Addendum B.—Hospital Outpatient Department (HOPD) Payment Status by hCPCS Code and Related INFORMATION-Continued 

| CPT/ <br> HCPCS | HOPD Status Indicator | Description | APC | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| E0953 | A | Pneumatic tire |  |  |  |  |  |
| E0954 | A | Wheelchair semi-pneumatic ca .. |  |  |  |  |  |
| E0958 | A | Whichr att-conv 1 arm drive |  |  | ..................... | ..................... |  |
| E0959 | A | Amputee adapter |  |  |  |  |  |
| E0961 | A | Wheelchair brake extension |  |  |  |  |  |
| E0962 | A | Wheelchair 1 inch cushion |  |  |  |  |  |
| E0963 | A | Wheelchair 2 inch cushion |  |  |  |  |  |
| E0964 | A | Wheelchair 3 inch cushion |  | ................... | ..................... |  |  |
| E0965 | A | Wheelchair 4 inch cushion |  |  |  |  |  |
| E0966 | A | Wheelchair head rest extensi |  |  |  |  |  |
| E0967 | A | Wheelchair hand rims |  |  |  |  |  |
| E0968 | A | Wheelchair commode seat |  |  |  |  |  |
| E0969 | A | Wheelchair narrowing device |  |  |  |  |  |
| E0970 | A | Wheelchair no. 2 footplates |  |  |  |  |  |
| E0971 | A | Wheelchair anti-tipping devi ... |  | .................... | ................. |  |  |
| E0972 | A | Transfer board or device |  |  |  |  |  |
| E0973 | A | Wheelchair adjustabl height . |  |  |  |  |  |
| E0974 | A | Wheelchair grade-aid |  |  |  |  |  |
| E0975 | A | Wheelchair reinforced seat u |  |  |  |  |  |
| E0976 | A | Wheelchair reinforced back u |  |  |  |  |  |
| E0977 | A | Wheelchair wedge cushion |  |  |  |  |  |
| E0978 | A | Wheelchair belt w/airplane b |  |  |  |  |  |
| E0979 | A | Wheelchair belt with velcro |  |  |  |  |  |
| E0980 | A | Wheelchair safety vest |  |  |  |  |  |
| E0990 | A | Whellchair elevating leg res |  |  | .................... |  |  |
| E0991 | A | Wheelchair upholstry seat |  |  |  |  |  |
| E0992 | A | Wheelchair solid seat insert |  |  |  |  |  |
| E0993 | A | Wheelchair back upholstery |  |  | .................... |  |  |
| E0994 | A | Wheelchair arm rest |  |  |  |  |  |
| E0995 | A | Wheelchair calf rest |  |  |  |  |  |
| E0996 | A | Wheelchair tire solid |  |  |  |  |  |
| E0997 | A | Wheelchair caster w/a fork |  |  |  |  |  |
| E0998 | A | Wheelchair caster w/o a fork |  |  |  |  |  |
| E0999 | A | Wheelchr pneumatic tire w/wh |  |  | .................... |  |  |
| E1000 | A | Wheelchair tire pneumatic ca |  |  |  |  |  |
| E1001 | A | Wheelchair wheel |  |  |  |  |  |
| E1031 | A | Rollabout chair with casters |  |  |  |  |  |
| E1050 | A | Whelchr fxd full length arms |  |  | ..................... |  |  |
| E1060 | A | Wheelchair detachable arms |  |  |  |  |  |
| E1065 | A | Wheelchair power attachment |  |  |  |  |  |
| E1066 | A | Wheelchair battery charger |  |  |  |  |  |
| E1069 | A | Wheelchair deep cycle batter |  |  |  |  |  |
| E1070 | A | Wheelchair detachable foot $r$ |  |  |  |  |  |
| E1083 | A | Hemi-wheelchair fixed arms |  |  |  |  |  |
| E1084 | A | Hemi-wheelchair detachable a |  |  | ................... |  |  |
| E1085 | A | Hemi-wheelchair fixed arms |  |  |  |  |  |
| E1086 | A | Hemi-wheelchair detachable a |  |  |  |  |  |
| E1087 | A | Wheelchair lightwt fixed arm |  |  |  |  |  |
| E1088 | A | Wheelchair lightweight det a |  |  |  |  |  |
| E1089 | A | Wheelchair lightwt fixed arm ... |  |  |  |  |  |
| E1090 | A | Wheelchair lightweight det a .................................. |  |  |  | . |  |
| E1091 | A | Wheelchair youth .................................................. |  |  |  |  |  |
| E1092 | A | Wheelchair wide w/leg rests . |  |  |  |  |  |
| E1093 | A | Wheelchair wide w/foot rest |  |  |  |  |  |
| E1100 | A | Whehr s-recl fxd arm leg res |  |  |  |  |  |
| E1110 | A | Wheelchair semi-recl detach .. |  |  |  |  |  |
| E1130 | A | Whichr stand fxd arm ft rest |  |  |  |  |  |
| E1140 | A | Wheelchair standard detach a |  |  | .................... | .................... |  |
| E1150 | A | Wheelchair standard w/leg r |  |  |  |  |  |
| E1160 | A | Wheelchair fixed arms |  |  |  |  |  |
| E1170 | A | Whlchr ampu fxd arm leg rest ................................. |  |  |  | .................... |  |
| E1171 | A | Wheelchair amputee w/o leg r |  |  |  |  |  |
| E1172 | A | Wheelchair amputee detach ar |  |  |  |  |  |
| E1180 | A | Wheelchair amputee w/foot r ................................... |  |  | ..................... | ..................... |  |
| E1190 | A | Wheelchair amputee w/leg re |  |  |  |  |  |
| E1195 | A | Wheelchair amputee heavy dut |  |  |  |  |  |
| E1200 | A | Wheelchair amputee fixed arm ................................ |  |  |  |  |  |
| E1210 | A | Whlchr moto ful arm leg rest ... |  |  | ..................... |  |  |
| E1211 | A | Wheelchair motorized w/det . |  |  |  |  |  |
| E1212 | A | Wheelchair motorized w full ... |  |  |  |  |  |
| E1213 | A | Wheelchair motorized w/det .... |  | ...................... | ...................... | ...................... |  |
| E1220 | A | Whlchr special size/constrc | ...................... | ..................... | ...................... |  |  |
| E1221 | A | Wheelchair spec size w foot |  |  |  |  |  |

CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
Copyright American Dental Association. All rights reserved.
${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment.
${ }^{2}$ Not subject to national coinsurance.
${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

# Addendum B.—Hospital Outpatient Department (HOPD) Payment Status by hCPCS Code and Related Information-Continued 

| CPT/ HCPCS | HOPD Status Indicator | Description | APC | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| E1222 | A | Wheelchair spec size w/leg |  |  |  |  |  |
| E1223 | A | Wheelchair spec size w foot |  |  |  |  |  |
| E1224 | A | Wheelchair spec size w/leg |  |  |  |  |  |
| E1225 | A | Wheelchair spec sz semi-recl |  |  |  |  |  |
| E1226 | A | Wheelchair spec sz full-recl ... |  |  |  |  |  |
| E1227 | A | Wheelchair spec sz spec ht a |  |  |  |  |  |
| E1228 | A | Wheelchair spec sz spec ht b |  |  |  |  |  |
| E1230 | A | Power operated vehicle |  |  |  |  |  |
| E1240 | A | Whchr litwt det arm leg rest |  |  |  | ...................... |  |
| E1250 | A | Wheelchair lightwt fixed arm |  |  |  |  |  |
| E1260 | A | Wheelchair lightwt foot rest . |  |  |  |  |  |
| E1270 | A | Wheelchair lightweight leg r |  |  |  |  |  |
| E1280 | A | Whchr h-duty det arm leg res |  |  |  |  |  |
| E1285 | A | Wheelchair heavy duty fixed |  |  |  |  |  |
| E1290 | A | Wheelchair hvy duty detach a |  |  |  |  |  |
| E1295 | A | Wheelchair heavy duty fixed |  |  |  |  |  |
| E1296 | A | Wheelchair special seat heig |  |  |  |  |  |
| E1297 | A | Wheelchair special seat dept |  |  |  |  |  |
| E1298 | A | Wheelchair spec seat depth/w |  |  |  | .................... |  |
| E1300 | A | Whirlpool portable |  |  |  |  |  |
| E1310 | A | Whirlpool non-portable |  |  |  |  |  |
| E1340 | A | Repair for DME, per 15 min |  |  |  |  |  |
| E1353 | A | Oxygen supplies regulator |  |  |  |  |  |
| E1355 | A | Oxygen supplies stand/rack |  |  |  |  |  |
| E1372 | A | Oxy suppl heater for nebuliz |  |  |  |  |  |
| E1375 | A | Oxygen suppl nebulizer porta |  |  |  | ..................... |  |
| E1377 | A | Oxygen concentrator to 244 c |  |  |  |  |  |
| E1378 | A | Oxygen concentrator to 488 c |  |  |  | ................... |  |
| E1379 | A | Oxygen concentrator to 732 c |  |  |  |  |  |
| E1380 | A | Oxygen concentrator to 976 c |  |  |  |  |  |
| E1381 | A | Oxygen concentrat to 1220 cu |  |  |  |  |  |
| E1382 | A | Oxygen concentrat to 1464 cu |  |  |  | ..................... |  |
| E1383 | A | Oxygen concentrat to 1708 cu |  |  |  |  |  |
| E1384 | A | Oxygen concentrat to 1952 cu |  |  |  |  |  |
| E1385 | A | Oxygen concentrator > 1952 c |  |  |  |  |  |
| E1390 | A | Oxygen concentrator |  |  |  | .................... |  |
| E1399 | A | Durable medical equipment mi |  |  |  |  |  |
| E1405 | A | O2/water vapor enrich w/heat |  |  |  |  |  |
| E1406 | A | O2/water vapor enrich w/o he |  |  |  | .................... |  |
| E1510 | A | Kidney dialysate delivry sys |  |  |  |  |  |
| E1520 | A | Heparin infusion pump for di |  |  |  |  |  |
| E1530 | A | Air bubble detector for dial |  |  |  |  |  |
| E1540 | A | Pressure alarm for dialysis |  |  |  |  |  |
| E1550 | A | Bath conductivity meter |  |  |  |  |  |
| E1560 | A | Blood leak detector for dial |  |  |  | ...................... |  |
| E1570 | A | Adjustable chair for esrd pt |  |  |  |  |  |
| E1575 | A | Transducer protector/fluid b |  |  |  |  |  |
| E1580 | A | Unipuncture control system |  |  |  |  |  |
| E1590 | A | Hemodialysis machine |  |  |  |  |  |
| E1592 | A | Auto interm peritoneal dialy |  |  |  |  |  |
| E1594 | A | Cycler dialysis machine ...... |  |  |  |  |  |
| E1600 | A | Deliv/install equip for dial |  |  |  | .................... |  |
| E1610 | A | Reverse osmosis water purifi |  |  |  | ...................... |  |
| E1615 | A | Deionizer water purification |  |  |  |  |  |
| E1620 | A | Blood pump for dialysis |  |  |  | ...................... |  |
| E1625 | A | Water softening system |  |  |  | ...................... |  |
| E1630 | A | Reciprocating peritoneal dia |  |  |  |  |  |
| E1632 | A | Wearable artificial kidney |  |  |  |  |  |
| E1635 | A | Compact travel hemodialyzer |  |  |  | ...................... |  |
| E1636 | A | Sorbent cartridges for dialy |  |  |  |  |  |
| E1640 | A | Replacement components for d |  |  |  |  |  |
| E1699 | A | Dialysis equipment unspecifi |  |  |  |  |  |
| E1700 | A | Jaw motion rehab system |  |  |  |  |  |
| E1701 | A | Repl cushions for jaw motion |  |  |  |  |  |
| E1702 | A | Repl measr scales jaw motion |  |  |  |  |  |
| E1800 | A | Adjust elbow ext/flex device . |  |  |  | ...................... |  |
| E1805 | A | Adjust wrist ext/flex device ... |  |  |  |  |  |
| E1810 | A | Adjust knee ext/flex device ..................................... |  |  |  | ..................... |  |
| E1815 | A | Adjust ankle ext/flex device |  |  |  | ...................... |  |
| E1820 | A | Soft interface material ............................................ |  |  |  |  |  |
| E1825 | A | Adjust finger ext/flex devc ...................................... | .................. | ................. |  | ...................... |  |
| E1830 | A | Adjust toe ext/flex device ........................................ | ...................... | ...................... | ...................... | .... |  |
| E1900 | A | Speech communication device |  |  |  |  |  |

CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
Copyright American Dental Association. All rights reserved.
${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment.
${ }^{2}$ Not subject to national coinsurance.
${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

# Addendum B.-Hospital Outpatient Department (HOPD) Payment Status by HCPCS Code and Related Information-Continued 

| CPT/ HCPCS | HOPD Status Indicator | Description | APC | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| G0001 | A | Drawing blood for specimen |  |  |  |  |  |
| G0002 | N | Temporary urinary catheter |  |  |  |  |  |
| G0004 | S | ECG transm phys review \& int | 0100 | 1.70 | \$82.43 | \$71.57 | \$16.49 |
| G0005 | S | ECG 24 hour recording | 0099 | 0.38 | \$18.43 | \$14.68 | \$3.69 |
| G0006 | S | ECG transmission \& analysis | 0100 | 1.70 | \$82.43 | \$71.57 | \$16.49 |
| G0007 | N | ECG phy review \& interpret |  |  |  |  |  |
| ${ }^{2}$ G0008 | X | Admin influenza virus vac | 0354 | 0.13 | \$6.19 | ................... |  |
| G0009 | N | Admin pneumococcal vaccine ................................. |  |  |  |  |  |
| G0010 | N | Admin hepatitis b vaccine ... |  |  |  |  |  |
| G0015 | S | Post symptom ECG tracing | 0099 | 0.38 | \$18.43 | \$14.68 | \$3.69 |
| G0016 | N | Post symptom ECG md review ............................... |  |  |  |  |  |
| G0025 | X | Collagen skin test kit | 0343 | 0.45 | \$21.82 | \$12.16 | \$4.36 |
| G0026 | A | Fecal leukocyte examination .................................. |  |  |  |  |  |
| G0027 | A | Semen analysis ................................................... |  |  |  |  |  |
| G0030 | S | PET imaging prev PET single | 0285 | 15.06 | \$730.22 | \$415.21 | \$146.04 |
| G0031 | S | PET imaging prev PET multple | 0285 | 15.06 | \$730.22 | \$415.21 | \$146.04 |
| G0032 | S | PET follow SPECT 78464 singl ............................... | 0285 | 15.06 | \$730.22 | \$415.21 | \$146.04 |
| G0033 | S | PET follow SPECT 78464 mult | 0285 | 15.06 | \$730.22 | \$415.21 | \$146.04 |
| G0034 | S | PET follow SPECT 76865 singl | 0285 | 15.06 | \$730.22 | \$415.21 | \$146.04 |
| G0035 | S | PET follow SPECT 78465 mult | 0285 | 15.06 | \$730.22 | \$415.21 | \$146.04 |
| G0036 | S | PET follow cornry angio sing | 0285 | 15.06 | \$730.22 | \$415.21 | \$146.04 |
| G0037 | S | PET follow cornry angio mult | 0285 | 15.06 | \$730.22 | \$415.21 | \$146.04 |
| G0038 | S | PET follow myocard perf sing | 0285 | 15.06 | \$730.22 | \$415.21 | \$146.04 |
| G0039 | S | PET follow myocard perf mult | 0285 | 15.06 | \$730.22 | \$415.21 | \$146.04 |
| G0040 | S | PET follow stress echo singl | 0285 | 15.06 | \$730.22 | \$415.21 | \$146.04 |
| G0041 | S | PET follow stress echo mult | 0285 | 15.06 | \$730.22 | \$415.21 | \$146.04 |
| G0042 | S | PET follow ventriculogm sing | 0285 | 15.06 | \$730.22 | \$415.21 | \$146.04 |
| G0043 | S | PET follow ventriculogm mult | 0285 | 15.06 | \$730.22 | \$415.21 | \$146.04 |
| G0044 | S | PET following rest ECG singl | 0285 | 15.06 | \$730.22 | \$415.21 | \$146.04 |
| G0045 | S | PET following rest ECG mult | 0285 | 15.06 | \$730.22 | \$415.21 | \$146.04 |
| G0046 | S | PET follow stress ECG singl | 0285 | 15.06 | \$730.22 | \$415.21 | \$146.04 |
| G0047 | S | PET follow stress ECG mult | 0285 | 15.06 | \$730.22 | \$415.21 | \$146.04 |
| G0050 | S | Residual urine by ultrasound | 0265 | 1.17 | \$56.73 | \$38.08 | \$11.35 |
| G0101 | V | CA screen; pelvic/breast exam | 0601 | 1.00 | \$48.49 | \$9.70 | \$9.70 |
| G0102 | E | Prostate ca screening; dre |  |  |  |  |  |
| G0103 | E | Psa, total screening .............................................. |  |  |  | ..................... |  |
| ${ }^{1}$ G0104 | S | CA screen; flexi sigmoidscope ................................ | 0158 | 7.98 | \$386.93 |  | \$96.73 |
| ${ }^{1}$ G0105 | S | Colorectal scrn; hi risk ind ...................................... | 0159 | 2.83 | \$137.22 |  | \$34.31 |
| ${ }^{2}$ G0106 | S | Colon CA screen; barium enema | 0157 | 1.79 | \$86.79 |  | \$17.36 |
| G0107 | A | CA screen; fecal blood test |  |  |  |  |  |
| G0108 | A | Diab manage trn per indiv ...................................... |  | ..................... | .................... | ..................... |  |
| G0109 | A | Diab manage trn ind/group |  |  |  |  |  |
| G0110 | A | Nett pulm-rehab educ; ind |  |  |  |  |  |
| G0111 | A | Nett pulm-rehab educ; group |  | .................... | .................... | ..................... |  |
| G0112 | A | Nett; nutrition guid, initial |  |  |  |  |  |
| G0113 | A | Nett; nutrition guid, subseqnt ................................... |  | ..................... | ..................... | ..................... |  |
| G0114 | A | Nett; psychosocial consult ...................................... | ..................... | ...................... | .................... | ...................... |  |
| G0115 | A | Nett; psychological testing ...................................... |  |  |  |  |  |
| G0116 | A | Nett; psychosocial counsel ..................................... |  |  |  |  |  |
| ${ }^{2}$ G0120 | S | Colon ca scrn; barium enema | 0157 | 1.79 | \$86.79 | .................... | \$17.36 |
| G0121 | E | Colon ca scrn not hi rsk ind |  |  |  | .................... |  |
| G0122 | E | Colon ca scrn; barium enema ................................ |  |  |  |  |  |
| G0123 | E | Screen cerv/vag thin layer ...................................... |  |  |  | .................... |  |
| G0124 | E | Screen c/v thin layer by MD |  |  |  |  |  |
| ${ }^{2}$ G0125 | T | Lung image (PET) ................................................ | 0980 | 38.67 | \$1,875.00 |  | \$375.00 |
| ${ }^{2}$ G0126 | T | Lung image (PET) staging | 0980 | 38.67 | \$1,875.00 |  | \$375.00 |
| G0127 | T | Trim nail(s) | 0009 | 0.74 | \$35.88 | \$9.63 | \$7.18 |
| G0128 | E | CORF skilled nursing service |  |  |  |  |  |
| G0129 | P | Partial hosp prog service | 0033 | 4.17 | \$202.19 | \$48.17 | \$40.44 |
| G0130 | X | Single energy x-ray study ....................................... | 0261 | 1.38 | \$66.91 | \$38.77 | \$13.38 |
| G0131 | X | CT scan, bone density study | 0261 | 1.38 | \$66.91 | \$38.77 | \$13.38 |
| G0132 | X | CT scan, bone density study ................................... | 0261 | 1.38 | \$66.91 | \$38.77 | \$13.38 |
| G0141 | E | Scr c/v cyto, autosys and md .................................. | ...................... | ...................... | ...................... | ...................... |  |
| G0143 | E | Scr c/v cyto, thinlayer, rescr |  |  |  |  |  |
| G0144 | E | Scr c/v cyto, thinlayer, rescr ................................... |  |  |  |  |  |
| G0145 | E | Scr c/v cyto, thinlayer, rescr ................................... | .................... | .................... | ..................... | ..................... | ..................... |
| G0147 | E | Scr c/v cyto, automated sys ................................... |  |  |  | ..................... |  |
| G0148 | E | Scr c/v cyto, autosys, rescr |  |  |  |  |  |
| G0151 | E | HHCP-serv of pt, ea 15 min | ................. | ..................... | ......... | .................... | .................... |
| G0152 | E | HHCP-serv of ot, ea 15 min .................................. | ................... | ..................... |  | ................... |  |
| G0153 | E | HHCP-svs of s/l path, ea 15mn ............................... |  | .................... | .................... | .................... |  |
| G0154 | E | HHCP-svs of rn, ea 15 min |  |  |  |  |  |
| G0155 | E | HHCP-svs of csw, ea 15 min |  |  |  |  |  |

[^234]
# Addendum B.—Hospital Outpatient Department (HOPD) Payment Status by hCPCS Code and Related Information-Continued 

| $\begin{gathered} \text { CPT/ } \\ \text { HCPCS } \end{gathered}$ | HOPD Status Indicator | Description | APC | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| G0156 | E | HHCP-svs of aide, ea 15 min |  |  |  |  |  |
| G0159 | T | Perc declot dialysis graft | 0088 | 26.49 | \$1,284.42 | \$678.68 | \$256.88 |
| G0160 | C | Cryo. ablation, prostate |  |  |  |  |  |
| G0161 | X | Echo guide for cryo probes | 0268 | 2.23 | \$108.13 | \$69.51 | \$21.63 |
| ${ }^{2}$ G0163 | T | Pet for rec of colorectal ca | 0980 | 38.67 | \$1,875.00 |  | \$375.00 |
| ${ }^{2}$ G0164 | T | Pet for lymphoma staging | 0980 | 38.67 | \$1,875.00 |  | \$375.00 |
| ${ }^{2}$ G0165 | T | Pet, rec of melanoma/met ca | 0980 | 38.67 | \$1,875.00 |  | \$375.00 |
| ${ }^{2}$ G0166 | T | Extrnl counterpulse, per tx | 0972 | 3.09 | \$149.83 |  | \$29.97 |
| G0167 | S | Hyperbaric oz tx; no md reqrd | 0031 | 3.00 | \$145.46 | \$140.85 | \$29.09 |
| G0168 | T | Wound closure by adhesive | 0026 | 12.11 | \$587.18 | \$277.92 | \$117.44 |
| G0169 | T | Removal tissue; no anesthsia | 0026 | 12.11 | \$587.18 | \$277.92 | \$117.44 |
| G0170 | T | Skin biograft | 0026 | 12.11 | \$587.18 | \$277.92 | \$117.44 |
| G0171 | T | Skin biograft add-on | 0026 | 12.11 | \$587.18 | \$277.92 | \$117.44 |
| G0172 | P | Partial hosp prog service | 0033 | 4.17 | \$202.19 | \$48.17 | \$40.44 |
| G0173 | S | Stereotactic, one session | 0302 | 8.21 | \$398.08 | \$216.55 | \$79.62 |
| G0174 | S | Stereotactic, mult session | 0302 | 8.21 | \$398.08 | \$216.55 | \$79.62 |
| G0175 | V | Multidisciplinary team visit | 0603 | 1.66 | \$80.49 | \$16.29 | \$16.10 |
| J0120 | N | Tetracyclin injection |  |  |  |  |  |
| J0130 | N | Abciximab injection . |  |  |  | .... |  |
| ${ }^{2} \mathrm{~J} 0150$ | X | Injection adenosine 6 MG | 0917 | 0.36 | \$17.46 |  | \$3.49 |
| J0151 | E | Adenosine injection ..... |  |  |  |  |  |
| J0170 | N | Adrenalin epinephrin inject |  |  |  |  |  |
| J0190 | N | Inj biperiden lactate/5 mg |  |  |  |  |  |
| J0200 | N | Alatrofloxacin mesylate |  |  |  |  |  |
| ${ }^{3} \mathrm{~J} 0205$ | X | Alglucerase injection | 0900 |  |  |  | \$5.14 |
| ${ }^{3} \mathrm{~J} 0207$ | X | Amifostine ...... | 7000 | .................. |  | .................... | \$41.99 |
| J0210 | N | Methyldopate hcl injection |  |  |  |  |  |
| ${ }^{3} \mathrm{~J} 0256$ | X | Alpha 1 proteinase inhibitor | 0901 | .................... |  |  | \$15.22 |
| J0270 | E | Alprostadil for injection |  |  |  |  |  |
| J0275 | E | Alprostadil urethral suppos |  |  |  |  |  |
| J0280 | N | Aminophyllin 250 MG inj |  |  |  |  |  |
| J0285 | N | Amphotericin B |  |  |  |  |  |
| ${ }^{3} \mathrm{~J} 0286$ | X | Amphotericin B lipid complex | 7001 |  |  |  | \$12.12 |
| J0290 | N | Ampicillin 500 MG inj ... |  |  |  |  |  |
| J0295 | N | Ampicillin sodium per 1.5 gm |  |  |  |  |  |
| J0300 | N | Amobarbital 125 MG inj ... |  |  |  |  |  |
| J0330 | N | Succinycholine chloride inj |  |  |  |  |  |
| J0340 | N | Nandrolon phenpropionate inj |  |  |  |  |  |
| J0350 | N | Injection anistreplase 30 u . |  |  |  | ..................... | ...................... |
| J0360 | N | Hydralazine hcl injection |  |  |  |  |  |
| J0380 | N | Inj metaraminol bitartrate |  |  |  |  |  |
| J0390 | N | Chloroquine injection |  |  |  | ..................... |  |
| J0395 | N | Arbutamine HCl injection |  |  |  |  |  |
| J0400 | N | Inj trimethaphan camsylate |  |  |  |  |  |
| J0456 | N | Azithromycin ....................................................... |  | ................. |  | ..................... | ...................... |
| J0460 | N | Atropine sulfate injection |  |  |  |  |  |
| J0470 | N | Dimecaprol injection |  |  |  |  |  |
| J0475 | N | Baclofen 10 MG injection |  |  |  |  |  |
| ${ }^{3} \mathrm{~J} 0476$ | X | Baclofen intrathecal trial | 7021 | ..................... |  | .................... | \$. 10 |
| J0500 | N | Dicyclomine injection ............................................. |  |  |  |  |  |
| J0510 | N | Benzquinamide injection |  |  |  |  |  |
| J0515 | N | Inj benztropine mesylate |  |  |  |  |  |
| J0520 | N | Bethanechol chloride inject |  | ..................... |  | ...................... |  |
| J0530 | N | Penicillin g benzathine inj |  |  |  |  |  |
| J0540 | N | Penicillin g benzathine inj |  |  |  | ...................... | ..................... |
| J0550 | N | Penicillin g benzathine inj ..................................... |  |  |  |  |  |
| J0560 | $N$ | Penicillin g benzathine inj |  |  |  |  |  |
| J0570 | N | Penicillin g benzathine inj ...................................... |  |  |  |  |  |
| J0580 | N | Penicillin g benzathine inj |  |  |  |  |  |
| ${ }^{3} \mathrm{~J} 0585$ | X | Botulinum toxin a per unit | 0902 |  |  |  | \$56.05 |
| J0590 | N | Ethylnorepinephrine hol inj |  |  |  |  | ........ |
| J0600 | N | Edetate calcium disodium inj |  |  |  |  |  |
| J0610 | N | Calcium gluconate injection ................................... |  |  |  |  |  |
| J0620 | N | Calcium glycer \& lact/10 ML .................................... |  |  |  |  |  |
| J0630 | N | Calcitonin salmon injection |  |  |  | ...................... |  |
| J0635 | N | Calcitriol injection ............... |  |  |  | ..................... |  |
| ${ }^{3} \mathrm{~J} 0640$ | X | Leucovorin calcium injection | 0725 |  |  |  | \$1.07 |
| J0670 | N | Inj mepivacaine HCL/10 ml .................................... |  |  |  | ..................... | ..................... |
| J0690 | N | Cefazolin sodium injection ...................................... |  |  |  | ...................... |  |
| J0694 | N | Cefoxitin sodium injection ...................................... |  |  |  |  |  |
| J0695 | N | Cefonocid sodium injection ..................................... | ................. | ................. | ...................... | ..................... |  |
| J0696 | N | Ceftriaxone sodium injection .................................. | ..................... | ...................... | ..................... | .................... | ...................... |
| J0697 | N | Sterile cefuroxime injection |  |  |  |  |  |

[^235]
# Addendum B.—Hospital Outpatient Department (HOPD) Payment Status by hCPCS Code and Related INFORMATION-Continued 

| CPT/ HCPCS | HOPD Status Indicator | Description | APC | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| J0698 | $N$ | Cefotaxime sodium injection |  | ..................... | .................... | .................... |  |
| J0702 | N | Betamethasone acet \& sod phosp |  |  |  |  |  |
| J0704 | N | Betamethasone sod phosp/4 MG ..... |  |  |  |  |  |
| J0710 | N | Cephapirin sodium injection ............ |  |  |  |  |  |
| J0713 | N | Inj ceftazidime per 500 mg | ...................... |  |  |  |  |
| J0715 | N | Ceftizoxime sodium/500 MG |  |  |  |  |  |
| J0720 | N | Chloramphenicol sodium injec |  |  |  |  |  |
| J0725 | N | Chorionic gonadotropin/1000u ................................. |  |  |  |  |  |
| J0730 | N | Chlorpheniramin maleate inj ................................... |  |  |  |  |  |
| ${ }^{3} \mathrm{~J} 0735$ | X | Clonidine hydrochloride | 7002 |  |  |  | \$4.17 |
| J0740 | N | Cidofovir injection . |  |  |  |  |  |
| J0743 | N | Cilastatin sodium injection |  |  |  |  |  |
| J0745 | N | Inj codeine phosphate/30 MG |  |  |  |  |  |
| J0760 | N | Colchicine injection .............. |  |  |  |  |  |
| J0770 | $N$ | Colistimethate sodium inj | .................... |  | ... | .... |  |
| J0780 | N | Prochlorperazine injection |  |  |  |  |  |
| J0800 | N | Corticotropin injection ..... |  |  |  |  |  |
| J0810 | N | Cortisone injection ... |  |  |  |  |  |
| J0835 | N | Inj cosyntropin per 0.25 MG |  |  |  |  |  |
| ${ }^{3} \mathrm{~J} 0850$ | X | Cytomegalovirus imm IV/vial | 0903 |  |  |  | \$54.11 |
| J0895 | N | Deferoxamine mesylate inj ..................................... |  |  |  |  |  |
| J0900 | N | Testosterone enanthate inj |  |  |  |  |  |
| J0945 | $N$ | Brompheniramine maleate inj |  |  |  |  |  |
| J0970 | N | Estradiol valerate injection |  |  |  |  |  |
| J1000 | N | Depo-estradiol cypionate inj |  |  |  |  |  |
| J1020 | N | Methylprednisolone 20 MG inj ................................ |  |  |  |  |  |
| J1030 | N | Methylprednisolone 40 MG inj ................................. |  |  |  |  |  |
| J1040 | N | Methylprednisolone 80 MG inj |  |  |  |  |  |
| J1050 | N | Medroxyprogesterone inj |  |  |  |  |  |
| J1055 | E | Medrxyprogester acetate inj |  |  |  |  |  |
| J1060 | N | Testosterone cypionate 1 ML |  |  |  |  |  |
| J1070 | N | Testosterone cypionat 100 MG ............................... |  |  |  |  |  |
| J1080 | N | Testosterone cypionat 200 MG |  |  |  |  |  |
| J1090 | N | Testosterone cypionate 50 MG |  |  |  |  |  |
| J1095 | N | Inj dexamethasone acetate |  |  |  | ................... |  |
| J1100 | N | Dexamethasone sodium phos ................................. |  |  |  |  |  |
| J1110 | N | Inj dihydroergotamine mesylt |  |  |  |  |  |
| J1120 | N | Acetazolamid sodium injectio |  |  |  |  |  |
| $J 1160$ | N | Digoxin injection |  |  |  |  |  |
| J1165 | N | Phenytoin sodium injection |  |  |  |  |  |
| J1170 | N | Hydromorphone injection ........................................ |  |  |  | ..................... |  |
| $J 1180$ | N | Dyphylline injection |  |  |  |  |  |
| ${ }^{3} \mathrm{~J} 1190$ | X | Dexrazoxane HCl injection | 0726 |  |  |  | \$18.81 |
| $J 1200$ | N | Diphenhydramine hol injectio .................................. |  |  |  |  |  |
| J1205 | N | Chlorothiazide sodium inj ...................................... |  |  |  |  |  |
| J1212 | N | Dimethyl sulfoxide 50\% 50 ML |  |  |  |  |  |
| $J 1230$ | N | Methadone injection |  |  |  |  |  |
| J1240 | N | Dimenhydrinate injection ....................................... |  |  |  |  |  |
| ${ }^{2} \mathrm{~J} 1245$ | X | Dipyridamole injection ............................................ | 0917 | 0.36 | \$17.46 |  | \$3.49 |
| J1250 | N | Inj dobutamine HCL/250 mg ................................... |  |  |  |  |  |
| ${ }^{3} \mathrm{~J} 1260$ | X | Dolasetron mesylate | 0750 |  |  |  | \$1.94 |
| $J 1320$ | N | Amitriptyline injection ............................................ |  |  |  |  |  |
| ${ }^{3} \mathrm{~J} 1325$ | X | Epoprostenol injection | 7003 |  |  |  | \$2.23 |
| J1327 | N | Eptifibatide injection .............................................. |  |  |  |  |  |
| J1330 | N | Ergonovine maleate injection ................................. |  |  |  |  |  |
| J1362 | N | Erythromycin glucep/250 MG ................................. |  |  |  |  |  |
| J1364 | N | Erythro lactobionate/500 MG |  |  |  |  |  |
| J1380 | N | Estradiol valerate 10 MG inj |  |  |  |  |  |
| J1390 | N | Estradiol valerate 20 MG inj |  |  |  |  |  |
| J1410 | N | Inj estrogen conjugate 25 MG |  |  |  |  |  |
| J1435 | N | Injection estrone per 1 MG ..................................... |  |  |  |  |  |
| $J 1436$ | X | Etidronate disodium inj | 0727 |  |  |  | \$9.31 |
| J1438 | N | Etanercept injection .............................................. |  |  |  |  |  |
| ${ }^{3} \mathrm{~J} 1440$ | X | Filgrastim 300 mcg injeciton ................................... | 0728 | ..................... |  | .................... | \$25.21 |
| J1441 | E | Filgrastim 480 mcg injection ... |  |  |  | ..................... |  |
| J1450 | N | Fluconazole |  |  |  |  |  |
| J1455 | N | Foscarnet sodium injection |  |  |  |  |  |
| J1460 | N | Gamma globulin 1 CC inj ....................................... |  |  |  | ..... |  |
| J1470 | E | Gamma globulin 2 CC inj ...................................... |  |  |  |  |  |
| J1480 | E | Gamma globulin 3 CC inj ....................................... |  |  |  |  |  |
| J1490 | E | Gamma globulin 4 CC inj ....................................... | .................. | . | ..................... | .... |  |
| J1500 | E | Gamma globulin 5 CC inj. | ..... | ..................... | ..... | ............... |  |
| J1510 | E | Gamma globulin 6 CC inj |  |  |  |  |  |

CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
Copyright American Dental Association. All rights reserved.
${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment.
${ }^{2}$ Not subject to national coinsurance
${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

# Addendum B.-Hospital Outpatient Department (HOPD) Payment Status by hCPCS Code and Related INFORMATION-Continued 

| $\begin{gathered} \text { CPT/ } \\ \text { HCPCS } \end{gathered}$ | HOPD Status Indicator | Description | APC | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| J1520 | E | Gamma globulin 7 CC inj |  |  |  |  |  |
| J1530 | E | Gamma globulin 8 CC inj |  |  |  |  |  |
| J1540 | E | Gamma globulin 9 CC inj |  |  |  |  |  |
| J1550 | E | Gamma globulin 10 CC inj |  |  |  |  |  |
| J1560 | E | Gamma globulin > 10 CC inj |  |  |  |  |  |
| ${ }^{3} \mathrm{~J} 1561$ | X | Immune globulin 500 mg ....... | 0905 |  |  |  | \$6.40 |
| ${ }^{3} \mathrm{~J} 1562$ | X | Immune globulin 5 gms | 7004 |  |  |  | \$45.48 |
| ${ }^{3} \mathrm{~J} 1565$ | X | RSV-ivig | 0906 |  |  |  | \$85.53 |
| ${ }^{2} \mathrm{~J} 1570$ | X | Ganciclovir sodium injection | 0907 | 0.51 | \$24.73 |  | \$4.95 |
| J1580 | N | Garamycin gentamicin inj |  |  |  |  |  |
| J1600 | N | Gold sodium thiomaleate inj | ...... |  |  |  |  |
| J1610 | N | Glucagon hydrochloride/1 MG |  |  |  |  |  |
| ${ }^{3} \mathrm{~J} 1620$ | X | Gonadorelin hydroch/100 mcg | 7005 |  |  |  | \$9.12 |
| ${ }^{3} \mathrm{~J} 1626$ | X | Granisetron HCl injection | 0764 |  |  |  | \$2.33 |
| J1630 | N | Haloperidol injection |  |  |  |  |  |
| J1631 | N | Haloperidol decanoate inj |  |  |  |  |  |
| J1642 | N | Inj heparin sodium per 10 u |  |  |  |  |  |
| J1644 | N | Inj heparin sodium per 1000u |  |  |  |  |  |
| J1645 | N | Dalteparin sodium |  |  |  |  |  |
| J1650 | N | Inj enoxaparin sodium |  |  |  |  |  |
| ${ }^{2} \mathrm{~J} 1670$ | X | Tetanus immune globulin inj | 0908 | 0.90 | \$43.64 |  | \$8.73 |
| J1690 | N | Prednisolone tebutate inj |  |  |  |  |  |
| J1700 | N | Hydrocortisone acetate inj |  |  |  |  |  |
| J1710 | N | Hydrocortisone sodium ph inj |  |  |  |  |  |
| J1720 | N | Hydrocortisone sodium succ i |  |  |  |  |  |
| J1730 | N | Diazoxide injection ...... |  |  |  |  | ..................... |
| J1739 | N | Hydroxyprogesterone cap 125 |  |  |  |  |  |
| J1741 | N | Hydroxyprogesterone cap 250 |  |  |  |  |  |
| J1742 | N | Ibutilide fumarate injection |  |  |  |  |  |
| ${ }^{3} \mathrm{~J} 1745$ | X | Infliximab injection | 7043 |  |  |  | \$6.89 |
| J1750 | N | Iron dextran |  |  |  |  |  |
| ${ }^{3} 17885$ | X | Injection imiglucerase/unit | 0916 |  |  |  | \$. 58 |
| $J 1790$ | N | Droperidol injection .............................................. |  |  | ..................... | .................... | ..................... |
| J1800 | N | Propranolol injection |  |  | ...................... |  |  |
| J1810 | N | Droperidol/fentanyl inj |  |  |  |  |  |
| J1820 | N | Insulin injection |  |  |  |  |  |
| ${ }^{3} \mathrm{~J} 1825$ | X | Interferon beta-1a | 0909 |  |  |  | \$28.70 |
| ${ }^{3} \mathrm{~J} 1830$ | X | Interferon beta-1b/. 25 MG | 0910 |  |  |  | \$8.44 |
| J1840 | N | Kanamycin sulfate 500 MG inj |  |  |  |  |  |
| J1850 | N | Kanamycin sulfate 75 MG inj |  |  |  | . |  |
| J1885 | N | Ketorolac tromethamine inj |  |  |  |  |  |
| J1890 | N | Cephalothin sodium injection |  |  |  |  |  |
| J1910 | N | Kutapressin injection |  |  |  |  |  |
| J1930 | N | Propiomazine injection ........................................... |  |  |  |  |  |
| J1940 | N | Furosemide injection |  |  |  |  |  |
| ${ }^{3} \mathrm{~J} 1950$ | X | Leuprolide acetate/3.75 MG | 0800 |  |  |  | \$68.56 |
| J1955 | E | Inj levocarnitine per 1 gm |  |  |  | .................... |  |
| J1956 | N | Levofloxacin injection |  |  |  |  |  |
| J1960 | N | Levorphanol tartrate inj .......................................... |  |  |  |  |  |
| J1970 | N | Methotrimeprazine injection |  |  |  | ...................... |  |
| J1980 | N | Hyoscyamine sulfate inj |  |  |  |  |  |
| J1990 | N | Chlordiazepoxide injection |  |  |  |  |  |
| J2000 | N | Lidocaine injection ................................................ |  |  |  | .................... | .................... |
| J2010 | N | Lincomycin injection .............................................. |  |  |  |  |  |
| J2060 | N | Lorazepam injection |  |  |  |  |  |
| J2150 | N | Mannitol injection .................................................. |  |  | .................... | .................... | .................... |
| J2175 | N | Meperidine hydrochl/100 MG |  |  |  |  |  |
| J2180 | N | Meperidine/promethazine inj ................................... |  |  |  |  |  |
| J2210 | N | Methylergonovin maleate inj ................................... |  |  |  |  |  |
| J2240 | N | Metocurine iodide injection |  |  |  |  |  |
| J2250 | N | Inj midazolam hydrochloride ................................... |  |  |  |  |  |
| ${ }^{2} \mathrm{~J} 2260$ | X | Inj milrinone lactate/5 ML | 7007 | 0.47 | \$22.79 |  | \$4.56 |
| J2270 | N | Morphine sulfate injection ....................................... |  |  |  | .................... |  |
| J2271 | N | Morphine so4 injection 100mg ................................ |  |  |  |  |  |
| ${ }^{3} \mathrm{~J} 2275$ | X | Morphine sulfate injection ...................................... | 7010 |  |  |  | \$. 68 |
| J2300 | N | Inj nalbuphine hydrochloride ................................... | ..................... |  | ...................... | .................... | ...................... |
| J2310 | N | Inj naloxone hydrochloride |  |  |  |  |  |
| J2320 | N | Nandrolone decanoate 50 MG |  |  |  |  |  |
| J2321 | N | Nandrolone decanoate 100 MG |  |  |  |  |  |
| J2322 | N | Nandrolone decanoate 200 MG | ..................... | ...................... | ...................... | .... |  |
| J2330 | N | Thiothixene injection |  | ...................... | ...................... |  |  |
| J2350 | N | Niacinamide/niacin injection ................................... |  | ................... | ................... |  |  |
| ${ }^{3} \mathrm{~J} 2352$ | N | Octreotide acetate injection | 7031 |  |  |  | \$5.43 |

CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
Copyright American Dental Association. All rights reserved.
${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment
${ }^{2}$ Not subject to national coinsurance.
${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

# Addendum B.-Hospital Outpatient Department (HOPD) Payment Status by HCPCS Code and Related INFORMATION-Continued 

| CPT/ HCPCS | HOPD Status Indicator | Description | APC | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| ${ }^{3} \mathrm{~J} 2355$ | X | Oprelvekin injection | 7011 |  |  |  | \$30.35 |
| J2360 | N | Orphenadrine injection |  |  |  |  |  |
| J2370 | N | Phenylephrine hcl injection |  |  | .................... | .................... |  |
| J2400 | N | Chloroprocaine hol injection |  |  |  |  |  |
| ${ }^{3} \mathrm{~J} 2405$ | X | Ondansetron hcl injection | 0768 |  |  |  | \$. 87 |
| J2410 | N | Oxymorphone hcl injection |  |  |  |  |  |
| ${ }^{3} \mathrm{~J} 2430$ | X | Pamidronate disodium/30 MG | 0730 |  |  |  | \$30.93 |
| J2440 | N | Papaverin hcl injection |  | .................... |  |  |  |
| J2460 | N | Oxytetracycline injection |  |  |  |  |  |
| J2480 | N | Hydrochlorides of opium inj |  |  |  |  |  |
| J2500 | N | Paricalcitol |  |  |  |  |  |
| J2510 | N | Penicillin g procaine inj |  |  |  |  |  |
| J2512 | N | Inj pentagastrin per 2 ML |  |  |  |  |  |
| J2515 | N | Pentobarbital sodium inj |  |  |  |  |  |
| J2540 | N | Penicillin g potassium inj |  |  |  |  |  |
| J2543 | N | Piperacillin/tazobactam . |  |  |  |  |  |
| ${ }^{3} \mathrm{~J} 2545$ | X | Pentamidine isethionte/300mg ............................... | 7012 |  |  |  | \$8.73 |
| J2550 | N | Promethazine hcl injection ...................................... |  |  | .................... |  |  |
| J2560 | N | Phenobarbital sodium inj |  |  |  |  |  |
| J2590 | N | Oxytocin injection ...... |  |  |  |  |  |
| J2597 | E | Inj desmopressin acetate |  |  |  |  |  |
| J2640 | N | Prednisolone sodium ph inj .................................... |  |  |  |  |  |
| J2650 | N | Prednisolone acetate inj |  |  |  |  |  |
| J2670 | N | Totazoline hcl injection |  |  |  |  |  |
| J2675 | N | Inj progesterone per 50 MG |  |  |  |  |  |
| J2680 | N | Fluphenazine decanoate 25 MG |  |  |  |  |  |
| J2690 | N | Procainamide hcl injection .. |  |  |  |  |  |
| J2700 | N | Oxacillin sodium injeciton |  |  |  |  |  |
| J2710 | N | Neostigmine methylslfte inj |  |  |  |  |  |
| J2720 | N | Inj protamine sulfate/10 MG . |  |  |  |  |  |
| J2725 | N | Inj protirelin per 250 mcg |  |  |  |  |  |
| J2730 | N | Pralidoxime chloride inj |  |  |  |  |  |
| J2760 | N | Phentolaine mesylate inj |  |  |  |  |  |
| ${ }^{3} \mathrm{~J} 2765$ | X | Metoclopramide hcl injection .................................. | 0754 |  |  |  | \$. 19 |
| J2780 | N | Ranitidine hydrochloride inj |  |  |  |  |  |
| ${ }^{3} \mathrm{~J} 2790$ | X | Rho d immune globulin inj | 0884 |  |  |  | \$3.78 |
| J2792 | N | Rho(D) immune globulin h, sd ................................. |  |  |  |  |  |
| J2800 | N | Methocarbamol injection |  |  |  |  |  |
| J2810 | N | Inj theophylline per 40 MG ..................................... |  |  |  |  |  |
| ${ }^{3} \mathrm{~J} 2820$ | X | Sargramostim injection | 0731 |  |  |  | \$16.97 |
| J2860 | N | Secobarbital sodium inj |  |  |  |  |  |
| J2910 | N | Aurothioglucose injeciton |  |  |  |  |  |
| J2912 | N | Sodium chloride injection |  |  |  |  |  |
| J2920 | N | Methylprednisolone injection .................................. |  |  |  |  | ..................... |
| J2930 | N | Methylprednisolone injection |  |  |  |  |  |
| J2950 | N | Promazine hcl injeciton .......................................... |  |  |  |  |  |
| J2970 | N | Methicillin sodium injection ..................................... |  |  |  |  |  |
| ${ }^{2} \mathrm{~J} 2994$ | X | Reteplase double bolus .......................................... | 0914 | 38.20 | \$1,852.21 |  | \$370.44 |
| ${ }^{2} \mathrm{~J} 2995$ | X | Inj streptokinase/250000 IU .................................... | 0911 | 1.64 | \$79.69 |  | \$15.94 |
| ${ }^{2} \mathrm{~J} 2996$ | X | Alteplase recombinant inj ...................................... | 0915 | 5.85 | \$283.70 |  | \$56.74 |
| J3000 | N | Streptomycin injection ............................................ |  |  |  |  |  |
| ${ }^{3} \mathrm{~J} 3010$ | X | Fentanyl citrate injeciton ........................................ | 7014 |  |  |  | \$. 19 |
| J3030 | N | Sumatriptan succinate/6 MG . |  |  |  |  |  |
| J3070 | N | Pentazocine hcl injeciton ........................................ |  |  |  |  |  |
| J3080 | N | Chlorprothixene injection |  |  |  |  |  |
| J3105 | N | Terbutaline sulfate inj ..... |  |  |  |  |  |
| J3120 | N | Testosterone enanthate inj ..................................... |  |  |  |  |  |
| J3130 | N | Testosterone enanthate inj |  |  |  |  |  |
| J3140 | N | Testosterone suspension inj |  |  |  |  |  |
| J3150 | N | Testosteron propionate inj ...................................... |  |  |  |  |  |
| J3230 | N | Chlorpromazine hcl injection |  |  |  |  |  |
| J3240 | N | Thyrotropin injection .............................................. |  |  |  |  |  |
| ${ }^{2}$ J3245 | X | Tirofiban hydrochloride | 7041 | 0.02 | \$. 97 |  | \$. 19 |
| J3250 | N | Trimethobenzamide hcl inj ...................................... |  |  |  |  |  |
| J3260 | N | Tobramycin sulfate injection ................................... |  |  | ..................... |  |  |
| J3265 | N | Injection torsemide $10 \mathrm{mg} / \mathrm{ml}$.................................. |  |  |  |  |  |
| J3270 | N | Imipramine hcl injection ......................................... |  |  |  |  |  |
| ${ }^{3} \mathrm{~J} 3280$ | X | Thiethylperazine maleate inj ................................... | 0755 | .................. | ...................... |  | \$. 68 |
| J3301 | N | Triamcinolone acetonide inj .................................... |  |  |  |  |  |
| J3302 | N | Triamcinolone diacetate inj ... |  |  | ..................... |  |  |
| J3303 | N | Triamcinolone hexacetonl inj ................................... |  |  |  | ...................... |  |
| ${ }^{3} \mathrm{~J} 3305$ | X | Inj trimetrexate glucoronate .................................... | 7045 | ...................... | ...................... | ..................... | \$8.15 |
| J3310 | N | Perphenazine injeciton ........ |  |  |  |  |  |

CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
Copyright American Dental Association. All rights reserved.
${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment.
${ }^{2}$ Not subject to national coinsurance
${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

# Addendum B.-Hospital Outpatient Department (HOPD) Payment Status by hCPCS Code and Related INFORMATION-Continued 

| CPT/ HCPCS | HOPD Status Indicator | Description | APC | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| J3320 | N | Spectinomycn di-hcl inj. |  |  | ..................... | ..................... |  |
| J3350 | N | Urea injection |  |  |  | ..................... |  |
| J3360 | N | Diazepam injection |  |  |  |  |  |
| J3364 | N | Urokinase 5000 IU injection |  |  |  |  |  |
| ${ }^{2} \mathrm{~J} 3365$ | X | Urokinase 250,000 IU inj ... | 7036 | 0.73 | \$35.40 |  | \$7.08 |
| J3370 | N | Vancomycin hcl injeciton |  |  |  |  |  |
| J3390 | N | Methoxamine injection .. |  |  |  |  |  |
| J3400 | N | Triflupromazine hcl inj |  |  |  |  |  |
| J3410 | N | Hydroxyzine hcl injeciton |  |  |  |  |  |
| J3420 | N | Vitamin b12 injection |  |  |  |  |  |
| J3430 | N | Vitamin k phytonadione inj . |  |  |  |  |  |
| J3450 | N | Mephentermine sulfate inj |  |  |  |  |  |
| J3470 | N | Hyaluronidase injection |  |  |  |  |  |
| J3475 | N | Inj magnesium sulfate .. |  |  |  |  |  |
| J3480 | N | Inj potassium chloride |  |  |  |  |  |
| J3490 | N | Drugs unclassified injection |  |  |  |  |  |
| J3520 | E | Edetate disodium per 150 mg |  |  |  |  |  |
| J3530 | N | Nasal vaccine inhalation |  |  |  |  |  |
| J3535 | E | Metered dose inhaler drug | .................... | ... | $\ldots$ | ..... |  |
| J3570 | E | Laetrile amygdalin vit B17 |  |  |  |  |  |
| J7030 | N | Normal saline solution infus |  |  |  |  |  |
| J7040 | N | Normal saline solution infus |  |  |  |  |  |
| J7042 | N | 5\% dextrose/normal saline |  |  |  |  |  |
| J7050 | N | Normal saline solution infus |  |  |  |  |  |
| J7051 | N | Sterile saline/water |  |  |  |  |  |
| J7060 | N | 5\% dextrose/water |  | .................... | .................... | ..................... | ..................... |
| J7070 | N | D5w infusion |  |  |  |  |  |
| J7100 | N | Dextran 40 infusion |  |  |  |  |  |
| J7110 | N | Dextran 75 infusion |  |  |  |  |  |
| $J 7120$ | N | Ringers lactate infusion |  |  | .................... |  |  |
| J7130 | N | Hypertonic saline solution |  |  |  |  |  |
| ${ }^{3} \mathrm{~J} 7190$ | X | Factor viii | 0925 |  |  |  | \$. 19 |
| ${ }^{3} \mathrm{~J} 7191$ | X | Factor VIII (porcine) | 0926 |  |  |  | \$. 19 |
| ${ }^{3} \mathrm{~J} 7192$ | X | Factor viii recombinant | 0927 |  |  |  | \$. 19 |
| ${ }^{3} \mathrm{~J} 7194$ | X | Factor ix complex | 0928 |  |  |  | \$. 08 |
| ${ }^{3} \mathrm{~J} 7197$ | X | Antithrombin iii injection | 0930 |  |  |  | \$. 19 |
| ${ }^{3} \mathrm{~J} 7198$ | X | Anti-inhibitor | 0929 |  |  |  | \$. 27 |
| J7199 | E | Hemophilia clot factor noc. |  |  |  |  |  |
| J7300 | E | Intraut copper contraceptive |  |  |  | ................... |  |
| ${ }^{3} \mathrm{~J} 7310$ | X | Ganciclovir long act implant | 0913 |  |  |  | \$701.51 |
| J7315 | N | Sodium hyaluronate injection |  |  |  |  |  |
| J7320 | N | Hylan G-F 20 injection |  |  |  |  |  |
| ${ }^{2} \mathrm{~J} 7500$ | X | Azathioprine oral 50 mg | 0886 | 0.02 | \$.97 |  | \$. 19 |
| ${ }^{2} \mathrm{~J} 7501$ | X | Azathioprine parenteral | 0887 | 1.40 | \$67.88 |  | \$13.58 |
| ${ }^{2} \mathrm{~J} 7502$ | X | Cyclosporine oral 100 mg .. | 0888 | 0.08 | \$3.88 |  | \$.78 |
| ${ }^{2} \mathrm{~J} 7504$ | X | Lymphocyte immune globulin | 0890 | 3.79 | \$183.77 |  | \$36.75 |
| ${ }^{3} \mathrm{~J} 7505$ | E | Monoclonal antibodies | 7038 |  |  |  | \$89.60 |
| J7506 | N | Prednisone oral |  |  |  |  |  |
| ${ }^{2} \mathrm{~J} 7507$ | X | Tacrolimus oral per 1 MG | 0891 | 3.15 | \$152.73 |  | \$30.55 |
| J7508 | E | Tacrolimus oral per 5 MG |  |  |  |  |  |
| J7509 | N | Methylprednisolone oral |  |  |  |  |  |
| J7510 | N | Prednisolone oral per 5 mg |  |  |  |  |  |
| $J 7513$ | X | Daclizumab, parenteral |  |  |  |  |  |
| J7515 | N | Cyclosporine oral 25 mg . |  |  |  |  |  |
| ${ }^{2} \mathrm{~J} 7516$ | X | Cyclosporin parenteral 250 mg | 0889 | 0.36 | \$17.46 |  | \$3.49 |
| $J 7517$ | N | Mycophenolate mofetil oral .... |  |  |  | ..................... |  |
| J7599 | E | Immunosuppressive drug noc |  |  |  |  |  |
| J7608 | A | Acetylcysteine inh sol u d |  |  |  |  |  |
| $J 7610$ | A | Acetylcysteine 10\% injection |  |  |  | ..................... |  |
| $J 7615$ | A | Acetylcysteine 20\% injection |  |  |  |  |  |
| $J 7618$ | A | Albuterol inh sol con .............................................. |  |  |  |  |  |
| J7619 | A | Albuterol inh sol u d |  |  |  |  |  |
| $J 7620$ | A | Albuterol sulfate $.083 \% / \mathrm{ml}$ |  |  |  | ..................... |  |
| J7625 | A | Albuterol sulfate . $5 \% \mathrm{inj}$ |  |  |  |  |  |
| J7627 | A | Bitolterolmesylate inhal sol |  |  |  |  |  |
| $J 7628$ | A | Bitolterol mes inhal sol con |  |  |  | ...................... |  |
| J7629 | A | Bitolterol mes inh sol u d |  |  |  |  |  |
| $J 7630$ | A | Cromolyn sodium injeciton ..................................... |  |  |  | .................... |  |
| J7631 | A | Cromolyn sodium inh sol u d |  | ..................... |  | ..................... |  |
| J7635 | A | Atropine inhal sol con ............................................ |  |  |  |  |  |
| J7636 | A | Atropine inhal sol unit dose |  |  |  |  |  |
| J7637 | A | Dexamethasone inhal sol con ................................. | ...................... | ...................... | ..................... | .... | .................... |
| J7638 | A | Dexamethasone inhal sol u d |  |  |  |  |  |

[^236]
# Addendum B.-Hospital Outpatient Department (HOPD) Payment Status by HCPCS Code and Related INFORMATION-Continued 

| $\begin{aligned} & \text { CPT/ } \\ & \text { HCPCS } \end{aligned}$ | HOPD Status Indicator | Description | APC | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| J7639 | A | Dornase alpha inhal sol u d |  |  |  |  |  |
| J7640 | A | Epinephrine injection ..... |  |  |  |  |  |
| J7642 | A | Glycopyrrolate inhal sol con |  |  |  | ...................... |  |
| J7643 | A | Glycopyrrolate inhal sol u d | ..................... | ..................... | ..................... | .................... |  |
| J7644 | A | Ipratropium brom inh sol u d |  |  |  |  |  |
| J7645 | A | Ipratropium bromide . $02 \% / \mathrm{ml}$... |  |  |  |  |  |
| J7648 | A | Isoetharine hcl inh sol con |  |  |  |  |  |
| J7649 | A | Isoetharine hcl inh sol u d |  |  |  |  |  |
| J7650 | A | Isoetharine hcl . $1 \% \mathrm{inj}$ |  |  |  |  |  |
| J7651 | A | Isoetharine hcl . $125 \% \mathrm{inj}$ |  |  |  |  |  |
| J7652 | A | Isoetharine hcl .167\% inj |  |  |  |  |  |
| J7653 | A | Isoetharine hcl .2\%/inj |  | .................... |  |  |  |
| J7654 | A | Isoetharine hcl . $25 \% \mathrm{inj}$ |  |  |  |  |  |
| J7655 | A | Isoetharine hcl 1\% inj |  |  |  |  |  |
| J7658 | A | Isoproterenolhcl inh sol con |  |  |  |  |  |
| J7659 | A | Isoproterenol hcl inh sol ud |  |  |  |  |  |
| J7660 | A | Isoproterenol hcl .5\% inj ... |  |  |  |  |  |
| J7665 | A | Isoproterenol hcl 1\% inj |  |  |  |  |  |
| J7668 | A | Metaproterenol inh sol con ..................................... |  |  |  |  |  |
| J7669 | A | Metaproterenol inh sol u d |  |  |  |  |  |
| J7670 | A | Metaproterenol sulfate .4\% |  |  |  |  |  |
| J7672 | A | Metaproterenol sulfate .6\% |  |  |  |  |  |
| J7675 | A | Metaproterenol sulfate 5\% |  |  |  |  |  |
| J7680 | A | Terbutaline so4 inh sol con |  |  |  |  |  |
| J7681 | A | Terbutaline so4 inh sol u d |  |  |  |  |  |
| J7682 | A | Tobramycin inhalation sol |  |  |  |  |  |
| J7683 | A | Triamcinolone inh sol con |  |  |  |  |  |
| J7684 | A | Triamcinolone inh sol u d | ..................... |  |  | .................... | ................... |
| J7699 | A | Inhalation solution for DME |  |  |  |  |  |
| J7799 | A | Non-inhalation drug for DME |  |  |  |  |  |
| ${ }^{3} \mathrm{~J} 7913$ | X | Daclizumab, Parenteral, 25 m ................................. | 0892 |  |  |  | \$54.11 |
| J8499 | E | Oral prescrip drug non chemo |  |  |  |  |  |
| ${ }^{3} \mathrm{~J} 8510$ | X | Oral busulfan . | 7015 |  |  |  | \$. 19 |
| ${ }^{3} \mathrm{~J} 8520$ | X | Capecitabine, oral, 150 mg | 7042 |  |  |  | \$. 19 |
| J8521 | N | Capecitabine, oral, 500 mg .................................... |  |  |  |  |  |
| ${ }^{3} \mathrm{~J} 8530$ | X | Cyclophosphamide oral 25 MG ............................... | 0801 |  |  |  | \$. 19 |
| ${ }^{3} \mathrm{~J} 8560$ | X | Etoposide oral 50 MG | 0802 |  |  |  | \$3.10 |
| ${ }^{3} \mathrm{~J} 8600$ | X | Melphalan oral 2 MG | 0803 |  |  |  | \$. 19 |
| ${ }^{3} \mathrm{~J} 8610$ | X | Methotrexate oral 2.5 MG | 0826 |  |  | .................... | \$. 29 |
| J8999 | E | Oral prescription drug chemo |  |  |  |  |  |
| ${ }^{3} \mathrm{~J} 9000$ | X | Doxorubic hol 10 MG vl chemo | 0847 |  |  |  | \$2.81 |
| ${ }^{3} \mathrm{~J} 9001$ | X | Doxorubicin hcl liposome inj | 7046 |  |  |  | \$39.18 |
| ${ }^{3} \mathrm{~J} 9015$ | X | Aldesleukin/single use vial | 0807 |  |  |  | \$65.07 |
| ${ }^{3} \mathrm{~J} 9020$ | X | Asparaginase injection | 0814 |  |  |  | \$8.34 |
| ${ }^{3} \mathrm{~J} 9031$ | X | Bcg live intravesical vac | 0809 |  |  |  | \$19.78 |
| ${ }^{3} \mathrm{~J} 9040$ | X | Bleomycin sulfate injection | 0857 |  |  |  | \$48.29 |
| ${ }^{3} \mathrm{~J} 9045$ | X | Carboplatin injection ..... | 0811 |  |  |  | \$13.96 |
| ${ }^{3} \mathrm{~J} 9050$ | X | Carmus bischl nitro inj | 0812 |  |  |  | \$10.57 |
| ${ }^{3} \mathrm{~J} 9060$ | X | Cisplatin 10 MG injeciton ........................................ | 0813 |  |  |  | \$4.56 |
| J9062 | E | Cisplatin 50 MG injeciton ........................................ |  |  |  |  |  |
| ${ }^{3} \mathrm{~J} 9065$ | X | Inj cladribine per 1 MG | 0858 |  |  |  | \$8.24 |
| ${ }^{3} \mathrm{~J} 9070$ | X | Cyclophosphamide 100 MG inj ............................... | 0815 |  |  | ................... | \$.48 |
| J9080 | E | Cyclophosphamide 200 MG inj ............................... |  |  |  |  |  |
| J9090 | E | Cyclophosphamide 500 MG inj ............................... |  |  |  | ..................... |  |
| J9091 | E | Cyclophosphamide 1.0 grm inj ............................... |  |  |  |  |  |
| J9092 | E | Cyclophosphamide 2.0 grm inj ................................ |  |  |  |  |  |
| ${ }^{3} \mathrm{~J} 9093$ | X | Cyclophosphamide lyophilized | 0816 |  |  |  | \$1.16 |
| J9094 | E | Cyclophosphamide lyophilized ................................ |  | ................... | .................... | .................... |  |
| J9095 | E | Cyclophosphamide lyophilized |  |  |  |  |  |
| J9096 | E | Cyclophosphamide lyophilized ............................... |  |  |  |  |  |
| J9097 | E | Cyclophosphamide lyophilized ................................ |  |  |  |  |  |
| ${ }^{3} \mathrm{~J} 9100$ | X | Cytarabine hcl 100 MG inj ... | 0817 | .................. |  |  | \$. 68 |
| J9110 | E | Cytarabine hcl 500 MG inj ...................................... |  |  |  |  |  |
| ${ }^{3} \mathrm{~J} 9120$ | X | Dactinomycin actinomycin d ................................... | 0818 | .................... |  | ................... | \$1.75 |
| ${ }^{3} \mathrm{~J} 9130$ | X | Dacarbazine 10 MG inj . | 0819 |  |  | ..................... | \$1.26 |
| J9140 | E | Dacarbazine 200 MG inj ......................................... |  |  |  |  |  |
| ${ }^{3} \mathrm{~J} 9150$ | X | Daunorubicin ......................................................... | 0820 |  |  |  | \$11.64 |
| ${ }^{3} \mathrm{~J} 9151$ | X | Daunorubicin citrate liposom ................................... | 0821 | .................... |  |  | \$7.76 |
| ${ }^{3} \mathrm{~J} 9165$ | X | Diethylstilbestrol injection | 0822 |  |  |  | \$2.13 |
| ${ }^{3} \mathrm{~J} 9170$ | X | Docetaxel | 0823 |  |  |  | \$34.72 |
| ${ }^{3} \mathrm{~J} 9181$ | X | Etoposide 10 MG inj | 0824 | ..................... | ..................... | ...................... | \$. 58 |
| $J 9182$ | E | Etoposide 100 MG inj ..... |  |  |  |  |  |
| ${ }^{3} \mathrm{~J} 9185$ | X | Fludarabine phosphate inj | 0842 |  |  |  | \$30.84 |

[^237]
# Addendum B.—Hospital Outpatient Department (HOPD) Payment Status by hCPCS Code and Related INFORMATION-Continued 

| $\begin{gathered} \text { CPT/ } \\ \text { HCPCS } \end{gathered}$ | HOPD Status Indicator | Description | APC | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| ${ }^{3} \mathrm{~J} 9190$ | X | Fluorouracil injection | 0859 |  | ..................... |  | \$. 19 |
| ${ }^{3} \mathrm{~J} 9200$ | X | Floxuridine injection | 0827 |  |  |  | \$18.81 |
| ${ }^{3} \mathrm{~J} 9201$ | X | Gemcitabine HCl | 0828 |  |  |  | \$9.31 |
| ${ }^{3} \mathrm{~J} 9202$ | X | Goserelin acetate implant | 0810 |  |  |  | \$59.74 |
| ${ }^{3} \mathrm{~J} 9206$ | X | Irinotecan injection | 0830 |  |  |  | \$14.16 |
| ${ }^{3} \mathrm{~J} 9208$ | X | Ifosfomide injection | 0831 |  |  |  | \$13.58 |
| ${ }^{3} \mathrm{~J} 9209$ | X | Mesna injection | 0732 |  |  |  | \$2.42 |
| ${ }^{3} \mathrm{~J} 9211$ | X | Idarubicin hcl injeciton | 0832 |  |  |  | \$46.45 |
| ${ }^{3} \mathrm{~J} 9212$ | X | Interferon alfacon-1 | 0833 |  |  |  | \$. 19 |
| ${ }^{3} \mathrm{~J} 9213$ | X | Interferon alfa-2a inj | 0834 |  |  |  | \$3.20 |
| ${ }^{3} \mathrm{~J} 9214$ | X | Interferon alfa-2b inj | 0836 |  |  |  | \$1.36 |
| ${ }^{3} \mathrm{~J} 9215$ | X | Interferon alfa-n3 inj | 0865 |  |  |  | \$1.07 |
| ${ }^{3} \mathrm{~J} 9216$ | X | Interferon gamma 1-b inj | 0838 |  |  |  | \$22.79 |
| J9217 | E | Leuprolide acetate suspnsion |  |  |  |  |  |
| ${ }^{3} \mathrm{~J} 9218$ | X | Leuprolide acetate injeciton .. | 0861 |  |  |  | \$19.39 |
| ${ }^{3} \mathrm{~J} 9230$ | X | Mechlorethamine hol inj | 0839 |  |  |  | \$1.65 |
| ${ }^{3} \mathrm{~J} 9245$ | X | Inj melphalan hydrochl 50 MG | 0840 |  |  |  | \$44.71 |
| ${ }^{3} \mathrm{~J} 9250$ | X | Methotrexate sodium inj. | 0841 |  |  |  | \$. 10 |
| J9260 | E | Methotrexate sodium inj |  |  |  |  |  |
| ${ }^{3} \mathrm{~J} 9265$ | X | Paclitaxel injection | 0863 |  |  |  | \$30.16 |
| ${ }^{3} \mathrm{~J} 9266$ | X | Pegaspargase/singl dose vial | 0843 |  |  |  | \$178.72 |
| ${ }^{3} \mathrm{~J} 9268$ | X | Pentostatin injection | 0844 |  |  |  | \$133.73 |
| ${ }^{3} \mathrm{~J} 9270$ | X | Plicamycin (mithramycin) inj | 0860 |  |  |  | \$1.36 |
| ${ }^{3} \mathrm{~J} 9280$ | X | Mitomycin 5 MG inj | 0862 |  |  |  | \$19.88 |
| J9290 | E | Mitomycin 20 MG inj |  |  |  |  |  |
| J9291 | E | Mitomycin 40 MG inj |  |  |  |  |  |
| ${ }^{3} \mathrm{~J} 9293$ | X | Mitoxantrone hydrochl/5 MG | 0864 |  |  |  | \$25.80 |
| ${ }^{3} \mathrm{~J} 9310$ | X | Rituximab cancer treatment | 0849 |  |  |  | \$51.40 |
| ${ }^{3} \mathrm{~J} 9320$ | X | Streptozocin injection | 0850 |  |  |  | \$14.64 |
| ${ }^{3} \mathrm{~J} 9340$ | X | Thiotepa injection | 0851 |  |  |  | \$9.50 |
| ${ }^{3} \mathrm{~J} 9350$ | X | Topotecan | 0852 |  |  |  | \$73.22 |
| J9355 | N | Trastuzumab |  | ...... | .................... |  |  |
| J9357 | N | Valrubicin, 200 mg . |  |  |  |  |  |
| ${ }^{3} \mathrm{~J} 9360$ | X | Vinblastine sulfate inj | 0853 |  |  |  | \$. 39 |
| ${ }^{3} \mathrm{~J} 9370$ | X | Vincristine sulfate 1 MG inj | 0854 |  |  |  | \$2.23 |
| J9375 | E | Vincristine sulfate 2 MG inj |  |  |  |  |  |
| J9380 | E | Vincristine sulfate 5 MG inj |  |  |  |  |  |
| ${ }^{3} \mathrm{~J} 9390$ | X | Vinorelbine tartrate/10 mg | 0855 |  |  |  | \$9.60 |
| ${ }^{3} \mathrm{~J} 9600$ | X | Porfimer sodium | 0856 |  |  |  | \$34.62 |
| J9999 | E | Chemotherapy drug ............................................... |  |  |  |  |  |
| K0001 | A | Standard wheelchair | .................... |  | ...................... | . | ...................... |
| K0002 | A | Stnd hemi (low seat) whlchr |  |  |  |  |  |
| K0003 | A | Lightweight wheelchair |  |  |  |  |  |
| K0004 | A | High strength Itwt whlchr ....................................... |  |  |  | ...................... | ..................... |
| K0005 | A | Ultralightweight wheelchair |  |  |  |  |  |
| K0006 | A | Heavy duty wheelchair |  |  |  |  |  |
| K0007 | A | Extra heavy duty wheelchair .................................. |  |  | ...................... |  |  |
| K0008 | A | Cstm manual wheelchair/base |  |  |  | ..................... |  |
| K0009 | A | Other manual wheelchair/base |  |  |  |  |  |
| K0010 | A | Stnd wt frame power whlchr |  |  |  |  |  |
| K0011 | A | Stnd wt pwr whlchr w control |  |  |  | .................... | ..................... |
| K0012 | A | Ltwt portbl power whichr |  |  |  |  |  |
| K0013 | A | Custom power whlchr base ... |  |  |  |  |  |
| K0014 | A | Other power whlchr base ..... |  |  |  |  |  |
| K0015 | A | Detach non-adjus hght armrst |  |  |  |  |  |
| K0016 | A | Detach adjust armrst cmplete . |  |  |  |  |  |
| K0017 | A | Detach adjust armrest base ................................... |  |  |  |  |  |
| K0018 | A | Detach adjust armrst upper |  |  |  | ...................... |  |
| K0019 | A | Arm pad each |  |  |  |  |  |
| K0020 | A | Fixed adjust armrest pair ....................................... |  |  | ..................... | ..................... |  |
| K0021 | A | Anti-tipping device each .... |  |  |  | ..................... |  |
| K0022 | A | Reinforced back upholstery |  |  |  |  |  |
| K0023 | A | Planr back instt foam w/strp |  |  |  |  |  |
| K0024 | A | Plnr back insrt foam w/hrdwr | .. | ..................... | . | .................... | . |
| K0025 | A | Hook-on headrest extension |  |  |  | ..................... |  |
| K0026 | A | Back upholst Igtwt whlchr |  |  |  |  |  |
| K0027 | A | Back upholst other whlchr |  |  |  |  |  |
| K0028 | A | Manual fully reclining back |  |  |  |  |  |
| K0029 | A | Reinforced seat upholstery ..................................... |  |  |  |  |  |
| K0030 | A | Solid plnr seat sngl dnsfoam ................................... |  |  |  |  |  |
| K0031 | A | Safety belt/pelvic strap |  | ... | ...................... | ..................... | ...................... |
| K0032 | A | Seat uphols Igtwt whlchr .... | ..................... | ..................... | ...................... |  |  |
| K0033 | A | Seat upholstery other whlchr |  |  |  |  |  |

[^238]
# Addendum B.—Hospital Outpatient Department (HOPD) Payment Status by hCPCS Code and Related Information-Continued 

| CPT/ <br> HCPCS | HOPD Status Indicator | Description | APC | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| K0034 | A | Heel loop each |  |  |  |  |  |
| K0035 | A | Heel loop with ankle strap .. |  |  |  |  |  |
| K0036 | A | Toe loop each ........ |  |  | ..................... | .................... |  |
| K0037 | A | High mount flip-up footrest |  |  |  |  |  |
| K0038 | A | Leg strap each |  |  |  |  |  |
| K0039 | A | Leg strap h style each |  |  | .................... |  |  |
| K0040 | A | Adjustable angle footplate |  |  |  |  |  |
| K0041 | A | Large size footplate each ....................................... |  | . | ..................... |  |  |
| K0042 | A | Standard size footplate each. |  |  |  |  |  |
| K0043 | A | Ftrst lower extension tube |  |  |  |  |  |
| K0044 | A | Ftrst upper hanger bracket |  |  |  |  |  |
| K0045 | A | Footrest complete assembly |  |  |  |  |  |
| K0046 | A | Elevat legrst low extension . |  |  |  |  |  |
| K0047 | A | Elevat legrst up hangr brack |  |  |  |  |  |
| K0048 | A | Elevate legrest complete |  | .................... | ................. |  |  |
| K0049 | A | Calf pad each |  |  |  |  |  |
| K0050 | A | Ratchet assembly . |  |  |  |  |  |
| K0051 | A | Cam relese assem ftrst/grst |  |  |  |  |  |
| K0052 | A | Swingaway detach footrest |  |  |  |  |  |
| K0053 | A | Elevate footrest articulate ... |  |  |  |  |  |
| K0054 | A | Seat wdth 10-12/15/17/20 wc |  |  |  |  |  |
| K0055 | A | Seat dpth 15/17/18 ltwt wc |  |  |  |  |  |
| K0056 | A | Seat ht <17 or >=21 ltwt wc. |  |  |  |  |  |
| K0057 | A | Seat wdth 19/20 hvy dty wc |  |  |  |  |  |
| K0058 | A | Seat dpth 17/18 power wc .. |  |  | .................... |  |  |
| K0059 | A | Plastic coated handrim each |  |  |  |  |  |
| K0060 | A | Steel handrim each |  |  |  |  |  |
| K0061 | A | Aluminum handrim each |  |  | .................... |  |  |
| K0062 | A | Handrim 8-10 vert/obliq proj |  |  |  |  |  |
| K0063 | A | Hndrm 12-16 vert/obliq proj |  |  |  |  |  |
| K0064 | A | Zero pressure tube flat free |  |  |  |  |  |
| K0065 | A | Spoke protectors |  |  |  |  |  |
| K0066 | A | Solid tire any size each |  |  |  |  |  |
| K0067 | A | Pneumatic tire any size each |  |  | .................... |  |  |
| K0068 | A | Pneumatic tire tube each |  |  | ...................... |  |  |
| K0069 | A | Rear whl complete solid tire |  |  |  |  |  |
| K0070 | A | Rear whl compl pneum tire .. |  |  | ...................... | ...................... |  |
| K0071 | A | Front castr compl pneum tire |  |  | ...................... |  |  |
| K0072 | A | Frnt cstr cmpl sem-pneum tir |  |  |  |  |  |
| K0073 | A | Caster pin lock each |  |  |  |  |  |
| K0074 | A | Pneumatic caster tire each |  |  | ..................... | . |  |
| K0075 | A | Semi-pneumatic caster tire |  |  |  |  |  |
| K0076 | A | Solid caster tire each |  |  |  |  |  |
| K0077 | A | Front caster assem complete ................................. |  |  |  |  |  |
| K0078 | A | Pneumatic caster tire tube |  |  |  |  |  |
| K0079 | A | Wheel lock extension pair |  |  |  |  |  |
| K0080 | A | Anti-rollback device pair ........................................ |  |  |  |  |  |
| K0081 | A | Wheel lock assembly complete |  |  |  |  |  |
| K0082 | A | 22 nf deep cycl acid battery |  |  |  |  |  |
| K0083 | A | 22 nf gel cell battery each ..... |  |  |  |  |  |
| K0084 | A | Grp 24 deep cycl acid battry |  |  |  | ...................... |  |
| K0085 | A | Group 24 gel cell battery ....................................... |  |  |  |  |  |
| K0086 | A | U-1 lead acid battery each .................................... |  |  |  |  |  |
| K0087 | A | U-1 gel cell battery each ....... |  |  |  |  |  |
| K0088 | A | Battry chrgr acid/gel cell |  |  |  |  |  |
| K0089 | A | Battery charger dual mode |  |  |  |  |  |
| K0090 | A | Rear tire power wheelchair. |  |  |  |  |  |
| K0091 | A | Rear tire tube power whlchr |  |  | .................... | ................... |  |
| K0092 | A | Rear assem cmplt powr whlchr |  |  |  |  |  |
| K0093 | A | Rear zero pressure tire tube ................................... |  |  |  |  |  |
| K0094 | A | Wheel tire for power base |  |  |  | .................... |  |
| K0095 | A | Wheel tire tube each base |  |  |  |  |  |
| K0096 | A | Wheel assem powr base complt |  |  |  |  |  |
| K0097 | A | Wheel zero presure tire tube ................................... |  |  | ..................... | ..................... |  |
| K0098 | A | Drive belt power wheelchair |  |  |  |  |  |
| K0099 | A | Pwr wheelchair front caster. |  |  |  |  |  |
| K0100 | A | Amputee adapter pair ....... |  |  |  | ................... | .................... |
| K0101 | A | One-arm drive attachment |  |  | ...................... | ...................... |  |
| K0102 | A | Crutch and cane holder |  |  |  |  |  |
| K0103 | A | Transfer board < 25" |  |  |  |  |  |
| K0104 | A | Cylinder tank carrier .... |  |  | .... | ..... |  |
| K0105 | A | Iv hanger ........ |  | ..................... | ...................... | ...................... |  |
| K0106 | A | Arm trough each |  |  |  |  |  |

[^239]
# Addendum B.—Hospital Outpatient Department (HOPD) Payment Status by hCPCS Code and Related Information-Continued 

| CPT/ HCPCS | HOPD Status Indicator | Description | APC | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| K0107 | A | Wheelchair tray |  |  |  | ..................... |  |
| K0108 | A | W/c component-accessory NOS |  |  |  | ...................... |  |
| K0112 | A | Trunk vest supprt innr frame |  |  |  |  |  |
| K0113 | A | Trunk vest suprt w/o inr frm |  |  |  |  |  |
| K0114 | A | Whlchr back suprt inr frame |  |  |  |  |  |
| K0115 | A | Back module orthotic system |  |  |  |  |  |
| K0116 | A | Back \& seat modul orthot sys |  |  |  |  |  |
| K0182 | A | Water distilled w/nebulizer . |  |  |  |  |  |
| K0183 | A | Nasal application device |  |  |  |  |  |
| K0184 | A | Nasal pillows/seals pair |  |  |  |  |  |
| K0185 | A | Pos airway pressure headgear |  |  |  |  |  |
| K0186 | A | Pos airway prssure chinstrap |  |  |  |  |  |
| K0187 | A | Pos airway pressure tubing .. |  |  |  |  |  |
| K0188 | A | Pos airway pressure filter |  |  |  |  |  |
| K0189 | A | Filter nondisposable w PAP |  |  |  |  |  |
| K0195 | A | Elevating whlchair leg rests |  |  |  |  |  |
| K0268 | A | Humidifier nonheated w PAP |  |  |  |  |  |
| K0269 | A | Aerosol compressor cpap dev |  |  |  |  |  |
| K0270 | A | Ultrasonic generator w nebul. |  |  |  | .................... |  |
| K0280 | A | Extension drainage tubing . |  |  |  |  |  |
| K0281 | A | Lubricant catheter insertion |  |  |  |  |  |
| K0283 | A | Saline solution dispenser |  |  |  |  |  |
| K0407 | A | Urinary cath skin attachment |  |  |  |  |  |
| K0408 | A | Urinary cath leg strap |  |  |  |  |  |
| K0409 | A | Sterile H2O irrigation solut |  |  |  |  |  |
| K0410 | A | Male ext cath w/adh coating |  |  |  | ..................... |  |
| K0411 | A | Male ext cath w/adh strip |  |  |  |  |  |
| K0415 | E | RX antiemetic drg, oral NOS |  |  |  | .................... |  |
| K0416 | E | Rx antiemetic drg, rectal NOS |  |  |  |  |  |
| K0440 | A | Nasal prosthesis |  |  |  |  |  |
| K0441 | A | Midfacial prosthesis |  |  |  |  |  |
| K0442 | A | Orbital prosthesis |  |  |  | ..................... |  |
| K0443 | A | Upper facial prosthesis |  |  |  |  |  |
| K0444 | A | Hemi-facial prosthesis |  |  |  |  |  |
| K0445 | A | Auricular prosthesis |  |  |  |  |  |
| K0446 | A | Partial facial prosthesis |  |  |  | ...................... |  |
| K0447 | A | Nasal septal prosthesis |  |  |  |  |  |
| K0448 | A | Unspec maxillofacial prosth |  |  |  |  |  |
| K0449 | A | Repair maxillofacial prosth |  |  |  | .................... |  |
| K0450 | A | Liq adhes for facial prosth |  |  |  |  |  |
| K0451 | A | Adhesive remover wipes |  |  |  | ...................... |  |
| K0452 | A | Wheelchair bearings |  |  |  | ...................... |  |
| K0455 | A | Pump uninterrupted infusion |  |  |  |  |  |
| K0456 | A | Heavyduty/xtra wide hosp bed |  |  |  |  |  |
| K0457 | A | Heavyduty/wide commode chair |  |  |  | ...................... |  |
| K0458 | A | Heavyduty walker no wheels |  |  |  |  |  |
| K0459 | A | Heavy duty wheeled walker |  |  |  |  |  |
| K0460 | A | WC power add-on joystick |  |  |  |  |  |
| K0461 | A | WC power add-on tiller cntrl. |  |  |  | ..................... |  |
| K0462 | A | Temporary replacement eqpmnt |  |  |  |  |  |
| K0501 | A | Aerosol compressor for svneb |  |  |  |  |  |
| K0529 | A | Sterile H20 or nss w lv neb |  |  |  | .................... |  |
| K0531 | A | Heated humidifier used w pap |  |  |  |  |  |
| K0532 | A | Noninvasive assist wo backup |  |  |  |  |  |
| K0533 | A | Noninvasive assist w backup |  |  |  | ..................... |  |
| K0534 | A | Invasive assist w backup . |  |  |  | ..................... |  |
| L0100 | A | Cerv craniosten helmet mold |  |  |  |  |  |
| L0110 | A | Cerv craniostenosis hel non- |  |  |  |  |  |
| L0120 | A | Cerv flexible non-adjustable |  |  |  | ...................... |  |
| L0130 | A | Flex thermoplastic collar mo |  |  |  |  |  |
| L0140 | A | Cervical semi-rigid adjustab |  |  |  |  |  |
| L0150 | A | Cerv semi-rig adj molded chn |  |  |  |  |  |
| L0160 | A | Cerv semi-rig wire occ/mand |  |  |  |  |  |
| L0170 | A | Cervical collar molded to pt |  |  |  |  |  |
| L0172 | A | Cerv col thermplas foam 2 pi |  |  |  |  |  |
| L0174 | A | Cerv col foam 2 piece w thor |  |  |  | ...................... |  |
| L0180 | A | Cer post col occ/man sup adj |  |  |  |  |  |
| L0190 | A | Cerv collar supp adj cerv ba .................................. |  |  |  | ..................... |  |
| L0200 | A | Cerv col supp adj bar \& thor |  |  |  | ...................... |  |
| L0210 | A | Thoracic rib belt ................................................... |  |  |  |  |  |
| L0220 | A | Thor rib belt custom fabrica .................................... |  |  |  |  |  |
| L0300 | A | TLSO flex surgical support ..................................... | ..................... | ..................... | ..................... | .... |  |
| L0310 | A | Tlso flexible custom fabrica |  |  |  |  |  |

CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
Copyright American Dental Association. All rights reserved.
${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment.
${ }^{2}$ Not subject to national coinsurance.
${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

# Addendum B.-Hospital Outpatient Department (HOPD) Payment Status by HCPCS Code and Related INFORMATION-Continued 

| $\begin{aligned} & \text { CPT/ } \\ & \text { HCPCS } \end{aligned}$ | HOPD Status Indicator | Description | APC | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| L0315 | A | Tlso flex elas rigid post pa |  | ... | .................... | ..... |  |
| L0317 | A | Tlso flex hypext elas post $p$ |  |  |  |  |  |
| L0320 | A | TIso a-p contrl w apron frnt |  |  |  |  |  |
| L0330 | A | Tlso ant-pos-lateral control |  |  |  |  |  |
| L0340 | A | TIso a-p-l-rotary with apron |  |  |  |  |  |
| L0350 | A | Tlso flex compress jacket cu |  |  |  |  |  |
| L0360 | A | Tiso flex compress jacket mo |  |  |  |  |  |
| L0370 | A | Tlso a-p-l-rotary hyperexten |  |  |  |  |  |
| L0380 | A | Tlso a-p-l-rot w/pos extens . |  |  |  |  |  |
| L0390 | A | Tlso a-p-I control molded |  |  |  |  |  |
| L0400 | A | Tlso a-p-l w interface mater |  |  |  |  |  |
| L0410 | A | Tlso a-p-l two piece constr |  |  |  |  |  |
| L0420 | A | TIso a-p-l 2 piece w interfa |  |  |  | .................... |  |
| L0430 | A | Tlso a-p-1 w interface custm |  |  |  |  |  |
| L0440 | A | Tlso a-p-l overlap frnt cust .. |  |  |  |  |  |
| L0500 | A | Lso flex surgical support |  |  |  | ..................... |  |
| L0510 | A | Lso flexible custom fabricat |  |  |  |  |  |
| L0515 | A | Lso flex elas w/rig post pa |  |  |  |  |  |
| L0520 | A | Lso a-p-I control with apron |  |  |  |  |  |
| L0530 | A | Lso ant-pos control w apron |  |  |  |  |  |
| L0540 | A | Lso lumbar flexion a-p-l |  |  |  |  |  |
| L0550 | A | Lso a-p-I control molded |  |  |  |  |  |
| L0560 | A | Lso a-p-I w interface |  |  |  |  |  |
| L0565 | A | Lso a-p-l control custom |  |  |  |  |  |
| L0600 | A | Sacroiliac flex surg support |  |  |  |  |  |
| L0610 | A | Sacroiliac flexible custm fa |  |  |  | ..................... |  |
| L0620 | A | Sacroiliac semi-rig w apron |  |  |  |  |  |
| L0700 | A | Ctlso a-p-I control molded |  |  |  |  |  |
| L0710 | A | Ctlso a-p-l control w/inter |  |  |  |  |  |
| L0810 | A | Halo cervical into jckt vest | ................... | ...................... | .................... | .................... |  |
| L0820 | A | Halo cervical into body jack |  |  |  |  |  |
| L0830 | A | Halo cerv into milwaukee typ |  |  |  |  |  |
| $L 0860$ | A | Magnetic resonanc image comp |  | .................... | ................... | .................... |  |
| L0900 | A | Torso/ptosis support |  |  |  |  |  |
| L0910 | A | Torso \& ptosis supp custm fa |  |  |  |  |  |
| L0920 | A | Torso/pendulous abd support |  |  |  | ..................... |  |
| L0930 | A | Pendulous abdomen supp custm |  |  |  |  |  |
| L0940 | A | Torso/postsurgical support |  |  |  |  |  |
| L0950 | A | Post surg support custom fab |  |  |  |  |  |
| L0960 | A | Post surgical support pads |  |  |  |  |  |
| L0970 | A | TIso corset front |  |  |  |  |  |
| L0972 | A | Lso corset front |  |  |  |  |  |
| L0974 | A | Tlso full corset |  |  |  |  |  |
| L0976 | A | Lso full corset |  |  |  |  |  |
| L0978 | A | Axillary crutch extension |  |  |  |  |  |
| L0980 | A | Peroneal straps pair |  |  |  |  |  |
| L0982 | A | Stocking supp grips set of f |  |  |  |  |  |
| L0984 | A | Protective body sock each |  |  |  |  |  |
| L0999 | A | Add to spinal orthosis NOS |  |  |  | .. |  |
| L1000 | A | Ctlso milwauke initial model |  |  |  |  |  |
| L1010 | A | Ctlso axilla sling |  |  |  |  |  |
| L1020 | A | Kyphosis pad |  |  |  |  |  |
| L1025 | A | Kyphosis pad floating |  |  |  |  |  |
| L1030 | A | Lumbar bolster pad |  |  |  |  |  |
| L1040 | A | Lumbar or lumbar rib pad |  |  |  | ...................... |  |
| L1050 | A | Sternal pad |  |  |  | ...................... |  |
| L1060 | A | Thoracic pad |  |  |  |  |  |
| L1070 | A | Trapezius sling |  |  |  | ..................... |  |
| L1080 | A | Outrigger |  |  |  | ...................... |  |
| L1085 | A | Outrigger bil w/vert extens |  |  |  |  |  |
| L1090 | A | Lumbar sling |  |  |  |  |  |
| L1100 | A | Ring flange plastic/leather |  |  |  |  |  |
| L1110 | A | Ring flange plas/leather mol |  |  | ........ |  |  |
| L1120 | A | Covers for upright each |  |  |  |  |  |
| L1200 | A | Furnsh initial orthosis only ..................................... |  |  |  | .................... |  |
| L1210 | A | Lateral thoracic extension |  |  | ..................... | ...................... |  |
| L1220 | A | Anterior thoracic extension |  |  |  |  |  |
| L1230 | A | Milwaukee type superstructur ................................. |  |  |  | .................... |  |
| L1240 | A | Lumbar derotation pad |  |  | ..................... | ...................... |  |
| L1250 | A | Anterior asis pad .......... |  |  |  |  |  |
| L1260 | A | Anterior thoracic derotation ..................................... |  |  |  |  |  |
| L1270 | A | Abdominal pad ..................................................... |  |  | ..................... | .... |  |
| L1280 | A | Rib gusset (elastic) each |  |  |  |  |  |

[^240]
# Addendum B.—Hospital Outpatient Department (HOPD) Payment Status by hCPCS Code and Related INFORMATION-Continued 

| CPT/ HCPCS | HOPD Status Indicator | Description | APC | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| L1290 | A | Lateral trochanteric pad |  |  |  | . |  |
| L1300 | A | Body jacket mold to patient |  |  |  | ...................... |  |
| L1310 | A | Post-operative body jacket |  |  |  |  |  |
| L1499 | A | Spinal orthosis NOS ......... |  |  |  |  |  |
| L1500 | A | Thkao mobility frame |  |  |  |  |  |
| L1510 | A | Thkao standing frame |  |  |  |  |  |
| L1520 | A | Thkao swivel walker |  |  |  |  |  |
| L1600 | A | Abduct hip flex frejka w cvr |  |  |  |  |  |
| L1610 | A | Abduct hip flex frejka covr |  |  |  |  |  |
| L1620 | A | Abduct hip flex pavlik harne |  |  |  |  |  |
| L1630 | A | Abduct control hip semi-flex |  |  |  |  |  |
| L1640 | A | Pelv band/spread bar thigh c |  |  |  |  |  |
| L1650 | A | HO abduction hip adjustable |  |  |  |  |  |
| L1660 | A | HO abduction static plastic |  |  |  |  |  |
| L1680 | A | Pelvic \& hip control thigh c |  |  |  |  |  |
| L1685 | A | Post-op hip abduct custom fa |  |  |  |  |  |
| L1686 | A | HO post-op hip abduction |  |  |  |  |  |
| L1690 | A | Combination bilateral HO |  |  |  |  |  |
| L1700 | A | Leg perthes orth toronto typ |  |  |  | ..... |  |
| L1710 | A | Legg perthes orth newington |  |  |  |  |  |
| L1720 | A | Legg perthes orthosis trilat |  |  |  |  |  |
| L1730 | A | Legg perthes orth scottish r |  |  |  |  |  |
| L1750 | A | Legg perthes sling |  |  |  |  |  |
| L1755 | A | Legg perthes patten bottom t |  |  |  |  |  |
| L1800 | A | Knee orthoses elas w stays |  |  |  |  |  |
| L1810 | A | Ko elastic with joints |  |  |  | .................... |  |
| L1815 | A | Elastic with condylar pads |  |  |  |  |  |
| L1820 | A | Ko elas w/condyle pads \& jo |  |  |  |  |  |
| L1825 | A | Ko elastic knee cap . |  |  |  |  |  |
| L1830 | A | Ko immobilizer canvas longit |  |  |  |  |  |
| L1832 | A | KO adj jnt pos rigid support |  |  |  |  |  |
| L1834 | A | Ko w/0 joint rigid molded to |  |  |  | ..................... |  |
| L1840 | A | Ko derot ant cruciate custom |  |  |  | .................... |  |
| L1843 | A | KO single upright custom fit |  |  |  |  |  |
| L1844 | A | Ko w/adj jt rot cntrl molded |  |  |  |  |  |
| L1845 | A | Ko w/adj flex/ext rotat cus |  |  |  | ...................... |  |
| L1846 | A | Ko w adj flex/ext rotat mold |  |  |  |  |  |
| L1847 | A | KO adjustable w air chambers |  |  |  |  |  |
| L1850 | A | Ko swedish type |  |  |  | ................... |  |
| L1855 | A | Ko plas doub upright jnt mol |  |  |  |  |  |
| L1858 | A | Ko polycentric pneumatic pad |  |  |  |  |  |
| L1860 | A | Ko supracondylar socket mold |  |  |  |  |  |
| L1870 | A | Ko doub upright lacers molde |  |  |  |  |  |
| L1880 | A | Ko doub upright cuffs/lacers |  |  |  |  |  |
| L1885 | A | Knee upright w/resistance |  |  |  | ...................... |  |
| L1900 | A | Afo sprng wir drsflx calf bd |  |  |  |  |  |
| L1902 | A | Afo ankle gauntlet |  |  |  |  |  |
| L1904 | A | Afo molded ankle gauntlet |  |  |  |  |  |
| L1906 | A | Afo multiligamentus ankle su |  |  |  | .................... |  |
| L1910 | A | Afo sing bar clasp attach sh |  |  |  |  |  |
| L1920 | A | Afo sing upright w/adjust s ... |  |  |  |  |  |
| L1930 | A | Afo plastic |  |  |  |  |  |
| L1940 | A | Afo molded to patient plasti |  |  |  | ..................... |  |
| L1945 | A | Afo molded plas rig ant tib |  |  |  |  |  |
| L1950 | A | Afo spiral molded to pt plas |  |  |  | .................... |  |
| L1960 | A | Afo pos solid ank plastic mo |  |  |  | ...................... |  |
| L1970 | A | Afo plastic molded w/ankle j . |  |  |  |  |  |
| L1980 | A | Afo sing solid stirrup calf |  |  |  |  |  |
| L1990 | A | Afo doub solid stirrup calf |  |  |  | ...................... |  |
| L2000 | A | Kafo sing fre stirr thi/calf |  |  |  |  |  |
| L2010 | A | Kafo sng solid stirrup w/o j |  |  |  |  |  |
| L2020 | A | Kafo dbl solid stirrup band/ |  |  |  |  |  |
| L2030 | A | Kafo dbl solid stirrup w/o j |  |  |  |  |  |
| $L 2035$ | A | KAFO plastic pediatric size .................................... |  |  |  |  |  |
| L2036 | A | Kafo plas doub free knee mol |  |  |  |  |  |
| L2037 | A | Kafo plas sing free knee mol ... |  |  |  | ...................... |  |
| L2038 | A | Kafo w/o joint multi-axis an |  |  |  |  |  |
| L2039 | A | KAFO, plstic, medlat rotat con ................................ |  |  |  | ..................... |  |
| L2040 | A | Hkafo torsion bil rot straps ....... |  |  |  | ...................... |  |
| L2050 | A | Hkafo torsion cable hip pelv ................................... |  |  |  |  |  |
| L2060 | A | Hkafo torsion ball bearing j ..................................... |  |  |  | ..................... |  |
| L2070 | A | Hkafo torsion unilat rot str ...................................... | ..................... | ..................... | ..................... | .... |  |
| L2080 | A | Hkafo unilat torsion cable |  |  |  |  |  |

CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
Copyright American Dental Association. All rights reserved.
${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment.
${ }^{2}$ Not subject to national coinsurance.
${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

# Addendum B.—Hospital Outpatient Department (HOPD) Payment Status by hCPCS Code and Related Information-Continued 

| CPT/ HCPCS | HOPD Status Indicator | Description | APC | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| L2090 | A | Hkafo unilat torsion ball br ... |  |  |  |  |  |
| L2102 | A | Afo tibial fx cast plstr mol |  |  |  |  |  |
| L2104 | A | Afo tib fx cast synthetic mo | .................. | ...................... | ..................... | ...................... |  |
| L2106 | A | Afo tib fx cast plaster mold |  |  |  |  |  |
| L2108 | A | Afo tib fx cast molded to pt .. |  |  |  |  |  |
| L2112 | A | Afo tibial fracture soft |  |  |  | ............. |  |
| L2114 | A | Afo tib fx semi-rigid |  |  |  |  |  |
| L2116 | A | Afo tibial fracture rigid |  |  |  |  |  |
| L2122 | A | Kafo fem fx cast plaster mol |  |  |  |  |  |
| L2124 | A | Kafo fem fx cast synthet mol |  | .................... | .................... | .................... |  |
| L2126 | A | Kafo fem fx cast thermoplas .................................... |  |  | ...................... |  |  |
| L2128 | A | Kafo fem fx cast molded to p |  |  |  |  |  |
| L2132 | A | Kafo femoral fx cast soft |  |  |  |  |  |
| L2134 | A | Kafo fem fx cast semi-rigid |  |  |  |  |  |
| L2136 | A | Kafo femoral fx cast rigid |  |  |  |  |  |
| L2180 | A | Plas shoe insert w ank joint |  |  |  |  |  |
| L2182 | A | Drop lock knee |  |  | .................... |  |  |
| L2184 | A | Limited motion knee joint |  |  |  |  |  |
| L2186 | A | Adj motion knee jnt lerman t |  |  |  |  |  |
| L2188 | A | Quadrilateral brim |  |  |  |  |  |
| L2190 | A | Waist belt |  |  |  |  |  |
| L2192 | A | Pelvic band \& belt thigh fla |  |  |  |  |  |
| L2200 | A | Limited ankle motion ea jnt |  |  |  |  |  |
| L2210 | A | Dorsiflexion assist each joi |  |  |  |  |  |
| L2220 | A | Dorsi \& plantar flex ass/res ... |  |  |  |  |  |
| L2230 | A | Split flat caliper stirr \& p |  |  |  |  |  |
| L2240 | A | Round caliper and plate atta |  |  |  |  |  |
| L2250 | A | Foot plate molded stirrup at |  |  |  |  |  |
| L2260 | A | Reinforced solid stirrup |  |  |  |  |  |
| L2265 | A | Long tongue stirrup |  |  | ..................... |  |  |
| L2270 | A | Varus/valgus strap padded/li |  |  | ................... | ..................... |  |
| L2275 | A | Plastic mod low ext pad/line .. |  |  |  |  |  |
| L2280 | A | Molded inner boot |  |  |  |  |  |
| L2300 | A | Abduction bar jointed adjust |  |  | .................... |  |  |
| L2310 | A | Abduction bar-straight |  |  |  |  |  |
| L2320 | A | Non-molded lacer |  | ..................... |  |  |  |
| $L 2330$ | A | Lacer molded to patient mode |  |  |  | ..................... |  |
| L2335 | A | Anterior swing band |  |  |  |  |  |
| L2340 | A | Pre-tibial shell molded to $p$ |  |  |  |  |  |
| L2350 | A | Prosthetic type socket molde |  |  |  |  |  |
| L2360 | A | Extended steel shank |  |  |  |  |  |
| L2370 | A | Patten bottom |  |  |  |  |  |
| L2375 | A | Torsion ank \& half solid sti |  |  |  |  |  |
| L2380 | A | Torsion straight knee joint |  |  |  |  |  |
| L2385 | A | Straight knee joint heavy du |  |  |  |  |  |
| L2390 | A | Offset knee joint each .. |  |  |  |  |  |
| L2395 | A | Offset knee joint heavy duty ................................... |  |  |  | .................... |  |
| L2397 | A | Suspension sleeve lower ext |  |  |  |  |  |
| L2405 | A | Knee joint drop lock ea jnt ... |  |  |  |  |  |
| L2415 | A | Knee joint cam lock each joi ................................... |  |  |  |  |  |
| L2425 | A | Knee disc/dial lock/adj flex ..................................... |  |  |  |  |  |
| L2430 | A | Knee jnt ratchet lock ea jnt ..................................... |  |  |  |  |  |
| L2435 | A | Knee joint polycentric joint ...................................... |  |  |  |  |  |
| L2492 | A | Knee lift loop drop lock rin |  |  |  |  |  |
| L2500 | A | Thi/glut/ischia wgt bearing ...................................... |  |  |  |  |  |
| L2510 | A | Th/wght bear quad-lat brim m ................................. |  |  |  |  |  |
| L2520 | A | Th/wght bear quad-lat brim c .................................. |  |  |  | .................... |  |
| L2525 | A | Th/wght bear nar m-I brim mo ................................. |  |  |  |  |  |
| L2526 | A | Th/wght bear nar m-I brim cu |  |  |  |  |  |
| L2530 | A | Thigh/wght bear lacer non-mo ................................. |  |  |  | . |  |
| L2540 | A | Thigh/wght bear lacer molded ................................. |  |  |  | ...................... |  |
| L2550 | A | Thigh/wght bear high roll cu .. |  |  |  |  |  |
| L2570 | A | Hip clevis type 2 posit jnt ...................................... |  |  |  |  |  |
| L2580 | A | Pelvic control pelvic sling |  |  |  |  |  |
| L2600 | A | Hip clevis/thrust bearing fr |  |  |  |  |  |
| L2610 | A | Hip clevis/thrust bearing lo ..................................... |  |  |  | .................... |  |
| L2620 | A | Pelvic control hip heavy dut .................................... |  |  |  | ...................... |  |
| L2622 | A | Hip joint adjustable flexion |  |  |  |  |  |
| L2624 | A | Hip adj flex ext abduct cont | ................... | ................... | .................... | ..................... |  |
| L2627 | A | Plastic mold recipro hip \& c .................................... |  |  |  | ...................... |  |
| L2628 | A | Metal frame recipro hip \& ca .................................. |  | .................... | .................... |  |  |
| L2630 | A | Pelvic control band \& belt u .................................... |  | ...................... |  |  |  |
| L2640 | A | Pelvic control band \& belt b |  |  |  |  |  |

CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
Copyright American Dental Association. All rights reserved.
${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment.
${ }^{2}$ Not subject to national coinsurance.
${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

# Addendum B.—Hospital Outpatient Department (HOPD) Payment Status by hCPCS Code and Related Information-Continued 

| CPT/ HCPCS | HOPD Status Indicator | Description | APC | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| L2650 | A | Pelv \& thor control gluteal |  |  |  | . |  |
| L2660 | A | Thoracic control thoracic ba |  |  |  | ...................... |  |
| L2670 | A | Thorac cont paraspinal uprig |  |  |  |  |  |
| L2680 | A | Thorac cont lat support upri . |  |  |  |  |  |
| L2750 | A | Plating chrome/nickel pr bar |  |  |  |  |  |
| L2755 | A | Carbon graphite lamination |  |  |  |  |  |
| L2760 | A | Extension per extension per |  |  |  |  |  |
| L2770 | A | Low ext orthosis per bar/jnt |  |  |  |  |  |
| L2780 | A | Non-corrosive finish |  |  |  | .................... |  |
| L2785 | A | Drop lock retainer each |  |  |  |  |  |
| L2795 | A | Knee control full kneecap |  |  |  |  |  |
| L2800 | A | Knee cap medial or lateral p |  |  |  |  |  |
| L2810 | A | Knee control condylar pad . |  |  |  |  |  |
| L2820 | A | Soft interface below knee se |  |  |  |  |  |
| $L 2830$ | A | Soft interface above knee se |  |  |  |  |  |
| L2840 | A | Tibial length sock fx or equ |  |  |  |  |  |
| L2850 | A | Femoral lgth sock fx or equa |  |  |  |  |  |
| L2860 | A | Torsion mechanism knee/ankle |  |  |  |  |  |
| L2999 | A | Lower extremity orthosis NOS |  |  |  | .... |  |
| L3000 | A | Ft insert ucb berkeley shell |  |  |  |  |  |
| L3001 | A | Foot insert remov molded spe |  |  |  |  |  |
| L3002 | A | Foot insert plastazote or eq |  |  |  |  |  |
| L3003 | A | Foot insert silicone gel eac |  |  |  |  |  |
| L3010 | A | Foot longitudinal arch suppo |  |  |  |  |  |
| L3020 | A | Foot longitud/metatarsal sup |  |  |  |  |  |
| L3030 | A | Foot arch support remov prem |  |  |  | .................... |  |
| L3040 | A | Ft arch suprt premold longit |  |  |  |  |  |
| L3050 | A | Foot arch supp premold metat |  |  |  |  |  |
| L3060 | A | Foot arch supp longitud/meta |  |  |  |  |  |
| L3070 | A | Arch suprt att to sho longit |  |  |  |  |  |
| L3080 | A | Arch supp att to shoe metata |  |  |  |  |  |
| L3090 | A | Arch supp att to shoe long/m |  |  |  | ..................... |  |
| L3100 | A | Hallus-valgus nght dynamic s |  |  |  | .................... |  |
| L3140 | A | Abduction rotation bar shoe |  |  |  |  |  |
| L3150 | A | Abduct rotation bar w/o shoe |  |  |  |  |  |
| L3160 | A | Shoe styled positioning dev |  |  |  | ..................... |  |
| L3170 | A | Foot plastic heel stabilizer |  |  |  |  |  |
| L3201 | A | Oxford w supinat/pronat inf |  |  |  |  |  |
| L3202 | A | Oxford w/supinat/pronator c |  |  |  | ................... |  |
| L3203 | A | Oxford w/supinator/pronator |  |  |  |  |  |
| L3204 | A | Hightop w/supp/pronator inf |  |  |  |  |  |
| L3206 | A | Hightop w/supp/pronator chi |  |  |  |  |  |
| L3207 | A | Hightop w/supp/pronator jun |  |  |  |  |  |
| L3208 | A | Surgical boot each infant |  |  |  |  |  |
| L3209 | A | Surgical boot each child |  |  |  |  |  |
| L3211 | A | Surgical boot each junior |  |  |  |  |  |
| L3212 | A | Benesch boot pair infant |  |  |  |  |  |
| L3213 | A | Benesch boot pair child |  |  |  |  |  |
| L3214 | A | Benesch boot pair junior .... |  |  |  |  |  |
| L3215 | A | Orthopedic ftwear ladies oxf |  |  |  |  |  |
| L3216 | A | Orthoped ladies shoes dpth i |  |  |  |  |  |
| L3217 | A | Ladies shoes hightop depth i |  |  |  |  |  |
| L3218 | A | Ladies surgical boot each . |  |  |  | ...................... |  |
| L3219 | A | Orthopedic mens shoes oxford |  |  |  |  |  |
| L3221 | A | Orthopedic mens shoes dpth i |  |  |  | .................... |  |
| L3222 | A | Mens shoes hightop depth inl |  |  |  | ...................... |  |
| L3223 | A | Mens surgical boot each |  |  |  |  |  |
| L3224 | A | Woman's shoe oxford brace ................................... |  |  |  |  |  |
| L3225 | A | Man's shoe oxford brace |  |  |  | ...................... |  |
| L3230 | A | Custom shoes depth inlay |  |  |  |  |  |
| L3250 | A | Custom mold shoe remov prost |  |  |  |  |  |
| L3251 | A | Shoe molded to pt silicone s |  |  |  |  |  |
| L3252 | A | Shoe molded plastazote cust |  |  |  |  |  |
| L3253 | A | Shoe molded plastazote cust |  |  |  |  |  |
| L3254 | A | Orth foot non-stndard size/w |  |  |  |  |  |
| L3255 | A | Orth foot non-standard size/ |  |  |  | ...................... |  |
| L3257 | A | Orth foot add charge split s |  |  |  |  |  |
| L3260 | A | Ambulatory surgical boot eac .................................. |  |  |  | ..................... |  |
| L3265 | A | Plastazote sandal each |  | ..................... |  | ...................... |  |
| L3300 | A | Sho lift taper to metatarsal ..................................... |  |  |  |  |  |
| L3310 | A | Shoe lift elev heel/sole neo ..................................... |  |  |  |  |  |
| L3320 | A | Shoe lift elev heel/sole cor ..................................... | ...................... | ...................... | ..................... | .... |  |
| L3330 | A | Lifts elevation metal extens |  |  |  |  |  |

[^241]
# Addendum B.-Hospital Outpatient Department (HOPD) Payment Status by HCPCS Code and Related Information-Continued 

| CPT/ <br> HCPCS | HOPD Status Indicator | Description | APC | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| L3332 | A | Shoe lifts tapered to one-ha |  |  |  |  |  |
| L3334 | A | Shoe lifts elevation heel/i .... |  |  |  |  |  |
| L3340 | A | Shoe wedge sach |  |  | .................... | .................... |  |
| L3350 | A | Shoe heel wedge |  |  |  |  |  |
| L3360 | A | Shoe sole wedge outside sole |  |  |  |  |  |
| L3370 | A | Shoe sole wedge between sole ... |  |  |  |  |  |
| L3380 | A | Shoe clubfoot wedge .... |  |  |  |  |  |
| L3390 | A | Shoe outflare wedge ............................................ |  |  | .................... |  |  |
| L3400 | A | Shoe metatarsal bar wedge ro |  |  |  |  |  |
| L3410 | A | Shoe metatarsal bar between |  |  |  |  |  |
| L3420 | A | Full sole/heel wedge btween |  |  |  |  |  |
| L3430 | A | Sho heel count plast reinfor |  |  |  |  |  |
| L3440 | A | Heel leather reinforced |  |  |  |  |  |
| L3450 | A | Shoe heel sach cushion type |  |  |  |  |  |
| L3455 | A | Shoe heel new leather standa |  | .................... | ................... |  |  |
| L3460 | A | Shoe heel new rubber standar |  |  |  |  |  |
| L3465 | A | Shoe heel thomas with wedge |  |  |  |  |  |
| L3470 | A | Shoe heel thomas extend to b |  |  |  |  |  |
| L3480 | A | Shoe heel pad \& depress for |  |  |  |  |  |
| L3485 | A | Shoe heel pad removable for. |  |  |  |  |  |
| L3500 | A | Ortho shoe add leather insol |  |  |  |  |  |
| L3510 | A | Orthopedic shoe add rub insl |  |  |  |  |  |
| L3520 | A | O shoe add felt w leath insl |  |  |  |  |  |
| L3530 | A | Ortho shoe add half sole |  |  |  |  |  |
| L3540 | A | Ortho shoe add full sole |  |  | .................... |  |  |
| L3550 | A | O shoe add standard toe tap |  |  |  |  |  |
| L3560 | A | O shoe add horseshoe toe tap |  |  |  |  |  |
| L3570 | A | O shoe add instep extension |  |  |  |  |  |
| L3580 | A | O shoe add instep velcro clo .................................. |  |  |  |  |  |
| L3590 | A | O shoe convert to sof counte |  |  |  |  |  |
| L3595 | A | Ortho shoe add march bar |  |  |  |  |  |
| L3600 | A | Trans shoe calip plate exist |  |  |  |  |  |
| L3610 | A | Trans shoe caliper plate new |  |  |  |  |  |
| L3620 | A | Trans shoe solid stirrup exi .................................... |  |  | ..................... |  |  |
| L3630 | A | Trans shoe solid stirrup new |  |  |  |  |  |
| L3640 | A | Shoe dennis browne splint bo |  |  |  |  |  |
| L3649 | A | Orthopedic shoe modifica NOS |  |  |  |  |  |
| L3650 | A | Shlder fig 8 abduct restrain ....... |  |  | ...................... |  |  |
| L3660 | A | Abduct restrainer canvas \& web |  |  |  |  |  |
| L3670 | A | Acromio/clavicular canvas \& we |  |  |  |  |  |
| L3675 | A | Canvas vest SO |  |  |  |  |  |
| L3700 | A | Elbow orthoses elas w stays |  |  |  |  |  |
| L3710 | A | Elbow elastic with metal joi |  |  |  |  |  |
| L3720 | A | Forearm/arm cuffs free motio |  |  |  |  |  |
| L3730 | A | Forearm/arm cuffs ext/flex a |  |  |  |  |  |
| L3740 | A | Cuffs adj lock w/active con |  |  |  |  |  |
| L3800 | A | Whfo short opponen no attach ................................ |  |  |  |  |  |
| L3805 | A | Whfo long opponens no attach ............................... |  |  |  |  |  |
| L3807 | A | Whfo w inflatable airchamber |  |  |  |  |  |
| L3810 | A | Whfo thumb abduction bar |  |  |  |  |  |
| L3815 | A | Whfo second m.p. abduction a ................................ |  |  |  | .................... |  |
| L3820 | A | Whfo ip ext asst w/mp ext s ................................... |  |  |  |  |  |
| L3825 | A | Whfo m.p. extension stop ....... |  |  |  |  |  |
| L3830 | A | Whfo m.p. extension assist .. |  |  |  |  |  |
| L3835 | A | Whfo m.p. spring extension a .................................. |  |  |  |  |  |
| L3840 | A | Whfo spring swivel thumb |  |  |  |  |  |
| L3845 | A | Whfo thumb ip ext ass w/mp ................................... |  |  |  |  |  |
| L3850 | A | Action wrist w/dorsiflex as |  |  | ...................... | ...................... |  |
| L3855 | A | Whfo adj m.p. flexion contro |  |  |  |  |  |
| L3860 | A | Whfo adj m.p. flex ctrl \& i. ...................................... |  |  |  |  |  |
| L3890 | A | Torsion mechanism wrist/elbo |  |  |  | .................... |  |
| L3900 | A | Hinge extension/flex wrist/f . |  |  |  |  |  |
| L3901 | A | Hinge ext/flex wrist finger .... |  |  |  |  |  |
| L3902 | A | Whfo ext power compress gas ................................ |  |  |  | ..................... |  |
| L3904 | A | Whfo electric custom fitted |  |  | ...................... |  |  |
| L3906 | A | Wrist gauntlet molded to pt |  |  |  |  |  |
| L3907 | A | Whfo wrst gauntlt thmb spica .................................. |  |  |  | ...................... |  |
| L3908 | A | Wrist cock-up non-molded .. |  |  | ...................... |  |  |
| L3910 | A | Whfo swanson design |  |  |  |  |  |
| L3912 | A | Flex glove w/elastic finger .... |  | ..................... | ...................... | ...................... |  |
| L3914 | A | WHO wrist extension cock-up .. |  |  |  | ...................... |  |
| L3916 | A | Whfo wrist extens w/outrigg | ..................... | ..................... | ...................... |  |  |
| L3918 | A | HFO knuckle bender |  |  |  |  |  |

[^242]
# Addendum B.—Hospital Outpatient Department (HOPD) Payment Status by hCPCS Code and Related Information-Continued 

| CPT/ HCPCS | HOPD Status Indicator | Description | APC | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| L3920 | A | Knuckle bender with outrigge |  |  |  | . |  |
| L3922 | A | Knuckle bend 2 seg to flex j |  |  |  | ...................... |  |
| L3924 | A | Oppenheimer ...... |  |  |  |  |  |
| L3926 | A | Thomas suspension |  |  |  |  |  |
| L3928 | A | Finger extension w/clock sp |  |  |  |  |  |
| L3930 | A | Finger extension with wrist |  |  |  |  |  |
| L3932 | A | Safety pin spring wire ..... |  |  |  |  |  |
| L3934 | A | Safety pin modified .. |  |  |  |  |  |
| L3936 | A | Palmer ................. |  |  |  | ...................... |  |
| L3938 | A | Dorsal wrist |  |  |  |  |  |
| L3940 | A | Dorsal wrist w/outrigger at |  |  |  |  |  |
| L3942 | A | Reverse knuckle bender |  |  |  |  |  |
| L3944 | A | Reverse knuckle bend w/outr |  | ........ |  | ............... |  |
| L3946 | A | HFO composite elastic |  |  |  |  |  |
| L3948 | A | Finger knuckle bender |  |  |  |  |  |
| L3950 | A | Oppenheimer w/knuckle bend |  |  |  |  |  |
| L3952 | A | Oppenheimer w/rev knuckle 2 |  |  |  |  |  |
| L3954 | A | Spreading hand .................... |  |  |  |  |  |
| L3956 | A | Add joint upper ext orthosis |  |  |  | .... |  |
| L3960 | A | Sewho airplan desig abdu pos |  |  |  |  |  |
| L3962 | A | Sewho erbs palsey design abd |  |  |  |  |  |
| L3963 | A | Molded w/articulating elbow |  |  |  |  |  |
| L3964 | A | Seo mobile arm sup att to wc |  |  |  |  |  |
| L3965 | A | Arm supp att to wc rancho ty |  |  |  |  |  |
| L3966 | A | Mobile arm supports reclinin |  |  |  |  |  |
| L3968 | A | Friction dampening arm supp |  |  |  | .................... |  |
| L3969 | A | Monosuspension arm/hand supp |  |  |  |  |  |
| L3970 | A | Elevat proximal arm support. |  |  |  |  |  |
| L3972 | A | Offset/lat rocker arm w/ela |  |  |  |  |  |
| L3974 | A | Mobile arm support supinator |  |  |  |  |  |
| L3980 | A | Upp ext fx orthosis humeral |  |  |  |  |  |
| L3982 | A | Upper ext fx orthosis rad/ul |  |  |  | ..................... |  |
| L3984 | A | Upper ext fx orthosis wrist |  |  |  | .................... |  |
| L3985 | A | Forearm hand fx orth w/wr h |  |  |  |  |  |
| L3986 | A | Humeral rad/ulna wrist fx or |  |  |  |  |  |
| L3995 | A | Sock fracture or equal each |  |  |  | ..................... |  |
| L3999 | A | Upper limb orthosis NOS |  |  |  |  |  |
| L4000 | A | Repl girdle milwaukee orth .. |  |  |  |  |  |
| L4010 | A | Replace trilateral socket br |  |  |  | ................... |  |
| L4020 | A | Replace quadlat socket brim |  |  |  |  |  |
| L4030 | A | Replace socket brim cust fit |  |  |  |  |  |
| L4040 | A | Replace molded thigh lacer |  |  |  |  |  |
| L4045 | A | Replace non-molded thigh lac |  |  |  |  |  |
| L4050 | A | Replace molded calf lacer |  |  |  |  |  |
| L4055 | A | Replace non-molded calf lace |  |  |  | ..................... |  |
| L4060 | A | Replace high roll cuff |  |  |  |  |  |
| L4070 | A | Replace prox \& dist upright |  |  |  |  |  |
| L4080 | A | Repl met band kafo-afo prox |  |  |  |  |  |
| L4090 | A | Repl met band kafo-afo calf/ |  |  |  | .................... |  |
| L4100 | A | Repl leath cuff kafo prox th |  |  |  |  |  |
| L4110 | A | Repl leath cuff kafo-afo cal |  |  |  |  |  |
| L4130 | A | Replace pretibial shell |  |  |  |  |  |
| $\llcorner 4205$ | A | Ortho dvc repair per 15 min |  |  |  | ..................... |  |
| L4210 | A | Orth dev repair/repl minor p |  |  |  |  |  |
| $\llcorner 4350$ | A | Pneumatic ankle cntrl splint |  |  |  | .................... |  |
| L4360 | A | Pneumatic walking splint |  |  |  | ...................... |  |
| $\llcorner 4370$ | A | Pneumatic full leg splint |  |  |  |  |  |
| L4380 | A | Pneumatic knee splint |  |  |  |  |  |
| L4392 | A | Replace AFO soft interface |  |  |  | ...................... |  |
| L4394 | A | Replace foot drop spint |  |  |  |  |  |
| L4396 | A | Static AFO |  |  |  |  |  |
| L4398 | A | Foot drop splint recumbent |  |  |  |  |  |
| L5000 | A | Sho insert w arch toe filler |  |  |  |  |  |
| L5010 | A | Mold socket ank hgt w/toe f |  |  |  |  |  |
| L5020 | A | Tibial tubercle hgt w/toe f |  |  |  |  |  |
| L5050 | A | Ank symes mold sckt sach ft |  |  |  | ...................... |  |
| L5060 | A | Symes met fr leath socket ar |  |  |  |  |  |
| L5100 | A | Molded socket shin sach foot .................................. |  |  |  | .................... |  |
| L5105 | A | Plast socket jts/thgh lacer .... |  |  |  | ...................... |  |
| L5150 | A | Mold sckt ext knee shin sach .................................. |  |  |  |  |  |
| L5160 | A | Mold socket bent knee shin s .................................. |  |  |  |  |  |
| L5200 | A | Kne sing axis fric shin sach. | ...................... | .... | ..... | .... |  |
| L5210 | A | No knee/ankle joints w/ft b |  |  |  |  |  |

CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
Copyright American Dental Association. All rights reserved.
${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment
${ }^{2}$ Not subject to national coinsurance.
${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

# Addendum B.—Hospital Outpatient Department (HOPD) Payment Status by hCPCS Code and Related Information-Continued 

| $\begin{aligned} & \text { CPT/ } \\ & \text { HCPCS } \end{aligned}$ | HOPD Status Indicator | Description | APC | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| L5220 | A | No knee joint with artic ali |  |  |  | ..................... |  |
| L5230 | A | Fem focal defic constant fri |  |  |  | .................... |  |
| L5250 | A | Hip canad sing axi cons fric |  |  |  |  |  |
| L5270 | A | Tilt table locking hip sing .. |  |  |  |  |  |
| L5280 | A | Hemipelvect canad sing axis |  |  |  |  |  |
| L5300 | A | Bk sach soft cover \& finish |  |  |  |  |  |
| L5310 | A | Knee disart sach soft cv/fin |  |  |  |  |  |
| L5320 | A | Ak open end sach soft cv/fin |  |  |  |  |  |
| L5330 | A | Hip canadian sach sft cv/fin |  |  | ...................... |  |  |
| L5340 | A | Hemipelvectomy canad cv/fin |  |  |  |  |  |
| L5400 | A | Postop dress \& 1 cast chg bk |  |  |  |  |  |
| L5410 | A | Postop dsg bk ea add cast ch |  |  |  |  |  |
| L5420 | A | Postop dsg \& 1 cast chg ak/d ................................ |  |  |  |  |  |
| L5430 | A | Postop dsg ak ea add cast ch |  |  |  |  |  |
| L5450 | A | Postop app non-wgt bear dsg |  |  |  |  |  |
| L5460 | A | Postop app non-wgt bear dsg |  |  |  |  |  |
| L5500 | A | Init bk ptb plaster direct |  |  |  |  |  |
| L5505 | A | Init ak ischal plstr direct |  |  |  |  |  |
| L5510 | A | Prep BK ptb plaster molded |  |  |  |  |  |
| L5520 | A | Perp BK ptb thermopls direct ................................. |  |  |  |  |  |
| L5530 | A | Prep BK ptb thermopls molded |  |  |  |  |  |
| L5535 | A | Prep BK ptb open end socket |  |  |  |  |  |
| L5540 | A | Prep BK ptb laminated socket |  |  |  |  |  |
| L5560 | A | Prep AK ischial plast molded |  |  |  |  |  |
| L5570 | A | Prep AK ischial direct form .... |  |  |  |  |  |
| L5580 | A | Prep AK ischial thermo mold |  |  |  |  |  |
| L5585 | A | Prep AK ischial open end |  |  |  |  |  |
| L5590 | A | Prep AK ischial laminated |  |  |  |  |  |
| L5595 | A | Hip disartic sach thermopls |  |  |  |  |  |
| L5600 | A | Hip disart sach laminat mold |  |  |  |  |  |
| L5610 | A | Above knee hydracadence |  |  |  |  |  |
| L5611 | A | Ak 4 bar link w/fric swing |  |  |  |  |  |
| L5613 | A | Ak 4 bar ling w/hydraul swig .................................. |  |  | .................... |  |  |
| L5614 | A | 4-bar link above knee w/swng |  |  |  |  |  |
| L5616 | A | Ak univ multiplex sys frict . |  |  |  |  |  |
| L5617 | A | AK/BK self-aligning unit ea ..................................... |  |  |  |  |  |
| L5618 | A | Test socket symes |  |  |  |  |  |
| L5620 | A | Test socket below knee |  |  |  |  |  |
| L5622 | A | Test socket knee disarticula |  |  |  |  |  |
| L5624 | A | Test socket above knee |  |  |  |  |  |
| L5626 | A | Test socket hip disarticulat |  |  |  |  |  |
| L5628 | A | Test socket hemipelvectomy |  |  |  |  |  |
| L5629 | A | Below knee acrylic socket .... |  |  |  |  |  |
| L5630 | A | Syme typ expandabl wall sckt |  |  |  |  |  |
| L5631 | A | Ak/knee disartic acrylic soc .................................... |  |  |  |  |  |
| L5632 | A | Symes type ptb brim design s ................................. |  |  |  |  |  |
| L5634 | A | Symes type poster opening so ................................ |  |  |  |  |  |
| L5636 | A | Symes type medial opening so ............................... |  |  |  |  |  |
| L5637 | A | Below knee total contact ....................................... |  |  |  |  |  |
| L5638 | A | Below knee leather socket |  |  |  |  |  |
| L5639 | A | Below knee wood socket |  |  |  |  |  |
| L5640 | A | Knee disarticulat leather so .................................... |  |  |  |  |  |
| L5642 | A | Above knee leather socket |  |  |  |  |  |
| L5643 | A | Hip flex inner socket ext fr . |  |  |  |  |  |
| L5644 | A | Above knee wood socket |  |  |  |  |  |
| L5645 | A | Ak flexibl inner socket ext |  |  |  |  |  |
| L5646 | A | Below knee air cushion socke ................................. |  |  |  |  |  |
| L5647 | A | Below knee suction socket |  |  |  |  |  |
| L5648 | A | Above knee air cushion socke |  |  |  |  |  |
| L5649 | A | Isch containmt/narrow m-I so |  |  |  |  |  |
| L5650 | A | Tot contact ak/knee disart s |  |  |  |  |  |
| L5651 | A | Ak flex inner socket ext fra |  |  |  |  |  |
| L5652 | A | Suction susp ak/knee disart ................................... |  |  |  |  |  |
| L5653 | A | Knee disart expand wall sock |  |  |  |  |  |
| L5654 | A | Socket insert symes ............................................. |  |  |  |  |  |
| L5655 | A | Socket insert below knee |  |  | ...................... | ...................... |  |
| L5656 | A | Socket insert knee articulat |  |  |  |  |  |
| L5658 | A | Socket insert above knee ... |  |  |  | .................... |  |
| L5660 | A | Sock insrt syme silicone gel ................................... |  |  |  | .................... |  |
| L5661 | A | Multi-durometer symes .......................................... |  |  |  |  |  |
| L5662 | A | Socket insert bk silicone ge .................................... |  |  | ...................... | ..................... |  |
| L5663 | A | Sock knee disartic silicone ..................................... | ...................... | ..................... | ..................... | ..... |  |
| L5664 | A | Socket insert ak silicone ge |  |  |  |  |  |

CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
Copyright American Dental Association. All rights reserved.
${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment.
${ }^{2}$ Not subject to national coinsurance.
${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

# Addendum B.—Hospital Outpatient Department (HOPD) Payment Status by hCPCS Code and Related Information-Continued 

| CPT/ HCPCS | HOPD Status Indicator | Description | APC | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| L5665 | A | Multi-durometer below knee |  |  |  | . |  |
| L5666 | A | Below knee cuff suspension |  |  |  | ...................... |  |
| L5667 | A | Socket insert w lock lower |  |  |  |  |  |
| L5668 | A | Socket insert w/o lock lower |  |  |  |  |  |
| L5669 | A | Below knee socket w/o lock |  |  |  |  |  |
| L5670 | A | Bk molded supracondylar susp |  |  |  |  |  |
| L5672 | A | Bk removable medial brim sus |  |  |  |  |  |
| L5674 | A | Bk latex sleeve suspension/e |  |  |  |  |  |
| L5675 | A | Bk latex sleeve susp/eq hvy |  |  |  |  |  |
| L5676 | A | Bk knee joints single axis p |  |  |  |  |  |
| L5677 | A | Bk knee joints polycentric p. |  |  |  |  |  |
| L5678 | A | Bk joint covers pair |  |  |  |  |  |
| L5680 | A | Bk thigh lacer non-molded |  |  |  |  |  |
| L5682 | A | Bk thigh lacer glut/ischia m |  |  |  |  |  |
| L5684 | A | Bk fork strap . |  |  |  |  |  |
| L5686 | A | Bk back check |  |  |  |  |  |
| L5688 | A | Bk waist belt webbing |  |  |  |  |  |
| L5690 | A | Bk waist belt padded and lin |  |  |  |  |  |
| L5692 | A | Ak pelvic control belt light |  |  |  | .... |  |
| L5694 | A | Ak pelvic control belt pad/l |  |  |  |  |  |
| L5695 | A | Ak sleeve susp neoprene/equa |  |  |  |  |  |
| L5696 | A | Ak/knee disartic pelvic join |  |  |  |  |  |
| L5697 | A | Ak/knee disartic pelvic band |  |  |  |  |  |
| L5698 | A | Ak/knee disartic silesian ba |  |  |  |  |  |
| L5699 | A | Shoulder harness |  |  |  |  |  |
| L5700 | A | Replace socket below knee |  |  |  | .................... |  |
| L5701 | A | Replace socket above knee |  |  |  |  |  |
| L5702 | A | Replace socket hip |  |  |  |  |  |
| L5704 | A | Custom shape covr below knee |  |  |  |  |  |
| L5705 | A | Custm shape cover above knee |  |  |  |  |  |
| L5706 | A | Custm shape cvr knee disart |  |  |  |  |  |
| L5707 | A | Custm shape cover hip disart |  |  |  | ..................... |  |
| L5710 | A | Kne-shin exo sng axi mnl loc |  |  |  | .................... |  |
| L5711 | A | Knee-shin exo mnl lock ultra |  |  |  |  |  |
| L5712 | A | Knee-shin exo frict swg \& st. |  |  |  |  |  |
| L5714 | A | Knee-shin exo variable frict |  |  |  | ...................... |  |
| L5716 | A | Knee-shin exo mech stance ph |  |  |  |  |  |
| L5718 | A | Knee-shin exo frct swg \& sta |  |  |  |  |  |
| L5722 | A | Knee-shin pneum swg frct exo |  |  |  | ................... |  |
| L5724 | A | Knee-shin exo fluid swing ph |  |  |  |  |  |
| L5726 | A | Knee-shin ext jnts fld swg e . |  |  |  |  |  |
| L5728 | A | Knee-shin fluid swg \& stance |  |  |  |  |  |
| L5780 | A | Knee-shin pneum/hydra pneum |  |  |  |  |  |
| L5785 | A | Exoskeletal bk ultralt mater |  |  |  |  |  |
| L5790 | A | Exoskeletal ak ultra-light m |  |  |  |  |  |
| L5795 | A | Exoskel hip ultra-light mate |  |  |  |  |  |
| L5810 | A | Endoskel knee-shin mnl lock |  |  |  |  |  |
| L5811 | A | Endo knee-shin mil lck ultra |  |  |  |  |  |
| L5812 | A | Endo knee-shin frct swg \& st |  |  |  |  |  |
| L5814 | A | Endo knee-shin hydral swg ph |  |  |  |  |  |
| L5816 | A | Endo knee-shin polyc mch sta |  |  |  |  |  |
| L5818 | A | Endo knee-shin frct swg \& st |  |  |  |  |  |
| L5822 | A | Endo knee-shin pneum swg frc |  |  |  | ...................... |  |
| L5824 | A | Endo knee-shin fluid swing p |  |  |  |  |  |
| L5826 | A | Miniature knee joint ...... |  |  |  | .................... |  |
| L5828 | A | Endo knee-shin fluid swg/sta |  |  |  | ...................... |  |
| L5830 | A | Endo knee-shin pneum/swg pha |  |  |  |  |  |
| L5840 | A | Multi-axial knee/shin system ................................... |  |  |  |  |  |
| L5845 | A | Knee-shin sys stance flexion. |  |  |  | ..................... |  |
| L5846 | A | Knee-shin sys microprocessor |  |  |  |  |  |
| L5850 | A | Endo ak/hip knee extens assi |  |  |  |  |  |
| L5855 | A | Mech hip extension assist |  |  |  |  |  |
| L5910 | A | Endo below knee alignable sy ................................ |  |  |  |  |  |
| L5920 | A | Endo ak/hip alignable system |  |  |  |  |  |
| L5925 | A | Above knee manual lock |  |  |  |  |  |
| L5930 | A | High activity knee frame ... |  |  |  | ...................... |  |
| L5940 | A | Endo bk ultra-light material |  |  |  |  |  |
| L5950 | A | Endo ak ultra-light material ..................................... |  |  |  | ..................... |  |
| L5960 | A | Endo hip ultra-light materia |  |  |  | ...................... |  |
| L5962 | A | Below knee flex cover system ................................. |  |  |  |  |  |
| L5964 | A | Above knee flex cover system ................................ |  |  |  | ..................... |  |
| L5966 | A | Hip flexible cover system ........................................ | ..................... | ..................... | ..................... | .... |  |
| L5968 | A | Multiaxial ankle w dorsiflex |  |  |  |  |  |

CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
Copyright American Dental Association. All rights reserved.
${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment.
${ }^{2}$ Not subject to national coinsurance.
${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

# Addendum B.—Hospital Outpatient Department (HOPD) Payment Status by hCPCS Code and Related Information-Continued 

| CPT/ HCPCS | HOPD Status Indicator | Description | APC | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| L5970 | A | Foot external keel sach foot |  |  |  |  |  |
| L5972 | A | Flexible keel foot |  |  |  |  |  |
| L5974 | A | Foot single axis ankle/foot |  |  | .................... | .................... |  |
| L5975 | A | Combo ankle/foot prosthesis |  |  |  |  |  |
| L5976 | A | Energy storing foot |  |  |  |  |  |
| L5978 | A | Ft prosth multiaxial ankl/ft ..... |  |  |  |  |  |
| L5979 | A | Multi-axial ankle/ft prosth |  |  |  |  |  |
| L5980 | A | Flex foot system |  | ..................... | .................... |  |  |
| L5981 | A | Flex-walk sys low ext prosth |  |  |  |  |  |
| L5982 | A | Exoskeletal axial rotation u . |  |  |  |  |  |
| L5984 | A | Endoskeletal axial rotation |  |  |  |  |  |
| L5985 | A | Lwr ext dynamic prosth pylon |  |  |  |  |  |
| L5986 | A | Multi-axial rotation unit |  |  |  |  |  |
| L5987 | A | Shank ft w vert load pylon |  |  |  |  |  |
| L5988 | A | Vertical shock reducing pylo |  | .................... | .............. |  |  |
| L5999 | A | Lowr extremity prosthes NOS |  |  |  |  |  |
| L6000 | A | Par hand robin-aids thum rem |  |  |  |  |  |
| L6010 | A | Hand robin-aids little/ring |  |  |  |  |  |
| L6020 | A | Part hand robin-aids no fing |  |  |  |  |  |
| L6050 | A | Wrst MLd sck flx hng tri pad |  |  |  |  |  |
| L6055 | A | Wrst mold sock w/exp interfa |  |  |  |  |  |
| L6100 | A | Elb mold sock flex hinge pad |  |  |  |  |  |
| $L 6110$ | A | Elbow mold sock suspension t |  |  |  |  |  |
| L6120 | A | Elbow mold doub splt soc ste |  |  |  |  |  |
| $L 6130$ | A | Elbow stump activated lock h |  |  |  |  |  |
| L6200 | A | Elbow mold outsid lock hinge |  |  |  |  |  |
| L6205 | A | Elbow molded w/expand inter |  |  |  |  |  |
| L6250 | A | Elbow inter loc elbow forarm |  |  | .................... |  |  |
| L6300 | A | Shlder disart int lock elbow |  |  |  |  |  |
| L6310 | A | Shoulder passive restor comp |  |  |  |  |  |
| L6320 | A | Shoulder passive restor cap |  |  |  |  |  |
| L6350 | A | Thoracic intern lock elbow |  |  |  |  |  |
| L6360 | A | Thoracic passive restor comp |  |  |  |  |  |
| L6370 | A | Thoracic passive restor cap |  |  |  |  |  |
| L6380 | A | Postop dsg cast chg wrst/elb |  |  |  |  |  |
| L6382 | A | Postop dsg cast chg elb dis/ |  |  |  |  |  |
| L6384 | A | Postop dsg cast chg shlder/t |  |  | ..................... | ..................... |  |
| 16386 | A | Postop ea cast chg \& realign |  |  |  |  |  |
| L6388 | A | Postop applicat rigid dsg on |  |  |  |  |  |
| L6400 | A | Below elbow prosth tiss shap |  |  |  |  |  |
| L6450 | A | Elb disart prosth tiss shap .... |  |  |  |  |  |
| L6500 | A | Above elbow prosth tiss shap |  |  |  |  |  |
| L6550 | A | Shldr disar prosth tiss shap |  |  |  |  |  |
| $L 6570$ | A | Scap thorac prosth tiss shap .................................. |  |  |  |  |  |
| L6580 | A | Wrist/elbow bowden cable mol |  |  |  |  |  |
| L6582 | A | Wrist/elbow bowden cbl dir f |  |  |  |  |  |
| L6584 | A | Elbow fair lead cable molded |  |  |  |  |  |
| $L 6586$ | A | Elbow fair lead cable dir fo . |  |  |  |  |  |
| L6588 | A | Shdr fair lead cable molded |  |  |  |  |  |
| L6590 | A | Shdr fair lead cable direct |  |  |  |  |  |
| L6600 | A | Polycentric hinge pair ............................................ |  |  |  | . |  |
| $L 6605$ | A | Single pivot hinge pair ........................................... |  |  |  |  |  |
| L6610 | A | Flexible metal hinge pair |  |  |  |  |  |
| $L 6615$ | A | Disconnect locking wrist uni |  |  |  |  |  |
| L6616 | A | Disconnect insert locking wr ................................... |  |  |  |  |  |
| L6620 | A | Flexion-friction wrist unit |  |  |  |  |  |
| $L 6623$ | A | Spring-ass rot wrst w/latch ..................................... |  |  |  |  |  |
| L6625 | A | Rotation wrst w/cable lock |  |  | ...................... | ...................... |  |
| L6628 | A | Quick disconn hook adapter o |  |  |  |  |  |
| $L 6629$ | A | Lamination collar w/couplin .................................... |  |  |  |  |  |
| $L 6630$ | A | Stainless steel any wrist ..... |  |  |  | .................... |  |
| L6632 | A | Latex suspension sleeve each |  |  |  |  |  |
| L6635 | A | Lift assist for elbow |  |  |  |  |  |
| L6637 | A | Nudge control elbow lock ....................................... |  |  | ..................... | ..................... |  |
| $L 6640$ | A | Shoulder abduction joint pai |  |  |  |  |  |
| L6641 | A | Excursion amplifier pulley t . |  |  |  |  |  |
| L6642 | A | Excursion amplifier lever ty .................................... |  |  |  | ..................... |  |
| L6645 | A | Shoulder flexion-abduction j .. |  |  | ...................... |  |  |
| L6650 | A | Shoulder universal joint |  |  |  |  |  |
| L6655 | A | Standard control cable extra |  |  |  |  |  |
| L6660 | A | Heavy duty control cable ..... |  |  |  | ...................... |  |
| $L 6665$ | A | Teflon or equal cable lining | ...................... | ...................... | ...................... |  |  |
| L6670 | A | Hook to hand cable adapter |  |  |  |  |  |

[^243]
# Addendum B.—Hospital Outpatient Department (HOPD) Payment Status by hCPCS Code and Related Information-Continued 

| $\begin{aligned} & \text { CPT/ } \\ & \text { HCPCS } \end{aligned}$ | HOPD Status Indicator | Description | APC | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| L6672 | A | Harness chest/shlder saddle |  |  |  | ... |  |
| L6675 | A | Harness figure of 8 sing con |  |  | ....................... |  |  |
| $L 6676$ | A | Harness figure of 8 dual con ... |  |  |  |  |  |
| L6680 | A | Test sock wrist disart/bel e ..... |  |  |  |  |  |
| L6682 | A | Test sock elbw disart/above |  |  |  |  |  |
| L6684 | A | Test socket shldr disart/tho |  |  |  |  |  |
| L6686 | A | Suction socket |  |  |  |  |  |
| 16687 | A | Frame typ socket bel elbow/w |  |  |  |  |  |
| L6688 | A | Frame typ sock above elb/dis |  |  | ...................... |  |  |
| L6689 | A | Frame typ socket shoulder di .. |  |  |  |  |  |
| L6690 | A | Frame typ sock interscap-tho .. |  |  |  |  |  |
| L6691 | A | Removable insert each |  |  |  |  |  |
| $L 6692$ | A | Silicone gel insert or equal |  |  | ................... |  |  |
| L6693 | A | Lockingelbow forearm cntrbal |  |  |  |  |  |
| L6700 | A | Terminal device model \#3 |  |  |  |  |  |
| $\underline{L 6705}$ | A | Terminal device model \#5 |  |  |  |  |  |
| $L 6710$ | A | Terminal device model \#5x |  |  |  |  |  |
| L6715 | A | Terminal device model \#5xa |  |  |  |  |  |
| L6720 | A | Terminal device model \#6 ... |  |  | .................... | ..................... |  |
| L6725 | A | Terminal device model \#7 |  |  | ...................... |  |  |
| $L 6730$ | A | Terminal device model \#7lo |  |  |  |  |  |
| L6735 | A | Terminal device model \#8 |  |  |  |  |  |
| L6740 | A | Terminal device model \#8x |  |  |  |  |  |
| L6745 | A | Terminal device model \#88x |  |  |  |  |  |
| 16750 | A | Terminal device model \#10p ................................... |  |  |  |  |  |
| L6755 | A | Terminal device model \#10x |  |  | ..................... | ..................... |  |
| L6765 | A | Terminal device model \#12p |  |  |  |  |  |
| L6770 | A | Terminal device model \#99x |  |  |  |  |  |
| L6775 | A | Terminal device model \#555 |  |  |  |  |  |
| L6780 | A | Terminal device model \#ss555 |  |  | .................... |  |  |
| L6790 | A | Hooks-accu hook or equal. |  |  |  |  |  |
| L6795 | A | Hooks-2 load or equal |  |  |  |  |  |
| 16800 | A | Hooks-aprl vc or equal |  |  | . |  |  |
| L6805 | A | Modifier wrist flexion unit |  |  |  |  |  |
| L6806 | A | Trs grip vc or equal |  |  |  |  |  |
| L6807 | A | Term device grip 1/2 or equal |  |  |  |  |  |
| L6808 | A | Term device infant or child |  |  |  |  |  |
| L6809 | A | Trs super sport passive ......... |  |  |  |  |  |
| L6810 | A | Pincher tool otto bock or eq |  |  |  |  |  |
| L6825 | A | Hands dorrance vo |  |  |  |  |  |
| L6830 | A | Hand aprl vc |  |  |  |  |  |
| L6835 | A | Hand sierra vo |  |  |  |  |  |
| L6840 | A | Hand becker imperial |  |  |  |  |  |
| L6845 | A | Hand becker lock grip |  |  |  |  |  |
| L6850 | A | Term dvc-hand becker plylite |  |  |  |  |  |
| L6855 | A | Hand robin-aids vo |  |  |  |  |  |
| L6860 | A | Hand robin-aids vo soft |  |  |  |  |  |
| L6865 | A | Hand passive hand |  |  |  |  |  |
| L6867 | A | Hand detroit infant hand |  |  |  | . |  |
| L6868 | A | Passive inf hand steeper/hos |  |  |  |  |  |
| L6870 | A | Hand child mitt |  |  |  |  |  |
| $L 6872$ | A | Hand nyu child hand |  |  |  |  |  |
| $L 6873$ | A | Hand mech inf steeper or equ |  |  |  |  |  |
| L6875 | A | Hand bock vc |  |  |  |  |  |
| L6880 | A | Hand bock vo |  |  |  | ..................... |  |
| L6890 | A | Production glove |  |  |  |  |  |
| L6895 | A | Custom glove |  |  |  |  |  |
| L6900 | A | Hand restorat thumb/1 finger .................................. |  |  |  |  |  |
| L6905 | A | Hand restoration multiple fi . |  |  |  |  |  |
| L6910 | A | Hand restoration no fingers |  |  |  |  |  |
| L6915 | A | Hand restoration replacmnt g |  |  |  |  |  |
| L6920 | A | Wrist disarticul switch ctrl |  |  |  |  |  |
| $L 6925$ | A | Wrist disart myoelectronic c |  |  |  |  |  |
| $L 6930$ | A | Below elbow switch control |  |  |  |  |  |
| L6935 | A | Below elbow myoelectronic ct |  |  |  |  |  |
| 16940 | A | Elbow disarticulation switch |  |  |  |  |  |
| L6945 | A | Elbow disart myoelectronic c |  |  |  |  |  |
| 16950 | A | Above elbow switch control.. |  |  |  |  |  |
| L6955 | A | Above elbow myoelectronic ct ................................. |  |  |  | .................... |  |
| L6960 | A | Shldr disartic switch contro ..................................... |  |  | ...................... |  |  |
| L6965 | A | Shldr disartic myoelectronic |  |  |  |  |  |
| L6970 | A | Interscapular-thor switch ct ...................................... | .................... |  | .................... |  |  |
| L6975 | A | Interscap-thor myoelectronic |  |  |  |  |  |

[^244]
# Addendum B.-Hospital Outpatient Department (HOPD) Payment Status by HCPCS Code and Related Information-Continued 

| CPT/ HCPCS | HOPD Status Indicator | Description | APC | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| L7010 | A | Hand otto back steeper/eq sw .. |  | .................... | .................... | ..................... |  |
| L7015 | A | Hand sys teknik village swit |  |  |  |  |  |
| L7020 | A | Electronic greifer switch ct .. |  |  |  |  |  |
| L7025 | A | Electron hand myoelectronic |  |  |  |  |  |
| L7030 | A | Hand sys teknik vill myoelec |  |  |  |  |  |
| L7035 | A | Electron greifer myoelectro .. |  |  |  |  |  |
| L7040 | A | Prehensile actuator hosmer s |  |  |  |  |  |
| L7045 | A | Electron hook child michigan |  |  |  |  |  |
| L7170 | A | Electronic elbow hosmer swit .................................. |  |  |  |  |  |
| L7180 | A | Electronic elbow utah myoele |  |  |  |  |  |
| L7185 | A | Electron elbow adolescent sw |  |  |  |  |  |
| L7186 | A | Electron elbow child switch |  |  |  |  |  |
| L7190 | A | Elbow adolescent myoelectron |  |  |  |  |  |
| L7191 | A | Elbow child myoelectronic ct ... |  |  |  |  |  |
| L7260 | A | Electron wrist rotator otto ..... |  |  |  | ..................... |  |
| L7261 | A | Electron wrist rotator utah |  |  |  |  |  |
| L7266 | A | Servo control steeper or equ |  |  |  |  |  |
| L7272 | A | Analogue control unb or equa |  |  |  |  |  |
| L7274 | A | Proportional ctl 12 volt uta |  |  |  |  |  |
| L7360 | A | Six volt bat otto bock/eq ea |  |  |  |  |  |
| L7362 | A | Battery chrgr six volt otto .... |  |  |  |  |  |
| L7364 | A | Twelve volt battery utah/equ |  |  |  | ..................... |  |
| L7366 | A | Battery chrgr 12 volt utah/e |  |  |  |  |  |
| L7499 | A | Upper extremity prosthes NOS |  |  |  |  |  |
| L7500 | A | Prosthetic dvc repair hourly. |  |  |  |  |  |
| L7510 | A | Prosthetic device repair rep |  |  |  |  |  |
| L7520 | A | Repair prosthesis per 15 min |  |  |  |  |  |
| L7900 | A | Vacuum erection system |  |  |  |  |  |
| L8000 | A | Mastectomy bra |  |  |  |  |  |
| L8010 | A | Mastectomy sleeve |  |  |  |  |  |
| L8015 | A | Ext breastprosthesis garment |  |  |  |  |  |
| L8020 | A | Mastectomy form |  |  |  |  |  |
| L8030 | A | Breast prosthesis silicone/e |  |  |  |  |  |
| L8035 | A | Custom breast prosthesis |  |  |  |  |  |
| L8039 | A | Breast prosthesis NOS |  |  |  | . |  |
| L8100 | A | Compression stocking BK18-30 |  |  |  |  |  |
| L8110 | A | Compression stocking BK30-40 |  |  |  |  |  |
| L8120 | A | Compression stocking BK40-50 |  |  |  |  |  |
| L8130 | A | Gc stocking thighlngth 18-30 |  |  |  |  |  |
| L8140 | A | Gc stocking thighlngth 30-40 |  |  |  |  |  |
| L8150 | A | Gc stocking thighlngth 40-50 ................................. |  |  |  | .................... |  |
| L8160 | A | Gc stocking full Ingth 18-30 |  |  |  |  |  |
| L8170 | A | Gc stocking full Ingth 30-40 |  |  |  |  |  |
| L8180 | A | Gc stocking full Ingth 40-50 |  |  |  |  |  |
| L8190 | A | Gc stocking waistlngth 18-30 ................................. |  |  |  | . |  |
| L8195 | A | Gc stocking waistlngth 30-40 |  |  |  |  |  |
| L8200 | A | Gc stocking waistlngth 40-50 |  |  |  |  |  |
| L8210 | A | Gc stocking custom made |  |  |  |  |  |
| L8220 | A | Gc stocking lymphedema ...................................... |  |  |  | ...................... |  |
| L8230 | A | Gc stocking garter belt ..... |  |  |  |  |  |
| L8239 | A | G compression stocking NOS ................................. |  |  |  |  |  |
| L8300 | A | Truss single w/standard pad ................................. |  |  |  |  |  |
| L8310 | A | Truss double w/standard pad |  |  |  |  |  |
| L8320 | A | Truss addition to std pad wa .................................. |  |  |  |  |  |
| L8330 | A | Truss add to std pad scrotal |  |  |  | ..................... |  |
| L8400 | A | Sheath below knee |  |  |  |  |  |
| L8410 | A | Sheath above knee |  |  |  |  |  |
| L8415 | A | Sheath upper limb ................................................ |  |  |  | .................... |  |
| L8417 | A | Pros sheath/sock w gel cushn ................................. |  |  |  |  |  |
| L8420 | A | Prosthetic sock multi ply BK |  |  |  |  |  |
| L8430 | A | Prosthetic sock multi ply AK ................................... |  |  |  | .................... |  |
| L8435 | A | Pros sock multi ply upper Im |  |  |  |  |  |
| L8440 | A | Shrinker below knee |  |  |  |  |  |
| L8460 | A | Shrinker above knee |  | . | ..................... | ...................... |  |
| L8465 | A | Shrinker upper limb .... |  |  |  | ..... |  |
| L8470 | A | Pros sock single ply BK |  |  |  |  |  |
| L8480 | A | Pros sock single ply AK. |  |  |  |  |  |
| L8485 | A | Pros sock single ply upper I ................................... |  | .................... |  | ..................... |  |
| L8490 | A | Air seal suction reten systm |  |  |  |  |  |
| L8499 | A | Unlisted misc prosthetic ser |  |  |  |  |  |
| L8500 | A | Artificial larynx ..................................................... |  | ..................... | ..................... | $\cdots$ |  |
| L8501 | A | Tracheostomy speaking valve ................................ | ..................... | .................. | ................ | ...................... |  |
| L8600 | A | Implant breast silicone/eq |  |  |  |  |  |

CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
Copyright American Dental Association. All rights reserved.
${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment.
${ }^{2}$ Not subject to national coinsurance
${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

# Addendum B.—Hospital Outpatient Department (HOPD) Payment Status by hCPCS Code and Related INFORMATION-Continued 

| $\begin{aligned} & \text { CPT/ } \\ & \text { HCPCS } \end{aligned}$ | HOPD Status Indicator | Description | APC | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| L8603 | A | Collagen imp urinary 2.5 CC |  | ..................... |  |  |  |
| L8610 | A | Ocular implant ................... |  |  |  |  |  |
| L8612 | A | Aqueous shunt prosthesis |  |  |  |  |  |
| L8613 | A | Ossicular implant .......... |  |  |  |  |  |
| L8614 | A | Cochlear device/system |  |  |  |  |  |
| L8619 | A | Replace cochlear processor |  | .................... | .................... | .................... |  |
| L8630 | A | Metacarpophalangeal implant ................................ |  |  |  |  |  |
| L8641 | A | Metatarsal joint implant ....... |  |  |  |  |  |
| L8642 | A | Hallux implant .... |  |  |  |  |  |
| L8658 | A | Interphalangeal joint implnt |  |  |  |  |  |
| L8670 | A | Vascular graft, synthetic . |  |  |  |  |  |
| L8699 | A | Prosthetic implant NOS |  |  |  |  |  |
| L9900 | A | O\&P supply/accessory/service |  |  |  |  |  |
| M0064 | X | Visit for drug monitoring ........................................ | 0374 | 1.17 | \$56.73 | \$13.08 | \$11.35 |
| M0075 | E | Cellular therapy |  |  |  |  |  |
| M0076 | E | Prolotherapy |  |  |  |  |  |
| M0100 | E | Intragastric hypothermia |  |  |  |  |  |
| M0300 | E | IV chelationtherapy |  |  |  |  |  |
| M0301 | E | Fabric wrapping of aneurysm |  | .................... |  |  |  |
| M0302 | E | Assessment of cardiac output |  |  |  |  |  |
| P2028 | A | Cephalin floculation test ........................................ |  |  |  |  |  |
| P2029 | A | Congo red blood test |  |  |  |  |  |
| P2031 | E | Hair analysis |  |  |  |  |  |
| P2033 | A | Blood thymol turbidity |  |  |  |  |  |
| P2038 | A | Blood mucoprotein . |  |  |  |  |  |
| P3000 | A | Screen pap by tech w md supv ............................... |  | ..................... |  | ..................... |  |
| P3001 | E | Screening pap smear by phys |  |  |  |  |  |
| P7001 | E | Culture bacterial urine ... |  |  |  |  |  |
| ${ }^{2} \mathrm{P} 9010$ | S | Whole blood for transfusion | 0950 | 2.08 | \$101.02 |  | \$20.20 |
| P9011 | S | Blood split unit ..................................................... |  |  |  |  |  |
| ${ }^{2} \mathrm{P} 9012$ | S | Cryoprecipitate each unit | 0952 | 0.70 | \$33.92 |  | \$6.78 |
| ${ }^{2} \mathrm{P} 9013$ | S | Unit/s blood fibrinogen | 0953 | 0.48 | \$23.27 |  | \$4.65 |
| ${ }^{2} \mathrm{P} 9016$ | S | Leukocyte poor blood, unit | 0954 | 2.83 | \$137.21 |  | \$27.44 |
| ${ }^{2} \mathrm{P} 9017$ | S | One donor fresh frozn plasma | 0955 | 2.26 | \$109.35 |  | \$21.87 |
| ${ }_{2}$ P9018 | S | Plasma protein fract, unit | 0956 | 1.26 | \$61.09 |  | \$12.22 |
| ${ }^{2}$ P9019 | S | Platelet concentrate unit | 0957 | 0.98 | \$47.46 |  | \$9.49 |
| ${ }^{2} \mathrm{P} 9020$ | S | Platelet rich plasma unit | 0958 | 1.16 | \$56.25 |  | \$11.25 |
| ${ }^{2}$ P9021 | S | Red blood cells unit | 0959 | 2.04 | \$99.04 |  | \$19.81 |
| ${ }^{2} \mathrm{P} 9022$ | S | Washed red blood cells unit | 0960 | 3.81 | \$184.53 |  | \$36.91 |
| ${ }^{2} \mathrm{P} 9023$ | S | Frozen plasma, pooled, sd ..................................... | 0949 | 3.49 | \$169.22 |  | \$33.84 |
| P9603 | A | One-way allow prorated miles ................................. |  |  |  |  |  |
| P9604 | A | One-way allow prorated trip |  | .................... |  |  |  |
| P9612 | N | Catheterize for urine spec |  |  |  | ..................... |  |
| P9615 | N | Urine specimen collect mult ................................... |  |  |  |  |  |
| ${ }^{2}$ Q0034 | X | Admin of influenza vaccine | 0354 | 0.13 | \$6.19 |  |  |
| Q0035 | X | Cardiokymography | 0366 | 0.38 | \$18.43 | \$15.60 | \$3.69 |
| Q0081 | S | Infusion ther other than che | 0120 | 1.66 | \$80.49 | \$42.67 | \$16.10 |
| Q0082 | P | Activity therapy w/partial h | 0033 | 4.17 | \$202.19 | \$48.17 | \$40.44 |
| Q0083 | S | Chemo by other than infusion | 0116 | 2.34 | \$113.46 | \$22.69 | \$22.69 |
| Q0084 | S | Chemotherapy by infusion ...................................... | 0117 | 1.84 | \$89.22 | \$71.80 | \$17.84 |
| Q0085 | S | Chemo by both infusion and o | 0118 | 2.90 | \$140.61 | \$72.03 | \$28.12 |
| Q0086 | A | Physical therapy evaluation/ ....... |  |  |  |  |  |
| Q0091 | T | Obtaining screen pap smear ................................... | 0191 | 1.19 | \$57.70 | \$17.43 | \$11.54 |
| Q0092 | N | Set up port x-ray equipment |  |  |  |  |  |
| Q0111 | A | Wet mounts/w preparations. |  |  |  |  |  |
| Q0112 | A | Potassium hydroxide preps .................................... | .................... | .................... | .................... | .................... | .................... |
| Q0113 | A | Pinworm examinations |  |  | ...................... |  |  |
| Q0114 | A | Fern test |  |  |  |  |  |
| Q0115 | A | Post-coital mucous exam |  |  |  |  |  |
| ${ }^{3}$ Q0136 | X | Non esrd epoetin alpha inj ..................................... | 0733 |  |  | .................... | \$1.75 |
| Q0144 | E | Azithromycin dihydrate, oral ................................... |  |  |  |  |  |
| ${ }^{2}$ Q0156 | X | Human albumin 5\% | 0961 | 2.77 | \$134.31 |  | \$26.86 |
| ${ }^{2}$ Q0157 | X | Human albumin 25\% | 0962 | 1.38 | \$66.91 | .................... | \$13.38 |
| ${ }^{3}$ Q0160 | X | Factor IX non-recombinant | 0931 |  |  |  | \$. 04 |
| ${ }^{3}$ Q0161 | X | Factor IX recombinant | 0932 |  |  |  | \$. 10 |
| ${ }^{3}$ Q0163 | X | Diphenhydramine HCl 50mg .................................. | 0761 | .................... | .................... | .................... | \$. 10 |
| ${ }^{3}$ Q0164 | X | Prochlorperazine maleate 5mg | 0761 |  |  |  | \$. 10 |
| Q0165 | E | Prochlorperazine maleate10mg ............................... |  |  |  |  |  |
| ${ }^{3}$ Q0166 | X | Granisetron HCl 1 mg oral ..................................... | 0765 |  | ..................... | ..................... | \$3.20 |
| ${ }^{3}$ Q0167 | X | Dronabinol 2.5 mg oral .......... | 0762 | ...................... | ...................... | ... | \$. 48 |
| Q0168 | E | Dronabinol 5mg oral ...... |  | ...................... | ...................... |  |  |
| ${ }^{3}$ Q0169 | X | Promethazine HCl 12.5mg oral ............................... | 0761 |  | ................... |  | \$. 10 |
| Q0170 | E | Promethazine HCl 25 mg oral ....... |  |  |  |  |  |

[^245]
# Addendum B.—Hospital Outpatient Department (HOPD) Payment Status by hCPCS Code and Related Information-Continued 

| CPT/ HCPCS | HOPD Status Indicator | Description | APC | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| ${ }^{3}$ Q0171 | X | Chlorpromazine HCl 10 mg oral | 0761 | .................... | ..................... | ..................... | \$. 10 |
| Q0172 | E | Chlorpromazine HCl 25 mg oral .............................. |  |  |  |  |  |
| ${ }^{3}$ Q0173 | X | Trimethobenzamide HCl 250 mg | 0761 |  |  |  | \$. 10 |
| ${ }^{3}$ Q0174 | X | Thiethylperazine maleate10mg | 0761 |  |  |  | \$. 10 |
| ${ }^{3}$ Q0175 | X | Perphenazine 4mg oral ......................................... | 0761 |  |  |  | \$. 10 |
| Q0176 | E | Perphenazine 8mg oral ......................................... |  |  |  |  |  |
| ${ }^{3}$ Q0177 | X | Hydroxyzine pamoate 25mg | 0761 |  |  |  | \$. 10 |
| Q0178 | E | Hydroxyzine pamoate 50 mg |  |  |  |  |  |
| ${ }^{3}$ Q0179 | X | Ondansetron HCl 8mg oral ..................................... | 0769 |  |  |  | \$2.62 |
| ${ }^{3}$ Q0180 | X | Dolasetron mesylate oral | 0763 |  |  |  | \$8.53 |
| Q0181 | E | Unspecified oral anti-emetic |  |  |  |  |  |
| Q0183 | N | Nonmetabolic active tissue |  |  |  |  |  |
| Q0184 | N | Metabolically active tissue | ................... |  | ............... |  |  |
| Q0185 | N | Metabolic active D/E tissue |  |  |  |  |  |
| Q0186 | E | Paramedic intercept, rural . |  | ..................... | ................ |  |  |
| ${ }^{3}$ Q0187 | X | Factor viia recombinant ......................................... | 0929 |  |  |  | \$. 27 |
| Q1001 | E | Ntiol category 1 |  |  |  |  |  |
| Q1002 | E | Ntiol category 2 .................................................... |  |  |  |  |  |
| Q1003 | E | Ntiol category 3 |  |  |  |  |  |
| Q1004 | E | Ntiol category 4 |  |  |  |  |  |
| Q1005 | E | Ntiol category 5 |  |  |  |  |  |
| Q2001 | E | Cabergoline, 0.5 mg , oral ...................................... |  |  |  |  |  |
| ${ }^{3}$ Q2002 | X | Elliot's B solution | 7022 |  |  |  | \$19.20 |
| ${ }^{3}$ Q2003 | X | Aprotinin, 10,000 kiu | 7019 |  |  |  | \$2.42 |
| ${ }^{3}$ Q2004 | X | Treatment for bladder calcul | 7023 |  |  |  | \$4.46 |
| ${ }^{3}$ Q2005 | X | Corticorelin ovine triflutat | 7024 |  |  |  | \$45.77 |
| ${ }^{3}$ Q2006 | X | Digoxin immune FAB (Ovine), ................................. | 7025 |  |  |  | \$14.06 |
| ${ }^{3}$ Q2007 | X | Ethanolamine oleate, 1000 ml | 7026 |  |  |  | \$2.13 |
| ${ }^{3}$ Q2008 | X | Fomepizole, 1.5 G | 7027 |  |  |  | \$141.29 |
| ${ }^{3}$ Q2009 | X | Fosphenytoin, 50 mg ............................................ | 7028 |  |  |  | \$. 78 |
| ${ }^{3}$ Q2010 | X | Glatiramer acetate, 25 mgeny | 7029 |  |  |  | \$3.59 |
| ${ }^{3}$ Q2011 | X | Hemin, 1 mg ............. | 7030 |  |  |  | \$. 10 |
| ${ }^{3}$ Q2012 | X | Pegademase bovine inj 25 I.U | 7039 |  |  |  | \$1.16 |
| ${ }^{3}$ Q2013 | X | Pentastarch 10\% inj, 100 ml ................................... | 7040 |  |  |  | \$2.04 |
| ${ }^{3}$ Q2014 | X | Sermorelin acetate, 0.5 mg .................................... | 7032 |  |  |  | \$53.34 |
| ${ }^{3}$ Q2015 | X | Somatrem, 5 mg .................................................. | 7033 |  |  |  | \$28.03 |
| ${ }^{3}$ Q2016 | X | Somatropin, 1 mg | 7034 |  |  |  | \$5.04 |
| ${ }^{3}$ Q2017 | X | Teniposide, 50 mg | 7035 |  |  |  | \$20.85 |
| ${ }^{3}$ Q2018 | X | Urofollitropin, 75 I.U. | 7037 |  |  |  | \$8.24 |
| ${ }^{3}$ Q3001 | S | Brachytherapy Seeds ............................................ | 0918 |  |  |  | \$9.99 |
| Q9920 | A | Epoetin with hct <= 20 |  |  |  |  |  |
| Q9921 | A | Epoetin with hct $=21$ |  |  |  |  |  |
| Q9922 | A | Epoetin with hct $=22$.......................................... |  |  |  |  |  |
| Q9923 | A | Epoetin with hct = 23 ............................................ |  |  |  |  |  |
| Q9924 | A | Epoetin with hct = 24 ............................................. | ...................... |  | ..................... | .................... |  |
| Q9925 | A | Epoetin with hct $=25$ |  |  |  |  |  |
| Q9926 | A | Epoetin with hct = 26 ............................................. |  |  |  |  |  |
| Q9927 | A | Epoetin with hct $=27$ |  |  |  |  |  |
| Q9928 | A | Epoetin with hct = 28 ............................................. | .................... |  |  | .................... |  |
| Q9929 | A | Epoetin with hct $=29$............................................ |  |  |  |  |  |
| Q9930 | A | Epoetin with hct $=30$ |  |  |  |  |  |
| Q9931 | A | Epoetin with hct = 31 ............................................. | .................... |  |  | .................... |  |
| Q9932 | A | Epoetin with hct $=32$ |  |  |  |  |  |
| Q9933 | A | Epoetin with hct = 33 ............................................. |  |  |  |  |  |
| Q9934 | A | Epoetin with hct = 34 ............................................. | ...................... |  | ..................... | ................... |  |
| Q9935 | A | Epoetin with hct $=35$ |  |  |  | ..................... |  |
| Q9936 | A | Epoetin with hct $=36$ |  |  |  |  |  |
| Q9937 | A | Epoetin with hct = 37 ............................................. | .................... |  |  | ..................... |  |
| Q9938 | A | Epoetin with hct $=38$ |  |  |  | ...................... |  |
| Q9939 | A | Epoetin with hct $=39$ |  |  |  |  |  |
| Q9940 | A | Epoetin with hct >= 40 ........................................... |  |  |  |  |  |
| R0070 | N | Transport portable x-ray |  |  |  |  |  |
| R0075 | N | Transport port x-ray multipl ................................... |  |  |  |  |  |
| R0076 | N | Transport portable EKG ......................................... |  |  |  |  |  |
| V2020 | A | Vision svcs frames purchases ................................. |  |  |  | .................... |  |
| V2025 | E | Eyeglasses delux frames | ..................... |  | ...................... | ...................... |  |
| V2100 | A | Lens spher single plano 4.00 |  |  |  |  |  |
| V2101 | A | Single visn sphere 4.12-7.00 ................................. | ...................... |  | ..................... | .................... |  |
| V2102 | A | Singl visn sphere 7.12-20.00 ................................. | ...................... |  | ...................... | ..................... |  |
| V2103 | A | Spherocylindr 4.00d/12-2.00d ................................. | ..................... |  |  |  |  |
| V2104 | A | Spherocylindr 4.00d/2.12-4d |  |  |  |  |  |
| V2105 | A | Spherocylinder 4.00d/4.25-6d ................................. | ... | ... | ... | .... |  |
| V2106 | A | Spherocylinder 4.00d/>6.00d |  |  |  |  |  |

[^246]
# Addendum B.—Hospital Outpatient Department (HOPD) Payment Status by hCPCS Code and Related Information-Continued 

| CPT/ HCPCS | HOPD Status Indicator | Description | APC | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| V2107 | A | Spherocylinder 4.25d/12-2d |  |  |  | . |  |
| V2108 | A | Spherocylinder 4.25d/2.12-4d |  |  |  | ...................... |  |
| V2109 | A | Spherocylinder 4.25d/4.25-6d |  |  |  |  |  |
| V2110 | A | Spherocylinder 4.25d/over 6d |  |  |  |  |  |
| V2111 | A | Spherocylindr 7.25d/.25-2.25 |  |  |  |  |  |
| V2112 | A | Spherocylindr 7.25d/2.25-4d |  |  |  |  |  |
| V2113 | A | Spherocylindr 7.25d/4.25-6d |  |  |  |  |  |
| V2114 | A | Spherocylinder over 12.00d.. |  |  |  |  |  |
| V2115 | A | Lens lenticular bifocal ...... |  |  |  | ...................... |  |
| V2116 | A | Nonaspheric lens bifocal |  |  |  |  |  |
| V2117 | A | Aspheric lens bifocal ...... |  |  |  |  |  |
| V2118 | A | Lens aniseikonic single |  |  |  |  |  |
| V2199 | A | Lens single vision not oth c |  |  |  |  |  |
| V2200 | A | Lens spher bifoc plano 4.00d |  |  |  |  |  |
| V2201 | A | Lens sphere bifocal 4.12-7.0 |  |  |  |  |  |
| V2202 | A | Lens sphere bifocal 7.12-20. |  |  |  |  |  |
| V2203 | A | Lens sphcyl bifocal 4.00d/. 1 |  |  |  |  |  |
| V2204 | A | Lens sphcy bifocal 4.00d/2.1 |  |  |  |  |  |
| V2205 | A | Lens sphcy bifocal 4.00d/4.2 |  |  |  | .... |  |
| V2206 | A | Lens sphcy bifocal 4.00d/ove |  |  |  |  |  |
| V2207 | A | Lens sphcy bifocal 4.25-7d/. |  |  |  |  |  |
| V2208 | A | Lens sphcy bifocal 4.25-7/2. |  |  |  |  |  |
| V2209 | A | Lens sphcy bifocal 4.25-7/4. |  |  |  |  |  |
| V2210 | A | Lens sphcy bifocal 4.25-7/ov |  |  |  |  |  |
| V2211 | A | Lens sphcy bifo 7.25-12/.25- |  |  |  |  |  |
| V2212 | A | Lens sphcyl bifo 7.25-12/2.2 |  |  |  | .................... |  |
| V2213 | A | Lens sphcyl bifo 7.25-12/4.2 |  |  |  |  |  |
| V2214 | A | Lens sphcyl bifocal over 12. |  |  |  |  |  |
| V2215 | A | Lens lenticular bifocal |  |  |  |  |  |
| V2216 | A | Lens lenticular nonaspheric |  |  |  |  |  |
| V2217 | A | Lens lenticular aspheric bif |  |  |  |  |  |
| V2218 | A | Lens aniseikonic bifocal |  |  |  |  |  |
| V2219 | A | Lens bifocal seg width over |  |  |  | .................... |  |
| V2220 | A | Lens bifocal add over 3.25d |  |  |  |  |  |
| V2299 | A | Lens bifocal speciality |  |  |  |  |  |
| V2300 | A | Lens sphere trifocal 4.00d |  |  |  | ...................... |  |
| V2301 | A | Lens sphere trifocal 4.12-7. |  |  |  |  |  |
| V2302 | A | Lens sphere trifocal 7.12-20 |  |  |  |  |  |
| V2303 | A | Lens sphcy trifocal 4.0/.12- |  |  |  | ................... |  |
| V2304 | A | Lens sphcy trifocal 4.0/2.25 |  |  |  |  |  |
| V2305 | A | Lens sphcy trifocal 4.0/4.25 |  |  |  |  |  |
| V2306 | A | Lens sphcyl trifocal 4.00/>6 |  |  |  |  |  |
| V2307 | A | Lens sphcy trifocal 4.25-7/. |  |  |  |  |  |
| V2308 | A | Lens sphc trifocal 4.25-7/2. |  |  |  |  |  |
| V2309 | A | Lens sphc trifocal 4.25-7/4. |  |  |  | .................... |  |
| V2310 | A | Lens sphc trifocal 4.25-7/>6 |  |  |  |  |  |
| V2311 | A | Lens sphc trifo 7.25-12/.25- |  |  |  |  |  |
| V2312 | A | Lens sphc trifo 7.25-12/2.25 |  |  |  |  |  |
| V2313 | A | Lens sphc trifo 7.25-12/4.25 |  |  |  | .................... |  |
| V2314 | A | Lens sphcyl trifocal over 12 |  |  |  |  |  |
| V2315 | A | Lens lenticular trifocal |  |  |  |  |  |
| V2316 | A | Lens lenticular nonaspheric |  |  |  |  |  |
| V2317 | A | Lens lenticular aspheric tri |  |  |  | ..................... |  |
| V2318 | A | Lens aniseikonic trifocal |  |  |  |  |  |
| V2319 | A | Lens trifocal seg width > 28 |  |  |  | .................... |  |
| V2320 | A | Lens trifocal add over 3.25d |  |  |  | ...................... |  |
| V2399 | A | Lens trifocal speciality |  |  |  |  |  |
| V2410 | A | Lens variab asphericity sing |  |  |  |  |  |
| V2430 | A | Lens variable asphericity bi. |  |  |  | ..................... |  |
| V2499 | A | Variable asphericity lens |  |  |  |  |  |
| V2500 | A | Contact lens pmma spherical |  |  |  |  |  |
| V2501 | A | Cntct lens pmma-toric/prism |  |  |  |  |  |
| V2502 | A | Contact lens pmma bifocal |  |  |  |  |  |
| V2503 | A | Cntct lens pmma color vision |  |  |  |  |  |
| V2510 | A | Cntct gas permeable sphericl |  |  |  |  |  |
| V2511 | A | Cntct toric prism ballast |  |  |  | ...................... |  |
| V2512 | A | Cntct lens gas permbl bifocl |  |  |  |  |  |
| V2513 | A | Contact lens extended wear ................................... |  |  |  | .................... |  |
| V2520 | A | Contact lens hydrophilic |  |  |  | ..................... |  |
| V2521 | A | Cntct lens hydrophilic toric ..................................... |  |  |  |  |  |
| V2522 | A | Cntct lens hydrophil bifocl ....................................... |  |  |  |  |  |
| V2523 | A | Cntct lens hydrophil extend .................................... | ...................... | ...................... | ..................... | ... |  |
| V2530 | A | Contact lens gas impermeable |  |  |  |  |  |

[^247]
# Addendum B.—Hospital Outpatient Department (HOPD) Payment Status by hCPCS Code and Related Information-Continued 

| $\begin{gathered} \text { CPT/ } \\ \text { HCPCS } \end{gathered}$ | HOPD Status Indicator | Description | APC | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| V2531 | A | Contact lens gas permeable . |  |  |  |  |  |
| V2599 | A | Contact lens/es other type |  |  |  |  |  |
| V2600 | A | Hand held low vision aids |  |  |  |  |  |
| V2610 | A | Single lens spectacle mount |  |  |  |  |  |
| V2615 | A | Telescop/othr compound lens |  |  |  |  |  |
| V2623 | A | Plastic eye prosth custom ..... |  |  |  |  |  |
| V2624 | A | Polishing artifical eye |  |  |  |  |  |
| V2625 | A | Enlargemnt of eye prosthesis |  |  | .................... |  |  |
| V2626 | A | Reduction of eye prosthesis |  |  |  |  |  |
| V2627 | A | Scleral cover shell .......... |  |  |  |  |  |
| V2628 | A | Fabrication \& fitting |  |  |  |  |  |
| V2629 | A | Prosthetic eye other type |  | ..................... | ..................... | .................... |  |
| V2630 | N | Anter chamber intraocul lens |  |  |  |  |  |
| V2631 | N | Iris support intraoclr lens |  |  |  |  |  |
| V2632 | N | Post chmbr intraocular lens |  |  |  |  |  |
| V2700 | A | Balance lens |  |  |  |  |  |
| V2710 | A | Glass/plastic slab off prism |  |  |  |  |  |
| V2715 | A | Prism lens/es ... |  |  |  |  |  |
| V2718 | A | Fresnell prism press-on lens |  |  |  |  |  |
| V2730 | A | Special base curve |  |  |  |  |  |
| V2740 | A | Rose tint plastic |  |  |  |  |  |
| V2741 | A | Non-rose tint plastic |  |  |  |  |  |
| V2742 | A | Rose tint glass |  |  |  |  |  |
| V2743 | A | Non-rose tint glass |  |  |  |  |  |
| V2744 | A | Tint photochromatic lens/es |  |  |  |  |  |
| V2750 | A | Anti-reflective coating |  |  |  |  |  |
| V2755 | A | UV lens/es |  |  |  |  |  |
| V2760 | A | Scratch resistant coating |  |  |  |  |  |
| V2770 | A | Occluder lens/es | .................... | ................... | .................... | .................... |  |
| V2780 | A | Oversize lens/es |  |  |  |  |  |
| V2781 | A | Progressive lens per lens |  |  |  | ..................... |  |
| V2785 | A | Corneal tissue processing |  | ..................... | ..................... | ..................... |  |
| V2799 | A | Miscellaneous vision service |  |  |  |  |  |
| V5008 | E | Hearing screening |  |  |  |  |  |
| V5010 | E | Assessment for hearing aid |  |  |  |  |  |
| V5011 | E | Hearing aid fitting/checking |  |  | . | .................... |  |
| V5014 | E | Hearing aid repair/modifying ................................... |  |  |  | ...................... |  |
| V5020 | E | Conformity evaluation |  |  |  |  |  |
| V5030 | E | Body-worn hearing aid air |  |  |  |  |  |
| V5040 | E | Body-worn hearing aid bone |  |  |  |  |  |
| V5050 | E | Body-worn hearing aid in ear |  |  |  |  |  |
| V5060 | E | Behind ear hearing aid |  |  |  |  |  |
| V5070 | E | Glasses air conduction |  |  |  |  |  |
| V5080 | E | Glasses bone conduction |  |  | . | .................... |  |
| V5090 | E | Hearing aid dispensing fee |  |  |  |  |  |
| V5100 | E | Body-worn bilat hearing aid |  |  |  |  |  |
| V5110 | E | Hearing aid dispensing fee |  |  |  |  |  |
| V5120 | E | Body-worn binaur hearing aid |  |  |  | ..................... |  |
| V5130 | E | In ear binaural hearing aid |  |  |  |  |  |
| V5140 | E | Behind ear binaur hearing ai |  |  |  |  |  |
| V5150 | E | Glasses binaural hearing aid |  | .................... | .................... | .................... |  |
| V5160 | E | Dispensing fee binaural |  |  | . |  |  |
| V5170 | E | Within ear cros hearing aid |  |  |  |  |  |
| V5180 | E | Behind ear cros hearing aid .................................... |  |  |  |  |  |
| V5190 | E | Glasses cros hearing aid |  |  |  |  |  |
| V5200 | E | Cros hearing aid dispens fee ................................. | .................... |  | .................... | ..................... |  |
| V5210 | E | In ear bicros hearing aid. |  |  |  |  |  |
| V5220 | E | Behind ear bicros hearing ai .................................. |  |  |  | .................... |  |
| V5230 | E | Glasses bicros hearing aid ..................................... | ..................... | ..................... | ..................... | ..................... | ................... |
| V5240 | E | Dispensing fee bicros. | ...................... | ...................... | ...................... | .............. |  |
| V5299 | A | Hearing service |  |  |  |  |  |
| V5336 | E | Repair communication device ................................. | .................... | .................... | .................... | .................... |  |
| V5362 | A | Speech screening ................................................. | ...................... | ...................... | ...................... | ..................... |  |
| V5363 | A | Language screening .............................................. | .................... | .................... | .................... | .................... |  |
| V5364 | A | Dysphagia screening ............................................... |  |  |  |  |  |

Addendum C.-Proposed Hospital Outpatient Department (HOPD) Payment for Procedures by APC

| APC | CPT/ HCPCS | HCPCS Description | Status Indicator | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 0001 | Photoche |  | S | 0.47 | \$22.79 | \$8.49 | \$4.56 |

[^248]
## addendum C.-Proposed Hospital Outpatient Department (HOPD) Payment for Procedures by APCContinued

| APC | CPT/ <br> HCPCS | HCPCS Description | Status Indicator | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 0002 | 96900 | Ultraviolet light therapy |  |  |  |  |  |
|  | 96910 | Photochemotherapy with UV-B |  |  |  |  |  |
|  | 96912 | Photochemotherapy with UV-A |  |  |  |  |  |
|  | 96913 | Photochemotherapy, UV-A or B |  |  |  |  |  |
|  | 96999 | Dermatological procedure |  |  |  |  |  |
|  | Fine needle Biopsy/Aspiration |  | T | 0.62 | \$30.06 | \$17.66 | \$6.01 |
|  | 60001 | Aspirate/inject thyriod cyst |  |  |  |  |  |
|  | 88170 | Fine needle aspiration |  |  |  |  |  |
|  | 88171 | Fine needle aspiration |  |  |  |  |  |
| 0003 | Bone Marrow Biopsy/Aspiration |  | T | 0.98 | \$47.52 | \$27.99 | \$9.50 |
|  | 85095 | Bone marrow aspiration |  |  |  |  |  |
|  | 85102 | Bone marrow biopsy |  |  |  |  |  |
| 0004 | Level I Needle Biopsy/Aspiration Except Bone Marrow |  | T | 1.84 | \$89.22 | \$32.57 | \$17.84 |
|  | 17999 | Skin tissue procedure |  |  |  |  |  |
|  | 19000 | Drainage of breast lesion |  |  |  |  |  |
|  | 19001 | Drain breast lesion add-on |  |  |  |  |  |
|  | 20615 | Treatment of bone cyst |  |  |  |  |  |
|  | 42400 | Biopsy of salivary gland |  |  |  |  |  |
|  | 54800 | Biopsy of epididymis |  |  |  |  |  |
|  | 55000 | Drainage of hydrocele |  |  |  |  |  |
|  | 60100 | Biopsy of thyroid |  |  |  |  |  |
|  | 60699 | Endocrine surgery procedure |  |  |  |  |  |
| 0005 | Level II Needle Biopsy/Aspiration Except Bone Marrow |  | T | 5.41 | \$262.32 | \$119.75 | \$52.46 |
|  | 19100 | Biopsy of breast |  |  |  |  |  |
|  | 20206 | Needle biopsy, muscle |  |  |  |  |  |
|  | 32400 | Needle biopsy chest lining |  |  |  |  |  |
|  | 32405 | Biopsy, lung or mediastinum |  |  |  |  |  |
|  | 38505 | Needle biopsy, lymph nodes |  |  |  |  |  |
|  | 47000 | Needle biopsy of liver |  |  |  |  |  |
|  | 47399 | Liver surgery procedure |  |  |  |  |  |
|  | 48102 | Needle biopsy, pancreas |  |  |  |  |  |
|  | 48999 | Pancreas surgery procedure |  |  |  |  |  |
|  | 49180 | Biopsy, abdominal mass |  |  |  |  |  |
|  | 50200 | Biopsy of kidney |  |  |  |  |  |
|  | 50390 | Drainage of kidney lesion |  |  |  |  |  |
|  | 54500 | Biopsy of testis |  |  |  |  |  |
|  | 62269 | Needle biopsy, spinal cord |  |  |  |  |  |
| 0006 | Level I Incision \& Drainage |  | T | 2.00 | \$96.97 | \$33.95 | \$19.39 |
|  | 10040 | Acne surgery of skin abscess |  |  |  |  |  |
|  | 10060 | Drainage of skin abscess |  |  |  |  |  |
|  | 10061 | Drainage of skin abscess |  |  |  |  |  |
|  | 10080 | Drainage of pilonidal cyst |  |  |  |  |  |
|  | 10120 | Remove foreign body |  |  |  |  |  |
|  | 10160 | Puncture drainage of lesion |  |  |  |  |  |
|  | 20000 | Incision of abscess |  |  |  |  |  |
|  | 26010 | Drainage of finger abscess |  |  |  |  |  |
|  | 69000 | Drain external ear lesion |  |  |  |  |  |
|  | 69020 | Drain outer ear canal lesion |  |  |  |  |  |
| 0007 | Level II Incision \& Drainage |  | T | 3.68 | \$178.43 | \$72.03 | \$35.69 |
|  | 10081 | Drainage of pilonidal cyst |  |  |  |  |  |
|  | 10140 | Drainage of hematoma/fluid |  |  |  |  |  |
|  | 10180 | Complex drainage, wound |  |  |  |  |  |
|  | 26011 | Drainage of finger abscess |  |  |  |  |  |
|  | 69005 | Drain external ear lesion |  |  |  |  |  |
| 0008 | Level III Incision \& Drainage |  | T | 6.15 | \$298.20 | \$113.67 | \$59.64 |
|  | 19020 | Incision of breast lesion |  |  |  |  |  |
|  | 20950 | Fluid pressure, muscle |  |  |  |  |  |
|  | 21501 | Drain neck/chest lesion |  |  |  |  |  |
|  | 21700 | Revision of neck muscle |  |  |  |  |  |
|  | 21720 | Revision of neck muscle |  |  |  |  |  |
|  | 21725 | Revision of neck muscle |  |  |  |  |  |
|  | 23030 | Drain shoulder lesion |  |  |  |  |  |
|  | 23031 | Drain shoulder bursa |  |  |  |  |  |
|  | 23930 | Drainage of arm lesion |  |  |  |  |  |
|  | 23931 | Drainage of arm bursa |  |  |  |  |  |
|  | 27301 | Drain thigh/knee lesion |  |  |  |  |  |
|  | 27603 | Drain lower leg lesion |  |  |  |  |  |
|  | 28001 | Drainage of bursa of foot |  |  |  |  |  |
|  | 38300 | Drainage, lymph node lesion |  |  |  |  |  |
|  | 38305 | Drainage, lymph node lesion |  |  |  |  |  |
|  | 38999 | Blood/lymph system procedure |  |  |  |  |  |
|  | 51080 | Drainage of bladder abscess |  |  |  |  |  |
|  | 54015 | Drain penis lesion |  |  |  |  |  |

[^249]Addendum C.-Proposed Hospital Outpatient Department (HOPD) Payment for Procedures by APCContinued

| APC | CPT/ HCPCS | HCPCS Description | Status Indicator | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | $\begin{aligned} & 54115 \\ & 55100 \end{aligned}$ | Treatment of penis lesion Drainage of scrotum abscess |  |  |  |  |  |
| 0009 | Nail Proc | edures | T | 0.74 | \$35.88 | \$9.63 | \$7.18 |
|  | 11719 | Trim nail(s) |  |  |  |  |  |
|  | 11720 | Debride nail, 1-5 |  |  |  |  |  |
|  | 11721 | Debride nail, 6 or more |  |  |  |  |  |
|  | 11740 | Drain blood from under nail |  |  |  |  |  |
|  | G0127 | Trim nail(s) |  |  |  |  |  |
| 0010 | Level I D | Destruction of Lesion | T | 0.55 | \$26.67 | \$9.86 | \$5.33 |
|  | 17000 | Destroy benign/premal lesion |  |  |  |  |  |
|  | 17003 | Destroy lesions, 2-14 |  |  |  |  |  |
|  | 17110 | Destruct lesion, 1-14 |  |  |  |  |  |
| 0011 | Level II D | Destruction of Lesion | T | 2.72 | \$131.88 | \$50.01 | \$26.38 |
|  | 17004 | Destroy lesions, 15 or more |  |  |  |  |  |
|  | 17106 | Destruction of skin lesions |  |  |  |  |  |
|  | 17107 | Destruction of skin lesions |  |  |  |  |  |
|  | 17108 | Destruction of skin lesions |  |  |  |  |  |
|  | 17111 | Destruct lesion, 15 or more |  |  |  |  |  |
| 0012 | Level I D | Debridement \& Destruction | T | 0.53 | \$25.70 | \$9.18 | \$5.14 |
|  | 11732 | Remove nail plate, add-on |  |  |  |  |  |
|  | 11900 | Injection into skin lesions |  |  |  |  |  |
|  | 15852 | Dressing change, not for burn |  |  |  |  |  |
|  | 17340 | Cryotherapy of skin |  |  |  |  |  |
|  | 69220 | Clean out mastoid cavity |  |  |  |  |  |
| 0013 | Level II D | Debridement \& Destruction | T | 0.91 | \$44.12 | \$17.66 | \$8.82 |
|  | 11300 | Shave skin lesion |  |  |  |  |  |
|  | 11301 | Shave skin lesion |  |  |  |  |  |
|  | 11305 | Shave skin lesion |  |  |  |  |  |
|  | 11306 | Shave skin lesion |  |  |  |  |  |
|  | 11310 | Shave skin lesion |  |  |  |  |  |
|  | 11311 | Shave skin lesion |  |  |  |  |  |
|  | 11730 | Removal of nail plate |  |  |  |  |  |
|  | 11901 | Added skin lesions injection |  |  |  |  |  |
|  | 15786 | Abrasion, lesion, single |  |  |  |  |  |
|  | 15788 | Chemical peel, face, epiderm |  |  |  |  |  |
|  | 15850 | Removal of sutures |  |  |  |  |  |
|  | 15851 | Removal of sutures |  |  |  |  |  |
|  | 17260 | Destruction of skin lesions |  |  |  |  |  |
|  | 17261 | Destruction of skin lesions |  |  |  |  |  |
|  | 17262 | Destruction of skin lesions |  |  |  |  |  |
|  | 17263 | Destruction of skin lesions |  |  |  |  |  |
|  | 17271 | Destruction of skin lesions |  |  |  |  |  |
|  | 17272 | Destruction of skin lesions |  |  |  |  |  |
|  | 54050 | Destruction, penis lesion(s) |  |  |  |  |  |
|  | 54056 | Cryosurgery, penis lesion(s) |  |  |  |  |  |
| 0014 | Level III | Debridement \& Destruction | T | 1.50 | \$72.73 | \$24.55 | \$14.55 |
|  | 11302 | Shave skin lesion |  |  |  |  |  |
|  | 11307 | Shave skin lesion |  |  |  |  |  |
|  | 16025 | Treatment of burn(s) |  |  |  |  |  |
|  | 17250 | Chemical cautery, tissue |  |  |  |  |  |
|  | 46917 | Laser surgery, anal lesions |  |  |  |  |  |
| 0015 | Level IV | Debridement \& Destruction | T | 1.77 | \$85.82 | \$31.20 | \$17.16 |
|  | 11000 | Debride infected skin |  |  |  |  |  |
|  | 11001 | Debride infected skin add-on |  |  |  |  |  |
|  | 11040 | Debride skin, partial |  |  |  |  |  |
|  | 11041 | Debride skin, full |  |  |  |  |  |
|  | 11055 | Trim skin lesion |  |  |  |  |  |
|  | 11056 | Trim skin lesions, 2 to 4 |  |  |  |  |  |
|  | 11057 | Trim skin lesions, over 4 |  |  |  |  |  |
|  | 11200 | Removal of skin tags |  |  |  |  |  |
|  | 11201 | Remove skin tags add-on |  |  |  |  |  |
|  | 11303 | Shave skin lesion |  |  |  |  |  |
|  | 11308 | Shave skin lesion |  |  |  |  |  |
|  | 11312 | Shave skin lesion |  |  |  |  |  |
|  | 11765 | Excision of nail fold, toe |  |  |  |  |  |
|  | 15783 | Abrasion treatment of skin |  |  |  |  |  |
|  | 15789 | Chemical peel, face, dermal |  |  |  |  |  |
|  | 16000 | Initial treatment of burn(s) |  |  |  |  |  |
|  | 16010 | Treatment of burn(s) |  |  |  |  |  |
|  | 16020 | Treatment of burn(s) |  |  |  |  |  |
|  | 16030 | Treatment of burn(s) |  |  |  |  |  |
|  | 17264 | Destruction of skin lesions |  |  |  |  |  |
|  | 17270 | Destruction of skin lesions |  |  |  |  |  |

CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
Copyright American Dental Association. All rights reserved.
${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment.
${ }^{2}$ Not subject to national coinsurance.
${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

| Addendum C.-Proposed Hospital Outpatient Department (HOPD) Payment for Procedures by APC— Continued |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| APC | CPT/ HCPCS | HCPCS Description | Status Indicator | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| 0016 | 17273 | Destruction of skin lesions |  |  |  |  |  |
|  | 17274 | Destruction of skin lesions |  |  |  |  |  |
|  | 17276 | Destruction of skin lesions |  |  |  |  |  |
|  | 17280 | Destruction of skin lesions |  |  |  |  |  |
|  | 17281 | Destruction of skin lesions |  |  |  |  |  |
|  | 17282 | Destruction of skin lesions |  |  |  |  |  |
|  | 17283 | Destruction of skin lesions |  |  |  |  |  |
|  | Level V D | Debridement \& Destruction | T | 3.53 | \$171.16 | \$74.67 | \$34.23 |
|  | 11042 | Debride skin/tissue |  |  |  |  |  |
|  | 11043 | Debride tissue/muscle |  |  |  |  |  |
|  | 11313 | Shave skin lesion |  |  |  |  |  |
|  | 15787 | Abrasion, lesions, add-on |  |  |  |  |  |
|  | 15792 | Chemical peel, nonfacial |  |  |  |  |  |
|  | 15793 | Chemical peel, nonfacial |  |  |  |  |  |
|  | 15810 | Salabrasion |  |  |  |  |  |
|  | 17266 | Destruction of skin lesions |  |  |  |  |  |
|  | 17284 | Destruction of skin lesions |  |  |  |  |  |
|  | 17286 | Destruction of skin lesions |  |  |  |  |  |
|  | 17360 | Skin peel therapy |  |  |  |  |  |
|  | 17380 | Hair removal by electrolysis |  |  |  |  |  |
|  | 46900 | Destruction, anal lesion(s) |  |  |  |  |  |
|  | 46910 | Destruction, anal lesion(s) |  |  |  |  |  |
|  | 46916 | Cryosurgery, anal lesion(s) |  |  |  |  |  |
|  | 54055 | Destruction, penis lesion(s) |  |  |  |  |  |
|  | 56501 | Destruction, vulva lesion(s) |  |  |  |  |  |
| 0017 | Level VI D | Debridement \& Destruction | T | 12.45 | \$603.66 | \$289.16 | \$120.73 |
|  | 11044 | Debride tissue/muscle/bone |  |  |  |  |  |
|  | 16015 | Treatment of burn(s) |  |  |  |  |  |
|  | 46922 | Excision of anal lesion(s) |  |  |  |  |  |
|  | 46924 | Destruction, anal lesion(s) |  |  |  |  |  |
|  | 54057 | Laser surg, penis lesion(s) |  |  |  |  |  |
|  | 54060 | Excision of penis lesion(s) |  |  |  |  |  |
|  | 54065 | Destruction, penis lesion(s) |  |  |  |  |  |
|  | 56515 | Destruction, vulva lesion(s) |  |  |  |  |  |
| 0018 | Biopsy Skin, Subcutaneous Tissue or Mucous Membrane 11100 Biopsy of skin lesion <br> 11101 Biopsy, skin add-on |  | T | 0.94 | \$45.58 | \$17.66 | \$9.12 |
|  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |
| 0019 | Level I Excision/Biopsy |  | T | 4.00 | \$193.95 | \$78.91 | \$38.79 |
|  | $11400$ | Removal of skin lesion |  |  |  |  |  |
|  | 11401 | Removal of skin lesion |  |  |  |  |  |
|  | 11402 | Removal of skin lesion |  |  |  |  |  |
|  | 11420 | Removal of skin lesion |  |  |  |  |  |
|  | 11421 | Removal of skin lesion |  |  |  |  |  |
|  | 11422 | Removal of skin lesion |  |  |  |  |  |
|  | 11440 | Removal of skin lesion |  |  |  |  |  |
|  | 11441 | Removal of skin lesion |  |  |  |  |  |
|  | 11442 | Removal of skin lesion |  |  |  |  |  |
|  | 11600 | Removal of skin lesion |  |  |  |  |  |
|  | 11601 | Removal of skin lesion |  |  |  |  |  |
|  | 11602 | Removal of skin lesion |  |  |  |  |  |
|  | 11620 | Removal of skin lesion |  |  |  |  |  |
|  | 11621 | Removal of skin lesion |  |  |  |  |  |
|  | 11622 | Removal of skin lesion |  |  |  |  |  |
|  | 11640 | Removal of skin lesion |  |  |  |  |  |
|  | 11641 | Removal of skin lesion |  |  |  |  |  |
|  | 11642 | Removal of skin lesion |  |  |  |  |  |
|  | 11750 | Removal of nail bed |  |  |  |  |  |
|  | 11755 | Biopsy, nail unit |  |  |  |  |  |
|  | 11976 | Removal of contraceptive cap |  |  |  |  |  |
|  | 20220 | Bone biopsy, trocar/needle |  |  |  |  |  |
|  | 20520 | Removal of foreign body |  |  |  |  |  |
|  | 21550 | Biopsy of neck/chest |  |  |  |  |  |
|  | 23330 | Remove shoulder foreign body |  |  |  |  |  |
|  | 24200 | Removal of arm foreign body |  |  |  |  |  |
|  | 27086 | Remove hip foreign body |  |  |  |  |  |
|  | 28190 | Removal of foot foreign body |  |  |  |  |  |
|  | 56605 | Biopsy of vulva/perineum |  |  |  |  |  |
|  | 56606 | Biopsy of vulva/perineum |  |  |  |  |  |
|  | 58999 | Genital surgery procedure |  |  |  |  |  |
|  | 69100 | Biopsy of external ear |  |  |  |  |  |
| 0020 | Level II Excision/Biopsy |  | T | 6.51 | \$315.65 | \$130.53 | \$63.13 |
|  | 10121 | Remove foreign body |  |  |  |  |  |
|  | 11403 | Removal of skin lesion |  |  |  |  |  |

CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
Copyright American Dental Association. All rights reserved.
${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment.
${ }^{2}$ Not subject to national coinsurance.
${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

Addendum C.—Proposed Hospital Outpatient Department (HOPD) Payment for Procedures by APC— Continued

| APC | CPT/ <br> HCPCS | HCPCS Description | Status Indicator | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | 11404 | Removal of skin lesion |  |  |  |  |  |
|  | 11406 | Removal of skin lesion |  |  |  |  |  |
|  | 11423 | Removal of skin lesion |  |  |  |  |  |
|  | 11424 | Removal of skin lesion |  |  |  |  |  |
|  | 11443 | Removal of skin lesion |  |  |  |  |  |
|  | 11444 | Removal of skin lesion |  |  |  |  |  |
|  | 11603 | Removal of skin lesion |  |  |  |  |  |
|  | 11604 | Removal of skin lesion |  |  |  |  |  |
|  | 11623 | Removal of skin lesion |  |  |  |  |  |
|  | 11624 | Removal of skin lesion |  |  |  |  |  |
|  | 11643 | Removal of skin lesion |  |  |  |  |  |
|  | 11644 | Removal of skin lesion |  |  |  |  |  |
|  | 16035 | Incision of burn scab |  |  |  |  |  |
|  | 17304 | Chemosurgery of skin lesion |  |  |  |  |  |
|  | 17305 | 2nd stage chemosurgery |  |  |  |  |  |
|  | 17306 | 3rd stage chemosurgery |  |  |  |  |  |
|  | 17307 | Followup skin lesion therapy |  |  |  |  |  |
|  | 17310 | Extensive skin chemosurgery |  |  |  |  |  |
|  | 20200 | Muscle biopsy |  |  |  |  |  |
|  | 20225 | Bone biopsy, trocar/needle |  |  |  |  |  |
|  | 21920 | Biopsy soft tissue of back |  |  |  |  |  |
|  | 24065 | Biopsy arm/elbow soft tissue |  |  |  |  |  |
|  | 24066 | Biopsy arm/elbow soft tissue |  |  |  |  |  |
|  | 25065 | Biopsy forearm soft tissues |  |  |  |  |  |
|  | 25075 | Removal of forearm lesion |  |  |  |  |  |
|  | 26320 | Removal of implant from hand |  |  |  |  |  |
|  | 27613 | Biopsy lower leg soft tissue |  |  |  |  |  |
|  | 28193 | Removal of foot foreign body |  |  |  |  |  |
|  | 37609 | Temporal artery procedure |  |  |  |  |  |
|  | 37799 | Vascular surgery procedure |  |  |  |  |  |
|  | 54100 | Biopsy of penis |  |  |  |  |  |
|  | 69110 | Remove external ear, partial |  |  |  |  |  |
|  | 69145 | Remove ear canal lesion(s) |  |  |  |  |  |
| 0021 | Level III E | Excision/Biopsy | T | 10.49 | \$508.63 | \$236.51 | \$101.73 |
|  | 11606 | Removal of skin lesion |  |  |  |  |  |
|  | 11770 | Removal of pilonidal lesion |  |  |  |  |  |
|  | 20205 | Deep muscle biopsy |  |  |  |  |  |
|  | 20670 | Removal of support implant |  |  |  |  |  |
|  | 23000 | Removal of calcium deposits |  |  |  |  |  |
|  | 23065 | Biopsy shoulder tissues |  |  |  |  |  |
|  | 23075 | Removal of shoulder lesion |  |  |  |  |  |
|  | 24075 | Remove arm/elbow lesion |  |  |  |  |  |
|  | 24201 | Removal of arm foreign body |  |  |  |  |  |
|  | 27040 | Biopsy of soft tissues |  |  |  |  |  |
|  | 27323 | Biopsy, thigh soft tissues |  |  |  |  |  |
|  | 27618 | Remove lower leg lesion |  |  |  |  |  |
|  | 28043 | Excision of foot lesion |  |  |  |  |  |
|  | 28192 | Removal of foot foreign body |  |  |  |  |  |
|  | 54105 | Biopsy of penis |  |  |  |  |  |
| 0022 | Level IV E | Excision/Biopsy | T | 12.49 | \$605.60 | \$292.94 | \$121.12 |
|  | 11010 | Debride skin, fx |  |  |  |  |  |
|  | 11011 | Debride skin/muscle, fx |  |  |  |  |  |
|  | 11012 | Debride skin/muscle/bone, fx |  |  |  |  |  |
|  | 11426 | Removal of skin lesion |  |  |  |  |  |
|  | 11446 | Removal of skin lesion |  |  |  |  |  |
|  | 11450 | Removal, sweat gland lesion |  |  |  |  |  |
|  | 11451 | Removal, sweat gland lesion |  |  |  |  |  |
|  | 11462 | Removal, sweat gland lesion |  |  |  |  |  |
|  | 11463 | Removal, sweat gland lesion |  |  |  |  |  |
|  | 11470 | Removal, sweat gland lesion |  |  |  |  |  |
|  | 11471 | Removal, sweat gland lesion |  |  |  |  |  |
|  | 11626 | Removal of skin lesion |  |  |  |  |  |
|  | 11646 | Removal of skin lesion |  |  |  |  |  |
|  | 11752 | Remove nail bed/finger tip |  |  |  |  |  |
|  | 11771 | Removal of pilonidal lesion |  |  |  |  |  |
|  | 11772 | Removal of pilonidal lesion |  |  |  |  |  |
|  | 11971 | Remove tissue expander(s) |  |  |  |  |  |
|  | 15780 | Abrasion treatment of skin |  |  |  |  |  |
|  | 15781 | Abrasion treatment of skin |  |  |  |  |  |
|  | 15782 | Abrasion treatment of skin |  |  |  |  |  |
|  | 15811 | Salabrasion |  |  |  |  |  |
|  | 15838 | Excise excessive skin tissue |  |  |  |  |  |
|  | 15920 | Removal of tail bone ulcer |  |  |  |  |  |

CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
Copyright American Dental Association. All rights reserved.
${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment.
${ }^{2}$ Not subject to national coinsurance.
${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

| Addendum C.-Proposed Hospital Outpatient Department (HOPD) Payment for Procedures by APCContinued |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| APC | CPT/ HCPCS | HCPCS Description | Status Indicator | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
|  | 15931 R | Remove sacrum pressure sore |  |  |  |  |  |
|  | 15933 R | Remove sacrum pressure sore |  |  |  |  |  |
|  | 15940 R | Remove hip pressure sore |  |  |  |  |  |
|  | 15941 R | Remove hip pressure sore |  |  |  |  |  |
|  | 15950 R | Remove thigh pressure sore |  |  |  |  |  |
|  | 15951 R | Remove thigh pressure sore |  |  |  |  |  |
|  | 15999 P | Removal of pressure sore |  |  |  |  |  |
|  | 20240 B | Bone biopsy, excisional |  |  |  |  |  |
|  | 20245 B | Bone biopsy, excisional |  |  |  |  |  |
|  | 20525 P | Removal of foreign body |  |  |  |  |  |
|  | 20680 R | Removal of support implant |  |  |  |  |  |
|  | 21555 R | Remove lesion, neck/chest |  |  |  |  |  |
|  | 21556 P | Remove lesion, neck/chest |  |  |  |  |  |
|  | 21925 B | Biopsy soft tissue of back |  |  |  |  |  |
|  | 21930 R | Remove lesion, back or flank |  |  |  |  |  |
|  | 21935 R | Remove tumor, back |  |  |  |  |  |
|  | 22900 R | Remove abdominal wall lesion |  |  |  |  |  |
|  | 22999 A | Abdomen surgery procedure |  |  |  |  |  |
|  | 23066 B | Biopsy shoulder tissues |  |  |  |  |  |
|  | 23076 R | Removal of shoulder lesion |  |  |  |  |  |
|  | 23077 R | Remove tumor of shoulder |  |  |  |  |  |
|  | 23331 R | Remove shoulder foreign body |  |  |  |  |  |
|  | 24076 R | Remove arm/elbow lesion |  |  |  |  |  |
|  | 24077 P | Remove tumor of arm/elbow |  |  |  |  |  |
|  | 25066 B | Biopsy forearm soft tissues |  |  |  |  |  |
|  | 25076 R | Removal of forearm lesion |  |  |  |  |  |
|  | 25077 R | Remove tumor, forearm/wrist |  |  |  |  |  |
|  | 26115 P | Removal of hand lesion |  |  |  |  |  |
|  | 26116 P | Removal of hand lesion |  |  |  |  |  |
|  | 26117 P | Remove tumor, hand/finger |  |  |  |  |  |
|  | $27041$ | Biopsy of soft tissues |  |  |  |  |  |
|  | 27047 P | Remove hip/pelvis lesion |  |  |  |  |  |
|  | 27048 R | Remove hip/pelvis lesion |  |  |  |  |  |
|  | 27049 P | Remove tumor, hip/pelvis |  |  |  |  |  |
|  | 27324 B | Biopsy, thigh soft tissues |  |  |  |  |  |
|  | 27327 R | Removal of thigh lesion |  |  |  |  |  |
|  | 27328 R | Removal of thigh lesion |  |  |  |  |  |
|  | 27329 R | Remove tumor, thigh/knee |  |  |  |  |  |
|  | 27372 P | Removal of foreign body |  |  |  |  |  |
|  | $27614$ | Biopsy lower leg soft tissue |  |  |  |  |  |
|  | $27619$ | Remove lower leg lesion |  |  |  |  |  |
|  | 69205 | Clear outer ear canal |  |  |  |  |  |
| 0023 |  |  | T | 1.98 | \$96.00 | \$40.37 | \$19.20 |
|  | $20100$ | Explore wound, neck |  |  |  |  |  |
|  | 20103 Ex | Explore wound, extremity |  |  |  |  |  |
| 0024 | Level I Skin Repair |  | T | 2.43 | \$117.82 | \$44.50 | \$23.56 |
|  | $11760$ | Repair of nail bed |  |  |  |  |  |
|  | 11762 R | Reconstruction of nail bed |  |  |  |  |  |
|  | 11920 | Correct skin color defects |  |  |  |  |  |
|  | 11921 | Correct skin color defects |  |  |  |  |  |
|  | 11922 C | Correct skin color defects |  |  |  |  |  |
|  | 11950 T | Therapy for contour defects |  |  |  |  |  |
|  | 11951 T | Therapy for contour defects |  |  |  |  |  |
|  | 11952 T | Therapy for contour defects |  |  |  |  |  |
|  | 11954 T | Therapy for contour defects |  |  |  |  |  |
|  | 12001 P | Repair superficial wound(s) |  |  |  |  |  |
|  | 12002 R | Repair superficial wound(s) |  |  |  |  |  |
|  | 12004 P | Repair superficial wound(s) |  |  |  |  |  |
|  | 12005 R | Repair superficial wound(s) |  |  |  |  |  |
|  | 12006 R | Repair superficial wound(s) |  |  |  |  |  |
|  | 12007 R | Repair superficial wound(s) |  |  |  |  |  |
|  | 12011 R | Repair superficial wound(s) |  |  |  |  |  |
|  | 12013 R | Repair superficial wound(s) |  |  |  |  |  |
|  | 12014 P | Repair superficial wound(s) |  |  |  |  |  |
|  | 12015 R | Repair superficial wound(s) |  |  |  |  |  |
|  | 12016 P | Repair superficial wound(s) |  |  |  |  |  |
|  | 12017 R | Repair superficial wound(s) |  |  |  |  |  |
|  | 12018 R | Repair superficial wound(s) |  |  |  |  |  |
|  | 12020 | Closure of split wound |  |  |  |  |  |
|  | 12021 | Closure of split wound |  |  |  |  |  |
|  | 12031 L | Layer closure of wound(s) |  |  |  |  |  |
|  | 12032 L | Layer closure of wound(s) |  |  |  |  |  |
|  | 12034 L | Layer closure of wound(s) |  |  |  |  |  |

CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
Copyright American Dental Association. All rights reserved.
${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment.
${ }^{2}$ Not subject to national coinsurance.
${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

Addendum C.-Proposed Hospital Outpatient Department (HOPD) Payment for Procedures by APCContinued

| APC | CPT/ <br> HCPCS | HCPCS Description | Status Indicator | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | 12035 | Layer closure of wound(s) |  |  |  |  |  |
|  | 12036 | Layer closure of wound(s) |  |  |  |  |  |
|  | 12041 | Layer closure of wound(s) |  |  |  |  |  |
|  | 12042 | Layer closure of wound(s) |  |  |  |  |  |
|  | 12044 | Layer closure of wound(s) |  |  |  |  |  |
|  | 12045 | Layer closure of wound(s) |  |  |  |  |  |
|  | 12046 | Layer closure of wound(s) |  |  |  |  |  |
|  | 12051 | Layer closure of wound(s) |  |  |  |  |  |
|  | 12052 | Layer closure of wound(s) |  |  |  |  |  |
|  | 12053 | Layer closure of wound(s) |  |  |  |  |  |
|  | 12054 | Layer closure of wound(s) |  |  |  |  |  |
|  | 12055 | Layer closure of wound(s) |  |  |  |  |  |
|  | 12056 | Layer closure of wound(s) |  |  |  |  |  |
| 0025 | Level II Skin Repair |  | T | 3.74 | \$181.34 | \$70.66 | \$36.27 |
|  | 13100 | Repair of wound or lesion |  |  |  |  |  |
|  | 13101 | Repair of wound or lesion |  |  |  |  |  |
|  | 13102 | Repair wound/lesion add-on |  |  |  |  |  |
|  | 13120 | Repair of wound or lesion |  |  |  |  |  |
|  | 13121 | Repair of wound or lesion |  |  |  |  |  |
|  | 13122 | Repair wound/lesion add-on |  |  |  |  |  |
|  | 13131 | Repair of wound or lesion |  |  |  |  |  |
|  | 13132 | Repair of wound or lesion |  |  |  |  |  |
|  | 13133 | Repair wound/lesion add-on |  |  |  |  |  |
|  | 13151 | Repair of wound or lesion |  |  |  |  |  |
|  | 13152 | Repair of wound or lesion |  |  |  |  |  |
|  | 13153 | Repair wound/lesion add-on |  |  |  |  |  |
|  | 43870 | Repair stomach opening |  |  |  |  |  |
| 0026 | Level III Skin Repair |  | T | 12.11 | \$587.18 | \$277.92 | \$117.44 |
|  | 11960 | Insert tissue expander(s) |  |  |  |  |  |
|  | 11970 | Replace tissue expander |  |  |  |  |  |
|  | 12037 | Layer closure of wound(s) |  |  |  |  |  |
|  | 12047 | Layer closure of wound(s) |  |  |  |  |  |
|  | 12057 | Layer closure of wound(s) |  |  |  |  |  |
|  | 13150 | Repair of wound or lesion |  |  |  |  |  |
|  | 13160 | Late closure of wound |  |  |  |  |  |
|  | 14000 | Skin tissue rearrangement |  |  |  |  |  |
|  | 14001 | Skin tissue rearrangement |  |  |  |  |  |
|  | 14020 | Skin tissue rearrangement |  |  |  |  |  |
|  | 14021 | Skin tissue rearrangement |  |  |  |  |  |
|  | 14040 | Skin tissue rearrangement |  |  |  |  |  |
|  | 14041 | Skin tissue rearrangement |  |  |  |  |  |
|  | 14060 | Skin tissue rearrangement |  |  |  |  |  |
|  | 14061 | Skin tissue rearrangement |  |  |  |  |  |
|  | 14300 | Skin tissue rearrangement |  |  |  |  |  |
|  | 14350 | Skin tissue rearrangement |  |  |  |  |  |
|  | 15000 | Skin graft |  |  |  |  |  |
|  | 15001 | Skin graft add-on |  |  |  |  |  |
|  | 15050 | Skin pinch graft |  |  |  |  |  |
|  | 15100 | Skin split graft |  |  |  |  |  |
|  | 15101 | Skin split graft add-on |  |  |  |  |  |
|  | 15120 | Skin split graft |  |  |  |  |  |
|  | 15121 | Skin split graft add-on |  |  |  |  |  |
|  | 15200 | Skin full graft |  |  |  |  |  |
|  | 15201 | Skin full graft add-on |  |  |  |  |  |
|  | 15220 | Skin full graft |  |  |  |  |  |
|  | 15221 | Skin full graft add-on |  |  |  |  |  |
|  | 15240 | Skin full graft |  |  |  |  |  |
|  | 15241 | Skin full graft add-on |  |  |  |  |  |
|  | 15260 | Skin full graft |  |  |  |  |  |
|  | 15261 | Skin full graft add-on |  |  |  |  |  |
|  | 15350 | Skin homograft |  |  |  |  |  |
|  | 15351 | Skin homograft add-on |  |  |  |  |  |
|  | 15400 | Skin heterograft |  |  |  |  |  |
|  | 15401 | Skin heterograft add-on |  |  |  |  |  |
|  | 15570 | Form skin pedicle flap |  |  |  |  |  |
|  | 15572 | Form skin pedicle flap |  |  |  |  |  |
|  | 15574 | Form skin pedicle flap |  |  |  |  |  |
|  | 15576 | Form skin pedicle flap |  |  |  |  |  |
|  | 15600 | Skin graft |  |  |  |  |  |
|  | 15610 | Skin graft |  |  |  |  |  |
|  | 15620 | Skin graft |  |  |  |  |  |
|  | 15630 | Skin graft |  |  |  |  |  |
|  | 15650 | Transfer skin pedicle flap |  |  |  |  |  |

CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
Copyright American Dental Association. All rights reserved.
${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment.
${ }^{2}$ Not subject to national coinsurance.
${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

## addendum C.-Proposed Hospital Outpatient Department (HOPD) Payment for Procedures by APCContinued

| APC | CPT/ HCPCS | HCPCS Description | Status Indicator | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | 15775 | Hair transplant punch grafts |  |  |  |  |  |
|  | 15776 | Hair transplant punch grafts |  |  |  |  |  |
|  | 15819 | Plastic surgery, neck |  |  |  |  |  |
|  | 15820 | Revision of lower eyelid |  |  |  |  |  |
|  | 15821 | Revision of lower eyelid |  |  |  |  |  |
|  | 15822 | Revision of upper eyelid |  |  |  |  |  |
|  | 15823 | Revision of upper eyelid |  |  |  |  |  |
|  | 15825 | Removal of neck wrinkles |  |  |  |  |  |
|  | 15829 | Removal of skin wrinkles |  |  |  |  |  |
|  | 15835 | Excise excessive skin tissue |  |  |  |  |  |
|  | 20101 | Explore wound, chest |  |  |  |  |  |
|  | 20102 | Explore wound, abdomen |  |  |  |  |  |
|  | 20910 | Remove cartilage for graft |  |  |  |  |  |
|  | 20912 | Remove cartilage for graft |  |  |  |  |  |
|  | 20920 | Removal of fascia for graft |  |  |  |  |  |
|  | 20922 | Removal of fascia for graft |  |  |  |  |  |
|  | 20926 | Removal of tissue for graft |  |  |  |  |  |
|  | 23921 | Amputation follow-up surgery |  |  |  |  |  |
|  | 25929 | Amputation follow-up surgery |  |  |  |  |  |
|  | 33222 | Revise pocket, pacemaker |  |  |  |  |  |
|  | 33223 | Revise pocket, pacing-defib |  |  |  |  |  |
|  | 44312 | Revision of ileostomy |  |  |  |  |  |
|  | 44340 | Revision of colostomy |  |  |  |  |  |
|  | G0168 | Wound closure by adhesive |  |  |  |  |  |
|  | G0169 | Removal tissue; no anesthsia |  |  |  |  |  |
|  | G0170 | Skin biograft |  |  |  |  |  |
|  | G0171 | Skin biograft add-on |  |  |  |  |  |
| 0027 | Level IV S | Skin Repair | T | 15.80 | \$766.10 | \$383.10 | \$153.22 |
|  | 15732 | Muscle-skin graft, head/neck |  |  |  |  |  |
|  | 15734 | Muscle-skin graft, trunk |  |  |  |  |  |
|  | 15736 | Muscle-skin graft, arm |  |  |  |  |  |
|  | 15738 | Muscle-skin graft, leg |  |  |  |  |  |
|  | 15740 | Island pedicle flap graft |  |  |  |  |  |
|  | 15750 | Neurovascular pedicle graft |  |  |  |  |  |
|  | 15760 | Composite skin graft |  |  |  |  |  |
|  | 15770 | Derma-fat-fascia graft |  |  |  |  |  |
|  | 15824 | Removal of forehead wrinkles |  |  |  |  |  |
|  | 15826 | Removal of brow wrinkles |  |  |  |  |  |
|  | 15828 | Removal of face wrinkles |  |  |  |  |  |
|  | 15831 | Excise excessive skin tissue |  |  |  |  |  |
|  | 15832 | Excise excessive skin tissue |  |  |  |  |  |
|  | 15833 | Excise excessive skin tissue |  |  |  |  |  |
|  | 15834 | Excise excessive skin tissue |  |  |  |  |  |
|  | 15836 | Excise excessive skin tissue |  |  |  |  |  |
|  | 15837 | Excise excessive skin tissue |  |  |  |  |  |
|  | 15839 | Excise excessive skin tissue |  |  |  |  |  |
|  | 15840 | Graft for face nerve palsy |  |  |  |  |  |
|  | 15841 | Graft for face nerve palsy |  |  |  |  |  |
|  | 15842 | Graft for face nerve palsy |  |  |  |  |  |
|  | 15845 | Skin and muscle repair, face |  |  |  |  |  |
|  | 15876 | Suction assisted lipectomy |  |  |  |  |  |
|  | 15877 | Suction assisted lipectomy |  |  |  |  |  |
|  | 15878 | Suction assisted lipectomy |  |  |  |  |  |
|  | 15879 | Suction assisted lipectomy |  |  |  |  |  |
|  | 15922 | Removal of tail bone ulcer |  |  |  |  |  |
|  | 15934 | Remove sacrum pressure sore |  |  |  |  |  |
|  | 15935 | Remove sacrum pressure sore |  |  |  |  |  |
|  | 15936 | Remove sacrum pressure sore |  |  |  |  |  |
|  | 15937 | Remove sacrum pressure sore |  |  |  |  |  |
|  | 15944 | Remove hip pressure sore |  |  |  |  |  |
|  | 15945 | Remove hip pressure sore |  |  |  |  |  |
|  | 15946 | Remove hip pressure sore |  |  |  |  |  |
|  | 15952 | Remove thigh pressure sore |  |  |  |  |  |
|  | 15953 | Remove thigh pressure sore |  |  |  |  |  |
|  | 15956 | Remove thigh pressure sore |  |  |  |  |  |
|  | 15958 | Remove thigh pressure sore |  |  |  |  |  |
| 0029 | Incision/E | Excision Breast | T | 12.85 | \$623.06 | \$303.50 | \$124.61 |
|  | 19101 | Biopsy of breast |  |  |  |  |  |
|  | 19110 | Nipple exploration |  |  |  |  |  |
|  | 19112 | Excise breast duct fistula |  |  |  |  |  |
|  | 19120 | Removal of breast lesion |  |  |  |  |  |
|  | 19125 | Excision, breast lesion |  |  |  |  |  |
|  | 19126 | Excision, addl breast lesion |  |  |  |  |  |

CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
Copyright American Dental Association. All rights reserved.
${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment.
${ }^{2}$ Not subject to national coinsurance.
${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

Addendum C.-Proposed Hospital Outpatient Department (HOPD) Payment for Procedures by APC-

| APC | CPT/ <br> HCPCS | HCPCS Description | Status Indicator | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 0030 | 19140 | Removal of breast tissue |  |  |  |  |  |
|  | 19290 | Place needle wire, breast |  |  |  |  |  |
|  | 19291 | Place needle wire, breast |  |  |  |  |  |
|  | 19396 | Design custom breast implant |  |  |  |  |  |
|  | 19499 | Breast surgery procedure |  |  |  |  |  |
|  | Breast R | econstruction/Mastectomy | T | 20.19 | \$978.95 | \$523.95 | \$195.79 |
|  | 19160 | Removal of breast tissue |  |  |  |  |  |
|  | 19162 | Remove breast tissue, nodes |  |  |  |  |  |
|  | 19180 | Removal of breast |  |  |  |  |  |
|  | 19182 | Removal of breast |  |  |  |  |  |
|  | 19316 | Suspension of breast |  |  |  |  |  |
|  | 19318 | Reduction of large breast |  |  |  |  |  |
|  | 19324 | Enlarge breast |  |  |  |  |  |
|  | 19325 | Enlarge breast with implant |  |  |  |  |  |
|  | 19328 | Removal of breast implant |  |  |  |  |  |
|  | 19330 | Removal of implant material |  |  |  |  |  |
|  | 19340 | Immediate breast prosthesis |  |  |  |  |  |
|  | 19342 | Delayed breast prosthesis |  |  |  |  |  |
|  | 19350 | Breast reconstruction |  |  |  |  |  |
|  | 19355 | Correct inverted nipple(s) |  |  |  |  |  |
|  | 19357 | Breast reconstruction |  |  |  |  |  |
|  | 19366 | Breast reconstruction |  |  |  |  |  |
|  | 19370 | Surgery of breast capsule |  |  |  |  |  |
|  | 19371 | Removal of breast capsule |  |  |  |  |  |
|  | 19380 | Revise breast reconstruction |  |  |  |  |  |
| 0031 | Hyperbari | ic Oxygen | S | 3.00 | \$145.46 | \$140.85 | \$29.09 |
|  | 99183 | Hyperbaric oxygen therapy |  |  |  |  |  |
|  | G0167 | Hyperbaric oz tx; no md reqrd |  |  |  |  |  |
| 0032 | Placemen | nt Transvenous Catheters/Arterial Cutdown | T | 5.40 | \$261.83 | \$119.52 | \$52.37 |
|  | 36420 | Establish access to vein |  |  |  |  |  |
|  | 36425 | Establish access to vein |  |  |  |  |  |
|  | 36488 | Insertion of catheter, vein |  |  |  |  |  |
|  | 36489 | Insertion of catheter, vein |  |  |  |  |  |
|  | 36490 | Insertion of catheter, vein |  |  |  |  |  |
|  | 36491 | Insertion of catheter, vein |  |  |  |  |  |
|  | 36493 | Repositioning of cvc |  |  |  |  |  |
|  | 36640 | Insertion catheter, artery |  |  |  |  |  |
| 0033 |  | ospitalization | P | 4.17 | \$202.19 | \$48.17 | \$40.44 |
|  | G0129 | Partial hosp prog service |  |  |  |  |  |
|  | G0172 | Partial hosp prog service |  |  |  |  |  |
|  | Q0082 | Activity therapy w/partial h |  |  |  |  |  |
| 0040 | Arthrocen | htesis \& Ligament/Tendon Injection | T | 2.11 | \$102.31 | \$40.60 | \$20.46 |
|  | 20550 | Inject tendon/ligament/cyst |  |  |  |  |  |
|  | 20600 | Drain/inject, joint/bursa |  |  |  |  |  |
|  | 20605 | Drain/inject, joint/bursa |  |  |  |  |  |
|  | 20610 | Drain/inject, joint/bursa |  |  |  |  |  |
| 0041 | Arthroscopy |  | T | 24.57 | \$1,191.33 | \$592.08 | \$238.27 |
|  | 29800 | Jaw arthroscopy/surgery |  |  |  |  |  |
|  | 29804 | Jaw arthroscopy/surgery |  |  |  |  |  |
|  | 29815 | Shoulder arthroscopy |  |  |  |  |  |
|  | 29819 | Shoulder arthroscopy/surgery |  |  |  |  |  |
|  | 29820 | Shoulder arthroscopy/surgery |  |  |  |  |  |
|  | 29821 | Shoulder arthroscopy/surgery |  |  |  |  |  |
|  | 29822 | Shoulder arthroscopy/surgery |  |  |  |  |  |
|  | 29823 | Shoulder arthroscopy/surgery |  |  |  |  |  |
|  | 29825 | Shoulder arthroscopy/surgery |  |  |  |  |  |
|  | 29826 | Shoulder arthroscopy/surgery |  |  |  |  |  |
|  | 29830 | Elbow arthroscopy |  |  |  |  |  |
|  | 29834 | Elbow arthroscopy/surgery |  |  |  |  |  |
|  | 29835 | Elbow arthroscopy/surgery |  |  |  |  |  |
|  | 29836 | Elbow arthroscopy/surgery |  |  |  |  |  |
|  | 29837 | Elbow arthroscopy/surgery |  |  |  |  |  |
|  | 29838 | Elbow arthroscopy/surgery |  |  |  |  |  |
|  | 29840 | Wrist arthroscopy |  |  |  |  |  |
|  | 29843 | Wrist arthroscopy/surgery |  |  |  |  |  |
|  | 29844 | Wrist arthroscopy/surgery |  |  |  |  |  |
|  | 29845 | Wrist arthroscopy/surgery |  |  |  |  |  |
|  | 29846 | Wrist arthroscopy/surgery |  |  |  |  |  |
|  | 29847 | Wrist arthroscopy/surgery |  |  |  |  |  |
|  | 29848 | Wrist endoscopy/surgery |  |  |  |  |  |
|  | 29860 | Hip arthroscopy, dx |  |  |  |  |  |
|  | 29861 | Hip arthroscopy/surgery |  |  |  |  |  |
|  | 29862 | Hip arthroscopy/surgery |  |  |  |  |  |

CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
Copyright American Dental Association. All rights reserved.
${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment
${ }^{2}$ Not subject to national coinsurance.
${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

Addendum C.-Proposed Hospital Outpatient Department (hoPd) Payment for Procedures by APCContinued

| APC | CPT/ <br> HCPCS | HCPCS Description | Status Indicator | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | 29863 | Hip arthroscopy/surgery |  |  |  |  |  |
|  | 29870 | Knee arthroscopy, dx |  |  |  |  |  |
|  | 29871 | Knee arthroscopy/drainage |  |  |  |  |  |
|  | 29874 | Knee arthroscopy/surgery |  |  |  |  |  |
|  | 29875 | Knee arthroscopy/surgery |  |  |  |  |  |
|  | 29876 | Knee arthroscopy/surgery |  |  |  |  |  |
|  | 29877 | Knee arthroscopy/surgery |  |  |  |  |  |
|  | 29879 | Knee arthroscopy/surgery |  |  |  |  |  |
|  | 29880 | Knee arthroscopy/surgery |  |  |  |  |  |
|  | 29881 | Knee arthroscopy/surgery |  |  |  |  |  |
|  | 29882 | Knee arthroscopy/surgery |  |  |  |  |  |
|  | 29883 | Knee arthroscopy/surgery |  |  |  |  |  |
|  | 29884 | Knee arthroscopy/surgery |  |  |  |  |  |
|  | 29886 | Knee arthroscopy/surgery |  |  |  |  |  |
|  | 29887 | Knee arthroscopy/surgery |  |  |  |  |  |
|  | 29891 | Ankle arthroscopy/surgery |  |  |  |  |  |
|  | 29894 | Ankle arthroscopy/surgery |  |  |  |  |  |
|  | 29895 | Ankle arthroscopy/surgery |  |  |  |  |  |
|  | 29897 | Ankle arthroscopy/surgery |  |  |  |  |  |
|  | 29898 | Ankle arthroscopy/surgery |  |  |  |  |  |
|  | 29909 | Arthroscopy of joint |  |  |  |  |  |
| 0042 | Arthrosco | pically-Aided Procedures | T | 29.22 | \$1,416.79 | \$804.74 | \$283.36 |
|  | 29850 | Knee arthroscopy/surgery |  |  |  |  |  |
|  | 29851 | Knee arthroscopy/surgery |  |  |  |  |  |
|  | 29855 | Tibial arthroscopy/surgery |  |  |  |  |  |
|  | 29856 | Tibial arthroscopy/surgery |  |  |  |  |  |
|  | 29885 | Knee arthroscopy/surgery |  |  |  |  |  |
|  | 29888 | Knee arthroscopy/surgery |  |  |  |  |  |
|  | 29889 | Knee arthroscopy/surgery |  |  |  |  |  |
|  | 29892 | Ankle arthroscopy/surgery |  |  |  |  |  |
| 0043 | Closed Tr | reatment Fracture Finger/Toe/Trunk | T | 1.64 | \$79.52 | \$25.46 | \$15.90 |
|  | 21800 | Treatment of rib fracture |  |  |  |  |  |
|  | 21820 | Treat sternum fracture |  |  |  |  |  |
|  | 22305 | Treat spine process fracture |  |  |  |  |  |
|  | 22310 | Treat spine fracture |  |  |  |  |  |
|  | 22315 | Treat spine fracture |  |  |  |  |  |
|  | 22899 | Spine surgery procedure |  |  |  |  |  |
|  | 23500 | Treat clavicle fracture |  |  |  |  |  |
|  | 23505 | Treat clavicle fracture |  |  |  |  |  |
|  | 23520 | Treat clavicle dislocation |  |  |  |  |  |
|  | 23525 | Treat clavicle dislocation |  |  |  |  |  |
|  | 23540 | Treat clavicle dislocation |  |  |  |  |  |
|  | 23545 | Treat clavicle dislocation |  |  |  |  |  |
|  | 23570 | Treat shoulder blade fx |  |  |  |  |  |
|  | 23575 | Treat shoulder blade fx |  |  |  |  |  |
|  | 23650 | Treat shoulder dislocation |  |  |  |  |  |
|  | 23929 | Shoulder surgery procedure |  |  |  |  |  |
|  | 26700 | Treat knuckle dislocation |  |  |  |  |  |
|  | 26720 | Treat finger fracture, each |  |  |  |  |  |
|  | 26725 | Treat finger fracture, each |  |  |  |  |  |
|  | 26740 | Treat finger fracture, each |  |  |  |  |  |
|  | 26750 | Treat finger fracture, each |  |  |  |  |  |
|  | 26755 | Treat finger fracture, each |  |  |  |  |  |
|  | 26770 | Treat finger dislocation |  |  |  |  |  |
|  | 26989 | Hand/finger surgery |  |  |  |  |  |
|  | 27200 | Treat tail bone fracture |  |  |  |  |  |
|  | 27299 | Pelvis/hip joint surgery |  |  |  |  |  |
|  | 28490 | Treat big toe fracture |  |  |  |  |  |
|  | 28495 | Treat big toe fracture |  |  |  |  |  |
|  | 28510 | Treatment of toe fracture |  |  |  |  |  |
|  | 28515 | Treatment of toe fracture |  |  |  |  |  |
|  | 28630 | Treat toe dislocation |  |  |  |  |  |
|  | 28660 | Treat toe dislocation |  |  |  |  |  |
|  | 28899 | Foot/toes surgery procedure |  |  |  |  |  |
| 0044 | Closed Tr | reatment Fracture/Dislocation Except Finger/Toe/Trunk | T | 2.17 | \$105.22 | \$38.08 | \$21.04 |
|  | 23600 | Treat humerus fracture |  |  |  |  |  |
|  | 23605 | Treat humerus fracture |  |  |  |  |  |
|  | 23620 | Treat humerus fracture |  |  |  |  |  |
|  | 23625 | Treat humerus fracture |  |  |  |  |  |
|  | 23665 | Treat dislocation/fracture |  |  |  |  |  |
|  | 23675 | Treat dislocation/fracture |  |  |  |  |  |
|  | 24500 | Treat humerus fracture |  |  |  |  |  |
|  | 24505 | Treat humerus fracture |  |  |  |  |  |

CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
Copyright American Dental Association. All rights reserved.
${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment.
${ }^{2}$ Not subject to national coinsurance.
${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.


[^250]Copyright American Dental Association. All rights reserved.
${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment.
${ }^{2}$ Not subject to national coinsurance.
${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

Addendum C.-Proposed Hospital Outpatient Department (hopd) Payment for Procedures by apc-
Continued

| APC | CPT/ HCPCS | HCPCS Description | Status Indicator | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | 27810 | Treatment of ankle fracture |  |  |  |  |  |
|  | 27816 | Treatment of ankle fracture |  |  |  |  |  |
|  | 27818 | Treatment of ankle fracture |  |  |  |  |  |
|  | 27824 | Treat lower leg fracture |  |  |  |  |  |
|  | 27825 | Treat lower leg fracture |  |  |  |  |  |
|  | 27830 | Treat lower leg dislocation |  |  |  |  |  |
|  | 27840 | Treat ankle dislocation |  |  |  |  |  |
|  | 27899 | Leg/ankle surgery procedure |  |  |  |  |  |
|  | 28400 | Treatment of heel fracture |  |  |  |  |  |
|  | 28405 | Treatment of heel fracture |  |  |  |  |  |
|  | 28430 | Treatment of ankle fracture |  |  |  |  |  |
|  | 28435 | Treatment of ankle fracture |  |  |  |  |  |
|  | 28450 | Treat midfoot fracture, each |  |  |  |  |  |
|  | 28455 | Treat midfoot fracture, each |  |  |  |  |  |
|  | 28470 | Treat metatarsal fracture |  |  |  |  |  |
|  | 28475 | Treat metatarsal fracture |  |  |  |  |  |
|  | 28530 | Treat sesamoid bone fracture |  |  |  |  |  |
|  | 28540 | Treat foot dislocation |  |  |  |  |  |
|  | 28570 | Treat foot dislocation |  |  |  |  |  |
|  | 28600 | Treat foot dislocation |  |  |  |  |  |
| 0045 | Bone/Joint | t Manipulation Under Anesthesia | T | 11.02 | \$534.33 | \$277.12 | \$106.87 |
|  | 22505 | Manipulation of spine |  |  |  |  |  |
|  | 23655 | Treat shoulder dislocation |  |  |  |  |  |
|  | 23700 Fir | Fixation of shoulder |  |  |  |  |  |
|  | 24605 | Treat elbow dislocation |  |  |  |  |  |
|  | 26675 | Treat hand dislocation |  |  |  |  |  |
|  | 26705 | Treat knuckle dislocation |  |  |  |  |  |
|  | 26775 | Treat finger dislocation |  |  |  |  |  |
|  | 27194 | Treat pelvic ring fracture |  |  |  |  |  |
|  | 27252 | Treat hip dislocation |  |  |  |  |  |
|  | 27257 | Treat hip dislocation |  |  |  |  |  |
|  | 27275 | Manipulation of hip joint |  |  |  |  |  |
|  | 27552 | Treat knee dislocation |  |  |  |  |  |
|  | 27562 | Treat kneecap dislocation |  |  |  |  |  |
|  | 27570 | Fixation of knee joint |  |  |  |  |  |
|  | 27831 | Treat lower leg dislocation |  |  |  |  |  |
|  | 27842 | Treat ankle dislocation |  |  |  |  |  |
|  | 27860 | Fixation of ankle joint |  |  |  |  |  |
|  | 28545 | Treat foot dislocation |  |  |  |  |  |
|  | 28575 | Treat foot dislocation |  |  |  |  |  |
|  | 28605 | Treat foot dislocation |  |  |  |  |  |
|  | 28635 | Treat toe dislocation |  |  |  |  |  |
|  | 28665 | Treat toe dislocation |  |  |  |  |  |
| 0046 | Open/Perc | cutaneous Treatment Fracture or Dislocation | T | 22.29 | \$1,080.78 | \$535.76 | \$216.16 |
|  | 21336 | Treat nasal septal fracture |  |  |  |  |  |
|  | 21805 | Treatment of rib fracture |  |  |  |  |  |
|  | 23515 | Treat clavicle fracture |  |  |  |  |  |
|  | 23530 | Treat clavicle dislocation |  |  |  |  |  |
|  | 23532 | Treat clavicle dislocation |  |  |  |  |  |
|  | 23550 | Treat clavicle dislocation |  |  |  |  |  |
|  | 23552 | Treat clavicle dislocation |  |  |  |  |  |
|  | 23585 | Treat scapula fracture |  |  |  |  |  |
|  | 23615 | Treat humerus fracture |  |  |  |  |  |
|  | 23616 | Treat humerus fracture |  |  |  |  |  |
|  | 23630 | Treat humerus fracture |  |  |  |  |  |
|  | 23660 | Treat shoulder dislocation |  |  |  |  |  |
|  | 23670 | Treat dislocation/fracture |  |  |  |  |  |
|  | 23680 | Treat dislocation/fracture |  |  |  |  |  |
|  | 24515 | Treat humerus fracture |  |  |  |  |  |
|  | 24516 | Treat humerus fracture |  |  |  |  |  |
|  | 24538 | Treat humerus fracture |  |  |  |  |  |
|  | 24545 | Treat humerus fracture |  |  |  |  |  |
|  | 24546 | Treat humerus fracture |  |  |  |  |  |
|  | 24566 | Treat humerus fracture |  |  |  |  |  |
|  | 24575 | Treat humerus fracture |  |  |  |  |  |
|  | 24579 | Treat humerus fracture |  |  |  |  |  |
|  | 24582 | Treat humerus fracture |  |  |  |  |  |
|  | 24586 | Treat elbow fracture |  |  |  |  |  |
|  | 24587 | Treat elbow fracture |  |  |  |  |  |
|  | 24615 | Treat elbow dislocation |  |  |  |  |  |
|  | 24635 | Treat elbow fracture |  |  |  |  |  |
|  | 24665 | Treat radius fracture |  |  |  |  |  |
|  | 24666 | Treat radius fracture |  |  |  |  |  |

CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
Copyright American Dental Association. All rights reserved.
${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment.
${ }^{2}$ Not subject to national coinsurance.
${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

|  |  | C.-PRROPOSED Hospital OUTPatient | DEPARTMENT <br> Continued | PAYMEN | For Procedures by APC |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| APC | CPT/ HCPCS | HCPCS Description | Status Indicator | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
|  | 24685 | Treat ulnar fracture |  |  |  |  |  |
|  | 25515 | Treat fracture of radius |  |  |  |  |  |
|  | 25525 | Treat fracture of radius |  |  |  |  |  |
|  | 25526 | Treat fracture of radius |  |  |  |  |  |
|  | 25545 | Treat fracture of ulna |  |  |  |  |  |
|  | 25574 | Treat fracture radius \& ulna |  |  |  |  |  |
|  | 25575 | Treat fracture radius/ulna |  |  |  |  |  |
|  | 25611 | Treat fracture radius/ulna |  |  |  |  |  |
|  | 25620 | Treat fracture radius/ulna |  |  |  |  |  |
|  | 25628 | Treat wrist bone fracture |  |  |  |  |  |
|  | 25645 | Treat wrist bone fracture |  |  |  |  |  |
|  | 25670 | Treat wrist dislocation |  |  |  |  |  |
|  | 25676 | Treat wrist dislocation |  |  |  |  |  |
|  | 25685 | Treat wrist fracture |  |  |  |  |  |
|  | 25695 | Treat wrist dislocation |  |  |  |  |  |
|  | 26608 | Treat metacarpal fracture |  |  |  |  |  |
|  | 26615 | Treat metacarpal fracture |  |  |  |  |  |
|  | 26650 | Treat thumb fracture |  |  |  |  |  |
|  | 26665 | Treat thumb fracture |  |  |  |  |  |
|  | 26676 | Pin hand dislocation |  |  |  |  |  |
|  | 26685 | Treat hand dislocation |  |  |  |  |  |
|  | 26686 | Treat hand dislocation |  |  |  |  |  |
|  | 26715 | Treat knuckle dislocation |  |  |  |  |  |
|  | 26727 | Treat finger fracture, each |  |  |  |  |  |
|  | 26735 | Treat finger fracture, each |  |  |  |  |  |
|  | 26746 | Treat finger fracture, each |  |  |  |  |  |
|  | 26756 | Pin finger fracture, each |  |  |  |  |  |
|  | 26765 | Treat finger fracture, each |  |  |  |  |  |
|  | 26776 | Pin finger dislocation |  |  |  |  |  |
|  | 26785 | Treat finger dislocation |  |  |  |  |  |
|  | 27202 | Treat tail bone fracture |  |  |  |  |  |
|  | 27509 | Treatment of thigh fracture |  |  |  |  |  |
|  | 27556 | Treat knee dislocation |  |  |  |  |  |
|  | 27566 | Treat kneecap dislocation |  |  |  |  |  |
|  | 27615 | Remove tumor, lower leg |  |  |  |  |  |
|  | 27756 | Treatment of tibia fracture |  |  |  |  |  |
|  | 27758 | Treatment of tibia fracture |  |  |  |  |  |
|  | 27759 | Treatment of tibia fracture |  |  |  |  |  |
|  | 27766 | Treatment of ankle fracture |  |  |  |  |  |
|  | 27784 | Treatment of fibula fracture |  |  |  |  |  |
|  | 27792 | Treatment of ankle fracture |  |  |  |  |  |
|  | 27814 | Treatment of ankle fracture |  |  |  |  |  |
|  | 27822 | Treatment of ankle fracture |  |  |  |  |  |
|  | 27823 | Treatment of ankle fracture |  |  |  |  |  |
|  | 27826 | Treat lower leg fracture |  |  |  |  |  |
|  | 27827 | Treat lower leg fracture |  |  |  |  |  |
|  | 27828 | Treat lower leg fracture |  |  |  |  |  |
|  | 27829 | Treat lower leg joint |  |  |  |  |  |
|  | 27832 | Treat lower leg dislocation |  |  |  |  |  |
|  | 27846 | Treat ankle dislocation |  |  |  |  |  |
|  | 27848 | Treat ankle dislocation |  |  |  |  |  |
|  | 28406 | Treatment of heel fracture |  |  |  |  |  |
|  | 28415 | Treat heel fracture |  |  |  |  |  |
|  | 28420 | Treat/graft heel fracture |  |  |  |  |  |
|  | 28436 | Treatment of ankle fracture |  |  |  |  |  |
|  | 28445 | Treat ankle fracture |  |  |  |  |  |
|  | 28456 | Treat midfoot fracture |  |  |  |  |  |
|  | 28465 | Treat midfoot fracture, each |  |  |  |  |  |
|  | 28476 | Treat metatarsal fracture |  |  |  |  |  |
|  | 28485 | Treat metatarsal fracture |  |  |  |  |  |
|  | 28496 | Treat big toe fracture |  |  |  |  |  |
|  | 28505 | Treat big toe fracture |  |  |  |  |  |
|  | 28525 | Treat toe fracture |  |  |  |  |  |
|  | 28531 | Treat sesamoid bone fracture |  |  |  |  |  |
|  | 28546 | Treat foot dislocation |  |  |  |  |  |
|  | 28555 | Repair foot dislocation |  |  |  |  |  |
|  | 28576 | Treat foot dislocation |  |  |  |  |  |
|  | 28585 | Repair foot dislocation |  |  |  |  |  |
|  | 28606 | Treat foot dislocation |  |  |  |  |  |
|  | 28615 | Repair foot dislocation |  |  |  |  |  |
|  | 28636 | Treat toe dislocation |  |  |  |  |  |
|  | 28645 | Repair toe dislocation |  |  |  |  |  |
|  | 28666 | Treat toe dislocation |  |  |  |  |  |

CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
Copyright American Dental Association. All rights reserved.
${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment.
${ }^{2}$ Not subject to national coinsurance.
${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.


CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
Copyright American Dental Association. All rights reserved.
${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment.
${ }^{2}$ Not subject to national coinsurance.
${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.


[^251]Copyright American Dental Association. All rights reserved.
${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment
${ }^{2}$ Not subject to national coinsurance.
${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

| ADDENDUM |  | C.-Proposed Hospital Outpa | DEPARTMEN Continued | PAYMEN | FOR PR | EDURES B | APC |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| APC | CPT/ HCPCS | HCPCS Description | Status Indicator | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
|  | 24130 | Removal of head of radius |  |  |  |  |  |
|  | 24134 | Removal of arm bone lesion |  |  |  |  |  |
|  | 24136 | Remove radius bone lesion |  |  |  |  |  |
|  | 24138 | Remove elbow bone lesion |  |  |  |  |  |
|  | $24140$ | Partial removal of arm bone |  |  |  |  |  |
|  | 24145 | Partial removal of radius |  |  |  |  |  |
|  | 24147 | Partial removal of elbow |  |  |  |  |  |
|  | 24160 | Remove elbow joint implant |  |  |  |  |  |
|  | $24164$ | Remove radius head implant |  |  |  |  |  |
|  | 24301 | Muscle/tendon transfer |  |  |  |  |  |
|  | 24305 | Arm tendon lengthening |  |  |  |  |  |
|  | 24350 | Repair of tennis elbow |  |  |  |  |  |
|  | 24351 | Repair of tennis elbow |  |  |  |  |  |
|  | 24352 | Repair of tennis elbow |  |  |  |  |  |
|  | 24354 | Repair of tennis elbow |  |  |  |  |  |
|  | $24356$ | Revision of tennis elbow |  |  |  |  |  |
|  | 24400 | Revision of humerus |  |  |  |  |  |
|  | 24410 | Revision of humerus |  |  |  |  |  |
|  | 24495 | Decompression of forearm |  |  |  |  |  |
|  | 25023 | Decompression of forearm |  |  |  |  |  |
|  | 25040 | Explore/treat wrist joint |  |  |  |  |  |
|  | 25101 | Explore/treat wrist joint |  |  |  |  |  |
|  | 25105 | Remove wrist joint lining |  |  |  |  |  |
|  | 25107 | Remove wrist joint cartilage |  |  |  |  |  |
|  | 25118 | Excise wrist tendon sheath |  |  |  |  |  |
|  | 25119 | Partial removal of ulna |  |  |  |  |  |
|  | 25120 | Removal of forearm lesion |  |  |  |  |  |
|  | 25125 | Remove/graft forearm lesion |  |  |  |  |  |
|  | 25126 | Remove/graft forearm lesion |  |  |  |  |  |
|  | 25130 | Removal of wrist lesion |  |  |  |  |  |
|  | 25135 | Remove \& graft wrist lesion |  |  |  |  |  |
|  | 25136 | Remove \& graft wrist lesion |  |  |  |  |  |
|  | 25145 | Remove forearm bone lesion |  |  |  |  |  |
|  | 25150 | Partial removal of ulna |  |  |  |  |  |
|  | 25151 | Partial removal of radius |  |  |  |  |  |
|  | 25230 | Partial removal of radius |  |  |  |  |  |
|  | 25240 | Partial removal of ulna |  |  |  |  |  |
|  | 25250 | Removal of wrist prosthesis |  |  |  |  |  |
|  | 25251 | Removal of wrist prosthesis |  |  |  |  |  |
|  | 25260 | Repair forearm tendon/muscle |  |  |  |  |  |
|  | 25263 | Repair forearm tendon/muscle |  |  |  |  |  |
|  | 25265 | Repair forearm tendon/muscle |  |  |  |  |  |
|  | 25270 | Repair forearm tendon/muscle |  |  |  |  |  |
|  | 25272 | Repair forearm tendon/muscle |  |  |  |  |  |
|  | 25274 | Repair forearm tendon/muscle |  |  |  |  |  |
|  | 25280 | Revise wrist/forearm tendon |  |  |  |  |  |
|  | 25290 | Incise wrist/forearm tendon |  |  |  |  |  |
|  | 25300 | Fusion of tendons at wrist |  |  |  |  |  |
|  | 25301 | Fusion of tendons at wrist |  |  |  |  |  |
|  | 25360 | Revision of ulna |  |  |  |  |  |
|  | 25365 | Revise radius \& ulna |  |  |  |  |  |
|  | 25400 | Repair radius or ulna |  |  |  |  |  |
|  | 25415 | Repair radius \& ulna |  |  |  |  |  |
|  | 27001 | Incision of hip tendon |  |  |  |  |  |
|  | 27003 | Incision of hip tendon |  |  |  |  |  |
|  | 27066 | Removal of hip bone lesion |  |  |  |  |  |
|  | 27067 | Remove/graft hip bone lesion |  |  |  |  |  |
|  | 27080 | Removal of tail bone |  |  |  |  |  |
|  | 27097 | Revision of hip tendon |  |  |  |  |  |
|  | 27098 | Transfer tendon to pelvis |  |  |  |  |  |
|  | 27310 |  |  |  |  |  |  |
|  | 27330 | Biopsy, knee joint lining |  |  |  |  |  |
|  | 27331 | Explore/treat knee joint |  |  |  |  |  |
|  | 27332 | Removal of knee cartilage |  |  |  |  |  |
|  | 27333 | Removal of knee cartilage |  |  |  |  |  |
|  | 27334 | Remove knee joint lining |  |  |  |  |  |
|  | 27335 | Remove knee joint lining |  |  |  |  |  |
|  | 27350 | Removal of kneecap |  |  |  |  |  |
|  | 27355 | Remove femur lesion |  |  |  |  |  |
|  | 27356 | Remove femur lesion/graft |  |  |  |  |  |
|  | 27357 | Remove femur lesion/graft |  |  |  |  |  |
|  | 27358 | Remove femur lesion/fixation |  |  |  |  |  |
|  | 27360 | Partial removal, leg bone(s) |  |  |  |  |  |

CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
Copyright American Dental Association. All rights reserved.
${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment.
${ }^{2}$ Not subject to national coinsurance.
${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.


CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
Copyright American Dental Association. All rights reserved.
${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment
${ }^{2}$ Not subject to national coinsurance.
${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

Addendum C.-Proposed Hospital Outpatient Department (HOPD) Payment for Procedures by APC-

| APC | CPT/ <br> HCPCS | HCPCS Description | Status Indicator | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | 25491 | Reinforce ulna |  |  |  |  |  |
|  | 25492 | Reinforce radius and ulna |  |  |  |  |  |
|  | 25800 | Fusion of wrist joint |  |  |  |  |  |
|  | 25805 | Fusion/graft of wrist joint |  |  |  |  |  |
|  | 25810 | Fusion/graft of wrist joint |  |  |  |  |  |
|  | 25830 | Fusion, radioulnar jnt/ulna |  |  |  |  |  |
|  | 27033 | Exploration of hip joint |  |  |  |  |  |
|  | 27100 | Transfer of abdominal muscle |  |  |  |  |  |
|  | 27105 | Transfer of spinal muscle |  |  |  |  |  |
|  | 27110 | Transfer of iliopsoas muscle |  |  |  |  |  |
|  | 27111 | Transfer of iliopsoas muscle |  |  |  |  |  |
|  | 27395 | Lengthening of thigh tendons |  |  |  |  |  |
|  | 27397 | Transplants of thigh tendons |  |  |  |  |  |
|  | 27400 | Revise thigh muscles/tendons |  |  |  |  |  |
|  | 27405 | Repair of knee ligament |  |  |  |  |  |
|  | 27407 | Repair of knee ligament |  |  |  |  |  |
|  | 27409 | Repair of knee ligaments |  |  |  |  |  |
|  | 27418 | Repair degenerated kneecap |  |  |  |  |  |
|  | 27420 | Revision of unstable kneecap |  |  |  |  |  |
|  | 27422 | Revision of unstable kneecap |  |  |  |  |  |
|  | 27424 | Revision/removal of kneecap |  |  |  |  |  |
|  | 27430 | Revision of thigh muscles |  |  |  |  |  |
|  | 27435 | Incision of knee joint |  |  |  |  |  |
|  | 27640 | Partial removal of tibia |  |  |  |  |  |
|  | 27647 | Extensive ankle/heel surgery |  |  |  |  |  |
|  | 27650 | Repair achilles tendon |  |  |  |  |  |
|  | 27652 | Repair/graft achilles tendon |  |  |  |  |  |
|  | 27654 | Repair of achilles tendon |  |  |  |  |  |
|  | 27690 | Revise lower leg tendon |  |  |  |  |  |
|  | 27691 | Revise lower leg tendon |  |  |  |  |  |
|  | 27692 | Revise additional leg tendon |  |  |  |  |  |
|  | 27705 | Incision of tibia |  |  |  |  |  |
|  | 27742 | Repair of leg epiphyses |  |  |  |  |  |
|  | 27745 | Reinforce tibia |  |  |  |  |  |
|  | 27870 | Fusion of ankle joint |  |  |  |  |  |
|  | 27871 | Fusion of tibiofibular joint |  |  |  |  |  |
| 0052 | Level IV M | Musculoskeletal Procedures Except Hand and Foot | T | 36.16 | \$1,753.29 | \$930.91 | \$350.66 |
|  | 23410 | Repair of tendon(s) |  |  |  |  |  |
|  | 23412 | Repair of tendon(s) |  |  |  |  |  |
|  | 23420 | Repair of shoulder |  |  |  |  |  |
|  | 23430 | Repair biceps tendon |  |  |  |  |  |
|  | 23450 | Repair shoulder capsule |  |  |  |  |  |
|  | 23455 | Repair shoulder capsule |  |  |  |  |  |
|  | 23460 | Repair shoulder capsule |  |  |  |  |  |
|  | 23462 | Repair shoulder capsule |  |  |  |  |  |
|  | 23465 | Repair shoulder capsule |  |  |  |  |  |
|  | 23466 | Repair shoulder capsule |  |  |  |  |  |
|  | 24935 | Revision of amputation |  |  |  |  |  |
|  | 27427 | Reconstruction, knee |  |  |  |  |  |
|  | 27428 | Reconstruction, knee |  |  |  |  |  |
|  | 27429 | Reconstruction, knee |  |  |  |  |  |
| 0053 | Level I Ha | and Musculoskeletal Procedures | T | 11.32 | \$548.87 | \$253.49 | \$109.77 |
|  | 25111 | Remove wrist tendon lesion |  |  |  |  |  |
|  | 25112 | Reremove wrist tendon lesion |  |  |  |  |  |
|  | 25820 | Fusion of hand bones |  |  |  |  |  |
|  | 26020 | Drain hand tendon sheath |  |  |  |  |  |
|  | 26025 | Drainage of palm bursa |  |  |  |  |  |
|  | 26030 | Drainage of palm bursa(s) |  |  |  |  |  |
|  | 26034 | Treat hand bone lesion |  |  |  |  |  |
|  | 26035 | Decompress fingers/hand |  |  |  |  |  |
|  | 26037 | Decompress fingers/hand |  |  |  |  |  |
|  | 26055 | Incise finger tendon sheath |  |  |  |  |  |
|  | 26060 | Incision of finger tendon |  |  |  |  |  |
|  | 26070 | Explore/treat hand joint |  |  |  |  |  |
|  | 26075 | Explore/treat finger joint |  |  |  |  |  |
|  | 26080 | Explore/treat finger joint |  |  |  |  |  |
|  | 26100 | Biopsy hand joint lining |  |  |  |  |  |
|  | 26105 | Biopsy finger joint lining |  |  |  |  |  |
|  | 26110 | Biopsy finger joint lining |  |  |  |  |  |
|  | 26130 | Remove wrist joint lining |  |  |  |  |  |
|  | 26140 | Revise finger joint, each |  |  |  |  |  |
|  | 26145 | Tendon excision, palm/finger |  |  |  |  |  |
|  | 26160 | Remove tendon sheath lesion |  |  |  |  |  |

CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
Copyright American Dental Association. All rights reserved.
${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment.
${ }^{2}$ Not subject to national coinsurance.
${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.


CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
Copyright American Dental Association. All rights reserved.
${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment.
${ }^{2}$ Not subject to national coinsurance.
${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

Addendum C.-Proposed Hospital Outpatient Department (HOPD) Payment for Procedures by APC-
Continued

| APC | CPT/ HCPCS | HCPCS Description | Status Indicator | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | 26485 | Transplant palm tendon |  |  |  |  |  |
|  | 26489 | Transplant/graft palm tendon |  |  |  |  |  |
|  | 26490 | Revise thumb tendon |  |  |  |  |  |
|  | 26492 | Tendon transfer with graft |  |  |  |  |  |
|  | 26494 | Hand tendon/muscle transfer |  |  |  |  |  |
|  | 26496 | Revise thumb tendon |  |  |  |  |  |
|  | 26497 | Finger tendon transfer |  |  |  |  |  |
|  | 26498 | Finger tendon transfer |  |  |  |  |  |
|  | 26499 | Revision of finger |  |  |  |  |  |
|  | 26502 | Hand tendon reconstruction |  |  |  |  |  |
|  | 26504 | Hand tendon reconstruction |  |  |  |  |  |
|  | 26510 | Thumb tendon transfer |  |  |  |  |  |
|  | 26516 | Fusion of knuckle joint |  |  |  |  |  |
|  | 26517 | Fusion of knuckle joints |  |  |  |  |  |
|  | 26518 | Fusion of knuckle joints |  |  |  |  |  |
|  | 26541 | Repair hand joint with graft |  |  |  |  |  |
|  | 26545 | Reconstruct finger joint |  |  |  |  |  |
|  | 26546 | Repair nonunion hand |  |  |  |  |  |
|  | 26548 | Reconstruct finger joint |  |  |  |  |  |
|  | 26550 | Construct thumb replacement |  |  |  |  |  |
|  | 26555 | Positional change of finger |  |  |  |  |  |
|  | 26561 | Repair of web finger |  |  |  |  |  |
|  | 26562 | Repair of web finger |  |  |  |  |  |
|  | 26565 | Correct metacarpal flaw |  |  |  |  |  |
|  | 26567 | Correct finger deformity |  |  |  |  |  |
|  | 26568 | Lengthen metacarpal/finger |  |  |  |  |  |
|  | 26580 | Repair hand deformity |  |  |  |  |  |
|  | 26585 | Repair finger deformity |  |  |  |  |  |
|  | 26590 | Repair finger deformity |  |  |  |  |  |
|  | 26591 | Repair muscles of hand |  |  |  |  |  |
|  | 26596 | Excision constricting tissue |  |  |  |  |  |
|  | 26597 | Release of scar contracture |  |  |  |  |  |
|  | 26820 | Thumb fusion with graft |  |  |  |  |  |
|  | 26841 | Fusion of thumb |  |  |  |  |  |
|  | 26842 | Thumb fusion with graft |  |  |  |  |  |
|  | 26843 | Fusion of hand joint |  |  |  |  |  |
|  | 26844 | Fusion/graft of hand joint |  |  |  |  |  |
|  | 26850 | Fusion of knuckle |  |  |  |  |  |
|  | 26852 | Fusion of knuckle with graft |  |  |  |  |  |
|  | 26860 | Fusion of finger joint |  |  |  |  |  |
|  | 26861 | Fusion of finger jnt, add-on |  |  |  |  |  |
|  | 26862 | Fusion/graft of finger joint |  |  |  |  |  |
|  | 26863 | Fuse/graft added joint |  |  |  |  |  |
|  | 26910 | Amputate metacarpal bone |  |  |  |  |  |
| 0055 | Level I Fo | oot Musculoskeletal Procedures | T | 15.47 | \$750.10 | \$355.34 | \$150.02 |
|  | 27605 | Incision of achilles tendon |  |  |  |  |  |
|  | 28005 | Treat foot bone lesion |  |  |  |  |  |
|  | 28008 | Incision of foot fascia |  |  |  |  |  |
|  | 28010 | Incision of toe tendon |  |  |  |  |  |
|  | 28011 | Incision of toe tendons |  |  |  |  |  |
|  | 28020 | Exploration of foot joint |  |  |  |  |  |
|  | 28022 | Exploration of foot joint |  |  |  |  |  |
|  | 28024 | Exploration of toe joint |  |  |  |  |  |
|  | 28045 | Excision of foot lesion |  |  |  |  |  |
|  | 28046 | Resection of tumor, foot |  |  |  |  |  |
|  | 28050 | Biopsy of foot joint lining |  |  |  |  |  |
|  | 28052 | Biopsy of foot joint lining |  |  |  |  |  |
|  | 28054 | Biopsy of toe joint lining |  |  |  |  |  |
|  | 28080 | Removal of foot lesion |  |  |  |  |  |
|  | 28086 | Excise foot tendon sheath |  |  |  |  |  |
|  | 28088 | Excise foot tendon sheath |  |  |  |  |  |
|  | 28090 | Removal of foot lesion |  |  |  |  |  |
|  | 28092 | Removal of toe lesions |  |  |  |  |  |
|  | 28100 | Removal of ankle/heel lesion |  |  |  |  |  |
|  | 28104 | Removal of foot lesion |  |  |  |  |  |
|  | 28108 | Removal of toe lesions |  |  |  |  |  |
|  | 28111 | Part removal of metatarsal |  |  |  |  |  |
|  | 28112 | Part removal of metatarsal |  |  |  |  |  |
|  | 28113 | Part removal of metatarsal |  |  |  |  |  |
|  | 28114 | Removal of metatarsal heads |  |  |  |  |  |
|  | 28116 | Revision of foot |  |  |  |  |  |
|  | 28118 | Removal of heel bone |  |  |  |  |  |
|  | 28119 | Removal of heel spur |  |  |  |  |  |

CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
Copyright American Dental Association. All rights reserved.
${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment.
${ }^{2}$ Not subject to national coinsurance.
${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

Addendum C.-Proposed Hospital Outpatient Department (HOPD) Payment for Procedures by APC-
Continued

| APC | $\begin{gathered} \text { CPT/ } \\ \text { HCPCS } \end{gathered}$ | HCPCS Description | Status Indicator | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | 28120 | Part removal of ankle/heel |  |  |  |  |  |
|  | 28122 | Partial removal of foot bone |  |  |  |  |  |
|  | 28124 | Partial removal of toe |  |  |  |  |  |
|  | 28126 | Partial removal of toe |  |  |  |  |  |
|  | 28130 | Removal of ankle bone |  |  |  |  |  |
|  | 28140 | Removal of metatarsal |  |  |  |  |  |
|  | 28150 | Removal of toe |  |  |  |  |  |
|  | 28153 | Partial removal of toe |  |  |  |  |  |
|  | 28160 | Partial removal of toe |  |  |  |  |  |
|  | 28171 | Extensive foot surgery |  |  |  |  |  |
|  | 28173 | Extensive foot surgery |  |  |  |  |  |
|  | 28175 | Extensive foot surgery |  |  |  |  |  |
|  | 28200 | Repair of foot tendon |  |  |  |  |  |
|  | 28208 | Repair of foot tendon |  |  |  |  |  |
|  | 28210 | Repair/graft of foot tendon |  |  |  |  |  |
|  | 28220 | Release of foot tendon |  |  |  |  |  |
|  | 28222 | Release of foot tendons |  |  |  |  |  |
|  | 28225 | Release of foot tendon |  |  |  |  |  |
|  | 28226 | Release of foot tendons |  |  |  |  |  |
|  | 28230 | Incision of foot tendon(s) |  |  |  |  |  |
|  | 28232 | Incision of toe tendon |  |  |  |  |  |
|  | 28234 | Incision of foot tendon |  |  |  |  |  |
|  | 28240 | Release of big toe |  |  |  |  |  |
|  | 28270 | Release of foot contracture |  |  |  |  |  |
|  | 28272 | Release of toe joint, each |  |  |  |  |  |
|  | 28280 | Fusion of toes |  |  |  |  |  |
|  | 28285 | Repair of hammertoe |  |  |  |  |  |
|  | 28286 | Repair of hammertoe |  |  |  |  |  |
|  | 28310 | Revision of big toe |  |  |  |  |  |
|  | 28312 | Revision of toe |  |  |  |  |  |
|  | 28313 | Repair deformity of toe |  |  |  |  |  |
|  | 28315 | Removal of sesamoid bone |  |  |  |  |  |
|  | 28340 | Resect enlarged toe tissue |  |  |  |  |  |
|  | 28341 | Resect enlarged toe |  |  |  |  |  |
|  | 28737 | Revision of foot bones |  |  |  |  |  |
|  | 28750 | Fusion of big toe joint |  |  |  |  |  |
|  | 28755 | Fusion of big toe joint |  |  |  |  |  |
|  | 28810 | Amputation toe \& metatarsal |  |  |  |  |  |
|  | 28820 | Amputation of toe |  |  |  |  |  |
|  | 28825 | Partial amputation of toe |  |  |  |  |  |
|  | 29893 | Scope, plantar fasciotomy |  |  |  |  |  |
| 0056 | Level II F | oot Musculoskeletal Procedures | T | 17.30 | \$838.83 | \$405.81 | \$167.77 |
|  | 28060 | Partial removal, foot fascia |  |  |  |  |  |
|  | 28062 | Removal of foot fascia |  |  |  |  |  |
|  | 28070 | Removal of foot joint lining |  |  |  |  |  |
|  | 28072 | Removal of foot joint lining |  |  |  |  |  |
|  | 28102 | Remove/graft foot lesion |  |  |  |  |  |
|  | 28103 | Remove/graft foot lesion |  |  |  |  |  |
|  | 28106 | Remove/graft foot lesion |  |  |  |  |  |
|  | 28107 | Remove/graft foot lesion |  |  |  |  |  |
|  | 28202 | Repair/graft of foot tendon |  |  |  |  |  |
|  | 28238 | Revision of foot tendon |  |  |  |  |  |
|  | 28250 | Revision of foot fascia |  |  |  |  |  |
|  | 28260 | Release of midfoot joint |  |  |  |  |  |
|  | 28261 | Revision of foot tendon |  |  |  |  |  |
|  | 28262 | Revision of foot and ankle |  |  |  |  |  |
|  | 28264 | Release of midfoot joint |  |  |  |  |  |
|  | 28288 | Partial removal of foot bone |  |  |  |  |  |
|  | 28289 | Repair hallux rigidus |  |  |  |  |  |
|  | 28300 | Incision of heel bone |  |  |  |  |  |
|  | 28302 | Incision of ankle bone |  |  |  |  |  |
|  | 28304 | Incision of midfoot bones |  |  |  |  |  |
|  | 28305 | Incise/graft midfoot bones |  |  |  |  |  |
|  | 28306 | Incision of metatarsal |  |  |  |  |  |
|  | 28307 | Incision of metatarsal |  |  |  |  |  |
|  | 28308 | Incision of metatarsal |  |  |  |  |  |
|  | 28309 | Incision of metatarsals |  |  |  |  |  |
|  | 28320 | Repair of foot bones |  |  |  |  |  |
|  | 28322 | Repair of metatarsals |  |  |  |  |  |
|  | 28344 | Repair extra toe(s) |  |  |  |  |  |
|  | 28345 | Repair webbed toe(s) |  |  |  |  |  |
|  | 28360 | Reconstruct cleft foot |  |  |  |  |  |
|  | 28705 | Fusion of foot bones |  |  |  |  |  |

CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
Copyright American Dental Association. All rights reserved.
${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment.
${ }^{2}$ Not subject to national coinsurance.
${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.


Addendum C.-Proposed Hospital Outpatient Department (hopd) Payment for Procedures by apc-
Continued

| APC | CPT/ HCPCS | HCPCS Description | Status Indicator | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 0070 | 98925 | Osteopathic manipulation | T | 3.64 | \$176.49 | \$79.60 | \$35.30 |
|  | 98926 | Osteopathic manipulation |  |  |  |  |  |
|  | 98927 | Osteopathic manipulation |  |  |  |  |  |
|  | 98928 | Osteopathic manipulation |  |  |  |  |  |
|  | 98929 | Osteopathic manipulation |  |  |  |  |  |
|  | 98940 | Chiropractic manipulation |  |  |  |  |  |
|  | 98941 | Chiropractic manipulation |  |  |  |  |  |
|  | 98942 | Chiropractic manipulation |  |  |  |  |  |
|  | Thoracen | tesis/Lavage Procedures |  |  |  |  |  |
|  | 32000 | Drainage of chest |  |  |  |  |  |
|  | 32002 | Treatment of collapsed lung |  |  |  |  |  |
|  | 32005 | Treat lung lining chemically |  |  |  |  |  |
|  | 32020 | Insertion of chest tube |  |  |  |  |  |
|  | 32420 | Puncture/clear lung |  |  |  |  |  |
|  | 32960 | Therapeutic pneumothorax |  |  |  |  |  |
|  | 32999 | Chest surgery procedure |  |  |  |  |  |
|  | 33010 | Drainage of heart sac |  |  |  |  |  |
|  | 33011 | Repeat drainage of heart sac |  |  |  |  |  |
|  | 33999 | Cardiac surgery procedure |  |  |  |  |  |
|  | 49080 | Puncture, peritoneal cavity |  |  |  |  |  |
|  | 49081 | Removal of abdominal fluid |  |  |  |  |  |
| 0071 | Level I Endoscopy Upper Airway 31231 Nasal endoscopy, dx 31575 Diagnostic laryngoscopy 92511 Nasopharyngoscopy |  | T | 0.55 | \$26.67 | \$14.22 | \$5.33 |
|  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |
| 0072 | Level II Endoscopy Upper Airway |  | T | 1.26 | \$61.09 | \$41.52 | \$12.22 |
|  | 31233 | Nasal/sinus endoscopy, dx |  |  |  |  |  |
|  | 31505 | Diagnostic laryngoscopy |  |  |  |  |  |
|  | 31511 | Remove foreign body, larynx |  |  |  |  |  |
|  | 31520 | Diagnostic laryngoscopy |  |  |  |  |  |
|  | 31700 | Insertion of airway catheter |  |  |  |  |  |
|  | 31720 | Clearance of airways |  |  |  |  |  |
| 0073 | Level III Endoscopy Upper Airway |  | T | 4.11 | \$199.28 | \$91.07 | \$39.86 |
|  | 31513 | Injection into vocal cord |  |  |  |  |  |
|  | 31577 | Remove foreign body, larynx |  |  |  |  |  |
|  | 31579 | Diagnostic laryngoscopy |  |  |  |  |  |
|  | 31717 | Bronchial brush biopsy |  |  |  |  |  |
|  | 31730 | Intro, windpipe wire/tube |  |  |  |  |  |
| 0074 | Level IV Endoscopy Upper Airway |  | T | 13.61 | \$659.91 | \$347.54 | \$131.98 |
|  | 31235 | Nasal/sinus endoscopy, dx |  |  |  |  |  |
|  | 31237 | Nasal/sinus endoscopy, surg |  |  |  |  |  |
|  | 31238 | Nasal/sinus endoscopy, surg |  |  |  |  |  |
|  | 31240 | Nasal/sinus endoscopy, surg |  |  |  |  |  |
|  | 31510 | Laryngoscopy with biopsy |  |  |  |  |  |
|  | 31512 | Removal of larynx lesion |  |  |  |  |  |
|  | 31515 | Laryngoscopy for aspiration |  |  |  |  |  |
|  | 31525 | Diagnostic laryngoscopy |  |  |  |  |  |
|  | 31526 | Diagnostic laryngoscopy |  |  |  |  |  |
|  | 31528 | Laryngoscopy and dilatation |  |  |  |  |  |
|  | 31529 | Laryngoscopy and dilatation |  |  |  |  |  |
|  | 31576 | Laryngoscopy with biopsy |  |  |  |  |  |
|  | 31578 | Removal of larynx lesion |  |  |  |  |  |
| 0075 | Level V Endoscopy Upper Airway |  | T | 18.55 | \$899.44 | \$467.29 | \$179.89 |
|  | 31239 | Nasal/sinus endoscopy, surg |  |  |  |  |  |
|  | 31254 | Revision of ethmoid sinus |  |  |  |  |  |
|  | 31255 | Removal of ethmoid sinus |  |  |  |  |  |
|  | 31256 | Exploration maxillary sinus |  |  |  |  |  |
|  | 31267 | Endoscopy, maxillary sinus |  |  |  |  |  |
|  | 31276 | Sinus endoscopy, surgical |  |  |  |  |  |
|  | 31287 | Nasal/sinus endoscopy, surg |  |  |  |  |  |
|  | 31288 | Nasal/sinus endoscopy, surg |  |  |  |  |  |
|  | 31527 | Laryngoscopy for treatment |  |  |  |  |  |
|  | 31530 | Operative laryngoscopy |  |  |  |  |  |
|  | 31531 | Operative laryngoscopy |  |  |  |  |  |
|  | 31535 | Operative laryngoscopy |  |  |  |  |  |
|  | 31536 | Operative laryngoscopy |  |  |  |  |  |
|  | 31540 | Operative laryngoscopy |  |  |  |  |  |
|  | 31541 | Operative laryngoscopy |  |  |  |  |  |
|  | 31560 | Operative laryngoscopy |  |  |  |  |  |
|  | 31561 | Operative laryngoscopy |  |  |  |  |  |
|  | 31570 | Laryngoscopy with injection |  |  |  |  |  |
|  | 31571 | Laryngoscopy with injection |  |  |  |  |  |
|  | 96570 | Photodynamic tx, 30 min |  |  |  |  |  |

[^252]Copyright American Dental Association. All rights reserved.
${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment.
${ }^{2}$ Not subject to national coinsurance.
${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

## addendum C.-Proposed Hospital Outpatient Department (HOPD) Payment for Procedures by APCContinued

| APC | CPT/ $\quad$ HCPCS Description | Status Indicator | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 0076 | 96571 Photodynamic tx, addl 15 min |  |  |  |  |  |
|  | Endoscopy Lower Airway | T | 8.06 | \$390.81 | \$197.05 | \$78.16 |
|  | 31615 Visualization of windpipe |  |  |  |  |  |
|  | 31622 Dx bronchoscope/wash |  |  |  |  |  |
|  | 31623 Dx bronchoscope/brush |  |  |  |  |  |
|  | 31624 Dx bronchoscope/lavage |  |  |  |  |  |
|  | 31625 Bronchoscopy with biopsy |  |  |  |  |  |
|  | 31628 Bronchoscopy with biopsy |  |  |  |  |  |
|  | 31629 Bronchoscopy with biopsy |  |  |  |  |  |
|  | 31630 Bronchoscopy with repair |  |  |  |  |  |
|  | 31631 Bronchoscopy with dilation |  |  |  |  |  |
|  | 31635 Remove foreign body, airway |  |  |  |  |  |
|  | 31640 Bronchoscopy \& remove lesion |  |  |  |  |  |
|  | 31641 Bronchoscopy, treat blockage |  |  |  |  |  |
|  | 31643 Diag bronchoscope/catheter |  |  |  |  |  |
|  | 31645 Bronchoscopy, clear airways |  |  |  |  |  |
|  | 31646 Bronchoscopy, reclear airway |  |  |  |  |  |
|  | 31656 Bronchoscopy, inj for x-ray |  |  |  |  |  |
|  | 31899 Airways surgical procedure |  |  |  |  |  |
|  | 32601 Thoracoscopy, diagnostic |  |  |  |  |  |
|  | 32602 Thoracoscopy, diagnostic |  |  |  |  |  |
|  | 32603 Thoracoscopy, diagnostic |  |  |  |  |  |
|  | 32604 Thoracoscopy, diagnostic |  |  |  |  |  |
|  | 32605 Thoracoscopy, diagnostic |  |  |  |  |  |
|  | 32606 Thoracoscopy, diagnostic |  |  |  |  |  |
|  | 39400 Visualization of chest |  |  |  |  |  |
| 0077 | Level I Pulmonary Treatment | S | 0.43 | \$20.85 | \$12.62 | \$4.17 |
|  | 94640 Airway inhalation treatment |  |  |  |  |  |
|  | 94650 Pressure breathing (IPPB) |  |  |  |  |  |
|  | 94651 Pressure breathing (IPPB) |  |  |  |  |  |
|  | 94664 Aerosol or vapor inhalations |  |  |  |  |  |
|  | 94665 Aerosol or vapor inhalations |  |  |  |  |  |
|  | 94667 Chest wall manipulation |  |  |  |  |  |
|  | 94668 Chest wall manipulation |  |  |  |  |  |
| 0078 | Level II Pulmonary Treatment | S | 1.34 | \$64.97 | \$29.13 | \$12.99 |
|  | 94642 Aerosol inhalation treatment |  |  |  |  |  |
| 0079 | Ventilation Initiation and Management | S | 3.18 | \$154.19 | \$107.70 | \$30.84 |
|  | 94656 Initial ventilator mgmt |  |  |  |  |  |
|  | 94657 Continued ventilator mgmt |  |  |  |  |  |
|  | 94660 Pos airway pressure, CPAP |  |  |  |  |  |
|  | 94662 Neg press ventilation, cnp |  |  |  |  |  |
| 0080 | Diagnostic Cardiac Catheterization | T | 25.77 | \$1,249.51 | \$713.89 | \$249.90 |
|  | 93501 Right heart catheterization |  |  |  |  |  |
|  | 93503 Insert/place heart catheter |  |  |  |  |  |
|  | 93505 Biopsy of heart lining |  |  |  |  |  |
|  | 93510 Left heart catheterization |  |  |  |  |  |
|  | 93511 Left heart catheterization |  |  |  |  |  |
|  | 93514 Left heart catheterization |  |  |  |  |  |
|  | 93524 Left heart catheterization |  |  |  |  |  |
|  | 93526 Rt \& Lt heart catheters |  |  |  |  |  |
|  | 93527 Rt \& Lt heart catheters |  |  |  |  |  |
|  | 93528 Rt \& Lt heart catheters |  |  |  |  |  |
|  | 93529 Rt, Lt heart catheterization |  |  |  |  |  |
|  | 93530 Rt heart cath, congenital |  |  |  |  |  |
|  | 93531 R \& I heart cath, congenital |  |  |  |  |  |
|  | 93532 R \& I heart cath, congenital |  |  |  |  |  |
|  | 93533 R \& I heart cath, congenital |  |  |  |  |  |
|  | 93536 Insert circulation assi |  |  |  |  |  |
| 0081 | Non-Coronary Angioplasty or Atherectomy | T | 19.36 | \$938.71 | \$434.25 | \$187.74 |
|  | 35180 Repair blood vessel lesion |  |  |  |  |  |
|  | 35184 Repair blood vessel lesion |  |  |  |  |  |
|  | 35190 Repair blood vessel lesion |  |  |  |  |  |
|  | 35201 Repair blood vessel lesion |  |  |  |  |  |
|  | 35206 Repair blood vessel lesion |  |  |  |  |  |
|  | 35226 Repair blood vessel lesion |  |  |  |  |  |
|  | 35231 Repair blood vessel lesion |  |  |  |  |  |
|  | 35236 Repair blood vessel lesion |  |  |  |  |  |
|  | 35256 Repair blood vessel lesion |  |  |  |  |  |
|  | 35261 Repair blood vessel lesion |  |  |  |  |  |
|  | 35266 Repair blood vessel lesion |  |  |  |  |  |
|  | 35286 Repair blood vessel lesion |  |  |  |  |  |
|  | 35321 Rechanneling of artery |  |  |  |  |  |
|  | 35459 Repair arterial blockage |  |  |  |  |  |

CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
Copyright American Dental Association. All rights reserved.
${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment.
${ }^{2}$ Not subject to national coinsurance.
${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

Addendum C.—Proposed Hospital Outpatient Department (HOPD) Payment for Procedures by APC-
Continued

| APC | $\begin{gathered} \text { CPT/ } \\ \text { HCPCS } \end{gathered}$ | HCPCS Description | Status Indicator | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | 35460 R | Repair venous blockage |  |  |  |  |  |
|  | 35470 R | Repair arterial blockage |  |  |  |  |  |
|  | 35471 R | Repair arterial blockage |  |  |  |  |  |
|  | 35472 R | Repair arterial blockage |  |  |  |  |  |
|  | 35473 R | Repair arterial blockage |  |  |  |  |  |
|  | 35474 R | Repair arterial blockage |  |  |  |  |  |
|  | 35475 R | Repair arterial blockage |  |  |  |  |  |
|  | 35476 R | Repair venous blockage |  |  |  |  |  |
|  | 35484 | Atherectomy, open |  |  |  |  |  |
|  | 35485 A | Atherectomy, open |  |  |  |  |  |
|  | 35490 A | Atherectomy, percutaneous |  |  |  |  |  |
|  | 35491 A | Atherectomy, percutaneous |  |  |  |  |  |
|  | 35492 A | Atherectomy, percutaneous |  |  |  |  |  |
|  | 35493 A | Atherectomy, percutaneous |  |  |  |  |  |
|  | 35494 A | Atherectomy, percutaneous |  |  |  |  |  |
|  | 35495 A | Atherectomy, percutaneous |  |  |  |  |  |
|  | 35500 H | Harvest vein for bypass |  |  |  |  |  |
|  | 37204 T | Transcatheter occlusion |  |  |  |  |  |
|  | 37205 T | Transcatheter stent |  |  |  |  |  |
|  | 37206 T | Transcatheter stent add-on |  |  |  |  |  |
|  | 37207 T | Transcatheter stent |  |  |  |  |  |
|  | 37208 T | Transcatheter stent add-on |  |  |  |  |  |
|  | 37209 E | Exchange arterial catheter |  |  |  |  |  |
|  | 37250 Iv | Iv us first vessel add-on |  |  |  |  |  |
|  | 37251 I | Iv us each add vessel add-on |  |  |  |  |  |
|  | 37565 L | Ligation of neck vein |  |  |  |  |  |
|  | 37600 L | Ligation of neck artery |  |  |  |  |  |
| 0082 | Coronary A | Atherectomy | T | 40.34 | \$1,955.97 | \$859.56 | \$391.19 |
|  | $92995$ | Coronary atherectomy |  |  |  |  |  |
|  | 92996 | Coronary atherectomy add-on |  |  |  |  |  |
| 0083 |  |  | T | 45.79 | \$2,220.22 | \$1,322.95 | \$444.04 |
|  | $92980$ | Insert intracoronary stent |  |  |  |  |  |
|  | 92981 | Insert intracoronary stent |  |  |  |  |  |
|  | 92982 | Coronary artery dilation |  |  |  |  |  |
|  | 92984 | Coronary artery dilation |  |  |  |  |  |
| 0084 | Level I Elec | ectrophysiologic Evaluation | S | 10.70 | \$518.81 | \$177.79 | \$103.76 |
|  | 93640 E | Evaluation heart device |  |  |  |  |  |
|  | 93641 E | Electrophysiology evaluation |  |  |  |  |  |
|  | 93642 E | Electrophysiology evaluation |  |  |  |  |  |
| 0085 | Level II Ele | ectrophysiologic Evaluation | S | 27.06 | \$1,312.06 | \$654.48 | \$262.41 |
|  | $93619$ | Electrophysiology evaluation |  |  |  |  |  |
|  | 93620 E | Electrophysiology evaluation |  |  |  |  |  |
|  | 93621 E | Electrophysiology evaluation |  |  |  |  |  |
|  | 93622 E | Electrophysiology evaluation |  |  |  |  |  |
| 0086 | Ablate Hea | art Dysrhythm Focus | S | 47.62 | \$2,308.95 | \$1,265.37 | \$461.79 |
|  | 93650 A | Ablate heart dysrhythm focus |  |  |  |  |  |
|  | 93651 A | Ablate heart dysrhythm focus |  |  |  |  |  |
|  | 93652 A | Ablate heart dysrhythm focus |  |  |  |  |  |
| 0087 | Cardiac Ele | lectrophysiologic Recording/Mapping | S | 9.53 | \$462.08 | \$214.72 | \$92.42 |
|  | 93600 B | Bundle of His recording |  |  |  |  |  |
|  | 93602 I | Intra-atrial recording |  |  |  |  |  |
|  | 93603 R | Right ventricular recording |  |  |  |  |  |
|  | 93607 L | Left ventricular recording |  |  |  |  |  |
|  | 93609 M | Mapping of tachycardia |  |  |  |  |  |
|  | 93610 I | Intra-atrial pacing |  |  |  |  |  |
|  | 93612 I | Intraventricular pacing |  |  |  |  |  |
|  | 93615 | Esophageal recording |  |  |  |  |  |
|  | 93616 E | Esophageal recording |  |  |  |  |  |
|  | 93618 H | Heart rhythm pacing |  |  |  |  |  |
|  | 93623 S | Stimulation, pacing heart |  |  |  |  |  |
|  | 93624 E | Electrophysiologic study |  |  |  |  |  |
|  | 93631 H | Heart pacing, mapping |  |  |  |  |  |
| 0088 | Thrombectomy |  | T | 26.49 | \$1,284.42 | \$678.68 | \$256.88 |
|  | 34101 P | Removal of artery clot |  |  |  |  |  |
|  | 34111 R | Removal of arm artery clot |  |  |  |  |  |
|  | 34201 R | Removal of artery clot |  |  |  |  |  |
|  | 34203 R | Removal of leg artery clot |  |  |  |  |  |
|  | 34471 R | Removal of vein clot |  |  |  |  |  |
|  | 34490 R | Removal of vein clot |  |  |  |  |  |
|  | 34501 R | Repair valve, femoral vein |  |  |  |  |  |
|  | 34510 T | Transposition of vein valve |  |  |  |  |  |
|  | 34520 | Cross-over vein graft |  |  |  |  |  |
|  | 34530 L | Leg vein fusion |  |  |  |  |  |

[^253]Copyright American Dental Association. All rights reserved.
${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment.
${ }^{2}$ Not subject to national coinsurance.
${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

## addendum C.-Proposed Hospital Outpatient Department (HOPD) Payment for Procedures by APCContinued

| APC | CPT/ <br> HCPCS | HCPCS Description | Status Indicator | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | 35188 | Repair blood vessel lesion |  |  |  |  |  |
|  | 35207 | Repair blood vessel lesion |  |  |  |  |  |
|  | 35875 | Removal of clot in graft |  |  |  |  |  |
|  | 35876 | Removal of clot in graft |  |  |  |  |  |
|  | 35879 | Revise graft w/vein |  |  |  |  |  |
|  | 35881 | Revise graft w/vein |  |  |  |  |  |
|  | 36821 | Av fusion direct any site |  |  |  |  |  |
|  | 36825 | Artery-vein graft |  |  |  |  |  |
|  | 36830 | Artery-vein graft |  |  |  |  |  |
|  | 36831 | Av fistula excision |  |  |  |  |  |
|  | 36832 | Av fistula revision |  |  |  |  |  |
|  | 36833 | Av fistula revision |  |  |  |  |  |
|  | G0159 | Perc declot dialysis graft |  |  |  |  |  |
| 0089 | Level I Im | mplantation/Removal/Revision of Pacemaker, AICD or Vascular Device | T | 6.49 | \$314.68 | \$130.07 | 4 |
|  | 33210 | Insertion of heart electrode |  |  |  |  |  |
|  | 33211 | Insertion of heart electrode |  |  |  |  |  |
|  | 33220 | Revise eltrd pacing-defib |  |  |  |  |  |
|  | 33241 | Remove pulse generator |  |  |  |  |  |
|  | 36261 | Revision of infusion pump |  |  |  |  |  |
|  | 36262 | Removal of infusion pump |  |  |  |  |  |
|  | 36299 | Vessel injection procedure |  |  |  |  |  |
|  | 36531 | Revision of infusion pump |  |  |  |  |  |
|  | 36532 | Removal of infusion pump |  |  |  |  |  |
|  | 36534 | Revision of access device |  |  |  |  |  |
|  | 36535 | Removal of access device |  |  |  |  |  |
|  | 37203 | Transcatheter retrieval |  |  |  |  |  |
| 0090 | Level II Im | mplantation/Removal/Revision of Pacemaker, AICD or Vascular Device | T | 20.96 | \$1,016.29 | \$573.04 | \$203.26 |
|  | 33206 | Insertion of heart pacemaker |  |  |  |  |  |
|  | 33207 | Insertion of heart pacemaker |  |  |  |  |  |
|  | 33208 | Insertion of heart pacemaker |  |  |  |  |  |
|  | 33212 | Insertion of pulse generator |  |  |  |  |  |
|  | 33213 | Insertion of pulse generator |  |  |  |  |  |
|  | 33214 | Upgrade of pacemaker system |  |  |  |  |  |
|  | 33216 | Revise eltrd pacing-defib |  |  |  |  |  |
|  | 33217 | Revise eltrd pacing-defib |  |  |  |  |  |
|  | 33218 | Revise eltrd pacing-defib |  |  |  |  |  |
|  | 33233 | Removal of pacemaker system |  |  |  |  |  |
|  | 33234 | Removal of pacemaker system |  |  |  |  |  |
|  | 33235 | Removal pacemaker electrode |  |  |  |  |  |
|  | 33240 | Insert pulse generator |  |  |  |  |  |
|  | 33244 | Remove eltrd, transven |  |  |  |  |  |
|  | 33249 | Eltrd/insert pace-defib |  |  |  |  |  |
|  | 36860 | External cannula declotting |  |  |  |  |  |
|  | 36861 | Cannula declotting |  |  |  |  |  |
| 0091 | Level I V | ascular Ligation | T | 14.79 | \$717.12 | \$348.23 | \$143.42 |
|  | 30915 | Ligation, nasal sinus artery |  |  |  |  |  |
|  | 37605 | Ligation of neck artery |  |  |  |  |  |
|  | 37606 | Ligation of neck artery |  |  |  |  |  |
|  | 37615 | Ligation of neck artery |  |  |  |  |  |
|  | 37650 | Revision of major vein |  |  |  |  |  |
|  | 37700 | Revise leg vein |  |  |  |  |  |
|  | 37760 | Revision of leg veins |  |  |  |  |  |
|  | 37780 | Revision of leg vein |  |  |  |  |  |
|  | 37785 | Revise secondary varicosity |  |  |  |  |  |
| 0092 | Level II V | Vascular Ligation | T | 20.21 | \$979.92 | \$505.37 | \$195.98 |
|  | 30920 | Ligation, upper jaw artery |  |  |  |  |  |
|  | 37607 | Ligation of a-v fistula |  |  |  |  |  |
|  | 37720 | Removal of leg vein |  |  |  |  |  |
|  | 37730 | Removal of leg veins |  |  |  |  |  |
|  | 37735 | Removal of leg veins/lesion |  |  |  |  |  |
| 0093 | Vascular | Repair/Fistula Construction | T | 17.95 | \$870.34 | \$422.33 | \$174.07 |
|  | 36260 | Insertion of infusion pump |  |  |  |  |  |
|  | 36530 | Insertion of infusion pump |  |  |  |  |  |
|  | 36533 | Insertion of access device |  |  |  |  |  |
|  | 36800 | Insertion of cannula |  |  |  |  |  |
|  | 36810 | Insertion of cannula |  |  |  |  |  |
|  | 36815 | Insertion of cannula |  |  |  |  |  |
|  | 36819 | Av fusion by basilic vein |  |  |  |  |  |
|  | 36835 | Artery to vein shunt |  |  |  |  |  |
| 0094 | Resuscita | ation and Cardioversion | S | 4.51 | \$218.68 | \$105.29 | \$43.74 |
|  | 31500 | Insert emergency airway |  |  |  |  |  |
|  | 92950 | Heart/lung resuscitation cpr |  |  |  |  |  |
|  | 92953 | Temporary external pacing |  |  |  |  |  |

CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
Copyright American Dental Association. All rights reserved.
${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment
${ }^{2}$ Not subject to national coinsurance.
${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

## Addendum C.-Proposed Hospital Outpatient Department (HOPD) Payment for Procedures by APCContinued



CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
Copyright American Dental Association. All rights reserved.
${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment.
${ }^{2}$ Not subject to national coinsurance.
${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

## addendum C.-Proposed Hospital Outpatient Department (HOPD) Payment for Procedures by APCContinued

| APC | CPT/ HCPCS | HCPCS Description | Status Indicator | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 0111 | $\begin{aligned} & 36455 \\ & 36460 \end{aligned}$ | Exchange transfusion service Transfusion service, fetal | S | 14.17 | \$687.06 | \$300.74 | \$137.41 |
|  | Blood Pro | duct Exchange |  |  |  |  |  |
|  | 36520 | Plasma and/or cell exchange |  |  |  |  |  |
|  | 36521 | Apheresis w/adsorp/reinfuse |  |  |  |  |  |
|  | 38231 | Stem cell collection |  |  |  |  |  |
| 0112 | Extracorpo | oreal Photopheresis | S | 39.60 | \$1,920.09 | \$663.65 | \$384.02 |
|  | 36522 | Photopheresis |  |  |  |  |  |
| 0113 | Excision L | Lymphatic System | T | 13.89 | \$673.49 | \$326.55 | \$134.70 |
|  | 38308 | Incision of lymph channels |  |  |  |  |  |
|  | 38500 | Biopsy/removal, lymph nodes |  |  |  |  |  |
|  | 38510 | Biopsy/removal, lymph nodes |  |  |  |  |  |
|  | 38520 | Biopsy/removal, lymph nodes |  |  |  |  |  |
|  | 38525 | Biopsy/removal, lymph nodes |  |  |  |  |  |
|  | 38530 | Biopsy/removal, lymph nodes |  |  |  |  |  |
|  | 38550 | Removal, neck/armpit lesion |  |  |  |  |  |
| 0114 | Thyroid/Ly | ymphadenectomy Procedures | T | 19.56 | \$948.41 | \$493.78 | \$189.68 |
|  | 38542 | Explore deep node(s), neck |  |  |  |  |  |
|  | 38555 | Removal, neck/armpit lesion |  |  |  |  |  |
|  | 38720 | Removal of lymph nodes, neck |  |  |  |  |  |
|  | 38740 | Remove armpit lymph nodes |  |  |  |  |  |
|  | 38745 | Remove armpit lymph nodes |  |  |  |  |  |
|  | 38760 | Remove groin lymph nodes |  |  |  |  |  |
|  | 60200 | Remove thyroid lesion |  |  |  |  |  |
|  | 60210 | Partial thyroid excision |  |  |  |  |  |
|  | 60220 | Partial removal of thyroid |  |  |  |  |  |
|  | 60225 | Partial removal of thyroid |  |  |  |  |  |
|  | 60240 | Removal of thyroid |  |  |  |  |  |
|  | 60280 | Remove thyroid duct lesion |  |  |  |  |  |
|  | 60281 | Remove thyroid duct lesion |  |  |  |  |  |
| 0116 | Chemotherapy Administration by Other Technique Except Infusion |  | S | 2.34 | \$113.46 | \$22.69 | \$22.69 |
| 0117 | Chemotherapy Administration by Infusion Only |  | S | 1.84 | \$89.22 | \$71.80 | \$17.84 |
|  | Chemotherapy Administration by Both Infusion and Other Technique |  |  |  |  |  |  |
| 0118 | Q0085 | Chemo by both infusion and o | S | 2.90 | \$140.61 | \$72.03 | \$28.12 |
| 0120 | Infusion Therapy Except Chemotherapy |  | S | 1.66 | \$80.49 | \$42.67 | \$16.10 |
|  | 36680 | Insert needle, bone cavity |  |  |  |  |  |
|  | Q0081 | Infusion ther other than che |  |  |  |  |  |
| 0121 | Level I Tube changes and Repositioning |  | T | 2.36 | \$114.43 | \$52.53 | \$22.89 |
|  | 31502 | Change of windpipe airway |  |  |  |  |  |
|  | 43760 | Change gastrostomy tube |  |  |  |  |  |
|  | 43761 | Reposition gastrostomy tube |  |  |  |  |  |
|  | 43999 | Stomach surgery procedure |  |  |  |  |  |
|  | 47530 | Revise/reinsert bile tube |  |  |  |  |  |
|  | 47999 | Bile tract surgery procedure |  |  |  |  |  |
|  | 49999 | Abdomen surgery procedure |  |  |  |  |  |
|  | 50688 | Change of ureter tube |  |  |  |  |  |
|  | 51705 | Change of bladder tube |  |  |  |  |  |
|  | 51710 | Change of bladder tube |  |  |  |  |  |
|  | 62194 | Replace/irrigate catheter |  |  |  |  |  |
|  | 62225 | Replace/irrigate catheter |  |  |  |  |  |
| 0122 | Level II Tube changes and Repositioning |  | T | 5.04 | \$244.37 | \$114.93 | \$48.88 |
|  | 47525 | Change bile duct catheter |  |  |  |  |  |
|  | 50398 | Change kidney tube |  |  |  |  |  |
| 0123 | Level III Tube changes and Repositioning |  | T | 13.89 | \$673.49 | \$350.75 | \$134.70 |
|  | 49422 | Remove perm cannula/catheter |  |  |  |  |  |
|  | 49429 | Removal of shunt |  |  |  |  |  |
| 0130 | Level I Laparoscopy |  | T | 25.36 | \$1,229.63 | \$659.53 | \$245.93 |
|  | 38129 | Laparoscope proc, spleen |  |  |  |  |  |
|  | 38589 | Laparoscope proc, lymphatic |  |  |  |  |  |
|  | 43289 | Laparoscope proc, esoph |  |  |  |  |  |
|  | 43659 | Laparoscope proc, stom |  |  |  |  |  |
|  | 44209 | Laparoscope proc, intestine |  |  |  |  |  |
|  | 44970 | Laparoscopy, appendectomy |  |  |  |  |  |
|  | 44979 | Laparoscope proc, app |  |  |  |  |  |
|  | 47560 | Laparoscopy w/cholangio |  |  |  |  |  |
|  | 47561 | Laparo w/cholangio/biopsy |  |  |  |  |  |
|  | 47579 | Laparoscope proc, biliary |  |  |  |  |  |
|  | 49320 | Diag laparo separate proc |  |  |  |  |  |
|  | 49321 | Laparoscopy, biopsy |  |  |  |  |  |
|  | 49322 | Laparoscopy, aspiration |  |  |  |  |  |
|  | 49323 | Laparo drain lymphocele |  |  |  |  |  |

[^254]Addendum C.-Proposed Hospital Outpatient Department (HOPD) Payment for Procedures by APCContinued


[^255]Copyright American Dental Association. All rights reserved.
${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment.
${ }^{2}$ Not subject to national coinsurance.
${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

## addendum C.-Proposed Hospital Outpatient Department (HOPD) Payment for Procedures by APCContinued



CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
Copyright American Dental Association. All rights reserved.
${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment.
${ }^{2}$ Not subject to national coinsurance.
${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

Addendum C.—Proposed Hospital Outpatient Department (HOPD) Payment for Procedures by APC— Continued


CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
Copyright American Dental Association. All rights reserved.
${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment.
${ }^{2}$ Not subject to national coinsurance.
${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

Addendum C.-Proposed Hospital Outpatient Department (hopd) Payment for Procedures by APC-
Continued

| APC | CPT/ <br> HCPCS | HCPCS Description | Status Indicator | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | 43263 | Endo cholangiopancreatograph |  |  |  |  |  |
|  | 43264 | Endo cholangiopancreatograph |  |  |  |  |  |
|  | 43265 | Endo cholangiopancreatograph |  |  |  |  |  |
|  | 43267 | Endo cholangiopancreatograph |  |  |  |  |  |
|  | 43268 | Endo cholangiopancreatograph |  |  |  |  |  |
|  | 43269 | Endo cholangiopancreatograph |  |  |  |  |  |
|  | 43271 | Endo cholangiopancreatograph |  |  |  |  |  |
|  | 43272 | Endo cholangiopancreatograph |  |  |  |  |  |
| 0152 | Percutan | eous Biliary Endoscopic Procedures | T | 8.22 | \$398.56 | \$207.38 | \$79.71 |
|  | 47510 | Insert catheter, bile duct |  |  |  |  |  |
|  | 47511 | Insert bile duct drain |  |  |  |  |  |
|  | 47552 | Biliary endoscopy thru skin |  |  |  |  |  |
|  | 47553 | Biliary endoscopy thru skin |  |  |  |  |  |
|  | 47554 | Biliary endoscopy thru skin |  |  |  |  |  |
|  | 47555 | Biliary endoscopy thru skin |  |  |  |  |  |
|  | 47556 | Biliary endoscopy thru skin |  |  |  |  |  |
|  | 47630 | Remove bile duct stone |  |  |  |  |  |
| 0153 | Peritonea | and Abdominal Procedures | T | 19.62 | \$951.32 | \$496.31 | \$190.26 |
|  | 49085 | Remove abdomen foreign body |  |  |  |  |  |
|  | 49250 | Excision of umbilicus |  |  |  |  |  |
|  | 49420 | Insert abdominal drain |  |  |  |  |  |
|  | 49421 | Insert abdominal drain |  |  |  |  |  |
|  | 49423 | Exchange drainage catheter |  |  |  |  |  |
|  | 49426 | Revise abdomen-venous shunt |  |  |  |  |  |
| 0154 | Hernia/Hy | ydrocele Procedures | T | 22.43 | \$1,087.57 | \$556.98 | \$217.51 |
|  | 49495 | Repair inguinal hernia, init |  |  |  |  |  |
|  | 49496 | Repair inguinal hernia, init |  |  |  |  |  |
|  | 49500 | Repair inguinal hernia |  |  |  |  |  |
|  | 49501 | Repair inguinal hernia, init |  |  |  |  |  |
|  | 49505 | Repair inguinal hernia |  |  |  |  |  |
|  | 49507 | Repair inguinal hernia |  |  |  |  |  |
|  | 49520 | Rerepair inguinal hernia |  |  |  |  |  |
|  | 49521 | Repair inguinal hernia, rec |  |  |  |  |  |
|  | 49525 | Repair inguinal hernia |  |  |  |  |  |
|  | 49540 | Repair lumbar hernia |  |  |  |  |  |
|  | 49550 | Repair femoral hernia |  |  |  |  |  |
|  | 49553 | Repair femoral hernia, init |  |  |  |  |  |
|  | 49555 | Repair femoral hernia |  |  |  |  |  |
|  | 49557 | Repair femoral hernia, recur |  |  |  |  |  |
|  | 49560 | Repair abdominal hernia |  |  |  |  |  |
|  | 49561 | Repair incisional hernia |  |  |  |  |  |
|  | 49565 | Rerepair abdominal hernia |  |  |  |  |  |
|  | 49566 | Repair incisional hernia |  |  |  |  |  |
|  | 49568 | Hernia repair w/mesh |  |  |  |  |  |
|  | 49570 | Repair epigastric hernia |  |  |  |  |  |
|  | 49572 | Repair epigastric hernia |  |  |  |  |  |
|  | 49580 | Repair umbilical hernia |  |  |  |  |  |
|  | 49582 | Repair umbilical hernia |  |  |  |  |  |
|  | 49585 | Repair umbilical hernia |  |  |  |  |  |
|  | 49587 | Repair umbilical hernia |  |  |  |  |  |
|  | 49590 | Repair abdominal hernia |  |  |  |  |  |
|  | 49600 | Repair umbilical lesion |  |  |  |  |  |
|  | 51500 | Removal of bladder cyst |  |  |  |  |  |
|  | 54530 | Removal of testis |  |  |  |  |  |
|  | 54550 | Exploration for testis |  |  |  |  |  |
|  | 54640 | Suspension of testis |  |  |  |  |  |
|  | 55040 | Removal of hydrocele |  |  |  |  |  |
|  | 55041 | Removal of hydroceles |  |  |  |  |  |
|  | 55535 | Revise spermatic cord veins |  |  |  |  |  |
|  | 55540 | Revise hernia \& sperm veins |  |  |  |  |  |
| ${ }^{2} 0157$ | Colorecta | l Cancer Screening: Barium Enema | S | 1.79 | \$86.79 |  | \$17.36 |
|  | G0106 | Colon CA screen; barium enema |  |  |  |  |  |
|  | G0120 | Colon ca scrn; barium enema |  |  |  |  |  |
| ${ }^{1} 0158$ | Colorecta | I Cancer Screening: Colonoscopy | S | 7.98 | \$386.93 |  | \$96.73 |
|  | G0104 | CA screen; flexi sigmoidscope | S | 7.98 | \$137.22 |  | \$34.31 |
| ${ }^{1} 0159$ | G0105 | Colorectal scrn; hi risk ind |  |  |  |  |  |
| 0160 | Level I Cy | ystourethroscopy and other Genitourinary Procedures | T | 5.43 | \$263.28 | \$110.11 | \$52.66 |
|  | 50392 | Insert kidney drain |  |  |  |  |  |
|  | 50393 | Insert ureteral tube |  |  |  |  |  |
|  | 50395 | Create passage to kidney |  |  |  |  |  |
|  | 52000 | Cystoscopy |  |  |  |  |  |
|  | 52265 | Cystoscopy and treatment |  |  |  |  |  |

CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
Copyright American Dental Association. All rights reserved.
${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment.
${ }^{2}$ Not subject to national coinsurance.
${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

Addendum C.—Proposed Hospital Outpatient Department (HOPD) Payment for Procedures by APC— Continued


CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
Copyright American Dental Association. All rights reserved.
${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment.
${ }^{2}$ Not subject to national coinsurance.
${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

Addendum C.-Proposed Hospital Outpatient Department (HOPD) Payment for Procedures by APC-
Continued


CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
Copyright American Dental Association. All rights reserved.
${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment.
${ }^{2}$ Not subject to national coinsurance.
${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

Addendum C.—Proposed Hospital Outpatient Department (HOPD) Payment for Procedures by APC— Continued

| APC | CPT/ HCPCS | HCPCS Description | Status Indicator | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | 53240 S | Surgery for urethra pouch |  |  |  |  |  |
|  | 53400 R | Revise urethra, stage 1 |  |  |  |  |  |
|  | 53405 R | Revise urethra, stage 2 |  |  |  |  |  |
|  | 53410 R | Reconstruction of urethra |  |  |  |  |  |
|  | 53420 R | Reconstruct urethra, stage 1 |  |  |  |  |  |
|  | 53425 R | Reconstruct urethra, stage 2 |  |  |  |  |  |
|  | 53430 R | Reconstruction of urethra |  |  |  |  |  |
|  | 53447 R | Remove artificial sphincter |  |  |  |  |  |
|  | 53449 C | Correct artificial sphincter |  |  |  |  |  |
|  | 53450 R | Revision of urethra |  |  |  |  |  |
|  | 53460 R | Revision of urethra |  |  |  |  |  |
|  | 53515 R | Repair of urethra injury |  |  |  |  |  |
|  | 53520 R | Repair of urethra defect |  |  |  |  |  |
| 0169 | Lithotripsy |  | T | 46.72 | \$2,265.32 | \$1,384.20 | \$453.06 |
|  | 50590 F | Fragmenting of kidney stone |  |  |  |  |  |
| 0170 | Dialysis for | Other Than ESRD Patients | S | 6.68 | \$323.89 | \$72.26 | \$64.78 |
|  | 90935 H | Hemodialysis, one evaluation |  |  |  |  |  |
|  | 90945 D | Dialysis, one evaluation |  |  |  |  |  |
| 0180 | Circumcisio |  | T | 13.62 | \$660.39 | \$304.87 | \$132.08 |
|  | $54150$ | Circumcision |  |  |  |  |  |
|  | 54152 C | Circumcision |  |  |  |  |  |
|  | 54160 C | Circumcision |  |  |  |  |  |
|  | 54161 C | Circumcision |  |  |  |  |  |
| 0181 | Penile Proc | cedures | T | 32.37 | \$1,569.53 | \$906.36 | \$313.91 |
|  | 37790 P | Penile venous occlusion |  |  |  |  |  |
|  | 54110 T | Treatment of penis lesion |  |  |  |  |  |
|  | 54111 T | Treat penis lesion, graft |  |  |  |  |  |
|  | 54112 T | Treat penis lesion, graft |  |  |  |  |  |
|  | 54120 P | Partial removal of penis |  |  |  |  |  |
|  | 54205 T | Treatment of penis lesion |  |  |  |  |  |
|  | 54300 R | Revision of penis |  |  |  |  |  |
|  | 54304 R | Revision of penis |  |  |  |  |  |
|  | 54308 R | Reconstruction of urethra |  |  |  |  |  |
|  | 54312 R | Reconstruction of urethra |  |  |  |  |  |
|  | 54316 R | Reconstruction of urethra |  |  |  |  |  |
|  | 54318 R | Reconstruction of urethra |  |  |  |  |  |
|  | 54322 R | Reconstruction of urethra |  |  |  |  |  |
|  | 54324 R | Reconstruction of urethra |  |  |  |  |  |
|  | 54326 R | Reconstruction of urethra |  |  |  |  |  |
|  | 54328 R | Revise penis/urethra |  |  |  |  |  |
|  | 54340 S | Secondary urethral surgery |  |  |  |  |  |
|  | 54344 S | Secondary urethral surgery |  |  |  |  |  |
|  | 54348 S | Secondary urethral surgery |  |  |  |  |  |
|  | 54352 R | Reconstruct urethra/penis |  |  |  |  |  |
|  | 54360 P | Penis plastic surgery |  |  |  |  |  |
|  | 54380 R | Repair penis |  |  |  |  |  |
|  | 54385 R | Repair penis |  |  |  |  |  |
|  | 54402 R | Remove penis prosthesis |  |  |  |  |  |
|  | 54407 R | Remove multi-comp prosthesis |  |  |  |  |  |
|  | 54409 R | Revise penis prosthesis |  |  |  |  |  |
|  | 54420 R | Revision of penis |  |  |  |  |  |
|  | 54435 R | Revision of penis |  |  |  |  |  |
|  | 54440 R | Repair of penis |  |  |  |  |  |
| 0182 | Insertion of | Penile Prosthesis | T | 52.11 | \$2,526.66 | \$1,525.05 | \$505.33 |
|  | 53440 C | Correct bladder function |  |  |  |  |  |
|  | 53445 C | Correct urine flow control |  |  |  |  |  |
|  | 54400 In | Insert semi-rigid prosthesis |  |  |  |  |  |
|  | 54401 In | Insert self-contd prosthesis |  |  |  |  |  |
|  | 54405 In | Insert multi-comp prosthesis |  |  |  |  |  |
| 0183 | Testes/Epid | ididymis Procedures | T | 18.26 | \$885.37 | \$448.94 | \$177.07 |
|  | 54505 B | Biopsy of testis |  |  |  |  |  |
|  | 54510 R | Removal of testis lesion |  |  |  |  |  |
|  | 54520 R | Removal of testis |  |  |  |  |  |
|  | 54600 R | Reduce testis torsion |  |  |  |  |  |
|  | 54620 S | Suspension of testis |  |  |  |  |  |
|  | 54660 R | Revision of testis |  |  |  |  |  |
|  | 54670 R | Repair testis injury |  |  |  |  |  |
|  | 54680 R | Relocation of testis(es) |  |  |  |  |  |
|  | 54700 D | Drainage of scrotum |  |  |  |  |  |
|  | 54820 E | Exploration of epididymis |  |  |  |  |  |
|  | 54830 R | Remove epididymis lesion |  |  |  |  |  |
|  | 54840 R | Remove epididymis lesion |  |  |  |  |  |
|  | 54860 R | Removal of epididymis |  |  |  |  |  |

[^256]Copyright American Dental Association. All rights reserved.
${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment.
${ }^{2}$ Not subject to national coinsurance.
${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

## addendum C.-Proposed Hospital Outpatient Department (HOPD) Payment for Procedures by APCContinued

| APC | CPT/ <br> HCPCS | HCPCS Description | Status Indicator | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | 54861 | Removal of epididymis |  |  |  |  |  |
|  | 54900 | Fusion of spermatic ducts |  |  |  |  |  |
|  | 54901 | Fusion of spermatic ducts |  |  |  |  |  |
|  | 55060 | Repair of hydrocele |  |  |  |  |  |
|  | 55110 | Explore scrotum |  |  |  |  |  |
|  | 55120 | Removal of scrotum lesion |  |  |  |  |  |
|  | 55150 | Removal of scrotum |  |  |  |  |  |
|  | 55175 | Revision of scrotum |  |  |  |  |  |
|  | 55180 | Revision of scrotum |  |  |  |  |  |
|  | 55200 | Incision of sperm duct |  |  |  |  |  |
|  | 55250 | Removal of sperm duct(s) |  |  |  |  |  |
|  | 55400 | Repair of sperm duct |  |  |  |  |  |
|  | 55450 | Ligation of sperm duct |  |  |  |  |  |
|  | 55500 | Removal of hydrocele |  |  |  |  |  |
|  | 55520 | Removal of sperm cord lesion |  |  |  |  |  |
|  | 55530 | Revise spermatic cord veins |  |  |  |  |  |
|  | 55680 | Remove sperm pouch lesion |  |  |  |  |  |
| 0184 | Prostate B | Biopsy | T | 4.94 | \$239.53 | \$122.96 | \$47.91 |
|  | 55700 | Biopsy of prostate |  |  |  |  |  |
|  | 55705 | Biopsy of prostate |  |  |  |  |  |
| 0190 | Surgical H | Hysteroscopy | T | 17.85 | \$865.49 | \$443.89 | \$173.10 |
|  | 58558 | Hysteroscopy, biopsy |  |  |  |  |  |
|  | 58559 | Hysteroscopy, lysis |  |  |  |  |  |
|  | 58560 | Hysteroscopy, resect septum |  |  |  |  |  |
|  | 58561 | Hysteroscopy, remove myoma |  |  |  |  |  |
|  | 58562 | Hysteroscopy, remove fb |  |  |  |  |  |
|  | 58563 | Hysteroscopy, ablation |  |  |  |  |  |
|  | 58578 | Laparo proc, uterus |  |  |  |  |  |
|  | 58579 | Hysteroscope procedure |  |  |  |  |  |
| 0191 | Level I Fem | male Reproductive Procedures | T | 1.19 | \$57.70 | \$17.43 | \$11.54 |
|  | 57160 | Insert pessary/other device |  |  |  |  |  |
|  | 57170 | Fitting of diaphragm/cap |  |  |  |  |  |
|  | 57452 | Examination of vagina |  |  |  |  |  |
|  | 58100 | Biopsy of uterus lining |  |  |  |  |  |
|  | 58301 | Remove intrauterine device |  |  |  |  |  |
|  | 58555 | Hysteroscopy, dx, sep proc |  |  |  |  |  |
|  | 59200 | Insert cervical dilator |  |  |  |  |  |
|  | Q0091 | Obtaining screen pap smear |  |  |  |  |  |
| 0192 | Level II Fe | emale Reproductive Procedures | T | 2.38 | \$115.40 | \$35.33 | \$23.08 |
|  | 56405 | I \& D of vulva/perineum |  |  |  |  |  |
|  | 56420 | Drainage of gland abscess |  |  |  |  |  |
|  | 57100 | Biopsy of vagina |  |  |  |  |  |
|  | 57150 | Treat vagina infection |  |  |  |  |  |
|  | 57180 | Treat vaginal bleeding |  |  |  |  |  |
|  | 57454 | Vagina examination \& biopsy |  |  |  |  |  |
|  | 57505 | Endocervical curettage |  |  |  |  |  |
|  | 57511 | Cryocautery of cervix |  |  |  |  |  |
|  | 99170 | Anogenital exam, child |  |  |  |  |  |
| 0193 | Level III F | Female Reproductive Procedures | T | 8.93 | \$432.99 | \$171.13 | \$86.60 |
|  | 56441 | Lysis of labial lesion(s) |  |  |  |  |  |
|  | 56720 | Incision of hymen |  |  |  |  |  |
|  | 57020 | Drainage of pelvic fluid |  |  |  |  |  |
|  | 57460 | Cervix excision |  |  |  |  |  |
|  | 57500 | Biopsy of cervix |  |  |  |  |  |
|  | 57510 | Cauterization of cervix |  |  |  |  |  |
|  | 57513 | Laser surgery of cervix |  |  |  |  |  |
|  | 57800 | Dilation of cervical canal |  |  |  |  |  |
| 0194 | Level IV F | Female Reproductive Procedures | T | 16.21 | \$785.98 | \$395.94 | \$157.20 |
|  | 56440 | Surgery for vulva lesion |  |  |  |  |  |
|  | 56700 | Partial removal of hymen |  |  |  |  |  |
|  | 56740 | Remove vagina gland lesion |  |  |  |  |  |
|  | 56800 | Repair of vagina |  |  |  |  |  |
|  | 56810 | Repair of perineum |  |  |  |  |  |
|  | 57000 | Exploration of vagina |  |  |  |  |  |
|  | 57010 | Drainage of pelvic abscess |  |  |  |  |  |
|  | 57061 | Destruction vagina lesion(s) |  |  |  |  |  |
|  | 57065 | Destruction vagina lesion(s) |  |  |  |  |  |
|  | 57105 | Biopsy of vagina |  |  |  |  |  |
|  | 57106 | Remove vagina wall, partial |  |  |  |  |  |
|  | 57107 | Remove vagina tissue, part |  |  |  |  |  |
|  | 57109 | Vaginectomy partial w/nodes |  |  |  |  |  |
|  | 57130 | Remove vagina lesion |  |  |  |  |  |
|  | 57135 | Remove vagina lesion |  |  |  |  |  |

CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
Copyright American Dental Association. All rights reserved.
${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment.
${ }^{2}$ Not subject to national coinsurance.
${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

Addendum C.—Proposed Hospital Outpatient Department (HOPD) Payment for Procedures by APCContinued


CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
Copyright American Dental Association. All rights reserved.
${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment.
${ }^{2}$ Not subject to national coinsurance.
${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

| Addendum C.-Proposed Hospital Outpatient Department (HOPD) Payment for Procedures by APC- |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| APC | CPT/ HCPCS | HCPCS Description | Status Indicator | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| 0210 | $\begin{aligned} & \text { Spinal Tap } \\ & 62270 \quad \text { S } \\ & 62272 \quad \text { D } \end{aligned}$ | Spinal fluid tap, diagnostic Drain spinal fluid | T | 3.00 | \$145.46 | \$62.40 | \$29.09 |
| 0211 | Level I Nerv | vous System Injections | T | 3.32 | \$160.98 | \$74.78 | \$32.20 |
|  | 64400 In | Injection for nerve block |  |  |  |  |  |
|  | 64402 In | Injection for nerve block |  |  |  |  |  |
|  | 64405 In | Injection for nerve block |  |  |  |  |  |
|  | 64408 In | Injection for nerve block |  |  |  |  |  |
|  | 64410 In | Injection for nerve block |  |  |  |  |  |
|  | 64412 In | Injection for nerve block |  |  |  |  |  |
|  | 64413 In | Injection for nerve block |  |  |  |  |  |
|  | 64415 In | Injection for nerve block |  |  |  |  |  |
|  | 64417 In | Injection for nerve block |  |  |  |  |  |
|  | 64418 In | Injection for nerve block |  |  |  |  |  |
|  | 64420 In | Injection for nerve block |  |  |  |  |  |
|  | 64421 In | Injection for nerve block |  |  |  |  |  |
|  | 64425 In | Injection for nerve block |  |  |  |  |  |
|  | 64430 In | Injection for nerve block |  |  |  |  |  |
|  | 64435 In | Injection for nerve block |  |  |  |  |  |
|  | 64445 In | Injection for nerve block |  |  |  |  |  |
|  | 64450 In | Injection for nerve block |  |  |  |  |  |
|  | 64470 In | Inj paravertebral c/t |  |  |  |  |  |
|  | 64472 In | Inj paravertebral c/t add-on |  |  |  |  |  |
|  | 64475 In | Inj paravertebral l/s |  |  |  |  |  |
|  | 64476 In | Inj paravertebral I/s add-on |  |  |  |  |  |
|  | 64479 In | nj foramen epidural c/t |  |  |  |  |  |
|  | 64480 In | Inj foramen epidural add-on |  |  |  |  |  |
|  | 64483 In | Inj foramen epidural l/s |  |  |  |  |  |
|  | 64484 In | foramen epidural add-on |  |  |  |  |  |
|  | 64505 In | njection for nerve block |  |  |  |  |  |
|  | 64508 In | Injection for nerve block |  |  |  |  |  |
|  | 64510 In | Injection for nerve block |  |  |  |  |  |
|  | 64520 In | Injection for nerve block |  |  |  |  |  |
|  | 64530 In | Injection for nerve block |  |  |  |  |  |
|  | 64600 In | Injection treatment of nerve |  |  |  |  |  |
|  | 64605 In | Injection treatment of nerve |  |  |  |  |  |
|  | 64610 In | Injection treatment of nerve |  |  |  |  |  |
|  | 64612 D | Destroy nerve, face muscle |  |  |  |  |  |
|  | 64613 D | Destroy nerve, spine muscle |  |  |  |  |  |
|  | 64620 In | Injection treatment of nerve |  |  |  |  |  |
|  | 64622 D | Destr paravertebrl nerve l/s |  |  |  |  |  |
|  | 64623 D | Destr paravertebral n add-on |  |  |  |  |  |
|  | 64626 D | Destr paravertebrl nerve c/t |  |  |  |  |  |
|  | 64627 D | Destr paravertebral n add-on |  |  |  |  |  |
|  | 64630 In | Injection treatment of nerve |  |  |  |  |  |
|  | 64640 In | Injection treatment of nerve |  |  |  |  |  |
|  | 64680 In | Injection treatment of nerve |  |  |  |  |  |
|  | 64999 N | Nervous system surgery |  |  |  |  |  |
| 0212 | Level II Ner | rvous System Injections | T | 3.64 | \$176.49 | \$88.78 | \$35.30 |
|  | 61000 R | Remove cranial cavity fluid |  |  |  |  |  |
|  | 61001 R | Remove cranial cavity fluid |  |  |  |  |  |
|  | 61020 R | Remove brain cavity fluid |  |  |  |  |  |
|  | 61026 In | Injection into brain canal |  |  |  |  |  |
|  | 61050 R | Remove brain canal fluid |  |  |  |  |  |
|  | 61055 In | Injection into brain canal |  |  |  |  |  |
|  | 61070 B | Brain canal shunt procedure |  |  |  |  |  |
|  | 62263 L | Lysis epidural adhesions |  |  |  |  |  |
|  | 62268 D | Drain spinal cord cyst |  |  |  |  |  |
|  | 62273 T | Treat epidural spine lesion |  |  |  |  |  |
|  | 62280 T | Treat spinal cord lesion |  |  |  |  |  |
|  | 62281 T | Treat spinal cord lesion |  |  |  |  |  |
|  | 62282 T | Treat spinal canal lesion |  |  |  |  |  |
|  | 62292 In | Injection into disk lesion |  |  |  |  |  |
|  | 62294 In | njection into spinal artery |  |  |  |  |  |
|  | 62310 In | nject spine c/t |  |  |  |  |  |
|  | 62311 In | Inject spine I/s (cd) |  |  |  |  |  |
|  | 62318 In | Inject spine w/cath, c/t |  |  |  |  |  |
|  | 62319 In | Inject spine w/cath l/s (cd) |  |  |  |  |  |
| 0213 | Extended E | EEG Studies and Sleep Studies | S | 11.15 | \$540.63 | \$290.42 | \$108.13 |
|  | 95805 M | Multiple sleep latency test |  |  |  |  |  |
|  | 95806 S | Sleep study, unattended |  |  |  |  |  |
|  | 95807 S | Sleep study, attended |  |  |  |  |  |
|  | 95808 P | Polysomnography, 1-3 |  |  |  |  |  |

CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
Copyright American Dental Association. All rights reserved.
${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment.
${ }^{2}$ Not subject to national coinsurance.
${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

Addendum C.—Proposed Hospital Outpatient Department (HOPD) Payment for Procedures by APC— Continued

| APC | CPT/ <br> HCPCS | HCPCS Description | Status Indicator | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | 95810 | Polysomnography, 4 or more |  |  |  |  |  |
|  | 95811 | Polysomnography w/cpap |  |  |  |  |  |
|  | 95812 | Electroencephalogram (EEG) |  |  |  |  |  |
|  | 95813 | Electroencephalogram (EEG) |  |  |  |  |  |
|  | 95827 | Night electroencephalogram |  |  |  |  |  |
|  | 95951 | EEG monitoring/videorecord |  |  |  |  |  |
|  | 95953 | EEG monitoring/computer |  |  |  |  |  |
|  | 95954 | EEG monitoring/giving drugs |  |  |  |  |  |
|  | 95958 | EEG monitoring/function test |  |  |  |  |  |
| 0214 | Electroencephalogram |  | S | 2.32 | \$112.49 | \$58.50 | \$22.50 |
|  | 95816 | Electroencephalogram (EEG) |  |  |  |  |  |
|  | 95819 | Electroencephalogram (EEG) |  |  |  |  |  |
|  | 95822 | Sleep electroencephalogram |  |  |  |  |  |
|  | 95824 | Electroencephalography |  |  |  |  |  |
|  | 95829 | Surgery electrocorticogram |  |  |  |  |  |
|  | 95955 | EEG during surgery |  |  |  |  |  |
| 0215 | Level I Nerve and Muscle Tests |  | S | 1.15 | \$55.76 | \$30.05 | \$11.15 |
|  | 95857 | Tensilon test |  |  |  |  |  |
|  | 95858 | Tensilon test \& myogram |  |  |  |  |  |
|  | 95860 | Muscle test, one limb |  |  |  |  |  |
|  | 95861 | Muscle test, two limbs |  |  |  |  |  |
|  | 95864 | Muscle test, 4 limbs |  |  |  |  |  |
|  | 95869 | Muscle test, thor paraspinal |  |  |  |  |  |
|  | 95870 | Muscle test, nonparaspinal |  |  |  |  |  |
|  | 95872 | Muscle test, one fiber |  |  |  |  |  |
|  | 95900 | Motor nerve conduction test |  |  |  |  |  |
|  | 95903 | Motor nerve conduction test |  |  |  |  |  |
|  | 95904 | Sense/mixed n conduction tst |  |  |  |  |  |
|  | 95933 | Blink reflex test |  |  |  |  |  |
|  | 95934 | H-reflex test |  |  |  |  |  |
|  | 95937 | Neuromuscular junction test |  |  |  |  |  |
| 0216 | Level II Nerve and Muscle Tests |  | S | 2.87 | \$139.16 | \$64.69 | \$27.83 |
|  | 92275 | Electroretinography |  |  |  |  |  |
|  | 92585 | Auditory evoked potential |  |  |  |  |  |
|  | 95863 | Muscle test, 3 limbs |  |  |  |  |  |
|  | 95867 | Muscle test, head or neck |  |  |  |  |  |
|  | 95868 | Muscle test, head or neck |  |  |  |  |  |
|  | 95921 | Autonomic nerv function test |  |  |  |  |  |
|  | 95922 | Autonomic nerv function test |  |  |  |  |  |
|  | 95923 | Autonomic nerv function test |  |  |  |  |  |
|  | 95925 | Somatosensory testing |  |  |  |  |  |
|  | 95926 | Somatosensory testing |  |  |  |  |  |
|  | 95927 | Somatosensory testing |  |  |  |  |  |
|  | 95930 | Visual evoked potential test |  |  |  |  |  |
|  | 95936 | H-reflex test |  |  |  |  |  |
| 0217 | Level III Nerve and Muscle Tests |  | S | 5.87 | \$284.62 | \$156.68 | \$56.92 |
|  | 95875 | Limb exercise test |  |  |  |  |  |
|  | 95950 | Ambulatory eeg monitoring |  |  |  |  |  |
| 0220 | Level I Nerve Procedures |  | T | 13.96 | \$676.88 | \$326.21 | \$135.38 |
|  | 27315 | Partial removal, thigh nerve |  |  |  |  |  |
|  | 27320 | Partial removal, thigh nerve |  |  |  |  |  |
|  | 28030 | Removal of foot nerve |  |  |  |  |  |
|  | 28035 | Decompression of tibia nerve |  |  |  |  |  |
|  | 61790 | Treat trigeminal nerve |  |  |  |  |  |
|  | 62287 | Percutaneous diskectomy |  |  |  |  |  |
|  | 63600 | Remove spinal cord lesion |  |  |  |  |  |
|  | 63610 | Stimulation of spinal cord |  |  |  |  |  |
|  | 63615 | Remove lesion of spinal cord |  |  |  |  |  |
|  | 64702 | Revise finger/toe nerve |  |  |  |  |  |
|  | 64704 | Revise hand/foot nerve |  |  |  |  |  |
|  | 64708 | Revise arm/leg nerve |  |  |  |  |  |
|  | 64712 | Revision of sciatic nerve |  |  |  |  |  |
|  | 64713 | Revision of arm nerve(s) |  |  |  |  |  |
|  | 64714 | Revise low back nerve(s) |  |  |  |  |  |
|  | 64716 | Revision of cranial nerve |  |  |  |  |  |
|  | 64718 | Revise ulnar nerve at elbow |  |  |  |  |  |
|  | 64719 | Revise ulnar nerve at wrist |  |  |  |  |  |
|  | 64721 | Carpal tunnel surgery |  |  |  |  |  |
|  | 64722 | Relieve pressure on nerve(s) |  |  |  |  |  |
|  | 64726 | Release foot/toe nerve |  |  |  |  |  |
|  | 64727 | Internal nerve revision |  |  |  |  |  |
|  | 64732 | Incision of brow nerve |  |  |  |  |  |
|  | 64734 | Incision of cheek nerve |  |  |  |  |  |

CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
Copyright American Dental Association. All rights reserved.
${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment.
${ }^{2}$ Not subject to national coinsurance.
${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

Addendum C.-Proposed Hospital Outpatient Department (HOPD) Payment for Procedures by APC-

| APC | CPT/ <br> HCPCS | HCPCS Description | Status Indicator | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | 64736 | Incision of chin nerve |  |  |  |  |  |
|  | 64738 | Incision of jaw nerve |  |  |  |  |  |
|  | 64740 | Incision of tongue nerve |  |  |  |  |  |
|  | 64742 | Incision of facial nerve |  |  |  |  |  |
|  | 64744 | Incise nerve, back of head |  |  |  |  |  |
|  | 64746 | Incise diaphragm nerve |  |  |  |  |  |
|  | 64761 | Incision of pelvis nerve |  |  |  |  |  |
|  | 64771 | Sever cranial nerve |  |  |  |  |  |
|  | 64772 | Incision of spinal nerve |  |  |  |  |  |
|  | 64774 | Remove skin nerve lesion |  |  |  |  |  |
|  | 64776 | Remove digit nerve lesion |  |  |  |  |  |
|  | 64778 | Digit nerve surgery add-on |  |  |  |  |  |
|  | 64782 | Remove limb nerve lesion |  |  |  |  |  |
|  | 64783 | Limb nerve surgery add-on |  |  |  |  |  |
|  | 64784 | Remove nerve lesion |  |  |  |  |  |
|  | 64787 | Implant nerve end |  |  |  |  |  |
|  | 64788 | Remove skin nerve lesion |  |  |  |  |  |
|  | 64790 | Removal of nerve lesion |  |  |  |  |  |
|  | 64795 | Biopsy of nerve |  |  |  |  |  |
| 0221 | Level II Ne | erve Procedures | T | 18.36 | \$890.22 | \$463.62 | \$178.04 |
|  | $64786$ | Remove sciatic nerve lesion |  |  |  |  |  |
|  | 64792 | Removal of nerve lesion |  |  |  |  |  |
|  | 64831 | Repair of digit nerve |  |  |  |  |  |
|  | 64832 | Repair nerve add-on |  |  |  |  |  |
|  | 64834 | Repair of hand or foot nerve |  |  |  |  |  |
|  | 64835 | Repair of hand or foot nerve |  |  |  |  |  |
|  | 64836 | Repair of hand or foot nerve |  |  |  |  |  |
|  | 64837 | Repair nerve add-on |  |  |  |  |  |
|  | 64840 | Repair of leg nerve |  |  |  |  |  |
|  | 64856 | Repair/transpose nerve |  |  |  |  |  |
|  | 64857 | Repair arm/leg nerve |  |  |  |  |  |
|  | 64858 | Repair sciatic nerve |  |  |  |  |  |
|  | 64859 | Nerve surgery |  |  |  |  |  |
|  | 64861 | Repair of arm nerves |  |  |  |  |  |
|  | 64862 | Repair of low back nerves |  |  |  |  |  |
|  | 64864 | Repair of facial nerve |  |  |  |  |  |
|  | 64865 | Repair of facial nerve |  |  |  |  |  |
|  | 64870 | Fusion of facial/other nerve |  |  |  |  |  |
|  | 64872 | Subsequent repair of nerve |  |  |  |  |  |
|  | 64874 | Repair \& revise nerve add-on |  |  |  |  |  |
|  | 64876 | Repair nerve/shorten bone |  |  |  |  |  |
|  | 64885 | Nerve graft, head or neck |  |  |  |  |  |
|  | 64886 | Nerve graft, head or neck |  |  |  |  |  |
|  | 64890 | Nerve graft, hand or foot |  |  |  |  |  |
|  | 64891 | Nerve graft, hand or foot |  |  |  |  |  |
|  | 64892 | Nerve graft, arm or leg |  |  |  |  |  |
|  | 64893 | Nerve graft, arm or leg |  |  |  |  |  |
|  | 64895 | Nerve graft, hand or foot |  |  |  |  |  |
|  | 64896 | Nerve graft, hand or foot |  |  |  |  |  |
|  | 64897 | Nerve graft, arm or leg |  |  |  |  |  |
|  | 64898 | Nerve graft, arm or leg |  |  |  |  |  |
|  | 64901 | Nerve graft add-on |  |  |  |  |  |
|  | 64902 | Nerve graft add-on |  |  |  |  |  |
|  | 64905 | Nerve pedicle transfer |  |  |  |  |  |
|  | 64907 | Nerve pedicle transfer |  |  |  |  |  |
| 0222 | Implantatio | on of Neurological Device | T | 25.48 | \$1,235.45 | \$780.07 | \$247.09 |
|  | 61215 | Insert brain-fluid device |  |  |  |  |  |
|  | 61885 | Implant neurostim one array |  |  |  |  |  |
|  | 62360 | Insert spine infusion device |  |  |  |  |  |
|  | 62361 | Implant spine infusion pump |  |  |  |  |  |
|  | 62362 | Implant spine infusion pump |  |  |  |  |  |
|  | 63685 | Implant neuroreceiver |  |  |  |  |  |
|  | 64590 | Implant neuroreceiver |  |  |  |  |  |
| 0223 | Level I Rev | evision/Removal Neurological Device | T | 6.34 | \$307.41 | \$153.24 | \$61.48 |
|  | 62350 I | Implant spinal canal cath |  |  |  |  |  |
|  | 62355 | Remove spinal canal catheter |  |  |  |  |  |
|  | 63746 | Removal of spinal shunt |  |  |  |  |  |
| 0224 | Level II Revision/Removal Neurological Device |  | T | 15.94 | \$772.88 | \$374.61 | \$154.58 |
|  | 62230 | Replace/revise brain shunt |  |  |  |  |  |
|  | 62365 | Remove spine infusion device |  |  |  |  |  |
|  | 63650 | Implant neuroelectrodes |  |  |  |  |  |
|  | 63660 | Revise/remove neuroelectrode |  |  |  |  |  |
|  | 63688 | Revise/remove neuroreceiver |  |  |  |  |  |

CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
Copyright American Dental Association. All rights reserved.
${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment.
${ }^{2}$ Not subject to national coinsurance.
${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

Addendum C.-Proposed Hospital Outpatient Department (HOPD) Payment for Procedures by APC-
Continued

| APC | CPT/ HCPCS Description | Status Indicator | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 0225 | 63744 Revision of spinal shunt |  |  |  |  |  |
|  | Implantation of Neurostimulator Electrodes | T | 3.43 | \$166.31 | \$64.46 | \$33.26 |
|  | 64553 Implant neuroelectrodes |  |  |  |  |  |
|  | 64555 Implant neuroelectrodes |  |  |  |  |  |
|  | 64560 Implant neuroelectrodes |  |  |  |  |  |
|  | 64565 Implant neuroelectrodes |  |  |  |  |  |
|  | 64573 Implant neuroelectrodes |  |  |  |  |  |
|  | 64575 Implant neuroelectrodes |  |  |  |  |  |
|  | 64577 Implant neuroelectrodes |  |  |  |  |  |
|  | 64580 Implant neuroelectrodes |  |  |  |  |  |
|  | 64585 Revise/remove neuroelectrode |  |  |  |  |  |
|  | 64595 Revise/remove neuroreceiver |  |  |  |  |  |
| 0230 | Level I Eye Tests | S | 0.98 | \$47.52 | \$22.48 | \$9.50 |
|  | 68200 Treat eyelid by injection |  |  |  |  |  |
|  | 92020 Special eye evaluation |  |  |  |  |  |
|  | 92060 Special eye evaluation |  |  |  |  |  |
|  | 92065 Orthoptic/pleoptic training |  |  |  |  |  |
|  | 92081 Visual field examination(s) |  |  |  |  |  |
|  | 92082 Visual field examination(s) |  |  |  |  |  |
|  | 92083 Visual field examination(s) |  |  |  |  |  |
|  | 92120 Tonography \& eye evaluation |  |  |  |  |  |
|  | 92130 Water provocation tonography |  |  |  |  |  |
|  | 92225 Special eye exam, initial |  |  |  |  |  |
|  | 92250 Eye exam with photos |  |  |  |  |  |
|  | 92260 Ophthalmoscopy/dynamometry |  |  |  |  |  |
|  | 92265 Eye muscle evaluation |  |  |  |  |  |
|  | 92270 Electro-oculography |  |  |  |  |  |
|  | 92283 Color vision examination |  |  |  |  |  |
|  | 92285 Eye photography |  |  |  |  |  |
|  | 92330 Fitting of artificial eye |  |  |  |  |  |
|  | 92499 Eye service or procedure |  |  |  |  |  |
| 0231 | Level II Eye Tests | S | 2.64 | \$128.01 | \$59.87 | \$25.60 |
|  | 65205 Remove foreign body from eye |  |  |  |  |  |
|  | 65210 Remove foreign body from eye |  |  |  |  |  |
|  | 65220 Remove foreign body from eye |  |  |  |  |  |
|  | 65222 Remove foreign body from eye |  |  |  |  |  |
|  | 65430 Corneal smear |  |  |  |  |  |
|  | 67350 Biopsy eye muscle |  |  |  |  |  |
|  | 67500 Inject/treat eye socket |  |  |  |  |  |
|  | 68110 Remove eyelid lining lesion |  |  |  |  |  |
|  | 68761 Close tear duct opening |  |  |  |  |  |
|  | 68801 Dilate tear duct opening |  |  |  |  |  |
|  | 68810 Probe nasolacrimal duct |  |  |  |  |  |
|  | 68840 Explore/irrigate tear ducts |  |  |  |  |  |
|  | 68899 Tear duct system surgery |  |  |  |  |  |
|  | 92018 New eye exam \& treatment |  |  |  |  |  |
|  | 92019 Eye exam \& treatment |  |  |  |  |  |
|  | 92135 Opthalmic dx imaging |  |  |  |  |  |
|  | 92140 Glaucoma provocative tests |  |  |  |  |  |
|  | 92226 Special eye exam, subsequent |  |  |  |  |  |
|  | 92230 Eye exam with photos |  |  |  |  |  |
|  | 92235 Eye exam with photos |  |  |  |  |  |
|  | 92240 Icg angiography |  |  |  |  |  |
|  | 92284 Dark adaptation eye exam |  |  |  |  |  |
|  | 92286 Internal eye photography |  |  |  |  |  |
|  | 92287 Internal eye photography |  |  |  |  |  |
| 0232 | Level I Anterior Segment Eye | T | 6.04 | \$292.86 | \$134.66 | \$58.57 |
|  | 65235 Remove foreign body from eye |  |  |  |  |  |
|  | 65272 Repair of eye wound |  |  |  |  |  |
|  | 65286 Repair of eye wound |  |  |  |  |  |
|  | 65400 Removal of eye lesion |  |  |  |  |  |
|  | 65436 Curette/treat cornea |  |  |  |  |  |
|  | 65450 Treatment of corneal lesion |  |  |  |  |  |
|  | 65772 Correction of astigmatism |  |  |  |  |  |
|  | 65800 Drainage of eye |  |  |  |  |  |
|  | 65820 Relieve inner eye pressure |  |  |  |  |  |
|  | 65880 Incise inner eye adhesions |  |  |  |  |  |
|  | 65900 Remove eye lesion |  |  |  |  |  |
|  | 66020 Injection treatment of eye |  |  |  |  |  |
|  | 66030 Injection treatment of eye |  |  |  |  |  |
|  | 66500 Incision of iris |  |  |  |  |  |
|  | 66505 Incision of iris |  |  |  |  |  |
|  | 66625 Removal of iris |  |  |  |  |  |

CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
Copyright American Dental Association. All rights reserved.
${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment.
${ }^{2}$ Not subject to national coinsurance.
${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

## addendum C.-Proposed Hospital Outpatient Department (HOPD) Payment for Procedures by APCContinued



CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
Copyright American Dental Association. All rights reserved.
${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment.
${ }^{2}$ Not subject to national coinsurance.
${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

Addendum C.-Proposed Hospital Outpatient Department (HOPD) Payment for Procedures by APC-
Continued

| APC | $\begin{gathered} \text { CPT/ } \\ \text { HCPCS } \end{gathered}$ | HCPCS Description | Status Indicator | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 0238 | 67108 | Repair detached retina |  |  |  |  |  |
|  | 67112 | Rerepair detached retina |  |  |  |  |  |
|  | 67121 | Remove eye implant material |  |  |  |  |  |
|  | 67218 | Treatment of retinal lesion |  |  |  |  |  |
|  | 67220 | Treatment of choroid lesion |  |  |  |  |  |
|  | 67255 | Reinforce/graft eye wall |  |  |  |  |  |
|  | Level I Re | epair and Plastic Eye Procedures | T | 2.80 | \$135.76 | \$58.96 | \$27.15 |
|  | 67345 | Destroy nerve of eye muscle |  |  |  |  |  |
|  | 67505 | Inject/treat eye socket |  |  |  |  |  |
|  | 67700 | Drainage of eyelid abscess |  |  |  |  |  |
|  | 67800 | Remove eyelid lesion |  |  |  |  |  |
|  | 67805 | Remove eyelid lesions |  |  |  |  |  |
|  | 67810 | Biopsy of eyelid |  |  |  |  |  |
|  | 67820 | Revise eyelashes |  |  |  |  |  |
|  | 67825 | Revise eyelashes |  |  |  |  |  |
|  | 67938 | Remove eyelid foreign body |  |  |  |  |  |
|  | 68400 | Incise/drain tear gland |  |  |  |  |  |
|  | 68440 | Incise tear duct opening |  |  |  |  |  |
|  | 68705 | Revise tear duct opening |  |  |  |  |  |
|  | 68760 | Close tear duct opening |  |  |  |  |  |
| 0239 | Level II R | Repair and Plastic Eye Procedures | T | 6.26 | \$303.53 | \$123.42 | \$60.71 |
|  | 65435 | Curette/treat cornea |  |  |  |  |  |
|  | 67415 | Aspiration, orbital contents |  |  |  |  |  |
|  | 67515 | Inject/treat eye socket |  |  |  |  |  |
|  | 67599 | Orbit surgery procedure |  |  |  |  |  |
|  | 67710 | Incision of eyelid |  |  |  |  |  |
|  | 67801 | Remove eyelid lesions |  |  |  |  |  |
|  | 67830 | Revise eyelashes |  |  |  |  |  |
|  | 67840 | Remove eyelid lesion |  |  |  |  |  |
|  | 67850 | Treat eyelid lesion |  |  |  |  |  |
|  | 67875 | Closure of eyelid by suture |  |  |  |  |  |
|  | 67915 | Repair eyelid defect |  |  |  |  |  |
|  | 67922 | Repair eyelid defect |  |  |  |  |  |
|  | 68040 | Treatment of eyelid lesions |  |  |  |  |  |
|  | 68115 | Remove eyelid lining lesion |  |  |  |  |  |
|  | 68135 | Remove eyelid lining lesion |  |  |  |  |  |
|  | 68399 | Eyelid lining surgery |  |  |  |  |  |
| 0240 | Level III P | Repair and Plastic Eye Procedures | T | 13.47 | \$653.12 | \$315.31 | \$130.62 |
|  | 65125 | Revise ocular implant |  |  |  |  |  |
|  | 65175 | Removal of ocular implant |  |  |  |  |  |
|  | 65270 | Repair of eye wound |  |  |  |  |  |
|  | 65600 | Revision of cornea |  |  |  |  |  |
|  | 67250 | Reinforce eye wall |  |  |  |  |  |
|  | 67715 | Incision of eyelid fold |  |  |  |  |  |
|  | 67808 | Remove eyelid lesion(s) |  |  |  |  |  |
|  | 67835 | Revise eyelashes |  |  |  |  |  |
|  | 67882 | Revision of eyelid |  |  |  |  |  |
|  | 67900 | Repair brow defect |  |  |  |  |  |
|  | 67901 | Repair eyelid defect |  |  |  |  |  |
|  | 67902 | Repair eyelid defect |  |  |  |  |  |
|  | 67903 | Repair eyelid defect |  |  |  |  |  |
|  | 67904 | Repair eyelid defect |  |  |  |  |  |
|  | 67906 | Repair eyelid defect |  |  |  |  |  |
|  | 67908 | Repair eyelid defect |  |  |  |  |  |
|  | 67909 | Revise eyelid defect |  |  |  |  |  |
|  | 67911 | Revise eyelid defect |  |  |  |  |  |
|  | 67914 | Repair eyelid defect |  |  |  |  |  |
|  | 67916 | Repair eyelid defect |  |  |  |  |  |
|  | 67917 | Repair eyelid defect |  |  |  |  |  |
|  | 67921 | Repair eyelid defect |  |  |  |  |  |
|  | 67923 | Repair eyelid defect |  |  |  |  |  |
|  | 67924 | Repair eyelid defect |  |  |  |  |  |
|  | 67930 | Repair eyelid wound |  |  |  |  |  |
|  | 67935 | Repair eyelid wound |  |  |  |  |  |
|  | 67950 | Revision of eyelid |  |  |  |  |  |
|  | 67961 | Revision of eyelid |  |  |  |  |  |
|  | 67966 | Revision of eyelid |  |  |  |  |  |
|  | 67975 | Reconstruction of eyelid |  |  |  |  |  |
|  | 67999 | Revision of eyelid |  |  |  |  |  |
|  | 68020 | Incise/drain eyelid lining |  |  |  |  |  |
|  | 68320 | Revise/graft eyelid lining |  |  |  |  |  |
|  | 68340 | Separate eyelid adhesions |  |  |  |  |  |
|  | 68420 | Incise/drain tear sac |  |  |  |  |  |

CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
Copyright American Dental Association. All rights reserved.
${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment.
${ }^{2}$ Not subject to national coinsurance.
${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

Addendum C.-Proposed Hospital Outpatient Department (HOPD) Payment for Procedures by APC-

| APC | CPT/ |
| :--- | :---: | :---: | :---: | :---: | :---: |
| HCPCS |  |$\quad$ HCPCS Description $\quad$| Status |
| :---: |
| Indicator | | Relative |
| :---: |
| Weight | | Payment |
| :---: |
| Rate | | National |
| :---: |
| Unadjusted |
| Coinsurance |$\quad$| Minimum |
| :---: |
| Unadjusted |
| Coinsurance |


| 68510 | Biopsy of tear gland |
| :--- | :--- |
| 68525 | Biopsy of tear sac |
| 68530 | Clearance of tear duct |
| 68770 | Close tear system fistula |
| 68811 | Probe nasolacrimal duct |
| 68815 | Probe nasolacrimal duct |


| 0241 | Level IV Repair and Plastic Eye Procedures | T | 16.60 | $\$ 804.89$ |
| :--- | :--- | :--- | :--- | :--- |

65093 Revise eye with implant
65130 Insert ocular implant
65135 Insert ocular implant
65150 Revise ocular implant
67400 Explore/biopsy eye socket
67405 Explore/drain eye socket
67412 Explore/treat eye socket
67413 Explore/treat eye socket
67560 Revise eye socket implant
67971 Reconstruction of eyelid
67973 Reconstruction of eyelid
67974 Reconstruction of eyelid
68326 Revise/graft eyelid lining
68328 Revise/graft eyelid lining
68335 Revise/graft eyelid lining
68500 Removal of tear gland
68505 Partial removal, tear gland
68520 Removal of tear sac
68540 Remove tear gland lesion
68700 Repair tear ducts
68745 Create tear duct drain

| 0242 | Level V Repair and Plastic Eye Procedures | T | 23.70 | $\$ 1,149.14$ |
| :--- | :--- | :--- | :--- | :--- |

65091 Revise eye
65101 Removal of eye
65103 Remove eye/insert implant
65105 Remove eye/attach implant
65110 Removal of eye
65112 Remove eye/revise socket
65114 Remove eye/revise socket
65140 Attach ocular implant
65155 Reinsert ocular implant
67414 Explr/decompress eye socket
67420 Explore/treat eye socket
67430 Explore/treat eye socket
67440 Explore/drain eye socket
67445 Explr/decompress eye socket
67450 Explore/biopsy eye socket
67550 Insert eye socket implant
67570 Decompress optic nerve
68325 Revise/graft eyelid lining
68550 Remove tear gland lesion
68720 Create tear sac drain
68750 Create tear duct drain
0243 Strabismus/Muscle Procedures
65290 Repair of eye socket wound
67311 Revise eye muscle
67312 Revise two eye muscles
67314 Revise eye muscle
67316 Revise two eye muscles
67318 Revise eye muscle(s)
67320 Revise eye muscle(s) add-on
67331 Eye surgery follow-up add-on
67332 Rerevise eye muscles add-on
67334 Revise eye muscle w/suture
67335 Eye suture during surgery
67340 Revise eye muscle add-on
67343 Release eye tissue
67399 Eye muscle surgery procedure
65710 Corneal transplant
65730 Corneal transplant
65750 Corneal transplant
65755 Corneal transplant
65770 Revise cornea with implant
0245 Cataract Procedures without IOL Insert
66840 Removal of lens material

CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
Copyright American Dental Association. All rights reserved.
${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment.
${ }^{2}$ Not subject to national coinsurance.
${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

Addendum C.—Proposed Hospital Outpatient Department (HOPD) Payment for Procedures by APC— Continued


CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
Copyright American Dental Association. All rights reserved.
${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment.
${ }^{2}$ Not subject to national coinsurance.
${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.
addendum C.-Proposed Hospital Outpatient Department (hopd) Payment for Procedures by APC-
Continued

| APC | CPT/ HCPCS | HCPCS Description | Status Indicator | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | 31002 | Irrigation, sphenoid sinus |  |  |  |  |  |
|  | 31299 | Sinus surgery procedure |  |  |  |  |  |
|  | 40490 | Biopsy of lip |  |  |  |  |  |
|  | 40801 | Drainage of mouth lesion |  |  |  |  |  |
|  | 40805 | Removal, foreign body, mouth |  |  |  |  |  |
|  | 40812 | Excise/repair mouth lesion |  |  |  |  |  |
|  | 40819 | Excise lip or cheek fold |  |  |  |  |  |
|  | 40899 | Mouth surgery procedure |  |  |  |  |  |
|  | 41015 | Drainage of mouth lesion |  |  |  |  |  |
|  | 41100 | Biopsy of tongue |  |  |  |  |  |
|  | 41108 | Biopsy of floor of mouth |  |  |  |  |  |
|  | 41820 | Excision, gum, each quadrant |  |  |  |  |  |
|  | 41821 | Excision of gum flap |  |  |  |  |  |
|  | 42100 | Biopsy roof of mouth |  |  |  |  |  |
|  | 42140 | Excision of uvula |  |  |  |  |  |
|  | 42325 | Create salivary cyst drain |  |  |  |  |  |
|  | 42326 | Create salivary cyst drain |  |  |  |  |  |
|  | 42330 | Removal of salivary stone |  |  |  |  |  |
|  | 42650 | Dilation of salivary duct |  |  |  |  |  |
|  | 42660 | Dilation of salivary duct |  |  |  |  |  |
|  | 42800 | Biopsy of throat |  |  |  |  |  |
|  | 42999 | Throat surgery procedure |  |  |  |  |  |
|  | 69399 | Outer ear surgery procedure |  |  |  |  |  |
|  | 69405 | Catheterize middle ear canal |  |  |  |  |  |
|  | 69410 | Inset middle ear (baffle) |  |  |  |  |  |
|  | 69420 | Incision of eardrum |  |  |  |  |  |
|  | 69424 | Remove ventilating tube |  |  |  |  |  |
|  | 69433 | Create eardrum opening |  |  |  |  |  |
|  | 69979 | Temporal bone surgery |  |  |  |  |  |
| 0253 | Level III | ENT Procedures | T | 12.02 | \$582.81 | \$284.00 | \$116.56 |
|  | 21031 | Remove exostosis, mandible |  |  |  |  |  |
|  | 21032 | Remove exostosis, maxilla |  |  |  |  |  |
|  | 21040 | Removal of jaw bone lesion |  |  |  |  |  |
|  | 21085 | Prepare face/oral prosthesis |  |  |  |  |  |
|  | 21089 | Prepare face/oral prosthesis |  |  |  |  |  |
|  | 21282 | Revision of eyelid |  |  |  |  |  |
|  | 21295 | Revision of jaw muscle/bone |  |  |  |  |  |
|  | 21299 | Cranio/maxillofacial surgery |  |  |  |  |  |
|  | 21300 | Treatment of skull fracture |  |  |  |  |  |
|  | 21310 | Treatment of nose fracture |  |  |  |  |  |
|  | 21315 | Treatment of nose fracture |  |  |  |  |  |
|  | 21320 | Treatment of nose fracture |  |  |  |  |  |
|  | 21325 | Treatment of nose fracture |  |  |  |  |  |
|  | 21337 | Treat nasal septal fracture |  |  |  |  |  |
|  | 21401 | Treat eye socket fracture |  |  |  |  |  |
|  | 21440 | Treat dental ridge fracture |  |  |  |  |  |
|  | 21452 | Treat lower jaw fracture |  |  |  |  |  |
|  | 21485 | Reset dislocated jaw |  |  |  |  |  |
|  | 21497 | Interdental wiring |  |  |  |  |  |
|  | 21499 | Head surgery procedure |  |  |  |  |  |
|  | 30110 | Removal of nose polyp(s) |  |  |  |  |  |
|  | 30115 | Removal of nose polyp(s) |  |  |  |  |  |
|  | 30117 | Removal of intranasal lesion |  |  |  |  |  |
|  | 30120 | Revision of nose |  |  |  |  |  |
|  | 30130 | Removal of turbinate bones |  |  |  |  |  |
|  | 30140 | Removal of turbinate bones |  |  |  |  |  |
|  | 30200 | Injection treatment of nose |  |  |  |  |  |
|  | 30310 | Remove nasal foreign body |  |  |  |  |  |
|  | 30320 | Remove nasal foreign body |  |  |  |  |  |
|  | 30802 | Cauterization, inner nose |  |  |  |  |  |
|  | 30930 | Therapy, fracture of nose |  |  |  |  |  |
|  | 31020 | Exploration, maxillary sinus |  |  |  |  |  |
|  | 31585 | Treat larynx fracture |  |  |  |  |  |
|  | 31599 | Larynx surgery procedure |  |  |  |  |  |
|  | 31612 | Puncture/clear windpipe |  |  |  |  |  |
|  | 31820 | Closure of windpipe lesion |  |  |  |  |  |
|  | 40500 | Partial excision of lip |  |  |  |  |  |
|  | 40520 | Partial excision of lip |  |  |  |  |  |
|  | 40650 | Repair lip |  |  |  |  |  |
|  | 40652 | Repair lip |  |  |  |  |  |
|  | 40799 | Lip surgery procedure |  |  |  |  |  |
|  | 40810 | Excision of mouth lesion |  |  |  |  |  |
|  | 40814 | Excise/repair mouth lesion |  |  |  |  |  |

CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
Copyright American Dental Association. All rights reserved.
${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment.
${ }^{2}$ Not subject to national coinsurance.
${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.


| Addendum C.-Proposed Hospital Outpatient Department (HOPD) Payment for Procedures by APCContinued |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| APC | CPT/ <br> HCPCS | HCPCS Description | Status Indicator | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
|  | 21010 | Incision of jaw joint |  |  |  |  |  |
|  | 21015 | Resection of facial tumor |  |  |  |  |  |
|  | 21030 | Removal of face bone lesion |  |  |  |  |  |
|  | 21076 | Prepare face/oral prosthesis |  |  |  |  |  |
|  | 21110 | Interdental fixation |  |  |  |  |  |
|  | 21120 | Reconstruction of chin |  |  |  |  |  |
|  | 21121 | Reconstruction of chin |  |  |  |  |  |
|  | 21122 | Reconstruction of chin |  |  |  |  |  |
|  | 21123 | Reconstruction of chin |  |  |  |  |  |
|  | 21125 | Augmentation, lower jaw bone |  |  |  |  |  |
|  | 21137 | Reduction of forehead |  |  |  |  |  |
|  | 21181 | Contour cranial bone lesion |  |  |  |  |  |
|  | 21235 | Ear cartilage graft |  |  |  |  |  |
|  | 21296 | Revision of jaw muscle/bone |  |  |  |  |  |
|  | 21330 | Treatment of nose fracture |  |  |  |  |  |
|  | 21335 | Treatment of nose fracture |  |  |  |  |  |
|  | 21338 | Treat nasoethmoid fracture |  |  |  |  |  |
|  | 21339 | Treat nasoethmoid fracture |  |  |  |  |  |
|  | 21345 | Treat nose/jaw fracture |  |  |  |  |  |
|  | 21421 | Treat mouth roof fracture |  |  |  |  |  |
|  | 21445 | Treat dental ridge fracture |  |  |  |  |  |
|  | 21451 | Treat lower jaw fracture |  |  |  |  |  |
|  | 21454 | Treat lower jaw fracture |  |  |  |  |  |
|  | 30118 | Removal of intranasal lesion |  |  |  |  |  |
|  | 30430 | Revision of nose |  |  |  |  |  |
|  | 30630 | Repair nasal septum defect |  |  |  |  |  |
|  | 31040 | Exploration behind upper jaw |  |  |  |  |  |
|  | 31070 | Exploration of frontal sinus |  |  |  |  |  |
|  | 31600 | Incision of windpipe |  |  |  |  |  |
|  | 31601 | Incision of windpipe |  |  |  |  |  |
|  | 31603 | Incision of windpipe |  |  |  |  |  |
|  | 31605 | Incision of windpipe |  |  |  |  |  |
|  | 31610 | Incision of windpipe |  |  |  |  |  |
|  | 31611 | Surgery/speech prosthesis |  |  |  |  |  |
|  | 31613 | Repair windpipe opening |  |  |  |  |  |
|  | 31825 | Repair of windpipe defect |  |  |  |  |  |
|  | 31830 | Revise windpipe scar |  |  |  |  |  |
|  | 40510 | Partial excision of lip |  |  |  |  |  |
|  | 40525 | Reconstruct lip with flap |  |  |  |  |  |
|  | 40527 | Reconstruct lip with flap |  |  |  |  |  |
|  | 40530 | Partial removal of lip |  |  |  |  |  |
|  | 40654 | Repair lip |  |  |  |  |  |
|  | 40840 | Reconstruction of mouth |  |  |  |  |  |
|  | 40842 | Reconstruction of mouth |  |  |  |  |  |
|  | 40843 | Reconstruction of mouth |  |  |  |  |  |
|  | 41114 | Excision of tongue lesion |  |  |  |  |  |
|  | 42107 | Excision lesion, mouth roof |  |  |  |  |  |
|  | 42145 | Repair palate, pharynx/uvula |  |  |  |  |  |
|  | 42235 | Repair palate |  |  |  |  |  |
|  | 42500 | Repair salivary duct |  |  |  |  |  |
|  | 42950 | Reconstruction of throat |  |  |  |  |  |
|  | 42955 | Surgical opening of throat |  |  |  |  |  |
|  | 43020 | Incision of esophagus |  |  |  |  |  |
|  | 69140 | Remove ear canal lesion(s) |  |  |  |  |  |
|  | 69300 | Revise external ear |  |  |  |  |  |
|  | 69650 | Release middle ear bone |  |  |  |  |  |
| 0256 | Level V ENT | NT Procedures | T | 25.40 | \$1,231.57 | \$623.05 | \$246.31 |
|  | 21025 | Excision of bone, lower jaw |  |  |  |  |  |
|  | 21026 | Excision of facial bone(s) |  |  |  |  |  |
|  | 21029 | Contour of face bone lesion |  |  |  |  |  |
|  | 21034 | Removal of face bone lesion |  |  |  |  |  |
|  | 21041 | Removal of jaw bone lesion |  |  |  |  |  |
|  | 21044 | Removal of jaw bone lesion |  |  |  |  |  |
|  | 21050 | Removal of jaw joint |  |  |  |  |  |
|  | 21060 | Remove jaw joint cartilage |  |  |  |  |  |
|  | 21070 | Remove coronoid process |  |  |  |  |  |
|  | 21077 | Prepare face/oral prosthesis |  |  |  |  |  |
|  | 21079 | Prepare face/oral prosthesis |  |  |  |  |  |
|  | 21080 | Prepare face/oral prosthesis |  |  |  |  |  |
|  | 21081 | Prepare face/oral prosthesis |  |  |  |  |  |
|  | 21082 | Prepare face/oral prosthesis |  |  |  |  |  |
|  | 21083 | Prepare face/oral prosthesis |  |  |  |  |  |
|  | 21084 | Prepare face/oral prosthesis |  |  |  |  |  |

CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
Copyright American Dental Association. All rights reserved.
${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment.
${ }^{2}$ Not subject to national coinsurance.
${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

| Addendum C.-Proposed Hospital Outpatient |  |  | Department (HOPD) Continued | PAYMEN | FOR Procedures by APC |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| APC | CPT/ HCPCS | HCPCS Description | Status Indicator | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
|  | 21086 | Prepare face/oral prosthesis |  |  |  |  |  |
|  | 21087 | Prepare face/oral prosthesis |  |  |  |  |  |
|  | 21088 | Prepare face/oral prosthesis |  |  |  |  |  |
|  | 21100 | Maxillofacial fixation |  |  |  |  |  |
|  | 21127 | Augmentation, lower jaw bone |  |  |  |  |  |
|  | 21138 | Reduction of forehead |  |  |  |  |  |
|  | 21139 | Reduction of forehead |  |  |  |  |  |
|  | 21198 | Reconstruct lower jaw bone |  |  |  |  |  |
|  | 21206 | Reconstruct upper jaw bone |  |  |  |  |  |
|  | 21208 | Augmentation of facial bones |  |  |  |  |  |
|  | 21209 | Reduction of facial bones |  |  |  |  |  |
|  | 21210 | Face bone graft |  |  |  |  |  |
|  | 21215 | Lower jaw bone graft |  |  |  |  |  |
|  | 21230 | Rib cartilage graft |  |  |  |  |  |
|  | 21240 | Reconstruction of jaw joint |  |  |  |  |  |
|  | 21242 | Reconstruction of jaw joint |  |  |  |  |  |
|  | 21243 | Reconstruction of jaw joint |  |  |  |  |  |
|  | 21244 | Reconstruction of lower jaw |  |  |  |  |  |
|  | 21245 | Reconstruction of jaw |  |  |  |  |  |
|  | 21246 | Reconstruction of jaw |  |  |  |  |  |
|  | 21248 | Reconstruction of jaw |  |  |  |  |  |
|  | 21249 | Reconstruction of jaw |  |  |  |  |  |
|  | 21260 | Revise eye sockets |  |  |  |  |  |
|  | 21261 | Revise eye sockets |  |  |  |  |  |
|  | 21263 | Revise eye sockets |  |  |  |  |  |
|  | 21267 | Revise eye sockets |  |  |  |  |  |
|  | 21270 | Augmentation, cheek bone |  |  |  |  |  |
|  | 21275 | Revision, orbitofacial bones |  |  |  |  |  |
|  | 21280 | Revision of eyelid |  |  |  |  |  |
|  | 21340 | Treatment of nose fracture |  |  |  |  |  |
|  | 21355 | Treat cheek bone fracture |  |  |  |  |  |
|  | 21406 | Treat eye socket fracture |  |  |  |  |  |
|  | 21407 | Treat eye socket fracture |  |  |  |  |  |
|  | 21453 | Treat lower jaw fracture |  |  |  |  |  |
|  | 21461 | Treat lower jaw fracture |  |  |  |  |  |
|  | 21462 | Treat lower jaw fracture |  |  |  |  |  |
|  | 21465 | Treat lower jaw fracture |  |  |  |  |  |
|  | 21470 | Treat lower jaw fracture |  |  |  |  |  |
|  | 21490 | Repair dislocated jaw |  |  |  |  |  |
|  | 30125 | Removal of nose lesion |  |  |  |  |  |
|  | 30150 | Partial removal of nose |  |  |  |  |  |
|  | 30160 | Removal of nose |  |  |  |  |  |
|  | 30400 | Reconstruction of nose |  |  |  |  |  |
|  | 30410 | Reconstruction of nose |  |  |  |  |  |
|  | 30420 | Reconstruction of nose |  |  |  |  |  |
|  | 30435 | Revision of nose |  |  |  |  |  |
|  | 30450 | Revision of nose |  |  |  |  |  |
|  | 30460 | Revision of nose |  |  |  |  |  |
|  | 30462 | Revision of nose |  |  |  |  |  |
|  | 30520 | Repair of nasal septum |  |  |  |  |  |
|  | 30540 | Repair nasal defect |  |  |  |  |  |
|  | 30545 | Repair nasal defect |  |  |  |  |  |
|  | 30580 | Repair upper jaw fistula |  |  |  |  |  |
|  | 30600 | Repair mouth/nose fistula |  |  |  |  |  |
|  | 30620 | Intranasal reconstruction |  |  |  |  |  |
|  | 31030 | Exploration, maxillary sinus |  |  |  |  |  |
|  | 31032 | Explore sinus, remove polyps |  |  |  |  |  |
|  | 31050 | Exploration, sphenoid sinus |  |  |  |  |  |
|  | 31051 | Sphenoid sinus surgery |  |  |  |  |  |
|  | 31075 | Exploration of frontal sinus |  |  |  |  |  |
|  | 31080 | Removal of frontal sinus |  |  |  |  |  |
|  | 31081 | Removal of frontal sinus |  |  |  |  |  |
|  | 31084 | Removal of frontal sinus |  |  |  |  |  |
|  | 31085 | Removal of frontal sinus |  |  |  |  |  |
|  | 31086 | Removal of frontal sinus |  |  |  |  |  |
|  | 31087 | Removal of frontal sinus |  |  |  |  |  |
|  | 31090 | Exploration of sinuses |  |  |  |  |  |
|  | 31200 | Removal of ethmoid sinus |  |  |  |  |  |
|  | 31201 | Removal of ethmoid sinus |  |  |  |  |  |
|  | 31205 | Removal of ethmoid sinus |  |  |  |  |  |
|  | 31300 | Removal of larynx lesion |  |  |  |  |  |
|  | 31320 | Diagnostic incision, larynx |  |  |  |  |  |
|  | 31375 | Partial removal of larynx |  |  |  |  |  |

[^257]Copyright American Dental Association. All rights reserved.
${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment.
${ }^{2}$ Not subject to national coinsurance.
${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

| Addendum C.—Proposed Hospital Outpatient Department (HOPD) Payment for Procedures by APC— Continued |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| APC | CPT/ HCPCS | HCPCS Description | Status Indicator | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
|  | 31400 | Revision of larynx |  |  |  |  |  |
|  | 31420 | Removal of epiglottis |  |  |  |  |  |
|  | 31580 | Revision of larynx |  |  |  |  |  |
|  | 31586 | Treat larynx fracture |  |  |  |  |  |
|  | 31588 | Revision of larynx |  |  |  |  |  |
|  | 31590 | Reinnervate larynx |  |  |  |  |  |
|  | 31595 | Larynx nerve surgery |  |  |  |  |  |
|  | 31614 | Repair windpipe opening |  |  |  |  |  |
|  | 31750 | Repair of windpipe |  |  |  |  |  |
|  | 31755 | Repair of windpipe |  |  |  |  |  |
|  | 40700 | Repair cleft lip/nasal |  |  |  |  |  |
|  | 40701 | Repair cleft lip/nasal |  |  |  |  |  |
|  | 40702 | Repair cleft lip/nasal |  |  |  |  |  |
|  | 40720 | Repair cleft lip/nasal |  |  |  |  |  |
|  | 40761 | Repair cleft lip/nasal |  |  |  |  |  |
|  | 40844 | Reconstruction of mouth |  |  |  |  |  |
|  | 40845 | Reconstruction of mouth |  |  |  |  |  |
|  | 41120 | Partial removal of tongue |  |  |  |  |  |
|  | 42120 | Remove palate/lesion |  |  |  |  |  |
|  | 42182 | Repair palate |  |  |  |  |  |
|  | 42200 | Reconstruct cleft palate |  |  |  |  |  |
|  | 42205 | Reconstruct cleft palate |  |  |  |  |  |
|  | 42210 | Reconstruct cleft palate |  |  |  |  |  |
|  | 42215 | Reconstruct cleft palate |  |  |  |  |  |
|  | 42220 | Reconstruct cleft palate |  |  |  |  |  |
|  | 42225 | Reconstruct cleft palate |  |  |  |  |  |
|  | 42226 | Lengthening of palate |  |  |  |  |  |
|  | 42227 | Lengthening of palate |  |  |  |  |  |
|  | 42410 | Excise parotid gland/lesion |  |  |  |  |  |
|  | 42415 | Excise parotid gland/lesion |  |  |  |  |  |
|  | 42420 | Excise parotid gland/lesion |  |  |  |  |  |
|  | 42425 | Excise parotid gland/lesion |  |  |  |  |  |
|  | 42440 | Excise submaxillary gland |  |  |  |  |  |
|  | 42505 | Repair salivary duct |  |  |  |  |  |
|  | 42507 | Parotid duct diversion |  |  |  |  |  |
|  | 42508 | Parotid duct diversion |  |  |  |  |  |
|  | 42509 | Parotid duct diversion |  |  |  |  |  |
|  | 42510 | Parotid duct diversion |  |  |  |  |  |
|  | 42725 | Drainage of throat abscess |  |  |  |  |  |
|  | 42815 | Excision of neck cyst |  |  |  |  |  |
|  | 42844 | Extensive surgery of throat |  |  |  |  |  |
|  | 42890 | Partial removal of pharynx |  |  |  |  |  |
|  | 42892 | Revision of pharyngeal walls |  |  |  |  |  |
|  | 42962 | Control throat bleeding |  |  |  |  |  |
|  | 60500 | Explore parathyroid glands |  |  |  |  |  |
|  | 61330 | Decompress eye socket |  |  |  |  |  |
|  | 69310 | Rebuild outer ear canal |  |  |  |  |  |
|  | 69320 | Rebuild outer ear canal |  |  |  |  |  |
|  | 69450 | Eardrum revision |  |  |  |  |  |
|  | 69501 | Mastoidectomy |  |  |  |  |  |
|  | 69505 | Remove mastoid structures |  |  |  |  |  |
|  | 69511 | Extensive mastoid surgery |  |  |  |  |  |
|  | 69530 | Extensive mastoid surgery |  |  |  |  |  |
|  | 69550 | Remove ear lesion |  |  |  |  |  |
|  | 69552 | Remove ear lesion |  |  |  |  |  |
|  | 69601 | Mastoid surgery revision |  |  |  |  |  |
|  | 69602 | Mastoid surgery revision |  |  |  |  |  |
|  | 69603 | Mastoid surgery revision |  |  |  |  |  |
|  | 69604 | Mastoid surgery revision |  |  |  |  |  |
|  | 69605 | Mastoid surgery revision |  |  |  |  |  |
|  | 69631 | Repair eardrum structures |  |  |  |  |  |
|  | 69632 | Rebuild eardrum structures |  |  |  |  |  |
|  | 69633 | Rebuild eardrum structures |  |  |  |  |  |
|  | 69635 | Repair eardrum structures |  |  |  |  |  |
|  | 69636 | Rebuild eardrum structures |  |  |  |  |  |
|  | 69637 | Rebuild eardrum structures |  |  |  |  |  |
|  | 69641 | Revise middle ear \& mastoid |  |  |  |  |  |
|  | 69642 | Revise middle ear \& mastoid |  |  |  |  |  |
|  | 69643 | Revise middle ear \& mastoid |  |  |  |  |  |
|  | 69644 | Revise middle ear \& mastoid |  |  |  |  |  |
|  | 69645 | Revise middle ear \& mastoid |  |  |  |  |  |
|  | 69646 | Revise middle ear \& mastoid |  |  |  |  |  |
|  | 69660 | Revise middle ear bone |  |  |  |  |  |

CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
Copyright American Dental Association. All rights reserved.
${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment.
${ }^{2}$ Not subject to national coinsurance.
${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

Addendum C.-Proposed Hospital Outpatient Department (HOPD) Payment for Procedures by APC-
Continued

| APC | CPT/ <br> HCPCS | HCPCS Description | Status Indicator | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | 69661 | Revise middle ear bone |  |  |  |  |  |
|  | 69662 | Revise middle ear bone |  |  |  |  |  |
|  | 69666 | Repair middle ear structures |  |  |  |  |  |
|  | 69667 | Repair middle ear structures |  |  |  |  |  |
|  | 69670 | Remove mastoid air cells |  |  |  |  |  |
|  | 69676 | Remove middle ear nerve |  |  |  |  |  |
|  | 69700 | Close mastoid fistula |  |  |  |  |  |
|  | 69711 | Remove/repair hearing aid |  |  |  |  |  |
|  | 69720 | Release facial nerve |  |  |  |  |  |
|  | 69725 | Release facial nerve |  |  |  |  |  |
|  | 69740 | Repair facial nerve |  |  |  |  |  |
|  | 69745 | Repair facial nerve |  |  |  |  |  |
|  | 69801 | Incise inner ear |  |  |  |  |  |
|  | 69802 | Incise inner ear |  |  |  |  |  |
|  | 69805 | Explore inner ear |  |  |  |  |  |
|  | 69806 | Explore inner ear |  |  |  |  |  |
|  | 69820 | Establish inner ear window |  |  |  |  |  |
|  | 69840 | Revise inner ear window |  |  |  |  |  |
|  | 69905 | Remove inner ear |  |  |  |  |  |
|  | 69910 | Remove inner ear \& mastoid |  |  |  |  |  |
|  | 69915 | Incise inner ear nerve |  |  |  |  |  |
|  | 69955 | Release facial nerve |  |  |  |  |  |
|  | 69960 | Release inner ear canal |  |  |  |  |  |
| 0257 | Implantat | ion of Cochlear Device | T | 115.31 | \$5,591.04 | \$3,498.58 | \$1,118.21 |
|  | 69930 | Implant cochlear device |  |  |  |  |  |
| 0258 | Tonsil and | d Adenoid Procedures | T | 18.62 | \$902.83 | \$462.81 | \$180.57 |
|  | 42820 | Remove tonsils and adenoids |  |  |  |  |  |
|  | 42821 | Remove tonsils and adenoids |  |  |  |  |  |
|  | 42825 | Removal of tonsils |  |  |  |  |  |
|  | 42826 | Removal of tonsils |  |  |  |  |  |
|  | 42830 | Removal of adenoids |  |  |  |  |  |
|  | 42831 | Removal of adenoids |  |  |  |  |  |
|  | 42835 | Removal of adenoids |  |  |  |  |  |
|  | 42836 | Removal of adenoids |  |  |  |  |  |
|  | 42860 | Excision of tonsil tags |  |  |  |  |  |
|  | 42870 | Excision of lingual tonsil |  |  |  |  |  |
| 0260 |  | ain Film Except Teeth | X | 0.79 | \$38.30 | \$22.02 | \$7.66 |
|  | $70030$ | X-ray eye for foreign body |  |  |  |  |  |
|  | 70100 | X-ray exam of jaw |  |  |  |  |  |
|  | 70110 | X-ray exam of jaw |  |  |  |  |  |
|  | 70120 | X-ray exam of mastoids |  |  |  |  |  |
|  | 70130 | X-ray exam of mastoids |  |  |  |  |  |
|  | 70140 | X-ray exam of facial bones |  |  |  |  |  |
|  | 70150 | X-ray exam of facial bones |  |  |  |  |  |
|  | 70160 | X-ray exam of nasal bones |  |  |  |  |  |
|  | 70190 | X-ray exam of eye sockets |  |  |  |  |  |
|  | 70200 | X-ray exam of eye sockets |  |  |  |  |  |
|  | 70210 | X-ray exam of sinuses |  |  |  |  |  |
|  | 70220 | X-ray exam of sinuses |  |  |  |  |  |
|  | 70240 | X-ray exam, pituitary saddle |  |  |  |  |  |
|  | 70250 | X-ray exam of skull |  |  |  |  |  |
|  | 70328 | X-ray exam of jaw joint |  |  |  |  |  |
|  | 70330 | X-ray exam of jaw joints |  |  |  |  |  |
|  | 70350 | X-ray head for orthodontia |  |  |  |  |  |
|  | 70355 | Panoramic x-ray of jaws |  |  |  |  |  |
|  | 70360 | X-ray exam of neck |  |  |  |  |  |
|  | 70380 | X-ray exam of salivary gland |  |  |  |  |  |
|  | 71010 | Chest x-ray |  |  |  |  |  |
|  | 71015 | Chest x-ray |  |  |  |  |  |
|  | 71020 | Chest x-ray |  |  |  |  |  |
|  | 71021 | Chest x-ray |  |  |  |  |  |
|  | 71022 | Chest x-ray |  |  |  |  |  |
|  | 71030 | Chest x-ray |  |  |  |  |  |
|  | 71035 | Chest x-ray |  |  |  |  |  |
|  | 71100 | X-ray exam of ribs |  |  |  |  |  |
|  | 71101 | X-ray exam of ribs/chest |  |  |  |  |  |
|  | 71110 | X-ray exam of ribs |  |  |  |  |  |
|  | 71120 | X-ray exam of breastbone |  |  |  |  |  |
|  | 71130 | X-ray exam of breastbone |  |  |  |  |  |
|  | 72020 | X-ray exam of spine |  |  |  |  |  |
|  | 72040 | X-ray exam of neck spine |  |  |  |  |  |
|  | 72069 | X-ray exam of trunk spine |  |  |  |  |  |
|  | 72070 | X-ray exam of thoracic spine |  |  |  |  |  |

CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
Copyright American Dental Association. All rights reserved.
${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment.
${ }^{2}$ Not subject to national coinsurance.
${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

Addendum C.-Proposed Hospital Outpatient Department (HOPD) Payment for Procedures by APC-
Continued

| APC | CPT/ <br> HCPCS | HCPCS Description | Status Indicator | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | 72072 | X-ray exam of thoracic spine |  |  |  |  |  |
|  | 72074 | X-ray exam of thoracic spine |  |  |  |  |  |
|  | 72080 | X-ray exam of trunk spine |  |  |  |  |  |
|  | 72090 | X-ray exam of trunk spine |  |  |  |  |  |
|  | 72100 | X-ray exam of lower spine |  |  |  |  |  |
|  | 72120 | X-ray exam of lower spine |  |  |  |  |  |
|  | 72170 | X-ray exam of pelvis |  |  |  |  |  |
|  | 72190 | X-ray exam of pelvis |  |  |  |  |  |
|  | 72200 | X-ray exam sacroiliac joints |  |  |  |  |  |
|  | 72202 | X-ray exam sacroiliac joints |  |  |  |  |  |
|  | 72220 | X-ray exam of tailbone |  |  |  |  |  |
|  | 73000 | X-ray exam of collar bone |  |  |  |  |  |
|  | 73010 | X-ray exam of shoulder blade |  |  |  |  |  |
|  | 73020 | X-ray exam of shoulder |  |  |  |  |  |
|  | 73030 | X-ray exam of shoulder |  |  |  |  |  |
|  | 73050 | X-ray exam of shoulders |  |  |  |  |  |
|  | 73060 | X-ray exam of humerus |  |  |  |  |  |
|  | 73070 | X-ray exam of elbow |  |  |  |  |  |
|  | 73080 | X-ray exam of elbow |  |  |  |  |  |
|  | 73090 | X-ray exam of forearm |  |  |  |  |  |
|  | 73092 | X-ray exam of arm, infant |  |  |  |  |  |
|  | 73100 | X-ray exam of wrist |  |  |  |  |  |
|  | 73110 | X-ray exam of wrist |  |  |  |  |  |
|  | 73120 | X-ray exam of hand |  |  |  |  |  |
|  | 73130 | X-ray exam of hand |  |  |  |  |  |
|  | 73140 | X-ray exam of finger(s) |  |  |  |  |  |
|  | 73500 | X-ray exam of hip |  |  |  |  |  |
|  | 73510 | X-ray exam of hip |  |  |  |  |  |
|  | 73520 | X-ray exam of hips |  |  |  |  |  |
|  | 73540 | X-ray exam of pelvis \& hips |  |  |  |  |  |
|  | 73550 | X-ray exam of thigh |  |  |  |  |  |
|  | 73560 | X-ray exam of knee, 1 or 2 |  |  |  |  |  |
|  | 73562 | X-ray exam of knee, 3 |  |  |  |  |  |
|  | 73564 | X-ray exam, knee, 4 or more |  |  |  |  |  |
|  | 73565 | X-ray exam of knees |  |  |  |  |  |
|  | 73590 | X-ray exam of lower leg |  |  |  |  |  |
|  | 73600 | X-ray exam of ankle |  |  |  |  |  |
|  | 73610 | X-ray exam of ankle |  |  |  |  |  |
|  | 73620 | X-ray exam of foot |  |  |  |  |  |
|  | 73630 | X-ray exam of foot |  |  |  |  |  |
|  | 73650 | X-ray exam of heel |  |  |  |  |  |
|  | 73660 | X-ray exam of toe(s) |  |  |  |  |  |
|  | 74000 | X-ray exam of abdomen |  |  |  |  |  |
|  | 74010 | X-ray exam of abdomen |  |  |  |  |  |
|  | 74020 | X-ray exam of abdomen |  |  |  |  |  |
|  | 74710 | X-ray measurement of pelvis |  |  |  |  |  |
|  | 76010 | X-ray, nose to rectum |  |  |  |  |  |
|  | 76040 | X-rays, bone evaluation |  |  |  |  |  |
|  | 76066 | Joint(s) survey, single film |  |  |  |  |  |
|  | 76098 | X-ray exam, breast specimen |  |  |  |  |  |
|  | 76150 | X-ray exam, dry process |  |  |  |  |  |
|  | 76499 | Radiographic procedure |  |  |  |  |  |
|  | 77417 | Radiology port film(s) |  |  |  |  |  |
| 0261 | Level II P | Plain Film Except Teeth Including Bone Density Measurement | X | 1.38 | \$66.91 | \$38.77 | \$13.38 |
|  | 70134 | X-ray exam of middle ear |  |  |  |  |  |
|  | 70260 | X-ray exam of skull |  |  |  |  |  |
|  | 71111 | X-ray exam of ribs/chest |  |  |  |  |  |
|  | 72010 | X-ray exam of spine |  |  |  |  |  |
|  | 72050 | X-ray exam of neck spine |  |  |  |  |  |
|  | 72052 | X-ray exam of neck spine |  |  |  |  |  |
|  | 72110 | X-ray exam of lower spine |  |  |  |  |  |
|  | 72114 | X-ray exam of lower spine |  |  |  |  |  |
|  | 73530 | X-ray exam of hip |  |  |  |  |  |
|  | 73592 | X-ray exam of leg, infant |  |  |  |  |  |
|  | 74022 | X-ray exam series, abdomen |  |  |  |  |  |
|  | 76006 | X-ray stress view |  |  |  |  |  |
|  | 76020 | X-rays for bone age |  |  |  |  |  |
|  | 76061 | X-rays, bone survey |  |  |  |  |  |
|  | 76062 | X-rays, bone survey |  |  |  |  |  |
|  | 76065 | X-rays, bone evaluation |  |  |  |  |  |
|  | 76075 | Dual energy x-ray study |  |  |  |  |  |
|  | 76076 | Dual energy x-ray study |  |  |  |  |  |
|  | 76078 | Photodensitometry |  |  |  |  |  |

CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
Copyright American Dental Association. All rights reserved.
${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment.
${ }^{2}$ Not subject to national coinsurance.
${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

## Addendum C.—Proposed Hospital Outpatient Department (HOPD) Payment for Procedures by APCContinued

| APC | CPT/ <br> HCPCS | HCPCS Description | Status Indicator | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | 76100 | X-ray exam of body section |  |  |  |  |  |
|  | 76120 | Cinematic x-rays |  |  |  |  |  |
|  | 76125 | Cinematic x-rays add-on |  |  |  |  |  |
|  | 78350 | Bone mineral, single photon |  |  |  |  |  |
|  | G0130 | Single energy x-ray study |  |  |  |  |  |
|  | G0131 | CT scan, bone density study |  |  |  |  |  |
|  | G0132 | CT scan, bone density study |  |  |  |  |  |
| 0262 | Plain Film | of Teeth | X | 0.40 | \$19.39 | \$10.90 | \$3.88 |
|  | 70300 | X-ray exam of teeth |  |  |  |  |  |
|  | 70310 | X-ray exam of teeth |  |  |  |  |  |
|  | 70320 | Full mouth x-ray of teeth |  |  |  |  |  |
| 0263 | Level I M | iscellaneous Radiology Procedures | X | 1.68 | \$81.46 | \$45.88 | \$16.29 |
|  | 70170 | X-ray exam of tear duct |  |  |  |  |  |
|  | 70373 | Contrast x-ray of larynx |  |  |  |  |  |
|  | 70390 | X-ray exam of salivary duct |  |  |  |  |  |
|  | 71040 | Contrast x-ray of bronchi |  |  |  |  |  |
|  | 71060 | Contrast x-ray of bronchi |  |  |  |  |  |
|  | 74190 | X-ray exam of peritoneum |  |  |  |  |  |
|  | 74305 | X-ray bile ducts/pancreas |  |  |  |  |  |
|  | 76080 | X-ray exam of fistula |  |  |  |  |  |
|  | 76086 | X-ray of mammary duct |  |  |  |  |  |
|  | 76088 | X-ray of mammary ducts |  |  |  |  |  |
|  | 76096 | X-ray of needle wire, breast |  |  |  |  |  |
|  | 76101 | Complex body section x-ray |  |  |  |  |  |
| 0264 | Level II M | Miscellaneous Radiology Procedures | X | 3.83 | \$185.71 | \$108.97 | \$37.14 |
|  | 74320 | Contrast x-ray of bile ducts |  |  |  |  |  |
|  | 74328 | X-ray bile duct endoscopy |  |  |  |  |  |
|  | 74329 | X-ray for pancreas endoscopy |  |  |  |  |  |
|  | 74330 | X-ray bile/panc endoscopy |  |  |  |  |  |
|  | 74350 | X-ray guide, stomach tube |  |  |  |  |  |
|  | 74355 | X-ray guide, intestinal tube |  |  |  |  |  |
|  | 74470 | X-ray exam of kidney lesion |  |  |  |  |  |
|  | 74740 | X-ray, female genital tract |  |  |  |  |  |
|  | 74742 | X-ray, fallopian tube |  |  |  |  |  |
|  | 75801 | Lymph vessel x-ray, arm/leg |  |  |  |  |  |
|  | 75803 | Lymph vessel x-ray, arms/legs |  |  |  |  |  |
|  | 75805 | Lymph vessel x-ray, trunk |  |  |  |  |  |
|  | 75807 | Lymph vessel x-ray, trunk |  |  |  |  |  |
|  | 75809 | Nonvascular shunt, x-ray |  |  |  |  |  |
|  | 75898 | Follow-up angiogram |  |  |  |  |  |
|  | 76095 | Stereotactic breast biopsy |  |  |  |  |  |
|  | 76102 | Complex body section x-rays |  |  |  |  |  |
| 0265 | Level I Di | iagnostic Ultrasound Except Vascular | S | 1.17 | \$56.73 | \$38.08 | \$11.35 |
|  | 76513 | Echo exam of eye, water bath |  |  |  |  |  |
|  | 76529 | Echo exam of eye |  |  |  |  |  |
|  | 76536 | Echo exam of head and neck |  |  |  |  |  |
|  | 76645 | Echo exam of breast(s) |  |  |  |  |  |
|  | 76810 | Echo exam of pregnant uterus |  |  |  |  |  |
|  | 76815 | Echo exam of pregnant uterus |  |  |  |  |  |
|  | 76816 | Echo exam follow-up/repeat |  |  |  |  |  |
|  | 76857 | Echo exam of pelvis |  |  |  |  |  |
|  | 76970 | Ultrasound exam follow-up |  |  |  |  |  |
|  | 76977 | Us bone density measure |  |  |  |  |  |
|  | G0050 | Residual urine by ultrasound |  |  |  |  |  |
| 0266 | Level II D | Diagnostic Ultrasound Except Vascular | S | 1.79 | \$86.79 | \$57.35 | \$17.36 |
|  | 76506 | Echo exam of head |  |  |  |  |  |
|  | 76511 | Echo exam of eye |  |  |  |  |  |
|  | 76512 | Echo exam of eye |  |  |  |  |  |
|  | 76516 | Echo exam of eye |  |  |  |  |  |
|  | 76519 | Echo exam of eye |  |  |  |  |  |
|  | 76604 | Echo exam of chest |  |  |  |  |  |
|  | 76700 | Echo exam of abdomen |  |  |  |  |  |
|  | 76705 | Echo exam of abdomen |  |  |  |  |  |
|  | 76770 | Echo exam abdomen back wall |  |  |  |  |  |
|  | 76775 | Echo exam abdomen back wall |  |  |  |  |  |
|  | 76778 | Echo exam kidney transplant |  |  |  |  |  |
|  | 76800 | Echo exam spinal canal |  |  |  |  |  |
|  | 76805 | Echo exam of pregnant uterus |  |  |  |  |  |
|  | 76818 | Fetal biophysical profile |  |  |  |  |  |
|  | 76830 | Echo exam, transvaginal |  |  |  |  |  |
|  | 76831 | Echo exam, uterus |  |  |  |  |  |
|  | 76856 | Echo exam of pelvis |  |  |  |  |  |
|  | 76870 | Echo exam of scrotum |  |  |  |  |  |

[^258]Copyright American Dental Association. All rights reserved.
${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment.
${ }^{2}$ Not subject to national coinsurance
${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

## addendum C.-Proposed Hospital Outpatient Department (HOPD) Payment for Procedures by APCContinued

| APC | $\begin{aligned} & \text { CPT/ } \\ & \text { HCPCS } \end{aligned}$ | HCPCS Description | Status Indicator | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 0267 | 76872 E | Echo exam, transrectal | S | 2.72 | \$131.88 | \$80.06 | \$26.38 |
|  | 76873 E | Echograp trans r, pros study |  |  |  |  |  |
|  | 76880 E | Echo exam of extremity |  |  |  |  |  |
|  | 76885 E | Echo exam, infant hips |  |  |  |  |  |
|  | 76886 E | Echo exam, infant hips |  |  |  |  |  |
|  | 76975 G | Gl endoscopic ultrasound |  |  |  |  |  |
|  | 76986 E | Echo exam at surgery |  |  |  |  |  |
|  | 76999 E | Echo examination procedureUltrasound |  |  |  |  |  |
|  | Vascular Ult |  |  |  |  |  |  |
|  | 93880 E | Extracranial study |  |  |  |  |  |
|  | 93882 E | Extracranial study |  |  |  |  |  |
|  | 93886 In | Intracranial study |  |  |  |  |  |
|  | 93888 In | Intracranial study |  |  |  |  |  |
|  | 93925 L | Lower extremity study |  |  |  |  |  |
|  | 93926 L | Lower extremity study |  |  |  |  |  |
|  | 93930 U | Upper extremity study |  |  |  |  |  |
|  | 93931 Up | Upper extremity study |  |  |  |  |  |
|  | 93970 E | Extremity study |  |  |  |  |  |
|  | 93971 E | Extremity study |  |  |  |  |  |
|  | 93975 V | Vascular study |  |  |  |  |  |
|  | 93976 V | Vascular study |  |  |  |  |  |
|  | 93978 V | Vascular study |  |  |  |  |  |
|  | 93979 V | Vascular study |  |  |  |  |  |
|  | 93980 P | Penile vascular study |  |  |  |  |  |
|  | 93981 P | Penile vascular study |  |  |  |  |  |
|  | 93990 D | Doppler flow testing |  |  |  |  |  |
| 0268 | Guidance U | Under Ultrasound | X | 2.23 | \$108.13 | \$69.51 | \$21.63 |
|  | 76930 E | Echo guide for heart sac tap |  |  |  |  |  |
|  | 76932 E | Echo guide for heart biopsy |  |  |  |  |  |
|  | 76934 E | Echo guide for chest tap |  |  |  |  |  |
|  | 76936 E | Echo guide for artery repair |  |  |  |  |  |
|  | 76938 E | Echo exam for drainage |  |  |  |  |  |
|  | 76941 E | Echo guide for transfusion |  |  |  |  |  |
|  | 76942 E | Echo guide for biopsy |  |  |  |  |  |
|  | 76945 E | Echo guide, villus sampling |  |  |  |  |  |
|  | 76946 E | Echo guide for amniocentesis |  |  |  |  |  |
|  | 76948 E | Echo guide, ova aspiration |  |  |  |  |  |
|  | 76950 E | Echo guidance radiotherapy |  |  |  |  |  |
|  | 76960 E | Echo guidance radiotherapy |  |  |  |  |  |
|  | 76965 E | Echo guidance radiotherapy |  |  |  |  |  |
|  | G0161 E | Echo guide for cryo probes |  |  |  |  |  |
| 0269 | Echocardio | iogram Except Transesophageal | S | 4.40 | \$213.34 | \$114.01 | \$42.67 |
|  | 76825 E | Echo exam of fetal heart |  |  |  |  |  |
|  | 76826 E | Echo exam of fetal heart |  |  |  |  |  |
|  | 76827 E | Echo exam of fetal heart |  |  |  |  |  |
|  | 76828 E | Echo exam of fetal heart |  |  |  |  |  |
|  | 93303 E | Echo transthoracic |  |  |  |  |  |
|  | 93304 E | Echo transthoracic |  |  |  |  |  |
|  | 93307 E | Echo exam of heart |  |  |  |  |  |
|  | 93308 E | Echo exam of heart |  |  |  |  |  |
|  | 93320 D | Doppler echo exam, heart |  |  |  |  |  |
|  | 93321 D | Doppler echo exam, heart |  |  |  |  |  |
|  | 93325 D | Doppler color flow add-on |  |  |  |  |  |
|  | 93350 E | Echo transthoracic |  |  |  |  |  |
| 0270 | Transesoph | phageal Echocardiogram | S | 5.55 | \$269.10 | \$150.26 | \$53.82 |
|  | 93312 E | Echo transesophageal |  |  |  |  |  |
|  | 93313 E | Echo transesophageal |  |  |  |  |  |
|  | 93315 E | Echo transesophageal |  |  |  |  |  |
|  | 93316 E | Echo transesophageal |  |  |  |  |  |
| 0271 | Mammogra | raphy | S | 0.70 | \$33.94 | \$19.50 | \$6.79 |
|  | 76090 M | Mammogram, one breast |  |  |  |  |  |
|  | 76091 M | Mammogram, both breasts |  |  |  |  |  |
| 0272 | Level I Fluo | uoroscopy | X | 1.40 | \$67.88 | \$39.00 | \$13.58 |
|  | 70371 S | Speech evaluation, complex |  |  |  |  |  |
|  | 71023 | Chest x-ray and fluoroscopy |  |  |  |  |  |
|  | 71034 | Chest x-ray and fluoroscopy |  |  |  |  |  |
|  | 74340 X | X-ray guide for Gl tube |  |  |  |  |  |
|  | 76000 F | Fluoroscope examination |  |  |  |  |  |
|  | 76003 N | Needle localization by x-ray |  |  |  |  |  |
| 0273 | Level II Flu | uoroscopy | X | 2.49 | \$120.73 | \$61.02 | \$24.15 |
|  | 70370 T | Throat x-ray \& fluoroscopy |  |  |  |  |  |
|  | 71036 X | X-ray guidance for biopsy |  |  |  |  |  |
|  | 71090 X | X-ray \& pacemaker insertion |  |  |  |  |  |

[^259]Copyright American Dental Association. All rights reserved.
${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment.
${ }^{2}$ Not subject to national coinsurance.
${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

Addendum C.—Proposed Hospital Outpatient Department (HOPD) Payment for Procedures by APC—
Continued


CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
Copyright American Dental Association. All rights reserved.
${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment.
${ }^{2}$ Not subject to national coinsurance.
${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

## addendum C.-Proposed Hospital Outpatient Department (HOPD) Payment for Procedures by APCContinued

| APC | CPT/ HCPCS | HCPCS Description | Status Indicator | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | $\begin{aligned} & 75889 \\ & 75891 \end{aligned}$ | Vein x-ray, liver Vein x-ray, liver |  |  |  |  |  |
| 0280 | $\begin{gathered} \text { Level II D } \\ 75600 \end{gathered}$ | Diagnostic Angiography and Venography Except Extremity Contrast x-ray exam of aorta | S | 14.98 | \$726.34 | \$380.12 | \$145.27 |
|  | 75605 | Contrast x-ray exam of aorta |  |  |  |  |  |
|  | 75625 | Contrast x-ray exam of aorta |  |  |  |  |  |
|  | 75630 | X-ray aorta, leg arteries |  |  |  |  |  |
|  | 75650 | Artery x-rays, head \& neck |  |  |  |  |  |
|  | 75658 | Artery x-rays, arm |  |  |  |  |  |
|  | 75665 | Artery x-rays, head \& neck |  |  |  |  |  |
|  | 75671 | Artery x-rays, head \& neck |  |  |  |  |  |
|  | 75676 | Artery x-rays, neck |  |  |  |  |  |
|  | 75680 | Artery x-rays, neck |  |  |  |  |  |
|  | 75710 | Artery x-rays, arm/leg |  |  |  |  |  |
|  | 75716 | Artery x-rays, arms/legs |  |  |  |  |  |
|  | 75722 | Artery x-rays, kidney |  |  |  |  |  |
|  | 75724 | Artery x-rays, kidneys |  |  |  |  |  |
|  | 75726 | Artery x-rays, abdomen |  |  |  |  |  |
|  | 75731 | Artery x-rays, adrenal gland |  |  |  |  |  |
|  | 75733 | Artery x-rays, adrenals |  |  |  |  |  |
|  | 75736 | Artery x-rays, pelvis |  |  |  |  |  |
|  | 75743 | Artery x-rays, lungs |  |  |  |  |  |
|  | 75774 | Artery x-ray, each vessel |  |  |  |  |  |
|  | 75887 | Vein x-ray, liver |  |  |  |  |  |
| 0281 | Venograp | hy of Extremity | S | 4.40 | \$213.34 | \$115.16 | \$42.67 |
|  | 75790 | Visualize A-V shunt |  |  |  |  |  |
|  | 75820 | Vein x-ray, arm/leg |  |  |  |  |  |
|  | 75822 | Vein x-ray, arms/legs |  |  |  |  |  |
| 0282 | Level I C | omputerized Axial Tomography | S | 2.38 | \$115.40 | \$94.51 | \$23.08 |
|  | 70486 | Cat scan of face/jaw |  |  |  |  |  |
|  | 76370 | CAT scan for therapy guide |  |  |  |  |  |
|  | 76375 | 3d/holograph reconstr add-on |  |  |  |  |  |
|  | 76380 | CAT scan follow-up study |  |  |  |  |  |
| 0283 |  | Computerized Axial Tomography | S | 4.89 | \$237.10 | \$179.39 | \$47.42 |
|  | $70450$ | CAT scan of head or brain |  |  |  |  |  |
|  | 70460 | Contrast CAT scan of head |  |  |  |  |  |
|  | 70470 | Contrast CAT scans of head |  |  |  |  |  |
|  | 70480 | CAT scan of skull |  |  |  |  |  |
|  | 70481 | Contrast CAT scan of skull |  |  |  |  |  |
|  | 70482 | Contrast CAT scans of skull |  |  |  |  |  |
|  | 70487 | Contrast CAT scan, face/jaw |  |  |  |  |  |
|  | 70488 | Contrast cat scans, face/jaw |  |  |  |  |  |
|  | 70490 | CAT scan of neck tissue |  |  |  |  |  |
|  | 70491 | Contrast CAT of neck tissue |  |  |  |  |  |
|  | 70492 | Contrast CAT of neck tissue |  |  |  |  |  |
|  | 71250 | Cat scan of chest |  |  |  |  |  |
|  | 71260 | Contrast CAT scan of chest |  |  |  |  |  |
|  | 71270 | Contrast CAT scans of chest |  |  |  |  |  |
|  | 72125 | CAT scan of neck spine |  |  |  |  |  |
|  | 72126 | Contrast CAT scan of neck |  |  |  |  |  |
|  | 72127 | Contrast CAT scans of neck |  |  |  |  |  |
|  | 72128 | CAT scan of thorax spine |  |  |  |  |  |
|  | 72129 | Contrast CAT scan of thorax |  |  |  |  |  |
|  | 72130 | Contrast CAT scans of thorax |  |  |  |  |  |
|  | 72131 | CAT scan of lower spine |  |  |  |  |  |
|  | 72132 | Contrast CAT of lower spine |  |  |  |  |  |
|  | 72133 | Contrst cat scans, low spine |  |  |  |  |  |
|  | 72192 | CAT scan of pelvis |  |  |  |  |  |
|  | 72193 | Contrast CAT scan of pelvis |  |  |  |  |  |
|  | 72194 | Contrast CAT scans of pelvis |  |  |  |  |  |
|  | 73200 | CAT scan of arm |  |  |  |  |  |
|  | 73201 | Contrast CAT scan of arm |  |  |  |  |  |
|  | 73202 | Contrast CAT scans of arm |  |  |  |  |  |
|  | 73700 | CAT scan of leg |  |  |  |  |  |
|  | 73701 | Contrast CAT scan of leg |  |  |  |  |  |
|  | 73702 | Contrast CAT scans of leg |  |  |  |  |  |
|  | 74150 | CAT scan of abdomen |  |  |  |  |  |
|  | 74160 | Contrast CAT scan of abdomen |  |  |  |  |  |
|  | 74170 | Contrast CAT scans, abdomen |  |  |  |  |  |
|  | 76355 | CAT scan for localization |  |  |  |  |  |
|  | 76360 | CAT scan for needle biopsy |  |  |  |  |  |
|  | 76365 | CAT scan for cyst aspiration |  |  |  |  |  |
| 0284 | Magnetic | Resonance Imaging | S | 8.02 | \$388.87 | \$257.39 | \$77.77 |

CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
Copyright American Dental Association. All rights reserved.
${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment.
${ }^{2}$ Not subject to national coinsurance.
${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

Addendum C.—Proposed Hospital Outpatient Department (HOPD) Payment for Procedures by APC— Continued

| APC | CPT/ <br> HCPCS | HCPCS Description | Status Indicator | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | 70336 | Magnetic image, jaw joint |  |  |  |  |  |
|  | 70540 | Magnetic image, face/neck |  |  |  |  |  |
|  | 70541 | Magnetic image, head (MRA) |  |  |  |  |  |
|  | 70551 | Magnetic image, brain (MRI) |  |  |  |  |  |
|  | 70552 | Magnetic image, brain (MRI) |  |  |  |  |  |
|  | 70553 | Magnetic image, brain (mri) |  |  |  |  |  |
|  | 71550 | Magnetic image, chest (mri) |  |  |  |  |  |
|  | 72141 | Magnetic image, neck spine |  |  |  |  |  |
|  | 72142 | Magnetic image, neck spine |  |  |  |  |  |
|  | 72146 | Magnetic image, chest spine |  |  |  |  |  |
|  | 72147 | Magnetic image, chest spine |  |  |  |  |  |
|  | 72148 | Magnetic image, lumbar spine |  |  |  |  |  |
|  | 72149 | Magnetic image, lumbar spine |  |  |  |  |  |
|  | 72156 | Magnetic image, neck spine |  |  |  |  |  |
|  | 72157 | Magnetic image, chest spine |  |  |  |  |  |
|  | 72158 | Magnetic image, lumbar spine |  |  |  |  |  |
|  | 72196 | Magnetic image, pelvis |  |  |  |  |  |
|  | 73220 | Magnetic image, arm/hand |  |  |  |  |  |
|  | 73221 | Magnetic image, joint of arm |  |  |  |  |  |
|  | 73720 | Magnetic image, leg/foot |  |  |  |  |  |
|  | 73721 | Magnetic image, joint of leg |  |  |  |  |  |
|  | 74181 | Magnetic image/abdomen (mri) |  |  |  |  |  |
|  | 75552 | Magnetic image, myocardium |  |  |  |  |  |
|  | 75553 | Magnetic image, myocardium |  |  |  |  |  |
|  | 75554 | Cardiac MRI/function |  |  |  |  |  |
|  | 75555 | Cardiac MRI/limited study |  |  |  |  |  |
|  | 76093 | Magnetic image, breast |  |  |  |  |  |
|  | 76094 | Magnetic image, both breasts |  |  |  |  |  |
|  | 76390 | Mr spectroscopy |  |  |  |  |  |
|  | 76400 | Magnetic image, bone marrow |  |  |  |  |  |
| 0285 | Positron Em | mission Tomography (PET) | S | 15.06 | \$730.22 | \$415.21 | \$146.04 |
|  | G0030 P | PET imaging prev PET single |  |  |  |  |  |
|  | G0031 P | PET imaging prev PET multple |  |  |  |  |  |
|  | G0032 P | PET follow SPECT 78464 singl |  |  |  |  |  |
|  | G0033 P | PET follow SPECT 78464 mult |  |  |  |  |  |
|  | G0034 | PET follow SPECT 76865 singl |  |  |  |  |  |
|  | G0035 | PET follow SPECT 78465 mult |  |  |  |  |  |
|  | G0036 | PET follow cornry angio sing |  |  |  |  |  |
|  | G0037 | PET follow cornry angio mult |  |  |  |  |  |
|  | G0038 | PET follow myocard perf sing |  |  |  |  |  |
|  | G0039 | PET follow myocard perf mult |  |  |  |  |  |
|  | G0040 | PET follow stress echo singl |  |  |  |  |  |
|  | G0041 | PET follow stress echo mult |  |  |  |  |  |
|  | G0042 | PET follow ventriculogm sing |  |  |  |  |  |
|  | G0043 | PET follow ventriculogm mult |  |  |  |  |  |
|  | G0044 | PET following rest ECG singl |  |  |  |  |  |
|  | G0045 | PET following rest ECG mult |  |  |  |  |  |
|  | G0046 P | PET follow stress ECG singl |  |  |  |  |  |
|  | G0047 | PET follow stress ECG mult |  |  |  |  |  |
| 0286 | Myocardial | Scans | S | 7.28 | \$352.99 | \$200.04 | \$70.60 |
|  | 78460 | Heart muscle blood, single |  |  |  |  |  |
|  | 78461 | Heart muscle blood, multiple |  |  |  |  |  |
|  | 78464 | Heart image (3d), single |  |  |  |  |  |
|  | 78465 | Heart image (3d), multiple |  |  |  |  |  |
|  | 78472 | Gated heart, planar, single |  |  |  |  |  |
|  | 78473 | Gated heart, multiple |  |  |  |  |  |
|  | 78478 | Heart wall motion add-on |  |  |  |  |  |
|  | 78480 H | Heart function add-on |  |  |  |  |  |
|  | 78481 | Heart first pass, single |  |  |  |  |  |
|  | 78483 H | Heart first pass, multiple |  |  |  |  |  |
| 0290 | Standard | Non-Imaging Nuclear Medicine | S | 1.94 | \$94.06 | \$55.51 | \$18.81 |
|  | 78000 | Thyroid, single uptake |  |  |  |  |  |
|  | 78001 | Thyroid, multiple uptakes |  |  |  |  |  |
|  | 78003 | Thyroid suppress/stimul |  |  |  |  |  |
|  | 78010 | Thyroid imaging |  |  |  |  |  |
|  | 78011 | Thyroid imaging with flow |  |  |  |  |  |
|  | 78099 | Endocrine nuclear procedure |  |  |  |  |  |
|  | 78199 | Blood/lymph nuclear exam |  |  |  |  |  |
|  | 78270 | Vit B-12 absorption exam |  |  |  |  |  |
|  | 78271 | Vit B-12 absorp exam, IF |  |  |  |  |  |
|  | 78282 | Gl protein loss exam |  |  |  |  |  |
|  | 78299 | Gl nuclear procedure |  |  |  |  |  |
|  | 78399 | Musculoskeletal nuclear exam |  |  |  |  |  |

CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
Copyright American Dental Association. All rights reserved.
${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment.
${ }^{2}$ Not subject to national coinsurance.
${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

| Addendum C.-Proposed Hospital Outpatient Department (HOPD) Payment for Procedures by ApC- |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| APC | CPT/ HCPCS | HCPCS Description | Status Indicator | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| 0291 | Level I Di | iagnostic Nuclear Medicine Excluding Myocardial Scans | S | 3.15 | \$152.73 | \$93.14 | \$30.55 |
|  | 78006 | Thyroid imaging with uptake |  |  |  |  |  |
|  | 78007 | Thyroid image, mult uptakes |  |  |  |  |  |
|  | 78015 | Thyroid met imaging |  |  |  |  |  |
|  | 78102 | Bone marrow imaging, Itd |  |  |  |  |  |
|  | 78110 | Plasma volume, single |  |  |  |  |  |
|  | 78111 | Plasma volume, multiple |  |  |  |  |  |
|  | 78120 | Red cell mass, single |  |  |  |  |  |
|  | 78121 | Red cell mass, multiple |  |  |  |  |  |
|  | 78185 | Spleen imaging |  |  |  |  |  |
|  | 78190 | Platelet survival, kinetics |  |  |  |  |  |
|  | 78191 | Platelet survival |  |  |  |  |  |
|  | $78201$ | Liver imaging |  |  |  |  |  |
|  | 78202 | Liver imaging with flow |  |  |  |  |  |
|  | 78215 | Liver and spleen imaging |  |  |  |  |  |
|  | 78216 | Liver \& spleen image/flow |  |  |  |  |  |
|  | 78230 | Salivary gland imaging |  |  |  |  |  |
|  | 78231 | Serial salivary imaging |  |  |  |  |  |
|  | 78232 | Salivary gland function exam |  |  |  |  |  |
|  | 78258 | Esophageal motility study |  |  |  |  |  |
|  | 78261 | Gastric mucosa imaging |  |  |  |  |  |
|  | 78262 | Gastroesophageal reflux exam |  |  |  |  |  |
|  | 78272 | Vit B-12 absorp, combined |  |  |  |  |  |
|  | 78290 | Meckel's divert exam |  |  |  |  |  |
|  | 78300 | Bone imaging, limited area |  |  |  |  |  |
|  | 78445 | Vascular flow imaging |  |  |  |  |  |
|  | 78455 | Venous thrombosis study |  |  |  |  |  |
|  | 78456 | Acute venous thrombus image |  |  |  |  |  |
|  | 78457 | Venous thrombosis imaging |  |  |  |  |  |
|  | 78458 | Ven thrombosis images, bilat |  |  |  |  |  |
|  | 78580 | Lung perfusion imaging |  |  |  |  |  |
|  | 78591 | Vent image, 1 breath, 1 proj |  |  |  |  |  |
|  | 78599 | Respiratory nuclear exam |  |  |  |  |  |
|  | 78605 | Brain imaging, complete |  |  |  |  |  |
|  | 78610 | Brain flow imaging only |  |  |  |  |  |
|  | 78660 | Nuclear exam of tear flow |  |  |  |  |  |
|  | 78700 | Kidney imaging, static |  |  |  |  |  |
|  | 78701 | Kidney imaging with flow |  |  |  |  |  |
|  | 78715 | Renal vascular flow exam |  |  |  |  |  |
|  | 78725 | Kidney function study |  |  |  |  |  |
|  | 78730 | Urinary bladder retention |  |  |  |  |  |
|  | 78740 | Ureteral reflux study |  |  |  |  |  |
|  | 78760 | Testicular imaging |  |  |  |  |  |
|  | 78761 | Testicular imaging/flow |  |  |  |  |  |
|  | 78999 | Nuclear diagnostic exam |  |  |  |  |  |
| 0292 | Level II D | Diagnostic Nuclear Medicine Excluding Myocardial Scans | S | 4.36 | \$211.40 | \$126.63 | \$42.28 |
|  | 78016 | Thyroid met imaging/studies |  |  |  |  |  |
|  | 78018 | Thyroid met imaging, body |  |  |  |  |  |
|  | 78020 | Thyroid met uptake |  |  |  |  |  |
|  | 78070 | Parathyroid nuclear imaging |  |  |  |  |  |
|  | 78075 | Adrenal nuclear imaging |  |  |  |  |  |
|  | 78103 | Bone marrow imaging, mult |  |  |  |  |  |
|  | 78104 | Bone marrow imaging, body |  |  |  |  |  |
|  | 78122 | Blood volume |  |  |  |  |  |
|  | 78130 | Red cell survival study |  |  |  |  |  |
|  | 78135 | Red cell survival kinetics |  |  |  |  |  |
|  | 78140 | Red cell sequestration |  |  |  |  |  |
|  | 78160 | Plasma iron turnover |  |  |  |  |  |
|  | 78162 | Iron absorption exam |  |  |  |  |  |
|  | 78170 | Red cell iron utilization |  |  |  |  |  |
|  | 78172 | Total body iron estimation |  |  |  |  |  |
|  | 78195 | Lymph system imaging |  |  |  |  |  |
|  | 78205 | Liver imaging (3D) |  |  |  |  |  |
|  | 78206 | Liver image (3d) w/flow |  |  |  |  |  |
|  | 78220 | Liver function study |  |  |  |  |  |
|  | 78223 | Hepatobiliary imaging |  |  |  |  |  |
|  | 78264 | Gastric emptying study |  |  |  |  |  |
|  | 78278 | Acute GI blood loss imaging |  |  |  |  |  |
|  | 78291 | Leveen/shunt patency exam |  |  |  |  |  |
|  | 78305 | Bone imaging, multiple areas |  |  |  |  |  |
|  | 78306 | Bone imaging, whole body |  |  |  |  |  |
|  | 78315 | Bone imaging, 3 phase |  |  |  |  |  |
|  | 78320 | Bone imaging (3D) |  |  |  |  |  |

CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
Copyright American Dental Association. All rights reserved.
${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment.
${ }^{2}$ Not subject to national coinsurance.
${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

Addendum C.-Proposed Hospital Outpatient Department (HOPD) Payment for Procedures by APC-
Continued

| APC | CPT/ <br> HCPCS | HCPCS Description | Status Indicator | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | 78414 | Non-imaging heart function |  |  |  |  |  |
|  | 78428 | Cardiac shunt imaging |  |  |  |  |  |
|  | 78466 | Heart infarct image |  |  |  |  |  |
|  | 78468 | Heart infarct image (ef) |  |  |  |  |  |
|  | 78469 | Heart infarct image (3D) |  |  |  |  |  |
|  | 78499 | Cardiovascular nuclear exam |  |  |  |  |  |
|  | 78584 | Lung V/Q image single breath |  |  |  |  |  |
|  | 78585 | Lung V/Q imaging |  |  |  |  |  |
|  | 78586 | Aerosol lung image, single |  |  |  |  |  |
|  | 78587 | Aerosol lung image, multiple |  |  |  |  |  |
|  | 78588 | Perfusion lung image |  |  |  |  |  |
|  | 78593 | Vent image, 1 proj, gas |  |  |  |  |  |
|  | 78594 | Vent image, mult proj, gas |  |  |  |  |  |
|  | 78596 | Lung differential function |  |  |  |  |  |
|  | 78600 | Brain imaging, Itd static |  |  |  |  |  |
|  | 78601 | Brain imaging, Itd w/flow |  |  |  |  |  |
|  | 78606 | Brain imaging, compl w/flow |  |  |  |  |  |
|  | 78607 | Brain imaging (3D) |  |  |  |  |  |
|  | 78615 | Cerebral blood flow imaging |  |  |  |  |  |
|  | 78630 | Cerebrospinal fluid scan |  |  |  |  |  |
|  | 78635 | CSF ventriculography |  |  |  |  |  |
|  | 78645 | CSF shunt evaluation |  |  |  |  |  |
|  | 78647 | Cerebrospinal fluid scan |  |  |  |  |  |
|  | 78650 | CSF leakage imaging |  |  |  |  |  |
|  | 78699 | Nervous system nuclear exam |  |  |  |  |  |
|  | 78704 | Imaging renogram |  |  |  |  |  |
|  | 78707 | Kidney flow/function image |  |  |  |  |  |
|  | 78708 | Kidney flow/function image |  |  |  |  |  |
|  | 78709 | Kidney flow/function image |  |  |  |  |  |
|  | 78710 | Kidney imaging (3D) |  |  |  |  |  |
|  | 78799 | Genitourinary nuclear exam |  |  |  |  |  |
|  | 78800 | Tumor imaging, limited area |  |  |  |  |  |
|  | 78801 | Tumor imaging, mult areas |  |  |  |  |  |
|  | 78802 | Tumor imaging, whole body |  |  |  |  |  |
|  | 78803 | Tumor imaging (3D) |  |  |  |  |  |
|  | 78805 | Abscess imaging, Itd area |  |  |  |  |  |
|  | 78806 | Abscess imaging, whole body |  |  |  |  |  |
|  | 78807 | Nuclear localization/abscess |  |  |  |  |  |
| 0294 | Level I Th | herapeutic Nuclear Medicine | S | 5.13 | \$248.74 | \$144.06 | \$49.75 |
|  | 79000 | Init hyperthyroid therapy |  |  |  |  |  |
|  | 79001 | Repeat hyperthyroid therapy |  |  |  |  |  |
|  | 79020 | Thyroid ablation |  |  |  |  |  |
|  | 79030 | Thyroid ablation, carcinoma |  |  |  |  |  |
|  | 79035 | Thyroid metastatic therapy |  |  |  |  |  |
|  | 79100 | Hematopoetic nuclear therapy |  |  |  |  |  |
|  | 79300 | Interstitial nuclear therapy |  |  |  |  |  |
|  | 79440 | Nuclear joint therapy |  |  |  |  |  |
|  | 79999 | Nuclear medicine therapy |  |  |  |  |  |
| 0295 | Level II T | herapeutic Nuclear Medicine | S | 19.85 | \$962.47 | \$609.17 | \$192.49 |
|  | 79200 | Intracavitary nuclear trmt |  |  |  |  |  |
|  | 79400 | Nonhemato nuclear therapy |  |  |  |  |  |
|  | 79420 | Intravascular nuclear ther |  |  |  |  |  |
| 0296 | Level I Th | herapeutic Radiologic Procedures | S | 3.57 | \$173.10 | \$100.25 | \$34.62 |
|  | 74235 | Remove esophagus obstruction |  |  |  |  |  |
|  | 74327 | X-ray bile stone removal |  |  |  |  |  |
|  | 74360 | X-ray guide, Gl dilation |  |  |  |  |  |
|  | 74485 | X-ray guide, GU dilation |  |  |  |  |  |
|  | 75984 | X-ray control catheter change |  |  |  |  |  |
|  | 78494 | Heart image, spect |  |  |  |  |  |
|  | 78496 | Heart first pass add-on |  |  |  |  |  |
| 0297 | Level II T | herapeutic Radiologic Procedures | S | 6.13 | \$297.23 | \$172.51 | \$59.45 |
|  | 74363 | X-ray, bile duct dilation |  |  |  |  |  |
|  | 74475 | X-ray control, cath insert |  |  |  |  |  |
|  | 74480 | X-ray control, cath insert |  |  |  |  |  |
|  | 75894 | X-rays, transcath therapy |  |  |  |  |  |
|  | 75896 | X-rays, transcath therapy |  |  |  |  |  |
|  | 75980 | Contrast x-ray exam bile duct |  |  |  |  |  |
|  | 75982 | Contrast x-ray exam bile duct |  |  |  |  |  |
| 0300 | Level I Radiation Therapy |  | S | 1.98 | \$96.00 | \$47.72 | \$19.20 |
|  | 77401 | Radiation treatment delivery |  |  |  |  |  |
|  | 77402 | Radiation treatment delivery |  |  |  |  |  |
|  | 77403 | Radiation treatment delivery |  |  |  |  |  |
|  | 77404 | Radiation treatment delivery |  |  |  |  |  |

[^260]Copyright American Dental Association. All rights reserved.
${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment.
${ }^{2}$ Not subject to national coinsurance.
${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

## addendum C.-Proposed Hospital Outpatient Department (HOPD) Payment for Procedures by APCContinued

| APC | CPT/ HCPCS Description | Status Indicator | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 0301 | 77406 Radiation treatment delivery |  |  |  |  |  |
|  | 77407 Radiation treatment delivery |  |  |  |  |  |
|  | 77408 Radiation treatment delivery |  |  |  |  |  |
|  | 77409 Radiation treatment delivery |  |  |  |  |  |
|  | 77414 Radiation treatment delivery |  |  |  |  |  |
|  | 77789 Radioelement application |  |  |  |  |  |
|  | Level II Radiation Therapy | S | 2.21 | \$107.16 | \$52.53 | \$21.43 |
|  | 77411 Radiation treatment delivery |  |  |  |  |  |
|  | 77412 Radiation treatment delivery |  |  |  |  |  |
|  | 77413 Radiation treatment delivery |  |  |  |  |  |
|  | 77416 Radiation treatment delivery |  |  |  |  |  |
|  | 77520 Proton beam delivery |  |  |  |  |  |
|  | 77523 Proton beam delivery |  |  |  |  |  |
|  | 77750 Infuse radioactive materials |  |  |  |  |  |
| 0302 | Level III Radiation Therapy | S | 8.21 | \$398.08 | \$216.55 | \$79.62 |
|  | 77470 Special radiation treatment |  |  |  |  |  |
|  | G0173 Stereotactic, one session |  |  |  |  |  |
|  | G0174 Stereotactic, mult session |  |  |  |  |  |
| 0303 | Treatment Device Construction | X | 2.83 | \$137.22 | \$69.28 | \$27.44 |
|  | 77332 Radiation treatment aid(s) |  |  |  |  |  |
|  | 77333 Radiation treatment aid(s) |  |  |  |  |  |
|  | 77334 Radiation treatment aid(s) |  |  |  |  |  |
| 0304 | Level I Therapeutic Radiation Treatment Preparation | X | 1.49 | \$72.25 | \$41.52 | \$14.45 |
|  | 77280 Set radiation therapy field |  |  |  |  |  |
|  | 77300 Radiation therapy dose plan |  |  |  |  |  |
|  | 77305 Radiation therapy dose plan |  |  |  |  |  |
|  | 77310 Radiation therapy dose plan |  |  |  |  |  |
|  | 77331 Special radiation dosimetry |  |  |  |  |  |
| 0305 | Level II Therapeutic Radiation Treatment Preparation | X | 4.06 | \$196.86 | \$97.50 | \$39.37 |
|  | 77285 Set radiation therapy field |  |  |  |  |  |
|  | 77290 Set radiation therapy field |  |  |  |  |  |
|  | 77315 Radiation therapy dose plan |  |  |  |  |  |
|  | 77321 Radiation therapy port plan |  |  |  |  |  |
|  | 77326 Radiation therapy dose plan |  |  |  |  |  |
|  | 77327 Radiation therapy dose plan |  |  |  |  |  |
|  | 77328 Radiation therapy dose plan |  |  |  |  |  |
| 0310 | Level III Therapeutic Radiation Treatment Preparation | X | 13.98 | \$677.85 | \$339.05 | \$135.57 |
|  | 77295 Set radiation therapy field |  |  |  |  |  |
| 0311 | Radiation Physics Services | X | 1.32 | \$64.00 | \$31.66 | \$12.80 |
|  | 77336 Radiation physics consult |  |  |  |  |  |
|  | 77370 Radiation physics consult |  |  |  |  |  |
|  | 77399 External radiation dosimetry |  |  |  |  |  |
| 0312 | Radioelement Applications | S | 4.09 | \$198.31 | \$109.65 | \$39.66 |
|  | 77761 Radioelement application |  |  |  |  |  |
|  | 77762 Radioelement application |  |  |  |  |  |
|  | 77763 Radioelement application |  |  |  |  |  |
|  | 77776 Radioelement application |  |  |  |  |  |
|  | 77777 Radioelement application |  |  |  |  |  |
|  | 77778 Radioelement application |  |  |  |  |  |
| 0313 | Brachytherapy | S | 7.89 | \$382.56 | \$164.02 | \$76.51 |
|  | 77781 High intensity brachytherapy |  |  |  |  |  |
|  | 77782 High intensity brachytherapy |  |  |  |  |  |
|  | 77783 High intensity brachytherapy |  |  |  |  |  |
|  | 77784 High intensity brachytherapy |  |  |  |  |  |
|  | 77799 Radium/radioisotope therapy |  |  |  |  |  |
| 0314 | Hyperthermic Therapies | S | 5.88 | \$285.10 | \$150.95 | \$57.02 |
|  | 77600 Hyperthermia treatment |  |  |  |  |  |
|  | 77605 Hyperthermia treatment |  |  |  |  |  |
|  | 77610 Hyperthermia treatment |  |  |  |  |  |
|  | 77615 Hyperthermia treatment |  |  |  |  |  |
|  | 77620 Hyperthermia treatment |  |  |  |  |  |
| 0320 | Electroconvulsive Therapy | S | 3.68 | \$178.43 | \$80.06 | \$35.69 |
|  | 90870 Electroconvulsive therapy |  |  |  |  |  |
|  | 90871 Electroconvulsive therapy |  |  |  |  |  |
| 0321 | Biofeedback and Other Training | S | 1.26 | \$61.09 | \$29.25 | \$12.22 |
|  | 90901 Biofeedback train, any meth |  |  |  |  |  |
|  | 90911 Biofeedback peri/uro/rectal |  |  |  |  |  |
| 0322 | Brief Individual Psychotherapy | S | 1.32 | \$64.00 | \$14.22 | \$12.80 |
|  | 90804 Psytx, office, 20-30 min |  |  |  |  |  |
|  | 90805 Psytx, off, 20-30 min w/e\&m |  |  |  |  |  |
|  | 90810 Intac psytx, off, 20-30 min |  |  |  |  |  |
|  | 90811 Intac psytx, 20-30, w/e\&m |  |  |  |  |  |
|  | 90816 Psytx, hosp, 20-30 min |  |  |  |  |  |

[^261]Copyright American Dental Association. All rights reserved.
${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment.
${ }^{2}$ Not subject to national coinsurance.
${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.


|  | 90817 | Psytx, hosp, 20-30 min w/e\&m |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | 90823 | Intac psytx, hosp, 20-30 min |  |  |  |  |  |
|  | 90824 | Intac psytx, hsp 20-30 w/e\&m |  |  |  |  |  |
|  | 90899 | Psychiatric service/therapy |  |  |  |  |  |
| 0323 | Extended | Individual Psychotherapy | S | 1.85 | \$89.70 | \$22.48 | \$17.94 |
|  | 90801 | Psy dx interview |  |  |  |  |  |
|  | 90802 | Intac psy dx interview |  |  |  |  |  |
|  | 90806 | Psytx, off, 45-50 min |  |  |  |  |  |
|  | 90807 | Psytx, off, 45-50 min w/e\&m |  |  |  |  |  |
|  | 90808 | Psytx, office, 75-80 min |  |  |  |  |  |
|  | 90809 | Psytx, off, 75-80, w/e\&m |  |  |  |  |  |
|  | 90812 | Intac psytx, off, 45-50 min |  |  |  |  |  |
|  | 90813 | Intac psytx, 45-50 min w/e\&m |  |  |  |  |  |
|  | 90814 | Intac psytx, off, 75-80 min |  |  |  |  |  |
|  | 90815 | Intac psytx, 75-80 w/e\&m |  |  |  |  |  |
|  | 90818 | Psytx, hosp, 45-50 min |  |  |  |  |  |
|  | 90819 | Psytx, hosp, 45-50 min w/e\&m |  |  |  |  |  |
|  | 90821 | Psytx, hosp, 75-80 min |  |  |  |  |  |
|  | 90822 | Psytx, hosp, 75-80 min w/e\&m |  |  |  |  |  |
|  | 90826 | Intac psytx, hosp, 45-50 min |  |  |  |  |  |
|  | 90827 | Intac psytx, hsp 45-50 w/e\&m |  |  |  |  |  |
|  | 90828 | Intac psytx, hosp, 75-80 min |  |  |  |  |  |
|  | 90829 | Intac psytx, hsp 75-80 w/e\&m |  |  |  |  |  |
|  | 90845 | Psychoanalysis |  |  |  |  |  |
|  | 90865 | Narcosynthesis |  |  |  |  |  |
|  | 90880 | Hypnotherapy |  |  |  |  |  |
| 0324 | Family Psychotherapy |  | S | 1.87 | \$90.67 | \$20.19 | \$18.13 |
|  | 90846 | Family psytx w/o patient |  |  |  |  |  |
|  | 90847 | Family psytx w/patient |  |  |  |  |  |
| 0325 | Group Psychotherapy |  | S | 1.55 | \$75.16 | \$19.96 | \$15.03 |
|  | 90849 | Multiple family group psytx |  |  |  |  |  |
|  | 90853 | Group psychotherapy |  |  |  |  |  |
|  | 90857 | Intac group psytx |  |  |  |  |  |
| 0330 | Dental Procedures |  | S | 1.51 | \$73.22 | \$14.64 | \$14.64 |
|  | D0150 | Comprehensve oral evaluation |  |  |  |  |  |
|  | D0240 | Intraoral occlusal film |  |  |  |  |  |
|  | D0250 | Extraoral first film |  |  |  |  |  |
|  | D0260 | Extraoral ea additional film |  |  |  |  |  |
|  | D0270 | Dental bitewing single film |  |  |  |  |  |
|  | D0272 | Dental bitewings two films |  |  |  |  |  |
|  | D0274 | Dental bitewings four films |  |  |  |  |  |
|  | D0460 | Pulp vitality test |  |  |  |  |  |
|  | D0501 | Histopathologic examinations |  |  |  |  |  |
|  | D0502 | Other oral pathology procedu |  |  |  |  |  |
|  | D0999 | Unspecified diagnostic proce |  |  |  |  |  |
|  | D1510 | Space maintainer fxd unilat |  |  |  |  |  |
|  | D1515 | Fixed bilat space maintainer |  |  |  |  |  |
|  | D1520 | Remove unilat space maintain |  |  |  |  |  |
|  | D1525 | Remove bilat space maintain |  |  |  |  |  |
|  | D1550 | Recement space maintainer |  |  |  |  |  |
|  | D2970 | Temporary-fractured tooth |  |  |  |  |  |
|  | D2999 | Dental unspec restorative pr |  |  |  |  |  |
|  | D3460 | Endodontic endosseous implan |  |  |  |  |  |
|  | D3999 | Endodontic procedure |  |  |  |  |  |
|  | D4260 | Osseous surgery per quadrant |  |  |  |  |  |
|  | D4263 | Bone replce graft first site |  |  |  |  |  |
|  | D4264 | Bone replce graft each add |  |  |  |  |  |
|  | D4270 | Pedicle soft tissue graft pr |  |  |  |  |  |
|  | D4271 | Free soft tissue graft proc |  |  |  |  |  |
|  | D4273 | Subepithelial tissue graft |  |  |  |  |  |
|  | D4355 | Full mouth debridement |  |  |  |  |  |
|  | D4381 | Localized chemo delivery |  |  |  |  |  |
|  | D5911 | Facial moulage sectional |  |  |  |  |  |
|  | D5912 | Facial moulage complete |  |  |  |  |  |
|  | D5983 | Radiation applicator |  |  |  |  |  |
|  | D5984 | Radiation shield |  |  |  |  |  |
|  | D5985 | Radiation cone locator |  |  |  |  |  |
|  | D5987 | Commissure splint |  |  |  |  |  |
|  | D6920 | Dental connector bar |  |  |  |  |  |
|  | D7110 | Oral surgery single tooth |  |  |  |  |  |
|  | D7120 | Each add tooth extraction |  |  |  |  |  |
|  | D7130 | Tooth root removal |  |  |  |  |  |
|  | D7210 | Rem imp tooth w mucoper flp |  |  |  |  |  |

[^262]Addendum C.-Proposed Hospital Outpatient Department (hOPD) Payment for Procedures by APCContinued

| APC | CPT/ <br> HCPCS | HCPCS Description | Status Indicator | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | D7220 | Impact tooth remov soft tiss |  |  |  |  |  |
|  | D7230 | Impact tooth remov part bony |  |  |  |  |  |
|  | D7240 | Impact tooth remov comp bony |  |  |  |  |  |
|  | D7241 | Impact tooth rem bony w/comp |  |  |  |  |  |
|  | D7250 | Tooth root removal |  |  |  |  |  |
|  | D7260 | Oral antral fistula closure |  |  |  |  |  |
|  | D7291 | Transseptal fiberotomy |  |  |  |  |  |
|  | D7940 | Reshaping bone orthognathic |  |  |  |  |  |
|  | D9630 | Other drugs/medicaments |  |  |  |  |  |
|  | D9930 | Treatment of complications |  |  |  |  |  |
|  | D9940 | Dental occlusal guard |  |  |  |  |  |
|  | D9950 | Occlusion analysis |  |  |  |  |  |
|  | D9951 | Limited occlusal adjustment |  |  |  |  |  |
|  | D9952 | Complete occlusal adjustment |  |  |  |  |  |
| 0340 | Minor An | cillary Procedures | X | 1.04 | \$50.43 | \$12.85 | \$10.09 |
|  | 69200 | Clear outer ear canal |  |  |  |  |  |
|  | 69210 | Remove impacted ear wax |  |  |  |  |  |
| 0341 | Immunolo | gy Tests | X | 0.13 | \$6.30 | \$3.67 | \$1.26 |
|  | 86485 | Skin test, candida |  |  |  |  |  |
|  | 86490 | Coccidioidomycosis skin test |  |  |  |  |  |
|  | 86510 | Histoplasmosis skin test |  |  |  |  |  |
|  | 86580 | TB intradermal test |  |  |  |  |  |
|  | 86585 | TB tine test |  |  |  |  |  |
|  | 86586 | Skin test, unlisted |  |  |  |  |  |
| 0342 | Level I P | athology | X | 0.26 | \$12.61 | \$8.03 | \$2.52 |
|  | 85060 | Blood smear interpretation |  |  |  |  |  |
|  | 88160 | Cytopath smear, other source |  |  |  |  |  |
|  | 88199 | Cytopathology procedure |  |  |  |  |  |
|  | 88300 | Surgical path, gross |  |  |  |  |  |
|  | 88302 | Tissue exam by pathologist |  |  |  |  |  |
|  | 88311 | Decalcify tissue |  |  |  |  |  |
|  | 88313 | Special stains |  |  |  |  |  |
|  | 88319 | Enzyme histochemistry |  |  |  |  |  |
|  | 88321 | Microslide consultation |  |  |  |  |  |
|  | 88399 | Surgical pathology procedure |  |  |  |  |  |
| 0343 | Level II P | Pathology | X | 0.45 | \$21.82 | \$12.16 | \$4.36 |
|  | 80500 | Lab pathology consultation |  |  |  |  |  |
|  | 80502 | Lab pathology consultation |  |  |  |  |  |
|  | 86077 | Physician blood bank service |  |  |  |  |  |
|  | 88104 | Cytopathology, fluids |  |  |  |  |  |
|  | 88106 | Cytopathology, fluids |  |  |  |  |  |
|  | 88107 | Cytopathology, fluids |  |  |  |  |  |
|  | 88108 | Cytopath, concentrate tech |  |  |  |  |  |
|  | 88125 | Forensic cytopathology |  |  |  |  |  |
|  | 88161 | Cytopath smear, other source |  |  |  |  |  |
|  | 88162 | Cytopath smear, other source |  |  |  |  |  |
|  | 88172 | Evaluation of smear |  |  |  |  |  |
|  | 88173 | Interpretation of smear |  |  |  |  |  |
|  | 88304 | Tissue exam by pathologist |  |  |  |  |  |
|  | 88305 | Tissue exam by pathologist |  |  |  |  |  |
|  | 88312 | Special stains |  |  |  |  |  |
|  | 88314 | Histochemical stain |  |  |  |  |  |
|  | 88318 | Chemical histochemistry |  |  |  |  |  |
|  | 88323 | Microslide consultation |  |  |  |  |  |
|  | 88325 | Comprehensive review of data |  |  |  |  |  |
|  | 88329 | Pathology consult in surgery |  |  |  |  |  |
|  | 88331 | Pathology consult in surgery |  |  |  |  |  |
|  | 88332 | Pathology consult in surgery |  |  |  |  |  |
|  | 88346 | Immunofluorescent study |  |  |  |  |  |
|  | 88362 | Nerve teasing preparations |  |  |  |  |  |
|  | 89399 | Pathology lab procedure |  |  |  |  |  |
|  | G0025 | Collagen skin test kit |  |  |  |  |  |
| 0344 | Level III | Pathology | X | 0.79 | \$38.30 | \$23.63 | \$7.66 |
|  | 85097 | Bone marrow interpretation |  |  |  |  |  |
|  | 86078 | Physician blood bank service |  |  |  |  |  |
|  | 86079 | Physician blood bank service |  |  |  |  |  |
|  | 88180 | Cell marker study |  |  |  |  |  |
|  | 88182 | Cell marker study |  |  |  |  |  |
|  | 88307 | Tissue exam by pathologist |  |  |  |  |  |
|  | 88309 | Tissue exam by pathologist |  |  |  |  |  |
|  | 88342 | Immunocytochemistry |  |  |  |  |  |
|  | 88347 | Immunofluorescent study |  |  |  |  |  |
|  | 88348 | Electron microscopy |  |  |  |  |  |

CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
Copyright American Dental Association. All rights reserved.
${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment.
${ }^{2}$ Not subject to national coinsurance.
${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

## Addendum C.—Proposed Hospital Outpatient Department (HOPD) Payment for Procedures by APCContinued

| APC | CPT/ HCPCS | HCPCS Description | Status Indicator | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | 88349 | Scanning electron microscopy |  |  |  |  |  |
|  | 88355 | Analysis, skeletal muscle |  |  |  |  |  |
|  | 88356 | Analysis, nerve |  |  |  |  |  |
|  | 88358 | Analysis, tumor |  |  |  |  |  |
|  | 88365 | Tissue hybridization |  |  |  |  |  |
|  | 89350 | Sputum specimen collection |  |  |  |  |  |
|  | 89360 | Collect sweat for test |  |  |  |  |  |
| ${ }^{2} 0354$ | Administra | ation of Influenza Vaccine | X | 0.13 | \$6.19 | ................. |  |
|  | G0008 | Admin influenza virus vac |  |  |  |  |  |
|  | Q0034 | Admin of influenza vaccine |  |  |  |  |  |
| 0355 | Level I Im | munizations | X | 0.19 | \$9.21 | \$5.05 | \$1.84 |
|  | 90645 | Hib vaccine, hboc, im |  |  |  |  |  |
|  | 90646 | Hib vaccine, prp-d, im |  |  |  |  |  |
|  | 90647 | Hib vaccine, prp-omp, im |  |  |  |  |  |
|  | 90648 | Hib vaccine, prp-t, im |  |  |  |  |  |
|  | 90657 | Flu vaccine, 6-35 mo, im |  |  |  |  |  |
|  | 90658 | Flu vaccine, 3 yrs , im |  |  |  |  |  |
|  | 90659 | Flu vaccine, whole, im |  |  |  |  |  |
|  | 90660 | Flu vaccine, nasal |  |  |  |  |  |
|  | 90700 | Dtap vaccine, im |  |  |  |  |  |
|  | 90702 | Dt vaccine, im |  |  |  |  |  |
|  | 90704 | Mumps vaccine, sc |  |  |  |  |  |
|  | 90713 | Poliovirus, ipv, sc |  |  |  |  |  |
|  | 90716 | Chicken pox vaccine, sc |  |  |  |  |  |
|  | 90720 | Dtp/hib vaccine, im |  |  |  |  |  |
|  | 90721 | Dtap/hib vaccine, im |  |  |  |  |  |
|  | 90727 | Plague vaccine, im |  |  |  |  |  |
|  | 90732 | Pneumococcal vaccine, adult |  |  |  |  |  |
|  | 90749 | Vaccine toxoid |  |  |  |  |  |
| 0356 | Level II Im | mmunizations | X | 0.36 | \$17.46 | \$4.82 | \$3.49 |
|  | 90371 | Hep b ig, im |  |  |  |  |  |
|  | 90389 | Tetanus ig, im |  |  |  |  |  |
|  | 90396 | Varicella-zoster ig, im |  |  |  |  |  |
|  | 90476 | Adenovirus vaccine, type 4 |  |  |  |  |  |
|  | 90477 | Adenovirus vaccine, type 7 |  |  |  |  |  |
|  | 90585 | Bcg vaccine, percut |  |  |  |  |  |
|  | 90586 | Bcg vaccine, intravesical |  |  |  |  |  |
|  | 90632 | Hep a vaccine, adult im |  |  |  |  |  |
|  | 90633 | Hep a vacc, ped/adol, 2 dose |  |  |  |  |  |
|  | 90634 | Hep a vacc, ped/adol, 3 dose |  |  |  |  |  |
|  | 90680 | Rotovirus vaccine, oral |  |  |  |  |  |
|  | 90690 | Typhoid vaccine, oral |  |  |  |  |  |
|  | 90691 | Typhoid vaccine, im |  |  |  |  |  |
|  | 90692 | Typhoid vaccine, h-p, sc/id |  |  |  |  |  |
|  | 90693 | Typhoid vaccine, akd, sc |  |  |  |  |  |
|  | 90701 | Dtp vaccine, im |  |  |  |  |  |
|  | 90703 | Tetanus vaccine, im |  |  |  |  |  |
|  | 90707 | Mmr vaccine, sc |  |  |  |  |  |
|  | 90710 | Mmrv vaccine, sc |  |  |  |  |  |
|  | 90712 | Oral poliovirus vaccine |  |  |  |  |  |
|  | 90717 | Yellow fever vaccine, sc |  |  |  |  |  |
|  | 90718 | Td vaccine, im |  |  |  |  |  |
|  | 90744 | Hep b vaccine, ped/adol, im |  |  |  |  |  |
|  | 90746 | Hep b vaccine, adult, im |  |  |  |  |  |
|  | 90747 | Hep b vaccine, ill pat, im |  |  |  |  |  |
| 0357 | Level III Im | mmunizations | X | 1.85 | \$89.70 | \$38.31 | \$17.94 |
|  | 90287 | Botulinum antitoxin |  |  |  |  |  |
|  | 90296 | Diphtheria antitoxin |  |  |  |  |  |
|  | 90375 | Rabies ig, im/sc |  |  |  |  |  |
|  | 90376 | Rabies ig, heat treated |  |  |  |  |  |
|  | 90378 | Rsv ig, im |  |  |  |  |  |
|  | 90379 | Rsv ig, iv |  |  |  |  |  |
|  | 90384 | Rh ig, full-dose, im |  |  |  |  |  |
|  | 90385 | Rh ig, minidose, im |  |  |  |  |  |
|  | 90386 | Rh ig, iv |  |  |  |  |  |
|  | 90393 | Vaccina ig, im |  |  |  |  |  |
|  | 90581 | Anthrax vaccine, sc |  |  |  |  |  |
|  | 90636 | Hep a/hep b vacc, adult im |  |  |  |  |  |
|  | 90665 | Lyme disease vaccine, im |  |  |  |  |  |
|  | 90669 | Pneumococcal vaccine, ped |  |  |  |  |  |
|  | 90675 | Rabies vaccine, im |  |  |  |  |  |
|  | 90676 | Rabies vaccine, id |  |  |  |  |  |
|  | 90705 | Measles vaccine, sc |  |  |  |  |  |

CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
Copyright American Dental Association. All rights reserved.
${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment.
${ }^{2}$ Not subject to national coinsurance.
${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

## Addendum C.-Proposed Hospital Outpatient Department (hopd) Payment for Procedures by APC— Continued

| APC | CPT/ HCPCS Description | Status Indicator | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 0358 | 90719 Diphtheria vaccine, im |  |  |  |  |  |
|  | 90733 Meningococcal vaccine, sc |  |  |  |  |  |
|  | 90735 Encephalitis vaccine, sc |  |  |  |  |  |
|  | Level IV Immunizations | X | 6.98 | \$338.44 | \$126.74 | \$67.69 |
|  | 90706 Rubella vaccine, sc |  |  |  |  |  |
|  | 90708 Measles-rubella vaccine, sc |  |  |  |  |  |
|  | 90709 Rubella \& mumps vaccine, sc |  |  |  |  |  |
|  | 90725 Cholera vaccine, injectable |  |  |  |  |  |
|  | 90748 Hep b/hib vaccine, im |  |  |  |  |  |
| 0359 | Injections | X | 0.96 | \$46.55 | \$9.31 | \$9.31 |
|  | 90782 Injection, sc/im |  |  |  |  |  |
|  | 90783 Injection, ia |  |  |  |  |  |
|  | 90784 Injection, iv |  |  |  |  |  |
|  | 90788 Injection of antibiotic |  |  |  |  |  |
|  | 90799 Ther/prophylactic/dx inject |  |  |  |  |  |
| 0360 | Level I Alimentary Tests | X | 1.38 | \$66.91 | \$34.75 | \$13.38 |
|  | 89105 Sample intestinal contents |  |  |  |  |  |
|  | 89130 Sample stomach contents |  |  |  |  |  |
|  | 89132 Sample stomach contents |  |  |  |  |  |
|  | 89135 Sample stomach contents |  |  |  |  |  |
|  | 89136 Sample stomach contents |  |  |  |  |  |
|  | 89140 Sample stomach contents |  |  |  |  |  |
|  | 91030 Acid perfusion of esophagus |  |  |  |  |  |
|  | 91055 Gastric intubation for smear |  |  |  |  |  |
|  | 91065 Breath hydrogen test |  |  |  |  |  |
|  | 91100 Pass intestine bleeding tube |  |  |  |  |  |
|  | 91105 Gastric intubation treatment |  |  |  |  |  |
|  | 91299 Gastroenterology procedure |  |  |  |  |  |
| 0361 | Level II Alimentary Tests | X | 3.53 | \$171.16 | \$88.09 | \$34.23 |
|  | 89100 Sample intestinal contents |  |  |  |  |  |
|  | 89141 Sample stomach contents |  |  |  |  |  |
|  | 91000 Esophageal intubation |  |  |  |  |  |
|  | 91010 Esophagus motility study |  |  |  |  |  |
|  | 91011 Esophagus motility study |  |  |  |  |  |
|  | 91012 Esophagus motility study |  |  |  |  |  |
|  | 91020 Gastric motility |  |  |  |  |  |
|  | 91032 Esophagus, acid reflux test |  |  |  |  |  |
|  | 91033 Prolonged acid reflux test |  |  |  |  |  |
|  | 91052 Gastric analysis test |  |  |  |  |  |
|  | 91060 Gastric saline load test |  |  |  |  |  |
|  | 95075 Ingestion challenge test |  |  |  |  |  |
| 0362 | Fitting of Vision Aids | X | 0.51 | \$24.73 | \$9.63 | \$4.95 |
|  | 92311 Contact lens fitting |  |  |  |  |  |
|  | 92312 Contact lens fitting |  |  |  |  |  |
|  | 92313 Contact lens fitting |  |  |  |  |  |
|  | 92315 Prescription of contact lens |  |  |  |  |  |
|  | 92316 Prescription of contact lens |  |  |  |  |  |
|  | 92317 Prescription of contact lens |  |  |  |  |  |
|  | 92325 Modification of contact lens |  |  |  |  |  |
|  | 92326 Replacement of contact lens |  |  |  |  |  |
|  | 92352 Special spectacles fitting |  |  |  |  |  |
|  | 92353 Special spectacles fitting |  |  |  |  |  |
|  | 92354 Special spectacles fitting |  |  |  |  |  |
|  | 92355 Special spectacles fitting |  |  |  |  |  |
|  | 92358 Eye prosthesis service |  |  |  |  |  |
|  | 92371 Repair \& adjust spectacles |  |  |  |  |  |
| 0363 | Otorhinolaryngologic Function Tests | X | 2.83 | \$137.22 | \$53.22 | \$27.44 |
|  | 92512 Nasal function studies |  |  |  |  |  |
|  | 92516 Facial nerve function test |  |  |  |  |  |
|  | 92520 Laryngeal function studies |  |  |  |  |  |
|  | 92541 Spontaneous nystagmus test |  |  |  |  |  |
|  | 92542 Positional nystagmus test |  |  |  |  |  |
|  | 92543 Caloric vestibular test |  |  |  |  |  |
|  | 92544 Optokinetic nystagmus test |  |  |  |  |  |
|  | 92545 Oscillating tracking test |  |  |  |  |  |
|  | 92546 Sinusoidal rotational test |  |  |  |  |  |
|  | 92547 Supplemental electrical test |  |  |  |  |  |
|  | 92548 Posturography |  |  |  |  |  |
|  | 92584 Electrocochleography |  |  |  |  |  |
|  | 92587 Evoked auditory test |  |  |  |  |  |
|  | 92588 Evoked auditory test |  |  |  |  |  |
| 0364 | Level I Audiometry | X | 0.68 | \$32.97 | \$13.31 | \$6.59 |
|  | 92552 Pure tone audiometry, air |  |  |  |  |  |

CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
Copyright American Dental Association. All rights reserved.
${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment.
${ }^{2}$ Not subject to national coinsurance.
${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

Addendum C.—Proposed Hospital Outpatient Department (HOPD) Payment for Procedures by APCContinued


[^263]Copyright American Dental Association. All rights reserved.
${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment.
${ }^{2}$ Not subject to national coinsurance.
${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

## addendum C.-Proposed Hospital Outpatient Department (HOPD) Payment for Procedures by APCContinued

| APC | CPT/ $\quad$ HCPCS Description | Status Indicator | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 0371 | 95078 Provocative testing | X | 0.32 | \$15.52 | \$3.67 | \$3.10 |
|  | 95180 Rapid desensitization |  |  |  |  |  |
|  | 95199 Allergy immunology services |  |  |  |  |  |
|  | Allergy Injections |  |  |  |  |  |
|  | 95115 Immunotherapy, one injection |  |  |  |  |  |
|  | 95117 Immunotherapy injections |  |  |  |  |  |
|  | 95144 Antigen therapy services |  |  |  |  |  |
|  | 95145 Antigen therapy services |  |  |  |  |  |
|  | 95146 Antigen therapy services |  |  |  |  |  |
|  | 95147 Antigen therapy services |  |  |  |  |  |
|  | 95148 Antigen therapy services |  |  |  |  |  |
|  | 95149 Antigen therapy services |  |  |  |  |  |
|  | 95165 Antigen therapy services |  |  |  |  |  |
|  | 95170 Antigen therapy services |  |  |  |  |  |
| 0372 | Therapeutic Phlebotomy | X | 0.43 | \$20.85 | \$10.09 | \$4.17 |
|  | 99195 Phlebotomy |  |  |  |  |  |
| 0373 | Neuropsychological Testing | X | 3.21 | \$155.64 | \$44.96 | \$31.13 |
|  | 96100 Psychological testing |  |  |  |  |  |
|  | 96105 Assessment of aphasia |  |  |  |  |  |
|  | 96110 Developmental test, lim |  |  |  |  |  |
|  | 96111 Developmental test, extend |  |  |  |  |  |
|  | 96115 Neurobehavior status exam |  |  |  |  |  |
|  | 96117 Neuropsych test battery |  |  |  |  |  |
| 0374 | Monitoring Psychiatric Drugs | X | 1.17 | \$56.73 | \$13.08 | \$11.35 |
|  | 90862 Medication management |  |  |  |  |  |
|  | M0064 Visit for drug monitoring |  |  |  |  |  |
| 0600 | Low Level Clinic Visits | V | 0.98 | \$47.52 | \$9.50 | \$9.50 |
|  | 99201 Office/outpatient visit, new |  |  |  |  |  |
|  | 99202 Office/outpatient visit, new |  |  |  |  |  |
|  | 99211 Office/outpatient visit, est |  |  |  |  |  |
|  | 99212 Office/outpatient visit, est |  |  |  |  |  |
|  | 99241 Office consultation |  |  |  |  |  |
|  | 99242 Office consultation |  |  |  |  |  |
|  | 99271 Confirmatory consultation |  |  |  |  |  |
|  | 99272 Confirmatory consultation |  |  |  |  |  |
| 0601 | Mid Level Clinic Visits | V | 1.00 | \$48.49 | \$9.70 | \$9.70 |
|  | 92002 Eye exam, new patient |  |  |  |  |  |
|  | 92012 Eye exam established pat |  |  |  |  |  |
|  | 99203 Office/outpatient visit, new |  |  |  |  |  |
|  | 99213 Office/outpatient visit, est |  |  |  |  |  |
|  | 99243 Office consultation |  |  |  |  |  |
|  | 99273 Confirmatory consultation |  |  |  |  |  |
|  | G0101 CA screen; pelvic/breast exam |  |  |  |  |  |
| 0602 |  | V | 1.66 | \$80.49 | \$16.29 | \$16.10 |
|  | 92004 Eye exam, new patient |  |  |  |  |  |
|  | 92014 Eye exam \& treatment |  |  |  |  |  |
|  | 99204 Office/outpatient visit, new |  |  |  |  |  |
|  | 99205 Office/outpatient visit, new |  |  |  |  |  |
|  | 99214 Office/outpatient visit, est |  |  |  |  |  |
|  | 99215 Office/outpatient visit, est |  |  |  |  |  |
|  | 99244 Office consultation |  |  |  |  |  |
|  | 99245 Office consultation |  |  |  |  |  |
|  | 99274 Confirmatory consultation |  |  |  |  |  |
|  | 99275 Confirmatory consultation |  |  |  |  |  |
| 0603 | Interdisciplinary Team Conference | V | 1.66 | \$80.49 | \$16.29 | \$16.10 |
| G0175 | Multidisciplinary team visit |  |  |  |  |  |
| 0610 |  | V | 1.34 | \$64.97 | \$20.65 | \$12.99 |
|  | 99281 Emergency dept visit |  |  |  |  |  |
|  | 99282 Emergency dept visit |  |  |  |  |  |
| 0611 | Mid Level Emergency Visits | V | 2.11 | \$102.31 | \$36.47 | \$20.46 |
|  | 99283 Emergency dept visit |  |  |  |  |  |
| 0612 | High Level Emergency Visits 99284 Emergency dept visit | V | 3.19 | \$154.67 | \$54.14 | \$30.93 |
|  | 99285 Emergency dept visit |  |  |  |  |  |
| 0620 | Critical Care | S | 8.60 | \$416.99 | \$152.78 | \$83.40 |
|  | 99291 Critical care, first hour |  |  |  |  |  |
| ${ }^{3} 0701$ | Strontium | X |  |  |  | \$84.76 |
|  | A9600 Strontium-89 chloride |  |  |  |  |  |
| ${ }^{3} 0702$ | Samariam | X |  |  |  | \$139.06 |
|  | A9605 Samarium sm153 lexidronamm |  |  |  |  |  |
| ${ }^{3} 0704$ | Satumomab Pendetide | X |  |  |  | \$63.13 |
|  | A4642 Satumomab pendetide per dose |  |  |  |  |  |
| ${ }^{3} 0705$ | Tc99 Tetrofosmin | X |  |  |  | \$71.08 |

[^264]
## Addendum C.—Proposed Hospital Outpatient Department (HOPD) Payment for Procedures by APCContinued

| APC | CPT/ HCPCS Description | Status Indicator | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| A9502 Technetium TC99M tetrofosmin |  |  |  |  |  |  |
| ${ }^{3} 0725$ | Leucovorin Calcium | X |  |  |  | \$1.07 |
|  | J0640 Leucovorin calcium injection |  |  |  |  |  |
| ${ }^{3} 0726$ | Dexrazoxane Hydrochloride | X |  |  |  | \$18.81 |
|  | J1190 Dexrazoxane HCl injection |  |  |  |  |  |
| ${ }^{3} 0727$ | Injection, Etidronate Disodium | X |  |  |  | \$9.31 |
|  | J1436 Etidronate disodium inj |  |  |  |  |  |
| ${ }^{3} 0728$ | Filgrastim (G-CSF) | X |  |  |  | \$25.21 |
|  | J1440 Filgrastim 300 mcg injection |  |  |  |  |  |
| ${ }^{3} 0730$ | Pamidronate Disodium | X |  |  |  | \$30.93 |
|  | J2430 Pamidronate disodium/30 MG |  |  |  |  |  |
| ${ }^{3} 0731$ | Sargramostim (GM-CSF) | X |  |  |  | \$16.97 |
|  | J2820 Sargramostim injection |  |  |  |  |  |
| ${ }^{3} 0732$ | Mesna | X |  |  |  | \$2.42 |
|  | J9209 Mesna injection |  |  |  |  |  |
| ${ }^{3} 0733$ | Epoetin Alpha | X |  |  |  | \$1.75 |
|  | Q0136 Non esrd epoetin alpha inj |  |  |  |  |  |
| ${ }^{3} 0750$ | Dolasetron Mesylate 10 mg | X |  |  |  | \$1.94 |
|  | J1260 Dolasetron mesylate |  |  |  |  |  |
| ${ }^{3} 0754$ | Metoclopramide HCL | X |  |  |  | \$0.19 |
|  | J2765 Metoclopramide hcl injection |  |  |  |  |  |
| ${ }^{3} 0755$ | Thiethylperazine Maleate | X |  |  |  | \$0.68 |
|  | J3280 Thiethylperazine maleate inj |  |  |  |  |  |
| ${ }^{3} 0761$ | Oral Substitute for IV Antiemtic | X |  |  |  | \$0.10 |

Q0163 Diphenhydramine HCI 50 mg
Q0164 Prochlorperazine maleate 5mg
Q0169 Promethazine HCl 12.5 mg oral
Q0171 Chlorpromazine HCl 10 mg oral
Q0173 Trimethobenzamide HCl 250 mg
Q0174 Thiethylperazine maleate10mg
Q0175 Perphenazine 4mg oral
Q0177 Hydroxyzine pamoate 25 mg
${ }^{3} 0762$ Dronabinol

Q0167 Dronabinol 2.5 mg oral
X \$0.48
${ }^{3} 0763$ Dolasetron Mesylate 100 mg Oral
X \$8.53

Q0180 Dolasetron mesylate oral
${ }^{3} 0764$ Granisetron HCL, 100 mcg Granisetron HCl injection
${ }^{3} 0765$ Granisetron HCL, 1 mg Oral
X $\$ 3.20$

Q0166 Granisetron HCl 1 mg oral

| ${ }^{3} 0768$ | Ondansetron Hydrochloride per 1 mg Injection <br> J2405 Ondansetron hcl injection | X | $\$ 0.87$ |
| :--- | :--- | :--- | :--- |
| ${ }^{3} 0769$ | Ondansetron Hydrochloride 8 mg oral | X | $\$ 2.62$ |


|  |  |  |
| :--- | :--- | :--- |
| ${ }^{3} 0800$ | Q0179 Ondansetron HCl 8mg oral | $X$ |
| Leuprolide Acetate per 3.75 mg | $X$ | $\$ 68.56$ |

J1950 Leuprolide acetate/3.75 MG

X
J1950 Leuprolide acetate/3.75 MG
0801 Cyclophosphamide $\begin{aligned} & \text { J8530 Cyclophosphamide oral } 25 \text { MG }\end{aligned}$
${ }^{3} 0802$ Etoposide
X \$3.10
J8560 Etoposide oral 50 MG
X
J8600 Melphalan oral 2 MG
30807 Aldesleukin single use vial
X \$65.07

J9015 Aldesleukin/single use vial
30809
$\begin{gathered}\text { BCG (Intravesical) one vial } \\ \text { J9031 }\end{gathered}$ Bcg live intravesical vac
${ }^{3} 0810$ Goserelin Acetate Implant, per 3.6 mg
J9202 Goserelin acetate implant
${ }^{3} 0811$ Carboplatin 50 mg
J9045 Carboplatin injection
${ }^{3} 0812$ Carmustine 100 mg
J9050 Carmus bischl nitro inj
30813 Cisplatin 10 mg J9060 Cisplatin 10 MG injeciton
${ }^{3} 0814$ Asparaginase, 10,000 units
J9020 Asparaginase injection
${ }^{3} 0815$ Cyclophosphamide 100 mg
J9070 Cyclophosphamide 100 MG inj
${ }^{3} 0816$ Cyclophosphamide, Lyophilized 100 mg
J9093 Cyclophosphamide lyophilized
${ }^{3} 0817$ Cytrabine 100 mg
${ }^{3} 0818$ Dactinomycin $0.5 \mathrm{mg} \quad X$
X \$0.48
X \$1.16
X \$0.6
X \$59.7
X \$13.96
$X \quad \$ 10.57$
$X \quad \$ 4.56$
$x$ \$8.34

[^265]
## addendum C.-Proposed Hospital Outpatient Department (HOPD) Payment for Procedures by APCContinued

| APC | CPT/ $\quad$ HCPCCS Description | Status Indicator | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | J9120 Dactinomycin actinomycin d |  |  |  |  |  |
| ${ }^{3} 0819$ | Dacarbazine 100 mg | X |  |  |  | \$1.26 |
|  | J9130 Dacarbazine 10 MG inj |  |  |  |  |  |
| ${ }^{3} 0820$ | Daunorubicin HCl 10 mg | X |  |  |  | \$11.64 |
|  | J9150 Daunorubicin |  |  |  |  |  |
| ${ }^{3} 0821$ | Daunorubicin Citrate, Liposomal Formulation, 10 mg J9151 Daunorubicin citrate liposom | X |  |  |  | \$7.76 |
| ${ }^{3} 0822$ | Diethylstibestrol Diphosphate 250 mg | X |  |  |  | \$2.13 |
|  | J9165 Diethylstilbestrol injection |  |  |  |  |  |
| ${ }^{3} 0823$ | Docetaxel 20 mg J9170 Docetaxel | X |  |  |  | \$34.72 |
| ${ }^{3} 0824$ | Etoposide 10 mg J9181 Etoposide 10 MG inj | X |  |  |  | \$. 58 |
| ${ }^{3} 0826$ | Methotrexate Oral 2.5 mg J8610 Methotrexate oral 2.5 MG | X |  |  |  | \$. 29 |
| ${ }^{3} 0827$ | Floxuridine 500 mg J9200 Floxuridine injection | X |  |  |  | \$18.81 |
| ${ }^{3} 0828$ | Gemcitabine HCL 200 mg J9201 Gemcitabine HCl | X |  |  |  | \$9.31 |
| ${ }^{3} 0830$ | Irinotecan 20 mg J9206 Irinotecan injection | X |  |  |  | \$14.16 |
| ${ }^{3} 0831$ | Ifosfamide per 1 gram J9208 Ifosfomide injection | X |  |  |  | \$13.58 |
| ${ }^{3} 0832$ | Idarubicin Hydrochloride 5 mg J9211 Idarubicin hcl injeciton | X |  |  |  | \$46.45 |
| ${ }^{3} 0833$ | Interferon Alfacon-1, Recombinant, 1 mcg J9212 Interferon alfacon-1 | X |  |  |  | \$0.19 |
| ${ }^{3} 0834$ | Interferon, Alfa-2A, Recombinant 3 million units J9213 Interferon alfa-2a inj | X |  |  |  | \$3.20 |
| ${ }^{3} 0836$ | Interferon, Alfa-2B, Recombinant, 1 million units J9214 Interferon alfa-2b inj | X |  |  |  | \$1.36 |
| ${ }^{3} 0838$ | Interferon, Gamma 1-B, 3 million units J9216 Interferon gamma 1-b inj | X |  |  |  | \$22.79 |
| ${ }^{3} 0839$ | Mechlorethamine HCl 10 mg J9230 Mechlorethamine hcl inj | X |  |  |  | \$1.65 |
| ${ }^{3} 0840$ | Melphalan HCI 50 mg J9245 Inj melphalan hydrochl 50 MG | X |  |  |  | \$44.71 |
| ${ }^{3} 0841$ | Methotrexate Sodium 5 mg J9250 Methotrexate sodium inj | X |  |  |  | \$. 10 |
| ${ }^{3} 0842$ | Fludarabine Phosphate 50 mg J9185 Fludarabine phosphate inj | X |  |  |  | \$30.84 |
| ${ }^{3} 0843$ | Pegaspargase per single dose vial J9266 Pegaspargase/singl dose vial | X |  |  |  | \$178.72 |
| ${ }^{3} 0844$ | Pentostatin 10 mg J9268 Pentostatin injection | X |  |  |  | \$133.73 |
| ${ }^{3} 0847$ | Doxorubicin HCL 10 mg <br> J9000 Doxorubic hcl 10 MG vl chemo | X |  |  |  | \$2.81 |
| ${ }^{3} 0849$ | Rituximab, 100 mg J9310 Rituximab cancer treatment | X |  |  |  | \$51.40 |
| ${ }^{3} 0850$ | Streptozocin 1 gm J9320 Streptozocin injection | X |  |  |  | \$14.64 |
| ${ }^{3} 0851$ | Thiotepa 15 mg J9340 Thiotepa injection | X |  |  |  | \$9.50 |
| ${ }^{3} 0852$ | Topotecan 4 mg J9350 Topotecan | X |  |  |  | \$73.22 |
| ${ }^{3} 0853$ | Vinblastine Sulfate 1 mg J9360 Vinblastine sulfate inj | X |  |  |  | \$. 39 |
| ${ }^{3} 0854$ | Vincristine Sulfate 1 mg J9370 Vincristine sulfate 1 MG inj | X |  |  |  | \$2.23 |
| ${ }^{3} 0855$ | Vinorelbine Tartrate per 10 mg J9390 Vinorelbine tartrate/10 mg | X |  |  |  | \$9.60 |
| ${ }^{3} 0856$ | Porfimer Sodium 75 mg J9600 Porfimer sodium | X |  |  |  | \$34.62 |
| ${ }^{3} 0857$ | Bleomycin Sulfate 15 units J9040 Bleomycin sulfate injection | X |  |  |  | \$48.29 |
| ${ }^{3} 0858$ | Cladribine, 1 mg J9065 Inj cladribine per 1 MG | X |  |  |  | \$8.24 |
| ${ }^{3} 0859$ | Fluorouracil J9190 Fluorouracil injection | X |  |  |  | \$0.19 |
| ${ }^{3} 0860$ | Plicamycin 2.5 mg J9270 Plicamycin (mithramycin) inj | X |  |  |  | \$1.36 |
| ${ }^{3} 0861$ | Leuprolide Acetate 1 mg J9218 Leuprolide acetate injeciton | X |  |  |  | \$19.39 |

CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
Copyright American Dental Association. All rights reserved.
${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment.
${ }^{2}$ Not subject to national coinsurance.
${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

## Addendum C.-Proposed Hospital Outpatient Department (HOPD) Payment for Procedures by APCContinued

| APC | CPT/ HCPCS Description | Status Indicator | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| ${ }^{3} 0862$ | Mitomycin, 5 mg J9280 Mitomycin 5 MG inj | X |  |  |  | \$19.88 |
| ${ }^{3} 0863$ | Paclitaxel, 30mg J9265 Paclitaxel injection | X |  |  |  | \$30.16 |
| ${ }^{3} 0864$ | Mitoxantrone HCl , per 5 mg J9293 Mitoxantrone hydrochl/5 MG | X |  |  |  | \$25.80 |
| ${ }^{3} 0865$ | Interferon alfa-N3, 250,000 IU J9215 Interferon alfa-n3 inj | X |  |  |  | \$1.07 |
| ${ }^{3} 0884$ | Rho (D) Immune Globulin, Human one dose pack J2790 Rho d immune globulin inj | X |  |  |  | \$3.78 |
| ${ }^{2} 0886$ | Azathioprine, 50 mg oral J7500 Azathioprine oral 50 mg | X | 0.02 | \$. 97 |  | \$0.19 |
| ${ }^{2} 0887$ | Azathioprine, Parenteral $100 \mathrm{mg}, 20 \mathrm{ml}$ each injection J7501 Azathioprine parenteral | X | 1.40 | \$67.88 |  | \$13.58 |
| ${ }^{2} 0888$ | Cyclosporine, Oral 100 mg J7502 Cyclosporine oral 100 mg | X | 0.08 | \$3.88 |  | \$0.78 |
| ${ }^{2} 0889$ | Cyclosporine, Parenteral <br> J7516 Cyclosporin parenteral 250 mg | X | 0.36 | \$17.46 |  | \$3.49 |
| ${ }^{2} 0890$ | Lymphocyte Immune Globulin $50 \mathrm{mg} / \mathrm{ml}$, 5 ml each J7504 Lymphocyte immune globulin | X | 3.79 | \$183.77 |  | \$36.75 |
| ${ }^{2} 0891$ | Tacrolimus per 1 mg oral J7507 Tacrolimus oral per 1 MG | X | 3.15 | \$152.73 |  | \$30.55 |
| ${ }^{3} 0892$ | Daclizumab, Parenteral, 25 mg J7913 Daclizumab, Parenteral, 25 m | X |  |  |  | \$54.11 |
| ${ }^{3} 0900$ | Injection, Alglucerase per 10 units J0205 Alglucerase injection | X |  |  |  | \$5.14 |
| ${ }^{3} 0901$ | Alpha I, Proteinase Inhibitor, Human per 10 mg J0256 Alpha 1 proteinase inhibitor | X |  |  |  | \$15.22 |
| ${ }^{3} 0902$ | Botulinum Toxin, Type A per unit J0585 Botulinum toxin a per unit | X |  |  |  | \$56.05 |
| ${ }^{3} 0903$ | CMV Immune Globulin J0850 Cytomegalovirus imm IV/vial | X |  |  |  | \$54.11 |
| ${ }^{3} 0905$ | Immune Globulin per 500 mg J1561 Immune globulin 500 mg | X |  |  |  | \$6.40 |
| ${ }^{3} 0906$ | RSV Immune Globulin <br> J1565 RSV-ivig | X |  |  |  | \$85.53 |
| ${ }^{2} 0907$ | Ganciclovir Sodium 500 mg injection J1570 Ganciclovir sodium injection | X | 0.51 | \$24.73 |  | \$4.95 |
| ${ }^{2} 0908$ | Tetanus Immune Globulin, Human, up to 250 units J1670 Tetanus immune globulin inj | X | 0.90 | \$43.64 |  | \$8.73 |
| ${ }^{3} 0909$ | Interferon Beta-1a 33 mcg <br> J1825 Interferon beta-1a | X |  |  |  | \$28.70 |
| ${ }^{3} 0910$ | Interferon Beta-1b 0.25 mg J1830 Interferon beta-1b/. 25 MG | X |  |  |  | \$8.44 |
| ${ }^{2} 0911$ | Streptokinase per 250,000 iu J2995 Inj streptokinase/250000 IU | X | 1.64 | \$79.69 |  | \$15.94 |
| ${ }^{3} 0913$ | Ganciclovir 4.5 mg , Implant J7310 Ganciclovir long act implant | X |  |  |  | \$701.51 |
| ${ }^{2} 0914$ | Reteplase, 37.6 mg (Two Single Use Vials) J2994 Reteplase double bolus | X | 38.20 | \$1,852.21 |  | \$370.44 |
| ${ }^{2} 0915$ | Alteplase recombinant, 10 mg J2996 Alteplase recombinant inj | X | 5.85 | \$283.70 |  | \$56.74 |
| ${ }^{3} 0916$ | Imiglucerase per unit J1785 Injection imiglucerase/unit | X |  |  |  | \$0.58 |
| ${ }^{2} 0917$ | Dipyridamole, $10 \mathrm{mg} /$ Adenosine 6MG J0150 Injection adenosine 6 MG J1245 Dipyridamole injection | X | 0.36 | \$17.46 |  | \$3.49 |
| ${ }^{3} 0918$ | Brachytherapy Seeds, Any type, Each Q3001 Brachytherapy Seeds | S |  |  |  | \$9.99 |
| ${ }^{3} 0925$ | Factor VIII (Antihemophilic Factor, Human) per iu J7190 Factor viii | X |  |  |  | \$0.19 |
| ${ }^{3} 0926$ | Factor VIII (Antihemophilic Factor, Porcine) per iu J7191 Factor VIII (porcine) | X |  |  |  | \$0.19 |
| ${ }^{3} 0927$ | Factor VIII (Antihemophilic Factor, Recombinant) per iu J7192 Factor viii recombinant | X |  |  |  | \$0.19 |
| ${ }^{3} 0928$ | Factor IX, Complex J7194 Factor ix complex | X |  |  |  | \$0.08 |
| ${ }^{3} 0929$ | Other Hemophilia Clotting Factors per iu J7198 Anti-inhibitor <br> Q0187 Factor viia recombinant | X |  |  |  | \$0.27 |
| ${ }^{3} 0930$ | Antithrombin III (Human) per iu J7197 Antithrombin iii injection | X |  |  |  | \$0.19 |
| ${ }^{3} 0931$ | Factor IX (Antihemophilic Factor, Purified, Non-Recombinant) | X |  |  |  | \$0.04 |

[^266]
## Addendum C.-Proposed Hospital Outpatient Department (hopd) Payment for Procedures by ApCContinued

| APC | CPT/ |
| :--- | :---: | :---: | :---: | :---: | :---: | :---: |
| HCPCS |  | HCPCS Description $\quad$| Status |
| :---: |
| Indicator | | Relative |
| :---: |
| Weight | | Payment |
| :---: |
| Rate | | National |
| :---: |
| Unadjusted |
| Coinsurance | | Minimum |
| :---: |
| Unadjusted |
| Coinsurance |


|  | Q0160 Factor IX non-recombinant |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
| ${ }^{3} 0932$ | Factor IX (Antihemophilic Factor, Recombinant) Q0161 Factor IX recombinant | X |  |  | \$0.10 |
| ${ }^{2} 0949$ | Plasma, Pooled Multiple Donor, Solvent/Detergent Treated, Frozen P9023 Frozen plasma, pooled, sd | S | 3.49 | \$169.22 | \$33.84 |
| ${ }^{2} 0950$ | Blood (Whole) For Transfusion P9010 Whole blood for transfusion | S | 2.08 | \$101.02 | \$20.20 |
| ${ }^{2} 0952$ | Cryoprecipitate <br> P9012 Cryoprecipitate each unit | S | 0.70 | \$33.92 | \$6.78 |
| ${ }^{2} 0953$ | Fibrinogen Unit P9013 Unit/s blood fibrinogen | S | 0.48 | \$23.27 | \$4.65 |
| ${ }^{2} 0954$ | Leukocyte Poor Blood P9016 Leukocyte poor blood, unit | S | 2.83 | \$137.21 | \$27.44 |
| ${ }^{2} 0955$ | Plasma, Fresh Frozen P9017 One donor fresh frozn plasma | S | 2.26 | \$109.35 | \$21.87 |
| ${ }^{2} 0956$ | Plasma Protein Fraction P9018 Plasma protein fract, unit | S | 1.26 | \$61.09 | \$12.22 |
| ${ }^{2} 0957$ | Platelet Concentrate P9019 Platelet concentrate unit | S | 0.98 | \$47.46 | \$9.49 |
| ${ }^{2} 0958$ | Platelet Rich Plasma P9020 Platelet rich plasma unit | S | 1.16 | \$56.25 | \$11.25 |
| ${ }^{2} 0959$ | Red Blood Cells P9021 Red blood cells unit | S | 2.04 | \$99.04 | \$19.81 |
| ${ }^{2} 0960$ | Washed Red Blood Cells P9022 Washed red blood cells unit | S | 3.81 | \$184.53 | \$36.91 |
| ${ }^{2} 0961$ | Infusion, Albumin (Human) 5\%, 500 ml Q0156 Human albumin 5\% | X | 2.77 | \$134.31 | \$26.86 |
| ${ }^{2} 0962$ | Infusion, Albumin (Human) 25\%, 50 ml Q0157 Human albumin 25\% | X | 1.38 | \$66.91 | \$13.38 |
| ${ }^{2} 0970$ | New Technology - Level I (\$0-\$50) 78268 Breath test analysis, c-14 | T | 0.52 | \$25.21 | \$5.04 |
| ${ }^{2} 0971$ | New Technology - Level II (\$50-\$100) 78267 Breath tst attain/anal c-14 | S | 1.55 | \$75.16 | \$15.03 |
| ${ }^{2} 0972$ | New Technology - Level III (\$100-\$200) G0166 Extrnl counterpulse, per tx | T | 3.09 | \$149.83 | \$29.97 |
| ${ }^{2} 0980$ | New Technology - Level XI (\$1750-\$2000) <br> 53850 Prostatic microwave thermotx <br> 53852 Prostatic of thermotx <br> G0125 Lung image (PET) <br> G0126 Lung image (PET) staging <br> G0163 Pet for rec of colorectal ca <br> G0164 Pet for lymphoma staging <br> G0165 Pet, rec of melanoma/met ca | S | 38.67 | \$1,875.00 | \$375.00 |
| ${ }^{3} 7000$ | Amifostine, 500 mg J0207 Amifostine | X |  |  | \$41.99 |
| ${ }^{3} 7001$ | Amphotericin B lipid complex, 50 mg , Inj J0286 Amphotericin B lipid complex | X |  |  | \$12.12 |
| ${ }^{3} 7002$ | Clonidine, $\mathrm{HCl}, 1 \mathrm{MG}$ J0735 Clonidine hydrochloride | X |  |  | \$4.17 |
| ${ }^{3} 7003$ | Epoprostenol, 0.5 MG , inj <br> J1325 Epoprostenol injection | X |  |  | \$2.23 |
| ${ }^{3} 7004$ | Immune globulin intravenous human 5 g , inj J1562 Immune globulin 5 gms | X |  |  | \$45.48 |
| ${ }^{3} 7005$ | Gonadorelin hcl, 100 mcg <br> J1620 Gonadorelin hydroch/100 mcg | X |  |  | \$9.12 |
| 27007 | Milrinone lacetate, per 5 ml , inj J2260 Inj milrinone lactate/5 ML | X | 0.47 | \$22.79 | \$4.56 |
| ${ }^{3} 7010$ | Morphine sulfate concentrate (preservative free) per 10 mg J2275 Morphine sulfate injection | X |  |  | \$. 68 |
| ${ }^{3} 7011$ | Oprelevekin, inj, 5 mg J2355 Oprelvekin injection | X |  |  | \$30.35 |
| ${ }^{3} 7012$ | Pentamidine isethionate, 300 mg J2545 Pentamidine isethionte/300mg | X |  |  | \$8.73 |
| ${ }^{3} 7014$ | Fentanyl citrate, inj, up to 2 ml J3010 Fentanyl citrate injeciton | X |  |  | \$. 19 |
| ${ }^{3} 7015$ | Busulfan, oral 2 mg J8510 Oral busulfan | X |  |  | \$0.19 |
| ${ }^{3} 7019$ | Aprotinin, 10,000 kiu Q2003 Aprotinin, 10,000 kiu | X |  |  | \$2.42 |
| ${ }^{3} 7021$ | Baclofen, intrathecal, 50 mcg J0476 Baclofen intrathecal trial | X |  |  | \$0.10 |
| ${ }^{3} 7022$ | Elliotts B Solution, per ml Q2002 Elliot's B solution | X |  |  | \$19.20 |

CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
Copyright American Dental Association. All rights reserved.
${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment.
${ }^{2}$ Not subject to national coinsurance.
${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

## Addendum C.-Proposed Hospital Outpatient Department (HOPD) Payment for Procedures by APC— Continued

| APC | CPT/ HCPCS Description | Status Indicator | Relative Weight | Payment Rate | National Unadjusted Coinsurance | Minimum Unadjusted Coinsurance |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| ${ }^{3} 7023$ | Treatment for bladder calculi, I.e. Renacidin per 500 ml Q2004 Treatment for bladder calcul | X |  |  |  | \$4.46 |
| ${ }^{3} 7024$ | Corticorelin ovine triflutate, 0.1 mg Q2005 Corticorelin ovine triflutat | X |  |  |  | \$45.77 |
| ${ }^{3} 7025$ | Digoxin immune FAB (Ovine), 10 mg Q2006 Digoxin immune FAB (Ovine), | X |  |  |  | \$14.06 |
| ${ }^{3} 7026$ | Ethanolamine oleate, 1000 ml Q2007 Ethanolamine oleate, 1000 ml | X |  |  |  | \$2.13 |
| ${ }^{3} 7027$ | Fomepizole, 1.5 G Q2008 Fomepizole, 1.5 G | X |  |  |  | \$141.29 |
| ${ }^{3} 7028$ | Fosphenytoin, 50 mg Q2009 Fosphenytoin, 50 mg | X |  |  |  | \$0.78 |
| ${ }^{3} 7029$ | Glatiramer acetate, 25 mg Q2010 Glatiramer acetate, 25 mgeny | X |  |  |  | \$3.59 |
| ${ }^{3} 7030$ | Hemin, 1 mg Q2011 Hemin, 1 mg | X |  |  |  | \$0.10 |
| ${ }^{3} 7031$ | Octreotide Acetate, 500 mcg J2352 Octreotide acetate injection | X |  |  |  | \$5.43 |
| ${ }^{3} 7032$ | Sermorelin acetate, 0.5 mg Q2014 Sermorelin acetate, 0.5 mg | X |  |  |  | \$53.34 |
| ${ }^{3} 7033$ | Somatrem, 5 mg Q2015 Somatrem, 5 mg | X |  |  |  | \$28.03 |
| ${ }^{3} 7034$ | Somatropin, 1 mg Q2016 Somatropin, 1 mg | X |  |  |  | \$5.04 |
| ${ }^{3} 7035$ | Teniposide, 50 mg Q2017 Teniposide, 50 mg | X |  |  |  | \$20.85 |
| ${ }^{2} 7036$ | Urokinase, inj, IV, 250,000 I.U. <br> J3365 Urokinase 250,000 IU inj | X | 0.73 | \$35.40 |  | \$7.08 |
| ${ }^{3} 7037$ | Urofollitropin, 75 I.U. Q2018 Urofollitropin, 75 I.U. | X |  |  |  | \$8.24 |
| ${ }^{3} 7038$ | Muromonab-CD3, 5 mg <br> J7505 Monoclonal antibodies | X |  |  |  | \$89.60 |
| ${ }^{3} 7039$ | Pegademase bovine inj 25 I.U. <br> Q2012 Pegademase bovine inj 25 I.U | X |  |  |  | \$1.16 |
| ${ }^{3} 7040$ | Pentastarch 10\% inj, 100 ml Q2013 Pentastarch $10 \% \mathrm{inj}, 100 \mathrm{ml}$ | X |  |  |  | \$2.04 |
| ${ }^{2} 7041$ | Tirofiban HCL, 0.5 mg J3245 Tirofiban hydrochloride | X | 0.02 | \$. 97 |  | \$0.19 |
| ${ }^{3} 7042$ | Capecitabine, oral 150 mg <br> J8520 Capecitabine, oral, 150 mg | X |  |  |  | \$0.19 |
| ${ }^{3} 7043$ | Infliximab, 10 MG J1745 Infliximab injection | X |  |  |  | \$6.89 |
| ${ }^{3} 7045$ | Trimetrexate Glucoronate J3305 Inj trimetrexate glucoronate | X |  |  |  | \$8.15 |
| ${ }^{3} 7046$ | Doxorubicin Hcl Liposome J9001 Doxorubicin hcl liposome inj | X |  |  |  | \$39.18 |

Addendum D.-1996 HCPC Codes
Used To Calculate Pay

| CPT/HCPCS | Termination Date |
| :---: | :---: |
| 00420 | 12/31/1999 |
| 01000 | 12/31/1999 |
| 01110 | 12/31/1999 |
| 01240 | 12/31/1999 |
| 01300 | 12/31/1999 |
| 01460 | 12/31/1999 |
| 01600 | 12/31/1999 |
| 01700 | 12/31/1999 |
| 01800 | 12/31/1999 |
| 01900 | 12/31/1999 |
| 01902 | 12/31/1999 |
| 11050 | 12/31/1997 |
| 11051 | 12/31/1997 |
| 11052 | 12/31/1997 |
| 11700 | 12/31/1996 |
| 11701 | 12/31/1996 |

Addendum D.-1996 HCPC Codes Used To Calculate Pay-Continued

| CPT/HCPCS | Termination Date |
| :---: | :---: |
| 11710 | 12/31/1996 |
| 11711 | 12/31/1996 |
| 11731 | 12/31/1998 |
| 13300 | 12/31/1999 |
| 15580 | 12/31/1999 |
| 15625 | 12/31/1999 |
| 15755 | 12/31/1996 |
| 16040 | 12/31/1998 |
| 16041 | 12/31/1998 |
| 16042 | 12/31/1998 |
| 17001 | 12/31/1997 |
| 17002 | 12/31/1997 |
| 17010 | 12/31/1997 |
| 17100 | 12/31/1997 |
| 17101 | 12/31/1997 |
| 17102 | 12/31/1997 |

Addendum D.-1996 HCPC Codes Used To Calculate Pay-Continued


[^267]Addendum D.-1996 HCPC Codes Used To Calculate Pay-Continued

| CPT/HCPCS | $\begin{array}{c}\text { Termination } \\ \text { Date }\end{array}$ |
| :---: | :---: |
| 53640 | $12 / 31 / 1996$ | 53640 56301 . 56303 .. 56304 56305 .. 56307 .. 56309 ..

56310 56312. 56313 56314
56315
56316
56317
56318 ...
56320 ..
56321 ...
56323
56324
56340
56341 ...
56343 ...
56344
56346 ...
56347
56348 ...
56350 ...
56351 …...............................................
56352 .............................................................
56354
56355 ...
56356
56360
56362
56363.

57108 ..
61106
61130.

61712 ...
61855
61865
62274.

62275 ...
62276 ..
62277 ...........................................
62278 ......................................

62279 ..
62288
62298
63690
63691
64441
 12/31/1999 $12 / 31 / 1999$
$12 / 31 / 1999$ $12 / 31 / 1999$
$12 / 31 / 1999$ $12 / 31 / 1999$
$12 / 31 / 1996$
$12 / 31 / 1996$ $12 / 31 / 1999$
$12 / 31 / 1999$ $12 / 31 / 1999$
$12 / 31 / 1998$ $12 / 31 / 1998$
$12 / 31 / 1998$
$12 / 31 / 1998$
$1231 / 199$ 12/31/1999 12/31/1999 12/31/1999 12/31/1999 12/31/1999 12/31/1999 $12 / 31 / 1999$
$12 / 31 / 1999$ 12/31/1999 $12 / 31 / 1999$
$12 / 31 / 1998$ 12/31/1998 12/31/1999 12/31/1999

Addendum D.-1996 HCPC Codes Used To Calculate Pay-Continued

| CPT/HCPCS | Termination <br> Date |
| :---: | :---: |
| 64442 .................................. | $12 / 31 / 1999$ |


| 64442 | 12/31/1999 |
| :---: | :---: |
| 64443 | 12/31/1999 |
| 64830 | 12/31/1998 |
| 68800 | 12/31/1996 |

68825 …............................................... 12/31/1996
68830 …............................................... $12 / 31 / 1996$

| 74405 ............................................................................121/1998 |  |
| :--- | :--- | :--- |
| 77380 | $12 / 31 / 1999$ |

77381 ...................................................................12/31/1999
77425 …........................................................ 12/31/1999

| 77430 | ......................................................................12/31/1999 |
| :--- | :--- | :--- |
| 78017 | $12 / 31 / 1998$ |


| 78726 ............................................................... |
| :--- |
| 78727 |$\quad 12 / 31 / 1997$

78727 ........................................................................... $12 / 31 / 1997$
80002 12/31/1997
880002 ............................................................... $12 / 31 / 1997$

| 80004 ....................................................................................... |
| :--- |
| 80005 12/31/1997 |

## 80006 …....................................................12/31/1997

| 80007 ................................................................. |
| :--- |
| 80008 12/31/1997 |
| $12 / 31 / 1997$ |

80009 ..................................................................................... $12 / 31 / 1997$

80010 12/31/1997 \begin{tabular}{l}
80011 ............................................................................................ <br>
80012 12/31/1997 <br>
\hline

 

80012 .................................................................. <br>
\hline
\end{tabular} 980018 ............................................................................................12/31/1997 980049 …......................................... $12 / 31 / 1999$ 980054 …...............................................................121/1999



Addendum D.-1996 HCPC CODES Used To Calculate Pay-Continued

|  | CPT/HCPCS | Termination Date |
| :---: | :---: | :---: |
| 88260 |  | 12/31/1998 |
| 90592 |  | 12/31/1999 |
| 90711 |  | 12/31/1998 |
| 90714 |  | 12/31/1998 |
| 90724 |  | 12/31/1998 |
| 90726 |  | 12/31/1998 |
| 90728 |  | 12/31/1998 |
| 90730 |  | 12/31/1998 |
| 90737 |  | 12/31/1998 |
| 90741 |  | 12/31/1998 |
| 90742 |  | 12/31/1998 |
| 90745 |  | 12/31/1999 |
| 90820 |  | 12/31/1997 |
| 90825 |  | 12/31/1997 |
| 90835 |  | 12/31/1997 |
| 90841 |  | 12/31/1997 |
| 90842 |  | 12/31/1997 |
| 90843 |  | 12/31/1997 |
| 90844 |  | 12/31/1997 |
| 90855 |  | 12/31/1997 |
| 90900 |  | 12/31/1996 |
| 90902 |  | 12/31/1996 |
| 90904 |  | 12/31/1996 |
| 90906 |  | 12/31/1996 |
| 90908 |  | 12/31/1996 |
| 90910 |  | 12/31/1996 |
| 90915 |  | 12/31/1996 |
| 93201 |  | 12/31/1996 |
| 93202 |  | 12/31/1996 |
| 93204 |  | 12/31/1996 |
| 93205 |  | 12/31/1996 |
| 93208 |  | 12/31/1996 |
| 93209 |  | 12/31/1996 |
| 93210 |  | 12/31/1996 |
| 93220 |  | 12/31/1996 |
| 93221 |  | 12/31/1996 |
| 93222 |  | 12/31/1996 |
| 94160 |  | 12/31/1996 |
| 97122 |  | 12/31/1998 |
| 97250 |  | 12/31/1998 |
| 97260 |  | 12/31/1998 |
| 97261 |  | 12/31/1998 |
| 97265 |  | 12/31/1998 |
| 97500 |  | 12/31/1996 |
| 97501 |  | 12/31/1996 |
| 97521 |  | 12/31/1996 |
| 99351 |  | 12/31/1997 |
| 99352 |  | 12/31/1997 |
| 99353 |  | 12/31/1997 |
| 99376 |  | 12/31/1997 |
| A2000 |  | 12/31/1997 |
| A4190 |  | 12/31/1996 |
| A4200 |  | 12/31/1996 |
| A4202 |  | 12/31/1996 |
| A4203 |  | 12/31/1996 |
| A4204 |  | 12/31/1996 |
| A4205 |  | 12/31/1996 |
| A4363 |  | 12/31/1999 |
| A4581 |  | 12/31/1996 |
| A4610 |  | 12/31/1996 |
| D0471 |  | 12/31/1999 |
| D2210 |  | 12/31/1999 |
| D2810 |  | 12/31/1999 |
| D3960 |  | 12/31/1999 |
| D4250 |  | 12/31/1999 |
| D7470 |  | 12/31/1999 |

[^268]Addendum D.-1996 HCPC CODES Used To Calculate Pay-Continued

|  | CPT/HCPCS | $\underset{\text { Date }}{\text { Termination }}$ |
| :---: | :---: | :---: |
| D7942 |  | 12/31/1999 |
| D9240 |  | 12/31/1999 |
| E0237 |  | 12/31/1996 |
| E0452 |  | 12/31/1999 |
| E0453 |  | 12/31/1999 |
| E1350 |  | 12/31/1996 |
| E1400 |  | 12/31/1999 |
| E1401 |  | 12/31/1999 |
| E1402 |  | 12/31/1999 |
| E1403 |  | 12/31/1999 |
| E1404 |  | 12/31/1999 |
| G0051 |  | 12/31/1997 |
| G0052 |  | 12/31/1997 |
| G0053 |  | 12/31/1997 |
| G0054 |  | 09/30/1996 |
| G0055 |  | 09/30/1996 |
| G0056 |  | 09/30/1996 |
| G0057 |  | 09/30/1996 |
| G0058 |  | 12/31/1997 |
| G0059 |  | 12/31/1997 |
| G0060 |  | 12/31/1997 |
| G0061 |  | 12/31/1996 |
| G0062 |  | 12/31/1997 |
| G0063 |  | 12/31/1997 |
| G0064 |  | 12/31/1997 |
| G0065 |  | 12/31/1997 |
| G0066 |  | 12/31/1997 |
| G0071 |  | 12/31/1997 |
| G0072 |  | 12/31/1997 |
| G0073 |  | 12/31/1997 |
| G0074 |  | 12/31/1997 |
| G0075 |  | 12/31/1997 |
| G0076 |  | 12/31/1997 |
| G0077 |  | 12/31/1997 |
| G0078 |  | 12/31/1997 |
| G0079 |  | 12/31/1997 |
| G0080 |  | 12/31/1997 |
| G0081 |  | 12/31/1997 |
| G0082 |  | 12/31/1997 |
| G0083 |  | 12/31/1997 |
| G0084 |  | 12/31/1997 |
| G0085 |  | 12/31/1997 |
| G0086 |  | 12/31/1997 |
| G0087 |  | 12/31/1997 |
| G0088 |  | 12/31/1997 |
| G0089 |  | 12/31/1997 |
| G0090 |  | 12/31/1997 |
| G0091 |  | 12/31/1997 |
| G0092 |  | 12/31/1997 |
| G0093 |  | 12/31/1997 |
| G0094 |  | 12/31/1997 |
| G0095 |  | 12/31/1997 |
| G0096 |  | 12/31/1997 |
| G0097 |  | 12/31/1997 |
| G0098 |  | 12/31/1997 |
| G0100 |  | 12/31/1997 |
| G0133 |  | 12/31/1998 |
| H5300 |  | 12/31/1997 |
| J1625 |  | 12/31/1997 |
| J1760 |  | 12/31/1999 |
| J1770 |  | 12/31/1999 |
| J1780 |  | 12/31/1999 |
| J2050 |  | 12/31/1996 |
| J3005 |  | 12/31/1997 |
| J7140 |  | 12/31/1996 |
| J7150 |  | 12/31/1996 |

## Addendum D.-1996 HCPC Codes Used To Calculate Pay-Continued

| CPT/HCPCS | Termination <br> Date |
| :---: | :---: |
| J7196 .................................. | $12 / 31 / 1999$ |


| J7196 | 12/31/1999 |
| :---: | :---: |
| J7503 | 12/31/1999 |
| J9010 | 12/31/1996 |
| K0109 | 09/30/1999 |


| K0110 | .....................................................................................1996 | $12 / 31 / 1996$ |
| :--- | :--- | :--- |

K0119 ....................................... 12/31/1999

| K0120 | ................................ |
| :--- | :--- |
| K0121 | $12 / 31 / 1999$ |


| K0122 …......................................................... | $12 / 31 / 1999$ |
| :--- | :--- |
| K0123 | $12 / 311999$ |

K0125
K0126
K0127
K0128
K0129
K0130
K0137
K0138
K0139
K0140

K0142
K0143
K0145
K0146
K0152
K0154 …....................................................... 12/31/1996

K0168
K0169
K0170 ....
K0172 .....
K0173 ........................................... $\quad 12 / 31 / 1999$
K0174
K0175 .
K0176 ....
K0178 ...
K0180 ….................................................... $12 / 31 / 1999$
K0181 …......... 12/31/1999
K0190 .
K0191
K0192
K0193
K0194 ....
K0197 ....
K0198
K0199
K0203
K0204 ....
K0205 ....
K0206 .....
K0207
K0208
K0209
K0210 ....
K0211 ...................................................... 12/31/1996
K0212 ..................................................12/31/1996

| K0213 | .............................................. | $12 / 31 / 1996$ |
| :--- | :--- | :--- |
| K0214 | ............................ | $12 / 31 / 1996$ |

Addendum D.-1996 HCPC Codes Used To Calculate Pay-Continued

| CPT/HCPCS | Termination <br> Date |
| :---: | :---: |
| K0215 ................................. | $12 / 31 / 1996$ |

12/31/1996
12/31/1996
12/31/1996
12/31/1996
$12 / 31 / 1996$
$12 / 31 / 1996$
12/31/1996
12/31/1996
12/31/1996
12/31/1996
12/31/1996
12/31/1996
12/31/1996
12/31/1996
12/31/1996
12/31/1996
12/31/1996
12/31/1996
12/31/1996
12/31/1996
12/31/1996
12/31/1996
12/31/1996
12/31/1996
12/31/1996
12/31/1996
12/31/1996
12/31/1996
12/31/1996
12/31/1996
12/31/1996
12/31/1996
12/31/1996
12/31/1996
12/31/1996
12/31/1996
12/31/1996
12/31/1996
12/31/1996
12/31/1996
12/31/1996
12/31/1996
12/31/1996
12/31/1996
12/31/1996
06/30/1996
06/30/1996
06/30/1996
06/30/1996
06/30/1996
06/30/1996
12/31/1999
12/31/1999
12/31/1999
12/31/1999
12/31/1996
12/31/1999
12/31/1999
12/31/1996
12/31/1996
12/31/1996
12/31/1996
12/31/1999
12/31/1997

[^269]Addendum D.-1996 HCPC Codes Used To Calculate Pay-Continued

|  | CPT/HCPCS | Termination Date | CPT/HCPCS |  |  | Termination Date |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| K0414 |  | 12/31/1997 | L8623 |  |  | 12/31/1997 |
| K0417 |  | 12/31/1999 | L8624 |  |  | 12/31/1997 |
| K0418 |  | 12/31/1999 | L8625 |  |  | 12/31/1997 |
| K0419 |  | 12/31/1999 | L8626 |  |  | 12/31/1997 |
| K0420 |  | 12/31/1999 | L8627 |  |  | 12/31/1997 |
| K0421 |  | 12/31/1999 | L8628 |  |  | 12/31/1997 |
| K0422 |  | 12/31/1999 | L8629 |  |  | 12/31/1997 |
| K0423 |  | 12/31/1999 | L8640 |  |  | 12/31/1997 |
| K0424 |  | 12/31/1999 | L8655 |  |  | 12/31/1997 |
| K0425 |  | 12/31/1999 | L8656 |  |  | 12/31/1997 |
| K0426 |  | 12/31/1999 | L8657 |  |  | 12/31/1997 |
| K0427 |  | 12/31/1999 | L8680 |  |  | 12/31/1997 |
| K0428 |  | 12/31/1999 | L8690 |  |  | 12/31/1997 |
| K0429 |  | 12/31/1999 | L9999 |  |  | 12/31/1996 |
| K0430 |  | 12/31/1999 | M0005 |  |  | 12/31/1997 |
| K0431 |  | 12/31/1999 | M0006 |  |  | 12/31/1997 |
| K0432 |  | 12/31/1999 | M0007 |  |  | 12/31/1997 |
| K0433 |  | 12/31/1999 | M0008 |  |  | 12/31/1997 |
| K0434 |  | 12/31/1999 | M0101 |  |  | 12/31/1998 |
| K0435 |  | 12/31/1999 | P9014 |  |  | 12/31/1998 |
| K0436 |  | 12/31/1999 | P9015 |  |  | 12/31/1998 |
| K0437 |  | 12/31/1999 | P9610 |  |  | 12/31/1998 |
| K0438 |  | 12/31/1999 | Q0068 |  |  | 12/31/1999 |
| K0439 |  | 12/31/1999 | Q0103 |  |  | 12/31/1997 |
| K0453 |  | 12/31/1998 | Q0104 |  |  | 12/31/1997 |
| K0454 |  | 12/31/1997 | Q0109 |  |  | 12/31/1997 |
| K0503 |  | 12/31/1999 | Q0110 |  |  | 12/31/1997 |
| K0504 |  | 12/31/1999 | Q0116 |  |  | 09/30/1996 |
| K0505 |  | 12/31/1999 | Q0132 |  |  | 12/31/1999 |
| K0506 |  | 12/31/1999 | Q0158 |  |  | 12/31/1997 |
| K0507 |  | 12/31/1999 | Q0159 |  |  | 12/31/1998 |
| K0508 |  | 12/31/1999 | Q0162 |  |  | 12/31/1998 |
| K0509 |  | 12/31/1999 | Q0182 |  |  | 12/31/1998 |
| K0511 |  | 12/31/1999 |  |  |  |  |
| K0512 |  | 12/31/1999 |  |  |  |  |
| K0513 |  | 12/31/1999 | ADDEN | DUM | CPT | S WHICH |
| K0514 |  | 12/31/1999 |  | LD BE | IId Only | S INPATIENT |
| K0515 |  | 12/31/1999 |  | EDURE |  |  |
| K0516 |  | 12/31/1999 |  | EDURE |  |  |
| K0518 |  | 12/31/1999 |  |  |  |  |
| K0519 |  | 12/31/1999 | CPT/ | Status |  | iption |
| K0520 |  | 12/31/1999 | HCPCS | Indicator |  | , |
| K0521 |  | 12/31/1999 |  |  |  |  |
| K0522 |  | 12/31/1999 | 00174 | C | Anesth, pha | geal surgery |
| K0523 |  | 12/31/1999 | 00176 | C | Anesth, phar | geal surgery |
| K0524 |  | 12/31/1999 | 00214 | C | Anesth, facia <br> Anesth, skull | one surgery rainage |
| K0525 |  | 12/31/1999 | 00215 | C | Anesth, skull | racture |
| K0526 |  | 12/31/1999 | 00404 | C | Anesth, surg | of breast |
| K0527 |  | 12/31/1999 | 00406 | C | Anesth, surg | of breast |
| K0528 |  | 12/31/1999 | 00452 | C | Anesth, surg | of shoulder |
| K0530 |  | 12/31/1999 | 00474 | C | Anesth, surg | of rib(s) |
| L4200 |  | 12/31/1996 | 00524 | C | Anesth, ches | rainage |
| L4310 |  | 12/31/1998 | 00530 | C | Anesth, pac <br> Anesth, | aker insertion |
| $\llcorner 4320$ |  | 12/31/1998 | 00540 | C | Anesth, che Anesth, relea | urgery of lung |
| L4390 |  | 12/31/1998 | 00544 | C | Anesth, ches | ning removal |
| L7160 |  | 12/31/1996 | 00546 | C | Anesth, lung | nest wall surg |
| L7165 |  | 12/31/1996 | 00560 | C | Anesth, open | eart surgery |
| L8605 |  | 12/31/1997 | 00562 | C | Anesth, open | eart surgery |
| L8611 |  | 12/31/1997 | 00580 | C | Anesth heart | ng transplant |
| L8615 |  | 12/31/1997 | 00604 | C | Anesth, surg | of vertebra |
| L8616 |  | 12/31/1997 | 00622 | C | Anesth, removal | of nerves |
| L8617 |  | 12/31/1997 | 00632 | C | Anesth, rem Anesth for | of nerves monucleolysis |
| L8618 |  | 12/31/1997 | 00670 | C | Anesth, spin | cord surgery |
| L8620 |  | 12/31/1997 | 00792 | C | Anesth, part | removal |
| L8621 |  | 12/31/1997 | 00794 | C | Anesth, panc | as removal |
| L8622 | ......... | 12/31/1997 | 00796 | C | Anesth, for li | transplant |

## Addendum E.-CPT Codes Which <br> Would Be Paid Only As Inpatient Procedures-Continued

| CPT/ HCPCS | HOPD Status Indicator | Description |
| :---: | :---: | :---: |
| 00802 | C | Anesth, fat layer removal |
| 00844 | C | Anesth, pelvis surgery |
| 00846 | C | Anesth, hysterectomy |
| 00848 | C | Anesth, pelvic organ surg |
| 00850 | C | Anesth, cesarean section |
| 00855 | C | Anesth, hysterectomy |
| 00857 | C | Analgesia, labor \& c-section |
| 00864 | C | Anesth, removal of bladder |
| 00865 | C | Anesth, removal of prostate |
| 00866 | C | Anesth, removal of adrenal |
| 00868 | C | Anesth, kidney transplant |
| 00882 | C | Anesth, major vein ligation |
| 00884 | C | Anesth, major vein revision |
| 00904 | C | Anesth, perineal surgery |
| 00908 | C | Anesth, removal of prostate |
| 00928 | C | Anesth, removal of testis |
| 00932 | C | Anesth, amputation of penis |
| 00934 | C | Anesth, penis, nodes removal |
| 00936 | C | Anesth, penis, nodes removal |
| 00944 | C | Anesth, vaginal hysterectomy |
| 00955 | C | Analgesia, vaginal delivery |
| 01140 | C | Anesth, amputation at pelvis |
| 01150 | C | Anesth, pelvic tumor surgery |
| 01190 | C | Anesth, pelvis nerve removal |
| 01212 | C | Anesth, hip disarticulation |
| 01214 | C | Anesth, replacement of hip |
| 01232 | C | Anesth, amputation of femur |
| 01234 | C | Anesth, radical femur surg |
| 01272 | C | Anesth, femoral artery surg |
| 01274 | C | Anesth, femoral embolectomy |
| 01402 | C | Anesth, replacement of knee |
| 01404 | C | Anesth, amputation at knee |
| 01442 | C | Anesth, knee artery surg |
| 01444 | C | Anesth, knee artery repair |
| 01486 | C | Anesth, ankle replacement |
| 01502 | C | Anesth, Iwr leg embolectomy |
| 01632 | C | Anesth, surgery of shoulder |
| 01634 | C | Anesth, shoulder joint amput |
| 01636 | C | Anesth, forequarter amput |
| 01638 | C | Anesth, shoulder replacement |
| 01652 | C | Anesth, shoulder vessel surg |
| 01654 | C | Anesth, shoulder vessel surg |
| 01656 | C | Anesth, arm-leg vessel surg |
| 01756 | C | Anesth, radical humerus surg |
| 01772 | C | Anesth, uppr arm embolectomy |
| 01782 | C | Anesth, uppr arm vein repair |
| 01842 | C | Anesth, Iwr arm embolectomy |
| 01852 | C | Anesth, Iwr arm vein repair |
| 01904 | C | Anesth, skull x-ray inject |
| 01990 | C | Support for organ donor |
| 15756 | C | Free muscle flap, microvasc |
| 15757 | C | Free skin flap, microvasc |
| 15758 | C | Free fascial flap, microvasc |
| 19200 | C | Removal of breast |
| 19220 | C | Removal of breast |
| 19240 | C | Removal of breast |
| 19260 | C | Removal of chest wall lesion |
| 19271 | C | Revision of chest wall |
| 19272 | C | Extensive chest wall surgery |
| 19361 | C | Breast reconstruction |
| 19364 | C | Breast reconstruction |
| 19367 | C | Breast reconstruction |
| 19368 | C | Breast reconstruction |
| 19369 | C | Breast reconstruction |
| 20660 | C | Apply, remove fixation device |
| 20661 | C | Application of head brace |
| 20662 | C | Application of pelvis brace |
| 20663 | C | Application of thigh brace |
| 20664 | C | Halo brace application |
| 20802 | C | Replantation, arm, complete |
| 20805 | C | Replant, forearm, complete |

[^270]Addendum E.-CPT Codes Which
Would Be Paid Only As InPatient
Procedures-Continued
CPT/
HCPCS

| 20808 | C | Replantation hand, complete <br> 20816 |
| :--- | :--- | :--- |
| C | Replantation digit, complete |  |

20822
20824
20827
20838
20931
20936
20938
20955
20956
20957
20962
20970
20972
21045
21141
21142
21145
21146
21147
21150
2115
21155
21159
21160
21172
21175
21179
21180
21182
21183
21188
21193
21194
21196
21247
21255
21256
21268
21343
21346
21347
21348
21360
21365
21366
21385 21386
21390
21395
21408
21422
21423
21431
21432
21433
21435
21495
21510 C
Replant Replantation thumb, complete Replantation thumb, complete Replantation foot, complete Spinal bone allograft Spinal bone allograft Spinal bone autograft Spinal bone autograft Spinal bone autograft Fibula bone graft, microvasc lliac bone graft, microvasc Mt bone graft, microvasc Other bone graft, microvasc Bone/skin graft, microvasc Bone/skin graft, iliac crest Bone/skin graft, metatarsal Bone/skin graft, great toe Extensive jaw surgery Reconstruct midface, lefort Reconstruct midface, lefor Reconstruct midface, lefort Reconstruct midface, lefort Reconstruct midface, lefort Reconstruct midface, lefort Reconstruct midface, lefort Reconstruct midface, lefort Reconstruct midface, lefort Reconstruct midface, lefor Reconstruct midface, lefort Reconstruct midface, lefort Reconstruct orbit/forehead Reconstruct orbit/forehead Reconstruct entire forehead Reconstruct entire forehead Reconstruct cranial bone Reconstruct cranial bone Reconstruct cranial bone Reconstruction of midface Reconstruct lower jaw bone Reconstruct lower jaw bone Reconstruct lower jaw bone Reconstruct lower jaw bone Reconstruct lower jaw bone Reconstruct lower jaw bone Reconstruction of orbit Revise eye sockets Treatment of sinus fracture Treatment of sinus fracture Treat nose/jaw fracture Treat nose/jaw fracture Treat nose/jaw fracture Treat cheek bone fracture Treat cheek bone fracture Treat cheek bone fracture Treat cheek bone fracture Treat eye socket fracture Treat eye socket fracture Treat eye socket fracture Treat eye socket fracture Treat eye socket fracture Treat eye socket fracture Treat mouth roof fracture Treat mouth roof fracture Treat craniofacial fracture Treat craniofacial fracture Treat craniofacial fracture Treat craniofacial fracture Treat craniofacial fracture Treat hyoid bone fracture Drainage of bone lesion

Addendum E.-CPT Codes Which Would Be Paid Only As inpatient Procedures-Continued H

| C |
| ---: |
| HC |

CPT/
HCPCS
HOPD
Status
Indicator


| 21557 | C | Remove tumor, neck/chest |
| :--- | :--- | :--- |
| 21615 | C | Removal of rib |
| 21616 | C | Removal of rib and nerves |

Partial removal of sternum
Sternal debridement
Extensive sternum surgery
Extensive sternum surgery Revision of neck muscle/rib Reconstruction of sternum Repair of sternum separation Treatment of rib fracture(s) Treat sternum fracture Remove part of neck vertebra Remove part, thorax vertebra Remove part, lumbar vertebra Remove extra spine segment Remove part of neck vertebra Remove part, thorax vertebra Remove part, lumbar vertebra Remove extra spine segment Revision of neck spine Revision of thorax spine Revision of lumbar spine Revise, extra spine segment Revision of neck spine Revision of thorax spine Revision of lumbar spine Revise, extra spine segment Treat odontoid fx w/o graft Treat odontoid fx w/graft Treat spine fracture Treat neck spine fracture Treat thorax spine fracture Treat each add spine fx Neck spine fusion Neck spine fusion Thorax spine fusion Lumbar spine fusion Additional spinal fusion Spine \& skull spinal fusion Neck spinal fusion Neck spine fusion Thorax spine fusion Lumbar spine fusion Spine fusion, extra segment Lumbar spine fusion
Spine fusion, extra segment Fusion of spine
Fusion of spine
Fusion of spine
Fusion of spine
Fusion of spine
Fusion of spine
Kyphectomy, 1-2 segments
Kyphectomy, 3 or more Exploration of spinal fusion Insert spine fixation device Insert spine fixation device Insert spine fixation device Insert spine fixation device insert spine fixation device Insert spine fixation device Insert spine fixation device Insert spine fixation device Insert pelv fixation device Reinsert spinal fixation Remove spine fixation device Apply spine prosth device Remove spine fixation device Remove spine fixation device Drain shoulder bone lesion
Removal of collar bone

Addendum E.-CPT Codes Which Would Be Paid Only As Inpatient Procedures-Continued

| CPT/ HCPCS | HOPD Status Indicator | Description |
| :---: | :---: | :---: |
| 23195 | C | Removal of head of humerus |
| 23200 | C | Removal of collar bone |
| 23210 | C | Removal of shoulder blade |
| 23220 | C | Partial removal of humerus |
| 23221 | C | Partial removal of humerus |
| 23222 | C | Partial removal of humerus |
| 23332 | C | Remove shoulder foreign body |
| 23395 | C | Muscle transfer, shoulder/arm |
| 23397 | C | Muscle transfers |
| 23400 | C | Fixation of shoulder blade |
| 23440 | C | Remove/transplant tendon |
| 23470 | C | Reconstruct shoulder joint |
| 23472 | C | Reconstruct shoulder joint |
| 23900 | C | Amputation of arm \& girdle |
| 23920 | C | Amputation at shoulder joint |
| 24149 | C | Radical resection of elbow |
| 24150 | C | Extensive humerus surgery |
| 24151 | C | Extensive humerus surgery |
| 24152 | C | Extensive radius surgery |
| 24153 | C | Extensive radius surgery |
| 24900 | C | Amputation of upper arm |
| 24920 | C | Amputation of upper arm |
| 24930 | C | Amputation follow-up surgery |
| 24931 | C | Amputate upper arm \& implant |
| 24940 | C | Revision of upper arm |
| 25170 | C | Extensive forearm surgery |
| 25390 | C | Shorten radius or ulna |
| 25391 | C | Lengthen radius or ulna |
| 25392 | C | Shorten radius \& ulna |
| 25393 | C | Lengthen radius \& ulna |
| 25405 | C | Repair/graft radius or ulna |
| 25420 | C | Repair/graft radius \& ulna |
| 25900 | C | Amputation of forearm |
| 25905 | C | Amputation of forearm |
| 25909 | C | Amputation follow-up surgery |
| 25915 | C | Amputation of forearm |
| 25920 | C | Amputate hand at wrist |
| 25924 | C | Amputation follow-up surgery |
| 25927 | C | Amputation of hand |
| 25931 | C | Amputation follow-up surgery |
| 26551 | C | Great toe-hand transfer |
| 26553 | C | Single transfer, toe-hand |
| 26554 | C | Double transfer, toe-hand |
| 26556 | C | Toe joint transfer |
| 26992 | C | Drainage of bone lesion |
| 27005 | C | Incision of hip tendon |
| 27006 | C | Incision of hip tendons |
| 27025 | C | Incision of hip/thigh fascia |
| 27030 | C | Drainage of hip joint |
| 27035 | C | Denervation of hip joint |
| 27036 | C | Excision of hip joint/muscle |
| 27054 | C | Removal of hip joint lining |
| 27070 | C | Partial removal of hip bone |
| 27071 | C | Partial removal of hip bone |
| 27075 | C | Extensive hip surgery |
| 27076 | C | Extensive hip surgery |
| 27077 | C | Extensive hip surgery |
| 27078 | C | Extensive hip surgery |
| 27079 | C | Extensive hip surgery |
| 27090 | C | Removal of hip prosthesis |
| 27091 | C | Removal of hip prosthesis |
| 27120 | C | Reconstruction of hip socket |
| 27122 | C | Reconstruction of hip socket |
| 27125 | C | Partial hip replacement |
| 27130 | C | Total hip replacement |
| 27132 | C | Total hip replacement |
| 27134 | C | Revise hip joint replacement |
| 27137 | C | Revise hip joint replacement |
| 27138 | C | Revise hip joint replacement |
| 27140 | C | Transplant femur ridge |
| 27146 | C | Incision of hip bone |
| 27147 | C | Revision of hip bone |

Addendum E.-CPT Codes Which
Would Be Paid Only As InPatient
Procedures-Continued

| CPT/ |
| :--- |
| HCPCS |



| 27151 | C | Incision of hip bones |
| :--- | :--- | :--- |
| 27156 | C | Revision of hip bones |
| 27158 | C | Revision of pelvis |
| 27161 | C | Incision of neck of femur |
| 27165 | C | Incision/fixation of femur |
| 27170 | C | Repair/graft femur head/neck |


| 27175 | C |
| :--- | :--- |
| 27176 | C |


| 27176 | C |
| :--- | :--- |
| 27177 | C |
| 27178 | $C$ |




 Treat slipped epiphysis Treat slipped epiphysis Treat slipped epiphysis
Treat slipped epiphysis
Treat slipped epiphysis
Revise head/neck of femur Treat slipped epiphysis Revision of femur epiphysis
Reinforce hip bones Treat pelvic fracture(s) Treat pelvic ring fracture Treat pelvic ring fracture Treat pelvic ring fracture
Treat hip socket fracture
Treat hip wall fracture
Treat hip fracture(s)
Treat hip fracture(s)
Treat thigh fracture
Treat thigh fracture
Treat thigh fracture
Treat thigh fracture
Treat thigh fracture
Treat thigh fracture
Treat hip dislocation
Treat hip dislocation
Treat hip dislocation
Fusion of sacroiliac joint
Fusion of pubic bones
Fusion of hip joint
Fusion of hip joint
Amputation of leg at hip
Amputation of leg at hip
Drainage of bone lesion
Extensive leg surgery
Revision of knee joint
Revision of knee joint
Total knee replacement Incision of thigh
Incision of thigh
Realignment of thigh bone
Realignment of knee
Realignment of knee
Shortening of thigh bone
Lengthening of thigh bone Shorten/lengthen thighs Repair of thigh
Repair/graft of thigh
Surgery to stop leg growth
Surgery to stop leg growth
Surgery to stop leg growth
Surgery to stop leg growth
Revise/replace knee joint
Revise/replace knee joint
Removal of knee prosthesis
Reinforce thigh
Treatment of thigh fracture
Treatment of thigh fracture
Treatment of thigh fracture
Treatment of thigh fracture
Treatment of thigh fracture
Treat thigh fx growth plate
Treat kneecap fracture
Treat knee fracture
Treat knee fracture
Treat knee fracture

Addendum E.-CPT Codes Which
Would Be Paid Only As InPatient
Procedures-Continued HCP

| CPT/ | HOPD <br> Status <br> HCPCS |
| :---: | :---: |


NNNNAN N N N

| 27557 | C | Treat knee dislocation |
| :--- | :--- | :--- |
| 27558 | C | Treat knee dislocation |
| 27580 | C | Fusion of knee |
| 27590 | C | Amputate leg at thigh |
| 27591 | C | Amputate leg at thigh |
| 27592 | C | Amputate leg at thigh |
| 27596 | C | Amputation follow-up surgery |
| 27598 | C | Amputate lower leg at knee |
| 27645 | C | Extensive lower leg surgery |

Extensive lower leg surgery
Extensive lower leg surgery
Reconstruct ankle joint Reconstruction, ankle joint Realignment of lower leg Revision of lower leg Repair of tibia
Repair/graft of tibia
Repair/graft of tibia
Repair of lower leg
Repair of lower leg
Amputation of lower leg
Amputation of lower leg
Amputation of lower leg
Amputation follow-up surgery
Amputation of foot at ankle
Amputation of midfoot
Amputation thru metatarsal Removal of upper jaw
Removal of upper jaw Nasal/sinus endoscopy, surg Nasal/sinus endoscopy, surg Nasal/sinus endoscopy, surg
Nasal/sinus endoscopy, surg
Nasal/sinus endoscopy, surg
Removal of larynx
Removal of larynx
Partial removal of larynx
Partial removal of larynx
Partial removal of larynx
Partial removal of larynx
Partial removal of larynx Removal of larynx \& pharynx Reconstruct larynx \& pharynx
Revision of larynx
Treat larynx fracture
Revision of larynx
Clearance of airways
Repair of windpipe
Reconstruction of windpipe
Repair/graft of bronchus
Reconstruct bronchus
Reconstruct windpipe
Reconstruct windpipe Remove windpipe lesion Remove windpipe lesion Repair of windpipe injury Repair of windpipe injury Exploration of chest
Exploration of chest Biopsy through chest wall Exploration/biopsy of chest Explore/repair chest Re-exploration of chest Explore chest free adhesions Removal of lung lesion(s) Remove/treat lung lesions Removal of lung lesion(s) Remove lung foreign body Open chest heart massage
Drain, open, lung lesion Drain, percut, lung lesion Treat chest lining
Release of lung

Addendum E.-CPT Codes Which Would Be Paid Only As Inpatient Procedures-Continued

| $\begin{gathered} \text { CPT/ } \\ \text { HCPCS } \end{gathered}$ | HOPD Status Indicator | Description |
| :---: | :---: | :---: |
| 32225 | C | Partial release of lung |
| 32310 | C | Removal of chest lining |
| 32320 | C | Free/remove chest lining |
| 32402 | C | Open biopsy chest lining |
| 32440 | C | Removal of lung |
| 32442 | C | Sleeve pneumonectomy |
| 32445 | C | Removal of lung |
| 32480 | C | Partial removal of lung |
| 32482 | C | Bilobectomy |
| 32484 | C | Segmentectomy |
| 32486 | C | Sleeve lobectomy |
| 32488 | C | Completion pneumonectomy |
| 32491 | C | Lung volume reduction |
| 32500 | C | Partial removal of lung |
| 32501 | C | Repair bronchus add-on |
| 32520 | C | Remove lung \& revise chest |
| 32522 | C | Remove lung \& revise chest |
| 32525 | C | Remove lung \& revise chest |
| 32540 | C | Removal of lung lesion |
| 32650 | C | Thoracoscopy, surgical |
| 32651 | C | Thoracoscopy, surgical |
| 32652 | C | Thoracoscopy, surgical |
| 32653 | C | Thoracoscopy, surgical |
| 32654 | C | Thoracoscopy, surgical |
| 32655 | C | Thoracoscopy, surgical |
| 32656 | C | Thoracoscopy, surgical |
| 32657 | C | Thoracoscopy, surgical |
| 32658 | C | Thoracoscopy, surgical |
| 32659 | C | Thoracoscopy, surgical |
| 32660 | C | Thoracoscopy, surgical |
| 32661 | C | Thoracoscopy, surgical |
| 32662 | C | Thoracoscopy, surgical |
| 32663 | C | Thoracoscopy, surgical |
| 32664 | C | Thoracoscopy, surgical |
| 32665 | C | Thoracoscopy, surgical |
| 32800 | C | Repair lung hernia |
| 32810 | C | Close chest after drainage |
| 32815 | C | Close bronchial fistula |
| 32820 | C | Reconstruct injured chest |
| 32850 | C | Donor pneumonectomy |
| 32851 | C | Lung transplant, single |
| 32852 | C | Lung transplant with bypass |
| 32853 | C | Lung transplant, double |
| 32854 | C | Lung transplant with bypass |
| 32900 | C | Removal of rib(s) |
| 32905 | C | Revise \& repair chest wall |
| 32906 | C | Revise \& repair chest wall |
| 32940 | C | Revision of lung |
| 32997 | C | Total lung lavage |
| 33015 | C | Incision of heart sac |
| 33020 | C | Incision of heart sac |
| 33025 | C | Incision of heart sac |
| 33030 | C | Partial removal of heart sac |
| 33031 | C | Partial removal of heart sac |
| 33050 | C | Removal of heart sac lesion |
| 33120 | C | Removal of heart lesion |
| 33130 | C | Removal of heart lesion |
| 33140 | C | Heart revascularize (tmr) |
| 33200 | C | Insertion of heart pacemaker |
| 33201 | C | Insertion of heart pacemaker |
| 33236 | C | Remove electrode/ thoracotomy |
| 33237 | C | Remove electrode/ thoracotomy |
| 33238 | C | Remove electrode/ thoracotomy |
| 33243 | C | Remove eltrd/thoracotomy |
| 33245 | C | Insert epic eltrd pace-defib |
| 33246 | C | Insert epic eltrd/generator |
| 33250 | C | Ablate heart dysrhythm focus |
| 33251 | C | Ablate heart dysrhythm focus |
| 33253 | C | Reconstruct atria |

Addendum E.-CPT CODES WHICH
WOULD BE PAID ONLY As InPATIENT
Procedures-Continued
CPT/
HCPCS

| Indicator |
| :--- | :--- |


| 33261 | C | Ablate heart dysrhythm focus |
| :--- | :--- | :--- |
| 33282 | C | Implant pat-active ht record |
| 33284 | C | Remove pat-active ht record |
| 33300 | C | Repair of heart wound |
| 33305 | C | Repair of heart wound |
| 33310 | C | Exploratory heart surgery |
| 33315 | C | Exploratory heart surgery |
| 33320 | C | Repair major blood vessel(s) |
| 33321 | C | Repair major vessel |

33321
33322
33330
33332
33335
3340
334
334
3

| 334 |
| :--- |
| 334 |

334
334
334 334
334 33 33
${ }_{3}$


3
33
33
3





3



3
3
3



33


33


33
33


33



33
3
3



335
335
33


33
335334
33535
33536
33542

| 33542 | C |
| :--- | :--- | :--- |
| 33545 | C | Repair major vessel Insert major vessel graft Insert major vessel graft Insert major vessel graft Repair of aortic valve Valvuloplasty, open Valvuloplasty, w/cp bypass Prepare heart-aorta conduit Replacement of aortic valve Replacement of aortic valve Replacement of aortic valve Replacement of aortic valve Replacement of aortic valve Replacement of aortic valve Repair of aortic valve Revision, subvalvular tissue Revise ventricle muscle Repair of aortic valve Revision of mitral valve Revision of mitral valve Repair of mitral valve Repair of mitral valve Repair of mitral valve Replacement of mitral valve Revision of tricuspid valve Valvuloplasty, tricuspid Valvuloplasty, tricuspid Replace tricuspid valve Revision of tricuspid valve Revision of pulmonary valve Valvotomy, pulmonary valve Revision of pulmonary valve Revision of pulmonary valve Replacement, pulmonary valve Revision of heart chamber Revision of heart chamber Repair, prosth valve clot Repair heart vessel fistula Repair heart vessel fistula Coronary artery correction

Coronary artery graft Coronary artery graft Repair artery w/tunnel Repair artery, translocation CABG, vein, single CABG, vein, two CABG, vein, three CABG, vein, four CABG, vein, five Cabg, vein, six or more CABG, artery-vein, single CABG, artery-vein, two CABG, artery-vein, three CABG, artery-vein, four CABG, artery-vein, five Cabg, art-vein, six or more Coronary artery, bypass/reop CABG, arterial, single
CABG, arterial, two CABG, arterial, three Cabg, arterial, four or more Removal of heart lesion Repair of heart damage
 Procedures-Continued


| CPT/ | HOPD |
| :---: | :---: |
| Status |  |
| HCPCS | Indicator |

3357

33600
3360
336
336
336
336

| 33572 |
| :--- |
| 33600 |
| 33602 |
| 33606 |
| 33608 |
| 33610 |
| 33611 |


| 33572 | C |
| :--- | :--- |
|  |  |
| 33600 | C |
| 33602 | C |
| 33606 | C |
| 33608 | C |
| 33610 | C |

Open coronary
endarterectomy
Closure of valve
Closure of valve
Anastomosis/artery-aorta
Repair anomaly w/conduit

Repair anomaly w/conduit Repair by enlargement
Repair double ventricle
Repair double ventricle
Repair, simple fontan
Repair, modified fontan Repair single ventricle
Repair heart septum defect
Revision of heart veins
Repair heart septum defects
Repair of heart defects
Repair of heart defects
Repair of heart chambers
Repair heart septum defect
Repair heart septum defect
Repair heart septum defect
Reinforce pulmonary artery
Repair of heart defects
Repair of heart defects
Repair of heart defects
Repair of heart defects Repair of heart defects
Repair of heart defect
Repair of heart defect
Repair heart-vein defect(s)
Repair heart-vein defect
Revision of heart chamber Revision of heart chamber Revision of heart chamber Major vessel shunt
Major vessel shunt
Major vessel shunt
Major vessel shunt \& graft
Major vessel shunt
Major vessel shunt
Repair great vessels defect
Repair great vessels defect
Repair great vessels defect Repair great vessels defect Repair great vessels defect Repair great vessels defect Repair great vessels defect Repair great vessels defect Repair great vessels defect
Repair great vessels defect Repair arterial trunk Revision of pulmonary artery Aortic suspension
Repair vessel defect
Repair vessel defect
Repair septal defect
Repair septal defect
Revise major vessel
Revise major vessel
Revise major vessel
Remove aorta constriction
Remove aorta constriction
Remove aorta constriction
Repair septal defect
Repair septal defect
Ascending aortic graft Ascending aortic graft
Ascending aortic graft
Transverse aortic arch graft Thoracic aortic graft
Thoracoabdominal graft
Remove lung artery emboli

Addendum E.-CPT COdes Which Would Be Paid Only As Inpatient Procedures-Continued

| CPT/ | HOPD | Status |
| :--- | :--- | :--- |
| HCPCS |  |  |
|  | Indicator |  |
| 33915 | C | Description |
| 33916 | C | Remove lung artery emboli |
| 33917 | C | Repair pulmonary artery |
| 33918 | C | Repair pulmonary atresia |
| 33919 | C | Repair pulmonary atresia |
| 33920 | C | Repair pulmonary atresia |
| 33922 | C | Transect pulmonary artery |
| 33924 | C | Remove pulmonary shunt |
| 33930 | C | Removal of donor heart/lung |
| 33935 | C | Transplantation, heart/lung |
| 33940 | C | Removal of donor heart |
| 33945 | C | Transplantation of heart |
| 33960 | C | External circulation assist |
| 33961 | C | External circulation assist |
| 33968 | C | Remove aortic assist device |
| 33970 | C | Aortic circulation assist |
| 33971 | C | Aortic circulation assist |
| 33973 | C | Insert balloon device |
| 33974 | C | Remove intra-aortic balloon |
| 33975 | C | Implant ventricular device |
| 33976 | C | Implant ventricular device |
| 33977 | C | Remove ventricular device |
| 33978 | C | Remove ventricular device |
| 34001 | C | Removal of artery clot |
| 34051 | C | Removal of artery clot |
| 34151 | C | Removal of artery clot |
| 34401 | C | Removal of vein clot |
| 34421 | C | Removal of vein clot |
| 34451 | C | Removal of vein clot |
| 34502 | C | Reconstruct vena cava |
| 35001 | C | Repair defect of artery |
| 35002 | C | Repair artery rupture, neck |
| 35005 | C | Repair defect of artery |
| 35011 | C | Repair defect of artery |
| 35013 | C | Repair artery rupture, arm |
| 35021 | C | Repair defect of artery |
| 35022 | C | Repair artery rupture, chest |
| 35045 | C | Repair defect of arm artery |
| 35081 | C | Repair defect of artery |
| 35082 | C | Repair artery rupture, aorta |
| 35091 | C | Repair defect of artery |
| 35092 | C | Repair artery rupture, aorta |
| 35102 | C | Repair defect of artery |
| 35103 | C | Repair artery rupture, groin |
| 35111 | C | Repair defect of artery |
| 35112 | C | Repa |

Repair defect of artery
Repair artery rupture, spleen
Repair defect of artery
Repair artery rupture, belly
Repair defect of artery
Repair artery rupture, groin
Repair defect of artery
Repair artery rupture, thigh
Repair defect of artery
Repair artery rupture, knee
Repair defect of artery
Repair artery rupture
Repair blood vessel lesion
Repair blood vessel lesion
Repair blood vessel lesion Repair blood vessel lesion Repair blood vessel lesion Repair blood vessel lesion Repair blood vessel lesion Repair blood vessel lesion Repair blood vessel lesion Repair blood vessel lesion Repair blood vessel lesion Rechanneling of artery Rechanneling of artery Rechanneling of artery Rechanneling of artery Rechanneling of artery

Addendum E.-CPT Codes Which
Would Be Paid Only As InPatient
Procedures-Continued
CPT/
HCPCS

| Indicator |
| :--- | :--- |


| 35355 | C | Rech |
| :--- | :--- | :--- |
| 35361 | C | Rec |
| 35363 | C | Rec |
| 35371 | C | Rec |
| 35372 | C | Rec |
| 35381 | C | Rec |
| 35390 | C | Reo |
| 35400 | C | Ang |
| 35450 | C | Rep |
| 35452 | C | Rep |

35
35



35
35
35


35501
355
3
35507
35508
3
35
35
35
35
35


35
35
35
35
3
35
35
35
3
35
35
35
35
3


35
35
35
35
35
35
35
35
35
35
3


35
35
35



35
35
3
35
35
3


356



35
35


35671
35681
35682
35682
Rechanneling of artery
Rechanneling of artery
Rechanneling of artery
Rechanneling of artery
Rechanneling of artery
Reoperation, carotid add-on Angioscopy
Repair arterial blockage
Repair arterial blockage
Repair arterial blockage
Repair arterial blockage
Repair arterial blockage
Atherectomy, open
Atherectomy, open
Atherectomy, open
Atherectomy, open
Atherectomy, open
Artery bypass graft
Artery bypass graft
Artery bypass graft
Artery bypass graft
Artery bypass graft
Artery bypass graft
Artery bypass graft Artery bypass graft Artery bypass graft Artery bypass graft
Artery bypass graft Artery bypass graft Artery bypass graft Artery bypass graft Artery bypass graft Artery bypass graft
Artery bypass graft Artery bypass graft Artery bypass graft Artery bypass graft Artery bypass graft Artery bypass graft Artery bypass graft Artery bypass graft Artery bypass graft Artery bypass graft Vein bypass graft Vein bypass graft Vein bypass graft Vein bypass graft Artery bypass graft Artery bypass graft Artery bypass graft Artery bypass graft Artery bypass graft
Bypass graft, not ve Bypass graft, not vein Artery bypass graft Artery bypass graft Artery bypass graft Artery bypass graft Artery bypass graft Artery bypass graft Artery bypass graft Artery bypass graft Artery bypass graft
Artery bypass graft Artery bypass graft Artery bypass graft Artery bypass graft Artery bypass graft Artery bypass graft Artery bypass graft Composite bypass graft Composite bypass graft Composite bypass graft

 Procedures-Continued | CPT/ | $\begin{array}{c}\text { HOPD } \\ \text { HCPCS }\end{array}$ |
| :---: | :---: |

Addendum E.-CPT Codes Which
Would be Paid Only As Inpatient

Addendum E.-CPT Codes Which Would Be Paid Only As Inpatient Procedures-Continued

| CPT/ <br> HCPCS | HOPD <br> Status <br> Indicator | Description |
| :---: | :--- | :--- |
| 39561 | C | Resect diaphragm, complex <br> 39599 |
| C | Diaphragm surgery procedure |  |
| 41130 | C | Partial removal of tongue |
| 41135 | C | Tongue and neck surgery |
| 41140 | C | Removal of tongue |
| 41145 | C | Tongue removal, neck surgery |
| 41150 | C | Tongue, mouth |

Tongue removal, neck surgery
Tongue, mouth, jaw surgery
Tongue, mouth, neck surgery
Tongue, jaw, \& neck surgery
Excise parotid gland/lesion
Extensive surgery of throat
Extensive surgery of throat
Revision of pharyngeal walls
Repair throat, esophagus Control throat bleeding Control nose/throat bleeding Throat muscle surgery Incision of esophagus Excision of esophagus lesion Excision of esophagus lesion Removal of esophagus
Removal of esophagus
Removal of esophagus
Removal of esophagus Partial removal of esophagus Partial removal of esophagus Partial removal of esophagus
Partial removal of esophagus Parital removal of esophagus Partial removal of esophagus Removal of esophagus
Removal of esophagus pouch
Removal of esophagus pouch Repair of esophagus
Repair esophagus and fistula Repair of esophagus
Repair esophagus and fistula
Fuse esophagus \& stomach
Revise esophagus \& stomach
Revise esophagus \& stomach
Revise esophagus \& stomach
Repair of esophagus
Repair of esophagus
Fuse esophagus \& intestine
Fuse esophagus \& intestine Surgical opening, esophagus Surgical opening, esophagus Surgical opening, esophagus Gastrointestinal repair
Gastrointestinal repair Ligate esophagus veins Esophagus surgery for veins Ligate/staple esophagus Repair esophagus wound Repair esophagus wound Repair esophagus opening Repair esophagus opening Pressure treatment esophagus Free jejunum flap, microvasc Surgical opening of stomach Surgical repair of stomach Surgical repair of stomach Surgical opening of stomach Incision of pyloric muscle Biopsy of stomach
Excision of stomach lesion Excision of stomach lesion
Removal of stomach
Removal of stomach
Removal of stomach
Removal of stomach, partial
Removal of stomach, partial

Addendum E.-CPT CODES Which
WOULD Be Paid Only As InPatient
Procedures-Continued
CPT/
HCPCS

| 43633 | C | Removal of stomach, partial |
| :--- | :--- | :--- |
| 43634 | C | Removal of stomach, partial |
| 43635 | C | Removal of stomach, partial |
| 43638 | C | Removal of stomach, partial |
| 43639 | C | Removal of stomach, partial |
| 43640 | C | Vagotomy \& pylorus repair |
| 43641 | C | Vagotomy \& pylorus repair |
| 43800 | C | Reconstruction of pylorus |
| 43810 | C | Fusion of stomach and bowel |
| 43820 | C | Fusion of stomach and bowel |

43825 C $\quad$ Fusion of stomach and bowe
43832 C Place gastrostomy tube
43840 C Repair of stomach lesion
43842 C Gastroplasty for obesity 43843
43846
43847
43848
43850
43855
43860
43880
44005
44010
44015
44020
44021
44025
44050
44055
44110
44111
44120
44
44
44
44
4
4
4
4
4
44
4
44
4
44
4

## 44

443
4
44
4
44
4
44625
44626
44640
44650 C Gastroplasty for obesity Gastric bypass for obesity
Gastric bypass for obesity Revision gastroplasty Revise stomach-bowel fusion Revise stomach-bowel fusion Revise stomach-bowel fusion Revise stomach-bowel fusion Repair stomach-bowel fistula Freeing of bowel adhesion Incision of small bowel Insert needle cath bowel Exploration of small bowel Decompress small bowel Incision of large bowel Reduce bowel obstruction Correct malrotation of bowel Excision of bowel lesion(s) Excision of bowel lesion(s) Removal of small intestine Removal of small intestine Removal of small intestine Bowel to bowel fusion Mobilization of colon
Partial removal of colon
Partial removal of colon
Partial removal of colon
Partial removal of colon
Partial removal of colon
Partial removal of colon Partial removal of colon Removal of colon
Removal of colon/ileostomy
Removal of colon/ileostomy Removal of colon/ileostomy
Removal of colon/ileostomy
Removal of colon/ileostomy
Removal of colon
Laparo, resect intestine
Open bowel to skin lleostomy/jejunostomy Revision of ileostomy
Devise bowel pouch Colostomy
Colostomy with biopsies Revision of colostomy
Revision of colostomy Intro, gastrointestinal tube Suture, small intestine Suture, small intestine Suture, large intestine Repair of bowel lesion Intestinal stricturoplasty
Repair bowel opening
Repair bowel opening
Repair bowel opening
Repair bowel-skin fistula
Repair bowel fistula

Addendum E.-CPT CODES Which Would Be Paid Only As Inpatient Procedures-Continued

C

| CPT/ | HOPD <br> Status <br> HCPCS |
| :---: | :---: |



## Addendum E.-CPT COdes Which Would Be Paid Only As Inpatient Procedures-Continued

| $\begin{gathered} \text { CPT/ } \\ \text { HCPCS } \end{gathered}$ | HOPD <br> Status <br> Indicator | Description |
| :---: | :---: | :---: |
| 47605 | C | Removal of gallbladder |
| 47610 | C | Removal of gallbladder |
| 47612 | C | Removal of gallbladder |
| 47620 | C | Removal of gallbladder |
| 47700 | C | Exploration of bile ducts |
| 47701 | C | Bile duct revision |
| 47711 | C | Excision of bile duct tumor |
| 47712 | C | Excision of bile duct tumor |
| 47715 | C | Excision of bile duct cyst |
| 47716 | C | Fusion of bile duct cyst |
| 47720 | C | Fuse gallbladder \& bowel |
| 47721 | C | Fuse upper gi structures |
| 47740 | C | Fuse gallbladder \& bowel |
| 47741 | C | Fuse gallbladder \& bowel |
| 47760 | C | Fuse bile ducts and bowel |
| 47765 | C | Fuse liver ducts \& bowel |
| 47780 | C | Fuse bile ducts and bowel |
| 47785 | C | Fuse bile ducts and bowel |
| 47800 | C | Reconstruction of bile ducts |
| 47801 | C | Placement, bile duct support |
| 47802 | C | Fuse liver duct \& intestine |
| 47900 | C | Suture bile duct injury |
| 48000 | C | Drainage of abdomen |
| 48001 | C | Placement of drain, pancreas |
| 48005 | C | Resect/debride pancreas |
| 48020 | C | Removal of pancreatic stone |
| 48100 | C | Biopsy of pancreas |
| 48120 | C | Removal of pancreas lesion |
| 48140 | C | Partial removal of pancreas |
| 48145 | C | Partial removal of pancreas |
| 48146 | C | Pancreatectomy |
| 48148 | C | Removal of pancreatic duct |
| 48150 | C | Partial removal of pancreas |
| 48152 | C | Pancreatectomy |
| 48153 | C | Pancreatectomy |
| 48154 | C | Pancreatectomy |
| 48155 | C | Removal of pancreas |
| 48180 | C | Fuse pancreas and bowel |
| 48400 | C | Injection, intraop add-on |
| 48500 | C | Surgery of pancreas cyst |
| 48510 | C | Drain pancreatic pseudocyst |
| 48511 | C | Drain pancreatic pseudocyst |
| 48520 | C | Fuse pancreas cyst and bowel |
| 48540 | C | Fuse pancreas cyst and bowel |
| 48545 | C | Pancreatorrhaphy |
| 48547 | C | Duodenal exclusion |
| 48556 | C | Removal, allograft pancreas |
| 49000 | C | Exploration of abdomen |
| 49002 | C | Reopening of abdomen |
| 49010 | C | Exploration behind abdomen |
| 49020 | C | Drain abdominal abscess |
| 49021 | C | Drain abdominal abscess |
| 49040 | C | Drain, open, abdom abscess |
| 49041 | C | Drain, percut, abdom abscess |
| 49060 | C | Drain, open, retrop abscess |
| 49061 | C | Drain, percut, retroper absc |
| 49062 | C | Drain to peritoneal cavity |
| 49200 | C | Removal of abdominal lesion |
| 49201 | C | Removal of abdominal lesion |
| 49215 | C | Excise sacral spine tumor |
| 49220 | C | Multiple surgery, abdomen |
| 49255 | C | Removal of omentum |
| 49425 | C | Insert abdomen-venous drain |
| 49428 | C | Ligation of shunt |
| 49605 | C | Repair umbilical lesion |
| 49606 | C | Repair umbilical lesion |
| 49610 | C | Repair umbilical lesion |
| 49611 | C | Repair umbilical lesion |
| 49900 | C | Repair of abdominal wall |
| 49905 | C | Omental flap |
| 49906 | C | Free omental flap, microvasc |
| 50010 | C | Exploration of kidney |

Copyright American Dental Association. All rights reserved.

Addendum E.-CPT Codes Which
Would Be Paid Only As InPatient
Procedures-Continued
CPT/
HCPCS
5

| 50020 | C | Renal abscess, open drain |
| :--- | :--- | :--- |
| 50021 | C | Renal abscess, percut drain |
| 50040 | C | Drainage of kidney |
| 50045 | C | Exploration of kidney |
| 50060 | C | Removal of kidney stone |
| 50065 | C | Incision of kidney |
| 50070 | C | Incision of kidney |
| 50075 | C | Removal of kidney stone |
| 50100 | C | Revise kidney blood vessels |
| 50120 | C | Exploration of kidney |

Exploration of kidney
Explore and drain kidney Removal of kidney stone Exploration of kidney
Biopsy of kidney
Removal of kidney
Removal of kidney
Removal of kidney
Removal of kidney \& ureter
Removal of kidney \& ureter
Partial removal of kidney
Removal of kidney lesion
Removal of kidney lesion
Removal of donor kidney
Removal of donor kidney
Removal of kidney
Transplantation of kidney Transplantation of kidney
Remove transplanted kidney
Reimplantation of kidney
Revision of kidney/ureter Revision of kidney/ureter Repair of kidney wound Close kidney-skin fistula Repair renal-abdomen fistula Repair renal-abdomen fistula Revision of horseshoe kidney Laparoscopic nephrectomy Laparo removal donor kidney
Kidney endoscopy
Kidney endoscopy
Kidney endoscopy \& biopsy Kidney endoscopy
Kidney endoscopy \& treatment
Renal endoscopy/radiotracer
Kidney endoscopy \& treatment
Exploration of ureter
Insert ureteral support
Removal of ureter stone
Removal of ureter stone
Removal of ureter stone
Removal of ureter
Removal of ureter
Revision of ureter
Release of ureter
Release of ureter
Release/revise ureter
Revise ureter
Revise ureter
Fusion of ureter \& kidney
Fusion of ureter \& kidney
Fusion of ureters
Splicing of ureters
Reimplant ureter in bladder
Reimplant ureter in bladder
Reimplant ureter in bladder Reimplant ureter in bladder Implant ureter in bowel
Fusion of ureter \& bowel
Urine shunt to bowel
Construct bowel bladder
Construct bowel bladder
Revise urine flow

Addendum E.-CPT Codes Which
WOuld Be Paid Only As InPatient
Procedures-Continued

| CPT/ | HOPD <br> Status <br> HCPCS |
| :---: | :---: |


| 50840 | C | Replace ureter by bowel | 56633 | C | Extensive vulva surgery |
| :---: | :---: | :---: | :---: | :---: | :---: |
| 50845 | C | Appendico-vesicostomy | 56634 | C | Extensive vulva surgery |
| 50860 | C | Transplant ureter to skin | 56637 | C | Extensive vulva surgery |
| 50900 | C | Repair of ureter | 56640 | C | Extensive vulva surgery |
| 50920 | C | Closure ureter/skin fistula | 56805 | C | Repair clitoris |
| 50930 | C | Closure ureter/bowel fistula | 57110 | C | Remove vagina wall, complete |
| 50940 | C | Release of ureter | 57111 | C | Remove vagina tissue, compl |
| 50970 | C | Ureter endoscopy | 57112 | C | Vaginectomy w/nodes, compl |
| 50972 | C | Ureter endoscopy \& catheter | 57120 | C | Closure of vagina |
| 50974 | C | Ureter endoscopy \& biopsy | 57270 | C | Repair of bowel pouch |
| 50976 | C | Ureter endoscopy \& treatment | 57280 | C | Suspension of vagina |
| 50978 | C | Ureter endoscopy \& tracer | 57282 | C | Repair of vaginal prolapse |
| 50980 | C | Ureter endoscopy \& treatment | 57292 | C | Construct vagina with graft |
| 51060 | C | Removal of ureter stone | 57305 | C | Repair rectum-vagina fistula |
| 51525 | C | Removal of bladder lesion | 57307 | C | Fistula repair \& colostomy |
| 51530 | C | Removal of bladder lesion | 57308 | C | Fistula repair, transperine |
| 51535 | C | Repair of ureter lesion | 57310 | C | Repair urethrovaginal lesion |
| 51550 | C | Partial removal of bladder | 57311 | C | Repair urethrovaginal lesion |
| 51555 | C | Partial removal of bladder | 57320 | C | Repair bladder-vagina lesion |
| 51565 | C | Revise bladder \& ureter(s) | 57330 | C | Repair bladder-vagina lesion |
| 51570 | C | Removal of bladder | 57335 | C | Repair vagina |
| 51575 | C | Removal of bladder \& nodes | 57531 | C | Removal of cervix, radical |
| 51580 | C | Remove bladder/revise tract | 57540 | C | Removal of residual cervix |
| 51585 | C | Removal of bladder \& nodes | 57545 | C | Remove cervix/repair pelvis |
| 51590 | C | Remove bladder/revise tract | 58140 | C | Removal of uterus lesion |
| 51595 | C | Remove bladder/revise tract | 58150 | C | Total hysterectomy |
| 51596 | C | Remove bladder/create pouch | 58152 | C | Total hysterectomy |
| 51597 | C | Removal of pelvic structures | 58180 | C | Partial hysterectomy |
| 51800 | C | Revision of bladder/urethra | 58200 | C | Extensive hysterectomy |
| 51820 | C | Revision of urinary tract | 58210 | C | Extensive hysterectomy |
| 51840 | C | Attach bladder/urethra | 58240 | C | Removal of pelvis contents |
| 51841 | C | Attach bladder/urethra | 58260 | C | Vaginal hysterectomy |
| 51845 | C | Repair bladder neck | 58262 | C | Vaginal hysterectomy |
| 51860 | C | Repair of bladder wound | 58263 | C | Vaginal hysterectomy |
| 51865 | C | Repair of bladder wound | 58267 | C | Hysterectomy \& vagina repair |
| 51900 | C | Repair bladder/vagina lesion | 58270 | C | Hysterectomy \& vagina repair |
| 51920 | C | Close bladder-uterus fistula | 58275 | C | Hysterectomy/revise vagina |
| 51925 | C | Hysterectomy/bladder repair | 58280 | C | Hysterectomy/revise vagina |
| 51940 | C | Correction of bladder defect | 58285 | C | Extensive hysterectomy |
| 51960 | C | Revision of bladder \& bowel | 58400 | C | Suspension of uterus |
| 51980 | C | Construct bladder opening | 58410 | C | Suspension of uterus |
| 53085 | C | Drainage of urinary leakage | 58520 | C | Repair of ruptured uterus |
| 53415 | C | Reconstruction of urethra | 58540 | C | Revision of uterus |
| 53443 | C | Reconstruction of urethra | 58600 | C | Division of fallopian tube |
| 54125 | C | Removal of penis | 58605 | C | Division of fallopian tube |
| 54130 | C | Remove penis \& nodes | 58611 | C | Ligate oviduct(s) add-on |
| 54135 | C | Remove penis \& nodes | 58615 | C | Occlude fallopian tube(s) |
| 54332 | C | Revise penis/urethra | 58700 | C | Removal of fallopian tube |
| 54336 | C | Revise penis/urethra | 58720 | C | Removal of ovary/tube(s) |
| 54390 | C | Repair penis and bladder | 58740 | C | Revise fallopian tube(s) |
| 54430 | C | Revision of penis | 58750 | C | Repair oviduct |
| 54535 | C | Extensive testis surgery | 58752 | C | Revise ovarian tube(s) |
| 54560 | C | Exploration for testis | 58760 | C | Remove tubal obstruction |
| 54650 | C | Orchiopexy (Fowler-Stephens) | 58770 | C | Create new tubal opening |
| 55600 | C | Incise sperm duct pouch | 58805 | C | Drainage of ovarian cyst(s) |
| 55605 | C | Incise sperm duct pouch | 58822 | C | Drain ovary abscess, percut |
| 55650 | C | Remove sperm duct pouch | 58823 | C | Drain pelvic abscess, percut |
| 55801 | C | Removal of prostate | 58825 | C | Transposition, ovary(s) |
| 55810 | C | Extensive prostate surgery | 58940 | C | Removal of ovary(s) |
| 55812 | C | Extensive prostate surgery | 58943 | C | Removal of ovary(s) |
| 55815 | C | Extensive prostate surgery | 58950 | C | Resect ovarian malignancy |
| 55821 | C | Removal of prostate | 58951 | C | Resect ovarian malignancy |
| 55831 | C | Removal of prostate | 58952 | C | Resect ovarian malignancy |
| 55840 | C | Extensive prostate surgery | 58960 | C | Exploration of abdomen |
| 55842 | C | Extensive prostate surgery | 59100 | C | Remove uterus lesion |
| 55845 | C | Extensive prostate surgery | 59120 | C | Treat ectopic pregnancy |
| 55860 | C | Surgical exposure, prostate | 59121 | C | Treat ectopic pregnancy |
| 55862 | C | Extensive prostate surgery | 59130 | C | Treat ectopic pregnancy |
| 55865 | C | Extensive prostate surgery | 59135 | C | Treat ectopic pregnancy |
| 56630 | C | Extensive vulva surgery | 59136 | C | Treat ectopic pregnancy |
| 56631 | C | Extensive vulva surgery | 59140 | C | Treat ectopic pregnancy |
| 56632 | C | Extensive vulva surgery | 59325 | C | Revision of cervix |


| 50840 | C | Replace ureter by bowel | 56633 | C | Extensive vulva surgery |
| :---: | :---: | :---: | :---: | :---: | :---: |
| 50845 | C | Appendico-vesicostomy | 56634 | C | Extensive vulva surgery |
| 50860 | C | Transplant ureter to skin | 56637 | C | Extensive vulva surgery |
| 50900 | C | Repair of ureter | 56640 | C | Extensive vulva surgery |
| 50920 | C | Closure ureter/skin fistula | 56805 | C | Repair clitoris |
| 50930 | C | Closure ureter/bowel fistula | 57110 | C | Remove vagina wall, complete |
| 50940 | C | Release of ureter | 57111 | C | Remove vagina tissue, compl |
| 50970 | C | Ureter endoscopy | 57112 | C | Vaginectomy w/nodes, compl |
| 50972 | C | Ureter endoscopy \& catheter | 57120 | C | Closure of vagina |
| 50974 | C | Ureter endoscopy \& biopsy | 57270 | C | Repair of bowel pouch |
| 50976 | C | Ureter endoscopy \& treatment | 57280 | C | Suspension of vagina |
| 50978 | C | Ureter endoscopy \& tracer | 57282 | C | Repair of vaginal prolapse |
| 50980 | C | Ureter endoscopy \& treatment | 57292 | C | Construct vagina with graft |
| 51060 | C | Removal of ureter stone | 57305 | C | Repair rectum-vagina fistula |
| 51525 | C | Removal of bladder lesion | 57307 | C | Fistula repair \& colostomy |
| 51530 | C | Removal of bladder lesion | 57308 | C | Fistula repair, transperine |
| 51535 | C | Repair of ureter lesion | 57310 | C | Repair urethrovaginal lesion |
| 51550 | C | Partial removal of bladder | 57311 | C | Repair urethrovaginal lesion |
| 51555 | C | Partial removal of bladder | 57320 | C | Repair bladder-vagina lesion |
| 51565 | C | Revise bladder \& ureter(s) | 57330 | C | Repair bladder-vagina lesion |
| 51570 | C | Removal of bladder | 57335 | C | Repair vagina |
| 51575 | C | Removal of bladder \& nodes | 57531 | C | Removal of cervix, radical |
| 51580 | C | Remove bladder/revise tract | 57540 | C | Removal of residual cervix |
| 51585 | C | Removal of bladder \& nodes | 57545 | C | Remove cervix/repair pelvis |
| 51590 | C | Remove bladder/revise tract | 58140 | C | Removal of uterus lesion |
| 51595 | C | Remove bladder/revise tract | 58150 | C | Total hysterectomy |
| 51596 | C | Remove bladder/create pouch | 58152 | C | Total hysterectomy |
| 51597 | C | Removal of pelvic structures | 58180 | C | Partial hysterectomy |
| 51800 | C | Revision of bladder/urethra | 58200 | C | Extensive hysterectomy |
| 51820 | C | Revision of urinary tract | 58210 | C | Extensive hysterectomy |
| 51840 | C | Attach bladder/urethra | 58240 | C | Removal of pelvis contents |
| 51841 | C | Attach bladder/urethra | 58260 | C | Vaginal hysterectomy |
| 51845 | C | Repair bladder neck | 58262 | C | Vaginal hysterectomy |
| 51860 | C | Repair of bladder wound | 58263 | C | Vaginal hysterectomy |
| 51865 | C | Repair of bladder wound | 58267 | C | Hysterectomy \& vagina repair |
| 51900 | C | Repair bladder/vagina lesion | 58270 | C | Hysterectomy \& vagina repair |
| 51920 | C | Close bladder-uterus fistula | 58275 | C | Hysterectomy/revise vagina |
| 51925 | C | Hysterectomy/bladder repair | 58280 | C | Hysterectomy/revise vagina |
| 51940 | C | Correction of bladder defect | 58285 | C | Extensive hysterectomy |
| 51960 | C | Revision of bladder \& bowel | 58400 | C | Suspension of uterus |
| 51980 | C | Construct bladder opening | 58410 | C | Suspension of uterus |
| 53085 | C | Drainage of urinary leakage | 58520 | C | Repair of ruptured uterus |
| 53415 | C | Reconstruction of urethra | 58540 | C | Revision of uterus |
| 53443 | C | Reconstruction of urethra | 58600 | C | Division of fallopian tube |
| 54125 | C | Removal of penis | 58605 | C | Division of fallopian tube |
| 54130 | C | Remove penis \& nodes | 58611 | C | Ligate oviduct(s) add-on |
| 54135 | C | Remove penis \& nodes | 58615 | C | Occlude fallopian tube(s) |
| 54332 | C | Revise penis/urethra | 58700 | C | Removal of fallopian tube |
| 54336 | C | Revise penis/urethra | 58720 | C | Removal of ovary/tube(s) |
| 54390 | C | Repair penis and bladder | 58740 | C | Revise fallopian tube(s) |
| 54430 | C | Revision of penis | 58750 | C | Repair oviduct |
| 54535 | C | Extensive testis surgery | 58752 | C | Revise ovarian tube(s) |
| 54560 | C | Exploration for testis | 58760 | C | Remove tubal obstruction |
| 54650 | C | Orchiopexy (Fowler-Stephens) | 58770 | C | Create new tubal opening |
| 55600 | C | Incise sperm duct pouch | 58805 | C | Drainage of ovarian cyst(s) |
| 55605 | C | Incise sperm duct pouch | 58822 | C | Drain ovary abscess, percut |
| 55650 | C | Remove sperm duct pouch | 58823 | C | Drain pelvic abscess, percut |
| 55801 | C | Removal of prostate | 58825 | C | Transposition, ovary(s) |
| 55810 | C | Extensive prostate surgery | 58940 | C | Removal of ovary(s) |
| 55812 | C | Extensive prostate surgery | 58943 | C | Removal of ovary(s) |
| 55815 | C | Extensive prostate surgery | 58950 | C | Resect ovarian malignancy |
| 55821 | C | Removal of prostate | 58951 | C | Resect ovarian malignancy |
| 55831 | C | Removal of prostate | 58952 | C | Resect ovarian malignancy |
| 55840 | C | Extensive prostate surgery | 58960 | C | Exploration of abdomen |
| 55842 | C | Extensive prostate surgery | 59100 | C | Remove uterus lesion |
| 55845 | C | Extensive prostate surgery | 59120 | C | Treat ectopic pregnancy |
| 55860 | C | Surgical exposure, prostate | 59121 | C | Treat ectopic pregnancy |
| 55862 | C | Extensive prostate surgery | 59130 | C | Treat ectopic pregnancy |
| 55865 | C | Extensive prostate surgery | 59135 | C | Treat ectopic pregnancy |
| 56630 | C | Extensive vulva surgery | 59136 | C | Treat ectopic pregnancy |
| 56631 | C | Extensive vulva surgery | 59140 | C | Treat ectopic pregnancy |
| 56632 | C | Extensive vulva surgery | 59325 | C | Revision of cervix |

## Addendum E.-CPT COdes Which Would Be Paid Only As Inpatient Procedures-Continued

| CPT/ <br> HCPCS | HOPD <br> Status <br> Indicator | Description |
| :---: | :--- | :--- |
| 56633 | C | Extensive vulva surgery |
| 56634 | C | Extensive vulva surgery |
| 56637 | C | Extensive vulva surgery |
| 56640 | C | Extensive vulva surgery |
| 56805 | C | Repair clitoris |
| 57110 | C | Remove vagina wall, complete |
| 57111 | C | Remove vagina tissue, compl |
| 57112 | C | Vaginectomy w/nodes, compl |
| 57120 | C | Closure of vagina |
| 57270 | C | Repair of bowel pouch |
| 57280 | C | Suspension of vagina |
| 57282 | C | Repair of vaginal prolapse |
| 57292 | C | Construct vagina with graft |
| 57305 | C | Repair rectum-vagina fistula |
| 57307 | C | Fistula repair \& colostomy |
| 57308 | C | Fistula repair, transperine |
| 57310 | C | Repair urethrovaginal lesion |
| 57311 | C | Repair urethrovaginal lesion |
| 57320 | C | Repair bladder-vagina lesion |
| 57330 | C | Repair bladder-vagina lesion |
| 57335 | C | Repair vagina |

Repair vagina
Removal of cervix, radical
oval of residual cervix
Removal of uterus lesion
Total hysterectomy
hysterectomy
Partial hysterectomy
Extensive hysterectomy
Removal of pelvis contents
Vaginal hysterectomy
Vaginal hysterectomy
Hysterectomy \& vagina repair Hysterectomy \& vagina repair Hysterectomy/revise vagina Extensive hysterectomy Suspension of uterus Repair of ruptured uterus Revision of uterus Division of fallopian tube Ligate oviduct(s) add-on Occlude fallopian tube(s) Removal of fallopian tube oval of ovary/tube(s) Repair oviduct
Revise ovarian tube(s) Remove tubal obstruction

Create new tubal opening Drain ovary abscess, percut Drain pelvic abscess, percut Transposition, ovary(s) Removal of ovary(s) Resect ovarian malignancy Resect ovarian malignancy
Resect ovarian malignancy Exploration of abdomen Remove uterus lesion Treat ectopic pregnancy Treat ectopic pregnancy reat ectopic pregnancy Treat ectopic pregnancy Treat ectopic pregnancy
Revision of cervix

Addendum E.-CPT CODES WHICH
WOULD Be Paid Only As InPatient
Procedures-Continued

| CPT/ | HOPD |  |
| :---: | :---: | :---: |
| SCPCS | Status |  |
|  | Indicator | Description |


| 59350 | C | Repair of uterus |
| :--- | :--- | :--- |
| 59514 | C | Cesarean delivery only |
| 59525 | C | Remove uterus after cesarea |
| 59620 | C | Attempted vbac delivery only |
| 59830 | C | Treat uterus infection |

59830
59851
59852
59855
59856
59866
60212
60252
60254
60270
60270
60271
60502 C
60512
60520
60521
60522
60540
60545
60600
60605
60650
61105
61107
61108
61120
61140
61150
61151
61154
61156
61210
61250
61253
61304
61305
61312
61313
61313
61314
61315
61320
61321
61332
61333
61334
61340
61343
61345
61440
61458 61460
61470

61480
61490
61500
61501
61510
61512
61514
61516
61518
61518
61519
61519 C
61521 C
Abortion
Abortion
Abortion
Abortion
Abortion
Abortion
Abortion (mpr)
Parital thyroid excision
Removal of thyroid
Extensive thyroid surgery
Repeat thyroid surgery
Removal of thyroid
Removal of thyroid
Re-explore parathyroids
Explore parathyroid glands
Autotransplant parathyroid
Removal of thymus gland
Removal of thymus gland
Removal of thymus gland
Explore adrenal gland
Explore adrenal gland Remove carotid body lesion
Remove carotid body lesion Laparoscopy adrenalectomy Twist drill hole
Drill skull for implantation
Drill skull for drainage
Burr hole for puncture
Pierce skull for biopsy
Pierce skull for drainage
Pierce skull for drainage
Pierce skull \& remove clot Pierce skull for drainage Pierce skull, implant device Pierce skull \& explore Pierce skull \& explore Open skull for exploration Open skull for exploration Open skull for drainage Open skull for drainage Open skull for drainage Open skull for drainage Open skull for drainage Open skull for drainage Explore/biopsy eye socket Explore orbit/remove lesion Explore orbit/remove object Relieve cranial pressure Incise skull (press relief) Relieve cranial pressure Incise skull for surgery Incise skull for surgery Incise skull for brain wound Incise skull for surgery Incise skull for surgery Incise skull for surgery Incise skull for surgery Removal of skull lesion Remove infected skull bone Removal of brain lesion Remove brain lining lesion Removal of brain abscess
Removal of brain lesion
Removal of brain lesion
Remove brain lining lesion
Removal of brain lesion
Removal of brain lesion

Addendum E.-CPT Codes Which Would Be Paid Only As Inpatient Procedures-Continued

| CPT/ |
| :---: |
| HCPCS |


| HOPD |
| :---: | :---: |
| Status |
| Indicator |


|  |
| :--- |

Removal of brain abscess
Removal of brain lesion Removal of brain lesion Removal of brain lesion mplant brain electrodes mplant brain electrodes Removal of brain lesion Remove brain electrodes
Removal of brain lesion
Removal of brain tissue
Removal of brain tissue Incision of brain tissue
Removal of brain tissue
Removal of brain tissue Remove \& treat brain lesion Excision of brain tumor Removal of pituitary gland Removal of pituitary gland Release of skull seams Release of skull seams Incise skull/sutures Incise skull/sutures Excision of skull/sutures Excision of skull/sutures Excision of skull tumor Excision of skull tumo Remove foreign body, brain Incise skull for brain wound Skull base/brainstem surgery Skull base/brainstem surgery Craniofacial approach, skull Craniofacial approach, skull Craniofacial approach, skull Craniofacial approach, skull Orbitocranial approach/skull Orbitocranial approach/skull Resect nasopharynx, skull Infratemporal approach/skull Infratemporal approach/skull Orbitocranial approach/skull Transtemporal approach/skull Transcochlear approach/skull Transcondylar approach/skull Transpetrosal approach/skull Resect/excise cranial lesion Resect/excise cranial lesion Resect/excise cranial lesion Resect/excise cranial lesion Resect/excise cranial lesion Resect/excise cranial lesion Transect artery, sinus Transect artery, sinus Transect artery, sinus Transect artery, sinus Remove aneurysm, sinus Resect/excise lesion, skull Resect/excise lesion, skull Repair dura

## Repair dura

Occlusion/embolization cath Occlusion/embolization cath Intracranial vessel surgery Intracranial vessel surgery Intracranial vessel surgery Intracranial vessel surgery Intracranial vessel surgery Intracranial vessel surgery Inner skull vessel surgery Inner skull vessel surgery Clamp neck artery Revise circulation to head
Revise circulation to head

Addendum E.-CPT COdes Which Would Be Paid Only As Inpatient Procedures-Continued

|  | HOPD |  |
| :--- | :--- | :--- |
| CPT/ | Status | Description |
|  |  | Indicator |

Copyright American Dental Association. All rights reserved.

## Addendum E.-CPT Codes Which Would Be Paid Only As Inpatient Procedures-Continued <br> Addendum E.-CPT Codes Which Would Be Paid Only As Inpatient Procedures-Continued

| CPT/ |
| :--- |
| HCPCS |

6

| $\begin{aligned} & \text { CPT/ } \\ & \text { HCPCS } \end{aligned}$ | HOPD Status Indicator | Description |
| :---: | :---: | :---: |
| 63081 | C | Removal of vertebral body |
| 63082 | C | Remove vertebral body add-on |
| 63085 | C | Removal of vertebral body |
| 63086 | C | Remove vertebral body add-on |
| 63087 | C | Removal of vertebral body |
| 63088 | C | Remove vertebral body add-on |
| 63090 | C | Removal of vertebral body |
| 63091 | C | Remove vertebral body add-on |
| 63170 | C | Incise spinal cord tract(s) |
| 63172 | C | Drainage of spinal cyst |
| 63173 | C | Drainage of spinal cyst |
| 63180 | C | Revise spinal cord ligaments |
| 63182 | C | Revise spinal cord ligaments |
| 63185 | C | Incise spinal column/nerves |
| 63190 | C | Incise spinal column/nerves |
| 63191 | C | Incise spinal column/nerves |
| 63194 | C | Incise spinal column \& cord |
| 63195 | C | Incise spinal column \& cord |
| 63196 | C | Incise spinal column \& cord |
| 63197 | C | Incise spinal column \& cord |
| 63198 | C | Incise spinal column \& cord |
| 63199 | C | Incise spinal column \& cord |
| 63200 | C | Release of spinal cord |
| 63250 | C | Revise spinal cord vessels |
| 63251 | C | Revise spinal cord vessels |
| 63252 | C | Revise spinal cord vessels |
| 63265 | C | Excise intraspinal lesion |
| 63266 | C | Excise intraspinal lesion |
| 63267 | C | Excise intraspinal lesion |
| 63268 | C | Excise intraspinal lesion |
| 63270 | C | Excise intraspinal lesion |
| 63271 | C | Excise intraspinal lesion |
| 63272 | C | Excise intraspinal lesion |
| 63273 | C | Excise intraspinal lesion |
| 63275 | C | Biopsy/excise spinal tumor |
| 63276 | C | Biopsy/excise spinal tumor |
| 63277 | C | Biopsy/excise spinal tumor |
| 63278 | C | Biopsy/excise spinal tumor |
| 63280 | C | Biopsy/excise spinal tumor |
| 63281 | C | Biopsy/excise spinal tumor |
| 63282 | C | Biopsy/excise spinal tumor |
| 63283 | C | Biopsy/excise spinal tumor |
| 63285 | C | Biopsy/excise spinal tumor |
| 63286 | C | Biopsy/excise spinal tumor |
| 63287 | C | Biopsy/excise spinal tumor |
| 63290 | C | Biopsy/excise spinal tumor |
| 63300 | C | Removal of vertebral body |
| 63301 | C | Removal of vertebral body |
| 63302 | C | Removal of vertebral body |

63087
63088
63088
6
6
6
6
6
6
6
6
63
6
63
6
6
63 6
6
6
6
6
6
6
6
6
6
6
6
6
6
63301
63302

| CPT/ | HOPD <br> Status <br> HCPCS | Description |
| :---: | :---: | :---: |
| 63303 | Indicator |  |



## 6

6
+
6

## Addendum E.-CPT Codes Which Would Be Paid Only As Inpatient Procedures-Continued

| CPT/ HCPCS | HOPD Status Indicator | Description |
| :---: | :---: | :---: |
| 75978 | C | Repair venous blockage |
| 75992 | C | Atherectomy, x-ray exam |
| 75993 | C | Atherectomy, x-ray exam |
| 75994 | C | Atherectomy, x-ray exam |
| 75995 | C | Atherectomy, x-ray exam |
| 75996 | C | Atherectomy, x-ray exam |
| 92970 | C | Cardioassist, internal |
| 92971 | C | Cardioassist, external |
| 92975 | C | Dissolve clot, heart vessel |
| 92977 | C | Dissolve clot, heart vessel |
| 92978 | C | Intravasc us, heart add-on |
| 92979 | C | Intravasc us, heart add-on |
| 92986 | C | Revision of aortic valve |
| 92987 | C | Revision of mitral valve |
| 92990 | C | Revision of pulmonary valve |
| 92992 | C | Revision of heart chamber |
| 92993 | C | Revision of heart chamber |
| 92997 | C | Pul art balloon repr, percut |
| 92998 | C | Pul art balloon repr, percut |
| 94652 | C | Pressure breathing (IPPB) |
| 94762 | C | Measure blood oxygen level |
| 95920 | C | Intraop nerve test add-on |
| 95961 | C | Electrode stimulation, brain |
| 95962 | C | Electrode stim, brain add-on |
| 99190 | C | Special pump services |
| 99191 | C | Special pump services |
| 99192 | C | Special pump services |
| 99234 | C | Observ/hosp same date |
| 99235 | C | Observ/hosp same date |
| 99236 | C | Observ/hosp same date |
| 99251 | C | Initial inpatient consult |
| 99252 | C | Initial inpatient consult |
| 99253 | C | Initial inpatient consult |
| 99254 | C | Initial inpatient consult |
| 99255 | C | Initial inpatient consult |
| 99261 | C | Follow-up inpatient consult |
| 99262 | C | Follow-up inpatient consult |
| 99263 | C | Follow-up inpatient consult |
| 99295 | C | Neonatal critical care |
| 99296 | C | Neonatal critical care |
| 99297 | C | Neonatal critical care |
| 99298 | C | Neonatal critical care |
| 99356 | C | Prolonged service, inpatient |
| 99357 | C | Prolonged service, inpatient |
| 99433 | C | Normal newborn care/hospital |
| G0160 | C | Cryo. ablation, prostate |

Addendum F.-Status Indicators: How Various Services Are Treated Under Outpatient PPS

| Indicator | Service | Status |
| :---: | :---: | :---: |
| A .. | Pulmonary Rehabilitation Clinical Trial | Not Paid Under PPS |
| C ............. | Inpatient Procedures | Admit Patient; Bill as Inpatient |
| A ... | Durable Medical Equipment, Prosthetics and | DMEPOS Fee Schedule |
| E | Non-Covered Items and Services | Non-paid |
| A ............ | Physical, Occupational and SpeechTherapy | Rehabilitation Fee Schedule |
| A ............. | Ambulance | Ambulance Fee Schedule |
| A | EPO for ESRD Patients | National Rate |
| A | Clinical Diagnostic Laboratory Services | Laboratory Fee Schedule |
| A .... | Physican Services for ESRD Patients | Not Paid Under PPS |
| A | Screening Mammography | National Rate |
| N .. | Incidental Services, packaged into APC Rat | Packaged |
| P ............. | Partial Hospitalization | Paid Per Diem APC |
| S ............. | Significant Procedure, Not Discounted When | Paid |
| T .............. | Procedure, Multiple When Discount Applies | Paid |
| V ............. | Visit to Clinic or Emergency Department | Paid |
| X ............. | Ancillary Service ................................................................................................ | Paid |

Addendum G.-Service Mix Indices by Hospital

|  | Hospital |
| :---: | :---: |
| 010001 |  |
| 010004 |  |
| 010005 |  |
| 010006 |  |
| 010007 |  |
| 010008 |  |
| 010009 |  |
| 010010 |  |
| 010011 |  |
| 010012 |  |
| 010015 |  |
| 010016 |  |
| 010018 |  |
| 010019 |  |
| 010021 |  |
| 010022 |  |
| 010023 |  |
| 010024 |  |
| 010025 |  |
| 010027 |  |
| 010029 |  |
| 010031 |  |
| 010032 |  |
| 010033 |  |
| 010034 |  |
| 010035 |  |
| 010036 |  |
| 010038 |  |
| 010039 |  |
| 010040 |  |
| 010043 |  |
| 010044 |  |
| 010045 |  |
| 010046 |  |
| 010047 |  |
| 010049 |  |
| 010050 |  |
| 010051 |  |
| 010052 |  |
| 010053 |  |
| 010054 |  |
| 010055 |  |
| 010056 |  |
| 010058 |  |
| 010059 |  |
| 010061 |  |
| 010062 |  |
| 010064 |  |
| 10065 |  |
| 10066 |  |
| 010068 |  |
| 010069 |  |
| 010072 |  |
| 010073 |  |
| 010078 |  |
| 010079 |  |
| 010080 |  |
| 010083 |  |
| 010084 |  |
| 010087 |  |
| 010089 |  |
| 010090 |  |
| 010091 |  |
| 010092 |  |
| 010094 |  |
| 010095 |  |
| 010097 |  |
| 010098 |  |
| 010099 |  |
| 010100 |  |
| 010101 |  |

010101 .............................................. 2.38
3.13
1.77
2.17
3.08
3.08
1.70
1.86
1.86
1.69
1.69
2.44
2.56
2.21
2.29
2.29
2.55
6.45
2.41
1.74
2.02
2.85
2.88
2.14
1.10
1.10
3.22
3.22
2.04
1.28
1.53
1.53
2.69
3.05
2.72
2.72
4.48
2.19
2.62
2.62
2.32
2.21
2.21
2.00
2.00
2.09
1.67
3.06
1.93
1.60
1.60
1.60
2.00
1.88
2.86
2.70
1.25
1.25
1.90
2.62
1.81
3.43
3.43
2.41
1.42
1.39
2.34
2.34
2.61
2.61
2.55
2.52
2.52
1.08
2.25
4.17
2.71
2.61
2.43
1.63
2.55
2.50
1.50
2.07
1.75
2.14
2.38

## Addendum G.-Service Mix Indices <br> by Hospital-Continued

| Hospital | SMI |
| :---: | :---: |


| Hospital | SMI |
| :--- | :--- |


| 010102 ........................................... 1.32 |
| :--- |


2.66
1.95
2.24
1.20
1.20030025 ...................................................................... 1.79
1.87030027 .............................................. 1.63

| 2.85 | 030030 | .......................................................... | 3.06 |
| :--- | :--- | :--- | :--- |
| 2.48 | 030033 |  |  |

$\begin{array}{lll}2.48 & 030033 & \text {........................................................................................... } \\ 1.47 & 030034\end{array}$
2.56030035 ................................................................. 3.18
$\begin{array}{lll}2.13 & 030036 & \text {.................................................................................................. } \\ 2.04 & 030037 & 4.59\end{array}$
3.11030038 ................................................. 3.33
$\begin{array}{llll}3.42 & 030040 & \ldots . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ~ & 1.99 \\ 1.44 & 030041 & & \\ 1.30\end{array}$
$\begin{array}{lll}1.44 & 030041 & \text {...................................................................... } \\ 2.11 & 030043 & 1.30 \\ 2.57\end{array}$
3.32030044 ......................................................................... 2.07
$\begin{array}{lll}1.40 & 030047 & \ldots . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ~ \\ 1.84 & 030049 & 1.68 \\ 1.7 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ~ & 0.78\end{array}$
1.67030054 …............................................ 0.83
$\begin{array}{llll}2.80 & 030055 & \text {........................................................................................ } & 2.47 \\ 1.56 & 030059 & \end{array}$

| 1.57 | 030060 .............................................................................. |
| :--- | :--- |
| 1.25 |  |

1.32030061 ....................................................................... 2.09
$\begin{array}{llll}2.72 & 030062 & \text {.............................................................................................. } & 2.47 \\ 2.02 & 030064\end{array}$
2.70030065 .................................................... 3.18
1.61030067 ....................................................... 1.59
3.10030068 .................................................. 2.56
$\begin{array}{llll}1.94 & 030069 & \text {............................................................................................. } & 3.74 \\ 2.84 & 030080\end{array}$
2.15030083 ................................................... 2.58
$\begin{array}{llll}2.14 & 030085 & \text {........................................................................................... } & 2.55 \\ 1.63 & 030086 & 2 . . . . . . .\end{array}$
1.64030087 .................................................................. 3.66
1.11030088 ............................................. 2.22
$\begin{array}{llll}0.93 & 030089 & \text {........................................................................................... } & 2.94 \\ 1.48 & 030092\end{array}$
$\begin{array}{lllll}1.41 & 030093 & \text {............................................................................................ } & & 1.63 \\ 2.78 & 030094\end{array}$
2.30030095 .............................................. 3.28
1.92030099 ................................................ 2.09
1.07033025 ............................................ 1.82
2.04033026 ............................................. $\quad 2.18$
$\begin{array}{llll}0.87 & 033028 & \text {............................................. } & 1.64 \\ 233 & 034004 & \end{array}$
$\begin{array}{llll}2.33 & 034004 & \text {.......................................................................................... } & 1.58 \\ 1.05 & 034008\end{array}$
0.58034009 .............................................. 1.55
1.02034010 .................................................... 1.55
3.41034013 ................................................ 1.57

3.41040002 ............................................ 2.24

| 1.84 | 040003 | ............................................... | 1.98 |
| :--- | :--- | :--- | :--- |
| 1.06 | 040004 | $\ldots \ldots \ldots \ldots \ldots \ldots \ldots .$. |  |


| 1.65 | 040005 | $\ldots . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ~$ |
| :--- | :--- | :--- |

2.73040007 ............................................... 4.24
2.64040008 ............................................. $\quad 1.31$
2.15040010 ...................................................... 3.21
$\begin{array}{lll}0.86 & 040011 \\ 2.79 & 040014 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ~ & 2.11 \\ & 2.81\end{array}$
2.55040015 ............................................. 1.77
1.43040016 ............................................... 2.02
2.87040017 …........................................... 2.57
3.75040018 ............................................ 2.87
$\begin{array}{ll}1.90 & 040019 \text {.............................................. } \\ 2.10 \\ 2.01\end{array}$
3.09040021 ............................................................................. 3.28
1.86040022 ............................................. 2.43
2.92040024 .......................................................... 1.8

Addendum G.-Service Mix Indices by Hospital-Continued

|  | SMI |
| :---: | :---: |
| 040025 | 1.76 |
| 040026 | 2.63 |
| 040027 | 3.19 |
| 040028 | 2.17 |
| 040029 | 3.57 |
| 040030 | 1.37 |
| 040032 | 0.92 |
| 040035 | 1.17 |
| 040036 | 3.29 |
| 040037 | 2.01 |
| 040039 | 2.51 |
| 040040 | 1.35 |
| 040041 | 3.36 |
| 040042 | 2.13 |
| 040044 | 1.40 |
| 040045 | 1.65 |
| 040047 | 1.77 |
| 040048 | 2.46 |
| 040050 | 2.88 |
| 040051 | 2.07 |
| 040053 | 1.60 |
| 040054 | 3.26 |
| 040055 | 2.81 |
| 040058 | 2.42 |
| 040060 | 1.45 |
| 040062 | 2.58 |
| 040064 | 1.41 |
| 040066 | 3.53 |
| 040067 | 1.19 |
| 040070 | 1.77 |
| 040072 | 2.31 |
| 040074 | 2.91 |
| 040075 | 1.74 |
| 040076 | 1.79 |
| 040077 | 1.77 |
| 040078 | 2.74 |
| 040080 | 1.87 |
| 040081 | 0.93 |
| 040082 | 1.77 |
| 040084 | 3.12 |
| 040085 | 1.90 |
| 040088 | 3.29 |
| 040090 | 1.43 |
| 040091 | 1.73 |
| 040093 | 1.37 |
| 040100 | 2.39 |
| 040105 | 1.29 |
| 040106 | 2.06 |
| 040107 | 1.59 |
| 040109 | 2.02 |
| 040114 | 5.13 |
| 040116 | 2.93 |
| 040118 | 2.82 |
| 040119 | 3.14 |
| 040124 | 2.53 |
| 040126 | 1.95 |
| 040132 | 0.96 |
| 043026 | 1.30 |
| 043027 | 0.85 |
| 043028 | 1.17 |
| 043029 | 1.86 |
| 043031 | 0.82 |
| 043032 | 3.76 |
| 043300 | 1.57 |
| 044004 | 1.54 |
| 044005 | 1.57 |
| 044006 | 1.64 |
| 044010 | 1.65 |
| 044012 | 1.59 |
| 050002 | 2.06 |
| 050006 | 2.44 |

    1.76
    
## Addendum G.-Service Mix Indices By Hospital-Continued

| Hospital | SMI |
| :--- | :--- |

050007 .....................................................................................

050014 .............................................. $\quad 2.86$
050016 ...
050017
050018
050021
050022
050024
050026
050028
050029
050030.
050032
050033
050036
050039 ..
050042
050043
050045
050046
050047 ...
050054
050055.
050056
050057 ...
050060
050061
050063 ...
050065 ...
050066
050067
050068
050069
050077
050078
050079
050080
050081
050082
050082
050088
050089
050090
050091
050092
050095
050096
050097
050099
050100
050101
050102
050103
050104
050107
050109
050110
050111
050112
050113
050114
050115
050093
050108
0500093
050095
.


| 2.29 | 050116 | 2.99 |
| :---: | :---: | :---: |
| 2.97 | 050117 | 3.02 |
| 3.22 | 050118 | 2.63 |
| 2.86 | 050121 | 3.26 |
| 2.38 | 050122 | 2.54 |

    \(\begin{array}{llll}2.38 & 050122 & \ldots . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ~ & 2.54 \\ 2.13 & 00124 & 2.32 \\ 5 & & \end{array}\)
    5.03050125 ...................................................................... 3.20
    
$\begin{array}{llll}2.26 & 050127 & \text {.............................................................................................. } & 2.45 \\ 2.85 & 050128\end{array}$

2.34050131 ..................................................................... 2.45
$\begin{array}{ll}2.34 & 050132 \text {............................................................................... } \\ 2.98 \\ 2.52\end{array}$
2.52050133 ............................................. $\quad 2.08$
2.32050135 .................................................... 1.59
1.88050136 ................................................................... 2.67
$\begin{array}{llll}3.20 & 050144 & \ldots . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ~ & 2.46 \\ 2.24 & 050145 & 2.76 \\ 267 & 050146 & \end{array}$
2.67050146 ........................................................................ $\quad 1.41$

$\begin{array}{lll}2.85 & 050149 & \text {.......................................................................... } \\ 3.26 & 050150 & 2.40 \\ 2.74\end{array}$
2.85050152 ................................................ 2.31
$\begin{array}{lll}2.17 & 050153 & \text {............................................................................................................ } \\ 3.38 \\ 2.32 & 050155 & 2.14\end{array}$
2.32050155 ............................................................................ $\quad 2.14$
3.05050158 .............................................. 3.58
$\begin{array}{lll}3.05 & 050158 & \text {...................................................................................... } \\ 1.60 & 050159 & 1.48 \\ 1.75 & 050167 & \end{array}$
1.75050167 .............................................. 1.42
1.93050168 .............................................................................. $\quad 3.42$
3.46050169 ................................................................... 2.78
3.51050170 ..................................................................... 2.83
2.74050172 ...................................................................... $\quad 1.89$
2.11050173 ............................................. 2.82
$\begin{array}{ll}2.122 & 050174 \text {........................................................................ } \\ 5 . & 3.38 \\ 3 .\end{array}$
$\begin{array}{llll}2.75 & 050175 & \text {..................................................................... } & 3.37 \\ 2.53 & 050177 & 1.89\end{array}$
2.43050179 .............................................. 2.63

| 1.93 | 050180 |
| :--- | :--- |
| 271 | ......................................................................... |

    \(\begin{array}{lll}1.93 & 050180 & \text {........................................................................................... } \\ 2.71 & 050183 \\ 278 & 050186 & 1.30 \\ & 1.96\end{array}\)
    $\begin{array}{llll}2.78 & 050186 & \text {......................................................................................... } & 1.96 \\ 3.23 & 050188\end{array}$

$\begin{array}{llll}2.67 & 050189 & \text {................................................................... } & 2.48 \\ 2.20 & 050191 & \text {................. }\end{array}$
$\begin{array}{lll}2.20 & 050191 & . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ~\end{array} .69$
$\begin{array}{llll}2.13 & 050192 & \text {........................................................................................... } & 1.80 \\ 1.14 & 050193 \\ 2.90 & 050194 & & 2.70\end{array}$
2.90050194 ............................................................... 2.70

$\begin{array}{llll}1.44 & 050196 & . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ~ & 2.38 \\ 2.10 & 050197 & 2.39\end{array}$
2.10050197 ............................................. 2.76
$\begin{array}{lll}2.52 & 050204 & \text {................................................................................................. } \\ 2.57 & 050205 & 3.22\end{array}$


| 1.87 | 050207 |
| :--- | :--- |
| $3.7 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ~$ | 3.48 |

$\begin{array}{llll}3.76 & 050208 & . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ~ & 2.71\end{array}$

| 3.98 | 050211 | ................................................................................................ | 1.28 |
| :--- | :--- | :--- | :--- |

    3.94050213 .................................................................. 1.28
    | 3.79 | 050214 | ...................................................................................... | 2.05 |
| :--- | :--- | :--- | :--- |
| 2.27 | 050215 |  |  |

$\begin{array}{lll}3.79 & 050214 & \text {........................................................................................ } \\ 2.27 & 050215 & 3.07 \\ 2.75 & 050217\end{array}$



| 2.80 | 05029 |
| :--- | :--- |
| 2.14 | $05022 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ~$ |
| 3 | 2.61 |

3.29050224 .................................................. 2.71
$\begin{array}{lll}3.29 & 050224 & . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ~ \\ 2.28\end{array}$
2.69050226 ............................................... 2.85
2.76050228 ..................................................................... $\quad 1.17$

| 2.76 | 050228 | ............................................................................................ | 1.17 |
| :--- | :--- | :--- | :--- |
| 2.26 | 050230 |  |  |


| 2.76 | 050228 | ............................................................................................ | 1.17 |
| :--- | :--- | :--- | :--- |
| 2.26 | 050230 |  |  |

3.28050231 .................................................................. $\quad 3.44$

| 3.28 | 050231 | ............................................................................................ | 3.94 |
| :--- | :--- | :--- | :--- |
| 5.30 | 050232 |  |  |

2.67050233 ................................................................. $\quad 3.37$

$\begin{array}{lll}1.35 & 050235 & \text {.................................................................................... } \\ 2.18 & 050236 & 2.64\end{array}$

| 2.76 | 050235 | ................................................................................................ | 2.64 |
| :--- | :--- | :--- | :--- |
| 2.18 | 050236 |  |  |

2.64
2.17

Addendum G.-Service Mix Indices BY HOSPITAL-Continued

| Hospital | SMI |
| :---: | :---: |

    ...............................................
    

050017
Hospital $\quad$ SMI

2.45
2.73
2.45


2.08
1.59

1.67
2.46
2.76
1.41
1.41
2.31
2.40
2.44
2.31

2.31
2.14
3.58
050054 ..
.99

3.20
2.24
2.67
050038




050058 ...
-
050060 ...
$\qquad$ 2.7505017


| 1.93 | 050180 | ........................................................................................... |
| :--- | :--- | :--- |
| 2.71 | 050183 | 1.30 |








3.48
2.09
2.71



Addendum G.-Service Mix Indices by Hospital-Continued

|  | SMI |
| :---: | :---: |
| 050238 | 2.14 |
| 050239 | 2.64 |
| 050240 | 2.66 |
| 050241 | 2.55 |
| 050242 | 2.23 |
| 050243 | 2.05 |
| 050245 | 1.24 |
| 050248 | 1.49 |
| 050251 | 2.23 |
| 050253 | 2.29 |
| 050254 | 3.23 |
| 050256 | 1.39 |
| 050257 | 1.90 |
| 050260 | 1.38 |
| 050261 | 2.11 |
| 050262 | 2.22 |
| 050264 | 2.24 |
| 050267 | 2.80 |
| 050270 | 2.61 |
| 050272 | 2.14 |
| 050274 | 1.56 |
| 050276 | 1.32 |
| 050277 | 2.59 |
| 050278 | 2.70 |
| 050279 | 1.93 |
| 050280 | 2.70 |
| 050281 | 3.99 |
| 050282 | 2.17 |
| 050283 | 1.16 |
| 050286 | 1.02 |
| 050289 | 2.76 |
| 050290 | 2.40 |
| 050291 | 1.73 |
| 050292 | 1.41 |
| 050293 | 1.42 |
| 050295 | 2.63 |
| 050296 | 2.45 |
| 050298 | 2.08 |
| 050299 | 3.08 |
| 050300 | 2.95 |
| 050301 | 2.95 |
| 050302 | 2.87 |
| 050305 | 2.12 |
| 050307 | 3.67 |
| 050308 | 2.42 |
| 050309 | 3.00 |
| 050310 | 2.96 |
| 050312 | 2.71 |
| 050313 | 3.15 |
| 050315 | 1.20 |
| 050317 | 1.84 |
| 050320 | 1.26 |
| 050324 | 3.46 |
| 050325 | 1.73 |
| 050327 | 2.36 |
| 050328 | 2.69 |
| 050329 | 1.93 |
| 050331 | 2.12 |
| 050333 | 1.10 |
| 050334 | 3.36 |
| 050335 | 1.34 |
| 050336 | 2.48 |
| 050337 | 1.78 |
| 050342 | 2.84 |
| 050343 | 3.36 |
| 050348 | 1.87 |
| 050349 | 1.17 |
| 050350 | 2.25 |
| 050351 | 3.35 |
| 050352 | 2.05 |
| 050353 | 2.61 |

## Addendum G.-Service Mix Indices by Hospital-Continued

| Hospital | SMI |
| :--- | :--- |

050355 ..............................................................................................

050359
050360
050366
050367
050369
050378
050379
050380
050388
050390
050391
050393
050394
050397
050401
050404
050407
050410
050414
050418
050419
050420
050421
050424
050426
050427
050430
050432
050433
050435
050436
050438
050440
050441
050444
050446
050447
050448
050454
050455
050457
050459
050468
050469
050470
050471
050476
050477
050478
050481
050482
050483
050485
050486
050488
050491
050494

Addendum G.-Service Mix Indices by Hospital-Continued

| Hospital | SMI |
| :---: | :---: |
| 050496 .............................................. | 2.55 |


| 0.98 | 050496 | $\ldots . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ~$ |
| :--- | :--- | :--- |
| 2.47 | 0549 |  |


| 2.47 | 050497 | .............................................................................. | 2.58 |
| :--- | :--- | :--- | :--- |
| 3.58 | 050498 |  |  |

3.42050502 ........................................................................ 3.66

| 2.09 | 050503 |
| :--- | :--- |
| 1.90 | 050506 |
| ............................................................................... | 3.44 |
| 2.44 |  |

2.41050516 ................................................... 3.39


3.91050526 ................................................... 2.04
2.62050528 ............................................. 2.12
1.03050531 .............................................. 3.41
2.02050535 ............................................................................ 2.86
1.48050537 .............................................. 2.76
$\begin{array}{ll}2.93 & 050539 \\ 3.37 & 050542 \\ \text {................................................................................ } & 2.31 \\ 2.06\end{array}$
4.28050543 ….................................................................... 3.65
$\begin{array}{ll}1.44 & 050545 \\ \text {............................................. } & 0.99 \\ 0.94\end{array}$
1.55050547 ...................................................................... $\quad 1.12$
1.36050548 ............................................... 0.81

| 2.93 | 050549 | ............................................................................................... | 2.87 |
| :--- | :--- | :--- | :--- |
| 1.05 | 050550 |  |  |

2.65050551 .............................................. 2.61
3.03050552 …............................................... $\quad 1.32$
$\begin{array}{lll}1.29 & 050557 & \text {.................................................................. } \\ 2.69 & 050559 & 2.30 \\ & 2.89\end{array}$
2.12050560 ................................................................. 2.10
2.38050564 ............................................. 2.61

2.60050567 ........................................................................... 2.31
0.76050568 .............................................. 2.82
$\begin{array}{lll}1.38 & 050569 & \text {............................................. } \\ 3.90 & 050570 & 2.55 \\ 3.36\end{array}$
2.60050571 .............................................. 3.32
$\begin{array}{llll}1.55 & 050573 & \text {............................................. } & 2.43 \\ 1.37 & 050577\end{array}$
2.38050579 .......................................................................... $\quad 2.59$
1.58050580 ............................................ 2.36
$\begin{array}{llll}2.65 & 050581 & \ldots \ldots . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ~ & 2.45 \\ 1.53 & 050583\end{array}$
2.19050584 .......................................................................... 2.20
1.62050585 ............................................. 2.85

| 2.31 | 050586 | $\ldots . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ~$ | 3.12 |
| :--- | :--- | :--- | :--- |
| 1.43 | 050588 |  |  |

1.60050589 ............................................. 3.13
3.14050590 ................................................. 3.28
1.78050591 ................................................. 2.53
$\begin{array}{llll}3.70 & 050592 & \text {................................................................................................... } & 1.95 \\ 5.49 & 050593\end{array}$
2.23050594 .............................................. 3.76
$\begin{array}{lll}2.44 & 050597 & \ldots . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ~ \\ 171 & 050599 & 2.92 \\ 1.65\end{array}$
1.68050601 ............................................................. $\quad 2.91$
2.22050607 ............................................... 1.80
3.14050608 ............................................. 1.91
$\begin{array}{ll}2.73 & 050613 \\ 461 & 050615\end{array}$........................................... $\quad 0.75$
1.57050616 ........................................................................ 2.60
2.80050618 ............................................... 1.32
1.06050624 ............................................ 2.96
3.44050625 ............................................ $\quad 2.60$
3.44050630 ........................................... 2.33
2.39050633 .............................................. 2.71
2.52050638 .............................................................................. $\quad 1.47$
2.39050641 ............................................ 2.70
3.25050644
2.58

Addendum G.-Service Mix Indices Addendum G.-Service Mix Indices by Hospital-Continued

|  | Hospital | SMI |
| :---: | :---: | :---: |
| 050660 |  | 1.47 |
| 050661 |  | 1.54 |
| 050662 |  | 1.05 |
| 050663 |  | 2.23 |
| 050667 |  | 1.07 |
| 050668 |  | 1.18 |
| 050676 |  | 0.91 |
| 050678 |  | 3.03 |
| 050680 |  | 1.56 |
| 050682 |  | 1.29 |
| 050684 |  | 2.07 |
| 050685 |  | 2.62 |
| 050688 |  | 1.75 |
| 050689 |  | 2.53 |
| 050693 |  | 2.19 |
| 050694 |  | 2.25 |
| 050695 |  | 1.71 |
| 050696 |  | 3.37 |
| 050697 |  | 4.88 |
| 050699 |  | 2.68 |
| 050700 |  | 2.52 |
| 050701 |  | 2.18 |
| 050702 |  | 0.93 |
| 050704 |  | 2.10 |
| 050709 |  | 2.93 |
| 050713 |  | 3.24 |
| 052031 |  | 1.13 |
| 053026 |  | 1.62 |
| 053027 |  | 1.03 |
| 053028 |  | 1.25 |
| 053029 |  | 1.40 |
| 053030 |  | 0.97 |
| 053031 |  | 1.25 |
| 053032 |  | 0.83 |
| 053033 |  | 1.14 |
| 053034 |  | 1.85 |
| 053035 |  | 1.41 |
| 053036 |  | 1.39 |
| 053037 |  | 1.42 |
| 053300 | ... | 1.47 |
| 053301 | ...... | 2.09 |
| 053302 | .... | 1.70 |
| 053305 | . | 1.00 |
| 054001 |  | 1.55 |
| 054003 |  | 2.23 |
| 054009 |  | 1.56 |
| 054012 |  | 1.60 |
| 054032 |  | 1.55 |
| 054050 |  | 1.85 |
| 054053 |  | 1.66 |
| 054055 |  | 1.32 |
| 054060 |  | 1.55 |
| 054064 |  | 1.32 |
| 054065 |  | 1.53 |
| 054069 |  | 1.55 |
| 054074 |  | 1.55 |
| 054078 |  | 2.06 |
| 054085 |  | 1.55 |
| 054087 |  | 1.55 |
| 054091 |  | 1.82 |
| 054093 |  | 2.49 |
| 054094 |  | 1.59 |
| 054095 |  | 1.55 |
| 054096 |  | 1.58 |
| 054097 |  | 1.57 |
| 054098 |  | 1.32 |
| 054099 | ........................ | 1.69 |
| 054104 | .... | 2.67 |
| 054105 | ............ | 1.55 |
| 054106 | ........ | 1.56 |
| 054108 |  | 1.45 |

by Hospital-Continued

| Hospital | SMI |
| :---: | :---: |

054111 ............................................. 1.55
054113 ..
054115 ..
054116
054119
054122
054125
054126 ..
054130
054131
060001
060003
060004
060006
060008
060009
060010
060012
060013
060014
060016
060018
060020
060022
060024
060027
060028
060029
060031
060032
060034
060036
060037 ..
060041
060042
060044
060046
060047
060049
060050
060053
060054
060056
060057
060058
060060
060063
060064
060065
060068
060070
060073
060075
060076
060085
060087
060088

Addendum G.-Service Mix Indices by Hospital-Continued

| Hospital | SMI |
| :---: | :---: |
| 060090 .............................................. | 1.60 |

1.55060096 ....................................................................... 2.09

| 1.55 | 060100 | ............................................................................................... |
| :--- | :--- | :--- | :--- |
| 1.55 | 060103 | 46 |

1.57060104 ....................................................................... 2.40
1.55060107 .................................................. 1.34

| 1.05 | 062009 | $\ldots . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ~$ | 0.80 |
| :--- | :--- | :--- | :--- |
| 1.58 | 062011 | 2.22 |  |

1.83063026 ............................................... 1.58
$\begin{array}{llll}1.55 & 063027 & . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ~\end{array}$.
1.85063301 ............................................... 1.51
$\begin{array}{llll}0.72 & 063302 & \text {............................................................................................. } & 1.41 \\ 3.12 & 064007\end{array}$
3.01064009 ....................................................................... 1.39
$\begin{array}{lll}1.51 & 064010 & \text {................................................................................................. } \\ 2.24 & 064012 & 1.52\end{array}$
1.59064016 ............................................... 2.18
$\begin{array}{llll}2.16 & 064020 & \text {............................................................................................. } & 2.85 \\ 2.35 & 070001\end{array}$
2.53070002 .................................................. 2.63
1.32070003 .............................................. 2.19
$\begin{array}{llll}1.94 & 070004 & \text {...................................................................................... } & 2.36 \\ 1.91 & 070005\end{array}$
2.56070006 .............................................. 2.48
$\begin{array}{llll}1.84 & 070007 & \text {................................................................... } & 2.92 \\ 2.15 & 070008 & & 2.12\end{array}$
2.30070009 ............................................. 2.79
$\begin{array}{llll}2.29 & 070010 & \text {.................................................................................................. } & 2.12 \\ 1.85 & 070011\end{array}$
2.62070012 .............................................................. 2.27
1.62070015 .............................................. 2.25
$\begin{array}{llll}2.77 & 070017 & \text {............................................................................. } & 2.15 \\ 2.26\end{array}$
1.10070018 ............................................ 2.28

| 2.93 | 070019 | ............................................. | 2.96 |
| :--- | :--- | :--- | :--- |
| 2.37 | 070020 |  | 2.24 |

2.92070021 ............................................................................. $\quad 2.61$
1.69070022 ............................................. $\quad 2.69$
$\begin{array}{lll}1.88 & 070025 & \text {............................................................................... } \\ 1.48 & & 2.52 \\ 3.27\end{array}$
1.48070026 ............................................ 2.20
$\begin{array}{lll}1.46 & 070027 & \text {.......................................................................................... } \\ 0.99 & 070028 \\ & 2.28\end{array}$
1.65070029 .............................................. 2.48
1.29070030 ................................................. 2.60
$\begin{array}{lll}2.43 & 070031 & \ldots . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ~ \\ 3.04\end{array}$
0.95070035 ............................................. 2.48
2.79070036 .................................................... 2.07
2.00070039 ............................................. $\quad 1.17$
1.79072003 .............................................. 1.05
1.78072004 ............................................. $\quad 0.87$

| 2.64 | 072008 | ............................................................................ | 1.16 |
| :--- | :--- | :--- | :--- |
| 1.10 | 073025 |  |  |

2.11074000 ................................................ 1.50
1.34074007 ............................................... 1.55
1.27074008 ................................................. 1.78
1.52080001 ............................................. 3.31
$\begin{array}{lll}0.78 & 080002 & \text {.............................................. } \\ 3.29 & 080003 & 2.32 \\ & 2 .\end{array}$
2.34080004 …............................................. 2.55
1.25080005 ................................................ 2.95
1.32080006 ................................................... 2.52
2.19080007 ................................................ 2.26
1.33083300 .............................................. $\quad 3.78$
$\begin{array}{ll}2.68 & 084002 \text {.............................................. } \quad 1.67 \\ 1.96 & 090001\end{array}$
1.17090002 ............................................... 1.92
2.10090003 ............................................. 1.81

| 1.53 | 090004 | $\ldots \ldots \ldots \ldots . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ~$ |
| :--- | :--- | :--- |

Addendum G.-Service Mix Indices Addendum G.-Service Mix Indices by Hospital-Continued

|  | SMI |
| :---: | :---: |
| 090006 | 2.60 |
| 090007 | 1.28 |
| 090008 | 2.52 |
| 090010 | 2.06 |
| 090011 | 2.49 |
| 090015 | 0.75 |
| 092002 | 0.80 |
| 093025 | 1.08 |
| 093300 | 2.05 |
| 094004 | 1.33 |
| 100001 | 1.62 |
| 100002 | 2.75 |
| 100004 | 1.94 |
| 100006 | 2.43 |
| 100007 | 3.08 |
| 100008 | 3.40 |
| 100009 | 2.57 |
| 100010 | 2.79 |
| 100012 | 3.06 |
| 100014 | 2.68 |
| 100015 | 2.69 |
| 100017 | 2.75 |
| 100018 | 2.01 |
| 100019 | 3.36 |
| 100020 | 3.14 |
| 100022 | 1.43 |
| 100023 | 2.70 |
| 100024 | 3.07 |
| 100025 | 2.33 |
| 100026 | 2.86 |
| 100027 | 1.58 |
| 100028 | 2.94 |
| 100029 | 2.61 |
| 100030 | 3.15 |
| 100032 | 2.22 |
| 100034 | 2.49 |
| 100035 | 2.62 |
| 100038 | 2.39 |
| 100039 | 2.94 |
| 100040 | 3.26 |
| 100043 | 2.46 |
| 100044 | 2.58 |
| 100045 | 2.36 |
| 100046 | 2.41 |
| 100047 | 2.06 |
| 100048 | 1.71 |
| 100049 | 2.76 |
| 100050 | 2.35 |
| 100051 | 2.67 |
| 100052 | 4.07 |
| 100053 | 2.62 |
| 100054 | 2.09 |
| 100055 | 2.32 |
| 100056 | 3.65 |
| 100057 | 3.13 |
| 100060 | 2.58 |
| 100061 | 2.80 |
| 100062 | 3.23 |
| 100063 | 2.34 |
| 100067 | 2.59 |
| 100068 | 2.16 |
| 100069 | 2.65 |
| 100070 | 2.58 |
| 100071 | 2.27 |
| 100072 | 2.44 |
| 100073 | 2.03 |
| 100075 | 2.32 |
| 100076 | 2.55 |
| 100077 | 3.36 |
| 100078 | 1.17 |
| 100079 | 1.77 |

by Hospital-Continued

| Hospital | SMI |
| :---: | :---: |

100080 ......................................................................................

100082
100084
100086
100087
100088
100090
100098 ...
100099 ..
100103
100105 ..
100106 ..
100108 ...
100109 .
100112
100113 ...
100114 ...
100118
100121 ..
100124
100125 ..
86100126 ...
100127 ..
100129
100130 ...
100131 ...
100134
100135 ...
100138 …
100139 ...
100140 ...
100144
100145 ...
100146
100147 ..
100150 ...
100151 ... 100156
100157
100159 ...
100160
100161 ...
100162 100165. 100167 ... 100168 .. 100169 ... 100170 .. 100172. 100173 100174 ... 100175 ... 100176 . 100177 ... 100179 .. $\begin{array}{ll}.36 & 100180\end{array}$ 17100181 .77

Addendum G.-Service Mix Indices by Hospital—Continued

|  | SMI |
| :---: | :---: |
| 103031 | 1.52 |
| 103032 | 1.73 |
| 103034 | 1.36 |
| 103300 | 7.02 |
| 103301 | 2.56 |
| 104008 | 1.72 |
| 104015 | 1.55 |
| 104016 | 1.53 |
| 104017 | 1.55 |
| 104024 | 1.75 |
| 104026 | 1.55 |
| 104029 | 1.55 |
| 104034 | 1.56 |
| 104036 | 1.58 |
| 104037 | 1.55 |
| 104038 | 1.68 |
| 104041 | 1.81 |
| 104045 | 1.69 |
| 104046 | 1.55 |
| 104047 | 1.55 |
| 104052 | 1.56 |
| 104054 | 1.57 |
| 104056 | 1.54 |
| 104060 | 1.43 |
| 110001 | 2.73 |
| 110002 | 1.75 |
| 110003 | 2.69 |
| 110004 | 2.62 |
| 110005 | 2.65 |
| 110006 | 3.33 |
| 110007 | 2.64 |
| 110008 | 2.44 |
| 110009 | 1.15 |
| 110010 | 3.09 |
| 110011 | 2.39 |
| 110013 | 1.55 |
| 110014 | 1.70 |
| 110015 | 1.76 |
| 110016 | 3.17 |
| 110017 | 1.28 |
| 110018 | 2.22 |
| 110020 | 3.19 |
| 110023 | 2.44 |
| 110024 | 3.80 |
| 110025 | 2.85 |
| 110026 | 1.76 |
| 110027 | 1.62 |
| 110028 | 2.89 |
| 110029 | 2.10 |
| 110030 | 3.04 |
| 110031 | 2.55 |
| 110032 | 2.72 |
| 110033 | 2.97 |
| 110034 | 1.43 |
| 110035 | 2.93 |
| 110036 | 2.93 |
| 110037 | 1.63 |
| 110038 | 2.20 |
| 110039 | 2.96 |
| 110040 | 2.05 |
| 110041 | 2.04 |
| 110042 | 3.56 |
| 110043 | 3.18 |
| 110044 | 2.66 |
| 110045 | 2.47 |
| 110046 | 2.26 |
| 110048 | 1.63 |
| 110049 | 1.30 |
| 110050 | 1.78 |
| 110051 | 1.91 |
| 110052 | 1.04 |

Addendum G.-Service Mix Indices by Hospital-Continued

| Hospital | SMI |
| :---: | :---: |


| 110054 .......................................................................................... | 26 |
| :--- | :--- | :--- |
| 110056 .......... |  |

Addendum G.-Service Mix Indices by Hospital-Continued

| Hospital | SMI |
| :---: | :---: |
| 110156 _.............................................. | 1.52 |
| 110161 |  |

110161 ............................................. 3.5
1.25110164 .................................................................. 2.47
0.97110165 .............................................. 2.62

| 1.50 | 110166 |
| :--- | :--- |
| ................................................. | 2.82 |


| 1.05 | 10168 | ...................................................................... |
| :--- | :--- | :--- |
| 1.13 | 110169 | 2.47 |
| 7.21 |  |  |

2.56110171 .............................................. 2.37

| 2.55 | 110172 ...................................................... 3.25 |
| :--- | :--- |
| 1.84 |  |

1.84110174 .............................................. 1.87
1.29110176 ............................................. 2.69

| 1.55 | 110177 |
| :--- | :--- |
| .............................................. | 2.47 |
| 8.34 |  |


| 2.78 | 110179 ........................................................................ | 8.22 |
| :--- | :--- | :--- |

2.39110181 ................................................ 1.14

1.23110185 .............................................. 1.45
1.97110186 ...................................................................... $\quad 3.32$
$3.62-110187$............................................ 2.4

| 3.30 | 110188 | ............................................................................................... |
| :--- | :--- | :--- |
| 1.97 | 110189 |  |

2.75110190 ................................................................... 1.73
2.39
3.09
1.71
1.48
1.01
2.97
1.48
1.32
1.77
1.27
1.56
1.28
2.20
2.49
2.05
0.81

| 1.61 | 113026 ................................................ |
| :--- | :--- |

1.68113027 .............................................. 0.40
1.52113300 .............................................. 2.36
1.4114000 ............................................. 1.55
1.60114003 ..................................................................... 1.55
2.62
0.76
1.15
4.84
2.79
2.79
3.21
1.59114027 .............................................. 1.55
2.41114030 ............................................... 1.67
2.94114032 .............................................. 1.55
1.82114033 ............................................. 1.54
2.04114034 .............................................. 1.55
1.23120001 .............................................. 2.95
4.68120002 …................................................. 2.93
2.41120003 .............................................. 2.15
$\begin{array}{ll}1.22 & 120004 \\ 1 . & \text {............................................. } \\ 120 & 120005\end{array} \quad \begin{aligned} & 2.18 \\ & 3.1\end{aligned}$
1.50120005 ............................................. 3.21
$\begin{array}{lll}3.07 & 120006 & \text {................................................................................................ } \\ 1.92 & 120007 \\ & & 3.17\end{array}$
1.72120009 .................................................................... 1.26
1.57120010 .............................................. 2.69
2.56120012 ............................................... 1.32
$\begin{array}{ll}1.77 & 120014 \\ 20 & \text {............................................. } \\ 2.83 \\ & 2.81\end{array}$
2.02120018 ............................................. $\quad 0.71$

Addendum G.-Service Mix Indices by Hospital-Continued
 2.56

Addendum G.-Service Mix Indices By Hospital-Continued

| Hospital | SMI |
| :---: | :---: |
| 140027 .............................................. | 1.84 | 140029 . 140030 140031. 140033 140034 .. 140035 ...

$\begin{array}{ll}1.53 & 140036 \\ 1.60 & 140037\end{array}$ . 18140038 ...
$\begin{array}{ll}3.14 & 140040 \ldots \\ 3.43 & 140041 \ldots\end{array}$
. 12140042 ..
.94140045
140047 ...
140048
140049 ..
140052 ...
1.20140053
. 06140054 ...
140055 ...
140058 ..
09140061.
2.48140062 ...
2.89140063 ..
.91140064 ...
60140066 .
140067 ...
. 89140069 ..
34140070 ..
$.61 \quad 140074 \ldots$
90140077 ..
. 90 140079 ...
68140080 ..
.65140082
. 30140083 ...
. 59 140084 ...
76140086 …
73140088 ...
.55140089 ..
.47140090 ...
. 55 140091 ...
21140094
35140095 ...
. 61140097 ...
.45140100 ...
. 5740101.
49140102.
35140103.
.78140105 ..
2.22140107.
76140108.
. 4140109 ...
82140110 ...
140112 ..
65140114 .
.81140115
.53140116
2.30 140117.

Addendum G.-Service Mix Indices by Hospital-Continued

| Hospital | SMI |
| :---: | :---: |

1.84140118 ............................................... 2.83

| 2.17 | 140119 | 2.96 |
| :---: | :---: | :---: |
| 2.97 | 140120 | 2.46 |

1.64140121 .................................................................... 2.2 .64
3.04140122 ................................................. 2.48
$\begin{array}{llll}2.61 & 140125 & \text {.......................................................................................... } & 2.18 \\ 2.39 & 140127 & 4.46\end{array}$
$\begin{array}{ll}2.39 & 140127 \\ 1.66 & 140128 \\ \text {.............................................................................. } & 4.46 \\ 1.79\end{array}$


| 1.44 | 140130 | ........................................................................................... | 2.80 |
| :--- | :--- | :--- | :--- |
| 1.59 | 140132 |  |  |

$\begin{array}{llll}1.29 & 140133 & \text {....................................................................................................................... } & 2.78 \\ 2.20 & 140135\end{array}$
1.64140137 …........................................... 1.67

$\begin{array}{ll}.63 & 140139 \text {........................................................................................... } \\ 2.40140\end{array}$

$\begin{array}{lll}2.18 & 140143 & \ldots \ldots . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ~\end{array} 1.68$
$\begin{array}{lllll}2.56 & 140145 & \text {............................................................................................. } & 2.62 \\ 2.79 & 140146 & \end{array}$
3.25140147 ............................................................................ 2.31
$\begin{array}{lll}2.63 & 140148 & \text {.......................................................................................... } \\ 1.58 & 140150 & 1.61\end{array}$

| 1.58 | 140150 | ....................................................................................... | 1.34 |
| :--- | :--- | :--- | :--- |
| 2.30 | 140151 |  |  |


| 2.50 | 140155 | $\ldots . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ~$ |
| :--- | :--- | :--- | 171.4 .43


| 1.71 | 140158 | ............................................................................................ | 1.73 |
| :--- | :--- | :--- | :--- |
| 2.16 | 140160 |  |  |

2.29140161 .................................................................... 2.48
3.76140162 .............................................. 2.30
$\begin{array}{ll}2.44 & 140164 \\ 2 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ~ & 2.77 \\ 2.75\end{array}$

1.77140167 ................................................... 2.59
$\begin{array}{llll}1.89 & 140168 & \text {............................................. } & 1.97 \\ 200 & 140170 & & 1.37\end{array}$
$\begin{array}{llll}2.00 & 140170 & \text {.................................................................... } & 1.62 \\ 1.21 & 140171 & 1.37\end{array}$
2.41 140172 .......................................................................... 1.61

| 1.66 | 140173 | $\ldots . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ~$ | 18 |
| :--- | :--- | :--- | :--- |

2.19140176 ............................................ 2.67
$\begin{array}{ll}1.66 & 140177 \\ \text {.............................................. } & 2.11 \\ 1.94 & 140179\end{array}$
1.45140180 ........................................................................ 2.01
2.94140181 ................................................................... 1.95
$\begin{array}{llll}2.09 & 140182 & \text {........................................................................................ } & 2.00 \\ 2.41 & 140184\end{array}$
1.65140185 …........................................... 2.35

| 2.96 | 140186 | .............................................. | 2.10 |
| :--- | :--- | :--- | :--- |
| 2.57 | 140187 |  |  |

$\begin{array}{llll}2.57 & 140187 & \text {............................................................................................. } & 1.37 \\ 5.51 & 140188\end{array}$
$2.71 \quad 140189$................................................ 2.21
$\begin{array}{llllll}2.24 & 140190 & \text {............................................................................................. } & 2.08 \\ 1.93 & 140191\end{array}$
1.37140193 .............................................. 2.51
2.74140197 .............................................. 1.99
2.02140199 .............................................. 1.78
1.99140200 .................................................. 1.94
1.62140202 .................................................... 2.55
$\begin{array}{llll}2.70 & 140203 & \text {............................................................................................ } & 43 \\ 1.67 & 140205\end{array}$
2.82140206 .............................................. 2.22

| 1.69 | 140207 |
| :--- | :--- |
| ............................................. | 2.12 |

2.28140208 .............................................. 2.47
1.85140209 .............................................. 2.71
2.49140210 ................................................................. 2.15
2.42140211 .............................................. $\quad 2.35$
2.07140212 ............................................ $\quad 1.38$
2.63140213 ................................................ 2.63

Addendum G.-Service Mix Indices Addendum G.-Service Mix Indices by Hospital-Continued

|  | Hospital |
| :---: | :---: |
| 140217 |  |
| 140218 |  |
| 140220 |  |
| 140223 |  |
| 140224 |  |
| 140228 |  |
| 140230 |  |
| 140231 |  |
| 140233 |  |
| 140234 |  |
| 140236 |  |
| 140239 |  |
| 140240 |  |
| 140242 |  |
| 140245 |  |
| 140246 |  |
| 140250 |  |
| 140251 |  |
| 140252 |  |
| 140253 |  |
| 140258 |  |
| 140271 |  |
| 140275 |  |
| 140276 |  |
| 140280 |  |
| 140281 |  |
| 140285 |  |
| 140286 |  |
| 140288 |  |
| 140289 |  |
| 140290 |  |
| 140291 |  |
| 140292 |  |
| 140294 |  |
| 140297 |  |
| 140300 |  |
| 142006 |  |
| 143025 |  |
| 143026 |  |
| 143027 |  |
| 143300 |  |
| 143301 |  |
| 144005 |  |
| 144025 |  |
| 144026 |  |
| 144031 |  |
| 144033 |  |
| 144034 |  |
| 144036 |  |
| 150001 |  |
| 150002 |  |
| 150003 |  |
| 150004 |  |
| 150005 |  |
| 150006 |  |
| 150007 |  |
| 150008 |  |
| 150009 |  |
| 150011 |  |
| 150012 |  |
| 150013 |  |
| 150014 |  |
| 150015 |  |
| 150018 |  |
| 150019 |  |
| 150020 |  |
| 150022 |  |
| 150023 |  |
| 150024 |  |
| 150026 |  |
| 150027 |  | .............................................

Addendum G.-Service Mix Indices by Hospital-Continued

|  | Hospital | SMI |
| :---: | :---: | :---: |
| 160056 |  | 1.68 |
| 160057 |  | 2.59 |
| 160058 |  | 1.63 |
| 160060 |  | 1.89 |
| 160061 |  | 2.10 |
| 160062 |  | 1.74 |
| 160063 |  | 1.61 |
| 160064 |  | 3.14 |
| 160065 |  | 2.01 |
| 160066 |  | 2.40 |
| 160067 |  | 2.42 |
| 160068 |  | 1.88 |
| 160069 |  | 3.27 |
| 160070 |  | 1.70 |
| 160072 |  | 2.23 |
| 160073 |  | 1.35 |
| 160074 |  | 1.46 |
| 160075 |  | 1.79 |
| 160076 |  | 2.64 |
| 160077 |  | 1.83 |
| 160079 |  | 3.44 |
| 160080 |  | 2.72 |
| 160081 |  | 1.92 |
| 160082 |  | 3.36 |
| 160083 |  | 2.89 |
| 160085 |  | 1.61 |
| 160086 |  | 1.33 |
| 160088 |  | 1.65 |
| 160089 |  | 2.80 |
| 160090 |  | 1.59 |
| 160091 |  | 1.75 |
| 160092 |  | 1.82 |
| 160093 |  | 1.40 |
| 160094 |  | 2.93 |
| 160095 |  | 1.16 |
| 160097 |  | 2.12 |
| 160098 |  | 1.38 |
| 160099 |  | 1.74 |
| 160101 |  | 1.22 |
| 160102 |  | 2.85 |
| 160103 |  | 1.30 |
| 160104 |  | 2.24 |
| 160106 |  | 3.18 |
| 160107 |  | 1.49 |
| 160108 |  | 2.35 |
| 160109 |  | 1.62 |
| 160110 |  | 2.28 |
| 160111 |  | 1.64 |
| 160112 |  | 2.48 |
| 160113 |  | 1.34 |
| 160114 |  | 2.75 |
| 160115 |  | 2.45 |
| 160116 |  | 1.98 |
| 160117 |  | 2.86 |
| 160118 | . | 1.80 |
| 160120 | ..... | 0.95 |
| 160122 |  | 2.30 |
| 160124 | - | 2.14 |
| 160126 |  | 1.82 |
| 160129 |  | 2.98 |
| 160130 |  | 1.42 |
| 160131 |  | 1.61 |
| 160134 |  | 1.13 |
| 160135 |  | 1.78 |
| 160138 |  | 1.34 |
| 160140 |  | 1.69 |
| 160142 |  | 1.41 |
| 160143 |  | 1.92 |
| 160145 |  | 1.64 |
| 160146 |  | 2.96 |
| 160147 |  | 1.66 |

## Addendum G.-Service Mix Indices by Hospital-Continued

| Hospital | SMI |
| :---: | :---: |


| 160151 ........................................................................................... | 1.31 |
| :--- | :--- |
| 160152 ......... |  |

164002 ................................................. $\quad 4.09$

170001 .............................................. 3.29
170004 ...
170006
170009 .
170010
170012
170014
170015
170016
170017
170019
170020
170022
170023
170025
170026
170027
170030
170032
170033
170034
170036
170037
170038
170041
170043
170044
170049
170051
170052
170053
170055
170056
170057
170060
170063
170064
170066
170067
170070
170072
170073
70074
170076
170077
170081
170082
170084
170085
170086
170088
170089
170090
170092
2 ....

Addendum G.-Service Mix Indices by Hospital-Continued

| Hospital | SMI |
| :---: | :---: |
| 170093 ............................................. | 1.58 |
| 170094 | 200 |


| 176095 ....................................................................... | 2.00 |
| :--- | :--- |
|  | 17097 |

4.09170097 .................................................. 1.89
$1.61 \quad 170099$........................................................................... 2.27
2.01170100 .............................................. 0.80

| 2.18 | 170101 | ............................................................................................ |
| :--- | :--- | :--- |
| 2.47 | 170102 | 1.80 |

2.83170103 .............................................. 4.48
3.18170104 ................................................... 3.66

| 3.53 | 170105 ............................................ $\quad 2.02$ |
| :--- | :--- |


2.73170110 ............................................................................ $\quad 1.70$
2.59170112 ............................................. 1.48

| 1.74 | 170113 |
| :--- | :--- |
| ........................................................................................... | 2.46 |
| 3.41 | 170114 |

$3.81 \quad 170115$............................................. 1.89

| 2.57 | 170116 | $\ldots . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ~$ | 2.91 |
| :--- | :--- | :--- | :--- |
| 5 |  |  |  |

2.36170119 ........................................................................... $\quad 1.37$
2.06170120 ............................................... 3.12
3.15170122 .............................................. 2.74
3.18170123 ............................................. 3.90
1.56170124 .............................................. 2.13

| 1.04 | 170126 ..................................................... |
| :--- | :--- |
| 1 | 1.20 |
| 1 |  |


| 2.67 | 170131 | $\ldots . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ~$ | 1.93 |
| :--- | :--- | :--- | :--- |

1.90170133 .............................................. $\quad 3.64$

| 1.52 | 170134 | ................................................................................................ | 2.80 |
| :--- | :--- | :--- | :--- |
| 1.04 | 170137 |  |  |

3.34170139 ............................................. 0.72
1.64170143 .......................................................... 3.11
1.43170144 ............................................... 3.09

| 170145 | $170145 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ~$ |
| :--- | :--- |
| . | 2.18 |


| 1.58 | 170146 | ............................................................................................... |
| :--- | :--- | :--- |
| 1.74 | 170147 | 1.44 |

3.00170148 ............................................. 2.58

1.02170152 ..................................................................... 1.46
1.71170160 .............................................. 1.49
1.80170164 ............................................ 1.69
1.04170166 ............................................ 1.42

| 1.62 | 170171 | ................................................................. |
| :--- | :--- | :--- |
| 2.49 | 170175 | 1.39 |
| 4.34 |  |  |

2.07 170176 ............................................ 2.71

.......
2.08171305 ..................................................................... 0.38
3.51171310 ............................................ 0.32

| 2.26 | 172004 |
| :--- | :--- | ............................................. $\quad 0.68$

173025 ............................................ 1.55

1.16. 26
$3.38 \quad 180005$.............................................................. $\quad 2.23$
1.48180006 .............................................. 1.20
.28180007 …........................................ 2.91
1.26180009 .............................................. 2.80
2.17
1.35
0.83
1.55
1.79
1.46
1.56
1.97
2.23
2.91
2.80

Addendum G.-Service Mix Indices by Hospital-Continued

|  | Hospital |
| :---: | :---: |
| 180011 |  |
| 180012 |  |
| 180013 |  |
| 180014 |  |
| 180015 |  |
| 180016 |  |
| 180017 |  |
| 180018 |  |
| 180019 |  |
| 180021 |  |
| 180023 |  |
| 180024 |  |
| 180025 |  |
| 180026 |  |
| 180027 |  |
| 180030 |  |
| 180031 |  |
| 180032 |  |
| 180033 |  |
| 180034 |  |
| 180035 |  |
| 180036 |  |
| 180037 |  |
| 180038 |  |
| 180040 |  |
| 180041 |  |
| 180042 |  |
| 180043 |  |
| 180044 |  |
| 180045 |  |
| 180046 |  |
| 180047 |  |
| 180048 |  |
| 180049 |  |
| 180051 |  |
| 180054 |  |
| 180055 |  |
| 180056 |  |
| 180058 |  |
| 180059 |  |
| 180060 |  |
| 180063 |  |
| 180064 |  |
| 180065 |  |
| 180066 |  |
| 180067 |  |
| 180070 |  |
| 180072 |  |
| 180075 |  |
| 180078 |  |
| 180079 |  |
| 180080 |  |
| 180087 |  |
| 180088 |  |
| 180092 |  |
| 180093 |  |
| 180094 |  |
| 180095 |  |
| 80099 |  |
| 80101 |  |
| 80102 |  |
| 80103 |  |
| 180104 |  |
| 180105 |  |
| 180106 |  |
| 180108 |  |
| 180115 |  |
| 180116 |  |
| 180117 |  |
| 80118 |  |
| 180120 |  |

180120 ............................. 2.33
2.60
2.86

Addendum G.-Service Mix Indices by Hospital-Continued

| Hospital | SMI |
| :---: | :---: |
| 180121 .............................................. | 2.48 |

2.86180123 ..
$\begin{array}{ll}3.17 & 180124 . \\ 174 & 18012\end{array}$
$\begin{array}{ll}1.74 & 180126 \ldots \\ 2.32 & 180127\end{array}$
2.53180128 .
$2.71 \quad 180129$...
2.90180130 ..
$\begin{array}{ll}1.92 & 180132 \\ 1.82 & 180133\end{array}$
$2.06180134 \ldots$
$\begin{array}{ll}2.13 & 180136 \\ 2.07 & 180137\end{array}$
3.08180138 ...
1.42180139 .
$\begin{array}{ll}1.58 & 180140 \\ 1.34 & 180141\end{array}$
$\begin{array}{ll}1.34 & 180141 \\ 1.83 & 182001\end{array}$
1.97183027 ...
$\begin{array}{ll}2.67 & 183028 \\ 2.73 & 184000\end{array}$
2.60184002 ...
2.25184007 …
$\begin{array}{ll}3.61 & 184008 \\ 2.44 & 184009\end{array}$
$\begin{array}{ll}1.92 & 184011 \ldots \\ 1.43 & 184015\end{array}$
$\begin{array}{ll}1.43 & 184015 . . \\ 2.50 & 190003 . .\end{array}$
2.60190004 ...
$\begin{array}{ll}2.24 & 190007 \\ 1.66 & 190008\end{array}$
2.39190013 ..
3.18190014 ...
2.98190015 ..
2.22190017 ..
1.99190018 ..
2.49190019 ..
$\begin{array}{ll}1.42 & 190020 \\ 1.54 & 190025\end{array}$
$\begin{array}{ll}1.54 & 190025 \text {.. } \\ 0.81 & 190026 \text {.. }\end{array}$
1.48190027 .
$\begin{array}{ll}2.22 & 190029 . \\ 1.37 & 190033\end{array}$
$\begin{array}{ll}1.37 & 190033 \text {.. } \\ 2.49 & 190034 .\end{array}$
2.63190036 ...
.79190037 ...
$\begin{array}{ll}1.70 & 190039 . . \\ 1.82 & 190040 \text {.. }\end{array}$
2.22190041 ..
1.77190043 ...
$\begin{array}{ll}3.22 & 190044 \ldots \\ 2.94 & 190045 \ldots\end{array}$
3.54190046
2.19190048 ..
$\begin{array}{ll}2.72 & 190049 \\ 1.54 & 190050\end{array}$
1.97190053
1.75190054 ...
1.73190059 ...
2.84190060
2.88190064
2.58190065
$1.70 \quad 190071$
1.50190077
1.47190078 .
1.63190079
2.41190081
$\begin{array}{ll}2.43 & 190083 \\ 1 & 153 \\ 190086\end{array}$
1.53190086
1.55190088

Addendum G.-Service Mix Indices by Hospital-Continued

|  | SMI |
| :---: | :---: |
| 190231 | 4.55 |
| 190236 | 3.56 |
| 192004 | 1.30 |
| 192006 | 1.78 |
| 192016 | 3.50 |
| 192020 | 0.79 |
| 193027 | 1.77 |
| 193028 | 1.84 |
| 193034 | 1.22 |
| 193038 | 1.62 |
| 193041 | 0.89 |
| 193044 | 2.62 |
| 193300 | 1.52 |
| 194000 | 3.15 |
| 194004 | 1.32 |
| 194014 | 1.53 |
| 194019 | 1.57 |
| 194022 | 1.32 |
| 194023 | 1.52 |
| 194024 | 1.40 |
| 194027 | 1.56 |
| 194031 | 1.63 |
| 194036 | 1.47 |
| 194044 | 1.54 |
| 194058 | 1.55 |
| 200001 | 2.71 |
| 200002 | 2.25 |
| 200003 | 1.96 |
| 200006 | 1.43 |
| 200007 | 1.64 |
| 200008 | 2.14 |
| 200009 | 2.23 |
| 200012 | 1.69 |
| 200013 | 2.05 |
| 200015 | 2.19 |
| 200016 | 1.92 |
| 200017 | 2.72 |
| 200018 | 2.23 |
| 200019 | 2.23 |
| 200020 | 2.32 |
| 200021 | 2.52 |
| 200023 | 1.08 |
| 200024 | 2.50 |
| 200025 | 2.47 |
| 200026 | 1.83 |
| 200027 | 1.77 |
| 200028 | 1.83 |
| 200031 | 1.84 |
| 200032 | 1.99 |
| 200033 | 2.24 |
| 200034 | 2.74 |
| 200037 | 1.95 |
| 200038 | 2.48 |
| 200039 | 2.55 |
| 200040 | 2.89 |
| 200041 | 2.42 |
| 200043 | 1.29 |
| 200050 | 2.80 |
| 200051 | 2.73 |
| 200052 | 1.79 |
| 200055 | 1.47 |
| 200062 | 1.46 |
| 200063 | 2.52 |
| 200066 | 2.16 |
| 204005 | 1.68 |
| 204006 | 1.54 |
| 220001 | 2.29 |
| 220003 | 2.21 |
| 220004 | 2.30 |
| 220006 | 2.26 |
| 220008 | 2.19 |

## Addendum G.-Service Mix Indices by Hospital-Continued

| Hospital | SMI |
| :---: | :---: |

220010 ............................................. 2.68

| 220010 | 2.68 |
| :---: | :---: |
| 220011 | 1.67 |
| 220015 | 2.19 |1.822.132.35

1.852.02
1.571.872.37

$$
2.29
$$

$$
\begin{aligned}
& 2.29 \\
& 2.16 \\
& .17
\end{aligned}
$$

$$
\begin{aligned}
& 2.10 \\
& 2.57 \\
& 2.46
\end{aligned}
$$

$$
\begin{aligned}
& 2.46 \\
& 2.20
\end{aligned}
$$

$$
\begin{aligned}
& 2.20 \\
& 2.52
\end{aligned}
$$2.532.30

2.07
22.361.922.621.422.081.882.062.831.931.89
2.09

    2.94
    1.971.922.28
1.871.871.932.06
2.12
2.05
2.22
2.04
1.92
2.29
1.96
2.231.442.212.172.342.112.342300621.81230063232230065.99

| SMI | Hospital | SMI |
| :---: | :---: | :---: |
| 2.68 | 220135 | 2.20 |
| 1.67 | 220162 | 1.56 |
| 2.19 | 220163 | 1.59 |
| 2.31 | 220171 | 1.62 |
| 2.13 | 222000 | 1.54 |
| 2.43 | 222002 | 1.04 |
| 1.82 | 222006 | 1.10 |
| 2.13 | 222008 | 0.98 |
| 2.01 | 222024 | 2.57 |
| 2.35 | 222026 | 1.01 |
| 1.85 | 222027 | 1.01 |
| 2.02 | 222029 | 1.24 |
| 2.15 | 222035 | 1.30 |
| 1.57 | 222041 | 0.45 |
| 1.87 | 222043 | 1.10 |
| 2.15 | 222044 | 1.10 |
| 2.37 | 223026 | 1.14 |
| 2.07 | 223027 | 1.49 |
| 2.29 | 223028 | 1.62 |
| 2.16 | 223029 | 1.05 |
| 2.57 | 223030 | 1.52 |
| 2.46 | 223032 | 1.26 |
| 2.20 | 223302 | 1.99 |
| 2.52 | 224007 | 1.75 |
| 2.08 | 224018 | 1.64 |
| 2.05 | 224021 | 1.54 |
| 2.53 | 224022 | 2.67 |
| 2.30 | 224034 | 1.57 |
| 2.07 | 224035 | 1.31 |
| 2.36 | 230001 | 1.98 |
| 1.78 | 230002 | 3.04 |
| 2.16 | 230003 | 1.99 |
| 2.33 | 230004 | 2.85 |
| 1.92 | 230005 | 2.32 |
| 2.62 | 230006 | 2.20 |$\begin{array}{llll}2.31 & 220171 & \text {............................................................................................ } & 1.62 \\ 2.13 & 222000\end{array}$

2.43
2.15$\begin{array}{ll}224018 \text {.............................................................. } & 1.75 \\ 1.64\end{array}$
2.051.78230002 .............................................. 3.04
2.33

## Addendum G.-Service Mix Indices by Hospital-Continued

230007 ............................................................. $\quad 2.20$
2.85
1.22
1.22
2.28
2.28
2.20
2.90
3.09
3.32
3.02
2.25
1.97
2.37
2.37
2.80
2.80
2.57
3.42
2.13
2.21
2.21
2.62
2.62
2.46
2.97
2.66
2.56
2.04
2.04
2.04
3.03
1.46
2.58
2.07
1.77
2.77
3.12
3.12
2.39
1.78
2.18
2.69
2.62

Addendum G.-Service Mix Indices by Hospital-Continued


## Addendum G.-Service Mix Indices By Hospital-Continued

| Hospital | SMI |
| :--- | :--- |


| 230172 | 1.86 |
| :---: | :---: |
| 230174 | 2.13 |
| 230175 | 1.55 |

230176 ........................................................... 2.96
230178
230180
230184
230188
230189
230190 ..
230191
230194
230195
230197.
230199
230201
230204
230205 ...
230207 ..
230208 ..
230212 .
230213.
230216.
230217 ...
230219
230222 ..
230223 .
230230.
230232 ...
230236 ...
230239 ..
230241
230244 ..
230253.
230254
230257
230259
230269
230270
230273
230275
230276
230277
230278
230279
230280 ..
233025 .
233026 ...
233027 .
233300
234006
234011.
234030
240001
240002
240004
240005
240006
240007
240008
$\begin{array}{ll}72 & 240010 \\ 61 & 240011\end{array}$
240011
2.58

Addendum G.-Service Mix Indices by Hospital-Continued

| Hospital | SMI |
| :---: | :---: |
| 240013 ..................................................... | 2.49 |

240014 ............................................. $\quad 2.65$
2.96240017 ............................................................. 3.88
1.91240018 ....................................................................... 3.20
2.02240019 ................................................................... 2.20
$\begin{array}{llll}5.45 & 240020 & \text {................................................................................. } & 1.94 \\ 1.92 & 240021\end{array}$
2.38240022 ....................................................................... 2.29

| 1.41 | 240023 | ............................................................................................ | 2.01 |
| :--- | :--- | :--- | :--- |
| 1.28 | 240025 |  |  |

    \(\begin{array}{llll}1.28 & 240025 & \text {.................................................................. } & 2.01 \\ 2.01 & 240027 & 2.68\end{array}\)
    2.22240028 ........................................................................ 2.16
    
3.63240031 ................................................... 2.26
$\begin{array}{lll}2.25 & 240036 & \text {......................................................................................... } \\ 2.58 & 240037 & 1.93\end{array}$
$2.72{ }^{240038}$.............................................................................. $\quad 1.93$

$\begin{array}{llll}2.22 & 240041 & \text {............................................................................ } & 2.49 \\ 2.41 & 240043 \\ & \text { and }\end{array}$
0.91240044 ................................................. 2.56
$\begin{array}{lll}2.15 & 240045 & \text {............................................................................................. } \\ 1.35 & 240047 & 3.16\end{array}$
2.08240048 ............................................................................ 3.81


| 2.46 | 240050 | $\ldots . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ~$ |
| :--- | :--- | :--- |

    2.66240052 ............................................... 2.17
    2.86240053 ................................................ 3.27
    \(\begin{array}{ll}240056 & 240 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ~ \\ 3\end{array}\)
    \begin{tabular}{lll}
    2.88 \& 240057 \& .............................................................................. <br>
1.16 \& 240058 \& 1.44 <br>
\hline
\end{tabular}

    2.24240059 .............................................. 3.44
    \begin{tabular}{lll|l}
    2.79 \& 240061 \& ......................................................................................... \& 4.55 <br>
2.40 \& 240063
\end{tabular}

    \(\begin{array}{lll}2.48 & 240063 & \text {.......................................................................... } \\ 240064 & 2.66 \\ & 3\end{array}\)
    2.53 240065 …....................................................................... 1.73
    
5.56240071 ............................................. 2.37
2.83240072 ................................................. 2.79
3.02240073 .............................................. 1.65

| 2.85 | 240075 | .............................................................................................. | 2.75 |
| :--- | :--- | :--- | :--- |
| 3.10 | 240076 |  |  |

    1.95240077 ............................................. \(\quad 2.34\)
    \(\begin{array}{ll}1.90 & 240078 \\ 1.34 & 240079 \text {................................................................................. } \\ & 3.66 \\ 1.91\end{array}\)
    \begin{tabular}{lll}
    1.31 \& 240079 \& ............................................................................ <br>
2.81 \& 1.91 <br>
\hline
\end{tabular}

    1.84240082 .............................................. 1.86
    1.59240083 ............................................... 2.36
    \(\begin{array}{llll}2.00 & 240084 & \text {............................................. } & 2.83 \\ 1\end{array}\)
    \(\begin{array}{llll}1.26 & 240085 & \text {................................................................... } & 1.53 \\ 1.09 & 240086 & 2.09\end{array}\)
    1.24240087 ........................................... 2.23
    3.39240088 ................................................ 1.90
    1.63240089 ............................................. 1.37
    \(\begin{array}{llll}1.71 & 240090 & \text {............................................................................................. } & 39 \\ 1.46 & 240093\end{array}\)
    1.64240094 .............................................. 1.66
    3.26240096 ......................................................... 1.46
    2.84240097 .............................................. 6.54
    1.30240098 ................................................ 2.05
    1.12240099 ............................................... 1.53
    2.89240100 ............................................. 2.83
    2.92240101 .............................................. \(\quad 2.00\)
    2.88240102 ............................................. 1.70
    1.53240103 .................................................. 1.87
    \(\begin{array}{ll}3.69 & 240104 \text {.............................................. } \\ 2.58 & 240105\end{array}\)
    1.33
    Addendum G.-Service Mix Indices by Hospital-Continued

|  | SMI |
| :---: | :---: |
| 240106 | 1.44 |
| 240107 | 1.69 |
| 240108 | 2.55 |
| 240109 | 1.82 |
| 240110 | 2.39 |
| 240111 | 2.28 |
| 240112 | 1.98 |
| 240114 | 1.84 |
| 240115 | 3.13 |
| 240116 | 1.61 |
| 240117 | 1.29 |
| 240119 | 1.19 |
| 240121 | 1.94 |
| 240122 | 1.45 |
| 240123 | 2.37 |
| 240124 | 2.36 |
| 240125 | 1.91 |
| 240127 | 2.25 |
| 240128 | 2.55 |
| 240129 | 2.38 |
| 240130 | 3.06 |
| 240132 | 2.75 |
| 240133 | 3.45 |
| 240137 | 3.54 |
| 240138 | 1.42 |
| 240139 | 2.01 |
| 240141 | 2.49 |
| 240142 | 1.80 |
| 240143 | 1.54 |
| 240144 | 2.78 |
| 240145 | 1.37 |
| 240146 | 2.11 |
| 240148 | 1.64 |
| 240152 | 2.60 |
| 240153 | 1.82 |
| 240154 | 1.44 |
| 240155 | 2.59 |
| 240157 | 2.46 |
| 240160 | 2.58 |
| 240161 | 1.77 |
| 240162 | 2.16 |
| 240163 | 1.89 |
| 240166 | 3.66 |
| 240169 | 2.39 |
| 240170 | 1.83 |
| 240171 | 2.87 |
| 240172 | 2.01 |
| 240173 | 2.63 |
| 240179 | 1.84 |
| 240184 | 1.71 |
| 240187 | 3.42 |
| 240193 | 2.12 |
| 240200 | 0.91 |
| 240207 | 2.75 |
| 240210 | 2.78 |
| 240211 | 1.04 |
| 242004 | 1.59 |
| 243300 | 1.41 |
| 243301 | 1.45 |
| 243302 | 6.10 |
| 244009 | 3.31 |
| 250001 | 2.17 |
| 250002 | 1.57 |
| 250003 | 1.07 |
| 250004 | 2.27 |
| 250005 | 0.94 |
| 250006 | 2.22 |
| 250007 | 1.98 |
| 250008 | 1.07 |
| 250009 | 2.99 |
| 250010 | 1.62 |

## Addendum G.-Service Mix Indices by Hospital-Continued

| Hospital | SMI |
| :---: | :---: |
| 250012 | 1.46 |
| 250015 | 2.25 |
| 250017 | 1.36 |
| 250018 | 0.66 |
| 250019 | 2.28 |


| Hospital | SMI |
| :---: | :---: |
| 250012 | 1.46 |
| 250015 | 2.25 |
| 250017 | 1.36 |
| 250018 | 0.66 |
| 250019 | 2.28 |

250015 ............................................... 2.25
$\begin{array}{ll}250017 \text {........................................................................................... } & 1.36 \\ 250018\end{array}$
250019
250020
250021
250023
250024
250025
250027
250029
250030
250031
250032
250033
250034
250035
250036
250037
250039
250040
250042
250043
250044
250048
250049
250050
250051
250057
250058
250059
250060
250061
250063
250065.
250066
250067 ...
250068
250069
250071
250072.
250076
250077.
250078
250079
250081
250082
250083
250084
250085
250088
250089
250093
250094
250095
250096
250097
250098
250099.
250100
250101
250102
250104 ...
250105
250107
250109
250112
250117 ...

Addendum G.-Service Mix Indices by Hospital-Continued

| Hospital | SMI |
| :--- | :--- |

2.28
1.40

| 0.75 | 250126 | ................................................................ | 2.27 |
| :--- | :--- | :--- | :--- |
| 0.70 | 250128 |  |  |



|  |
| :---: |
| 0136 |
| 250138 |



| 1.06 | 250145 | .................................................................................. |
| :--- | :--- | :--- |

$\begin{array}{llll}2.52 & 250146 & \text {........................................................................................... } & 1.31 \\ 1.96 & 250148 \\ 170 & 250149 & \end{array}$
1.70250149 ............................................. $\quad 1.26$
$\begin{array}{lll}3.67 & 252003 & \text {........................................................................................... } \\ 1.84 & 253025 & 1.93\end{array}$
1.88254001 ...................................................................... 1.55
$\begin{array}{ll}1.50 & 254002 \\ 135 & 260001 \\ 1\end{array}$

| 1.35 | 260001 | ................................................. |
| :--- | :--- | :--- |
| 1.02 | 260002 | 2.41 |
| ..............................$~$ | 2.38 |  |

2.53260003 .............................................. $\quad 1.52$

| 2.37 | 260004 | ................................................................................................. | 260005 |
| :--- | :--- | :--- | :--- |

1.99260006 ................................................. 2.13

| 1.77 | 260008 |
| :--- | :--- |
| 3 | ................................................ | 1.17


2.13260012 ............................................. 1.48
1.22260013 ............................................. 2.16
$\begin{array}{ll}2.41 & 260014 \\ 2 & \text {............................................. } \\ 260015 & 2.52 \\ 2 .\end{array}$
$\begin{array}{lll}1.87 & 260017 & \text {............................................................... } \\ 2.87\end{array}$
1.04260018 ............................................ 1.11
1.51260019 ............................................. 1.77
1.43260020 .............................................. 2.41
$\begin{array}{llll}1.46 & 260021 & \text {................................................................... } & 2.14 \\ 1.13 & 260022 & 2.47\end{array}$
1.45260023 ............................................. $\quad 2.33$

1.19260027 ........................................................................ 2.51
2.38260029 ............................................. $\quad 2.18$
$\begin{array}{lll}0.67 & 260030 & \text {.............................................................................................. } \\ 1.38 & 260031\end{array}$
2.73260032 ............................................. $\quad 2.44$
$\begin{array}{llll}1.17 & 260034 & \text {............................................................................................ } & 1.35 \\ 3.27 & 260035\end{array}$
2.32260036 ...................................................................... $\quad 1.87$
1.27260039 .............................................. 1.61
2.89260040 ............................................. $\quad 2.57$
1.35260044 ............................................. 1.97

| 1.70 | 260048 .................................................................. |
| :--- | :--- |

1.88260050 ….......................................... 2.60
3.86260052 ............................................... $\quad 2.22$
2.03260053 ............................................. 1.82
$\begin{array}{lll}1.97 & 260054 & \text {.................................................................. } \\ 2.14 & 260055 \text {............... } & 1.72\end{array}$
1.33260057 .............................................. 1.70
3.06260059 .............................................. 2.45
2.80260061 ............................................ 2.72
$\begin{array}{ll}1.10 & 260062 \text {.............................................................................................. } \\ 2.82 & 260063 \text {........... }\end{array}$
3.29260064 ............................................... 2.46
$\begin{array}{ll}1.35 & 260065 \text {.............................................. } \\ 260066 & 2.51 \\ 1.99\end{array}$
1.25260067 ............................................................................ 1.26
1.25260068 ............................................. $\quad 2.91$

Addendum G.-Service Mix Indices by Hospital-Continued

|  | SMI |
| :---: | :---: |
| 260073 | 1.81 |
| 260074 | 1.74 |
| 260077 | 2.60 |
| 260078 | 2.61 |
| 260079 | 1.56 |
| 260080 | 2.08 |
| 260081 | 2.08 |
| 260082 | 1.60 |
| 260085 | 2.75 |
| 260086 | 1.77 |
| 260091 | 2.98 |
| 260094 | 2.39 |
| 260095 | 2.22 |
| 260096 | 3.19 |
| 260097 | 3.14 |
| 260100 | 1.86 |
| 260102 | 1.11 |
| 260103 | 1.96 |
| 260104 | 2.36 |
| 260105 | 2.69 |
| 260107 | 3.54 |
| 260108 | 2.38 |
| 260109 | 2.03 |
| 260110 | 2.51 |
| 260113 | 2.30 |
| 260115 | 1.73 |
| 260116 | 2.40 |
| 260119 | 2.68 |
| 260120 | 2.17 |
| 260122 | 2.04 |
| 260123 | 1.31 |
| 260127 | 1.90 |
| 260128 | 1.42 |
| 260129 | 2.18 |
| 260131 | 2.05 |
| 260134 | 2.38 |
| 260137 | 3.09 |
| 260138 | 2.50 |
| 260141 | 2.03 |
| 260142 | 2.64 |
| 260143 | 1.28 |
| 260147 | 1.76 |
| 260148 | 1.29 |
| 260158 | 1.69 |
| 260159 | 2.08 |
| 260160 | 1.74 |
| 260162 | 2.75 |
| 260163 | 1.89 |
| 260164 | 1.69 |
| 260166 | 2.33 |
| 260172 | 2.00 |
| 260173 | 1.31 |
| 260175 | 2.92 |
| 260176 | 2.60 |
| 260177 | 3.33 |
| 260178 | 3.53 |
| 260179 | 2.42 |
| 260180 | 2.28 |
| 260183 | 2.77 |
| 260186 | 2.66 |
| 260188 | 2.21 |
| 260189 | 0.89 |
| 260190 | 2.65 |
| 260191 | 2.69 |
| 260193 | 2.34 |
| 260195 | 2.21 |
| 260197 | 2.35 |
| 260198 | 2.50 |
| 260200 | 1.98 |
| 262001 | 1.00 |
| 262011 | 0.81 |

0.81

## Addendum G.-Service Mix Indices by Hospital-Continued

| Hospital | SMI |
| :--- | :--- |



263300
263301.

264004
264005
264008
264011 ...
264017 .
264021.

264024 ..
270003.

270004 .
270006 ..
270007 ..
270011 270012 .
270013 .
270014 .
270016 ..
270017 ..
270021 ..
270023 ..
270024 .
270026 ..
270027 .
270029 .
270032 ...
270035 ..
270036 .
270039 ..
270040 ..
270044 ..
270046
270048 ..
270049 ..
270050.

270051 ..
270053 ..
270057 .
270058 ..
270059 .
270063 .
270068 .
270072 .
270073 .
270079 ..
270081 .
270082 ..
270083
270084
271226
271228
271229
271231.

271232
271234
280001

## Addendum G.-Service Mix Indices by Hospital-Continued

| Hospital | SMI |
| :---: | :---: |
| 280005 ........................................ | 2.57 |


| 1.49 | 280005 | .............................................. |
| :--- | :--- | :--- |
| 2.37 | 280009 | 2.57 |
| 1.85 | $280010 . \ldots . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ~$ | 3.51 |
| 1.7 | 1.15 |  |

1.61280011 ................................................ 1.53
$\begin{array}{llll}1.62 & 280012 & \text {..................................................................... } & 2.09 \\ 0.98 & 280013 & 2.00\end{array}$

| 0.98 | 280014 | .......................................................................................... | 1.81 |
| :--- | :--- | :--- | :--- |
| 0.98 | 280015 |  |  |

1.51280017 ........................................................................ 1.92

| 2.48 | 280018 | ............................................................................................. |
| :--- | :--- | :--- |
| 1.84 | 280020 |  |


$\begin{array}{lll}1.55 & 280022 & \text {.................................................................................................. } \\ 2.36 & 280023 & \\ 2.78\end{array}$

$\begin{array}{llll}3.29 & 280025 & \text {.................................................................. } & 1.09 \\ 0.62 & 280026 & 1.69\end{array}$

| 1.03 | 280028 |
| :--- | :--- |
| 1.65 | 280029 |
| ................................................................................................... | 26 |


| 1.64 | 280030 | ................................................................. |
| :--- | :--- | :--- |
| 3.44 | 2.19 |  |
| .280031 |  |  |

$\begin{array}{lll}3.67 & 280032 \text {............................................................... } & 1.42 \\ 3.03\end{array}$
$\begin{array}{llll}3.11 & 280033 & \text {.................................................................................................... } & 284\end{array}$
2.02280035 .............................................................. 1.59

| 1.17 | 280037 | ............................................................................................. | 21 |
| :--- | :--- | :--- | :--- |
| 1.95 | 280038 | 2.20 |  |

2.88280039 …......................................................................... 2.21

| 1.06 | 280040 | .............................................. | 3.15 |
| :--- | :--- | :--- | :--- |
| 1.72 | 280041 | 1.34 |  |

$\begin{array}{ll}1.40 & 280042 \text {......................................................................... } \\ 1.26 \\ & 1.27\end{array}$

| 2.43 | 280043 |
| :--- | :--- |
| $1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ~$ | 1.87 |


0.91280047 …......................................... 2.12

| 1.65 | 280048 | ............................................. | 1.58 |
| :--- | :--- | :--- | :--- |
| 1.13 | 280049 |  |  |

1.94280050 ............................................................................... $\quad 1.15$
1.88280051 ................................................ 2.61

| 1.49 | 280052 | ............................................................................................. | 2.00 |
| :--- | :--- | :--- | :--- |
| 2.58 | 280054 |  |  |

1.26280055 ............................................. 1.75
1.91280056 ................................................... 1.45
1.88280057 .............................................. 1.69
$\begin{array}{ll}1.95 & 280058 \text {............................................................................................... } \\ 2.84 & 280060 \\ & 2.26\end{array}$
1.06280061 ............................................. 3.72
0.98280062 ............................................. $\quad 1.90$
2.29280064 ............................................... 2.28

| 1.70 | 280065 | ............................................................................................ |  |
| :--- | :--- | :--- | :--- |
| 0.71 | 280066 |  |  |

$\begin{array}{llll}0.71 & 280066 & \text {................................................................... } & 1.67 \\ 1.01 & 280068 & 1.42\end{array}$
$\begin{array}{ll}1.17 & 280070 \\ 2 & 285 \\ 280073 & . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ~ \\ 2.01 \\ 1.79\end{array}$
$\begin{array}{llll}1.25 & 280073 & \ldots . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ~ & 1.63 \\ 0.64 & 280074 & \end{array}$
1.28280075 ............................................... 2.76
1.52280076 ............................................... 1.80
2.01280077 ............................................. 2.61
1.07280079 ............................................. $\quad 1.19$

| 1.01 | 280080 |
| :--- | :--- |
| 1.36 | $280081 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ~$ |

1.59280082 ........................................................................... $\quad 1.53$
0.72280083 .............................................. 1.88

| 1.06 | 280084 | .............................................................................................. |  | 2.61 |
| :--- | :--- | :--- | :--- | :--- |
| 0.89 | 280085 |  |  |  |

1.04280088 ................................................ 3.10

| 1.00 | 280089 .............................................. |
| :--- | :--- |
| 0 | 1.91 |
| 1.24 |  |

$\begin{array}{lll}1.94 & 280090 & \ldots . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ~\end{array} 124$
$\begin{array}{llll}1.56 & 280092 & \text {........................................................................................... } & 1.65 \\ 2.04 & 280094\end{array}$

Addendum G.-Service Mix Indices
by Hospital-Continued

| Hospital | SMI |
| :---: | :---: | | $280097 \ldots$ |
| :--- |
| $280098 \ldots$ |
| $280101 \ldots$ |
| $280102 \ldots$ |
| $280104 \ldots$ |
| $280105 \ldots$ |
| $280106 \ldots$ |
| $280107 \ldots$ |
| $280108 \ldots$ |
| $280109 \ldots$ |
| $280110 \ldots$ |

280114. 

280115
280117.

280125
283301
284007
290001
290003
290005
290007
290008
290009
290011
290012
290013
290015
290016 ..
290020 ..
290021
290027
290032
290038
290039
293027
294003
294005
300001
300003
300006
300007
300009
300010
300011
300013
300014
300015
300016
300018
300019 300022 300023 300028 300029 300033
1.57
1.09
1.12
1.09
1.60
1.60
1.97
2.63
2.63
2.20
1.20
2.61
2.61
2.00
1.49
2.04
2.23
1.79
2.66
1.13
2.66
1.13
3.09
2.20
0.80
2.93
2.93
3.18
1.70
.70
1.48
2.80
2.15
2.20
1.11
2.61
1.04
2.15
$\begin{array}{ll}1.38 & 310 \\ 2.15 & 3100\end{array}$
$\begin{array}{ll}2.15 & 3100 \\ 2.42 & 3100\end{array}$
$\begin{array}{ll}2.42 \\ 2.94 & 31\end{array}$
$\begin{array}{ll}2.36 & 31 \\ 2.77 & 31\end{array}$
$\begin{array}{ll}2.77 & 3100 \\ 127 & 3100\end{array}$
2.343
1.7031
2.603
1.01310
$\begin{array}{ll}2.09 & 3 \\ 1.57 & 3\end{array}$
$1.56 \quad 3$
2.31310
2.653100
1.8031
$2.43 \quad 310$
.57
2.44
.10
1.75
2.21
1.65
2.30
2.49
2.08
1.97
2.48
2.25
1.87
2.33
1.99
2.11
1.65
2.86
1.52
2.17310006

## Addendum G.-Service Mix Indices by Hospital-Continued <br> Addendum G.-Service Mix Indices by Hospital-Continued

| Hospital | SMI |
| :--- | :--- |

3.91310008 .

310009
10010.

310013
310015.
310016.

310017 .
310018 ..
10020
310021 ..
10024 ..
10025.

310026 ..
310027 .
310029 ..
10031 ..
10034 ...
10036 ..
10037.

10041 ..
10043.

10044
10047 ...
10050 ...
10051 .
10054 ..
10056 .. 10057. 10060 .. 10063 10064 310069 310070 310072 .. 310074 .. 310076
310077 310078 310081 310083 310086 310088 310090 310091 310092 310093 310105

Addendum G.-Service Mix Indices by Hospital-Continued

| Hospital | SMI |
| :---: | :---: |
| 310111 .............................................. | 2.02 |

0.47310112 ..................................................... $\quad 2.02$

| 11.15 | 310113 | .......................................................... |
| ---: | ---: | ---: |
| 1.55 | 310115 | 2.47 |

1.98310116 .................................................................. 2.54
2.01310118 .................................................... 2.36
2.33 310120 .............................................. 1.73

2.59313026 ......................................................................... 1.19
1.99313027 .............................................. 1.24

| 2.95 | 313029 ............................................. $\quad 1.64$ |
| :--- | :--- | :--- |
| 1.2 |  |

2.30313030 ................................................... 1.05

| 2.52 | 314001 | $\ldots . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ~$ | 1.71 |
| :--- | :--- | :--- | :--- |

2.70314010 .............................................. 1.72
2.16314011 .................................................... 1.56
2.49314012 .............................................. 2.07

2.52320001 ................................................. 1.50
2.45320002 ................................................. 1.78
2.33320003 ................................................ 2.47
2.09320004 .............................................. 2.43
2.40320005 .............................................. 2.98

|  |  |
| :---: | :---: |
| 320009 |  |

2.24320011 .................................................. 1.76

1.93320014 .......................................................................... $\quad 1.79$
2.32320016 .............................................. 2.94

| 2.33 | 320018 | $\ldots \ldots \ldots . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ~$ |
| :--- | :--- | :--- |
| 2 | 2.03 |  |

2.58320019 ............................................. $\quad 1.21$

| 2.81 | 320021 | ............................................. |
| :--- | :--- | :--- |
| 2.19 | 1.80 |  |
| 320022 |  |  |

320022 ............................................. 3.20
2.62320030 …........................................................................ 2.00
2.55320031 ............................................... 1.27
1.91320032 .............................................. 1.44
2.79320033 ............................................. 2.26
2.08320035 .................................................. 1.18
2.34320037 ............................................. 2.32
$\begin{array}{lll}1.89 & 320038 & \text {.............................................................................................. } \\ 2.44 & 320046\end{array}$
1.31320048 .................................................... 1.53
$\begin{array}{lll}3.24 & 320063 & \text {.............................................. } \\ 220065 & 2.36 \\ 2.27\end{array}$
2.27320067 ........................................................................ $\quad 1.21$
2.39320068 ................................................ 2.33
2.57320069 .............................................. 1.96
2.66320074 ................................................. 2.12
2.43320079 ............................................... 2.29
2.98322002 .................................................. 3.05
1.92322003 .............................................. 0.68
1.47323027 ..................................................... 0.58
2.40323028 ................................................. 1.76
2.66323029 ................................................ 1.43
2.28324003 .............................................. $\quad 1.56$

| 2.40 | 324004 | ................................................................................................ | 1.68 |
| :--- | :--- | :--- | :--- | :--- |
| 1.69 | 324007 |  |  |

2.17324010 .............................................. 1.85
$\begin{array}{llll}2.33 & 330001 & \text {.......................................................................................... } & 2.13 \\ 1.84 & 330002\end{array}$
2.29330003 ............................................. 2.40
2.73330004 ................................................... 2.49
$\begin{array}{llll}2.38 & 330005 & \text {............................................................................ } & 2.32 \\ 230006 & & 2.27\end{array}$
2.69330007 ............................................... 2.26
1.47330008 ............................................................. 2.47

Addendum G.-Service Mix Indices by Hospital-Continued

|  | Hospital |
| :---: | :---: |
| 330010 |  |
| 330011 |  |
| 330012 |  |
| 330013 |  |
| 330014 |  |
| 330016 |  |
| 330023 |  |
| 330024 |  |
| 330025 |  |
| 330027 |  |
| 330028 |  |
| 330029 |  |
| 330030 |  |
| 330033 |  |
| 330034 |  |
| 330036 |  |
| 330037 |  |
| 330038 |  |
| 330039 |  |
| 330041 |  |
| 330043 |  |
| 330044 |  |
| 330045 |  |
| 330046 |  |
| 330047 |  |
| 330048 |  |
| 330049 |  |
| 330053 |  |
| 330055 |  |
| 330056 |  |
| 330057 |  |
| 330058 |  |
| 330059 |  |
| 330061 |  |
| 330062 |  |
| 330064 |  |
| 330065 |  |
| 330066 |  |
| 330067 |  |
| 330072 |  |
| 330073 |  |
| 330074 |  |
| 330075 |  |
| 330078 |  |
| 330079 |  |
| 330084 |  |
| 330085 |  |
| 330086 |  |
| 330088 |  |
| 330090 |  |
| 330091 |  |
| 330092 |  |
| 330094 |  |
| 330095 |  |
| 330096 |  |
| 330097 |  |
| 330100 |  |
| 330101 |  |
| 330102 |  |
| 330103 |  |
| 330104 |  |
| 330106 |  |
| 330107 |  |
| 330108 |  |
| 330111 |  |
| 330114 |  |
| 330115 |  |
| 330116 |  |
| 330118 |  |
| $330119$ |  |
|  |  |

Addendum G.-Service Mix Indices by Hospital-Continued

|  | Hospital |
| :---: | :---: |
| 340008 |  |
| 340010 |  |
| 340011 |  |
| 340012 |  |
| 340013 |  |
| 340014 |  |
| $340015$ |  |
|  |  |
| 340017 |  |
| 340018 |  |
| 340019 |  |
| 340020 |  |
| 340021 |  |
| 340022 |  |
| 340023 |  |
| 340024 |  |
| 340025 |  |
| 340027 |  |
| 340028 |  |
| 340030 |  |
| 340031 |  |
| 340032 |  |
| 340035 |  |
| 340036 |  |
| 340037 |  |
| 340038 |  |
| 340039 |  |
| 340040 |  |
| 340041 |  |
| 340042 |  |
| 340044 |  |
| 340045 |  |
| 340047 |  |
| 340049 |  |
| 340050 |  |
| 340051 |  |
| 340052 |  |
| $340053$ |  |
| $340054$ |  |
| 340055 |  |
| 340060 |  |
| 340061 |  |
| 340063 |  |
| 340064 |  |
| 340065 |  |
| 340067 |  |
| 340068 |  |
| 340069 |  |
| 340070 |  |
| 340071 |  |
| 340072 |  |
| 340073 |  |
| 340075 |  |
| 340080 |  |
| 340084 |  |
| 340085 |  |
| 340087 |  |
| 340088 |  |
| $340089$ |  |
| 340090 |  |
| 340091 |  |
| 340093 |  |
| 340094 |  |
| 340096 |  |
| 340097 |  |
| 340098 |  |
| 340099 |  |
| 340101 |  |
| 340104 |  |
| $340105$$340106$ |  |
|  |  |

.............................................

| Hospital | SMI |
| :---: | :---: |

340008
340010
340011
340012
340013
340014
340015
340016
340017
340018
340019
340020
340021
340022
340023
340024
340025
340027
340028
340030
340032
340036
340038
340039
340041
340044
340047
340050
340051
340053
340055
340061
340064
340065
340068
340070
340071
340073
340080
340085
340087 340089

340091
340093
340096
340098
340099
340101

340106
2.17
2.97
1.80
1.80
2.23
1.88
1.55
1.55
2.89
2.89
2.02
2.73
2.73
2.38
1.73
1.73
2.03
2.55
2.55
2.01
2.01
2.95
2.16
2.16
2.66
2.93
2.93
2.42
2.25
2.08
2.08
2.37
2.22
2.22
1.70
1.77
1.40
2.13
2.01
2.52
2.46
2.66
2.02
2.29
2.29
3.16
3.16
2.12
2.01
3.10
1.58
2.03
2.88
2.88
1.99
3.53
2.50
2.52
2.52
2.42
2.42
2.05
2.58
1.67
1.67
3.75
1.71

## Addendum G.-Service Mix Indices <br> by Hospital-Continued

| Hospital | SMI |
| :---: | :---: |

1.77340144 .
3.18340146 .
2.57340147 ...
2.88340148 ..
$\begin{array}{ll}1.93 & 340151 . . \\ 235 & 340153\end{array}$
$\begin{array}{ll}2.35 & 340153 \\ 1.73 & 340155\end{array}$
$\begin{array}{ll}1.73 & 340155 \text {.. } \\ 1.26 & 340158 \text {... }\end{array}$
$\begin{array}{ll}2.39 & 340159 \text {.. } \\ 7.04 & 340160 \text {.. }\end{array}$
2.41340164
2.60340166
1.84340171 .
3.14340173 .
2.59
1.98
342002.
$\begin{array}{ll}2.98 & 342003 \\ 2.27 & 342012\end{array}$
1.97343025
2.33
1.71350006
1.83350006
2.18350008

| Hospital | SMI |
| :--- | :--- |


| Hospital | SMI |
| :--- | :---: |
| 340107 ............................................. | 2.92 |

2.92
3.44

| 3.44 | 350027 | ........................................................................................................... | 1.36 |
| :--- | :--- | :--- | :--- |
| 2.10 | 350029 |  |  |

1.77350030 ......................................................................... 2.77

| 2.38 | 350033 | ................................................................. | 2.00 |
| :---: | :---: | :---: | :---: | :---: |
| 200 | 350034 |  |  |


| 2.00 | 350034 | $\ldots . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ~$ |
| :--- | :--- | :--- |
| 2.50 | 350035 | 1.89 |


| 2.50 | 350035 | ........................................................................... | 0.85 |
| :--- | :--- | :--- | :--- |
| 2.78 | 350038 | 2.02 |  |

2.31350039 ............................................................................ 2.08


| 2.15 | 350042 |
| :--- | :--- |
| ............................................ | 3.25 |


| 2.13 | 350043 | ......................................................................................... |
| :--- | :--- | :--- |
| 350044 | 1.70 |  |


| 2.61 | 350047 |
| :--- | :--- |
| $1 . \ldots 9$ | 350049 | ......................................... 1.95


| 1.99 | 350049 | .......................................................................................... |
| :--- | :--- | :--- |
| 2.51 | 350050 | 1.55 |


| 2.51 | 350050 |
| :---: | :---: |
| 2.48 | 350051 |2.04350055 ..................................................................... 1.22

2.73350058 .................................................. 1.712.77350061 .............................................. 2.56
2.45360002 ..................................................... 2.52
$3.033_{360006}$................................................................ 3.15

|  | 360008 |
| :---: | :---: |
|  | 3.95360009 |


| 2.38 | 360010 | ......................................................................................... | 2.00 |
| :--- | :--- | :--- | :--- |
| 2.82 | 360011 |  |  |2.47 360013 .................................................................... $\quad 2.27$2.10360016 ................................................................. 1.932.50360018 .............................................................................. $\quad 2.52$1.39360020 ......................................................................... 2.201.71360024 .............................................. 2.411.55360026 .............................................. 1.801.55360028 ........................................................................... 4.56| 1.55 | 360029 | .............................................................................. | 2.31 |
| :--- | :--- | :--- | :--- |
| 1.55 | 360030 | 2.4 |  |

3.66360032 ............................................... 2.593.95360035 ................................................................ 2.101.99360037 .............................................. 2.271.73360040 ............................................... 2.083.09360042 .............................................. 2.23

| 3.13 | 360045 | ................................................................ |
| :--- | :--- | :--- |


| 1.93 | 360047 ................................................................... | 1.34 |
| :--- | :--- | :--- |
| 2600 |  |  |$\begin{array}{ll}1.18 & 360049 \\ \text {........................................................... } & 2.31 \\ 26.78\end{array}$2.58360051 ........................................................... 3.04

3.33360052 ........................................................................... 2.41
1.45360054 ............................................ 2.70
2.55360055 ............................................ 2.55
2.01360056 ............................................. 2.63

Addendum G.-Service Mix Indices by Hospital-Continued

|  | Hospital |
| :---: | :---: |
| 360058 |  |
| 360059 |  |
| 360062 |  |
| 360063 |  |
| 360064 |  |
| 360065 |  |
| $360066$ |  |
| 360067 |  |
| 360068 |  |
| 360069 |  |
| 360070 |  |
| 360071 |  |
| 360074 |  |
| 360075 |  |
| 360076 |  |
| 360077 |  |
| 360078 |  |
| 360079 |  |
| 360080 |  |
| 360081 |  |
| 360082 |  |
| 360083 |  |
| 360084 |  |
| 360085 |  |
| 360086 |  |
| 360087 |  |
| 360088 |  |
| 360089 |  |
|  |  |
| 360091 |  |
| 360092 |  |
| 360093 |  |
| 360094 |  |
| 360095 |  |
| 360096 |  |
| 360098 |  |
| 360099 |  |
| 360100 |  |
| 360101 |  |
| 360102 |  |
| 360103 |  |
| 360106 |  |
| 360107 |  |
| 360108 |  |
| 360109 |  |
| 360112 |  |
| 360113 |  |
| 360114 |  |
| 360115 |  |
| 360116 |  |
| 360118 |  |
| 360121 |  |
| 360123 |  |
| 360125 |  |
| 360126 |  |
| 360127 |  |
| 360128 |  |
| 360129 |  |
| 360130 |  |
| 360131 |  |
| 360132 |  |
| 360133 |  |
| 360134 |  |
| 360136 |  |
| 360137 |  |
| 360140 |  |
| 360141 |  |
| 360142 |  |
| 360143 |  |
| 360144 |  |
| 360145 |  |

360145

SMI
2.16
1.67
2.77
1.73
2.65
2.22
2.59
1.77
2.50
1.86
2.00
2
2.21360161.
2.27360163
2.58360164 .
2.38360165 .
$\begin{array}{ll}2.63 & 360166 \\ 2.90 & 360170\end{array}$
$2.18 \quad 360172$
$2.32360174 \ldots$
2.84
2.23
2.47
2.81
2.46
2.34
1.96
2.20360185
3.47360186 ..
2.34360187 …
$\begin{array}{ll}1.84 & 360188 \\ 3.05 & 360189\end{array}$
2.00360192 ..
2.72360193 ...
$\begin{array}{ll}2.37 & 360194 . . \\ 3.04 & 360195 \text {.. }\end{array}$
2.32360197
$\begin{array}{ll}2.58 & 360200 \\ 3.13 & 360203\end{array}$
2.70360204 ..
2.15360210 ...
1.68360211 .
2.19360212 ..
$\begin{array}{ll}1.72 & 360213 . \\ 2.35 & 360218 .\end{array}$
2.63360230 ...
2.64360231
2.18360234 ...
$\begin{array}{ll}2.16 & 360236 \\ 1.88 & 360239\end{array}$.
2.26360241 ..

| 2.88 | 360242. |
| :--- | :--- |
| 260243. |  |

1.75360244
1.92360245 ...
2.27362004 ..
1.65
1.77
2.00
$2.43 \quad 363300$
2.66363303
2.53363305
1.62363306.
2.29364003.
$1.73 \quad 364017$

| 2.77 | 364029 |
| :--- | :--- |
| 1 | 99 |

$\begin{array}{ll}1.99 & 364038 \\ 2.23 & 370001\end{array}$
2.68370002
2.60

## Addendum G.-Service Mix Indices by Hospital-Continued

Hospital $\quad$ SMI

| Hospital | SMI |
| :---: | :---: |
| 360147 ................................ | 227 |

2.27
2.21
2.65
3.15
3.15370008 ….......................................... 1.79

| 3.60 | 370008 |
| :--- | :--- |
| .............................................. | 2.75 |


| 2.60 | 370011 | ........................................................................................ | 1.29 |
| :--- | :--- | :--- | :--- |
| 2.65 | 370012 |  |  |

1.88370013 …........................................... 2.96
1.61370014 .................................................. 2.86
2.64370015 .............................................. 1.85

| 2.36 | 370016 | ............................................................................................ | 2.53 |
| :--- | :--- | :--- | :--- |
| 2.16 | 370017 |  |  |

2.35370018 ................................................................... 3.22
$\begin{array}{ll}1.75 & 370019 \\ 290 & 370020 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ~ \\ 2.37\end{array}$
1.72370021 .............................................................................. 1.40
1.84370022 .............................................. 2.97

2.93370026 ....................................................................... 3.08
$\begin{array}{llll}2.57 & 370028 & \text {............................................. } & 3.11 \\ 258 & 370029 & & 3.1\end{array}$
$\begin{array}{lll}2.58 & 370029 & \text {................................................. } \\ 1.80 & 370030 & 2.34 \\ 1.52 & 37003 . . . . . . . . . . . . . . . . . . . . . . . . . . . ~ & 1.95\end{array}$
$\begin{array}{llll}1.52 & 370032 & \ldots . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ~\end{array}$
2.31370034 ....................................................................... 2.57

| 2.68 | 370035 | ................................................................................................ | 0.76 |
| :--- | :--- | :--- | :--- |
| 1.65 | 370036 |  |  |

1.85370037 .............................................. 3.69
1.54370038 .............................................. 1.47
2.58370039 .............................................. 1.91
$\begin{array}{llll}1.82 & 370040 & \text {......................................................................................... } & 3.03 \\ 2.44 & 370041\end{array}$
2.28370042 ....................................................................... 1.40
2.49370043 ............................................. $\quad 1.12$
$\begin{array}{lllll}2.25 & 370045 & \text {...................................................................... } & 1.56 \\ 2.67 & 370046 & \text {...................... }\end{array}$
1.98370047 ............................................. $\quad 2.41$

| 1.78 | 370048 | ............................................................................................. | 1.96 |
| :--- | :--- | :--- | :--- |
| 2.43 | 370049 |  |  |

1.94370051 …........................................... 1.31
$\begin{array}{llll}2.67 & 370054 & \ldots . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ~ & 2.51 \\ 2.20 & 370056 & & \end{array}$

2.01370059 ............................................... 1.02
2.40370060 ............................................. $\quad 2.17$
2.88370063 .............................................. 1.38
$\begin{array}{lllll}1.46 & 370064 & \text {............................................................................................. } & & 1.45 \\ 2.16 & 370065 & \end{array}$
2.41370071 ................................................. 1.48

| 2.61 | 370072 | ........................................................................................ | 1.33 |
| :--- | :--- | :--- | :--- |
| 1.27 | 370076 |  |  |

1.72370077 .............................................. 1.96

| 1.55 | 370078 |
| :--- | :--- |
|  | ............................................. |$\quad 370070$

$\begin{array}{ll}1.58 & 370080 \\ & \text {......................................................................... } \\ 1.83\end{array}$
1.97370082 ............................................... 1.29

7.33370085 ...................................................................... 1.79
1.48370086 ........................................................ 2.26
1.97370089 ............................................... 2.25

$\begin{array}{llll}1.94 & 370092 & \text {............................................................................................ } & 41 \\ 1.34 & 370093\end{array}$
1.64370094 .............................................. 3.00
1.97370095 ............................................. 1.37
1.64370097 ............................................. $\quad 2.07$
3.25370100 ............................................................................... $\quad 1.27$
2.74370103 ............................................. 1.60

Addendum G.-Service Mix Indices by Hospital-Continued

|  | SMI |
| :---: | :---: |
| 370106 | 4.05 |
| 370108 | 1.62 |
| 370112 | 1.52 |
| 370113 | 2.06 |
| 370114 | 3.04 |
| 370121 | 2.51 |
| 370122 | 0.92 |
| 370123 | 2.45 |
| 370125 | 1.86 |
| 370126 | 1.38 |
| 370131 | 1.27 |
| 370133 | 1.83 |
| 370138 | 2.30 |
| 370139 | 1.62 |
| 370140 | 1.92 |
| 370141 | 1.89 |
| 370146 | 2.19 |
| 370148 | 2.26 |
| 370149 | 2.90 |
| 370153 | 2.47 |
| 370154 | 2.61 |
| 370156 | 2.47 |
| 370158 | 1.66 |
| 370159 | 2.44 |
| 370163 | 1.25 |
| 370166 | 1.99 |
| 370169 | 1.88 |
| 370176 | 2.14 |
| 370177 | 1.53 |
| 370178 | 2.10 |
| 370179 | 1.49 |
| 370183 | 2.08 |
| 370186 | 2.55 |
| 370190 | 2.49 |
| 370192 | 2.87 |
| 372004 | 0.74 |
| 373025 | 0.87 |
| 373026 | 1.03 |
| 374008 | 1.84 |
| 374012 | 1.50 |
| 374013 | 1.36 |
| 374020 | 1.63 |
| 380001 | 2.80 |
| 380002 | 3.93 |
| 380004 | 3.63 |
| 380005 | 5.17 |
| 380006 | 2.75 |
| 380007 | 3.08 |
| 380008 | 1.66 |
| 380009 | 2.18 |
| 380010 | 1.76 |
| 380011 | 2.28 |
| 380013 | 1.59 |
| 380014 | 2.69 |
| 380017 | 3.80 |
| 380018 | 2.58 |
| 380019 | 1.83 |
| 380020 | 3.61 |
| 380021 | 2.54 |
| 380022 | 2.71 |
| 380023 | 2.43 |
| 380025 | 2.73 |
| 380026 | 2.33 |
| 380027 | 1.96 |
| 380029 | 2.14 |
| 380031 | 1.63 |
| 380033 | 3.16 |
| 380035 | 2.96 |
| 380036 | 2.44 |
| 380037 | 2.28 |
| 380038 | 2.93 |

## Addendum G.-Service Mix Indices by Hospital-Continued

| Hospital | SMI |
| :---: | :---: |


| 380039 | 1.89 |
| :---: | :---: |
| 380040 | 2.17 |
| 380042 | 1.8 |

Addendum G.-Service Mix Indices by Hospital-Continued

| Hospital | SMI |
| :---: | :---: |
| 390047 .............................................. | 2.50 |

2.17390048 .............................................. 2.31

| 1.87 | 390049 | .............................................................................................. |
| :--- | :--- | :--- |
| 3.63 | 390050 | 3.05 |

2.14390051 .............................................. 2.65

| 2.51 | 390054 |
| :--- | :--- | .............................................. $\quad 1.97$


| 2.57 | 390056 | ...................................................................... |
| :--- | :--- | :--- |
| 20051 | 2.07 |  |$\begin{array}{llll}1.51 & 390057 & \text {................................................................. } & 2.39 \\ 2.44 & 390058 & 3.14\end{array}$0.92390061 ............................................................... 2.26

1.96390063 .......................................................................... 35
1.84390065 …................................................. 2.31
1.49390067 ................................................................... 2.55
1.93390069 ............................................................. 2.13
3.341.771.77
3.14
1.850.99390074 ........................................................... 2.2 .6
2.442.442.422.32
2.732.731.632.472.56.742.56
2.282.28
1.651.19
1.941.94
2.49
2.64
2.542.84............................................
2.14390109 ......................................................... 1.55 233901111.931.753.141.031.963.012.74390119 ............................................. 2.51
2.193901212.123901222.283901232.563901252.573901272.74390128$\begin{array}{ll}2.41 & 390130 \\ 1.90 & 390131\end{array}$2.863901322.29390133
3901352.65390136$1.97-390138$2.492.49
2.332.352.312.51
2.472.47
2.042.04
2.992.332.58
2.85
2.18
2.602.082.68

Addendum G.-Service Mix Indices by Hospital-Continued

|  | Hospital | SMI |
| :---: | :---: | :---: |
| 390139 |  | 2.58 |
| 390142 |  | 1.93 |
| 390145 |  | 2.38 |
| 390146 |  | 2.04 |
| 390147 |  | 2.44 |
| 390150 |  | 1.94 |
| 390151 |  | 2.55 |
| 390153 |  | 1.96 |
| 390154 |  | 2.36 |
| 390155 |  | 1.31 |
| 390156 |  | 2.51 |
| 390157 |  | 2.50 |
| 390158 |  | 2.42 |
| 390160 |  | 2.91 |
| 390161 |  | 2.26 |
| 390162 |  | 2.25 |
| 390163 |  | 2.38 |
| 390164 |  | 2.12 |
| 390166 |  | 1.76 |
| 390167 |  | 2.18 |
| 390168 |  | 2.13 |
| 390169 |  | 3.11 |
| 390173 |  | 2.08 |
| 390174 |  | 2.42 |
| 390176 |  | 2.22 |
| 390178 |  | 2.55 |
| 390179 |  | 2.33 |
| 390180 |  | 2.38 |
| 390181 |  | 2.39 |
| 390183 |  | 2.61 |
| 390184 |  | 1.63 |
| 390185 |  | 2.85 |
| 390189 |  | 2.30 |
| 390191 |  | 3.17 |
| 390192 |  | 2.03 |
| 390193 |  | 2.60 |
| 390194 |  | 2.57 |
| 390195 |  | 2.89 |
| 390196 |  | 2.16 |
| 390197 |  | 3.10 |
| 390198 |  | 1.87 |
| 390199 |  | 1.79 |
| 390200 |  | 1.50 |
| 390201 |  | 2.23 |
| 390203 |  | 2.59 |
| 390204 |  | 2.50 |
| 390205 |  | 2.42 |
| 390206 |  | 2.05 |
| 390209 |  | 2.00 |
| 390211 |  | 2.74 |
| 390213 |  | 1.07 |
| 390215 |  | 2.28 |
| 390217 |  | 2.20 |
| 390219 |  | 1.91 |
| 390222 |  | 2.84 |
| 390223 |  | 2.25 |
| 390224 |  | 1.69 |
| 390225 |  | 2.31 |
| 390226 |  | 2.31 |
| 390228 |  | 2.24 |
| 390231 |  | 2.19 |
| 390233 |  | 2.03 |
| 390235 | ................. | 1.87 |
| 390236 | .................... | 2.15 |
| 390237 | ........ | 2.25 |
| 390238 | .......... | 2.43 |
| 390242 |  | 2.48 |
| 390244 |  | 1.01 |
| 390245 |  | 2.18 |
| 390246 |  | 2.44 |
| 390247 |  | 1.13 |

## Addendum G.-Service Mix Indices By Hospital-Continued

| Hospital | SMI |
| :---: | :---: |


| 390249 | 1.13 |
| :---: | :---: |
| 390256 | 1.87 |
| 390258 | 2.45 |

Addendum G.-Service Mix Indices by Hospital-Continued

| Hospital | SMI |
| :---: | :---: |
| 400117 ............................................ | 2.22 |
| 40118 | 189 |

1.87400118 .............................................. 1.89
3.75400122 ................................................ 0.96

| 2.73 | 400123 |
| :--- | :--- |
|  | .............................................. |
| 3.02 | 400124 |$\quad 3.95$

3.02400124 ............................................. $\quad 7.82$

| 1.57 | 404002 | ......................................................................................... |
| :--- | :--- | :--- |
| 3 | 40001 |  |

2.67410004 ............................................... 2.02
2.66410005 …........................................... 2.79
2.58410006 ............................................. 2.27

| 1.31 | 410007 | ..................................................................... |
| :--- | :--- | :--- |
| 2.40 | 40008 | 2.55 |

1.64410009 ................................................ 3.00

1.38410012 ......................................................... 2.67

1.99
1.67
0.55420002 .............................................. 2.54
0.94420004 .............................................. 1.95
1.55420005 ............................................... 2.12
1.90420006 .............................................. 1.29
1.10420007 ............................................. 2.64
$\begin{array}{lll}3.59 & 420009 & \text {.................................................................. } \\ 2.26 & 420010 & 2.81 \\ 2.7 . . . .\end{array}$
1.77420011 ............................................ 1.83
$\begin{array}{lll}0.98 & 420014 & \ldots . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ~ \\ 1.73 & 420015 & 1.46 \\ & & \end{array}$
1.58420016 ............................................................................. $\quad 1.79$
1.55420018 .............................................. 1.96
$\begin{array}{ll}1.84 & 420019 \\ 3.26 & 420020 \\ \text {............................................................................. } & 1.99 \\ 2.50\end{array}$
1.36420023 …........................................... 3.02
1.57420026 ............................................... 3.87
1.48420027 ............................................. 2.27
1.56420030 ............................................. $\quad 2.23$
$\begin{array}{lll}1.32 & 420031 & \text {............................................. } \\ 1.32 & 420033 & 1.44 \\ 1.98\end{array}$

| 1.65 | 420036 ................................................................... |
| :--- | :--- |
| 1.92 |  |

3.95420037 .............................................. 1.83
1.58420038 ............................................. 1.72
2.04420039 ............................................. 1.93
1.76420042 ............................................. 1.80
2.56420043 ............................................... 2.20
1.11420048 .............................................. 2.30

| 1.87 | 420049 ............................................. |
| :--- | :--- |
| 2.7 |  |
| 2.77 |  |

2.39420051 ......................................... 2.47
1.22420053 ............................................. 2.35
1.42420054 ............................................. $\quad 1.72$
4.78420055 ..................................................... 1.70
1.87420056 ............................................ $\quad 2.74$

3.28420061 .............................................. 1.94
1.94420062 .................................................. 2.34
1.95420064 ............................................. 1.64
0.88420065 .............................................. 2.89
1.61420066 .............................................. 2.05
$\begin{array}{lll}1.12 & 420067 & \text {.................................................................. } \\ 1.18 & 420068 & 3.28 \\ & 2.98\end{array}$
1.13420069 .............................................. 1.67
1.40420070 ............................................... 2.46
2.07420071 .............................................. 2.61
1.60420072 .............................................. 1.34
$\begin{array}{ll}2.06 & 420073 \\ 1.37 & 420074\end{array}$........................................... $\quad 2.64$
$\begin{array}{lll}1.37 & 420074 & \text {........................................................................... } \\ 1.87 & 420075 & 1.89\end{array}$
1.46420078 .............................................. 2.77

Addendum G.-Service Mix Indices by Hospital-Continued

|  | SMI |
| :---: | :---: |
| 420080 | 2.73 |
| 420082 | 2.46 |
| 420083 | 3.56 |
| 420085 | 2.11 |
| 420086 | 2.53 |
| 420087 | 2.67 |
| 420088 | 2.69 |
| 420089 | 2.78 |
| 420091 | 2.90 |
| 420093 | 1.72 |
| 423025 | 2.87 |
| 423026 | 1.85 |
| 424006 | 1.55 |
| 424008 | 1.55 |
| 424010 | 1.72 |
| 430004 | 1.93 |
| 430005 | 2.85 |
| 430007 | 2.59 |
| 430008 | 2.76 |
| 430010 | 2.44 |
| 430011 | 3.17 |
| 430012 | 3.67 |
| 430013 | 3.09 |
| 430014 | 2.74 |
| 430015 | 3.04 |
| 430016 | 2.68 |
| 430018 | 1.52 |
| 430022 | 1.19 |
| 430023 | 1.38 |
| 430024 | 1.09 |
| 430026 | 1.24 |
| 430027 | 3.97 |
| 430028 | 2.58 |
| 430029 | 1.96 |
| 430031 | 1.74 |
| 430033 | 1.72 |
| 430034 | 1.42 |
| 430036 | 2.00 |
| 430037 | 1.34 |
| 430038 | 2.55 |
| 430040 | 2.03 |
| 430041 | 1.71 |
| 430043 | 2.19 |
| 430044 | 1.45 |
| 430047 | 1.89 |
| 430048 | 2.33 |
| 430049 | 1.38 |
| 430051 | 1.03 |
| 430054 | 1.91 |
| 430056 | 1.34 |
| 430057 | 1.61 |
| 430060 | 1.05 |
| 430062 | 1.79 |
| 430064 | 1.98 |
| 430065 | 1.41 |
| 430066 | 1.16 |
| 430073 | 1.69 |
| 430076 | 1.05 |
| 430077 | 3.25 |
| 430079 | 1.00 |
| 430087 | 1.15 |
| 434004 | 1.77 |
| 440001 | 1.78 |
| 440002 | 3.88 |
| 440003 | 2.91 |
| 440006 | 3.43 |
| 440007 | 1.27 |
| 440008 | 2.51 |
| 440009 | 3.09 |
| 440010 | 1.83 |
| 440011 | 2.47 |

## Addendum G.-Service Mix Indices by Hospital-Continued

| Hospital | SMI |
| :---: | :---: |


| Hospital | SMI |  |
| :--- | ---: | :--- | :--- |


440015
440016
440017
440018 .
440019 ..
440023 .
440024
440025 ..
440026
440030
440031
440032
440033
440034
440035
440039 ...
440041
440046
440047
440048 ..
440049
440051
440052
440053
440054
440056 ...
440057 .
440059
440060
440061
440063
440064
440065
440067
440068
440070
440071
440072
440078
440081
440082
440083
440084
440090
440091
440100
440102
440103
440105
440109
440110
440111
440114
440115
440120 .
440125
440130
440131
440132
440133
440135
440137 ...
1.65
3.03
2.08
3.27440180 ............................................................................. $\quad 1.76$
2.65440181 ............................................. 1.99

$\begin{array}{llll}1.73 & 440183 & \ldots . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ~ & 3.34 \\ 1.62 & 440184 & & 3.08\end{array}$
3.01440185 ................................................ 2.49
2.09440186 ...................................................................... $\quad 2.23$
$\begin{array}{lll}1.86 & 440187 & \text { …........................................................................... } \\ 1.98 & 40189 \\ 1.94\end{array}$
$\begin{array}{llll}1.98 & 440189 & \text {........................................................................................... } & 3.47 \\ 3.01 & 440192\end{array}$
2.48440193 .............................................................. 3.20
1.61440194 ................................................................. 2.14
2.13440197 ................................................. 2.76
$\begin{array}{llll}2.77 & 440200 & \text {.......................................................................................... } & 2.02 \\ 1.83 & 440203\end{array}$
$\begin{array}{lll}1.83 & 440203 & \text {................................................................................................................ } \\ 2.46 \\ 2.45 & 440205\end{array}$
$\begin{array}{llll}2.45 & 440205 & \ldots . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ~ & 1.46 \\ 2.80 & 440206 & 1.95\end{array}$
2.52440211 .............................................. 1.50
1.77442007 ................................................... 0.93
2.56443025 ….............................................................. 1.69
2.79443026 .............................................. 1.27
2.64443029 ...................................................................... 3.28
1.68444003 .............................................. 1.36
$\begin{array}{llll}2.03 & 444004 & \ldots . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ~ & 1.56 \\ 282 & 444006 & & 1.20\end{array}$
2.82444006 ............................................. 1.50

| 1.67 | 444010 | ........................................................................................... | 1.70 |
| :--- | :--- | :--- | :--- |
| 1.44 | 444011 |  |  |

    1.44444011 ............................................ 1.70
    1.66444012 ........................................... 1.48
    3.29450002 ................................................... 2.42
    1.89450004 .............................................. 1.82
    \(\begin{array}{llll}1.89 & 450004 & \ldots . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ~ & 10\end{array}\)
    2.48450007 .............................................. 2.96
    2.70450008 .................................................................... 1.81
    6.65450010 .............................................. 2.54
    2.02450011 ..................................................... 2.92
$\begin{array}{lll}2.05 & 450014 & \text {............................................................... } \\ 1.34 & 45015 & 1.79 \\ 1.30\end{array}$
$\begin{array}{llll}1.34 & 450015 & \text {............................................................................................. } & 1.30 \\ 1.96 & 450016\end{array}$
$\begin{array}{llll}1.96 & 450016 & \text {.......................................................................................... } & 3.15 \\ 1.91 & 450018\end{array}$
$\begin{array}{llll}1.91 & 450018 & \text {.................................................................. } & 1.54 \\ 3.52 & 450020 & & 2.19\end{array}$
2.79450021 ............................................................... 1.91
2.95450023 .............................................. 2.67
2.77450024 .................................................................... 1.59
2.22450025 ............................................. 2.88
3.04450028 ............................................................................ 2.44
2.23450029 ................................................ 2.05
$2.14-450031$

| 2.08 | 440144 | ...................................................................................... | 1.64 |
| :--- | :--- | :--- | :--- |
|  | 3.94 |  |  |

    \(\begin{array}{llll}2.53 & 440145 \ldots \ldots \ldots \ldots . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ~ & 1.38 \\ 1.62 & 440147\end{array}\)
    \begin{tabular}{ll}
    1.62 \& 440147 <br>
2.79 \& 40148 <br>
\& ................................................................... <br>
\hline
\end{tabular}$\quad 7.20$

| 2.59 | 440148 | ..................................................................................................................... |
| :--- | :--- | :--- |
| 2.08 | 440149 |  |

    1.65440150 …........................................................ \(\quad 3.46\)
    3.03440151 ............................................................................. 1.93
    2.28440152 .......................................................................... 1.93
    \(\begin{array}{llll}0.96 & 440153 & \text {............................................................................................. } & 3.10 \\ 3.02 & 440156\end{array}\)
    3.03440157 …........................................... 1.61
    \(\begin{array}{lll}2.41 & 440159 \ldots \ldots \ldots . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ~\end{array}\)
    \begin{tabular}{lll|l}
    1.55 \& 440161 \& ............................................................................................. \& 1.33 <br>
1.95 \& 440162
\end{tabular}

    2.66440166 ….............................................................. \(\quad 1.69\)
    2.55440168 ....................................................................... 2.48
    2.24440173 ...................................................................... 4.08
    1.63440174 .............................................. 2.07
    \(\begin{array}{llll}1.78 & 440175 & \ldots . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ~\end{array}\)
    \begin{tabular}{lll|l}
    2.60 \& 440176 \& ..................................................................................... \& 3.28 <br>
1.87 \& 440178
\end{tabular}

Addendum G.-Service Mix Indices by Hospital-Continued

2.05
2.15
1.76
1.99
2.30
3.34
3.08
2.49
2.23
1.94
3.47
1.80
3.20
3.20
2.14
2.76
2.02
1.96
1.46
1.95
1.50
0.93
1.69
1.27
3.28
1.36
1.56
1.50
1.47
1.70
1.48
2.42
1.82
2.10
1.81
2.54
2.92
1.79
1.30
3.15
1.54
2.19
1.91
2.67
1.59
2.88
2.44
2.05
2.15

Addendum G.-Service Mix Indices by Hospital-Continued

|  | SMI |
| :---: | :---: |
| 450032 | 1.58 |
| 450033 | 2.00 |
| 450034 | 2.20 |
| 450037 | 2.45 |
| 450039 | 1.15 |
| 450040 | 2.06 |
| 450042 | 2.28 |
| 450044 | 2.42 |
| 450046 | 2.83 |
| 450047 | 2.39 |
| 450050 | 1.32 |
| 450051 | 1.88 |
| 450052 | 1.52 |
| 450053 | 2.39 |
| 450054 | 3.44 |
| 450055 | 1.76 |
| 450056 | 3.27 |
| 450058 | 3.45 |
| 450059 | 2.75 |
| 450063 | 0.93 |
| 450064 | 2.96 |
| 450065 | 1.66 |
| 450068 | 2.03 |
| 450072 | 2.31 |
| 450073 | 1.43 |
| 450076 | 1.74 |
| 450078 | 1.20 |
| 450079 | 2.85 |
| 450080 | 3.06 |
| 450081 | 1.93 |
| 450082 | 1.66 |
| 450083 | 3.49 |
| 450085 | 1.74 |
| 450087 | 1.92 |
| 450090 | 2.50 |
| 450092 | 1.92 |
| 450094 | 2.64 |
| 450096 | 1.90 |
| 450097 | 3.26 |
| 450098 | 1.14 |
| 450099 | 2.07 |
| 450101 | 2.56 |
| 450102 | 3.28 |
| 450104 | 2.89 |
| 450107 | 2.09 |
| 450108 | 1.34 |
| 450109 | 1.62 |
| 450111 | 2.55 |
| 450112 | 2.73 |
| 450113 | 2.75 |
| 450118 | 3.27 |
| 450119 | 2.49 |
| 450121 | 2.67 |
| 450123 | 1.81 |
| 450124 | 2.19 |
| 450126 | 1.79 |
| 450128 | 1.96 |
| 450130 | 3.66 |
| 450131 | 1.87 |
| 450132 | 2.27 |
| 450133 | 2.37 |
| 450135 | 2.53 |
| 450137 | 2.28 |
| 450140 | 1.45 |
| 450142 | 2.07 |
| 450143 | 1.77 |
| 450144 | 1.72 |
| 450145 | 1.28 |
| 450146 | 0.96 |
| 450147 | 1.94 |
| 450148 | 2.31 |

## Addendum G.-Service Mix Indices By Hospital-Continued

| Hospital | SMI |
| :---: | :---: |

450149 ..............................................................................................
450150 .......

450151 .
450152.
450154.

450155
450157
450160 ..
450162
450163
450164
450165 ..
450166
450170
450177
450178
450181
450184
450185
450187
450188
450190
450191
450192
450193
450194
450196
450200
450201
450203
450210
450211
450213
450214
450217
450219
450221
450222
450224
450229
450231
450234
450235
450236
450237
450239
450241
450243
450246
450249
450250
450253
450258
450259
450264
450269
450270
450271
450272
450278
450280
450283
450286
450288
450289
450293

Addendum G.-Service Mix Indices by Hospital-Continued

| Hospital | SMI |
| :---: | :---: |
| 450296 | 2.21 |

$\begin{array}{lll}2.01 & 450296 & \text {............................................................................................. } \\ 1.68 & 450299 & 2.38\end{array}$

2.31450307 ............................................................................ $\quad 0.96$

| 1.65 | 450309 |
| :--- | :--- |
| $1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ~$ | 1.55 |

$\begin{array}{lll}1.62 & 450315 & \ldots . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ~ \\ 1.35 & 450320 & 1.95 \\ 1 . . . . .\end{array}$
1.92450321 .................................................................. 1.19

| 2.04 | 450322 | ........................................................................................... |  |
| :--- | :--- | :--- | :--- |
| 1.73 | 450324 |  |  |

1.25450327 …............................................ 0.99

| 1.80 | 450330 |
| :--- | :--- |
| ............................................................................... | 1.72 |


| 1.89 | 450334 | ........................................................................... | 1.11 |
| :--- | :--- | :--- | :--- |
| 1.58 | 450337 |  |  |

2.39450340 .................................................................. 2.59

| 2.15 | 450341 | ......................................................................................... | 1.92 |
| :--- | :--- | :--- | :--- |
| 1.45 | 450346 |  |  |

1.30450347 ................................................................. 2.42
$\begin{array}{ll}1.00 & 450348 \\ 148 & 450351 \\ \text {...................................................................... } & 19 \\ 4.30\end{array}$
$\begin{array}{lll}1.48 & 450351 & \ldots . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ~\end{array} 28$
1.85450353 ............................................... 1.76
2.93450355 .................................................. 1.19
2.63450358 ............................................ $\quad 2.70$

2.36450370 ................................................ 4.89

| 2.70 | 450371 | .................................................................................................. | 2.85 |
| :--- | :--- | :--- | :--- |
| 2.44 | 450372 |  |  |

2.44450372 ............................................. 2.85
$\begin{array}{lll}2.12 & 450373 & \text {.............................................................................................. } \\ 1.91 & 450374 & 1.01\end{array}$
1.87450376 .................................................... 2.42

| 1.70 | 450378 | ............................................. | 1.88 |
| :--- | :--- | :--- | :--- |
| 2.35 | 450379 |  |  |

$\begin{array}{lll}1.41 & 450379 & \text {................................................................. } \\ 1.458\end{array}$
2.68450389 ............................................. 1.82

1.26450399 .............................................. 1.01
2.43450400 ................................................. $\quad 1.84$
1.98450403 ............................................ 1.86
2.67450411 ................................................... 1.60
2.88450417 .............................................. 1.87
1.46450419 .............................................. 1.63
2.06450423 .............................................. 2.53

| 2.65 | 450424 | ..................................................................... | 2.48 |
| :--- | :--- | :--- | :--- |
| 1.91 | 450429 | 0.92 |  |

1.44450431 .............................................. 3.06
1.30450438 .............................................. $\quad 2.81$
1.51450446 ................................................. 1.56
1.41450447 .............................................. 3.17
1.26450451 ............................................. 2.28
$\begin{array}{lll}1.24 & 450457 & \text {................................................................. } \\ 2.53 & 450460 & 3.06 \\ 1.80\end{array}$
1.10450462 .............................................. 2.18
2.23450464 ............................................. 1.52
0.95450465 …........................................... 3.29
1.27450467 ............................................. 1.51
$\begin{array}{ll}1.51 & 450469 \text {............................................ } \\ 1.29 & 2.86 \\ 1.18\end{array}$
2.97450475 ........................................................................... 2.34
1.49450484 .............................................. 2.35
1.31450488 ............................................ 1.99
1.89450489 ............................................. $\quad 1.16$
1.44450497 …........................................... 1.87
1.18450498 ............................................. $\quad 2.36$
$\begin{array}{lll}1.62 & 450514 & \ldots . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ~ \\ 1.23\end{array} \quad 2.23$
1.86450517 ............................................ 1.38
1.74450518 .............................................. 2.21

Addendum G.-Service Mix Indices by Hospital-Continued

|  | Hospital | SMI |
| :---: | :---: | :---: |
| 450523 |  | 2.86 |
| 450530 |  | 2.51 |
| 450534 |  | 1.19 |
| 450535 |  | 2.43 |
| 450537 |  | 1.99 |
| 450538 |  | 1.73 |
| 450539 |  | 2.51 |
| 450544 |  | 2.04 |
| 450545 |  | 3.67 |
| 450547 |  | 1.58 |
| 450550 |  | 2.14 |
| 450551 |  | 2.35 |
| 450558 |  | 2.15 |
| 450559 |  | 1.17 |
| 450561 |  | 2.38 |
| 450563 |  | 2.67 |
| 450565 |  | 2.26 |
| 450570 |  | 1.54 |
| 450571 |  | 2.72 |
| 450573 |  | 1.71 |
| 450574 |  | 0.86 |
| 450575 |  | 1.23 |
| 450578 |  | 0.99 |
| 450580 |  | 2.31 |
| 450583 |  | 1.05 |
| 450584 |  | 1.81 |
| 450586 |  | 1.68 |
| 450587 |  | 2.02 |
| 450591 |  | 2.79 |
| 450596 |  | 2.40 |
| 450597 |  | 1.62 |
| 450603 |  | 1.13 |
| 450604 |  | 2.50 |
| 450605 |  | 2.09 |
| 450609 |  | 1.13 |
| 450610 |  | 2.61 |
| 450614 |  | 1.50 |
| 450615 |  | 2.10 |
| 450617 |  | 2.32 |
| 450620 |  | 1.54 |
| 450623 |  | 1.90 |
| 450626 |  | 1.25 |
| 450628 |  | 1.23 |
| 450630 |  | 2.13 |
| 450631 |  | 2.35 |
| 450632 |  | 0.82 |
| 450633 |  | 2.66 |
| 450634 |  | 2.74 |
| 450638 |  | 3.03 |
| 450639 |  | 2.56 |
| 450641 |  | 1.78 |
| 450643 |  | 2.22 |
| 450644 |  | 2.61 |
| 450646 |  | 2.30 |
| 450647 |  | 3.16 |
| 450648 |  | 1.81 |
| 450649 |  | 1.41 |
| 450651 |  | 2.23 |
| 450652 |  | 1.56 |
| 450653 |  | 2.45 |
| 450654 |  | 1.13 |
| 450656 |  | 2.67 |
| 450658 |  | 1.99 |
| 450659 |  | 2.45 |
| 450661 |  | 3.17 |
| 450662 |  | 1.88 |
| 450665 |  | 1.72 |
| 450666 |  | 2.05 |
| 450668 |  | 2.88 |
| 450669 |  | 2.34 |
| 450670 |  | 2.50 |

## Addendum G.-Service Mix Indices By Hospital-Continued

| Hospital | SMI |
| :---: | :---: |


| 450672 | $\ldots \ldots . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ~$ | 2.85 |
| :--- | :--- | :--- |

450672 ..................................................................................... 27


## Addendum G.-Service Mix Indices by Hospital-Continued

0.99
1.241.97453028 .............................................. 0.80
2.14453031 ....................................................... 1.67

0.80
1.162.52453034 ........................................................... 1.11
2.05

1.194
0.96453037 .............................................. 1.55
1.29453038 .............................................. 1.38
2.40

1.311.31
2.262.283.052.54
1.58
2.33
2.68

1.56
1.702.112.381.913.75
174
453070

....

3.51
1.94
2.19453072 …............................................................................. 1.31
2.480.612.28
1.402.661.101.49
1.70

1.05| 2.25 | 454031 ...................................................... 1.46 |
| :--- | :--- |1.23

1.795.91
1.091.31

1.555.042.38
1.421.42
2.04
6.29

1.550.859.960.522.59
1.091.64
1.59
454089 ................................................ 1.59

3.01
3.25.960.962.02
1.67
0.76
1.11
2.14
1.55
1.38
0.98
1.12
1.12
2.33
1.33
1.22
1.07
1.56
1.56
1.15
1.64
1.41
0.79
1.31
0.83
0.83
1.48
1.48
1.36
1.48
1.75
1.03
1.55
1.55
1.55
1.50
1.56
2.26
1.55
1.46
1.41
1.19
1.19
1.55
1.55
1.54
1.55
1.61
1.55
1.55
1.85
1.59
1.55
1.43
1.60
1.57
3.09
1.55
2.07
1.55
1.64
1.59

460003
3.25
2.54
2.52
3.82

450809
450811
450813
452013
452019
452022

Addendum G.-Service Mix Indices by Hospital-Continued

|  | SMI |
| :---: | :---: |
| 460007 | 2.96 |
| 460008 | 2.63 |
| 460010 | 2.49 |
| 460011 | 2.23 |
| 460013 | 2.78 |
| 460014 | 1.34 |
| 460015 | 2.90 |
| 460016 | 1.45 |
| 460017 | 3.22 |
| 460018 | 1.64 |
| 460019 | 2.15 |
| 460020 | 1.91 |
| 460021 | 2.21 |
| 460022 | 1.38 |
| 460023 | 3.19 |
| 460024 | 1.13 |
| 460026 | 2.02 |
| 460027 | 1.60 |
| 460029 | 1.95 |
| 460030 | 1.97 |
| 460033 | 1.71 |
| 460035 | 1.25 |
| 460036 | 2.22 |
| 460037 | 2.00 |
| 460039 | 1.74 |
| 460041 | 2.92 |
| 460042 | 2.75 |
| 460044 | 2.19 |
| 460047 | 1.87 |
| 460050 | 2.05 |
| 463025 | 1.62 |
| 463301 | 2.49 |
| 464003 | 1.55 |
| 464010 | 1.49 |
| 470001 | 2.03 |
| 470003 | 2.64 |
| 470004 | 1.61 |
| 470005 | 2.36 |
| 470006 | 2.57 |
| 470008 | 1.91 |
| 470010 | 1.97 |
| 470011 | 2.35 |
| 470012 | 2.92 |
| 470015 | 2.00 |
| 470018 | 2.08 |
| 470020 | 1.21 |
| 470023 | 2.58 |
| 470024 | 2.14 |
| 474001 | 1.00 |
| 480001 | 1.71 |
| 480002 | 2.28 |
| 490001 | 1.65 |
| 490002 | 1.67 |
| 490004 | 2.35 |
| 490005 | 2.56 |
| 490006 | 2.26 |
| 490007 | 2.58 |
| 490009 | 1.92 |
| 490011 | 2.79 |
| 490012 | 1.55 |
| 490013 | 2.66 |
| 490014 | 1.99 |
| 490015 | 3.19 |
| 490017 | 2.89 |
| 490018 | 2.98 |
| 490019 | 2.31 |
| 490020 | 2.71 |
| 490021 | 4.47 |
| 490022 | 2.51 |
| 490023 | 2.38 |
| 490024 | 2.41 |

## Addendum G.-Service Mix Indices by Hospital-Continued

| Hospital | SMI |
| :---: | :---: |


| 490027 .................................................................................. | 1.99 |
| :--- | :--- |
| 490030 |  |
| 490031 | 2.72 |

2.72
1.99
1.79

Addendum G.-Service Mix Indices by Hospital-Continued

| Hospital | SMI |
| :---: | :---: |
| 493026 .............................................. | 0.95 |

1.79494001 …...................................................................... 1.55
1.86494002 .............................................. 2.09
2.24
2.53
2.45
3.17
3.49
2.44
2.05
2.36
2.18
3.14
3.14
1.54
1.54
2.50
2.83
2.52
2.52
3.03
.
2.55500011 ..................................................................... 2.06
3.37500012 ............................................... 2.89
2.50500014 .................................................. 2.81
3.91500015 .............................................. 2.18

269500016 ............................................ 2.18
$\begin{array}{ll}2.92 & 500019 \\ 1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ~ & 2.86 \\ 500021 & 2.86\end{array}$
$\begin{array}{llll}1.47 & 500021 & \text {............................................................................ } & 2.40 \\ 3.11 & 500023\end{array}$
3.88500024 .............................................. 4.42
4.12500025 .............................................. 3.38
2.71500026 ..................................................................... 2.35
2.70500027 ............................................. $\quad 3.25$
$\begin{array}{ll}2.29 & 500028 \\ 2 & \text {............................................. } \quad 1.40 \\ 1.4\end{array}$
$\begin{array}{lll}2.34 & 500029 \text {............................................................................ } & 1.05 \\ 2.06\end{array}$
2.76500031 ................................................. 2.22
1.66500033 ................................................ 2.86

| 2.56 | 500036 |
| :--- | :--- |
| .............................................. | 2.81 |

$\begin{array}{llll}2.51 & 500037 & \ldots . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ~ & 1.78 \\ 2.40 & 500039 & \\ 3.11\end{array}$
2.47500041 .............................................. 2.44
1.80500042 .................................................... 3.48
2.26500043 ................................................ 1.89
2.14500044 ................................................... 2.71
2.23500045 .............................................. 2.58
1.15500048 .............................................. 1.78
3.77500049 ................................................ 3.44
2.60500050 ............................................. 2.66

| 3.12 | 500051 | ....................................................................................... | 2.46 |
| :--- | :--- | :--- | :--- |
| 3.44 | 500053 |  |  |

2.35500054 ....................................................................... 2.75
2.51500055 ................................................ 1.92
2.59500057 ............................................... 2.86

| 1.71 | 500058 |
| :--- | :--- |
| ............................................. | 2.71 |

$\begin{array}{llll}2.14 & 500059 & \text {............................................................................................. } & 27 \\ 2.10 & 500060\end{array}$
1.36500061 ................................................ 1.20
2.66500062 .............................................. 1.05
2.87500064 ............................................... 1.39
2.67500065 ................................................. 2.77
$\begin{array}{llll}2.96 & 500068 & \ldots \ldots . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ~ & 1.20 \\ 2.48 & 500069\end{array}$
$\begin{array}{llll}2.48 & 500069 & \text {............................................................................................. } & 36 \\ 2.04 & 500071\end{array}$
2.43500072 ............................................... 2.47
1.71500073 ................................................ 1.53
2.18500074 .................................................... 2.55
1.76500077 ............................................. 2.36
$\begin{array}{llll}1.35 & 500079 & \ldots \ldots . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ~ & 1.88 \\ 0.79 & 500080 & \\ 1.24\end{array}$
$\begin{array}{lllll}0.79 & 500080 & . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ~ & 1.24 \\ 1.33 & 500084 & 2.51\end{array}$

Addendum G.-Service Mix Indices by Hospital-Continued

|  | Hospital | SMI |
| :---: | :---: | :---: |
| 500085 |  | 1.80 |
| 500086 |  | 2.16 |
| 500088 |  | 3.09 |
| 500089 |  | 1.95 |
| 500090 |  | 0.72 |
| 500092 |  | 1.86 |
| 500094 |  | 0.90 |
| 500096 |  | 1.92 |
| 500097 |  | 1.37 |
| 500098 |  | 1.55 |
| 500101 |  | 1.28 |
| 500102 |  | 1.87 |
| 500104 |  | 2.26 |
| 500106 |  | 0.74 |
| 500107 |  | 1.59 |
| 500108 |  | 2.82 |
| 500110 |  | 3.07 |
| 500118 |  | 2.65 |
| 500119 |  | 1.90 |
| 500122 |  | 2.64 |
| 500123 |  | 0.91 |
| 500124 |  | 2.31 |
| 500125 |  | 1.49 |
| 500129 |  | 2.22 |
| 500132 |  | 1.55 |
| 500138 |  | 1.18 |
| 500139 |  | 2.80 |
| 500141 |  | 3.36 |
| 500146 |  | 2.38 |
| 502002 |  | 3.92 |
| 503025 |  | 0.98 |
| 503300 |  | 2.92 |
| 504002 |  | 2.30 |
| 510001 |  | 2.30 |
| 510002 |  | 2.52 |
| 510004 |  | 1.11 |
| 510005 |  | 1.58 |
| 510006 |  | 3.16 |
| 510007 |  | 2.23 |
| 510008 |  | 2.53 |
| 510012 |  | 2.16 |
| 510013 |  | 1.65 |
| 510015 |  | 1.20 |
| 510016 |  | 1.25 |
| 510018 |  | 1.83 |
| 510020 |  | 1.28 |
| 510022 |  | 2.50 |
| 510023 |  | 2.47 |
| 510024 |  | 3.34 |
| 510026 |  | 1.65 |
| 510027 |  | 1.74 |
| 510028 |  | 1.53 |
| 510029 |  | 2.69 |
| 510030 |  | 2.36 |
| 510031 |  | 3.42 |
| 510033 |  | 2.25 |
| 510038 |  | 1.72 |
| 510039 |  | 2.54 |
| 510043 |  | 1.04 |
| 510046 |  | 2.15 |
| 510047 |  | 2.69 |
| 510048 |  | 1.50 |
| 510050 |  | 2.35 |
| 510053 |  | 1.65 |
| 510055 |  | 2.34 |
| 510058 |  | 2.55 |
| 510059 |  | 8.87 |
| 510060 |  | 1.67 |
| 510063 |  | 1.27 |
| 510065 |  | 1.25 |
| 510066 |  | 2.08 |

## Addendum G.-Service Mix Indices by Hospital-Continued

| Hospital | SMI |
| :---: | :---: |

510067 ..........................................................................................
510070 .............................................

510072
510077
510081
510082
510084
510086
511300.

511302 ..
511303
513026 .
513027
513028 ..
514001 ..
514007
514008 .
520002 ..
520003 ..
520006 ..
520007 ...
520008
520010
520011 ..
520013
520015 …
520016 ...
520017 ...
520019 .
520021.

520024 ..
520026 ..
520028 .
520029 .
520030 .. 520031 ..
520033
520034
520035 ..
520038 .
520039 ..
520041
520042
520044
520047.

520048
520049
520054
520057 520058 520059 .. 520060 . 520062 520064 520066

Addendum G.-Service Mix Indices by Hospital-Continued


| 2.41 | 520069 | 2.12 |
| :---: | :---: | :---: |
| 3.32 | 520070 | 2.50 |
| 27 | 520074 | 1.63 |

2.27520074 ................................................................ 1.63

$\begin{array}{lllll}1.38 & 520077 & \text {............................................................................................. } & & 1.23 \\ 1.71 & 520078\end{array}$
1.51520082 .......................................................................... 2.99
$\begin{array}{llll}1.82 & 520083 & \text {.................................................................................................... } & 1.84 \\ 1.23 & 520084\end{array}$

| 1.44 | 520087 | ................................................................................. | 1.35 |
| :--- | :--- | :--- | :--- |
| 1.06 | 520088 |  |  |
|  |  |  |  |

$\begin{array}{llll}1.06 & 520088 & \text {.......................................................................................... } & 2.57 \\ 0.83 & 520089\end{array}$
$\begin{array}{llll}1.82089 & 520089 & \text {...................................................................................... } & 3.53 \\ 0.76 & 520090\end{array}$

| 0.85 | 520091 | ............................................................................................................................ |
| :--- | :--- | :--- |

1.85520094 ................................................................. $\quad 2.16$
$\begin{array}{llll}1.62 & 520095 & \text {................................................................. } & 2.78 \\ 3.01 & 520096 & 2.59\end{array}$
6.63520097 ….......................................... 2.39
$\begin{array}{llll}2.21 & 520098 & \text {................................................................... } & 1.53 \\ 2.77 & 520100 & 2.57\end{array}$


$\begin{array}{lll}1.68 & 520107 & \text { …............................................................... } \\ 2.45 & 5010 . & 1.94 \\ & & \end{array}$
$\begin{array}{llll}2.45 & 520109 & \text {........................................................................... } & 2.11 \\ 2.18 & 520110\end{array}$
2.42520111 .............................................. 2.23
3.20520112 ............................................. $\quad 3.43$
$\begin{array}{lll}2.03 & 520113 & \ldots . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ~ \\ 2.4 & 2.74 \\ 2.43 & 520114 & 2.15\end{array}$
2.52520115 ......................................................................... 2.08

| 1.89 | 520116 | ..................................................................... | 2.63 |
| :--- | :--- | :--- | :--- |
| 2.13 | 520117 | 1.88 |  |


$2.83520121 \ldots \ldots \ldots \ldots \ldots \ldots \ldots . .$.
$\begin{array}{lll}1.93 & 520122 & \ldots . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ~ \\ 2.07 & 520123 & 1.74 \\ 2 . . . . . .\end{array}$

1.40520131 ................................................. 2.07
$\begin{array}{lll}3.48 & 520132 & \text {.......................................................................................... } \\ 4.15 & 520134 & 1.61\end{array}$
1.98520135 ........................................................................ 1.93

| 2.12 | 520136 | .............................................. | 2.43 |
| :--- | :--- | :--- | :--- |
| 2.48 | 520138 |  |  |

3.09520139 ......................................................................... 2.66
$\begin{array}{lll}2.90 & 520140 & \text {........................................................................................... } \\ 3.33 & 520141 & 2.06\end{array}$
1.83520142 ................................................ $\quad 1.24$
$\begin{array}{lll}2.06 & 520144 & \ldots . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ~ \\ 20145\end{array} \quad 1.66$
2.08520146 .............................................. 2.38
3.29520148 .............................................. 1.87
2.41520149 .................................................... 1.20
$\begin{array}{lll}2.14 & 520151 & \text {.................................................................. } \\ 2.38 & 520152 & 2.64 \\ 2.15\end{array}$
3.14520153 ............................................. $\quad 1.47$

| 1.79 | 520154 | ............................................................................................. |
| :--- | :--- | :--- |
| 1.65 | 520156 |  |
|  | 3.30 |  |

3.07520157 ................................................. $\quad 1.65$
2.94520159 .............................................. 1.39
2.95 520160 ............................................. $\quad 2.79$
$\begin{array}{lll}1.75 & 520161 & \ldots . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ~ \\ 2.36 \\ 2.31 & 520170 & 2.36 \\ 3\end{array}$
3.04520171 .......................................................................... 1.86
1.94520173 ............................................. 2.91
3.17520177 ............................................................... 2.45

## Addendum G.-Service Mix Indices by Hospital-Continued <br> Addendum G.-Service Mix Indices by Hospital-Continued

|  | Hospital | SMI |
| :---: | :---: | :---: |
| 520178 |  | 2.40 |
| 523025 |  | 1.73 |
| 523026 |  | 1.64 |
| 523300 |  | 2.75 |
| 524000 |  | 1.64 |
| 524003 |  | 1.42 |
| 524017 |  | 0.47 |
| 524034 |  | 1.54 |
| 524038 |  | 1.80 |
| 524040 |  | 1.66 |
| 530002 |  | 2.28 |
| 530003 |  | 1.36 |
| 530004 |  | 1.89 |


| Hospital | SMI |
| :---: | :---: |
| 530005 | 1.75 |
| 530006 | 2.21 |
| 530007 | 2.02 |
| 530008 | 2.57 |
| 530009 | 2.04 |
| 530010 | 2.43 |
| 530011 | 2.24 |
| 530012 | 2.33 |
| 530014 | 2.79 |
| 530015 | 2.27 |
| 530016 | 2.03 |
| 530017 | 2.10 |
| 530018 | 1.65 |

Addendum G.-Service Mix Indices by Hospital-Continued


## Addendum H.-Wage Index for Urban Areas

| Urban Code | Urban Area (Constituent Counties) | Wage Index |
| :---: | :---: | :---: |
| 0040 | Abil | 0.8179 |
| 0060 | ${ }^{2}$ Aguadilla, PR Aguada, PR Aguadilla, PR Moca, PR | 0.4249 |
| 0080 | Akron, OH Portage, OH Summit, OH | 1.0163 |
| 0120 | Albany, GA Dougherty, GA Lee, GA | 1.0372 |
| 0160 .... | Albany-Schenectady-Troy, NY Albany, NY Montgomery, NY Rensselaer, NY Saratoga, NY Schenectady, NY Schoharie, NY. | 0.8754 |
| 0200 | Albuquerque, NM Bernalillo, NM Sandoval, NM Valencia, NM | 0.8499 |
| 0220 | Alexandria, LA Rapides, LA | 0.7910 |
| 0240 | Allentown-Bethlehem-Easton, PA Carbon, PA Lehigh, PA Northampton, PA | 0.9550 |
| 0280 | Altoona, PA Blair, PA | 0.9342 |
| 0320 | Amarillo, TX Potter, TX Randall, TX | 0.8435 |
| 0380 | Anchorage, AK Anchorage, AK | 1.3009 |
| 0440 | Ann Arbor, MI Lenawee, MI Livingston, MI Washtenaw, MI | 1.1483 |
| 0450 | Anniston, AL Calhoun, AL | 0.8462 |
| 0460 | Appleton-Oshkosh-Neenah, WI Calumet, WI Outagamie, WI Winnebago, WI | 0.8913 |
| 0470 | Arecibo, PR Arecibo, PR Camuy, PR Hatillo, PR | 0.4815 |
| 0480. | Asheville, NC Buncombe, NC Madison, NC | 0.8884 |
| 0500 .. | Athens, GA Clarke, GA Madison, GA Oconee, GA | 0.9800 |
| 0520 .... | ${ }^{1}$ Atlanta, GA Barrow, GA Bartow, GA Carroll, GA Cherokee, GA Clayton, GA Cobb, GA Coweta, GA DeKalb, GA Douglas, GA Fayette, GA Forsyth, GA Fulton, GA Gwinnett, GA Henry, GA Newton, GA Paulding, GA Pickens, GA Rockdale, GA Spalding, GA Walton. | 1.0050 |
| 0560 | Atlantic-Cape May, NJ Atlantic, NJ Cape May, NJ | 1.1050 |
| 580 | Auburn-Opelika, AL Lee, AL | 0.7748 |
| 0600 | Augusta-Aiken, GA-SC Columbia, GA McDuffie, GA Richmond, GA Aiken, SC Edgefield, SC | 13 |
| 0640 | ${ }^{1}$ Austin-San Marcos, TX Bastrop, TX Caldwell, TX Hays, TX Travis, TX Williamson, TX | 1 |
| 680 | ${ }^{2}$ Bakersfield, CA Kern, CA | 1 |
| 0720 .. | ${ }^{1}$ Baltimore, MD Anne Arundel, MD Baltimore, MD Baltimore City, MD Carroll, MD Harford, MD Howard, MD Queen Anne's, MD. | 0.9891 |
| 0733 | Bangor, ME Penobscot, ME | 0.9609 |
| 0743 | Barnstable-Yarmouth, MA Barnstable, MA | 1.3302 |
| 0760 | Baton Rouge, LA Ascension, LA East Baton Rouge, LA Livingston, LA West Baton Rouge, LA | 0.8707 |
| 0840 | Beaumont-Port Arthur, TX Hardin, TX Jefferson, TX Orange, TX | 0.8624 |
| 0860 | Bellingham, WA Whatcom, WA | 1.1394 |
| 0870 | ${ }^{2}$ Benton Harbor, MI Berrien, MI | 0.8831 |
| 0875 | ${ }^{1}$ Bergen-Passaic, NJ Bergen, NJ Passaic, NJ | 1.1833 |
| 0880 | Billings, MT Yellowstone, MT | 1.0038 |
| 0920 | Biloxi-Gulfport-Pascagoula, MS Hancock, MS Harrison, MS Jackson, MS | 0.7949 |
| 0960 | Binghamton, NY Broome, NY Tioga, NY | 0.8750 |
| 1000 | Birmingham, AL Blount, AL Jefferson, AL St. Clair, AL Shelby, AL | 0.8994 |
| 1010 | Bismarck, ND Burleigh, ND Morton, ND | 0.7893 |
| 1020 | Bloomington, IN Monroe, IN | 0.8593 |
| 1040 | Bloomington-Normal, IL McLean, IL | 0.8993 |
| 1080 | Boise City, ID Ada, ID Canyon, ID | 0.9086 |
| 1123 ..... | ${ }^{12}$ Boston-Worcester-Lawrence-Lowell-Brockton, MA-NH (MA Hospitals) Bristol, MA Essex, MA Middlesex, MA Norfolk, MA Plymouth, MA Suffolk, MA Worcester, MA Hillsborough, NH Merrimack, NH Rockingham, NH Strafford, NH. | 1.1369 |
| 1123 ........ | ${ }^{1}$ Boston-Worcester-Lawrence-Lowell-Brockton, MA-NH (NH Hospitals) Bristol, MA Essex, MA Middlesex, MA Norfolk, MA Plymouth, MA Suffolk, MA Worcester, MA Hillsborough, NH Merrimack, NH Rockingham, NH Strafford, NH. | 1.1358 |

[^271]Addendum H.-Wage Index for Urban Areas-Continued

| Urban Code | Urban Area (Constituent Counties) | Wage Index |
| :---: | :---: | :---: |
| 1125 | Boulder-Longmont, CO Boulder, CO | 0.9944 |
| 1145 | Brazoria, TX Brazoria, TX | 0.8516 |
| 1150 | Bremerton, WA Kitsap, WA | 1.1011 |
| 1240 | Brownsville-Harlingen-San Benito, TX Cameron, TX | 0.9212 |
| 1260 | Bryan-College Station, TX Brazos, TX | 0.8501 |
| 1280 | ${ }^{1}$ Buffalo-Niagara Falls, NY Erie, NY Niagara, NY | 0.9604 |
| 1303 | Burlington, VT Chittenden, VT Franklin, VT Grand Isle, VT | 1.0558 |
| 1310 | Caguas, PR Caguas, PR Cayey, PR Cidra, PR Gurabo, PR San Lorenzo, PR | 0.4561 |
| 1320 | ${ }^{2}$ Canton-Massillon, OH Carroll, OH Stark, OH | 0.8649 |
| 1350 | Casper, WY Natrona, WY | 0.9199 |
| 1360 | Cedar Rapids, IA Linn, IA | 0.9018 |
| 1400 | Champaign-Urbana, IL Champaign, IL | 0.9163 |
| 1440 | Charleston-North Charleston, SC Berkeley, SC Charleston, SC Dorchester, SC | 0.8988 |
| 1480 | Charleston, WV Kanawha, WV Putnam, WV | 0.9095 |
| 1520. | ${ }^{1}$ Charlotte-Gastonia-Rock Hill, NC-SC Cabarrus, NC Gaston, NC Lincoln, NC Mecklenburg, NC Rowan, NC Stanly, NC Union, NC York, SC. | 0.9433 |
| 1540 | Charlottesville, VA Albemarle, VA Charlottesville City, VA Fluvanna, VA Greene, VA | 1.0573 |
| 1560 .. | Chattanooga, TN-GA Catoosa, GA Dade, GA Walker, GA Hamilton, TN Marion, TN | 0.9731 |
| 1580. | ${ }^{2}$ Cheyenne, WY Laramie, WY | 0.8859 |
| 1600 | ${ }^{1}$ Chicago, IL Cook, IL DeKalb, IL DuPage, IL Grundy, IL Kane, IL Kendall, IL Lake, IL McHenry, IL Will, IL | 1.0872 |
| 1620. | Chico-Paradise, CA Butte, CA | 1.0390 |
| 1640 ... | ${ }^{1}$ Cincinnati, OH-KY-IN Dearborn, IN Ohio, IN Boone, KY Campbell, KY Gallatin, KY Grant, KY Kenton, KY Pendleton, KY Brown, OH Clermont, OH Hamilton, OH Warren, OH. | 0.9434 |
| 1660 ... | Clarksville-Hopkinsville, TN-KY Christian, KY Montgomery, TN | 0.8283 |
| 1680 ... | ${ }^{1}$ Cleveland-Lorain-Elyria, OH Ashtabula, OH Cuyahoga, OH Geauga, OH Lake, OH Lorain, OH Medina, OH | 0.9688 |
| 1720 .. | Colorado Springs, CO EI Paso, CO | 0.9218 |
| 1740. | Columbia, MO Boone, MO | 0.8904 |
| 1760. | Columbia, SC Lexington, SC Richland, SC | 0.9357 |
| 1800. | Columbus, GA-AL Russell, AL Chattahoochee, GA Harris, GA Muscogee, GA | 0.8510 |
| 1840. | ${ }^{1}$ Columbus, OH Delaware, OH Fairfield, OH Franklin, OH Licking, OH Madison, OH Pickaway, OH | 0.9907 |
| 1880 | Corpus Christi, TX Nueces, TX San Patricio, TX | 0.8702 |
| 1890 | Corvallis, OR Benton, OR | 1.1087 |
| 1900. | Cumberland, MD-WV (Maryland Hospitals) Allegany, MD Mineral, WV | 0.8801 |
| 1920. | ${ }^{1}$ Dallas, TX Collin, TX Dallas, TX Denton, TX Ellis, TX Henderson, TX Hunt, TX Kaufman, TX Rockwall, TX | 0.9589 |
| 1950. | Danville, VA Danville City, VA Pittsylvania, VA | 0.9061 |
| 1960. | Davenport-Moline-Rock Island, IA-IL Scott, IA Henry, IL Rock Island, IL | 0.8706 |
| 2000. | Dayton-Springfield, OH Clark, OH Greene, OH Miami, OH Montgomery, OH | 0.9336 |
| 2020 | ${ }^{2}$ Daytona Beach, FL Flagler, FL Volusia, FL | 0.8986 |
| 2030 | Decatur, AL Lawrence, AL Morgan, AL | 0.8679 |
| 2040 | Decatur, IL Macon, IL | 0.8321 |
| 2080 | ${ }^{1}$ Denver, CO Adams, CO Arapahoe, CO Denver, CO Douglas, CO Jefferson, CO | 1.0197 |
| 2120 .. | Des Moines, IA Dallas, IA Polk, IA Warren, IA | 0.8754 |
| 2160 .. | ${ }^{1}$ Detroit, MI Lapeer, MI Macomb, MI Monroe, MI Oakland, MI St. Clair, MI Wayne, MI | 1.0421 |
| 2180 | Dothan, AL Dale, AL Houston, AL | 0.7836 |
| 2190 | Dover, DE Kent, DE | 0.9335 |
| 2200 | Dubuque, IA Dubuque, IA | 0.8520 |
| 2240 .. | Duluth-Superior, MN-WI St. Louis, MN Douglas, WI | 1.0165 |
| 2281 ... | Dutchess County, NY Dutchess, NY | 0.9872 |
| 2290. | Eau Claire, WI Chippewa, WI Eau Claire, WI | 0.8957 |
| 2320 | El Paso, TX El Paso, TX | 0.8947 |
| 2330 | Elkhart-Goshen, IN Elkhart, IN | 0.9379 |
| 2335 | ${ }^{2}$ Elmira, NY Chemung, NY | 0.8636 |
| 2340. | Enid, OK Garfield, OK | 0.7953 |
| 2360. | Erie, PA Erie, PA | 0.9023 |
| 2400. | Eugene-Springfield, OR Lane, OR | 1.0765 |
| 2440. | ${ }^{2}$ Evansville-Henderson, IN-KY (IN Hospitals) Posey, IN Vanderburgh, IN Warrick, IN Henderson, KY | 0.8396 |
| 2440 | Evansville-Henderson, IN-KY (KY Hospitals) Posey, IN Vanderburgh, IN Warrick, IN Henderson, KY | 0.8303 |
| 2520 | Fargo-Moorhead, ND-MN Clay, MN Cass, ND | 0.8620 |
| 2560 .. | Fayetteville, NC Cumberland, NC | 0.8494 |
| 2580 | Fayetteville-Springdale-Rogers, AR Benton, AR Washington, AR | 0.7773 |
| 2620 | Flagstaff, AZ-UT Coconino, AZ Kane, UT | 1.0348 |
| 2640 | Flint, MI Genesee, MI | 1.1020 |
| 2650 | Florence, AL Colbert, AL Lauderdale, AL | 0.7927 |
| 2655 | Florence, SC Florence, SC | 0.8618 |
| 2670 | Fort Collins-Loveland, CO Larimer, CO | 1.0302 |
| 2680 | ${ }^{1}$ Ft. Lauderdale, FL Broward, FL | 1.0172 |
| 2700 | ${ }^{2}$ Fort Myers-Cape Coral, FL Lee, FL | 0.8986 |

[^272]Addendum H.-Wage Index for Urban Areas-Continued

| Urban Code | Urban Area (Constituent Counties) | Wage Index |
| :---: | :---: | :---: |
| 2710 | Fort Pierce-Port St. Lucie, FL Martin, FL St. Lucie, FL | 1.0109 |
| 2720 | Fort Smith, AR-OK Crawford, AR Sebastian, AR Sequoyah, OK | 0.7844 |
| 2750 | ${ }^{2}$ Fort Walton Beach, FL Okaloosa, FL | 0.8986 |
| 2760 | Fort Wayne, IN Adams, IN Allen, IN De Kalb, IN Huntington, IN Wells, IN Whitley, IN | 0.9096 |
| 2800 | ${ }^{1}$ Forth Worth-Arlington, TX Hood, TX Johnson, TX Parker, TX Tarrant, TX | 0.9835 |
| 2840 .. | Fresno, CA Fresno, CA Madera, CA | 1.0262 |
| 2880 | Gadsden, AL Etowah, AL | 0.8754 |
| 2900 | Gainesville, FL Alachua, FL | 1.0102 |
| 2920 | Galveston-Texas City, TX Galveston, TX | 0.9732 |
| 2960 | Gary, IN Lake, IN Porter, IN | 0.9369 |
| 2975 | ${ }^{2}$ Glens Falls, NY Warren, NY Washington, NY | 0.8636 |
| 2980 | Goldsboro, NC Wayne, NC | 0.8333 |
| 2985 | Grand Forks, ND-MN Polk, MN Grand Forks, ND | 0.9097 |
| 2995 | Grand Junction, CO Mesa, CO | 0.9188 |
| 3000 | ${ }^{1}$ Grand Rapids-Muskegon-Holland, MI Allegan, MI Kent, MI Muskegon, MI Ottawa, MI | 1.0135 |
| 3040 | Great Falls, MT Cascade, MT | 1.0459 |
| 3060 | Greeley, CO Weld, CO | 0.9722 |
| 3080 | Green Bay, WI Brown, WI | 0.9215 |
| 3120 ... | ${ }^{1}$ Greensboro-Winston-Salem-High Point, NC Alamance, NC Davidson, NC Davie, NC Forsyth, NC Guilford, NC Randolph, NC Stokes, NC Yadkin, NC. | 0.9037 |
| 3150 | Greenville, NC Pitt, NC | 0.9500 |
| 3160 | Greenville-Spartanburg-Anderson, SC Anderson, SC Cherokee, SC Greenville, SC Pickens, SC Spartanburg, SC | 0.9188 |
| 3180 | Hagerstown, MD Washington, MD | 0.8853 |
| 3200 | Hamilton-Middletown, OH Butler, OH | 0.8989 |
| 3240 | Harrisburg-Lebanon-Carlisle, PA Cumberland, PA Dauphin, PA Lebanon, PA Perry, PA | 0.9917 |
| 3283 | ${ }^{12}$ Hartford, CT Hartford, CT Litchfield, CT Middlesex, CT Tolland, CT | 1.2413 |
| 3285 | ${ }^{2}$ Hattiesburg, MS Forrest, MS Lamar, MS | 0.7306 |
| 3290 | Hickory-Morganton-Lenoir, NC Alexander, NC Burke, NC Caldwell, NC Catawba, NC | 0.9148 |
| 3320 .. | Honolulu, HI Honolulu, HI | 1.1479 |
| 3350 .. | Houma, LA Lafourche, LA Terrebonne, LA | 0.7837 |
| 3360 .. | ${ }^{1}$ Houston, TX Chambers, TX Fort Bend, TX Harris, TX Liberty, TX Montgomery, TX Waller, TX | 0.9387 |
| 3400 | Huntington-Ashland, WV-KY-OH Boyd, KY Carter, KY Greenup, KY Lawrence, OH Cabell, WV Wayne, WV | 0.9757 |
| 3440 | Huntsville, AL Limestone, AL Madison, AL | 0.8822 |
| 3480 | ${ }^{1}$ Indianapolis, IN Boone, IN Hamilton, IN Hancock, IN Hendricks, IN Johnson, IN Madison, IN Marion, IN Morgan, IN Shelby, IN. | 0.9792 |
| 3500 | Iowa City, IA Johnson, IA | 0.9607 |
| 3520 | Jackson, MI Jackson, MI | 0.8840 |
| 3560 | Jackson, MS Hinds, MS Madison, MS Rankin, MS | 0.8387 |
| 3580 | Jackson, TN Madison, TN Chester, TN | 0.8600 |
| 3600 | ${ }^{12}$ Jacksonville, FL Clay, FL Duval, FL Nassau, FL St. Johns, FL | 0.8986 |
| 3605 | ${ }^{2}$ Jacksonville, NC Onslow, NC | 0.8290 |
| 3610 | ${ }^{2}$ Jamestown, NY Chautauqua, NY | 0.8636 |
| 3620 | Janesville-Beloit, WI Rock, WI | 0.9656 |
| 3640 | Jersey City, NJ Hudson, NJ | 1.1674 |
| 3660 .. | Johnson City-Kingsport-Bristol, TN-VA Carter, TN Hawkins, TN Sullivan, TN Unicoi, TN Washington, TN Bristol City, VA Scott, VA Washington, VA. | 0.8894 |
| 3680 | ${ }^{2}$ Johnstown, PA Cambria, PA Somerset, PA | 0.8524 |
| 3700 | Jonesboro, AR Craighead, AR | 0.7251 |
| 3710 | ${ }^{2}$ Joplin, MO Jasper, MO Newton, MO | 0.7723 |
| 3720 .. | Kalamazoo-Battlecreek, MI Calhoun, MI Kalamazoo, MI Van Buren, MI | 0.9981 |
| 3740 ... | Kankakee, IL Kankakee, IL | 0.8598 |
| 3760 .... | ${ }^{1}$ Kansas City, KS-MO Johnson, KS Leavenworth, KS Miami, KS Wyandotte, KS Cass, MO Clay, MO Clinton, MO Jackson, MO Lafayette, MO Platte, MO Ray, MO. | 0.9322 |
| 3800 | Kenosha, WI Kenosha, WI | 0.9033 |
| 3810 | Killeen-Temple, TX Bell, TX Coryell, TX | 0.9932 |
| 3840 .. | Knoxville, TN Anderson, TN Blount, TN Knox, TN Loudon, TN Sevier, TN Union, TN | 0.9199 |
| 3850 .. | Kokomo, IN Howard, IN Tipton, IN | 0.8984 |
| 3870 | La Crosse, WI-MN Houston, MN La Crosse, WI | 0.8933 |
| 3880 | Lafayette, LA Acadia, LA Lafayette, LA St. Landry, LA St. Martin, LA | 0.8397 |
| 3920 | Lafayette, IN Clinton, IN Tippecanoe, IN | 0.8809 |
| 3960 | Lake Charles, LA Calcasieu, LA | 0.7966 |
| 3980 | ${ }^{2}$ Lakeland-Winter Haven, FL Polk, FL | 0.8986 |
| 4000 | Lancaster, PA Lancaster, PA | 0.9255 |
| 4040 | Lansing-East Lansing, MI Clinton, MI Eaton, MI Ingham, MI | 0.9977 |
| 4080 | Laredo, TX Webb, TX | 0.8323 |
| 4100 | Las Cruces, NM Dona Ana, NM | 0.8590 |
| 4120 | ${ }^{1}$ Las Vegas, NV-AZ Mohave, AZ Clark, NV Nye, NV | 1.1258 |

[^273]Addendum H.-Wage Index for Urban Areas-Continued

| Urban Code | Urban Area (Constituent Counties) | Wage Index |
| :---: | :---: | :---: |
| 4150 | Lawrence, KS Douglas, | 0.8222 |
| 4200 .. | Lawton, OK Comanche, OK | 0.9532 |
| 4243 .. | Lewiston-Auburn, ME Androscoggin, ME | 0.8899 |
| 4280 .. | Lexington, KY Bourbon, KY Clark, KY Fayette, KY Jessamine, KY Madison, KY Scott, KY Woodford, KY | 0.8552 |
| 4320 | Lima, OH Allen, OH Auglaize, OH | 0.9108 |
| 4360 | Lincoln, NE Lancaster, NE | 0.9670 |
| 4400 | Little Rock-North Little Rock, AR Faulkner, AR Lonoke, AR Pulaski, AR Saline, AR | 0.8614 |
| 4420 | Longview-Marshall, TX Gregg, TX Harrison, TX Upshur, TX | 0.8738 |
| 4480 | ${ }^{1}$ Los Angeles-Long Beach, CA Los Angeles, CA | 1.2085 |
| 4520 | Louisville, KY-IN Clark, IN Floyd, IN Harrison, IN Scott, IN Bullitt, KY Jefferson, KY Oldham, KY | 0.9381 |
| 4600 | Lubbock, TX Lubbock, TX | 0.8411 |
| 4640 | Lynchburg, VA Amherst, VA Bedford, VA Bedford City, VA Campbell, VA Lynchburg City, VA | 0.8814 |
| 4680 | Macon, GA Bibb, GA Houston, GA Jones, GA Peach, GA Twiggs, GA | 0.8530 |
| 4720 | Madison, WI Dane, WI | 0.9729 |
| 4800 | ${ }^{2}$ Mansfield, OH Crawford, OH Richland, OH | 0.8649 |
| 4840 | Mayaguez, PR Anasco, PR Cabo Rojo, PR Hormigueros, PR Mayaguez, PR Sabana Grande, PR San German, PR ........ | 0.4674 |
| 4880 | McAllen-Edinburg-Mission, TX Hidalgo, TX | 0.8120 |
| 4890 | Medford-Ashland, OR Jackson, OR | 1.0492 |
| 4900 | Melbourne-Titusville-Palm Bay, FL Brevard, FI | 0.9296 |
| 4920 | ${ }^{1}$ Memphis, TN-AR-MS Crittenden, AR DeSoto, MS Fayette, TN Shelby, TN Tipton, TN | 0.8244 |
| 4940 | Merced, CA Merced, CA | 1.0509 |
| 5000 | ${ }^{1}$ Miami, FL Dade, FL | 1.0233 |
| 5015. | ${ }^{1}$ Middlesex-Somerset-Hunterdon, NJ Hunterdon, NJ Middlesex, NJ Somerset, NJ | 1.0876 |
| 5080 .. | ${ }^{1}$ Milwaukee-Waukesha, WI Milwaukee, WI Ozaukee, WI Washington, WI Waukesha, WI | 0.9845 |
| 5120 | ${ }^{1}$ Minneapolis-St. Paul, MN-WI Anoka, MN Carver, MN Chisago, MN Dakota, MN Hennepin, MN Isanti, MN Ramsey, MN Scott, MN Sherburne, MN Washington, MN Wright, MN Pierce, WI St. Croix, WI. | 1.0929 |
| 5140 | Missoula, MT Missoula, MT | 0.9085 |
| 5160 | Mobile, AL Baldwin, AL Mobile, AL | 0.8267 |
| 5170 | Modesto, CA Stanislaus, CA | 1.0111 |
| 5190 | ${ }^{1}$ Monmouth-Ocean, NJ Monmouth, NJ Ocean, NJ | 1.1258 |
| 5200 | Monroe, LA Ouachita, LA | 0.8221 |
| 5240 | Montgomery, AL Autauga, AL Elmore, AL Montgomery, AL | 0.7724 |
| 5280 | Muncie, IN Delaware, IN | 1.0834 |
| 5330 | Myrtle Beach, SC Horry, SC | 0.8529 |
| 5345 | Naples, FL Collier, FL | 0.9839 |
| 5360 ... | ${ }^{1}$ Nashville, TN Cheatham, TN Davidson, TN Dickson, TN Robertson, TN Rutherford TN Sumner, TN Williamson, TN Wilson, TN. | 0.9449 |
| 5380 | ${ }^{1}$ Nassau-Suffolk, NY Nassau, NY Suffolk, NY | 1.4074 |
| 5483 | ${ }^{1}$ New Haven-Bridgeport-Stamford-Waterbury-Danbury, CT Fairfield, CT New Haven, CT | 1.2417 |
| 5523 | New London-Norwich, CT New London, CT | 1.2428 |
| 5560 .. | ${ }^{1}$ New Orleans, LA Jefferson, LA Orleans, LA Plaquemines, LA St. Bernard, LA St. Charles, LA St. James, LA St. John The Baptist, LA St. Tammany, LA. | 0.9089 |
| 5600 ... | ${ }^{1}$ New York, NY Bronx, NY Kings, NY New York, NY Putnam, NY Queens, NY Richmond, NY Rockland, NY Westchester, NY. | 1.4517 |
| 5640 | ${ }^{1}$ Newark, NJ Essex, NJ Morris, NJ Sussex, NJ Union, NJ Warren, NJ | 1.0772 |
| 5660. | Newburgh, NY-PA Orange, NY Pike, PA | 1.0908 |
| 5720 ... | ${ }^{1}$ Norfolk-Virginia Beach-Newport News, VA-NC Currituck, NC Chesapeake City, VA Gloucester, VA Hampton City, VA Isle of Wight, VA James City, VA Mathews, VA Newport News City, VA Norfolk City, VA Poquoson City, VA Portsmouth City, VA Suffolk C. | 0.8442 |
| 5775 | ${ }^{1}$ Oakland, CA Alameda, CA Contra Costa, CA | 1.5095 |
| 5790 | Ocala, FL Marion, FL | 0.9615 |
| 5800. | Odessa-Midland, TX Ector, TX Midland, TX | 0.8873 |
| 5880 ... | ${ }^{1}$ Oklahoma City, OK Canadian, OK Cleveland, OK Logan, OK McClain, OK Oklahoma, OK Pottawatomie, OK ............... | 0.8589 |
| 5910. | Olympia, WA Thurston, WA | 1.0932 |
| 5920 | Omaha, NE-IA Pottawattamie, IA Cass, NE Douglas, NE Sarpy, NE Washington, NE | 1.0455 |
| 5945 | ${ }^{1}$ Orange County, CA Orange, CA | 1.1592 |
| 5960 | ${ }^{1}$ Orlando, FL Lake, FL Orange, FL Osceola, FL Seminole, FL | 0.9806 |
| 5990 | Owensboro, KY Daviess, KY | 0.8104 |
| 6015 | Panama City, FL Bay, FL | 0.9169 |
| 6020 | Parkersburg-Marietta, WV-OH (WV Hospitals) Washington, OH Wood, WV | 0.8414 |
| 6020 | ${ }^{2}$ Parkersburg-Marietta, WV-OH (OH Hospitals) Washington, OH Wood, WV | 0.8649 |
| 6080 | ${ }^{2}$ Pensacola, FL Escambia, FL Santa Rosa, FL | 0.8986 |
| 6120 | Peoria-Pekin, IL Peoria, IL Tazewell, IL Woodford, IL | 0.8399 |
| 6160 ...... | ${ }^{1}$ Philadelphia, PA-NJ Burlington, NJ Camden, NJ Gloucester, NJ Salem, NJ Bucks, PA Chester, PA Delaware, PA Montgomery, PA Philadelphia, PA. | 1.1186 |
| 6200 ..... | ${ }^{1}$ Phoenix-Mesa, AZ Maricopa, AZ Pinal, AZ | 0.9464 |
| 6240 | Pine Bluff, AR Jefferson, AR | 0.7697 |

[^274]Addendum H.-Wage Index for Urban Areas-Continued

| Urban Code | Urban Area (Constituent Counties) | Wage Index |
| :---: | :---: | :---: |
| 6280 | ${ }^{1}$ Pittsburgh, PA Allegheny, PA Beaver, PA Butler, PA Fayette, PA Washington, PA Westmoreland, PA | 0.9634 |
| 6323 | ${ }^{2}$ Pittsfield, MA Berkshire, MA | 1.1369 |
| 6340 | Pocatello, ID Bannock, ID | 0.8973 |
| 6360 | Ponce, PR Guayanilla, PR Juana Diaz, PR Penuelas, PR Ponce, PR Villalba, PR Yauco, PR | 0.4971 |
| 6403 | Portland, ME Cumberland, ME Sagadahoc, ME York, ME | 0.9487 |
| 6440 | ${ }^{1}$ Portland-Vancouver, OR-WA Clackamas, OR Columbia, OR Multnomah, OR Washington, OR Yamhill, OR Clark, WA .. | 1.0996 |
| 6483 | ${ }^{1}$ Providence-Warwick-Pawtucket, RI Bristol, RI Kent, RI Newport, RI Providence, RI Washington, RI | 1.0690 |
| 6520 | Provo-Orem, UT Utah, UT | 0.9818 |
| 6560 | Pueblo, CO Pueblo, CO | 0.8853 |
| 6580 | Punta Gorda, FL Charlotte, FL | 0.9508 |
| 6600 | Racine, WI Racine, WI | 0.9216 |
| 6640 | ${ }^{1}$ Raleigh-Durham-Chapel Hill, NC Chatham, NC Durham, NC Franklin, NC Johnston, NC Orange, NC Wake, NC | 0.9544 |
| 6660 | Rapid City, SD Pennington, SD | 0.8363 |
| 6680 | Reading, PA Berks, PA | 0.9436 |
| 6690 | Redding, CA Shasta, CA | 1.1263 |
| 6720 | Reno, NV Washoe, NV | 1.0655 |
| 6740 | Richland-Kennewick-Pasco, WA Benton, WA Franklin, WA | 1.1224 |
| 6760 ..... | Richmond-Petersburg, VA Charles City County, VA Chesterfield, VA Colonial Heights City, VA Dinwiddie, VA Goochland, VA Hanover, VA Henrico, VA Hopewell City, VA New Kent, VA Petersburg City, VA Powhatan, VA Prince George, VA Richmond City, V. | 0.9545 |
| 6780 | ${ }^{1}$ Riverside-San Bernardino, CA Riverside, CA San Bernardino, CA | 1.1061 |
| 6800 | Roanoke, VA Botetourt, VA Roanoke, VA Roanoke City, VA Salem City, VA | 0.8142 |
| 6820 | Rochester, MN Olmsted, MN | 1.1429 |
| 6840 | ${ }^{1}$ Rochester, NY Genesee, NY Livingston, NY Monroe, NY Ontario, NY Orleans, NY Wayne, NY | 0.9184 |
| 6880 | Rockford, IL Boone, IL Ogle, IL Winnebago, IL | 0.8783 |
| 6895 | Rocky Mount, NC Edgecombe, NC Nash, NC | 0.8735 |
| 6920 | ${ }^{1}$ Sacramento, CA El Dorado, CA Placer, CA Sacramento, CA | 1.2284 |
| 6960 | Saginaw-Bay City-Midland, MI Bay, MI Midland, MI Saginaw, MI | 0.9294 |
| 6980 | St. Cloud, MN Benton, MN Stearns, MN | 0.9608 |
| 7000 | St. Joseph, MO Andrew, MO Buchanan, MO | 0.8943 |
| 7040 | ${ }^{1}$ St. Louis, MO-IL Clinton, IL Jersey, IL Madison, IL Monroe, IL St. Clair, IL Franklin, MO Jefferson, MO Lincoln, MO St. Charles, MO St. Louis, MO St. Louis City, MO Warren, MO. | 0.9052 |
| 7080 | Salem, OR Marion, OR Polk, OR | 0.9949 |
| 7120 | Salinas, CA Monterey, CA | 1.4710 |
| 7160 | ${ }^{1}$ Salt Lake City-Ogden, UT Davis, UT Salt Lake, UT Weber, UT | 0.9854 |
| 7200 | San Angelo, TX Tom Green, TX | 0.7845 |
| 7240 | ${ }^{1}$ San Antonio, TX Bexar, TX Comal, TX Guadalupe, TX Wilson, TX | 0.8318 |
| 7320 | ${ }^{1}$ San Diego, CA San Diego, CA | 1.1955 |
| 7360 | ${ }^{1}$ San Francisco, CA Marin, CA San Francisco, CA San Mateo, CA | 1.3784 |
| 7400 | ${ }^{1}$ San Jose, CA Santa Clara, CA | 1.3492 |
| 7440 ....... | ${ }^{1}$ San Juan-Bayamon, PR Aguas Buenas, PR Barceloneta, PR Bayamon, PR Canovanas, PR Carolina, PR Catano, PR Ceiba, PR Comerio, PR Corozal, PR Dorado, PR Fajardo, PR Florida, PR Guaynabo, PR Humacao, PR Juncos, PR Los Piedras, PR Loiza, PR Lug. | 0.4657 |
| 7460 | San Luis Obispo-Atascadero-Paso Robles, CA San Luis Obispo, CA | 1.0470 |
| 7480 | Santa Barbara-Santa Maria-Lompoc, CA Santa Barbara, CA | 1.0819 |
| 7485 | Santa Cruz-Watsonville, CA Santa Cruz, CA | 1.3927 |
| 7490 | Santa Fe, NM Los Alamos, NM Santa Fe, NM | 1.0437 |
| 7500 | Santa Rosa, CA Sonoma, CA | 1.3000 |
| 7510 | Sarasota-Bradenton, FL Manatee, FL Sarasota, FL | 0.9905 |
| 7520 | Savannah, GA Bryan, GA Chatham, GA Effingham, GA | 0.9953 |
| 7560 | ${ }^{2}$ Scranton-Wilkes-Barre-Hazleton, PA Columbia, PA Lackawanna, PA Luzerne, PA Wyoming, PA | 0.8524 |
| 7600 | ${ }^{1}$ Seattle-Bellevue-Everett, WA Island, WA King, WA Snohomish, WA | 1.1289 |
| 7610 | ${ }^{2}$ Sharon, PA Mercer, PA | 0.8524 |
| 7620 | ${ }^{2}$ Sheboygan, WI Sheboygan, WI | 0.8759 |
| 7640 | Sherman-Denison, TX Grayson, TX | 0.9329 |
| 7680 | Shreveport-Bossier City, LA Bossier, LA Caddo, LA Webster, LA | 0.9049 |
| 7720 | Sioux City, IA-NE Woodbury, IA Dakota, NE | 0.8549 |
| 7760 | Sioux Falls, SD Lincoln, SD Minnehaha, SD | 0.8776 |
| 7800 | South Bend, IN St. Joseph, IN | 0.9793 |
| 7840 | Spokane, WA Spokane, WA | 1.0799 |
| 7880 | Springfield, IL Menard, IL Sangamon, IL | 0.8684 |
| 7920 | Springfield, MO Christian, MO Greene, MO Webster, MO | 0.7991 |
| 8003 | ${ }^{2}$ Springfield, MA Hampden, MA Hampshire, MA | 1.1369 |
| 8050 | State College, PA Centre, PA | 0.9138 |
| 8080 | ${ }^{2}$ Steubenville-Weirton, OH-WV (OH Hospitals) Jefferson, OH Brooke, WV Hancock, WV | 0.8649 |
| 8080 | Steubenville-Weirton, OH-WV (WV Hospitals) Jefferson, OH Brooke, WV Hancock, WV | 0.8614 |
| 8120 ....... | Stockton-Lodi, CA San Joaquin, CA | 1.0518 |

[^275]Addendum H.-Wage Index for Urban Areas-Continued

| Urban Code | Urban Area (Constituent Counties) | Wage Index |
| :---: | :---: | :---: |
| 8140 | ${ }^{2}$ Sumter, SC Sumter, | 0.8264 |
| 8160 | Syracuse, NY Cayuga, NY Madison, NY Onondaga, NY Oswego, NY | 0.9441 |
| 8200. | Tacoma, WA Pierce, WA | 1.1631 |
| 8240. | ${ }^{2}$ Tallahassee, FL Gadsden, FL Leon, FL | 0.8986 |
| 8280. | ${ }^{1}$ Tampa-St. Petersburg-Clearwater, FL Hernando, FL Hillsborough, FL Pasco, FL Pinellas, FL | 0.9119 |
| 8320. | Terre Haute, IN Clay, IN Vermillion, IN Vigo, IN | 0.8570 |
| 8360 | Texarkana, AR-Texarkana, TX Miller, AR Bowie, TX | 0.8174 |
| 8400 | Toledo, OH Fulton, OH Lucas, OH Wood, OH | 0.9593 |
| 8440. | Topeka, KS Shawnee, KS | 0.9326 |
| 8480. | Trenton, NJ Mercer, NJ . | 0.9955 |
| 8520 | Tucson, AZ Pima, AZ | 0.8742 |
| 8560. | Tulsa, OK Creek, OK Osage, OK Rogers, OK Tulsa, OK Wagoner, OK | 0.8086 |
| 8600. | Tuscaloosa, AL Tuscaloosa, AL | 0.8064 |
| 8640. | Tyler, TX Smith, TX | 0.9369 |
| 8680. | 2 Utica-Rome, NY Herkimer, NY Oneida, NY | 0.8636 |
| 8720. | Vallejo-Fairfield-Napa, CA Napa, CA Solano, CA | 1.2655 |
| 8735. | Ventura, CA Ventura, CA | 1.0952 |
| 8750. | Victoria, TX Victoria, TX | 0.8378 |
| 8760. | Vineland-Millville-Bridgeton, NJ Cumberland, NJ | 1.0517 |
| 8780. | Visalia-Tulare-Porterville, CA Tulare, CA | 1.0411 |
| 8800 ..... | Waco, TX McLennan, TX | 0.8075 |
| 8840 ..... | ${ }^{1}$ Washington, DC-MD-VA-WV District of Columbia, DC Calvert, MD Charles, MD Frederick, MD Montgomery, MD Prince Georges, MD Alexandria City, VA Arlington, VA Clarke, VA Culpeper, VA Fairfax, VA Fairfax City, VA Falls Church City, VA Fauquier,. |  |
| 8920 ... | Waterloo-Cedar Falls, IA Black Hawk, IA | 0.8841 |
| 8940 .. | Wausau, WI Marathon, WI | 0.9445 |
| 8960 ... | ${ }^{1}$ West Palm Beach-Boca Raton, FL Palm Beach, FL | 0.9909 |
| 9000 .. | ${ }^{2}$ Wheeling, WV-OH (WV Hospitals) Belmont, OH Marshall, WV Ohio, WV | 0.8068 |
| 9000 | ${ }^{2}$ Wheeling, WV-OH (OH Hospitals) Belmont, OH Marshall, WV Ohio, WV | 0.8649 |
| 9040 . | Wichita, KS Butler, KS Harvey, KS Sedgwick, KS | 0.9421 |
| 9080 .... | Wichita Falls, TX Archer, TX Wichita, TX | 0.7652 |
| 9140. | ${ }^{2}$ Williamsport, PA Lycoming, PA | 0.8524 |
| 9160. | Wilmington-Newark, DE-MD New Castle, DE Cecil, MD | 1.1274 |
| 9200 .. | Wilmington, NC New Hanover, NC Brunswick, NC | 0.9707 |
| 9260 .. | ${ }^{2}$ Yakima, WA Yakima, WA | 1.0446 |
| 9270 | Yolo, CA Yolo, CA | 1.0485 |
| 9280 | York, PA York, PA | 0.9309 |
| 9320 .. | Youngstown-Warren, OH Columbiana, OH Mahoning, OH Trumbull, OH | 0.9996 |
| 9340 | Yuba City, CA Sutter, CA Yuba, CA | 1.0662 |
| 9360 | Yuma, AZ Yuma, AZ | 0.9924 |

## Addendum I.-WAGE Index for Rural Areas

| Nonurban Area | Wage Index |
| :---: | :---: |
| Alabama | 0.7390 |
| Alaska | 1.2057 |
| Arizona | 0.8544 |
| Arkansas | 0.7236 |
| California | 0.9951 |
| Colorado | 0.8813 |
| Connecticut | 1.2413 |
| Delaware | 0.9166 |
| Florida | 0.8986 |
| Georgia | 0.8094 |
| Hawaii | 1.0726 |
| Idaho | 0.8651 |
| Illinois | 0.8047 |
| Indiana | 0.8396 |
| lowa | 0.7926 |
| Kansas | 0.7460 |
| Kentucky | 0.8043 |
| Louisiana | 0.7486 |

## Addendum I.-Wage Index for Rural Areas-Continued

| Nonurban Area | Wage Index |
| :---: | :---: |
| Maine | 0.8639 |
| Maryland | 0.8631 |
| Massachusetts | 1.1369 |
| Michigan | 0.8831 |
| Minnesota | 0.8669 |
| Mississippi | 0.7306 |
| Missouri | 0.7723 |
| Montana | 0.8398 |
| Nebraska | 0.8007 |
| Nevada | 0.9097 |
| New Hampshire | 0.9905 |
| ${ }^{1}$ New Jersey ....... |  |
| New Mexico | 0.8378 |
| New York | 0.8636 |
| North Carolina | 0.8290 |
| North Dakota | 0.7647 |
| Ohio | 0.8649 |
| Oklahoma | 0.7255 |

Addendum I.-Wage Index for Rural Areas-Continued

| Nonurban Area | Wage Index |
| :---: | :---: |
| Oregon | 0.9873 |
| Pennsylvania | 0.8524 |
| Puerto Rico | 0.4249 |
| ${ }^{1}$ Rhode Island |  |
| South Carolina | 0.8264 |
| South Dakota | 0.7576 |
| Tennessee | 0.7650 |
| Texas | 0.7471 |
| Utah | 0.8906 |
| Vermont | 0.9427 |
| Virginia | 0.7916 |
| Washington | 1.0446 |
| West Virginia | 0.8068 |
| Wisconsin | 0.8759 |
| Wyoming | 0.8859 |

[^276]
## Addendum J.-Wage Index for

 Hospitals That Are Reclassified| Area | Wage Index |
| :---: | :---: |
| Abilene, TX | 0.8179 |
| Akron, OH | 0.9981 |
| Albany, GA | 0.9544 |
| Alexandria, LA | 0.7910 |
| Amarillo, TX | 0.8435 |
| Anchorage, AK | 1.3009 |
| Ann Arbor, MI | 1.1343 |
| Atlanta, GA | 1.0050 |
| Austin-San Marcos, TX | 0.9081 |
| Baltimore, MD | 0.9891 |
| Baton Rouge, LA | 0.8707 |
| Beaumont-Port Arthur, TX | 0.8624 |
| Benton Harbor, MI | 0.8831 |
| Bergen-Passaic, NJ | 1.1833 |
| Billings, MT | 1.0038 |
| Biloxi-Gulfport-Pascagoula, MS ....... | 0.7949 |
| Binghamton, NY | 0.8750 |
| Birmingham, AL | 0.8994 |
| Bismarck, ND | 0.7893 |
| Boise City, ID | 0.9086 |
| Boston-Worcester-Lawrence-Lowell- <br> Brockton, MA-NH | 1.1358 |
| Burlington, VT | 1.0122 |
| Caguas, PR | 0.4561 |
| Champaign-Urbana, IL | 0.9163 |
| Charleston-North Charleston, SC | 0.8988 |
| Charleston, WV | 0.8861 |
| Charlotte-Gastonia-Rock Hill, NCSC $\qquad$ | 0.9433 |
| Chattanooga, TN-GA ..................... | 0.9453 |
| Chicago, IL | 1.0872 |
| Cincinnati, OH-KY-IN | 0.9434 |
| Clarksville-Hopkinsville, TN-KY ...... | 0.8283 |
| Cleveland-Lorain-Elyria, OH ............ | 0.9688 |
| Columbia, MO | 0.8736 |
| Columbia, SC | 0.9215 |
| Columbus, GA-AL | 0.8318 |
| Columbus, OH | 0.9728 |
| Corpus Christi, TX | 0.8599 |
| Dallas, TX | 0.9589 |
| Danville, VA | 0.8706 |
| Davenport-Moline-Rock Island, IA-IL | 0.8606 |
| Dayton-Springfield, OH | 0.9231 |
| Denver, CO ................................... | 1.0197 |
| Des Moines, IA | 0.8754 |
| Dothan, AL | 0.7836 |
| Dover, DE | 1.0511 |
| Duluth-Superior, MN-WI ................. | 1.0165 |
| Elkhart-Goshen, IN | 0.9379 |
| Eugene-Springfield, OR | 1.0765 |
| Evansville-Henderson, IN-KY | 0.8396 |
| Fargo-Moorhead, ND-MN (ND and SD Hospitals) | 0.8620 |
| Fargo-Moorhead, ND-MN (MN Hospital) | 0.8669 |
| Fayetteville, NC | 0.8494 |
| Flagstaff, AZ-UT | 0.9860 |
| Flint, MI | 1.0918 |
| Fort Collins-Loveland, CO ............... | 1.0197 |
| Fort Pierce-Port St. Lucie, FL | 1.0109 |
| Fort Smith, AR-OK | 0.7696 |
| Fort Walton Beach, FL ................... | 0.8713 |
| Forth Worth-Arlington, TX ............... | 0.9835 |
| Fresno, CA | 1.0262 |
| Gadsden, AL | 0.8754 |

Addendum J.-Wage Index for Hospitals That are Reclassi-FIED-Continued

| Area |
| :---: |
| Gainesville, FL |
| Goldsboro, NC |
| Grand Forks, ND-MN |
| Grand Rapids-Muskegon-Holland |
| Great Falls, MT |
| Greeley, CO |
| Green Bay, WI |
| Greensboro-Winston-Salem-High Point, NC $\qquad$ |
| Greenville, NC |
| Greenville-Spartanburg-Anderson, | SC

Hagerstown, MD
Harrisburg-Lebanon-Carlisle, PA
Hartford, CT
Hickory-Morganton-Lenoir, NC ........
Honolulu, HI
Houston, TX
Huntington-Ashland, WV-KY-OH
Huntsville, AL
Indianapolis, IN
Iowa City, IA
Jackson, MS
Jackson, TN
Jacksonville, FL
Johnson City-Kingsport-Bristol, TNVA
Jonesboro, AR
Joplin, MO
Kalamazoo-Battlecreek MI $\quad 0.7678$
Kansas City, KS-MO
Knoxville, TN
Kokomo, IN
Lafayette, LA
Lansing-East Lansing, MI
Las Vegas, NV-AZ
Lexington, KY
Lima, OH
Lincoln, NE
$\qquad$
.................................
Rock-North Little Rock, AR
Longview-Marshall, TX
Los Angeles-Long Beach, CA
Louisville, KY-IN
Macon, GA
Madison, WI
Mansfield, OH
Memphis, TN-AR-MS
Merced, CA
Milwaukee-Waukesha, WI
Minneapolis-St. Paul, MN-WI ..........
Missoula, MT
Monmouth-Ocean, NJ
Monroe, LA
Montgomery, AL
Myrtle Beach, SC
Nashville, TN
New Haven-Bridgeport-Stamford-
Waterbury-Danbury, CT
New London-Norwich, CT
New Orleans, LA
New York, NY
Newark, NJ
Newburgh, NY-PA

Addendum J.-Wage Index for hospitals That are Reclassi-FIED-Continued

| Area | Wage Index |
| :---: | :---: |
| Norfolk-Virginia <br> Beach-Newport <br> News, VA-NC $\qquad$ | 0.8442 |
| Oakland, CA | 1.5095 |
| Oklahoma City, OK | 0.8589 |
| Omaha, NE-IA | 1.0455 |
| Orange County, CA | 1.1592 |
| Orlando, FL | 0.9806 |
| Peoria-Pekin, IL ............................. | 0.8399 |
| Philadelphia, PA-NJ ....................... | 1.1186 |
| Phoenix-Mesa, AZ | 0.9464 |
| Pittsburgh, PA | 0.9496 |
| Pocatello, ID ................................. | 0.8651 |
| Portland, ME | 0.9487 |
| Portland-Vancouver, OR-WA .......... | 1.0996 |
| Provo-Orem, UT ............................ | 0.9818 |
| Raleigh-Durham-Chapel Hill, NC ..... | 0.9544 |
| Roanoke, VA | 0.8142 |
| Rockford, IL | 0.8783 |
| Sacramento, CA ............................ | 1.2284 |
| Saginaw-Bay City-Midland, MI ........ | 0.9294 |
| St. Cloud, MN ................................ | 0.9608 |
| St. Louis, MO-IL ............................ | 0.9052 |
| Salt Lake City-Ogden, UT ............... | 0.9854 |
| San Diego, CA | 1.1955 |
| Santa Fe, NM | 0.9911 |
| Santa Rosa, CA ............................ | 1.3000 |
| Seattle-Bellevue-Everett, WA .......... | 1.1289 |
| Sharon, PA ................................... | 0.8524 |
| Sherman-Denison, TX .................... | 0.8833 |
| Sioux City, IA-NE .......................... | 0.8549 |
| South Bend, IN | 0.9692 |
| Springfield, IL ................................ | 0.8684 |
| Springfield, MO .............................. | 0.7991 |
| Syracuse, NY | 0.9441 |
| Tallahassee, FL ............................ | 0.8274 |
| Tampa-St. Petersburg-Clearwater, FL $\qquad$ | 0.9119 |
| Texarkana, AR-Texarkana, TX ........ | 0.8174 |
| Toledo, OH ................................... | 0.9593 |
| Topeka, KS ................................... | 0.9326 |
| Tulsa, OK | 0.7931 |
| Tuscaloosa, AL ............................. | 0.8064 |
| Tyler, TX ...................................... | 0.9199 |
| Vallejo-Fairfield-Napa, CA ............... | 1.2167 |
| Victoria, TX | 0.8378 |
| Waco, TX ..................................... | 0.8075 |
| Washington, DC-MD-VA-WV ........ | 1.1053 |
| Waterloo-Cedar Falls, IA ................ | 0.8841 |
| Wausau, WI .................................. | 0.9445 |
| Wichita, KS ................................... | 0.9082 |
| Rural Colorado | 0.8813 |
| Rural Florida | 0.8986 |
| Rural Illinois | 0.8047 |
| Rural Louisiana | 0.7486 |
| Rural Michigan | 0.8831 |
| Rural Minnesota ............................ | 0.8669 |
| Rural Missouri | 0.7723 |
| Rural Montana | 0.8398 |
| Rural Oregon | 0.9873 |
| Rural Tennessee | 0.7650 |
| Rural Texas | 0.7471 |
| Rural Virginia (KY Hospital) ............ | 0.8043 |
| Rural Washington .......................... | 1.0333 |
| Rural Wyoming | 0.8859 |


| Addendum K.-Codes Eligible for Pass-Through Payment |  | AdDENDUM K.-CODES Eligible FOR Pass-Through Payment-Continued |  |
| :---: | :---: | :---: | :---: |
| CPT/ HCPCS | Description | CPT/ <br> HCPCS | Description |
| A4642 | Satumomab pendetide per dose | J7913 | Daclizumab, Parenteral, 25 m |
| A9502 | Technetium TC99M tetrofosmin | J8510 | Oral busulfan |
| A9600 | Strontium-89 chloride | J8520 | Capecitabine, oral, 150 mg |
| A9605 | Samarium sm153 lexidronamm | J8530 | Cyclophosphamide oral 25 MG |
| J0205 | Alglucerase injection | J8560 | Etoposide oral 50 MG |
| J0207 | Amifostine | J8600 | Melphalan oral 2 MG |
| J0256 | Alpha 1 proteinase inhibitor | J8610 | Methotrexate oral 2.5 MG |
| J0286 | Amphotericin B lipid complex | J9000 | Doxorubic hel 10 MG vl chemo |
| J0476 | Baclofen intrathecal trial | J9001 | Doxorubicin hcl liposome inj |
| J0585 | Botulinum toxin a per unit | J9015 | Aldesleukin/single use vial |
| J0640 | Leucovorin calcium injection | J9020 | Asparaginase injection |
| J0735 | Clonidine hydrochloride | J9031 | Bcg live intravesical vac |
| J0850 | Cytomegalovirus imm IV/vial | J9040 | Bleomycin sulfate injection |
| $J 1190$ | Dexrazoxane HCl injection | J9045 | Carboplatin injection |
| J1260 | Dolasetron mesylate | J9050 | Carmus bischl nitro inj |
| $J 1325$ | Epoprostenol injection | J9060 | Cisplatin 10 MG injeciton |
| $J 1436$ | Etidronate disodium inj | J9065 | Inj cladribine per 1 MG |
| J1440 | Filgrastim 300 mcg injeciton | J9070 | Cyclophosphamide 100 MG inj |
| J1561 | Immune globulin 500 mg | J9093 | Cyclophosphamide lyophilized |
| $J 1562$ | Immune globulin 5 gms | J9100 | Cytarabine hcl 100 MG inj |
| J1565 | RSV-ivig | $J 9120$ | Dactinomycin actinomycin d |
| $J 1620$ | Gonadorelin hydroch/100 mcg | $J 9130$ | Dacarbazine 10 MG inj |
| J1626 | Granisetron HCl injection | J9150 | Daunorubicin |
| $J 1745$ | Infliximab injection | J9151 | Daunorubicin citrate liposom |
| J1785 | Injection imiglucerase/unit | J9165 | Diethylstilbestrol injection |
| J1825 | Interferon beta-1a | J9170 | Docetaxel |
| J1830 | Interferon beta-1b/. 25 MG | J9181 | Etoposide 10 MG inj |
| J1950 | Leuprolide acetate/3.75 MG | J9185 | Fludarabine phosphate inj |
| J2275 | Morphine sulfate injection | J9190 | Fluorouracil injection |
| J2352 | Octreotide acetate injection | J9200 | Floxuridine injection |
| J2355 | Oprelvekin injection | J9201 | Gemcitabine HCl |
| J2405 | Ondansetron hcl injection | J9202 | Goserelin acetate implant |
| J2430 | Pamidronate disodium/30 MG | J9206 | Irinotecan injection |
| J2545 | Pentamidine isethionte/300mg | J9208 | Ifosfomide injection |
| J2765 | Metoclopramide hcl injection | J9209 | Mesna injection |
| J2790 | Rho d immune globulin inj | J9211 | Idarubicin hcl injeciton |
| J2820 | Sargramostim injection | J9212 | Interferon alfacon-1 |
| J3010 | Fentanyl citrate injeciton | J9213 | Interferon alfa-2a inj |
| J3280 | Thiethylperazine maleate inj | J9214 | Interferon alfa-2b inj |
| J3305 | Inj trimetrexate glucoronate | J9215 | Interferon alfa-n3 inj |
| J7190 | Factor viii | J9216 | Interferon gamma 1-b inj |
| J7191 | Factor VIII (porcine) | J9218 | Leuprolide acetate injeciton |
| J7192 | Factor viii recombinant | J9230 | Mechlorethamine hcl inj |
| J7194 | Factor ix complex | J9245 | Inj melphalan hydrochl 50 MG |
| $J 7197$ | Antithrombin iii injection | J9250 | Methotrexate sodium inj |
| $J 7198$ | Anti-inhibitor | J9265 | Paclitaxel injection |
| J7310 | Ganciclovir long act implant | J9266 | Pegaspargase/singl dose vial |
| J7505 | Monoclonal antibodies | J9268 | Pentostatin injection |

Addendum K.-Codes Eligible for Pass-Through Payment-Continued

| $\begin{gathered} \text { CPT/ } \\ \text { HCPCS } \end{gathered}$ | Description |
| :---: | :---: |
| J9270 | Plicamycin (mithramycin) inj |
| J9280 | Mitomycin 5 MG inj |
| J9293 | Mitoxantrone hydrochl/5 MG |
| J9310 | Rituximab cancer treatment |
| J9320 | Streptozocin injection |
| J9340 | Thiotepa injection |
| J9350 | Topotecan |
| J9360 | Vinblastine sulfate inj |
| J9370 | Vincristine sulfate 1 MG inj |
| J9390 | Vinorelbine tartrate/10 mg |
| J9600 | Porfimer sodium |
| Q0136 | Non esrd epoetin alpha inj |
| Q0160 | Factor IX non-recombinant |
| Q0161 | Factor IX recombinant |
| Q0163 | Diphenhydramine HCl 50 mg |
| Q0164 | Prochlorperazine maleate 5 mg |
| Q0166 | Granisetron HCl 1 mg oral |
| Q0167 | Dronabinol 2.5 mg oral |
| Q0169 | Promethazine HCl 12.5 mg oral |
| Q0171 | Chlorpromazine HCl 10 mg oral |
| Q0173 | Trimethobenzamide HCl 250 mg |
| Q0174 | Thiethylperazine maleate10mg |
| Q0175 | Perphenazine 4mg oral |
| Q0177 | Hydroxyzine pamoate 25mg |
| Q0179 | Ondansetron HCl 8 mg oral |
| Q0180 | Dolasetron mesylate oral |
| Q0187 | Factor viia recombinant |
| Q2002 | Elliot's B solution |
| Q2003 | Aprotinin, 10,000 kiu |
| Q2004 | Treatment for bladder calcul |
| Q2005 | Corticorelin ovine triflutat |
| Q2006 | Digoxin immune FAB (Ovine), |
| Q2007 | Ethanolamine oleate, 1000 ml |
| Q2008 | Fomepizole, 1.5 G |
| Q2009 | Fosphenytoin, 50 mg |
| Q2010 | Glatiramer acetate, 25 mgeny |
| Q2011 | Hemin, 1 mg |
| Q2012 | Pegademase bovine inj 25 I.U |
| Q2013 | Pentastarch 10\% inj, 100 ml |
| Q2014 | Sermorelin acetate, 0.5 mg |
| Q2015 | Somatrem, 5 mg |
| Q2016 | Somatropin, 1 mg |
| Q2017 | Teniposide, 50 mg |
| Q2018 | Urofollitropin, 75 I.U. |
| Q3001 | Brachytherapy Seeds |

[FR Doc. 00-8215 Filed 3-31-00 11:00 am]

[^277]

## Friday,

April 7, 2000

## Part III

## Department of Agriculture

Cooperative State Research, Education, and Extension Service

Integrated Research, Education, and Extension Competitive Grants ProgramPest Management: Request for Proposals and Request for Input; Notice

## DEPARTMENT OF AGRICULTURE

## Cooperative State Research, Education, and Extension Service

Integrated Research, Education, and Extension Competitive Grants Program—Pest Management: Request for Proposals and Request for Input
AGENCY: Cooperative State Research, Education, and Extension Service.
ACTION: Notice of Request for Proposals and Request for Input.

SUMMARY: The Cooperative State Research, Education and Extension Service (CSREES) announces the availability of grant funds and requests proposals for the Integrated Research, Education, and Extension Competitive Grants Program-Pest Management for fiscal year (FY) 2000 to support integrated, multifunctional agricultural research, extension, and education activities that address pest management priorities in United States agriculture, particularly those priorities addressing anticipated regulatory losses of key pest management tools resulting from the implementation of the Food Quality Protection Act (FQPA) of 1996. The Integrated Research, Education, and Extension Competitive Grants Program-Pest Management will have four program components: Crops at Risk from FQPA Implementation (CAR); FQPA Risk Avoidance and Mitigation for Major Food Crop Systems (RAMP); Methyl Bromide Transitions (MBT); and Pest Management Centers. The amount available for support of this program in FY 2000 is approximately $\$ 11,000,000$.
This notice sets out the objectives for these projects, the eligibility criteria for projects and applicants, the application procedures, and the set of instructions needed to apply for a Pest Management grant under this authority.
By this notice, CSREES additionally solicits stakeholder input from any interested party regarding the FY 2000 Integrated Research, Education, and Extension Competitive Grants Program-Pest Management for use in the development of any future requests for proposals for this program.
DATES: Proposals must be transmitted by June 6, 2000, as indicated by the postmark or date on courier bill of lading. Proposals transmitted after this date will not be considered for funding. Comments regarding this request for proposals are requested within six months from the issuance of this notice. Comments received after that date will be considered to the extent practicable.
addresses: The address for handdelivered proposals or proposals
submitted using an express mail or overnight courier service is: Integrated Research, Education, and Extension Competitive Grants Program-Pest Management; c/o Proposal Services Unit; Cooperative State Research, Education, and Extension Service; U.S. Department of Agriculture; Room 303, Aerospace Center; 901 D Street, S.W.; Washington, D.C. 20024.

Proposals sent via the U.S. Postal Service must be sent to the following address: Integrated Research, Education, and Extension Competitive Grants Program-Pest Management; Cooperative State Research, Education, and Extension Service; U.S. Department of Agriculture; STOP 2245; 1400 Independence Avenue, S.W.; Washington, D.C. 20250-2245.

Written user comments should be submitted by first-class mail to: Policy and Program Liaison Staff; Office of Extramural Programs; USDA-CSREES; STOP 2299; 1400 Independence Avenue, S.W.; Washington, D.C. 202502299; or via e-mail to: RFP-
OEP@reeusda.gov. In your comments, please include the name of the program and the fiscal year of the RFP to which you are responding.

## FOR FURTHER INFORMATION CONTACT:

Applicants and other interested parties are encouraged to contact the following individuals: CAR: Dr. Rick Meyer; National Program Leader; Plant and Animal Systems Unit; Cooperative State Research, Education, and Extension Service; U.S. Department of Agriculture; STOP 2210; 1400 Independence Avenue, S.W.; Washington, D.C. 202502210; Telephone: (202) 401-4891; Fax: (202) 401-4888; e-mail address: hmeyer@reeusda.gov.; RAMP: Dr. Steve Yaninek; National Program Leader; Plant and Animal Systems Unit; Cooperative State Research, Education, and Extension Service; U.S. Department of Agriculture; STOP 2210; 1400 Independence Avenue, S.W.; Washington, D.C.; Telephone: (202) 401-6702; Fax: 202-401-4888; e-mail address: syaninek@reeusda.gov.; MBT: Dr. Robin Huettel; National Program Leader; Plant and Animal Systems Unit; Cooperative State Research, Education, and Extension Service; U.S. Department of Agriculture; STOP 2210; 1400
Independence Avenue, S.W.;
Washington, D.C.; Telephone: (202) 401-5804; Fax: (202) 401-4888; e-mail address: rhuettel@reeusda.gov; Pest Management Centers: Dr. Dennis Kopp; National Program Leader; Plant and Animal Systems Unit; Cooperative State Research, Education, and Extension Service; U.S. Department of Agriculture; STOP 2210; 1400 Independence

Avenue, S.W.; Washington, D.C.;
Telephone: (202) 401-6437; Fax: (202) 401-4888; e-mail address: dkopp@reeusda.gov.

## SUPPLEMENTARY INFORMATION:

## Table of Contents

Stakeholder Input
Catalog of Federal Domestic Assistance
Part I-General Information
A. Legislative Authority and Background
B. Purpose, Priorities, and Fund

Availability
C. Definitions
D. Eligibility
E. Matching Requirements
F. Funding Restrictions
G. Types of Grant Instruments
H. Funding Mechanisms

Part II-Program Description
A. Project Types
B. Program Area Description
C. Expected Program Outputs and

Reporting Requirements
Part III-Preparation of a Proposal
A. Program Application Materials
B. Content of Proposals
C. Submission of Proposals
D. Acknowledgment of Proposals

Part IV-Review Process
A. General
B. Evaluation Factors
C. Conflicts-of-Interest and Confidentiality

Part V—Additional Information
A. Access to Review Information
B. Grant Awards
C. Use of Funds; Changes
D. Applicable Federal Statues and Regulations
E. Confidential Aspects of Proposals and Awards
F. Regulatory Information

## Stakeholder Input

CSREES is soliciting comments regarding this solicitation of applications from any interested party. These comments will be considered in the development of any future RFP for the program. Such comments will be forwarded to the Secretary or his designee for use in meeting the requirements of section 103(c)(2) of the Agricultural Research, Extension, and Education Reform Act of 1998 (7 U.S.C. 7613(c)(2)). This section requires the Secretary to solicit and consider input on a current RFP from persons who conduct or use agricultural research, education and extension for use in formulating future RFPs for competitive programs. Comments should be submitted as provided for in the
ADDRESSES and DATES portions of this Notice.

## Catalog of Federal Domestic Assistance

This program is listed in the Catalog of Federal Domestic Assistance under 10.303, Integrated Research, Education, and Extension Competitive Grants Program.

## Part I—General Information

## A. Legislative Authority and Background

Section 406 of the Agricultural Research, Extension, and Education Reform Act of 1998 (AREERA) (7 U.S.C. 7626) authorized the Secretary of Agriculture to establish a research, education, and extension competitive grants program to provide funding for integrated, multifunctional agricultural research, extension, and education activities. Subject to the availability of appropriations to carry out this program, the Secretary may award grants to colleges and universities (as defined by 1404 of the National Agricultural Research, Extension, and Teaching Policy Act of 1977
(NARETPA) (7 U.S.C. 3103)) on a competitive basis for integrated research, education, and extension projects. Grants are to be awarded to address priorities in United States agriculture that involve integrated research, education, and extension activities as determined by the Secretary in consultation with the National Agricultural Research, Extension, Education, and Economics Advisory Board.
On November 19, 1999, the Secretary published in the Federal Register [64 FR 63560] a notice that the
administration of this grant program had been delegated to the Cooperative State Research, Education, and Extension Service (CSREES). This notice also solicited public comment from persons who use or conduct research, extension, or education regarding the priorities to be addressed by this new program. In addition, this notice announced a public meeting to obtain comments to use in developing the proposed rule and requests for proposals for this new grant program. The public meeting was held on December 6, 1999. All the comments and the official transcript of the meeting have been made available for review on the CSREES web page (http:// www.reeusda.gov/integrated/). This RFP was developed in consultation with the Advisory Board. In addition, the comments and testimonies from the December 6, 1999, public meeting were considered in the formulation of this RFP.
The entire program is funded in FY 2000 at $\$ 37,637,702$ (after deduction for administrative expenses) for the following integrated activities: Water Quality ( $\$ 12,374,115$ ), Food Safety ( $\$ 14,277,277$ ), and the Pest Management Component that includes: Pesticide Impact Assessment $(\$ 4,322,310)$, Crops at Risk from Food Quality and Protection Act (FQPA) Implementation
(\$952,000), FQPA Risk Mitigation Program for Major Food Crop Systems ( $\$ 3,808,000$ ), and Methyl Bromide Transitions ( $\$ 1,904,000$ ). There will be three RFP's for this program. The Water Quality and Food Safety Programs will each have a separate RFP, while the latter four programs will be announced as one RFP. This notice announces and describes the Pest Management component of the Program.

CSREES will administer the Integrated Research, Education, and Extension Competitive Grants Program by determining priorities in United States agriculture through Agency stakeholder input processes and in consultation with the National Agricultural Research, Extension, Education, and Economics Advisory Board. Each RFP for the different program areas (i.e., Water Quality, Food Safety, etc.) will be developed each fiscal year based on these established priorities and the resulting determined approaches to solving these critical agricultural issues. Although this overall grant program seeks to solve critical agricultural issues through an integration of research, education, and extension activities, a component of a RFP, depending on the priority being addressed and/or the stage at which the priority is being addressed, may request proposals that are research, education, or extension only, or a combination thereof. However, the overall overarching approach to solving the critical agricultural issue, priority, or problem will be through an integration of research, education, and extension activities within each individual program area.

## B. Purpose, Priorities, and Fund Availability

The components of the Integrated Competitive Grants Program-Pest Management are Crops at Risk from FQPA Implementation program (CAR); FQPA Risk Avoidance and Mitigation for Major Food Crop Systems (RAMP); Methyl Bromide Transitions Program (MBTP); and Pesticide Impact Assessment Program (hereafter referred to as "Pest Management Centers"). These four components will address anticipated regulatory losses of key pest management tools resulting from the implementation of the Food Quality Protection Act of 1996 (FQPA) (see http://www.epa.gov/oppfead1/fqpa/ index.html), other regulatory actions, or other agreements (e.g., Clean Air Act, as amended 1990).

The four components of the Integrated Research, Education, and Extension Competitive Grants Program-Pest Management will support a wide range
of complementary research, education, and extension activities. Together, these four components support activities to assess the use and efficacy of available pest management tools, develop and demonstrate the efficacy of reduced-risk pesticides and other pest management alternatives, and identify possible transition and mitigation strategies that serve as viable pest management options for crops and agro-ecosystems at risk due to anticipated regulatory actions.

By integrating these four separate program components into a single competitive grants program, CSREES has responded to stakeholder suggestions that the Agency develop a coordinated program to address pest management challenges that face the Nation in the short- and long-terms. Projects supported by the four components of the Integrated Activities Pest Management Competitive Grants Program provide a coordinated response to FQPA needs and issues. CSREES also expects that Integrated Research, Education, and Extension Competitive Grants Program—Pest Management projects will be integral components of other CSREES pest management programs such as the Pest Management Alternatives Program (PMAP), the Regional Integrated Pest Management Grants Program (RIPM), the Pesticide Applicator Training program (PAT), the Minor Crops Program (IR-4), and to pest management activities funded under the regional Sustainable Agriculture Research and Education program (SARE) and the National Research Initiative (NRI).
There is no commitment by USDA to fund any particular proposal or to make a specific number of awards.
Approximately $\$ 11$ million will be available to fund proposals in FY 2000 distributed among the program components as follows: CAR-\$952,000, RAMP-\$3,808,000, MBT-\$1,904,000 and Pest Management Centers$\$ 4,322,310$.

## C. Definitions

For the purpose of awarding grants under this program, the following definitions are applicable:
(1) Administrator means the Administrator of the Cooperative State Research, Education, and Extension Service (CSREES) and any other officer or employee of the Department to whom the authority involved my be delegated.
(2) Authorized departmental officer means the Secretary or any employee of the Department who has the authority to issue or modify grant instruments on behalf of the Secretary.
(3) Authorized organizational representative means the president or
chief executive officer of the applicant organization or the official, designated by the president or chief executive officer of the applicant organization, who has the authority to commit the resources of the organization.
(4) Budget period means the interval of time (usually 12 months) into which the project period is divided for budgetary and reporting purposes.
(5) Cash contributions means the applicant's cash outlay, including the outlay of money contributed to the applicant by non-Federal third parties.
(6) Department or USDA means the United States Department of Agriculture.
(7) Education activity means formal classroom instruction, laboratory instruction, and practicum experience in the food and agricultural sciences and other related matters such as faculty development, student recruitment and services, curriculum development, instructional materials and equipment, and innovative teaching methodologies.
(8) Extension activity means an act or process that delivers science-based knowledge and informal educational programs to people, enabling them to make practical decisions
(9) Grant means the award by the Secretary of funds to an eligible organization or individual to assist in meeting the costs of conducting, for the benefit of the public, an identified project which is intended and designed to accomplish the purpose of the program as identified in these guidelines.
(10) Grantee means an organization designated in the grant award document as the responsible legal entity to which a grant is awarded.
(11) Integrated means to bring the three components of the agricultural knowledge system (research, education, and extension) together around a problem area or activity.
(12) Matching means that portion of allowable project costs not borne by the Federal Government, including the value of in-kind contributions.
(13) Peer review means an evaluation of a proposed project for scientific or technical quality and relevance performed by experts with the scientific knowledge and technical skills to conduct the proposed work or to give expert advice on the merits of a proposal.
(14) Principal investigator/Project director means the single individual designated by the grantee in the grant application and approved by the Secretary who is responsible for the direction and management of the project.
(15) Prior approval means written approval evidencing prior consent by an authorized departmental officer as defined in (2) above.
(16) Project means the particular activity within the scope of the program supported by a grant award.
(17) Project period means the period, as stated in the award document and modifications thereto, if any, during which Federal sponsorship begins and ends.
(18) Research activity means a scientific investigation or inquiry that results in the generation of knowledge.
(19) Secretary means the Secretary of Agriculture and any other officer or employee of the Department to whom the authority involved may be delegated.
(20) Third party in-kind contributions means non-cash contributions of property or services provided by nonFederal third parties, including real property, equipment, supplies and other expendable property, directly benefitting and specifically identifiable to a funded project or program.
(21) Total integrated, multifunctional research, education, and extension approach means that the combination of grants (although the individual grants may involve only research, education, or extension activities or a combination thereof) awarded under the fiscal year's program components will work together to address the priorities in United States agriculture as determined by the Secretary of Agriculture in consultation with the Advisory Board, that involve integrated research, extension, and education activities.

## D. Eligibility

Proposals may be submitted by colleges and universities as defined in section 1404 of the National
Agricultural research, Extension, and Teaching Policy Act of 1977
(NARETPA). The terms "college" and "university" mean an educational institution in any State which (1) admits as regular students only persons having a certificate of graduation from a school providing secondary education, or the recognized equivalent of such a certificate, (2) is legally authorized within such State to provide a program of education beyond secondary education, (3) provides an educational program for which a bachelor's degree or any other higher degree is awarded, (4) is a public or other nonprofit institution, and (5) is accredited by a nationally recognized accrediting agency or association. Although an applicant may be eligible based on its status as one of these entities, there are factors which may exclude an applicant
from receiving Federal financial and nonfinancial assistance and benefits under this program (e.g., debarment or suspension of an individual involved or a determination that an applicant is not responsible based on submitted organizational management information). Eligible applicants may subcontract to organizations not eligible under these requirements.
Please note that a research foundation maintained by a college or university is not eligible to receive an award under this program.

## E. Matching Requirements

## 1. General Requirement

If a grant provides a particular benefit to a specific agricultural commodity, the grant recipient is required to provide funds or in-kind support to match the amount of the grant funds provided. See section 10. c. on "Matching Funds"' under Part III, B, "Content of Proposals" for more details.

## 2. Waiver

CSREES may waive the matching funds requirement specified in the above paragraph for a grant if CSREES determines that (a) the results of the project, while of particular benefit to a specific agricultural commodity, are likely to be applicable to agricultural commodities generally; or (b) the project involves a minor commodity, the project deals with scientifically important research, and the grant recipient is unable to satisfy the matching funds requirement.

## F. Funding Restrictions

CSREES has determined that grant funds awarded under this authority may not be used for the renovation or refurbishment of research, education, or extension space; the purchase or installation of fixed equipment in such space; or the planning, repair, rehabilitation, acquisition, or construction of buildings or facilities.

## G. Types of Grant Instruments

In FY 2000 all projects will be awarded using a "New Grant" instrument. In future years, projects under the Integrated Research, Education, and Extension Competitive Grants Program authority can be awarded using one of the grant instruments described below:
(1) New grant. This is a grant instrument by which the Department agrees to support a specified level of effort for a project that generally has not been supported previously under this program. This type of grant is approved on the basis of peer review recommendations.
(2) Renewal grant. This is a grant instrument by which the Department agrees to provide additional funding for a project period beyond that approved in an original or amended award, provided that the cumulative period does not exceed the statutory limitation. When a renewal application is submitted, it should include a summary of progress to date from the previous granting period. A renewal grant shall be based upon new application, de novo peer review and staff evaluation, new recommendation and approval, and a new award instrument.
(3) Supplemental grant. This is an instrument by which the department agrees to provide small amounts of additional funding under a new or renewal grant as specified above and may involve a short-term (usually six months or less) extension of the project period beyond that approved in an original or amended award, but in no case may the cumulative period for the project exceed the statutory limitation. A supplement is awarded only if required to assure adequate completion of the original scope of work and if there is sufficient justification to warrant such action. A request of this nature normally will not require additional peer review.

## H. Funding Mechanisms

The two mechanisms by which new, renewal, and supplemental grants shall be awarded are as follows:
(1) Standard grant. This is a funding mechanism whereby the Department agrees to support a specified level of effort for a predetermined time period without the announced intention of providing additional support at a future date.
(2) Continuation grant. This is a funding mechanism whereby the Department agrees to support a specified level of effort for a predetermined period of time with a statement of intention to provide additional support at a future date, provided that performance has been satisfactory, appropriations are available for this purpose, and continued support will be in the best interests of the Federal government and the public. This kind of mechanism normally will be awarded for an initial one-year period, and any subsequent continuation project grants will be awarded in one-year increments. The award of a continuation project grant to fund an initial or succeeding budget period does not constitute an obligation to fund any subsequent budget period. Unless prescribed otherwise by CSREES, a grantee must submit a separate application for continued support for each subsequent fiscal year.

Requests for such continued support must be submitted in duplicate at least three months prior to the expiration date of the budget period currently being funded. Decisions regarding continued support and the actual funding levels of such support in future years usually will be made administratively after consideration of such factors as the grantee's progress and management practices and the availability of funds. Since initial peer reviews are based upon the full term and scope of the original application, additional evaluations of this type generally are not required prior to successive years' support. However, in unusual cases (e.g., when the nature of the project or key personnel change or when the amount of future support requested substantially exceeds the grant application originally reviewed and approved), additional reviews may be required prior to approving continued funding.

## Part II—Program Description

## A. Project Types

Approximately, $\$ 952,000$ is available for CAR projects in FY 2000. Proposals should be between two to four years in duration with a budget of not more than $\$ 200,000$ per year.

Approximately $\$ 3,808,000$ is available for RAMP projects in FY 2000.
Proposals can be up to five years in duration with a maximum budget of $\$ 500,000$ per year.

Approximately $\$ 1,904,000$ is available for MBT proposals. It is anticipated that $12-15$ grants of up to two years in duration will be awarded in this program component.

Approximately $\$ 4,322,000$ is available for Pest Management Center proposals. Pest Management Centers will be supported for a 3-year period at levels reflective of the activities proposed.

Grants awarded under the Program Area Description of MBT (as described in this RFP) will be issued as "New Grant" instruments and will be awarded as "Standard Grants." Grants awarded under the Program Area Descriptions of CAR, RAMP, and Pest Management Center (as described in this RFP) will be issued as "New Grant" instruments and may be awarded as "Continuation Grants."

## B. Program Area Description

The Integrated Research, Education, and Extension Competitive Grants Program-Pest Management supports efforts to modify existing pest management approaches or develop new methods that address needs created by the implementation of regulatory
actions. Projects supported under this authority must show evidence of research, education, and extension integration at the program or institutional level.

Alternative pest control chemistries and practices resulting from FQPA tolerance reassessment and reregistration should be considered when preparing proposals for this program. These priorities are determined through a critical evaluation of pest management needs for a commodity and the effect of regulatory changes on current pest management practices. These priorities were published in a November 18, 1999, Federal Register notice titled "Pesticide Reregistration Performance Measures and Goals" [64 FR 63036-63045]. This notice is available on the Environmental Protection Agency (EPA) web site at http://www.epa.gov/ fedrgstr/EPAFR-CONTENTS/1999/November/Day-18/ contents.htm/. This notice provides the schedule for completion of regulatory review for high priority chemicals. The overall priorities for FQPA review are also available on the EPA web site at http://www.eps.gov/oppfead1/fqpa/ toleran.htm/.

Activities funded by the Integrated Research, Education, and Extension Competitive Grants Program-Pest Management will address work needed to facilitate grower knowledge and adoption of pesticides that are newly registered or are candidates for registration. Recently-registered chemical pesticides are identified in annual reports on the web site of the EPA Office of Pesticide Programs at http://www.epa.gov/pesticides. Pesticides that are candidates for registration in FY 2000 are named in the interim work plan of the EPA Registration Division. The interim work plan is available on the web at http:// www.epa.gov/opprd001/workplan. Twenty-five new chemicals are included in the work plan in addition to many new uses for 64 alreadyregistered chemicals. The work plan provides the trade name, crops, and company for each chemical and identifies those chemicals that qualified for the EPA reduced-risk status. Biopesticides that are recently registered and those under consideration for registration are identified on the web site at www.epa.gov/pesticides/ biopesticides/. Updates to EPA pesticide priority review and reregistration lists are available at http://www.epa.gov/ pesticides. EPA also issues an electronic newsletter that will announce updates. Sign-up information for the electronic newsletter is available at http:// www.epa.gov/pesticides.

The phase out of methyl bromide is required under Title IV of the Clean Air Act (as amended in 1990) because of its ozone-depleting potential. In October 1998, the Clean Air Act was amended to change the phase out date to 2005 , in harmonization with the date agreed to in the Montreal Protocol. More information on the phase out of methyl bromide is available on the EPA website at http://www.epa. gov/ozone/mbr/ harmoniz.html.
Proposals are solicited for the following program areas:

1. Crops at Risk From FQPA Implementation (CAR) (Program Area 112.1)
(Maximum award: \$200,000 per year for two to four years).
The Crops at Risk from FQPA Implementation (CAR) program is an intermediate-term (two to four years) research, education, and extension competitive grants program with at-risk crops or cropping systems as the focal point. Several crops and cropping systems face potentially severe economic impacts as a result of the possible restrictions or elimination of certain pesticides resulting from implementation of the Food Quality Protection Act (FQPA) of 1996 and other regulatory actions. In the short-term, small-acreage fruit and vegetable crops are most vulnerable. However, many more crops, including large-acreage grain, forage and fiber crops, will be impacted during the pesticide review process. Development of new multipletactic pest management strategies designed to assist producers during the transition is the goal of this program component.
Specific Objectives: a. Evaluate new approaches to pest management techniques and technology (rates, timing,pre-harvest intervals, application methods and equipment, post-harvest treatment etc.) That could reduce or eliminate pesticide residues of concern or the effects of these residues.
b. Develop new pest management tactics based on alternative technologies, including products of genetic engineering, biological organisms, biological pesticides, new chemical pesticides, and cultural practices; and
c. Demonstrate and describe how new tactics can be economically and practically integrated into pest management programs for individual crops.

Updates to EPA pesticide priority review and registration lists are available at http://www.epa.gov/ pesticides. EPA also issues an electronic newsletter that will announce updates.

Sign-up information for the electronic newsletter is available at http:// www.epa.gov/pesticides.

Proposals that address priorities established by stakeholders representing an entire crop production region, consider crosscutting challenges, and show evidence of multi-state or withinstate cooperation regarding research, education, and extension will be given preference.
2. FQPA Risk Avoidance and Mitigation for Major Food Crop Systems Program (RAMP) (Program Area 112.2)
(Maximum award: \$500,000 per year for up to five years).

The FQPA Risk Avoidance and Mitigation for Major Food Crop Systems Program (RAMP) is a long-term (up to five years) research, education, and extension competitive grants program to develop reduced risk pest management strategies for agro-ecosystems. Global markets for food and grain products demand high quality at competitive prices. Growers are faced with meeting market demands and ever-increasing production costs coupled with decreasing or unstable commodity prices. Added to these constraints are concerns posed by implementation of regulatory actions over the next decade. Many of the pest management tools growers have depended on in the past may be restricted or eliminated. Growers face uncertainty regarding which pest management tactics will continue to be available and how to make use of new technologies, such as bioengineered crop innovations and precision agriculture in their production systems. There is a critical need to devise pest management systems that consider all aspects of crop production

Projects supported by RAMP will have a food, fiber and grain production system focus and can include consideration of food safety, occupational safety, water quality and other environmental concerns. The program will address the major acreage cropping systems including, but not limited to, corn, soybean, wheat, cotton and rice, as well as, the fruits and vegetables most important in the human diet, especially the diets of infants and children. Emphasis will be placed on development and implementation of new and innovative pest management systems designed to maintain crop productivity and profitability while addressing environmental quality and human health concerns. The goal of this long-term effort is to eliminate or minimize pesticide residues of concern on foods, in drinking water, and in the environment. This program also
supports projects to reduce occupational risk for producers and their employees. These will be long-term projects and will evolve from in-depth discussions of pest management needs and priorities involving stakeholders. Projects are intended to enhanced stability and sustainability of agricultural production systems and will be multi-state or regional in scale, typically involve multiple cropping systems that define an agroecosystem. A major goal of this effort will be the development of pest management systems that are based on an advanced understanding of cropping system biology and ecology.
Specific Objectives: a. Develop methods of pest management that reduce or eliminate the risk from pesticide residues; and b. Develop and implement information intensive approaches to pest management based on a more complete understanding of crop and pest biology, their interactions and mutual impacts, and factors impacting the stability of pest management systems in major cropping systems.
Proposals that strive to maintain crop economic viability based on a diverse bio-based pest management system are encouraged. Proposals should address priorities established by stakeholders representing an entire cropping system and consider crosscutting challenges, and must show evidence for multi-state and multi-disciplinary cooperation regarding research, education, and extension. Proposals should catalog and review the pest management tactics currently being used in the targeted cropping system, then define opportunities for new pest management approaches as part of the proposal. All proposals should include an outreach component to promote the exchange of pest management information among researchers, extension agents, producers, and commodity groups as it relates to the project. Outreach efforts can make use of publications, website development, field days, workshops or other relevant planning and outreach activities. Successful proposals will provide milestones and independently verifiable indicators that can be used to measure progress and impact across a range of ecological, agronomic and economic criteria. Budgetary provisions should be made to support formal stakeholder reviews after the second field season and at the end of the project.

## 3. Methyl Bromide Transitions Program (MBT) (Progam Area 112.3)

(No Maximum award and up to two years; however, it is anticipated that 1215 grants will be funded).

The Methyl Bromide Transitions Program (MBT) supports the discovery and implementation of practical pest management alternatives for commodities affected by the phase-out of methyl bromide. Projects supported by MBT will focus on short- to intermediate-term solutions for all commodities at risk using presently available or newly developed pest management technologies and practices Since alternatives to methyl bromide that have thus far been developed require different pest management strategies than those used for methyl bromide alone, projects supported by MBT will emphasize the development and implementation of integrated management approaches. This includes increased research, education and extension activities on all commodities at risk, including field trials and other demonstration projects that enhance the adoption of pest management alternatives for all commodities. It also will support the technology transfer of results to growers through education and outreach programs.
Specific Objectives: a. Conduct integrated research, education, and extension activities for pest management alternatives on strawberry, tomato, other vegetables, fruits and nuts;
b. Conduct integrated research, education, and extension activities for pest management alternatives for nurseries, including the floral industry and forest nurseries (e.g., general nursery production, production for pest and pathogen-free rootstocks);
c. Develop extension activities to implement pest management alternatives, including field trials and other demonstration projects that enhance the adoption of alternative management practices; and
d. Increase transfer of results to growers through education and outreach programs that promote the implementation of pest management alternatives.
Proposals that address priorities established by stakeholders, consider crosscutting challenges, and show evidence of multi-state or within-state cooperation involving research, education, and extension will be given preference.

## 4. Pest Management Centers (Program Area 112.4)

(No maximum award; however, budget requests should be at levels reflective of the complexity and intensity of agriculture within the region for a duration up to three years).

USDA has placed a high priority on the establishment of Pest Management Centers as a means of strengthening its
connection with production agriculture, research and extension programs, and agricultural stakeholders throughout the United States. USDA and EPA have recognized the need for a pest management information network that can quickly respond to information needs of the public and private sectors. When fully implemented, Pest Management Centers will help USDA and its partner institutions identify, prioritize and coordinate a national pest management research, extension, and education program implemented on a regional basis.

Pest Management Centers will be the focal point for team building efforts, communication networks, and stakeholder participation within a given region. Pest Management Centers will promote open communication, exchange of information and resources, collaboration, and integration of activities among individuals, institutions, states, and regions into coordinated efforts around common themes that span institutional or geographical boundaries. Pest Management Centers also will bring together and help focus the institutional and individual expertise needed to successfully address a range of pest management issues confronting farmers and other pest managers (e.g., regulatory restrictions, development of pest resistance, invasive species, and biotechnology). When fully implemented, Pest Management Centers will maximize the availability of dispersed expertise, reduce duplication of effort, enhance interdisciplinary and multiorganizational efforts, and provide regional expert information, technology, and education upon which production agriculture, government agencies, and agricultural stakeholders can draw.

The process to develop the Pest Management Centers will begin in FY 2000 with the formation of four geographically-based regional Pest Management Centers with one in each of the north central, northeastern, southern, and western regions of the United States. The four regional Pest Management Centers funded in FY 2000 by this RFP will be instrumental in creating a regional process that will evolve into Agroecological Pest Management Centers in FY 2003, based upon agroecologically defined crop production regions.

Pest Impact Assessment Program funds will be used to implement and support the regional Pest Management Centers. The regional Pest Management Centers will fulfill a real and immediate need in establishing a national 2-way pest management communication network which includes USDA and
other government agencies, scientists at colleges and universities, and stakeholders focusing on pest management issues. These activities, among other things, will ensure broad based stakeholder participation in initiating a 3 -year process to facilitate the planning and development of future Agroecological Pest Management Centers.

Successful applicants for FY 2000 regional Pest Management Centers should present a plan that will demonstrate their capacity to form and fund collaborative information networks that cross traditional institutional, disciplinary, and geographic boundaries to address the region's pest management priorities. The four successful proposals funded in FY 2000 will be expected to conduct the following activities:
a. Establish a team of pest managers, producers and commodity groups, and other stakeholders that represent the diversity of capabilities, institutions, and pest management issues found in the region.
b. Establish a regionally-based pest management information and communication network linking USDA and other Federal agencies with agricultural researchers and stakeholders throughout the region. Among the responsibilities of the network will be to (1) collect, synthesize, and disseminate information on pest management practices; (2) coordinate crop profile development and develop pest management strategy plans for important commodities in the region; and (3) coordinate science reviews of documents related to crop production, pest management, regulatory, health, and environmental risk issues.
c. Facilitate an interactive process designed to identify appropriate boundaries for agroecological pest management areas in the United States. Once determined, agroecological areas will serve to demarcate the Agroecological Pest Management Centers needed to address regional and National priorities. These Agroecological Pest Management Centers will be geographically defined by an appropriate set of criteria, such as agroecological or crop production regions, that reflect principal agricultural production zones in the country and address the broad spectrum of pest management needs within each region. The function of the regional Pest Management Centers will be redistributed in FY 2003 to the newly defined Agroecological Pest Management Centers that will be established in an open and fair competitive process during FY 2003.

The planning for the FY 2003 Pest Management Centers should be an integral part of the proposal for the FY 2000 regional Pest Management Centers Thus applicants should include plans for:
a. Bringing together pest management professionals and stakeholders to establish the pest management information network and to identify and prioritize agroecological pest management needs. Agroecological Pest Management Centers will serve as regional hubs responsible for ensuring efficient access to pest management expertise and data available through colleges and universities.
b. Defining functional agroecologoically based pest management regions within the four geographic regions of the country to facilitate the evolution of regional Pest Management Centers into Agroecological Pest Management Centers.
c. Participating as a regional representative on a national steering committee established by CSREES to harmonize regional pest management needs into a proposed comprehensive national network compatible and complimentary agroecologically based Pest Management Centers.
Proposed budgets could include funding for a regional Pest Management Center director and support staff, and to support the information network. Regional Pest Management Centers will be supported for a 3 -year period. Annual funding beyond the first year will be dependent upon demonstration of the regional Pest Management Center's accomplishments and the continued availability of Federal funds.

## C. Expected Program Outputs and Reporting Requirements

The grantee must prepare an annual report that details all significant activities towards achieving the goals and objectives of the project. The narrative should be succinct and be no longer than five pages, using 12-point, single-spaced type. The report also should include a listing of any students who worked on the project (report graduate degrees awarded and undergraduates trained, as applicable). A budget summary should be attached to this report, which will provide an overview of all monies spent during the reporting period.

## Part III—Preparation of a Proposal

## A. Program Application Materials

Program application materials are available at the Integrated Research, Education, and Extension Competitive

Grants Program website (http:// www.reeusda.gov/integrated/). If you do not have access to our web page or have trouble downloading material, you may contact the Proposal Services Unit, Office of Extramural Programs, USDA/ CSREES at (202) 401-5048. When calling the Proposal Services Unit, please indicate that you are requesting forms for the Integrated Research, Education, and Extension Competitive Grants Program—Pest Management These materials may also be requested via Internet by sending a message with your name, mailing address (not e-mail) and phone number to psb@reeusda.gov. State that you want a copy of the Program Description and application materials (orange book) for the Fiscal Year 2000 Integrated Research, Education, and Extension Competitive Grants Program-Pest Management.

## B. Content of Proposals

## 1. General

The proposal should follow these guidelines, enabling reviewers to more easily evaluate the merits of each proposal in a systematic, consistent fashion:
(a) The proposal should be prepared on only one side of the page using standard size ( $81 / 2^{\prime \prime} \times 11^{\prime \prime}$ ) white paper, one inch margins, typed or word processed using no type smaller than 12 point font, and single or double spaced. Use an easily readable font face (e.g., Geneva, Helvetica, Times Roman).
(b) Each page of the proposal, including the Project Summary, budget pages, required forms, and any appendices, should be numbered sequentially.
(c) The proposal should be stapled in the upper left-hand corner. Do not bind. An original and 14 copies ( 15 total) must be submitted in one package, along with 10 copies of the "Project Summary" as a separate attachment.
(d) If applicable, proposals should include original illustrations (photographs, color prints, etc.) in all copies of the proposal to prevent loss of meaning through poor quality reproduction.

## 2. Cover Page (Form CSREES-661)

Each copy of each grant proposal must contain an "Application for Funding", Form CSREES-661. One copy of the application, preferably the original, must contain the pen-and-ink signature(s) of the proposing principal investigator(s)/project director(s) (PI/PD) and the authorized organizational representative who possesses the necessary authority to commit the organization's time and other relevant
resources to the project. Any proposed PI/PD or co-PI/PD whose signature does not appear on Form CSREES-661 will not be listed on any resulting grant award. Complete both signature blocks located at the bottom of the
"Application for Funding" form.
Form CSREES-661 serves as a source document for the CSREES grant database; it is therefore important that it be completed accurately. The following items are highlighted as having a high potential for errors or
misinterpretations:
(a) Title of Project (Block 6). The title of the project must be brief (80-character maximum), yet represent the major thrust of the effort being proposed. Project titles are read by a variety of nonscientific people; therefore, highly technical words or phraseology should be avoided where possible. In addition, introductory phrases such as "investigation of" or "research on" "education for" or "outreach that" should not be used.
(b) Program to Which You Are Applying (Block 7). "Integrated Research, Education, and Extension Competitive Grants Program—Pest Management."
(c) Program Area and Number (Block 8). The name of the program component, e.g., CAR, 112.1 or RAMP, 112.2 should be inserted in this block.
(d) Type of Award Request (Block 13). Check the block for "new."
(e) Principal Investigator(s)/Project Director(s) (PI/PD) (Block 15). The designation of excessive numbers of coPI/PD's creates problems during final review and award processing. Listing multiple co-PI/PD's, beyond those required for genuine collaboration, is therefore discouraged. Note that providing a Social Security Number is voluntary, but is an integral part of the CSREES information system and will assist in the processing of the proposal.
(f) Type of Performing Organization (Block 18). A check should be placed in the box beside the type of organization which actually will carry out the effort. For example, if the proposal is being submitted by an 1862 Land-Grant Institution but the work will be performed in a department, laboratory, or other organizational unit of an agricultural experiment station, box " 03 " should be checked. If portions of the effort are to be performed in several departments, check the box that applies to the individual listed as PI/PD \#1 in Block 15.a.
(g) Other Possible Sponsors (Block 22). List the names or acronyms of all other public or private sponsors including other agencies within USDA and other programs funded by CSREES
to whom your application has been or might be sent. In the event you decide to send your application to another organization or agency at a later date, you must inform the identified CSREES Program Director as soon as practicable. Submitting your proposal to other potential sponsors will not prejudice its review by CSREES; however, duplicate support for the same project will not be provided. Complete the "Application for Funding," Form CSREES-661, in its entirety.
(h) One copy of the "Application for Funding" form must contain the signatures (in ink) of the PI/PD's and authorized organizational representative for the applicant organization.

## 3. Table of Contents

For consistency and ease in locating information, each proposal must contain a detailed Table of Contents just after the cover page. The Table of Contents should contain page numbers for each component of the proposal. Page numbers should begin with the first page of the Project Description.

## 4. Project Summary

The proposal must contain a Project Summary of 250 words or less on a separate page which should be placed immediately after the Table of Contents and should not be numbered. The names and affiliated organizations of all PI/PD's and co-PI/PD's should be listed on this form as well as the title of the project, in addition to the title of the project. The summary should be a selfcontained, specific description of the activity to be undertaken and should focus on: overall project goal(s) and supporting objectives; plans to accomplish project goal(s); and relevance of the project to the Integrated Competitive Grants Program-Pest Management. The importance of a concise, informative Project Summary cannot be overemphasized.

## 5. Project Description

For CAR, RAMP, and MBT proposals, the project description may not exceed 15 single- or double-spaced pages. Project descriptions for Pest Management Centers may not exceed 20 single- or double-spaced pages. The Project Description should include the following components.
a. Introduction and Rationale: Include a clear statement of the problems to be addressed and goals expected to be accomplished. Describe the supporting objectives; questions; research, education and/or extension components to be included; and/or partners that will be used to accomplish the goal(s) set. In addition, this section should include in-
depth information on the following, when applicable:

1. Estimates of the magnitude of the issues and their relevance to stakeholders and to ongoing StateFederal food and agricultural research, education and extension programs.
2. Role of stakeholders in problem identification, planning, implementation and evaluation as appropriate.
3. Reasons for having the work performed by the proposing institution. 4. For CAR, RAMP, and MBTP proposals only: A detailed plan for the research, education, and technology transfer that will be used to implement the pest management alternative solution in the field, and should identify milestones and independently verifiable indicators.
b. Objectives: Clear, concise, complete, and logically arranged statement(s) of the specific aims of the proposed effort must be included in all proposals. Pest Management Center proposals should indicate which information needs will be given first priority, and identify major Center deliverables, such as crop profiles, reports, databases, and Web sites.
c. Procedures: For CAR, RAMP, and MBTP Proposals: The procedures or methodology to be applied to the proposed effort should be explicitly stated. This section should include but not necessarily be limited to:
4. A description of the proposed investigations and/or experiments in the sequence in which it is planned to carry them out;
5. Techniques to be employed, including their feasibility;
6. Kinds of results expected;
7. Means by which data will be analyzed or interpreted;
8. Pitfalls that might be encountered; and
9. Limitations to proposed procedures.

For Pest Management Center Proposals: The proposal should provide details regarding the procedures and processes that will be used to manage the Pest Management Center. Proposals should include, but not necessarily be limited to, the following aspects of Center management:

1. Identify the Center Director and other key personnel who will comprise the Center's staff;
2. Describe how the Pest Management Center will be managed, including how and by who work priorities will be established (e.g., steering and stakeholder advisory committees), how partner institutions and stakeholders will participate in Center management, how information collected by the Center
will be aggregated and disseminated, and how Center activities will be coordinated with the activities of the other three regional Centers;
3. Describe the open and competitive process that will be used to identify the institutions and individuals that will form the information network in the region (Centers should build upon existing regional coordination efforts to the extent possible or should indicate why existing efforts are not relevant. The proposal should also describe how coordination with the National Agricultural Statistics Service (NASS), the Economic Research Service (ERS), EPA, the Agricultural Research Service (ARS), and other government agencies will be ensured;
4. Provide an action plan, including milestones, for the establishment of the Pest Management Center, the regional information network, the participatory process to identify agro-ecosystems centers; and
5. Describe the process that will be used to hold an "independent" evaluation of the Center on an annual basis (Members of the review team should reflect the Center's "community of interest'", including member institutions, Center clients, and stakeholder groups. The results of the annual review will be used by CSREES to determine whether continued funding of the Center is justified.).
d. Cooperation and Institutional Units Involved: Cooperative and multi-state applications are encouraged. Identify each institutional unit contributing to the project. Identify each institution in a multiple-institution proposal and designate the lead institution. When appropriate, the project should be coordinated with the efforts of other State and/or national programs. Clearly define the roles and responsibilities of each institutional unit of the project team, if applicable.
e. Literature Review: A summary of pertinent publications with emphasis on their relationship to the effort being proposed should be provided and should include all important and recent publications from other institutions, as well as those from the applicant institution. The citations themselves should be accurate, complete, and written in an acceptable journal format.

## 6. Appendices to Project Description

Appendices to the Project Description are allowed if they are directly germane to the proposed project and are limited to a total of two of the following: reprints (papers that have been published in peer reviewed journals) and preprints (manuscripts in press for a peer reviewed journal; these must be
accompanied by a letter of acceptance from the publishing journal).

## 7. Key Personnel

All senior personnel who are expected to be involved in the effort must be clearly identified. For each person, the following should be included:
a. The roles and responsibilities of each PI/PD and/or collaborator should be clearly described;
b. An estimate of the time commitment involved for each PI/PD and/or collaborator; and
c. Vitae of each PI/PD, senior associate, and other professional personnel. This section should include vitae of all key persons who are expected to work on the project, whether or not CSREES funds are sought for their support. The vitae should be limited to two (2) pages each in length, excluding publications listings. A chronological list of all publications in refereed journals during the past four (4) years, including those in press, must be provided for each project member for which a curriculum vitae is provided. Also list only those non-refereed technical publications that have relevance to the proposed project. All authors should be listed in the same order as they appear on each paper cited, along with the title and complete reference as these usually appear in journals.

## 8. Conflict-of-Interest List

A Conflict-of-Interest List must be provided for all individuals involved in the project (identified as key personnel). Each list should be on a separate page and include alphabetically the full names of the individuals in the following categories: (a) All collaborators on projects within the past four years, including current and planned collaborations; (b) all coauthors on publications within the past four years, including pending publications and submissions; (c) all persons in your field with whom you have had a consulting or financial arrangement within the past four years, who stand to gain by seeing the project funded; and (d) all thesis or postdoctoral advisees/advisors within the past four years (some may wish to call these life-time conflicts). This form is necessary to assist program staff in excluding from proposal review those individuals who have conflicts-ofinterest with the personnel in the grant proposal. The Program Director must be informed of any additional conflicts-ofinterest that arise after the proposal is submitted.
9. Collaborative and/or Subcontractual Arrangements

If it will be necessary to enter into formal consulting or collaborative arrangements with others, such arrangements should be fully explained and justified. In addition, evidence should be provided that the collaborators involved have agreed to render these services. If the need for consultant services is anticipated, the proposal narrative should provide a justification for the use of such services, a statement of work to be performed, and a resume or curriculum vita for each consultant. For purposes of proposal development, informal day-today contacts between key project personnel and outside experts are not considered to be collaborative arrangements and thus do not need to be detailed.

All anticipated subcontractual arrangements also should be explained and justified in this section. A proposed statement of work and a budget for each arrangement involving the transfer of substantive programmatic work or the providing of financial assistance to a third party must be provided. Agreements between departments or other units of your own institution and minor arrangements with entities outside of your institution (e.g., requests for outside laboratory analyses) are excluded from this requirement.

If you expect to enter into subcontractual arrangements, please note that the provisions contained in 7 CFR Part 3019, USDA Uniform Administrative Requirements for Grant and Other Agreements with Institutions of Higher Education, Hospitals, and Other Non-Profit Organizations, and the general provisions contained in 7 CFR Part 3015.205, USDA Uniform Federal Assistance Regulations, flow down to subrecipients. In addition, required clauses from Sections 40-48 ("Procurement Standards") and Appendix A ("Contract Provisions’’) to 7 CFR Part 3019 should be included in final contractual documents, and it is necessary for the subawardee to make a certification relating to debarment/ suspension.

## 10. Budget (Form CSREES-55)

a. Budget Form. Prepare the budget, Form CSREES-55, in accordance with instructions provided. A budget form is required for each year of requested support. In addition, a cumulative budget is required detailing the requested total support for the overall project period. The budget form may be reproduced as needed by applicants. Funds may be requested under any of
the categories listed on the form, provided that the item or service for which support is requested is allowable under the authorizing legislation, the applicable Federal cost principles, and these program guidelines, and can be justified as necessary for the successful conduct of the proposed project. Applicants must also include a Budget Narrative to justify their budgets (see section b below.)
The following guidelines should be used in developing your proposal budget(s):

1. Salaries and Wages. Salaries and wages are allowable charges and may be requested for personnel who will be working on the project in proportion to the time such personnel will devote to the project. If salary funds are requested, the number of Senior and Other Personnel and the number of CSREESFunded Work Months must be shown in the spaces provided. Grant funds may not be used to augment the total salary or rate of salary of project personnel or to reimburse them for time in addition to a regular full-time salary covering the same general period of employment Salary funds requested must be consistent with the normal policies of the institution.
2. Fringe Benefits. Funds may be requested for fringe benefit costs if the usual accounting practices of your organization provide that organizational contributions to employee benefits (social security, retirement, etc.) be treated as direct costs. Fringe benefit costs may be included only for those personnel whose salaries are charged as a direct cost to the project.
3. Nonexpendable Equipment. Nonexpendable equipment means tangible nonexpendable personal property including exempt property charged directly to the award having a useful life of more than one year and an acquisition cost of $\$ 5,000$ (or lower depending on institutional policy) or more per unit. As such, items of necessary instrumentation or other nonexpendable equipment should be listed individually by description and estimated cost in the Budget Narrative. This applies to revised budgets as well, as the equipment item(s) and amount(s) may change.
4. Materials and Supplies. The types of expendable materials and supplies which are required to carry out the project should be indicated in general terms with estimated costs in the Budget Narrative.
5. Travel. The type and extent of travel and its relationship to project objectives should be described briefly and justified. If foreign travel is proposed, the country to be visited, the
specific purpose of the travel, a brief itinerary, inclusive dates of travel, and estimated cost must be provided for each trip. Airfare allowances normally will not exceed round-trip jet economy air accommodations. U.S. flag carriers must be used when available. See 7 CFR Part 3015.205(b)(4) for further guidance.
6. Publication Costs/Page Charges. Include anticipated costs associated with publications in a journal (preparing and publishing results including page charges, necessary illustrations, and the cost of a reasonable number of coverless reprints) and audio-visual materials that will be produced. Photocopying and printing brochure, etc., should be shown in Section I., "All Other Direct Costs" of Form CSREES-55.
7. Computer (ADPE) Costs. Reimbursement for the costs of using specialized facilities (such as a university- or department-controlled computer mainframe or data processing center) may be requested if such services are required for completion of the work.
8. All Other Direct Costs. Anticipated direct project charges not included in other budget categories must be itemized with estimated costs and justified in the Budget Narrative. This also applies to revised budgets, as the item(s) and dollar amount(s) may change. Examples may include space rental at remote locations, subcontractual costs, and charges for consulting services, telephone, facsimile, shipping costs, and fees necessary for laboratory analyses. You are encouraged to consult the "Instructions for Completing Form CSREES-55, Budget," of the Application Kit for detailed guidance relating to this budget category. Form AD-1048 must be completed by each subcontractor or consultant and retained by the grantee. Pest Management Centers proposals should indicate that sub-contractual arrangements are anticipated, but should not identify specific institutions. Successful Pest Management Center applicants will be expected to conduct an open and competitive process to identify institutional members of its regionallybased information network, after which subcontractual arrangements can be made between the Center's host institution and member institutions.
9. Indirect Costs. Section 1462 of the National Agricultural Research, Extension, and Teaching Policy Act of 1977 (7 U.S.C. 3310) limits indirect costs for this program to 19 percent of total Federal funds provided under each award. Therefore the recovery of indirect costs under this program may
not exceed the lesser of the institution's official negotiated indirect cost rate or the equivalent of 19 percent of total Federal funds awarded. If no rate has been negotiated, a reasonable dollar amount (equivalent to less than 19 percent of total Federal funds requested) in lieu of indirect costs may be requested, subject to approval by USDA.
b. Budget Narrative. All budget categories, excluding Indirect Costs, for which support is requested, must be individually listed (with costs) and justified on a separate sheet of paper and placed immediately behind the Budget Form. Explanations of matching funds or lack there of on commodityspecific projects also are to be included in this section.
c. Matching Funds. If an applicant concludes that matching funds are not required as specified under Part I (e), a justification should be included in the Budget Narrative. CSREES will consider this justification when ascertaining final matching requirements or in determining if required matching can be waived. CSREES retains the right to make final determinations regarding matching requirements.

For those grants requiring matching funds as specified under Part I (e), proposals should include written verification of commitments of matching support (including both cash and in-kind contributions) from third parties. Written verification means:
(a) For any third party cash contributions, a separate pledge agreement for each donation, signed by the authorized organizational representatives of the donor organization and the applicant organization, which must include: (1) The name, address, and telephone number of the donor; (2) the name of the applicant organization; (3) the title of the project for which the donation is made; (4) the dollar amount of the cash donation; and (5) a statement that the donor will pay the cash contribution during the grant period; and
(b) For any third party in-kind contributions, a separate pledge agreement for each contribution, signed by the authorized organizational representatives of the donor organization and the applicant organization, which must include: (1) The name, address, and telephone number of the donor; (2) the name of the applicant organization; (3) the title of the project for which the donation is made; (4) a good faith estimate of the current fair market value of the third party in-kind contribution; and (5) a statement that the donor will make the contribution during the grant period.

The sources and amount of all matching support from outside the applicant institution should be summarized on a separate page and placed in the proposal immediately following the Budget Narrative. All pledge agreements must be placed in the proposal immediately following the summary of matching support.

The value of applicant contributions to the project shall be established in accordance with applicable cost principles. Applicants should refer to OMB Circular A-21, Cost Principles for Educational Institutions, for further guidance and other requirements relating to matching and allowable costs.

## 11. Current and Pending Support (Form CSREES-663)

All proposals must contain Form CSREES-663 listing other current public or private support (including in-house support) to which key personnel identified in the proposal have committed portions of their time, whether or not salary support for person(s) involved is included in the budget. Analogous information must be provided for any pending proposals that are being considered by, or that will be submitted in the near future to, other possible sponsors, including other USDA Programs or agencies. Concurrent submission of identical or similar proposals to the possible sponsors will not prejudice proposal review or evaluation by the CSREES for this purpose. However, a proposal that duplicates or overlaps substantially with a proposal already reviewed and funded (or to be funded) by another organization or agency will not be funded under this program. Note that the project being proposed should be included in the pending section of the form.

## 12. Assurance Statement(s), (Form CSREES-662)

A number of situations encountered in the conduct of projects require special assurances, supporting documentation, etc., before funding can be approved for the project. In addition to any other situation that may exist with regard to a particular project, it is expected that some applications submitted in response to these guidelines will involve the following:
a. Recombinant DNA or RNA Research. As stated in 7 CFR Part 3015.205 (b)(3), all key personnel identified in the proposal and all endorsing officials of the proposing organization are required to comply with the guidelines established by the National Institutes of Health entitled,
"Guidelines for Research Involving Recombinant DNA Molecules," as revised. If your project proposes to use recombinant DNA or RNA techniques, you must so indicate by checking the "yes" box in Block 19 of Form CSREES661 (the Cover Page) and by completing Section A of Form CSREES-662. For applicable proposals recommended for funding, Institutional Biosafety Committee approval is required before CSREES funds will be released.
b. Animal Care. Responsibility for the humane care and treatment of live vertebrate animals used in any grant project supported with funds provided by CSREES rests with the performing organization. Where a project involves the use of living vertebrate animals for experimental purposes, all key project personnel identified in a proposal and all endorsing officials of the proposing organization are required to comply with the applicable provisions of the Animal Welfare Act of 1966, as amended (7 U.S.C. 2131 et seq.) and the regulations promulgated thereunder by the Secretary in 9 CFR Parts 1, 2, 3, and 4 pertaining to the care, handling, and treatment of these animals. If your project will involve these animals, you should check "yes" in block 20 of Form CSREES-661 and complete Section B of Form CSREES-662. In the event a project involving the use of live vertebrate animals results in a grant award, funds will be released only after the Institutional Animal Care and Use Committee has approved the project.
c. Protection of Human Subjects. Responsibility for safeguarding the rights and welfare of human subjects used in any grant project supported with funds provided by CSREES rests with the performing organization. Guidance on this issue is contained in the National Research Act, Pub. L. No. 93-348, as amended, and implementing regulations promulgated by the Department under 7 CFR Part 1c. If you propose to use human subjects for experimental purposes in your project, you should check the "yes" box in Block 21 of Form CSREES-661 and complete Section C of Form CSREES662. In the event a project involving human subjects results in a grant award, funds will be released only after the appropriate Institutional Review Board has approved the project.

## 13. Certifications

Note that by signing Form CSREES661 the applicant is providing the certifications required by 7 CFR Part 3017, as amended, regarding Debarment and Suspension and Drug Free Workplace, and 7 CFR Part 3018, regarding Lobbying. The certification
forms are included in the application package for informational purposes only. These forms should not be submitted with the proposal since by signing form CSREES-661 your organization is providing the required certifications. If the project will involve a subcontractor or consultant, the subcontractor/consultant should submit a form AD-1048 to the grantee organization for retention in their records. This form should not be submitted to USDA.

## 14. Compliance With the National Environmental Policy Act (NEPA) (Form CSREES-1234)

As outlined in 7 CFR Part 3407 (the Cooperative State Research, Education, and Extension Service regulations implementing NEPA), the environmental data for any proposed project is to be provided to CSREES so that CSREES may determine whether any further action is needed. In some cases, however, the preparation of environmental data may not be required. Certain categories of actions are excluded from the requirements of NEPA.

In order for CSREES to determine whether any further action is needed with respect to NEPA, pertinent information regarding the possible environmental impacts of a particular project is necessary; therefore, Form CSREES-1234, "NEPA Exclusions Form," must be included in the proposal indicating whether the applicant is of the opinion that the project falls within a categorical exclusion and the reasons therefore. If it is the applicant's opinion that the proposed project falls within the categorical exclusions, the specific exclusion must be identified. Form CSREES-1234 and supporting documentation should be included as the last page of this proposal.

Even though a project may fall within the categorical exclusions, CSREES may determine that an Environmental Assessment or an Environmental Impact Statement is necessary for an activity, if substantial controversy on environmental grounds exists or if other extraordinary conditions or circumstances are present which may cause such activity to have a significant environmental effect.

## C. Submission of Proposals

## 1. When To Submit (Deadline Date)

Proposals must be transmitted by June 6,2000 , as indicated by postmark or date of courier bill of lading. Proposals transmitted after this date will not be considered for funding.

## 2. What To Submit

An original and 14 copies must be submitted. In addition submit 10 copies of the proposal's Project Summary. All copies of the proposals and the Project Summaries must be submitted in one package.

## 3. Where To Submit

Applicants are strongly encouraged to submit completed proposals via overnight mail or delivery service to ensure timely receipt by the USDA. The address for hand-delivered proposals or proposals submitted using an express mail or overnight courier service is: Integrated Research, Education, and Extension Competitive Grants Program -Pest Managment; c/o Proposal Services Unit; Cooperative State Research, Education, and Extension Service; U.S. Department of Agriculture; Room 303, Aerospace Center; 901 D Street, S.W.; Washington, D.C. 20024.
Proposals sent via the U.S. Postal Service must be sent to the following address: Integrated Research, Education, and Extension Competitive Grants Program-Pest Management; c/o Proposal Services Unit; Cooperative State Research, Education, and Extension Service; U.S. Department of Agriculture; STOP 2245; 1400 Independence Avenue, S.W.; Washington, D.C. 20250-2245.

## D. Acknowledgment of Proposals

The receipt of all proposals will be acknowledged by e-mail. Therefore, applicants strongly are encouraged to provide e-mail addresses, where designated, on the Form CSREES-661. If the applicant's email address is not indicated, CSREES will acknowledge receipt of proposal by letter.

Once the proposal has been assigned an identification number, please cite that number on all future correspondence. If the applicant does not receive an acknowledgment within 60 days of the submission deadline, please contact the Program Director.

## Part IV—Review Process

## A. General

Each proposal will be evaluated using a 3-part process. First, each proposal will be screened to ensure that it meets the administrative requirements as set forth in this request for proposals-tier review process. Second, a panel will consider the relevance of the proposal to program objectives. Third, a technical peer panel will consider the technical merits of the proposal. The relevancy panel will be comprised of representatives from USDA and other federal agencies, farm and commodity
organizations, environmental and consumer groups, experts from colleges and universities, and others as needed. The technical peer panel will include representatives with appropriate scientific backgrounds from colleges and universities, USDA, EPA, and organizations with research, education, and extension expertise as needed. Funding determinations will come from a rank-ordered list of projects based on the combined relevancy and scientific peer panel scores. CSREES has found the above review process most appropriate for evaluating pest management grant proposals as proven through the administration of the Pest Management Alternatives Research Program as authorized under the Competitive, Special, and Facilities Research Grant Act.
Overall, peer review panel members will be selected based upon their training and experience in relevant scientific, education or extension fields taking into account the following factors: (a) The level of formal scientific technical education, and extension experience of the individual, as well as the extent to which an individual is engaged in relevant research, education and/or extension activities; (b) the need to include as peer reviewers experts from various areas of specialization within relevant scientific, education, and extension fields; (c) the need to include as reviewers other experts (producers, range or forest managers/ operators, consumers, etc.) who can assess relevance of the proposals to targeted audiences and to program needs; (d) the need to include as peer reviewers experts from a variety of organizational types (e.g., colleges, universities, industry, state and Federal agencies, private profit and non-profit organizations), and geographic locations; (e) the need to maintain a balanced composition of peer review groups with regard to minority and female representation and an equitable age distribution; and (f) the need to include members that can judge the effective usefulness to producers and the general public of each proposal.

## B. Evaluation Criteria

Priority will be given for integrated, multifunctional research, education, and extension projects.
The criteria used to evaluate proposals submitted to the Integrated Research, Education, and Extension Competitive Grants Program-Pest Management will vary depending on which of the four program components you are requesting funding from. The two sets of evaluation criteria are listed below.

1. Evaluation Criteria for CAR, RAMP, and MBT Proposals

Proposals for CAR, RAMP, and MBT funding will be evaluated based on the criteria described below. The relevancy panel will assign up to 30 points based on Criterion a, and the technical panel will assign up to 70 points based on Criteria b-f. The criteria are listed below.
a. Relevance to Program Objectives (30 points): Factors that will be considered include the importance of the crop/pest combination (particularly agronomic and economic considerations; e.g., magnitude of the pest problem if a widely used pesticide is no longer available), number of crops and pesticides addressed, user involvement in planning and implementation, potential for rapid integration into production practices, and demonstration of consideration of existing pest management programs.
b. Importance of the Problem (10 points): particularly ecological and agronomic considerations.
c. Technical Quality of the Approach (15 points): include the feasibility of attaining objectives; and the adequacy of professional training and experience, facilities and equipment.
d. Potential to Reduce Reliance on Pesticides (15 points).
e. Level of End-User Involvement (20 points): Examples are grower or commodity group involvement in planning or conducting research trials and demonstrations.
f. Appropriateness of the Budget (10 points).

## 2. Evaluation Criteria for Pest Management Center Proposals

Proposals for Pest Management Center funding will be evaluated based on the criteria described below. The relevancy panel will assign up to 30 points based on Criterion a, and the technical panel will assign up to 70 points based on Criteria b-e. The criteria are listed below.
a. Relevance to Program Objectives (30 points).
b. Appropriateness of Process to Establish Information Network (20 points): The process to establish the information network should ensure that all eligible colleges and universities have an opportunity to be become a member of the regional Center's information network.
c. Capacity to Attain Program Objectives (20 points): Factors that will be considered include the ability to provide leadership to form a broadbased regional information network; the strength of the action plan for
development of Pest Management Centers organized around crop production regions (agro-ecosystems); the ability to foster research, extension and education collaborations, interdisciplinary teams, and interinstitutional partnerships; the adequacy, professional training and experience of Center staff; and the level of institutional support for Center including facilities and equipment.
d. Level of End-User Involvement (20 points): Factors that will be considered include evidence that stakeholders were consulted during proposal preparation and will participate in operation of the Center, and the ability to establish partnerships with stakeholders to accomplish Center objectives.
e. Appropriateness of the Budget (10 points): The budget should be reflective of the complexity and intensity of agriculture within the region.

## C. Conflicts-of-Interest and Confidentiality

During the peer evaluation process, extreme care will be taken to prevent any actual or perceived conflicts-ofinterest that may impact review or evaluation. For the purpose of determining conflicts-of-interest, the academic and administrative autonomy of an institution shall be determined by reference to the January 1998 issue of the Codebook for Compatible Statistical Reporting of Federal Support to Universities, Colleges, and Nonprofit Institutions, prepared by Quantum Research Corporation for the National Science Foundation.

Names of submitting institutions and individuals, as well as proposal content and peer evaluations, will be kept confidential, except to those involved in the review process, to the extent permitted by law. In addition, the identities of peer reviewers will remain confidential throughout the entire review process. Therefore, the names of the reviewers will not be released to applicants. At the end of the fiscal year, names of panelists will be made available in such a way that the panelists cannot be identified with the review of any particular proposal.

## Part V—Additional Information

## A. Access To Review Information

Copies of summary reviews, not including the identity of reviewers, will be sent to the applicant PI/PD after the review process has been completed.

## B. Grant Awards

## (1) General

Within the limit of funds available for such purpose, the awarding official of

CSREES shall make grants to those responsible, eligible applicants whose proposals are judged most meritorious under the procedures set forth in this RFP. The date specified by the awarding official of CSREES as the effective date of the grant shall be no later than September 30 of the Federal fiscal year in which the project is approved for support and funds are appropriated for such purpose, unless otherwise permitted by law. It should be noted that the project need not be initiated on the grant effective date, but as soon thereafter as practical so that project goals may be attained within the funded project period. All funds granted by CSREES under this RFP shall be expended solely for the purpose for which the funds are granted in accordance with the approved application and budget, the regulations, the terms and conditions of the award, the applicable Federal cost principles, and the Department's assistance regulations (parts 3015 and 3019 of 7 CFR).
(2) Organizational Management Information
Specific management information relating to an applicant shall be submitted on a one-time basis as part of the responsibility determination prior to the award of a grant identified under this RFP, if such information has not been provided previously under this or another CSREES program. CSREES will provide copies of forms recommended for use in fulfilling these requirements as part of the preaward process.
(3) Grant Award Document and Notice of Grant Award

The grant award document shall include at a minimum the following:
(a) Legal name and address of performing organization or institution to whom the Administrator has awarded a grant under the terms of this request for proposals;
(b) Title of project;
(c) Name(s) and address(es) of PI/PD's chosen to direct and control approved activities;
(d) Identifying grant number assigned by the Department;
(e) Project period, specifying the amount of time the Department intends to support the project without requiring recompetition for funds;
(f) Total amount of Departmental financial assistance approved by the Administrator during the project period;
(g) Legal authority(ies) under which the grant is awarded;
(h) Approved budget plan for categorizing allocable project funds to
accomplish the stated purpose of the grant award; and
(i) Other information or provisions deemed necessary by CSREES to carry out its respective granting activities or to accomplish the purpose of a particular grant.

The notice of grant award, in the form of a letter, will be prepared and will provide pertinent instructions or information to the grantee that is not included in the grant award document.

## C. Use of Funds; Changes

(1) Delegation of Fiscal Responsibility

Unless the terms and conditions of the grant state otherwise, the grantee may not in whole or in part delegate or transfer to another person, institution, or organization the responsibility for use or expenditure of grant funds.

## (2) Changes in Project Plans

(a) The permissible changes by the grantee, PI/PD(s), or other key project personnel in the approved project grant shall be limited to changes in methodology, techniques, or other aspects of the project to expedite achievement of the project's approved goals. If the grantee and/or the PI/PD(s) are uncertain as to whether a change complies with this provision, the question must be referred to the CSREES Authorized Departmental Officer (ADO) for a final determination.
(b) Changes in approved goals or objectives shall be requested by the grantee and approved in writing by the ADO prior to effecting such changes. In no event shall requests for such changes be approved which are outside the scope of the original approved project.
(c) Changes in approved project leadership or the replacement or reassignment of other key project personnel shall be requested by the grantee and approved in writing by the awarding official of CSREES prior to effecting such changes.
(d) Transfers of actual performance of the substantive programmatic work in whole or in part and provisions for payment of funds, whether or not Federal funds are involved, shall be requested by the grantee and approved in writing by the ADO prior to effecting such transfers, unless prescribed otherwise in the terms and conditions of the grant.
(e) Changes in Project Period: The project period may be extended by CSREES without additional financial support, for such additional period(s) as the ADO determines may be necessary to complete or fulfill the purposes of an approved project, but in no case shall the total project period exceed five
years. Any extension of time shall be conditioned upon prior request by the grantee and approval in writing by the ADO, unless prescribed otherwise in the terms and conditions of a grant.
(f) Changes in Approved Budget: Changes in an approved budget must be requested by the grantee and approved in writing by the ADO prior to instituting such changes if the revision will involve transfers or expenditures of amounts requiring prior approval as set forth in the applicable Federal cost principles, Departmental regulations, or in the grant award.

## D. Applicable Federal Statutes and Regulations

Several Federal statutes and regulations apply to grant proposals considered for review and to project grants awarded under this program. These include, but are not limited to:

7 CFR Part 1.1—USDA
implementation of the Freedom of Information Act.
7 CFR Part 3—USDA implementation of OMB Circular No. A-129 regarding debt collection.
7 CFR Part 15, subpart A—USDA implementation of Title VI of the Civil Rights Act of 1964, as amended.

7 CFR Part 3015—USDA Uniform Federal Assistance Regulations, implementing OMB directives (i.e., Circular Nos. A-21 and A-122) and incorporating provisions of 31 U.S.C. 6301-6308 (the Federal Grant and Cooperative Agreement Act of 1977, Pub. L. No. 95-224), as well as general policy requirements applicable to recipients of Departmental financial assistance.

7 CFR Part 3017—USDA
implementation of Governmentwide Debarment and Suspension (Nonprocurement) and Governmentwide Requirements for Drug-Free Workplace (Grants).
7 CFR Part 3018—USDA
implementation of Restrictions on Lobbying. Imposes prohibitions and requirements for disclosure and certification related to lobbying on recipients of Federal contracts, grants, cooperative agreements, and loans.

7 CFR Part 3019—USDA
implementation of OMB Circular A110, Uniform Administrative Requirements for Grants and Other Agreements With Institutions of Higher Education, Hospitals, and Other
Nonprofit Organizations.
7 CFR Part 3052—USDA
implementation of OMB Circular No. A133, Audits of States, Local
Governments, and Non-profit
Organizations.

7 CFR Part 3407-CSREES procedures to implement the National Environmental Policy Act of 1969, as amended.

29 U.S.C. 794 (section 504, Rehabilitation Act of 1973) and 7 CFR Part 15B (USDA implementation of statute)—prohibiting discrimination based upon physical or mental handicap in Federally assisted programs.
35 U.S.C. 200 et seq.-Bayh-Dole Act, controlling allocation of rights to inventions made by employees of small business firms and domestic nonprofit organizations, including universities, in Federally assisted programs
(implementing regulations are contained in 37 CFR Part 401).

## E. Confidential Aspects of Proposals

 and AwardsWhen a proposal results in a grant, it becomes a part of the record of CSREES
transactions, available to the public upon specific request. Information that the Secretary determines to be of a confidential, privileged, or proprietary nature will be held in confidence to the extent permitted by law. Therefore, any information that the applicant wishes to have considered as confidential, privileged, or proprietary should be clearly marked within the proposal. The original copy of a proposal that does not result in a grant will be retained by the Agency for a period of one year. Other copies will be destroyed. Such a proposal will be released only with the consent of the applicant or to the extent required by law. A proposal may be withdrawn at any time prior to the final action thereon.

## F. Regulatory Information

For the reasons set forth in the final Rule-related Notice to 7 CFR part 3015, subpart V (48 FR 29115, June 24, 1983), this program is excluded from the scope of the Executive Order 12372 which requires intergovernmental consultation with State and local officials. Under the provisions of the Paperwork Reduction Act of 1995, as amended (44 U.S.C. chapter 35), the collection of information requirements contained in this Notice have been approved under OMB Document No. 0524-0022.

Done at Washington, D.C., this 4th day of April 2000.

## Charles W. Laughlin,

Administrator, Cooperative State Research, Education, and Extension Service.
[FR Doc. 00-8641 Filed 4-4-00; 2:36 pm]
biLLing Code 3410-22-P


## Friday,

April 7, 2000

## Part IV

## Department of Agriculture

Cooperative State Research, Education, and Extension Service

Integrated Research, Education, and Extension Competitive Grants ProgramNational Food Safety Initiative: Request for Proposals and Request for Input; Notice

## DEPARTMENT OF AGRICULTURE

## Cooperative State Research, Education, and Extension Service

Integrated Research, Education, and Extension Competitive Grants Program—National Food Safety Initiative: Request for Proposals and Request for Input

AGENCY: Cooperative State Research, Education, and Extension Service, USDA.
ACTION: Notice of request for proposals and request for input.
summary: The Cooperative State Research, Education and Extension Service (CSREES) announces the availability of grant funds and requests proposals for the Integrated Research, Education, and Extension Competitive Grants Program—National Food Safety Initiative for fiscal year (FY) 2000 to support integrated, multifunctional agricultural research, extension, and education activities that address food safety priorities in United States agriculture. The amount available for support of this program in FY 2000 is approximately $\$ 14,277,000$.
This notice sets out the objectives for these projects, the eligibility criteria for projects and applicants, the application procedures, and the set of instructions needed to apply for a Food Safety grant under this authority.
By this notice, CSREES additionally solicits stakeholder input from any interested party regarding the FY 2000 Integrated Research, Education, and Extension Competitive Grants Program—National Food Safety Initiative for use in the development of any future requests for proposals for this program.
DATES: Proposals must be transmitted by June 6,2000 , as indicated by the postmark or date on courier bill of lading. Proposals transmitted after this date will not be considered for funding. Comments regarding this request for proposals are requested within six months from the issuance of this notice. Comments received after that date will be considered to the extent practicable. adDresses: The address for handdelivered proposals or proposals submitted using an express mail or overnight courier service is: Integrated Research, Education, and Extension Competitive Grants Program-National Food Safety Initiative; c/o Proposal Services Unit; Cooperative State Research, Education, and Extension Service; U.S. Department of Agriculture; Room 303, Aerospace Center; 901 D Street, S.W.; Washington, D.C. 20024.

Proposals sent via the U.S. Postal Service must be sent to the following address: Integrated Research, Education, and Extension Competitive Grants Program—National Food Safety Initiative; Cooperative State Research, Education, and Extension Service; U.S. Department of Agriculture; STOP 2245; 1400 Independence Avenue, S.W.; Washington, D.C. 20250-2245.

Written user comments should be submitted by first-class mail to: Policy and Program Liaison Staff; Office of Extramural Programs; USDA-CSREES; STOP 2299; 1400 Independence
Avenue, S.W.; Washington, D.C. 202502299; or via e-mail to: RFP-
OEP@reeusda.gov. In your comments, please include the name of the program and the fiscal year of the RFP to which you are responding.
FOR FURTHER INFORMATION: Applicants and other interested parties are encouraged to contact Dr. Jan Singleton; National Program Leader, Food Science and Food Safety; Plant and Animal Systems Unit; Cooperative State Research, Education, and Extension Service; U.S. Department of Agriculture; STOP 2220; 1400 Independence
Avenue, S.W.; Washington, D.C. 202502220; telephone: (202) 401-1954; fax: (202) 401-5179; email:
jsingleton@reeusda.gov.

## SUPPLEMENTARY INFORMATION:

## Table of Contents

Stakeholder Input
Catalog of Federal Domestic Assistance

## Part I-General Information

A. Legislative Authority and Background
B. Purpose, Priorities, and Fund Availability
C. Definitions
D. Eligibility
E. Matching Requirements
F. Funding Restrictions
G. Types of Grant Instruments
H. Funding Mechanisms

Part II—Program Description
A. Project Types
B. Program Area Description
C. Expected Program Outputs and Reporting Requirements

Part III—Preparation of a Proposal
A. Program Application Materials
B. Content of Proposals
C. Submission of Proposals
D. Acknowledgment of Proposals

Part IV—Review Process
A. General
B. Evaluation Factors
C. Conflicts-of-Interest and Confidentiality

Part V—Additional Information
A. Access to Review Information
B. Grant Awards
C. Use of Funds; Changes
D. Applicable Federal Statues and

Regulations
E. Confidential Aspects of Proposals and Awards
F. Regulatory Information

## Stakeholder Input

CSREES is soliciting comments regarding this solicitation of applications from any interested party. These comments will be considered in the development of any future RFP for the program. Such comments will be forwarded to the Secretary or his designee for use in meeting the requirements of section 103(c)(2) of the Agricultural Research, Extension, and Education Reform Act of 1998 (7 U.S.C. 7613(c)(2)). This section requires the Secretary to solicit and consider input on a current RFP from persons who conduct or use agricultural research, education and extension for use in formulating future RFPs for competitive programs. Comments should be submitted as provided for in the ADDRESSES and DATES portions of this Notice.

## Catalog of Federal Domestic Assistance

This program is listed in the Catalog of Federal Domestic Assistance under 10.303, Integrated Research, Education, and Extension Competitive Grants Program.

## Part I—General Information

## A. Legislative Authority and Background

Section 406 of the Agricultural Research, Extension, and Education Reform Act of 1998 (AREERA) (7 U.S.C. 7626) authorized the Secretary of Agriculture to establish a research, education, and extension competitive grants program to provide funding for integrated, multifunctional agricultural research, extension, and education activities. Subject to the availability of appropriations to carry out this program, the Secretary may award grants to colleges and universities (as defined by 1404 of the National Agricultural Research, Extension, and Teaching Policy Act of 1977
(NARETPA) (7 U.S.C. 3103)) on a competitive basis for integrated research, education, and extension projects. Grants are to be awarded to address priorities in United States agriculture that involve integrated research, education, and extension activities as determined by the Secretary in consultation with the National Agricultural Research, Extension, Education, and Economics Advisory Board.

On November 19, 1999, the Secretary published in the Federal Register (64

FR 63560) a notice that the administration of this grant program had been delegated to the Cooperative State Research, Education, and Extension Service (CSREES). This notice also solicited public comment from persons who use or conduct research, extension, or education regarding the priorities to be addressed by this new program. In addition, this notice announced a public meeting to obtain comments to use in developing the proposed rule and requests for proposals for this new grant program. The public meeting was held on December 6, 1999. All the comments and the official transcript of the meeting have been made available for review on the CSREES web page (http://
www.reeusda.gov/integrated/). This RFP was developed in consultation with the Advisory Board. In addition, the comments and testimonies from the December 6, 1999, public meeting were considered in the formulation of this RFP.
The entire program is funded in FY 2000 at $\$ 37,637,702$ (after deduction for administrative expenses) for the following integrated activities: Water Quality (\$12,374,115), Food Safety (\$14,277,277), Pesticide Impact Assessment $(\$ 4,322,310)$, Crops at Risk from Food Quality and Protection Act (FQPA) Implementation ( $\$ 952,000$ ), FQPA Risk Mitigation Program for Major Food Crop Systems $(\$ 3,808,000)$, and Methyl Bromide Transition Program ( $\$ 1,904,000$ ). There will be three RFP's for this program. The Water Quality and Food Safety Programs will each have a separate RFP, while the latter four programs will be announced as one RFP. This notice announces and describes the Food Safety component of the Program.
CSREES will administer the Integrated Research, Education, and Extension Competitive Grants Program by determining priorities in United States agriculture through Agency stakeholder input processes and in consultation with the National Agricultural Research, Extension, Education, and Economics Advisory Board. Each RFP for the different program areas (i.e., Water Quality, Food Safety, etc.) will be developed each fiscal year based on these established priorities and the resulting determined approaches to solving these critical agricultural issues. Although this overall grant program seeks to solve critical agricultural issues through an integration of research, education, and extension activities, a component of a RFP, depending on the priority being addressed and/or the stage at which the priority is being addressed, may request proposals that are research, education,
or extension only, or a combination thereof. However, the overall overarching approach to solving the critical agricultural issue, priority, or problem will be through an integration of research, education, and extension activities within each individual program area.

## B. Purpose, Priorities, and Fund Availability

The purpose of the National Food Safety Initiative is to support projects that address selected priority issues in food safety and demonstrate an integrated approach to solving problems in food safety research, education, and extension as described in this RFP. Various models for integration of research, education, and extension will be considered for funding. Proposals describing multistate, multiinstitutional, multidisciplinary, and/or multifunctional activities (and combinations thereof) are acceptable. However, special emphasis will be given to proposals describing multifunctional activities that integrate research, education, and extension (i.e. those that contain research, education, and extension components).

The component areas described below address priority issues in food safety that were identified by stakeholders during a series of public meetings held to solicit program input from various users of food safety information at the local, state, regional, and national levels. Interdepartmental food safety priorities and those supported by the Presidential Food Safety Initiative were also considered in the development of this RFP.
There is no commitment by USDA to fund any particular proposal or to make a specific number of awards.
Approximately $\$ 14,277,000$ will be available to fund proposals in FY 2000. Proposals are being solicited in 12 component areas: (1) Qualitative and Quantitative Risk Assessments; (2) Control Measures for Food-Borne Microbial Pathogens; (3) Sources and Incidence of Microbial Pathogens; (4) Antibiotic Resistant Microbial Pathogens; (5) Improving the Safety of Fresh Fruits and Vegetables; (6) Food Handler Education and Training for Consumer and Youth; (7) Food Handler Education for High-risk and Hard-toreach Audiences; (8) Food Handler Education for Commercial and NonCommercial Audiences; (9) Hazard Analysis and Critical Control Points Model Development, Testing and Implementation; and (10) Integrating Food Safety into Related Agricultural Problems. In addition, proposals are being solicited for (11) National

Coordination of Integrated Food Safety Programs and Resources and a (12) National Center for Home Food Processing and Preservation.

## C. Definitions

For the purpose of awarding grants under this program, the following definitions are applicable:
(1) Administrator means the Administrator of the Cooperative State Research, Education, and Extension Service (CSREES) and any other officer or employee of the Department to whom the authority involved my be delegated.
(2) Authorized departmental officer means the Secretary or any employee of the Department who has the authority to issue or modify grant instruments on behalf of the Secretary.
(3) Authorized organizational representative means the president or chief executive officer of the applicant organization or the official, designated by the president or chief executive officer of the applicant organization, who has the authority to commit the resources of the organization.
(4) Budget period means the interval of time (usually 12 months) into which the project period is divided for budgetary and reporting purposes.
(5) Cash contributions means the applicant's cash outlay, including the outlay of money contributed to the applicant by non-Federal third parties.
(6) Department or USDA means the United States Department of Agriculture.
(7) Education activity means formal classroom instruction, laboratory instruction, and practicum experience in the food and agricultural sciences and other related matters such as faculty development, student recruitment and services, curriculum development, instructional materials and equipment, and innovative teaching methodologies.
(8) Extension activity means an act or process that delivers science-based knowledge and informal educational programs to people, enabling them to make practical decisions.
(9) Grant means the award by the Secretary of funds to an eligible organization or individual to assist in meeting the costs of conducting, for the benefit of the public, an identified project which is intended and designed to accomplish the purpose of the program as identified in these guidelines.
(10) Grantee means an organization designated in the grant award document as the responsible legal entity to which a grant is awarded.
(11) Integrated means to bring the three components of the agricultural knowledge system (research, education,
and extension) together around a problem area or activity.
(12) Matching means that portion of allowable project costs not borne by the Federal Government, including the value of in-kind contributions.
(13) Peer review means an evaluation of a proposed project for scientific or technical quality and relevance performed by experts with the scientific knowledge and technical skills to conduct the proposed work or to give expert advice on the merits of a proposal.
(14) Principal investigator/Project director means the single individual designated by the grantee in the grant application and approved by the Secretary who is responsible for the direction and management of the project.
(15) Prior approval means written approval evidencing prior consent by an authorized departmental officer as defined in (2) above.
(16) Project means the particular activity within the scope of the program supported by a grant award.
(17) Project period means the period, as stated in the award document and modifications thereto, if any, during which Federal sponsorship begins and ends.
(18) Research activity means a scientific investigation or inquiry that results in the generation of knowledge.
(19) Secretary means the Secretary of Agriculture and any other officer or employee of the Department to whom the authority involved may be delegated.
(20) Third party in-kind contributions means non-cash contributions of property or services provided by nonFederal third parties, including real property, equipment, supplies and other expendable property, directly benefitting and specifically identifiable to a funded project or program.
(21) Total integrated, multifunctional research, education, and extension approach means that the combination of grants (although the individual grants may involve only research, education, or extension activities or a combination thereof) awarded under the fiscal year's program components will work together to address the priorities in United States agriculture as determined by the Secretary of Agriculture in consultation with the Advisory Board, that involve integrated research, extension, and education activities.

## D. Eligibility

Proposals may be submitted by colleges and universities as defined in section 1404 of the National
Agricultural Research, Extension, and

Teaching Policy Act of 1977 (NARETPA). The terms "college" and "university" mean an educational institution in any State which (1) admits as regular students only persons having a certificate of graduation from a school providing secondary education, or the recognized equivalent of such a certificate, (2) is legally authorized within such State to provide a program of education beyond secondary education, (3) provides an educational program for which a bachelor's degree or any other higher degree is awarded, (4) is a public or other nonprofit institution, and (5) is accredited by a nationally recognized accrediting agency or association. Although an applicant may be eligible based on its status as one of these entities, there are factors which may exclude an applicant from receiving Federal financial and nonfinancial assistance and benefits under this program (e.g., debarment or suspension of an individual involved or a determination that an applicant is not responsible based on submitted organizational management information). Eligible applicants may subcontract to organizations not eligible under these requirements.

Please note that a research foundation maintained by a college or university is not eligible to receive an award under this program.

## E. Matching Requirements

## 1. General Requirement

If a grant provides a particular benefit to a specific agricultural commodity, the grant recipient is required to provide funds or in-kind support to match the amount of the grant funds provided. See section 10. c. on "Matching Funds" under Part III, B, "Content of Proposals" for more details.

## 2. Waiver

CSREES may waive the matching funds requirement specified in the above paragraph for a grant if CSREES determines that (a) the results of the project, while of particular benefit to a specific agricultural commodity, are likely to be applicable to agricultural commodities generally; or (b) the project involves a minor commodity, the project deals with scientifically important research, and the grant recipient is unable to satisfy the matching funds requirement.

## F. Funding Restrictions

CSREES has determined that grant funds awarded under this authority may not be used for the renovation or refurbishment of research, education, or extension space; the purchase or
installation of fixed equipment in such space; or the planning, repair, rehabilitation, acquisition, or construction of buildings or facilities.

## G. Types of Grant Instruments

In FY 2000 all projects will be awarded using a "New Grant" instrument. In future years, projects under the Integrated Research, Education, and Extension Competitive Grants Program authority can be awarded using one of the grant instruments described below:
(1) New grant. This is a grant instrument by which the Department agrees to support a specified level of effort for a project that generally has not been supported previously under this program. This type of grant is approved on the basis of peer review recommendations
(2) Renewal grant. This is a grant instrument by which the Department agrees to provide additional funding for a project period beyond that approved in an original or amended award, provided that the cumulative period does not exceed the statutory limitation. When a renewal application is submitted, it should include a summary of progress to date from the previous granting period. A renewal grant shall be based upon new application, de novo peer review and staff evaluation, new recommendation and approval, and a new award instrument.
(3) Supplemental grant. This is an instrument by which the department agrees to provide small amounts of additional funding under a new or renewal grant as specified above and may involve a short-term (usually six months or less) extension of the project period beyond that approved in an original or amended award, but in no case may the cumulative period for the project exceed the statutory limitation. A supplement is awarded only if required to assure adequate completion of the original scope of work and if there is sufficient justification to warrant such action. A request of this nature normally will not require additional peer review.

## H. Funding Mechanisms

The two mechanisms by which new, renewal, and supplemental grants shall be awarded are as follows:
(1) Standard grant. This is a funding mechanism whereby the Department agrees to support a specified level of effort for a predetermined time period without the announced intention of providing additional support at a future date.
(2) Continuation grant. This is a funding mechanism whereby the Department agrees to support a
specified level of effort for a predetermined period of time with a statement of intention to provide additional support at a future date, provided that performance has been satisfactory, appropriations are available for this purpose, and continued support will be in the best interests of the Federal government and the public. This kind of mechanism normally will be awarded for an initial one-year period, and any subsequent continuation project grants will be awarded in one-year increments. The award of a continuation project grant to fund an initial or succeeding budget period does not constitute an obligation to fund any subsequent budget period. Unless prescribed otherwise by CSREES, a grantee must submit a separate application for continued support for each subsequent fiscal year. Requests for such continued support must be submitted in duplicate at least three months prior to the expiration date of the budget period currently being funded. Decisions regarding continued support and the actual funding levels of such support in future years usually will be made administratively after consideration of such factors as the grantee's progress and management practices and the availability of funds. Since initial peer reviews are based upon the full term and scope of the original application, additional evaluations of this type generally are not required prior to successive years' support. However, in unusual cases (e.g., when the nature of the project or key personnel change or when the amount of future support requested substantially exceeds the grant application originally reviewed and approved), additional reviews may be required prior to approving continued funding.

## Part II—Program Description

## A. Project Types

For Program Areas 1 through 10, the maximum total award is $\$ 600,000$, and for a project period up to three years. For Program Areas 11 and 12, the maximum total award is $\$ 600,000$ per year and for a project period up to four years.
Proposals that focus on one functional area (i.e., research only, education only, or extension only) are acceptable. However, applicants should explain how the separate functional area will meet the overall goal of a total integrated, multifunctional research, education, and extension approach.
Applications received in any of the aforementioned program areas should include budgets commensurate with the
activities proposed. Grants awarded under Program Description Areas 1 through 10 of this RFP will be issued as "New Grant" instruments and will be awarded as "Standard Grants." Grants awarded under Program Description Areas 11 and 12 of this RFP will be issued as "New Grant" instruments and may be awarded as "Continuation Grants."

## B. Program Area Description

Integrated research, education, and/or extension proposals that address the following selected priority issues are requested:

For Program Areas 1 through 10:
(Maximum award: \$600,000 and up to three years).
(1) Qualitative and Quantitative Risk Assessments (Program Area 111.1)

This category will support the development and testing of comprehensive, qualitative and/or quantitative science-based risk assessments for microbial food-borne pathogens (e.g., Listeria monocytogenes, Campylobacter jejuni, Cyclospora, Salmonella, etc.) and/or their toxins associated with ready-to-eat foods, including those foods that are fresh, minimally processed or processed.
(2) Control Measures for Food-borne Microbial Pathogens (Program Area 111.2)

This category will support the establishment of the scientific bases for, and the development of, models for identifying and validating critical control points, critical limits, and process capability related to control measures for significant food-borne microbial pathogens and/or their toxins in production, processing and distribution of foods.
(3) Sources and Incidence of Microbial Pathogens (Program Area 111.3)

This category will support identification of the sources and incidence of microbial pathogens of animal and human origin that impact on food safety and the development and implementation of strategies for their prevention and control.
(4) Antibiotic Resistant Microbial Pathogens (Program Area 111.4)

This category will support: (a) The identification of factors that lead to the development of antibiotic resistant microbial pathogens related to food safety; (b) the identification and application of measures to prevent antibiotic resistence; and (c) the development and application of
alternative approaches to the use of antibiotics.
(5) Improving the Safety of Fresh Fruits and Vegetables (Program Area 111.5)

This category will support the development of projects that focus on improving the safety of fresh and minimally processed imported and domestic fruits and vegetables, which includes: (a) The development of safe and efficacious techniques to enhance or ensure microbiological safety; (b) approaches that relate to postproduction, harvesting, handling, transportation, and distribution control measures to the prevention of microbial pathogen infection or crosscontamination; or (c) development of procedures for sampling to accurately detect the presence of microbial pathogens and/or their toxins.
(6) Food Handler Education and Training for Consumers and Youth (Program Area 111.6)
This category will support the development of education and training programs that promote and enhance general food safety and food handler education for youths, adults, and older Americans preparing food in the home. Special emphasis will be given to education efforts that support activities of the Presidential Food Safety Initiative and the Fight BAC campaign of the government and industry-wide Partnership for Food Safety Education. Information about the Presidential Initiative, Fight BAC, and the Partnership for Food Safety Education can be found at the following website: http://www.foodsafety.gov.
(7) Food Handler Education for Highrisk and Hard-to-reach Audiences (Program Area 111.7)

This category will support the development of consumer education and training programs for high-risk or under-served groups (i.e. pregnant or nursing mothers, infants, children, the chronically ill, those with limited resources, those with low literacy skills, or those who speak English as a second language). Projects that target families receiving Federal food assistance are encouraged.
(8) Food Handler Education for Commercial and Non-commercial Audiences, Including Food Handler Certification Training and Other Train-the-trainer Programs (Program Area 111.8)

This category will support the development, implementation, and evaluation of train-the-trainer programs for food handlers in commercial and
non-commercial settings (e.g., institutional food service, retail establishments, hospitals, health care facilities, day care facilities, congregate meal sites, gleaning and food recovery programs, food banks, soup kitchens, churches, service clubs, etc.). Special emphasis will be given to the development and implementation of food handler certification programs.
(9) Hazard Analysis and Critical Control Points (HACCP) Model Development, Testing, and Implementation (Program Area 111.9)

This category will support the development of projects that focus on the development of HACCP models for education and training in four targeted areas: (a) Minimizing microbial food safety hazards for fresh fruits and vegetables through the development of training and education programs for domestic and international growers and producers; (b) HACCP plan development and implementation in small and very small meat and poultry plants and other small food processing plants; (c) HACCP plan development and implementation in retail establishments, including distribution and transportation sectors of the food industry; (d) HACCP train-the-trainer programs using currently available models, curricula, and materials. HACCP model development must include pilot-testing, model implementation and evaluation. Regional, multi-state, or national workshops focused on training potential users of the HACCP models will be supported and are encouraged.
(10) Integrating Food Safety into Related Agricultural Programs (Program Area 111.10)

This category will support the development of projects that incorporate food safety concepts and food safety education into other topical areas in agriculture including, but not limited to, those focusing on: (a) Water quality; (b) animal waste management; (c) integrated pest management; (d) small farms; and (e) sustainable agriculture. For example, projects in this category might focus on developing educational programs that teach growers and producers how to reduce the risk of food-borne illness by minimizing microbial and pesticide contamination through integrated pest management, the control of pesticide application, water quality, and animal waste management. Priority consideration will be given to proposals that describe multi-disciplinary efforts that include those with expertise in food safety and nutrition.

In addition CSREES is soliciting proposals in the following areas:

For Program Areas 11 and 12:
(Maximum award: \$600,000/per year and up to four years)
(11) National Coordination of Integrated Food Safety Programs and Resources (Program Area 111.11)

This category will support the development of integrated food safety resources that facilitate national and international networking and coordination among the various users of food safety information, from production to consumption (i.e. farmers, producers, growers, packers, shippers, retailers, food service workers, processors, inspectors, veterinarians, sanitarians, educators, researchers, consumers, etc.). Special emphasis will be given to the development of databases and interactive software that support decision-making and problemsolving among food safety researchers, educators, consumers, and others. Proposals to support national or regional conferences, multi-user distance education programs, satellite videoteleconferences, and other communication transfer technologies will be supported.
(12) Home Food Processing and Preservation (Program Area 111.12)

This category will support the development of a National Center for Home Food Processing and Preservation. Activities conducted by the Center should include: (a) Reviewing recent research conducted in the public and private sectors on home food processing and preservation techniques, and formulating recommendations for new recipes and guidelines based on the reviews; (b) updating current guidelines on home food processing and preservation; (c) developing and testing new recipes and guidelines on home food processing and preservation methods for specialty foods, ethnic foods, and new varieties of fruits and vegetables; (d) establishing distribution mechanisms for disseminating new guidelines for home food processing and preservation; and (e) identifying areas where further research in home food processing and preservation techniques are needed.

## C. Expected Program Outputs and Reporting Requirements

The grantee must prepare an annual report that details all significant activities towards achieving the goals and objectives of the project. The narrative should be succinct and be no longer than five pages, using 12-point, single-spaced type. The report also
should include a listing of any students who worked on the project (report graduate degrees awarded and undergraduates trained, as applicable). A budget summary should be attached to this report, which will provide an overview of all monies spent during the reporting period.

## Part III—Preparation of a Proposal

## A. Program Application Materials

Program application materials are available at the Integrated Research, Education, and Extension Competitive Grants Program website (http:// www.reeusda.gov/integrated/). If you do not have access to our web page or have trouble downloading material, you may contact the Proposal Services Unit, Office of Extramural Programs, USDA/ CSREES at (202) 401-5048. When calling the Proposal Services Unit, please indicate that you are requesting forms for the Integrated Research, Education, and Extension Competitive Grants Program—National Food Safety Initiative. These materials may also be requested via Internet by sending a message with your name, mailing address (not e-mail) and phone number to psb@reeusda.gov. State that you want a copy of the Program Description and application materials (orange book) for the Fiscal Year 2000 Integrated
Research, Education, and Extension Competitive Grants Program-National Food Safety Initiative.

## B. Content of Proposals

## 1. General

The proposal should follow these guidelines, enabling reviewers to more easily evaluate the merits of each proposal in a systematic, consistent fashion:
(a) The proposal should be prepared on only one side of the page using standard size ( $8^{1 / 2^{\prime \prime}} \times 11^{\prime \prime}$ ) white paper, one inch margins, typed or word processed using no type smaller than 12 point font, and single or double spaced. Use an easily readable font face (e.g., Geneva, Helvetica, Times Roman).
(b) Each page of the proposal, including the Project Summary, budget pages, required forms, and any appendices, should be numbered sequentially.
(c) The proposal should be stapled in the upper left-hand corner. Do not bind. An original and 14 copies ( 15 total) must be submitted in one package, along with 10 copies of the "Project Summary" as a separate attachment.
(d) If applicable, proposals should include original illustrations
(photographs, color prints, etc.) in all copies of the proposal to prevent loss of
meaning through poor quality reproduction.

## 2. Cover Page (Form CSREES-661)

Each copy of each grant proposal must contain an "Application for Funding’", Form CSREES-661. One copy of the application, preferably the original, must contain the pen-and-ink signature(s) of the proposing principal investigator(s)/project director(s)(PI/PD) and the authorized organizational representative who possesses the necessary authority to commit the organization's time and other relevant resources to the project. Any proposed PI/PD or co-PI/PD whose signature does not appear on Form CSREES-661 will not be listed on any resulting grant award. Complete both signature blocks located at the bottom of the
"Application for Funding" form.
Form CSREES-661 serves as a source document for the CSREES grant database; it is therefore important that it be completed accurately. The following items are highlighted as having a high potential for errors or
misinterpretations:
(a) Title of Project (Block 6). The title of the project must be brief (80-character maximum), yet represent the major thrust of the effort being proposed. Project titles are read by a variety of nonscientific people; therefore, highly technical words or phraseology should be avoided where possible. In addition, introductory phrases such as "investigation of" or "research on", "education for" or "outreach that" should not be used.
(b) Program to Which You Are Applying (Block 7). ' Integrated Research, Education, and Extension Competitive Grants Program—National
Food Safety Initiative."
(c) Program Area and Number (Block
8). The name of the program
component, e.g. Qualitative and
Quantitative Risk Assessments, 111.1 or Control Measures for Food-borne Microbial Pathogens, 111.2 should be inserted in this block.
(d) Type of Award Request (Block 13). Check the block for "new."
(e) Principal Investigator(s)/Project Director(s) (PI/PD) (Block 15). The designation of excessive numbers of coPI/PD's creates problems during final review and award processing. Listing multiple co-PI/PD's, beyond those required for genuine collaboration, is therefore discouraged. Note that providing a Social Security Number is voluntary, but is an integral part of the CSREES information system and will assist in the processing of the proposal.
(f) Type of Performing Organization
(Block 18). A check should be placed in
the box beside the type of organization which actually will carry out the effort. For example, if the proposal is being submitted by an 1862 Land-Grant Institution but the work will be performed in a department, laboratory, or other organizational unit of an agricultural experiment station, box " 03 " should be checked. If portions of the effort are to be performed in several departments, check the box that applies to the individual listed as PI/PD \#1 in Block 15.a.
(g) Other Possible Sponsors (Block 22). List the names or acronyms of all other public or private sponsors including other agencies within USDA and other programs funded by CSREES to whom your application has been or might be sent. In the event you decide to send your application to another organization or agency at a later date, you must inform the identified CSREES Program Director as soon as practicable. Submitting your proposal to other potential sponsors will not prejudice its review by CSREES; however, duplicate support for the same project will not be provided. Complete the "Application for Funding," Form CSREES-661, in its entirety.
(h) One copy of the "Application for Funding" form must contain the signatures (in ink) of the PI/PD's and authorized organizational representative for the applicant organization.

## 3. Table of Contents

For consistency and ease in locating information, each proposal must contain a detailed Table of Contents just after the cover page. The Table of Contents should contain page numbers for each component of the proposal. Page numbers should begin with the first page of the Project Description.

## 4. Project Summary

The proposal must contain a Project Summary of 250 words or less on a separate page which should be placed immediately after the Table of Contents and should not be numbered. The names and institutions of all PI/PD's and co-PI/PD's should be listed on this form, in addition to the title of the project. The summary should be a selfcontained, specific description of the activity to be undertaken and should focus on: overall project goal(s) and supporting objectives; plans to accomplish project goal(s); and relevance of the project to the goals of the National Food Safety Initiative. The importance of a concise, informative Project Summary cannot be overemphasized.

## 5. Project Description

The Project Description may not exceed a total of 18 pages including figures and tables.
(a) Justification: This section should include in-depth information on the following, when applicable:
(i) a statement must be given at the beginning of the justification that clearly identifies the area(s) in Part II B that is (are) addressed in the proposal;
(ii) estimates of the magnitude of the food safety problem and its relevance to ongoing National food and agricultural research programs; and
(iii) reasons for having the work performed by the proposing institution.
(b) Objectives: Clear, concise, complete, and logically arranged statement(s) of specific aims of the proposed effort must be included in all proposals.
(c) Methodology: The procedures or methodology to be applied to the proposed effort should be explicitly stated. This section should include but not necessarily be limited to:
(i) a description of the proposed activities and the sequence in which they will be carried out;
(ii) procedures, techniques, methodologies, or approaches to be employed, including their feasibility;
(iii) kinds of results or expected outcomes;
(iv) evaluation methods or means by which data/information will be analyzed or interpreted;
(v) problems that might be encountered; and
(vi) limitations to proposed procedures, techniques, methodologies, or approaches.
(d) Literature Review: A summary of pertinent publications with emphasis of their relationship to the effort being proposed should be provided and should include all important and recent publications from other institutions, as well as those from the applicant institution. The citations themselves should be accurate, complete, and written in an acceptable journal format.
(e) Current Work: Current unpublished institutional activities "to date" in the program area under which the proposal is being submitted should be described.
(f) Cooperation and Institutional Units Involved: Cooperative, multiinstitutional and multidisciplinary applications are encouraged. Identify each institutional unit contributing to the project and designate the lead institution or institutional unit. When appropriate, the project should be coordinated with the efforts of other State and/or national programs. Clearly
define the roles and responsibilities of each institutional unit of the project team, if applicable.
(g) Equipment and Facilities: All facilities which are available for use or assignment to the project during the requested period of support should be reported and described briefly. Any potentially hazardous materials, procedures, situations, or activities, whether or not directly related to a particular phase of the effort, must be explained fully, along with an outline of the precautions to be exercised.
Examples include work with toxic chemicals and experiments that may put human subjects or animals at risk. All items of major instrumentation available for use or assignment to the proposed project should be itemized. In addition, items of non-expendable equipment needed to conduct and bring the project to a successful conclusion should be listed, including dollar amounts and, if funds are requested for their acquisition, justified.
(h) Project Timetable: The proposal should outline all important phases as a function of time, year by year, for the entire project, including periods beyond the grant funding period.

An applicant for the National Center for Home Food Processing and Preservation should include a management plan to ensure efficient administration of the grant and how activities will be integrated across collaborators.

## 6. Appendices to Project Description

Appendices to the Project Description are allowed if they are directly germane to the proposed project and are limited to a total of two of the following: Reprints (papers that have been published in peer reviewed journals) and preprints (manuscripts in press for a peer reviewed journal; these must be accompanied by a letter of acceptance from the publishing journal).

## 7. Key Personnel

All senior personnel who are expected to be involved in the effort must be clearly identified. For each person, the following should be included:
a. The roles and responsibilities of each PI/PD and/or collaborator should be clearly described;
b. An estimate of the time commitment involved for each PI/PD and/or collaborator; and
c. Vitae of each PI/PD, senior associate, and other professional personnel. This section should include vitae of all key persons who are expected to work on the project, whether or not CSREES funds are
sought for their support. The vitae should be limited to two (2) pages each in length, excluding publications listings. A chronological list of all publications in refereed journals during the past four (4) years, including those in press, must be provided for each project member for which a curriculum vitae is provided. Also list only those non-refereed technical publications that have relevance to the proposed project. All authors should be listed in the same order as they appear on each paper cited, along with the title and complete reference as these usually appear in journals.

## 8. Conflict-of-Interest List

A Conflict-of-Interest List must be provided for all individuals involved in the project (identified as key personnel). Each list should be on a separate page and include alphabetically the full names of the individuals in the following categories: (a) All collaborators on projects within the past four years, including current and planned collaborations; (b) all coauthors on publications within the past four years, including pending publications and submissions; (c) all persons in your field with whom you have had a consulting or financial arrangement within the past four years, who stand to gain by seeing the project funded; and (d) all thesis or postdoctoral advisees/advisors within the past four years (some may wish to call these life-time conflicts). This form is necessary to assist program staff in excluding from proposal review those individuals who have conflicts-ofinterest with the personnel in the grant proposal. The Program Director must be informed of any additional conflicts-ofinterest that arise after the proposal is submitted.
9. Collaborative and/or Subcontractual Arrangements

If it will be necessary to enter into formal consulting or collaborative arrangements with others, such arrangements should be fully explained and justified. In addition, evidence should be provided that the collaborators involved have agreed to render these services. If the need for consultant services is anticipated, the proposal narrative should provide a justification for the use of such services, a statement of work to be performed, and a resume or curriculum vita for each consultant. For purposes of proposal development, informal day-today contacts between key project personnel and outside experts are not considered to be collaborative
arrangements and thus do not need to be detailed.
All anticipated subcontractual arrangements also should be explained and justified in this section. A proposed statement of work and a budget for each arrangement involving the transfer of substantive programmatic work or the providing of financial assistance to a third party must be provided.
Agreements between departments or other units of your own institution and minor arrangements with entities outside of your institution (e.g., requests for outside laboratory analyses) are excluded from this requirement.

If you expect to enter into subcontractual arrangements, please note that the provisions contained in 7 CFR Part 3019, USDA Uniform Administrative Requirements for Grant and Other Agreements with Institutions of Higher Education, Hospitals, and Other Non-Profit Organizations, and the general provisions contained in 7 CFR Part 3015.205, USDA Uniform Federal Assistance Regulations, flow down to subrecipients. In addition, required clauses from Sections 40-48 ("Procurement Standards") and Appendix A ("Contract Provisions'") to 7 CFR Part 3019 should be included in final contractual documents, and it is necessary for the subawardee to make a certification relating to debarment/ suspension.

## 10. Budget (Form CSREES-55)

a. Budget Form. Prepare the budget, Form CSREES-55, in accordance with instructions provided. A budget form is required for each year of requested support. In addition, a cumulative budget is required detailing the requested total support for the overall project period. The budget form may be reproduced as needed by applicants. Funds may be requested under any of the categories listed on the form, provided that the item or service for which support is requested is allowable under the authorizing legislation, the applicable Federal cost principles, and these program guidelines, and can be justified as necessary for the successful conduct of the proposed project. Applicants must also include a Budget Narrative to justify their budgets (see section b below.)
The following guidelines should be used in developing your proposal budget(s):

1. Salaries and Wages. Salaries and wages are allowable charges and may be requested for personnel who will be working on the project in proportion to the time such personnel will devote to the project. If salary funds are requested, the number of Senior and Other

Personnel and the number of CSREESFunded Work Months must be shown in the spaces provided. Grant funds may not be used to augment the total salary or rate of salary of project personnel or to reimburse them for time in addition to a regular full-time salary covering the same general period of employment. Salary funds requested must be consistent with the normal policies of the institution.
2. Fringe Benefits. Funds may be requested for fringe benefit costs if the usual accounting practices of your organization provide that organizational contributions to employee benefits (social security, retirement, etc.) be treated as direct costs. Fringe benefit costs may be included only for those personnel whose salaries are charged as a direct cost to the project.

## 3. Nonexpendable Equipment.

 Nonexpendable equipment means tangible nonexpendable personal property including exempt property charged directly to the award having a useful life of more than one year and an acquisition cost of $\$ 5,000$ (or lower depending on institutional policy) or more per unit. As such, items of necessary instrumentation or other nonexpendable equipment should be listed individually by description and estimated cost in the Budget Narrative. This applies to revised budgets as well, as the equipment item(s) and amount(s) may change.4. Materials and Supplies. The types of expendable materials and supplies which are required to carry out the project should be indicated in general terms with estimated costs in the Budget Narrative.
5. Travel. The type and extent of travel and its relationship to project objectives should be described briefly and justified. If foreign travel is proposed, the country to be visited, the specific purpose of the travel, a brief itinerary, inclusive dates of travel, and estimated cost must be provided for each trip. Airfare allowances normally will not exceed round-trip jet economy air accommodations. U.S. flag carriers must be used when available. See 7 CFR Part 3015.205(b)(4) for further guidance.
6. Publication Costs/Page Charges. Include anticipated costs associated with publications in a journal (preparing and publishing results including page charges, necessary illustrations, and the cost of a reasonable number of coverless reprints) and audio-visual materials that will be produced. Photocopying and printing brochure, etc., should be shown in Section I., "All Other Direct Costs" of Form CSREES-55.
7. Computer (ADPE) Costs. Reimbursement for the costs of using specialized facilities (such as a university- or department-controlled computer mainframe or data processing center) may be requested if such services are required for completion of the work.
8. All Other Direct Costs. Anticipated direct project charges not included in other budget categories must be itemized with estimated costs and justified in the Budget Narrative. This also applies to revised budgets, as the item(s) and dollar amount(s) may change. Examples may include space rental at remote locations, subcontractual costs, and charges for consulting services, telephone, facsimile, shipping costs, and fees necessary for laboratory analyses. You are encouraged to consult the "Instructions for Completing Form CSREES-55, Budget," of the Application Kit for detailed guidance relating to this budget category. Form AD-1048 must be completed by each subcontractor or consultant and retained by the grantee.
9. Indirect Costs. Section 1462 of the National Agricultural Research, Extension, and Teaching Policy Act of 1977 (7 U.S.C. 3310) limits indirect costs for this program to 19 percent of total Federal funds provided under each award. Therefore the recovery of indirect costs under this program may not exceed the lesser of the institution's official negotiated indirect cost rate or the equivalent of 19 percent of total Federal funds awarded. If no rate has been negotiated, a reasonable dollar amount (equivalent to less than 19 percent of total Federal funds requested) in lieu of indirect costs may be requested, subject to approval by USDA.
b. Budget Narrative. All budget categories, with the exception of Indirect Costs for which support is requested, must be individually listed (with costs) and justified on a separate sheet of paper and placed immediately behind the Budget Form. Explanations of matching funds or lack thereof on commodity-specific projects also are to be included in this section.
c. Matching Funds. If an applicant concludes that matching funds are not required as specified under Part I (e), a justification should be included in the Budget Narrative. CSREES will consider this justification when ascertaining final matching requirements or in determining if required matching can be waived. CSREES retains the right to make final determinations regarding matching requirements.

For those grants requiring matching funds as specified under Part I (e),
proposals should include written verification of commitments of matching support (including both cash and in-kind contributions) from third parties. Written verification means:
(a) For any third party cash contributions, a separate pledge agreement for each donation, signed by the authorized organizational representatives of the donor organization and the applicant organization, which must include: (1) The name, address, and telephone number of the donor; (2) the name of the applicant organization; (3) the title of the project for which the donation is made; (4) the dollar amount of the cash donation; and (5) a statement that the donor will pay the cash contribution during the grant period; and
(b) For any third party in-kind contributions, a separate pledge agreement for each contribution, signed by the authorized organizational representatives of the donor organization and the applicant organization, which must include: (1) The name, address, and telephone number of the donor; (2) the name of the applicant organization; (3) the title of the project for which the donation is made; (4) a good faith estimate of the current fair market value of the third party in-kind contribution; and (5) a statement that the donor will make the contribution during the grant period.
The sources and amount of all matching support from outside the applicant institution should be summarized on a separate page and placed in the proposal immediately following the Budget Narrative. All pledge agreements must be placed in the proposal immediately following the summary of matching support.

The value of applicant contributions to the project shall be established in accordance with applicable cost principles. Applicants should refer to OMB Circular A-21, Cost Principles for Educational Institutions, for further guidance and other requirements relating to matching and allowable costs.

## 11. Current and Pending Support (Form CSREES-663)

All proposals must contain Form CSREES-663 listing other current public or private support (including in-house support) to which key personnel identified in the proposal have committed portions of their time, whether or not salary support for person(s) involved is included in the budget. Analogous information must be provided for any pending proposals that are being considered by, or that will be submitted in the near future to, other
possible sponsors, including other USDA Programs or agencies. Concurrent submission of identical or similar proposals to the possible sponsors will not prejudice proposal review or evaluation by the CSREES for this purpose. However, a proposal that duplicates or overlaps substantially with a proposal already reviewed and funded (or to be funded) by another organization or agency will not be funded under this program. Note that the project being proposed should be included in the pending section of the form.
12. Assurance Statement(s), (Form CSREES-662)

A number of situations encountered in the conduct of projects require special assurances, supporting documentation, etc., before funding can be approved for the project. In addition to any other situation that may exist with regard to a particular project, it is expected that some applications submitted in response to these guidelines will involve the following:
a. Recombinant DNA or RNA Research. As stated in 7 CFR Part 3015.205 (b)(3), all key personnel identified in the proposal and all endorsing officials of the proposing organization are required to comply with the guidelines established by the National Institutes of Health entitled, "Guidelines for Research Involving Recombinant DNA Molecules," as revised. If your project proposes to use recombinant DNA or RNA techniques, you must so indicate by checking the "yes" box in Block 19 of Form CSREES661 (the Cover Page) and by completing Section A of Form CSREES-662. For applicable proposals recommended for funding, Institutional Biosafety Committee approval is required before CSREES funds will be released.
b. Animal Care. Responsibility for the humane care and treatment of live vertebrate animals used in any grant project supported with funds provided by CSREES rests with the performing organization. Where a project involves the use of living vertebrate animals for experimental purposes, all key project personnel identified in a proposal and all endorsing officials of the proposing organization are required to comply with the applicable provisions of the Animal Welfare Act of 1966, as amended (7 U.S.C. 2131 et seq.) and the regulations promulgated thereunder by the Secretary in 9 CFR Parts 1, 2, 3, and 4 pertaining to the care, handling, and treatment of these animals. If your project will involve these animals, you should check "yes" in block 20 of Form CSREES-661 and complete Section B of

Form CSREES-662. In the event a project involving the use of live vertebrate animals results in a grant award, funds will be released only after the Institutional Animal Care and Use Committee has approved the project.
c. Protection of Human Subjects. Responsibility for safeguarding the rights and welfare of human subjects used in any grant project supported with funds provided by CSREES rests with the performing organization. Guidance on this issue is contained in the National Research Act, Pub. L. No. 93-348, as amended, and implementing regulations promulgated by the Department under 7 CFR Part 1c. If you propose to use human subjects for experimental purposes in your project, you should check the "yes" box in Block 21 of Form CSREES-661 and complete Section C of Form CSREES662. In the event a project involving human subjects results in a grant award, funds will be released only after the appropriate Institutional Review Board has approved the project.

## 13. Certifications

Note that by signing Form CSREES661 the applicant is providing the certifications required by 7 CFR Part 3017, as amended, regarding Debarment and Suspension and Drug Free Workplace, and 7 CFR Part 3018, regarding Lobbying. The certification forms are included in the application package for informational purposes only. These forms should not be submitted with the proposal since by signing form CSREES-661 your organization is providing the required certifications. If the project will involve a subcontractor or consultant, the subcontractor/consultant should submit a form $\mathrm{AD}-1048$ to the grantee organization for retention in their records. This form should not be submitted to USDA.

## 14. Compliance with the National Environmental Policy Act (NEPA) (Form CSREES-1234)

As outlined in 7 CFR Part 3407 (the Cooperative State Research, Education, and Extension Service regulations implementing NEPA), the environmental data for any proposed project is to be provided to CSREES so that CSREES may determine whether any further action is needed. In some cases, however, the preparation of environmental data may not be required. Certain categories of actions are excluded from the requirements of NEPA.

In order for CSREES to determine whether any further action is needed with respect to NEPA, pertinent
information regarding the possible environmental impacts of a particular project is necessary; therefore, Form CSREES-1234, "NEPA Exclusions Form," must be included in the proposal indicating whether the applicant is of the opinion that the project falls within a categorical exclusion and the reasons therefore. If it is the applicant's opinion that the proposed project falls within the categorical exclusions, the specific exclusion must be identified. Form CSREES-1234 and supporting documentation should be included as the last page of this proposal.
Even though a project may fall within the categorical exclusions, CSREES may determine that an Environmental Assessment or an Environmental Impact Statement is necessary for an activity, if substantial controversy on environmental grounds exists or if other extraordinary conditions or circumstances are present which may cause such activity to have a significant environmental effect.

## C. Submission of Proposals

## 1. When To Submit (Deadline Date)

Proposals must be transmitted by June 6,2000 , as indicated by postmark or date of courier bill of lading. Proposals transmitted after this date will not be considered for funding.

## 2. What To Submit

An original and 14 copies must be submitted. In addition submit 10 copies of the proposal's Project Summary. All copies of the proposals and the Project Summaries must be submitted in one package.

## 3. Where To Submit

Applicants are strongly encouraged to submit completed proposals via overnight mail or delivery service to ensure timely receipt by the USDA. The address for hand-delivered proposals or proposals submitted using an express mail or overnight courier service is: Integrated Research, Education, and Extension Competitive Grants Program—National Food Safety Initiative; c/o Proposal Services Unit; Cooperative State Research, Education, and Extension Service; U.S. Department of Agriculture; Room 303, Aerospace Center; 901 D Street, S.W.; Washington, D.C. 20024.

Proposals sent via the U.S. Postal Service must be sent to the following address: Integrated Research, Education, and Extension Competitive Grants Program—National Food Safety Initiative; c/o Proposal Services Unit; Cooperative State Research, Education,
and Extension Service; U.S. Department
of Agriculture; STOP 2245; 1400
Independence Avenue, S.W.;
Washington, D.C. 20250-2245.

## D. Acknowledgment of Proposals

The receipt of all proposals will be acknowledged by e-mail. Therefore, applicants are encouraged to provide email addresses, where designated, on the Form CSREES-661. If the applicant's e-mail address is not indicated, CSREES will acknowledge receipt of the proposal by letter.
Once the proposal has been assigned an identification number, please cite that number on all future correspondence. If the applicant does not receive an acknowledgment within 60 days of the submission deadline, please contact the Program Director.

## Part IV—Review Process

## A. General

Each proposal will be evaluated in a 2-part process. First, each proposal will be screened to ensure that it meets the administrative requirements as set forth in this request for proposals. Second, proposals that meet these requirements will be technically evaluated by a peer review panel.

Peer review panel members will be selected based upon their training and experience in relevant scientific, education or extension fields taking into account the following factors: (a) The level of formal scientific, technical education, and extension experience of the individual, as well as the extent to which an individual is engaged in relevant research, education and/or extension activities; (b) the need to include as peer reviewers experts from various areas of specialization within relevant scientific, education, and extension fields; (c) the need to include as reviewers other experts (producers, range or forest managers/operators, consumers, etc.) who can assess relevance of the proposals to targeted audiences and to program needs; (d) the need to include as peer reviewers experts from a variety of organizational types (e.g., colleges, universities, industry, state and Federal agencies, private profit and non-profit organizations), and geographic locations; (e) the need to maintain a balanced composition of peer review groups with regard to minority and female representation and an equitable age distribution; and (f) the need to include members that can judge the effective usefulness to producers and the general public of each proposal.

## B. Evaluation Factors

The evaluation factors below will be used in reviewing applications submitted in response to this request for proposals:
(1) Overall merit of the proposal.
(a) The project goal, approach, or hypothesis is conceptually adequate and related to selected priority issues identified in the request for proposals;
(b) Objectives are clearly described and related to selected priority issues identified in the request for proposals;
(c) There is a demonstrated need for the project;
(d) The target audience(s) is identified (where appropriate);
(e) The proposed technique, procedure, or methodology is clearly described;
(f) The technique, procedure, or methodology is suitable and feasible for the proposed project;
(g) The evaluation procedures, or means by which data will be analyzed and interpreted, are clearly described and are suitable for the proposed project;
(h) The expected results or outcomes are clearly stated; and (i) The probability of success of the project is indicated.
(2) Qualifications of the proposed project personnel, adequacy of the facilities, and budget request.
(a) The roles of all project personnel are clearly defined;
(b) There is evidence that project personnel have sufficient expertise needed to complete the project;
(c) There is evidence of partnerships with other disciplines and institutions;
(d) There is sufficient time allocated
for systematic attainment of objectives;
(e) There is evidence of institutional experience and competence in the identified area of work;
(f) There is adequate support personnel, facilities, and instrumentation;
(g) All necessary budget information is provided and all figures are tallied correctly;
(h) The budget narrative provides adequate justification for all budget categories; and
(i) The proposed budget is appropriate for the scope of the project.
(3) The relevance of the proposed project to current issues in food safety and related topical areas.
(a) The relevance to current issues in food safety is described; and
(b) The project makes a unique and original contribution to food safety. Proposals submitted for the National Center for Home Food Processing and Preservation also will be judged on the
quality of the management plan that is proposed.

Priority will be given for integrated, multifunctional research, education, and extension projects.

## C. Conflicts-of-Interest and Confidentiality

During the peer evaluation process, extreme care will be taken to prevent any actual or perceived conflicts-ofinterest that may impact review or evaluation. For the purpose of determining conflicts-of-interest, the academic and administrative autonomy of an institution shall be determined by reference to the January 1998 issue of the Codebook for Compatible Statistical Reporting of Federal Support to Universities, Colleges, and Nonprofit Institutions, prepared by Quantum Research Corporation for the National Science Foundation.
Names of submitting institutions and individuals, as well as proposal content and peer evaluations, will be kept confidential, except to those involved in the review process, to the extent permitted by law. In addition, the identities of peer reviewers will remain confidential throughout the entire review process. Therefore, the names of the reviewers will not be released to applicants. At the end of the fiscal year, names of panelists will be made available in such a way that the panelists cannot be identified with the review of any particular proposal.

## Part V—Additional Information

## A. Access To Review Information

Copies of summary reviews, not including the identity of reviewers, will be sent to the applicant PI/PD after the review process has been completed.

## B. Grant Awards

## (1) General

Within the limit of funds available for such purpose, the awarding official of CSREES shall make grants to those responsible, eligible applicants whose proposals are judged most meritorious under the procedures set forth in this RFP. The date specified by the awarding official of CSREES as the effective date of the grant shall be no later than September 30 of the Federal fiscal year in which the project is approved for support and funds are appropriated for such purpose, unless otherwise permitted by law. It should be noted that the project need not be initiated on the grant effective date, but as soon thereafter as practical so that project goals may be attained within the funded project period. All funds granted by CSREES under this RFP shall be
expended solely for the purpose for which the funds are granted in accordance with the approved application and budget, the regulations, the terms and conditions of the award, the applicable Federal cost principles, and the Department's assistance regulations (parts 3015 and 3019 of 7 CFR).
(2) Organizational Management Information
Specific management information relating to an applicant shall be submitted on a one-time basis as part of the responsibility determination prior to the award of a grant identified under this RFP, if such information has not been provided previously under this or another CSREES program. CSREES will provide copies of forms recommended for use in fulfilling these requirements as part of the preaward process.
(3) Grant Award Document and Notice of Grant Award

The grant award document shall include at a minimum the following:
(a) Legal name and address of performing organization or institution to whom the Administrator has awarded a grant under the terms of this request for proposals;
(b) Title of project;
(c) Name(s) and address(es) of PI/PD's chosen to direct and control approved activities;
(d) Identifying grant number assigned by the Department;
(e) Project period, specifying the amount of time the Department intends to support the project without requiring recompetition for funds;
(f) Total amount of Departmental financial assistance approved by the Administrator during the project period;
(g) Legal authority(ies) under which the grant is awarded;
(h) Approved budget plan for categorizing allocable project funds to accomplish the stated purpose of the grant award; and
(i) Other information or provisions deemed necessary by CSREES to carry out its respective granting activities or to accomplish the purpose of a particular grant.

The notice of grant award, in the form of a letter, will be prepared and will provide pertinent instructions or information to the grantee that is not included in the grant award document.

## C. Use of Funds; Changes

(1) Delegation of Fiscal Responsibility

Unless the terms and conditions of the grant state otherwise, the grantee may not in whole or in part delegate or
transfer to another person, institution, or organization the responsibility for use or expenditure of grant funds.

## (2) Changes in Project Plans

(a) The permissible changes by the grantee, $\mathrm{PI} / \mathrm{PD}(\mathrm{s})$, or other key project personnel in the approved project grant shall be limited to changes in methodology, techniques, or other aspects of the project to expedite achievement of the project's approved goals. If the grantee and/or the PI/PD(s) are uncertain as to whether a change complies with this provision, the question must be referred to the CSREES Authorized Departmental Officer (ADO) for a final determination.
(b) Changes in approved goals or objectives shall be requested by the grantee and approved in writing by the ADO prior to effecting such changes. In no event shall requests for such changes be approved which are outside the scope of the original approved project.
(c) Changes in approved project leadership or the replacement or reassignment of other key project personnel shall be requested by the grantee and approved in writing by the awarding official of CSREES prior to effecting such changes.
(d) Transfers of actual performance of the substantive programmatic work in whole or in part and provisions for payment of funds, whether or not Federal funds are involved, shall be requested by the grantee and approved in writing by the ADO prior to effecting such transfers, unless prescribed otherwise in the terms and conditions of the grant.
(e) Changes in Project Period: The project period may be extended by CSREES without additional financial support, for such additional period(s) as the ADO determines may be necessary to complete or fulfill the purposes of an approved project, but in no case shall the total project period exceed five years. Any extension of time shall be conditioned upon prior request by the grantee and approval in writing by the ADO, unless prescribed otherwise in the terms and conditions of a grant.
(f) Changes in Approved Budget: Changes in an approved budget must be requested by the grantee and approved in writing by the ADO prior to instituting such changes if the revision will involve transfers or expenditures of amounts requiring prior approval as set forth in the applicable Federal cost principles, Departmental regulations, or in the grant award.

## D. Applicable Federal Statutes and Regulations

Several Federal statutes and regulations apply to grant proposals considered for review and to project grants awarded under this program. These include, but are not limited to:
7 CFR Part 1.1—USDA
implementation of the Freedom of Information Act.
7 CFR Part 3—USDA implementation of OMB Circular No. A-129 regarding debt collection.

7 CFR Part 15, subpart A—USDA implementation of Title VI of the Civil Rights Act of 1964, as amended.

7 CFR Part 3015—USDA Uniform Federal Assistance Regulations, implementing OMB directives (i.e., Circular Nos. A-21 and A-122) and incorporating provisions of 31 U.S.C. 6301-6308 (the Federal Grant and Cooperative Agreement Act of 1977, Pub. L. No. 95-224), as well as general policy requirements applicable to recipients of Departmental financial assistance.
7 CFR Part 3017—USDA implementation of Governmentwide Debarment and Suspension (Nonprocurement) and Governmentwide Requirements for Drug-Free Workplace (Grants).

7 CFR Part 3018—USDA
implementation of Restrictions on Lobbying. Imposes prohibitions and requirements for disclosure and certification related to lobbying on recipients of Federal contracts, grants, cooperative agreements, and loans.

7 CFR Part 3019—USDA implementation of OMB Circular A110, Uniform Administrative Requirements for Grants and Other Agreements With Institutions of Higher Education, Hospitals, and Other Nonprofit Organizations.

7 CFR Part 3052—USDA
implementation of OMB Circular No. A133, Audits of States, Local Governments, and Non-profit Organizations.
7 CFR Part 3407-CSREES procedures to implement the National Environmental Policy Act of 1969, as amended.

29 U.S.C. 794 (section 504,
Rehabilitation Act of 1973) and 7 CFR
Part 15B (USDA implementation of statute)—prohibiting discrimination based upon physical or mental handicap in Federally assisted programs.
35 U.S.C. 200 et seq.-Bayh-Dole Act, controlling allocation of rights to inventions made by employees of small business firms and domestic nonprofit organizations, including universities, in Federally assisted programs
(implementing regulations are contained in 37 CFR Part 401).

## E. Confidential Aspects of Proposals

 and AwardsWhen a proposal results in a grant, it becomes a part of the record of CSREES transactions, available to the public upon specific request. Information that the Secretary determines to be of a confidential, privileged, or proprietary nature will be held in confidence to the extent permitted by law. Therefore, any information that the applicant wishes to have considered as confidential, privileged, or proprietary should be
clearly marked within the proposal. The original copy of a proposal that does not result in a grant will be retained by the Agency for a period of one year. Other copies will be destroyed. Such a proposal will be released only with the consent of the applicant or to the extent required by law. A proposal may be withdrawn at any time prior to the final action thereon.

## F. Regulatory Information

For the reasons set forth in the final Rule-related Notice to 7 CFR part 3015, subpart V (48 FR 29115, June 24, 1983), this program is excluded from the scope
of the Executive Order 12372 which requires intergovernmental consultation with State and local officials. Under the provisions of the Paperwork Reduction Act of 1995, as amended ( 44 U.S.C. chapter 35), the collection of information requirements contained in this Notice have been approved under OMB Document No. 0524-0022.

Done at Washington, D.C., this 4th day of April 2000.

## Charles W. Laughlin,

Administrator, Cooperative State Research, Education, and Extension Service.
[FR Doc. 00-8642 Filed 4-4-00; 2:36 pm]
BILLING CODE 3410-22-P


## Friday,

April 7, 2000

## Part V

## Department of Agriculture

Cooperative State Research, Education and Extension Service

Integrated Research, Education, and Extension Competitive Grants ProgramWater Quality: Request for Proposals and Request for Input; Notice

## DEPARTMENT OF AGRICULTURE

## Cooperative State Research, Education, and Extension Service

Integrated Research, Education, and Extension Competitive Grants Program-Water Quality: Request for Proposals and Request for Input
AGENCY: Cooperative State Research, Education, and Extension Service.
ACTION: Notice of request for proposals and request for input.

SUMMARY: The Cooperative State Research, Education and Extension Service (CSREES) announces the availability of grant funds and requests proposals for the Integrated Research, Education, and Extension Competitive Grants Program-Water Quality for fiscal year (FY) 2000 to support integrated, multifunctional agricultural research, extension, and education activities that address water quality priorities in United States agriculture. The amount available for support of this program in FY 2000 is approximately \$12,400,000.
This notice sets out the objectives for these projects, the eligibility criteria for projects and applicants, the application procedures, and the set of instructions needed to apply for a Water Quality grant under this authority.
By this notice, CSREES additionally solicits stakeholder input from any interested party regarding the FY 2000 Integrated Research, Education, and Extension Competitive Grants Program-Water Quality for use in the development of any future requests for proposals for this program.
DATES: Proposals must be transmitted by June 6,2000 , as indicated by the postmark or date on courier bill of lading. Proposals transmitted after this date will not be considered for funding. Comments regarding this request for proposals are requested within six months from the issuance of this notice. Comments received after that date will be considered to the extent practicable.
ADDRESSES: The address for handdelivered proposals or proposals submitted using an express mail or overnight courier service is: Integrated Research, Education, and Extension Competitive Grants Program-Water Quality; c/o Proposal Services Unit; Cooperative State Research, Education, and Extension Service; U.S. Department of Agriculture; Room 303, Aerospace Center; 901 D Street, SW; Washington, DC 20024.
Proposals sent via the U.S. Postal Service must be sent to the following address: Integrated Research, Education,
and Extension Competitive Grants Program—Water Quality; Cooperative State Research, Education, and Extension Service; U.S. Department of Agriculture; STOP 2245; 1400 Independence Avenue, SW;
Washington, DC 20250-2245.
Written user comments should be submitted by first-class mail to: Policy and Program Liaison Staff; Office of Extramural Programs; USDA-CSREES; STOP 2299; 1400 Independence Avenue, S.W.; Washington, D.C. 202502299; or via e-mail to: RFP-
OEP@reeusda.gov. In your comments, please include the name of the program and the fiscal year of the RFP to which you are responding.
FOR FURTHER INFORMATION: Applicants and other interested parties are encouraged to contact Dr. Timothy C.
Strickland; Water Quality Chair; Natural Resources and Environment Unit; Cooperative State Research, Education, and Extension Service; U.S. Department of Agriculture; STOP 2210; 1400 Independence Avenue, S.W.;
Washington, D.C. 20250-2210; telephone: (202) 205-5952; fax: (202) 401-1706; email:
tstrickland@reeusda.gov or Dr.
Raymond Knighton; National Program
Leader; Natural Resources and
Environment Unit; Cooperative State
Research, Education, and Extension
Service; U.S. Department of Agriculture;
STOP 2210; 1400 Independence
Avenue, S.W.; Washington, D.C. 20250-
2210; telephone: (202) 401-6417; fax:
(202) 401-1706; email:
rknighton@reeusda.gov.
SUPPLEMENTARY INFORMATION:

## Table of Contents

Stakeholder Input
Catalog of Federal Domestic Assistance
Part I-General Information
A. Legislative Authority and Background
B. Purpose, Priorities, and Fund Availability
C. Definitions
D. Eligibility
E. Matching Requirements
F. Funding Restrictions
G. Types of Grant Instruments
H. Funding Mechanisms

Part II—Program Description
A. Project Types
B. Program Area Description
C. Expected Program Outputs and Reporting Requirements
Part III-Preparation of a Proposal
A. Program Application Materials
B. Content of Proposals
C. Submission of Proposals
D. Acknowledgment of Proposals

Part IV-Review Process
A. General
B. Evaluation Factors
C. Conflicts-of-Interest and Confidentiality

Part V—Additional Information
A. Access to Review Information
B. Grant Awards
C. Use of Funds; Changes
D. Applicable Federal Statues and Regulations
E. Confidential Aspects of Proposals and Awards
F. Regulatory Information

## Stakeholder Input

CSREES is soliciting comments regarding this solicitation of applications from any interested party. These comments will be considered in the development of any future RFP for the program. Such comments will be forwarded to the Secretary or his designee for use in meeting the requirements of section 103(c)(2) of the Agricultural Research, Extension, and Education Reform Act of 1998 (7 U.S.C. 7613(c)(2)). This section requires the Secretary to solicit and consider input on a current RFP from persons who conduct or use agricultural research, education and extension for use in formulating future RFPs for competitive programs. Comments should be submitted as provided for in the ADDRESSES and DATES portions of this Notice.

## Catalog of Federal Domestic Assistance

This program is listed in the Catalog of Federal Domestic Assistance under 10.303, Integrated Research, Education, and Extension Competitive Grants Program.

## Part I-General Information

## A. Legislative Authority and Background

Section 406 of the Agricultural Research, Extension, and Education Reform Act of 1998 (AREERA) (7 U.S.C. 7626) authorized the Secretary of Agriculture to establish a research, education, and extension competitive grants program to provide funding for integrated, multifunctional agricultural research, extension, and education activities. Subject to the availability of appropriations to carry out this program, the Secretary may award grants to colleges and universities (as defined by 1404 of the National Agricultural Research, Extension, and Teaching Policy Act of 1977 (NARETPA) (7 U.S.C. 3103)) on a competitive basis for integrated research, education, and extension projects. Grants are to be awarded to address priorities in United States agriculture that involve integrated research, education, and extension activities as determined by the Secretary in consultation with the National

Agricultural Research, Extension, Education, and Economics Advisory Board.

On November 19, 1999, the Secretary published in the Federal Register [64 FR 63560] a notice that the administration of this grant program had been delegated to the Cooperative State Research, Education, and Extension Service (CSREES). This notice also solicited public comment from persons who use or conduct research, extension, or education regarding the priorities to be addressed by this new program. In addition, this notice announced a public meeting to obtain comments to use in developing the proposed rule and requests for proposals for this new grant program. The public meeting was held on December 6, 1999. All the comments and the official transcript of the meeting have been made available for review on the CSREES web page (http:// www.reeusda.gov/integrated/). This RFP was developed in consultation with the Advisory Board. In addition, the comments and testimonies from the December 6, 1999, public meeting were considered in the formulation of this RFP.

The entire program is funded in FY 2000 at $\$ 37,637,702$ (after deduction for administrative expenses) for the following integrated activities: Water Quality (\$12,374,115), Food Safety (\$14,277,277), Pesticide Impact Assessment $(\$ 4,322,310)$, Crops at Risk from Food Quality and Protection Act (FQPA) Implementation $(\$ 952,000)$, FQPA Risk Mitigation Program for Major Food Crop Systems $(\$ 3,808,000)$, and Methyl Bromide Transition Program ( $\$ 1,904,000$ ). There will be three RFP's for this program. The Water Quality and Food Safety Programs will each have a separate RFP, while the latter four programs will be announced as one RFP. This notice announces and describes the Water Quality component of the Program.
CSREES will administer the Integrated Research, Education, and Extension Competitive Grants Program by determining priorities in United States agriculture through Agency stakeholder input processes and in consultation with the National Agricultural Research, Extension, Education, and Economics Advisory Board. Each RFP for the different program areas (i.e., Water Quality, Food Safety, etc.) will be developed each fiscal year based on these established priorities and the resulting determined approaches to solving these critical agricultural issues. Although this overall grant program seeks to solve critical agricultural issues through an integration of research, education, and
extension activities, a component of a RFP, depending on the priority being addressed and/or the stage at which the priority is being addressed, may request proposals that are research, education, or extension only, or a combination thereof. However, the overall overarching approach to solving the critical agricultural issue, priority, or problem will be through an integration of research, education, and extension activities within each individual program area.

## B. Purpose, Priorities, and Fund Availability

The CSREES Water Quality Program is being enhanced by the establishment of a new water quality program authorized under section 406 of AREERA for an Integrated Research, Education, and Extension Competitive Grants Program. This program will bring university scientists, instructors, and extension educators into more effective and efficient partnerships with Federal interagency priority programs in addressing water quality issues in U.S. agriculture. This program will also provide the flexibility necessary for CSREES to bring the resources of researchers, instructors, and extension educators to national initiatives and programmatic partnerships that target evolving water quality needs.

The Water Quality Program is targeted directly to the identification and resolution of agriculturally-related degradation of water quality. Proposals are sought that will provide watershedbased information that can be used to: Assess sources of water quality impairment in targeted watersheds; develop and/or recommend options for continued improvement of water quality in targeted watersheds; and evaluate the relative costs and benefits associated with cleanup from all responsible sectors (e.g., farming, processing, urban runoff, municipal waste treatment, etc.). The program will favor proposals that have a clear problem statement and that are "place-based." "Place-based" means that the proposers have identified a specific location where the work is to be conducted so that the results and implications of the work conducted can be associated with a specific, georeferenced location. Categories of water quality needs that have been identified, both individually by USDA and in partnership with other Federal programs, include:
-Development and implementation of voluntary approaches that will enable producers to comply with newly developing Federal and State Total

Maximum Daily Load regulations for non-point source pollutants.
-Coordination of targeted research, education, and extension activities to minimize any adverse impacts that agricultural, forest, and range management practices; food and agricultural product processing; and/ or livestock production systems may have on the Nation's water quality.
-Applied research evaluating the efficacy of currently recommended management practices and strategies to improve water quality.
-Evaluation and error assessment of currently available data sets being used for Geographic Information Systems (GIS) based decision-support models for watershed management.
-Projects supporting the pilot activities of the National Science and Technology Council's National Environmental Monitoring Initiative. This initiative seeks to integrate the Nation's environmental monitoring and related research networks and programs. For more information, see (http://www.epa.gov/cludygxb/Pubs/ factsheet.html).
-Development and validation of costeffective means to reduce the contribution of agriculture to the development of harmful algal blooms and hypoxic conditions in coastal systems.
-Development and validation of costeffective means to reduce the contribution of animal and food processing wastes to water quality degradation.
-Documenting the coincident status and trends of multiple resources and related water quality, demographic, and socioeconomic condition; relating status and trends to human and natural causes and consequences; predicting future trajectories and rates of change; assessing associated uncertainties; and identifying data, information and research needed to reduce future uncertainties.
-Evaluation of the efficacy of USDA conservation programs' implementation.
-Projects addressing the Action Items identified in the President's Clean Water Action Plan (February 1998), see (http://www.cleanwater.gov/) for more information.
There is no commitment by USDA to fund any particular proposal or to make a specific number of awards.
Approximately $\$ 12.4$ million will be available to fund proposals in FY 2000. Proposals are being solicited in each of four component areas: National Facilitation proposals, Regional Water Quality Coordination proposals,

Extension Education proposals, and Integrated Research, Education, and Extension proposals.

## C. Definitions

For the purpose of awarding grants under this program, the following definitions are applicable:
(1) Administrator means the Administrator of the Cooperative State Research, Education, and Extension Service (CSREES) and any other officer or employee of the Department to whom the authority involved my be delegated.
(2) Authorized departmental officer means the Secretary or any employee of the Department who has the authority to issue or modify grant instruments on behalf of the Secretary.
(3) Authorized organizational representative means the president or chief executive officer of the applicant organization or the official, designated by the president or chief executive officer of the applicant organization, who has the authority to commit the resources of the organization.
(4) Budget period means the interval of time (usually 12 months) into which the project period is divided for budgetary and reporting purposes.
(5) Cash contributions means the applicant's cash outlay, including the outlay of money contributed to the applicant by non-Federal third parties.
(6) Department or USDA means the United States Department of Agriculture.
(7) Education activity means formal classroom instruction, laboratory instruction, and practicum experience in the food and agricultural sciences and other related matters such as faculty development, student recruitment and services, curriculum development, instructional materials and equipment, and innovative teaching methodologies.
(8) Extension activity means an act or process that delivers science-based knowledge and informal educational programs to people, enabling them to make practical decisions.
(9) Grant means the award by the Secretary of funds to an eligible organization or individual to assist in meeting the costs of conducting, for the benefit of the public, an identified project which is intended and designed to accomplish the purpose of the program as identified in these guidelines.
(10) Grantee means an organization designated in the grant award document as the responsible legal entity to which a grant is awarded.
(11) Integrated means to bring the three components of the agricultural knowledge system (research, education,
and extension) together around a problem area or activity.
(12) Matching means that portion of allowable project costs not borne by the Federal Government, including the value of in-kind contributions.
(13) Peer review means an evaluation of a proposed project for scientific or technical quality and relevance performed by experts with the scientific knowledge and technical skills to conduct the proposed work or to give expert advice on the merits of a proposal.

## (14) Principal investigator/Project

 director means the single individual designated by the grantee in the grant application and approved by the Secretary who is responsible for the direction and management of the project.(15) Prior approval means written approval evidencing prior consent by an authorized departmental officer as defined in (2) above.
(16) Project means the particular activity within the scope of the program supported by a grant award.
(17) Project period means the period, as stated in the award document and modifications thereto, if any, during which Federal sponsorship begins and ends.
(18) Research activity means a scientific investigation or inquiry that results in the generation of knowledge.
(19) Secretary means the Secretary of Agriculture and any other officer or employee of the Department to whom the authority involved may be delegated.
(20) Third party in-kind contributions means non-cash contributions of property or services provided by nonFederal third parties, including real property, equipment, supplies and other expendable property, directly benefitting and specifically identifiable to a funded project or program.
(21) Total integrated, multifunctional research, education, and extension approach means that the combination of grants (although the individual grants may involve only research, education, or extension activities or a combination thereof) awarded under the fiscal year's program components will work together to address the priorities in United States agriculture as determined by the Secretary of Agriculture in consultation with the Advisory Board, that involve integrated research, extension, and education activities.

## D. Eligibility

Proposals may be submitted by colleges and universities as defined in section 1404 of the National
Agricultural research, Extension, and

Teaching Policy Act of 1977
(NARETPA). The terms "college" and "university" mean an educational institution in any State which (1) admits as regular students only persons having a certificate of graduation from a school providing secondary education, or the recognized equivalent of such a certificate, (2) is legally authorized within such State to provide a program of education beyond secondary education, (3) provides an educational program for which a bachelor's degree or any other higher degree is awarded, (4) is a public or other nonprofit institution, and (5) is accredited by a nationally recognized accrediting agency or association. Although an applicant may be eligible based on its status as one of these entities, there are factors which may exclude an applicant from receiving Federal financial and nonfinancial assistance and benefits under this program (e.g., debarment or suspension of an individual involved or a determination that an applicant is not responsible based on submitted organizational management information). Eligible applicants may subcontract to organizations not eligible under these requirements.
Please note that a research foundation maintained by a college or university is not eligible to receive an award under this program.

## E. Matching Requirements

## 1. General Requirement

If a grant provides a particular benefit to a specific agricultural commodity, the grant recipient is required to provide funds or in-kind support to match the amount of the grant funds provided. See section 10. c. on "Matching Funds"' under Part III, B, "Content of Proposals" for more details.

## 2. Waiver

CSREES may waive the matching funds requirement specified in the above paragraph for a grant if CSREES determines that (a) the results of the project, while of particular benefit to a specific agricultural commodity, are likely to be applicable to agricultural commodities generally; or (b) the project involves a minor commodity, the project deals with scientifically important research, and the grant recipient is unable to satisfy the matching funds requirement.

## F. Funding Restrictions

CSREES has determined that grant funds awarded under this authority may not be used for the renovation or refurbishment of research, education, or extension space; the purchase or
installation of fixed equipment in such space; or the planning, repair, rehabilitation, acquisition, or construction of buildings or facilities.

## G. Types of Grant Instruments

In FY 2000 all projects will be awarded using a "New Grant" instrument. In future years, projects under the Integrated Research, Education, and Extension Competitive Grants Program authority can be awarded using one of the grant instruments described below:
(1) New grant. This is a grant instrument by which the Department agrees to support a specified level of effort for a project that generally has not been supported previously under this program. This type of grant is approved on the basis of peer review recommendations.
(2) Renewal grant. This is a grant instrument by which the Department agrees to provide additional funding for a project period beyond that approved in an original or amended award, provided that the cumulative period does not exceed the statutory limitation. When a renewal application is submitted, it should include a summary of progress to date from the previous granting period. A renewal grant shall be based upon new application, de novo peer review and staff evaluation, new recommendation and approval, and a new award instrument.
(3) Supplemental grant. This is an instrument by which the department agrees to provide small amounts of additional funding under a new or renewal grant as specified above and may involve a short-term (usually six months or less) extension of the project period beyond that approved in an original or amended award, but in no case may the cumulative period for the project exceed the statutory limitation. A supplement is awarded only if required to assure adequate completion of the original scope of work and if there is sufficient justification to warrant such action. A request of this nature normally will not require additional peer review.

## H. Funding Mechanisms

The two mechanisms by which new, renewal, and supplemental grants shall be awarded are as follows:
(1) Standard grant. This is a funding mechanism whereby the Department agrees to support a specified level of effort for a predetermined time period without the announced intention of providing additional support at a future date.
(2) Continuation grant. This is a funding mechanism whereby the Department agrees to support a
specified level of effort for a predetermined period of time with a statement of intention to provide additional support at a future date, provided that performance has been satisfactory, appropriations are available for this purpose, and continued support will be in the best interests of the Federal government and the public. This kind of mechanism normally will be awarded for an initial one-year period, and any subsequent continuation project grants will be awarded in one-year increments. The award of a continuation project grant to fund an initial or succeeding budget period does not constitute an obligation to fund any subsequent budget period. Unless prescribed otherwise by CSREES, a grantee must submit a separate application for continued support for each subsequent fiscal year. Requests for such continued support must be submitted in duplicate at least three months prior to the expiration date of the budget period currently being funded. Decisions regarding continued support and the actual funding levels of such support in future years usually will be made administratively after consideration of such factors as the grantee's progress and management practices and the availability of funds. Since initial peer reviews are based upon the full term and scope of the original application, additional evaluations of this type generally are not required prior to successive years' support. However, in unusual cases (e.g., when the nature of the project or key personnel change or when the amount of future support requested substantially exceeds the grant application originally reviewed and approved), additional reviews may be required prior to approving continued funding.

## Part II—Program Description

## A. Project Types

Approximately $\$ 1,000,000$ is available for National Facilitation proposals. The maximum total award is $\$ 400,000$, with an annual funding limitation of $\$ 100,000$. The project period may be one to four years in duration. It is anticipated that two to five grants will be awarded in this program component.

Approximately $\$ 5,000,000$ is available for Regional Water Quality Coordination proposals. Projects will be supported at expected levels of up to $\$ 650,000$ per year/per region for up to four years. Projects involving more than one region may be considered for larger funding. CSREES expects that some regions will request less funding due to a smaller number of states within the region. It is
anticipated that ten grants will be awarded in this program component.

Approximately $\$ 1,400,000$ is available for Extension Education proposals. The maximum total award is $\$ 300,000$, with an annual funding limitation of $\$ 100,000$. The project period may be one to three years in duration. It is anticipated that 12-15 grants will be awarded in this program component.

Approximately $\$ 3,600,000$ is available for Integrated Research, Education and Extension proposals. The maximum total award is $\$ 600,000$, with an annual funding limitation of $\$ 200,000$. The project period may be one to three years in duration. It is anticipated that 5-15 grants will be awarded in this program component.

Applications received in any of the aforementioned program areas should include budgets commensurate with the activities proposed. Grants awarded under the Program Description Areas of National Facilitation, Extension Education, and Integrated Research, Education, and Extension (as described in this RFP) will be issued as "New Grant" instruments and will be awarded as "Standard Grants." Grants awarded under the Program Area Description of Regional Water Quality Coordination (as described in this RFP) will be issued as "New Grant" instruments and may be awarded as "Continuation Grants."

## B. Program Area Description

1. National Facilitation Proposals (Program Area 110.1)

## (Maximum award: \$100,000/year for up to four years).

Proposals are invited for projects that develop and initiate nationally coordinated programs that will contribute to an increase in public understanding and involvement in community decision-making and that facilitate the development of public policy on water resources issues. Because protection of local watersheds and aquifers often requires communitybased actions, decisions about land use, land management practices, waste water management alternatives for areas without sewers, storm water controls, and the protection and restoration of riparian zones are critical to individual and public planning. All proposals are required to include specific, measurable accomplishments for each project year and a projected time-line. While it is not required that projects be fully independent within the 4 -year project period, it is expected that the timeline will culminate in the establishment of an independently supported national coordination effort.

This component of the CSREES Water Quality Program seeks to provide a common base of knowledge in support of individuals and communities grappling to formulate public policy and management strategies that will allow growth and increased profitability while protecting the water resource. Projects will be supported that facilitate the appropriate application of tools and techniques (i.e., Geographic Information Systems, decision support systems, remote sensing, economic analysis, and world wide web technologies) to strengthen awareness of the water quality impacts of current and proposed land use activities by both community decision-makers and individual property owners. These tools can also be used to target specific problems and locations in need of additional attention. Projects should contribute to an increase in community partnerships and networks that develop solutions to particular concerns identified through the projects and in response to increased citizen awareness of local issues. The result will be more citizen involvement, wider dispersal of information, and more rational analysis of environmental decisions in the community and the nation. Metadata and accomplishment reports should be delivered annually to the appropriate regional coordination group (see Regional Water Quality Coordination Proposals below).
2. Regional Water Quality Coordination Proposals (Program Area 110.2)
(Maximum award: \$650,000 per year/ per region for up to four years. Projects involving more than one region may be considered for larger funding. CSREES expects that some regions will request less funding due to a smaller number of states within the region).
CSREES invites proposals to ensure the integration of water quality efforts within the jurisdiction of each of the ten regions established by the U.S.
Environmental Protection Agency
(EPA). The EPA Regions are:
Region 1-Connecticut, Maine, Massachusetts, New Hampshire, Rhode Island, and Vermont.
Region 2-New Jersey, New York, and the territories of Puerto Rico and the U.S. Virgin Islands.

Region 3-Delaware, Maryland, Pennsylvania, Virginia, West Virginia, and the District of Columbia.

Region 4-Alabama, Florida, Georgia, Kentucky, Mississippi, North Carolina, South Carolina, and Tennessee.
Region 5-Illinois, Indiana, Michigan, Minnesota, Ohio, and Wisconsin.
Region 6-Arkansas, Louisiana, New Mexico, Oklahoma, and Texas.

Region 7-Iowa, Kansas, Missouri, and Nebraska.

Region 8-Colorado, Montana, North Dakota, South Dakota, Utah, and Wyoming.

Region 9—Arizona, California, Hawaii, Nevada, and the territories of Guam and American Samoa.

Region 10-Alaska, Idaho, Oregon, and Washington.
Proposals may be submitted for one or any combination of regions.

This component of the CSREES Water Quality Program is designed to make research, education, and extension resources of the university system more accessible to Federal, State, and local water quality improvement efforts, thus enhancing opportunities for agricultural producers and agriculturally impacted communities to adopt voluntary approaches for the improvement of water quality. Grantees are expected to facilitate the conceptualization and implementation of multi-partner efforts that minimize duplication of effort and that leverage multiple funding sources into a common collaborative effort. As such, it is expected that coordination grantees will initiate partnership activities with key water quality efforts in their region. Proposers should clearly identify the water quality issues and education, extension, and research efforts that are common to the region. A plan should be presented that lays out the approaches to be employed for regional resource sharing, communication, priority setting, and outreach. The proposal should also discuss Federal and State water quality activities in the region and present a strategy for establishing partnerships with appropriate programs.

Each proposal must include provision for a regional coordination mechanism (whether an individual, a committee, or an office) and for a Water Quality Research, Education, and Extension Coordinator in each State or Territory in the Region. Regional coordinators will be expected to work with CSREES National Program Leaders to provide liaison among Federal activities (e.g., U.S. Environmental Protection Agency (EPA) Regional Offices, U.S. Geological Survey National Water Quality Assessment Program (USGS NAWQA) Coordination Offices, USDA
Agricultural Research Service(ARS) Regional Offices, USDA Forest Service (FS) Regional Offices, National
Aeronautics and Space Administration (NASA), National Oceanic and
Atmospheric Administration (NOAA), Bureau of Land Management (BLM), etc.), State environmental organizations, and the State Water Quality Research,

Education, and Extension Coordinators within the Region. Successful projects will thus provide more efficient development, evaluation, and dissemination of information on watershed improvement, management, and monitoring, and in the development of comparable watershed sampling protocols, data, metadata, and reporting. Provision should be included in the budget request for the regional coordinator to participate in monthly conference calls as well as a national coordination meeting to be held annually in the Washington, D.C. area.

Each regional project must include a plan for the development and maintenance of a georeferenced, watershed-based reporting system. This reporting system will serve as the primary vehicle for reporting progress and accomplishments of the CSREES Water Quality Program. Regional projects are expected: (1) To serve as the repository for the reporting of all projects funded on an ad hoc basis by other components of the CSREES Water Quality Program; (2) to collaborate in the linkage of their databases and reporting systems to other funded regions; (3) to periodically conduct water quality needs assessments for the region and report on partnerships and progress in water quality improvement; (4) to facilitate the incorporation of relevant projects that may become funded in the region through CSREES programs (including other sections of the Water Quality Program, the National Research Initiative, the Animal Waste Center, the Initiative for Future Agriculture and Food Systems) or through other federal and state programs (e.g., EPA 319, EPA National Center for Environmental Research and Quality Assurance (NCERQA), National Science Foundation (NSF), NOAA, etc.); and (5) to be compatible with related information sources (e.g., USGS NAWQA Program, EPA Know Your Watershed, CSREES Integrated Pest Management Program, and the CSREES Pesticide Impact Assessment Program, etc.).
3. Extension Education Proposals (Program Area 110.3)
(Maximum award: \$100,000/year for one to three years).

Proposals are invited for Extension Education projects to address water quality issues of State or local importance. One mission of the CSREES Water Quality Program is to provide leadership in extension education that will enable individuals, industry, and government to effect changes enhancing and protecting the Nation's water
resources for the public good. The vision is to be recognized as an important and effective partnership providing leadership for water quality education to help people, industry, and governments prevent and solve current and emerging water quality problems. Proposals for this program are expected to address one or more of the seven strategic extension priorities of the Water Quality Program (see http:// www.reeusda.gov/nre/water/ strategi.htm). The seven areas of emphasis for the education program are under-served audiences, watersheds and aquifers, surface water systems, public policy, individual actions, volunteerism,and partnership. All proposals are required to include specific, measureable accomplishments for each project year. Metadata and accomplishments reports will be delivered annually to the appropriate regional coordination group. See "Regional Water Quality Coordination Proposals" above.
4. Integrated Research, Education, and Extension Proposals (Program Area 110.4)
(Maximum award: \$200,000/year up to three years).
Proposals are invited that integrate water quality research, education, and extension to solve water quality problems at the whole watershed. Proposals should: (a) Identify the cause of water quality degradation;
(b) conduct research filling the gaps that are critical to the development of water improvement practices and programs; (c) implement watershedscale improvement programs; (d) evaluate and monitor the efficacy of the improvement programs implemented; (e) assess the costs and benefits of water quality management practices that are developed; and (f) conduct evaluations closing the loop and improving our understanding of the drivers of water quality degradation. Each proposal is expected to present a fully integrated research, education, and extension approach to accomplish the objectives listed in a-f above. CSREES also encourages the inclusion of a curriculum development component that takes advantage of the integrated watershed activities to enhance environmental education at all levels. The proposing investigators are expected to justify watershed selection (e.g., the level of water quality degradation-chemical, physical, and biological; the relative distribution of agricultural, range or forestry land uses within the watershed; and/or proximity to coastal resources) and to demonstrate
capacities for establishing and/or maintaining watershed-wide partnerships for the project's implementation. Preference will be given to proposals that: (1) Demonstrate a substantial potential to contribute long term information, existing opportunities for leveraging support and cost sharing, and active public and private sector participation; (2) take advantage of the participatory educational and extension opportunities engendered by the watershed's restoration and by its continued management; and/or (3) focus on watersheds where the project will better inform policy makers in developing the most equitable multistate and/or regional strategies for water quality improvement. All proposals are required to include specific, measurable accomplishments each project year. Metadata and accomplishments reports will be delivered annually to the appropriate regional coordination groups. See "Regional Water Quality Coordination Proposals" above.

## C. Expected Program Outputs and Reporting Requirements

It is expected that outputs from successful projects will include: the development of watershed management partnerships, increased involvement of community and business sectors in watershed restoration and management, enhanced understanding of regionallyappropriate watershed management practices, increased coordination and partnership between universities and other Federal research and management agencies, and the establishment and maintenance of monitoring and assessment activities related to the agricultural-water quality interface.

All projects selected for award will be required to deliver metadata and annual reports, a final summary report, a bibliography of publications and training materials resulting from support, and an impacts analysis. All reports will be geo-referenced to the watersheds where activities were performed. The final summary report must include total funding (Federal, matching and other) and a listing of students who worked on the project (report graduate degrees awarded and undergraduates trained).

The grantee must prepare an annual report that details all significant activities towards achieving the goals and objectives of the project. The narrative should be succinct and be no longer than 10 pages, using 12-point, single-spaced type. A budget summary should be attached to this report, which will provide an overview of all monies spent during the reporting period.

## Part III—Preparation of a Proposal

## A. Program Application Materials

Program application materials are available at the Integrated Research, Education, and Extension Competitive Grants Program website (http:// www.reeusda.gov/integrated/). If you do not have access to our web page or have trouble downloading material, you may contact the Proposal Services Unit, Office of Extramural Programs, USDA/ CSREES at (202) 401-5048. When calling the Proposal Services Unit, please indicate that you are requesting forms for the Integrated Research, Education, and Extension Competitive Grants Program—Water Quality. These materials may also be requested via Internet by sending a message with your name, mailing address (not e-mail) and phone number to psb@reeusda.gov. State that you want a copy of the Program Description and application materials (orange book) for the Fiscal Year 2000 Integrated Research, Education, and Extension Competitive Grants Program—Water Quality.

## B. Content of Proposals

## 1. General

The proposal should follow these guidelines, enabling reviewers to more easily evaluate the merits of each proposal in a systematic, consistent fashion:
(a) The proposal should be prepared on only one side of the page using standard size ( $81 / 2^{\prime \prime} \times 11^{\prime \prime}$ ) white paper, one inch margins, typed or word processed using no type smaller than 12 point font, and single or double spaced. Use an easily readable font face (e.g., Geneva, Helvetica, Times Roman).
(b) Each page of the proposal, including the Project Summary, budget pages, required forms, and any appendices, should be numbered sequentially.
(c) The proposal should be stapled in the upper left-hand corner. Do not bind. An original and 14 copies ( 15 total) must be submitted in one package, along with 10 copies of the "Project Summary" as a separate attachment.
(d) If applicable, proposals should include original illustrations (photographs, color prints, etc.) in all copies of the proposal to prevent loss of meaning through poor quality reproduction.

## 2. Cover Page (Form CSREES-661)

Each copy of each grant proposal must contain an "Application for Funding'", Form CSREES-661. One copy of the application, preferably the original, must contain the pen-and-ink
signature(s) of the proposing principal investigator(s)/project director(s)(PI/PD) and the authorized organizational representative who possesses the necessary authority to commit the organization's time and other relevant resources to the project. Any proposed PI/PD or co-PI/PD whose signature does not appear on Form CSREES-661 will not be listed on any resulting grant award. Complete both signature blocks located at the bottom of the
"Application for Funding" form.
Form CSREES-661 serves as a source document for the CSREES grant database; it is therefore important that it be completed accurately. The following items are highlighted as having a high potential for errors or misinterpretations:
(a) Title of Project (Block 6). The title of the project must be brief (80-character maximum), yet represent the major thrust of the effort being proposed. Project titles are read by a variety of nonscientific people; therefore, highly technical words or phraseology should be avoided where possible. In addition, introductory phrases such as
"investigation of" or "research on" "education for" or "outreach that" should not be used.
(b) Program to Which You Are Applying (Block 7). "Integrated Research, Education, and Extension Competitive Grants Program—Water Quality."
(c) Program Area and Number (Block 8). The name of the program component, e.g. National Facilitation Proposal, 110.1 or Regional Water Quality Coordination Proposal, 110.2 should be inserted in this block.
(d) Type of Award Request (Block 13). Check the block for "new."
(e) Principal Investigator(s)/Project Director(s) (PI/PD) (Block 15). The designation of excessive numbers of coPI/PD's creates problems during final review and award processing. Listing multiple co-PI/PDs, beyond those required for genuine collaboration, is therefore discouraged. Note that providing a Social Security Number is voluntary, but is an integral part of the CSREES information system and will assist in the processing of the proposal.
(f) Type of Performing Organization (Block 18). A check should be placed in the box beside the type of organization which actually will carry out the effort. For example, if the proposal is being submitted by an 1862 Land-Grant Institution but the work will be performed in a department, laboratory, or other organizational unit of an agricultural experiment station, box " 03 " should be checked. If portions of the effort are to be performed in several
departments, check the box that applies to the individual listed as PI/PD \#1 in Block 15.a.
(g) Other Possible Sponsors (Block 22). List the names or acronyms of all other public or private sponsors including other agencies within USDA and other programs funded by CSREES to whom your application has been or might be sent. In the event you decide to send your application to another organization or agency at a later date, you must inform the identified CSREES program manager as soon as practicable. Submitting your proposal to other potential sponsors will not prejudice its review by CSREES; however, duplicate support for the same project will not be provided. Complete the "Application for Funding," Form CSREES-661, in its entirety
(h) One copy of the "Application for Funding" form must contain the signatures (in ink) of the PI/PD's and authorized organizational representative for the applicant organization.

## 3. Table of Contents

For consistency and ease in locating information, each proposal must contain a detailed Table of Contents just after the cover page. The Table of Contents should contain page numbers for each component of the proposal. Page numbers should begin with the first page of the Project Description.

## 4. Project Summary

The proposal must contain a Project Summary of 250 words or less on a separate page which should be placed immediately after the Table of Contents and should not be numbered. The names and institutions of all PI/PD's and co-PI/PD's should be listed on this form, in addition to the title of the project. The summary should be a selfcontained, specific description of the activity to be undertaken and should focus on: overall project goal(s) and supporting objectives; plans to accomplish project goal(s); and relevance of the project to regional, State, or local water quality efforts and/ or list of CSREES Water Quality Program Priorities listed above. The importance of a concise, informative Project Summary cannot be overemphasized. Summaries for Regional Water Quality Coordination Proposals should also indicate all organizations participating in the effort, the organization that will house the database effort, and the mechanism that will be used to coordinate between organizations.

## 5. Project Description

For Regional Water Quality Coordination and for Integrated Research, Education, and Extension proposals, the project description may not exceed 15 single- or double-spaced pages of written text and may not exceed a total of 20 pages after inclusion of figures and tables.

For National Facilitation and for Extension Education proposals, the project description may not exceed 8 single- or double-spaced pages of written text and may not exceed a total of ten pages after inclusion of figures and tables.
The project description should include the following:
a. Introduction and Rationale: Include a clear statement of the problems to be addressed and goals expected to be accomplished. Describe the supporting objectives; questions; research, education and/or extension components to be included; and/or partners that will be used to accomplish the goal(s) set. If preparing a Regional Coordination proposal, describe the current limitations to effective regional water quality management and describe the key stakeholders that must be included to overcome these limitations.
b. Approach:
(1) Describe the activities to be performed, the means by which data and information will be analyzed and interpreted, the methods that will be used for information transfer, the methods that will be used to evaluate adoption and project impact, and the limitations and pitfalls to the approaches selected.
(2) A plan should be presented for coordination and communication between project collaborators.
(3) A project timeline.
(4) A description of outcomes and expected deliverables.
(5) Literature Review. All references cited should be complete, including titles and all co-authors, and should conform to an acceptable journal format.
In addition to the above, the National Facilitation and Regional Coordination proposals should describe the roles and responsibilities of central coordinators and should present a management plan for the administration of the project including facilitation of communication, planning, and annual report preparation.

## 6. Appendices to Project Description

Appendices to the Project Description are allowed if they are directly germane to the proposed project and are limited to a total of two of the following: reprints (papers that have been
published in peer reviewed journals) and preprints (manuscripts in press for a peer reviewed journal; these must be accompanied by a letter of acceptance from the publishing journal).

## 7. Key Personnel

All senior personnel who are expected to be involved in the effort must be clearly identified. For each person, the following should be included:
a. The roles and responsibilities of each PI/PD and/or collaborator should be clearly described;
b. An estimate of the time commitment involved for each PI/PD and/or collaborator; and
c. Vitae of each PI/PD, senior associate, and other professional personnel. This section should include vitae of all key persons who are expected to work on the project, whether or not CSREES funds are sought for their support. The vitae should be limited to two (2) pages each in length, excluding publications listings. A chronological list of all publications in refereed journals during the past four (4) years, including those in press, must be provided for each project member for which a curriculum vitae is provided. Also list those nonrefereed technical publications that have relevance to the proposed project. All authors should be listed in the same order as they appear on each paper cited, along with the title and complete reference as these usually appear in journals.

## 8. Conflict-of-Interest List

A Conflict-of-Interest List must be provided for all individuals involved in the project (identified as key personnel). Each list should be on a separate page and include alphabetically the full names of the individuals in the following categories: (a) All collaborators on projects within the past four years, including current and planned collaborations; (b) all coauthors on publications within the past four years, including pending publications and submissions; (c) all persons in your field with whom you have had a consulting or financial arrangement within the past four years, who stand to gain by seeing the project funded; and (d) all thesis or postdoctoral advisees/advisors within the past four years (some may wish to call these life-time conflicts). This form is necessary to assist program staff in excluding from proposal review those individuals who have conflicts-ofinterest with the personnel in the grant proposal. The Program Director must be informed of any additional conflicts-of-
interest that arise after the proposal is submitted.
9. Collaborative and/or Subcontractual Arrangements

If it will be necessary to enter into formal consulting or collaborative arrangements with others, such arrangements should be fully explained and justified. In addition, evidence should be provided that the collaborators involved have agreed to render these services. If the need for consultant services is anticipated, the proposal narrative should provide a justification for the use of such services, a statement of work to be performed, and a resume or curriculum vita for each consultant. For purposes of proposal development, informal day-today contacts between key project personnel and outside experts are not considered to be collaborative arrangements and thus do not need to be detailed.

All anticipated subcontractual arrangements also should be explained and justified in this section. A proposed statement of work and a budget for each arrangement involving the transfer of substantive programmatic work or the providing of financial assistance to a third party must be provided. Agreements between departments or other units of your own institution and minor arrangements with entities outside of your institution (e.g., requests for outside laboratory analyses) are excluded from this requirement.

If you expect to enter into subcontractual arrangements, please note that the provisions contained in 7 CFR Part 3019, USDA Uniform Administrative Requirements for Grant and Other Agreements with Institutions of Higher Education, Hospitals, and Other Non-Profit Organizations, and the general provisions contained in 7 CFR Part 3015.205, USDA Uniform Federal Assistance Regulations, flow down to subrecipients. In addition, required clauses from Sections 40-48 ("Procurement Standards") and Appendix A ("Contract Provisions") to 7 CFR Part 3019 should be included in final contractual documents, and it is necessary for the subawardee to make a certification relating to debarment/ suspension.

## 10. Budget (Form CSREES-55)

a. Budget Form. Prepare the budget, Form CSREES-55, in accordance with instructions provided. A budget form is required for each year of requested support. In addition, a cumulative budget is required detailing the requested total support for the overall project period. The budget form may be
reproduced as needed by applicants. Funds may be requested under any of the categories listed on the form, provided that the item or service for which support is requested is allowable under the authorizing legislation, the applicable Federal cost principles, and these program guidelines, and can be justified as necessary for the successful conduct of the proposed project.
Applicants must also include a Budget Narrative to justify their budgets (see section b below.)
The following guidelines should be used in developing your proposal budget(s):

1. Salaries and Wages. Salaries and wages are allowable charges and may be requested for personnel who will be working on the project in proportion to the time such personnel will devote to the project. If salary funds are requested, the number of Senior and Other Personnel and the number of CSREESFunded Work Months must be shown in the spaces provided. Grant funds may not be used to augment the total salary or rate of salary of project personnel or to reimburse them for time in addition to a regular full-time salary covering the same general period of employment. Salary funds requested must be consistent with the normal policies of the institution.
2. Fringe Benefits. Funds may be requested for fringe benefit costs if the usual accounting practices of your organization provide that organizational contributions to employee benefits (social security, retirement, etc.) be treated as direct costs. Fringe benefit costs may be included only for those personnel whose salaries are charged as a direct cost to the project.
3. Nonexpendable Equipment. Nonexpendable equipment means tangible nonexpendable personal property including exempt property charged directly to the award having a useful life of more than one year and an acquisition cost of $\$ 5,000$ (or lower depending on institutional policy) or more per unit. As such, items of necessary instrumentation or other nonexpendable equipment should be listed individually by description and estimated cost in the Budget Narrative. This applies to revised budgets as well, as the equipment item(s) and amount(s) may change.
4. Materials and Supplies. The types of expendable materials and supplies which are required to carry out the project should be indicated in general terms with estimated costs in the Budget Narrative.
5. Travel. The type and extent of travel and its relationship to project objectives should be described briefly
and justified. If foreign travel is proposed, the country to be visited, the specific purpose of the travel, a brief itinerary, inclusive dates of travel, and estimated cost must be provided for each trip. Airfare allowances normally will not exceed round-trip jet economy air accommodations. U.S. flag carriers must be used when available. See 7 CFR Part 3015.205(b)(4) for further guidance.
6. Publication Costs/Page Charges. Include anticipated costs associated with publications in a journal (preparing and publishing results including page charges, necessary illustrations, and the cost of a reasonable number of coverless reprints) and audio-visual materials that will be produced. Photocopying and printing brochure, etc., should be shown in Section I., "All Other Direct Costs" of Form CSREES-55.

## 7. Computer (ADPE) Costs.

Reimbursement for the costs of using specialized facilities (such as a university- or department-controlled computer mainframe or data processing center) may be requested if such services are required for completion of the work.
8. All Other Direct Costs. Anticipated direct project charges not included in other budget categories must be itemized with estimated costs and justified in the Budget Narrative. This also applies to revised budgets, as the item(s) and dollar amount(s) may change. Examples may include space rental at remote locations, subcontractual costs, and charges for consulting services, telephone, facsimile, shipping costs, and fees necessary for laboratory analyses. You are encouraged to consult the "Instructions for Completing Form CSREES-55, Budget," of the Application Kit for detailed guidance relating to this budget category. Form AD-1048 must be completed by each subcontractor or consultant and retained by the grantee.
9. Indirect Costs. Section 1462 of the National Agricultural Research, Extension, and Teaching Policy Act of 1977 (7 U.S.C. 3310) limits indirect costs for this program to 19 percent of total Federal funds provided under each award. Therefore the recovery of indirect costs under this program may not exceed the lesser of the institution's official negotiated indirect cost rate or the equivalent of 19 percent of total Federal funds awarded. If no rate has been negotiated, a reasonable dollar amount (equivalent to less than 19 percent of total Federal funds requested) in lieu of indirect costs may be requested, subject to approval by USDA.
b. Budget Narrative. All budget categories, excluding Indirect Costs, for which support is requested must be individually listed (with costs) and justified on a separate sheet of paper and placed immediately behind the Budget Form. Explanations of matching funds or lack thereof on commodityspecific projects also are to be included in this section.
c. Matching Funds. If an applicant concludes that matching funds are not required as specified under Part I (e), a justification should be included in the Budget Narrative. CSREES will consider this justification when ascertaining final matching requirements or in determining if required matching can be waived. CSREES retains the right to make final determinations regarding matching requirements.

For those grants requiring matching funds as specified under Part I (e), proposals should include written verification of commitments of matching support (including both cash and in-kind contributions) from third parties. Written verification means:
(a) For any third party cash contributions, a separate pledge agreement for each donation, signed by the authorized organizational representatives of the donor organization and the applicant organization, which must include: (1) The name, address, and telephone number of the donor; (2) the name of the applicant organization; (3) the title of the project for which the donation is made; (4) the dollar amount of the cash donation; and (5) a statement that the donor will pay the cash contribution during the grant period; and
(b) For any third party in-kind contributions, a separate pledge agreement for each contribution, signed by the authorized organizational representatives of the donor organization and the applicant organization, which must include: (1) The name, address, and telephone number of the donor; (2) the name of the applicant organization; (3) the title of the project for which the donation is made; (4) a good faith estimate of the current fair market value of the third party in-kind contribution; and (5) a statement that the donor will make the contribution during the grant period.

The sources and amount of all matching support from outside the applicant institution should be summarized on a separate page and placed in the proposal immediately following the Budget Narrative. All pledge agreements must be placed in the proposal immediately following the summary of matching support.

The value of applicant contributions to the project shall be established in accordance with applicable cost principles. Applicants should refer to OMB Circulars A-21, Cost Principles for Educational Institutions, for further guidance and other requirements relating to matching and allowable costs.
11. Current and Pending Support (Form CSREES-663)
All proposals must contain Form CSREES-663 listing other current public or private support (including in-house support) to which key personnel identified in the proposal have committed portions of their time, whether or not salary support for person(s) involved is included in the budget. Analogous information must be provided for any pending proposals that are being considered by, or that will be submitted in the near future to, other possible sponsors, including other USDA Programs or agencies. Concurrent submission of identical or similar proposals to the possible sponsors will not prejudice proposal review or evaluation by the CSREES for this purpose. However, a proposal that duplicates or overlaps substantially with a proposal already reviewed and funded (or to be funded) by another organization or agency will not be funded under this program. Note that the project being proposed should be included in the pending section of the form.

## 12. Assurance Statement(s), (Form CSREES-662)

A number of situations encountered in the conduct of projects require special assurances, supporting documentation, etc., before funding can be approved for the project. In addition to any other situation that may exist with regard to a particular project, it is expected that some applications submitted in response to these guidelines will involve the following:
a. Recombinant DNA or RNA Research. As stated in 7 CFR Part 3015.205 (b)(3), all key personnel identified in the proposal and all endorsing officials of the proposing organization are required to comply with the guidelines established by the National Institutes of Health entitled, "Guidelines for Research Involving Recombinant DNA Molecules," as revised. If your project proposes to use recombinant DNA or RNA techniques, you must so indicate by checking the "yes" box in Block 19 of Form CSREES661 (the Cover Page) and by completing Section A of Form CSREES-662. For applicable proposals recommended for
funding, Institutional Biosafety Committee approval is required before CSREES funds will be released.
b. Animal Care. Responsibility for the humane care and treatment of live vertebrate animals used in any grant project supported with funds provided by CSREES rests with the performing organization. Where a project involves the use of living vertebrate animals for experimental purposes, all key project personnel identified in a proposal and all endorsing officials of the proposing organization are required to comply with the applicable provisions of the Animal Welfare Act of 1966, as amended (7 U.S.C. 2131 et seq.) and the regulations promulgated thereunder by the Secretary in 9 CFR Parts 1, 2, 3, and 4 pertaining to the care, handling, and treatment of these animals. If your project will involve these animals, you should check "yes" in block 20 of Form CSREES-661 and complete Section B of Form CSREES-662. In the event a project involving the use of live vertebrate animals results in a grant award, funds will be released only after the Institutional Animal Care and Use Committee has approved the project.
c. Protection of Human Subjects. Responsibility for safeguarding the rights and welfare of human subjects used in any grant project supported with funds provided by CSREES rests with the performing organization. Guidance on this issue is contained in the National Research Act, Pub. L. No. 93-348, as amended, and implementing regulations promulgated by the Department under 7 CFR Part 1c. If you propose to use human subjects for experimental purposes in your project, you should check the "yes" box in Block 21 of Form CSREES-661 and complete Section C of Form CSREES662. In the event a project involving human subjects results in a grant award, funds will be released only after the appropriate Institutional Review Board has approved the project.

## 13. Certifications

Note that by signing Form CSREES661 the applicant is providing the certifications required by 7 CFR Part 3017, as amended, regarding Debarment and Suspension and Drug Free Workplace, and 7 CFR Part 3018, regarding Lobbying. The certification forms are included in the application package for informational purposes only. These forms should not be submitted with the proposal since by signing form CSREES-661 your organization is providing the required certifications. If the project will involve a subcontractor or consultant, the subcontractor/consultant should submit
a form AD-1048 to the grantee organization for retention in their records. This form should not be submitted to USDA.
14. Compliance with the National Environmental Policy Act (NEPA) (Form CSREES-1234)

As outlined in 7 CFR Part 3407 (the Cooperative State Research, Education, and Extension Service regulations implementing NEPA), the environmental data for any proposed project is to be provided to CSREES so that CSREES may determine whether any further action is needed. In some cases, however, the preparation of environmental data may not be required. Certain categories of actions are excluded from the requirements of NEPA.

In order for CSREES to determine whether any further action is needed with respect to NEPA, pertinent information regarding the possible environmental impacts of a particular project is necessary; therefore, Form CSREES-1234, "NEPA Exclusions Form," must be included in the proposal indicating whether the applicant is of the opinion that the project falls within a categorical exclusion and the reasons therefore. If it is the applicant's opinion that the proposed project falls within the categorical exclusions, the specific exclusion must be identified. Form CSREES-1234 and supporting documentation should be included as the last page of this proposal.

Even though a project may fall within the categorical exclusions, CSREES may determine that an Environmental Assessment or an Environmental Impact Statement is necessary for an activity, if substantial controversy on
environmental grounds exists or if other extraordinary conditions or circumstances are present which may cause such activity to have a significant environmental effect.

## C. Submission of Proposals

## 1. When to Submit (Deadline Date)

Proposals must be transmitted by June 6,2000 , as indicated by postmark or date of courier bill of lading. Proposals transmitted after this date will not be considered for funding.

## 2. What to Submit

An original and 14 copies must be submitted. In addition submit 10 copies of the proposal's Project Summary. All copies of the proposals and the Project Summaries must be submitted in one package.
3. Where to Submit

Applicants are strongly encouraged to submit completed proposals via overnight mail or delivery service to ensure timely receipt by the USDA. The address for hand-delivered proposals or proposals submitted using an express mail or overnight courier service is: Integrated Research, Education, and Extension Competitive Grants Program—Water Quality; c/o Proposal Services Unit; Cooperative State Research, Education, and Extension Service; U.S. Department of Agriculture; Room 303, Aerospace Center; 901 D Street, S.W.; Washington, D.C. 20024.

Proposals sent via the U.S. Postal Service must be sent to the following address: Integrated Research, Education, and Extension Competitive Grants Program-Water Quality; c/o Proposal Services Unit; Cooperative State Research, Education, and Extension Service; U.S. Department of Agriculture; STOP 2245; 1400 Independence Avenue, S.W.; Washington, D.C. 202502245.

## D. Acknowledgment of Proposals

The receipt of all proposals will be acknowledged by e-mail. Therefore, applicants are encouraged to provide email addresses, where designated, on the Form CSREES-661. If the applicant's email address is not indicated, CSREES will acknowledge receipt of the proposal by letter

Once the proposal has been assigned an identification number, please cite that number on all future correspondence. If the applicant does not receive an acknowledgment within 60 days of the submission deadline, please contact the Program Director.

## Part IV-Review Process

## A. General

Each proposal will be evaluated in a 3-part process. First, each proposal will be screened to ensure that it meets the administrative requirements as set forth in this request for proposals. Second, proposals that meet these requirements will be technically evaluated by a peer review panel. Each program component will have a separate review panel. Third, proposals ranked highly by the technical peer review panel will be evaluated by a panel of experts that will select awardees based on an evaluation of: national coverage, topical coverage, level of participation from stakeholder community, likelihood for the implementation of voluntary approaches to water quality improvement, and convergence with USDA and federal partnership priorities.

Peer review panel members will be selected based upon their training and experience in relevant scientific, education or extension fields taking into account the following factors: (a) The level of formal scientific, technical education, and extension experience of the individual, as well as the extent to which an individual is engaged in relevant research, education and/or extension activities; (b) the need to include as peer reviewers experts from various areas of specialization within relevant scientific, education, and extension fields; (c) the need to include as reviewers other experts (producers, range or forest managers/operators, consumers, etc.) who can assess relevance of the proposals to targeted audiences and to program needs; (d) the need to include as peer reviewers experts from a variety of organizational types (e.g., colleges, universities, industry, state and Federal agencies, private profit and non-profit organizations), and geographic locations; (e) the need to maintain a balanced composition of peer review groups with regard to minority and female representation and an equitable age distribution; and (f) the need to include members that can judge the effective usefulness to producers and the general public of each proposal.

## B. Evaluation Factors

The evaluation factors below will be used in reviewing applications submitted in response to this request for proposals:
(1) The proposal specifies realistic water quality-related outcomes and presents an approach with high
technical and/or educational merit.
(2) The proposal identifies, documents, and addresses water quality problems of Federal, State, regional, or local importance.
(3) The proposal specifically addresses one or more of the program priorities identified in Part II.
(4) The proposal establishes the integrated nature of the Water Quality program and includes inter-disciplinary approaches.
(5) The proposal encompasses the development of partnerships among the various stakeholders to generate support and resources.
(6) The proposal includes a budget adequate to carry out project activities and which is cost-effective and justified.
(7) The proposal provides a clear plan for accomplishments reporting.
(8) The proposal clearly demonstrates that the investigators and institutions involved in the project exhibit that: (a) Project personnel have appropriate training and a demonstrated awareness
of previous and alternative approaches to the problem identified in the proposal, and performance record and/ or potential for future accomplishments; (b) appropriate time has been allocated for systematic attainment of objectives; (c) the participating institutions have experience and competence in subject areas appropriate to the successful completion of the project; and (d) adequate support personnel, facilities, and instrumentation are available or obtainable. For the National Facilitation proposals and Regional Water Quality Coordination proposals will also be judged on the quality of the management plan that is proposed. Priority will be given for integrated, multifunctional research, education, and extension projects.

## C. Conflicts-of-Interest and Confidentiality

During the peer evaluation process, extreme care will be taken to prevent any actual or perceived conflicts-ofinterest that may impact review or evaluation. For the purpose of determining conflicts-of-interest, the academic and administrative autonomy of an institution shall be determined by reference to the January 1998 issue of the Codebook for Compatible Statistical Reporting of Federal Support to Universities, Colleges, and Nonprofit Institutions, prepared by Quantum Research Corporation for the National Science Foundation.

Names of submitting institutions and individuals, as well as proposal content and peer evaluations, will be kept confidential, except to those involved in the review process, to the extent permitted by law. In addition, the identities of peer reviewers will remain confidential throughout the entire review process. Therefore, the names of the reviewers will not be released to applicants. At the end of the fiscal year, names of panelists will be made available in such a way that the panelists cannot be identified with the review of any particular proposal.

## Part V—Additional Information

## A. Access to Review Information

Copies of summary reviews, not including the identity of the reviewers, will be sent to all applicant PI/PD's automatically, after the review process has been completed.

## B. Grant Awards

(1) General.

Within the limit of funds available for such purpose, the awarding official of CSREES shall make grants to those responsible, eligible applicants whose
proposals are judged most meritorious under the procedures set forth in this RFP. The date specified by the awarding official of CSREES as the effective date of the grant shall be no later than September 30 of the Federal fiscal year in which the project is approved for support and funds are appropriated for such purpose, unless otherwise permitted by law. It should be noted that the project need not be initiated on the grant effective date, but as soon thereafter as practical so that project goals may be attained within the funded project period. All funds granted by CSREES under this RFP shall be expended solely for the purpose for which the funds are granted in accordance with the approved application and budget, the regulations, the terms and conditions of the award, the applicable Federal cost principles, and the Department's assistance regulations (parts 3015 and 3019 of 7 CFR).
(2) Organizational Management Information.

Specific management information relating to an applicant shall be submitted on a one-time basis as part of the responsibility determination prior to the award of a grant identified under this RFP, if such information has not been provided previously under this or another CSREES program. CSREES will provide copies of forms recommended for use in fulfilling these requirements as part of the preaward process.
(3) Grant Award Document and Notice of Grant Award.
The grant award document shall include at a minimum the following:
(a) Legal name and address of performing organization or institution to whom the Administrator has awarded a grant under the terms of this request for proposals;
(b) Title of project;
(c) Name(s) and address(es) of PI/PD's chosen to direct and control approved activities;
(d) Identifying grant number assigned by the Department;
(e) Project period, specifying the amount of time the Department intends to support the project without requiring recompetition for funds;
(f) Total amount of Departmental financial assistance approved by the Administrator during the project period;
(g) Legal authority(ies) under which the grant is awarded;
(h) Approved budget plan for categorizing allocable project funds to accomplish the stated purpose of the grant award; and
(i) Other information or provisions deemed necessary by CSREES to carry out its respective granting activities or
to accomplish the purpose of a particular grant.
The notice of grant award, in the form of a letter, will be prepared and will provide pertinent instructions or information to the grantee that is not included in the grant award document.

## C. Use of Funds; Changes

(1) Delegation of Fiscal Responsibility

Unless the terms and conditions of the grant state otherwise, the grantee may not in whole or in part delegate or transfer to another person, institution, or organization the responsibility for use or expenditure of grant funds.
(2) Changes in Project Plans
(a) The permissible changes by the grantee, $\mathrm{PI} / \mathrm{PD}(\mathrm{s})$, or other key project personnel in the approved project grant shall be limited to changes in methodology, techniques, or other aspects of the project to expedite achievement of the project's approved goals. If the grantee and/or the PI/PD(s) are uncertain as to whether a change complies with this provision, the question must be referred to the CSREES Authorized Departmental Officer (ADO) for a final determination.
(b) Changes in approved goals or objectives shall be requested by the grantee and approved in writing by the ADO prior to effecting such changes. In no event shall requests for such changes be approved which are outside the scope of the original approved project.
(c) Changes in approved project leadership or the replacement or reassignment of other key project personnel shall be requested by the grantee and approved in writing by the awarding official of CSREES prior to effecting such changes.
(d) Transfers of actual performance of the substantive programmatic work in whole or in part and provisions for payment of funds, whether or not Federal funds are involved, shall be requested by the grantee and approved in writing by the ADO prior to effecting such transfers, unless prescribed otherwise in the terms and conditions of the grant.
(e) Changes in Project Period: The project period may be extended by CSREES without additional financial support, for such additional period(s) as the ADO determines may be necessary to complete or fulfill the purposes of an approved project, but in no case shall the total project period exceed five years. Any extension of time shall be conditioned upon prior request by the grantee and approval in writing by the

ADO, unless prescribed otherwise in the terms and conditions of a grant.
(f) Changes in Approved Budget: Changes in an approved budget must be requested by the grantee and approved in writing by the ADO prior to instituting such changes if the revision will involve transfers or expenditures of amounts requiring prior approval as set forth in the applicable Federal cost principles, Departmental regulations, or in the grant award.

## D. Applicable Federal Statutes and Regulations

Several Federal statutes and regulations apply to grant proposals considered for review and to project grants awarded under this program. These include but are not limited to: 7 CFR Part 1.1—USDA
implementation of the Freedom of Information Act.

7 CFR Part 3—USDA implementation of OMB Circular No. A-129 regarding debt collection.

7 CFR Part 15, subpart A—USDA implementation of Title VI of the Civil Rights Act of 1964, as amended. 7 CFR Part 3015—USDA Uniform Federal Assistance Regulations, implementing OMB directives (i.e., Circular Nos. A-21 and A-122) and incorporating provisions of 31 U.S.C. 6301-6308 (the Federal Grant and Cooperative Agreement Act of 1977, Pub. L. No. 95-224), as well as general policy requirements applicable to recipients of Departmental financial assistance.

7 CFR Part 3017—USDA
implementation of Governmentwide Debarment and Suspension (Nonprocurement) and Governmentwide Requirements for Drug-Free Workplace (Grants). 7 CFR Part 3018—USDA
implementation of Restrictions on Lobbying. Imposes prohibitions and requirements for disclosure and certification related to lobbying on recipients of Federal contracts, grants, cooperative agreements, and loans.

7 CFR Part 3019—USDA
implementation of OMB Circular A110, Uniform Administrative Requirements for Grants and Other Agreements With Institutions of Higher Education, Hospitals, and Other Nonprofit Organizations. 7 CFR Part 3052—USDA implementation of OMB Circular No. A133, Audits of States, Local Governments, and Non-profit Organizations.

7 CFR Part 3407-CSREES procedures to implement the National Environmental Policy Act of 1969, as amended.
29 U.S.C. 794 (section 504, Rehabilitation Act of 1973) and 7 CFR Part 15B (USDA implementation of statute)—prohibiting discrimination based upon physical or mental handicap in Federally assisted programs.
35 U.S.C. 200 et seq.-Bayh-Dole Act, controlling allocation of rights to inventions made by employees of small business firms and domestic nonprofit organizations, including universities, in Federally assisted programs
(implementing regulations are contained in 37 CFR Part 401).

## E. Confidential Aspects of Proposals and Awards

When a proposal results in a grant, it becomes a part of the record of CSREES transactions, available to the public upon specific request. Information that the Secretary determines to be of a confidential, privileged, or proprietary nature will be held in confidence to the extent permitted by law. Therefore, any information that the applicant wishes to have considered as confidential, privileged, or proprietary should be clearly marked within the proposal. The original copy of a proposal that does not result in a grant will be retained by the Agency for a period of one year. Other copies will be destroyed. Such a proposal will be released only with the consent of the applicant or to the extent required by law. A proposal may be withdrawn at any time prior to the final action thereon.

## F. Regulatory Information

For the reasons set forth in the final Rule-related Notice to 7 CFR part 3015, subpart V (48 FR 29115, June 24, 1983), this program is excluded from the scope of the Executive Order 12372 which requires intergovernmental consultation with State and local officials. Under the provisions of the Paperwork Reduction Act of 1995, as amended ( 44 U.S.C. chapter 35), the collection of information requirements contained in this Notice have been approved under OMB Document No. 0524-0022.
Done at Washington, D.C., this 4th day of April 2000.

## Charles W. Laughlin,

Administrator, Cooperative State Research, Education, and Extension Service.
[FR Doc. 00-8643 Filed 4-4-00; 2:36 pm]
BILLING CODE 3410-22-P


## Friday,

April 7, 2000

## Part VI

# Department of the Treasury 

Fiscal Service
31 CFR Part 210
Federal Government Participation in the Automated Clearing House; Interim Rule

## DEPARTMENT OF THE TREASURY

## Fiscal Service

## 31 CFR Part 210

## RIN 1510-AA81

## Federal Government Participation in the Automated Clearing House

agency: Financial Management Service, Fiscal Service, Treasury.
ACTION: Interim Rule with request for comment.

SUMMARY: We're issuing an interim rule amending our regulation governing the use of the Automated Clearing House (ACH) system by Federal agencies. Our regulation generally adopts the ACH rules developed by NACHA-The Electronic Payments Association (NACHA) (ACH Rules) as the rules governing ACH transactions by Federal agencies. We're revising our regulation to reflect changes that NACHA has made to the ACH Rules since the publication of NACHA's 1999 rule book. DATES: This interim rule is effective May 8,2000 . Comments must be received by June 6, 2000. The incorporation by reference of the publication listed in the rule is approved by the Director of the Federal Register as of May 8, 2000.
ADDRESSES: You can download this interim rule at the following World Wide Web address: http:// www.fms.treas.gov/ach/.
You may also inspect and copy this interim rule at: Treasury Department Library, Freedom of Information Act (FOIA) Collection, Room 5030, Main Treasury Building, 1500 Pennsylvania Avenue, NW, Washington, DC 20220. Before visiting, you must call (202) 6220990 for an appointment.
You may send comments electronically to the following address: 210comments@fms.treas.gov. You may also mail comments to Cynthia L. Johnson, Director, Cash Management Policy and Planning Division, Financial Management Service, 401 14th Street, SW, Room 420, Washington, DC 20227.

## FOR FURTHER INFORMATION CONTACT:

Walt Henderson, Senior Financial Program Specialist, at (202) 8746705 or
walt.henderson@fms.treas.gov;
Natalie H. Diana at (202) 874-6590 or natalie.diana@fms.treas.gov;
Adam Martin, Financial Program Specialist, at (202) 874-6881 or adam.martin@fms.treas.gov;
Cynthia L. Johnson, Director, Cash Management Policy and Planning Division, at (202) 874-6590 or cindy.johnson@fms.treas.gov; or

Margaret Marquette, Deputy Chief
Counsel, at (202) 874-6681.

## SUPPLEMENTARY INFORMATION:

## I. Background

On April 9, 1999, we published a final rule in the Federal Register (64 FR 17472). The final rule amended our regulations at 31 CFR Part 210 (Part 210), which govern the use of the ACH system by Federal agencies (agencies). The ACH system is a nationwide electronic funds transfer system that provides for the interbank clearing of credit and debit transactions and for the exchange of information among participating financial institutions. The final rule adopted the ACH Rules published in NACHA's 1999 rule book (including rule changes with an effective date on or before September $17,1999)$ as the rules governing all Government ACH transactions, with 11 exceptions.

NACHA periodically updates the ACH Rules. Each year NACHA publishes a new rule book that reflects the changes to the ACH Rules that have been approved since the publication of the previous rule book. NACHA recently published its 2000 rule book.

Part 210 provides that any amendment to the ACH Rules, as published in the 1999 Rule Book, that takes effect after September 17, 1999, will not apply to Government ACH entries unless we publish notice of acceptance of the amendment in the Federal Register. 31 CFR 210.3(b)(2). We're publishing this interim rule in order to indicate which amendments to the ACH Rules we're accepting and which amendments we're rejecting, and to provide an opportunity for comment.

## II. Summary of Rule Changes

## A. Changes to ACH Rules

The ACH Rules published in NACHA's 2000 rule book reflect changes to the ACH Rules published in NACHA's 1999 rule book related to seven topics:

## 1. Self-Audit Requirements

NACHA has revised the self-audit provisions of the ACH Rules to require self-audits annually rather than every three years; to require third-party service providers to conduct self-audits; to require proof be retained that a selfaudit was completed; and to require that originating depository financial institutions (ODFIs) and receiving depository financial institutions (RDFIs) specifically warrant that they have completed self-audits. The effective date of these changes was December 17, 1999.

## 2. Point-of-Purchase Electronic Check

 TransactionsNACHA has adopted an interim rule to provide a legal framework for the conversion of checks to ACH debit entries at the point-of-purchase. The interim rule expands the definition of Prearranged Payment and Deposit (PPD) format in the ACH Rules to allow this format to be used to initiate a one-time ACH debit entry to a Receiver's account for purchases made in person at the point-of-purchase. The implementation period for the interim rule began on September 17, 1999 and will continue through September 14, 2000.

NACHA also has adopted a final rule, which will take effect when the interim rule ends, that amends the ACH Rules by establishing a legal framework to allow for the conversion of checks to ACH debit entries at the point-ofpurchase. The amendment creates a new Standard Entry Class (SEC) code, POP (Point-of-Purchase Entry), that will allow for an Originator to initiate a onetime ACH debit entry to a Receiver's account for purchases made in person at the point-of-purchase. This rule change will become effective as of September 15, 2000.

## 3. Accounts Receivable Check Truncation

NACHA has adopted an interim rule expanding the definition of the PPD format in the ACH Rules to allow Originators to utilize the PPD format to truncate checks received through the U.S. mail for payment for goods or services and convert them to ACH debit entries. The rule provides a legal framework to allow pilot tests of lockbox check truncation. The rule requires the Originator to provide the consumer with notice of the check truncation policy prior to receiving the first check payment that will be truncated. The consumer must authorize the entry in writing, signed or similarly authenticated, unless the notice to the consumer indicates that the item will be truncated if the consumer doesn't provide the Originator with written notice not to truncate. The implementation period for the interim rule began on December 17, 1999, and will continue through December 15, 2000.

## 4. ACH Operator Definition

NACHA has revised the definition of ACH Operator to more clearly define the role and functions assumed by ACH Operators when clearing and settling

ACH transactions. This revision became effective June 18, 1999. ${ }^{1}$

## 5. Cross-Border Payments

NACHA has amended the ACH Rules to establish two new SEC codes, CBR (Corporate Cross-Border Transactions) and PBR (Consumer Cross-Border Transactions), to be used for the origination and receipt of cross-border ACH entries. The amendment will become effective as of September 15, 2000.

## 6. Re-Presented Check Entries

NACHA has established a new SEC code to provide commercial depositors and their financial institutions with a legal framework and technical specifications to transmit ACH debit entries to collect checks that have been returned for insufficient or uncollected funds. The new code will become effective as of September 15, 2000.

## 7. Types of Accounts for ACH <br> Transactions

NACHA has established two new sets of transaction codes to support the transmission of ACH credit and debit entries to financial institutions' general ledger accounts and the transmission of credit entries to loan accounts. This change to the ACH Rules will become effective as of September 15, 2000.

## B. ACH Rule Changes That We Are Accepting

We are accepting all of the changes to the ACH Rules that are reflected in the 2000 Rule Book with two exceptions discussed in Section C below. Under the interim rule, there are still 11 provisions of the ACH Rules that Part 210 preempts, except that we are broadening our preemption of the ACH rules enforcement provisions to include the self-audit requirements (see 210.2(d)(3)). No change to the 11 preempted provisions is necessary to reflect our preemption of the changes related to types of accounts, because we were aware of NACHA's intention to permit the crediting of ACH credits to general ledger and loan accounts and had already preempted that provision of the ACH Rules for Federal payments other than vendor payments. See 64 FR 17474.

All of the ACH rule changes that we are accepting are effective as of the

[^278]effective date of publication of this interim rule or NACHA's effective date for the rule change, whichever is later.
Point-of-Purchase Electronic Check Transactions

We're accepting both the interim and the final ACH rule changes that allow an Originator to initiate a one-time ACH debit entry to a Receiver's account for purchases made in person at the point-of-purchase.

We are currently engaged in pilot programs with several agencies to test the conversion of checks to ACH debit entries at the point-of-purchase. We believe that these transactions could expand the utility of the ACH system and might provide useful and costeffective applications for Government agency collections. We also recognize, however, that the conversion of checks to ACH debits raises various issues, including the kind of disclosure and authorization that is appropriate for such transactions and the kinds of checks that can or should be converted.

While we believe that the establishment of a legal framework for such transactions is desirable, it's difficult to determine the appropriate responsibilities and liabilities of the parties before the application of this technology has been tested. Moreover, attempting to establish a definitive legal framework for point-of-purchase check conversion by agencies at this time could hamper innovation and impede operational flexibility. Because of the diversity and unique concerns of Government check collections, it's unclear whether the model of POP check conversion will be workable or appropriate on a Government-wide basis. Accordingly, although we're accepting the NACHA's interim and final rule changes in order to provide a basic legal foundation for these transactions, we anticipate that we would seek public comment on the rules governing POP check conversion before engaging in POP check conversion on anything other than a pilot basis. In addition, in view of the experimental nature of pilot programs, it is possible that our pilots may not conform to all of the requirements otherwise imposed under the ACH Rules. It is our intention, however, to ensure that any on-going Government POP check conversion programs that we might establish in the future will conform to the ACH Rules that we incorporate in Part 210.

## Accounts Receivable Check Truncation

We're accepting the Interim Rule that provides a legal framework for
Originators to truncate checks received
through the mail in payment for goods or services and convert them to ACH debit entries. The rule requires the Originator to provide the consumer with notice of the check truncation policy prior to receiving the first check payment that will be truncated. The Receiver must authorize the truncation, either by "opting-in" (meaning that the Receiver must authorize the entry in writing, signed or similarly authenticated), or "opting-out" (meaning that the notice to the Receiver indicates that the Receiver may provide the Originator with written notice not to truncate the check).

Although we're not engaged in lockbox check truncation at this time, we are aware that lockbox check truncation could offer significant cost savings for Government collections. However, we're concerned that consumers understand and consent to such transactions. It is therefore our intention to seek public comment on the rules governing lockbox check truncation before engaging in lockbox check truncation other than on a pilot basis. As discussed above in the context of POP check conversion, pilot programs, by virtue of their very nature in exploring new or novel applications of technology, may not conform to all of the requirements otherwise imposed under the ACH Rules.

## ACH Operator Definition

We are accepting the revisions to the ACH Operator definition.

## Cross-Border Payments

We are accepting the rules establishing two new SEC codes to be used for the origination and receipt of cross-border ACH entries. We don't anticipate that agencies will be utilizing these codes for the origination or receipt of cross-border entries in the immediate future. However, it is possible that at some future time, agencies may wish to utilize these codes.

## Re-Presented Check Entries

We're accepting the rule changes that establish a new SEC code to provide commercial depositors and their financial institutions with a legal framework and technical specifications to transmit ACH debit entries to collect checks that have been returned for insufficient or uncollected funds. We believe that the ability to use ACH debit entries in this manner may facilitate the Government's ability to collect on checks that have been returned unpaid.

## C. ACH Rule Changes That We Aren't Accepting

## Self-Audit Requirements

We aren't accepting the ACH Rule changes related to the self-audit requirements. The purpose of the changes to the self-audit requirements is to promote better compliance with the ACH Rules. We believe that compliance with the ACH Rules is important and we are working with agencies to achieve Government-wide compliance with all ACH Rule requirements, including applicable time frames. Federal agencies are subject to oversight and audit requirements unique to the Federal Government. For example, the Office of the Inspector General and the General Accounting Office periodically review and audit various aspects of Federal agencies' operations. Accordingly, we believe that the imposition of a separate ACH compliance self-examination is both unnecessary and unlikely to significantly enhance the Government's compliance with Part 210.

## Types of Accounts for ACH

Transactions
We're not accepting, for Federal payments other than vendor payments, the changes to the ACH Rules that permit the crediting of ACH credits to a financial institution general ledger account or to a loan account. Section 210.5 provides that ACH credit entries representing Federal payments other than vendor payments must be deposited to an account at a financial institution in the name of the recipient, with three exceptions. As discussed in the rulemaking release that accompanied our adoption of this requirement, the term "account" for purposes of $\S 210.5$ is intended to mean a deposit account and not a loan account or general ledger account. See 64 FR 17472, 17474 (1999). We believe that important consumer protections are associated with the crediting of Federal payments to a deposit account, including those available under Regulation E (12 CFR Part 205) and Regulation DD (12 CFR Part 230), as well as the availability of Federal deposit or share insurance. Therefore, we're not accepting this change to the ACH Rules with respect to payments other than vendor payments.

## D. Section-by-Section Analysis

Section 210.2(a)
We are amending the definition of ACH Rules to reflect NACHA's name change from the National Automated Clearing House Association to

NACHA—The Electronic Payments Association.

## Section 210.2(d)

We are amending the definition of "applicable ACH Rules" at section 210.2(d) to reference the rules published in NACHA's 2000 rule book rather than the rules published in NACHA's 1999 rule book. In addition, we are amending section 210.2(d)(3) to exclude the selfaudit requirements of the ACH Rules.
Section 210.3(b)
We are amending subsection 210.3(b), "Incorporation by reference-applicable ACH Rules," by replacing the references to the ACH Rules as published in the 1999 rule book with references to the ACH Rules as published in the 2000 rule book.

## Section 210.5

We are revising section 210.5, "Account requirements for Federal payments," by specifically providing in subsection 210.5(a) that an ACH entry representing a Federal payment other than a vendor payment must be deposited into a deposit account at a financial institution. This revision of the regulatory language does not represent a substantive change from the existing rule since, as discussed above, the rulemaking release that accompanied our adoption of this requirement indicated that § 210.5 was intended to require that Federal payments other than vendor payments must be deposited to a deposit account and not a loan account or general ledger account. See 64 FR 17472, 17474 (1999).

We also are amending the first sentence of § 210.5 to read,
"Notwithstanding ACH Rules 2.1.2, 4.1.3, and Appendix Two, section 2.2 (listing general ledger and loan accounts as permissible transaction codes) * * *" in order to clarify that the requirements of § 210.5 preempt the ACH Rules that would otherwise allow ACH credits generally to be sent to general ledger or loan accounts.

## III. Procedural Requirements

## A. Request for Comment

We invite comment on all aspects of the interim rule.

## B. Request for Comment on Plain Language

On June 1, 1998, the President issued a memorandum directing each agency in the Executive branch to write its rules in plain language. This directive is effective for all new proposed and final rulemaking documents issued on or after January 1, 1999. We invite comment on how to make this interim
rule clearer. For example, you may wish to discuss: (1) Whether we have organized the material to suit your needs; (2) whether the requirements of this interim rule are clear; or (3) whether there is something else we could do to make this rule easier to understand.

## C. Notice and Comment; Effective Date

We find that good cause exists for issuing this interim rule without prior notice and comment. Under the Administrative Procedure Act, an agency is permitted to issue a rule without prior notice and comment when the agency for good cause finds that notice and public procedure thereon are impracticable, unnecessary, or contrary to the public interest. 5 U.S.C. 553(b)(B). We believe that it is important to address the publication of new ACH rules as quickly as possible in order to mitigate the uncertainty and inconvenience to financial institutions that would result from a time lag in responding to NACHA's rule changes. When we proposed to address changes to the ACH Rules by reviewing and responding to rule changes on an annual basis, we received many comments expressing concern over the potential consequences of such a time lag. For these reasons, we conclude that we have good cause for issuing this interim rule without prior notice and comment. Nevertheless, we are inviting comment and will consider the comments received. For these reasons we also find that good cause exists to make this interim rule effective without a delayed effective date.

## D. Executive Order 12866

This interim rule does not meet the criteria for a "significant regulatory action" as defined in Executive Order 12866. Therefore, the regulatory review procedures contained therein do not apply.

## E. Regulatory Flexibility Act

Because notice and public comment are not required, the Regulatory Flexibility Act (5 U.S.C. 601) does not apply.

## F. Paperwork Reduction Act

We ask for no new collections of information in this final rule. Therefore, the Paperwork Reduction Act (44 U.S.C. 3501) does not apply.

## List of Subjects in 31 CFR Part 210

Automated Clearing House, Electronic funds transfers, Financial institutions, Fraud, Incorporation by reference.

## Authority and Issuance

For the reasons set out in the preamble, 31 CFR Part 210 is amended as follows:

## PART 210—FEDERAL GOVERNMENT PARTICIPATION IN THE AUTOMATED CLEARING HOUSE

1. The authority citation for part 210 continues to read as follows:

Authority: 5 U.S.C. 5525; 12 U.S.C. 391; 31 U.S.C. 321, 3301, 3302, 3321, 3332, 3335, and 3720.
2. Revise § 210.2(a) and (d) to read as follows:

## §210.2 Definitions.

*     *         *             *                 * 

(a) ACH Rules means the Operating Rules and the Operating Guidelines published by NACHA-The Electronic Payments Association (NACHA), a national association of regional member clearing house associations, ACH Operators and participating financial institutions located in the United States.
(d) Applicable ACH Rules means the ACH Rules with an effective date on or before September 15, 2000, as published in Parts I, II, and IV of the " 2000 ACH Rules: A Complete Guide to Rules \& Regulations Governing the ACH Network," except:
(1) ACH Rule 1.1 (limiting the applicability of the ACH Rules to members of an ACH association);
(2) ACH Rule 1.2.2 (governing claims for compensation);
(3) ACH Rule 1.2.4; 2.2.1.10; Appendix Eight and Appendix Eleven (governing the enforcement of the ACH Rules, including self-audit requirements);
(4) ACH Rules 2.2.1.8; 2.6; and 4.7 (governing the reclamation of benefit payments);
(5) ACH Rule 8.3 and Appendix Two (requiring that a credit entry be originated no more than two banking days before the settlement date of the entry-see definition of "Effective Entry Date" in Appendix Two).

* ${ }^{*}{ }^{*}{ }^{*}{ }^{*}{ }^{*}{ }^{*}$ * ${ }^{\text {® }}$ 210.3(b) to read as follows:


## §210.3 Governing law.

(b) Incorporation by referenceapplicable ACH Rules. (1) This part incorporates by reference the applicable ACH Rules, including rule changes with an effective date on or before September 15, 2000, as published in Parts I, II, and IV of the " 2000 ACH Rules: A Complete Guide to Rules \& Regulations Governing the ACH Network." The Director of the Federal Register approves this incorporation by reference in accordance with 5 U.S.C. 552(a) and 1 CFR Part 51. Copies of the " 2000 ACH Rules" are available from NACHA-The Electronic Payments Association, 13665 Dulles Technology Drive, Suite 300, Herndon, Virginia 20171. Copies also are available for public inspection at the Office of the Federal Register, 800 North

Capitol Street, NW., Suite 700, Washington, D.C.
(2) Any amendment to the applicable ACH Rules that takes effect after September 15, 2000, shall not apply to Government entries unless the Service expressly accepts such amendment by publishing notice of acceptance of the amendment to this part in the Federal Register. An amendment to the ACH Rules that is accepted by the Service shall apply to Government entries on the effective date of the rulemaking specified by the Service in the Federal Register document expressly accepting such amendment.
4. Revise § 210.5 to read as follows:

## §210.5 Account requirements for Federal payments.

(a) Notwithstanding ACH Rules 2.1.2, 4.1.3, and Appendix Two, section 2.2 (listing general ledger and loan accounts as permissible transaction codes), an ACH credit entry representing a Federal payment other than a vendor payment shall be deposited into a deposit account at a financial institution. For all payments other than vendor payments, the account at the financial institution shall be in the name of the recipient, except as provided in paragraph (b) of this section.

Dated: April 4, 2000.
Richard L. Gregg,
Commissioner.
[FR Doc. 00-8636 Filed 4-6-00; 8:45 am]
BILLING CODE 4810-35-P

## Reader Aids

## Federal Register

Vol. 65, No. 68
Friday, April 7, 2000

## CUSTOMER SERVICE AND INFORMATION

## Federal Register/Code of Federal Regulations

General Information, indexes and other finding 202-523-5227 aids

| Laws | 523-5227 |
| :--- | :--- |
| Presidential Documents |  |
| Executive orders and proclamations | $\mathbf{5 2 3 - 5 2 2 7}$ |
| The United States Government Manual | $\mathbf{5 2 3 - 5 2 2 7}$ |
|  |  |
| Other Services | $\mathbf{5 2 3 - 4 5 3 4}$ |
| Electronic and on-line services (voice) | $\mathbf{5 2 3 - 3 1 8 7}$ |
| Privacy Act Compilation | 523-6641 |
| Public Laws Update Service (numbers, dates, etc.) | $\mathbf{5 2 3 - 5 2 2 9}$ |

## ELECTRONIC RESEARCH

World Wide Web
Full text of the daily Federal Register, CFR and other publications:

## http://www.access.gpo.gov/nara

Federal Register information and research tools, including Public Inspection List, indexes, and links to GPO Access:
http://www.nara.gov/fedreg

## E-mail

PENS (Public Law Electronic Notification Service) is an E-mail service for notification of recently enacted Public Laws. To subscribe, send E-mail to
listserv@www.gsa.gov
with the text message:

> subscribe PUBLAWS-L your name

Use listserv@www.gsa.gov only to subscribe or unsubscribe to PENS. We cannot respond to specific inquiries.
Reference questions. Send questions and comments about the Federal Register system to:
info@fedreg.nara.gov
The Federal Register staff cannot interpret specific documents or regulations.

## FEDERAL REGISTER PAGES AND DATE, APRIL



17987-18220...
18221-18870.......................... 7

| At the end of each month, the Office of the Federal Register publishes separately a List of CFR Sections Affected (LSA), which lists parts and sections affected by documents published since the revision date of each title. |  |
| :---: | :---: |
| 3 CFR | 35....................18221, 18229 |
| Proclamations: | 385.............................. 18229 |
| 7283............................ 17552 | 19 CFR |
| 7284............................. 17981 |  |
| 7285........................................ 17983 | Proposed Rules: 17473 |
| 7286............................. 17985 | 134............................... 17473 |
| 5 CFR | 20 CFR |
| 532.............................. 17755 | 404............................... 17994 |
| 7 CFR |  |
| 985.............................. 17756 | 21 CFR |
| Proposed Rules: | 809.............................. 18230 |
| 28................................ 17609 | 864.............................. 18230 |
| 984............................... 17809 | 872............................... 18234 |
| 1218............................ 17612 | 876............................... 18236 |
|  | 1301............................. 17552 |
| 8 CFR | 1308..................17440, 17552 |
| 214.............................. 18432 | Proposed Rules: |
| 248.............................. 18432 | 111.............................. 17474 |
| 9 CFR | 24 CFR |
| 201.............................. 17758 | 200.............................. 17974 |
| Proposed Rules: $\text { 93...................................... } 17455$ | 26 CFR |
| 10 CFR | Proposed Rules: |
| 72................................ 17552 | 20...................................... 17835 |
| Proposed Rules: | 25................................ 17835 |
| 71................................ 18010 | 301.............................. 17617 |
| 73................................ 18010 |  |
| 12 CFR | 27 CFR |
|  | Proposed Rules: |
| 951.............................. 17435 | 4.................................. 17839 |
| 997............................... 17435 | 275.............................. 17477 |
| Proposed Rules: |  |
| 560............................... 17811 | 30 CFR |
| 915.............................. 17458 | 250............................... 18432 |
| 13 CFR 913............................ 18237 |  |
| 120.............................. 17439 | 31 CFR |
| 14 CFR | Ch. 5............................ 17590 |
| $39 \ldots \ldots . . . .17583,17586,17763$, 210............................. 18866 |  |
| , 17987 | 32 CFR |
| 71.....................17588, 17589 |  |
| 91................................ 17736 | $581 . . . . . . . . . . . . . . . . . . . . . . . . . . . . ~ 17440 ~$ |
| 93............................... 17736 | 33 CFR |
| 97......................17990, 17991 |  |
| 121.............................. 17736 | 117 .........17443, 17766, 18242 |
| 135............................... 17736 | 162................................ 18242 |
| Proposed Rules: <br> 23 . 17613 | Proposed Rules: 110................................ 18261 |
| 39 ..........17471, 17818, 17822, | 117.............................. 18264 |
| $17824,17827,18010,18258$ | 165............................. 18261 |
| 7118260 | 34 CFR |
| 71................................ 17616 | 379.............................. 18214 |
| 16 CFR | 674.............................. 18001 |
| 305.............................. 17554 |  |
| 18 CFR | Proposed Rules: |
| 2.................................. 18221 | 1........................17946, 18154 |



## REMINDERS

The items in this list were editorially compiled as an aid to Federal Register users. Inclusion or exclusion from this list has no legal significance.

RULES GOING INTO EFFECT APRIL 7, 2000

## AGRICULTURE

DEPARTMENT
Agricultural Marketing Service
Prunes (dried) produced inCalifornia; published 3-8-00
ENERGY DEPARTMENT
Federal Energy Regulatory Commission
Electric utilities (Federal Power Act):
Rate schedules filing-
Regional Transmission Organizations; published 3-8-00
Secton 205 filings; intervention and protest time frame; correction; published 4-7-00
Natural gas companies
(Natural Gas Act):
Facilities construction and operation, etc.; filing of applications; correction; published 4-7-00
Practice and procedure:
Off-the-record communications Correction; published 4-700
ENVIRONMENTAL PROTECTION AGENCY
Air quality implementation
plans; approval and
promulgation; various
States:
California; published 3-8-00
FEDERAL
COMMUNICATIONS
COMMISSION
Common carrier services:
Cellular Telecommunications Industry Association' petition for forbearance from commercial mobile radio services number portability obligations; published 4-7-00
Communications Assistance for Law Enforcement Act; implementation; correction; published 4-7-00
INTERIOR DEPARTMENT
Surface Mining Reclamation and Enforcement Office
Permanent program and abandoned mine land reclamation plan submissions:

Illinois; published 4-7-00
TRANSPORTATION
DEPARTMENT

## Federal Aviation

## Administration

Airworthiness directives:
General Electric Co.; published 2-7-00
Industrie Aeronautiche e Meccaniche; published 2-16-00
Partenavia Costruzioni Aeronauticas S.p.A.; published 2-16-00
Rolls-Royce plc; published 3-8-00

## TREASURY DEPARTMENT

## Fiscal Service

Federal management services:
Federal government participation in automated clearing house; published 4-7-00

COMMENTS DUE NEXT WEEK

## AGRICULTURE

DEPARTMENT

## Agricultural Marketing

Service
Plant variety protection office:
Fees revision; comments due by 4-14-00; published 3-15-00
Raisins produced from grapes grown in-
California; comments due by 4-10-00; published 2-9-00
AGRICULTURE
DEPARTMENT
Animal and Plant Health
Inspection Service
Exportation and importation of animals and animal products:
Poultry products from Mexico transiting U.S.; comments due by 4-1000; published 2-8-00

## AGRICULTURE

DEPARTMENT
Food Safety and Inspection Service
Meetings:
E. coli in beef products; risk assessment; policy and regulatory changes; comments due by 4-1100; published 2-11-00

## AGRICULTURE

DEPARTMENT
Rural Utilities Service
Electric loans:
Minimum Times Interest Earned Ratio (TIER) requirements; reduction; comments due by $4-10-$ 00 ; published $3-10-00$

COMMERCE DEPARTMENT
National Oceanic and Atmospheric Administration
Endangered and threatened species:
Gulf of Maine; Atlantic salmon; comments due by 4-14-00; published 3-1500
Marine and anadromous species-
West coast steelhead in California et al.; comments due by 4-1100; published 2-11-00
DEFENSE DEPARTMENT
Acquisition regulations:
Contract drawings, maps, and specifications; comments due by 4-1000; published 2-10-00
Mentor-protege program improvements; comments due by $4-10-00$; published 2-10-00
ENERGY DEPARTMENT
Defense nuclear facilities; disposal of real property for economic development; comments due by 4-14-00; published 2-29-00
ENERGY DEPARTMENT
Federal Energy Regulatory

## Commission

Practice and procedure:
Well category determinations; comments due by $4-10-00$; published 2-8-00

## ENVIRONMENTAL

PROTECTION AGENCY
Air quality implementation
plans; approval and
promulgation; various
States:
California; comments due by 4-10-00; published 3-9-00
Connecticut and Rhode Island; comments due by 4-10-00; published 3-9-00
Delaware; comments due by 4-10-00; published 3-9-00
Georgia; comments due by 4-12-00; published 3-1300
Kentucky; comments due by 4-10-00; published 3-1000
FEDERAL
COMMUNICATIONS
COMMISSION
Practice and procedure:
Communication between applicants in spectrum auctions; comments due by 4-10-00; published 2-800
Radio stations; table of assignments:
Florida; comments due by 4-10-00; published 3-3-00

Texas; comments due by 4-10-00; published 3-3-00

## FEDERAL EMERGENCY

 MANAGEMENT AGENCYDisaster assistance:
Hurricane Floyd property acquisition and relocation grants; comments due by 4-11-00; published 2-1100
Public assistance program administration-
Insurance requirements; comments due by 4-1000; published 2-23-00

## FEDERAL HOUSING

FINANCE BOARD
Federal home loan bank system:
Membership regulations; comments due by 4-1400 ; published 3-15-00
HEALTH AND HUMAN
SERVICES DEPARTMENT
Food and Drug
Administration
Medical devices:
American Society for Testing and Materials; amendments to reflect current citations; comments due by 4-1000 ; published 1-24-00
HOUSING AND URBAN
DEVELOPMENT
DEPARTMENT
Federal Housing Enterprise
Oversight Office
Equal Access to Justice Act; implementation; comments due by $4-14-00$; published 2-14-00
Risk-based capital:
Stress test; House Price Index (HPI) use and benchmark credit loss experience determination; comments due by 4-1400 ; published 3-13-00
INTERIOR DEPARTMENT
Land Management Bureau
Land resource management:
Disposition; occupancy and use-
Alaska occupany and use; Alaska Native veterans allotments; comments due by $4-10-00$; published 2-8-00
INTERIOR DEPARTMENT
Fish and Wildlife Service
Endangered and threatened species:
Gulf of Maine; Atlantic salmon; comments due by 4-14-00; published 3-1500
Ohlone tiger beetle; comments due by 4-1100 ; published 2-11-00

| Showy stickseed; comments due by $4-14-00$; published 2-14-00 | comments due by 4-14- <br> 00; published 2-29-00 <br> Practice and procedure: | OPSAIL 2000, Hampton Roads, VA; regulated areas; comments due by | Class D and Class E airspace; comments due by 4-14-00; published 2-29-00 |
| :---: | :---: | :---: | :---: |
| INTERIOR DEPARTMENT Surface Mining Reclamation and Enforcement Office | False representation and lottery orders; proceedings; subpoenas | 4-14-00; published 2-2900 <br> TRANSPORTATION | Class E airspace; comments due by 4-10-00; published 2-24-00 |
| Permanent program and abandoned mine land reclamation plan | and civil penalties; comments due by 4-1300; published 3-14-00 | DEPARTMENT <br> Federal Aviation Administration | TRANSPORTATION DEPARTMENT |
| submissions: <br> Indiana; comments due by 4-10-00; published 3-9-00 | SMALL BUSINESS <br> ADMINISTRATION <br> Small business size standards: | Airworthiness directives: Ayres Corp.; comments due by $4-10-00$; published 2 - | Federal Highway <br> Administration <br> Engineering and traffic |
| LIBRARY OF CONGRESS Copyright Office, Library of Congress | 8(a) business development/ small disadvantaged business status | Eurocopter Deutschland GmbH; comments due by 4-11-00; published 2-11- | operations: <br> Utilities; comments due by 4-10-00; published 2-9-00 |
| Cable compulsory licese: Network station definition; comments due by 4-1100; published 2-11-00 | due by $4-10-00$; published $3-10-00$ <br> SOCIAL SECURITY ADMINISTRATION | 00 <br> Eurocopter France; comments due by 4-1100 ; published 2-11-00 | TREASURY DEPARTMENT Customs Service Customs bonds: |
| NORTHEAST INTERSTATE LOW-LEVEL RADIOACTIVE WASTE COMMISSION <br> Party to Compact; State eligibility declaration; comments due by $4-13-00$; published 3-14-00 | Social security benefits: Federal old age, survivors, and disability insuranceMedical criteria for disability determinations; comments due by $4-11$ 00; published 2-11-00 | Fairchild; comments due by 4-10-00; published 2-1600 <br> Fokker; comments due by 4-14-00; published 3-1500 <br> Saab; comments due by 4 -14-00; published 3-15-00 | Articles subject to exclusion orders issued by International Trade Commission; bond procedures; comments due by $4-10-00$; published 2-8-00 |
| POSTAL SERV | STATE DEPARTMENT | Airworthiness standards | EASURY DEPART |
| Commercial mail receiving agency; mail delivery; comments due by 4-1200; published 3-13-00 | Consular services; fee schedule; comments due by 4-12-00; published 3-13-00 <br> TRANSPORTATION DEPARTMENT | Special conditionsBoeing Model 727-200 and $727-200 \mathrm{~F}$ series airplanes; comments due by 4-13-00; <br> published 3-14-00 | Internal Revenue Service <br> Income taxes: <br> Partnership debt allocation; comments due by 4-1200 ; published 1-13-00 |
| periodicals nonletters and standard mail (A) flats, traying first-class flats, and labeling pallets; | Coast Guard <br> Regattas and marine parades, anchorage regulations, and ports and waterways safety: | Raytheon Aircraft Co. Model 4000 airplane; comments due by 4-1300 ; published $3-14-00$ | Partnership mergers and divisions; hearing; comments due by $4-10$ 00 ; published 1-11-00 |


[^0]:    ${ }^{1}$ For purposes here, "designation" refers to the practice of assigning rate schedule numbers as well as sheet designations, for purposes of identification and document tracking.
    ${ }^{2}$ For purposes of this rule, use of the term "rate schedule" refers to three types of filings: sets of terms and conditions for service offered to all who qualify for the service, such as an Open Access Transmission Tariff; agreements with specific terms for service negotiated between named seller(s) and buyer(s), such as a Facilities Agreement or Coordination Agreement; or form agreements under which a specific customer takes service under a tariff.
    ${ }^{3}$ The Commission is adopting the gas program's pagination guidelines as the model for the electric program for several reasons. The gas guidelines use unique tariff sheet designations that, once assigned, cannot be reused. Therefore, the applicants, the Commission, and the public will have a common point of reference for every rate schedule sheet without the need for further identifiers, such as the date of filing or the docket number. Further, the gas guidelines provide for the use of standardized nomenclature, which conveys important information about the applicants' filings (e.g. a proposed change in the tariff pursuant to FPA section 205 ('"Third Revised Sheet No.") or a

[^1]:    ${ }^{7} 49$ U.S.C. app. 1 (1988).
    ${ }^{8} 18$ CFR Part 35; 18 CFR Part 154; 18 CFR Part 341.
    ${ }^{9}$ See 18 CFR 154.5; 18 CFR 341.11.
    ${ }^{10} 18$ CFR 35.9.
    ${ }^{11}$ The proposed revision provided that the Director of the Office of Electric Power Regulation (OEPR) would have the power to reject these filings. OEPR has since been dissolved and functionally replaced by the Office of Markets, Tariffs, and Rates.
    ${ }^{12}$ For the convenience of the reader, unless the context otherwise indicates, we will use the term

[^2]:    "tariff sheet" in the remainder of the narrative discussion when referring to public utility rate schedules.

[^3]:    ${ }^{13}$ See 18 CFR 35.2(b) and n.1.

[^4]:    ${ }^{14}$ See 18 CFR 154.1(d).
    ${ }^{15}$ Final Regulations Clarifying the Filing Obligations for Part 284 Transportation and Sale of Natural Gas, Order No. 516, 54 FR 47758 (November 17, 1989), FERC Stats. \& Regs., Regulation Preambles 1986-1990 II 30,864 (November 9, 1989). See also 18 CFR 154.1(d).

[^5]:    1618 CFR 35.5

[^6]:    ${ }^{17}$ The Commission recently reorganized the delegation authorities to reflect the creation of the Office of Markets, Tariffs, and Rates (OMTR). Section 375.308(a)(3) has been redesignated $\S 375.307(\mathrm{k})(3)$. The final regulations adopted here reflect this change.
    ${ }^{18}$ Consumers notes that the Director of the Office of Pipeline Regulation, through delegated authority, frequently informs gas pipelines that their electronically-filed tariff sheets failed to comply with certain formatting and/or pagination requirements without rejecting those filings. However, we note that those letters also inform the gas pipelines that, if not corrected, usually within one working day, their filing and effective dates may be delayed.
    ${ }^{19}$ The WPSC suggests that the Director be allowed to reject only those tariff sheets that are not properly paginated. We are not persuaded to limit the circumstances in which filings may be rejected only to those not properly paginated. In any event, we note that a filing that is incomplete is not properly filed with the Commission, and there is nothing for the Commission to act on, either directly or by delegation.

[^7]:    ${ }^{20}$ See 18 CFR 385.713.

[^8]:    ${ }^{21}$ Section 205(d) of the FPA (16 U.S.C. 824 d (d)) provides that, unless the Commission otherwise provides, no change shall be made to a tariff except after 60 days' notice given by a filing by the utility, and that the filing must plainly state the changes

[^9]:    being made and the time when the changes will go into effect.
    ${ }^{22}$ Consumers also raises questions and issues related to filing tariff sheets electronically. As the Commission has not yet initiated any proceeding

[^10]:    addressing electronic filing, it is premature to address these issues at this time.
    ${ }^{23}$ See 18 CFR 35.2(b) and n.1.
    ${ }^{24} 44$ U.S.C. 3507(d).

[^11]:    ${ }^{25}$ The proposed change may have even less impact on utilities, as the Commission assumes utilities currently maintain an informal recordkeeping system for proposed tariff sheets pending a final designation from the Commission. This informal system will no longer be necessary to maintain, as tariff sheet designations will be assigned by the utilities prior to filing the tariff sheets.
    265 CFR 1320.11

[^12]:    27 See Order No. 486, 52 FR 47897 (December 17, 1987), FERC Stats. \& Regs. Regulations Preambles 1986-1990 【I 30,783 (December 10, 1987).
    ${ }^{28}$ See 5 U.S.C. 601(3).

[^13]:    ${ }^{1}$ The Commission is issuing a notice contemporaneous with this Final Rule informing

[^14]:    ${ }^{1}$ Indicates a newly listed company which must file a report beginning with the report due October 25, 2000.

[^15]:    ${ }^{1}$ After receiving from Cablesa a waiver of the normal time limits for a new shipper review under 19 CFR § 351.214(j)(3), we determined to publish the results of this new shipper review simultaneously with the results of the administrative review. See 64 FR 61825 (November 15, 1999).

[^16]:    ${ }^{1}$ See September 24, 1999, Request for an Extension to File Rebuttal Comments in the Sunset Reviews of Antidumping and Countervailing Duty Orders: A-602-803; A-351-817; C-351-818, A-122-822, A-122-823, A-405-802, A-588-826, A-421-804, A-455-802, A-485-803, C-401-401, C-401-804, C-401-805, from Valerie S. Schindler, Skadden, Arps, Slate, Meagher \& Flom LLP, to Jeffrey A. May, Office of Policy.
    ${ }^{2}$ See September 30, 1999, Letter from Jeffrey A. May, Director, Office of Policy to Valerie S. Schindler, Skadden, Arps, Slate, Meagher \& Flom LLP.

[^17]:    ${ }^{1}$ See September 24, 1999, Request for an Extension to File Rebuttal Comments in the Sunset Reviews of Antidumping and Countervailing Duty Orders: A-602-803; A-351-817; C-351-818, A-122-822, A-122-823, A-405-802, A-588-826, A-421-804, A-455-802, A-485-803, C-401-401, C-401-804, C-401-805, from Valerie S. Schindler, Skadden, Arps, Slate, Meagher \& Flom LLP, to Jeffrey A. May, Office of Policy.
    ${ }^{2}$ See September 30, 1999, Letter from Jeffrey A. May, Director, Office of Policy to Valerie S. Schindler, Skadden, Arps, Slate, Meagher \& Flom LLP.
    ${ }^{3}$ See October 20, 1999, Memorandum for Jeffrey A. May, Re: Certain Cut-to-Length Carbon Steel Flat Plate from Canada: Adequacy of Respondent Interested Party Response to the Notice of Initiation.

[^18]:    ${ }^{4}$ See Extension of Time Limit for Final Results of Expedited Five-Year Reviews, 64 FR 71726
    (December 22, 1999).

[^19]:    ${ }^{5}$ See Certain Cut-to-Length Carbon Steel Plate from Canada: Final Results of Changed Circumstances Antidumping Duty Administrative Review, and Revocation in Part of Antidumping Duty Order, 61 FR 7471 (February 28, 1996).
    ${ }^{6}$ See Certain Cut-to-Length Carbon Steel Plate from Canada: Final Results of Changed Circumstances Antidumping Duty Administrative Review, and Revocation in Part of Antidumping Duty Order, 64 FR 7167 (February 12, 1999).
    ${ }^{7}$ See Cut-to-Length Carbon Steel Plate from Canada; Initiation of Anticircumvention Inquiry on Antidumping Duty Order, 63 FR 29179 (May 28, 1998).

[^20]:    ${ }^{1}$ See September 20, 1999, Request for an Extension to File Rebuttal Comments in the Sunset Reviews of Antidumping and Countervailing Duty Orders on Certain Steel Products from Belgium, France, Germany, Mexico, Spain, South Korea, Taiwan and the United Kingdom: A-583-080, A-423-805, A-427-808, A-428-815, A-428-814, A-428-816, A-580-815, A-580-816, S-201-809, A-469-803, A-412-814, C-423-806, C-427-810, C-428-817 (CTL), C-428-817 (CR), C-580-818 (CORE), C-201-810, C-469-804, C-412-815, from Bradford L. Ward, Dewey Balantine LLP, to Jeffrey A. May, Office of Policy.
    ${ }^{2}$ See September 30, 1999, Letter from Jeffrey A. May, Director, Office of Policy to Michael H. Stein, Dewey Ballantine LLP.
    ${ }^{3}$ See October 21, 1999, Memorandum for Jeffrey A. May, Re: Certain Cut-to-Length Carbon Steel Flat Plate from Belgium: Adequacy of Respondent Interested Party Response to the Notice of Initiation.

[^21]:    ${ }^{4}$ See Extension of Time Limit for Final Results of Expedited Five-Year Reviews, 64 FR 71726
    (December 22, 1999).

[^22]:    *Adverse Facts Available Rate.

[^23]:    ${ }^{1}$ Exporters Yude (Yude/Xinyu) and Zhenxing (Zhenxing/Mancheng) have been collapsed for the purposes of this administrative review. See Sulfanilic Acid from the People's Republic of China: Preliminary Results of Antidumping Administrative Review, 64 FR 48788 (September 8 , 1999); Decision Memo, Affiliation/Collapsing section.
    ${ }^{2}$ This rate will be applied to all firms other than Yude (Yude/Xinyu) and Zhenxing (Zhenxing/Mancheng), including all firms which did not respond to our questionnaire.

[^24]:    ${ }^{1}$ See September 24, 1999, Request for an Extension to File Rebuttal Comments in the Sunset Reviews of Antidumping and Countervailing Duty Orders: A-602-803; A-351-817; C-351-818, A-122-822, A-122-823, A-405-802, A-588-826, A-421-804, A-455-802, A-485-803, C-401-401, C-401-804, C-401-805, from Valerie S. Schindler, Skadden, Arps, Slate, Meagher \& Flom LLP, to Jeffrey A. May, Office of Policy.
    ${ }^{2}$ See September 30, 1999, Letter from Jeffrey A. May, Director, Office of Policy to Valerie S. Schindler, Skadden, Arps, Slate, Meagher \& Flom LLP.

[^25]:    ${ }^{5}$ We note that as of January 1, 2000, Article 6.1 has ceased to apply (see Article 31 of the Subsidies Agreement).

[^26]:    ${ }^{1}$ See September 24, 1999, Request for an Extension to File Rebuttal Comments in the Sunset Reviews of Antidumping and Countervailing Duty Orders: A-602-803; A-351-817; C-351-818, A-122-822, A-122-823, A-405-802, A-588-826, A-421-804, A-455-802, A-485-803, C-401-401, C-

[^27]:    ${ }^{4}$ See Extension of Time Limit for Final Results of Expedited Five-Year Reviews, 64 FR 71726
    (December 22, 1999).

[^28]:    ${ }^{1}$ See September 20, 1999, Request for an Extension to File Rebuttal Comments in the Sunset Reviews of Antidumping and Countervailing Duty Orders on Certain Steel Products from Belgium, France, Germany, Mexico, Spain, South Korea, Taiwan and the United Kingdom: A-583-080, A-423-805, A-427-808, A-428-815, A-428-814, A-428-816, A-580-815, A-580-816, S-201-809, A-469-803, A-412-814, C-423-806, C-427-810, C-428-817 (CTL), C-428-817 (CR), C-580-818 (CORE), C-201-810, C-469-804, C-412-815, from Bradford L. Ward, Dewey Balantine LLP, to Jeffrey A. May, Office of Policy.

[^29]:    ${ }^{1}$ See September 20, 1999, Request for an Extension to File Rebuttal Comments in the Sunset Reviews of Antidumping and Countervailing Duty Orders on Certain Steel Products from Belgium, France, Germany, Mexico, Spain, South Korea, Taiwan and the United Kingdom: A-583-080, A-423-805, A-427-808, A-428-815, A-428-814, A-428-816, A-580-815, A-580-816, S-201-809, A-469-803, A-412-814, C-423-806, C-427-810, C-$428-817$ (CTL), C-428-817 (CR), C-580-818 (CORE), C-201-810, C-469-804, C-412-815, from Barbara Ward, Dewey Balantine LLP, to Jeffrey A. May, Office of Policy.
    ${ }^{2}$ See September 30, 1999, Letter from Jeffrey A. May, Director, Office of Policy to Michael H. Stein, Dewey Ballantine LLP.

[^30]:    ${ }^{3}$ See September 30, 1999, Letter from Joseph P. Griffin, the British Embassy, to Scott Smith, Office of Policy.
    ${ }^{4}$ See October 20, 1999, Memorandum for Jeffrey A. May, Re: Certain Cut-to-Length Carbon Steel Plate from Sweden: Adequacy of Respondent Interested Party Response to the Notice of Initiation.
    ${ }^{5}$ See Extension of Time Limit for Final Results of Expedited Five-Year Reviews, 64 FR 71726 (December 22, 1999).

[^31]:    ${ }^{1} 64$ FR 31195 (June 10, 1999); 64 FR 34851 (corrections). The Commission first raised the subject of alternative execution, or block trading, procedures in its Concept Release on the Regulation of Noncompetitive Transaction Executed on or Subject to the Rules of a Contract Market. 63 FR 3708 (January 26, 1998). Through the Concept Release, the Commission wished to explore whether certain alternative executive procedures for large size or other types of orders could be developed to satisfy the needs of market participants while furthering the policies and purposes of the Commodity Exchange Act and the Commission's Regulations.
    ${ }^{2}$ The CX's block trading proposal was published in the Federal Register for public comment on October 7, 1999. 64 FR 54620.

[^32]:    ${ }^{3}$ The Commission approved the CME's application for designation as a contract market in the Five-Year and Ten Year Agency Note futures contracts on March 13, 2000. The current trading hours for these contracts are as follows: 7:20 a.m.2 p.m. Central Time Monday through Friday for open outcry trading; 2:10 p.m.-7:05 a.m. Central Time Monday through Thursday for GLOBEX2 trading; and 5:30 p.m.-7:05 a.m. Central Time Sundays and holidays for GLOBEX2 trading.

[^33]:    ${ }^{4}$ The CTA must be registered under the Act (which includes without limitation any investment advisor registered as such with the Securities and Exchange Commission that is exempt from regulation under the Act or the Commission's regulations) with total assets under management exceeding \$50 million.
    ${ }^{5}$ In connection with block trades entered into by a CTA (which satisfies certain registration and financial conditions) on behalf of its customers, the underlying customer orders do not have to satisfy the minimum threshold requirement. Accordingly, a CTA registered under the Act (including without limitation any investment advisor registered as such with the Securities and Exchange Commission that is exempt from regulation under the Act or the Commission's regulations) with total assets under management exceeding \$50 million may aggregate orders from different accounts to satisfy the minimum size requirement.
    ${ }^{6}$ Completed block transactions may be reported to the Exchange in one of two ways: (1) through telephone to the Exchange's GLOBEX Control Center from 5:30 p.m. Central Time on Sunday through 2:00 p.m. Central time on Friday; and (2) through select price reporting terminals available

[^34]:    on the Exchange floor during Regular Trading
    Hours (7:30 a.m.-2:00 p.m. Central Time) Monday through Friday.

[^35]:    ${ }^{1}$ Since Mr. McPhail is the only participant in the Plan, there is no jurisdiction under Title I of the Act pursuant to 29 CFR 2510.3-3(b). However, there is jurisdiction under Title II of the Act pursuant to section 4975 of the Code.

[^36]:    ${ }^{2}$ As discussed herein, Triumph Funds are generally expected to be organized as venture capital operating companies that are managed by Triumph.

[^37]:    ${ }^{3}$ For purposes of this exemption, the term "full investment responsibility" means that the fiduciary responsible for making the investment decision has and exercises discretionary management authority over all of the assets of the group trust or other plan assets entity.

[^38]:    ${ }^{4}$ The Department's regulation at 29 CFR 2510.3101(c) defines the term "operating company" as an entity that is primarily engaged, directly or through a majority-owned subsidiary or subsidiaries, in the production or sale of a product or service other than the investment of capital. The term "operating

[^39]:    ${ }^{7}$ According to the applicant, the term "portfolio company" refers to each of the operating companies in which a private equity fund has made an investment. Thus, for example, when a private equity fund, such as a Triumph Fund, makes an investment in a start-up, high tech company, that company becomes one of the private equity fund's portfolio companies and will remain so as long as the private equity fund retains its investment in that high tech company. Similarly, if a private equity fund acquires an interest in an investment management firm, the investment management firm will become a portfolio company of the private equity fund.

[^40]:    ${ }^{8}$ In this regard, it is noted that the corresponding section of the Code relating to "disqualified persons" (see section 4975(e)(2)(H) and (I)) does not contain a similar provision which would make the owner of 10 percent or more of a service provider a disqualified person with respect to a Plan. Nevertheless, because the service provider is a "disqualified person" under section $4975(\mathrm{e})(2)(\mathrm{B})$ of the Code, Triumph has requested that the exemption extend to both the Code and the Act in order to avoid any potential concerns regarding the possibility of indirect prohibited transactions.

[^41]:    ${ }^{9}$ The Department is providing no opinion in this proposed exemption regarding whether, or to what extent, a Plan engaging in the subject transaction with a Triumph Fund would violate section 406(a) of the Act, once the Triumph Fund becomes a party in interest with respect to the Plan, under the circumstances described herein.

[^42]:    ${ }^{10}$ PTE 84-14 permits various parties which are related to employee benefit plans to engage in transactions involving plan assets if, among other conditions, the assets are managed by QPAMs (i.e., banks, savings and loan associations, insurance companies or investment advisers registered under the Investment Advisers Act of 1940), which are independent of the parties in interest involved in such transactions and meet certain specified financial standards. PTE 96-23 permits various transactions involving employee benefit plans whose assets are managed by INHAMs and parties in interest to such plans, who are service providers or their affiliates (other than the INHAM and its affiliates).

[^43]:    ${ }^{11}$ For purposes of this exemption, reference to provisions of Title I of the Act, unless otherwise specified, refer also to the corresponding provisions of the Code.

[^44]:    ${ }^{12}$ Under the Original Plan, the term
    "Impairment" was defined as "* * * the sum of (a) the loss of interest which would have been credited to Participating Contractholders in the normal course of business had FML not been placed in rehabilitation, as determined by the Receiver, and (b) the loss of liquidity due to the limited access of Participating Contractholders to their cash values, as determined by the Receiver."
    ${ }^{13}$ It is represented that many of the objections concerning the Original Plan of Rehabilitation related to the fact that the Plan had not included

[^45]:    ${ }^{15}$ In this regard, since its rehabilitation, FML has improved the investment quality of its assets and its financial strength. In addition, FML has stabilized its revenue and achieved levels of surplus in excess of minimum state regulatory requirements. Further, FML has continued to pay dividends to Contractholders under participating Contracts and excess interest credits under other Contracts (e.g., universal life and deferred annuity contracts).
    By an order of the Court dated April 30, 1996, FML increased policyholder dividends and declared interest crediting rates of certain Contracts beginning in 1996. In addition, FML petitioned the Court to pay an increased one-time policyholder dividend and declared interest credit beginning in 1999 because of its financial capacity to do so and in recognition of the fact that the policyholder dividends and declared interest credits paid on its Contracts had generally been lower during the period of rehabilitation than those for comparable policies of other insurers.
    ${ }^{16}$ The Closing Date of the rehabilitation under the Third Amended Plan of Rehabilitation is expected to occur after December 31, 2000.
    ${ }^{17}$ The Rehabilitator has been advised by outside securities and tax counsel that the Preferred Stock constitutes equity rather than debt. Additionally, the Rehabilitator has relied upon a private letter ruling issued by the Internal Revenue Service on July 14, 1999 which treats the Preferred Stock and the Common Stock as equity rather than as debt.

[^46]:    ${ }^{18}$ However, the Department expresses no opinion herein on whether such distributions will satisfy the terms and conditions of section 408(e) of the Act.
    ${ }^{19}$ The bid procedures, which will strictly control the selection process for the Investor as well as the post-closing activities of the Investor, are designed to prevent any negotiation among potential Investors because the winning bid is to be determined solely on the basis of the bid price per share, the financial condition of the Investor and the statutory requirements of the Pennsylvania Rehabilitation Statute.

[^47]:    ${ }^{20}$ It is represented that the Rehabilitator has been advised by outside rehabilitation counsel and attorneys for the Pennsylvania Insurance Department that the Pennsylvania Insurance Company Mutual Stock Conversion Act (Conversion Act), which governs the demutualization of an insurer under Pennsylvania law, will not be applicable to FML's situation. It was determined that the Third Amended Plan of Rehabilitation did not contemplate a conversion transaction since the assets of FML would be transferred to a separate company (FLIC) by assumption reinsurance and FML would then be liquidated. Also, it was determined that the Conversion Act would not apply to a company in rehabilitation or liquidation because conflicts would exist with the applicable Pennsylvania rehabilitation/liquidation laws.

[^48]:    ${ }^{21}$ Even though Mutual Members are deemed "Contractholders" for purposes of claims distribution, they are not entitled to receive cash as are Class 3 Claimants. Instead, Mutual Members will be entitled to receive Plan Stock. Class 3 Claims include claims for losses under the insurance policy such as death proceeds, annuity proceeds or investment values. Class 10 Claims, which represent the claims of shareholders or other owners, are not deemed "loss claims" under a policy. Rather, such claims are deemed analogous to mutual membership interests.
    ${ }^{22}$ Article IV of the Third Amended Plan of Rehabilitation generally provides that the policyholder eligible to participate in the distribution of Plan Stock or Plan Credits resulting from such Plan is "the Person specified in the Contract, or in a subsequent document, as the 'Contractholder' or 'owner' of such Contract, or any similar designation in the Contract, as shown on the books and records of FML." FML further represents that its insurance contracts that provide benefits under an employee benefit plan, typically designate the employer that sponsors the plan, or a trustee acting on behalf of the plan, as the Contractholder or owner of the policy. In regard to those Contracts that designate the employer or trustee as Contractholder or owner of the policy, FML represents that under Article IV of the Third Amended Plan of Rehabilitation, it will make distributions resulting from such Plan to the employer or trustee as Contractholder or owner of the Contract.

    In general, it is the Department's view that, if an insurance policy is purchased with assets of an employee benefit plan, including participant contributions, and if there exist any participants under the plan (as defined at 29 CFR 2510.3-3) at the time when FML incurs the obligation to distribute Plan Stock or Plan Credits, then such consideration would constitute an assets of such employee benefit plan. Under these circumstances, the appropriate plan fiduciaries must take all necessary steps to safeguard the assets of the plan in order to avoid engaging in a violation of the fiduciary responsibility provisions of the Act.

[^49]:    ${ }^{23}$ Voting rights are set forth in the FML By-laws which provide: "At all meetings, each member shall be entitled to one vote irrespective of the number of policies or amount of insurance held by a member."

[^50]:    ${ }^{24}$ It should be noted that the value of the Plan Stock or Plan Credits that will be received by a Mutual Member will reflect the bid price paid by the Investor for Group Common Stock. Because the bid process does not allow the Investor to bid on or purchase Preferred Stock (except for the Plan Credit Shares), there is no means of establishing an immediate market value. Consequently, the $\$ 25$ per share liquidation value as described herein is deemed to approximate the fair market value of such stock. The Investor will also be required to purchase Preferred Stock at that price as well.
    ${ }^{25}$ In other words, if a Mutual Member is eligible to receive Plan Credits, the Common Stock allocated to that Mutual Member will become part of the Plan Credit Shares that will be purchased by the Investor in order to fund the purchase of Plan Credits for the Mutual Member.

[^51]:    ${ }^{26}$ As noted in Section III(i) of the Definitions, "Policyholder Stock" refers to those shares of Group Common or Group Preferred Stock that will be issued and distributed to Mutual Members. Thus, it consists of Plan Stock plus any shares of Group Stock (in excess of Plan Stock) that are issued for purposes of correcting errors in the allocation of Plan Stock, less Plan Credit Shares and any disclaimed shares.

[^52]:    ${ }^{27}$ Specifically, Section 5.08 of the Third Amended Plan of Rehabilitation provides that for one year after closing, the Investor may not purchase or enter into an agreement to purchase Group Stock from Group or the shareholders of Group, or take other action which would result in the Investor being affiliated with Group. In addition, Section 5.09 of the Third Amended Plan provides that for one year after closing, Group and any company controlled directly or indirectly by Group will not purchase or redeem nor enter into an agreement to purchase or redeem, Group Stock from Mutual Members that, when combined with the value of Plan Credit Shares, has an aggregate value that exceeds 50 percent of the value of the Plan Stock.
    ${ }^{28}$ FML has still not determined how many shares of Plan Stock will constitute the "small number of shares" required for a Mutual Member to participate in the commission-free purchase and sales program nor has it decided on the duration of such program.

[^53]:    ${ }^{29}$ Section I.A. provides no relief from sections 406(a)(1)(E), 406(a)(2) and 407 for any person rendering investment advice to an Excluded Plan within the meaning of section 3(21)(A)(ii) and regulation 29 CFR 2510.3-21(c).

[^54]:    ${ }^{30}$ For purposes of this proposed exemption, each plan participating in a commingled fund (such as a bank collective trust fund or insurance company pooled separate account) shall be considered to own the same proportionate undivided interest in each asset of the commingled fund as its proportionate interest in the total assets of the commingled fund as calculated on the most recent preceding valuation date of the fund.
    ${ }^{31}$ In the case of a private placement memorandum, such memorandum must contain substantially the same information that would be disclosed in a prospectus if the offering of the certificates were made in a registered public offering under the Securities Act of 1933. In the Department's view, the private placement memorandum must contain sufficient information to permit plan fiduciaries to make informed investment decisions. For purposes of this proposed exemption, references to "prospectus" include any related prospectus supplement thereto, pursuant to which certificates are offered to investors.

[^55]:    ${ }^{32}$ The Department notes that PTE 83-1 [48 FR 895, January 7, 1983], a class exemption for mortgage pool investment trusts, would generally apply to trusts containing single-family residential mortgages, provided that the applicable conditions of PTE 83-1 are met. McDonald requests relief for single-family residential mortgages in this exemption because it would prefer one exemption for all trusts of similar structure. However, McDonald has stated that it may still avail itself of the exemptive relief provided by PTE 83-1.
    ${ }^{33}$ Guaranteed governmental mortgage pool certificates are mortgage-backed securities with respect to which interest and principal payable is guaranteed by the Government National Mortgage Association (GNMA), the Federal Home Loan Mortgage Corporation (FHLMC), or the Federal National Mortgage Association (FNMA). The Department's regulation relating to the definition of

[^56]:    "trust" rights under any yield supplement or similar arrangement which obligates the sponsor or master servicer, or another party specified in the relevant pooling and servicing agreement, to supplement the interest rates otherwise payable on the obligations described in section III.B.(1), in accordance with the terms of a yield supplement arrangement described in the pooling and servicing agreement, provided that such arrangements do not involve swap agreements or other notional principal contracts.

[^57]:    ${ }^{38}$ It is the Department's understanding that where a plan invests in REMIC "residual" interest certificates to which this exemption applies, some of the income received by the plan as a result of such investment may be considered unrelated business taxable income to the plan, which is subject to income tax under the Code. The Department emphasizes that the prudence requirement of section 404(a)(1)(B) of the Act would require plan fiduciaries to carefully consider this and other tax consequences prior to causing plan assets to be invested in certificates pursuant to this proposed exemption.

[^58]:    ${ }^{39}$ If a trust issues subordinated certificates, holders of such subordinated certificates may not share in the amount distributed on a pro rata basis with the senior certificateholders. The Department notes that the proposed exemption does not provide relief for plan investment in such subordinated certificates.

[^59]:    ${ }^{40}$ The pass-through rate on certificates representing interests in trusts holding leases is determined by breaking down lease payments into "principal" and "interest" components based on an implicit interest rate.

[^60]:    ${ }^{1}$ Any portion of the closed session consisting solely of staff briefings does not fall within the Sunshine Act's definition of the term "meeting" and, therefore, the requirements of the Sunshine Act do not apply to any such portion of the closed session. 5 U.S.C. 552(b)(a)(2) and (b). See also 45 CFR § 1622.2 \& 1622.3.

[^61]:    ${ }^{1}$ These estimates are based on Form $\mathrm{N}-23 \mathrm{C}-1$ filings for 1999.
    ${ }^{2}$ The burden hour estimates are based upon consultation with lawyers and accountants familiar with the practices of fund boards and the staff of investment advisers.

[^62]:    ${ }^{1}$ JP Life, through JP Life Account A, issued two forms of individual flexible payment variable annuity contracts (the "Alpha Contracts"). Applicants represent that the Alpha Contracts are not currently being offered and that JP Life Account A does not file updated post-effective amendments consistent with the terms and conditions of relevant SEC no-action precedent. See, e.g., Great-West Life \& Annuity and Insurance Company (pub. avail. Oct. 23, 1990) ("Great-West"). Applicants state that in reliance on such precedent, certain information about the Alpha Contracts, JP Life Account A, and JPVF is provided to Alpha Contractowners in lieu of filing post-effective amendments to the registration statements relating to the Alpha Contracts or delivering updated Contract prospectuses to those Contractowners.

[^63]:    ${ }^{2}$ In the Matter of Jefferson Pilot Variable Fund, Inc. and Jefferson Pilot Advisory Corporation, Investment Company Act Rel. Nos. 23301 (July 1, 1998) (Order) and 23242 (June 5, 1998) (Notice). Applicants state that, because the JPVF 500 Portfolio is a series of JPVF, it will be entitled to rely on the JPVF Order. As a condition to the application, Applicants state that they will take no action in reliance on the JPVF Order with respect to the JPVF 500 Portfolio unless and until the operation of the Portfolio in the manner contemplated by the JPVF Order is approved, following the Substitution, by the holders of a "majority of the outstanding voting securities" of the Portfolio within the meaning of the 1940 Act.

[^64]:    ${ }^{3}$ As here applicable, Rule 17a-7 exempts transactions between registered investment companies or separate series of registered investment companies from Section 17(a) of the 1940 Act, provided the conditions specified in that Rule are met. Applicants cannot literally comply with the terms of Rule 17a-17 because paragraph (a) thereof requires that the transaction be "for no consideration other than cash," whereas the subject transactions will involve the use of portfolio securities as consideration. However, the SEC Staff has granted several no-action letters under similar circumstances. See, e.g., Federated Investors (pub avail. April 21, 1994); Trust Funds Institutional Managers Trust (pub. avail. July 20, 1988); Metropolitan Series Fund, Inc. (pub. avail Aug. 29, 1986).

[^65]:    ${ }^{4}$ Applicants state that they have sent and will continue to send to Alpha Contractowners all relevant information about the proposed Substitution in accordance with the terms of GreatWest. Applicants further state that the substance of the disclosures about the Substitution that they have made or will make to Alpha Contractowners was or will be essentially identical to the disclosures about the Substitution that have already been made or will be made to all other affected Contractowners. Applicants state that certain of these disclosures have already been delivered and that all such further disclosures will be sent at approximately the same time to owners of Alpha Contracts as to all other affected Contractowners.

[^66]:    ${ }^{1}$ The GPU subsidiaries that purchase workers compensation insurance from UMI as the following: GPU Advanced Resources, Inc., Metropolitan Edison Company, Pennsylvania Electric Company, Jersey Central Power \& Light Company, GPU International, Inc., GPU Service, Inc., GPU Nuclear, Inc., Prime Energy Limited Partnership ('Prime") and Onondaga Cogeneration Limited Partnership ("Onondaga") (collectively, "Subsidiaries").
    ${ }^{2}$ In addition to GPU and its Subsidiaries, the current UMI members and policy holders are the following: South Jersey Industries, Inc., Central Hudson Gas \& Electric Corp., Empire State Electric Energy Research Corp., Griffth Oil Co., Long Island Water Corp., Middleburg Telephone, New York State Electric \& Gas Corp., Niagara Mohawk Power Corp., Rochester Gas \& Electric Corp. and Fi-Net Technologies.

[^67]:    ${ }^{1}$ Western-Southern and Western Southern Life are Touchstone Affiliates.

[^68]:    ${ }^{2}$ The Funds will combine as follows: TS Bond with and into CW Bond, TS G \& I with and into CW Value Plus, TS Value Plus with and into CW Value Plus, TS International with and into CW International and TS Emerging with and into CW Emerging.
    ${ }^{3}$ Class A shares of each Acquired Fund and each Acquiring Fund have the same maximum sales load. Class A shares of TS G \& I, TS Value Plus, TS International and TS Emerging and each corresponding Acquiring Fund have the same maximum distribution fee. Class A shares of TS Bond have a maximum distribution fee of $0.25 \%$ and Class A shares of CW Bond have a maximum distribution fee of $0.35 \%$. From May 1, 2000 to October 31, 2001, Touchstone Advisors will waive a portion of the distribution fee on Class A shares of CW Bond so that the maximum distribution fee on the shares will be $0.25 \%$. Class C shares of each Acquired Fund and each Acquiring Fund have the same maximum CDSC and the same maximum distribution fee. Class C shares of each Acquired Fund are not subject to a sales load while Class C shares of each Acquiring Fund have a maximum sales load of $1.25 \%$. The $1.25 \%$ sales load will be waived on future purchases of Class $C$ shares of the Acquiring Funds by the current shareholders of the Acquired Funds.

[^69]:    ${ }^{4}$ The Board's consideration of this factor included considering that, upon giving effect to the waivers of certain fees, that the advisory fees and other fees of an Acquiring Fund will be no higher than those paid by the corresponding Acquired Fund.

[^70]:    ${ }^{1} 15$ U.S.C. $78 \mathrm{~s}(\mathrm{~b})(1)$.
    ${ }^{2} 17$ CFR 240.19b-4.
    ${ }^{3}$ PDRs are shares in a unit investment trust registered under the Investment Company Act of 1940, as amended, whose assets are a securities portfolio.
    ${ }^{4}$ Index Fund Shares are shares in an open-end management investment company registered under

[^71]:    ${ }^{9} 12$ CFR 220. The Federal Reserve Board issued Regulation T pursuant to Section 7(c) of the Act.
    ${ }^{10}$ SPDRs represent interests in a unit investment trust that holds a portfolio of stocks replicating the S\&P 500 Index. See Securities Exchange Act Release No. 31591 (December 11, 1992), 57 FR 60253 (order approving File No. SR-Amex-92-18).
    ${ }^{11}$ See letter from Michael J. Schoenfeld, Senior Securities Regulation Analyst, Federal Reserve Board, to James M. McNeil, Chief Examiner, Amex, dated February 1, 1993 ("1993 Letter").
    ${ }^{12}$ See Letter, supra note 11.
    ${ }^{13}$ MidCap SPDRs represent interests in a unit investment trust that holds a portfolio of stocks replicating the S\&P MidCap 400 Index. See Securities Exchange Act Release No. 35534 (March 24, 1995), 60 FR 16686 (order approving File No. SR-Amex-94-52).
    ${ }^{14}$ According to the Amex, the Federal Reserve Board staff confirmed this position in a telephone conversation between Michael J. Schoenfeld, Senior Securities Regulation Analyst, Federal Reserve Board, and James M. McNeil, Chief Examiner, Amex, on May 1, 1995. Conversation between Michael Cavalier, Associate General Counsel, Legal and Regulatory Policy, Amex, and Yvonne Fraticelli, Special Counsel, Division, Commission, on February 24, 2000.
    ${ }^{15}$ See Board of Governors of the Federal Reserve System Docket No. R-977 (April 24, 1996), 61 FR 20386 (permitting the adoption of margin requirements "deemed appropriate by the exchange that trades the option, subject to the approval of the Securities and Exchange Commission'").

[^72]:    ${ }^{16}$ DIAMONDS are units of beneficial interest in the DIAMONDS Trust, which holds a portfolio of stocks replicating the Dow Jones Industrial Average. See Securities Exchange Act Release No. 39525 (January 8, 1998), 63 FR 2438 (order approving File No. SR-Amex-97-29). In connection with the commencement of trading in DIAMONDS, the Amex requested confirmation from the Federal Reserve Board staff that margin treatment of DIAMONDS would be comparable to that for SPDRs under Regulation T. See letter from James M. McNeil, Chief Examiner, Amex, to Scott Holz, Senior Attorney, Legal Division, The Federal Reserve Board, dated December 3, 1997. In response, the Federal Reserve Board staff noted, among other things, that the amendments to Regulation T that became effective on June 1, 1997, provide that the margin requirement for listed options is the amount specified by the national securities exchange that trades the option. Thus, the Federal Reserve Board staff indicated that DIAMONDS could serve as cover for a short position in index options if the rules of the appropriate self-regulatory organization specified that DIAMONDS qualify for such treatment. See letter from Scott Holz, Senior Attorney, the Federal Reserve Board, to James M. McNeil, Chief Examiner, Amex, dated January 8, 1998.
    ${ }^{17}$ Nasdaq 100 shares are units of beneficial interest in the Nasdaq-100 Trust, a portfolio of stocks replicating the Nasdaq 100 Index. See Securities Exchange Act Release No. 41119 (February 26, 1999, 64 FR 11510 (order approving File No. SR-Amex-98-34).
    ${ }^{18}$ Under Amex Rule 900C, the "aggregate current index value" is the current index group value (i.e., the current numerical index value of a stock index group multiplied by $\$ 1.00$ ) multiplied by the index multiplier (i.e. the number specified in a stock index option contract by which the market closing index group value is to be multiplied to arrive at the value required to be delivered upon valid exercise of the contract).
    ${ }^{19}$ See Amendment No. 3, supra note 8.

[^73]:    ${ }^{20}$ See Amendment No. 3, supra, note 8.
    ${ }^{21} 15$ U.S.C. 78f(b)(5).
    ${ }^{22}$ In approving this rule, the Commission has considered the proposal's impact on efficiency, competition, and capital formation. 15 U.S.C. $78 \mathrm{c}(\mathrm{f})$.
    ${ }^{23}$ See Amendment No. 3, supra note 8.

[^74]:    ${ }^{24}$ See 1993 Letter, supra note 11, and note 14, supra.
    ${ }^{25}$ The proposal will renumber current Amex Rule $462(\mathrm{~d})(2)(\mathrm{H})(\mathrm{iv})$ as Amex Rule $462(\mathrm{~d})(2)(\mathrm{H})(\mathrm{v})$.
    ${ }^{26}$ Specially, current Amex Rule 462(d)(2)(H)(iv) provides that in computing margin on an existing net security position carried against a short put or short call, the current market price to be used shall

[^75]:    ${ }^{28} 15$ U.S.C. $78 \mathrm{~s}(\mathrm{~b})(2)$.
    ${ }^{29} 17$ CFR 200.30-3(a)(12).
    ${ }^{1} 15$ U.S.C. $78 \mathrm{~s}(\mathrm{~b})(1)$.
    ${ }^{2} 17$ CFR 240.19b-4.
    ${ }^{3}$ The pilot program was first approved by the Commission effective February 9, 1999 through March 31, 2000. See Securities Exchange Act Release No. 41033 (February 9, 1999), 64 FR 8156 (February 18, 1999.)

[^76]:    ${ }^{4} I d$.
    ${ }^{5} I d$.
    ${ }^{6}$ Telephone conversation between Tim Thompson, Director of Regulatory Affairs, CBOE, and Terri Evans, Special Counsel, Division of Market Regulation ("Division"), SEC, March 28, 2000 (clarifying the definition of non-bookable orders and the manual entry of such orders.
    ${ }^{7}$ The Pacific Exchange, Inc. ("PCX") has adopted a similar procedure for manually handling nonbookable orders in connection with the use of the PCX's Automated Opening Rotation system. See Securities Exchange Act Release No. 41970 (September 30, 1999), 64 FR 54713 (October 7, 1999).

[^77]:    ${ }^{8}$ Telephone conversation between Tim
    Thompson, Director of Regulatory Affairs, CBOE, and Terri Evans, Special Counsel, Division, SEC, March 28, 2000.
    ${ }^{9}$ Id.
    ${ }^{10} I d$.
    ${ }^{11}$ See Securities Exchange Act Release No. 41033 (February 9, 1999), 64 FR 8156 (February 18, 1999).

[^78]:    ${ }^{12} 15$ U.S.C. 78f(b)
    ${ }^{13} 15$ U.S.C. $78 f(b)(5)$.
    ${ }^{14} 15$ U.S.C. $78 \mathrm{~s}(\mathrm{~b})(3)(\mathrm{A})$
    ${ }^{15} 17$ CFR 240.19b-4(f)(6)
    ${ }^{16}$ Id.
    ${ }^{17} 17$ CFR 240.19b-4(f)(6)(iii)

[^79]:    ${ }^{18}$ Further, the Commission approved a similar system proposed by the PCX on a pilot basis until September 30, 2000. See Securities Exchange Act Release No. 41970, supra note 7.
    ${ }^{19}$ See Securities Exchange Act Release No. 41033, supra note 3.
    ${ }^{20}$ Id.
    ${ }^{21}$ In reviewing this proposal, the Commission has considered its impact on efficiency, competition, and capital formation. 15 U.S.C. $78 \mathrm{c}(\mathrm{f})$.

[^80]:    ${ }^{22} 17$ CFR 200.30-3(a)(12)
    ${ }^{1} 15$ U.S.C. $78 \mathrm{~s}(\mathrm{~b})(1)$.

[^81]:    ${ }^{2}$ The Commission has modified the text of the summaries prepared by DTC.
    ${ }^{3}$ Securities Exchange Act Release No. 37314 (June 21, 1996), 61 FR 31989.

[^82]:    ${ }^{4}$ Securities Exchange Act Release No. 41508 (June 17, 1999), 64 FR 32574.
    ${ }^{5} 15$ U.S.C. $78 q-1$.

[^83]:    ${ }^{6} 15$ U.S.C. 78s(b)(3)(A)(iii).
    717 CFR 240.19b-4(f)(4).

[^84]:    ${ }^{8} 17$ CFR 200.30-3(a)(12).
    ${ }^{1} 15$ U.S.C. $78 \mathrm{~s}(\mathrm{~b})(1)$.
    ${ }^{2}$ Securities Exchange Act Release No. 42257 (Dec. 20, 1999), 64 FR 72709 (Dec. 28, 1999).
    ${ }^{3}$ See Securities Exchange Act Release No. 39658 (Feb. 12, 1998), 63 FR 8726 (Feb. 20, 1998) [File No. SR-DTC-97-14].
    ${ }^{4}$ For a history of DTC's call lottery process, refer to Securities Exchange Act Release Nos. 21523 (Nov. 27, 1984), 49 FR 47352 [File No. SR-DTC-84-09] (notice of filing and immediate effectiveness of proposed rule change); 30552 (Apr. 2, 1992) 57 FR 12352 [File No. SR-DTC-90-02] (order temporarily approving a proposed rule change by DTC relating to the establishment of a procedure to recall certain deliveries which have created short positions as a result of call lotteries); 35034 (Nov.

[^85]:    30, 1994) 59 FR 63396 [File Nos. SR-DTC-94-08 and SR-DTC-94-09] (order granting temporary approval of proposed rule changes to establish procedures to recall certain deliveries which have created short positions as a result of call lotteries and rejected deposits); 36651 (Dec. 28, 1995) 61 FR 429 [File No. SR-DTC-21] (order granting accelerated permanent approval of a proposed rule change concerning short position reclamation procedures); and 39658 (Feb. 20, 1998) 63 FR 8726 [File No. SR-DTC-97-14] (order approving proposed rule change regarding call lottery procedures for BEO securities).
    ${ }^{5} 15$ U.S.C. 78-1(b)(3)(F).

[^86]:    ${ }^{6} 17$ CFR 200.30-3(a)(12).
    ${ }^{1} 15$ U.S.C. $78 \mathrm{~s}(\mathrm{~b})(1)$.

[^87]:    ${ }^{2}$ The Commission has modified the text of the summaries prepared by EMCC.
    ${ }^{3} 15$ U.S.C. $78 q-1$.
    ${ }^{4}$ Letter from Vincent G. Rayano, Vice President, Tullett and Tokyo Securities, Inc., to Karen Saperstein, General Counsel and Secretary, EMCC (November 23, 1999).
    ${ }^{5}$ In its reply letter, EMCC responded to the commenter by stating that interdealer broker members, such as the commenter, will pay a lower fee under the revised fee schedule than it previously was paying. Letter from Keith C. Kanaga, Managing Director, EMCC, to Vincent G. Rayano, Vice President, Tullet and Tokyo Securities, Inc. (December 7, 1999).
    ${ }^{6} 15$ U.S.C. 78s(b)(3)(A)(ii).
    ${ }^{7} 17$ CFR 240.19b-4(f)(2).

[^88]:    ${ }^{1} 15$ U.S.C. $78 \mathrm{~s}(\mathrm{~b})(1)$.

[^89]:    ${ }^{2} 17$ CFR 240.19b-4.
    ${ }^{3}$ The MSRB changed the text of question three from, "May the dealer choose whether the consultant is an individual or a company?", See letter from Ronald W. Smith, Senior Legal Associate, MSRB, to Katherine England, Assistant Director, Division of Market Regulation ('‘Division’), SEC, dated March 30, 2000.

[^90]:    ${ }^{3}$ The MSRB changed the text of question three from, "May the dealer choose whether the consultant is an individual or a company?" See letter from Ronald W. Smith, Senior Legal
    Associate, MSRB, to Katherine England, Assistant Director, Division of Market Regulation ('‘Division"), SEC, dated March 30, 2000.

[^91]:    ${ }^{4}$ The MSRB changed "are" to "is." See letter from Ronald W. Smith, Senior Legal Associate, MSRB, to Katherine England, Assistant Director, Division, SEC, dated March 2, 2000.

[^92]:    ${ }^{5}$ Securities Exchange Act Release No. 36727 (January 17, 1996), 61 FR 1955 (1996). The rule became effective on March 18, 1996
    ${ }^{6}$ Securities Exchange Act Release No. 42205 (December 7, 1999), 64 FR 69808 (1999).

[^93]:    ${ }^{7}$ For previous notices, see MSRB Reports, Vol. 16, No. 2 (June 1996) at 3-5; Vol. 17, No. 1 (January 1997) at 15; Vol. 18, No. 2 (August 1998) at 13; and Vol. 19, No. 2 (April 1999) at 23. See also MSRB Rule Book (January 1, 2000) at 208-211.
    ${ }^{8} 15$ U.S.C. 780-4(b)(2)(C).
    ${ }^{9}$ In reviewing the proposed rule change, the Commission considered its impact on efficiency competition, and capital formation. 15 U.S.C. 78c(f).
    ${ }^{10} 15$ U.S.C. $78 \mathrm{~s}(\mathrm{~b})(3)(\mathrm{A})$.

[^94]:    ${ }^{11} 17$ CFR 240.19b-4(f)(1).
    1217 CFR 200.30-3(a)(12).

[^95]:    ${ }^{1} 15$ U.S.C. $78 \mathrm{~s}(\mathrm{~b})(1)$
    ${ }^{2} 17$ CFR 240.19b-4.
    ${ }^{3}$ See February 28, 2000 letter and attachments from Joan C. Conley, Secretary, NASD Regulation, Inc. to Katherine A. England, Assistant Director, Division of Market Regulation ('Division’'), SEC ("Amendment No. 1"). In Amendment No. 1, NASD Regulation made changes to the language of the proposed new rule. Exhibits 2 through 4 that were attached to the original filing are incorporated by reference in Amendment No. 1.
    ${ }^{4}$ See March 17, 2000 letter from Suzanne E. Rothwell, Chief Counsel, Corporate Financing, NASD Regulation, Inc. to Katherine A. England, Assistant Director, Division, SEC, ("Amendment No. 2'"). Amendment No. 2 made minor technical changes to the proposal.
    ${ }^{5} 17$ CFR 270.23c-3(b)

[^96]:    ${ }^{6} 15$ U.S.C. 80a

[^97]:    ${ }^{7} 15$ U.S.C. 80a.
    ${ }^{8} 15$ U.S.C. 80a-5(a)(2).
    ${ }^{9} 15$ U.S.C. 80a.
    ${ }^{10}$ Section 5(a)(1) of the 1940 Act defines "openend company" as "a management company which is offering for sale or has outstanding any redeemable security for which it is the issuer." Section 5(a)(2) of the 1940 Act defines "closed-end company" as "any management company other than an open-end company." 15 U.S.C. 80a-5(a)(1) and (2).
    ${ }^{11} 15$ U.S.C. 80a.
    ${ }^{12} \mathrm{Id}$.

[^98]:    ${ }^{13} 17$ CFR 230.415.
    ${ }^{14} 15$ U.S.C. 77a et seq.
    ${ }^{15} 17$ CFR 270.23c-3(b).
    ${ }^{16} 15$ U.S.C. 80a.
    ${ }^{17} 17$ CFR 270.23c-3(b).
    1815 U.S.C. 80a.

[^99]:    ${ }^{19}$ Interval funds are distinguished from other hybrid closed-end funds that make periodic selftenders in compliance with Rule 13e-4 and Schedule 13E-4 under the Act ("tender offer funds'’). See 17 CFR 240.13e-4 and 17 CFR 240.13e-101 et seq. Such tender offer funds are not required to establish as a fundamental policy that they will make periodic repurchases, as required by Rule 23c-3(b) under the 1940 Act. 17 CFR 270.23c3(b), 15 U.S.C. 80a. The rule change proposed herein would not exempt tender offer funds from the Corporate Financing Rule. However, NASD Regulation will consider individual requests for exemption under the NASD Rule 9600 series from the requirements of the Corporate Financing Rule for such tender offer funds. See, Exemption granted October 29, 1999 under "Corporate Financing Rule-Rule 2710" at www.nasd.com.
    ${ }^{20} 17$ CFR 270.23c-3(b).
    ${ }^{21} 17$ CFR 230.415.
    ${ }^{22} 15$ U.S.C. 77a et seq.
    ${ }^{23} \mathrm{An}$ interval fund that has received a "no objections" opinion from the Corporate Financing Department based upon representations that underwriting compensation will not exceed a certain amount will become subject to the Sales Charge Rule upon effectiveness of the proposed amendments, provided that the compensation limit has not already been met or exceeded. Any interval fund that has reached the applicable compensation limit under the Corporate Financing Rule shall remain subject to the requirements of the Rule until the fund files a post-effective amendment with the Commission registering additional securities.
    ${ }^{24} 15$ U.S.C. 78o-3(b)(6).

[^100]:    ${ }^{25} 17$ CFR 200.30-3(a)(12).
    ${ }^{1} 15$ U.S.C. 78s(b)(1).
    ${ }^{2} 17$ CFR 240.19b-4.
    ${ }^{3}$ On March 9, 2000 and March 15, 2000 the NASD submitted Amendments No. 1 and 2 to the proposed rule change, respectively, the substance of which is incorporated into the notice. See letters to Katherine A. England, Assistant Director, Division of Market Regulation, Commission, from Patrice Gliniecki, Vice President and Deputy General Counsel, NASD Regulation, dated March 7, 2000 ("Amendment No. 1") and March 24, 2000 (Amendment No. " 2 ").

[^101]:    ${ }^{4}$ See Securities Exchange Act Release No. 42280 (December 28, 1999), 65 FR 1211 (January 7, 2000).

[^102]:    ${ }^{5}$ The payment of ordinary honoraria, as provided in IM-10104 of the Code, shall not be affected by this provision.

[^103]:    ${ }^{6}$ See 15 U.S.C. 78o-3(b)(9)
    ${ }^{7}$ See 15 U.S.C. 78o-3(b)(5).
    ${ }^{8}$ See, e.g., Securities Exchange Act Release No. 41056 (February 16, 1999), 64 FR 10041 (March 1, 1999).
    ${ }^{9} 17$ CFR 200.30-3(a)(12).

[^104]:    ${ }^{1} 15$ U.S.C. $78 \mathrm{~s}(\mathrm{~b})(1)$
    ${ }^{2} 17$ CFR 240.19b-4.
    ${ }^{3}$ In Amendment No. 1, the NYSE made several clarifications to the intent and proposed interpretation of the proposed rule change. The Exchange expanded its discussion regarding the use of convertible securities in calculating the market capitalization of an issuer, and provided several examples of the proposed rule's application. The Exchange also explained the IRS-related basis for the proposed changes to the calculation of market capitalization for partnerships. Finally, the Exchange clarified that the proposed change to the bankruptcy provision would not restart the eighteen-month clock for an Exchange-approved plan. See Letter to Belinda Blaine, Associate Directors, Division of Market Regulation ("Division"), SEC, from James E. Buck, Senior Vice President and Secretary, NYSE, dated March 21, 2000 ("Amendment No. 1").
    ${ }^{4}$ In Amendment No. 2, the Exchange made several technical changes to the rule text which are reflected in this notice. See Letter to Belinda Blaine, Associate Director, Division, SEC, from James E. Buck, Senior Vice President and Secretary, NYSE, dated March 24, 2000 ("Amendment No. 2").

[^105]:    ${ }^{5}$ See Securities Exchange Act Release No. 42194 (December 1, 1999), 64 FR 69311 (December 10, 1999).

[^106]:    ${ }^{7} 15$ U.S.C. 78f(b)(5).

[^107]:    ${ }^{8} 17$ CFR 200.30-3(a)(12).
    ${ }^{1} 15$ U.S.C. 78s(b)(1)
    ${ }^{2} 17$ CFR 240.19b-4.
    ${ }^{3}$ In Amendment No. 1, the NYSE clarified its purpose for proposing the rule change. See letter from James E. Buck, Senior Vice President and Secretary, NYSE, to Deborah Flynn, Division of Market Regulation ("Division"), SEC, dated March 21, 2000 ("Amendment No. 1").

[^108]:    ${ }^{4}$ The Exchange currently charges a special charge of $\$ 36,800$ in addition to initial listing fees. See Paragraph 902.02 A of the Manual.
    ${ }^{5}$ See Amendment No. 1, supra, note 3.

[^109]:    ${ }^{8}$ In approving this rule, the Commission has considered its impact on efficiency, competition, and capital formation. 15 U.S.C. 78c(f).
    ${ }^{9} 15$ U.S.C. $78 f(b)(4)$.
    ${ }^{10}$ Telephone conversation between Amy Bilbija, Counsel, NYSE, and Heather Traeger, Attorney, Division, SEC, on March 29, 20000.
    ${ }^{11} 15$ U.S.C. $78 f(b)(5)$ and $78 s(b)(2)$.
    ${ }^{12} 15$ U.S.C. $78 \mathrm{~s}(\mathrm{~b})(2)$.
    ${ }^{13} 17$ CFR 200.30-3(a)(12).

[^110]:    ${ }^{1} 15$ U.S.c. $78 \mathrm{~s}(\mathrm{~b})(1)$.
    ${ }^{2} 17$ CFR 240.19b-4.
    ${ }^{3}$ The VTS was developed by Universal Trading Technologies Corporation ("UTTC TM'"), and was approved by the Commission to operate as a facility of the Exchange. See Securities Exchange Act Release No. 41210 (March 24, 1999) (SR-Phlx-9614).
    ${ }^{4}$ The Exchange filed a proposed rule change to change the name of the VTS to "eVWAP", SR-Phlx-00-19.

[^111]:    ${ }^{5}$ See Exchange Rule 237(c)(ii).
    ${ }^{6}$ The SCCP member and the respective customer agree upon the appropriate credit limits. Neither the Exchange nor SCCP approves credit limits for customers.

[^112]:    ${ }^{7} 15$ U.S.C. $78 \mathrm{~s}(\mathrm{~b})(3)(\mathrm{A})$.
    ${ }^{8} 17$ CFR 240.19b-4(f)(5).
    ${ }^{9} 17$ CFR 200.30-3(a)(12).

[^113]:    ${ }^{1}$ RSPA notes that New Jersey has also adopted, as State law, the requirements in the HMR. N.J.A.C. 16:49-1.3(i).

[^114]:    ${ }^{2}$ DOT's standards and procedures for State and Indian tribe requirements for highway routing of non-radioactive hazardous materials are issued under 49 U.S.C. 5112(b) and contained in 49 CFR Part 397, subpart C.

[^115]:    ${ }^{1}$ N.J.S.A. 21:1A-137F
    ${ }^{2}$ N.J.S.A. 21:1A-140.
    ${ }^{3}$ N.J.S.A. 21:1A-130.

[^116]:    ${ }^{4}$ N.J.A.C. 12:190-6.5(d)
    ${ }^{5}$ N.J.A.C. 12:190-6.5-Off highway transportation of explosives.
    ${ }^{6}$ N.J.S.A. 21:1A-137-Transportation of explosives.
    ${ }^{7}$ Attached to this compliant are affidavits that attest to the issues we have submitted for review. ${ }^{8}$ P.L. 93-633 § 102.
    ${ }^{9}$ S. Rept. 1192, 93rd Cong., 2d Sess., 1974, page 2.
    ${ }^{10}$ S. Rept. 1192, 93rd Cong., 2d Sess., 1974, page 37.
    ${ }^{11}$ P.L. 93-633 § 112 (a).
    ${ }^{12} 41$ FR 38171 (September 9, 1976).

[^117]:    ${ }^{13} 41$ FR 38168 (September 9, 1976).
    1449 U.S.C. 5125(a).
    ${ }^{15} 49$ U.S.C. 5125(b)(1)(B).
    ${ }^{16} 49$ CFR 107.202(d).
    ${ }^{17}$ Colo. Pub. Util. Comm'n v. Harmon, 951 F. 2d, 1571, 1581 n. 10. (10th Cir. 1991).
    1849 U.S.C. 5103(b).
    1949 U.S.C. 5102(12).
    ${ }^{20}$ Along with Division 1.1, 1.2, 1.3, and 1.4 materials, 49 CFR $177.835(\mathrm{~g})$ exceptions apply to "explosives for blasting." Anything classified as a division 1.5 can be used as an "explosive for blasting."
    ${ }^{21} 49$ CFR 177.835(g).
    ${ }^{22}$ N.J.S.A. 21:1A-29 (f).

[^118]:    ${ }^{23} 49$ CFR 177.835(j).
    ${ }^{24} 49$ U.S.C. 5102 (1) and (12).

[^119]:    ${ }^{25}$ Serious incidents are those that result in one or more of the following: death; accident/ derailment of vehicle; evacuation of six or more individuals; injury requiring hospitalization; or road closure.
    ${ }^{26} 49$ CFR 176.2. We recognize that this definition is contained in that section of the HMR dealing with the carriage of hazardous materials by vessel. However, we cannot believe that RSPA would define this term inconsistently as it is applied to other modes of transportation

[^120]:    ${ }^{1}$ Greyhound controls 9 of the 23 carriers.

[^121]:    ${ }^{1}$ Court Hammond and James Sanders are the controlling shareholders, officers and directors of Colorado Central Railroad Company, Yreka Western Railroad Company, Rocky Mountain Railway and Mining Museum, and Colorado, Kansas \& Pacific Railway Company.
    ${ }^{2}$ RMRMM is a noncarrier holding company which controls $100 \%$ of the stock of YWRR but does not itself provide any common carrier rail freight service.
    ${ }^{3}$ The Hammond Group reports that it intended for CCRC to commence providing common carrier service over YWRR's line on or about March 27, 2000. YWRR will continue to own the line, to have a residual common carrier obligation on the line, and to provide excursion rail passenger service.

[^122]:    Notes:
    ${ }^{1}$ Includes all BBRA provisions except the transitional corridor provisions that expire 01/01/04.
    ${ }^{2}$ Does not include impact of reclassifications as allowed under section 401 of the BBRA 1999.
    ${ }^{3}$ Estimate of change compared to pre-PPS payments, which reflect the payment methodologies in effect as of January 1, 2000, and prior to July 1, 2000.

[^123]:    ${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The Payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment.
    ${ }^{2}$ Not subject to national coinsurance.
    ${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

[^124]:    Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The Payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment.
    ${ }^{2}$ Not subject to national coinsurance.
    ${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

[^125]:    ${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The Payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment.
    ${ }^{2}$ Not subject to national coinsurance.
    ${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

[^126]:    ${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The Payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment
    ${ }^{2}$ Not subject to national coinsurance.
    ${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

[^127]:    ${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The Payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment.
    ${ }^{2}$ Not subject to national coinsurance.
    ${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

[^128]:    Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The Payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment
    ${ }^{2}$ Not subject to national coinsurance.
    ${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

[^129]:    CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
    Copyright American Dental Association. All rights reserved.
    ${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment
    ${ }^{2}$ Not subject to national coinsurance.
    ${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

[^130]:    CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
    Copyright American Dental Association. All rights reserved.
    ${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment
    ${ }^{2}$ Not subject to national coinsurance.
    ${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

[^131]:    CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
    Copyright American Dental Association. All rights reserved.
    ${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment
    ${ }^{2}$ Not subject to national coinsurance.
    ${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

[^132]:    CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
    Copyright American Dental Association. All rights reserved.
    ${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment
    ${ }^{2}$ Not subject to national coinsurance.
    ${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

[^133]:    CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
    Copyright American Dental Association. All rights reserved.
    ${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment.
    ${ }^{2}$ Not subject to national coinsurance.
    ${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

[^134]:    CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
    Copyright American Dental Association. All rights reserved.
    ${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment
    ${ }^{2}$ Not subject to national coinsurance.
    ${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

[^135]:    CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
    Copyright American Dental Association. All rights reserved.
    ${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment.
    ${ }^{2}$ Not subject to national coinsurance.
    ${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

[^136]:    CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
    Copyright American Dental Association. All rights reserved.
    ${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment
    ${ }^{2}$ Not subject to national coinsurance.
    ${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

[^137]:    CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
    Copyright American Dental Association. All rights reserved.
    ${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment.
    ${ }^{2}$ Not subject to national coinsurance.
    ${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

[^138]:    CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
    Copyright American Dental Association. All rights reserved.
    ${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment
    ${ }^{2}$ Not subject to national coinsurance
    ${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

[^139]:    CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
    Copyright American Dental Association. All rights reserved.
    ${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment.
    ${ }^{2}$ Not subject to national coinsurance.
    ${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

[^140]:    CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
    Copyright American Dental Association. All rights reserved
    ${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment
    ${ }^{2}$ Not subject to national coinsurance
    ${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

[^141]:    CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
    Copyright American Dental Association. All rights reserved.
    ${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment.
    ${ }^{2}$ Not subject to national coinsurance.
    ${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

[^142]:    CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
    Copyright American Dental Association. All rights reserved.
    ${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment
    ${ }^{2}$ Not subject to national coinsurance.
    ${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

[^143]:    CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
    Copyright American Dental Association. All rights reserved.
    ${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment.
    2 Not subject to national coinsurance.
    ${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

[^144]:    CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
    Copyright American Dental Association. All rights reserved.
    ${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment.
    2 Not subject to national coinsurance.
    ${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

[^145]:    CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
    Copyright American Dental Association. All rights reserved.
    ${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment.
    ${ }^{2}$ Not subject to national coinsurance.
    ${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

[^146]:    CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
    Copyright American Dental Association. All rights reserved.
    ${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment.
    ${ }^{2}$ Not subject to national coinsurance.
    ${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

[^147]:    CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
    Copyright American Dental Association. All rights reserved.
    ${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment.
    ${ }^{2}$ Not subject to national coinsurance.
    ${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

[^148]:    CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
    Copyright American Dental Association. All rights reserved.
    ${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment.
    2 Not subject to national coinsurance.
    ${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

[^149]:    CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
    Copyright American Dental Association. All rights reserved.
    ${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment.
    ${ }^{2}$ Not subject to national coinsurance.
    ${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

[^150]:    CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
    Copyright American Dental Association. All rights reserved.
    ${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment
    ${ }^{2}$ Not subject to national coinsurance
    ${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

[^151]:    CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
    Copyright American Dental Association. All rights reserved.
    ${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment.
    ${ }^{2}$ Not subject to national coinsurance.
    ${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

[^152]:    CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
    Copyright American Dental Association. All rights reserved.
    ${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment
    ${ }^{2}$ Not subject to national coinsurance.
    ${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

[^153]:    CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
    Copyright American Dental Association. All rights reserved.
    ${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment.
    ${ }^{2}$ Not subject to national coinsurance.
    ${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

[^154]:    CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
    Copyright American Dental Association. All rights reserved.
    ${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment.
    ${ }^{2}$ Not subject to national coinsurance.
    ${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

[^155]:    CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
    Copyright American Dental Association. All rights reserved.
    ${ }^{1}$ Nop subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment.
    ${ }^{2}$ Not subject to national coinsurance.
    ${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

[^156]:    CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
    Copyright American Dental Association. All rights reserved.
    ${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment.
    ${ }^{2}$ Not subject to national coinsurance.
    ${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

[^157]:    CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
    Copyright American Dental Association. All rights reserved.
    ${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment.
    ${ }^{2}$ Not subject to national coinsurance.
    ${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

[^158]:    CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
    Copyright American Dental Association. All rights reserved.
    ${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment.
    ${ }^{2}$ Not subject to national coinsurance.
    ${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

[^159]:    CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
    Copyright American Dental Association. All rights reserved.
    ${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment.
    ${ }^{2}$ Not subject to national coinsurance.
    ${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

[^160]:    CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
    Copyright American Dental Association. All rights reserved.
    ${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment.
    ${ }^{2}$ Not subject to national coinsurance.
    ${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

[^161]:    CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
    Copyright American Dental Association. All rights reserved.
    ${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment
    ${ }^{2}$ Not subject to national coinsurance.
    ${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

[^162]:    CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
    Copyright American Dental Association. All rights reserved.
    ${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment
    ${ }^{2}$ Not subject to national coinsurance.
    ${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

[^163]:    CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
    Copyright American Dental Association. All rights reserved.
    ${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment
    ${ }^{2}$ Not subject to national coinsurance.
    ${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

[^164]:    CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
    Copyright American Dental Association. All rights reserved.
    ${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment
    ${ }^{2}$ Not subject to national coinsurance.
    ${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

[^165]:    CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
    Copyright American Dental Association. All rights reserved.
    ${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment
    ${ }^{2}$ Not subject to national coinsurance.
    ${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

[^166]:    CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
    Copyright American Dental Association. All rights reserved.
    ${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment
    ${ }^{2}$ Not subject to national coinsurance
    ${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

[^167]:    CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
    Copyright American Dental Association. All rights reserved.
    ${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment
    ${ }^{2}$ Not subject to national coinsurance.
    ${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

[^168]:    CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
    Copyright American Dental Association. All rights reserved.
    ${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment
    ${ }^{2}$ Not subject to national coinsurance
    ${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

[^169]:    CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
    Copyright American Dental Association. All rights reserved.
    ${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment.
    ${ }^{2}$ Not subject to national coinsurance.
    ${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

[^170]:    CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
    Copyright American Dental Association. All rights reserved.
    ${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment
    ${ }^{2}$ Not subject to national coinsurance.
    ${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

[^171]:    CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
    Copyright American Dental Association. All rights reserved.
    ${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment.
    ${ }^{2}$ Not subject to national coinsurance.
    ${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

[^172]:    CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
    Copyright American Dental Association. All rights reserved.
    ${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment.
    ${ }^{2}$ Not subject to national coinsurance.
    ${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

[^173]:    CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
    Copyright American Dental Association. All rights reserved.
    ${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment.
    ${ }^{2}$ Not subject to national coinsurance.
    ${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

[^174]:    CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
    Copyright American Dental Association. All rights reserved.
    ${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment.
    ${ }^{2}$ Not subject to national coinsurance.
    ${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

[^175]:    CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
    Copyright American Dental Association. All rights reserved.
    ${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment.
    ${ }^{2}$ Not subject to national coinsurance.
    ${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

[^176]:    CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
    Copyright American Dental Association. All rights reserved.
    ${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment.
    ${ }^{2}$ Not subject to national coinsurance.
    ${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

[^177]:    CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
    Copyright American Dental Association. All rights reserved.
    ${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment.
    ${ }^{2}$ Not subject to national coinsurance.
    ${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

[^178]:    CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
    Copyright American Dental Association. All rights reserved.
    ${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment
    ${ }^{2}$ Not subject to national coinsurance.
    ${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

[^179]:    CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
    Copyright American Dental Association. All rights reserved.
    ${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment.
    ${ }^{2}$ Not subject to national coinsurance.
    ${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

[^180]:    CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
    Copyright American Dental Association. All rights reserved.
    ${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment
    ${ }^{2}$ Not subject to national coinsurance.
    ${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

[^181]:    CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
    Copyright American Dental Association. All rights reserved.
    ${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment
    ${ }^{2}$ Not subject to national coinsurance.
    ${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

[^182]:    CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
    Copyright American Dental Association. All rights reserved.
    ${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment
    ${ }^{2}$ Not subject to national coinsurance.
    ${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

[^183]:    CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
    Copyright American Dental Association. All rights reserved.
    ${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment.
    ${ }^{2}$ Not subject to national coinsurance.
    ${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

[^184]:    CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
    Copyright American Dental Association. All rights reserved.
    ${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment
    ${ }^{2}$ Not subject to national coinsurance.
    ${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

[^185]:    CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
    Copyright American Dental Association. All rights reserved.
    ${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment.
    ${ }^{2}$ Not subject to national coinsurance.
    ${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

[^186]:    CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
    Copyright American Dental Association. All rights reserved.
    ${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment
    ${ }^{2}$ Not subject to national coinsurance.
    ${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

[^187]:    CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
    Copyright American Dental Association. All rights reserved.
    ${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment.
    ${ }^{2}$ Not subject to national coinsurance.
    ${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

[^188]:    CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
    Copyright American Dental Association. All rights reserved.
    ${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment
    ${ }^{2}$ Not subject to national coinsurance.
    ${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

[^189]:    CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
    Copyright American Dental Association. All rights reserved.
    ${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment.
    ${ }^{2}$ Not subject to national coinsurance.
    ${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

[^190]:    CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
    Copyright American Dental Association. All rights reserved.
    ${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment.
    ${ }^{2}$ Not subject to national coinsurance.
    ${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

[^191]:    CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
    Copyright American Dental Association. All rights reserved.
    ${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment.
    ${ }^{2}$ Not subject to national coinsurance.
    ${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

[^192]:    CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
    Copyright American Dental Association. All rights reserved.
    ${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment.
    ${ }^{2}$ Not subject to national coinsurance.
    ${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

[^193]:    CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
    Copyright American Dental Association. All rights reserved.
    ${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment
    ${ }^{2}$ Not subject to national coinsurance.
    ${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

[^194]:    CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
    Copyright American Dental Association. All rights reserved.
    ${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment.
    ${ }^{2}$ Not subject to national coinsurance.
    ${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

[^195]:    CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
    Copyright American Dental Association. All rights reserved.
    ${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment
    ${ }^{2}$ Not subject to national coinsurance.
    ${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

[^196]:    CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
    Copyright American Dental Association. All rights reserved.
    ${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment.
    ${ }^{2}$ Not subject to national coinsurance.
    ${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

[^197]:    CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
    Copyright American Dental Association. All rights reserved.
    ${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment
    ${ }^{2}$ Not subject to national coinsurance.
    ${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

[^198]:    CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
    Copyright American Dental Association. All rights reserved.
    ${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment.
    ${ }^{2}$ Not subject to national coinsurance.
    ${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

[^199]:    CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
    Copyright American Dental Association. All rights reserved.
    ${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment
    ${ }^{2}$ Not subject to national coinsurance.
    ${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

[^200]:    CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
    Copyright American Dental Association. All rights reserved.
    ${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment.
    ${ }^{2}$ Not subject to national coinsurance.
    ${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

[^201]:    CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
    Copyright American Dental Association. All rights reserved.
    ${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment.
    ${ }^{2}$ Not subject to national coinsurance.
    ${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

[^202]:    CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
    Copyright American Dental Association. All rights reserved.
    ${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment.
    ${ }^{2}$ Not subject to national coinsurance.
    ${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

[^203]:    CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
    Copyright American Dental Association. All rights reserved.
    ${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment.
    ${ }^{2}$ Not subject to national coinsurance.
    ${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

[^204]:    CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
    Copyright American Dental Association. All rights reserved.
    ${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment.
    ${ }^{2}$ Not subject to national coinsurance.
    ${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

[^205]:    CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply
    Copyright American Dental Association. All rights reserved.
    ${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment
    ${ }^{2}$ Not subject to national coinsurance.
    ${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

[^206]:    CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
    Copyright American Dental Association. All rights reserved.
    ${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment
    ${ }^{2}$ Not subject to national coinsurance.
    ${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

[^207]:    CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
    Copyright American Dental Association. All rights reserved.
    ${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment
    ${ }^{2}$ Not subject to national coinsurance.
    ${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

[^208]:    CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
    Copyright American Dental Association. All rights reserved.
    ${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment
    ${ }^{2}$ Not subject to national coinsurance.
    ${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

[^209]:    CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
    Copyright American Dental Association. All rights reserved.
    ${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment
    ${ }^{2}$ Not subject to national coinsurance.
    ${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

[^210]:    CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
    Copyright American Dental Association. All rights reserved.
    ${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment
    ${ }^{2}$ Not subject to national coinsurance.
    ${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

[^211]:    CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
    Copyright American Dental Association. All rights reserved.
    ${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment
    ${ }^{2}$ Not subject to national coinsurance.
    ${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

[^212]:    CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
    Copyright American Dental Association. All rights reserved.
    ${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment
    ${ }^{2}$ Not subject to national coinsurance.
    ${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

[^213]:    CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
    Copyright American Dental Association. All rights reserved.
    ${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment
    ${ }^{2}$ Not subject to national coinsurance.
    ${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

[^214]:    CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
    Copyright American Dental Association. All rights reserved.
    ${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment.
    ${ }^{2}$ Not subject to national coinsurance.
    ${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

[^215]:    CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
    Copyright American Dental Association. All rights reserved.
    ${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment
    ${ }^{2}$ Not subject to national coinsurance.
    ${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

[^216]:    CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
    Copyright American Dental Association. All rights reserved.
    ${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment.
    ${ }^{2}$ Not subject to national coinsurance.
    ${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

[^217]:    CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
    Copyright American Dental Association. All rights reserved.
    ${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment
    ${ }^{2}$ Not subject to national coinsurance.
    ${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

[^218]:    CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
    Copyright American Dental Association. All rights reserved.
    ${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment.
    ${ }^{2}$ Not subject to national coinsurance.
    ${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

[^219]:    CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
    Copyright American Dental Association. All rights reserved.
    ${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment.
    ${ }^{2}$ Not subject to national coinsurance.
    ${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

[^220]:    CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
    Copyright American Dental Association. All rights reserved.
    ${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment.
    ${ }^{2}$ Not subject to national coinsurance.
    ${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

[^221]:    CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
    Copyright American Dental Association. All rights reserved.
    ${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment
    ${ }^{2}$ Not subject to national coinsurance.
    ${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

[^222]:    CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
    Copyright American Dental Association. All rights reserved.
    ${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment
    ${ }^{2}$ Not subject to national coinsurance.
    ${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

[^223]:    CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
    Copyright American Dental Association. All rights reserved.
    ${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment
    ${ }^{2}$ Not subject to national coinsurance.
    ${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

[^224]:    CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
    Copyright American Dental Association. All rights reserved.
    ${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment.
    ${ }^{2}$ Not subject to national coinsurance.
    ${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

[^225]:    CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
    Copyright American Dental Association. All rights reserved.
    ${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment
    ${ }^{2}$ Not subject to national coinsurance.
    ${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

[^226]:    CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
    Copyright American Dental Association. All rights reserved.
    ${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment
    ${ }^{2}$ Not subject to national coinsurance.
    ${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

[^227]:    CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
    Copyright American Dental Association. All rights reserved.
    ${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment.
    ${ }^{2}$ Not subject to national coinsurance.
    ${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

[^228]:    CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
    Copyright American Dental Association. All rights reserved.
    ${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment
    ${ }^{2}$ Not subject to national coinsurance
    ${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

[^229]:    CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
    Copyright American Dental Association. All rights reserved.
    ${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment
    ${ }^{2}$ Not subject to national coinsurance.
    ${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

[^230]:    CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
    Copyright American Dental Association. All rights reserved.
    ${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment.
    ${ }^{2}$ Not subject to national coinsurance.
    ${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

[^231]:    CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
    Copyright American Dental Association. All rights reserved
    ${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment
    ${ }^{2}$ Not subject to national coinsurance.
    ${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

[^232]:    CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
    Copyright American Dental Association. All rights reserved.
    ${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment
    ${ }^{2}$ Not subject to national coinsurance.
    ${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

[^233]:    CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
    Copyright American Dental Association. All rights reserved
    ${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment
    ${ }^{2}$ Not subject to national coinsurance.
    ${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

[^234]:    CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
    Copyright American Dental Association. All rights reserved.
    ${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment
    ${ }^{2}$ Not subject to national coinsurance.
    ${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

[^235]:    CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
    Copyright American Dental Association. All rights reserved.
    ${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment
    ${ }^{2}$ Not subject to national coinsurance.
    ${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

[^236]:    CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
    Copyright American Dental Association. All rights reserved.
    ${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment
    ${ }^{2}$ Not subject to national coinsurance.
    ${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

[^237]:    CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
    Copyright American Dental Association. All rights reserved
    ${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment
    ${ }^{2}$ Not subject to national coinsurance
    ${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

[^238]:    CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
    Copyright American Dental Association. All rights reserved.
    ${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment
    ${ }^{2}$ Not subject to national coinsurance.
    ${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

[^239]:    CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
    Copyright American Dental Association. All rights reserved.
    ${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment
    ${ }^{2}$ Not subject to national coinsurance.
    ${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

[^240]:    CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply
    Copyright American Dental Association. All rights reserved.
    ${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment
    ${ }^{2}$ Not subject to national coinsurance.
    ${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

[^241]:    CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
    Copyright American Dental Association. All rights reserved.
    ${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment.
    ${ }^{2}$ Not subject to national coinsurance.
    ${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

[^242]:    CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
    Copyright American Dental Association. All rights reserved.
    ${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment
    ${ }^{2}$ Not subject to national coinsurance.
    ${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

[^243]:    CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
    Copyright American Dental Association. All rights reserved.
    ${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment.
    ${ }^{2}$ Not subject to national coinsurance.
    ${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

[^244]:    CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
    Copyright American Dental Association. All rights reserved.
    ${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment
    ${ }^{2}$ Not subject to national coinsurance.
    ${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

[^245]:    CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
    Copyright American Dental Association. All rights reserved.
    ${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment.
    ${ }^{2}$ Not subject to national coinsurance.
    ${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

[^246]:    CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
    Copyright American Dental Association. All rights reserved.
    ${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment.
    ${ }^{2}$ Not subject to national coinsurance.
    ${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

[^247]:    CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
    Copyright American Dental Association. All rights reserved.
    ${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment.
    ${ }^{2}$ Not subject to national coinsurance.
    ${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

[^248]:    CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
    Copyright American Dental Association. All rights reserved.
    ${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment
    ${ }^{2}$ Not subject to national coinsurance.
    ${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

[^249]:    CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
    Copyright American Dental Association. All rights reserved.
    ${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment.
    ${ }^{2}$ Not subject to national coinsurance.
    ${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

[^250]:    CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply

[^251]:    CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply

[^252]:    CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply

[^253]:    CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply

[^254]:    CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
    Copyright American Dental Association. All rights reserved.
    ${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment.
    ${ }^{2}$ Not subject to national coinsurance.
    ${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

[^255]:    CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply

[^256]:    CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply

[^257]:    CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply

[^258]:    CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply

[^259]:    CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.

[^260]:    CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply

[^261]:    CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply

[^262]:    CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
    Copyright American Dental Association. All rights reserved.
    ${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment
    ${ }^{2}$ Not subject to national coinsurance.
    ${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

[^263]:    CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply

[^264]:    CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
    Copyright American Dental Association. All rights reserved.
    ${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment.
    ${ }^{2}$ Not subject to national coinsurance.
    ${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

[^265]:    CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
    Copyright American Dental Association. All rights reserved.
    ${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment
    ${ }^{2}$ Not subject to national coinsurance.
    ${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

[^266]:    CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
    Copyright American Dental Association. All rights reserved.
    ${ }^{1}$ Not subject to national coinsurance. Minimum unadjusted coinsurance is $25 \%$ of the payment rate. The payment rate is the lower of the HOPD payment rate or the Ambulatory Surgical Center payment
    ${ }^{2}$ Not subject to national coinsurance.
    ${ }^{3}$ Eligible for pass-through payments. See Preamble for payment rate determination. See Addendum K for complete list of pass-through codes.

[^267]:    CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
    Copyright American Dental Association. All rights reserved.

[^268]:    CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
    Copyright American Dental Association. All rights reserved.

[^269]:    CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
    Copyright American Dental Association. All rights reserved.

[^270]:    CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply.
    Copyright American Dental Association. All rights reserved.

[^271]:    ${ }^{1}$ Large Urban Area
    ${ }^{2}$ Hospitals geographically located in the area are assigned the statewide rural wage index for FY 2000

[^272]:    ${ }^{1}$ Large Urban Area
    ${ }^{2}$ Hospitals geographically located in the area are assigned the statewide rural wage index for FY 2000

[^273]:    ${ }^{1}$ Large Urban Area
    ${ }^{2}$ Hospitals geographically located in the area are assigned the statewide rural wage index for FY 2000.

[^274]:    ${ }^{1}$ Large Urban Area
    ${ }^{2}$ Hospitals geographically located in the area are assigned the statewide rural wage index for FY 2000.

[^275]:    ${ }^{1}$ Large Urban Area
    ${ }^{2}$ Hospitals geographically located in the area are assigned the statewide rural wage index for FY 2000.

[^276]:    ${ }^{1}$ All counties within state are classified as urban.

[^277]:    BILLINGCODE4120-
    ${ }^{01-P}$ CPT codes and descriptions only are copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS Apply. Copyright American Dental Association. All rights reserved.

[^278]:    ${ }^{1}$ Part 210 adopted the ACH Rules published in NACHA's 1999 rule book (including rule changes with an effective date on or before September 17, 1999) as the rules governing all Government ACH transactions, with certain exceptions. Although NACHA's effective date for the ACH Operator definition was June 18, 1999, the changes to the definition were not published in the 1999 rule book and thus not previously incorporated in Part 210.

